PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Currow, DC; Abernethy, AP				Currow, David C.; Abernethy, Amy P.			Lessons from the Liverpool Care Pathway-evidence is key	LANCET			English	Editorial Material							LIFE CARE; END		[Currow, David C.] Flinders Univ S Australia, Discipline Serv, Bedford Pk, SA 5042, Australia; [Currow, David C.] Flinders Univ S Australia, Palliat Serv, Bedford Pk, SA 5042, Australia; [Currow, David C.] Flinders Univ S Australia, Support Serv, Bedford Pk, SA 5042, Australia; [Abernethy, Amy P.] Duke Clin Res Inst, Duke Ctr Learning Hlth Care, Dept Med, Div Med Oncol, Durham, NC 27710 USA	Flinders University South Australia; Flinders University South Australia; Flinders University South Australia; Duke University	Abernethy, AP (corresponding author), Duke Clin Res Inst, Duke Ctr Learning Hlth Care, Dept Med, Div Med Oncol, Durham, NC 27710 USA.	amy.abernethy@duke.edu		Currow, David/0000-0003-1988-1250				Abernethy AP, 2009, ANN INTERN MED, V150, P336, DOI 10.7326/0003-4819-150-5-200903030-00107; Brownson RC, 2009, AM J PUBLIC HEALTH, V99, P1576, DOI 10.2105/AJPH.2008.156224; Chorley M, 2013, DAILY MAIL; Costantini M, 2013, LANCET; Costantini M, 2011, BMC HEALTH SERV RES, V11, DOI 10.1186/1472-6963-11-13; Department of Health, 2013, MOR CAR LESS PATHW R; Duffy Anne, 2006, Nurs Older People, V18, P33; Miriovsky BJ, 2012, J CLIN ONCOL, V30, P4243, DOI 10.1200/JCO.2012.42.8011; MRC (Medical Research Council UK), 2008, DEV EVALUATING COMPL; Paterson BC, 2009, EMERG MED J, V26, P777, DOI 10.1136/emj.2008.067249; Phillips JL, 2011, J PAIN SYMPTOM MANAG, V41, P940, DOI 10.1016/j.jpainsymman.2010.07.020; Smith M, 2013, BEST CAR LOW COST PA; Walker R, 2010, INT J PALLIAT NURS, V16, P267, DOI 10.12968/ijpn.2010.16.6.48825	13	15	15	0	7	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 18	2014	383	9913					192	193		10.1016/S0140-6736(13)62039-5	http://dx.doi.org/10.1016/S0140-6736(13)62039-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	294FC	24139707				2023-01-03	WOS:000330027500006
J	Sekihara, K; Harashima, N; Tongu, M; Tamaki, Y; Uchida, N; Inomata, T; Harada, M				Sekihara, Kazumasa; Harashima, Nanae; Tongu, Miki; Tamaki, Yukihisa; Uchida, Nobue; Inomata, Taisuke; Harada, Mamoru			Pifithrin-mu, an Inhibitor of Heat-Shock Protein 70, Can Increase the Antitumor Effects of Hyperthermia Against Human Prostate Cancer Cells	PLOS ONE			English	Article							HEAT-SHOCK PROTEINS; SMALL-MOLECULE INHIBITOR; RANDOMIZED-TRIAL; HSP70; APOPTOSIS; SURVIVAL; FAMILY; RADIOTHERAPY; QUERCETIN; STRESS	Hyperthermia (HT) improves the efficacy of anti-cancer radiotherapy and chemotherapy. However, HT also inevitably evokes stress responses and increases the expression of heat-shock proteins (HSPs) in cancer cells. Among the HSPs, HSP70 is known as a pro-survival protein. In this study, we investigated the sensitizing effect of pifithrin (PFT)-mu, a small molecule inhibitor of HSP70, when three human prostate cancer cell lines (LNCaP, PC-3, and DU-145) were treated with HT (43 degrees C for 2 h). All cell lines constitutively expressed HSP70, and HT further increased its expression in LNCaP and DU-145. Knockdown of HSP70 with RNA interference decreased the viability and colony-forming ability of cancer cells. PFT-mu decreased the viabilities of all cell lines at one-tenth the dose of Quercetin, a well-known HSP inhibitor. The combination therapy with suboptimal doses of PFT-mu and HT decreased the viability of cancer cells most effectively when PFT-mu was added immediately before HT, and this combination effect was abolished by pre-knockdown of HSP70, suggesting that the effect was mediated via HSP70 inhibition. The combination therapy induced cell death, partially caspase-dependent, and decreased proliferating cancer cells, with decreased expression of c-Myc and cyclin D1 and increased expression of p21(WAF1/Cip), indicating arrest of cell growth. Additionally, the combination therapy significantly decreased the colony-forming ability of cancer cells compared to therapy with either alone. Furthermore, in a xenograft mouse model, the combination therapy significantly inhibited PC-3 tumor growth. These findings suggest that PFT-mu can effectively enhance HT-induced antitumor effects via HSP70 inhibition by inducing cell death and arrest of cell growth, and that PFT-mu is a promising agent for use in combination with HT to treat prostate cancer.	[Sekihara, Kazumasa; Harashima, Nanae; Harada, Mamoru] Shimane Univ, Fac Med, Dept Immunol, Matsue, Shimane, Japan; [Sekihara, Kazumasa; Tamaki, Yukihisa; Inomata, Taisuke] Shimane Univ, Fac Med, Dept Radiat Oncol, Matsue, Shimane, Japan; [Tongu, Miki] Shimane Univ, Dept Expt Anim, Izumo, Shimane, Japan; [Uchida, Nobue] Tottori Prefectural Cent Hosp, Dept Radiat Oncol, Tottori, Japan	Shimane University; Shimane University; Shimane University	Harada, M (corresponding author), Shimane Univ, Fac Med, Dept Immunol, Matsue, Shimane, Japan.	haramamo@med.shimane-u.ac.jp			Ministry of Education, Culture, Sports, Science, and Technology, Japan [18591449, 23701074]; Shimane University "S-TAKUMI Medical Nanotechnology" Project	Ministry of Education, Culture, Sports, Science, and Technology, Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Shimane University "S-TAKUMI Medical Nanotechnology" Project	This study was supported in part by Grants-in-aid for Scientific Research from the Ministry of Education, Culture, Sports, Science, and Technology, Japan (no. 18591449 to M. Harada and no. 23701074 to N. Harashima), and from Shimane University "S-TAKUMI Medical Nanotechnology" Project (to M. Harada). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aghdassi A, 2007, CANCER RES, V67, P616, DOI 10.1158/0008-5472.CAN-06-1567; Asea A, 2001, INT J HYPERTHER, V17, P347, DOI 10.1080/02656730110053146; Balaburski GM, 2013, MOL CANCER RES, V11, P219, DOI 10.1158/1541-7786.MCR-12-0547-T; Banerji U, 2005, J CLIN ONCOL, V23, P4152, DOI 10.1200/JCO.2005.00.612; Beere HM, 2004, J CELL SCI, V117, P2641, DOI 10.1242/jcs.01284; Cande C, 2004, CELL DEATH DIFFER, V11, P591, DOI 10.1038/sj.cdd.4401400; Colombo R, 2003, J CLIN ONCOL, V21, P4270, DOI 10.1200/JCO.2003.01.089; Daugaard M, 2007, FEBS LETT, V581, P3702, DOI 10.1016/j.febsiet.2007.05.039; Davenport EL, 2010, LEUKEMIA, V24, P1804, DOI 10.1038/leu.2010.168; Dudeja V, 2009, GASTROENTEROLOGY, V136, P1772, DOI 10.1053/j.gastro.2009.01.070; Gabai VL, 1998, FEBS LETT, V438, P1, DOI 10.1016/S0014-5793(98)01242-3; Galluzzi L, 2009, MOL CELL, V36, P176, DOI 10.1016/j.molcel.2009.10.003; Gleave ME, 1999, CAN MED ASSOC J, V160, P225; GRESS TM, 1994, CANCER RES, V54, P547; Haveman J, 2005, ONCOL REP, V14, P561; Jaattela M, 1999, EXP CELL RES, V248, P30, DOI 10.1006/excr.1999.4455; Jemal A, 2009, CA-CANCER J CLIN, V59, P225, DOI 10.3322/caac.20006; Jones EL, 2005, J CLIN ONCOL, V23, P3079, DOI 10.1200/JCO.2005.05.520; Kalapurakal JA, 2003, INT J RADIAT ONCOL, V57, P654, DOI 10.1016/S0360-3016(03)00625-4; Kampinga HH, 2001, INT J RADIAT BIOL, V77, P399, DOI 10.1080/09553000010024687; Kang BH, 2007, CELL, V131, P257, DOI 10.1016/j.cell.2007.08.028; Kouloulias V, 2005, AM J CLIN ONCOL-CANC, V28, P91, DOI 10.1097/01.coc.0000139939.60056.42; Leu JIJ, 2011, MOL CANCER RES, V9, P936, DOI 10.1158/1541-7786.MCR-11-0019; Leu JIJ, 2009, MOL CELL, V36, P15, DOI 10.1016/j.molcel.2009.09.023; Mayer MP, 2005, CELL MOL LIFE SCI, V62, P670, DOI 10.1007/s00018-004-4464-6; Michalakis J, 2007, ANN SURG ONCOL, V14, P1220, DOI 10.1245/s10434-006-9305-4; Monma H, 2013, MOL CANCER THER, V12, P341, DOI 10.1158/1535-7163.MCT-12-0954; Morishima Y, 2000, J BIOL CHEM, V66, P535; Murphy ME, 2013, CARCINOGENESIS, V34, P1181, DOI 10.1093/carcin/bgt111; NAGAI N, 1995, BIOCHEM BIOPH RES CO, V208, P1099, DOI 10.1006/bbrc.1995.1447; Nylandsted J, 2000, ANN NY ACAD SCI, V926, P122; Nylandsted J, 2004, J EXP MED, V200, P425, DOI 10.1084/jem.20040531; Nylandsted J, 2002, CANCER RES, V62, P7139; OVERGAARD J, 1995, LANCET, V345, P540, DOI 10.1016/S0140-6736(95)90463-8; Powers MV, 2008, CANCER CELL, V14, P250, DOI 10.1016/j.ccr.2008.08.002; Ravagnan L, 2001, NAT CELL BIOL, V3, P839, DOI 10.1038/ncb0901-839; Rohde M, 2005, GENE DEV, V19, P570, DOI 10.1101/gad.305405; Roigas J, 1998, PROSTATE, V34, P195; Schmitt E, 2006, CANCER RES, V66, P4191, DOI 10.1158/0008-5472.CAN-05-3778; Strom E, 2006, NAT CHEM BIOL, V2, P474, DOI 10.1038/nchembio809; Tso CL, 2000, CANCER J, V6, P220; van der Zee J, 2000, LANCET, V355, P1119, DOI 10.1016/S0140-6736(00)02059-6	42	45	46	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 14	2013	8	11							e78772	10.1371/journal.pone.0078772	http://dx.doi.org/10.1371/journal.pone.0078772			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	254DJ	24244355	Green Published, Green Submitted, gold			2023-01-03	WOS:000327143800014
J	Smit, M; Smit, C; Geerlings, S; Gras, L; Brinkman, K; Hallett, TB; de Wolf, F				Smit, Mikaela; Smit, Colette; Geerlings, Suzanne; Gras, Luuk; Brinkman, Kees; Hallett, Timothy B.; de Wolf, Frank		Athena Observational Cohort	Changes in First-Line cART Regimens and Short-Term Clinical Outcome between 1996 and 2010 in The Netherlands	PLOS ONE			English	Article							ACTIVE ANTIRETROVIRAL THERAPY; TENOFOVIR DISOPROXIL FUMARATE; NAIVE PATIENTS; HIV-1-INFECTED PATIENTS; COMBINATION THERAPY; GENDER-DIFFERENCES; EFAVIRENZ; MORTALITY; EMTRICITABINE; PROGRESSION	Objectives: Document progress in HIV-treatment in the Netherlands since 1996 by reviewing changing patterns of cART use and relating those to trends in patients' short-term clinical outcomes between 1996 and 2010. Design and Methods: 1996-2010 data from 10,278 patients in the Dutch ATHENA national observational cohort were analysed. The annual number of patients starting a type of regimen was quantified. Trends in the following outcomes were described: i) recovery of 150 CD4 cells/mm(3) within 12 months of starting cART; ii) achieving viral load (VL) suppression <= 1,000 copies/ml within 12 months of starting cART; iii) switching from first-line to second-line regimen within three years of starting treatment; and iv) all-cause mortality rate per 100 person-years within three years of starting treatment. Results: Between 1996 and 2010, first-line regimens changed from lamivudine/zidovudine-based or lamivudine/stavudine-based regimens with unboosted-PIs to tenofovir with either emtricitabine or lamivudine with NNRTIs. Mortality rates did not change significantly over time. VL suppression and CD4 recovery improved over time, and the incidence of switching due to virological failure and toxicity more than halved between 1996 and 2010. These effects appear to be related to the use of new regimens rather than improvements in clinical care. Conclusion: The use of first-line cART in the Netherlands closely follows changes in guidelines, to the benefit of patients. While there was no significant improvement in mortality, newer drugs with better tolerability and simpler dosing resulted in improved immunological and virological recovery and reduced incidences of switching due to toxicity and virological failure.	[Smit, Mikaela; Hallett, Timothy B.; de Wolf, Frank] Univ London Imperial Coll Sci Technol & Med, Dept Infect Dis Epidemiol, Fac Med, London, England; [Smit, Colette; Gras, Luuk; de Wolf, Frank] HIV Monitoring Fdn, Amsterdam, Netherlands; [Geerlings, Suzanne] Dis Amsterdam Med Ctr, Div Infect, Amsterdam, Netherlands; [Brinkman, Kees] Onze Lieve Vrouw Hosp, Dept Internal Med, Amsterdam, Netherlands	Imperial College London; Onze Lieve Vrouwe Gasthuis Hospital	Smit, M (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Infect Dis Epidemiol, Fac Med, London, England.	mikaela.smit@imperial.ac.uk	van der Ven, A.J.A.M./H-8102-2014	van der Ven, A.J.A.M./0000-0003-1833-3391; Warris, Adilia/0000-0001-6586-3358; Hallett, Timothy/0000-0002-9681-0424; Smit, Mikaela/0000-0001-8530-748X; Rijnders, Bart/0000-0003-3343-9610	Medical Research Council; Medical Research Council [MR/K010174/1B, MR/K010174/1] Funding Source: researchfish; MRC [MR/K010174/1] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	MS's PhD is funded by the Medical Research Council. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Arribas JR, 2008, JAIDS-J ACQ IMM DEF, V47, P74, DOI 10.1097/QAI.0b013e31815acab8; Bhaskaran K, 2008, JAMA-J AM MED ASSOC, V300, P51, DOI 10.1001/jama.300.1.51; Bogner JR, 2001, J ACQ IMMUN DEF SYND, V27, P237, DOI 10.1097/00126334-200107010-00004; Carr A, 2000, AIDS, V14, pF25, DOI 10.1097/00002030-200002180-00001; DOLL R, 1954, BMJ-BRIT MED J, V1, P1451, DOI 10.1136/bmj.1.4877.1451; Dube MP, 2002, ANTIVIR THER, V7, pL18; Egger M, 2002, LANCET, V360, P119, DOI 10.1016/S0140-6736(02)09411-4; Elzi L, 2010, ARCH INTERN MED, V170, P57, DOI 10.1001/archinternmed.2009.432; European AIDS Clinical Society, 2011, GUIDELINES; Falco V, 2003, EXPERT OPIN PHARMACO, V4, P1321, DOI 10.1517/14656566.4.8.1321; FDA, 2012, ANT DRUGS US TREATM; Floridia M, 2008, PHARMACOL RES, V58, P173, DOI 10.1016/j.phrs.2008.07.007; Gallant JE, 2006, NEW ENGL J MED, V354, P251, DOI 10.1056/NEJMoa051871; Gallant JE, 2004, JAMA-J AM MED ASSOC, V292, P191, DOI 10.1001/jama.292.2.191; Gilead Sciences, 2009, TRUV; Gilead Sciences and Bristol-Myers Squibb, 2010, ATR; Hernan MA, 2000, EPIDEMIOLOGY, V11, P561, DOI 10.1097/00001648-200009000-00012; Hill A, 2007, EXPERT OPIN PHARMACO, V8, P679, DOI 10.1517/14656566.8.5.679; Kirk O, 1999, AIDS, V13, pF9, DOI 10.1097/00002030-199901140-00002; Ledergerber B, 1999, LANCET, V353, P863, DOI 10.1016/S0140-6736(99)01122-8; Madruga JVR, 2007, HIV CLIN TRIALS, V8, P381, DOI 10.1310/hct0806-381; Martin A, 2004, AIDS, V18, P1029, DOI 10.1097/00002030-200404300-00011; Marzolini C, 2011, J ANTIMICROB CHEMOTH, V66, P2107, DOI 10.1093/jac/dkr248; Mocroft A, 2003, LANCET, V362, P22, DOI 10.1016/S0140-6736(03)13802-0; Mocroft A, 2005, REASONS STOPPING ANT; Monforte AD, 2000, AIDS, V14, P499, DOI 10.1097/00002030-200003310-00005; Nederlandse Verening van HIV-Behandelaren, 2012, RICHTL HIV; Nicastri E, 2005, AIDS, V19, P577, DOI 10.1097/01.aids.0000163934.22273.06; Ofotokun I, 2007, GENDER MED, V4, P106, DOI 10.1016/S1550-8579(07)80025-8; Paredes R, 2000, ARCH INTERN MED, V160, P1123, DOI 10.1001/archinte.160.8.1123; Portsmouth Simon D, 2007, Ther Clin Risk Manag, V3, P579; Pozniak AL, 2006, JAIDS-J ACQ IMM DEF, V43, P535; Prosperi MCF, 2012, BMC INFECT DIS, V12, DOI 10.1186/1471-2334-12-296; Rhone SA, 1998, AIDS, V12, P619, DOI 10.1097/00002030-199806000-00011; Robbins GK, 2003, NEW ENGL J MED, V349, P2293, DOI 10.1056/NEJMoa030264; Robison LS, 2008, AIDS RES HUM RETROV, V24, P1347, DOI 10.1089/aid.2008.0083; Smit M, 2012, AIDS, V26, P1953, DOI 10.1097/QAD.0b013e32835722bd; van Griensven J, 2011, T ROY SOC TROP MED H, V105, P694, DOI 10.1016/j.trstmh.2011.08.007; van Sighem AI, 2003, AIDS, V17, P2227, DOI 10.1097/00002030-200310170-00011; Wandeler G, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027903; Willig JH, 2008, AIDS, V22, P1951, DOI 10.1097/QAD.0b013e32830efd79; Yuan Y, 2006, HIV MED, V7, P156, DOI 10.1111/j.1468-1293.2006.00355.x	42	9	10	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 30	2013	8	9							e76071	10.1371/journal.pone.0076071	http://dx.doi.org/10.1371/journal.pone.0076071			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	231NL	24098764	Green Published, Green Submitted, gold			2023-01-03	WOS:000325423500134
J	Azmat, SK; Shaikh, BT; Hameed, W; Mustafa, G; Hussain, W; Asghar, J; Ishaque, M; Ahmed, A; Bilgrami, M				Azmat, Syed Khurram; Shaikh, Babar Tasneem; Hameed, Waqas; Mustafa, Ghulam; Hussain, Wajahat; Asghar, Jamshaid; Ishaque, Muhammad; Ahmed, Aftab; Bilgrami, Mohsina			Impact of Social Franchising on Contraceptive Use When Complemented by Vouchers: A Quasi-Experimental Study in Rural Pakistan	PLOS ONE			English	Article							PRIVATE-SECTOR; HEALTH; SERVICES; NEED	Background: Pakistan has had a low contraceptive prevalence rate for the last two decades; with preference for natural birth spacing methods and condoms. Family planning services offered by the public sector have never fulfilled the demand for contraception, particularly in rural areas. In the private sector, cost is a major constraint. In 2008, Marie Stopes Society - a local NGO started a social franchise programme along with a free voucher scheme to promote uptake of IUCDs amongst the poor. This paper evaluates the effectiveness of this approach, which is designed to increase modern long term contraceptive awareness and use in rural areas of Pakistan. Methodology: We used a quasi-experimental study design with controls, selecting one intervention district and one control district from the Sindh and Punjab provinces. In each district, we chose a total of four service providers. A baseline survey was carried out among 4,992 married women of reproductive age (MWRA) in February 2009. Eighteen months after the start of intervention, an independent endline survey was conducted among 4,003 women. We used multilevel logistic regression for analysis using Stata 11. Results: Social franchising used alongside free vouchers for long term contraceptive choices significantly increased the awareness of modern contraception. Awareness increased by 5% in the intervention district. Similarly, the ever use of modern contraceptive increased by 28.5%, and the overall contraceptive prevalence rate increased by 19.6%. A significant change (11.1%) was recorded in the uptake of IUCDs, which were being promoted with vouchers. Conclusion: Family planning franchise model promotes awareness and uptake of contraceptives. Moreover, supplemented with vouchers, it may enhance the use of IUCDs, which have a significant cost attached. Our research also supports a multi-pronged approach-generating demand through counselling, overcoming financial constraints by offering vouchers, training, accreditation and branding of the service providers, and ensuring uninterrupted contraceptive supplies.	[Azmat, Syed Khurram; Shaikh, Babar Tasneem; Hameed, Waqas; Mustafa, Ghulam; Hussain, Wajahat; Asghar, Jamshaid; Ishaque, Muhammad; Ahmed, Aftab; Bilgrami, Mohsina] Marie Stopes Soc, Karachi, Pakistan		Shaikh, BT (corresponding author), Marie Stopes Soc, Karachi, Pakistan.	shaikh.babar@gmail.com	Azmat, Syed Khurram/C-7244-2019; Shaikh, Babar Tasneem/J-4900-2017	Shaikh, Babar Tasneem/0000-0002-2056-4132; Azmat, Syed Khurram/0000-0003-0158-8734	Marie Stopes International	Marie Stopes International	Marie Stopes International provided the necessary funding for the research. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ahmed S, 2012, LANCET, V380, P111, DOI 10.1016/S0140-6736(12)60478-4; Azmat SK, 2012, BMC WOMENS HEALTH, V12, DOI 10.1186/1472-6874-12-8; Bank World, 1993, WORLD DEV REP 1993; Basinga P, 2011, B WORLD HEALTH ORGAN, V89, P698, DOI 10.2471/BLT.11.089912; Beyeler N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060669; Chandani T, 2006, PRIVATE PROVIDER NET; Cleland J, 2006, LANCET, V368, P1810, DOI 10.1016/S0140-6736(06)69480-4; Eldridge C, 2009, HEALTH POLICY PLANN, V24, P160, DOI 10.1093/heapol/czp002; Frost N, 2006, SOCIAL FRANCHISING S; Gold RB, 2010, GUTTMACHER POLICY RE, V13; Government of Pakistan, 2011, PAK SURV LIV STAND M; Hafeez A, 2011, J PAK MED ASSOC, V61, P210; Hardee K., 2008, POPULATION ACTION IN, P1; Khan A, 2012, POLICY BRIEFS SERIES, V1; Koehlmoos TP, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007136.pub2; Kumaranayake I, 2000, HEALTH POLICY PLANN, V15, P357, DOI 10.1093/heapol/15.4.357; Lassner K J, 1995, Bull Pan Am Health Organ, V29, P206; Marek T., 2005, TRENDS OPPORTUNITIES; Mills A, 2002, B WORLD HEALTH ORGAN, V80, P325; Montagu D, 2013, INT J EQUITY HEALTH, V12, DOI 10.1186/1475-9276-12-5; National Institute of Population Studies (NIPS) [Pakistan] and Macro International Inc, 2008, PAK DEM HLTH SURV 20; O'Connell K, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028364; Prata N, 2005, B WORLD HEALTH ORGAN, V83, P274; Preker AS, 2000, B WORLD HEALTH ORGAN, V78, P779; Qureshi AM, 2010, BMC INT HEALTH HUM R, V10, P25, DOI [10.1186/1472-698X-10-25, DOI 10.1186/1472-698X-10-25]; Shah NM, 2011, HEALTH POLICY PLANN, V26, pi63, DOI 10.1093/heapol/czr027; Shaikh BT, 2010, OPEN ACCESS J CONTR, V1, P113, DOI 10.2147/OAJC.S13715; Shaikh BT., 2008, WORLD HLTH POPUL, V10, P44; Smith E, 2001, WORKING PRIVATE SECT; Stephenson R, 2004, HEALTH SERV RES, V39, P2053, DOI 10.1111/j.1475-6773.2004.00332.x; Swan M, 1997, PRIVATE PRACTITIONER; Winfrey W, 2000, POLICY PROJECT WORKI, V6; World Health Organization, 2007, PUBL POL FRANCH REPR; World Health Organization, 2000, WORLD HLTH REP 2000	34	37	37	1	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 12	2013	8	9							e74260	10.1371/journal.pone.0074260	http://dx.doi.org/10.1371/journal.pone.0074260			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	242KO	24069287	Green Published, gold, Green Submitted			2023-01-03	WOS:000326240100094
J	Appleton, AA; Armstrong, DA; Lesseur, C; Lee, J; Padbury, JF; Lester, BM; Marsit, CJ				Appleton, Allison A.; Armstrong, David A.; Lesseur, Corina; Lee, Joyce; Padbury, James F.; Lester, Barry M.; Marsit, Carmen J.			Patterning in Placental 11-B Hydroxysteroid Dehydrogenase Methylation According to Prenatal Socioeconomic Adversity	PLOS ONE			English	Article							PSYCHOSOCIAL FACTORS; HEALTH; LIFE; CHILDHOOD; STRESS; IMPACT; GROWTH; RISK; EXPOSURE; PROMOTER	Background: Prenatal socioeconomic adversity as an intrauterine exposure is associated with a range of perinatal outcomes although the explanatory mechanisms are not well understood. The development of the fetus can be shaped by the intrauterine environment through alterations in the function of the placenta. In the placenta, the HSD11B2 gene encodes the 11-beta hydroxysteroid dehydrogenase enzyme, which is responsible for the inactivation of maternal cortisol thereby protecting the developing fetus from this exposure. This gene is regulated by DNA methylation, and this methylation and the expression it controls has been shown to be susceptible to a variety of stressors from the maternal environment. The association of prenatal socioeconomic adversity and placental HSD11B2 methylation has not been examined. Following a developmental origins of disease framework, prenatal socioeconomic adversity may alter fetal response to the postnatal environment through functional epigenetic alterations in the placenta. Therefore, we hypothesized that prenatal socioeconomic adversity would be associated with less HSD11B2 methylation. Methods and Findings: We examined the association between DNA methylation of the HSD11B2 promoter region in the placenta of 444 healthy term newborn infants and several markers of prenatal socioeconomic adversity: maternal education, poverty, dwelling crowding, tobacco use and cumulative risk. We also examined whether such associations were sex-specific. We found that infants whose mothers experienced the greatest levels of socioeconomic adversity during pregnancy had the lowest extent of placental HSD11B2 methylation, particularly for males. Associations were maintained for maternal education when adjusting for confounders (p<0.05). Conclusions: Patterns of HSD11B2 methylation suggest that environmental cues transmitted from the mother during gestation may program the developing fetus's response to an adverse postnatal environment, potentially via less exposure to cortisol during development. Less methylation of placental HSD11B2 may therefore be adaptive and promote the effective management of stress associated with social adversity in a postnatal environment.	[Appleton, Allison A.; Marsit, Carmen J.] Geisel Sch Med Dartmouth, Dept Community & Family Med, Hanover, NH USA; [Armstrong, David A.; Lesseur, Corina; Marsit, Carmen J.] Geisel Sch Med Dartmouth, Dept Pharmacol & Toxicol, Hanover, NH USA; [Lee, Joyce; Padbury, James F.; Lester, Barry M.] Brown Univ, Women & Infants Hosp, Dept Pediat, Providence, RI 02908 USA; [Lee, Joyce; Lester, Barry M.] Brown Univ, Women & Infants Hosp, Brown Ctr Study Children Risk, Providence, RI USA	Dartmouth College; Dartmouth College; Brown University; Women & Infants Hospital Rhode Island; Brown University; Women & Infants Hospital Rhode Island	Appleton, AA (corresponding author), Geisel Sch Med Dartmouth, Dept Community & Family Med, Hanover, NH USA.	Allison.A.Appleton@Dartmouth.edu	Lesseur, Corina/W-1034-2019	Lesseur, Corina/0000-0001-6744-6750; Marsit, Carmen/0000-0003-4566-150X	NIH-NIMH [R01MH094609]; NIH-NIGMS [P20GM103537]; NIH-NCI [R25CA134286]; NATIONAL CANCER INSTITUTE [R25CA134286] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P20GM103537] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH094609] Funding Source: NIH RePORTER	NIH-NIMH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIH-NIGMS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIH-NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))	Funding Sources: NIH-NIMH R01MH094609, NIH-NIGMS P20GM103537, NIH-NCI R25CA134286. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ADLER NE, 1994, AM PSYCHOL, V49, P15, DOI 10.1037/0003-066X.49.1.15; Alegra-Torres JA, 2011, EPIGENOMICS-UK, V3, P267, DOI [10.2217/EPI.11.22, 10.2217/epi.11.22]; Alikhani-Koopaei R, 2004, J CLIN INVEST, V114, P1146, DOI 10.1172/JCI200421647; Almeida ND, 2010, PSYCHOSOM MED, V72, P148, DOI 10.1097/PSY.0b013e3181c925cb; [Anonymous], 2012, FED REG, V77, P4034; Appleton AA, 2013, CIRCULATION, V127, P905, DOI 10.1161/CIRCULATIONAHA.112.115782; As I.F., 2009, FED REG, V74, P4199; Barker DJP, 1998, CLIN SCI, V95, P115, DOI 10.1042/CS19980019; Baum A, 1999, ANN NY ACAD SCI, V896, P131, DOI 10.1111/j.1749-6632.1999.tb08111.x; Braveman PA, 2005, JAMA-J AM MED ASSOC, V294, P2879, DOI 10.1001/jama.294.22.2879; Case A, 2005, J HEALTH ECON, V24, P365, DOI 10.1016/j.jhealeco.2004.09.008; Cottrell EC, 2009, FRONT BEHAV NEUROSCI, V3, DOI 10.3389/neuro.08.019.2009; Cuffe JSM, 2012, ENDOCRINOLOGY, V153, P5500, DOI 10.1210/en.2012-1479; Evans GW, 2012, PEDIATRICS, V129, pE68, DOI 10.1542/peds.2010-3647; Fenton Tanis R, 2003, BMC Pediatr, V3, P13; Friso S, 2008, ATHEROSCLEROSIS, V199, P323, DOI 10.1016/j.atherosclerosis.2007.11.029; Gilbert JS, 2008, AM J PHYSIOL-REG I, V295, pR1941, DOI 10.1152/ajpregu.90724.2008; Gluckman PD, 2007, AM J HUM BIOL, V19, P1, DOI 10.1002/ajhb.20590; Hackman DA, 2010, NAT REV NEUROSCI, V11, P651, DOI 10.1038/nrn2897; Joseph KS, 2007, CAN MED ASSOC J, V177, P583, DOI 10.1503/cmaj.061198; Kramer MS, 2000, PAEDIATR PERINAT EP, V14, P194, DOI 10.1046/j.1365-3016.2000.00266.x; Lam LL, 2012, P NATL ACAD SCI USA, V109, P17253, DOI 10.1073/pnas.1121249109; Lesage J, 2001, ENDOCRINOLOGY, V142, P1692, DOI 10.1210/en.142.5.1692; Lester BM, 2011, ANN NY ACAD SCI, V1226, P14, DOI 10.1111/j.1749-6632.2011.06037.x; Lester BM, 2009, DEV NEUROSCI, P31; Mairesse J, 2007, AM J PHYSIOL-ENDOC M, V292, pE1526, DOI 10.1152/ajpendo.00574.2006; Marsit CJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033794; Matthews KA, 2010, ANN NY ACAD SCI, V1186, P146, DOI 10.1111/j.1749-6632.2009.05332.x; Meaney Michael J, 2005, Dialogues Clin Neurosci, V7, P103; Mulligan CJ, 2012, EPIGENETICS-US, V7, P853, DOI 10.4161/epi.21180; Mychasiuk R, 2011, NEUROSCIENCE, V180, P105, DOI 10.1016/j.neuroscience.2011.02.026; O'Donnell KJ, 2012, PSYCHONEUROENDOCRINO, V37, P818, DOI 10.1016/j.psyneuen.2011.09.014; Pena C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039071; Power C, 2005, AM J PUBLIC HEALTH, V95, P1396, DOI 10.2105/AJPH.2004.047340; Raat H, 2011, EARLY HUM DEV, V87, P729, DOI 10.1016/j.earlhumdev.2011.08.022; Radtke KM, 2011, TRANSL PSYCHIAT, V1, DOI 10.1038/tp.2011.21; Repetti RL, 2002, PSYCHOL BULL, V128, P330, DOI 10.1037/0033-2909.128.2.330; Robins Jared C, 2011, Front Biosci (Elite Ed), V3, P690, DOI 10.2741/e279; Rothman KJ, 1998, MODERN EPIDEMIOLOGY; Rucklidge JJ, 2010, PSYCHIAT CLIN N AM, V33, P357, DOI 10.1016/j.psc.2010.01.006; Schlotz W, 2009, BRAIN BEHAV IMMUN, V23, P905, DOI 10.1016/j.bbi.2009.02.001; Sebelius K, 2010, FED REGISTER, V75, P45628; Sebelius K, 2011, FED REGISTER, V76, P3637; Shonkoff J.P., 2000, NEURONS NEIGHBORHOOD, DOI [10.17226/9824, DOI 10.17226/9824]; Staud F, 2006, PLACENTA, V27, P171, DOI 10.1016/j.placenta.2005.01.001; Tehranifar P, 2013, EPIGENETICS-US, V8, P23, DOI 10.4161/epi.22989; van den Berg G, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037002; Waterland RA, 2007, ANNU REV NUTR, V27, P363, DOI 10.1146/annurev.nutr.27.061406.093705; Weaver ICG, 2004, NAT NEUROSCI, V7, P847, DOI 10.1038/nn1276; Wyrwoll CS, 2011, FRONT NEUROENDOCRIN, V32, P265, DOI 10.1016/j.yfrne.2010.12.001	50	100	101	0	17	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 5	2013	8	9							e74691	10.1371/journal.pone.0074691	http://dx.doi.org/10.1371/journal.pone.0074691			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	219CG	24040322	Green Published, gold, Green Submitted			2023-01-03	WOS:000324481600144
J	Li, QH; Kawamura, K; Yang, S; Okamoto, S; Kobayashi, H; Tada, Y; Sekine, I; Takiguchi, Y; Shingyouji, M; Tatsumi, K; Shimada, H; Hiroshima, K; Tagawa, M				Li, Quanhai; Kawamura, Kiyoko; Yang, Shan; Okamoto, Shinya; Kobayashi, Hiroshi; Tada, Yuji; Sekine, Ikuo; Takiguchi, Yuichi; Shingyouji, Masato; Tatsumi, Koichiro; Shimada, Hideaki; Hiroshima, Kenzo; Tagawa, Masatoshi			Interferon-beta Produces Synergistic Combinatory Anti-Tumor Effects with Cisplatin or Pemetrexed on Mesothelioma Cells	PLOS ONE			English	Article							MALIGNANT PLEURAL MESOTHELIOMA; I INTERFERON; GENE-TRANSFER; P53; APOPTOSIS; TRIAL; SENSITIVITY; ALPHA/BETA; MECHANISMS; PATHWAYS	Interferons (IFNs) have been tested for the therapeutic effects in various types of malignancy, but mechanisms of the anti-tumors effects and the differential biological activities among IFN members are dependent on respective cell types. In this study, we examined growth inhibitory activities of type I and III IFNs on 5 kinds of human mesothelioma cells bearing wild-type p53 gene, and showed that type I IFNs but not type III IFNs decreased the cell viabilities. Moreover, growth inhibitory activities and up-regulated expression levels of the major histocompatibility complexes class I antigens were greater with IFN-beta than with IFN-alpha treatments. Cell cycle analyses demonstrated that type I IFNs increased S-and G2/M-phase populations, and subsequently sub-G1-phase fractions. The cell cycle changes were also greater with IFN-beta than IFN-alpha treatments, and these data collectively showed that IFN-beta had stronger biological activities than IFN-alpha in mesothelioma. Type I IFNs-treated cells increased p53 expression and the phosphorylation levels, and activated apoptotic pathways. A combinatory use of IFN-beta and cisplatin or pemetrexed, both of which are the current first-line chemotherapeutic agents for mesothelioma, produced synergistic anti-tumor effects, which were also evidenced by increased sub-G1-phase fractions. These data demonstrated firstly to our knowledge that IFN-beta produced synergistic anti-tumor effects with cisplatin or pemetrexed on mesothelioma through up-regulated p53 expression.	[Li, Quanhai; Kawamura, Kiyoko; Yang, Shan; Tagawa, Masatoshi] Chiba Canc Ctr, Res Inst, Div Pathol & Cell Therapy, Chiba 2608717, Japan; [Li, Quanhai; Yang, Shan; Tagawa, Masatoshi] Chiba Univ, Grad Sch Med, Dept Mol Biol & Oncol, Chiba, Japan; [Okamoto, Shinya; Kobayashi, Hiroshi] Chiba Univ, Grad Sch Pharmaceut Sci, Dept Biochem, Chiba, Japan; [Tada, Yuji; Tatsumi, Koichiro] Chiba Univ, Grad Sch Med, Dept Respirol, Chiba, Japan; [Sekine, Ikuo; Takiguchi, Yuichi] Chiba Univ, Grad Sch Med, Dept Med Oncol, Chiba, Japan; [Shingyouji, Masato] Chiba Canc Ctr, Res Inst, Div Thorac Dis, Chiba 2608717, Japan; [Shimada, Hideaki] Toho Univ, Dept Surg, Sch Med, Tokyo, Japan; [Hiroshima, Kenzo] Tokyo Womens Med Univ, Dept Pathol, Yachiyo Med Ctr, Yachiyo, Japan	Chiba Cancer Center; Chiba University; Chiba University; Chiba University; Chiba University; Chiba Cancer Center; Toho University; Tokyo Women's Medical University	Tagawa, M (corresponding author), Chiba Canc Ctr, Res Inst, Div Pathol & Cell Therapy, 666-2 Nitonacho, Chiba 2608717, Japan.	mtagawa@chiba-cc.jp			Ministry of Education, Culture, Sports, Science and Technology of Japan; Ministry of Health, Labor and Welfare of Japan; Nichias Corporation; Grants-in-Aid for Scientific Research [23591136] Funding Source: KAKEN	Ministry of Education, Culture, Sports, Science and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Ministry of Health, Labor and Welfare of Japan(Ministry of Health, Labour and Welfare, Japan); Nichias Corporation; Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	Grants-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology of Japan, the Grant-in-Aid for Research on seeds for Publicly Essential Drugs and Medical Devices from the Ministry of Health, Labor and Welfare of Japan, and a Grant-in-aid from the Nichias Corporation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Carbone M, 2002, SEMIN ONCOL, V29, P2, DOI 10.1053/sonc.2002.30227; de Weerd NA, 2007, J BIOL CHEM, V282, P20053, DOI 10.1074/jbc.R700006200; Deshpande A, 2005, ONCOGENE, V24, P2909, DOI 10.1038/sj.onc.1208618; Fujie H, 2011, CANCER SCI, V102, P1977, DOI 10.1111/j.1349-7006.2011.02079.x; George PM, 2012, PHARMACOL THERAPEUT, V135, P44, DOI 10.1016/j.pharmthera.2012.03.006; Giovannetti E, 2007, BRIT J CANCER, V96, P769, DOI 10.1038/sj.bjc.6603639; Halme M, 1999, BRIT J CANCER, V80, P1781, DOI 10.1038/sj.bjc.6690597; KE Y, 1989, AM J PATHOL, V134, P979; La QH, 2010, EUR J CANCER, V46, P180, DOI 10.1016/j.ejca.2009.10.002; Lee AY, 2007, CANCER-AM CANCER SOC, V109, P1454, DOI 10.1002/cncr.22552; Li MC, 2009, J LEUKOCYTE BIOL, V86, P23, DOI [10.1189/jlb.1208761, 10.1189/JLB.1208761]; Li Q, 2012, CANCER GENE THER, V19, P218, DOI 10.1038/cgt.2011.86; Lu XH, 2001, CLIN CANCER RES, V7, P2114; Metintas M, 1999, CHEST, V116, P391, DOI 10.1378/chest.116.2.391; Parra HS, 2001, CANCER, V92, P650, DOI 10.1002/1097-0142(20010801)92:3<650::AID-CNCR1366>3.0.CO;2-0; Pokrovskaja K, 2005, J INTERF CYTOK RES, V25, P799, DOI 10.1089/jir.2005.25.799; Robinson BWS, 2005, LANCET, V366, P397, DOI 10.1016/S0140-6736(05)67025-0; Sandoval R, 2004, J BIOL CHEM, V279, P32275, DOI 10.1074/jbc.M313830200; Sangfelt O, 1999, ONCOGENE, V18, P2798, DOI 10.1038/sj.onc.1202609; Satyanarayana A, 2009, ONCOGENE, V28, P2925, DOI 10.1038/onc.2009.170; Sterman DH, 2007, CLIN CANCER RES, V13, P4456, DOI 10.1158/1078-0432.CCR-07-0403; Sterman DH, 2011, AM J RESP CRIT CARE, V184, P1395, DOI 10.1164/rccm.201103-0554CR; Takaoka A, 2003, NATURE, V424, P516, DOI 10.1038/nature01850; Vannucchi S, 2005, ONCOGENE, V24, P2536, DOI 10.1038/sj.onc.1208403; Vogelzang NJ, 2003, J CLIN ONCOL, V21, P2636, DOI 10.1200/JCO.2003.11.136; Yang TY, 2013, MOL CARCINOGEN, V52, P183, DOI 10.1002/mc.21842; Zhang SY, 2008, IMMUNOL REV, V226, P29, DOI 10.1111/j.1600-065X.2008.00698.x; Zucali PA, 2011, CANCER TREAT REV, V37, P543, DOI 10.1016/j.ctrv.2011.01.001	28	5	5	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 16	2013	8	8							e72709	10.1371/journal.pone.0072709	http://dx.doi.org/10.1371/journal.pone.0072709			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	207BA	23977343	Green Published, gold, Green Submitted			2023-01-03	WOS:000323570200081
J	Chen, XG; Jiao, JH; Cong, XF; Liu, L; Wu, XM				Chen, Xiaoguang; Jiao, Jinghua; Cong, Xuefeng; Liu, Lei; Wu, Xiaomei			A Comparison of the Performance of the I-gel (TM) vs. the LMA-S (TM) during Anesthesia: A Meta-Analysis of Randomized Controlled Trials	PLOS ONE			English	Article							NON-PARALYZED PATIENTS; LMA SUPREME(TM); ANESTHETIZED PATIENTS; SUPRAGLOTTIC AIRWAY; ADULT PATIENTS; SURGERY; QUALITY	Background and Objective: Conflicting results were found between the I-gel (TM) and the LMA-Supreme (TM) during anesthesia, so we conducted a meta-analysis of randomized controlled trials (RCTs) to compare the effectiveness and safety of the I-gel (TM) vs. the LMA-Supreme (TM) during anesthesia. Methods: A comprehensive search was conducted using Pubmed, EMbase, ISI Web of Knowledge, the Cochrane Library, China Journal Full-text Database, Chinese Biomedical Database, Chinese Scientific Journals Full-text Database, CMA Digital Periodicals, and Google scholar to find RCTs that compare the LMA-S (TM) with the i-gel (TM) during anesthesia. Two reviewers independently selected trials, extracted data, and assessed the methodological qualities and evidence levels. Data were analyzed by RevMan 5.0 and comprehensive meta-analysis software. Results: Ten RCTs were included. There were no significant differences in oropharyngeal leak pressures (mean difference [MD] 0.72, 95% confidence interval [CI] -1.10 2.53), device placement time (MD -1.3, 95% CI -4.07 1.44), first attempt insertion success (risk ratio [RR] 1.01, 95% CI 0.9 1.14), grade 3 and 4 fiberoptic view (RR 0.89, 95% CI 0.65 1.21), and blood on removal (RR 0.62, 95% CI 0.32 1.22) between the i-gel (TM) and the LMA-Supreme (TM), respectively. However, the LMA-Supreme (TM) was associated with easier gastric tube insertion (RR 1.17, 95% CI 1.07 1.29), and more sore throat (RR 2.56, 95% CI 1.60 4.12) than the i-gel (TM) group. Conclusions: The LMA-Supreme (TM) and i-gel (TM) were similarly successful and rapidly inserted. However, the LMA-Supreme (TM) was shown to be easier for gastric tube insertion and associated with more sore throat compared with the i-gel (TM).	[Chen, Xiaoguang] China Med Univ, Hosp 1, Dept Anesthesiol, Shenyang, Peoples R China; [Jiao, Jinghua] Shengyang Med Coll, Fengtian Hosp, Dept Anesthesiol, Shenyang, Peoples R China; [Cong, Xuefeng] First Hosp Shenyang, Dept Neurosurg, Shenyang, Peoples R China; [Liu, Lei] China Med Univ, Hosp 1, Dept Ophthalmol, Shenyang, Peoples R China; [Wu, Xiaomei] China Med Univ, Hosp 1, Dept Clin Epidemiol & Evidence Med, Shenyang, Peoples R China	China Medical University; Shenyang Medical College; China Medical University; China Medical University	Chen, XG (corresponding author), China Med Univ, Hosp 1, Dept Anesthesiol, Shenyang, Peoples R China.	chenxiaoguangcxf@163.com						CAO J-B, 2012, J CHINESE PLA POSTGR, V33, P362; Chew EFF, 2010, ANAESTH INTENS CARE, V38, P1018, DOI 10.1177/0310057X1003800609; Cook TM, 2009, ANAESTHESIA, V64, P555, DOI 10.1111/j.1365-2044.2008.05824.x; Doi SAR, 2008, EPIDEMIOLOGY, V19, P94, DOI 10.1097/EDE.0b013e31815c24e7; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Eschertzhuber S, 2009, ANAESTHESIA, V64, P79, DOI 10.1111/j.1365-2044.2008.05682.x; Gatward JJ, 2008, ANAESTHESIA, V63, P1124, DOI 10.1111/j.1365-2044.2008.05561.x; Helmy AM, 2010, SAUDI J ANAESTH, V4, P131, DOI 10.4103/1658-354X.71250; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Higgins JPT, COCHRANE HDB SYSTEMA, P4; Levitan RM, 2005, ANAESTHESIA, V60, P1022, DOI 10.1111/j.1365-2044.2005.04258.x; Mann V, 2012, ANAESTHESIA, V67, P1260, DOI 10.1111/j.1365-2044.2012.07303.x; Moher D, 2009, J CLIN EPIDEMIOL, V62, P1006, DOI 10.1016/j.jclinepi.2009.06.005; Ragazzi R, 2012, ANAESTHESIA, V67, P384, DOI 10.1111/j.1365-2044.2011.07002.x; Russo SG, 2012, BMC ANESTHESIOL, V12, DOI 10.1186/1471-2253-12-18; Schunemann HJ, 2006, AM J RESP CRIT CARE, V174, P605, DOI 10.1164/rccm.200602-197ST; Sharma V, 2010, BRIT J ANAESTH, V105, P228, DOI 10.1093/bja/aeq118; Teoh WHL, 2010, ANAESTHESIA, V65, P1173, DOI 10.1111/j.1365-2044.2010.06534.x; Theiler LG, 2009, ANESTHESIOLOGY, V111, P55, DOI 10.1097/ALN.0b013e3181a4c6b9; Tiesmeier J, 2011, RESUSCITATION, V82, P1358, DOI 10.1016/j.resuscitation.2011.07.004; Timmermann A, 2009, ANESTHESIOLOGY, V110, P262, DOI 10.1097/ALN.0b013e3181942c4d; van Zundert A, 2008, ANAESTHESIA, V63, P209, DOI 10.1111/j.1365-2044.2007.05421.x; van Zundert TCRV, 2012, ACTA ANAESTH BELG, V63, P35; Verghese C, 2008, BRIT J ANAESTH, V101, P405, DOI 10.1093/bja/aen174; [喻震 YU Zhen], 2011, [中华麻醉学杂志, Chinese Journal of Anesthesiology], V31, P223; 黎阳, 2011, [中华麻醉学杂志, Chinese Journal of Anesthesiology], V31, P1146	26	22	23	1	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 12	2013	8	8							e71910	10.1371/journal.pone.0071910	http://dx.doi.org/10.1371/journal.pone.0071910			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	200UV	23951266	Green Published, Green Submitted, gold			2023-01-03	WOS:000323097300170
J	Chtourou, H; Aloui, A; Hammouda, O; Chaouachi, A; Chamari, K; Souissi, N				Chtourou, Hamdi; Aloui, Asma; Hammouda, Omar; Chaouachi, Anis; Chamari, Karim; Souissi, Nizar			Effect of Static and Dynamic Stretching on the Diurnal Variations of Jump Performance in Soccer Players	PLOS ONE			English	Article							TIME-OF-DAY; PROPRIOCEPTIVE NEUROMUSCULAR FACILITATION; TERM EXERCISE PERFORMANCES; WARM-UP; WINGATE TEST; STRENGTH; MUSCLE; FORCE; POWER; MECHANISMS	Purpose: The present study addressed the lack of data on the effect of different types of stretching on diurnal variations in vertical jump height -i.e., squat-jump (SJ) and countermovement-jump (CMJ). We hypothesized that dynamic stretching could affect the diurnal variations of jump height by producing a greater increase in short-term maximal performance in the morning than the evening through increasing core temperature at this time-of-day. Methods: Twenty male soccer players (age, 18.6 +/- 1.3 yrs; height, 174.6 +/- 3.8 cm; body-mass, 71.1 +/- 8.6 kg; mean +/- SD) completed the SJ and CMJ tests either after static stretching, dynamic stretching or no-stretching protocols at two times of day, 07: 00 h and 17: 00 h, with a minimum of 48 hours between testing sessions. One minute after warming-up for 5 minutes by light jogging and performing one of the three stretching protocols (i.e., static stretching, dynamic stretching or no-stretching) for 8 minutes, each subject completed the SJ and CMJ tests. Jumping heights were recorded and analyzed using a two-way analysis of variance with repeated measures (3 [stretching] x2 [time-of-day]). Results: The SJ and CMJ heights were significantly higher at 17: 00 than 07: 00 h (p<0.01) after the no-stretching protocol. These daily variations disappeared (i.e., the diurnal gain decreased from 4.2 +/- 2.81% (p<0.01) to 1.81 +/- 4.39% (not-significant) for SJ and from 3.99 +/- 3.43% (p<0.01) to 1.51 +/- 3.83% (not-significant) for CMJ) after dynamic stretching due to greater increases in SJ and CMJ heights in the morning than the evening (8.4 +/- 6.36% vs. 4.4 +/- 2.64%, p<0.05 for SJ and 10.61 +/- 5.49% vs. 6.03 +/- 3.14%, p<0.05 for CMJ). However, no significant effect of static stretching on the diurnal variations of SJ and CMJ heights was observed. Conclusion: Dynamic stretching affects the typical diurnal variations of SJ and CMJ and helps to counteract the lower morning values in vertical jump height.	[Chtourou, Hamdi; Aloui, Asma; Hammouda, Omar; Chaouachi, Anis; Chamari, Karim; Souissi, Nizar] Natl Ctr Med & Sci Sport CNMSS, Res Lab Sport Performance Optimizat, Tunis, Tunisia; [Chtourou, Hamdi] Sfax Univ, High Inst Sport & Phys Educ, Res Unit EM2S, Sfax, Tunisia; [Chamari, Karim] Qatar Orthoped & Sports Med Hosp, Res & Educ Ctr, Aspetar, Doha, Qatar; [Souissi, Nizar] Manouba Univ, High Inst Sport & Phys Educ, Manouba, Tunisia	Centre National de la Medecine Sciences des Sports; Universite de Sfax; Aspetar Orthopaedic & Sports Medicine Hospital; Universite de la Manouba	Chtourou, H (corresponding author), Natl Ctr Med & Sci Sport CNMSS, Res Lab Sport Performance Optimizat, Tunis, Tunisia.	h_chtourou@yahoo.fr	Chtourou, Hamdi/GVU-1967-2022; CHAMARI, Karim/AAJ-7938-2021; Aloui, Asma/J-1300-2019; Nizar, Souissi/AAF-4490-2019	Chtourou, Hamdi/0000-0002-5482-9151; CHAMARI, Karim/0000-0001-9178-7678; Aloui, Asma/0000-0001-5054-1540; Nizar, Souissi/0000-0003-1227-8221; HAMMOUDA, Omar/0000-0002-5002-687X	Ministry of Higher Education and Scientific Research, Tunisia	Ministry of Higher Education and Scientific Research, Tunisia	The authors wish to thank Prof. Jim Waterhouse who checked the English of the manuscript. This study was supported by the Ministry of Higher Education and Scientific Research, Tunisia. We are grateful to all the players who participated so willingly in the study.	Aloui A, 2013, INT J SPORT PHYSIOL, V8, P254, DOI 10.1123/ijspp.8.3.254; Behm DG, 2011, EUR J APPL PHYSIOL, V111, P2633, DOI 10.1007/s00421-011-1879-2; Behm DG, 2006, J SPORT SCI MED, V5, P33; Bishop D, 2003, SPORTS MED, V33, P439, DOI 10.2165/00007256-200333060-00005; Bougard C, 2009, CHRONOBIOL INT, V26, P307, DOI 10.1080/07420520902774532; Bradley PS, 2007, J STRENGTH COND RES, V21, P223, DOI 10.1519/00124278-200702000-00040; Chamari K, 2004, BRIT J SPORT MED, V38, P191, DOI 10.1136/bjsm.2002.004374; Christensen BK, 2008, J STRENGTH COND RES, V22, P1826, DOI 10.1519/JSC.0b013e31817ae316; Chtourou H, 2012, INT J SPORTS MED, V33, P142, DOI 10.1055/s-0031-1286251; Chtourou H, 2012, INT J SPORTS MED, V33, P43, DOI 10.1055/s-0031-1284398; Chtourou H., 2013, J NOV PHYSIOTHER, V3, P160, DOI [10.4172/2165-7025.1000160, DOI 10.4172/2165-7025.1000160]; Chtourou H, 2012, SCI SPORT, V27, P85, DOI [10.1016/j.scispo.2012.02.006, DOI 10.1016/J.SCISPO.2012.02.006]; Chtourou H, 2013, BIOL RHYTHM RES, V44, P797, DOI 10.1080/09291016.2012.756269; Chtourou Hamdi, 2012, Asian J Sports Med, V3, P139; Chtourou H, 2012, J STRENGTH COND RES, V26, P1984, DOI 10.1519/JSC.0b013e31825770a7; Chtourou H, 2012, J STRENGTH COND RES, V26, P697, DOI 10.1519/JSC.0b013e3182281c87; Chtourou Hamdi, 2011, Asian J Sports Med, V2, P177; Chtourou H, 2012, J STRENGTH COND RES, V26, P217, DOI 10.1519/JSC.0b013e31821d5e8d; Chtourou H, 2011, CHRONOBIOL INT, V28, P706, DOI 10.3109/07420528.2011.596295; Cornwell A, 2001, J HUM MOVEMENT STUD, V40, P307; Dalrymple KJ, 2010, J STRENGTH COND RES, V24, P149, DOI 10.1519/JSC.0b013e3181b29614; Fletcher IM, 2010, APPL PHYSIOL NUTR ME, V35, P27, DOI 10.1139/H09-125; Fowles JR, 2000, J APPL PHYSIOL, V89, P1179, DOI 10.1152/jappl.2000.89.3.1179; Gauthier A, 1996, CHRONOBIOL INT, V13, P135, DOI 10.3109/07420529609037077; Hammouda O, 2011, CHRONOBIOL INT, V28, P958, DOI 10.3109/07420528.2011.613683; Hamouda O, 2012, BIOL RHYTHM RES, V43, P177, DOI 10.1080/09291016.2011.560050; Holt BW, 2008, J STRENGTH COND RES, V22, P226, DOI 10.1519/JSC.0b013e31815f9d6a; HORNE J A, 1976, International Journal of Chronobiology, V4, P97; Hough PA, 2009, J STRENGTH COND RES, V23, P507, DOI 10.1519/JSC.0b013e31818cc65d; Jaggers JR, 2008, J STRENGTH COND RES, V22, P1844, DOI 10.1519/JSC.0b013e3181854a3d; Marek SM, 2005, J ATHL TRAINING, V40, P94; Gonzalez-Rave JM, 2009, J STRENGTH COND RES, V23, P472, DOI 10.1519/JSC.0b013e318198f912; Martin A, 1999, MUSCLE NERVE, V22, P1380, DOI 10.1002/(SICI)1097-4598(199910)22:10<1380::AID-MUS7>3.3.CO;2-L; McNeal JR, 2003, PEDIATR EXERC SCI, V15, P139, DOI 10.1123/pes.15.2.139; Nelson AG, 2001, J STRENGTH COND RES, V15, P241; Nicolas A, 2005, CHRONOBIOL INT, V22, P997, DOI 10.1080/07420520500397892; Pearce AJ, 2009, EUR J APPL PHYSIOL, V105, P175, DOI 10.1007/s00421-008-0887-3; Robbins JW, 2008, J STRENGTH COND RES, V22, P781, DOI 10.1519/JSC.0b013e31816a59a9; Samuel MN, 2008, J STRENGTH COND RES, V22, P1422, DOI 10.1519/JSC.0b013e318181a314; Souissi H, 2012, J SPORT SCI MED, V11, P380; Souissi H, 2012, PEDIATR EXERC SCI, V24, P84, DOI 10.1123/pes.24.1.84; Souissi H, 2010, PEDIATR EXERC SCI, V22, P613, DOI 10.1123/pes.22.4.613; Souissi M, 2013, BIOL RHYTHM RES, V44, P245, DOI 10.1080/09291016.2012.667981; Souissi M, 2012, BIOL RHYTHM RES, V43, P323, DOI 10.1080/09291016.2011.589159; Souissi N, 2004, INT J SPORTS MED, V25, P14; Souissi N, 2010, CHRONOBIOL INT, V27, P640, DOI 10.3109/07420528.2010.483157; Torres EM, 2008, J STRENGTH COND RES, V22, P1279, DOI 10.1519/JSC.0b013e31816eb501; Turki-Belkhiria L, 2014, EUR J SPORT SCI, V14, P19, DOI 10.1080/17461391.2012.726651; Unick J, 2005, J STRENGTH COND RES, V19, P206; Wallmann HW, 2005, J STRENGTH COND RES, V19, P684; Waterhouse J, 2005, CHRONOBIOL INT, V22, P207, DOI 10.1081/CBI-200053477; Yamaguchi T, 2005, J STRENGTH COND RES, V19, P677; Young WB, 2003, J SPORT MED PHYS FIT, V43, P21; Young WB, 2002, STRENGTH COND J, V24, P33, DOI 10.1519/1533-4295(2002)024<0033:SSSBUD>2.0.CO;2; Zarrouk N, 2012, INT J SPORTS MED, V33, P975, DOI 10.1055/s-0032-1312626; Zarrouk N, 2012, SCI SPORT, V27, P101, DOI 10.1016/j.scispo.2011.07.002	56	28	29	0	60	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 5	2013	8	8							e70534	10.1371/journal.pone.0070534	http://dx.doi.org/10.1371/journal.pone.0070534			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	218XC	23940589	gold, Green Published, Green Submitted			2023-01-03	WOS:000324465000083
J	Li, JH; Loukili, N; Rosenblatt-Velin, N; Pacher, P; Feihl, F; Waeber, B; Liaudet, L				Li, Jianhui; Loukili, Noureddine; Rosenblatt-Velin, Nathalie; Pacher, Pal; Feihl, Francois; Waeber, Bernard; Liaudet, Lucas			Peroxynitrite Is a Key Mediator of the Cardioprotection Afforded by Ischemic Postconditioning In Vivo	PLOS ONE			English	Article							REPERFUSION INJURY; NITRIC-OXIDE; REACTIVE OXYGEN; MYOCARDIAL-INFARCTION; MECHANISM; HEART; VITRO; ACTIVATION; PROTECTS; RECEPTOR	Myocardial ischemic postconditioning (PosC) describes an acquired resistance to lethal ischemia-reperfusion (I/R) injury afforded by brief episodes of I/R applied immediately after the ischemic insult. Cardioprotection is conveyed by parallel signaling pathways converging to prevent mitochondria permeability transition. Recent observations indicated that PostC is associated with free radicals generation, including nitric oxide (NO.) and superoxide (O-2.(-)), and that cardioprotection is abrogated by antioxidants. Since NO. And O-2.(-) react to form peroxynitrite, we hypothesized that postC might trigger the formation of peroxyntrite to promote cardioprotection in vivo. Rats were exposed to 45 min of myocardial ischemia followed by 3h reperfusion. PostC (3 cycles of 30 seconds ischemia/30 seconds reperfusion) was applied at the end of index ischemia. In a subgroup of rats, the peroxynitrite decomposition catalyst 5,10,15,20-tetrakis(4-sulphonatophenyl) porphyrinato iron (FeTPPS) was given intravenously (10 mg/kg(-1)) 5 minutes before PostC. Myocardial nitrotyrosine was determined as an index of peroxynitrite formation. Infarct size (colorimetric technique and plasma creatine kinase-CK-levels) and left ventricle (LV) function (micro-tip pressure transducer), were determined. A significant generation of 3-nitrotyrosine was detected just after the PostC manoeuvre. PostC resulted in a marked reduction of infarct size, CK release and LV systolic dysfunction. Treatment with FeTPPS before PostC abrogated the beneficial effects of PostC on myocardial infarct size and LV function. Thus, peroxynitrite formed in the myocardium during PostC induces cardioprotective mechanisms improving both structural and functional integrity of the left ventricle exposed to ischemia and reperfusion in vivo.	[Li, Jianhui] Zhejiang Univ, Coll Med, Affiliated Hosp 1, Dept Hepatobiliary Surg, Hangzhou 310003, Zhejiang, Peoples R China; [Li, Jianhui; Loukili, Noureddine; Liaudet, Lucas] Univ Lausanne Hosp, Med Ctr, Dept Intens Care Med, Lausanne, Switzerland; [Li, Jianhui; Loukili, Noureddine; Liaudet, Lucas] Univ Lausanne Hosp, Med Ctr, Burn Ctr, Lausanne, Switzerland; [Rosenblatt-Velin, Nathalie; Feihl, Francois; Waeber, Bernard; Liaudet, Lucas] Univ Lausanne Hosp, Med Ctr, Dept Internal Med, Div Clin Pathophysiol, Lausanne, Switzerland; [Pacher, Pal] NIAAA, Lab Physiol Studies, NIH, Bethesda, MD USA	Zhejiang University; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); National Institutes of Health (NIH) - USA; NIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)	Liaudet, L (corresponding author), Univ Lausanne Hosp, Med Ctr, Dept Intens Care Med, Lausanne, Switzerland.	lucas.liaudet@chuv.ch	Liaudet, Lucas/E-1322-2017; Pacher, Pal/B-6378-2008	Liaudet, Lucas/0000-0003-2670-4930; Pacher, Pal/0000-0001-7036-8108; Rosenblatt, Nathalie/0000-0003-2011-2862	Swiss National Fund for Scientific Research [320000/118174]; National Natural Science Foundation of China [81000137]; Qianjiang Talent Program of Zhejiang Province, China [2012R10045]; Scientific Research program for the Returned Overseas Chinese Scholars, Ministry of Health, Zhejiang Province, China [491010-G51104]; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [ZIAAA000375] Funding Source: NIH RePORTER	Swiss National Fund for Scientific Research(Swiss National Science Foundation (SNSF)); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Qianjiang Talent Program of Zhejiang Province, China; Scientific Research program for the Returned Overseas Chinese Scholars, Ministry of Health, Zhejiang Province, China; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))	This work was supported, in part, by a grant from the Swiss National Fund for Scientific Research (Nr 320000/118174) to Lucas Liaudet and grants from the National Natural Science Foundation of China (Nr 81000137), the Qianjiang Talent Program of Zhejiang Province, China (Nr2012R10045), and the Scientific Research program for the Returned Overseas Chinese Scholars, Ministry of Health, Zhejiang Province, China (Nr 491010-G51104) to Jianhui Li. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Altug S, 2000, BRIT J PHARMACOL, V130, P125, DOI 10.1038/sj.bjp.0703280; Altup S, 2001, EUR J PHARMACOL, V415, P239, DOI 10.1016/S0014-2999(01)00843-3; Balafanova Z, 2002, J BIOL CHEM, V277, P15021, DOI 10.1074/jbc.M112451200; Cohen MV, 2011, ANTIOXID REDOX SIGN, V14, P821, DOI 10.1089/ars.2010.3318; Duplain H, 2008, J PHYSIOL-LONDON, V586, P4011, DOI 10.1113/jphysiol.2008.154302; Fantinelli JC, 2007, MOL CELL BIOCHEM, V296, P45, DOI 10.1007/s11010-006-9296-2; Ferdinandy P, 2003, BRIT J PHARMACOL, V138, P532, DOI 10.1038/sj.bjp.0705080; Figueira TR, 2013, ANTIOXID REDOX SIGN, V18, P2029, DOI 10.1089/ars.2012.4729; GONZALEZFLECHA B, 1993, J CLIN INVEST, V91, P456, DOI 10.1172/JCI116223; Heusch G, 2013, LANCET, V381, P166, DOI 10.1016/S0140-6736(12)60916-7; Klassen S, 2009, N-S ARCH PHARMACOL, V379, P149, DOI 10.1007/s00210-008-0342-3; Kupai K, 2009, AM J PHYSIOL-HEART C, V297, pH1729, DOI 10.1152/ajpheart.00484.2009; Lefer DJ, 1997, J CLIN INVEST, V99, P684, DOI 10.1172/JCI119212; Lemoine S, 2010, BMC ANESTHESIOL, V10, DOI 10.1186/1471-2253-10-12; Levrand S, 2007, BIOCHEM BIOPH RES CO, V359, P445, DOI 10.1016/j.bbrc.2007.05.147; Levrand S, 2006, FREE RADICAL BIO MED, V41, P886, DOI 10.1016/j.freeradbiomed.2006.04.034; Liaudet L, 2001, BRIT J PHARMACOL, V133, P1424, DOI 10.1038/sj.bjp.0704185; Liaudet L, 2001, MOL MED, V7, P406, DOI 10.1007/BF03402187; Liaudet Lucas, 2009, Front Biosci (Landmark Ed), V14, P4809, DOI 10.2741/3569; Loukili N, 2011, CARDIOVASC RES, V89, P586, DOI 10.1093/cvr/cvq373; Manintveld OC, 2007, AM J PHYSIOL-HEART C, V292, pH1551, DOI 10.1152/ajpheart.00151.2006; Mewton N, 2013, CIRC J, V77, P1123, DOI 10.1253/circj.CJ-13-0385; Nossuli TO, 1997, CIRCULATION, V96, P2317; Ovize M, 2010, CARDIOVASC RES, V87, P406, DOI 10.1093/cvr/cvq129; Pacher P, 2005, TRENDS PHARMACOL SCI, V26, P302, DOI 10.1016/j.tips.2005.04.003; Pacher P, 2003, CIRCULATION, V107, P896, DOI 10.1161/01.CIR.0000048192.52098.DD; Pacher P, 2007, PHYSIOL REV, V87, P315, DOI 10.1152/physrev.00029.2006; Pagliaro P, 2011, ANTIOXID REDOX SIGN, V14, P833, DOI 10.1089/ars.2010.3245; Penna C, 2006, BASIC RES CARDIOL, V101, P180, DOI 10.1007/s00395-006-0584-5; Penna C, 2013, ANTIOXID REDOX SIGN, V18, P556, DOI 10.1089/ars.2011.4459; Penna C, 2009, BBA-BIOENERGETICS, V1787, P781, DOI 10.1016/j.bbabio.2009.02.008; Penna C, 2009, BASIC RES CARDIOL, V104, P390, DOI 10.1007/s00395-008-0762-8; Pesse B, 2005, J MOL CELL CARDIOL, V38, P765, DOI 10.1016/j.yjmcc.2005.02.020; Sanada S, 2011, AM J PHYSIOL-HEART C, V301, pH1723, DOI 10.1152/ajpheart.00553.2011; Shi WW, 2012, CARDIOVASC RES, V94, P206, DOI 10.1093/cvr/cvs088; Tsutsumi YM, 2007, LIFE SCI, V81, P1223, DOI 10.1016/j.lfs.2007.08.031; Yellon DM, 2007, NEW ENGL J MED, V357, P1121, DOI 10.1056/NEJMra071667; Zhao ZQ, 2003, AM J PHYSIOL-HEART C, V285, pH579, DOI 10.1152/ajpheart.01064.2002; ZWEIER JL, 1995, NAT MED, V1, P804, DOI 10.1038/nm0895-804	39	22	22	1	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 10	2013	8	7							e70331	10.1371/journal.pone.0070331	http://dx.doi.org/10.1371/journal.pone.0070331			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	182SU	23875026	Green Published, gold			2023-01-03	WOS:000321765300085
J	Cai, J; Xie, SL; Feng, J; Wang, FP; Xu, QF				Cai, Jin; Xie, Shulian; Feng, Jia; Wang, Feipeng; Xu, Qiufeng			Protective Effect of Polygonum orientale L. Extracts against Clavibater michiganense subsp sepedonicum, the Causal Agent of Bacterial Ring Rot of Potato	PLOS ONE			English	Article							PLANT ESSENTIAL OILS; ANTIMICROBIAL ACTIVITY; ANTIFUNGAL ACTIVITY; CHEMICAL-COMPOSITION; IN-VITRO; OPTIMIZATION; DISEASE; CINNAMOMUM; HERBICIDES; FUNGUS	The Polygonum orientale L. extracts were investigated for antibacterial activity against Clavibater michiganense subsp. sepedonicum (Spieckermann & Kotthoff) Davis et al., the causal agent of a serious disease called bacterial ring rot of potato. The results showed that the leaf extracts of P. orientale had significantly (p<0.05) greater antibacterial activity against C. michiganense subsp. sepedonicum than root, stem, flower extracts in vitro. According to the results of single factor experiments and L(27)3((13)) orthogonal experiments, optimum extraction conditions were A(1)B(3)C(1), extraction time 6 h, temperature 80 degrees C, solid to liquid ratio 1:10 (g:mL). The highest (p<0.05) antibacterial activity was observed when pH was 5, excluding the effect of control. The extracts were stable under ultraviolet (UV). In vivo analysis revealed that 50 mg/mL of P. orientale leaf extracts was effective in controlling decay. Under field conditions, 50 mg/ mL of P. orientale leaf extracts also improved growth parameters (whole plant length, shoot length, root length, plant fresh weight, shoot fresh weight, root fresh weight, dry weight, and number of leaves), in the 2010 and 2011 two growing seasons. Further solvent partition assays showed that the most active compounds were in the petroleum ether fractionation. Transmission electron microscopy (TEM) showed drastic ultrastructural changes caused by petroleum ether fractionation, including bacterial deformation, electron-dense particles, formation of vacuoles and lack of cytoplasmic materials. These results indicated that P. orientale extracts have strong antibacterial activity against C. michiganense subsp. sepedonicum and a promising effect in control of bacterial ring rot of potato disease.	[Cai, Jin; Xie, Shulian; Feng, Jia; Wang, Feipeng; Xu, Qiufeng] Shanxi Univ, Sch Life Sci, Taiyuan, Shanxi, Peoples R China	Shanxi University	Xie, SL (corresponding author), Shanxi Univ, Sch Life Sci, Taiyuan, Shanxi, Peoples R China.	xiesl@sxu.edu.cn						Abdel-Monaim MF, 2011, CROP PROT, V30, P185, DOI 10.1016/j.cropro.2010.09.016; Akhtar Y., 2008, Phytochemistry Reviews, V7, P77, DOI 10.1007/s11101-006-9048-7; Antony J., 2006, Sensor Review, V26, P227, DOI 10.1108/02602280610675519; Askarne L, 2012, CROP PROT, V40, P53, DOI 10.1016/j.cropro.2012.04.023; Aziz AN, 2013, J ETHNOPHARMACOL, V145, P798, DOI 10.1016/j.jep.2012.12.024; Bernardo-Gil MG, 2009, J SUPERCRIT FLUID, V49, P32, DOI 10.1016/j.supflu.2008.12.004; Brady N. C., 1984, NATURE PROPERTIES SO, P528; Cardoso RA, 2010, GENET MOL RES, V9, P231, DOI 10.4238/vol9-1gmr688; Carson Christine F, 2003, Commun Dis Intell Q Rep, V27 Suppl, pS143; Chao LK, 2005, J AGR FOOD CHEM, V53, P7274, DOI 10.1021/jf051151u; Cheikhyoussef A, 2009, FOOD CONTROL, V20, P553, DOI 10.1016/j.foodcont.2008.08.003; Chen YJ, 2012, J SCI FOOD AGR, V92, P1937, DOI 10.1002/jsfa.5565; Choi GJ, 2010, PLANT PATHOLOGY J, V26, P360, DOI 10.5423/PPJ.2010.26.4.360; Cowan MM, 1999, CLIN MICROBIOL REV, V12, P564, DOI 10.1128/CMR.12.4.564; De Corato U, 2010, CROP PROT, V29, P142, DOI 10.1016/j.cropro.2009.10.012; Demoz BT, 2006, BIOL CONTROL, V37, P68, DOI 10.1016/j.biocontrol.2005.11.010; Diez C, 2008, J CHROMATOGR A, V1180, P10, DOI 10.1016/j.chroma.2007.12.036; Elbadri Gamal Abdalla, 2008, Journal of Asia-Pacific Entomology, V11, P99, DOI 10.1016/j.aspen.2008.04.004; Fousek J, 2003, FOLIA MICROBIOL, V48, P682, DOI 10.1007/BF02993479; Fu WJ, 2005, FOREST BY PRODUCT SP, P40; Harish S, 2008, BIOCONTROL, V53, P555, DOI 10.1007/s10526-007-9098-9; Holley RA, 2005, FOOD MICROBIOL, V22, P273, DOI 10.1016/j.fm.2004.08.006; Ibrahim HR, 1996, J AGR FOOD CHEM, V44, P3799, DOI 10.1021/jf960133x; Ippolito A, 2000, CROP PROT, V19, P715, DOI 10.1016/S0261-2194(00)00095-8; Ismail S, 2013, BIOMED RES INT, V2013, DOI [10.1155/2013/696835, 10.1155/2013/269724]; Isman MB, 2000, CROP PROT, V19, P603, DOI 10.1016/S0261-2194(00)00079-X; Jia XY, 2010, CHROMATOGRAPHIA, V71, P839, DOI 10.1365/s10337-010-1547-4; Joshi S, 2008, BIORESOURCE TECHNOL, V99, P4603, DOI 10.1016/j.biortech.2007.07.030; Kagale S, 2004, PHYSIOL MOL PLANT P, V65, P91, DOI 10.1016/j.pmpp.2004.11.008; Khan MSA, 2011, PHYTOMEDICINE, V19, P48, DOI 10.1016/j.phymed.2011.07.005; Kilickap E, 2010, INT J ADV MANUF TECH, V49, P911, DOI 10.1007/s00170-009-2469-x; Knight SC, 1997, ANNU REV PHYTOPATHOL, V35, P349, DOI 10.1146/annurev.phyto.35.1.349; Li HJ, 2012, CURR MICROBIOL, V65, P156, DOI 10.1007/s00284-012-0135-2; Li Z, 2010, FOOD SCI BIOTECHNOL, V19, P1047, DOI 10.1007/s10068-010-0147-2; Liu RM, 2002, FOOD FERM IND, V29, P61; Liu YJ, 2004, MYCOPATHOLOGIA, V157, P185, DOI 10.1023/B:MYCO.0000020598.91469.d1; Mares D, 2005, MYCOPATHOLOGIA, V160, P85, DOI 10.1007/s11046-004-6635-2; Marino M, 2001, INT J FOOD MICROBIOL, V67, P187, DOI 10.1016/S0168-1605(01)00447-0; Mercan N, 2006, ANN MICROBIOL, V56, P373, DOI 10.1007/BF03175035; Michielin EMZ, 2009, BIORESOURCE TECHNOL, V100, P6615, DOI 10.1016/j.biortech.2009.07.061; Nishida M, 2006, J CHROMATOGR B, V842, P106, DOI 10.1016/j.jchromb.2006.07.039; Qasem JR, 1995, ANN APPL BIOL, V127, P215, DOI 10.1111/j.1744-7348.1995.tb06666.x; Qiu YE, 2004, XINJIANG AGR SCI, P88; SECOR GA, 1987, AM POTATO J, V64, P699; SIKKEMA J, 1995, MICROBIOL REV, V59, P201, DOI 10.1128/MMBR.59.2.201-222.1995; Smania A. Jr., 1999, International Journal of Medicinal Mushrooms, V1, P325; Soylu EM, 2006, MYCOPATHOLOGIA, V161, P119, DOI 10.1007/s11046-005-0206-z; Sun L, 2003, J CHROMATOGR A, V1014, P165, DOI 10.1016/S0021-9673(03)00574-0; Tanaka A, 2013, J WOOD SCI, V59, P155, DOI 10.1007/s10086-012-1310-6; Tao R, 2013, MOLECULES, V18, P2166, DOI 10.3390/molecules18022166; Tegegne G, 2008, CROP PROT, V27, P1052, DOI 10.1016/j.cropro.2007.12.007; Teixeira PC, 2007, INT J FOOD MICROBIOL, V118, P15, DOI 10.1016/j.ijfoodmicro.2007.05.008; van der Wolf JM, 2005, J PHYTOPATHOL, V153, P358, DOI 10.1111/j.1439-0434.2005.00985.x; Viswanathan MBG, 2012, FITOTERAPIA, V83, P1153, DOI 10.1016/j.fitote.2012.07.007; Wang B., 2012, NAT PROD RES DEV, V24, P23, DOI [10.16333/j.1001-6880.2012.s1.005, DOI 10.16333/J.1001-6880.2012.S1.005]; Wang HK, 2012, PLOS ONE, V7, DOI [10.1371/journal.pone.0029452, 10.1371/journal.pone.0038619, 10.1371/journal.pone.0041330]; Wang L, 2010, BIORESOURCE TECHNOL, V101, P5808, DOI 10.1016/j.biortech.2010.02.099; Wang L, 2010, DESALINATION, V254, P68, DOI 10.1016/j.desal.2009.12.012; Wang RuiXia, 2010, Acta Phytopathologica Sinica, V40, P66; Wei Y, 2009, J FOOD COMPOS ANAL, V22, P154, DOI 10.1016/j.jfca.2008.08.006; Wilson CL, 1997, PLANT DIS, V81, P204, DOI 10.1094/PDIS.1997.81.2.204; Wu GQ, 2008, CURR MICROBIOL, V57, P552, DOI 10.1007/s00284-008-9241-6; Xie BX, 2004, NONWOOD FOREST RES, V22, P5; Xiong JH, 2007, FOOD MACH, V23, P78; Yang DM, 2010, J CHIN I FOOD SCI TE, V10, P47; Yazaki Kazufumi, 2008, Phytochemistry Reviews, V7, P513, DOI 10.1007/s11101-007-9079-8; Zhang ZY, 2008, CROP PROT, V27, P920, DOI 10.1016/j.cropro.2007.11.012; [赵海伊 Zhao Haiyi], 2013, [食品科学, Food Science], V34, P236; Zheng XD, 2009, GANSU AGR SCI TECHN, V1, P11; Zhou W, 2010, CHROMATOGRAPHIA, V72, P719, DOI 10.1365/s10337-010-1747-y; 苏峰平, 2012, [中成药, Chinese Traditional Patent Medicine], V34, P938; 陈云, 2010, [山西农业科学, Journal of Shanxi Agricultural Sciences], V38, P140	72	8	9	1	32	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 4	2013	8	7							e68480	10.1371/journal.pone.0068480	http://dx.doi.org/10.1371/journal.pone.0068480			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	204FO	23861908	Green Published, gold, Green Submitted			2023-01-03	WOS:000323350700088
J	Abed, HS; Wittert, GA; Leong, DP; Shirazi, MG; Bahrami, B; Middeldorp, ME; Lorimer, MF; Lau, DH; Antic, NA; Brooks, AG; Abhayaratna, WP; Kalman, JM; Sanders, P				Abed, Hany S.; Wittert, Gary A.; Leong, Darryl P.; Shirazi, Masoumeh G.; Bahrami, Bobak; Middeldorp, Melissa E.; Lorimer, Michelle F.; Lau, Dennis H.; Antic, Nicholas A.; Brooks, Anthony G.; Abhayaratna, Walter P.; Kalman, Jonathan M.; Sanders, Prashanthan			Effect of Weight Reduction and Cardiometabolic Risk Factor Management on Symptom Burden and Severity in Patients With Atrial Fibrillation A Randomized Clinical Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							C-REACTIVE PROTEIN; QUALITY-OF-LIFE; ALCOHOL-CONSUMPTION; BLOOD-PRESSURE; SINUS RHYTHM; OBESITY; RECOMMENDATIONS; HYPERTENSION; PERFORMANCE; MECHANISMS	IMPORTANCE Obesity is a risk factor for atrial fibrillation. Whether weight reduction and cardiometabolic risk factor management can reduce the burden of atrial fibrillation is not known. OBJECTIVE To determine the effect of weight reduction and management of cardiometabolic risk factors on atrial fibrillation burden and cardiac structure. DESIGN, SETTING, AND PATIENTS Single-center, partially blinded, randomized controlled study conducted between June 2010 and December 2011 in Adelaide, Australia, among overweight and obese ambulatory patients (N = 150) with symptomatic atrial fibrillation. Patients underwent a median of 15 months of follow-up. INTERVENTIONS Patients were randomized to weight management (intervention) or general lifestyle advice (control). Both groups underwent intensive management of cardiometabolic risk factors. MAIN OUTCOMES AND MEASURES The primary outcomes were Atrial Fibrillation Severity Scale scores: symptom burden and symptom severity. Scores were measured every 3 months from baseline to 15 months. Secondary outcomes performed at baseline and 12 months were total atrial fibrillation episodes and cumulative duration measured by 7-day Holter, echocardiographic left atrial area, and interventricular septal thickness. RESULTS Of 248 patients screened, 150 were randomized (75 per group) and underwent follow-up. The intervention group showed a significantly greater reduction, compared with the control group, in weight (14.3 and 3.6 kg, respectively; P<.001) and in atrial fibrillation symptom burden scores (11.8 and 2.6 points, P<.001), symptom severity scores (8.4 and 1.7 points, P<.001), number of episodes (2.5 and no change, P=.01), and cumulative duration (692-minute decline and 419-minute increase, P=.002). Additionally, there was a reduction in interventricular septal thickness in the intervention and control groups (1.1 and 0.6 mm, P=.02) and left atrial area (3.5 and 1.9 cm(2), P=.02). CONCLUSIONS AND RELEVANCE In this study, weight reduction with intensive risk factor management resulted in a reduction in atrial fibrillation symptom burden and severity and in beneficial cardiac remodeling. These findings support therapy directed at weight and risk factors in the management of atrial fibrillation.	[Abed, Hany S.; Leong, Darryl P.; Shirazi, Masoumeh G.; Bahrami, Bobak; Middeldorp, Melissa E.; Lau, Dennis H.; Brooks, Anthony G.; Sanders, Prashanthan] Univ Adelaide, Ctr Heart Rhythm Disorders, Adelaide, SA, Australia; [Abed, Hany S.; Wittert, Gary A.; Leong, Darryl P.; Shirazi, Masoumeh G.; Bahrami, Bobak; Middeldorp, Melissa E.; Lau, Dennis H.; Brooks, Anthony G.; Sanders, Prashanthan] Royal Adelaide Hosp, Adelaide, SA 5000, Australia; [Abed, Hany S.; Wittert, Gary A.] Univ Adelaide, Dept Med, Adelaide, SA 5001, Australia; [Lorimer, Michelle F.] Univ Adelaide, Data Management & Anal Ctr, Sch Populat Hlth & Clin Practice, Adelaide, SA, Australia; [Antic, Nicholas A.] Repatriat Gen Hosp, Adelaide Inst Sleep Hlth, Adelaide, SA, Australia; [Abhayaratna, Walter P.] Australian Natl Univ, Coll Med Biol & Environm, Canberra, ACT, Australia; [Abhayaratna, Walter P.] Canberra Hosp, Canberra, ACT, Australia; [Kalman, Jonathan M.] Univ Melbourne, Royal Melbourne Hosp, Dept Cardiol, Melbourne, Vic 3050, Australia; [Kalman, Jonathan M.] Univ Melbourne, Dept Med, Melbourne, Vic, Australia	University of Adelaide; Royal Adelaide Hospital; University of Adelaide; University of Adelaide; Flinders University South Australia; Australian National University; Australian National University; Canberra Hospital; Royal Melbourne Hospital; University of Melbourne; University of Melbourne	Sanders, P (corresponding author), Royal Adelaide Hosp, Dept Cardiol, Ctr Heart Rhythm Disorders, Adelaide, SA 5000, Australia.	prash.sanders@adelaide.edu.au	Middeldorp, Melissa/C-6414-2019; Lau, Dennis H/G-6234-2013; wittert, gary/AAE-2398-2019; Sanders, Prashanthan/D-7641-2013	Middeldorp, Melissa/0000-0002-4106-9771; Lau, Dennis H/0000-0001-7753-1318; Sanders, Prashanthan/0000-0003-3803-8429; Lorimer, Michelle/0000-0003-3785-4395; Wittert, Gary/0000-0001-6818-6065; Abhayaratna, Walter/0000-0002-4908-0641	University of Adelaide; Centre of Heart Rhythm Disorders at the University of Adelaide; Prima Health Solutions Pty Ltd. Prima Health Solutions; Abbott Australia	University of Adelaide; Centre of Heart Rhythm Disorders at the University of Adelaide; Prima Health Solutions Pty Ltd. Prima Health Solutions; Abbott Australia(Abbott Laboratories)	This study was sponsored by the University of Adelaide. It was supported by funds from the Centre of Heart Rhythm Disorders at the University of Adelaide. The meal replacements were provided without cost by Prima Health Solutions Pty Ltd. Prima Health Solutions had no other involvement in the study. OBEMAN was developed by Dr Wittert with funding from Abbott Australia. The IP for the software is fully held by Dr Wittert and was used without the payment of any license fees.	Abed HS, 2013, HEART RHYTHM, V10, P90, DOI 10.1016/j.hrthm.2012.08.043; Appel LJ, 2011, NEW ENGL J MED, V365, P1959, DOI 10.1056/NEJMoa1108660; Benjamin EJ, 1998, CIRCULATION, V98, P946, DOI 10.1161/01.CIR.98.10.946; BENJAMIN EJ, 1994, JAMA-J AM MED ASSOC, V271, P840, DOI 10.1001/jama.271.11.840; BONNET MH, 1992, SLEEP, V15, P526; Braunwald E, 1997, NEW ENGL J MED, V337, P1360, DOI 10.1056/NEJM199711063371906; Cocco G, 2011, J CLIN HYPERTENS, V13, P23, DOI 10.1111/j.1751-7176.2010.00380.x; Coyne KS, 2006, VALUE HEALTH, V9, P348, DOI 10.1111/j.1524-4733.2006.00124.x; Dimitri H, 2012, HEART RHYTHM, V9, P321, DOI 10.1016/j.hrthm.2011.10.017; Disertori M, 2009, NEW ENGL J MED, V360, P1606, DOI 10.1056/NEJMoa0805710; Dorian P, 2000, J AM COLL CARDIOL, V36, P1303, DOI 10.1016/S0735-1097(00)00886-X; Elobeid MA, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006624; Flemons WW, 1999, SLEEP, V22, P667, DOI 10.1093/sleep/22.5.667; Fontes JD, 2012, AM J CARDIOL, V109, P87, DOI 10.1016/j.amjcard.2011.08.008; Gottdiener JS, 1998, CIRCULATION, V98, P140, DOI 10.1161/01.CIR.98.2.140; Grundy SM, 2002, CIRCULATION, V106, P3143, DOI 10.1161/circ.106.25.3143; Healey JS, 2005, J AM COLL CARDIOL, V45, P1832, DOI 10.1016/j.jacc.2004.11.070; Kannel WB, 1998, AM J CARDIOL, V82, p2N, DOI 10.1016/S0002-9149(98)00583-9; Karason K, 1999, AM J CARDIOL, V83, P1242, DOI 10.1016/S0002-9149(99)00066-1; Khoo J, 2010, INT J OBESITY, V34, P1396, DOI 10.1038/ijo.2010.76; KLATSKY AL, 1977, NEW ENGL J MED, V296, P1194, DOI 10.1056/NEJM197705262962103; Kodama S, 2011, J AM COLL CARDIOL, V57, P427, DOI 10.1016/j.jacc.2010.08.641; Lang RM, 2005, J AM SOC ECHOCARDIOG, V18, P1440, DOI 10.1016/j.echo.2005.10.005; Madrid AH, 2002, CIRCULATION, V106, P331, DOI 10.1161/01.CIR.0000022665.18619.83; Marcus GM, 2008, PACE, V31, P266, DOI 10.1111/j.1540-8159.2008.00985.x; Miyasaka Y, 2006, CIRCULATION, V114, P119, DOI 10.1161/CIRCULATIONAHA.105.595140; Munger TM, 2012, J AM COLL CARDIOL, V60, P851, DOI 10.1016/j.jacc.2012.03.042; Nattel S, 2008, CIRC-ARRHYTHMIA ELEC, V1, P62, DOI 10.1161/CIRCEP.107.754564; Pena JM, 2012, EUR HEART J, V33, P531, DOI 10.1093/eurheartj/ehr460; Russo C, 2011, J AM COLL CARDIOL, V57, P1368, DOI 10.1016/j.jacc.2010.10.042; Singh SN, 2006, J AM COLL CARDIOL, V48, P721, DOI 10.1016/j.jacc.2006.03.051; Stritzke J, 2009, J AM COLL CARDIOL, V54, P1982, DOI 10.1016/j.jacc.2009.07.034; Sumithran P, 2011, NEW ENGL J MED, V365, P1597, DOI 10.1056/NEJMoa1105816; Tedrow UB, 2010, J AM COLL CARDIOL, V55, P2319, DOI 10.1016/j.jacc.2010.02.029; Tsang TSM, 2008, EUR HEART J, V29, P2227, DOI 10.1093/eurheartj/ehn324; Visser M, 1999, JAMA-J AM MED ASSOC, V282, P2131, DOI 10.1001/jama.282.22.2131; Wachtell K, 2005, J AM COLL CARDIOL, V45, P712, DOI 10.1016/j.jacc.2004.10.068; Wachtell K, 2010, BLOOD PRESSURE, V19, P169, DOI 10.3109/08037051.2010.481811; Wanahita N, 2008, AM HEART J, V155, P310, DOI 10.1016/j.ahj.2007.10.004; Wang TJ, 2004, JAMA-J AM MED ASSOC, V292, P2471, DOI 10.1001/jama.292.20.2471; Wong CX, 2011, J AM COLL CARDIOL, V57, P1745, DOI 10.1016/j.jacc.2010.11.045; Wright JJ, 2009, CARDIOVASC RES, V82, P351, DOI 10.1093/cvr/cvp017	42	548	560	1	30	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 20	2013	310	19					2050	2060		10.1001/jama.2013.280521	http://dx.doi.org/10.1001/jama.2013.280521			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	253OQ	24240932	Bronze			2023-01-03	WOS:000327098900021
J	Hajek, P				Hajek, Peter			Electronic cigarettes for smoking cessation	LANCET			English	Editorial Material									[Hajek, Peter] Queen Mary Univ London, Wolfson Inst Prevent Med, London E1 2AD, England; [Hajek, Peter] Queen Mary Univ London, UK Ctr Tobacco & Alcohol Studies, London E1 2AD, England	University of London; Queen Mary University London; University of London; Queen Mary University London	Hajek, P (corresponding author), Queen Mary Univ London, Wolfson Inst Prevent Med, London E1 2AD, England.	p.hajek@qmul.ac.uk						Bullen C, 2013, LANCET, V382, P1629, DOI 10.1016/S0140-6736(13)61842-5; Caponnetto P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066317; Dockrell M, 2013, NICOTINE TOB RES, V15, P1737, DOI 10.1093/ntr/ntt057; Douptcheva N, 2013, J EPIDEMIOL COMMUNIT, DOI 10.1136/jech-2013-203152; European Commission, 2012, PROP DIR EUR PARL CO; Goniewicz ML, 2014, TOB CONTROL, V23, P133, DOI 10.1136/tobaccocontrol-2012-050859; McCauley L, 2012, CHEST, V141, P1110, DOI 10.1378/chest.11-1334	7	25	26	0	31	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 16	2013	382	9905					1614	1616		10.1016/S0140-6736(13)61534-2	http://dx.doi.org/10.1016/S0140-6736(13)61534-2			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	254CN	24029168				2023-01-03	WOS:000327140700007
J	Buhrman, JD; Jordan, KR; Munson, DJ; Moore, BL; Kappler, JW; Slansky, JE				Buhrman, Jonathan D.; Jordan, Kimberly R.; Munson, Daniel J.; Moore, Brandon L.; Kappler, John W.; Slansky, Jill E.			Improving Antigenic Peptide Vaccines for Cancer Immunotherapy Using a Dominant Tumor-specific T Cell Receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article						Antigen; Peptide Arrays; T Cell; T Cell Receptor; Tumor Immunology; Vaccines	MAJOR HISTOCOMPATIBILITY COMPLEX; CLASS-I BINDING; SELF-ANTIGEN; ANTITUMOR IMMUNITY; MOLECULAR MIMICRY; CENTRAL TOLERANCE; MHC COMPLEXES; HIGH-AFFINITY; TCR-BINDING; RECOGNITION	Background: Vaccination with mimotopes, peptide mimics of epitopes, stimulates a range of T cell protection. Results: Mimotopes identified from peptide libraries by T cells with common receptors increased immunity more than those with rare high affinity receptors. Conclusion: T cell prevalence must be considered when designing peptide vaccines. Significance: Optimizing mimotopes will improve antigen-specific vaccines for applications including cancer immunotherapies. Vaccines that incorporate peptide mimics of tumor antigens, or mimotope vaccines, are commonly used in cancer immunotherapy and function by eliciting increased numbers of T cells that cross-react with the native tumor antigen. Unfortunately, they often elicit T cells that do not cross-react with or that have low affinity for the tumor antigen. Using a high affinity tumor-specific T cell clone, we identified a panel of mimotope vaccines for the dominant peptide antigen from a mouse colon tumor that elicits a range of tumor protection following vaccination. The TCR from this high affinity T cell clone was rarely identified in ex vivo evaluation of tumor-specific T cells elicited by mimotope vaccination. Conversely, a low affinity clone found in the tumor and following immunization was frequently identified. Using peptide libraries, we determined if this frequently identified TCR improved the discovery of efficacious mimotopes. We demonstrated that the representative TCR identified more protective mimotopes than the high affinity TCR. These results suggest that targeting a dominant fraction of tumor-specific T cells generates potent immunity and that consideration of the available T cell repertoire is necessary for targeted T cell therapy. These results have important implications when optimizing mimotope vaccines for cancer immunotherapy.	[Buhrman, Jonathan D.; Jordan, Kimberly R.; Munson, Daniel J.; Moore, Brandon L.; Kappler, John W.; Slansky, Jill E.] Univ Colorado, Sch Med, Integrated Dept Immunol, Aurora, CO 80045 USA; [Jordan, Kimberly R.] Univ Colorado, Sch Med, Dept Surg, Aurora, CO 80045 USA; [Kappler, John W.] Natl Jewish Hlth, Howard Hughes Med Inst, Denver, CO 80206 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus; Howard Hughes Medical Institute; National Jewish Health	Slansky, JE (corresponding author), Univ Colorado, Sch Med, Integrated Dept Immunol, Natl Jewish Hlth, 1400 Jackson St,Rm K511, Denver, CO 80206 USA.	Jill.Slansky@ucdenver.edu			National Institutes of Health [CA109560, P30CA046934]; American Cancer Society [RSG-08-184-01-L1B]; Cancer Research Institute Pre-doctoral Emphasis Pathway in Tumor Immunology Fellowship; NATIONAL CANCER INSTITUTE [R01CA109560, P30CA046934] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Cancer Society(American Cancer Society); Cancer Research Institute Pre-doctoral Emphasis Pathway in Tumor Immunology Fellowship; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported, in whole or in part, by National Institutes of Health Grants CA109560 and P30CA046934. This work was also supported by American Cancer Society Grant RSG-08-184-01-L1B.; Both authors contributed equally to this work. Supported by the Cancer Research Institute Pre-doctoral Emphasis Pathway in Tumor Immunology Fellowship.	Adams JJ, 2011, IMMUNITY, V35, P681, DOI 10.1016/j.immuni.2011.09.013; Almeida JR, 2009, BLOOD, V113, P6351, DOI 10.1182/blood-2009-02-206557; Appay V, 2008, NAT MED, V14, P623, DOI 10.1038/nm.f.1774; Appay V, 2006, EUR J IMMUNOL, V36, P1805, DOI 10.1002/eji.200535805; Balendiran GK, 1997, P NATL ACAD SCI USA, V94, P6880, DOI 10.1073/pnas.94.13.6880; Birnbaum ME, 2012, IMMUNOL REV, V250, P82, DOI 10.1111/imr.12006; Bridgeman JS, 2012, IMMUNOLOGY, V135, P9, DOI 10.1111/j.1365-2567.2011.03515.x; Buhrman JD, 2013, CANCER RES, V73, P74, DOI 10.1158/0008-5472.CAN-12-1005; Chastain EML, 2012, IMMUNOL REV, V245, P227, DOI 10.1111/j.1600-065X.2011.01076.x; Clay TM, 1999, J IMMUNOL, V162, P1749; Cole DK, 2007, J IMMUNOL, V178, P5727, DOI 10.4049/jimmunol.178.9.5727; Cole DK, 2010, J IMMUNOL, V185, P2600, DOI 10.4049/jimmunol.1000629; Colf LA, 2007, CELL, V129, P135, DOI 10.1016/j.cell.2007.01.048; Crawford F, 2006, IMMUNOL REV, V210, P156, DOI 10.1111/j.0105-2896.2006.00365.x; Crawford F, 2004, PLOS BIOL, V2, P523, DOI 10.1371/journal.pbio.0020090; de Visser KE, 2003, J IMMUNOTHER, V26, P1, DOI 10.1097/00002371-200301000-00001; de Visser KE, 2001, J IMMUNOL, V167, P3818, DOI 10.4049/jimmunol.167.7.3818; Ding YH, 1998, IMMUNITY, V8, P403, DOI 10.1016/S1074-7613(00)80546-4; Ekeruche-Makinde J, 2012, J BIOL CHEM, V287, P37269, DOI 10.1074/jbc.M112.386409; Enouz S, 2012, J EXP MED, V209, P1769, DOI 10.1084/jem.20120905; HASKINS K, 1983, J EXP MED, V157, P1149, DOI 10.1084/jem.157.4.1149; Hogquist KA, 2005, NAT REV IMMUNOL, V5, P772, DOI 10.1038/nri1707; Holler PD, 2003, NAT IMMUNOL, V4, P55, DOI 10.1038/ni863; Hou YF, 2008, J IMMUNOL, V180, P1526, DOI 10.4049/jimmunol.180.3.1526; Iero M, 2007, CANCER IMMUNOL IMMUN, V56, P1979, DOI 10.1007/s00262-007-0342-z; Jordan KR, 2008, J IMMUNOL, V180, P188, DOI 10.4049/jimmunol.180.1.188; Jordan KR, 2012, CANCER IMMUNOL IMMUN, V61, P1627, DOI 10.1007/s00262-012-1217-5; Jordan KR, 2010, P NATL ACAD SCI USA, V107, P4652, DOI 10.1073/pnas.0914879107; Kedl RM, 2000, J EXP MED, V192, P1105, DOI 10.1084/jem.192.8.1105; Kedl RM, 2002, NAT IMMUNOL, V3, P27, DOI 10.1038/ni742; Kersh GJ, 1996, J EXP MED, V184, P1259, DOI 10.1084/jem.184.4.1259; KHILKO SN, 1993, J BIOL CHEM, V268, P15425; Liu CP, 1998, P NATL ACAD SCI USA, V95, P4522, DOI 10.1073/pnas.95.8.4522; LIU GY, 1995, IMMUNITY, V3, P407, DOI 10.1016/1074-7613(95)90170-1; Macdonald WA, 2009, IMMUNITY, V31, P897, DOI 10.1016/j.immuni.2009.09.025; McMahan RH, 2006, J CLIN INVEST, V116, P2543, DOI 10.1172/JCI26936; McWilliams JA, 2008, VACCINE, V26, P1863, DOI 10.1016/j.vaccine.2008.01.052; Miles JJ, 2011, IMMUNOL CELL BIOL, V89, P375, DOI 10.1038/icb.2010.139; Miller JFAP, 1996, CURR OPIN IMMUNOL, V8, P815, DOI 10.1016/S0952-7915(96)80010-0; Ohlen C, 2002, J EXP MED, V195, P1407, DOI 10.1084/jem.20011063; Overwijk WW, 1998, J EXP MED, V188, P277, DOI 10.1084/jem.188.2.277; OZATO K, 1980, J IMMUNOL, V125, P2473; Rubio V, 2003, NAT MED, V9, P1377, DOI 10.1038/nm942; Sanchez PJ, 2007, J IMMUNOL, V178, P1564, DOI 10.4049/jimmunol.178.3.1564; Seder RA, 2008, NAT REV IMMUNOL, V8, P247, DOI 10.1038/nri2274; Sewell AK, 2012, NAT REV IMMUNOL, V12, P668, DOI 10.1038/nri3279; Slansky JE, 2000, IMMUNITY, V13, P529, DOI 10.1016/S1074-7613(00)00052-2; Speiser DE, 2008, P NATL ACAD SCI USA, V105, P3849, DOI 10.1073/pnas.0800080105; Stuge TB, 2004, PLOS MED, V1, P149, DOI 10.1371/journal.pmed.0010028; Tam RC, 1996, J IMMUNOL, V156, P3765; Tang Y, 2007, CANCER IMMUNOL IMMUN, V56, P319, DOI 10.1007/s00262-006-0195-x; Truscott SM, 2007, J IMMUNOL, V178, P6280, DOI 10.4049/jimmunol.178.10.6280; Tumenjargal S, 2003, EUR J IMMUNOL, V33, P3175, DOI 10.1002/eji.200324244; Wang YB, 2005, P NATL ACAD SCI USA, V102, P2476, DOI 10.1073/pnas.0409798102; Wieckowski S, 2009, J IMMUNOL, V183, P5397, DOI 10.4049/jimmunol.0901460; WILSON RK, 1988, IMMUNOL REV, V101, P149, DOI 10.1111/j.1600-065X.1988.tb00736.x; Zaremba S, 1997, CANCER RES, V57, P4570; Zugel U, 1998, J IMMUNOL, V161, P1705	59	16	16	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	2013	288	46					33213	33225		10.1074/jbc.M113.509554	http://dx.doi.org/10.1074/jbc.M113.509554			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	277TH	24106273	Green Published, hybrid			2023-01-03	WOS:000328841700036
J	Preussel, K; Hohle, M; Stark, K; Werber, D				Preussel, Karina; Hoehle, Michael; Stark, Klaus; Werber, Dirk			Shiga Toxin-Producing Escherichia coli O157 Is More Likely to Lead to Hospitalization and Death than Non-O157 Serogroups - Except O104	PLOS ONE			English	Article							HEMOLYTIC-UREMIC SYNDROME; UNITED-STATES; RISK-FACTORS; BLOODY DIARRHEA; INFECTIONS; GERMANY; VIRULENCE; OUTBREAK; DETERMINANTS; SURVEILLANCE	The clinical spectrum following infection with Shiga toxin-producing Escherichia coli (STEC) is wide ranging and includes hemorrhagic colitis and life-threatening hemolytic uremic syndrome (HUS). Severity of STEC illness depends on patients' age and strongly on the infecting strains' virulence. Serogroup O157 is often assumed to be more virulent than others. Age-adjusted population-based data supporting this view are lacking thus far. We conducted a large retrospective cohort study among patients of community-acquired gastroenteritis or HUS diagnosed with STEC infection, reported in Germany January 2004 through December 2011. Age-adjusted risks for reported hospitalization and death, as proxies for disease severity, were estimated for STEC serogroups separately, and compared with STEC O157 (reference group) using Poisson regression models with robust error estimation. A total of 8,400 case-patients were included in the analysis; for 2,454 (29%) and 30 (0.4%) hospitalization and death was reported, respectively. Highest risks for hospitalization, adjusted for age and region of residence, were estimated for STEC O104 (68%; risk ratio [RR], 1.33; 95% confidence interval [CI], 1.19-1.45), followed by STEC O157 (46%). Hospitalization risks for the most prevalent non-O157 serogroups (O26, O103, O91, O145, O128, O111) were consistently and markedly lower than for O157, with the highest RR for O145 (0.54; 95% CI, 0.41-0.70) and the lowest for O103 (0.27; 95% CI, 0.20-0.35). Mortality risk of O104 was similar to O157 (1.2% each), but the group of all other non-O157 STEC had only 1/10 the risk (RR, 0.09; 95% CI, 0.02-0.32) compared to O157. The study provides population-based and age-adjusted evidence for the exceptional high virulence of STEC O157 in relation to non-O157 STEC other than O104. Timely diagnosis and surveillance of STEC infections should prioritize HUS-associated E. coli, of which STEC O157 is the most important serogroup.	[Preussel, Karina; Hoehle, Michael; Stark, Klaus; Werber, Dirk] Robert Koch Inst, Dept Infect Dis Epidemiol, Berlin, Germany; [Preussel, Karina] Charite, Berlin Sch Publ Hlth, D-13353 Berlin, Germany	Robert Koch Institute; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Preussel, K (corresponding author), Robert Koch Inst, Dept Infect Dis Epidemiol, Berlin, Germany.	PreusselK@rki.de	Werber, Dirk/L-2264-2019; Höhle, Michael/AFM-0575-2022	Höhle, Michael/0000-0002-0423-6702; Werber, Dirk/0000-0002-8076-788X				[Anonymous], 2022, ZULETZT GEANDERT DUR; Banatvala N, 2001, J INFECT DIS, V183, P1063, DOI 10.1086/319269; Bettelheim KA, 2007, CRIT REV MICROBIOL, V33, P67, DOI 10.1080/10408410601172172; Bielaszewska M, 2011, LANCET INFECT DIS, V11, P671, DOI 10.1016/S1473-3099(11)70165-7; Blanco JE, 2004, J CLIN MICROBIOL, V42, P311, DOI 10.1128/JCM.42.1.311-319.2004; Boerlin P, 1999, J CLIN MICROBIOL, V37, P497, DOI 10.1128/JCM.37.3.497-503.1999; Brooks JT, 2005, J INFECT DIS, V192, P1422, DOI 10.1086/466536; Brzuszkiewicz E, 2011, ARCH MICROBIOL, V193, P883, DOI 10.1007/s00203-011-0725-6; Buvens G, 2012, FOODBORNE PATHOG DIS, V9, P530, DOI 10.1089/fpd.2011.1073; Buvens G, 2012, J CLIN MICROBIOL, V50, P1336, DOI 10.1128/JCM.05317-11; CLEVELAND WS, 1979, J AM STAT ASSOC, V74, P829, DOI 10.2307/2286407; Clogher P, 2012, CLIN INFECT DIS, V54, pS446, DOI 10.1093/cid/cis246; Donnenberg MS, 2001, J CLIN INVEST, V107, P539, DOI 10.1172/JCI12404; Fey PD, 2000, EMERG INFECT DIS, V6, P530, DOI 10.3201/eid0605.000513; Frank C, 2011, NEW ENGL J MED, V365, P1771, DOI 10.1056/NEJMoa1106483; Friedrich AW, 2002, J INFECT DIS, V185, P74, DOI 10.1086/338115; Gould LH, 2013, FOODBORNE PATHOG DIS, V10, P453, DOI 10.1089/fpd.2012.1401; Gould L. Hannah, 2009, Morbidity and Mortality Weekly Report, V58, P1; Gould LH, 2009, CLIN INFECT DIS, V49, P1480, DOI 10.1086/644621; Hadler JL, 2011, CLIN INFECT DIS, V53, P269, DOI 10.1093/cid/cir377; Hedican EB, 2009, CLIN INFECT DIS, V49, P358, DOI 10.1086/600302; Hermos CR, 2011, J CLIN MICROBIOL, V49, P955, DOI 10.1128/JCM.02119-10; Hickey CA, 2011, ARCH PEDIAT ADOL MED, V165, P884, DOI 10.1001/archpediatrics.2011.152; Holtz LR, 2009, GASTROENTEROLOGY, V136, P1887, DOI 10.1053/j.gastro.2009.02.059; Jelacic JK, 2003, J INFECT DIS, V188, P719, DOI 10.1086/376999; Johnson KE, 2006, CLIN INFECT DIS, V43, P1587, DOI 10.1086/509573; KARMALI MA, 1989, CLIN MICROBIOL REV, V2, P15, DOI 10.1128/CMR.2.1.15-38.1989; King LA, 2012, CLIN INFECT DIS, V54, P1588, DOI 10.1093/cid/cis255; Klein EJ, 2002, J PEDIATR-US, V141, P172, DOI 10.1067/mpd.2002.125908; Lathrop S, 2009, EMERG INFECT DIS, V15, P1289, DOI [10.3201/eid1508.081616, 10.3201/eid1508.08151515]; Lockary VM, 2007, EMERG INFECT DIS, V13, P1262; Loos S, 2012, CLIN INFECT DIS, V55, P753, DOI 10.1093/cid/cis531; Manning SD, 2007, EMERG INFECT DIS, V13, P318, DOI 10.3201/eid1302.060813; MARCH SB, 1986, J CLIN MICROBIOL, V23, P869, DOI 10.1128/JCM.23.5.869-872.1986; McPherson M, 2009, CLIN INFECT DIS, V49, P249, DOI 10.1086/599370; Mead PS, 1998, LANCET, V352, P1207, DOI 10.1016/S0140-6736(98)01267-7; Nielsen S, 2011, ZOONOSES PUBLIC HLTH, V58, P567, DOI 10.1111/j.1863-2378.2011.01405.x; Ogura Y, 2009, P NATL ACAD SCI USA, V106, P17939, DOI 10.1073/pnas.0903585106; OSTROFF SM, 1989, J INFECT DIS, V160, P994, DOI 10.1093/infdis/160.6.994; Rangel JM, 2005, EMERG INFECT DIS, V11, P603, DOI 10.3201/eid1104.040739; Soborg B, 2013, EURO SURVEILL, V18; Souza MRSM, 2010, MEM I OSWALDO CRUZ, V105, P318, DOI 10.1590/S0074-02762010000300013; Stigi KA, 2012, EMERG INFECT DIS, V18, P477, DOI 10.3201/eid1803.111358; Verweyen HM, 1999, INFECTION, V27, P341, DOI 10.1007/s150100050040; Werber D, 2004, J INFECT DIS, V189, P1335, DOI 10.1086/382282; Werber D, 2013, AM J EPIDEMIOL; Werber D, 2008, EMERG INFECT DIS, V14, P1803, DOI 10.3201/eid1411.080361; Werber D, 2008, CLIN INFECT DIS, V46, P1189, DOI 10.1086/587670; Werber D, 2007, AM J EPIDEMIOL, V165, P425, DOI 10.1093/aje/kwk023; Wylie JL, 2013, J CLIN MICROBIOL, V51, P466, DOI 10.1128/JCM.02329-12; Zou GY, 2004, AM J EPIDEMIOL, V159, P702, DOI 10.1093/aje/kwh090	51	26	26	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 14	2013	8	11							e78180	10.1371/journal.pone.0078180	http://dx.doi.org/10.1371/journal.pone.0078180			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	254DJ	24244292	Green Published, Green Submitted, gold			2023-01-03	WOS:000327143800006
J	Guest, JA; Quincy, L				Guest, James A.; Quincy, Lynn			Consumers Gaining Ground in Health Care	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Guest, James A.] Consumer Reports, Yonkers, NY 10703 USA; [Quincy, Lynn] Consurmer Reports, Washington, DC USA		Guest, JA (corresponding author), Consumer Reports, 101 Truman Ave, Yonkers, NY 10703 USA.	jguest@consumer.org						James JT, 2013, J PATIENT SAF, V9, P122, DOI 10.1097/PTS.0b013e3182948a69; Millman J., 2013, POLITICO PAVIA  0319; Quincy L., 2012, WHATS DOOR CONSUMERS; Quincy L., 2013, EARLY EXPERIENCE NEW; The American College of Obstetricians and Gynecologists Committee on Obstetric Practice the Society for Maternal-Fetal Medicine, 2013, NONM IND EARL TERM D, P561	5	6	6	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 13	2013	310	18					1939	1940		10.1001/jama.2013.282000	http://dx.doi.org/10.1001/jama.2013.282000			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	250EJ	24219947				2023-01-03	WOS:000326832900016
J	Du, CYQ; Choi, RCY; Zheng, KYZ; Dong, TTX; Lau, DTW; Tsim, KWK				Du, Crystal Y. Q.; Choi, Roy C. Y.; Zheng, Ken Y. Z.; Dong, Tina T. X.; Lau, David T. W.; Tsim, Karl W. K.			Yu Ping Feng San, an Ancient Chinese Herbal Decoction Containing Astragali Radix, Atractylodis Macrocephalae Rhizoma and Saposhnikoviae Radix, Regulates the Release of Cytokines in Murine Macrophages	PLOS ONE			English	Article							DANGGUI-BUXUE-TANG; NF-KAPPA-B; ANGELICAE-SINENSIS; NO PRODUCTION; CELLS; ERYTHROPOIETIN; EXPRESSION; COMPONENTS; MEDICINE; ALPHA	Yu Ping Feng San (YPFS), a Chinese herbal decoction, is composed of Astragali Radix (AR; Huangqi), Atractylodis Macrocephalae Rhizoma (AMR; Baizhu) and Saposhnikoviae Radix (SR; Fangfeng) in a weight ratio of 1:2:1. Clinically, YPFS has been widely used to regulate immune functions; however, the action mechanism of it is not known. Here, we addressed this issue by providing detail analyses of chemical and biological properties of YPFS. By using rapid resolution liquid chromatography coupled with mass spectrometry, fifteen chemicals deriving from different herbs of YPFS were determined, and which served as a control for the standardization of the herbal extract of YPFS. In general, the amounts of chosen chemical markers were higher in a preparation of YPFS as compared to that of single herb or two-herb compositions. In order to reveal the immune functions of YPFS, the standardized extract was applied onto cultured murine macrophages. The treatment of YPFS stimulated the mRNA and protein expressions of pro-inflammatory cytokines via activation of NF-kappa B by enhancing I kappa B alpha degradation. In contrast, the application of YPFS suppressed the expressions of pro-inflammatory cytokines significantly in the lipopolysaccharide (LPS)-induced chronic inflammation model. In addition, YPFS could up regulate the phagocytic activity in cultured macrophages. These results therefore supported the bi-directional immunemodulatory roles of YPFS in regulating the releases of cytokines from macrophages.	[Du, Crystal Y. Q.; Choi, Roy C. Y.; Dong, Tina T. X.; Lau, David T. W.; Tsim, Karl W. K.] Hong Kong Univ Sci & Technol, Div Life Sci, Hong Kong, Hong Kong, Peoples R China; [Du, Crystal Y. Q.; Choi, Roy C. Y.; Dong, Tina T. X.; Lau, David T. W.; Tsim, Karl W. K.] Hong Kong Univ Sci & Technol, Ctr Chinese Med, Hong Kong, Hong Kong, Peoples R China; [Du, Crystal Y. Q.; Zheng, Ken Y. Z.] Hanshan Normal Univ, Dept Biol, Chaozhou, Guangdong, Peoples R China	Hong Kong University of Science & Technology; Hong Kong University of Science & Technology; Hanshan Normal University	Tsim, KWK (corresponding author), Hong Kong Univ Sci & Technol, Div Life Sci, Hong Kong, Hong Kong, Peoples R China.	botsim@ust.hk	Du, Crystal Yingqing/AAH-5824-2020	Du, Crystal Yingqing/0000-0003-1353-4477; Lau, Tai Wai David/0000-0002-3443-1808; Zheng, Yuzhong/0000-0001-7208-0642; Tsim, Karl/0000-0003-4808-1674	 [661110];  [662911];  [663012];  [UIM/208];  [UIM/214];  [GHP/030/09SZ];  [Z0315];  [TUYF12SC03];  [GHP/032/09SZ]	; ; ; ; ; ; ; ; 	This research was supported by Research Grants (661110, 662911, 663012, UIM/208, UIM/214, GHP/030/09SZ, Z0315 and TUYF12SC03 to KWKT and GHP/032/09SZ to RCYC). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aderem A, 1999, ANNU REV IMMUNOL, V17, P593, DOI 10.1146/annurev.immunol.17.1.593; Ashley JW, 2011, ASSAY DRUG DEV TECHN, V9, P40, DOI 10.1089/adt.2010.0307; Chen X, 2000, J Tradit Chin Med, V20, P302; Chiu SC, 2009, PHYTOTHER RES, V23, P363, DOI 10.1002/ptr.2633; Choi KW, 2003, ANN INTERN MED, V139, P715, DOI 10.7326/0003-4819-139-9-200311040-00005; Choi RCY, 2011, EVID-BASED COMPL ALT, V2011, P1, DOI 10.1093/ecam/nen085; Dong HY, 2008, NAT PROD RES, V22, P1418, DOI 10.1080/14786410801931629; Dong TTX, 2006, J AGR FOOD CHEM, V54, P2767, DOI 10.1021/jf053163l; Gao QT, 2008, PLANTA MED, V74, P392, DOI 10.1055/s-2008-1034322; Gao QT, 2007, FEBS LETT, V581, P233, DOI 10.1016/j.febslet.2006.12.018; Gao QT, 2006, PLANTA MED, V72, P1227, DOI 10.1055/s-2006-947186; Gao Qiutao, 2007, Chin Med, V2, P12, DOI 10.1186/1749-8546-2-12; Guo WX, 2012, INFLAMMATION, V35, P1764, DOI 10.1007/s10753-012-9495-9; Hong M, 2011, J PHARMACEUT BIOMED, V54, P87, DOI 10.1016/j.jpba.2010.08.016; Hoo RLC, 2010, NUTR METAB, V7, DOI 10.1186/1743-7075-7-67; Huang HL, 2005, J ETHNOPHARMACOL, V97, P21, DOI 10.1016/j.jep.2004.09.058; Kang SR, 2011, EVID-BASED COMPL ALT, V2011, DOI 10.1155/2011/248592; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; KISO Y, 1985, PLANTA MED, V51, P97, DOI 10.1055/s-2007-969416; Laskin DL, 2009, CHEM RES TOXICOL, V22, P1376, DOI 10.1021/tx900086v; Lee JC, 2007, PHYTOMEDICINE, V14, P390, DOI 10.1016/j.phymed.2006.09.012; Li CQ, 2007, PHYTOTHER RES, V21, P347, DOI 10.1002/ptr.2040; Lv T, 2006, WORLD J GASTROENTERO, V12, P2195, DOI 10.3748/wjg.v12.i14.2195; Ma XQ, 2002, J AGR FOOD CHEM, V50, P4861, DOI 10.1021/jf0202279; Ning Lian, 2002, Zhongguo Zhongyao Zazhi, V27, P50; Poon PMK, 2006, AM J CHINESE MED, V34, P13, DOI 10.1142/S0192415X0600359X; SAKURAI T, 1994, BIOL PHARM BULL, V17, P1364, DOI 10.1248/bpb.17.1364; STRUGALA GJ, 1985, DIGESTION, V32, P255, DOI 10.1159/000199246; Tai J, 2007, ONCOL REP, V18, P227; Tanton DW, 2007, DRUG FREE APPROACH H; Toda S, 1998, PHYTOTHER RES, V12, P59, DOI 10.1002/(SICI)1099-1573(19980201)12:1&lt;59::AID-PTR182&gt;3.0.CO;2-R; WU DZ, 1999, PHARM CLIN CHIN MAT, V15, P3; Wu JH, 2010, J NUTR BIOCHEM, V21, P613, DOI 10.1016/j.jnutbio.2009.03.010; Xue Bao-yun, 2000, Zhongguo Zhongyao Zazhi, V25, P297; You Y, 2012, BMC COMPLEM ALTERN M, V12, DOI 10.1186/1472-6882-12-54; Yu L, 2000, CHINESE J NEPHROLOGY, V16, P282; Yu S, 2012, EVID-BASED COMPL ALT, V2012; Zhang XP, 2007, J PANCREAS, V8, P704; Zhao B, 2012, J ASIAN NAT PROD RES, V14, P886, DOI 10.1080/10286020.2012.702756; Zheng KYZ, 2011, J AGR FOOD CHEM, V59, P1697, DOI 10.1021/jf104018u; Zheng KYZ, 2010, J ETHNOPHARMACOL, V132, P259, DOI 10.1016/j.jep.2010.08.029	41	47	49	0	27	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 11	2013	8	11							e78622	10.1371/journal.pone.0078622	http://dx.doi.org/10.1371/journal.pone.0078622			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	255EG	24244327	Green Submitted, Green Published, gold			2023-01-03	WOS:000327221600037
J	Spence, D				Spence, Des			FROM THE FRONTLINE Bad medicine: gabapentin and pregabalin	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							MISUSE											Centers for Disease Control and Prevention (CDC), 2013, POL IMP PRESCR PAINK; Gureje O, 1998, JAMA-J AM MED ASSOC, V280, P147, DOI 10.1001/jama.280.2.147; Health and Social Care Information Centre, 2013, PRESCR COST AN ENGL; Kessler RC, 2005, ARCH GEN PSYCHIAT, V62, P593, DOI 10.1001/archpsyc.62.6.593; Maskell PD, 2013, BMJ; Millar J, 2013, EMERG MED J, V30, P874, DOI DOI 10.1136/EMERMED-2013-203113.20; Moore RA, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007938.pub2; Moore RA, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007076.pub2; Moore RA, 2012, COCHRANE DB SYST REV, V12, DOI DOI 10.1002/14651858.CD008242.PUB2; NICE CfCPa, 2010, NEUR PAIN PHARM MAN; Schifano F, 2011, PSYCHOTHER PSYCHOSOM, V80, P118, DOI 10.1159/000321079; Smith BH, 2012, BRIT J GEN PRACT, V62, P406, DOI 10.3399/bjgp12X653516; US Drug Enforcement Agency (DEA), DRUG SCHED; Wiffen PJ, 2013, COCHRANE DB SYST REV, V6	14	25	27	0	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 8	2013	347								f6747	10.1136/bmj.f6747	http://dx.doi.org/10.1136/bmj.f6747			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	250XT	24212252				2023-01-03	WOS:000326890800014
J	Kshirsagar, AV; Freburger, JK; Ellis, AR; Wang, L; Winkelmayer, WC; Brookhart, MA				Kshirsagar, Abhijit V.; Freburger, Janet K.; Ellis, Alan R.; Wang, Lily; Winkelmayer, Wolfgang C.; Brookhart, M. Alan			Intravenous Iron Supplementation Practices and Short-Term Risk of Cardiovascular Events in Hemodialysis Patients	PLOS ONE			English	Article							ANEMIA MANAGEMENT; MORTALITY; THERAPY; PRODUCTS; PATTERNS; OUTCOMES; DISEASE; ALPHA	Background & Objectives: Intravenous iron supplementation is widespread in the hemodialysis population, but there is uncertainty about the safest dosing strategy. We compared the safety of different intravenous iron dosing practices on the risk of adverse cardiovascular outcomes in a large population of hemodialysis patients. Design settings, participants, & measurements: A retrospective cohort was created from the clinical database of a large dialysis provider (years 2004-2008) merged with administrative data from the United States Renal Data System. Dosing comparisons were (1) bolus (consecutive doses >= 100 mg exceeding 600 mg during one month) versus maintenance (all other iron doses during the month); and (2) high (> 200 mg over 1 month) versus low dose (<= 200 mg over 1 month). We established a 6-month baseline period (to identify potential confounders and effect modifiers), a one-month iron exposure period, and a three-month follow-up period. Outcomes were myocardial infarction, stroke, and death from cardiovascular disease. Results: 117,050 patients contributed 776,203 unique iron exposure/follow-up periods. After adjustment, we found no significant associations of bolus dose versus maintenance, hazards ratio for composite outcome, 1.03 (95% C. I. 0.99, 1.07), or high dose versus low dose intravenous iron, hazards ratio for composite outcome, 0.99 (95% C. I. 0.96, 1.03). There were no consistent associations of either high or bolus dose versus low or maintenance respectively among pre-specified subgroups. Conclusions: Strategies favoring large doses of intravenous iron were not associated with increased short-term cardiovascular morbidity and mortality. Investigation of the long-term safety of the various intravenous iron supplementation strategies may still be warranted.	[Kshirsagar, Abhijit V.] Univ N Carolina, Sch Med, Kidney Ctr, Chapel Hill, NC 27515 USA; [Freburger, Janet K.; Ellis, Alan R.; Wang, Lily] Univ N Carolina, Cecil G Sheps Ctr Hlth Serv Res, Chapel Hill, NC USA; [Winkelmayer, Wolfgang C.] Stanford Univ, Sch Med, Dept Med, Div Nephrol, Palo Alto, CA 94304 USA; [Brookhart, M. Alan] UNC, Gillings Sch Global Publ Hlth, Chapel Hill, NC USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; Stanford University; University of North Carolina; University of North Carolina Chapel Hill	Kshirsagar, AV (corresponding author), Univ N Carolina, Sch Med, Kidney Ctr, Chapel Hill, NC 27515 USA.	sagar@med.unc.edu			Agency for Healthcare Research and Quality (AHRQ), United States Department of Health and Human Services (DHHS) as part of the Developing Evidence to Inform Decisions about Effectiveness (DECIDE) program [HHSA290200500401]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK090181] Funding Source: NIH RePORTER	Agency for Healthcare Research and Quality (AHRQ), United States Department of Health and Human Services (DHHS) as part of the Developing Evidence to Inform Decisions about Effectiveness (DECIDE) program; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This project was funded under contract number HHSA290200500401 from the Agency for Healthcare Research and Quality (AHRQ), United States Department of Health and Human Services (DHHS) as part of the Developing Evidence to Inform Decisions about Effectiveness (DECIDE) program. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Akizawa T, 2008, NEPHROL DIAL TRANSPL, V23, P3643, DOI 10.1093/ndt/gfn346; Berliner JA, 1996, FREE RADICAL BIO MED, V20, P707, DOI 10.1016/0891-5849(95)02173-6; BIEMOND P, 1988, FREE RADICAL BIO MED, V4, P185, DOI 10.1016/0891-5849(88)90026-3; Brewster UC, 2006, SEMIN DIALYSIS, V19, P285, DOI 10.1111/j.1525-139X.2006.00174.x; *CTR MED MED SERV, 2012, FED REGISTER, V77, P133; *CTR MED MED SERV, 2011, FED REGISTER, V76, P218; de Jager DJ, 2009, JAMA-J AM MED ASSOC, V302, P1782, DOI 10.1001/jama.2009.1488; Drueke T, 2002, CIRCULATION, V106, P2212, DOI 10.1161/01.CIR.0000035250.66458.67; Drueke TB, 2006, NEW ENGL J MED, V355, P2071, DOI 10.1056/NEJMoa062276; Elixhauser A, 1998, MED CARE, V36, P8, DOI 10.1097/00005650-199801000-00004; *FDA, 2011, DRUG SAF COMM MOD DO; Feldman HI, 2004, J AM SOC NEPHROL, V15, P1623, DOI 10.1097/01.ASN.0000128009.69594.BE; Fishbane S, 1999, AM J KIDNEY DIS, V34, pS47, DOI 10.1053/ajkd.1999.v34.aajkd0344b0047; Freburger JK, 2012, AM J MED, V125, P906, DOI 10.1016/j.amjmed.2012.03.011; HALLIWELL B, 1984, BIOCHEM J, V219, P1, DOI 10.1042/bj2190001; Himmelfarb J, 2002, KIDNEY INT, V62, P1524, DOI 10.1046/j.1523-1755.2002.00600.x; Hoen B, 1998, J AM SOC NEPHROL, V9, P869; Kalantar-Zadeh K, 2005, J AM SOC NEPHROL, V16, P3070, DOI 10.1681/ASN.2005040423; KSHIRSAGAR AV, 2013, AM J MED IN PRESS, P97800; LIN DY, 1994, BIOMETRIKA, V81, P61, DOI 10.1093/biomet/81.1.61; *NAT I HLTH, 2011, RES GUID USRDS DAT 2; Parkkinen J, 2000, NEPHROL DIAL TRANSPL, V15, P1827, DOI 10.1093/ndt/15.11.1827; Pfeffer MA, 2009, NEW ENGL J MED, V361, P2019, DOI 10.1056/NEJMoa0907845; Pisoni RL, 2004, AM J KIDNEY DIS, V44, P94, DOI 10.1053/j.ajkd.2004.03.023; Reis KA, 2005, INT HEART J, V46, P255, DOI 10.1536/ihj.46.255; Robins JM, 2000, EPIDEMIOLOGY, V11, P550, DOI 10.1097/00001648-200009000-00011; SEVANIAN A, 1985, ANNU REV NUTR, V5, P365, DOI 10.1146/annurev.nu.05.070185.002053; Singh AK, 2006, NEW ENGL J MED, V355, P2085, DOI 10.1056/NEJMoa065485; Singh N, 2012, CLIN NEPHROL, V77, P188, DOI 10.5414/CN107266; Spiegel DM, 2009, CLIN J AM SOC NEPHRO, V4, P1009, DOI 10.2215/CJN.00270109; Thakuria M, 2011, SEMIN DIALYSIS, V24, P597, DOI 10.1111/j.1525-139X.2011.00975.x; Vaziri ND, 2012, AM J MED, V125, P951, DOI 10.1016/j.amjmed.2012.02.009; Yong K, 2010, NEPHROLOGY, V15, P288, DOI 10.1111/j.1440-1797.2009.01184.x; Zanen AL, 1996, NEPHROL DIAL TRANSPL, V11, P820, DOI 10.1093/oxfordjournals.ndt.a027405	34	54	56	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 1	2013	8	11							e78930	10.1371/journal.pone.0078930	http://dx.doi.org/10.1371/journal.pone.0078930			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	245XZ	24223866	Green Published, gold, Green Submitted			2023-01-03	WOS:000326499300043
J	Vincent, JL; De Backer, D				Vincent, Jean-Louis; De Backer, Daniel			Circulatory Shock	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							SEPTIC SHOCK; SEVERE SEPSIS; MICROCIRCULATORY ALTERATIONS; NOREPINEPHRINE; DOPAMINE; RESUSCITATION; FLUID; VASOPRESSIN; EPINEPHRINE; DOBUTAMINE	Circulatory shock is present when physical signs and changes in laboratory values suggest tissue hypoperfusion. This article in the Critical Care Medicine series reviews the diagnosis and treatment of various forms of shock. Shock is the clinical expression of circulatory failure that results in inadequate cellular oxygen utilization. Shock is a common condition in critical care, affecting about one third of patients in the intensive care unit (ICU).(1) A diagnosis of shock is based on clinical, hemodynamic, and biochemical signs, which can broadly be summarized into three components. First, systemic arterial hypotension is usually present, but the magnitude of the hypotension may be only moderate, especially in patients with chronic hypertension. Typically, in adults, the systolic arterial pressure is less than 90 mm Hg or the mean arterial pressure is less than 70 ...	[Vincent, Jean-Louis; De Backer, Daniel] Univ Libre Bruxelles, Erasme Hosp, Dept Intens Care, Brussels, Belgium	Universite Libre de Bruxelles	Vincent, JL (corresponding author), Erasme Univ Hosp, Dept Intens Care, Rte Lennik 808, B-1070 Brussels, Belgium.	jlvincen@ulb.ac.be	Soong, John Tshon Yit/I-2008-2018; Rodrigues, Alfredo/C-3426-2013; De Backer, Daniel/AAF-4177-2020	Soong, John Tshon Yit/0000-0003-4235-8505; Rodrigues, Alfredo/0000-0002-0654-2893; De Backer, Daniel/0000-0001-9841-5762; Vincent, Jean-Louis/0000-0001-6011-6951				Annane D, 2007, LANCET, V370, P676, DOI 10.1016/S0140-6736(07)61344-0; Bellomo R, 2000, LANCET, V356, P2139; Cavallaro F, 2010, INTENS CARE MED, V36, P1475, DOI 10.1007/s00134-010-1929-y; Combes A, 2008, CRIT CARE MED, V36, P1404, DOI 10.1097/CCM.0b013e31816f7cf7; Correa TD, 2012, CRIT CARE MED, V40, P2841, DOI 10.1097/CCM.0b013e31825b916b; Creteur J, 2007, INTENS CARE MED, V33, P1549, DOI 10.1007/s00134-007-0739-3; De Backer D, 2006, CRIT CARE MED, V34, P403, DOI 10.1097/01.CCM.0000198107.61493.5A; De Backer D, 2007, CRIT CARE, V11, DOI 10.1186/cc6118; De Backer D, 2012, CRIT CARE MED, V40, P725, DOI 10.1097/CCM.0b013e31823778ee; De Backer D, 2010, NEW ENGL J MED, V362, P779, DOI 10.1056/NEJMoa0907118; Delaney AP, 2011, CRIT CARE MED, V39, P386, DOI 10.1097/CCM.0b013e3181ffe217; Dellinger RP, 2013, CRIT CARE MED, V41, P580, DOI 10.1097/CCM.0b013e31827e83af; Gomez H, 2008, INTENS CARE MED, V34, P1600, DOI 10.1007/s00134-008-1145-1; Hochman JS, 2007, JAMA-J AM MED ASSOC, V297, P1657; Jansen TC, 2010, AM J RESP CRIT CARE, V182, P752, DOI 10.1164/rccm.200912-1918OC; Labovitz AJ, 2010, J AM SOC ECHOCARDIOG, V23, P1225, DOI 10.1016/j.echo.2010.10.005; Levy B, 2011, CRIT CARE MED, V39, P450, DOI 10.1097/CCM.0b013e3181ffe0eb; Lopez A, 2004, CRIT CARE MED, V32, P21, DOI 10.1097/01.CCM.0000105581.01815.C6; Marik PE, 2009, CRIT CARE MED, V37, P2642, DOI 10.1097/CCM.0b013e3181a590da; Myburgh JA, 2013, NEW ENGL J MED, V369, P1243, DOI 10.1056/NEJMra1208627; Myburgh JA, 2008, INTENS CARE MED, V34, P2226, DOI 10.1007/s00134-008-1219-0; Rivers E, 2001, NEW ENGL J MED, V345, P1368, DOI 10.1056/NEJMoa010307; Rivers EP, 2007, CRIT CARE MED, V35, P2016, DOI 10.1097/01.CCM.0000281637.08984.6E; Russell JA, 2008, NEW ENGL J MED, V358, P877, DOI 10.1056/NEJMoa067373; Russell JA, 2009, CRIT CARE MED, V37, P811, DOI 10.1097/CCM.0b013e3181961ace; Sakr Y, 2004, CRIT CARE MED, V32, P1825, DOI 10.1097/01.CCM.0000138558.16257.3F; Sakr Y, 2006, CRIT CARE MED, V34, P589, DOI 10.1097/01.CCM.0000201896.45809.E3; Thiele H, 2012, NEW ENGL J MED, V367, P1287, DOI 10.1056/NEJMoa1208410; Vincent JL, 2012, CRIT CARE, V16, DOI 10.1186/cc11510; Vincent JL, 2011, CRIT CARE, V15, DOI 10.1186/cc10291; Vincent JL, 2008, CRIT CARE, V12, DOI 10.1186/cc6975; VINCENT JL, 1983, CRIT CARE MED, V11, P449, DOI 10.1097/00003246-198306000-00012; Vincent JL, 2006, CRIT CARE MED, V34, P1333, DOI 10.1097/01.CCM.0000214677.76535.A5; Weil M H, 1971, Adv Exp Med Biol, V23, P13; WEIL MH, 1969, J AMER MED ASSOC, V207, P337, DOI 10.1001/jama.207.2.337	35	638	733	6	58	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 31	2013	369	18					1726	1734		10.1056/NEJMra1208943	http://dx.doi.org/10.1056/NEJMra1208943			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	243IY	24171518				2023-01-03	WOS:000326311300010
J	Snapp-Childs, W; Casserly, E; Mon-Williams, M; Bingham, GP				Snapp-Childs, Winona; Casserly, Elizabeth; Mon-Williams, Mark; Bingham, Geoffrey P.			Active Prospective Control Is Required for Effective Sensorimotor Learning	PLOS ONE			English	Article							ROBOT-ASSISTED THERAPY; MOTOR CONTROL; INTERCEPTIVE ACTIONS; VISUAL ANTICIPATION; MOVEMENT; CHILDREN; SYSTEM; MODEL; COORDINATION; STRATEGIES	Passive modeling of movements is often used in movement therapy to overcome disabilities caused by stroke or other disorders (e.g. Developmental Coordination Disorder or Cerebral Palsy). Either a therapist or, recently, a specially designed robot moves or guides the limb passively through the movement to be trained. In contrast, action theory has long suggested that effective skill acquisition requires movements to be actively generated. Is this true? In view of the former, we explicitly tested the latter. Previously, a method was developed that allows children with Developmental Coordination Disorder to produce effective movements actively, so as to improve manual performance to match that of typically developing children. In the current study, we tested practice using such active movements as compared to practice using passive movement. The passive movement employed, namely haptic tracking, provided a strong test of the comparison, one that showed that the mere inaction of the muscles is not the problem. Instead, lack of prospective control was. The result was no effective learning with passive movement while active practice with prospective control yielded significant improvements in performance.	[Snapp-Childs, Winona; Casserly, Elizabeth; Bingham, Geoffrey P.] Indiana Univ, Dept Psychol & Brain Sci, Bloomington, IN 47405 USA; [Mon-Williams, Mark] Univ Leeds, Inst Psychol Sci, Leeds, W Yorkshire, England	Indiana University System; Indiana University Bloomington; University of Leeds	Snapp-Childs, W (corresponding author), Indiana Univ, Dept Psychol & Brain Sci, Bloomington, IN 47405 USA.	wsnappch@indiana.edu		Mon-Williams, Mark/0000-0001-7595-8545; Snapp-Childs, Winona/0000-0003-4354-7092	NIH NIDCD Training Grant [T32DC00012]; NIH NICHD [R01HD070832]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD070832] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [T32DC000012] Funding Source: NIH RePORTER	NIH NIDCD Training Grant; NIH NICHD(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))	This work was supported by NIH NIDCD Training Grant T32DC00012 and NIH NICHD R01HD070832. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abernethy B., 1987, PHYSICAL ED REV, V10, P5; Abernethy B, 1990, J SPORT SCI, V8, P17, DOI 10.1080/02640419008732128; Bastin J, 2006, HUM MOVEMENT SCI, V25, P718, DOI 10.1016/j.humov.2006.04.001; Beets IAM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037687; BINGHAM GP, 1988, HUM MOVEMENT SCI, V7, P225, DOI 10.1016/0167-9457(88)90013-9; Bingham GP, 2011, J VIS, V11, P960; Clark F. J. a. H.. K. W., 1986, HDB PERCEPTION HUMAN, V1; Clark JE, 2005, J PHYS EDUC RECREAT, V76, P49, DOI 10.1080/07303084.2005.10608237; Cole J., 1995, PRIDE DAILY MARATHON; Culmer PR, 2011, J NEUROSCI METH, V197, P259, DOI 10.1016/j.jneumeth.2011.03.004; Dessing JC, 2002, NEURAL NETWORKS, V15, P163, DOI 10.1016/S0893-6080(01)00136-8; Farrow D, 2005, MOTOR CONTROL, V9, P332; Farrow D, 2003, PERCEPTION, V32, P1127, DOI 10.1068/p3323; FELDMAN AG, 1966, BIOPHYS-USSR, V11, P565; FELDMAN AG, 1986, J MOTOR BEHAV, V18, P17; FELDMAN AG, 1990, MULTIPLE MUSCLE SYST, P195, DOI DOI 10.1007/978-1-4613-9030-5_12; Feldman AG, 2009, EXP BRAIN RES, V194, P39, DOI 10.1007/s00221-008-1667-3; Goodwin G M, 1976, Exerc Sport Sci Rev, V4, P87; Hildreth EC, 2000, J EXP PSYCHOL HUMAN, V26, P1106, DOI 10.1037//0096-1523.26.3.1106; HOGAN N, 1987, EXERCISE SPORT SCI R, V15, P153; HOGAN N, 1985, BIOL CYBERN, V52, P315, DOI 10.1007/BF00355754; Hogan N., 1990, MULTIPLE MUSCLE SYST, P149, DOI [10.1007/978-1-4613-9030-5_9, DOI 10.1007/978-1-4613-9030-5_9]; Kwakkel G, 2008, NEUROREHAB NEURAL RE, V22, P111, DOI 10.1177/1545968307305457; LAND M, 1995, NATURE, V377, P339, DOI 10.1038/377339a0; Latash M., 1993, CONTROL HUMAN MOVEME; Latash ML, 2012, FUNDAMENTALS OF MOTOR CONTROL, P1; Latash ML, 1996, PROGR MOTOR CONTROL, P289; Lee DN, 1993, ECOLOGICAL INTERPERS, P68; Liu J, 2006, J NEUROENG REHABIL, V3, DOI 10.1186/1743-0003-3-20; Lo AC, 2010, NEW ENGL J MED, V362, P1772, DOI 10.1056/NEJMoa0911341; Marchal-Crespo L, 2010, EXP BRAIN RES, V201, P209, DOI 10.1007/s00221-009-2026-8; Marchal-Crespo L, 2009, J NEUROENG REHABIL, V6, DOI 10.1186/1743-0003-6-20; MCCLOSKEY DI, 1978, PHYSIOL REV, V58, P763, DOI 10.1152/physrev.1978.58.4.763; McCloskey DI, 1980, SPINAL SUPRASPINAL M; MIALL RC, 1993, J MOTOR BEHAV, V25, P203, DOI 10.1080/00222895.1993.9942050; Milot MH, 2010, EXP BRAIN RES, V201, P119, DOI 10.1007/s00221-009-2014-z; Montagne G, 2005, INT J SPORT PSYCHOL, V36, P127; Montagne G, 2008, INT J SPORT PSYCHOL, V39, P149; NEWELL KM, 1991, ANNU REV PSYCHOL, V42, P213, DOI 10.1146/annurev.ps.42.020191.001241; Pedhazur E.J., 1997, MULTIPLE REGRESSION; POULTON EC, 1957, PSYCHOL BULL, V54, P467, DOI 10.1037/h0045515; Reinkensmeyer DJ, 2009, EXERC SPORT SCI REV, V37, P43, DOI 10.1097/JES.0b013e3181912108; Salvucci DD, 2004, PERCEPTION, V33, P1233, DOI 10.1068/p5343; Smits-Engelsman BCM, 2001, HUM MOVEMENT SCI, V20, P161, DOI 10.1016/S0167-9457(01)00033-1; Snapp-Childs W, 2013, J CHILD NEUROL, V28, P204, DOI 10.1177/0883073812461945; Studenka BE, 2013, J EXP PSYCHOL HUMAN, V39, P1557, DOI 10.1037/a0031744; Swinnen S., 1996, ADV MOTOR LEARNING C; Turvey M. T., 1992, ECOL PSYCHOL, V4, P173, DOI [10.1207/s15326969eco0403_3, DOI 10.1207/S15326969EC00403_]; TURVEY MT, 1990, AM PSYCHOL, V45, P938, DOI 10.1037/0003-066X.45.8.938; Van der Kamp J, 2008, INT J SPORT PSYCHOL, V39, P100; VONHOFSTEN C, 1993, HUM DEV, V36, P253, DOI 10.1159/000278212; Warren WH, 2001, NAT NEUROSCI, V4, P213, DOI 10.1038/84054; Weightman A, 2011, J REHABIL MED, V43, P359, DOI 10.2340/16501977-0679; Wilkie RM, 2010, EXP BRAIN RES, V204, P539, DOI 10.1007/s00221-010-2321-4; Wolpert DM, 2010, CURR BIOL, V20, pR467, DOI 10.1016/j.cub.2010.04.035; WOLPERT DM, 1995, SCIENCE, V269, P1880, DOI 10.1126/science.7569931; Wolpert DM, 1998, NEURAL NETWORKS, V11, P1317, DOI 10.1016/S0893-6080(98)00066-5; Wong JD, 2012, J NEUROPHYSIOL, V108, P3313, DOI 10.1152/jn.00122.2012	58	14	14	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 23	2013	8	10							e77609	10.1371/journal.pone.0077609	http://dx.doi.org/10.1371/journal.pone.0077609			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	239PE	24194891	Green Published, gold, Green Submitted			2023-01-03	WOS:000326037000070
J	Hawking, MKD; Lecky, DM; Verlander, NQ; McNulty, CAM				Hawking, Meredith K. D.; Lecky, Donna M.; Verlander, Neville Q.; McNulty, Cliodna A. M.			Fun on the Farm: Evaluation of a Lesson to Teach Students about the Spread of Infection on School Farm Visits	PLOS ONE			English	Article							ESCHERICHIA-COLI O157; CAMPYLOBACTER-JEJUNI; SAFETY KNOWLEDGE; RISK-FACTORS; E-BUG; CATTLE; HYGIENE; PERSISTENCE; BEHAVIORS	Background: School visits to farms are a positive educational experience but pose risks due to the spread of zoonotic infections. A lesson plan to raise awareness about microbes on the farm and preventative behaviours was developed in response to the Griffin Investigation into the E. coli outbreak associated with Godstone Farm in 2009. This study evaluated the effectiveness of the delivery of the lesson plan in increasing knowledge about the spread of infection on the farm, amongst school students. Methods: Two hundred and twenty-five 9-11 year old students from seven junior schools in England participated. Two hundred and ten students filled in identical questionnaires covering microbes, hand hygiene, and farm hygiene before and after the lesson. Statistical analysis assessed knowledge change using difference in percentage correct answers. Results: Significant knowledge improvement was observed for all sections. In the 'Farm Hygiene' section, girls and boys demonstrated 18% (p<0.001) and 11% (p<0.001) improvement, respectively (girls vs. boys p<0.004). As girls had lower baseline knowledge the greater percentage improvement resulted in similar post intervention knowledge scores between genders (girls 80%, boys 83%). Conclusions: The lesson plan was successful at increasing awareness of microbes on the farm and infection prevention measures and should be used by teachers in preparation for a farm visit.	[Hawking, Meredith K. D.; Lecky, Donna M.; McNulty, Cliodna A. M.] Gloucestershire Royal Hosp, Dept Microbiol, Publ Hlth England, Primary Care Unit, Gloucester GL1 3NN, England; [Verlander, Neville Q.] Publ Hlth England Ctr Infect, Stat Modelling & Econ Dept, London, England	Gloucestershire Royal Hospital; Public Health England; Public Health England	Hawking, MKD (corresponding author), Gloucestershire Royal Hosp, Dept Microbiol, Publ Hlth England, Primary Care Unit, Gloucester GL1 3NN, England.	meredith.hawking@phe.gov.uk	Hawking, Meredith KD/E-7692-2015; Lecky, Donna Marie/AAB-6849-2019	Hawking, Meredith KD/0000-0003-1519-2458; Lecky, Donna Marie/0000-0002-1223-9356	Health Protection Agency, UK	Health Protection Agency, UK	This work was supported by the Health Protection Agency, UK (http://www.hpa.org.uk/). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Belongia EA, 2003, J INFECT DIS, V187, P1460, DOI 10.1086/374622; Berry DS, 2006, J SAFETY RES, V37, P333, DOI 10.1016/j.jsr.2006.05.003; Charlett A, 2003, EPIDEMIOL INFECT, V130, P367; Crump JA, 2003, EPIDEMIOL INFECT, V131, P1055, DOI 10.1017/S0950268803001237; Ejemot-Nwadiaro R. I., 2012, COCHRANE DB SYST REV, V2, P1; Eves A, 2010, HEALTH EDUC J, V69, P21, DOI 10.1177/0017896910363313; Farming and Countryside Education, 2011, PREV CONTR ILL HLTH; Farming and Countryside Education, 2012, CONTR INF FARMS; Farming and Countryside Education, 2011, RES SCH BENCHM VIEWS; GARBER LP, 1995, J AM VET MED ASSOC, V207, P46; Goode B, 2009, ARCH PEDIAT ADOL MED, V163, P42, DOI 10.1001/archpediatrics.2008.525; Grohskopf L, 2011, AM J TRANSPLANT, V11, P2250, DOI 10.1111/j.1600-6143.2011.03793.x; Health and Safety Executive, 2007, KIDS SAF HELP CHILDR; Health Protection Agency, 2011, AV INF FARM VIS ADV; Health Protection Agency, 2010, REV MAJ OUTBR E COLI; Health Protection Agency, 2011, MAN AC BLOOD DIARRH; Health Protection Scotland, 2010, SIMPL PREC RED RISK; Heuvelink AE, 2007, EPIDEMIOL INFECT, V135, P1174, DOI 10.1017/S0950268807008072; Hoelzer K, 2011, VET RES, V42, DOI 10.1186/1297-9716-42-34; Jones DL, 1999, SOIL USE MANAGE, V15, P76, DOI 10.1111/j.1475-2743.1999.tb00069.x; Lecky DM, 2010, J ANTIMICROB CHEMOTH, V65, P2674, DOI 10.1093/jac/dkq356; Lee MB, 2010, J SCH HLTH, V80, P589; LeJeune JT, 2001, APPL ENVIRON MICROB, V67, P3053, DOI 10.1128/AEM.67.7.3053-3057.2001; McMillian M, 2007, JAVMA-J AM VET MED A, V231, P1036, DOI 10.2460/javma.231.7.1036; McNulty CAM, 2011, J ANTIMICROB CHEMOTH, V66, pV3, DOI 10.1093/jac/dkr119; Nichols GL, 2012, BMJ OPEN, V2, DOI 10.1136/bmjopen-2012-001179; Paiba GA, 2003, VET REC, V153, P347, DOI 10.1136/vr.153.12.347; Prince M, 2004, J ENG EDUC, V93, P223, DOI 10.1002/j.2168-9830.2004.tb00809.x; Rahn K, 1997, EPIDEMIOL INFECT, V119, P251, DOI 10.1017/S0950268897007929; Sandora TJ, 2008, PEDIATRICS, V121, pE1555, DOI 10.1542/peds.2007-2597; Stanley K, 1998, J APPL MICROBIOL, V85, P187; Thomson JA, 2005, J EXP PSYCHOL-APPL, V11, P175, DOI 10.1037/1076-898X.11.3.175; Wesley IV, 2000, APPL ENVIRON MICROB, V66, P1994, DOI 10.1128/AEM.66.5.1994-2000.2000	33	8	8	0	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 16	2013	8	10							e75641	10.1371/journal.pone.0075641	http://dx.doi.org/10.1371/journal.pone.0075641			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	239JR	24146765	gold, Green Published, Green Submitted			2023-01-03	WOS:000326019400011
J	Mitchell, CJ; Churchward-Venne, TA; Bellamy, L; Parise, G; Baker, SK; Phillips, SM				Mitchell, Cameron J.; Churchward-Venne, Tyler A.; Bellamy, Leeann; Parise, Gianni; Baker, Steven K.; Phillips, Stuart M.			Muscular and Systemic Correlates of Resistance Training-Induced Muscle Hypertrophy	PLOS ONE			English	Article							ANDROGEN RECEPTOR EXPRESSION; SKELETAL-MUSCLE; MYOFIBER HYPERTROPHY; CLUSTER-ANALYSIS; IGF-I; LENGTHENING CONTRACTIONS; HORMONAL ADAPTATIONS; PROTEIN-SYNTHESIS; YOUNG MEN; EXERCISE	Purpose: To determine relationships between post-exercise changes in systemic [testosterone, growth hormone (GH), insulin like grow factor 1 (IGF-1) and interleukin 6 (IL-6)], or intramuscular [skeletal muscle androgen receptor (AR) protein content and p70S6K phosphorylation status] factors in a moderately-sized cohort of young men exhibiting divergent resistance training-mediated muscle hypertrophy. Methods: Twenty three adult males completed 4 sessions.wk(-1) of resistance training for 16 wk. Muscle biopsies were obtained before and after the training period and acutely 1 and 5 h after the first training session. Serum hormones and cytokines were measured immediately, 15, 30 and 60 minutes following the first and last training sessions of the study. Results: Mean fiber area increased by 20% (range: -7 to 80%; P<0.001). Protein content of the AR was unchanged with training (fold change = 1.17 +/- 0.61; P = 0.19); however, there was a significant correlation between the changes in AR content and fiber area (r = 0.60, P = 0.023). Phosphorylation of p70S6K was elevated 5 hours following exercise, which was correlated with gains in mean fiber area (r = 0.54, P = 0.007). There was no relationship between the magnitude of the pre- or post-training exercise-induced changes in free testosterone, GH, or IGF-1 concentration and muscle fiber hypertrophy; however, the magnitude of the post exercise IL-6 response was correlated with muscle hypertrophy (r = 0.48, P = 0.019). Conclusion: Post-exercise increases in circulating hormones are not related to hypertrophy following training. Exercise-induced changes in IL-6 correlated with hypertrophy, but the mechanism for the role of IL-6 in hypertrophy is not known. Acute increases, in p70S6K phosphorylation and changes in muscle AR protein content correlated with muscle hypertrophy implicating intramuscular rather than systemic processes in mediating hypertrophy.	[Mitchell, Cameron J.; Churchward-Venne, Tyler A.; Bellamy, Leeann; Parise, Gianni; Phillips, Stuart M.] McMaster Univ, Dept Kinesiol, Exercise Metab Res Grp, Hamilton, ON, Canada; [Baker, Steven K.] McMaster Univ, Sch Med, Dept Neurol, Hamilton, ON L8S 4L8, Canada	McMaster University; McMaster University	Phillips, SM (corresponding author), McMaster Univ, Dept Kinesiol, Exercise Metab Res Grp, Hamilton, ON, Canada.	phillis@mcmaster.ca	Mitchell, Cameron/I-4423-2019; Phillips, Stuart/B-2343-2009	Mitchell, Cameron/0000-0003-3843-6806; Phillips, Stuart/0000-0002-1956-4098; Churchward-Venne, Tyler/0000-0001-6006-5461	Natural Sciences and Engineering Research Council of Canada	Natural Sciences and Engineering Research Council of Canada(Natural Sciences and Engineering Research Council of Canada (NSERC)CGIAR)	This work was supported by a grant from the Natural Sciences and Engineering Research Council of Canada to SMP. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adams GR, 2002, J APPL PHYSIOL, V93, P1159, DOI 10.1152/japplphysiol.01264.2001; Ahtiainen JP, 2005, J STRENGTH COND RES, V19, P572, DOI 10.1519/00124278-200508000-00015; Ahtiainen JP, 2003, EUR J APPL PHYSIOL, V89, P555, DOI 10.1007/s00421-003-0833-3; Ahtiainen JP, 2011, STEROIDS, V76, P183, DOI 10.1016/j.steroids.2010.10.012; Baar K, 1999, AM J PHYSIOL-CELL PH, V276, pC120, DOI 10.1152/ajpcell.1999.276.1.C120; Bamman MM, 2007, J APPL PHYSIOL, V102, P2232, DOI 10.1152/japplphysiol.00024.2007; Bamman MM, 2001, AM J PHYSIOL-ENDOC M, V280, pE383; Bhasin S, 1996, NEW ENGL J MED, V335, P1, DOI 10.1056/NEJM199607043350101; Burd NA, 2012, J PHYSIOL-LONDON, V590, P351, DOI 10.1113/jphysiol.2011.221200; Burd NA, 2010, J PHYSIOL-LONDON, V588, P3119, DOI 10.1113/jphysiol.2010.192856; Burd NA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012033; Campos GER, 2002, EUR J APPL PHYSIOL, V88, P50, DOI 10.1007/s00421-002-0681-6; Cermak NM, 2012, AM J CLIN NUTR, V96, P1454, DOI 10.3945/ajcn.112.037556; Churchward-Venne TA, 2012, J PHYSIOL-LONDON, V590, P2751, DOI 10.1113/jphysiol.2012.228833; Davidsen PK, 2011, J APPL PHYSIOL, V110, P309, DOI 10.1152/japplphysiol.00901.2010; DAYNES RA, 1993, J IMMUNOL, V150, P5219; de Souza TP, 2010, J STRENGTH COND RES, V24, P1843, DOI 10.1519/JSC.0b013e3181ddae4a; Dickinson JM, 2011, J NUTR, V141, P856, DOI 10.3945/jn.111.139485; Febbraio MA, 2002, FASEB J, V16, P1335, DOI 10.1096/fj.01-0876rev; Fonseca JE, 2009, AUTOIMMUN REV, V8, P538, DOI 10.1016/j.autrev.2009.01.012; Hartman JW, 2007, AM J CLIN NUTR, V86, P373, DOI 10.1093/ajcn/86.2.373; Kraemer WJ, 2010, CURR SPORT MED REP, V9, P242, DOI 10.1249/JSR.0b013e3181e976df; Kraemer WJ, 2005, SPORTS MED, V35, P339, DOI 10.2165/00007256-200535040-00004; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; McCall GE, 1999, CAN J APPL PHYSIOL, V24, P96, DOI 10.1139/h99-009; Mckay BR, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006027; McKay BR, 2008, J PHYSIOL-LONDON, V586, P5549, DOI 10.1113/jphysiol.2008.160176; Mitchell CJ, 2012, J APPL PHYSIOL, V113, P71, DOI 10.1152/japplphysiol.00307.2012; Nindl BC, 2012, AM J PHYSIOL-REG I, V303, pR1080, DOI 10.1152/ajpregu.00275.2012; Orsatti FL, 2012, J STRENGTH COND RES, V26, P2130, DOI 10.1519/JSC.0b013e318239f837; Park HS, 2005, DIABETES RES CLIN PR, V69, P29, DOI 10.1016/j.diabres.2004.11.007; Petrella JK, 2008, J APPL PHYSIOL, V104, P1736, DOI 10.1152/japplphysiol.01215.2007; Phillips BE, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003389; Phillips SM, 2004, NUTRITION, V20, P689, DOI 10.1016/j.nut.2004.04.009; Phillips SM, 2000, CAN J APPL PHYSIOL, V25, P185, DOI 10.1139/h00-014; Rommel C, 2001, NAT CELL BIOL, V3, P1009, DOI 10.1038/ncb1101-1009; Terzis G, 2008, EUR J APPL PHYSIOL, V102, P145, DOI 10.1007/s00421-007-0564-y; Thalacker-Mercer AE, 2009, APPL PHYSIOL NUTR ME, V34, P632, DOI 10.1139/H09-038; Timmons JA, 2011, J APPL PHYSIOL, V110, P846, DOI 10.1152/japplphysiol.00934.2010; Vingren JL, 2010, SPORTS MED, V40, P1037, DOI 10.2165/11536910-000000000-00000; West DWD, 2012, EUR J APPL PHYSIOL, V112, P2693, DOI 10.1007/s00421-011-2246-z; West DWD, 2010, J APPL PHYSIOL, V108, P60, DOI 10.1152/japplphysiol.01147.2009; Willoughby DS, 2004, MED SCI SPORT EXER, V36, P1499, DOI 10.1249/01.MSS.0000139795.83030.D1	43	115	117	1	25	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 9	2013	8	10							e78636	10.1371/journal.pone.0078636	http://dx.doi.org/10.1371/journal.pone.0078636			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	236PJ	24130904	Green Published, gold, Green Submitted			2023-01-03	WOS:000325810900144
J	Hung, MC; Hsieh, CL; Hwang, JS; Jeng, JS; Wang, JD				Hung, Mei-Chuan; Hsieh, Ching-Lin; Hwang, Jing-Shiang; Jeng, Jiann-Shing; Wang, Jung-Der			Estimation of the Long-Term Care Needs of Stroke Patients by Integrating Functional Disability and Survival	PLOS ONE			English	Article							1ST-EVER ISCHEMIC-STROKE; QUALITY-ADJUSTED SURVIVAL; BARTHEL INDEX; PSYCHOMETRIC CHARACTERISTICS; EXPECTED YEARS; YOUNG-ADULTS; RISK-FACTORS; LIFE LOST; AGED 15; SUBTYPES	Objectives: This study aimed to estimate the dynamic changes of different physical functional disabilities and life-time care needs for patients with stroke. Data Sources and Study Design: We examined a hospital-based cohort including 16,043 patients who had their first stroke during 1995-2010. The Barthel Index (BI) was used to measure disability levels in 1,162 consecutive patients, with a total of 1,294 measurements at the stroke clinics and the rehabilitation wards, and a cross-sectional design. Extraction Methods: The survival function was extrapolated to lifetime by a semi-parametric method and multiplied with proportions of different disabilities over time to obtain the long-term care needs for different stroke subtypes. Principal Findings: On average, stroke patients would suffer at least 0.86 years with mild disability, 1.24 years with moderate disability and 1.39 years with severe disability, as measured by the BI. Among these, patients with a cardio-embolic infarct or intracerebral hemorrhage (ICH) suffered more than 2 years of severe disability. Assistance in bathing was the most common need for care in stroke patients. Conclusions: Among different subtypes of stroke, cardio-embolic infarct and ICH lead to the longest durations of severe physical functional disability. The method presented in this work may also be applied to other chronic diseases and different functional disabilities.	[Hung, Mei-Chuan; Wang, Jung-Der] Natl Cheng Kung Univ Coll Med, Dept Publ Hlth, Tainan, Taiwan; [Hsieh, Ching-Lin] Natl Taiwan Univ, Sch Occupat Therapy, Coll Med, Taipei 10764, Taiwan; [Hsieh, Ching-Lin] Natl Taiwan Univ Hosp, Dept Phys Med & Rehabil, Taipei, Taiwan; [Hwang, Jing-Shiang] Acad Sinica, Inst Stat Sci, Taipei 11529, Taiwan; [Jeng, Jiann-Shing] Natl Taiwan Univ Hosp, Stroke Ctr, Taipei, Taiwan; [Jeng, Jiann-Shing] Natl Taiwan Univ Hosp, Dept Neurol, Taipei, Taiwan; [Wang, Jung-Der] Natl Cheng Kung Univ Hosp, Dept Internal Med, Tainan 70428, Taiwan; [Wang, Jung-Der] Natl Cheng Kung Univ Hosp, Dept Occupat & Environm Med, Tainan 70428, Taiwan	National Cheng Kung University; National Cheng Kung University Hospital; National Taiwan University; National Taiwan University; National Taiwan University Hospital; Academia Sinica - Taiwan; National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University Hospital; National Cheng Kung University; National Cheng Kung University Hospital; National Cheng Kung University; National Cheng Kung University Hospital	Jeng, JS (corresponding author), Natl Taiwan Univ Hosp, Stroke Ctr, Taipei, Taiwan.	jsjeng@ntu.edu.tw; jdwang121@gmail.com	Hwang, Jing-Shiang/AAP-2835-2021; Hsieh, Ching-Lin/G-6057-2011	Hwang, Jing-Shiang/0000-0002-5807-7583; Hsieh, Ching-Lin/0000-0001-9468-9969; JENG, JIANN-SHING/0000-0002-1456-3686	National Science Council of the Executive Yuan of Taiwan [NSC 102-2314-B-006-029-MY2, NSC 101-2314-B-006-077]	National Science Council of the Executive Yuan of Taiwan	This study is supported by the following two grants of the National Science Council of the Executive Yuan of Taiwan (NSC 102-2314-B-006-029-MY2 and NSC 101-2314-B-006-077). The funding agency has no role or interference in the hypothesis formation, study design, data analysis, inference, or conclusion.	ADAMS HP, 1993, STROKE, V24, P35, DOI 10.1161/01.STR.24.1.35; [Anonymous], 2007, HLTH EXPECTANCY CALC; Castellani RJ, 2010, DM-DIS MON, V56, P484, DOI 10.1016/j.disamonth.2010.06.001; Chu PC, 2008, VALUE HEALTH, V11, P1102, DOI 10.1111/j.1524-4733.2008.00350.x; Della Pietra GL, 2011, STROKE, V42, P2077, DOI 10.1161/STROKEAHA.111.613521; Fang CT, 2007, QJM-INT J MED, V100, P97, DOI 10.1093/qjmed/hcl141; Go AS, 2013, CIRCULATION, V127, pE6, DOI 10.1161/CIR.0b013e31828124ad; GRANGER CV, 1979, ARCH PHYS MED REHAB, V60, P14; Grau AJ, 2001, STROKE, V32, P2559, DOI 10.1161/hs1101.098524; Hsueh IP, 2001, J FORMOS MED ASSOC, V100, P526; Hsueh IP, 2002, J NEUROL NEUROSUR PS, V73, P188, DOI 10.1136/jnnp.73.2.188; Hwang JS, 1999, STAT MED, V18, P1627, DOI 10.1002/(SICI)1097-0258(19990715)18:13<1627::AID-SIM159>3.3.CO;2-4; Hwang JS, 1996, STAT MED, V15, P93, DOI 10.1002/(SICI)1097-0258(19960115)15:1<93::AID-SIM155>3.0.CO;2-2; Kimura K, 2004, CEREBROVASC DIS, V18, P47, DOI 10.1159/000078749; Kolominsky-Rabas PL, 2001, STROKE, V32, P2735, DOI 10.1161/hs1201.100209; Lee ET, 2009, STAT METHODS SURVIVA, P64; Lee HY, 2010, STROKE, V41, P739, DOI 10.1161/STROKEAHA.109.573543; Liu PH, 2013, PREV MED, V56, P309, DOI 10.1016/j.ypmed.2013.02.003; Petty GW, 2000, STROKE, V31, P1062, DOI 10.1161/01.STR.31.5.1062; Putaala J, 2009, STROKE, V40, P2698, DOI 10.1161/STROKEAHA.109.554998; Putaala J, 2009, STROKE, V40, P1195, DOI 10.1161/STROKEAHA.108.529883; Quinn TJ, 2011, STROKE, V42, P1146, DOI 10.1161/STROKEAHA.110.598540; Shin SY, 2012, J GERONTOL NURS, V38, P33, DOI 10.3928/00989134-20120807-03; Spengos K, 2010, EUR J NEUROL, V17, P1358, DOI 10.1111/j.1468-1331.2010.03065.x; Turin TC, 2010, STROKE, V41, P1871, DOI 10.1161/STROKEAHA.110.581033; Uyttenboogaart M, 2005, STROKE, V36, P1984, DOI 10.1161/01.STR.0000177872.87960.61; Xie J., 2007, Morbidity and Mortality Weekly Report, V56, P504; Yip PK, 1997, STROKE, V28, P2507, DOI 10.1161/01.STR.28.12.2507	28	16	16	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 4	2013	8	10							e75605	10.1371/journal.pone.0075605	http://dx.doi.org/10.1371/journal.pone.0075605			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	232JF	24124500	Green Published, gold, Green Submitted			2023-01-03	WOS:000325489100057
J	Wang, J; Ptacek, JB; Kirkegaard, K; Bullitt, E				Wang, Jing; Ptacek, Jennifer B.; Kirkegaard, Karla; Bullitt, Esther			Double-membraned Liposomes Sculpted by Poliovirus 3AB Protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPLICATION COMPLEX; ENDOPLASMIC-RETICULUM; RNA REPLICATION; POLYMERASE 3D(POL); VIRUS-REPLICATION; VIRAL-PROTEINS; IN-VITRO; ASSOCIATION; ARCHITECTURE; LC3	Infection with many positive-strand RNA viruses dramatically remodels cellular membranes, resulting in the accumulation of double-membraned vesicles that resemble cellular autophagosomes. In this study, a single protein encoded by poliovirus, 3AB, is shown to be sufficient to induce the formation of double-membraned liposomes via the invagination of single-membraned liposomes. Poliovirus 3AB is a 109-amino acid protein with a natively unstructured N-terminal domain. HeLa cells transduced with 3AB protein displayed intracellular membrane disruption; specifically, the formation of cytoplasmic invaginations. The ability of a single viral protein to produce structures of similar topology to cellular autophagosomes should facilitate the understanding of both cellular and viral mechanisms for membrane remodeling.	[Wang, Jing; Bullitt, Esther] Boston Univ, Sch Med, Dept Physiol & Biophys, Boston, MA 02118 USA; [Ptacek, Jennifer B.; Kirkegaard, Karla] Stanford Univ, Sch Med, Dept Microbiol & Immunol, Stanford, CA 94301 USA	Boston University; Stanford University	Kirkegaard, K (corresponding author), Stanford Univ, Sch Med, Dept Microbiol & Immunol, 299 Campus Dr,Fairchild D325, Stanford, CA 94301 USA.	karlak@stanford.edu; bullitt@bu.edu		Bullitt, Esther/0000-0003-2447-6209	National Institutes of Health [GM102474]; American Cancer Society; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR025434] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM102474] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Cancer Society(American Cancer Society); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported, in whole or in part, by the National Institutes of Health Director's Pioneer Award (to K. K.) and National Institutes of Health Grant GM102474 (to E. B.). This work was also supported by the American Cancer Society (to J. B. P.).	Belov GA, 2012, J VIROL, V86, P302, DOI 10.1128/JVI.05937-11; Belov GA, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000216; BIENZ K, 1992, J VIROL, V66, P2740, DOI 10.1128/JVI.66.5.2740-2747.1992; BIENZ K, 1987, VIROLOGY, V160, P220, DOI 10.1016/0042-6822(87)90063-8; BIENZ K, 1990, J VIROL, V64, P1156, DOI 10.1128/JVI.64.3.1156-1163.1990; Boura E, 2012, STRUCTURE, V20, P874, DOI 10.1016/j.str.2012.03.008; CHO MW, 1994, VIROLOGY, V202, P129, DOI 10.1006/viro.1994.1329; Dafforn TR, 2004, EMBO REP, V5, P1046, DOI 10.1038/sj.embor.7400276; DALES S, 1973, BACTERIOL REV, V37, P103, DOI 10.1128/MMBR.37.2.103-135.1973; DALES S, 1965, AM J MED, V38, P699, DOI 10.1016/0002-9343(65)90191-9; Dodd DA, 2001, J VIROL, V75, P8158, DOI 10.1128/JVI.75.17.8158-8165.2001; Doedens JR, 1997, J VIROL, V71, P9054, DOI 10.1128/JVI.71.12.9054-9064.1997; Egger D, 1996, J VIROL, V70, P8675, DOI 10.1128/JVI.70.12.8675-8683.1996; Ehrlich LS, 2011, J MOL BIOL, V413, P347, DOI 10.1016/j.jmb.2011.08.038; Ferraris P, 2010, J GEN VIROL, V91, P2230, DOI 10.1099/vir.0.022186-0; Fujita K, 2007, BIOCHEMISTRY-US, V46, P5185, DOI 10.1021/bi6024758; Gosert R, 2003, J VIROL, V77, P5487, DOI 10.1128/JVI.77.9.5487-5492.2003; Gosert R, 2002, J VIROL, V76, P3697, DOI 10.1128/JVI.76.8.3697-3708.2002; Haas A, 2007, TRAFFIC, V8, P311, DOI 10.1111/j.1600-0854.2006.00531.x; HARRIS KS, 1994, J BIOL CHEM, V269, P27004; Hayashi-Nishino M, 2009, NAT CELL BIOL, V11, P1433, DOI 10.1038/ncb1991; Heaton NS, 2010, CELL HOST MICROBE, V8, P422, DOI 10.1016/j.chom.2010.10.006; Hoekstra D., 1991, MEMBRANE FUSION, P89; Hsu NY, 2010, CELL, V141, P799, DOI 10.1016/j.cell.2010.03.050; Jackson WT, 2005, PLOS BIOL, V3, P861, DOI 10.1371/journal.pbio.0030156; Khan SH, 2012, MOL BIOSYST, V8, P91, DOI 10.1039/c1mb05265a; LAMA J, 1994, J BIOL CHEM, V269, P66; Lanman J, 2008, J STRUCT BIOL, V161, P439, DOI 10.1016/j.jsb.2007.09.009; Longatti A, 2009, CELL DEATH DIFFER, V16, P956, DOI 10.1038/cdd.2009.39; Mateo R, 2013, J VIROL, V87, P1312, DOI 10.1128/JVI.02177-12; McLaughlin S, 2005, NATURE, V438, P605, DOI 10.1038/nature04398; McMahon HT, 2005, NATURE, V438, P590, DOI 10.1038/nature04396; MOLLA A, 1994, J BIOL CHEM, V269, P27015; Nakatogawa H, 2007, CELL, V130, P165, DOI 10.1016/j.cell.2007.05.021; O'Donnell V, 2011, VIROLOGY, V410, P142, DOI 10.1016/j.virol.2010.10.042; Pasieka TJ, 2003, J VIROL METHODS, V111, P157, DOI 10.1016/S0166-0934(03)00152-6; Paul AV, 1998, VIROLOGY, V250, P241, DOI 10.1006/viro.1998.9376; PAUL AV, 1994, J BIOL CHEM, V269, P29173; Peker B, 2004, BIOTECHNOL PROGR, V20, P262, DOI 10.1021/bp034182n; PLOTCH SJ, 1995, J VIROL, V69, P7169, DOI 10.1128/JVI.69.11.7169-7179.1995; Prinz WA, 2009, CRIT REV BIOCHEM MOL, V44, P278, DOI 10.1080/10409230903183472; Ragusa MJ, 2012, CELL, V151, P1501, DOI 10.1016/j.cell.2012.11.028; Schlegel A, 1996, J VIROL, V70, P6576, DOI 10.1128/JVI.70.10.6576-6588.1996; Schwartz M, 2002, MOL CELL, V9, P505, DOI 10.1016/S1097-2765(02)00474-4; SEDDON JM, 1990, BIOCHIM BIOPHYS ACTA, V1031, P1, DOI 10.1016/0304-4157(90)90002-T; Sou Y, 2006, J BIOL CHEM, V281, P3017, DOI 10.1074/jbc.M505888200; Spagnolo JF, 2010, RNA, V16, P382, DOI 10.1261/rna.1955410; Strauss DM, 2003, J MOL BIOL, V330, P225, DOI 10.1016/S0022-2836(03)00577-1; Suhy DA, 2000, J VIROL, V74, P8953, DOI 10.1128/JVI.74.19.8953-8965.2000; Takahashi Y, 2009, CELL DEATH DIFFER, V16, P947, DOI 10.1038/cdd.2009.19; Taylor MP, 2007, J VIROL, V81, P12543, DOI 10.1128/JVI.00755-07; Teterina NL, 2006, J VIROL, V80, P5327, DOI 10.1128/JVI.02684-05; Teterina NL, 2011, J VIROL, V85, P4284, DOI 10.1128/JVI.02398-10; Thaa B, 2011, BIOCHEM J, V437, P389, DOI 10.1042/BJ20110706; Towner JS, 1996, J BIOL CHEM, V271, P26810, DOI 10.1074/jbc.271.43.26810; Uchil PD, 2003, J BIOL CHEM, V278, P24388, DOI 10.1074/jbc.M301717200; van Meer G, 2008, NAT REV MOL CELL BIO, V9, P112, DOI 10.1038/nrm2330; VerPlank L, 2001, P NATL ACAD SCI USA, V98, P7724, DOI 10.1073/pnas.131059198; Weidberg H, 2011, DEV CELL, V20, P444, DOI 10.1016/j.devcel.2011.02.006; Weill CO, 2008, CYTOTECHNOLOGY, V56, P41, DOI 10.1007/s10616-007-9102-3; Welsch S, 2009, CELL HOST MICROBE, V5, P365, DOI 10.1016/j.chom.2009.03.007; Wollert T, 2009, NATURE, V458, P172, DOI 10.1038/nature07836; Wong J, 2008, J VIROL, V82, P9143, DOI 10.1128/JVI.00641-08; Xiang WK, 1995, RNA, V1, P892; Xiang WK, 1998, J VIROL, V72, P6732, DOI 10.1128/JVI.72.8.6732-6741.1998; Zimmerberg J, 2006, NAT REV MOL CELL BIO, V7, P9, DOI 10.1038/nrm1784	66	15	15	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 20	2013	288	38					27287	27298		10.1074/jbc.M113.498899	http://dx.doi.org/10.1074/jbc.M113.498899			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	302IG	23908350	Green Published, hybrid			2023-01-03	WOS:000330597300025
J	Sliwkowski, MX; Mellman, I				Sliwkowski, Mark X.; Mellman, Ira			Antibody Therapeutics in Cancer	SCIENCE			English	Review							GROWTH-FACTOR RECEPTOR; METASTATIC BREAST-CANCER; CELL LUNG-CANCER; DRUG CONJUGATE; GEMTUZUMAB OZOGAMICIN; TRASTUZUMAB EMTANSINE; MONOCLONAL-ANTIBODIES; EFFECTOR FUNCTIONS; COLORECTAL-CANCER; CYTOTOXIC DRUG	In a relatively short period of time, monoclonal antibodies have entered the mainstream of cancer therapy. Their first use was as antagonists of oncogenic receptor tyrosine kinases, but today monoclonal antibodies have emerged as long-sought vehicles for the targeted delivery of potent chemotherapeutic agents and as powerful tools to manipulate anticancer immune responses. With ever more promising results from the clinic, the future will likely see continued growth in the discovery and development of therapeutic antibodies and their derivatives.	[Sliwkowski, Mark X.; Mellman, Ira] Genentech Inc, San Francisco, CA 94080 USA	Roche Holding; Genentech	Sliwkowski, MX (corresponding author), Genentech Inc, 1 DNA Way, San Francisco, CA 94080 USA.	marks@gene.com; mellman.ira@gene.com	Mellman, Ira/ABG-5896-2020					Astsaturov I, 2006, CURR CANCER DRUG TAR, V6, P691, DOI 10.2174/156800906779010191; Bargou R, 2008, SCIENCE, V321, P974, DOI 10.1126/science.1158545; Baselga J, 2012, NEW ENGL J MED, V366, P109, DOI 10.1056/NEJMoa1113216; Baselga J, 2010, J CLIN ONCOL, V28, P1138, DOI 10.1200/JCO.2009.24.2024; Brahmer JR, 2010, J CLIN ONCOL, V28, P3167, DOI 10.1200/JCO.2009.26.7609; Carter PJ, 2006, NAT REV IMMUNOL, V6, P343, DOI 10.1038/nri1837; Castaigne S, 2013, BLOOD, V121, P4813, DOI 10.1182/blood-2013-05-498683; Chambers CA, 2001, ANNU REV IMMUNOL, V19, P565, DOI 10.1146/annurev.immunol.19.1.565; Chan AC, 2010, NAT REV IMMUNOL, V10, P301, DOI 10.1038/nri2761; Chen DS, 2013, IMMUNITY, V39, P1, DOI 10.1016/j.immuni.2013.07.012; Clynes RA, 2000, NAT MED, V6, P443, DOI 10.1038/74704; Eberhard DA, 2005, J CLIN ONCOL, V23, P5900, DOI 10.1200/JCO.2005.02.857; Erickson HK, 2012, MOL CANCER THER, V11, P1133, DOI 10.1158/1535-7163.MCT-11-0727; Ferrara N, 2004, NAT REV DRUG DISCOV, V3, P391, DOI 10.1038/nrd1381; Garrett CR, 2011, EXPERT OPIN BIOL TH, V11, P937, DOI 10.1517/14712598.2011.582464; Geyer CE, 2006, NEW ENGL J MED, V355, P2733, DOI 10.1056/NEJMoa064320; Gianni L, 2012, LANCET ONCOL, V13, P25, DOI 10.1016/S1470-2045(11)70336-9; Hamid O, 2013, NEW ENGL J MED, V369, P134, DOI 10.1056/NEJMoa1305133; Herbst RS, 2005, J CLIN ONCOL, V23, P5892, DOI 10.1200/JCO.2005.02.840; Herbst RS, 2013, J CLIN ONCOL S, V31; Hirsch FR, 2013, J THORAC ONCOL, V8, P373, DOI 10.1097/JTO.0b013e31827ed0ff; Hodi FS, 2010, NEW ENGL J MED, V363, P711, DOI 10.1056/NEJMoa1003466; Hurvitz SA, 2012, CLIN CANCER RES, V18, P3478, DOI 10.1158/1078-0432.CCR-11-2294; Jin HK, 2008, CANCER RES, V68, P4360, DOI 10.1158/0008-5472.CAN-07-5960; JONES PT, 1986, NATURE, V321, P522, DOI 10.1038/321522a0; Junttila TT, 2009, CANCER CELL, V15, P429, DOI 10.1016/j.ccr.2009.03.020; Junutula JR, 2008, NAT BIOTECHNOL, V26, P925, DOI 10.1038/nbt.1480; Kalos M, 2013, IMMUNITY, V39, P49, DOI 10.1016/j.immuni.2013.07.002; Keir ME, 2008, ANNU REV IMMUNOL, V26, P677, DOI 10.1146/annurev.immunol.26.021607.090331; Kubota T, 2009, CANCER SCI, V100, P1566, DOI 10.1111/j.1349-7006.2009.01222.x; LEWIS GD, 1993, CANCER IMMUNOL IMMUN, V37, P255, DOI 10.1007/BF01518520; LoRusso PM, 2011, CLIN CANCER RES, V17, P6437, DOI 10.1158/1078-0432.CCR-11-0762; Mathas S, 2000, CANCER RES, V60, P7170; McCormack E, 2013, CANCER IMMUNOL IMMUN, V62, P773, DOI 10.1007/s00262-012-1384-4; Mellman I, 2011, NATURE, V480, P480, DOI 10.1038/nature10673; Mendelsohn J, 2000, ONCOGENE, V19, P6550, DOI 10.1038/sj.onc.1204082; Okeley NM, 2010, CLIN CANCER RES, V16, P888, DOI 10.1158/1078-0432.CCR-09-2069; Olafsen Tove, 2012, Methods Mol Biol, V907, P537, DOI 10.1007/978-1-61779-974-7_31; Park S, 2010, CANCER CELL, V18, P160, DOI 10.1016/j.ccr.2010.06.014; Phillips GDL, 2008, CANCER RES, V68, P9280, DOI 10.1158/0008-5472.CAN-08-1776; Raju TS, 2008, CURR OPIN IMMUNOL, V20, P471, DOI 10.1016/j.coi.2008.06.007; Ricart AD, 2011, CLIN CANCER RES, V17, P6417, DOI 10.1158/1078-0432.CCR-11-0486; RIECHMANN L, 1988, NATURE, V332, P323, DOI 10.1038/332323a0; Rispens T, 2013, MOL IMMUNOL, V53, P35, DOI 10.1016/j.molimm.2012.06.012; Schaefer G, 2011, CANCER CELL, V20, P472, DOI 10.1016/j.ccr.2011.09.003; Selby MJ, 2013, CANCER IMMUNOL RES, V1, P32, DOI 10.1158/2326-6066.CIR-13-0013; Sievers EL, 2001, CURR OPIN ONCOL, V13, P522, DOI 10.1097/00001622-200111000-00016; Simpson TR, 2013, J EXP MED; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; Stagg J, 2011, P NATL ACAD SCI USA, V108, P7142, DOI 10.1073/pnas.1016569108; Swain SM, 2013, LANCET ONCOL, V14, P461, DOI 10.1016/S1470-2045(13)70130-X; Topalian SL, 2012, NEW ENGL J MED, V366, P2443, DOI 10.1056/NEJMoa1200690; Topalian SL, 2012, CURR OPIN IMMUNOL, V24, P207, DOI 10.1016/j.coi.2011.12.009; Verma S, 2012, NEW ENGL J MED, V367, P1783, DOI 10.1056/NEJMoa1209124; Weickhardt AJ, 2012, J CLIN ONCOL, V30, P1505, DOI 10.1200/JCO.2011.38.6599; Wilson NS, 2011, CANCER CELL, V19, P101, DOI 10.1016/j.ccr.2010.11.012; Wolchok JD, 2013, NEW ENGL J MED, V369, P122, DOI 10.1056/NEJMoa1302369; Wolf E, 2005, DRUG DISCOV TODAY, V10, P1237, DOI 10.1016/S1359-6446(05)03554-3; Younes A, 2010, NEW ENGL J MED, V363, P1812, DOI 10.1056/NEJMoa1002965	60	410	455	19	399	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 13	2013	341	6151					1192	1198		10.1126/science.1241145	http://dx.doi.org/10.1126/science.1241145			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	215ZA	24031011				2023-01-03	WOS:000324248800031
J	Schugar, RC; Huang, XJ; Moll, AR; Brunt, EM; Crawford, PA				Schugar, Rebecca C.; Huang, Xiaojing; Moll, Ashley R.; Brunt, Elizabeth M.; Crawford, Peter A.			Role of Choline Deficiency in the Fatty Liver Phenotype of Mice Fed a Low Protein, Very Low Carbohydrate Ketogenic Diet	PLOS ONE			English	Article							KETONE-BODY METABOLISM; INSULIN-RESISTANCE; MITOCHONDRIAL DYSFUNCTION; CONTROL MECHANISMS; ACID OXIDATION; RAT; WEIGHT; METHIONINE; DISEASE; GLUCONEOGENESIS	Though widely employed for clinical intervention in obesity, metabolic syndrome, seizure disorders and other neurodegenerative diseases, the mechanisms through which low carbohydrate ketogenic diets exert their ameliorative effects still remain to be elucidated. Rodent models have been used to identify the metabolic and physiologic alterations provoked by ketogenic diets. A commonly used rodent ketogenic diet (Bio-Serv F3666) that is very high in fat (similar to 94% kcal), very low in carbohydrate (similar to 1% kcal), low in protein (similar to 5% kcal), and choline restricted (similar to 300 mg/kg) provokes robust ketosis and weight loss in mice, but through unknown mechanisms, also causes significant hepatic steatosis, inflammation, and cellular injury. To understand the independent and synergistic roles of protein restriction and choline deficiency on the pleiotropic effects of rodent ketogenic diets, we studied four custom diets that differ only in protein (5% kcal vs. 10% kcal) and choline contents (300 mg/kg vs. 5 g/kg). C57BL/6J mice maintained on the two 5% kcal protein diets induced the most significant ketoses, which was only partially diminished by choline replacement. Choline restriction in the setting of 10% kcal protein also caused moderate ketosis and hepatic fat accumulation, which were again attenuated when choline was replete. Key effects of the 5% kcal protein diet - weight loss, hepatic fat accumulation, and mitochondrial ultrastructural disarray and bioenergetic dysfunction - were mitigated by choline repletion. These studies indicate that synergistic effects of protein restriction and choline deficiency influence integrated metabolism and hepatic pathology in mice when nutritional fat content is very high, and support the consideration of dietary choline content in ketogenic diet studies in rodents to limit hepatic mitochondrial dysfunction and fat accumulation.	[Schugar, Rebecca C.; Huang, Xiaojing; Moll, Ashley R.; Crawford, Peter A.] Washington Univ, Dept Med, Cardiovasc Res Ctr, St Louis, MO 63130 USA; [Brunt, Elizabeth M.] Washington Univ, Dept Pathol & Immunol, St Louis, MO USA; [Crawford, Peter A.] Washington Univ, Dept Genet, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Crawford, PA (corresponding author), Washington Univ, Dept Med, Cardiovasc Res Ctr, St Louis, MO 63130 USA.	pcrawford@wustl.edu	Huang, Xiaojing/GOV-3212-2022	Crawford, Peter/0000-0001-8597-4426; Huang, Xiaojing/0000-0003-0107-0783	NIH [HL007275, DK091538]; Diabetic Cardiovascular Disease Center at Washington University; David and Deborah Winston Fellowship in Diabetic Cardiovascular Disease; Diabetic Research Center [DK020579]; Nutrition and Obesity Research Center at Washington University School of Medicine [DK056341]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020579, P30DK020579, P30DK056341, R01DK091538] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Diabetic Cardiovascular Disease Center at Washington University; David and Deborah Winston Fellowship in Diabetic Cardiovascular Disease; Diabetic Research Center; Nutrition and Obesity Research Center at Washington University School of Medicine; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported in part by NIH grants HL007275 (a training grant that supports RCS), DK091538 (to PAC), and a grant from the Diabetic Cardiovascular Disease Center at Washington University (to PAC), the David and Deborah Winston Fellowship in Diabetic Cardiovascular Disease (to RCS), the Diabetic Research Center (DK020579), and the Nutrition and Obesity Research Center (DK056341) at Washington University School of Medicine. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ables GP, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051357; Aguila M, 2003, LIVER INT, V23, P363, DOI 10.1034/j.1478-3231.2003.00858.x; An J, 2004, NAT MED, V10, P268, DOI 10.1038/nm995; Arendt BM, 2013, APPL PHYSIOL NUTR ME, V38, P334, DOI 10.1139/apnm-2012-0261; Badman MK, 2007, CELL METAB, V5, P426, DOI 10.1016/j.cmet.2007.05.002; Badman MK, 2009, ENDOCRINOLOGY, V150, P4931, DOI 10.1210/en.2009-0532; Badman MK, 2009, AM J PHYSIOL-ENDOC M, V297, pE1197, DOI 10.1152/ajpendo.00357.2009; Bielohuby M, 2011, AM J PHYSIOL-ENDOC M, V300, pE65, DOI 10.1152/ajpendo.00478.2010; Browning JD, 2011, AM J CLIN NUTR, V93, P1048, DOI 10.3945/ajcn.110.007674; Caballero F, 2010, J BIOL CHEM, V285, P18528, DOI 10.1074/jbc.M109.099333; COLBEAU A, 1971, BIOCHIM BIOPHYS ACTA, V249, P462, DOI 10.1016/0005-2736(71)90123-4; Corbin KD, 2012, CURR OPIN GASTROEN, V28, P159, DOI 10.1097/MOG.0b013e32834e7b4b; Cotter DG, 2013, AM J PHYSIOL-HEART C, V304, pH1060, DOI 10.1152/ajpheart.00646.2012; Crawford PA, 2009, P NATL ACAD SCI USA, V106, P11276, DOI 10.1073/pnas.0902366106; DANIAL NN, 2013, J CHILD NEUROL, P70253; DAUM G, 1985, BIOCHIM BIOPHYS ACTA, V822, P1, DOI 10.1016/0304-4157(85)90002-4; Fabbrini E, 2010, HEPATOLOGY, V51, P679, DOI 10.1002/hep.23280; FLORES H, 1970, BRIT J NUTR, V24, P1005, DOI 10.1079/BJN19700103; Foster GD, 2010, ANN INTERN MED, V153, P147, DOI 10.7326/0003-4819-153-3-201008030-00005; Freeman John M, 2010, Adv Pediatr, V57, P315, DOI 10.1016/j.yapd.2010.08.003; Garbow JR, 2011, AM J PHYSIOL-GASTR L, V300, pG956, DOI 10.1152/ajpgi.00539.2010; GOETTSCH M, 1960, J NUTR, V70, P307; Guerrerio AL, 2012, AM J CLIN NUTR, V95, P892, DOI 10.3945/ajcn.111.020156; Handler Philip, 1946, JOUR NUTRITION, V31, P141, DOI 10.1093/jn/31.2.141; Jornayvaz FR, 2010, AM J PHYSIOL-ENDOC M, V299, pE808, DOI 10.1152/ajpendo.00361.2010; Kennedy AR, 2007, AM J PHYSIOL-ENDOC M, V292, pE1724, DOI 10.1152/ajpendo.00717.2006; Kirk JK, 2008, J AM DIET ASSOC, V108, P91, DOI 10.1016/j.jada.2007.10.003; KREBS HA, 1970, BIOCHEM J, V119, P525, DOI 10.1042/bj1190525; Krebs P, 2011, P NATL ACAD SCI USA, V108, P19678, DOI 10.1073/pnas.1117835108; Lehman JJ, 2008, AM J PHYSIOL-HEART C, V295, pH185, DOI 10.1152/ajpheart.00081.2008; Li ZY, 2006, CELL METAB, V3, P321, DOI 10.1016/j.cmet.2006.03.007; Maalouf M, 2009, BRAIN RES REV, V59, P293, DOI 10.1016/j.brainresrev.2008.09.002; MacDonald MJ, 2005, AM J PHYSIOL-ENDOC M, V288, pE1, DOI 10.1152/ajpendo.00218.2004; Maher JJ, 2011, ANTIOXID REDOX SIGN, V15, P535, DOI 10.1089/ars.2010.3749; Mas E, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007929; MCMAHON KE, 1986, J NUTR, V116, P936, DOI 10.1093/jn/116.6.936; Oliveira CPMS, 2006, BRAZ J MED BIOL RES, V39, P189, DOI 10.1590/S0100-879X2006000200004; Osman C, 2011, J CELL BIOL, V192, P7, DOI 10.1083/jcb.201006159; Paumard P, 2002, EMBO J, V21, P221, DOI 10.1093/emboj/21.3.221; Petrosillo G, 2007, BBA-BIOENERGETICS, V1767, P1260, DOI 10.1016/j.bbabio.2007.07.011; Pickens MK, 2010, LIVER INT, V30, P1229, DOI 10.1111/j.1478-3231.2010.02285.x; Pickens MK, 2009, J LIPID RES, V50, P2072, DOI 10.1194/jlr.M900022-JLR200; Poff AM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065522; Raubenheimer PJ, 2006, DIABETES, V55, P2015, DOI 10.2337/db06-0097; Romestaing C, 2008, AM J PHYSIOL-ENDOC M, V294, pE110, DOI 10.1152/ajpendo.00407.2007; Ruskin DN, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065021; Sanchez-Garrido MA, 2009, INNATE IMMUN-LONDON, V15, P337, DOI 10.1177/1753425909104900; Serviddio G, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024084; Seyfried TN, 2011, BBA-BIOENERGETICS, V1807, P577, DOI 10.1016/j.bbabio.2010.08.009; Shai I, 2008, NEW ENGL J MED, V359, P229, DOI 10.1056/NEJMoa0708681; SHIEMKE AK, 1995, ARCH BIOCHEM BIOPHYS, V321, P421, DOI 10.1006/abbi.1995.1413; Srivastava S, 2013, IUBMB LIFE, V65, P58, DOI 10.1002/iub.1102; Sunny NE, 2011, CELL METAB, V14, P804, DOI 10.1016/j.cmet.2011.11.004; Tasseva G, 2013, J BIOL CHEM, V288, P4158, DOI 10.1074/jbc.M112.434183; Teodoro JS, 2008, MITOCHONDRION, V8, P367, DOI 10.1016/j.mito.2008.07.008; Thio LL, 2006, PEDIATR RES, V60, P413, DOI 10.1203/01.pdr.0000238244.54610.27; Veech RL, 2004, PROSTAG LEUKOTR ESS, V70, P309, DOI 10.1016/j.plefa.2003.09.007; Wentz AE, 2010, J BIOL CHEM, V285, P24447, DOI 10.1074/jbc.M110.100651; Westman EC, 2007, AM J CLIN NUTR, V86, P276, DOI 10.1093/ajcn/86.2.276; WILLIAMSON JR, 1969, J BIOL CHEM, V244, P4617; WILLIAMSON JR, 1969, J BIOL CHEM, V244, P4607; Wu GS, 2012, J OBES, V2012, DOI 10.1155/2012/319172; Yang XX, 2010, J MOL NEUROSCI, V42, P145, DOI 10.1007/s12031-010-9336-y; Yao J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021788; Zick M, 2009, BBA-MOL CELL RES, V1793, P5, DOI 10.1016/j.bbamcr.2008.06.013	65	33	33	0	18	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 29	2013	8	8							e74806	10.1371/journal.pone.0074806	http://dx.doi.org/10.1371/journal.pone.0074806			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	209DO	24009777	Green Published, gold, Green Submitted			2023-01-03	WOS:000323734600087
J	Takanashi, K; Quyen, DT; Le Hoa, NT; Khan, NC; Yasuoka, J; Jimba, M				Takanashi, Kumiko; Dao To Quyen; Nguyen Thi Le Hoa; Nguyen Cong Khan; Yasuoka, Junko; Jimba, Masamine			Long-Term Impact of Community-Based Information, Education and Communication Activities on Food Hygiene and Food Safety Behaviors in Vietnam: A Longitudinal Study	PLOS ONE			English	Article							DIARRHEA; INTERVENTION; SANITATION; PROMOTION; CHILDREN; WATER; COUNTRIES; CHANNELS; HANOI; WOMEN	Background: Ingestion of contaminated water or food is a major contributor to childhood diarrhea in developing countries. In Vietnam, the use of community-based information, education and communication (IEC) activities could be a sustainable strategy to improve food hygiene and food safety behaviors. This study thus examined the long-term impact of community-based IEC activities on food hygiene and food safety behaviors. Methods: In this longitudinal study, we interviewed caregivers of children aged between six months and four years in suburban Hanoi. Baseline data were collected in January 2006 (n = 125). After conducting IEC interventions, we collected a 1st set of evaluation data in January 2007 (n = 132). To examine the long-term impact of the interventions, we then collected a 2nd set of evaluation data in January 2008 (n = 185). Changes in childhood diarrhea prevalence, IEC coverage, and food hygiene and food safety behaviors were assessed over a two-year period using bivariate and logistic regression analyses. Effective IEC channels were determined through multiple linear regression analysis. Results: Childhood diarrhea was significantly reduced from 21.6% at baseline to 7.6% at the 1st post-intervention evaluation (P = 0.002), and to 5.9% at the 2nd evaluation. Among 17 food hygiene and food safety behaviors measured, a total of 11 behaviors were improved or maintained by the 2nd evaluation. Handwashing after toilet use was significantly improved at both evaluation points. Overall, 3 food safety behaviors and 7 food hygiene behaviors were found to have significantly improved at the 1st and at the 2nd evaluations, respectively. Flip chart communication administered by community groups was identified to be the most effective IEC channel for effecting behavior change (P = 0.018). Conclusions: Flip chart communication administered by community groups is effective for improving multiple food hygiene and food safety behaviors in sustainable ways, and should be included in water and health promotion programs.	[Takanashi, Kumiko; Yasuoka, Junko; Jimba, Masamine] Univ Tokyo, Grad Sch Med, Dept Community & Global Hlth, Tokyo, Japan; [Takanashi, Kumiko] Int Life Sci Inst Japan, Ctr Hlth Promot, Tokyo, Japan; [Dao To Quyen; Nguyen Thi Le Hoa] Natl Inst Nutr, Dept Food Sci & Safety, Hanoi, Vietnam; [Nguyen Cong Khan] Minist Hlth, Dept Sci & Training Management, Hanoi, Vietnam	University of Tokyo	Jimba, M (corresponding author), Univ Tokyo, Grad Sch Med, Dept Community & Global Hlth, Tokyo, Japan.	mjimba@m.u-tokyo.ac.jp	Jimba, Masamine/AAF-5630-2020; Yasuoka, Junko/GVT-8950-2022		Japan International Cooperation Agency	Japan International Cooperation Agency	This study was funded by the Grassroots Partner Project Fund from Japan International Cooperation Agency (http://www.jica.go.jp/). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	AHMED NU, 1993, SOC SCI MED, V37, P159, DOI 10.1016/0277-9536(93)90452-A; Bajracharya D, 2003, INT J ENVIRON HEAL R, V13, pS141, DOI 10.1080/0960312031000102903; Cairncross S, 2005, SOC SCI MED, V61, P2212, DOI 10.1016/j.socscimed.2005.04.019; Center for Rural Water Supply and Sanitation Ministry of Agriculture and Rural Development, 2003, GUID INF ED COMM RUR; Chase C, 2012, HANDWASHING BEHAV CH; CURTIS V, 1993, B WORLD HEALTH ORGAN, V71, P23; Curtis V, 2003, LANCET INFECT DIS, V3, P275, DOI 10.1016/S1473-3099(03)00606-6; Curtis V, 2001, B WORLD HEALTH ORGAN, V79, P518; Curtis V, 2000, TROP MED INT HEALTH, V5, P22, DOI 10.1046/j.1365-3156.2000.00512.x; Curtis V, 2011, LANCET INFECT DIS, V11, P312, DOI 10.1016/S1473-3099(10)70224-3; Ejemot-Nwadiaro RI, 2012, HAND WASHING PREVENT, P1; FEACHEM RG, 1984, B WORLD HEALTH ORGAN, V62, P467; Fewtrell L, 2005, LANCET INFECT DIS, V5, P42, DOI 10.1016/S1473-3099(04)01253-8; Food and Nutrition Technical Assistance, 1999, WAT SAN IND MEAS GUI; Hornik R., 2002, PUBLIC HLTH COMMUNIC; Hunter PR, 2010, BMC PUBLIC HEALTH, V10, DOI 10.1186/1471-2458-10-219; Joint FAO/WHO Codex Alimentarius Commission, 2003, FOOD HYG BAS TEXTS, P1; Lanata CF, 2003, INT J ENVIRON HEAL R, V13, pS175, DOI 10.1080/0960312031000102921; Laverack G., 2003, HLTH ED, V103, P363, DOI DOI 10.1108/09654280310502852; LOEVINSOHN BP, 1990, INT J EPIDEMIOL, V19, P788, DOI 10.1093/ije/19.4.788; Ministry of Health Center for Preventive Medicine of Nam Dinh Province, 2003, KAP PRES REP ASS KNO, P1; Nguyen TVH, 2008, WATER SCI TECHNOL, V58, P2403, DOI 10.2166/wst.2008.435; Nguyen TV, 2006, INT J INFECT DIS, V10, P298, DOI 10.1016/j.ijid.2005.05.009; Pinfold JV, 1996, T ROY SOC TROP MED H, V90, P366, DOI 10.1016/S0035-9203(96)90507-6; Pinfold JV, 1999, HEALTH EDUC RES, V14, P629, DOI 10.1093/her/14.5.629; Scott BE, 2008, HEALTH EDUC RES, V23, P392, DOI 10.1093/her/cym056; Sheth Mini, 2004, Indian Journal of Pediatrics, V71, P879, DOI 10.1007/BF02830824; Takanashi K, 2009, J HEALTH POPUL NUTR, V27, P602; Toure O, 2011, FOOD CONTROL, V22, P1565, DOI 10.1016/j.foodcont.2011.03.012; [UNICEF WHO], 2009, DIARRH WHY CHILDR ST; UNICEF Vietnam, 2002, EFF INF ED COMM VIET; van den Berg LM, 2003, ENVIRON URBAN, V15, P35, DOI 10.1177/095624780301500122; [Vietnam Ministry of Health UNICEF], 2011, SUMM REP STUD CORRE; Vietnam Ministry of Health, 2005, 142005QDBYT VIET MIN; Waterkeyn J, 2005, SOC SCI MED, V61, P1958, DOI 10.1016/j.socscimed.2005.04.012; WHO, 2006, 5 KEYS SAF FOOD MAN; WILSON JM, 1993, T ROY SOC TROP MED H, V87, P615, DOI 10.1016/0035-9203(93)90260-W; World Health Organization, 1996, BAS PRINC PREP SAF F; World Health Organization, 2001, INF ED COMM LESS PER	39	15	16	1	26	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 12	2013	8	8							e70654	10.1371/journal.pone.0070654	http://dx.doi.org/10.1371/journal.pone.0070654			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	200UV	23950978	Green Submitted, Green Published, gold			2023-01-03	WOS:000323097300038
J	Banstola, A; Banstola, A				Banstola, Amrit; Banstola, Ashik			The Epidemiology of Hospitalization for Pneumonia in Children under Five in the Rural Western Region of Nepal: A Descriptive Study	PLOS ONE			English	Article							CHILDHOOD PNEUMONIA; TAIWAN	Pneumonia is one of the major public health problems in children under five years of age. The aim of this study was to analyze the time, place, and characteristics of the distribution of pneumonia in hospitalized children under five years of age at the Dhaulagiri Zonal Hospital (DZH) in Nepal. A descriptive cross-sectional study was carried out at DZH from July 16, 2008 to August 17, 2011 for hospitalized children under five years of age and diagnosed with pneumonia. The main bacterial cause of pneumonia was Streptococcus pneumoniae and the main viral cause was Respiratory Syntical Virus (RSV). The majority of children admitted for treatment of pneumonia were males (60%), from upper class ethnic groups, and common among those aged 29 days to one year (49.1% of overall pneumonia cases). Data from this study show that pneumonia episodes in DZH occurred throughout the year with a sharp increase in the occurrence at the end of August to September. More cases were recorded during the rainy seasons and winter months in all three study years. The cases were from households most concentrated in Baglung municipality where the hospital is located. Pneumonia was found in higher proportions among hospitalized male children, those aged 29 days to one year, and in upper ethnic groups, during the rainy seasons and in winter months, and among local populations near the hospital in the rural western region of Nepal. Strengthening community-based case management, prevention strategies, and health care delivery system would help reduce pneumonia cases and the overall burden associated with it.	[Banstola, Amrit] Pokhara Univ, Sch Hlth & Allied Sci, Dept Publ Hlth, Kaski, Nepal; [Banstola, Ashik] Valley Coll Sci & Technol, Dept Pharm, Kathmandu, Nepal		Banstola, A (corresponding author), Pokhara Univ, Sch Hlth & Allied Sci, Dept Publ Hlth, Kaski, Nepal.	amritbanstola@outlook.com	Banstola, Amrit/T-4242-2019	Banstola, Amrit/0000-0003-3185-9638; Banstola, Ashik/0000-0002-2842-5567				Akbar MS, 1992, J CHILD HLTH, V16, P5; [Anonymous], 2009, GLOB ACT PLAN PREV C; Department of Health Services, 2012, 206768 MIN HLTH POP; Ghimire M, 2012, INDIAN J MED RES, V135, P459; Madhi SA, 2008, B WORLD HEALTH ORGAN, V86, P365, DOI 10.2471/BLT.07.044503; Mathisen M, 2009, BMC MED, V7, DOI 10.1186/1741-7015-7-35; Michelow IC, 2004, PEDIATRICS, V113, P701, DOI 10.1542/peds.113.4.701; Rudan I, 2008, B WORLD HEALTH ORGAN, V86, P408, DOI 10.2471/BLT.07.048769; Tsai HP, 2001, J CLIN MICROBIOL, V39, P111, DOI 10.1128/JCM.39.1.111-118.2001; Wahed MA, 2008, ORION MED J, V29, P519; Wardlaw TM, 2006, PNEUMONIA FORGOTTEN; World Health Organization, 2012, PNEUM; World Health Organization, 2011, PNEUM KEY FACTS; Wu PS, 2009, PEDIATR PULM, V44, P162, DOI 10.1002/ppul.20969	14	15	16	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 7	2013	8	8							e71311	10.1371/journal.pone.0071311	http://dx.doi.org/10.1371/journal.pone.0071311			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	200ZE	23940739	Green Submitted, Green Published, gold			2023-01-03	WOS:000323109700093
J	Sridharan, V; Tripathi, P; Sharma, S; Corry, PM; Moros, EG; Singh, A; Compadre, CM; Hauer-Jensen, M; Boerma, M				Sridharan, Vijayalakshmi; Tripathi, Preeti; Sharma, Sunil; Corry, Peter M.; Moros, Eduardo G.; Singh, Awantika; Compadre, Cesar M.; Hauer-Jensen, Martin; Boerma, Marjan			Effects of Late Administration of Pentoxifylline and Tocotrienols in an Image-Guided Rat Model of Localized Heart Irradiation	PLOS ONE			English	Article							VITAMIN-E; ENDOTHELIAL DYSFUNCTION; RADIATION-INJURY; CARDIAC-FUNCTION; EARLY-STAGE; THROMBOMODULIN; RADIOTHERAPY; DISEASE; DAMAGE; ALPHA	Radiation-induced heart disease (RIHD) is a long-term side effect of radiotherapy of intrathoracic, chest wall and breast tumors when radiation fields encompass all or part of the heart. Previous studies have shown that pentoxifylline (PTX) in combination with alpha-tocopherol reduced manifestations of RIHD in rat models of local heart irradiation. The relative contribution of PTX and alpha-tocopherol to these beneficial effects are not known. This study examined the effects of PTX alone or in combination with tocotrienols, forms of vitamin E with potential potent radiation mitigation properties. Rats received localized X-irradiation of the heart with an image-guided irradiation technique. At 3 months after irradiation rats received oral treatment with vehicle, PTX, or PTX in combination with a tocotrienol-enriched formulation. At 6 months after irradiation, PTX-treated rats showed arrhythmia in 5 out of 14 animals. PTX alone or in combination with tocotrienols did not alter cardiac radiation fibrosis, left ventricular protein expression of the endothelial markers von Willebrand factor and neuregulin-1, or phosphorylation of the signal mediators Akt, Erk1/2, or PKC alpha. On the other hand, tocotrienols reduced cardiac numbers of mast cells and macrophages, but enhanced the expression of tissue factor. While this new rat model of localized heart irradiation does not support the use of PTX alone, the effects of tocotrienols on chronic manifestations of RIHD deserve further investigation.	[Sridharan, Vijayalakshmi; Tripathi, Preeti; Hauer-Jensen, Martin; Boerma, Marjan] Univ Arkansas Med Sci, Div Radiat Hlth, Little Rock, AR 72205 USA; [Sharma, Sunil; Corry, Peter M.] Univ Arkansas Med Sci, Dept Radiat Oncol, Little Rock, AR 72205 USA; [Moros, Eduardo G.] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Radiat Oncol, Tampa, FL 33612 USA; [Singh, Awantika; Compadre, Cesar M.] Univ Arkansas Med Sci, Dept Pharmaceut Sci, Little Rock, AR 72205 USA; [Hauer-Jensen, Martin] Cent Arkansas Vet Healthcare Syst, Surg Serv, Little Rock, AR USA	University of Arkansas System; University of Arkansas Medical Sciences; University of Arkansas System; University of Arkansas Medical Sciences; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; University of Arkansas System; University of Arkansas Medical Sciences; US Department of Veterans Affairs; Veterans Health Administration (VHA); Central Arkansas Veterans Healthcare System	Boerma, M (corresponding author), Univ Arkansas Med Sci, Div Radiat Hlth, Little Rock, AR 72205 USA.	mboerma@uams.edu	Moros, Eduardo G./AAY-2771-2020; Compadre, Cesar M/D-1286-2009	Moros, Eduardo G./0000-0003-1964-2460; Compadre, Cesar M/0000-0002-5652-0203	American Cancer Society [RSG-10-125-01-CCE]; National Institutes of Health [CA148679, CA71382]; National Center for Research Resources [1UL1RR029884]; NATIONAL CANCER INSTITUTE [R01CA148679, R37CA071382, R01CA071382] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR029884] Funding Source: NIH RePORTER	American Cancer Society(American Cancer Society); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Center for Research Resources(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))	This work was supported in part by the American Cancer Society (RSG-10-125-01-CCE to MB), the National Institutes of Health (CA148679 to MB, CA71382 to MH-J), and the National Center for Research Resources (1UL1RR029884 to CMC). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Berbee M, 2012, GENES NUTR, V7, P75, DOI 10.1007/s12263-011-0228-8; Berbee M, 2011, RADIAT RES, V175, P297, DOI 10.1667/RR2399.1; Berbee M, 2011, INT J RADIAT ONCOL, V79, P884, DOI 10.1016/j.ijrobp.2010.08.032; Berbee M, 2009, RADIAT RES, V171, P596, DOI 10.1667/RR1632.1; Bian Y, 2009, AM J PHYSIOL-HEART C, V297, pH1974, DOI 10.1152/ajpheart.01010.2008; Boerma M, 2005, CANCER RES, V65, P3100, DOI 10.1158/0008-5472.CAN-04-4333; Boerma M, 2004, STRAHLENTHER ONKOL, V180, P109, DOI 10.1007/s00066-004-1138-0; Boerma M, 2008, INT J RADIAT ONCOL, V72, P170, DOI 10.1016/j.ijrobp.2008.04.042; Chera BS, 2009, INT J RADIAT ONCOL, V75, P1173, DOI 10.1016/j.ijrobp.2008.12.048; Coe DA, 1997, J SURG RES, V67, P21, DOI 10.1006/jsre.1996.4940; Conway EM, 2012, SEMIN IMMUNOPATHOL, V34, P107, DOI 10.1007/s00281-011-0282-8; Delanian S, 1999, J CLIN ONCOL, V17, P3283, DOI 10.1200/JCO.1999.17.10.3283; Devic S, 2005, MED PHYS, V32, P2245, DOI 10.1118/1.1929253; Early Breast Canc Trialists Collaborat, 2000, LANCET, V355, P1757, DOI 10.1016/S0140-6736(00)02263-7; FAJARDO LF, 1973, LAB INVEST, V29, P244; Fang CC, 2003, PERITON DIALYSIS INT, V23, P228; Galper SL, 2011, BLOOD, V117, P412, DOI 10.1182/blood-2010-06-291328; Ghobadi G, 2012, INT J RADIAT ONCOL, V84, pE639, DOI 10.1016/j.ijrobp.2012.07.2362; Heidenreich PA, 2009, HEART, V95, P252, DOI 10.1136/hrt.2008.149088; Hille A, 2005, STRAHLENTHER ONKOL, V181, P606, DOI 10.1007/s00066-005-1390-y; Hopewell JW, 1980, RAD BIOL CANCER RES, P449; Khosla P, 2006, ANTIOXID REDOX SIGN, V8, P1059, DOI 10.1089/ars.2006.8.1059; Kole TP, 2012, INT J RADIAT ONCOL, V83, P1580, DOI 10.1016/j.ijrobp.2011.10.053; Koutsi A, 2008, INT J BIOCHEM CELL B, V40, P1669, DOI 10.1016/j.biocel.2007.06.024; Lemmens K, 2004, CIRCULATION, V109, P324, DOI 10.1161/01.CIR.0000114521.88547.5E; Leroy J, 2011, J CLIN INVEST, V121, P2651, DOI 10.1172/JCI44747; Li XM, 2009, CLIN EXP PHARMACOL P, V36, P1054, DOI 10.1111/j.1440-1681.2009.05243.x; Liu H, 2009, INT J RADIAT ONCOL, V73, P1552, DOI 10.1016/j.ijrobp.2008.12.005; Liu QH, 2011, J MOL CELL CARDIOL, V51, P474, DOI 10.1016/j.yjmcc.2010.10.004; Liu XF, 2006, J AM COLL CARDIOL, V48, P1438, DOI 10.1016/j.jacc.2006.05.057; Ma CM, 2001, MED PHYS, V28, P868, DOI 10.1118/1.1374247; Malerba M, 2011, J BIOL REG HOMEOS AG, V25, P443; Moriwaki H, 2004, CIRC RES, V95, P637, DOI 10.1161/01.RES.0000141427.61023.f4; Naito Y, 2005, ATHEROSCLEROSIS, V180, P19, DOI 10.1016/j.atherosclerosis.2004.11.017; National Research Council of the National Academies, 2011, GUIDE CARE USE LAB A, V8th, DOI DOI 10.17226/12910; OHDAMA S, 1991, THROMB RES, V62, P745, DOI 10.1016/0049-3848(91)90378-A; Ozturk B, 2004, INT J RADIAT ONCOL, V58, P213, DOI 10.1016/S0360-3016(03)01444-5; PARKER RA, 1993, J BIOL CHEM, V268, P11230; Ravens U, 1996, MOL CELL BIOCHEM, V157, P245; Rose BA, 2010, PHYSIOL REV, V90, P1507, DOI 10.1152/physrev.00054.2009; Rube CE, 2002, RADIOTHER ONCOL, V64, P177, DOI 10.1016/S0167-8140(02)00077-4; Satyamitra MM, 2011, RADIAT RES, V175, P736, DOI 10.1667/RR2460.1; Sbroggio M, 2011, CARDIOVASC RES, V91, P456, DOI 10.1093/cvr/cvr103; SCHUBOTZ R, 1977, CURR MED RES OPIN, V4, P609, DOI 10.1185/03007997709115279; Seemann I, 2012, RADIOTHER ONCOL, V103, P143, DOI 10.1016/j.radonc.2011.10.011; Seigneur M, 1995, J CARDIOVASC PHARM, V25, pS85, DOI 10.1097/00005344-199500252-00018; Sharma S, 2013, TCRT EXPRESS, V1, P47; Song BL, 2006, J BIOL CHEM, V281, P25054, DOI 10.1074/jbc.M605575200; Sridharan V, 2013, INT J RAD B IN PRESS; Sridharan V, 2012, CANCER RES, V72, P4984, DOI 10.1158/0008-5472.CAN-12-1831; VERHEIJ M, 1995, THROMB HAEMOSTASIS, V73, P894; Verstegen NE, 2012, ANN ONCOL, V23, P46, DOI 10.1093/annonc/mds301; Wang JR, 2002, AM J PATHOL, V160, P2063, DOI 10.1016/S0002-9440(10)61156-X; Wang JR, 2007, WORLD J GASTROENTERO, V13, P3047, DOI 10.3748/wjg.v13.i22.3047; Wu WC, 2010, BRIT J RADIOL, V83, P252, DOI 10.1259/bjr/33094251; Zingg JM, 2007, VITAM HORM, V76, P393, DOI 10.1016/S0083-6729(07)76015-6	56	22	26	3	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 22	2013	8	7							e68762	10.1371/journal.pone.0068762	http://dx.doi.org/10.1371/journal.pone.0068762			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	187PW	23894340	Green Published, Green Submitted, gold			2023-01-03	WOS:000322132100023
J	Visser, K; Mortimer, M; Louw, A				Visser, Koch; Mortimer, Morne; Louw, Ann			Cyclopia Extracts Act as ER alpha Antagonists and ER beta Agonists, In Vitro and In Vivo	PLOS ONE			English	Article							ESTROGEN-RECEPTOR-BETA; NF-KAPPA-B; HUMAN-BREAST-CANCER; INTERLEUKIN-6 GENE-EXPRESSION; BONE-MINERAL DENSITY; POSTMENOPAUSAL WOMEN; SELECTIVE LIGANDS; HONEYBUSH TEA; ASPALATHUS-LINEARIS; ANIMAL-MODELS	Hormone replacement therapy associated risks, and the concomitant reluctance of usage, has instigated the search for new generations of estrogen analogues that would maintain estrogen benefits without associated risks. Furthermore, if these analogues display chemo-preventative properties in breast and endometrial tissues it would be of great value. Both the selective estrogen receptor modulators as well as the selective estrogen receptor subtype modulators have been proposed as estrogen analogues with improved risk profiles. Phytoestrogen containing extracts of Cyclopia, an indigenous South African fynbos plant used to prepare Honeybush tea may serve as a source of new estrogen analogues. In this study three extracts, P104, SM6Met, and cup-of-tea, from two species of Cyclopia, C. genistoides and C. subternata, were evaluated for ER subtype specific agonism and antagonism both in transactivation and transrepression. For transactivation, the Cyclopia extracts displayed ER alpha antagonism and ER beta agonism when ER subtypes were expressed separately, however, when co-expressed only agonism was uniformly observed. In contrast, for transrepression, this uniform behavior was lost, with some extracts (P104) displaying uniform agonism, while others (SM6Met) displayed antagonism when subtypes were expressed separately and agonism when co-expressed. In addition, breast cancer cell proliferation assays indicate that extracts antagonize cell proliferation in the presence of estrogen at lower concentrations than that required for proliferation. Furthermore, lack of uterine growth and delayed vaginal opening in an immature rat uterotrophic model validates the ERa antagonism of extracts observed in vitro and supports the potential of the Cyclopia extracts as a source of estrogen analogues with a reduced risk profile.	[Visser, Koch; Mortimer, Morne; Louw, Ann] Univ Stellenbosch, Dept Biochem, ZA-7600 Stellenbosch, South Africa	Stellenbosch University	Louw, A (corresponding author), Univ Stellenbosch, Dept Biochem, ZA-7600 Stellenbosch, South Africa.	al@sun.ac.za	Louw, Ann/A-7620-2012	Louw, Ann/0000-0002-1021-6732	Medical Research Council (MRC); Cancer Association of South Africa (CANSA)	Medical Research Council (MRC)(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Cancer Association of South Africa (CANSA)	The authors would like to thank the Medical Research Council (MRC) and the Cancer Association of South Africa (CANSA) for financial support to A.L. (grant for projects entitled "Cyclopia Phytoestrogens" and "Cyclopia and breast cancer") and for financial support to K. V. and M. M. the National Research Foundation (NRF) and the Harry Crossley foundation is acknowledged. Any opinion, findings and conclusions or recommendations expressed in this material are those of the author(s) and therefore the funders do not accept any liability in regard thereto. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ali S, 2000, J MAMMARY GLAND BIOL, V5, P271, DOI 10.1023/A:1009594727358; Anderson GL, 2004, JAMA-J AM MED ASSOC, V291, P1701, DOI 10.1001/jama.291.14.1701; ARONICA SM, 1994, P NATL ACAD SCI USA, V91, P8517, DOI 10.1073/pnas.91.18.8517; Ball LJ, 2009, MOL CELL ENDOCRINOL, V299, P204, DOI 10.1016/j.mce.2008.10.050; Banks E, 2003, LANCET, V362, P419, DOI 10.1016/S0140-6736(03)14065-2; Baud V, 2009, NAT REV DRUG DISCOV, V8, P33, DOI 10.1038/nrd2781; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brzezinski A, 1999, EUR J OBSTET GYN R B, V85, P47, DOI 10.1016/S0301-2115(98)00281-4; Burger HG, 2008, MENOPAUSE, V15, P603, DOI 10.1097/gme.0b013e318174ea4d; Cacquevel M, 2004, CURR DRUG TARGETS, V5, P529, DOI 10.2174/1389450043345308; Cao YX, 2003, J MAMMARY GLAND BIOL, V8, P215, DOI 10.1023/A:1025905008934; Chang EC, 2006, ENDOCRINOLOGY, V147, P4831, DOI 10.1210/en.2006-0563; Chen XW, 2003, J NUTR BIOCHEM, V14, P342, DOI 10.1016/S0955-2863(03)00056-1; Choi EM, 2012, INT IMMUNOPHARMACOL, V12, P139, DOI 10.1016/j.intimp.2011.11.003; Collins-Burow BM, 2000, NUTR CANCER, V38, P229, DOI 10.1207/S15327914NC382_13; Cranney A, 2005, DRUG SAFETY, V28, P721, DOI 10.2165/00002018-200528080-00006; Cvoro A, 2006, MOL CELL, V21, P555, DOI 10.1016/j.molcel.2006.01.014; Cvoro A, 2008, J IMMUNOL, V180, P630, DOI 10.4049/jimmunol.180.1.630; Cvoro A, 2007, ENDOCRINOLOGY, V148, P538, DOI 10.1210/en.2006-0803; D'Amelio P, 2013, EXPERT OPIN PHARMACO, V14, P949, DOI 10.1517/14656566.2013.782002; de Beer D, 2012, MOLECULES, V17, P14602, DOI 10.3390/molecules171214602; DELIMA, 2008, PHYTOMEDICINE, V15, P31, DOI DOI 10.1016/J.PHYMED.2007.06.006; Delmas PD, 1997, NEW ENGL J MED, V337, P1641, DOI 10.1056/NEJM199712043372301; Denger S, 2001, MOL CELL ENDOCRINOL, V178, P155, DOI 10.1016/S0303-7207(01)00417-8; Dennerstein L, 2000, OBSTET GYNECOL, V96, P351, DOI 10.1016/S0029-7844(00)00930-3; du Toit J, 1998, J SUSTAIN AGR, V12, P67, DOI 10.1300/J064v12n02_06; Duncan AM, 2003, BEST PRACT RES CL EN, V17, P253, DOI 10.1016/S1521-690X(02)00103-3; Enmark E, 1999, J INTERN MED, V246, P133, DOI 10.1046/j.1365-2796.1999.00545.x; Ettinger B, 1999, JAMA-J AM MED ASSOC, V282, P637, DOI 10.1001/jama.282.7.637; FELSON DT, 1993, NEW ENGL J MED, V329, P1141, DOI 10.1056/NEJM199310143291601; Flototto T, 2004, J STEROID BIOCHEM, V88, P131, DOI 10.1016/j.jsbmb.2003.11.004; Flouriot G, 2000, EMBO J, V19, P4688, DOI 10.1093/emboj/19.17.4688; Fong CJ, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-151; Fong CJ, 2010, J MOL ENDOCRINOL, V45, P161, DOI 10.1677/JME-09-0158; Frasor J, 2009, CANCER RES, V69, P8918, DOI 10.1158/0008-5472.CAN-09-2608; FRIEND DR, 1984, J MED CHEM, V27, P261, DOI 10.1021/jm00369a005; Galien R, 1997, NUCLEIC ACIDS RES, V25, P2424, DOI 10.1093/nar/25.12.2424; Ghisletti S, 2005, MOL CELL BIOL, V25, P2957, DOI 10.1128/MCB.25.8.2957-2968.2005; Glazier MG, 2001, ARCH INTERN MED, V161, P1161, DOI 10.1001/archinte.161.9.1161; Gosselin D, 2011, CELL, V145, P495, DOI 10.1016/j.cell.2011.04.018; Grivennikov SI, 2010, CELL, V140, P883, DOI 10.1016/j.cell.2010.01.025; Gronemeyer H, 2004, NAT REV DRUG DISCOV, V3, P950, DOI 10.1038/nrd1551; Gruber CJ, 2004, TRENDS ENDOCRIN MET, V15, P73, DOI 10.1016/j.tem.2004.01.008; HABEL LA, 1993, EPIDEMIOL REV, V15, P209, DOI 10.1093/oxfordjournals.epirev.a036107; HALL J, 2008, MENOPAUSAL MED, P16; Hall JM, 2002, MOL ENDOCRINOL, V16, P469, DOI 10.1210/me.16.3.469; Hall JM, 2001, J BIOL CHEM, V276, P36869, DOI 10.1074/jbc.R100029200; Han DH, 2002, BIOSCI BIOTECH BIOCH, V66, P1479, DOI 10.1271/bbb.66.1479; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Harnish DC, 2000, ENDOCRINOLOGY, V141, P3403, DOI 10.1210/en.141.9.3403; Harrington WR, 2003, MOL CELL ENDOCRINOL, V206, P13, DOI 10.1016/S0303-7207(03)00255-7; Harris HA, 2003, ENDOCRINOLOGY, V144, P4241, DOI 10.1210/en.2003-0550; Harris HA, 2002, ENDOCRINOLOGY, V143, P4172, DOI 10.1210/en.2002-220403; Harris HA, 2007, MOL ENDOCRINOL, V21, P1, DOI 10.1210/me.2005-0459; Helguero LA, 2005, ONCOGENE, V24, P6605, DOI 10.1038/sj.onc.1208807; Hertrampf T, 2008, BRIT J PHARMACOL, V153, P1432, DOI 10.1038/sj.bjp.0707664; Hillisch A, 2004, MOL ENDOCRINOL, V18, P1599, DOI 10.1210/me.2004-0050; Hiremath SP, 2000, EUR J PHARMACOL, V391, P193, DOI 10.1016/S0014-2999(99)00723-2; Hiroi H, 1999, ENDOCR J, V46, P773, DOI 10.1507/endocrj.46.773; Jordan VC, 2007, J CLIN ONCOL, V25, P5815, DOI 10.1200/JCO.2007.11.3886; Jordan VC, 2007, NAT REV CANCER, V7, P46, DOI 10.1038/nrc2048; JORDAN VC, 1988, CANCER INVEST, V6, P589, DOI 10.3109/07357908809082124; Joubert E, 2008, J ETHNOPHARMACOL, V119, P376, DOI 10.1016/j.jep.2008.06.014; Kamara BI, 2004, J AGR FOOD CHEM, V52, P5391, DOI 10.1021/jf040097z; Kamara BI, 2003, J AGR FOOD CHEM, V51, P3874, DOI 10.1021/jf0210730; Kanno J, 2001, ENVIRON HEALTH PERSP, V109, P785, DOI 10.2307/3454820; KIES P., 1951, BOTHALIA, V6, P161; KNABBE C, 1987, CELL, V48, P417, DOI 10.1016/0092-8674(87)90193-0; Kuiper GGJM, 1998, ENDOCRINOLOGY, V139, P4252, DOI 10.1210/en.139.10.4252; Kulling SE, 2002, J CHROMATOGR B, V777, P211, DOI 10.1016/S1570-0232(02)00215-5; Kushner PJ, 2000, J STEROID BIOCHEM, V74, P311, DOI 10.1016/S0960-0760(00)00108-4; Lattrich C, 2013, STEROIDS, V78, P195, DOI 10.1016/j.steroids.2012.10.014; Lazennec G, 2001, ENDOCRINOLOGY, V142, P4120, DOI 10.1210/en.142.9.4120; Lee SO, 2005, CANCER RES, V65, P3487, DOI 10.1158/0008-5472.CAN-04-3267; LERNER LJ, 1990, CANCER RES, V50, P4177; LI H, 2013, TOXICOL APPL PHARM; LIBERMANN TA, 1990, MOL CELL BIOL, V10, P2327, DOI 10.1128/MCB.10.5.2327; Lindsay R, 1996, OBSTET GYNECOL, V87, pS16, DOI 10.1016/0029-7844(95)00430-0; Louw A, 2013, PLANTA MED, V79, P580, DOI 10.1055/s-0032-1328463; LOVE RR, 1992, NEW ENGL J MED, V326, P852, DOI 10.1056/NEJM199203263261302; MacGregor JI, 1998, PHARMACOL REV, V50, P151; Malamas MS, 2004, J MED CHEM, V47, P5021, DOI 10.1021/jm049719y; Maximov PY, 2013, CURR CLIN PHARMACOL, V8, P135, DOI 10.2174/1574884711308020006; Mersereau JE, 2008, MOL CELL ENDOCRINOL, V283, P49, DOI 10.1016/j.mce.2007.11.020; Meyers MJ, 2001, J MED CHEM, V44, P4230, DOI 10.1021/jm010254a; Mfenyana C, 2008, J STEROID BIOCHEM, V112, P74, DOI 10.1016/j.jsbmb.2008.08.005; Monroe DG, 2003, J CELL BIOCHEM, V90, P315, DOI 10.1002/jcb.10633; Murkies AL, 1998, J CLIN ENDOCR METAB, V83, P297, DOI 10.1210/jc.83.2.297; Nand SL, 1998, OBSTET GYNECOL, V91, P678, DOI 10.1016/S0029-7844(98)00038-6; Nemeth K, 2003, EUR J NUTR, V42, P29, DOI 10.1007/s00394-003-0397-3; Nettles KW, 2008, MOL ENDOCRINOL, V22, P263, DOI 10.1210/me.2007-0324; Nettles KW, 2005, ANNU REV PHYSIOL, V67, P309, DOI 10.1146/annurev.physiol.66.032802.154710; Nicholson RI, 1999, ENDOCR-RELAT CANCER, V6, P373, DOI 10.1677/erc.0.0060373; Nilsson S, 2001, PHYSIOL REV, V81, P1535, DOI 10.1152/physrev.2001.81.4.1535; O'Regan RM, 2002, LANCET ONCOL, V3, P207, DOI 10.1016/S1470-2045(02)00711-8; Odum J, 1997, REGUL TOXICOL PHARM, V25, P176, DOI 10.1006/rtph.1997.1100; Oseni T, 2008, PLANTA MED, V74, P1656, DOI 10.1055/s-0028-1088304; Pacifici R, 1996, J BONE MINER RES, V11, P1043; Palmieri C, 2002, ENDOCR-RELAT CANCER, V9, P1, DOI 10.1677/erc.0.0090001; Paruthiyil S, 2004, CANCER RES, V64, P423, DOI 10.1158/0008-5472.CAN-03-2446; Paruthiyil S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006271; Plaisance S, 1997, MOL CELL BIOL, V17, P3733, DOI 10.1128/MCB.17.7.3733; Powell E, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030993; Powell E, 2008, P NATL ACAD SCI USA, V105, P19012, DOI 10.1073/pnas.0807274105; Primiano T, 2001, PHARM BIOL, V39, P83, DOI 10.1076/phbi.39.2.83.6256; Ray P, 1997, FEBS LETT, V409, P79, DOI 10.1016/S0014-5793(97)00487-0; Riggs BL, 2003, NEW ENGL J MED, V348, P618, DOI 10.1056/NEJMra022219; Riggs BL, 2002, ENDOCR REV, V23, P279, DOI 10.1210/er.23.3.279; Romas E, 1997, OSTEOPOROSIS INT, V7, P47, DOI 10.1007/BF03194342; Ross RK, 2000, JNCI-J NATL CANCER I, V92, P328, DOI 10.1093/jnci/92.4.328; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; Rymer J, 2003, BRIT MED J, V326, P322, DOI 10.1136/bmj.326.7384.322; Safe S, 2008, J MOL ENDOCRINOL, V41, P263, DOI 10.1677/JME-08-0103; Saji S, 2000, P NATL ACAD SCI USA, V97, P337, DOI 10.1073/pnas.97.1.337; Scafonas A, 2008, J STEROID BIOCHEM, V110, P197, DOI 10.1016/j.jsbmb.2007.10.013; Schmidt C, 2010, J NATL CANCER I, V102, P1690, DOI 10.1093/jnci/djq477; Schreurs R, 2002, ARCH TOXICOL, V76, P257, DOI 10.1007/s00204-002-0348-4; Setchell KDR, 2002, AM J CLIN NUTR, V76, P447, DOI 10.1093/ajcn/76.2.447; Shaaban AM, 2003, AM J SURG PATHOL, V27, P1502, DOI 10.1097/00000478-200312000-00002; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Shang YF, 2002, SCIENCE, V295, P2465, DOI 10.1126/science.1068537; SHIRAKAWA F, 1989, MOL CELL BIOL, V9, P2424, DOI 10.1128/MCB.9.6.2424; Slavin JL, 1998, AM J CLIN NUTR, V68, p1492S, DOI 10.1093/ajcn/68.6.1492S; Snijman PW, 2007, MUTAT RES-GEN TOX EN, V631, P111, DOI 10.1016/j.mrgentox.2007.03.009; Stossi F, 2004, ENDOCRINOLOGY, V145, P3473, DOI 10.1210/en.2003-1682; Stroheker T, 2003, REPROD TOXICOL, V17, P421, DOI 10.1016/S0890-6238(03)00044-3; Strom A, 2004, P NATL ACAD SCI USA, V101, P1566, DOI 10.1073/pnas.0308319100; Sun J, 2002, ENDOCRINOLOGY, V143, P941, DOI 10.1210/en.143.3.941; Tee MK, 2004, MOL BIOL CELL, V15, P1262, DOI 10.1091/mbc.E03-06-0360; Tikkanen MJ, 2000, BIOCHEM PHARMACOL, V60, P1, DOI 10.1016/S0006-2952(99)00409-8; Tremblay A, 1999, MOL CELL, V3, P513, DOI 10.1016/S1097-2765(00)80479-7; Trock BJ, 2006, JNCI-J NATL CANCER I, V98, P459, DOI 10.1093/jnci/djj102; Tu SH, 2013, FOOD CHEM, V141, P1553, DOI 10.1016/j.foodchem.2013.04.077; Verhoog NJD, 2007, S AFR J SCI, V103, P13; Verhoog NJD, 2007, J AGR FOOD CHEM, V55, P4371, DOI 10.1021/jf063588n; VILLALOBOS M, 1995, ENVIRON HEALTH PERSP, V103, P844, DOI 10.2307/3432398; Vogel VG, 2006, JAMA-J AM MED ASSOC, V295, P2727, DOI 10.1001/jama.295.23.joc60074; Vosse M, 2002, EUR J OBSTET GYN R B, V101, P58, DOI 10.1016/S0301-2115(01)00516-4; Wardell SE, 2013, CLIN CANCER RES, V19, P2420, DOI 10.1158/1078-0432.CCR-12-3771; Weiderpass E, 1999, J NATL CANCER I, V91, P1131, DOI 10.1093/jnci/91.13.1131; Williams C, 2008, ONCOGENE, V27, P1019, DOI 10.1038/sj.onc.1210712; Yeh WL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060889; Zhu JTT, 2007, J AGR FOOD CHEM, V55, P2438, DOI 10.1021/jf063299z	143	12	12	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 4	2013	8	11							e79223	10.1371/journal.pone.0079223	http://dx.doi.org/10.1371/journal.pone.0079223			22	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	245ZC	24223909	Green Published, gold, Green Submitted			2023-01-03	WOS:000326503400103
J	Wang, M; Wang, F; Wang, YN; Ma, XN; Zhao, M; Zhao, CJ				Wang, Miao; Wang, Fei; Wang, Yinan; Ma, Xiaonan; Zhao, Min; Zhao, Chunjie			Metabonomics Study of the Therapeutic Mechanism of Gynostemma pentaphyllum and Atorvastatin for Hyperlipidemia in Rats	PLOS ONE			English	Article							TRADITIONAL CHINESE MEDICINE; DIET-INDUCED HYPERLIPIDEMIA; NMR-SPECTROSCOPY; METABOLOMICS; URINE; SERUM; BERBERINE; SAPONINS	Gynostemma pentaphyllum (GP) is widely used for the treatment of diseases such as hyperlipidemia, fatty liver and obesity in China, and atorvastatin is broadly used as an anti-hyperlipidemia drug. This research focuses on the plasma and liver metabolites in the following four groups of rats: control, a hyperlipidemia model, a hyperlipidemia model treated with GP and a hyperlipidemia model treated with atorvastatin. Using H-1-NMR-based metabonomics, we elucidated the therapeutic mechanisms of GP and atorvastatin. Orthogonal Partial Least Squares-Discriminant analysis (OPLS-DA) plotting of the metabolic state and analysis of potential biomarkers in the plasma and liver correlated well with the results of biochemical assays. GP can effectively affect lipid metabolism, and it exerts its anti-hyperlipidemia effect by elevating the level of phosphatidylcholine and decreasing the level of trimethylamine N-oxide (TMAO). In contrast, atorvastatin affects hyperlipidemia mainly during lipid metabolism and protein metabolism in vivo.	[Wang, Miao; Wang, Yinan; Zhao, Min; Zhao, Chunjie] Shenyang Pharmaceut Univ, Sch Pharm, Shenyang, Peoples R China; [Wang, Fei] Northeastern Univ, Coll Informat Sci & Eng, Shenyang, Peoples R China; [Wang, Miao; Ma, Xiaonan] Shenyang Pharmaceut Univ, Sch Life Sci & Biopharmaceut, Shenyang, Peoples R China	Shenyang Pharmaceutical University; Northeastern University - China; Shenyang Pharmaceutical University	Zhao, CJ (corresponding author), Shenyang Pharmaceut Univ, Sch Pharm, Shenyang, Peoples R China.	zcjjljj@sina.com						Azmi J, 2005, BIOMARKERS, V10, P401, DOI 10.1080/13547500500309259; BALES JR, 1984, CLIN CHEM, V30, P426; Barker M, 2003, J CHEMOMETR, V17, P166, DOI 10.1002/cem.785; Beckonert O, 2007, NAT PROTOC, V2, P2692, DOI 10.1038/nprot.2007.376; Bollard ME, 2000, MAGNET RESON MED, V44, P201, DOI 10.1002/1522-2594(200008)44:2<201::AID-MRM6>3.0.CO;2-5; CHEN HZ, 2004, J CHINESE INTEG 0302, V2, P81; DONALD V, 2000, FUNDAMENTALS BIOCH; Fan WMT, 1996, PROG NUCL MAG RES SP, V28, P161, DOI 10.1016/0079-6565(95)01017-3; Gavaghan CL, 2002, FEBS LETT, V530, P191, DOI 10.1016/S0014-5793(02)03476-2; Gibellini F, 2010, IUBMB LIFE, V62, P414, DOI 10.1002/iub.337; Gu Y, 2010, TALANTA, V81, P766, DOI 10.1016/j.talanta.2010.01.015; He QH, 2012, J NUTR BIOCHEM, V23, P133, DOI 10.1016/j.jnutbio.2010.11.007; Hollywood K, 2006, PROTEOMICS, V6, P4716, DOI 10.1002/pmic.200600106; Huyen VTT, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/452313; JEAN CM, 2009, ATHEROSCLEROSIS, V206, P127, DOI DOI 10.1016/J.ATHEROSCLEROSIS.2009.01.040; Kao TH, 2008, ANAL CHIM ACTA, V626, P200, DOI 10.1016/j.aca.2008.07.049; LACOUR B, 1995, J ETHNOPHARMACOL, V46, P125, DOI 10.1016/0378-8741(95)01234-5; Li N, 2012, EUR J MED CHEM, V50, P173, DOI 10.1016/j.ejmech.2012.01.052; Liang SX, 2002, SPECTROSC SPECT ANAL, V22, P847; Liang XP, 2011, J PROTEOME RES, V10, P790, DOI 10.1021/pr1009299; Lindon JC, 2004, EXPERT REV MOL DIAGN, V4, P189, DOI 10.1586/14737159.4.2.189; Liu F, 2012, ANAL BIOANAL CHEM, V403, P847, DOI 10.1007/s00216-012-5923-9; Naoumova RP, 1997, J LIPID RES, V38, P1496; Nicholson JK, 1999, XENOBIOTICA, V29, P1181, DOI 10.1080/004982599238047; Qin RA, 2012, ARCH PHARM RES, V35, P1241, DOI 10.1007/s12272-012-0715-5; Sun Y, 2012, PLOS ONE, V7, DOI [10.1371/journal.pone.0032115, 10.1371/journal.pone.0047003]; Wang ZN, 2011, NATURE, V472, P57, DOI 10.1038/nature09922; Watkins SM, 2002, CURR OPIN MOL THER, V4, P224; Wei L, 2008, TOXICOL APPL PHARM, V227, P417, DOI 10.1016/j.taap.2007.11.015; Wishart DS, 2008, J CHROMATOGR B, V871, P164, DOI 10.1016/j.jchromb.2008.05.001; Wishart DS, 2007, BRIEF BIOINFORM, V8, P279, DOI 10.1093/bib/bbm030; Yang XB, 2008, J AGR FOOD CHEM, V56, P6905, DOI 10.1021/jf801101u; Zha WB, 2009, BIOMARKERS, V14, P372, DOI 10.1080/13547500903026401; Zhang AH, 2012, PHARMAZIE, V67, P667, DOI 10.1691/ph.2012.2511; Zhang Q, 2010, BIOMARKERS, V15, P205, DOI 10.3109/13547500903419049; Zhang Q, 2009, ACTA PHARMACOL SIN, V30, P1674, DOI 10.1038/aps.2009.173	36	17	22	5	94	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 1	2013	8	11							e78731	10.1371/journal.pone.0078731	http://dx.doi.org/10.1371/journal.pone.0078731			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	245XZ	24223845	Green Submitted, Green Published, gold			2023-01-03	WOS:000326499300032
J	Sun, Y; Guo, R; Yin, WJ; Tang, LL; Yu, XL; Chen, M; Qi, ZY; Liu, MZ; Ma, J				Sun, Ying; Guo, Rui; Yin, Wen-Jing; Tang, Ling-Long; Yu, Xiao-Li; Chen, Mo; Qi, Zhen-Yu; Liu, Meng-Zhong; Ma, Jun			Which T Category of Nasopharyngeal Carcinoma May Benefit Most from Volumetric Modulated Arc Therapy Compared with Step and Shoot Intensity Modulated Radiation Therapy	PLOS ONE			English	Article							NECK CANCER; HEAD; RADIOTHERAPY; IMRT; RISK	Background: To compare volumetric modulated arc therapy (VMAT) with conventional step and shoot intensity modulated radiation therapy (s-IMRT) in nasopharyngeal carcinoma (NPC) patients, and identify which T category patient gains the maximum benefit from VMAT. Methods: Fifty-two patients that randomly selected from 205 patients received VMAT at a single center were retrospectively replanned with s-IMRT. For a fair comparison, the planning target volume (PTV) coverage of the 2 plans was normalized to the same level. A standard planning constraint set was used; the constraints for the organs at risk (OARs) were individually adapted. The calculated doses to the PTV and OARs were compared for s-IMRT and VMAT plans generated using the Monaco treatment planning system. Results: VMAT and s-IMRT plans had similar PTV coverage and OAR sparing within all T categories. However, in stratified analysis, VMAT plans lead to better or similar sparing of the OARs in early T category patients; and lead to poorer sparing of the OARs in advanced T category patients (P<0.05). VMAT shows significant advantages for low dose burden (P<0.05) compared with s-IMRT. The delivery time per fraction for VMAT (424 +/- 64 s) was shorter than s-IMRT (778 +/- 126 s, p<0.01). Conclusions: VMAT provides similar dose coverage of the PTVs and similar/better normal tissue sparing in early T category NPC, and poorer OARs sparing in advanced T category NPC. And VMAT shows significant advantages for low dose burden and delivery time.	[Sun, Ying; Guo, Rui; Yin, Wen-Jing; Tang, Ling-Long; Yu, Xiao-Li; Chen, Mo; Qi, Zhen-Yu; Liu, Meng-Zhong; Ma, Jun] Sun Yat Sen Univ, Ctr Canc, Dept Radiat Oncol, State Key Lab Oncol Southern China, Guangzhou 510275, Guangdong, Peoples R China	State Key Lab Oncology South China; Sun Yat Sen University	Ma, J (corresponding author), Sun Yat Sen Univ, Ctr Canc, Dept Radiat Oncol, State Key Lab Oncol Southern China, Guangzhou 510275, Guangdong, Peoples R China.	drjunma@hotmail.com			National Natural Science Foundation of China [81071836]; Guangdong Provincial Science and Technology Department [2009B03080101]; Science Foundation of Key Hospital Clinical Program of Ministry of Health, P. R. China [2010-178]; Guangdong Province Universities and Colleges Pearl River Scholar Funded Scheme	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Guangdong Provincial Science and Technology Department; Science Foundation of Key Hospital Clinical Program of Ministry of Health, P. R. China; Guangdong Province Universities and Colleges Pearl River Scholar Funded Scheme	This work was supported by grants from the National Natural Science Foundation of China (81071836), Guangdong Provincial Science and Technology Department (2009B03080101), the Science Foundation of Key Hospital Clinical Program of Ministry of Health, P. R. China (2010-178), and the Guangdong Province Universities and Colleges Pearl River Scholar Funded Scheme (2010). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2002, IARC SCI PUBL, VVIII; Bertelsen A, 2010, RADIOTHER ONCOL, V95, P142, DOI 10.1016/j.radonc.2010.01.011; Bortfeld T, 2009, PHYS MED BIOL, V54, pN9, DOI 10.1088/0031-9155/54/1/N02; Clemente S, 2011, INT J RADIAT ONCOL, V80, P1248, DOI 10.1016/j.ijrobp.2010.08.007; Doornaert P, 2011, INT J RADIAT ONCOL, V79, P429, DOI 10.1016/j.ijrobp.2009.11.014; Guckenberger M, 2009, RADIOTHER ONCOL, V93, P259, DOI 10.1016/j.radonc.2009.08.015; Hall EJ, 2006, INT J RADIAT ONCOL, V65, P1, DOI 10.1016/j.ijrobp.2006.01.027; Hartford AC, 2009, INT J RADIAT ONCOL, V73, P9, DOI 10.1016/j.ijrobp.2008.04.049; Hoogeman MS, 2008, INT J RADIAT ONCOL, V70, P609, DOI 10.1016/j.ijrobp.2007.08.066; Johnston M, 2011, CLIN ONCOL-UK, V23, P503, DOI 10.1016/j.clon.2011.02.002; Kam MKM, 2003, INT J RADIAT ONCOL, V56, P145, DOI 10.1016/S0360-3016(03)00075-0; Kam MKM, 2004, INT J RADIAT ONCOL, V60, P1440, DOI 10.1016/j.ijrobp.2004.05.022; Liang SB, 2009, INT J RADIAT ONCOL, V75, P742, DOI 10.1016/j.ijrobp.2008.11.053; Patil VM, 2010, J CANCER RES THER, V6, P442, DOI 10.4103/0973-1482.77082; Vanetti E, 2009, RADIOTHER ONCOL, V92, P111, DOI 10.1016/j.radonc.2008.12.008; Verbakel WFAR, 2009, INT J RADIAT ONCOL, V74, P252, DOI 10.1016/j.ijrobp.2008.12.033; Wiezorek T, 2011, RADIAT ONCOL, V6, DOI 10.1186/1748-717X-6-20; Wolden SL, 2006, INT J RADIAT ONCOL, V64, P57, DOI 10.1016/j.ijrobp.2005.03.057; YU CX, 1995, PHYS MED BIOL, V40, P1435, DOI 10.1088/0031-9155/40/9/004	19	9	12	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 25	2013	8	9							e75304	10.1371/journal.pone.0075304	http://dx.doi.org/10.1371/journal.pone.0075304			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	228VC	24086503	gold, Green Submitted, Green Published			2023-01-03	WOS:000325218700072
J	Kullmann, FA; Wells, GI; Langdale, CL; Zheng, JH; Thor, KB				Kullmann, F. Aura; Wells, Grace I.; Langdale, Christopher L.; Zheng, Jihong; Thor, Karl B.			Stability of the Acetic Acid-Induced Bladder Irritation Model in Alpha Chloralose-Anesthetized Female Cats	PLOS ONE			English	Article							LOWER URINARY-TRACT; NEURAL-CONTROL; SPINAL-CORD; POSTNATAL-DEVELOPMENT; PUDENDAL AFFERENTS; MICTURITION; STIMULATION; RECEPTORS; REFLEX; SEROTONIN	Time- and vehicle-related variability of bladder and urethral rhabdosphincter (URS) activity as well as cardiorespiratory and blood chemistry values were examined in the acetic acid-induced bladder irritation model in alpha-chloralose-anesthetized female cats. Additionally, bladder and urethra were evaluated histologically using Mason trichrome and toluidine blue staining. Urodynamic, cardiovascular and respiratory parameters were collected during intravesical saline infusion followed by acetic acid (0.5%) to irritate the bladder. One hour after starting acetic acid infusion, a protocol consisting of a cystometrogram, continuous infusion-induced rhythmic voiding contractions, and a 5 min "quiet period" (bladder emptied without infusion) was precisely repeated every 30 minutes. Administration of vehicle (saline i.v.) occurred 15 minutes after starting each of the first 7 cystometrograms and duloxetine (1mg/kg i.v.) after the 8th. Acetic acid infusion into the bladder increased URS-EMG activity, bladder contraction frequency, and decreased contraction amplitude and capacity, compared to saline. Bladder activity and URS activity stabilized within 1 and 2 hours, respectively. Duloxetine administration significantly decreased bladder contraction frequency and increased URS-EMG activity to levels similar to previous reports. Cardiorespiratory parameters and blood gas levels remained consistent throughout the experiment. The epithelium of the bladder and urethra were greatly damaged and edema and infiltration of neutrophils in the lamina propria of urethra were observed. These data provide an ample evaluation of the health of the animals, stability of voiding function and appropriateness of the model for testing drugs designed to evaluate lower urinary tract as well as cardiovascular and respiratory systems function.	[Kullmann, F. Aura; Wells, Grace I.; Langdale, Christopher L.; Zheng, Jihong; Thor, Karl B.] Urogenix Inc Astellas, Durham, NC USA		Kullmann, FA (corresponding author), Urogenix Inc Astellas, Durham, NC USA.	Aura.Kullmann@gmail.com	Langdale, Christopher/R-7209-2019	Langdale, Christopher/0000-0002-6704-2665; Kullmann, F. Aura/0000-0001-6625-2946	Astellas Pharma	Astellas Pharma(Astellas Pharmaceuticals)	This study was supported by Astellas Pharma. The funders had no role in study design, data collection and analysis or preparation of the manuscript. The funders approved the manuscript for publication.	ANGEL MJ, 1994, J PHYSIOL-LONDON, V479, P451, DOI 10.1113/jphysiol.1994.sp020309; ARFORS KE, 1971, ACTA PHYSIOL SCAND, V81, P47, DOI 10.1111/j.1748-1716.1971.tb04876.x; Birder LA, 2010, AUTON NEUROSCI-BASIC, V153, P33, DOI 10.1016/j.autneu.2009.07.005; Boggs JW, 2006, J PHYSIOL-LONDON, V577, P115, DOI 10.1113/jphysiol.2006.111815; Chang HY, 2008, AM J PHYSIOL-RENAL, V295, pF1248, DOI 10.1152/ajprenal.90259.2008; Chen Z, 2001, J UROLOGY, V166, P1539, DOI 10.1016/S0022-5347(05)65827-2; CIRIELLO J, 1980, AM J PHYSIOL, V239, pR137, DOI 10.1152/ajpregu.1980.239.1.R137; COVERT RF, 1988, AM J PHYSIOL, V255, pH419, DOI 10.1152/ajpheart.1988.255.3.H419; COVERT RF, 1994, BIOL NEONATE, V66, P316; COX RH, 1972, AM J PHYSIOL, V223, P660, DOI 10.1152/ajplegacy.1972.223.3.660; Dass N, 2001, J UROLOGY, V165, P1294, DOI 10.1016/S0022-5347(01)69887-2; de Groat WC, 2006, BRIT J PHARMACOL, V147, pS25, DOI 10.1038/sj.bjp.0706604; DEGROAT WC, 1990, J AUTONOM NERV SYST, V30, pS71, DOI 10.1016/0165-1838(90)90105-R; DEGROAT WC, 1969, J PHYSIOL-LONDON, V200, P87, DOI 10.1113/jphysiol.1969.sp008683; DOWNIE JW, 1991, EUR J PHARMACOL, V195, P301, DOI 10.1016/0014-2999(91)90551-Z; Espey MJ, 1995, EUR J PHARMACOL, V287, P173, DOI 10.1016/0014-2999(95)00614-1; FELDBERG W, 1965, J PHYSIOL-LONDON, V179, P509, DOI 10.1113/jphysiol.1965.sp007677; Fowler CJ, 2008, NAT REV NEUROSCI, V9, P453, DOI 10.1038/nrn2401; Gabella G, 1998, J NEUROCYTOL, V27, P141, DOI 10.1023/A:1006903507321; Garrett KM, 1998, J PHARMACOL EXP THER, V285, P680; GILLIS RA, 1988, J PHARMACOL EXP THER, V247, P765; Habler HJ, 1997, J AUTONOM NERV SYST, V66, P97, DOI 10.1016/S0165-1838(97)00073-8; Johnston B, 1999, J CLIN INVEST, V103, P1269, DOI 10.1172/JCI5208; Karicheti V, 2006, 2006 AUA ANN M ATL G; Karicheti V, 2010, AM J PHYSIOL-REG I, V298, pR1198, DOI 10.1152/ajpregu.00599.2009; Katofiasc MA, 2002, LIFE SCI, V71, P1227, DOI 10.1016/S0024-3205(02)01848-9; Kirby M, 2008, NAT CLIN PRACT UROL, V5, P188, DOI 10.1038/ncpuro1077; Kullmann FA, 2009, AM J PHYSIOL-RENAL, V296, pF892, DOI 10.1152/ajprenal.90718.2008; Larson JA, 2011, J PHYSIOL-LONDON, V589, P5833, DOI 10.1113/jphysiol.2011.215657; Lee JA, 2003, J VET EMERG CRIT CAR, V13, P227, DOI 10.1111/j.1534-6935.2003.00100.x; LEES P, 1972, VET REC, V91, P330, DOI 10.1136/vr.91.14.330; MACKEL R, 1979, J PHYSIOL-LONDON, V294, P105, DOI 10.1113/jphysiol.1979.sp012918; Matsuura S, 2000, NEUROUROL URODYNAM, V19, P87, DOI 10.1002/(SICI)1520-6777(2000)19:1<87::AID-NAU9>3.0.CO;2-O; Mitobe Manabu, 2008, Journal of Pharmacological and Toxicological Methods, V57, P188, DOI 10.1016/j.vascn.2007.12.001; MORTON CR, 1989, NEUROSCIENCE, V31, P807; Radziszewski P, 1996, SCAND J UROL NEPHROL, V30, P81; RAMAGE AG, 1984, NEUROPHARMACOLOGY, V23, P43, DOI 10.1016/0028-3908(84)90215-6; Roppolo JR, 2005, J UROLOGY, V173, P1011, DOI 10.1097/01.ju.0000145591.35569.9e; RUDY DC, 1991, AM J PHYSIOL, V261, pR1560, DOI 10.1152/ajpregu.1991.261.6.R1560; Sadananda P, 2009, BRIT J PHARMACOL, V158, P1655, DOI 10.1111/j.1476-5381.2009.00431.x; Sadananda P, 2012, EUR J PHARMACOL, V683, P252, DOI 10.1016/j.ejphar.2012.02.041; Smith PP, 2012, NEUROUROL URODYNAM, V31, P30, DOI 10.1002/nau.21223; Snellings AE, 2012, NEUROSCI LETT, V516, P34, DOI 10.1016/j.neulet.2012.03.045; Stone EA, 2005, LONG TERM REAL TIME; Tai CF, 2011, J UROLOGY, V186, P326, DOI 10.1016/j.juro.2011.04.023; TANG PC, 1956, J COMP NEUROL, V106, P213, DOI 10.1002/cne.901060108; TAYLOR DEM, 1965, Q J EXP PHYSIOL CMS, V50, P263, DOI 10.1113/expphysiol.1965.sp001791; Thor KB, 2010, AM J PHYSIOL-REG I, V299, pR416, DOI 10.1152/ajpregu.00111.2010; THOR KB, 1994, NEUROREPORT, V5, P1673, DOI 10.1097/00001756-199408150-00033; Thor KB, 1999, AM J PHYSIOL-REG I, V277, pR1002, DOI 10.1152/ajpregu.1999.277.4.R1002; Thor KB, 2003, UROLOGY, V62, P3, DOI 10.1016/S0090-4295(03)00754-4; THOR KB, 1990, DEV BRAIN RES, V57, P255, DOI 10.1016/0165-3806(90)90051-Y; THOR KB, 1995, J PHARMACOL EXP THER, V274, P1014; THOR KB, 1983, J UROLOGY, V129, P202, DOI 10.1016/S0022-5347(17)51984-9; THOR KB, 1989, DEV BRAIN RES, V46, P137, DOI 10.1016/0165-3806(89)90151-X; Wang JC, 2009, BJU INT, V103, P530, DOI 10.1111/j.1464-410X.2008.08029.x; Westropp JL, 2007, AM J VET RES, V68, P203, DOI 10.2460/ajvr.68.2.203; Wibberley A, 2006, BRIT J PHARMACOL, V148, P154, DOI 10.1038/sj.bjp.0706715; Woock JP, 2009, J UROLOGY, V182, P366, DOI 10.1016/j.juro.2009.02.110; Wu CH, 2011, AM J VET RES, V72, P578, DOI 10.2460/ajvr.72.4.578; Yoo PB, 2008, EXP NEUROL, V212, P218, DOI 10.1016/j.expneurol.2008.04.010	61	12	12	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 9	2013	8	9							e73771	10.1371/journal.pone.0073771	http://dx.doi.org/10.1371/journal.pone.0073771			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	244QV	24040064	Green Submitted, Green Published, gold			2023-01-03	WOS:000326405300127
J	Zhao, YZ; Lv, HF; Lu, CT; Chen, LJ; Lin, M; Zhang, M; Jiang, X; Shen, XT; Jin, RR; Cai, J; Tian, XQ; Wong, HL				Zhao, Ying-Zheng; Lv, Hai-Feng; Lu, Cui-Tao; Chen, Li-Juan; Lin, Min; Zhang, Ming; Jiang, Xi; Shen, Xiao-Tong; Jin, Rong-Rong; Cai, Jun; Tian, Xin-Qiao; Wong, Ho Lun			Evaluation of a Novel Thermosensitive Heparin-Poloxamer Hydrogel for Improving Vascular Anastomosis Quality and Safety in a Rabbit Model	PLOS ONE			English	Article							MOLECULAR-WEIGHT HEPARIN; VEIN GRAFT ANASTOMOSES; FIBRIN GLUE; DELIVERY; GELS; PROLIFERATION; TEMPERATURE; COPOLYMERS; GELATION; STRENGTH	Despite progress in the design of advanced surgical techniques, stenosis recurs in a large percentage of vascular anastomosis. In this study, a novel heparin-poloxamer (HP) hydrogel was designed and its effects for improving the quality and safety of vascular anastomosis were studied. HP copolymer was synthesized and its structure was confirmed by Fourier transform infrared spectroscopy (FTIR) and nuclear magnetic resonance spectroscopy (H-1-NMR). Hydrogels containing HP were prepared and their important characteristics related to the application in vascular anastomosis including gelation temperature, rheological behaviour and micromorphology were measured. Vascular anastomosis were performed on the right common carotid arteries of rabbits, and the in vivo efficiency and safety of HP hydrogel to achieve vascular anastomosis was verified and compared with Poloxamer 407 hydrogel and the conventional hand-sewn method using Doppler ultrasound, CT angiograms, scanning electron microscopy (SEM) and histological technique. Our results showed that HP copolymer displayed special gel-sol-gel phase transition behavior with increasing temperature from 5 to 60 degrees C. HP hydrogel prepared from 18 wt% HP solution had a porous sponge-like structure, with gelation temperature at approximately 38 degrees C and maximum elastic modulus at 10,000 Pa. In animal studies, imaging and histological examination of rabbit common jugular artery confirmed that HP hydrogel group had similar equivalent patency, flow and burst strength as Poloxamer 407 group. Moreover, HP hydrogel was superior to poloxamer 407 hydrogel and hand-sewn method for restoring the functions and epithelial structure of the broken vessel junctions after operation. By combining the advantages of heparin and poloxamer 407, HP hydrogel holds high promise for improving vascular anastomosis quality and safety.	[Zhao, Ying-Zheng; Lv, Hai-Feng; Lu, Cui-Tao; Chen, Li-Juan; Lin, Min; Zhang, Ming; Jiang, Xi; Shen, Xiao-Tong; Jin, Rong-Rong] Wenzhou Med Univ, Wenzhou City, Zhejiang, Peoples R China; [Zhao, Ying-Zheng] Drexel Univ, Coll Med, Philadelphia, PA 19104 USA; [Cai, Jun] Univ Louisville, Sch Med, Dept Pediat, Louisville, KY 40292 USA; [Cai, Jun] Univ Louisville, Sch Med, Dept Anat Sci & Neurobiol, Louisville, KY 40292 USA; [Tian, Xin-Qiao] Wenzhou Med Univ, Affiliated Hosp 2, Dept Ultrasonog, Wenzhou, Peoples R China; [Wong, Ho Lun] Temple Univ, Sch Pharm, Philadelphia, PA 19122 USA	Wenzhou Medical University; Drexel University; University of Louisville; University of Louisville; Wenzhou Medical University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Lu, CT (corresponding author), Wenzhou Med Univ, Wenzhou City, Zhejiang, Peoples R China.	lctuua@sina.com; pharmtds@163.com; ho-lun.wong@temple.edu	Cai, Jun/AFP-0700-2022	Cai, Jun/0000-0003-1721-7786	National Natural Science Funds [81272160]; Zhejiang Provincial Natural Science Foundation [LY12H30003, LY12H18001]; Zhejiang Provincial Foundation for Health Department [2011ZDA017, 2012KYB126, 2012KYA134]; Zhejiang Provincial Project of Key Scientific Group [2010R50042, 2012R10042-06]	National Natural Science Funds(National Natural Science Foundation of China (NSFC)); Zhejiang Provincial Natural Science Foundation(Natural Science Foundation of Zhejiang Province); Zhejiang Provincial Foundation for Health Department; Zhejiang Provincial Project of Key Scientific Group	This research was supported by the National Natural Science Funds (Grant No. 81272160), Zhejiang Provincial Natural Science Foundation (Grant No. LY12H30003 and LY12H18001), Zhejiang Provincial Foundation for Health Department (Grant No. 2011ZDA017, 2012KYB126 and 2012KYA134), Zhejiang Provincial Project of Key Scientific Group (Grant No. 2010R50042 and 2012R10042-06). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alghoul MS, 2011, MICROSURG, V31, P72, DOI 10.1002/micr.20813; Beris AE, 2010, ARCH ORTHOP TRAUM SU, V130, P1141, DOI 10.1007/s00402-009-1021-7; CASTELLOT JJ, 1986, J CELL BIOL, V102, P1979, DOI 10.1083/jcb.102.5.1979; Chang EI, 2011, NAT MED, V17, P1147, DOI 10.1038/nm.2424; Chen JP, 2011, J PHARM SCI-US, V100, P655, DOI 10.1002/jps.22309; Chernichenko N, 2008, LARYNGOSCOPE, V118, P2146, DOI 10.1097/MLG.0b013e3181839b75; Cho AB, 2009, MICROSURG, V29, P24, DOI 10.1002/micr.20554; CLOWES AW, 1977, NATURE, V265, P625, DOI 10.1038/265625a0; Nguyen DH, 2011, BIOMED MATER, V6, DOI 10.1088/1748-6041/6/5/055004; Dumortier G, 2006, DRUG DEV IND PHARM, V32, P63, DOI 10.1080/03639040500390934; Egemen O, 2011, J CRANIOFAC SURG, V22, P1047, DOI 10.1097/SCS.0b013e3182135f39; Heitmann C, 2007, J PLAST RECONSTR AES, V60, P1296, DOI 10.1016/j.bjps.2006.10.017; Kabanov AV, 2002, J CONTROL RELEASE, V82, P189, DOI 10.1016/S0168-3659(02)00009-3; Khorgami Z, 2011, MED HYPOTHESES, V77, P94, DOI 10.1016/j.mehy.2011.03.035; Kloppel M, 2007, J RECONSTR MICROSURG, V23, P45, DOI 10.1055/s-2006-958702; Koffi AA, 2006, EUR J PHARM SCI, V27, P328, DOI 10.1016/j.ejps.2005.11.001; Koppensteiner R, 2006, J VASC SURG, V44, P1247, DOI 10.1016/j.jvs.2006.07.044; Leclere FMP, 2011, ANN CHIR PLAST ESTH, V56, P232, DOI 10.1016/j.anplas.2009.12.009; Lee JS, 2007, J CONTROL RELEASE, V117, P204, DOI 10.1016/j.jconrel.2006.11.004; Liu LQ, 2006, ANN THORAC SURG, V82, P303, DOI 10.1016/j.athoracsur.2006.01.099; Menzoian JO, 2011, J VASC SURG, V54, P571, DOI 10.1016/j.jvs.2011.04.028; Mori H, 2013, MAT SCI ENG C-MATER, V33, P3230, DOI 10.1016/j.msec.2013.03.047; Nisbet DR, 2006, BIOPHYS CHEM, V121, P14, DOI 10.1016/j.bpc.2005.12.005; Niu GG, 2008, BIOMACROMOLECULES, V9, P2621, DOI 10.1021/bm800573e; Park KM, 2009, ACTA BIOMATER, V5, P1956, DOI 10.1016/j.actbio.2009.01.040; Rangelov S, 2005, J PHYS CHEM B, V109, P1162, DOI 10.1021/jp046118+; Rectenwald JE, 2006, J VASC SURG, V43, P800, DOI 10.1016/j.jvs.2005.12.010; ROSS R, 1986, NEW ENGL J MED, V314, P488, DOI 10.1056/NEJM198602203140806; SCHMIDT A, 1992, J BIOL CHEM, V267, P19242; Tan HP, 2009, BIOMATERIALS, V30, P6844, DOI 10.1016/j.biomaterials.2009.08.058; Tian JL, 2010, DRUG DEV IND PHARM, V36, P832, DOI 10.3109/03639040903520983; Waisberg DR, 2011, MICROSURG, V31, P584, DOI 10.1002/micr.20924; Wiklund L, 2005, J THORAC CARDIOV SUR, V129, P146, DOI 10.1016/j.jtcvs.2004.02.027; Xu HHK, 2004, BIOMATERIALS, V25, P1029, DOI 10.1016/S0142-9612(03)00608-2; Xuan JJ, 2010, INT J PHARMACEUT, V395, P317, DOI 10.1016/j.ijpharm.2010.05.042; Yong CS, 2004, INT J PHARMACEUT, V269, P169, DOI 10.1016/j.ijpharm.2003.09.013; Yong CS, 2001, INT J PHARM, V226, P195, DOI 10.1016/S0378-5173(01)00809-2; Yoo MK, 2005, DRUG DEV IND PHARM, V31, P455, DOI 10.1080/03639040500214688; Yu L, 2008, CHEM SOC REV, V37, P1473, DOI 10.1039/b713009k	39	31	34	4	41	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 27	2013	8	8							e73178	10.1371/journal.pone.0073178	http://dx.doi.org/10.1371/journal.pone.0073178			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	210FR	24015296	Green Published, gold			2023-01-03	WOS:000323815200070
J	Mertz, D; Kim, TH; Johnstone, J; Lam, PP; Science, M; Kuster, SP; Fadel, SA; Tran, D; Fernandez, E; Bhatnagar, N; Loeb, M				Mertz, Dominik; Kim, Tae Hyong; Johnstone, Jennie; Lam, Po-Po; Science, Michelle; Kuster, Stefan P.; Fadel, Shaza A.; Tran, Dat; Fernandez, Eduardo; Bhatnagar, Neera; Loeb, Mark			Populations at risk for severe or complicated influenza illness: systematic review and meta-analysis	BMJ-BRITISH MEDICAL JOURNAL			English	Article							A(H1N1) VIRUS; A H1N1; CHILDREN; QUALITY; RATIO; WOMEN; 1ST	Objective To evaluate risk factors for severe outcomes in patients with seasonal and pandemic influenza. Design Systematic review. Study selection Observational studies reporting on risk factor-outcome combinations of interest in participants with influenza. Outcomes included death, ventilator support, admission to hospital, admission to an intensive care unit, pneumonia, and composite outcomes. Data sources Medline, Embase, CINAHL, Global Health, and the Cochrane Central Register of Controlled Trials to March 2011. Risk of bias assessment Newcastle-Ottawa scale to assess the risk of bias. GRADE framework to evaluate the quality of evidence. Results 63 537 articles were identified of which 234 with a total of 610 782 participants met the inclusion criteria. The evidence supporting risk factors for severe outcomes of influenza ranged from being limited to absent. This was particularly relevant for the relative lack of data for non-2009 H1N1 pandemics and for seasonal influenza studies. Limitations in the published literature included lack of power and lack of adjustment for confounders was widespread: adjusted risk estimates were provided for only 5% of risk factor-outcome comparisons in 39 of 260 (15%) studies. The level of evidence was low for "any risk factor" (odds ratio for mortality 2.77, 95% confidence interval 1.90 to 4.05 for pandemic influenza and 2.04, 1.74 to 2.39 for seasonal influenza), obesity (2.74, 1.56 to 4.80 and 30.1, 1.74 to 2.39), cardiovascular diseases (2.92, 1.76 to 4.86 and 1.97, 1.06 to 3.67), and neuromuscular disease (2.68, 1.91 to 3.75 and 3.21, 1.84 to 5.58). The level of evidence was very low for all other risk factors. Some well accepted risk factors such as pregnancy and belonging to an ethnic minority group could not be identified as risk factors. In contrast, women who were less than four weeks post partum had a significantly increased risk of death from pandemic influenza (4.43, 1.24 to 15.81). Conclusion The level of evidence to support risk factors for influenza related complications is low and some well accepted risk factors, including pregnancy and ethnicity, could not be confirmed as risks. Rigorous and adequately powered studies are needed.	[Mertz, Dominik] McMaster Univ, Dept Med, Hamilton, ON L8N 3Z5, Canada; [Mertz, Dominik; Kim, Tae Hyong; Johnstone, Jennie; Fernandez, Eduardo; Loeb, Mark] McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON L8N 3Z5, Canada; [Lam, Po-Po] Mt Sinai Hosp, Toronto, ON M5G 1X5, Canada; [Lam, Po-Po; Fadel, Shaza A.] Univ Toronto, Div Epidemiol, Dalla Lana Sch Publ Hlth, Toronto, ON, Canada; [Science, Michelle; Tran, Dat] Univ Toronto, Hosp Sick Children, Dept Pediat, Toronto, ON M5G 1X8, Canada; [Kuster, Stefan P.] Univ Zurich Hosp, CH-8091 Zurich, Switzerland; [Kuster, Stefan P.] Univ Zurich, Zurich, Switzerland; [Bhatnagar, Neera] McMaster Univ, Hlth Sci Lib, Hamilton, ON L8N 3Z5, Canada; [Loeb, Mark] McMaster Univ, Dept Pathol & Mol Med, Hamilton, ON L8N 3Z5, Canada; [Loeb, Mark] McMaster Univ, Michael G DeGroote Inst Infect Dis Res, Hamilton, ON L8N 3Z5, Canada	McMaster University; McMaster University; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Zurich; University Zurich Hospital; University of Zurich; McMaster University; McMaster University; McMaster University	Loeb, M (corresponding author), McMaster Univ, Dept Pathol & Mol Med, MDCL 3203,1200 Main St W, Hamilton, ON L8N 3Z5, Canada.	loebm@mcmaster.ca	Kuster, Stefan/T-7388-2019; Kim, Tae Hyong/L-7336-2015	Kuster, Stefan/0000-0002-0525-6529; Kim, Tae Hyong/0000-0003-2920-9038; Fadel, Shaza/0000-0002-2336-6254	WHO	WHO(World Health Organization)	This systematic review was funded by WHO as part of an ongoing process of reviewing and revising current WHO recommendations. The protocol for the review was discussed with WHO and its suggestions were incorporated into the protocol.	[Anonymous], 2009, WKLY EPIDEMIOL REC, V84, P301; Atkins D, 2004, BMJ-BRIT MED J, V328, P1490; Bender JM, 2009, PEDIATR EMERG CARE, V25, P369, DOI 10.1097/PEC.0b013e3181a792a9; Buda S, 2010, BUNDESGESUNDHEITSBLA, V53, P1223, DOI 10.1007/s00103-010-1158-0; Campbell A, 2010, CAN MED ASSOC J, V182, P349, DOI 10.1503/cmaj.091823; Center for Disease Control and Prevention, 2012, PEOPL HIGH RISK DEV; Dawood FS, 2012, LANCET INFECT DIS, V12, P687, DOI 10.1016/S1473-3099(12)70121-4; Dawood FS, 2010, PEDIATR INFECT DIS J, V29, P585, DOI 10.1097/INF.0b013e3181d411c5; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Dubar G, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013112; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Fell DB, 2013, PREGNANCY OUTCOMES A; Nuorti J. Pekka, 2010, Morbidity and Mortality Weekly Report, V59, P1; Flegal KM, 2005, JAMA-J AM MED ASSOC, V293, P1861, DOI 10.1001/jama.293.15.1861; Guyatt GH, 2011, J CLIN EPIDEMIOL, V64, P1283, DOI 10.1016/j.jclinepi.2011.01.012; Harbord RM, 2006, STAT MED, V25, P3443, DOI 10.1002/sim.2380; Helferty M, 2010, CAN MED ASSOC J, V182, P1981, DOI 10.1503/cmaj.100746; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Higgins J, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.ED000049; Hsu J, 2012, ANN INTERN MED, V156, P512, DOI 10.7326/0003-4819-156-7-201204030-00411; Louie JK, 2011, CLIN INFECT DIS, V52, P301, DOI 10.1093/cid/ciq152; Louie JK, 2010, NEW ENGL J MED, V362, P27, DOI 10.1056/NEJMoa0910444; McMillan M, 2013, INFLUENZA VACCINATIO; Michiels B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060348; Neupane B, 2010, J CLIN EPIDEMIOL, V63, P926, DOI 10.1016/j.jclinepi.2009.11.006; Neuzil KM, 1998, AM J EPIDEMIOL, V148, P1094, DOI 10.1093/oxfordjournals.aje.a009587; OConnell D, 2019, NEWCASTLE OTTAWA SCA; Perneger TV, 2008, CONTEMP CLIN TRIALS, V29, P762, DOI 10.1016/j.cct.2008.06.002; Riley RD, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001380; Riley RD, 2011, BMJ-BRIT MED J, V342, DOI 10.1136/bmj.d549; Siston AM, 2010, JAMA-J AM MED ASSOC, V303, P1517, DOI 10.1001/jama.2010.479; Stein M, 2010, ARCH PEDIAT ADOL MED, V164, P1015, DOI 10.1001/archpediatrics.2010.195; Thorlund K, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025491; Van Kerkhove MD, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001053; World Health Organization, 2009, FACT SHEET INFL; Xi XM, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-256; Zhang J, 1998, JAMA-J AM MED ASSOC, V280, P1690, DOI 10.1001/jama.280.19.1690	37	361	373	2	37	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 23	2013	347								f5061	10.1136/bmj.f5061	http://dx.doi.org/10.1136/bmj.f5061			16	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	207TC	23974637	Green Published, Green Accepted, hybrid			2023-01-03	WOS:000323625800002
J	Yao, YW; Gu, XL; Zhu, JH; Yuan, DM; Song, Y				Yao, Yanwen; Gu, Xiaoling; Zhu, Juehua; Yuan, Dongmei; Song, Yong			Hormone Replacement Therapy in Females Can Decrease the Risk of Lung Cancer: A Meta-Analysis	PLOS ONE			English	Article							ESTROGEN PLUS PROGESTIN; CORONARY-HEART-DISEASE; POSTMENOPAUSAL WOMEN; FOLLOW-UP; HEALTH; ADENOCARCINOMA; MORTALITY; SURVIVAL; BENEFITS; RECEPTOR	The purpose of the present meta-analysis was to determine the relationship between hormone replacement therapy (HRT) and lung cancer risk in females. Publications were reviewed and obtained through a PubMed, EMBASE database and Cochrane Library literature search up to May, 2012. The detailed numbers of patients in different groups, odd ratios (ORs) and corresponding 95% confidence intervals (CIs) were collected and estimated using a random-effects model. Twenty five studies entered into the meta-analysis. The total number of participates and lung cancer patients was 656,403 and 11,442, respectively. The OR of all 25 studies was 0.91 (95% CI = 0.83 to 0.99) and P value was 0.033. In stratified analyses, the positive association between HRT use and decreased lung cancer risk was also found in the patients with BMI <25 kg/m(2) (OR = 0.65, P = 0.000), and never smokers patients (OR = 0.86, P = 0.042). However, HRT use in patients with artificial menopause could increase the lung cancer risk, OR = 1.51(P = 0.001). The result of Egger's test did not show any evidence of publican bias (P = 0.069). In conclusion, our meta-analysis on HRT and lung cancer risk suggests that HRT use is correlated with decreased lung cancer risk in female, especially in female with BMI <25 kg/m(2) and never smokers.	[Yao, Yanwen; Gu, Xiaoling; Yuan, Dongmei; Song, Yong] Nanjing Univ, Jinling Hosp, Dept Resp Med, Sch Med, Nanjing 210008, Jiangsu, Peoples R China; [Zhu, Juehua] Nanjing Univ, Jinling Hosp, Dept Neurol Med, Sch Med, Nanjing 210008, Jiangsu, Peoples R China	Nanjing University; Nanjing University	Song, Y (corresponding author), Nanjing Univ, Jinling Hosp, Dept Resp Med, Sch Med, Nanjing 210008, Jiangsu, Peoples R China.	yong_song6310@yahoo.com						ADAMI HO, 1989, INT J CANCER, V44, P833, DOI 10.1002/ijc.2910440515; Biglia N, 2004, MATURITAS, V48, P333, DOI 10.1016/j.maturitas.2003.09.031; Blackman JA, 2002, PHARMACOEPIDEM DR S, V11, P561, DOI 10.1002/pds.733; Brinton LA, 2012, CANCER CAUSE CONTROL, V23, P487, DOI 10.1007/s10552-012-9904-2; Chen KY, 2007, CANCER-AM CANCER SOC, V110, P1768, DOI 10.1002/cncr.22987; Chene G, 1996, AM J EPIDEMIOL, V144, P610; Chlebowski RT, 2010, JNCI-J NATL CANCER I, V102, P1413, DOI 10.1093/jnci/djq285; Chlebowski RT, 2009, LANCET, V374, P1243, DOI 10.1016/S0140-6736(09)61526-9; Clague J, 2011, CANCER EPIDEM BIOMAR, V20, P560, DOI 10.1158/1055-9965.EPI-10-1182; Crosbie EJ, 2010, CANCER EPIDEM BIOMAR, V19, P3119, DOI 10.1158/1055-9965.EPI-10-0832; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Elliott AM, 2006, CONTRACEPTION, V73, P331, DOI 10.1016/j.contraception.2005.10.003; Freedman DM, 2010, INT J CANCER, V126, P1997, DOI 10.1002/ijc.24903; Ganti AK, 2006, J CLIN ONCOL, V24, P59, DOI 10.1200/JCO.2005.02.9827; Gompel A, 2012, CLIMACTERIC, V15, P241, DOI 10.3109/13697137.2012.666456; Hodis HN, 2009, CLIMACTERIC, V12, P71, DOI 10.1080/13697130903095178; Hulley S, 2002, JAMA-J AM MED ASSOC, V288, P58, DOI 10.1001/jama.288.1.58; Ishibashi H, 2005, CANCER RES, V65, P6450, DOI 10.1158/0008-5472.CAN-04-3087; Kabat GC, 2007, INT J CANCER, V120, P2214, DOI 10.1002/ijc.22543; Kreuzer M, 2003, INT J EPIDEMIOL, V32, P263, DOI 10.1093/ije/dyg064; Liu Y, 2005, INT J CANCER, V117, P662, DOI 10.1002/ijc.21229; Low AK, 2002, AM J MED SCI, V324, P180, DOI 10.1097/00000441-200210000-00003; Mahabir S, 2008, AM J EPIDEMIOL, V167, P1070, DOI 10.1093/aje/kwn021; MANTEL N, 1959, J NATL CANCER I, V22, P719; Meinhold CL, 2011, INT J CANCER, V128, P1404, DOI 10.1002/ijc.25434; Moore KA, 2003, ANN THORAC SURG, V76, P1789, DOI 10.1016/S0003-4975(03)01024-5; Olsson H, 2003, OBSTET GYNECOL, V102, P565, DOI 10.1016/S0029-7844(03)00564-7; Omoto Y, 2001, BIOCHEM BIOPH RES CO, V285, P340, DOI 10.1006/bbrc.2001.5158; Persson I, 1996, INT J CANCER, V67, P327, DOI 10.1002/(SICI)1097-0215(19960729)67:3<327::AID-IJC4>3.3.CO;2-J; Prentice RL, 2008, EPIDEMIOLOGY, V19, P785, DOI 10.1097/EDE.0b013e318188e83b; Pukkala E, 2001, CANCER CAUSE CONTROL, V12, P111, DOI 10.1023/A:1008934919159; Ramnath N, 2007, ONCOLOGY-BASEL, V73, P305, DOI 10.1159/000134238; Rodriguez C, 2008, CANCER EPIDEM BIOMAR, V17, P655, DOI 10.1158/1055-9965.EPI-07-2683; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; Schabath MB, 2004, CLIN CANCER RES, V10, P113, DOI 10.1158/1078-0432.CCR-0911-3; Siegel R, 2012, CA-CANCER J CLIN, V62, P10, DOI 10.3322/caac.20138; Siegel R, 2011, CA-CANCER J CLIN, V61, P212, DOI 10.3322/caac.20121; Siegfried JM, 2006, J CLIN ONCOL, V24, P9, DOI 10.1200/JCO.2005.04.2531; Slatore CG, 2010, J CLIN ONCOL, V28, P1540, DOI 10.1200/JCO.2009.25.9739; Smith JR, 2009, MENOPAUSE, V16, P1044, DOI 10.1097/gme.0b013e3181a1ba04; TAIOLI E, 1994, J NATL CANCER I, V86, P869, DOI 10.1093/jnci/86.11.869; Thomas L, 2005, CHEST, V128, P370, DOI 10.1378/chest.128.1.370; Thun MJ, 2013, NEW ENGL J MED, V368, P351, DOI 10.1056/NEJMsa1211127; Vandenbroucke JP, 2008, JAMA-J AM MED ASSOC, V300, P2417, DOI 10.1001/jama.2008.723; Vandenbroucke JP, 2009, LANCET, V373, P1233, DOI 10.1016/S0140-6736(09)60708-X; Vandenbroucke JP, 2004, LANCET, V363, P1728, DOI 10.1016/S0140-6736(04)16261-2; WU AH, 1988, CANCER RES, V48, P7279; Zhang YG, 2011, BMC MED GENET, V12, DOI 10.1186/1471-2350-12-159	48	32	32	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 14	2013	8	8							e71236	10.1371/journal.pone.0071236	http://dx.doi.org/10.1371/journal.pone.0071236			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	202MQ	23967172	Green Submitted, Green Published, gold			2023-01-03	WOS:000323221500061
J	Batchelor, PE; Skeers, P; Antonic, A; Wills, TE; Howells, DW; Macleod, MR; Sena, ES				Batchelor, Peter E.; Skeers, Peta; Antonic, Ana; Wills, Taryn E.; Howells, David W.; Macleod, Malcolm R.; Sena, Emily S.			Systematic Review and Meta-Analysis of Therapeutic Hypothermia in Animal Models of Spinal Cord Injury	PLOS ONE			English	Review							COMPRESSION INJURY; RAT; CONTUSION; OUTCOMES	Background: Therapeutic hypothermia is a clinically useful neuroprotective therapy for cardiac arrest and neonatal hypoxic ischemic encephalopathy and may potentially be useful for the treatment of other neurological conditions including traumatic spinal cord injury (SCI). The pre-clinical studies evaluating the effectiveness of hypothermia in acute SCI broadly utilise either systemic hypothermia or cooling regional to the site of injury. The literature has not been uniformly positive with conflicting studies of varying quality, some performed decades previously. Methods: In this study, we systematically review and meta-analyse the literature to determine the efficacy of systemic and regional hypothermia in traumatic SCI, the experimental conditions influencing this efficacy, and the influence of study quality on outcome. Three databases were utilised; PubMed, ISI Web of Science and Embase. Our inclusion criteria consisted of the (i) reporting of efficacy of hypothermia on functional outcome (ii) number of animals and (iii) mean outcome and variance in each group. Results: Systemic hypothermia improved behavioural outcomes by 24.5% (95% CI 10.2 to 38.8) and a similar magnitude of improvement was seen across a number of high quality studies. The overall behavioural improvement with regional hypothermia was 26.2%, but the variance was wide (95% CI 23.77 to 56.2). This result may reflect a preponderance of positive low quality data, although a preferential effect of hypothermia in ischaemic models of injury may explain some of the disparate data. Sufficient heterogeneity was present between studies of regional hypothermia to reveal a number of factors potentially influencing efficacy, including depth and duration of hypothermia, animal species, and neurobehavioural assessment. However, these factors could reflect the influence of earlier lower quality literature. Conclusion: Systemic hypothermia appears to be a promising potential method of treating acute SCI on the basis of metaanalysis of the pre-clinical literature and the results of high quality animal studies.	[Batchelor, Peter E.; Antonic, Ana; Wills, Taryn E.; Howells, David W.; Sena, Emily S.] Florey Inst Neurosci & Mental Hlth, Heidelberg, Vic, Australia; [Batchelor, Peter E.; Skeers, Peta; Antonic, Ana; Wills, Taryn E.] Univ Melbourne, Dept Med, Heidelberg, Vic, Australia; [Macleod, Malcolm R.; Sena, Emily S.] Univ Edinburgh, Div Clin Neurosci, Edinburgh, Midlothian, Scotland	Florey Institute of Neuroscience & Mental Health; University of Melbourne; University of Edinburgh	Batchelor, PE (corresponding author), Florey Inst Neurosci & Mental Hlth, Heidelberg, Vic, Australia.	batch@bigpond.net.au	Antonic-Baker, Ana/K-5968-2019; Macleod, Malcolm Robert/B-2052-2010; Anotnic-Baker, Ana/K-6361-2019	Macleod, Malcolm Robert/0000-0001-9187-9839; Anotnic-Baker, Ana/0000-0003-4275-7557; Howells, David/0000-0002-2512-7724; Sena, Emily S/0000-0002-3282-8502	National Health and Medical Research Council; Transport Accident Commission of Australia; National Centre for the Replacement [NC/L000970/1] Funding Source: researchfish	National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia); Transport Accident Commission of Australia; National Centre for the Replacement	Authors acknowledge the generous financial support of the National Health and Medical Research Council and the Transport Accident Commission of Australia. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ahmad F, 2013, WORLD NEUROSURGERY; ALBIN MS, 1967, ANESTH ANAL CURR RES, V46, P8; ALBIN MS, 1968, J NEUROSURG, V29, P113, DOI 10.3171/jns.1968.29.2.0113; Batchelor PE, 2011, J NEUROTRAUM, V28, P809, DOI 10.1089/neu.2010.1622; Batchelor PE, 2010, J NEUROTRAUM, V27, P1357, DOI 10.1089/neu.2010.1360; Casas C, 2003, SOC NEUR ABSTR VIEW; Casas CE, 2005, J NEUROSURG-SPINE, V2, P308, DOI 10.3171/spi.2005.2.3.0308; Chatzipanteli K, 2000, J NEUROTRAUM, V17, P321, DOI 10.1089/neu.2000.17.321; Dididze M, 2012, SPINAL CORD; Dietrich WD, 2011, NEUROTHERAPEUTICS, V8, P229, DOI 10.1007/s13311-011-0035-3; Dietrich WD, 2009, J NEUROTRAUM, V26, P301, DOI 10.1089/neu.2008.0806; Dietrich WD, 2009, CRIT CARE MED, V37, pS238, DOI 10.1097/CCM.0b013e3181aa5d85; Dimar JR, 2000, SPINE, V25, P2294, DOI 10.1097/00007632-200009150-00006; Farooque M, 1997, J NEUROTRAUM, V14, P63, DOI 10.1089/neu.1997.14.63; Ha KY, 2008, SPINE, V33, P2059, DOI 10.1097/BRS.0b013e31818018f6; Hansebout R R, 1975, Surg Neurol, V4, P531; Jerndal M, 2010, J CEREBR BLOOD F MET, V30, P961, DOI 10.1038/jcbfm.2009.267; Jou IM, 2000, SPINE, V25, P1878, DOI 10.1097/00007632-200008010-00004; Kwon BK, 2008, SPINE J, V8, P859, DOI 10.1016/j.spinee.2007.12.006; Levi AD, 2010, NEUROSURGERY, V66, P670, DOI 10.1227/01.NEU.0000367557.77973.5F; Levi AD, 2009, J NEUROTRAUM, V26, P407, DOI 10.1089/neu.2008.0745; Lo TP, 2009, J COMP NEUROL, V514, P433, DOI 10.1002/cne.22014; Macleod MR, 2008, STROKE, V39, P2824, DOI 10.1161/STROKEAHA.108.515957; Macleod MR, 2009, J CEREBR BLOOD F MET, V29, P221, DOI 10.1038/jcbfm.2008.101; Macleod MR, 2004, STROKE, V35, P1203, DOI 10.1161/01.STR.0000125719.25853.20; Marion D, 2009, J NEUROTRAUM, V26, P455, DOI 10.1089/neu.2008.0582; Martinez-Arizala A, 1995, SOC NEUR ABSTR; MARTINEZARIZALA A, 1992, J NEUROTRAUM, V9, pS497; Moher D, 2009, PLOS MED, V6, DOI [10.1371/journal.pmed.1000097, 10.1136/bmj.b4037]; Morino T, 2008, SPINAL CORD, V46, P425, DOI 10.1038/sj.sc.3102163; Morochovic R, 2008, INT J NEUROSCI, V118, P555, DOI 10.1080/00207450601123456; Savovic J, 2012, ANN INTERNAL MED; Sena ES, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000344; Shibuya S, 2004, SPINAL CORD, V42, P29, DOI 10.1038/sj.sc.3101516; Tator CH, 1972, SURG FORUM, V23; Topuz K, 2010, ARCH MED RES, V41, P506, DOI 10.1016/j.arcmed.2010.10.004; Vesterinen HM, 2010, MULT SCLER J, V16, P1044, DOI 10.1177/1352458510379612; Westergren H, 2000, ACTA NEUROCHIR, V142, P567, DOI 10.1007/s007010050471; Yamamoto K, 1998, NEUROREPORT, V9, P1655, DOI 10.1097/00001756-199805110-00072; Yu CG, 2000, J NEUROSURG, V93, P85, DOI 10.3171/spi.2000.93.1.0085; Yu WR, 1999, ACTA NEUROPATHOL, V98, P15, DOI 10.1007/s004010051046	41	40	41	0	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 9	2013	8	8							e71317	10.1371/journal.pone.0071317	http://dx.doi.org/10.1371/journal.pone.0071317			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	245OM	23951131	Green Published, gold			2023-01-03	WOS:000326473200040
J	Shin, YS; Shin, HA; Kang, SU; Kim, JH; Oh, YT; Park, KH; Kim, CH				Shin, Yoo Seob; Shin, Hyang Ae; Kang, Sung Un; Kim, Jang Hee; Oh, Young-Taek; Park, Keun Hyung; Kim, Chul-Ho			Effect of Epicatechin against Radiation-Induced Oral Mucositis: In Vitro and In Vivo Study	PLOS ONE			English	Article							EPIDERMAL-GROWTH-FACTOR; GREEN TEA; ULCERATIVE MUCOSITIS; DOUBLE-BLIND; NECK-CANCER; HEAD; CELLS; RADIOTHERAPY; POLYPHENOLS; PREVENTION	Purpose: Radiation-induced oral mucositis limits the delivery of high-dose radiation to head and neck cancer. This study investigated the effectiveness of epicatechin (EC), a component of green tea extracts, on radiation-induced oral mucositis in vitro and in vivo. Experimental Design: The effect of EC on radiation-induced cytotoxicity was analyzed in the human keratinocyte line HaCaT. Radiation-induced apoptosis, change in mitochondrial membrane potential (MMP), reactive oxygen species (ROS) generation and changes in the signaling pathway were investigated. In vivo therapeutic effects of EC for oral mucositis were explored in a rat model. Rats were monitored by daily inspections of the oral cavity, amount of oral intake, weight change and survival rate. For histopathologic evaluation, hematoxylin-eosin staining and TUNEL staining were performed. Results: EC significantly inhibited radiation-induced apoptosis, change of MMP, and intracellular ROS generation in HaCaT cells. EC treatment markedly attenuated the expression of p-JNK, p-38, and cleaved caspase-3 after irradiation in the HaCaT cells. Rats with radiation-induced oral mucositis showed decreased oral intake, weight and survival rate, but oral administration of EC significantly restored all three parameters. Histopathologic changes were significantly decreased in the EC-treated irradiated rats. TUNEL staining of rat oral mucosa revealed that EC treatment significantly decreased radiation-induced apoptotic cells. Conclusions: This study suggests that EC significantly inhibited radiation-induced apoptosis in keratinocytes and rat oral mucosa and may be a safe and effective candidate treatment for the prevention of radiation-induced mucositis.	[Shin, Yoo Seob; Kang, Sung Un; Park, Keun Hyung; Kim, Chul-Ho] Ajou Univ, Sch Med, Dept Otolaryngol, Suwon 441749, South Korea; [Shin, Hyang Ae] Ilsan Hosp, Natl Hlth Insurance Corp, Dept Otorhinolaryngol Head & Neck Surg, Goyang, South Korea; [Kim, Jang Hee] Ajou Univ, Sch Med, Dept Pathol, Suwon 441749, South Korea; [Oh, Young-Taek] Ajou Univ, Sch Med, Dept Radiat Oncol, Suwon 441749, South Korea	Ajou University; NHIS Ilsan Hospital; Ajou University; Ajou University	Kim, CH (corresponding author), Ajou Univ, Sch Med, Dept Otolaryngol, Suwon 441749, South Korea.	ostium@ajou.ac.kr	Kim, Jang-Hee/AAI-9917-2020; kang, sung un/AAK-8050-2021	Kim, Jang-Hee/0000-0001-5825-1361	National Research Foundation of Korea (NRF); Korea government (MEST) [2010-0012821]; CCRB through the "GRRC" Project of Gyeonggi Provincial Government, Korea [GRRC Ajou-2012-A03]	National Research Foundation of Korea (NRF)(National Research Foundation of Korea); Korea government (MEST)(Ministry of Education, Science & Technology (MEST), Republic of KoreaKorean Government); CCRB through the "GRRC" Project of Gyeonggi Provincial Government, Korea	This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MEST) (2010-0012821) and CCRB through the "GRRC" Project of Gyeonggi Provincial Government, Korea (GRRC Ajou-2012-A03). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Antunes HS, 2007, BLOOD, V109, P2250, DOI 10.1182/blood-2006-07-035022; Artali R, 2009, J ENZYM INHIB MED CH, V24, P287, DOI 10.1080/14756360802177282 ; Brizel DM, 2000, J CLIN ONCOL, V18, P3339, DOI 10.1200/JCO.2000.18.19.3339; Cai JY, 1998, BBA-BIOENERGETICS, V1366, P139, DOI 10.1016/S0005-2728(98)00109-1; Cho SA, 2006, EXP TOXICOL PATHOL, V57, P321, DOI 10.1016/j.etp.2005.09.006; Chung JY, 1999, CANCER RES, V59, P4610; Chung JY, 2001, FASEB J, V15, P2022, DOI 10.1096/fj.01-0031fje; de Mejia EG, 2009, BRAIN BEHAV IMMUN, V23, P721, DOI 10.1016/j.bbi.2009.02.013; Epstein JB, 2000, CANCER-AM CANCER SOC, V89, P2258, DOI 10.1002/1097-0142(20001201)89:11<2258::AID-CNCR14>3.0.CO;2-Z; Epstein JB, 2001, HEAD NECK-J SCI SPEC, V23, P389, DOI 10.1002/hed.1049; Epstein JB, 2001, CANCER, V92, P875, DOI 10.1002/1097-0142(20010815)92:4<875::AID-CNCR1396>3.0.CO;2-1; Guo QN, 1996, BBA-LIPID LIPID MET, V1304, P210, DOI 10.1016/S0005-2760(96)00122-1; Higdon JV, 2003, CRIT REV FOOD SCI, V43, P89, DOI 10.1080/10408690390826464; Hille A, 2003, INT J RADIAT BIOL, V79, P119, DOI 10.1080/0955300021000045682; Kim CH, 2008, APOPTOSIS, V13, P1184, DOI 10.1007/s10495-008-0242-5; Kuo YC, 2009, CANCER CAUSE CONTROL, V20, P57, DOI 10.1007/s10552-008-9217-7; Lalla RV, 2006, CANCER J, V12, P348, DOI 10.1097/00130404-200609000-00004; Leborgne JH, 1998, RADIOTHER ONCOL, V47, P145, DOI 10.1016/S0167-8140(97)00174-6; Lee JS, 2010, TOXICOL LETT, V199, P308, DOI 10.1016/j.toxlet.2010.09.013; Lee SW, 2007, INT J RADIAT ONCOL, V67, P1172, DOI 10.1016/j.ijrobp.2006.10.038; Mann CD, 2009, EUR J CANCER PREV, V18, P13, DOI 10.1097/CEJ.0b013e3282f0c090; Murphy CK, 2008, CLIN CANCER RES, V14, P4292, DOI 10.1158/1078-0432.CCR-07-4669; Pignon JP, 2000, LANCET, V355, P949, DOI 10.1016/S0140-6736(00)90011-4; Plevova P, 1999, ORAL ONCOL, V35, P453, DOI 10.1016/S1368-8375(99)00033-0; Prince PSM, 2013, FOOD CHEM TOXICOL, V53, P409, DOI 10.1016/j.fct.2012.12.010; Pyun JH, 2011, NEUROSCIENCE, V199, P410, DOI 10.1016/j.neuroscience.2011.09.012; Rosenthal DI, 2009, SEMIN RADIAT ONCOL, V19, P29, DOI 10.1016/j.semradonc.2008.09.006; Rovirosa A, 1998, INT J RADIAT ONCOL, V41, P747, DOI 10.1016/S0360-3016(98)00109-6; Sankaranarayanan R, 1998, ANTICANCER RES, V18, P4779; Schroeder P, 2003, BIOCHEM BIOPH RES CO, V307, P69, DOI 10.1016/S0006-291X(03)01132-X; Schroeter H, 2007, J NEUROCHEM, V101, P1596, DOI 10.1111/j.1471-4159.2006.04434.x; Sheng-Tanner X, 1998, RADIAT RES, V150, P636, DOI 10.2307/3579886; Shin YS, 2013, NEUROSCIENCE, V232, P1, DOI 10.1016/j.neuroscience.2012.12.008; Siomek A, 2006, INT J CANCER, V119, P2228, DOI 10.1002/ijc.22088; Sonis SL, 2002, CRIT REV ORAL BIOL M, V13, P380, DOI 10.1177/154411130201300502; SONIS ST, 1994, CANCER RES, V54, P1135; Spielberger R, 2004, NEW ENGL J MED, V351, P2590, DOI 10.1056/NEJMoa040125; Suntharalingam M, 2004, SEMIN ONCOL, V31, P2, DOI 10.1053/j.seminoncol.2005.02.001; Trotti A, 2004, INT J RADIAT ONCOL, V58, P674, DOI 10.1016/S0360-3016(03)01627-4; Wilkes JD, 1998, SEMIN ONCOL, V25, P538	40	30	31	0	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 18	2013	8	7							e69151	10.1371/journal.pone.0069151	http://dx.doi.org/10.1371/journal.pone.0069151			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	214PM	23874895	Green Published, Green Submitted, gold			2023-01-03	WOS:000324146200062
J	Fourtassi, M; Hajjioui, A; Urquizar, C; Rossetti, Y; Rode, G; Pisella, L				Fourtassi, Maryam; Hajjioui, Abderrazak; Urquizar, Christian; Rossetti, Yves; Rode, Gilles; Pisella, Laure			Iterative Fragmentation of Cognitive Maps in a Visual Imagery Task	PLOS ONE			English	Article							LATERAL EYE-MOVEMENTS; PREMOTOR THEORY; MENTAL-IMAGERY; ATTENTION; LOOKING; INFORMATION; PERCEPTION; LANGUAGE; INPUT; WORLD	It remains unclear whether spontaneous eye movements during visual imagery reflect the mental generation of a visual image (i.e. the arrangement of the component parts of a mental representation). To address this specificity, we recorded eye movements in an imagery task and in a phonological fluency (non-imagery) task, both consisting in naming French towns from long-term memory. Only in the condition of visual imagery the spontaneous eye positions reflected the geographic position of the towns evoked by the subjects. This demonstrates that eye positions closely reflect the mapping of mental images. Advanced analysis of gaze positions using the bi-dimensional regression model confirmed the spatial correlation of gaze and towns' locations in every single individual in the visual imagery task and in none of the individuals when no imagery accompanied memory retrieval. In addition, the evolution of the bi-dimensional regression's coefficient of determination revealed, in each individual, a process of generating several iterative series of a limited number of towns mapped with the same spatial distortion, despite different individual order of towns' evocation and different individual mappings. Such consistency across subjects revealed by gaze (the mind's eye) gives empirical support to theories postulating that visual imagery, like visual sampling, is an iterative fragmented processing.	[Fourtassi, Maryam; Urquizar, Christian; Rossetti, Yves; Rode, Gilles; Pisella, Laure] ImpAct Team, Lyon Neurosci Res Ctr, UMR5292, INSERM,U1028,CNRS, Lyon, France; [Fourtassi, Maryam; Urquizar, Christian; Rossetti, Yves; Rode, Gilles; Pisella, Laure] Univ Lyon 1, F-69365 Lyon, France; [Fourtassi, Maryam; Urquizar, Christian; Rossetti, Yves; Rode, Gilles; Pisella, Laure] Hop Henry Gabrielle, Hosp Civils Lyon, St Genis Laval, France; [Fourtassi, Maryam; Urquizar, Christian; Rossetti, Yves; Rode, Gilles; Pisella, Laure] Hop Neurol, Lyon, France; [Fourtassi, Maryam] Univ Mohamed Premier, Fac Med & Pharm, Oujda, Morocco; [Hajjioui, Abderrazak] Univ Mohammed Benabdellah, Fac Med & Pharm, CHU Hassan Fez 2, Fes, Morocco	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); CHU Lyon; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; CHU Lyon; CHU Lyon; Mohammed First University of Oujda; Mohammed VI University Hospital Center of Oujda; Hassan II University Hospital Center of Fez; Mohammed First University of Oujda; Sidi Mohamed Ben Abdellah University of Fez	Pisella, L (corresponding author), ImpAct Team, Lyon Neurosci Res Ctr, UMR5292, INSERM,U1028,CNRS, Lyon, France.	laure.pisella@inserm.fr	Rode, Gilles/J-8933-2017; Rossetti, Yves/H-3693-2017; Pisella, Laure/H-6072-2017	Rossetti, Yves/0000-0001-8867-4496; Pisella, Laure/0000-0001-6550-3774; FOURTASSI, Maryam/0000-0003-4915-5399; Hajjioui, Abderrazak/0000-0002-2311-5543				Altmann GTM, 2009, COGNITION, V111, P55, DOI 10.1016/j.cognition.2008.12.005; Altmann GTM, 2004, COGNITION, V93, pB79, DOI 10.1016/j.cognition.2004.02.005; Blangero A, 2010, CORTEX, V46, P1132, DOI 10.1016/j.cortex.2009.06.014; Borst G, 2006, MEM COGNITION, V34, P475, DOI 10.3758/BF03193572; Bourlon C, 2011, BRAIN RES, V1367, P287, DOI 10.1016/j.brainres.2010.10.039; Brandt SA, 1997, J COGN NEUROSC, V26, P207; Cauvin C, 2009, LOGICIEL COMPARAISON; Deubel H, 1996, VISION RES, V36, P1827, DOI 10.1016/0042-6989(95)00294-4; EHRLICHMAN H, 1983, ACTA PSYCHOL, V53, P9, DOI 10.1016/0001-6918(83)90013-6; EHRLICHMAN H, 1978, PSYCHOL BULL, V85, P1080, DOI 10.1037/0033-2909.85.5.1080; Ehrlichman H, 2007, BRAIN COGNITION, V64, P7, DOI 10.1016/j.bandc.2006.10.001; Ferreira F, 2008, TRENDS COGN SCI, V12, P405, DOI 10.1016/j.tics.2008.07.007; Friedman A, 2003, PSYCHOL METHODS, V8, P468, DOI 10.1037/1082-989X.8.4.468; GUREVITCH B, 1959, NATURE, V184, P1219, DOI 10.1038/1841219a0; Hassabis D, 2007, P NATL ACAD SCI USA, V104, P1726, DOI 10.1073/pnas.0610561104; HEBB DO, 1968, PSYCHOL REV, V75, P466, DOI 10.1037/h0026771; Hessler J, 2006, CARTOGRAPHIA, V4, P101; Huijbers W, 2011, NEUROPSYCHOLOGIA, V49, P1730, DOI 10.1016/j.neuropsychologia.2011.02.051; Johansson R, 2006, COGNITIVE SCI, V30, P1053, DOI 10.1207/s15516709cog0000_86; Johansson R, 2012, J EXP PSYCHOL HUMAN, V38, P1289, DOI 10.1037/a0026585; Khan AZ, 2009, CEREB CORTEX, V19, P383, DOI 10.1093/cercor/bhn088; Laeng B, 2002, COGNITIVE SCI, V26, P207, DOI 10.1016/S0364-0213(01)00065-9; LORENS SA, 1962, ELECTROEN CLIN NEURO, V14, P739, DOI 10.1016/0013-4694(62)90088-3; Martarelli CS, 2013, PSYCHOL RES-PSYCH FO, V77, P303, DOI 10.1007/s00426-012-0439-7; Martarelli CS, 2011, BRIT J DEV PSYCHOL, V29, P425, DOI 10.1348/026151010X495844; Mast FW, 2002, TRENDS COGN SCI, V6, P271, DOI 10.1016/S1364-6613(02)01931-9; Neisser U., 1967, COGNITIVE PSYCHOL; O'Regan JK, 2001, BEHAV BRAIN SCI, V24, P939, DOI 10.1017/S0140525X01000115; Pisella L, 2004, NEUROSCI BIOBEHAV R, V28, P181, DOI 10.1016/j.neubiorev.2004.03.003; Pisella L, 2011, PHILOS T R SOC B, V366, P572, DOI 10.1098/rstb.2010.0258; RAINE A, 1991, BRIT J PSYCHOL, V82, P129, DOI 10.1111/j.2044-8295.1991.tb02388.x; Rensink RA, 2000, VIS COGN, V7, P17, DOI 10.1080/135062800394667; Richardson DC, 2009, TRENDS COGN SCI, V13, P235, DOI 10.1016/j.tics.2009.02.006; Richardson DC, 2004, J EXP PSYCHOL GEN, V133, P46, DOI 10.1037/0096-3445.133.1.46; RIZZOLATTI G, 1987, NEUROPSYCHOLOGIA, V25, P31, DOI 10.1016/0028-3932(87)90041-8; Rode G, 2007, NEUROLOGY, V68, P432, DOI 10.1212/01.wnl.0000252936.54063.b0; RODE G, 1995, REV NEUROL, V151, P161; Rode G, 2004, CORTEX, V40, P391, DOI 10.1016/S0010-9452(08)70133-3; ROLL R, 1991, EXP BRAIN RES, V85, P423; Smith DT, 2012, NEUROPSYCHOLOGIA, V50, P1104, DOI 10.1016/j.neuropsychologia.2012.01.025; Spivey MJ, 2001, PSYCHOL RES-PSYCH FO, V65, P235, DOI 10.1007/s004260100059; Thomas LE, 2009, COGNITION, V111, P168, DOI 10.1016/j.cognition.2009.01.005; Tobler W, 1965, PAPERS REGIONAL SCI, V15, P131; van Reekum CM, 2007, NEUROIMAGE, V36, P1041, DOI 10.1016/j.neuroimage.2007.03.052; Wakefield CE, 2006, J VISUAL IMPAIR BLIN, V100, P306; WILCOXON F, 1946, J ECON ENTOMOL, V39, P269, DOI 10.1093/jee/39.2.269; Yarbus A. L., 1967, EYE MOVEMENTS VISION, DOI 10.1007/978-1-4899-5379-7	47	10	10	1	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 17	2013	8	7							e68560	10.1371/journal.pone.0068560	http://dx.doi.org/10.1371/journal.pone.0068560			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	185WH	23874672	Green Published, gold, Green Submitted			2023-01-03	WOS:000322000600011
J	Cheng, AC; Holmes, M; Irving, LB; Brown, SGA; Waterer, GW; Korman, TM; Friedman, ND; Senanayake, S; Dwyer, DE; Brady, S; Simpson, G; Wood-Baker, R; Upham, J; Paterson, D; Jenkins, C; Wark, P; Kelly, PM; Kotsimbos, T				Cheng, Allen C.; Holmes, Mark; Irving, Louis B.; Brown, Simon G. A.; Waterer, Grant W.; Korman, Tony M.; Friedman, N. Deborah; Senanayake, Sanjaya; Dwyer, Dominic E.; Brady, Stephen; Simpson, Grahame; Wood-Baker, Richard; Upham, John; Paterson, David; Jenkins, Christine; Wark, Peter; Kelly, Paul M.; Kotsimbos, Tom			Influenza Vaccine Effectiveness against Hospitalisation with Confirmed Influenza in the 2010-11 Seasons: A Test-negative Observational Study	PLOS ONE			English	Article							SENTINEL SURVEILLANCE; AUTUMN 2009; EFFICACY; AUSTRALIA; TRIVALENT; COHORT; VIRUS	Immunisation programs are designed to reduce serious morbidity and mortality from influenza, but most evidence supporting the effectiveness of this intervention has focused on disease in the community or in primary care settings. We aimed to examine the effectiveness of influenza vaccination against hospitalisation with confirmed influenza. We compared influenza vaccination status in patients hospitalised with PCR-confirmed influenza with patients hospitalised with influenza-negative respiratory infections in an Australian sentinel surveillance system. Vaccine effectiveness was estimated from the odds ratio of vaccination in cases and controls. We performed both simple multivariate regression and a stratified analysis based on propensity score of vaccination. Vaccination status was ascertained in 333 of 598 patients with confirmed influenza and 785 of 1384 test-negative patients. Overall estimated crude vaccine effectiveness was 57% (41%, 68%). After adjusting for age, chronic comorbidities and pregnancy status, the estimated vaccine effectiveness was 37% (95% CI: 12%, 55%). In an analysis accounting for a propensity score for vaccination, the estimated vaccine effectiveness was 48.3% (95% CI: 30.0, 61.8%). Influenza vaccination was moderately protective against hospitalisation with influenza in the 2010 and 2011 seasons.	[Cheng, Allen C.] Alfred Hosp, Infect Dis Unit, Melbourne, Vic, Australia; [Cheng, Allen C.; Holmes, Mark] Monash Univ, Dept Epidemiol & Prevent Med, Melbourne, Vic 3004, Australia; [Holmes, Mark; Irving, Louis B.] Royal Adelaide Hosp, Dept Resp & Sleep Med, Adelaide, SA 5000, Australia; Univ Adelaide, Dept Med, Adelaide, SA 5001, Australia; [Brown, Simon G. A.] Royal Perth Hosp, Dept Emergency Med, Perth, WA, Australia; [Brown, Simon G. A.] Univ Western Australia, Western Australian Inst Med Res, Ctr Clin Res Emergency Med, Perth, WA 6009, Australia; [Waterer, Grant W.] Univ Western Australia, Sch Med & Pharmacol, Royal Perth Hosp, Dept Resp Med, Perth, WA 6009, Australia; [Korman, Tony M.] Monash Med Ctr, Melbourne, Vic, Australia; [Korman, Tony M.] Monash Univ, Melbourne, Vic 3004, Australia; [Friedman, N. Deborah] Barwon Hlth, Geelong Hosp, Geelong, Vic, Australia; [Senanayake, Sanjaya] Canberra Hosp, Infect Dis Unit, Canberra, ACT, Australia; [Senanayake, Sanjaya] Australian Natl Univ, Sch Med, Canberra, ACT, Australia; [Dwyer, Dominic E.] Univ Sydney, Westmead Hosp, Ctr Infect Dis & Microbiol Lab Serv, Sydney, NSW 2006, Australia; [Brady, Stephen] Alice Springs Hosp, Alice Springs, NT, Australia; [Simpson, Grahame] Cairns Base Hosp, Cairns, Qld, Australia; [Wood-Baker, Richard] Univ Tasmania, Menzies Res Inst, Hobart, Tas, Australia; [Upham, John] Univ Queensland, Princess Alexandra Hosp, Brisbane, Qld 4072, Australia; [Paterson, David] Univ Queensland, Royal Brisbane & Womens Hosp, Brisbane, Qld, Australia; [Jenkins, Christine] Univ Sydney, Concord Hosp, Woolcock Inst Med Res, Sydney, NSW 2006, Australia; [Wark, Peter] Univ Newcastle, Newcastle, NSW 2300, Australia; [Wark, Peter] John Hunter Hosp, Newcastle, NSW, Australia; [Kelly, Paul M.] ACT Govt Hlth Directorate, Populat Hlth Div, Canberra, ACT, Australia; [Kelly, Paul M.] Australian Natl Univ, Sch Med, Canberra, ACT, Australia; [Kotsimbos, Tom] Monash Univ, Alfred Hosp, Dept Med, Allergy Immunol & Resp Med Unit, Melbourne, Vic 3181, Australia	Florey Institute of Neuroscience & Mental Health; Monash University; Royal Adelaide Hospital; University of Adelaide; Royal Perth Hospital; University of Western Australia; University of Western Australia; Royal Perth Hospital; University of Western Australia; Monash University; Monash University; Geelong Hospital; Australian National University; Canberra Hospital; Australian National University; University of Sydney; University of Tasmania; Menzies Institute for Medical Research; University of Queensland; Royal Brisbane & Women's Hospital; University of Queensland; Concord Repatriation General Hospital; University of Sydney; Woolcock Institute of Medical Research; University of Newcastle; John Hunter Hospital; Australian National University; Florey Institute of Neuroscience & Mental Health; Monash University	Cheng, AC (corresponding author), Alfred Hosp, Infect Dis Unit, Melbourne, Vic, Australia.	allen.cheng@monash.edu	Upham, John/F-4420-2010; Korman, Tony M/I-3099-2013; Wark, Peter/G-7037-2013; Waterer, Grant/AAG-2385-2021	Upham, John/0000-0002-0017-3433; Korman, Tony M/0000-0002-6155-8353; Wark, Peter/0000-0001-5676-6126; Cheng, Allen/0000-0003-3152-116X; Paterson, David/0000-0003-2079-4437	Australian Government Department of Health and Ageing; NHMRC	Australian Government Department of Health and Ageing(Australian GovernmentDepartment of Health & Ageing); NHMRC(National Health and Medical Research Council (NHMRC) of Australia)	The Australian Government Department of Health and Ageing provided funding for this study via an extension to a National Health and Medical Research Council grant. ACC is funded by a NHMRC Career Development Fellowship. The funder had input into the data collection instruments as it is a public health surveillance system but had no role in the analysis, the writing of the article or decision to publish this paper.	ATAGI, 2008, AUSTR IMM HDB; Austin PC, 2007, STAT MED, V26, P734, DOI 10.1002/sim.2580; Australian Institute of Health and Welfare (AIHW), 2009, 2009 AD VACC SURV SU; Belshe RB, 1998, NEW ENGL J MED, V338, P1405, DOI 10.1056/NEJM199805143382002; Cheng AC, 2011, VACCINE, V29, P7320, DOI 10.1016/j.vaccine.2011.07.087; DoHA, 2011, AUSTR INFL SURV SUMM; FEDSON DS, 1993, JAMA-J AM MED ASSOC, V270, P1956, DOI 10.1001/jama.270.16.1956; Fielding JE, 2011, EMERG INFECT DIS, V17, P1181, DOI 10.3201/eid1707.101959; Griffin MR, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023085; Hancock K, 2009, NEW ENGL J MED, V361, P1945, DOI 10.1056/NEJMoa0906453; Hardelid P, 2011, EURO SURVEILL, V16; Jefferson TO, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001269.pub3; Kelly PM, 2011, MED J AUSTRALIA, V194, P169, DOI 10.5694/j.1326-5377.2011.tb03764.x; Kissling E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027622; Mansson R, 2007, AM J EPIDEMIOL, V166, P332, DOI 10.1093/aje/kwm069; Nichol KL, 2007, NEW ENGL J MED, V357, P1373, DOI 10.1056/NEJMoa070844; Osterholm MT, 2011, LANCET INFECT DIS; Petrie JG, 2011, J INFECT DIS, V203, P1309, DOI 10.1093/infdis/jir015; Puig-Barbera J, 2010, VACCINE, V28, P7460, DOI 10.1016/j.vaccine.2010.09.042; Rivetti D, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004876.pub2; Skowronski DM, 2011, BMJ-BRIT MED J, V342, DOI 10.1136/bmj.c7297; SMITH PG, 1984, INT J EPIDEMIOL, V13, P87, DOI 10.1093/ije/13.1.87; Song JY, 2011, VACCINE, V29, P1395, DOI 10.1016/j.vaccine.2010.12.050; Steens A, 2011, BMC INFECT DIS, V11, DOI 10.1186/1471-2334-11-196; Talbot HK, 2011, J INFECT DIS, V203, P500, DOI 10.1093/infdis/jiq076	25	37	37	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 16	2013	8	7							e68760	10.1371/journal.pone.0068760	http://dx.doi.org/10.1371/journal.pone.0068760			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	186SF	23874754	Green Published, gold			2023-01-03	WOS:000322064300070
J	Johnson, SC; Yanos, ME; Kayser, EB; Quintana, A; Sangesland, M; Castanza, A; Uhde, L; Hui, J; Wall, VZ; Gagnidze, A; Oh, K; Wasko, BM; Ramos, FJ; Palmiter, RD; Rabinovitch, PS; Morgan, PG; Sedensky, MM; Kaeberlein, M				Johnson, Simon C.; Yanos, Melana E.; Kayser, Ernst-Bernhard; Quintana, Albert; Sangesland, Maya; Castanza, Anthony; Uhde, Lauren; Hui, Jessica; Wall, Valerie Z.; Gagnidze, Arni; Oh, Kelly; Wasko, Brian M.; Ramos, Fresnida J.; Palmiter, Richard D.; Rabinovitch, Peter S.; Morgan, Philip G.; Sedensky, Margaret M.; Kaeberlein, Matt			mTOR Inhibition Alleviates Mitochondrial Disease in a Mouse Model of Leigh Syndrome	SCIENCE			English	Article							COMPLEX-I DEFICIENCY; SUBUNIT; NDUFS4; MICE	Mitochondrial dysfunction contributes to numerous health problems, including neurological and muscular degeneration, cardiomyopathies, cancer, diabetes, and pathologies of aging. Severe mitochondrial defects can result in childhood disorders such as Leigh syndrome, for which there are no effective therapies. We found that rapamycin, a specific inhibitor of the mechanistic target of rapamycin (mTOR) signaling pathway, robustly enhances survival and attenuates disease progression in a mouse model of Leigh syndrome. Administration of rapamycin to these mice, which are deficient in the mitochondrial respiratory chain subunit Ndufs4 [NADH dehydrogenase (ubiquinone) Fe-S protein 4], delays onset of neurological symptoms, reduces neuroinflammation, and prevents brain lesions. Although the precise mechanism of rescue remains to be determined, rapamycin induces a metabolic shift toward amino acid catabolism and away from glycolysis, alleviating the buildup of glycolytic intermediates. This therapeutic strategy may prove relevant for a broad range of mitochondrial diseases.	[Johnson, Simon C.; Yanos, Melana E.; Sangesland, Maya; Castanza, Anthony; Uhde, Lauren; Hui, Jessica; Wall, Valerie Z.; Gagnidze, Arni; Oh, Kelly; Wasko, Brian M.; Ramos, Fresnida J.; Rabinovitch, Peter S.; Kaeberlein, Matt] Univ Washington, Dept Pathol, Seattle, WA 98195 USA; [Yanos, Melana E.] Univ Washington, Dept Psychol, Seattle, WA 98195 USA; [Kayser, Ernst-Bernhard; Morgan, Philip G.; Sedensky, Margaret M.] Seattle Childrens Hosp, Seattle, WA 98105 USA; [Quintana, Albert] Univ Washington, Howard Hughes Med Inst, Seattle, WA 98195 USA; [Quintana, Albert] Univ Washington, Dept Biochem, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Seattle Children's Hospital; Howard Hughes Medical Institute; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Kaeberlein, M (corresponding author), Univ Washington, Dept Pathol, Seattle, WA 98195 USA.	kaeber@uw.edu	Wasko, Brian/N-2580-2019; Quintana, Albert/N-5544-2015; Wasko, Brian/J-9814-2019; Castanza, Anthony/AAQ-7137-2021	Quintana, Albert/0000-0003-1674-7160; Wasko, Brian/0000-0002-7090-086X; Castanza, Anthony/0000-0001-9795-0720; Johnson, Simon/0000-0002-1942-3674; Zebertavage, Lauren/0000-0003-2507-4084; Sangesland, Maya/0000-0001-8316-039X	University of Washington School of Medicine; Department of Pathology; NIH [T32AG000057, T32ES007032]; Amgen Scholar summer research scholarship; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES007032] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG039390, T32AG000057] Funding Source: NIH RePORTER	University of Washington School of Medicine; Department of Pathology; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Amgen Scholar summer research scholarship; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	We thank the University of Washington School of Medicine and Department of Pathology for funding to M. K. that allowed these studies to be performed. Supported by NIH training grant T32AG000057 (S.C.J., M.E.Y., and F.J.R.), NIH training grant T32ES007032 (B.M.W.), and an Amgen Scholar summer research scholarship (M.S.).	Arii J, 2000, AM J NEURORADIOL, V21, P1502; Blagosklonny MV, 2010, CELL CYCLE, V9, P683, DOI 10.4161/cc.9.4.10766; Breuer ME, 2013, IUBMB LIFE, V65, P202, DOI 10.1002/iub.1127; Darin N, 2001, ANN NEUROL, V49, P377, DOI 10.1002/ana.75; Harrison DE, 2009, NATURE, V460, P392, DOI 10.1038/nature08221; Johnson SC, 2013, NATURE, V493, P338, DOI 10.1038/nature11861; Kruse SE, 2008, CELL METAB, V7, P312, DOI 10.1016/j.cmet.2008.02.004; Laplante M, 2012, CELL, V149, P274, DOI 10.1016/j.cell.2012.03.017; Patel KP, 2012, MOL GENET METAB, V106, P384, DOI 10.1016/j.ymgme.2012.03.016; Quintana A, 2010, P NATL ACAD SCI USA, V107, P10996, DOI 10.1073/pnas.1006214107; Ramos FJ, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003802; Scacco S, 2000, J BIOL CHEM, V275, P17578, DOI 10.1074/jbc.M001174200; Schleit J, 2013, AGING CELL, V12, P1050, DOI 10.1111/acel.12130; Taylor AL, 2005, CRIT REV ONCOL HEMAT, V56, P23, DOI 10.1016/j.critrevonc.2005.03.012; VANERVEN PMM, 1987, CLIN NEUROL NEUROSUR, V89, P217, DOI 10.1016/S0303-8467(87)80020-3	15	329	334	11	55	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 20	2013	342	6165					1524	1528		10.1126/science.1244360	http://dx.doi.org/10.1126/science.1244360			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	274ZI	24231806	Green Accepted			2023-01-03	WOS:000328644300063
J	Vasconcelos, JF; Souza, BSF; Lins, TFS; Garcia, LMS; Kaneto, CM; Sampaio, GP; de Alcantara, AC; Meira, CS; Macambira, SG; Ribeiro-dos-Santos, R; Soares, MBP				Vasconcelos, Juliana F.; Souza, Bruno S. F.; Lins, Thayse F. S.; Garcia, Leticia M. S.; Kaneto, Carla M.; Sampaio, Geraldo P.; de Alcantara, Adriano C.; Meira, Cassio S.; Macambira, Simone G.; Ribeiro-dos-Santos, Ricardo; Soares, Milena B. P.			Administration of granulocyte colony-stimulating factor induces immunomodulation, recruitment of T regulatory cells, reduction of myocarditis and decrease of parasite load in a mouse model of chronic Chagas disease cardiomyopathy	FASEB JOURNAL			English	Article						Trypanosoma cruzi; cytokine therapy; inflammation; fibrosis; Th1 modulation	BONE-MARROW; G-CSF; DENDRITIC CELLS; IFN-GAMMA; IN-VITRO; EXPRESSION; INDUCTION; TRANSPLANTATION; MACROPHAGES; GENERATION	Chagas disease, caused by Trypanosoma cruzi infection, is a leading cause of heart failure in Latin American countries. In a previous study, we showed beneficial effects of granulocyte colony-stimulating factor (G-CSF) administration in the heart function of mice with chronic T. cruzi infection. Presently, we investigated the mechanisms by which this cytokine exerts its beneficial effects. Mice chronically infected with T. cruzi were treated with human recombinant G-CSF (3 courses of 200 mu g/kg/d for 5 d). Inflammation and fibrosis were reduced in the hearts of G-CSF-treated mice, compared with the hearts of vehicle-treated mice, which correlated with decreased syndecan-4, intercellular adhesion molecule-1, and galectin-3 expressions. Marked reductions in interferon-gamma and tumor necrosis factor-alpha and increased interleukin-10 and transforming growth factor-beta were found after G-CSF administration. Because the therapy did not induce a Th1 to Th2 immune response deviation, we investigated the role of regulatory T (T-reg) cells. A significant increase in CD3(+)Foxp3(+) cells was observed in the hearts of G-CSF-treated mice. In addition, a reduction of parasitism was observed after G-CSF treatment. Our results indicate a role of T-reg cells in the immunosuppression induced by G-CSF treatment and reinforces its potential therapeutic use for patients with Chagas disease.	[Vasconcelos, Juliana F.; Souza, Bruno S. F.; Lins, Thayse F. S.; Meira, Cassio S.; Macambira, Simone G.; Soares, Milena B. P.] Fundacao Oswaldo Cruz, Ctr Pesquisas Goncalo Moniz, BR-40296710 Salvador, BA, Brazil; [Vasconcelos, Juliana F.; Souza, Bruno S. F.; Garcia, Leticia M. S.; Kaneto, Carla M.; Sampaio, Geraldo P.; de Alcantara, Adriano C.; Macambira, Simone G.; Ribeiro-dos-Santos, Ricardo; Soares, Milena B. P.] Hosp Sao Rafael, Ctr Biotecnol & Terapia Celular, Salvador, BA, Brazil; [Kaneto, Carla M.] Univ Estadual Santa Cruz, Ilheus, BA, Brazil; [Macambira, Simone G.] Univ Fed Bahia, Salvador, BA, Brazil	Fundacao Oswaldo Cruz; Universidade Estadual de Santa Cruz; Universidade Federal da Bahia	Soares, MBP (corresponding author), Fundacao Oswaldo Cruz, Ctr Pesquisas Goncalo Moniz, Rua Waldemar Falcao 121, BR-40296710 Salvador, BA, Brazil.	milena@bahia.fiocruz.br	Souza, Bruno/AAO-4601-2021; Vasconcelos, Juliana/AAN-5274-2021; Soares, Milena B. P./O-3771-2018; de Alcântara, Adriano Costa/A-6333-2011	Souza, Bruno/0000-0003-3771-0439; de Alcântara, Adriano Costa/0000-0003-0115-4987; Vasconcelos, Juliana/0000-0003-4553-0315; Soares, Milena/0000-0001-7549-2992	Brazilian Ministry of Sciences and Technology (MCT); Conselho Nacional de Pesquisas (CNPq); Financiadora de Estudos e Projetos (FINEP); Fundacao Oswaldo Cruz (FIOCRUZ); Fundacao de Amparo as Pesquisas do Estado da Bahia (FAPESB); Coordination for the Improvement of Higher Education Personnel (CAPES) doctoral scholarship from Universidade Estadual de Feira de Santana/Programa de Pos-graduacao em Biotecnologia (UEFS/PPgBIOTEC); Rede Nordeste de Biotecnologia (RENORBIO) graduate programs; CNPq; FAPESB	Brazilian Ministry of Sciences and Technology (MCT); Conselho Nacional de Pesquisas (CNPq)(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); Financiadora de Estudos e Projetos (FINEP)(Financiadora de Inovacao e Pesquisa (Finep)); Fundacao Oswaldo Cruz (FIOCRUZ); Fundacao de Amparo as Pesquisas do Estado da Bahia (FAPESB); Coordination for the Improvement of Higher Education Personnel (CAPES) doctoral scholarship from Universidade Estadual de Feira de Santana/Programa de Pos-graduacao em Biotecnologia (UEFS/PPgBIOTEC); Rede Nordeste de Biotecnologia (RENORBIO) graduate programs; CNPq(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); FAPESB(Fundacao de Amparo a Pesquisa do Estado da Bahia (FAPESB))	The authors thank Kyan Allahdadi for careful review of the article. This work was supported by grants from the Brazilian Ministry of Sciences and Technology (MCT), Conselho Nacional de Pesquisas (CNPq), Financiadora de Estudos e Projetos (FINEP), Fundacao Oswaldo Cruz (FIOCRUZ), and Fundacao de Amparo as Pesquisas do Estado da Bahia (FAPESB). J.F.V. and A. C. D. A. were recipients of a Coordination for the Improvement of Higher Education Personnel (CAPES) doctoral scholarship from the Universidade Estadual de Feira de Santana/Programa de Pos-graduacao em Biotecnologia (UEFS/PPgBIOTEC) and Rede Nordeste de Biotecnologia (RENORBIO) graduate programs, respectively. B. S. F. S. holds a CNPq doctoral scholarship, and C. S. M. holds a FAPESB master scholarship. M. B. P. S. and R.R.-D.-S. are recipients of CNPq senior fellowships.	Angeli FS, 2010, CARDIOVASC DRUG THER, V24, P409, DOI 10.1007/s10557-010-6263-7; Bahia-Oliveira LMG, 1998, BRAZ J MED BIOL RES, V31, P127, DOI 10.1590/S0100-879X1998000100017; Belkaid Y, 2006, IMMUNOL REV, V212, P287, DOI 10.1111/j.0105-2896.2006.00409.x; Bocchi EA, 1996, ANN THORAC SURG, V61, P1727, DOI 10.1016/0003-4975(96)00141-5; Boneberg EM, 2002, INFLAMM RES, V51, P119, DOI 10.1007/PL00000283; Campos SV, 2008, J HEART LUNG TRANSPL, V27, P597, DOI 10.1016/j.healun.2008.02.017; de Araujo FF, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0000992; FEDERICI EE, 1964, AM J TROP MED HYG, V13, P272, DOI 10.4269/ajtmh.1964.13.272; Ferrari R, 1999, PHARMACOL RES, V40, P97, DOI 10.1006/phrs.1998.0463; Fontt EO, 1998, INFECT IMMUN, V66, P2722, DOI 10.1128/IAI.66.6.2722-2727.1998; Francis JN, 2003, J ALLERGY CLIN IMMUN, V111, P1255, DOI 10.1067/mai.2003.1570; Franco-Paredes Carlos, 2007, BMC Int Health Hum Rights, V7, P7, DOI 10.1186/1472-698X-7-7; Franco-Paredes C, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000470; Galhardo M C, 1999, Rev Soc Bras Med Trop, V32, P291, DOI 10.1590/S0037-86821999000300011; Gardner LM, 2004, CLIN EXP ALLERGY, V34, P1209, DOI 10.1111/j.1365-2222.2004.02009.x; Gomes JAS, 2003, INFECT IMMUN, V71, P1185, DOI 10.1128/IAI.71.3.1185-1193.2003; Hamon M, 2004, GLYCOBIOLOGY, V14, P311, DOI 10.1093/glycob/cwh038; Harada M, 2005, NAT MED, V11, P305, DOI 10.1038/nm1199; HARTUNG T, 1995, BLOOD, V85, P2482, DOI 10.1182/blood.V85.9.2482.bloodjournal8592482; Higuchi T, 2008, ANN THORAC SURG, V85, P1367, DOI 10.1016/j.athoracsur.2007.12.053; Hill GR, 2010, BLOOD, V116, P819, DOI 10.1182/blood-2009-11-256495; Horowitz A, 2002, J CELL BIOL, V157, P715, DOI 10.1083/jcb.200112145; Hotez PJ, 2008, PLOS NEGLECT TROP D, V2, P1, DOI DOI 10.1371/J0UR-NAL.PNTD.0000270; Ishiguro K, 2002, GLYCOCONJUGATE J, V19, P315, DOI 10.1023/A:1025308702966; Itoh M, 1999, J IMMUNOL, V162, P5317; Iwanaga K, 2004, BIOCHEM BIOPH RES CO, V325, P1353, DOI 10.1016/j.bbrc.2004.10.149; Joo HG, 2001, J LEUKOCYTE BIOL, V69, P555; Kared H, 2005, DIABETES, V54, P78, DOI 10.2337/diabetes.54.1.78; Koberle F., 1968, Advances in Parasitology, V6, P63, DOI 10.1016/S0065-308X(08)60472-8; LEDEBUR HC, 1995, J BIOL CHEM, V270, P933, DOI 10.1074/jbc.270.2.933; Macambira SG, 2009, FASEB J, V23, P3843, DOI 10.1096/fj.09-137869; Guedes PMM, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001630; Morris ES, 2004, BLOOD, V103, P3573, DOI 10.1182/blood-2003-08-2864; Soares MBP, 2010, J INFECT DIS, V202, P416, DOI 10.1086/653481; Rabinovich GA, 2002, CELL DEATH DIFFER, V9, P661, DOI 10.1038/sj.cdd.4401009; Reifenberg K, 2007, AM J PATHOL, V171, P463, DOI 10.2353/ajpath.2007.060906; Rossetti M, 2010, EUR J IMMUNOL, V40, P3097, DOI 10.1002/eji.201040659; Rutella S, 2005, J IMMUNOL, V175, P7085, DOI 10.4049/jimmunol.175.11.7085; Rutella S, 2004, EUR J IMMUNOL, V34, P1291, DOI 10.1002/eji.200324651; Rutella S, 2002, BLOOD, V100, P2562, DOI 10.1182/blood-2001-12-0291; Sakaguchi S, 2005, NAT IMMUNOL, V6, P345, DOI 10.1038/ni1178; Schijman AG, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0000931; Sharma UC, 2004, CIRCULATION, V110, P3121, DOI 10.1161/01.CIR.0000147181.65298.4D; Shevach EM, 2009, IMMUNITY, V30, P636, DOI 10.1016/j.immuni.2009.04.010; Sloand EM, 2000, BLOOD, V95, P2269, DOI 10.1182/blood.V95.7.2269.007k37_2269_2274; Soares MBP, 2001, AN ACAD BRAS CIENC, V73, P547, DOI 10.1590/S0001-37652001000400008; Soares MBP, 2001, AM J PATHOL, V159, P703, DOI 10.1016/S0002-9440(10)61741-5; Soares MBP, 2011, CELL CYCLE, V10, P1448, DOI 10.4161/cc.10.9.15487; Tadokoro CE, 2001, IMMUNOL LETT, V77, P31, DOI 10.1016/S0165-2478(01)00197-3; Urry Z, 2012, EUR J IMMUNOL, V42, P2697, DOI 10.1002/eji.201242370; Vitelli-Avelar DM, 2005, SCAND J IMMUNOL, V62, P297, DOI 10.1111/j.1365-3083.2005.01668.x; von Aulock S, 2004, J PHARMACOL EXP THER, V308, P754, DOI 10.1124/jpet.103.058198; World Health Organization, CHAG DIS; Zhang YF, 1999, J BIOL CHEM, V274, P14786, DOI 10.1074/jbc.274.21.14786; Zou LH, 2004, CANCER RES, V64, P8451, DOI 10.1158/0008-5472.CAN-04-1987	55	27	28	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2013	27	12					4691	4702		10.1096/fj.13-229351	http://dx.doi.org/10.1096/fj.13-229351			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	293UK	23964077	Green Published			2023-01-03	WOS:000329999000005
J	Chong, CR; Janne, PA				Chong, Curtis R.; Jaenne, Pasi A.			The quest to overcome resistance to EGFR-targeted therapies in cancer	NATURE MEDICINE			English	Review							EPIDERMAL-GROWTH-FACTOR; CELL LUNG-CANCER; TYROSINE KINASE INHIBITORS; PHASE-II TRIAL; FACTOR-RECEPTOR GENE; EPITHELIAL-MESENCHYMAL-TRANSITION; METASTATIC COLORECTAL-CANCER; CETUXIMAB PLUS IRINOTECAN; K-RAS MUTATIONS; ACQUIRED-RESISTANCE	All patients with metastatic lung, colorectal, pancreatic or head and neck cancers who initially benefit from epidermal growth factor receptor (EGFR)-targeted therapies eventually develop resistance. An increasing understanding of the number and complexity of resistance mechanisms highlights the Herculean challenge of killing tumors that are resistant to EGFR inhibitors. Our growing knowledge of resistance pathways provides an opportunity to develop new mechanism-based inhibitors and combination therapies to prevent or overcome therapeutic resistance in tumors. We present a comprehensive review of resistance pathways to EGFR-targeted therapies in lung, colorectal and head and neck cancers and discuss therapeutic strategies that are designed to circumvent resistance.	[Chong, Curtis R.; Jaenne, Pasi A.] Dana Farber Canc Inst, Lowe Ctr Thorac Oncol, Boston, MA 02115 USA; [Chong, Curtis R.; Jaenne, Pasi A.] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA; [Jaenne, Pasi A.] Dana Farber Canc Inst, Belfer Inst Appl Canc Sci, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Brigham & Women's Hospital; Harvard University; Dana-Farber Cancer Institute	Janne, PA (corresponding author), Dana Farber Canc Inst, Lowe Ctr Thorac Oncol, Boston, MA 02115 USA.	pjanne@partners.org			US National Institutes of Health [RO1CA114465, R01CA135257, P01CA154303]; American Society of Clinical Oncology; NATIONAL CANCER INSTITUTE [R01CA135257, P01CA154303, R01CA114465, T32CA009172] Funding Source: NIH RePORTER	US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Society of Clinical Oncology; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study is supported by US National Institutes of Health grants RO1CA114465 (P.A.J.), R01CA135257 (P.A.J.) and P01CA154303 (P.A.J.) and by an American Society of Clinical Oncology Young Investigator Award (C.R.C.).	Alam N, 2010, CLIN LUNG CANCER, V11, pE1, DOI 10.3816/CLC.2010.n.046; Amado RG, 2008, J CLIN ONCOL, V26, P1626, DOI 10.1200/JCO.2007.14.7116; Arcila ME, 2013, MOL CANCER THER, V12, P220, DOI 10.1158/1535-7163.MCT-12-0620; Ardito CM, 2012, CANCER CELL, V22, P304, DOI 10.1016/j.ccr.2012.07.024; Atagi S., 2011, 14 WORLD C LUNG CANC; Bean GR, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2003483; Bean J, 2007, P NATL ACAD SCI USA, V104, P20932, DOI 10.1073/pnas.0710370104; Becker A, 2011, EUR J CANCER, V47, P2603, DOI 10.1016/j.ejca.2011.06.046; Bell DW, 2005, NAT GENET, V37, P1315, DOI 10.1038/ng1671; Bivona TG, 2011, NATURE, V471, P523, DOI 10.1038/nature09870; Blanke CD, 2008, J CLIN ONCOL, V26, P620, DOI 10.1200/JCO.2007.13.4403; Bock C, 2012, NAT REV CANCER, V12, P494, DOI 10.1038/nrc3297; Bonner JA, 2006, NEW ENGL J MED, V354, P567, DOI 10.1056/NEJMoa053422; Box C, 2013, EUR J CANCER, V49, P2512, DOI 10.1016/j.ejca.2013.03.011; Bresler SC, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002950; Brewer MR, 2013, CANCER DISCOV, V3, P138, DOI 10.1158/2159-8290.CD-12-0581; Bridges AJ, 1999, CURR MED CHEM, V6, P825; Budha NR, 2012, CLIN PHARMACOL THER, V92, P203, DOI 10.1038/clpt.2012.73; Campoli M, 2010, CLIN CANCER RES, V16, P11, DOI 10.1158/1078-0432.CCR-09-2345; CARPENTER G, 1978, NATURE, V276, P409, DOI 10.1038/276409a0; Cataldo VD, 2011, NEW ENGL J MED, V364, P947, DOI 10.1056/NEJMct0807960; Chaft JE, 2011, CLIN CANCER RES, V17, P6298, DOI 10.1158/1078-0432.CCR-11-1468; Chen ZY, 2012, ONCOLOGIST, V17, P978, DOI 10.1634/theoncologist.2011-0385; Cheung HW, 2011, CANCER DISCOV, V1, P608, DOI 10.1158/2159-8290.CD-11-0046; Chmielecki J, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002356; Chmielecki J, 2010, CLIN CANCER RES, V16, P5371, DOI 10.1158/1078-0432.CCR-10-2405; Choi YL, 2010, NEW ENGL J MED, V363, P1734, DOI 10.1056/NEJMoa1007478; Chung KP, 2012, CLIN CANCER RES, V18, P3470, DOI 10.1158/1078-0432.CCR-11-2353; Ciardiello F, 2008, NEW ENGL J MED, V358, P1160, DOI 10.1056/NEJMra0707704; COHEN S, 1962, J BIOL CHEM, V237, P1555; Corcoran RB, 2012, CANCER DISCOV, V2, P227, DOI 10.1158/2159-8290.CD-11-0341; Cortot AB, 2013, CANCER RES, V73, P834, DOI 10.1158/0008-5472.CAN-12-2066; Cunningham D, 2004, NEW ENGL J MED, V351, P337, DOI 10.1056/NEJMoa033025; Das Thakur M, 2013, NATURE, V494, P251, DOI 10.1038/nature11814; Diaz LA, 2012, NATURE, V486, P537, DOI 10.1038/nature11219; Dienstmann R, 2012, MOL ONCOL, V6, P15, DOI 10.1016/j.molonc.2011.11.009; Douillard JY, 2010, J CLIN ONCOL, V28, P4697, DOI 10.1200/JCO.2009.27.4860; DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; Engelman JA, 2007, SCIENCE, V316, P1039, DOI 10.1126/science.1141478; Ercan D, 2010, ONCOGENE, V29, P2346, DOI 10.1038/onc.2009.526; Foo J, 2012, J THORAC ONCOL, V7, P1583, DOI 10.1097/JTO.0b013e31826146ee; Forshew T, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003726; FRY DW, 1994, SCIENCE, V265, P1093, DOI 10.1126/science.8066447; Fukuoka M, 2011, J CLIN ONCOL, V29, P2866, DOI 10.1200/JCO.2010.33.4235; Garofalo M, 2012, NAT MED, V18, P74, DOI 10.1038/nm.2577; Garraway LA, 2012, CANCER DISCOV, V2, P214, DOI 10.1158/2159-8290.CD-12-0012; Gentile A, 2011, CANCER RES, V71, P3132, DOI 10.1158/0008-5472.CAN-10-2662; Godin-Heymann N, 2008, MOL CANCER THER, V7, P874, DOI 10.1158/1535-7163.MCT-07-2387; Gorre ME, 2001, SCIENCE, V293, P876, DOI 10.1126/science.1062538; Gottesman MM, 2002, ANNU REV MED, V53, P615, DOI 10.1146/annurev.med.53.082901.103929; Greulich H, 2005, PLOS MED, V2, P1167, DOI 10.1371/journal.pmed.0020313; Gschwind A, 2004, NAT REV CANCER, V4, P361, DOI 10.1038/nrc1360; Guilhot F, 2012, HAEMATOL-HEMATOL J, V97, P731, DOI 10.3324/haematol.2011.045666; Guix M, 2008, J CLIN INVEST, V118, P2609, DOI 10.1172/JCI34588; Harada D, 2012, CANCER SCI, V103, P1795, DOI 10.1111/j.1349-7006.2012.02363.x; He M, 2012, CLIN CANCER RES, V18, P1790, DOI 10.1158/1078-0432.CCR-11-2361; Heinrich MC, 2006, J CLIN ONCOL, V24, P4764, DOI 10.1200/JCO.2006.06.2265; Herbst RS, 2011, LANCET, V377, P1846, DOI 10.1016/S0140-6736(11)60545-X; Hoellein A, 2011, ONCOTARGET, V2, P599; Holz C, 2011, RADIOTHER ONCOL, V101, P158, DOI 10.1016/j.radonc.2011.05.042; Huang SD, 2012, CELL, V151, P937, DOI 10.1016/j.cell.2012.10.035; HUNTER T, 1981, CELL, V24, P741, DOI 10.1016/0092-8674(81)90100-8; Inukai M, 2006, CANCER RES, V66, P7854, DOI 10.1158/0008-5472.CAN-06-1951; Jackman D, 2010, J CLIN ONCOL, V28, P357, DOI 10.1200/JCO.2009.24.7049; Jackman DM, 2009, CLIN CANCER RES, V15, P5267, DOI 10.1158/1078-0432.CCR-09-0888; Janne PA, 2012, J CLIN ONCOL, V30, P2063, DOI 10.1200/JCO.2011.40.1315; Janjigian YY, 2011, J CLIN ONCOL, V29, DOI 10.1200/jco.2011.29.15_suppl.7525; Janjigian YY, 2011, CLIN CANCER RES, V17, P2521, DOI 10.1158/1078-0432.CCR-10-2662; Johnson ML, 2011, J THORAC ONCOL, V6, P1128, DOI 10.1097/JTO.0b013e3182161508; KAMATA T, 1984, NATURE, V310, P147, DOI 10.1038/310147a0; Kantarjian H, 2002, NEW ENGL J MED, V346, P645, DOI 10.1056/NEJMoa011573; Karapetis CS, 2008, NEW ENGL J MED, V359, P1757, DOI 10.1056/NEJMoa0804385; KAWAMOTO T, 1983, P NATL ACAD SCI-BIOL, V80, P1337, DOI 10.1073/pnas.80.5.1337; Kim ES, 2011, CANCER DISCOV, V1, P44, DOI 10.1158/2159-8274.CD-10-0010; KING CR, 1985, SCIENCE, V229, P974, DOI 10.1126/science.2992089; Kobayashi S, 2005, NEW ENGL J MED, V352, P786, DOI 10.1056/NEJMoa044238; Kuang Y, 2009, CLIN CANCER RES, V15, P2630, DOI 10.1158/1078-0432.CCR-08-2592; Kuiper JL, 2013, LUNG CANCER, V80, P102, DOI 10.1016/j.lungcan.2012.12.024; Kwak EL, 2005, P NATL ACAD SCI USA, V102, P7665, DOI 10.1073/pnas.0502860102; Kwak E, 2011, ONCOLOGIST, V16, P1498, DOI 10.1634/theoncologist.2011-0087; Kwak EL, 2010, NEW ENGL J MED, V363, P1693, DOI 10.1056/NEJMoa1006448; La Fleur L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044071; Larson RA, 2008, BLOOD, V111, P4022, DOI 10.1182/blood-2007-10-116475; Laurent-Puig P, 2009, J CLIN ONCOL, V27, P5924, DOI 10.1200/JCO.2008.21.6796; Lee HJ, 2013, CANCER DISCOV, V3, P168, DOI 10.1158/2159-8290.CD-12-0357; Lee JK, 2013, ANN ONCOL, V24, P2080, DOI 10.1093/annonc/mdt127; Linardou H, 2008, LANCET ONCOL, V9, P962, DOI 10.1016/S1470-2045(08)70206-7; Liska D, 2011, CLIN CANCER RES, V17, P472, DOI 10.1158/1078-0432.CCR-10-0568; Liu HB, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055128; Lu Y, 2007, CANCER RES, V67, P8240, DOI 10.1158/0008-5472.CAN-07-0589; Lynch TJ, 2010, J CLIN ONCOL, V28, P911, DOI 10.1200/JCO.2009.21.9618; Lynch TJ, 2009, J THORAC ONCOL, V4, P1002, DOI 10.1097/JTO.0b013e3181aba89f; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Maemondo M, 2010, NEW ENGL J MED, V362, P2380, DOI 10.1056/NEJMoa0909530; Maheswaran S, 2008, NEW ENGL J MED, V359, P366, DOI 10.1056/NEJMoa0800668; Milton DT, 2006, J CLIN ONCOL, V24, P4940, DOI 10.1200/JCO.2006.06.4410; Mink SR, 2010, MOL CANCER RES, V8, P809, DOI 10.1158/1541-7786.MCR-09-0460; Mir O, 2011, NEW ENGL J MED, V365, P379, DOI 10.1056/NEJMc1105083; Misale S, 2012, NATURE, V486, P532, DOI 10.1038/nature11156; Mitsudomi T, 2007, CANCER SCI, V98, P1817, DOI 10.1111/j.1349-7006.2007.00607.x; Mitsudomi T, 2010, LANCET ONCOL, V11, P121, DOI 10.1016/S1470-2045(09)70364-X; Mitsudomi T, 2010, FEBS J, V277, P301, DOI 10.1111/j.1742-4658.2009.07448.x; Mok TS, 2009, NEW ENGL J MED, V361, P947, DOI 10.1056/NEJMoa0810699; Montagut C, 2012, NAT MED, V18, P221, DOI 10.1038/nm.2609; Moore MJ, 2007, J CLIN ONCOL, V25, P1960, DOI 10.1200/JCO.2006.07.9525; Murtaza M, 2013, NATURE, V497, P108, DOI 10.1038/nature12065; Naumov GN, 2009, CLIN CANCER RES, V15, P3484, DOI 10.1158/1078-0432.CCR-08-2904; Navas C, 2012, CANCER CELL, V22, P318, DOI 10.1016/j.ccr.2012.08.001; Ng KP, 2012, NAT MED, V18, P521, DOI 10.1038/nm.2713; Nicholson RI, 2001, EUR J CANCER, V37, pS9, DOI 10.1016/s0959-8049(01)00231-3; Ogawa T, 2012, CELL CYCLE, V11, P1656, DOI 10.4161/cc.20120; Ohashi K, 2013, J CLIN ONCOL, V31, P1070, DOI 10.1200/JCO.2012.43.3912; Ohashi K, 2012, P NATL ACAD SCI USA, V109, pE2127, DOI 10.1073/pnas.1203530109; Ou SHI, 2012, CRIT REV ONCOL HEMAT, V83, P407, DOI 10.1016/j.critrevonc.2011.11.010; Oxnard GR, 2013, J THORAC ONCOL, V8, P179, DOI 10.1097/JTO.0b013e3182779d18; Oxnard GR, 2012, J THORAC ONCOL, V7, P1049, DOI 10.1097/JTO.0b013e318250ed9d; Oxnard GR, 2011, CLIN CANCER RES, V17, P6322, DOI 10.1158/1078-0432.CCR-11-1080; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Pao W, 2005, PLOS MED, V2, P57, DOI 10.1371/journal.pmed.0020017; Pao W, 2005, PLOS MED, V2, P225, DOI 10.1371/journal.pmed.0020073; Pao W, 2004, P NATL ACAD SCI USA, V101, P13306, DOI 10.1073/pnas.0405220101; Pao W, 2010, NAT REV CANCER, V10, P760, DOI 10.1038/nrc2947; Park S, 2009, J THORAC ONCOL, V4, P809, DOI 10.1097/JTO.0b013e3181a94af4; Peeters M, 2010, J CLIN ONCOL, V28, P4706, DOI 10.1200/JCO.2009.27.6055; Petrelli F, 2012, LUNG CANCER, V78, P8, DOI 10.1016/j.lungcan.2012.06.009; Pirker R, 2009, LANCET, V373, P1525, DOI 10.1016/S0140-6736(09)60569-9; Prahallad A, 2012, NATURE, V483, P100, DOI 10.1038/nature10868; Rai K, 2011, MOL CANCER THER, V10, P1720, DOI 10.1158/1535-7163.MCT-11-0220; Ranson M., 2013, EUR CANC C AMST; Razak ARA, 2013, ANN ONCOL, V24, P761, DOI 10.1093/annonc/mds503; Regales L, 2009, J CLIN INVEST, V119, P3000, DOI 10.1172/JCI38746; Riely GJ, 2006, CLIN CANCER RES, V12, P839, DOI 10.1158/1078-0432.CCR-05-1846; Riely GJ, 2007, CLIN CANCER RES, V13, P5150, DOI 10.1158/1078-0432.CCR-07-0560; Rivera VM, 2012, CANCER RES, V72, DOI 10.1158/1538-7445.AM2012-1794; Robinson KW, 2013, ONCOLOGIST, V18, P115, DOI 10.1634/theoncologist.2012-0262; Rosell R, 2012, LANCET ONCOL, V13, P239, DOI 10.1016/S1470-2045(11)70393-X; Sartore-Bianchi A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007287; Sartore-Bianchi A, 2009, CANCER RES, V69, P1851, DOI 10.1158/0008-5472.CAN-08-2466; Sato J D, 1983, Mol Biol Med, V1, P511; Scagliotti GV, 2012, J CLIN ONCOL, V30, P2070, DOI 10.1200/JCO.2011.39.2993; Scartozzi M, 2009, J CLIN ONCOL, V27; Seiwert T., 2012, MULT HEAD NECK S LBP; Sequist LV, 2011, J CLIN ONCOL, V29, P3307, DOI 10.1200/JCO.2010.34.0570; Sharma SV, 2010, CELL, V141, P69, DOI 10.1016/j.cell.2010.02.027; Shepherd FA, 2005, NEW ENGL J MED, V353, P123, DOI 10.1056/NEJMoa050753; Shien K, 2013, CANCER RES, V73, P3051, DOI 10.1158/0008-5472.CAN-12-4136; Sledge GW, 2012, J CLIN ONCOL, V30, P203, DOI 10.1200/JCO.2011.39.0088; Sok JC, 2006, CLIN CANCER RES, V12, P5064, DOI 10.1158/1078-0432.CCR-06-0913; Sos ML, 2009, CANCER RES, V69, P3256, DOI 10.1158/0008-5472.CAN-08-4055; Sosman JA, 2012, NEW ENGL J MED, V366, P707, DOI 10.1056/NEJMoa1112302; Suda K, 2012, LUNG CANCER, V76, P292, DOI 10.1016/j.lungcan.2011.11.007; Suda K, 2010, CLIN CANCER RES, V16, P5489, DOI 10.1158/1078-0432.CCR-10-1371; Sun LN, 2011, J EXP CLIN CANC RES, V30, DOI 10.1186/1756-9966-30-30; Taguchi F, 2007, J NATL CANCER I, V99, P838, DOI 10.1093/jnci/djk195; Takezawa K, 2012, CANCER DISCOV, V2, P922, DOI 10.1158/2159-8290.CD-12-0108; Tallman MS, 1997, NEW ENGL J MED, V337, P1021, DOI 10.1056/NEJM199710093371501; Taniguchi K, 2008, CANCER SCI, V99, P929, DOI 10.1111/j.1349-7006.2008.00782.x; Terai H, 2013, MOL CANCER RES, V11, P759, DOI 10.1158/1541-7786.MCR-12-0652; Thomson S, 2005, CANCER RES, V65, P9455, DOI 10.1158/0008-5472.CAN-05-1058; Topalian SL, 2012, NEW ENGL J MED, V366, P2443, DOI 10.1056/NEJMoa1200690; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; Uramoto H, 2010, ANTICANCER RES, V30, P2513; Van Cutsem E, 2011, J CLIN ONCOL, V29, P2011, DOI 10.1200/JCO.2010.33.5091; Vermorken JB, 2008, NEW ENGL J MED, V359, P1116, DOI 10.1056/NEJMoa0802656; Viloria-Petit A, 2001, CANCER RES, V61, P5090; Wakelee H., 2010, J CLIN ONCOL, V28, P3017; Wakeling AE, 1996, BREAST CANCER RES TR, V38, P67, DOI 10.1007/BF01803785; Wang SZE, 2006, CANCER CELL, V10, P25, DOI 10.1016/j.ccr.2006.05.023; Ware KE, 2013, ONCOGENESIS, V2, DOI 10.1038/oncsis.2013.4; Ware Kathryn E, 2010, PLoS One, V5, pe14117, DOI 10.1371/journal.pone.0014117; Weickhardt AJ, 2012, J CLIN ONCOL, V30, P1505, DOI 10.1200/JCO.2011.38.6599; Weinstein IB, 2002, SCIENCE, V297, P63, DOI 10.1126/science.1073096; Wheeler DL, 2010, NAT REV CLIN ONCOL, V7, P493, DOI 10.1038/nrclinonc.2010.97; Won YW, 2011, J CLIN PATHOL, V64, P947, DOI 10.1136/jclinpath-2011-200169; WONG AJ, 1987, P NATL ACAD SCI USA, V84, P6899, DOI 10.1073/pnas.84.19.6899; Wu JY, 2011, CLIN CANCER RES, V17, P3812, DOI 10.1158/1078-0432.CCR-10-3408; Xie M, 2012, J CELL BIOCHEM, V113, P1501, DOI 10.1002/jcb.24019; Yamaguchi T, 2012, CANCER CELL, V21, P348, DOI 10.1016/j.ccr.2012.02.008; Yang J-CH, 2012, J CLIN ONCOL, V30; Yao Z, 2010, P NATL ACAD SCI USA, V107, P15535, DOI 10.1073/pnas.1009472107; Yatabe Y, 2011, J CLIN ONCOL, V29, P2972, DOI 10.1200/JCO.2010.33.3906; Yeh P, 2013, CLIN CANCER RES, V19, P1894, DOI 10.1158/1078-0432.CCR-12-1894; Yonesaka K, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002442; Yu HA, 2013, CLIN CANCER RES, V19, P2240, DOI 10.1158/1078-0432.CCR-12-2246; Yu HA, 2013, J NATL COMPR CANC NE, V11, P161, DOI 10.6004/jnccn.2013.0024; Yun CH, 2008, P NATL ACAD SCI USA, V105, P2070, DOI 10.1073/pnas.0709662105; Yun CH, 2007, CANCER CELL, V11, P217, DOI 10.1016/j.ccr.2006.12.017; Zakowski MF, 2006, NEW ENGL J MED, V355, P213, DOI 10.1056/NEJMc053610; Zhang ZF, 2012, NAT GENET, V44, P852, DOI 10.1038/ng.2330; Zhou BBS, 2006, CANCER CELL, V10, P39, DOI 10.1016/j.ccr.2006.05.024; Zhou CC, 2011, LANCET ONCOL, V12, P735, DOI 10.1016/S1470-2045(11)70184-X; Zhou WJ, 2009, NATURE, V462, P1070, DOI 10.1038/nature08622	192	687	720	12	236	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	2013	19	11					1389	1400		10.1038/nm.3388	http://dx.doi.org/10.1038/nm.3388			12	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	251IF	24202392	Green Accepted			2023-01-03	WOS:000326920300017
J	Adler, UC; Kruger, S; Teut, M; Ludtke, R; Schutzler, L; Martins, F; Willich, SN; Linde, K; Witt, CM				Adler, Ubiratan C.; Krueger, Stephanie; Teut, Michael; Luedtke, Rainer; Schuetzler, Lena; Martins, Friederike; Willich, Stefan N.; Linde, Klaus; Witt, Claudia M.			Homeopathy for Depression: A Randomized, Partially Double-Blind, Placebo-Controlled, Four-Armed Study (DEP-HOM)	PLOS ONE			English	Article							COMMUNICATION; OUTCOMES	Background: The specific clinical benefit of the homeopathic consultation and of homeopathic remedies in patients with depression has not yet been investigated. Aims: To investigate the 1) specific effect of individualized homeopathic Q-potencies compared to placebo and 2) the effect of an extensive homeopathic case taking (case history I) compared to a shorter, rather conventional one (case history II) in the treatment of acute major depression (moderate episode) after six weeks. Methods: A randomized, partially double-blind, placebo-controlled, four-armed trial using a 262 factorial design with a six-week study duration per patient was performed. Results: A total of 44 from 228 planned patients were randomized (2:1:2:1 randomization: 16 homeopathic Q-potencies/case history I, 7 placebo/case history I, 14 homeopathic Q-potencies/case history II, 7 placebo/case history II). Because of recruitment problems, the study was terminated prior to full recruitment, and was underpowered for the preplanned confirmatory hypothesis testing. Exploratory data analyses showed heterogeneous and inconclusive results with large variance in the sample. The mean difference for the Hamilton-D after 6 weeks was 2.0 (95% CI -1.2; 5.2) for Q-potencies vs. placebo and -3.1 (-5.9; 20.2) for case history I vs. case history II. Overall, no consistent or clinically relevant results across all outcomes between homeopathic Q-potencies versus placebo and homeopathic versus conventional case taking were observed. The frequency of adverse events was comparable for all groups. Conclusions: Although our results are inconclusive, given that recruitment into this trial was very difficult and we had to terminate early, we cannot recommend undertaking a further trial addressing this question in a similar setting. Prof. Dr. Claudia Witt had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. registration:	[Adler, Ubiratan C.; Teut, Michael; Schuetzler, Lena; Martins, Friederike; Willich, Stefan N.; Witt, Claudia M.] Charite, Inst Social Med Epidemiol & Hlth Econ, D-13353 Berlin, Germany; [Krueger, Stephanie] Charite, Teaching Hosp, Head Ctr Womens Mental Hlth, Vivantes Humboldt Klin, D-13353 Berlin, Germany; [Luedtke, Rainer] Karl & Veron Carstens Fdn, Essen, Germany; [Linde, Klaus] Tech Univ Munich, Inst Gen Practice, D-80290 Munich, Germany; [Witt, Claudia M.] Univ Maryland, Sch Med, Ctr Integrat Med, Baltimore, MD 21201 USA	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Technical University of Munich; University System of Maryland; University of Maryland Baltimore	Witt, CM (corresponding author), Charite, Inst Social Med Epidemiol & Hlth Econ, D-13353 Berlin, Germany.	claudia.witt@charite.de	Witt, Claudia M./AAX-2370-2021	Witt, Claudia M./0000-0002-5440-7805; Linde, Klaus/0000-0002-2902-970X; Teut, Michael/0000-0001-7150-7165	chair for complementary medicine research, Carstens Foundation	chair for complementary medicine research, Carstens Foundation	This project was funded within the grant of the chair for complementary medicine research by the Carstens Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adler UC, 2011, EVID-BASED COMPL ALT, V2011, P1, DOI 10.1093/ecam/nep114; Adler UC, 2011, TRIALS, V12, DOI 10.1186/1745-6215-12-43; Adler UC, 2009, INT J HIGH DILUTION, V8, P173; Bawden S, 2012, HOMEOPATHY, V101, P51, DOI 10.1016/j.homp.2011.10.003; Becker-Witt C, 2004, FORSCH KOMP KLAS NAT, V11, P98, DOI 10.1159/000078231; Bullinger M, 1998, SF 36 FRAGEBOGEN ZUM; Finset A, 2006, PATIENT EDUC COUNS, V60, P115, DOI 10.1016/j.pec.2005.03.005; Fournier JC, 2010, JAMA-J AM MED ASSOC, V303, P47, DOI 10.1001/jama.2009.1943; Frei H, 2009, HOMEOPATHY, V98, P49, DOI 10.1016/j.homp.2008.10.002; Grolleau A, 2011, EUR PSYCHIAT; Hahnemann S, 1992, ORGANON HEILKUNST; Hautzinger M, 1995, BECK DEPRESSIONS INV, P5; Jacobs J, 1998, ARCH FAM MED, V7, P537, DOI 10.1001/archfami.7.6.537; Katz T, 2005, Homeopathy, V94, P145, DOI 10.1016/j.homp.2005.04.002; National Institute for Clinical Excellence, 2004, DEPR MAN DEPR PRIM S; National Institute for Clinical Excellence, DEPR TREATM MAN DEPR; Posner K, COLUMBIA BEURTEILUNK; Sevar R, 2000, Br Homeopath J, V89, P178, DOI 10.1054/homp.1999.0438; Siebenwirth J, 2009, FORSCH KOMPLEMENTMED, V16, P315, DOI 10.1159/000242434; Spence DS, 2005, J ALTERN COMPLEM MED, V11, P793, DOI 10.1089/acm.2005.11.793; Steinsbekk A, 2008, HOMEOPATHY, V97, P178, DOI 10.1016/j.homp.2008.08.005; STEWART MA, 1995, CAN MED ASSOC J, V152, P1423; Thompson EA, 2008, HOMEOPATHY, V97, P114, DOI 10.1016/j.homp.2008.06.005; Walsh BT, 2002, JAMA-J AM MED ASSOC, V287, P1840, DOI 10.1001/jama.287.14.1840; Weyer G, 2004, INT SKALEN PSYCHIAT; Witt CM, 2008, BMC PUBLIC HEALTH, V8, DOI 10.1186/1471-2458-8-413; Wittchen HU, 2011, EUR NEUROPSYCHOPHARM, V21, P655, DOI 10.1016/j.euroneuro.2011.07.018; Zajecka J, 2010, J CLIN PSYCHOPHARM, V30, P135, DOI 10.1097/JCP.0b013e3181d420a7	28	7	7	0	26	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 23	2013	8	9							e74537	10.1371/journal.pone.0074537	http://dx.doi.org/10.1371/journal.pone.0074537			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	246EK	24086352	gold, Green Published, Green Submitted			2023-01-03	WOS:000326520200034
J	Berrier, C; Pozza, A; de Lavalette, AD; Chardonnet, S; Mesneau, A; Jaxel, C; le Maire, M; Ghazi, A				Berrier, Catherine; Pozza, Alexandre; de lavalette, Agnes de Lacroix; Chardonnet, Solenne; Mesneau, Agnes; Jaxel, Christine; le Maire, Marc; Ghazi, Alexandre			The Purified Mechanosensitive Channel TREK-1 Is Directly Sensitive to Membrane Tension	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; ACTIVATED CHANNELS; DETERGENT BINDING; CRYSTAL-STRUCTURE; ION CHANNELS; PATCH-CLAMP; YEAST; PURIFICATION; PROTEINS; EXPRESSION	Mechanosensitive channels are detected in all cells and are speculated to play a key role in many functions including osmoregulation, growth, hearing, balance, and touch. In prokaryotic cells, a direct gating of mechanosensitive channels by membrane tension was clearly demonstrated because the purified channels could be functionally reconstituted in a lipid bilayer. No such evidence has been presented yet in the case of mechanosensitive channels from animal cells. TREK-1, a two-pore domain K+ channel, was the first animal mechanosensitive channel identified at the molecular level. It is the target of a large variety of agents such as volatile anesthetics, neuroprotective agents, and antidepressants. We have produced the mouse TREK-1 in yeast, purified it, and reconstituted the protein in giant liposomes amenable to patch clamp recording. The protein exhibited the expected electrophysiological properties in terms of kinetics, selectivity, and pharmacology. Negative pressure (suction) applied through the pipette had no effect on the channel, but positive pressure could completely and reversibly close the channel. Our interpretation of these data is that the intrinsic tension in the lipid bilayer is sufficient to maximally activate the channel, which can be closed upon modification of the tension. These results indicate that TREK-1 is directly sensitive to membrane tension.	[Berrier, Catherine; Chardonnet, Solenne; Mesneau, Agnes; Ghazi, Alexandre] Univ Paris 11, CNRS, UMR 8619, IBBMC, F-91405 Orsay, France; [Pozza, Alexandre; de lavalette, Agnes de Lacroix; Jaxel, Christine; le Maire, Marc] Univ Paris 11, CNRS, UMR 8221, CEA,Inst Biol & Technol Saclay iBitec S, F-91191 Gif Sur Yvette, France; [Pozza, Alexandre; de lavalette, Agnes de Lacroix; Jaxel, Christine; le Maire, Marc] CEA Saclay, F-91191 Gif Sur Yvette, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; CEA; UDICE-French Research Universities; Universite Paris Saclay	Ghazi, A (corresponding author), Univ Paris 11, CNRS, UMR 8619, IBBMC, F-91405 Orsay, France.	alexandre.ghazi@u-psud.fr		JAXEL, CHRISTINE/0000-0002-1387-4458	Agence nationale de la recherche (ANR) [BLAN06-2_135035]	Agence nationale de la recherche (ANR)(French National Research Agency (ANR))	This work was supported by Agence nationale de la recherche (ANR) Grant BLAN06-2_135035.	Ajouz B, 2000, J BIOL CHEM, V275, P1015, DOI 10.1074/jbc.275.2.1015; Arnadottir J, 2010, ANNU REV BIOPHYS, V39, P111, DOI 10.1146/annurev.biophys.37.032807.125836; BERRIER C, 1992, EUR J BIOCHEM, V206, P559, DOI 10.1111/j.1432-1033.1992.tb16960.x; BERRIER C, 1989, FEBS LETT, V259, P27, DOI 10.1016/0014-5793(89)81486-3; Brohawn SG, 2012, SCIENCE, V335, P436, DOI 10.1126/science.1213808; Cardi D, 2010, J BIOL CHEM, V285, P26406, DOI 10.1074/jbc.M109.090340; Cardi D, 2010, METHODS MOL BIOL, V601, P247, DOI 10.1007/978-1-60761-344-2_15; Chemin J, 2005, EMBO J, V24, P44, DOI 10.1038/sj.emboj.7600494; Chemin J, 2007, PFLUG ARCH EUR J PHY, V455, P97, DOI 10.1007/s00424-007-0250-2; Coste B, 2012, NATURE, V483, P176, DOI 10.1038/nature10812; Di Cera E, 2001, ANN NY ACAD SCI, V936, P133; Enyedi P, 2010, PHYSIOL REV, V90, P559, DOI 10.1152/physrev.00029.2009; Ghazi A, 1998, BIOCHIMIE, V80, P357; GIETZ RD, 1995, YEAST, V11, P355, DOI 10.1002/yea.320110408; Hamill OP, 1997, ANNU REV PHYSIOL, V59, P621, DOI 10.1146/annurev.physiol.59.1.621; Haswell ES, 2011, STRUCTURE, V19, P1356, DOI 10.1016/j.str.2011.09.005; Honore E, 2002, EMBO J, V21, P2968, DOI 10.1093/emboj/cdf288; Honore E, 2006, P NATL ACAD SCI USA, V103, P6859, DOI 10.1073/pnas.0600463103; Honore E, 2007, NAT REV NEUROSCI, V8, P251, DOI 10.1038/nrn2117; Hortigon-Vinagre MP, 2011, FREE RADICAL BIO MED, V50, P323, DOI 10.1016/j.freeradbiomed.2010.11.017; Jidenko M, 2005, P NATL ACAD SCI USA, V102, P11687, DOI 10.1073/pnas.0503986102; Kang D, 2007, J PHYSIOL-LONDON, V583, P57, DOI 10.1113/jphysiol.2007.136150; Kim D, 2003, TRENDS PHARMACOL SCI, V24, P648, DOI 10.1016/j.tips.2003.10.008; Kloda A, 2001, CELL BIOCHEM BIOPHYS, V34, P349, DOI 10.1385/CBB:34:3:349; Kloda A, 2007, P NATL ACAD SCI USA, V104, P1540, DOI 10.1073/pnas.0609649104; Kung C, 2005, NATURE, V436, P647, DOI 10.1038/nature03896; Kung C, 2010, ANNU REV MICROBIOL, V64, P313, DOI 10.1146/annurev.micro.112408.134106; Lauritzen I, 2005, EMBO REP, V6, P642, DOI 10.1038/sj.embor.7400449; Le Maire M, 2008, NAT PROTOC, V3, P1782, DOI 10.1038/nprot.2008.177; Lenoir G, 2002, BBA-BIOMEMBRANES, V1560, P67, DOI 10.1016/S0005-2736(01)00458-8; Levina N, 1999, EMBO J, V18, P1730, DOI 10.1093/emboj/18.7.1730; Li XT, 2006, CARDIOVASC RES, V69, P86, DOI 10.1016/j.cardiores.2005.08.018; Maingret F, 2000, EMBO J, V19, P2483, DOI 10.1093/emboj/19.11.2483; Maingret F, 1999, J BIOL CHEM, V274, P26691, DOI 10.1074/jbc.274.38.26691; Miller AN, 2012, SCIENCE, V335, P432, DOI 10.1126/science.1213274; MOLLER JV, 1993, J BIOL CHEM, V268, P18659; Patel AJ, 1998, EMBO J, V17, P4283, DOI 10.1093/emboj/17.15.4283; Perozo E, 2006, NAT REV MOL CELL BIO, V7, P109, DOI 10.1038/nrm1833; Pompon D, 1996, METHOD ENZYMOL, V272, P51, DOI 10.1016/S0076-6879(96)72008-6; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Suchyna TM, 2009, BIOPHYS J, V97, P738, DOI 10.1016/j.bpj.2009.05.018; Sukharev S, 2002, BIOPHYS J, V83, P290, DOI 10.1016/S0006-3495(02)75169-2; SUKHAREV SI, 1993, BIOPHYS J, V65, P177, DOI 10.1016/S0006-3495(93)81044-0; SUKHAREV SI, 1994, NATURE, V368, P265, DOI 10.1038/368265a0; Thomas D, 2008, NEURON, V58, P859, DOI 10.1016/j.neuron.2008.04.016; Ursell T, 2011, BIOPHYS J, V101, P1913, DOI 10.1016/j.bpj.2011.08.057; Zhou XL, 2003, P NATL ACAD SCI USA, V100, P7105, DOI 10.1073/pnas.1230540100	47	54	54	1	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 20	2013	288	38					27307	27314		10.1074/jbc.M113.478321	http://dx.doi.org/10.1074/jbc.M113.478321			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	302IG	23897808	Green Published, hybrid			2023-01-03	WOS:000330597300027
J	Evans, T				Evans, Timothy			The Future Hospital Commission	LANCET			English	Editorial Material									Royal Coll Physicians, Future Hosp Commiss, London NW1 4LE, England	Royal College of Physicians	Evans, T (corresponding author), Royal Coll Physicians, Future Hosp Commiss, London NW1 4LE, England.	Linda.Cuthbertson@rcplondon.ac.uk						Fulop N, 2013, BMJ-BRIT MED J, V347, P4711; Future Hospital Commission Royal College of Physicians of London, 2013, FUT HOSP CAR MED PAT; Goddard A, 2012, BMJ-BRIT MED J, V344, P67; Gregory A, 2013, MIRROR          0801; NHS England, 2019, NHS INT PEOPL PLAN; Robert Francis QC, 2013, REP MIDST NHS FDN TR; Royal College of Physicians, 2013, MED REG EMP UNS HER	7	1	1	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	SEP 14	2013	382	9896					922	924		10.1016/S0140-6736(13)61894-2	http://dx.doi.org/10.1016/S0140-6736(13)61894-2			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	215VD	24034285				2023-01-03	WOS:000324238000008
J	Fritz, Z; Malyon, A; Frankau, JM; Parker, RA; Cohn, S; Laroche, CM; Palmer, CR; Fuld, JP				Fritz, Zoe; Malyon, Alexandra; Frankau, Jude M.; Parker, Richard A.; Cohn, Simon; Laroche, Clare M.; Palmer, Chris R.; Fuld, Jonathan P.			The Universal Form of Treatment Options (UFTO) as an Alternative to Do Not Attempt Cardiopulmonary Resuscitation (DNACPR) Orders: A Mixed Methods Evaluation of the Effects on Clinical Practice and Patient Care	PLOS ONE			English	Article							EARLY WARNING SCORE; LIFE-SUSTAINING TREATMENT; HOSPITALIZED-PATIENTS; MEDICAL PATIENTS; VALIDATION; MORBIDITY; MORTALITY; DECISIONS; QUALITY; IMPACT	Aims: To determine whether the introduction of the Universal Form of Treatment Options (the UFTO), as an alternative approach to Do Not Attempt Cardiopulmonary Resuscitation (DNACPR) orders, reduces harms in patients in whom a decision not to attempt cardiopulmonary resuscitation (CPR) was made, and to understand the mechanism for any observed change. Methods: A mixed-methods before-and-after study with contemporaneous case controls was conducted in an acute hospital. We examined DNACPR (103 patients with DNACPR orders in 530 admissions) and UFTO (118 decisions not to attempt resuscitation in 560 admissions) practice. The Global Trigger Tool was used to quantify harms. Qualitative interviews and observations were used to understand mechanisms and effects. Results: Rate of harms in patients for whom there was a documented decision not to attempt CPR was reduced: Rate difference per 1000 patient-days was 12.9 (95% CI: 2.6-23.2, p-value = 0.01). There was a difference in the proportion of harms contributing to patient death in the two period (23/71 in the period to 4/44 in the period (95% CI 7.8-36.1, p-value = 0.006). Significant differences were maintained after adjustment for known confounders. No significant change was seen on contemporaneous case control wards. Interviews with clinicians and observation of ward practice revealed the UFTO helped provide clarity of goals of care and reduced negative associations with resuscitation decisions. Conclusions: Introducing the UFTO was associated with a significant reduction in harmful events in patients in whom a decision not to attempt CPR had been made. Coupled with supportive qualitative evidence, this indicates the UFTO improved care for this vulnerable group.	[Fritz, Zoe; Malyon, Alexandra; Frankau, Jude M.; Fuld, Jonathan P.] Cambridge Univ Hosp NHS Fdn Trust, Dept Acute Med, Cambridge, England; [Parker, Richard A.; Palmer, Chris R.] Univ Cambridge, Ctr Appl Med Stat, Inst Publ Hlth, Cambridge, England; [Cohn, Simon] Univ Cambridge, Primary Care Unit, Inst Publ Hlth, Cambridge, England; [Laroche, Clare M.] W Suffolk Hosp, Dept Resp Med, Bury St Edmunds, Suffolk, England	University of Cambridge; University of Cambridge; University of Cambridge	Fritz, Z (corresponding author), Cambridge Univ Hosp NHS Fdn Trust, Dept Acute Med, Cambridge, England.	zoe.fritz@addenbrookes.nhs.uk		Fuld, Jonathan/0000-0003-1847-184X; Fritz, Zoe/0000-0001-9403-409X	National Institute for Health Research (NIHR) under its Research for Patient Benefit (RfPB) Programme [PB-PG-0808-17218]; National Institute for Health Research [PB-PG-0808-17218] Funding Source: researchfish	National Institute for Health Research (NIHR) under its Research for Patient Benefit (RfPB) Programme(National Institute for Health Research (NIHR)); National Institute for Health Research(National Institute for Health Research (NIHR))	This paper presents independent research commissioned by the National Institute for Health Research (NIHR) under its Research for Patient Benefit (RfPB) Programme (Grant Reference Number PB-PG-0808-17218). The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aune S, 2005, RESUSCITATION, V65, P291, DOI 10.1016/j.resuscitation.2004.11.028; Beach MC, 2002, J AM GERIATR SOC, V50, P2057, DOI 10.1046/j.1532-5415.2002.50620.x; Cei M, 2009, INT J CLIN PRACT, V63, P591, DOI 10.1111/j.1742-1241.2008.01986.x; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Chen JLT, 2008, AM HEART J, V156, P78, DOI 10.1016/j.ahj.2008.01.030; Classen DC, 2011, HEALTH AFFAIR, V30, P581, DOI 10.1377/hlthaff.2011.0190; Cohen RI, 2009, J CRIT CARE, V24, P311, DOI 10.1016/j.jcrc.2008.01.007; Cohn S, 2013, QJM-INT J MED, V106, P165, DOI 10.1093/qjmed/hcs222; Field RBA, 2012, RES COUNC 2012 SCI S; Fritz Z, 2010, J MED ETHICS, V36, P593, DOI 10.1136/jme.2010.035725; Fritz Z, 2010, RESUSCITATION, V81, P1138, DOI 10.1016/j.resuscitation.2010.05.014; Fullerton JN, 2012, RESUSCITATION, V83, P557, DOI 10.1016/j.resuscitation.2012.01.004; Gray T, 2012, J CLIN PATHOL; Henneman E A, 1994, Am J Crit Care, V3, P467; Kazaure H, 2011, ARCH SURG-CHICAGO, V146, P922, DOI 10.1001/archsurg.2011.69; Landrigan CP, 2010, NEW ENGL J MED, V363, P2124, DOI 10.1056/NEJMsa1004404; LAPUMA J, 1988, ARCH INTERN MED, V148, P2193, DOI 10.1001/archinte.148.10.2193; McAdam Catherine, 2005, Br J Nurs, V14, P1061; McNeill D, 2012, QJM-INT J MED, V105, P63, DOI 10.1093/qjmed/hcr137; MORGAN R, 1994, BRIT MED J, V308, P1677, DOI 10.1136/bmj.308.6945.1677a; National Confidential Enquiry into Patient Outcomes and Death, 2012, TIM INT REV PAT WHO, P1; National Office of Statistics, 2011, DEATHS REG ENGL WAL, V12; Nicolasora N, 2006, J HOSP MED, V1, P161, DOI 10.1002/jhm.78; Obolensky L, 2010, J MED ETHICS, V36, P518, DOI 10.1136/jme.2009.033977; R Development Core Team, 2012, R LANG ENV STAT COMP; Seaman J., 2008, QUALITATIVE METHODS; Shepardson LB, 1999, MED CARE, V37, P727, DOI 10.1097/00005650-199908000-00003; Sivakumar R, 2004, J MED ETHICS, V30, P311, DOI 10.1136/jme.2002.002915; SPSS/PASW for Windows, 2010, SPSS PASW WIND; Subbe CP, 2001, QJM-MON J ASSOC PHYS, V94, P521, DOI 10.1093/qjmed/94.10.521; Taylor EM, 1998, BIOETHICS, V12, P64, DOI 10.1111/1467-8519.00093; Tolle SW, 1998, J AM GERIATR SOC, V46, P1097, DOI 10.1111/j.1532-5415.1998.tb06647.x; Venneman SS, 2008, J MED ETHICS, V34, P2, DOI 10.1136/jme.2006.018317; WENGER NS, 1995, ARCH INTERN MED, V155, P2063, DOI 10.1001/archinte.155.19.2063	34	46	46	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 4	2013	8	9							e70977	10.1371/journal.pone.0070977	http://dx.doi.org/10.1371/journal.pone.0070977			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	219OE	24023718	Green Accepted, Green Published, gold, Green Submitted			2023-01-03	WOS:000324515600007
J	Sharma, G; Wang, Y; Graham, JE; Kuo, YF; Goodwin, JS				Sharma, Gulshan; Wang, Yue; Graham, James E.; Kuo, Yong-Fang; Goodwin, James S.			Provider Continuity Prior to the Diagnosis of Advanced Lung Cancer and End-of-Life Care	PLOS ONE			English	Article							EMERGENCY-DEPARTMENT USE; INTERPERSONAL CONTINUITY; PREVENTIVE SERVICES; PHYSICIAN; PATIENT; HOSPITALIZATION; BREAST	Background: Little is known about the effect of provider continuity prior to the diagnosis of advanced lung cancer and end-of-life care. Methods: Retrospective analysis of 69,247 Medicare beneficiaries aged 67 years or older diagnosed with Stage IIIB or IV lung cancer between January 1, 1993 and December 31, 2005 who died within two years of diagnosis. We examined visit patterns to a primary care physician (PCP) and/or any provider one year prior to the diagnosis of advanced lung cancer as measures of continuity of care. Outcome measures were hospitalization, ICU use and chemotherapy use during the last month of life, and hospice use during the last week of life. Results: Seeing a PCP or any provider in the year prior to the diagnosis of advanced lung cancer increased the likelihood of hospitalization, ICU care, chemotherapy and hospice use during the end of life. Patients with 1-3, 4-7 or >7 visits to their PCP in the year prior to the diagnosis of lung cancer had 1.0 (reference), 1.08 (95% CI; 1.04-1.13), and 1.14 (95% CI; 1.08-1.19) odds of hospitalization during the last month of life, respectively. Odds of hospice use during the last week of life were higher in patients with visits to multiple PCPs (OR 1.10: 95% CI; 1.06-1.15) compared to those whose visits were all to the same PCP. Conclusion: Provider continuity in the year prior to the diagnosis of advanced lung cancer was not associated with lower use of aggressive care during end of life. Our study did not have information on patient preferences and result should be interpreted accordingly.	[Sharma, Gulshan] Univ Texas Med Branch, Dept Internal Med, Div Pulm & Crit Care Med, Galveston, TX 77555 USA; [Wang, Yue] Univ Texas Med Branch, Dept Internal Med, Galveston, TX 77555 USA; [Graham, James E.] Univ Texas Med Branch, Dept Rehabil Sci, Galveston, TX 77555 USA; [Kuo, Yong-Fang] Univ Texas Med Branch, Dept PMCH Epidemiol & Biostat, Galveston, TX 77555 USA; [Goodwin, James S.] Univ Texas Med Branch, Dept Internal Med, Sealy Ctr Aging, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston	Sharma, G (corresponding author), Univ Texas Med Branch, Dept Internal Med, Div Pulm & Crit Care Med, Galveston, TX 77555 USA.	gulshan.sharma@utmb.edu	Sharma, Gulshan/AAC-5804-2019		National Institutes of Health [K-08 AG 031583, K05-CA134923, R01-AG033134]; Cancer Prevention and Research Institute of Texas [RP101207]; NATIONAL CANCER INSTITUTE [K05CA134923] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [K08AG031583, P30AG024832, R01AG033134] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Cancer Prevention and Research Institute of Texas; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This work was supported by grant K-08 AG 031583, K05-CA134923, and R01-AG033134 from the National Institutes of Health and RP101207 from the Cancer Prevention and Research Institute of Texas. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Burge F, 2003, MED CARE, V41, P992, DOI 10.1097/00005650-200308000-00012; Burge Frederick, 2003, J Palliat Med, V6, P911, DOI 10.1089/109662103322654794; Cheng SH, 2010, ARCH INTERN MED, V170, P1671, DOI 10.1001/archinternmed.2010.340; Dumont I, 2005, J PALLIATIVE CARE, V21, P49, DOI 10.1177/082585970502100108; Earle CC, 2004, J CLIN ONCOL, V22, P315, DOI 10.1200/JCO.2004.08.136; Ettner SL, 1999, MED CARE, V37, P547, DOI 10.1097/00005650-199906000-00004; Ettner SL, 1996, AM J PUBLIC HEALTH, V86, P1748, DOI 10.2105/AJPH.86.12.1748; Gill JM, 1998, ARCH FAM MED, V7, P352, DOI 10.1001/archfami.7.4.352; Gill JM, 2000, ARCH FAM MED, V9, P333, DOI 10.1001/archfami.9.4.333; Goodwin JS, 2011, MED CARE, V49, P225, DOI 10.1097/MLR.0b013e31820194f2; HOLLI K, 1993, SUPPORT CARE CANCER, V1, P263, DOI 10.1007/BF00366047; Jang TL, 2010, ARCH INTERN MED, V170, P440, DOI 10.1001/archinternmed.2010.1; King M, 2008, BRIT J CANCER, V98, P529, DOI 10.1038/sj.bjc.6604164; Klabunde CN, 2000, J CLIN EPIDEMIOL, V53, P1258, DOI 10.1016/S0895-4356(00)00256-0; Kronman AC, 2008, J GEN INTERN MED, V23, P1330, DOI 10.1007/s11606-008-0638-5; Mainous AG, 2004, FAM MED, V36, P35; Mainous AG, 1998, AM J PUBLIC HEALTH, V88, P1539, DOI 10.2105/AJPH.88.10.1539; OMalley AS, 1997, ARCH INTERN MED, V157, P1462, DOI 10.1001/archinte.157.13.1462; Parchman ML, 2004, FAM MED, V36, P22; Reid BC, 2006, ORAL ONCOL, V42, P510, DOI 10.1016/j.oraloncology.2005.10.009; Saultz JW, 2004, ANN FAM MED, V2, P445, DOI 10.1370/afm.91; Sharma G, 2009, ARCH INTERN MED, V169, P81, DOI 10.1001/archinternmed.2008.514; Temel JS, 2010, NEW ENGL J MED, V363, P733, DOI 10.1056/NEJMoa1000678; WASSON J H, 1984, Journal of the American Medical Association, V252, P2413, DOI 10.1001/jama.252.17.2413; Wolinsky FD, 2007, J GERONTOL B-PSYCHOL, V62, pS160, DOI 10.1093/geronb/62.3.S160; Wolinsky FD, 2010, J GERONTOL A-BIOL, V65, P421, DOI 10.1093/gerona/glp188	26	4	4	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 3	2013	8	9							e74690	10.1371/journal.pone.0074690	http://dx.doi.org/10.1371/journal.pone.0074690			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	217DY	24019974	gold, Green Published, Green Submitted			2023-01-03	WOS:000324338200117
J	Vonderheide, RH; Nathanson, KL				Vonderheide, Robert H.; Nathanson, Katherine L.			The road to personalized cancer vaccines	NATURE MEDICINE			English	Editorial Material							IMMUNOTHERAPY; VACCINATION; ANTIGENS; MUTANOME	The field of tumor immunology has been flooded with exciting therapeutic advances on many fronts. Immunotherapies targeting T cell inhibitory molecules have proven highly effective in some cancers, but additional strategies to induce tumor immunity, such as cancer vaccination, could further increase tumor killing. The combination of both will probably be the way forward in future immunotherapy. In 'Bedside to Bench', Robert Vonderheide and Katherine Nathanson discuss the potential of cancer genomics to identify specific tumor mutations in patients that may be used as targets in cancer vaccines to overcome problems linked to self-antigen epitopes used nowadays. Despite the existing biological and technical hurdles, a framework to implement personalized cancer vaccines in the clinic may be worth considering. In 'Bench to Bedside', Glenn Dranoff peruses the clinical efficacy and detrimental effects of two T cell immune-checkpoint inhibitors, alone and in combination, in patients with melanoma. The studies underscore the need to continue investigating specific tumor events directly involving tumor evasion to develop combinatorial strategies that will reduce drug-related pathology while achieving anti-tumor efficacy.	[Vonderheide, Robert H.; Nathanson, Katherine L.] Univ Penn, Dept Med, Abramson Canc Ctr, Perelman Sch Med, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine	Vonderheide, RH (corresponding author), Univ Penn, Dept Med, Abramson Canc Ctr, Perelman Sch Med, Philadelphia, PA 19104 USA.	rhv@exchange.upenn.edu		Nathanson, Katherine/0000-0002-6740-0901	NCI NIH HHS [R01 CA158186] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA158186] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Carbone DP, 2005, J CLIN ONCOL, V23, P5099, DOI 10.1200/JCO.2005.03.158; Castle JC, 2012, CANCER RES, V72, P1081, DOI 10.1158/0008-5472.CAN-11-3722; Cheever MA, 2009, CLIN CANCER RES, V15, P5323, DOI 10.1158/1078-0432.CCR-09-0737; Hacohen N, 2013, CANCER IMMUNOL RES, V1, P11, DOI 10.1158/2326-6066.CIR-13-0022; Kreiter S, 2012, ONCOIMMUNOLOGY, V1, P768, DOI 10.4161/onci.19727; Matsushita H, 2012, NATURE, V482, P400, DOI 10.1038/nature10755; Predina J, 2013, P NATL ACAD SCI USA, V110, pE415, DOI 10.1073/pnas.1211850110; Riley JL, 2013, NEW ENGL J MED, V369, P187, DOI 10.1056/NEJMe1305484; Sampson JH, 2009, MOL CANCER THER, V8, P2773, DOI 10.1158/1535-7163.MCT-09-0124; Schlom J, 2012, JNCI-J NATL CANCER I, V104, P599, DOI 10.1093/jnci/djs033; Schreiber RD, 2011, SCIENCE, V331, P1565, DOI 10.1126/science.1203486; Schultze JL, 2001, TRENDS IMMUNOL, V22, P516, DOI 10.1016/S1471-4906(01)02015-4; Segal NH, 2008, CANCER RES, V68, P889, DOI 10.1158/0008-5472.CAN-07-3095; Topalian SL, 2011, J CLIN ONCOL, V29, P4828, DOI 10.1200/JCO.2011.38.0899; Vonderheide RH, 2013, CURR OPIN IMMUNOL, V25, P200, DOI 10.1016/j.coi.2013.01.006; Weden S, 2011, INT J CANCER, V128, P1120, DOI 10.1002/ijc.25449	16	40	40	0	33	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	SEP	2013	19	9					1098	1100		10.1038/nm.3317	http://dx.doi.org/10.1038/nm.3317			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	213TP	24013748				2023-01-03	WOS:000324083500018
J	Siraichi, JTG; Felipe, DF; Brambilla, LZS; Gatto, MJ; Terra, VA; Cecchini, AL; Cortez, LER; Rodrigues, E; Cortez, DAG				Guinoza Siraichi, Jackeline Tiemy; Felipe, Daniele Fernanda; Serra Brambilla, Lara Zampar; Gatto, Melissa Junqueira; Terra, Vania Aparecida; Cecchini, Alessandra Lourenco; Ranieri Cortez, Lucia Elaine; Rodrigues-Filho, Edson; Garcia Cortez, Diogenes Aparicio			Antioxidant Capacity of the Leaf Extract Obtained from Arrabidaea chica Cultivated in Southern Brazil	PLOS ONE			English	Article							RADICAL SCAVENGING ACTIVITY; IN-VITRO ASSAYS; FLAVONOIDS; LEAVES; HPLC; IDENTIFICATION; PHENOLICS; SPICES; FOODS	Arrabidaea chica leaf extract has been used by people as an anti-inflammatory and astringent agent as well as a remedy for intestinal colic, diarrhea, leucorrhea, anemia, and leukemia. A. chica is known to be a good producer of phenolics. Therefore, in the present study, we investigated its antioxidant activity. The phenolic composition of A. chica leaves was studied by liquid chromatography coupled to diode array detection (LC-DAD) and liquid chromatography coupled to electrospray ionization-tandem mass spectrometry (LC-ESI-MS/MS), and isoscutellarein, 6-hydroxyluteolin, hispidulin, scutellarein, luteolin, and apigenin were identified. The extract from leaves of A. chica was tested for antioxidant activity using the 2,2-diphenyl-1-picrylhydrazyl (DPPH) method, beta-carotene bleaching test, and total reactive antioxidant potential (TRAP) method. The crude extract quenched DPPH free radicals in a dose-dependent manner, and the IC50 of the extract was 13.51 mu g/mL. The beta-carotene bleaching test showed that the addition of the A. chica extract in different concentrations (200 and 500 mg/mL) prevented the bleaching of beta-carotene at different degrees (51.2% +/- 3.38% and 94% +/- 4.61%, respectively). The TRAP test showed dose-dependent correlation between the increasing concentrations of A. chica extract (0.1, 0.5, and 1.0 mu g/mL) and the TRAP values obtained by trolox (hydro-soluble vitamin E) 0.4738 +/- 0.0466, 1.981 +/- 0.1603, and 6.877 +/- 1.445 mu M, respectively. The 2 main flavonoids, scutellarein and apigenin, were separated, and their antioxidant activity was found to be the same as that of the plant extract. These 2 flavonoids were quantified in the plant extract by using a validated HPLC-UV method. The results of these tests showed that the extract of A. chica had a significant antioxidant activity, which could be attributed to the presence of the mixture of flavonoids in the plant extract, with the main contribution of scutellarein and apigenin.	[Guinoza Siraichi, Jackeline Tiemy; Felipe, Daniele Fernanda; Serra Brambilla, Lara Zampar; Garcia Cortez, Diogenes Aparicio] Univ Estadual Maringa, Pharmaceut Sci Postgrad Program, Maringa, Parana, Brazil; [Gatto, Melissa Junqueira] Univ Estadual Maringa, Dept Pharm, Maringa, Parana, Brazil; [Guinoza Siraichi, Jackeline Tiemy] Inst Fed Parana, Londrina, Parana, Brazil; [Terra, Vania Aparecida; Cecchini, Alessandra Lourenco] Univ Estadual Londrina, Dept Pathol Sci, Londrina, Parana, Brazil; [Ranieri Cortez, Lucia Elaine] Ctr Univ Maringa, Postgrad Program Hlth Promot, State Of Maringa, Parana, Brazil; [Rodrigues-Filho, Edson] Univ Fed Sao Carlos, Dept Chem, BR-13560 Sao Carlos, SP, Brazil	Universidade Estadual de Maringa; Universidade Estadual de Maringa; Instituto Federal do Parana; Universidade Estadual de Londrina; Universidade Federal de Sao Carlos	Cortez, DAG (corresponding author), Univ Estadual Maringa, Pharmaceut Sci Postgrad Program, Maringa, Parana, Brazil.	dagcortez@uem.br	Rodrigues-Filho, Edson/C-5024-2009; Rodrigues-Filho, Edson/M-7657-2019	Rodrigues-Filho, Edson/0000-0003-4305-0326; Cecchini, Alessandra/0000-0003-0575-9879	Conselho Nacional de Desenvolvimento Cientifico e Tecnologico; Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior; Pro-Reitoria de Pesquisa e Pos-Graduacao da Universidade Estadual de Maringa; Programa de Pos-Graduacao em Ciencias Farmaceuticas da Universidade Estadual de Maringa	Conselho Nacional de Desenvolvimento Cientifico e Tecnologico(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)); Pro-Reitoria de Pesquisa e Pos-Graduacao da Universidade Estadual de Maringa; Programa de Pos-Graduacao em Ciencias Farmaceuticas da Universidade Estadual de Maringa	This study was supported by grants from the Conselho Nacional de Desenvolvimento Cientifico e Tecnologico, Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior, Pro-Reitoria de Pesquisa e Pos-Graduacao da Universidade Estadual de Maringa, and Programa de Pos-Graduacao em Ciencias Farmaceuticas da Universidade Estadual de Maringa. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bondet W, 1997, LEBENSM WISS TECHNOL, V30, P609; BRAND-WILLIAMS W, 1995, FOOD SCI TECHNOL-LEB, V28, P25; Calvo MI, 1997, CHROMATOGRAPHIA, V46, P241, DOI 10.1007/BF02496313; Cao GH, 1997, FREE RADICAL BIO MED, V22, P749, DOI 10.1016/S0891-5849(96)00351-6; Castaneda-Ovando A, 2009, FOOD CHEM, V113, P859, DOI 10.1016/j.foodchem.2008.09.001; Cheung LM, 2003, FOOD CHEM, V81, P249, DOI 10.1016/S0308-8146(02)00419-3; Ciz M, 2010, FOOD CONTROL, V21, P518, DOI 10.1016/j.foodcont.2009.07.017; de Souza AS, 2009, PHARM BIOL, V47, P154, DOI 10.1080/13880200802436281; Devia B, 2002, PHYTOCHEM ANALYSIS, V13, P114, DOI 10.1002/pca.632; Engida AM, 2013, IND CROP PROD, V41, P392, DOI 10.1016/j.indcrop.2012.04.043; Fecka I, 2008, FOOD CHEM, V108, P1039, DOI 10.1016/j.foodchem.2007.11.035; Ghiselli A, 2000, FREE RADICAL BIO MED, V29, P1106, DOI 10.1016/S0891-5849(00)00394-4; Greenham J, 2003, PHYTOCHEM ANALYSIS, V14, P100, DOI 10.1002/pca.693; Gu LW, 2001, FOOD CHEM, V73, P299, DOI 10.1016/S0308-8146(00)00300-9; Guvenc A, 2010, FOOD CHEM, V118, P686, DOI 10.1016/j.foodchem.2009.05.034; Hidalgo M, 2010, FOOD CHEM, V121, P691, DOI 10.1016/j.foodchem.2009.12.097; Jorge MP, 2008, J ETHNOPHARMACOL, V118, P361, DOI 10.1016/j.jep.2008.04.024; Kandasamy S, 2011, MOL PHYS, V109, P839, DOI 10.1080/00268976.2011.556576; Kumaran A, 2006, FOOD CHEM, V97, P109, DOI 10.1016/j.foodchem.2005.03.032; Lancas FM, 2004, VALIDATION CHROMATOG; Li YH, 2008, FOOD CHEM, V106, P444, DOI 10.1016/j.foodchem.2007.04.067; Magalhaes WV, 2011, BRAZ J PHARM SCI, V47, P693, DOI 10.1590/S1984-82502011000400005; Martens S, 2005, PHYTOCHEMISTRY, V66, P2399, DOI 10.1016/j.phytochem.2005.07.013; Montoro P, 2005, FOOD CHEM, V92, P349, DOI 10.1016/j.foodchem.2004.07.028; Pauletti PM, 2003, J NAT PROD, V66, P1384, DOI 10.1021/np030100t; Pellegrini N, 2003, J NUTR, V133, P2812, DOI 10.1093/jn/133.9.2812; Pellegrini N, 2006, MOL NUTR FOOD RES, V50, P1030, DOI 10.1002/mnfr.200600067; Peng ZF, 2003, PHYTOCHEMISTRY, V62, P219, DOI 10.1016/S0031-9422(02)00504-6; Prior RL, 2005, J AGR FOOD CHEM, V53, P4290, DOI 10.1021/jf0502698; Qui F, 2007, PLANTA MED, V73, P363; Barbosa WLR, 2008, REV BRAS FARMACOGN, V18, P544, DOI 10.1590/S0102-695X2008000400008; Ribeiro AFC, 2012, REV BRAS FARMACOGN, V22, P364, DOI 10.1590/S0102-695X2011005000225; Scherer R, 2009, FOOD CHEM, V112, P654, DOI 10.1016/j.foodchem.2008.06.026; Schiozer AL, 2008, ANAL LETT, V41, P1592, DOI 10.1080/00032710802122198; Schiozer AL, 2012, J BRAZIL CHEM SOC, V23, P409, DOI 10.1590/S0103-50532012000300006; Seyoum A, 2006, PHYTOCHEMISTRY, V67, P2058, DOI 10.1016/j.phytochem.2006.07.002; Sharififar F, 2009, FOOD CHEM, V112, P885, DOI 10.1016/j.foodchem.2008.06.064; Silva EM, 2007, FOOD CHEM, V101, P1012, DOI 10.1016/j.foodchem.2006.02.055; Simirgiotis MJ, 2013, MOLECULES, V18, P1672, DOI 10.3390/molecules18021672; TAKEMURA OS, 1995, PHYTOCHEMISTRY, V38, P1299, DOI 10.1016/0031-9422(94)00786-S; Terashima M, 2012, PLANT CELL REP, V31, P291, DOI 10.1007/s00299-011-1163-2; Yan RY, 2011, FITOTERAPIA, V82, P841, DOI 10.1016/j.fitote.2011.04.006; Yan ZX, 2011, ANAL CHIM ACTA, V691, P110, DOI 10.1016/j.aca.2011.02.046; Yokozawa T, 1997, PHYTOTHER RES, V11, P446, DOI 10.1002/(SICI)1099-1573(199709)11:6<446::AID-PTR128>3.3.CO;2-#; Zorn B, 2001, PHYTOCHEMISTRY, V56, P831, DOI 10.1016/S0031-9422(01)00038-3	45	39	39	0	39	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 29	2013	8	8							e72733	10.1371/journal.pone.0072733	http://dx.doi.org/10.1371/journal.pone.0072733			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	209DO	24009700	Green Published, gold, Green Submitted			2023-01-03	WOS:000323734600034
J	Gastanaduy, PA; Curns, AT; Parashar, UD; Lopman, BA				Gastanaduy, Paul A.; Curns, Aaron T.; Parashar, Umesh D.; Lopman, Ben A.			Gastroenteritis Hospitalizations in Older Children and Adults in the United States Before and After Implementation of Infant Rotavirus Vaccination	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							INDIRECT PROTECTION; NOROVIRUS		[Gastanaduy, Paul A.; Curns, Aaron T.; Parashar, Umesh D.; Lopman, Ben A.] Ctr Dis Control & Prevent, Div Viral Dis, Atlanta, GA 30333 USA	Centers for Disease Control & Prevention - USA	Gastanaduy, PA (corresponding author), Ctr Dis Control & Prevent, Div Viral Dis, 1600 Clifton Rd NE,Mailstop A-47, Atlanta, GA 30333 USA.	vid7@cdc.gov						Anderson EJ, 2013, CLIN INFECT DIS, V56, P755, DOI 10.1093/cid/cis1010; Anderson EJ, 2012, J INFECTION, V64, P89, DOI 10.1016/j.jinf.2011.09.003; Bresee JS, 2012, J INFECT DIS, V205, P1374, DOI 10.1093/infdis/jis206; Gastanaduy PA, 2013, J INFECT DIS, V207, P1058, DOI 10.1093/infdis/jis942; Lopman BA, 2011, J INFECT DIS, V204, P980, DOI 10.1093/infdis/jir492; Lopman BA, 2011, CLIN INFECT DIS, V52, P466, DOI 10.1093/cid/ciq163	6	64	65	0	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 28	2013	310	8					851	853		10.1001/jama.2013.170800	http://dx.doi.org/10.1001/jama.2013.170800			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	206YA	23982372				2023-01-03	WOS:000323561400026
J	Scott, CA; Iyer, HS; Bwalya, DL; Bweupe, M; Rosen, SB; Scott, N; Larson, BA				Scott, Callie A.; Iyer, Hari S.; Bwalya, Deophine Lembela; Bweupe, Maximillian; Rosen, Sydney B.; Scott, Nancy; Larson, Bruce A.			Uptake, Outcomes, and Costs of Antenatal, Well-Baby, and Prevention of Mother-to-Child Transmission of HIV Services under Routine Care Conditions in Zambia	PLOS ONE			English	Article							ANTIRETROVIRAL THERAPY	Background: Zambia adopted Option A for prevention of mother-to-child transmission of HIV (PMTCT) in 2010 and announced a move to Option B+ in 2013. We evaluated the uptake, outcomes, and costs of antenatal, well-baby, and PMTCT services under routine care conditions in Zambia after the adoption of Option A. Methods: We enrolled 99 HIV-infected/HIV-exposed (index) mother/baby pairs with a first antenatal visit in April-September 2011 at four study sites and 99 HIV-uninfected/HIV-unexposed (comparison) mother/baby pairs matched on site, gestational age, and calendar month at first visit. Data on patient outcomes and resources utilized from the first antenatal visit through six months postpartum were extracted from site registers. Costs in 2011 USD were estimated from the provider's perspective. Results: Index mothers presented for antenatal care at a mean 23.6 weeks gestation; 55% were considered to have initiated triple-drug antiretroviral therapy (ART) based on information recorded in site registers. Six months postpartum, 62% of index and 30% of comparison mother/baby pairs were retained in care; 67% of index babies retained had an unknown HIV status. Comparison and index mother/baby pairs utilized fewer resources than under fully guideline-concordant care; index babies utilized more well-baby resources than comparison babies. The average cost per comparison pair retained in care six months postpartum was $52 for antenatal and well-baby services. The average cost per index pair retained was $88 for antenatal, well-baby, and PMTCT services and increased to $185 when costs of triple-drug ART services were included. Conclusions: HIV-infected mothers present to care late in pregnancy and many are lost to follow up by six months postpartum. HIV-exposed babies are more likely to remain in care and receive non-HIV, well-baby care than HIV-unexposed babies. Improving retention in care, guideline concordance, and moving to Option B+ will result in increased service delivery costs in the short term.	[Scott, Callie A.; Rosen, Sydney B.; Scott, Nancy; Larson, Bruce A.] Boston Univ, Ctr Global Hlth & Dev, Boston, MA 02215 USA; [Scott, Callie A.; Iyer, Hari S.; Bwalya, Deophine Lembela] Zambia Ctr Appl Hlth Res & Dev, Lusaka, Zambia; [Bweupe, Maximillian] Zambian Minist Hlth, Lusaka, Zambia; [Rosen, Sydney B.] Univ Witwatersrand, Fac Hlth Sci, Wits Hlth Consortium, Hlth Econ & Epidemiol Res Off, Johannesburg, South Africa; [Larson, Bruce A.] Boston Univ, Sch Publ Hlth, Dept Int Hlth, Boston, MA 02215 USA	Boston University; University of Zambia; University of Witwatersrand; Boston University	Larson, BA (corresponding author), Boston Univ, Ctr Global Hlth & Dev, Boston, MA 02215 USA.	blarson@bu.edu	Iyer, Hari S./AAZ-1563-2020	Rosen, Sydney/0000-0002-6560-2964; Scott, Nancy/0000-0002-4713-4642; Larson, Bruce/0000-0002-9322-2387	President's Emergency Plan for AIDS Relief (PEPFAR) through the Centers for Disease Control and Prevention [5U2GPS001418-00]	President's Emergency Plan for AIDS Relief (PEPFAR) through the Centers for Disease Control and Prevention(United States Agency for International Development (USAID)United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA)	This research was funded by the President's Emergency Plan for AIDS Relief (PEPFAR) through the Centers for Disease Control and Prevention (5U2GPS001418-00). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2020, HIGH POSS COST COVID; Binagwaho A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054180; Bratt JH, 2011, TROP MED INT HEALTH, V16, P110, DOI 10.1111/j.1365-3156.2010.02640.x; Chi BH, 2011, INT J GYNECOL OBSTET, V113, P131, DOI 10.1016/j.ijgo.2010.11.013; Ciaranello AL, 2013, CLIN INFECT DIS, V56, P430, DOI 10.1093/cid/cis858; Government of the Republic of Zambia Ministry of Health, 2010, 2010 NAT PROT GUID I; Government of the Republic of Zambia Ministry of Health, 2013, LIF ANT DRUGS ARVS A; Hoffman RM, 2010, JAIDS-J ACQ IMM DEF, V54, P35, DOI 10.1097/QAI.0b013e3181cf9979; International Monetary Fund, 2012, WORLD EC OUTL DAT OC; Killam WP, 2010, AIDS, V24, P85, DOI 10.1097/QAD.0b013e32833298be; Limited MS, 2010, MED STOR LTD 2010 CA; Mandala J, 2009, BMC PUBLIC HEALTH, V9, DOI 10.1186/1471-2458-9-314; Oanda Corporation, 2012, HIST EXCH RAT DAIL M; Orlando S, 2010, JAIDS-J ACQ IMM DEF, V55, P631, DOI 10.1097/QAI.0b013e3181f9f9f5; Shah M, 2011, AIDS, V25, P1093, DOI 10.1097/QAD.0b013e32834670b9; Torpey K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042859; Torpey K, 2010, JAIDS-J ACQ IMM DEF, V54, P415, DOI 10.1097/QAI.0b013e3181e36616; Torpey K, 2010, BMC HEALTH SERV RES, V10, DOI 10.1186/1472-6963-10-29; Violari A, 2008, NEW ENGL J MED, V359, P2233, DOI 10.1056/NEJMoa0800971; WHO UNAIDS Unicef, 2011, GLOB HIV AIDS RESP E; World Health Organization, 2012, PROGR UPD US ANT DRU; World Health Organization, 2021, ANT DRUGS TREAT PREG	22	13	13	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 28	2013	8	8							e72444	10.1371/journal.pone.0072444	http://dx.doi.org/10.1371/journal.pone.0072444			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	209DG	24015245	Green Published, gold, Green Submitted			2023-01-03	WOS:000323733800053
J	Hirsch, C				Hirsch, Calvin			A 12-month, in-home exercise program delayed functional deterioration in Alzheimer disease	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							NEUROPSYCHIATRIC SYMPTOMS; CONTROLLED-TRIAL		Calif State Univ Sacramento, Davis Med Ctr, Sacramento, CA 95819 USA	California State University System; California State University Sacramento	Hirsch, C (corresponding author), Calif State Univ Sacramento, Davis Med Ctr, Sacramento, CA 95819 USA.							D'Onofrio G, 2012, CURR ALZHEIMER RES, V9, P759; Schulz R, 1999, JAMA-J AM MED ASSOC, V282, P2215, DOI 10.1001/jama.282.23.2215; Stella F, 2011, CLINICS, V66, P1353, DOI 10.1590/S1807-59322011000800008; Vreugdenhil A, 2012, SCAND J CARING SCI, V26, P12, DOI 10.1111/j.1471-6712.2011.00895.x	4	7	7	0	11	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 20	2013	159	4							JC10	10.7326/0003-4819-159-4-201308200-02010	http://dx.doi.org/10.7326/0003-4819-159-4-201308200-02010			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	205DM	24026274				2023-01-03	WOS:000323421700009
J	Slater, H; Briggs, AM; Watkins, K; Chua, J; Smith, AJ				Slater, Helen; Briggs, Andrew M.; Watkins, Kim; Chua, Jason; Smith, Anne J.			Translating Evidence for Low Back Pain Management into a Consumer-Focussed Resource for Use in Community Pharmacies: A Cluster-Randomised Controlled Trial	PLOS ONE			English	Article							POPULATION-BASED INTERVENTION; PRIMARY-CARE PATIENTS; SELF-MANAGEMENT; WESTERN-AUSTRALIA; BELIEFS; INFORMATION; HEALTH; SATISFACTION; DISABILITY; KNOWLEDGE	Background: This cluster-randomised controlled trial determined the effectiveness of an evidence-based, pamphlet intervention in improving low back pain (LBP)-related beliefs among pharmacy consumers. Methods: Thirty five community pharmacies were randomised to three groups: pamphlet+education intervention [n = 11]; pamphlet only intervention [n = 11]; control: usual care [n = 13]. Eligibility requirements for clusters included: community-based pharmacies and proprietor participation consent. Pharmacy consumers (N = 317) aged 18-65 years currently experiencing LBP participated. Intervention group allocation depended on the pharmacy attended. Individual-level outcomes were measured at pre-intervention (T0), at two (T1) and eight (T2) weeks post-intervention and included beliefs about LBP [Back Pain Beliefs Questionnaire (BBQ); Fear Avoidance Beliefs Questionnaire (FABQ)]. Secondary outcomes included pain severity, activity impairment and pamphlet perceived usefulness. Blinding to group allocation included primary investigators, outcome assessors and the statistician. Pharmacy staff and consumers were un-blinded. Results: Of 35 pharmacies recruited (317 consumers), no clusters were lost to follow-up. Follow-up was available for n = 24 at 2 weeks only; n = 38 at 8 weeks only; n = 148 at both time points, with n = 148+24+38 = 210 analysed (107 excluded: no follow up). Adjusting for baseline scores demonstrated no significant differences in beliefs (2 or at 8 weeks) between pamphlet (with or without education) versus control, or between 'pamphlet with' versus 'without' education. Work-related fear (FABQ) was significantly lower in consumers receiving pamphlet (with or without education) versus control (difference -2.3, 95%CI: -4.4 to -0.2). There was no significant difference between "pamphlet with" versus "pamphlet without" groups. Consumers receiving the "pamphlet with" reported greater perceived usefulness than consumers receiving the "pamphlet without" (difference 0.9 (95%CI: 0.0 to 1.8)). Conclusion: Community pharmacies provided a feasible primary care portal for implementing evidence-based information. The associated improvement in work-related LBP-beliefs for consumers receiving the pamphlet suggests this simple intervention may be a useful component of care.	[Slater, Helen; Smith, Anne J.] Curtin Univ, Sch Physiotherapy, Perth, WA 6845, Australia; [Slater, Helen; Briggs, Andrew M.; Chua, Jason; Smith, Anne J.] Curtin Univ, Curtin Hlth Innovat Res Inst, Perth, WA 6845, Australia; [Briggs, Andrew M.] Govt Western Australia, Dept Hlth, Perth, WA, Australia; [Briggs, Andrew M.] Arthrit & Osteoporosis Victoria, Melbourne, Vic, Australia; [Watkins, Kim] Univ Western Australia, Sch Med & Pharmacol, Perth, WA 6009, Australia	Curtin University; Curtin University; Government of Western Australia; University of Western Australia	Slater, H (corresponding author), Curtin Univ, Sch Physiotherapy, Perth, WA 6845, Australia.	h.slater@curtin.edu.au		Chua, Jason/0000-0002-0224-2818; Slater, Helen/0000-0002-4868-4988; Watkins, Kim/0000-0002-2836-4637; Smith, Anne/0000-0002-4667-7389	Department of Health, Government of Western Australia	Department of Health, Government of Western Australia	This study was funded, in part, by a grant provided by the Department of Health, Government of Western Australia (http://www.healthnetworks.health.wa.gov.au/home/). In kind support from Curtin University is acknowledged (http://www.curtin.edu.au). Production of the pamphlet for this trial was also funded by the Department of Health, Government of Western Australia. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Albaladejo C, 2010, SPINE, V35, P483, DOI 10.1097/BRS.0b013e3181b9c9a7; Australian and New Zealand College of Anaesthetists, 2010, NAT PAIN STRAT; Australian Bureau of Statistics, 2008, INTR SOC IND AR SEIF; Bennett MI, 2011, CLIN J PAIN, V27, P623, DOI 10.1097/AJP.0b013e31821b6be4; Blyth FM, 2005, PAIN, V113, P285, DOI 10.1016/j.pain.2004.12.004; Boonstra AM, 2008, INT J REHABIL RES, V31, P165, DOI 10.1097/MRR.0b013e3282fc0f93; Briggs AM, 2012, EUR J PAIN; Briggs AM, 2012, BMC HEALTH SERV RES, V12, DOI 10.1186/1472-6963-12-394; Briggs AM, 2012, BMC HEALTH SERV RES, V12, DOI 10.1186/1472-6963-12-357; Briggs AM, 2011, BMC MUSCULOSKEL DIS, V12, DOI 10.1186/1471-2474-12-161; Briggs AM, 2010, PAIN, V150, P275, DOI 10.1016/j.pain.2010.04.031; Briggs AM, 2009, MED J AUSTRALIA, V190, P499, DOI 10.5694/j.1326-5377.2009.tb02527.x; Buchbinder R, 2005, SPINE, V30, P1323, DOI 10.1097/01.brs.0000164121.77862.4b; Buchbinder R, 2004, BRIT MED J, V328, P321, DOI 10.1136/bmj.328.7435.321; Buchbinder R, 2001, BRIT MED J, V322, P1516, DOI 10.1136/bmj.322.7301.1516; Buchbinder R, 2008, SPINE, V33, P74, DOI 10.1097/BRS.0b013e31815e39c8; Burton AK, 2006, EUR SPINE J, V15, pS136, DOI 10.1007/s00586-006-1070-3; Burton AK, 1999, SPINE, V24, P2484, DOI 10.1097/00007632-199912010-00010; Campbell MK, 2012, BMJ-BRIT MED J, V345, DOI 10.1136/bmj.e5661; Campbell MK, 2000, FAM PRACT, V17, P192, DOI 10.1093/fampra/17.2.192; Cherkin DC, 1998, SPINE, V23, P607, DOI 10.1097/00007632-199803010-00015; Chou Roger, 2005, Pain Pract, V5, P153, DOI 10.1111/j.1533-2500.2005.05302.x; Coudeyre E, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000706; Damush TM, 2003, ARTHRIT RHEUM-ARTHR, V49, P179, DOI 10.1002/art.10995; Damush TM, 2003, ARCH INTERN MED, V163, P2632, DOI 10.1001/archinte.163.21.2632; Department of Health WA, 2011, WA PRIM HLTH CAR STR; Department of Health Western Australia, 2009, SPIN PAIN MOD CAR; Eldridge S, 2011, PRACTICAL GUIDE CLUS; Fary RE, 2012, INT J RHEUMATOL, V2012, DOI 10.1155/2012/240689; Grime J, 2007, HEALTH EXPECT, V10, P286, DOI 10.1111/j.1369-7625.2007.00454.x; Hancock MJ, 2007, LANCET, V370, P1638, DOI 10.1016/S0140-6736(07)61686-9; Hayes RJ, 2009, INTERD STAT, P3; Henrotin YE, 2006, SPINE, V31, pE326, DOI 10.1097/01.brs.0000217620.85893.32; Hill JC, 2008, ARTHRIT RHEUM-ARTHR, V59, P632, DOI 10.1002/art.23563; Hill JC, 2011, LANCET, V378, P1560, DOI 10.1016/S0140-6736(11)60937-9; Ho K, 2010, J CONTIN EDUC HEALTH, V30, P139, DOI 10.1002/chp.20071; Jensen MP, 1999, PAIN, V83, P157, DOI 10.1016/S0304-3959(99)00101-3; Jordan JE, 2010, PATIENT EDUC COUNS, V79, P36, DOI 10.1016/j.pec.2009.10.001; Joyce Andrew W., 2007, Journal of Pharmacy Practice and Research, V37, P42; Kamper SJ, 2010, J CLIN EPIDEMIOL, V63, P760, DOI 10.1016/j.jclinepi.2009.09.009; Kovacs F, 2011, SPINE, V36, pE505, DOI 10.1097/BRS.0b013e3181dccebc; Krismer M, 2007, BEST PRACT RES CL RH, V21, P77, DOI 10.1016/j.berh.2006.08.004; Linton SJ, 2000, SPINE, V25, P1148, DOI 10.1097/00007632-200005010-00017; Little P, 2001, SPINE, V26, P2065, DOI 10.1097/00007632-200110010-00003; Luo XM, 2004, SPINE, V29, pE531, DOI 10.1097/01.brs.0000146453.76528.7c; Luo XM, 2004, SPINE, V29, P884, DOI 10.1097/00007632-200404150-00012; Maher CG, 2011, AUST PRESCR, V34, P128; Marra CA, 2012, ARTHRIT CARE RES, V64, P1837, DOI 10.1002/acr.21763; Martin BI, 2009, SPINE, V34, P2077, DOI 10.1097/BRS.0b013e3181b1fad1; McCracken LM, 1997, J PAIN SYMPTOM MANAG, V14, P292, DOI 10.1016/S0885-3924(97)00225-X; McKenzie JE, 2008, IMPLEMENT SCI, V3, DOI 10.1186/1748-5908-3-11; Moher D, 2012, INT J SURG, V10, P28, DOI 10.1016/j.ijsu.2011.10.001; O'Sullivan P, 2012, BRIT J SPORT MED, V46, P224, DOI 10.1136/bjsm.2010.081638; Palmer D, 2011, ADV NURS SCI, V34, P29, DOI 10.1097/ANS.0b013e318209439f; Passik SD, 2002, J PAIN SYMPTOM MANAG, V24, P361, DOI 10.1016/S0885-3924(02)00505-5; Silcock J, 2007, BMC MUSCULOSKEL DIS, V8, DOI 10.1186/1471-2474-8-10; Sitzia J, 1997, SOC SCI MED, V45, P1829, DOI 10.1016/S0277-9536(97)00128-7; Slater H, 2012, BMC MUSCULOSKEL DIS, V13, DOI 10.1186/1471-2474-13-69; Slater H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038037; Symonds TL, 1995, SPINE, V20, P2738, DOI 10.1097/00007632-199512150-00016; Symonds TL, 1996, OCCUP MED-OXFORD, V46, P25, DOI 10.1093/occmed/46.1.25; Urquhart DM, 2008, BMC MUSCULOSKEL DIS, V9, DOI 10.1186/1471-2474-9-148; van Leeuwen MT, 2006, EUR J PAIN, V10, P161, DOI 10.1016/j.ejpain.2005.02.007; Vogt MT, 2005, SPINE, V30, P1075, DOI 10.1097/01.brs.0000160843.77091.07; WADDELL G, 1993, PAIN, V52, P157, DOI 10.1016/0304-3959(93)90127-B; Western Australia Department of Health, 2011, WA CHRON HLTH COND F; Wibowo Y, 2010, RURAL REMOTE HEALTH, V10	67	21	22	0	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 20	2013	8	8							e71918	10.1371/journal.pone.0071918	http://dx.doi.org/10.1371/journal.pone.0071918			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	219RU	23977178	Green Submitted, Green Published, gold			2023-01-03	WOS:000324527300052
J	Tibaldi, L; Leyman, S; Nicolas, A; Notebaert, S; Dewulf, M; Ngo, TH; Zuany-Amorim, C; Amzallag, N; Bernard-Pierrot, I; Sastre-Garau, X; Thery, C				Tibaldi, Lorenzo; Leyman, Shirley; Nicolas, Andre; Notebaert, Sofie; Dewulf, Melissa; Thu Hoa Ngo; Zuany-Amorim, Claudia; Amzallag, Nathalie; Bernard-Pierrot, Isabelle; Sastre-Garau, Xavier; Thery, Clotilde			New Blocking Antibodies Impede Adhesion, Migration and Survival of Ovarian Cancer Cells, Highlighting MFGE8 as a Potential Therapeutic Target of Human Ovarian Carcinoma	PLOS ONE			English	Article							HUMAN-BREAST-TUMORS; MONOCLONAL-ANTIBODIES; APOPTOTIC CELLS; GROWTH; PROTEIN; MFG-E8/LACTADHERIN; IDENTIFICATION; ANTIGENS; LINKS	Milk Fat Globule -EGF -factor VIII (MFGE8), also called lactadherin, is a secreted protein, which binds extracellularly to phosphatidylserine and to alpha v beta 3 and alpha v beta 5 integrins. On human and mouse cells expressing these integrins, such as endothelial cells, phagocytes and some tumors, MFGE8/lactadherin has been shown to promote survival, epithelial to mesenchymal transition and phagocytosis. A protumoral function of MFGE8 has consequently been documented for a few types of human cancers, including melanoma, a subtype of breast cancers, and bladder carcinoma. Inhibiting the functions of MFGE8 could thus represent a new type of therapy for human cancers. Here, we show by immunohistochemistry on a collection of human ovarian cancers that MFGE8 is overexpressed in 45% of these tumors, and we confirm that it is specifically overexpressed in the triple-negative subtype of human breast cancers. We have established new in vitro assays to measure the effect of MFGE8 on survival, adhesion and migration of human ovarian and triple-negative breast cancer cell lines. Using these assays, we could identify new MFGE8-specific monoclonal antibodies, which efficiently blocked these three tumor-promoting effects of MFGE8. Our results suggest future use of MFGE8-blocking antibodies as new anti-cancer therapeutics in subgroups of ovarian carcinoma, and triple-negative breast carcinoma patients.	[Tibaldi, Lorenzo; Dewulf, Melissa; Amzallag, Nathalie; Bernard-Pierrot, Isabelle; Thery, Clotilde] Inst Curie, Ctr Rech, Paris, France; [Tibaldi, Lorenzo; Dewulf, Melissa; Amzallag, Nathalie; Thery, Clotilde] INSERM, U932, Paris, France; [Leyman, Shirley; Notebaert, Sofie; Thu Hoa Ngo; Zuany-Amorim, Claudia] ThromboGenics NV, Heverlee, Belgium; [Nicolas, Andre; Sastre-Garau, Xavier] Inst Curie, Dept Tumor Biol, Paris, France; [Bernard-Pierrot, Isabelle] CNRS, UMR144, Paris, France; [Thery, Clotilde] CBT 507 IGR Curie, Paris, France	UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite Paris Cite; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Sorbonne Universite	Thery, C (corresponding author), INSERM, U932, Paris, France.	clotilde.thery@curie.fr	thery, clotilde/F-6373-2013	thery, clotilde/0000-0001-8294-6884; Sastre-Garau, Xavier/0000-0001-5992-2083	Institut Curie; INSERM; Association pour La Recherche contre le Cancer	Institut Curie; INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); Association pour La Recherche contre le Cancer(Fondation ARC pour la Recherche sur le Cancer)	This work was supported by Institut Curie, INSERM, Association pour La Recherche contre le Cancer, a prize from Fondation de France, and a two-years collaboration contract between Institut Curie, INSERM, and ThromboGenics NV, Leuven, Belgium (www.thrombogenics.com). ThromboGenics NV outlined the strategy for antibody generation, performed the mice immunization, checked the specificity of the new anti-human MFGE8 antibodies, sequenced their variable regions, and participated in the design of the tests for selection of the lead candidate antibodies.	Bu HF, 2007, J CLIN INVEST, V117, P3673, DOI 10.1172/JCI31841; Carrascosa C, 2012, ONCOGENE, V31, P1521, DOI 10.1038/onc.2011.356; CERIANI RL, 1988, CANCER RES, V48, P4664; CERIANI RL, 1982, P NATL ACAD SCI-BIOL, V79, P5420, DOI 10.1073/pnas.79.17.5420; CERIANI RL, 1987, CANCER RES, V47, P532; COUTO JR, 1995, CANCER RES, V55, P1717; Ensslin MA, 2003, CELL, V114, P405, DOI 10.1016/S0092-8674(03)00643-3; Fens MHAM, 2008, BLOOD, V111, P4542, DOI 10.1182/blood-2007-06-094763; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hanayama R, 2002, NATURE, V417, P182, DOI 10.1038/417182a; IMAI S, 1990, ONCOLOGY, V47, P177; Jinushi M, 2008, CANCER RES, V68, P8889, DOI 10.1158/0008-5472.CAN-08-2147; Jinushi M, 2007, J CLIN INVEST, V117, P1902, DOI 10.1172/JCI30966; Jinushi M, 2011, P NATL ACAD SCI USA, V108, P12425, DOI 10.1073/pnas.1106645108; Jinushi M, 2009, J EXP MED, V206, P1317, DOI 10.1084/jem.20082614; LAROCCA D, 1991, CANCER RES, V51, P4994; PETERSON JA, 1995, CANCER RES, V55, pS5847; R Development Core Team, 2012, R LANG ENV STAT COMP; Shojaei F, 2012, J EXP CLIN CANC RES, V31, DOI 10.1186/1756-9966-31-26; Silvestre JS, 2005, NAT MED, V11, P499, DOI 10.1038/nm1233; STUBBS JD, 1990, P NATL ACAD SCI USA, V87, P8417, DOI 10.1073/pnas.87.21.8417; Sugano G, 2011, ONCOGENE, V30, P642, DOI 10.1038/onc.2010.446; Veron P, 2005, BLOOD CELL MOL DIS, V35, P81, DOI 10.1016/j.bcmd.2005.05.001; Yang CW, 2011, CANCER RES, V71, P937, DOI 10.1158/0008-5472.CAN-10-1471	24	34	37	1	18	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 16	2013	8	8							e72708	10.1371/journal.pone.0072708	http://dx.doi.org/10.1371/journal.pone.0072708			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	207BA	23977342	gold, Green Published, Green Submitted			2023-01-03	WOS:000323570200080
J	Ringshausen, FC; de Roux, A; Pletz, MW; Hamalainen, N; Welte, T; Rademacher, J				Ringshausen, Felix C.; de Roux, Andres; Pletz, Mathias W.; Haemaelaeinen, Nina; Welte, Tobias; Rademacher, Jessica			Bronchiectasis-Associated Hospitalizations in Germany, 2005-2011: A Population-Based Study of Disease Burden and Trends	PLOS ONE			English	Article							OBSTRUCTIVE PULMONARY-DISEASE; ORPHAN DISEASE; AZITHROMYCIN; COPD; EXACERBATIONS; PREVENTION	Background: Representative population-based data on the epidemiology of bronchiectasis in Europe are limited. The aim of the present study was to investigate the current burden and the trends of bronchiectasis-associated hospitalizations and associated conditions in Germany in order to inform focused patient care and to facilitate the allocation of healthcare resources. Methods: The nationwide diagnosis-related groups hospital statistics for the years 2005-2011 were used in order to identify hospitalizations with bronchiectasis as any hospital discharge diagnosis according to the International Classification of Diseases, 10th revision, code J47, (acquired) bronchiectasis. Poisson log-linear regression analysis was used to assess the significance of trends. In addition, the overall length of hospital stay (LOS) and the in-hospital mortality in comparison to the nationwide overall mortality due to bronchiectasis as the primary diagnosis was assessed. Results: Overall, 61,838 records with bronchiectasis were extracted from more than 125 million hospitalizations. The average annual age-adjusted rate for bronchiectasis as any diagnosis was 9.4 hospitalizations per 100,000 population. Hospitalization rates increased significantly during the study period, with the highest rate of 39.4 hospitalizations per 100,000 population among men aged 75-84 years and the most pronounced average annual increases among females. Besides numerous bronchiectasis-associated conditions, chronic obstructive pulmonary disease (COPD) was most frequently found in up to 39.2% of hospitalizations with bronchiectasis as the primary diagnosis. The mean LOS was comparable to that for COPD. Overall, only 40% of bronchiectasis-associated deaths occurred inside the hospital. Conclusions: The present study provides evidence of a changing epidemiology and a steadily increasing prevalence of bronchiectasis-associated hospitalizations. Moreover, it confirms the diversity of bronchiectasis-associated conditions and the possible association between bronchiectasis and COPD. As the major burden of disease may be managed out-of-hospital, prospective patient registries are needed to establish the exact prevalence of bronchiectasis according to the specific underlying condition.	[Ringshausen, Felix C.; Welte, Tobias; Rademacher, Jessica] Hannover Med Sch, Dept Resp Med, Hannover, Germany; [de Roux, Andres] Ctr Resp Med Charlottenburg Castle, Berlin, Germany; [Pletz, Mathias W.] Jena Univ Hosp, Ctr Infect Dis & Infect Control, Jena, Germany; [Haemaelaeinen, Nina] Inst Lung Res, Berlin, Germany	Hannover Medical School; Friedrich Schiller University of Jena	Ringshausen, FC (corresponding author), Hannover Med Sch, Dept Resp Med, Hannover, Germany.	Ringshausen.Felix@mh-hannover.de	Ringshausen, Felix C./AAA-9154-2021; Rademacher, Jessica/ABG-1898-2020; Pletz, Mathias Wilhelm/H-9782-2019	Ringshausen, Felix C./0000-0001-9084-4968; Pletz, Mathias Wilhelm/0000-0001-8157-2753	German Research Foundation (Deutsche Forschungsgemeinschaft, DFG); German Ministry of Education and Research (Bundesministerium fur Bildung und Forschung	German Research Foundation (Deutsche Forschungsgemeinschaft, DFG)(German Research Foundation (DFG)); German Ministry of Education and Research (Bundesministerium fur Bildung und Forschung(Federal Ministry of Education & Research (BMBF))	The authors acknowledge financial support for open access publishing by the German Research Foundation (Deutsche Forschungsgemeinschaft, DFG). MWP was supported by a grant from the German Ministry of Education and Research (Bundesministerium fur Bildung und Forschung), grant number 01KI1204. However, the funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Albert RK, 2011, NEW ENGL J MED, V365, P689, DOI 10.1056/NEJMoa1104623; Andres J, 2011, VERSORGUNGSBERICHT 2; Martinez-Garcia MA, 2011, CHEST, V140, P1130, DOI 10.1378/chest.10-1758; Bilton D, 2011, EUR RESPIR MONOGR, P1, DOI 10.1183/1025448x.10003110; European Centre for Disease Prevention and Control (ECDC)/WHO Regional Office for Europe, 2012, TUB SURV MON EUR 201; FIELD CE, 1969, ARCH DIS CHILD, V44, P551, DOI 10.1136/adc.44.237.551; Floto RA, 2011, EUROPEAN RESP MONOGR, V52; German Federal Statistical Office, 2013, FACTS FIG STAT SOC; Keistinen T, 1997, EUR RESPIR J, V10, P2784, DOI 10.1183/09031936.97.10122784; King Paul T, 2009, Int J Chron Obstruct Pulmon Dis, V4, P411; Kwak HJ, 2010, TOHOKU J EXP MED, V222, P237, DOI 10.1620/tjem.222.237; Landry JS, 2012, CHRON DIS INJ CAN, V33, P47; Martinez-Garcia MA, 2013, AM J RESP CRIT CARE, V187, P823, DOI 10.1164/rccm.201208-1518OC; Miravitiles M, 2013, EUR RESPIR J, V41, P1252, DOI 10.1183/09031936.00118912; O'Malley KJ, 2005, HEALTH SERV RES, V40, P1620, DOI 10.1111/j.1475-6773.2005.00444.x; Pasteur MC, 2010, THORAX, V65, pI1, DOI 10.1136/thx.2010.136119; Patel IS, 2004, AM J RESP CRIT CARE, V170, P400, DOI 10.1164/rccm.200305-648OC; Rademacher J, 2011, DTSCH ARZTEBL INT, V108, P809, DOI 10.3238/arztebl.2011.0809; Renna M, 2011, J CLIN INVEST, V121, P3554, DOI 10.1172/JCI46095; Robert Koch Institute and Federal Statistical Office, 2013, GERM FED HLTH MON SY; Saynajakangas O, 1997, RESP MED, V91, P395, DOI 10.1016/S0954-6111(97)90251-1; Seitz AE, 2012, CHEST, DOI 10.1378/chest.11-2209; Seitz AE, 2010, CHEST, V138, P944, DOI 10.1378/chest.10-0099; Shoemark A, 2007, RESP MED, V101, P1163, DOI 10.1016/j.rmed.2006.11.008; Tsang KW, 2004, INT J TUBERC LUNG D, V8, P691; Twiss J, 2005, ARCH DIS CHILD, V90, P737, DOI 10.1136/adc.2004.066472; Viviani L, 2012, EUROPEAN CYSTIC FIBR; Weycker D., 2005, Clinical Pulmonary Medicine, V12, P205, DOI 10.1097/01.cpm.0000171422.98696.ed; Wilson R, 2012, LANCET, V380, P627, DOI 10.1016/S0140-6736(12)61261-6; Wong C, 2012, LANCET, V380, P660, DOI 10.1016/S0140-6736(12)60953-2	30	97	98	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 1	2013	8	8							e71109	10.1371/journal.pone.0071109	http://dx.doi.org/10.1371/journal.pone.0071109			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	219PB	23936489	Green Submitted, Green Published, gold			2023-01-03	WOS:000324518400095
J	Wang, YH; Xiang, LM; Wang, CH; Tang, C; He, XJ				Wang, Yihai; Xiang, Limin; Wang, Chunhua; Tang, Chao; He, Xiangjiu			Antidiabetic and Antioxidant Effects and Phytochemicals of Mulberry Fruit (Morus alba L.) Polyphenol Enhanced Extract	PLOS ONE			English	Article							ALPHA-GLUCOSIDASE; FLAVONOID GLYCOSIDES; IN-VITRO; PHENOLICS; DEPSIDES; ANTHOCYANINS; INHIBITION; ALKALOIDS; AMYLASE; PARTS	The antidiabetic and antioxidant activities of the ethyl acetate-soluble extract (MFE) of mulberry fruit (Morus alba L.) were investigated. In vitro, MFE showed potent a-glucosidase inhibitory activity and radical-scavenging activities against DPPH and superoxide anion radicals. In vivo, MFE could significantly decrease fasting blood glucose (FBG) and glycosylated serum protein (GSP), and increase antioxidant enzymatic activities (SOD, CAT, GSH-Px) in streptozotocin (STZ)-induced diabetic mice. Bioactivity-guided fractionation of the MFE led to the isolation of 25 phenolic compounds, and their structures were identified on the basis of MS and NMR data. All the 25 compounds were isolated from mulberry fruit for the first time. Also, the a-glucosidase inhibitory activity and antioxidant activity of the phenolics were evaluated. Potent a-glucosidase inhibitory and radical-scavenging activities of these phenolics suggested that they may be partially responsible for the antidiabetic and antioxidant activities of mulberry fruit.	[Wang, Yihai; Xiang, Limin; Wang, Chunhua; Tang, Chao; He, Xiangjiu] Wuhan Univ, Sch Pharmaceut Sci, Wuhan 430072, Peoples R China	Wuhan University	He, XJ (corresponding author), Wuhan Univ, Sch Pharmaceut Sci, Wuhan 430072, Peoples R China.	hexiangjiu@whu.edu.cn	Wang, Yihai/L-7462-2019; He, Xiangjiu/M-4008-2016	He, Xiangjiu/0000-0002-1631-7657				ARMBRUSTER DA, 1987, CLIN CHEM, V33, P2153; Asano N, 2001, J AGR FOOD CHEM, V49, P4208, DOI 10.1021/jf010567e; BENNINI B, 1992, PHYTOCHEMISTRY, V31, P2483, DOI 10.1016/0031-9422(92)83305-I; Bettaieb I, 2010, J AGR FOOD CHEM, V58, P10410, DOI 10.1021/jf102248j; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chen CC, 2005, FOOD CHEM, V91, P601, DOI 10.1016/j.foodchem.2004.06.039; DELLEMONACHE G, 1995, PHYTOCHEMISTRY, V39, P575, DOI 10.1016/0031-9422(94)00971-U; El Mousallami AMD, 2002, PHYTOCHEMISTRY, V60, P807, DOI 10.1016/S0031-9422(02)00177-2; Ranilla LG, 2010, BIORESOURCE TECHNOL, V101, P4676, DOI 10.1016/j.biortech.2010.01.093; Granica S, 2013, J AGR FOOD CHEM, V61, P801, DOI 10.1021/jf304002h; Hillenbrand M, 2004, PLANTA MED, V70, P380, DOI 10.1055/s-2004-818956; Hong JungHee, 2004, Nutritional Sciences, V7, P127; Huang HP, 2008, J AGR FOOD CHEM, V56, P9286, DOI 10.1021/jf8013102; Jeong JC, 2010, NUTR CANCER, V62, P402, DOI 10.1080/01635580903441287; Kang MH, 2012, J AGR FOOD CHEM, V60, P2517, DOI 10.1021/jf205086b; Kang TH, 2006, NEUROSCI LETT, V391, P122, DOI 10.1016/j.neulet.2005.08.053; Kerem Z, 2006, J AGR FOOD CHEM, V54, P1243, DOI 10.1021/jf052436+; Kim HG, 2010, BRIT J NUTR, V104, P8, DOI 10.1017/S0007114510000218; KIM MN, 1992, PLANTA MED, V58, P285, DOI 10.1055/s-2006-961460; Kim SB, 2013, J ETHNOPHARMACOL, V145, P393, DOI 10.1016/j.jep.2012.11.007; Kishore PH, 2003, CHEM PHARM BULL, V51, P194, DOI 10.1248/cpb.51.194; LARSON RA, 1988, PHYTOCHEMISTRY, V27, P969, DOI 10.1016/0031-9422(88)80254-1; Li T., 2005, CHINESE J CLIN PHARM, V10, P1129; Liu LK, 2009, J AGR FOOD CHEM, V57, P7605, DOI 10.1021/jf9014697; Lv PC, 2010, J ENZYM INHIB MED CH, V25, P590, DOI 10.3109/14756360903357551; Mai TT, 2007, J NUTR SCI VITAMINOL, V53, P267, DOI 10.3177/jnsv.53.267; MARKHAM KR, 1984, PHYTOCHEMISTRY, V23, P2049, DOI 10.1016/S0031-9422(00)84968-7; MERFORT I, 1987, PLANTA MED, P434, DOI 10.1055/s-2006-962766; Orhan DD, 2003, PHARM BIOL, V41, P475, DOI 10.1080/13880200308951337; Orhan N, 2006, J ETHNOPHARMACOL, V108, P280, DOI 10.1016/j.jep.2006.05.010; OYANAGUI Y, 1984, ANAL BIOCHEM, V142, P290; Pehluvan M, 2012, J ANIM PLANT SCI, V22, P665; Pistelli L, 1996, PHYTOCHEMISTRY, V42, P1455, DOI 10.1016/0031-9422(96)00128-8; Rao RJ, 2003, BIOORG MED CHEM LETT, V13, P2777, DOI 10.1016/S0960-894X(03)00494-3; Reis B, 2010, J AGR FOOD CHEM, V58, P6986, DOI 10.1021/jf100569j; Reynertson KA, 2006, J NAT PROD, V69, P1228, DOI 10.1021/np0600999; Ryu HW, 2010, J AGR FOOD CHEM, V58, P202, DOI 10.1021/jf903068k; SATO Y, 1979, BIOCHEM MED METAB B, V21, P104, DOI 10.1016/0006-2944(79)90061-9; SEDLAK J, 1968, ANAL BIOCHEM, V25, P192, DOI 10.1016/0003-2697(68)90092-4; Seyoum A, 2006, PHYTOCHEMISTRY, V67, P2058, DOI 10.1016/j.phytochem.2006.07.002; Sharma R, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013463; SHEN Z, 1985, PHYTOCHEMISTRY, V24, P155, DOI 10.1016/S0031-9422(00)80826-2; Sroka Z, 2003, FOOD CHEM TOXICOL, V41, P753, DOI 10.1016/S0278-6915(02)00329-0; Tadera K, 2006, J NUTR SCI VITAMINOL, V52, P149, DOI 10.3177/jnsv.52.149; Turner A, 2007, J NAT PROD, V70, P253, DOI 10.1021/np060260f; Valentao P, 2001, J AGR FOOD CHEM, V49, P3476, DOI 10.1021/jf001145s; Velioglu YS, 1998, J AGR FOOD CHEM, V46, P4113, DOI 10.1021/jf9801973; Wang H, 2010, FOOD CHEM, V123, P6, DOI 10.1016/j.foodchem.2010.03.088; Wolfe K, 2003, J AGR FOOD CHEM, V51, P609, DOI 10.1021/jf020782a; Wu T, 2008, CHEM NAT COMPD+, V44, P370, DOI 10.1007/s10600-008-9067-2; Wurms K. V., 2006, Asian Journal of Biochemistry, V1, P325; Yang XL, 2010, FOOD CHEM TOXICOL, V48, P2374, DOI 10.1016/j.fct.2010.05.074; Yao Sheng, 2005, Chinese Journal of Natural Medicines, V3, P219; Zhang W, 2008, J FOOD SCI, V73, pC512, DOI 10.1111/j.1750-3841.2008.00854.x	54	156	171	5	119	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 30	2013	8	7							e71144	10.1371/journal.pone.0071144	http://dx.doi.org/10.1371/journal.pone.0071144			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	201AX	23936259	Green Published, Green Submitted, gold			2023-01-03	WOS:000323114200112
J	Wu, JH; Zhu, SH; Yao, GL; Mohammed, MA; Marshall, T				Wu, Jianhua; Zhu, Shihua; Yao, Guiqing Lily; Mohammed, Mohammed A.; Marshall, Tom			Patient Factors Influencing the Prescribing of Lipid Lowering Drugs for Primary Prevention of Cardiovascular Disease in UK General Practice: A National Retrospective Cohort Study	PLOS ONE			English	Article							CORONARY-HEART-DISEASE; MULTIVARIATE PREDICTION; EUROPEAN GUIDELINES; HEALTH-CARE; CHOLESTEROL; RISK; HYPERCHOLESTEROLEMIA; UNDERTREATMENT; POPULATION; MANAGEMENT	Background: Guidelines indicate eligibility for lipid lowering drugs, but it is not known to what extent GPs' follow guidelines in routine clinical practice or whether additional clinical factors systematically influence their prescribing decisions. Methods: A retrospective cohort analysis was undertaken using electronic primary care records from 421 UK general practices. At baseline (May 2008) patients were aged 30 to 74 years, free from cardiovascular disease and not taking lipid lowering drugs. The outcome was prescription of a lipid lowering drug within the next two years. The proportions of eligible and ineligible patients prescribed lipid lowering drugs were reported and multivariable logistic regression models were used to investigate associations between age, sex, cardiovascular risk factors and prescribing. Results: Of 365,718 patients with complete data, 13.8% (50,558) were prescribed lipid lowering drugs: 28.5% (21,101/74,137) of those eligible and 10.1% (29,457/291,581) of those ineligible. Only 41.7% (21,101/50,558) of those prescribed lipid lowering drugs were eligible. In multivariable analysis prescribing was most strongly associated with increasing age (OR for age >= 65 years 4.21; 95% CI 4.05-4.39); diabetes (OR 4.49; 95% CI 4.35-4.64); total cholesterol level >= 7 mmol/L (OR 2.20; 95% CI 2.12-2.29); and >= 4 blood pressure measurements in the past year (OR 4.24; 95% CI 4.06-4.42). The predictors were similar in eligible and ineligible patients. Conclusions: Most lipid lowering drugs for primary prevention are prescribed to ineligible patients. There is underuse of lipid lowering drugs in eligible patients.	[Wu, Jianhua] Univ London, Ctr Environm & Prevent Med, Barts & London Sch Med & Dent, London, England; [Zhu, Shihua; Mohammed, Mohammed A.; Marshall, Tom] Univ Birmingham, Sch Publ Hlth & Populat Sci, Birmingham, W Midlands, England; [Yao, Guiqing Lily] Univ Southampton, Fac Med, Southampton SO9 5NH, Hants, England	University of London; Queen Mary University London; University of Birmingham; University of Southampton	Marshall, T (corresponding author), Univ Birmingham, Sch Publ Hlth & Populat Sci, Birmingham, W Midlands, England.	t.p.marshall@bham.ac.uk	Wu, Jianhua/G-1080-2019	Wu, Jianhua/0000-0001-6093-599X; Marshall, Tom/0000-0001-9277-5214	National Institute for Health Research (NIHR) through the Collaborations for Leadership in Applied Health Research and Care for Birmingham and Black Country (CLAHRC-BBC) programme	National Institute for Health Research (NIHR) through the Collaborations for Leadership in Applied Health Research and Care for Birmingham and Black Country (CLAHRC-BBC) programme(National Institute for Health Research (NIHR))	Tom Marshall, Guiqing Lily Yao and Jianhua Wu were partly funded by the National Institute for Health Research (NIHR) through the Collaborations for Leadership in Applied Health Research and Care for Birmingham and Black Country (CLAHRC-BBC) programme. The views expressed in this publication are not necessarily those of the NIHR, the Department of Health, NHS Partner Trusts, University of Birmingham or the CLAHRC-BBC Management Group. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abookire SA, 2001, ARCH INTERN MED, V161, P53, DOI 10.1001/archinte.161.1.53; ANDERSON KM, 1991, AM HEART J, V121, P293, DOI 10.1016/0002-8703(91)90861-B; [Anonymous], 2012, PRESCR COST AN ENGL; [Anonymous], 2012, CEG STRAT DAT; Ashworth M, 2007, J PUBLIC HEALTH-UK, V29, P40, DOI 10.1093/pubmed/fdl068; ASSMANN G, 1990, AM J CARDIOL, V65, pF11, DOI 10.1016/0002-9149(90)91248-5; Barham Ann Hiott, 2009, Prev Cardiol, V12, P95, DOI 10.1111/j.1751-7141.2008.00019.x; BLACKBURN H, 1974, NEW ENGL J MED, V290, P1315, DOI 10.1056/NEJM197406062902310; BRAND RJ, 1976, CIRCULATION, V53, P348, DOI 10.1161/01.CIR.53.2.348; Bryan S, 2006, SOC SCI MED, V63, P2698, DOI 10.1016/j.socscimed.2006.07.008; Christian AH, 2006, J GEN INTERN MED, V21, P231, DOI 10.1111/j.1525-1497.2006.00331.x; CLEEMAN JI, 1988, ARCH INTERN MED, V148, P36, DOI 10.1001/archinte.148.1.36; Conroy RM, 2003, EUR HEART J, V24, P987, DOI 10.1016/S0195-668X(03)00114-3; De Backer G, 2003, EUR HEART J, V24, P1601, DOI 10.1016/S0195-668X(03)00347-6; Downs JR, 1998, JAMA-J AM MED ASSOC, V279, P1615, DOI 10.1001/jama.279.20.1615; Forde I, 2011, ATHEROSCLEROSIS, V215, P223, DOI 10.1016/j.atherosclerosis.2010.12.012; Frohlich J, 1998, CAN J CARDIOL, V14, p17A; Getz L, 2003, BMJ-BRIT MED J, V327, P498, DOI 10.1136/bmj.327.7413.498; Goldstein JL, 1983, METABOLIC BASIS INHE, P672; Grundy SM, 2002, CIRCULATION, V106, P3143, DOI 10.1161/circ.106.25.3143; Gumbs PD, 2006, DRUG AGING, V23, P733, DOI 10.2165/00002512-200623090-00003; HAQ IU, 1995, LANCET, V346, P1467, DOI 10.1016/S0140-6736(95)92477-9; KANNEL WB, 1976, AM J CARDIOL, V38, P46, DOI 10.1016/0002-9149(76)90061-8; KEYS A, 1972, CIRCULATION, V45, P815, DOI 10.1161/01.CIR.45.4.815; Krum H, 2001, MED J AUSTRALIA, V194, pS57; Lopez-Carmona D, 2012, EUR J PREV CARDIOL, V19, P1074, DOI 10.1177/1741826711418166; Ma J, 2005, PLOS MED, V2, P434, DOI 10.1371/journal.pmed.0020123; Macklin J, 2011, SCOT MED J, V56, P33, DOI 10.1258/smj.2010.010016; Maguire A, 2009, PHARMACOEPIDEM DR S, V18, P76, DOI 10.1002/pds.1688; Mantel-Teeuwisse AK, 2003, BRIT J CLIN PHARMACO, V55, P389, DOI 10.1046/j.1365-2125.2003.01769.x; Marshall T, 2006, HEART, V92, P1651, DOI 10.1136/hrt.2005.072405; Marston L, 2010, PHARMACOEPIDEM DR S, V19, P618, DOI 10.1002/pds.1934; McBride P, 1998, ARCH INTERN MED, V158, P1238, DOI 10.1001/archinte.158.11.1238; Menotti A, 1975, G Ital Cardiol, V5, P843; Mohammed MA, 2012, MED DECIS MAKING, V32, P498, DOI 10.1177/0272989X12437246; Montgomery AA, 2001, FAM PRACT, V18, P309, DOI 10.1093/fampra/18.3.309; National Institute for Clinical Excellence, 2008, CLIN GUID EV REV LIP; National Institute for Clinical Excellence, 2008, CG71 FAM HYP NICE GU; National Institute for Clinical Excellence, 2008, TYP 2 DIAB CLIN GUID; Ohlsson H, 2009, PHARMACOEPIDEM DR S, V18, P682, DOI 10.1002/pds.1767; PAGE IH, 1970, CIRCULATION, V42, P625, DOI 10.1161/01.CIR.42.4.625; PEDERSEN TR, 1994, LANCET, V344, P1383; Petursson H, 2009, BMC FAM PRACT, V10, DOI 10.1186/1471-2296-10-70; RICHARD JL, 1977, ARCH MAL COEUR VAISS, V70, P531; Roumie CL, 2007, JT COMM J QUAL PATIE, V33, P277, DOI 10.1016/S1553-7250(07)33032-8; Sacks FM, 1996, NEW ENGL J MED, V335, P1001, DOI 10.1056/NEJM199610033351401; Scottish Intercollegiate Guidelines Network SIGN 97, 2007, RISK EST PREV CARD D; Selmer R, 2009, BRIT J CLIN PHARMACO, V67, P355, DOI 10.1111/j.1365-2125.2008.03360.x; SHEPHERD J, 1987, BRIT MED J, V295, P1245, DOI 10.1136/bmj.295.6608.1245; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001; Stafford L, 2009, AUST FAM PHYSICIAN, V38, P739; Taylor F, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004816.pub5; Tonstad S, 2004, J INTERN MED, V255, P494, DOI 10.1111/j.1365-2796.2004.01315.x; Townsend PP., 1988, HLTH DEPRIVATION INE; van Duijn HJ, 2011, BRIT J GEN PRACT, V61, DOI 10.3399/bjgp11X578025; Verma A, 2012, SOUTH MED J, V105, P329, DOI 10.1097/SMJ.0b013e318259bad3; Vinogradova Y., 2009, TRENDS CONSULTATION; Weinstein M C, 1978, Ann N Y Acad Sci, V304, P424, DOI 10.1111/j.1749-6632.1978.tb25625.x; WILLIAMS RR, 1993, AM J CARDIOL, V72, P171, DOI 10.1016/0002-9149(93)90155-6; WOLFE BMJ, 1990, CAN MED ASSOC J, V142, P1371; Wood D, 2005, HEART, V91, P1, DOI 10.1136/hrt.2005.079988; Wood D, 1998, HEART S2, V80	64	39	39	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 26	2013	8	7							e67611	10.1371/journal.pone.0067611	http://dx.doi.org/10.1371/journal.pone.0067611			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	197GU	23922649	Green Published, Green Submitted, gold, Green Accepted			2023-01-03	WOS:000322838900005
J	Kumar, C; Rai, RK; Singh, PK; Singh, L				Kumar, Chandan; Rai, Rajesh Kumar; Singh, Prashant Kumar; Singh, Lucky			Socioeconomic Disparities in Maternity Care among Indian Adolescents, 1990-2006	PLOS ONE			English	Article							HEALTH-CARE; CHILD HEALTH; WOMEN; DIFFERENTIALS; SERVICES	Background: India, with a population of more than 1.21 billion, has the highest maternal mortality in the world (estimated to be 56000 in 2010); and adolescent (aged 15-19) mortality shares 9% of total maternal deaths. Addressing the maternity care needs of adolescents may have considerable ramifications for achieving the Millennium Development Goal (MDG)-5. This paper assesses the socioeconomic differentials in accessing full antenatal care and professional attendance at delivery by adolescent mothers (aged 15-19) in India during 1990-2006. Methods and Findings: Data from three rounds of the National Family Health Survey of India conducted during 1992-93, 1998-99, and 2005-06 were analyzed. The Cochran-Armitage and Chi-squared test for linear and non-linear time trends were applied, respectively, to understand the trend in the proportion of adolescent mothers utilizing select maternity care services during 1990-2006. Using pooled multivariate logistic regression models, the probability of select maternal healthcare utilization among women by key socioeconomic characteristics was appraised. After adjusting for potential socio-demographic and economic characteristics, the likelihood of adolescents accessing full antenatal care increased by only 4% from 1990 to 2006. However, the probability of adolescent women availing themselves of professional attendance at delivery increased by 79% during the same period. The study also highlights the desolate disparities in maternity care services among adolescents across the most and the least favoured groups. Conclusion: Maternal care interventions in India need focused programs for rural, uneducated, poor adolescent women so that they can avail themselves of measures to delay child bearing, and for better antenatal consultation and delivery care in case of pregnancy. This study strongly advocates the promotion of a comprehensive 'adolescent scheme' along the lines of 'Continuum of Maternal, Newborn and Child health Care' to address the unmet need of reproductive and maternal healthcare services among adolescent women in India.	[Kumar, Chandan] IITR, Dept Humanities & Social Sci, Roorkee, Uttarakhand, India; [Rai, Rajesh Kumar] TISS, Bombay, Maharashtra, India; [Singh, Prashant Kumar] IIPS, Bombay, Maharashtra, India; [Singh, Lucky] TISS, Sch Hlth Syst Studies, Bombay, Maharashtra, India	Indian Institute of Technology System (IIT System); Indian Institute of Technology (IIT) - Roorkee; Tata Institute of Social Sciences; International Institute for Population Sciences; Tata Institute of Social Sciences	Kumar, C (corresponding author), IITR, Dept Humanities & Social Sci, Roorkee, Uttarakhand, India.	c.kumar803@gmail.com	Kumar, Chandan/AAS-4525-2020	Kumar, Chandan/0000-0002-2351-2442; Singh, Lucky/0000-0003-2590-6135; Singh, Prashant Kumar/0000-0003-1742-5534; Rai, Rajesh Kumar/0000-0002-5249-9937				Agha S, 2011, INT J EQUITY HEALTH, V10, DOI 10.1186/1475-9276-10-31; Amin R, 2010, INT J EQUITY HEALTH, V9, DOI 10.1186/1475-9276-9-9; Andrade MV, 2012, HEALTH PLACE, V18, P942, DOI 10.1016/j.healthplace.2012.06.014; Armitage P., 2002, STAT METHODS MED RES, V4th; Bhutta ZA, 2012, INT J GYNECOL OBSTET, V119, pS13, DOI 10.1016/j.ijgo.2012.04.001; Commission on the Social Determinants of Health, 2008, CLOS GAP GEN HLTH EQ; Corsi DJ, 2012, SOC SCI MED, V75, P311, DOI 10.1016/j.socscimed.2012.02.014; Dangal G., 2005, INTERNET J GYNECOLOG, V5, P13; Fotso Jean-Christophe, 2006, Int J Equity Health, V5, P9, DOI 10.1186/1475-9276-5-9; Fotso JC, 2007, HEALTH PLACE, V13, P205, DOI 10.1016/j.healthplace.2006.01.004; Government of India, 2006, JAN SURK YOJ; Government of India, 2011, MAT MORT IND 2007 09; Hampton T, 2010, JAMA-J AM MED ASSOC, V304, P509, DOI 10.1001/jama.2010.1009; Howe LD, 2009, J EPIDEMIOL COMMUN H, V63, P871, DOI 10.1136/jech.2009.088021; *INT I POP SCI, 2000, NAT FAM HLTH SURV IN; International Institute for Population Sciences, 2010, DISTR LEV HOUS FAC S; International Institute for Population Sciences ORC Macro, 2007, NAT FAM HLTH SURV IN; International Institute of Population Sciences, 1995, NAT FAM HLTH SURV IN; James KS, 2011, SCIENCE, V333, P576, DOI 10.1126/science.1207969; Jeffrey C, 2001, T I BRIT GEOGR, V26, P217, DOI 10.1111/1475-5661.00016; Jensen R., 2003, GENDER DEV, V11, P9, DOI DOI 10.1080/741954311; KORN EL, 1990, AM STAT, V44, P270, DOI 10.2307/2684345; Kumar C, 2013, J COMMUN HEALTH, V38, P120, DOI 10.1007/s10900-012-9590-8; LEGRAND TK, 1993, STUD FAMILY PLANN, V24, P137, DOI 10.2307/2939229; Machel G, 2012, WASHINGTON POST; Mavalankar DV, 2005, AM J PUBLIC HEALTH, V95, P200, DOI 10.2105/AJPH.2003.036715; Ministry of Health and Family Welfare, 2010, RUR HLTH STAT IND 20; Mishra V, 2004, POPUL DEV REV, V30, P269, DOI 10.1111/j.1728-4457.2004.013_1.x; Navaneetham K, 2002, SOC SCI MED, V55, P1849, DOI 10.1016/S0277-9536(01)00313-6; Ogunlesi TA, 2012, MATERN CHILD HLTH J, V16, P677, DOI 10.1007/s10995-011-0765-1; Pallikadavath S, 2004, SOC SCI MED, V59, P1147, DOI 10.1016/j.socscimed.2003.11.045; Paul VK, 2011, LANCET, V377, P332, DOI 10.1016/S0140-6736(10)61492-4; Paxton A, 2011, NEW ENGL J MED, V364, P1990, DOI 10.1056/NEJMp1012860; Planning Commission, 2011, HIGH LEV EXP GROUP R; Rai RK, 2015, ASIA-PAC J PUBLIC HE, V27, pNP1161, DOI [10.1177/1010539512436883, 10.1177/101053951]; Rai RK, 2013, J PUBLIC HEALTH-HEID, V21, P379, DOI 10.1007/s10389-012-0551-6; Rai RK, 2012, WOMEN HEALTH ISS, V22, pE407, DOI 10.1016/j.whi.2012.05.001; Raj A, 2009, LANCET, V373, P1883, DOI 10.1016/S0140-6736(09)60246-4; RAO JNK, 1984, ANN STAT, V12, P46, DOI 10.1214/aos/1176346391; Reddy KS, 2012, NATL MED J INDIA, V25, P65; Ronsmans C, 2006, LANCET, V368, P1189, DOI 10.1016/S0140-6736(06)69380-X; Santhya KG, 2008, EARLY MARRIAGE SEXUA; Singh L, 2012, J BIOSOC SCI, V44, P1, DOI 10.1017/S0021932011000472; Singh PK, 2014, HEALTH POLICY PLANN, V29, P542, DOI 10.1093/heapol/czt039; Singh PK, 2013, J PUBLIC HEALTH-HEID, V21, P15, DOI 10.1007/s10389-012-0516-9; Singh PK, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044901; Singh PK, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031666; Statacorp, 2007, STAT STAT SOFTW REL; Subramanyam MA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011392; United Nations, 2011, STESASERA303 UN DEP; Vyas S, 2006, HEALTH POLICY PLANN, V21, P459, DOI 10.1093/heapol/czl029; World Health Organization, 2012, RIO POL DECL SOC DET; World Health Organization United Nations Children's Fund, 2012, COUNT DOWN 2015 MAT; World Health Organization (WHO), 2012, TRENDS MAT MORT 1990; World Health Organization(WHO), 2006, PROV EFF ANT CAR INT	55	8	9	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 23	2013	8	7							e69094	10.1371/journal.pone.0069094	http://dx.doi.org/10.1371/journal.pone.0069094			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	228SX	23894412	Green Published, gold, Green Submitted			2023-01-03	WOS:000325211000076
J	Al Dhaheri, Y; Attoub, S; Arafat, K; AbuQamar, S; Viallet, J; Saleh, A; Al Agha, H; Eid, A; Iratni, R				Al Dhaheri, Yusra; Attoub, Samir; Arafat, Kholoud; AbuQamar, Synan; Viallet, Jean; Saleh, Alaaeldin; Al Agha, Hala; Eid, Ali; Iratni, Rabah			Anti-Metastatic and Anti-Tumor Growth Effects of Origanum majorana on Highly Metastatic Human Breast Cancer Cells: Inhibition of NF kappa B Signaling and Reduction of Nitric Oxide Production	PLOS ONE			English	Article							E-CADHERIN EXPRESSION; MATRIX METALLOPROTEINASES; TUMOR-GROWTH; PHOSPHATIDYLINOSITOL 3-KINASE; INVASIVE GROWTH; E-SELECTIN; IN-VITRO; MDA-MB-231; ANGIOGENESIS; MIGRATION	Background: We have recently reported that Origanum majorana exhibits anticancer activity by promoting cell cycle arrest and apoptosis of the metastatic MDA-MB-231 breast cancer cell line. Here, we extended our study by investigating the effect of O. majorana on the migration, invasion and tumor growth of these cells. Results: We demonstrate that non-cytotoxic concentrations of O. majorana significantly inhibited the migration and invasion of the MDA-MB-231 cells as shown by wound-healing and matrigel invasion assays. We also show that O. majorana induce homotypic aggregation of MDA-MB-231 associated with an upregulation of E-cadherin protein and promoter activity. Furthermore, we show that O. majorana decrease the adhesion of MDA-MB-231 to HUVECs and inhibits transendothelial migration of MDA-MB-231 through TNF-alpha-activated HUVECs. Gelatin zymography assay shows that O. majorana suppresses the activities of matrix metalloproteinase-2 and -9 (MMP-2 and MMP-9). ELISA, RT-PCR and Western blot results revealed that O. majorana decreases the expression of MMP-2, MMP-9, urokinase plasminogen activator receptor (uPAR), ICAM-1 and VEGF. Further investigation revealed that O. majorana suppresses the phosphorylation of I kappa B, downregulates the nuclear level of NF kappa B and reduces Nitric Oxide (NO) production in MDA-MB-231 cells. Most importantly, by using chick embryo tumor growth assay, we also show that O. majorana promotes inhibition of tumor growth and metastasis in vivo. Conclusion: Our findings identify Origanum majorana as a promising chemopreventive and therapeutic candidate that modulate breast cancer growth and metastasis.	[Al Dhaheri, Yusra; AbuQamar, Synan; Iratni, Rabah] United Arab Emirates Univ, Coll Sci, Dept Biol, Alabama, Ain, U Arab Emirates; [Attoub, Samir; Arafat, Kholoud] United Arab Emirates Univ, Fac Med & Hlth Sci, Dept Pharmacol & Therapeut, Alabama, Ain, U Arab Emirates; [Viallet, Jean] Univ Grenoble 1, INSERM, U823, Grenoble, France; [Saleh, Alaaeldin; Al Agha, Hala; Eid, Ali] Qatar Univ, Coll Arts & Sci, Dept Biol & Environm Sci, Doha, Qatar	United Arab Emirates University; United Arab Emirates University; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Qatar University	Eid, A (corresponding author), Qatar Univ, Coll Arts & Sci, Dept Biol & Environm Sci, Doha, Qatar.	ali.eid@qu.edu.qa; R_iratni@uaeu.ac.ae	Eid, Ali Hussein/ABD-6291-2021; Attoub, Samir/N-6852-2018; AbuQamar, Synan/AAV-1229-2021	Eid, Ali Hussein/0000-0003-3004-5675; AbuQamar, Synan/0000-0002-2129-7689; Viallet, Jean/0000-0003-1137-0093	College of Science (UAEU); Terry Fox research grant	College of Science (UAEU); Terry Fox research grant	This work was supported by the College of Science (UAEU) interdisciplinary research grant to RI and by a Terry Fox research grant to SA. The funders had no role in study design, data collection, and analysis, decision to publish, or preparation of the manuscript.	Adams LS, 2010, CANCER RES, V70, P3594, DOI 10.1158/0008-5472.CAN-09-3565; Al Dhaheri Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056649; Al-Harbi NO, 2011, J MED PLANTS RES, V5, P5479; Ambs S, 1998, NAT MED, V4, P1371, DOI 10.1038/3957; Attoub S, 2011, EUR J PHARMACOL, V651, P18, DOI 10.1016/j.ejphar.2010.10.063; Bachmeier BE, 2001, ANTICANCER RES, V21, P3821; Baranwal S, 2009, BIOCHEM BIOPH RES CO, V384, P6, DOI 10.1016/j.bbrc.2009.04.051; Berx G, 1995, EMBO J, V14, P6107, DOI 10.1002/j.1460-2075.1995.tb00301.x; Bigelow RLH, 2006, ONCOGENE, V25, P1922, DOI 10.1038/sj.onc.1209227; BROWN LF, 1993, CANCER RES, V53, P4727; Cao Q, 2008, ONCOGENE, V27, P7274, DOI 10.1038/onc.2008.333; Corn PG, 2000, CLIN CANCER RES, V6, P4243; El-Ashmawy IM, 2005, BASIC CLIN PHARMACOL, V97, P238, DOI 10.1111/j.1742-7843.2005.pto_136.x; Garbett EA, 2000, J CLIN PATHOL-MOL PA, V53, P99, DOI 10.1136/mp.53.2.99; Gialeli C, 2011, FEBS J, V278, P16, DOI 10.1111/j.1742-4658.2010.07919.x; Glynn SA, 2010, J CLIN INVEST, V120, P3843, DOI 10.1172/JCI42059; Green CE, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006713; Gu YH, 2006, ONCOL REP, V15, P417; Jadeski LC, 2000, INT J CANCER, V86, P30, DOI 10.1002/(SICI)1097-0215(20000401)86:1<30::AID-IJC5>3.0.CO;2-I; Jiang JH, 2008, INT J MOL MED, V21, P577; Kerbel R, 2002, NAT REV CANCER, V2, P727, DOI 10.1038/nrc905; Kerbel RS, 2006, SCIENCE, V312, P1171, DOI 10.1126/science.1125950; Kim NH, 2011, BIOCHEM BIOPH RES CO, V404, P915, DOI 10.1016/j.bbrc.2010.12.081; KLEINER DE, 1994, ANAL BIOCHEM, V218, P325, DOI 10.1006/abio.1994.1186; KOCH AE, 1995, NATURE, V376, P517, DOI 10.1038/376517a0; Kowalski PJ, 2003, BREAST CANCER RES, V5, pR217, DOI 10.1186/bcr651; Kuno T., 2012, Journal of Biophysical Chemistry, V3, P156, DOI 10.4236/jbpc.2012.32018; Lee HS, 2008, J NUTR BIOCHEM, V19, P313, DOI 10.1016/j.jnutbio.2007.05.008; Lee WJ, 2008, TOXICOL APPL PHARM, V226, P178, DOI 10.1016/j.taap.2007.09.013; Lee YJ, 2012, EUR J MED CHEM, V56, P361, DOI 10.1016/j.ejmech.2012.07.041; Leeja L, 2007, J ENVIRON BIOL, V28, P145; Lerebours F, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-41; Li CJ, 2013, CELL BIOCHEM FUNCT, V31, P263, DOI 10.1002/cbf.2899; Li FN, 2012, TOXICOL APPL PHARM, V261, P217, DOI 10.1016/j.taap.2012.04.011; Ling H, 2010, BRIT J PHARMACOL, V161, P1763, DOI 10.1111/j.1476-5381.2010.00991.x; LIOTTA LA, 1980, NATURE, V284, P67, DOI 10.1038/284067a0; Liu YN, 2005, ONCOGENE, V24, P8277, DOI 10.1038/sj.onc.1208991; MEROMSKY L, 1986, CANCER RES, V46, P5270; Miron TL, 2011, J CHROMATOGR A, V1218, P4918, DOI 10.1016/j.chroma.2010.11.055; Mohammadizadeh F, 2009, CANCER BIOMARK, V5, P1, DOI 10.3233/CBM-2009-0551; Muntane J, 2010, WORLD J HEPATOL, V2, P337, DOI 10.4254/wjh.v2.i9.337; Nizamutdinova IT, 2008, CARCINOGENESIS, V29, P1885, DOI 10.1093/carcin/bgn151; NOVAK U, 1991, NUCLEIC ACIDS RES, V19, P3389, DOI 10.1093/nar/19.12.3389; Pacheco MM, 1998, CLIN EXP METASTAS, V16, P577, DOI 10.1023/A:1006580415796; Park JS, 2009, ANTICANCER RES, V29, P355; PERKINS ND, 2012, NAT REV CANCER, V12, P21131; Prudent R, 2013, BRIT J PHARMACOL, V168, P673, DOI 10.1111/j.1476-5381.2012.02230.x; Przybylowska K, 2006, BREAST CANCER RES TR, V95, P65, DOI 10.1007/s10549-005-9042-6; Relf M, 1997, CANCER RES, V57, P963; Reuben SC, 2012, MOL NUTR FOOD RES, V56, P14, DOI 10.1002/mnfr.201100619; Rose P, 2005, TOXICOL APPL PHARM, V209, P105, DOI 10.1016/j.taap.2005.04.010; Rosette C, 2005, CARCINOGENESIS, V26, P943, DOI 10.1093/carcin/bgi070; Schroder C, 2011, J CANCER RES CLIN, V137, P1193, DOI 10.1007/s00432-011-0984-2; Sliva D, 2002, BIOCHEM BIOPH RES CO, V298, P603, DOI 10.1016/S0006-291X(02)02496-8; Sliva D, 2002, J BIOL CHEM, V277, P3150, DOI 10.1074/jbc.M109579200; Switzer CH, 2011, TRENDS PHARMACOL SCI, V32, P644, DOI 10.1016/j.tips.2011.07.001; Teiten MH, 2010, GENES NUTR, V5, P61, DOI 10.1007/s12263-009-0152-3; Tsimogiannis D, 2006, INT J FOOD SCI TECH, V41, P39, DOI 10.1111/j.1365-2621.2006.01259.x; Vagi E, 2005, J AGR FOOD CHEM, V53, P17, DOI 10.1021/jf048777p; Vakkala M, 2000, CLIN CANCER RES, V6, P2408; Wang AY, 2000, EUR J BIOCHEM, V267, P3248, DOI 10.1046/j.1432-1327.2000.01350.x; Wang C, 2003, CHEM RES TOXICOL, V16, P1004, DOI 10.1021/tx0340448; Yachida S, 2010, NATURE, V467, P1114, DOI 10.1038/nature09515; Yang HL, 2011, FOOD CHEM TOXICOL, V49, P290, DOI 10.1016/j.fct.2010.10.031; Yodkeeree S, 2010, EUR J PHARMACOL, V627, P8, DOI 10.1016/j.ejphar.2009.09.052; Zen K, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001826	66	46	48	0	24	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 10	2013	8	7							e68808	10.1371/journal.pone.0068808	http://dx.doi.org/10.1371/journal.pone.0068808			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	182SU	23874773	Green Submitted, Green Published, gold			2023-01-03	WOS:000321765300067
J	Gao, FS; Feng, L; Zhang, Q; Yan, RQ; Li, YG; Li, XS				Gao, Feng-Shan; Feng, Lei; Zhang, Qiang; Yan, Ruo-qian; Li, Yun-Gang; Li, Xin-sheng			Immunogenicity of Two FMDV Nonameric Peptides Encapsulated in Liposomes in Mice and the Protective Efficacy in Guinea Pigs	PLOS ONE			English	Article							MOUTH-DISEASE VIRUS; CYTOTOXIC T-LYMPHOCYTES; IMMUNE-RESPONSE; BINDING PREDICTION; CELL EPITOPES; CTL EPITOPE; IN-VIVO; IMMUNODOMINANT; COMPLEX; IMMUNIZATION	It has been predicted that nonameric peptides I (VP1(26-34), RRQHTDVSF), II (VP1(157-165), RTLPTSFNY) and III (VP1(45-53), KEQVNVLDL) from the VP1 capsid protein of the foot-and-mouth disease virus ( FMDV) are T cell epitopes. To investigate whether these peptides have immunological activity, BALB/c mice were immunized with peptide I, II or III conjugated with immunostimulating complexes (ISCOMs). A cytotoxic T lymphocyte assay was used to evaluate the cytotoxic activity induced by peptides along with by measuring peptide-specific T-cell proliferation and CD8(+) T lymphocyte numbers in whole blood and interferon (IFN)-gamma production in peripheral blood mononuclear cells induced by peptides. To further identify the protective efficacy of peptides, an FMDV challenge assay was done in guinea pigs. Peptides I and II stimulated significant increases in T-cell proliferation, CD8(+) T lymphocytes, and IFN-gamma secretion and cytotoxic activity compared to controls. The FMDV challenge assay indicated peptides I and II can protect over 60% of animals from virus attack. The results demonstrate that peptides I and II encapsulated in liposomes should be CTL epitopes of FMDV and can protect animals from virus attack to some extent.	[Gao, Feng-Shan; Feng, Lei] Dalian Univ, Coll Life Sci & Technol, Dept Biochem & Mol Biol, Dalian 116012, Liaoning, Peoples R China; [Zhang, Qiang] Chinese Acad Agr Sci, Lanzhou Vet Res Inst, Lanzhou, Gansu, Peoples R China; [Yan, Ruo-qian] Anim Husb Bur Henan Prov, Henan Ctr Anim Dis Control & Prevent, Zhengzhou, Henan, Peoples R China; [Li, Yun-Gang] Shandong Ctr Anim Dis Prevent & Control, Jinan, Shandong, Peoples R China; [Li, Xin-sheng] Henan Agr Univ, Coll Anim Husb & Vet Sci, Zhengzhou, Henan, Peoples R China	Dalian University; Chinese Academy of Agricultural Sciences; Lanzhou Veterinary Research Institute, CAAS; Henan Agricultural University	Gao, FS (corresponding author), Dalian Univ, Coll Life Sci & Technol, Dept Biochem & Mol Biol, Dalian 116012, Liaoning, Peoples R China.	gfsh0626@126.com	li, xin/HHS-9461-2022		National Natural Science Foundation of China [30972169, 31172304]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This study was supported by the National Natural Science Foundation of China (grant nos. 30972169 and 31172304). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Altman JD, 1996, SCIENCE, V274, P94, DOI 10.1126/science.274.5284.94; Barfoed AM, 2006, ANTIVIR RES, V72, P178, DOI 10.1016/j.antiviral.2006.07.002; Becker Y, 1997, VIRUS GENES, V14, P123, DOI 10.1023/A:1007965200932; Bengtsson KL, 2011, EXPERT REV VACCINES, V10, P401, DOI [10.1586/erv.11.25, 10.1586/ERV.11.25]; BITTLE JL, 1982, NATURE, V298, P30, DOI 10.1038/298030a0; Blanco E, 2001, J VIROL, V75, P3164, DOI 10.1128/JVI.75.7.3164-3174.2001; BLUESTONE JA, 1987, EUR J IMMUNOL, V17, P1035, DOI 10.1002/eji.1830170721; Borrego B, 2006, VACCINE, V24, P3889, DOI 10.1016/j.vaccine.2006.02.028; BRUNNER KT, 1968, IMMUNOLOGY, V14, P181; Castellanos MR, 2001, CRIT REV ONCOL HEMAT, V39, P133, DOI 10.1016/S1040-8428(01)00112-3; Choi EY, 2001, J IMMUNOL, V166, P4370, DOI 10.4049/jimmunol.166.7.4370; COLLEN T, 1991, J IMMUNOL, V146, P749; DERES K, 1989, NATURE, V342, P561, DOI 10.1038/342561a0; Ercolini AM, 2007, J NEUROIMMUNOL, V186, P5, DOI 10.1016/j.jneuroim.2007.02.002; FELTKAMP MCW, 1994, MOL IMMUNOL, V31, P1391, DOI 10.1016/0161-5890(94)90155-4; Gao FS, 2006, VET IMMUNOL IMMUNOP, V113, P328, DOI 10.1016/j.vetimm.2006.06.002; Guzman E, 2008, J GEN VIROL, V89, P667, DOI 10.1099/vir.0.83417-0; Harris SJ, 1997, INT IMMUNOL, V9, P273, DOI 10.1093/intimm/9.2.273; HEEG K, 1991, EUR J IMMUNOL, V21, P1523, DOI 10.1002/eji.1830210628; Hoof I, 2009, IMMUNOGENETICS, V61, P1, DOI 10.1007/s00251-008-0341-z; Hsu SC, 1996, VACCINE, V14, P1159, DOI 10.1016/0264-410X(95)00241-R; Juleff N, 2009, J VIROL, V83, P3626, DOI 10.1128/JVI.02613-08; Lawson TM, 2001, INT IMMUNOL, V13, P1383, DOI 10.1093/intimm/13.11.1383; Li WM, 2003, VACCINE, V21, P3319, DOI 10.1016/S0264-410X(03)00172-5; Li YF, 2008, ONCOL REP, V19, P1445; LIPFORD GB, 1994, VACCINE, V12, P73, DOI 10.1016/0264-410X(94)90013-2; Moore DP, 2011, VET PARASITOL, V175, P245, DOI 10.1016/j.vetpar.2010.10.020; O'Connor DH, 2003, J VIROL, V77, P9029, DOI 10.1128/JVI.77.16.9029-9040.2003; PANJEVIC D, 1989, J VET MED B, V36, P119, DOI 10.1111/j.1439-0450.1989.tb00577.x; PFAFF E, 1982, EMBO J, V1, P869, DOI 10.1002/j.1460-2075.1982.tb01262.x; Rodriguez LL, 2011, EXPERT REV VACCINES, V10, P377, DOI [10.1586/erv.11.4, 10.1586/ERV.11.4]; Sheng XL, 2007, WORLD J GASTROENTERO, V13, P5944, DOI 10.3748/wjg.v13.i44.5944; Su CX, 2007, VET MICROBIOL, V124, P256, DOI 10.1016/j.vetmic.2007.04.030; Sullivan JA, 1997, J IMMUNOL, V159, P2318; Summerfield A, 2009, VET IMMUNOL IMMUNOP, V128, P205, DOI 10.1016/j.vetimm.2008.10.296; Uger RA, 1998, J IMMUNOL, V160, P1598; VANBINNENDIJK RS, 1990, J IMMUNOL, V144, P2394; Vithayasai V, 1997, ASIAN PAC J ALLERGY, V15, P141; Zhang DY, 2008, WORLD J GASTROENTERO, V14, P3554, DOI 10.3748/wjg.14.3554; Zhang HY, 2003, VACCINE, V21, P4704, DOI 10.1016/S0264-410X(03)00519-X; Zhao B, 2003, HUM IMMUNOL, V64, P1123, DOI 10.1016/j.humimm.2003.08.343; Zhao GY, 2010, VIROL J, V7, DOI 10.1186/1743-422X-7-151	42	38	40	0	19	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 9	2013	8	7							e68658	10.1371/journal.pone.0068658	http://dx.doi.org/10.1371/journal.pone.0068658			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	182JD	23874709	Green Published, gold, Green Submitted			2023-01-03	WOS:000321736900101
J	Mishra, R; Kaur, G				Mishra, Rachana; Kaur, Gurcharan			Aqueous Ethanolic Extract of Tinospora cordifolia as a Potential Candidate for Differentiation Based Therapy of Glioblastomas	PLOS ONE			English	Article							ADHESION MOLECULE NCAM; CELL-ADHESION; CYCLIN D1; POLYSIALIC ACID; IN-VITRO; DICHLOROMETHANE EXTRACT; NEUROBLASTOMA-CELLS; ANTITUMOR-ACTIVITY; OXIDATIVE STRESS; GENE-EXPRESSION	Glioblastomas are the most aggressive primary brain tumors and their heterogeneity and complexity often renders them non responsive to various conventional treatments. Search for herbal products having potential anti-cancer activity is an active area of research in the Indian traditional system of medicine i.e., Ayurveda. Tinospora cordifolia, also named as 'heavenly elixir' is used in various ayurvedic decoctions as panacea to treat several body ailments. The current study investigated the anti-brain cancer potential of 50% ethanolic extract of Tinospora cordifolia (TCE) using C6 glioma cells. TCE significantly reduced cell proliferation in dose-dependent manner and induced differentiation in C6 glioma cells, resulting in astrocyte-like morphology as indicated by phase contrast images, GFAP expression and process outgrowth data of TCE treated cells which exhibited higher number and longer processes than untreated cells. Reduced proliferation of cells was accompanied by enhanced expression of senescence marker, mortalin and its translocation from perinuclear to pancytoplasmic spaces. Further, TCE showed anti-migratory and anti-invasive potential as depicted by wound scratch assay and reduced expression of plasticity markers NCAM and PSA-NCAM along with MMP-2 and 9. On analysis of the cell cycle and apoptotic markers, TCE treatment was seen to arrest the C6 cells in G0/G1 and G2/M phase, suppressing expression of G1/S phase specific protein cyclin D1 and anti-apoptotic protein Bcl-xL, thus supporting its anti-proliferative and apoptosis inducing potential. Present study provides the first evidence for the presence of anti-proliferative, differentiation-inducing and anti-migratory/anti-metastatic potential of TCE in glioma cells and possible signaling pathways involved in its mode of action. Our primary data suggests that TCE and its active components may prove to be promising phytotherapeutic interventions in gliobalstoma multiformae.	[Mishra, Rachana; Kaur, Gurcharan] Guru Nanak Dev Univ, Dept Biotechnol, Amritsar, Punjab, India	Guru Nanak Dev University	Kaur, G (corresponding author), Guru Nanak Dev Univ, Dept Biotechnol, Amritsar, Punjab, India.	kgurcharan.neuro@yahoo.com	Mishra, Rachana/Q-1706-2019; Kaur, Gurcharan/V-6033-2019		UGC-UPE (University Grant Commission-Universities with Potential for Excellence, Government of India); DBT, GOI	UGC-UPE (University Grant Commission-Universities with Potential for Excellence, Government of India); DBT, GOI(Department of Biotechnology (DBT) India)	The study was partially supported by UGC-UPE (University Grant Commission-Universities with Potential for Excellence, Government of India) Grant to the University. Ms Rachana Mishra is thankful to the DBT, GOI for the research fellowship grant. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adhvaryu MR, 2008, AFR J TRADIT COMPLEM, V5, P409; Agrawal SS, 2012, FOOD CHEM TOXICOL, V50, P3126, DOI 10.1016/j.fct.2012.05.057; Amoureux MC, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-91; Aranha I, 2012, J ETHNOPHARMACOL, V139, P366, DOI 10.1016/j.jep.2011.11.013; Arato-Ohshima T, 1999, INT J CANCER, V83, P387, DOI 10.1002/(SICI)1097-0215(19991029)83:3<387::AID-IJC15>3.0.CO;2-O; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BATES S, 1994, ONCOGENE, V9, P1633; Bishayi Biswadev, 2002, J Toxicol Sci, V27, P139, DOI 10.2131/jts.27.139; BLACK MM, 1991, J NEUROSCI, V11, P1163; Bussolati B, 2006, EXP CELL RES, V312, P913, DOI 10.1016/j.yexcr.2005.12.004; Cavallaro U, 2001, NAT CELL BIOL, V3, P650, DOI 10.1038/35083041; Chaudhary R, 2008, J ENVIRON PATHOL TOX, V27, P233, DOI 10.1615/JEnvironPatholToxicolOncol.v27.i3.70; Chiasserini D, 2011, MOVEMENT DISORD, V26, P1639, DOI 10.1002/mds.23647; Ciznadija D, 2011, CANCER RES, V71, P6174, DOI 10.1158/0008-5472.CAN-11-1031; Daniel L, 2003, HUM PATHOL, V34, P528, DOI 10.1016/S0046-8177(03)00178-3; Das A, 2008, BRAIN RES, V1227, P207, DOI 10.1016/j.brainres.2008.06.045; Deocaris CC, 2007, CANCER LETT, V252, P259, DOI 10.1016/j.canlet.2006.12.038; Desai VR, 2007, INT IMMUNOPHARMACOL, V7, P1375, DOI 10.1016/j.intimp.2007.06.004; Dhanasekaran M, 2009, INVEST NEW DRUG, V27, P347, DOI 10.1007/s10637-008-9181-9; DOLE MG, 1995, CANCER RES, V55, P2576; Donnellan R, 1998, J CLIN PATHOL-MOL PA, V51, P1; Fauzi FM, 2013, J CHEM INF MODEL, V53, P661, DOI 10.1021/ci3005513; Georgopoulou N, 2006, J BIOL CHEM, V281, P33606, DOI 10.1074/jbc.M602689200; Goel H. C., 2002, Indian Journal of Experimental Biology, V40, P727; Grobben B, 2002, CELL TISSUE RES, V310, P257, DOI 10.1007/s00441-002-0651-7; Guruprasad K P, 2010, J Ayurveda Integr Med, V1, P40, DOI 10.4103/0975-9476.59826; Hamsa TP, 2012, EXP TOXICOL PATHOL, V64, P307, DOI 10.1016/j.etp.2010.09.003; HANSEN MB, 1989, J IMMUNOL METHODS, V119, P203, DOI 10.1016/0022-1759(89)90397-9; Harborne J.B., 1998, BUSINESS MEDIA, V3rd ed., DOI DOI 10.1007/978-94-009-5570-7; HEIKKILA JJ, 1993, DEV GENET, V14, P87, DOI 10.1002/dvg.1020140202; Jagetia GC, 2006, EVID-BASED COMPL ALT, V3, P267, DOI 10.1093/ecam/nel011; Jagetia GC, 2006, BIOL PHARM BULL, V29, P460, DOI 10.1248/bpb.29.460; Jain BNG, 2010, J ADV PHARM TECHNOL, V1, P30; Kataria H, 2012, PLOS ONE, V5; Kokate C. K., 2001, PHARMACOGNOSY, V16th; Koppada R, 2009, BASIC CLIN PHARMACOL, V105, P217, DOI 10.1111/j.1742-7843.2009.00383.x; Leyon PV, 2004, INT IMMUNOPHARMACOL, V4, P1569, DOI 10.1016/j.intimp.2004.06.015; Liu Wei, 2011, Reports in Parasitology, V1, P1; Loones MT, 2000, CELL STRESS CHAPERON, V5, P291, DOI 10.1379/1466-1268(2000)005<0291:TDOHSP>2.0.CO;2; Muhlenhoff M, 1998, CURR OPIN STRUC BIOL, V8, P558, DOI 10.1016/S0959-440X(98)80144-9; Nadig PD, 2012, INDIAN J PHARMACOL, V44, P580, DOI 10.4103/0253-7613.100380; Nair R B, 1992, Anc Sci Life, V12, P280; Pandey VK, 2012, INT IMMUNOPHARMACOL, V14, P641, DOI 10.1016/j.intimp.2012.09.020; Paratcha G, 2003, CELL, V113, P867, DOI 10.1016/S0092-8674(03)00435-5; Patel MB, 2011, PHYTOMEDICINE, V18, P1045, DOI 10.1016/j.phymed.2011.05.006; Perl AK, 1999, NAT MED, V5, P286, DOI 10.1038/6502; PIERCE GB, 1961, CANCER, V14, P1017, DOI 10.1002/1097-0142(196109/10)14:5<1017::AID-CNCR2820140516>3.0.CO;2-P; Prince Ponnaian Stanely Mainzen, 2004, Acta Pol Pharm, V61, P283; Raghu R, 2009, IMMUNOL LETT, V123, P60, DOI 10.1016/j.imlet.2009.02.005; Rao PR, 2005, BIOL PHARM BULL, V28, P2319, DOI 10.1248/bpb.28.2319; Rao SK, 2010, INTEGR CANCER THER, V9, P378, DOI 10.1177/1534735410387598; Rawal Avinash K, 2004, BMC Complement Altern Med, V4, P11, DOI 10.1186/1472-6882-4-11; Reddy SS, 2009, FOOD CHEM TOXICOL, V47, P2224, DOI 10.1016/j.fct.2009.06.008; Rege NN, 1999, PHYTOTHER RES, V13, P275, DOI 10.1002/(SICI)1099-1573(199906)13:4&lt;275::AID-PTR510&gt;3.0.CO;2-S; Ronn LCB, 1998, EXP GERONTOL, V33, P853, DOI 10.1016/S0531-5565(98)00040-0; Rutishauser U, 1996, TRENDS NEUROSCI, V19, P422; RUTKA JT, 1994, CANCER RES, V54, P3267; Saha S, 2012, ANC SCI LIFE, V31, P151, DOI 10.4103/0257-7941.107344; Sallinen SL, 1999, J PATHOL, V188, P289; Sangeetha MK, 2011, J NAT MED-TOKYO, V65, P544, DOI 10.1007/s11418-011-0538-6; Schmidt F, 2000, CELL PHYSIOL BIOCHEM, V10, P159, DOI 10.1159/000016346; Seidenfaden R, 2003, MOL CELL BIOL, V23, P5908, DOI 10.1128/MCB.23.16.5908-5918.2003; Sengupta M, 2011, BMC COMPLEM ALTERN M, V11, DOI 10.1186/1472-6882-11-102; Sengupta S, 2009, J ENZYM INHIB MED CH, V24, P684, DOI 10.1080/14756360802333075; Sharma P, 2011, EVID-BASED COMPL ALT, V2011, DOI [10.1155/2011/643847, DOI 10.1155/2011/643847.PUBMED:21350610]; Sharma U, 2012, J ETHNOPHARMACOL, V141, P918, DOI 10.1016/j.jep.2012.03.027; Sharma V, 2010, Toxicol Int, V17, P12, DOI 10.4103/0971-6580.68343; Shih YY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026236; Shim JW, 2004, J NEUROSCI, V24, P843, DOI 10.1523/JNEUROSCI.3977-03.2004; Singh AP, 2012, INT J ONCOL, V40, P99, DOI 10.3892/ijo.2011.1225; Singh N, 2005, IMMUNOPHARM IMMUNOT, V27, P1, DOI 10.1081/IPH-200051287; Subramanian M, 2002, REDOX REP, V7, P137, DOI 10.1179/135100002125000370; Sukumari-Ramesh S, 2011, INT J DEV NEUROSCI, V29, P701, DOI 10.1016/j.ijdevneu.2011.06.002; Thippeswamy G, 2008, EUR J PHARMACOL, V588, P141, DOI 10.1016/j.ejphar.2008.04.027; Thippeswamy G, 2007, ENVIRON TOXICOL PHAR, V23, P212, DOI 10.1016/j.etap.2006.10.004; Toda M, 1999, NEUROCHEM RES, V24, P339, DOI 10.1023/A:1022538810581; Velazquez EA, 2009, BASIC CLIN PHARMACOL, V105, P301, DOI 10.1111/j.1742-7843.2009.00447.x; WADHWA R, 1995, EXP CELL RES, V216, P101, DOI 10.1006/excr.1995.1013; WADHWA R, 1993, EXP CELL RES, V207, P442, DOI 10.1006/excr.1993.1213; Yang JX, 2008, BRAIN RES, V1203, P39, DOI 10.1016/j.brainres.2008.01.082	80	41	41	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 24	2013	8	10							e78764	10.1371/journal.pone.0078764	http://dx.doi.org/10.1371/journal.pone.0078764			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	241FR	24205314	Green Published, gold			2023-01-03	WOS:000326152300082
J	van Vonderen, JJ; Narayen, NE; Walther, FJ; Siew, ML; Davis, PG; Hooper, SB; te Pas, AB				van Vonderen, Jeroen J.; Narayen, Nadia E.; Walther, Frans J.; Siew, Melissa L.; Davis, Peter G.; Hooper, Stuart B.; te Pas, Arjan B.			The Administration of 100% Oxygen and Respiratory Drive in Very Preterm Infants at Birth	PLOS ONE			English	Article							ROOM-AIR; BREATHING PATTERNS; NEWBORN-INFANTS; RESUSCITATION; VENTILATION; VOLUME	Aim: To retrospectively investigate the changes of SpO(2) and respiratory drive in preterm infants at birth after administration of 100% oxygen. Methods: Respiratory parameters, FiO(2) and oximetry of infants <32 weeks gestation before and after receiving FiO(2) 1.0 were reviewed during continuous positive airway pressure (CPAP) or positive pressure ventilation (PPV). Results: Results are given as median (IQR) or percentages where appropriate. Suitable recordings were made in 50 infants (GA 27 (26-29) weeks), 17 received CPAP and 33 PPV. SpO(2) increased rapidly in the first minute after FiO(2) 1.0 and remained stable. The duration of FiO(2) 1.0 tended to be shorter in the CPAP group than in the PPV group (CPAP vs. PPV: 65 (33-105) vs. 100 (40-280) s; p = 0.05), SpO(2) >95% occurred more often in PPV group (53% vs. 69%) and lasted longer (70(40-95) vs. 120(50-202) s). In CPAP group, minute volume increased from 134 (76-265) mL/kg/min 1 minute before to 240 (157-370) mL/kg/min (p<0.01) 1 minute after start FiO(2) 1.0 and remained stable at 2 minutes (252 (135-376) mL/kg/min; ns). The rate of rise to maximum tidal volume increased (from 13.8 (8.0-22.4) mL/kg/s to 18.2 (11.0-27.5) mL/kg/s; p<0.0001) to 18.8 (11.8-27.8) mL/kg/s; ns). In the PPV group respiratory rate increased from 0(0-4) to 9(0-20) at 1 minute (p<0.001) to 23 (0-34) breaths per minute at 2 minutes (p<0.01). Conclusion: In preterm infants at birth, a rapid increase in oxygenation, resulting from a transient increase to 100% oxygen might improve respiratory drive, but increases the risk for hyperoxia.	[van Vonderen, Jeroen J.; Narayen, Nadia E.; Walther, Frans J.; Siew, Melissa L.; te Pas, Arjan B.] Leiden Univ, Dept Pediat, Div Neonatol, Med Ctr, Leiden, Netherlands; [Siew, Melissa L.; Hooper, Stuart B.; te Pas, Arjan B.] Monash Inst Med Res, Ritchie Ctr, Clayton, Vic, Australia; [Davis, Peter G.] Royal Womens Hosp, Dept Newborn Res, Melbourne, Vic, Australia	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Monash University	van Vonderen, JJ (corresponding author), Leiden Univ, Dept Pediat, Div Neonatol, Med Ctr, Leiden, Netherlands.	J.J.van_Vonderen@lumc.nl	pas, arjan te/AAA-9019-2020; van Vonderen, Jeroen J./L-4067-2019	pas, arjan te/0000-0001-7831-8797; van Vonderen, Jeroen J./0000-0002-1258-5224; Hooper, Stuart/0000-0003-1676-4825; Walther, Frans/0000-0003-1931-159X	Veni-grant, The Netherlands Organisation for Health Research and Development (ZonMw), part of the Innovational Research Incentives Scheme Veni-Vidi-Vici [91612027]; Willem-Alexander Children's Foundation scholarship	Veni-grant, The Netherlands Organisation for Health Research and Development (ZonMw), part of the Innovational Research Incentives Scheme Veni-Vidi-Vici; Willem-Alexander Children's Foundation scholarship	A.B. te Pas is the recipient of a Veni-grant, The Netherlands Organisation for Health Research and Development (ZonMw), part of the Innovational Research Incentives Scheme Veni-Vidi-Vici, project number 91612027. J.J. van Vonderen is the recipient of a Willem-Alexander Children's Foundation scholarship www.willem-alexanderkinderfonds.nl. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bookatz GB, 2007, PEDIATR RES, V61, P698, DOI 10.1203/pdr.0b013e3180534171; Davey MG, 1996, RESP PHYSIOL, V105, P57, DOI 10.1016/0034-5687(96)00038-2; Dawson JA, 2010, PEDIATRICS, V125, pE1340, DOI 10.1542/peds.2009-1510; Escrig R, 2008, PEDIATRICS, V121, P875, DOI 10.1542/peds.2007-1984; Finer NN, 2009, PEDIATRICS, V123, P865, DOI 10.1542/peds.2008-0560; Fischer HS, 2008, PHYSIOL MEAS, V29, P95, DOI 10.1088/0967-3334/29/1/007; FOITZIK B, 1994, BIOMED TECH, V39, P85, DOI 10.1515/bmte.1994.39.4.85; Givan Deborah C, 2003, Semin Pediatr Neurol, V10, P271, DOI 10.1016/S1071-9091(03)00073-1; GLUCKMAN PD, 1987, J PHYSIOL-LONDON, V382, P373, DOI 10.1113/jphysiol.1987.sp016372; Hellstrom-Westas L, 2006, PEDIATRICS, V118, pE1798, DOI 10.1542/peds.2006-0102; Higgins RD, 2007, PEDIATRICS, V119, P790, DOI 10.1542/peds.2006-2200; Lakshminrusimha S, 2011, J APPL PHYSIOL, V111, P1441, DOI 10.1152/japplphysiol.00711.2011; O'Donnell CPF, 2010, J PEDIATR-US, V156, P846, DOI 10.1016/j.jpeds.2010.01.007; Pas ABT, 2008, PEDIATR RES, V64, P281, DOI 10.1203/PDR.0b013e31817d9c35; Perlman JM, 2010, CIRCULATION, V122, P8516, DOI 10.1161/CIRCULATIONAHA.110.971127; Rabi Y, 2007, RESUSCITATION, V72, P353, DOI 10.1016/j.resuscitation.2006.06.134; Rabi Y, 2011, PEDIATRICS, V128, pE374, DOI 10.1542/peds.2010-3130; Roske K, 1998, J CLIN MONIT COMPUT, V14, P413, DOI 10.1023/A:1009993916980; Saugstad OD, 1998, PEDIATRICS, V102, DOI 10.1542/peds.102.1.e1; Saugstad OD, 2008, NEONATOLOGY, V94, P176, DOI 10.1159/000143397; Schilleman K, 2012, RESUSCITATION, V83, P1135, DOI 10.1016/j.resuscitation.2012.01.036; Schmolzer GM, 2011, ARCH DIS CHILD-FETAL, V96, pF254, DOI 10.1136/adc.2010.191171; Sobotka KS, 2011, PEDIATR RES, V70, P56, DOI 10.1203/PDR.0b013e31821d06a1; Tan A, 2005, COCHRANE DB SYST REV, V2; te Pas AB, 2009, J PEDIATR-US, V154, P369, DOI 10.1016/j.jpeds.2008.09.029; te Pas AB, 2009, PEDIATR RES, V65, P352, DOI 10.1203/PDR.0b013e318193f117; TEITEL DF, 1990, PEDIATR RES, V27, P372, DOI 10.1203/00006450-199004000-00010; Vento M, 2011, J PEDIAT S, V158, P5; Vento M, 2009, PEDIATRICS, V124, pE439, DOI 10.1542/peds.2009-0434; Wang CL, 2008, PEDIATRICS, V121, P1083, DOI 10.1542/peds.2007-1460; Wyllie J, 2010, RESUSCITATION, V81, pE260, DOI 10.1016/j.resuscitation.2010.08.029	31	8	8	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 18	2013	8	10							e76898	10.1371/journal.pone.0076898	http://dx.doi.org/10.1371/journal.pone.0076898			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	239MM	24204698	Green Published, gold			2023-01-03	WOS:000326029300063
J	Li, M; Gao, JP; Feng, RH; Wang, YL; Chen, XH; Sun, JY; Zhang, DQ; Zhu, ZG; Ellis, LM; Lu, M; Lee, JE; Feng, ZQ; Liu, BY				Li, Ming; Gao, Jianpeng; Feng, Runhua; Wang, Yuling; Chen, Xuehua; Sun, Jianyu; Zhang, Dongqing; Zhu, Zhenggang; Ellis, Lee M.; Lu, Mason; Lee, Jeffrey E.; Feng, Zhenqing; Liu, Bingya			Generation of Monoclonal Antibody MS17-57 Targeting Secreted Alkaline Phosphatase Ectopically Expressed on the Surface of Gastrointestinal Cancer Cells	PLOS ONE			English	Article							EPIDERMAL-GROWTH-FACTOR; ANTIGEN; INHIBITION; BIOMARKERS; ISOENZYMES; DIAGNOSIS; FEATURES; REGIONS; MARKER	Background: Therapeutic antibody development is one of the fastest growing areas of the pharmaceutical industry. Generating high-quality monoclonal antibodies against a given therapeutic target is crucial for successful drug development. However, due to immune tolerance, making it difficult to generate antibodies using conventional approaches. Methodology/Findings: Mixed four human gastric cancer (GC) cell lines were used as the immunogen in A/J mice; sixteen highly positive hybridoma colonies were selected via fluorescence-activated cell sorting-high throughput screening (FACS-HTS) using a total of 20,000 colonies in sixty-seven 96-well plates against live cells (mixed human GC cells versus human PBMC controls). MS17-57 and control commercial Alkaline Phosphatase (ALP) mAbs were used to confirm the target antigens (Ags), which were identified as ALPs expressed on the GC cell surface through a combination of western blot, immunoprecipitation and mass spectrometry (MS). MS identified the Ags recognized by MS17-57 to be two variants of a secreted ALP, PALP and IALP (Placental and intestinal ALP). These proteins belong to a hydrolase enzyme family responsible for removing phosphate groups from many types of molecules. Immunofluorescence staining using MS17-57 demonstrated higher staining of gastrointestinal (GI) cancer tissues compared to normal GI tissues (P<0.03), and confirmed binding of MS17-57 to be restricted to a functional epitope expressed on the cancer cell surface. Proliferation assays using the PALP/IALP-expressing GC cell lines demonstrated that MS17-57 inhibited cell growth by 32 +/- 8%. Transwell cell migration assays documented that MS17-57 can inhibit PALP/IALP-expressing GI cancer cell migration by 25 +/- 5%. MS17-57 mAb inhibited tumor growth in nude mice. Conclusions: Our findings indicate that PALP and IALP can be ectopically expressed on extracellular matrix of GI cancers, and that MS17-57 directed against PALP/IALP can inhibit GI cancer cells growth and migration in vitro and in vivo. This investigation provides an example of identification of cancer biomarkers representing promising therapeutic targets using mAb generated through a novel HTS technology.	[Li, Ming; Feng, Zhenqing] Nanjing Med Univ, Dept Pathol, Nanjing, Jiangsu, Peoples R China; [Gao, Jianpeng; Feng, Runhua; Chen, Xuehua; Zhu, Zhenggang; Liu, Bingya] Shanghai Jiao Tong Univ, Shanghai Key Lab Gastr Neoplasms, Shanghai Inst Digest Surg, Ruijing Hosp,Sch Med, Shanghai 200030, Peoples R China; [Feng, Runhua; Wang, Yuling; Ellis, Lee M.; Lu, Mason; Lee, Jeffrey E.] Univ Texas MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA; [Sun, Jianyu; Lu, Mason] Shanghai MabStar Inc, Shanghai, Peoples R China; [Zhang, Dongqing] Shanghai Jiao Tong Univ, Shanghai Inst Immunol, Sch Med, Shanghai 200030, Peoples R China	Nanjing Medical University; Shanghai Jiao Tong University; University of Texas System; UTMD Anderson Cancer Center; Chinese Academy of Sciences; Shanghai Jiao Tong University	Feng, ZQ (corresponding author), Nanjing Med Univ, Dept Pathol, Nanjing, Jiangsu, Peoples R China.	fengzhenqing@njmu.edu.cn; byliu@sjtu.edu.cn	Liu, Bingya/GMW-5655-2022; Gao, Jianpeng/ABA-5373-2020	Liu, Bingya/0000-0002-4406-3762	National Natural Science Foundation of China [81201596, 81101847, 81172324, 91229106, 31270963]; Key Projects in the National Science & Technology Pillar Program of China [2011BA203191]; Science and Technology Commission of Shanghai Municipality [12XD1403700, 12PJ1406300]; Research Fund for the Doctoral Program of Higher Education of China [20110073110071]; Key Project of Shanghai Education Committee [12ZZ105]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Key Projects in the National Science & Technology Pillar Program of China; Science and Technology Commission of Shanghai Municipality(Science & Technology Commission of Shanghai Municipality (STCSM)); Research Fund for the Doctoral Program of Higher Education of China(Research Fund for the Doctoral Program of Higher Education of China (RFDP)Specialized Research Fund for the Doctoral Program of Higher Education (SRFDP)); Key Project of Shanghai Education Committee	This work was supported by the National Natural Science Foundation of China (grant numbers 81201596, 81101847, 81172324, 91229106, 31270963); Key Projects in the National Science & Technology Pillar Program of China (2011BA203191); Science and Technology Commission of Shanghai Municipality (12XD1403700, 12PJ1406300); Research Fund for the Doctoral Program of Higher Education of China (20110073110071); Key Project of Shanghai Education Committee (12ZZ105). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ABOUDPIRAK E, 1988, J NATL CANCER I, V80, P1605, DOI 10.1093/jnci/80.20.1605; Akagi M, 2003, BRIT J CANCER, V88, P796, DOI 10.1038/sj.bjc.6600811; Arvy L, 1969, Int Rev Cytol, V25, P333, DOI 10.1016/S0074-7696(08)60207-7; Bornschein J, 2012, BMC GASTROENTEROL, V12, DOI 10.1186/1471-230X-12-10; CHOMCZYNSKI P, 1995, BIOTECHNIQUES, V19, P942; Ferianec V, 2011, NEUROENDOCRINOL LETT, V32, P154; GALAM L, 2007, HIGH THROUGHPUT ASSA; Gotoh A, 2008, CLIN CHIM ACTA, V397, P13, DOI 10.1016/j.cca.2008.07.006; Guimaraes AJ, 2009, INFECT IMMUN, V77, P1357, DOI 10.1128/IAI.01443-08; Honda K, 2013, JPN J CLIN ONCOL, V43, P103, DOI 10.1093/jjco/hys200; Hong CW, 2012, CANCER RES, V72, P3715, DOI 10.1158/0008-5472.CAN-12-0063; Iqbal SJ, 2000, ANN CLIN BIOCHEM, V37, P775, DOI 10.1258/0004563001900093; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; Kotloff KL, 1996, VACCINE, V14, P1174; Krieg R, 2003, CELL MOL BIOL, V49, P547; Laune D, 1997, J BIOL CHEM, V272, P30937, DOI 10.1074/jbc.272.49.30937; Li JJ, 2013, TRANSL ONCOL, V6, P42, DOI 10.1593/tlo.12367; Li L, 2012, ASIAN PAC J CANCER P, V13, P2069, DOI 10.7314/APJCP.2012.13.5.2069; LINDHOLM L, 1983, INT ARCH ALLER A IMM, V71, P178, DOI 10.1159/000233384; LINNENBACH AJ, 1989, P NATL ACAD SCI USA, V86, P27, DOI 10.1073/pnas.86.1.27; Mehan MR, 2013, ADV EXP MED BIOL, V735, P283, DOI 10.1007/978-1-4614-4118-2_20; Motwani M, 2003, MOL CANCER THER, V2, P549; Ofran Y, 2008, J IMMUNOL, V181, P6230, DOI 10.4049/jimmunol.181.9.6230; Ozyoruk F, 2001, CLIN DIAGN LAB IMMUN, V8, P44, DOI 10.1128/CDLI.8.1.44-51.2001; Pardoll DM, 2012, NAT REV CANCER, V12, P252, DOI 10.1038/nrc3239; Peters E, 2013, J PHARMACOL EXP THER, V344, P2, DOI 10.1124/jpet.112.198226; Prassas I, 2008, CLIN CANCER RES, V14, P5778, DOI 10.1158/1078-0432.CCR-08-0706; RATHJEN DA, 1986, HYBRIDOMA, V5, P255, DOI 10.1089/hyb.1986.5.255; Siddique A, 2012, CLIN LIVER DIS, V16, P199, DOI 10.1016/j.cld.2012.03.012; Song JG, 2006, NEOPLASIA, V8, P995, DOI 10.1593/neo.06592; Takahashi Y, 2000, INT J CANCER, V85, P243, DOI 10.1002/(SICI)1097-0215(20000115)85:2<243::AID-IJC15>3.0.CO;2-2; WHYTE MP, 1995, J CLIN INVEST, V95, P1440, DOI 10.1172/JCI117814; WINTER G, 1991, NATURE, V349, P293, DOI 10.1038/349293a0; Wong HH, 2012, J GASTROINTEST ONCOL, V3, P262, DOI 10.3978/j.issn.2078-6891.2012.019; Wu HR, 1999, J MOL BIOL, V294, P151, DOI 10.1006/jmbi.1999.3141; Yang XQ, 2009, HEPATO-GASTROENTEROL, V56, P1388; Yoshinari K, 1999, CYTOTECHNOLOGY, V31, P255, DOI 10.1023/A:1008061424281	37	5	7	0	23	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 15	2013	8	10							e77398	10.1371/journal.pone.0077398	http://dx.doi.org/10.1371/journal.pone.0077398			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	237TP	24143229	Green Published, gold, Green Submitted			2023-01-03	WOS:000325894100066
J	Ruschitzka, F; Abraham, WT; Singh, JP; Bax, JJ; Borer, JS; Brugada, J; Dickstein, K; Ford, I; Gorcsan, J; Gras, D; Krum, H; Sogaard, P; Holzmeister, J				Ruschitzka, Frank; Abraham, William T.; Singh, Jagmeet P.; Bax, Jeroen J.; Borer, Jeffrey S.; Brugada, Josep; Dickstein, Kenneth; Ford, Ian; Gorcsan, John; Gras, Daniel; Krum, Henry; Sogaard, Peter; Holzmeister, Johannes		EchoCRT Study Grp	Cardiac-Resynchronization Therapy in Heart Failure with a Narrow QRS Complex	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LEFT-VENTRICULAR DYSSYNCHRONY; LONG-TERM SURVIVAL; MECHANICAL DYSSYNCHRONY; RADIAL STRAIN; TRIAL; ECHOCARDIOGRAPHY; DEFIBRILLATOR; PREVALENCE; ASYNCHRONY; REDUCTION	BackgroundCardiac-resynchronization therapy (CRT) reduces morbidity and mortality in chronic systolic heart failure with a wide QRS complex. Mechanical dyssynchrony also occurs in patients with a narrow QRS complex, which suggests the potential usefulness of CRT in such patients. MethodsWe conducted a randomized trial involving 115 centers to evaluate the effect of CRT in patients with New York Heart Association class III or IV heart failure, a left ventricular ejection fraction of 35% or less, a QRS duration of less than 130 msec, and echocardiographic evidence of left ventricular dyssynchrony. All patients underwent device implantation and were randomly assigned to have CRT capability turned on or off. The primary efficacy outcome was the composite of death from any cause or first hospitalization for worsening heart failure. ResultsOn March 13, 2013, the study was stopped for futility on the recommendation of the data and safety monitoring board. At study closure, the 809 patients who had undergone randomization had been followed for a mean of 19.4 months. The primary outcome occurred in 116 of 404 patients in the CRT group, as compared with 102 of 405 in the control group (28.7% vs. 25.2%; hazard ratio, 1.20; 95% confidence interval [CI], 0.92 to 1.57; P=0.15). There were 45 deaths in the CRT group and 26 in the control group (11.1% vs. 6.4%; hazard ratio, 1.81; 95% CI, 1.11 to 2.93; P=0.02). ConclusionsIn patients with systolic heart failure and a QRS duration of less than 130 msec, CRT does not reduce the rate of death or hospitalization for heart failure and may increase mortality. (Funded by Biotronik and GE Healthcare; EchoCRT ClinicalTrials.gov number, NCT00683696.) In a randomized trial, patients with heart failure and a QRS duration of less than 130 msec were assigned to cardiac-resynchronization therapy (CRT) or no CRT. There were no significant differences in rates of death from any cause or hospitalization for heart failure. Despite recent advances, heart failure remains a common cause of death and morbidity. According to current guidelines, cardiac-resynchronization therapy (CRT) is indicated for patients receiving stable medical therapy recommended by current guidelines who have moderate-to-severe heart failure, a left ventricular ejection fraction of 35% or less, and a QRS duration of 120 msec or more as assessed electrocardiographically.(1) However, many patients with heart failure have a QRS duration of less than 120 msec,(2) and it is currently not recommended that they receive CRT. Up to 50% of these patients show echocardiographic evidence of ventricular dyssynchrony(3),(4) and hence might benefit ...	[Ruschitzka, Frank; Holzmeister, Johannes] Univ Zurich Hosp, Clin Cardiol, CH-8091 Zurich, Switzerland; [Abraham, William T.] Ohio State Univ, Med Ctr, Div Cardiovascular Med, Davis Heart & Lung Res Inst, Columbus, OH 43210 USA; [Singh, Jagmeet P.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Cardiac Arrhythmia Serv, Boston, MA USA; [Bax, Jeroen J.] Leiden Univ, Dept Cardiol, Med Ctr, Leiden, Netherlands; [Borer, Jeffrey S.] State Univ New York Downstate Coll Med, Div Cardiovasc Med, New York, NY USA; [Borer, Jeffrey S.] State Univ New York Downstate Coll Med, Howard Gilman & Ron Inst, New York, NY USA; [Borer, Jeffrey S.] State Univ New York Downstate Coll Med, Jean Schiavone Inst, New York, NY USA; [Brugada, Josep] Univ Barcelona, Dept Cardiol, Thorax Inst, Hosp Clin, Barcelona, Spain; [Dickstein, Kenneth] Univ Bergen, Stavanger Univ Hosp, Stavanger, Norway; [Ford, Ian] Univ Glasgow, Robertson Ctr Biostat, Glasgow, Lanark, Scotland; [Gorcsan, John] Univ Pittsburgh, Pittsburgh, PA USA; [Gras, Daniel] Nouvelles Clin Nantaises, Nantes, France; [Krum, Henry] Monash Ctr Cardiovasc Res & Educ Therapeut, Melbourne, Vic, Australia; [Sogaard, Peter] Aalborg Univ, Aalborg, Denmark	University of Zurich; University Zurich Hospital; University System of Ohio; Ohio State University; Harvard University; Harvard Medical School; Massachusetts General Hospital; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; University of Barcelona; Stavanger University Hospital; University of Bergen; University of Glasgow; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Aalborg University	Holzmeister, J (corresponding author), Univ Zurich Hosp, Clin Cardiol, Raemistr 100, CH-8091 Zurich, Switzerland.	johannes.holzmeister@usz.ch; johannes.holzmeister@usz.ch	Ford, Ian/ABE-6145-2020; Ponikowski, Piotr/O-6454-2015	Ponikowski, Piotr/0000-0002-3391-7064; Ng, G. Andre/0000-0001-5965-0671; BRUGADA, JOSEP/0000-0002-5662-8302	Biotronik; GE Healthcare	Biotronik; GE Healthcare(General ElectricGE Healthcare)	Supported by Biotronik and GE Healthcare.	Achilli A, 2003, J AM COLL CARDIOL, V42, P2117, DOI 10.1016/j.jacc.2003.08.024; Beshai JF, 2007, NEW ENGL J MED, V357, P2461, DOI 10.1056/NEJMoa0706695; Bleeker GB, 2006, J AM COLL CARDIOL, V48, P2243, DOI 10.1016/j.jacc.2006.07.067; Bristow MR, 2004, NEW ENGL J MED, V350, P2140, DOI 10.1056/NEJMoa032423; Cazeau SJ, 2008, EUR J HEART FAIL, V10, P273, DOI 10.1016/j.ejheart.2008.02.007; Cleland JGF, 2005, NEW ENGL J MED, V352, P1539, DOI 10.1056/NEJMoa050496; Delgado V, 2008, J AM COLL CARDIOL, V51, P1944, DOI 10.1016/j.jacc.2008.02.040; Delgado V, 2011, CIRCULATION, V123, P70, DOI 10.1161/CIRCULATIONAHA.110.945345; Dickstein K, 2009, EUR HEART J, V30, P2450, DOI 10.1093/eurheartj/ehp359; Donahue T, 2012, J CARDIOVASC TRANSL, V5, P232, DOI 10.1007/s12265-011-9338-3; Foley PWX, 2011, HEART, V97, P1041, DOI 10.1136/hrt.2010.208355; Garin O, 2009, QUAL LIFE RES, V18, P71, DOI 10.1007/s11136-008-9416-4; Gorcsan J, 2008, J AM SOC ECHOCARDIOG, V21, P191, DOI 10.1016/j.echo.2008.01.003; Gorcsan J, 2007, J AM COLL CARDIOL, V50, P1476, DOI 10.1016/j.jacc.2007.06.043; Gorcsan J, 2010, CIRCULATION, V122, P1910, DOI 10.1161/CIRCULATIONAHA.110.954768; Hawkins NM, 2006, EUR HEART J, V27, P1270, DOI 10.1093/eurheartj/ehi826; Khan FZ, 2012, J AM COLL CARDIOL, V59, P1509, DOI 10.1016/j.jacc.2011.12.030; Khan NK, 2007, EUR J HEART FAIL, V9, P491, DOI 10.1016/j.ejheart.2006.11.003; McMurray JJV, 2013, EUR HEART J, V34, P158, DOI 10.1093/eurheartj/ehs370; Moss AJ, 2012, NEW ENGL J MED, V367, P2275, DOI 10.1056/NEJMoa1211107; Moss AJ, 2009, NEW ENGL J MED, V361, P1329, DOI 10.1056/NEJMoa0906431; Muto C, 2013, CIRC-ARRHYTHMIA ELEC, V6, P538, DOI 10.1161/CIRCEP.113.000135; Saba S, 2013, CIRC-HEART FAIL, V6, P427, DOI 10.1161/CIRCHEARTFAILURE.112.000078; Sipahi I, 2011, ARCH INTERN MED, V171, P1454, DOI 10.1001/archinternmed.2011.247; Suffoletto MS, 2006, CIRCULATION, V113, P960, DOI 10.1161/CIRCULATIONAHA.105.571455; Tang ASL, 2010, NEW ENGL J MED, V363, P2385, DOI 10.1056/NEJMoa1009540; Taylor AL, 2004, NEW ENGL J MED, V351, P2049, DOI 10.1056/NEJMoa042934; Thibault B, 2013, CIRCULATION, V127, P873, DOI 10.1161/CIRCULATIONAHA.112.001239; van Bommel RJ, 2010, EUR HEART J, V31, P3054, DOI 10.1093/eurheartj/ehq334; Young JB, 2003, JAMA-J AM MED ASSOC, V289, P2685, DOI 10.1001/jama.289.20.2685; Yu CM, 2006, J AM COLL CARDIOL, V48, P2251, DOI 10.1016/j.jacc.2006.07.054; Yu CM, 2003, HEART, V89, P54, DOI 10.1136/heart.89.1.54	32	501	521	1	46	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 10	2013	369	15					1395	1405		10.1056/NEJMoa1306687	http://dx.doi.org/10.1056/NEJMoa1306687			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	231QE	23998714	Bronze, Green Accepted			2023-01-03	WOS:000325431500007
J	Shen, J; Wei, J; Wang, H; Yang, Y; Yue, GF; Wang, L; Yu, LX; Xie, L; Sun, X; Bian, XY; Zou, ZY; Qian, XP; Guan, WX; Liu, BR				Shen, Jie; Wei, Jia; Wang, Hao; Yang, Yang; Yue, Guofeng; Wang, Lin; Yu, Lixia; Xie, Li; Sun, Xia; Bian, Xinyu; Zou, Zhengyun; Qian, Xiaoping; Guan, Wenxian; Liu, Baorui			SULF2 Methylation Is Associated with In Vitro Cisplatin Sensitivity and Clinical Efficacy for Gastric Cancer Patients Treated with a Modified FOLFOX Regimen	PLOS ONE			English	Article							MESSENGER-RNA EXPRESSION; CELL LUNG-CANCER; HEPARAN-SULFATE; TUMOR-CELLS; BINDING; GROWTH; SURVIVAL; ERCC1; CHEMOTHERAPY; TARGET	Objective: Biomarkers capable of discriminating the patients who are likely to respond to certain chemotherapeutic agents could improve the clinical efficiency. The sulfatases(SULFs) play a critical role in the pathogenesis of a variety of human cancers. Here, we focused our investigation on the prognostic and predictive impact of SULF2 methylation in gastric cancer. Methods: Promoter CpG island methylation of SULF2 was analyzed in 100 gastric cancer samples. The in vitro sensitivity to cisplatin, docetaxel, gemcitabine, irinotecan and pemetrexed were determined by histoculture drug response assay(HDRA). Additionally, 56 gastric cancer patients treated with a modified FOLFOX regimen(biweekly oxaliplatin plus 5-FU and folinic acid) were retrospectively analyzed to further evaluate the prognostic and predictive impact of SULF2 methylation in gastric cancer. Results: Methylated SULF2(SULF2M) was detected in 28 patients, while the remaining 72 patients showed unmethylated SULF2(SULF2U, methylation rate: 28%). Samples with SULF2U were more sensitive to cisplatin than those with SULF2M(inhibition rate: 48.80% vs. 38.15%, P = 0.02), while samples with SULF2M were more sensitive to irinotecan than SULF2U(inhibition rate: 53.61% vs. 40.92%, P = 0.01). There were no association between SULF2 methylation and in vitro sensitivity to docetaxel, gemcitabine and pemetrexed. SULF2 methylation was found to have a significant association with cisplatin efficacy(SULF2M: 57.14%, SULF2U: 80.56%, P = 0.02) and irinotecan efficacy(SULF2M: 89.29%, SULF2U: 62.50%, P = 0.01). Among the 56 patients receiving the modified FOLFOX regimen, a significant association was observed between survival and SULF2 methylation status(SULF2M: 309 days, 95% CI = 236 to 382 days; SULF2U: 481 days, 95% CI = 418 to 490 days; P = 0.02). Multivariate analysis revealed that SULF2 methylation was an independent prognostic factor of overall survival in gastric cancer patients treated with platinum-based chemotherapy. Conclusion: SULF2 methylation is negatively associated with cisplatin sensitivity in vitro. SULF2 methylation may be a novel prognostic biomarker for gastric cancer patients treated with platinum-based chemotherapy.	[Shen, Jie; Wei, Jia; Yang, Yang; Wang, Lin; Yu, Lixia; Xie, Li; Sun, Xia; Bian, Xinyu; Zou, Zhengyun; Qian, Xiaoping; Liu, Baorui] Nanjing Univ, Clin Canc Inst, Ctr Comprehens Canc, Drum Tower Hosp,Med Sch, Nanjing 210008, Jiangsu, Peoples R China; [Wang, Hao; Guan, Wenxian] Nanjing Univ, Sch Med, Drum Tower Hosp, Dept Gen Surg, Nanjing 210008, Jiangsu, Peoples R China; [Yue, Guofeng] Nanjing Med Univ, Nanjing, Jiangsu, Peoples R China	Nanjing University; Nanjing University; Nanjing Medical University	Guan, WX (corresponding author), Nanjing Univ, Sch Med, Drum Tower Hosp, Dept Gen Surg, Nanjing 210008, Jiangsu, Peoples R China.	guanwenxiannj@163.com; baoruiliu@nju.edu.cn	Wei, Jia/AAE-9973-2020		National Natural Science Foundation of China [81220108023, 81172094]; Top Six Talents Project of Jiangsu Province [2011ws005]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Top Six Talents Project of Jiangsu Province	This work was funded by grants from the National Natural Science Foundation of China (Grant No. 81220108023 and 81172094) and Top Six Talents Project of Jiangsu Province (Grant No. 2011ws005). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ai XB, 2007, DEVELOPMENT, V134, P3327, DOI 10.1242/dev.007674; Castro NP, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2157; Chau BN, 2009, CANCER RES, V69, P1368, DOI 10.1158/0008-5472.CAN-08-2742; Chen CY, 2011, LUNG CANCER, V74, P132, DOI 10.1016/j.lungcan.2011.01.024; Chen Z, 2009, INT J CANCER, V124, P739, DOI 10.1002/ijc.23960; Dhoot GK, 2001, SCIENCE, V293, P1663, DOI 10.1126/science.293.5535.1663; Fujita Y, 2009, ONCOL REP, V21, P499, DOI 10.3892/or_00000250; FURUKAWA T, 1995, CLIN CANCER RES, V1, P305; Hanauske AR, 2007, INVEST NEW DRUG, V25, P417, DOI 10.1007/s10637-007-9060-9; Hayashi Y, 2009, INTERNAL MED, V48, P203, DOI 10.2169/internalmedicine.48.1659; Hur K, 2012, J PATHOL, V228, P88, DOI 10.1002/path.4055; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.20107]; Kim H, 2007, SCIENCE, V316, P1202, DOI 10.1126/science.1139621; Kudo K, 2012, ONCOGENE, V31, P4718, DOI 10.1038/onc.2011.610; Kudo Y, 2006, CANCER RES, V66, P6928, DOI 10.1158/0008-5472.CAN-05-4540; Lai JP, 2008, HEPATOLOGY, V47, P1211, DOI 10.1002/hep.22202; Lai JP, 2004, GASTROENTEROLOGY, V126, P231, DOI 10.1053/j.gastro.2003.09.043; Lai JP, 2003, J BIOL CHEM, V278, P23107, DOI 10.1074/jbc.M302203200; Li JS, 2005, MOL CANCER, V4, DOI 10.1186/1476-4598-4-14; Liu L, 2011, LUNG CANCER, V73, P110, DOI 10.1016/j.lungcan.2010.11.004; Lyakhovich A, 2004, ONCOGENE, V23, P3097, DOI 10.1038/sj.onc.1207449; Mutze K, 2011, EUR J CANCER, V47, P1817, DOI 10.1016/j.ejca.2011.02.024; Olaussen KA, 2006, NEW ENGL J MED, V355, P983, DOI 10.1056/NEJMoa060570; Rosell R, 2010, EXPERT OPIN PHARMACO, V11, P1683, DOI 10.1517/14656566.2010.482101; Shim HJ, 2010, CANCER SCI, V101, P1247, DOI 10.1111/j.1349-7006.2010.01514.x; Tessema M, 2012, ONCOGENE, V31, P4107, DOI 10.1038/onc.2011.577; Viviano BL, 2004, J BIOL CHEM, V279, P5604, DOI 10.1074/jbc.M310691200; Wagner AD, 2006, J CLIN ONCOL, V24, P2903, DOI 10.1200/JCO.2005.05.0245; Wang LF, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-97; Wei J, 2008, BRIT J CANCER, V98, P1398, DOI 10.1038/sj.bjc.6604317; Wei J, 2011, J NATL CANCER I, V103, P1552, DOI 10.1093/jnci/djr326; Wesolowski R, 2009, LANCET ONCOL, V10, P903, DOI 10.1016/S1470-2045(09)70136-6	32	10	11	1	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 4	2013	8	10							e75564	10.1371/journal.pone.0075564	http://dx.doi.org/10.1371/journal.pone.0075564			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	232JF	24124496	Green Published, gold, Green Submitted			2023-01-03	WOS:000325489100053
J	Tsou, YL; Lin, YW; Chang, HW; Lin, HY; Shao, HY; Yu, SL; Liu, CC; Chitra, E; Sia, C; Chow, YH				Tsou, Yueh-Liang; Lin, Yi-Wen; Chang, Hsuen-Wen; Lin, Hsiang-Yin; Shao, Hsiao-Yun; Yu, Shu-Ling; Liu, Chia-Chyi; Chitra, Ebenezer; Sia, Charles; Chow, Yen-Hung			Heat Shock protein 90: Role in Enterovirus 71 Entry and Assembly and Potential Target for Therapy	PLOS ONE			English	Article							SELECTIN GLYCOPROTEIN LIGAND-1; CENTRAL-NERVOUS-SYSTEM; MOLECULAR CHAPERONE; CYNOMOLGUS MONKEYS; CELLULAR RECEPTOR; CAPSID PROTEIN; MOUTH-DISEASE; INFECTION; HSP90; GELDANAMYCIN	Although several factors participating in enterovirus 71 (EV71) entry and replication had been reported, the precise mechanisms associated with these events are far from clear. In the present study, we showed that heat shock protein 90 (HSP90) is a key element associated with EV71 entry and replication in a human rhabdomyosarcoma of RD cells. Inhibition of HSP90 by pretreating host cells with HSP90 beta siRNA or blocking HSP90 with a HSP90-specific antibody or geldanamycin (GA), a specific inhibitor of HSP90, as well as recombinant HSP90 beta resulted in inhibiting viral entry and subsequent viral replication. Co-immunprecipitation of EV71 with recombinant HSP90 beta and colocalization of EV71-HSP90 in the cells demonstrated that HSP90 was physically associated with EV71 particles. HSP90 seems to mediate EV71 replication by preventing proteosomal degradation of the newly synthesized capsid proteins, but does not facilitate viral gene expression at transcriptional level. This was evident by post-treatment of host cells with GA, which did not affect the expression of viral transcripts but accelerated the degradation of viral capsid proteins and interfered with the formation of assembled virions. In vivo studies were carried out using human SCARB2-transgenic mice to evaluate the protection conferred by HSP90 inhibitor, 17-allyamino-17-demethoxygeldanamycin (17-AAG), an analog of geldanamycin, that elicited similar activity but with less toxicity. The results showed that the administration of 17-AAG twice conferred the resistance to hSCARB2 mice challenged with C2, C4, and B4 genotypes of EV71. Our data supports HSP90 plays an important role in EV71 infection. Targeting of HSP90 with clinically available drugs might provide a feasible therapeutic approach to treat EV71 infection.	[Tsou, Yueh-Liang; Lin, Yi-Wen; Chang, Hsuen-Wen; Lin, Hsiang-Yin; Shao, Hsiao-Yun; Yu, Shu-Ling; Liu, Chia-Chyi; Chitra, Ebenezer; Sia, Charles; Chow, Yen-Hung] Natl Hlth Res Inst, Inst Infect Dis & Vaccinol, Zhunan Town, Miaoli County, Taiwan; [Tsou, Yueh-Liang; Lin, Yi-Wen] Natl Tsing Hua Univ, Grad Program Biotechnol Med, Inst Mol & Cellular Biol, Hsinchu, Taiwan; [Sia, Charles] China Med Univ, Grad Inst Immunol, Taichung, Taiwan	National Health Research Institutes - Taiwan; National Tsing Hua University; China Medical University Taiwan	Sia, C (corresponding author), Natl Hlth Res Inst, Inst Infect Dis & Vaccinol, Zhunan Town, Miaoli County, Taiwan.	siady@nhri.org.tw; choeyenh@nhri.org.tw	Chitra, Ebenezer/F-5984-2019; Liu, Chia-Chyi/A-8215-2012; Chow, Yen-Hung/E-3863-2010; Sia, Dwo-Yuan/E-3860-2010	Chitra, Ebenezer/0000-0002-5818-6587; Liu, Chia-Chyi/0000-0002-6257-0389; 	National Science Council [100-2311-B-400-003-, 101-2311-B-400-002-]	National Science Council(Ministry of Science and Technology, Taiwan)	This work was supported by National Science Council's funding (http://web1.nsc.gov.tw/), 100-2311-B-400-003- and 101-2311-B-400-002-. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	AbuBakar S, 1999, VIRUS RES, V61, P1, DOI 10.1016/S0168-1702(99)00019-2; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; Calderwood SK, 2006, TRENDS BIOCHEM SCI, V31, P164, DOI 10.1016/j.tibs.2006.01.006; Chen YC, 2004, J GEN VIROL, V85, P69, DOI 10.1099/vir.0.19423-0; Chung YC, 2008, VACCINE, V26, P1855, DOI 10.1016/j.vaccine.2008.01.058; Eustace BK, 2004, NAT CELL BIOL, V6, P507, DOI 10.1038/ncb1131; Geller R, 2007, GENE DEV, V21, P195, DOI 10.1101/gad.1505307; Glaze ER, 2005, CANCER CHEMOTH PHARM, V56, P637, DOI 10.1007/s00280-005-1000-9; Guang D, 2007, VIRUS RES, V125, P61, DOI 10.1016/j.virusres.2006.12.005; HASHIMOTO I, 1978, ARCH VIROL, V56, P257, DOI 10.1007/BF01317855; Ho MT, 1999, NEW ENGL J MED, V341, P929, DOI 10.1056/NEJM199909233411301; Huang CC, 1999, NEW ENGL J MED, V341, P936, DOI 10.1056/NEJM199909233411302; Huang PN, 2011, NUCLEIC ACIDS RES, V39, P9633, DOI 10.1093/nar/gkr682; Hung CY, 2011, J GEN VIROL, V92, P2803, DOI 10.1099/vir.0.033993-0; Isaacs JS, 2003, CANCER CELL, V3, P213, DOI 10.1016/S1535-6108(03)00029-1; Kamal A, 2003, NATURE, V425, P407, DOI 10.1038/nature01913; Kawashima D, 2013, J VIROL, V87, P6482, DOI 10.1128/JVI.03428-12; Khong WX, 2012, J VIROL, V86, P2121, DOI 10.1128/JVI.06103-11; Lee DH, 1998, TRENDS CELL BIOL, V8, P397, DOI 10.1016/S0962-8924(98)01346-4; Lin JY, 2008, J GEN VIROL, V89, P2540, DOI 10.1099/vir.0.2008/003673-0; Lin KH, 2006, J MED VIROL, V78, P254, DOI 10.1002/jmv.20534; Lin TW, 2007, J VIROL, V81, P8730, DOI 10.1128/JVI.00332-07; Lin YW, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057591; Lin YW, 2012, PLOS ONE, V7, DOI [10.1371/journal.pone.0030507, 10.1371/journal.pone.0052490]; Liu CC, 2000, J CLIN VIROL, V17, P23, DOI 10.1016/S1386-6532(00)00068-8; Liu CC, 2007, VACCINE, V25, P19, DOI 10.1016/j.vaccine.2006.06.083; Liu CC, 2011, VACCINE, V29, P4362, DOI 10.1016/j.vaccine.2011.04.010; Liu JN, 2012, ARCH VIROL, V157, P539, DOI 10.1007/s00705-011-1198-2; Lu CH, 2008, PROTEINS, V72, P625, DOI 10.1002/prot.21954; MELNICK JL, 1979, INTERVIROLOGY, V12, P297, DOI 10.1159/000149088; Nagata N, 2004, J GEN VIROL, V85, P2981, DOI 10.1099/vir.0.79883-0; NAGY G, 1982, ARCH VIROL, V71, P217, DOI 10.1007/BF01314873; Neckers L, 1999, INVEST NEW DRUG, V17, P361, DOI 10.1023/A:1006382320697; Neckers Len, 2003, Current Opinion in Oncology, V15, P419, DOI 10.1097/00001622-200311000-00003; Nishimura Y, 2009, NAT MED, V15, P794, DOI 10.1038/nm.1961; Ochel HJ, 2001, CELL STRESS CHAPERON, V6, P105, DOI 10.1379/1466-1268(2001)006<0105:GTPOAC>2.0.CO;2; Ong KC, 2008, J NEUROPATH EXP NEUR, V67, P532, DOI 10.1097/NEN.0b013e31817713e7; Perez-Velez CM, 2007, CLIN INFECT DIS, V45, P950, DOI 10.1086/521895; Pratt WB, 2003, EXP BIOL MED, V228, P111, DOI 10.1177/153537020322800201; REED L. J., 1938, AMER JOUR HYG, V27, P493; Schneider-Schaulies J, 2000, J GEN VIROL, V81, P1413, DOI 10.1099/0022-1317-81-6-1413; Schulte TW, 1998, CANCER CHEMOTH PHARM, V42, P273, DOI 10.1007/s002800050817; Sharp S, 2006, ADV CANCER RES, V95, P323, DOI 10.1016/S0065-230X(06)95009-X; Sidera K, 2004, J BIOL CHEM, V279, P45379, DOI 10.1074/jbc.M405486200; Smith AE, 2004, SCIENCE, V304, P237, DOI 10.1126/science.1094823; Stuart Kirsty, 2006, Aust Fam Physician, V35, P219; SUPKO JG, 1995, CANCER CHEMOTH PHARM, V36, P305, DOI 10.1007/s002800050328; Tan CW, 2013, J VIROL, V87, P611, DOI 10.1128/JVI.02226-12; Tung Wong Siew, 2007, Genet Vaccines Ther, V5, P6, DOI 10.1186/1479-0556-5-6; Valle JRD, 2005, J VIROL, V79, P4557, DOI 10.1128/JVI.79.8.4557-4567.2005; Wang RYL, 2013, VIROLOGY, V443, P236, DOI 10.1016/j.virol.2013.05.001; Wang SM, 1999, CLIN INFECT DIS, V29, P184, DOI 10.1086/520149; Wang YF, 2004, J VIROL, V78, P7916, DOI 10.1128/JVI.78.15.7916-7924.2004; Waza M, 2005, NAT MED, V11, P1088, DOI 10.1038/nm1298; Wegele H, 2004, REV PHYSIOL BIOCH P, V151, P1, DOI 10.1007/s10254-003-0021-1; Weng KF, 2010, MICROBES INFECT, V12, P505, DOI 10.1016/j.micinf.2010.03.006; Wu CN, 2001, VACCINE, V20, P895, DOI 10.1016/S0264-410X(01)00385-1; Wu SC, 2004, VACCINE, V22, P3858, DOI 10.1016/j.vaccine.2004.05.037; Wu TN, 1999, EMERG INFECT DIS, V5, P458, DOI 10.3201/eid0503.990321; Xu WP, 2001, J BIOL CHEM, V276, P3702, DOI 10.1074/jbc.M006864200; Yamayoshi S, 2009, NAT MED, V15, P798, DOI 10.1038/nm.1992; Yang B, 2009, VIROL J, V6, DOI 10.1186/1743-422X-6-141; Yang SL, 2011, J VIROL, V85, P11809, DOI 10.1128/JVI.00297-11	64	40	46	1	26	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 2	2013	8	10							e77133	10.1371/journal.pone.0077133	http://dx.doi.org/10.1371/journal.pone.0077133			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	231RG	24098578	Green Submitted, Green Published, gold			2023-01-03	WOS:000325434500095
J	Huang, WH; Lin, JL; Lin-Tan, DT; Chen, KH; Hsu, CW; Yen, TH				Huang, Wen-Hung; Lin, Ja-Liang; Lin-Tan, Dan-Tzu; Chen, Kuan-Hsing; Hsu, Ching-Wei; Yen, Tzung-Hai			Impact of Living Environment on 2-Year Mortality in Elderly Maintenance Hemodialysis Patients	PLOS ONE			English	Article							CAUSE 1-YEAR MORTALITY; STAGE RENAL-DISEASE; LONG-TERM EXPOSURE; AIR-POLLUTION; DIALYSIS OUTCOMES; STARTING DIALYSIS; PRACTICE PATTERNS; ALL-CAUSE; INFLAMMATION; MALNUTRITION	Background: Studies on risk factors of mortality in elderly patients with hemodialysis usually focus on comorbidities, nutrition, and inflammation. Discussion on the correlation between living environment and mortality of these patients is limited. Methods: A total of 256 elderly hemodialysis patients participated in this 2-year prospective observational study. The subjects were divided into 2 subgroups based on whether they were living in Taipei Basin (n = 63) or not (n = 193). Demographic, hematological, nutritional, inflammatory, biochemical, and dialysis-related data were obtained for cross-sectional analysis. Causes of death and mortality rates were also analyzed for each subgroup. Results: Patients in the basin group had a higher incidence of combined protein-energy wasting and inflammation than those in the around basin group. At the end of the 2-year follow-up, 68 patients had died. Univariate binary logistic regression analysis revealed that a very advanced age, basin group, serum albumin levels, serum creatinine levels, non-anuria, and the complications of stroke and CAD were associated with 2-year mortality. Meanwhile, log high-sensitivity Creactive protein (hs-CRP) levels were not associated with 2-year mortality. Multivariate Cox regression analysis revealed that basin group, serum albumin levels, and the complications of stroke and CAD were significant risk factors for 2-year mortality in these patients. Conclusion: The results of this study indicate that factors such as living in the Taipei Basin with higher air pollutant levels in elderly hemodialysis patients is associated with protein-energy wasting and inflammation, as well as 2-year mortality. These findings suggest that among this population, living environment is as important as comorbidities and nutrition. Furthermore, air pollution should be getting more attention especially in the overcrowding Basin topography.	[Lin, Ja-Liang] Chang Gung Univ, Chang Gung Mem Hosp, Lin Kou Med Ctr, Div Nephrol & Clin Toxicol, Taipei, Taiwan; Sch Med, Taipei, Taiwan	Chang Gung Memorial Hospital; Chang Gung University	Lin, JL (corresponding author), Chang Gung Univ, Chang Gung Mem Hosp, Lin Kou Med Ctr, Div Nephrol & Clin Toxicol, Taipei, Taiwan.	tzunghaiyen@ntu.edu.tw	Yen, Tzung-Hai/AAQ-4525-2020; huang, wen/GXW-0661-2022	Yen, Tzung-Hai/0000-0002-0907-1505; 				Alexeeff SE, 2011, ENVIRON HEALTH PERSP, V119, P481, DOI 10.1289/ehp.1002560; Bind MA, 2012, EPIDEMIOLOGY, V23, P332, DOI 10.1097/EDE.0b013e31824523f0; Bradbury BD, 2007, CLIN J AM SOC NEPHRO, V2, P89, DOI 10.2215/CJN.01170905; Canaud B, 2011, CLIN J AM SOC NEPHRO, V6, P1651, DOI 10.2215/CJN.03530410; Centers for Disease Control and Prevention and National Center for Health Statistics, 2003, 3 NAT HLTH NUTR EX S; Couchoud C, 2009, NEPHROL DIAL TRANSPL, V24, P1553, DOI 10.1093/ndt/gfn698; Dasgupta I, 2007, NAT CLIN PRACT NEPHR, V3, P480, DOI 10.1038/ncpneph0569; Dasgupta I, 2009, SEMIN DIALYSIS, V22, P476, DOI 10.1111/j.1525-139X.2009.00617.x; DAUGIRDAS JT, 1989, INT J ARTIF ORGANS, V12, P420; Dockery D W, 1993, N Engl J Med, V329, P1753, DOI 10.1056/NEJM199312093292401; Dockery DW, 2007, NEW ENGL J MED, V356, P511, DOI 10.1056/NEJMe068274; Gan WQ, 2012, AM J EPIDEMIOL, V175, P898, DOI 10.1093/aje/kwr424; Hsiao CH, 2011, NEPHROL DIAL TRANSPL, V26, P1016, DOI 10.1093/ndt/gfq485; Hsu CW, 2010, NEPHROLOGY, V15, P313, DOI 10.1111/j.1440-1797.2009.01202.x; Miranda JJ, 2011, HEART, V97, P787, DOI 10.1136/hrt.2010.218537; Jassal V, 1996, NEPHROL DIAL TRANSPL, V11, P1052; Jenq CC, 2009, AM J MED SCI, V337, P188, DOI 10.1097/MAJ.0b013e31818d8bbe; Kalantar-Zadeh K, 2003, AM J KIDNEY DIS, V42, P864, DOI 10.1016/j.ajkd.2003.07.016; Kunzli N, 2005, ENVIRON HEALTH PERSP, V113, P201, DOI 10.1289/ehp.7523; Kurella M, 2007, ANN INTERN MED, V146, P177, DOI 10.7326/0003-4819-146-3-200702060-00006; Laden F, 2006, AM J RESP CRIT CARE, V173, P667, DOI 10.1164/rccm.200503-443OC; Lamping DL, 2000, LANCET, V356, P1543, DOI 10.1016/S0140-6736(00)03123-8; Mateen FJ, 2011, JAMA-J AM MED ASSOC, V305, P1240, DOI 10.1001/jama.2011.352; Miller KA, 2007, NEW ENGL J MED, V356, P447, DOI 10.1056/NEJMoa054409; Nascimento MM, 2002, BLOOD PURIFICAT, V20, P454, DOI 10.1159/000063559; Pecoits R, 2002, NEPHROL DIAL TRANSPL, V17, P28, DOI 10.1093/ndt/17.suppl_11.28; Rich DQ, 2012, JAMA-J AM MED ASSOC, V307, P2068, DOI 10.1001/jama.2012.3488; Samet JM, 2011, NEW ENGL J MED, V365, P198, DOI 10.1056/NEJMp1103332; SARGENT JA, 1983, KIDNEY INT, pS19; Sezer S, 2002, NEPHRON, V91, P456, DOI 10.1159/000064287; Sun QH, 2005, JAMA-J AM MED ASSOC, V294, P3003, DOI 10.1001/jama.294.23.3003; Tsai SS, 2003, STROKE, V34, P2612, DOI 10.1161/01.STR.0000095564.33543.64; Yang WC, 2008, NEPHROL DIAL TRANSPL, V23, P3977, DOI 10.1093/ndt/gfn406; Yeh ETH, 2003, CIRCULATION, V107, P370, DOI 10.1161/01.CIR.0000053731.05365.5A; Yen TH, 2010, THER APHER DIAL, V14, P400, DOI 10.1111/j.1744-9987.2010.00818.x; Yen TH, 2009, AM J MED SCI, V337, P421, DOI 10.1097/MAJ.0b013e31819bbec1	36	8	8	1	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 18	2013	8	9							e74358	10.1371/journal.pone.0074358	http://dx.doi.org/10.1371/journal.pone.0074358			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	221YD	24058552	Green Submitted, Green Published, gold			2023-01-03	WOS:000324695900042
J	Rawizza, HE; Chaplin, B; Meloni, ST; Darin, KM; Olaitan, O; Scarsi, KK; Onwuamah, CK; Audu, RA; Chebu, PR; Imade, GE; Okonkwo, P; Kanki, PJ				Rawizza, Holly E.; Chaplin, Beth; Meloni, Seema T.; Darin, Kristin M.; Olaitan, Oluremi; Scarsi, Kimberly K.; Onwuamah, Chika K.; Audu, Rosemary A.; Chebu, Philippe R.; Imade, Godwin E.; Okonkwo, Prosper; Kanki, Phyllis J.			Accumulation of Protease Mutations among Patients Failing Second-Line Antiretroviral Therapy and Response to Salvage Therapy in Nigeria	PLOS ONE			English	Article							LOPINAVIR-RITONAVIR MONOTHERAPY; DRUG-RESISTANCE MUTATIONS; 1-INFECTED PATIENTS; PLUS ZIDOVUDINE; OUTCOMES; LAMIVUDINE; INHIBITORS; SELECTION; FAILURE; PROGRAM	Background: To date, antiretroviral therapy (ART) guidelines and programs in resource-limited settings (RLS) have focused on 1st- and 2nd-line (2 L) therapy. As programs approach a decade of implementation, policy regarding access to 3rd-line (3 L) ART is needed. We aimed to examine the impact of maintaining patients on failing 2 L ART on the accumulation of protease (PR) mutations. Methods and Findings: From 2004-2011, the Harvard/APIN PEPFAR Program provided ART to >100,000 people in Nigeria. Genotypic resistance testing was performed on a subset of patients experiencing 2 L failure, defined as 2 consecutive viral loads (VL)>1000 copies/mL after >= 6 months on 2 L. Of 6714 patients who received protease inhibitor (PI)-based ART, 673 (10.0%) met virologic failure criteria. Genotypes were performed on 61 samples. Patients on non-suppressive 2 L therapy for <12 months prior to genotyping had a median of 2 (IQR: 0-5) International AIDS Society (IAS) PR mutations compared with 5 (IQR: 0-6) among patients failing for >24 months. Patients developed a median of 0.6 (IQR: 0-1.4) IAS PR mutations per 6 months on failing 2 L therapy. In 38% of failing patients no PR mutations were present. For patients failing >24 months, high-or intermediate-level resistance to lopinavir and atazanavir was present in 63%, with 5% to darunavir. Conclusions: This is the first report assessing the impact of duration of non-suppressive 2 L therapy on the accumulation of PR resistance in a RLS. This information provides insight into the resistance cost of failing to switch non-suppressive 2 L regimens and highlights the issue of 3 L access.	[Rawizza, Holly E.] Brigham & Womens Hosp, Boston, MA 02115 USA; [Rawizza, Holly E.; Chaplin, Beth; Meloni, Seema T.; Kanki, Phyllis J.] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA; [Darin, Kristin M.; Scarsi, Kimberly K.] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA; [Olaitan, Oluremi; Okonkwo, Prosper] AIDS Prevent Initiat Nigeria, Abuja, Nigeria; [Onwuamah, Chika K.; Audu, Rosemary A.] Nigerian Inst Med Res, Lagos, Nigeria; [Chebu, Philippe R.; Imade, Godwin E.] Jos Univ Teaching Hosp, Jos, Nigeria	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard T.H. Chan School of Public Health; Northwestern University; Feinberg School of Medicine	Rawizza, HE (corresponding author), Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA.	hrawizza@hsph.harvard.edu	Audu, Rosemary A/G-1726-2017; Onwuamah, Chika Kingsley/ABB-9926-2020	Audu, Rosemary A/0000-0002-0330-5219; Onwuamah, Chika Kingsley/0000-0002-5111-1822; Scarsi, Kimberly/0000-0001-9406-693X	US Department of Health and Human Services, Health Resources and Services Administration [U51HA02522]; Centers for Disease Control and Prevention (CDC) [PS 001058]; Harvard School of Public Health	US Department of Health and Human Services, Health Resources and Services Administration(United States Department of Health & Human ServicesUnited States Health Resources & Service Administration (HRSA)); Centers for Disease Control and Prevention (CDC)(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA); Harvard School of Public Health	This work was funded in part by the US Department of Health and Human Services, Health Resources and Services Administration (U51HA02522) and the Centers for Disease Control and Prevention (CDC) through a cooperative agreement with APIN (PS 001058). The authors would also like to acknowledge the Harvard School of Public Health for the provision of funds for a portion of the third-line antiretrovirals. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], HIV SEQ AL; Bangsberg DR, 2000, AIDS, V14, P357, DOI 10.1097/00002030-200003100-00008; Chaplin B, 2011, AIDS RES HUM RETROV, V27, P71, DOI 10.1089/aid.2010.0050; Condra JH, 1998, HAEMOPHILIA, V4, P610, DOI 10.1046/j.1365-2516.1998.440610.x; Delaugerre C, 2009, ANTIMICROB AGENTS CH, V53, P2934, DOI 10.1128/AAC.01643-08; Delfraissy JFO, 2008, AIDS, V22, P385, DOI 10.1097/QAD.0b013e3282f3f16d; El-Khatib Z, 2010, AIDS, V24, P1679, DOI 10.1097/QAD.0b013e32833a097b; Federal Ministry of Health Nigeria, 2010, NAT GUID HIV AIDS TR; Ferradini L, 2011, J INT AIDS SOC, V14, DOI 10.1186/1758-2652-14-14; FOX M, 2009, J ACQ IMMUN DEF SYND, V53, P500; Gutmann C, 2010, AIDS, V24, P2347, DOI 10.1097/QAD.0b013e32833db9a1; Hosseinipour MC, 2010, HIV MED, V11, P510, DOI 10.1111/j.1468-1293.2010.00825.x; Johnson Victoria A, 2011, Top Antivir Med, V19, P156; Johnston V, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036997; Joint United Nations Programme on HIV/AIDS (UNAIDS), 2012, UNAIDSJC2296E; Koenig SP, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001095; Kuritzkes DR, 2004, AIDS, V18, pS45, DOI 10.1097/00002030-200406003-00009; Levison JH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032144; Levison JH, 2011, ANTIVIR THER, V16, P853, DOI 10.3851/IMP1819; Loemba H, 2002, ANTIMICROB AGENTS CH, V46, P2087, DOI 10.1128/AAC.46.7.2087-2094.2002; Maguire M, 2002, ANTIMICROB AGENTS CH, V46, P731, DOI 10.1128/AAC.46.3.731-738.2002; Maiga AI, 2012, J ANTIMICROB CHEMOTH, V67, P2943, DOI [10.1093/jac/dks310, 10.1093]; Mo HM, 2005, J VIROL, V79, P3329, DOI 10.1128/JVI.79.6.3329-3338.2005; Molla A, 1996, NAT MED, V2, P760, DOI 10.1038/nm0796-760; Murphy RA, 2012, JAIDS-J ACQ IMM DEF, V61, P158, DOI 10.1097/QAI.0b013e3182615ad1; Murphy RA, 2010, AIDS, V24, P1007, DOI 10.1097/QAD.0b013e3283333639; Pulido F, 2008, AIDS, V22, pF1, DOI 10.1097/QAD.0b013e3282f4243b; Rosenbloom DIS, 2012, NAT MED, V18, P1378, DOI 10.1038/nm.2892; Saravanan S, 2012, CLIN INFECT DIS, V54, P995, DOI 10.1093/cid/cir967; Steegen Kim, 2009, AIDS Res Ther, V6, P12, DOI 10.1186/1742-6405-6-12; Sungkanuparph S, 2007, CLIN INFECT DIS, V44, P447, DOI 10.1086/510745; Supply Chain Management System (SCMS), PEPFAR IMPL PARTN EC; Wainberg MA, 2011, NEW ENGL J MED, V365, P637, DOI 10.1056/NEJMra1004180; Walensky RP, 2009, ANN INTERN MED, V151, P157, DOI 10.7326/0003-4819-151-3-200908040-00138; Wallis CL, 2011, AIDS RES TREAT, V2011, DOI 10.1155/2011/769627; WHO, 2010, ANT THER HIV INF AD; World Health Organization, 2006, ANT THER HIV INF AD; Zazzi M, 2009, J ANTIMICROB CHEMOTH, V64, P616, DOI 10.1093/jac/dkp252	38	31	31	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 17	2013	8	9							e73582	10.1371/journal.pone.0073582	http://dx.doi.org/10.1371/journal.pone.0073582			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	219YJ	24069209	Green Published, gold, Green Submitted			2023-01-03	WOS:000324547300015
J	Ferrari, J; Knoflach, M; Seyfang, L; Lang, W				Ferrari, Julia; Knoflach, Michael; Seyfang, Leonhard; Lang, Wilfried		Austrian Stroke Unit Registry	Differences in Process Management and In-Hospital Delays in Treatment with iv Thrombolysis	PLOS ONE			English	Article							STROKE UNIT REGISTRY; ACUTE ISCHEMIC-STROKE; ALTEPLASE; INTERVENTION; THERAPY; SCALE; TIME	Objectives: Rapid initiation of intravenous thrombolysis improves patient's outcome in acute stroke. We analyzed intercenter variability and factors that influence the door-to-needle time with a special focus on process measurements in all Austrian stroke units. Methods: Case level data of patients receiving intravenous thrombolysis in the Austrian Stroke Unit Registry were enriched with information of a structured questionnaire on center specific process measures of all Austrian stroke units. Influence of case and center specific variables was determined by LASSO procedure. Results: Center specific median door-to-needle time ranged between 30 and 78 minutes. Between April 2004 and November 2012, 6246 of 57991 patients treated in Austrian stroke units with acute ischemic stroke received intravenous thrombolysis. An onset-to-door time >120 minutes, patients with total anterior circulation stroke, recent year of admission, patient transportation with ambulance crew and emergency physician, the use of point of care tests reduced the door-to-needle time, whereas onset-to-door <= 60 minutes, unknown onset-to-door, patients with an NIHSS <= 4 or posterior circulation stroke, initial admission to a general emergency department, a distant radiology department, primary imaging modality other than plain CT and waiting for the lab results were associated with an increase in door-to-needle time. Case level and center specific factors could explain the inter center variability of door-to-needle times in 31 of 34 stroke units in Austria. Conclusions: In light of our results it seems crucial that every single stroke center documents and critically reviews possibilities of optimizing practice strategies in acute stroke care.	[Ferrari, Julia; Lang, Wilfried] Hosp Barmherzige Brueder, Dept Neurol, Vienna, Austria; [Knoflach, Michael] Med Univ Innsbruck, Dept Neurol, A-6020 Innsbruck, Austria; [Seyfang, Leonhard] Danube Univ, Dept Clin Neurosci & Prevent Med, Krems, Austria; Gesundheit Osterreich GmbH BIQG, Vienna, Austria	Konventhospital Der Barmherzigen Bruder; Medical University of Innsbruck; Danube University Krems	Knoflach, M (corresponding author), Med Univ Innsbruck, Dept Neurol, A-6020 Innsbruck, Austria.	michael.knoflach@i-med.ac.at		Trinka, Eugen/0000-0002-5950-2692; Knoflach, Michael/0000-0001-5576-6562				Adams HP, 2007, CIRCULATION, V115, pE478, DOI 10.1161/CIRCULATIONAHA.107.181486; Ferrari J, 2010, NEUROLOGY, V74, P136, DOI 10.1212/WNL.0b013e3181c9188b; Ferrari J, 2010, STROKE, V41, P2001, DOI 10.1161/STROKEAHA.110.590372; Fonarow GC, 2011, STROKE, V42, P2983, DOI 10.1161/STROKEAHA.111.621342; Fonarow GC, 2011, CIRCULATION, V123, P750, DOI 10.1161/CIRCULATIONAHA.110.974675; Ford AL, 2012, STROKE, V43, P3395, DOI 10.1161/STROKEAHA.112.670687; Hacke W, 2008, NEW ENGL J MED, V359, P1317, DOI 10.1056/NEJMoa0804656; Hastie T., 2011, LARS LEAST ANGLE REG; Knoflach M, 2012, NEUROLOGY, V78, P279, DOI 10.1212/WNL.0b013e31824367ab; Lees KR, 2010, LANCET, V375, P1695, DOI 10.1016/S0140-6736(10)60491-6; Linfante I, 2001, ARCH NEUROL-CHICAGO, V58, P621, DOI 10.1001/archneur.58.4.621; MARLER JR, 1995, NEW ENGL J MED, V333, P1581, DOI 10.1056/nejm199512143332401; Meretoja A, 2012, NEUROLOGY, V79, P306, DOI 10.1212/WNL.0b013e31825d6011; Mikulik R, 2012, STROKE, V43, P1578, DOI 10.1161/STROKEAHA.111.644120; R Development Core Team, 2010, R LANG ENV STAT COMP; Rizos T, 2009, STROKE, V40, P3547, DOI 10.1161/STROKEAHA.109.562769; Rost NS, 2009, NEUROLOGY, V73, P1957, DOI 10.1212/WNL.0b013e3181c5b46d; Sato S, 2008, NEUROLOGY, V70, P2371, DOI 10.1212/01.wnl.0000304346.14354.0b; Scott PA, 2013, LANCET NEUROL, V12, P139, DOI 10.1016/S1474-4422(12)70311-3; Tibshirani R, 1996, J ROY STAT SOC B MET, V58, P267, DOI 10.1111/j.2517-6161.1996.tb02080.x; Topakian R, 2011, EUR J NEUROL, V18, P306, DOI 10.1111/j.1468-1331.2010.03141.x; Wardlaw JM, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000213.pub2	22	12	13	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 12	2013	8	9							e75378	10.1371/journal.pone.0075378	http://dx.doi.org/10.1371/journal.pone.0075378			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	242KO	24069406	Green Published, gold, Green Submitted			2023-01-03	WOS:000326240100123
J	Wang, ZC; Cai, F; Chen, XY; Luo, MH; Hu, LL; Lu, Y				Wang, Zhicheng; Cai, Feng; Chen, Xiaoyu; Luo, Meihong; Hu, Lingling; Lu, Yuan			The Role of Mitochondria-Derived Reactive Oxygen Species in Hyperthermia-Induced Platelet Apoptosis	PLOS ONE			English	Article							NITRIC-OXIDE SYNTHASE; OXIDATIVE STRESS; OVARIAN-CANCER; CYTOCHROME-C; HEAT-STRESS; CELL-DEATH; SUPEROXIDE; ROS; CARDIOLIPIN; DYSFUNCTION	A combination of hyperthermia with radiotherapy and chemotherapy for various solid tumors has been practiced clinically. However, hyperthermic therapy has side effects, such as thrombocytopenia. Up to now, the pathogenesis of hyperthermia-induced thrombocytopenia remains unclear. Previous studies have shown that hyperthermia induces platelet apoptosis. However, the signaling pathways and molecular mechanisms involved in hyperthermia-induced platelet apoptosis have not been determined. Here we show that hyperthermia induced intracellular reactive oxygen species (ROS) production and mitochondrial ROS generation in a time-dependent manner in platelets. The mitochondria-targeted ROS scavenger Mito-TEMPO blocked intracellular ROS and mitochondrial ROS generation. By contrast, inhibitors of reduced nicotinamide adenine dinucleotide phosphate (NADPH) oxidase, nitric oxide synthase, cyclooxygenase and lipoxygenase did not. Furthermore, Mito-TEMPO inhibited hyperthermia-induced malonyldialdehyde production and cardiolipin peroxidation. We also showed that hyperthermia-triggered platelet apoptosis was inhibited by Mito-TEMPO. Furthermore, Mito-TEMPO ameliorated hyperthermia-impaired platelet aggregation and adhesion function. Lastly, hyperthermia decreased platelet manganese superoxide dismutase (MnSOD) protein levels and enzyme activity. These data indicate that mitochondrial ROS play a pivotal role in hyperthermia-induced platelet apoptosis, and decreased of MnSOD activity might, at least partially account for the enhanced ROS levels in hyperthermia-treated platelets. Therefore, determining the role of mitochondrial ROS as contributory factors in platelet apoptosis, is critical in providing a rational design of novel drugs aimed at targeting mitochondrial ROS. Such therapeutic approaches would have potential clinical utility in platelet-associated disorders involving oxidative damage.	[Wang, Zhicheng; Lu, Yuan] Fudan Univ, Shanghai Med Coll, Huashan Hosp, Dept Lab Med, Shanghai 200433, Peoples R China; [Wang, Zhicheng; Cai, Feng; Luo, Meihong; Hu, Lingling] Shanghai Univ Tradit Chinese Med, Shanghai Hosp Tradit Chinese Med, Dept Lab Med, Shanghai, Peoples R China; [Chen, Xiaoyu] Anhui Med Univ, Dept Histol & Embryol, Hefei, Peoples R China	Fudan University; Shanghai University of Traditional Chinese Medicine; Anhui Medical University	Lu, Y (corresponding author), Fudan Univ, Shanghai Med Coll, Huashan Hosp, Dept Lab Med, Shanghai 200433, Peoples R China.	yuanlu@hsh.stn.sh.cn	hu, ling/GWC-1104-2022		National Natural Science Foundation of China [NSFC 81270650]; Innovation Program of Shanghai Municipal Education Commission [12YZ068]; Natural Science Foundation of Shanghai [12ZR1429900]; Postdoctoral Science Foundation of Shanghai [12R21411700]; China Postdoctoral Science Foundation [2012M511043]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Innovation Program of Shanghai Municipal Education Commission(Innovation Program of Shanghai Municipal Education Commission); Natural Science Foundation of Shanghai(Natural Science Foundation of Shanghai); Postdoctoral Science Foundation of Shanghai(China Postdoctoral Science Foundation); China Postdoctoral Science Foundation(China Postdoctoral Science Foundation)	This study was supported by grants from the National Natural Science Foundation of China (NSFC 81270650), the Innovation Program of Shanghai Municipal Education Commission (12YZ068), the Natural Science Foundation of Shanghai (12ZR1429900), the Postdoctoral Science Foundation of Shanghai (12R21411700), the China Postdoctoral Science Foundation (2012M511043). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Atmaca A, 2009, GYNECOL ONCOL, V112, P384, DOI 10.1016/j.ygyno.2008.11.001; Balaban RS, 2005, CELL, V120, P483, DOI 10.1016/j.cell.2005.02.001; Begonja AJ, 2005, BLOOD, V106, P2757, DOI 10.1182/blood-2005-03-1047; Bolisetty S, 2013, INT J MOL SCI, V14, P6306, DOI 10.3390/ijms14036306; Brand MD, 2011, BIOCHEM J, V435, P297, DOI 10.1042/BJ20110162; Bryan N, 2012, EUR CELLS MATER, V24, P249, DOI 10.22203/eCM.v024a18; Celotto AM, 2012, BRAIN BEHAV, V2, P424, DOI 10.1002/brb3.73; Dai KS, 2009, THROMB RES, V124, P101, DOI 10.1016/j.thromres.2008.12.044; Dikalova AE, 2010, CIRC RES, V107, P106, DOI 10.1161/CIRCRESAHA.109.214601; Drose S, 2008, J BIOL CHEM, V283, P21649, DOI 10.1074/jbc.M803236200; Ferlini C, 2007, NAT PROTOC, V2, P3111, DOI 10.1038/nprot.2007.397; Fotopoulou C, 2010, INT J HYPERTHER, V26, P118, DOI 10.3109/02656730903369200; Kagan VE, 2009, MOL NUTR FOOD RES, V53, P104, DOI 10.1002/mnfr.200700402; Kagan VE, 2005, NAT CHEM BIOL, V1, P223, DOI 10.1038/nchembio727; Kalvegren H, 2005, THROMB HAEMOSTASIS, V94, P327, DOI 10.1160/TH04-06-0360; Kanter M, 2013, TOXICOL IND HEALTH, V29, P99, DOI 10.1177/0748233711425082; Katschinski DM, 2000, J BIOL CHEM, V275, P21094, DOI 10.1074/jbc.M001629200; Klaunig JE, 2011, TOXICOL APPL PHARM, V254, P86, DOI 10.1016/j.taap.2009.11.028; Krotz F, 2004, ARTERIOSCL THROM VAS, V24, P1988, DOI 10.1161/01.ATV.0000145574.90840.7d; Lambert AJ, 2008, BBA-BIOENERGETICS, V1777, P397, DOI 10.1016/j.bbabio.2008.03.005; Lim S, 2011, CELL PHYSIOL BIOCHEM, V28, P873, DOI 10.1159/000335802; Loor G, 2011, BBA-MOL CELL RES, V1813, P1382, DOI 10.1016/j.bbamcr.2010.12.008; Luanpitpong S, 2013, MOL BIOL CELL, V24, P858, DOI 10.1091/mbc.E12-10-0747; Luanpitpong S, 2012, BIOCHEM PHARMACOL, V83, P1643, DOI 10.1016/j.bcp.2012.03.010; Luchetti F, 2003, HISTOL HISTOPATHOL, V18, P1041, DOI 10.14670/HH-18.1041; Luo HM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060065; Marjanovic JA, 2008, J BIOL CHEM, V283, P28827, DOI 10.1074/jbc.M801646200; Moon EJ, 2010, P NATL ACAD SCI USA, V107, P20477, DOI 10.1073/pnas.1006646107; Pajonk F, 2005, CANCER RES, V65, P4836, DOI 10.1158/0008-5472.CAN-03-2749; Pandey KB, 2010, OXID MED CELL LONGEV, V3, P2, DOI 10.4161/oxim.3.1.10476; Petrosillo G, 2003, FASEB J, V17, P2202, DOI 10.1096/fj.03-0012com; Quinlan CL, 2012, J BIOL CHEM, V287, P27255, DOI 10.1074/jbc.M112.374629; Renault TT, 2011, BIOCHIMIE, V93, P1379, DOI 10.1016/j.biochi.2011.05.013; SCHULZ E, 2012, ANTIOXID REDOX SIGN, P57349; Sciancalepore M, 2012, FREE RADICAL BIO MED, V53, P1392, DOI 10.1016/j.freeradbiomed.2012.08.002; Shen Garry X., 2012, Cardiovascular & Hematological Disorders - Drug Targets, V12, P106; Souslova T, 2004, INT J RADIAT ONCOL, V60, P1538, DOI 10.1016/j.ijrobp.2004.07.686; Stankiewicz AR, 2009, CELL DEATH DIFFER, V16, P638, DOI 10.1038/cdd.2008.189; Swerdlow RH, 2007, ANTIOXID REDOX SIGN, V9, P1591, DOI 10.1089/ars.2007.1676; Tissier R, 2013, RESUSCITATION, V84, P249, DOI 10.1016/j.resuscitation.2012.06.030; Tyurina YY, 2010, AM J PHYSIOL-LUNG C, V299, pL73, DOI 10.1152/ajplung.00035.2010; Vela L, 2011, J INORG BIOCHEM, V105, P1306, DOI 10.1016/j.jinorgbio.2011.06.004; Venkataraman S, 2004, FREE RADICAL RES, V38, P1119, DOI 10.1080/10715760400010470; Wang ZC, 2010, PLATELETS, V21, P229, DOI 10.3109/09537100903443949; Wang ZC, 2010, THROMB RES, V125, P340, DOI 10.1016/j.thromres.2010.02.001; Wang ZC, 2010, ARCH BIOCHEM BIOPHYS, V495, P136, DOI 10.1016/j.abb.2010.01.003; Wartenberg M, 2005, INT J CANCER, V113, P229, DOI 10.1002/ijc.20596; White MG, 2012, J NEUROPHYSIOL, V108, P2203, DOI 10.1152/jn.00638.2011; Willems SH, 2010, BIOCHEM J, V428, P439, DOI 10.1042/BJ20100179; Yuki H, 2003, FREE RADICAL RES, V37, P631, DOI 10.1080/1071576031000088292; Zhang S, 2013, J THROMB HAEMOST, V11, P149, DOI 10.1111/jth.12063; Zhang WL, 2012, THROMB RES, V130, P81, DOI 10.1016/j.thromres.2012.02.013; Zhao QL, 2006, FREE RADICAL BIO MED, V40, P1131, DOI 10.1016/j.freeradbiomed.2005.10.064; Zhou MY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032349	54	39	40	2	41	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 4	2013	8	9							e75044	10.1371/journal.pone.0075044	http://dx.doi.org/10.1371/journal.pone.0075044			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	219OE	24023970	Green Published, gold, Green Submitted			2023-01-03	WOS:000324515600164
J	Li, WW; Wei, YH; Li, H; Lai, DM; Lin, TN				Li, Wen-Wen; Wei, Yau-Huei; Li, Hung; Lai, Dar-Ming; Lin, Teng-Nan			Isolation and Characterization of a Novel Strain of Mesenchymal Stem Cells from Mouse Umbilical Cord: Potential Application in Cell-Based Therapy	PLOS ONE			English	Article							HUMAN BONE-MARROW; STROMAL CELLS; ADIPOSE-TISSUE; HEPATIC DIFFERENTIATION; LIVER-FAILURE; IN-VITRO; ISCHEMIC-STROKE; HUMAN PLACENTA; MATRIX CELLS; SPINAL-CORD	Human umbilical cord-derived mesenchymal stem cells (hUC-MSCs) have recently been recognized as a potential source for cell-based therapy in various preclinical animal models, such as Parkinson's disease, cerebral ischemia, spinal cord injury, and liver failure; however, the precise cellular and molecular mechanisms underlying the beneficial outcomes remain under investigation. There is a growing concern regarding rejection and alteration of genetic code using this xenotransplantation approach. In this study, a novel strain of murine MSCs derived from the umbilical cord of wild-type and green fluorescent protein (GFP) transgenic mice have been successfully isolated, expanded, and characterized. After 10 passages, the mUC-MSCs developed a rather homogeneous, triangular, spindle-shaped morphology, and were sub-cultured up to 7 months (over 50 passages) without overt changes in morphology and doubling time. Cell surface markers are quite similar to MSCs isolated from other tissue origins as well as hUC-MSCs. These mUC-MSCs can differentiate into osteoblasts, adipocytes, neurons, and astrocytes in vitro, as well as hematopoietic lineage cells in vivo. mUC-MSCs also possess therapeutic potential against two disease models, focal ischemic stroke induced by middle cerebral artery occlusion (MCAo) and acute hepatic failure. Subtle differences in the expression of cytokine-related genes exist between mUC-MSCs and hUC-MSCs, which may retard and jeopardize the advance of cell therapy. Allografts of these newly established mUC-MSCs into various mouse disease models may deepen our insights into the development of more effective cell therapy regimens.	[Li, Wen-Wen; Wei, Yau-Huei] Natl Yang Ming Univ, Inst Biochem & Mol Biol, Taipei 112, Taiwan; [Wei, Yau-Huei] Mackay Med Coll, Dept Med, New Taipei City, Taiwan; [Li, Hung] Acad Sinica, Inst Mol Biol, Taipei, Taiwan; [Lai, Dar-Ming] Natl Taiwan Univ Hosp, Dept Surg, Div Neurosurg, Taipei 100, Taiwan; [Lin, Teng-Nan] Natl Yang Ming Univ, Inst Neurosci, Taipei 112, Taiwan; [Lin, Teng-Nan] Acad Sinica, Inst Biomed Sci, Taipei, Taiwan	National Yang Ming Chiao Tung University; Mackay Medical College; Academia Sinica - Taiwan; National Taiwan University; National Taiwan University Hospital; National Yang Ming Chiao Tung University; Academia Sinica - Taiwan	Lai, DM (corresponding author), Natl Taiwan Univ Hosp, Dept Surg, Div Neurosurg, Taipei 100, Taiwan.	dmdlai@ntu.edu.tw; bmltn@ibms.sinica.edu.tw	Lin, Teng-nan/Q-4566-2018; Wei, Yau-Huei/ABA-6841-2021	Lin, Teng-nan/0000-0002-4009-0798; Wei, Yau-Huei/0000-0002-6429-2546	Academia Sinica; National Science Council of Taiwan Government	Academia Sinica(Academia Sinica - Taiwan); National Science Council of Taiwan Government(Ministry of Science and Technology, Taiwan)	This work was supported by grants from Academia Sinica and National Science Council of Taiwan Government. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bai CY, 2013, MOL CELL BIOCHEM, V376, P95, DOI 10.1007/s11010-012-1553-y; Baksh D, 2007, STEM CELLS, V25, P1384, DOI 10.1634/stemcells.2006-0709; Banas A, 2009, J GASTROEN HEPATOL, V24, P70, DOI 10.1111/j.1440-1746.2008.05496.x; Ben-Ami E, 2011, AUTOIMMUN REV, V10, P410, DOI 10.1016/j.autrev.2011.01.005; Bieback K, 2004, STEM CELLS, V22, P625, DOI 10.1634/stemcells.22-4-625; Bjornson CRR, 1999, SCIENCE, V283, P534, DOI 10.1126/science.283.5401.534; Burdon TJ, 2011, BONE MARROW RES, DOI 10.1155/2011/207326; Cai JL, 2010, J BIOL CHEM, V285, P11227, DOI 10.1074/jbc.M109.086389; Cardoso TC, 2012, BMC BIOTECHNOL, V12, DOI 10.1186/1472-6750-12-18; Carlin R, 2006, REPROD BIOL ENDOCRIN, V4, DOI 10.1186/1477-7827-4-8; Castillo MD, 2008, CTS-CLIN TRANSL SCI, V1, P27, DOI 10.1111/j.1752-8062.2008.00018.x; Chao KC, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001451; Chao YH, 2012, J BIOMED BIOTECHNOL, DOI 10.1155/2012/759503; CHEN ST, 1986, STROKE, V17, P738, DOI 10.1161/01.STR.17.4.738; Chu MS, 2006, CELL SIGNAL, V18, P519, DOI 10.1016/j.cellsig.2005.05.018; De Bari C, 2001, ARTHRITIS RHEUM-US, V44, P1928, DOI 10.1002/1529-0131(200108)44:8<1928::AID-ART331>3.0.CO;2-P; de Miranda AS, 2010, ARQ NEURO-PSIQUIAT, V68, P597, DOI 10.1590/S0004-282X2010000400022; Di Nicola M, 2002, BLOOD, V99, P3838, DOI 10.1182/blood.V99.10.3838; Ding DC, 2007, NEUROBIOL DIS, V27, P339, DOI 10.1016/j.nbd.2007.06.010; Fu YS, 2006, STEM CELLS, V24, P115, DOI 10.1634/stemcells.2005-0053; Fukuchi Y, 2004, STEM CELLS, V22, P649, DOI 10.1634/stemcells.22-5-649; Greco SJ, 2007, STEM CELLS DEV, V16, P811, DOI 10.1089/scd.2007.0011; Guillot PV, 2007, STEM CELLS, V25, P646, DOI 10.1634/stemcells.20060208; Harting MT, 2009, STEM CELLS DEV, V18, P127, DOI 10.1089/scd.2008.0046; Hu Y, 2003, J LAB CLIN MED, V141, P342, DOI 10.1016/S0022-2143(03)00022-2; Hwang S, 2012, CELL BIOL INT, V36, P279, DOI 10.1042/CBI20110325; Iacono E, 2012, REPRODUCTION, V143, P455, DOI 10.1530/REP-10-0408; in't Anker PS, 2004, STEM CELLS, V22, P1338, DOI 10.1634/stemcells.2004-0058; Jackson KA, 1999, P NATL ACAD SCI USA, V96, P14482, DOI 10.1073/pnas.96.25.14482; Jiang YH, 2002, NATURE, V418, P41, DOI 10.1038/nature00870; Kajstura J, 1998, P NATL ACAD SCI USA, V95, P8801, DOI 10.1073/pnas.95.15.8801; Karahuseyinoglu S, 2007, STEM CELLS, V25, P319, DOI 10.1634/stemcells.2006-0286; Kim SJ, 2011, J KOREAN SURG SOC, V81, P176, DOI 10.4174/jkss.2011.81.3.176; Koh SH, 2008, BRAIN RES, V1229, P233, DOI 10.1016/j.brainres.2008.06.087; Lee KS, 2013, RES VET SCI, V94, P144, DOI 10.1016/j.rvsc.2012.07.033; Lee KD, 2004, HEPATOLOGY, V40, P1275, DOI 10.1002/hep.20469; Lee OK, 2004, BLOOD, V103, P1669, DOI 10.1182/blood-2003-05-1670; Liao WB, 2009, TRANSPLANTATION, V87, P350, DOI 10.1097/TP.0b013e318195742e; LIN TN, 1993, STROKE, V24, P117, DOI 10.1161/01.STR.24.1.117; Liu WH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055487; LURIA EA, 1971, TRANSFUSION, V11, P345, DOI 10.1111/j.1537-2995.1971.tb04426.x; Meirelles LD, 2009, CYTOKINE GROWTH F R, V20, P419, DOI 10.1016/j.cytogfr.2009.10.002; Mitchell KE, 2003, STEM CELLS, V21, P50, DOI 10.1634/stemcells.21-1-50; Moodley Y, 2009, AM J PATHOL, V175, P303, DOI 10.2353/ajpath.2009.080629; Nauta AJ, 2007, BLOOD, V110, P3499, DOI 10.1182/blood-2007-02-069716; Pierdomenico L, 2005, TRANSPLANTATION, V80, P836, DOI 10.1097/01.tp.0000173794.72151.88; Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143; Revell CM, 2009, TISSUE ENG PART B-RE, V15, P1, DOI 10.1089/ten.teb.2008.0189; Ryan Jennifer M, 2005, J Inflamm (Lond), V2, P8, DOI 10.1186/1476-9255-2-8; Sigrist S, 2005, TRANSPL P, V37, P3516, DOI 10.1016/j.transproceed.2005.09.048; Togel F, 2007, AM J PHYSIOL-RENAL, V292, pF1626, DOI 10.1152/ajprenal.00339.2006; Troyer DL, 2008, STEM CELLS, V26, P591, DOI 10.1634/stemcells.2007-0439; Tsai PC, 2009, LIVER TRANSPLANT, V15, P484, DOI 10.1002/lt.21715; Tuli R, 2003, STEM CELLS, V21, P681, DOI 10.1634/stemcells.21-6-681; Wagner W, 2005, EXP HEMATOL, V33, P1402, DOI 10.1016/j.exphem.2005.07.003; Wang HS, 2004, STEM CELLS, V22, P1330, DOI 10.1634/stemcells.2004-0013; Yang CC, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003336; YOUNG HE, 1995, DEV DYNAM, V202, P137, DOI 10.1002/aja.1002020205; Yu J, 2012, BIOCHEM BIOPH RES CO, V422, P539, DOI 10.1016/j.bbrc.2012.04.156; Zanini C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028175; Zhang SC, 2012, TISSUE ENG PT A, V18, P1352, DOI [10.1089/ten.tea.2011.0516, 10.1089/ten.TEA.2011.0516]; Zhao SM, 2010, STEM CELLS DEV, V19, P607, DOI 10.1089/scd.2009.0345; Zhou ZL, 2013, CYTOTHERAPY, V15, P434, DOI 10.1016/j.jcyt.2012.11.015; Zuk PA, 2001, TISSUE ENG, V7, P211, DOI 10.1089/107632701300062859	64	15	16	0	19	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 26	2013	8	8							e74478	10.1371/journal.pone.0074478	http://dx.doi.org/10.1371/journal.pone.0074478			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	215RU	23991222	gold, Green Published, Green Submitted			2023-01-03	WOS:000324228800120
J	Hu, RK; Yan, H; Hao, XJ; Liu, HY; Wu, JR				Hu, Rongkuan; Yan, Huan; Hao, Xiaojiang; Liu, Haiyang; Wu, Jiarui			Shizukaol D Isolated from Chloranthus japonicas Inhibits AMPK-Dependent Lipid Content in Hepatic Cells by Inducing Mitochondrial Dysfunction	PLOS ONE			English	Article							ACTIVATED PROTEIN-KINASE; FATTY-ACID OXIDATION; RESPIRATORY COMPLEX-I; INSULIN-RESISTANCE; MALONYL-COA; SIGNALING PATHWAYS; GLUCOSE-UPTAKE; L6 MYOTUBES; HEPG2 CELLS; METFORMIN	This study is the first to demonstrate that shizukaol D, a natural compound isolated from Chloranthus japonicus, can activate AMP-activated protein kinase (AMPK), a key sensor and regulator of intracellular energy metabolism, leading to a decrease in triglyceride and cholesterol levels in HepG2 cells. Furthermore, we found that shizukaol D induces mitochondrial dysfunction by depolarizing the mitochondrial membrane and suppressing energy production, which may result in AMPK activation. Our results provide a possible link between mitochondrial dysfunction and AMPK activation and suggest that shizukaol D might be used to treat metabolic syndrome.	[Hu, Rongkuan; Wu, Jiarui] Univ Sci & Technol China, Hefei Natl Lab Phys Sci Microscale, Hefei 230026, Anhui, Peoples R China; [Hu, Rongkuan; Wu, Jiarui] Univ Sci & Technol China, Sch Life Sci, Hefei 230026, Anhui, Peoples R China; [Yan, Huan; Hao, Xiaojiang; Liu, Haiyang] Chinese Acad Sci, Kunming Inst Bot, State Key Lab Phytochem & Plant Resources West Ch, Kunming, Yunnan, Peoples R China; [Wu, Jiarui] Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Biochem & Cell Biol, Key Lab Syst Biol, Shanghai, Peoples R China; [Wu, Jiarui] Chinese Acad Sci, Shanghai Adv Res Inst, Shanghai, Peoples R China	Chinese Academy of Sciences; University of Science & Technology of China, CAS; Chinese Academy of Sciences; University of Science & Technology of China, CAS; Chinese Academy of Sciences; Kunming Institute of Botany, CAS; Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Chinese Academy of Sciences; Shanghai Advanced Research Institute, CAS	Liu, HY (corresponding author), Univ Sci & Technol China, Hefei Natl Lab Phys Sci Microscale, Hefei 230026, Anhui, Peoples R China.	haiyangliu@mail.kib.ac.cn; wujr@sibs.ac.cn	Hu, Rongkuan/M-8781-2018	Hu, Rongkuan/0000-0001-6293-2004	Ministry of Science and Technology [2010CB912102, 2011CB910200]; National Natural Science Foundation of China [31130034]; Knowledge Innovation Program of the Chinese Academy of Sciences [KSCX2-EW-Q-10]	Ministry of Science and Technology(Ministry of Science, ICT & Future Planning, Republic of Korea); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Knowledge Innovation Program of the Chinese Academy of Sciences(Chinese Academy of SciencesKnowledge Innovation Program of the Chinese Academy of Sciences)	This work was supported in part by grants from Ministry of Science and Technology (#2010CB912102, 2011CB910200), a grant from the National Natural Science Foundation of China (#31130034) (to JRW); and a grant from the Knowledge Innovation Program of the Chinese Academy of Sciences (KSCX2-EW-Q-10) (to HL). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Anurag P, 2002, DIABETES OBES METAB, V4, P36, DOI 10.1046/j.1463-1326.2002.00178.x; Brunmair B, 2004, DIABETES, V53, P1052, DOI 10.2337/diabetes.53.4.1052; Cao CM, 2008, CHEM BIODIVERS, V5, P219, DOI 10.1002/cbdv.200890020; Carling D, 2004, TRENDS BIOCHEM SCI, V29, P18, DOI 10.1016/j.tibs.2003.11.005; Caton PW, 2010, J ENDOCRINOL, V205, P97, DOI 10.1677/JOE-09-0345; Cheng Z, 2006, BBA-GEN SUBJECTS, V1760, P1682, DOI 10.1016/j.bbagen.2006.09.007; Cool B, 2006, CELL METAB, V3, P403, DOI 10.1016/j.cmet.2006.05.005; COONEY GJ, 1977, BIOCHEM PHARMACOL, V26, P2463, DOI 10.1016/0006-2952(77)90462-2; COONEY GJ, 1979, BIOCHEM PHARMACOL, V28, P1067, DOI 10.1016/0006-2952(79)90305-8; Davidson MB, 1997, AM J MED, V102, P99, DOI 10.1016/S0002-9343(96)00353-1; de Graaf AO, 2004, EXP CELL RES, V299, P533, DOI 10.1016/j.yexcr.2004.06.024; Deng WJ, 2010, MOL CELL PROTEOMICS, V9, P100, DOI 10.1074/mcp.M900020-MCP200; Fang PL, 2011, J NAT PROD, V74, P1408, DOI 10.1021/np200087d; Foretz M, 2010, J CLIN INVEST, V120, P2355, DOI 10.1172/JCI40671; Fryer LGD, 2002, J BIOL CHEM, V277, P25226, DOI 10.1074/jbc.M202489200; Fujii N, 2000, BIOCHEM BIOPH RES CO, V273, P1150, DOI 10.1006/bbrc.2000.3073; Fujimoto S, 2007, DIABETES RES CLIN PR, V77, pS2, DOI 10.1016/j.diabres.2007.01.026; GLOCKLIN VC, 1952, J CELL COMPAR PHYSL, V39, P341, DOI 10.1002/jcp.1030390302; Hagen RM, 2010, FEBS LETT, V584, P2689, DOI 10.1016/j.febslet.2010.04.004; Hahn-Windgassen A, 2005, J BIOL CHEM, V280, P32081, DOI 10.1074/jbc.M502876200; Hardie DG, 2003, FEBS LETT, V546, P113, DOI 10.1016/S0014-5793(03)00560-X; Hardie DG, 1997, EUR J BIOCHEM, V246, P259, DOI 10.1111/j.1432-1033.1997.00259.x; Hardie DG, 2004, J CELL SCI, V117, P5479, DOI 10.1242/jcs.01540; Harvatine KJ, 2006, J NUTR, V136, P2468, DOI 10.1093/jn/136.10.2468; Hawley SA, 2012, SCIENCE, V336, P918, DOI 10.1126/science.1215327; Hou XY, 2008, J BIOL CHEM, V283, P20015, DOI 10.1074/jbc.M802187200; Huang SL, 2012, DIABETOLOGIA, V55, P1469, DOI 10.1007/s00125-011-2366-3; Janovska A, 2008, MOL CELL ENDOCRINOL, V284, P1, DOI 10.1016/j.mce.2007.12.013; Kahn BB, 2005, CELL METAB, V1, P15, DOI 10.1016/j.cmet.2004.12.003; Kim MK, 2012, INT J NEUROPSYCHOPH, V15, P907, DOI 10.1017/S1461145711000976; Kim MS, 2012, MOL CELL ENDOCRINOL, V358, P127, DOI 10.1016/j.mce.2012.03.013; Kraegen EW, 2006, AM J PHYSIOL-ENDOC M, V290, pE471, DOI 10.1152/ajpendo.00316.2005; Kuang HX, 2008, CHEM BIODIVERS, V5, P1736, DOI 10.1002/cbdv.200890162; Kwon KY, 2011, BIOCHEM BIOPH RES CO, V416, P343, DOI 10.1016/j.bbrc.2011.11.038; Kwon OE, 2006, J ETHNOPHARMACOL, V104, P270, DOI 10.1016/j.jep.2005.09.018; Lochhead PA, 2000, DIABETES, V49, P896, DOI 10.2337/diabetes.49.6.896; McCullough LD, 2005, J BIOL CHEM, V280, P20493, DOI 10.1074/jbc.M409985200; Minokoshi Y, 2002, NATURE, V415, P339, DOI 10.1038/415339a; Nachbur U, 2006, BLOOD, V107, P2790, DOI 10.1182/blood-2005-07-2744; Nelson BA, 2000, DIABETES, V49, P981, DOI 10.2337/diabetes.49.6.981; Peterson JM, 2012, J BIOL CHEM, V287, P1576, DOI 10.1074/jbc.M111.278333; Qiu BY, 2010, DIABETES, V59, P256, DOI 10.2337/db09-0223; Ruderman NB, 2003, BIOCHEM SOC T, V31, P202, DOI 10.1042/bst0310202; Sambandam N, 2004, EUR J BIOCHEM, V271, P2831, DOI 10.1111/j.1432-1033.2004.04218.x; Sanders MJ, 2007, BIOCHEM J, V403, P139, DOI 10.1042/BJ20061520; Shaw RJ, 2004, P NATL ACAD SCI USA, V101, P3329, DOI 10.1073/pnas.0308061100; Turner N, 2008, DIABETES, V57, P1414, DOI 10.2337/db07-1552; Wang QH, 2011, J NAT PROD, V74, P16, DOI 10.1021/np100504m; Wen JP, 2010, MOL CELL BIOCHEM, V344, P109, DOI 10.1007/s11010-010-0534-2; Xiong L, 2007, J CELL BIOL, V178, P995, DOI 10.1083/jcb.200703044; Yamauchi T, 2002, NAT MED, V8, P1288, DOI 10.1038/nm788; Yim NH, 2008, BIOL PHARM BULL, V31, P1041, DOI 10.1248/bpb.31.1041; Yonemitsu S, 2001, DIABETES, V50, P1093, DOI 10.2337/diabetes.50.5.1093; Zammit VA, 2008, CELL METAB, V8, P175, DOI 10.1016/j.cmet.2008.07.009; Zang MW, 2004, J BIOL CHEM, V279, P47898, DOI 10.1074/jbc.M408149200; Zhan ZJ, 2011, NAT PROD REP, V28, P594, DOI 10.1039/c0np00050g; Zhang M, 2012, J NAT PROD, V75, P694, DOI 10.1021/np200968p; Zhang WY, 2010, HORM METAB RES, V42, P930, DOI 10.1055/s-0030-1265219; Zhou GC, 2001, J CLIN INVEST, V108, P1167, DOI 10.1172/JCI200113505	59	26	27	1	20	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 14	2013	8	8							e73527	10.1371/journal.pone.0073527	http://dx.doi.org/10.1371/journal.pone.0073527			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	202MQ	23967345	Green Submitted, gold, Green Published			2023-01-03	WOS:000323221500147
J	Perez-Valero, I; Gonzalez-Baeza, A; Estebanez, M; Montes-Ramirez, ML; Bayon, C; Pulido, F; Bernardino, JI; Zamora, FX; Monge, S; Gaya, F; Lagarde, M; Rubio, R; Hernando, A; Arnalich, F; Arribas, JR				Perez-Valero, Ignacio; Gonzalez-Baeza, Alicia; Estebanez, Miriam; Montes-Ramirez, Maria L.; Bayon, Carmen; Pulido, Federico; Bernardino, Jose I.; Zamora, Francisco X.; Monge, Susana; Gaya, Francisco; Lagarde, Maria; Rubio, Rafael; Hernando, Asuncion; Arnalich, Francisco; Arribas, Jose R.			Neurocognitive Impairment in Patients Treated with Protease Inhibitor Monotherapy or Triple Drug Antiretroviral Therapy	PLOS ONE			English	Article							FLUID HIV RNA; CEREBROSPINAL-FLUID; NUCLEOSIDE ANALOGS; MONET TRIAL; DARUNAVIR/RITONAVIR; CNS; DISORDERS; RITONAVIR; INFECTION	Background: In patients who remain virologically suppressed in plasma with triple-drug ART a switch to protease inhibitor monotherapy maintains high rates of suppression; however it is unknown if protease inhibitor monotherapy is associated to a higher rate of neurocognitive impairment. Methods: In this observational, cross-sectional study we included patients with plasma virological suppression (>= 1 year) without concomitant major neurocognitive confounders, currently receiving for >= 1 year boosted lopinavir or darunavir as monotherapy or as triple ART. Neurocognitive impairment was defined as per the 2007 consensus of the American Association of Neurology. The association between neurocognitive impairment and protease inhibitor monotherapy, adjusted by significant confounders, was analysed. Results: Of the 191 included patients - triple therapy: 96, 1-2 years of monotherapy: 40 and > 2 years of monotherapy: 55 proportions (95% CI) with neurocognitive impairment were: overall, 27.2% (20.9-33.6); triple therapy, 31.6% (22.1-41.0); short-term monotherapy, 25.0% (11.3-38.7); long-term monotherapy: 21.4% (10.5-32.3); p = 0.38. In all groups, neurocognitive impairment was mildly symptomatic or asymptomatic by self-report. There were not significant differences in Global Deficit Score by group. In the regression model confounding variables for neurocognitive impairment were years on ART, ethnicity, years of education, transmission category and the HOMA index. Adjusted by these variables the Odds Ratio ( 95% CI) for neurocognitive impairment of patients receiving short-term monotherapy was 0.85 (0.29-2.50) and for long-term monotherapy 0.40 (0.14-1.15). Conclusions: Compared to triple drug antiretroviral therapy, monotherapy with lopinavir/ritonavir or darunavir/ritonavir in patients with adequate plasma suppression was not associated with a higher rate of asymptomatic neurocognitive impairment than triple drug ART.	[Perez-Valero, Ignacio; Gonzalez-Baeza, Alicia; Estebanez, Miriam; Montes-Ramirez, Maria L.; Bernardino, Jose I.; Zamora, Francisco X.; Gaya, Francisco; Arnalich, Francisco; Arribas, Jose R.] Hosp Univ La Paz IdiPAZ, HIV Unit, Internal Med Serv, Madrid, Spain; [Bayon, Carmen] Hosp Univ La Paz IdiPAZ, Psychiat Serv, Madrid, Spain; [Pulido, Federico; Lagarde, Maria; Rubio, Rafael] Hosp Univ 12 Octubre I 12, HIV Unit, Internal Med Serv, Madrid, Spain; [Monge, Susana] Inst Salud Carlos III, Ctr Nacl Epidemiol, Madrid, Spain; [Hernando, Asuncion] Univ Europea Madrid, Dept Especialidades Med, Madrid, Spain	Hospital Universitario La Paz; Hospital Universitario La Paz; Hospital Universitario 12 de Octubre; Instituto de Salud Carlos III; Centro Nacional de Epidemiologia (CNE); European University of Madrid	Perez-Valero, I (corresponding author), Hosp Univ La Paz IdiPAZ, HIV Unit, Internal Med Serv, Madrid, Spain.	iperez.hulp@salud.madrid.org	Pulido, Federico/B-8417-2009; Bernardino, Jose Ignacio/H-7898-2017; Gayá Moreno, Francisco/ABE-9251-2021; GRANDE, ANTONIO HERNANDO/U-1411-2019; Valero, Ignacio Pérez/G-5909-2016; Arnalich, Francisco/AAF-5924-2021; Arnalich, Francisco/K-7723-2014; Bernardino, José Ignacio/AAD-1637-2019; Valero, Ignacio Perez/AAL-5466-2021; Monge, Susana/H-9210-2017; Arnalich, Francisco/J-8184-2017; Valero, Ignacio Pérez/AAD-6566-2020; Arribas, Jose/A-1595-2015; Hernando, Asuncion/M-7916-2014	Pulido, Federico/0000-0002-7414-8812; Bernardino, Jose Ignacio/0000-0003-3501-8529; Gayá Moreno, Francisco/0000-0002-9779-4876; GRANDE, ANTONIO HERNANDO/0000-0002-7307-8859; Valero, Ignacio Pérez/0000-0002-3488-7135; Arnalich, Francisco/0000-0003-2943-0373; Bernardino, José Ignacio/0000-0003-3501-8529; Valero, Ignacio Pérez/0000-0002-3488-7135; Arribas, Jose/0000-0002-7410-9450; Hernando, Asuncion/0000-0002-1901-1119; Monge, Susana/0000-0003-1412-3012; GONZALEZ-BAEZA, ALICIA/0000-0002-2265-8976; Bayon, Carmen/0000-0002-2018-6135; Gonzalez-Baeza, Alicia/0000-0003-4351-5947; Rubio Garcia, Rafael/0000-0001-8132-4303; de Lagarde, Maria/0000-0002-7712-6977; Estebanez, Miriam/0000-0003-4509-9123	Fondo de Investigaciones Sanitarias, Insituto de Salud Carlos III [PI10/00483]; Rio Hortega fellowships; Fondo de Investigaciones Sanitarias; Instituto de Investigacion Hospital 12 de Octubre (i+12); "Red de Investigacion en SIDA'' (AIDS Research Network) (RIS) [RD07/0006/2007]; NATIONAL INSTITUTE OF MENTAL HEALTH [P30MH062512] Funding Source: NIH RePORTER	Fondo de Investigaciones Sanitarias, Insituto de Salud Carlos III; Rio Hortega fellowships; Fondo de Investigaciones Sanitarias(Instituto de Salud Carlos III); Instituto de Investigacion Hospital 12 de Octubre (i+12); "Red de Investigacion en SIDA'' (AIDS Research Network) (RIS); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))	This work was supported by grant PI10/00483, Fondo de Investigaciones Sanitarias, Insituto de Salud Carlos III. Dr I. Perez-Valero, Dr. M. Estebanez, Dr. F. X. Zamora and S. Monge are supported by Rio Hortega fellowships financed by Fondo de Investigaciones Sanitarias. Dr. M. Lagarde is supported by a fellowship financed by Instituto de Investigacion Hospital 12 de Octubre (i+12). Dr. J.R. Arribas is an investigator from the Programa de Intensificacion de la Actividad Investigadora en el SNS (I3SNS). IdiPAZ AIDS and infectious diseases investigator group is partially supported by "Red de Investigacion en SIDA'' (AIDS Research Network) (RIS) RD07/0006/2007. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Antinori A, 2007, NEUROLOGY, V69, P1789, DOI 10.1212/01.WNL.0000287431.88658.8b; Arribas JR, 2010, AIDS, V24, P223, DOI 10.1097/QAD.0b013e3283348944; Arribas JR, 2009, JAIDS-J ACQ IMM DEF, V51, P147, DOI 10.1097/QAI.0b013e3181a56de5; Canestri A, 2010, CLIN INFECT DIS, V50, P773, DOI 10.1086/650538; Capparelli EV, 2005, AIDS, V19, P949, DOI 10.1097/01.aids.0000171409.38490.48; Carey CL, 2004, J CLIN EXP NEUROPSYC, V26, P307, DOI 10.1080/13803390490510031; Clifford DB, 2010, NEUROLOGY, V74, P1248, DOI 10.1212/WNL.0b013e3181dd4e31; Du Pasquier RA, 2013, AIDS, V27, P203, DOI 10.1097/QAD.0b013e32835a9a4a; Ellis RJ, 2000, NEUROLOGY, V54, P927, DOI 10.1212/WNL.54.4.927; Estebanez M, 2012, CURR HIV-AIDS REP, V9, P179, DOI 10.1007/s11904-012-0112-1; Gisslen M, 2012, SCAND J INFECT DIS, V44, P997, DOI 10.3109/00365548.2012.690526; Gutmann C, 2010, AIDS, V24, P2347, DOI 10.1097/QAD.0b013e32833db9a1; Heaton RK, 2010, NEUROLOGY, V75, P2087, DOI 10.1212/WNL.0b013e318200d727; Katlama C, 2010, AIDS, V24, P2365, DOI 10.1097/QAD.0b013e32833dec20; Letendre S., 2010, 17 C RETR OPP INF SA; Letendre S, 2008, ARCH NEUROL-CHICAGO, V65, P65, DOI 10.1001/archneurol.2007.31; Marraa CM, 2009, AIDS, V23, P1359, DOI 10.1097/QAD.0b013e32832c4152; Panel members of the European AIDS Clinical Society, 2012, EUR AIDS CLIN SOC GU; Paton NI, 2011, AIDS, V25, P393, DOI 10.1097/QAD.0b013e328342fb7b; Peluso MJ, 2012, AIDS, V26, P1765, DOI 10.1097/QAD.0b013e328355e6b2; Perez-Valero I, 2011, J ANTIMICROB CHEMOTH, V66, P1954, DOI 10.1093/jac/dkr229; Robertson KR, 2010, NEUROLOGY, V74, P1260, DOI 10.1212/WNL.0b013e3181d9ed09; Robertson K, 2012, J NEUROVIROL, V18, P388, DOI 10.1007/s13365-012-0120-3; Santos J, 2012, 19 C RETR OPP INF SE; Santos JR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037442; Simioni S, 2010, AIDS, V24, P1243, DOI 10.1097/QAD.0b013e3283354a7b; Smurzynski M, 2011, AIDS, V25, P357, DOI 10.1097/QAD.0b013e32834171f8; Thompson MA, 2012, JAMA-J AM MED ASSOC, V308, P387, DOI 10.1001/jama.2012.7961; Winston A, 2012, INT J STD AIDS, V23, P225, DOI 10.1258/ijsa.2011.011330; Winston A, 2011, 13 EUR AIDS C BELGR; Yilmaz A, 2009, AIDS RES HUM RETROV, V25, P457, DOI 10.1089/aid.2008.0216; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	32	22	22	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 25	2013	8	7							e69493	10.1371/journal.pone.0069493	http://dx.doi.org/10.1371/journal.pone.0069493			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	191SQ	23936029	Green Published, gold, Green Submitted			2023-01-03	WOS:000322433300043
J	Chen, Y; Lin, G; Guo, ZQ; Zhou, ZF; He, ZY; Ye, YB				Chen, Yu; Lin, Gen; Guo, Zeng-qing; Zhou, Zhi-feng; He, Zhi-yong; Ye, Yun-bin			Effects of MICA Expression on the Prognosis of Advanced Non-Small Cell Lung Cancer and the Efficacy of CIK Therapy	PLOS ONE			English	Article							MHC CLASS-I; CUTTING EDGE; NK CELLS; NKG2D; STRESS; RECEPTOR; LIGANDS; IMMUNORECEPTOR; IMMUNOTHERAPY; RECOGNITION	Objective: To investigate the clinical significance of the expression of MHC class I chain-related gene A (MICA) in patients with advanced non-small cell lung cancer and explore the relationship between MICA expression and the efficacy of cytokine-induced killer cell (CIK) therapy for treating advanced non-small cell lung cancer. Methods: We obtained data on 222 patients with advanced non-small cell lung cancer, including data on MICA expression, age, gender, ECOG score, pathological type, stage, treatment history (including 38 patients who were given autologous CIK cell infusion), and overall survival (OS). MICA expression in lung cancer tissue was evaluated by immunohistochemical staining. Analyses of MICA expression, and CIK therapy association with survival outcomes were performed using Cox proportional models, Kaplan-Meier methods, and the log-rank test. Result: s MICA was expressed in both membrane and cytoplasm. MICA expression correlated with the stage of lung cancer, ECOG score, gender and age. Multivariate COX regression analysis showed that the expression of MICA was an independent prognostic factor of advanced non-small cell lung cancer (p = 0.002). In subgroup analysis, we divided the 222 patients into CIK and control groups. In the CIK group, the medium OS (mOS) of patients with a high expression of MICA was longer than in those with low expression of MICA (27 months vs. 13 months). In the control group, the mOS in patients with a high expression of MICA was shorter than in patients with low MICA expression (9 months vs. 18 months). COX regression analysis showed that the MICA expression affects the effect of CIK therapy (p<0.0001). Conclusion: 1) The high expression of MICA is one of the indicators of a poor prognosis for advanced non-small cell lung cancer patients. 2) The high expression of MICA might be one of the predictive factors for successful CIK therapy.	[Chen, Yu; Lin, Gen; Guo, Zeng-qing; He, Zhi-yong] Fujian Med Univ, Teaching Hosp, Fujian Prov Canc Hosp, Dept Med Oncol, Fuzhou, Fujian Province, Peoples R China; [Zhou, Zhi-feng; Ye, Yun-bin] Fujian Med Univ, Teaching Hosp, Fujian Prov Canc Hosp, Lab Immunooncol, Fuzhou, Fujian Province, Peoples R China; [Chen, Yu; Lin, Gen; Guo, Zeng-qing; Zhou, Zhi-feng; He, Zhi-yong; Ye, Yun-bin] Fujian Key Lab Translat Canc Med, Fuzhou, Fujian Province, Peoples R China; [Guo, Zeng-qing] Fujian Prov Key Lab Tumor Biotherapy, Fuzhou, Fujian Province, Peoples R China	Fujian Medical University; Fujian Medical University	He, ZY (corresponding author), Fujian Med Univ, Teaching Hosp, Fujian Prov Canc Hosp, Dept Med Oncol, Fuzhou, Fujian Province, Peoples R China.	heyong1015@163.com; zjyunbin@189.cn			Foundation for Young Scholars of Fujian Provincial Department of Health, China [2011-1-24]	Foundation for Young Scholars of Fujian Provincial Department of Health, China	The project was supported by the Foundation for Young Scholars of Fujian Provincial Department of Health, China. (Grant No. 2011-1-24). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bauer S, 1999, SCIENCE, V285, P727, DOI 10.1126/science.285.5428.727; Busche A, 2006, HUM GENE THER, V17, P135, DOI 10.1089/hum.2006.17.135; Diefenbach A, 2001, NATURE, V413, P165, DOI 10.1038/35093109; Dougan M, 2009, ANNU REV IMMUNOL, V27, P83, DOI 10.1146/annurev.immunol.021908.132544; Dunn GP, 2004, ANNU REV IMMUNOL, V22, P329, DOI 10.1146/annurev.immunol.22.012703.104803; Friese MA, 2003, CANCER RES, V63, P8996; Gleimer M, 2003, IMMUNITY, V19, P469, DOI 10.1016/S1074-7613(03)00272-3; Groh V, 2002, NATURE, V419, P734, DOI 10.1038/nature01112; Groh V, 1998, SCIENCE, V279, P1737, DOI 10.1126/science.279.5357.1737; Guerra N, 2008, IMMUNITY, V28, P571, DOI 10.1016/j.immuni.2008.02.016; Hayakawa Y, 2002, J IMMUNOL, V169, P5377, DOI 10.4049/jimmunol.169.10.5377; Helms MW, 2010, CANCER IMMUNOL IMMUN, V59, P1325, DOI 10.1007/s00262-010-0860-y; Hontscha C, 2011, J CANCER RES CLIN, V137, P305, DOI 10.1007/s00432-010-0887-7; Huang BC, 2011, J IMMUNOTHER, V34, P289, DOI 10.1097/CJI.0b013e31820e1b0d; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.20107]; Kakimi K, 2009, LUNG CANCER, V65, P1, DOI 10.1016/j.lungcan.2008.10.018; Lanier LL, 2001, NAT MED, V7, P1178, DOI 10.1038/nm1101-1178; Madjd Zahra, 2007, Cancer Immun, V7, P17; MCCARTY KS, 1985, ARCH PATHOL LAB MED, V109, P716; Mesiano G, 2012, EXPERT OPIN BIOL TH, V12, P673, DOI 10.1517/14712598.2012.675323; Pardoll DM, 2001, SCIENCE, V294, P534, DOI 10.1126/science.1066284; Raulet DH, 2003, NAT REV IMMUNOL, V3, P781, DOI 10.1038/nri1199; Salih HR, 2003, BLOOD, V102, P1389, DOI 10.1182/blood-2003-01-0019; Salih HR, 2002, J IMMUNOL, V169, P4098, DOI 10.4049/jimmunol.169.8.4098; SCHMIDTWOLF IGH, 1993, EXP HEMATOL, V21, P1673; SCHMIDTWOLF IGH, 1991, J EXP MED, V174, P139, DOI 10.1084/jem.174.1.139; Shi M, 2004, WORLD J GASTROENTERO, V10, P1146; Stroncek D, 2010, CYTOTHERAPY, V12, P425, DOI 10.3109/14653240903511952; Verneris MR, 2004, BLOOD, V103, P3065, DOI 10.1182/blood-2003-06-2125; Wang Y, 2011, CLIN DEV IMMUNOL, DOI 10.1155/2011/621414; Watson NFS, 2006, INT J CANCER, V118, P1445, DOI 10.1002/ijc.21510; Xiao P, 2008, HISTOPATHOLOGY, V52, P640, DOI 10.1111/j.1365-2559.2008.02989.x; Zamai L, 2007, J IMMUNOL, V178, P4011, DOI 10.4049/jimmunol.178.7.4011	33	26	32	1	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 23	2013	8	7							e69044	10.1371/journal.pone.0069044	http://dx.doi.org/10.1371/journal.pone.0069044			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	228SX	23935919	gold, Green Published, Green Submitted			2023-01-03	WOS:000325211000070
J	Marietta, EV; Gomez, AM; Yeoman, C; Tilahun, AY; Clark, CR; Luckey, DH; Murray, JA; White, BA; Kudva, YC; Rajagopalan, G				Marietta, Eric V.; Gomez, Andres M.; Yeoman, Carl; Tilahun, Ashenafi Y.; Clark, Chad R.; Luckey, David H.; Murray, Joseph A.; White, Bryan A.; Kudva, Yogish C.; Rajagopalan, Govindarajan			Low Incidence of Spontaneous Type 1 Diabetes in NonObese Diabetic Mice Raised on Gluten-Free Diets Is Associated with Changes in the Intestinal Microbiome	PLOS ONE			English	Article							CELIAC-DISEASE; EXPOSURE; RISK; TRIGGER; WHEAT	Human and animal studies strongly suggest that dietary gluten could play a causal role in the etiopathogenesis of type 1 diabetes (T1D). However, the mechanisms have not been elucidated. Recent reports indicate that the intestinal microbiome has a major influence on the incidence of T1D. Since diet is known to shape the composition of the intestinal microbiome, we investigated using non-obese diabetic (NOD) mice whether changes in the intestinal microbiome could be attributed to the pro-and anti-diabetogenic effects of gluten-containing and gluten-free diets, respectively. NOD mice were raised on gluten-containing chows (GCC) or gluten-free chows (GFC). The incidence of diabetes was determined by monitoring blood glucose levels biweekly using a glucometer. Intestinal microbiome composition was analyzed by sequencing 16S rRNA amplicons derived from fecal samples. First of all, GCC-fed NOD mice had the expected high incidence of hyperglycemia whereas NOD mice fed with a GFC had significantly reduced incidence of hyperglycemia. Secondly, when the fecal microbiomes were compared, Bifidobacterium, Tannerella, and Barnesiella species were increased (p = 0.03, 0.02, and 0.02, respectively) in the microbiome of GCC mice, where as Akkermansia species was increased (p = 0.02) in the intestinal microbiomes of NOD mice fed GFC. Thirdly, both of the gluten-free chows that were evaluated, either egg white based (EW-GFC) or casein based (C-GFC), significantly reduced the incidence of hyperglycemia. Interestingly, the gut microbiome from EW-GFC mice was similar to C-GFC mice. Finally, adding back gluten to the gluten-free diet reversed its anti-diabetogenic effect, reduced Akkermansia species and increased Bifidobacterium, Tannerella, and Barnesiella suggesting that the presence of gluten is directly responsible for the pro-diabetogenic effects of diets and it determines the gut microflora. Our novel study thus suggests that dietary gluten could modulate the incidence of T1D by changing the gut microbiome.	[Marietta, Eric V.; Tilahun, Ashenafi Y.; Clark, Chad R.; Luckey, David H.; Rajagopalan, Govindarajan] Mayo Clin, Dept Immunol, Rochester, MN 55905 USA; [Marietta, Eric V.] Mayo Clin, Dept Dermatol, Rochester, MN USA; [Marietta, Eric V.; Murray, Joseph A.] Mayo Clin, Div Gastroenterol & Hepatol, Rochester, MN USA; [Gomez, Andres M.; White, Bryan A.] Univ Illinois, Inst Genom Biol, Urbana, IL 61801 USA; [Yeoman, Carl] Montana State Univ, Coll Agr, Dept Anim & Range Sci, Bozeman, MT 59717 USA; [Kudva, Yogish C.] Mayo Clin, Div Endocrinol Diabet Metab & Nutr, Rochester, MN USA	Mayo Clinic; Mayo Clinic; Mayo Clinic; University of Illinois System; University of Illinois Urbana-Champaign; Montana State University System; Montana State University Bozeman; Mayo Clinic	Marietta, EV (corresponding author), Mayo Clin, Dept Immunol, Rochester, MN 55905 USA.	marietta.eric@mayo.edu; rajagopalan.govindarajan@Mayo.edu	Yeoman, Carl/ABA-1906-2021	Yeoman, Carl/0000-0002-8775-7879	Iacocca Foundation; NIH R01 grant [DK071003]; Office Of The Director [1443108] Funding Source: National Science Foundation; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK071003] Funding Source: NIH RePORTER	Iacocca Foundation; NIH R01 grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Office Of The Director(National Science Foundation (NSF)NSF - Office of the Director (OD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This study was funded by grants from the Iacocca Foundation (GR) and NIH R01 grant (DK071003) (JAM). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Barera G, 2002, PEDIATRICS, V109, P833, DOI 10.1542/peds.109.5.833; Berer K, 2011, NATURE, V479, P538, DOI 10.1038/nature10554; BOTTAZZO GF, 1978, BRIT MED J, V2, P165, DOI 10.1136/bmj.2.6131.165; de Goffau MC, 2012, FECAL MICROBIOTA COM; Edgar RC, 2011, BIOINFORMATICS, V27, P2194, DOI 10.1093/bioinformatics/btr381; ELLIOTT RB, 1984, DIABETOLOGIA, V26, P297, DOI 10.1007/BF00283653; Erb-Downward JR, 2012, SCI REP-UK, V2, DOI 10.1038/srep00774; Gomez A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036095; Hansen CHF, 2012, DIABETOLOGIA, V55, P2285, DOI 10.1007/s00125-012-2564-7; Hooper LV, 2012, SCIENCE, V336, P1268, DOI 10.1126/science.1223490; Huse SM, 2010, ENVIRON MICROBIOL, V12, P1889, DOI 10.1111/j.1462-2920.2010.02193.x; Kashyap PC, 2013, GASTROENTEROLOGY, V144, P967, DOI 10.1053/j.gastro.2013.01.047; Kriegel MA, 2011, P NATL ACAD SCI USA, V108, P11548, DOI 10.1073/pnas.1108924108; Liu ZZ, 2007, NUCLEIC ACIDS RES, V35, DOI 10.1093/nar/gkm541; Ludvigsson JF, 2006, DIABETES CARE, V29, P2483, DOI 10.2337/dc06-0794; MAKI M, 1984, ARCH DIS CHILD, V59, P739, DOI 10.1136/adc.59.8.739; Maurano F, 2005, DIABETOLOGIA, V48, P931, DOI 10.1007/s00125-005-1718-2; Neu J, 2010, ENDOCRIN METAB CLIN, V39, P563, DOI 10.1016/j.ecl.2010.05.008; Norris JM, 2003, JAMA-J AM MED ASSOC, V290, P1713, DOI 10.1001/jama.290.13.1713; Schmid S, 2004, DIABETOLOGIA, V47, P1130; Schmid S, 2004, CLIN IMMUNOL, V111, P108, DOI 10.1016/j.clim.2003.09.012; Suzuki MT, 1996, APPL ENVIRON MICROB, V62, P625, DOI 10.1128/AEM.62.2.625-630.1996; Van Belle TL, 2012, J AUTOIMMUNITY; Ventura A, 1999, GASTROENTEROLOGY, V117, P297, DOI 10.1053/gast.1999.0029900297; Yildirim S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013963; Yoon Ji-Won, 2005, Am J Ther, V12, P580, DOI 10.1097/01.mjt.0000178767.67857.63	26	87	93	2	70	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 13	2013	8	11							e78687	10.1371/journal.pone.0078687	http://dx.doi.org/10.1371/journal.pone.0078687			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	255QK	24236037	Green Submitted, Green Published, gold			2023-01-03	WOS:000327254700034
J	Siena, S; Van Cutsem, E; Li, MY; Jungnelius, U; Romano, A; Beck, R; Bencardino, K; Elez, ME; Prenen, H; Sanchis, M; Sartore-Bianchi, A; Tejpar, S; Gandhi, A; Shi, T; Tabernero, J				Siena, Salvatore; Van Cutsem, Eric; Li, Mingyu; Jungnelius, Ulf; Romano, Alfredo; Beck, Robert; Bencardino, Katia; Elena Elez, Maria; Prenen, Hans; Sanchis, Mireia; Sartore-Bianchi, Andrea; Tejpar, Sabine; Gandhi, Anita; Shi, Tao; Tabernero, Josep			Phase II Open-Label Study to Assess Efficacy and Safety of Lenalidomide in Combination with Cetuximab in KRAS-Mutant Metastatic Colorectal Cancer	PLOS ONE			English	Article							GROWTH-FACTOR RECEPTOR; GENE COPY NUMBER; MONOCLONAL-ANTIBODY; PLUS DEXAMETHASONE; THERAPY; TRIAL; EGFR; IMMUNOGLOBULIN; POLYMORPHISM; CLEARANCE	This study aimed to assess the efficacy and safety of combination treatment with lenalidomide and cetuximab in KRAS-mutant metastatic colorectal cancer patients. This was a phase II multicenter, open-label trial comprising a safety lead-in phase (phase IIa) to determine the maximum tolerated dose, and a randomized proof of concept phase (phase IIb) to determine the response rate of lenalidomide plus cetuximab combination therapy. Phase IIa treatment comprised oral lenalidomide (starting dose 25 mg/day) and intravenous cetuximab (400 mg/m(2) followed by weekly 250 mg/m(2)) in 28-day cycles. In phase IIb patients were randomized to either the phase IIa treatment schedule of lenalidomide plus cetuximab combination therapy or lenalidomide 25 mg/day monotherapy. Eight patients were enrolled into phase IIa. One patient developed a dose-limiting toxicity and the maximum tolerated dose of lenalidomide was determined at 25 mg/day. Forty-three patients were enrolled into phase IIb proof of concept. Best response was stable disease in 9 patients and study enrollment was terminated prematurely due to lack of efficacy in both treatment arms and failure to achieve the planned response objective. The majority of adverse events were grade 1 and 2. In both phases, the adverse events most commonly attributed to any study drugs were fatigue, rash and other skin disorders, diarrhea, nausea, and stomatitis. Thirty-nine deaths occurred; none was related to study drug. The combination of lenalidomide and cetuximab appeared to be well tolerated but did not have clinically meaningful activity in KRAS-mutant metastatic colorectal cancer patients.	[Siena, Salvatore; Bencardino, Katia; Sartore-Bianchi, Andrea] Osped Niguarda Ca Granda, Milan, Italy; [Van Cutsem, Eric; Prenen, Hans; Tejpar, Sabine] Katholieke Univ Leuven Hosp, Louvain, Belgium; [Van Cutsem, Eric; Prenen, Hans; Tejpar, Sabine] Katholieke Univ Leuven, Louvain, Belgium; [Li, Mingyu; Jungnelius, Ulf; Romano, Alfredo; Beck, Robert; Gandhi, Anita; Shi, Tao] Celgene Corp, Summit, NJ USA; [Elena Elez, Maria; Sanchis, Mireia; Tabernero, Josep] Univ Autonoma Barcelona, Vall dHebron Univ Hosp, E-08193 Barcelona, Spain	IRCCS Ca Granda Ospedale Maggiore Policlinico; Ospedale Niguarda Ca' Granda; Flanders Institute for Biotechnology (VIB); KU Leuven; University Hospital Leuven; KU Leuven; Bristol-Myers Squibb; Celgene Corporation; Autonomous University of Barcelona; Hospital Universitari Vall d'Hebron	Siena, S (corresponding author), Osped Niguarda Ca Granda, Milan, Italy.	Salvatore.Siena@OspedaleNiguarda.it	Tabernero, Josep/AAG-5026-2019; Sartore-Bianchi, Andrea/AAB-9848-2019; Van+Cutsem, Eric/ABE-1762-2021; SIENA, SALVATORE/AAC-5806-2019; Élez, Elena/AAH-2945-2019	Tabernero, Josep/0000-0002-2495-8139; Sartore-Bianchi, Andrea/0000-0003-0780-0409; SIENA, SALVATORE/0000-0002-2681-2846; , Tao/0000-0001-5489-2655; Prenen, Hans/0000-0001-8802-7352	Celgene Corporation	Celgene Corporation(Bristol-Myers SquibbCelgene Corporation)	This study was funded by Celgene Corporation. Cetuximab was provided by Merck KGaA. Medical writing services were provided by Kim Grootscholten, MSc, of Excerpta Medica BV, funded by Celgene Corporation. Celgene Corporation had a role in the study design, data collection and analysis, decision to publish, and preparation of the manuscript. However, the authors are fully responsible for content and editorial decisions for this manuscript.	Bendell JC, 2012, J CLIN ONCOL S15, V30; Bendell JC, 2011, J CLIN ONCOL, V29, P4394, DOI 10.1200/JCO.2011.36.1980; Benvenuti S, 2007, CANCER RES, V67, P2643, DOI 10.1158/0008-5472.CAN-06-4158; Breunis WB, 2008, BLOOD, V111, P1029, DOI 10.1182/blood-2007-03-079913; Cartron G, 2002, BLOOD, V99, P754, DOI 10.1182/blood.V99.3.754; Cunningham D, 2004, NEW ENGL J MED, V351, P337, DOI 10.1056/NEJMoa033025; Dahut WL, 2009, J CLIN PHARMACOL, V49, P650, DOI 10.1177/0091270009335001; Dimopoulos M, 2007, NEW ENGL J MED, V357, P2123, DOI 10.1056/NEJMoa070594; Dredge K, 2002, BRIT J CANCER, V87, P1166, DOI 10.1038/sj.bjc.6600607; Ferlay J, 2010, IARC CANCERBASE; Gibson TB, 2006, CLIN COLORECTAL CANC, V6, P29, DOI 10.3816/CCC.2006.n.01; Grothey A, 2012, LANCET IN PRESS; Jonker DJ, 2007, NEW ENGL J MED, V357, P2040, DOI 10.1056/NEJMoa071834; Kavai M, 2007, AUTOIMMUN REV, V6, P497, DOI 10.1016/j.autrev.2007.01.017; Li SQ, 2005, CANCER CELL, V7, P301, DOI 10.1016/j.ccr.2005.03.003; Lievre A, 2006, CANCER RES, V66, P3992, DOI 10.1158/0008-5472.CAN-06-0191; List A, 2006, NEW ENGL J MED, V355, P1456, DOI 10.1056/NEJMoa061292; Lopez-Albaitero A, 2009, CANCER IMMUNOL IMMUN, V58, P1855, DOI 10.1007/s00262-009-0697-4; Miller AA, 2007, J THORAC ONCOL, V2, P445, DOI 10.1097/01.JTO.0000268679.33238.67; Moroni M, 2005, LANCET ONCOL, V6, P279, DOI 10.1016/S1470-2045(05)70102-9; Nishio M, 2009, EUR J HAEMATOL, V82, P143, DOI 10.1111/j.1600-0609.2008.01174.x; Normanno N, 2003, ENDOCR-RELAT CANCER, V10, P1, DOI 10.1677/erc.0.0100001; Personeni N, 2008, CLIN CANCER RES, V14, P5869, DOI 10.1158/1078-0432.CCR-08-0449; REILLY AF, 1994, CLIN DIAGN LAB IMMUN, V1, P640, DOI 10.1128/CDLI.1.6.640-644.1994; Saltz LB, 2004, J CLIN ONCOL, V22, P1201, DOI 10.1200/JCO.2004.10.182; SANDERS LAM, 1994, J INFECT DIS, V170, P854, DOI 10.1093/infdis/170.4.854; Sartore-Bianchi A, 2007, J CLIN ONCOL, V25, P3238, DOI 10.1200/JCO.2007.11.5956; Sartore-Bianchi A, 2012, J CLIN PATHOL, V65, P218, DOI 10.1136/jclinpath-2011-200353; Sharma RA, 2006, EUR J CANCER, V42, P2318, DOI 10.1016/j.ejca.2006.05.018; Siena S, 2009, JNCI-J NATL CANCER I, V101, P1308, DOI 10.1093/jnci/djp280; Weber DM, 2007, NEW ENGL J MED, V357, P2133, DOI 10.1056/NEJMoa070596; Weinberg RA., 2007, BIOL CANC, V11, P399; Wu L, 2011, CANCER IMMUNOL IMMUN, V60, P61, DOI 10.1007/s00262-010-0919-9; Yan L, 2008, CANCER J, V14, P178, DOI 10.1097/PPO.0b013e318172d71a; Yesmin K, 2010, CLIN ENDOCRINOL, V73, P119, DOI 10.1111/j.1365-2265.2010.03780.x; Zhang W, 2007, J CLIN ONCOL, V25, P3712, DOI 10.1200/JCO.2006.08.8021	36	19	19	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 11	2013	8	11							e62264	10.1371/journal.pone.0062264	http://dx.doi.org/10.1371/journal.pone.0062264			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	255EG	24244261	Green Published, Green Submitted, gold			2023-01-03	WOS:000327221600001
J	Hus, I; Bojarska-Junak, A; Chocholska, S; Tomczak, W; Wos, J; Dmoszynska, A; Rolinski, J				Hus, Iwona; Bojarska-Junak, Agnieszka; Chocholska, Sylwia; Tomczak, Waldemar; Wos, Justyna; Dmoszynska, Anna; Rolinski, Jacek			Th17/IL-17A Might Play a Protective Role in Chronic Lymphocytic Leukemia Immunity	PLOS ONE			English	Article							REGULATORY T-CELLS; NECROSIS-FACTOR-ALPHA; HELPER 17 CELLS; TH17 CELLS; PERIPHERAL-BLOOD; B-CELLS; INTERLEUKIN-10 LEVELS; CLINICAL-SIGNIFICANCE; DISEASE PROGRESSION; T(H)17 CELLS	Th17 cells, a recently discovered subset of T helper cells that secrete IL-17A, can affect the inflammation process autoimmune and cancer diseases development. The purpose of this study was to evaluate the role of Th17 cells and IL17A in biology of CLL. The study group included 294 untreated CLL patients in different clinical stages. Here, we show that higher Th17 and IL-17A values were associated with less advanced clinical stage of CLL. Th17 cells' percentages in PB were lower in patients who died due to CLL during follow-up due to CLL (as compared to surviving patients) and in patients responding to first-line therapy with fludarabine-based regimens (as compared to non-responders). IL-17A inversely correlated with the time from CLL diagnosis to the start of therapy and was lower in patients who required treatment during follow-up. Th-17 and IL-17A values were lower in patients with adverse prognostic factors (17p and 11q deletion, CD38 and ZAP-70 expression). CLL patients with detectable IL-17A mRNA in T cells were in Rai Stage 0 and negative for both ZAP-70 and CD38 expression. Th17 percentages positively correlated with iNKT and adversely with Treg cells. The results of this study suggest that Th17 may play a beneficial role in CLL immunity.	[Hus, Iwona; Chocholska, Sylwia; Tomczak, Waldemar; Dmoszynska, Anna] Med Univ Lublin, Dept Haematooncol & Bone Marrow Transplantat, Lublin, Poland; [Bojarska-Junak, Agnieszka; Wos, Justyna; Rolinski, Jacek] Med Univ Lublin, Dept Clin Immunol, Lublin, Poland	Medical University of Lublin; Medical University of Lublin	Bojarska-Junak, A (corresponding author), Med Univ Lublin, Dept Clin Immunol, Lublin, Poland.	agnieszkajunak@poczta.onet.pl	Hus, Iwona/AAB-2809-2020; Bojarska-Junak, Agnieszka/AAK-3714-2021	Hus, Iwona/0000-0002-6096-4093; Bojarska-Junak, Agnieszka/0000-0003-2340-9442; Rolinski, Jacek Mariusz/0000-0001-5596-2651; Chocholska, Sylwia/0000-0002-5001-9258; Tomczak, Waldemar/0000-0002-3205-5781; wos, justyna/0000-0002-9597-5331; Rolinski, Jacek/0000-0003-4841-6120	State Funds for Scientific Research of National Science Centre (NCN) [GR831];  [N N402 351438];  [N N404 682440];  [N N402 439139];  [N N402 683140]	State Funds for Scientific Research of National Science Centre (NCN); ; ; ; 	This work was supported by research grants: N N402 351438, N N404 682440, N N402 439139, N N402 683140 and Development Grant GR831 from State Funds for Scientific Research of National Science Centre (NCN). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Beyer M, 2005, BLOOD, V106, P2018, DOI 10.1182/blood-2005-02-0642; Beyer M, 2009, CURR PHARM DESIGN, V15, P1879, DOI 10.2174/138161209788453211; Bojarska-Junak A, 2002, HAEMATOLOGICA, V87, P490; Bojarska-Junak A, 2008, LEUKEMIA RES, V32, P225, DOI 10.1016/j.leukres.2007.06.007; Chong SY, 2001, GENES IMMUN, V2, P239, DOI 10.1038/sj.gene.6363773; Curiel TJ, 2004, NAT MED, V10, P942, DOI 10.1038/nm1093; D'Arena G, 2011, LEUKEMIA RES, V35, P363, DOI 10.1016/j.leukres.2010.08.010; DANCESCU M, 1992, J EXP MED, V176, P1319, DOI 10.1084/jem.176.5.1319; de Jong E, 2010, CLIN EXP IMMUNOL, V159, P148, DOI 10.1111/j.1365-2249.2009.04041.x; Fayad L, 2001, BLOOD, V97, P256, DOI 10.1182/blood.V97.1.256; Ferrajoli A, 2002, BLOOD, V100, P1215, DOI 10.1182/blood.V100.4.1215.h81602001215_1215_1219; Furman RR, 2010, HEMATOL-AM SOC HEMAT, P77, DOI 10.1182/asheducation-2010.1.77; Gaffen Sarah L, 2009, Curr Rheumatol Rep, V11, P365; Gaffen SL, 2008, CYTOKINE, V43, P402, DOI 10.1016/j.cyto.2008.07.017; Hallek M, 2008, BLOOD, V111, P5446, DOI 10.1182/blood-2007-06-093906; Hus I, 2006, ANN ONCOL, V17, P683, DOI 10.1093/annonc/mdj120; Jadidi-Niaragh F, 2013, TUMOR BIOL, V34, P929, DOI 10.1007/s13277-012-0628-4; Jain P, 2012, HAEMATOL-HEMATOL J, V97, P599, DOI 10.3324/haematol.2011.047316; Ji YQ, 2010, CANCER IMMUNOL IMMUN, V59, P979, DOI 10.1007/s00262-010-0849-6; Khader SA, 2009, MUCOSAL IMMUNOL, V2, P403, DOI 10.1038/mi.2009.100; Kordasti SY, 2009, BRIT J HAEMATOL, V145, P64, DOI 10.1111/j.1365-2141.2009.07593.x; Kryczek I, 2009, BLOOD, V114, P1141, DOI 10.1182/blood-2009-03-208249; Lech-Maranda E, 2012, ARCH IMMUNOL THER EX, V60, P477, DOI 10.1007/s00005-012-0197-7; Liu JK, 2011, BIOCHEM BIOPH RES CO, V407, P348, DOI 10.1016/j.bbrc.2011.03.021; Maruyama T, 2010, CANCER SCI, V101, P1947, DOI 10.1111/j.1349-7006.2010.01624.x; Mellstedt H, 2006, CANCER IMMUNOL IMMUN, V55, P210, DOI 10.1007/s00262-005-0675-4; Murugaiyan G, 2009, J IMMUNOL, V183, P4169, DOI 10.4049/jimmunol.0901017; Palmer S, 2008, BRIT J HAEMATOL, V141, P607, DOI 10.1111/j.1365-2141.2008.07070.x; Podhorecka M, 2002, LEUKEMIA RES, V26, P657, DOI 10.1016/S0145-2126(01)00194-1; Podhorecka Monika, 2004, Postepy Hig Med Dosw (Online), V58, P236; Prabhala RH, 2010, BLOOD, V115, P5385, DOI 10.1182/blood-2009-10-246660; RAI KR, 1975, BLOOD, V46, P219, DOI 10.1182/blood.V46.2.219.219; Sasada T, 2003, CANCER-AM CANCER SOC, V98, P1089, DOI 10.1002/cncr.11618; Scrivener S, 2003, LEUKEMIA LYMPHOMA, V44, P383, DOI 10.1080/1042819021000029993; Seino K, 2006, CANCER SCI, V97, P807, DOI 10.1111/j.1349-7006.2006.00257.x; Tinhofer I, 2006, BLOOD, V108, P2950, DOI 10.1182/blood-2006-03-010553; Wang J, 2011, J INT MED RES, V39, P691, DOI 10.1177/147323001103900301; Weinkove R, 2013, HAEMATOLOGICA, V98, P376, DOI 10.3324/haematol.2012.072835; Wilke CM, 2011, CARCINOGENESIS, V32, P643, DOI 10.1093/carcin/bgr019; Wu C, 2009, CLIN EXP IMMUNOL, V158, P199, DOI 10.1111/j.1365-2249.2009.04011.x; Ye ZJ, 2011, RESP RES, V12, DOI 10.1186/1465-9921-12-77; Zhang JP, 2009, J HEPATOL, V50, P980, DOI 10.1016/j.jhep.2008.12.033; Zhou P, 2010, J INT MED RES, V38, P611, DOI 10.1177/147323001003800223; Zou WP, 2010, NAT REV IMMUNOL, V10, P248, DOI 10.1038/nri2742	44	41	42	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 1	2013	8	11							e78091	10.1371/journal.pone.0078091	http://dx.doi.org/10.1371/journal.pone.0078091			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	245XZ	24223764	Green Published, gold, Green Submitted			2023-01-03	WOS:000326499300021
J	Zaza, G; Granata, S; Masola, V; Rugiu, C; Fantin, F; Gesualdo, L; Schena, FP; Lupo, A				Zaza, Gianluigi; Granata, Simona; Masola, Valentina; Rugiu, Carlo; Fantin, Francesco; Gesualdo, Loreto; Schena, Francesco Paolo; Lupo, Antonio			Downregulation of Nuclear-Encoded Genes of Oxidative Metabolism in Dialyzed Chronic Kidney Disease Patients	PLOS ONE			English	Article							PERITONEAL-DIALYSIS FLUIDS; MITOCHONDRIA; STRESS; DYSREGULATION; BIOSYNTHESIS; COACTIVATORS; ACTIVATION; MECHANISMS; HEALTH	Background: Mitochondria, essential eukaryotic cells organelles defined as the "powerhouse of the cell" because of their ability to produce the vast majority of energy necessary for cellular metabolism, may have a primary role in the oxidative stress-related intracellular machinery associated to chronic kidney disease (CKD). Methods: To better assess this research assumption, we decided to study the key factors regulating mitochondrial oxidative metabolism in CKD patients in peritoneal dialysis (PD, n = 15) using several bio-molecular methodologies. Results: RT-PCR experiments demonstrate that the expression level of peroxisome proliferator-activated receptor gamma coactivator 1 alpha (PGC-1 alpha) and nuclear respiratory factor-1 (NRF-1), two genes primarily involved in mitochondrial biogenesis and functions, were significantly hypo-expressed in peripheral blood mononuclear cells of PD patients compared to healthy subjects (HS, n = 15). Additionally, mRNA levels of several PGC1-alpha downstream target genes (TFAM, COX6C, COX7C, UQCRH and MCAD) were profoundly down-regulated in PD cells. TFAM protein analysis confirmed gene-expression results. High plasmatic concentration of Malondialdehyde found in PD patients, confirmed the contribution of the oxidative stress to these biological effects. Finally, Nuclear factor erythroid-derived 2-like 2 (NRF2 or NFE2L2), a transcription factor for numerous antioxidant/detoxifying enzymes and one of its target genes, superoxide dismutase-2 mitochondrial (SOD2) were up-regulated in PD compared to HS. Conclusions: Our results revealed, for the first time, that CKD-PD patients' PBMC, through a complex intracellular biochemical machinery, are able to modulate their mitochondrial functions probably in the attempt to reduce oxidative metabolic damage and to turn on a valuable defense cellular strategy against oxidative stress.	[Zaza, Gianluigi; Granata, Simona; Masola, Valentina; Rugiu, Carlo; Lupo, Antonio] Univ Hosp Verona, Dept Med, Renal Unit, Verona, Italy; [Fantin, Francesco] Univ Hosp Verona, Sect Geriatr, Dept Med, Verona, Italy; [Gesualdo, Loreto; Schena, Francesco Paolo] Univ Bari, Dept Emergency & Transplantat, Renal Dialysis & Transplant Unit, Bari, Italy	University of Verona; Azienda Ospedaliera Universitaria Integrata Verona; University of Verona; Azienda Ospedaliera Universitaria Integrata Verona; Universita degli Studi di Bari Aldo Moro	Zaza, G (corresponding author), Univ Hosp Verona, Dept Med, Renal Unit, Verona, Italy.	gianluigi.zaza@univr.it	Schena, Francesco P/K-6982-2016; Zaza, Gianluigi/K-3827-2018; Gesualdo, Loreto/K-7751-2016; granata, simona/K-4148-2016	Schena, Francesco P/0000-0001-7927-5207; Gesualdo, Loreto/0000-0002-4861-0911; /0000-0003-1763-6024; granata, simona/0000-0002-3740-7598; Masola, Valentina/0000-0003-2341-2481; Zaza, Gianluigi/0000-0002-6004-6196	Ministero dell' Universita e della Ricerca Scientifica (PRIN)	Ministero dell' Universita e della Ricerca Scientifica (PRIN)(Ministry of Education, Universities and Research (MIUR))	This study was supported by Ministero dell' Universita e della Ricerca Scientifica (PRIN 2003 granted to G. Pertosa, L. Gesualdo and G. Grandaliano and PRIN 2005 granted to G. Pertosa and L. Gesualdo). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ajioka RS, 2006, BBA-MOL CELL RES, V1763, P723, DOI 10.1016/j.bbamcr.2006.05.005; Almeida S, 2010, NEUROTOX RES, V17, P399, DOI 10.1007/s12640-009-9116-z; Arnoult D, 2011, EMBO REP, V12, P901, DOI 10.1038/embor.2011.157; Bazanelli AP, 2006, PERITON DIALYSIS INT, V26, P697; Beinert H., 1963, ENZYMES, P447; Blake PG, 2001, NEPHROL DIAL TRANSPL, V16, P61, DOI 10.1093/ndt/16.suppl_5.61; BREBOROWICZ A, 1992, PERITON DIALYSIS INT, V12, P194; Catalan MPE, 2005, KIDNEY INT, V68, P1303; Chatterjee A, 2011, CANCER PREV RES, V4, P638, DOI 10.1158/1940-6207.CAPR-10-0326; Davies SJ, 2001, PERITON DIALYSIS INT, V21, pS269; Dou L, 2007, J THROMB HAEMOST, V5, P1302, DOI 10.1111/j.1538-7836.2007.02540.x; Eknoyan G, 2002, AM J KIDNEY DIS, V39, pS14, DOI 10.1053/ajkd.2002.30939; Finck BN, 2006, J CLIN INVEST, V116, P615, DOI 10.1172/JCI27794; Granata S, 2009, BMC GENOMICS, V10, DOI 10.1186/1471-2164-10-388; Green DR, 1998, CELL, V94, P695, DOI 10.1016/S0092-8674(00)81728-6; Gyorgy H, 2006, CELL CALCIUM, V40, P553, DOI 10.1016/j.ceca.2006.08.016; Hall AM, 2007, NEPHRON PHYSIOL, V105, P1, DOI 10.1159/000096860; Kalantar-Zadeh K, 2001, AM J KIDNEY DIS, V38, P1343, DOI 10.1053/ajkd.2001.29250; Kelly DP, 2004, GENE DEV, V18, P357, DOI 10.1101/gad.1177604; Kim KW, 2012, ENVIRON GEOCHEM HLTH, V34, P1, DOI 10.1007/s10653-011-9402-6; Liang HY, 2006, ADV PHYSIOL EDUC, V30, P145, DOI 10.1152/advan.00052.2006; Lin JD, 2005, CELL METAB, V1, P361, DOI 10.1016/j.cmet.2005.05.004; Liu YB, 2002, J NEUROCHEM, V80, P780, DOI 10.1046/j.0022-3042.2002.00744.x; McDonald SP, 2009, J AM SOC NEPHROL, V20, P155, DOI 10.1681/ASN.2007111188; Meyer TW, 2007, NEW ENGL J MED, V357, P1316, DOI 10.1056/NEJMra071313; Michel H, 1999, BIOCHEMISTRY-US, V38, P15129, DOI 10.1021/bi9910934; MITCHELL P, 1976, J THEOR BIOL, V62, P327, DOI 10.1016/0022-5193(76)90124-7; Mortier S, 2003, J AM SOC NEPHROL, V14, P1296, DOI 10.1097/01.ASN.0000060681.91079.30; Nguyen T, 2009, J BIOL CHEM, V284, P13291, DOI 10.1074/jbc.R900010200; Noh H, 2006, KIDNEY INT, V69, P2022, DOI 10.1038/sj.ki.5001506; Rains JL, 2011, FREE RADICAL BIO MED, V50, P567, DOI 10.1016/j.freeradbiomed.2010.12.006; Robinson BH, 1998, J INHERIT METAB DIS, V21, P598, DOI 10.1023/A:1005427323835; Rossier MF, 2006, CELL CALCIUM, V40, P155, DOI 10.1016/j.ceca.2006.04.020; Scarpulla RC, 2002, GENE, V286, P81, DOI 10.1016/S0378-1119(01)00809-5; Schepers E, 2007, NEPHROL DIAL TRANSPL, V22, P592, DOI 10.1093/ndt/gfl584; Serviddio G, 2011, CURR PHARM DESIGN, V17, P2036, DOI 10.2174/138161211796904740; Starkov AA, 2008, ANN NY ACAD SCI, V1147, P37, DOI 10.1196/annals.1427.015; Tam P, 2009, PERITON DIALYSIS INT, V29, pS108; Tarng DC, 2002, J AM SOC NEPHROL, V13, DOI 10.1097/01.ASN.0000013301.11876.7E; Theofilou Paraskevi, 2011, J Clin Med Res, V3, P132, DOI 10.4021/jocmr552w; TOPLEY N, 1991, NEPHROL DIAL TRANSPL, V6, P574, DOI 10.1093/ndt/6.8.574; Van Biesen W, 2007, NEPHROL DIAL TRANSPL, V22, P53, DOI 10.1093/ndt/gfl601; Widlansky ME, 2011, ANTIOXID REDOX SIGN, V15, P1517, DOI 10.1089/ars.2010.3642; WITOWSKI J, 1995, KIDNEY INT, V47, P282, DOI 10.1038/ki.1995.36; Yagi K, 1998, Methods Mol Biol, V108, P101; Zaza G, 2008, NEPHROL DIAL TRANSPL, V23, P1673, DOI 10.1093/ndt/gfm804	46	50	50	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 28	2013	8	10							e77847	10.1371/journal.pone.0077847	http://dx.doi.org/10.1371/journal.pone.0077847			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	242KW	24204994	Green Submitted, gold, Green Published			2023-01-03	WOS:000326241200046
J	Kurapati, KRV; Atluri, VSR; Samikkannu, T; Nair, MPN				Kurapati, Kesava Rao Venkata; Atluri, Venkata Subba Rao; Samikkannu, Thangavel; Nair, Madhavan P. N.			Ashwagandha (Withania somnifera) Reverses beta-Amyloid(1-42) Induced Toxicity in Human Neuronal Cells: Implications in HIV-Associated Neurocognitive Disorders (HAND)	PLOS ONE			English	Article							AMYLOID-BETA-PROTEIN; ALZHEIMERS-DISEASE; LIPID-PEROXIDATION; NATURAL-PRODUCTS; IN-VITRO; A-BETA; HYDROGEN-PEROXIDE; MALACHITE GREEN; ROOT EXTRACT; PEPTIDE	Alzheimer's disease (AD) is characterized by progressive dysfunction of memory and higher cognitive functions with abnormal accumulation of extracellular amyloid plaques and intracellular neurofibrillary tangles throughout cortical and limbic brain regions. At present no curative treatment is available, and research focuses on drugs for slowing disease progression or providing prophylaxis. Withania somnifera (WS) also known as 'ashwagandha' is used widely in Ayurvedic medicine as a nerve tonic and memory enhancer. However, there is a paucity of data on the potential neuroprotective effects of W. somnifera against beta-Amyloid (1-42)-induced neuropathogenesis. In the present study, we have tested the neuroprotective effects of methanol: Chloroform (3:1) extract of ashwagandha against beta-amyloid induced toxicity and HIV-1(Ba-L) (clade B) infection using a human neuronal SK-N-MC cell line. Our results showed that beta-amyloid induced cytotoxic effects in SK-N-MC cells as shown by decreased cell growth when tested individually. Also, confocal microscopic analysis showed decreased spine density, loss of spines and decreased dendrite diameter, total dendrite and spine area in clade B infected SK-N-MC cells compared to uninfected cells. However, when ashwagandha was added to beta-amyloid treated and HIV-1 infected samples, the toxic effects were neutralized. Further, the MTT cell viability assays and the peroxisome proliferator-activated receptor-gamma (PPAR gamma) levels supported these observations indicating the neuroprotective effect of WS root extract against beta-amyloid and HIV-1(Ba-L) (clade B) induced neuro-pathogenesis.	[Kurapati, Kesava Rao Venkata; Atluri, Venkata Subba Rao; Samikkannu, Thangavel; Nair, Madhavan P. N.] Florida Int Univ, Dept Immunol, Inst NeuroImmune Pharmacol, Herbert Wertheim Coll Med, Miami, FL 33199 USA	State University System of Florida; Florida International University	Nair, MPN (corresponding author), Florida Int Univ, Dept Immunol, Inst NeuroImmune Pharmacol, Herbert Wertheim Coll Med, Modesto A Maidique Campus, Miami, FL 33199 USA.	nairm@fiu.edu	Atluri, Venkata/G-3277-2014	Atluri, Venkata/0000-0002-8070-6745	National Institutes Health [1R01MH085259, 1R37DA025576, 5RO1DA021537, 1RO1DA027049]; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH085259] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R37DA025576, R01DA021537, R01DA027049] Funding Source: NIH RePORTER	National Institutes Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)	This study was supported by grants from the National Institutes Health: 1R01MH085259, 1R37DA025576, 5RO1DA021537, and 1RO1DA027049 to Prof. Madhavan Nair. No additional external funding was received for this study. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ahmad M, 2005, HUM EXP TOXICOL, V24, P137, DOI 10.1191/0906327105ht209oa; Archana R, 1999, J ETHNOPHARMACOL, V64, P91, DOI 10.1016/S0378-8741(98)00107-X; Atluri VSR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061399; Bailey JA, 2011, GENE, V488, P13, DOI 10.1016/j.gene.2011.06.017; BEHL C, 1992, BIOCHEM BIOPH RES CO, V186, P944, DOI 10.1016/0006-291X(92)90837-B; BEHL C, 1994, CELL, V77, P817, DOI 10.1016/0092-8674(94)90131-7; Behl C, 1997, CELL TISSUE RES, V290, P471, DOI 10.1007/s004410050955; Bertram L, 2010, NEURON, V68, P270, DOI 10.1016/j.neuron.2010.10.013; Bhatnagar M, 2009, NEUROCHEM RES, V34, P1975, DOI 10.1007/s11064-009-9987-7; Bhattacharya A, 2001, J ETHNOPHARMACOL, V74, P1, DOI 10.1016/S0378-8741(00)00309-3; Canevari L, 2004, NEUROCHEM RES, V29, P637, DOI 10.1023/B:NERE.0000014834.06405.af; Chawla A, 2010, CIRC RES, V106, P1559, DOI 10.1161/CIRCRESAHA.110.216523; Chinetti-Gbaguidi G, 2011, CIRC RES, V108, P985, DOI 10.1161/CIRCRESAHA.110.233775; Citron M, 2004, NAT REV NEUROSCI, V5, P677, DOI 10.1038/nrn1495; Citron M, 2010, NAT REV DRUG DISCOV, V9, P387, DOI 10.1038/nrd2896; Deshpande A, 2006, J NEUROSCI, V26, P6011, DOI 10.1523/JNEUROSCI.1189-06.2006; Eckman EA, 2001, J BIOL CHEM, V276, P24540, DOI 10.1074/jbc.M007579200; Esiri MM, 1998, J NEUROL NEUROSUR PS, V65, P29, DOI 10.1136/jnnp.65.1.29; Gandy S, 2005, J CLIN INVEST, V115, P1121, DOI 10.1172/JCI200525100; Gatz M, 2006, ARCH GEN PSYCHIAT, V63, P168, DOI 10.1001/archpsyc.63.2.168; Giunta B, 2011, MOL BRAIN, V4, DOI 10.1186/1756-6606-4-23; Gordon S, 2003, NAT REV IMMUNOL, V3, P23, DOI 10.1038/nri978; GRANDHI A, 1994, J ETHNOPHARMACOL, V44, P131, DOI 10.1016/0378-8741(94)01119-2; Green DA, 2005, AIDS, V19, P407, DOI 10.1097/01.aids.0000161770.06158.5c; GREENLUND LJS, 1995, NEURON, V14, P303, DOI 10.1016/0896-6273(95)90287-2; Griciuc A, 2013, NEURON, V78, P631, DOI 10.1016/j.neuron.2013.04.014; Hardy J, 2006, NEURON, V52, P3, DOI 10.1016/j.neuron.2006.09.016; Houghton PJ, 2005, NEUROSIGNALS, V14, P6, DOI 10.1159/000085382; Hu JG, 2001, J BIOL CHEM, V276, P47863, DOI 10.1074/jbc.M104068200; IVERSEN LL, 1995, BIOCHEM J, V311, P1; Jain S, 2001, PHYTOTHER RES, V15, P544, DOI 10.1002/ptr.802; Ji HF, 2008, ACTA PHARMACOL SIN, V29, P143, DOI 10.1111/j.1745-7254.2008.00752.x; KOH JY, 1990, BRAIN RES, V533, P315, DOI 10.1016/0006-8993(90)91355-K; Kuboyama T, 2005, BRIT J PHARMACOL, V144, P961, DOI 10.1038/sj.bjp.0706122; Kulkarni SK, 2008, PROG NEURO-PSYCHOPH, V32, P1093, DOI 10.1016/j.pnpbp.2007.09.011; Kumar S, 2010, PHYTOTHER RES, V24, P1567, DOI 10.1002/ptr.3261; Kurapati Kesava Rao V., 2012, Journal of Basic and Clinical Physiology and Pharmacology, V23, P139, DOI 10.1515/jbcpp-2012-0021; London JA, 1996, P NATL ACAD SCI USA, V93, P4147, DOI 10.1073/pnas.93.9.4147; LOO DT, 1993, P NATL ACAD SCI USA, V90, P7951, DOI 10.1073/pnas.90.17.7951; Lyketsos CG, 2006, AM J GERIAT PSYCHIAT, V14, P561, DOI 10.1097/01.JGP.0000221334.65330.55; Mandrekar-Colucci S, 2012, J NEUROSCI, V32, P10117, DOI 10.1523/JNEUROSCI.5268-11.2012; Mandrekar-Colucci S, 2010, CNS NEUROL DISORD-DR, V9, P156, DOI 10.2174/187152710791012071; Michaelis ML, 2005, J PHARMACOL EXP THER, V312, P659, DOI 10.1124/jpet.104.074450; Mishra L C, 2000, Altern Med Rev, V5, P334; Mohamed A, 2011, INT J ALZHEIMERS DIS, V12, P79; Mosser DM, 2008, NAT REV IMMUNOL, V8, P958, DOI 10.1038/nri2448; Newman DJ, 2007, J NAT PROD, V70, P461, DOI 10.1021/np068054v; Ohyagi Y, 2005, FASEB J, V19, P255, DOI 10.1096/fj.04-2637fje; Ohyagi Y, 2008, CURR ALZHEIMER RES, V5, P555, DOI 10.2174/156720508786898514; Ohyagi Y, 2006, MINI-REV MED CHEM, V6, P1075, DOI 10.2174/138955706778560175; PANANDIKER A, 1992, CANCER LETT, V67, P93, DOI 10.1016/0304-3835(92)90131-E; PANANDIKER A, 1994, CARCINOGENESIS, V15, P2445, DOI 10.1093/carcin/15.11.2445; Rao KVK, 2012, ASIAN PAC J CANCER P, V13, P1031, DOI 10.7314/APJCP.2012.13.3.1031; Ross CA, 2004, NAT MED, V10, pS10, DOI 10.1038/nm1066; Sankar SR, 2007, CELL MOL BIOL LETT, V12, P473, DOI 10.2478/s11658-007-0015-0; Scartezzini P, 2000, J ETHNOPHARMACOL, V71, P23, DOI 10.1016/S0378-8741(00)00213-0; Schliebs R, 1997, NEUROCHEM INT, V30, P181, DOI 10.1016/S0197-0186(96)00025-3; Sehgal N, 2012, P NATL ACAD SCI USA, V109, P3510, DOI 10.1073/pnas.1112209109; SHEARMAN MS, 1994, P NATL ACAD SCI USA, V91, P1470, DOI 10.1073/pnas.91.4.1470; Shirotani K, 2001, J BIOL CHEM, V276, P21895, DOI 10.1074/jbc.M008511200; Smith DL, 2009, P NATL ACAD SCI USA, V106, P16877, DOI 10.1073/pnas.0908706106; Soontornniyomkij V, 2012, AIDS, V26, P2327, DOI 10.1097/QAD.0b013e32835a117c; Tanzi RE, 2005, CELL, V120, P545, DOI 10.1016/j.cell.2005.02.008; Tohda C, 2000, NEUROREPORT, V11, P1981, DOI 10.1097/00001756-200006260-00035; van Marum RJ, 2008, FUND CLIN PHARMACOL, V22, P265, DOI 10.1111/j.1472-8206.2008.00578.x; Van Nostrand WE, 1999, BIOCHEMISTRY-US, V38, P11570, DOI 10.1021/bi990610f; Vinutha B, 2007, J ETHNOPHARMACOL, V109, P359, DOI 10.1016/j.jep.2006.06.014; Williams P, 2011, NAT PROD REP, V28, P48, DOI 10.1039/c0np00027b; Wirths O, 2012, LIFE SCI, V91, P1148, DOI 10.1016/j.lfs.2012.02.001; Wogulis M, 2005, J NEUROSCI, V25, P1071, DOI 10.1523/JNEUROSCI.2381-04.2005; Yan P, 2006, J BIOL CHEM, V281, P24566, DOI 10.1074/jbc.M602440200; YANKNER BA, 1990, SCIENCE, V250, P279, DOI 10.1126/science.2218531; Zhang C, 2012, Curr Alzheimer Res; Zhao J, 2002, CHEM PHARM BULL, V50, P760, DOI 10.1248/cpb.50.760	74	59	60	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 16	2013	8	10							e77624	10.1371/journal.pone.0077624	http://dx.doi.org/10.1371/journal.pone.0077624			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	239JR	24147038	Green Published, Green Submitted, gold			2023-01-03	WOS:000326019400123
J	Azushima, K; Tamura, K; Wakui, H; Maeda, A; Ohsawa, M; Uneda, K; Kobayashi, R; Kanaoka, T; Dejima, T; Fujikawa, T; Yamashita, A; Toya, Y; Umemura, S				Azushima, Kengo; Tamura, Kouichi; Wakui, Hiromichi; Maeda, Akinobu; Ohsawa, Masato; Uneda, Kazushi; Kobayashi, Ryu; Kanaoka, Tomohiko; Dejima, Toru; Fujikawa, Tetsuya; Yamashita, Akio; Toya, Yoshiyuki; Umemura, Satoshi			Bofu-Tsu-Shosan, an Oriental Herbal Medicine, Exerts a Combinatorial Favorable Metabolic Modulation Including Antihypertensive Effect on a Mouse Model of Human Metabolic Disorders with Visceral Obesity	PLOS ONE			English	Article							RECEPTOR-ASSOCIATED PROTEIN; CARDIAC-HYPERTROPHY; LIVER LIPIDS; PPAR-GAMMA; ADIPONECTIN; GHRELIN; PEPTIDE; WEIGHT; TYPE-1; SAN	Accumulating evidence indicates that metabolic dysfunction with visceral obesity is a major medical problem associated with the development of hypertension, type 2 diabetes (T2DM) and dyslipidemia, and ultimately severe cardiovascular and renal disease. Therefore, an effective anti-obesity treatment with a concomitant improvement in metabolic profile is important for the treatment of metabolic dysfunction with visceral obesity. Bofu-tsu-shosan (BOF) is one of oriental herbal medicine and is clinically available to treat obesity in Japan. Although BOF is a candidate as a novel therapeutic strategy to improve metabolic dysfunction with obesity, the mechanism of its beneficial effect is not fully elucidated. Here, we investigated mechanism of therapeutic effects of BOF on KKAy mice, a model of human metabolic disorders with obesity. Chronic treatment of KKAy mice with BOF persistently decreased food intake, body weight gain, low-density lipoprotein cholesterol and systolic blood pressure. In addition, both tissue weight and cell size of white adipose tissue (WAT) were decreased, with concomitant increases in the expression of adiponectin and peroxisome proliferator-activated receptors genes in WAT as well as the circulating adiponectin level by BOF treatment. Furthermore, gene expression of uncoupling protein-1, a thermogenesis factor, in brown adipose tissue and rectal temperature were both elevated by BOF. Intriguingly, plasma acylated-ghrelin, an active form of orexigenic hormone, and short-term food intake were significantly decreased by single bolus administration of BOF. These results indicate that BOF exerts a combinatorial favorable metabolic modulation including antihypertensive effect, at least partially, via its beneficial effect on adipose tissue function and its appetite-inhibitory property through suppression on the ghrelin system.	[Azushima, Kengo; Tamura, Kouichi; Wakui, Hiromichi; Maeda, Akinobu; Ohsawa, Masato; Uneda, Kazushi; Kobayashi, Ryu; Kanaoka, Tomohiko; Dejima, Toru; Fujikawa, Tetsuya; Toya, Yoshiyuki; Umemura, Satoshi] Yokohama City Univ, Grad Sch Med, Dept Med Sci & Cardiorenal Med, Yokohama, Kanagawa 232, Japan; [Yamashita, Akio] Yokohama City Univ, Grad Sch Med, Dept Mol Biol, Yokohama, Kanagawa 232, Japan	Yokohama City University; Yokohama City University	Tamura, K (corresponding author), Yokohama City Univ, Grad Sch Med, Dept Med Sci & Cardiorenal Med, Yokohama, Kanagawa 232, Japan.	tamukou@med.yokohama-cu.ac.jp	Fujikawa, Tetsuya/N-6520-2014	Fujikawa, Tetsuya/0000-0002-0533-3061; Azushima, Kengo/0000-0002-5136-0730	Health and Labor Sciences Research grant; Japanese Ministry of Education, Science, Sports and Culture; Salt Science Research Foundation [1134]; Yokohama Foundation for Advancement of Medical Science; Kidney Foundation, Japan [JKFB13-17]; Novartis Foundation for Gerontological Research; Grants-in-Aid for Scientific Research [25460906] Funding Source: KAKEN	Health and Labor Sciences Research grant(Ministry of Health, Labour and Welfare, Japan); Japanese Ministry of Education, Science, Sports and Culture(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Salt Science Research Foundation; Yokohama Foundation for Advancement of Medical Science; Kidney Foundation, Japan(Kidney Foundation, Japan); Novartis Foundation for Gerontological Research(Novartis Foundation for Gerontological Research); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	This work was supported by a Health and Labor Sciences Research grant and by grants from the Japanese Ministry of Education, Science, Sports and Culture, the Salt Science Research Foundation (number 1134), the Yokohama Foundation for Advancement of Medical Science, the Kidney Foundation, Japan (JKFB13-17) and the Novartis Foundation for Gerontological Research (2012). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Akagiri S, 2008, J CLIN BIOCHEM NUTR, V42, P158, DOI 10.3164/jcbn.2008023; Alberti KGMM, 2009, CIRCULATION, V120, P1640, DOI 10.1161/CIRCULATIONAHA.109.192644; Date Y, 2002, GASTROENTEROLOGY, V123, P1120, DOI 10.1053/gast.2002.35954; Desvergne B, 1999, ENDOCR REV, V20, P649, DOI 10.1210/er.20.5.649; Dietrich MO, 2012, NAT REV DRUG DISCOV, V11, P675, DOI 10.1038/nrd3739; Dolinsky VW, 2010, HYPERTENSION, V56, P412, DOI 10.1161/HYPERTENSIONAHA.110.154732; Dorresteijn JAN, 2012, OBES REV, V13, P17, DOI 10.1111/j.1467-789X.2011.00914.x; Goodpaster BH, 2010, JAMA-J AM MED ASSOC, V304, P1795, DOI 10.1001/jama.2010.1505; Hioki C, 2004, CLIN EXP PHARMACOL P, V31, P614, DOI 10.1111/j.1440-1681.2004.04056.x; Hiuge A, 2007, ARTERIOSCL THROM VAS, V27, P635, DOI 10.1161/01.ATV.0000256469.06782.d5; Horvath K, 2008, ARCH INTERN MED, V168, P571, DOI 10.1001/archinte.168.6.571; Iwamoto T, 2004, NAT MED, V10, P1193, DOI 10.1038/nm1118; Kamegai J, 2000, ENDOCRINOLOGY, V141, P4797, DOI 10.1210/en.141.12.4797; Kojima M, 1999, NATURE, V402, P656, DOI 10.1038/45230; Maeda N, 2001, DIABETES, V50, P2094, DOI 10.2337/diabetes.50.9.2094; Maggs Fenella G, 2012, Acute Med, V11, P107; Matsuda M, 2011, PHYSIOL GENOMICS, V43, P884, DOI 10.1152/physiolgenomics.00005.2011; Morimoto Y, 2002, YAKUGAKU ZASSHI, V122, P163, DOI 10.1248/yakushi.122.163; Morimoto Yasuo, 2001, Folia Pharmacologica Japonica, V117, P77, DOI 10.1254/fpj.117.77; Nakayama T, 2007, J ETHNOPHARMACOL, V109, P236, DOI 10.1016/j.jep.2006.07.041; Nakazato M, 2001, NATURE, V409, P194, DOI 10.1038/35051587; Ohashi K, 2006, HYPERTENSION, V47, P1108, DOI 10.1161/01.HYP.0000222368.43759.a1; Qiao LP, 2011, AM J PHYSIOL-ENDOC M, V300, pE809, DOI 10.1152/ajpendo.00004.2011; Rosen ED, 2001, J BIOL CHEM, V276, P37731, DOI 10.1074/jbc.R100034200; Sakamoto S, 2005, IN VIVO, V19, P1029; Seoane LM, 2003, ENDOCRINOLOGY, V144, P544, DOI 10.1210/en.2002-220795; Strazzullo P, 2010, STROKE, V41, pE418, DOI 10.1161/STROKEAHA.109.576967; Takemori K, 2011, LIFE SCI, V88, P1088, DOI 10.1016/j.lfs.2011.04.002; Thomas G, 2011, CLIN J AM SOC NEPHRO, V6, P2364, DOI 10.2215/CJN.02180311; Tsurumi Y, 2006, KIDNEY INT, V69, P488, DOI 10.1038/sj.ki.5000130; Uno K, 2012, EUR HEART J, V33, P1279, DOI 10.1093/eurheartj/ehr265; van der Lely AJ, 2004, ENDOCR REV, V25, P426, DOI 10.1210/er.2002-0029; Wakui H, 2010, AM J PHYSIOL-RENAL, V299, pF991, DOI 10.1152/ajprenal.00738.2009; Wakui H, 2010, HYPERTENSION, V55, P1157, DOI 10.1161/HYPERTENSIONAHA.109.147207; Wang ZV, 2008, HYPERTENSION, V51, P8, DOI 10.1161/HYPERTENSIONAHA.107.099424; Whitlock G, 2009, LANCET, V373, P1083, DOI 10.1016/S0140-6736(09)60318-4; Wren AM, 2000, ENDOCRINOLOGY, V141, P4325, DOI 10.1210/en.141.11.4325; Yiannikouris F, 2010, CURR OPIN NEPHROL HY, V19, P195, DOI 10.1097/MNH.0b013e3283366cd0; YOSHIDA T, 1995, INT J OBESITY, V19, P717; Zhu M, 2004, EXP GERONTOL, V39, P1049, DOI 10.1016/j.exger.2004.03.024	40	24	24	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 9	2013	8	10							e75560	10.1371/journal.pone.0075560	http://dx.doi.org/10.1371/journal.pone.0075560			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	236PJ	24130717	Green Published, Green Submitted, gold			2023-01-03	WOS:000325810900040
J	Manson, JE; Chlebowski, RT; Stefanick, ML; Aragaki, AK; Rossouw, JE; Prentice, RL; Anderson, G; Howard, BV; Thomson, CA; LaCroix, AZ; Wactawski-Wende, J; Jackson, RD; Limacher, M; Margolis, KL; Wassertheil-Smoller, S; Beresford, SA; Cauley, JA; Eaton, CB; Gass, M; Hsia, J; Johnson, KC; Kooperberg, C; Kuller, LH; Lewis, CE; Liu, SM; Martin, LW; Ockene, JK; O'Sullivan, MJ; Powell, LH; Simon, MS; Van Horn, L; Vitolins, MZ; Wallace, RB				Manson, JoAnn E.; Chlebowski, Rowan T.; Stefanick, Marcia L.; Aragaki, Aaron K.; Rossouw, Jacques E.; Prentice, Ross L.; Anderson, Garnet; Howard, Barbara V.; Thomson, Cynthia A.; LaCroix, Andrea Z.; Wactawski-Wende, Jean; Jackson, Rebecca D.; Limacher, Marian; Margolis, Karen L.; Wassertheil-Smoller, Sylvia; Beresford, Shirley A.; Cauley, Jane A.; Eaton, Charles B.; Gass, Margery; Hsia, Judith; Johnson, Karen C.; Kooperberg, Charles; Kuller, Lewis H.; Lewis, Cora E.; Liu, Simin; Martin, Lisa W.; Ockene, Judith K.; O'Sullivan, Mary Jo; Powell, Lynda H.; Simon, Michael S.; Van Horn, Linda; Vitolins, Mara Z.; Wallace, Robert B.			Menopausal Hormone Therapy and Health Outcomes During the Intervention and Extended Poststopping Phases of the Women's Health Initiative Randomized Trials	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ESTROGEN PLUS PROGESTIN; CONJUGATED EQUINE ESTROGEN; CORONARY-HEART-DISEASE; MILD COGNITIVE IMPAIRMENT; POSTMENOPAUSAL WOMEN; BREAST-CANCER; HYSTERECTOMY; RISK; MAMMOGRAPHY; DEMENTIA	IMPORTANCE Menopausal hormone therapy continues in clinical use but questions remain regarding its risks and benefits for chronic disease prevention. OBJECTIVE To report a comprehensive, integrated overview of findings from the 2 Women's Health Initiative (WHI) hormone therapy trials with extended postintervention follow-up. DESIGN, SETTING, AND PARTICIPANTS A total of 27 347 postmenopausal women aged 50 to 79 years were enrolled at 40 US centers. INTERVENTIONS Women with an intact uterus received conjugated equine estrogens (CEE; 0.625 mg/d) plus medroxyprogesterone acetate (MPA; 2.5 mg/d) (n = 8506) or placebo (n = 8102). Women with prior hysterectomy received CEE alone (0.625 mg/d) (n = 5310) or placebo (n = 5429). The intervention lasted a median of 5.6 years in CEE plus MPA trial and 7.2 years in CEE alone trial with 13 years of cumulative follow-up until September 30, 2010. MAIN OUTCOMES AND MEASURES Primary efficacy and safety outcomes were coronary heart disease (CHD) and invasive breast cancer, respectively. A global index also included stroke, pulmonary embolism, colorectal cancer, endometrial cancer, hip fracture, and death. RESULTS During the CEE plus MPA intervention phase, the numbers of CHD cases were 196 for CEE plus MPA vs 159 for placebo (hazard ratio [HR], 1.18; 95% CI, 0.95-1.45) and 206 vs 155, respectively, for invasive breast cancer (HR, 1.24; 95% CI, 1.01-1.53). Other risks included increased stroke, pulmonary embolism, dementia (in women aged >= 65 years), gallbladder disease, and urinary incontinence; benefits included decreased hip fractures, diabetes, and vasomotor symptoms. Most risks and benefits dissipated postintervention, although some elevation in breast cancer risk persisted during cumulative follow-up (434 cases for CEE plus MPA vs 323 for placebo; HR, 1.28 [95% CI, 1.11-1.48]). The risks and benefits were more balanced during the CEE alone intervention with 204 CHD cases for CEE alone vs 222 cases for placebo (HR, 0.94; 95% CI, 0.78-1.14) and 104 vs 135, respectively, for invasive breast cancer (HR, 0.79; 95% CI, 0.61-1.02); cumulatively, there were 168 vs 216, respectively, cases of breast cancer diagnosed (HR, 0.79; 95% CI, 0.65-0.97). Results for other outcomes were similar to CEE plus MPA. Neither regimen affected all-cause mortality. For CEE alone, younger women(aged 50-59 years) had more favorable results for all-cause mortality, myocardial infarction, and the global index (nominal P<.05 for trend by age). Absolute risks of adverse events (measured by the global index) per 10 000 women annually taking CEE plus MPA ranged from 12 excess cases for ages of 50-59 years to 38 for ages of 70-79 years; for women taking CEE alone, from 19 fewer cases for ages of 50-59 years to 51 excess cases for ages of 70-79 years. Quality-of-life outcomes had mixed results in both trials. CONCLUSIONS AND RELEVANCE Menopausal hormone therapy has a complex pattern of risks and benefits. Findings from the intervention and extended postintervention follow-up of the 2 WHI hormone therapy trials do not support use of this therapy for chronic disease prevention, although it is appropriate for symptom management in some women.	[Manson, JoAnn E.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Boston, MA 02215 USA; [Chlebowski, Rowan T.] Harbor UCLA Med Ctr, Los Angeles Biomed Res Inst, Torrance, CA 90509 USA; [Stefanick, Marcia L.] Stanford Prevent Res Ctr, Stanford, CA USA; [Aragaki, Aaron K.; Prentice, Ross L.; Anderson, Garnet; LaCroix, Andrea Z.; Beresford, Shirley A.; Kooperberg, Charles] Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Seattle, WA 98104 USA; [Rossouw, Jacques E.] NHLBI, Bethesda, MD 20892 USA; [Howard, Barbara V.] MedStar Hlth Res Inst, Washington, DC USA; [Howard, Barbara V.] Georgetown Howard Univ Ctr Clin & Translat Sci, Washington, DC USA; [Thomson, Cynthia A.] Univ Arizona, Mel & Enid Zuckerman Coll Publ Hlth, Tucson, AZ USA; [Wactawski-Wende, Jean] SUNY Buffalo, Dept Social & Prevent Med, Buffalo, NY 14260 USA; [Jackson, Rebecca D.] Ohio State Univ, Div Endocrinol Diabet & Metab, Columbus, OH 43210 USA; [Limacher, Marian] Univ Florida, Gainesville, FL USA; [Margolis, Karen L.] HealthPartners Inst Educ & Res, Minneapolis, MN USA; [Wassertheil-Smoller, Sylvia] Albert Einstein Coll Med, New York, NY USA; [Cauley, Jane A.; Kuller, Lewis H.] Univ Pittsburgh, Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA 15260 USA; [Eaton, Charles B.] Brown Univ, Dept Family Med & Epidemiol, Alpert Med Sch, Providence, RI 02912 USA; [Gass, Margery] Cleveland Clin, North Amer Menopause Soc, Cleveland, OH 44106 USA; [Gass, Margery] Case Western Reserve Univ, Sch Med, Cleveland, OH USA; [Hsia, Judith] AstraZeneca, Clin Res, Wilmington, DE USA; [Johnson, Karen C.] Univ Tennessee, Hlth Sci Ctr, Dept Prevent Med, Memphis, TN USA; [Lewis, Cora E.] Univ Alabama, Dept Med, Tuscaloosa, AL 35487 USA; [Liu, Simin] Brown Univ, Dept Epidemiol, Providence, RI 02912 USA; [Liu, Simin] Brown Univ, Dept Med, Providence, RI 02912 USA; [Martin, Lisa W.] George Washington Univ, Div Cardiol, Sch Med & Hlth Sci, Washington, DC USA; [Ockene, Judith K.] Univ Massachusetts, Sch Med, Worcester, MA USA; [O'Sullivan, Mary Jo] Univ Miami, Dept Obstet & Gynecol, Div Res, Miami, FL USA; [Powell, Lynda H.] Rush Univ, Med Ctr, Dept Prevent Med, Chicago, IL 60612 USA; [Simon, Michael S.] Wayne State Univ, Karmanos Canc Inst, Detroit, MI USA; [Van Horn, Linda] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA; [Vitolins, Mara Z.] Wake Forest Sch Med, Dept Epidemiol & Prevent, Winston Salem, NC USA; [Wallace, Robert B.] Univ Iowa, Dept Epidemiol, Coll Publ Hlth, Iowa City, IA USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; Lundquist Institute; Stanford University; Fred Hutchinson Cancer Center; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); MedStar Health Research Institute; University of Arizona; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; University System of Ohio; Ohio State University; State University System of Florida; University of Florida; Yeshiva University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Brown University; Cleveland Clinic Foundation; Case Western Reserve University; AstraZeneca; University of Tennessee System; University of Tennessee Health Science Center; University of Alabama System; University of Alabama Tuscaloosa; Brown University; Brown University; George Washington University; University of Massachusetts System; University of Massachusetts Worcester; University of Miami; Rush University; Barbara Ann Karmanos Cancer Institute; Wayne State University; Northwestern University; Feinberg School of Medicine; Wake Forest University; University of Iowa	Manson, JE (corresponding author), Harvard Univ, Sch Med, Brigham & Womens Hosp, 900 Commonwealth Ave,3rd Floor, Boston, MA 02215 USA.	jmanson@rics.bwh.harvard.edu	Liu, Simin/GSN-4159-2022; Liu, Simin/I-3689-2014; LaCroix, Andrea/N-9880-2018; Wactawski-Wende, Jean/AGH-5457-2022	Liu, Simin/0000-0003-2098-3844; LaCroix, Andrea/0000-0002-9532-976X; Wactawski-Wende, Jean/0000-0003-3096-9595; Eaton, Charles/0000-0002-7723-9461; Cauley, Jane A/0000-0003-0752-4408; Margolis, Karen/0000-0003-1862-7402; Martin, Lisa Warsinger/0000-0003-4352-0914	National Heart, Lung, and Blood Institute, National Institutes of Health, US Department of Health and Human Services [N01WH22110, 24152, 32100-2, 32105-6, 32108-9, 32111-13, 321115, 32118-32119, 32122, 42107-26, 42129-32, 44221]; WOMEN&apos;S HEALTH INITIATIVE - OFFICE OF THE DIRECTOR NIH [N01WH042125, N01WH042116, N01WH032112, N01WH042109, N01WH042110, N01WH042124, N01WH042114, N01WH032113, N01WH032118, N01WH042115, N01WH042119, N01WH042126, N01WH042130, N01WH032109, N01WH032108, N01WH032105, N01WH042112, N01WH042132, N01WH042107, N01WH042121, N01WH042122, N01WH042123, N01WH042111, N01WH042129, N01WH032106, N01WH042117, N01WH032102, N01WH042120, N01WH042131, N01WH042108, N01WH032101, N01WH032100, N01WH022110, N01WH032122, N01WH042113, N01WH042118, N01WH032111, N01WH032119] Funding Source: NIH RePORTER	National Heart, Lung, and Blood Institute, National Institutes of Health, US Department of Health and Human Services(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); WOMEN&apos;S HEALTH INITIATIVE - OFFICE OF THE DIRECTOR NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	The Women's Health Initiative is funded by the National Heart, Lung, and Blood Institute, National Institutes of Health, US Department of Health and Human Services through contracts N01WH22110, 24152, 32100-2, 32105-6, 32108-9, 32111-13, 321115, 32118-32119, 32122, 42107-26, 42129-32, and 44221. Wyeth-Ayerst donated the study drugs.	Anderson G, 1998, CONTROL CLIN TRIALS, V19, P61; Anderson GL, 2012, LANCET ONCOL, V13, P476, DOI 10.1016/S1470-2045(12)70075-X; Anderson GL, 2003, JAMA-J AM MED ASSOC, V290, P1739, DOI 10.1001/jama.290.13.1739; Anderson GL, 2004, JAMA-J AM MED ASSOC, V291, P1701, DOI 10.1001/jama.291.14.1701; Archer DF, 2009, CLIMACTERIC, V12, P368, DOI 10.1080/13697130903195606; Banks E, 2003, LANCET, V362, P419, DOI 10.1016/S0140-6736(03)14065-2; Beral V, 1997, LANCET, V350, P1047, DOI 10.1016/S0140-6736(97)08233-0; Bonds DE, 2006, DIABETOLOGIA, V49, P459, DOI 10.1007/s00125-005-0096-0; Brunner RL, 2005, ARCH INTERN MED, V165, P1976, DOI 10.1001/archinte.165.17.1976; Chlebowski RT, 2008, ARCH INTERN MED, V168, P370, DOI 10.1001/archinternmed.2007.123; Chlebowski RT, 2012, JNCI-J NATL CANCER I, V104, P517, DOI 10.1093/jnci/djs014; Chlebowski RT, 2010, JNCI-J NATL CANCER I, V102, P1413, DOI 10.1093/jnci/djq285; Chlebowski RT, 2009, LANCET, V374, P1243, DOI 10.1016/S0140-6736(09)61526-9; Chlebowski RT, 2009, NEW ENGL J MED, V360, P573, DOI 10.1056/NEJMoa0807684; Chlebowski RT, 2004, NEW ENGL J MED, V350, P991, DOI 10.1056/NEJMoa032071; Chlebowski RT, 2003, JAMA-J AM MED ASSOC, V289, P3243, DOI 10.1001/jama.289.24.3243; Espeland MA, 2013, JAMA INTERN MED, V173, P1429, DOI 10.1001/jamainternmed.2013.7727; Gast GCM, 2011, MATURITAS, V70, P373, DOI 10.1016/j.maturitas.2011.09.005; Gast GCM, 2011, MENOPAUSE, V18, P146, DOI 10.1097/gme.0b013e3181f464fb; GRADY D, 1992, ANN INTERN MED, V117, P1016, DOI 10.7326/0003-4819-117-12-1016; GRADY D, 1992, ANN INTERN MED, V117, P1038; Hays J, 2003, NEW ENGL J MED, V348, P1839, DOI 10.1056/NEJMoa030311; Heiss G, 2008, JAMA-J AM MED ASSOC, V299, P1036, DOI 10.1001/jama.299.9.1036; Hendrix SL, 2005, JAMA-J AM MED ASSOC, V293, P935, DOI 10.1001/jama.293.8.935; Hendrix SL, 2006, CIRCULATION, V113, P2425, DOI 10.1161/CIRCULATIONAHA.105.594077; Hersh AL, 2004, JAMA-J AM MED ASSOC, V291, P47, DOI 10.1001/jama.291.1.47; Hsia J, 2006, ARCH INTERN MED, V166, P357, DOI 10.1001/archinte.166.3.357; Huang AJ, 2009, MENOPAUSE, V16, P639, DOI 10.1097/gme.0b013e31819c11e4; Jackson RD, 2006, J BONE MINER RES, V21, P817, DOI 10.1359/JBMR.060312; Jordan VC, 2011, CANCER PREV RES, V4, P633, DOI 10.1158/1940-6207.CAPR-11-0185; Kim JJ, 2013, ENDOCR REV, V34, P130, DOI 10.1210/er.2012-1043; LaCroix AZ, 2011, JAMA-J AM MED ASSOC, V305, P1305, DOI 10.1001/jama.2011.382; Lantto H, 2012, MENOPAUSE, V19, P82, DOI 10.1097/gme.0b013e318221bae8; Levine DW, 2005, PSYCHOSOM MED, V67, P98, DOI 10.1097/01.psy.0000151743.58067.f0; Levine DW, 2003, PSYCHOL ASSESSMENT, V15, P137, DOI 10.1037/1040-3590.15.2.137; Lewis-Wambi JS, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2255; Manson JE, 2003, NEW ENGL J MED, V349, P523, DOI 10.1056/NEJMoa030808; Margolis KL, 2004, DIABETOLOGIA, V47, P1175, DOI 10.1007/s00125-004-1448-x; Mendelsohn ME, 2005, SCIENCE, V308, P1583, DOI 10.1126/science.1112062; Mikkola TS, 2002, CARDIOVASC RES, V53, P605, DOI 10.1016/S0008-6363(01)00466-7; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; Santen RJ, 2010, J CLIN ENDOCR METAB, V95, pS7, DOI 10.1210/jc.2009-2509; Shumaker SA, 2004, JAMA-J AM MED ASSOC, V291, P2947, DOI 10.1001/jama.291.24.2947; Shumaker SA, 2003, JAMA-J AM MED ASSOC, V289, P2651, DOI 10.1001/jama.289.20.2651; Stefanick ML, 2006, JAMA-J AM MED ASSOC, V295, P1647, DOI 10.1001/jama.295.14.1647; Utian WH, 2010, MENOPAUSE, V17, P242, DOI 10.1097/gme.0b013e3181d0f6b9; Walitt B, 2008, ARTHRIT RHEUM-ARTHR, V59, P302, DOI 10.1002/art.23325; Wassertheil-Smoller S, 2003, JAMA-J AM MED ASSOC, V289, P2673, DOI 10.1001/jama.289.20.2673	48	840	892	0	72	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 2	2013	310	13					1353	1368		10.1001/jama.2013.278040	http://dx.doi.org/10.1001/jama.2013.278040			16	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	227GB	24084921	Green Accepted, Bronze			2023-01-03	WOS:000325098100021
J	Botanov, Y; Ilardi, SS				Botanov, Yevgeny; Ilardi, Stephen S.			The Acute Side Effects of Bright Light Therapy: A Placebo-Controlled Investigation	PLOS ONE			English	Article							SEASONAL AFFECTIVE-DISORDER; CONSENSUS REPORT; NONSEASONAL DEPRESSION; CIRCADIAN-RHYTHMS; CONTROLLED-TRIAL; MORNING LIGHT; DOUBLE-BLIND; SLEEP PHASE; PHOTOTHERAPY; MELATONIN	Despite the emergence of numerous clinical and non-clinical applications of bright light therapy (LT) in recent decades, the prevalence and severity of LT side effects have not yet been fully explicated. A few adverse LT effects -headache, eye strain, irritability, and nausea-have been consistently reported among depressed individuals and other psychiatric cohorts, but there exists little published evidence regarding LT side effects in non-clinical populations, who often undergo LT treatment of considerably briefer duration. Accordingly, in the present study we examined, in a randomized sample of healthy young adults, the acute side effects of exposure to a single 30-minute session of bright white light (10,000 lux) versus dim red light (< 500 lux). Across a broad range of potential side effects, repeated-measures analyses of variance revealed no significant group-by-time (Pre, Post) interactions. In other words, bright light exposure was not associated with a significantly higher incidence of any reported side effect than was the placebo control condition. Nevertheless, small but statistically significant increases in both eye strain and blurred vision were observed among both the LT and control groups. Overall, these results suggest that the relatively common occurrence of adverse side effects observed in the extant LT literature may not fully extend to non-clinical populations, especially for healthy young adults undergoing LT for a brief duration.	[Botanov, Yevgeny; Ilardi, Stephen S.] Univ Kansas, Dept Psychol, Lawrence, KS 66045 USA	University of Kansas	Botanov, Y (corresponding author), Univ Kansas, Dept Psychol, Lawrence, KS 66045 USA.	ybotanov@ku.edu	Botanov, Yevgeny/AAH-9507-2020					Ancoli-Israel S, 2002, J AM GERIATR SOC, V50, P282, DOI 10.1046/j.1532-5415.2002.50060.x; Boivin DB, 2002, J BIOL RHYTHM, V17, P266, DOI 10.1177/07430402017003010; Boulos Z, 1995, J BIOL RHYTHM, V10, P167, DOI 10.1177/074873049501000209; Braun DL, 1999, COMPR PSYCHIAT, V40, P442, DOI 10.1016/S0010-440X(99)90088-3; Brinkhuijsen M, 2003, J AFFECT DISORDERS, V74, P307, DOI 10.1016/S0165-0327(03)00003-X; Burgess HJ, 2002, SLEEP MED REV, V6, P407, DOI 10.1053/smrv.2001.0215; Cohen J., 2013, STAT POWER ANAL BEHA; Daansen PJ, 2010, NEUROENDOCRINOL LETT, V31, P290; DELTITO JA, 1991, J AFFECT DISORDERS, V23, P231, DOI 10.1016/0165-0327(91)90105-2; Eastman CI, 1995, J BIOL RHYTHM, V10, P157, DOI 10.1177/074873049501000208; Erickson K, 2005, AM J PSYCHIAT, V162, P2171, DOI 10.1176/appi.ajp.162.11.2171; Goel N, 2005, PSYCHOL MED, V35, P945, DOI 10.1017/S0033291705005027; Golden RN, 2005, AM J PSYCHIAT, V162, P656, DOI 10.1176/appi.ajp.162.4.656; KELLOGG JH, 2003, LIGHT THERAPEUTICS P; Kogan AO, 1998, AM J PSYCHIAT, V155, P293; Krasnik C, 2005, AM J OBSTET GYNECOL, V193, P658, DOI 10.1016/j.ajog.2005.01.055; Kripke DF, 1998, J AFFECT DISORDERS, V49, P109, DOI 10.1016/S0165-0327(98)00005-6; LABBATE LA, 1994, J CLIN PSYCHIAT, V55, P189; LACK L, 1993, SLEEP, V16, P436, DOI 10.1093/sleep/16.5.436; Lack L, 2005, SLEEP, V28, P616, DOI 10.1093/sleep/28.5.616; Lam RW, 2006, AM J PSYCHIAT, V163, P805, DOI 10.1176/appi.ajp.163.5.805; Lam RW, 1999, PSYCHIAT RES, V86, P185, DOI 10.1016/S0165-1781(99)00043-8; LAM RW, 1994, AM J PSYCHIAT, V151, P744; Lambert GW, 2002, LANCET, V360, P1840, DOI 10.1016/S0140-6736(02)11737-5; LEVITT AJ, 1993, AM J PSYCHIAT, V150, P650; LEWY AJ, 1980, SCIENCE, V210, P1267, DOI 10.1126/science.7434030; Neumeister A, 2001, PSYCHOL MED, V31, P1467, DOI 10.1017/S003329170105434z; Nowak L, 2011, WESTERN J NURS RES, V33, P933, DOI 10.1177/0193945910386248; Oren DA, 2002, AM J PSYCHIAT, V159, P666, DOI 10.1176/appi.ajp.159.4.666; OREN DA, 1991, COMPR PSYCHIAT, V32, P147, DOI 10.1016/0010-440X(91)90007-Y; OREN DA, 1991, J NEURAL TRANSM-GEN, V83, P85, DOI 10.1007/BF01244455; Rastad C, 2008, J AFFECT DISORDERS, V108, P291, DOI 10.1016/j.jad.2007.10.009; ROSENTHAL NE, 1984, ARCH GEN PSYCHIAT, V41, P72; ROSENTHAL NE, 1990, SLEEP, V13, P354; Rybak YE, 2007, COMPR PSYCHIAT, V48, P562, DOI 10.1016/j.comppsych.2007.05.008; Sit D, 2007, BIPOLAR DISORD, V9, P918, DOI 10.1111/j.1399-5618.2007.00451.x; Strigo IA, 2008, ARCH GEN PSYCHIAT, V65, P1275, DOI 10.1001/archpsyc.65.11.1275; Strigo IA, 2008, PSYCHOSOM MED, V70, P338, DOI 10.1097/PSY.0b013e3181656a48; Terman M, 1995, J BIOL RHYTHM, V10, P135, DOI 10.1177/074873049501000206; Terman M, 2005, CNS SPECTRUMS, V10, P647, DOI 10.1017/S1092852900019611; Terman M, 1999, J CLIN PSYCHIAT, V60, P799; Thomas L, 2008, TRIALS, V9, DOI 10.1186/1745-6215-9-29; Vanderkooy JD, 2002, CAN J PSYCHIAT, V47, P174, DOI 10.1177/070674370204700208; VOLZ HP, 1991, PHARMACOPSYCHIATRY, V24, P141, DOI 10.1055/s-2007-1014458; WEHR TA, 1989, AM J PSYCHIAT, V146, P829; WETTERBERG L, 1978, J NEURAL TRANSM-SUPP, V13, P389; Willis GL, 2007, CHRONOBIOL INT, V24, P521, DOI 10.1080/07420520701420717; Wirz-Justice A, 2009, CHRONOTHERAPEUTICS A; Wirz-Justice A, 2011, J CLIN PSYCHIAT, V72, P986, DOI 10.4088/JCP.10m06188blu; Zimmerman M, 2010, J CLIN PSYCHIAT, V71, P484, DOI 10.4088/JCP.08m04978blu	50	15	15	0	18	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 24	2013	8	9							e75893	10.1371/journal.pone.0075893	http://dx.doi.org/10.1371/journal.pone.0075893			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	226HG	24086658	Green Submitted, gold, Green Published			2023-01-03	WOS:000325025200068
J	Hwang, CC; Umeki, S; Kubo, M; Hayashi, T; Shimoda, H; Mochizuki, M; Maeda, K; Baba, K; Hiraoka, H; Coffey, M; Okuda, M; Mizuno, T				Hwang, Chung Chew; Umeki, Saori; Kubo, Masahito; Hayashi, Toshiharu; Shimoda, Hiroshi; Mochizuki, Masami; Maeda, Ken; Baba, Kenji; Hiraoka, Hiroko; Coffey, Matt; Okuda, Masaru; Mizuno, Takuya			Oncolytic Reovirus in Canine Mast Cell Tumor	PLOS ONE			English	Article							TYROSINE KINASE; MUTATIONS; INFECTION; APOPTOSIS; THERAPY; ANTIBODIES; RELEASE; PATHWAY; VIRUS; LINES	The usage of reovirus has reached phase II and III clinical trials in human cancers. However, this is the first study to report the oncolytic effects of reovirus in veterinary oncology, focusing on canine mast cell tumor (MCT), the most common cutaneous tumor in dogs. As human and canine cancers share many similarities, we hypothesized that the oncolytic effects of reovirus can be exploited in canine cancers. The objective of this study was to determine the oncolytic effects of reovirus in canine MCT in vitro, in vivo and ex vivo. We demonstrated that MCT cell lines were highly susceptible to reovirus as indicated by marked cell death, high production of progeny virus and virus replication. Reovirus induced apoptosis in the canine MCT cell lines with no correlation to their Ras activation status. In vivo studies were conducted using unilateral and bilateral subcutaneous MCT xenograft models with a single intratumoral reovirus treatment and apparent reduction of tumor mass was exhibited. Furthermore, cell death was induced by reovirus in primary canine MCT samples in vitro. However, canine and murine bone marrow-derived mast cells (BMCMC) were also susceptible to reovirus. The combination of these results supports the potential value of reovirus as a therapy in canine MCT but warrants further investigation on the determinants of reovirus susceptibility.	[Hwang, Chung Chew; Umeki, Saori; Okuda, Masaru; Mizuno, Takuya] Yamaguchi Univ, United Grad Sch Vet Sci, Lab Vet Internal Med, Yamaguchi, Japan; [Kubo, Masahito; Hayashi, Toshiharu] Yamaguchi Univ, Joint Fac Vet Med, Lab Vet Pathol, Yamaguchi, Japan; [Shimoda, Hiroshi; Maeda, Ken] Yamaguchi Univ, Joint Fac Vet Med, Lab Vet Microbiol, Yamaguchi, Japan; [Mochizuki, Masami] Kagoshima Univ, Joint Fac Vet Med, Kagoshima 890, Japan; [Baba, Kenji; Hiraoka, Hiroko] Yamaguchi Univ, Anim Med Ctr, Yamaguchi, Japan; [Coffey, Matt] Oncolyt Biotech Inc, Calgary, AB, Canada; [Okuda, Masaru; Mizuno, Takuya] Yamaguchi Univ, Joint Fac Vet Med, Lab Vet Internal Med, Yamaguchi, Japan; [Okuda, Masaru; Mizuno, Takuya] Yamaguchi Univ, United Grad Sch Vet Sci, Biomed Sci Ctr Translat Res, Yamaguchi, Japan	Yamaguchi University; Yamaguchi University; Yamaguchi University; Kagoshima University; Yamaguchi University; Oncolytics Biotech; Yamaguchi University; Yamaguchi University	Mizuno, T (corresponding author), Yamaguchi Univ, United Grad Sch Vet Sci, Lab Vet Internal Med, Yamaguchi, Japan.	mizutaku@yamaguchi-u.ac.jp		Mizuno, Takuya/0000-0002-9580-7557; Okuda, Masaru/0000-0003-4690-8244	Grants-in-Aid for Scientific Research [24580460, 25850208] Funding Source: KAKEN	Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))		Adair RA, 2013, INT J CANCER, V132, P2327, DOI 10.1002/ijc.27918; Alain T, 2002, BLOOD, V100, P4146, DOI 10.1182/blood-2002-02-0503; Barton ES, 2001, CELL, V104, P441, DOI 10.1016/S0092-8674(01)00231-8; Butler M., 2013, SMALL ANIMAL CLIN ON, P68; Chappell JD, 1997, J VIROL, V71, P1834, DOI 10.1128/JVI.71.3.1834-1841.1997; Cho IR, 2010, INT J ONCOL, V36, P1023, DOI 10.3892/ijo_00000583; Clarke P, 2004, J VIROL, V78, P13132, DOI 10.1128/JVI.78.23.13132-13138.2004; Coffey MC, 1998, SCIENCE, V282, P1332, DOI 10.1126/science.282.5392.1332; Connolly JL, 2000, J VIROL, V74, P2981, DOI 10.1128/JVI.74.7.2981-2989.2000; Decaro N, 2005, VET MICROBIOL, V109, P19, DOI 10.1016/j.vetmic.2005.05.014; DUNCAN MR, 1978, J VIROL, V28, P444, DOI 10.1128/JVI.28.2.444-449.1978; Errington F, 2008, GENE THER, V15, P1257, DOI 10.1038/gt.2008.58; Errington F, 2008, J IMMUNOL, V180, P6018, DOI 10.4049/jimmunol.180.9.6018; Escobar HM, 2004, ANTICANCER RES, V24, P3027; FUKUMI H, 1969, JPN J MED SCI BIOL, V22, P13, DOI 10.7883/yoken1952.22.13; Gordon IK, 2010, ILAR J, V51, P214, DOI 10.1093/ilar.51.3.214; Heinrich MC, 2002, J CLIN ONCOL, V20, P1692, DOI 10.1200/JCO.2002.20.6.1692; Ilett EJ, 2011, CLIN CANCER RES, V17, P2767, DOI 10.1158/1078-0432.CCR-10-3266; Ishiguro T, 2001, J VET MED SCI, V63, P1031, DOI 10.1292/jvms.63.1031; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.20107]; Kalesnikoff J, 2011, METHODS MOL BIOL, V677, P207, DOI 10.1007/978-1-60761-869-0_15; Kawarai S, 2010, J VET MED SCI, V72, P131, DOI 10.1292/jvms.09-0281; Kim M, 2010, ONCOGENE, V29, P3990, DOI 10.1038/onc.2010.137; Lin TY, 2006, VET IMMUNOL IMMUNOP, V113, P37, DOI 10.1016/j.vetimm.2006.03.024; Loken SD, 2004, CANCER BIOL THER, V3, P734, DOI 10.4161/cbt.3.8.963; Lolkema MP, 2011, CLIN CANCER RES, V17, P581, DOI 10.1158/1078-0432.CCR-10-2159; London C, 2013, WITHROW MACEWENS SMA, P335; Marcato P, 2007, MOL THER, V15, P1522, DOI 10.1038/sj.mt.6300179; Meerani S, 2010, EUROPEAN J SCI RES, V40, P156; Metcalfe Dean D, 2005, Trans Am Clin Climatol Assoc, V116, P185; MURAKAMI T, 1975, NATL I ANIM HEALTH Q, V15, P8; Norman KL, 2004, P NATL ACAD SCI USA, V101, P11099, DOI 10.1073/pnas.0404310101; Ohmori K, 2008, VET IMMUNOL IMMUNOP, V126, P43, DOI 10.1016/j.vetimm.2008.06.014; Pan D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054006; Patil SS, 2012, J TRANSL MED, V10, DOI 10.1186/1479-5876-10-3; Prestwich RJ, 2009, HUM GENE THER, V20, P1119, DOI 10.1089/hum.2009.135; Reed L.J., 1938, AM J HYG, V27, P493, DOI [10.1093/oxfordjournals.aje.a118408, DOI 10.1093/OXFORDJOURNALS.AJE.A118408]; Roskoski R, 2005, BIOCHEM BIOPH RES CO, V338, P1307, DOI 10.1016/j.bbrc.2005.09.150; Sei S, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-47; SELB B, 1994, J VIROL METHODS, V47, P15, DOI 10.1016/0166-0934(94)90062-0; Strong JE, 1996, J VIROL, V70, P612, DOI 10.1128/JVI.70.1.612-616.1996; Strong JE, 1998, EMBO J, V17, P3351, DOI 10.1093/emboj/17.12.3351; Takahashi T, 2001, INT ARCH ALLERGY IMM, V125, P228, DOI 10.1159/000053820; Takeuchi Y, 2012, J VET PHARMACOL THER, V35, P97, DOI 10.1111/j.1365-2885.2011.01296.x; Taylor SJ, 2001, METHOD ENZYMOL, V333, P333; Thirukkumaran CM, 2010, CANCER RES, V70, P2435, DOI 10.1158/0008-5472.CAN-09-2408; Thirukkumaran CM, 2003, BLOOD, V102, P377, DOI 10.1182/blood-2002-08-2508; Twigger K, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-368; Umeki S, 2011, VET IMMUNOL IMMUNOP, V142, P119, DOI 10.1016/j.vetimm.2011.04.009; van Houdt WJ, 2008, CANCER GENE THER, V15, P284, DOI 10.1038/cgt.2008.2; Watzinger F, 2001, MOL CARCINOGEN, V30, P190, DOI 10.1002/mc.1027	51	25	25	0	17	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 20	2013	8	9							e73555	10.1371/journal.pone.0073555	http://dx.doi.org/10.1371/journal.pone.0073555			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	222YC	24073198	Green Published, Green Submitted, gold			2023-01-03	WOS:000324768000007
J	Bergt, S; Guter, A; Grub, A; Wagner, NM; Beltschany, C; Langner, S; Wree, A; Hildebrandt, S; Noldge-Schomburg, G; Vollmar, B; Roesner, JP				Bergt, Stefan; Gueter, Anne; Grub, Andrea; Wagner, Nana-Maria; Beltschany, Claudia; Langner, Soenke; Wree, Andreas; Hildebrandt, Steve; Noeldge-Schomburg, Gabriele; Vollmar, Brigitte; Roesner, Jan P.			Impact of Toll-Like Receptor 2 Deficiency on Survival and Neurological Function after Cardiac Arrest: A Murine Model of Cardiopulmonary Resuscitation	PLOS ONE			English	Article							TLR2; INJURY; REPERFUSION; GUIDELINES; MANAGEMENT; CELLS; CARE	Background: Cardiac arrest (CA) followed by cardiopulmonary resuscitation (CPR) is associated with poor survival rate and neurofunctional outcome. Toll-like receptor 2 (TLR2) plays an important role in conditions of sterile inflammation such as reperfusion injury. Recent data demonstrated beneficial effects of the administration of TLR2-blocking antibodies in ischemia/reperfusion injury. In this study we investigated the role of TLR2 for survival and neurofunctional outcome after CA/CPR in mice. Methods: Female TLR2-deficient (TLR2(-/-)) and wild type (WT) mice were subjected to CA for eight min induced by intravenous injection of potassium chloride and CPR by external chest compression. Upon the beginning of CPR, n = 15 WT mice received 5 mu g/g T2.5 TLR2 inhibiting antibody intravenously while n = 30 TLR2(-/-) and n = 31 WT controls were subjected to injection of normal saline. Survival and neurological outcome were evaluated during a 28-day follow up period. Basic neurological function, balance, coordination and overall motor function as well as spatial learning and memory were investigated, respectively. In a separate set of experiments, six mice per group were analysed for cytokine and corticosterone serum levels eight hours after CA/CPR. Results: TLR2 deficiency and treatment with a TLR2 blocking antibody were associated with increased survival (77% and 80% vs. 51% of WT control; both P < 0.05). Neurofunctional performance was less compromised in TLR2(-/-) and antibody treated mice. Compared to WT and antibody treated mice, TLR2(-/-) mice exhibited reduced IL-6 (both P < 0.05) but not IL-1 beta levels and increased corticosterone plasma concentrations (both P < 0.05). Conclusion: Deficiency or functional blockade of TLR2 is associated with increased survival and improved neurofunctional outcome in a mouse model of CA/CPR. Thus, TLR2 inhibition could provide a novel therapeutic approach for reducing mortality and morbidity after cardiac arrest and cardiopulmonary resuscitation.	[Bergt, Stefan; Gueter, Anne; Grub, Andrea; Wagner, Nana-Maria; Beltschany, Claudia; Noeldge-Schomburg, Gabriele; Roesner, Jan P.] Univ Hosp Rostock, Clin Anaesthesiol & Crit Care Med, Rostock, Germany; [Langner, Soenke] Univ Hosp Greifswald, Inst Neuroradiol, Greifswald, Germany; [Wree, Andreas; Hildebrandt, Steve] Univ Rostock, Dept Anat, D-18055 Rostock, Germany; [Vollmar, Brigitte] Univ Rostock, Inst Expt Surg, D-18055 Rostock, Germany	University of Rostock; University of Rostock; University of Rostock	Bergt, S (corresponding author), Univ Hosp Rostock, Clin Anaesthesiol & Crit Care Med, Rostock, Germany.	stefan.bergt@medizin.uni-rostock.de	Langner, Soenke/ABB-6744-2021; Wagner, Nana-Maria/AAB-3953-2021	Langner, Soenke/0000-0001-7241-1173; Wagner, Nana-Maria/0000-0002-4610-6666				Abella BS, 2004, CIRCULATION, V109, P2786, DOI 10.1161/01.CIR.0000131940.19833.85; Arslan F, 2010, MEDIAT INFLAMM, V2010, DOI 10.1155/2010/704202; Arslan F, 2010, CIRCULATION, V121, P80, DOI 10.1161/CIRCULATIONAHA.109.880187; Ben Mkaddem S, 2010, ONCOTARGET, V1, P741, DOI 10.18632/oncotarget.209; Bohacek I, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-191; Bornstein SR, 2004, P NATL ACAD SCI USA, V101, P16695, DOI 10.1073/pnas.0407550101; Bottiger BW, 2002, CRIT CARE MED, V30, P2473, DOI 10.1097/01.CCM.0000034689.78033.E2; DECKER MW, 1989, BRAIN RES, V477, P29, DOI 10.1016/0006-8993(89)91391-7; Farrar CA, 2012, FASEB J, V26, P799, DOI 10.1096/fj.11-195396; Fink K, 2010, CRIT CARE, V14, DOI 10.1186/cc9050; Geocadin RG, 2008, NEUROL CLIN, V26, P487, DOI 10.1016/j.ncl.2008.03.015; Hajishengallis G, 2011, NAT REV IMMUNOL, V11, P187, DOI 10.1038/nri2918; Hutchens MP, 2008, RESUSCITATION, V76, P89, DOI 10.1016/j.resuscitation.2007.06.031; Koster RW, 2010, RESUSCITATION, V81, pE48, DOI 10.1016/j.resuscitation.2010.08.005; KRMPOTIC L, NEUROSCIENCE; Kuhlicke J, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001364; Lorne E, 2010, INTENS CARE MED, V36, P1826, DOI 10.1007/s00134-010-1983-5; Menzebach A, 2010, SHOCK, V33, P189, DOI 10.1097/SHK.0b013e3181ad59a3; Neigh GN, 2004, EUR J NEUROSCI, V20, P1865, DOI 10.1111/j.1460-9568.2004.03649.x; Neigh GN, 2004, J CEREBR BLOOD F MET, V24, P372, DOI 10.1097/00004647-200404000-00002; Nicholson A, 2009, J AM ASSOC LAB ANIM, V48, P740; Nolan JP, 2010, RESUSCITATION, V81, P1219, DOI 10.1016/j.resuscitation.2010.08.021; Norman GJ, 2011, J NEUROSCI, V31, P3446, DOI 10.1523/JNEUROSCI.4558-10.2011; Okun E, 2011, TRENDS NEUROSCI, V34, P269, DOI 10.1016/j.tins.2011.02.005; Peberdy MA, 2010, CIRCULATION, V122, pS768, DOI 10.1161/CIRCULATIONAHA.110.971002; Puttgen HA, 2009, CURR OPIN CRIT CARE, V15, P118, DOI 10.1097/MCC.0b013e328326077c; Rolls A, 2007, NAT CELL BIOL, V9, P1081, DOI 10.1038/ncb1629; Samborska-Sablik A, 2011, ARCH MED SCI, V7, P619, DOI 10.5114/aoms.2011.24131; Tang CH, 2010, BIOCHEM PHARMACOL, V79, P1648, DOI 10.1016/j.bcp.2010.01.025; Tsai MS, 2007, AM J EMERG MED, V25, P318, DOI 10.1016/j.ajem.2006.12.007; Varon J, 2007, AM J EMERG MED, V25, P376, DOI 10.1016/j.ajem.2006.12.023; Ziegler G, 2007, BIOCHEM BIOPH RES CO, V359, P574, DOI 10.1016/j.bbrc.2007.05.157; Ziegler G, 2011, J CEREBR BLOOD F MET, V31, P757, DOI 10.1038/jcbfm.2010.161	33	8	8	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 16	2013	8	9							e74944	10.1371/journal.pone.0074944	http://dx.doi.org/10.1371/journal.pone.0074944			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	219GJ	24066159	Green Published, Green Submitted, gold			2023-01-03	WOS:000324494000141
J	Ben-Aharon, I; Vidal, L; Rizel, S; Yerushalmi, R; Shpilberg, O; Sulkes, A; Stemmer, SM				Ben-Aharon, Irit; Vidal, Liat; Rizel, Shulamith; Yerushalmi, Rinat; Shpilberg, Ofer; Sulkes, Aaron; Stemmer, Salomon M.			Bisphosphonates in the Adjuvant Setting of Breast Cancer Therapy-Effect on Survival: A Systematic Review and Meta-Analysis	PLOS ONE			English	Review							NITROGEN-CONTAINING BISPHOSPHONATES; BONE-MINERAL DENSITY; POSTMENOPAUSAL WOMEN; ZOLEDRONIC ACID; ORAL CLODRONATE; FOLLOW-UP; DOUBLE-BLIND; LETROZOLE; PLACEBO; RISK	Background: The role of bisphosphonates (BP) in early breast cancer (BC) has been considered controversial. We performed a meta-analysis of all randomized controlled trials (RCTs) that appraised the effects of BP on survival in early BC. Methods: RCTs were identified by searching the Cochrane Library, MEDLINE databases and conference proceedings. Hazard ratios (HRs) of overall survival (OS), disease-free survival (DFS) and relative risks of adverse events were estimated and pooled. Results: Thirteen trials met the inclusion criteria, evaluating a total of 15,762 patients. Meta-analysis of ten trials which reported OS revealed no statistically significant benefit in OS for BP (HR 0.89, 95% CI = 0.79 to 1.01). Meta-analysis of nine trials which reported the DFS revealed no benefit in DFS (HR 0.95 (0.81-1.12)). Meta-analysis upon menopausal status showed a statistically significant better DFS in the BP-treated patients (HR 0.81(0.69-0.95)). In meta-regression, chemotherapy was negatively associated with HR of survival. Conclusions: Our meta-analysis indicates a positive effect for adjuvant BP on survival only in postmenopausal patients. Meta-regression demonstrated a negative association between chemotherapy use BP effect on survival. Further large scale RCTs are warranted to unravel the specific subgroups that would benefit from the addition of BP in the adjuvant setting.	[Ben-Aharon, Irit; Rizel, Shulamith; Yerushalmi, Rinat; Sulkes, Aaron; Stemmer, Salomon M.] Rabin Med Ctr, Davidoff Ctr, Inst Oncol, Petah Tiqwa, Israel; [Vidal, Liat; Shpilberg, Ofer] Rabin Med Ctr, Davidoff Ctr, Inst Hematol, Petah Tiqwa, Israel; [Ben-Aharon, Irit; Vidal, Liat; Yerushalmi, Rinat; Shpilberg, Ofer; Sulkes, Aaron; Stemmer, Salomon M.] Tel Aviv Univ, Sackler Fac Med, IL-69978 Tel Aviv, Israel	Rabin Medical Center; Rabin Medical Center; Tel Aviv University; Sackler Faculty of Medicine	Ben-Aharon, I (corresponding author), Rabin Med Ctr, Davidoff Ctr, Inst Oncol, Petah Tiqwa, Israel.	iritbenaharon@gmail.com						Bianchi G, 2008, CURR MED RES OPIN, V24, P2669, DOI 10.1185/03007990802370912 ; Boissier S, 2000, CANCER RES, V60, P2949; Brufsky AM, 2012, CANCER-AM CANCER SOC, V118, P1192, DOI 10.1002/cncr.26313; Brufsky AM, 2009, CLIN BREAST CANCER, V9, P77, DOI 10.3816/CBC.2009.n.015; Cauley JA, 2012, LANCET ONCOL; Cheung AM, 2012, LANCET ONCOL; Chlebowski RT, 2010, J CLIN ONCOL, V28, P3582, DOI 10.1200/JCO.2010.28.2095; Coleman R, 2011, BREAST CANCER RES TR, V127, P429, DOI 10.1007/s10549-011-1429-y; Coleman R, 2009, SAN ANT BREAST CANC; Coleman RE, 2007, LANCET ONCOL, V8, P119, DOI 10.1016/S1470-2045(07)70003-7; Coleman RE, 2006, CLIN CANCER RES, V12, p6243S, DOI 10.1158/1078-0432.CCR-06-0931; Coleman RE, 2011, NEW ENGL J MED, V365, P1396, DOI 10.1056/NEJMoa1105195; Daubine F, 2007, J NATL CANCER I, V99, P322, DOI 10.1093/jnci/djk054; de Boer RH BC, 2011, SAN ANT BREAST CANC; Delmas PD, 1997, J CLIN ONCOL, V15, P955, DOI 10.1200/JCO.1997.15.3.955; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Diel IJ, 2008, ANN ONCOL, V19, P2007, DOI 10.1093/annonc/mdn429; Eidtmann H, 2010, ANN ONCOL, V21, P2188, DOI 10.1093/annonc/mdq217; Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516; Fisher JE, 1999, P NATL ACAD SCI USA, V96, P133, DOI 10.1073/pnas.96.1.133; Gallo M, 2011, ANN ONCOL, V1, P1; Gnant M, 2011, SAN ANT BREAST CANC; Gnant M, 2011, LANCET ONCOL, V12, P631, DOI 10.1016/S1470-2045(11)70122-X; Greenspan SL, 2008, J CLIN ONCOL, V26, P2644, DOI 10.1200/JCO.2007.15.2967; Hadji P, 2008, ANN ONCOL, V19, P1407, DOI 10.1093/annonc/mdn164; Hadji P, 2009, ANN ONCOL, V20, P1203, DOI 10.1093/annonc/mdn762; Hadji P, 2007, SEMIN ONCOL, V34, pS4, DOI 10.1053/j.seminoncol.2007.10.005; Higgins Julian PT, 2011, COCHRANE HDB SYSTEMA, P649; Holen I, 2010, CURR PHARM DESIGN, V16, P1262, DOI 10.2174/138161210791034003; Kanis JA, 1996, BONE, V19, P663, DOI 10.1016/S8756-3282(96)00285-2; Kavanagh KL, 2006, P NATL ACAD SCI USA, V103, P7829, DOI 10.1073/pnas.0601643103; Kristensen B, 2008, ACTA ONCOL, V47, P740, DOI 10.1080/02841860801964988; Kunzmann V, 1999, NEW ENGL J MED, V340, P737, DOI 10.1056/NEJM199903043400914; Leal T, 2010, CLIN BREAST CANCER, V10, P471, DOI 10.3816/CBC.2010.n.062; Lester JE, 2008, CLIN CANCER RES, V14, P6336, DOI 10.1158/1078-0432.CCR-07-5101; MANTEL N, 1959, J NATL CANCER I, V22, P719; Mauri D, 2009, BREAST CANCER RES TR, V116, P433, DOI 10.1007/s10549-009-0432-z; Mobus V, 2011, SAN ANT BREAST CANC; Neville-Webbe HL, 2010, EUR J CANCER, V46, P1211, DOI 10.1016/j.ejca.2010.02.041; Neville-Webbe HL, 2010, SEMIN ONCOL, V37, pS53, DOI 10.1053/j.seminoncol.2010.06.008; Ottewell PD, 2009, MOL CANCER THER, V8, P2821, DOI 10.1158/1535-7163.MCT-09-0462; Paterson AHG, 2012, LANCET ONCOL, V13, P734, DOI 10.1016/S1470-2045(12)70226-7; Pavlakis N, 2005, COCHRANE DB SYST REV, V3; Perez EA, 2006, J CLIN ONCOL, V24, P3629, DOI 10.1200/JCO.2005.05.4882; Powles T, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1384; Rennert G, 2010, J CLIN ONCOL, V28, P3577, DOI 10.1200/JCO.2010.28.1113; Rodan GA, 1998, ANNU REV PHARMACOL, V38, P375, DOI 10.1146/annurev.pharmtox.38.1.375; Saarto T, 2004, ACTA ONCOL, V43, P650, DOI 10.1080/02841860410032885; Safra T, 2011, ONCOLOGY-BASEL, V81, P298, DOI 10.1159/000334456; Sweeting MJ, 2004, STAT MED, V23, P1351, DOI 10.1002/sim.1761; van der Vliet HJ, 2012, NEW ENGL J MED, V366, P188, DOI 10.1056/NEJMc1113049; Van Poznak C, 2010, J CLIN ONCOL, V28, P967, DOI 10.1200/JCO.2009.24.5902; vanderPluijm G, 1996, J CLIN INVEST, V98, P698, DOI 10.1172/JCI118841; Winter MC, 2008, CANCER TREAT REV, V34, P453, DOI 10.1016/j.ctrv.2008.02.004; Wong R., 2002, COCHRANE DB SYST REV, V2002, pCD002068, DOI [DOI 10.1002/14651858.CD002068, 10.1002/14651858.CD002068]	55	29	30	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 26	2013	8	8							e70044	10.1371/journal.pone.0070044	http://dx.doi.org/10.1371/journal.pone.0070044			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	215RU	23990894	Green Published, gold			2023-01-03	WOS:000324228800006
J	Rosell, R; Bivona, TG; Karachaliou, N				Rosell, Rafael; Bivona, Trever G.; Karachaliou, Niki			Genetics and biomarkers in personalisation of lung cancer treatment	LANCET			English	Article							GROWTH-FACTOR RECEPTOR; EGFR T790M MUTATION; INDUCED APOPTOSIS; ACQUIRED-RESISTANCE; THERAPEUTIC TARGET; PI3K INHIBITORS; MEK INHIBITION; KINASE; PATHWAY; ACTIVATION	Non-small-cell lung cancer is often diagnosed at the metastatic stage, with median survival of just 1 year. The identification of driver mutations in the epidermal growth factor receptor (EGFR) as the primary oncogenic event in a subset of lung adenocarcinomas led to a model of targeted treatment and genetic profiling of the disease. EGFR tyrosine kinase inhibitors confer remission in 60% of patients, but responses are short-lived. The pre-existing EGFR Thr790Met mutation could be a subclonal driver responsible for these transient responses. Overexpression of AXL and reduced MED12 function are hallmarks of resistance to tyrosine kinase inhibitors in EGFR-mutant non-small-cell lung cancer. Crosstalk between signalling pathways is another mechanism of resistance; therefore, identification of the molecular components involved could lead to the development of combination therapies cotargeting these molecules instead of EGFR tyrosine kinase inhibitor monotherapy. Additionally, novel biomarkers could be identified through deep sequencing analysis of serial rebiopsies before and during treatment.	[Rosell, Rafael] Catalan Inst Oncol Badalona, Badalona, Spain; [Rosell, Rafael; Karachaliou, Niki] Pangaea Biotech, Breakthrough Canc Res Unit, Barcelona, Spain; [Rosell, Rafael; Bivona, Trever G.; Karachaliou, Niki] Canc Therapeut Innovat Grp, New York, NY USA; [Bivona, Trever G.] Univ Calif San Francisco, Dept Med, Div Hematol & Oncol, UCSF Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA; [Karachaliou, Niki] Quiron Dexeus Univ Hosp, Barcelona, Spain	Catalan Institute of Oncology; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center	Rosell, R (corresponding author), Hosp Badalona Germans Trias & Pujol, Catalan Inst Oncol, Med Oncol Serv, Ctra Canyet S-N, Badalona 08916, Barcelona, Spain.	rrosell@iconcologia.net			LaCaixa Foundation; Redes Tematicas de Investigacion en Cancer [RD12/0036/0072]; NIH Director's New Innovator Award; Howard Hughes Medical Institute; Doris Duke Charitable Foundation; American Lung Association; National Lung Cancer Partnership; Sidney Kimmel Foundation for Cancer Research; Searle Scholars Program; Wendell and Eddi Van Auken; California Institute for Quantitative Biosciences	LaCaixa Foundation(La Caixa Foundation); Redes Tematicas de Investigacion en Cancer; NIH Director's New Innovator Award(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Howard Hughes Medical Institute(Howard Hughes Medical Institute); Doris Duke Charitable Foundation(Doris Duke Charitable Foundation (DDCF)); American Lung Association; National Lung Cancer Partnership; Sidney Kimmel Foundation for Cancer Research; Searle Scholars Program; Wendell and Eddi Van Auken; California Institute for Quantitative Biosciences	Work in RR's laboratory is supported by a grant from LaCaixa Foundation and by a grant from Redes Tematicas de Investigacion en Cancer (RD12/0036/0072). TGB acknowledges research funding support from the following sources: NIH Director's New Innovator Award, Howard Hughes Medical Institute, Doris Duke Charitable Foundation, American Lung Association, National Lung Cancer Partnership, Sidney Kimmel Foundation for Cancer Research, Searle Scholars Program, Wendell and Eddi Van Auken, and California Institute for Quantitative Biosciences. The funding agencies had no role in the drafting of the report or in the decision to publish.	Akiyama T, 2009, MOL CANCER THER, V8, P3173, DOI 10.1158/1535-7163.MCT-09-0685; Allen JE, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3004828; Ammoun S, 2014, ONCOGENE, V33, P336, DOI 10.1038/onc.2012.587; Arcila ME, 2011, CLIN CANCER RES, V17, P1169, DOI 10.1158/1078-0432.CCR-10-2277; Atwood SX, 2013, NATURE, V494, P484, DOI 10.1038/nature11889; Bernards R, 2012, CELL, V151, P465, DOI 10.1016/j.cell.2012.10.014; Bivona T, 2013, J CLIN ONCOL S, V31; Bivona TG, 2011, NATURE, V471, P523, DOI 10.1038/nature09870; Blakely CM, 2012, CANCER DISCOV, V2, P872, DOI 10.1158/2159-8290.CD-12-0387; Buettner R, 2013, J CLIN ONCOL, V31, P1858, DOI 10.1200/JCO.2012.45.9867; Byers LA, 2013, CLIN CANCER RES, V19, P279, DOI 10.1158/1078-0432.CCR-12-1558; Chen Z, 2012, NATURE, V483, P613, DOI 10.1038/nature10937; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; Corcoran RB, 2013, CANCER CELL, V23, P121, DOI 10.1016/j.ccr.2012.11.007; Costa DB, 2007, PLOS MED, V4, P1669, DOI 10.1371/journal.pmed.0040315; Cragg MS, 2007, PLOS MED, V4, P1681, DOI 10.1371/journal.pmed.0040316; CULLEN MH, 1988, BRIT J CANCER, V58, P359, DOI 10.1038/bjc.1988.219; Dimberg LY, 2013, ONCOGENE, V32, P1341, DOI 10.1038/onc.2012.164; Drilon A, 2012, LANCET ONCOL, V13, pE418, DOI 10.1016/S1470-2045(12)70291-7; Duncan JS, 2012, CELL, V149, P307, DOI 10.1016/j.cell.2012.02.053; Eberl M, 2012, EMBO MOL MED, V4, P218, DOI 10.1002/emmm.201100201; Engelman JA, 2008, NAT MED, V14, P1351, DOI 10.1038/nm.1890; Faber AC, 2011, CANCER DISCOV, V1, P352, DOI 10.1158/2159-8290.CD-11-0106; Fiory F, 2009, AM J PHYSIOL-ENDOC M, V297, pE592, DOI 10.1152/ajpendo.00228.2009; Fujita Y, 2012, J THORAC ONCOL, V7, P1640, DOI 10.1097/JTO.0b013e3182653d7f; Gao SP, 2007, J CLIN INVEST, V117, P3846, DOI 10.1172/JCI31871; Garraway LA, 2013, CELL, V153, P17, DOI 10.1016/j.cell.2013.03.002; Goldstraw P, 2011, LANCET, V378, P1727, DOI 10.1016/S0140-6736(10)62101-0; Gong YX, 2007, PLOS MED, V4, P1655, DOI 10.1371/journal.pmed.0040294; Gutschner T, 2012, RNA BIOL, V9, P703, DOI 10.4161/rna.20481; He L, 2013, CANCER DISCOV, V3, P324, DOI 10.1158/2159-8290.CD-12-0417; Hegde GV, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3004438; Heist Rebecca S, 2012, Cancer Cell, V21, DOI 10.1016/j.ccr.2012.03.007; Huang SD, 2012, CELL, V151, P937, DOI 10.1016/j.cell.2012.10.035; Incoronato M, 2010, CANCER RES, V70, P3638, DOI 10.1158/0008-5472.CAN-09-3341; Jablonski D, 2001, P NATL ACAD SCI USA, V98, P5393, DOI 10.1073/pnas.101092598; Janne PA, 2013, LANCET ONCOL, V14, P38, DOI 10.1016/S1470-2045(12)70489-8; Kobayashi S, 2005, NEW ENGL J MED, V352, P786, DOI 10.1056/NEJMoa044238; Konishi J, 2010, ONCOGENE, V29, P589, DOI 10.1038/onc.2009.366; Kuroda J, 2006, P NATL ACAD SCI USA, V103, P14907, DOI 10.1073/pnas.0606176103; Kwak EL, 2010, NEW ENGL J MED, V363, P1693, DOI 10.1056/NEJMoa1006448; Lam YWF, 2014, OMICS IN CLINICAL PRACTICE: GENOMICS, PHARMACOGENOMICS, PROTEOMICS, AND TRANSCRIPTOMICS IN CLINICAL RESEARCH, P95, DOI 10.1155/2013/641089; Lipworth BJ, 2005, LANCET, V365, P167, DOI 10.1016/S0140-6736(05)17708-3; Lito P, 2012, CANCER CELL, V22, P668, DOI 10.1016/j.ccr.2012.10.009; Little AS, 2013, ONCOGENE, V32, P1207, DOI 10.1038/onc.2012.160; Littlepage LE, 2012, CANCER DISCOV, V2, P638, DOI 10.1158/2159-8290.CD-12-0093; Lu M, 2013, CANCER CELL, V23, P618, DOI 10.1016/j.ccr.2013.03.013; Mahadevan D, 2007, ONCOGENE, V26, P3909, DOI 10.1038/sj.onc.1210173; Maheswaran S, 2008, NEW ENGL J MED, V359, P366, DOI 10.1056/NEJMoa0800668; Malik S, 2010, NAT REV GENET, V11, P761, DOI 10.1038/nrg2901; Maraver A, 2012, CANCER CELL, V22, P222, DOI 10.1016/j.ccr.2012.06.014; Massague J, 2012, NAT REV MOL CELL BIO, V13, P616, DOI 10.1038/nrm3434; Misale S, 2012, NATURE, V486, P532, DOI 10.1038/nature11156; Molina-Arcas M, 2013, CANCER DISCOV, V3, P548, DOI 10.1158/2159-8290.CD-12-0446; Naumov GN, 2009, CLIN CANCER RES, V15, P3484, DOI 10.1158/1078-0432.CCR-08-2904; Nieminen AI, 2013, P NATL ACAD SCI USA, V110, pE1839, DOI 10.1073/pnas.1208530110; Paccez JD, 2013, ONCOGENE, V32, P689, DOI 10.1038/onc.2012.89; Pao W, 2005, PLOS MED, V2, P225, DOI 10.1371/journal.pmed.0020073; Pao W, 2011, LANCET ONCOL, V12, P175, DOI 10.1016/S1470-2045(10)70087-5; Pullamsetti SS, 2013, ONCOGENE, V32, P1121, DOI 10.1038/onc.2012.136; Reavie L, 2013, CANCER CELL, V23, P362, DOI 10.1016/j.ccr.2013.01.025; Rikova K, 2007, CELL, V131, P1190, DOI 10.1016/j.cell.2007.11.025; Romano G, 2012, P NATL ACAD SCI USA, V109, P16570, DOI 10.1073/pnas.1207917109; Rosell R, 2012, ESMO C VIENN AUSTR S; Rosell R., 2012, MOL BASED DECISION M, P137; Rosell R., 2012, MOL BASED DECISION M, P75; Rosell R, 2013, NEW ENGL J MED, V368, P1551, DOI 10.1056/NEJMcibr1214549; Rosell R, 2012, LANCET ONCOL, V13, P971, DOI 10.1016/S1470-2045(12)70369-8; Rosell R, 2012, LANCET ONCOL, V13, P239, DOI 10.1016/S1470-2045(11)70393-X; Rosell R, 2011, CLIN CANCER RES, V17, P1160, DOI 10.1158/1078-0432.CCR-10-2158; Rosell R, 2009, NEW ENGL J MED, V361, P958, DOI 10.1056/NEJMoa0904554; Schiller JH, 2002, NEW ENGL J MED, V346, P92, DOI 10.1056/NEJMoa011954; Schmidt LH, 2011, J THORAC ONCOL, V6, P1984, DOI 10.1097/JTO.0b013e3182307eac; Schnidar H, 2009, CANCER RES, V69, P1284, DOI 10.1158/0008-5472.CAN-08-2331; Seo JS, 2012, GENOME RES, V22, P2109, DOI 10.1101/gr.145144.112; Sequist LV, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002003; Serizawa M, 2013, J THORAC ONCOL, V8, P259, DOI 10.1097/JTO.0b013e318279e942; Shackelford DB, 2013, CANCER CELL, V23, P143, DOI 10.1016/j.ccr.2012.12.008; Sos ML, 2012, ONCOGENE, V31, P4811, DOI 10.1038/onc.2011.640; Spoerke JM, 2012, CLIN CANCER RES, V18, P6771, DOI 10.1158/1078-0432.CCR-12-2347; Stern HM, 2010, CLIN CANCER RES, V16, P1587, DOI 10.1158/1078-0432.CCR-09-3108; Stommel JM, 2007, SCIENCE, V318, P287, DOI 10.1126/science.1142946; Su KY, 2012, J CLIN ONCOL, V30, P433, DOI 10.1200/JCO.2011.38.3224; Tabara K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041017; Tanizaki J, 2011, ONCOGENE, V30, P4097, DOI 10.1038/onc.2011.111; Vogelstein B, 2013, SCIENCE, V339, P1546, DOI 10.1126/science.1235122; Wagner KW, 2007, NAT MED, V13, P1070, DOI 10.1038/nm1627; Wang Y, 2012, CANCER CELL, V21, P374, DOI 10.1016/j.ccr.2011.12.028; Wertz IE, 2011, NATURE, V471, P110, DOI 10.1038/nature09779; Westhoff B, 2009, P NATL ACAD SCI USA, V106, P22293, DOI 10.1073/pnas.0907781106; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; Xargay-Torrent S, 2011, CLIN CANCER RES, V17, P3956, DOI 10.1158/1078-0432.CCR-10-3412; Yang JY, 2010, CANCER RES, V70, P4709, DOI 10.1158/0008-5472.CAN-09-4524; Yang X, 2012, P NATL ACAD SCI USA, V109, pE2813, DOI 10.1073/pnas.1204311109; Zander T, 2012, J CLIN ONCOL S, V30; Zhang ZF, 2012, NAT GENET, V44, P852, DOI 10.1038/ng.2330	96	220	239	2	76	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 24	2013	382	9893					720	731		10.1016/S0140-6736(13)61715-8	http://dx.doi.org/10.1016/S0140-6736(13)61715-8			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	206SI	23972815				2023-01-03	WOS:000323542400030
J	Leeming, DJ; Karsdal, MA; Rasmussen, LM; Scholze, A; Tepel, M				Leeming, Diana J.; Karsdal, Morten A.; Rasmussen, Lars M.; Scholze, Alexandra; Tepel, Martin			Association of Systemic Collagen Type IV Formation with Survival among Patients Undergoing Hemodialysis	PLOS ONE			English	Article							CHRONIC KIDNEY-DISEASE; UREMIC CARDIOMYOPATHY; BASEMENT-MEMBRANE; MYOCARDIAL-INFARCTION; EXTRACELLULAR-MATRIX; ARTERIAL STIFFNESS; RENAL-FAILURE; TGF-BETA; FIBROSIS; SERUM	Objective: The 7S domain of collagen type IV (P4NP_7S) assessed in plasma represents systemic collagen type IV formation. The objective of the study was to investigate the association of systemic collagen type IV formation with survival among patients undergoing hemodialysis. Methods: We performed an observational cohort study of 371 hemodialysis patients. Plasma P4NP_7S was analyzed using a specific enzyme-linked immunosorbent assay detecting the amino-terminal propeptide of type IV procollagen. Association between categories of plasma P4NP_7S concentrations and survival was initially assessed by Kaplan-Meier analysis, then in an adjusted Cox model. Results: For hemodialysis patients in the highest category of systemic collagen type IV formation, i.e. plasma P4NP_7S concentrations more than 775 pg/L, an increased risk for death was observed (highest P4NP_7S category vs all other categories, hazard ratio, 1.934; 95% confidence interval, 1.139 to 3.285). Survival analysis showed an increased risk of death in the highest P4NP_7S category compared to the other categories (Chi square 6.903; P = 0.032). Median survival was only 105 days in the highest P4NP_7S category whereas it was 629 days in the medium category, and 905 days in the lowest category. Multivariable-adjusted Cox regression showed increased odds for death with higher age and higher P4NP_7S categories. Systemic collagen type IV formation was associated with plasma concentrations of the collagen IV degradation product C4M (Spearman r = 0.764; P<0.0001) confirming extracellular matrix turnover. Conclusion: Among hemodialysis patients elevated systemic collagen type IV formation suggesting accelerating systemic fibrosis was associated with increased risk of death.	[Leeming, Diana J.; Karsdal, Morten A.] Nord Biosci, Herlev, Denmark; [Rasmussen, Lars M.] Odense Univ Hosp, Dept Clin Biochem & Pharmacol, DK-5000 Odense, Denmark; [Scholze, Alexandra; Tepel, Martin] Univ Southern Denmark, Odense Univ Hosp, Inst Mol Med Cardiovasc & Renal Res, Dept Nephrol,Inst Clin Res, Odense, Denmark	Nordic Bioscience; University of Southern Denmark; Odense University Hospital; University of Southern Denmark; Odense University Hospital	Tepel, M (corresponding author), Univ Southern Denmark, Odense Univ Hosp, Inst Mol Med Cardiovasc & Renal Res, Dept Nephrol,Inst Clin Res, Odense, Denmark.	mtepel@health.sdu.dk	Scholze, Alexandra/ABD-2442-2020; Tepel, Martin/GRS-9581-2022	Scholze, Alexandra/0000-0002-3100-8692; Karsdal, Morten/0000-0001-5026-8740; Tepel, Martin/0000-0002-0086-0997; Rasmussen, Lars Melholt/0000-0001-5795-4794				Araki S, 2010, DIABETES CARE, V33, P1805, DOI 10.2337/dc10-0199; Barasch E, 2011, CIRC-HEART FAIL, V4, P733, DOI 10.1161/CIRCHEARTFAILURE.111.962027; Briet M, 2012, KIDNEY INT, V82, P388, DOI 10.1038/ki.2012.131; Briet M, 2012, CLIN SCI, V123, P399, DOI 10.1042/CS20120074; Cho KH, 2009, AM J PHYSIOL-RENAL, V297, pF106, DOI 10.1152/ajprenal.00126.2009; de Jager DJ, 2009, JAMA-J AM MED ASSOC, V302, P1782, DOI 10.1001/jama.2009.1488; DIXIT SN, 1981, COLLAGEN REL RES, V1, P549; Elkareh J, 2007, HYPERTENSION, V49, P215, DOI 10.1161/01.HYP.0000252409.36927.05; Gross ML, 2008, SEMIN DIALYSIS, V21, P308, DOI 10.1111/j.1525-139X.2008.00454.x; Gu HP, 2012, ENDOCRINOLOGY, V153, P3692, DOI 10.1210/en.2012-1114; Henderson NC, 2012, BIOCHIM BIOPHYS ACTA, DOI [10.1016/j.bbadis.2012.10.005, DOI 10.1016/J.BBADIS.2012.10.005.[]; Herzog CA, 1998, NEW ENGL J MED, V339, P799, DOI 10.1056/NEJM199809173391203; Himmelfarb J, 2002, KIDNEY INT, V62, P1524, DOI 10.1046/j.1523-1755.2002.00600.x; KARTTUNEN T, 1986, KIDNEY INT, V30, P586, DOI 10.1038/ki.1986.225; KELLER F, 1992, EUR J CLIN INVEST, V22, P175, DOI 10.1111/j.1365-2362.1992.tb01823.x; Kim dH, 2013, PLOS ONE, V8, DOI [DOI 10.1371/J0URNAL.-P0NE.0055323, 10.1371/journal.-pone.0055323]; Kovesdy CP, 2012, CIRCULATION, V125, P677, DOI 10.1161/CIRCULATIONAHA.111.065391; Leask A, 2010, CIRC RES, V106, P1675, DOI 10.1161/CIRCRESAHA.110.217737; Leeming DJ, 2012, HEPATOL RES, V42, P482, DOI 10.1111/j.1872-034X.2011.00946.x; Lekawanvijit S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041281; Losi MA, 2010, NEPHROL DIAL TRANSPL, V25, P1950, DOI 10.1093/ndt/gfp747; Miyamoto T, 2011, CURR OPIN NEPHROL HY, V20, P662, DOI 10.1097/MNH.0b013e32834ad504; Molnar MZ, 2010, AM J KIDNEY DIS, V56, P102, DOI 10.1053/j.ajkd.2010.02.350; Morita M, 2011, AM J KIDNEY DIS, V58, P915, DOI 10.1053/j.ajkd.2011.04.019; Murakami M, 1998, J MOL CELL CARDIOL, V30, P1191, DOI 10.1006/jmcc.1998.0684; NIEMELA O, 1988, J HEPATOL, V6, P307, DOI 10.1016/S0168-8278(88)80047-3; Pohlers D, 2009, BBA-MOL BASIS DIS, V1792, P746, DOI 10.1016/j.bbadis.2009.06.004; Scholze A, 2009, AM J NEPHROL, V29, P598, DOI 10.1159/000193145; Semple D, 2011, J AM SOC NEPHROL, V22, P207, DOI 10.1681/ASN.2009090900; Thornalley PJ, 2011, FREE RADICAL RES, V45, P89, DOI 10.3109/10715762.2010.534162; Tornig J, 1996, J AM SOC NEPHROL, V7, P667; VLEMING LJ, 1995, CLIN NEPHROL, V44, P211; Wong G, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029591; Wynn TA, 2012, NAT MED, V18, P1028, DOI 10.1038/nm.2807; Zeisberg M, 2010, J AM SOC NEPHROL, V21, P1247, DOI 10.1681/ASN.2010060616; Zolty R, 2008, AM J TRANSPLANT, V8, P2219, DOI 10.1111/j.1600-6143.2008.02407.x	36	24	24	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 22	2013	8	8							e71050	10.1371/journal.pone.0071050	http://dx.doi.org/10.1371/journal.pone.0071050			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	218ZA	23990924	Green Published, gold, Green Submitted			2023-01-03	WOS:000324470700010
J	Muchnik, L; Aral, S; Taylor, SJ				Muchnik, Lev; Aral, Sinan; Taylor, Sean J.			Social Influence Bias: A Randomized Experiment	SCIENCE			English	Article							WORD-OF-MOUTH; NETWORKS; CONTAGION; EMERGENCE; REVIEWS	Our society is increasingly relying on the digitized, aggregated opinions of others to make decisions. We therefore designed and analyzed a large-scale randomized experiment on a social news aggregation Web site to investigate whether knowledge of such aggregates distorts decision-making. Prior ratings created significant bias in individual rating behavior, and positive and negative social influences created asymmetric herding effects. Whereas negative social influence inspired users to correct manipulated ratings, positive social influence increased the likelihood of positive ratings by 32% and created accumulating positive herding that increased final ratings by 25% on average. This positive herding was topic-dependent and affected by whether individuals were viewing the opinions of friends or enemies. A mixture of changing opinion and greater turnout under both manipulations together with a natural tendency to up-vote on the site combined to create the herding effects. Such findings will help interpret collective judgment accurately and avoid social influence bias in collective intelligence in the future.	[Muchnik, Lev] Hebrew Univ Jerusalem, Sch Business Adm, IL-91905 Jerusalem, Israel; [Aral, Sinan] MIT, Alfred P Sloan Sch Management, Cambridge, MA 02142 USA; [Taylor, Sean J.] NYU, Stern Sch Business, New York, NY 10012 USA	Hebrew University of Jerusalem; Massachusetts Institute of Technology (MIT); New York University	Aral, S (corresponding author), MIT, Alfred P Sloan Sch Management, 100 Main St, Cambridge, MA 02142 USA.	sinana@mit.edu		Aral, Sinan/0000-0002-2762-058X; Muchnik, Lev/0000-0002-5011-8336	Microsoft Research faculty fellowship; NSF Career Award [0953832]	Microsoft Research faculty fellowship(Microsoft); NSF Career Award(National Science Foundation (NSF)NSF - Office of the Director (OD))	We thank D. Eckles and D. Watts for invaluable discussions. This work was supported by a Microsoft Research faculty fellowship (S. A.) and by NSF Career Award 0953832 (S. A.). The research was approved by the New York University institutional review board. There are legal obstacles to making the data available and revealing the name of the Web site, but code is available upon request. All of the user data that we analyzed is publically available, except the treatment assignment and the random identifier that links a deidentified user to a vote, and therefore does not contain any other information that cannot be obtained by crawling the Web site. The randomized testing that the Web site performed is covered by the Web site's terms of service. Opt-in permissions were granted by the users when they registered for the Web site. No data on nonregistered users was collected.	Apicella CL, 2012, NATURE, V481, P497, DOI 10.1038/nature10736; Aral S, 2012, SCIENCE, V337, P337, DOI 10.1126/science.1215842; Aral S, 2011, IEEE INTELL SYST, V26, P91, DOI 10.1109/MIS.2011.89; Aral S, 2011, MANAGE SCI, V57, P1623, DOI 10.1287/mnsc.1110.1421; Aral S, 2011, MARKET SCI, V30, P217, DOI 10.1287/mksc.1100.0596; Aral S, 2009, P NATL ACAD SCI USA, V106, P21544, DOI 10.1073/pnas.0908800106; Archak N, 2011, MANAGE SCI, V57, P1485, DOI 10.1287/mnsc.1110.1370; Bakshy E, 2009, 10TH ACM CONFERENCE ON ELECTRONIC COMMERCE - EC 2009, P325; Barabasi AL, 1999, SCIENCE, V286, P509, DOI 10.1126/science.286.5439.509; BIKHCHANDANI S, 1992, J POLIT ECON, V100, P992, DOI 10.1086/261849; Cabral L., 2004, W10363 NAT BUR EC RE; Centola D, 2005, AM J SOCIOL, V110, P1009, DOI 10.1086/427321; Chevalier JA, 2006, J MARKETING RES, V43, P345, DOI 10.1509/jmkr.43.3.345; Danescu-Niculescu-Mizil C., 2009, WWW, P141, DOI [10.1145/1526709.1526729, DOI 10.1145/1526709.1526729]; Dellarocas C, 2003, MANAGE SCI, V49, P1407, DOI 10.1287/mnsc.49.10.1407.17308; Hidalgo CA, 2006, NEW J PHYS, V8, DOI 10.1088/1367-2630/8/4/052; Hirshleifer D., 1995, NEW EC HUMAN BEHAV, P188; Janis IL, 1982, GROUPTHINK PSYCHOL S; Leskovec J, 2006, LECT NOTES ARTIF INT, V3918, P380; Lorenz J, 2011, P NATL ACAD SCI USA, V108, P9020, DOI 10.1073/pnas.1008636108; MANSKI CF, 1993, REV ECON STUD, V60, P531, DOI 10.2307/2298123; Merton, 1968, SOCIAL THEORY SOCIAL; Onnela JP, 2010, P NATL ACAD SCI USA, V107, P18375, DOI 10.1073/pnas.0914572107; Pope DG, 2009, J HEALTH ECON, V28, P1154, DOI 10.1016/j.jhealeco.2009.08.006; Salganik MJ, 2006, SCIENCE, V311, P854, DOI 10.1126/science.1121066; Shalizi CR, 2011, SOCIOL METHOD RES, V40, P211, DOI 10.1177/0049124111404820; SIMON HA, 1955, BIOMETRIKA, V42, P425; Woolley AW, 2010, SCIENCE, V330, P686, DOI 10.1126/science.1193147; Wu F, 2008, LECT NOTES COMPUT SC, V5385, P334	29	425	439	21	287	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 9	2013	341	6146					647	651		10.1126/science.1240466	http://dx.doi.org/10.1126/science.1240466			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	197XC	23929980				2023-01-03	WOS:000322884800036
J	Amaro, S; Llull, L; Urra, X; Obach, V; Cervera, A; Chamorro, A				Amaro, Sergio; Llull, Laura; Urra, Xabier; Obach, Victor; Cervera, Alvaro; Chamorro, Angel			Risks and Benefits of Early Antithrombotic Therapy after Thrombolytic Treatment in Patients with Acute Stroke	PLOS ONE			English	Article							ACUTE ISCHEMIC-STROKE; TISSUE-PLASMINOGEN ACTIVATOR; RANDOMIZED CONTROLLED-TRIAL; INTRAVENOUS THROMBOLYSIS; ARTERIAL REOCCLUSION; ATRIAL-FIBRILLATION; WRITING COMMITTEE; HEPARIN; RECANALIZATION; ALTEPLASE	Background: Current guidelines recommend withholding antithrombotic therapy (ATT) for at least 24 h in patients with acute ischemic stroke treated with thrombolytic therapy. Herein, we report a retrospective analysis of a single-centre experience on the safety and efficacy of antithrombotic therapy (ATT) started before or after 24 h of intravenous thrombolysis in a cohort of acute ischemic stroke patients. Methods: A total of 139 patients (Rapid ATT group) received antithrombotic therapy before 24 h of thrombolysis, and 33 patients (Standard ATT group) after 24 h. The brain parenchyma and vessel status were assessed using simple CT scan on admission, multimodal CT scan at the end of thrombolysis, and angio-CT/MRI scan at day 3. Functional outcome was scored using the modified Rankin Scale (mRS) at day 90. Results: The two ATT groups had similar demographics, stroke subtypes, baseline NIHSS, thrombolytic strategies, vessel-patency rates at the end of thrombolysis, and incidence of bleeding complications at follow up. At day 3, the Rapid ATT group had a non-significant improved vessel-patency rate than the Standard ATT group. At day 90, a greater proportion of patients in the rapid ATT group had shifted down the mRS, and had improved in the NIHSS score. Conclusions: ATT initiated before 24 h of intravenous thrombolytic therapy in acute stroke patients disclosed no safety concerns compared with a conventional antithrombotic therapy delay of 24 h and showed better functional outcome at follow up. The value of early initiation of ATT after thrombolysis deserves further assessment in randomized controlled trials.	[Amaro, Sergio; Llull, Laura; Urra, Xabier; Obach, Victor; Cervera, Alvaro; Chamorro, Angel] Hosp Clin Barcelona, Funct Unit Cerebrovasc Dis, Barcelona, Spain; [Amaro, Sergio; Urra, Xabier; Cervera, Alvaro; Chamorro, Angel] Inst Invest Biomed August Pi & Sunyer, Barcelona, Spain; [Chamorro, Angel] Univ Barcelona, Sch Med, Dept Med, Barcelona, Spain	University of Barcelona; Hospital Clinic de Barcelona; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; University of Barcelona	Chamorro, A (corresponding author), Hosp Clin Barcelona, Funct Unit Cerebrovasc Dis, Barcelona, Spain.	achamorro@ub.edu	Urra, Xabier/B-7637-2019	Urra, Xabier/0000-0002-4763-5252				Abilleira S, 2011, STROKE, V42, P2001, DOI 10.1161/STROKEAHA.110.605030; Adams HP, 2007, STROKE, V38, P1655, DOI 10.1161/STROKEAHA.107.181486; ADAMS HP, 1993, STROKE, V24, P35, DOI 10.1161/01.STR.24.1.35; Albers GW, 2000, JAMA-J AM MED ASSOC, V283, P1145, DOI 10.1001/jama.283.9.1145; Alexandrov AV, 2002, NEUROLOGY, V59, P862, DOI 10.1212/WNL.59.6.862; Barber PA, 2000, LANCET, V355, P1670, DOI 10.1016/S0140-6736(00)02237-6; Cervera A, 2004, J NEUROSCI RES, V77, P565, DOI 10.1002/jnr.20186; Chamorro A, 2005, CEREBROVASC DIS, V19, P402, DOI 10.1159/000086100; Chamorro A, 1999, ARCH NEUROL-CHICAGO, V56, P1098, DOI 10.1001/archneur.56.9.1098; Chamorro A, 2006, STROKE, V37, P3052, DOI 10.1161/01.STR.0000248952.59078.7a; Demchuk AM, 2001, NEUROLOGY, V57, P474, DOI 10.1212/WNL.57.3.474; Grond M, 1998, STROKE, V29, P1544, DOI 10.1161/01.STR.29.8.1544; Hacke W, 1998, LANCET, V352, P1245, DOI 10.1016/S0140-6736(98)08020-9; Hacke W, 2008, CEREBROVASC DIS, V25, P457, DOI 10.1159/000131083; Janjua N, 2008, AM J NEURORADIOL, V29, P253, DOI 10.3174/ajnr.A0825; Lever R, 2002, NAT REV DRUG DISCOV, V1, P140, DOI 10.1038/nrd724; MARLER JR, 1995, NEW ENGL J MED, V333, P1581, DOI 10.1056/nejm199512143332401; Molina CA, 2004, STROKE, V35, P151, DOI 10.1161/01.STR.0000106485.04500.4A; Multicentre Acute Stroke Trial-Italy Group, 1995, LANCET, V346, P1509; Phan CM, 2012, AM J NEURORADIOL, V33, P1088, DOI 10.3174/ajnr.A2909; Rha JH, 2007, STROKE, V38, P967, DOI 10.1161/01.STR.0000258112.14918.24; Sanak D, 2012, EUR NEUROL, V67, P52, DOI 10.1159/000333064; Schmulling S, 2003, CEREBROVASC DIS, V16, P183, DOI 10.1159/000071114; SEIFRIED E, 1989, THROMB HAEMOSTASIS, V61, P497; The Thrombolysis In Myocardial Infarction (TIMI) trial, 1985, N ENGL J MED, V312, P932; Zinkstok SM, 2012, LANCET, V380, P731, DOI 10.1016/S0140-6736(12)60949-0	26	9	12	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 8	2013	8	8							e71132	10.1371/journal.pone.0071132	http://dx.doi.org/10.1371/journal.pone.0071132			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	201ER	23951093	Green Published, gold, Green Submitted			2023-01-03	WOS:000323124000040
J	Hung, SW; Mody, H; Marrache, S; Bhutia, YD; Davis, F; Cho, JH; Zastre, J; Dhar, S; Chu, CK; Govindarajan, R				Hung, Sau Wai; Mody, Hardik; Marrache, Sean; Bhutia, Yangzom D.; Davis, Franklin; Cho, Jong Hyun; Zastre, Jason; Dhar, Shanta; Chu, Chung K.; Govindarajan, Rajgopal			Pharmacological Reversal of Histone Methylation Presensitizes Pancreatic Cancer Cells to Nucleoside Drugs: In Vitro Optimization and Novel Nanoparticle Delivery Studies	PLOS ONE			English	Article							ZESTE HOMOLOG 2; INHIBITOR 3-DEAZANEPLANOCIN; EZH2 EXPRESSION; TUMOR-GROWTH; CARCINOMA; ENHANCER; BREAST; DZNEP; H3; TROXACITABINE	We evaluated the potential of an investigational histone methylation reversal agent, 3-deazaneplanocin A (DZNep), in improving the chemosensitivity of pancreatic cancer to nucleoside analogs (i.e., gemcitabine). DZNep brought delayed but selective cytotoxicity to pancreatic cancer cells without affecting normal human pancreatic ductal epithelial (HPDE) cells. Co-exposure of DZNep and gemcitabine induced cytotoxic additivity or synergism in both well-and poorly-differentiated pancreatic cell lines by increased apoptosis. In contrast, DZNep exerted antagonism with gemcitabine against HPDE cells with significant reduction in cytotoxicity compared with the gemcitabine-alone regimen. DZNep marginally depended on purine nucleoside transporters for its cytotoxicity, but the transport dependence was circumvented by acyl derivatization. Drug exposure studies revealed that a short priming with DZNep followed by gemcitabine treatment rather than co-treatment of both agents to produce a maximal chemosensitization response in both gemcitabine-sensitive and gemcitabine-resistant pancreatic cancer cells. DZNep rapidly and reversibly decreased trimethylation of histone H3 lysine 27 but increased trimethylation of lysine 9 in an EZH2- and JMJD1A/2C-dependent manner, respectively. However, DZNep potentiation of nucleoside analog chemosensitization was found to be temporally coupled to trimethylation changes in lysine 27 and not lysine 9. Polymeric nanoparticles engineered to chronologically release DZNep followed by gemcitabine produced pronounced chemosensitization and dose-lowering effects. Together, our results identify that an optimized DZNep exposure can presensitize pancreatic cancer cells to anticancer nucleoside analogs through the reversal of histone methylation, emphasizing the promising clinical utilities of epigenetic reversal agents in future pancreatic cancer combination therapies.	[Hung, Sau Wai; Mody, Hardik; Bhutia, Yangzom D.; Cho, Jong Hyun; Zastre, Jason; Chu, Chung K.; Govindarajan, Rajgopal] Univ Georgia, Dept Pharmaceut & Biomed Sci, Athens, GA 30602 USA; [Marrache, Sean; Dhar, Shanta] Univ Georgia, Dept Chem, Athens, GA 30602 USA; [Davis, Franklin] Univ Georgia, Dept Biol Sci, Athens, GA 30602 USA	University System of Georgia; University of Georgia; University System of Georgia; University of Georgia; University System of Georgia; University of Georgia	Govindarajan, R (corresponding author), Univ Georgia, Dept Pharmaceut & Biomed Sci, Athens, GA 30602 USA.	rgovinda@rx.uga.edu	Mody, Hardik/J-8054-2019	Dhar, Shanta/0000-0003-3042-5272	National Institutes of Health [P30GM092378]; National Cancer Institute [1R03CA161832-01]; Georgia Cancer Coalition; OVPR of The University of Georgia; NATIONAL CANCER INSTITUTE [R03CA161832] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P30GM092378] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Georgia Cancer Coalition; OVPR of The University of Georgia; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by the National Institutes of Health [Grant P30GM092378] (S.D.), the National Cancer Institute [Grant 1R03CA161832-01] (R.G.), the Georgia Cancer Coalition (R.G.), and OVPR of The University of Georgia (S.D.). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abdel-Wahab O, 2010, CANCER CELL, V18, P105, DOI 10.1016/j.ccr.2010.07.006; Adema AD, 2007, NUCLEOS NUCLEOT NUCL, V26, P1073, DOI 10.1080/15257770701515591; Avan A, 2012, MOL CANCER THER, V11, P1735, DOI 10.1158/1535-7163.MCT-12-0037; Bao B, 2012, CANCER RES, V72, P335, DOI 10.1158/0008-5472.CAN-11-2182; Bayraktar S, 2010, WORLD J GASTROENTERO, V16, P673, DOI 10.3748/wjg.v16.i6.673; Bhutia YD, 2011, CANCER RES, V71, P1825, DOI 10.1158/0008-5472.CAN-10-2736; Chang C.J., 2011, BRIT J CANCER, V106, P243; Chase A, 2011, CLIN CANCER RES, V17, P2613, DOI 10.1158/1078-0432.CCR-10-2156; Chen YC, 2010, CANCER LETT, V297, P109, DOI 10.1016/j.canlet.2010.05.003; Cheng LL, 2012, CLIN CANCER RES, V18, P4201, DOI 10.1158/1078-0432.CCR-12-0036; CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4; Choudhury SR, 2011, CARCINOGENESIS, V32, P1525, DOI 10.1093/carcin/bgr171; COULOMBE RA, 1995, EUR J DRUG METAB PH, V20, P197, DOI 10.1007/BF03189670; Crea F, 2012, CANCER METAST REV, P1; Crea F, 2012, CRIT REV ONCOL HEMAT, V83, P184, DOI 10.1016/j.critrevonc.2011.10.007; Crea F, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-40; DEROOSE FD, 1995, J ORG CHEM, V60, P321, DOI 10.1021/jo00107a009; Fujii S, 2008, J BIOL CHEM, V283, P17324, DOI 10.1074/jbc.M800224200; Fujii S, 2012, BIOCHEM BIOPH RES CO, V417, P1074, DOI 10.1016/j.bbrc.2011.12.099; Fussbroich B, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021651; GLAZER RI, 1986, BIOCHEM BIOPH RES CO, V135, P688, DOI 10.1016/0006-291X(86)90048-3; Govindarajan R, 2008, AM J PHYSIOL-GASTR L, V295, pG570, DOI 10.1152/ajpgi.00542.2007; Hayden A, 2011, BREAST CANCER RES TR, V127, P109, DOI 10.1007/s10549-010-0982-0; Hou JL, 2012, AM J TRANSL RES, V4, P247; Kang N, 2010, J BIOL CHEM, V285, P28343, DOI 10.1074/jbc.M110.109199; Mallen-St Clair J, 2012, GENE DEV, V26, P439, DOI 10.1101/gad.181800.111; Marrache S, 2012, P NATL ACAD SCI USA, V109, P16288, DOI 10.1073/pnas.1210096109; Ougolkov AV, 2008, CLIN CANCER RES, V14, P6790, DOI 10.1158/1078-0432.CCR-08-1013; Paproski RJ, 2008, MOL PHARMACOL, V74, P1372, DOI 10.1124/mol.108.048900; Plunkett W, 1995, SEMIN ONCOL, V22; Puppe J, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2354; Qazi AM, 2011, METHODS MOL BIOL, V755, P245, DOI 10.1007/978-1-61779-163-5_20; Radi M, 2007, J MED CHEM, V50, P2249, DOI 10.1021/jm0612923; Rogenhofer S, 2012, ANTICANCER RES, V32, P879; Shi L, 2011, P NATL ACAD SCI USA, V108, P7541, DOI 10.1073/pnas.1017374108; Simon JA, 2009, NAT REV MOL CELL BIO, V10, P697, DOI 10.1038/nrm2763; Stathis A, 2010, NAT REV CLIN ONCOL, V7, P163, DOI 10.1038/nrclinonc.2009.236; Suva ML, 2009, CANCER RES, V69, P9211, DOI 10.1158/0008-5472.CAN-09-1622; Tan J, 2007, GENE DEV, V21, P1050, DOI 10.1101/gad.1524107; Toll AD, 2010, HUM PATHOL, V41, P1205, DOI 10.1016/j.humpath.2010.03.004; Toth M, 2012, CANCER SCI, V103, P659, DOI 10.1111/j.1349-7006.2012.02215.x; Wei YK, 2008, MOL CARCINOGEN, V47, P701, DOI 10.1002/mc.20413; Wong A, 2009, DRUG METAB REV, V41, P77, DOI 10.1080/03602530902741828; Yang XJ, 2010, TRENDS PHARMACOL SCI, V31, P536, DOI 10.1016/j.tips.2010.08.001; Zhou JB, 2011, BLOOD, V118, P2830, DOI 10.1182/blood-2010-07-294827	45	14	15	2	29	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 6	2013	8	8							e71196	10.1371/journal.pone.0071196	http://dx.doi.org/10.1371/journal.pone.0071196			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	217ZG	23940717	Green Submitted, gold, Green Published			2023-01-03	WOS:000324401500061
J	Hill, E; Han, D; Dumouchel, P; Dehak, N; Quatieri, T; Moehs, C; Oscar-Berman, M; Giordano, J; Simpatico, T; Blum, K				Hill, Edward; Han, David; Dumouchel, Pierre; Dehak, Najim; Quatieri, Thomas; Moehs, Charles; Oscar-Berman, Marlene; Giordano, John; Simpatico, Thomas; Blum, Kenneth			Long Term Suboxone (TM) Emotional Reactivity As Measured by Automatic Detection in Speech	PLOS ONE			English	Article							POSITIVE EMOTIONS; SUBSTANCE-ABUSE; BUPRENORPHINE; DEPRESSION; DYSREGULATION; PREVALENCE; METHADONE; BENEFITS; ALCOHOL; CUES	Addictions to illicit drugs are among the nation's most critical public health and societal problems. The current opioid prescription epidemic and the need for buprenorphine/naloxone (Suboxone (R); SUBX) as an opioid maintenance substance, and its growing street diversion provided impetus to determine affective states ("true ground emotionality'') in long-term SUBX patients. Toward the goal of effective monitoring, we utilized emotion-detection in speech as a measure of "true'' emotionality in 36 SUBX patients compared to 44 individuals from the general population (GP) and 33 members of Alcoholics Anonymous (AA). Other less objective studies have investigated emotional reactivity of heroin, methadone and opioid abstinent patients. These studies indicate that current opioid users have abnormal emotional experience, characterized by heightened response to unpleasant stimuli and blunted response to pleasant stimuli. However, this is the first study to our knowledge to evaluate "true ground'' emotionality in long-term buprenorphine/naloxone combination (Suboxone (TM)). We found in long-term SUBX patients a significantly flat affect (p<0.01), and they had less self-awareness of being happy, sad, and anxious compared to both the GP and AA groups. We caution definitive interpretation of these seemingly important results until we compare the emotional reactivity of an opioid abstinent control using automatic detection in speech. These findings encourage continued research strategies in SUBX patients to target the specific brain regions responsible for relapse prevention of opioid addiction.	[Hill, Edward; Dumouchel, Pierre] Univ Quebec, Dept Software & Informat Technol Engn, Ecole Technol Super, Montreal, PQ H3C 3P8, Canada; [Han, David] Univ Texas San Antonio, Dept Management Sci & Stat, San Antonio, TX USA; [Dehak, Najim] MIT, Comp Sci & Artificial Intelligence Lab, Cambridge, MA 02139 USA; [Quatieri, Thomas] MIT, Lincoln Lab, Lexington, MA 02173 USA; [Moehs, Charles] Occupat Med Associates, Watertown, NY USA; [Oscar-Berman, Marlene] Boston Univ, Dept Psychol, Sch Med, Boston, MA 02215 USA; [Oscar-Berman, Marlene] Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA; [Oscar-Berman, Marlene] Boston Univ, Sch Med, Dept Anat & Neurobiol, Boston, MA 02118 USA; [Oscar-Berman, Marlene] Boston Veteran Affaires Healthcare Syst, Boston, MA USA; [Giordano, John; Blum, Kenneth] G&G Holist Hlth Care Serv LLC, North Miami Beach, FL USA; [Simpatico, Thomas; Blum, Kenneth] Univ Vermont, Coll Med, Ctr Clin & Translat Sci, Global Integrated Serv Unit, Burlington, VT USA; [Blum, Kenneth] Univ Florida, Dept Psychiat, Coll Med, Gainesville, FL 32611 USA; [Blum, Kenneth] Univ Florida, Coll Med, McKnight Brain Inst, Gainesville, FL USA; [Blum, Kenneth] Dominion Diagnost LLC, North Kingstown, RI USA; [Blum, Kenneth] Path Fdn New York, Dept Clin Neurol, New York, NY USA; [Blum, Kenneth] Malibu Beach Recovery Ctr, Dept Addict Res & Therapy, Malibu Beach, CA USA; [Blum, Kenneth] Inst Integrat Omics & Appl Biotechnol, Purba Medinipur, W Bengal, India	University of Quebec; Ecole de Technologie Superieure - Canada; University of Quebec Montreal; University of Texas System; University of Texas at San Antonio (UTSA); Massachusetts Institute of Technology (MIT); Lincoln Laboratory; Massachusetts Institute of Technology (MIT); Boston University; Boston University; Boston University; University of Vermont; State University System of Florida; University of Florida; State University System of Florida; University of Florida	Blum, K (corresponding author), G&G Holist Hlth Care Serv LLC, North Miami Beach, FL USA.	drd2gene@gmail.com	Simpatico, Thomas/O-1971-2019	Dehak, Najim/0000-0002-4489-5753; Berman, Marlene Oscar/0000-0003-0100-8883	National Institutes of Health, NIAAA [RO1-AA07112, K05-AA00219]; Medical Research Service of the US Department of Veterans Affairs; Assistant Secretary of Defense for Research & Engineering under Air Force [FA8721-05-C-0002]; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA007112, K05AA000219] Funding Source: NIH RePORTER	National Institutes of Health, NIAAA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); Medical Research Service of the US Department of Veterans Affairs(US Department of Veterans Affairs); Assistant Secretary of Defense for Research & Engineering under Air Force; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))	Marlene Oscar-Berman is the recipient of grants from the National Institutes of Health, NIAAA (RO1-AA07112 and K05-AA00219) and the Medical Research Service of the US Department of Veterans Affairs. Thomas Quatieri's work is sponsored by the Assistant Secretary of Defense for Research & Engineering under Air Force contract #FA8721-05-C-0002. Opinions, interpretations, conclusions, and recommendations are those of the authors and are not necessarily endorsed by the United States Government. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	American Psychiatric Association, 2000, DIAGN STAT MAN MENT; Arnott MI, 1993, J ACOUSTICAL SOC SPE, V93, P1097; Baroni M, 2012, REGRESSION 3 LOGISTI; Bates D., 2012, COMPUTATIONAL METHOD; Bates D., 2011, PACKAGE LME4 LINEAR; Blum K, 2012, ADDICTION RES THERAP, V3; Blum K, 2011, MOL NEUROBIOL, V44, P250, DOI 10.1007/s12035-011-8206-0; Bowirrat A, 2012, MOL NEUROBIOL, V45, P298, DOI 10.1007/s12035-012-8247-z; Cannizzaro MS, 2005, CLIN LINGUIST PHONET, V19, P649, DOI 10.1080/02699200412331271125; Centers for Disease Control and Prevention, 2007, BEST PRACT COMPR TOB; Cheetham A, 2010, CLIN PSYCHOL REV, V30, P621, DOI 10.1016/j.cpr.2010.04.005; Chiang CN, 2003, DRUG ALCOHOL DEPEN, V70, pS39, DOI 10.1016/S0376-8716(03)00058-9; COMINGS DE, 1995, BIOL PSYCHIAT, V37, P798, DOI 10.1016/0006-3223(94)00222-O; Connell J, 2012, HEALTH QUAL LIFE OUT, V10, DOI 10.1186/1477-7525-10-138; de Arcos FA, 2008, PSYCHOPHARMACOLOGY, V198, P159, DOI 10.1007/s00213-008-1110-2; Dehak N, 2011, IEEE T AUDIO SPEECH, V19, P788, DOI 10.1109/TASL.2010.2064307; Dodge R, 2005, J SUBST ABUSE TREAT, V28, P189, DOI 10.1016/j.jsat.2004.12.005; Dumouchel P, 2009, INTERSPEECH 2009: 10TH ANNUAL CONFERENCE OF THE INTERNATIONAL SPEECH COMMUNICATION ASSOCIATION 2009, VOLS 1-5, P344; Fredrickson BL, 2001, AM PSYCHOL, V56, P218, DOI 10.1037/0003-066X.56.3.218; Goldstein RZ, 2007, NEUROIMAGE, V35, P194, DOI 10.1016/j.neuroimage.2006.12.004; Graham C, 2004, J ECON BEHAV ORGAN, V55, P319, DOI 10.1016/j.jebo.2003.09.002; Grant BF, 2004, ARCH GEN PSYCHIAT, V61, P807, DOI 10.1001/archpsyc.61.8.807; Hill E, 2011, STUDIES HLTH TECHNOL, V167; Horyniak D, 2011, INT J DRUG POLICY, V22, P167, DOI 10.1016/j.drugpo.2010.10.004; Hufford Michael R, 2007, SCI REAL TIME DATA C, P54; Institute for Signal and Information Processing Mississippi State University, 2012, ISIP TOOLK; Jaffe JH, 2003, DRUG ALCOHOL DEPEN, V70, pS3, DOI 10.1016/S0376-8716(03)00055-3; Luo RC, 2002, IEEE SENS J, V2, P107, DOI 10.1109/JSEN.2002.1000251; Lynch F, 2012, CLIN MED RES, V10, P170; Lyubomirsky S, 2005, PSYCHOL BULL, V131, P803, DOI 10.1037/0033-2909.131.6.803; Madrid GA, 2001, ALCOHOL, V23, P117, DOI 10.1016/S0741-8329(00)00138-5; Mei W, 2010, NEUROSCIENCE, V170, P808, DOI 10.1016/j.neuroscience.2010.07.033; MILLER GA, 1956, PSYCHOL REV, V63, P81, DOI 10.1037/0033-295X.101.2.343; Monette G, 2012, SUMMER PROGRAM DATA; Mundt JC, 2007, J NEUROLINGUIST, V20, P50, DOI 10.1016/j.jneuroling.2006.04.001; Office of National Drug Control Policy, 2004, EC COSTS DRUG AB US; Ozdas A, 2004, IEEE T BIO-MED ENG, V51, P1530, DOI 10.1109/TBME.2004.827544; Piette JD, 2000, AM J MANAG CARE, V6, P817; Rehm J, 2009, LANCET, V373, P2223, DOI 10.1016/S0140-6736(09)60746-7; REYNOLDS DA, 1995, IEEE T SPEECH AUDI P, V3, P72, DOI 10.1109/89.365379; Reynolds DA, 2000, DIGIT SIGNAL PROCESS, V10, P19, DOI 10.1006/dspr.1999.0361; Savvas SM, 2012, ADDICTION, V107, P388, DOI 10.1111/j.1360-0443.2011.03634.x; Schuller B., 2009, INTERSPEECH 2009 EMO; Scott RL, 2001, ADDICTION RECOVERY T, P191; Snijders T. A. B., 2011, MULTILEVEL ANAL INTR; Steenbergen MR, 2002, AM J POLIT SCI, V46, P218, DOI 10.2307/3088424; Steidl S, 2005, INT CONF ACOUST SPEE, P317; Stone AA, 2002, ANN BEHAV MED, V24, P236, DOI 10.1207/S15324796ABM2403_09; Stone AA., 2007, SCI REAL TIME DATA C, P3; Sturim D, 2011, 12 ANN C INT SPEECH; Tato R, 2002, P INT C SPOK LANG PR; Tugade MM, 2004, J PERS, V72, P1161, DOI 10.1111/j.1467-6494.2004.00294.x; Verstraete AG, 2004, THER DRUG MONIT, V26, P200, DOI 10.1097/00007691-200404000-00020; von Ahn L, 2008, SCIENCE, V321, P1465, DOI 10.1126/science.1160379; Weisberg S., 2010, R COMPANION APPL REG; Wesson DR, 2010, J PSYCHOACTIVE DRUGS, V42, P161, DOI 10.1080/02791072.2010.10400689; Winstock AR, 2008, INT J DRUG POLICY, V19, P450, DOI 10.1016/j.drugpo.2007.03.002; WURMSER L, 1974, J AM PSYCHOANAL ASS, V22, P820, DOI 10.1177/000306517402200407; Young S, 2006, HTKBOOK	59	15	15	0	18	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 9	2013	8	7							e69043	10.1371/journal.pone.0069043	http://dx.doi.org/10.1371/journal.pone.0069043			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	182JD	23874860	Green Published, Green Submitted, Green Accepted, gold			2023-01-03	WOS:000321736900131
J	Von Hoff, DD; Ervin, T; Arena, FP; Chiorean, EG; Infante, J; Moore, M; Seay, T; Tjulandin, SA; Ma, WW; Saleh, MN; Harris, M; Reni, M; Dowden, S; Laheru, D; Bahary, N; Ramanathan, RK; Tabernero, J; Hidalgo, M; Goldstein, D; Van Cutsem, E; Wei, XY; Iglesias, J; Renschler, MF				Von Hoff, Daniel D.; Ervin, Thomas; Arena, Francis P.; Chiorean, E. Gabriela; Infante, Jeffrey; Moore, Malcolm; Seay, Thomas; Tjulandin, Sergei A.; Ma, Wen Wee; Saleh, Mansoor N.; Harris, Marion; Reni, Michele; Dowden, Scot; Laheru, Daniel; Bahary, Nathan; Ramanathan, Ramesh K.; Tabernero, Josep; Hidalgo, Manuel; Goldstein, David; Van Cutsem, Eric; Wei, Xinyu; Iglesias, Jose; Renschler, Markus F.			Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PHASE-III TRIAL; 1ST-LINE TREATMENT; RANDOMIZED-TRIAL; ONCOLOGY-GROUP; ADENOCARCINOMA; MONOTHERAPY; PLACEBO	BackgroundIn a phase 1-2 trial of albumin-bound paclitaxel (nab-paclitaxel) plus gemcitabine, substantial clinical activity was noted in patients with advanced pancreatic cancer. We conducted a phase 3 study of the efficacy and safety of the combination versus gemcitabine monotherapy in patients with metastatic pancreatic cancer. MethodsWe randomly assigned patients with a Karnofsky performance-status score of 70 or more (on a scale from 0 to 100, with higher scores indicating better performance status) to nab-paclitaxel (125 mg per square meter of body-surface area) followed by gemcitabine (1000 mg per square meter) on days 1, 8, and 15 every 4 weeks or gemcitabine monotherapy (1000 mg per square meter) weekly for 7 of 8 weeks (cycle 1) and then on days 1, 8, and 15 every 4 weeks (cycle 2 and subsequent cycles). Patients received the study treatment until disease progression. The primary end point was overall survival; secondary end points were progression-free survival and overall response rate. ResultsA total of 861 patients were randomly assigned to nab-paclitaxel plus gemcitabine (431 patients) or gemcitabine (430). The median overall survival was 8.5 months in the nab-paclitaxel-gemcitabine group as compared with 6.7 months in the gemcitabine group (hazard ratio for death, 0.72; 95% confidence interval [CI], 0.62 to 0.83; P<0.001). The survival rate was 35% in the nab-paclitaxel-gemcitabine group versus 22% in the gemcitabine group at 1 year, and 9% versus 4% at 2 years. The median progression-free survival was 5.5 months in the nab-paclitaxel-gemcitabine group, as compared with 3.7 months in the gemcitabine group (hazard ratio for disease progression or death, 0.69; 95% CI, 0.58 to 0.82; P<0.001); the response rate according to independent review was 23% versus 7% in the two groups (P<0.001). The most common adverse events of grade 3 or higher were neutropenia (38% in the nab-paclitaxel-gemcitabine group vs. 27% in the gemcitabine group), fatigue (17% vs. 7%), and neuropathy (17% vs. 1%). Febrile neutropenia occurred in 3% versus 1% of the patients in the two groups. In the nab-paclitaxel-gemcitabine group, neuropathy of grade 3 or higher improved to grade 1 or lower in a median of 29 days. ConclusionsIn patients with metastatic pancreatic adenocarcinoma, nab-paclitaxel plus gemcitabine significantly improved overall survival, progression-free survival, and response rate, but rates of peripheral neuropathy and myelosuppression were increased. (Funded by Celgene; ClinicalTrials.gov number, NCT00844649.) In this report, the addition of nab-paclitaxel to standard gemcitabine increased the response rate, progression-free survival, and overall survival among patients with metastatic pancreatic adenocarcinoma. Pancreatic cancer is the fourth leading cause of cancer-related death in Europe and the United States.(1),(2) Since 1997, gemcitabine therapy has been the standard first-line treatment for patients with unresectable locally advanced or metastatic pancreatic cancer.(3) Among patients with metastatic disease, the 5-year survival rate is only 2%,(1) and 1-year survival rates of 17 to 23% have been reported with gemcitabine.(3)-(5) Numerous phase 2 studies involving patients with advanced pancreatic cancer have shown promising results; however, most subsequent large phase 3 studies have not shown significantly improved survival,(6)-(16) with the exception of a study involving patients who ...	[Von Hoff, Daniel D.; Ramanathan, Ramesh K.] Translat Genom Res Inst, Phoenix, AZ 85004 USA; [Von Hoff, Daniel D.; Ramanathan, Ramesh K.] Virginia G Piper Canc Ctr, Scottsdale, AZ USA; [Ervin, Thomas] Canc Specialists, Ft Myers, FL USA; [Arena, Francis P.] Arena Oncol Associates, Lake Success, NY USA; [Ma, Wen Wee] Roswell Pk Canc Inst, Buffalo, NY 14263 USA; [Chiorean, E. Gabriela] Univ Washington, Seattle, WA 98195 USA; [Infante, Jeffrey] Sarah Cannon Res Inst Tennessee Oncol, Nashville, TN USA; [Moore, Malcolm] Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada; [Seay, Thomas] Atlanta Canc Care, Atlanta, GA USA; [Saleh, Mansoor N.] Georgia Canc Specialists, Atlanta, GA USA; [Tjulandin, Sergei A.] Blokhin Canc Res Ctr, Moscow, Russia; [Harris, Marion] Southern Hlth, East Bentleigh, Vic, Australia; [Goldstein, David] Prince Wales Hosp, Sydney, NSW, Australia; [Iglesias, Jose] Bionomics, Thebarton, SA, Australia; [Reni, Michele] Ist Sci San Raffaele, I-20132 Milan, Italy; [Dowden, Scot] Tom Baker Canc Clin, Calgary, AB, Canada; [Laheru, Daniel] Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Baltimore, MD USA; [Bahary, Nathan] Univ Pittsburgh Med Ctr, Pittsburgh, PA USA; [Tabernero, Josep] Univ Autonoma Barcelona, Vall dHebron Univ Hosp, E-08193 Barcelona, Spain; [Harris, Marion] Ctr Integral Oncol Clara Campal, Madrid, Spain; [Van Cutsem, Eric] Katholieke Univ Leuven Hosp, Louvain, Belgium; [Van Cutsem, Eric] Katholieke Univ Leuven, Louvain, Belgium; [Wei, Xinyu; Renschler, Markus F.] Celgene, Summit, NJ USA	Translational Genomics Research Institute; Florida Cancer Specialists; Roswell Park Cancer Institute; University of Washington; University of Washington Seattle; Sarah Cannon Research Institute; Tennessee Oncology; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; N.N. Blokhin Russian Cancer Research Center; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Tom Baker Cancer Clinic; University of Calgary; Johns Hopkins University; Johns Hopkins Medicine; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Autonomous University of Barcelona; Hospital Universitari Vall d'Hebron; Flanders Institute for Biotechnology (VIB); KU Leuven; University Hospital Leuven; KU Leuven; Bristol-Myers Squibb; Celgene Corporation	Von Hoff, DD (corresponding author), Translat Genom Res Inst, 445 N 5th St,Ste 600, Phoenix, AZ 85004 USA.	dvh@tgen.org	goldstein, david/J-6711-2012; Reni, Michele/J-8296-2016; Tabernero, Josep/AAG-5026-2019; HIDALGO, MANUEL/I-4995-2015; Tjulandin, Sergei/Y-5069-2018; Van+Cutsem, Eric/ABE-1762-2021	Reni, Michele/0000-0002-6463-0293; Tabernero, Josep/0000-0002-2495-8139; HIDALGO, MANUEL/0000-0002-3765-3318; 	Celgene; NATIONAL CANCER INSTITUTE [P30CA006973] Funding Source: NIH RePORTER	Celgene(Bristol-Myers SquibbCelgene Corporation); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Supported by Celgene.	Abou-Alfa GK, 2006, J CLIN ONCOL, V24, P4441, DOI 10.1200/JCO.2006.07.0201; American Cancer Society, 2013, CANC FACTS FIG 2013; [Anonymous], 2008, J ONCOL PRACT, V4, P233; Buccheri G, 1996, EUR J CANCER, V32A, P1135, DOI 10.1016/0959-8049(95)00664-8; Burris HA, 1997, J CLIN ONCOL, V15, P2403, DOI 10.1200/JCO.1997.15.6.2403; Chauffert B, 2008, ANN ONCOL, V19, P1592, DOI 10.1093/annonc/mdn281; Colucci G, 2010, J CLIN ONCOL, V28, P1645, DOI 10.1200/JCO.2009.25.4433; Conroy T, 2011, NEW ENGL J MED, V364, P1817, DOI 10.1056/NEJMoa1011923; Cunningham D, 2009, J CLIN ONCOL, V27, P5513, DOI 10.1200/JCO.2009.24.2446; Frese KK, 2012, CANCER DISCOV, V2, P260, DOI 10.1158/2159-8290.CD-11-0242; Goncalves A, 2012, ANN ONCOL, V23, P2799, DOI 10.1093/annonc/mds135; Gradishar WJ, 2005, J CLIN ONCOL, V23, P7794, DOI 10.1200/JCO.2005.04.937; Kindler HL, 2010, J CLIN ONCOL, V28, P3617, DOI 10.1200/JCO.2010.28.1386; Lima CMR, 2004, J CLIN ONCOL, V22, P3776, DOI 10.1200/JCO.2004.12.082; Malvezzi M, 2013, ANN ONCOL, V24, P792, DOI 10.1093/annonc/mdt010; Moore MJ, 2007, J CLIN ONCOL, V25, P1960, DOI 10.1200/JCO.2006.07.9525; Oettle H, 2006, ANN ONCOL, V17, P535, DOI 10.1093/annonc/mdl032; Oettle H, 2005, ANN ONCOL, V16, P1639, DOI 10.1093/annonc/mdi309; Philip PA, 2010, J CLIN ONCOL, V28, P3605, DOI 10.1200/JCO.2009.25.7550; Poplin E, 2009, J CLIN ONCOL, V27, P3778, DOI 10.1200/JCO.2008.20.9007; Reni M, 2009, CANCER-AM CANCER SOC, V115, P2630, DOI 10.1002/cncr.24302; Stathopoulos GP, 2006, BRIT J CANCER, V95, P587, DOI 10.1038/sj.bjc.6603301; Therasse P, 2000, J NATL CANCER I, V92, P205, DOI 10.1093/jnci/92.3.205; Von Hoff DD, 2011, J CLIN ONCOL, V29, P4548, DOI 10.1200/JCO.2011.36.5742	24	3903	3968	18	302	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 31	2013	369	18					1691	1703		10.1056/NEJMoa1304369	http://dx.doi.org/10.1056/NEJMoa1304369			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	243IY	24131140	Green Accepted, Bronze			2023-01-03	WOS:000326311300007
J	Vijgen, GHEJ; Bouvy, ND; Leenen, L; Rijkers, K; Cornips, E; Majoie, M; Brans, B; Lichtenbelt, WDV				Vijgen, Guy H. E. J.; Bouvy, Nicole D.; Leenen, Loes; Rijkers, Kim; Cornips, Erwin; Majoie, Marian; Brans, Boudewijn; Lichtenbelt, Wouter D. van Marken			Vagus Nerve Stimulation Increases Energy Expenditure: Relation to Brown Adipose Tissue Activity	PLOS ONE			English	Article							WEIGHT-LOSS; VENTROMEDIAL HYPOTHALAMUS; FEEDING-BEHAVIOR; RATS; OBESITY; ADULTS; THERMOGENESIS; ENTEROSTATIN; VAGOTOMY; GALANIN	Background: Human brown adipose tissue (BAT) activity is inversely related to obesity and positively related to energy expenditure. BAT is highly innervated and it is suggested the vagus nerve mediates peripheral signals to the central nervous system, there connecting to sympathetic nerves that innervate BAT. Vagus nerve stimulation (VNS) is used for refractory epilepsy, but is also reported to generate weight loss. We hypothesize VNS increases energy expenditure by activating BAT. Methods and Findings: Fifteen patients with stable VNS therapy (age: 45 +/- 10yrs; body mass index; 25.2 +/- 3.5 kg/m(2)) were included between January 2011 and June 2012. Ten subjects were measured twice, once with active and once with inactivated VNS. Five other subjects were measured twice, once with active VNS at room temperature and once with active VNS under cold exposure in order to determine maximal cold-induced BAT activity. BAT activity was assessed by 18-Fluoro-Deoxy-Glucose-Positron-Emission-Tomography-and-Computed-Tomography. Basal metabolic rate (BMR) was significantly higher when VNS was turned on (mean change; +2.2%). Mean BAT activity was not significantly different between active VNS and inactive VNS (BAT SUVMean; 0.55 +/- 0.25 versus 0.67 +/- 0.46, P = 0.619). However, the change in energy expenditure upon VNS intervention (On-Off) was significantly correlated to the change in BAT activity (r = 0.935, P < 0.001). Conclusions: VNS significantly increases energy expenditure. The observed change in energy expenditure was significantly related to the change in BAT activity. This suggests a role for BAT in the VNS increase in energy expenditure. Chronic VNS may have a beneficial effect on the human energy balance that has potential application for weight management therapy.	[Vijgen, Guy H. E. J.; Lichtenbelt, Wouter D. van Marken] Maastricht Univ, Med Ctr, Sch Nutr Toxicol & Metab NUTRIM, Dept Human Biol, Maastricht, Netherlands; [Vijgen, Guy H. E. J.; Bouvy, Nicole D.] Maastricht Univ, Med Ctr, Dept Gen Surg, Maastricht, Netherlands; [Rijkers, Kim; Cornips, Erwin] Maastricht Univ, Med Ctr, Dept Neurosurg, Maastricht, Netherlands; [Brans, Boudewijn] Maastricht Univ, Med Ctr, Dept Nucl Med, Maastricht, Netherlands; [Leenen, Loes; Majoie, Marian] Epilepsy Ctr Kempenhaeghe, Heeze, Netherlands	Maastricht University; Maastricht University; Maastricht University; Maastricht University	Vijgen, GHEJ (corresponding author), Maastricht Univ, Med Ctr, Sch Nutr Toxicol & Metab NUTRIM, Dept Human Biol, Maastricht, Netherlands.	guy.vijgen@gmail.com	Bouvy, Nicole/AAD-2844-2021	Majoie, Marian/0000-0003-0579-8122; Vijgen, Guy/0000-0002-6011-753X; Leenen, Loes/0000-0002-7117-8768	Netherlands Science Foundation ZonMw [TOP 91209037]; Netherlands Organization for Scientific Research (NWO); Maastricht University Medical Centre	Netherlands Science Foundation ZonMw; Netherlands Organization for Scientific Research (NWO)(Netherlands Organization for Scientific Research (NWO)); Maastricht University Medical Centre	This work is part of the research program TOP-subsidies (Netherlands Science Foundation ZonMw, TOP 91209037 to W. D. van Marken Lichtenbelt), which is (partly) financed by the Netherlands Organization for Scientific Research (NWO). Guy H. Vijgen received a Kootstra Talent Fellowship from the Maastricht University Medical Centre that allowed him to perform this study. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Agrawal A, 2009, BRIT J RADIOL, V82, P625, DOI 10.1259/bjr/24661539; ARCH JRS, 1984, NATURE, V309, P163, DOI 10.1038/309163a0; Balbo SL, 2007, ENDOCRINE, V31, P142, DOI 10.1007/s12020-007-0021-z; BLIGH J, 1973, Journal of Applied Physiology, V35, P941; Bodenlos JS, 2007, APPETITE, V48, P145, DOI 10.1016/j.appet.2006.07.080; Bodenlos Jamie S, 2007, J Diabetes Sci Technol, V1, P771; Burneo JG, 2002, NEUROLOGY, V59, P463, DOI 10.1212/WNL.59.3.463; Cannon B, 2004, PHYSIOL REV, V84, P277, DOI 10.1152/physrev.00015.2003; Dedeurwaerdere S, 2006, NEUROSCIENCE, V140, P1443, DOI 10.1016/j.neuroscience.2006.03.014; Fruhbeck G, 2009, TRENDS PHARMACOL SCI, V30, P387, DOI 10.1016/j.tips.2009.05.003; Kingma Boris, 2012, Front Biosci (Elite Ed), V4, P1975; Kosel M, 2003, CNS SPECTRUMS, V8, P515, DOI 10.1017/S1092852900018988; Laskiewicz J, 2003, J PHYSIOL PHARMACOL, V54, P603; Lichtenbelt WDV, 2009, NEW ENGL J MED, V360, P1500, DOI 10.1056/NEJMoa0808718; Mano-Otagiri A, REGUL PEPT, V160, P81; Mano-Otagiri A, 2009, J ENDOCRINOL, V201, P341, DOI 10.1677/JOE-08-0374; Murphy KG, 2006, NATURE, V444, P854, DOI 10.1038/nature05484; Nagase H, 2002, J GASTROENTEROL, V37, P118, DOI 10.1007/BF03326430; Nagase H, 1996, BRAIN RES, V709, P44, DOI 10.1016/0006-8993(95)01292-3; Pardo JV, 2007, INT J OBESITY, V31, P1756, DOI 10.1038/sj.ijo.0803666; PERKINS MN, 1981, NATURE, V289, P401, DOI 10.1038/289401a0; PRECHTL JC, 1990, ANAT EMBRYOL, V181, P101; Privitera MD, 2002, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD002896; RANDLE PJ, 1963, LANCET, V1, P785; Ruffin MP, 1999, BRAIN RES, V846, P23, DOI 10.1016/S0006-8993(99)01922-8; Saindon CS, 2001, AUTON NEUROSCI-BASIC, V87, P243, DOI 10.1016/S1566-0702(00)00280-0; SAITO M, 1989, BRAIN RES, V481, P298, DOI 10.1016/0006-8993(89)90806-8; Saito M, 2009, DIABETES, V58, P1526, DOI 10.2337/db09-0530; Simpson SA, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d8042; Sobocki J, 2006, SURGERY, V139, P209, DOI 10.1016/j.surg.2005.06.025; Val-Laillet D, 2010, APPETITE, V55, P245, DOI 10.1016/j.appet.2010.06.008; Lichtenbelt WDV, 2006, PHYSIOL BEHAV, V88, P489, DOI 10.1016/j.physbeh.2006.04.026; Vijgen GH, 2012, J CLIN ENDOCRINOL ME; Vijgen GH, 2012, FRONT BIOSC IN PRESS; Vijgen GHEJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017247; Virtanen KA, 2009, NEW ENGL J MED, V360, P1518, DOI 10.1056/NEJMoa0808949; Vosselman MJ, 2013, AM J CLIN NUTR; Wu CX, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/159834; Yoneshiro T, 2011, OBESITY, V19, P13, DOI 10.1038/oby.2010.105; Zingaretti MC, 2009, FASEB J, V23, P3113, DOI 10.1096/fj.09-133546	40	52	53	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 23	2013	8	10							e77221	10.1371/journal.pone.0077221	http://dx.doi.org/10.1371/journal.pone.0077221			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	239PE	24194874	Green Submitted, Green Published, gold			2023-01-03	WOS:000326037000053
J	Thomas, KH; Martin, RM; Davies, NM; Metcalfe, C; Windmeijer, F; Gunnell, D				Thomas, Kyla H.; Martin, Richard M.; Davies, Neil M.; Metcalfe, Chris; Windmeijer, Frank; Gunnell, David			Smoking cessation treatment and risk of depression, suicide, and self harm in the Clinical Practice Research Datalink: prospective cohort study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PRACTICE RESEARCH DATABASE; GENERAL-PRACTICE; VARENICLINE; INSTRUMENTS; VALIDATION; NICOTINE; EVENTS; SAFETY	Objective To compare the risk of suicide, self harm, and depression in patients prescribed varenicline or bupropion with those prescribed nicotine replacement therapy. Design Prospective cohort study within the Clinical Practice Research Datalink. Setting 349 general practices in England. Participants 119 546 men and women aged 18 years and over who used a smoking cessation product between 1 September 2006 and 31 October 2011. There were 81 545 users of nicotine replacement products (68.2% of all users of smoking cessation medicines), 6741 bupropion (5.6%), and 31 260 varenicline (26.2%) users. Main outcome measures Outcomes were treated depression and fatal and non-fatal self harm within three months of the first smoking cessation prescription, determined from linkage with mortality data from the Office for National Statistics (for suicide) and Hospital Episode Statistics data (for hospital admissions relating to non-fatal self harm). Hazard ratios or risk differences were estimated using Cox multivariable regression models, propensity score matching, and instrumental variable analysis using physicians' prescribing preferences as an instrument. Sensitivity analyses were performed for outcomes at six and nine months. Results We detected 92 cases of fatal and non-fatal self harm (326.5 events per 100 000 person years) and 1094 primary care records of treated depression (6963.3 per 100 000 person years). Cox regression analyses showed no evidence that patients prescribed varenicline had higher risks of fatal or non-fatal self harm (hazard ratio 0.88, 95% confidence interval 0.52 to 1.49) or treated depression (0.75, 0.65 to 0.87) compared with those prescribed nicotine replacement therapy. There was no evidence that patients prescribed bupropion had a higher risk of fatal or non-fatal self harm (0.83, 0.30 to 2.31) or of treated depression (0.63, 0.46 to 0.87) compared with patients prescribed nicotine replacement therapy. Similar findings were obtained using propensity score methods and instrumental variable analyses. Conclusions There is no evidence of an increased risk of suicidal behaviour in patients prescribed varenicline or bupropion compared with those prescribed nicotine replacement therapy. These findings should be reassuring for users and prescribers of smoking cessation medicines.	[Thomas, Kyla H.; Martin, Richard M.; Metcalfe, Chris; Gunnell, David] Univ Bristol, Sch Social & Community Med, Bristol BS8 2PS, Avon, England; [Martin, Richard M.; Davies, Neil M.] Univ Bristol, MRC Integrat Epidemiol Unit IEU, Bristol BS8 2PS, Avon, England; [Windmeijer, Frank] Univ Bristol, Dept Econ, CMPO, Bristol BS8 2PS, Avon, England	University of Bristol; University of Bristol; University of Bristol	Thomas, KH (corresponding author), Univ Bristol, Sch Social & Community Med, Bristol BS8 2PS, Avon, England.	kyla.thomas@bristol.ac.uk	Gunnell, David/ABE-6653-2020; Windmeijer, Frank/AAL-5695-2020	Gunnell, David/0000-0002-0829-6470; Metcalfe, Chris/0000-0001-8318-8907; Davies, Neil/0000-0002-2460-0508; Thomas, Kyla/0000-0001-5418-4034; Martin, Richard/0000-0002-7992-7719; Windmeijer, Frank/0000-0002-4232-2783	ESRC [ES/H005331/1] Funding Source: UKRI; MRC [G0600705] Funding Source: UKRI; Medical Research Council [G0600705] Funding Source: Medline; Department of Health [DRF-2010-03-138] Funding Source: Medline; Economic and Social Research Council [ES/H005331/1] Funding Source: researchfish; National Institute for Health Research [NF-SI-0512-10068, DRF-2010-03-138] Funding Source: researchfish	ESRC(UK Research & Innovation (UKRI)Economic & Social Research Council (ESRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Department of Health; Economic and Social Research Council(UK Research & Innovation (UKRI)Economic & Social Research Council (ESRC)); National Institute for Health Research(National Institute for Health Research (NIHR))		Angrist JD, 2009, MOSTLY HARMLESS ECONOMETRICS: AN EMPIRICISTS COMPANION, P1; Baum C.F., 2002, IVREG2 STATA MODULE; Brookhart MA, 2006, EPIDEMIOLOGY, V17, P268, DOI 10.1097/01.ede.0000193606.58671.c5; Cahill K, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006103.pub6; Cahill K, 2009, DRUG SAFETY, V32, P119, DOI 10.2165/00002018-200932020-00005; Campbell AR, 2010, AM J HEALTH-SYST PH, V67, P1832, DOI 10.2146/ajhp100196; Clarke PS, 2012, J AM STAT ASSOC, V107, P1638, DOI 10.1080/01621459.2012.734171; Davies NM, 2013, EPIDEMIOLOGY, V24, P352, DOI 10.1097/EDE.0b013e318289e024; Davies NM, 2013, EPIDEMIOLOGY, V24, P363, DOI 10.1097/EDE.0b013e31828abafb; Dhillon S, 2008, DRUGS, V68, P653, DOI 10.2165/00003495-200868050-00011; Farrell M, 2001, BRIT J PSYCHIAT, V179, P432, DOI 10.1192/bjp.179.5.432; Faulk K., 2013, BIRMINGHAM NEWS 0301; Gallagher AM, 2011, PHARMACOEPIDEM DR S, V20, pS230; Glynn RJ, 2006, BASIC CLIN PHARMACOL, V98, P253, DOI 10.1111/j.1742-7843.2006.pto_293.x; Gunnell D, 2009, BRIT MED J, V339, DOI 10.1136/bmj.b3805; Gunnell D, 2005, BMJ-BRIT MED J, V330, P385, DOI 10.1136/bmj.330.7488.385; Harrison-Woolrych M, 2011, DRUG SAFETY, V34, P763, DOI 10.2165/11594450-000000000-00000; Hernan MA, 2006, EPIDEMIOLOGY, V17, P360, DOI 10.1097/01.ede.0000222409.00878.37; Hughes JR, 2008, DRUG ALCOHOL DEPEN, V98, P169, DOI 10.1016/j.drugalcdep.2008.06.003; Kasliwal R, 2009, DRUG SAFETY, V32, P499, DOI 10.2165/00002018-200932060-00006; Khan NF, 2010, BMC FAM PRACT, V11, DOI 10.1186/1471-2296-11-1; Leuven E., 2003, PSMATCH2 STATA MODUL; Linsley KR, 2001, BRIT J PSYCHIAT, V178, P465, DOI 10.1192/bjp.178.5.465; Martens EP, 2006, EPIDEMIOLOGY, V17, P260, DOI 10.1097/01.ede.0000215160.88317.cb; Martin RM, 2006, BRIT J CLIN PHARMACO, V61, P224, DOI 10.1111/j.1365-2125.2005.02527.x; Martinez C, 2005, BRIT MED J, V330, P389, DOI 10.1136/bmj.330.7488.389; Medicines and Healthcare Products Regulatory Agency, 2008, DRUG SAFETY UPDATE, V2, P2; Meyer TE, 2013, ADDICTION, V108, P203, DOI 10.1111/j.1360-0443.2012.04024.x; Miller M, 2000, AM J PUBLIC HEALTH, V90, P768, DOI 10.2105/AJPH.90.5.768; Miller M, 2000, AM J EPIDEMIOL, V151, P1060, DOI 10.1093/oxfordjournals.aje.a010148; Mills EJ, 2009, HARM REDUCT J, V6, DOI 10.1186/1477-7517-6-25; Moore M, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b3999; Moore TJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027016; National Institute for Health and Clinical Excellence, 2010, NICE IMPL UPT REP SM; National Institute for Health and Clinical Excellence, 2008, NICE PUBL HLTH GUID; Office for National Statistics, 2011, STAT B, P1; Rassen JA, 2009, J CLIN EPIDEMIOL, V62, P1233, DOI 10.1016/j.jclinepi.2008.12.006; Rassen JA, 2009, J CLIN EPIDEMIOL, V62, P1226, DOI 10.1016/j.jclinepi.2008.12.005; Rodriguez LAG, 1998, BRIT J CLIN PHARMACO, V45, P419; Setakis E, 2010, PHARMACOEPIDEM DR S, V19, pS310; Stock JH, 2002, J BUS ECON STAT, V20, P518, DOI 10.1198/073500102288618658; Thomas KH, 2013, BRIT J CLIN PHARMACO, V76, P145, DOI 10.1111/bcp.12059; Twigg L, 2004, SMOKING EPIDEMIC ENG; US Food and Drug Administration, 2009, FDA DRUG SAFETY NEWS; Wooldridge JM, 2010, ECONOMETRIC ANALYSIS OF CROSS SECTION AND PANEL DATA, 2ND EDITION, P1; World Health Organization, 2019, WHO REPORT GLOBAL TO	46	77	78	1	22	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 11	2013	347								f5704	10.1136/bmj.f5704	http://dx.doi.org/10.1136/bmj.f5704			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	235OP	24124105	hybrid, Green Published			2023-01-03	WOS:000325729300001
J	Parikh, SM; Obuku, EA; Walker, SA; Semeere, AS; Auerbach, BJ; Hakim, JG; Mayanja-Kizza, H; Mugyenyi, PN; Salata, RA; Kityo, CM				Parikh, Sujal M.; Obuku, Ekwaro A.; Walker, Sarah A.; Semeere, Aggrey S.; Auerbach, Brandon J.; Hakim, James G.; Mayanja-Kizza, Harriet; Mugyenyi, Peter N.; Salata, Robert A.; Kityo, Cissy M.		DART Trial Team	Clinical Differences between Younger and Older Adults with HIV/AIDS Starting Antiretroviral Therapy in Uganda and Zimbabwe: A Secondary Analysis of the DART Trial	PLOS ONE			English	Article							VAGINAL SYMPTOMS; HIV-INFECTION; PREVALENCE; COHORT; AIDS; BEHAVIOR; WOMEN; AGE	Objective: Clinical and immunological data about HIV in older adults from low and middle income countries is scarce. We aimed to describe differences between younger and older adults with HIV starting antiretroviral therapy in two low-income African countries. Methods: Setting: HIV clinics in Uganda and Zimbabwe. Design: Secondary exploratory cross-sectional analysis of the DART randomized controlled trial. Outcome Measures: Clinical and laboratory characteristics were compared between adults aged 18-49 years (younger) and >= 50 years (older), using two exploratory multivariable logistic regression models, one with HIV viral load (measured in a subset pre-ART) and one without. Results: A total of 3316 eligible participants enrolled in DART were available for analysis; 219 (7%) were >= 50 years and 1160 (35%) were male. Across the two adjusted regression models, older adults had significantly higher systolic blood pressure, lower creatinine clearance and were consistently less likely to be females compared to younger adults with HIV. Paradoxically, the models separately suggested that older adults had statistically significant (but not clinically important) higher CD4+ cell counts and higher plasma HIV-1 viral copies at initiation. Crude associations between older age and higher baseline hemoglobin, body mass index, diastolic blood pressure and lower WHO clinical stage were not sustained in the adjusted analysis. Conclusions: Our study found clinical and immunological differences between younger and older adults, in a cohort of Africans starting antiretroviral therapy. Further investigations should explore how these differences could be used to ensure equity in service delivery and affect outcomes of antiretroviral therapy.	[Parikh, Sujal M.; Obuku, Ekwaro A.; Mugyenyi, Peter N.; Kityo, Cissy M.] Joint Clin Res, Kampala, Uganda; [Walker, Sarah A.] Med Res Council Clin Trials Unit, London, England; [Parikh, Sujal M.] Univ Michigan, Sch Med, Ann Arbor, MI USA; [Salata, Robert A.] Case Western Reserve Univ, Dept Med, Cleveland, OH 44106 USA; [Mayanja-Kizza, Harriet] Makerere Univ, Coll Hlth Sci, Dept Med, Kampala, Uganda; [Semeere, Aggrey S.; Auerbach, Brandon J.] Makerere Univ, Coll Hlth Sci, Infect Dis Inst, Kampala, Uganda; [Auerbach, Brandon J.] Harvard Univ, Harvard Med Sch, Boston, MA 02115 USA; [Hakim, James G.] Univ Zimbabwe, Clin Res Ctr, Coll Hlth Sci, Harare, Zimbabwe	Medical Research Council Clinical Trials Unit; University of Michigan System; University of Michigan; Case Western Reserve University; Makerere University; Makerere University; Harvard University; Harvard Medical School; University of Zimbabwe	Obuku, EA (corresponding author), Joint Clin Res, Kampala, Uganda.	eobuku@jcrc.org.ug	Mayanja-Kizza, Harriet/AAM-5372-2020; Obuku, Ekwaro A./H-4988-2011	Mayanja-Kizza, Harriet/0000-0002-9297-6208; Semeere, Aggrey/0000-0003-1826-2239; Grosskurth, Heiner/0000-0001-9960-7280	Fogarty International Clinical Research Scholars and Fellows Program at Vanderbilt University [R24 TW007988]; American Relief and Recovery Act, Fogarty International Centre, National Institutes of Health, USA; United Kingdom Medical Research Council [G0600344]; United Kingdom Department for International Development; Rockefeller Foundation; Medical Research Council [G0600344] Funding Source: researchfish; FOGARTY INTERNATIONAL CENTER [R24TW007988] Funding Source: NIH RePORTER; MRC [G0600344] Funding Source: UKRI	Fogarty International Clinical Research Scholars and Fellows Program at Vanderbilt University; American Relief and Recovery Act, Fogarty International Centre, National Institutes of Health, USA; United Kingdom Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); United Kingdom Department for International Development; Rockefeller Foundation; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	This work was supported by the Fogarty International Clinical Research Scholars and Fellows Program at Vanderbilt University (R24 TW007988) and the American Relief and Recovery Act, Fogarty International Centre, National Institutes of Health, USA. DART was funded by the United Kingdom Medical Research Council (grant number G0600344), the United Kingdom Department for International Development, and the Rockefeller Foundation. Viiv Healthcare/GlaxoSmithKline, Gilead and Boehringer-Ingelheim donated first-line drugs for DART, and Abbott provided Kaletra/Aluvia as part of the second-line regimen for DART. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Agate LL, 2003, JAIDS-J ACQ IMM DEF, V33, pS238, DOI 10.1097/00126334-200306012-00024; Bakanda C, 2011, AIDS, V25, P701, DOI 10.1097/QAD.0b013e3283437ed7; Balestre E, 2012, AIDS, V26, P951, DOI 10.1097/QAD.0b013e3283528ad4; Biraro S, 2009, SEX TRANSM INFECT, V85, pI3, DOI 10.1136/sti.2008.033928; Buchacz K, 2008, AIDS, V22, P1345, DOI 10.1097/QAD.0b013e328304b38b; Centers for Disease Control and Prevention, 2010, CAS HIV AIDS US DEP; Centers for Disease Control and Prevention, 2005, CAS HIV AIDS US DEP; COCKCROFT DW, 1976, NEPHRON, V16, P31, DOI 10.1159/000180580; Conde DM, 2009, MENOPAUSE, V16, P199, DOI 10.1097/gme.0b013e318177352c; Druyts E, 2013, AIDS, V27, P417, DOI 10.1097/QAD.0b013e328359b89b; El-Sadr WM, 2006, NEW ENGL J MED, V355, P2283, DOI 10.1056/NEJMoa062360; Eylar E H, 2001, BMC Immunol, V2, P10, DOI 10.1186/1471-2172-2-10; Feruglio F S, 1966, G Gerontol, V14, P229; Freeman E, 2012, INT J STD AIDS, V23, P490, DOI 10.1258/ijsa.2011.011340; Geneau Robert, 2012, AIDS, V26 Suppl 1, pS7; High KP, 2012, JAIDS-J ACQ IMM DEF, V60, pS1, DOI 10.1097/QAI.0b013e31825a3668; Huang AJ, 2010, MENOPAUSE, V17, P121, DOI 10.1097/gme.0b013e3181acb9ed; Justice AC, 2001, J CLIN EPIDEMIOL, V54, pS3, DOI 10.1016/S0895-4356(01)00440-1; Kuller LH, 2008, PLOS MED, V5, P1496, DOI 10.1371/journal.pmed.0050203; Levitt NS, 2011, AM J CLIN NUTR, V94, p1690S, DOI 10.3945/ajcn.111.019075; Marcus Mary Brophy, 2002, US News World Rep, V133, P40; McGrath N, 2009, SEX TRANSM INFECT, V85, pI49, DOI 10.1136/sti.2008.033324; Mugyenyi P, 2010, LANCET, V375, P123, DOI 10.1016/S0140-6736(09)62067-5; Murrow E, 1996, S C NURSE, V3, P20; Mutevedzi PC, 2011, FUTURE VIROL, V6, P755, DOI 10.2217/FVL.11.43; Negin Joel, 2012, AIDS, V26 Suppl 1, pS1; Negin J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026546; Negin J, 2010, B WORLD HEALTH ORGAN, V88, P847, DOI 10.2471/BLT.10.076349; Palella FJ, 2010, AIDS, V24, P1657, DOI 10.1097/QAD.0b013e3283389dfa; Ress B, 2003, CRIT CARE NURSE, V23, P34; Santoro N, 2009, J SEX MED, V6, P2133, DOI 10.1111/j.1743-6109.2009.01335.x; SCHIMMLE.W, 1965, ARCH KREISLAUFFORSCH, V47, P189, DOI 10.1007/BF02119983; SCHIMMLER W, 1965, Z KREISLAUFFORSCH, V54, P802; Schmid GP, 2009, B WORLD HEALTH ORGAN, V87, P162, DOI 10.2471/BLT.09.064030; Ssali F, 2006, ANTIVIR THER, V11, P741; Stoff DM, 2004, AIDS, V18, pS1, DOI 10.1097/00002030-200401001-00001; Tsai AC, 2009, AIDS CARE, V21, P59, DOI 10.1080/09540120802068811; United Nations, 2009, WORLD POP AG 2009 NE; Waysdorf Susan L, 2002, Elder Law J, V10, P47; Zingmond DS, 2003, JAIDS-J ACQ IMM DEF, V33, pS84, DOI 10.1097/00126334-200306012-00005	40	5	6	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 2	2013	8	10							e76158	10.1371/journal.pone.0076158	http://dx.doi.org/10.1371/journal.pone.0076158			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	231RG	24098434	Green Published, gold, Green Submitted, Green Accepted			2023-01-03	WOS:000325434500046
J	Huang, N; Singh, N; Yoon, K; Loiacono, CM; Kohut, ML; Birt, DF				Huang, Nan; Singh, Navrozedeep; Yoon, Kyoungjin; Loiacono, Christina M.; Kohut, Marian L.; Birt, Diane F.			The Immuno-Regulatory Impact of Orally-Administered Hypericum perforatum Extract on Balb/C Mice Inoculated with H1n1 Influenza A Virus	PLOS ONE			English	Article							ST JOHNS WORT; ALVEOLAR MACROPHAGES; INFECTION; SOCS3; IDENTIFICATION; INFLAMMATION; INVOLVEMENT; INHIBITION; ACTIVATION; SUPPRESSOR	Hypericum perforatum (H. perforatum) ethanol extract has been found to inhibit lipopolysaccharide-induced production of inflammatory mediators and cytokines in cultured macrophages. Therefore, it may be able to protect the host from excessive inflammation during viral infection. In the current study, the immune-regulatory effect of H. perforatum extract was evaluated in A549 lung epithelial cells and BALB/c mice exposed to Influenza A/PR/8/34 H1N1 virus. In A549 cells, the extract (30 mu g/mL) significantly inhibited influenza virus induced monocyte chemotactic protein (MCP)-1 and interferon-gamma induced protein 10 kD (IP-10), but dramatically increased interleukin-6 (IL-6). In mice inoculated intranasally with 10(7.9) EID50 of Influenza A/PR/8/34 H1N1 (high dose), daily oral treatment of H. perforatum extract at a rate of 110 mg/kg of body weight increased lung viral titer, bronchoalveolar lavage (BAL) pro-inflammatory cytokine and chemokine levels, and the infiltration of pro-inflammatory cells in the lung 5 days post-inoculation, as compared to ethanol vehicle treated mice. Transcription of suppressor of cytokine signaling 3 (SOCS3) was increased by H. perforatum extract both in A549 cells and BALB/c mice, which could have interrupted anti-viral immune response and thus led to the inefficient viral clearance and increased lung inflammation. H. perforatum treatment resulted in minor reduction in viral titer without affecting body weight when mice were inoculated with a lower dose (similar to 10(5.0) EID50) and H. perforatum was applied in the later phase of infection. Mice challenged intranasally with high dose of influenza virus (10(7.9) EID50) suffered from a higher mortality rate when dosed with H. perforatum extract. In conclusion, the current study showed that SOCS3 elevation by H. perforatum may cause impaired immune defense against influenza virus infection and lead to higher mortality.	[Huang, Nan; Singh, Navrozedeep; Kohut, Marian L.; Birt, Diane F.] Iowa State Univ, Ctr Res Bot Dietary Supplements, Ames, IA 50011 USA; [Huang, Nan] Iowa State Univ, Interdept Grad Program Nutr Sci, Ames, IA 50011 USA; [Huang, Nan; Birt, Diane F.] Iowa State Univ, Dept Food Sci & Human Nutr, Ames, IA 50011 USA; [Singh, Navrozedeep; Kohut, Marian L.] Iowa State Univ, Dept Kinesiol, Ames, IA 50011 USA; [Yoon, Kyoungjin] Iowa State Univ, Coll Vet Med, Dept Vet Diagnost & Prod Anim Med, Ames, IA 50011 USA; [Loiacono, Christina M.] Anim & Plant Hlth Inspect Serv, USDA, Natl Vet Serv Labs, Pathobiol Lab,Pathol Sect, Ames, IA USA	Iowa State University; Iowa State University; Iowa State University; Iowa State University; Iowa State University; United States Department of Agriculture (USDA)	Birt, DF (corresponding author), Iowa State Univ, Ctr Res Bot Dietary Supplements, Ames, IA 50011 USA.	dbirt@iastate.edu	Huang, Nan/J-1916-2019; Huang, Nan/B-3435-2009	Huang, Nan/0000-0002-7873-7294; Huang, Nan/0000-0002-7873-7294; Birt, Diane/0000-0002-1784-5582	National Center for Complementary and Alternative [P50 AT004155-06]; Medicine/Office of Dietary Supplements, National Institute of Health; NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE [P50AT004155] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P01ES012020] Funding Source: NIH RePORTER	National Center for Complementary and Alternative; Medicine/Office of Dietary Supplements, National Institute of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	This work is sponsored by P50 AT004155-06 from National Center for Complementary and Alternative and Medicine/Office of Dietary Supplements, National Institute of Health. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the ODS, NCCAM, or NIH. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Baetz A, 2004, J BIOL CHEM, V279, P54708, DOI 10.1074/jbc.M410992200; Berlato C, 2002, J IMMUNOL, V168, P6404, DOI 10.4049/jimmunol.168.12.6404; Birt DF, 2009, PHARM BIOL, V47, P774, DOI 10.1080/13880200902988645; Calapai G, 2001, PHARMACOPSYCHIATRY, V34, pS8, DOI 10.1055/s-2001-15507; Davidson BA, 2005, EXP LUNG RES, V31, P323, DOI 10.1080/01902140590918524; Davis JM, 2008, AM J PHYSIOL-REG I, V295, pR505, DOI 10.1152/ajpregu.90319.2008; Di Carlo G, 2001, TRENDS PHARMACOL SCI, V22, P292, DOI 10.1016/S0165-6147(00)01716-8; Dushoff J, 2006, AM J EPIDEMIOL, V163, P181, DOI 10.1093/aje/kwj024; Gao HW, 2006, J IMMUNOL, V177, P612, DOI 10.4049/jimmunol.177.1.612; Grundmann O, 2010, NEUROPHARMACOLOGY, V58, P767, DOI 10.1016/j.neuropharm.2009.12.014; Hammer KDP, 2010, PHYTOCHEMISTRY, V71, P716, DOI 10.1016/j.phytochem.2010.02.006; HARTSHORN KL, 1990, J LEUKOCYTE BIOL, V47, P176, DOI 10.1002/jlb.47.2.176; Herold S, 2008, J EXP MED, V205, P3065, DOI 10.1084/jem.20080201; Huang N, 2012, PHYTOCHEMISTRY, V76, P106, DOI 10.1016/j.phytochem.2011.12.001; Huang N, 2011, PHYTOCHEMISTRY, V72, P2015, DOI 10.1016/j.phytochem.2011.07.016; Huang N, 2009, J AGR FOOD CHEM, V57, P10579, DOI 10.1021/jf9023728; Kobasa D, 2007, NATURE, V445, P319, DOI 10.1038/nature05495; Kohut ML, 2009, J INFECT DIS, V200, P1434, DOI 10.1086/606014; Liu Zhao, 2010, Virologica Sinica, V25, P445, DOI 10.1007/s12250-010-3142-0; MAUS UA, 2006, J IMMUNOL, V177, P1817; McGill J, 2009, J LEUKOCYTE BIOL, V86, P803, DOI 10.1189/jlb.0509368; Mordstein M, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000151; Pamer EG, 2009, P NATL ACAD SCI USA, V106, P4961, DOI 10.1073/pnas.0901574106; Paterniti I, 2010, BMC COMPLEM ALTERN M, V10, DOI 10.1186/1472-6882-10-73; Pauli EK, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000196; Peiris JSM, 2009, TRENDS IMMUNOL, V30, P574, DOI 10.1016/j.it.2009.09.004; Pothlichet J, 2008, J IMMUNOL, V180, P2034, DOI 10.4049/jimmunol.180.4.2034; Qasimi P, 2006, J BIOL CHEM, V281, P6316, DOI 10.1074/jbc.M508608200; Rawlings JS, 2004, J CELL SCI, V117, P1281, DOI 10.1242/jcs.00963; Sanders CJ, 2011, CELL TISSUE RES, V343, P13, DOI 10.1007/s00441-010-1043-z; Tate MD, 2009, J IMMUNOL, V183, P7441, DOI 10.4049/jimmunol.0902497; Taubenberger JK, 2008, ANNU REV PATHOL-MECH, V3, P499, DOI 10.1146/annurev.pathmechdis.3.121806.154316; Tscherne DM, 2011, J CLIN INVEST, V121, P6, DOI 10.1172/JCI44947; Viksman MY, 1997, AM J RESP CRIT CARE, V155, P858, DOI 10.1164/ajrccm.155.3.9117017; Wareing MD, 2004, J LEUKOCYTE BIOL, V76, P886, DOI 10.1189/jlb.1203644; Yasukawa H, 2003, NAT IMMUNOL, V4, P551, DOI 10.1038/ni938	36	13	13	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 30	2013	8	9							e76491	10.1371/journal.pone.0076491	http://dx.doi.org/10.1371/journal.pone.0076491			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	231NL	24098792	gold, Green Published, Green Submitted			2023-01-03	WOS:000325423500163
J	Oullier, O				Oullier, Olivier			Behavioural insights are vital to policy-making	NATURE			English	Editorial Material									[Oullier, Olivier] Aix Marseille Univ, Marseilles, France	UDICE-French Research Universities; Aix-Marseille Universite	Oullier, O (corresponding author), Aix Marseille Univ, Marseilles, France.	olivier@oullier.fr							0	15	15	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 26	2013	501	7468					463	463		10.1038/501463a	http://dx.doi.org/10.1038/501463a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	223RP	24067675	Bronze			2023-01-03	WOS:000324826300021
J	Guzman-Quevedo, O; Aragao, RD; Garcia, GP; Matos, RJB; Oliveira, ADB; de Castro, RM; Bolanos-Jimenez, F				Guzman-Quevedo, Omar; Aragao, Raquel Da Silva; Garcia, Georgina Perez; Matos, Rhowena J. B.; Braga Oliveira, Andre de Sa; de Castro, Raul Manhaes; Bolanos-Jimenez, Francisco			Impaired Hypothalamic mTOR Activation in the Adult Rat Offspring Born to Mothers Fed a Low-Protein Diet	PLOS ONE			English	Article							DEPENDENT DIABETES-MELLITUS; INDUCED OBESITY; METABOLIC SYNDROME; FOOD-INTAKE; INSULIN SENSITIVITY; PRENATAL INFLUENCES; GENE-EXPRESSION; BLOOD-PRESSURE; EARLY-LIFE; PREGNANCY	Several epidemiological and experimental studies have clearly established that maternal malnutrition induces a high risk of developing obesity and related metabolic diseases in the offspring. To determine if altered nutrient sensing might underlie this enhanced disease susceptibility, here we examined the effects of perinatal protein restriction on the activation of the nutrient sensor mTOR in response to acute variations in the nutritional status of the organism. Female Wistar rats were fed isocaloric diets containing either 17% protein (control) or 8% protein (PR) throughout pregnancy and lactation. At weaning offspring received standard chow and at 4 months of age the effects of fasting or fasting plus re-feeding on the phosphorylation levels of mTOR and its downstream target S6 ribosomal protein (rpS6) in the hypothalamus were assessed by immuno-fluorescence and western blot. Under ad libitum feeding conditions, PR rats exhibited decreased mTOR and rpS6 phosphorylation in the arcuate (ARC) and ventromedial (VMH) hypothalamic nuclei. Moreover, the phosphorylation of mTOR and rpS6 in these hypothalamic nuclei decreased with fasting in control but not in PR animals. Conversely, PR animals exhibited enhanced number of pmTOR imunostained cells in the paraventricular nucleus (PVN) and fasting decreased the activation of mTOR in the PVN of malnourished but not of control rats. These alterations occurred at a developmental stage at which perinatally-undernourished animals do not show yet obesity or glucose intolerance. Collectively, our observations suggest that altered hypothalamic nutrient sensing in response to an inadequate foetal and neonatal energetic environment is one of the basic mechanisms of the developmental programming of metabolic disorders and might play a causing role in the development of the metabolic syndrome induced by malnutrition during early life.	[Guzman-Quevedo, Omar; Aragao, Raquel Da Silva; Garcia, Georgina Perez; Braga Oliveira, Andre de Sa; Bolanos-Jimenez, Francisco] INRA, Unite Mixte Rech Physiol Adaptat Nutr 1280, Nantes, France; [Guzman-Quevedo, Omar; Aragao, Raquel Da Silva; Garcia, Georgina Perez; Braga Oliveira, Andre de Sa; Bolanos-Jimenez, Francisco] Nantes Atlantique Univ, Univ Nantes, Nantes, France; [Matos, Rhowena J. B.] Univ Fed Pernambuco, Nucleo Educ Fis & Ciencias Esporte, Vitoria De Santo Antao, PE, Brazil; [Aragao, Raquel Da Silva; Braga Oliveira, Andre de Sa; de Castro, Raul Manhaes] Univ Fed Pernambuco, Ctr Ciencias Saude, Dept Nutr, Recife, PE, Brazil	INRAE; Nantes Universite; Universidade Federal de Pernambuco; Universidade Federal de Pernambuco	Bolanos-Jimenez, F (corresponding author), INRA, Unite Mixte Rech Physiol Adaptat Nutr 1280, Nantes, France.	Francisco.Bolanos@univ-nantes.fr	da Silva Aragão, Raquel/AAE-4215-2019; Quevedo, omar Guzman/AAG-6327-2020; de Castro, Raul Manhaes/A-1635-2014; Guzman Quevedo, Omar/ABU-5276-2022	da Silva Aragão, Raquel/0000-0003-0630-7030; Quevedo, omar Guzman/0000-0003-1358-1783; Guzman Quevedo, Omar/0000-0003-1358-1783	Mexican Consejo Nacional de Ciencia y Tecnologia (CONACYT); Brazilian Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES); Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES); Comite Francais d'Evaluation de la Cooperation Universitaire et Scientifique avec le Bresil (COFECUB) [Me 657/09]	Mexican Consejo Nacional de Ciencia y Tecnologia (CONACYT)(Consejo Nacional de Ciencia y Tecnologia (CONACyT)); Brazilian Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)); Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)); Comite Francais d'Evaluation de la Cooperation Universitaire et Scientifique avec le Bresil (COFECUB)	O. Guzman-Quevedo and G. Perez Garcia were the recipients of, respectively, a doctoral and a post-doctoral fellowship from the Mexican Consejo Nacional de Ciencia y Tecnologia (CONACYT). R. Da Silva Aragao was the recipient of a doctoral fellowship from the Brazilian Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES). This work was partially supported by the Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES) and the Comite Francais d'Evaluation de la Cooperation Universitaire et Scientifique avec le Bresil (COFECUB) (Action Number Me 657/09). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	BARKER DJP, 1993, DIABETOLOGIA, V36, P62, DOI 10.1007/BF00399095; Bellinger L, 2005, CLIN SCI, V109, P413, DOI 10.1042/CS20050127; Bieswal F, 2006, OBESITY, V14, P1330, DOI 10.1038/oby.2006.151; Blouet C, 2008, CELL METAB, V8, P459, DOI 10.1016/j.cmet.2008.10.004; Chen JH, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004950; Cota D, 2006, SCIENCE, V312, P927, DOI 10.1126/science.1124147; Cota D, 2008, J NEUROSCI, V28, P7202, DOI 10.1523/JNEUROSCI.1389-08.2008; Cottrell EC, 2012, FASEB J, V26, P1866, DOI 10.1096/fj.12-203489; Coupe B, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030616; Coupe B, 2010, ENDOCRINOLOGY, V151, P702, DOI 10.1210/en.2009-0893; Cripps RL, 2009, CLIN SCI, V117, P85, DOI 10.1042/CS20080393; de Souza SL, 2008, EUR J NEUROSCI, V27, P1400, DOI 10.1111/j.1460-9568.2008.06105.x; Desai M, 2007, AM J PHYSIOL-REG I, V293, pR2306, DOI 10.1152/ajpregu.00783.2006; Desai M, 2007, REPROD SCI, V14, P329, DOI 10.1177/1933719107303983; Erhuma A, 2007, AM J PHYSIOL-ENDOC M, V292, pE1702, DOI 10.1152/ajpendo.00605.2006; Fowden AL, 2009, EXP PHYSIOL, V94, P607, DOI 10.1113/expphysiol.2008.046359; Gambling L, 2003, J PHYSIOL-LONDON, V552, P603, DOI 10.1113/jphysiol.2003.051383; Gluckman PD, 2004, TRENDS ENDOCRIN MET, V15, P183, DOI 10.1016/j.tem.2004.03.002; Gopalakrishnan GS, 2005, BRIT J NUTR, V94, P938, DOI 10.1079/BJN20051559; HALES CN, 1992, DIABETOLOGIA, V35, P595, DOI 10.1007/BF00400248; Ikenasio-Thorpe BA, 2007, J ENDOCRINOL, V193, P31, DOI 10.1677/joe.1.07017; Krechowec SO, 2006, J ENDOCRINOL, V189, P355, DOI 10.1677/joe.1.06679; Leduc L, 2010, EUR J OBSTET GYN R B, V149, P127, DOI 10.1016/j.ejogrb.2009.12.005; Lillycrop KA, 2011, INT J OBESITY, V35, P72, DOI 10.1038/ijo.2010.122; Martin-Gronert MS, 2008, AM J PHYSIOL-REG I, V294, pR494, DOI 10.1152/ajpregu.00530.2007; McMullen S, 2005, AM J PHYSIOL-REG I, V288, pR85, DOI 10.1152/ajpregu.00435.2004; McMullen S, 2012, MED HYPOTHESES, V78, P88, DOI 10.1016/j.mehy.2011.09.047; Merezak S, 2004, DIABETOLOGIA, V47, P669, DOI 10.1007/s00125-004-1357-z; Mori H, 2009, CELL METAB, V9, P362, DOI 10.1016/j.cmet.2009.03.005; Orozco-Solis R, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013537; Orozco-Solis R, 2009, PHYSIOL BEHAV, V96, P481, DOI 10.1016/j.physbeh.2008.11.016; Ozanne SE, 1996, AM J PHYSIOL-ENDOC M, V271, pE1128, DOI 10.1152/ajpendo.1996.271.6.E1128; Ozanne SE, 1997, AM J PHYSIOL-ENDOC M, V273, pE46, DOI 10.1152/ajpendo.1997.273.1.E46; Plagemann A, 2009, J PHYSIOL-LONDON, V587, P4963, DOI 10.1113/jphysiol.2009.176156; Reeves PG, 1997, J NUTR, V127, pS838; Reusens B, 2011, WORLD J DIABETES, V2, P149, DOI 10.4239/wjd.v2.i9.149; Samuelsson AM, 2008, HYPERTENSION, V51, P383, DOI 10.1161/HYPERTENSIONAHA.107.101477; Sancak Y, 2007, MOL CELL, V25, P903, DOI 10.1016/j.molcel.2007.03.003; Sardinha FLC, 2006, NUTRITION, V22, P1152, DOI 10.1016/j.nut.2006.07.002; Toscano AE, 2008, NUTRITION, V24, P270, DOI 10.1016/j.nut.2007.12.004; Um SH, 2004, NATURE, V431, P200, DOI 10.1038/nature02866; Vander Haar E, 2007, NAT CELL BIOL, V9, P316, DOI 10.1038/ncb1547; Vehaskari VM, 2001, KIDNEY INT, V59, P238, DOI 10.1046/j.1523-1755.2001.00484.x; Vickers MH, 2000, AM J PHYSIOL-ENDOC M, V279, pE83; Villanueva EC, 2009, ENDOCRINOLOGY, V150, P4541, DOI 10.1210/en.2009-0642; Woods SC, 2008, ANNU REV NUTR, V28, P295, DOI 10.1146/annurev.nutr.28.061807.155505; Zambrano E, 2006, J PHYSIOL-LONDON, V571, P221, DOI 10.1113/jphysiol.2005.100313; Zhang BB, 2009, CELL METAB, V9, P407, DOI 10.1016/j.cmet.2009.03.012	48	5	5	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 9	2013	8	9							e74990	10.1371/journal.pone.0074990	http://dx.doi.org/10.1371/journal.pone.0074990			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	244QV	24040371	Green Published, Green Submitted, gold			2023-01-03	WOS:000326405300195
J	Huang, W; Zhang, JF; Dorn, HC; Zhang, CM				Huang, Wei; Zhang, Jianfei; Dorn, Harry C.; Zhang, Chenming			Assembly of Bio-Nanoparticles for Double Controlled Drug Release	PLOS ONE			English	Article							METASTATIC BREAST-CANCER; WALL CARBON NANOHORN; DELIVERY; CHEMOTHERAPY; DOXORUBICIN; MECHANISMS; PACLITAXEL; TOXICITY; TUMORS; HER-2	A critical limiting factor of chemotherapy is the unacceptably high toxicity. The use of nanoparticle based drug carriers has significantly reduced the side effects and facilitated the delivery of drugs. Source of the remaining side effect includes (1) the broad final in vivo distribution of the administrated nanoparticles, and (2) strong basal drug release from nanoparticles before they could reach the tumor. Despite the advances in pH-triggered release, undesirable basal drug release has been a constant challenge under in vivo conditions. In this study, functionalized single walled carbon nanohorn supported immunoliposomes were assembled for paclitaxel delivery. The immunoliposomes were formulated with polyethylene glycol, thermal stable and pH sensitive phospholipids. Each nanohorn was found to be encapsulated within one immunoliposome. Results showed a highly pH dependent release of paclitaxel in the presence of serum at body temperature with minimal basal release under physiological conditions. Upon acidification, paclitaxel was released at a steady rate over 30 days with a cumulative release of 90% of the loaded drug. The drug release results proved our hypothesized double controlled release mechanism from the nanoparticles. Other results showed the nanoparticles have doubled loading capacity compared to that of traditional liposomes and higher affinity to breast cancer cells overexpressing Her2 receptors. Internalized nanoparticles were found in lysosomes.	[Huang, Wei; Zhang, Chenming] Virginia Tech, Dept Biol Syst Engn, Blacksburg, VA 24061 USA; [Zhang, Jianfei; Dorn, Harry C.] Virginia Tech, Dept Chem, Blacksburg, VA USA	Virginia Polytechnic Institute & State University; Virginia Polytechnic Institute & State University	Zhang, CM (corresponding author), Virginia Tech, Dept Biol Syst Engn, Blacksburg, VA 24061 USA.	Chzhang2@vt.edu	Zhang, Jianfei/D-7749-2012		Institute for Critical Technology and Applied Science (ICTAS) at Virginia Tech; Jeffress Memorial Trust [J-994]	Institute for Critical Technology and Applied Science (ICTAS) at Virginia Tech; Jeffress Memorial Trust	This work was supported primarily by the Institute for Critical Technology and Applied Science (ICTAS) at Virginia Tech, and partially funded by a grant from Jeffress Memorial Trust, Grant no. J-994. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Andreetta C, 2010, CRIT REV ONCOL HEMAT, V76, P99, DOI 10.1016/j.critrevonc.2010.01.007; Ashley CE, 2011, NAT MATER, V10, P389, DOI [10.1038/NMAT2992, 10.1038/nmat2992]; Baban DF, 1998, ADV DRUG DELIVER REV, V34, P109, DOI 10.1016/S0169-409X(98)00003-9; BRANNONPEPPAS L, 1995, INT J PHARMACEUT, V116, P1, DOI 10.1016/0378-5173(94)00324-X; Brigger I, 2002, ADV DRUG DELIVER REV, V54, P631, DOI 10.1016/S0169-409X(02)00044-3; Cho HS, 2003, NATURE, V421, P756, DOI 10.1038/nature01392; Cho MJ, 2009, TOXICOL LETT, V189, P177, DOI 10.1016/j.toxlet.2009.04.017; Cirstoiu-Hapca A, 2010, J CONTROL RELEASE, V144, P324, DOI 10.1016/j.jconrel.2010.02.026; Dams ETM, 2000, J PHARMACOL EXP THER, V292, P1071; Dean-Colomb W, 2008, EUR J CANCER, V44, P2806, DOI 10.1016/j.ejca.2008.09.013; Dufort S, 2012, ADV DRUG DELIVER REV, V64, P179, DOI 10.1016/j.addr.2011.09.009; Ehrenberg MS, 2009, BIOMATERIALS, V30, P603, DOI 10.1016/j.biomaterials.2008.09.050; Extra JM, 2003, BREAST CANC RES T S1, V82, pA 217; Firme CP, 2010, NANOMED-NANOTECHNOL, V6, P245, DOI 10.1016/j.nano.2009.07.003; Fredenberg S, 2011, INT J PHARMACEUT, V415, P34, DOI 10.1016/j.ijpharm.2011.05.049; Gerweck LE, 1998, SEMIN RADIAT ONCOL, V8, P176, DOI 10.1016/S1053-4296(98)80043-X; Grobmyer SR, 2012, MATURITAS, V73, P19, DOI 10.1016/j.maturitas.2012.02.003; Guo W, 2005, ANAL BIOCHEM, V336, P213, DOI 10.1016/j.ab.2004.09.046; He CB, 2010, BIOMATERIALS, V31, P3657, DOI 10.1016/j.biomaterials.2010.01.065; Huang W, 2011, BIOCONJUGATE CHEM, V22, P1012, DOI 10.1021/bc200098k; Hughes GA, 2005, NANOMED-NANOTECHNOL, V1, P22, DOI 10.1016/j.nano.2004.11.009; HYNES NE, 1994, BBA-REV CANCER, V1198, P165, DOI 10.1016/0304-419X(94)90012-4; Iijima S, 1999, CHEM PHYS LETT, V309, P165, DOI 10.1016/S0009-2614(99)00642-9; Jie P, 2005, J CONTROL RELEASE, V110, P20, DOI 10.1016/j.jconrel.2005.09.011; JONES MN, 1991, BIOCHIM BIOPHYS ACTA, V1065, P145, DOI 10.1016/0005-2736(91)90224-V; Kang SI, 2003, COLLOID SURFACE A, V231, P103, DOI 10.1016/j.colsurfa.2003.09.006; Kasuya D, 2002, J PHYS CHEM B, V106, P4947, DOI 10.1021/jp020387n; Kennel SJ, 2008, NUCL MED BIOL, V35, P501, DOI 10.1016/j.nucmedbio.2008.02.001; Lammers T, 2012, J CONTROL RELEASE, V161, P175, DOI 10.1016/j.jconrel.2011.09.063; Lasic DD, 1996, NATURE, V380, P561, DOI 10.1038/380561a0; Li SD, 2009, BBA-BIOMEMBRANES, V1788, P2259, DOI 10.1016/j.bbamem.2009.06.022; Liu JW, 2009, J AM CHEM SOC, V131, P1354, DOI 10.1021/ja808018y; Lynch RM, 2007, NANOTOXICOLOGY, V1, P157, DOI 10.1080/17435390701598496; Manjappa AS, 2011, J CONTROL RELEASE, V150, P2, DOI 10.1016/j.jconrel.2010.11.002; Marty M, 2005, J CLIN ONCOL, V23, P4265, DOI 10.1200/JCO.2005.04.173; Miyawaki J, 2008, ACS NANO, V2, P213, DOI 10.1021/nn700185t; Olayioye MA, 2000, EMBO J, V19, P3159, DOI 10.1093/emboj/19.13.3159; Parveen S, 2012, NANOMED-NANOTECHNOL, V8, P147, DOI 10.1016/j.nano.2011.05.016; Patil Y, 2009, J CONTROL RELEASE, V136, P21, DOI 10.1016/j.jconrel.2009.01.021; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Puglisi F, 2006, AM J CANC, V5, P99; Reddy LH, 2005, J PHARM PHARMACOL, V57, P1231, DOI 10.1211/jpp.57.10.0001; Repnik U, 2012, BBA-PROTEINS PROTEOM, V1824, P22, DOI 10.1016/j.bbapap.2011.08.016; Sato KT, 2005, ACAD RADIOL, V12, P1342, DOI 10.1016/j.acra.2005.06.019; Shu CY, 2010, CHEM MATER, V22, P347, DOI 10.1021/cm902710n; Simoes S, 2001, BBA-BIOMEMBRANES, V1515, P23, DOI 10.1016/S0005-2736(01)00389-3; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Wilcken N, 2008, EUR J CANCER, V44, P2218, DOI 10.1016/j.ejca.2008.07.019; Xiao K, 2011, BIOMATERIALS, V32, P3435, DOI 10.1016/j.biomaterials.2011.01.021; Xu JX, 2008, CHEM PHYS LETT, V461, P189, DOI 10.1016/j.cplett.2008.06.077; Yang T, 2007, J CONTROL RELEASE, V120, P169, DOI 10.1016/j.jconrel.2007.05.011; Zhang JF, 2010, NANO LETT, V10, P2843, DOI 10.1021/nl1008635	53	17	19	0	77	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 6	2013	8	9							e74679	10.1371/journal.pone.0074679	http://dx.doi.org/10.1371/journal.pone.0074679			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	224BO	24040316	Green Published, gold, Green Submitted			2023-01-03	WOS:000324856500092
J	Brown, SGA; Macdonald, SPJ; Hankey, GJ				Brown, Simon G. A.; Macdonald, Stephen P. J.; Hankey, Graeme J.			Do risks outweigh benefits in thrombolysis for stroke?	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							ACUTE ISCHEMIC-STROKE; TISSUE-PLASMINOGEN ACTIVATOR; INTRACEREBRAL HEMORRHAGE; SAFE IMPLEMENTATION; CANADIAN ALTEPLASE; COST-EFFECTIVENESS; TRIAL; ONSET; REANALYSIS		[Brown, Simon G. A.; Macdonald, Stephen P. J.] Univ Western Australia, Sch Primary Aboriginal & Rural Hlth Care, Perth, WA 6009, Australia; [Brown, Simon G. A.] Royal Perth Hosp, Emergency Dept, Perth, WA 6847, Australia; [Macdonald, Stephen P. J.] Armadale Hlth Serv, Emergency Dept, Armadale, WA 6992, Australia; [Hankey, Graeme J.] Univ Western Australia, Sch Med & Pharmacol, Perth, WA 6009, Australia; [Hankey, Graeme J.] Sir Charles Gairdner Hosp, Dept Neurol, Nedlands, WA 6009, Australia	University of Western Australia; Royal Perth Hospital; University of Western Australia; University of Western Australia; University of Western Australia	Brown, SGA (corresponding author), Univ Western Australia, Sch Primary Aboriginal & Rural Hlth Care, Perth, WA 6009, Australia.	simon.brown@uwa.edu.au; graeme.hankey@uwa.edu.au	Macdonald, Stephen PJ/H-5339-2014; Hankey, Graeme J/H-4968-2014	Hankey, Graeme J/0000-0002-6044-7328; Macdonald, Stephen/0000-0001-9921-4620				Ahmed N, 2013, JAMA NEUROL, V70, P837, DOI 10.1001/jamaneurol.2013.406; Ahmed N, 2010, LANCET NEUROL, V9, P866, DOI 10.1016/S1474-4422(10)70165-4; Boudreau DM, 2013, ANN EMERG MED, V61, P46, DOI 10.1016/j.annemergmed.2012.04.020; Clark WM, 1999, JAMA-J AM MED ASSOC, V282, P2019, DOI 10.1001/jama.282.21.2019; Clark WM, 2000, STROKE, V31, P811, DOI 10.1161/01.STR.31.4.811; Collins R, 2001, LANCET, V357, P373, DOI 10.1016/S0140-6736(00)03651-5; Emberson J, 2013, INT J STROKE, V8, P278, DOI 10.1111/ijs.12040; Fatovich DM, 2012, EMERG MED AUSTRALAS, V24, P477, DOI 10.1111/j.1742-6723.2012.01605.x; Ferguson C, 2010, EMERG MED J, V27, P245, DOI 10.1136/emj.2009.089656c; Hacke W, 2008, NEW ENGL J MED, V359, P1317, DOI 10.1056/NEJMoa0804656; Hill MD, 2005, CAN MED ASSOC J, V172, P1307, DOI 10.1503/cmaj.1041561; Hoffman JR, 2012, EMERG MED AUSTRALAS, V24, P473, DOI 10.1111/j.1742-6723.2012.01604.x; Hoffman JR, 2009, ANN EMERG MED, V54, P329, DOI 10.1016/j.annemergmed.2009.03.019; Ingall TJ, 2004, STROKE, V35, P2418, DOI 10.1161/01.STR.0000140891.70547.56; Lyden PD, 2012, STROKE, V43, P1691, DOI 10.1161/STROKEAHA.112.656876; MARLER JR, 1995, NEW ENGL J MED, V333, P1581, DOI 10.1056/nejm199512143332401; Mazya MV, 2013, STROKE, V44, P1595, DOI 10.1161/STROKEAHA.113.000794; Pocock SJ, 2002, STAT MED, V21, P2917, DOI 10.1002/sim.1296; Quinn TJ, 2009, STROKE, V40, P3393, DOI [10.1161/STROKEAHA.109.557256, 10.1161/STROKEAHA.108.522516]; Radecki RP, 2013, ANN EMERG MED, V61, P489, DOI 10.1016/j.annemergmed.2012.12.008; Radecki RP, 2012, NAT REV NEUROL, V8, P176, DOI 10.1038/nrneurol.2011.89-c1; Rocco A, 2013, STROKE, V44, P2134, DOI 10.1161/STROKEAHA.111.675918; Sandercock P, 2013, LANCET NEUROL, V12, P768, DOI 10.1016/S1474-4422(13)70130-3; Sandercock P, 2012, LANCET, V379, P2352, DOI 10.1016/S0140-6736(12)60768-5; Saposnik G, 2013, NEUROLOGY, V80, P21, DOI 10.1212/WNL.0b013e31827b1ace; Saposnik G, 2012, STROKE, V43, P1315, DOI 10.1161/STROKEAHA.111.646265; Saver JL, 2013, JAMA-J AM MED ASSOC, V309, P2480, DOI 10.1001/jama.2013.6959; Saver JL, 2010, STROKE, V41, P2381, DOI 10.1161/STROKEAHA.110.583807; Shobha N, 2011, CEREBROVASC DIS, V31, P223, DOI 10.1159/000321893; Shy BD, 2012, J EMERG MED; Strbian D, 2012, NEUROLOGY, V78, P427, DOI 10.1212/WNL.0b013e318245d2a9; Sung SF, 2013, STROKE, V44, P1561, DOI 10.1161/STROKEAHA.111.000651; Tanny SPT, 2013, STROKE, V44, P2269, DOI 10.1161/STROKEAHA.113.001295; Wahlgren N, 2007, LANCET, V369, P275, DOI 10.1016/S0140-6736(07)60149-4; Wardlaw JM, 2012, LANCET, V379, P2364, DOI 10.1016/S0140-6736(12)60738-7; Whiteley WN, 2012, STROKE, V43, P2904, DOI 10.1161/STROKEAHA.112.665331	36	12	12	0	10	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 29	2013	347								f5215	10.1136/bmj.f5215	http://dx.doi.org/10.1136/bmj.f5215			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	211CI	23990634				2023-01-03	WOS:000323881300009
J	Kumar, N; Kanchan, T; Unnikrishnan, B; Rekha, T; Mithra, P; Kulkarni, V; Papanna, MK; Holla, R; Uppal, S				Kumar, Nithin; Kanchan, Tanuj; Unnikrishnan, Bhaskaran; Rekha, T.; Mithra, Prasanna; Kulkarni, Vaman; Papanna, Mohan Kumar; Holla, Ramesh; Uppal, Surabhi			Perceptions and Practices of Self-Medication among Medical Students in Coastal South India	PLOS ONE			English	Article							UNIVERSITY-STUDENTS; ANTIBIOTICS; PATTERNS; COLLEGE	Self-medication is a common practice worldwide and the irrational use of drugs is a cause of concern. This study assessed the prevalence of self-medication among the medical students in South India. The data was analysed using SPSS version 11.5. A total of 440 students were included in the study. The prevalence of self-medication was 78.6%. A larger number of females were self-medicating (81.2%) than males (75.3%). The majority of the students self-medicated because of the illness being too trivial for consultation (70.5%). Antipyretics were most commonly self-medicated by the participants (74.8%). Only 47% of the participants opined that self-medication was a part of self-care and it needs to be encouraged. 39.3% of the participants perceived that the supply of medicine without prescription by the pharmacist can prevent the growing trend of self-medication. Easy availability and accessibility to health care facilities remains the cornerstone for reducing the practice of self-medication.	[Kumar, Nithin; Unnikrishnan, Bhaskaran; Rekha, T.; Mithra, Prasanna; Kulkarni, Vaman; Papanna, Mohan Kumar; Holla, Ramesh] Manipal Univ, Kasturba Med Coll, Dept Community Med, Mangalore, Karnataka, India; [Kanchan, Tanuj] Manipal Univ, Kasturba Med Coll, Dept Forens Med, Mangalore, Karnataka, India; [Uppal, Surabhi] Manipal Univ, Kasturba Med Coll, Mangalore, Karnataka, India	Manipal Academy of Higher Education (MAHE); Kasturba Medical College, Mangalore; Manipal Academy of Higher Education (MAHE); Kasturba Medical College, Mangalore; Manipal Academy of Higher Education (MAHE); Kasturba Medical College, Mangalore	Kumar, N (corresponding author), Manipal Univ, Kasturba Med Coll, Dept Community Med, Mangalore, Karnataka, India.	nithin.gatty@manipal.edu	KANCHAN, TANUJ/L-8547-2015; Prasanna Mithra, MBBS/J-9621-2018; Kumar, Nithin/P-2781-2015; Holla, Ramesh/P-2785-2015; Unnikrishnan, Bhaskaran/O-1025-2015; Thapar, Rekha/A-7098-2016	KANCHAN, TANUJ/0000-0003-0346-1075; Prasanna Mithra, MBBS/0000-0002-7153-411X; Kumar, Nithin/0000-0003-4665-9401; Holla, Ramesh/0000-0002-2296-3719; Unnikrishnan, Bhaskaran/0000-0003-0892-8551; Thapar, Rekha/0000-0003-2278-1445; Kulkarni, Vaman/0000-0002-6518-2277	Department of Community Medicine, Kasturba Medical College, Mangalore; Manipal University; FOGARTY INTERNATIONAL CENTER [D43TW008332] Funding Source: NIH RePORTER	Department of Community Medicine, Kasturba Medical College, Mangalore; Manipal University; FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC))	The authors are grateful to the study participants who voluntarily took part in the study. We wish to acknowledge the support provided by the Department of Community Medicine, Kasturba Medical College, Mangalore and Manipal University for encouraging research and its publication in international journals of repute.	Abay SM, 2010, J YOUNG PHARM, V2, P306, DOI 10.4103/0975-1483.66798; Ali Sohair E., 2010, Pharmacy Pract (Granada), V8, P226; Azevedo MM, 2009, BMC PUBLIC HEALTH, V9, DOI 10.1186/1471-2458-9-359; Badiger S, 2012, AUSTRALAS MED J, V5, P217, DOI 10.4066/AMJ.2012.1007; Balamurugan E., 2011, British Journal of Medical Practitioners, V4, pa428; Banerjee I, 2012, J POSTGRAD MED, V58, P127, DOI 10.4103/0022-3859.97175; Belachew G., 2011, J APPL PHARM SCI, V1, P183; Buke C, 2005, J INFECTION, V51, P135, DOI 10.1016/j.jinf.2004.12.001; Burak LJ, 2000, J AM COLL HEALTH, V49, P118, DOI 10.1080/07448480009596293; Donkor ES, 2012, INT J ENV RES PUB HE, V9, P3519, DOI 10.3390/ijerph9103519; Ehigiator O., 2013, EUR J GEN DENT, V2, P54, DOI [10.4103/2278-9626.106813, DOI 10.4103/2278-9626.106813]; El Ezz NF, 2011, EGYPT J PREV MED HYG, V52, P196; Eng JV, 2003, EMERG INFECT DIS, V9, P1128; Fadare J. O., 2011, Journal of Public Health and Epidemiology, V3, P217; Grigoryan L, 2006, EMERG INFECT DIS, V12, P452, DOI 10.3201/eid1203.050992; Gupta V., 2011, J DRUG DELIV THER, V1, P27; Hem E, 2005, BMC MED, V3, DOI 10.1186/1741-7015-3-16; Klemenc-Ketis Z, 2011, COLLEGIUM ANTROPOL, V35, P329; Loyola Filho Antônio I. de, 2004, Cad. Saúde Pública, V20, P1661, DOI 10.1590/S0102-311X2004000600025; Lucas R, 2007, CAD SAUDE PUBLICA, V23, P2845, DOI 10.1590/S0102-311X2007001200005; Olayemi OJ, 2010, RES J APPL SCI ENG T, V2, P35; Pan H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041314; Sarahroodi S, 2012, J FAM COMMUNITY MED, V19, P125, DOI 10.4103/2230-8229.98302; Sarkar P, 2006, DRUGS, V66, P893, DOI 10.2165/00003495-200666070-00001; Selley P, 1988, Health Trends, V20, P128; Skliros E, 2010, BMC FAM PRACT, V11, DOI 10.1186/1471-2296-11-58; Smogavec M, 2010, ZDR VESTN, V79, P757; Sontakke SD, 2011, INT J BIOL MED RES, V2, P561; Verma RK, 2010, ASIAN J PHARM CLIN R, V3, P60; Vizhi SK, 2010, INT J ENTREP INNOV M, V3, P40; World Health Organization, 2000, REG GUID TEL PROD; Zafar SN, 2008, BMC PUBLIC HEALTH, V8, DOI 10.1186/1471-2458-8-162	32	81	83	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 28	2013	8	8							e72247	10.1371/journal.pone.0072247	http://dx.doi.org/10.1371/journal.pone.0072247			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	209DG	24015223	Green Published, Green Submitted, gold			2023-01-03	WOS:000323733800038
J	Pagoto, SL; Appelhans, BM				Pagoto, Sherry L.; Appelhans, Bradley M.			A Call for an End to the Diet Debates	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							LOW-FAT DIETS; DIABETES PREVENTION; LIFE-STYLE; FOLLOW-UP; METAANALYSIS; RISK		[Pagoto, Sherry L.] Univ Massachusetts, Sch Med, Worcester, MA 01655 USA; [Appelhans, Bradley M.] Rush Univ, Med Ctr, Chicago, IL 60612 USA	University of Massachusetts System; University of Massachusetts Worcester; Rush University	Pagoto, SL (corresponding author), Univ Massachusetts, Sch Med, Dept Med, Div Prevent & Behav Med, 55 Lake Ave N, Worcester, MA 01655 USA.	sherry.pagoto@umassmed.edu	Pagoto, Sherry L/L-2014-2013	Pagoto, Sherry L/0000-0002-2462-8797				Ajala O, 2013, AM J CLIN NUTR, V97, P505, DOI 10.3945/ajcn.112.042457; Bacon L, 2011, NUTR J, V10, DOI 10.1186/1475-2891-10-9; Bray GA, 2009, LANCET, V374, P1677, DOI 10.1016/S0140-6736(09)61457-4; Bueno NB, 2013, BRIT J NUTR, V110, P1178, DOI 10.1017/S0007114513000548; Hu T, 2012, AM J EPIDEMIOL, V176, pS44, DOI 10.1093/aje/kws264; Kraschnewski JL, 2013, MED CARE, V51, P186, DOI 10.1097/MLR.0b013e3182726c33; Li GW, 2008, LANCET, V371, P1783, DOI 10.1016/S0140-6736(08)60766-7; Lindstrom J, 2013, DIABETOLOGIA, V56, P284, DOI 10.1007/s00125-012-2752-5; Wycherley TP, 2012, AM J CLIN NUTR, V96, P1281, DOI 10.3945/ajcn.112.044321	9	74	75	0	21	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 21	2013	310	7					687	688		10.1001/jama.2013.8601	http://dx.doi.org/10.1001/jama.2013.8601			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	202XP	23989081				2023-01-03	WOS:000323254500013
J	Vissing, NH; Sevelsted, A; Bisgaard, H				Vissing, Nadja Hawwa; Sevelsted, Astrid; Bisgaard, Hans			Public Hygiene Campaign in Denmark during the 2009 H1N1 Pandemic Had No Effect on Hospitalization Rate of Communicable Diseases in Children	PLOS ONE			English	Article							CONTROLLED-TRIAL; CARE	Background: During the 2009 H1N1 pandemic the Danish National board of Health carried out massive public hygiene campaigns to limit spread of disease. We aimed to investigate whether this resulted in lower incidences of communicable diseases in the paediatric population. Methods: The study compared annual hospitalization rates for childhood infections from 2005 to 2011. Results: Admission rates for infections were higher during the year of the pandemic compared to the rest of the period. Conclusion: There were no indications of a preventive effect by the hygiene campaign on incidence of severe common childhood infections.	[Vissing, Nadja Hawwa; Sevelsted, Astrid; Bisgaard, Hans] Copenhagen Univ Hosp, Copenhagen Prospect Studies Asthma Childhood, COPSAC, Gentofte, Denmark	University of Copenhagen	Bisgaard, H (corresponding author), Copenhagen Univ Hosp, Copenhagen Prospect Studies Asthma Childhood, COPSAC, Gentofte, Denmark.	bisgaard@copsac.com	Bisgaard, Hans/N-4761-2016	Bisgaard, Hans/0000-0003-4131-7592; sevelsted, astrid/0000-0001-7117-2334				Aiello AE, 2002, LANCET INFECT DIS, V2, P103, DOI 10.1016/S1473-3099(02)00184-6; Curtis V, 2003, LANCET INFECT DIS, V3, P275, DOI 10.1016/S1473-3099(03)00606-6; Danish Association of Communications (Dansk Kommunikationsforening), INFL A KUNST INF UD; Ejemot RJ, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004265.pub2; Gubbels S, 2010, EURO SURVEILL, V15; KOTCH JB, 1994, PEDIATRICS, V94, P991; Luby SP, 2005, LANCET, V366, P225, DOI 10.1016/S0140-6736(05)66912-7; Lynge E, 2011, SCAND J PUBLIC HEALT, V39, P30, DOI 10.1177/1403494811401482; Molbak K, 2011, VACCINE, V29, pB63, DOI 10.1016/j.vaccine.2011.03.064; *NAT BOARD HLTH, 2006, PAND PLAN 2006; National Board of Health, INF REG INFL; Roberts L, 2000, PEDIATRICS, V105, P738, DOI 10.1542/peds.105.4.738; Rostgaard Klaus, 2008, Epidemiol Perspect Innov, V5, P7, DOI 10.1186/1742-5573-5-7; Stone SP, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e3005; Widgren K, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013939; World Health Organization, INT CLASS DIS	16	1	1	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 30	2013	8	7							e70946	10.1371/journal.pone.0070946	http://dx.doi.org/10.1371/journal.pone.0070946			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	201AX	23936255	gold, Green Published, Green Submitted			2023-01-03	WOS:000323114200109
J	Lim, CY; Junit, SM; Abdulla, MA; Aziz, AA				Lim, Chor Yin; Junit, Sarni Mat; Abdulla, Mahmood Ameen; Aziz, Azlina Abdul			In Vivo Biochemical and Gene Expression Analyses of the Antioxidant Activities and Hypocholesterolaemic Properties of Tamarindus indica Fruit Pulp Extract	PLOS ONE			English	Article							HDL CHOLESTEROL LEVELS; LDL RECEPTOR; DIETARY-CHOLESTEROL; PLASMA-CHOLESTEROL; COA REDUCTASE; HEART-DISEASE; LEAF EXTRACT; CYTOCHROME-P450; PROTEIN; CANCER	Background: Tamarindus indica (T. indica) is a medicinal plant with many biological activities including anti-diabetic, hypolipidaemic and anti-bacterial activities. A recent study demonstrated the hypolipidaemic effect of T. indica fruit pulp in hamsters. However, the biochemical and molecular mechanisms responsible for these effects have not been fully elucidated. Hence, the aims of this study were to evaluate the antioxidant activities and potential hypocholesterolaemic properties of T. indica, using in vitro and in vivo approaches. Methodology/Principal Findings: The in vitro study demonstrated that T. indica fruit pulp had significant amount of phenolic (244.9 +/- 10.1 mg GAE/extract) and flavonoid (93.9 +/- 2.6 mg RE/g extract) content and possessed antioxidant activities. In the in vivo study, hamsters fed with high-cholesterol diet for ten weeks showed elevated serum triglyceride, total cholesterol, HDL-C and LDL-C levels. Administration of T. indica fruit pulp to hypercholesterolaemic hamsters significantly lowered serum triglyceride, total cholesterol and LDL-C levels but had no effect on the HDL-C level. The lipid-lowering effect was accompanied with significant increase in the expression of Apo A1, Abcg5 and LDL receptor genes and significant decrease in the expression of HMG-CoA reductase and Mtp genes. Administration of T. indica fruit pulp to hypercholesterolaemic hamsters also protected against oxidative damage by increasing hepatic antioxidant enzymes, antioxidant activities and preventing hepatic lipid peroxidation. Conclusion/Significance: It is postulated that tamarind fruit pulp exerts its hypocholesterolaemic effect by increasing cholesterol efflux, enhancing LDL-C uptake and clearance, suppressing triglyceride accumulation and inhibiting cholesterol biosynthesis. T. indica fruit pulp has potential antioxidative effects and is potentially protective against diet-induced hypercholesterolaemia.	[Lim, Chor Yin; Junit, Sarni Mat; Abdulla, Mahmood Ameen; Aziz, Azlina Abdul] Univ Malaya, Fac Med, Dept Mol Med, Kuala Lumpur, Malaysia	Universiti Malaya	Aziz, AA (corresponding author), Univ Malaya, Fac Med, Dept Mol Med, Kuala Lumpur, Malaysia.	azlina_aziz@um.edu.my	MAT-JUNIT, SARNI/GXW-0277-2022; AZIZ, AZLINA ABDUL/B-8303-2010; mat-junit, sarni/J-5838-2015	AZIZ, AZLINA ABDUL/0000-0002-9210-5066; Mat Junit, Sarni/0000-0002-9813-452X	High Impact Research Grant [H-20001-00-E000009]; University of Malaya [RG458-12HTM]; Postgraduate Research Fund from University of Malaya, Malaysia [PV116-2012A]	High Impact Research Grant; University of Malaya(Universiti Malaya); Postgraduate Research Fund from University of Malaya, Malaysia	This research was financially supported by the High Impact Research Grant (H-20001-00-E000009), University of Malaya Research Grant (RG458-12HTM) and Postgraduate Research Fund (PV116-2012A) from University of Malaya, Malaysia. The funders had no role in the study design, data collection and analysis and preparation of the manuscript.	Alsaif M. A., 2007, IJP - International Journal of Pharmacology, V3, P123; Androutsopoulos VP, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-187; [Anonymous], CARD DIS; Ben Khaled H, 2012, FOOD RES INT, V45, P60, DOI 10.1016/j.foodres.2011.10.003; Bennett AJ, 1996, FEBS LETT, V394, P247, DOI 10.1016/0014-5793(96)00962-3; Benzie IFF, 1996, ANAL BIOCHEM, V239, P70, DOI 10.1006/abio.1996.0292; Berge KE, 2000, SCIENCE, V290, P1771, DOI 10.1126/science.290.5497.1771; BRINTON EA, 1990, J CLIN INVEST, V85, P144, DOI 10.1172/JCI114405; Bundy R, 2008, PHYTOMEDICINE, V15, P668, DOI 10.1016/j.phymed.2008.03.001; Bursill CA, 2007, ATHEROSCLEROSIS, V193, P86, DOI 10.1016/j.atherosclerosis.2006.08.033; Chong URW, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039476; Ciolino HP, 1999, BIOCHEM J, V340, P715, DOI 10.1042/0264-6021:3400715; Cos P, 2002, FREE RADICAL RES, V36, P711, DOI 10.1080/10715760290029182; Daniel Reji Susan, 1998, Indian Journal of Experimental Biology, V36, P902; Davidson MH, 2007, AM J CARDIOL, V99, p3C, DOI 10.1016/j.amjcard.2006.11.016; Doughari J. H., 2006, Tropical Journal of Pharmaceutical Research, V5, P597; Du EZ, 1996, J LIPID RES, V37, P1309; Frishman William H., 1998, American Journal of Medicine, V104, p18S, DOI 10.1016/S0002-9343(98)00184-3; Fruchart JC, 1996, ISRAEL J MED SCI, V32, P498; Gao S, 2010, BIOCHEM BIOPH RES CO, V398, P619, DOI 10.1016/j.bbrc.2010.05.114; Gregg Richard E., 1994, Current Opinion in Lipidology, V5, P81, DOI 10.1097/00041433-199404000-00003; HALLIWELL B, 1984, BIOCHEM J, V219, P1, DOI 10.1042/bj2190001; HAYEK T, 1993, J CLIN INVEST, V91, P1665, DOI 10.1172/JCI116375; He FJ, 2006, LANCET, V367, P320, DOI 10.1016/S0140-6736(06)68069-0; Hoffmann A, 1996, BBA-LIPID LIPID MET, V1299, P95, DOI 10.1016/0005-2760(95)00201-4; HORTON JD, 1993, J CLIN INVEST, V92, P743, DOI 10.1172/JCI116645; Huang XQ, 2010, LIPIDS HEALTH DIS, V9, DOI 10.1186/1476-511X-9-9; INGEBRITSEN TS, 1979, J BIOL CHEM, V254, P9986; Kahlon TS, 1999, CEREAL CHEM, V76, P772, DOI 10.1094/CCHEM.1999.76.5.772; Katalinic V, 2004, FOOD CHEM, V86, P593, DOI 10.1016/j.foodchem.2003.10.007; Katan MB, 1997, AM J CLIN NUTR, V65, P1542, DOI 10.1093/ajcn/65.5.1542; Kim KT, 2008, FOOD SCI BIOTECHNOL, V17, P1361; Kittichanun C, 2010, J HEALTH RES, V24, P1; LAKSHMANAN M R, 1973, Biochemical and Biophysical Research Communications, V50, P704, DOI 10.1016/0006-291X(73)91301-6; Lee MK, 2002, BIOORGAN MED CHEM, V10, P2239, DOI 10.1016/S0968-0896(02)00059-7; Ling JJ, 2012, FOOD CHEM, V130, P229, DOI 10.1016/j.foodchem.2011.07.039; Liu HY, 2008, FOOD RES INT, V41, P363, DOI 10.1016/j.foodres.2007.12.012; Martinello F, 2006, FOOD CHEM TOXICOL, V44, P810, DOI 10.1016/j.fct.2005.10.011; Masood N, 2011, ASIAN PAC J CANCER P, V12, P377; MENGEL CE, 1966, J CLIN INVEST, V45, P1150, DOI 10.1172/JCI105421; MILLER NE, 1987, AM HEART J, V113, P589, DOI 10.1016/0002-8703(87)90638-7; Nammi S, 2010, BASIC CLIN PHARMACOL, V106, P389, DOI 10.1111/j.1742-7843.2009.00497.x; Patalay M, 2005, J NUTR, V135, P735, DOI 10.1093/jn/135.4.735; Pitman WA, 1998, ATHEROSCLEROSIS, V138, P43, DOI 10.1016/S0021-9150(97)00302-X; Pushparaj P, 2000, J ETHNOPHARMACOL, V72, P69, DOI 10.1016/S0378-8741(00)00200-2; Quinones L, 2001, CANCER LETT, V174, P35, DOI 10.1016/S0304-3835(01)00686-3; Ramiro-Puig E, 2007, J AGR FOOD CHEM, V55, P6431, DOI 10.1021/jf070487w; Razali N, 2012, FOOD CHEM, V131, P441, DOI 10.1016/j.foodchem.2011.09.001; Razali N, 2010, GENES NUTR, V5, P331, DOI 10.1007/s12263-010-0187-5; Re R, 1999, FREE RADICAL BIO MED, V26, P1231, DOI 10.1016/S0891-5849(98)00315-3; Rimbau V, 1999, PHYTOTHER RES, V13, P128, DOI 10.1002/(SICI)1099-1573(199903)13:2&lt;128::AID-PTR399&gt;3.0.CO;2-7; RUBIN EM, 1991, NATURE, V353, P265, DOI 10.1038/353265a0; Sever PS, 2003, LANCET, V361, P1149, DOI 10.1016/S0140-6736(03)12948-0; SHOULDERS CC, 1983, NUCLEIC ACIDS RES, V11, P2827, DOI 10.1093/nar/11.9.2827; SINGLETON V. L., 1965, AMER J ENOL VITICULT, V16, P144; SPADY DK, 1985, J LIPID RES, V26, P465; Sudjaroen Y, 2005, FOOD CHEM TOXICOL, V43, P1673, DOI 10.1016/j.fct.2005.05.013; Surekha D, 2009, Indian J Med Sci, V63, P13, DOI 10.4103/0019-5359.49077; Suzuki K, 2003, CANCER LETT, V195, P177, DOI 10.1016/S0304-3835(03)00182-4; Theriault A, 2000, J LIPID RES, V41, P1969; Uno S, 2004, MOL PHARMACOL, V65, P1225, DOI 10.1124/mol.65.5.1225; WETTERAU JR, 1992, SCIENCE, V258, P999; White DA, 1997, PROSTAG LEUKOTR ESS, V57, P455, DOI 10.1016/S0952-3278(97)90428-2; Wilcox LJ, 2001, J LIPID RES, V42, P725; Wilson PWF, 1998, CIRCULATION, V97, P1837, DOI 10.1161/01.CIR.97.18.1837; Wilund KR, 2004, J LIPID RES, V45, P1429, DOI 10.1194/jlr.M400167-JLR200; Yasuda A, 2011, J AGR FOOD CHEM, V59, P1470, DOI 10.1021/jf103820b; Yazdanparast R, 2008, CHEM-BIOL INTERACT, V172, P176, DOI 10.1016/j.cbi.2008.01.006; Yu LQ, 2002, J CLIN INVEST, V110, P671, DOI [10.1172/JCI0216001, 10.1172/JCI200216001]; Zhang AH, 2004, FEBS LETT, V570, P25, DOI 10.1016/j.febslet.2004.06.017; Zhao JC, 1998, WORLD J GASTROENTERO, V4, P337, DOI 10.3748/wjg.v4.i4.337	71	39	40	0	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 23	2013	8	7							e70058	10.1371/journal.pone.0070058	http://dx.doi.org/10.1371/journal.pone.0070058			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	228SX	23894592	Green Published, Green Submitted, gold			2023-01-03	WOS:000325211000182
J	Forster, A; Dickerson, J; Young, J; Patel, A; Kalra, L; Nixon, J; Smithard, D; Knapp, M; Holloway, I; Anwar, S; Farrin, A				Forster, Anne; Dickerson, Josie; Young, John; Patel, Anita; Kalra, Lalit; Nixon, Jane; Smithard, David; Knapp, Martin; Holloway, Ivana; Anwar, Shamaila; Farrin, Amanda		TRACS Trial Collaboration	A structured training programme for caregivers of inpatients after stroke (TRACS): a cluster randomised controlled trial and cost-effectiveness analysis	LANCET			English	Article							ADMINISTERED VERSION; CARE GIVERS; SURVIVORS; BURDEN; IMPACT	Background Most patients who have had a stroke are dependent on informal caregivers for activities of daily living. The TRACS trial investigated a training programme for caregivers (the London Stroke Carers Training Course, LSCTC) on physical and psychological outcomes, including cost-effectiveness, for patients and caregivers after a disabling stroke. Methods We undertook a pragmatic, multicentre, cluster randomised controlled trial with a parallel cost-effectiveness analysis. Stroke units were eligible if four of five criteria used to define a stroke unit were met, a substantial number of patients on the unit had a diagnosis of stroke, staff were able to deliver the LSCTC, and most patients were discharged to a permanent place of residence. Stroke units were randomly assigned to either LSCTC or usual care (control group), stratified by geographical region and quality of care, and using blocks of size 2. Patients with a diagnosis of stroke, likely to return home with residual disability and with a caregiver providing support were eligible. The primary outcome for patients was self-reported extended activities of daily living at 6 months, measured with the Nottingham Extended Activities of Daily Living (NEADL) scale. The primary outcome for caregivers was self-reported burden at 6 months, measured with the caregivers burden scale (CBS). We combined patient and caregiver costs with primary outcomes and quality-adjusted life-years (QALYs) to assess cost-effectiveness. This trial is registered with controlled-trials.com, number ISRCTN 49208824. Findings We assessed 49 stroke units for eligibility, of which 36 were randomly assigned to either the intervention group or the control group. Between Feb 27, 2008, and Feb 9, 2010, 928 patient and caregiver dyads were registered, of which 450 were in the intervention group, and 478 in the control group. Patients' self-reported extended activities of daily living did not differ between groups at 6 months (adjusted mean NEADL score 27.4 in the intervention group versus 27.6 in the control group, difference -0.2 points [95% CI -3.0 to 2.5], p value=0.866, ICC=0.027). The caregiver burden scale did not differ between groups either (adjusted mean CBS 45.5 in the intervention group versus 45.0 in the control group, difference 0.5 points [95% CI -1.7 to 2.7], p value=0.660, ICC=0.013). Patient and caregiver costs were similar in both groups (length of the initial stroke admission and associated costs were 13 pound 127 for the intervention group and 12 pound 471 for the control group; adjusted mean difference 1243 pound [95% CI -1533 to 4019]; p value=0.380). Probabilities of cost-effectiveness based on QALYs were low. Interpretation In a large scale, robust evaluation, results from this study have shown no differences between the LSCTC and usual care on any of the assessed outcomes. The immediate period after stroke might not be the ideal time to deliver structured caregiver training.	[Forster, Anne; Dickerson, Josie; Young, John] Bradford Teaching Hosp NHS Fdn Trust, Acad Unit Elderly Care & Rehabil, Bradford, W Yorkshire, England; [Forster, Anne; Dickerson, Josie; Young, John] Univ Leeds, Bradford, W Yorkshire, England; [Patel, Anita; Knapp, Martin] Kings Coll London, Inst Psychiat, London WC2R 2LS, England; [Kalra, Lalit; Smithard, David] Kings Coll London, Dept Stroke Med, London WC2R 2LS, England; [Nixon, Jane; Holloway, Ivana; Anwar, Shamaila; Farrin, Amanda] Univ Leeds, Clin Trials Res Unit, Leeds, W Yorkshire, England; [Knapp, Martin] Univ London London Sch Econ & Polit Sci, Personal Social Serv Res Unit, London WC2A 2AE, England	University of Leeds; University of London; King's College London; University of London; King's College London; University of Leeds; University of London; London School Economics & Political Science	Forster, A (corresponding author), Bradford Royal Infirm, Acad Unit Elderly Care & Rehabil, Temple Bank House, Bradford BD9 6RJ, W Yorkshire, England.	a.forster@leeds.ac.uk	Patel, Anita/F-9832-2010	Farrin, Amanda/0000-0002-2876-0584; Knapp, Martin/0000-0003-1427-0215; Bowen, Audrey/0000-0003-4075-1215; Forster, Anne/0000-0001-7466-4414; Patel, Anita/0000-0003-0769-1732; young, john/0000-0003-4085-9306	Medical Research Council; MRC [G0501807] Funding Source: UKRI; Medical Research Council [G0501807] Funding Source: researchfish	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	Medical Research Council.	Brooke P, 1999, INT J GERIATR PSYCH, V14, P936, DOI 10.1002/(SICI)1099-1166(199911)14:11<936::AID-GPS39>3.0.CO;2-1; Brooks R, 1996, HEALTH POLICY, V37, P53, DOI 10.1016/0168-8510(96)00822-6; Carter J, 1997, CLIN REHABIL, V11, P131, DOI 10.1177/026921559701100206; Dennis M, 2003, STROKE, V34, P127, DOI 10.1161/01.STR.0000044165.41303.50; Dewey HM, 2002, STROKE, V33, P1028, DOI 10.1161/01.STR.0000013067.24300.B0; Duncan PW, 2002, CLIN REHABIL, V16, P493, DOI 10.1191/0269215502cr510oa; Elmstahl S, 1996, ARCH PHYS MED REHAB, V77, P177, DOI 10.1016/S0003-9993(96)90164-1; Forster A, 2012, INT J STROKE, V7, P94, DOI 10.1111/j.1747-4949.2011.00722.x; Gompertz P., 1994, CLIN REHABIL, V8, P233, DOI [DOI 10.1177/026921559400800308, 10.1177/026921559400800308]; Grant JS, 2013, TOP STROKE REHABIL, V20, P44, DOI 10.1310/tsr2001-44; Intercollegiate Stroke Working Party, 2006, NAT SENT STROK AUD 2; Intercollegiate Stroke Working Party, 2010, NAT SENT STROK AUD 2; Intercollegiate Stroke Working Party, 2008, NAT CLIN GUID STROK; Kalra L, 2004, BMJ-BRIT MED J, V328, P1099, DOI 10.1136/bmj.328.7448.1099; Larson J, 2005, J CLIN NURS, V14, P995, DOI 10.1111/j.1365-2702.2005.01206.x; Legg LA, 2011, COCHRANE DB SYST REV, V10; Lincoln N B, 1992, Disabil Rehabil, V14, P41; Mackenzie A, 2007, DISABIL REHABIL, V29, P111, DOI 10.1080/09638280600731599; Murray J, 2003, BRIT J GEN PRACT, V53, P803; National Audit Office, 2005, HC452 NAT AUD OFF; Nouri FMLN., 1987, CLIN REHABIL, V1, P301, DOI DOI 10.1177/026921558700100409; Parker CJ, 2001, CLIN REHABIL, V15, P42, DOI 10.1191/026921501666968247; Patel A, 2004, BMJ-BRIT MED J, V328, P1102, DOI 10.1136/bmj.328.7448.1102; Patel A, 2004, STROKE, V35, P196, DOI 10.1161/01.STR.0000105390.20430.9F; Rothwell PM, 2004, LANCET, V363, P1925, DOI 10.1016/S0140-6736(04)16405-2; Tooth L, 2005, BRAIN INJURY, V19, P963, DOI 10.1080/02699050500110785; Ukoumunne OC, 1999, HLTH TECHNOLOGY ASSE, V3, piii, DOI [DOI 10.3310/HTA3050, DOI 10.3310/hta3050]; Visser-Meily A, 2005, PATIENT EDUC COUNS, V56, P257, DOI 10.1016/j.pec.2004.02.013; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	29	85	88	0	39	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 21	2013	382	9910					2069	2076		10.1016/S0140-6736(13)61603-7	http://dx.doi.org/10.1016/S0140-6736(13)61603-7			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	275OX	24054816	Green Accepted			2023-01-03	WOS:000328687800027
J	ten Hoope-Bender, P				ten Hoope-Bender, Petra			Continuity of maternity carer for all women	LANCET			English	Editorial Material							HEALTH		ICS Integrare, CH-1202 Geneva, Switzerland		ten Hoope-Bender, P (corresponding author), ICS Integrare, CH-1202 Geneva, Switzerland.	petra.tenhoope@integrare.es						[Anonymous], 2016, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD003519.PUB3; Hodnett ED, 2013, COCHRANE DB SYST REV, V5; International Confederation of Midwives, INTERNATIONAL DEFINI; Johanson R, 2002, BRIT MED J, V324, P892, DOI 10.1136/bmj.324.7342.892; Requejo J, 2012, COUNTDOWN TO 2015 MA; Sandall J, 2013, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD004667.pub5, 10.1002/14651858.CD004667.pub3]; Souza JP, 2013, LANCET, V381, P1747, DOI 10.1016/S0140-6736(13)60686-8; Tinajero AR, 2010, THE REVIEW OF CARE E; Tracy SK, 2013, LANCET, V382, P1723, DOI 10.1016/S0140-6736(13)61406-3; Villar J, 2006, LANCET, V367, P1819, DOI 10.1016/S0140-6736(06)68704-7	10	5	5	0	7	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 23	2013	382	9906					1685	1687		10.1016/S0140-6736(13)61793-6	http://dx.doi.org/10.1016/S0140-6736(13)61793-6			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	259PX	24050809				2023-01-03	WOS:000327539900008
J	Xia, WX; Ye, YF; Lu, X; Wang, L; Ke, LR; Zhang, HB; Roycik, MD; Yang, J; Shi, JL; Cao, KJ; Guo, X; Xiang, YQ				Xia, Wei-Xiong; Ye, Yan-Fang; Lu, Xing; Wang, Lin; Ke, Liang-Ru; Zhang, Hai-Bo; Roycik, Mark D.; Yang, Jing; Shi, Jun-Li; Cao, Ka-Jia; Guo, Xiang; Xiang, Yan-Qun			The Impact of Baseline Serum C-Reactive Protein and C-Reactive Protein Kinetics on the Prognosis of Metastatic Nasopharyngeal Carcinoma Patients Treated with Palliative Chemotherapy	PLOS ONE			English	Article							RESTING ENERGY-EXPENDITURE; BARR-VIRUS DNA; TUMOR; SCORE; SURVIVAL; EXPRESSION; MANAGEMENT; UPDATE	Background: The aim of this study was to determine whether baseline C-reactive protein (CRP) levels and CRP kinetics predict the overall survival in metastatic nasopharyngeal carcinoma (mNPC) patients. Methods: A total of 116 mNPC patients from January 2006 to July 2011 were retrospectively reviewed. Serum CRP level was measured at baseline and thereafter at the start of each palliative chemotherapy cycle for all patients. Results: Patients with higher values of baseline CRP (>= 3.4 mg/L) had significantly worse survival than those with lower baseline CRP values (< 3.4 mg/L). Patients were divided into four groups according to baseline CRP and CRP kinetics: (1) patients whose CRP < 3.4 mg/L and never elevated during treatment; (2) patients whose CRP < 3.4 mg/L and elevated at least one time during treatment; (3) patients whose CRP >= 3.4 mg/L and normalized at least one time during treatment; and (4) patients whose CRP >= 3.4 mg/L and never normalized during treatment. The patients were further assigned to non-elevated, elevated, normalized, and non-normalized CRP groups. Overall survival rates were significantly different among the four groups, with three-year survival rates of 68%, 41%, 33%, and 0.03% for non-elevated, elevated, normalized, and non-normalized CRP groups respectively. When compared with the non-elevated group, hazard ratios of death were 1.69, 2.57, and 10.34 in the normalized, elevated, and non-normalized groups (P < 0.001). Conclusions: Baseline CRP and CRP kinetics may be useful to predict the prognosis of metastatic NPC patients treated with palliative chemotherapy and facilitate individualized treatment. A prospective study to validate this prognostic model is still needed however.	[Xia, Wei-Xiong; Ye, Yan-Fang; Lu, Xing; Wang, Lin; Ke, Liang-Ru; Zhang, Hai-Bo; Yang, Jing; Shi, Jun-Li; Cao, Ka-Jia; Guo, Xiang; Xiang, Yan-Qun] Sun Yat Sen Univ, Ctr Canc, Dept Nasopharyngeal Carcinoma, Guangzhou 510275, Guangdong, Peoples R China; [Xia, Wei-Xiong; Ye, Yan-Fang; Lu, Xing; Wang, Lin; Ke, Liang-Ru; Zhang, Hai-Bo; Yang, Jing; Shi, Jun-Li; Cao, Ka-Jia; Guo, Xiang; Xiang, Yan-Qun] State Key Lab Oncol Southern China, Guangzhou, Guangdong, Peoples R China; [Ye, Yan-Fang] Sun Yat Sen Univ, Sch Publ Hlth, Dept Biostat & Epidemiol, Guangzhou 510275, Guangdong, Peoples R China; [Roycik, Mark D.] Florida State Univ, Dept Chem & Biochem, Tallahassee, FL 32306 USA; [Roycik, Mark D.] Florida State Univ, Inst Mol Biophys, Tallahassee, FL 32306 USA	Sun Yat Sen University; State Key Lab Oncology South China; Sun Yat Sen University; State University System of Florida; Florida State University; State University System of Florida; Florida State University	Guo, X (corresponding author), Sun Yat Sen Univ, Ctr Canc, Dept Nasopharyngeal Carcinoma, Guangzhou 510275, Guangdong, Peoples R China.	guoxiang@sysucc.org.cn; xiangyq@sysucc.org.cn			National Natural Science Foundation of China [81172041]; Natural Science Foundation of Guangdong Province, China [S2011010005312]; Science and Technology Planning Project of Guangdong Province, China [B031500037]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Guangdong Province, China(National Natural Science Foundation of Guangdong Province); Science and Technology Planning Project of Guangdong Province, China	Supported by National Natural Science Foundation of China (No. 81172041), Natural Science Foundation of Guangdong Province, China (S2011010005312) and Science and Technology Planning Project of Guangdong Province, China (No. B031500037). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ACRES RB, 1987, MOL IMMUNOL, V24, P479, DOI 10.1016/0161-5890(87)90022-8; Allin KH, 2011, CRIT REV CL LAB SCI, V48, P155, DOI 10.3109/10408363.2011.599831; An X, 2011, CANCER-AM CANCER SOC, V117, P3750, DOI 10.1002/cncr.25932; An X, 2011, TUMOR BIOL, V32, P317, DOI 10.1007/s13277-010-0124-7; Bidart JM, 1999, CLIN CHEM, V45, P1695; Cao Su-Mei, 2011, Chin J Cancer, V30, P114; Eliopoulos AG, 1997, ONCOGENE, V14, P2899, DOI 10.1038/sj.onc.1201258; FALCONER JS, 1994, ANN SURG, V219, P325, DOI 10.1097/00000658-199404000-00001; Fandi A, 2000, J CLIN ONCOL, V18, P1324, DOI 10.1200/JCO.2000.18.6.1324; Gioulbasanis I, 2012, LUNG CANCER, V77, P383, DOI 10.1016/j.lungcan.2012.04.008; He JR, 2012, HEAD NECK-J SCI SPEC, V34, P1769, DOI 10.1002/hed.22008; Huang YT, 1999, CANCER RES, V59, P1599; Hui EP, 2004, CANCER-AM CANCER SOC, V101, P300, DOI 10.1002/cncr.20358; Iwanicki-Caron I, 2008, J CLIN ONCOL, V26, P3681, DOI 10.1200/JCO.2007.15.0904; Jin Y, 2012, EUR J CANCER, V48, P882, DOI 10.1016/j.ejca.2011.09.004; KWONG D, 1994, INT J RADIAT ONCOL, V30, P1029, DOI 10.1016/0360-3016(94)90306-9; LEE AWM, 1992, INT J RADIAT ONCOL, V23, P261, DOI 10.1016/0360-3016(92)90740-9; Li XJ, 2012, CARCINOGENESIS, V33, P1302, DOI 10.1093/carcin/bgs181; Lin JC, 2004, NEW ENGL J MED, V350, P2461, DOI 10.1056/NEJMoa032260; Lo YMD, 1999, CANCER RES, V59, P5452; Loong HH, 2008, HEMATOL ONCOL CLIN N, V22, P1267, DOI 10.1016/j.hoc.2008.08.012; Lu X, 2011, EUR J CANCER, V47, P339, DOI 10.1016/j.ejca.2010.09.025; Ma BBY, 2008, CANCER SCI, V99, P1311, DOI 10.1111/j.1349-7006.2008.00836.x; Mahmoud Fade Aziz, 2002, Curr Oncol Rep, V4, P250, DOI 10.1007/s11912-002-0023-1; McMillan DC, 2008, P NUTR SOC, V67, P257, DOI 10.1017/S0029665108007131; Pan CC, 2012, EXP THER MED, V4, P334, DOI 10.3892/etm.2012.584; Pepys MB, 2003, J CLIN INVEST, V111, P1805, DOI 10.1172/JCI200318921; Saito K, 2012, BJU INT, V110, P1478, DOI 10.1111/j.1464-410X.2012.11153.x; Saito K, 2009, EUR UROL, V55, P1145, DOI 10.1016/j.eururo.2008.10.012; Scott HR, 2001, LUNG CANCER, V32, P307, DOI 10.1016/S0169-5002(00)00244-0; Shimoda M, 2010, CHEMOTHERAPY, V56, P501, DOI 10.1159/000321014; Srimuninnimit Vichien, 2012, J Med Assoc Thai, V95 Suppl 2, pS199; VANDENBREKEL AJS, 1995, J CLIN ONCOL, V13, P2600, DOI 10.1200/JCO.1995.13.10.2600; Wee Joseph Tien Seng, 2010, Chin J Cancer, V29, P517; Wei WI, 2005, LANCET, V365, P2041, DOI 10.1016/S0140-6736(05)66698-6; Wo JY, 2009, J CLIN ONCOL, V27, P6000, DOI 10.1200/JCO.2009.23.6067; Wolden SL, 2006, INT J RADIAT ONCOL, V64, P57, DOI 10.1016/j.ijrobp.2005.03.057; Xia WX, 2013, EUR J CANC, P00188; YOUNG LS, 1988, J GEN VIROL, V69, P1051, DOI 10.1099/0022-1317-69-5-1051; ZURHAUSE.H, 1970, NATURE, V228, P1056, DOI 10.1038/2281056a0	40	22	22	2	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 10	2013	8	10							e76958	10.1371/journal.pone.0076958	http://dx.doi.org/10.1371/journal.pone.0076958			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	236QM	24130817	Green Submitted, gold, Green Published			2023-01-03	WOS:000325814200045
J	Zhu, ML; Wang, MY; Shi, TY; Li, QX; Xi, P; Xia, KQ; Zheng, LZ; Wei, QY				Zhu, Mei-Ling; Wang, MengYun; Shi, Ting-Yan; Li, Qiao-Xin; Xi, Pan; Xia, Kai-Qin; Zheng, Leizhen; Wei, Qing-Yi			No Association between TGFB1 Polymorphisms and Late Radiotherapy Toxicity: A Meta-Analysis	PLOS ONE			English	Article							SINGLE NUCLEOTIDE POLYMORPHISMS; NORMAL TISSUE RADIOSENSITIVITY; CANCER PATIENTS; TGF-BETA-1; BREAST; FIBROSIS; XRCC1; RISK; GENE; DNA	Background: Transforming growth factor-beta 1 (TGF-beta 1) protein may be multifunctional and related to the development of fibrosis, induction of apoptosis, extracellular signaling and inhibition of proliferation in response to radiation-induced DNA damage. Several studies have investigated associations between single nucleotide polymorphisms (SNPs) in the TGFB1 gene and risk of late radiation-induced injury of normal tissue, but the conclusions remain controversial. Methods: We searched three electronic databases (i.e., MEDLINE, EMBASE and EBSCO) for eligible publications and performed a meta-analysis assessing the association of three commonly studied SNPs in TGFB1 (i.e., rs1800469, rs1800470 and rs1800471) with risk of late radiation-induced injury of normal tissue. Results: We finally included 28 case-only studies from 16 publications on aforementioned SNPs in TGFB1. However, we did not find statistical evidence of any significant association with overall risk of late radiotherapy toxicity in the pooled analysis or in further stratified analysis by cancer type, endpoint, ethnicity and sample size. Conclusions: This meta-analysis did not find statistical evidence for an association between SNPs in TGFB1 and risk of late radiation-induced injury of normal tissue, but this finding needs further confirmation by a single large study.	[Zhu, Mei-Ling; Xi, Pan; Zheng, Leizhen] Shanghai Jiao Tong Univ, Dept Oncol, Xin Hua Hosp, Sch Med, Shanghai 200030, Peoples R China; [Wang, MengYun; Shi, Ting-Yan; Li, Qiao-Xin; Wei, Qing-Yi] Fudan Univ, Inst Canc, Shanghai Canc Ctr, Shanghai 200433, Peoples R China; [Xia, Kai-Qin] Fudan Univ, Dept Pathol, Shanghai Canc Ctr, Shanghai 200433, Peoples R China; [Wei, Qing-Yi] Univ Texas MD Anderson Canc Ctr, Dept Epidemiol, Houston, TX 77030 USA	Shanghai Jiao Tong University; Fudan University; Fudan University; University of Texas System; UTMD Anderson Cancer Center	Zheng, LZ (corresponding author), Shanghai Jiao Tong Univ, Dept Oncol, Xin Hua Hosp, Sch Med, Shanghai 200030, Peoples R China.	zhengleizhen2006@126.com; weiqingyi@yahoo.com			"China's Thousand Talents Program" Recruitment at Fudan University	"China's Thousand Talents Program" Recruitment at Fudan University	This study was supported by the funds from "China's Thousand Talents Program" Recruitment at Fudan University. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alsbeih G, 2010, RADIAT RES, V173, P505, DOI 10.1667/RR1769.1; Alsner J, 2008, SEMIN RADIAT ONCOL, V18, P126, DOI 10.1016/j.semradonc.2007.10.004; Andreassen CN, 2006, INT J RADIAT BIOL, V82, P577, DOI 10.1080/09553000600876637; Andreassen CN, 2010, RADIOTHER ONCOL, V97, P1, DOI 10.1016/j.radonc.2010.07.018; Andreassen CN, 2003, RADIOTHER ONCOL, V69, P127, DOI 10.1016/j.radonc.2003.09.010; Andreassen CN, 2005, RADIOTHER ONCOL, V75, P18, DOI 10.1016/j.radonc.2004.12.012; Anscher MS, 2010, ONCOLOGIST, V15, P350, DOI 10.1634/theoncologist.2009-S101; ANSCHER MS, 1990, RADIAT RES, V122, P77, DOI 10.2307/3577586; Azria D, 2008, CLIN CANCER RES, V14, P6284, DOI 10.1158/1078-0432.CCR-08-0700; Barnett GC, 2012, RADIOTHER ONCOL, V105, P289, DOI 10.1016/j.radonc.2012.10.017; Barnett GC, 2012, LANCET ONCOL, V13, P65, DOI 10.1016/S1470-2045(11)70302-3; Barnett GC, 2010, RADIOTHER ONCOL, V97, P9, DOI 10.1016/j.radonc.2009.12.006; Bentzen SM, 2006, NAT REV CANCER, V6, P702, DOI 10.1038/nrc1950; Damaraju S, 2006, CLIN CANCER RES, V12, P2545, DOI 10.1158/1078-0432.CCR-05-2703; De Ruyck K, 2006, INT J RADIAT ONCOL, V65, P1240, DOI 10.1016/j.ijrobp.2006.03.047; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Dunning AM, 2003, CANCER RES, V63, P2610; Duval S, 2000, BIOMETRICS, V56, P455, DOI 10.1111/j.0006-341X.2000.00455.x; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Ehrhart EJ, 1997, FASEB J, V11, P991, DOI 10.1096/fasebj.11.12.9337152; El-Gamel A, 1999, J HEART LUNG TRANSPL, V18, P517, DOI 10.1016/S1053-2498(98)00024-2; Evans ES, 2006, CYTOKINE, V35, P186, DOI 10.1016/j.cyto.2006.07.021; Ewan KB, 2002, CANCER RES, V62, P5627; Fachal L, 2012, RADIOTHER ONCOL, V103, P206, DOI 10.1016/j.radonc.2012.01.015; FINKELSTEIN JN, 1994, INT J RADIAT ONCOL, V28, P621, DOI 10.1016/0360-3016(94)90187-2; Giotopoulos G, 2007, BRIT J CANCER, V96, P1001, DOI 10.1038/sj.bjc.6603637; Grainger DJ, 1999, HUM MOL GENET, V8, P93, DOI 10.1093/hmg/8.1.93; Lyons AJ, 2011, OSTEORADIONECROSIS T; MANTEL N, 1959, J NATL CANCER I, V22, P719; Martin M, 2000, INT J RADIAT ONCOL, V47, P277, DOI 10.1016/S0360-3016(00)00435-1; Martin SI, 2010, CONTEMP HEMATOL, P15, DOI 10.1007/978-1-59745-415-5_2; Peters CA, 2008, INT J RADIAT ONCOL, V70, P752, DOI 10.1016/j.ijrobp.2007.05.023; Quarmby S, 2003, INT J RADIAT BIOL, V79, P137, DOI 10.1080/0955300021000045673; Suga T, 2008, INT J RADIAT ONCOL, V72, P808, DOI 10.1016/j.ijrobp.2008.01.029; Terrazzino S, 2012, INT J RADIAT ONCOL, V83, P504, DOI 10.1016/j.ijrobp.2011.06.2012; Thurner EM, 2012, GENETIC VARIANTS TGF; WEST CML, 1995, BRIT J RADIOL, V68, P827, DOI 10.1259/0007-1285-68-812-827; Yokota M, 2000, CIRCULATION, V101, P2783, DOI 10.1161/01.CIR.101.24.2783; Yuan SH, 2013, J THORAC ONCOL, V8, P208, DOI 10.1097/JTO.0b013e318274592e; Zhang G, 2010, ASS POLYMORPHISMS DN; Zschenker O, 2010, RADIOTHER ONCOL, V97, P26, DOI 10.1016/j.radonc.2010.01.016	41	9	9	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 9	2013	8	10							e76964	10.1371/journal.pone.0076964	http://dx.doi.org/10.1371/journal.pone.0076964			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	236PJ	24130819	gold, Green Published, Green Submitted			2023-01-03	WOS:000325810900112
J	Price, CI; Rae, V; Duckett, J; Wood, R; Gray, J; McMeekin, P; Rodgers, H; Portas, K; Ford, GA				Price, Christopher I.; Rae, Victoria; Duckett, Jay; Wood, Ruth; Gray, Joanne; McMeekin, Peter; Rodgers, Helen; Portas, Karen; Ford, Gary A.			An Observational Study of Patient Characteristics Associated with the Mode of Admission to Acute Stroke Services in North East, England	PLOS ONE			English	Article							PREHOSPITAL DELAY; CARE	Objective: Effective provision of urgent stroke care relies upon admission to hospital by emergency ambulance and may involve pre-hospital redirection. The proportion and characteristics of patients who do not arrive by emergency ambulance and their impact on service efficiency is unclear. To assist in the planning of regional stroke services we examined the volume, characteristics and prognosis of patients according to the mode of presentation to local services. Study design and setting: A prospective regional database of consecutive acute stroke admissions was conducted in North East, England between 01/09/10-30/09/11. Case ascertainment and transport mode were checked against hospital coding and ambulance dispatch databases. Results: Twelve acute stroke units contributed data for a mean of 10.7 months. 2792/3131 (89%) patients received a diagnosis of stroke within 24 hours of admission: 2002 arrivals by emergency ambulance; 538 by private transport or non-emergency ambulance; 252 unknown mode. Emergency ambulance patients were older (76 vs 69 years), more likely to be from institutional care (10% vs 1%) and experiencing total anterior circulation symptoms (27% vs 6%). Thrombolysis treatment was commoner following emergency admission (11% vs 4%). However patients attending without emergency ambulance had lower inpatient mortality (2% vs 18%), a lower rate of institutionalisation (1% vs 6%) and less need for daily carers (7% vs 16%). 149/155 (96%) of highly dependent patients were admitted by emergency ambulance, but none received thrombolysis. Conclusion: Presentations of new stroke without emergency ambulance involvement were not unusual but were associated with a better outcome due to younger age, milder neurological impairment and lower levels of pre-stroke dependency. Most patients with a high level of pre-stroke dependency arrived by emergency ambulance but did not receive thrombolysis. It is important to be aware of easily identifiable demographic groups that differ in their potential to gain from different service configurations.	[Price, Christopher I.; Rodgers, Helen; Ford, Gary A.] Newcastle Univ, Stroke Res Grp, Inst Ageing & Hlth, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; [Rae, Victoria; Wood, Ruth; Gray, Joanne; McMeekin, Peter] Newcastle Univ, Inst Hlth & Soc, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; [Duckett, Jay] North East Ambulance Serv NHS Fdn Trust, Newcastle Upon Tyne, Tyne & Wear, England; [Portas, Karen] North England Cardiovasc Network, Darlington, Durham, England	Newcastle University - UK; Newcastle University - UK	Price, CI (corresponding author), Newcastle Univ, Stroke Res Grp, Inst Ageing & Hlth, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England.	c.i.m.price@ncl.ac.uk	Ford, Gary/AAY-6405-2020	Ford, Gary/0000-0001-8719-4968; gray, joanne/0000-0001-6157-230X; McMeekin, Peter/0000-0003-0946-7224; Price, Christopher/0000-0003-3566-3157	NIHR Programme Grant for Applied Research [RP-PG-0606-1241]; National Institute for Health Research [NF-SI-0507-10249, RP-PG-0606-1241] Funding Source: researchfish; Stroke Association [TSAPMF2013/02] Funding Source: researchfish	NIHR Programme Grant for Applied Research; National Institute for Health Research(National Institute for Health Research (NIHR)); Stroke Association	This research was funded by an NIHR Programme Grant for Applied Research (RP-PG-0606-1241). The views and opinions expressed here are those of the authors and do not necessarily reflect those of the Department of Health. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abilleira S, 2011, EUR J NEUROL, V18, P850, DOI 10.1111/j.1468-1331.2010.03258.x; Anonymous, 2007, Morbidity and Mortality Weekly Report, V56, P474; Audebert HJ, 2006, STROKE, V37, P1822, DOI 10.1161/01.STR.0000226741.20629.b2; BONITA R, 1988, STROKE, V19, P1497, DOI 10.1161/01.STR.19.12.1497; Bray Janet E, 2005, Prehosp Emerg Care, V9, P297, DOI 10.1080/10903120590962382; Bray JE, 2011, STROKE, V42, P2154, DOI 10.1161/STROKEAHA.110.612036; Cramer SC, 2012, STROKE, V43, P1089, DOI 10.1161/STROKEAHA.111.635334; Harbison J, 2003, STROKE, V34, P71, DOI 10.1161/01.STR.0000044170.46643.5E; Heuschmann PU, 2011, NEUROLOGY, V76, P159, DOI 10.1212/WNL.0b013e318206ca1e; Intercollegiate Stroke Working Party, 2011, NAT SENT STROK CLIN; Kamel H, 2012, JAMA-J AM MED ASSOC, V307, P1026, DOI 10.1001/jama.2012.285; Kerns JM, 2011, AM J THER, V18, P81, DOI 10.1097/MJT.0b013e3181e123cd; Kidwell CS, 2000, STROKE, V31, P71, DOI 10.1161/01.STR.31.1.71; Kim YS, 2011, BMC NEUROL, V11, DOI 10.1186/1471-2377-11-2; Kleindorfer D, 2010, AM J EMERG MED, V28, P607, DOI 10.1016/j.ajem.2009.02.016; Kwok CS, 2012, J AM GERIATR SOC, V60, P726, DOI 10.1111/j.1532-5415.2011.03889.x; MAHONEY F I, 1965, Md State Med J, V14, P61; Mikulik R, 2011, CEREBROVASC DIS, V32, P342, DOI 10.1159/000330339; Mohammad Yousef M, 2008, J Vasc Interv Neurol, V1, P83; Mosley I, 2007, STROKE, V38, P361, DOI 10.1161/01.STR.0000254528.17405.cc; Nagaraja N, 2012, J NEUROL SCI, V314, P88, DOI 10.1016/j.jns.2011.10.022; National Audit Office, 2005, RED BRAIN DAM FAST A; Price CI, 2009, EXPERT REV NEUROTHER, V9, P211, DOI 10.1586/14737175.9.2.211; Quain DA, 2008, MED J AUSTRALIA, V189, P429, DOI 10.5694/j.1326-5377.2008.tb02114.x; Rymer MM, 2003, STROKE, V34, pE58, DOI 10.1161/01.STR.0000071107.66925.93; Saposnik G, 2011, STROKE, V42, P3421, DOI 10.1161/STROKEAHA.111.623116; Spark JI, 2011, MED J AUSTRALIA, V195, P16, DOI 10.5694/j.1326-5377.2011.tb03181.x; *STROK UN TRAL COL, 2003, ORG INP STROK UN CAR; Teuschl Y, 2010, INT J STROKE, V5, P187, DOI 10.1111/j.1747-4949.2010.00428.x; Turan Tanya N, 2005, J Stroke Cerebrovasc Dis, V14, P272, DOI 10.1016/j.jstrokecerebrovasdis.2005.07.002; Wardlaw JM, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000213.pub2; Weir NU, 2005, J NEUROL NEUROSUR PS, V76, P863, DOI 10.1136/jnnp.2004.053462	32	16	18	0	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 8	2013	8	10							e76997	10.1371/journal.pone.0076997	http://dx.doi.org/10.1371/journal.pone.0076997			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	233FK	24116195	Green Published, Green Accepted, Green Submitted, gold			2023-01-03	WOS:000325552200092
J	Ayles, H; Muyoyeta, M; Du Toit, E; Schaap, A; Floyd, S; Simwinga, M; Shanaube, K; Chishinga, N; Bond, V; Dunbar, R; De Haas, P; James, A; Gey van Pittius, NC; Claassens, M; Fielding, K; Fenty, J; Sismanidis, C; Hayes, RJ; Beyers, N; Godfrey-Faussett, P				Ayles, Helen; Muyoyeta, Monde; Du Toit, Elizabeth; Schaap, Ab; Floyd, Sian; Simwinga, Musonda; Shanaube, Kwame; Chishinga, Nathaniel; Bond, Virginia; Dunbar, Rory; De Haas, Petra; James, Anelet; Gey van Pittius, Nico C.; Claassens, Mareli; Fielding, Katherine; Fenty, Justin; Sismanidis, Charalampos; Hayes, Richard J.; Beyers, Nulda; Godfrey-Faussett, Peter		ZAMSTAR Team	Effect of household and community interventions on the burden of tuberculosis in southern Africa: the ZAMSTAR community-randomised trial	LANCET			English	Article							HIGH HIV PREVALENCE; INFECTIOUS TUBERCULOSIS; TB; DISEASE; ZAMBIA; HARARE; RISK	Background Southern Africa has had an unprecedented increase in the burden of tuberculosis, driven by the HIV epidemic. The Zambia, South Africa Tuberculosis and AIDS Reduction (ZAMSTAR) trial examined two public health interventions that aimed to reduce the burden of tuberculosis by facilitating either rapid sputum diagnosis or integrating tuberculosis and HIV services within the community. Methods ZAMSTAR was a community-randomised trial done in Zambia and the Western Cape province of South Africa. Two interventions, community-level enhanced tuberculosis case-fi nding (ECF) and household level tuberculosis-HIV care, were implemented between Aug 1, 2006, and July 31, 2009, and assessed in a 2x2 factorial design between Jan 9, 2010, and Dec 6, 2010. All communities had a strengthened tuberculosis-HIV programme implemented in participating health-care centres. 24 communities, selected according to population size and tuberculosis notifi cation rate, were randomly allocated to one of four study groups using a randomisation schedule stratifi ed by country and baseline prevalence of tuberculous infection: group 1 strengthened tuberculosis-HIV programme at the clinic alone; group 2, clinic plus ECF; group 3, clinic plus household intervention; and group 4, clinic plus ECF and household interventions. The primary outcome was the prevalence of culture-confi rmed pulmonary tuberculosis in adults (>= 18 years), defi ned as Mycobacterium tuberculosis isolated from one respiratory sample, measured 4 years after the start of interventions in a survey of 4000 randomly selected adults in each community in 2010. The secondary outcome was the incidence of tuberculous infection, measured using tuberculin skin testing in a cohort of schoolchildren, a median of 4 years after a baseline survey done before the start of interventions. This trial is registered, number ISRCTN36729271. Findings Prevalence of tuberculosis was evaluated in 64 463 individuals randomly selected from the 24 communities; 894 individuals had active tuberculosis. Averaging over the 24 communities, the geometric mean of tuberculosis prevalence was 832 per 100 000 population. The adjusted prevalence ratio for the comparison of ECF versus non-ECF intervention groups was 1.09 (95% CI 0.86-1.40) and of household versus non-household intervention groups was 0.82 (0.64-1.04). The incidence of tuberculous infection was measured in a cohort of 8809 children, followed up for a median of 4 years; the adjusted rate ratio for ECF versus non-ECF groups was 1.36 (95% CI 0.59-3.14) and for household versus non-household groups was 0.45 (0.20-1.05). Interpretation Although neither intervention led to a statistically signifi cant reduction in tuberculosis, two independent indicators of burden provide some evidence of a reduction in tuberculosis among communities receiving the household intervention. By contrast the ECF intervention had no eff ect on either outcome.	[Ayles, Helen; De Haas, Petra; Godfrey-Faussett, Peter] London Sch Hyg & Trop Med, Fac Infect & Trop Dis, Dept Clin Res, London WC1, England; [Schaap, Ab; Floyd, Sian; Fielding, Katherine; Fenty, Justin; Sismanidis, Charalampos; Hayes, Richard J.] London Sch Hyg & Trop Med, Fac Epidemiol & Populat Hlth, Dept Infect Dis Epidemiol, London WC1, England; [Bond, Virginia] London Sch Hyg & Trop Med, Fac Publ Hlth & Policy, Dept Global Hlth & Dev, London WC1, England; [Ayles, Helen; Muyoyeta, Monde; Schaap, Ab; Simwinga, Musonda; Shanaube, Kwame; Chishinga, Nathaniel; Bond, Virginia] Univ Zambia, ZAMBART Project, Lusaka, Zambia; [Du Toit, Elizabeth; Dunbar, Rory; James, Anelet; Claassens, Mareli; Beyers, Nulda] Univ Stellenbosch, Dept Paediat & Child Hlth, Desmond Tutu TB Ctr, Cape Town, South Africa; [Gey van Pittius, Nico C.] Univ Stellenbosch, Fac Med & Hlth Sci, Cape Town, South Africa	University of London; London School of Hygiene & Tropical Medicine; University of London; London School of Hygiene & Tropical Medicine; University of London; London School of Hygiene & Tropical Medicine; University of Zambia; Stellenbosch University; Stellenbosch University	Ayles, H (corresponding author), ZAMBART Project, POB 50697, Lusaka, Zambia.	helen@zambart.org.zm	van Pittius, Nicolaas C Gey/D-3434-2015; Trajman, Anete/C-7679-2016; Claassens, Mareli/Y-3544-2019	van Pittius, Nicolaas C Gey/0000-0002-8807-4105; Trajman, Anete/0000-0002-4000-4984; Claassens, Mareli/0000-0002-5927-284X; Fielding, Katherine/0000-0002-6524-3754; Shanaube, Kwame/0000-0001-7899-0890; Ayles, Helen/0000-0003-4108-2842; Hayes, Richard/0000-0002-1729-9892	Bill & Melinda Gates Foundation; Medical Research Council [G0700837] Funding Source: researchfish; MRC [G0700837] Funding Source: UKRI	Bill & Melinda Gates Foundation(Bill & Melinda Gates FoundationCGIAR); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	Bill & Melinda Gates Foundation.	[Anonymous], 2011, GLOB TUB CONTR 2011; Arnadottir T, 1996, TUBERCLE LUNG DIS, V77, P1, DOI 10.1016/S0962-8479(96)90127-6; Ayles H, 2012, 19 C RETR OPP INF 5; Ayles H, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005602; Ayles HM, 2008, TRIALS, V9, DOI 10.1186/1745-6215-9-63; Cavalcante SC, 2007, INT J TUBERC LUNG D, V11, P544; Cavalcante SC, 2010, INT J TUBERC LUNG D, V14, P203; Corbett EL, 2009, INT J TUBERC LUNG D, V13, P1231; Corbett EL, 2010, LANCET, V376, P1244, DOI 10.1016/S0140-6736(10)61425-0; Costello A, 2006, LANCET, V368, P1477, DOI 10.1016/S0140-6736(06)69388-4; den Boon S, 2007, EMERG INFECT DIS, V13, P1189, DOI 10.3201/eid1308.051327; ELLIOTT AM, 1993, TUBERCLE LUNG DIS, V74, P191, DOI 10.1016/0962-8479(93)90010-U; Feachem RGA, 2004, TROP MED INT HEALTH, V9, P1139, DOI 10.1111/j.1365-3156.2004.01343.x; Flores G, 2005, PEDIATRICS, V116, P1433, DOI 10.1542/peds.2005-0786; Glynn JR, 2005, J INFECT DIS, V192, P480, DOI 10.1086/431517; Godfrey-Faussett P, 2000, LANCET, V356, P1066, DOI 10.1016/S0140-6736(00)02730-6; Golub JE, 2005, INT J TUBERC LUNG D, V9, P1183; Hayes RJ, 2009, INTERD STAT, P3; Health Systems Trust, CAP TOWN TB CONTR PR; Kranzer K, 2013, INT J TUBERC LUNG D, V17, P432, DOI 10.5588/ijtld.12.0743; Manandhar DS, 2004, LANCET, V364, P970, DOI 10.1016/S0140-6736(04)17021-9; Middelkoop K, 2011, JAIDS-J ACQ IMM DEF, V56, P263, DOI 10.1097/QAI.0b013e31820413b3; Miller AC, 2010, INT J TUBERC LUNG D, V14, P720; Partnership ST, 2006, GLOB PLAN STOP TB 20; Shanaube K, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007749; Shapiro AE, 2012, AM J RESP CRIT CARE, V185, P1110, DOI 10.1164/rccm.201111-1941OC; Sismanidis C, 2008, CLIN TRIALS, V5, P316, DOI 10.1177/1740774508094747; van't Hoog AH, 2011, AM J RESP CRIT CARE, V183, P1245, DOI 10.1164/rccm.201008-1269OC; Verver S, 2004, INT J EPIDEMIOL, V33, P351, DOI 10.1093/ije/dyh021; Vynnycky E, 1997, EPIDEMIOL INFECT, V119, P183, DOI 10.1017/S0950268897007917; Wood R, 2007, AM J RESP CRIT CARE, V175, P87, DOI 10.1164/rccm.200606-759OC; World Health Organization, 2012, WHO POL COLL TB HIV	32	145	145	0	27	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 5	2013	382	9899					1183	1194		10.1016/S0140-6736(13)61131-9	http://dx.doi.org/10.1016/S0140-6736(13)61131-9			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	228SL	23915882				2023-01-03	WOS:000325209100023
J	Lafontaine, ER; Zimmerman, SM; Shaffer, TL; Michel, F; Gao, XD; Hogan, RJ				Lafontaine, Eric R.; Zimmerman, Shawn M.; Shaffer, Teresa L.; Michel, Frank; Gao, Xiudan; Hogan, Robert J.			Use of a Safe, Reproducible, and Rapid Aerosol Delivery Method to Study Infection by Burkholderia pseudomallei and Burkholderia mallei in Mice	PLOS ONE			English	Article							POLYSACCHARIDE MICROARRAY TECHNOLOGY; CAPSULAR POLYSACCHARIDE; MOLECULAR CHARACTERIZATION; SUBTRACTIVE HYBRIDIZATION; IN-VITRO; MELIOIDOSIS; GLANDERS; VIRULENCE; IDENTIFICATION; BALB/C	Burkholderia pseudomallei, the etiologic agent of melioidosis, is a saprophytic bacterium readily isolated from wet soils of countries bordering the equator. Burkholderia mallei is a host-adapted clone of B. pseudomallei that does not persist outside of its equine reservoir and causes the zoonosis glanders, which is endemic in Asia, Africa, the Middle East and South America. Infection by these organisms typically occurs via percutaneous inoculation or inhalation of aerosols, and the most common manifestation is severe pneumonia leading to fatal bacteremia. Glanders and melioidosis are difficult to diagnose and require prolonged antibiotic therapy with low success rates. There are no vaccines available to protect against either Burkholderia species, and there is concern regarding their use as biological warfare agents given that B. mallei has previously been utilized in this manner. Hence, experiments were performed to establish a mouse model of aerosol infection to study the organisms and develop countermeasures. Using a hand-held aerosolizer, BALB/c mice were inoculated intratracheally with strains B. pseudomallei 1026b and B. mallei ATCC23344 and growth of the agents in the lungs, as well as dissemination to the spleen, were examined. Mice infected with 10(2), 10(3) and 10(4) organisms were unable to control growth of B. mallei in the lungs and bacteria rapidly disseminated to the spleen. Though similar results were observed in mice inoculated with 10(3) and 10(4) B. pseudomallei cells, animals infected with 10(2) organisms controlled bacterial replication in the lungs, dissemination to the spleen, and the extent of bacteremia. Analysis of sera from mice surviving acute infection revealed that animals produced antibodies against antigens known to be targets of the immune response in humans. Taken together, these data show that small volume aerosol inoculation of mice results in acute disease, dose-dependent chronic infection, and immune responses that correlate with those seen in human infections.	[Lafontaine, Eric R.; Zimmerman, Shawn M.] Univ Georgia, Dept Infect Dis, Athens, GA 30602 USA; [Shaffer, Teresa L.] Univ Georgia, Dept Microbiol, Athens, GA 30602 USA; [Michel, Frank; Gao, Xiudan; Hogan, Robert J.] Univ Georgia, Dept Vet Biosci & Diagnost Imaging, Athens, GA 30602 USA	University System of Georgia; University of Georgia; University System of Georgia; University of Georgia; University System of Georgia; University of Georgia	Hogan, RJ (corresponding author), Univ Georgia, Dept Vet Biosci & Diagnost Imaging, Athens, GA 30602 USA.	jhogan@uga.edu			DTRA [HDTRA1-09-1-0003]	DTRA(United States Department of DefenseDefense Threat Reduction Agency)	This study was supported by DTRA contract HDTRA1-09-1-0003. The funders had input in the study design and decision to publish (DTRA PA-13-325). The funders had no role in data collection and analysis or preparation of the manuscript.	Adler NRL, 2009, FEMS MICROBIOL REV, V33, P1079, DOI 10.1111/j.1574-6976.2009.00189.x; Alibek K, 1999, BIOHAZARD CHILLING T; Andreu N, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010777; Anuntagool N, 2002, MICROBIOL IMMUNOL, V46, P143, DOI 10.1111/j.1348-0421.2002.tb02679.x; Arun S, 1999, VET REC, V144, P255, DOI 10.1136/vr.144.10.255; ATOYNATAN T, 1969, AM J EPIDEMIOL, V89, P472, DOI 10.1093/oxfordjournals.aje.a120959; Balder R, 2007, INFECT IMMUN, V75, P2765, DOI 10.1128/IAI.00079-07; Balder R, 2010, BMC MICROBIOL, V10, DOI 10.1186/1471-2180-10-250; Barnes KB, 2013, INT J ANTIMICROB AG, V41, P552, DOI 10.1016/j.ijantimicag.2013.02.007; Bivas-Benita M, 2005, EUR J PHARM BIOPHARM, V61, P214, DOI 10.1016/j.ejpb.2005.04.009; Bondi SK, 2008, EXPERT REV VACCINES, V7, P1357, DOI 10.1586/14760584.7.9.1357; Bryan L E, 1994, Can J Infect Dis, V5, P170; Burtnick MN, 2012, FRONT CELL INFECT MI, V2, DOI 10.3389/fcimb.2012.00108; Burtnick MN, 1999, ANTIMICROB AGENTS CH, V43, P2648, DOI 10.1128/AAC.43.11.2648; Carr-Gregory B, 2007, MED ASPECTS BIOL WAR, P121; Chandenier J, 2009, MYCOSES, V52, P239, DOI 10.1111/j.1439-0507.2009.01695.x; Cheng AC, 2005, CLIN MICROBIOL REV, V18, P383, DOI 10.1128/CMR.18.2.383-416.2005; Cowell R, 2008, DIAGNOSTIC CYTOLOGY, P238; Cowell R, 2002, DIAGNOSTIC CYTOLOGY, P70; Currie BJ, 2000, T ROY SOC TROP MED H, V94, P301, DOI 10.1016/S0035-9203(00)90333-X; Currie BJ, 2000, CLIN INFECT DIS, V31, P981, DOI 10.1086/318116; Dance DAB, 2000, ACTA TROP, V74, P115, DOI 10.1016/S0001-706X(99)00059-5; DeShazer D, 2001, MICROB PATHOGENESIS, V30, P253, DOI 10.1006/mpat.2000.0430; DeShazer D, 1998, MOL MICROBIOL, V30, P1081, DOI 10.1046/j.1365-2958.1998.01139.x; DeShazer D, 1997, J BACTERIOL, V179, P2116, DOI 10.1128/jb.179.7.2116-2125.1997; Felgner PL, 2009, P NATL ACAD SCI USA, V106, P13499, DOI 10.1073/pnas.0812080106; Funk CJ, 2009, J GEN VIROL, V90, P2956, DOI 10.1099/vir.0.014282-0; Galyov EE, 2010, ANNU REV MICROBIOL, V64, P495, DOI 10.1146/annurev.micro.112408.134030; Goff AJ, 2011, J VIROL, V85, P4898, DOI 10.1128/JVI.02525-10; Goodyear A, 2012, INFECT IMMUN, V80, P110, DOI 10.1128/IAI.05819-11; Goodyear A, 2010, J IMMUNOL, V184, P1445, DOI 10.4049/jimmunol.0900411; Goodyear A, 2009, INFECT IMMUN, V77, P1579, DOI 10.1128/IAI.01384-08; Harkema JR, 2006, TOXICOL PATHOL, V34, P252, DOI 10.1080/01926230600713475; Ho M, 1997, INFECT IMMUN, V65, P3648, DOI 10.1128/IAI.65.9.3648-3653.1997; Holden MTG, 2004, P NATL ACAD SCI USA, V101, P14240, DOI 10.1073/pnas.0403302101; Howe C., 1950, OXFORD MED, P185; Jeddeloh JA, 2003, INFECT IMMUN, V71, P584, DOI 10.1128/IAI.71.1.584-587.2003; Judy BM, 2009, BMC MICROBIOL, V9, DOI 10.1186/1471-2180-9-88; KNIREL YA, 1992, CARBOHYD RES, V233, P185, DOI 10.1016/S0008-6215(00)90930-3; Kortepeter M, 2001, USAMRIIDS MED MANAGE, P44; Lehavi O, 2002, HAREFUAH, V141, P88; Lever MS, 2009, INT J EXP PATHOL, V90, P16, DOI 10.1111/j.1365-2613.2008.00619.x; Lever MS, 2003, J MED MICROBIOL, V52, P1109, DOI 10.1099/jmm.0.05180-0; Lipsitz R., 2012, EMERG INFECT DIS, V18, pe2; Lipski SL, 2007, INFECT IMMUN, V75, P314, DOI 10.1128/IAI.01330-06; Majerczyk C, 2013, INFECT IMMUN, V81, P1471, DOI 10.1128/IAI.00048-13; Massey S, 2011, FRONT MICROBIOL, V2, DOI 10.3389/fmicb.2011.00174; Munder A, 2002, EXP TOXICOL PATHOL, V54, P127, DOI 10.1078/0940-2993-00240; Neubauer H., 1997, Revue Internationale des Services de Sante des Forces Armees, V70, P258; Nierman WC, 2004, P NATL ACAD SCI USA, V101, P14246, DOI 10.1073/pnas.0403306101; Owen SJ, 2009, J INFECT DIS, V199, P1761, DOI 10.1086/599210; Parthasarathy N, 2008, CARBOHYD RES, V343, P2783, DOI 10.1016/j.carres.2008.05.021; Parthasarathy N, 2008, J CARBOHYD CHEM, V27, P32, DOI 10.1080/07328300802030761; Parthasarathy N, 2006, DIAGN MICR INFEC DIS, V56, P329, DOI 10.1016/j.diagmicrobio.2006.04.018; PERRY MB, 1995, INFECT IMMUN, V63, P3348, DOI 10.1128/IAI.63.9.3348-3352.1995; Peyron P, 2001, J BIOL CHEM, V276, P35512, DOI 10.1074/jbc.M104399200; Prakash H, 2010, J BIOL CHEM, V285, P20291, DOI 10.1074/jbc.M109.096297; Reckseidler SL, 2001, INFECT IMMUN, V69, P34, DOI 10.1128/IAI.69.1.34-44.2001; Reed L.J., 1938, AM J HYG, V27, P793; Regis E, 1999, BIOL DOOM; Revelli DA, 2012, FRONT CELL INFECT MI, V2, DOI 10.3389/fcimb.2012.00164; Rolim DB, 2005, EMERG INFECT DIS, V11, P1458, DOI 10.3201/eid1109.050493; Sambrook J., 2001, MOL CLONING LAB MANU, V3; SHOHAM D, 1998, NONPROLIFERATION REV, V5, P48, DOI DOI 10.1080/10736709808436720; Sim BMQ, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-8-r89; Smart JK, 1997, TXB MILITARY MED, P16; Song H, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000922; Srinivasan A, 2001, NEW ENGL J MED, V345, P256, DOI 10.1056/NEJM200107263450404; Su X, 2004, EXP LUNG RES, V30, P479, DOI 10.1080/01902140490476382; Tan GYG, 2008, J MED MICROBIOL, V57, P508, DOI 10.1099/jmm.0.47596-0; Thibault FM, 2004, J ANTIMICROB CHEMOTH, V54, P1134, DOI 10.1093/jac/dkh471; Titball Richard W, 2008, Trans R Soc Trop Med Hyg, V102 Suppl 1, pS111, DOI 10.1016/S0035-9203(08)70026-9; Tiyawisutsri R, 2007, BMC MICROBIOL, V7, DOI 10.1186/1471-2180-7-19; Ulrich RL, 2005, VACCINE, V23, P1986, DOI 10.1016/j.vaccine.2004.10.017; Vietri N. J., 2007, MED ASPECTS BIOL WAR, P147; Viktorov Dimitry V, 2008, Trans R Soc Trop Med Hyg, V102 Suppl 1, pS103, DOI 10.1016/S0035-9203(08)70025-7; Waag DM, 2004, BIOL WEAPONS DEFENSE; Warawa JM, 2011, FRONT MICROBIOL, V2, DOI 10.3389/fmicb.2011.00133; Warawa JM, 2010, FRONT MICROBIOL, V1, DOI 10.3389/fmicb.2010.00141; Weiss D, 2010, SCHALMS VET HEMATOLO, P270; Wheelis M, 1998, NATURE, V395, P213, DOI 10.1038/26089; Wheelis M., 1999, BIOLOGICAL TOXIN WEA, P35; White NJ, 2003, LANCET, V361, P1715, DOI 10.1016/S0140-6736(03)13374-0; Whitlock GC, 2007, FEMS MICROBIOL LETT, V277, P115, DOI 10.1111/j.1574-6968.2007.00949.x; Whitlock GC, 2009, J MED MICROBIOL, V58, P554, DOI 10.1099/jmm.0.007724-0; Wiersinga WJ, 2012, NEW ENGL J MED, V367, P1035, DOI 10.1056/NEJMra1204699; Wiersinga WJ, 2009, CURR OPIN INFECT DIS, V22, P102, DOI 10.1097/QCO.0b013e328322e727; Wiersinga WJ, 2006, NAT REV MICROBIOL, V4, P272, DOI 10.1038/nrmicro1385; Zou NX, 2008, HYBRIDOMA, V27, P231, DOI 10.1089/hyb.2008.0012	89	23	23	0	20	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 2	2013	8	10							e76804	10.1371/journal.pone.0076804	http://dx.doi.org/10.1371/journal.pone.0076804			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	231RG	24098563	Green Published, Green Submitted, gold			2023-01-03	WOS:000325434500085
J	Guan, SJ; Ma, JJ; Zhang, Y; Gao, YG; Zhang, YY; Zhang, X; Wang, N; Xie, Y; Wang, JY; Zhang, JP; Chu, L				Guan, Shengjiang; Ma, Juanjuan; Zhang, Ying; Gao, Yonggang; Zhang, Yuanyuan; Zhang, Xuan; Wang, Na; Xie, Yun; Wang, Jiangyan; Zhang, Jianping; Chu, Li			Danshen (Salvia miltiorrhiza) Injection Suppresses Kidney Injury Induced by Iron Overload in Mice	PLOS ONE			English	Article							RAT CORONARY-ARTERY; CALCIUM-CHANNELS; LITHOSPERMATE-B; ACID-B; INHIBITION; METABOLISM; CHEMISTRY; CARDIOMYOCYTES; APOPTOSIS; EXTRACT	Objectives: Excessive iron can accumulate in the kidney and induce tissue damage. Danshen (Salvia miltiorrhiza) injection is a traditional Chinese medicinal preparation used for preventing and treating chronic renal failure. The aim of the present study was to evaluate the effects of treatment with Danshen injection on iron overload-induced kidney damage. Methods: Mice were mock-treated with saline (control group) or given a single dose of iron dextran without treatment (iron overload group, 50 mg/kg/day for 2 weeks) or with daily treatments of low-dose Danshen (3 g/kg/day), high-dose Danshen (6 g/kg/day) or deferoxamine (100 mg/kg/day). Results: Treatment of iron-overloaded mice with Danshen injection led to significant improvements of body weight and decreased iron levels in the kidney. Danshen injection treatment also reduced concentrations of blood urea nitrogen, creatinine and malondialdehyde and enhanced glutathione peroxidase and superoxide dismutase activities. Histopathological examinations showed that Danshen injection ameliorated pathological changes and reduced iron deposition in kidneys of iron overloaded mice. Furthermore, the treatment was demonstrated to suppress apoptosis in nephrocytes. Conclusions: These results indicated that Danshen injection exerted significant renal protective effects in iron-overloaded mice, which were closely associated with the decrease of iron deposition and suppression of lipid peroxidation and apoptosis in the kidney.	[Guan, Shengjiang; Ma, Juanjuan; Zhang, Ying; Gao, Yonggang; Zhang, Yuanyuan; Zhang, Xuan; Wang, Na; Xie, Yun; Zhang, Jianping; Chu, Li] Hebei Med Univ, Sch Basic Med, Dept Pharmacol, Shijiazhuang, Peoples R China; [Wang, Jiangyan] Bethune Mil Med Coll, Dept Biochem, Shijiazhuang, Peoples R China	Hebei Medical University	Zhang, JP (corresponding author), Hebei Med Univ, Sch Basic Med, Dept Pharmacol, Shijiazhuang, Peoples R China.	zhangjianping14@126.com; chuli0614@126.com	zhang, yuanyuan/GYA-4428-2022		Nature Fund of Hebei Province, China [C2011206025]; Fund of Hebei Science and Technology Bureau [10276105D-2]	Nature Fund of Hebei Province, China; Fund of Hebei Science and Technology Bureau	This work was supported by the Nature Fund of Hebei Province, China (No. C2011206025) and the Fund of Hebei Science and Technology Bureau (No. 10276105D-2). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aisen P, 2001, INT J BIOCHEM CELL B, V33, P940, DOI 10.1016/S1357-2725(01)00063-2; ALREFAIE FN, 1992, BLOOD, V80, P593; Andrews NC, 1999, NEW ENGL J MED, V341, P1986, DOI 10.1056/NEJM199912233412607; Berdoukas V, 2012, J BLOOD MED, V3, P119, DOI 10.2147/JBM.S27400; Cao CM, 2003, LIFE SCI, V72, P2451, DOI 10.1016/S0024-3205(03)00142-5; Chen CG, 2006, ACTA PHARMACOL SIN, V27, P217, DOI 10.1111/j.1745-7254.2006.00225.x; DILLARD CJ, 1984, LIPIDS, V19, P127, DOI 10.1007/BF02534503; Fraga CG, 2002, TOXICOLOGY, V180, P23, DOI 10.1016/S0300-483X(02)00379-7; Fu JJ, 2007, EUR J PHARMACOL, V568, P213, DOI 10.1016/j.ejphar.2007.04.031; Galleano M, 1997, TOXICOLOGY, V124, P73, DOI 10.1016/S0300-483X(97)00135-2; Gambling L, 2002, BIOL REPROD, V66, P516, DOI 10.1095/biolreprod66.2.516; Gao YG, 2013, J ETHNOPHARMACOL, V145, P254, DOI 10.1016/j.jep.2012.10.060; Geisser P, 1997, Met Based Drugs, V4, P137, DOI 10.1155/MBD.1997.137; Hentze MW, 2004, CELL, V117, P285, DOI 10.1016/S0092-8674(04)00343-5; Katafuchi R, 1998, CLIN NEPHROL, V49, P1; Kudo H, 2008, TOXICOLOGY, V246, P143, DOI 10.1016/j.tox.2008.01.004; Lam FFY, 2006, EUR J PHARMACOL, V553, P240, DOI 10.1016/j.ejphar.2006.09.030; Lam FFY, 2007, VASC PHARMACOL, V46, P271, DOI 10.1016/j.vph.2006.10.011; Lee TY, 2006, J PHARM PHARMACOL, V58, P659, DOI 10.1211/jpp.58.5.0011; LI JL, 1987, CANCER RES, V47, P1867; Miyajima H, 1997, ANN NEUROL, V41, P404, DOI 10.1002/ana.410410318; Ong-ajyooth L, 1998, NEPHRON, V78, P156, DOI 10.1159/000044904; Oudit GY, 2003, NAT MED, V9, P1187, DOI 10.1038/nm920; PARKS RR, 1994, LARYNGOSCOPE, V104, P1389; SHIH W, 1988, KIDNEY INT, V33, P1113, DOI 10.1038/ki.1988.119; Soung DY, 2003, J PHARM PHARMACOL, V55, P1427, DOI 10.1211/0022357021891; Tsushima RG, 1999, CIRC RES, V84, P1302, DOI 10.1161/01.RES.84.11.1302; Wang XH, 2007, MED RES REV, V27, P133, DOI 10.1002/med.20077; Zhang Y, 2013, J ETHNOPHARMACOL, V148, P671, DOI 10.1016/j.jep.2013.05.028; Zhao BL, 1996, BIOCHEM MOL BIOL INT, V38, P1171; Zhao GR, 2008, FOOD CHEM TOXICOL, V46, P73, DOI 10.1016/j.fct.2007.06.034; Zhou LM, 2005, J CLIN PHARMACOL, V45, P1345, DOI 10.1177/0091270005282630; Zou C, 2012, J ALTERN COMPLEM MED, V18, P394, DOI 10.1089/acm.2011.0041	33	26	29	0	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 16	2013	8	9							e74318	10.1371/journal.pone.0074318	http://dx.doi.org/10.1371/journal.pone.0074318			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	219GJ	24066136	Green Published, Green Submitted, gold			2023-01-03	WOS:000324494000118
J	Mueller, KL				Mueller, Kristen L.			The Future Is Now INTRODUCTION	SCIENCE			English	Editorial Material																			0	2	4	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 13	2013	341	6151					1191	1191		10.1126/science.341.6151.1191	http://dx.doi.org/10.1126/science.341.6151.1191			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	215ZA	24031010				2023-01-03	WOS:000324248800030
J	Miklas, JW; Dallabrida, SM; Reis, LA; Ismail, N; Rupnick, M; Radisic, M				Miklas, Jason W.; Dallabrida, Susan M.; Reis, Lewis A.; Ismail, Nesreen; Rupnick, Maria; Radisic, Milica			QHREDGS Enhances Tube Formation, Metabolism and Survival of Endothelial Cells in Collagen-Chitosan Hydrogels	PLOS ONE			English	Article							DESIGNED ANGIOPOIETIN-1 VARIANT; BIOMIMETIC SURFACTANT POLYMERS; IN-VIVO; LUMEN FORMATION; BLOOD-FLOW; PEPTIDE; ADHESION; MORPHOGENESIS; BIOMATERIALS; MIGRATION	Cell survival in complex, vascularized tissues, has been implicated as a major bottleneck in advancement of therapies based on cardiac tissue engineering. This limitation motivates the search for small, inexpensive molecules that would simultaneously be cardio-protective and vasculogenic. Here, we present peptide sequence QHREDGS, based upon the fibrinogen-like domain of angiopoietin-1, as a prime candidate molecule. We demonstrated previously that QHREDGS improved cardiomyocyte metabolism and mitigated serum starved apoptosis. In this paper we further demonstrate the potency of QHREDGS in its ability to enhance endothelial cell survival, metabolism and tube formation. When endothelial cells were exposed to the soluble form of QHREDGS, improvements in endothelial cell barrier functionality, nitric oxide production and cell metabolism (ATP levels) in serum starved conditions were found. The functionality of the peptide was then examined when conjugated to collagen-chitosan hydrogel, a potential carrier for in vivo application. The presence of the peptide in the hydrogel mitigated paclitaxel induced apoptosis of endothelial cells in a dose dependent manner. Furthermore, the peptide modified hydrogels stimulated tube-like structure formation of encapsulated endothelial cells. When integrin alpha v beta 3 or alpha 5 beta 1were antibody blocked during cell encapsulation in peptide modified hydrogels, tube formation was abolished. Therefore, the dual protective nature of the novel peptide QHREDGS may position this peptide as an appealing augmentation for collagen-chitosan hydrogels that could be used for biomaterial delivered cell therapies in the settings of myocardial infarction.	[Miklas, Jason W.; Reis, Lewis A.; Radisic, Milica] Univ Toronto, Inst Biomat & Biomed Engn, Toronto, ON, Canada; [Dallabrida, Susan M.; Ismail, Nesreen] Beth Israel Deaconess Med Ctr, Vasc Biol Res Ctr, Boston, MA 02215 USA; [Rupnick, Maria] Brigham & Womens Hosp, Div Cardiovasc, Boston, MA 02115 USA; [Rupnick, Maria] Harvard Univ, Sch Med, Boston, MA USA; [Radisic, Milica] Univ Toronto, Dept Chem Engn & Appl Chem, Toronto, ON, Canada	University of Toronto; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; University of Toronto	Radisic, M (corresponding author), Univ Toronto, Inst Biomat & Biomed Engn, Toronto, ON, Canada.	m.radisic@utoronto.ca		Miklas, Jason/0000-0002-9002-0667	NSERC [STPGP 381002-09, RGPIN 326982-10]; NSERC-CIHR [CHRPJ 385981-10]; Discovery Accelerator Supplement [RGPAS 396125-10]; ORF GL2 grant; McLean Award	NSERC(Natural Sciences and Engineering Research Council of Canada (NSERC)); NSERC-CIHR(Natural Sciences and Engineering Research Council of Canada (NSERC)Canadian Institutes of Health Research (CIHR)); Discovery Accelerator Supplement; ORF GL2 grant; McLean Award	The authors wish to acknowledge the following funding sources: NSERC Strategic Grant (STPGP 381002-09), NSERC-CIHR Collaborative Health Research Grant (CHRPJ 385981-10), NSERC Discovery Grant (RGPIN 326982-10) and Discovery Accelerator Supplement (RGPAS 396125-10), ORF GL2 grant and McLean Award (to MR). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Augustin HG, 2009, NAT REV MOL CELL BIO, V10, P165, DOI 10.1038/nrm2639; Bayless KJ, 2000, AM J PATHOL, V156, P1673, DOI 10.1016/S0002-9440(10)65038-9; BREDT DS, 1994, ANNU REV BIOCHEM, V63, P175, DOI 10.1146/annurev.bi.63.070194.001135; Camenisch G, 2002, J BIOL CHEM, V277, P17281, DOI 10.1074/jbc.M109768200; Carlson TR, 2001, J BIOL CHEM, V276, P26516, DOI 10.1074/jbc.M100282200; Cascone I, 2005, J CELL BIOL, V170, P993, DOI 10.1083/jcb.200507082; Chiu LLY, 2010, MACROMOL BIOSCI, V10, P1286, DOI 10.1002/mabi.201000202; Chiu LLY, 2010, BIOMATERIALS, V31, P226, DOI 10.1016/j.biomaterials.2009.09.039; Cho CH, 2005, CIRC RES, V97, P86, DOI 10.1161/01.RES.0000174093.64855.a6; Cho CH, 2004, P NATL ACAD SCI USA, V101, P5547, DOI 10.1073/pnas.0307574101; Cho CH, 2004, P NATL ACAD SCI USA, V101, P5553, DOI 10.1073/pnas.0307575101; Coultas L, 2005, NATURE, V438, P937, DOI 10.1038/nature04479; Dallabrida Susan M, 2005, Circ Res, V96, pe8, DOI 10.1161/01.RES.0000158285.57191.60; David S, 2011, ARTERIOSCL THROM VAS, V31, P2643, DOI 10.1161/ATVBAHA.111.233189; Davis GE, 1996, EXP CELL RES, V224, P39, DOI 10.1006/excr.1996.0109; Davis George E., 2007, Birth Defects Research, V81, P270, DOI 10.1002/bdrc.20107; DeBusk LM, 2004, EXP CELL RES, V298, P167, DOI 10.1016/j.yexcr.2004.04.013; Fachinger G, 1999, ONCOGENE, V18, P5948, DOI 10.1038/sj.onc.1202992; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; Fukuhara S, 2008, NAT CELL BIOL, V10, P513, DOI 10.1038/ncb1714; Gavard J, 2008, DEV CELL, V14, P25, DOI 10.1016/j.devcel.2007.10.019; Guarnieri D, 2010, ACTA BIOMATER, V6, P2532, DOI 10.1016/j.actbio.2009.12.050; Hanjaya-Putra D, 2011, BLOOD, V118, P804, DOI 10.1182/blood-2010-12-327338; Harrison DG, 1997, J CLIN INVEST, V100, P2153, DOI 10.1172/JCI119751; Hersel U, 2003, BIOMATERIALS, V24, P4385, DOI 10.1016/S0142-9612(03)00343-0; Holland J, 1996, BIOMATERIALS, V17, P2147, DOI 10.1016/0142-9612(96)00028-2; Ilan N, 2003, CURR OPIN CELL BIOL, V15, P515, DOI 10.1016/S0955-0674(03)00100-5; Ismail NS, 2010, J INVEST DERMATOL, V130, P1307, DOI 10.1038/jid.2009.431; Khan OF, 2011, TRENDS BIOTECHNOL, V29, P379, DOI 10.1016/j.tibtech.2011.03.004; Kim I, 2000, CIRC RES, V86, P24, DOI 10.1161/01.RES.86.1.24; Koblizek TI, 1998, CURR BIOL, V8, P529, DOI 10.1016/S0960-9822(98)70205-2; Kwak HJ, 1999, FEBS LETT, V448, P249, DOI 10.1016/S0014-5793(99)00378-6; Lee K, 2011, J R SOC INTERFACE, V8, P153, DOI 10.1098/rsif.2010.0223; Mammoto T, 2007, J BIOL CHEM, V282, P23910, DOI 10.1074/jbc.M702169200; Mikos AG, 2006, TISSUE ENG, V12, P3307, DOI 10.1089/ten.2006.12.3307; Mochizuki N, 2009, CIRC J, V73, P2183, DOI 10.1253/circj.CJ-09-0666; Newman PJ, 2003, ARTERIOSCL THROM VAS, V23, P953, DOI 10.1161/01.ATV.0000071347.69358.D9; Noll G, 1998, EUR HEART J, V19, pC30; Oubaha M, 2009, BLOOD, V114, P3343, DOI 10.1182/blood-2008-12-196584; Papapetropoulos A, 2000, J BIOL CHEM, V275, P9102, DOI 10.1074/jbc.275.13.9102; Phelps EA, 2010, P NATL ACAD SCI USA, V107, P3323, DOI 10.1073/pnas.0905447107; Place ES, 2009, NAT MATER, V8, P457, DOI [10.1038/nmat2441, 10.1038/NMAT2441]; Rask F, 2010, SOFT MATTER, V6, P5089, DOI 10.1039/c0sm00362j; Rask F, 2010, J BIOMED MATER RES A, V95A, P105, DOI 10.1002/jbm.a.32808; Reis LA, 2012, ACTA BIOMATER, V8, P1022, DOI 10.1016/j.actbio.2011.11.030; Rustad KC, 2010, ORGANOGENESIS, V6, P151, DOI 10.4161/org.6.3.12139; Sagnella S, 2005, TISSUE ENG, V11, P226, DOI 10.1089/ten.2005.11.226; Sagnella SM, 2004, BIOMATERIALS, V25, P1249, DOI 10.1016/S0142-9612(03)00634-3; Saharinen P, 2008, NAT CELL BIOL, V10, P527, DOI 10.1038/ncb1715; Tinsley JH, 2000, AM J PHYSIOL-CELL PH, V279, pC1285, DOI 10.1152/ajpcell.2000.279.4.C1285; Topper JN, 1999, MOL MED TODAY, V5, P40, DOI 10.1016/S1357-4310(98)01372-0; van der Heijden M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023448; Van Slyke P, 2009, TISSUE ENG PT A, V15, P1269, DOI 10.1089/ten.tea.2007.0400; Wang X, 2012, J BIOMED MATER RES A, V100A, P794, DOI 10.1002/jbm.a.34026; Zhang C, 2013, J BIOMEDICAL MAT R A	55	30	30	0	34	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 27	2013	8	8							e72956	10.1371/journal.pone.0072956	http://dx.doi.org/10.1371/journal.pone.0072956			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	210FR	24013716	Green Submitted, Green Published, gold			2023-01-03	WOS:000323815200061
J	Kemmling, A; Lev, MH; Payabvash, S; Betensky, RA; Qian, J; Masrur, S; Schwamm, LH				Kemmling, Andre; Lev, Michael H.; Payabvash, Seyedmehdi; Betensky, Rebecca A.; Qian, Jing; Masrur, Shihab; Schwamm, Lee H.			Hospital Acquired Pneumonia Is Linked to Right Hemispheric Peri-Insular Stroke	PLOS ONE			English	Article							ACUTE ISCHEMIC-STROKE; LATERALIZATION; CORTEX; COMPLICATIONS; INFECTION; IMMUNODEPRESSION; CONSEQUENCES; LOCALIZATION; PREDICTORS; ACTIVATION	Purpose: Hospital acquired pneumonia (HAP) is a major complication of stroke. We sought to determine associations between infarction of specific brain regions and HAP. Methods: 215 consecutive acute stroke patients with HAP (2003-2009) were carefully matched with 215 non-pneumonia controls by gender, then NIHSS, then age. Admission imaging and binary masks of infarction were registered to MNI-152 space. Regional atlas and voxel-based log-odds were calculated to assess the relationship between infarct location and the likelihood of HAP. An independently validated penalized conditional logistic regression model was used to identify HAP associated imaging regions. Results: The HAP and control patients were well matched by gender (100%), age (95% within 5-years), NIHSS (98% within 1-point), infarct size, dysphagia, and six other clinical variables. Right hemispheric infarcts were more frequent in patients with HAP versus controls (43.3% vs. 34.0%, p = 0.054), whereas left hemispheric infarcts were more frequent in controls (56.7% vs. 44.7%, p = 0.012); there was no significant difference between groups in the rate of brainstem strokes (p = 1.0). Of the 10 most infarcted regions, only right insular cortex volume was different in HAP versus controls (20 vs. 12 ml, p = 0.02). In univariate analyses, the highest log-odds regions for pneumonia were right hemisphere, cerebellum, and brainstem. The best performing multivariate model selected 7 brain regions of infarction and 2 infarct volume-based variables independently associated with HAP. Conclusions: HAP is associated with right hemispheric peri-insular stroke. These associations may be related to autonomic modulation of immune mechanisms, supporting recent hypotheses of stroke mediated immune suppression.	[Kemmling, Andre; Lev, Michael H.; Payabvash, Seyedmehdi] Harvard Univ, Sch Med, Dept Radiol, Div Neuroradiol,Massachusetts Gen Hosp, Boston, MA 02115 USA; [Betensky, Rebecca A.; Qian, Jing] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA; [Kemmling, Andre] Univ Med Ctr Hamburg Eppendorf, Dept Diagnost & Intervent Neuroradiol, Hamburg, Germany; [Masrur, Shihab; Schwamm, Lee H.] Harvard Univ, Dept Neurol, Massachusetts Gen Hosp, Sch Med, Boston, MA 02115 USA; [Qian, Jing] Univ Massachusetts, Div Biostat & Epidemiol, Amherst, MA 01003 USA	Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard T.H. Chan School of Public Health; University of Hamburg; University Medical Center Hamburg-Eppendorf; Harvard University; Harvard Medical School; Massachusetts General Hospital; University of Massachusetts System; University of Massachusetts Amherst	Kemmling, A (corresponding author), Harvard Univ, Sch Med, Dept Radiol, Div Neuroradiol,Massachusetts Gen Hosp, Boston, MA 02115 USA.	a.kemmling@uke.de	Payabvash, Sam/I-1859-2019	Payabvash, Sam/0000-0003-4628-0370; Schwamm, Lee/0000-0003-0592-9145	National Institutes of Health [NIH CA075971]; NATIONAL CANCER INSTITUTE [R01CA075971, R29CA075971] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	The study was supported in part by the National Institutes of Health (NIH CA075971). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aslanyan S, 2004, EUR J NEUROL, V11, P49, DOI 10.1046/j.1468-1331.2003.00749.x; CECHETTO DF, 1990, AM J PHYSIOL, V258, pR245, DOI 10.1152/ajpregu.1990.258.1.R245; Colivicchi F, 2004, STROKE, V35, P2094, DOI 10.1161/01.STR.0000138452.81003.4c; Davenport RJ, 1996, STROKE, V27, P415, DOI 10.1161/01.STR.27.3.415; Desikan RS, 2006, NEUROIMAGE, V31, P968, DOI 10.1016/j.neuroimage.2006.01.021; Dirnagl U, 2007, STROKE, V38, P770, DOI 10.1161/01.STR.0000251441.89665.bc; Foerch C, 2005, LANCET, V366, P392, DOI 10.1016/S0140-6736(05)67024-9; Fonarow GC, 2010, CIRC-CARDIOVASC QUAL, V3, P291, DOI 10.1161/CIRCOUTCOMES.109.921858; Harms H, 2011, CEREBROVASC DIS, V32, P552, DOI 10.1159/000331922; Hernandez SAR, 2003, HYPERTENSION, V42, P56, DOI 10.1161/01.HYP.0000077983.66161.6F; Hilker R, 2003, STROKE, V34, P975, DOI 10.1161/01.STR.0000063373.70993.CD; Hua K, 2008, NEUROIMAGE, V39, P336, DOI 10.1016/j.neuroimage.2007.07.053; Hug A, 2009, STROKE, V40, P3226, DOI 10.1161/STROKEAHA.109.557967; Johnston KC, 1998, STROKE, V29, P447, DOI 10.1161/01.STR.29.2.447; Kalra L, 1995, STROKE J CEREBRAL CI; Kammersgaard L P, 2001, J Stroke Cerebrovasc Dis, V10, P217, DOI 10.1053/jscd.2001.30366; Katzan IL, 2007, NEUROLOGY, V68, P1938, DOI 10.1212/01.wnl.0000263187.08969.45; Kim H, 2000, ARCH NEUROL-CHICAGO, V57, P478, DOI 10.1001/archneur.57.4.478; Koch HJ, 2006, NEUROIMMUNOMODULAT, V13, P8, DOI 10.1159/000092108; Masrur S, 2013, J STROKE CEREBROVASC; Meader KJ, 1999, NEUROLOGY, V52, P1183, DOI 10.1212/WNL.52.6.1183; Meador KJ, 2004, ANN NEUROL, V55, P840, DOI 10.1002/ana.20105; Meisel C, 2005, NAT REV NEUROSCI, V6, P775, DOI 10.1038/nrn1765; Meyer S, 2004, NEUROREPORT, V15, P357, DOI 10.1097/00001756-200402090-00029; Minnerup J, 2009, J NEUROL NEUROSUR PS, P1; Neveu P. J., 1992, BRAIN RES REV; Nichols T, 2003, STAT METHODS MED RES, V12, P419, DOI 10.1191/0962280203sm341ra; Ovbiagele Bruce, 2006, J Stroke Cerebrovasc Dis, V15, P209; Pittock Sean J, 2003, J Stroke Cerebrovasc Dis, V12, P175, DOI 10.1016/S1052-3057(03)00078-8; Pittock Sean J, 2003, J Stroke Cerebrovasc Dis, V12, P1; SANDER D, 1995, J NEUROL, V242, P313, DOI 10.1007/BF00878874; Steinhagen V, 2009, STROKE, V40, P1903, DOI 10.1161/STROKEAHA.108.535468; Tarkowski E, 1998, SCAND J IMMUNOL, V47, P30; TARKOWSKI E, 1991, J NEUROIMMUNOL, V34, P61, DOI 10.1016/0165-5728(91)90099-S; Upadya A, 2004, J CRIT CARE, V19, P16, DOI 10.1016/j.jcrc.2004.02.004; Vargas M, 2006, STROKE, V37, P461, DOI 10.1161/01.STR.0000199138.73365.b3; Walter U, 2007, J NEUROL, V254, P1323, DOI 10.1007/s00415-007-0520-0; Weimar C, 2002, STROKE, V33, P2053, DOI 10.1161/01.STR.0000022808.21776.BF; Weimar C, 2002, EUR NEUROL, V48, P133, DOI 10.1159/000065512	39	32	36	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 7	2013	8	8							e71141	10.1371/journal.pone.0071141	http://dx.doi.org/10.1371/journal.pone.0071141			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	200ZE	23951094	Green Submitted, Green Published, gold			2023-01-03	WOS:000323109700081
J	Kong, J; Spaeth, R; Cook, A; Kirsch, I; Claggett, B; Vangel, M; Gollub, RL; Smoller, JW; Kaptchuk, TJ				Kong, Jian; Spaeth, Rosa; Cook, Amanda; Kirsch, Irving; Claggett, Brian; Vangel, Mark; Gollub, Randy L.; Smoller, Jordan W.; Kaptchuk, Ted J.			Are All Placebo Effects Equal? Placebo Pills, Sham Acupuncture, Cue Conditioning and Their Association	PLOS ONE			English	Article							DISPOSITIONAL OPTIMISM; ANALGESIA; EXPECTANCY; NEEDLE; DISSOCIATION; MECHANISMS; TRIALS; BLIND; FMRI	Placebo treatments and healing rituals have been used to treat pain throughout history. The present within-subject crossover study examines the variability in individual responses to placebo treatment with verbal suggestion and visual cue conditioning by investigating whether responses to different types of placebo treatment, as well as conditioning responses, correlate with one another. Secondarily, this study also examines whether responses to sham acupuncture correlate with responses to genuine acupuncture. Healthy subjects were recruited to participate in two sequential experiments. Experiment one is a five-session crossover study. In each session, subjects received one of four treatments: placebo pills (described as Tylenol), sham acupuncture, genuine acupuncture, or no treatment rest control condition. Before and after each treatment, paired with a verbal suggestion of positive effect, each subject's pain threshold, pain tolerance, and pain ratings to calibrated heat pain were measured. At least 14 days after completing experiment one, all subjects were invited to participate in experiment two, during which their analgesic responses to conditioned visual cues were tested. Forty-eight healthy subjects completed experiment one, and 45 completed experiment two. The results showed significantly different effects of genuine acupuncture, placebo pill and rest control on pain threshold. There was no significant association between placebo pills, sham acupuncture and cue conditioning effects, indicating that individuals may respond to unique healing rituals in different ways. This outcome suggests that placebo response may be a complex behavioral phenomenon that has properties that comprise a state, rather than a trait characteristic. This could explain the difficulty of detecting a signature for "placebo responders." However, a significant association was found between the genuine and sham acupuncture treatments, implying that the non-specific effects of acupuncture may contribute to the analgesic effect observed in genuine acupuncture analgesia.	[Kong, Jian; Spaeth, Rosa; Cook, Amanda; Gollub, Randy L.; Smoller, Jordan W.] Massachusetts Gen Hosp, Dept Psychiat, Charlestown, MA USA; [Kong, Jian; Spaeth, Rosa; Cook, Amanda; Gollub, Randy L.; Smoller, Jordan W.] Harvard Univ, Sch Med, Charlestown, MA USA; [Kirsch, Irving; Kaptchuk, Ted J.] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Program Placebo Studies, Boston, MA 02215 USA; [Kirsch, Irving] Univ Plymouth, Sch Psychol, Plymouth PL4 8AA, Devon, England; [Claggett, Brian] Harvard Univ, Sch Med, Div Cardiovasc Med, Boston, MA USA; [Claggett, Brian] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA; [Vangel, Mark] MGH MIT HMS Athinoula A Martinos Ctr Biomed Imagi, Charlestown, MA USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; University of Plymouth; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health	Kong, J (corresponding author), Massachusetts Gen Hosp, Dept Psychiat, Charlestown, MA USA.	kongj@nmr.mgh.harvard.edu	Kirsch, Irving/P-9316-2019	Gollub, Randy L./0000-0002-9434-4044	NCCAM [KO1AT003883, R21AT004497, R01AT006364, R01AT005280, K24AT004095, P01 AT006663]; NIDA [R03AT218317]; NIMH [K24MH094614]; NATIONAL CENTER FOR COMPLEMENTARY & ALTERNATIVE MEDICINE [R01AT005280] Funding Source: NIH RePORTER; NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE [K01AT003883, R21AT004497] Funding Source: NIH RePORTER; National Center for Complementary & Integrative Health [K24AT004095, R01AT006364, P01AT006663] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [K24MH094614] Funding Source: NIH RePORTER	NCCAM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NIDA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIMH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL CENTER FOR COMPLEMENTARY & ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); National Center for Complementary & Integrative Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))	This work was supported by KO1AT003883 (NCCAM), R21AT004497 (NCCAM), R03AT218317 (NIDA), and R01AT006364 (NCCAM) to Jian Kong; R01AT005280 (NCCAM) to Randy Gollub; K24AT004095 (NCCAM) to Ted Kaptchuk; K24MH094614 (NIMH) to Jordan W. Smoller, and P01 AT006663 (NCCAM) to Bruce Rosen. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bingel U, 2006, PAIN, V120, P8, DOI 10.1016/j.pain.2005.08.027; Bingel U, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3001244; Brody H, 2011, JAMA-J AM MED ASSOC, V306, P2612, DOI 10.1001/jama.2011.1850; Charron J, 2006, CLIN J PAIN, V22, P204, DOI 10.1097/01.ajp.0000161526.25374.e5; Cheng XN, 1987, CHINESE ACUPUNCTURE, P513; Colloca L, 2008, PAIN, V139, P306, DOI 10.1016/j.pain.2008.04.021; CONOVER WJ, 1982, BIOMETRICS, V38, P715, DOI 10.2307/2530051; de Craen AJM, 2000, J NEUROL, V247, P183, DOI 10.1007/s004150050560; De Pascalis V, 2002, PAIN, V96, P393, DOI 10.1016/S0304-3959(01)00485-7; Finniss DG, 2010, LANCET, V375, P686, DOI 10.1016/S0140-6736(09)61706-2; Geers AL, 2005, J PSYCHOSOM RES, V58, P121, DOI 10.1016/j.jpsychores.2004.08.011; Geers AL, 2010, J PAIN, V11, P1165, DOI 10.1016/j.jpain.2010.02.014; GELFAND S, 1964, CAN J PSYCHOLOGY, V18, P36, DOI 10.1037/h0083283; GOLDMAN AR, 1965, J NERV MENT DIS, V140, P272, DOI 10.1097/00005053-196504000-00003; GRACELY RH, 1978, PAIN, V5, P5, DOI 10.1016/0304-3959(78)90020-9; Gracely RH, 1994, TXB PAIN, P315; GRENFELL RF, 1961, JAMA-J AM MED ASSOC, V176, P124, DOI 10.1001/jama.1961.03040150040010; Hrobjartsson A, 2001, NEW ENGL J MED, V344, P1594, DOI 10.1056/NEJM200105243442106; Hrobjartsson A, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003974.pub3; HUBER PJ, 1973, ANN STAT, V1, P799, DOI 10.1214/aos/1176342503; Kaptchuk TJ, 2008, CONTEMP CLIN TRIALS, V29, P587, DOI 10.1016/j.cct.2008.02.002; Kaptchuk TJ, 2011, PHILOS T R SOC B, V366, P1849, DOI 10.1098/rstb.2010.0385; Kaptchuk TJ, 2006, BMJ-BRIT MED J, V332, P391, DOI 10.1136/bmj.38726.603310.55; Kaptchuk TJ, 2000, J CLIN EPIDEMIOL, V53, P786, DOI 10.1016/S0895-4356(00)00206-7; Kaptchuk TJ, 2002, ANN INTERN MED, V136, P374, DOI 10.7326/0003-4819-136-5-200203050-00010; Kleinhenz J, 1999, PAIN, V83, P235, DOI 10.1016/S0304-3959(99)00107-4; Kong J, 2006, J NEUROSCI, V26, P381, DOI 10.1523/JNEUROSCI.3556-05.2006; Kong J, 2005, J PAIN, V6, P55, DOI 10.1016/j.jpain.2004.10.005; Kong J, 2007, J ALTERN COMPLEM MED, V13, P1059, DOI 10.1089/acm.2007.0524; Kong J, 2013, PAIN, V154, P459, DOI 10.1016/j.pain.2012.12.004; Kong J, 2009, NEUROIMAGE, V47, P1066, DOI 10.1016/j.neuroimage.2009.05.087; Kong J, 2009, NEUROIMAGE, V45, P940, DOI 10.1016/j.neuroimage.2008.12.025; Kong J, 2008, J NEUROSCI, V28, P13354, DOI 10.1523/JNEUROSCI.2944-08.2008; Linde K, 2010, BMC MED, V8, DOI 10.1186/1741-7015-8-75; Linde K, 2010, FORSCH KOMPLEMENTMED, V17, P259, DOI 10.1159/000320374; Montgomery GH, 1997, PAIN, V72, P107, DOI 10.1016/S0304-3959(97)00016-X; Morton DL, 2009, PAIN, V146, P194, DOI 10.1016/j.pain.2009.07.026; Price DD, 1999, PAIN, V83, P147, DOI 10.1016/S0304-3959(99)00081-0; ROBERTS AH, 1993, CLIN PSYCHOL REV, V13, P375, DOI 10.1016/0272-7358(93)90010-J; Shapiro Elaine, 1997, POWERFUL PLACEBO ANC; Streitberger K, 1998, LANCET, V352, P364, DOI 10.1016/S0140-6736(97)10471-8; Stux G, 1997, BASICS ACUPUNCTURE, P110; TRAUT EF, 1956, ARCH INTERN MED, V98, P181, DOI 10.1001/archinte.1956.00250260055007; TRAUT EF, 1957, ANN RHEUM DIS, V16, P18, DOI 10.1136/ard.16.1.18; Vickers AJ, 2012, ARCH INTERN MED, V172, P1444, DOI 10.1001/archinternmed.2012.3654; VOUDOURIS NJ, 1990, PAIN, V43, P121, DOI 10.1016/0304-3959(90)90057-K; Wager TD, 2004, SCIENCE, V303, P1162, DOI 10.1126/science.1093065; Wasan AD, 2010, J PAIN, V11, P555, DOI 10.1016/j.jpain.2009.09.013; Whalley B, 2008, J PSYCHOSOM RES, V64, P537, DOI 10.1016/j.jpsychores.2007.11.007; White P, 2003, PAIN, V106, P401, DOI 10.1016/j.pain.2003.08.013	50	66	68	1	40	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 31	2013	8	7							e67485	10.1371/journal.pone.0067485	http://dx.doi.org/10.1371/journal.pone.0067485			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	194LB	23935833	Green Submitted, Green Published, gold			2023-01-03	WOS:000322633700004
J	Costa, EC; Gaspar, VM; Marques, JG; Coutinho, P; Correia, IJ				Costa, Elisabete C.; Gaspar, Vitor M.; Marques, Joao G.; Coutinho, Paula; Correia, Ilidio J.			Evaluation of Nanoparticle Uptake in Co-culture Cancer Models	PLOS ONE			English	Article							DRUG-DELIVERY; BREAST-CANCER; CELL-CULTURE; MICROENVIRONMENTAL INFLUENCES; EXTRACELLULAR-MATRIX; TUMOR-CELLS; FIBROBLASTS; THERAPEUTICS; NANOTECHNOLOGY; MECHANISMS	Co-culture models are currently bridging the gap between classical cultures and in vivo animal models. Exploring this novel approach unlocks the possibility to mimic the tumor microenvironment in vitro, through the establishment of cancer-stroma synergistic interactions. Notably, these organotypic models offer a perfect platform for the development and preclinical evaluation of candidate nanocarriers loaded with anti-tumoral drugs in a high throughput screening mode, with lower costs and absence of ethical issues. However, this evaluation was until now limited to co-culture systems established with precise cell ratios, not addressing the natural cell heterogeneity commonly found in different tumors. Therefore, herein the multifunctional nanocarriers efficiency was characterized in various fibroblast-MCF-7 co-culture systems containing different cell ratios, in order to unravel key design parameters that influence nanocarrier performance and the therapeutic outcome. The successful establishment of the co-culture models was confirmed by the tissue-like distribution of the different cells in culture. Nanoparticles incubation in the various co-culture systems reveals that these nanocarriers possess targeting specificity for cancer cells, indicating their suitability for being used in this illness therapy. Additionally, by using different co-culture ratios, different nanoparticle uptake profiles were obtained. These findings are of crucial importance for the future design and optimization of new drug delivery systems, since their real targeting capacity must be addressed in heterogenous cell populations, such as those found in tumors.	[Costa, Elisabete C.; Gaspar, Vitor M.; Marques, Joao G.; Coutinho, Paula; Correia, Ilidio J.] Univ Beira Interior, CICS, Covilha, Portugal; [Coutinho, Paula] Unidade Invest Desenvolvimento Interior UDI, Guarda, Portugal	Universidade da Beira Interior	Correia, IJ (corresponding author), Univ Beira Interior, CICS, Covilha, Portugal.	icorreia@ubi.pt	Gaspar, Vítor/B-1602-2017; Gaspar, Vítor/AAB-3045-2022; Correia, I. J./AAE-2400-2020; Correia, Ilidio/S-8295-2016; Coutinho, Paula/H-5423-2013	Gaspar, Vítor/0000-0002-0372-2493; Correia, I. J./0000-0003-1613-9675; Correia, Ilidio/0000-0003-1613-9675; Coutinho, Paula/0000-0001-6832-3082; Costa, Elisabete/0000-0002-0490-0095	Portuguese Foundation for Science and Technology (FCT) [SFRH/BD/80402/2011, PTDC/EME-TME/103375/2008, PTDC/EBB-BIO/114320/2009, PEst-OE/EGE/UI4056/2011]	Portuguese Foundation for Science and Technology (FCT)(Portuguese Foundation for Science and Technology)	This work was supported by the Portuguese Foundation for Science and Technology (FCT), SFRH/BD/80402/2011, PTDC/EME-TME/103375/2008, PTDC/EBB-BIO/114320/2009 and PEst-OE/EGE/UI4056/2011. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Allen TM, 2002, NAT REV CANCER, V2, P750, DOI 10.1038/nrc903; Allred DC, 2008, CLIN CANCER RES, V14, P370, DOI 10.1158/1078-0432.CCR-07-1127; BASKIN LS, 1993, J UROLOGY, V150, P1260, DOI 10.1016/S0022-5347(17)35757-9; Ben-Baruch A, 2003, BREAST CANCER RES, V5, P31, DOI 10.1186/bcr554; Bhowmick NA, 2004, NATURE, V432, P332, DOI 10.1038/nature03096; Bissell MJ, 2007, BIOCHEM SOC T, V35, P18, DOI 10.1042/BST0350018; Bissell MJ, 2002, DIFFERENTIATION, V70, P537, DOI 10.1046/j.1432-0436.2002.700907.x; Borchard G, 2001, ADV DRUG DELIVER REV, V52, P145, DOI 10.1016/S0169-409X(01)00198-3; Borm P, 2006, TOXICOL SCI, V90, P23, DOI 10.1093/toxsci/kfj084; Burguera EF, 2010, EUR CELLS MATER, V19, P166, DOI 10.22203/eCM.v019a17; Cho KJ, 2008, CLIN CANCER RES, V14, P1310, DOI 10.1158/1078-0432.CCR-07-1441; Cirri P, 2012, CANCER METAST REV, V31, P195, DOI 10.1007/s10555-011-9340-x; Duell BL, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/852419; ENGEL LW, 1978, CANCER RES, V38, P4327; Feinberg AP, 2006, NAT REV GENET, V7, P21, DOI 10.1038/nrg1748; Gaspar VM, 2011, J CONTROL RELEASE, V156, P212, DOI 10.1016/j.jconrel.2011.08.007; Gaspar VM, 2013, NANOTECHNOL IN PRESS, V24, DOI [10.1088/0957-4484/1024/1027/275101, DOI 10.1088/0957-4484/1024/1027/275101]; Heneweer M, 2005, TOXICOL SCI, V83, P257, DOI 10.1093/toxsci/kfi025; HogenEsch H, 2012, J CONTROL RELEASE, V164, P183, DOI 10.1016/j.jconrel.2012.02.031; Iamazaki ET, 2004, COLLOID POLYM SCI, V283, P33, DOI 10.1007/s00396-004-1083-6; KNAZEK RA, 1977, J NATL CANCER I, V58, P419, DOI 10.1093/jnci/58.2.419; Ko YH, 2011, CANCER BIOL THER, V12, P1085, DOI 10.4161/cbt.12.12.18671; Krause S, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-263; Le Droumaguet B, 2012, ACS NANO, V6, P5866, DOI 10.1021/nn3004372; Liotta LA, 2001, NATURE, V411, P375, DOI 10.1038/35077241; Liu LX, 2010, J NANOPART RES, V12, P1637, DOI 10.1007/s11051-009-9722-y; Loeffler M, 2006, J CLIN INVEST, V116, P1955, DOI 10.1172/JCI26532; Lu PF, 2012, J CELL BIOL, V196, P395, DOI 10.1083/jcb.201102147; Luo K, 2012, BIOMATERIALS, V33, P4917, DOI 10.1016/j.biomaterials.2012.03.030; Malvezzi M, 2012, ANN ONCOL, V23, P1044, DOI 10.1093/annonc/mds024; Martinez-Outschoorn UE, 2011, CELL CYCLE, V10, P2521, DOI 10.4161/cc.10.15.16584; Martinez-Outschoorn UE, 2010, CELL CYCLE, V9, P2423, DOI 10.4161/cc.9.12.12048; Miki Y, 2012, J STEROID BIOCHEM, V131, P68, DOI 10.1016/j.jsbmb.2011.12.004; Mitra S, 2012, CANCER SCI, V103, P400, DOI 10.1111/j.1349-7006.2011.02183.x; Moreira C, 2009, ACTA BIOMATER, V5, P2995, DOI 10.1016/j.actbio.2009.04.021; Moses MA, 2003, CANCER CELL, V4, P337, DOI 10.1016/S1535-6108(03)00276-9; Nagpal K, 2010, CHEM PHARM BULL, V58, P1423, DOI 10.1248/cpb.58.1423; Nakase I, 2012, J CONTROL RELEASE, V159, P181, DOI 10.1016/j.jconrel.2012.01.016; Ostman A, 2012, NAT MED, V18, P1332, DOI 10.1038/nm.2938; Parveen S, 2012, NANOMED-NANOTECHNOL, V8, P147, DOI 10.1016/j.nano.2011.05.016; Polyak K, 2009, TRENDS GENET, V25, P30, DOI 10.1016/j.tig.2008.10.012; Purpura KA, 2012, BIOMATERIALS, V33, P1271, DOI 10.1016/j.biomaterials.2011.10.051; Santos JL, 2010, MOL PHARMACEUT, V7, P763, DOI 10.1021/mp9002877; Shi JJ, 2010, NANO LETT, V10, P3223, DOI 10.1021/nl102184c; Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166; Sinha R, 2006, MOL CANCER THER, V5, P1909, DOI 10.1158/1535-7163.MCT-06-0141; SOULE HD, 1973, J NATL CANCER I, V51, P1409, DOI 10.1093/jnci/51.5.1409; STAMMATI AP, 1981, TOXICOLOGY, V20, P91, DOI 10.1016/0300-483X(81)90046-9; Straussman R, 2012, NATURE, V487, P500, DOI 10.1038/nature11183; Strell C, 2012, UPSALA J MED SCI, V117, P187, DOI 10.3109/03009734.2012.654859; STREULI CH, 1991, J CELL BIOL, V115, P1383, DOI 10.1083/jcb.115.5.1383; Suzuki T, 2002, J BIOL CHEM, V277, P2437, DOI 10.1074/jbc.M110017200; Tumarkin E, 2011, INTEGR BIOL-UK, V3, P653, DOI 10.1039/c1ib00002k; Wagner V, 2006, NAT BIOTECHNOL, V24, P1211, DOI 10.1038/nbt1006-1211; Weigelt B, 2008, SEMIN CANCER BIOL, V18, P311, DOI 10.1016/j.semcancer.2008.03.013; Whitaker-Menezes D, 2011, CELL CYCLE, V10, P1772, DOI 10.4161/cc.10.11.15659; Wu H, 2013, BIOMATERIALS, V34, P1213, DOI 10.1016/j.biomaterials.2012.08.072; Yih TC, 2006, J CELL BIOCHEM, V97, P1184, DOI 10.1002/jcb.20796	58	38	38	0	36	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 26	2013	8	7							e70072	10.1371/journal.pone.0070072	http://dx.doi.org/10.1371/journal.pone.0070072			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	197GU	23922909	Green Published, gold, Green Submitted			2023-01-03	WOS:000322838900141
J	Marshall, CS; Curtis, AJ; Spelman, T; O'Brien, DP; Greig, J; Shanks, L; du Cros, P; Casas, EC; da Fonseca, MS; Athan, E; Elliott, JH				Marshall, Catherine S.; Curtis, Andrea J.; Spelman, Tim; O'Brien, Daniel P.; Greig, Jane; Shanks, Leslie; du Cros, Philipp; Casas, Esther C.; da Fonseca, Marcio Silveira; Athan, Eugene; Elliott, Julian H.			Impact of Hiv-Associated Conditions on Mortality in People Commencing Anti-Retroviral Therapy in Resource Limited Settings	PLOS ONE			English	Article							RECONSTITUTION INFLAMMATORY SYNDROME; SUB-SAHARAN AFRICA; CRYPTOCOCCAL MENINGITIS; IMMUNE RECONSTITUTION; 1ST YEAR; TUBERCULOSIS; OUTCOMES; PREDICTORS; PROGRAM; BURDEN	Objectives: To identify associations between specific WHO stage 3 and 4 conditions diagnosed after ART initiation and all cause mortality for patients in resource-limited settings (RLS). Design, Setting: Analysis of routine program data collected prospectively from 25 programs in eight countries between 2002 and 2010. Subjects, Participants: 36,664 study participants with median ART follow-up of 1.26 years (IQR 0.55-2.27). Outcome Measures: Using a proportional hazards model we identified factors associated with mortality, including the occurrence of specific WHO clinical stage 3 and 4 conditions during the 6-months following ART initiation. Results: There were 2922 deaths during follow-up (8.0%). The crude mortality rate was 5.41 deaths per 100 person-years (95% CI: 5.21-5.61). The diagnosis of any WHO stage 3 or 4 condition during the first 6 months of ART was associated with increased mortality (HR: 2.21; 95% CI: 1.97-2.47). After adjustment for age, sex, region and pre-ART CD4 count, a diagnosis of extrapulmonary cryptococcosis (aHR: 3.54; 95% CI: 2.74-4.56), HIV wasting syndrome (aHR: 2.92; 95% CI: 2.21 -3.85), non-tuberculous mycobacterial infection (aHR: 2.43; 95% CI: 1.80-3.28) and Pneumocystis pneumonia (aHR: 2.17; 95% CI 1.80-3.28) were associated with the greatest increased mortality. Cerebral toxoplasmosis, pulmonary and extra-pulmonary tuberculosis, Kaposi's sarcoma and oral and oesophageal candidiasis were associated with increased mortality, though at lower rates. Conclusions: A diagnosis of certain WHO stage 3 and 4 conditions is associated with an increased risk of mortality in those initiating ART in RLS. This information will assist initiatives to reduce excess mortality, including prioritization of resources for diagnostics, therapeutic interventions and research.	[Marshall, Catherine S.; Elliott, Julian H.] Alfred Hosp, Infect Dis Unit, Melbourne, Vic, Australia; [Curtis, Andrea J.; Spelman, Tim; Elliott, Julian H.] Monash Univ, Dept Epidemiol & Prevent Med, Melbourne, Vic 3004, Australia; [Spelman, Tim; Elliott, Julian H.] Burnet Inst, Ctr Populat Hlth, Melbourne, Vic, Australia; [O'Brien, Daniel P.; Shanks, Leslie; Casas, Esther C.; da Fonseca, Marcio Silveira] Medecins Sans Frontieres, Dept Publ Hlth, Amsterdam, Netherlands; [O'Brien, Daniel P.; Athan, Eugene] Geelong Hosp, Dept Infect Dis, Geelong, Vic, Australia; [O'Brien, Daniel P.] Univ Melbourne, Royal Melbourne Hosp, Dept Med & Infect Dis, Melbourne, Vic 3050, Australia; [Greig, Jane; du Cros, Philipp] Medecins Sans Frontieres, Manson Unit, London, England; [Athan, Eugene] Deakin Univ, Sch Med, Geelong, Vic 3217, Australia	Florey Institute of Neuroscience & Mental Health; Monash University; Burnet Institute; Doctors Without Borders; Geelong Hospital; Royal Melbourne Hospital; University of Melbourne; Doctors Without Borders; Deakin University	Marshall, CS (corresponding author), Royal Darwin Hosp, Div Med, Darwin, NT, Australia.	catherine.marshall@nt.gov.au	O'Brien, Daniel/ABE-9658-2020	O'Brien, Daniel/0000-0001-5418-3330; du Cros, Philipp/0000-0002-3599-029X; Curtis, Andrea/0000-0003-2407-770X; Greig, Jane/0000-0003-2732-0023; Athan, Eugene/0000-0001-9838-6471	M�decins Sans Fronti�res [OCA_pilot_00_Greig, OCA_ERB_009_20_OBrien] Funding Source: researchfish	M�decins Sans Fronti�res		Alemu AW, 2010, GLOBAL HEALTH ACTION, V3, DOI 10.3402/gha.v3i0.5398; [Anonymous], 1992, MMWR Recomm Rep, V41, P1; [Anonymous], 2011, AUT REAL TIM NUCL AC; Bicanic T, 2007, CLIN INFECT DIS, V45, P76, DOI 10.1086/518607; Bisson GP, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001725; Braitstein P, 2006, LANCET, V367, P817, DOI 10.1016/S0140-6736(06)68337-2; Curtis AJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052019; Etard JF, 2006, AIDS, V20, P1181, DOI 10.1097/01.aids.0000226959.87471.01; Haddow LJ, 2010, LANCET INFECT DIS, V10, P791, DOI 10.1016/S1473-3099(10)70170-5; Jarvis JN, 2010, CLIN INFECT DIS, V51, P1463, DOI 10.1086/657405; Johannessen A, 2008, BMC INFECT DIS, V8, DOI 10.1186/1471-2334-8-52; Kambugu A, 2008, CLIN INFECT DIS, V46, P1694, DOI 10.1086/587667; Keiser O, 2008, PLOS MED, V5, P1102, DOI 10.1371/journal.pmed.0050148; Kingkaew N, 2009, INT J INFECT DIS, V13, P722, DOI 10.1016/j.ijid.2008.11.013; Koole O, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018502; Lawn SD, 2005, AIDS, V19, P2141, DOI 10.1097/01.aids.0000194802.89540.e1; Lawn SD, 2008, AM J RESP CRIT CARE, V177, P680, DOI 10.1164/rccm.200709-1311PP; Lawn SD, 2006, AIDS, V20, P1605, DOI 10.1097/01.aids.0000238406.93249.cd; Lawn SD, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001067; Lawn SD, 2010, AIDS, V24, P1323, DOI 10.1097/QAD.0b013e3283390dd1; Lessells RJ, 2011, SAMJ S AFR MED J, V101, P251, DOI 10.7196/SAMJ.4378; Lynen L, 2006, CLIN HIV AIDS CARE G; Marazzi MC, 2008, AIDS RES HUM RETROV, V24, P555, DOI 10.1089/aid.2007.0217; May M, 2010, LANCET, V376, P449, DOI 10.1016/S0140-6736(10)60666-6; Meintjes G, 2008, LANCET INFECT DIS, V8, P516, DOI 10.1016/S1473-3099(08)70184-1; Meya DB, 2010, CLIN INFECT DIS, V51, P448, DOI 10.1086/655143; Mocroft A, 2009, CLIN INFECT DIS, V48, P1138, DOI 10.1086/597468; Moore D, 2007, AIDS, V21, P713, DOI 10.1097/QAD.0b013e328013f632; Ojikutu B, 2008, SAMJ S AFR MED J, V98, P204; Sloan DJ, 2009, CURR OPIN INFECT DIS, V22, P455, DOI 10.1097/QCO.0b013e32832fa214; WHO, 2010, ANT THER HIV INF AD; Wilson D, 2011, INT J TUBERC LUNG D, V15, P919, DOI 10.5588/ijtld.10.0440; World Health Organisation, 2006, ANT THER AD AD RES L; World Health Organization, 2004, SCAL ANT THER RES LT; World Health Organization, 2004, TB HIV CLIN MAN, V2nd; World Health Organization (WHO) Guideline Development group, 2011, RAP ADV DIAGN PREV M	36	15	16	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 23	2013	8	7							e68445	10.1371/journal.pone.0068445	http://dx.doi.org/10.1371/journal.pone.0068445			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	228SX	23935870	Green Published, gold			2023-01-03	WOS:000325211000030
J	Scheibe, FJB; Waiswa, P; Kadobera, D; Muller, O; Ekstrom, AM; Sarker, M; Neuhann, HWF				Scheibe, Florian J. B.; Waiswa, Peter; Kadobera, Daniel; Mueller, Olaf; Ekstroem, Anna M.; Sarker, Malabika; Neuhann, H. W. Florian			Effective Coverage for Antiretroviral Therapy in a Ugandan District with a Decentralized Model of Care	PLOS ONE			English	Article							SUB-SAHARAN AFRICA; RESOURCE-LIMITED SETTINGS; HIV-1 DRUG-RESISTANCE; FOLLOW-UP; TREATMENT PROGRAMS; VIROLOGICAL FAILURE; PATIENT RETENTION; HIGH PREVALENCE; PATIENTS LOST; 1ST YEAR	Introduction: While increasing access to antiretroviral therapy (ART) is reported from many African countries, data on effective coverage particular from settings without external support or research remains scarce. We examined and report effective coverage data from a public ART program in rural Uganda. Methods: We conducted a retrospective cohort study at all ART-providing governmental health facilities in Iganga District, Eastern Uganda. Based on all HIV patients registered between April 2004 and September 2009 (n = 4775), we assessed indicators of program performance and determined rates of retention and Cox proportional hazards for attrition. Effective ART coverage was calculated using projections (SPECTRUM software) adapted to the district demographic structure and number of people receiving ART. Results: By September 2009, district public sector effective ART coverage was 10.3% for adults and 1.9% for children. After a median follow-up of 26.9 months, overall ART retention was 54.7%. The probability of retention was 0.72 (95% confidence interval (CI) 0.69-0.75) at 12 and 0.58 (CI 0.54-0.62) at 36 months after ART initiation. Individual health facilities differed considerably regarding performance indicators and retention. Overall, 198 (16.9%) individual files of 1171 registered ART patients were lost. Young adult age (15-24 years) had a higher risk of attrition (HR 2.1, CI 1.4-3.2) as well as WHO stage I (HR 4.8, CI 1.9-11.8) and WHO stage IV (HR 2.5, CI 1.3-4.7). An interval >= 6 weeks between HIV testing and ART initiation was associated with a reduced risk (HR 0.6, CI 0.47-0.78). Conclusion: Compared to reported national data effective ART coverage in Iganga District was low. Intensified efforts to improve access, retention in care, and quality of documentation are urgently needed. Children and young adults require special attention in the program.	[Scheibe, Florian J. B.; Mueller, Olaf; Sarker, Malabika; Neuhann, H. W. Florian] Heidelberg Univ, Inst Publ Hlth, Heidelberg, Germany; [Scheibe, Florian J. B.] Ortenau Klinikum, Dept Cardiol Pulmonol, Offenburg, Germany; [Waiswa, Peter; Ekstroem, Anna M.] Makerere Univ, Sch Publ Hlth, Dept Hlth Policy Planning & Management, Kampala, Uganda; [Waiswa, Peter] Karolinska Inst, IHCAR, Div Global Hlth, Stockholm, Sweden; [Waiswa, Peter; Kadobera, Daniel] Iganga Mayuge Hlth & Demog Surveillance Site, Iganga, Uganda; [Sarker, Malabika] BRAC Univ, James P Grant Sch Publ Hlth, Dhaka, Bangladesh	Ruprecht Karls University Heidelberg; Makerere University; Karolinska Institutet; Bangladesh Rural Advancement Committee BRAC; BRAC University	Neuhann, HWF (corresponding author), Heidelberg Univ, Inst Publ Hlth, Heidelberg, Germany.	florian.neuhann@uni-heidelberg.de		Sarker, Malabika/0000-0001-7293-8805	European Commission	European Commission(European CommissionEuropean Commission Joint Research Centre)	This work is a part of the project "Effects of Antiretrovirals for HIV on African health systems, Maternal and Child Health" (ARVMAC, www.arvmac.eu), supported financially by the European Commission 6th Framework Program. The funding institution had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adjorlolo-Johnson G, 2013, JAIDS-J ACQ IMM DEF, V62, pE7, DOI 10.1097/QAI.0b013e3182706401; Ahoua L, 2009, BMC INFECT DIS, V9, DOI 10.1186/1471-2334-9-81; Assefa Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038555; Bajunirwe Francis, 2009, J Int Assoc Physicians AIDS Care (Chic), V8, P139, DOI 10.1177/1545109709332470; Boyles TH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019201; Brinkhof MWG, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005790; Chang LVW, 2009, JAIDS-J ACQ IMM DEF, V50, P276, DOI 10.1097/QAI.0b013e3181988375; Charurat M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010584; Clouse K, 2013, JAIDS-J ACQ IMM DEF, V62, pE39, DOI 10.1097/QAI.0b013e318273ac48; Cohen MS, 2011, NEW ENGL J MED, V365, P493, DOI [10.1056/NEJMoa1105243, 10.1056/NEJMoa1600693]; Dagnra AY, 2011, J INT AIDS SOC, V14, DOI 10.1186/1758-2652-14-30; District Health Office Iganga, 2009, ANN REPORT; Ekouevi DK, 2010, TROP MED INT HEALTH, V15, P34, DOI 10.1111/j.1365-3156.2010.02505.x; El-Khatib Z, 2011, J AIDS CLIN RES, V2; Estopinal CB, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049564; Evans D, 2013, AIDS RES HUM RETROV, V29, P892, DOI [10.1089/aid.2012.0215, 10.1089/AID.2012.0215]; Ford N, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001060; Fox MP, 2010, TROP MED INT HEALTH, V15, P1, DOI 10.1111/j.1365-3156.2010.02508.x; Geng EH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021797; Geng EH, 2010, JAIDS-J ACQ IMM DEF, V53, P405, DOI 10.1097/QAI.0b013e3181b843f0; Hamers RL, 2011, LANCET INFECT DIS, V11, P750, DOI 10.1016/S1473-3099(11)70149-9; Harries AD, 2010, LANCET INFECT DIS, V10, P60, DOI 10.1016/S1473-3099(09)70321-4; Kiboneka A, 2009, BMJ-BRIT MED J, V338, DOI 10.1136/bmj.b201; Kipp W, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040902; Kirunda KA, 2008, SATURDAY MONITOR, P11; Koole O, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040971; Kranzer K, 2012, J INT AIDS SOC, V15, DOI 10.7448/IAS.15.2.17383; Lamb MR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038443; Lambdin BH, 2011, JAIDS-J ACQ IMM DEF, V57, pE33, DOI 10.1097/QAI.0b013e3182167e90; Lubega M, 2010, HEALTH POLICY, V95, P153, DOI 10.1016/j.healthpol.2009.11.021; Luebbert J, 2012, CLIN INFECT DIS, V55, P441, DOI 10.1093/cid/cis438; MacPherson P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044794; Mahy M, 2010, SEX TRANSM INFECT, V86, pI28, DOI 10.1136/sti.2010.044255; Martin JA, 2008, AEROSPACE AM, V46, P6; Massaquoi M, 2009, T ROY SOC TROP MED H, V103, P594, DOI 10.1016/j.trstmh.2009.02.012; Miiro G, 2009, TROP MED INT HEALTH, V14, P556, DOI 10.1111/j.1365-3156.2009.02259.x; Ministry of Health Republic of Uganda, 2007, 2004 2005 SER BEH SU; Ministry of Health RoU, 2012, 2011 UG AIDS IND SUR; Ministry of Health - Government of Malawi, 2011, Q HIV PROGR REP; Morgan D, 2002, AIDS, V16, P597, DOI 10.1097/00002030-200203080-00011; O'Connor C, 2011, JAIDS-J ACQ IMM DEF, V58, P429, DOI 10.1097/QAI.0b013e318230d507; Olle-Goig JE, 2009, HLTH POLICY DEV, P60; Rich ML, 2012, JAIDS-J ACQ IMM DEF, V59, pE35, DOI 10.1097/QAI.0b013e31824476c4; Rwabwogo Odrek, 2007, UG DISTR INF HDB; Scanlon ML, 2013, HIV AIDS-RES PALLIAT, V5, P1, DOI 10.2147/HIV.S28912; Searle C, 2010, STUD HEALTH TECHNOL, V160, P476, DOI 10.3233/978-1-60750-588-4-476; Somi G, 2012, TROP MED INT HEALTH, V17, P497, DOI 10.1111/j.1365-3156.2011.02952.x; Stover J, 2008, SEX TRANSM INFECT, V84, pI24, DOI 10.1136/sti.2008.029868; Stover J, 2010, SEX TRANSM INFECT, V86, pII16, DOI 10.1136/sti.2010.044222; Tenthani L, 2012, BMC HEALTH SERV RES, V12, DOI 10.1186/1472-6963-12-140; The Director General Health Services, 2008, NAT ANT TREATM CAR G; The STD/AIDS Control Programme Ministry of Health Republic of Uganda The HIVDR Technical Working Group for Uganda, 2009, TRACK HIV DRUG RES F; Tweya H, 2010, TROP MED INT HEALTH, V15, P82, DOI 10.1111/j.1365-3156.2010.02509.x; Uganda AIDS Commission, 2010, UG COUNTR PROGR REP; Uganda Bureau of Statistics, 2009, 2009 STAT ABSTR; Uganda Bureau of Statistics, 2011, 2011 STAT ABSTR; Uganda Ministry of Health and ICF International, 2012, 2011 UG AIDS IND SUR; UNAIDS, 2011, UNAIDS 2011 2015 STR; UNAIDS, 2011, UG HIV EST 2009; UNAIDS, 2011, WORLD AIDS DAY REP 2; Unge C, 2009, JAIDS-J ACQ IMM DEF, V50, P397, DOI 10.1097/QAI.0b013e318194618e; Vermund SH, 2012, AIDS, V26, P1303, DOI 10.1097/QAD.0b013e3283552185; Wandeler G, 2012, JAIDS-J ACQ IMM DEF, V59, pE9, DOI 10.1097/QAI.0b013e31823edb6a; Ware NC, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001369; Weidle PJ, 2002, LANCET, V360, P34, DOI 10.1016/S0140-6736(02)09330-3; Weigel R, 2012, AIDS, V26, P365, DOI 10.1097/QAD.0b013e32834ed814; Windisch R, 2011, GLOBALIZATION HEALTH, V7, DOI 10.1186/1744-8603-7-25; World Health Organization, 2010, MON EQ ACC AIDS TREA, P69; World Health Organization, 2010, HIV DRUG RES EARL WA; World Health Organization, 2011, M REP 13 15 SEPT 201; Yu JKL, 2007, B WORLD HEALTH ORGAN, V85, P550, DOI 10.2471/BLT.06.037739; Yu JKL, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002065	72	3	3	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 23	2013	8	7							e69433	10.1371/journal.pone.0069433	http://dx.doi.org/10.1371/journal.pone.0069433			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	228SX	23936015	Green Published, gold, Green Submitted			2023-01-03	WOS:000325211000119
J	Zhou, GQ; Yu, XL; Chen, M; Guo, R; Lei, Y; Sun, Y; Mao, YP; Liu, LZ; Li, L; Lin, AH; Ma, J				Zhou, Guan-Qun; Yu, Xiao-Li; Chen, Mo; Guo, Rui; Lei, Ying; Sun, Ying; Mao, Yan-Ping; Liu, Li-Zhi; Li, Li; Lin, Ai-Hua; Ma, Jun			Radiation-Induced Temporal Lobe Injury for Nasopharyngeal Carcinoma: A Comparison of Intensity-Modulated Radiotherapy and Conventional Two-Dimensional Radiotherapy	PLOS ONE			English	Article							NECROSIS FOLLOWING RADIOTHERAPY; CLINICAL-DIAGNOSIS; THERAPY; FRACTIONATION; FEASIBILITY; PLANS	Background: To compare the radiation-induced temporal lobe injury (TLI) in patients with nasopharyngeal carcinoma (NPC) treated with intensity-modulated radiotherapy (IMRT) or two-dimensional conventional radiotherapy (2D-CRT). Patients and Methods: 1276 cases of NPC treated with IMRT or 2D-CRT were retrospectively reviewed. A diagnosis of TLI was made on follow-up magnetic resonance imaging (MRI). Results: The crude incidence of TLI was 7.5% and 10.8% (P = 0.048), and the actuarial 5-year incidence was 16% and 34.9% (P < 0.001) for the IMRT and 2D-CRT groups, respectively. Multivariate analysis revealed both T stage (P < 0.001) and radiation technique (P, 0.001) as independent predictors. Patients with T1, T2 and T3 disease had a significantly higher risk when treated with 2D-CRT (P = 0.005, 0.016, <0.001, respectively). This trend was not evident for T4 patients (P = 0.680). The 2D-CRT group had a longer latency for the development of TLI (P, 0.001). Those with T4 disease had a shorter median time to TLI (P = 0.006, 0.042, <0.001 when compared with T1, T2 and T3, respectively). Conclusions: IMRT is superior to 2DRT for the management of T1-T3 NPC in terms of sparing the temporal lobe. The high incidence of TLI in T4 disease needs to be addressed.	[Zhou, Guan-Qun; Yu, Xiao-Li; Chen, Mo; Guo, Rui; Lei, Ying; Sun, Ying; Mao, Yan-Ping; Ma, Jun] Sun Yat Sen Univ, State Key Lab Oncol Southern China, Dept Radiat Oncol, Ctr Canc, Guangzhou 510275, Guangdong, Peoples R China; [Liu, Li-Zhi; Li, Li] Sun Yat Sen Univ, State Key Lab Oncol Southern China, Imaging Diag & Intervent Ctr, Ctr Canc, Guangzhou 510275, Guangdong, Peoples R China; [Lin, Ai-Hua] Sun Yat Sen Univ, Sch Publ Hlth, Dept Med Stat & Epidemiol, Guangzhou 510275, Guangdong, Peoples R China	State Key Lab Oncology South China; Sun Yat Sen University; State Key Lab Oncology South China; Sun Yat Sen University; Sun Yat Sen University	Ma, J (corresponding author), Sun Yat Sen Univ, State Key Lab Oncol Southern China, Dept Radiat Oncol, Ctr Canc, Guangzhou 510275, Guangdong, Peoples R China.	drjunma@hotmail.com			Guangdong Province Universities and Colleges Pearl River Scholar Funded Scheme; Science Foundation of Key Hospital Clinical Program of Ministry of Health, P. R. China [2010-178]; National Natural Science Foundation of China [81071836]	Guangdong Province Universities and Colleges Pearl River Scholar Funded Scheme; Science Foundation of Key Hospital Clinical Program of Ministry of Health, P. R. China; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported by grants from the Project Supported by Guangdong Province Universities and Colleges Pearl River Scholar Funded Scheme (2010), the Science Foundation of Key Hospital Clinical Program of Ministry of Health, P. R. China (No.2010-178); and the National Natural Science Foundation of China (No. 81071836). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	American Joint Committee on Cancer (AJCC), 2002, AJCC CANC STAG MAN, P157; Bakst RL, 2011, INT J RADIAT ONCOL, V80, P148, DOI 10.1016/j.ijrobp.2010.01.026; Ballivy O, 2006, Curr Oncol, V13, P108; CHATANI M, 1986, CANCER, V57, P2267, DOI 10.1002/1097-0142(19860615)57:12<2267::AID-CNCR2820571205>3.0.CO;2-C; Chen SW, 2005, MED DOSIM, V30, P219, DOI 10.1016/j.meddos.2005.07.001; Cheung MC, 2003, CANCER-AM CANCER SOC, V97, P2019, DOI 10.1002/cncr.11295; Dorr W, 2010, NUKLEARMED-NUCL MED, V49, pS53; Edge SB., 2009, AM JOINT COMMITTEE C; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.20107]; Kam MKM, 2003, INT J RADIAT ONCOL, V56, P145, DOI 10.1016/S0360-3016(03)00075-0; Lai SZ, 2011, INT J RADIAT ONCOL, V80, P661, DOI 10.1016/j.ijrobp.2010.03.024; LEE AWM, 1992, BRIT J RADIOL, V65, P918, DOI 10.1259/0007-1285-65-778-918; Lee AWM, 1999, RADIOTHER ONCOL, V52, P207; LEE AWM, 1990, CLIN RADIOL, V42, P24, DOI 10.1016/S0009-9260(05)81617-4; LEE AWM, 1988, CANCER-AM CANCER SOC, V61, P1535, DOI 10.1002/1097-0142(19880415)61:8<1535::AID-CNCR2820610809>3.0.CO;2-E; Lee AWM, 1998, INT J RADIAT ONCOL, V40, P35, DOI 10.1016/S0360-3016(97)00580-4; Lee AWM, 2002, INT J RADIAT ONCOL, V53, P75, DOI 10.1016/S0360-3016(02)02711-6; Li WF, 2012, CHIN J CANCER, V31, P579, DOI 10.5732/cjc.012.10095; PEREZ CA, 1992, INT J RADIAT ONCOL, V23, P271, DOI 10.1016/0360-3016(92)90741-Y; SHAM J, 1994, INT J RADIAT ONCOL, V29, P699, DOI 10.1016/0360-3016(94)90556-8; Wang J, 2009, RADIOTHER ONCOL, V90, P221, DOI 10.1016/j.radonc.2008.08.017; Wang YXJ, 2010, RADIOLOGY, V254, P210, DOI 10.1148/radiol.09090428; Xia P, 2000, INT J RADIAT ONCOL, V48, P329, DOI 10.1016/S0360-3016(00)00585-X	23	58	61	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 10	2013	8	7							e67488	10.1371/journal.pone.0067488	http://dx.doi.org/10.1371/journal.pone.0067488			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	182SU	23874422	gold, Green Published, Green Submitted			2023-01-03	WOS:000321765300011
J	Huang, CR; Kan, JT; Liu, X; Ma, FF; Tran, H; Zou, YZ; Wang, SJ; Zhu, YZ				Huang, Chengrong; Kan, Juntao; Liu, Xu; Ma, Fenfen; Tran, Hieu; Zou, Yunzeng; Wang, Shujun; Zhu, Yi Zhun			Cardioprotective Effects of a Novel Hydrogen Sulfide Agent-Controlled Release Formulation of S-Propargyl-Cysteine on Heart Failure Rats and Molecular Mechanisms	PLOS ONE			English	Article							OXIDATIVE STRESS; MYOCARDIAL-ISCHEMIA; H2S; PROTECTS; APOPTOSIS; MICE; CARDIOMYOCYTES; VASORELAXANT; HYPERTROPHY; MYOCYTES	Objective: Heart failure (HF) is one of the most serious diseases worldwide. S-propargyl-cysteine (SPRC), a novel modulator of endogenous hydrogen sulfide, is proved to be able to protect against acute myocardial ischemia. In order to produce more stable and sustainable hydrogen sulfide, we used controlled release formulation of SPRC (CR-SPRC) to elucidate possible cardioprotective effects on HF rats and investigate involved mechanisms on apoptosis and oxidation. Methods: Left coronary artery was occluded to induce HF model of rat. The survival rats were randomly divided into 7 groups after 24 hours and treated with drugs for 6 weeks. Echocardiographic indexes were recorded to determine cardiac function. TTC staining was performed to determine infarct size. Plasmatic level of hydrogen sulfide was detected by modified sulfide electrode. Activity of enzyme and expression of protein were determined by colorimetry and Western blot, respectively. Results: The cardioprotective effects of CR-SPRC on HF rats were confirmed by significant reduction of infarct size and improvement of cardiac function, with better effects compared to normal SPRC. CR-SPRC modulated antioxidant defenses by preserving levels of GSH, CAT and SOD and reducing CK leakage. In addition, CR-SPRC elevated ratio of Bcl-2/Bax and inhibited activity of caspases to protect against myocardial apoptosis. The cardioprotective effects of CR-SPRC were mediated by hydrogen sulfide. Conclusions: All experiment data indicated cardioprotective effects of CR-SPRC on HF rats. More importantly, CR-SPRC exerted better effects than normal SPRC in all respects, providing a new perspective on hydrogen sulfide-mediated drug therapy.	[Huang, Chengrong; Kan, Juntao; Ma, Fenfen; Tran, Hieu; Zhu, Yi Zhun] Fudan Univ, Sch Pharm, Shanghai 200433, Peoples R China; [Kan, Juntao; Zou, Yunzeng; Zhu, Yi Zhun] Fudan Univ, Inst Biomed Sci, Shanghai 200433, Peoples R China; [Zou, Yunzeng] Fudan Univ, Zhongshan Hosp, Shanghai 200433, Peoples R China; [Liu, Xu; Wang, Shujun] Shenyang Pharmaceut Univ, Sch Pharm, Shenyang, Liaoning, Peoples R China	Fudan University; Fudan University; Fudan University; Shenyang Pharmaceutical University	Wang, SJ (corresponding author), Shenyang Pharmaceut Univ, Sch Pharm, Shenyang, Liaoning, Peoples R China.	wangshujun@syphu.edu.cn; zhuyz@fudan.edu.cn	Zhu, Yi Zhun/ABG-8449-2021	Zhu, Yi Zhun/0000-0001-7700-8041	National Basic Research Program of China (973 Program) [2010CB912600]; National Science Fund for Distinguished Young Scholars [30888002]; Key Program of Shanghai Committee of Science and Technology in China [10431900100]	National Basic Research Program of China (973 Program)(National Basic Research Program of China); National Science Fund for Distinguished Young Scholars(National Natural Science Foundation of China (NSFC)National Science Fund for Distinguished Young Scholars); Key Program of Shanghai Committee of Science and Technology in China	This work was supported by the National Basic Research Program of China (973 Program, No.: 2010CB912600), the National Science Fund for Distinguished Young Scholars (No.: 30888002), and the Key Program of Shanghai Committee of Science and Technology in China (No.: 10431900100). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abe K, 1996, J NEUROSCI, V16, P1066; Bui AL, 2011, NAT REV CARDIOL, V8, P30, DOI 10.1038/nrcardio.2010.165; Calvert JW, 2010, CIRCULATION, V122, P11, DOI 10.1161/CIRCULATIONAHA.109.920991; Calvert JW, 2009, CIRC RES, V105, P365, DOI 10.1161/CIRCRESAHA.109.199919; Cohn JN, 1996, NEW ENGL J MED, V335, P490, DOI 10.1056/NEJM199608153350707; Dhalla AK, 1996, J AM COLL CARDIOL, V28, P506, DOI 10.1016/0735-1097(96)00140-4; Elrod JW, 2007, P NATL ACAD SCI USA, V104, P15560, DOI 10.1073/pnas.0705891104; Jessup M, 2003, NEW ENGL J MED, V348, P2007, DOI 10.1056/NEJMra021498; Kang PM, 2000, CIRC RES, V86, P1107; Keith M, 1998, J AM COLL CARDIOL, V31, P1352, DOI 10.1016/S0735-1097(98)00101-6; Kimura Y, 2004, FASEB J, V18, P1165, DOI 10.1096/fj.04-1815fje; Lefer DJ, 2007, P NATL ACAD SCI USA, V104, P17907, DOI 10.1073/pnas.0709010104; Mallat Z, 1998, CIRCULATION, V97, P1536, DOI 10.1161/01.CIR.97.16.1536; Mishra PK, 2010, AM J PHYSIOL-HEART C, V298, pH451, DOI 10.1152/ajpheart.00682.2009; Narula J, 1996, NEW ENGL J MED, V335, P1182, DOI 10.1056/NEJM199610173351603; Sawyer DB, 2002, J MOL CELL CARDIOL, V34, P379, DOI 10.1006/jmcc.2002.1526; Szabo C, 2007, NAT REV DRUG DISCOV, V6, P917, DOI 10.1038/nrd2425; Takano H, 2003, ANTIOXID REDOX SIGN, V5, P789, DOI 10.1089/152308603770380098; Varshosaz J, 2006, DRUG DELIV, V13, P295, DOI 10.1080/10717540500459308; Wang Q, 2010, ANTIOXID REDOX SIGN, V12, P1155, DOI 10.1089/ars.2009.2947; Wang Q, 2009, J CARDIOVASC PHARM, V54, P139, DOI 10.1097/FJC.0b013e3181ac8e12; Wang R, 2002, FASEB J, V16, P1792, DOI 10.1096/fj.02-0211hyp; Wang XL, 2011, BIOSCIENCE REP, V31, P87, DOI 10.1042/BSR20100003; Wang YF, 2009, ARTERIOSCL THROM VAS, V29, P173, DOI 10.1161/ATVBAHA.108.179333; Yang GD, 2008, SCIENCE, V322, P587, DOI 10.1126/science.1162667; Yao LL, 2010, AM J PHYSIOL-HEART C, V298, pH1310, DOI 10.1152/ajpheart.00339.2009; Zhao WM, 2001, EMBO J, V20, P6008, DOI 10.1093/emboj/20.21.6008; Zhu YZ, 2007, J APPL PHYSIOL, V102, P261, DOI 10.1152/japplphysiol.00096.2006	28	38	40	0	38	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 9	2013	8	7							e69205	10.1371/journal.pone.0069205	http://dx.doi.org/10.1371/journal.pone.0069205			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	182JD	23874913	Green Published, gold, Green Submitted			2023-01-03	WOS:000321736900141
J	Costantini, M; Romoli, V; Di Leo, S; Beccaro, M; Bono, L; Pilastri, P; Miccinesi, G; Valenti, D; Peruselli, C; Bulli, F; Franceschini, C; Grubich, S; Brunelli, C; Martini, C; Pellegrini, F; Higginson, IJ				Costantini, Massimo; Romoli, Vittoria; Di Leo, Silvia; Beccaro, Monica; Bono, Laura; Pilastri, Paola; Miccinesi, Guido; Valenti, Danila; Peruselli, Carlo; Bulli, Francesco; Franceschini, Catia; Grubich, Sergio; Brunelli, Cinzia; Martini, Cinzia; Pellegrini, Fabio; Higginson, Irene J.		Liverpool Care Pathway Italian Clu	Liverpool Care Pathway for patients with cancer in hospital: a cluster randomised trial	LANCET			English	Article							END-OF-LIFE; ITALIAN SURVEY; DYING PATIENT; IMPROVING END; LAST HOURS; PLACE; DEATH; IMPLEMENTATION; INTERVENTIONS; POPULATION	Background The quality of care provided to patients with cancer who are dying in hospital and their families is suboptimum. The UK Liverpool Care Pathway (LCP) for patients who are dying was developed with the aim of transferring the best practice of hospices to hospitals. We therefore assessed the effectiveness of LCP in the Italian context (LCP-I) in improving the quality of end-of-life care for patients with cancer in hospitals and for their family. Methods In this pragmatic cluster randomised trial, 16 Italian general medicine hospital wards were randomly assigned to implement the LCP-I programme or standard health-care practice. For each ward, we identified all patients who died from cancer in the 3 months before randomisation (preintervention) and in the 6 months after the completion of the LCP-I training programme. The primary endpoint was the overall quality of care toolkit scale. Analysis was by intention to treat. This study is registered with ClinicalTrials.gov, number NCT01081899. Findings During the postintervention assessment, data were gathered for 308 patients who died from cancer (147 in LCP-I programme wards and 161 in control wards). 232 (75%) of 308 family members were interviewed, 119 (81%) of 147 with relatives cared for in the LCP-I wards (mean cluster size 14.9 [range eight to 22]) and 113 (70%) of 161 in the control wards (14.1 [eight to 22]). After implementation of the LCP-I programme, no significant difference was noted in the distribution of the overall quality of care toolkit scores between the wards in which the LCP-I programme was implemented and the control wards (score 70.5 of 100 vs 63.0 of 100; cluster-adjusted mean difference 7.6 [95% CI -3.6 to 18.7]; p=0.186). Interpretation The effect of the LCP-I programme in our study is less than the effects noted in earlier phase 2 trials. However, if the programme is implemented well it has the potential to reduce the gap in quality of care between hospices and hospitals. Further research is needed to ascertain what components of the LCP-I programme might be effective and to develop and assess a wider range of approaches to quality improvement in hospital care for people at the end of their lives and for their families.	[Costantini, Massimo] Ist Ricovero & Cura Carattere Sci IRCCS Arcispeda, Palliat Care Unit, Reggio Emilia, Italy; [Romoli, Vittoria; Di Leo, Silvia; Beccaro, Monica; Bono, Laura] IRCCS Azienda Osped Univ San Martino, Ist Nazl Ric Canc, Reg Palliat Care Network, Genoa, Italy; [Pilastri, Paola] IRCCS Azienda Osped Univ San Martino, Ist Nazl Ric Canc, Hosp Maria Chighine, Genoa, Italy; [Miccinesi, Guido; Bulli, Francesco] Ist Studio & Prevenz Oncol, Clin & Descript Epidemiol Unit, Florence, Italy; [Valenti, Danila] Azienda Unita Sanit Locale Bologna, Palliat Care Network, Bologna, Italy; [Peruselli, Carlo; Grubich, Sergio] Biella Hosp, Palliat Care Unit, Biella, Italy; [Franceschini, Catia] Fdn Hosp Maria Teresa Chiantore Seragnoli, Bologna, Italy; [Brunelli, Cinzia; Martini, Cinzia] Fdn IRCCS Ist Nazl Tumori, Palliat Care Pain Therapy & Rehabil Unit, Milan, Italy; [Brunelli, Cinzia] Norwegian Univ Sci & Technol, Fac Med, European Palliat Care Res Ctr, N-7034 Trondheim, Norway; [Pellegrini, Fabio] Mario Negri Sud Consortium, Mario Negri Sud Inst, Chieti, Italy; [Higginson, Irene J.] Kings Coll London, Cicely Saunders Inst, Dept Palliat Care Policy & Rehabil, London WC2R 2LS, England	University of Genoa; IRCCS AOU San Martino IST; University of Genoa; IRCCS AOU San Martino IST; Fondazione IRCCS Istituto Nazionale Tumori Milan; Norwegian University of Science & Technology (NTNU); Consorzio Mario Negri Sud; University of London; King's College London	Costantini, M (corresponding author), IRCCS Arcispedale S Maria Nuova, Palliat Care Unit, Viale Umberto 1,50, I-42123 Reggio Emilia, Italy.	costantini.massimo@asmn.re.it	Harding, Richard/G-9729-2012; miccinesi, guido/AAB-5476-2022; costantini, massimo/AAK-5388-2021; Brunelli, Cinzia/B-9361-2017; Di Leo, Silvia/AAA-3180-2021; Higginson, Irene Julie/C-7309-2012	miccinesi, guido/0000-0002-7452-9594; costantini, massimo/0000-0002-5293-7079; Brunelli, Cinzia/0000-0003-3905-1289; Di Leo, Silvia/0000-0003-1673-2786; Higginson, Irene Julie/0000-0002-3687-1313	Italian Ministry of Health; Maruzza Lefebvre D'Ovidio Foundation-Onlus; National Institute for Health Research [NF-SI-0611-10209] Funding Source: researchfish	Italian Ministry of Health(Ministry of Health, Italy); Maruzza Lefebvre D'Ovidio Foundation-Onlus; National Institute for Health Research(National Institute for Health Research (NIHR))	Italian Ministry of Health and Maruzza Lefebvre D'Ovidio Foundation-Onlus.	[Anonymous], 2012, LANCET, V379, P1171, DOI 10.1016/S0140-6736(12)60490-5; [Anonymous], 2011, NAR CAR DYING AUD HO; Bailey FA, 2005, ARCH INTERN MED, V165, P1722, DOI 10.1001/archinte.165.15.1722; Beccaro M, 2006, J EPIDEMIOL COMMUN H, V60, P412, DOI 10.1136/jech.2005.043646; Beccaro M, 2010, J PAIN SYMPTOM MANAG, V39, P1003, DOI 10.1016/j.jpainsymman.2009.11.317; Bookbinder M, 2005, J PAIN SYMPTOM MANAG, V29, P529, DOI 10.1016/j.jpainsymman.2004.05.011; Bowden J, 2013, J ROY COLL PHYS EDIN, V43, P24, DOI 10.4997/JRCPE.2013.105; Chan R, 2010, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD008006.pub2, 10.1002/14651858.CD008006.pub4]; ClinicalTrials.gov, IMPR QUAL CAR DYING; Cohen J, 2008, PALLIATIVE MED, V22, P702, DOI 10.1177/0269216308092285; Cohen J., 2013, STAT POWER ANAL BEHA; Conry MC, 2012, BMC HEALTH SERV RES, V12, DOI 10.1186/1472-6963-12-275; Costantini M, 2006, ANN ONCOL, V17, P853, DOI 10.1093/annonc/mdl028; Costantini M, 2005, PALLIATIVE MED, V19, P628, DOI 10.1191/0269216305pm1086oa; Costantini M, 2014, PALLIATIVE MED, V28, P10, DOI 10.1177/0269216313487569; Costantini M, 2011, PALLIATIVE MED, V25, P766, DOI 10.1177/0269216311418870; Costantini M, 2011, BMC HEALTH SERV RES, V11, DOI 10.1186/1472-6963-11-13; Costantini M, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-127; Department of Health, 2008, END LIF CAR STRAT PR; Department of Health, 2013, MAR CAR LESS PATHW R; Di Leo S, 2011, PALLIATIVE MED, V25, P293, DOI 10.1177/0269216310392436; Ellershaw J, 2003, BRIT MED J, V326, P30, DOI 10.1136/bmj.326.7379.30; Farquhar Morag C, 2009, BMC Palliat Care, V8, P9, DOI 10.1186/1472-684X-8-9; Gao W, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001410; Gibbins J, 2011, MED EDUC, V45, P389, DOI 10.1111/j.1365-2923.2010.03873.x; Gomes B, 2008, PALLIATIVE MED, V22, P33, DOI 10.1177/0269216307084606; Gysels MH, 2012, BMC MED RES METHODOL, V12, DOI 10.1186/1471-2288-12-123; Gysels MH, 2011, BMC PALLIAT CARE, V10, DOI 10.1186/1472-684X-10-15; Hall S, 2011, PALL CAR OLD PEOPL B; Higginson IJ, 2008, EUR J CANCER, V44, P1414, DOI 10.1016/j.ejca.2008.02.024; Higginson IJ, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-111; Jack Barbara A, 2003, Int J Palliat Nurs, V9, P375; KNAUS WA, 1995, JAMA-J AM MED ASSOC, V274, P1591, DOI 10.1001/jama.1995.03530200027032; Luhrs CA, 2005, J PAIN SYMPTOM MANAG, V29, P544, DOI 10.1016/j.jpainsymman.2005.02.010; McConnell T, 2013, WORLDV EVID-BASED NU, V10, P218, DOI 10.1111/wvn.12003; National Health System (NHS), 2010, NAT END LIF CAR PROG; NHS Medical Directorate, 2012, END LIF CAR 1 NAT VO; Phillips JL, 2011, J PAIN SYMPTOM MANAG, V41, P940, DOI 10.1016/j.jpainsymman.2010.07.020; Raijmakers NJH, 2013, SUPPORT CARE CANCER, V21, P1003, DOI 10.1007/s00520-012-1619-0; Sepulveda C, 2002, J PAIN SYMPTOM MANAG, V24, P91, DOI 10.1016/S0885-3924(02)00440-2; SILVERMAN HJ, 1995, ARCH INTERN MED, V155, P502, DOI 10.1001/archinte.155.5.502; Simon ST, 2012, PUBLIC HEALTH, V126, P937, DOI 10.1016/j.puhe.2012.06.014; Singer Peter A, 2002, BMC Palliat Care, V1, P4, DOI 10.1186/1472-684X-1-4; Snijders T. A., 2012, MULTILEVEL ANAL INTR; Teno JM, 2001, J PAIN SYMPTOM MANAG, V22, P752, DOI 10.1016/S0885-3924(01)00331-1; Teno JM, 2004, JAMA-J AM MED ASSOC, V291, P88, DOI 10.1001/jama.291.1.88; Teno JM, 2001, J PAIN SYMPTOM MANAG, V22, P738, DOI 10.1016/S0885-3924(01)00335-9; Teno JM, 2001, TOOLKIT INSTRUMENTS; Veerbeek L, 2008, AM J HOSP PALLIAT ME, V25, P207, DOI 10.1177/1049909108315515; Veerbeek L, 2008, PALLIATIVE MED, V22, P145, DOI 10.1177/0269216307087164	50	57	57	0	20	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 18	2014	383	9913					226	237		10.1016/S0140-6736(13)61725-0	http://dx.doi.org/10.1016/S0140-6736(13)61725-0			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	294FC	24139708				2023-01-03	WOS:000330027500031
J	Su, JC; Gu, YC; Pruijn, FB; Smaill, JB; Patterson, AV; Guise, CP; Wilson, WR				Su, Jiechuang; Gu, Yongchuan; Pruijn, Frederik B.; Smaill, Jeff B.; Patterson, Adam V.; Guise, Christopher P.; Wilson, William R.			Zinc Finger Nuclease Knock-out of NADPH: Cytochrome P450 Oxidoreductase (POR) in Human Tumor Cell Lines Demonstrates That Hypoxia-activated Prodrugs Differ in POR Dependence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article						Flavoproteins; Gene Knock-out; Hypoxia; Mass Spectrometry (MS); Molecular Cell Biology; Reductase; NADPH:Cytochrome P450 Oxidoreductase; Hypoxia-activated Prodrug; Proteotypic Peptides; Zinc Finger Nuclease	4-ALKYLAMINO-5-NITROQUINOLINE BIOREDUCTIVE DRUGS; HAMSTER OVARY CELLS; C P450 REDUCTASE; MITOMYCIN-C; P-450 REDUCTASE; AEROBIC CONDITIONS; CANCER-THERAPY; GENE KNOCKOUT; TROG 02.02; CYTOTOXICITY	Hypoxia, a ubiquitous feature of tumors, can be exploited by hypoxia-activated prodrugs (HAP) that are substrates for one-electron reduction in the absence of oxygen. NADPH:cytochrome P450 oxidoreductase (POR) is considered one of the major enzymes responsible, based on studies using purified enzyme or forced overexpression in cell lines. To examine the role of POR in HAP activation at endogenous levels of expression, POR knock-outs were generated in HCT116 and SiHa cells by targeted mutation of exon 8 using zinc finger nucleases. Absolute quantitation by proteotypic peptide mass spectrometry of DNA sequence-confirmed multiallelic mutants demonstrated expression of proteins with residual one-electron reductase activity in some clones and identified two (Hko2 from HCT116 and S2ko1 from SiHa) that were functionally null by multiple criteria. Sensitivities of the clones to 11 HAP (six nitroaromatics, three benzotriazine N-oxides, and two quinones) were compared with wild-type and POR-overexpressing cells. All except the quinones were potentiated by POR overexpression. Knocking out POR had a marked effect on antiproliferative activity of the 5-nitroquinoline SN24349 in both genetic backgrounds after anoxic exposure but little or no effect on activity of most other HAP, including the clinical stage 2-nitroimidazole mustard TH-302, dinitrobenzamide mustard PR-104A, and benzotriazine N-oxide SN30000. Clonogenic cell killing and reductive metabolism of PR-104A and SN30000 under anoxia also showed little change in the POR knock-outs. Thus, although POR expression is a potential biomarker of sensitivity to some HAP, identification of other one-electron reductases responsible for HAP activation is needed for their rational clinical development.	[Su, Jiechuang; Gu, Yongchuan; Pruijn, Frederik B.; Smaill, Jeff B.; Patterson, Adam V.; Guise, Christopher P.; Wilson, William R.] Univ Auckland, Fac Med & Hlth Sci, Auckland Canc Soc Res Ctr, Auckland, New Zealand	University of Auckland	Wilson, WR (corresponding author), Univ Auckland, Fac Med & Hlth Sci, Auckland Canc Soc Res Ctr, Private Bag 92019, Auckland, New Zealand.	wr.wilson@auckland.ac.nz		Guise, Chris/0000-0001-8739-6682; Pruijn, Frederik/0000-0002-7354-5840; Gu, Yongchuan/0000-0001-5679-168X; Patterson, Adam/0000-0001-5138-1227	Health Research Council of New Zealand [11/1103]; University of Auckland	Health Research Council of New Zealand(Health Research Council of New Zealand); University of Auckland	This work was supported by Grant 11/1103 from the Health Research Council of New Zealand and a doctoral scholarship from the University of Auckland (to J. S.).	Bailey SM, 2001, BIOCHEM PHARMACOL, V62, P461, DOI 10.1016/S0006-2952(01)00674-8; Baumann RP, 2001, CANCER RES, V61, P7770; Belcourt MF, 1996, P NATL ACAD SCI USA, V93, P456, DOI 10.1073/pnas.93.1.456; Beumer K, 2006, GENETICS, V172, P2391, DOI 10.1534/genetics.105.052829; Beumer KJ, 2008, P NATL ACAD SCI USA, V105, P19821, DOI 10.1073/pnas.0810475105; Carroll D, 2008, GENE THER, V15, P1463, DOI 10.1038/gt.2008.145; Chen Y, 2009, MED RES REV, V29, P29, DOI 10.1002/med.20137; Cost GJ, 2010, BIOTECHNOL BIOENG, V105, P330, DOI 10.1002/bit.22541; Denny WA, 2010, FUTURE ONCOL, V6, P419, DOI [10.2217/fon.10.1, 10.2217/FON.10.1]; Doyon Y, 2008, NAT BIOTECHNOL, V26, P702, DOI 10.1038/nbt1409; Elwell JH, 1997, BIOCHEM PHARMACOL, V54, P249, DOI 10.1016/S0006-2952(97)00171-8; Gaj T, 2013, TRENDS BIOTECHNOL, V31, P397, DOI 10.1016/j.tibtech.2013.04.004; Geurts AM, 2009, SCIENCE, V325, P433, DOI 10.1126/science.1172447; Guengerich FP, 2009, NAT PROTOC, V4, P1245, DOI 10.1038/nprot.2009.121; Guise CP, 2007, BIOCHEM PHARMACOL, V74, P810, DOI 10.1016/j.bcp.2007.06.014; Guise CP, 2012, MOL PHARMACOL, V81, P31, DOI 10.1124/mol.111.073759; Guise CP, 2010, CANCER RES, V70, P1573, DOI 10.1158/0008-5472.CAN-09-3237; Gutschner T, 2011, GENOME RES, V21, P1944, DOI 10.1101/gr.122358.111; Hauschild J, 2011, P NATL ACAD SCI USA, V108, P12013, DOI 10.1073/pnas.1106422108; Heine T, 2006, FREE RADICAL BIO MED, V40, P801, DOI 10.1016/j.freeradbiomed.2005.10.033; Henderson CJ, 2013, MOL PHARMACOL, V83, P1209, DOI 10.1124/mol.112.084616; Hendricksen K, 2012, J UROLOGY, V187, P1195, DOI 10.1016/j.juro.2011.11.101; HOBAN PR, 1990, CANCER RES, V50, P4692; Hunter FW, 2012, BIOCHEM PHARMACOL, V83, P574, DOI 10.1016/j.bcp.2011.12.005; Kim HJ, 2009, GENOME RES, V19, P1279, DOI 10.1101/gr.089417.108; KURZBAN GP, 1986, J BIOL CHEM, V261, P7824; Le Floch R, 2011, P NATL ACAD SCI USA, V108, P16663, DOI 10.1073/pnas.1106123108; Liu PQ, 2010, BIOTECHNOL BIOENG, V106, P97, DOI 10.1002/bit.22654; MacLean B, 2010, BIOINFORMATICS, V26, P966, DOI 10.1093/bioinformatics/btq054; Maeder ML, 2008, MOL CELL, V31, P294, DOI 10.1016/j.molcel.2008.06.016; Marohnic CC, 2006, J BIOL CHEM, V281, P35975, DOI 10.1074/jbc.M607095200; MASON RP, 1975, BIOCHEM BIOPH RES CO, V67, P1267, DOI 10.1016/0006-291X(75)90163-1; McKeage MJ, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-496; Meng FY, 2012, MOL CANCER THER, V11, P740, DOI 10.1158/1535-7163.MCT-11-0634; Meng XD, 2008, NAT BIOTECHNOL, V26, P695, DOI 10.1038/nbt1398; Moeller BJ, 2007, CANCER METAST REV, V26, P241, DOI 10.1007/s10555-007-9056-0; Morton J, 2006, P NATL ACAD SCI USA, V103, P16370, DOI 10.1073/pnas.0605633103; Newton DC, 1998, ARCH BIOCHEM BIOPHYS, V359, P249, DOI 10.1006/abbi.1998.0917; Nordsmark M, 2005, RADIOTHER ONCOL, V77, P18, DOI 10.1016/j.radonc.2005.06.038; Olteanu H, 2001, J BIOL CHEM, V276, P35558, DOI 10.1074/jbc.M103707200; Paine MJI, 2000, J BIOL CHEM, V275, P1471, DOI 10.1074/jbc.275.2.1471; Patterson AV, 2007, CLIN CANCER RES, V13, P3922, DOI 10.1158/1078-0432.CCR-07-0478; PATTERSON AV, 1995, BRIT J CANCER, V72, P1144, DOI 10.1038/bjc.1995.478; Patterson AV, 1997, BRIT J CANCER, V76, P1338, DOI 10.1038/bjc.1997.558; Peters LJ, 2010, J CLIN ONCOL, V28, P2996, DOI 10.1200/JCO.2009.27.4498; Richter S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065267; Riddick DS, 2013, DRUG METAB DISPOS, V41, P12, DOI 10.1124/dmd.112.048991; Rischin D, 2010, J CLIN ONCOL, V28, P2989, DOI 10.1200/JCO.2009.27.4449; Rohwer N, 2011, DRUG RESIST UPDATE, V14, P191, DOI 10.1016/j.drup.2011.03.001; Santiago Y, 2008, P NATL ACAD SCI USA, V105, P5809, DOI 10.1073/pnas.0800940105; Saunders MP, 2000, BIOCHEM PHARMACOL, V59, P993, DOI 10.1016/S0006-2952(99)00405-0; Shen AL, 2002, J BIOL CHEM, V277, P6536, DOI 10.1074/jbc.M111408200; SIIM BG, 1995, BIOCHEM PHARMACOL, V50, P75, DOI 10.1016/0006-2952(95)00112-D; SIIM BG, 1994, BRIT J CANCER, V70, P596, DOI 10.1038/bjc.1994.357; SIIM BG, 1994, BIOCHEM PHARMACOL, V48, P1593, DOI 10.1016/0006-2952(94)90204-6; SILVA JM, 1993, BRIT J CANCER, V68, P484, DOI 10.1038/bjc.1993.374; Singleton RS, 2009, CANCER RES, V69, P3884, DOI 10.1158/0008-5472.CAN-08-4023; Smaill J. B., 2010, U. S. Patent, Patent No. [2010/0173332 A1, 20100173332]; Su JC, 2013, BIOCHEM J, V452, P79, DOI 10.1042/BJ20121695; Tercel M, 2009, J MED CHEM, V52, P7258, DOI 10.1021/jm901202b; Urnov FD, 2005, NATURE, V435, P646, DOI 10.1038/nature03556; Urnov FD, 2010, NAT REV GENET, V11, P636, DOI 10.1038/nrg2842; Vaupel P, 2009, ADV EXP MED BIOL, V645, P241, DOI 10.1007/978-0-387-85998-9_36; WALTON MI, 1992, BIOCHEM PHARMACOL, V44, P251, DOI 10.1016/0006-2952(92)90007-6; Wang JL, 2012, CLIN CANCER RES, V18, P1684, DOI 10.1158/1078-0432.CCR-11-2296; Wang YL, 2010, MOL CANCER THER, V9, P410, DOI 10.1158/1535-7163.MCT-09-0555; WARDMAN P, 1976, BIOCHEM BIOPH RES CO, V69, P942, DOI 10.1016/0006-291X(76)90464-2; Wilson WR, 2011, NAT REV CANCER, V11, P393, DOI 10.1038/nrc3064	68	21	21	0	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 27	2013	288	52					37138	37153		10.1074/jbc.M113.505222	http://dx.doi.org/10.1074/jbc.M113.505222			16	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	282RH	24196959	Green Published, hybrid			2023-01-03	WOS:000329189700033
J	Alfandre, D; Schumann, JH				Alfandre, David; Schumann, John Henning			What Is Wrong With Discharges Against Medical Advice (and How to Fix Them)	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Alfandre, David] NYU, Sch Med, VA Natl Ctr Eth Hlth Care, New York, NY 10010 USA; [Schumann, John Henning] Univ Oklahoma, Sch Community Med, Dept Internal Med, Tulsa, OK USA	New York University; University of Oklahoma System; University of Oklahoma - Tulsa	Alfandre, D (corresponding author), NYU, Sch Med, VA Natl Ctr Eth Hlth Care, 423 E 23rd St,10P6, New York, NY 10010 USA.	david.alfandre@va.gov		Alfandre, David/0000-0001-9778-7580				Alfandre D, 2013, J GEN INTERN MED, V28, P1657, DOI 10.1007/s11606-013-2540-z; BECKMAN HB, 1994, ARCH INTERN MED, V154, P1365, DOI 10.1001/archinte.154.12.1365; Devitt PJ, 2000, J FAM PRACTICE, V49, P224; Fiscella K, 2007, AM J MED, V120, P1047, DOI 10.1016/j.amjmed.2007.08.024; Glasgow JM, 2010, J GEN INTERN MED, V25, P926, DOI 10.1007/s11606-010-1371-4; Schaefer GR, 2012, J GEN INTERN MED, V27, P825, DOI 10.1007/s11606-012-1984-x; Schumann J., 2012, CAN IGNORING MED ADV	7	19	19	0	10	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 11	2013	310	22					2393	2394		10.1001/jama.2013.280887	http://dx.doi.org/10.1001/jama.2013.280887			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	266NN	24216713				2023-01-03	WOS:000328030900014
J	Tomlinson, LA; Abel, GA; Chaudhry, AN; Tomson, CR; Wilkinson, IB; Roland, MO; Payne, RA				Tomlinson, Laurie A.; Abel, Gary A.; Chaudhry, Afzal N.; Tomson, Charles R.; Wilkinson, Ian B.; Roland, Martin O.; Payne, Rupert A.			ACE Inhibitor and Angiotensin Receptor-II Antagonist Prescribing and Hospital Admissions with Acute Kidney Injury: A Longitudinal Ecological Study	PLOS ONE			English	Article							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; CONVERTING ENZYME-INHIBITORS; RISK; COMBINATIONS; MORTALITY; BLOCKERS	Background: ACE Inhibitors (ACE-I) and Angiotensin-Receptor Antagonists (ARAs) are commonly prescribed but can cause acute kidney injury (AKI) during intercurrent illness. Rates of hospitalization with AKI are increasing. We aimed to determine whether hospital AKI admission rates are associated with increased ACE-I/ARA prescribing. Methods and Findings: English NHS prescribing data for ACE-I/ARA prescriptions were matched at the level of the general practice to numbers of hospital admissions with a primary diagnosis of AKI. Numbers of prescriptions were weighted for the demographic characteristics of general practices by expressing prescribing as rates where the denominator is Age, Sex, and Temporary Resident Originated Prescribing Units (ASTRO-PUs). We performed a mixed-effect Poisson regression to model the number of admissions for AKI occurring in each practice for each of 4 years from 1/4/2007. From 2007/8-2010/11, crude AKI admission rates increased from 0.38 to 0.57 per 1000 patients (51.6% increase), and national annual ACE-I/ARA prescribing rates increased by 0.032 from 0.202 to 0.234 (15.8% increase). There was strong evidence (p<0.001) that increases in practice-level prescribing of ACE-I/ARA over the study period were associated with an increase in AKI admission rates. The increase in prescribing seen in a typical practice corresponded to an increase in admissions of approximately 5.1% (rate ratio = 1.051 for a 0.03 per ASTRO-PU increase in annual prescribing rate, 95% CI 1.047-1.055). Using the regression model we predict that 1,636 (95% CI 1,540-1,780) AKI admissions would have been avoided if prescribing rates were at the 2007/8 level, equivalent to 14.8% of the total increase in AKI admissions. Conclusion: In this ecological analysis, up to 15% of the increase in AKI admissions in England over a 4-year time period is potentially attributable to increased prescribing of ACE-I and ARAs. However, these findings are limited by the lack of patient level data such as indication for prescribing and patient characteristics.	[Tomlinson, Laurie A.; Wilkinson, Ian B.] Univ Cambridge, Cambridge Clin Trials Unit, Cambridge, England; [Abel, Gary A.; Roland, Martin O.; Payne, Rupert A.] Cambridge Ctr Hlth Serv Res, Inst Publ Hlth, Cambridge, England; [Chaudhry, Afzal N.] Cambridge Univ Hosp Natl Hlth Serv Fdn Trust, Dept Nephrol, Cambridge, England; [Tomson, Charles R.] North Bristol Natl Hlth Serv Trust, Richard Bright Renal Unit, Bristol, Avon, England	University of Cambridge; University of Cambridge	Tomlinson, LA (corresponding author), Univ Cambridge, Cambridge Clin Trials Unit, Cambridge, England.	lat42@cam.ac.uk	Abel, Gary/ABE-1765-2021	Abel, Gary/0000-0003-2231-5161; Roland, Martin/0000-0002-8533-3060; Tomlinson, Laurie/0000-0001-8848-9493; wilkinson, ian/0000-0001-6598-9399; Tomson, Charles/0000-0002-0224-8726	Cambridge Biomedical Research Institute; British Heart Foundation; British Heart Foundation [FS/12/8/29377] Funding Source: researchfish; National Institute for Health Research [CL-2010-14-003] Funding Source: researchfish	Cambridge Biomedical Research Institute; British Heart Foundation(British Heart Foundation); British Heart Foundation(British Heart Foundation); National Institute for Health Research(National Institute for Health Research (NIHR))	ANC is supported by the Cambridge Biomedical Research Institute and IBW by the British Heart Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abraham KA, 2012, INEQUALITIES OUTCOME; Adhiyaman V, 2001, J ROY SOC MED, V94, P512, DOI 10.1177/014107680109401005; Arora P, 2008, CLIN J AM SOC NEPHRO, V3, P1266, DOI 10.2215/CJN.05271107; Barnett K, 2012, LANCET, V380, P37, DOI 10.1016/S0140-6736(12)60240-2; Bellomo R, 2012, LANCET, V380, P756, DOI 10.1016/S0140-6736(11)61454-2; Brody H, 2011, AM J PUBLIC HEALTH, V101, P399, DOI 10.2105/AJPH.2010.199844; Chertow GM, 2005, J AM SOC NEPHROL, V16, P3365, DOI 10.1681/ASN.2004090740; Fournier JP, 2012, FUNDAM CLIN PHARM; Hsu CY, 2007, KIDNEY INT, V72, P208, DOI 10.1038/sj.ki.5002297; Huerta C, 2005, AM J KIDNEY DIS, V45, P531, DOI 10.1053/j.ajkd.2004.12.005; Joint Formulary Committee, BRIT NATL FORMULARY; Lapi F, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.e8525; Loboz KK, 2005, BRIT J CLIN PHARMACO, V59, P239, DOI 10.1111/j.0306-5251.2004.2188.x; National Health Service, 2011, PRESCR COST AN; National Health Service. The Information Centre, QUAL OUTC FRAM; National Health Service. The Information Centre, HOSP EP STAT; National Institute for Health and Clinical Excellence, 2011, CHRON KIDN DIS QUAL; Okunola O, 2012, Afr J Med Med Sci, V41, P119; Plataki M, 2011, CLIN J AM SOC NEPHRO, V6, P1744, DOI 10.2215/CJN.05480610; Rifkin DE, 2012, J AM SOC NEPHROL, V23, P979, DOI 10.1681/ASN.2011121185; Rim MY, 2012, AM J KIDNEY DIS, V60, P576, DOI 10.1053/j.ajkd.2012.04.017; ROBERTS SJ, 1993, BRIT MED J, V307, P485, DOI 10.1136/bmj.307.6902.485; Smets HLE, 2008, PHARMACOEPIDEM DR S, V17, P1014, DOI 10.1002/pds.1641; Tomlinson LA, 2013, BMC NEPHROL, V14, DOI 10.1186/1471-2369-14-58; Vlasschaert MEO, 2011, AM J KIDNEY DIS, V57, P29, DOI 10.1053/j.ajkd.2010.08.031; Wang HE, 2012, AM J NEPHROL, V35, P349, DOI 10.1159/000337487; Wheeler DC, 2013, KIDNEY INT, V83, P377, DOI 10.1038/ki.2012.425; World Health Organization, 2010, PACK ESS NONC PEN DI; World Health Organization, 1990, INT CLASS DIS, V10th	29	50	50	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 6	2013	8	11							e78465	10.1371/journal.pone.0078465	http://dx.doi.org/10.1371/journal.pone.0078465			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	247XD	24223154	gold, Green Published, Green Submitted			2023-01-03	WOS:000326656200046
J	Bird, ST; Delaney, JAC; Brophy, JM; Etminan, M; Skeldon, SC; Hartzema, AG				Bird, Steven T.; Delaney, Joseph A. C.; Brophy, James M.; Etminan, Mahyar; Skeldon, Sean C.; Hartzema, Abraham G.			Tamsulosin treatment for benign prostatic hyperplasia and risk of severe hypotension in men aged 40-85 years in the United States: risk window analyses using between and within patient methodology	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CONTROLLED CASE SERIES; URINARY-TRACT SYMPTOMS; BLOCKERS; SAFETY	Objective To characterize risk of hypotension requiring admission to hospital in middle aged and older men treated with tamsulosin for benign prostatic hyperplasia. Design Population based retrospective cohort study (between patient methodology) and self controlled case series (within patient methodology). Setting Healthcare claims data from the IMS Lifelink database in the United States. Participants Men aged 40-85 years with private US healthcare insurance entering the cohort at their first dispensing for tamsulosin or for a 5a reductase inhibitor (5ARI) between January 2001 and June 2011 after a minimum of six months' enrolment. Main outcomes measures Hypotension requiring admission to hospital. Cox proportional hazards models estimated rate ratios at time varying intervals during follow-up: weeks 1-4, 5-8, and 9-12 after tamsulosin initiation; weeks 1-4, 5-8, and 9-12 after restarting tamsulosin (after a four week gap); and maintenance tamsulosin treatment (remaining exposed person time). Covariates included age, calendar year, demographics, antihypertensive use, healthcare use, and a Charlson comorbidity score. A self controlled case series, having implicit control for time invariant covariates, was additionally conducted. Results Among 383 567 new users of study drugs (tamsulosin 297 596; 5ARI 85 971), 2562 admissions to hospital for severe hypotension were identified. The incidence for hypotension was higher for tamsulosin (42.4 events per 10 000 person years) than for 5ARIs (31.3 events per 10 000 person years) or all accrued person time (29.1 events per 10 000 person years). After tamsulosin initiation, the cohort analysis identified an increased rate of hypotension during weeks 1-4 (rate ratio 2.12 (95% confidence interval 1.29 to 3.04)) and 5-8 (1.51 (1.04 to 2.18)), and no significant increase at weeks 9-12. The rate ratio for hypotension also increased at weeks 1-4 (1.84 (1.46 to 2.33)) and 5-8 (1.85 (1.45 to 2.36)) after restarting tamsulosin, as did maintenance tamsulosin treatment (1.19 (1.07 to 1.32)). The self controlled case series gave similar results as the cohort analysis. Conclusions We observed a temporal association between tamsulosin use for benign prostatic hyperplasia and severe hypotension during the first eight weeks after initiating treatment and the first eight weeks after restarting treatment. This association suggests that physicians should focus on improving counseling strategies to warn patients regarding the "first dose phenomenon" with tamsulosin.	[Bird, Steven T.] US FDA, Ctr Drug Evaluat & Res, Off Surveillance & Epidemiol, Dept Epidemiol, Silver Spring, MD USA; [Bird, Steven T.; Hartzema, Abraham G.] Univ Florida, Coll Pharm & Epidemiol Pharmaceut Outcomes & Poli, Gainesville, FL USA; [Delaney, Joseph A. C.] Univ Washington, Sch Publ Hlth, Dept Epidemiol, Seattle, WA 98195 USA; [Brophy, James M.] McGill Univ, Royal Victoria Hosp, Ctr Hlth, Montreal, PQ H3A 1A1, Canada; [Etminan, Mahyar] Univ British Columbia, Fac Med, Therapeut Evaluat Unit, Prov Hlth Serv Author, Vancouver, BC V5Z 1M9, Canada; [Skeldon, Sean C.] Univ Toronto, Dept Surg, Div Urol, Toronto, ON, Canada; [Skeldon, Sean C.] Univ British Columbia, Dept Urol Sci, Vancouver, BC V5Z 1M9, Canada	US Food & Drug Administration (FDA); State University System of Florida; University of Florida; University of Washington; University of Washington Seattle; McGill University; Royal Victoria Hospital; University of British Columbia; University of Toronto; University of British Columbia	Etminan, M (corresponding author), Univ British Columbia, Fac Med, Therapeut Evaluat Unit, Prov Hlth Serv Author, Vancouver, BC V5Z 1M9, Canada.	metminan@popi.ubc.ca	brophy, james/H-6673-2019; Delaney, Joseph A/J-8204-2019	brophy, james/0000-0001-8049-6875; Delaney, Joseph A/0000-0003-1771-1776	McGill University Health Center; Fonds de la Recherche en Sante du Quebec; Ministere de la Sante et des Services Sociaux	McGill University Health Center; Fonds de la Recherche en Sante du Quebec(Fonds de la Recherche en Sante du Quebec); Ministere de la Sante et des Services Sociaux	This work was funded in part by the McGill University Health Center, Fonds de la Recherche en Sante du Quebec, and the Ministere de la Sante et des Services Sociaux. The authors had full autonomy in the study design; the collection, analysis, and interpretation of data; the writing of the article; and the decision to submit it for publication. The authors have no other conflicts or competing interests to declare. Competing interests: All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure. pdf and declare: support from the McGill University Health Center, Fonds de la Recherche en Sante du Quebec, and the Ministere de la Sante et des Services Sociaux for the submitted work; JMB has received peer review financial support from le Fonds de la Recherche en Sante du Quebec, JACD has a research grant from the Agency for Healthcare Research and Quality, AGH is a principal investigator for the Observational Medical Outcomes Partnership, a private-public partnership designed to help improve drug safety monitoring, and STB is employed by the US Food and Drug Administration; no other relationships or activities that could appear to have influenced the submitted work.	American Urological Association, 2010, MAN BEN PROST HYP BP; [Anonymous], 1997, 20579 NDA FOOD DRUG; BENDALL MJ, 1975, BRIT MED J, V2, P727, DOI 10.1136/bmj.2.5973.727-a; Bird ST, 2013, CAN MED ASSOC J, V185, pE475, DOI 10.1503/cmaj.121730; Black L, 2006, AM J MANAG CARE, V12, pS99; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; DEYO RA, 1992, J CLIN EPIDEMIOL, V45, P613, DOI 10.1016/0895-4356(92)90133-8; Douglas IJ, 2013, BMJ-BRIT MED J, V346, P1936; Farrington CP, 2006, J R STAT SOC C-APPL, V55, P553, DOI 10.1111/j.1467-9876.2006.00554.x; Farrington CP, 2011, J AM STAT ASSOC, V106, P417, DOI 10.1198/jasa.2011.ap10108; Farrington CP, 2009, BIOSTATISTICS, V10, P3, DOI 10.1093/biostatistics/kxn013; FORRAY C, 1994, MOL PHARMACOL, V45, P703; IMS Health, 2010, LIFELINK HLTH PLAN C; Jacobsen SJ, 2008, JAMA-J AM MED ASSOC, V300, P1660, DOI 10.1001/jama.300.14.1660; Jick SS, 2011, BMJ-BRIT MED J, V342, DOI 10.1136/bmj.d2151; Maclure M, 2012, PHARMACOEPIDEM DR S, V21, P50, DOI 10.1002/pds.2330; NASH DT, 1990, CLIN CARDIOL, V13, P764, DOI 10.1002/clc.4960131104; Parsons JK, 2009, BJU INT, V104, P63, DOI 10.1111/j.1464-410X.2008.08317.x; Pfizer Pharmaceuticals, 2010, CARD PACK INS; Prasad V, 2013, JAMA-J AM MED ASSOC, V309, P241, DOI 10.1001/jama.2012.96867; Provider Synergies, 2010, BEN PROST HYP BPH TR; Stafford RS, 2004, JAMA-J AM MED ASSOC, V291, P54, DOI 10.1001/jama.291.1.54; Whitaker HJ, 2007, ENVIRONMETRICS, V18, P157, DOI 10.1002/env.809; Whitaker HJ, 2006, STAT MED, V25, P1768, DOI 10.1002/sim.2302; Whitaker HJ, 2009, STAT METHODS MED RES, V18, P7, DOI 10.1177/0962280208092342; Wilt T, 2002, COCHRANE DB SYST REV, V4; Winterstein AG, 2012, BMJ-BRIT MED J, V345, DOI 10.1136/bmj.e4627; Wright AJ, 2011, CAN MED ASSOC J, V183, P303, DOI 10.1503/cmaj.100702; Yoshimura K, 2013, INT J MED SCI, V10, P864, DOI 10.7150/ijms.5892	29	48	50	0	7	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 5	2013	347								f6320	10.1136/bmj.f6320	http://dx.doi.org/10.1136/bmj.f6320			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	250XL	24192967	hybrid, Green Published			2023-01-03	WOS:000326890000002
J	Retana, C; Sanchez, EI; Gonzalez, S; Perez-Lopez, A; Cruz, A; Lagunas-Munoz, J; Alfaro-Cruz, C; Vital-Flores, S; Reyes, JL				Retana, Carmen; Sanchez, Elsa I.; Gonzalez, Sirenia; Perez-Lopez, Alejandro; Cruz, Armando; Lagunas-Munoz, Jesus; Alfaro-Cruz, Carmen; Vital-Flores, Socorro; Reyes, Jose L.			Retinoic Acid Improves Morphology of Cultured Peritoneal Mesothelial Cells from Patients Undergoing Dialysis	PLOS ONE			English	Article							EPIDERMAL-GROWTH-FACTOR; HIGH GLUCOSE; MESENCHYMAL TRANSITION; FACTOR-BETA; SURFACE; EXPRESSION; SINUS; DIFFERENTIATION; MICROVILLI; INDUCTION	Patients undergoing continuous ambulatory peritoneal dialysis are classified according to their peritoneal permeability as low transporter (low solute permeability) or High transporter (high solute permeability). Factors that determine the differences in permeability between them have not been fully disclosed. We investigated morphological features of cultured human peritoneal mesothelial cells from low or high transporter patients and its response to All trans retinoic Acid (ATRA, vitamin A active metabolite), as compared to non-uremic human peritoneal mesothelial cells. Control cells were isolated from human omentum. High or low transporter cells were obtained from dialysis effluents. Cells were cultured in media containing ATRA (0, 50, 100 or 200 nM). We studied length and distribution of microvilli and cilia (scanning electron microscopy), epithelial (cytokeratin, claudin-1, ZO-1 and occludin) and mesenchymal (vimentin and alpha-smooth muscle actin) transition markers by immunofluorescence and Western blot, and transforming growth factor beta 1 expression by Western blot. Low and high transporter exhibited hypertrophic cells, reduction in claudin-1, occludin and ZO-1 expression, cytokeratin and vimentin disorganization and positive alpha-smooth muscle actin label. Vimentin, alpha-smooth muscle actin and transforming growth factor- beta 1 were overexpressed in low transporter. Ciliated cells were diminished in low and high transporters. Microvilli number and length were severely reduced in high transporter. ATRA reduced hypertrophic cells number in low transporter. It also improved cytokeratin and vimentin organization, decreased vimentin and alpha-smooth muscle actin expression, and increased claudin 1, occludin and ZO-1 expression, in low and high transporter. In low transporter, ATRA reduced transforming growth factor-beta 1 expression. ATRA augmented percentage of ciliated cells in low and high transporter. It also augmented cilia length in high transporter. Alterations in structure, epithelial mesenchymal markers and transforming growth factor-beta 1expression were differential between low and high transporter. Beneficial effects of ATRA were improved human peritoneal mesothelial cells morphology tending to normalize structures.	[Retana, Carmen] Natl Polytech Inst, Ctr Res & Adv Studies, Dept Pharmacol, Mexico City, DF, Mexico; [Sanchez, Elsa I.; Reyes, Jose L.] Natl Polytech Inst, Ctr Res & Adv Studies, Physiol Biophys & Neurosci Dept, Mexico City, DF, Mexico; [Gonzalez, Sirenia] Natl Polytech Inst, Ctr Res & Adv Studies, Cent Labs, Mexico City, DF, Mexico; [Perez-Lopez, Alejandro] Hosp Cent Norte Petr Mexicanos, Dept Nephrol, Mexico City, DF, Mexico; [Cruz, Armando; Lagunas-Munoz, Jesus] Hosp Gen Raza, Inst Mexicano Seguro Social, Dept Nephrol, Unidad Med Alta Especialidad, Mexico City, DF, Mexico; [Cruz, Armando; Lagunas-Munoz, Jesus] Hosp Gen Raza, Inst Mexicano Seguro Social, Dept Gynecol, Unidad Med Alta Especialidad, Mexico City, DF, Mexico; [Alfaro-Cruz, Carmen] Hosp Reg 1, Inst Mexicano Seguro Social, Dept Nephrol, Mexico City, DF, Mexico; [Vital-Flores, Socorro] Hosp Juarez Mexico, Dept Nephrol, Mexico City, DF, Mexico	Instituto Politecnico Nacional - Mexico; Instituto Politecnico Nacional - Mexico; Instituto Politecnico Nacional - Mexico; Instituto Mexicano del Seguro Social; Instituto Mexicano del Seguro Social; Instituto Mexicano del Seguro Social	Reyes, JL (corresponding author), Natl Polytech Inst, Ctr Res & Adv Studies, Physiol Biophys & Neurosci Dept, Mexico City, DF, Mexico.	jreyes@fisio.cinvestav.mx	Retana Contreras, Maria del Carmen/Q-8946-2018	Retana Contreras, Maria del Carmen/0000-0003-0457-8478	Consejo Nacional de Ciencia y Tecnologia (CONACYT), Mexico [0179870];  [CONACYT 176602]	Consejo Nacional de Ciencia y Tecnologia (CONACYT), Mexico(Consejo Nacional de Ciencia y Tecnologia (CONACyT)); 	Study partially supported by Consejo Nacional de Ciencia y Tecnologia (CONACYT), Mexico (Grant 0179870). Carmen Retana had a postgraduate fellowship (CONACYT 176602). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bird SD, 2004, CELL BIOL INT, V28, P79, DOI 10.1016/j.cellbi.2003.11.014; BOMAN BM, 1983, LAB INVEST, V48, P199; BORNSTEIN MB, 1958, LAB INVEST, V7, P134; Cardenas-Rodriguez M, 2009, AM J MED GENET C, V151C, P263, DOI 10.1002/ajmg.c.30227; Chan TM, 2003, NEPHROL DIAL TRANSPL, V18, P1086, DOI 10.1093/ndt/gfg096; Clagett-Dame M, 2011, NUTRIENTS, V3, P385, DOI 10.3390/nu3040385; COHEN PS, 1995, CANCER RES, V55, P2380; Correa-Rotter R, 2001, PERITON DIALYSIS INT, V21, pS75; Danielpour D, 1996, J CELL PHYSIOL, V166, P231, DOI 10.1002/(SICI)1097-4652(199601)166:1<231::AID-JCP24>3.0.CO;2-G; Diaz C, 1998, ADV PERIT D, V14, P19; Erickson VR, 2008, AM J RHINOL, V22, P334, DOI 10.2500/ajr.2008.22.3176; Fang W, 2004, CHINESE MED J-PEKING, V117, P862; Germain P, 2006, PHARMACOL REV, V58, P712, DOI 10.1124/pr.58.4.4; GOTLOIB L, 1989, NEPHRON, V51, P77, DOI 10.1159/000185247; GuerreroBarrera AL, 1996, MICROBIOL-SGM, V142, P1133, DOI 10.1099/13500872-142-5-1133; Hill EM, 1998, AM J RESP CELL MOL, V18, P662, DOI 10.1165/ajrcmb.18.5.2985; Hills CE, 2012, DIABETOLOGIA, V55, P812, DOI 10.1007/s00125-011-2409-9; HONG WK, 1994, LEUKEMIA, V8, pS33; Hwang PH, 2006, LARYNGOSCOPE, V116, P1080, DOI 10.1097/01.mlg.0000224352.50256.99; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Kang DH, 1999, PERITON DIALYSIS INT, V19, P221; KIM KH, 1987, J CELL BIOL, V105, P3039, DOI 10.1083/jcb.105.6.3039; Ksiazek K, 2007, LAB INVEST, V87, P345, DOI 10.1038/labinvest.3700519; Kultti A, 2006, J BIOL CHEM, V281, P15821, DOI 10.1074/jbc.M512840200; Lange K, 2001, AM J PHYSIOL-CELL PH, V281, pC369, DOI 10.1152/ajpcell.2001.281.2.C369; Lange K, 2011, J CELL PHYSIOL, V226, P896, DOI 10.1002/jcp.22302; Lee EA, 2001, PERITON DIALYSIS INT, V21, P245; Lee HB, 2007, J KOREAN MED SCI, V22, P943, DOI 10.3346/jkms.2007.22.6.943; Lee YM, 2008, J BIOL CHEM, V283, P33969, DOI 10.1074/jbc.M804469200; Leung MK, 2007, AM J RHINOL, V21, P271, DOI 10.2500/ajr.2007.21.3035; Liu QH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032009; Lopez-Cabrera M, 2006, PERITON DIALYSIS INT, V26, P26; Million K, 2001, AM J RESP CELL MOL, V25, P744, DOI 10.1165/ajrcmb.25.6.4549; Mutsaers SE, 2002, RESPIROLOGY, V7, P171, DOI 10.1046/j.1440-1843.2002.00404.x; Mutsaers SE, 2004, INT J BIOCHEM CELL B, V36, P9, DOI 10.1016/S1357-2725(03)00242-5; Mutsaers SE, 1996, J PATHOL, V180, P333; Pasonen-Seppanen SM, 2008, J INVEST DERMATOL, V128, P797, DOI 10.1038/sj.jid.5701098; Piskunov A, 2012, ONCOGENE, V31, P3333, DOI 10.1038/onc.2011.499; Rohatgi R, 2010, CURR OPIN CELL BIOL, V22, P541, DOI 10.1016/j.ceb.2010.03.010; Saavalainen K, 2005, J BIOL CHEM, V280, P14636, DOI 10.1074/jbc.M500206200; Singh B, 2007, MOL CANCER, V6, DOI 10.1186/1476-4598-6-82; Strippoli R, 2010, J CELL SCI, V123, P4321, DOI 10.1242/jcs.071647; Wang Gui-hua, 2008, Sichuan Da Xue Xue Bao Yi Xue Ban, V39, P575; Wang T, 1998, NEPHROL DIAL TRANSPL, V13, P1242, DOI 10.1093/ndt/13.5.1242; Witowski J, 2008, NEPHRON EXP NEPHROL, V108, pE69, DOI 10.1159/000126920; Wolf G, 2001, AM J PATHOL, V158, P1091, DOI 10.1016/S0002-9440(10)64056-4; YANEZ MM, 2003, N ENGL MED, P403; Yang AH, 2003, KIDNEY INT, V63, P1530, DOI 10.1046/j.1523-1755.2003.00861.x; Yung S, 2006, PERITON DIALYSIS INT, V26, P162; Yung S, 2007, PERITON DIALYSIS INT, V27, pS110; Yung S, 2012, MEDIAT INFLAMM, V2012, DOI 10.1155/2012/484167; Zhong H, 2009, INT J HEMATOL, V89, P438, DOI 10.1007/s12185-009-0293-6	52	3	3	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 4	2013	8	11							e79678	10.1371/journal.pone.0079678	http://dx.doi.org/10.1371/journal.pone.0079678			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	245ZC	24223992	Green Submitted, Green Published, gold			2023-01-03	WOS:000326503400137
J	Mayer, KH				Mayer, Kenneth H.			Thinking about an AIDS end game	LANCET			English	Editorial Material							HIV-1 INFECTION; PREVENTION; MEN		Fenway Hlth, Fenway Inst, Boston, MA 02118 USA	Fenway Health	Mayer, KH (corresponding author), Fenway Hlth, Fenway Inst, Boston, MA 02118 USA.	khmayer@gmail.com						Baeten JM, 2012, NEW ENGL J MED, V367, P399, DOI 10.1056/NEJMoa1108524; Cohen MS, 2011, NEW ENGL J MED, V365, P493, DOI [10.1056/NEJMoa1105243, 10.1056/NEJMoa1600693]; Dubin C, 2013, TRANSFUSION, V53, P2359, DOI 10.1111/trf.12374; Ghoshal N., 2013, HUMAN RIGHTS WATCH; Grant RM, 2010, NEW ENGL J MED, V363, P2587, DOI 10.1056/NEJMoa1011205; GROOPMAN JE, 1985, ANN INTERN MED, V102, P334, DOI 10.7326/0003-4819-102-3-334; Henrich T, 2013, 7TH IAS CONFERENCE O; Hutter G, 2009, NEW ENGL J MED, V360, P692, DOI 10.1056/NEJMoa0802905; Persaud D., 2013, SATELLITE OF THE INT; Rerks-Ngarm S, 2009, NEW ENGL J MED, V361, P2209, DOI 10.1056/NEJMoa0908492; Simon V, 2006, LANCET, V368, P489, DOI 10.1016/S0140-6736(06)69157-5; Sullivan, 1996, NEW YORK TIMES MAGAZ; UNAIDS, 2013, DATA AND ANALYSIS	13	0	0	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 2	2013	382	9903					1462	1464		10.1016/S0140-6736(13)62029-2	http://dx.doi.org/10.1016/S0140-6736(13)62029-2			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	247MR	24182528				2023-01-03	WOS:000326622500005
J	Amoabeng, BW; Gurr, GM; Gitau, CW; Nicol, HI; Munyakazi, L; Stevenson, PC				Amoabeng, Blankson W.; Gurr, Geoff M.; Gitau, Catherine W.; Nicol, Helen I.; Munyakazi, Louis; Stevenson, Phil C.			Tri-Trophic Insecticidal Effects of African Plants against Cabbage Pests	PLOS ONE			English	Article							PLUTELLA-XYLOSTELLA LEPIDOPTERA; CRUDE SEED EXTRACTS; DIAMONDBACK MOTH; MELIA-AZEDARACH; AZADIRACHTA-INDICA; ANNONA-SQUAMOSA; STORAGE PESTS; MANAGEMENT; L.; FIELD	Botanical insecticides are increasingly attracting research attention as they offer novel modes of action that may provide effective control of pests that have already developed resistance to conventional insecticides. They potentially offer cost-effective pest control to smallholder farmers in developing countries if highly active extracts can be prepared simply from readily available plants. Field cage and open field experiments were conducted to evaluate the insecticidal potential of nine common Ghanaian plants: goat weed, Ageratum conyzoides (Asteraceae), Siam weed, Chromolaena odorata (Asteraceae), Cinderella weed, Synedrella nodiflora (Asteraceae), chili pepper, Capsicum frutescens (Solanaceae), tobacco, Nicotiana tabacum (Solanaceae) cassia, Cassia sophera (Leguminosae), physic nut, Jatropha curcas (Euphorbiaceae), castor oil plant, Ricinus communis (Euphorbiaceae) and basil, Ocimum gratissimum (Lamiaceae). In field cage experiments, simple detergent and water extracts of all botanical treatments gave control of cabbage aphid, Brevicoryne brassicae and diamondback moth, Plutella xylostella, equivalent to the synthetic insecticide Attack (R) (emamectin benzoate) and superior to water or detergent solution. In open field experiments in the major and minor rainy seasons using a sub-set of plant extracts (A. conyzoides, C. odorata, S. nodiflora, N. tabacum and R. communis), all controlled B. brassicae and P. xylostella more effectively than water control and comparably with or better than Attack (R). Botanical and water control treatments were more benign to third trophic level predators than Attack (R). Effects cascaded to the first trophic level with all botanical treatments giving cabbage head weights, comparable to Attack (R) in the minor season. In the major season, R. communis and A conyzoides treatment gave lower head yields than Attack (R) but the remaining botanicals were equivalent or superior to this synthetic insecticide. Simply-prepared extracts from readily-available Ghanaian plants give beneficial, tri-trophic benefits and merit further research as an inexpensive plant protection strategy for smallholder farmers in West Africa.	[Amoabeng, Blankson W.; Nicol, Helen I.] Charles Sturt Univ, Sch Agr & Wine Sci, Orange, NSW, Australia; [Gurr, Geoff M.; Gitau, Catherine W.] NSW Dept Primary Ind, EH Graham Ctr Agr Innovat, Orange, NSW, Australia; [Gurr, Geoff M.; Gitau, Catherine W.] Charles Sturt Univ, Orange, NSW, Australia; [Munyakazi, Louis] Kumasi Polytech, Dept Math & Stat, Kumasi, Ghana; [Stevenson, Phil C.] Royal Bot Gardens, Richmond, Surrey, England; [Amoabeng, Blankson W.] Crops Res Inst, Council Sci & Ind Res, Kumasi, Ghana	Charles Sturt University; NSW Department of Primary Industries; Charles Sturt University; Royal Botanic Gardens, Kew	Amoabeng, BW (corresponding author), Charles Sturt Univ, Sch Agr & Wine Sci, Orange Campus, Orange, NSW, Australia.	kblanksin@yahoo.com	Clarke, Catherine Wanjiru/K-2944-2019; stevenson, philip c/E-8741-2013; Stevenson, Philip C/E-8822-2013; GURR, GEOFFREY M/F-3519-2011	Clarke, Catherine Wanjiru/0000-0002-4397-9381; stevenson, philip c/0000-0002-0736-3619; Stevenson, Philip C/0000-0002-0736-3619; Gurr, Geoff/0000-0001-5008-7966	Charles Sturt University; AusAID	Charles Sturt University; AusAID(Australian Aid (AusAID))	Financial support was given by Charles Sturt University and AusAID. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	AFUN JVK, 1991, CROP PROT, V10, P363, DOI 10.1016/S0261-2194(06)80025-6; Ahmed B. I., 2009, Journal of Biopesticides, V2, P37; [Anonymous], 1925, J ECON ENTOMOL; Ayalew G, 2006, J APPL ENTOMOL, V130, P343, DOI 10.1111/j.1439-0418.2006.01078.x; Baker GJ, 1999, AUST J ENTOMOL, V38, P132, DOI 10.1046/j.1440-6055.1999.00087.x; Buss EA, 2002, UF IFAS PUBLICATION; Charleston DS, 2006, BIOL CONTROL, V39, P105, DOI 10.1016/j.biocontrol.2006.05.012; Charleston DS, 2005, B ENTOMOL RES, V95, P457, DOI 10.1079/BER2005377; Coulibaly O., 2007, J VEG SCI, V12, P27; de Oliveira AC, 2011, SCI AGR, V68, P154, DOI 10.1590/S0103-90162011000200004; Devanand Peta, 2008, Journal of Biopesticides, V1, P170; Dubey NK, 2011, NATURAL PRODUCTS IN PLANT PEST MANAGEMENT, P1, DOI 10.1079/9781845936716.0001; Fening K. O., 2011, Organic is Life - Knowledge for Tomorrow. Volume 1 - Organic Crop Production. Proceedings of the Third Scientific Conference of the International Society of Organic Agriculture Research (ISOFAR), held at the 17th IFOAM Organic World Congress in cooperation with the International Federation of Organic Agriculture Movements (IFOAM) and the Korean Organizing Committee (KOC), 28. September - 1. October 2011 in Namyangju, Korea Republic, P567; Flint M, 1991, INTEGRATED PEST MANA; Furlong MJ, 2013, ANNU REV ENTOMOL, V58, P517, DOI 10.1146/annurev-ento-120811-153605; Gendo JO, 2008, J STORED PROD RES, V44, P328, DOI 10.1016/j.jspr.2008.02.009; Gerken A., 2001, PESTICIDE POLICY PRO, V10, P90; Grzywacz D, 2010, CROP PROT, V29, P68, DOI 10.1016/j.cropro.2009.08.009; HUGHES RD, 1963, J ANIM ECOL, V32, P393, DOI 10.2307/2600; Isman MB, 2000, CROP PROT, V19, P603, DOI 10.1016/S0261-2194(00)00079-X; Jansson R., 1997, P 3 INT WORKSH MAN D; Kawuki RS, 2005, CROP PROT, V24, P473, DOI 10.1016/j.cropro.2004.09.017; Kestenholz C, 2007, J STORED PROD RES, V43, P79, DOI 10.1016/j.jspr.2005.11.003; Kianmatee Supawan, 2007, Journal of Asia-Pacific Entomology, V10, P69, DOI 10.1016/S1226-8615(08)60333-7; Kibrom Gebremariam, 2012, Archives of Phytopathology and Plant Protection, V45, P1273, DOI 10.1080/03235408.2012.673260; Leatemia JA, 2004, INT J PEST MANAGE, V50, P129, DOI 10.1080/096708704100001691821; Liu SS, 2000, B ENTOMOL RES, V90, P221; Macharia I, 2005, CROP PROT, V24, P981, DOI 10.1016/j.cropro.2005.02.005; Mitchell ER, 1997, FLA ENTOMOL, V80, P477, DOI 10.2307/3495613; Mochiah M. B., 2011, Journal of Applied Biosciences, V38, P2564; Mochiah M.B., 2011, J ENTOMOL NEMATOL, V3, P85; Ntow WJ, 2006, PEST MANAG SCI, V62, P356, DOI 10.1002/ps.1178; Obeng-Ofori D., 2002, AGR FOOD SCI J GHANA, V1, P83; Obopile M, 2008, CROP PROT, V27, P1220, DOI 10.1016/j.cropro.2008.03.003; Opender Koul, 2003, Predators and parasitoids, P1; Rando J. S. S., 2011, Semina: Ciencias Agrarias (Londrina), V32, P503; Rathi JM, 2005, J CENT EUR AGRIC, V6, P223; Reuben S. O. W. M., 2006, Asian Journal of Plant Sciences, V5, P85; Sarfraz M, 2005, BIOCONTROL SCI TECHN, V15, P763, DOI 10.1080/09583150500136956; SAS, 2005, SAS US GUID SAS US G; Seffrin RD, 2010, CROP PROT, V29, P20, DOI 10.1016/j.cropro.2009.09.003; Waiganjo MM., 2011, E AFR AGR FORESTRY J, V77, P545; Wei SJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059654; Weinberger Katinka, 2009, Journal of Asia-Pacific Entomology, V12, P253, DOI 10.1016/j.aspen.2009.08.003; Zalucki MP, 2012, J ECON ENTOMOL, V105, P1115, DOI 10.1603/EC12107	45	65	71	1	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 24	2013	8	10							e78651	10.1371/journal.pone.0078651	http://dx.doi.org/10.1371/journal.pone.0078651			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	241FR	24205287	Green Published, Green Submitted, gold			2023-01-03	WOS:000326152300077
J	Jepson, R; Craig, J; Williams, G				Jepson, Ruth; Craig, Jonathan; Williams, Gabrielle			Cranberry Products and Prevention of Urinary Tract Infections	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Jepson, Ruth] Univ Edinburgh, Scottish Collaborat Publ Hlth Res & Policy, Ctr Populat Hlth Sci, Edinburgh EH8 9DX, Midlothian, Scotland; [Craig, Jonathan; Williams, Gabrielle] Univ Sydney, Sch Publ Hlth, Sydney, NSW 2006, Australia	University of Edinburgh; University of Sydney	Jepson, R (corresponding author), Univ Edinburgh, Scottish Collaborat Publ Hlth Res & Policy, Edinburgh EH8 9DX, Midlothian, Scotland.	ruth.jepson@ed.ac.uk	Craig, Jonathan/E-2813-2013	Craig, Jonathan/0000-0002-2548-4035; Jepson, Ruth/0000-0002-9446-445X	MRC [MR/K023209/1] Funding Source: UKRI; Medical Research Council [O12345678] Funding Source: researchfish; Medical Research Council [MR/K023209/1] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Howell AB, 2005, PHYTOCHEMISTRY, V66, P2281, DOI 10.1016/j.phytochem.2005.05.022; Howell AB, 2002, JAMA-J AM MED ASSOC, V287, P3082, DOI 10.1001/jama.287.23.3082; Howell AB, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-94; Jepson RG, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001321.pub5	4	20	21	1	40	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 2	2013	310	13					1395	1396		10.1001/jama.2013.277509	http://dx.doi.org/10.1001/jama.2013.277509			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	227GB	24084925				2023-01-03	WOS:000325098100025
J	Kaplan, WA; Wirtz, VJ; Stephens, P				Kaplan, Warren A.; Wirtz, Veronika J.; Stephens, Peter			The Market Dynamics of Generic Medicines in the Private Sector of 19 Low and Middle Income Countries between 2001 and 2011: A Descriptive Time Series Analysis	PLOS ONE			English	Article							PRICE	This observational study investigates the private sector, retail pharmaceutical market of 19 low and middle income countries (LMICs) in Latin America, Asia and the Middle East/South Africa analyzing the relationships between volume market share of generic and originator medicines over a time series from 2001 to 2011. Over 5000 individual pharmaceutical substances were divided into generic (unbranded generic, branded generic medicines) and originator categories for each country, including the United States as a comparator. In 9 selected LMICs, the market share of those originator substances with the largest decrease over time was compared to the market share of their counterpart generic versions. Generic medicines (branded generic plus unbranded generic) represent between 70 and 80% of market share in the private sector of these LMICs which exceeds that of most European countries. Branded generic medicine market share is higher than that of unbranded generics in all three regions and this is in contrast to the U. S. Although switching from an originator to its generic counterpart can save money, this narrative in reality is complex at the level of individual medicines. In some countries, the market behavior of some originator medicines that showed the most temporal decrease, showed switching to their generic counterpart. In other countries such as in the Middle East/South Africa and Asia, the loss of these originators was not accompanied by any change at all in market share of the equivalent generic version. For those countries with a significant increase in generic medicines market share and/or with evidence of comprehensive "switching" to generic versions, notably in Latin America, it would be worthwhile to establish cause-effect relationships between pharmaceutical policies and uptake of generic medicines. The absence of change in the generic medicines market share in other countries suggests that, at a minimum, generic medicines have not been strongly promoted.	[Kaplan, Warren A.; Wirtz, Veronika J.] Boston Univ, Sch Publ Hlth, Ctr Global Hlth & Dev, Boston, MA USA; [Kaplan, Warren A.; Wirtz, Veronika J.] Boston Univ, World Hlth Org Collaborating Ctr Pharmaceut Polic, Boston, MA 02215 USA; [Stephens, Peter] IMS Hlth, London, England; [Stephens, Peter] UIPS, World Hlth Org Collaborating Ctr Pharmacoepidemio, Utrecht, Netherlands	Boston University; Boston University; World Health Organization; Utrecht University; World Health Organization	Wirtz, VJ (corresponding author), Boston Univ, Sch Publ Hlth, Ctr Global Hlth & Dev, Boston, MA USA.	vwirtz@bu.edu	Wirtz, Veornika/AAG-9712-2019	Kaplan, Warren/0000-0001-6127-4820; Wirtz, Veronika J./0000-0002-0863-8768				Cameron A, 2012, VALUE HEALTH, V15, P664, DOI 10.1016/j.jval.2012.04.004; Dylst P, 2011, PHARMACOECONOMICS, V29, P875, DOI 10.2165/11585970-000000000-00000; Dylst P, 2010, PHARMACEUTICALS, V3, P471, DOI 10.3390/ph3030471; Generic Pharmaceutical Association, 2012, SAV 1 TRILL 10 YEARS; Gomes Barra AC, 2011, J GENERIC MED, V2, P72, DOI DOI 10.1177/1741134311411266; Gonzalez Pier E, 2011, WORKING HLTH POPULAT; Hamburg M, 2012, GPHA ANN M; IMS Health, IMS HLTH GLOB HLTH R; Kanavos P, 2008, EUROPEAN OBSERVATORY; Kaplan WA, 2012, HEALTH POLICY, V106, P211, DOI 10.1016/j.healthpol.2012.04.015; King DR, 2002, CROAT MED J, V43, P462; Madden JM, 2010, REV PANAM SALUD PUBL, V27, P291, DOI 10.1590/S1020-49892010000400008; Pan American Health Organization (Organizacion Panamericana de Salud), 2010, GUID IMPL GEN MED ST; Sheppard A., 2011, GENERIC MED ESSENTIA; Singal GL, 2011, INDIAN J PHARMACOL, V43, P131, DOI 10.4103/0253-7613.77344; Sooksriwong C., 2009, Southern Med Review, V2, P10; The Global Use of Medicines, 2012, OUTLOOK 2016 REPORT; Tobar F, 2008, REV PANAM SALUD PUBL, V23, P59, DOI 10.1590/S1020-49892008000100008; US Department of Health and Human Services, 2010, ASPE ISS BRIEF EXP U; van Mourik MSM, 2010, BMC CARDIOVASC DISOR, V10, DOI 10.1186/1471-2261-10-25; Waning B, 2010, GLOB HLTH, V6; Waning B, 2010, J INT AIDS SOC, V13, DOI 10.1186/1758-2652-13-35; Waning B, 2009, B WORLD HEALTH ORGAN, V87, P520, DOI 10.2471/BLT.08.058925	23	33	33	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 30	2013	8	9							e74399	10.1371/journal.pone.0074399	http://dx.doi.org/10.1371/journal.pone.0074399			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	231NL	24098644	Green Submitted, Green Published, gold			2023-01-03	WOS:000325423500015
J	Chen, XR; Yang, ZG; Lu, YF; Xu, QN; Wang, Q; Chen, L				Chen, Xiaorong; Yang, Zongguo; Lu, Yunfei; Xu, Qingnian; Wang, Qiang; Chen, Liang			Clinical Features and Factors Associated with Outcomes of Patients Infected with a Novel Influenza A (H7N9) Virus: A Preliminary Study	PLOS ONE			English	Article							AVIAN INFLUENZA; T-CELLS; CD45; H1N1; GENE; MEDICINE; H5N1	Objective: The present study aimed to analyze clinical features and factors associated with treatment outcomes of H7N9 influenza A virus infection. Methods: The clinical progress in 18 H7N9-infected patients was monitored and recorded. The clinical features of H7N9 infection were noted and factors associated with treatment outcomes were analyzed by univariate analyses. Results: The average ages of patients in recovered and critical conditions were 67.0 +/- 10.83 years and 72.75 +/- 12.0 years, respectively. Renal insufficiency developed more frequently in critically ill patients (P = 0.023). The duration of traditional Chinese medicine (TCM) therapy was longer in recovered patients than in critically ill patients (P = 0.01). Laboratory tests showed that levels of C-reactive protein, serum creatinine, and myoglobin were significantly higher in critically ill patients than in recovered patients (P = 0.011, 0.04, and 0.016, respectively). Meanwhile, levels of all T cell subsets examined including total CD3(+), CD4(+), CD8(+), and CD45(+) T cells were lower in critically ill patients than in recovered patients (P = 0.033, 0.059, 0.015, and 0.039, respectively). Logistic regression analysis demonstrated that C-reactive protein level, myoglobin level and TCM therapy duration were likely associated with treatment outcomes of H7N9 infection (P = 0.032, 0.041 and 0.017, respectively). Conclusion: Elderly people may have increased risk for H7N9 virus infection. T cell-mediated responses play an important role in defense against the H7N9 virus. C-reactive protein level, myoglobin level and TCM duration may be associated with treatment outcomes of H7N9 infection.	[Chen, Xiaorong; Yang, Zongguo; Lu, Yunfei; Xu, Qingnian; Wang, Qiang] Fudan Univ, Shanghai Publ Hlth Clin Ctr, Dept Tradit Chinese Med, Shanghai 200433, Peoples R China; [Chen, Xiaorong; Yang, Zongguo; Lu, Yunfei; Xu, Qingnian] State Adm Tradit Chinese Med, Key Lab Infect Dis, Clin Base, Shanghai, Peoples R China; [Chen, Liang] Fudan Univ, Shanghai Publ Hlth Clin Ctr, Dept Hepatitis, Shanghai 200433, Peoples R China	Fudan University; Fudan University	Chen, XR (corresponding author), Fudan Univ, Shanghai Publ Hlth Clin Ctr, Dept Tradit Chinese Med, Shanghai 200433, Peoples R China.	xiaorong3chen@163.com	Yang, Zongguo/AAY-4190-2021; Lu, Yunfei/GQZ-6526-2022	Yang, Zongguo/0000-0002-6623-4841; 	National Science and Technology Major Projects of the Twelfth Five-year Plan [2012ZX10004301004]; Shanghai Traditional Chinese Medicine Development of the Three-year Action Plan (ZYSNXD-GW-JDJS)	National Science and Technology Major Projects of the Twelfth Five-year Plan; Shanghai Traditional Chinese Medicine Development of the Three-year Action Plan (ZYSNXD-GW-JDJS)	This work was supported mainly by the National Science and Technology Major Projects of the Twelfth Five-year Plan (2012ZX10004301004) and the Shanghai Traditional Chinese Medicine Development of the Three-year Action Plan (ZYSNXD-GW-JDJS). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alexander DJ, 2000, VET MICROBIOL, V74, P3, DOI 10.1016/S0378-1135(00)00160-7; Brincks EL, 2008, J IMMUNOL, V181, P4918, DOI 10.4049/jimmunol.181.7.4918; Brown DM, 2004, SEMIN IMMUNOL, V16, P171, DOI 10.1016/j.smim.2004.02.004; Byth KF, 1996, J EXP MED, V183, P1707, DOI 10.1084/jem.183.4.1707; Capua I, 2004, AVIAN PATHOL, V33, P393, DOI 10.1080/03079450410001724085; Carter MJ, 2007, J MED MICROBIOL, V56, P875, DOI 10.1099/jmm.0.47124-0; Gao RB, 2013, NEW ENGL J MED, V368, P1888, DOI 10.1056/NEJMoa1304459; Gatherer D, 2009, J CLIN VIROL, V45, P174, DOI 10.1016/j.jcv.2009.06.004; Guan Y, 2013, J INFECT DEV COUNTR, V7, P302, DOI 10.3855/jidc.3675; Guleria R, 2009, INDIAN J MICROBIOL, V49, P315, DOI 10.1007/s12088-009-0056-3; Han K, 2011, CLIN INFECT DIS, V53, P326, DOI 10.1093/cid/cir398; Haran John P, 2012, J Emerg Trauma Shock, V5, P149, DOI 10.4103/0974-2700.96484; He Zhihui, 2010, Zhong Nan Da Xue Xue Bao Yi Xue Ban, V35, P655, DOI 10.3969/j.issn.1672-7347.2010.07.003; Hermiston ML, 2003, ANNU REV IMMUNOL, V21, P107, DOI 10.1146/annurev.immunol.21.120601.140946; Kung C, 2000, NAT MED, V6, P343; Li Q, 2014, NEW ENGL J MED, V370, P520, DOI 10.1056/NEJMoa1304617; Liu JP, 2004, J ALTERN COMPLEM MED, V10, P1041, DOI 10.1089/acm.2004.10.1041; Lu CJ, 2010, CHIN J INTEGR MED, V16, P493, DOI 10.1007/s11655-010-0563-4; National Health and Family Planning Commission of the People's Republic of China, 2013, DIAGN TREATM PROGR H; Parry J, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f2222; Parry J, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f2151; Penninger JM, 2001, NAT IMMUNOL, V2, P389, DOI 10.1038/87687; Reemers SSN, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031953; Swain SL, 2006, IMMUNOL REV, V211, P8, DOI 10.1111/j.0105-2896.2006.00388.x; Swayne DE, 2000, REV SCI TECH OIE, V19, P463; Swayne DE, 2000, VACCINE, V18, P1088, DOI 10.1016/S0264-410X(99)00369-2; Tchilian EZ, 2001, J IMMUNOL, V166, P1308, DOI 10.4049/jimmunol.166.2.1308; The World Health Organization Influenza at human-animal interface, CUM NUMB CONF HUM CA; Uyeki TM, 2013, NEW ENGL J MED, V368, P1862, DOI 10.1056/NEJMp1304661; Xinhua News, XINHUA NEWS; Zimmerman O, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-288	31	22	25	0	21	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 17	2013	8	9							e73362	10.1371/journal.pone.0073362	http://dx.doi.org/10.1371/journal.pone.0073362			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	219YJ	24069191	Green Submitted, Green Published, gold			2023-01-03	WOS:000324547300009
J	Moller, W; Schuschnig, U; Celik, G; Munzing, W; Bartenstein, P; Haussinger, K; Kreyling, WG; Knoch, M; Canis, M; Becker, S				Moeller, Winfried; Schuschnig, Uwe; Celik, Guelnaz; Muenzing, Wolfgang; Bartenstein, Peter; Haeussinger, Karl; Kreyling, Wolfgang G.; Knoch, Martin; Canis, Martin; Becker, Sven			Topical Drug Delivery in Chronic Rhinosinusitis Patients before and after Sinus Surgery Using Pulsating Aerosols	PLOS ONE			English	Article							PARANASAL SINUSES; AIR-FLOW; NASAL POLYPOSIS; INHALATION; MANAGEMENT; DEPOSITION; THERAPY; VENTILATION; CLEARANCE; DEVICES	Objectives: Chronic rhinosinusitis (CRS) is a common chronic disease of the upper airways and has considerable impact on quality of life. Topical delivery of drugs to the paranasal sinuses is challenging, therefore the rate of surgery is high. This study investigates the delivery efficiency of a pulsating aerosol in comparison to a nasal pump spray to the sinuses and the nose in healthy volunteers and in CRS patients before and after sinus surgery. Methods: Tc-99m-DTPA pulsating aerosols were applied in eleven CRSsNP patients without nasal polyps before and after sinus surgery. In addition, pulsating aerosols were studied in comparison to nasal pump sprays in eleven healthy volunteers. Total nasal and frontal, maxillary and sphenoidal sinus aerosol deposition and lung penetration were assessed by anterior and lateral planar gamma camera imaging. Results: In healthy volunteers nasal pump sprays resulted in 100% nasal, non-significant sinus and lung deposition, while pulsating aerosols resulted 61.3+/-8.6% nasal deposition and 38.7% exit the other nostril. 9.7+/-2.0 % of the nasal dose penetrated into maxillary and sphenoidal sinuses. In CRS patients, total nasal deposition was 56.7+/-13.3% and 46.7+/-12.7% before and after sinus surgery, respectively (p<0.01). Accordingly, maxillary and sphenoidal sinus deposition was 4.8+/-2.2% and 8.2+/-3.8% of the nasal dose (p<0.01). Neither in healthy volunteers nor in CRS patients there was significant dose in the frontal sinuses. Conclusion: In contrast to nasal pump sprays, pulsating aerosols can deliver significant doses into posterior nasal spaces and paranasal sinuses, providing alternative therapy options before and after sinus surgery. Patients with chronic lung diseases based on clearance dysfunction may also benefit from pulsating aerosols, since these diseases also manifest in the upper airways.	[Moeller, Winfried; Celik, Guelnaz; Kreyling, Wolfgang G.] Helmholtz Zentrum Munchen, Inst Lung Biol & Dis, Neuherberg, Germany; [Schuschnig, Uwe; Knoch, Martin] PARI Pharma GmbH, BU Pharma, Grafelfing, Germany; [Muenzing, Wolfgang; Bartenstein, Peter] LMU Med Ctr Grosshadern, Dept Nucl Med, Munich, Germany; [Haeussinger, Karl] Asklepios Hosp, Dept Pulm Med, Gauting, Germany; [Canis, Martin] Univ Gottingen, Med Ctr, Dept Otolaryngol, D-37073 Gottingen, Germany; [Becker, Sven] LMU Med Ctr Grosshadern, Dept Otolaryngol Head & Neck Surg, Munich, Germany	Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Munich; University of Gottingen; University of Munich	Moller, W (corresponding author), Helmholtz Zentrum Munchen, Inst Lung Biol & Dis, Neuherberg, Germany.	moeller@helmholtz-muenchen.de	Becker, Sven/AEN-1860-2022; Kreyling, rer. nat. Wolfgang G./P-6515-2018; Becker, Sven/AAV-5316-2021; Strebhardt, Klaus/E-8765-2011	Kreyling, rer. nat. Wolfgang G./0000-0002-0702-6567; Schuschnig, Uwe/0000-0002-7142-3575	Pari GmbH, Starnberg, Germany; Bavarian Research foundation [AZ-914-10]	Pari GmbH, Starnberg, Germany; Bavarian Research foundation	The study was supported by research grants from Pari GmbH, Starnberg, Germany and from the Bavarian Research foundation (AZ-914-10). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Achilles N, 2013, CURR ALLERGY ASTHM R, V13, P229, DOI 10.1007/s11882-013-0339-y; [Anonymous], 1994, Ann ICRP, V24, P1; Bachert C, 2003, ALLERGY, V58, P176, DOI 10.1034/j.1398-9995.2003.02172.x; Cochrane MG, 2000, CHEST, V117, P542, DOI 10.1378/chest.117.2.542; Dolovich MB, 2011, LANCET, V377, P1032, DOI 10.1016/S0140-6736(10)60926-9; Eccles R, 2010, CURR MED RES OPIN, V26, P889, DOI 10.1185/03007991003648015; Fasano MB, 2010, CURR OPIN OTOLARYNGO, V18, P15, DOI 10.1097/MOO.0b013e328334aa0e; FOKKENS W, 2007, RHINOL S, V20, P1; FOKKENS WJ, 2012, RHINOLOGY, V50, P1, DOI DOI 10.4193/RHINO12.000; GUILLERM R, 1959, PRESSE MED, V67, P1097; Hamilos DL, 2011, J ALLERGY CLIN IMMUN, V128, P693, DOI 10.1016/j.jaci.2011.08.004; Huang A, 2013, CURR OPIN OTOLARYNGO, V21, P31, DOI 10.1097/MOO.0b013e32835bc4ab; HYO N, 1989, Rhinology (Utrecht), V27, P17; KALENDER WA, 1985, J COMPUT ASSIST TOMO, V9, P524, DOI 10.1097/00004728-198505000-00022; Kauf H., 1968, ARCH KLIN EXPT OHREN, V190, P95; Lai L, 2006, J ASTHMA, V43, P719, DOI 10.1080/02770900600620269; Laube BL, 2011, EUR RESPIR J, V37, P1308, DOI 10.1183/09031936.00166410; Laube BL, 2007, J AEROSOL MED, V20, pS5, DOI 10.1089/jam.2007.0569; Lund Valerie J., 1993, Rhinology (Utrecht), V31, P183; Mainz JG, 2012, CURR ALLERGY ASTHM R, V12, P163, DOI 10.1007/s11882-012-0250-y; Mainz JG, 2011, AURIS NASUS LARYNX, V38, P220, DOI 10.1016/j.anl.2010.09.001; Maniscalco M, 2006, EUR J CLIN INVEST, V36, P509, DOI 10.1111/j.1365-2362.2006.01654.x; Moller W, 2011, RHINOLOGY, V49, P286, DOI 10.4193/Rhino10.268; Moller W, 2011, CURR OPIN OTOLARYNGO, V19, P48, DOI 10.1097/MOO.0b013e3283420f39; Moller W, 2010, OTOLARYNG HEAD NECK, V142, P382, DOI 10.1016/j.otohns.2009.12.028; Moller W, 2009, RHINOLOGY, V47, P405, DOI 10.4193/Rhin08.180; Molimard M, 2005, CURR MED RES OPIN, V21, pS33, DOI 10.1185/030079905X61776; Pleis John R, 2009, Vital Health Stat 10, P1; Sahin-Yilmaz Asli, 2011, Proc Am Thorac Soc, V8, P31, DOI 10.1513/pats.201007-050RN; SCHAPPERT SM, 2008, NATL HLTH STAT REPOR, V8, P1; Shields RC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055339; Skretting A, 2009, NUCL MED COMMUN, V30, P629, DOI 10.1097/MNM.0b013e32832c32b3; Suh JD, 2010, CURR OPIN OTOLARYNGO, V18, P27, DOI 10.1097/MOO.0b013e328334f670; Suman JD, 1999, PHARMACEUT RES, V16, P1648, DOI 10.1023/A:1011933410898; Zinreich SJ, 2004, ANN OTO RHINOL LARYN, V113, P19, DOI 10.1177/00034894041130S506	35	39	43	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 11	2013	8	9							e74991	10.1371/journal.pone.0074991	http://dx.doi.org/10.1371/journal.pone.0074991			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	248VW	24040372	Green Submitted, Green Published, gold			2023-01-03	WOS:000326734500130
J	Wang, HQ; Chen, NHG; Minev, BR; Zimmermann, M; Aguilar, RJ; Zhang, Q; Sturm, JB; Fend, F; Yu, YA; Cappello, J; Lauer, UM; Szalay, AA				Wang, Huiqiang; Chen, Nanhai G.; Minev, Boris R.; Zimmermann, Martina; Aguilar, Richard J.; Zhang, Qian; Sturm, Julia B.; Fend, Falko; Yu, Yong A.; Cappello, Joseph; Lauer, Ulrich M.; Szalay, Aladar A.			Optical Detection and Virotherapy of Live Metastatic Tumor Cells in Body Fluids with Vaccinia Strains	PLOS ONE			English	Article							CARCINOMATOSIS CYTOREDUCTIVE SURGERY; CANCER-CELLS; BREAST-CANCER; FLUORESCENT PROTEIN; ADHESION MOLECULE; EXPRESSION; VIRUS; ADENOVIRUS; BLOOD; HIPEC	Metastatic tumor cells in body fluids are important targets for treatment, and critical surrogate markers for evaluating cancer prognosis and therapeutic response. Here we report, for the first time, that live metastatic tumor cells in blood samples from mice bearing human tumor xenografts and in blood and cerebrospinal fluid samples from patients with cancer were successfully detected using a tumor cell-specific recombinant vaccinia virus (VACV). In contrast to the FDA-approved CellSearch system, VACV detects circulating tumor cells (CTCs) in a cancer biomarker-independent manner, thus, free of any bias related to the use of antibodies, and can be potentially a universal system for detection of live CTCs of any tumor type, not limited to CTCs of epithelial origin. Furthermore, we demonstrate for the first time that VACV was effective in preventing and reducing circulating tumor cells in mice bearing human tumor xenografts. Importantly, a single intraperitoneal delivery of VACV resulted in a dramatic decline in the number of tumor cells in the ascitic fluid from a patient with gastric cancer. Taken together, these results suggest VACV to be a useful tool for quantitative detection of live tumor cells in liquid biopsies as well as a potentially effective treatment for reducing or eliminating live tumor cells in body fluids of patients with metastatic disease.	[Wang, Huiqiang; Chen, Nanhai G.; Minev, Boris R.; Aguilar, Richard J.; Zhang, Qian; Yu, Yong A.; Cappello, Joseph; Szalay, Aladar A.] Genelux Corp, San Diego Sci Ctr, San Diego, CA USA; [Chen, Nanhai G.; Minev, Boris R.; Zhang, Qian; Yu, Yong A.; Szalay, Aladar A.] Univ Calif San Diego, Rebecca & John Moores Comprehens Canc Ctr, Dept Radiat Med & Appl Sci, San Diego, CA 92103 USA; [Minev, Boris R.] Univ Calif San Diego, UCSD Div Neurosurg, San Diego, CA 92103 USA; [Zimmermann, Martina; Sturm, Julia B.; Lauer, Ulrich M.] Univ Hosp, Dept Gastroenterol & Hepatol, Tubingen, Germany; [Fend, Falko] Univ Hosp, Inst Pathol, Tubingen, Germany; [Szalay, Aladar A.] Univ Wurzburg, Rudolf Virchow Ctr Expt Biomed, Dept Biochem, D-97070 Wurzburg, Germany; [Szalay, Aladar A.] Univ Wurzburg, Inst Mol Infect Biol, D-97070 Wurzburg, Germany	University of California System; University of California San Diego; University of California System; University of California San Diego; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; University of Wurzburg; University of Wurzburg	Szalay, AA (corresponding author), Genelux Corp, San Diego Sci Ctr, San Diego, CA USA.	aaszalay@genelux.com	Wang, Huiqiang/N-3825-2013	Wang, Huiqiang/0000-0001-5144-3731	Genelux Corporation (RAMP;D facility in San Diego, CA)	Genelux Corporation (RAMP;D facility in San Diego, CA)	This work was supported by grants from Genelux Corporation (R&D facility in San Diego, CA). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adusumilli PS, 2011, MOL MED, V17, P628, DOI 10.2119/molmed.2011.00078; Allard WJ, 2004, CLIN CANCER RES, V10, P6897, DOI 10.1158/1078-0432.CCR-04-0378; Balic M, 2012, EXPERT REV MOL DIAGN, V12, P303, DOI [10.1586/ERM.12.12, 10.1586/erm.12.12]; Biondo A, 2011, EUR J CANCER, V47, pS162, DOI 10.1016/S0959-8049(11)70870-X; Bonnomet A, 2010, J MAMMARY GLAND BIOL, V15, P261, DOI 10.1007/s10911-010-9174-0; Brucher BLDM, 2012, CANCER INVEST, V30, P209, DOI 10.3109/07357907.2012.654871; Chaffer CL, 2011, SCIENCE, V331, P1559, DOI 10.1126/science.1203543; Chamberlain MC, 2010, CURR OPIN ONCOL, V22, P627, DOI 10.1097/CCO.0b013e32833de986; Chen NHG, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-164; Chen NG, 2011, CANCER GROW PROG-DOR, V13, P295, DOI 10.1007/978-90-481-9704-0_16; Chen NG, 2010, FUTURE VIROL, V5, P763, DOI 10.2217/FVL.10.58; Donat U, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045942; Fong SMB, 2009, SURGERY, V146, P498, DOI 10.1016/j.surg.2008.12.007; Gentschev I, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037239; Grewal J, 2012, J NEURO-ONCOL, V106, P225, DOI 10.1007/s11060-011-0686-2; Kim SJ, 2011, BREAST CANCER RES TR, V128, P765, DOI 10.1007/s10549-011-1603-2; Ksiazkiewicz M, 2012, PATHOBIOLOGY, V79, P195, DOI 10.1159/000337106; Miller MC, 2010, J ONCOL, V2010, DOI 10.1155/2010/617421; Moss B, 2012, VIRUSES-BASEL, V4, P688, DOI 10.3390/v4050688; Paccione RJ, 2008, MOL CANCER THER, V7, P2894, DOI 10.1158/1535-7163.MCT-08-0450; Pierga JY, 2008, CLIN CANCER RES, V14, P7004, DOI 10.1158/1078-0432.CCR-08-0030; Rao CG, 2005, INT J ONCOL, V27, P49; Sanchez-Puig JM, 2004, VIROL J, V1, DOI 10.1186/1743-422X-1-10; Shcherbo D, 2007, NAT METHODS, V4, P741, DOI 10.1038/NMETH1083; Spano D, 2012, SEMIN CANCER BIOL, V22, P234, DOI 10.1016/j.semcancer.2012.03.006; Spiliotis JD, 2010, HEPATO-GASTROENTEROL, V57, P1173; Talmadge JE, 2010, CANCER RES, V70, P5649, DOI 10.1158/0008-5472.CAN-10-1040; Tan SJ, 2009, BIOMED MICRODEVICES, V11, P883, DOI 10.1007/s10544-009-9305-9; Thurm H, 2003, CLIN CANCER RES, V9, P2598; van de Stolpe A, 2011, CANCER RES, V71, P5955, DOI 10.1158/0008-5472.CAN-11-1254; Went PT, 2004, HUM PATHOL, V35, P122, DOI 10.1016/j.humpath.2003.08.026; Wunder T, 2013, CANCER GENE THER, V20, P25, DOI 10.1038/cgt.2012.80; Zhang Q, 2007, CANCER RES, V67, P10038, DOI 10.1158/0008-5472.CAN-07-0146	33	7	14	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 3	2013	8	9							e71105	10.1371/journal.pone.0071105	http://dx.doi.org/10.1371/journal.pone.0071105			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	217DY	24019862	Green Published, Green Submitted, gold			2023-01-03	WOS:000324338200004
J	Nair, KL; Jagadeeshan, S; Nair, SA; Kumar, GSV				Nair, Lekha K.; Jagadeeshan, Sankar; Nair, Asha S.; Kumar, G. S. Vinod			Folic Acid Conjugated delta-Valerolactone-Poly(ethylene glycol) Based Triblock Copolymer as a Promising Carrier for Targeted Doxorubicin Delivery	PLOS ONE			English	Article							DRUG-DELIVERY; POLYMER MICELLES; IMAGING AGENTS; NANOPARTICLES; CELLS; LIPOSOMES; EXPRESSION; PEPTIDE; TPGS	The aim of this study is to test the hypothesis that the newly synthesized poly(delta-valerolactone)/poly(ethylene glycol)/poly(delta-valerolactone) (VEV) copolymer grafted with folic acid would impart targetability and further enhance the anti-tumor efficacy of doxorubicin (DOX). Here, folic acid conjugated VEV (VEV-FOL) was synthesized by a modified esterification method and characterized using IR and NMR. DOX loaded VEV-FOL micelles were synthesized using a novel solvent evaporation method and were obtained with a mean diameter of 97 nm with high encapsulation efficiency and sustained in vitro release profile. Comparative studies of polymer micelles with and without folate for cellular uptake and cytotoxicity were done on folate receptor-positive breast cancer cell line, MDAMB231. The intracellular uptake tests showed significant increase in folate micellar uptake when compared to non-folate-mediated micelles. MTT assay followed by apoptosis assays clearly indicated that folate decorated micelles showed significantly better cytotoxicity (IC50 = 0.014 mu M) and efficiency to induce apoptosis than other treated groups. Moreover, a significant G2/M arrest was induced by DOX loaded VEV-FOL micelles at a concentration where free drug failed to show any activity. Thus, our results show that the folic acid-labeled VEV copolymer is a promising biomaterial with controlled and sustainable tumor targeting ability for anticancer drugs which can open new frontiers in the area of targeted chemotherapy.	[Nair, Lekha K.; Jagadeeshan, Sankar; Nair, Asha S.; Kumar, G. S. Vinod] Rajiv Gandhi Ctr Biotechnol, Poojappura, Kerala, India	Department of Biotechnology (DBT) India; Rajiv Gandhi Centre for Biotechnology (RGCB)	Kumar, GSV (corresponding author), Rajiv Gandhi Ctr Biotechnol, Poojappura, Kerala, India.	gsvinod@rgcb.res.in	JAGADEESHAN, SANKAR/S-8384-2019	JAGADEESHAN, SANKAR/0000-0002-3778-8757	Council of Scientific and Industrial Research, New Delhi, India	Council of Scientific and Industrial Research, New Delhi, India(Council of Scientific & Industrial Research (CSIR) - India)	LNK sincerely acknowledges Council of Scientific and Industrial Research, New Delhi, India, for providing research fellowship and the authors' gratefully acknowledge National Institute of Interdisciplinary Sciences and Technology, Kerala, India, for NMR studies. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Acharya S, 2009, BIOMATERIALS, V30, P5737, DOI 10.1016/j.biomaterials.2009.07.008; BARLOGIE B, 1976, CANCER RES, V36, P1975; Dilnawaz F, 2010, BIOMATERIALS, V31, P3694, DOI 10.1016/j.biomaterials.2010.01.057; DiPaola RS, 2002, CLIN CANCER RES, V8, P3311; Fritzer M, 1996, BIOCHEM PHARMACOL, V51, P489, DOI 10.1016/0006-2952(95)02225-2; Gabizon A, 2003, CLIN CANCER RES, V9, P6551; Kakudo T, 2004, BIOCHEMISTRY-US, V43, P5618, DOI 10.1021/bi035802w; Kang KW, 2010, NANOMED-NANOTECHNOL, V6, P210, DOI 10.1016/j.nano.2009.12.006; Kikuchi A, 1996, BIOCHEM BIOPH RES CO, V227, P666, DOI 10.1006/bbrc.1996.1566; Kim SY, 2007, MACROMOL RES, V15, P646, DOI 10.1007/BF03218945; KOOPMAN G, 1994, BLOOD, V84, P1415, DOI 10.1182/blood.V84.5.1415.1415; Lee JB, 2012, INT J CANCER, V131, pE781, DOI 10.1002/ijc.27361; Lee K, 2010, BIOMATERIALS, V31, P6530, DOI 10.1016/j.biomaterials.2010.04.046; Liu SQ, 2007, BIOMATERIALS, V28, P1423, DOI 10.1016/j.biomaterials.2006.11.013; Liu YT, 2010, BIOMATERIALS, V31, P330, DOI 10.1016/j.biomaterials.2009.09.036; Matteucci C, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2010.58; Meier R, 2010, RADIOLOGY, V255, P527, DOI 10.1148/radiol.10090050; Nair KL, 2012, J APPL POLYM SCI, V124, P2030, DOI 10.1002/app.35229; Nair K Lekha, 2011, Int J Nanomedicine, V6, P1685, DOI 10.2147/IJN.S20165; Nair KL, 2011, J NANOBIOTECHNOL, V9, DOI 10.1186/1477-3155-9-42; Nasongkla N, 2006, NANO LETT, V6, P2427, DOI 10.1021/nl061412u; O'Loughlin C, 2000, EUR J CANCER, V36, P1149, DOI 10.1016/S0959-8049(00)00071-X; Ohara Y, 2012, INT J CANCER, V131, P2402, DOI 10.1002/ijc.27502; Park EK, 2005, BIOMATERIALS, V26, P1053, DOI 10.1016/j.biomaterials.2004.04.008; Peer D, 2007, NAT NANOTECHNOL, V2, P751, DOI 10.1038/nnano.2007.387; Reddy JA, 2005, CURR PHARM BIOTECHNO, V6, P131, DOI 10.2174/1389201053642376; Sapra Puja, 2005, Current Drug Delivery, V2, P369, DOI 10.2174/156720105774370159; Shmeeda H, 2006, MOL CANCER THER, V5, P818, DOI 10.1158/1535-7163.MCT-05-0543; Sudimack J, 2000, ADV DRUG DELIVER REV, V41, P147, DOI 10.1016/S0169-409X(99)00062-9; Tanaka K, 2010, INT J PHARMACEUT, V396, P229, DOI 10.1016/j.ijpharm.2010.06.028; Tao XJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049304; Wang S, 1998, J CONTROL RELEASE, V53, P39, DOI 10.1016/S0168-3659(97)00236-8; Wu J, 2006, INT J PHARMACEUT, V316, P148, DOI 10.1016/j.ijpharm.2006.02.027; Zeng FQ, 2006, BIOCONJUGATE CHEM, V17, P399, DOI 10.1021/bc050350g; Zhang ZP, 2007, BIOMATERIALS, V28, P1889, DOI 10.1016/j.biomaterials.2006.12.018; Zhao HZ, 2008, INT J PHARMACEUT, V349, P256, DOI 10.1016/j.ijpharm.2007.07.040; Zhao HZ, 2009, J BIOMED MATER RES A, V91A, P505, DOI 10.1002/jbm.a.32220	37	16	16	1	41	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 21	2013	8	8							e70697	10.1371/journal.pone.0070697	http://dx.doi.org/10.1371/journal.pone.0070697			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	218YW	23990912	Green Submitted, gold, Green Published			2023-01-03	WOS:000324470100032
J	Chiang, JK; Lin, YL; Chen, CL; Ouyang, CM; Wu, YT; Chi, YC; Huang, KC; Yang, WS				Chiang, Jui-Kun; Lin, Ying-Lung; Chen, Chi-Ling; Ouyang, Chung-Mei; Wu, Ying-Tai; Chi, Yu-Chiao; Huang, Kuo-Chin; Yang, Wei-Shiung			Reduced Risk for Metabolic Syndrome and Insulin Resistance Associated with Ovo-Lacto-Vegetarian Behavior in Female Buddhists: A Case-Control Study	PLOS ONE			English	Article							LIFE-STYLE; WEIGHT MANAGEMENT; PHYSICAL-ACTIVITY; DIETARY PATTERNS; CHOLESTEROL; DISEASE; VEGAN; SENSITIVITY; HEALTH	Introduction: The association of vegetarian status with the risk of metabolic syndrome (MetS) is not clear. In Asia, Buddhists often have vegetarian behavior for religious rather than for health reasons. We hypothesize that the vegetarian in Buddhism is associated with better metabolic profiles, lower risk for the MetS and insulin resistance (IR). Methods: We enrolled 391 female vegetarians (similar to 80% lacto-ovo-vegetarians) and 315 non-vegetarians from health-checkup clinics at a Buddhist hospital in Taiwan. Results: The vegetarian status was associated with lower body mass index, smaller waist circumference, lower total cholesterol, lower low density lipoprotein-cholesterol (LDL-C), and lower HDL-C in multivariate linear regression analyses. Despite having lower HDL-C level, the vegetarians had significantly lower total cholesterol/HDL-C and LDL-C/HDL-C ratios. After adjusting the other covariates, the risks for the MetS were lower for ovo-lacto-vegetarians of 1-11 years and >11 years respectively by 54% (odds ratio [OR] = 0.46, 95%C.I.:0.26-0.79) and 57% (OR = 0.43, 95%C.I.: 0.23-0.76) compared to non-vegetarians by the IDF criteria. Likewise, they were lower respectively by 45% (OR = 0.55, 95%C.I.:0.32-0.92) and 42% (OR = 0.58, 95%C.I.:0.33-0.997), for the MetS by the modified NCEP criteria. In the subgroup of non-diabetic subjects, the vegetarians also had lower risk for IR by HOMA compared to the non-vegetarians (OR = 0.71, 95%C.I.:0.48-1.06). Conclusion: The vegetarian behavior, mainly lacto-ovo-vegetarian, related to Buddhism, although not meant for its health effects, is associated with reduced risk for the MetS and IR and may potentially provide metabolic and cardiovascular protective effects in women.	[Chiang, Jui-Kun; Lin, Ying-Lung] Buddhist Tzuchi Med Fdn, Dalin Tzuchi Hosp, Dept Family Med, Chiayi, Taiwan; [Chen, Chi-Ling; Chi, Yu-Chiao; Yang, Wei-Shiung] Natl Taiwan Univ, Coll Med, Grad Inst Clin Med, Taipei 10764, Taiwan; [Wu, Ying-Tai] Natl Taiwan Univ, Coll Med, Grad Inst Phys Therapy, Taipei 10764, Taiwan; [Chen, Chi-Ling] Natl Taiwan Univ, Coll Publ Hlth, Grad Inst Epidemiol, Taipei 10764, Taiwan; [Ouyang, Chung-Mei] Natl Taiwan Univ Hosp, Dept Dietet, Taipei, Taiwan; [Huang, Kuo-Chin] Natl Taiwan Univ Hosp, Dept Family Med, Taipei, Taiwan; [Yang, Wei-Shiung] Natl Taiwan Univ Hosp, Dept Internal Med, Taipei 100, Taiwan	National Taiwan University; National Taiwan University; National Taiwan University; National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University Hospital	Yang, WS (corresponding author), Natl Taiwan Univ, Coll Med, Grad Inst Clin Med, Taipei 10764, Taiwan.	wsyang@ntu.edu.tw		Ouyang, Chung-Mei/0000-0002-1377-772X; YANG, WEI-SHIUNG/0000-0001-5087-373X; HUANG, KUO-CHIN/0000-0002-6029-5520	Buddhist Dalin Tzu Chi General Hospital [DTCRD 96-13, 97-18, 98 (2)-07]; National Taiwan University Hospital [MG151]	Buddhist Dalin Tzu Chi General Hospital; National Taiwan University Hospital(National Taiwan University)	JKC received research grants from Buddhist Dalin Tzu Chi General Hospital (DTCRD 96-13, 97-18, and 98 (2)-07) and WSY had a Research Supportive Fund from the National Taiwan University Hospital (MG151). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	BAECKE JAH, 1982, AM J CLIN NUTR, V36, P936; Balkau B, 2002, DIABETES METAB, V28, P364; Ballantyne CM, 2003, AM HEART J, V146, P227, DOI 10.1016/S0002-8703(02)94701-0; Baxter AJ, 2006, ASIA PAC J CLIN NUTR, V15, P134; Berg CM, 2008, AM J CLIN NUTR, V88, P289; Berkow SE, 2006, NUTR REV, V64, P175, DOI [10.1301/nr.2006.apr.175-188, 10.1111/j.1753-4887.2006.tb00200.x]; Bray GA, 2008, J CLIN ENDOCR METAB, V93, pS81, DOI 10.1210/jc.2008-1294; Burke LE, 2006, OBESITY, V14, P2007, DOI 10.1038/oby.2006.235; Chen CW, 2008, EUR J CLIN NUTR, V62, P138, DOI 10.1038/sj.ejcn.1602689; Chien M.-Y., 2003, FORMOSAN J PHYS THER, V28, P1; Craig WJ, 2009, J AM DIET ASSOC, V109, P1266, DOI 10.1016/j.jada.2009.05.027; Fontana L, 2007, REJUV RES, V10, P225, DOI 10.1089/rej.2006.0529; Fraser GE, 2009, AM J CLIN NUTR, V89, pS1607, DOI 10.3945/ajcn.2009.26736K; Goff LM, 2005, EUR J CLIN NUTR, V59, P291, DOI 10.1038/sj.ejcn.1602076; Grundy SM, 2002, CIRCULATION, V106, P3143, DOI 10.1161/circ.106.25.3143; Hung CJ, 2006, BRIT J NUTR, V95, P129, DOI 10.1079/BJN20051588; Jiang R, 2004, DIABETES CARE, V27, P1991, DOI 10.2337/diacare.27.8.1991; KINOSIAN B, 1994, ANN INTERN MED, V121, P641, DOI 10.7326/0003-4819-121-9-199411010-00002; Klein S, 2004, AM J CLIN NUTR, V80, P257, DOI 10.1093/ajcn/80.2.257; Kuo CS, 2004, EUR J CLIN NUTR, V58, P312, DOI 10.1038/sj.ejcn.1601783; Lee YJ, 2009, ASIA PAC J CLIN NUTR, V18, P265; Lin CK, 2010, J HEALTH POPUL NUTR, V28, P470; MATTHEWS DR, 1985, DIABETOLOGIA, V28, P412, DOI 10.1007/BF00280883; McLaughlin T, 2003, ANN INTERN MED, V139, P802, DOI 10.7326/0003-4819-139-10-200311180-00007; Reaven G, 2006, ARCH INTERN MED, V166, P249, DOI 10.1001/archinte.166.2.249-a; Rizzo NS, 2011, DIABETES CARE, V34, P1225, DOI 10.2337/dc10-1221; SALLIS JF, 1985, AM J EPIDEMIOL, V121, P91, DOI 10.1093/oxfordjournals.aje.a113987; Tan CE, 2004, DIABETES CARE, V27, P1182, DOI 10.2337/diacare.27.5.1182; Trapp CB, 2010, CURR DIABETES REP, V10, P152, DOI 10.1007/s11892-010-0093-7; Waldmann A, 2005, ANN NUTR METAB, V49, P366, DOI 10.1159/000088888	30	34	35	0	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 9	2013	8	8							e71799	10.1371/journal.pone.0071799	http://dx.doi.org/10.1371/journal.pone.0071799			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	245OM	23951247	gold, Green Submitted, Green Published			2023-01-03	WOS:000326473200074
J	Colbert, JA				Colbert, James A.			Experiments in Continuity Rethinking Residency Training in Ambulatory Care	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							INTERNAL-MEDICINE		[Colbert, James A.] Newton Wellesley Hosp, Dept Med, Newton, MA USA; [Colbert, James A.] Brigham & Womens Hosp, Div Med Commun, Boston, MA 02115 USA	Newton Wellesley Hospital; Harvard University; Brigham & Women's Hospital	Colbert, JA (corresponding author), Newton Wellesley Hosp, Dept Med, Newton, MA USA.							Bodenheimer T, 2011, NEW ENGL J MED, V365, P5, DOI 10.1056/NEJMp1104942; Chang A, 2013, J GEN INTERN MED, V28, P801, DOI 10.1007/s11606-012-2193-3; Meyers FJ, 2007, ACAD MED, V82, P1211, DOI 10.1097/ACM.0b013e318159d010; Mladenovic J, 2008, J GEN INTERN MED, V23, P914, DOI 10.1007/s11606-008-0511-6; Warm EJ, 2008, J GEN INTERN MED, V23, P921, DOI 10.1007/s11606-008-0588-y	5	8	8	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 8	2013	369	6					504	505		10.1056/NEJMp1301604	http://dx.doi.org/10.1056/NEJMp1301604			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	197HX	23924001				2023-01-03	WOS:000322842000005
J	Koivisto, M; Kirjanen, S; Revonsuo, A; Kallio, S				Koivisto, Mika; Kirjanen, Svetlana; Revonsuo, Antti; Kallio, Sakari			A Preconscious Neural Mechanism of Hypnotically Altered Colors: A Double Case Study	PLOS ONE			English	Article							HYPNOSIS	Hypnotic suggestions may change the perceived color of objects. Given that chromatic stimulus information is processed rapidly and automatically by the visual system, how can hypnotic suggestions affect perceived colors in a seemingly immediate fashion? We studied the mechanisms of such color alterations by measuring electroencephalography in two highly suggestible participants as they perceived briefly presented visual shapes under posthypnotic color alternation suggestions such as "all the squares are blue''. One participant consistently reported seeing the suggested colors. Her reports correlated with enhanced evoked upper beta-band activity (22 Hz) 70-120 ms after stimulus in response to the shapes mentioned in the suggestion. This effect was not observed in a control condition where the participants merely tried to simulate the effects of the suggestion on behavior. The second participant neither reported color alterations nor showed the evoked beta activity, although her subjective experience and event-related potentials were changed by the suggestions. The results indicate a preconscious mechanism that first compares early visual input with a memory representation of the suggestion and consequently triggers the color alteration process in response to the objects specified by the suggestion. Conscious color experience is not purely the result of bottom-up processing but it can be modulated, at least in some individuals, by top-down factors such as hypnotic suggestions.	[Koivisto, Mika; Revonsuo, Antti] Univ Turku, Dept Psychol, Turku, Finland; [Koivisto, Mika; Revonsuo, Antti; Kallio, Sakari] Univ Turku, Ctr Cognit Neurosci, Turku, Finland; [Kirjanen, Svetlana] Univ Helsinki, Dept Behav Sci, Helsinki, Finland; [Revonsuo, Antti; Kallio, Sakari] Univ Skovde, Sch Humanities & Informat, Skovde, Sweden	University of Turku; University of Turku; University of Helsinki; University of Skovde	Kallio, S (corresponding author), Univ Turku, Ctr Cognit Neurosci, Turku, Finland.	sakari.kallio@his.se		Koivisto, Mika/0000-0002-5227-0091	Academy of Finland [125175, 266434, 218272]	Academy of Finland(Academy of Finland)	This study was funded by the Academy of Finland (http://www.aka.fi/eng)(grant numbers 125175, 266434 and 218272). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Barber TX, 2000, AM J CLIN HYPN, V42, P208, DOI 10.1080/00029157.2000.10734361; Dehaene S, 2011, NEURON, V70, P200, DOI 10.1016/j.neuron.2011.03.018; Fingelkurts AA, 2007, CONT HYPNOSIS, V24, P3, DOI DOI 10.1002/CH.327; Fingelkurts AA, 2007, NEUROPSYCHOLOGIA, V45, P1452, DOI 10.1016/j.neuropsychologia.2006.11.018; Hansen T, 2006, NAT NEUROSCI, V11, P1637; Herrmann CS, 2010, NEUROSCI BIOBEHAV R, V34, P981, DOI 10.1016/j.neubiorev.2009.09.001; Hillyard SA, 1998, P NATL ACAD SCI USA, V95, P781, DOI 10.1073/pnas.95.3.781; Kadosh RC, 2009, PSYCHOL SCI, V20, P258, DOI 10.1111/j.1467-9280.2009.02286.x; Kallio S, 1999, NEUROREPORT, V10, P3579, DOI 10.1097/00001756-199911260-00021; Kallio S., 2003, CONT HYPNOSIS, V20, P111, DOI [10.1002/ch.273, DOI 10.1002/CH.273]; Kallio S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026374; Kihlstrom J.F., 2008, OXFORD HDB HYPNOSIS, P21, DOI [https://doi.org/10.1093/oxfordhb/9780198570097.013.0002, DOI 10.1093/OXFORDHB/9780198570097.013.0002]; King BJ, 1998, INT J CLIN EXP HYP, V46, P295, DOI 10.1080/00207149808410009; Kinnunen T, 2001, INT J CLIN EXP HYP, V49, P83, DOI 10.1080/00207140108410060; Kirsch I, 2001, CURR DIR PSYCHOL SCI, V10, P57, DOI 10.1111/1467-8721.00115; Kosslyn SM, 2000, AM J PSYCHIAT, V157, P1279, DOI 10.1176/appi.ajp.157.8.1279; Lamme VAF, 2004, NEURAL NETWORKS, V17, P861, DOI 10.1016/j.neunet.2004.02.005; Lynn S., 2012, OXFORD HDB HYPNOSIS, P111, DOI DOI 10.1093/OXFORDHB/9780198570097.013.0005; Mazzoni G, 2009, CONSCIOUS COGN, V18, P494, DOI 10.1016/j.concog.2009.02.002; MCCONKEY K M, 1989, Australian Journal of Clinical and Experimental Hypnosis, V17, P131; McGeown WJ, 2012, CONSCIOUS COGN, V21, P100, DOI 10.1016/j.concog.2011.10.015; Perugini EM, 1998, INT J CLIN EXP HYP, V46, P191, DOI 10.1080/00207149808409999; Raz A, 2005, P NATL ACAD SCI USA, V102, P9978, DOI 10.1073/pnas.0503064102; Shor RE, 1962, HARVARD GROUP SCALE; Terhune DB, 2011, COGN NEUROPSYCHIATRY, V16, P113, DOI 10.1080/13546805.2010.503048; Wagstaff G, 1981, HYPNOSIS COMPLIANCE; Weitzenhoffer A. M., 1962, STANFORD HYPNOTIC SU; Weitzenhoffer AM, 1980, AM J CLIN HYPN, V44, P69	28	10	10	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 5	2013	8	8							e70900	10.1371/journal.pone.0070900	http://dx.doi.org/10.1371/journal.pone.0070900			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	218XC	23940663	Green Published, gold, Green Submitted			2023-01-03	WOS:000324465000152
J	Mutsaers, HAM; Engelke, UFH; Wilmer, MJG; Wetzels, JFM; Wevers, RA; van den Heuvel, LP; Hoenderop, JG; Masereeuw, R				Mutsaers, Henricus A. M.; Engelke, Udo F. H.; Wilmer, Martijn J. G.; Wetzels, Jack F. M.; Wevers, Ron A.; van den Heuvel, Lambertus P.; Hoenderop, Joost G.; Masereeuw, Rosalinde			Optimized Metabolomic Approach to Identify Uremic Solutes in Plasma of Stage 3-4 Chronic Kidney Disease Patients	PLOS ONE			English	Article							DIMETHYL SULFONE; P-CRESOL; METABOLITES; TOXINS; DIMETHYLSULFOXIDE; SERUM; H-1; TOXICOKINETICS; ACCUMULATION; SULFOXIDE	Background: Chronic kidney disease (CKD) is characterized by the progressive accumulation of various potential toxic solutes. Furthermore, uremic plasma is a complex mixture hampering accurate determination of uremic toxin levels and the identification of novel uremic solutes. Methods: In this study, we applied H-1-nuclear magnetic resonance (NMR) spectroscopy, following three distinct deproteinization strategies, to determine differences in the plasma metabolic status of stage 3-4 CKD patients and healthy controls. Moreover, the human renal proximal tubule cell line (ciPTEC) was used to study the influence of newly indentified uremic solutes on renal phenotype and functionality. Results: Protein removal via ultrafiltration and acetonitrile precipitation are complementary techniques and both are required to obtain a clear metabolome profile. This new approach, revealed that a total of 14 metabolites were elevated in uremic plasma. In addition to confirming the retention of several previously identified uremic toxins, including p-cresyl sulphate, two novel uremic retentions solutes were detected, namely dimethyl sulphone (DMSO2) and 2-hydroxyisobutyric acid (2-HIBA). Our results show that these metabolites accumulate in non-dialysis CKD patients from 9 +/- 7 mu M (control) to 51 +/- 29 mu M and from 7 (0-9) mu M (control) to 32 +/- 15 mu M, respectively. Furthermore, exposure of ciPTEC to clinically relevant concentrations of both solutes resulted in an increased protein expression of the mesenchymal marker vimentin with more than 10% (p < 0.05). Moreover, the loss of epithelial characteristics significantly correlated with a loss of glucuronidation activity (Pearson r = -0.63; p<0.05). In addition, both solutes did not affect cell viability nor mitochondrial activity. Conclusions: This study demonstrates the importance of sample preparation techniques in the identification of uremic retention solutes using H-1-NMR spectroscopy, and provide insight into the negative impact of DMSO2 and 2-HIBA on ciPTEC, which could aid in understanding the progressive nature of renal disease.	[Mutsaers, Henricus A. M.; Wilmer, Martijn J. G.; Masereeuw, Rosalinde] Radboud Univ Nijmegen, Med Ctr, Nijmegen Ctr Mol Life Sci, Dept Pharmacol & Toxicol, NL-6525 ED Nijmegen, Netherlands; [Mutsaers, Henricus A. M.; Hoenderop, Joost G.] Radboud Univ Nijmegen, Med Ctr, Nijmegen Ctr Mol Life Sci, Dept Physiol, NL-6525 ED Nijmegen, Netherlands; [Engelke, Udo F. H.; Wevers, Ron A.; van den Heuvel, Lambertus P.] Radboud Univ Nijmegen, Med Ctr, Lab Genet Endocrine & Metab Dis, Dept Lab Med, NL-6525 ED Nijmegen, Netherlands; [Wetzels, Jack F. M.] Radboud Univ Nijmegen, Med Ctr, Dept Nephrol, NL-6525 ED Nijmegen, Netherlands; [van den Heuvel, Lambertus P.] Radboud Univ Nijmegen, Med Ctr, Dept Pediat, NL-6525 ED Nijmegen, Netherlands; [van den Heuvel, Lambertus P.] Catholic Univ Louvain, Dept Pediat, B-3000 Louvain, Belgium	Radboud University Nijmegen; Radboud University Nijmegen; Radboud University Nijmegen; Radboud University Nijmegen; Radboud University Nijmegen; Universite Catholique Louvain	Masereeuw, R (corresponding author), Radboud Univ Nijmegen, Med Ctr, Nijmegen Ctr Mol Life Sci, Dept Pharmacol & Toxicol, NL-6525 ED Nijmegen, Netherlands.	r.masereeuw@pharmtox.umcn.nl	Masereeuw, Roos/N-3582-2014; Wevers, Ron A./H-8116-2014; Engelke, U.F.H./L-4293-2015; Hoenderop, Joost G.J./H-8047-2014; van den Heuvel, Lambertus/AAM-1772-2021; Mutsaers, Henricus/AAK-6321-2020; van den Heuvel, L.P.W.J./H-8044-2014; Wetzels, Jack F.M./A-1720-2014; Masereeuw, Roos/I-5276-2016; Wilmer, Martijn J/I-7455-2015	Wevers, Ron A./0000-0003-2278-9746; Hoenderop, Joost G.J./0000-0002-1816-8544; van den Heuvel, Lambertus/0000-0003-3917-6727; Mutsaers, Henricus/0000-0002-9553-8860; van den Heuvel, L.P.W.J./0000-0003-3917-6727; Wetzels, Jack F.M./0000-0002-0650-6921; Masereeuw, Roos/0000-0002-1560-1074; Wilmer, Martijn J/0000-0003-4832-105X	Dutch Kidney Foundation [IK08.03]; Dutch government [FES0908]; EURYI award from the European Science Foundation	Dutch Kidney Foundation; Dutch government; EURYI award from the European Science Foundation	This work was supported by the Dutch Kidney Foundation (grant number IK08.03; www.nierstichting.nl). M.J.G. Wilmer was supported by a grant from the Dutch government to the Netherlands Institute for Regenerative Medicine (NIRM, grant No. FES0908; www.nirm.nl) and J.G. Hoenderop was supported by an EURYI award from the European Science Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Amberg A, 2001, TOXICOL SCI, V61, P62, DOI 10.1093/toxsci/61.1.62; Aronov PA, 2011, J AM SOC NEPHROL, V22, P1769, DOI 10.1681/ASN.2010121220; BEILKE MA, 1987, J LAB CLIN MED, V110, P91; Choi JY, 2011, NEPHROL DIAL TRANSPL, V26, P1304, DOI 10.1093/ndt/gfq554; Daykin CA, 2002, ANAL BIOCHEM, V304, P220, DOI 10.1006/abio.2002.5637; de Loor H, 2005, CLIN CHEM, V51, P1535, DOI 10.1373/clinchem.2005.050781; Dekant W, 2001, TOXICOL LETT, V124, P37, DOI 10.1016/S0378-4274(00)00284-8; Duranton F, 2012, J AM SOC NEPHROL, V23, P1258, DOI 10.1681/ASN.2011121175; Eloot S, 2011, CLIN J AM SOC NEPHRO, V6, P1266, DOI 10.2215/CJN.09981110; Engelke UFH, 2005, NMR BIOMED, V18, P331, DOI 10.1002/nbm.966; Evenepoel P, 2009, KIDNEY INT, V76, pS12, DOI 10.1038/ki.2009.402; Feigenbaum J, 1941, J AM CHEM SOC, V63, P3529, DOI 10.1021/ja01857a508; Ferreira ACS, 2003, J AGR FOOD CHEM, V51, P727, DOI 10.1021/jf025934g; Herget-Rosenthal S, 2009, SEMIN DIALYSIS, V22, P445, DOI 10.1111/j.1525-139X.2009.00598.x; JACOB SW, 1983, ANN NY ACAD SCI, V411, pR13, DOI 10.1111/j.1749-6632.1983.tb47276.x; Kloesch B, 2011, LIFE SCI, V89, P473, DOI 10.1016/j.lfs.2011.07.015; LAYMAN DL, 1985, LIFE SCI, V37, P2431, DOI 10.1016/0024-3205(85)90111-0; LAYMAN DL, 1987, IN VITRO CELL DEV B, V23, P422; Li X, 2009, ANAL CHIM ACTA, V633, P257, DOI 10.1016/j.aca.2008.11.058; Lopez-Novoa JM, 2010, PHARMACOL THERAPEUT, V128, P61, DOI 10.1016/j.pharmthera.2010.05.006; Meisinger C, 2009, AM J HUM GENET, V84, P66, DOI 10.1016/j.ajhg.2008.11.015; Moghadasali R, 2013, EXP TOXICOL PATHOL, V65, P595, DOI 10.1016/j.etp.2012.06.002; Mutsaers HAM, 2013, BBA-MOL BASIS DIS, V1832, P142, DOI 10.1016/j.bbadis.2012.09.006; Mutsaers HAM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018438; Neirynck N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044201; Niwa T, 1998, KIDNEY INT, V53, P1801, DOI 10.1046/j.1523-1755.1998.00944.x; Psychogios N, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016957; Raj DSC, 2000, BLOOD PURIFICAT, V18, P97, DOI 10.1159/000014431; Rhee EP, 2010, J AM SOC NEPHROL, V21, P1041, DOI 10.1681/ASN.2009111132; Shah VO, 2013, CLIN J AM SOC NEPHRO, V8, P363, DOI 10.2215/CJN.05540512; Shaykhutdinov RA, 2009, METABOLOMICS, V5, P307, DOI 10.1007/s11306-009-0155-5; Suhre K, 2011, NAT GENET, V43, P565, DOI 10.1038/ng.837; Tiziani S, 2008, ANAL BIOCHEM, V377, P16, DOI 10.1016/j.ab.2008.01.037; Vanholder R, 2003, KIDNEY INT, V63, P1934, DOI 10.1046/j.1523-1755.2003.00924.x; Vanholder R, 2011, NEPHROL DIAL TRANSPL, V26, P1464, DOI 10.1093/ndt/gfr056; Weiss RH, 2012, NAT REV NEPHROL, V8, P22, DOI 10.1038/nrneph.2011.152; WILLIAMS KI, 1966, ARCH BIOCHEM BIOPHYS, V113, P251, DOI 10.1016/0003-9861(66)90182-2; WILLIAMS KI, 1966, P SOC EXP BIOL MED, V122, P865, DOI 10.3181/00379727-122-31272; Wilmer MJ, 2011, BBA-MOL BASIS DIS, V1812, P643, DOI 10.1016/j.bbadis.2011.02.010; Wilmer MJ, 2010, CELL TISSUE RES, V339, P449, DOI 10.1007/s00441-009-0882-y; Wishart DS, 2009, NUCLEIC ACIDS RES, V37, pD603, DOI 10.1093/nar/gkn810; Wittgen HGM, 2012, DRUG METAB DISPOS, V40, P1076, DOI 10.1124/dmd.111.044438	42	51	52	0	24	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 2	2013	8	8							e71199	10.1371/journal.pone.0071199	http://dx.doi.org/10.1371/journal.pone.0071199			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	219XU	23936492	Green Published, Green Submitted, gold			2023-01-03	WOS:000324545800060
J	Chiyomaru, T; Yamamura, S; Fukuhara, S; Yoshino, H; Kinoshita, T; Majid, S; Saini, S; Chang, I; Tanaka, Y; Enokida, H; Seki, N; Nakagawa, M; Dahiya, R				Chiyomaru, Takeshi; Yamamura, Soichiro; Fukuhara, Shinichiro; Yoshino, Hirofumi; Kinoshita, Takashi; Majid, Shahana; Saini, Sharanjot; Chang, Inik; Tanaka, Yuichiro; Enokida, Hideki; Seki, Naohiko; Nakagawa, Masayuki; Dahiya, Rajvir			Genistein Inhibits Prostate Cancer Cell Growth by Targeting miR-34a and Oncogenic HOTAIR	PLOS ONE			English	Article							LONG NONCODING RNA; HEPATOCELLULAR-CARCINOMA; SIGNALING PATHWAYS; EXPRESSION; BETA; MICRORNA-27A; PROGRESSION; SOX17; RISK	Objective: Genistein is a soy isoflavone that has antitumor activity both in vitro and in vivo. It has been shown that genistein inhibits many type of cancers including prostate cancer (PCa) by regulating several cell signaling pathways and microRNAs (miRNAs). Recent studies suggest that the long non-coding RNAs (lncRNAs) are also involved in many cellular processes. At present there are no reports about the relationship between gensitein, miRNAs and lncRNAs. In this study, we focused on miRNAs, lncRNA that are regulated by genistein and investigated their functional role in PCa. Method: Microarray (SurePrint G3 Human GE 8x60K) was used for expression profiling of genistein treated and control PCa cells (PC3 and DU145). Functional assay (cell proliferation, migration, invasion, apoptosis and cell cycle assays) were performed with the PCa cell lines, PC3 and DU145. Both in vitro and in vivo (nude mouse) models were used for growth assays. Luciferase reporter assays were used for binding of miR-34a to HOTAIR. Results: LncRNA profiling showed that HOTAIR was highly regulated by genistein and its expression was higher in castration-resistant PCa cell lines than in normal prostate cells. Knockdown (siRNA) of HOTAIR decreased PCa cell proliferation, migration and invasion and induced apoptosis and cell cycle arrest. miR-34a was also up-regulated by genistein and may directly target HOTAIR in both PC3 and DU145 PCa cells. Conclusions: Our results indicated that genistein inhibited PCa cell growth through down-regulation of oncogenic HOTAIR that is also targeted by tumor suppressor miR-34a. These findings enhance understanding of how genistein regulates lncRNA HOTAIR and miR-34a in PCa.	[Chiyomaru, Takeshi; Yamamura, Soichiro; Fukuhara, Shinichiro; Majid, Shahana; Saini, Sharanjot; Chang, Inik; Tanaka, Yuichiro; Dahiya, Rajvir] San Francisco VA Med Ctr, Dept Urol, San Francisco, CA USA; [Chiyomaru, Takeshi; Yamamura, Soichiro; Fukuhara, Shinichiro; Majid, Shahana; Saini, Sharanjot; Chang, Inik; Tanaka, Yuichiro; Dahiya, Rajvir] Univ Calif San Francisco, San Francisco, CA 94143 USA; [Yoshino, Hirofumi; Enokida, Hideki] Kagoshima Univ, Dept Urol, Grad Sch Med & Dent Sci, Kagoshima 890, Japan; [Kinoshita, Takashi; Seki, Naohiko; Nakagawa, Masayuki] Chiba Univ, Dept Funct Genom, Grad Sch Med, Chiba, Japan	US Department of Veterans Affairs; Veterans Health Administration (VHA); San Francisco VA Medical Center; University of California System; University of California San Francisco; Kagoshima University; Chiba University	Dahiya, R (corresponding author), San Francisco VA Med Ctr, Dept Urol, San Francisco, CA USA.	rdahiya@urology.ucsf.edu			National Center for Research Resources of the National Institutes of Health [R01CA160079, R01CA138642, T32DK007790]; VA Merit Review and VA Program Project; NATIONAL CANCER INSTITUTE [R01CA138642, R01CA160079] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007790] Funding Source: NIH RePORTER	National Center for Research Resources of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); VA Merit Review and VA Program Project(US Department of Veterans Affairs); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This research was supported by the National Center for Research Resources of the National Institutes of Health through Grant Number R01CA160079, R01CA138642, T32DK007790 and VA Merit Review and VA Program Project. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; Amaral PP, 2011, NUCLEIC ACIDS RES, V39, pD146, DOI 10.1093/nar/gkq1138; Braconi C, 2011, ONCOGENE, V30, P4750, DOI 10.1038/onc.2011.193; Carmona-Saez P, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-1-r3; Chen K, 2007, NAT REV GENET, V8, P93, DOI 10.1038/nrg1990; Chiyomaru T, 2010, BRIT J CANCER, V102, P883, DOI 10.1038/sj.bjc.6605570; Chiyomaru T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058929; Chiyomaru T, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043812; Cui Z, 2012, UROL ONCOL; de Souza PL, 2010, NUTR REV, V68, P542, DOI 10.1111/j.1753-4887.2010.00314.x; Dovas A, 2005, BIOCHEM J, V390, P1, DOI 10.1042/BJ20050104; Friedman RC, 2009, GENOME RES, V19, P92, DOI 10.1101/gr.082701.108; Geng YJ, 2011, J INT MED RES, V39, P2119, DOI 10.1177/147323001103900608; Gupta RA, 2010, NATURE, V464, P1071, DOI 10.1038/nature08975; Hansen TB, 2011, EMBO J, V30, P4414, DOI 10.1038/emboj.2011.359; Harrow J, 2012, GENOME RES, V22, P1760, DOI 10.1101/gr.135350.111; Hwang YW, 2009, NUTR CANCER, V61, P598, DOI 10.1080/01635580902825639; Jia Y, 2010, EPIGENETICS-US, V5, P743, DOI 10.4161/epi.5.8.13104; Kim EK, 2007, MOL CELL ENDOCRINOL, V278, P18, DOI 10.1016/j.mce.2007.08.003; Kim K, 2013, ONCOGENE, V32, P1616, DOI 10.1038/onc.2012.193; Kogo R, 2011, CANCER RES, V71, P6320, DOI 10.1158/0008-5472.CAN-11-1021; Kuiper GGJM, 1998, ENDOCRINOLOGY, V139, P4252, DOI 10.1210/en.139.10.4252; Lai YL, 2013, INT J ONCOL, V42, P776, DOI 10.3892/ijo.2012.1743; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Li DD, 2013, AM J PATHOL, V182, P64, DOI 10.1016/j.ajpath.2012.08.042; Li YW, 2010, CANCER RES, V70, P1486, DOI 10.1158/0008-5472.CAN-09-2792; Li YW, 2002, CLIN CANCER RES, V8, P2369; Liss Michael A., 2010, Cancer Genomics & Proteomics, V7, P245; Prensner JR, 2011, NAT BIOTECHNOL, V29, P742, DOI 10.1038/nbt.1914; Rinn JL, 2007, CELL, V129, P1311, DOI 10.1016/j.cell.2007.05.022; Ryan BM, 2010, NAT REV CANCER, V10, P389, DOI 10.1038/nrc2867; Sang NL, 2003, J BIOL CHEM, V278, P14013, DOI 10.1074/jbc.M209702200; Schlessinger K, 2009, GENE DEV, V23, P265, DOI 10.1101/gad.1760809; Sinner D, 2007, MOL CELL BIOL, V27, P7802, DOI 10.1128/MCB.02179-06; Sun QM, 2009, ONCOL REP, V22, P563, DOI 10.3892/or_00000472; Tabas-Madrid D, 2012, NUCLEIC ACIDS RES, V40, pW478, DOI 10.1093/nar/gks402; Tsai MC, 2010, SCIENCE, V329, P689, DOI 10.1126/science.1192002; Vader P, 2011, ANGIOGENESIS, V14, P457, DOI 10.1007/s10456-011-9229-x; Wang JY, 2010, NUCLEIC ACIDS RES, V38, P5366, DOI 10.1093/nar/gkq285; Xue Y, 2013, PROSTATE CANCER P D, V16, P139, DOI 10.1038/pcan.2013.6; Yamamura S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029722; Yan GR, 2011, J PROTEOMICS, V75, P695, DOI 10.1016/j.jprot.2011.09.008; Yang Z, 2011, ANN SURG ONCOL, V18, P1243, DOI 10.1245/s10434-011-1581-y; Zhang W, 2008, CANCER RES, V68, P2764, DOI 10.1158/0008-5472.CAN-07-6349	44	195	204	0	36	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 1	2013	8	8							e70372	10.1371/journal.pone.0070372	http://dx.doi.org/10.1371/journal.pone.0070372			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	219PB	23936419	Green Published, gold, Green Submitted			2023-01-03	WOS:000324518400062
J	Li, RT; Wu, W; Liu, Q; Wu, PY; Xie, L; Zhu, ZS; Yang, M; Qian, XP; Ding, Y; Yu, LX; Jiang, XQ; Guan, WX; Liu, BR				Li, Rutian; Wu, Wei; Liu, Qin; Wu, Puyuan; Xie, Li; Zhu, Zhenshu; Yang, Mi; Qian, Xiaoping; Ding, Yin; Yu, Lixia; Jiang, Xiqun; Guan, Wenxian; Liu, Baorui			Intelligently Targeted Drug Delivery and Enhanced Antitumor Effect by Gelatinase-Responsive Nanoparticles	PLOS ONE			English	Article							MATRIX METALLOPROTEINASES; POOR-PROGNOSIS; CANCER-THERAPY; CONJUGATE; MMP-9; METASTASIS; EXPRESSION; INHIBITORS; CARCINOMA; EFFICACY	Aims: The matrix metalloproteinase (MMP) 2/9, also known as collagenases IV and gelatinases A/B, play a key role in cancer invasion and metastasis. However, the clinical trials of the MMP inhibitors (MMPIs) ended up with disappointing results. In this paper, we synthesized a gelatinase-responsive copolymer (mPEG-PCL) by inserting a gelatinase cleavable peptide (PVGLIG) between mPEG and PCL blocks of mPEG-PCL for anticancer drug delivery to make use of MMP2/9 as an intelligent target for drug delivery. Materials and Methods: mPEG-pep-PCL copolymer was synthesized via ring-opening copolymerization and double-amidation. To evaluate whether Nanoparticles (NPs) prepared from this copolymer are superior to NPs prepared from mPEG-PCL, NPs prepared from mPEG-PCL copolymer were used as positive control. Docetaxel-loading NPs using mPEG-pep-PCL and mPEG-PCL were prepared by nano-precipitation method, mentioned as Gel-NPs and Con-NPs, respectively. The morphologic changes of the NPs after treatment with gelatinases were observed macroscopically by spectrophotometer and microscopically by transmission electron microscopy (TEM) and atomic force microscopy (AFM). The cellular uptake amount and cytotoxicity of Gel-NPs and Con-NPs, respectively, in cell lines with different levels of gelatinase expression were studied. Moreover, the cytotoxicity study on the primary cancer cells isolated from pericardial fluids from a patient with late-stage lung cancer was conducted. Results: The Gel-NPs aggregated in response to gelatinases, which was confirmed macroscopically and microscopically. The cellular uptake amount of Gel-NPs was correlated with the level of gelatinases. The in vitro antitumor effect of Gel-NPs was also correlated with the level of gelatinases and was superior to Taxotere (commercially available docetaxel) as well as the Con-NPs. The cytotoxicity study on the primary lung cancer cells also confirmed the effectiveness of Gel-NPs. Conclusion: The results in this study preliminarily demonstrated the effectiveness of gelatinase-responsive targeting strategy and the prospect of this intelligent nano-drug delivery system though further studies are needed.	[Li, Rutian; Liu, Qin; Wu, Puyuan; Xie, Li; Yang, Mi; Qian, Xiaoping; Yu, Lixia; Liu, Baorui] Nanjing Univ, Sch Med, Drum Tower Hosp, Ctr Comprehens Canc, Nanjing 210008, Jiangsu, Peoples R China; [Li, Rutian; Liu, Qin; Wu, Puyuan; Xie, Li; Yang, Mi; Qian, Xiaoping; Yu, Lixia; Liu, Baorui] Nanjing Univ, Clin Canc Inst, Nanjing 210008, Jiangsu, Peoples R China; [Wu, Wei; Jiang, Xiqun] Nanjing Univ, Lab Mesoscop Chem, Nanjing 210008, Jiangsu, Peoples R China; [Wu, Wei; Jiang, Xiqun] Nanjing Univ, Dept Polymer Sci & Engn, Coll Chem & Chem Engn, Nanjing 210008, Jiangsu, Peoples R China; [Zhu, Zhenshu] China Pharmaceut Univ, Dept Pharmaceut Anal, Nanjing, Jiangsu, Peoples R China; [Ding, Yin] Nanjing Univ, Sch Chem & Chem Engn, Key Lab Analyt Chem Life Sci, Nanjing 210008, Jiangsu, Peoples R China; [Guan, Wenxian] Nanjing Univ, Sch Med, Drum Tower Hosp, Dept Gen Surg, Nanjing 210008, Jiangsu, Peoples R China	Nanjing University; Nanjing University; Nanjing University; Nanjing University; China Pharmaceutical University; Nanjing University; Nanjing University	Guan, WX (corresponding author), Nanjing Univ, Sch Med, Drum Tower Hosp, Dept Gen Surg, Nanjing 210008, Jiangsu, Peoples R China.	Guanwenxian@163.com; Baoruiliu@nju.edu.cn	Wu, Wei/ABC-1888-2021; Jiang, Xiqun/I-8128-2014; Yang, Mi/GQA-8758-2022	Wu, Wei/0000-0003-1845-2809; Jiang, Xiqun/0000-0003-0483-0282; 	National Natural Science Foundation of China [81101751, 81172281 81101816, 21105047]; Nanjing Medical Science and technique Development Foundation (Youth Foundation Level 3); Nanjing Medical Science and technique Development Foundation (Outstanding Youth Foundation) [JQX12003]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Nanjing Medical Science and technique Development Foundation (Youth Foundation Level 3); Nanjing Medical Science and technique Development Foundation (Outstanding Youth Foundation)	This work was supported by National Natural Science Foundation of China (no. 81101751, 81172281 81101816 and 21105047), Nanjing Medical Science and technique Development Foundation (Youth Foundation Level 3) and Nanjing Medical Science and technique Development Foundation (Outstanding Youth Foundation, JQX12003). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Buergy D, 2009, INT J CANCER, V125, P894, DOI 10.1002/ijc.24462; Chau Y, 2006, INT J CANCER, V118, P1519, DOI 10.1002/ijc.21495; Coussens LM, 2002, SCIENCE, V295, P2387, DOI 10.1126/science.1067100; Desai N, 2006, CLIN CANCER RES, V12, P1317, DOI 10.1158/1078-0432.CCR-05-1634; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Foda HD, 2001, DRUG DISCOV TODAY, V6, P478, DOI 10.1016/S1359-6446(01)01752-4; Folgueras AR, 2004, INT J DEV BIOL, V48, P411, DOI 10.1387/ijdb.041811af; Ganta S, 2008, J CONTROL RELEASE, V126, P187, DOI 10.1016/j.jconrel.2007.12.017; Ghadiali JE, 2008, ADV MATER, V20, P4359, DOI 10.1002/adma.200703158; Gullotti E, 2009, MOL PHARMACEUT, V6, P1041, DOI 10.1021/mp900090z; Hatakeyama H, 2007, GENE THER, V14, P68, DOI 10.1038/sj.gt.3302843; Huo TY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048752; Jia YL, 2011, HEPATOLOGY, V54, P1808, DOI 10.1002/hep.24562; Kang GD, 2006, EUR J PHARM BIOPHARM, V63, P340, DOI 10.1016/j.ejpb.2006.01.001; Karakoti AS, 2011, ANGEW CHEM INT EDIT, V50, P1980, DOI 10.1002/anie.201002969; Kremer R, 2010, BRIT J CANCER, V102, P1180, DOI 10.1038/sj.bjc.6605607; Kuittinen O, 1999, ANTICANCER RES, V19, P4395; Lamparter S, 2005, AM J CARDIOL, V95, P1065, DOI 10.1016/j.amjcard.2004.12.059; Lee GY, 2007, EUR J PHARM BIOPHARM, V67, P646, DOI 10.1016/j.ejpb.2007.03.023; Li R, 2011, PLOS ONE, V6; Li RT, 2009, INT J PHARMACEUT, V379, P158, DOI 10.1016/j.ijpharm.2009.06.007; Li XL, 2008, EUR J PHARM BIOPHARM, V70, P726, DOI 10.1016/j.ejpb.2008.06.016; Liu Q, 2012, INT J NANOMED, V7, P281, DOI 10.2147/IJN.S26697; Liu Z, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-270; Maeda H, 2009, EUR J PHARM BIOPHARM, V71, P409, DOI 10.1016/j.ejpb.2008.11.010; Makhof A, 2009, EUR J PHARM BIOPHARM, V72, P1, DOI 10.1016/j.ejpb.2008.12.013; Martin MD, 2007, CANCER METAST REV, V26, P717, DOI 10.1007/s10555-007-9089-4; Mishra DK, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045308; Mohamad A, 2006, EUR J PHARM BIOPHARM, V64, P173, DOI 10.1016/j.ejpb.2006.04.006; Nomura Y, 2007, SCAND J GASTROENTERO, V42, P1070, DOI 10.1080/00365520701435881; Overall CM, 2006, NAT REV CANCER, V6, P227, DOI 10.1038/nrc1821; Pasut G, 2009, ADV DRUG DELIVER REV, V61, P1177, DOI 10.1016/j.addr.2009.02.010; Pellikainen JM, 2004, CLIN CANCER RES, V10, P7621, DOI 10.1158/1078-0432.CCR-04-1061; Pinhassi RI, 2010, BIOMACROMOLECULES, V11, P294, DOI 10.1021/bm900853z; Rosen H, 2005, NAT REV DRUG DISCOV, V4, P381, DOI 10.1038/nrd1721; Scherer RL, 2008, MOL IMAGING, V7, P118, DOI 10.2310/7290.2008.00010; Schmaljohann D, 2006, ADV DRUG DELIVER REV, V58, P1655, DOI 10.1016/j.addr.2006.09.020; Sharma S, 2011, MOL VIS, V17, P2898; Singh A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026803; Turk BE, 2001, NAT BIOTECHNOL, V19, P661, DOI 10.1038/90273; WEINGARTEN H, 1986, BIOCHEM BIOPH RES CO, V139, P1184, DOI 10.1016/S0006-291X(86)80302-3; Wu W, 2009, MED ONCOL, V26, P117, DOI 10.1007/s12032-008-9087-6; Yang P, 2009, HEPATOL RES, V39, P1169, DOI 10.1111/j.1872-034X.2009.00563.x; Zhang Y, 2006, NANO LETT, V6, P1988, DOI 10.1021/nl0611586	44	22	22	1	84	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 30	2013	8	7							e69643	10.1371/journal.pone.0069643	http://dx.doi.org/10.1371/journal.pone.0069643			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	201AX	23936062	gold, Green Published, Green Submitted			2023-01-03	WOS:000323114200041
J	Lim, PS; Jeng, YC; Wu, MY; Pai, MA; Wu, TK; Liu, CS; Chen, CH; Kuo, YC; Chien, SW; Chen, HP				Lim, Paik Seong; Jeng, Yachung; Wu, Ming Ying; Pai, Mei-Ann; Wu, Tsai-Kun; Liu, Chia-San; Chen, Chan Hsu; Kuo, Yuan-Chuan; Chien, Shiaw-Wen; Chen, Hung Ping			Serum Oxidized Albumin and Cardiovascular Mortality in Normoalbuminemic Hemodialysis Patients: A Cohort Study	PLOS ONE			English	Article							OXIDATIVE STRESS; REDOX STATE; MERCAPT CONVERSION; DIALYSIS PATIENTS; OXIDANT STRESS; NITRIC-OXIDE; ANTIOXIDANT; PLASMA; INFLAMMATION; ASSOCIATION	Background: Substantial evidence suggests that increased oxidative stress in hemodialysis (HD) patients may contribute to cardiovascular complications. Oxidative modifications of human serum albumin (HSA), the largest thiol pool in plasma, alter its biological properties and may affect its antioxidant potential in HD patients. Methods: We conducted a long-term follow-up study in a cohort of normoalbuminemic HD patients to examine the impact of redox state of serum albumin on patients' survival by measuring the human nonmercaptoalbumin (HNA) fraction of HSA. Results: After adjusting for potential demographic, anthropometric, and clinical confounders, a positive association of HNA level with the risk of death from cardiovascular disease (CVD) and all-cause mortality was observed in normoalbuminemic HD patients. Using stratified analysis, we found a stronger association between HNA level and the risk of death from CVD and all-cause mortality in patients with pre-existing CVD. Conclusions: Serum HNA level is a positive predictor of mortality in normoalbuminemic HD patients, especially among those with pre-existing CVD. Increased oxidative stress resulting from biological changes in serum albumin levels could contribute to accelerated atherosclerosis and the development of cardiovascular disease in HD patients.	[Lim, Paik Seong; Wu, Ming Ying; Pai, Mei-Ann; Wu, Tsai-Kun; Liu, Chia-San; Chen, Chan Hsu; Kuo, Yuan-Chuan; Chien, Shiaw-Wen; Chen, Hung Ping] Tungs Taichung Metroharbour Hosp, Div Renal Med, Taichung, Taiwan; [Lim, Paik Seong] Providence Univ, Dept Food & Nutr, Taichung, Taiwan; [Jeng, Yachung] Tungs Taichung Metroharbour Hosp, Dept Med Res, Div Epidemiol & Biostat, Taichung, Taiwan	Providence University - Taiwan	Jeng, YC (corresponding author), Tungs Taichung Metroharbour Hosp, Dept Med Res, Div Epidemiol & Biostat, Taichung, Taiwan.	yachungjeng@gmail.com						Amaral S, 2008, CLIN J AM SOC NEPHRO, V3, P759, DOI 10.2215/CJN.02720707; Beddhu S, 2002, AM J KIDNEY DIS, V40, P721, DOI 10.1053/ajkd.2002.35679; Bourdon E, 1999, FASEB J, V13, P233, DOI 10.1096/fasebj.13.2.233; Cha MK, 1996, BIOCHEM BIOPH RES CO, V222, P619, DOI 10.1006/bbrc.1996.0793; Cooper BA, 2004, AM J KIDNEY DIS, V43, P61, DOI 10.1053/j.ajkd.2003.08.045; Danielski M, 2003, AM J KIDNEY DIS, V42, P286, DOI 10.1016/S0272-6386(03)00653-X; Daschner M, 1996, KIDNEY INT, V50, P1268, DOI 10.1038/ki.1996.437; de Mutsert R, 2009, J RENAL NUTR, V19, P127, DOI 10.1053/j.jrn.2008.08.003; DEAN RT, 1991, FREE RADICAL BIO MED, V11, P161, DOI 10.1016/0891-5849(91)90167-2; DEMASTER EG, 1995, BIOCHEMISTRY-US, V34, P11494, DOI 10.1021/bi00036a023; Descamps-Latscha B, 2001, KIDNEY INT, V59, pS108; Djousse L, 2002, CIRCULATION, V106, P2919, DOI 10.1161/01.CIR.0000042673.07632.76; Don BR, 2004, SEMIN DIALYSIS, V17, P432, DOI 10.1111/j.0894-0959.2004.17603.x; ERA S, 1995, BBA-PROTEIN STRUCT M, V1247, P12, DOI 10.1016/0167-4838(94)00166-E; FINCH JW, 1993, ARCH BIOCHEM BIOPHYS, V305, P595, DOI 10.1006/abbi.1993.1466; Foley RN, 1998, AM J KIDNEY DIS, V32, pS112, DOI 10.1053/ajkd.1998.v32.pm9820470; GATTI RM, 1994, FEBS LETT, V348, P287, DOI 10.1016/0014-5793(94)00625-3; Goldwasser P, 1997, J CLIN EPIDEMIOL, V50, P693, DOI 10.1016/S0895-4356(97)00015-2; HALLIWELL B, 1988, BIOCHEM PHARMACOL, V37, P569, DOI 10.1016/0006-2952(88)90126-8; Hayashi T., 2000, PATHOPHYSIOLOGY, V6, P237, DOI [10.1016/S0928-4680(99)00022-X, DOI 10.1016/S0928-4680(99)00022-X]; Himmelfarb J, 2001, KIDNEY INT, V60, P358, DOI 10.1046/j.1523-1755.2001.00807.x; Himmelfarb J, 2002, KIDNEY INT, V62, P1524, DOI 10.1046/j.1523-1755.2002.00600.x; ISEKI K, 1993, KIDNEY INT, V44, P115, DOI 10.1038/ki.1993.220; Ishii T, 2011, NEPHRON CLIN PRACT, V117, pC230, DOI 10.1159/000320201; JANATOVA J, 1968, J BIOL CHEM, V243, P3612; Kalantar-Zadeh K, 2005, NEPHROL DIAL TRANSPL, V20, P1880, DOI 10.1093/ndt/gfh941; Kalantar-Zadeh K, 2006, AM J KIDNEY DIS, V48, P59, DOI 10.1053/j.ajkd.2006.03.047; Levin A, 1996, AM J KIDNEY DIS, V27, P347, DOI 10.1016/S0272-6386(96)90357-1; Lim PS, 2007, NEPHROLOGY, V12, P18, DOI 10.1111/j.1440-1797.2006.00745.x; Mera K, 2005, BIOCHEM BIOPH RES CO, V334, P1322, DOI 10.1016/j.bbrc.2005.07.035; Mera K, 2005, HYPERTENS RES, V28, P973, DOI 10.1291/hypres.28.973; Michelis R, 2010, BIOCHEM BIOPH RES CO, V401, P137, DOI 10.1016/j.bbrc.2010.09.027; Oettl K, 2007, BRIT J PHARMACOL, V151, P580, DOI 10.1038/sj.bjp.0707251; Ogasawara Y, 2007, J CHROMATOGR B, V845, P157, DOI 10.1016/j.jchromb.2006.08.006; Peters T, 1996, ALL ALBUMIN BIOCH GE, P51; RADI R, 1991, J BIOL CHEM, V266, P4244; Roberts MA, 2006, NEPHROL DIAL TRANSPL, V21, P1611, DOI 10.1093/ndt/gfl053; Soejima A, 2004, BLOOD PURIFICAT, V22, P525, DOI 10.1159/000082524; SOGAMI M, 1985, INT J PEPT PROT RES, V25, P398; SOGAMI M, 1985, J CHROMATOGR, V332, P19, DOI 10.1016/S0021-9673(01)83283-0; Terawaki H, 2004, KIDNEY INT, V66, P1988, DOI 10.1111/j.1523-1755.2004.00969.x; Terawaki H, 2010, THER APHER DIAL, V14, P465, DOI 10.1111/j.1744-9987.2010.00841.x; THOMAS JA, 1995, ARCH BIOCHEM BIOPHYS, V319, P1, DOI 10.1006/abbi.1995.1261; Tomida M, 2003, JPN J PHYSIOL, V53, P351, DOI 10.2170/jjphysiol.53.351	44	26	26	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 29	2013	8	7							e70822	10.1371/journal.pone.0070822	http://dx.doi.org/10.1371/journal.pone.0070822			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	204MP	23923025	gold, Green Submitted, Green Published			2023-01-03	WOS:000323369700208
J	Kekre, N; Mallick, R; Allan, D; Tinmouth, A; Tay, J				Kekre, Natasha; Mallick, Ranjeeta; Allan, David; Tinmouth, Alan; Tay, Jason			The Impact of Prolonged Storage of Red Blood Cells on Cancer Survival	PLOS ONE			English	Article							RANDOMIZED CONTROLLED-TRIAL; CRITICALLY-ILL PATIENTS; IN-HOSPITAL MORTALITY; BYPASS GRAFT-SURGERY; DEEP-VEIN THROMBOSIS; TRANSFUSED BLOOD; CARDIAC-SURGERY; COLORECTAL-CANCER; AGE; DURATION	Background: The duration of storage of transfused red blood cells (RBC) has been associated with poor clinical outcomes in some studies. We sought to establish whether prolonged storage of transfused RBC in cancer patients influences overall survival (OS) or cancer recurrence. Methods and Findings: Patients diagnosed with cancer at The Ottawa Regional Cancer Centre between January 01, 2000 and December 31, 2005 were included (n = 27,591) where 1,929 (7.0%) received RBC transfusions within one year from diagnosis. Transfused RBC units were categorized as "new'' if stored for less than 14 days, "intermediate'' if stored between 14 and 28 days and "old'' if stored for more than 28 days. Baseline characteristics between the comparative groups were compared by ANOVA test. Categorical variables and continuous variables were compared using Chi-squared and Wilcoxan rank-sum tests respectively. Overall survival was not associated with duration of storage of transfused RBC with a median survival of 1.2, 1.7, 1.1 years for only new, intermediate and old RBC units respectively (p = 0.36). Cancer recurrence was significantly higher in patients who received a RBC transfusion than those who did not (56.3% vs 33.0% respectively; p<0.0001) but was not affected by the duration of storage of transfused RBC (p = 0.06). In multivariate analysis, lung cancer, advanced stage, chemotherapy, radiation, cancer-related surgery and cancer recurrence were associated with inferior OS (p<0.05), while age, advanced stage, lung cancer, and more than 6 units of blood transfused were associated with cancer recurrence (p,<0.05). The duration of storage of RBC before transfusion was not associated with OS or cancer recurrence in multivariate analysis. Conclusion: In patients diagnosed with cancer, the duration of storage of transfused RBC had no impact on OS or cancer recurrence. This suggests that our current RBC storage policy of providing RBC of variable duration of storage for patients with malignancy is safe.	[Kekre, Natasha] Ottawa Hosp, Dept Med, Div Hematol, Ottawa, ON, Canada; [Mallick, Ranjeeta; Tinmouth, Alan; Tay, Jason] Ottawa Hosp, Ctr Transfus Res, Ottawa, ON, Canada; [Allan, David; Tinmouth, Alan; Tay, Jason] Ottawa Hosp, Clin Epidemiol Program, Ottawa, ON, Canada; [Allan, David; Tinmouth, Alan; Tay, Jason] Ottawa Hosp Res Inst, Regenerat Med Program, Ottawa, ON, Canada; [Allan, David; Tay, Jason] Ottawa Hosp, Blood & Marrow Transplant Program, Div Hematol, Ottawa, ON, Canada	University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; Ottawa Hospital Research Institute	Tay, J (corresponding author), Ottawa Hosp, Ctr Transfus Res, Ottawa, ON, Canada.	jtay@ottawahospital.on.ca	Tay, Jason/J-5061-2019	Tay, Jason/0000-0002-5969-9755; Allan, David/0000-0003-3261-8289	ASH trainee research award	ASH trainee research award	NK was supported by an ASH trainee research award. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Andreasen JJ, 2011, EUR J CARDIO-THORAC, V39, P329, DOI 10.1016/j.ejcts.2010.06.019; Cata JP, 2011, MAYO CLIN PROC, V86, P120, DOI 10.4065/mcp.2010.0313; de Watering LV, 2006, TRANSFUSION, V46, P1712, DOI 10.1111/j.1537-2995.00958.x; Dessertaine G, 2008, TRANSFUS CLIN BIOL, V15, P154, DOI 10.1016/j.tracli.2008.06.001; Dunn LK, 2012, LIVER TRANSPLANT, V18, P475, DOI 10.1002/lt.23379; Edna TH, 1998, EUR J SURG, V164, P449; Eikelboom JW, 2010, AM HEART J, V159, P737, DOI 10.1016/j.ahj.2009.12.045; Estrin J T, 1999, Oncologist, V4, P318; Fergusson D, 2009, TRANSFUS MED REV, V23, P55, DOI 10.1016/j.tmrv.2008.09.005; Hamasaki N, 2000, VOX SANG, V79, P191, DOI 10.1159/000056729; HEATON A, 1984, BRIT J HAEMATOL, V57, P467, DOI 10.1111/j.1365-2141.1984.tb02921.x; Hebert PC, 2005, ANESTH ANALG, V100, P1433, DOI 10.1213/01.ANE.0000148690.48803.27; HOGMAN CF, 1983, VOX SANG, V45, P217; Isbister JP, 2011, TRANSFUS MED REV, V25, P89, DOI 10.1016/j.tmrv.2010.11.001; Katsios C, 2011, CRIT CARE, V15, DOI 10.1186/cc10526; Kekre N, 2011, TRANSFUSION, V51, P2488, DOI 10.1111/j.1537-2995.2011.03166.x; Keller ME, 2002, J TRAUMA, V53, P1023, DOI 10.1097/00005373-200211000-00037; Koch CG, 2008, NEW ENGL J MED, V358, P1229, DOI 10.1056/NEJMoa070403; Lacroix J, 2011, TRANSFUS MED REV, V25, P197, DOI 10.1016/j.tmrv.2011.03.001; Leal-Noval SR, 2003, ANESTHESIOLOGY, V98, P815, DOI 10.1097/00000542-200304000-00005; Lelubre C, 2009, TRANSFUSION, V49, P1384, DOI 10.1111/j.1537-2995.2009.02211.x; MARTIN CM, 1994, CLIN INVEST MED, V17, P124; Murrell Z, 2005, AM SURGEON, V71, P781; Mynster T, 2000, SCAND J GASTROENTERO, V35, P212; Mynster T, 2001, DIS COLON RECTUM, V44, P955, DOI 10.1007/BF02235483; Offner PJ, 2002, ARCH SURG-CHICAGO, V137, P711, DOI 10.1001/archsurg.137.6.711; Panagopoulos ND, 2008, LUNG CANCER, V62, P273, DOI 10.1016/j.lungcan.2008.02.025; Pettila V, 2011, CRIT CARE, V15, DOI 10.1186/cc10142; Purdy FR, 1997, CAN J ANAESTH, V44, P1256, DOI 10.1007/BF03012772; Robinson SD, 2010, AM HEART J, V159, P876, DOI 10.1016/j.ahj.2010.02.018; Sanders J, 2011, TRANSFUSION, V51, P2286, DOI 10.1111/j.1537-2995.2011.03170.x; SIMON TL, 1987, TRANSFUSION, V27, P178, DOI 10.1046/j.1537-2995.1987.27287150195.x; Skillings J R, 1999, Cancer Prev Control, V3, P207; SOHMER PR, 1982, TRANSFUSION, V22, P479, DOI 10.1046/j.1537-2995.1982.22683068607.x; Sparrow RL, 2010, BLOOD TRANSFUS-ITALY, V8, pS26, DOI 10.2450/2010.005S; Spinella PC, 2009, CRIT CARE, V13, DOI 10.1186/cc8050; Stehling LC, 1996, ANESTHESIOLOGY, V84, P732; Taylor RW, 2006, CRIT CARE MED, V34, P2302, DOI 10.1097/01.CCM.0000234034.51040.7F; Tinmouth A, 2006, TRANSFUSION, V46, P2014, DOI 10.1111/j.1537-2995.2006.01026.x; Valeri CR, 2002, VOX SANG, V83, P193, DOI 10.1111/j.1423-0410.2002.tb05299.x; Vamvakas EC, 1999, TRANSFUSION, V39, P701, DOI 10.1046/j.1537-2995.1999.39070701.x; Vamvakas EC, 2001, BLOOD, V97, P1180, DOI 10.1182/blood.V97.5.1180; Vamvakas EC, 2000, TRANSFUSION, V40, P101, DOI 10.1046/j.1537-2995.2000.40010101.x; van Straten AHM, 2011, J THORAC CARDIOV SUR, V141, P231, DOI 10.1016/j.jtcvs.2010.02.059; Weinberg JA, 2008, J TRAUMA, V65, P279, DOI 10.1097/TA.0b013e31817c9687; Wu Y, 2009, CLIN THER, V31, P2416, DOI 10.1016/j.clinthera.2009.11.020; Yap CH, 2008, ANN THORAC SURG, V86, P554, DOI 10.1016/j.athoracsur.2008.04.040; Yeh JJ, 2007, BRIT J SURG, V94, P466, DOI 10.1002/bjs.5488; Zallen G, 1999, AM J SURG, V178, P570, DOI 10.1016/S0002-9610(99)00239-1	49	16	16	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 16	2013	8	7							e68820	10.1371/journal.pone.0068820	http://dx.doi.org/10.1371/journal.pone.0068820			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	186SF	23874777	gold, Green Submitted, Green Published			2023-01-03	WOS:000322064300073
J	Chen, WW; Wang, F; Xu, RH				Chen, Wei-Wei; Wang, Feng; Xu, Rui-Hua			Platinum-Based Versus Non-Platinum-Based Chemotherapy as First Line Treatment of Inoperable, Advanced Gastric Adenocarcinoma: A Meta-Analysis	PLOS ONE			English	Article							PROSPECTIVE RANDOMIZED-TRIAL; ITALIAN-ONCOLOGY-GROUP; MULTICENTER PHASE-II; EUROPEAN ORGANIZATION; FOLINIC ACID; JUNCTION ADENOCARCINOMA; PLUS CISPLATIN; CANCER; FLUOROURACIL; DOXORUBICIN	Background: Although the platinum regimen is adopted widely nowadays in spite of the excessive side effects, there is still no international standard for palliative chemotherapy of advanced gastric cancer. This meta-analysis assessed the efficacy and tolerability of platinum versus non-platinum chemotherapy as first-line palliative treatment in patients with inoperable, advanced gastric cancer. Methods: Randomized phase II and III clinical trials on first-line palliative chemotherapy in inoperable, advanced gastric cancer were identified by electronic searches of PubMed, Embase, and the Cochrane Controlled Trial Register, and hand searches of relevant abstract books and reference lists. Response rates, overall survival, and toxicity were analyzed. Depending on whether new-generation agents (S-1, taxanes and irinotecan) were utilized, the non-platinum regimens were divided into two subgroup. Results: Compared to non-platinum regimens containing new-generation agents, the use of platinum-based regimens was associated with better response (risk ratio (RR) = 1.94, 95% CI[1.48, 2.55], p<0.001), an increase of overall survival (hazard ratio (HR) = 0.85, 95% CI[0.78, 0.92], p<0.001), a higher risk of hematological and non-hematological toxicity. No statistically significant increase in response (RR = 1.03, 95% CI [0.85, 1.24], p = 0.76) or overall survival (HR = 1.07, 95% CI [0.88, 1.30], p = 0.49) was found when platinum therapies were compared to new-generation agent based combination regimens. The toxicity of platinum-based regimens was significantly higher for hematologic toxicity, nausea and vomiting, and neurotoxicity, but not for diarrhea and toxic death rate. Conclusion: New-generation agent based combination regimens achieved similar response rate and overall survival as platinum-based therapy that had generally higher side effects. S-1, taxanes and irinotecan seemed to be valid options for patients with inoperable, advanced gastric cancer as first-line chemotherapy.	[Xu, Rui-Hua] Sun Yat Sen Univ, Ctr Canc, Dept Med Oncol, Guangzhou 510275, Guangdong, Peoples R China; Sun Yat Sen Univ, Ctr Canc, State Key Lab Oncol South China, Guangzhou 510275, Guangdong, Peoples R China	Sun Yat Sen University; State Key Lab Oncology South China; Sun Yat Sen University	Xu, RH (corresponding author), Sun Yat Sen Univ, Ctr Canc, Dept Med Oncol, Guangzhou 510275, Guangdong, Peoples R China.	xurh@mail.sysu.edu.cn	Xu, Rui-Hua/AAW-4766-2021; xu, rui/GRX-5734-2022	Xu, Rui-Hua/0000-0001-9771-8534; 	National High Technology Research and Development Program of China (863 Program) [2012AA02A5060]; Science and Technology Department of Guangdong Province [2012B031800088]; Medical Scientific Research Foundation of Guangdong Province [C2011019]	National High Technology Research and Development Program of China (863 Program)(National High Technology Research and Development Program of China); Science and Technology Department of Guangdong Province; Medical Scientific Research Foundation of Guangdong Province	This work was supported by the National High Technology Research and Development Program of China (863 Program)(No.2012AA02A5060), the Science and Technology Department of Guangdong Province(No. 2012B031800088), and the Medical Scientific Research Foundation of Guangdong Province (No.C2011019). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 1988, J Natl Cancer Inst, V80, P1011; Barone C, 1998, CANCER-AM CANCER SOC, V82, P1460, DOI 10.1002/(SICI)1097-0142(19980415)82:8<1460::AID-CNCR5>3.0.CO;2-D; Boku N, 2009, LANCET ONCOL, V10, P1063, DOI 10.1016/S1470-2045(09)70259-1; Bouche O, 2004, J CLIN ONCOL, V22, P4319, DOI 10.1200/JCO.2004.01.140; Brown Linda Morris, 2002, Surg Oncol Clin N Am, V11, P235, DOI 10.1016/S1055-3207(02)00002-9; COCCONI G, 1994, J CLIN ONCOL, V12, P2687, DOI 10.1200/JCO.1994.12.12.2687; Cocconi G, 2003, ANN ONCOL, V14, P1258, DOI 10.1093/annonc/mdg329; Crew KD, 2006, WORLD J GASTROENTERO, V12, P354, DOI 10.3748/wjg.v12.i3.354; CULLINAN SA, 1994, J CLIN ONCOL, V12, P412, DOI 10.1200/JCO.1994.12.2.412; Dank M, 2008, ANN ONCOL, V19, P1450, DOI 10.1093/annonc/mdn166; DeLisi V, 1996, CANCER, V77, P245, DOI 10.1002/(SICI)1097-0142(19960115)77:2<245::AID-CNCR4>3.3.CO;2-#; Field K, 2008, DRUGS, V68, P299, DOI 10.2165/00003495-200868030-00004; Hou AnJi, 2009, Tumor, V29, P160; Jeung HC, 2011, CANCER-AM CANCER SOC, V117, P2050, DOI 10.1002/cncr.25729; KELSEN D, 1992, J CLIN ONCOL, V10, P541, DOI 10.1200/JCO.1992.10.4.541; Kikuchi K, 1990, Gan To Kagaku Ryoho, V17, P655; Kim JA, 2011, CANCER CHEMOTH PHARM, V68, P177, DOI 10.1007/s00280-010-1452-4; KIM NK, 1993, CANCER, V71, P3813, DOI 10.1002/1097-0142(19930615)71:12<3813::AID-CNCR2820711205>3.0.CO;2-5; Koizumi W, 2008, LANCET ONCOL, V9, P215, DOI 10.1016/S1470-2045(08)70035-4; Liberati A, 2009, PLOS MED, V6, DOI [10.1371/journal.pmed.1000100, 10.1136/bmj.b2700, 10.7326/0003-4819-151-4-200908180-00136]; Lutz MP, 2007, J CLIN ONCOL, V25, P2580, DOI 10.1200/JCO.2007.11.1666; Maiello E, 2011, J CLIN ONCOL SUPPL 4, V29; Maiello E, 2011, EPIRUBICIN E IN COMB; Mochiki E, 2012, BRIT J CANCER, V107, P31, DOI 10.1038/bjc.2012.222; Moehler M, 2010, ANN ONCOL, V21, P71, DOI 10.1093/annonc/mdp269; Moher David, 2009, BMJ, V339, pb2535, DOI [10.1016/j.ijsu.2010.02.007, 10.1136/bmj.b2535]; Park JO, 2003, JPN J CLIN ONCOL, V33, P533, DOI 10.1093/jjco/hyg093; Parmar MKB, 1998, STAT MED, V17, P2815, DOI 10.1002/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8; Popov IP, 2008, MED ONCOL, V25, P73, DOI 10.1007/s12032-007-0042-8; Pozzo C, 2004, ANN ONCOL, V15, P1773, DOI 10.1093/annonc/mdh473; Tebbutt NC, 2010, BRIT J CANCER, V102, P475, DOI 10.1038/sj.bjc.6605522; Thuss-Patience PC, 2005, J CLIN ONCOL, V23, P494, DOI 10.1200/JCO.2005.02.163; Van Cutsem E, 2008, EUR J CANCER, V44, P182, DOI 10.1016/j.ejca.2007.11.001; Vanhoefer U, 2000, J CLIN ONCOL, V18, P2648, DOI 10.1200/JCO.2000.18.14.2648; Wagner AD, 2006, J CLIN ONCOL, V24, P2903, DOI 10.1200/JCO.2005.05.0245; Waters JS, 1999, BRIT J CANCER, V80, P269, DOI 10.1038/sj.bjc.6690350; Webb A, 1997, J CLIN ONCOL, V15, P261, DOI 10.1200/JCO.1997.15.1.261; Yang Jian-Wei, 2005, Ai Zheng, V24, P1531; Zhao Wen-ying, 2011, Zhonghua Zhong Liu Za Zhi, V33, P295	39	15	15	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 11	2013	8	7							e68974	10.1371/journal.pone.0068974	http://dx.doi.org/10.1371/journal.pone.0068974			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	188UA	23874831	Green Published, Green Submitted, gold			2023-01-03	WOS:000322218800055
J	Rubertsson, S; Lindgren, E; Smekal, D; Ostlund, O; Silfverstolpe, J; Lichtveld, RA; Boomars, R; Ahlstedt, B; Skoog, G; Kastberg, R; Halliwell, D; Box, M; Herlitz, J; Karlsten, R				Rubertsson, Sten; Lindgren, Erik; Smekal, David; Ostlund, Ollie; Silfverstolpe, Johan; Lichtveld, Robert A.; Boomars, Rene; Ahlstedt, Bjorn; Skoog, Gunnar; Kastberg, Robert; Halliwell, David; Box, Martyn; Herlitz, Johan; Karlsten, Rolf			Mechanical Chest Compressions and Simultaneous Defibrillation vs Conventional Cardiopulmonary Resuscitation in Out-of-Hospital Cardiac Arrest The LINC Randomized Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							VENTRICULAR-FIBRILLATION; PERFUSION-PRESSURE; BLOOD-FLOW; DEVICE; LUCAS; SURVIVAL; QUALITY	IMPORTANCE A strategy using mechanical chest compressions might improve the poor outcome in out-of-hospital cardiac arrest, but such a strategy has not been tested in large clinical trials. OBJECTIVE To determine whether administering mechanical chest compressions with defibrillation during ongoing compressions (mechanical CPR), compared with manual cardiopulmonary resuscitation (manual CPR), according to guidelines, would improve 4-hour survival. DESIGN, SETTING, AND PARTICIPANTS Multicenter randomized clinical trial of 2589 patients with out-of-hospital cardiac arrest conducted between January 2008 and February 2013 in 4 Swedish, 1 British, and 1 Dutch ambulance services and their referring hospitals. Duration of follow-up was 6 months. INTERVENTIONS Patients were randomized to receive either mechanical chest compressions (LUCAS Chest Compression System, Physio-Control/Jolife AB) combined with defibrillation during ongoing compressions (n = 1300) or to manual CPR according to guidelines (n = 1289). MAIN OUTCOMES AND MEASURES Four-hour survival, with secondary end points of survival up to 6 months with good neurological outcome using the Cerebral Performance Category (CPC) score. A CPC score of 1 or 2 was classified as a good outcome. RESULTS Four-hour survival was achieved in 307 patients (23.6%) with mechanical CPR and 305 (23.7%) with manual CPR (risk difference, -0.05%; 95% CI, -3.3% to 3.2%; P > .99). Survival with a CPC score of 1 or 2 occurred in 98 (7.5%) vs 82 (6.4%) (risk difference, 1.18%; 95% CI, -0.78% to 3.1%) at intensive care unit discharge, in 108 (8.3%) vs 100 (7.8%) (risk difference, 0.55%; 95% CI, -1.5% to 2.6%) at hospital discharge, in 105 (8.1%) vs 94 (7.3%) (risk difference, 0.78%; 95% CI, -1.3% to 2.8%) at 1 month, and in 110 (8.5%) vs 98 (7.6%) (risk difference, 0.86%; 95% CI, -1.2% to 3.0%) at 6 months with mechanical CPR and manual CPR, respectively. Among patients surviving at 6 months, 99% in the mechanical CPR group and 94% in the manual CPR group had CPC scores of 1 or 2. CONCLUSIONS AND RELEVANCE Among adults with out-of-hospital cardiac arrest, there was no significant difference in 4-hour survival between patients treated with the mechanical CPR algorithm or those treated with guideline-adherent manual CPR. The vast majority of survivors in both groups had good neurological outcomes by 6 months. In clinical practice, mechanical CPR using the presented algorithm did not result in improved effectiveness compared with manual CPR.	[Rubertsson, Sten; Lindgren, Erik; Smekal, David; Karlsten, Rolf] Uppsala Univ, Dept Surg Sci Anaesthesiol & Intens Care, SE-75185 Uppsala, Sweden; [Ostlund, Ollie] Uppsala Univ, Uppsala Clin Res Ctr, SE-75185 Uppsala, Sweden; [Silfverstolpe, Johan] Reg Skane Prehosp Ctr, Lund, Sweden; [Silfverstolpe, Johan] Skane Univ Hosp, Lund, Sweden; [Lichtveld, Robert A.; Boomars, Rene] Reg Ambulance Serv Utrecht, Utrecht, Netherlands; [Ahlstedt, Bjorn] Vasteras Hosp, Vasteras, Sweden; [Skoog, Gunnar; Kastberg, Robert] Gavle Cent Hosp, Gavle, Sweden; [Halliwell, David; Box, Martyn] South Western Ambulance Serv NHS Fdn Trust Abbey, Exeter, Devon, England; [Herlitz, Johan] Ctr Prehosp Res Western Sweden, Gothenburg, Sweden; [Herlitz, Johan] Univ Coll Boras, Gothenburg, Sweden; [Herlitz, Johan] Sahlgrens Univ Hosp, Gothenburg, Sweden	Uppsala University; Uppsala University; Lund University; Skane University Hospital; Vasteras Central Hospital; University of Boras; Sahlgrenska University Hospital	Rubertsson, S (corresponding author), Uppsala Univ, Univ Uppsala Hosp, Dept Surg Sci Anaestesiol & Intens Care, SE-75185 Uppsala, Sweden.	sten.rubertsson@akademiska.se	Smekal, David/AAG-5334-2021	Ostlund, Ollie/0000-0001-8028-2308; Smekal, David/0000-0002-3563-6450; Lichtveld, Robert/0000-0002-3957-7056; Karlsten, Rolf/0000-0003-3923-4093	Uppsala University; Physio-Control/Jolife AB	Uppsala University; Physio-Control/Jolife AB	This work was supported by institutional grants from Uppsala University and by Physio-Control/Jolife AB.	Aufderheide TP, 2011, LANCET, V377, P301, DOI 10.1016/S0140-6736(10)62103-4; Axelsson C, 2009, RESUSCITATION, V80, P1099, DOI 10.1016/j.resuscitation.2009.08.006; Axelsson C, 2006, RESUSCITATION, V71, P47, DOI 10.1016/j.resuscitation.2006.02.011; Christenson J, 2009, CIRCULATION, V120, P1241, DOI 10.1161/CIRCULATIONAHA.109.852202; Cobb LA, 1999, JAMA-J AM MED ASSOC, V281, P1182, DOI 10.1001/jama.281.13.1182; Eftestol T, 2002, CIRCULATION, V105, P2270, DOI 10.1161/01.CIR.0000016362.42586.FE; Jacobs IG, 2011, RESUSCITATION, V82, P1138, DOI 10.1016/j.resuscitation.2011.06.029; JENNETT B, 1975, LANCET, V1, P480; Kramer-Johansen J, 2007, RESUSCITATION, V73, P212, DOI 10.1016/j.resuscitation.2006.09.006; Nolan JP, 2005, RESUSCITATION, V67, pS39, DOI 10.1016/j.resuscitation.2005.10.009; Olasveengen TM, 2008, RESUSCITATION, V76, P185, DOI 10.1016/j.resuscitation.2007.07.001; Olasveengen TM, 2009, JAMA-J AM MED ASSOC, V302, P2222, DOI 10.1001/jama.2009.1729; PARADIS NA, 1990, JAMA-J AM MED ASSOC, V263, P1106, DOI 10.1001/jama.263.8.1106; Rubertsson S, 2005, RESUSCITATION, V65, P357, DOI 10.1016/j.resuscitation.2004.12.006; RUBERTSSON S, 1995, CRIT CARE MED, V23, P1984, DOI 10.1097/00003246-199512000-00007; Rubertsson S, 2013, SCAND J TRAUMA RESUS, V21, DOI 10.1186/1757-7241-21-5; Sato Y, 1997, CRIT CARE MED, V25, P733, DOI 10.1097/00003246-199705000-00005; Smekal D, 2011, RESUSCITATION, V82, P702, DOI 10.1016/j.resuscitation.2011.01.032; Steen S, 2003, RESUSCITATION, V58, P249, DOI 10.1016/S0300-9572(03)00265-X; Steen S, 2002, RESUSCITATION, V55, P285, DOI 10.1016/S0300-9572(02)00271-X; Valenzuela TD, 1997, CIRCULATION, V96, P3308; Wagner H, 2010, RESUSCITATION, V81, P383, DOI 10.1016/j.resuscitation.2009.11.006; WEIL MH, 1985, CRIT CARE MED, V13, P907, DOI 10.1097/00003246-198511000-00011; Wik L, 2005, RESUSCITATION, V66, P391, DOI 10.1016/j.resuscitation.2005.03.011; Wik L, 2003, JAMA-J AM MED ASSOC, V289, P1389, DOI 10.1001/jama.289.11.1389	26	274	295	0	37	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 1	2014	311	1					53	61		10.1001/jama.2013.282538	http://dx.doi.org/10.1001/jama.2013.282538			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	282HN	24240611				2023-01-03	WOS:000329161400018
J	Dunleavy, K; Pittaluga, S; Shovlin, M; Steinberg, SM; Cole, D; Grant, C; Widemann, B; Staudt, LM; Jaffe, ES; Little, RF; Wilson, WH				Dunleavy, Kieron; Pittaluga, Stefania; Shovlin, Margaret; Steinberg, Seth M.; Cole, Diane; Grant, Cliona; Widemann, Brigitte; Staudt, Louis M.; Jaffe, Elaine S.; Little, Richard F.; Wilson, Wyndham H.			Low-Intensity Therapy in Adults with Burkitt's Lymphoma	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DOSE-ADJUSTED EPOCH; NON-HODGKINS-LYMPHOMA; EVENT-FREE SURVIVAL; B-CELL LYMPHOMAS; CODOX-M/IVAC; ANTIRETROVIRAL THERAPY; CHEMOTHERAPY REGIMEN; CHILDREN; RITUXIMAB; DOXORUBICIN	BACKGROUND Burkitt's lymphoma is an aggressive B-cell lymphoma that occurs in children and adults and is largely curable with the use of intensive and toxic chemotherapy. Current treatments are less effective and have more severe side effects in adults and patients with immunodeficiency than in children. METHODS We studied low-intensity treatment consisting of infused etoposide, doxorubicin, and cyclophosphamide with vincristine, prednisone, and rituximab (EPOCH-R) in patients with untreated Burkitt's lymphoma. Two EPOCH-R regimens were tested: a standard dose-adjusted combination in human immunodeficiency virus (HIV)-negative patients (DA-EPOCH-R group) and a lower-dose short-course combination with a double dose of rituximab in HIV-positive patients (SC-EPOCH-RR group). RESULTS A total of 30 consecutive patients were treated; 19 patients were in the DA-EPOCH-R group, and 11 in the SC-EPOCH-RR group. The overall median age of the patients was 33 years, and 40% were 40 years of age or older; 73% of the patients had intermediate-risk disease, and 10% had high-risk disease. The principal toxic events, fever and neutropenia, were observed during 22% of the DA-EPOCH-R treatment cycles and 10% of the SC-EPOCH-RR treatment cycles. The tumor lysis syndrome developed in 1 patient; no treatment-related deaths occurred. The median cumulative doses of doxorubicin-etoposide and cyclophosphamide administered in the SC-EPOCH-RR group were 47% and 57% lower, respectively, than those administered in the DA-EPOCH-R group. With median follow-up times of 86 months in the DA-EPOCH-R group and 73 months in the SC-EPOCH-RR group, the rates of freedom from progression of disease and overall survival were, respectively, 95% and 100% with DA-EPOCH-R and 100% and 90% with SC-EPOCH-RR. None of the patients died from Burkitt's lymphoma. CONCLUSIONS In this uncontrolled prospective study, low-intensity EPOCH-R-based treatment was highly effective in adults with sporadic or immunodeficiency-associated Burkitt's lymphoma.	[Dunleavy, Kieron; Pittaluga, Stefania; Shovlin, Margaret; Steinberg, Seth M.; Cole, Diane; Grant, Cliona; Widemann, Brigitte; Staudt, Louis M.; Jaffe, Elaine S.; Little, Richard F.; Wilson, Wyndham H.] NCI, Ctr Canc Res, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Wilson, WH (corresponding author), NCI, Lymphoid Malignancy Branch, Bldg 10,Rm 4N-115,9000 Rockville Pike, Bethesda, MD 20892 USA.	wilsonw@mail.nih.gov	Staudt, Louis/AAC-5324-2019; Jaffe, Elaine/G-8981-2014	Jaffe, Elaine/0000-0003-4632-0301	National Cancer Institute; NATIONAL CANCER INSTITUTE [ZIASC006741, ZIASC000550, ZIABC011070] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Funded by the National Cancer Institute; ClinicalTrials.gov numbers, NCT00001337 and NCT00006436.	Barnes JA, 2011, ANN ONCOL, V22, P1859, DOI 10.1093/annonc/mdq677; Blum KA, 2004, BLOOD, V104, P3009, DOI 10.1182/blood-2004-02-0405; Burkhardt B, 2011, LEUKEMIA, V25, P153, DOI 10.1038/leu.2010.245; BURKITT D, 1958, BRIT J SURG, V46, P218, DOI 10.1002/bjs.18004619704; Cheson BD, 2007, J CLIN ONCOL, V25, P579, DOI 10.1200/JCO.2006.09.2403; Cortes J, 2002, CANCER, V94, P1492, DOI 10.1002/cncr.10365; Divine M, 2005, ANN ONCOL, V16, P1928, DOI 10.1093/annonc/mdi403; Dunleavy K, 2013, NEW ENGL J MED, V368, P1408, DOI 10.1056/NEJMoa1214561; Dunleavy K, 2010, BLOOD, V115, P3017, DOI 10.1182/blood-2009-11-253039; Gerrard M, 2008, BRIT J HAEMATOL, V141, P840, DOI 10.1111/j.1365-2141.2008.07144.x; Gibaldi M., 1982, PHARMACOKINETICS, Vsecond; Gundersen GG, 1999, CURR OPIN CELL BIOL, V11, P81, DOI 10.1016/S0955-0674(99)80010-6; Kasamon YL, 2013, LEUKEMIA LYMPHOMA, V54, P483, DOI 10.3109/10428194.2012.715346; Kirwan M, 2009, HUM MUTAT, V30, P1567, DOI 10.1002/humu.21115; Kontny NE, 2013, CANCER CHEMOTH PHARM, V71, P749, DOI 10.1007/s00280-013-2069-1; Little RF, 2003, BLOOD, V101, P4653, DOI 10.1182/blood-2002-11-3589; Longo, 1996, J CLIN ONCOL, V14, P1969; LONGO DL, 1994, J CLIN ONCOL, V12, P2153, DOI 10.1200/JCO.1994.12.10.2153; Magrath I, 1996, J CLIN ONCOL, V14, P925, DOI 10.1200/JCO.1996.14.3.925; Mead GM, 2002, ANN ONCOL, V13, P1264, DOI 10.1093/annonc/mdf253; MEHTA CR, 1983, J AM STAT ASSOC, V78, P427, DOI 10.2307/2288652; Montoto S, 2010, AIDS, V24, P851, DOI 10.1097/QAD.0b013e3283301578; OCONNOR PM, 1991, CANCER RES, V51, P6550; Oeffinger KC, 2006, NEW ENGL J MED, V355, P1572, DOI 10.1056/NEJMsa060185; Offer H, 2002, CARCINOGENESIS, V23, P1025, DOI 10.1093/carcin/23.6.1025; Patte C, 2001, BLOOD, V97, P3370, DOI 10.1182/blood.V97.11.3370; Patte C, 2007, BLOOD, V109, P2773, DOI 10.1182/blood-2006-07-036673; Ratain MJ, 2001, PHARM CANC CHEMOTHER; Reiter A, 2000, BLOOD, V95, P416; Reiter A, 1999, BLOOD, V94, P3294; Schmitz R, 2012, NATURE, V490, P116, DOI 10.1038/nature11378; Sutton L, 2001, BRIT J HAEMATOL, V112, P900, DOI 10.1046/j.1365-2141.2001.02661.x; Swerdlow S.H., 2008, WHO CLASSIFICATION T; TAUB R, 1984, CELL, V36, P339, DOI 10.1016/0092-8674(84)90227-7; Todeschini G, 2012, AM J HEMATOL, V87, P22, DOI 10.1002/ajh.22189; Wang ES, 2003, CANCER-AM CANCER SOC, V98, P1196, DOI 10.1002/cncr.11628; Warren KE, 2000, CANCER CHEMOTH PHARM, V45, P207, DOI 10.1007/s002800050031; Wasterlid T, 2013, ANN ONCOL, V24, P1879, DOI 10.1093/annonc/mdt058; Wilson WH, 2002, BLOOD, V99, P2685, DOI 10.1182/blood.V99.8.2685; Wilson WH, 2008, J CLIN ONCOL, V26, P2717, DOI 10.1200/JCO.2007.13.1391; Wilson WH, 2012, HAEMATOL-HEMATOL J, V97, P758, DOI 10.3324/haematol.2011.056531	41	214	220	0	12	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 14	2013	369	20					1915	1925		10.1056/NEJMoa1308392	http://dx.doi.org/10.1056/NEJMoa1308392			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	300MP	24224624	Green Accepted			2023-01-03	WOS:000330468300009
J	Maier, LJ; Liechti, ME; Herzig, F; Schaub, MP				Maier, Larissa J.; Liechti, Matthias E.; Herzig, Fiona; Schaub, Michael P.			To Dope or Not to Dope: Neuroenhancement with Prescription Drugs and Drugs of Abuse among Swiss University Students	PLOS ONE			English	Article							COLLEGE-STUDENTS; NONMEDICAL USE; PHARMACOLOGICAL NEUROENHANCEMENT; COGNITIVE ENHANCEMENT; ADHD MEDICATIONS; ILLICIT USE; STIMULANTS; HEALTHY; PREVALENCE; METHYLPHENIDATE	Background: Neuroenhancement is the use of substances by healthy subjects to enhance mood or cognitive function. The prevalence of neuroenhancement among Swiss university students is unknown. Investigating the prevalence of neuroenhancement among students is important to monitor problematic use and evaluate the necessity of prevention programs. Study aim: To describe the prevalence of the use of prescription medications and drugs of abuse for neuroenhancement among Swiss university students. Method: In this cross-sectional study, students at the University of Zurich, University of Basel, and Swiss Federal Institute of Technology Zurich were invited via e-mail to participate in an online survey. Results: A total of 28,118 students were contacted, and 6,275 students completed the survey. Across all of the institutions, 13.8% of the respondents indicated that they had used prescription drugs (7.6%) or drugs of abuse including alcohol (7.8%) at least once specifically for neuroenhancement. The most frequently used prescription drugs for neuroenhancement were methylphenidate (4.1%), sedatives (2.7%), and beta-blockers (1.2%). Alcohol was used for this purpose by 5.6% of the participants, followed by cannabis (2.5%), amphetamines (0.4%), and cocaine (0.2%). Arguments for neuroenhancement included increased learning (66.2%), relaxation or sleep improvement (51.2%), reduced nervousness (39.1%), coping with performance pressure (34.9%), increased performance (32.2%), and experimentation (20%). Neuroenhancement was significantly more prevalent among more senior students, students who reported higher levels of stress, and students who had previously used illicit drugs. Although "soft enhancers", including coffee, energy drinks, vitamins, and tonics, were used daily in the month prior to an exam, prescription drugs or drugs of abuse were used much less frequently. Conclusions: A significant proportion of Swiss university students across most academic disciplines reported neuroenhancement with prescription drugs and drugs of abuse. However, these substances are rarely used on a daily basis and more sporadically used prior to exams.	[Maier, Larissa J.; Schaub, Michael P.] Univ Zurich, Associated Inst, Swiss Res Inst Publ Hlth & Addict, Zurich, Switzerland; [Maier, Larissa J.; Schaub, Michael P.] WHO Collaborating Ctr, Zurich, Switzerland; [Liechti, Matthias E.] Univ Basel Hosp, Div Clin Pharmacol & Toxicol, Dept Biomed, CH-4031 Basel, Switzerland; [Liechti, Matthias E.] Univ Basel Hosp, Dept Internal Med, CH-4031 Basel, Switzerland; [Liechti, Matthias E.] Univ Basel, Basel, Switzerland; [Herzig, Fiona] Univ Zurich, Div Psychopathol & Clin Intervent, Zurich, Switzerland	University of Zurich; World Health Organization; University of Basel; University of Basel; University of Basel; University of Zurich	Maier, LJ (corresponding author), Univ Zurich, Associated Inst, Swiss Res Inst Publ Hlth & Addict, Zurich, Switzerland.	larissa.maier@isgf.uzh.ch	Maier, Larissa/P-8669-2014; Schaub, Michael P./ABF-9468-2021; Maier, Larissa J/C-2922-2017	Maier, Larissa/0000-0002-4302-0488; Schaub, Michael P./0000-0002-8375-4005; Maier, Larissa J/0000-0002-4302-0488				Arria AM, 2008, PHARMACOTHERAPY, V28, P156, DOI 10.1592/phco.28.2.156; Banjo OC, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014322; Bell S, 2013, NEUROETHICS-NETH, V6, P197, DOI 10.1007/s12152-012-9153-9; BRUGGISSER M, 2012, SCHWEIZ RUNDSCH MED, V101, P299; Bruggisser M, 2011, SWISS MED WKLY, V141, DOI 10.4414/smw.2011.13267; Cakic V, 2009, J MED ETHICS, V35, P611, DOI 10.1136/jme.2009.030882; DeSantis AD, 2008, J AM COLL HEALTH, V56, P315, DOI 10.3200/JACH.57.3.315-324; Dietz P, 2013, PHARMACOTHERAPY, V33, P44, DOI 10.1002/phar.1166; Eckhardt A, 2011, HUMAN ENHANCEMENT, DOI [10.3218/3404-2., DOI 10.3218/3404-2]; Eickenhorst P, 2012, J PSYCHOACTIVE DRUGS, V44, P418, DOI 10.1080/02791072.2012.736845; Elliott R, 1997, PSYCHOPHARMACOLOGY, V131, P196, DOI 10.1007/s002130050284; Forstl H, 2009, NERVENARZT, V80, P840, DOI 10.1007/s00115-009-2801-6; Franke AG, 2011, PHARMACOPSYCHIATRY, V44, P60, DOI 10.1055/s-0030-1268417; Franke AG, 2010, BUNDESGESUNDHEITSBLA, V53, P853, DOI 10.1007/s00103-010-1105-0; Franke AG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040047; Franke AG, 2012, PSYCHIAT PRAX, V39, P174, DOI 10.1055/s-0031-1298900; Gmel G., 2012, SUCHTMONITORING SCHW; Grebner S, 2010, STRESS BEI SCHWEIZER; Greely H, 2008, NATURE, V456, P702, DOI 10.1038/456702a; Hildt E, 2011, NERVENHEILKUNDE, V30, P833; Ilieva I, 2013, NEUROPHARMACOLOGY, V64, P496, DOI 10.1016/j.neuropharm.2012.07.021; Kaloyanides KB, 2007, PHARMACOTHERAPY, V27, P666, DOI 10.1592/phco.27.5.666; Kordt M, 2009, DAK GESUNDHEITSREPOR; Kuhne R., 2011, SCHWEIZERISCHE ARZTE, V92, P1295; Mache S, 2012, WIEN MED WOCHENSCHR, V162, P440, DOI [10.1007/s10354-012-0144-6, 10.1007/s10354-012-0115-y]; Maher B, 2008, NATURE, V452, P674, DOI 10.1038/452674a; McCabe SE, 2005, ADDICTION, V100, P96, DOI 10.1111/j.1360-0443.2005.00944.x; Middendorff E., 2012, HOCHSCHUL INF SYST E, P11; Normann C, 2008, EUR ARCH PSY CLIN N, V258, P110, DOI 10.1007/s00406-008-5022-2; Novak SP, 2007, SUBST ABUSE TREAT PR, V2, DOI 10.1186/1747-597X-2-32; Ott R, 2012, SWISS MED WKLY, V142, DOI 10.4414/smw.2012.13707; Partridge B, 2013, DRUG ALCOHOL REV, V32, P295, DOI 10.1111/dar.12005; Quednow B.B, 2010, SUCHTMAGAZIN, V36, P19; Quednow BB, 2010, BIOSOCIETIES, V5, P153, DOI 10.1057/biosoc.2009.13; Repantis D, 2011, PSYCHOPHARMAKOLOGISC; Repantis D, 2009, VERBESSERUNG MENSCHE, P63; Repantis D, 2010, PHARMACOL RES, V62, P187, DOI 10.1016/j.phrs.2010.04.002; Sahakian B, 2007, NATURE, V450, P1157, DOI 10.1038/4501157a; Sucht Schweiz, 2012, DOP ALLT; Sussman S, 2006, SUBST ABUSE TREAT PR, V1, DOI 10.1186/1747-597X-1-15; Turner DC, 2003, PSYCHOPHARMACOLOGY, V165, P260, DOI 10.1007/s00213-002-1250-8; Wilens TE, 2008, J AM ACAD CHILD PSY, V47, P21, DOI 10.1097/chi.0b013e31815a56f1; Wulf MA, 2012, ETHIK MED, V24, P29, DOI 10.1007/s00481-011-0137-9	43	116	120	0	56	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 13	2013	8	11							e77967	10.1371/journal.pone.0077967	http://dx.doi.org/10.1371/journal.pone.0077967			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	255QK	24236008	Green Published, Green Accepted, gold, Green Submitted			2023-01-03	WOS:000327254700005
J	Sokol, DK				Sokol, Daniel K.			ETHICS MAN "First do no harm" revisited	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material									Kings Coll London, London WC2R 2LS, England	University of London; King's College London	Sokol, DK (corresponding author), Kings Coll London, London WC2R 2LS, England.	daniel.sokol@talk21.com						[Anonymous], 1860, FDN NEW THEORY PRACT; Daniel Michelle, 2012, J Clin Ethics, V23, P331; Gillon R, 1985, PHILOS MED ETHICS; Holmes Oliver Wendell, 1865, CURRENTS COUNTER CUR	4	37	38	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 25	2013	347								f6426	10.1136/bmj.f6426	http://dx.doi.org/10.1136/bmj.f6426			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	243CM	24163087				2023-01-03	WOS:000326294200010
J	Mitchell, JM				Mitchell, Jean M.			Urologists' Use of Intensity-Modulated Radiation Therapy for Prostate Cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							QUALITY-OF-LIFE; SPECIALTY HOSPITALS; SURGERY; IMPACT	BackgroundSome urology groups have integrated intensity-modulated radiation therapy (IMRT), a radiation treatment with a high reimbursement rate, into their practice. This is permitted by the exception for in-office ancillary services in the federal prohibition against self-referral. I examined the association between ownership of IMRT services and use of IMRT to treat prostate cancer. MethodsUsing Medicare claims from 2005 through 2010, I constructed two samples: one comprising 35 self-referring urology groups in private practice and a matched control group comprising 35 non-self-referring urology groups in private practice, and the other comprising non-self-referring urologists employed at 11 National Comprehensive Cancer Network centers matched with 11 self-referring urology groups in private practice. I compared the use of IMRT in the periods before and during ownership and used a difference-in-differences analysis to evaluate changes in IMRT use according to self-referral status. ResultsThe rate of IMRT use by self-referring urologists in private practice increased from 13.1 to 32.3%, an increase of 19.2 percentage points (P<0.001). Among non-self-referring urologists, the rate of IMRT use increased from 14.3 to 15.6%, an increase of 1.3 percentage points (P=0.05). The unadjusted difference-in-differences effect was 17.9 percentage points (P<0.001). The regression-adjusted increase in IMRT use associated with self-referral was 16.4 percentage points (P<0.001). The rate of IMRT use by urologists working at National Comprehensive Cancer Network centers remained stable at 8.0% but increased by 33.0 percentage points among the 11 matched self-referring urology groups. The regression-adjusted difference-in-differences effect was 29.3 percentage points (P<0.001). ConclusionsUrologists who acquired ownership of IMRT services increased their use of IMRT substantially more than urologists who did not own such services. Allowing urologists to self-refer for IMRT may contribute to increased use of this expensive therapy. (Funded by the American Society for Radiation Oncology.)	Georgetown Univ, Washington, DC 20057 USA	Georgetown University	Mitchell, JM (corresponding author), Georgetown Univ, Old North 314,37th & O Sts NW, Washington, DC 20057 USA.	mitchejm@georgetown.edu			American Society for Radiation Oncology; Georgetown University	American Society for Radiation Oncology; Georgetown University	Supported by an unrestricted educational research contract between the American Society for Radiation Oncology and Georgetown University.	Addressing the growth of ancillary services in physicians' offices, 2010, REP C AG INC MED PRO, P213; American Cancer Society, PROST CANC OV; [Anonymous], 2008, COMP EFF THER CLIN L; Baker LC, 2010, HEALTH AFFAIR, V29, P2252, DOI 10.1377/hlthaff.2009.1099; Bishop TF, 2010, J GEN INTERN MED, V25, P1057, DOI 10.1007/s11606-010-1409-7; Carreyrou J, 2010, WALL STREET J, pA1; DRANOVE D, 1988, ECON INQ, V26, P281, DOI 10.1111/j.1465-7295.1988.tb01494.x; Elixhauser A, 1998, MED CARE, V36, P8, DOI 10.1097/00005650-199801000-00004; Gazelle GS, 2007, RADIOLOGY, V245, P517, DOI 10.1148/radiol.2452070193; HILLMAN BJ, 1992, JAMA-J AM MED ASSOC, V268, P2050, DOI 10.1001/jama.268.15.2050; Hillman BJ, 2010, HEALTH AFFAIR, V29, P2231, DOI 10.1377/hlthaff.2010.1019; Hughes DR, 2010, HEALTH AFFAIR, V29, P2244, DOI 10.1377/hlthaff.2010.0413; Jacobs BL, 2012, HLTH AFF MILLWOOD, V1, P750; Kerr RR, 2011, UROLOGY TIMES   1201, P1; Litwin MS, 2007, CANCER, V109, P2239, DOI 10.1002/cncr.22676; Management options for low-risk prostate cancer, 2010, MAN OPT LOW RISK PRO; Medicare Payment Advisory Commission, 2009, REP C IMPR INC MED P, P81; Mitchell JM, 2008, MED CARE, V46, P732, DOI 10.1097/MLR.0b013e31817892a7; Mitchell JM, 2007, MED CARE RES REV, V64, P395, DOI 10.1177/1077558707301953; Mitchell JM, 2007, HEALTH AFFAIR, V26, pW415, DOI 10.1377/hlthaff.26.3.w415; Mitchell JM, 2012, HEALTH AFFAIR, V31, P741, DOI 10.1377/hlthaff.2011.1372; Nallamothu BK, 2007, JAMA-J AM MED ASSOC, V297, P962, DOI 10.1001/jama.297.9.962; Newhouse JP, 2013, NEW ENGL J MED, V368, P1465, DOI 10.1056/NEJMp1302981; Nguyen PL, 2011, J CLIN ONCOL, V29, P1517, DOI 10.1200/JCO.2010.31.1217; Pauly MV, 1980, DOCTORS THEIR WORKSH, P1; Sanda MG, 2008, NEW ENGL J MED, V358, P1250, DOI 10.1056/NEJMoa074311; Shahinian VB, 2010, NEW ENGL J MED, V363, P1822, DOI 10.1056/NEJMsa0910784; Shreibati JB, 2011, HEALTH SERV RES, V46, P1362, DOI 10.1111/j.1475-6773.2011.01265.x; Sunshine J, 2010, HEALTH AFFAIR, V29, P2237, DOI 10.1377/hlthaff.2009.1081; Thompson I, 2007, J UROLOGY, V177, P2106, DOI 10.1016/j.juro.2007.03.003; Zuckerman S, 2010, NEW ENGL J MED, V363, P54, DOI 10.1056/NEJMsa0909253	31	107	108	0	9	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 24	2013	369	17					1629	1637		10.1056/NEJMsa1201141	http://dx.doi.org/10.1056/NEJMsa1201141			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	239MZ	24152262				2023-01-03	WOS:000326031100012
J	MacPherson, H; Maschino, AC; Lewith, G; Foster, NE; Witt, C; Vickers, AJ				MacPherson, Hugh; Maschino, Alexandra C.; Lewith, George; Foster, Nadine E.; Witt, Claudia; Vickers, Andrew J.		Acupuncture Trialists'	Characteristics of Acupuncture Treatment Associated with Outcome: An Individual Patient Meta-Analysis of 17,922 Patients with Chronic Pain in Randomised Controlled Trials	PLOS ONE			English	Article							LOW-BACK-PAIN; TREATING PATIENTS; OSTEOARTHRITIS; CARE; KNEE	Background: Recent evidence shows that acupuncture is effective for chronic pain. However we do not know whether there are characteristics of acupuncture or acupuncturists that are associated with better or worse outcomes. Methods: An existing dataset, developed by the Acupuncture Trialists' Collaboration, included 29 trials of acupuncture for chronic pain with individual data involving 17,922 patients. The available data on characteristics of acupuncture included style of acupuncture, point prescription, location of needles, use of electrical stimulation and moxibustion, number, frequency and duration of sessions, number of needles used and acupuncturist experience. We used random-effects meta-regression to test the effect of each characteristic on the main effect estimate of pain. Where sufficient patient-level data were available, we conducted patient-level analyses. Results: When comparing acupuncture to sham controls, there was little evidence that the effects of acupuncture on pain were modified by any of the acupuncture characteristics evaluated, including style of acupuncture, the number or placement of needles, the number, frequency or duration of sessions, patient-practitioner interactions and the experience of the acupuncturist. When comparing acupuncture to non-acupuncture controls, there was little evidence that these characteristics modified the effect of acupuncture, except better pain outcomes were observed when more needles were used (p=0.010) and, from patient level analysis involving a sub-set of five trials, when a higher number of acupuncture treatment sessions were provided (p<0.001). Conclusion: There was little evidence that different characteristics of acupuncture or acupuncturists modified the effect of treatment on pain outcomes. Increased number of needles and more sessions appear to be associated with better outcomes when comparing acupuncture to non-acupuncture controls, suggesting that dose is important. Potential confounders include differences in control group and sample size between trials. Trials to evaluate potentially small differences in outcome associated with different acupuncture characteristics are likely to require large sample sizes.	[MacPherson, Hugh] Univ York, Dept Hlth Sci, York YO10 5DD, N Yorkshire, England; [Maschino, Alexandra C.; Vickers, Andrew J.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA; [Lewith, George] Univ Southampton, Southampton, Hants, England; [Foster, Nadine E.] Keele Univ, Inst Primary Care & Hlth Sci, Arthrit Res UK Primary Care Ctr, Keele ST5 5BG, Staffs, England; [Witt, Claudia] Charite, Inst Social Med Epidemiol & Hlth Econ, D-13353 Berlin, Germany	University of York - UK; Memorial Sloan Kettering Cancer Center; University of Southampton; Keele University; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	MacPherson, H (corresponding author), Univ York, Dept Hlth Sci, York YO10 5DD, N Yorkshire, England.	hugh.macpherson@york.ac.uk	Witt, Claudia M./AAX-2370-2021; Lao, Lixing/P-9107-2019; Brinkhaus, Benno/AAU-2428-2021	Witt, Claudia M./0000-0002-5440-7805; Lao, Lixing/0000-0003-0198-9714; Brinkhaus, Benno/0000-0001-6290-744X; Linde, Klaus/0000-0002-2902-970X; Foster, Nadine/0000-0003-4429-9756; Lewith, George/0000-0002-2364-3960; MacPherson, Hugh/0000-0003-4255-4768; Vickers, Andrew/0000-0003-1525-6503	National Center for Complementary and Alternative Medicine (NCCAM) at the National Institutes of Health (NIH); United Kingdom National Institute for Health Research (NIHR) [RP-PG-0707-10186]; Carstens Foundation; National Institute of Health Research; National Institute for Health Research [RP-PG-0707-10186] Funding Source: researchfish; NATIONAL CANCER INSTITUTE [P30CA008748] Funding Source: NIH RePORTER; National Center for Complementary & Integrative Health [R01AT006794] Funding Source: NIH RePORTER	National Center for Complementary and Alternative Medicine (NCCAM) at the National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); United Kingdom National Institute for Health Research (NIHR)(National Institute for Health Research (NIHR)); Carstens Foundation; National Institute of Health Research(National Institute for Health Research (NIHR)); National Institute for Health Research(National Institute for Health Research (NIHR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Center for Complementary & Integrative Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	The Acupuncture Trialists' Collaboration is funded by an R21 (AT004189I from the National Center for Complementary and Alternative Medicine (NCCAM) at the National Institutes of Health (NIH) to AV) and by a grant from the Samueli Institute. HM's work has been supported in part by the United Kingdom National Institute for Health Research (NIHR) under its Programme Grants for Applied Research scheme (RP-PG-0707-10186). CW's work has been supported by the Carstens Foundation within the grant for the Chair for Complementary Medicine Research. NF is supported by a Research Professorship from the National Institute of Health Research. The views expressed in this publication are those of the author(s) and not necessarily those of the NCCAM, NHS, NIHR or the Department of Health in England. No sponsor had any role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Birch S., 2007, J CHIN MED, V83, P12; Brinkhaus B, 2006, ARCH INTERN MED, V166, P450; Brookes ST, 2004, J CLIN EPIDEMIOL, V57, P229, DOI 10.1016/j.jclinepi.2003.08.009; Foster NE, 2007, BMJ-BRIT MED J, V335, P436, DOI 10.1136/bmj.39280.509803.BE; Hanfileti L, 2013, MED ACUPUNCTURE TRAD; Hopton AK, 2012, BMJ OPEN, V2, DOI 10.1136/bmjopen-2011-000456; Hughes JG, 2007, COMPLEMENT THER MED, V15, P101, DOI 10.1016/j.ctim.2006.09.008; Lewis M, 2010, EUR J PAIN, V14, P1033, DOI 10.1016/j.ejpain.2010.04.002; Moffett JAK, 2004, SPINE, V29, P1167, DOI 10.1097/00007632-200406010-00002; National Institute for Health and Clinical Excellence, 2009, LOW BACK PAIN EARL M; Paterson C, 2004, J ALTERN COMPLEM MED, V10, P791; Price S, 2006, PATIENT EDUC COUNS, V63, P239, DOI 10.1016/j.pec.2005.11.006; Scheid V., 2012, INTEGRATING E ASIAN, P13; Stewart LA, 2002, EVAL HEALTH PROF, V25, P76, DOI 10.1177/0163278702025001006; Underwood MR, 2007, RHEUMATOLOGY, V46, P1297, DOI 10.1093/rheumatology/kem113; Vickers AJ, 2012, ARCH INTERN MED, V172, P1444, DOI 10.1001/archinternmed.2012.3654; Wampold BE, 2005, J CONSULT CLIN PSYCH, V73, P914, DOI 10.1037/0022-006X.73.5.914; Witt C, 2005, LANCET, V366, P136, DOI 10.1016/S0140-6736(05)66871-7; Witt CM, 2010, J PAIN, V11, P431, DOI 10.1016/j.jpain.2009.08.010	19	79	86	0	49	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 11	2013	8	10							e77438	10.1371/journal.pone.0077438	http://dx.doi.org/10.1371/journal.pone.0077438			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	236SL	24146995	gold, Green Accepted, Green Published, Green Submitted			2023-01-03	WOS:000325819400118
J	Wadhwa, R; Singh, R; Gao, R; Shah, N; Widodo, N; Nakamoto, T; Ishida, Y; Terao, K; Kaul, SC				Wadhwa, Renu; Singh, Rumani; Gao, Ran; Shah, Navjot; Widodo, Nashi; Nakamoto, Tomoko; Ishida, Yoshiyuki; Terao, Keiji; Kaul, Sunil C.			Water Extract of Ashwagandha Leaves Has Anticancer Activity: Identification of an Active Component and Its Mechanism of Action	PLOS ONE			English	Article							SOMNIFERA ROOT EXTRACT; NF-KAPPA-B; WITHANIA-SOMNIFERA; CANCER-CELLS; WITHANOLIDE-A; LEAF EXTRACT; BALB/C MICE; WITHAFERIN; APOPTOSIS; DISEASE	Background: Cancer is a leading cause of death accounting for 15-20% of global mortality. Although advancements in diagnostic and therapeutic technologies have improved cancer survival statistics, 75% of the world population live in underdeveloped regions and have poor access to the advanced medical remedies. Natural therapies hence become an alternative choice of treatment. Ashwagandha, a tropical herb used in Indian Ayurvedic medicine, has a long history of its health promoting and therapeutic effects. In the present study, we have investigated an anticancer activity in the water extract of Ashwagandha leaves (ASH-WEX). Methodology/Principal Findings: Anticancer activity in the water extract of Ashwagandha leaves (ASH-WEX) was detected by in vitro and in vivo assays. Bioactivity-based size fractionation and NMR analysis were performed to identify the active anticancer component(s). Mechanism of anticancer activity in the extract and its purified component was investigated by biochemical assays. We report that the ASH-WEX is cytotoxic to cancer cells selectively, and causes tumor suppression in vivo. Its active anticancer component was identified as triethylene glycol (TEG). Molecular analysis revealed activation of tumor suppressor proteins p53 and pRB by ASH-WEX and TEG in cancer cells. In contrast to the hypophosphorylation of pRB, decrease in cyclin B1 and increase in cyclin D1 in ASH-WEX and TEG-treated cancer cells (undergoing growth arrest), normal cells showed increase in pRB phosphorylation and cyclin B1, and decrease in cyclin D1 (signifying their cell cycle progression). We also found that the MMP-3 and MMP-9 that regulate metastasis were down regulated in ASH-WEX and TEG-treated cancer cells; normal cells remained unaffected. Conclusion: We provide the first molecular evidence that the ASH-WEX and TEG have selective cancer cell growth arrest activity and hence may offer natural and economic resources for anticancer medicine.	[Wadhwa, Renu; Singh, Rumani; Gao, Ran; Shah, Navjot; Widodo, Nashi; Nakamoto, Tomoko; Kaul, Sunil C.] Natl Inst Adv Ind Sci & Technol, Tsukuba, Ibaraki, Japan; [Ishida, Yoshiyuki; Terao, Keiji] Brawijaya Univ, Fac Math & Nat Sci, Dept Biol, Malang, Indonesia; [Widodo, Nashi] CycloChem Co Ltd, Chuo Ku, Kobe, Hyogo, Japan	National Institute of Advanced Industrial Science & Technology (AIST); Brawijaya University	Kaul, SC (corresponding author), Natl Inst Adv Ind Sci & Technol, Tsukuba, Ibaraki, Japan.	s-kaul@aist.go.jp	Wadhwa, Renu/L-8898-2018; Kaul, Sunil C/L-8671-2018; widodo, nashi/X-4595-2019	Wadhwa, Renu/0000-0001-8248-5192; Kaul, Sunil C/0000-0002-0046-3916; widodo, nashi/0000-0002-1126-498X; Gao, Ran/0000-0001-8712-429X	Ministry of Education, Culture, Sports, Science & Technology (MEXT) Scholarship, Japan; Innovation School Post-doctoral Fellowship, National Institute of Advanced Industrial Science & Technology (AIST), Japan	Ministry of Education, Culture, Sports, Science & Technology (MEXT) Scholarship, Japan; Innovation School Post-doctoral Fellowship, National Institute of Advanced Industrial Science & Technology (AIST), Japan	Rumani Singh was supported by the Ministry of Education, Culture, Sports, Science & Technology (MEXT) Scholarship, Japan. Ran Gao was supported by Innovation School Post-doctoral Fellowship, National Institute of Advanced Industrial Science & Technology (AIST), Japan. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aalinkeel R, 2010, EVID-BASED COMPL ALT, V7, P177, DOI 10.1093/ecam/nem184; Ahmad M, 2005, HUM EXP TOXICOL, V24, P137, DOI 10.1191/0906327105ht209oa; Ali NAA, 2001, J ETHNOPHARMACOL, V74, P173, DOI 10.1016/S0378-8741(00)00364-0; Bolleddula J, 2012, RAPID COMMUN MASS SP, V26, P1277, DOI 10.1002/rcm.6221; Davis L, 2001, J ETHNOPHARMACOL, V75, P165, DOI 10.1016/S0378-8741(00)00404-9; Grin B, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039065; Gupta SK, 2004, MOL CELL BIOCHEM, V260, P39; Hahm ER, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023354; Ichikawa H, 2006, MOL CANCER THER, V5, P1434, DOI 10.1158/1535-7163.MCT-06-0096; Jayaprakasam B, 2010, PHYTOTHER RES, V24, P859, DOI 10.1002/ptr.3033; Kaileh M, 2007, J BIOL CHEM, V282, P4253, DOI 10.1074/jbc.M606728200; Kataria H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037080; Khan S, 2009, VACCINE, V27, P6080, DOI 10.1016/j.vaccine.2009.07.011; Konar A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027265; Kuboyama T, 2005, BRIT J PHARMACOL, V144, P961, DOI 10.1038/sj.bjp.0706122; Kulkarni SK, 2008, INDIAN J EXP BIOL, V46, P633; Kumar P, 2009, J MED FOOD, V12, P591, DOI 10.1089/jmf.2008.0028; Kushwaha S, 2012, VACCINE, V30, P1083, DOI 10.1016/j.vaccine.2011.12.031; Lee W, 2012, TOXICOL APPL PHARM, V262, P91, DOI 10.1016/j.taap.2012.04.025; Liu JH, 2008, BIOMED PHARMACOTHER, V62, P480, DOI 10.1016/j.biopha.2007.11.003; LLanos GG, 2012, EUR J MED CHEM, V54, P499, DOI 10.1016/j.ejmech.2012.05.032; Malik F, 2007, LIFE SCI, V80, P1525, DOI 10.1016/j.lfs.2007.01.029; Malik F, 2009, EUR J CANCER, V45, P1494, DOI 10.1016/j.ejca.2009.01.034; Matsuda H, 2001, BIOORGAN MED CHEM, V9, P1499, DOI 10.1016/S0968-0896(01)00024-4; Maurya R, 2010, J PHARM PHARMACOL, V62, P153, DOI 10.1211/jpp.62.02.0001; Mirjalili MH, 2009, MOLECULES, V14, P2373, DOI 10.3390/molecules14072373; Mohan Royce, 2004, Angiogenesis, V7, P115, DOI 10.1007/s10456-004-1026-3; Mondal S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034277; Murthy M. R. Ven, 2010, Central Nervous System Agents in Medicinal Chemistry, V10, P238; NITSCHKE L, 1994, FRESEN J ANAL CHEM, V349, P451, DOI 10.1007/BF00322932; Owais M, 2005, PHYTOMEDICINE, V12, P229, DOI 10.1016/j.phymed.2003.07.012; OWEN LN, 1962, BRIT J CANCER, V16, P441, DOI 10.1038/bjc.1962.49; Padmavathi B, 2005, EVID-BASED COMPL ALT, V2, P99, DOI 10.1093/ecam/neh064; Park HJ, 2008, BIOFACTORS, V33, P137, DOI 10.1002/biof.5520330206; Pawar P, 2011, BMC COMPLEM ALTERN M, V11, DOI 10.1186/1472-6882-11-34; RajaSankara S, 2009, NEUROSCI LETT, V454, P11, DOI 10.1016/j.neulet.2009.02.044; Rasool M, 2006, CHEM-BIOL INTERACT, V164, P174, DOI 10.1016/j.cbi.2006.09.011; Rudnick SN, 2009, AM J INFECT CONTROL, V37, P813, DOI 10.1016/j.ajic.2009.06.007; Sehgal N, 2012, P NATL ACAD SCI USA, V109, P3510, DOI 10.1073/pnas.1112209109; Shah N, 2009, CANCER SCI, V100, P1740, DOI 10.1111/j.1349-7006.2009.01236.x; Singh D, 2007, PHYTOTHER RES, V21, P905, DOI 10.1002/ptr.2180; Singh G, 2011, INDIAN J PHARM SCI, V73, P473, DOI 10.4103/0250-474X.95656; Tohda C, 2005, NEUROSIGNALS, V14, P34, DOI 10.1159/000085384; Widodo N, 2008, CANCER LETT, V262, P37, DOI 10.1016/j.canlet.2007.11.037; Widodo N, 2007, CLIN CANCER RES, V13, P2298, DOI 10.1158/1078-0432.CCR-06-0948; Widodo N, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013536; Winters M, 2006, ALTERN MED REV, V11, P269; Xu YM, 2011, PHYTOCHEMISTRY, V72, P518, DOI 10.1016/j.phytochem.2010.12.020; Yang ES, 2011, CHEM-BIOL INTERACT, V190, P9, DOI 10.1016/j.cbi.2011.01.015; Zhang X, 2012, GYNECOL ONCOL, V124, P606, DOI 10.1016/j.ygyno.2011.11.044; Zhang X, 2011, BMC COMPLEM ALTERN M, V11, DOI 10.1186/1472-6882-11-84	51	42	42	0	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 10	2013	8	10							e77189	10.1371/journal.pone.0077189	http://dx.doi.org/10.1371/journal.pone.0077189			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	236QM	24130852	Green Published, Green Submitted, gold			2023-01-03	WOS:000325814200067
J	Frick, U; Frick, H; Langguth, B; Landgrebe, M; Hubner-Liebermann, B; Hajak, G				Frick, Ulrich; Frick, Hannah; Langguth, Berthold; Landgrebe, Michael; Huebner-Liebermann, Bettina; Hajak, Goeran			The Revolving Door Phenomenon Revisited: Time to Readmission in 17'415 Patients with 37'697 Hospitalisations at a German Psychiatric Hospital	PLOS ONE			English	Article							SURVIVAL-ANALYSIS; RECURRENT EVENTS; FRAILTY MODELS; UNITED-STATES; EARLY-ONSET; FOLLOW-UP; SCHIZOPHRENIA; DISORDER; STAY; RISK	Objective: Despite the recurring nature of the disease process in many psychiatric patients, individual careers and time to readmission rarely have been analysed by statistical models that incorporate sequence and velocity of recurrent hospitalisations. This study aims at comparing four statistical models specifically designed for recurrent event history analysis and evaluating the potential impact of predictor variables from different sources (patient, treatment process, social environment). Method: The so called Andersen-Gil counting process model, two variants of the conditional models of Prentice, Williams, and Peterson (gap time model, conditional probability model), and the so called frailty model were applied to a dataset of 17'415 patients observed during a 12 years period starting from 1996 and leading to 37'697 psychiatric hospitalisations. Potential prognostic factors stem from a standardized patient documentation form. Results: Estimated regression coefficients over different models were highly similar, but the frailty model best represented the sequentiality of individual treatment careers and differing velocities of disease progression. It also avoided otherwise likely misinterpretations of the impact of gender, partnership, historical time and length of stay. A widespread notion of psychiatric diseases as inevitably chronic and worsening could be rejected. Time in community was found to increase over historical time for all patients. Most important protective factors beyond diagnosis were employment, partnership, and sheltered living situation. Risky conditions were urban living and a concurrent substance use disorder. Conclusion: Prognostic factors for course of diseases should be determined only by statistical models capable of adequately incorporating the recurrent nature of psychiatric illnesses.	[Frick, Ulrich; Langguth, Berthold; Landgrebe, Michael; Huebner-Liebermann, Bettina; Hajak, Goeran] Univ Regensburg, Dept Psychiat & Psychotherapy, D-93053 Regensburg, Germany; [Frick, Ulrich] Dopfer Univ Appl Sci, Dept Psychol, Cologne, Germany; [Frick, Ulrich] Univ Zurich, Res Inst Publ Hlth & Addict, Zurich, Switzerland; [Frick, Hannah] Univ Innsbruck, Dept Stat, A-6020 Innsbruck, Austria; [Landgrebe, Michael; Hajak, Goeran] Sozialstiftung Bamberg, Dept Psychiat Psychosomat & Psychotherapy, Bamberg, Germany	University of Regensburg; University of Zurich; University of Innsbruck	Langguth, B (corresponding author), Univ Regensburg, Dept Psychiat & Psychotherapy, D-93053 Regensburg, Germany.	Berthold.Langguth@medbo.de	Langguth, Berthold/AAP-2638-2021		UIniversity of Regensburg	UIniversity of Regensburg	The study was funded by the UIniversity of Regensburg, The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ANDERSEN PK, 1982, ANN STAT, V10, P1100, DOI 10.1214/aos/1176345976; [Anonymous], 2010, R LANG ENV STAT COMP; Appleby L, 1996, PSYCHIATR SERV, V47, P985; APPLEBY L, 1993, AM J PSYCHIAT, V150, P72; Baethge C, 2004, BIPOLAR DISORD, V6, P115, DOI 10.1111/j.1399-5618.2004.00104.x; Clemmensen L, 2012, BMC PSYCHIATRY, V12, DOI 10.1186/1471-244X-12-150; Cording C, 1995, SPEKTRUM PSYCHIAT PS, V24, P3; Coryell W, 2012, J AFFECTIVE DISORDER; Doering S, 1998, SCHIZOPHRENIA BULL, V24, P87, DOI 10.1093/oxfordjournals.schbul.a033316; Frank D, 2005, PSYCHIAT SERV, V56, P867, DOI 10.1176/appi.ps.56.7.867; Frick U, 2010, DREHTURE STATIONAREN; Frick U, 2008, BASISDATEN STATIONAR; Frick U, 1999, QUALITAT PSYCHIAT RE, P11; Frick U, 2010, ERGEBNISSE MED STAT; Glidden DV, 2004, STAT MED, V23, P369, DOI 10.1002/sim.1599; Hardeveld F, 2013, PSYCHOL MED, V43, P39, DOI 10.1017/S0033291712002395; Heggestad T, 2011, SOC PSYCH PSYCH EPID, V46, P1275, DOI 10.1007/s00127-010-0295-y; HERZ MI, 1979, ARCH GEN PSYCHIAT, V36, P701; Johnstone P, 1999, BRIT MED J, V318, P1387, DOI 10.1136/bmj.318.7195.1387; Kessing Lars Vedel, 2005, Curr Psychiatry Rep, V7, P413, DOI 10.1007/s11920-005-0061-0; Kessing LV, 1999, AM J EPIDEMIOL, V149, P404; Kessler RC, 2001, BIOL PSYCHIAT, V49, P1002, DOI 10.1016/S0006-3223(01)01129-5; Kim HM, 2011, PSYCHIAT SERV, V62, P1346, DOI 10.1176/ps.62.11.pss6211_1346; Krabbendam L, 2005, SCHIZOPHRENIA BULL, V31, P795, DOI 10.1093/schbul/sbi060; Kuehner C, 2012, EUR ARCH PSYCHIAT CL; Lederbogen F, 2011, NATURE, V474, P498, DOI 10.1038/nature10190; Lees J, 1999, THERAPEUTIC COMMUNIT; LEWIS T, 1990, ACTA PSYCHIAT SCAND, V82, P130, DOI 10.1111/j.1600-0447.1990.tb01369.x; Lim HJ, 2007, ACCIDENT ANAL PREV, V39, P290, DOI 10.1016/j.aap.2006.07.009; LIN DY, 1989, J AM STAT ASSOC, V84, P1074, DOI 10.2307/2290085; MARTIN BA, 1976, CAN MED ASSOC J, V115, P322; Menezes NM, 2006, PSYCHOL MED, V36, P1349, DOI 10.1017/S0033291706007951; Meyer-Lindenberg A, 2012, NAT NEUROSCI, V15, P663, DOI 10.1038/nn.3083; MODESTIN J, 1988, NERVENARZT, V59, P344; Mojtabai R, 2005, AM J PSYCHIAT, V162, P1291, DOI 10.1176/appi.ajp.162.7.1291; Mojtabai R, 1997, PSYCHIAT QUART, V68, P117, DOI 10.1023/A:1025401621060; MORTENSEN PB, 1994, PSYCHOL MED, V24, P223, DOI 10.1017/S0033291700026982; Newgard CD, 2007, ACAD EMERG MED, V14, P669, DOI 10.1197/j.aem.2006.11.038; Olesen AV, 2006, STAT MED, V25, P1672, DOI 10.1002/sim.2298; Olesen AV, 2002, PSYCHOL MED, V32, P1301, DOI 10.1017/S0033291702005548; Perlis RH, 2004, BIOL PSYCHIAT, V55, P875, DOI 10.1016/j.biopsych.2004.01.022; PRENTICE RL, 1981, BIOMETRIKA, V68, P373, DOI 10.1093/biomet/68.2.373; Prince JD, 2008, PSYCHIAT SERV, V59, P1038, DOI 10.1176/appi.ps.59.9.1038; Saarento O, 1997, ACTA PSYCHIAT SCAND, V95, P132, DOI 10.1111/j.1600-0447.1997.tb00386.x; Schennach R, 2012, CURR PSYCHIAT REP, V14, P229, DOI 10.1007/s11920-012-0261-3; Schmutte T, 2010, J NERV MENT DIS, V198, P860, DOI 10.1097/NMD.0b013e3181fe726b; Silva NC, 2009, PSYCHIAT SERV, V60, P786, DOI 10.1176/ps.2009.60.6.786; Stahler GJ, 2009, AM J PSYCHIAT, V166, P1258, DOI 10.1176/appi.ajp.2009.08111667; Terry Therneau and original Splus-&GT;R port by Thomas Lumley, 2010, SURVIVAL SURVIVAL AN; Therneau TM, 2003, J COMPUT GRAPH STAT, V12, P156, DOI 10.1198/1061860031365; Tulloch AD, 2011, ADM POLICY MENT HLTH, V38, P155, DOI 10.1007/s10488-010-0310-3; Viinamaki H, 1996, ACTA PSYCHIAT SCAND, V94, P365, DOI 10.1111/j.1600-0447.1996.tb09874.x; Viinamaki H, 1998, ACTA PSYCHIAT SCAND, V97, P47, DOI 10.1111/j.1600-0447.1998.tb09962.x; Wienke A, 2003, BIOMETRICS, V59, P1178, DOI 10.1111/j.0006-341X.2003.00135.x; Wieselgren IM, 1996, ACTA PSYCHIAT SCAND, V93, P9, DOI 10.1111/j.1600-0447.1996.tb10613.x; WOOGH CM, 1986, CAN J PSYCHIAT, V31, P214, DOI 10.1177/070674378603100306; WOOGH CM, 1977, CAN MED ASSOC J, V116, P876	57	32	33	0	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 8	2013	8	10							e75612	10.1371/journal.pone.0075612	http://dx.doi.org/10.1371/journal.pone.0075612			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	233FK	24116059	Green Submitted, Green Accepted, gold, Green Published			2023-01-03	WOS:000325552200029
J	Boettcher, J; Leek, L; Matson, L; Holmes, EA; Browning, M; MacLeod, C; Andersson, G; Carlbring, P				Boettcher, Johanna; Leek, Linda; Matson, Lisa; Holmes, Emily A.; Browning, Michael; MacLeod, Colin; Andersson, Gerhard; Carlbring, Per			Internet-Based Attention Bias Modification for Social Anxiety: A Randomised Controlled Comparison of Training towards Negative and Training Towards Positive Cues	PLOS ONE			English	Article							SELECTIVE ATTENTION; SELF-REPORT; PSYCHOMETRIC PROPERTIES; MODIFICATION PROGRAM; FACIAL EXPRESSIONS; AVOIDANCE PATTERN; PHOBIA; THREAT; VULNERABILITY; VALIDATION	Biases in attention processes are thought to play a crucial role in the aetiology and maintenance of Social Anxiety Disorder (SAD). The goal of the present study was to examine the efficacy of a programme intended to train attention towards positive cues and a programme intended to train attention towards negative cues. In a randomised, controlled, double-blind design, the impact of these two training conditions on both selective attention and social anxiety were compared to that of a control training condition. A modified dot probe task was used, and delivered via the internet. A total of 129 individuals, diagnosed with SAD, were randomly assigned to one of these three conditions and took part in a 14-day programme with daily training/control sessions. Participants in all three groups did not on average display an attentional bias prior to the training. Critically, results on change in attention bias implied that significantly differential change in selective attention to threat was not detected in the three conditions. However, symptoms of social anxiety reduced significantly from pre- to follow-up-assessment in all three conditions (d(within) = 0.63-1.24), with the procedure intended to train attention towards threat cues producing, relative to the control condition, a significantly greater reduction of social fears. There were no significant differences in social anxiety outcome between the training condition intended to induce attentional bias towards positive cues and the control condition. To our knowledge, this is the first RCT where a condition intended to induce attention bias to negative cues yielded greater emotional benefits than a control condition. Intriguingly, changes in symptoms are unlikely to be by the mechanism of change in attention processes since there was no change detected in bias per se. Implications of this finding for future research on attention bias modification in social anxiety are discussed. Trial Registration: ClinicalTrials.gov NCT01463137	[Boettcher, Johanna; Carlbring, Per] Stockholm Univ, Dept Psychol, S-10691 Stockholm, Sweden; [Boettcher, Johanna] Free Univ Berlin, Berlin, Germany; [Leek, Linda; Matson, Lisa] Umea Univ, Dept Psychol, S-90187 Umea, Sweden; [Holmes, Emily A.] MRC Cognit & Brain Sci Unit, Cambridge, England; [Browning, Michael] Univ Oxford, Funct MRI Brain Ctr, Oxford, England; [MacLeod, Colin] Univ Western Australia, Sch Psychol, Perth, WA 6009, Australia; [Andersson, Gerhard] Linkoping Univ, Dept Behav Sci & Learning, Linkoping, Sweden; [Andersson, Gerhard] Karolinska Inst, Dept Clin Neurosci, Psychiat Sect, Stockholm, Sweden	Stockholm University; Free University of Berlin; Umea University; University of Oxford; University of Western Australia; Linkoping University; Karolinska Institutet	Boettcher, J (corresponding author), Stockholm Univ, Dept Psychol, S-10691 Stockholm, Sweden.	johanna.boettcher@fu-berlin.de	browning, michael/M-7338-2017; Andersson, Gerhard/J-8529-2012; Carlbring, Per/D-3628-2009; Holmes, Emily/ABD-4367-2020; Carlbring, Per/R-1220-2019	browning, michael/0000-0001-9108-3144; Andersson, Gerhard/0000-0003-4753-6745; Carlbring, Per/0000-0002-2172-8813; Holmes, Emily/0000-0001-7319-3112; Carlbring, Per/0000-0002-2172-8813; Boettcher, Johanna/0000-0002-8220-9291; MacLeod, Colin/0000-0003-2407-7339	Swedish Council for Working Life and Social Research [FAS 2009-0222]; MRC [MC_UP_0901/1] Funding Source: UKRI; Medical Research Council [MC_UP_0901/1] Funding Source: researchfish	Swedish Council for Working Life and Social Research(Swedish Research CouncilSwedish Research Council for Health Working Life & Welfare (Forte)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	This study was made possible by a grant from the Swedish Council for Working Life and Social Research (www.fas.se; Grant number: FAS 2009-0222). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Amir N, 2003, BEHAV RES THER, V41, P1325, DOI 10.1016/S0005-7967(03)00039-1; Amir N, 2008, J ABNORM PSYCHOL, V117, P860, DOI 10.1037/a0013445; Amir N, 2011, J CONSULT CLIN PSYCH, V79, P533, DOI 10.1037/a0023808; Amir N, 2009, J CONSULT CLIN PSYCH, V77, P961, DOI 10.1037/a0016685; Andersson Gerhard, 2006, Cognitive Behaviour Therapy, V35, P55, DOI 10.1080/16506070500372469; [Anonymous], 2010, R LANG ENV STAT COMP; ASMUNDSON GJG, 1994, J ANXIETY DISORD, V8, P107, DOI 10.1016/0887-6185(94)90009-4; Baker SL, 2002, BEHAV RES THER, V40, P701, DOI 10.1016/S0005-7967(01)00060-2; Beard C, 2012, BEHAV THER, V43, P724, DOI 10.1016/j.beth.2012.01.002; BECK AT, 1988, J CONSULT CLIN PSYCH, V56, P893, DOI 10.1037/0022-006X.56.6.893; Berry AC, 2009, DEPRESS ANXIETY, V26, P22, DOI 10.1002/da.20511; Biehl M, 1997, J NONVERBAL BEHAV, V21, P3, DOI 10.1023/A:1024902500935; Boettcher J, 2012, COGNITIVE THER RES, V36, P522, DOI 10.1007/s10608-011-9374-y; Bradley BP, 1997, BEHAV RES THER, V35, P911, DOI 10.1016/S0005-7967(97)00053-3; Browning M, 2010, COGN AFFECT BEHAV NE, V10, P8, DOI 10.3758/CABN.10.1.8; Calamaras MR, 2012, J CLIN PSYCHOL, V68, P745, DOI 10.1002/jclp.21875; Carlbring P, 2012, BMC PSYCHIATRY, V12, DOI 10.1186/1471-244X-12-66; Chen YP, 2002, BEHAV RES THER, V40, P677, DOI 10.1016/S0005-7967(01)00086-9; Cisler JM, 2010, CLIN PSYCHOL REV, V30, P203, DOI 10.1016/j.cpr.2009.11.003; Clark D.M., 1995, SOCIAL PHOBIA DIAGNO, P69; Clark DM, 2006, J CONSULT CLIN PSYCH, V74, P568, DOI 10.1037/0022-006X.74.3.568; Dear BF, 2011, J PAIN, V12, P1247, DOI 10.1016/j.jpain.2011.07.003; Eldar S, 2012, AM J PSYCHIAT, V169, P213, DOI 10.1176/appi.ajp.2011.11060886; Field A., 2012, FIELD DISCOVERING ST, V1st, DOI 10.7326/M16-0968; First M. B., 2004, COMPREHENSIVE HDB PS, V2, P134; Fresco DM, 2001, PSYCHOL MED, V31, P1025, DOI 10.1017/S0033291701004056; Frisch MB, 1992, PSYCHOL ASSESS, V4, P92, DOI 10.1037/1040-3590.4.1.92; Furmark T, 1999, SOC PSYCH PSYCH EPID, V34, P416, DOI 10.1007/s001270050163; Goeleven E, 2008, COGNITION EMOTION, V22, P1094, DOI 10.1080/02699930701626582; Gotlib IH, 2004, J ABNORM PSYCHOL, V113, P127, DOI 10.1037/0021-843X.113.1.121; Hakamata Y, 2010, BIOL PSYCHIAT, V68, P982, DOI 10.1016/j.biopsych.2010.07.021; Hedman E, 2010, COMPUT HUM BEHAV, V26, P736, DOI 10.1016/j.chb.2010.01.010; Heeren A, 2012, BEHAV RES THER, V50, P30, DOI 10.1016/j.brat.2011.10.005; Helfinstein SM, 2008, BEHAV RES THER, V46, P799, DOI 10.1016/j.brat.2008.03.011; HOPE DA, 1990, COGNITIVE THER RES, V14, P177, DOI 10.1007/BF01176208; Houck PR, 2004, PSYCHIAT RES, V129, P209, DOI 10.1016/j.psychres.2004.08.001; JACOBSON NS, 1991, J CONSULT CLIN PSYCH, V59, P12, DOI 10.1037/0022-006X.59.1.12; Jose P., 2012, NLME LINEAR NONLINEA; Julian K, 2012, BEHAV RES THER, V50, P350, DOI 10.1016/j.brat.2012.02.015; Klumpp H, 2010, COGNITIVE THER RES, V34, P263, DOI 10.1007/s10608-009-9251-0; Klumpp H, 2009, ANXIETY STRESS COPIN, V22, P283, DOI 10.1080/10615800802449602; Kraemer HC, 2002, ARCH GEN PSYCHIAT, V59, P877, DOI 10.1001/archpsyc.59.10.877; LeMoult J, 2012, COGNITIVE THER RES, V36, P47, DOI 10.1007/s10608-010-9322-2; Li SW, 2008, BEHAV RES THER, V46, P905, DOI 10.1016/j.brat.2008.04.005; Lindner P, COGNITIVE B IN PRESS; Lundh LG, 1996, PERS INDIV DIFFER, V20, P725, DOI 10.1016/0191-8869(96)00008-6; MacLeod C, 2002, J ABNORM PSYCHOL, V111, P107, DOI 10.1037//0021-843X.111.1.107; MACLEOD C, 1986, J ABNORM PSYCHOL, V95, P15, DOI 10.1037/0021-843X.95.1.15; Macleod C, 2012, AM J PSYCHIAT, V169, P118, DOI 10.1176/appi.ajp.2011.11111682; Maidenberg E, 1996, J ANXIETY DISORD, V10, P529, DOI 10.1016/S0887-6185(96)00028-X; MATTIA JI, 1993, BEHAV RES THER, V31, P305, DOI 10.1016/0005-7967(93)90029-T; Mattick RP, 1998, BEHAV RES THER, V36, P455, DOI 10.1016/S0005-7967(97)10031-6; Mogg K, 2004, J ABNORM PSYCHOL, V113, P160, DOI 10.1037/0021-843X.113.1.160; Mogg K, 2002, BEHAV RES THER, V40, P1403, DOI 10.1016/S0005-7967(02)00017-7; Muhlberger A, 2008, CYBERPSYCHOL BEHAV, V11, P425, DOI 10.1089/cpb.2007.0084; Mueller EM, 2009, PSYCHOL MED, V39, P1141, DOI 10.1017/S0033291708004820; Musa C, 2003, BEHAV RES THER, V41, P1043, DOI 10.1016/S0005-7967(02)00212-7; Neubauer K, 2013, BEHAV RES THER, V51, P87, DOI 10.1016/j.brat.2012.10.006; Nielsen T, 2007, NORD PSYCHOL, V59, P231, DOI 10.1027/1901-2276.59.3.231; Ononaiye MSP, 2007, COGNITIVE THER RES, V31, P727, DOI 10.1007/s10608-006-9096-8; PATTERSON WM, 1983, PSYCHOSOMATICS, V24, P343, DOI 10.1016/S0033-3182(83)73213-5; Pflugshaupt T, 2005, J ANXIETY DISORD, V19, P105, DOI 10.1016/j.janxdis.2003.12.002; Pineles SL, 2005, J ABNORM PSYCHOL, V114, P314, DOI 10.1037/0021-843X.114.2.314; POSNER MI, 1980, Q J EXP PSYCHOL, V32, P3, DOI 10.1080/00335558008248231; Rapee RM, 1997, BEHAV RES THER, V35, P741, DOI 10.1016/S0005-7967(97)00022-3; Roberts KE, 2010, COGNITIVE THER RES, V34, P388, DOI 10.1007/s10608-009-9245-y; ROSNOW RL, 1991, PSYCHOL BULL, V110, P574, DOI 10.1037/0033-2909.110.3.574; Samuelsson H, 2012, J MED INTERNET RES, V14, DOI 10.2196/jmir.2196; Schmidt NB, 2009, J ABNORM PSYCHOL, V118, P5, DOI 10.1037/a0013643; Schmukle SC, 2005, EUR J PERSONALITY, V19, P595, DOI 10.1002/per.554; Schofield CA, 2012, COGNITION EMOTION, V26, P300, DOI 10.1080/02699931.2011.602050; See J, 2009, J ABNORM PSYCHOL, V118, P65, DOI 10.1037/a0014377; Staugaard S. R., 2009, PSYCHOL SCI Q, V51, P339, DOI [DOI 10.1080/02699930903205698, DOI 10.4081/MI.2011.E5]; SVANBORG P, 1994, ACTA PSYCHIAT SCAND, V89, P21, DOI 10.1111/j.1600-0447.1994.tb01480.x; Thorndike FP, 2009, COMPUT HUM BEHAV, V25, P393, DOI 10.1016/j.chb.2008.05.006; Vassilopoulos SP, 2005, BEHAV COGN PSYCHOTH, V33, P13, DOI 10.1017/S1352465804001730; Wieser MJ, 2009, J NEURAL TRANSM, V116, P717, DOI 10.1007/s00702-008-0101-0; Williams JMG, 1996, PSYCHOL BULL, V120, P3, DOI 10.1037/0033-2909.120.1.3	78	70	71	0	59	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 30	2013	8	9							e71760	10.1371/journal.pone.0071760	http://dx.doi.org/10.1371/journal.pone.0071760			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	231NL	24098630	Green Published, gold, Green Submitted			2023-01-03	WOS:000325423500002
J	Maynard, ME; Leasure, JL				Maynard, Mark E.; Leasure, J. Leigh			Exercise Enhances Hippocampal Recovery following Binge Ethanol Exposure	PLOS ONE			English	Article							CELL-PROLIFERATION; ALCOHOL DEPENDENCE; PHYSICAL-EXERCISE; MESSENGER-RNA; GROWTH-FACTOR; BRAIN-DAMAGE; ADULT-RATS; NEUROGENESIS; ABSTINENCE; INDUCTION	Binge drinking damages the brain, and although a significant amount of recovery occurs with abstinence, there is a need for effective strategies to maximize neurorestoration. In contrast to binge drinking, exercise promotes brain health, so the present study assessed whether it could counteract ethanol-induced damage by augmenting natural self-repair processes following one or more binge exposures. Adult female rats were exposed to 0 (control), 1 or 2 binges, using an established 4-day model of binge-induced neurodegeneration. Half of the animals in each group remained sedentary, or had running wheel access beginning 7 days after the final binge, and were sacrificed 28 days later. To assess binge-induced hippocampal damage and exercise restoration, we quantified volume of the dentate gyrus and number of granule neurons. We found that a single binge exposure significantly decreased the volume of the dentate gyrus and number of granule neurons. A second binge did not exacerbate the damage. Exercise completely restored baseline volume and granule neuron numbers. To investigate a potential mechanism of this restoration, we administered IdU (a thymidine analog) in order to label cells generated after the first binge. Previous studies have shown that neurogenesis in the dentate gyrus is decreased by binge alcohol exposure, and that the hippocampus responds to this insult by increasing cell genesis during abstinence. We found increased IdU labeling in binge-exposed animals, and a further increase in binged animals that exercised. Our results indicate that exercise reverses long-lasting hippocampal damage by augmenting natural self-repair processes.	[Maynard, Mark E.; Leasure, J. Leigh] Univ Houston, Dept Psychol, Houston, TX USA; [Leasure, J. Leigh] Univ Houston, Dept Biol & Biochem, Houston, TX USA	University of Houston System; University of Houston; University of Houston System; University of Houston	Leasure, JL (corresponding author), Univ Houston, Dept Psychol, Houston, TX USA.	jlleasure@uh.edu		Leasure, J. Leigh/0000-0002-9014-2525	University of Houston's College of Liberal Arts and Social Sciences; University of Houston's Biology of Behavior Institute	University of Houston's College of Liberal Arts and Social Sciences; University of Houston's Biology of Behavior Institute	This study was supported by a Grant in Aid to J.L.L. from the University of Houston's College of Liberal Arts and Social Sciences, and a summer fellowship awarded to M. M. by the University of Houston's Biology of Behavior Institute. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Agartz I, 2003, ALCOHOL ALCOHOLISM, V38, P71, DOI 10.1093/alcalc/agg020; Bechara A, 2005, NAT NEUROSCI, V8, P1458, DOI 10.1038/nn1584; Berchtold NC, 2001, EUR J NEUROSCI, V14, P1992, DOI 10.1046/j.0953-816x.2001.01825.x; Berchtold NC, 2005, NEUROSCIENCE, V133, P853, DOI 10.1016/j.neuroscience.2005.03.026; Cardenas VA, 2007, NEUROIMAGE, V34, P879, DOI 10.1016/j.neuroimage.2006.10.015; Collins MA, 1996, ALCOHOL CLIN EXP RES, V20, P284, DOI 10.1111/j.1530-0277.1996.tb01641.x; Crews FT, 2009, ALCOHOL ALCOHOLISM, V44, P115, DOI 10.1093/alcalc/agn079; Crews FT, 2009, PHARMACOL BIOCHEM BE, V93, P237, DOI 10.1016/j.pbb.2009.04.018; Duka T, 2004, ALCOHOL CLIN EXP RES, V28, P233, DOI 10.1097/01.ALC.0000113780.41701.81; Duka T, 2003, ALCOHOL CLIN EXP RES, V27, P1563, DOI 10.1097/01.ALC.0000090142.11260.D7; Duka T, 2011, BIOL PSYCHIAT, V70, P545, DOI 10.1016/j.biopsych.2011.04.006; Goldman JM, 2007, BIRTH DEFECTS RES B, V80, P84, DOI 10.1002/bdrb.20106; Gomez-Pinilla F, 1998, NEUROSCIENCE, V85, P53, DOI 10.1016/S0306-4522(97)00576-9; Gomez-Pinilla F, 2001, EUR J NEUROSCI, V13, P1078, DOI 10.1046/j.0953-816x.2001.01484.x; Gomez-Pinilla F, 2008, EUR J NEUROSCI, V28, P2278, DOI 10.1111/j.1460-9568.2008.06524.x; GomezPinilla F, 1997, BRAIN RES, V764, P1, DOI 10.1016/S0006-8993(97)00375-2; Griesbach GS, 2004, BRAIN RES, V1016, P154, DOI 10.1016/j.brainres.2004.04.079; Gupta S, 2008, BRIT J PSYCHIAT, V193, P351, DOI 10.1192/bjp.bp.108.051425; Helfer JL, 2009, BRAIN RES, V1294, P1, DOI 10.1016/j.brainres.2009.07.090; Humm JL, 1998, BRAIN RES, V783, P286, DOI 10.1016/S0006-8993(97)01356-5; HUNT WA, 1993, ALCOHOL, V10, P559, DOI 10.1016/0741-8329(93)90083-Z; Jarvenpaa T, 2005, EPIDEMIOLOGY, V16, P766, DOI 10.1097/01.ede.0000181307.30826.6c; Kanny Dafna, 2012, Morbidity and Mortality Weekly Report, V61, P14; Kelso ML, 2011, NEUROSCIENCE, V197, P381, DOI 10.1016/j.neuroscience.2011.09.019; Kozlowski DA, 2013, COMPR PHYSIOL, V3, P121, DOI 10.1002/cphy.c110005; Leasure JL, 2010, ALCOHOL CLIN EXP RES, V34, P404, DOI 10.1111/j.1530-0277.2009.01105.x; MAJCHROWICZ E, 1975, PSYCHOPHARMACOLOGIA, V43, P245, DOI 10.1007/BF00429258; Nixon K, 2008, NEUROBIOL DIS, V31, P218, DOI 10.1016/j.nbd.2008.04.009; Nixon K, 2004, J NEUROSCI, V24, P9714, DOI 10.1523/JNEUROSCI.3063-04.2004; Nixon K, 2002, J NEUROCHEM, V83, P1087, DOI 10.1046/j.1471-4159.2002.01214.x; Obernier JA, 2002, PHARMACOL BIOCHEM BE, V72, P521, DOI 10.1016/S0091-3057(02)00715-3; Obernier JA, 2002, ALCOHOL CLIN EXP RES, V26, P547, DOI 10.1097/00000374-200204000-00016; Paxinos G, 1998, RAT BRAIN IN STEREOTAXIC COORDINATES, FOURTH ED., pix; Penland S, 2001, ALCOHOL, V24, P45, DOI 10.1016/S0741-8329(01)00142-2; PFEFFERBAUM A, 1995, ALCOHOL CLIN EXP RES, V19, P1177, DOI 10.1111/j.1530-0277.1995.tb01598.x; Redila VA, 2006, HIPPOCAMPUS, V16, P305, DOI 10.1002/hipo.20164; ROOF RL, 1993, BRAIN RES, V607, P333, DOI 10.1016/0006-8993(93)91526-X; SCHALLERT T, 1993, J NEURAL TRANSP PLAS, V4, P193, DOI 10.1155/NP.1993.193; Schallert T, 1997, ADV NEUROL, V73, P229; Stephens DN, 2008, PHILOS T R SOC B, V363, P3169, DOI 10.1098/rstb.2008.0097; Sundell L, 2008, STROKE, V39, P3179, DOI 10.1161/STROKEAHA.108.520817; Tanapat P, 1999, J NEUROSCI, V19, P5792, DOI 10.1523/JNEUROSCI.19-14-05792.1999; Thomas JD, 2008, BEHAV NEUROSCI, V122, P1264, DOI 10.1037/a0013271; TIVIS R, 1995, ALCOHOL CLIN EXP RES, V19, P496, DOI 10.1111/j.1530-0277.1995.tb01537.x; Trejo JL, 2002, REV NEUROSCIENCE, V13, P365; van Praag H, 1999, P NATL ACAD SCI USA, V96, P13427, DOI 10.1073/pnas.96.23.13427; van Praag H, 1999, NAT NEUROSCI, V2, P266, DOI 10.1038/6368; Will B, 2004, PROG NEUROBIOL, V72, P167, DOI 10.1016/j.pneurobio.2004.03.001; Wobrock T, 2009, EUR ARCH PSY CLIN N, V259, P143, DOI 10.1007/s00406-008-0846-3	49	32	32	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 30	2013	8	9							e76644	10.1371/journal.pone.0076644	http://dx.doi.org/10.1371/journal.pone.0076644			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	231NL	24098797	Green Submitted, Green Published, gold			2023-01-03	WOS:000325423500168
J	Theobaldo, MC; Llimona, F; Petroni, RC; Rios, ECS; Velasco, IT; Soriano, FG				Theobaldo, Mariana Cardillo; Llimona, Flavia; Petroni, Ricardo Costa; Rios, Ester Correia Sarmento; Velasco, Irineu Tadeu; Soriano, Francisco Garcia			Hypertonic Saline Solution Drives Neutrophil from Bystander Organ to Infectious Site in Polymicrobial Sepsis: A Cecal Ligation and Puncture Model	PLOS ONE			English	Article							SEVERE HEMORRHAGIC-SHOCK; SEPTIC SHOCK; RESUSCITATION; MORTALITY; EPIDEMIOLOGY; PATHOGENESIS; PERITONITIS; RECRUITMENT; STRATEGIES; CLEARANCE	The effects of hypertonic saline solution (HSS) have been shown in several animal models of ischemia and shock. Literature has shown potential benefits of HSS modulating inflammatory response after sepsis in an animal model. We studied the HSS effects in sepsis through cecal ligation and puncture (CLP) in Balb-C mice. Groups studied: 1-CLP without treatment (CLP-C); 2-CLP treated with normal saline solution NaCl 0.9% - 34 ml/Kg (CLP-S); 3-CLP treated with HSS NaCl 7.5% - 4 ml/Kg (CLPH); and 4-group (Basal) without no CLP or treatment. Volume infusion was always applied 30 min after CLP. Lung and peritoneal lavage were harvested after 6h and 24h of CLP to analyze cytokines amount, oxide nitric, lipid peroxidation and neutrophil infiltration. Neutrophil infiltration, ICAM-1, CXCR-2, and CXCL-1 in lung were reduced by HSS (CLP-H) compared to CLP-C or CLP-S. Neutrophil in peritoneal lavage was increased in 24h with HSS (CLP-H) compared to CLP and CLP-S. Peritoneal CXCR-2 was increased in CLP-C and CLP-S but presented a lower increase with HSS (CLP-H) after 6 hours. GRK-2 presented difference among the groups at 24 h, showing a profile similar to neutrophil infiltration. Pro-inflammatory cytokines (TNF-alpha and IL-6) were reduced by HSS treatment; CLP-S increased TNF-alpha IL-10 was increased in lung tissue by the HSS treatment. The oxidative stress (TBARS and nitric oxide biochemistry markers) was reduced with HSS. Animal survival was 33.3% in CLP-C group, 46.6% in CLP-S group and 60% in the CLP-H group after the sixth day. The HSS protects the animal against sepsis. Our results suggest that the volume replacement modulate pro and anti-inflammatory mediators of an inflammatory response, but HSS presented a more effective and potent effect.	[Theobaldo, Mariana Cardillo; Llimona, Flavia; Petroni, Ricardo Costa; Rios, Ester Correia Sarmento; Velasco, Irineu Tadeu; Soriano, Francisco Garcia] Univ Sao Paulo, Fac Med, Emergency Med Div, Sao Paulo, Brazil	Universidade de Sao Paulo	Soriano, FG (corresponding author), Univ Sao Paulo, Fac Med, Emergency Med Div, Sao Paulo, Brazil.	gsoriano@usp.br	Petroni, Ricardo/K-5144-2013; Soriano, Francisco/C-3382-2012	Soriano, Francisco/0000-0003-4898-0135	FAPESP [2009/15530-0]	FAPESP(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP))	This study was supported by FAPESP grant 2009/15530-0. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abraham E, 1999, INTENS CARE MED, V25, P556, DOI 10.1007/s001340050903; ALBELDA SM, 1994, FASEB J, V8, P504, DOI 10.1096/fasebj.8.8.8181668; Alberti C, 2002, INTENS CARE MED, V28, P108, DOI 10.1007/s00134-001-1143-z; Alves JC, 2008, SHOCK, V30, P3, DOI 10.1097/SHK.0b013e3181818466; Angus D C, 2001, Crit Care Med, V29, P1303, DOI 10.1097/00003246-200107000-00002; BONE RC, 1992, CHEST, V101, P1644, DOI 10.1378/chest.101.6.1644; Cohen J, 2002, NATURE, V420, P885, DOI 10.1038/nature01326; Craciun FL, 2010, J IMMUNOL, V185, P6930, DOI 10.4049/jimmunol.1002300; da Silva FP, 2009, FRONT BIOSCI-LANDMRK, V14, P4464, DOI 10.2741/3542; Dal-Pizzol F, 2006, AM J RESP CRIT CARE, V173, P84, DOI 10.1164/rccm.200507-1118OC; Dinarello CA, 1997, CHEST, V112, p321S, DOI 10.1378/chest.112.6_Supplement.321S; Frazier WJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050071; Friedman G, 1998, CRIT CARE MED, V26, P2078, DOI 10.1097/00003246-199812000-00045; GLAUSER MP, 1994, CLIN INFECT DIS, V18, pS205, DOI 10.1093/clinids/18.Supplement_2.S205; HENSON PM, 1987, J CLIN INVEST, V79, P669, DOI 10.1172/JCI112869; HOLZHEIMER RG, 1991, INFECTION, V19, P447, DOI 10.1007/BF01726463; Leendertse M, 2009, INFECT IMMUN, V77, P485, DOI 10.1128/IAI.00863-08; Majcherczyk PA, 1999, J BIOL CHEM, V274, P12537, DOI 10.1074/jbc.274.18.12537; Malbrain MLNG, 2005, CURR OPIN CRIT CARE, V11, P156, DOI 10.1097/01.ccx.0000155355.86241.1b; Melo ES, 2010, MOL IMMUNOL, V47, P2587, DOI 10.1016/j.molimm.2010.06.011; MercerJones MA, 1997, SHOCK, V8, P193, DOI 10.1097/00024382-199709000-00007; Morath S, 2001, J EXP MED, V193, P393, DOI 10.1084/jem.193.3.393; Nduka OO, 2009, CRIT CARE CLIN, V25, P677, DOI 10.1016/j.ccc.2009.08.002; Noppens RR, 2012, CRIT CARE MED, V40, P2149, DOI 10.1097/CCM.0b013e31824e6750; Oliveira RP, 2002, CRIT CARE, V6, P418, DOI 10.1186/cc1541; Conde KAP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064790; Petroni RC, 2012, SHOCK, V37, P524, DOI 10.1097/SHK.0b013e31824c7665; Remick DG, 1998, CRIT CARE MED, V26, P895, DOI 10.1097/00003246-199805000-00025; Rittirsch D, 2007, J LEUKOCYTE BIOL, V81, P137, DOI 10.1189/jlb.0806542; Rivers E, 2001, NEW ENGL J MED, V345, P1368, DOI 10.1056/NEJMoa010307; Rios ECS, 2011, CLINICS, V66, P469, DOI 10.1590/S1807-59322011000300019; Shimazu R, 1999, J EXP MED, V189, P1777, DOI 10.1084/jem.189.11.1777; SILVA MRF, 1987, AM J PHYSIOL, V253, pH751, DOI 10.1152/ajpheart.1987.253.4.H751; Soriano FG, 2002, SHOCK, V17, P286, DOI 10.1097/00024382-200204000-00008; Soriano FG, 2001, CRIT CARE MED, V29, P703, DOI 10.1097/00003246-200104000-00001; Soriano FG, 2011, SHOCK, V35, P560, DOI 10.1097/SHK.0b013e31820fe5d5; Takeuchi O, 1999, IMMUNITY, V11, P443, DOI 10.1016/S1074-7613(00)80119-3; van Haren FMP, 2012, SHOCK, V37, P268, DOI 10.1097/SHK.0b013e31823f152f; VELASCO IT, 1989, CRIT CARE MED, V17, P261, DOI 10.1097/00003246-198903000-00012; VELASCO IT, 1980, AM J PHYSIOL, V239, pH664, DOI 10.1152/ajpheart.1980.239.5.H664; WEISS SJ, 1989, NEW ENGL J MED, V320, P365; Wiedemann HP, 2006, NEW ENGL J MED, V354, P2564; ZAPATASIRVENT RL, 1995, BURNS, V21, P185, DOI 10.1016/0305-4179(95)80006-A	43	11	13	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 17	2013	8	9							e74369	10.1371/journal.pone.0074369	http://dx.doi.org/10.1371/journal.pone.0074369			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	219YJ	24069301	Green Published, Green Submitted, gold			2023-01-03	WOS:000324547300037
J	Thompson, BT				Thompson, B. Taylor			Prone positioning for 16 h/d reduced mortality more than supine positioning in early severe ARDS	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							RESPIRATORY-DISTRESS-SYNDROME; ACUTE LUNG INJURY; METAANALYSIS		Massachusetts Gen Hosp, Boston, MA 02114 USA	Harvard University; Massachusetts General Hospital	Thompson, BT (corresponding author), Massachusetts Gen Hosp, Boston, MA 02114 USA.							Abroug F, 2008, INTENS CARE MED, V34, P1002, DOI 10.1007/s00134-008-1062-3; Briel M, 2010, JAMA-J AM MED ASSOC, V303, P865, DOI 10.1001/jama.2010.218; Gattinoni L, 2010, MINERVA ANESTESIOL, V76, P448	3	2	2	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 17	2013	159	6							JC2	10.7326/0003-4819-159-6-201309170-02002	http://dx.doi.org/10.7326/0003-4819-159-6-201309170-02002			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	234EY	24042385				2023-01-03	WOS:000325625900001
J	Bretagnol, A; Tamburini, J; Guedj, M; Denier, C; Pene, F				Bretagnol, Anne; Tamburini, Jerome; Guedj, Mikael; Denier, Charlotte; Pene, Frederic			Profound anaemia and acute blindness in a Jehovah's Witness	LANCET			English	Editorial Material									[Bretagnol, Anne; Pene, Frederic] Hop Cochin, AP HP, Med Intens Care Unit, F-75014 Paris, France; [Tamburini, Jerome] Hop Cochin, AP HP, Haematol Unit, F-75014 Paris, France; [Guedj, Mikael; Denier, Charlotte] Hop Cochin, AP HP, Ophthalmol Unit, F-75014 Paris, France; Paris Descartes Univ, Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite	Pene, F (corresponding author), Hop Cochin, 27 Rue Faubourg, F-75014 Paris, France.	frederic.pene@cch.aphp.fr	tamburini, jerome/AAT-9506-2020	Pene, Frederic/0000-0003-3639-3849; Tamburini, Jerome/0000-0002-0167-5996				Al-Nawakil C, 2013, BRIT J HAEMATOL, V161, P738, DOI 10.1111/bjh.12284; HOLT JM, 1969, BRIT J OPHTHALMOL, V53, P145, DOI 10.1136/bjo.53.3.145; Rouge-Maillart C, 2004, Med Law, V23, P715	3	0	0	0	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 14	2013	382	9896					998	998		10.1016/S0140-6736(13)61443-9	http://dx.doi.org/10.1016/S0140-6736(13)61443-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	215VD	24034299				2023-01-03	WOS:000324238000033
J	Weibel, R; Reiss, D; Karchewski, L; Gardon, O; Matifas, A; Filliol, D; Becker, JAJ; Wood, JN; Kieffer, BL; Gaveriaux-Ruff, C				Weibel, Raphael; Reiss, David; Karchewski, Laurie; Gardon, Olivier; Matifas, Audrey; Filliol, Dominique; Becker, Jerome A. J.; Wood, John N.; Kieffer, Brigitte L.; Gaveriaux-Ruff, Claire			Mu Opioid Receptors on Primary Afferent Nav1.8 Neurons Contribute to Opiate-Induced Analgesia: Insight from Conditional Knockout Mice	PLOS ONE			English	Article							DORSAL-ROOT GANGLIA; MESSENGER-RNA EXPRESSION; SPINAL-CORD; SENSORY NEURONS; RELATIVE CONTRIBUTION; NEUROPATHIC PAIN; RAT MODEL; MORPHINE; DELTA; GENE	Opiates are powerful drugs to treat severe pain, and act via mu opioid receptors distributed throughout the nervous system. Their clinical use is hampered by centrally-mediated adverse effects, including nausea or respiratory depression. Here we used a genetic approach to investigate the potential of peripheral mu opioid receptors as targets for pain treatment. We generated conditional knockout (cKO) mice in which mu opioid receptors are deleted specifically in primary afferent Nav1.8-positive neurons. Mutant animals were compared to controls for acute nociception, inflammatory pain, opiate-induced analgesia and constipation. There was a 76% decrease of mu receptor-positive neurons and a 60% reduction of mu-receptor mRNA in dorsal root ganglia of cKO mice. Mutant mice showed normal responses to heat, mechanical, visceral and chemical stimuli, as well as unchanged morphine antinociception and tolerance to antinociception in models of acute pain. Inflammatory pain developed similarly in cKO and controls mice after Complete Freund's Adjuvant. In the inflammation model, however, opiate-induced (morphine, fentanyl and loperamide) analgesia was reduced in mutant mice as compared to controls, and abolished at low doses. Morphine-induced constipation remained intact in cKO mice. We therefore genetically demonstrate for the first time that mu opioid receptors partly mediate opiate analgesia at the level of Nav1.8-positive sensory neurons. In our study, this mechanism operates under conditions of inflammatory pain, but not nociception. Previous pharmacology suggests that peripheral opiates may be clinically useful, and our data further demonstrate that Nav1.8 neuron-associated mu opioid receptors are feasible targets to alleviate some forms of persistent pain.	[Weibel, Raphael; Reiss, David; Karchewski, Laurie; Gardon, Olivier; Matifas, Audrey; Filliol, Dominique; Becker, Jerome A. J.; Kieffer, Brigitte L.; Gaveriaux-Ruff, Claire] UdS Univ Strasbourg, IGBMC, Translat Med & Neurogenet Programme, INSERM,U964,CNRS,UMR7104, Illkirch Graffenstaden, France; [Wood, John N.] UCL, Wolfson Inst Biomed Res, Mol Nocicept Grp, London, England; [Gaveriaux-Ruff, Claire] UdS Univ Strasbourg, ESBS, Strasbourg, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); University of London; University College London	Gaveriaux-Ruff, C (corresponding author), UdS Univ Strasbourg, IGBMC, Translat Med & Neurogenet Programme, INSERM,U964,CNRS,UMR7104, Illkirch Graffenstaden, France.	gaveriau@igbmc.fr	Becker, Jerome/I-7879-2016; GAVERIAUX-RUFF, Claire/A-9671-2017	Becker, Jerome/0000-0002-0039-0067; GAVERIAUX-RUFF, Claire/0000-0002-3523-8102	Universite de Strasbourg (UdS); CNRS; INSERM; ANR LYMPHOPIOID (CG-R); National Institute of Health, USA [NIAAA 016658, NIDA 005010, NIDA 016768]; European Union [GENADDICT/FP6 005166]; Wellcome Trust; MRC; BBSRC; Universite de Strasbourg (CG-R); MRC [G0901905] Funding Source: UKRI; Medical Research Council [G0901905] Funding Source: researchfish; Wellcome Trust [101054/Z/13/Z] Funding Source: researchfish; NATIONAL INSTITUTE ON DRUG ABUSE [P50DA005010] Funding Source: NIH RePORTER	Universite de Strasbourg (UdS); CNRS(Centre National de la Recherche Scientifique (CNRS)); INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); ANR LYMPHOPIOID (CG-R)(French National Research Agency (ANR)); National Institute of Health, USA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); European Union(European Commission); Wellcome Trust(Wellcome Trust); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Universite de Strasbourg (CG-R); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); Wellcome Trust(Wellcome TrustEuropean Commission); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)	This work was supported by: Universite de Strasbourg (UdS, CG-R), CNRS, INSERM, ANR LYMPHOPIOID (CG-R), the National Institute of Health, USA (NIAAA 016658, BLK; NIDA 005010, BLK; NIDA 016768, BLK and RM), and the European Union (GENADDICT/FP6 005166, BLK RM); the Wellcome Trust, MRC and BBSRC (JNW). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abbadie C, 2002, BRAIN RES, V930, P150, DOI 10.1016/S0006-8993(02)02242-4; Abrahamsen B, 2008, SCIENCE, V321, P702, DOI 10.1126/science.1156916; Agarwal N, 2007, NAT NEUROSCI, V10, P870, DOI 10.1038/nn1916; Al-Hasani R, 2011, ANESTHESIOLOGY, V115, P1363, DOI 10.1097/ALN.0b013e318238bba6; Baamonde A, 2005, N-S ARCH PHARMACOL, V372, P213, DOI 10.1007/s00210-005-0013-6; Ballet S, 2003, NEUROPEPTIDES, V37, P211, DOI 10.1016/S0143-4179(03)00045-3; Barrot M, 2012, NEUROSCIENCE, V211, P39, DOI 10.1016/j.neuroscience.2011.12.041; BESSE D, 1992, BRAIN RES, V578, P115, DOI 10.1016/0006-8993(92)90237-4; Boue J, 2012, PAIN, V153, P485, DOI 10.1016/j.pain.2011.11.013; Cabanero D, 2009, PAIN, V141, P88, DOI 10.1016/j.pain.2008.10.011; Calza L, 2000, EXP NEUROL, V164, P333, DOI 10.1006/exnr.2000.7442; CHAPLAN SR, 1994, J NEUROSCI METH, V53, P55, DOI 10.1016/0165-0270(94)90144-9; Chattopadhyay M, 2008, J NEUROSCI, V28, P6652, DOI 10.1523/JNEUROSCI.5530-07.2008; Chen SR, 2006, J NEUROPHYSIOL, V95, P3086, DOI 10.1152/jn.01343.2005; Contet C, 2006, NEUROPSYCHOPHARMACOL, V31, P1733, DOI 10.1038/sj.npp.1300934; Dehaven-Hudkins DL, 1999, J PHARMACOL EXP THER, V289, P494; Dominguez JE, 2013, CURR OPIN ANESTHESIO, V26, P288, DOI 10.1097/ACO.0b013e328360b086; Endres-Becker J, 2007, MOL PHARMACOL, V71, P12, DOI 10.1124/mol.106.026740; Ferrini F, 2013, NAT NEUROSCI, V16, P183, DOI 10.1038/nn.3295; Fields H, 2004, NAT REV NEUROSCI, V5, P565, DOI 10.1038/nrn1431; Gautron L, 2011, J COMP NEUROL, V519, P3085, DOI 10.1002/cne.22667; Gaveriaux-Ruff C, 2007, PHARMACOL THERAPEUT, V113, P619, DOI 10.1016/j.pharmthera.2006.12.003; Gaveriaux-Ruff C, 2011, PAIN, V152, P1238, DOI 10.1016/j.pain.2010.12.031; GAVERIAUXRUFF C, 2013, CURR PHARM DESIGN, P48470; Gonzalez-Rodriguez S, 2010, CELL MOL NEUROBIOL, V30, P113, DOI 10.1007/s10571-009-9436-9; GUSTAFSSON LL, 1985, ANESTHESIOLOGY, V63, P483, DOI 10.1097/00000542-198511000-00003; HARGREAVES K, 1988, PAIN, V32, P77, DOI 10.1016/0304-3959(88)90026-7; Joseph EK, 2010, NEUROSCIENCE, V171, P344, DOI 10.1016/j.neuroscience.2010.08.035; Khalefa BI, 2012, EUR J PAIN, V16, P690, DOI 10.1002/j.1532-2149.2011.00070.x; Kreek MJ, 2012, J CLIN INVEST, V122, P3387, DOI 10.1172/JCI60390; Labuz D, 2007, BRAIN RES, V1160, P30, DOI 10.1016/j.brainres.2007.05.049; Labuz D, 2009, J CLIN INVEST, V119, P278, DOI [10.1172/JCI36246, 10.1172/JCI36246C1]; LAMOTTE C, 1976, BRAIN RES, V112, P407, DOI 10.1016/0006-8993(76)90296-1; Le Merrer J, 2009, PHYSIOL REV, V89, P1379, DOI 10.1152/physrev.00005.2009; Lewanowitsch T, 2006, LIFE SCI, V78, P682, DOI 10.1016/j.lfs.2005.05.062; Luger NM, 2002, PAIN, V99, P397, DOI 10.1016/S0304-3959(02)00102-1; Lutz PE, 2013, CURR OPIN NEUROBIOL, V23, P473, DOI 10.1016/j.conb.2013.02.005; Lynch JL, 2008, BRAIN RES, V1191, P180, DOI 10.1016/j.brainres.2007.11.034; Mansikka H, 2004, ANESTHESIOLOGY, V100, P912, DOI 10.1097/00000542-200404000-00022; MANSOUR A, 1995, TRENDS NEUROSCI, V18, P22, DOI 10.1016/0166-2236(95)93946-U; Matthes HWD, 1996, NATURE, V383, P819, DOI 10.1038/383819a0; Minami K, 2009, J PHARMACOL SCI, V111, P60, DOI 10.1254/jphs.09139FP; Mogil JS, 2009, NAT REV NEUROSCI, V10, P283, DOI 10.1038/nrn2606; Negus SS, 2006, J PHARMACOL EXP THER, V319, P507, DOI 10.1124/jpet.106.106377; Nozaki C, 2011, NAT NEUROSCI, V14, P1017, DOI 10.1038/nn.2844; Obara I, 2009, PAIN, V141, P283, DOI 10.1016/j.pain.2008.12.006; Ossipov MH, 2010, J CLIN INVEST, V120, P3779, DOI 10.1172/JCI43766; Pol O, 2006, NEUROPHARMACOLOGY, V50, P123, DOI 10.1016/j.neuropharm.2005.11.002; Pradhan AAA, 2010, J NEUROSCI, V30, P16459, DOI 10.1523/JNEUROSCI.3748-10.2010; Pradhan AAA, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005425; Puehler W, 2004, NEUROSCIENCE, V129, P473, DOI 10.1016/j.neuroscience.2004.06.086; Raehal KM, 2005, J PHARMACOL EXP THER, V314, P1195, DOI 10.1124/jpet.105.087254; Raouf R, 2010, J CLIN INVEST, V120, P3745, DOI 10.1172/JCI43158; Ringkamp M, 2012, EUR J PAIN, V16, P621, DOI 10.1002/j.1532-2149.2012.00110.x; Roy S, 1998, MOL BRAIN RES, V56, P281, DOI 10.1016/S0169-328X(98)00051-5; Sasaki A, 2008, NEUROREPORT, V19, P975, DOI 10.1097/WNR.0b013e328302f123; Scherrer G, 2009, CELL, V137, P1148, DOI 10.1016/j.cell.2009.04.019; Schramm CL, 2010, PAIN, V151, P763, DOI 10.1016/j.pain.2010.09.009; Schug SA, 2006, CNS DRUGS, V20, P917, DOI 10.2165/00023210-200620110-00005; Shaqura MA, 2004, J PHARMACOL EXP THER, V308, P712, DOI 10.1124/jpet.103.057257; Shinoda K, 2007, NEUROSCI LETT, V411, P143, DOI 10.1016/j.neulet.2006.10.027; Simonin F, 1998, EMBO J, V17, P886, DOI 10.1093/emboj/17.4.886; Sora I, 1997, P NATL ACAD SCI USA, V94, P1544, DOI 10.1073/pnas.94.4.1544; Stein C, 2011, PHARMACOL REV, V63, P860, DOI 10.1124/pr.110.003145; Stirling LC, 2005, PAIN, V113, P27, DOI 10.1016/j.pain.2004.08.015; Thibault K, 2008, EUR J PHARMACOL, V600, P71, DOI 10.1016/j.ejphar.2008.10.004; Vetter I, 2012, EMBO J, V31, P3795, DOI 10.1038/emboj.2012.207; Wang H, 2001, J COMP NEUROL, V429, P590, DOI 10.1002/1096-9861(20010122)429:4<590::AID-CNE6>3.0.CO;2-V; Williams JT, 2013, PHARMACOL REV, V65, P223, DOI 10.1124/pr.112.005942; Zhang GH, 2008, ANESTHESIOLOGY, V108, P305, DOI 10.1097/01.anes.0000299836.61785.79; Zhang Z, 2010, J NEUROSCI, V30, P4735, DOI 10.1523/JNEUROSCI.5968-09.2010; Zollner C, 2008, J CLIN INVEST, V118, P1065, DOI 10.1172/JCI25911	72	78	81	0	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 12	2013	8	9							e74706	10.1371/journal.pone.0074706	http://dx.doi.org/10.1371/journal.pone.0074706			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	242KO	24069332	Green Published, gold			2023-01-03	WOS:000326240100116
J	Chen, HY; Ma, XM; Ye, M; Hou, YL; Xie, HY; Bai, YR				Chen, Hai-yan; Ma, Xiu-mei; Ye, Ming; Hou, Yan-li; Xie, Hua-Ying; Bai, Yong-rui			Effectiveness and Toxicities of Intensity-Modulated Radiotherapy for Patients with Locally Recurrent Nasopharyngeal Carcinoma	PLOS ONE			English	Article							RETROSPECTIVE ANALYSIS; RADIATION-THERAPY; REIRRADIATION; SURVIVAL; PATTERNS; SALVAGE	Purpose: To analyze the effectiveness and toxicities in the re-irradiation of locally recurrent nasopharyngeal carcinoma (NPC) using intensity-modulated radiotherapy (IMRT). Methods: This is a retrospective analysis of 54 NPC patients with local recurrence re-irradiated with IMRT. The re-staging for rT1, rT2, rT3, rT4 were 3 (5.6%), 8 (14.8%), 9 (16.7%), 34 (63%) respectively. The average dose to GTV was 69.95 Gy (49.8-76.58 Gy), the average BED3Gy was 116.8 Gy (83.5-127.9 Gy). V-95 was 96%, and D-95 was 65.75Gy. 33.3% of them received concurrent chemoradiotherapy. Results: Median overall survival (OS) was 21 months (1-93 mon). The 1-, 2-year local progression free survival (LPFS) rate was 84.5%, 64% and OS rate was 71.7%, 44.3%. Severe late adverse events (SLAE) occurred in 48.1% of patients, including 31.5% with ulcer or necrosis of the nasopharyngeal mucosa, 20.4% with difficulty in feeding, 18.5% with temporal lobe necrosis, 11.1% with massive hemorrhage. 15.4% died of local regional progression, 5.8% died of distant metastasis, 25% died of SLAE, 9.6% died of both local regional progression and SLAE that could not be differentiated, 5.8% died of other medical complications. Concurrent chemoradiotherapy was the independent negative prognostic factors for LPFS; PTV>100 ml was a predictive factor of poor OS; patients with invasion of post-styloid space were at higher risk of SLAE. Conclusions: The present study demonstrated that IMRT with 70Gy was efficient for local tumor control. However, we observed a high frequency of serious late complications. More optimized combination treatment and patient selection are required to achieve excellent local control without significant late morbidities in locally recurrent NPC.	[Chen, Hai-yan; Ma, Xiu-mei; Ye, Ming; Hou, Yan-li; Xie, Hua-Ying; Bai, Yong-rui] Shanghai Jiao Tong Univ, Sch Med, Renji Hosp, Dept Radiat Oncol, Shanghai 200030, Peoples R China	Shanghai Jiao Tong University	Bai, YR (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Renji Hosp, Dept Radiat Oncol, Shanghai 200030, Peoples R China.	baiyongrui@renji.com	Chen, Haiyan/HGB-6216-2022					Chang JTC, 2000, RADIOTHER ONCOL, V54, P135, DOI 10.1016/S0167-8140(99)00177-2; Chua DTT, 2005, RADIOTHER ONCOL, V77, P290, DOI 10.1016/j.radonc.2005.10.010; Corry J, 2006, INT J RADIAT ONCOL, V64, P63, DOI 10.1016/j.ijrobp.2005.06.041; Han F, 2012, CLIN ONCOL-UK, V24, P569, DOI 10.1016/j.clon.2011.11.010; Hua YJ, 2009, HEAD NECK-J SCI SPEC, V31, P807, DOI 10.1002/hed.21036; Jurado JA, 2008, CATHETER CARDIO INTE, V72, P563, DOI 10.1002/ccd.21681; Koutcher L, 2010, INT J RADIAT ONCOL, V76, P130, DOI 10.1016/j.ijrobp.2009.01.055; LEE AWM, 1993, INT J RADIAT ONCOL, V26, P773, DOI 10.1016/0360-3016(93)90491-D; LEE AWM, 1992, INT J RADIAT ONCOL, V23, P261, DOI 10.1016/0360-3016(92)90740-9; Leung TW, 2000, INT J RADIAT ONCOL, V48, P1331, DOI 10.1016/S0360-3016(00)00776-8; Lu TX, 2004, INT J RADIAT ONCOL, V58, P682, DOI 10.1016/S0360-3016(03)01508-6; MARX RE, 1983, J ORAL MAXIL SURG, V41, P283, DOI 10.1016/0278-2391(83)90294-X; Ozyigit G, 2011, INT J RADIAT ONCOL, V81, pE263, DOI 10.1016/j.ijrobp.2011.02.054; Qiu SF, 2012, INT J RADIAT ONCOL, V83, P676, DOI 10.1016/j.ijrobp.2011.07.006; Suarez C, 2010, EUR ARCH OTO-RHINO-L, V267, P1811, DOI 10.1007/s00405-010-1385-x; WANG CC, 1987, INT J RADIAT ONCOL, V13, P953, DOI 10.1016/0360-3016(87)90030-7; Wee J, 2005, J CLIN ONCOL, V23, P6730, DOI 10.1200/JCO.2005.16.790; Wu Jun-xin, 2012, Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi, V47, P185	18	39	45	1	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 10	2013	8	9							e73918	10.1371/journal.pone.0073918	http://dx.doi.org/10.1371/journal.pone.0073918			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	259PK	24040115	Green Published, gold, Green Submitted			2023-01-03	WOS:000327538600052
J	Head, S				Head, Stephen			CARE OF THE DYING IN THE COMMUNITY New pharmacological models needed to care for dying patients at home	BMJ-BRITISH MEDICAL JOURNAL			English	Letter									Nottinghamshire Healthcare Trust, Edwinstowe Hlth Ctr, Mansfield NG21 9QS, England		Head, S (corresponding author), Nottinghamshire Healthcare Trust, Edwinstowe Hlth Ctr, Mansfield NG21 9QS, England.	shead@doctors.org.uk						Collis E, 2013, BMJ-BRIT MED J, V347, DOI 10.1136/bmj.f4085	1	0	0	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 14	2013	347								f4882	10.1136/bmj.f4882	http://dx.doi.org/10.1136/bmj.f4882			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	203YP	23945357				2023-01-03	WOS:000323331100001
J	Natoli, R; Valter, K; Barbosa, M; Dahlstrom, J; Rutar, M; Kent, A; Provis, J				Natoli, Riccardo; Valter, Krisztina; Barbosa, Marconi; Dahlstrom, Jane; Rutar, Matt; Kent, Alison; Provis, Jan			670nm Photobiomodulation as a Novel Protection against Retinopathy of Prematurity: Evidence from Oxygen Induced Retinopathy Models	PLOS ONE			English	Article							NEAR-INFRARED LIGHT; CYTOCHROME-C-OXIDASE; ABSORPTION-MEASUREMENTS; RISK-FACTORS; CHILDREN; PRETERM; RETINA; PHOTOTHERAPY; PATHOGENESIS; MECHANISMS	Introduction: To investigate the validity of using 670nm red light as a preventative treatment for Retinopathy of Prematurity in two animal models of oxygen-induced retinopathy (OIR). Materials and Methods: During and post exposure to hyperoxia, C57BL/6J mice or Sprague-Dawley rats were exposed to 670nm light for 3 minutes a day (9J/cm(2)). Whole mounted retinas were investigated for evidence of vascular abnormalities, while sections of neural retina were used to quantify levels of cell death using the TUNEL technique. Organs were removed, weighed and independent histopathology examination performed. Results: 670nm light reduced neovascularisation, vaso-obliteration and abnormal peripheral branching patterns of retinal vessels in OIR. The neural retina was also protected against OIR by 670nm light exposure. OIR-exposed animals had severe lung pathology, including haemorrhage and oedema, that was significantly reduced in 670nm +OIR light-exposed animals. There were no significance differences in the organ weights of animals in the 670nm light-exposed animals, and no adverse effects of exposure to 670nm light were detected. Discussion: Low levels of exposure to 670nm light protects against OIR and lung damage associated with exposure to high levels of oxygen, and may prove to be a non-invasive and inexpensive preventative treatment for ROP and chronic lung disease associated with prematurity.	[Natoli, Riccardo; Valter, Krisztina; Barbosa, Marconi; Dahlstrom, Jane; Rutar, Matt; Provis, Jan] Australian Natl Univ, John Curtin Sch Med Res, Canberra, ACT 2601, Australia; [Natoli, Riccardo; Valter, Krisztina; Barbosa, Marconi; Rutar, Matt; Provis, Jan] Australian Natl Univ, ARC Ctr Excellence Vis Sci, Canberra, ACT, Australia; [Natoli, Riccardo; Valter, Krisztina; Dahlstrom, Jane; Kent, Alison; Provis, Jan] Australian Natl Univ, ANU Med Sch, Canberra, ACT, Australia; [Dahlstrom, Jane] Canberra Hosp, Dept Anat Pathol, Woden, ACT, Australia; [Kent, Alison] Canberra Hosp, Dept Neonatol, Woden, ACT, Australia	Australian National University; John Curtin School of Medical Research; Australian National University; Australian National University; Australian National University; Canberra Hospital; Australian National University; Canberra Hospital	Natoli, R (corresponding author), Australian Natl Univ, John Curtin Sch Med Res, Canberra, ACT 2601, Australia.	riccardo.natoli@anu.edu.au	Valter, Krisztina/L-3015-2016; Kent, Alison/AAC-9063-2019; Dahlstrom, Jane/E-4683-2018; Provis, Jan/C-9529-2009	Natoli, Riccardo/0000-0002-9350-0439; Dahlstrom, Jane/0000-0001-5608-693X; Valter, Krisztina/0000-0002-2033-0408; Provis, Jan/0000-0002-6405-2868; Rutar, Matthew/0000-0002-8893-5120	Australian Research Council Centres of Excellence Program Grant [CE0561903]; Canberra Hospital Private Practice Fund	Australian Research Council Centres of Excellence Program Grant(Australian Research Council); Canberra Hospital Private Practice Fund	Australian Research Council Centres of Excellence Program Grant (CE0561903); Canberra Hospital Private Practice Fund. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Akula JD, 2010, DOC OPHTHALMOL, V120, P41, DOI 10.1007/s10633-009-9198-1; Albarracin R, 2012, PHOTOCHEM PHOTOBIOL; Albarracin R, 2011, INVEST OPHTH VIS SCI, V52, P3582, DOI 10.1167/iovs.10-6664; Alpay A, 2012, TURKISH J PEDIATR, V54, P113; Askie LM, 2011, BMC PEDIATR, V11, DOI 10.1186/1471-2431-11-6; Chen J, 2011, CURR OPIN PEDIATR, V23, P173, DOI 10.1097/MOP.0b013e3283423f35; Chess PR, 2006, SEMIN PERINATOL, V30, P171, DOI 10.1053/j.semperi.2006.05.003; Connor KM, 2009, NAT PROTOC, V4, P1565, DOI 10.1038/nprot.2009.187; Dave HB, 2012, AM J OPHTHALMOL, V154, P750, DOI 10.1016/j.ajo.2012.04.003; Dembinska O, 2002, INVEST OPHTH VIS SCI, V43, P2481; Eells JT, 2004, MITOCHONDRION, V4, P559, DOI 10.1016/j.mito.2004.07.033; Fierson WM, 1997, PEDIATRICS, V100, P273, DOI 10.1542/peds.100.2.273; Fitzgerald M, 2013, REV NEUROSCIENCE, V24, P205, DOI 10.1515/revneuro-2012-0086; Fitzgerald M, 2010, J NEUROTRAUM, V27, P2107, DOI 10.1089/neu.2010.1426; Fletcher EL, 2010, DOC OPHTHALMOL, V120, P67, DOI 10.1007/s10633-009-9193-6; Fulton AB, 2009, PROG RETIN EYE RES, V28, P452, DOI 10.1016/j.preteyeres.2009.06.003; Giusti B, 2012, FREE RADICAL RES, V46, P1130, DOI 10.3109/10715762.2012.692787; GORGELS TGMF, 1995, INVEST OPHTH VIS SCI, V36, P851; Grossniklaus HE, 2010, PROG RETIN EYE RES, V29, P500, DOI 10.1016/j.preteyeres.2010.05.003; Hakeem AHAA, 2012, MIDDLE EAST AFR J OP, V19, P289, DOI 10.4103/0974-9233.97927; Heckmann M, 2008, OPHTHALMOLOGE, V105, P1101, DOI 10.1007/s00347-008-1789-9; Hentschke VS, 2013, LASER MED SCI, V28, P1007, DOI 10.1007/s10103-012-1190-4; Ilia M, 1999, J COMP NEUROL, V405, P394, DOI 10.1002/(SICI)1096-9861(19990315)405:3<394::AID-CNE9>3.0.CO;2-Y; Jeffery G, 1997, TRENDS NEUROSCI, V20, P165, DOI 10.1016/S0166-2236(96)10080-1; Karu T, 1999, J PHOTOCH PHOTOBIO B, V49, P1, DOI 10.1016/S1011-1344(98)00219-X; Karu TI, 2005, J PHOTOCH PHOTOBIO B, V81, P98, DOI 10.1016/j.jphotobiol.2005.07.002; KARU TI, 1995, DOKL AKAD NAUK+, V342, P693; Karu TI, 2008, PHOTOMED LASER SURG, V26, P593, DOI 10.1089/pho.2008.2246; Kokkinopoulos I, 2013, NEUROBIOL AGING, V34, P602, DOI 10.1016/j.neurobiolaging.2012.04.014; Larsson E, 2006, BRIT J OPHTHALMOL, V90, P87, DOI 10.1136/bjo.2005.081653; Larsson E, 2004, J PEDIAT OPHTH STRAB, V41, P39, DOI 10.3928/0191-3913-20040101-10; Larsson EK, 2005, ARCH OPHTHALMOL-CHIC, V123, P825, DOI 10.1001/archopht.123.6.825; Maslim J, 1997, INVEST OPHTH VIS SCI, V38, P1667; Meirelles GCS, 2008, PHOTOMED LASER SURG, V26, P159, DOI 10.1089/pho.2007.2052; Natoli R, 2010, MOL VIS, V16, P1801; Noell W K, 1966, Invest Ophthalmol, V5, P450; O'Connor AR, 2002, ARCH OPHTHALMOL-CHIC, V120, P767; Quinn GE, 2010, CHINESE MED J-PEKING, V123, P2929, DOI 10.3760/cma.j.issn.0366-6999.2010.20.033; Rojas JC, 2008, J NEUROSCI, V28, P13511, DOI 10.1523/JNEUROSCI.3457-08.2008; Rutar M, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-257; Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089; Semo M, 2001, EUR J NEUROSCI, V13, P1257, DOI 10.1046/j.0953-816x.2001.01495.x; SHVEDOVA AA, 1983, CURR EYE RES, V2, P683, DOI 10.3109/02713688209019997; Silveira PCL, 2007, J PHOTOCH PHOTOBIO B, V86, P279, DOI 10.1016/j.jphotobiol.2006.10.002; Simons BD, 1999, INT OPHTHALMOL CLIN, V39, P29, DOI 10.1097/00004397-199903920-00004; SMITH LEH, 1994, INVEST OPHTH VIS SCI, V35, P101; Smith LEH, 2004, GROWTH HORM IGF RES, V14, pS140, DOI 10.1016/j.ghir.2004.03.030; Wong-Riley MTT, 2005, J BIOL CHEM, V280, P4761, DOI 10.1074/jbc.M409650200; Ying R, 2008, BRAIN RES, V1243, P167, DOI 10.1016/j.brainres.2008.09.057	49	32	35	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 8	2013	8	8							e72135	10.1371/journal.pone.0072135	http://dx.doi.org/10.1371/journal.pone.0072135			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	201ER	23951291	Green Published, Green Submitted, gold			2023-01-03	WOS:000323124000079
J	Schiebel, J; Kapilashrami, K; Fekete, A; Bommineni, GR; Schaefer, CM; Mueller, MJ; Tonge, PJ; Kisker, C				Schiebel, Johannes; Kapilashrami, Kanishk; Fekete, Agnes; Bommineni, Gopal R.; Schaefer, Christin M.; Mueller, Martin J.; Tonge, Peter J.; Kisker, Caroline			Structural Basis for the Recognition of Mycolic Acid Precursors by KasA, a Condensing Enzyme and Drug Target from Mycobacterium Tuberculosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article						Enzyme Inhibitors; Enzyme Mechanisms; Enzyme Structure; Lipid Synthesis; Mycobacterium tuberculosis; Phospholipid; KasA; Condensing Enzyme; Enzyme Dynamics; Induced Fit Substrate Recognition	ACYL CARRIER PROTEIN; FATTY-ACIDS; POSITIONAL DISTRIBUTION; SUBSTRATE RECOGNITION; CRYSTAL-STRUCTURE; RESIDENCE TIME; SYNTHASE-II; INHIBITOR; THIOLACTOMYCIN; BIOSYNTHESIS	Background: Although induced fit binding is central to molecular recognition, in most cases, the structural basis for this process remains to be elucidated. Results: We determined structural snapshots along the substrate binding reaction coordinate for the drug target Mycobacterium tuberculosis KasA. Conclusion: KasA binds acyl substrates via the induced fit concerted opening of a hydrophobic cavity. Significance: Improved understanding of induced fit binding is crucial for inhibitor design. The survival of Mycobacterium tuberculosis depends on mycolic acids, very long -alkyl--hydroxy fatty acids comprising 60-90 carbon atoms. However, despite considerable efforts, little is known about how enzymes involved in mycolic acid biosynthesis recognize and bind their hydrophobic fatty acyl substrates. The condensing enzyme KasA is pivotal for the synthesis of very long (C38-42) fatty acids, the precursors of mycolic acids. To probe the mechanism of substrate and inhibitor recognition by KasA, we determined the structure of this protein in complex with a mycobacterial phospholipid and with several thiolactomycin derivatives that were designed as substrate analogs. Our structures provide consecutive snapshots along the reaction coordinate for the enzyme-catalyzed reaction and support an induced fit mechanism in which a wide cavity is established through the concerted opening of three gatekeeping residues and several -helices. The stepwise characterization of the binding process provides mechanistic insights into the induced fit recognition in this system and serves as an excellent foundation for the development of high affinity KasA inhibitors.	[Schiebel, Johannes; Schaefer, Christin M.; Kisker, Caroline] Univ Wurzburg, Inst Biol Struct, Rudolf Virchow Ctr Expt Biomed, D-97080 Wurzburg, Germany; [Schiebel, Johannes] Univ Wurzburg, Inst Pharm & Food Chem, D-97074 Wurzburg, Germany; [Kapilashrami, Kanishk; Bommineni, Gopal R.; Tonge, Peter J.] SUNY Stony Brook, Dept Chem, Inst Chem Biol & Drug Discovery, Stony Brook, NY 11794 USA; [Fekete, Agnes; Mueller, Martin J.] Univ Wurzburg, Dept Pharmaceut Biol, Bioctr, Julius von Sachs Inst Biosci, D-97082 Wurzburg, Germany	University of Wurzburg; University of Wurzburg; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; University of Wurzburg	Kisker, C (corresponding author), Univ Wurzburg, Inst Biol Struct, Rudolf Virchow Ctr Expt Biomed, D-97080 Wurzburg, Germany.	caroline.kisker@virchow.uni-wuerzburg.de	mueller, martin j/C-7616-2019; Fekete, Agnes/C-8048-2019; Tonge, Peter J/A-7443-2009	Fekete, Agnes/0000-0003-3058-7570; Tonge, Peter J/0000-0003-1606-3471; Kisker, Caroline/0000-0002-0216-6026	National Institutes of Health [GM102864]; Deutsche Forschungsgemeinschaft [SFB630]; Forschungszentrum [FZ82]; German Excellence Initiative; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM102864] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Forschungszentrum; German Excellence Initiative; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported, in whole or in part, by National Institutes of Health Grant GM102864 (to P.J.T.). This work was also supported by Deutsche Forschungsgemeinschaft SFB630 and Forschungszentrum FZ82 (to C.K.).; Supported by a grant of the German Excellence Initiative to the Graduate School of Life Sciences, University of Wurzburg.	Alhamadsheh MM, 2007, CHEM BIOL, V14, P513, DOI 10.1016/j.chembiol.2007.03.013; Benkovic SJ, 2003, SCIENCE, V301, P1196, DOI 10.1126/science.1085515; Bhatt A, 2005, J BACTERIOL, V187, P7596, DOI 10.1128/JB.187.22.7596-7606.2005; Bhatt A, 2007, MOL MICROBIOL, V64, P1442, DOI 10.1111/j.1365-2958.2007.05761.x; Bissantz C, 2010, J MED CHEM, V53, P5061, DOI 10.1021/jm100112j; Borgaro JG, 2011, BIOCHEMISTRY-US, V50, P10678, DOI 10.1021/bi201199x; Brown MS, 2003, J AM CHEM SOC, V125, P10166, DOI 10.1021/ja034540i; BURGI HB, 1974, TETRAHEDRON, V30, P1563, DOI 10.1016/S0040-4020(01)90678-7; Chang A, 2013, BIOCHEMISTRY-US, V52, P4217, DOI 10.1021/bi400413c; Choi KH, 2000, J BIOL CHEM, V275, P28201; Copeland RA, 2006, NAT REV DRUG DISCOV, V5, P730, DOI 10.1038/nrd2082; Delano W.L, 2002, DELANO SCI; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Evans P, 2006, ACTA CRYSTALLOGR D, V62, P72, DOI 10.1107/S0907444905036693; Fieulaine S, 2011, PLOS BIOL, V9, DOI 10.1371/journal.pbio.1001066; FRENCH GL, 1987, LANCET, V2, P117; Harding MM, 2006, ACTA CRYSTALLOGR D, V62, P678, DOI 10.1107/S0907444906014594; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; Kapilashrami K, 2013, J BIOL CHEM, V288, P6045, DOI 10.1074/jbc.M112.414516; Kremer L, 2000, J BIOL CHEM, V275, P16857, DOI 10.1074/jbc.M000569200; Kremer L, 2002, BIOCHEM J, V364, P423, DOI 10.1042/BJ20011628; Krug M, 2012, J APPL CRYSTALLOGR, V45, P568, DOI 10.1107/S0021889812011715; Lee W, 2011, BIOCHEMISTRY-US, V50, P5743, DOI 10.1021/bi200006t; LESLIE AGW, 1992, JNT CCP4 ESF EAMCB N, V26, P27; LI Y, 1990, J ORG CHEM, V55, P481, DOI 10.1021/jo00289a020; Lu C., 2012, PLOS ONE, V7; Lu H, 2010, CURR OPIN CHEM BIOL, V14, P467, DOI 10.1016/j.cbpa.2010.06.176; Luckner SR, 2010, J BIOL CHEM, V285, P14330, DOI 10.1074/jbc.M109.090373; Luckner SR, 2009, STRUCTURE, V17, P1004, DOI 10.1016/j.str.2009.04.012; Machutta CA, 2010, J BIOL CHEM, V285, P6161, DOI 10.1074/jbc.M109.077909; Mccoy AJ, 2007, J APPL CRYSTALLOGR, V40, P658, DOI 10.1107/S0021889807021206; McFadden JM, 2005, J MED CHEM, V48, P946, DOI 10.1021/jm049389h; McFadden JM, 2002, ORG LETT, V4, P3859, DOI 10.1021/ol026685k; Milletti F, 2007, J CHEM INF MODEL, V47, P2172, DOI 10.1021/ci700018y; MIYAKAWA S, 1982, J ANTIBIOT, V35, P411, DOI 10.7164/antibiotics.35.411; Muller P, 2003, ACTA CRYSTALLOGR D, V59, P32, DOI 10.1107/S0907444902018000; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; OKUYAMA H, 1967, J BIOCHEM-TOKYO, V61, P732, DOI 10.1093/oxfordjournals.jbchem.a128607; Olsen JG, 2001, STRUCTURE, V9, P233, DOI 10.1016/S0969-2126(01)00583-4; Painter J, 2006, J APPL CRYSTALLOGR, V39, P109, DOI 10.1107/S0021889805038987; Price AC, 2003, J BACTERIOL, V185, P4136, DOI 10.1128/JB.185.14.4136-4143.2003; Price AC, 2001, J BIOL CHEM, V276, P6551, DOI 10.1074/jbc.M007101200; Qiu XY, 2001, J MOL BIOL, V307, P341, DOI 10.1006/jmbi.2000.4457; Richard JP, 2013, BIOCHEMISTRY-US, V52, P2009, DOI 10.1021/bi3017119; Sacco E, 2007, P NATL ACAD SCI USA, V104, P14628, DOI 10.1073/pnas.0704132104; Sachdeva S, 2008, CHEM BIOL, V15, P402, DOI 10.1016/j.chembiol.2008.03.007; Schaefer B, 2011, J COMPUT AID MOL DES, V25, P1053, DOI 10.1007/s10822-011-9483-4; Schaeffer ML, 2001, J BIOL CHEM, V276, P47029, DOI 10.1074/jbc.M108903200; Schiebel J, 2012, STRUCTURE, V20, P802, DOI 10.1016/j.str.2012.03.013; Schramm VL, 2011, ANNU REV BIOCHEM, V80, P703, DOI 10.1146/annurev-biochem-061809-100742; Silver LL, 2011, CLIN MICROBIOL REV, V24, P71, DOI 10.1128/CMR.00030-10; Slayden RA, 2002, TUBERCULOSIS, V82, P149, DOI 10.1054/tube.2002.0333; Sridharan S, 2007, J MOL BIOL, V366, P469, DOI 10.1016/j.jmb.2006.11.006; Sullivan TJ, 2006, ACS CHEM BIOL, V1, P43, DOI 10.1021/cb0500042; Swanson S, 2009, STRUCTURE, V17, P914, DOI 10.1016/j.str.2009.06.006; Takayama K, 2005, CLIN MICROBIOL REV, V18, P81, DOI 10.1128/CMR.18.1.81-101.2005; Theobald DL, 2008, PLOS COMPUT BIOL, V4, DOI 10.1371/journal.pcbi.0040043; von Wettstein-Knowles P, 2006, FEBS J, V273, P695, DOI 10.1111/j.1742-4658.2005.05101.x; WALKER RW, 1970, LIPIDS, V5, P684, DOI 10.1007/BF02531435; Wang J, 2006, NATURE, V441, P358, DOI 10.1038/nature04784; White SW, 2005, ANNU REV BIOCHEM, V74, P791, DOI 10.1146/annurev.biochem.74.082803.133524; Wilmouth RC, 1997, NAT STRUCT BIOL, V4, P456, DOI 10.1038/nsb0697-456; Witkowski A, 2002, BIOCHEMISTRY-US, V41, P10877, DOI 10.1021/bi0259047; Wong HC, 2002, J BIOL CHEM, V277, P15874, DOI 10.1074/jbc.M112300200; Zhang HN, 2010, COMPREHENSIVE NATURAL PRODUCTS II: CHEMISTRY AND BIOLOGY, VOL 8: ENZYMES AND ENZYME MECHANISMS, P231; Zhang YM, 2006, J BIOL CHEM, V281, P17390, DOI 10.1074/jbc.M513199200	66	27	29	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 22	2013	288	47					34190	34204		10.1074/jbc.M113.511436	http://dx.doi.org/10.1074/jbc.M113.511436			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	255OR	24108128	hybrid, Green Published			2023-01-03	WOS:000327250200062
J	Lee, TH				Lee, Thomas H.			The Word That Shall Not Be Spoken	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material								Physicians and health care organizations know that pain, anxiety, uncertainty, and confusion are common among patients, and we work hard to reduce these problems. So why do we avoid the word suffering, which captures so completely what patients endure? During the years when I worked in an academic integrated delivery system, my colleagues and I would frequently discuss patients' experiences and ways to improve our management of their pain and reduce their confusion as they navigated our complex organization. We knew that anxiety is inevitable for patients facing health issues, but we also knew that there is anxiety, and there is unnecessary anxiety caused, for example, by the uncertainty that weighs on patients and their families while they await a consultation for a potentially serious diagnosis, or the confusion induced when clinicians give conflicting information. We worked hard ...	Press Ganey, Wakefield, MA USA		Lee, TH (corresponding author), Press Ganey, Wakefield, MA USA.								0	19	21	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 7	2013	369	19					1777	1779		10.1056/NEJMp1309660	http://dx.doi.org/10.1056/NEJMp1309660			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	247HF	24195546				2023-01-03	WOS:000326607800004
J	Rui, YY; Zhang, D; Zhou, ZG; Wang, C; Yang, L; Yu, YY; Chen, HN				Rui, Yuan-Yi; Zhang, Dan; Zhou, Zong-Guang; Wang, Cun; Yang, Lie; Yu, Yong-Yang; Chen, Hai-Ning			Can K-ras Gene Mutation Be Utilized as Prognostic Biomarker for Colorectal Cancer Patients Receiving Chemotherapy? A Meta-Analysis and Systematic Review	PLOS ONE			English	Review							COLON-CANCER; ADJUVANT CHEMOTHERAPY; KRAS MUTATION; STAGE-II; CETUXIMAB; THERAPY; FLUOROURACIL; OXALIPLATIN; SURVIVAL; BEHAVIOR	Introduction: K-ras gene mutations were common in colorectal patients, but their relationship with prognosis was unclear. Objective: Verify prognostic differences between patient with and without mutant K-ras genes by reviewing the published evidence. Method: Systematic reviews and data bases were searched for cohort/case-control studies of prognosis of colorectal cancer patients with detected K-ras mutations versus those without mutant K-ras genes, both of whom received chemotherapy. Number of patients, regimens of chemotherapy, and short-term or long-term survival rate (disease-free or overall) were extracted. Quality of studies was also evaluated. Principal Findings: 7 studies of comparisons with a control group were identified. No association between K-ras gene status with neither short-term disease free-survival (OR=1.01, 95% CI, 0.73-1.38, P=0.97) nor overall survival (OR=1.06, 95% CI, 0.82-1.36, P=0.66) in CRC patients who received chemotherapy was indicated. Comparison of long-term survival between two groups also indicated no significant difference after heterogeneity was eliminated (OR=1.09, 95% CI, 0.85-1.40, P=0.49). Conclusions: K-ras gene mutations may not be a prognostic index for colorectal cancer patients who received chemotherapy.	[Rui, Yuan-Yi; Zhang, Dan; Zhou, Zong-Guang; Wang, Cun; Yang, Lie; Yu, Yong-Yang; Chen, Hai-Ning] Sichuan Univ, West China Hosp, Dept Gastrointestinal Surg, Chengdu, Sichuan, Peoples R China; [Rui, Yuan-Yi; Zhang, Dan; Zhou, Zong-Guang; Chen, Hai-Ning] Sichuan Univ, West China Hosp, Inst Digest Surg, Chengdu, Sichuan, Peoples R China	Sichuan University; Sichuan University	Zhou, ZG (corresponding author), Sichuan Univ, West China Hosp, Dept Gastrointestinal Surg, Chengdu, Sichuan, Peoples R China.	zhou767@163.com	Chen, Hai-Ning/AAR-8059-2021; Wang, Cun/C-5600-2015; rui, yuanyi/ABB-4050-2021	Chen, Hai-Ning/0000-0003-0104-8498; , Zongguang/0000-0002-7616-1199	Ministry of Education [2007B66]	Ministry of Education	This study was supported by Doctoral thesis special fund of Ministry of Education, number 2007B66. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ahnen DJ, 1998, CANCER RES, V58, P1149; Andreyev HJN, 2001, BRIT J CANCER, V85, P692, DOI 10.1054/bjoc.2001.1964; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; Bleeker WA, 2001, DIS COLON RECTUM, V44, P358, DOI 10.1007/BF02234733; Boughdady I S, 1992, Surg Oncol, V1, P269, DOI 10.1016/0960-7404(92)90087-2; Chang MH, 2011, CANCER CHEMOTH PHARM, V68, P317, DOI 10.1007/s00280-010-1496-5; Chen MB, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045388; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FINKELSTEIN SD, 1993, CANCER, V71, P3827, DOI 10.1002/1097-0142(19930615)71:12<3827::AID-CNCR2820711207>3.0.CO;2-N; Gnanasampanthan G, 2001, J PATHOL, V195, P543, DOI 10.1002/path.990; Hutchins G, 2011, J CLIN ONCOL, V29, P1261, DOI 10.1200/JCO.2010.30.1366; Imamura Y, 2012, CLIN CANCER RES, V18, P4753, DOI 10.1158/1078-0432.CCR-11-3210; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.20107]; Karapetis CS, 2008, NEW ENGL J MED, V359, P1757, DOI 10.1056/NEJMoa0804385; Liao XY, 2012, CLIN CANCER RES, V18, P2257, DOI 10.1158/1078-0432.CCR-11-2410; Lievre A, 2006, CANCER RES, V66, P3992, DOI 10.1158/0008-5472.CAN-06-0191; Macara IG, 1996, FASEB J, V10, P625, DOI 10.1096/fasebj.10.5.8621061; Macdonald G, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001930.pub3; Network National Comprehensive Cancer Network, 2013, CLIN PRACT GUID ONC; Normanno N, 2009, NAT REV CLIN ONCOL, V6, P519, DOI 10.1038/nrclinonc.2009.111; Ogino S, 2009, CLIN CANCER RES, V15, P7322, DOI 10.1158/1078-0432.CCR-09-1570; Ren JJ, 2012, DIS COLON RECTUM, V55, P913, DOI 10.1097/DCR.0b013e318251d8d9; Roth AD, 2010, J CLIN ONCOL, V28, P466, DOI 10.1200/JCO.2009.23.3452; Rui YY, HEPATO GAST IN PRESS; Sargent DJ, 2010, J CLIN ONCOL, V28, P3219, DOI 10.1200/JCO.2009.27.1825; Shea B., 2013, NEWCASTLE OTTAWA SCA; Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166; Stec R, 2012, CANCER BIOL THER, V13, P1235, DOI 10.4161/cbt.21813; Tejpar S, 2012, J CLIN ONCOL, V30, P3570, DOI 10.1200/JCO.2012.42.2592; Tournigand C, 2012, J CLIN ONCOL, V30, P3353, DOI 10.1200/JCO.2012.42.5645; Van Cutsem E, 2009, NEW ENGL J MED, V360, P1408, DOI 10.1056/NEJMoa0805019; Yang L, 2004, BRIT J CANCER, V90, P2157, DOI 10.1038/sj.bjc.6601813	32	13	13	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 21	2013	8	10							e77901	10.1371/journal.pone.0077901	http://dx.doi.org/10.1371/journal.pone.0077901			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	239NN	24205021	Green Published, Green Submitted, gold			2023-01-03	WOS:000326032600053
J	van den Bergh, JPW; Bouts, ME; van der Veer, E; van der Velde, RY; Janssen, MJW; Geusens, PP; Winkens, B; Oldenhof, NJJ; van Geel, TACM				van den Bergh, Joop P. W.; Bouts, Marian E.; van der Veer, Eveline; van der Velde, Robert Y.; Janssen, Marcel J. W.; Geusens, Piet P.; Winkens, Bjorn; Oldenhof, Nico J. J.; van Geel, Tineke A. C. M.			Comparing Tolerability and Efficacy of Generic versus Brand Alendronate: A Randomized Clinical Study in Postmenopausal Women with a Recent Fracture	PLOS ONE			English	Article							BONE TURNOVER MARKERS; LIAISON SERVICES; SODIUM TABLETS; OSTEOPOROSIS; DISINTEGRATION; IMPLEMENTATION; SUBSTITUTION; COPIES; SCALE	Introduction: An increasing number of generic alendronate formulations have become available. Although expected to have the same tolerability and efficacy, head-to head comparison of generic and brand alendronate was never performed. Therefore, we compared the tolerability and efficacy of generic and brand alendronate. Methods: In a randomized double-blinded single centre cross-over study in 37 postmenopausal women (mean age 65.4+/-6.4 years) with osteoporosis were treated with generic and branded alendronate during 24 (2x12) weeks. Tolerance was evaluated by the Gastro intestinal Symptom Rating Scale (GSRS) and self-reported side effects. Efficacy was assessed by serum bone turnover markers, carboxy terminal telopeptide (CTX) and procollagen type I N-terminal propeptide (PINP). No wash out period was allowed (ethical reasons). Because of possible carry over effect only data of the first 12 weeks were analyzed using linear mixed models. Results: There were no significant differences in overall tolerance (GSRS) between treatment groups. However, for subscale abdominal pain, patients using generic had a significantly higher mean GSRS score at week 4 (estimated mean difference (B): 0.40; 95% CI: 0.05 to 0.74, p = 0.024). The level of bone turnover markers significantly decreased over 12 weeks of follow-up for generic and branded alendronate (p < 0.001). Mean level of CTX was significantly lower with branded at week 4 (B: 121.3; 95% CI: 52.0 to 190.5), but not at week 12 (B: 53.6; 95% CI:-3.7 to 110.9). No significant differences were found for PINP at week 4 or 12. Conclusions: Bone turnover markers were significantly reduced with branded and generic alendronate. With branded, CTX was significantly lower at 4 weeks. Generic caused significantly higher abdominal pain scores in the first 4 weeks of treatment. Therefore, generic alendronate may not have the same tolerability and efficacy as branded alendronate in the first weeks after starting treatment in patients with a recent fracture. Trial Registration: Dutch Trial Register NTR number 1867 http://www.trialregister.nl/trialreg/admin/rctview.asp?TC=1867	[van den Bergh, Joop P. W.; Bouts, Marian E.; van der Velde, Robert Y.] VieCuri Med Ctr Noord Limburg, Dept Internal Med, Venlo, Netherlands; [van den Bergh, Joop P. W.; Geusens, Piet P.] Maastricht Univ, Med Ctr, Dept Internal Med, Maastricht, Netherlands; [van den Bergh, Joop P. W.; van Geel, Tineke A. C. M.] Maastricht Univ, NUTRIM Sch Nutr Toxicol & Metab, Maastricht, Netherlands; [van den Bergh, Joop P. W.; Geusens, Piet P.] Univ Hasselt, Biomed Res Ctr, Diepenbeek, Belgium; [van der Veer, Eveline] Univ Groningen, Univ Med Ctr Groningen, Lab Med, NL-9713 AV Groningen, Netherlands; [Janssen, Marcel J. W.] VieCuri Med Ctr Noord Limburg, Lab Clin Chem & Haematol, Venlo, Netherlands; [Geusens, Piet P.; Winkens, Bjorn; van Geel, Tineke A. C. M.] Maastricht Univ, CAPHRI Sch Publ Hlth & Primary Care, Maastricht, Netherlands; [Winkens, Bjorn] Maastricht Univ, Dept Methodol & Stat, Maastricht, Netherlands; [Oldenhof, Nico J. J.] VieCuri Med Ctr Noord Limburg, Hosp Pharm, Venlo, Netherlands; [van Geel, Tineke A. C. M.] Maastricht Univ, Dept Family Med, Maastricht, Netherlands	VieCuri Medical Center; Maastricht University; Maastricht University; Maastricht University Medical Centre (MUMC); Hasselt University; University of Groningen; VieCuri Medical Center; Maastricht University; Maastricht University; VieCuri Medical Center; Maastricht University	van Geel, TACM (corresponding author), Maastricht Univ, NUTRIM Sch Nutr Toxicol & Metab, Maastricht, Netherlands.	tineke.vangeel@maastrichtuniversity.nl		Winkens, Bjorn/0000-0002-6747-6228; van Geel, Tineke/0000-0003-2022-6552; van den Bergh, Joop/0000-0003-3984-2232; van der Veer, Eveline/0000-0002-4825-9981	Stichting Wetenschappelijk onderzoek Interne Geneeskunde (WOIG)	Stichting Wetenschappelijk onderzoek Interne Geneeskunde (WOIG)	This study was funded by Stichting Wetenschappelijk onderzoek Interne Geneeskunde (WOIG). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Arends S, 2011, OSTEOPOROSIS INT, V22, P1431, DOI 10.1007/s00198-010-1338-7; Bauer DC, 2004, J BONE MINER RES, V19, P1250, DOI 10.1359/JBMR.040512; Boudou L, 2011, OSTEOPOROSIS INT, V22, P2099, DOI 10.1007/s00198-011-1638-6; Bours SPG, 2011, J CLIN ENDOCR METAB, V96, P1360, DOI 10.1210/jc.2010-2135; Dansereau RJ, 2008, CURR MED RES OPIN, V24, P1137, DOI 10.1185/030079908X280725 ; Eisman JA, 2012, J BONE MINER RES, V27, P2039, DOI 10.1002/jbmr.1698; Epstein S, 2003, CURR MED RES OPIN, V19, P781, DOI 10.1185/030079903125002577; Epstein S, 2005, J APPL RES, V2, P1; Greenspan SL, 2000, J CLIN ENDOCR METAB, V85, P3537, DOI 10.1210/jc.85.10.3537; Grima DT, 2010, BMC MUSCULOSKEL DIS, V11, DOI 10.1186/1471-2474-11-68; Huntjens KMB, 2011, OSTEOPOROSIS INT, V22, P2129, DOI 10.1007/s00198-010-1442-8; Huntjens KMB, 2011, INJURY, V42, pS39, DOI 10.1016/S0020-1383(11)70011-0; Institute Dutchfor Healthcare Improvement (CBO), 2011, GUID OST FRACT PREV; Ivaska KK, 2007, J BONE MINER RES, V22, P1155, DOI 10.1359/JBMR.070505; Lai PSM, 2012, CURR MED RES OPIN, V28, P1347, DOI 10.1185/03007995.2012.708326; Landfeldt E, 2012, BONE, V51, P637, DOI 10.1016/j.bone.2012.07.009; McLellan AR, 2011, OSTEOPOROSIS INT, V22, P2083, DOI 10.1007/s00198-011-1534-0; Perkins AC, 2008, CLIN THER, V30, P834, DOI 10.1016/j.clinthera.2008.04.018; Revicki DA, 1998, QUAL LIFE RES, V7, P75; Ringe JD, 2009, RHEUMATOL INT, V30, P213, DOI 10.1007/s00296-009-0940-5; Risser J, 2007, J NURS MEAS, V15, P203, DOI 10.1891/106137407783095757; Rosner B., 2006, FUNDAMENTALS BIOSTAT; Strom O, 2012, OSTEOPOROSIS INT, V23, P2201, DOI 10.1007/s00198-011-1850-4; Svarstad BL, 1999, PATIENT EDUC COUNS, V37, P113, DOI 10.1016/S0738-3991(98)00107-4; Szulc P, 2012, CLIN BIOCHEM, V45, P907, DOI 10.1016/j.clinbiochem.2012.01.022; van den Bergh JP, 2012, NAT REV RHEUMATOL, V8, P163, DOI 10.1038/nrrheum.2011.217; van Geel TACM, 2010, MATURITAS, V65, P143, DOI 10.1016/j.maturitas.2009.12.007; Vasikaran S, 2011, OSTEOPOROSIS INT, V22, P391, DOI 10.1007/s00198-010-1501-1; Wells G, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004523.pub3; Wells GA, 2008, COCHRANE DB SYST REV	30	9	9	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 21	2013	8	10							e78153	10.1371/journal.pone.0078153	http://dx.doi.org/10.1371/journal.pone.0078153			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	239NN	24205135	gold, Green Published			2023-01-03	WOS:000326032600075
J	Bekelman, JE; Epstein, AJ; Emanuel, EJ				Bekelman, Justin E.; Epstein, Andrew J.; Emanuel, Ezekiel J.			Single- vs Multiple-Fraction Radiotherapy for Bone Metastases From Prostate Cancer	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter									[Bekelman, Justin E.] Univ Penn, Perelman Sch Med, Dept Radiat Oncol, Philadelphia, PA 19104 USA; [Epstein, Andrew J.] Philadelphia Vet Affairs Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA; [Emanuel, Ezekiel J.] Univ Penn, Perelman Sch Med, Dept Med Eth & Hlth Policy, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Pennsylvania; Pennsylvania Medicine; Philadelphia Veterans Affairs Medical Center; University of Pennsylvania; Pennsylvania Medicine	Bekelman, JE (corresponding author), Univ Penn, Perelman Sch Med, 3400 Civ Ctr Blvd, Philadelphia, PA 19104 USA.	bekelman@uphs.upenn.edu		Epstein, Andrew/0000-0001-5078-6564	NATIONAL CANCER INSTITUTE [K07CA163616] Funding Source: NIH RePORTER; NCI NIH HHS [K07 CA163616, K07-CA163616] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Brown ML, 2002, MED CARE, V40, P104; Elshaug AG, 2013, JAMA-J AM MED ASSOC, V309, P775, DOI 10.1001/jama.2013.828; Fairchild A, 2009, INT J RADIAT ONCOL, V75, P1501, DOI 10.1016/j.ijrobp.2008.12.084; Hartsell WF, 2005, JNCI-J NATL CANCER I, V97, P798, DOI 10.1093/jnci/dji139; POTOSKY AL, 1993, MED CARE, V31, P732; Sze WM, 2004, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD004721	6	69	69	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 9	2013	310	14					1501	1502		10.1001/jama.2013.277081	http://dx.doi.org/10.1001/jama.2013.277081			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	230PK	24104375	Green Accepted			2023-01-03	WOS:000325354100027
J	Tu, YF; Wan, L; Fan, YH; Wang, KZ; Bu, LH; Huang, T; Cheng, Z; Shen, BZ				Tu, Yingfeng; Wan, Lin; Fan, Yuhua; Wang, Kezheng; Bu, Lihong; Huang, Tao; Cheng, Zhen; Shen, Baozhong			Ischemic Postconditioning-Mediated miRNA-21 Protects against Cardiac ischemia/reperfusion Injury via PTEN/Akt Pathway	PLOS ONE			English	Article							PERCUTANEOUS CORONARY INTERVENTION; ACUTE MYOCARDIAL-INFARCTION; NITRIC-OXIDE SYNTHASE; CARDIOMYOCYTE APOPTOSIS; HEART; MICRORNA; EXPRESSION; CARDIOPROTECTION; ATTENUATION; ACTIVATION	Background: Ischemic postconditioning (IPost) protects the reperfused heart from infarction which has drawn much attention recently. However, studies to date have rarely investigated the role of microRNAs (miRNAs) in IPost. The aims of this study were to investigate whether miR-21 is involved in the protective effect of IPost against myocardial ischemia-reperfusion (I/R) injury and disclose the potential molecular mechanisms involved. Methods and Results: We found that miR-21 was remarkably up-regulated in mouse hearts after IPost. To determine the protective role of IPost-induced miR-21 up-regulation, the mice were divided into the following four groups: I/R group; I/R+IPost group (I/R mice treated with IPost); Antagomir-21+IPost+I/R group (I/R mice treated with anagomir-21 and IPost); Scramble+IPost+I/R group (I/R mice treated with scramble and IPost). The results showed IPost could reduce I/R injury-induced infarct size of the left ventricle, improve cardiac function, and prevent myocardial apoptosis, while knockdown of miR-21 with antagomir-21 could reverse these protective effects of IPost against mouse I/R injury. Furthermore, we confirmed that miR-21 plays a protective role in myocardial apoptosis through PTEN/Akt signaling pathway, which was abrogated by the PI3K inhibitor LY294002. The protective effect of miR-21 on myocardial apoptosis was further revealed in mouse hearts after IPost treatment in vivo. Conclusions: Our data clearly demonstrate that miR-21 is involved in IPost-mediated cardiac protection against I/R injury and dysfunction through the PTEN/Akt signaling pathway in vivo. Identifying the beneficial roles of IPost-regulated miRNAs in cardiac protection, which may be a rational target selection for ischemic cardioprotection.	[Tu, Yingfeng; Wan, Lin; Wang, Kezheng; Bu, Lihong; Huang, Tao; Shen, Baozhong] Harbin Med Univ, Hosp 4, Dept Radiol, Harbin, Heilongjiang, Peoples R China; [Tu, Yingfeng; Wan, Lin; Wang, Kezheng; Bu, Lihong; Huang, Tao; Shen, Baozhong] Harbin Med Univ, Hosp 4, Key Lab Mol Imaging, Harbin, Heilongjiang, Peoples R China; [Tu, Yingfeng] Harbin Med Univ, Hosp 4, Dept Cardiol, Harbin, Heilongjiang, Peoples R China; [Fan, Yuhua] Harbin Med Univ, Affiliated Hosp 2, Inst Clin Pharmacol, Harbin, Heilongjiang, Peoples R China; [Cheng, Zhen] Stanford Univ, Mol Imaging Program Stanford, Dept Radiol, Stanford, CA 94305 USA; [Cheng, Zhen] Stanford Univ, Biox Program, Stanford, CA 94305 USA	Harbin Medical University; Harbin Medical University; Harbin Medical University; Harbin Medical University; Stanford University; Stanford University	Shen, BZ (corresponding author), Harbin Med Univ, Hosp 4, Dept Radiol, Harbin, Heilongjiang, Peoples R China.	shenbzh@vip.sina.com	Cheng, Zhen/K-2843-2012	Cheng, Zhen/0000-0001-8177-9463	National Natural Science Foundation of China [30970807, 31210103913]; Harbin Medical University [WLD-QN1120]; China Postdoctoral Science Foundation [2012M520765-119186]; Research Fund for the Doctoral Program of Higher Education of China [20112307120025]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Harbin Medical University; China Postdoctoral Science Foundation(China Postdoctoral Science Foundation); Research Fund for the Doctoral Program of Higher Education of China(Research Fund for the Doctoral Program of Higher Education of China (RFDP)Specialized Research Fund for the Doctoral Program of Higher Education (SRFDP))	This work was supported by National Natural Science Foundation of China (30970807), National Natural Science Foundation of China (31210103913), "Liande Wu Funding" of Harbin Medical University (WLD-QN1120), China Postdoctoral Science Foundation (2012M520765-119186), Research Fund for the Doctoral Program of Higher Education of China (20112307120025). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abbate A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027923; Ambros V, 2003, CELL, V113, P673, DOI 10.1016/S0092-8674(03)00428-8; Bai HT, 2011, FEBS LETT, V585, P402, DOI 10.1016/j.febslet.2010.12.027; Chen ZG, 2011, J CARDIOTHORAC SURG, V6, DOI 10.1186/1749-8090-6-80; Cheng YH, 2010, CARDIOVASC RES, V87, P431, DOI 10.1093/cvr/cvq082; Dong SM, 2009, J BIOL CHEM, V284, P29514, DOI 10.1074/jbc.M109.027896; Duan X, 2012, CARDIOLOGY, V122, P36, DOI 10.1159/000338149; Forouzanfar MH, 2012, GLOB HEART, V7, P331, DOI 10.1016/j.gheart.2012.10.003; Frank D, 2012, J MOL CELL CARDIOL, V52, P711, DOI 10.1016/j.yjmcc.2011.12.001; Gross GJ, 2009, AM J PHYSIOL-HEART C, V297, pH47, DOI 10.1152/ajpheart.01084.2008; Guo YR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041178; He B, 2011, J BIOMED SCI, V18, DOI 10.1186/1423-0127-18-22; Jabs A, 2010, CLIN HEMORHEOL MICRO, V45, P185, DOI 10.3233/CH-2010-1297; Zhang J, 2010, MOL MED, V16, P307, DOI 10.2119/molmed.2009.00121; Jujo K, 2013, CIRCULATION, V127, P63, DOI 10.1161/CIRCULATIONAHA.112.099242; Krutzfeldt J, 2005, NATURE, V438, P685, DOI 10.1038/nature04303; Lin XM, 2010, CHINESE MED J-PEKING, V123, P1833, DOI 10.3760/cma.j.issn.0366-6999.2010.14.002; Lonborg J, 2010, CIRC-CARDIOVASC INTE, V3, P34, DOI 10.1161/CIRCINTERVENTIONS.109.905521; Lu YJ, 2009, CARDIOVASC RES, V84, P434, DOI 10.1093/cvr/cvp232; Ma XJ, 2012, CORONARY ARTERY DIS, V23, P245, DOI 10.1097/MCA.0b013e3283526a7d; Mukhopadhyay P, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015705; Oudit GY, 2004, J MOL CELL CARDIOL, V37, P449, DOI 10.1016/j.yjmcc.2004.05.015; Pan ZW, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050515; Ren XP, 2009, CIRCULATION, V119, P2357, DOI 10.1161/CIRCULATIONAHA.108.814145; Roy S, 2009, CARDIOVASC RES, V82, P21, DOI 10.1093/cvr/cvp015; Ruan HM, 2009, J MOL CELL CARDIOL, V46, P193, DOI 10.1016/j.yjmcc.2008.10.021; Selvamani A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032662; Somers SJ, 2011, PHYSIOL RES, V60, P971, DOI 10.33549/physiolres.932129; Sumi S, 2010, AM J PHYSIOL-HEART C, V299, pH1174, DOI 10.1152/ajpheart.00116.2010; Sun DD, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033491; Sun HM, 2010, HEART SURG FORUM, V13, pE305, DOI 10.1532/HSF98.20101013; van Rooij E, 2008, P NATL ACAD SCI USA, V105, P13027, DOI 10.1073/pnas.0805038105; Wang XH, 2010, CIRCULATION, V122, P1308, DOI 10.1161/CIRCULATIONAHA.110.964684; Wu QL, 2012, SHOCK, V38, P165, DOI 10.1097/SHK.0b013e31825b5633; Xu XD, 2012, J CELL PHYSIOL, V227, P1391, DOI 10.1002/jcp.22852; Xue F, 2010, CLIN CARDIOL, V33, P439, DOI 10.1002/clc.20796; Yang BF, 2007, NAT MED, V13, P486, DOI 10.1038/nm1569; Yin C, 2009, CIRC RES, V104, P572, DOI 10.1161/CIRCRESAHA.108.193250; Zhuo CJ, 2011, MOL CELL BIOCHEM, V346, P39, DOI 10.1007/s11010-010-0589-0; Zu LY, 2011, AM J PHYSIOL-HEART C, V300, pH2177, DOI 10.1152/ajpheart.01138.2010	40	98	105	1	25	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 3	2013	8	10							e75872	10.1371/journal.pone.0075872	http://dx.doi.org/10.1371/journal.pone.0075872			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	232HM	24098402	Green Published, gold, Green Submitted			2023-01-03	WOS:000325483600025
J	Saha, D; Pal, A; Biswas, A; Panigrahi, R; Sarkar, N; Sarkar, J; Pal, M; Guha, SK; Saha, B; Chakrabarti, S; Chakravarty, R				Saha, Debraj; Pal, Ananya; Biswas, Avik; Panigrahi, Rajesh; Sarkar, Neelakshi; Sarkar, Jayeeta; Pal, Manisha; Guha, Subhasish Kamal; Saha, Bibhuti; Chakrabarti, Sekhar; Chakravarty, Runu			Characterization of Treatment-Naive HIV/HBV Co-Infected Patients Attending ART Clinic of a Tertiary Healthcare Centre in Eastern India	PLOS ONE			English	Article							HEPATITIS-B-VIRUS; HUMAN-IMMUNODEFICIENCY-VIRUS; INJECTION-DRUG USERS; VIRAL-HEPATITIS; BLOOD-DONORS; LIVER-DISEASE; GENOTYPES; HBV; ASSOCIATION; PREVALENCE	Objective: The study was designed to assess the hepatitis B virus (HBV) and hepatitis C virus (HCV) co-infection scenario among the human immunodeficiency virus (HIV) infected patients attending a tertiary healthcare unit in eastern India. Additionally, clinical and virological characterization of these viruses, prior to antiretroviral therapy (ART) initiation was also done for better understanding of the disease profile. Methods: Pool of ART-naive HIV/HBV co-infected and HIV mono-infected patients, participating in two different studies, were included in this study. HBV DNA was detected by nested-PCR amplification followed by HBV genotype determination and HBV reverse transcriptase (RT) region amplification and direct sequencing for detecting drug resistance. Results: The prevalence of HBsAg (11.3%) was higher compared to anti-HCV (1.9%) among the HIV infected ART-naive patients. Moreover, majority of the HBeAg positive HIV/HBV co-infected patients (87.7%) had HBV DNA >= 20,000 IU/ml with median HBV DNA significantly higher than that of HBeAg negative subjects (5.7 log(10) IU/ml vs. 4.2 log(10) IU/ml; p<0.0001). Multivariate analysis also showed that HBeAg-positive status was independently associated with higher HBV DNA level (p = <0.001). Notably, 60.9% of the HBeAg negative co-infected subjects had HBV DNA >= 2,000 IU/ml of which 37.0% had HBV DNA >= 20,000 IU/ml. Genotype HBV/D (68.2%) was the predominant genotype followed by HBV/A (24.3%) and HBV/C (7.5%). Anti-HBV drug resistant mutations were detected in two (3.8%) of the ART-naive patients. Conclusion: The prevalence of HIV/HBV co-infection was relatively higher in our study subjects. HBeAg testing might provide clue for early treatment initiation. Furthermore, HBeAg negative patients are also associated with high HBV DNA levels and therefore require appropriate medical attention. Pre-treatment screening for anti-HBV drug resistant mutations is not necessary before ART initiation.	[Saha, Debraj; Pal, Ananya; Biswas, Avik; Panigrahi, Rajesh; Sarkar, Neelakshi; Chakravarty, Runu] ICMR Virus Unit, Kolkata, India; [Sarkar, Jayeeta; Guha, Subhasish Kamal; Saha, Bibhuti] Calcutta Sch Trop Med, Kolkata, India; [Chakrabarti, Sekhar] Natl Inst Cholera & Enter Dis, Kolkata, India; [Pal, Manisha] Univ Calcutta, Dept Stat, Kolkata, India	Indian Council of Medical Research (ICMR); ICMR - National Institute of Cholera & Enteric Diseases (NICED); ICMR - Virus Unit, Kolkata; Calcutta School of Tropical Medicine (CSTM); Indian Council of Medical Research (ICMR); ICMR - National Institute of Cholera & Enteric Diseases (NICED); University of Calcutta	Chakravarty, R (corresponding author), ICMR Virus Unit, ID & BG Hosp Campus, Kolkata, India.	runugc@gmail.com	PAL, MRINAL/ABG-9676-2020	PAL, MRINAL/0000-0002-1032-272X; Panigrahi, Rajesh/0000-0002-6704-0029	Department of Biotechnology, Government of India [BT/PR14485/Med/29/203/2010]; Indian Council of Medical Research [HIV/50/128/2010-ECD-II, 29/3/11]	Department of Biotechnology, Government of India(Department of Biotechnology (DBT) India); Indian Council of Medical Research(Indian Council of Medical Research (ICMR))	Funded by Department of Biotechnology, Government of India (No. BT/PR14485/Med/29/203/2010), and the part of clinical trial (IRIS ID No. 200905630) was funded by Indian Council of Medical Research (No. HIV/50/128/2010-ECD-II, 29/3/11). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Acharya SK, 2006, NATL MED J INDIA, V19, P203; Alter MJ, 2006, J HEPATOL, V44, pS6, DOI 10.1016/j.jhep.2005.11.004; Banerjee A, 2005, INTERVIROLOGY, V48, P389, DOI 10.1159/000086066; Banerjee A, 2006, WORLD J GASTROENTERO, V12, P5964, DOI 10.3748/wjg.v12.i37.5964; Biswas A, 2009, HEPATOL RES, V39, P53, DOI 10.1111/j.1872-034X.2008.00403.x; Biswas A, 2011, J MED VIROL, V83, P253, DOI 10.1002/jmv.21979; Chandra PK, 2007, INTERVIROLOGY, V50, P173, DOI 10.1159/000098960; Chauhan R, 2006, J MED VIROL, V78, P1047, DOI 10.1002/jmv.20661; Chelleng PK, 2008, INDIAN J MED RES, V128, P640; Clements CJ, 2010, B WORLD HEALTH ORGAN, V88, P66, DOI 10.2471/BLT.08.065722; Corbet S, 2003, J CLIN MICROBIOL, V41, P1091, DOI 10.1128/JCM.41.3.1091-1100.2003; Datta S, 2006, EMERG INFECT DIS, V12, P1954; de Vries-Sluijs TEMS, 2010, GASTROENTEROLOGY, V139, P1934, DOI 10.1053/j.gastro.2010.08.045; Gandhe SS, 2003, J MED VIROL, V69, P324, DOI 10.1002/jmv.10292; Gupta S, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-53; Idoko J, 2007, CLIN INFECT DIS, V49, P1268; Iser D. M., 2009, HIV Therapy, V3, P405, DOI 10.2217/HIV.09.19; Jobarteh M, 2010, VIROL J, V7, DOI 10.1186/1743-422X-7-230; Koziel MJ, 2007, NEW ENGL J MED, V356, P1445, DOI 10.1056/NEJMra065142; KWOK S, 1989, NATURE, V339, P237, DOI 10.1038/339237a0; Locarnini S, 2008, HEPATOL INT, V2, P147, DOI 10.1007/s12072-008-9048-3; Lok ASF, 2009, HEPATOLOGY, V50, P661, DOI 10.1002/hep.23190; National AIDS Control Organization (NACO), 2012, NACO ANN REP 2011 20, P2011; Neuschwander-Tetri BA, 2003, HEPATOLOGY, V37, P1202, DOI 10.1053/jhep.2003.50193; Pal A, 2013, VIROLOGY, V436, P134, DOI 10.1016/j.virol.2012.11.003; Panigrahi R, 2010, VIROL J, V7, DOI 10.1186/1743-422X-7-204; Rockstroh JK, 2008, HIV MED, V9, P82, DOI 10.1111/j.1468-1293.2007.00535.x; Saha MK, 2000, INDIAN J MED RES, V111, P37; Sellier P, 2010, J CLIN VIROL, V47, P13, DOI 10.1016/j.jcv.2009.10.010; Sheldon J, 2008, J ANTIMICROB CHEMOTH, V61, P766, DOI 10.1093/jac/dkn014; Soriano V, 2010, ANTIVIR RES, V85, P303, DOI 10.1016/j.antiviral.2009.10.021; Soriano V, 2010, J ANTIMICROB CHEMOTH, V65, P548, DOI 10.1093/jac/dkp479; Thibault V, 2002, AIDS, V16, P131, DOI 10.1097/00002030-200201040-00020; Thio CL, 2013, AIDS, V27, P191, DOI 10.1097/QAD.0b013e32835a9984; Trevino A, 2009, AIDS RES HUM RETROV, V25, P1273, DOI 10.1089/aid.2009.0119; Tuma P, 2011, ANTIVIR THER, V16, P585, DOI 10.3851/IMP1778; Vivekanandan P, 2004, CLIN INFECT DIS, V38, pE81, DOI 10.1086/383144; Weber R, 2006, ARCH INTERN MED, V166, P1632, DOI 10.1001/archinte.166.15.1632; Yan YX, 2011, EPIDEMIOL INFECT, V139, P354, DOI 10.1017/S0950268810001597	39	17	17	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 30	2013	8	8							e73613	10.1371/journal.pone.0073613	http://dx.doi.org/10.1371/journal.pone.0073613			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	211BX	24023688	Green Published, Green Submitted, gold			2023-01-03	WOS:000323880200085
J	Wang, LL; Zheng, WS; Chen, SH; Fang, XQ				Wang, Lu-Lu; Zheng, Wen-Sheng; Chen, Shao-Hua; Fang, Xia-Qin			Development of In Situ Gelling and Bio Adhesive 5-Fluorouracil Enema	PLOS ONE			English	Article							ACETAMINOPHEN LIQUID SUPPOSITORY; SURFACE-ENERGY ANALYSIS; RADIATION-THERAPY; DRUG-DELIVERY; PREOPERATIVE IRRADIATION; SODIUM-CHLORIDE; POLOXAMER GELS; RECTAL-CANCER; CARCINOMA; RELEASE	In this study, a novel 5-Fluorouracil (5-FU) enema with good bio adhesion and temperature sensitivity was developed using in situ gelling technology. The preparation was formulated as a free-flowing liquid before use, while a layer of gel film was quickly formed when administered in the rectum, with a large contact surface area. It also demonstrated good biocompatibility, appropriate gel strength and bio adhesive force with excellent adhesion to rectal mucosa and prolonged action time, allowing more effective drug absorption and diffusion to surrounding tissues. Poloxamer 407 and poloxamer 188 were applied to adjust the gelling temperature. With the addition of carbopol and polycarbophil (bio adhesive substances), the solubility of 5-FU and gel strength increased, the temperature of gelation and the surface area of drug contact on mucous epithelium decreased. Decreased adhesive force between the preparation and the mucous membrane of the rectum was demonstrated with improving carbopol and polycarbophil's concentration. In vitro release demonstrated that 5-FU in situ gelling enema with different bases had a rapid and almost complete drug release. We used an optimized formulation of P407/P188/polycarbophil/5-FU (17/2.5/0.2/1.0) for animal experiments. The result showed that the drug evenly covered the surface of the rectum and there was no leakage in 6 hours. The in situ gelling enema showed significantly higher rectal tissue levels of 5-FU compared with suppository and intravenous administration, indicating that 5-FU could be well absorbed due to the enlarged releasing area, longer retention time and larger amount of dissolved active ingredients. Systemically, 5-FU levels in the enema group were similar to those in the suppository group and significantly lower than the intravenous group. The enema was not associated with morphological damage to rectal tissue. These results suggest that the bio adhesive and in situ gelling enema could be a more effective rectal delivery system of 5-FU.	[Zheng, Wen-Sheng] Chinese Acad Med Sci, Inst Mat Med, Beijing 100050, Peoples R China; Peking Union Med Coll, Beijing City Key Lab Drug Delivery Technol & Nove, Beijing 100021, Peoples R China	Chinese Academy of Medical Sciences - Peking Union Medical College; Institute of Materia Medica - CAMS; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College	Zheng, WS (corresponding author), Chinese Acad Med Sci, Inst Mat Med, Beijing 100050, Peoples R China.	zhengwensheng@imm.ac.cn						Anderson BC, 2001, J CONTROL RELEASE, V70, P157, DOI 10.1016/S0168-3659(00)00341-2; ANDERSON JH, 1992, BRIT J CANCER, V65, P133, DOI 10.1038/bjc.1992.26; Barakat NS, 2009, AAPS PHARMSCITECH, V10, P724, DOI 10.1208/s12249-009-9261-y; BOUBLIL JL, 1985, BRIT J CANCER, V52, P15, DOI 10.1038/bjc.1985.142; Charrueau C, 2001, DRUG DEV IND PHARM, V27, P351, DOI 10.1081/DDC-100103735; Chen MJ, 2012, INT J COLORECTAL DIS, V27, P869, DOI 10.1007/s00384-011-1393-3; Choi HG, 1998, INT J PHARM, V165, P33, DOI 10.1016/S0378-5173(97)00386-4; Choi HG, 1998, INT J PHARM, V165, P23, DOI 10.1016/S0378-5173(97)00385-2; DUCHENE D, 1988, DRUG DEV IND PHARM, V14, P283, DOI 10.3109/03639048809151972; El-Kamel A, 2006, DRUG DELIV, V13, P143, DOI 10.1080/10717540500316003; ESPOSITO P, 1994, BIOMATERIALS, V15, P177, DOI 10.1016/0142-9612(94)90064-7; FRAILE RJ, 1980, CANCER RES, V40, P2223; Galandiuk S, 1996, ANN SURG ONCOL, V3, P270, DOI 10.1007/BF02306282; Ganguly S, 2004, INT J PHARMACEUT, V276, P83, DOI 10.1016/j.ijpharm.2004.02.014; GU JM, 1988, CRC CR REV THER DRUG, V5, P21; Havaldar, 2009, INT J CHEM TECH RES, V1, P953; Hearan SJun HW, 1996, INT J PHARM, V129, P13; Jeong B, 2002, ADV DRUG DELIVER REV, V54, P37, DOI 10.1016/S0169-409X(01)00242-3; JUNGINGER HE, 1991, PHARM IND, V53, P1056; Keny R.V., 2010, INT J PHARM BIO SCI, V1, P1; Kim CK, 1998, INT J PHARM, V174, P201, DOI 10.1016/S0378-5173(98)00258-0; Koffi AA, 2008, EUR J PHARM BIOPHARM, V69, P167, DOI 10.1016/j.ejpb.2007.09.017; Krishnaiah YSR, 2002, EUR J PHARM SCI, V16, P185, DOI 10.1016/S0928-0987(02)00081-7; L MA, 1994, CHINESE J PHARM, P433; LANDRY JC, 1993, RADIOLOGY, V188, P423, DOI 10.1148/radiology.188.2.8327689; LEHR CM, 1992, PHARMACEUT RES, V9, P70, DOI 10.1023/A:1018931811189; LEHR CM, 1993, EUR J PHARM SCI, V1, P19, DOI 10.1016/0928-0987(93)90014-2; Leung SS, 1990, POLYM NEWS, V15, P333; Lu GW, 1998, INT J PHARM, V160, P1, DOI 10.1016/S0378-5173(97)00187-7; Mayol L, 2011, BIOMACROMOLECULES, V12, P28, DOI 10.1021/bm1008958; MINSKY BD, 1993, INT J RADIAT ONCOL, V25, P821, DOI 10.1016/0360-3016(93)90311-I; Nieto NL, 2010, EUR J PHARM SCI, V80, P585; NISHIOKA B, 1980, Japanese Journal of Surgery, V10, P110, DOI 10.1007/BF02468674; Pandit NK, 1998, INT J PHARM, V167, P183, DOI 10.1016/S0378-5173(98)00074-X; Park YJ, 2003, INT J PHARM, V263, P105, DOI 10.1016/S0378-5173(03)00362-4; PEPPAS N A, 1985, Journal of Controlled Release, V2, P257, DOI 10.1016/0168-3659(85)90050-1; Percarpio B, 1992, Conn Med, V56, P7; PHILLIPS TA, 1980, J PHARM SCI, V69, P1428, DOI 10.1002/jps.2600691220; Reanmongkol W, 2011, ASIAN BIOMED, V5, P269, DOI 10.5372/1905-7415.0502.037; RICH TA, 1985, J CLIN ONCOL, V3, P402, DOI 10.1200/JCO.1985.3.3.402; ROBERT C, 1988, ACTA PHARM TECHNOL, V34, P95; Rougler P, 1993, ANN ONCOL, V4, P821; Ryu JM, 1999, J CONTROL RELEASE, V59, P163, DOI 10.1016/S0168-3659(98)00189-8; Sanders NN, 2000, J PHARM SCI-US, V89, P835, DOI 10.1002/1520-6017(200007)89:7<835::AID-JPS1>3.0.CO;2-6; Schmoll HJ, 1999, SEMIN ONCOL, V26, P589; Shulka HS, 1977, AM J SURG, V133, P346; SHUMATE CR, 1993, CANCER-AM CANCER SOC, V71, P3690, DOI 10.1002/1097-0142(19930601)71:11<3690::AID-CNCR2820711136>3.0.CO;2-H; SMART JD, 1984, J PHARM PHARMACOL, V36, P295, DOI 10.1111/j.2042-7158.1984.tb04377.x; TAKAHASHI T, 1982, AM J SURG, V143, P183, DOI 10.1016/0002-9610(82)90062-9; TAKAHASHI T, 1988, AM J SURG, V156, P58, DOI 10.1016/S0002-9610(88)80173-9; Theodore M, 2000, J CONTROL RELEASE, V67, P191; Watanabe S, 1980, JPN J SURG, V10, P17; Yong CS, 2004, EUR J PHARM SCI, V23, P347, DOI 10.1016/j.ejps.2004.08.008; Yong CS, 2001, INT J PHARM, V226, P195, DOI 10.1016/S0378-5173(01)00809-2; Yuan Y, 2012, INT J PHARMACEUT, V430, P114, DOI 10.1016/j.ijpharm.2012.03.054; Yun MO, 1999, INT J PHARM, V189, P137, DOI 10.1016/S0378-5173(99)00227-6	56	6	6	0	20	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 16	2013	8	8							e71037	10.1371/journal.pone.0071037	http://dx.doi.org/10.1371/journal.pone.0071037			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	207BA	23976976	Green Published, gold, Green Submitted			2023-01-03	WOS:000323570200018
J	Fitzgerald, P; Leonard, H; Pikora, TJ; Bourke, J; Hammond, G				Fitzgerald, Patrick; Leonard, Helen; Pikora, Terri J.; Bourke, Jenny; Hammond, Geoffrey			Hospital Admissions in Children with Down Syndrome: Experience of a Population-Based Cohort Followed from Birth	PLOS ONE			English	Article								Objective: Children with Down syndrome, the most common genetic cause of intellectual disability, are prone to multiple and varied health-related problems. This study describes patterns of hospitalisations for children and young people with Down syndrome in Western Australia. Methods: Birth records were linked to the Western Australian population-based Intellectual Disability database to identify all children born with Down syndrome in Western Australia between 1 January, 1983 and 31 December, 1999. These records were linked to the Hospital Morbidity Data System to provide information on all hospitalisations up to 31 December, 2004. Hospitalisation data, coded using ICD-9CM or ICD-10 (v0.5) were grouped into clinically relevant categories using the primary diagnosis. Rates of hospital admission for all and specific diagnoses were expressed in 1000-person-years at-risk and median age at first admission and length of stay were calculated. Results: Of the 405 children, 395 had one or more hospital admissions, totalling 3786 admissions for all children and an estimated 39.5 person-years in hospital. On average, children were admitted 9.7 times, with an estimated rate of 757.2 admissions per 1000pyr (95% CI: 680, 843). A quarter of all admissions occurred in the first year of life. The average hospital length of stay was 3.8 days (95% CI: 3.7, 4.1). Upper respiratory tract conditions affected the most children (58.5%) and accounted for 12.1% of all admissions. Other disorders which affected a high percentage of children were ear/hearing conditions (50.6%), disorders of the oral cavity (38.0%) and lower respiratory tract conditions (37.5%). Overall, children with Down syndrome were hospitalised at a rate five times (95% CI = 4.3-6.2) that of the general population. Conclusion: Children with Down syndrome are at increased risk of morbidity for varied causes underlining the importance of comprehensive and targeted primary care for this group.	[Fitzgerald, Patrick; Leonard, Helen; Pikora, Terri J.; Bourke, Jenny; Hammond, Geoffrey] Univ Western Australia, Ctr Child Hlth Res, Telethon Inst Child Hlth Res, Crawley, WA, Australia	Telethon Kids Institute; University of Western Australia	Leonard, H (corresponding author), Univ Western Australia, Ctr Child Hlth Res, Telethon Inst Child Hlth Res, Crawley, WA, Australia.	hleonard@ichr.uwa.edu.au	Pikora, Terri/AAB-1759-2019; Leonard, Helen/A-1010-2013	Pikora, Terri/0000-0002-9099-1607; Leonard, Helen/0000-0001-6405-5834	Australian National Health and Medical Research Council (NHMRC) [572742]; NHMRC [572568]	Australian National Health and Medical Research Council (NHMRC)(National Health and Medical Research Council (NHMRC) of Australia); NHMRC(National Health and Medical Research Council (NHMRC) of Australia)	Funding was provided by the Australian National Health and Medical Research Council (NHMRC, http://www.nhmrc.gov.au/) Program Grants 572742, NHMRC Research Fellowship (572568) (to HL). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Agresti A., 2007, INTRO CATEGORICAL DA, V2nd; Bergholdt R, 2006, DIABETOLOGIA, V49, P1179, DOI 10.1007/s00125-006-0231-6; Bloemers BLP, 2007, PEDIATRICS, V120, pE1076, DOI 10.1542/peds.2007-0788; Bower C, 2011, W AUSTR REGISTER DEV; Cleves MA, 2007, BIRTH DEFECTS RES A, V79, P657, DOI 10.1002/bdra.20393; Colvin L, 2009, BMC PEDIATR, V9, DOI 10.1186/1471-2431-9-32; De Hingh YCM, 2005, J PEDIATR-US, V147, P744, DOI 10.1016/j.jpeds.2005.07.022; Driscoll Carlie, 2003, Australian and New Zealand Journal of Audiology, V25, P85, DOI 10.1375/audi.25.2.85.31120; Foley KR, CHILD CARE HLTH DEV; Frid C, 2002, J INTELL DISABIL RES, V46, P310, DOI 10.1046/j.1365-2788.2002.00392.x; Geelhoed EA, 2011, J PEDIATR-US, V159, P541, DOI 10.1016/j.jpeds.2011.06.007; Goldacre MJ, 2004, ARCH DIS CHILD, V89, P1014, DOI 10.1136/adc.2003.046219; Guazzarotti L, 2009, AJIDD-AM J INTELLECT, V114, P100, DOI 10.1352/2009.114.100-109; Hill DA, 2003, ARCH INTERN MED, V163, P705, DOI 10.1001/archinte.163.6.705; Hilton JM, 1999, J PAEDIATR CHILD H, V35, P383, DOI 10.1046/j.1440-1754.1999.00386.x; Holman CDJ, 1999, AUST NZ J PUBL HEAL, V23, P453, DOI 10.1111/j.1467-842X.1999.tb01297.x; Irving CA, 2012, ARCH DIS CHILD, V97, P326, DOI 10.1136/adc.2010.210534; Joyce A, 2009, 27 ANN REPORT W AUST; Klein JP, 2003, SURVIVAL ANAL TECHNI, V2nd, DOI DOI 10.1007/B97377; Kruger E, 2006, AUST DENT J, V51, P231, DOI 10.1111/j.1834-7819.2006.tb00434.x; Kupferman JC, 2009, PEDIATRICS, V124, pE615, DOI 10.1542/peds.2009-0181; Leonard S, 1999, DEV MED CHILD NEUROL, V41, P683, DOI 10.1017/S0012162299001401; Leonard S, 2000, PAEDIATR PERINAT EP, V14, P163; Maatta Tuomo, 2006, Downs Syndr Res Pract, V11, P78, DOI 10.3104/reports.317; MARCELL MM, 1995, J INTELL DISABIL RES, V39, P215, DOI 10.1111/j.1365-2788.1995.tb00504.x; Microsoft Corporation, 2010, EXC 2010 VERS 14; Milne E, 2008, INT J CANCER, V122, P1130, DOI 10.1002/ijc.23226; National Coding Centre, 1996, AUSTR VERS INT CLASS; O'Leary P, 2006, AUST NZ J OBSTET GYN, V46, P427, DOI 10.1111/j.1479-828X.2006.00629.x; OLeary P, 1996, AUST NZ J OBSTET GYN, V36, P385, DOI 10.1111/j.1479-828X.1996.tb02176.x; Patja K, 2006, INT J CANCER, V118, P1769, DOI 10.1002/ijc.21518; Petterson B, 2005, ANN HUM BIOL, V32, P237, DOI 10.1080/03014460500075035; Ram G, 2011, CLIN EXP IMMUNOL, V164, P9, DOI 10.1111/j.1365-2249.2011.04335.x; Roizen NJ, 2003, LANCET, V361, P1281, DOI 10.1016/S0140-6736(03)12987-X; Schieve LA, 2009, PEDIATRICS, V123, pE253, DOI 10.1542/peds.2008-1440; Shott SR, 2006, AM J MED GENET C, V142C, P131, DOI 10.1002/ajmg.c.30095; Silva D, 1999, SPECIFIC CHILD ADOLE; Silva D, 1999, CHILD ADOLESCENT HLT; Slack-Smith L, 2009, ARCH DIS CHILD, V94, P517, DOI 10.1136/adc.2008.145672; So SA, 2007, J INTELL DISABIL RES, V51, P1030, DOI 10.1111/j.1365-2788.2007.01013.x; StataCorp, 2019, STATA STAT SOFTWARE; Sullivan SG, 2007, J INTELL DISABIL RES, V51, P228, DOI 10.1111/j.1365-2788.2006.00862.x; Thomas K, 2011, J PEDIATR-US, V158, P194, DOI 10.1016/j.jpeds.2010.08.045; Thomas K, 2010, INT REV RES MENT RET, V39, P67, DOI 10.1016/S0074-7750(10)39003-3; Van Cleve Susan N, 2006, J Pediatr Health Care, V20, P47, DOI 10.1016/j.pedhc.2005.10.004; van Trotsenburg ASP, 2006, PEDIATRICS, V118, P1633, DOI 10.1542/peds.2006-1136; Venail F, 2004, CLIN PEDIATR, V43, P783, DOI 10.1177/000992280404300902; Williams K, 2005, ARCH DIS CHILD, V90, P1243, DOI 10.1136/adc.2004.062422; Zachariah P, 2012, J PEDIATR-US, V160, P827, DOI 10.1016/j.jpeds.2011.11.004; Zeller B, 2005, BRIT J HAEMATOL, V128, P797, DOI 10.1111/j.1365-2141.2005.05398.x	50	47	47	0	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 13	2013	8	8							e70401	10.1371/journal.pone.0070401	http://dx.doi.org/10.1371/journal.pone.0070401			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	201BN	23967074	Green Submitted, Green Published, gold			2023-01-03	WOS:000323115800006
J	Annane, D; Siami, S; Jaber, S; Martin, C; Elatrous, S; Declere, AD; Preiser, JC; Outin, H; Troche, G; Charpentier, C; Trouillet, JL; Kimmoun, A; Forceville, X; Darmon, M; Lesur, O; Regnier, J; Abroug, F; Berger, P; Clec'h, C; Cousson, J; Thibault, L; Chevret, S				Annane, Djillali; Siami, Shidasp; Jaber, Samir; Martin, Claude; Elatrous, Souheil; Declere, Adrien Descorps; Preiser, Jean Charles; Outin, Herve; Troche, Gilles; Charpentier, Claire; Trouillet, Jean Louis; Kimmoun, Antoine; Forceville, Xavier; Darmon, Michael; Lesur, Olivier; Regnier, Jean; Abroug, Fekri; Berger, Philippe; Clec'h, Christophe; Cousson, Joel; Thibault, Laure; Chevret, Sylvie		CRISTAL Investigators	Effects of Fluid Resuscitation With Colloids vs Crystalloids on Mortality in Critically Ill Patients Presenting With Hypovolemic Shock The CRISTAL Randomized Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HYDROXYETHYL STARCH; ACUTE PHYSIOLOGY; KIDNEY INJURY; SEPSIS; SALINE; SCORE; CLASSIFICATION; ASSOCIATION; ALBUMIN	IMPORTANCE Evidence supporting the choice of intravenous colloid vs crystalloid solutions for management of hypovolemic shock remains unclear. OBJECTIVE To test whether use of colloids compared with crystalloids for fluid resuscitation alters mortality in patients admitted to the intensive care unit (ICU) with hypovolemic shock. DESIGN, SETTING, AND PARTICIPANTS A multicenter, randomized clinical trial stratified by case mix (sepsis, trauma, or hypovolemic shock without sepsis or trauma). Therapy in the Colloids Versus Crystalloids for the Resuscitation of the Critically Ill (CRISTAL) trial was open label but outcome assessment was blinded to treatment assignment. Recruitment began in February 2003 and ended in August 2012 of 2857 sequential ICU patients treated at 57 ICUs in France, Belgium, North Africa, and Canada; follow-up ended in November 2012. INTERVENTIONS Colloids (n = 1414; gelatins, dextrans, hydroxyethyl starches, or 4% or 20% of albumin) or crystalloids (n = 1443; isotonic or hypertonic saline or Ringer lactate solution) for all fluid interventions other than fluid maintenance throughout the ICU stay. MAIN OUTCOMES AND MEASURES The primary outcome was death within 28 days. Secondary outcomes included 90-day mortality; and days alive and not receiving renal replacement therapy, mechanical ventilation, or vasopressor therapy. RESULTS Within 28 days, there were 359 deaths (25.4%) in colloids group vs 390 deaths (27.0%) in crystalloids group (relative risk [RR], 0.96 [95% CI, 0.88 to 1.04]; P = .26). Within 90 days, there were 434 deaths (30.7%) in colloids group vs 493 deaths (34.2%) in crystalloids group (RR, 0.92 [95% CI, 0.86 to 0.99]; P = .03). Renal replacement therapy was used in 156 (11.0%) in colloids group vs 181 (12.5%) in crystalloids group (RR, 0.93 [95% CI, 0.83 to 1.03]; P = .19). There were more days alive without mechanical ventilation in the colloids group vs the crystalloids group by 7 days (mean: 2.1 vs 1.8 days, respectively; mean difference, 0.30 [95% CI, 0.09 to 0.48] days; P = .01) and by 28 days (mean: 14.6 vs 13.5 days; mean difference, 1.10 [95% CI, 0.14 to 2.06] days; P = .01) and alive without vasopressor therapy by 7 days (mean: 5.0 vs 4.7 days; mean difference, 0.30 [95% CI, -0.03 to 0.50] days; P = .04) and by 28 days (mean: 16.2 vs 15.2 days; mean difference, 1.04 [95% CI, -0.04 to 2.10] days; P = .03). CONCLUSIONS AND RELEVANCE Among ICU patients with hypovolemia, the use of colloids vs crystalloids did not result in a significant difference in 28-day mortality. Although 90-day mortality was lower among patients receiving colloids, this finding should be considered exploratory and requires further study before reaching conclusions about efficacy.	[Annane, Djillali] Hop Raymond Poincare, Garches, France; [Siami, Shidasp] CH Etampes, Etampes, France; [Jaber, Samir] CHU Montpelier, Montpellier, France; [Martin, Claude] AP HM Hop Nord, Marseille, France; [Elatrous, Souheil] EPS Taher Sfar Mahdia, Mahdia, Tunisia; [Declere, Adrien Descorps] Antoine Beclere, Clamart, France; [Preiser, Jean Charles] CHU Liege, Liege, Belgium; [Outin, Herve] CHI Poissy St Germain, Poissy, France; [Troche, Gilles] CH Andre Mignot, Versailles, France; [Charpentier, Claire] Hop Cent, Nancy, France; [Trouillet, Jean Louis] Pitie Salpetriere, Paris, France; [Kimmoun, Antoine] Hop Brabois, Nancy, France; [Forceville, Xavier] CH Meaux, Meaux, France; [Darmon, Michael; Chevret, Sylvie] Hop St Louis, Paris, France; [Lesur, Olivier] CH Sherbrooke, Sherbrooke, PQ, Canada; [Regnier, Jean] CH Roche Sur Yon, Roche Sur Yon, France; [Abroug, Fekri] CHU Monastir, Monastir, Tunisia; [Berger, Philippe] CH Chalons Champagne, Champagne, France; [Clec'h, Christophe] Hop Avicenne, F-93009 Bobigny, France; [Cousson, Joel] CHU Reims, Reims, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Raymond-Poincare - APHP; Universite de Montpellier; CHU de Montpellier; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Antoine-Beclere - APHP; University of Liege; Hospital Chi of Poissy Saint Germain; Centre Hospitalier de Versailles; CHU de Nancy; CHU de Nancy; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; CHD Vendee; Universite de Monastir; Hopital Fattouma Bourguiba; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Avicenne - APHP; Universite Paris 13; CHU de Reims	Annane, D (corresponding author), Univ Versailles, 104 Blvd Raymond Poincare, F-92380 Garches, France.	djillali.annane@rpc.aphp.fr	Preiser, Jean-Charles/AAL-2355-2021; Kimmoun, Antoine/ADQ-2174-2022; Abroug, Fekri/ABI-6564-2022; Abroug, Fekri/ADJ-0934-2022; Annane, Djillali/R-7947-2019	Preiser, Jean-Charles/0000-0003-3163-0390; Abroug, Fekri/0000-0002-5626-5329; Darmon, Michael/0000-0003-4198-8038; chevret, sylvie/0000-0001-6449-4730; Troche, Gilles/0000-0002-8150-6630	French Ministry of Health, Programme Hospitalier de Recherche Clinique [AOM 01 020]	French Ministry of Health, Programme Hospitalier de Recherche Clinique	The study was funded by the French Ministry of Health, Programme Hospitalier de Recherche Clinique 2001 and 2010 (AOM 01 020).	[Anonymous], COCHRANE DATABASE SY; [Anonymous], 1992, DESIGN ANAL SEQUENTI; BONE RC, 1992, CRIT CARE MED, V20, P864, DOI 10.1097/00003246-199206000-00025; Brunkhorst FM, 2008, NEW ENGL J MED, V358, P125, DOI 10.1056/NEJMoa070716; Cox B. G, 1972, FUNDAMENTAL MECHANIS, P13; Delaney AP, 2011, CRIT CARE MED, V39, P386, DOI 10.1097/CCM.0b013e3181ffe217; Dellinger RP, 2013, CRIT CARE MED, V41, P580, DOI 10.1097/CCM.0b013e31827e83af; Finfer S, 2004, NEW ENGL J MED, V350, P2247; Finfer S, 2010, CRIT CARE, V14, DOI 10.1186/cc9293; Kim Y, 2000, J TRAUMA, V48, P280, DOI 10.1097/00005373-200002000-00014; KNAUS WA, 1981, CRIT CARE MED, V9, P591, DOI 10.1097/00003246-198108000-00008; LEGALL JR, 1993, JAMA-J AM MED ASSOC, V270, P2957, DOI 10.1001/jama.270.24.2957; Martin GS, 2004, AM J RESP CRIT CARE, V170, P1247, DOI 10.1164/rccm.200208-909ST; MCCABE WR, 1962, ARCH INTERN MED, V110, P847, DOI 10.1001/archinte.1962.03620240029006; Myburgh JA, 2012, NEW ENGL J MED, V367, P1901, DOI 10.1056/NEJMoa1209759; Oliveira RP, 2002, CRIT CARE, V6, P418, DOI 10.1186/cc1541; Perel P, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000567.pub6; Perner A, 2012, NEW ENGL J MED, V367, P124, DOI 10.1056/NEJMoa1204242; Vincent JL, 1996, INTENS CARE MED, V22, P707, DOI 10.1007/BF01709751; WEINBERG PF, 1984, AM REV RESPIR DIS, V130, P791; Yunos NM, 2012, JAMA-J AM MED ASSOC, V308, P1566, DOI 10.1001/jama.2012.13356; Zarychanski R, 2013, JAMA-J AM MED ASSOC, V309, P678, DOI 10.1001/jama.2013.430	22	391	417	1	64	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 6	2013	310	17					1809	1817		10.1001/jama.2013.280502	http://dx.doi.org/10.1001/jama.2013.280502			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	246PH	24108515	Bronze			2023-01-03	WOS:000326550900014
J	Leutheuser, H; Schuldhaus, D; Eskofier, BM				Leutheuser, Heike; Schuldhaus, Dominik; Eskofier, Bjoern M.			Hierarchical, Multi-Sensor Based Classification of Daily Life Activities: Comparison with State-of-the-Art Algorithms Using a Benchmark Dataset	PLOS ONE			English	Article							PHYSICAL-ACTIVITY; ACTIVITY RECOGNITION; WALKING; PREVENTION; PATTERNS; SENSOR; SPORTS; HEALTH	Insufficient physical activity is the 4th leading risk factor for mortality. Methods for assessing the individual daily life activity (DLA) are of major interest in order to monitor the current health status and to provide feedback about the individual quality of life. The conventional assessment of DLAs with self-reports induces problems like reliability, validity, and sensitivity. The assessment of DLAs with small and light-weight wearable sensors (e. g. inertial measurement units) provides a reliable and objective method. State-of-the-art human physical activity classification systems differ in e. g. the number and kind of sensors, the performed activities, and the sampling rate. Hence, it is difficult to compare newly proposed classification algorithms to existing approaches in literature and no commonly used dataset exists. We generated a publicly available benchmark dataset for the classification of DLAs. Inertial data were recorded with four sensor nodes, each consisting of a triaxial accelerometer and a triaxial gyroscope, placed on wrist, hip, chest, and ankle. Further, we developed a novel, hierarchical, multi-sensor based classification system for the distinction of a large set of DLAs. Our hierarchical classification system reached an overall mean classification rate of 89.6% and was diligently compared to existing state-of-the-art algorithms using our benchmark dataset. For future research, the dataset can be used in the evaluation process of new classification algorithms and could speed up the process of getting the best performing and most appropriate DLA classification system.	[Leutheuser, Heike; Schuldhaus, Dominik; Eskofier, Bjoern M.] Univ Erlangen Nurnberg, Digital Sports Grp, Pattern Recognit Lab, Dept Comp Sci, Nurnberg, Germany	University of Erlangen Nuremberg	Leutheuser, H (corresponding author), Univ Erlangen Nurnberg, Digital Sports Grp, Pattern Recognit Lab, Dept Comp Sci, Nurnberg, Germany.	heike.leutheuser@cs.fau.de; dominik.schuldhaus@cs.fau.de	Leutheuser, Heike/GYJ-1186-2022; Eskofier, Bjoern/ABF-1284-2021	Eskofier, Bjoern/0000-0002-0417-0336	Bavarian Ministry for Economic Affairs, Infrastructure, Transport, and Technology; European fund for regional development [IUK-1103-0012//IUK383/001]; adidas AG; Deutsche Forschungsgemeinschaft; Friedrich-Alexander-University Erlangen-Nuremberg	Bavarian Ministry for Economic Affairs, Infrastructure, Transport, and Technology; European fund for regional development(European Commission); adidas AG; Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Friedrich-Alexander-University Erlangen-Nuremberg	This work was supported by the Bavarian Ministry for Economic Affairs, Infrastructure, Transport, and Technology and the European fund for regional development (grant number: IUK-1103-0012//IUK383/001; http://www.stmwivt.bayern.de/themen/). Financial and technical support of the study were provided by adidas AG. We acknowledge support by Deutsche Forschungsgemeinschaft and Friedrich-Alexander-University Erlangen-Nuremberg within the funding program Open Access Publishing. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adams R, 1999, CAN FAM PHYSICIAN, V45, P992; Agostini G, 2003, EURASIP J APPL SIG P, V2003, P5, DOI 10.1155/S1110865703210118; Ainsworth BE, 2011, MED SCI SPORT EXER, V43, P1575, DOI 10.1249/MSS.0b013e31821ece12; AINSWORTH BE, 1993, MED SCI SPORT EXER, V25, P71, DOI 10.1249/00005768-199301000-00011; Ainsworth BE, 2000, MED SCI SPORT EXER, V32, pS498, DOI 10.1097/00005768-200009001-00009; Altun K, 2010, LECT NOTES COMPUT SC, V6219, P38, DOI 10.1007/978-3-642-14715-9_5; Bao L, 2004, LECT NOTES COMPUT SC, V3001, P1, DOI 10.1007/978-3-540-24646-6_1; BERLIN JA, 1990, AM J EPIDEMIOL, V132, P612, DOI 10.1093/oxfordjournals.aje.a115704; Blair SN, 2001, MED SCI SPORT EXER, V33, pS379, DOI 10.1097/00005768-200106001-00007; Burns A, 2010, IEEE SENS J, V10, P1527, DOI 10.1109/JSEN.2010.2045498; Duda R.O., 2000, PATTERN CLASSIFICATI, V2nd; Ermes M, 2008, IEEE T INF TECHNOL B, V12, P20, DOI 10.1109/TITB.2007.899496; Karantonis DM, 2006, IEEE T INF TECHNOL B, V10, P156, DOI 10.1109/TITB.2005.856864; Koskimaki H, 2009, MED C CONTR AUTOMAT, P401, DOI 10.1109/MED.2009.5164574; Lee IM, 2000, AM J EPIDEMIOL, V151, P293, DOI 10.1093/oxfordjournals.aje.a010205; Liu SP, 2012, IEEE T BIO-MED ENG, V59, P687, DOI 10.1109/TBME.2011.2178070; Mannini A, 2010, SENSORS-BASEL, V10, P1154, DOI 10.3390/s100201154; Mariani B, 2010, J BIOMECH, V43, P2999, DOI 10.1016/j.jbiomech.2010.07.003; Najafi B, 2003, IEEE T BIO-MED ENG, V50, P711, DOI 10.1109/TBME.2003.812189; Nyan MN, 2006, J BIOMECH, V39, P2647, DOI 10.1016/j.jbiomech.2005.08.014; Ogden CL, 2006, JAMA-J AM MED ASSOC, V295, P1549, DOI 10.1001/jama.295.13.1549; Oguma Y, 2002, BRIT J SPORT MED, V36, P162, DOI 10.1136/bjsm.36.3.162; Parkka J, 2006, IEEE T INF TECHNOL B, V10, P119, DOI 10.1109/TITB.2005.856863; PATE RR, 1995, JAMA-J AM MED ASSOC, V273, P402, DOI 10.1001/jama.273.5.402; Peng HC, 2005, IEEE T PATTERN ANAL, V27, P1226, DOI 10.1109/TPAMI.2005.159; Physical Activity Guidelines Advisory Committee, 2008, PHYS ACT GUID ADV CO; POWELL KE, 1987, ANNU REV PUBL HEALTH, V8, P253, DOI 10.1146/annurev.publhealth.8.1.253; Preece SJ, 2009, IEEE T BIO-MED ENG, V56, P871, DOI 10.1109/TBME.2008.2006190; Ravi N., 2005, P 17 C INN APPL ART, P1541, DOI DOI 10.1007/978-3-642-02481-8_120; Schuldhaus D, 2012, INT C PATT RECOG, P2258; Sekine M, 2000, MED ENG PHYS, V22, P285, DOI 10.1016/S1350-4533(00)00041-2; Sekine M, 2002, IEEE T NEUR SYS REH, V10, P188, DOI 10.1109/TNSRE.2002.802879; Shephard RJ, 2003, BRIT J SPORT MED, V37, P197, DOI 10.1136/bjsm.37.3.197; Tamura T, 1997, METHOD INFORM MED, V36, P356; Theodoridis S, 2009, PATTERN RECOGNITION, 4RTH EDITION, P1; Trost SG, 2005, MED SCI SPORT EXER, V37, pS531, DOI 10.1249/01.mss.0000185657.86065.98; Wang N, 2007, P ANN INT IEEE EMBS, P4899, DOI 10.1109/IEMBS.2007.4353438; Warburton DER, 2006, CAN MED ASSOC J, V174, P801, DOI 10.1503/cmaj.051351; Ward DS, 2005, MED SCI SPORT EXER, V37, pS582, DOI 10.1249/01.mss.0000185292.71933.91; Warren JM, 2010, EUR J CARDIOV PREV R, V17, P127, DOI 10.1097/HJR.0b013e32832ed875; Wing RR, 1999, MED SCI SPORT EXER, V31, pS547, DOI 10.1097/00005768-199911001-00010; Witten IH, 2011, MOR KAUF D, P1	43	107	109	1	18	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 9	2013	8	10							e75196	10.1371/journal.pone.0075196	http://dx.doi.org/10.1371/journal.pone.0075196			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	236PJ	24130686	Green Published, gold, Green Submitted			2023-01-03	WOS:000325810900019
J	Picca, A; Pesce, V; Fracasso, F; Joseph, AM; Leeuwenburgh, C; Lezza, AMS				Picca, Anna; Pesce, Vito; Fracasso, Flavio; Joseph, Anna-Maria; Leeuwenburgh, Christiaan; Lezza, Angela M. S.			Aging and Calorie Restriction Oppositely Affect Mitochondrial Biogenesis through TFAM Binding at Both Origins of Mitochondrial DNA Replication in Rat Liver	PLOS ONE			English	Article							TRANSCRIPTION FACTOR-A; HEAVY-STRAND PROMOTER; PEROXIREDOXIN-III; PHENOTYPIC ALTERATIONS; OXIDATIVE STRESS; SKELETAL-MUSCLE; AGE; EXPRESSION; BRAIN; NEURODEGENERATION	Aging affects mitochondria in a tissue-specific manner. Calorie restriction (CR) is, so far, the only intervention able to delay or prevent the onset of several age-related changes also in mitochondria. Using livers from middle age (18-month-old), 28-month-old and 32-month-old ad libitum-fed and 28-month-old calorie-restricted rats we found an age-related decrease in mitochondrial DNA (mtDNA) content and mitochondrial transcription factor A (TFAM) amount, fully prevented by CR. We revealed also an age-related decrease, completely prevented by CR, for the proteins PGC-1 alpha NRF-1 and cytochrome c oxidase subunit IV, supporting the efficiency of CR to forestall the age-related decrease in mitochondrial biogenesis. Furthermore, CR counteracted the age-related increase in oxidative damage to proteins, represented by the increased amount of oxidized peroxiredoxins (PRX-SO3) in the ad libitum-fed animals. An unexpected age-related decrease in the mitochondrial proteins peroxiredoxin III (Prx III) and superoxide dismutase 2 (SOD2), usually induced by increased ROS and involved in mitochondrial biogenesis, suggested a prevailing relevance of the age-reduced mitochondrial biogenesis above the induction by ROS in the regulation of expression of these genes with aging. The partial prevention of the decrease in Prx III and SOD2 proteins by CR also supported the preservation of mitochondrial biogenesis in the anti-aging action of CR. To investigate further the age- and CR-related effects on mitochondrial biogenesis we analyzed the in vivo binding of TFAM to specific mtDNA regions and demonstrated a marked increase in the TFAM-bound amounts of mtDNA at both origins of replication with aging, fully prevented by CR. A novel, positive correlation between the paired amounts of TFAM-bound mtDNA at these sub-regions was found in the joined middle age ad libitum-fed and 28-month-old calorie-restricted groups, but not in the 28-month-old ad libitum-fed counterpart suggesting a quite different modulation of TFAM binding at both origins of replication in aging and CR.	[Picca, Anna; Joseph, Anna-Maria; Leeuwenburgh, Christiaan] Univ Florida, Div Biol Aging, Inst Aging, Dept Aging & Geriatr Res, Gainesville, FL USA; [Pesce, Vito; Fracasso, Flavio; Lezza, Angela M. S.] Univ Bari, Dept Biosci Biotechnol & Biopharmaceut, Bari, Italy	State University System of Florida; University of Florida; Universita degli Studi di Bari Aldo Moro	Lezza, AMS (corresponding author), Univ Bari, Dept Biosci Biotechnol & Biopharmaceut, Bari, Italy.	angelamariaserena.lezza@uniba.it	Picca, Anna/K-2305-2018	Picca, Anna/0000-0001-7032-3487; PESCE, VITO/0000-0002-9148-3129; Leeuwenburgh, Christiaan/0000-0003-0826-4257	University of Florida Institute on Aging; Claude D. Pepper Older Americans Independence Center [1 P30 AG028740];  [NIA R01 AG17994]; NATIONAL INSTITUTE ON AGING [R01AG017994, P30AG028740] Funding Source: NIH RePORTER	University of Florida Institute on Aging; Claude D. Pepper Older Americans Independence Center; ; NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This research was supported by grants to CL (NIA R01 AG17994), the University of Florida Institute on Aging and the Claude D. Pepper Older Americans Independence Center (1 P30 AG028740). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Anderson RM, 2008, AGING CELL, V7, P101, DOI 10.1111/j.1474-9726.2007.00357.x; Aspnes LE, 1997, FASEB J, V11, P573, DOI 10.1096/fasebj.11.7.9212081; Barazzoni R, 2000, J BIOL CHEM, V275, P3343, DOI 10.1074/jbc.275.5.3343; Barja G, 2007, REJUV RES, V10, P215, DOI 10.1089/rej.2006.0516; Barrientos A, 1997, MOL BRAIN RES, V52, P284, DOI 10.1016/S0169-328X(97)00278-7; Bua EA, 2004, FASEB J, V18, P582, DOI 10.1096/fj.03-0668fje; Canugovi C, 2010, DNA REPAIR, V9, P1080, DOI 10.1016/j.dnarep.2010.07.009; Cassano P, 2006, REJUV RES, V9, P211, DOI 10.1089/rej.2006.9.211; Cassano P, 2004, ANN NY ACAD SCI, V1019, P269, DOI 10.1196/annals.1297.045; Chang TS, 2004, J BIOL CHEM, V279, P41975, DOI 10.1074/jbc.M407707200; Chiribau CB, 2008, J BIOL CHEM, V283, P8211, DOI 10.1074/jbc.M710610200; Civitarese AE, 2007, PLOS MED, V4, P485, DOI 10.1371/journal.pmed.0040076; DAIRAGHI DJ, 1995, BBA-MOL BASIS DIS, V1271, P127, DOI 10.1016/0925-4439(95)00019-Z; Dinardo MM, 2003, BIOCHEM BIOPH RES CO, V301, P187, DOI 10.1016/S0006-291X(02)03008-5; Druzhyna NM, 2008, MECH AGEING DEV, V129, P383, DOI 10.1016/j.mad.2008.03.002; FISHER RP, 1988, MOL CELL BIOL, V8, P3496, DOI 10.1128/MCB.8.8.3496; GADALETA MN, 1990, EUR J BIOCHEM, V187, P501, DOI 10.1111/j.1432-1033.1990.tb15331.x; Gredilla R, 2001, J BIOENERG BIOMEMBR, V33, P279, DOI 10.1023/A:1010603206190; Guarente L, 2008, CELL, V132, P171, DOI 10.1016/j.cell.2008.01.007; HARMAN D, 1972, J AM GERIATR SOC, V20, P145, DOI 10.1111/j.1532-5415.1972.tb00787.x; Hebert AS, 2013, MOL CELL, V49, P186, DOI 10.1016/j.molcel.2012.10.024; Huang JH, 2009, IUBMB LIFE, V61, P201, DOI 10.1002/iub.164; Huh JY, 2012, ANTIOXID REDOX SIGN, V16, P229, DOI [10.1089/ars.2010.3766, 10.1089/ars.2011.3952]; Hwang IK, 2010, FREE RADICAL BIO MED, V48, P1242, DOI 10.1016/j.freeradbiomed.2010.02.007; Kang CM, 1998, FREE RADICAL BIO MED, V24, P148, DOI 10.1016/S0891-5849(97)00204-9; Kanki T, 2004, MOL CELL BIOL, V24, P9823, DOI 10.1128/MCB.24.22.9823-9834.2004; Kaufman BA, 2007, MOL BIOL CELL, V18, P3225, DOI 10.1091/mbc.E07-05-0404; Larsson NG, 1998, NAT GENET, V18, P231, DOI 10.1038/ng0398-231; Lezza Angela M S, 2012, [Frontiers in Biology, 生物学前沿], V7, P30; LINNANE AW, 1989, LANCET, V1, P642, DOI 10.1016/S0140-6736(89)92145-4; Lodeiro MF, 2012, P NATL ACAD SCI USA, V109, P6513, DOI 10.1073/pnas.1118710109; Lopez-Torres M, 2002, FREE RADICAL BIO MED, V32, P882, DOI 10.1016/S0891-5849(02)00773-6; Masoro EJ, 2000, EXP GERONTOL, V35, P299, DOI 10.1016/S0531-5565(00)00084-X; McInerny SC, 2009, MECH AGEING DEV, V130, P343, DOI 10.1016/j.mad.2009.01.008; MIGUEL J, 1986, ALAN REV LISS, P51; Musicco C, 2009, BBA-BIOENERGETICS, V1787, P890, DOI 10.1016/j.bbabio.2009.03.002; Navarro A, 2007, AM J PHYSIOL-CELL PH, V292, pC670, DOI 10.1152/ajpcell.00213.2006; Navarro A, 2010, FRONT AGING NEUROSCI, V2, DOI 10.3389/fnagi.2010.00034; Paradies G, 2010, FREE RADICAL BIO MED, V48, P1286, DOI 10.1016/j.freeradbiomed.2010.02.020; PARISI MA, 1991, SCIENCE, V252, P965, DOI 10.1126/science.2035027; Pesce V, 2001, FREE RADICAL BIO MED, V30, P1223, DOI 10.1016/S0891-5849(01)00517-2; Pesce V, 2005, J GERONTOL A-BIOL, V60, P715, DOI 10.1093/gerona/60.6.715; Pesce V, 2012, REJUV RES, V15, P136, DOI 10.1089/rej.2011.1255; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; PICCA A, 2012, DORDR AGE       0904, DOI DOI 10.1007/S11357-012-9465-Z; Sahin E, 2012, NAT REV MOL CELL BIO, V13, P397, DOI 10.1038/nrm3352; Scarpulla RC, 2002, BBA-GENE STRUCT EXPR, V1576, P1, DOI 10.1016/S0167-4781(02)00343-3; Shutt TE, 2011, TRANSCR-AUSTIN, V2, P55, DOI 10.4161/trns.2.2.14296; St-Pierre J, 2006, CELL, V127, P397, DOI 10.1016/j.cell.2006.09.024; Storz P, 2005, MOL CELL BIOL, V25, P8520, DOI 10.1128/MCB.25.19.8520-8530.2005; Stuart JA, 2004, FASEB J, V18, P595, DOI 10.1096/fj.03-0890fje; Van Houten B, 2006, DNA REPAIR, V5, P145, DOI 10.1016/j.dnarep.2005.03.002; Vercauteren K, 2006, MOL CELL BIOL, V26, P7409, DOI 10.1128/MCB.00585-06; WALLACE DC, 1992, SCIENCE, V256, P628, DOI 10.1126/science.1533953; Woo DK, 2012, AM J PATHOL, V180, P24, DOI 10.1016/j.ajpath.2011.10.003; Yoshida Y, 2002, BIOCHEM BIOPH RES CO, V295, P945, DOI 10.1016/S0006-291X(02)00757-X; Zollo O, 2012, P NATL ACAD SCI USA, V109, P6508, DOI 10.1073/pnas.1118594109	57	51	53	0	17	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 13	2013	8	9							e74644	10.1371/journal.pone.0074644	http://dx.doi.org/10.1371/journal.pone.0074644			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	218BU	24058615	Green Published, gold, Green Submitted			2023-01-03	WOS:000324408400092
J	Yang, Z; Garcia, A; Xu, SL; Powell, DR; Vertino, PM; Singh, S; Marcus, AI				Yang, Zhen; Garcia, Anapatricia; Xu, Songli; Powell, Doris R.; Vertino, Paula M.; Singh, Shivendra; Marcus, Adam I.			Withania somnifera Root Extract Inhibits Mammary Cancer Metastasis and Epithelial to Mesenchymal Transition	PLOS ONE			English	Article							BREAST-CANCER; WITHAFERIN-A; PROGNOSTIC-SIGNIFICANCE; INTERMEDIATE-FILAMENTS; REGULATED EXPRESSION; VIMENTIN EXPRESSION; UP-REGULATION; CELL-CYCLE; CARCINOMA; APOPTOSIS	Though clinicians can predict which patients are at risk for developing metastases, traditional therapies often prove ineffective and metastatic disease is the primary cause of cancer patient death; therefore, there is a need to develop anti-metastatic therapies that can be administered over long durations to specifically inhibit the motility of cancer cells. Withania somnifera root extracts (WRE) have anti-proliferative activity and the active component, Withaferin A, inhibits the pro-metastatic protein, vimentin. Vimentin is an intermediate filament protein and is part of the epithelial to mesenchymal transition (EMT) program to promote metastasis. Here, we determined whether WRE standardized to Withaferin A (sWRE) possesses anti-metastatic activity and whether it inhibits cancer motility via inhibition of vimentin and the EMT program. Several formulations of sWRE were created to enrich for Withaferin A and a stock solution of sWRE in EtOH could recover over 90% of the Withaferin A found in the original extract powder. This sWRE formulation inhibited breast cancer cell motility and invasion at concentrations less than 1 mu M while having negligible cytotoxicity at this dose. sWRE treatment disrupted vimentin morphology in cell lines, confirming its vimentin inhibitory activity. To determine if sWRE inhibited EMT, TGF-beta was used to induce EMT in MCF10A human mammary epithelial cells. In this case, sWRE prevented EMT induction and inhibited 3-D spheroid invasion. These studies were taken into a human xenograft and mouse mammary carcinoma model. In both models, sWRE and Withaferin A showed dose-dependent inhibition of tumor growth and metastatic lung nodule formation with minimal systemic toxicity. Taken together, these data support the hypothesis that low concentrations of sWRE inhibit cancer metastasis potentially through EMT inhibition. Moreover, these doses of sWRE have nearly no toxicity in normal mouse organs, suggesting the potential for clinical use of orally administered WRE capsules.	[Yang, Zhen; Xu, Songli; Marcus, Adam I.] Emory Univ, Sch Med, Dept Hematol & Med Oncol, Winship Canc Inst, Atlanta, GA 30322 USA; [Garcia, Anapatricia] Emory Univ, Sch Med, Yerkes Natl Primate Res Ctr, Atlanta, GA USA; [Powell, Doris R.; Vertino, Paula M.] Emory Univ, Dept Radiat Oncol, Winship Canc Inst, Sch Med, Atlanta, GA USA; [Singh, Shivendra] Univ Pittsburgh, Dept Pharmacol & Chem Biol, Sch Med, Pittsburgh, PA USA; [Singh, Shivendra] Univ Pittsburgh, Sch Med, Inst Canc, Pittsburgh, PA USA	Emory University; Emory University; Emory University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Marcus, AI (corresponding author), Emory Univ, Sch Med, Dept Hematol & Med Oncol, Winship Canc Inst, Atlanta, GA 30322 USA.	aimarcu@emory.edu			National Center for Complementary and Alternative Medicine [1R21AT005231]; Godfrey Charitable Trust; Golfer's Against Cancer; P30 CCSG [3P30CA138292]; NATIONAL CANCER INSTITUTE [P30CA138292, R01CA077337] Funding Source: NIH RePORTER; NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE [R21AT005231] Funding Source: NIH RePORTER	National Center for Complementary and Alternative Medicine(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); Godfrey Charitable Trust; Golfer's Against Cancer; P30 CCSG; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine)	This work was supported by an R21 from the National Center for Complementary and Alternative Medicine (1R21AT005231) awarded to AIM, the Godfrey Charitable Trust, and Golfer's Against Cancer. This work was also supported by a P30 CCSG awarded to the Winship Cancer Institute (3P30CA138292). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Al-Saad S, 2008, BRIT J CANCER, V99, P1476, DOI 10.1038/sj.bjc.6604713; Ali M, 1997, PHYTOCHEMISTRY, V44, P1163, DOI 10.1016/S0031-9422(96)00656-5; ANDREOLI JM, 1995, CELL MOTIL CYTOSKEL, V32, P10, DOI 10.1002/cm.970320103; Bacac M, 2008, ANNU REV PATHOL-MECH, V3, P221, DOI 10.1146/annurev.pathmechdis.3.121806.151523; Bargagna-Mohan P, 2007, CHEM BIOL, V14, P623, DOI 10.1016/j.chembiol.2007.04.010; Chaffer CL, 2011, SCIENCE, V331, P1559, DOI 10.1126/science.1203543; Chang L, 2004, NAT REV MOL CELL BIO, V5, P601, DOI 10.1038/nrm1438; Chen MHS, 2008, MODERN PATHOL, V21, P1183, DOI 10.1038/modpathol.2008.90; Choo Jennifer R, 2010, Cancers (Basel), V2, P1040, DOI 10.3390/cancers2021040; Christina AJM, 2004, J ETHNOPHARMACOL, V93, P359, DOI 10.1016/j.jep.2004.04.004; Chung BM, 2013, CURR OPIN CELL BIOL, V25, P600, DOI 10.1016/j.ceb.2013.06.008; COLUCCIGUYON E, 1994, CELL, V79, P679, DOI 10.1016/0092-8674(94)90553-3; Das Chaurasiya N, 2008, PHYTOCHEM ANALYSIS, V19, P148, DOI 10.1002/pca.1029; Dauphin M, 2013, LUNG CANCER, V81, P117, DOI 10.1016/j.lungcan.2013.03.011; Domagala W, 1996, CLIN CANCER RES, V2, P147; Eckes B, 2000, J CELL SCI, V113, P2455; Fan LY, 2012, SCAND J RHEUMATOL, V41, P354, DOI 10.3109/03009742.2012.670263; Grin B, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039065; Grogan PT, 2013, INVEST NEW DRUG, V31, P545, DOI 10.1007/s10637-012-9888-5; Gunasinghe NPAD, 2012, CANCER METAST REV, V31, P469, DOI 10.1007/s10555-012-9377-5; Hahm ER, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023354; Hardy KM, 2010, J MAMMARY GLAND BIOL, V15, P191, DOI 10.1007/s10911-010-9172-2; Holwell TA, 1997, J CELL SCI, V110, P1947; Hu L, 2004, ONCOGENE, V23, P298, DOI 10.1038/sj.onc.1206483; Jones SE, 2008, CLIN BREAST CANCER, V8, P224, DOI 10.3816/CBC.2008.n.025; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Koduru S, 2010, MOL CANCER THER, V9, P202, DOI 10.1158/1535-7163.MCT-09-0771; Kusinska RU, 2009, J EXP CLIN CANC RES, V28, DOI 10.1186/1756-9966-28-118; Lahat G, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010105; Lee J, 2010, CARCINOGENESIS, V31, P1991, DOI 10.1093/carcin/bgq175; Leyon PV, 2004, PHYTOTHER RES, V18, P118, DOI 10.1002/ptr.1378; Liu LK, 2010, MODERN PATHOL, V23, P213, DOI 10.1038/modpathol.2009.160; Liu ZD, 1997, BIOCHEM BIOPH RES CO, V231, P283, DOI 10.1006/bbrc.1997.6083; Lund N, 2010, BIOCHEM BIOPH RES CO, V395, P401, DOI 10.1016/j.bbrc.2010.04.033; Mathur R, 2006, J ETHNOPHARMACOL, V105, P336, DOI 10.1016/j.jep.2005.11.020; Mayola E, 2011, APOPTOSIS, V16, P1014, DOI 10.1007/s10495-011-0625-x; Misra L, 2008, PHYTOCHEMISTRY, V69, P1000, DOI 10.1016/j.phytochem.2007.10.024; Mohan Royce, 2004, Angiogenesis, V7, P115, DOI 10.1007/s10456-004-1026-3; Munagala R, 2011, CARCINOGENESIS, V32, P1697, DOI 10.1093/carcin/bgr192; Muralikrishnan G, 2010, IMMUNOL INVEST, V39, P688, DOI 10.3109/08820139.2010.487083; Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008; Prakash J, 2002, NUTR CANCER, V42, P91, DOI 10.1207/S15327914NC421_12; Prakash J, 2001, PHYTOTHER RES, V15, P240, DOI 10.1002/ptr.779; Rodriguez Luis G., 2004, V294, P23; Roxanis I, 2013, J CLIN PATHOL, V66, P517, DOI 10.1136/jclinpath-2012-201348; SARRIA AJ, 1990, J CELL BIOL, V111, P553, DOI 10.1083/jcb.111.2.553; Sarrio D, 2008, CANCER RES, V68, P989, DOI 10.1158/0008-5472.CAN-07-2017; Senthilnathan P, 2006, CHEM-BIOL INTERACT, V159, P180, DOI 10.1016/j.cbi.2005.11.003; Singh S, 2003, CANCER RES, V63, P2306; Soltermann A, 2008, CLIN CANCER RES, V14, P7430, DOI 10.1158/1078-0432.CCR-08-0935; Srinivasan S, 2007, CANCER RES, V67, P246, DOI 10.1158/0008-5472.CAN-06-2430; Stan SD, 2008, CANCER RES, V68, P7661, DOI 10.1158/0008-5472.CAN-08-1510; Stan SD, 2008, NUTR CANCER, V60, P51, DOI 10.1080/01635580802381477; Sun BC, 2008, CLIN CANCER RES, V14, P7050, DOI 10.1158/1078-0432.CCR-08-0520; Takebe N, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2876; Taylor MA, 2010, J MAMMARY GLAND BIOL, V15, P169, DOI 10.1007/s10911-010-9181-1; Thaiparambil JT, 2012, MOL CELL BIOL, V32, P3203, DOI 10.1128/MCB.00418-12; Thaiparambil JT, 2011, INT J CANCER, V129, P2744, DOI 10.1002/ijc.25938; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Tomaskovic-Crook E, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2416; Urn HJ, 2012, BIOCHEM BIOPH RES CO, V427, P24, DOI 10.1016/j.bbrc.2012.08.133; Vanden Berghe W, 2012, BIOCHEM PHARMACOL, V84, P1282, DOI 10.1016/j.bcp.2012.08.027; Viale Giuseppe, 2009, Eur J Cancer, V45 Suppl 1, P5, DOI 10.1016/S0959-8049(09)70011-5; Wang JW, 2009, CANCER LETT, V281, P71, DOI 10.1016/j.canlet.2009.02.020; Wei JC, 2008, ANTICANCER RES, V28, P327; Yamashita N, 2013, J CANCER RES CLIN, V139, P739, DOI 10.1007/s00432-013-1376-6; Zeisberg M, 2009, J CLIN INVEST, V119, P1429, DOI 10.1172/JCI36183	67	38	40	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 12	2013	8	9							e75069	10.1371/journal.pone.0075069	http://dx.doi.org/10.1371/journal.pone.0075069			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	242KO	24069380	Green Published, gold, Green Submitted, Green Accepted			2023-01-03	WOS:000326240100120
J	Rosell, A; Morancho, A; Navarro-Sobrino, M; Martinez-Saez, E; Hernandez-Guillamon, M; Lope-Piedrafita, S; Barcelo, V; Borras, F; Penalba, A; Garcia-Bonilla, L; Montaner, J				Rosell, Anna; Morancho, Anna; Navarro-Sobrino, Miriam; Martinez-Saez, Elena; Hernandez-Guillamon, Mar; Lope-Piedrafita, Silvia; Barcelo, Veronica; Borras, Francesc; Penalba, Anna; Garcia-Bonilla, Lidia; Montaner, Joan			Factors Secreted by Endothelial Progenitor Cells Enhance Neurorepair Responses after Cerebral Ischemia in Mice	PLOS ONE			English	Article							STEM-CELLS; STROKE; NEUROGENESIS; ANGIOGENESIS; INJURY; TRANSPLANTATION	Cell therapy with endothelial progenitor cells (EPCs) has emerged as a promising strategy to regenerate the brain after stroke. Here, we aimed to investigate if treatment with EPCs or their secreted factors could potentiate angiogenesis and neurogenesis after permanent focal cerebral ischemia in a mouse model of ischemic stroke. BALB/C male mice were subjected to distal occlusion of the middle cerebral artery, and EPCs, cell-free conditioned media (CM) obtained from EPCs, or vehicle media were administered one day after ischemia. Magnetic resonance imaging (MRI) was performed at baseline to confirm that the lesions were similar between groups. Immunohistochemical and histological evaluation of the brain was performed to evaluate angio-neurogenesis and neurological outcome at two weeks. CM contained growth factors, such as VEGF, FGF-b and PDGF-bb. A significant increase in capillary density was noted in the peri-infarct areas of EPC- and CM-treated animals. Bielschowsky's staining revealed a significant increase in axonal rewiring in EPC-treated animals compared with shams, but not in CM-treated mice, in close proximity with DCX-positive migrating neuroblasts. At the functional level, post-ischemia forelimb strength was significantly improved in animals receiving EPCs or CM, but not in those receiving vehicle media. In conclusion, we demonstrate for the first time that the administration of EPC-secreted factors could become a safe and effective cell-free option to be considered in future therapeutic strategies for stroke.	[Rosell, Anna; Morancho, Anna; Navarro-Sobrino, Miriam; Hernandez-Guillamon, Mar; Barcelo, Veronica; Penalba, Anna; Garcia-Bonilla, Lidia; Montaner, Joan] Univ Autonoma Barcelona, Neurovasc Res Lab, Dept Neurol, Vall dHebron Res Inst, E-08193 Barcelona, Catalonia, Spain; [Rosell, Anna; Morancho, Anna; Navarro-Sobrino, Miriam; Hernandez-Guillamon, Mar; Barcelo, Veronica; Penalba, Anna; Garcia-Bonilla, Lidia; Montaner, Joan] Univ Autonoma Barcelona, Dept Internal Med, Vall dHebron Res Inst, E-08193 Barcelona, Catalonia, Spain; [Martinez-Saez, Elena; Borras, Francesc] Hosp Valle De Hebron, Dept Pathol, Neuropathol Unit, Barcelona, Catalonia, Spain; [Lope-Piedrafita, Silvia] Univ Autonoma Barcelona, Serv RMN, Cerdanyola Del Valles, Catalonia, Spain; [Lope-Piedrafita, Silvia] Ctr Invest Biomed Red Bioingn Biomat & Nanomed CI, Cerdanyola Del Valles, Catalonia, Spain	Autonomous University of Barcelona; Hospital Universitari Vall d'Hebron; Vall d'Hebron Institut de Recerca (VHIR); Autonomous University of Barcelona; Hospital Universitari Vall d'Hebron; Vall d'Hebron Institut de Recerca (VHIR); Hospital Universitari Vall d'Hebron; Autonomous University of Barcelona; CIBER - Centro de Investigacion Biomedica en Red; CIBERBBN	Rosell, A (corresponding author), Univ Autonoma Barcelona, Neurovasc Res Lab, Dept Neurol, Vall dHebron Res Inst, E-08193 Barcelona, Catalonia, Spain.	anna.rosell@vhir.org	Lope-Piedrafita, Silvia/I-4808-2012; Montaner, Joan/D-3063-2015; Borràs, Francesc E/P-2287-2017; Retana, Anna Morancho/K-8804-2014; Martinez-Saez, Elena/E-9097-2018	Lope-Piedrafita, Silvia/0000-0002-8127-6425; Montaner, Joan/0000-0003-4845-2279; Borràs, Francesc E/0000-0003-4038-1912; Retana, Anna Morancho/0000-0001-9059-3206; Martinez-Saez, Elena/0000-0001-6004-5364; Hernandez Guillamon, Maria Mar/0000-0001-8844-0091; Rosell Novel, Anna/0000-0003-1082-3599	Miguel Servetprogramme from the Spanish Ministry of Health (Instituto de Salud Carlos III) [CP09/00265]; Spanish Ministry of Health (Instituto de Salud Carlos III); Fondo de InvestigacionesSanitarias [PI10/00694]; Spanish stroke research network RENEVAS [RD06/0026/0010]; EUROSALUD programme (MICCIN); European Union [201024, 202213]	Miguel Servetprogramme from the Spanish Ministry of Health (Instituto de Salud Carlos III); Spanish Ministry of Health (Instituto de Salud Carlos III)(Instituto de Salud Carlos IIISpanish Government); Fondo de InvestigacionesSanitarias(Instituto de Salud Carlos III); Spanish stroke research network RENEVAS; EUROSALUD programme (MICCIN); European Union(European Commission)	AR is supported by the Miguel Servetprogramme (CP09/00265) from the Spanish Ministry of Health (Instituto de Salud Carlos III). LGB holds a Sara Borrell grant, and EMS holds a Rio Ortega grant from the Spanish Ministry of Health (Instituto de Salud Carlos III). This work has been supported by research grants from the Fondo de InvestigacionesSanitarias (PI10/00694), the Spanish stroke research network RENEVAS (RD06/0026/0010) and EUROSALUD programme (MICCIN). The research leading to these results has received funding from the European Union's Seventh Framework Programme (FP7/2007-2013) under grant agreement numbers 201024 and 202213 (European Stroke Network). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Andres RH, 2011, BRAIN, V134, P1777, DOI 10.1093/brain/awr094; Asahara T, 1997, SCIENCE, V275, P964, DOI 10.1126/science.275.5302.964; Bang OY, 2005, ANN NEUROL, V57, P874, DOI 10.1002/ana.20501; Battistella V, 2011, REGEN MED, V6, P45, DOI 10.2217/RME.10.97; Carmichael ST, 2008, STROKE, V39, P1380, DOI 10.1161/STROKEAHA.107.499962; Di Santo S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005643; Fan YF, 2010, ANN NEUROL, V67, P488, DOI 10.1002/ana.21919; Guo QM, 2009, BRAIN RES, V1279, P121, DOI 10.1016/j.brainres.2009.04.055; Hayakawa K, 2012, P NATL ACAD SCI USA, V109, P7505, DOI 10.1073/pnas.1121146109; Horie N, 2011, STEM CELLS, V29, P274, DOI 10.1002/stem.584; Jiang Q, 2006, NEUROIMAGE, V32, P1080, DOI 10.1016/j.neuroimage.2006.05.025; Kim JY, 2010, CELL TRANSPLANT, V19, P1635, DOI 10.3727/096368910X516637; Kondziolka D, 2005, J NEUROSURG, V103, P38, DOI 10.3171/jns.2005.103.1.0038; Le Bihan D, 2001, J MAGN RESON IMAGING, V13, P534, DOI 10.1002/jmri.1076; Liu HS, 2011, NEUROIMAGE, V56, P280, DOI 10.1016/j.neuroimage.2011.02.049; Lodi D, 2011, J EXP CLIN CANC RES, V30, DOI 10.1186/1756-9966-30-9; Molina CA, 2011, STROKE, V42, pS16, DOI 10.1161/STROKEAHA.110.598763; Moniche F, 2012, STROKE, V43, P2242, DOI 10.1161/STROKEAHA.112.659409; Morancho A, 2012, NEUROPATH APPL NEURO, V38, P617, DOI 10.1111/j.1365-2990.2012.01252.x; Moubarik C, 2011, STEM CELL REV REP, V7, P208, DOI 10.1007/s12015-010-9157-y; Navarro-Sobrino M, 2010, MICROVASC RES, V80, P317, DOI 10.1016/j.mvr.2010.05.008; Ohab JJ, 2008, NEUROSCIENTIST, V14, P369, DOI 10.1177/1073858407309545; Ohab JJ, 2006, J NEUROSCI, V26, P13007, DOI 10.1523/JNEUROSCI.4323-06.2006; Ohta T, 2006, NEUROSURGERY, V59, P679, DOI 10.1227/01.NEU.0000229058.08706.88; Pepper MS, 1997, ARTERIOSCL THROM VAS, V17, P605, DOI 10.1161/01.ATV.17.4.605; Rosell A, 2013, TRANSL STROKE RES, V4, P297, DOI 10.1007/s12975-012-0234-1; Rosell A, 2009, J CEREBR BLOOD F MET, V29, P933, DOI 10.1038/jcbfm.2009.17; Seminatore C, 2010, STROKE, V41, P153, DOI 10.1161/STROKEAHA.109.563015; Shen Q, 2004, SCIENCE, V304, P1338, DOI 10.1126/science.1095505; Shimamura M, 2004, CIRCULATION, V109, P424, DOI 10.1161/01.CIR.0000109496.82683.49; Taguchi A, 2004, J CLIN INVEST, V114, P330, DOI 10.1172/jci200420622; Ward NL, 2007, J APPL PHYSIOL, V102, P1927, DOI 10.1152/japplphysiol.00909.2006; Yan R, 2011, SWISS MED WKLY, V141, DOI 10.4414/smw.2011.13314; Yanamoto H, 1996, BRAIN RES, V718, P207, DOI 10.1016/0006-8993(96)00122-9; Zhang ZG, 2000, J CLIN INVEST, V106, P829, DOI 10.1172/JCI9369	35	79	82	0	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 4	2013	8	9							e73244	10.1371/journal.pone.0073244	http://dx.doi.org/10.1371/journal.pone.0073244			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	219OE	24023842	Green Submitted, gold, Green Published			2023-01-03	WOS:000324515600083
J	Teloh, JK; Ferenz, KB; Petrat, F; Mayer, C; de Groot, H				Teloh, Johanna K.; Ferenz, Katja B.; Petrat, Frank; Mayer, Christian; de Groot, Herbert			Acid-Base and Electrolyte Status during Normovolemic Hemodilution with Succinylated Gelatin or HES-Containing Volume Replacement Solutions in Rats	PLOS ONE			English	Article							6-PERCENT HYDROXYETHYL STARCH; MODIFIED FLUID GELATIN; OSMOTIC-NEPHROSIS; 4-PERCENT GELATIN; 5-PERCENT ALBUMIN; RESUSCITATION; COLLOIDS; COAGULATION; ISOFLURANE; VOLUVEN	Background: In the past, several studies have compared different colloidal replacement solutions, whereby the focus was usually on the respective colloid. We therefore systematically studied the influence of the carrier solution's composition of five approved colloidal volume replacement solutions (Gelafundin, Gelafusal, Geloplasma, Voluven and Volulyte) on acid-base as well as electrolyte status during and following acute severe normovolemic hemodilution. The solutions differed in the colloid used (succinylated gelatin vs. HES) and in the presence and concentration of metabolizable anions as well as in their electrolyte composition. Methods: Anesthetized Wistar rats were subjected to a stepwise normovolemic hemodilution with one of the solutions until a final hematocrit of 10%. Subsequent to dilution (162 min), animals were observed for an additional period (150 min). During dilution and observation time blood gas analyses were performed eight times in total. Additionally, in the Voluven and Volulyte groups as well as in 6 Gelafundin animals, electrolyte concentrations, glucose, pH and succinylated gelatin were measured in urine and histopathological evaluation of the kidney was performed. Results: All animals survived without any indications of injury. Although the employed solutions differed in their respective composition, comparable results in all plasma acid-base and electrolyte parameters studied were obtained. Plasma pH increased from approximately 7.28 to 7.39, the plasma K+ concentration decreased from circa 5.20 mM to 4.80-3.90 mM and the plasma Cl- concentration rose from approximately 105 mM to 111-120 mM. Urinary analysis revealed increased excretion of K+, H+ and Cl-. Conclusions: The present data suggest that the carrier solution's composition with regard to metabolizable anions as well as K+, Ca2+ only has a minor impact on acid-base and electrolyte status after application of succinylated gelatin or HES-containing colloidal volume replacement solutions.	[Teloh, Johanna K.; Ferenz, Katja B.; Petrat, Frank; de Groot, Herbert] Univ Duisburg Essen, Univ Hosp Essen, Inst Physiol Chem, Essen, Germany; [Mayer, Christian] Univ Duisburg Essen, Inst Phys Chem, Essen, Germany	University of Duisburg Essen; University of Duisburg Essen	de Groot, H (corresponding author), Univ Duisburg Essen, Univ Hosp Essen, Inst Physiol Chem, Essen, Germany.	herbert.de-groot@uni-duisburg-essen.de	Ferenz, Katja/AAX-4076-2020; Mayer, Christian/D-2144-2019	Ferenz, Katja/0000-0001-6011-2467; 				Aksu U, 2012, SHOCK, V37, P205, DOI 10.1097/SHK.0b013e31823ca89c; Almac E, 2012, RESUSCITATION, V83, P1166, DOI 10.1016/j.resuscitation.2012.02.011; ALPERT NR, 1954, AM J PHYSIOL, V177, P455, DOI 10.1152/ajplegacy.1954.177.3.455; [Anonymous], COCHRANE DATABASE SY; Base EM, 2011, J CARDIOTHOR VASC AN, V25, P407, DOI 10.1053/j.jvca.2010.12.005; Casutt M, 2010, BRIT J ANAESTH, V105, P273, DOI 10.1093/bja/aeq173; Choi PTL, 1999, CRIT CARE MED, V27, P200, DOI 10.1097/00003246-199901000-00053; DARDAI E, 1987, METHOD FIND EXP CLIN, V9, P717; Dickenmann M, 2008, AM J KIDNEY DIS, V51, P491, DOI 10.1053/j.ajkd.2007.10.044; Dubniks M, 2007, INTENS CARE MED, V33, P293, DOI 10.1007/s00134-006-0454-5; EDWARDS JD, 1989, CRIT CARE MED, V17, P996, DOI 10.1097/00003246-198910000-00006; Forster H, 1997, Krankenpfl J, V35, P497; Forster HAF, 1998, J ANAESTH INTENSIVBE, V5, P2; Freyburger G, 1996, BRIT J ANAESTH, V76, P519, DOI 10.1093/bja/76.4.519; FROHLICH ED, 1965, AM J PHYSIOL, V208, P149, DOI 10.1152/ajplegacy.1965.208.1.149; Godier A, 2010, ACTA ANAESTH SCAND, V54, P1241, DOI 10.1111/j.1399-6576.2010.02306.x; Haas T, 2008, ANESTH ANALG, V106, P1078, DOI 10.1213/ane.0b013e318165df18; Hauet T, 1998, TRANSPLANT P, V30, P2796, DOI 10.1016/S0041-1345(98)00812-4; Imai A, 1999, AM J VET RES, V60, P1577; JANSSEN CW, 1968, ACTA CHIR SCAND, V134, P481; Johannes T, 2007, AM J PHYSIOL-RENAL, V292, pF796, DOI 10.1152/ajprenal.00206.2006; KIEF H, 1968, VIRCHOWS ARCH B, V1, P240; LEGENDRE C, 1993, LANCET, V342, P248, DOI 10.1016/0140-6736(93)92345-T; Lehmann L, 2013, NEUROCRIT CARE, V18, P5, DOI 10.1007/s12028-012-9764-3; Levi M, 2007, SEMIN THROMB HEMOST, V33, P810, DOI 10.1055/s-2007-1000370; Lobo DN, 2010, CRIT CARE MED, V38, P464, DOI 10.1097/CCM.0b013e3181bc80f1; Margarido CB, 2007, SHOCK, V27, P390, DOI 10.1097/01.shk.0000245026.01365.55; Mitra S, 2009, INDIAN J ANAESTH, V53, P592; Mizzi Anna, 2011, Anesthesiol Clin, V29, P547, DOI 10.1016/j.anclin.2011.05.012; MORRIS M, 1982, HYPERTENSION, V4, P161, DOI 10.1161/01.HYP.4.1.161; MORTELMANS YJ, 1995, ANESTH ANALG, V81, P1235, DOI 10.1097/00000539-199512000-00020; Nolan J, 1999, BRIT MED BULL, V55, P821, DOI 10.1258/0007142991902808; OBERLEITHNER H, 1987, P NATL ACAD SCI USA, V84, P1464, DOI 10.1073/pnas.84.5.1464; Rehm M, 2000, ANESTHESIOLOGY, V93, P1174, DOI 10.1097/00000542-200011000-00007; Sirtl C, 2008, ANASTHESIOLOGIE, P384; Westphal M, 2009, ANESTHESIOLOGY, V111, P187, DOI 10.1097/ALN.0b013e3181a7ec82; Wiedermann CJ, 2004, WIEN KLIN WOCHENSCHR, V116, P583, DOI 10.1007/s00508-004-0237-3; Winkelmayer WC, 2003, KIDNEY INT, V64, P1046, DOI 10.1046/j.1523-1755.2003.00186.x; Yang ZJ, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002010; Zander R., 2006, EJHP PRACT, V12, P60; Zander R, 2009, FLUID MANAGEMENT, P15	41	4	5	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 2	2013	8	9							e72848	10.1371/journal.pone.0072848	http://dx.doi.org/10.1371/journal.pone.0072848			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	215VH	24023785	Green Submitted, Green Published, gold			2023-01-03	WOS:000324238400029
J	Payne, AC; Andregg, M; Kemmish, K; Hamalainen, M; Bowell, C; Bleloch, A; Klejwa, N; Lehrach, W; Schatz, K; Stark, H; Marblestone, A; Church, G; Own, CS; Andregg, W				Payne, Andrew C.; Andregg, Michael; Kemmish, Kent; Hamalainen, Mark; Bowell, Charlotte; Bleloch, Andrew; Klejwa, Nathan; Lehrach, Wolfgang; Schatz, Ken; Stark, Heather; Marblestone, Adam; Church, George; Own, Christopher S.; Andregg, William			Molecular Threading: Mechanical Extraction, Stretching and Placement of DNA Molecules from a Liquid-Air Interface	PLOS ONE			English	Article							HIGH-RESOLUTION; TEMPLATED FABRICATION; SINGLE; ALIGNMENT; MICROSCOPE; TWEEZERS; BIOLOGY; ARRAYS	We present "molecular threading", a surface independent tip-based method for stretching and depositing single and double-stranded DNA molecules. DNA is stretched into air at a liquid-air interface, and can be subsequently deposited onto a dry substrate isolated from solution. The design of an apparatus used for molecular threading is presented, and fluorescence and electron microscopies are used to characterize the angular distribution, straightness, and reproducibility of stretched DNA deposited in arrays onto elastomeric surfaces and thin membranes. Molecular threading demonstrates high straightness and uniformity over length scales from nanometers to micrometers, and represents an alternative to existing DNA deposition and linearization methods. These results point towards scalable and high-throughput precision manipulation of single-molecule polymers.	[Payne, Andrew C.; Marblestone, Adam; Church, George] Harvard Univ, Wyss Inst, Boston, MA 02115 USA; [Payne, Andrew C.; Andregg, Michael; Kemmish, Kent; Hamalainen, Mark; Bowell, Charlotte; Bleloch, Andrew; Klejwa, Nathan; Lehrach, Wolfgang; Schatz, Ken; Stark, Heather; Own, Christopher S.; Andregg, William] Halcyon Mol Inc, Redwood City, CA USA; [Marblestone, Adam; Church, George] Harvard Univ, Biophys Program, Boston, MA 02115 USA; [Church, George] Harvard Univ, Sch Med, Dept Genet, Boston, MA USA	Harvard University; Harvard University; Harvard University; Harvard Medical School	Church, G (corresponding author), Harvard Univ, Biophys Program, Boston, MA 02115 USA.	gchurch@genetics.med.harvard.edu; csown@voxa.co		church, george/0000-0001-6232-9969; Marblestone, Adam/0000-0001-9833-9931	U.S. Department of Energy [DE-FG02-02ER63445]; NIH [RC2 HG005592]; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [RC2HG005592] Funding Source: NIH RePORTER	U.S. Department of Energy(United States Department of Energy (DOE)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))	The authors thank the U.S. Department of Energy Grant No. DE-FG02-02ER63445 and NIH Grant No. RC2 HG005592 for financial support. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Allemand JF, 1997, BIOPHYS J, V73, P2064, DOI 10.1016/S0006-3495(97)78236-5; Andregg W, 2010, US Patent App, Patent No. [12/753,722, 12753722]; Bell DC, 2012, MICROSC MICROANAL, V18, P1049, DOI 10.1017/S1431927612012615; BENSIMON A, 1994, SCIENCE, V265, P2096, DOI 10.1126/science.7522347; BENSIMON D, 1995, PHYS REV LETT, V74, P4754, DOI 10.1103/PhysRevLett.74.4754; Bleloch A.L., 2011, MICROSCOPY MICRO SS2, V17, P1274; Bustamante C, 2003, NATURE, V421, P423, DOI 10.1038/nature01405; Cerf A, 2011, NANO LETT; Cerf A, 2009, MICROELECTRON ENG, V86, P1419, DOI 10.1016/j.mee.2009.01.057; Cluzel P, 1996, SCIENCE, V271, P792, DOI 10.1126/science.271.5250.792; Deng ZX, 2003, NANO LETT, V3, P1545, DOI 10.1021/nl034720q; Feynman R.P., 1960, ENG SCI, V23-5, DOI 10.1109/84.128057; Gentile F, 2012, NANO LETT, V12, P6453, DOI 10.1021/nl3039162; Greenleaf WJ, 2007, ANNU REV BIOPH BIOM, V36, P171, DOI 10.1146/annurev.biophys.36.101106.101451; Gu Q, 2006, PHYSICA E, V33, P92, DOI 10.1016/j.physe.2005.11.010; Herrick J, 1999, CHROMOSOME RES, V7, P409, DOI 10.1023/A:1009276210892; Kanavarioti A, 2012, ELEC TROPHORESIS; Kim HJ, 2012, NANOSCALE RES LETT, V7, P1, DOI 10.1186/1556-276X-7-30; Kim HJ, 2009, DIAM RELAT MATER, V18, P1015, DOI 10.1016/j.diamond.2009.02.027; Krivanek OL, 2008, ULTRAMICROSCOPY, V108, P179, DOI 10.1016/j.ultramic.2007.07.010; Kudo H, 2008, COLLOID SURFACE A, V313, P651, DOI 10.1016/j.colsurfa.2007.04.126; Kwak KJ, 2003, APPL SURF SCI, V210, P73, DOI 10.1016/S0169-4332(02)01482-4; Lam E, 2012, NATURE BIOTECHNOLOGY; Lebofsky Ronald, 2003, Briefings in Functional Genomics & Proteomics, V1, P385, DOI 10.1093/bfgp/1.4.385; Lizardi PM, 1998, NAT GENET, V19, P225, DOI 10.1038/898; Lund J, 2006, NANOTECHNOLOGY, V17, P2752, DOI 10.1088/0957-4484/17/11/007; Michalet X, 1997, SCIENCE, V277, P1518, DOI 10.1126/science.277.5331.1518; Nakao H, 2003, J AM CHEM SOC, V125, P7162, DOI 10.1021/ja034185w; Nyamjav D, 2003, ADV MATER, V15, P1805, DOI 10.1002/adma.200305342; Oshige M, 2010, ANAL BIOCHEM, V400, P145, DOI 10.1016/j.ab.2010.01.021; Own CS, UNPUB; Own CS, 2013, MICROSCOPY IN PRESS; Pinheiro AV, 2011, NAT NANOTECHNOL, V6, P763, DOI [10.1038/nnano.2011.187, 10.1038/NNANO.2011.187]; Sagnes M, 2003, MICROELECTRON ENG, V67-8, P683, DOI 10.1016/S0167-9317(03)00130-8; Sasou M, 2003, LANGMUIR, V19, P9845, DOI 10.1021/la035054b; Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089; Schwob Etienne, 2009, V521, P673, DOI 10.1007/978-1-60327-817-5_36; SMITH SB, 1992, SCIENCE, V258, P1122, DOI 10.1126/science.1439819; Strick T, 2000, PROG BIOPHYS MOL BIO, V74, P115, DOI 10.1016/S0079-6107(00)00018-3; Tanase M, 2007, METHOD CELL BIOL, V83, P473, DOI 10.1016/S0091-679X(07)83020-2; Wang MD, 1997, BIOPHYS J, V72, P1335, DOI 10.1016/S0006-3495(97)78780-0; WILKINS MHF, 1951, NATURE, V167, P759, DOI 10.1038/167759a0; Zhang JM, 2005, LANGMUIR, V21, P4180, DOI 10.1021/la050129s; Zlatanova J, 2000, PROG BIOPHYS MOL BIO, V74, P37, DOI 10.1016/S0079-6107(00)00014-6	44	5	5	1	19	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 31	2013	8	7							e69058	10.1371/journal.pone.0069058	http://dx.doi.org/10.1371/journal.pone.0069058			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	194LB	23935923	Green Published, gold, Green Submitted			2023-01-03	WOS:000322633700017
J	Huang, YY; Yang, Q; Zhou, SW; Wei, Y; Chen, YX; Xie, DR; Zhang, B				Huang, Yuan-Yuan; Yang, Qiong; Zhou, Si-Wei; Wei, Ying; Chen, Yan-Xian; Xie, De-Rong; Zhang, Bei			Postoperative Chemoradiotherapy versus Postoperative Chemotherapy for Completely Resected Gastric Cancer with D2 Lymphadenectomy: A Meta-Analysis	PLOS ONE			English	Article							PHASE-III TRIAL; RANDOMIZED CLINICAL-TRIALS; LYMPH-NODE DISSECTION; ADJUVANT CHEMOTHERAPY; CHEMORADIATION; BENEFIT; ADENOCARCINOMA; CAPECITABINE; RADIOTHERAPY; GASTRECTOMY	Background: Both chemoradiotherapy and chemotherapy are used in postoperative adjuvant therapy for resected gastric cancer. However, it is controversial whether chemoradiotherapy or chemotherapy is the optimal strategy for patients with gastric cancer after D2 lymphadenectomy. The present meta-analysis aims to provide more evidence on the relative benefits of adjuvant therapies in this setting. Methods: We conducted a systematic review of randomized controlled trials, extracted time-to-event data using Tierney methods (when not reported), and performed meta-analysis to obtain the relative hazards of adjuvant chemoradiotherapy to chemotherapy on efficacy and toxicities. Results: A total of 895 patients from 3 randomized controlled trials were identified for this meta-analysis. All patients were from Asian countries. Our results showed that postoperative chemoradiotherapy significantly improved locoregional recurrence-free survival [LRRFS: hazard ratio (HR) = 0.53, 95% CI = 0.32-0.87, p = 0.01] and disease-free survival (DFS: HR = 0.72, 95% CI = 0.59-0.89, p = 0.002); however, the improvement of distant metastasis recurrence-free survival (DMRFS: HR = 0.86; 95% CI = 0.66-1.11, p = 0.25) and overall survival (OS: HR = 0.79, 95% CI = 0.61-1.03, p = 0.08) were non-significant. The main grade 3 or 4 toxicities were equivalent between the two groups. Conclusion: In non-selected Asian patients with resected gastric cancer who underwent D2 lymphadenectomy, postoperative chemoradiotherapy improved LRRFS and DFS but might not improve OS compared to postoperative chemotherapy.	[Huang, Yuan-Yuan; Zhang, Bei] Sun Yat Sen Univ, Sun Yat Sen Univ Canc Ctr, Dept VIP, Guangzhou 510275, Guangdong, Peoples R China; [Yang, Qiong; Zhou, Si-Wei; Wei, Ying; Chen, Yan-Xian; Xie, De-Rong] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Dept Oncol, Guangzhou 510275, Guangdong, Peoples R China	Sun Yat Sen University; Sun Yat Sen University	Zhang, B (corresponding author), Sun Yat Sen Univ, Sun Yat Sen Univ Canc Ctr, Dept VIP, Guangzhou 510275, Guangdong, Peoples R China.	sumsdoctor@hotmail.com						Bang YJ, 2012, LANCET, V379, P315, DOI 10.1016/S0140-6736(11)61873-4; Bria E, 2007, J CLIN ONCOL, V25; Brooks GA, 2012, J CLIN ONCOL, V30, P2297, DOI 10.1200/JCO.2012.42.4069; Cirera L, 1999, J CLIN ONCOL, V17, P3810, DOI 10.1200/JCO.1999.17.12.3810; Costa WL, 2012, RADIAT ONCOL, V7, DOI 10.1186/1748-717X-7-169; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Hartgrink HH, 2004, J CLIN ONCOL, V22, P2069, DOI 10.1200/JCO.2004.08.026; Hsu C, 2012, GASTRIC CANCER, V15, P265, DOI [10.1007/s10120-011-0106-5, 10.1007/s10120-012-0151-8]; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.20107]; Kim S, 2005, INT J RADIAT ONCOL, V63, P1279, DOI 10.1016/j.ijrobp.2005.05.005; Kim TH, 2012, INT J RADIAT ONCOL, V84, pE585, DOI 10.1016/j.ijrobp.2012.07.2378; Lau J, 1997, ANN INTERN MED, V127, P820, DOI 10.7326/0003-4819-127-9-199711010-00008; Lee J, 2012, J CLIN ONCOL, V30, P268, DOI 10.1200/JCO.2011.39.1953; Macdonald JS, 2005, J SURG ONCOL, V90, P166, DOI 10.1002/jso.20223; Macdonald JS, 2001, NEW ENGL J MED, V345, P725, DOI 10.1056/NEJMoa010187; Moher D, 2009, PLOS MED, V6, DOI [10.1371/journal.pmed.1000097, 10.1136/bmj.b4037]; Paoletti X, 2010, JAMA-J AM MED ASSOC, V303, P1729, DOI 10.1001/jama.2010.534; Qi WX, 2013, INT J CANCER, V132, pE66, DOI 10.1002/ijc.27775; Sasako M, 2011, J CLIN ONCOL, V29, P4387, DOI 10.1200/JCO.2011.36.5908; Smalley SR, 2012, J CLIN ONCOL, V30, P2327, DOI 10.1200/JCO.2011.36.7136; Tierney JF, 2007, TRIALS, V8, DOI 10.1186/1745-6215-8-16; Tsujinaka T, 2008, INT J CLIN ONCOL, V13, P117, DOI 10.1007/s10147-007-0743-1; Wu CW, 2006, LANCET ONCOL, V7, P309, DOI 10.1016/S1470-2045(06)70623-4; Zhu WG, 2012, RADIOTHER ONCOL, V104, P361, DOI 10.1016/j.radonc.2012.08.024	25	24	26	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 18	2013	8	7							e68939	10.1371/journal.pone.0068939	http://dx.doi.org/10.1371/journal.pone.0068939			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	214PM	23874819	Green Published, Green Submitted, gold			2023-01-03	WOS:000324146200041
J	Pinel, S; Mriouah, J; Vandamme, M; Chateau, A; Plenat, F; Guerin, E; Taillandier, L; Bernier-Chastagner, V; Merlin, JL; Chastagner, P				Pinel, Sophie; Mriouah, Jihane; Vandamme, Marc; Chateau, Alicia; Plenat, Francois; Guerin, Eric; Taillandier, Luc; Bernier-Chastagner, Valerie; Merlin, Jean-Louis; Chastagner, Pascal			Synergistic Antitumor Effect between Gefitinib and Fractionated Irradiation in Anaplastic Oligodendrogliomas Cannot Be Predicted by the Egfr Signaling Activity	PLOS ONE			English	Article							EPIDERMAL-GROWTH-FACTOR; PHASE-II TRIAL; DIAGNOSED GLIOBLASTOMA-MULTIFORME; FACTOR RECEPTOR INHIBITION; BRAIN-STEM GLIOMAS; MALIGNANT GLIOMAS; RECURRENT GLIOBLASTOMA; ONCOGENE ADDICTION; RADIATION-THERAPY; KINASE INHIBITION	In high-grade gliomas, the identification of patients that could benefit from EGFR inhibitors remains a challenge, hindering the use of these agents. Using xenografts models, we evaluated the antitumor effect of the combined treatment "gefitinib + radiotherapy" and aimed to identify the profile of responsive tumors. Expression of phosphorylated proteins involved in the EGFR-dependent signaling pathways was analyzed in 10 glioma models. We focused on three models of anaplastic oligodendrogliomas (TCG2, TCG3 and TCG4) harboring high levels of phospho-EGFR, phospho-AKT and phospho-MEK1. They were treated with gefitinib (GEF 75 mg/kg/day x 5 days/week, for 2 weeks) and/or fractionated radiotherapy (RT: 5x2Gy/week for 2 weeks). Our results showed that GEF and/or RT induced significant tumor growth delays. However, only the TCG3 xenografts were highly responsive to the combination GEF+RT, with similar to 50% of tumor cure. Phosphoproteins analysis five days after treatment onset demonstrated in TCG3 xenografts, but not in TCG2 model, that the EGFR-dependent pathways were inhibited after GEF treatment. Moreover, TCG3-bearing mice receiving GEF monotherapy exhibited a transient beneficial therapeutic response, rapidly followed by tumor regrowth, along with a major vascular remodeling. Taken together, our data evoked an "EGFR-addictive" behavior for TCG3 tumors. This study confirms that combination of gefitinib with fractionated irradiation could be a potent therapeutic strategy for anaplastic oligodendrogliomas harboring EGFR abnormalities but this treatment seems mainly beneficial for "EGFR-addictive" tumors. Unfortunately, neither the usual molecular markers (EGFR amplification, PTEN loss) nor the basal overexpression of phosphoproteins were useful to distinguish this responsive tumor. Evaluating the impact of TKIs on the EGFR-dependent pathways during the treatment might be more relevant, and requires further validation.	[Pinel, Sophie; Mriouah, Jihane; Vandamme, Marc; Chateau, Alicia; Plenat, Francois; Taillandier, Luc; Merlin, Jean-Louis; Chastagner, Pascal] Univ Lorraine, CRAN, UMR 7039, Vandoeuvre Les Nancy, France; [Pinel, Sophie; Mriouah, Jihane; Vandamme, Marc; Chateau, Alicia; Plenat, Francois; Taillandier, Luc; Merlin, Jean-Louis; Chastagner, Pascal] CNRS, CRAN, UMR 7039, Vandoeuvre Les Nancy, France; [Plenat, Francois] Hop Brabois CHRU Nancy, Serv Anat & Cytol Pathol, Vandoeuvre Les Nancy, France; [Guerin, Eric] Univ Strasbourg, EA 4438, Strasbourg, France; [Taillandier, Luc] Hop Cent CHRU Nancy, Serv Neurol, Nancy, France; [Bernier-Chastagner, Valerie; Merlin, Jean-Louis] Inst Cancerol Lorraine, Vandoeuvre Les Nancy, France; [Chastagner, Pascal] Hop Enfants CHRU Nancy, Serv Onco Hematol Pediat, Vandoeuvre Les Nancy, France	Universite de Lorraine; Centre National de la Recherche Scientifique (CNRS); Universite de Lorraine; CHU de Nancy; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; CHU de Nancy; UNICANCER; Institut de cancerologie de Lorraine (ICL); CHU de Nancy	Pinel, S (corresponding author), Univ Lorraine, CRAN, UMR 7039, Campus Sci, Vandoeuvre Les Nancy, France.	sophie.pinel@univ-lorraine.fr	Guerin, Eric/R-3426-2016	GUERIN, ERIC/0000-0003-1388-2834	French "Ligue Contre le Cancer, Comites Lorrains"; "Association pour la Recherche et les Etudes sur les Maladies Infantiles Graves"	French "Ligue Contre le Cancer, Comites Lorrains"; "Association pour la Recherche et les Etudes sur les Maladies Infantiles Graves"	Financial support for this work was obtained from the French "Ligue Contre le Cancer, Comites Lorrains" and the "Association pour la Recherche et les Etudes sur les Maladies Infantiles Graves." The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Arko L, 2010, PHARMACOL THERAPEUT, V128, P1, DOI 10.1016/j.pharmthera.2010.04.015; Brandes AA, 2008, CLIN CANCER RES, V14, P957, DOI 10.1158/1078-0432.CCR-07-1810; Bredel M, 1999, CLIN CANCER RES, V5, P1786; Brown PD, 2008, J CLIN ONCOL, V26, P5603, DOI 10.1200/JCO.2008.18.0612; Calabrese C, 2007, CANCER CELL, V11, P69, DOI 10.1016/j.ccr.2006.11.020; Cancer Genome Atlas Research Network, 2008, NATURE, V455, P1061; Cerniglia GJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006539; Chakravarti A, 2002, CANCER RES, V62, P4307; Chergui F, 2009, CLIN CHEM, V55, P1327, DOI 10.1373/clinchem.2008.116632; Cooper LAD, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012548; de Groot JF, 2008, J NEURO-ONCOL, V90, P89, DOI 10.1007/s11060-008-9637-y; Geoerger B, 2008, INT J CANCER, V123, P209, DOI 10.1002/ijc.23488; Geyer JR, 2010, EUR J CANCER, V46, P3287, DOI 10.1016/j.ejca.2010.07.005; Gorovets D, 2012, CLIN CANCER RES, V18, P2490, DOI 10.1158/1078-0432.CCR-11-2977; Guillamo JS, 2009, CLIN CANCER RES, V15, P3697, DOI 10.1158/1078-0432.CCR-08-2042; Haas-Kogan DA, 2005, JNCI-J NATL CANCER I, V97, P880, DOI 10.1093/jnci/dji161; Hatanpaa KJ, 2010, NEOPLASIA, V12, P675, DOI 10.1593/neo.10688; Hegi ME, 2011, MOL CANCER THER, V10, P1102, DOI 10.1158/1535-7163.MCT-11-0048; Huang JZ, 2004, MOL CANCER RES, V2, P36; Idbaih A, 2008, INT J CANCER, V122, P1778, DOI 10.1002/ijc.23270; Idbaih A, 2011, J NEURO-ONCOL, V103, P221, DOI 10.1007/s11060-010-0380-9; Labussiere M, 2008, ANTI-CANCER DRUG, V19, P991, DOI 10.1097/CAD.0b013e328313e172; Labussiere M, 2011, INT J RADIAT ONCOL, V79, P892, DOI 10.1016/j.ijrobp.2010.09.051; Lassman AB, 2005, CLIN CANCER RES, V11, P7841, DOI 10.1158/1078-0432.CCR-05-0421; LUNDJOHANSEN M, 1990, CANCER RES, V50, P6039; McNamara MG, 2013, CURR TREAT OPTION NE, V24, P24; Mellinghoff IK, 2005, NEW ENGL J MED, V353, P2012, DOI 10.1056/NEJMoa051918; Miqueli AD, 2009, BRIT J CANCER, V100, P950, DOI 10.1038/sj.bjc.6604943; Mukherjee B, 2009, CANCER RES, V69, P4252, DOI 10.1158/0008-5472.CAN-08-4853; Pao W, 2005, PLOS MED, V2, P225, DOI 10.1371/journal.pmed.0020073; Park SY, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-222; Peereboom DM, 2010, J NEURO-ONCOL, V98, P93, DOI 10.1007/s11060-009-0067-2; Perkins G, 2010, INT J CANCER, V127, P1321, DOI 10.1002/ijc.25152; Pinel S, 2004, INT J RADIAT ONCOL, V59, P250, DOI 10.1016/j.ijrobp.2003.12.022; Pollack IF, 2011, NEURO-ONCOLOGY, V13, P290, DOI 10.1093/neuonc/noq199; Prados MD, 2009, J CLIN ONCOL, V27, P579, DOI 10.1200/JCO.2008.18.9639; Qayum N, 2009, CANCER RES, V69, P6347, DOI 10.1158/0008-5472.CAN-09-0657; Raizer JJ, 2010, NEURO-ONCOLOGY, V12, P95, DOI 10.1093/neuonc/nop015; Raizer RJ, 2005, J NEURO-ONCOL, V74, P77, DOI 10.1007/s11060-005-0603-7; Rich JN, 2004, J CLIN ONCOL, V22, P133, DOI 10.1200/JCO.2004.08.110; Sambade MJ, 2010, INT J RADIAT ONCOL, V77, P575, DOI 10.1016/j.ijrobp.2009.12.063; Sarkaria JN, 2007, MOL CANCER THER, V6, P1167, DOI 10.1158/1535-7163.MCT-06-0691; Sharma SV, 2006, CLIN CANCER RES, V12, p4392S, DOI 10.1158/1078-0432.CCR-06-0096; Stea B, 2003, CANCER LETT, V202, P43, DOI 10.1016/j.canlet.2003.07.006; Stupp R, 2009, LANCET ONCOL, V10, P459, DOI 10.1016/S1470-2045(09)70025-7; Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020; Weinstein IB, 2008, CANCER RES, V68, P3077, DOI 10.1158/0008-5472.CAN-07-3293; Weinstein IB, 2002, SCIENCE, V297, P63, DOI 10.1126/science.1073096; Westphal M, 2011, NAT REV NEUROSCI, V12, P495, DOI 10.1038/nrn3060; Zhuang HQ, 2009, CANCER SCI, V100, P1520, DOI 10.1111/j.1349-7006.2009.01190.x	50	3	3	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 18	2013	8	7							e68333	10.1371/journal.pone.0068333	http://dx.doi.org/10.1371/journal.pone.0068333			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	214PM	23874590	Green Published, gold, Green Submitted			2023-01-03	WOS:000324146200017
J	Frieden, TR; King, SMC; Wright, JS				Frieden, Thomas R.; King, Sallyann M. Coleman; Wright, Janet S.			Protocol-Based Treatment of Hypertension A Critical Step on the Pathway to Progress	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							BLOOD-PRESSURE; TRENDS		[Frieden, Thomas R.; King, Sallyann M. Coleman; Wright, Janet S.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA	Centers for Disease Control & Prevention - USA	Frieden, TR (corresponding author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,MS D-14, Atlanta, GA 30333 USA.	tfrieden@cdc.gov		Frieden, Thomas/0000-0002-4759-2256				Egan BM, 2010, JAMA-J AM MED ASSOC, V303, P2043, DOI 10.1001/jama.2010.650; Handler J, 2011, J AM SOC HYPERTENS, V5, P197, DOI 10.1016/j.jash.2011.03.002; Hypertension Detection Follow-up Program Cooperative Group, 1979, JAMA-J AM MED ASSOC, V242, P2562, DOI DOI 10.1001/JAMA.1979.03300230018021; Jaffe MG, 2013, JAMA-J AM MED ASSOC, V310, P699, DOI 10.1001/jama.2013.108769; Joffres M, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2013-003423; Luepker RV, 2012, CIRCULATION, V126, P1852, DOI 10.1161/CIRCULATIONAHA.112.098517; Valderrama Amy L., 2012, Morbidity and Mortality Weekly Report, V61, P703	7	47	47	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 1	2014	311	1					21	22		10.1001/jama.2013.282615	http://dx.doi.org/10.1001/jama.2013.282615			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	282HN	24231925				2023-01-03	WOS:000329161400010
J	Butler, J; Fonarow, GC; Gheorghiade, M				Butler, Javed; Fonarow, Gregg C.; Gheorghiade, Mihai			Need for Increased Awareness and Evidence-Based Therapies for Patients Hospitalized for Heart Failure	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							MORTALITY; RATES		[Butler, Javed] Emory Univ, Div Cardiol, Atlanta, GA 30322 USA; [Fonarow, Gregg C.] Univ Calif Los Angeles, Div Cardiol, Los Angeles, CA 90024 USA; [Gheorghiade, Mihai] Northwestern Univ, Feinberg Sch Med, Ctr Cardiovasc Innovat, Chicago, IL 60601 USA	Emory University; University of California System; University of California Los Angeles; Northwestern University; Feinberg School of Medicine	Gheorghiade, M (corresponding author), Northwestern Univ, Feinberg Sch Med, Ctr Cardiovasc Innovat, 201 E Huron,Galter 3-150, Chicago, IL 60601 USA.	m-gheorghiade@northwestern.edu	Fonarow, Gregg C/D-5988-2014	Fonarow, Gregg C/0000-0002-3192-8093				Allen LA, 2008, JAMA-J AM MED ASSOC, V299, P2533, DOI 10.1001/jama.299.21.2533; Bradley EH, 2013, CIRC-CARDIOVASC QUAL, V6, P444, DOI 10.1161/CIRCOUTCOMES.111.000101; Chen J, 2011, JAMA-J AM MED ASSOC, V306, P1669, DOI 10.1001/jama.2011.1474; Gheorghiade M, 2006, JAMA-J AM MED ASSOC, V296, P2217, DOI 10.1001/jama.296.18.2217; Gheorghiade M, 2013, JAMA-J AM MED ASSOC, V309, P1125, DOI 10.1001/jama.2013.1954; Gheorghiade M, 2012, HEART FAIL REV, V17, P485, DOI 10.1007/s10741-011-9280-0; Go AS, 2013, CIRCULATION, V127, pE6, DOI 10.1161/CIR.0b013e31828124ad; Heidenreich PA, 2013, CIRC-HEART FAIL, V6, P606, DOI 10.1161/HHF.0b013e318291329a	8	30	30	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 20	2013	310	19					2035	2036		10.1001/jama.2013.282815	http://dx.doi.org/10.1001/jama.2013.282815			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	253OQ	24240925				2023-01-03	WOS:000327098900014
J	Yamada, T; Azuma, K; Muta, E; Kim, J; Sugawara, S; Zhang, GL; Matsueda, S; Kasama-Kawaguchi, Y; Yamashita, Y; Yamashita, T; Nishio, K; Itoh, K; Hoshino, T; Sasada, T				Yamada, Teppei; Azuma, Koichi; Muta, Emi; Kim, Jintaek; Sugawara, Shunichi; Zhang, Guang Lan; Matsueda, Satoko; Kasama-Kawaguchi, Yuri; Yamashita, Yuichi; Yamashita, Takuto; Nishio, Kazuto; Itoh, Kyogo; Hoshino, Tomoaki; Sasada, Tetsuro			EGFR T790M Mutation as a Possible Target for Immunotherapy; Identification of HLA-A*0201-Restricted T Cell Epitopes Derived from the EGFR T790M Mutation	PLOS ONE			English	Article							GROWTH-FACTOR RECEPTOR; TYROSINE KINASE INHIBITORS; LUNG-CANCER; ACQUIRED-RESISTANCE; CLINICAL-RESPONSE; PEPTIDE COMPLEX; POINT MUTATION; HIGH-AFFINITY; GEFITINIB; LYMPHOCYTES	Treatment with epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), such as gefitinib and erlotinib, has achieved high clinical response rates in patients with non-small cell lung cancers (NSCLCs). However, over time, most tumors develop acquired resistance to EGFR-TKIs, which is associated with the secondary EGFR T790M resistance mutation in about half the cases. Currently there are no effective treatment options for patients with this resistance mutation. Here we identified two novel HLA-A*0201 (A2)-restricted T cell epitopes containing the mutated methionine residue of the EGFR T790M mutation, T790M-5 (MQLMPFGCLL) and T790M-7 (LIMQLMPFGCL), as potential targets for EGFR-TKI-resistant patients. When peripheral blood cells were repeatedly stimulated in vitro with these two peptides and assessed by antigen-specific IFN-gamma secretion, T cell lines responsive to T790M-5 and T790M-7 were established in 5 of 6 (83%) and 3 of 6 (50%) healthy donors, respectively. Additionally, the T790M-5- and T790M-7-specific T cell lines displayed an MHC class I-restricted reactivity against NSCLC cell lines expressing both HLA-A2 and the T790M mutation. Interestingly, the NSCLC patients with antigen-specific T cell responses to these epitopes showed a significantly less frequency of EGFR-T790M mutation than those without them [1 of 7 (14%) vs 9 of 15 (60%); chi-squared test, p = 0.0449], indicating the negative correlation between the immune responses to the EGFR-T790M-derived epitopes and the presence of EGFR-T790M mutation in NSCLC patients. This finding could possibly be explained by the hypothesis that immune responses to the mutated neo-antigens derived from T790M might prevent the emergence of tumor cell variants with the T790M resistance mutation in NSCLC patients during EGFR-TKI treatment. Together, our results suggest that the identified T cell epitopes might provide a novel immunotherapeutic approach for prevention and/or treatment of EGFR-TKI resistance with the secondary EGFR T790M resistance mutation in NSCLC patients.	[Yamada, Teppei; Muta, Emi; Kim, Jintaek; Matsueda, Satoko; Kasama-Kawaguchi, Yuri; Itoh, Kyogo; Sasada, Tetsuro] Kurume Univ, Sch Med, Dept Immunol & Immunotherapy, Kurume, Fukuoka 830, Japan; [Yamada, Teppei; Yamashita, Yuichi] Fukuoka Univ, Sch Med, Dept Surg, Fukuoka 81401, Japan; [Azuma, Koichi; Hoshino, Tomoaki] Kurume Univ, Sch Med, Dept Internal Med, Div Respirol Neurol & Rheumatol, Kurume, Fukuoka 830, Japan; [Sugawara, Shunichi] Sendai Kousei Hosp, Dept Pulm Med, Sendai, Miyagi, Japan; [Zhang, Guang Lan] Boston Univ, Metropolitan Coll, Boston, MA 02215 USA; [Zhang, Guang Lan] Harvard Univ, Sch Med, Dana Farber Canc Inst, Canc Vaccine Ctr, Boston, MA 02115 USA; [Yamashita, Takuto] Kurume Univ, Grad Sch Med, Ctr Biostat, Kurume, Fukuoka 830, Japan; [Nishio, Kazuto] Kinki Univ, Sch Med, Dept Genome Biol, Osaka 589, Japan	Kurume University; Fukuoka University; Kurume University; Sendai Kousei Hospital; Boston University; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Kurume University; Kindai University (Kinki University)	Sasada, T (corresponding author), Kurume Univ, Sch Med, Dept Immunol & Immunotherapy, Kurume, Fukuoka 830, Japan.	tsasada@med.kurume-u.ac.jp			JSPS [23591913]; Mitsubishi Foundation; Grants-in-Aid for Scientific Research [23591913] Funding Source: KAKEN	JSPS(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Mitsubishi Foundation; Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	This study was supported by the JSPS Grant-in-Aid for Scientific Research (C) 23591913 and the Mitsubishi Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ayoola A, 2012, CANCER INVEST, V30, P433, DOI 10.3109/07357907.2012.666691; Bernatchez C, 2011, VACCINE, V29, P3021, DOI 10.1016/j.vaccine.2011.01.115; Buettner R, 2013, J CLIN ONCOL, V31, P1858, DOI 10.1200/JCO.2012.45.9867; Camidge DR, 2012, NAT REV CLIN ONCOL, V9, P268, DOI 10.1038/nrclinonc.2012.43; Castle JC, 2012, CANCER RES, V72, P1081, DOI 10.1158/0008-5472.CAN-11-3722; Cheever MA, 2009, CLIN CANCER RES, V15, P5323, DOI 10.1158/1078-0432.CCR-09-0737; CHEN Y, 1994, J IMMUNOL, V152, P2874; Ding YH, 1998, IMMUNITY, V8, P403, DOI 10.1016/S1074-7613(00)80546-4; Echchakir H, 2001, CANCER RES, V61, P4078; Finn OJ, 2008, NEW ENGL J MED, V358, P2704, DOI 10.1056/NEJMra072739; Gazdar AF, 2009, ONCOGENE, V28, pS24, DOI 10.1038/onc.2009.198; Heemskerk B, 2013, EMBO J, V32, P194, DOI 10.1038/emboj.2012.333; Hindson BJ, 2011, ANAL CHEM, V83, P8604, DOI 10.1021/ac202028g; Hogan KT, 1998, CANCER RES, V58, P5144; Ichiki Y, 2004, J IMMUNOL, V172, P4844, DOI 10.4049/jimmunol.172.8.4844; Jin M, 2008, CANCER SCI, V99, P1656, DOI 10.1111/j.1349-7006.2008.00866.x; Karanikas V, 2001, CANCER RES, V61, P3718; Khan AR, 2000, J IMMUNOL, V164, P6398, DOI 10.4049/jimmunol.164.12.6398; Kobayashi S, 2005, NEW ENGL J MED, V352, P786, DOI 10.1056/NEJMoa044238; Koizumi F, 2005, INT J CANCER, V116, P36, DOI 10.1002/ijc.20985; La Rosa C, 2001, BLOOD, V97, P1776; Lennerz V, 2005, P NATL ACAD SCI USA, V102, P16013, DOI 10.1073/pnas.0500090102; Lin HH, 2008, BMC IMMUNOL, V9, DOI 10.1186/1471-2172-9-8; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Maemondo M, 2010, NEW ENGL J MED, V362, P2380, DOI 10.1056/NEJMoa0909530; McKee MD, 2005, J TRANSL MED, V3, P1, DOI 10.1186/1479-5876-3-35; Mellman I, 2011, NATURE, V480, P480, DOI 10.1038/nature10673; Mitsudomi T, 2013, NAT REV CLIN ONCOL, V10, P235, DOI 10.1038/nrclinonc.2013.22; Mitsudomi T, 2010, LANCET ONCOL, V11, P121, DOI 10.1016/S1470-2045(09)70364-X; Mok TS, 2009, NEW ENGL J MED, V361, P947, DOI 10.1056/NEJMoa0810699; Nagai Y, 2005, CANCER RES, V65, P7276, DOI 10.1158/0008-5472.CAN-05-0331; Nakao M, 2000, J IMMUNOL, V164, P2565, DOI 10.4049/jimmunol.164.5.2565; Oxnard GR, 2011, CLIN CANCER RES, V17, P5530, DOI 10.1158/1078-0432.CCR-10-2571; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Pao W, 2005, PLOS MED, V2, P225, DOI 10.1371/journal.pmed.0020073; Pao W, 2004, P NATL ACAD SCI USA, V101, P13306, DOI 10.1073/pnas.0405220101; POGUE RR, 1995, P NATL ACAD SCI USA, V92, P8166, DOI 10.1073/pnas.92.18.8166; Reck M, 2013, LANCET, V382, P709, DOI 10.1016/S0140-6736(13)61502-0; Rosenberg SA, 2004, NAT MED, V10, P909, DOI 10.1038/nm1100; Sampson JH, 2010, J CLIN ONCOL, V28, P4722, DOI 10.1200/JCO.2010.28.6963; Sasada T, 2004, CANCER RES, V64, P2882, DOI 10.1158/0008-5472.CAN-03-3549; Sasada T, 2010, EUR J CANCER, V46, P1514, DOI 10.1016/j.ejca.2010.03.013; Schlom J, 2012, JNCI-J NATL CANCER I, V104, P599, DOI 10.1093/jnci/djs033; SHICHIO S, 1995, INT J CANCER, V64, P158, DOI 10.1002/ijc.2910640303; Sidney J, 2001, HUM IMMUNOL, V62, P1200, DOI 10.1016/S0198-8859(01)00319-6; Takenoyama M, 2006, INT J CANCER, V118, P1992, DOI 10.1002/ijc.21594; Toubaji A, 2008, CANCER IMMUNOL IMMUN, V57, P1413, DOI 10.1007/s00262-008-0477-6; Weden S, 2011, INT J CANCER, V128, P1120, DOI 10.1002/ijc.25449; Yoshida T, 2010, CANCER SCI, V101, P167, DOI 10.1111/j.1349-7006.2009.01368.x	49	17	19	1	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 5	2013	8	11							e78389	10.1371/journal.pone.0078389	http://dx.doi.org/10.1371/journal.pone.0078389			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	247EE	24223798	Green Published, Green Submitted, gold			2023-01-03	WOS:000326597400023
J	Su, LH; Wan, CX; Zhou, JR; Wang, YG; Wang, L; Ai, YL; Zhao, X				Su, Lihong; Wan, Caixia; Zhou, Jianren; Wang, Yiguang; Wang, Liang; Ai, Yanling; Zhao, Xu			Piezochromic Phenomena of Nanometer Voids Formed by Mono-Dispersed Nanometer Powders Compacting Process	PLOS ONE			English	Article							ZINC-OXIDE; HIGH-PRESSURES; COMPLEXES; EMISSION; BEHAVIOR; PHOTOLUMINESCENT; NANOPARTICLES; TRANSITIONS	Piezochromism describes a tendency of certain materials changing colors when they are subjected to various pressure levels. It occurs particularly in some polymers or inorganic materials, such as in palladium complexes. However, piezochromism is generally believed to work at high pressure range of 0.1-10 GPa. This research work focused on unique piezochromism responses of the nanometer voids formed by the 5-20 nm inorganic ISOH nanometer powders. It was discovered that microstructures of the nanometer voids could change color at very low pressures of only 0.002-0.01 GPa; its sensitivity to pressure was increased by tens of times. It is believed that the uniform microstructures of nanometer powders contributed to the material's high sensitivity of piezochromic phenomena. One factor which quantum optical change caused by nanometer voids affected the quantum confinement effect; another is surface Plasmon Resonance of great difference dielectric property between conductive ITO powder and insulation hydroxide.	[Su, Lihong; Wan, Caixia; Wang, Yiguang; Wang, Liang; Ai, Yanling; Zhao, Xu] Northwestern Polytech Univ, Dept Applying Chem, Xian, Shaanxi Provinc, Peoples R China; [Zhou, Jianren] Prairie View A&M Univ, Coll Engn, Prairie View, TX USA	Northwestern Polytechnical University; Texas A&M University System; Prairie View A&M University	Su, LH (corresponding author), Northwestern Polytech Univ, Dept Applying Chem, Xian, Shaanxi Provinc, Peoples R China.	hlshong@nwpu.edu.cn	Wang, Liang/N-8904-2014	Wang, Liang/0000-0001-6223-5962; su, lihong/0000-0001-8889-4624				Bagnall DM, 1998, APPL PHYS LETT, V73, P1038, DOI 10.1063/1.122077; BARNETT JD, 1973, REV SCI INSTRUM, V44, P1, DOI 10.1063/1.1685943; BYLANDER EG, 1978, J APPL PHYS, V49, P1188, DOI 10.1063/1.325059; Daniel MC, 2004, CHEM REV, V104, P293, DOI 10.1021/cr030698+; DINGLE R, 1969, PHYS REV LETT, V23, P579, DOI 10.1103/PhysRevLett.23.579; Galloway KW, 2010, CRYSTENGCOMM, V12, P2516, DOI 10.1039/c001376e; Henry PF, 2010, ACTA CRYSTALLOGR B, V66, P412, DOI 10.1107/S0108768110020720; Hideo DT, 2004, PLATIN MET REV, V48, P117; Kim MI, 2011, CHEM-EUR J, V17, P10700, DOI 10.1002/chem.201101191; KOTOWSKI M, 1987, INORG CHIM ACTA, V131, P225, DOI 10.1016/S0020-1693(00)96029-8; Lihong S, 2009, MICRO NANO LETT, V4, P48, DOI 10.1049/mnl:20080055; Linhong S, 2011, PHYS DIFFERENCE BOUN; Muramatsu Y, 2001, POLYMER, V42, P6673, DOI 10.1016/S0032-3861(01)00136-7; Nalwa H. S., 1988, HDB ORGANIC CONDUCTI, V2; Righetti L, 2011, ACS APPL MATER INTER, V3, P1319, DOI 10.1021/am2001218; Sagara Y, 2008, ANGEW CHEM INT EDIT, V47, P5175, DOI 10.1002/anie.200800164; Sagara Y, 2009, NAT CHEM, V1, P605, DOI [10.1038/nchem.411, 10.1038/NCHEM.411]; Sagara Y, 2009, ADV FUNCT MATER, V19, P1869, DOI 10.1002/adfm.200801726; Salaneck MR, 1998, J CHEM PHYS, V89, P4613; Samuelsen EJ, 1999, SYNTHETIC MET, V101, P98, DOI 10.1016/S0379-6779(98)01241-7; Sase M, 2011, J MATER CHEM, V21, P8347, DOI 10.1039/c0jm03950k; SHIROTANI I, 1991, B CHEM SOC JPN, V64, P1607, DOI 10.1246/bcsj.64.1607; SHIROTANI I, 1992, B CHEM SOC JPN, V65, P1078, DOI 10.1246/bcsj.65.1078; Skotheim T.A., 1997, HDB CONDUCTING POLYM; Van de Walle CG, 2000, PHYS REV LETT, V85, P1012, DOI 10.1103/PhysRevLett.85.1012; Zhang ZL, 2011, CHEM COMMUN, V47, P7782, DOI 10.1039/c1cc11882j	26	0	0	5	35	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 7	2013	8	10							e72964	10.1371/journal.pone.0072964	http://dx.doi.org/10.1371/journal.pone.0072964			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	232NS	24115999	Green Submitted, Green Published, gold			2023-01-03	WOS:000325501300002
J	Pavlidou, K; Savvas, I; Moens, YPS; Vasilakos, D; Raptopoulos, D				Pavlidou, Kiriaki; Savvas, Ioannis; Moens, Yves P. S.; Vasilakos, Dimitrios; Raptopoulos, Dimitrios			The Effect of Four Anaesthetic Protocols for Maintenance of Anaesthesia on Trans-Diaphragmatic Pressure in Dogs	PLOS ONE			English	Article							TRANSDIAPHRAGMATIC PRESSURE; INTRAABDOMINAL PRESSURE; RESPIRATORY MUSCLE; BLOOD-FLOW; PROPOFOL; KETAMINE; HALOTHANE; INFUSION; SEVOFLURANE; FENTANYL	The diaphragm is the main inspiratory muscle and the main indicator of diaphragmatic contractility is the transdiaphragmatic pressure (P-di). The aim of this clinical study was to determine the effect of four different anaesthetic protocols on P-di in anaesthetized healthy dogs. Eighty client-owned dogs were recruited in this clinical study. All the animals received dexmedetomidine and morphine as premedication and propofol for induction. Anaesthesia was maintained with one of four protocols: isoflurane (I), isoflurane with CRI of propofol (IP), isoflurane with CRI of fentanyl (IF), and isoflurane with CRI of ketamine (IK). When the surgical plane of anaesthesia was achieved, two balloon catheters were inserted, one into the stomach and one into the mid-third of the oesophagus for P-di measurement. P-di value was the highest in groups I (14.9 +/- 4.7 mmHg) and IK (15.2 +/- 3.5 mmHg) and the lowest in groups IP (12.2 +/- 3.2 mmHg) and IF (12.0 +/- 5.9 mmHg). There was a statistically significant difference (p = 0.029) between groups IK and IF. PE'CO2 was statistically significantly higher (p<0.0005) in group IF (7.7 +/- 0.8 kPa) than in group IK (6.5 +/- 0.7 kPa). Isoflurane alone or isoflurane with ketamine for the maintenance of anaesthesia seem to better preserve the respiratory function and the diaphragmatic contractility than isoflurane with either propofol or fentanyl in dogs. Therefore, the use of isoflurane or isoflurane with ketamine may be of benefit when animals with respiratory problems have to be anaesthetized.	[Pavlidou, Kiriaki; Savvas, Ioannis; Raptopoulos, Dimitrios] Aristotle Univ Thessaloniki, Fac Vet Med, Compan Anim Clin, Anaesthesiol & Intens Care Unit, GR-54006 Thessaloniki, Greece; [Moens, Yves P. S.] Vet Univ Vienna, A-1030 Vienna, Austria; [Vasilakos, Dimitrios] AHEPA Univ Hosp, Anaesthesiol & ICU Dept, Thessaloniki, Greece	Aristotle University of Thessaloniki; University of Veterinary Medicine Vienna; Aristotle University of Thessaloniki; Ahepa University Hospital	Savvas, I (corresponding author), Aristotle Univ Thessaloniki, Fac Vet Med, Compan Anim Clin, Anaesthesiol & Intens Care Unit, GR-54006 Thessaloniki, Greece.	isavas@vet.auth.gr	Savvas, Ioannis/H-9622-2019	Savvas, Ioannis/0000-0001-5575-7244; Pavlidou, Kiriaki/0000-0002-1771-3811	European Union (European Social Fund - ESF); Greek national funds through the Operational Program "Education and Lifelong Learning" of the National Strategic Reference Framework (NSRF) - Research Funding Program: Heracleitus II	European Union (European Social Fund - ESF)(European Social Fund (ESF)); Greek national funds through the Operational Program "Education and Lifelong Learning" of the National Strategic Reference Framework (NSRF) - Research Funding Program: Heracleitus II	This research has been co-financed by the European Union (European Social Fund - ESF) and Greek national funds through the Operational Program "Education and Lifelong Learning" of the National Strategic Reference Framework (NSRF) - Research Funding Program: Heracleitus II. Investing in knowledge society through the European Social Fund. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ADAMS JM, 1988, J APPL PHYSIOL, V64, P2279, DOI 10.1152/jappl.1988.64.6.2279; ANDREWS CJH, 1983, BRIT J ANAESTH, V55, pS211; AUBIER M, 1981, NEW ENGL J MED, V305, P249, DOI 10.1056/NEJM198107303050503; Benditt Joshua O, 2005, Respir Care, V50, P68; Boriek AM, 2006, J APPL PHYSIOL, V101, P794, DOI 10.1152/japplphysiol.00865.2004; Bufalari A, 2012, SCHWEIZ ARCH TIERH, V154, P105, DOI 10.1024/0036-7281/a000308; CLERGUE F, 1986, ANESTHESIOLOGY, V64, P181, DOI 10.1097/00000542-198602000-00009; De Keulenaer BL, 2009, INTENS CARE MED, V35, P969, DOI 10.1007/s00134-009-1445-0; Dorfelt R, 2012, VET ANAESTH ANALG, V39, P390, DOI 10.1111/j.1467-2995.2012.00710.x; Drummond GB, 1996, BRIT J ANAESTH, V76, P663, DOI 10.1093/bja/76.5.663; Drummond GB, 2002, BRIT J ANAESTH, V88, P384, DOI 10.1093/bja/88.3.384; FARKAS G, 1990, CHEST, V97, pS39; GILBERT R, 1979, J APPL PHYSIOL, V47, P628, DOI 10.1152/jappl.1979.47.3.628; HASKINS SC, 1985, AM J VET RES, V46, P1855; HIGGS BD, 1983, ANESTHESIOLOGY, V59, P340, DOI 10.1097/00000542-198310000-00012; HILLMAN DR, 1990, J APPL PHYSIOL, V68, P2296, DOI 10.1152/jappl.1990.68.6.2296; HUBMAYR RD, 1990, J APPL PHYSIOL, V69, P2050, DOI 10.1152/jappl.1990.69.6.2050; HUSSAIN SNA, 1988, J APPL PHYSIOL, V64, P329, DOI 10.1152/jappl.1988.64.1.329; IDE T, 1992, ANESTH ANALG, V74, P739; IDE T, 1991, CAN J ANAESTH, V38, P116, DOI 10.1007/BF03009174; IDE T, 1993, ACTA ANAESTH SCAND, V37, P253, DOI 10.1111/j.1399-6576.1993.tb03710.x; Kagawa T, 1998, ANESTH ANALG, V86, P392, DOI 10.1097/00000539-199802000-00033; KOCHI T, 1990, ANESTH ANALG, V70, P362; KOCHI T, 1992, BRIT J ANAESTH, V68, P562, DOI 10.1093/bja/68.6.562; Kuusela E, 2003, J VET PHARMACOL THER, V26, P199, DOI 10.1046/j.1365-2885.2003.00465.x; Lambert DM, 2005, OBES SURG, V15, P1225, DOI 10.1381/096089205774512546; Lamont LA, 2007, LUMB JONES VET ANEST, P241; LAPORTA D, 1985, J APPL PHYSIOL, V58, P1469, DOI 10.1152/jappl.1985.58.5.1469; Laredo FG, 2004, VET REC, V155, P667, DOI 10.1136/vr.155.21.667; Lumb A.B., 2010, NUNNS APPL RESP PHYS, P327; MAGDER S, 1985, J APPL PHYSIOL, V58, P1148, DOI 10.1152/jappl.1985.58.4.1148; MANKIKIAN B, 1986, ANESTHESIOLOGY, V65, P492, DOI 10.1097/00000542-198611000-00007; Mannarino R, 2012, VET ANAESTH ANALG, V39, P160, DOI 10.1111/j.1467-2995.2011.00679.x; MATTHEWS JNS, 1990, BRIT MED J, V300, P230, DOI 10.1136/bmj.300.6719.230; McDonell W.N., 2007, LUMB JONES VET ANEST, P117; Moore RL, 1927, J EXP MED, V45, P1065, DOI 10.1084/jem.45.6.1065; Nishina K, 2003, ANESTH ANALG, V96, P1674, DOI 10.1213/01.ANE.0000060455.94684.69; Ora J, 2011, J APPL PHYSIOL, V111, P10, DOI 10.1152/japplphysiol.01131.2010; Pavlidou K, 2014, VET ANAESTH ANALG, V41, P278, DOI 10.1111/vaa.12073; POLKEY MI, 1995, THORAX, V50, P1131, DOI 10.1136/thx.50.11.1131; Sano T, 2006, VET ANAESTH ANALG, V33, P266, DOI 10.1111/j.1467-2995.2005.00266.x; SANTIAGO TV, 1979, J APPL PHYSIOL, V47, P112, DOI 10.1152/jappl.1979.47.1.112; SANTIAGO TV, 1985, J APPL PHYSIOL, V59, P1675, DOI 10.1152/jappl.1985.59.6.1675; Seliskar A, 2007, VET REC, V160, P85, DOI 10.1136/vr.160.3.85; SPRUNG J, 1990, J APPL PHYSIOL, V69, P2296, DOI 10.1152/jappl.1990.69.6.2296; Udeshi A, 2010, J CRIT CARE, V25, DOI 10.1016/j.jcrc.2009.12.014; ULKER S, 1991, INT J EXP PATHOL, V72, P527; WANKE T, 1993, CLIN PHYSIOL, V13, P349, DOI 10.1111/j.1475-097X.1993.tb00335.x; WATERMAN AE, 1991, VET REC, V129, P261, DOI 10.1136/vr.129.12.261; Zakynthinos S., 2005, PHYSL BASIS RESP DIS, P289; Zhang XJ, 2009, BRIT J ANAESTH, V102, P61, DOI 10.1093/bja/aen327; Zin W. A., 2005, PHYSL BASIS RESP DIS, P639	52	7	7	1	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 4	2013	8	10							e75341	10.1371/journal.pone.0075341	http://dx.doi.org/10.1371/journal.pone.0075341			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	232JF	24124482	Green Published, Green Submitted, gold			2023-01-03	WOS:000325489100039
J	Dryden-Peterson, S; Jayeoba, O; Hughes, MD; Jibril, H; McIntosh, K; Modise, TA; Asmelash, A; Powis, KM; Essex, M; Shapiro, RL; Lockman, S				Dryden-Peterson, Scott; Jayeoba, Oluwemimo; Hughes, Michael D.; Jibril, Haruna; McIntosh, Kenneth; Modise, Taolo A.; Asmelash, Aida; Powis, Kathleen M.; Essex, Max; Shapiro, Roger L.; Lockman, Shahin			Cotrimoxazole Prophylaxis and Risk of Severe Anemia or Severe Neutropenia in HAART-Exposed, HIV-Uninfected Infants	PLOS ONE			English	Article							TO-CHILD TRANSMISSION; ANTIRETROVIRAL THERAPY; AFRICAN ADULTS; COTE-DIVOIRE; PREVENTION; ZIDOVUDINE; WOMEN; PREGNANCY; BOTSWANA; REGIMENS	Background: Prophylactic cotrimoxazole is recommended for infants born to HIV-infected mothers. However, cotrimoxazole may increase the risk of severe anemia or neutropenia. Methods: We compared the proportion of HIV-exposed uninfected (HIV-EU) infants experiencing incident severe anemia (and separately, severe neutropenia) between a prospective cohort receiving prophylactic cotrimoxazole from 1 to 6 months vs. infants from two prior trials who did not receive cotrimoxazole. Infants were from rural and urban communities in southern Botswana. Results: A total of 1705 HIV-EU infants were included. Among these 645 (37.8%) were fed with iron-supplemented formula from birth. Severe anemia developed in 87 (5.1%) infants, and severe neutropenia in 164 (9.6%) infants. In an analysis stratified by infant feeding method, there were no significant differences in the risk of severe anemia by prophylactic cotrimoxazole exposure-risk difference, -0.69% (95% confidence interval [CI] -2.1 to 0.76%). Findings were similar in multivariable analysis, adjusted odds ratio (aOR) 0.35 (95% CI 0.07 to 1.65). There were also no significant differences observed for severe neutropenia by cotrimoxazole exposure, risk difference 2.0% (95% CI -1.3 to 5.2%) and aOR 0.80 (95% CI 0.33 to 1.93). Conclusions: Severe anemia and severe neutropenia were infrequent among HIV-exposed uninfected infants receiving cotrimoxazole from 1-6 months of age. Concerns regarding hematologic toxicity should not limit the use of prophylactic cotrimoxazole in HIV-exposed uninfected infants.	[Dryden-Peterson, Scott; Lockman, Shahin] Brigham & Womens Hosp, Div Infect Dis, Boston, MA 02115 USA; [Dryden-Peterson, Scott; Jayeoba, Oluwemimo; Modise, Taolo A.; Asmelash, Aida; Powis, Kathleen M.; Essex, Max; Shapiro, Roger L.; Lockman, Shahin] Botswana Harvard AIDS Inst Partnership, Gaborone, Botswana; [Dryden-Peterson, Scott; McIntosh, Kenneth; Powis, Kathleen M.; Essex, Max; Shapiro, Roger L.; Lockman, Shahin] Harvard Univ, Sch Publ Hlth, Dept Immunol & Infect Dis, Boston, MA 02115 USA; [Hughes, Michael D.] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA; [Jibril, Haruna] Minist Hlth, Dept Publ Hlth, Gaborone, Botswana; [McIntosh, Kenneth] Boston Childrens Hosp, Div Infect Dis, Boston, MA USA; [Powis, Kathleen M.] Massachusetts Gen Hosp, Dept Internal Med, Boston, MA 02114 USA; [Powis, Kathleen M.] Massachusetts Gen Hosp, Dept Pediat, Boston, MA 02114 USA; [Shapiro, Roger L.] Beth Israel Deaconess Med Ctr, Div Infect Dis, Boston, MA 02215 USA	Harvard University; Brigham & Women's Hospital; Botswana-Harvard AIDS Institute Partnership; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Boston Children's Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Beth Israel Deaconess Medical Center	Dryden-Peterson, S (corresponding author), Brigham & Womens Hosp, Div Infect Dis, 75 Francis St, Boston, MA 02115 USA.	scott_peterson@post.harvard.edu	Powis, Kathleen/AAU-5123-2021	Dryden-Peterson, Scott/0000-0002-8487-9731	Harvard University Center for AIDS Research (CFAR), a National Institutes of Health (NIH) [P30 AI060354]; NIH; NIAID; NCI; NICHD; NHLBI; NIDA; NIMH; NIA; MCCAM; FIC; OAR; Fogarty International Center [R24 TW007988]; Burroughs Wellcome Fund/American Society of Tropical Medicine and Hygiene; Harvard Institute for Global Health; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [K23HD070774] Funding Source: NIH RePORTER; FOGARTY INTERNATIONAL CENTER [R24TW007988] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K23AI091434, P30AI060354] Funding Source: NIH RePORTER	Harvard University Center for AIDS Research (CFAR), a National Institutes of Health (NIH); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIAID(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NHLBI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIMH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); MCCAM; FIC(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); OAR; Fogarty International Center(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); Burroughs Wellcome Fund/American Society of Tropical Medicine and Hygiene(Burroughs Wellcome Fund); Harvard Institute for Global Health; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Work supported by a research grant from the Harvard University Center for AIDS Research (CFAR), a National Institutes of Health (NIH)-funded program (P30 AI060354) which is supported by the following NIH Co-Funding and Participating Institutes and Centers: NIAID, NCI, NICHD, NHLBI, NIDA, NIMH, NIA, MCCAM, FIC, and OAR, and career development grants (to S. D. P) from the Fogarty International Center (R24 TW007988), Burroughs Wellcome Fund/American Society of Tropical Medicine and Hygiene, and the Harvard Institute for Global Health. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aizire J, 2012, AIDS, V26, P325, DOI 10.1097/QAD.0b013e32834e892c; Botswana Ministry of Health, 2008, BOTSW 2008 NAT HIV A; BROWN MS, 1988, DEV NEONATAL HEMATOL; Bunders MJ, 2005, ACTA PAEDIATR, V94, P1571, DOI 10.1080/08035250510042951; Chatziioannou A., 2009, PUBLIC HEALTH NUTR, P1; Coutsoudis A, 2010, B WORLD HEALTH ORGAN, V88, P949, DOI 10.2471/BLT.10.076422; Dryden-Peterson S, 2011, JAIDS-J ACQ IMM DEF, V58, P353, DOI 10.1097/QAI.0b013e31822d4063; Dryden-Peterson S, 2011, JAIDS-J ACQ IMM DEF, V56, P428, DOI 10.1097/QAI.0b013e31820bd2b6; Feiterna-Sperling C, 2007, JAIDS-J ACQ IMM DEF, V45, P43, DOI 10.1097/QAI.0b013e318042d5e3; Fernandez Ibieta M, 2008, An Pediatr (Barc), V69, P533; Hwan W, 2008, AIDS, V22, P1633, DOI 10.1097/QAD.0b013e328307a029; IMRIE KR, 1995, BONE MARROW TRANSPL, V15, P267; Kourtis Athena P, 2005, J Int Assoc Physicians AIDS Care (Chic), V4, P73, DOI 10.1177/1545109705282591; Lahoz R, 2009, PEDIAT INFECT DIS J; Le Chenadec J, 2003, AIDS, V17, P2053, DOI 10.1097/00002030-200309260-00006; Moh R, 2005, ANTIVIR THER, V10, P615; Mwinga K, 2009, BMC PEDIATR, V9, DOI 10.1186/1471-2431-9-49; NIH DoA, 2009, DIV AIDS TABL GRAD S; OBRIEN RT, 1971, J PEDIATR-US, V79, P132, DOI 10.1016/S0022-3476(71)80076-8; Pacheco SE, 2006, J INFECT DIS, V194, P1089, DOI 10.1086/507645; Palombi L, 2007, AIDS, V21, pS65, DOI 10.1097/01.aids.0000279708.09180.f5; Powis KM, 2011, J INFECT DIS, V204, P506, DOI 10.1093/infdis/jir307; Powis KM, 2011, JAIDS-J ACQ IMM DEF, V56, P131, DOI 10.1097/QAI.0b013e3181ffa4f5; Shapiro RL, 2010, NEW ENGL J MED, V362, P2282, DOI 10.1056/NEJMoa0907736; Ssali F, 2006, ANTIVIR THER, V11, P741; Tapp H, 1997, J PAEDIATR CHILD H, V33, P166, DOI 10.1111/j.1440-1754.1997.tb01022.x; Toure S, 2006, T ROY SOC TROP MED H, V100, P785, DOI 10.1016/j.trstmh.2005.11.008; Wells J, 2006, JAIDS-J ACQ IMM DEF, V42, P460, DOI 10.1097/01.qai.0000224975.45091.a5; WHO, 2001, IRON DEFICIENCY ANAE; WHO UNAIDS UNICEF, 2008, UN ACC SCAL PRIOR HI; WOODS WG, 1984, J PEDIATR-US, V105, P639, DOI 10.1016/S0022-3476(84)80439-4; World Health Organization, 2021, ANT DRUGS TREAT PREG; World Health Organization (WHO), 2006, GUID COTR PROPH HIV	33	7	7	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 23	2013	8	9							e74171	10.1371/journal.pone.0074171	http://dx.doi.org/10.1371/journal.pone.0074171			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	246EK	24086319	Green Published, gold, Green Submitted			2023-01-03	WOS:000326520200024
J	Li, S; Hu, T; Chen, YL; Zhou, H; Li, X; Cheng, XD; Yang, R; Wang, SX; Xie, X; Ma, D				Li, Shuang; Hu, Ting; Chen, Yile; Zhou, Hang; Li, Xiong; Cheng, Xiaodong; Yang, Ru; Wang, Shixuan; Xie, Xing; Ma, Ding			Adjuvant Chemotherapy, a Valuable Alternative Option in Selected Patients with Cervical Cancer	PLOS ONE			English	Article							QUALITY-OF-LIFE; SQUAMOUS-CELL CARCINOMA; EARLY-STAGE CANCER; HIGH-RISK; RADICAL HYSTERECTOMY; CONCURRENT CHEMORADIATION; PELVIC RADIATION; UTERINE CERVIX; PHASE-III; RADIOTHERAPY	Radiotherapy is the standard treatment for cervical cancer, but causes radiotherapy-induced complications. Recently, chemotherapy has been more extensively utilized. Here, we perform a large-scale comparison of chemotherapy and radiotherapy. From 2002 to 2008, 2,268 patients were grouped according to adjuvant radiotherapy or chemotherapy before and/or after surgery, and we compared the 5-year overall survival (OS) and disease-free survival (DFS) rates, recurrence rates, side effects, quality of life (QoL), and sexual activity. There were no significant differences between the treatment groups for the 5-year OS and DFS rates (OS: p = 0.053, DFS: p = 0.095), although marginally improved outcomes were observed in the chemotherapy group (OS: 86.5% vs. 82.8%; DFS: 84.5% vs. 81.4%). However, patients with early-stage disease, clinical response, and younger age had increased 5-year OS and DFS rates following chemotherapy compared to radiotherapy (p < 0.05). The chemotherapy group exhibited significantly lower 5-year recurrence and distant failure rates compared to the radiotherapy group (p < 0.001 and p = 0.007, respectively). Nausea and vomiting were the most frequent short-term complications of chemotherapy, whereas bowel and urinary complications were more frequent in the radiotherapy group. Compared to the chemotherapy group, patients who received radiotherapy reported a lower QoL, less frequent sexual activity, and more severe menopausal symptoms (p < 0.05). Cervical cancer patients treated with chemotherapy, especially those with early-stage disease, clinical responses, and younger ages, have more positive outcomes, fewer complications, better QoL and sexual activity, suggesting that chemotherapy may be a valuable alternative option for selected patients.	[Li, Shuang; Hu, Ting; Zhou, Hang; Li, Xiong; Yang, Ru; Wang, Shixuan; Ma, Ding] Huazhong Univ Sci & Technol, Dept Obstet & Gynecol, Tongji Hosp, Tongji Med Coll, Wuhan 430074, Peoples R China; [Chen, Yile] Cent S Univ, Affiliated Tumor Hosp, Hunan Prov Tumor Hosp, Dept Gynecol Neoplasms, Changsha, Hunan, Peoples R China; [Cheng, Xiaodong; Xie, Xing] Womens Reprod Hlth Lab Zhejiang Prov, Hangzhou, Zhejiang, Peoples R China	Huazhong University of Science & Technology; Central South University	Wang, SX (corresponding author), Huazhong Univ Sci & Technol, Dept Obstet & Gynecol, Tongji Hosp, Tongji Med Coll, Wuhan 430074, Peoples R China.	sxwang@tjh.tjmu.edu.cn; xiex@zju.edu.cn; dma@tjh.tjmu.edu.cn		Zhou, Hang/0000-0003-2719-790X	Foundation of China (973 Program) [2009CB521808]; National Natural Science Foundation of China [81230038, 81230052, 30973472, 81001151, 81071663, 30973205, 30973184, 81172464, 81101964]; National Major Science and Technology Project [2009ZX09103-739]	Foundation of China (973 Program); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Major Science and Technology Project	This work was supported by the Foundation of China (973 Program; No. 2009CB521808) and by grants from the National Natural Science Foundation of China (NO. 81230038; 81230052; 30973472; 81001151; 81071663; 30973205; 30973184; 81172464; 81101964) and National Major Science and Technology Project (No. 2009ZX09103-739). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Arbyn M, 2007, ANN ONCOL, V18, P1423, DOI 10.1093/annonc/mdm377; Banzai C, 2011, EUR J GYNAECOL ONCOL, V32, P521; Einstein MH, 2007, CANCER-AM CANCER SOC, V109, P48, DOI 10.1002/cncr.22369; Fayers PM, 2001, EORTC QLQC30 SCORING, V3rd; FIGO, FIGO GLOB GUID CERV; Frumovitz M, 2005, J CLIN ONCOL, V23, P7428, DOI 10.1200/JCO.2004.00.3996; Ganz PA, 2000, JNCI-J NATL CANCER I, V92, P1054, DOI 10.1093/jnci/92.13.1054; Green JA, 2001, LANCET, V358, P781, DOI 10.1016/S0140-6736(01)05965-7; Greimel ER, 2006, CANCER-AM CANCER SOC, V107, P1812, DOI 10.1002/cncr.22217; Greimel ER, 2009, PSYCHO-ONCOLOGY, V18, P476, DOI 10.1002/pon.1426; Hosaka M, 2008, J OBSTET GYNAECOL RE, V34, P552, DOI 10.1111/j.1447-0756.2008.00739.x; Hsu WC, 2009, GYNECOL ONCOL, V115, P41, DOI 10.1016/j.ygyno.2009.06.028; Hu T, 2012, EUR J CANC; Institutes NC, GUID GYN TUM CERV CA; Jensen PT, 2002, RADIOTHER ONCOL, V65, P29, DOI 10.1016/S0167-8140(02)00263-3; Kasamatsu T, 2009, BRIT J CANCER, V100, P1400, DOI 10.1038/sj.bjc.6605048; Kim JH, 2005, GYNECOL ONCOL, V96, P407, DOI 10.1016/j.ygyno.2004.10.025; Kosmas C, 2009, BRIT J CANCER, V101, P1059, DOI 10.1038/sj.bjc.6605305; Landoni F, 1997, LANCET, V350, P535, DOI 10.1016/S0140-6736(97)02250-2; Liu J, 2010, J HUAZHONG U SCI-MED, V30, P626, DOI 10.1007/s11596-010-0554-x; Llorca J, 2006, CANCER LETT, V240, P36, DOI 10.1016/j.canlet.2005.08.021; Long HJ, 2005, J CLIN ONCOL, V23, P4626, DOI 10.1200/JCO.2005.10.021; May Taymaa, 2011, Chemother Res Pract, V2011, P806256, DOI 10.1155/2011/806256; Moore DH, 2004, J CLIN ONCOL, V22, P3113, DOI 10.1200/JCO.2004.04.170; Morris M, 1999, NEW ENGL J MED, V340, P1137, DOI 10.1056/NEJM199904153401501; Organization WH, 1979, OFFS PUBL, V48, P16; Perez-Irizarry J, 2010, P R HEALTH SCI J, V29, P364; Peters WA, 2000, J CLIN ONCOL, V18, P1606, DOI 10.1200/JCO.2000.18.8.1606; Robova H, 2008, INT J GYNECOL CANCER, V18, DOI 10.1111/j.1525-1438.2007.01178.x; Ryu HS, 2005, GYNECOL ONCOL, V96, P490, DOI 10.1016/j.ygyno.2004.10.038; Shibata K, 2008, INT J CLIN ONCOL, V13, P233, DOI 10.1007/s10147-007-0744-0; Takeshima N, 2006, GYNECOL ONCOL, V103, P618, DOI 10.1016/j.ygyno.2006.04.019; THIGPEN T, 1981, CANCER, V48, P899, DOI 10.1002/1097-0142(19810815)48:4<899::AID-CNCR2820480406>3.0.CO;2-6; Thirlaway K, 1996, QUAL LIFE RES, V5, P81, DOI 10.1007/BF00435972; Tsai CS, 1999, GYNECOL ONCOL, V75, P328, DOI 10.1006/gyno.1999.5527; Vale C, 2008, J CLIN ONCOL, V26, P5802, DOI 10.1200/JCO.2008.16.4368; Vistad I, 2011, J CANCER SURVIV, V5, P208, DOI 10.1007/s11764-011-0172-z; Vizcaino AP, 2000, INT J CANCER, V86, P429, DOI 10.1002/(SICI)1097-0215(20000501)86:3<429::AID-IJC20>3.0.CO;2-D; Yamashita H, 2010, AM J CLIN ONCOL-CANC, V33, P583, DOI 10.1097/COC.0b013e3181cae5b7; Yoo SC, 2010, ACTA OBSTET GYN SCAN, V89, P126, DOI 10.3109/00016340903348383	40	11	13	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 13	2013	8	9							e73837	10.1371/journal.pone.0073837	http://dx.doi.org/10.1371/journal.pone.0073837			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	218BU	24058496	Green Published, gold, Green Submitted			2023-01-03	WOS:000324408400037
J	Li, WL; Li, K; Wei, WG; Ding, S				Li, Wenlin; Li, Ke; Wei, Wanguo; Ding, Sheng			Chemical Approaches to Stem Cell Biology and Therapeutics	CELL STEM CELL			English	Review							SMALL-MOLECULE INHIBITOR; PLUS G-CSF; HEMATOPOIETIC STEM; HUMAN FIBROBLASTS; SELF-RENEWAL; MOUSE FIBROBLASTS; DIRECT CONVERSION; SOMATIC-CELLS; FUNCTIONAL-NEURONS; PROGENITOR CELLS	Small molecules that modulate stem cell fate and function offer significant opportunities that will allow the full realization of the therapeutic potential of stem cells. Rational design and screening for small molecules have identified useful compounds to probe fundamental mechanisms of stem cell self-renewal, differentiation, and reprogramming and have facilitated the development of cell-based therapies and therapeutic drugs targeting endogenous stem and progenitor cells for repair and regeneration. Here, we will discuss recent scientific and therapeutic progress, as well as new perspectives and future challenges for using chemical approaches in stem cell biology and regenerative medicine.	[Li, Wenlin] Second Mil Med Univ, Dept Cell Biol, Shanghai 200433, Peoples R China; [Li, Ke; Ding, Sheng] Univ Calif San Francisco, Dept Pharmaceut Chem, Gladstone Inst Cardiovasc Dis, San Francisco, CA 94158 USA; [Wei, Wanguo] Chinese Acad Sci, Shanghai Adv Res Inst, Stem Cell & Regenerat Med Ctr, Shanghai 201210, Peoples R China	Naval Medical University; University of California System; University of California San Francisco; The J David Gladstone Institutes; Chinese Academy of Sciences; Shanghai Advanced Research Institute, CAS	Ding, S (corresponding author), Univ Calif San Francisco, Dept Pharmaceut Chem, Gladstone Inst Cardiovasc Dis, San Francisco, CA 94158 USA.	sheng.ding@gladstone.ucsf.edu	Li, Ke/K-9417-2015; Wei, Wanguo/H-3172-2012	Wei, Wanguo/0000-0002-2429-8281; li, wenlin/0000-0002-0842-222X	National Institutes of Health; California Institute for Regenerative Medicine; Gladstone Institutes; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD064610] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); California Institute for Regenerative Medicine(California Institute for Regenerative Medicine); Gladstone Institutes(University of California System); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))	Sheng Ding is supported by funding from National Institutes of Health, California Institute for Regenerative Medicine, and the Gladstone Institutes. We would like to thank Gary Howard and Anna Lisa Lucido for the editing of this manuscript. The authors apologize to all scientists whose research could not be properly discussed and cited in this Review owing to space limitations. Author contributions were as follows: Wenlin Li, Ke Li, and Wanguo Wei wrote the manuscript and Sheng Ding wrote, conceived of, and designed the manuscript. S.D. is a founder of Fate Therapeutics and Stemgent.	Ambasudhan R, 2011, CELL STEM CELL, V9, P113, DOI 10.1016/j.stem.2011.07.002; Askari AT, 2003, LANCET, V362, P697, DOI 10.1016/S0140-6736(03)14232-8; Ben-David U, 2013, CELL STEM CELL, V12, P167, DOI 10.1016/j.stem.2012.11.015; Boitano AE, 2010, SCIENCE, V329, P1345, DOI 10.1126/science.1191536; Borowiak M, 2009, CELL STEM CELL, V4, P348, DOI 10.1016/j.stem.2009.01.014; Brons IGM, 2007, NATURE, V448, P191, DOI 10.1038/nature05950; Broxmeyer HE, 2012, NAT MED, V18, P1786, DOI 10.1038/nm.2991; Buehr M, 2008, CELL, V135, P1287, DOI 10.1016/j.cell.2008.12.007; Caiazzo M, 2011, NATURE, V476, P224, DOI 10.1038/nature10284; Calandra G, 2008, BONE MARROW TRANSPL, V41, P331, DOI 10.1038/sj.bmt.1705908; Cao N, 2013, CELL RES, V23, P1119, DOI 10.1038/cr.2013.102; Chambers SM, 2012, NAT BIOTECHNOL, V30, P715, DOI 10.1038/nbt.2249; Chambers SM, 2009, NAT BIOTECHNOL, V27, P275, DOI 10.1038/nbt.1529; Chen GK, 2010, CELL STEM CELL, V7, P240, DOI 10.1016/j.stem.2010.06.017; Chen SB, 2006, P NATL ACAD SCI USA, V103, P17266, DOI 10.1073/pnas.0608156103; Chen S, 2009, NAT CHEM BIOL, V5, P258, DOI 10.1038/nchembio.154; Chen TT, 2010, STEM CELLS, V28, P1315, DOI 10.1002/stem.456; Chou YF, 2008, CELL, V135, P449, DOI 10.1016/j.cell.2008.08.035; Christopherson KW, 2004, SCIENCE, V305, P1000, DOI 10.1126/science.1097071; Huangfu DW, 2008, NAT BIOTECHNOL, V26, P1269, DOI 10.1038/nbt.1502; Efe JA, 2011, NAT CELL BIOL, V13, P215, DOI 10.1038/ncb2164; Fasano CA, 2010, CELL STEM CELL, V6, P336, DOI 10.1016/j.stem.2010.03.001; Feldman N, 2006, NAT CELL BIOL, V8, P188, DOI 10.1038/ncb1353; Feng R, 2008, P NATL ACAD SCI USA, V105, P6057, DOI 10.1073/pnas.0711961105; Flomenberg N, 2005, BLOOD, V106, P1867, DOI 10.1182/blood-2005-02-0468; Florian MC, 2012, CELL STEM CELL, V10, P520, DOI 10.1016/j.stem.2012.04.007; Folmes CDL, 2012, CELL STEM CELL, V11, P596, DOI 10.1016/j.stem.2012.10.002; Folmes CDL, 2011, CELL METAB, V14, P264, DOI 10.1016/j.cmet.2011.06.011; Goessling W, 2009, CELL, V136, P1136, DOI 10.1016/j.cell.2009.01.015; Gonzalez R, 2011, ANGEW CHEM INT EDIT, V50, P11181, DOI 10.1002/anie.201103909; Guo G, 2009, DEVELOPMENT, V136, P1063, DOI 10.1242/dev.030957; Han DW, 2012, CELL STEM CELL, V10, P465, DOI 10.1016/j.stem.2012.02.021; Hanna J, 2010, P NATL ACAD SCI USA, V107, P9222, DOI 10.1073/pnas.1004584107; Hanna J, 2009, CELL STEM CELL, V4, P513, DOI 10.1016/j.stem.2009.04.015; He L, 2009, CELL, V137, P635, DOI 10.1016/j.cell.2009.03.016; Heng JCD, 2010, CELL STEM CELL, V6, P167, DOI 10.1016/j.stem.2009.12.009; Hou PP, 2013, SCIENCE, V341, P651, DOI 10.1126/science.1239278; Huang PY, 2011, NATURE, V475, P386, DOI 10.1038/nature10116; Huang YL, 2012, CELL REP, V2, P1571, DOI 10.1016/j.celrep.2012.10.022; Huangfu DW, 2008, NAT BIOTECHNOL, V26, P795, DOI 10.1038/nbt1418; Ichida JK, 2009, CELL STEM CELL, V5, P491, DOI 10.1016/j.stem.2009.09.012; Ieda M, 2010, CELL, V142, P375, DOI 10.1016/j.cell.2010.07.002; Jeon SJ, 2011, J NEUROSCI, V31, P8351, DOI 10.1523/JNEUROSCI.6366-10.2011; Johnson K, 2012, SCIENCE, V336, P717, DOI 10.1126/science.1215157; Kawamata M, 2010, P NATL ACAD SCI USA, V107, P14223, DOI 10.1073/pnas.1009582107; Kim J, 2011, P NATL ACAD SCI USA, V108, P7838, DOI 10.1073/pnas.1103113108; Kim WY, 2009, NAT NEUROSCI, V12, P1390, DOI 10.1038/nn.2408; Kriks S, 2011, NATURE, V480, P547, DOI 10.1038/nature10648; Kubicek S, 2007, MOL CELL, V25, P473, DOI 10.1016/j.molcel.2007.01.017; Ladewig J, 2012, NAT METHODS, V9, P575, DOI [10.1038/NMETH.1972, 10.1038/nmeth.1972]; Lee J, 2000, J MOL NEUROSCI, V15, P99, DOI 10.1385/JMN:15:2:99; Li HR, 2012, P NATL ACAD SCI USA, V109, P4609, DOI 10.1073/pnas.1200305109; Li J, 2013, ARTERIOSCL THROM VAS, V33, P1366, DOI 10.1161/ATVBAHA.112.301167; Li P, 2008, CELL, V135, P1299, DOI 10.1016/j.cell.2008.12.006; Li WL, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3000996; Li WL, 2011, P NATL ACAD SCI USA, V108, P8299, DOI 10.1073/pnas.1014041108; Li WL, 2009, STEM CELLS, V27, P2992, DOI 10.1002/stem.240; Li WL, 2009, CELL STEM CELL, V4, P16, DOI 10.1016/j.stem.2008.11.014; Lian XJ, 2012, P NATL ACAD SCI USA, V109, pE1848, DOI 10.1073/pnas.1200250109; Liles WC, 2003, BLOOD, V102, P2728, DOI 10.1182/blood-2003-02-0663; Lin TX, 2009, NAT METHODS, V6, P805, DOI [10.1038/NMETH.1393, 10.1038/nmeth.1393]; MacMillan KS, 2011, J AM CHEM SOC, V133, P1428, DOI 10.1021/ja108211m; Maherali N, 2009, CURR BIOL, V19, P1718, DOI 10.1016/j.cub.2009.08.025; Mali P, 2010, STEM CELLS, V28, P713, DOI 10.1002/stem.402; Mao YW, 2009, CELL, V136, P1017, DOI 10.1016/j.cell.2008.12.044; Marson A, 2008, CELL STEM CELL, V3, P132, DOI 10.1016/j.stem.2008.06.019; Miller FD, 2012, CELL STEM CELL, V10, P650, DOI 10.1016/j.stem.2012.05.004; Minami I, 2012, CELL REP, V2, P1448, DOI 10.1016/j.celrep.2012.09.015; Mizutari K, 2013, NEURON, V77, P58, DOI 10.1016/j.neuron.2012.10.032; Naito AT, 2006, P NATL ACAD SCI USA, V103, P19812, DOI 10.1073/pnas.0605768103; North TE, 2007, NATURE, V447, P1007, DOI 10.1038/nature05883; Ohgushi M, 2010, CELL STEM CELL, V7, P225, DOI 10.1016/j.stem.2010.06.018; Onder TT, 2012, NATURE, V483, P598, DOI 10.1038/nature10953; Pang ZPP, 2011, NATURE, V476, P220, DOI 10.1038/nature10202; Petit I, 2002, NAT IMMUNOL, V3, P687, DOI 10.1038/ni813; Pfisterer U, 2011, P NATL ACAD SCI USA, V108, P10343, DOI 10.1073/pnas.1105135108; Pieper AA, 2010, CELL, V142, P39, DOI 10.1016/j.cell.2010.06.018; Pitchford SC, 2009, CELL STEM CELL, V4, P62, DOI 10.1016/j.stem.2008.10.017; Qian L, 2012, NATURE, V485, P593, DOI 10.1038/nature11044; Ramirez P, 2009, BLOOD, V114, P1340, DOI 10.1182/blood-2008-10-184721; Reya T, 2005, NATURE, V434, P843, DOI 10.1038/nature03319; Ryan MA, 2010, NAT MED, V16, P1141, DOI 10.1038/nm.2217; Schugar RC, 2008, GENE THER, V15, P126, DOI 10.1038/sj.gt.3303062; Sekiya S, 2011, NATURE, V475, P390, DOI 10.1038/nature10263; Shi Y, 2008, CELL STEM CELL, V3, P568, DOI 10.1016/j.stem.2008.10.004; Shi Y, 2008, CELL STEM CELL, V2, P525, DOI 10.1016/j.stem.2008.05.011; Silva J, 2008, PLOS BIOL, V6, P2237, DOI 10.1371/journal.pbio.0060253; Song KH, 2012, NATURE, V485, P599, DOI 10.1038/nature11139; Stadtfeld M., 2012, NAT GENET, V44, pS1, DOI DOI 10.1038/NG.1110; Stadtfeld M, 2012, NAT GENET, V44, P398, DOI 10.1038/ng.1110; Staerk J, 2011, ANGEW CHEM INT EDIT, V50, P5733, DOI 10.1002/anie.201101042; Takubo K, 2013, CELL STEM CELL, V12, P49, DOI 10.1016/j.stem.2012.10.011; Tesar PJ, 2007, NATURE, V448, P196, DOI 10.1038/nature05972; Ueno S, 2007, P NATL ACAD SCI USA, V104, P9685, DOI 10.1073/pnas.0702859104; Vierbuchen T, 2010, NATURE, V463, P1035, DOI 10.1038/nature08797; Wagers AJ, 2012, CELL STEM CELL, V10, P362, DOI 10.1016/j.stem.2012.02.018; Walker A, 2010, NAT COMMUN, V1, DOI 10.1038/ncomms1074; Wang J, 2012, CELL STEM CELL, V11, P23, DOI 10.1016/j.stem.2012.03.016; Wang L, 2007, P NATL ACAD SCI USA, V104, P1248, DOI 10.1073/pnas.0609149104; Wang T, 2011, CELL STEM CELL, V9, P575, DOI 10.1016/j.stem.2011.10.005; Wang W, 2011, P NATL ACAD SCI USA, V108, P18283, DOI 10.1073/pnas.1100893108; Wang Y, 2011, STEM CELL REV REP, V7, P331, DOI 10.1007/s12015-010-9209-3; Watanabe K, 2007, NAT BIOTECHNOL, V25, P681, DOI 10.1038/nbt1310; Watt FM, 2000, SCIENCE, V287, P1427, DOI 10.1126/science.287.5457.1427; Xu Y, 2008, NATURE, V453, P338, DOI 10.1038/nature07042; Xu Y, 2010, P NATL ACAD SCI USA, V107, P8129, DOI 10.1073/pnas.1002024107; Yanes O, 2010, NAT CHEM BIOL, V6, P411, DOI 10.1038/nchembio.364; Yang W, 2009, STEM CELLS, V27, P383, DOI 10.1634/stemcells.2008-0974; Ying QL, 2008, NATURE, V453, P519, DOI 10.1038/nature06968; Yoo AS, 2011, NATURE, V476, P228, DOI 10.1038/nature10323; Yuan X, 2011, STEM CELLS, V29, P549, DOI 10.1002/stem.594; Zaruba MM, 2009, CELL STEM CELL, V4, P313, DOI 10.1016/j.stem.2009.02.013; Zhang J, 2012, CELL STEM CELL, V11, P589, DOI 10.1016/j.stem.2012.10.005; Zhou HY, 2010, J BIOL CHEM, V285, P29676, DOI 10.1074/jbc.C110.150599; Zhou HY, 2009, CELL STEM CELL, V4, P381, DOI 10.1016/j.stem.2009.04.005; Zhou Q, 2008, NATURE, V455, P627, DOI 10.1038/nature07314; Zhu SY, 2010, CELL STEM CELL, V7, P651, DOI 10.1016/j.stem.2010.11.015	117	126	131	1	59	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	1934-5909	1875-9777		CELL STEM CELL	Cell Stem Cell	SEP 5	2013	13	3					270	283		10.1016/j.stem.2013.08.002	http://dx.doi.org/10.1016/j.stem.2013.08.002			14	Cell & Tissue Engineering; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	287VQ	24012368	Bronze, Green Accepted			2023-01-03	WOS:000329570800006
J	Chen, SJ; Asakawa, T; Ding, SS; Liao, LH; Zhang, LY; Shen, JY; Yu, J; Sugiyama, K; Namba, H; Li, CD				Chen, Shujiao; Asakawa, Tetsuya; Ding, Shanshan; Liao, Linghong; Zhang, Lingyuan; Shen, Jianying; Yu, Jie; Sugiyama, Kenji; Namba, Hiroki; Li, Candong			Chaihu-Shugan-San Administration Ameliorates Perimenopausal Anxiety and Depression in Rats	PLOS ONE			English	Article							ESTROGEN-RECEPTOR MODULATORS; MENOPAUSAL STATUS; HORMONE-THERAPY; WOMEN; MODEL; EXPRESSION; SYMPTOMS; BEHAVIOR; STRESS; GENE	Chaihu-Shugan-San (CSS) is a traditional Chinese herbal formula that is widely used for treating perimenopausal symptoms in China; however, its mechanisms remain unknown. The present study was designed to investigate potential CSS mechanisms in rats with unpredicted chronic mild stress (UCMS) and normally aging rats (52 weeks of age). We performed the sucrose consumption test along with the forced swimming test to confirm depression like behaviour and the open field test (OFT) to confirm anxiety-like behavior in the animals. In addition, we used an enzyme-linked immunosorbent assay to measure serum and hippocampal estradiol (E-2) levels and a quantitative real-time polymerase chain reaction to assess hippocampal mRNA levels of estrogen receptors (ERs) alpha and beta as well as G protein-coupled receptor 30 (GPR30). We found that CSS administration resulted in a significant increase in the ratio of hippocampal ER alpha and ER beta mRNA (ER alpha/ER beta ratio) in expression. In contrast, changes in ER alpha/ER beta mRNA ratio were sensitively associated with changes in mood states in the animal models. These findings suggest that enhancement of ER alpha/ER beta ratio may play a role in the pharmacological mechanisms of CSS. Furthermore, this ratio can be employed as a potential index for evaluating mood states in animal models and can be considered as a therapeutic target for perimenopausal anxiety and depression in the furture.	[Chen, Shujiao; Ding, Shanshan; Liao, Linghong; Zhang, Lingyuan; Shen, Jianying; Yu, Jie; Li, Candong] Fujian Univ Tradit Chinese Med, Res Base TCM Syndrome, Minhou Fuzhou City, Peoples R China; [Asakawa, Tetsuya; Sugiyama, Kenji; Namba, Hiroki] Hamamatsu Univ, Sch Med, Dept Neurosurg, Hamamatsu, Shizuoka 4312102, Japan	Fujian University of Traditional Chinese Medicine; Hamamatsu University School of Medicine	Asakawa, T (corresponding author), Hamamatsu Univ, Sch Med, Dept Neurosurg, Hamamatsu, Shizuoka 4312102, Japan.	asakawat1971@gmail.com; cdli@fjtcm.edu.cn	Asakawa, Tetsuya/ABE-5307-2020	Asakawa, Tetsuya/0000-0002-2300-3509	National Sciences Foundation of China [81173203]; Grants-in-Aid for Scientific Research [24592157] Funding Source: KAKEN	National Sciences Foundation of China(National Natural Science Foundation of China (NSFC)); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	This work was supported by the National Sciences Foundation of China (No: 81173203) http://www.nsfc.gov.cn/Portal0/default166htm. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alaerts G, 2010, J CHROMATOGR A, V1217, P7706, DOI 10.1016/j.chroma.2010.10.010; Anderson G, 2013, PROG NEURO-PSYCHOPH, V42, P101, DOI 10.1016/j.pnpbp.2012.07.016; ARCHER J, 1973, ANIM BEHAV, V21, P205, DOI 10.1016/S0003-3472(73)80065-X; Asakawa T, 2012, CURRENT RES ACUPUNCT, P215; Barber RD, 2005, PHYSIOL GENOMICS, V21, P389, DOI 10.1152/physiolgenomics.00025.2005; Barros RPA, 2011, CELL METAB, V14, P289, DOI 10.1016/j.cmet.2011.08.005; Bosworth HB, 2001, PSYCHOSOM MED, V63, P603, DOI 10.1097/00006842-200107000-00013; Calmarza-Font I, 2012, BEHAV BRAIN RES, V227, P287, DOI 10.1016/j.bbr.2011.10.036; Chim H, 2002, MATURITAS, V41, P275, DOI 10.1016/S0378-5122(01)00299-7; Ducottet C, 2003, PROG NEURO-PSYCHOPH, V27, P625, DOI 10.1016/S0278-5846(03)00051-4; Freeman EW, 2004, ARCH GEN PSYCHIAT, V61, P62, DOI 10.1001/archpsyc.61.1.62; Gyllstrom ME, 2007, BEST PRACT RES CL OB, V21, P275, DOI 10.1016/j.bpobgyn.2006.11.002; Harlow BL, 2003, ARCH GEN PSYCHIAT, V60, P29, DOI 10.1001/archpsyc.60.1.29; Henderson VW, 2005, J NEUROL NEUROSUR PS, V76, P103, DOI 10.1136/jnnp.2003.024927; Huang W, 2011, J GASTROINTEST SURG, V15, P87, DOI 10.1007/s11605-010-1374-9; Jansson C, 2003, MATURITAS, V45, P129, DOI 10.1016/S0378-5122(03)00127-0; Jones NC, 2008, EXP NEUROL, V209, P254, DOI 10.1016/j.expneurol.2007.09.026; KATZ RJ, 1981, NEUROSCI BIOBEHAV R, V5, P247, DOI 10.1016/0149-7634(81)90005-1; Kim SH, 2005, LIFE SCI, V76, P1297, DOI 10.1016/j.lfs.2004.10.022; Li SL, 2009, J PHARMACEUT BIOMED, V49, P253, DOI 10.1016/j.jpba.2008.11.007; Liang W, 2010, CHINA J TRADITIONAL, V2, P201; Maki PM, 2006, NEUROSCIENCE, V138, P1027, DOI 10.1016/j.neuroscience.2006.01.001; Montoro P, 2011, J PHARMACEUT BIOMED, V54, P535, DOI 10.1016/j.jpba.2010.10.004; Moretti M, 2013, J MOL NEUROSCI, V49, P68, DOI 10.1007/s12031-012-9892-4; Nadal-Serrano M, 2012, J CELL BIOCHEM, V113, P3178, DOI 10.1002/jcb.24192; Owens JF, 1998, MATURITAS, V30, P41, DOI 10.1016/S0378-5122(98)00039-5; Pandya CD, 2012, PROG NEUROP IN PRESS; PORSOLT RD, 1977, NATURE, V266, P730, DOI 10.1038/266730a0; Russo E, 2013, NEUROPHARMACOLOGY, V64, P371, DOI 10.1016/j.neuropharm.2012.06.039; Ryan J, 2012, DRUGS, V72, P1725, DOI 10.2165/11635960-000000000-00000; Sarkisova KY, 2010, EPILEPSIA, V51, P146, DOI 10.1111/j.1528-1167.2009.02260.x; Suzuki H, 2013, MOL PSYCHIATR, V18, P674, DOI 10.1038/mp.2012.62; Takeo S, 2005, DEV BIOL, V284, P204, DOI 10.1016/j.ydbio.2005.05.014; Thomas C, 2012, J CLIN INVEST, V122, P2771, DOI 10.1172/JCI65133; Tian RT, 2009, J CHROMATOGR A, V1216, P2150, DOI 10.1016/j.chroma.2008.10.127; Usall J, 2011, ACTAS ESP PSIQUIATRI, V39, P334; Versini A, 2010, NEUROPSYCHOPHARMACOL, V35, P1818, DOI 10.1038/npp.2010.49; Walf AA, 2007, PHARMACOL BIOCHEM BE, V86, P407, DOI 10.1016/j.pbb.2006.07.003; Wang L, 2012, SHAANXI J TRADITIONA, V33, P105; Wang Y, 2012, J ETHNOPHARMACOL, V141, P571, DOI 10.1016/j.jep.2011.08.079; Zandi PP, 2002, JAMA-J AM MED ASSOC, V288, P2123, DOI 10.1001/jama.288.17.2123; Zhang YJ, 2011, BRAIN RES BULL, V86, P222, DOI 10.1016/j.brainresbull.2011.07.002; Zhao T, 2010, J HUM GENET, V55, P50, DOI 10.1038/jhg.2009.122	43	29	33	2	34	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 27	2013	8	8							e72428	10.1371/journal.pone.0072428	http://dx.doi.org/10.1371/journal.pone.0072428			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	210FR	24015243	gold, Green Published, Green Submitted			2023-01-03	WOS:000323815200042
J	Saito, K; Inagaki, K; Kamimoto, T; Ito, Y; Sugita, T; Nakajo, S; Hirasawa, A; Iwamaru, A; Ishikura, T; Hanaoka, H; Okubo, K; Onozaki, T; Zama, T				Saito, Koichiro; Inagaki, Koji; Kamimoto, Takahiro; Ito, Yoko; Sugita, Toshiaki; Nakajo, Satoko; Hirasawa, Akira; Iwamaru, Arifumi; Ishikura, Takashi; Hanaoka, Hideki; Okubo, Keisuke; Onozaki, Tokio; Zama, Takeru			MicroRNA-196a Is a Putative Diagnostic Biomarker and Therapeutic Target for Laryngeal Cancer	PLOS ONE			English	Article							DOWN-REGULATION; COLORECTAL-CANCER; MESSENGER-RNAS; EXPRESSION; GENES; SIGNATURES; GROWTH; DEREGULATION; BIOGENESIS; MECHANISM	Background: MicroRNA (miRNA) is an emerging subclass of small non-coding RNAs that regulates gene expression and has a pivotal role for many physiological processes including cancer development. Recent reports revealed the role of miRNAs as ideal biomarkers and therapeutic targets due to their tissue-or disease-specific nature. Head and neck cancer (HNC) is a major cause of cancer-related mortality and morbidity, and laryngeal cancer has the highest incidence in it. However, the molecular mechanisms involved in laryngeal cancer development remain to be known and highly sensitive biomarkers and novel promising therapy is necessary. Methodology/Principal Findings: To explore laryngeal cancer-specific miRNAs, RNA from 5 laryngeal surgical specimens including cancer and non-cancer tissues were hybridized to microarray carrying 723 human miRNAs. The resultant differentially expressed miRNAs were further tested by using quantitative real time PCR (qRT-PCR) on 43 laryngeal tissue samples including cancers, noncancerous counterparts, benign diseases and precancerous dysplasias. Significant expressional differences between matched pairs were reproduced in miR-133b, miR-455-5p, and miR-196a, among which miR-196a being the most promising cancer biomarker as validated by qRT-PCR analyses on additional 84 tissue samples. Deep sequencing analysis revealed both quantitative and qualitative deviation of miR-196a isomiR expression in laryngeal cancer. In situ hybridization confirmed laryngeal cancer-specific expression of miR-196a in both cancer and cancer stroma cells. Finally, inhibition of miR-196a counteracted cancer cell proliferation in both laryngeal cancer-derived cells and mouse xenograft model. Conclusions/Significance: Our study provided the possibilities that miR-196a might be very useful in diagnosing and treating laryngeal cancer.	[Saito, Koichiro; Inagaki, Koji; Kamimoto, Takahiro; Iwamaru, Arifumi; Zama, Takeru] Keio Univ, Sch Med, Dept Otolaryngol Head & Neck Surg, Tokyo, Japan; [Ito, Yoko; Sugita, Toshiaki; Nakajo, Satoko] SRL Inc, Ctr Genet & Chromosomal Anal, Genet Testing Sect, Tokyo, Japan; [Hirasawa, Akira] Keio Univ, Sch Med, Dept Obstet & Gynecol, Tokyo 160, Japan; [Iwamaru, Arifumi] Federat Natl Publ Serv Personnel Mutual Aid Assoc, Dept Surg, Tokyo, Japan; [Ishikura, Takashi; Hanaoka, Hideki; Onozaki, Tokio] Life Technol Japan, Tokyo, Japan; [Okubo, Keisuke] Sano Kousei Gen Hosp, Dept Otolaryngol, Sano, Tochigi, Japan	Keio University; SRL Inc.; Keio University; Thermo Fisher Scientific	Zama, T (corresponding author), Keio Univ, Sch Med, Dept Otolaryngol Head & Neck Surg, Tokyo, Japan.	tzama-kei@umin.ac.jp		Saito, Koichiro/0000-0002-8107-2967	New Energy and Industrial Technology Development Organization (NEDO)	New Energy and Industrial Technology Development Organization (NEDO)(New Energy and Industrial Technology Development Organization (NEDO))	A part of this work was supported by a Grant for Industrial Technology Research of the New Energy and Industrial Technology Development Organization (NEDO; http://www.nedo.go.jp/english/index.html). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. No additional external funding was received for this study.	Abella V, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052568; Akao Y, 2007, CANCER SCI, V98, P1914, DOI 10.1111/j.1349-7006.2007.00618.x; Akao Y, 2007, DNA CELL BIOL, V26, P311, DOI 10.1089/dna.2006.0550; Bandres E, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-29; Bandres E, 2007, DNA CELL BIOL, V26, P273, DOI 10.1089/dna.2006.0544; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Burmistrova OA, 2007, BIOCHEMISTRY-MOSCOW+, V72, P578, DOI 10.1134/S0006297907050161; Calin GA, 2004, P NATL ACAD SCI USA, V101, P2999, DOI 10.1073/pnas.0307323101; Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997; Cao PY, 2013, HEAD NECK-J SCI SPEC, V35, P720, DOI 10.1002/hed.23011; Carvalho AL, 2005, INT J CANCER, V114, P806, DOI 10.1002/ijc.20740; Chang SS, 2008, INT J CANCER, V123, P2791, DOI 10.1002/ijc.23831; Chang TC, 2007, ANNU REV GENOM HUM G, V8, P215, DOI 10.1146/annurev.genom.8.080706.092351; Chen HC, 2009, BRIT J CANCER, V100, P1002, DOI 10.1038/sj.bjc.6604948; Chen KN, 2005, CLIN CANCER RES, V11, P1044; Coskun E, LEUK RES; de Carcer G, 2007, CURR MED CHEM, V14, P969, DOI 10.2174/092986707780362925; Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840; Filipowicz W, 2008, NAT REV GENET, V9, P102, DOI 10.1038/nrg2290; Fish JE, 2009, SCI SIGNAL, V1, DOI 10.1126/scisignal.252pe1; Flynt AS, 2008, NAT REV GENET, V9, P831, DOI 10.1038/nrg2455; Friedman RC, 2009, GENOME RES, V19, P92, DOI 10.1101/gr.082701.108; Garzon R, 2006, TRENDS MOL MED, V12, P580, DOI 10.1016/j.molmed.2006.10.006; Gregersen LH, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008836; Guled M, 2009, GENE CHROMOSOME CANC, V48, P615, DOI 10.1002/gcc.20669; Hammond SM, 2006, CURR OPIN GENET DEV, V16, P4, DOI 10.1016/j.gde.2005.12.005; Hermeking H, 2007, CANCER CELL, V12, P414, DOI 10.1016/j.ccr.2007.10.028; Hiroki E, 2009, CANC SCI; Hiyoshi Y, 2009, CLIN CANCER RES, V15, P1915, DOI 10.1158/1078-0432.CCR-08-2545; Hughes TR, 2001, NAT BIOTECHNOL, V19, P342, DOI 10.1038/86730; Hui ABY, 2009, LAB INVEST, V89, P597, DOI 10.1038/labinvest.2009.12; Hurst DR, 2009, CANCER RES, V69, P1279, DOI 10.1158/0008-5472.CAN-08-3559; Ichimi T, 2009, INT J CANCER, V125, P345, DOI 10.1002/ijc.24390; Iekushi K, 2012, CIRCULATION, V125, P1765, DOI 10.1161/CIRCULATIONAHA.111.079699; Iorio MV, 2007, CANCER RES, V67, P8699, DOI 10.1158/0008-5472.CAN-07-1936; Iorio MV, 2005, CANCER RES, V65, P7065, DOI 10.1158/0008-5472.CAN-05-1783; Isenberg JS, 2008, ANN OTO RHINOL LARYN, V117, P74, DOI 10.1177/000348940811700114; Izzotti A, 2009, FASEB J, V23, P806, DOI 10.1096/fj.08-121384; Jemal A, 2002, CA-CANCER J CLIN, V52, P23, DOI 10.3322/canjclin.52.1.23; Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43; KANO M, INT J CANC; Kim VN, 2005, NAT REV MOL CELL BIO, V6, P376, DOI 10.1038/nrm1644; Kim YJ, 2009, J BONE MINER RES, V24, P816, DOI 10.1359/JBMR.081230; Landgraf P, 2007, CELL, V129, P1401, DOI 10.1016/j.cell.2007.04.040; Li C, 2009, AAPS J; Li JH, 2007, BMC BIOTECHNOL, V7, DOI 10.1186/1472-6750-7-36; Lim LP, 2005, NATURE, V433, P769, DOI 10.1038/nature03315; Liu X, 2009, CLIN CANCER RES, V15, P1177, DOI 10.1158/1078-0432.CCR-08-1355; Liu X, 2008, BRAIN PATHOL, V18, P113, DOI 10.1111/j.1750-3639.2007.00121.x; Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702; Luthra R, 2008, ONCOGENE, V27, P6667, DOI 10.1038/onc.2008.256; Mercatelli N, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0004029; MILLS GB, 1992, J BIOL CHEM, V267, P16000; Morin RD, 2008, GENOME RES, V18, P610, DOI 10.1101/gr.7179508; Ng EKO, 2009, BRIT J CANCER, V101, P699, DOI 10.1038/sj.bjc.6605195; Ozen M, 2008, ONCOGENE, V27, P1788, DOI 10.1038/sj.onc.1210809; Rosenfeld N, 2008, NAT BIOTECHNOL, V26, P462, DOI 10.1038/nbt1392; Schimanski CC, 2009, WORLD J GASTROENTERO, V15, P2089, DOI 10.3748/wjg.15.2089; Sempere LF, 2007, CANCER RES, V67, P11612, DOI 10.1158/0008-5472.CAN-07-5019; Suda T, 2007, CANC SCI; Szafranska AE, 2007, ONCOGENE, V26, P4442, DOI 10.1038/sj.onc.1210228; Takagi T, 2009, ONCOLOGY-BASEL, V77, P12, DOI 10.1159/000218166; Takahashi O, 2007, ONCOL REP, V17, P753; Taylor DD, 2008, GYNECOL ONCOL, V110, P13, DOI 10.1016/j.ygyno.2008.04.033; Tazawa H, 2007, P NATL ACAD SCI USA, V104, P15472, DOI 10.1073/pnas.0707351104; Tie J, PLOS GEN, V6; Tsai WC, 2009, HEPATOLOGY, V49, P1571, DOI 10.1002/hep.22806; Valadi H, 2007, NAT CELL BIOL, V9, P654, DOI 10.1038/ncb1596; Vermeulen A, 2007, RNA, V13, P723, DOI 10.1261/rna.448107; Volinia S, 2006, P NATL ACAD SCI USA, V103, P2257, DOI 10.1073/pnas.0510565103; Wang H, 2007, RNA, V13, P151, DOI 10.1261/rna.234507; Wang YF, 2009, J BIOL CHEM, V284, P23094, DOI 10.1074/jbc.M109.012617; Wong TS, 2008, CLIN CANCER RES, V14, P2588, DOI 10.1158/1078-0432.CCR-07-0666; Wu H, 2009, EXPERT OPIN THER TAR; Wynter CVA, 2006, MED HYPOTHESES, V66, P612, DOI 10.1016/j.mehy.2005.10.024; Yanaihara N, 2006, CANCER CELL, V9, P189, DOI 10.1016/j.ccr.2006.01.025; Yekta S, 2004, SCIENCE, V304, P594, DOI 10.1126/science.1097434; Yuan BB, 2006, CLIN CANCER RES, V12, P405, DOI 10.1158/1078-0432.CCR-05-0903; Zhang BH, 2007, DEV BIOL, V302, P1, DOI 10.1016/j.ydbio.2006.08.028; Zhang BH, 2007, J CELL PHYSIOL, V210, P279, DOI 10.1002/jcp.20869; Zorn KK, 2003, CLIN CANCER RES, V9, P4811	81	66	68	0	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 14	2013	8	8							e71480	10.1371/journal.pone.0071480	http://dx.doi.org/10.1371/journal.pone.0071480			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	202MQ	23967217	gold, Green Published, Green Submitted			2023-01-03	WOS:000323221500087
J	Elster, EA; Butler, FK; Rasmussen, TE				Elster, Eric A.; Butler, Frank K.; Rasmussen, Todd E.			Implications of Combat Casualty Care for Mass Casualty Events	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							MORTALITY; DEATH		[Elster, Eric A.; Rasmussen, Todd E.] Uniformed Serv Univ Hlth Sci, Norman M Rich Dept Surg, Bethesda, MD 20814 USA; [Elster, Eric A.] Naval Med Res Ctr, Silver Spring, MD USA; [Butler, Frank K.; Rasmussen, Todd E.] US Army Inst Surg Res, Joint Base San Antonio, Ft Sam Houston, TX USA	Uniformed Services University of the Health Sciences - USA; Naval Medical Research Center (NMRC); United States Department of Defense; United States Army	Elster, EA (corresponding author), Uniformed Serv Univ Hlth Sci, Dept Surg, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA.	eric.elster@usuhs.edu	Elster, Eric/ABG-6091-2021; Rasmussen, Todd/Y-2122-2019	Rasmussen, Todd/0000-0003-1120-4116; Elster, Eric/0000-0002-0981-2748				Borgman MA, 2007, J TRAUMA, V63, P805, DOI 10.1097/TA.0b013e3181271ba3; Butler FK, 2012, J TRAUMA ACUTE CARE, V73, pS395, DOI 10.1097/TA.0b013e3182754850; Eastridge BJ, 2012, J TRAUMA ACUTE CARE, V73, pS431, DOI 10.1097/TA.0b013e3182755dcc; Kotwal RS, 2011, ARCH SURG-CHICAGO, V146, P1349, DOI 10.1001/archsurg.2011.213; Mabry RL, 2012, J TRAUMA ACUTE CARE, V73, pS32, DOI 10.1097/TA.0b013e3182606001; Morrison JJ, 2013, ANN SURG, V257, P330, DOI 10.1097/SLA.0b013e31827eefcf; Morrison JJ, 2012, ARCH SURG-CHICAGO, V147, P113, DOI 10.1001/archsurg.2011.287; Propper BW, 2009, ANN SURG, V250, P311, DOI 10.1097/SLA.0b013e3181ae34a2; Timbie JW, 2012, AHRQ PUBLICATION 12, V12-E006-EF	9	40	40	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 7	2013	310	5					475	476		10.1001/jama.2013.167481	http://dx.doi.org/10.1001/jama.2013.167481			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	196OZ	23925612				2023-01-03	WOS:000322786400014
J	Jilaveanu, LB; Zhao, FM; Zito, CR; Kirkwood, JM; Nathanson, KL; D'Andrea, K; Wilson, M; Rimm, DL; Flaherty, KT; Lee, SJ; Kluger, HM				Jilaveanu, Lucia B.; Zhao, Fengmin; Zito, Christopher R.; Kirkwood, John M.; Nathanson, Katherine L.; D'Andrea, Kurt; Wilson, Melissa; Rimm, David L.; Flaherty, Keith T.; Lee, Sandra J.; Kluger, Harriet M.			Expression of Drug Targets in Patients Treated with Sorafenib, Carboplatin and Paclitaxel	PLOS ONE			English	Article							RAF/MEK/ERK PATHWAY; METASTATIC MELANOMA; IMPROVED SURVIVAL; PHASE-III; APOPTOSIS; GROWTH; INHIBITOR; CELLS; TRIAL; ANGIOGENESIS	Introduction: Sorafenib, a multitarget kinase inhibitor, targets members of the mitogen-activated protein kinase (MAPK) pathway and VEGFR kinases. Here we assessed the association between expression of sorafenib targets and biomarkers of taxane sensitivity and response to therapy in pre-treatment tumors from patients enrolled in ECOG 2603, a phase III comparing sorafenib, carboplatin and paclitaxel (SCP) to carboplatin, paclitaxel and placebo (CP). Methods: Using a method of automated quantitative analysis (AQUA) of in situ protein expression, we quantified expression of VEGF-R2, VEGF-R1, VEGF-R3, FGF-R1, PDGF-Rb, c-Kit, B-Raf, C-Raf, MEK1, ERK1/2, STMN1, MAP2, EB1 and Bcl-2 in pretreatment specimens from 263 patients. Results: An association was found between high FGF-R1 and VEGF-R1 and increased progression-free survival (PFS) and overall survival (OS) in our combined cohort (SCP and CP arms). Expression of FGF-R1 and VEGF-R1 was higher in patients who responded to therapy ((CR+PR) vs. (SD+PD+ un-evaluable)). Conclusions: In light of the absence of treatment effect associated with sorafenib, the association found between FGF-R1 and VEGF-R1 expression and OS, PFS and response might reflect a predictive biomarker signature for carboplatin/paclitaxel-based therapy. Seeing that carboplatin and pacitaxel are now widely used for this disease, corroboration in another cohort might enable us to improve the therapeutic ratio of this regimen.	[Jilaveanu, Lucia B.; Zito, Christopher R.; Kluger, Harriet M.] Yale Univ, Sch Med, Yale Canc Ctr, New Haven, CT 06520 USA; [Zhao, Fengmin; Lee, Sandra J.] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA; [Zito, Christopher R.] Univ St Joseph, Dept Biol, Sch Hlth & Nat Sci, Hartford, CT USA; [Kirkwood, John M.] Univ Pittsburgh, Pittsburgh Hillman Canc Ctr, Pittsburgh, PA USA; [Nathanson, Katherine L.; D'Andrea, Kurt; Wilson, Melissa; Flaherty, Keith T.] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA; [Rimm, David L.] Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06510 USA; [Flaherty, Keith T.] Massachusetts Gen Hosp, Dept Med, Ctr Canc, Boston, MA 02114 USA	Yale University; Harvard University; Dana-Farber Cancer Institute; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Pennsylvania; Pennsylvania Medicine; Yale University; Harvard University; Massachusetts General Hospital	Kluger, HM (corresponding author), Yale Univ, Sch Med, Yale Canc Ctr, New Haven, CT 06520 USA.	Harriet.Kluger@yale.edu		Wilson, Melissa/0000-0002-5391-7838; Nathanson, Katherine/0000-0002-6740-0901; Rimm, David/0000-0001-5820-4397	National Institutes of Health [CA115756]; NATIONAL CANCER INSTITUTE [R01CA115756, U10CA021115, K24CA172123, P50CA121973, T32CA009615, U24CA114737] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by National Institutes of Health grant CA115756 (to H. Kluger). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adnane L, 2006, METHOD ENZYMOL, V407, P597, DOI 10.1016/S0076-6879(05)07047-3; Arkenau HT, 2011, BRIT J CANCER, V104, P392, DOI 10.1038/sj.bjc.6606030; Camp RL, 2003, CANCER RES, V63, P1445; Camp RL, 2002, NAT MED, V8, P1323, DOI 10.1038/nm791; Chapman PB, 2011, NEW ENGL J MED, V364, P2507, DOI 10.1056/NEJMoa1103782; Coleman AB, 2000, MOL PHARMACOL, V57, P324; Dolled-Filhart M, 2006, CANCER RES, V66, P5487, DOI 10.1158/0008-5472.CAN-06-0100; Eisen T, 2006, BRIT J CANCER, V95, P581, DOI 10.1038/sj.bjc.6603291; Flaherty KT, 2008, CLIN CANCER RES, V14, P4836, DOI 10.1158/1078-0432.CCR-07-4123; Flaherty KT, 2013, J CLIN ONCOL, V31, P373, DOI 10.1200/JCO.2012.42.1529; Flaherty KT, 2012, NEW ENGL J MED, V367, P107, DOI 10.1056/NEJMoa1203421; FLAHERTY KT, 2010, J CLIN ONCOL S, V28, pS15; Hauschild A, 2012, LANCET, V380, P358, DOI 10.1016/S0140-6736(12)60868-X; Hauschild A, 2009, J CLIN ONCOL, V27, P2823, DOI 10.1200/JCO.2007.15.7636; Hodi FS, 2010, NEW ENGL J MED, V363, P711, DOI 10.1056/NEJMoa1003466; Jilaveanu L, 2009, CLIN CANCER RES, V15, P1076, DOI 10.1158/1078-0432.CCR-08-2280; Jilaveanu LB, 2009, CLIN DERMATOL, V27, P614, DOI 10.1016/j.clindermatol.2008.09.020; Karasarides M, 2004, ONCOGENE, V23, P6292, DOI 10.1038/sj.onc.1207785; Kluger HM, 2007, J TRANSL MED, V5, DOI 10.1186/1479-5876-5-6; Lang L, 2008, GASTROENTEROLOGY, V134, P379, DOI 10.1053/j.gastro.2007.12.038; Liu L, 2006, CANCER RES, V66, P11851, DOI 10.1158/0008-5472.CAN-06-1377; Long GV, 2011, J CLIN ONCOL, V29, P1239, DOI 10.1200/JCO.2010.32.4327; McCarthy MM, 2008, ANN ONCOL, V19, P590, DOI 10.1093/annonc/mdm545; McCarthy MM, 2006, CLIN CANCER RES, V12, P3856, DOI 10.1158/1078-0432.CCR-06-0190; Mehnert JM, 2010, HUM PATHOL, V41, P375, DOI 10.1016/j.humpath.2009.08.016; Murphy DA, 2006, AM J PATHOL, V169, P1875, DOI 10.2353/ajpath.2006.050711; Niessner H, 2011, J INVEST DERMATOL, V131, P468, DOI 10.1038/jid.2010.297; Ott PA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015588; Robert C, 2011, NEW ENGL J MED, V364, P2517, DOI 10.1056/NEJMoa1104621; Scolyer RA, 2011, MOL ONCOL, V5, P124, DOI 10.1016/j.molonc.2011.03.002; Sharma A, 2005, CANCER RES, V65, P2412, DOI 10.1158/0008-5472.CAN-04-2423; Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166; Stein MN, 2007, CLIN CANCER RES, V13, P3765, DOI 10.1158/1078-0432.CCR-06-2844; Wang Q, 1998, EXP CELL RES, V238, P177, DOI 10.1006/excr.1997.3820; Wilhelm SM, 2004, CANCER RES, V64, P7099, DOI 10.1158/0008-5472.CAN-04-1443; Yayon A, 1997, ONCOGENE, V14, P2999, DOI 10.1038/sj.onc.1201159; Zhang SL, 2011, ANTICANCER RES, V31, P3259	37	3	3	1	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 6	2013	8	8							e69748	10.1371/journal.pone.0069748	http://dx.doi.org/10.1371/journal.pone.0069748			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	217ZG	23936348	Green Published, Green Submitted, gold, Green Accepted			2023-01-03	WOS:000324401500017
J	Chou, CY; Hsu, CC; Chiang, SC; Ho, CC; Chou, CL; Wu, MS; Chang, YL; Tsai, HY; Chen, TJ; Chou, YC				Chou, Chia-Yu; Hsu, Chia-Chen; Chiang, Shu-Chiung; Ho, Chin-Chin; Chou, Chia-Lin; Wu, Min-Shan; Chang, Yuh-Lih; Tsai, Han-Yi; Chen, Tzeng-Ji; Chou, Yueh-Ching			Association between Physician Specialty and Risk of Prescribing Inappropriate Pill Splitting	PLOS ONE			English	Article							ERRORS; MEDICATIONS; TABLETS; SAFETY; CARE	Background: Prescription errors that occur due to the process of pill splitting are a common medication problem; however, available prescription information involving inappropriate pill splitting and its associated factors is lacking. Methods: We retrospectively evaluated a cohort of ambulatory prescriptions involving extended-release or enteric-coated formulations in a Taiwan medical center during a 5-month period in 2010. For this study, those pill splitting prescriptions involving special oral formulations were defined as inappropriate prescriptions. Information obtained included patient demographics, prescriber specialty and prescription details, which were assessed to identify factors associated with inappropriate pill splitting. Results: There were 1,252 inappropriate prescriptions identified in this cohort study, representing a prescription frequency for inappropriate pill splitting of 1.0% among 124,300 prescriptions with special oral formulations. Among 35 drugs with special oral formulations in our study, 20 different drugs (57.1%, 20/35) had ever been prescribed to split. Anti-diabetic agents, cardiovascular agents and central nervous system agents were the most common drug classes involved in inappropriate splitting. The rate of inappropriate pill splitting was higher in older (over 65 years of age) patients (1.1%, 832/75,387). Eighty-seven percent (1089/1252) of inappropriate prescriptions were prescribed by internists. The rate of inappropriate pill splitting was highest from endocrinologists (3.4%, 429/12,477), nephrologists (1.3%, 81/6,028) and cardiologists (1.3%, 297/23,531). Multivariate logistic regression analysis revealed that the strongest factor associated with individual specific drug of inappropriate splitting was particular physician specialties. Conclusion: This study provides important insights into the inappropriate prescription of special oral formulation related to pill splitting, and helps to aggregate information that can assist medical professionals in creating processes for reducing inappropriate pill splitting in the future.	[Chou, Chia-Yu] Taipei Vet Gen Hosp, Dept Crit Care Med, Taipei, Taiwan; [Chou, Chia-Yu; Chang, Yuh-Lih; Chou, Yueh-Ching] Natl Yang Ming Univ, Dept & Inst Pharmacol, Taipei 112, Taiwan; [Chou, Chia-Yu; Ho, Chin-Chin; Chou, Yueh-Ching] Taipei Med Univ, Coll Pharm, Taipei, Taiwan; [Chou, Chia-Yu] Natl Def Med Ctr, Dept Internal Med, Sch Med, Taipei, Taiwan; [Chou, Chia-Yu; Tsai, Han-Yi] Natl Yang Ming Univ, Inst Biomed Informat, Taipei 112, Taiwan; [Hsu, Chia-Chen; Ho, Chin-Chin; Chou, Chia-Lin; Wu, Min-Shan; Chang, Yuh-Lih; Tsai, Han-Yi; Chou, Yueh-Ching] Taipei Vet Gen Hosp, Dept Pharm, Taipei, Taiwan; [Chiang, Shu-Chiung; Chen, Tzeng-Ji] Natl Yang Ming Univ, Inst Hosp & Hlth Care Adm, Taipei 112, Taiwan; [Chen, Tzeng-Ji] Taipei Vet Gen Hosp, Dept Family Med, Taipei, Taiwan	Taipei Veterans General Hospital; National Yang Ming Chiao Tung University; Taipei Medical University; National Defense Medical Center; National Yang Ming Chiao Tung University; Taipei Veterans General Hospital; National Yang Ming Chiao Tung University; Taipei Veterans General Hospital	Chou, YC (corresponding author), Natl Yang Ming Univ, Dept & Inst Pharmacol, Taipei 112, Taiwan.	ycchou@vghtpe.gov.tw	Chen, TJ/AAH-8430-2021; Hsu, Chia-Chen/AAB-3117-2019		Taipei Veterans General Hospital [V102A-053]; National Science Council	Taipei Veterans General Hospital(Taipei Veterans General Hospital); National Science Council(Ministry of Science and Technology, Taiwan)	This study was supported by grants from Taipei Veterans General Hospital (V102A-053) and the National Science Council. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Al Khaja KAJ, 2005, INT J CLIN PHARM TH, V43, P294; Bachynsky J, 2002, PHARMACOECONOMICS, V20, P339, DOI 10.2165/00019053-200220050-00005; Cohen JS, 2000, GERIATRICS-US, V55, P54; Cornish P, 2005, CAN MED ASSOC J, V172, P871, DOI 10.1503/cmaj.050176; Lesar TS, 2002, J GEN INTERN MED, V17, P579, DOI 10.1046/j.1525-1497.2002.11056.x; Lesar TS, 1997, ARCH INTERN MED, V157, P1569, DOI 10.1001/archinte.157.14.1569; Lewis PJ, 2009, DRUG SAFETY, V32, P379, DOI 10.2165/00002018-200932050-00002; Munar MY, 2007, AM FAM PHYSICIAN, V75, P1487; Noviasky J, 2006, J FAM PRACTICE, V55, P707; Paparella S, 2010, J EMERG NURS, V36, P156, DOI 10.1016/j.jen.2009.11.019; Quinzler R, 2009, BMC MED INFORM DECIS, V9, DOI 10.1186/1472-6947-9-30; Schier JG, 2003, ANN PHARMACOTHER, V37, P1420, DOI 10.1345/aph.1D091; Senst BL, 2001, AM J HEALTH-SYST PH, V58, P1126, DOI 10.1093/ajhp/58.12.1126; Sera LC, 2012, CLIN GERIATR MED, V28, P273, DOI 10.1016/j.cger.2012.01.007; van Santen E, 2002, EUR J PHARM BIOPHARM, V53, P139, DOI 10.1016/S0939-6411(01)00228-4; Verrue C, 2011, J ADV NURS, V67, P26, DOI 10.1111/j.1365-2648.2010.05477.x	16	8	8	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 29	2013	8	7							e70113	10.1371/journal.pone.0070113	http://dx.doi.org/10.1371/journal.pone.0070113			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	204MP	23922926	Green Published, Green Submitted, gold			2023-01-03	WOS:000323369700138
J	Zhang, J; Wang, P; Ouyang, HQ; Yin, JH; Liu, AH; Ma, CZ; Liu, LM				Zhang, Juan; Wang, Peng; Ouyang, Huaqiang; Yin, Jianhua; Liu, Aihua; Ma, Chunzheng; Liu, Luming			Targeting Cancer-Related Inflammation: Chinese Herbal Medicine Inhibits Epithelial-to-Mesenchymal Transition in Pancreatic Cancer	PLOS ONE			English	Article							TUMOR-ASSOCIATED MACROPHAGES; ALTERNATIVE MEDICINE; QINGYIHUAJI FORMULA; LIVER METASTASES; MOUSE MODEL; CELLS; CARCINOMA; GEMCITABINE; PROGRESSION; COMPLEMENTARY	Pancreatic cancer is an almost universally fatal disease resulting from early invasion of adjacent structures and metastasis and the lack of an effective treatment modality. Our previous studies have shown that Qingyihuaji Formula (QYHJ), a seven-herb Chinese medicine formula, had significant anti-cancer effects in pancreatic cancer. Here, we examined the effects of QYHJ on pancreatic cancer cell invasion and metastasis and the potential associated mechanism(s). We found that QYHJ inhibited both tumor growth and metastasis in nude mice with human pancreatic cancer cell xenografts. Further study indicated that QYHJ inhibited epithelial-to-mesenchymal transition (EMT), which is characterized by increased E-cadherin expression and decreased vimentin, N-cadherin and Slug expression. Interleukin 6 (IL-6), a pro-inflammatory cytokine produced mainly by macrophages, could promote cancer cell EMT and invasion. In contrast, treatment with QYHJ inhibited cancer-related inflammation in tumors by decreasing infiltration of tumor-associated macrophages and IL-6 production, thus preventing cell invasion and metastasis. These results suggested that the Chinese herbal medicine QYHJ could inhibit pancreatic cancer cell invasion and metastasis in part by reversing tumor-supporting inflammation.	[Zhang, Juan; Wang, Peng; Ouyang, Huaqiang; Yin, Jianhua; Liu, Luming] Fudan Univ, Dept Integrat Oncol, Shanghai Canc Ctr, Shanghai 200433, Peoples R China; [Zhang, Juan; Wang, Peng; Ouyang, Huaqiang; Yin, Jianhua; Liu, Luming] Fudan Univ, Dept Oncol, Shanghai Med Coll, Shanghai 200433, Peoples R China; [Zhang, Juan; Liu, Aihua; Ma, Chunzheng] Henan Univ TCM, Dept Clin Med Coll 2, Zhengzhou, Peoples R China	Fudan University; Fudan University; Henan University of Traditional Chinese Medicine	Ma, CZ (corresponding author), Henan Univ TCM, Dept Clin Med Coll 2, Zhengzhou, Peoples R China.	mchzh666@126.com; llm1010@yahoo.com.cn		Ouyang, Huaqiang/0000-0002-7702-2545	National Science Foundation of China [81001061, 81072942, 81173461]; Shanghai Nature Science Fund, Shanghai, China [09ZR1406800]; Doctoral Programs Foundation of Ministry of Education of China [20090071120076]; Shanghai Science and Technology Committee Rising-Star Program [11QA1401300]; Medical Talents Training Program of Health Bureau of Shanghai [XYQ2011008]	National Science Foundation of China(National Natural Science Foundation of China (NSFC)); Shanghai Nature Science Fund, Shanghai, China; Doctoral Programs Foundation of Ministry of Education of China(Ministry of Education, China); Shanghai Science and Technology Committee Rising-Star Program; Medical Talents Training Program of Health Bureau of Shanghai	This study was supported by National Science Foundation of China (81001061, 81072942, 81173461); Shanghai Nature Science Fund, Shanghai, China (09ZR1406800); Doctoral Programs Foundation of Ministry of Education of China (20090071120076); Shanghai Science and Technology Committee Rising-Star Program (11QA1401300); and Medical Talents Training Program of Health Bureau of Shanghai (XYQ2011008). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Balkwill F, 2005, CANCER CELL, V7, P211, DOI 10.1016/j.ccr.2005.02.013; Belguise K, 2007, CANCER RES, V67, P11742, DOI 10.1158/0008-5472.CAN-07-2730; Bouvet M, 2000, CLIN EXP METASTAS, V18, P213, DOI 10.1023/A:1006767405609; Bunt SK, 2007, CANCER RES, V67, P10019, DOI 10.1158/0008-5472.CAN-07-2354; Chang KH, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-196; Chen Z, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/635702; Chen Z, 2008, J ALTERN COMPLEM MED, V14, P1049, DOI 10.1089/acm.2008.0039; Dong P, 2011, J ETHNOPHARMACOL, V137, P1373, DOI 10.1016/j.jep.2011.08.005; Ebrahimi B, 2004, CANCER-AM CANCER SOC, V101, P2727, DOI 10.1002/cncr.20672; Fernando RI, 2011, CANCER RES, V71, P5296, DOI 10.1158/0008-5472.CAN-11-0156; Graeser R, 2009, PANCREAS, V38, P330, DOI 10.1097/MPA.0b013e31819436e6; HELLE M, 1991, PROG CLIN BIOL RES, V367, P61; Hezel AF, 2006, GENE DEV, V20, P1218, DOI 10.1101/gad.1415606; Huang C, 2011, NEOPLASMA, V58, P396, DOI 10.4149/neo_2011_05_396; Javle MM, 2007, ANN SURG ONCOL, V14, P3527, DOI 10.1245/s10434-007-9540-3; Kim DK, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-155; Lam W, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001270; Lesina M, 2011, CANCER CELL, V19, P456, DOI 10.1016/j.ccr.2011.03.009; Li CW, 2012, CANCER RES, V72, P1290, DOI 10.1158/0008-5472.CAN-11-3123; [刘恩莉 Liu Enchi], 2004, [肿瘤, Tumor], V24, P11; MANTOVANI A, 1992, IMMUNOL TODAY, V13, P265, DOI 10.1016/0167-5699(92)90008-U; Mantovani A, 2008, NATURE, V454, P436, DOI 10.1038/nature07205; Mantovani A, 2006, CANCER METAST REV, V25, P315, DOI 10.1007/s10555-006-9001-7; Mantovani A, 2010, CURR OPIN IMMUNOL, V22, P231, DOI 10.1016/j.coi.2010.01.009; McCulloch M, 2006, J CLIN ONCOL, V24, P419, DOI 10.1200/JCO.2005.03.6392; Moore MJ, 2007, J CLIN ONCOL, V25, P1960, DOI 10.1200/JCO.2006.07.9525; Ouyang HQ, 2011, PANCREAS, V40, P120, DOI 10.1097/MPA.0b013e3181e6e398; Peinado H, 2007, NAT REV CANCER, V7, P415, DOI 10.1038/nrc2131; Shi WD, 2009, CANCER LETT, V283, P84, DOI 10.1016/j.canlet.2009.03.030; Siegel R, 2012, CA-CANCER J CLIN, V62, P10, DOI 10.3322/caac.20138; Steidl C, 2010, NEW ENGL J MED, V362, P875, DOI 10.1056/NEJMoa0905680; Sullivan NJ, 2009, ONCOGENE, V28, P2940, DOI 10.1038/onc.2009.180; Sun YY, 2009, ANTI-CANCER DRUG, V20, P757, DOI 10.1097/CAD.0b013e328330d95b; Tawara Ken, 2011, Cancer Manag Res, V3, P177, DOI 10.2147/CMR.S18101; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Tsai CH, 2009, CLIN CANCER RES, V15, P5435, DOI 10.1158/1078-0432.CCR-09-0298; von Burstin J, 2009, GASTROENTEROLOGY, V137, P361, DOI 10.1053/j.gastro.2009.04.004; Wang L, 2008, P NATL ACAD SCI USA, V105, P4826, DOI 10.1073/pnas.0712365105; Wang P, 2014, ONCOGENE, V33, P514, DOI 10.1038/onc.2012.598; Wang P, 2010, INTEGR CANCER THER, V9, P50, DOI 10.1177/1534735409359179; Wang P, 2009, CARCINOGENESIS, V30, P1497, DOI 10.1093/carcin/bgp154; Wang ZW, 2009, CANCER RES, V69, P2400, DOI 10.1158/0008-5472.CAN-08-4312; Xiong W, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-219; Yadav A, 2011, MOL CANCER RES, V9, P1658, DOI 10.1158/1541-7786.MCR-11-0271; Yin JH, 2012, INTEGR CANCER THER, V11, P37, DOI 10.1177/1534735411400315; Zhen T, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003562	46	27	29	2	20	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 29	2013	8	7							e70334	10.1371/journal.pone.0070334	http://dx.doi.org/10.1371/journal.pone.0070334			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	204MP	23922983	Green Published, gold, Green Submitted			2023-01-03	WOS:000323369700177
J	Kundel, Y; Nasser, NJ; Purim, O; Yerushalmi, R; Fenig, E; Pfeffer, RM; Stemmer, SM; Rizel, S; Symon, Z; Kaufman, B; Sulkes, A; Brenner, B				Kundel, Yulia; Nasser, Nicola J.; Purim, Ofer; Yerushalmi, Rinat; Fenig, Eyal; Pfeffer, Raphael M.; Stemmer, Salomon M.; Rizel, Shulamith; Symon, Zvi; Kaufman, Bella; Sulkes, Aaron; Brenner, Baruch			Phase II Study of Concurrent Capecitabine and External Beam Radiotherapy for Pain Control of Bone Metastases of Breast Cancer Origin	PLOS ONE			English	Article							RECTAL-CANCER; RADIATION-THERAPY; PREOPERATIVE CHEMORADIATION; MULTIFRACTION RADIOTHERAPY; OSSEOUS METASTASES; RANDOMIZED-TRIAL; SINGLE FRACTION; PALLIATION; 5-FLUOROURACIL; OXALIPLATIN	Background: Pain from bone metastases of breast cancer origin is treated with localized radiation. Modulating doses and schedules has shown little efficacy in improving results. Given the synergistic therapeutic effect reported for combined systemic chemotherapy with local radiation in anal, rectal, and head and neck malignancies, we sought to evaluate the tolerability and efficacy of combined capecitabine and radiation for palliation of pain due to bone metastases from breast cancer. Methodology/Principal Findings: Twenty-nine women with painful bone metastases from breast cancer were treated with external beam radiation in 10 fractions of 3 Gy, 5 fractions a week for 2 consecutive weeks. Oral capecitabine 700 mg/m(2) twice daily was administered throughout radiation therapy. Rates of complete response, defined as a score of 0 on a 10-point pain scale and no increase in analgesic consumption, were 14% at 1 week, 38% at 2 weeks, 52% at 4 weeks, 52% at 8 weeks, and 48% at 12 weeks. Corresponding rates of partial response, defined as a reduction of at least 2 points in pain score without an increase in analgesics consumption, were 31%, 38%, 28%, 34% and 38%. The overall response rate (complete and partial) at 12 weeks was 86%. Side effects were of mild intensity (grade I or II) and included nausea (38% of patients), weakness (24%), diarrhea (24%), mucositis (10%), and hand and foot syndrome (7%). Conclusions/Significance: External beam radiation with concurrent capecitabine is safe and tolerable for the treatment of pain from bone metastases of breast cancer origin. The overall and complete response rates in our study are unusually high compared to those reported for radiation alone. Further evaluation of this approach, in a randomized study, is warranted.	[Kundel, Yulia; Nasser, Nicola J.; Purim, Ofer; Yerushalmi, Rinat; Fenig, Eyal; Stemmer, Salomon M.; Rizel, Shulamith; Sulkes, Aaron; Brenner, Baruch] Rabin Med Ctr, Davidoff Canc Ctr, Inst Oncol, Petah Tiqwa, Israel; [Pfeffer, Raphael M.; Symon, Zvi; Kaufman, Bella] Chaim Sheba Med Ctr, Inst Oncol, IL-52621 Tel Hashomer, Israel; [Kundel, Yulia; Purim, Ofer; Yerushalmi, Rinat; Fenig, Eyal; Pfeffer, Raphael M.; Stemmer, Salomon M.; Symon, Zvi; Kaufman, Bella; Sulkes, Aaron; Brenner, Baruch] Tel Aviv Univ, Sackler Fac Med, IL-69978 Tel Aviv, Israel	Rabin Medical Center; Chaim Sheba Medical Center; Tel Aviv University; Sackler Faculty of Medicine	Brenner, B (corresponding author), Rabin Med Ctr, Davidoff Canc Ctr, Inst Oncol, Beilinson Campus, Petah Tiqwa, Israel.	brennerb@clalit.org.il	Symon, Zvi/GNH-3482-2022					AlSarraf M, 1997, J CLIN ONCOL, V15, P277, DOI 10.1200/JCO.1997.15.1.277; [Anonymous], 2006, NCI COMMON TERMINOLO; Ben-Josef E, 1999, INT J RADIAT ONCOL, V45, P715, DOI 10.1016/S0360-3016(99)00231-X; BLITZER PH, 1985, CANCER-AM CANCER SOC, V55, P1468, DOI 10.1002/1097-0142(19850401)55:7<1468::AID-CNCR2820550708>3.0.CO;2-M; BYFIELD JE, 1982, INT J RADIAT ONCOL, V8, P1923, DOI 10.1016/0360-3016(82)90451-5; Carlomagno C, 2009, ANN ONCOL, V20, P906, DOI 10.1093/annonc/mdn719; Chow E, 2002, RADIOTHER ONCOL, V64, P275, DOI 10.1016/S0167-8140(02)00170-6; Chow E, 2007, J CLIN ONCOL, V25, P1423, DOI 10.1200/JCO.2006.09.5281; Crane CH, 2010, INT J RADIAT ONCOL, V76, P824, DOI 10.1016/j.ijrobp.2009.02.037; De Paoli A, 2006, ANN ONCOL, V17, P246, DOI 10.1093/annonc/mdj041; DOUGLASS HO, 1987, CANCER, V59, P2006; Arnalot PF, 2008, RADIOTHER ONCOL, V89, P150, DOI 10.1016/j.radonc.2008.05.018; Gerard JP, 2006, J CLIN ONCOL, V24, P4620, DOI 10.1200/JCO.2006.06.7629; Hartsell WF, 2005, JNCI-J NATL CANCER I, V97, P798, DOI 10.1093/jnci/dji139; Hofheinz R, 2011, J CLIN ONCOL S, V29; Hong YS, 2011, INT J RADIAT ONCOL, V79, P1171, DOI 10.1016/j.ijrobp.2009.12.073; HOSKIN PJ, 1988, CANCER SURV, V7, P69; KALSER MH, 1985, ARCH SURG-CHICAGO, V120, P899; Kim JC, 2005, INT J RADIAT ONCOL, V63, P346, DOI 10.1016/j.ijrobp.2005.02.046; Kim JS, 2002, INT J RADIAT ONCOL, V54, P403, DOI 10.1016/S0360-3016(02)02856-0; Klautke G, 2006, BRIT J CANCER, V94, P976, DOI 10.1038/sj.bjc.6603053; LAWRENCE TS, 1994, INT J RADIAT ONCOL, V29, P519, DOI 10.1016/0360-3016(94)90448-0; Morris M, 1999, NEW ENGL J MED, V340, P1137, DOI 10.1056/NEJM199904153401501; NAKAJIMA Y, 1979, CANCER RES, V39, P3763; Ofner D, 2011, STRAHLENTHER ONKOL, V187, P100, DOI 10.1007/s00066-010-2182-6; PRICE P, 1986, RADIOTHER ONCOL, V6, P247, DOI 10.1016/S0167-8140(86)80191-8; Ryan DP, 2000, NEW ENGL J MED, V342, P792, DOI 10.1056/NEJM200003163421107; SERLIN RC, 1995, PAIN, V61, P277, DOI 10.1016/0304-3959(94)00178-H; Sze WM, 2003, CLIN ONCOL-UK, V15, P345, DOI 10.1016/S0936-6555(03)00113-4; TONG D, 1982, CANCER, V50, P893, DOI 10.1002/1097-0142(19820901)50:5<893::AID-CNCR2820500515>3.0.CO;2-Y; Vaishampayan UN, 2002, INT J RADIAT ONCOL, V53, P675, DOI 10.1016/S0360-3016(02)02772-4; van der Linden YM, 2004, INT J RADIAT ONCOL, V59, P528, DOI 10.1016/j.ijrobp.2003.10.006; WEINBERG MJ, 1987, INT J RADIAT ONCOL, V13, P1691; Wendt TG, 1998, J CLIN ONCOL, V16, P1318, DOI 10.1200/JCO.1998.16.4.1318; Wu JSY, 2003, INT J RADIAT ONCOL, V55, P594, DOI 10.1016/S0360-3016(02)04147-0	35	5	5	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 10	2013	8	7							e68327	10.1371/journal.pone.0068327	http://dx.doi.org/10.1371/journal.pone.0068327			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	182SU	23874586	Green Published, gold			2023-01-03	WOS:000321765300043
J	Huang, Y; Yu, P; Li, W; Ren, G; Roberts, AI; Cao, W; Zhang, X; Su, J; Chen, X; Chen, Q; Shou, P; Xu, C; Du, L; Lin, L; Xie, N; Zhang, L; Wang, Y; Shi, Y				Huang, Y.; Yu, P.; Li, W.; Ren, G.; Roberts, A. I.; Cao, W.; Zhang, X.; Su, J.; Chen, X.; Chen, Q.; Shou, P.; Xu, C.; Du, L.; Lin, L.; Xie, N.; Zhang, L.; Wang, Y.; Shi, Y.			p53 regulates mesenchymal stem cell-mediated tumor suppression in a tumor microenvironment through immune modulation	ONCOGENE			English	Article						mesenchymal stem cells; p53; immunomodulation; iNOS	NITRIC-OXIDE; INFILTRATING LYMPHOCYTES; GENETIC ALTERATIONS; STROMAL CELLS; MUTANT P53; T-CELLS; CANCER; MUTATIONS; CARCINOMA; EXPRESSION	p53 is one of the most studied genes in cancer biology, and mutations in this gene may be predictive for the development of many types of cancer in humans and in animals. However, whether p53 mutations in non-tumor stromal cells can affect tumor development has received very little attention. In this study, we show that B16F0 melanoma cells form much larger tumors in p53-deficient mice than in wild-type mice, indicating a potential role of p53 deficiency in non-tumor cells of the microenvironment. As mesenchymal stem cells (MSCs) are attracted to tumors and form a major component of the tumor microenvironment, we examined the potential role of p53 status in MSCs in tumor development. We found that larger tumors resulted when B16F0 melanoma cells were co-injected with bone marrow MSCs derived from p53-deficient mice rather than MSCs from wild-type mice. Interestingly, this tumor-promoting effect by p53-deficient MSCs was not observed in non-obese diabetic/severe combined immunodeficiency mice, indicating the immune response has a critical role. Indeed, in the presence of inflammatory cytokines, p53-deficient MSCs expressed more inducible nitric oxide synthase (iNOS) and exhibited greater immunosuppressive capacity. Importantly, tumor promotion by p53-deficient MSCs was abolished by administration of S-methylisothiourea, an iNOS inhibitor. Therefore, our data demonstrate that p53 status in tumor stromal cells has a key role in tumor development by modulating immune responses.	[Huang, Y.; Yu, P.; Li, W.; Cao, W.; Zhang, X.; Su, J.; Chen, X.; Chen, Q.; Shou, P.; Xu, C.; Du, L.; Lin, L.; Xie, N.; Wang, Y.; Shi, Y.] Shanghai Jiao Tong Univ, Chinese Acad Sci, Sch Med,Shanghai Inst Biol Sci, Inst Hlth Sci,Key Lab Stem Cell Biol, Shanghai 200025, Peoples R China; [Ren, G.; Roberts, A. I.; Zhang, L.; Shi, Y.] Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Child Hlth Inst New Jersey, New Brunswick, NJ USA; [Ren, G.; Roberts, A. I.; Zhang, L.; Shi, Y.] Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Pharmacol, New Brunswick, NJ USA	Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Shanghai Jiao Tong University; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center	Wang, Y (corresponding author), Shanghai Jiao Tong Univ, Chinese Acad Sci, Sch Med,Shanghai Inst Biol Sci, Inst Hlth Sci,Key Lab Stem Cell Biol, 225 S Chongqing Rd,1 Bldg, Shanghai 200025, Peoples R China.	yingwang@sibs.ac.cn; yufangshi@sibs.ac.cn	Yu, Pengfei/AHC-3497-2022; Li, Wenzhao/H-4235-2016; Xu, Chunliang/R-7065-2018; Shi, Yufang/AAE-4431-2020; Su, Juanjuan/C-4040-2018; Shou, Peishun/J-7985-2014; HUANG, YIN/AAH-6871-2020; Du, Liming/M-8227-2019	Yu, Pengfei/0000-0002-3894-5697; Li, Wenzhao/0000-0002-3878-3333; Shi, Yufang/0000-0001-8964-319X; Su, Juanjuan/0000-0002-6159-1954; Shou, Peishun/0000-0001-7685-7471; HUANG, YIN/0000-0001-5602-9871; Chen, Qing/0000-0002-2088-0370; wang, ying/0000-0002-2571-9367; Du, Liming/0000-0002-0527-3556	Ministry of Science and Technology of China [2010CB945600, 2011DFA30630]; Chinese Academy of Sciences [XDA01040107, KSCX1-YW-22-04]; NSFC [31010103908]	Ministry of Science and Technology of China(Ministry of Science and Technology, China); Chinese Academy of Sciences(Chinese Academy of Sciences); NSFC(National Natural Science Foundation of China (NSFC))	This work was supported by grants from the Ministry of Science and Technology of China (2010CB945600 and 2011DFA30630), Scientific Innovation Project of the Chinese Academy of Sciences (XDA01040107 and KSCX1-YW-22-04) and International Cooperation and Exchanges NSFC (31010103908). We are also grateful to Yikun Yao (IHS, CAS) for his assistance and suggestions.	Addadi Y, 2010, CANCER RES, V70, P9650, DOI 10.1158/0008-5472.CAN-10-1146; Andersen MH, 2009, J CLIN INVEST, V119, P2245, DOI 10.1172/JCI38739; Armesilla-Diaz A, 2009, EXP CELL RES, V315, P3598, DOI 10.1016/j.yexcr.2009.08.004; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; Bell D, 2011, NATURE, V474, P609, DOI 10.1038/nature10166; Bergfeld SA, 2010, CANCER METAST REV, V29, P249, DOI 10.1007/s10555-010-9222-7; Bingisser RM, 1998, J IMMUNOL, V160, P5729; Bogdan C, 2001, NAT IMMUNOL, V2, P907, DOI 10.1038/ni1001-907; Brito C, 1999, J IMMUNOL, V162, P3356; Brown GC, 1997, BIOCHEM SOC T, V25, P901, DOI 10.1042/bst0250901; Cassina A, 1996, ARCH BIOCHEM BIOPHYS, V328, P309, DOI 10.1006/abbi.1996.0178; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; Curiel TJ, 2004, NAT MED, V10, P942, DOI 10.1038/nm1093; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Donia M, 2012, ONCOIMMUNOLOGY, V1, P1476, DOI 10.4161/onci.21940; Donia M, 2012, ONCOIMMUNOLOGY, V1, P1297, DOI 10.4161/onci.21659; Dougan M, 2009, ANNU REV IMMUNOL, V27, P83, DOI 10.1146/annurev.immunol.021908.132544; DVORAK HF, 1986, NEW ENGL J MED, V315, P1650; Forrester K, 1996, P NATL ACAD SCI USA, V93, P2442, DOI 10.1073/pnas.93.6.2442; Giono LE, 2006, J CELL PHYSIOL, V209, P13, DOI 10.1002/jcp.20689; Gooden MJM, 2011, BRIT J CANCER, V105, P93, DOI 10.1038/bjc.2011.189; Green DR, 2009, NATURE, V458, P1127, DOI 10.1038/nature07986; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; HARVEY M, 1995, NAT GENET, V9, P305, DOI 10.1038/ng0395-305; Hill R, 2005, CELL, V123, P1001, DOI 10.1016/j.cell.2005.09.030; Hodis E, 2012, CELL, V150, P251, DOI 10.1016/j.cell.2012.06.024; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Hussain SP, 2008, CANCER RES, V68, P7130, DOI 10.1158/0008-5472.CAN-08-0410; Joyce JA, 2009, NAT REV CANCER, V9, P239, DOI 10.1038/nrc2618; Karnoub AE, 2007, NATURE, V449, P557, DOI 10.1038/nature06188; Kidd S, 2009, STEM CELLS, V27, P2614, DOI 10.1002/stem.187; Kuperwasser C, 2004, P NATL ACAD SCI USA, V101, P4966, DOI 10.1073/pnas.0401064101; Kurose K, 2002, NAT GENET, V32, P355, DOI 10.1038/ng1013; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LAVIGUEUR A, 1989, MOL CELL BIOL, V9, P3982, DOI 10.1128/MCB.9.9.3982; LEPOIVRE M, 1991, BIOCHEM BIOPH RES CO, V179, P442, DOI 10.1016/0006-291X(91)91390-X; Levine AJ, 2011, NAT REV MOL CELL BIO, V12, P259, DOI 10.1038/nrm3086; Li W, 2012, CELL DEATH DIFFER, V19, P1505, DOI 10.1038/cdd.2012.26; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; MacMicking J, 1997, ANNU REV IMMUNOL, V15, P323, DOI 10.1146/annurev.immunol.15.1.323; Maffini MV, 2004, J CELL SCI, V117, P1495, DOI 10.1242/jcs.01000; Matsumoto N, 2003, BRIT J CANCER, V89, P707, DOI 10.1038/sj.bjc.6601141; Miranda KM, 2001, NITRIC OXIDE-BIOL CH, V5, P62, DOI 10.1006/niox.2000.0319; Moinfar F, 2000, CANCER RES, V60, P2562; Moskovits N, 2006, CANCER RES, V66, P10671, DOI 10.1158/0008-5472.CAN-06-2323; Murray-Zmijewski F, 2008, NAT REV MOL CELL BIO, V9, P702, DOI 10.1038/nrm2451; Nakano O, 2001, CANCER RES, V61, P5132; NGUYEN T, 1992, P NATL ACAD SCI USA, V89, P3030, DOI 10.1073/pnas.89.7.3030; Nishida N, 2012, CLIN CANCER RES, V18, P3054, DOI 10.1158/1078-0432.CCR-11-1078; Paterson RF, 2003, CANCER, V98, P1830, DOI 10.1002/cncr.11747; Patocs A, 2007, NEW ENGL J MED, V357, P2543, DOI 10.1056/NEJMoa071825; Pollard JW, 2004, NAT REV CANCER, V4, P71, DOI 10.1038/nrc1256; Radi R, 2004, P NATL ACAD SCI USA, V101, P4003, DOI 10.1073/pnas.0307446101; Ren GW, 2008, CELL STEM CELL, V2, P141, DOI 10.1016/j.stem.2007.11.014; Ren GW, 2012, CELL STEM CELL, V11, P812, DOI 10.1016/j.stem.2012.08.013; Rodriguez R, 2009, NEOPLASIA, V11, P397, DOI 10.1593/neo.81620; Roninson IB, 2003, CANCER RES, V63, P2705; Sato E, 2005, P NATL ACAD SCI USA, V102, P18538, DOI 10.1073/pnas.0509182102; Schmitt CA, 2002, CELL, V109, P335, DOI 10.1016/S0092-8674(02)00734-1; Sharma MD, 2009, BLOOD, V113, P6102, DOI 10.1182/blood-2008-12-195354; Sharma P, 2007, P NATL ACAD SCI USA, V104, P3967, DOI 10.1073/pnas.0611618104; Simelyte E, 2005, ARTHRITIS RHEUM-US, V52, P1876, DOI 10.1002/ART.21099; Soleimani M, 2009, NAT PROTOC, V4, P102, DOI 10.1038/nprot.2008.221; STRETCH JR, 1991, CANCER RES, V51, P5976; Studeny M, 2002, CANCER RES, V62, P3603; Suzuki YJ, 2010, ANTIOXID REDOX SIGN, V12, P323, DOI 10.1089/ars.2009.2887; Tasdemir E, 2008, NAT CELL BIOL, V10, P676, DOI 10.1038/ncb1730; Tuhkanen H, 2004, INT J CANCER, V109, P247, DOI 10.1002/ijc.11733; Uccelli A, 2008, NAT REV IMMUNOL, V8, P726, DOI 10.1038/nri2395; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; Vukmanovic-Stejic M, 2006, J CLIN INVEST, V116, P2423, DOI 10.1172/JCI28941; XIE KP, 1995, J EXP MED, V181, P1333, DOI 10.1084/jem.181.4.1333; Xu WM, 2002, CELL RES, V12, P311, DOI 10.1038/sj.cr.7290133; Yamanishi Y, 2002, P NATL ACAD SCI USA, V99, P10025, DOI 10.1073/pnas.152333199; Zhu H, 2010, NAT PROTOC, V5, P550, DOI 10.1038/nprot.2009.238; Zilfou JT, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a001883; Zou WB, 2012, CANCER RES, V72, P2980, DOI 10.1158/0008-5472.CAN-11-4216	77	50	54	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 17	2014	33	29					3830	3838		10.1038/onc.2013.355	http://dx.doi.org/10.1038/onc.2013.355			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AL8MU	23975435				2023-01-03	WOS:000339394100009
J	Lin, JZ; Wu, HF; Shi, H; Pan, W; Yu, HB; Zhu, JG				Lin, Jianzhong; Wu, Hongfei; Shi, Hui; Pan, Wei; Yu, Hongbo; Zhu, Jiageng			Combined Inhibition of Epidermal Growth Factor Receptor and Cyclooxygenase-2 Leads to Greater Anti-tumor Activity of Docetaxel in Advanced Prostate Cancer	PLOS ONE			English	Article							PHASE-II TRIAL; FACTOR-KAPPA-B; TUMOR-GROWTH; ANDROGEN RECEPTOR; BREAST-CANCER; CELL-LINES; EXPRESSION; GEFITINIB; EFFICACY; DRUGS	The epidermal growth factor receptor (EGFR) and cyclooxygenase-2(COX-2) play a critical role in disease progression, relapse and therapeutic resistance of advanced prostate cancer (PCa). In this paper, we evaluated, for the first time, the therapeutic benefit of blocking EGRF and/or COX-2 (using gefitinib and NS-398, respectively) in terms of improving the efficacy of the conventional clinical chemotherapeutic drug docetaxel in vitro and vivo. We showed that EGFR and COX-2 expression was higher in metastatic than non-metastatic PCa tissues and cells. Docetaxel, alone or in combination with gefitinib or NS-398, resulted in a small decrease in cell viability. The three drug combination decreased cell viability to a greater extent than docetaxel alone or in combination with gefitinib or NS-398. Docetaxel resulted in a modest increase in apoptotic cell in metastatic and non-metastatic cell lines. NS-398 markedly enhanced docetaxel-induced cell apoptosis. The combination of the three drugs caused even more marked apoptosis and resulted in greater suppression of invasive potential than docetaxel alone or in association with gefitinib or NS-398. The combination of all three drugs also resulted in a more marked decrease in NF-kappa B, MMP-9 and VEGF levels in PC-3M cells. These in vitro findings were supported by in vivo studies showing that docetaxel in combination with gefitinib and NS-398 was significantly more effective than any individual agent. Based on previous preclinical research, we conclude that simultaneously blocking EGFR and COX-2 by gefitinib and NS-398 sensitizes advanced PCa cells to docetaxel-induced cytotoxicity.	[Lin, Jianzhong; Wu, Hongfei; Yu, Hongbo] Nanjing Med Univ, BenQ Med Ctr, Dept Urol, Nanjing, Jiangsu, Peoples R China; [Shi, Hui] Jiangsu Inst Planned Parenthood Res, Lab Reprod Hlth, Nanjing, Jiangsu, Peoples R China; [Pan, Wei] Second Hosp Nanjing Jiangning, Dept Oncol, Nanjing, Jiangsu, Peoples R China; [Zhu, Jiageng] Nanjing Med Univ, Nanjing Hosp 1, Dept Urol, Nanjing, Jiangsu, Peoples R China	Nanjing Medical University; Nanjing Medical University	Zhu, JG (corresponding author), Nanjing Med Univ, Nanjing Hosp 1, Dept Urol, Nanjing, Jiangsu, Peoples R China.	zhujiageng1972@hotmail.com			Science and Technology planning project of Nanjing, China [201201088]	Science and Technology planning project of Nanjing, China	The work has supported by Science and Technology planning project of Nanjing, China (201201088). The URL of funder's website is http://202.127.12.44/XMSB/Show_JBXXB.jsp?XMBH=2012sc315043&DJXH=20121069. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abedinpour P, 2011, PROSTATE, V71, P813, DOI 10.1002/pros.21297; Albertsen PC, 2005, JAMA-J AM MED ASSOC, V293, P2095, DOI 10.1001/jama.293.17.2095; Ali S, 2010, J CELL BIOCHEM, V110, P171, DOI 10.1002/jcb.22523; Bao B, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043726; Borghese C, 2013, J CELL BIOCHEM, V114, P1135, DOI 10.1002/jcb.24456; Cathomas R, 2012, CLIN CANCER RES, V18, P6049, DOI 10.1158/1078-0432.CCR-12-2219; Chan Emily, 2011, Am J Clin Oncol, V34, P581, DOI 10.1097/COC.0b013e3181fe46a1; Cho KS, 2008, PROSTATE, V68, P803, DOI 10.1002/pros.20743; CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4; Clarke NW, 2006, EUR UROL, V50, P428, DOI 10.1016/j.eururo.2006.05.017; Codony-Servat J, 2013, PROSTATE, V73, P512, DOI 10.1002/pros.22591; Cohen BL, 2006, INT J CANCER, V119, P1082, DOI 10.1002/ijc.21749; Dandekar DS, 2005, INT J CANCER, V115, P484, DOI 10.1002/ijc.20878; Dandekar DS, 2004, CLIN CANCER RES, V10, P8037, DOI 10.1158/1078-0432.CCR-04-1208; Farnebo L, 2011, J ORAL PATHOL MED, V40, P739, DOI 10.1111/j.1600-0714.2011.01036.x; Feng Ni, 2012, PLOS ONE, V7; Furstenberger G, 2006, INT J CANCER, V119, P2247, DOI 10.1002/ijc.22153; Galsky MD, 2010, ANN ONCOL, V21, P2135, DOI 10.1093/annonc/mdq050; Gregory CW, 2004, J BIOL CHEM, V279, P7119, DOI 10.1074/jbc.M307649200; Halabi S, 2011, CANCER, V117, P526; Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43; Kang JH, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-334; Kim SM, 2010, EUR J PHARMACOL, V10, P631; Lanza-Jacoby S, 2006, CLIN CANCER RES, V12, P6161, DOI 10.1158/1078-0432.CCR-06-0042; Li YW, 2006, CANCER RES, V66, P4816, DOI 10.1158/0008-5472.CAN-05-3752; Mathew P, 2011, J INTERF CYTOK RES, V31, P539, DOI 10.1089/jir.2010.0142; Mimeault M, 2006, CARCINOGENESIS, V27, P1, DOI 10.1093/carcin/bgi229; Mimeault M, 2007, MOL CANCER THER, V6, P967, DOI 10.1158/1535-7163.MCT-06-0648; O'Neill AJ, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-126; Ortholan C, 2010, EUR J CANCER, V46, P3022, DOI 10.1016/j.ejca.2010.07.021; Pan YQ, 2003, CANCER EPIDEM BIOMAR, V12, P769; Park SY, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-222; Reuter CWM, 2010, WORLD J UROL, V28, P391, DOI 10.1007/s00345-010-0527-5; Salzberg M, 2007, ONKOLOGIE, V30, P355, DOI 10.1159/000102452; Stavridi F, 2010, CANCER TREAT REV, V36, P122, DOI 10.1016/j.ctrv.2009.06.001; Stock D, 2008, UROL CLIN N AM, V35, P117, DOI 10.1016/j.ucl.2007.09.006; Stoppoloni D, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-27; Tamura K, 2007, CANCER RES, V67, P5117, DOI 10.1158/0008-5472.CAN-06-4040; Traish AM, 2009, BRIT J CANCER, V101, P1949, DOI 10.1038/sj.bjc.6605376; Walter B, 2010, WORLD J UROL, V28, P745, DOI 10.1007/s00345-010-0567-x; Zhang X, 2005, CLIN CANCER RES, V11, P6261, DOI 10.1158/1078-0432.CCR-04-2102	41	8	9	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 14	2013	8	10							e76169	10.1371/journal.pone.0076169	http://dx.doi.org/10.1371/journal.pone.0076169			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	237RD	24155892	Green Published, Green Submitted, gold			2023-01-03	WOS:000325887300026
J	Peng, QX; Cai, HB; Sun, XG; Li, X; Mo, ZX; Shi, J				Peng, Qiuxian; Cai, Hongbing; Sun, Xuegang; Li, Xin; Mo, Zhixian; Shi, Jue			Alocasia cucullata Exhibits Strong Antitumor Effect In Vivo by Activating Antitumor Immunity	PLOS ONE			English	Article							CANCER; CELLS; IMMUNOTHERAPY; GLIOBLASTOMA; INFLAMMATION; MACROPHAGES; MIGRATION; RANTES	Chinese herbal medicines have long been used to treat various illnesses by modulating the human immune response. In this study, we investigate the immuno-modulating effect and antitumor activity of Alocasia Cucullata (AC), a Chinese herb traditionally used to treat infection and cancer. We found that the whole water extract of AC roots could significantly attenuate tumor growth in mouse tumor models. The median survival time of the AC-treated mice was 43 days, 16 days longer than that of the control group. Moreover, the AC-treated mice showed substantially higher induction of key antitumor cytokines, such as IL-2, IFN-gamma, and TNF-alpha, indicating that AC may exert antitumor effect by activating antitumor immunity. To further pinpoint the cellular and molecular mechanism of AC, we studied the dose response of a human monocytic cell line, THP-1, to the whole water extract of AC. Treatment of the AC extract significantly induced THP-1 differentiation into macrophage-like cells and the differentiated THP-1 showed expression of specific macrophage surface markers, such as CD11b and CD14, as well as productions of antitumor cytokines, e.g. IFN-gamma and TNF-alpha. Our data thus point to AC as potentially a new, alternative immuno-modulating herbal remedy for anticancer treatment.	[Peng, Qiuxian; Cai, Hongbing; Sun, Xuegang; Li, Xin; Mo, Zhixian; Shi, Jue] Southern Med Univ, Sch Chinese Med, Guangzhou, Guangdong, Peoples R China; [Peng, Qiuxian; Shi, Jue] Hong Kong Baptist Univ, Ctr Quantitat Syst Biol, Dept Phys, Hong Kong, Hong Kong, Peoples R China; [Peng, Qiuxian; Shi, Jue] Hong Kong Baptist Univ, Dept Biol, Hong Kong, Hong Kong, Peoples R China	Southern Medical University - China; Hong Kong Baptist University; Hong Kong Baptist University	Mo, ZX (corresponding author), Southern Med Univ, Sch Chinese Med, Guangzhou, Guangdong, Peoples R China.	cherrymo@fimmu.com; jshi@hkbu.edu.hk	Shi, Jue/J-9714-2014	Shi, Jue/0000-0003-4061-3496; Mo, Zhixian/0000-0002-4100-7298	faculty research fund of HKBU [FRG2/09-10/019]; Special Program for Key Basic Research of the Ministry of Science and Technology China [2006CB708516]; Guangzhou Municipal research grant [201300000152]	faculty research fund of HKBU; Special Program for Key Basic Research of the Ministry of Science and Technology China; Guangzhou Municipal research grant	The work was supported by faculty research fund of HKBU #FRG2/09-10/019) to J. Shi, the Special Program for Key Basic Research of the Ministry of Science and Technology China (No. 2006CB708516) to Z. Mo and the Guangzhou Municipal research grant (#201300000152) to H. Cai. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Candolfi M, 2011, NEOPLASIA, V13, P947, DOI 10.1593/neo.11024; Chow KKH, 2013, MOL THER, V21, P629, DOI 10.1038/mt.2012.210; Coussens LM, 2013, SCIENCE, V339, P286, DOI 10.1126/science.1232227; Daigneault M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008668; Diesner SC, 2012, THER DELIV, V3, P377, DOI 10.4155/TDE.11.146; Fiorenza S, 2012, J IMMUNOL, V189, P5622, DOI 10.4049/jimmunol.1200709; Gao YH, 2005, J MED FOOD, V8, P159, DOI 10.1089/jmf.2005.8.159; Ghosh AK, 2012, CANCER LETT, V324, P91, DOI 10.1016/j.canlet.2012.05.002; Greenman C, 2007, NATURE, V446, P153, DOI 10.1038/nature05610; Guo J, 2002, GENE THER, V9, P793, DOI 10.1038/sj.gt.3301688; Hou XueWen, 1998, Journal of South China Agricultural University, V19, P106; Ina K, 2013, ANTI-CANCER AGENT ME, V13, P681, DOI 10.2174/1871520611313050002; Kaur A, 2005, BIOTECHNOL LETT, V27, P1815, DOI 10.1007/s10529-005-3559-y; [雷霄 Lei Xiao], 2012, [中国医药工业杂志, Chinese Journal of Pharmaceuticals], V43, P340; Lesterhuis WJ, 2011, NAT REV DRUG DISCOV, V10, P591, DOI 10.1038/nrd3500; MEGYERI P, 1990, J LEUKOCYTE BIOL, V47, P70, DOI 10.1002/jlb.47.1.70; Overwijk WW, 2011, CURR PROTOC IMMUNOL; Ramakrishnan R, 2011, CANCER IMMUNOL IMMUN, V60, P419, DOI 10.1007/s00262-010-0930-1; Sjoblom T, 2006, SCIENCE, V314, P268, DOI 10.1126/science.1133427; Tundup S, 2012, ANN NY ACAD SCI, V1253, pE1, DOI 10.1111/j.1749-6632.2012.06618.x; Wettergren Y, 2012, CANCER-AM CANCER SOC, V118, P2935, DOI 10.1002/cncr.26595; Yang XY, 2010, VACCINE, V28, P737, DOI 10.1016/j.vaccine.2009.10.065; Yoon TJ, 2008, APPL MICROBIOL BIOT, V80, P1087, DOI 10.1007/s00253-008-1607-y; Yoshino Shigefumi, 2008, Gan To Kagaku Ryoho, V35, P2239; Zang YCQ, 2000, BRAIN, V123, P1874, DOI 10.1093/brain/123.9.1874; Zhu KJ, 2000, CHINESE MED J-PEKING, V113, P1124	26	12	15	1	20	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 25	2013	8	9							e75328	10.1371/journal.pone.0075328	http://dx.doi.org/10.1371/journal.pone.0075328			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	228VC	24086508	gold, Green Published, Green Submitted			2023-01-03	WOS:000325218700076
J	Vodstrcil, LA; Hocking, JS; Law, M; Walker, S; Tabrizi, SN; Fairley, CK; Bradshaw, CS				Vodstrcil, Lenka A.; Hocking, Jane S.; Law, Matthew; Walker, Sandra; Tabrizi, Sepehr N.; Fairley, Christopher K.; Bradshaw, Catriona S.			Hormonal Contraception Is Associated with a Reduced Risk of Bacterial Vaginosis: A Systematic Review and Meta-Analysis	PLOS ONE			English	Review							SEXUALLY-TRANSMITTED INFECTIONS; FEMALE SEX WORKERS; NEISSERIA-GONORRHOEAE; CHLAMYDIA-TRACHOMATIS; REPRODUCTIVE-TRACT; LACTIC-ACID; WOMEN; PREVALENCE; ACQUISITION; LACTOBACILLI	Objective: To examine the association between hormonal contraception (HC) and bacterial vaginosis (BV) by systematic review and meta-analysis. Methods: Medline, Web of Science and Embase databases were searched to 24/1/13 and duplicate references removed. Inclusion criteria 1) >20 BV cases; 2) accepted BV diagnostic method; 3) measure of HC-use either as combined oestrogen-progesterone HC (combined), progesterone-only contraception (POC) or unspecified HC (u-HC); 4) >= 10% of women using HC; 5) analysis of the association between BV and HC-use presented; 6) appropriate control group. Data extracted included: type of HC, BV diagnostic method and outcome (prevalent, incident, recurrent), and geographical and clinic-setting. Meta-analyses were conducted to calculate pooled effect sizes (ES), stratified by HC-type and BV outcome. This systematic review is registered with PROSPERO (CRD42013003699). Results: Of 1713 unique references identified, 502 full-text articles were assessed for eligibility and 55 studies met inclusion criteria. Hormonal contraceptive use was associated with a significant reduction in the odds of prevalent BV (pooled effect size by random-effects [reES] = 0.68, 95% CI0.63-0.73), and in the relative risk (RR) of incident (reES = 0.82, 95% CI: 0.72-0.92), and recurrent (reES = 0.69, 95% CI: 0.59-0.91) BV. When stratified by HC-type, combined-HC and POC were both associated with decreased prevalence of BV and risk of incident BV. In the pooled analysis of the effect of HC-use on the composite outcome of prevalent/incident/recurrent BV, HC-use was associated with a reduced risk of any BV (reES = 0.78, 95% CI: 0.74-0.82). Conclusion: HC-use was associated with a significantly reduced risk of BV. This negative association was robust and present regardless of HC-type and evident across all three BV outcome measures. When stratified by HC-type, combined-HC and POC were both individually associated with a reduction in the prevalence and incidence of BV. This meta-analysis provides compelling evidence that HC-use influences a woman's risk of BV, with important implications for clinicians and researchers in the field.	[Vodstrcil, Lenka A.; Walker, Sandra; Fairley, Christopher K.; Bradshaw, Catriona S.] Univ Melbourne, Sexual Hlth Unit, Melbourne Sch Populat & Global Hlth, Parkville, Vic 3052, Australia; [Vodstrcil, Lenka A.; Walker, Sandra; Fairley, Christopher K.; Bradshaw, Catriona S.] Alfred Hosp, Melbourne Sexual Hlth Ctr, Carlton, Vic, Australia; [Vodstrcil, Lenka A.; Tabrizi, Sepehr N.] Murdoch Childrens Res Inst, Parkville, Vic, Australia; [Hocking, Jane S.] Univ Melbourne, Ctr Womens Hlth Gender & Soc, Melbourne Sch Populat & Global Hlth, Parkville, Vic 3052, Australia; [Law, Matthew] Univ New S Wales, Kirby Inst, Coogee, Australia; [Tabrizi, Sepehr N.] Royal Womens Hosp, Dept Microbiol & Infect Dis, Parkville, Vic, Australia; [Tabrizi, Sepehr N.] Univ Melbourne, Royal Womens Hosp Parkville, Dept Obstet & Gynaecol, Melbourne, Vic 3010, Australia; [Bradshaw, Catriona S.] Monash Univ, Dept Epidemiol & Preventat Med, Melbourne, Vic 3004, Australia	University of Melbourne; Florey Institute of Neuroscience & Mental Health; Murdoch Children's Research Institute; University of Melbourne; University of New South Wales Sydney; Kirby Institute; University of Melbourne; Monash University	Bradshaw, CS (corresponding author), Univ Melbourne, Sexual Hlth Unit, Melbourne Sch Populat & Global Hlth, Parkville, Vic 3052, Australia.	cbradshaw@mshc.org.au	Vodstrcil, Lenka/AAC-1896-2019; Hocking, Jane/AAD-5203-2021; Vodstrcil, Lenka/AAF-8722-2020	Hocking, Jane/0000-0001-9329-8501; Vodstrcil, Lenka/0000-0003-3679-9195; bradshaw, catriona/0000-0002-6643-5678; Christopher, Fairley/0000-0001-9081-1664; Law, Matthew/0000-0002-3540-8837	NHMRC [1020457, 568971]	NHMRC(National Health and Medical Research Council (NHMRC) of Australia)	Two grants contributed funding to this study; an NHMRC Project Grant (1020457) & an NHMRC Program grant (568971). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Allsworth JE, 2007, OBSTET GYNECOL, V109, P114, DOI 10.1097/01.AOG.0000247627.84791.91; Amaral R, 2007, INT J STD AIDS, V18, P770, DOI 10.1258/095646207782212333; AMSEL R, 1983, AM J MED, V74, P14, DOI 10.1016/0002-9343(83)91112-9; Artz L, 2000, AM J PUBLIC HEALTH, V90, P237, DOI 10.2105/AJPH.90.2.237; Ashraf-Ganjoei T., 2005, Eastern Mediterranean Health Journal, V11, P410; Atashili J, 2008, AIDS, V22, P1493, DOI 10.1097/QAD.0b013e3283021a37; Baeten JM, 2001, AM J OBSTET GYNECOL, V185, P380, DOI 10.1067/mob.2001.115862; Bai GY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036934; Baisley K, 2009, SEX TRANSM INFECT, V85, P370, DOI 10.1136/sti.2008.035543; BARBONE F, 1990, AM J OBSTET GYNECOL, V163, P510, DOI 10.1016/0002-9378(90)91186-G; Boskey ER, 2001, HUM REPROD, V16, P1809, DOI 10.1093/humrep/16.9.1809; Bradshaw CS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057688; Bradshaw CS, 2013, CLIN INFECT DIS, V56, P777, DOI 10.1093/cid/cis1030; Bradshaw CS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034540; Bradshaw CS, 2006, J INFECT DIS, V193, P1478, DOI 10.1086/503780; Bradshaw CS, 2005, OBSTET GYNECOL, V106, P105, DOI 10.1097/01.AOG.0000163247.78533.7b; Brotman RM, 2011, INT J STD AIDS, V22, P231, DOI 10.1258/ijsa.2011.010307; Bukusi E, 2011, SEX TRANSM DIS, V38, P483, DOI 10.1097/OLQ.0b013e318214b82d; Caldeira D, 2012, BMJ-BRIT MED J, V345, DOI 10.1136/bmj.e4260; Calzolari E, 2000, INT J GYNECOL OBSTET, V70, P341, DOI 10.1016/S0020-7292(00)00217-4; Cauci S, 2007, MOL HUM REPROD, V13, P243, DOI 10.1093/molehr/gam002; Cherpes TL, 2008, SEX TRANSM DIS, V35, P78, DOI 10.1097/OLQ.0b013e318156a5d0; COHEN CR, 1995, AIDS, V9, P1093, DOI 10.1097/00002030-199509000-00017; Dan M, 2003, ISRAEL MED ASSOC J, V5, P629; Evans AL, 2007, SEX TRANSM INFECT, V83, P470, DOI 10.1136/sti.2006.022277; Fethers KA, 2008, CLIN INFECT DIS, V47, P1426, DOI 10.1086/592974; Fethers KA, 2009, J INFECT DIS, V200, P1662, DOI 10.1086/648092; Fonck K, 2001, SEX TRANSM INFECT, V77, P271, DOI 10.1136/sti.77.4.271; Gallo MF, 2012, ANN EPIDEMIOL, V22, P213, DOI 10.1016/j.annepidem.2011.11.005; Grio R, 2004, Minerva Ginecol, V56, P141; Guerreiro D, 1998, INT J GYNECOL OBSTET, V63, pS167, DOI 10.1016/S0020-7292(98)00201-X; HART G, 1993, INT J STD AIDS, V4, P21, DOI 10.1177/095646249300400105; Harville EW, 2005, J WOMENS HEALTH, V14, P627, DOI 10.1089/jwh.2005.14.627; Hassan WM, 2007, SEX TRANSM DIS, V34, P384, DOI 10.1097/01.olq.0000243624.74573.63; HAY PE, 1994, BRIT J OBSTET GYNAEC, V101, P1048, DOI 10.1111/j.1471-0528.1994.tb13580.x; Heffron R, 2012, LANCET INFECT DIS, V12, P19, DOI 10.1016/S1473-3099(11)70247-X; Hel Z, 2010, ENDOCR REV, V31, P79, DOI 10.1210/er.2009-0018; Hensel KJ, 2011, AM J OBSTET GYNECOL, V204, DOI 10.1016/j.ajog.2010.08.013; HILLIER SL, 1991, GENITOURIN MED, V67, P26; Hillier SL, 1995, NEW ENGL J MED, V333, P1737, DOI 10.1056/NEJM199512283332604; Holzman C, 2001, AM J PUBLIC HEALTH, V91, P1664, DOI 10.2105/AJPH.91.10.1664; Jarosik GP, 1998, INFECT IMMUN, V66, P5041, DOI 10.1128/IAI.66.10.5041-5047.1998; Joesoef MR, 2001, CONTRACEPTION, V64, P169, DOI 10.1016/S0010-7824(01)00246-3; Kampan NC, 2011, SEX REPROD HEALTHC, V2, P1, DOI 10.1016/j.srhc.2010.11.002; King Anne E, 2003, Reprod Biol Endocrinol, V1, P116, DOI 10.1186/1477-7827-1-116; Klebanoff MA, 2010, SEX TRANSM DIS, V37, P184, DOI 10.1097/OLQ.0b013e3181c04865; Klebanoff MA, 2010, SEX TRANSM DIS, V37, P94, DOI 10.1097/OLQ.0b013e3181bc063c; Kleinschmidt I, 2007, CONTRACEPTION, V75, P461, DOI 10.1016/j.contraception.2007.02.002; Koumans EH, 2002, CLIN INFECT DIS, V35, pS152, DOI 10.1086/342103; Koumans EH, 2007, SEX TRANSM DIS, V34, P864, DOI 10.1097/OLQ.0b013e318074e565; LEFEVRE JC, 1988, SEX TRANSM DIS, V15, P110, DOI 10.1097/00007435-198804000-00009; Mares D, 2008, J REPROD IMMUNOL, V77, P91, DOI 10.1016/j.jri.2007.04.004; Martin HL, 1999, J INFECT DIS, V180, P1863, DOI 10.1086/315127; Mascarenhas Rita Elizabeth Moreira, 2012, Infect Dis Obstet Gynecol, V2012, P378640, DOI 10.1155/2012/378640; McClelland RS, 2008, SEX TRANSM DIS, V35, P617, DOI 10.1097/OLQ.0b013e31816907fa; Moher D, 2009, PLOS MED, V6, DOI [10.1371/journal.pmed.1000097, 10.1136/bmj.b4037]; Moi H, 1990, Int J STD AIDS, V1, P86; Morison L, 2005, SEX TRANSM INFECT, V81, P242, DOI 10.1136/sti.2004.011684; Mossop H, 2011, OBSTET GYNECOL, V118, P840, DOI 10.1097/AOG.0b013e31822da9e9; Nansel TR, 2006, AM J OBSTET GYNECOL, V194, P381, DOI 10.1016/j.ajog.2005.07.047; Ness RB, 2003, J NATL MED ASSOC, V95, P201; Ness RB, 2002, OBSTET GYNECOL, V100, P765, DOI 10.1016/S0029-7844(02)02184-1; O'Hanlon DE, 2011, BMC INFECT DIS, V11, DOI 10.1186/1471-2334-11-200; O'Hanlon DE, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-120; Oduyebo OO, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006055.pub2; Peipert JF, 2008, SEX TRANSM DIS, V35, P363, DOI 10.1097/OLQ.0b013e31815e4179; Perla M E, 2012, Infect Dis Obstet Gynecol, V2012, P739624, DOI 10.1155/2012/739624; Pettifor A, 2009, CONTRACEPTION, V80, P555, DOI 10.1016/j.contraception.2009.06.007; Plitt SS, 2005, SEX TRANSM DIS, V32, P446, DOI 10.1097/01.olq.0000154567.21291.59; Rifkin SB, 2009, CONTRACEPTION, V80, P63, DOI 10.1016/j.contraception.2009.01.008; Riggs M, 2007, SEX TRANSM DIS, V34, P954, DOI 10.1097/OLQ.0b013e31811ed0e4; Rugpao S, 2008, SEX TRANSM DIS, V35, P643, DOI 10.1097/OLQ.0b013e31816f70f2; Schwebke JR, 1997, SEX TRANSM DIS, V24, P236, DOI 10.1097/00007435-199704000-00009; Schwebke JR, 2005, SEX TRANSM DIS, V32, P654, DOI 10.1097/01.olq.0000175396.10304.62; Schwebke JR, 2004, SEX TRANSM DIS, V31, P433, DOI 10.1097/01.olq.0000129948.91055.9F; Shoubnikova M, 1997, CONTRACEPTION, V55, P355, DOI 10.1016/S0010-7824(97)00044-9; Smart S, 2004, SEX TRANSM INFECT, V80, P58, DOI 10.1136/sti.2003.004978; Srinivasan S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010197; Straub RH, 2007, ENDOCR REV, V28, P521, DOI 10.1210/er.2007-0001; Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008; Tibaldi C, 2009, CLIN MICROBIOL INFEC, V15, P670, DOI 10.1111/j.1469-0691.2009.02842.x; von Elm E, 2007, PLOS MED, V4, P1623, DOI [10.1371/journal.pmed.0040296, 10.1371/journal.pmed.0040297]; Watcharotone Wiset, 2004, Journal of the Medical Association of Thailand, V87, P1419; Wiesenfeld HC, 2003, CLIN INFECT DIS, V36, P663, DOI 10.1086/367658; Wira CR, 2010, AM J REPROD IMMUNOL, V63, P544, DOI 10.1111/j.1600-0897.2010.00842.x; Wong WCW, 2008, EMERG THEMES EPIDEMI, V5, DOI 10.1186/1742-7622-5-23; Yen S, 2003, OBSTET GYNECOL, V102, P927, DOI 10.1016/S0029-7844(03)00858-5; Yotebieng M, 2009, TROP MED INT HEALTH, V14, P480, DOI 10.1111/j.1365-3156.2009.02235.x; Zenilman JM, 1999, SEX TRANSM INFECT, V75, P347, DOI 10.1136/sti.75.5.347	89	74	85	0	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 4	2013	8	9							e73055	10.1371/journal.pone.0073055	http://dx.doi.org/10.1371/journal.pone.0073055			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	219OE	24023807	Green Published, Green Submitted, gold			2023-01-03	WOS:000324515600062
J	Sun, Y; Mukai, Y; Tanaka, M; Saito, T; Sato, S; Kurasaki, M				Sun, Yongkun; Mukai, Yuuka; Tanaka, Masato; Saito, Takeshi; Sato, Shin; Kurasaki, Masaaki			Green Tea Extract Increases mRNA Expression of Enzymes Which Influence Epigenetic Marks in Newborn Female Offspring from Undernourished Pregnant Mother	PLOS ONE			English	Article							ACTIVATED PROTEIN-KINASE; MATERNAL UNDERNUTRITION; OXIDATIVE STRESS; SIRT1; FETAL; RESTRICTION; AMPK; MALNUTRITION; POLYPHENOLS; PREVENTION	Biochemical and toxicological properties of catechin remain unclear, e.g.; how catechin affects female offspring from undernourished pregnant dams. Here, to elucidate effects of low prenatal protein on female offspring health status, changes of enzymes which modify epigenetic marks related with metabolism in kidneys from newborns were investigated after continuously administering catechin extracted from green tea to lactating maternal rats after pregnant undernourishment. We found that green tea extract intake during lactation up-regulated the activation of AMP-activated protein kinase in young female offspring from protein-restricted dams and modulated the AMP-activated protein kinase pathway in the kidney. This pathway was indicated to be stimulated by SIRT1 gene expression. The feeding of green tea extract to protein-restricted dams during lactation is likely to up-regulate AMP-activated protein kinase activation and may partly lead to alterations of the AMP-activated protein kinase pathway in female offspring kidneys. In addition, energy metabolism in fetal and offspring period with green tea extract administration might be related to enzymes which modify epigenetic marks such as DNA methyltransferase 1 and 3a.	[Sun, Yongkun; Kurasaki, Masaaki] Hokkaido Univ, Grad Sch Environm Sci, Sapporo, Hokkaido, Japan; [Mukai, Yuuka; Sato, Shin] Aomori Univ Hlth & Welf, Dept Nutr, Aomori, Japan; [Tanaka, Masato; Saito, Takeshi] Hokkaido Univ, Grad Sch Hlth Sci, Sapporo, Hokkaido, Japan; [Saito, Takeshi] Hokkaido Univ, Fac Hlth Sci, Sapporo, Hokkaido, Japan; [Kurasaki, Masaaki] Hokkaido Univ, Fac Environm Earth Sci, Sapporo, Hokkaido, Japan	Hokkaido University; Aomori University of Health & Welfare; Hokkaido University; Hokkaido University; Hokkaido University	Kurasaki, M (corresponding author), Hokkaido Univ, Grad Sch Environm Sci, Sapporo, Hokkaido, Japan.	kura@ees.hokudai.ac.jp	Kurasaki, Masaaki/B-8207-2012; SAITO, TAKESHI/E-5950-2012	Kurasaki, Masaaki/0000-0003-2125-095X; 	Japan Society for the Promotion of Science [23655139, 24350077, 20500710]	Japan Society for the Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science)	This research was supported by Grants-in-Aid from the Japan Society for the Promotion of Science (No. 23655139 and No. 24350077 for Kurasaki, and No. 20500710 for Sato). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alexandre-Gouabau MC, 2011, J PROTEOME RES, V10, P3292, DOI 10.1021/pr2003193; Arts ICW, 2000, J AGR FOOD CHEM, V48, P1752, DOI 10.1021/jf000026+; Begum G, 2012, FASEB J, V26, P1694, DOI 10.1096/fj.11-198762; Bieswal F, 2006, OBESITY, V14, P1330, DOI 10.1038/oby.2006.151; Botden IPG, 2012, DIABETES CARE, V35, P424, DOI 10.2337/dc11-1203; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chen Z, 2009, CIRC RES, V104, P496, DOI 10.1161/CIRCRESAHA.108.187567; Chmurzynska A, 2010, NUTR REV, V68, P87, DOI 10.1111/j.1753-4887.2009.00265.x; Chu KO, 2006, J PHARM SCI-US, V95, P1372, DOI 10.1002/jps.20594; Drake AJ, 2012, CLIN ENDOCRINOL, V77, P808, DOI 10.1111/j.1365-2265.2012.04453.x; Fullerton MD, 2010, DIABETES, V59, P551, DOI 10.2337/db09-1732; Garcia-Souza EP, 2008, AM J PHYSIOL-ENDOC M, V295, pE626, DOI 10.1152/ajpendo.00439.2007; Gramza Anna, 2005, Polish Journal of Food and Nutrition Sciences, V14, P219; Guilloteau P, 2009, J PHYSIOL PHARMACOL, V60, P17; Holness MJ, 2010, NUTRITION, V26, P491, DOI 10.1016/j.nut.2009.09.012; Ikeda M, 2007, MED SCI MONITOR, V13, pBR40; Isbrucker RA, 2006, FOOD CHEM TOXICOL, V44, P651, DOI 10.1016/j.fct.2005.11.002; Jin BY, 2009, P NATL ACAD SCI USA, V106, P17343, DOI 10.1073/pnas.0907409106; Kang LS, 2012, AM J PHYSIOL-HEART C, V302, pH560, DOI 10.1152/ajpheart.00277.2011; Kazantsev AG, 2008, NAT REV DRUG DISCOV, V7, P854, DOI 10.1038/nrd2681; Kume S, 2006, FREE RADICAL BIO MED, V40, P2175, DOI 10.1016/j.freeradbiomed.2006.02.014; Li SF, 2003, GYNECOL ONCOL, V90, P123, DOI 10.1016/S0090-8258(03)00194-X; Li Y, 2010, CURR MED CHEM, V17, P2141, DOI 10.2174/092986710791299966; Lloyd LJ, 2012, J PHYSIOL-LONDON, V590, P377, DOI 10.1113/jphysiol.2011.220186; Mesquita FF, 2010, BRAZ J MED BIOL RES, V43, P1010, DOI [10.1590/S0100-879X2010007500113, 10.1590/S0100-879X2010001100001]; Morita O, 2009, FOOD CHEM TOXICOL, V47, P1296, DOI 10.1016/j.fct.2009.03.005; Mukai Y, 2013, NUTRITION, V29, P291, DOI 10.1016/j.nut.2012.06.005; Mukai Y, 2011, J NUTR BIOCHEM, V22, P16, DOI 10.1016/j.jnutbio.2009.11.004; Ota H, 2007, J MOL CELL CARDIOL, V43, P571, DOI 10.1016/j.yjmcc.2007.08.008; Peng LR, 2011, MOL CELL BIOL, V31, P4720, DOI 10.1128/MCB.06147-11; Price NL, 2012, CELL METAB, V15, P675, DOI 10.1016/j.cmet.2012.04.003; Sato S, 2008, CLIN EXP PHARMACOL P, V35, P43, DOI 10.1111/j.1440-1681.2007.04743.x; Sato S, 2013, J NUTR BIOCHEM, V24, P118, DOI 10.1016/j.jnutbio.2012.03.007; SUN Y, 2012, J APPL TOXICOL, DOI DOI 10.1002/JAT.2816.PUBMED:22968747.IN; THORS B, 2009, BIOCHIM BIOPHYS ACTA, V1813, P322; Tiwari V, 2010, INT J NEUROPSYCHOPH, V13, P1053, DOI 10.1017/S146114571000060X; Tu HC, 2010, TAIWAN J OBSTET GYNE, V49, P174, DOI 10.1016/S1028-4559(10)60037-X; Wakeling LA, 2009, AGE, V31, P327, DOI 10.1007/s11357-009-9104-5; Wang HF, 2000, TRENDS FOOD SCI TECH, V11, P152, DOI 10.1016/S0924-2244(00)00061-3; Watkins AJ, 2008, J PHYSIOL-LONDON, V586, P2231, DOI 10.1113/jphysiol.2007.149229; Zhang YJ, 2006, ARTERIOSCL THROM VAS, V26, P1281, DOI 10.1161/01.ATV.0000221230.08596.98	41	7	8	0	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 29	2013	8	8							e74559	10.1371/journal.pone.0074559	http://dx.doi.org/10.1371/journal.pone.0074559			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	209DO	24009774	Green Submitted, Green Published, gold			2023-01-03	WOS:000323734600084
J	Boumil, MM; Curfman, GD				Boumil, Marcia M.; Curfman, Gregory D.			On Access and Accountability - Two Supreme Court Rulings on Generic Drugs	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material								<p id="p002">In June, the U.S. Supreme Court issued two rulings regarding the marketing of generic drugs. The decisions have mixed implications for consumers, but given the size and growth rate of the industry, their impact can be expected to be substantial. <p id="p003">In June, the U.S. Supreme Court issued two rulings regarding the marketing of generic drugs that may alter the pharmaceutical business landscape. First, in Federal Trade Commission v. Actavis, the Court confronted the law governing a controversial pharmaceutical marketing practice known as reverse payment agreements, or pay for delay.(1) This practice occurs when a generic drug company identifies a vulnerable patent held by a brand-name drug manufacturer and seeks approval from the Food and Drug Administration (FDA) for a generic version before the patent expires, provoking a lawsuit for infringement. The two companies then forge a settlement whereby the brand-name ...	[Boumil, Marcia M.] Tufts Univ, Sch Med, Boston, MA 02111 USA	Tufts University	Boumil, MM (corresponding author), Tufts Univ, Sch Med, Boston, MA 02111 USA.								0	3	3	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 22	2013	369	8					696	697		10.1056/NEJMp1308368	http://dx.doi.org/10.1056/NEJMp1308368			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	204FA	23923990				2023-01-03	WOS:000323349300005
J	Neuhaus, V; Schwarz, K; Klee, A; Seehase, S; Forster, C; Pfennig, O; Jonigk, D; Fieguth, HG; Koch, W; Warnecke, G; Yusibov, V; Sewald, K; Braun, A				Neuhaus, Vanessa; Schwarz, Katharina; Klee, Anna; Seehase, Sophie; Foerster, Christine; Pfennig, Olaf; Jonigk, Danny; Fieguth, Hans-Gerd; Koch, Wolfgang; Warnecke, Gregor; Yusibov, Vidadi; Sewald, Katherina; Braun, Armin			Functional Testing of an Inhalable Nanoparticle Based Influenza Vaccine Using a Human Precision Cut Lung Slice Technique	PLOS ONE			English	Article							AMORPHOUS SILICA; ANTIBODY-PRODUCTION; RAPID PRODUCTION; VIRUS; MUCOSAL; CELLS; RESPONSES; DELIVERY; PROTECTION; MEMORY	Annual outbreaks of influenza infections, caused by new influenza virus subtypes and high incidences of zoonosis, make seasonal influenza one of the most unpredictable and serious health threats worldwide. Currently available vaccines, though the main prevention strategy, can neither efficiently be adapted to new circulating virus subtypes nor provide high amounts to meet the global demand fast enough. New influenza vaccines quickly adapted to current virus strains are needed. In the present study we investigated the local toxicity and capacity of a new inhalable influenza vaccine to induce an antigen-specific recall response at the site of virus entry in human precision-cut lung slices (PCLS). This new vaccine combines recombinant H1N1 influenza hemagglutinin (HAC1), produced in tobacco plants, and a silica nanoparticle (NP)-based drug delivery system. We found no local cellular toxicity of the vaccine within applicable concentrations. However higher concentrations of NP (>= 10(3) mu g/ml) dose-dependently decreased viability of human PCLS. Furthermore NP, not the protein, provoked a dose-dependent induction of TNF-alpha and IL-1 beta, indicating adjuvant properties of silica. In contrast, we found an antigen-specific induction of the T cell proliferation and differentiation cytokine, IL-2, compared to baseline level (152 +/- 49 pg/mg vs. 22 +/- 5 pg/mg), which could not be seen for the NP alone. Additionally, treatment with 10 mu g/ml HAC1 caused a 6-times higher secretion of IFN-gamma compared to baseline (602 +/- 307 pg/mg vs. 97 +/- 51 pg/mg). This antigen-induced IFN-gamma secretion was further boosted by the adjuvant effect of silica NP for the formulated vaccine to a 12-fold increase (97 +/- 51 pg/mg vs. 1226 +/- 535 pg/mg). Thus we were able to show that the plant-produced vaccine induced an adequate innate immune response and re-activated an established antigen-specific T cell response within a non-toxic range in human PCLS at the site of virus entry.	[Neuhaus, Vanessa; Schwarz, Katharina; Klee, Anna; Koch, Wolfgang; Sewald, Katherina; Braun, Armin] Fraunhofer Inst Toxicol & Expt Med, Hannover, Germany; [Seehase, Sophie] ARCN, Leibniz Ctr Med & Biosci, Res Ctr Borstel, Borstel, Germany; [Foerster, Christine; Pfennig, Olaf; Fieguth, Hans-Gerd] KRH Klinikum Oststadt Heidehaus, Hannover, Germany; [Jonigk, Danny] Hannover Med Sch, Inst Pathol, Hannover, Germany; [Warnecke, Gregor] Hannover Med Sch, Div Cardiac Thorac Transplantat & Vasc Surg, Hannover, Germany; [Yusibov, Vidadi] Fraunhofer USA Ctr Mol Biotechnol, Newark, DE USA; [Braun, Armin] Hannover Med Sch, Inst Immunol, Hannover, Germany; [Neuhaus, Vanessa; Schwarz, Katharina; Klee, Anna; Jonigk, Danny; Koch, Wolfgang; Warnecke, Gregor; Sewald, Katherina; Braun, Armin] Biomed Res Endstage & Obstruct Lung Dis Hannover, Hannover, Germany; [Seehase, Sophie] German Ctr Lung Res DZL, Hannover, Germany	Fraunhofer Gesellschaft; Forschungszentrum Borstel; Hannover Medical School; Hannover Medical School; Hannover Medical School	Braun, A (corresponding author), Fraunhofer Inst Toxicol & Expt Med, Hannover, Germany.	armin.braun@item.fraunhofer.de	Yusibov, Vidadi/AAA-7408-2019; Braun, Armin/B-8750-2009	Braun, Armin/0000-0002-1142-1463; Fieguth, Hans G./0000-0003-1559-158X	Fraunhofer Society; Deutsche Forschungsgemeinschaft (DFG) [Graduiertenkolleg 1441]; Deutsche Forschungsgemeinschaft (DFG); Integriertes Forschungs- und Behandlungszentrum of Hannover Medical school;  [JO 743/2-1]	Fraunhofer Society; Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG)); Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG)); Integriertes Forschungs- und Behandlungszentrum of Hannover Medical school; 	The work was funded by the Fraunhofer Society. The Fraunhofer ITEM is a public non-profit research organisation doing contract research for e. g. pharmaceutical and biotech industry. www.fraunhofer.de. VN has received a PhD grant from the Graduiertenkolleg 1441 from the Deutsche Forschungsgemeinschaft (DFG); http://www.dfg.de. DJ has received a research grant from the Deutsche Forschungsgemeinschaft (DFG); grant ID JO 743/2-1; http://www.dfg.de. DJ is sponsored by the Integriertes Forschungs- und Behandlungszentrum of Hannover Medical school (IFB-Tx, MHH; Project 09- fibrotic remodelling in lung allografts). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Amidi M, 2007, VACCINE, V25, P144, DOI 10.1016/j.vaccine.2006.06.086; [Anonymous], 1980, B WORLD HEALTH ORGAN, V58, P585; Baldwin SL, 2009, VACCINE, V27, P5956, DOI 10.1016/j.vaccine.2009.07.081; Barnard DL, 2009, ANTIVIR RES, V82, pA110, DOI 10.1016/j.antiviral.2008.12.014; Carvalho LV, 2010, VACCINE, V28, P7829, DOI 10.1016/j.vaccine.2010.09.087; Centers for Disease Control and Prevention, 2009, MMWR-MORBID MORTAL W, V58, P1241; Chazaud C, 2006, DEV CELL, V10, P615, DOI 10.1016/j.devcel.2006.02.020; Chichester JA, 2007, HUM VACCINES, V3, P146, DOI 10.4161/hv.3.4.4148; Christensen D, 2010, INT J PHARMACEUT, V390, P19, DOI 10.1016/j.ijpharm.2009.10.043; Claas ECJ, 2000, VET MICROBIOL, V74, P133, DOI 10.1016/S0378-1135(00)00173-5; Doherty PC, 1997, IMMUNOL REV, V159, P105, DOI 10.1111/j.1600-065X.1997.tb01010.x; Gamblin SJ, 2010, J BIOL CHEM, V285, P28403, DOI 10.1074/jbc.R110.129809; Gupta V, 2006, VACCINE, V24, P3881, DOI 10.1016/j.vaccine.2006.01.010; Hancock K, 2009, NEW ENGL J MED, V361, P1945, DOI 10.1056/NEJMoa0906453; Holmgren J, 2012, CURR OPIN IMMUNOL, V24, P343, DOI 10.1016/j.coi.2012.03.014; Jiang WL, 2005, ADV DRUG DELIVER REV, V57, P391, DOI 10.1016/j.addr.2004.09.003; Jul-Larsen A, 2012, HUM VACCIN IMMUNOTHE, V8; Juno J, 2012, CLIN DEV IMMUNOL, DOI 10.1155/2012/797180; Koutsonanos DG, 2011, J INFECT DIS, V204, P582, DOI 10.1093/infdis/jir094; Madhun AS, 2011, VACCINE, V29, P4973, DOI 10.1016/j.vaccine.2011.04.094; MANCINO D, 1977, INT ARCH ALLER A IMM, V53, P97, DOI 10.1159/000231738; MANCINO D, 1980, INT ARCH ALLER A IMM, V61, P253, DOI 10.1159/000232443; Mortimer E, 2012, BMC BIOTECHNOL, V12, DOI 10.1186/1472-6750-12-14; Pedersen GK, 2012, J INFECT DIS, V206, P158, DOI 10.1093/infdis/jis330; PEREIRA HG, 1967, B WORLD HEALTH ORGAN, V37, P553; Purwar R, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016245; RAZ E, 1994, P NATL ACAD SCI USA, V91, P9519, DOI 10.1073/pnas.91.20.9519; Riberdy JM, 2000, J VIROL, V74, P9762, DOI 10.1128/JVI.74.20.9762-9765.2000; Richert LE, 2012, VACCINE, V30, P3653, DOI 10.1016/j.vaccine.2012.03.035; Shoji Y, 2008, VACCINE, V26, P2930, DOI 10.1016/j.vaccine.2008.03.045; Shoji Y, 2012, INFLUENZA OTHER RESP, V6, P204, DOI 10.1111/j.1750-2659.2011.00295.x; Shoji Y, 2011, HUM VACCINES, V7, P41, DOI 10.4161/hv.7.0.14561; Soppimath KS, 2001, J CONTROL RELEASE, V70, P1, DOI 10.1016/S0168-3659(00)00339-4; Switalla S, 2010, TOXICOL APPL PHARM, V246, P107, DOI 10.1016/j.taap.2010.04.010; Teijaro JR, 2011, J IMMUNOL, V187, P5510, DOI 10.4049/jimmunol.1102243; Teijaro JR, 2010, J VIROL, V84, P9217, DOI 10.1128/JVI.01069-10; Thangavel RR, 2011, VIROL J, V8, DOI 10.1186/1743-422X-8-180; Topham DJ, 1997, J IMMUNOL, V159, P5197; Tumpey TM, 2001, J VIROL, V75, P5141, DOI 10.1128/JVI.75.11.5141-5150.2001; Ulmer JB, 2006, NAT BIOTECHNOL, V24, P1377, DOI 10.1038/nbt1261; van Riel D, 2006, SCIENCE, V312, P399, DOI 10.1126/science.1125548; Wee JLK, 2008, MUCOSAL IMMUNOL, V1, P489, DOI 10.1038/mi.2008.59; Winter M, 2011, NANOTOXICOLOGY, V5, P326, DOI 10.3109/17435390.2010.506957; Wohlsen A, 2003, EUR RESPIR J, V21, P1024, DOI 10.1183/09031936.03.00027502; Wu WX, 2010, VIROLOGY, V396, P178, DOI 10.1016/j.virol.2009.10.016; Yazdi AS, 2010, P NATL ACAD SCI USA, V107, P19449, DOI 10.1073/pnas.1008155107; Zhu JF, 2010, CELL RES, V20, P4, DOI 10.1038/cr.2009.138	47	30	31	0	21	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 13	2013	8	8							e71728	10.1371/journal.pone.0071728	http://dx.doi.org/10.1371/journal.pone.0071728			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	201BN	23967238	Green Published, Green Submitted, gold			2023-01-03	WOS:000323115800076
J	Dalziel, SR; Thompson, JMD; Macias, CG; Fernandes, RM; Johnson, DW; Waisman, Y; Cheng, N; Acworth, J; Chamberlain, JM; Osmond, MH; Plint, A; Valerio, P; Black, KJL; Fitzpatrick, E; Newton, AS; Kuppermann, N; Klassen, TP				Dalziel, Stuart R.; Thompson, John M. D.; Macias, Charles G.; Fernandes, Ricardo M.; Johnson, David W.; Waisman, Yehezkel; Cheng, Nicholas; Acworth, Jason; Chamberlain, James M.; Osmond, Martin H.; Plint, Amy; Valerio, Paolo; Black, Karen J. L.; Fitzpatrick, Eleanor; Newton, Amanda S.; Kuppermann, Nathan; Klassen, Terry P.		Pediat Emergency Res Networks PERN	Predictors of severe H1N1 infection in children presenting within Pediatric Emergency Research Networks (PERN): retrospective case-control study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							INFLUENZA-A H1N1; PANDEMIC H1N1; SEASONAL INFLUENZA; VIRUS-INFECTION; UNITED-STATES; HOSPITALIZED-PATIENTS; A(H1N1) INFECTION; INTENSIVE-CARE; MEDICINE; CALIFORNIA	Objective To identify historical and clinical findings at emergency department presentation associated with severe H1N1 outcome in children presenting with influenza-like illness. Design Multicentre retrospective case-control study. Setting 79 emergency departments of hospitals associated with the Pediatric Emergency Research Networks in 12 countries. Participants 265 children (<16 years), presenting between 16 April and 31 December 2009, who fulfilled Centers for Disease Control and Prevention criteria for influenza-like illness and developed severe outcomes from laboratory confirmed H1N1 infection. For each case, two controls presenting with influenza-like illness but without severe outcomes were included: one random control and one age matched control. Main outcome measures Severe outcomes included death or admission to intensive care for assisted ventilation, inotropic support, or both. Multivariable conditional logistic regression was used to compare cases and controls, with effect sizes measured as adjusted odds ratios. Results 151 (57%) of the 265 cases were male, the median age was 6 (interquartile range 2.3-10.0) years, and 27 (10%) died. Six factors were associated with severe outcomes in children presenting with influenza-like illness: history of chronic lung disease (odds ratio 10.3, 95% confidence interval 1.5 to 69.8), history of cerebral palsy/developmental delay (10.2, 2.0 to 51.4), signs of chest retractions (9.6, 3.2 to 29.0), signs of dehydration (8.8, 1.6 to 49.3), requirement for oxygen (5.8, 2.0 to 16.2), and tachycardia relative to age). Conclusion These independent risk factors may alert clinicians to children at risk of severe outcomes when presenting with influenza-like illness during future pandemics.	[Dalziel, Stuart R.] Starship Childrens Hosp, Auckland, New Zealand; [Dalziel, Stuart R.; Thompson, John M. D.] Univ Auckland, Auckland 1, New Zealand; [Macias, Charles G.] Baylor Coll Med, Houston, TX 77030 USA; [Macias, Charles G.] Texas Childrens Hosp, Houston, TX 77030 USA; [Fernandes, Ricardo M.] Hosp Santa Maria, Dept Pediat, Lisbon, Portugal; [Fernandes, Ricardo M.] Inst Mol Med, Fac Med, Lab Clin Pharmacol & Therapeut, Lisbon, Portugal; [Johnson, David W.] Univ Calgary, Alberta Childrens Hosp, Res Inst, Calgary, AB, Canada; [Waisman, Yehezkel] Schneider Childrens Med Ctr Israel, Petah Tiqwa, Israel; [Cheng, Nicholas] Childrens Hosp Westmead, Sydney, NSW, Australia; [Acworth, Jason] Royal Childrens Hosp, Brisbane, Qld, Australia; [Chamberlain, James M.] Childrens Natl Med Ctr, Washington, DC 20010 USA; [Osmond, Martin H.; Plint, Amy] Univ Ottawa, Ottawa, ON, Canada; [Osmond, Martin H.; Plint, Amy] Childrens Hosp Eastern Ontario, Ottawa, ON K1H 8L1, Canada; [Valerio, Paolo] Onze Lieve Vrouw Hosp, Amsterdam, Netherlands; [Black, Karen J. L.; Fitzpatrick, Eleanor] IWK Hlth Ctr, Halifax, NS, Canada; [Newton, Amanda S.] Univ Alberta, Edmonton, AB, Canada; [Kuppermann, Nathan] Univ Calif Davis, Sch Med, Dept Emergency Med, Davis, CA 95616 USA; [Kuppermann, Nathan] Univ Calif Davis, Sch Med, Dept Pediat, Davis, CA 95616 USA; [Klassen, Terry P.] Univ Manitoba, Manitoba Inst Child Hlth, Winnipeg, MB, Canada	Starship Children's Hospital; University of Auckland; Baylor College of Medicine; Baylor College of Medicine; Universidade de Lisboa; Hospital Santa Maria; Universidade de Lisboa; Alberta Childrens Hospital; University of Calgary; University of Sydney; Royal Children's Hospital Brisbane; Children's National Health System; University of Ottawa; University of Ottawa; Children's Hospital of Eastern Ontario; Onze Lieve Vrouwe Gasthuis Hospital; Dalhousie University; University of Alberta; University of California System; University of California Davis; University of California System; University of California Davis; University of Manitoba	Dalziel, SR (corresponding author), Starship Childrens Hosp, Auckland, New Zealand.	sdalziel@adhb.govt.nz	Benito, Javier/G-9198-2011; Rodrigues, Fernanda/AAW-4615-2021; Jouvet, Philippe A/H-3293-2018; Plint, Amy/AAE-2250-2020; Ong, Gene/W-3154-2019; Mintegi, Santiago/G-8252-2011; Acworth, Jason/B-1339-2011; Fernandes, Ricardo M/C-7501-2015; Hendrickson, Marissa/ABA-7225-2021; Thompson, Graham/Y-4180-2019	Benito, Javier/0000-0003-1548-7408; Jouvet, Philippe A/0000-0001-5684-3398; Ong, Gene/0000-0002-9879-0594; Mintegi, Santiago/0000-0002-2342-8881; Acworth, Jason/0000-0002-6602-3155; Fernandes, Ricardo M/0000-0002-7253-6475; Thompson, Graham/0000-0002-6781-4186; Klassen, Terry/0000-0002-5309-7091; Hendrickson, Marissa/0000-0002-1545-0982; Lyttle, Mark/0000-0002-8634-7210; Van de Voorde, Patrick/0000-0001-9053-0475; Osmond, Martin/0000-0001-8275-8381	HRSA/MCHB/EMSC [U03MC00001, U03MC00003, U03MC00006, U03MC00007, U03MC00008, U03MC22684, U03MC22685]; Health Research Council of New Zealand; Logan Campbell Trust, Auckland, New Zealand; CureKids, New Zealand	HRSA/MCHB/EMSC(United States Department of Health & Human ServicesUnited States Health Resources & Service Administration (HRSA)); Health Research Council of New Zealand(Health Research Council of New Zealand); Logan Campbell Trust, Auckland, New Zealand; CureKids, New Zealand	PECARN is supported by HRSA/MCHB/EMSC through the following cooperative agreements: U03MC00001, U03MC00003, U03MC00006, U03MC00007, U03MC00008, U03MC22684, and U03MC22685. SRD is supported by the Health Research Council of New Zealand. JMDT received funding from the Logan Campbell Trust, Auckland, New Zealand, to attend an investigator meeting with time funded by CureKids, New Zealand. Investigators' time was funded by their host institutions. No funding bodies had any role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bagdure D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015173; Bautista E, 2010, NEW ENGL J MED, V362, P1708, DOI 10.1056/NEJMra1000449; Brierley J, 2009, CRIT CARE MED, V37, P666, DOI 10.1097/CCM.0b013e31819323c6; Bryant PA, 2010, PEDIATR INFECT DIS J, V29, P694, DOI 10.1097/INF.0b013e3181de4b9c; Calitri C, 2010, EUR J PEDIATR, V169, P1511, DOI 10.1007/s00431-010-1255-y; Campbell A, 2010, CAN MED ASSOC J, V182, P349, DOI 10.1503/cmaj.091823; Centers for Disease Control and Prevention (CDC), 2009, MMWR Morb Mortal Wkly Rep, V58, P941; Chamberlain JM, 2005, PEDIATRICS, V115, P388, DOI 10.1542/peds.2004-0586; Chowell G, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1000436; Fanella ST, 2011, INFECT CONT HOSP EP, V32, P435, DOI 10.1086/659401; Farias JA, 2010, INTENS CARE MED, V36, P1015, DOI 10.1007/s00134-010-1853-1; Fuhrman C, 2011, EPIDEMIOL INFECT, V139, P1202, DOI 10.1017/S0950268810002414; Gilbert EH, 1996, ANN EMERG MED, V27, P305, DOI 10.1016/S0196-0644(96)70264-0; Herberg JA, 2011, PEDIATR INFECT DIS J, V30, P438, DOI 10.1097/INF.0b013e3182040c90; Hiba V, 2011, J ANTIMICROB CHEMOTH, V66, P1150, DOI 10.1093/jac/dkr089; Jain S, 2009, NEW ENGL J MED, V361, P1935, DOI 10.1056/NEJMoa0906695; Jhung MA, 2011, CLIN INFECT DIS, V52, pS13, DOI 10.1093/cid/ciq008; Klassen TP, 2010, PEDIATR EMERG CARE, V26, P541, DOI 10.1097/PEC.0b013e3181e5bec1; Kumar S, 2010, PEDIATR INFECT DIS J, V29, P591, DOI 10.1097/INF.0b013e3181d73e32; Launay E, 2011, INT J INFECT DIS, V15, pE122, DOI 10.1016/j.ijid.2010.08.006; Lee N, 2011, J INFECT DIS, V203, P1739, DOI 10.1093/infdis/jir187; Libster R, 2010, NEW ENGL J MED, V363, P2472, DOI 10.1056/NEJMc1008806; Lister P, 2009, LANCET, V374, P605, DOI [10.1016/S0140-6736(09)61512-9, 10.1016/S0140-6736(09)61513-0]; Lockman JL, 2010, PEDIATR CRIT CARE ME, V11, P173, DOI 10.1097/PCC.0b013e3181ccedae; Louie JK, 2010, ARCH PEDIAT ADOL MED, V164, P1023, DOI 10.1001/archpediatrics.2010.203; Louie JK, 2009, JAMA-J AM MED ASSOC, V302, P1896, DOI 10.1001/jama.2009.1583; O'Riordan S, 2010, CAN MED ASSOC J, V182, P39, DOI 10.1503/cmaj.091724; Ostovar GA, 2011, CLIN PEDIATR, V50, P348, DOI 10.1177/0009922810390512; Shun-Shin M, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b3172; Stein M, 2010, ARCH PEDIAT ADOL MED, V164, P1015, DOI 10.1001/archpediatrics.2010.195; Sullivan PB, 2000, DEV MED CHILD NEUROL, V42, P674, DOI 10.1017/S0012162200001249; Van Kerkhove MD, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001053; Yung M, 2011, PEDIATRICS, V127, pE156, DOI 10.1542/peds.2010-0801	33	29	32	1	18	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 12	2013	347								f4836	10.1136/bmj.f4836	http://dx.doi.org/10.1136/bmj.f4836			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	203WU	23940290	Green Published, hybrid			2023-01-03	WOS:000323326000002
J	Weeks, HR; Tadler, SC; Smith, KW; Iacob, E; Saccoman, M; White, AT; Landvatter, JD; Chelune, GJ; Suchy, Y; Clark, E; Cahalan, MK; Bushnell, L; Sakata, D; Light, AR; Light, KC				Weeks, Howard R., III; Tadler, Scott C.; Smith, Kelly W.; Iacob, Eli; Saccoman, Mikala; White, Andrea T.; Landvatter, Joshua D.; Chelune, Gordon J.; Suchy, Yana; Clark, Elaine; Cahalan, Michael K.; Bushnell, Lowry; Sakata, Derek; Light, Alan R.; Light, Kathleen C.			Antidepressant and Neurocognitive Effects of Isoflurane Anesthesia versus Electroconvulsive Therapy in Refractory Depression	PLOS ONE			English	Article							AUTOBIOGRAPHICAL MEMORY; DISORDERS; ECT; NARCOTHERAPY; METAANALYSIS; STIMULATION; EDUCATION; MOOD; AGE	Background: Many patients have serious depression that is nonresponsive to medications, but refuse electroconvulsive therapy (ECT). Early research suggested that isoflurane anesthesia may be an effective alternative to ECT. Subsequent studies altered drug, dose or number of treatments, and failed to replicate this success, halting research on isoflurane's antidepressant effects for a decade. Our aim was to re-examine whether isoflurane has antidepressant effects comparable to ECT, with less adverse effects on cognition. Method: Patients with medication-refractory depression received an average of 10 treatments of bifrontal ECT (n = 20) or isoflurane (n = 8) over 3 weeks. Depression severity (Hamilton Rating Scale for Depression-24) and neurocognitive responses (anterograde and retrograde memory, processing speed and verbal fluency) were assessed at Pretreatment, Post all treatments and 4-week Follow-up. Results: Both treatments produced significant reductions in depression scores at Post-treatment and 4-week Follow-up; however, ECT had modestly better antidepressant effect at follow-up in severity-matched patients. Immediately Post-treatment, ECT (but not isoflurane) patients showed declines in memory, fluency, and processing speed. At Follow-up, only autobiographical memory remained below Pretreatment level for ECT patients, but isoflurane patients had greater test-retest neurocognitive score improvement. Conclusions: Our data reconfirm that isoflurane has an antidepressant effect approaching ECT with less adverse neurocognitive effects, and reinforce the need for a larger clinical trial.	[Weeks, Howard R., III; Bushnell, Lowry] Univ Utah, Sch Med, Univ Neuropsychiat Inst, Dept Psychiat, Salt Lake City, UT USA; [Tadler, Scott C.; Smith, Kelly W.; Iacob, Eli; White, Andrea T.; Landvatter, Joshua D.; Cahalan, Michael K.; Sakata, Derek; Light, Alan R.; Light, Kathleen C.] Univ Utah, Sch Med, Dept Anesthesiol, Salt Lake City, UT USA; [Iacob, Eli; Light, Alan R.] Univ Utah, Sch Med, Neurosci Program, Salt Lake City, UT USA; [Saccoman, Mikala; Clark, Elaine] Univ Utah, Dept Educ Psychol, Coll Educ, Salt Lake City, UT 84112 USA; [White, Andrea T.] Univ Utah, Coll Hlth, Dept Exercise & Sport Sci, Salt Lake City, UT USA; [Chelune, Gordon J.; Suchy, Yana] Univ Utah, Sch Med, Dept Neurol, Salt Lake City, UT USA; [Chelune, Gordon J.; Suchy, Yana] Univ Utah, Sch Med, Ctr Alzheimers Care Imaging & Res, Salt Lake City, UT USA; [Suchy, Yana] Univ Utah, Dept Psychol, Coll Social & Behav Sci, Salt Lake City, UT 84112 USA	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	Weeks, HR (corresponding author), Univ Utah, Sch Med, Univ Neuropsychiat Inst, Dept Psychiat, Salt Lake City, UT USA.	Howard.Weeks@hsc.utah.edu	Tadler, Scott C./AAG-3595-2019	Suchy, Yana/0000-0001-6513-565X	Department of Anesthesiology, University of Utah, Salt Lake City, Utah; intramural pilot study seed grant	Department of Anesthesiology, University of Utah, Salt Lake City, Utah; intramural pilot study seed grant	This study was supported by an intramural pilot study seed grant to SCT and ARL by the Department of Anesthesiology, University of Utah, Salt Lake City, Utah. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Allan CL, 2011, NEUROPSYCHOBIOLOGY, V64, P163, DOI 10.1159/000328951; Attix DK, 2009, CLIN NEUROPSYCHOL, V23, P21, DOI 10.1080/13854040801945078; BP Wang L, 2012, SOC NEUR ANN M PLANN; CARL C, 1988, PHARMACOPSYCHIATRY, V21, P432, DOI 10.1055/s-2007-1017040; Carney S, 2003, LANCET, V361, P799; Delis DC, 2001, DELIS KAPLAN D KEFS; Dunne RA, 2012, WORLD J BIOL PSYCHIA, V13, P248, DOI 10.3109/15622975.2011.615863; ENGELHARDT W, 1993, EUR J ANAESTH, V10, P113; Fraser LM, 2008, J ECT, V24, P10, DOI 10.1097/YCT.0b013e3181616c26; Garcia-Toro M, 2001, J ECT, V17, P284, DOI 10.1097/00124509-200112000-00009; GREENBERG LB, 1987, CONVULSIVE THER, V3, P269; Iacob E, 2012, BRAIN BEHAV IN PRESS; Khalid N, 2008, J ECT, V24, P141, DOI 10.1097/YCT.0b013e318157ac58; Kirov G, 2008, BRIT J PSYCHIAT, V193, P152, DOI 10.1192/bjp.bp.107.044362; LANGER G, 1995, NEUROPSYCHOBIOLOGY, V31, P182, DOI 10.1159/000119190; LANGER G, 1985, NEUROPSYCHOBIOLOGY, V14, P118, DOI 10.1159/000118216; Longman RS, 2007, ASSESSMENT, V14, P426, DOI 10.1177/1073191107304114; Loo CK, 2012, BRIT J PSYCHIAT, V200, P52, DOI 10.1192/bjp.bp.111.097634; Norman MA, 2011, J CLIN EXP NEUROPSYC, V33, P793, DOI 10.1080/13803395.2011.559157; Payne NA, 2009, J PSYCHIATR PRACT, V15, P346, DOI 10.1097/01.pra.0000361277.65468.ef; Perrin JS, 2012, P NATL ACAD SCI USA, V109, P5464, DOI 10.1073/pnas.1117206109; Prudic J, 2004, BIOL PSYCHIAT, V55, P301, DOI 10.1016/j.biopsych.2003.09.015; Prudic J, 1996, AM J PSYCHIAT, V153, P985; Rush AJ, 2006, NEW ENGL J MED, V354, P1231, DOI 10.1056/NEJMoa052963; Semkovska M, 2012, PSYCHIAT RES, V197, P41, DOI 10.1016/j.psychres.2011.12.010; Semkovska M, 2010, BIOL PSYCHIAT, V68, P568, DOI 10.1016/j.biopsych.2010.06.009; Tadler S, 2009, ANESTHESIA ANALGESIA, V108, P212; Theisen ME, 1998, ASSESSMENT, V5, P85, DOI 10.1177/107319119800500110; Tombaugh TN, 1999, ARCH CLIN NEUROPSYCH, V14, P167, DOI 10.1016/S0887-6177(97)00095-4; Wisdom NM, 2012, ARCH CLIN NEUROPSYCH, V27, P389, DOI 10.1093/arclin/acs041; Wroolie TE, 2006, J CLIN PSYCHOPHARM, V26, P361, DOI 10.1097/01.jcp.0000227699.26375.f8	31	28	29	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 26	2013	8	7							e69809	10.1371/journal.pone.0069809	http://dx.doi.org/10.1371/journal.pone.0069809			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	197GU	23922809	Green Submitted, Green Published, gold			2023-01-03	WOS:000322838900087
J	Chen, X; Wu, Q; Tan, L; Porter, D; Jager, MJ; Emery, C; Bastian, BC				Chen, X.; Wu, Q.; Tan, L.; Porter, D.; Jager, M. J.; Emery, C.; Bastian, B. C.			Combined PKC and MEK inhibition in uveal melanoma with GNAQ and GNA11 mutations	ONCOGENE			English	Article						GNAQ/GNA11; MAPK signaling; protein kinase C; combined PKC and MEK inhibition; melanoma; PKC inhibitor	PROTEIN-KINASE-C; PROMOTING PHORBOL ESTERS; SIGNAL-REGULATED KINASE; PHASE-II; BRAF INHIBITION; ALPHA-SUBUNIT; LUNG-CANCER; PATHWAY; RESISTANCE; RAF	Uveal melanoma (UM) is a genetically and biologically distinct type of melanoma, and once metastatic there is no effective treatment currently available. Eighty percent of UMs harbor mutations in the G alpha(q) family members GNAQ and GNA11. Understanding the effector pathways downstream of these oncoproteins is important to identify opportunities for targeted therapy. We report consistent activation of the protein kinase C (PKC) and MAPK pathways as a consequence of GNAQ or GNA11 mutation. PKC inhibition with AEB071 or AHT956 suppressed PKC and MAPK signalling and induced G1 arrest selectively in melanoma cell lines carrying GNAQ or GNA11 mutations. In contrast, treatment with two different MEK inhibitors, PD0325901 and MEK162, inhibited the proliferation of melanoma cell lines irrespective of their mutation status, indicating that in the context of GNAQ or GNA11 mutation MAPK activation can be attributed to activated PKC. AEB071 significantly slowed the growth of tumors in an allograft model of GNAQ(Q209L)-transduced melanocytes, but did not induce tumor shrinkage. In vivo and in vitro studies showed that PKC inhibitors alone were unable to induce sustained suppression of MAP-kinase signaling. However, combinations of PKC and MEK inhibition, using either PD0325901or MEK162, led to sustained MAP-kinase pathway inhibition and showed a strong synergistic effect in halting proliferation and in inducing apoptosis in vitro. Furthermore, combining PKC and MEK inhibition was efficacious in vivo, causing marked tumor regression in a UM xenograft model. Our data identify PKC as a rational therapeutic target for melanoma patients with GNAQ or GNA11 mutations and demonstrate that combined MEK and PKC inhibition is synergistic, with superior efficacy compared to treatment with either approach alone.	[Chen, X.; Bastian, B. C.] Mem Sloan Kettering Canc Ctr, Human Oncol & Pathogenesis Program, New York, NY 10021 USA; [Chen, X.; Wu, Q.; Bastian, B. C.] Univ Calif San Francisco, Dept Dermatol, San Francisco, CA 94143 USA; [Chen, X.; Wu, Q.; Bastian, B. C.] Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94140 USA; [Chen, X.; Wu, Q.; Bastian, B. C.] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA; [Tan, L.; Porter, D.; Emery, C.] Novartis, Novartis Inst BioMed Res, Cambridge, MA USA; [Jager, M. J.] Leiden Univ, Med Ctr, Dept Ophthalmol, Leiden, Netherlands	Memorial Sloan Kettering Cancer Center; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center; Novartis; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Emery, C (corresponding author), Novartis Inst BioMed Res, Cambridge, MA 02139 USA.	caroline.emery@novartis.com; Boris.Bastian@ucsf.edu	Jager, Martine/AAR-3525-2020	Jager, Martine/0000-0003-2261-3820; Bastian, Boris/0000-0003-1836-6062; chen, xu/0000-0003-2524-4979	National Cancer Institute [CA142873]; Melanoma Research Alliance Team Science Award; NATIONAL CANCER INSTITUTE [R01CA142873] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Melanoma Research Alliance Team Science Award; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by grant CA142873 from the National Cancer Institute and a Melanoma Research Alliance Team Science Award.	ARITA Y, 1992, CANCER RES, V52, P4514; BENNETT DC, 1987, INT J CANCER, V39, P414, DOI 10.1002/ijc.2910390324; BLACKSHEAR PJ, 1993, J BIOL CHEM, V268, P1501; Bosco R, 2011, MINI-REV MED CHEM, V11, P185, DOI 10.2174/138955711795049899; CASTAGNA M, 1982, J BIOL CHEM, V257, P7847; Chou TC, 2010, CANCER RES, V70, P440, DOI 10.1158/0008-5472.CAN-09-1947; Clement-Duchene C, 2012, LUNG CANCER, V78, P57, DOI 10.1016/j.lungcan.2012.06.003; Dorsam RT, 2007, NAT REV CANCER, V7, P79, DOI 10.1038/nrc2069; EGAN KM, 1988, SURV OPHTHALMOL, V32, P239, DOI 10.1016/0039-6257(88)90173-7; Flaherty KT, 2012, NEW ENGL J MED, V367, P1694, DOI 10.1056/NEJMoa1210093; Friday BB, 2008, CANCER RES, V68, P6145, DOI 10.1158/0008-5472.CAN-08-1430; Goldsmith ZG, 2007, ONCOGENE, V26, P3122, DOI 10.1038/sj.onc.1210407; GRAGOUDAS ES, 1991, OPHTHALMOLOGY, V98, P383; Griewank KG, 2012, PIGM CELL MELANOMA R, V25, DOI 10.1111/j.1755-148X.2012.00971.x; Griner EM, 2007, NAT REV CANCER, V7, P281, DOI 10.1038/nrc2110; Gronberg BH, 2012, LUNG CANCER, V78, P63, DOI 10.1016/j.lungcan.2012.07.007; HEEMSKERK FMJ, 1993, BIOCHEM BIOPH RES CO, V190, P236, DOI 10.1006/bbrc.1993.1036; HERGET T, 1995, EUR J BIOCHEM, V233, P448, DOI 10.1111/j.1432-1033.1995.448_2.x; Hubbard KB, 2006, CELL SIGNAL, V18, P135, DOI 10.1016/j.cellsig.2005.08.004; Johannessen CM, 2010, NATURE, V468, P968, DOI 10.1038/nature09627; KALINEC G, 1992, MOL CELL BIOL, V12, P4687, DOI 10.1128/MCB.12.10.4687; KIKKAWA U, 1983, J BIOL CHEM, V258, P1442; Kirkwood JM, 2012, CLIN CANCER RES, V18, P555, DOI 10.1158/1078-0432.CCR-11-1491; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; Lamba S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006833; Lehar J, 2009, NAT BIOTECHNOL, V27, P659, DOI 10.1038/nbt.1549; Mackay HJ, 2007, NAT REV CANCER, V7, P554, DOI 10.1038/nrc2168; MARKBY DW, 1993, SCIENCE, V262, P1895, DOI 10.1126/science.8266082; McLean IW, 2004, CAN J OPHTHALMOL, V39, P343, DOI 10.1016/S0008-4182(04)80004-8; Millward MJ, 2006, BRIT J CANCER, V95, P829, DOI 10.1038/sj.bjc.6603331; Montagut C, 2008, CANCER RES, V68, P4853, DOI 10.1158/0008-5472.CAN-07-6787; Naylor TL, 2011, CANCER RES, V71, P2643, DOI 10.1158/0008-5472.CAN-10-2525; Nazarian R, 2010, NATURE, V468, P973, DOI 10.1038/nature09626; Paraiso KHT, 2010, BRIT J CANCER, V102, P1724, DOI 10.1038/sj.bjc.6605714; Pratilas CA, 2009, P NATL ACAD SCI USA, V106, P4519, DOI 10.1073/pnas.0900780106; Schonwasser DC, 1998, MOL CELL BIOL, V18, P790, DOI 10.1128/MCB.18.2.790; Singh Arun D, 2005, Ophthalmol Clin North Am, V18, P75, DOI 10.1016/j.ohc.2004.07.002; Solit DB, 2011, NEW ENGL J MED, V364, P772, DOI 10.1056/NEJMcibr1013704; Solit DB, 2006, NATURE, V439, P358, DOI 10.1038/nature04304; Sturm OE, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2001212; Teicher BA, 2006, CLIN CANCER RES, V12, P5336, DOI 10.1158/1078-0432.CCR-06-0945; THELEN M, 1991, NATURE, V351, P320, DOI 10.1038/351320a0; Ueda Y, 1996, J BIOL CHEM, V271, P23512, DOI 10.1074/jbc.271.38.23512; Urtreger AJ, 2012, IUBMB LIFE, V64, P18, DOI 10.1002/iub.574; Van Raamsdonk CD, 2010, NEW ENGL J MED, V363, P2191, DOI 10.1056/NEJMoa1000584; Van Raamsdonk CD, 2009, NATURE, V457, P599, DOI 10.1038/nature07586; Wagner J, 2009, J MED CHEM, V52, P6193, DOI 10.1021/jm901108b; Wu XQ, 2012, MOL CANCER THER, V11, P1905, DOI 10.1158/1535-7163.MCT-12-0121; Wu XQ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029622	49	124	128	2	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 25	2014	33	39					4724	4734		10.1038/onc.2013.418	http://dx.doi.org/10.1038/onc.2013.418			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AR0ED	24141786	Green Accepted			2023-01-03	WOS:000343239500003
J	Kedir, H; Berhane, Y; Worku, A				Kedir, Haji; Berhane, Yemane; Worku, Alemayehu			Khat Chewing and Restrictive Dietary Behaviors Are Associated with Anemia among Pregnant Women in High Prevalence Rural Communities in Eastern Ethiopia	PLOS ONE			English	Article							CURRENT SITUATION; MATERNAL ANEMIA; RISK-FACTORS; HEMOGLOBIN; IRON; DETERMINANTS; NUTRITION; INFECTION; MALARIA; AFRICA	Background: Anemia affects a high proportion of pregnant women in the developing countries. Factors associated with it vary in context. This study aimed to determine the prevalence and predictors of anemia among pregnant women in the rural eastern Ethiopia. Methods: A community-based cross-sectional study was done on 1678 pregnant women who were selected by a cluster random sampling technique. A pregnant woman was identified as anemic if her hemoglobin concentration was <11 g/dl. Data were collected in a community-based setting. Multilevel mixed effect logistic regression was used to determine the adjusted odds ratios (AOR) with 95% confidence intervals (CI) for the predictors of anemia. Results: Anemia was observed among 737(43.9%) of the 1678 pregnant women studied (95% CI 41.5%-46.3%). After controlling for the confounders, the risk of anemia was 29% higher in the women who chewed khat daily than those who sometimes or never did so (AOR, 1.29; 95% CI, 1.02-1.62). The study subjects with restrictive dietary behavior (reduced either meal size or frequency) had a 39% higher risk of anemia compared to those without restrictive dietary behavior (AOR, 1.39; 95% CI, 1.02-1.88). The risk of anemia was increased by 68% (AOR, 1.68; 95% CI, 1.15-2.47), and 60% (AOR, 1.60; 95% CI, 1.08-2.37) in parity levels of 2 births and 3 births, respectively. Compared to the first trimester, the risk of anemia was higher by two-fold (AOR, 2.09; 95% CI, 1.46-3.00) in the second trimester and by four-fold (AOR, 4.23; 95% CI, 2.97-6.02) in the third trimester. Conclusion: In this study, two out of five women were anemic. Chewing khat and restrictive dietary habits that are associated with anemia in the setting should be addressed through public education programs. Interventions should also focus on the women at higher parity levels and those who are in advanced stages of pregnancy.	[Kedir, Haji] Haramaya Univ, Coll Hlth & Med Sci, Harar, Ethiopia; [Berhane, Yemane; Worku, Alemayehu] Addis Continental Inst Publ Hlth, Addis Ababa, Ethiopia; [Worku, Alemayehu] Univ Addis Ababa, Sch Publ Hlth, Addis Ababa, Ethiopia	Haramaya University; Addis Continental Institute of Public Health; Addis Ababa University	Kedir, H (corresponding author), Haramaya Univ, Coll Hlth & Med Sci, Harar, Ethiopia.	hajikedir2007@yahoo.com	Berhane, Yemane/ABB-8154-2020	Berhane, Yemane/0000-0002-2527-1339	Haramaya University	Haramaya University	This study was financially supported by Haramaya University as part of PhD program. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Agan TU, 2010, INT J WOMENS HEALTH, V2, P229; Al-Farsi YM, 2011, BMC PREGNANCY CHILDB, V11, DOI 10.1186/1471-2393-11-7; Al-Motarreb A, 2010, J ETHNOPHARMACOL, V132, P540, DOI 10.1016/j.jep.2010.07.001; Alem M., 2013, J INTERDISCIP HISTOP, V1, P137, DOI [10.5455/jihp.20130122042052, DOI 10.5455/JIHP.20130122042052]; [Anonymous], 2008, WORLDW PREV AN 1993; Ayoya MA, 2006, FOOD NUTR BULL, V27, P3, DOI 10.1177/156482650602700101; BAIDOO SE, 2010, J BACTERIOL RES, V2, P9; Balarajan Y, 2011, LANCET, V378, P2123, DOI 10.1016/S0140-6736(10)62304-5; Barroso F, 2011, EUR J OBSTET GYN R B, V159, P99, DOI 10.1016/j.ejogrb.2011.07.041; Beaton GH, 2000, AM J CLIN NUTR, V72, p265S, DOI 10.1093/ajcn/72.1.265S; Belachew Tefera, 2006, Ethiop Med J, V44, P211; Bodeau-Livinec F, 2011, AM J TROP MED HYG, V85, P414, DOI 10.4269/ajtmh.2011.10-0599; Brooker S, 2008, PLOS NEGLECT TROP D, V2, DOI 10.1371/journal.pntd.0000291; Central Statistical Agency [Ethiopia] and ICF International, 2012, ETH DEM HLTH SURV 20; *CTR STAT AG, 2006, ETH DEM HLTH SURV 20; DESALEGN S, 1993, ETHIOPIAN MED J, V31, P251; Diamantopoulos A, 2012, J ACAD MARKET SCI, V40, P434, DOI 10.1007/s11747-011-0300-3; Dim Cyril C, 2007, MedGenMed, V9, P11; Garg Aashima, 2006, Indian Journal of Pediatrics, V73, P687, DOI 10.1007/BF02898446; Gebissa E, 2010, J ETHNOPHARMACOL, V132, P607, DOI 10.1016/j.jep.2010.01.063; Gebremedhin S, 2011, ETHIOP J HEALTH DEV, V25, P22; Ghosh S, 2009, J BIOSOC SCI, V41, P763, DOI 10.1017/S0021932009990149; Gibson RS, 2008, J NUTR, V138, P581, DOI 10.1093/jn/138.3.581; Gies S, 2003, TROP MED INT HEALTH, V8, P301, DOI 10.1046/j.1365-3156.2003.01037.x; Griffiths P, 2010, J ETHNOPHARMACOL, V132, P578, DOI 10.1016/j.jep.2010.04.046; Haidar J, 2010, J HEALTH POPUL NUTR, V28, P359; Haidar Jemal A, 2009, BMC Blood Disord, V9, P7, DOI 10.1186/1471-2326-9-7; Hinderaker SG, 2002, EUR J CLIN NUTR, V56, P192, DOI 10.1038/sj.ejcn.1601300; Lamina S, 2010, S AFR J SCI, V106, P28, DOI 10.4102/sajs.v106i3/4.155; Lartey A, 2008, P NUTR SOC, V67, P105, DOI 10.1017/S0029665108006083; McLean E, 2009, PUBLIC HEALTH NUTR, V12, P444, DOI 10.1017/S1368980008002401; Melaku Umeta, 2008, Ethiopian Journal of Health Development, V22, P252; Morris LD, 2007, VOX SANG, V93, P64, DOI 10.1111/j.1423-0410.2007.00919.x; Msuya S. E., 2011, Tanzania Journal of Health Research, V13, P40; Ndyomugyenyi R, 2008, T ROY SOC TROP MED H, V102, P130, DOI 10.1016/j.trstmh.2007.09.015; Nestel P., 2002, ADJUSTING HEMOGLOBIN; Nkrumah B, 2011, BMC CLIN PATHOL, V11, DOI 10.1186/1472-6890-11-5; Odenwald M, 2010, J ETHNOPHARMACOL, V132, P615, DOI 10.1016/j.jep.2009.11.005; Robert T, 2011, AFR J HLTH SCI, V18, P96; Rothman K.J., 2008, MODERN EPIDEMIOLOGY, P128; Stanback J, 2008, REV PANAM SALUD PUBL, V23, P116, DOI 10.1590/S1020-49892008000200007; StataCorp, 2009, STAT QUICK REF IND R; Swindale A., 2006, FHI 360FANTA; Torpey K, 2010, BMC PUBLIC HEALTH, V10, DOI 10.1186/1471-2458-10-249; Uneke CJ, 2007, J HEALTH POPUL NUTR, V25, P328; Wabe N.T, 2012, J EXP INTEGR MED, V2, P29, DOI [DOI 10.5455/JEIM.221211.RW.005, 10.5455/jeim.221211.rw.005]; WHO, 2011, WHONMHNHDMNM111; World Health Organization, 1995, PHYS STAT US INT ANT; Zhang QY, 2009, PAEDIATR PERINAT EP, V23, P282, DOI 10.1111/j.1365-3016.2009.01031.x; Zimmermann M.B., 2007, NUTR ANEMIA, P199	50	39	39	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 4	2013	8	11							e78601	10.1371/journal.pone.0078601	http://dx.doi.org/10.1371/journal.pone.0078601			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	245ZC	24223828	gold, Green Published, Green Submitted			2023-01-03	WOS:000326503400076
J	McBane, JE; Vulesevic, B; Padavan, DT; McEwan, KA; Korbutt, GS; Suuronen, EJ				McBane, Joanne E.; Vulesevic, Branka; Padavan, Donna T.; McEwan, Kimberly A.; Korbutt, Gregory S.; Suuronen, Erik J.			Evaluation of a Collagen-Chitosan Hydrogel for Potential Use as a Pro-Angiogenic Site for Islet Transplantation	PLOS ONE			English	Article							PROGENITOR-CELL MOBILIZATION; PANCREATIC-ISLETS; DIABETES-MELLITUS; DEVICE; MICE; NEOVASCULARIZATION; SURVIVAL; PREIMPLANTATION; VASCULARIZATION; STREPTOZOTOCIN	Islet transplantation to treat type 1 diabetes (T1D) has shown varied long-term success, due in part to insufficient blood supply to maintain the islets. In the current study, collagen and collagen: chitosan (10: 1) hydrogels, +/-circulating angiogenic cells (CACs), were compared for their ability to produce a pro-angiogenic environment in a streptozotocin-induced mouse model of T1D. Initial characterization showed that collagen-chitosan gels were mechanically stronger than the collagen gels (0.7kPa vs. 0.4kPa elastic modulus, respectively), had more cross-links (9.2 vs. 7.4/mu m(2)), and were degraded more slowly by collagenase. After gelation with CACs, live/dead staining showed greater CAC viability in the collagen-chitosan gels after 18h compared to collagen (79% vs. 69%). In vivo, collagen-chitosan gels, subcutaneously implanted for up to 6 weeks in a T1D mouse, showed increased levels of pro-angiogenic cytokines over time. By 6 weeks, anti-islet cytokine levels were decreased in all matrix formulations +/- CACs. The 6-week implants demonstrated increased expression of VCAM-1 in collagen-chitosan implants. Despite this, infiltrating vWF(+) and CXCR4(+) angiogenic cell numbers were not different between the implant types, which may be due to a delayed and reduced cytokine response in a T1D versus non-diabetic setting. The mechanical, degradation and cytokine data all suggest that the collagen-chitosan gel may be a suitable candidate for use as a pro-angiogenic ectopic islet transplant site.	[McBane, Joanne E.; Vulesevic, Branka; Padavan, Donna T.; McEwan, Kimberly A.; Suuronen, Erik J.] Univ Ottawa, Inst Heart, Ottawa, ON, Canada; [McBane, Joanne E.; Vulesevic, Branka; Suuronen, Erik J.] Univ Ottawa, Dept Cellular & Mol Med, Ottawa, ON, Canada; [McEwan, Kimberly A.] Univ Ottawa, Fac Engn, Ottawa, ON, Canada; [Korbutt, Gregory S.] Univ Alberta, Alberta Diabet Inst, Edmonton, AB, Canada	University of Ottawa; University of Ottawa Heart Institute; University of Ottawa; University of Ottawa; University of Alberta	Suuronen, EJ (corresponding author), Univ Ottawa, Inst Heart, Ottawa, ON, Canada.	esuuronen@ottawaheart.ca		McBane, Joanne/0000-0002-9053-4668; Vulesevic, Branka/0000-0003-2297-2209	JDRF [41-2009-771]; CIHR Doctoral Research Award; University of Ottawa Cardiovascular Research Endowment Fund Fellowship; Ontario Graduate Scholarship; Molecular Function & Imaging Program; HSF of Ontario Program Grant [PRG 6242]; JDRF postdoctoral fellowship; CDA postdoctoral fellowship incentive program award	JDRF(Juvenile Diabetes Research Foundation); CIHR Doctoral Research Award(Canadian Institutes of Health Research (CIHR)); University of Ottawa Cardiovascular Research Endowment Fund Fellowship; Ontario Graduate Scholarship(Ontario Graduate Scholarship); Molecular Function & Imaging Program; HSF of Ontario Program Grant; JDRF postdoctoral fellowship(Juvenile Diabetes Research Foundation); CDA postdoctoral fellowship incentive program award	This work was supported by operating grant number 41-2009-771 from JDRF (to GSK and EJS). BV was funded by a CIHR Doctoral Research Award, DTP was funded by a University of Ottawa Cardiovascular Research Endowment Fund Fellowship, KM was supported by an Ontario Graduate Scholarship, and JEM was supported first by a fellowship from the Molecular Function & Imaging Program, funded by a HSF of Ontario Program Grant (PRG 6242), and then by a JDRF postdoctoral fellowship and a CDA postdoctoral fellowship incentive program award. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abaci A, 1999, CIRCULATION, V99, P2239, DOI 10.1161/01.CIR.99.17.2239; Albiero M, 2012, CURR VASC PHARMACOL, V10, P310, DOI 10.2174/157016112799959387; Annabi N, 2010, TISSUE ENG PART B-RE, V16, P371, DOI 10.1089/ten.TEB.2009.0639; Balamurugan AN, 2003, PANCREAS, V26, P279, DOI 10.1097/00006676-200304000-00012; Bowers DT, 2011, TRANSPL P, V43, P3285, DOI 10.1016/j.transproceed.2011.09.008; Cardozo AK, 2003, DIABETOLOGIA, V46, P255, DOI 10.1007/s00125-002-1017-0; Carlsson PO, 2011, UPSALA J MED SCI, V116, P1, DOI 10.3109/03009734.2010.548609; Chavakis E, 2005, J EXP MED, V201, P63, DOI 10.1084/jem.20041402; Deng C, 2011, J CONTROL RELEASE, V152, pE196, DOI 10.1016/j.jconrel.2011.09.005; Deng C, 2010, MACROMOL SYMP, V297, P138, DOI 10.1002/masy.200900149; Deng C, 2010, TISSUE ENG PT A, V16, P3099, DOI 10.1089/ten.tea.2009.0504; Dong L, 2011, MICROVASC RES, V82, P227, DOI 10.1016/j.mvr.2011.09.006; Eizirik DL, 2009, NAT REV ENDOCRINOL, V5, P219, DOI 10.1038/nrendo.2009.21; Engler AJ, 2006, CELL, V126, P677, DOI 10.1016/j.cell.2006.06.044; Fadini GP, 2005, CURR DIABETES REV, V1, P41, DOI 10.2174/1573399052952640; Forster NA, 2011, ISLETS, V3, P271, DOI 10.4161/isl.3.5.15942; Gallagher KA, 2007, J CLIN INVEST, V117, P1249, DOI 10.1172/JCI29710; Ishiyama K, 2011, TRANSPLANTATION, V91, P952, DOI 10.1097/TP.0b013e3182139dc1; Jacobs-Tulleneers-Thevissen D, 2010, DIABETOLOGIA, V53, P1690, DOI 10.1007/s00125-010-1721-0; Kakabadze Z, 2011, TRANSPL INT, V24, P175, DOI 10.1111/j.1432-2277.2010.01160.x; Kaufman-Francis K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040741; Kim JS, 2012, J CONTROL RELEASE, V162, P382, DOI 10.1016/j.jconrel.2012.07.018; Kriz J, 2010, TRANSPL P, V42, P2097, DOI 10.1016/j.transproceed.2010.05.088; Kriz J, 2012, AM J SURG, V203, P793, DOI 10.1016/j.amjsurg.2011.02.009; Kuraitis D, 2011, J MOL CELL CARDIOL, V51, P187, DOI 10.1016/j.yjmcc.2011.04.011; Lin CC, 2011, BIOMATERIALS, V32, P9685, DOI 10.1016/j.biomaterials.2011.08.083; Loomans CJM, 2004, DIABETES, V53, P195, DOI 10.2337/diabetes.53.1.195; MANDRUPPOULSEN T, 1990, CURR TOP MICROBIOL, V164, P169; McEwan K, 2012, J BIOMAT SCI-POLYM E, V23, P1467, DOI 10.1163/092050611X584397; Merani S, 2008, BRIT J SURG, V95, P1449, DOI 10.1002/bjs.6391; Moore WV, 2002, CELL TRANSPLANT, V11, P707, DOI 10.3727/000000002783985369; Muthyala S, 2010, ISLETS, V2, P357, DOI 10.4161/isl.2.6.13765; PAIK SG, 1980, P NATL ACAD SCI-BIOL, V77, P6129, DOI 10.1073/pnas.77.10.6129; Pan SK, 2011, J ZHEJIANG UNIV-SC B, V12, P931, DOI 10.1631/jzus.B1100065; Pileggi A, 2006, TRANSPLANTATION, V81, P1318, DOI 10.1097/01.tp.0000203858.41105.88; Rafael E, 2003, CELL TRANSPLANT, V12, P407, DOI 10.3727/000000003108746957; Ryan EA, 2005, DIABETES, V54, P2060, DOI 10.2337/diabetes.54.7.2060; Shapiro AMJ, 2006, NEW ENGL J MED, V355, P1318, DOI 10.1056/NEJMoa061267; Sorenby AK, 2008, TRANSPLANTATION, V86, P364, DOI 10.1097/TP.0b013e31817efc78; Stamenovic D, 2000, J APPL PHYSIOL, V89, P2085, DOI 10.1152/jappl.2000.89.5.2085; Takahashi T, 1999, NAT MED, V5, P434, DOI 10.1038/7434; Trichet L, 2012, P NATL ACAD SCI USA, V109, P6933, DOI 10.1073/pnas.1117810109; Weber LM, 2009, J BIOMED MATER RES A, V90A, P720, DOI 10.1002/jbm.a.32134; Witkowski P, 2009, TRANSPLANTATION, V88, P1065, DOI 10.1097/TP.0b013e3181ba2e87; YAMADA K, 1993, BIOCHEM BIOPH RES CO, V197, P22, DOI 10.1006/bbrc.1993.2435; Yeung TY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038189	46	40	42	0	28	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 18	2013	8	10							e77538	10.1371/journal.pone.0077538	http://dx.doi.org/10.1371/journal.pone.0077538			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	239MM	24204863	Green Published, Green Submitted, gold			2023-01-03	WOS:000326029300103
J	Arum, O; Rasche, ZA; Rickman, DJ; Bartke, A				Arum, Oge; Rasche, Zachary Andrew; Rickman, Dustin John; Bartke, Andrzej			Prevention of Neuromusculoskeletal Frailty in Slow-Aging Ames Dwarf Mice: Longitudinal Investigation of Interaction of Longevity Genes and Caloric Restriction	PLOS ONE			English	Article							RECEPTOR KNOCKOUT MICE; GROWTH-HORMONE; LIFE-SPAN; DIETARY RESTRICTION; OLDER-ADULTS; HEALTH; ASSOCIATION; EXTENSION; INSULIN; GLUCOSE	Ames dwarf (Prop1(df/df)) mice are remarkably long-lived and exhibit many characteristics of delayed aging and extended healthspan. Caloric restriction (CR) has similar effects on healthspan and lifespan, and causes an extension of longevity in Ames dwarf mice. Our study objective was to determine whether Ames dwarfism or CR influence neuromusculoskeletal function in middle-aged (82 +/- 12 weeks old) or old (128 +/- 14 w.o.) mice. At the examined ages, strength was improved by dwarfism, CR, and dwarfism plus CR in male mice; balance/motor coordination was improved by CR in old animals and in middle-aged females; and agility/motor coordination was improved by a combination of dwarfism and CR in both genders of middle-aged mice and in old females. Therefore, extension of longevity by congenital hypopituitarism is associated with improved maintenance of the examined measures of strength, agility, and motor coordination, key elements of frailty during human aging, into advanced age. This study serves as a particularly important example of knowledge related to addressing aging-associated diseases and disorders that results from studies in long-lived mammals.	[Arum, Oge; Rasche, Zachary Andrew; Rickman, Dustin John; Bartke, Andrzej] So Illinois Univ, Sch Med, Dept Internal Med, Springfield, IL 62702 USA	Southern Illinois University System; Southern Illinois University	Arum, O (corresponding author), So Illinois Univ, Sch Med, Dept Internal Med, Springfield, IL 62702 USA.	oge.arum@gmail.com	Bartke, Andzej/D-6640-2017	Bartke, Andzej/0000-0002-2569-557X	National Institute on Aging [AG19899, U19 AG023122, 3R01AG019899-07S1]; Ellison Medical Foundation; Glenn Foundation for Medical Research; Center for Alzheimer's Disease and Related Disorders at The Southern Illinois University; NATIONAL INSTITUTE ON AGING [U19AG023122, R01AG019899] Funding Source: NIH RePORTER	National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); Ellison Medical Foundation(Lawrence Ellison Foundation); Glenn Foundation for Medical Research; Center for Alzheimer's Disease and Related Disorders at The Southern Illinois University; NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This work was supported by National Institute on Aging Grants AG19899, U19 AG023122, and 3R01AG019899-07S1, as well as a Senior Scholar Award in Aging from The Ellison Medical Foundation, and The Glenn Foundation for Medical Research; this work was vitally supported by a grant from the Center for Alzheimer's Disease and Related Disorders at The Southern Illinois University, and the authors would especially like to thank Drs. Thomas A. Ala, M.D. & Robert G. Struble, Ph.D. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ahmed N, 2007, AM J MED, V120, P748, DOI 10.1016/j.amjmed.2006.10.018; Anisimov VN, 2009, BIOGERONTOLOGY, V10, P323, DOI 10.1007/s10522-008-9209-8; ARCE VM, 1991, NEUROENDOCRINOLOGY, V53, P467, DOI 10.1159/000125759; Aronow WS, 2006, MED CLIN N AM, V90, P849, DOI 10.1016/j.mcna.2006.05.009; Bartke A, 2004, CURR TOP DEV BIOL, V63, P189, DOI 10.1016/S0070-2153(04)63006-7; Bartke A, 2004, HORM METAB RES, V36, P550, DOI 10.1055/s-2004-825796; Bartke A, 2001, NATURE, V414, P412, DOI 10.1038/35106646; Bartke A, 2001, HDB BIOL AGING; Bartke A, 2008, CLIN INTERV AGING, V3, P659, DOI 10.2147/CIA.S3697; Barzilai N, 2012, DIABETES, V61, P1315, DOI 10.2337/db11-1300; Berryman DE, 2008, GROWTH HORM IGF RES, V18, P455, DOI 10.1016/j.ghir.2008.05.005; Bohannon Richard W, 2008, J Geriatr Phys Ther, V31, P3; Bonkowski MS, 2006, J GERONTOL A-BIOL, V61, P562, DOI 10.1093/gerona/61.6.562; BrownBorg HM, 1996, NATURE, V384, P33, DOI 10.1038/384033a0; Coschigano KT, 2000, ENDOCRINOLOGY, V141, P2608, DOI 10.1210/en.141.7.2608; Coschigano KT, 2003, ENDOCRINOLOGY, V144, P3799, DOI 10.1210/en.2003-0374; Crawley J.N., 2007, WHATS WRONG MY MOUSE; CREW MD, 1987, ENDOCRINOLOGY, V121, P1251, DOI 10.1210/endo-121-4-1251; De Laet CEDH, 2000, BEST PRACT RES CL EN, V14, P171, DOI 10.1053/beem.2000.0067; Dennison E, 2000, HORM RES, V54, P58, DOI 10.1159/000063449; Finch CE, 2009, NEUROBIOL AGING, V30, P515, DOI 10.1016/j.neurobiolaging.2008.11.011; Flurkey K, 2001, P NATL ACAD SCI USA, V98, P6736, DOI 10.1073/pnas.111158898; Gage PJ, 1996, DEVELOPMENT, V122, P151; Garcia AM, 2008, MECH AGEING DEV, V129, P528, DOI 10.1016/j.mad.2008.04.013; Giannoulis MG, 2012, ENDOCR REV, V33, P314, DOI 10.1210/er.2012-1002; Glantz SA, 2002, PRIMER BIOSTATISTICS; Kalyani RR, 2012, J GERONTOL A-BIOL, V67, P1300, DOI 10.1093/gerona/glr141; Kandel ER, 1991, PRINCIPLES NEURAL SC; Kenyon CJ, 2010, NATURE, V464, P504, DOI 10.1038/nature08980; Kinsella K, 2008, INT POPULATION REPOR; Ko FCY, 2011, CLIN GERIATR MED, V27, P89, DOI 10.1016/j.cger.2010.08.007; Landi F, 2010, BIOGERONTOLOGY, V11, P537, DOI 10.1007/s10522-010-9296-1; Lang PO, 2009, GERONTOLOGY, V55, P539, DOI 10.1159/000211949; Le Couteur DG, 2010, J GERONTOL A-BIOL, V65, P712, DOI 10.1093/gerona/glq082; Lee DM, 2013, J GERONTOL A-BIOL, V68, P837, DOI 10.1093/gerona/gls217; Levers MJ, 2006, J ADV NURS, V56, P282, DOI 10.1111/j.1365-2648.2006.04021.x; Liang HY, 2003, EXP GERONTOL, V38, P1353, DOI 10.1016/j.exger.2003.10.019; Liao CY, 2010, AGING CELL, V9, P92, DOI 10.1111/j.1474-9726.2009.00533.x; Liu CK, 2011, CLIN GERIATR MED, V27, P101, DOI 10.1016/j.cger.2010.08.001; Marin RV, 2010, J CLIN DENSITOM, V13, P96, DOI 10.1016/j.jocd.2009.12.001; Martin GM, 2007, PLOS GENET, V3, P1121, DOI 10.1371/journal.pgen.0030125; Marzetti E, 2006, EXP GERONTOL, V41, P1234, DOI 10.1016/j.exger.2006.08.011; Mattson MP, 2010, AGING CELL, V9, P448, DOI 10.1111/j.1474-9726.2010.00561.x; MCCAY CM, 1989, NUTRITION, V5, P155; Mercken EM, 2012, AGEING RES REV, V11, P390, DOI 10.1016/j.arr.2011.11.005; Miller RA, 1999, J GERONTOL A-BIOL, V54, pB358, DOI 10.1093/gerona/54.8.B358; Miller RA, 2009, J GERONTOL A-BIOL, V64, P157, DOI 10.1093/gerona/gln062; Montero-Odasso M, 2011, J GERONTOL A-BIOL, V66, P568, DOI 10.1093/gerona/glr007; Moreschi C, 1909, EXPER THERAP, V2, P651; Norrelund H, 2002, GROWTH HORM IGF RES, V12, P198, DOI 10.1016/S1096-6374(02)00043-6; Olshansky SJ, 2007, ANN NY ACAD SCI, V1114, P11, DOI 10.1196/annals.1396.050; Panici JA, 2009, J GERONTOL A-BIOL, V64, P1126, DOI 10.1093/gerona/glp111; Parks RJ, 2012, J GERONTOL A-BIOL, V67, P217, DOI 10.1093/gerona/glr193; Rajan KB, 2013, J GERONTOL A-BIOL, V68, P624, DOI 10.1093/gerona/gls208; Raji MA, 2010, J GERONTOL A-BIOL, V65, P1228, DOI 10.1093/gerona/glq121; Rantanen T, 2003, SCAND J MED SCI SPOR, V13, P3, DOI 10.1034/j.1600-0838.2003.00298.x; Roth LW, 2012, MATURITAS, V71, P315, DOI 10.1016/j.maturitas.2011.12.017; Rous P, 1914, J EXP MED, V20, P433, DOI 10.1084/jem.20.5.433; Schaible R., 1961, Genetics, V46, P896; Shamsi KS, 2012, J GERONTOL A-BIOL, V67, P853, DOI 10.1093/gerona/glr224; Shardell M, 2009, J GERONTOL A-BIOL, V64, P69, DOI 10.1093/gerona/gln007; SONNTAG WE, 1995, NEUROENDOCRINOLOGY, V61, P601, DOI 10.1159/000126885; Sornson MW, 1996, NATURE, V384, P327, DOI 10.1038/384327a0; Sourial N, 2012, J GERONTOL A-BIOL, V67, P1197, DOI 10.1093/gerona/gls084; Strawbridge WJ, 2002, GERONTOLOGIST, V42, P727, DOI 10.1093/geront/42.6.727; Syed Farhan A, 2011, Curr Osteoporos Rep, V9, P219, DOI 10.1007/s11914-011-0074-z; Syed Farhan A, 2010, Curr Osteoporos Rep, V8, P235, DOI 10.1007/s11914-010-0035-y; Thorner MO, 2009, J GERONTOL A-BIOL, V64, P1039, DOI 10.1093/gerona/glp091; Topinkova E, 2008, ANN NUTR METAB, V52, P6, DOI 10.1159/000115340; Walston J, 2006, J AM GERIATR SOC, V54, P991, DOI 10.1111/j.1532-5415.2006.00745.x; Wan H., 2005, CURRENT POPULATION R; Warner HR, 2009, CAN J AGING, V28, P391, DOI 10.1017/S0714980809990286; Weiss CO, 2011, CLIN GERIATR MED, V27, P39, DOI 10.1016/j.cger.2010.08.003; White DK, 2013, J GERONTOL A-BIOL, V68, P456, DOI 10.1093/gerona/gls197	74	24	24	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 14	2013	8	10							e72255	10.1371/journal.pone.0072255	http://dx.doi.org/10.1371/journal.pone.0072255			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	237RD	24155868	Green Submitted, Green Published, gold			2023-01-03	WOS:000325887300002
J	Castoria, G; Giovannelli, P; Di Donato, M; Hayashi, R; Arra, C; Appella, E; Auricchio, F; Migliaccio, A				Castoria, Gabriella; Giovannelli, Pia; Di Donato, Marzia; Hayashi, Ryo; Arra, Claudio; Appella, Ettore; Auricchio, Ferdinando; Migliaccio, Antimo			Targeting Androgen Receptor/Src Complex Impairs the Aggressive Phenotype of Human Fibrosarcoma Cells	PLOS ONE			English	Article							DEPENDENT NUCLEAR EXPORT; SOFT-TISSUE SARCOMAS; BREAST-CANCER CELLS; ESTRADIOL-RECEPTOR; MATRIX METALLOPROTEINASES; DNA-SYNTHESIS; STEROID-RECEPTORS; GROWTH; SRC; PEPTIDE	Background: Hormones and growth factors influence the proliferation and invasiveness of human mesenchymal tumors. The highly aggressive human fibrosarcoma HT1080 cell line harbors classical androgen receptor (AR) that responds to androgens triggering cell migration in the absence of significant mitogenesis. As occurs in many human cancer cells, HT1080 cells also express epidermal growth factor receptor (EGFR). Experimental: Findings: We report that the pure anti-androgen Casodex inhibits the growth of HT1080 cell xenografts in immune-depressed mice, revealing a novel role of AR in fibrosarcoma progression. In HT1080 cultured cells EGF, but not androgens, robustly increases DNA synthesis. Casodex abolishes the EGF mitogenic effect, implying a crosstalk between EGFR and AR. The mechanism underlying this crosstalk has been analyzed using an AR-derived small peptide, S1, which prevents AR/Src tyrosine kinase association and androgen-dependent Src activation. Present findings show that in HT1080 cells EGF induces AR/Src Association, and the S1 peptide abolishes both the assembly of this complex and Src activation. The S1 peptide inhibits EGF-stimulated DNA synthesis, cell matrix metalloproteinase-9 (MMP-9) secretion and invasiveness of HT1080 cells. Both Casodex and S1 peptide also prevent DNA synthesis and migration triggered by EGF in various human cancer-derived cells (prostate, breast, colon and pancreas) that express AR. Conclusion: This study shows that targeting the AR domain involved in AR/ Src association impairs EGF signaling in human fibrosarcoma HT1080 cells. The EGF-elicited processes inhibited by the peptide (DNA synthesis, MMP-9 secretion and invasiveness) cooperate in increasing the aggressive phenotype of HT1080 cells. Therefore, AR represents a new potential therapeutic target in human fibrosarcoma, as supported by Casodex inhibition of HT1080 cell xenografts. The extension of these findings in various human cancer-derived cell lines highlights the conservation of this process across divergent cancer cells and identifies new potential targets in the therapeutic approach to human cancers.	[Castoria, Gabriella; Giovannelli, Pia; Di Donato, Marzia; Auricchio, Ferdinando; Migliaccio, Antimo] Univ Naples 2, Dept Biochem Biophys & Gen Pathol, Naples, Italy; [Arra, Claudio] Ist Diag & Cura Tumori Fdn G Pascale, Naples, Italy; [Hayashi, Ryo; Appella, Ettore] NCI, Cell Biol Lab, Bethesda, MD 20892 USA	Universita della Campania Vanvitelli; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Migliaccio, A (corresponding author), Univ Naples 2, Dept Biochem Biophys & Gen Pathol, Naples, Italy.	antimo.migliaccio@unina2.it	Migliaccio, Antimo/AAB-3376-2019; Castoria, Gabriella/I-3349-2019; Giovannelli, Pia/J-7931-2019; Di Donato, Marzia/M-3114-2018	Castoria, Gabriella/0000-0002-0576-4494; Migliaccio, Antimo/0000-0002-4197-2055; Di Donato, Marzia/0000-0001-7207-826X; Giovannelli, Pia/0000-0002-2488-917X; Arra, Claudio/0000-0003-3162-2091	Italian Association for Cancer Research (A.I.R.C.) [IG 11520]; Italian Ministry for University and Scientific Research (P.R.I.N) [2010NFEB9L_002]; A.I.R.C.	Italian Association for Cancer Research (A.I.R.C.)(Fondazione AIRC per la ricerca sul cancro); Italian Ministry for University and Scientific Research (P.R.I.N)(Ministry of Education, Universities and Research (MIUR)Research Projects of National Relevance (PRIN)); A.I.R.C.(Fondazione AIRC per la ricerca sul cancro)	The Italian Association for Cancer Research (A.I.R.C.; grant number IG 11520 to AM), and the Italian Ministry for University and Scientific Research (P.R.I.N 2010-2011; grant number 2010NFEB9L_002 to GC) funded this work. Pia Giovannelli is supported by a fellowship from A.I.R.C. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bogush TA, 2010, BIOCHEMISTRY-MOSCOW+, V75, P1421, DOI 10.1134/S0006297910120011; Castoria G, 1999, EMBO J, V18, P2500, DOI 10.1093/emboj/18.9.2500; Castoria G, 2004, STEROIDS, V69, P517, DOI 10.1016/j.steroids.2004.05.001; Castoria G, 2012, ONCOGENE, V31, P4868, DOI 10.1038/onc.2011.642; Castoria G, 2003, J CELL BIOL, V161, P547, DOI 10.1083/jcb.200211099; Castoria G, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017218; CHANG CS, 1988, P NATL ACAD SCI USA, V85, P7211, DOI 10.1073/pnas.85.19.7211; CHAUDHURI PK, 1980, CANCER RES, V40, P861; Clark MA, 2005, NEW ENGL J MED, V353, P701, DOI 10.1056/NEJMra041866; DiDomenico M, 1996, CANCER RES, V56, P4516; Friedl P, 2012, NAT REV MOL CELL BIO, V13, P743, DOI 10.1038/nrm3459; GUSTERSON B, 1985, INT J CANCER, V36, P689; KNIGHT CG, 1992, FEBS LETT, V296, P263, DOI 10.1016/0014-5793(92)80300-6; Lombardi M, 2008, J CELL BIOL, V182, P327, DOI 10.1083/jcb.200712125; McCawley LJ, 2001, CURR OPIN CELL BIOL, V13, P534, DOI 10.1016/S0955-0674(00)00248-9; Migliaccio A, 2007, ONCOGENE, V26, P6619, DOI 10.1038/sj.onc.1210487; Migliaccio A, 2005, CANCER RES, V65, P10585, DOI 10.1158/0008-5472.CAN-05-0912; Migliaccio A, 2000, EMBO J, V19, P5406, DOI 10.1093/emboj/19.20.5406; Migliaccio A, 2011, METHODS MOL BIOL, V776, P361, DOI 10.1007/978-1-61779-243-4_21; Migliaccio A, 2010, MOL CELL ENDOCRINOL, V327, P19, DOI 10.1016/j.mce.2010.06.014; Okitsu Kohichiroh, 2010, Genes Cancer, V1, P859, DOI 10.1177/1947601910383417; Partridge JJ, 2007, J BIOL CHEM, V282, P35964, DOI 10.1074/jbc.M705993200; Ren WH, 2008, CLIN CANCER RES, V14, P2785, DOI 10.1158/1078-0432.CCR-07-4471; SMITH MM, 1995, J BIOL CHEM, V270, P6440, DOI 10.1074/jbc.270.12.6440; Stabile LP, 2002, CANCER RES, V62, P2141; Vanderschueren D, 2008, CURR OPIN ENDOCRINOL, V15, P250, DOI 10.1097/MED.0b013e3282fe6ca9; Varricchio L, 2007, MOL CANCER RES, V5, P1213, DOI 10.1158/1541-7786.MCR-07-0150; Verrijdt G, 2000, J BIOL CHEM, V275, P12298, DOI 10.1074/jbc.275.16.12298	28	20	20	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 9	2013	8	10							e76899	10.1371/journal.pone.0076899	http://dx.doi.org/10.1371/journal.pone.0076899			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	236PJ	24130806	Green Published, Green Submitted, gold			2023-01-03	WOS:000325810900100
J	Correia, AW; Peters, JL; Levy, JI; Melly, S; Dominici, F				Correia, Andrew W.; Peters, Junenette L.; Levy, Jonathan I.; Melly, Steven; Dominici, Francesca			Residential exposure to aircraft noise and hospital admissions for cardiovascular diseases: multi-airport retrospective study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							BLOOD-PRESSURE; AIR-POLLUTION; HYPERTENSION; MORTALITY; HEALTH; ACCURACY; SYSTEM; IMPACT	Objective To investigate whether exposure to aircraft noise increases the risk of hospitalization for cardiovascular diseases in older people (>= 65 years) residing near airports. Design Multi-airport retrospective study of approximately 6 million older people residing near airports in the United States. We superimposed contours of aircraft noise levels (in decibels, dB) for 89 airports for 2009 provided by the US Federal Aviation Administration on census block resolution population data to construct two exposure metrics applicable to zip code resolution health insurance data: population weighted noise within each zip code, and 90th centile of noise among populated census blocks within each zip code. Setting 2218 zip codes surrounding 89 airports in the contiguous states. Participants 6 027 363 people eligible to participate in the national medical insurance (Medicare) program (aged >= 65 years) residing near airports in 2009. Main outcome measures Percentage increase in the hospitalization admission rate for cardiovascular disease associated with a 10 dB increase in aircraft noise, for each airport and on average across airports adjusted by individual level characteristics (age, sex, race), zip code level socioeconomic status and demographics, zip code level air pollution (fine particulate matter and ozone), and roadway density. Results Averaged across all airports and using the 90th centile noise exposure metric, a zip code with 10 dB higher noise exposure had a 3.5% higher (95% confidence interval 0.2% to 7.0%) cardiovascular hospital admission rate, after controlling for covariates. Conclusions Despite limitations related to potential misclassification of exposure, we found a statistically significant association between exposure to aircraft noise and risk of hospitalization for cardiovascular diseases among older people living near airports.	[Correia, Andrew W.] NMR Grp, Somerville, NJ USA; [Peters, Junenette L.; Levy, Jonathan I.] Boston Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA USA; [Melly, Steven] Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02115 USA; [Dominici, Francesca] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA	Boston University; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health	Dominici, F (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA.	fdominic@hsph.harvard.edu	Levy, Jon/B-4542-2011	Levy, Jon/0000-0002-1116-4006; /0000-0003-4542-4563	Federal Aviation Administration, under FAA award [09-C-NE-HU, 10-C-NE-BU]	Federal Aviation Administration, under FAA award	This study was supported by the Federal Aviation Administration, under FAA award No 09-C-NE-HU amendment No 004 and 10-C-NE-BU amendment No 002. The sponsor provided the noise contours, but had no role in the analysis or interpretation of data; in the writing of the reports; or in the decision to submit the article for publication. Any opinions, findings, and conclusions or recommendations expressed in this material are those of the authors and do not necessarily reflect the views of the funder.	Babisch W., 2011, BURDEN DIS ENV NOISE; Babisch Wolfgang, 2006, Noise Health, V8, P1; Babisch W, 2009, NOISE HEALTH, V11, P161, DOI 10.4103/1463-1741.53363; Baicker K, 2004, HEALTH AFFAIR, V23, pVAR33, DOI 10.1377/hlthaff.var.33; Bates D., 2012, LINEAR MIXED MODEL I; Beelen R, 2009, OCCUP ENVIRON MED, V66, P243, DOI 10.1136/oem.2008.042358; Bluhm G, 2011, NOISE HEALTH, V13, P212, DOI 10.4103/1463-1741.80152; Button K., 2010, TRANSPORT EC; de Kluizenaar Y, 2007, J OCCUP ENVIRON MED, V49, P484, DOI 10.1097/JOM.0b013e318058a9ff; Dominici F, 2006, EPIDEMIOLOGY, V17, pS19, DOI 10.1097/00001648-200611001-00004; Dominici F, 2006, JAMA-J AM MED ASSOC, V295, P1127, DOI 10.1001/jama.295.10.1127; Eriksson C, 2007, EPIDEMIOLOGY, V18, P716, DOI 10.1097/EDE.0b013e3181567e77; Eriksson C, 2010, ENVIRON RES, V110, P764, DOI 10.1016/j.envres.2010.09.001; Federal Aviation Administration, 2007, INT NOIS MOD INM VER; Floud S, 2011, OCCUP ENVIRON MED, V68, P518, DOI 10.1136/oem.2010.058586; Franssen E.A., 2002, ENVIRON IMPACT ASSES, V22, P633, DOI [DOI 10.1016/S0195-9255(02)00015-X, 10.1016/S0195-9255(02)00015-X]; Franssen EAM, 2004, OCCUP ENVIRON MED, V61, P405, DOI 10.1136/oem.2002.005488; FRERICHS RR, 1980, AM J PUBLIC HEALTH, V70, P357, DOI 10.2105/AJPH.70.4.357; Grassi G, 2006, HYPERTENS RES, V29, P839, DOI 10.1291/hypres.29.839; Greiser E, 2007, EPIDEMIOLOGY, V18, pS33; Haralabidis AS, 2008, EUR HEART J, V29, P658, DOI 10.1093/eurheartj/ehn013; Haralabidis AS, 2011, J EPIDEMIOL COMMUN H, V65, P535, DOI 10.1136/jech.2009.102954; Hatfield J., 2001, Noise Health, V3, P1; Havranek EP, 2004, ARCH INTERN MED, V164, P1186, DOI 10.1001/archinte.164.11.1186; Heisterkamp SH, 2000, STAT MED, V19, P2569, DOI 10.1002/1097-0258(20000915/30)19:17/18<2569::AID-SIM588>3.0.CO;2-K; Huss A, 2010, EPIDEMIOLOGY, V21, P829, DOI 10.1097/EDE.0b013e3181f4e634; Ising H, 2004, Noise Health, V6, P5; Jarup L, 2008, ENVIRON HEALTH PERSP, V116, P329, DOI 10.1289/ehp.10775; Kiyota Y, 2004, AM HEART J, V148, P99, DOI 10.1016/j.ahj.2004.02.013; KNIPSCHILD P, 1977, INT ARCH OCC ENV HEA, V40, P185, DOI 10.1007/BF01842081; Losina E, 2003, J CLIN EPIDEMIOL, V56, P515, DOI 10.1016/S0895-4356(03)00056-8; Mancia G, 2007, J HYPERTENS, V25, P909, DOI 10.1097/HJH.0b013e328048d004; Mancia G, 2006, J HYPERTENS, V24, pS17, DOI 10.1097/01.hjh.0000220099.12154.c1; Matsui T, 2004, J SOUND VIB, V277, P469, DOI 10.1016/j.jsv.2004.03.007; Meecham W C, 1979, Br J Audiol, V13, P77, DOI 10.3109/03005367909078881; Miedema HME, 2000, J ACOUST SOC AM, V107, P3245, DOI 10.1121/1.429396; Nelson P, 2004, J TRANSP ECON POLICY, V38, P1; Rosenlund M, 2001, OCCUP ENVIRON MED, V58, P769, DOI 10.1136/oem.58.12.769; Selander J, 2009, ENVIRON HEALTH PERSP, V117, P1713, DOI 10.1289/ehp.0900933; Spreng M., 2000, Noise Health, V2, P59; Stansfeld S, 2011, NOISE HEALTH, V13, P229, DOI 10.4103/1463-1741.80159; Vander Hoorn S, 2004, COMP QUANTIFICATION, P2129; Wakefield J, 2006, BIOSTATISTICS, V7, P438, DOI 10.1093/biostatistics/kxj017; Zhou YJ, 2010, ANN APPL STAT, V4, P1451, DOI 10.1214/09-AOAS325	44	88	89	0	48	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 8	2013	347								f5561	10.1136/bmj.f5561	http://dx.doi.org/10.1136/bmj.f5561			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	235OJ	24103538	Green Published, hybrid			2023-01-03	WOS:000325728600002
J	Getahun, H; Raviglione, M				Getahun, Haileyesus; Raviglione, Mario			Household tuberculosis interventions-how confident are we?	LANCET			English	Editorial Material							SOUTH-AFRICA; ZAMSTAR		[Getahun, Haileyesus; Raviglione, Mario] WHO, Global TB Programme, CH-1211 Geneva, Switzerland	World Health Organization	Getahun, H (corresponding author), WHO, Global TB Programme, CH-1211 Geneva, Switzerland.	getahunh@who.int	Getahun, Haileyesus/ABC-5181-2020					Ayles H, 2013, LANCET; Ayles HM, 2008, TRIALS, V9, DOI 10.1186/1745-6215-9-63; Cavalcante SC, 2010, INT J TUBERC LUNG D, V14, P203; Corbett EL, 2010, LANCET, V376, P1244, DOI 10.1016/S0140-6736(10)61425-0; Dixon P, 2003, CAN J EXP PSYCHOL, V57, P189, DOI 10.1037/h0087425; Martinson N, 2013, 20 C RETR OPP INF AT; Sismanidis C, 2008, CLIN TRIALS, V5, P316, DOI 10.1177/1740774508094747; WHO, 2012, GLOBAL TUBERCULOSIS REPORT 2012, P1; Wood R, 2011, SAMJ S AFR MED J, V101, P111, DOI 10.7196/SAMJ.4587; World Health Organization,, 2011, TUB PREV SURV HDB, V2nd; World Health Organization, 2013, SYST SCREEN ACT TUB	11	0	0	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 5	2013	382	9899					1157	1159		10.1016/S0140-6736(13)61568-8	http://dx.doi.org/10.1016/S0140-6736(13)61568-8			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	228SL	23915880				2023-01-03	WOS:000325209100007
J	Cooper, AL; Kazis, LE; Dore, DD; Mor, V; Trivedi, AN				Cooper, Alicia L.; Kazis, Lewis E.; Dore, David D.; Mor, Vincent; Trivedi, Amal N.			Underreporting High-Risk Prescribing Among Medicare Advantage Plans	ANNALS OF INTERNAL MEDICINE			English	Article							QUALITY-OF-CARE	Background: Although Medicare Advantage plans are required to report clinical performance using Healthcare Effectiveness Data and Information Set (HEDIS) quality indicators, the accuracy of plan-reported performance rates is unknown. Objective: To compare calculated and reported rates of high-risk prescribing among Medicare Advantage plans. Design: Cross-sectional comparison. Setting: 172 Medicare Advantage plans. Patients: A random sample of beneficiaries in 172 Medicare Advantage plans in 2006 (n = 177 227) and 2007 (n = 173 655). Measurements: Plan-reported HEDIS rates of high-risk prescribing among elderly persons were compared with rates calculated from Medicare Advantage plans' Part D claims by using the same measure specifications and source population. Results: The mean rate of high-risk prescribing derived from Part D claims was 26.9% (95% CI, 25.9% to 28.0%), whereas the mean plan-reported rate was 21.1% (CI, 20.0% to 22.3%). Approximately 95% of plans underreported rates of high-risk prescribing relative to calculated rates derived from Part D claims. The differences in the calculated and reported rates negatively affected quality rankings for the plans that most accurately reported rates. For example, the 9 plans that reported rates of high-risk prescribing within 1 percentage point of calculated rates were ranked 43.4 positions lower when reported rates were used instead of calculated rates. Among 103 680 individuals present in both the sample of Part D claims and HEDIS data in 2006, Medicare Advantage plans incorrectly excluded 10.3% as ineligible for the HEDIS high-risk prescribing measure. Among those correctly included in the high-risk prescribing denominator, the reported rate of high-risk prescribing was 21.9% and the calculated rate was 26.2%. Limitation: A single quality measure was assessed. Conclusion: Medicare Advantage plans underreport rates of high-risk prescribing, suggesting a role for routine audits to ensure the validity of publicly reported quality measures. Primary Funding Source: Health Assessment Lab and National Institute on Aging.	Dept Vermont Hlth Access, Williston, VT USA; Brown Univ, Providence Vet Affairs Med Ctr, Providence, RI 02912 USA; [Trivedi, Amal N.] Brown Univ, Dept Hlth Serv Policy & Practice, Providence, RI 02912 USA; Boston Univ, Sch Publ Hlth, Ctr Assessment Pharmaceut Practices, Boston, MA USA; Edith Nourse Rogers Mem Vet Adm Hosp, Vet Affairs Med Ctr, Ctr Hlth Qual Outcomes & Econ Res, Bedford, MA 01730 USA	Brown University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Providence VA Medical Center; Brown University; Boston University; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Trivedi, AN (corresponding author), Brown Univ, Dept Hlth Serv Policy & Practice, Box G-S121-6, Providence, RI 02912 USA.	amal_trivedi@brown.edu		Dore, David/0000-0003-0810-6662	Health Assessment Lab; National Institute on Aging; NATIONAL INSTITUTE ON AGING [RC1AG036158] Funding Source: NIH RePORTER	Health Assessment Lab; National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	Health Assessment Lab and National Institute on Aging.	[Anonymous], 2008, HEDIS 2008 PAT LEV D; [Anonymous], 2007, HEDIS 2007 PAT LEV D; [Anonymous], 2008, MED HLTH OUTC SURV 2; [Anonymous], 2008, HOSP QUAL DAT ISS CH; [Anonymous], 2006, HOSP QUAL DAT CMS NE; [Anonymous], 2011, HEDIS COMPL AUD PROG; Berwick DM, 2002, JAMA-J AM MED ASSOC, V288, P1523, DOI 10.1001/jama.288.12.1523; Fung CH, 2008, ANN INTERN MED, V148, P111, DOI 10.7326/0003-4819-148-2-200801150-00006; Health Care Financing Administration US Department of Health and Human Services, 1998, MED HEDIS 3 0 1998 D; Jacobson G, 2011, MEDICARE ADVANTAGE P; Kaiser Family Foundation, 2013, TOT MED ADV MA ENR; Kern LM, 2013, ANN INTERN MED, V158, P77, DOI 10.7326/0003-4819-158-2-201301150-00001; Narins CR, 2005, ARCH INTERN MED, V165, P83, DOI 10.1001/archinte.165.1.83; Pawlson LG, 2007, AM J MANAG CARE, V13, P553; Trivedi AN, 2005, NEW ENGL J MED, V353, P692, DOI 10.1056/NEJMsa051207; Werner RM, 2005, JAMA-J AM MED ASSOC, V293, P1239, DOI 10.1001/jama.293.10.1239; Zhang YT, 2010, NEW ENGL J MED, V363, P1985, DOI 10.1056/NEJMp1010220	17	11	11	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819			ANN INTERN MED	Ann. Intern. Med.	OCT 1	2013	159	7					456	U162		10.7326/0003-4819-159-7-201310010-00005	http://dx.doi.org/10.7326/0003-4819-159-7-201310010-00005			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	234FQ	24081286	Green Accepted			2023-01-03	WOS:000325628000003
J	Ferner, R				Ferner, Robin			A bee in the bonnet about honey and healing	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material									Birmingham City Hosp, West Midlands Ctr Adverse Drug React, Birmingham B18 7QH, W Midlands, England		Ferner, R (corresponding author), Birmingham City Hosp, West Midlands Ctr Adverse Drug React, Birmingham B18 7QH, W Midlands, England.	R.E.Ferner@bham.ac.uk		Ferner, Robin/0000-0003-3769-1346				Bayram NA, 2012, J EMERG MED, V43, pE389, DOI 10.1016/j.jemermed.2011.02.021; Dat AD, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008762.pub2; Dumville JC, 2013, COCHRANE DB SYST REV, V6, DOI DOI 10.1002/14651858.CD009110.PUB3; Dumville JC, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009111.pub3; Dumville JC, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009099.pub2; Gamgee JS., 1861, BRIT MED J, V1, P211; Gamgee JS., 1857, BRIT MED J; Jull AB, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005083.pub3; Kapadia HM, 2002, J ROY SOC MED, V95, P96, DOI 10.1258/jrsm.95.2.96; Nelson EA, 2007, COCHRANE DB SYST REV, V1; Smith MEB, 2013, ANN INTERN MED, V159, P39, DOI 10.7326/0003-4819-159-1-201307020-00007; Storm-Versloot MN, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006478.pub2; Vermeulen H, 2004, COCHRANE DB SYST REV, V2, pCD003554; Vermeulen H, 2007, COCHRANE DB SYST REV, V1, DOI DOI 10.1002/14651858.CD005486.PUB.2	14	0	0	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 15	2013	347								f5015	10.1136/bmj.f5015	http://dx.doi.org/10.1136/bmj.f5015			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	203ZD	23950196				2023-01-03	WOS:000323332700002
J	Nottage, KA; Hankins, JS; Smeltzer, M; Mzayek, F; Wang, WC; Aygun, B; Gurney, JG				Nottage, Kerri A.; Hankins, Jane S.; Smeltzer, Matthew; Mzayek, Fawaz; Wang, Winfred C.; Aygun, Banu; Gurney, James G.			Hydroxyurea Use and Hospitalization Trends in a Comprehensive Pediatric Sickle Cell Program	PLOS ONE			English	Article							HEALTH-CARE; DISEASE; CHILDREN; ANEMIA; COSTS; EXPENDITURES; FREQUENCY; PATTERNS; BARRIERS; ADULTS	Background: A decline in hospitalizations and pain episodes among those with sickle cell disease (SCD) who take hydroxyurea (HU) has been shown when compared to pre-HU patterns but paradoxically, when compared to those who have never been treated, HU recipients often have more frequent hospitalizations. This analysis evaluates the impact of increasing usage of HU on trends in hospitalizations and blood transfusions within a large SCD treatment program. Methods: Eligibility was restricted to patients with Hb SS or Hb S beta(0)-thalassemia who were 2-18 years old between 2006-2010 and received care at St. Jude Children's Research Hospital (N = 508). Hospitalizations and blood transfusions were calculated for each of the years under study for those exposed and never exposed to HU. Differences in number of hospitalizations before and after HU initiation were compared. Results: The proportion of patients receiving HU increased by 4% per year on average. In the HU exposed group, a modest decline in mean per-patient hospitalizations and per-patient hospital days occurred, while those never exposed to HU trended toward a slight increase over time. Rates of blood transfusions declined among those on HU but not in patients never exposed to HU. Patients on HU had a median of one fewer hospital admission in the year after initiation of HU, compared to the year prior. Two deaths occurred in the patient population, both of whom were not exposed to HU. Conclusions: Increasing usage of HU was concurrent with decreased hospitalization rates and blood transfusions. Our results support the utility of HU on decreasing hospitalizations and transfusions for patients with SCD outside of the clinical trial setting.	[Nottage, Kerri A.; Hankins, Jane S.; Wang, Winfred C.] St Jude Childrens Res Hosp, Dept Hematol, Memphis, TN 38105 USA; [Smeltzer, Matthew] St Jude Childrens Res Hosp, Dept Biostat, Memphis, TN 38105 USA; [Mzayek, Fawaz; Gurney, James G.] Univ Memphis, Sch Publ Hlth, Div Epidemiol & Biostat, Memphis, TN 38152 USA; [Aygun, Banu] Steven & Alexandra Cohen Childrens Med Ctr New Yo, Div Pediat Hematol Oncol & Stem Cell Transplantat, New Hyde Pk, NY USA; [Gurney, James G.] St Jude Childrens Res Hosp, Dept Epidemiol & Canc Control, Memphis, TN 38105 USA	St Jude Children's Research Hospital; St Jude Children's Research Hospital; University of Memphis; Northwell Health; North Shore University Hospital; Steven & Alexandra Cohen Children's Medical Center of New York; St Jude Children's Research Hospital	Nottage, KA (corresponding author), St Jude Childrens Res Hosp, Dept Hematol, 332 N Lauderdale St, Memphis, TN 38105 USA.	kerri.nottage@stjude.org	Hankins, Jane/N-3362-2018	Smeltzer, Matthew/0000-0003-1366-9267	American Lebanese Syrian Associated Charities (ALSAC)	American Lebanese Syrian Associated Charities (ALSAC)(American Lebanese Syrian Associated Charities (ALSAC))	This work was supported by the American Lebanese Syrian Associated Charities (ALSAC). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Amendah DD, 2010, AM J PREV MED, V38, pS550, DOI 10.1016/j.amepre.2010.01.004; Brandow AM, 2010, AM J HEMATOL, V85, P611, DOI 10.1002/ajh.21749; Brawley OW, 2008, ANN INTERN MED, V148, P932, DOI 10.7326/0003-4819-148-12-200806170-00220; Chambers J. M., 1983, GRAPHICAL METHODS DA, P395; CHARACHE S, 1995, NEW ENGL J MED, V332, P1317, DOI 10.1056/NEJM199505183322001; Heeney MM, 2008, PEDIATR CLIN N AM, V55, P483, DOI 10.1016/j.pcl.2008.02.003; Heeney MM, 2010, HEMATOL ONCOL CLIN N, V24, P199, DOI 10.1016/j.hoc.2009.11.002; Kauf TL, 2009, AM J HEMATOL, V84, P323, DOI 10.1002/ajh.21408; Kinney TR, 1999, BLOOD, V94, P1550; Lanzkron S, 2008, J NATL MED ASSOC, V100, P968; Lanzkron S, 2006, AM J HEMATOL, V81, P927, DOI 10.1002/ajh.20703; Lanzkron S, 2010, J HEALTH CARE POOR U, V21, P277, DOI 10.1353/hpu.0.0272; Mvundura M, 2009, PEDIATR BLOOD CANCER, V53, P642, DOI 10.1002/pbc.22069; Nietert PJ, 1999, J PEDIAT HEMATOL ONC, V21, P389, DOI 10.1097/00043426-199909000-00010; Raphael JL, 2012, PEDIATR BLOOD CANCER, V58, P584, DOI 10.1002/pbc.23181; Stallworth JR, 2010, AM J HEMATOL, V85, P795, DOI 10.1002/ajh.21772; Wang WC, 2011, LANCET, V377, P1663, DOI 10.1016/S0140-6736(11)60355-3; Woods K, 1997, PUBLIC HEALTH REP, V112, P44; YANG YM, 1995, PUBLIC HEALTH REP, V110, P80; Zimmerman SA, 2004, BLOOD, V103, P2039, DOI 10.1182/blood-2003-07-2475; Zumberg MS, 2005, AM J HEMATOL, V79, P107, DOI 10.1002/ajh.20353	21	26	26	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 14	2013	8	8							e72077	10.1371/journal.pone.0072077	http://dx.doi.org/10.1371/journal.pone.0072077			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	202MQ	23967276	Green Published, Green Submitted, gold			2023-01-03	WOS:000323221500119
J	Rejiba, S; Bigand, C; Parmentier, C; Masmoudi, A; Hajri, A				Rejiba, Soukaina; Bigand, Christelle; Parmentier, Celine; Masmoudi, Ahmed; Hajri, Amor			Oncosuppressive Suicide Gene Virotherapy "PVH1-yCD/5-FC'' for Pancreatic Peritoneal Carcinomatosis Treatment: NF kappa B and Akt/PI3K Involvement	PLOS ONE			English	Article							PARVOVIRUS MINUTE VIRUS; AUTONOMOUS PARVOVIRUS; SELECTIVE REPLICATION; TUMOR-CELLS; WILD-TYPE; CANCER; MICE; H-1; INHIBITION; 5-FLUOROURACIL	Peritoneal carcinomatosis is common in advanced pancreatic cancer. Despite current standard treatment, patients with this disease until recently were considered incurable. Cancer gene therapy using oncolytic viruses have generated much interest over the past few years. Here, we investigated a new gene directed enzyme prodrug therapy (GDEPT) approach for an oncosuppressive virotherapy strategy using parvovirus H1 (PV-H1) which preferentially replicates and kills malignant cells. Although, PV-H1 is not potent enough to destroy tumors, it represents an attractive vector for cancer gene therapy. We therefore sought to determine whether the suicide gene/prodrug system, yCD/5-FC could be rationally combined to PV-H1 augmenting its intrinsic oncolytic activity for pancreatic cancer prevention and treatment. We showed that the engineered recombinant parvovirus rPVH1-yCD with 5-FC treatment increased significantly the intrinsic cytotoxic effect and resulted in potent induction of apoptosis and tumor growth inhibition in chemosensitive and chemoresistant cells. Additionally, the suicide gene-expressing PV-H1 infection reduced significantly the constitutive activities of NF kappa B and Akt/PI3K. Combination of their pharmacological inhibitors (MG132 and LY294002) with rPVH1-yCD/5-FC resulted in substantial increase of antitumor activity. In vivo, high and sustained expression of NS1 and yCD was observed in the disseminated tumor nodules and absent in normal tissues. Treatment of mice bearing intraperitoneal pancreatic carcinomatosis with rPVH1-yCD/5-FC resulted in a drastic inhibition of tumor cell spreading and subsequent increase in long-term survival. Together, the presented data show the improved oncolytic activity of wPV-H1 by yCD/5-FC and thus provides valuable effective and promising virotherapy strategy for prevention of tumor recurrence and treatment. In the light of this study, the suicide gene parvovirotherapy approach represents a new weapon in the war against pancreatic cancer. Moreover, these preliminary accomplishments are opening new field for future development of new combined targeted therapies to have a meaningful impact on advanced cancer.	[Rejiba, Soukaina; Bigand, Christelle; Parmentier, Celine] Univ Strasbourg, Strasbourg, France; [Masmoudi, Ahmed] Inst Super Biotechnol Sidi Thabet, Tunis, Tunisia; [Hajri, Amor] Univ Freiburg, FRIAS, Dept Bio3, D-79106 Freiburg, Germany	UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; University of Freiburg	Hajri, A (corresponding author), Univ Freiburg, FRIAS, Dept Bio3, Hugstetter Str 55, D-79106 Freiburg, Germany.	amor.hajri@biologie.uni-freiburg.de		Masmoudi, Ahmed/0000-0002-6418-705X; Masmoudi, Ahmed/0000-0003-4890-7173	club francais du pancreas; association pour la recherche contre le cancer	club francais du pancreas; association pour la recherche contre le cancer(Fondation ARC pour la Recherche sur le Cancer)	This study was supported by grants to SR from club francais du pancreas and association pour la recherche contre le cancer. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ahlgren JD, 1996, SEMIN ONCOL, V23, P241; Anderson KE PJ, 1996, CANC EPIDEMIOLOGY PR, P725; ANDERSON MJ, 1984, ARCH VIROL, V82, P137, DOI 10.1007/BF01311158; Arlt A, 2003, ONCOGENE, V22, P3243, DOI 10.1038/sj.onc.1206390; Beger HG, 2002, CAN J GASTROENTEROL, V16, P117, DOI 10.1155/2002/174320; Cattaneo R, 2008, NAT REV MICROBIOL, V6, P529, DOI 10.1038/nrmicro1927; CORNELIS JJ, 1988, J VIROL, V62, P3438, DOI 10.1128/JVI.62.9.3438-3444.1988; Deleu L, 1999, J VIROL, V73, P3877, DOI 10.1128/JVI.73.5.3877-3885.1999; DUPRESSOIR T, 1989, CANCER RES, V49, P3203; Faisst S, 1998, INT J CANCER, V75, P584, DOI 10.1002/(SICI)1097-0215(19980209)75:4<584::AID-IJC15>3.0.CO;2-9; FAISST SR, 1993, VIROLOGY, V197, P770, DOI 10.1006/viro.1993.1654; Giese NA, 2002, CANCER GENE THER, V9, P432, DOI 10.1038/sj.cgt.7700457; Guo ZS, 2008, BBA-REV CANCER, V1785, P217, DOI 10.1016/j.bbcan.2008.02.001; Haag A, 2000, HUM GENE THER, V11, P597, DOI 10.1089/10430340050015789; Hajri A, 2004, CANCER GENE THER, V11, P16, DOI 10.1038/sj.cgt.7700628; Hernandez-Alcoceba R, 2002, HUM GENE THER, V13, P1737, DOI 10.1089/104303402760293574; Hristov G, 2010, J VIROL, V84, P5909, DOI 10.1128/JVI.01797-09; Hu JCC, 2006, CLIN CANCER RES, V12, P6737, DOI 10.1158/1078-0432.CCR-06-0759; Huang TG, 2003, GENE THER, V10, P1241, DOI 10.1038/sj.gt.3301987; HUBER BE, 1994, P NATL ACAD SCI USA, V91, P8302, DOI 10.1073/pnas.91.17.8302; Karin M, 2004, NAT REV DRUG DISCOV, V3, P17, DOI 10.1038/nrd1279; Kestler J, 1999, HUM GENE THER, V10, P1619, DOI 10.1089/10430349950017626; Le Cesne A., 1993, PROC AM SOC CLIN ONC, V12, P297; Luo JL, 2005, J CLIN INVEST, V115, P2625, DOI 10.1172/JCI26322; MAXWELL IH, 1994, BIOTECHNIQUES, V16, P876; Melisi D, 2011, JNCI-J NATL CANCER I, V103, P1190, DOI 10.1093/jnci/djr243; Montagut C, 2006, ENDOCR-RELAT CANCER, V13, P607, DOI 10.1677/erc.1.01171; Mueller A, 2012, CANCER CHEMOTH PHARM, V69, P1601, DOI 10.1007/s00280-012-1869-z; Nassim MA, 2002, INT J MOL MED, V10, P513; Nemunaitis J, 2000, CANCER RES, V60, P6359; Nyati MK, 2002, GENE THER, V9, P844, DOI 10.1038/sj.gt.3301706; Pham CG, 2007, MOL CELL BIOL, V27, P3920, DOI 10.1128/MCB.01219-06; Pikarsky E, 2004, NATURE, V431, P461, DOI 10.1038/nature02924; Rayet B, 1998, J VIROL, V72, P8893, DOI 10.1128/JVI.72.11.8893-8903.1998; Regiba S, 2009, NEOPLASIA, V11, P637, DOI 10.1593/neo.81686; Santoro MG, 2003, EMBO J, V22, P2552, DOI 10.1093/emboj/cdg267; Shi X, 2002, ONCOLOGY-BASEL, V62, P354, DOI 10.1159/000065068; Siegl G., 1983, PARVOVIRUSES, P297; TAKAHASHI T, 1990, BLOOD, V75, P603; TOOLAN HW, 1965, P SOC EXP BIOL MED, V119, P711, DOI 10.3181/00379727-119-30278; Vollmer CM, 1999, CANCER RES, V59, P4369	41	14	14	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 14	2013	8	8							e70594	10.1371/journal.pone.0070594	http://dx.doi.org/10.1371/journal.pone.0070594			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	202MQ	23967078	Green Submitted, Green Published, gold			2023-01-03	WOS:000323221500018
J	Chisti, MJ; Salam, MA; Ashraf, H; Faruque, ASG; Bardhan, PK; Das, SK; Shahunja, KM; Shahid, ASMSB; Ahmed, T				Chisti, Mohammod Jobayer; Salam, Mohammed Abdus; Ashraf, Hasan; Faruque, Abu S. G.; Bardhan, Pradip Kumar; Das, Sumon Kumar; Shahunja, K. M.; Shahid, Abu S. M. S. B.; Ahmed, Tahmeed			Clinical Signs of Radiologic Pneumonia in Under-Five Hypokalemic Diarrheal Children Admitted to an Urban Hospital in Bangladesh	PLOS ONE			English	Article							PREDICTORS; MORTALITY; INFANTS; DHAKA	Background: Clinical signs of pneumonia are often veiled in under-five diarrheal children presenting with hypokalemia, making clinical diagnosis of pneumonia very difficult in such population. However, there is no published report that describes the influences of hypokalemia on the clinical signs of pneumonia in diarrheal children. Our objective was to assess the influences of hypokalemia, and their outcome in such children. Methods: We prospectively enrolled all under-five diarrheal children (n = 180) admitted to the Special Care Ward of the Dhaka Hospital of icddr,b from September-December 2007 with radiological pneumonia who also had their serum potassium estimated. We compared the clinical features and outcome of the diarrheal children having pneumonia with (cases = 55) and without hypokalemia (controls = 125). Results: The case-fatality among the cases was 2 times higher compared to the controls, but the difference was not statistically significant (p = 0.202). In logistic regression analysis, after adjusting for potential confounders such as age of the patient, clinical dehydration, severe wasting, abnormally sleepy, lower chest wall in-drawing, nasal flaring and inability to drink on admission, under-five diarrheal children with pneumonia who presented with nutritional edema had 3 times more risk to have hypokalemia compared to those without nutritional edema (OR = 2.76, 95% CI = 1.01-7.51) and these hypokalemic children were 64% less likely to present with fast breathing (OR = 0.36, 95% CI = 0.17-0.74). Conclusion and significance: The results of our analysis are simple but may have great public health implications and underscore the importance of diligent assessment for pneumonia in under-five diarrheal children having risk of hypokalemia as in children with nutritional edema even in absence of fast breathing, a useful sign of pneumonia. This may help for early initiation of first dose of parental antibiotics along with potassium supplementation before referral to tertiary hospitals by health workers to combat probability of deaths in such population especially in resource limited settings.	[Chisti, Mohammod Jobayer; Ashraf, Hasan; Faruque, Abu S. G.; Bardhan, Pradip Kumar; Das, Sumon Kumar; Shahunja, K. M.; Shahid, Abu S. M. S. B.; Ahmed, Tahmeed] Int Ctr Diarhoeal Dis Res, CNFS, Dhaka, Bangladesh; [Chisti, Mohammod Jobayer; Ashraf, Hasan; Bardhan, Pradip Kumar] ICDDR B, CS, Dhaka, Bangladesh; [Salam, Mohammed Abdus] ICDDR B, RA, Dhaka, Bangladesh	International Centre for Diarrhoeal Disease Research (ICDDR); International Centre for Diarrhoeal Disease Research (ICDDR); International Centre for Diarrhoeal Disease Research (ICDDR)	Chisti, MJ (corresponding author), Int Ctr Diarhoeal Dis Res, CNFS, Dhaka, Bangladesh.	chisti@icddrb.org	Das, Sumon Kumar/AAD-1551-2019; Shahunja, K M/AAR-6229-2020; Das, Sumon Kumar/T-6384-2019; Chisti, Mohammod J/A-7216-2018	Shahunja, K M/0000-0002-9345-206X; 	Dhaka Hospital of International Centre for Diarrhoeal Disease Research, Bangladesh (ICDDR, B) [Gr-00233]	Dhaka Hospital of International Centre for Diarrhoeal Disease Research, Bangladesh (ICDDR, B)	This research study was funded by the Dhaka Hospital of International Centre for Diarrhoeal Disease Research, Bangladesh (ICDDR, B; grant no Gr-00233) and its donors, which provide unrestricted support to ICDDR, B for its operations and research. Current donors providing unrestricted support include: Australian Agency for International Development, Government of the People's Republic of Bangladesh, Canadian International Development Agency, Swedish International Development Cooperation Agency, and the Department for International Development, United Kingdom. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ahlawat SK, 1999, POSTGRAD MED J, V75, P193, DOI 10.1136/pgmj.75.882.193; Ahmed T, 1999, LANCET, V353, P1919, DOI 10.1016/S0140-6736(98)07499-6; Black RE, 2010, LANCET, V375, P1969, DOI 10.1016/S0140-6736(10)60549-1; Brody Tom, 1998, NUTR BIOCH; Chhabra A, 1995, Indian Pediatr, V32, P409; Chisti MJ, 2011, ANN TROP PAEDIATR, V31, P311, DOI 10.1179/1465328111Y.0000000033; Chisti MJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025817; Chisti MJ, 2010, PEDIATR CRIT CARE ME, V11, P92, DOI 10.1097/PCC.0b013e3181b063e1; Chisti MJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0051376; Chisti MJ, 2010, PEDIATR INFECT DIS J, V29, P174, DOI 10.1097/INF.0b013e3181b9a4d5; Chisti Mohammod Jobayer, 2008, Southeast Asian Journal of Tropical Medicine and Public Health, V39, P719; Liu L, 2012, LANCET; Morgan G, 1997, LANCET, V349, P1693, DOI 10.1016/S0140-6736(96)12038-9; Odey F A, 2010, Niger Postgrad Med J, V17, P19; RAIZADA N, 1992, Indian Pediatrics, V29, P461; Shah G S, 2007, Kathmandu Univ Med J (KUMJ), V5, P60; STEDWELL RE, 1992, AM J EMERG MED, V10, P143, DOI 10.1016/0735-6757(92)90048-3; Suskind DMK, 1990, MALNOURISHED CHILD; Suskind RM, 1990, MALNOURISHED CHILD, P1; Talbert A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038321; WHO, 2012, POCK BOOK HOSP CAR C; World Health Organization, 1999, MAN SEV MALN MAN PHY	22	7	7	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 12	2013	8	8							e71911	10.1371/journal.pone.0071911	http://dx.doi.org/10.1371/journal.pone.0071911			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	200UV	23951267	Green Published, gold, Green Submitted			2023-01-03	WOS:000323097300171
J	Clemens, MJ; Elia, A; Morley, SJ				Clemens, Michael J.; Elia, Androulla; Morley, Simon J.			Requirement for the eIF4E Binding Proteins for the Synergistic Down-Regulation of Protein Synthesis by Hypertonic Conditions and mTOR Inhibition	PLOS ONE			English	Article							TRANSLATION INITIATION; MAMMALIAN TARGET; MESSENGER-RNA; BREAST-CANCER; C-MYC; RAPAMYCIN; CELLS; KINASE; GROWTH; 4E-BP1	The protein kinase mammalian target of rapamycin (mTOR) regulates the phosphorylation and activity of several proteins that have the potential to control translation, including p70S6 kinase and the eIF4E binding proteins 4E-BP1 and 4E-BP2. In spite of this, in exponentially growing cells overall protein synthesis is often resistant to mTOR inhibitors. We report here that sensitivity of wild-type mouse embryonic fibroblasts (MEFs) to mTOR inhibitors can be greatly increased when the cells are subjected to the physiological stress imposed by hypertonic conditions. In contrast, protein synthesis in MEFs with a double knockout of 4E-BP1 and 4E-BP2 remains resistant to mTOR inhibitors under these conditions. Phosphorylation of p70S6 kinase and protein kinase B (Akt) is blocked by the mTOR inhibitor Ku0063794 equally well in both wild-type and 4E-BP knockout cells, under both normal and hypertonic conditions. The response of protein synthesis to hypertonic stress itself does not require the 4E-BPs. These data suggest that under certain stress conditions: (i) translation has a greater requirement for mTOR activity and (ii) there is an absolute requirement for the 4E-BPs for regulation by mTOR. Importantly, dephosphorylation of p70S6 kinase and Akt is not sufficient to affect protein synthesis acutely.	[Clemens, Michael J.; Morley, Simon J.] Univ Sussex, Sch Life Sci, Dept Biochem & Mol Biol, Brighton, E Sussex, England; [Elia, Androulla] Univ London, Div Biomed Sci, London, England	University of Sussex; University of London	Elia, A (corresponding author), Univ London, Div Biomed Sci, Cranmer Terrace, London, England.	a.elia@sgul.ac.uk	Elia, Androulla/AAE-6854-2021		Biotechnology and Biological Sciences Research Council (BBSRC) U.K. [BB/H018956]; Ralph Bates Pancreatic Cancer Research Fund; Wellcome Trust	Biotechnology and Biological Sciences Research Council (BBSRC) U.K.(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Ralph Bates Pancreatic Cancer Research Fund; Wellcome Trust(Wellcome TrustEuropean Commission)	This work was supported by grants from the Biotechnology and Biological Sciences Research Council (BBSRC) U.K. (grant number BB/H018956) and the Ralph Bates Pancreatic Cancer Research Fund. The authors would also like to acknowledge the Wellcome Trust, which provided part of the funding. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Armengol G, 2007, CANCER RES, V67, P7551, DOI 10.1158/0008-5472.CAN-07-0881; Azar R, 2010, CELL CYCLE, V9, P1241, DOI 10.4161/cc.9.7.11047; Barnhart BC, 2008, CANCER BIOL THER, V7, P1443; BATTISTINI A, 1988, EXP CELL RES, V176, P162, DOI 10.1016/0014-4827(88)90130-9; Ortells MC, 2012, NUCLEIC ACIDS RES, V40, P4368, DOI 10.1093/nar/gks038; Cencic R, 2011, P NATL ACAD SCI USA, V108, P1046, DOI 10.1073/pnas.1011477108; Choo AY, 2008, P NATL ACAD SCI USA, V105, P17414, DOI 10.1073/pnas.0809136105; Constantinou C, 2007, CELL DEATH DIFFER, V14, P576, DOI 10.1038/sj.cdd.4402045; De Benedetti A, 2004, ONCOGENE, V23, P3189, DOI 10.1038/sj.onc.1207545; Dowling RJO, 2010, SCIENCE, V328, P1172, DOI 10.1126/science.1187532; Dubois L, 2009, INT J RADIAT ONCOL, V73, P1219, DOI 10.1016/j.ijrobp.2008.12.003; DUNCAN RF, 1987, MOL CELL BIOL, V7, P1293, DOI 10.1128/MCB.7.3.1293; Elia A, 2008, ONCOGENE, V27, P811, DOI 10.1038/sj.onc.1210678; Fenton TR, 2011, INT J BIOCHEM CELL B, V43, P47, DOI 10.1016/j.biocel.2010.09.018; Garcia-Martinez JM, 2009, BIOCHEM J, V421, P29, DOI 10.1042/BJ20090489; Genolet R, 2011, NUCLEIC ACIDS RES, V39, P989, DOI 10.1093/nar/gkq805; Genolet R, 2008, BMC MED GENOMICS, V1, DOI 10.1186/1755-8794-1-33; Graff JR, 2007, J CLIN INVEST, V117, P2638, DOI 10.1172/JCI32044; Graff JR, 2009, CANCER RES, V69, P3866, DOI 10.1158/0008-5472.CAN-08-3472; Grolleau A, 2002, J BIOL CHEM, V277, P22175, DOI 10.1074/jbc.M202014200; Grosso S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0029136; Hernandez-Jimenez M, 2012, BBA-MOL CELL RES, V1823, P430, DOI 10.1016/j.bbamcr.2011.11.008; Hers I, 2011, CELL SIGNAL, V23, P1515, DOI 10.1016/j.cellsig.2011.05.004; Hoang B, 2010, BLOOD, V116, P4560, DOI 10.1182/blood-2010-05-285726; Holz MK, 2005, J BIOL CHEM, V280, P26089, DOI 10.1074/jbc.M504045200; Hresko RC, 2005, J BIOL CHEM, V280, P40406, DOI 10.1074/jbc.M508361200; Hsieh AC, 2012, NATURE, V485, P55, DOI 10.1038/nature10912; Hsieh AC, 2010, CANCER CELL, V17, P249, DOI 10.1016/j.ccr.2010.01.021; Hsu PP, 2011, SCIENCE, V332, P1317, DOI 10.1126/science.1199498; Huo YL, 2012, BIOCHEM J, V444, P141, DOI 10.1042/BJ20112107; Huo YL, 2011, BIOCHEM SOC T, V39, P446, DOI 10.1042/BST0390446; Jeffrey IW, 2002, CANCER RES, V62, P2272; Jiang H, 2003, CANCER CELL INT, V3, DOI 10.1186/1475-2867-3-2; KRUPPA J, 1984, EMBO J, V3, P95, DOI 10.1002/j.1460-2075.1984.tb01767.x; Kwak D, 2012, J BIOL CHEM, V287, P18398, DOI 10.1074/jbc.M111.326538; Laplante M, 2012, CELL, V149, P274, DOI 10.1016/j.cell.2012.03.017; Lee T, 2012, FUTURE MED CHEM, V4, P19, DOI [10.4155/FMC.11.150, 10.4155/fmc.11.150]; Lehman JA, 2003, J BIOL CHEM, V278, P28130, DOI 10.1074/jbc.M300376200; Li S, 2003, J BIOL CHEM, V278, P3015, DOI 10.1074/jbc.M208821200; Li SN, 2004, J BIOL CHEM, V279, P21312, DOI 10.1074/jbc.M312467200; Lynch M, 2004, J BIOL CHEM, V279, P3327, DOI 10.1074/jbc.M310872200; Magnuson B, 2012, BIOCHEM J, V441, P1, DOI 10.1042/BJ20110892; Martelli AM, 2011, LEUKEMIA, V25, P1064, DOI 10.1038/leu.2011.46; MECHLER B, 1981, J CELL BIOL, V88, P42, DOI 10.1083/jcb.88.1.42; Morley SJ, 2002, J BIOL CHEM, V277, P32855, DOI 10.1074/jbc.C200376200; Naegele S, 2004, J BIOL CHEM, V279, P46023, DOI 10.1074/jbc.M404945200; Nathan CAO, 2004, CLIN CANCER RES, V10, P5820, DOI 10.1158/1078-0432.CCR-03-0483; Petroulakis E, 2009, CANCER CELL, V16, P439, DOI 10.1016/j.ccr.2009.09.025; Raynaud FI, 2007, CANCER RES, V67, P5840, DOI 10.1158/0008-5472.CAN-06-4615; Rousseau D, 1996, ONCOGENE, V13, P2415; Ruggero D, 2004, NAT MED, V10, P484, DOI 10.1038/nm1042; Scheuner D, 2001, MOL CELL, V7, P1165, DOI 10.1016/S1097-2765(01)00265-9; She QB, 2010, CANCER CELL, V18, P39, DOI 10.1016/j.ccr.2010.05.023; Sokolosky ML, 2011, ONCOTARGET, V2, P538, DOI 10.18632/oncotarget.302; Sonenberg N, 2009, CELL, V136, P731, DOI 10.1016/j.cell.2009.01.042; Sparks CA, 2010, ONCOGENE, V29, P3733, DOI 10.1038/onc.2010.139; Teleman AA, 2005, GENE DEV, V19, P1844, DOI 10.1101/gad.341505; Thoreen CC, 2012, NATURE, V485, P109, DOI 10.1038/nature11083; Thoreen CC, 2009, J BIOL CHEM, V284, P8023, DOI 10.1074/jbc.M900301200; Wells SE, 1998, MOL CELL, V2, P135, DOI 10.1016/S1097-2765(00)80122-7; Wendel HG, 2004, NATURE, V428, P332, DOI 10.1038/nature02369; Workman P, 2010, CANCER RES, V70, P2146, DOI 10.1158/0008-5472.CAN-09-4355; YATES JR, 1982, J BIOL CHEM, V257, P5030	63	7	8	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 5	2013	8	8							e71138	10.1371/journal.pone.0071138	http://dx.doi.org/10.1371/journal.pone.0071138			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	218XC	23940704	Green Published, Green Accepted, gold, Green Submitted			2023-01-03	WOS:000324465000183
J	Carr, C; Odell-Miller, H; Priebe, S				Carr, Catherine; Odell-Miller, Helen; Priebe, Stefan			A Systematic Review of Music Therapy Practice and Outcomes with Acute Adult Psychiatric In-Patients	PLOS ONE			English	Review							SCHIZOPHRENIA; ARTS	Background and Objectives: There is an emerging evidence base for the use of music therapy in the treatment of severe mental illness. Whilst different models of music therapy have been developed in mental health care, none have specifically accounted for the features and context of acute in-patient settings. This review aimed to identify how music therapy is provided for acute adult psychiatric in-patients and what outcomes have been reported. Review Methods: A systematic review using medical, psychological and music therapy databases. Papers describing music therapy with acute adult psychiatric in-patients were included. Analysis utilised narrative synthesis. Results: 98 papers were identified, of which 35 reported research findings. Open group work and active music making for nonverbal expression alongside verbal reflection was emphasised. Aims were engagement, communication and interpersonal relationships focusing upon immediate areas of need rather than longer term insight. The short stay, patient diversity and institutional structure influenced delivery and resulted in a focus on single sessions, high session frequency, more therapist direction, flexible use of musical activities, predictable musical structures, and clear realistic goals. Outcome studies suggested effectiveness in addressing a range of symptoms, but were limited by methodological shortcomings and small sample sizes. Studies with significant positive effects all used active musical participation with a degree of structure and were delivered in four or more sessions. Conclusions: No single clearly defined model exists for music therapy with adults in acute psychiatric in-patient settings, and described models are not conclusive. Greater frequency of therapy, active structured music making with verbal discussion, consistency of contact and boundaries, an emphasis on building a therapeutic relationship and building patient resources may be of particular importance. Further research is required to develop specific music therapy models for this patient group that can be tested in experimental studies.	[Carr, Catherine; Priebe, Stefan] Queen Mary Univ London, Barts & London Sch Med & Dent, Unit Social & Community Psychiat, London, England; [Odell-Miller, Helen] Anglia Ruskin Univ, Mus & Performing Arts Dept, Cambridge, England	University of London; Queen Mary University London; Anglia Ruskin University	Carr, C (corresponding author), Queen Mary Univ London, Barts & London Sch Med & Dent, Unit Social & Community Psychiat, London, England.	c.e.carr@qmul.ac.uk		Priebe, Stefan/0000-0001-9864-3394	National Institute for Health Research Clinical Doctoral Research Fellowship for Allied Health Professionals [CAT-CDRF 10-006]; National Institute for Health Research (NIHR); National Institute for Health Research [CAT CDRF 10-006] Funding Source: researchfish	National Institute for Health Research Clinical Doctoral Research Fellowship for Allied Health Professionals; National Institute for Health Research (NIHR)(National Institute for Health Research (NIHR)); National Institute for Health Research(National Institute for Health Research (NIHR))	Catherine Carr is funded by the National Institute for Health Research Clinical Doctoral Research Fellowship for Allied Health Professionals: CAT-CDRF 10-006; www.nihrtcc.nhs.uk. This paper presents independent research funded by the National Institute for Health Research (NIHR). The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abs B, 1983, MUSIKTHERAPEUTISCHE, V4, P266; Ansdell G., 2010, MUSIC MED, V2, P29, DOI [DOI 10.1177/1943862109352482, 10.47513/mmd.v2i1.237, DOI 10.47513/MMD.V2I1.237]; Arnason CLR, 1993, CANADIAN J MUSIC THE, V1, P77; Baumgarten H, 1986, MUSIKTHERAPEUTISCHE, V7, P51; Blake R., 1994, MUSIC THERAPY PERSPE, V12, P125, DOI DOI 10.1093/MTP/12.2.125; Bonde LO, 2012, MUSIKTERAPI PSYKIATR, V7; BRASWELL C, 1986, J MUSIC THER, V23, P126, DOI 10.1093/jmt/23.3.126; Bruscia KE, 1998, DEFINING MUSIC THERA, V2nd; Bunt L., 1987, BRIT J MUSIC THERAPY, V1, P22, DOI [10.1177/135945758700100205, DOI 10.1177/135945758700100205]; Cassity M., 2006, MULTIMODAL PSYCHIAT; CASSITY MD, 1976, J MUSIC THER, V13, P66, DOI 10.1093/jmt/13.2.66; CASSITY MD, 1994, J MUSIC THER, V31, P2, DOI 10.1093/jmt/31.1.2; Clemencic-Jones V, 1998, MUSICMEDICINE, P264; Cullen I, 1993, AUSTR J MUSIC THERAP, V4, P36; Davies A, 2010, GROUPS, V34, P21; Davies A, 1998, BRIT J MUSIC THERAPY, V12, P53; De Backer J, 2003, PSYCHODYNAMIC MUSIC, P273; De Backer J, 2006, THESIS AALBORG U AAL; Department of Health, 2001, MENT HLTH POL IMPL G; di Massimo G, 1998, MUSIC THERAPY DIALOG, P53; Dileo C., 2005, MUSIC THERAPY RES, P105; Dokter D., 2010, GROUP, V34, P67; Downs SH, 1998, J EPIDEMIOL COMMUN H, V52, P377, DOI 10.1136/jech.52.6.377; Drieschner K, 2002, MUSIC THERAPY TODAY; Dvorkin J, 2008, DYNAMICS MUSIC PSYCH, P287; Dye S, 1994, AUSTR J MUSIC THERAP, V5, P19; *EPPI CTR, 2002, GUID EXTR DAT QUAL A; Erkkila J, 2011, BRIT J PSYCHIAT, V199, P132, DOI 10.1192/bjp.bp.110.085431; Exner J, 1998, MUSIKTERAPI PSYKIATR, V1, P107; Eyre L, 2011, DEV MUSIC THERAPY PR, P385; Featherstone J, 2008, FORMATIVE EVAL UNPUB; Fenwick A, 1973, MUSIC THERAPY MENTAL, VII, P21; Frederiksen B, 1998, MUSIKTERAPI PSYKIATR, V1, P165; Gibson R, 2008, MENT HEALTH REV J, V13, P32, DOI 10.1108/13619322200800020; Gilbertson S, 2003, MUSIC THERAPY TODAY, V4; Gold C, 2005, BMC PSYCHIATRY, V5, DOI 10.1186/1471-244X-5-39; Gold C, 2009, CLIN PSYCHOL REV, V29, P193, DOI 10.1016/j.cpr.2009.01.001; Goldberg F., 1994, J ASS MUSIC IMAGERY, V3, P18; Goldberg F.S., 1989, MUSIC THERAPY PERSPE, V6, P40, DOI https://doi.org/10.1093/mtp/6.1.40; GOLDBERG FS, 1988, GROUP, V12, P145, DOI 10.1007/BF01456564; Gough D, 2007, RES PAP EDUC, V22, P213, DOI [10.1080/02671520701296189, DOI 10.1080/02671520701296189]; Grandison S, 1991, ARTS THERAPIES UNPUB; Haase U, 2011, DEV MUSIC THERAPY PR, P453; Hannibal N, 2005, MUSIKTERAPI PSYKIATR, V4, P65; Hannibal N, 2002, MUSIKTERAPI PSYKIATR, V3, P57; Hannibal N, 2012, NORD J PSYCHIAT, V66, P376, DOI 10.3109/08039488.2012.655775; Hara G, 1999, MUSIC THERAPY GLOBAL, P17; HEANEY CJ, 1992, J MUSIC THER, V29, P70, DOI 10.1093/jmt/29.2.70; Hopster G, 2005, MUSIKTHERAPEUTISCHE, V26, P18; Hudson-Smith G, 1991, CASE STUDIES MUSIC T, P481; Jensen B, 2000, MUSIKTERAPI PSYKIATR, V2, P129; Jensen B, 2002, MUSIK TERAPI; Leite T, 2008, MUSICOTERAPIA EUROPE, P89; LIBBEY M, 1983, GROUP, V7, P27, DOI 10.1007/BF01456470; Lindvang C, 2008, MUSIKTERAPI PSYKIATR, V5, P123; Lindvang C, 1991, NORD J MUSIC THER, V8, P47, DOI [10.1080/08098139909477953, DOI 10.1080/08098139909477953]; Lindvang C, 2005, MUSIKTERAPI PSYCHIAT, V4, P107; Lund H, 2008, MUSIKTERAPI PSYKIATR, V5, P123; MALER T, 1994, PSYCHOTHER PSYCH MED, V44, P122; Maratos AS, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004517.pub2; Meekums B, 2011, ART PSYCHOTHER, V38, P229, DOI 10.1016/j.aip.2011.06.003; Metzner S, 2003, PSYCHODYNAMIC MUSIC, P257; Metzner S, 2010, NORD J MUSIC THER, V19, P133, DOI 10.1080/08098131.2010.489996; Moe T., 2000, NORD J MUSIC THER, V9, P36, DOI [10.1080/08098130009478000, DOI 10.1080/08098130009478000]; Moe T., 2002, NORD J MUSIC THER, V11, P152, DOI [10.1080/08098130209478057, DOI 10.1080/08098130209478057]; Mossler K, 2011, BRIT J MUSIC THER, V25, P72; Moller AS, 1996, NORD J MUSIC THER, V5, P128, DOI [10.1080/08098139609477882, DOI 10.1080/08098139609477882]; Morgan K, 2011, ACTA PSYCHIAT SCAND, V124, P363, DOI 10.1111/j.1600-0447.2011.01739.x; Moss H, 1999, BRIT J MUSIC THERAPY, V13, P49; Mossler K, 2012, ART PSYCHOTHER, V39, P333, DOI 10.1016/j.aip.2012.05.002; Mossler K, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004025.pub3; Moura Costa C, 2011, ACTION RELATIONSHIP, V11; Murphy ME, 1991, CASE STUDIES MUSIC T, P465; Murphy ME, 1992, MUSIC THERAPY, V11, P99; Nolan P, 1991, CASE STUDIES MUSIC T, P451; Nolan P, 2007, MUSIC THERAPY CHILDR, P45; Odell Helen, 1988, PSYCHOL MUSIC, V16, P52, DOI [10.1177/0305735688161005, DOI 10.1177/0305735688161005]; Odell-Miller H, 2006, PSYCHOTHER RES, V16, P122, DOI 10.1080/10503300500268342; Odell-Miller H, 2001, MUSICOTERAPIA EUROPA, P1464; Odell-Miller H, 1986, MUSIC THERAPY UNPUB; Odell-Miller H, 1992, COMMUNICAT UNPUB MAR; Odell-Miller H., 2007, THESIS AALBORG U AAL; PAVLICEVIC M, 1989, PSYCHOPATHOLOGY, V22, P325, DOI 10.1159/000284615; Pavlicevic M, 1987, BRIT J MUSIC THERAPY, V1, P22; Pawson R, 2003, ESRC UK CTR EVIDENCE, V18, P1; Popay J, 2006, GUIDANCE CONDUCT NAR, V1, pb92; Priestley M., 1975, MUSIC THERAPY ACTION; Procter S, 2002, DIALOGUE DEBATE MUSI, P184; Ragland ZS, 1973, J MUSIC THER, V10, P194; Ready T, 2011, MUSIC MED, V3, P246; REKER T, 1991, PSYCHIAT PRAX, V18, P216; Ring NA, 2011, GUIDE SYNTHESISING Q; Rodgers M, 2009, EVALUATION, V15, P47, DOI DOI 10.1177/1356389008097871; Rolvsjord R., 2010, RESOURCE ORIENTED MU; Rowland C, 2011, BRIT J MUSIC THER, V25, P48, DOI 10.1177/135945751102500105; Sainsbury Centre for Mental Health (SCMH), 2006, SEARCH AC SOL IMPR Q; Saitoh T, 2011, MUSIC THERAPY TODAY, V9, P60; Seitz E, 2002, EINBLICKE BEITRAGE M, P53; Sekeles C, 1999, CLINICAL APPLICATIONS OF MUSIC THERAPY IN PSYCHIATRY, P176; Shultis CL, 1999, PSYCHIAT TIMES, V16, P46; Silverman MJ, 2007, J MUSIC THER, V44, P388, DOI 10.1093/jmt/44.4.388; Silverman MJ, 2009, J CREAT MENT HEALTH, V4, P17, DOI 10.1080/15401380802672518; Silverman MJ, 2011, J MUSIC THER, V48, P103, DOI 10.1093/jmt/48.1.103; Silverman MJ, 2011, ART PSYCHOTHER, V38, P125, DOI 10.1016/j.aip.2011.02.004; Silverman MJ, 2010, ART PSYCHOTHER, V37, P264, DOI 10.1016/j.aip.2010.05.002; Silverman MJ, 2009, J MUSIC THER, V46, P105, DOI 10.1093/jmt/46.2.105; Silverman MJ, 2004, ART PSYCHOTHER, V31, P291, DOI 10.1016/j.aip.2004.06.008; Silverman MJ, 2003, J MUSIC THER, V40, P27, DOI 10.1093/jmt/40.1.27; Silverman MJ, 2003, ART PSYCHOTHER, V30, P25, DOI 10.1016/S0197-4556(02)00231-9; Sloboda A, 2008, INTEGRATED TEAM WORK, P141; Smeijsters H., 2005, SOUNDING SELF ANALOG; SMITH SM, 1975, HOSP COMMUNITY PSYCH, V26, P420; Solli HP, 2008, NORD J MUSIC THER, V17, P67, DOI 10.1080/08098130809478197; Solli HP, 2009, MUSIKKTERAPI, V3, P8; Solli HP, 2009, SKRIFTSERIE SENTER M, P15; Solli HP, 2006, MUSIKK HELSE, P113; Solli HP, 2003, MUSIKKTERAPI, V2, P10; Spencer L, 2003, QUALITY QUALITATIVE; Stern D. N., 2010, FORMS VITALITY EXPLO; Stern D, 2010, NORD J MUSIC THER, V19, P88, DOI 10.1080/08098131.2010.497634; Stige B, 2011, DEV MUSIC THERAPY PR, P416; Storz D, 2005, MUSIC THERAPY TODAY, V6, P1514; Strehlow G, 2007, INT J PSYCHOTHER, V11, P25; Strunck R, 1986, MUSIKTHERAPEUTISCHE, V7, P209; Sullivan J, 2003, GROUP, V27, P31, DOI 10.1023/A:1022980603069; Talwar N, 2006, BRIT J PSYCHIAT, V189, P405, DOI 10.1192/bjp.bp.105.015073; Thomas C., 2007, MUSIC THERAPY CHILDR, P125; Thomas J, 2008, BMC MED RES METHODOL, V8, DOI 10.1186/1471-2288-8-45; Ulrich G, 2007, ACTA PSYCHIAT SCAND, V116, P362, DOI 10.1111/j.1600-0447.2007.01073.x; Unkefer RF, 2005, MUSIC THERAPY TREATM; Vogt-Schaeffer K, 1991, MUSIKTHER UMSCH, V12, P185; Wolfe DE, 1996, EFFECTIVENESS MUSIC, P106; Yalom ID, 1983, INN PATIENT GROUP PS; Yalom ID, 2005, THEORY PRACTICE GROU	134	102	102	2	52	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 2	2013	8	8							e70252	10.1371/journal.pone.0070252	http://dx.doi.org/10.1371/journal.pone.0070252			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	219XU	23936399	gold, Green Published, Green Submitted			2023-01-03	WOS:000324545800038
J	van Schalkwyk, C; Mndzebele, S; Hlophe, T; Calleja, JMG; Korenromp, EL; Stoneburner, R; Pervilhac, C				van Schalkwyk, Cari; Mndzebele, Sibongile; Hlophe, Thabo; Calleja, Jesus Maria Garcia; Korenromp, Eline L.; Stoneburner, Rand; Pervilhac, Cyril			Outcomes and Impact of HIV Prevention, ART and TB Programs in Swaziland - Early Evidence from Public Health Triangulation	PLOS ONE			English	Article							ANTIRETROVIRAL THERAPY; MALAWI	Introduction: Swaziland's severe HIV epidemic inspired an early national response since the late 1980s, and regular reporting of program outcomes since the onset of a national antiretroviral treatment (ART) program in 2004. We assessed effectiveness outcomes and mortality trends in relation to ART, HIV testing and counseling (HTC), tuberculosis (TB) and prevention of mother to child transmission (PMTCT). Methods: Data triangulated include intervention coverage and outcomes according to program registries (2001-2010), hospital admissions and deaths disaggregated by age and sex (2001-2010) and population mortality estimates from the 1997 and 2007 censuses and the 2007 demographic and health survey. Results: By 2010, ART reached 70% of the estimated number of people living with HIV/AIDS with CD4<350/mm(3), with progressively improving patient retention and survival. As of 2010, 88% of health facilities providing antenatal care offered comprehensive PMTCT services. The HTC program recorded a halving in the proportion of adults tested who were HIV-infected; similarly HIV infection rates among HIV-exposed babies halved from 2007 to 2010. Case fatality rates among hospital patients diagnosed with HIV/AIDS started to decrease from 2005-6 in adults and especially in children, contrasting with stable case fatality for other causes including TB. All-cause child in-patient case fatality rates started to decrease from 2005-6. TB case notifications as well as rates of HIV/TB co-infection among notified TB patients continued a steady increase through 2010, while coverage of HIV testing and CPT for co-infected patients increased to above 80%. Conclusion: Against a background of high, but stable HIV prevalence and decreasing HIV incidence, we documented early evidence of a mortality decline associated with the expanded national HIV response since 2004. Attribution of impact to specific interventions (versus natural epidemic dynamics) will require additional data from future household surveys, and improved routine (program, surveillance, and hospital) data at district level.	[van Schalkwyk, Cari] Univ Stellenbosch, Natl Res Fdn Ctr Excellence Epidemiol Modelling &, South African Dept Sci & Technol, Cape Town, South Africa; [Mndzebele, Sibongile; Hlophe, Thabo] Swaziland Minist Hlth, Strateg Informat Dept, Mbabane, Swaziland; [Calleja, Jesus Maria Garcia; Pervilhac, Cyril] WHO, Dept HIV AIDS, CH-1211 Geneva, Switzerland; [Korenromp, Eline L.] Univ Med Ctr, Erasmus MC, Dept Publ Hlth, Rotterdam, Netherlands; [Stoneburner, Rand] UNAIDS, Geneva, Switzerland	National Research Foundation - South Africa; Stellenbosch University; World Health Organization; Erasmus University Rotterdam; Erasmus MC; UNAIDS	van Schalkwyk, C (corresponding author), Univ Stellenbosch, Natl Res Fdn Ctr Excellence Epidemiol Modelling &, South African Dept Sci & Technol, Cape Town, South Africa.	carivs@sun.ac.za; rlstoneburner@gmail.com; pervilhacc@gmail.com		van Schalkwyk, Cari/0000-0001-5154-1390	Global Fund to fight AIDS, Tuberculosis and Malaria [PO 20024822]	Global Fund to fight AIDS, Tuberculosis and Malaria	The work was supported under direct funding of the Global Fund to fight AIDS, Tuberculosis and Malaria through Contribution Agreement PO 20024822. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2011, GLOB PLAN EL NEW HIV; [Anonymous], 2009, GUID MON EV COLL TB; [Anonymous], JOINT UN PROGR HIV A; [Anonymous], 2011, GUID INT TUB CAS FIN; Canadian International Development Agency World Health Organization, 2012, AR WE ACH GOALS GLOB; Chadborn T, 2012, 19 INT AIDS C; Columbia University Mailman School of Public Health, 2012, 1 FIND REL SWAZ HIV; Desmond Christopher, 2004, Afr J AIDS Res, V3, P43, DOI 10.2989/16085900409490317; Floyd S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013499; Granich R, 2011, CURR HIV RES, V9, P446, DOI 10.2174/157016211798038597; International Health Partnership and World Health Organization, 2011, MON EV REV NAT HLTH; Jahn A, 2008, LANCET, V371, P1603, DOI 10.1016/S0140-6736(08)60693-5; Johnson LF, 2012, SO AFR J HIV MED, V13; Malawi Ministry of Health the South African DST/NRF Centre of Excellence, 2011, EP MOD AN GLOB UNPUB; Mwagomba B, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010452; Organization WH, 2011, GUID MON EV NAT HIV; Rutherford GW, 2010, BMC PUBLIC HEALTH, V10, DOI 10.1186/1471-2458-10-447; Ruutel K, 2011, HIV EPIDEMIC ESTONIA; Stoneburner R, 2013, USING HLTH SUR UNPUB; Stoneburner R, 2006, 16 INT TOR CAN AIDS; STOP AIDS NOW! The Clinton Health Access Initiative (CHAI), 2010, END NEW HIV INF SWAZ; Swaziland Central Statistical Office, 2006, SWAZ DEM HLTH SURV; Swaziland Central Statistical Office, 2007, SWAZ POP HOUS CENS 2; Swaziland Ministry of Health and Social Services, 2010, SWAZ TUB CONTR ANN R; Swaziland Ministry of Health and Social Services, 2011, PMTCT PROGR ANN REP; Swaziland Ministry of Health and Social Services, 2011, ART PROGR ANN REP; Swaziland Ministry of Health and Social Services, 2010, 12 NAT HIV SER WOM A; Swaziland Ministry of Health and Social Services, 2012, NAT GUID IMPL TUB IN; Swaziland Ministry of Health and Social Services, 2010, SERV AV MAPP; Swaziland Ministry of Health and Social Services World Health Organization United Nations Children's Fund, 2011, EV EFF NAT PREV MOTH; Swaziland Ministry of Health/ Monitoring and Evaluation the South African DST/ NRF Centre of Excellence, 2011, REV EMERGENCIES SWAZ; Swaziland National Emergency Response Council on HIV and AIDS, 2009, NAT MULT FRAM HIV AI; Swaziland National Emergency Response Council on HIV and AIDS Joint. United Nations Programme on HIV/AIDS, 2010, 12 NAT HIV SER WOM A; Swaziland Nutrition Council World Food Programme Action Against Hunger, 2010, NAT GUID INT MAN AC; The Global Fund to Fight AIDS Tuberculosis and Malaria, 2011, MON EV TOOLK 2; The Global Fund to Fight AIDS Tuberculosis and Malaria, 2009, SWZ405G04H GLOB FUND; The Global Fund to Fight AIDS Tuberculosis and Malaria. World Health Organization Joint United Nations Programme on HIV/AIDS, 2009, HIV TRIANG RES GUID; Velephi Okello, 2012, BASELINE CHARACTERIS; Whiteside A, 2007, REV EMERGENCIES SWAZ; WHO, 2012, GLOBAL TUBERCULOSIS REPORT 2012, P1; WHO, 2012, MEAS IMP NAT PMTCT P; WHO, 2003, PUBL HLTH APPR ANT T; Williams BG, 2003, SCIENCE, V301, P1535, DOI 10.1126/science.1086845; World Health Organization, 2003, HIV TEST COUNS GAT T; World Health Organization, 2006, CAS STUD COUNTR ENH, P924; World Health Organization Joint United Nations Programme on HIV/AIDS United Nations Children's Fund, 2010, GLOB FUND FIGHT AIDS; World Health Organization United Nations Children's Fund, 2010, MON EV PREV MOTH TO; World Health Organization United Nations Children's Fund Joint United Nations Programme on HIV/AIDS, 2012, HDB IND KEY HIV INT; [World Health Organization; WHO UNAIDS UNICEF], 2011, EP UPD HLTH SECT PRO; Zachariah R, 2011, INT J TUBERC LUNG D, V15, P933, DOI 10.5588/ijtld.10.0666	50	17	17	0	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 26	2013	8	7							e69437	10.1371/journal.pone.0069437	http://dx.doi.org/10.1371/journal.pone.0069437			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	197GU	23922711	Green Published, gold, Green Submitted			2023-01-03	WOS:000322838900041
J	Gray, JAM				Gray, J. A. Muir			The Art of Medicine The shift to personalised and population medicine	LANCET			English	Editorial Material									Oxford Univ Hosp NHS Trust, Oxford OX3 9DU, England	Oxford University Hospitals NHS Foundation Trust	Gray, JAM (corresponding author), Oxford Univ Hosp NHS Trust, Oxford OX3 9DU, England.	muir.gray@medknox.net						[Anonymous], 1995, LANCET, V346, P785; British Thoracic Society and the Primary Care Respiratory Society UK, 2012, BRITISH THORACIC SOC, V4; Christensen CM, 2009, THE INNOVATORS PRESC; Goldberg D., 1983, INT J REHABIL RES, V6, P127, DOI [10.1097/00004356-198303000-00021, DOI 10.1097/00004356-198303000-00021]; Gray JAM, 2007, HOW GET BETTER VALUE; Gray M, 2009, J HEALTH SERV RES PO, V14, P129, DOI 10.1258/jhsrp.2008.008105; Mulley AG, 2012, BMJ-BRIT MED J, V345, DOI 10.1136/bmj.e6572; NHS, 2010, THE NHS ATLAS OF VAR; Ohno T., 1988, THE TOYOTA PRODUCTIO; Porter ME, 2008, WHAT IS VALUE IN HEA; Rothwell Peter M., 2007, TREATING INDIVIDUALS; Sackett DL, 1996, BRIT MED J, V312, P71, DOI 10.1136/bmj.312.7023.71	12	39	40	0	8	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 20	2013	382	9888					200	201		10.1016/S0140-6736(13)61590-1	http://dx.doi.org/10.1016/S0140-6736(13)61590-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	193FL	23878859				2023-01-03	WOS:000322543700016
J	Allen, HG; Stanton, TR; Di Pietro, F; Moseley, GL				Allen, Heidi G.; Stanton, Tasha R.; Di Pietro, Flavia; Moseley, G. Lorimer			Social Media Release Increases Dissemination of Original Articles in the Clinical Pain Sciences	PLOS ONE			English	Article							APOMEDIATION	A barrier to dissemination of research is that it depends on the end-user searching for or 'pulling' relevant knowledge from the literature base. Social media instead 'pushes' relevant knowledge straight to the end-user, via blogs and sites such as Facebook and Twitter. That social media is very effective at improving dissemination seems well accepted, but, remarkably, there is no evidence to support this claim. We aimed to quantify the impact of social media release on views and downloads of articles in the clinical pain sciences. Sixteen PLOS ONE articles were blogged and released via Facebook, Twitter, LinkedIn and ResearchBlogging.org on one of two randomly selected dates. The other date served as a control. The primary outcomes were the rate of HTML views and PDF downloads of the article, over a seven-day period. The critical result was an increase in both outcome variables in the week after the blog post and social media release. The mean +/- SD rate of HTML views in the week after the social media release was 18 +/- 18 per day, whereas the rate during the other three weeks was no more than 6 +/- 3 per day. The mean +/- SD rate of PDF downloads in the week after the social media release was 4 +/- 4 per day, whereas the rate during the other three weeks was less than 1 +/- 1 per day (p<0.05 for all comparisons). However, none of the recognized measures of social media reach, engagement or virality related to either outcome variable, nor to citation count one year later (p>0.3 for all). We conclude that social media release of a research article in the clinical pain sciences increases the number of people who view or download that article, but conventional social media metrics are unrelated to the effect.	[Allen, Heidi G.; Stanton, Tasha R.; Moseley, G. Lorimer] Univ S Australia, Sansom Inst Hlth Res, Adelaide, SA 5001, Australia; [Allen, Heidi G.; Stanton, Tasha R.; Di Pietro, Flavia; Moseley, G. Lorimer] Neurosci Res Australia, Sydney, NSW, Australia; [Di Pietro, Flavia] Univ New S Wales, Sydney, NSW, Australia	University of South Australia; Neuroscience Research Australia; University of New South Wales Sydney	Moseley, GL (corresponding author), Univ S Australia, Sansom Inst Hlth Res, Adelaide, SA 5001, Australia.	lorimer.moseley@gmail.com	Moseley, Lorimer/A-7095-2009; Stanton, Tasha/F-4038-2013; Di Pietro, Flavia/P-5415-2018	Moseley, Lorimer/0000-0002-3750-4945; Stanton, Tasha/0000-0001-7106-4456; Di Pietro, Flavia/0000-0002-9642-0805	Canadian Institutes of Health Research [223354]; National Health & Medical Research Council [571090]; Australian Government	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); National Health & Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia); Australian Government(Australian GovernmentCGIAR)	Tasha Stanton is supported by the Canadian Institutes of Health Research Postdoctoral Training Fellowship [ID 223354]; G. Lorimer Moseley is supported by the National Health & Medical Research Council Research Fellowship [ID 571090]. Flavia Di Pietro is supported by a Australian Government Postgraduate award. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], PLOS; Cheston Christine C, 2012, MED 2 0 C MED 2 0; Creamer M., 2012, STUDY ONLY 1 FACEBOO; Eysenbach G, 2011, J MED INTERNET RES, V13, DOI 10.2196/jmir.2012; Eysenbach G, 2007, STUD HEALTH TECHNOL, V129, P162; Eysenbach G, 2008, J MED INTERNET RES, V10, DOI 10.2196/jmir.1030; Lavis JN, 2003, MILBANK Q, V81, P221, DOI 10.1111/1468-0009.t01-1-00052; Priem J, 2012, ALTMETRICS WILD USIN; Priem J, 2011, ALTMETRICS MANIFEST; Salganik MJ, 2006, SCIENCE, V311, P854, DOI 10.1126/science.1121066; Van de Belt TH, 2012, J MED INTERNET RES, V14, P227, DOI 10.2196/jmir.1992; Vaughan P, 2011, 23 REASONS INBOUND M	12	121	123	0	34	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 17	2013	8	7							e68914	10.1371/journal.pone.0068914	http://dx.doi.org/10.1371/journal.pone.0068914			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	185WH	23874810	gold, Green Published, Green Submitted, Green Accepted			2023-01-03	WOS:000322000600034
J	Thent, ZC; Das, S; Henry, LJ				Thent, Zar Chi; Das, Srijit; Henry, Leonard Joseph			Role of Exercise in the Management of Diabetes Mellitus: the Global Scenario	PLOS ONE			English	Article							RANDOMIZED CONTROLLED-TRIAL; INSULIN SENSITIVITY; RESISTANCE EXERCISE; AEROBIC EXERCISE; SKELETAL-MUSCLE; RISK-FACTORS; GLUCOSE-TRANSPORT; PHYSICAL-ACTIVITY; GLYCEMIC CONTROL; OLDER-ADULTS	Background: Exercise training programs have emerged as a useful therapeutic regimen for the management of type 2 diabetes mellitus (T2DM). Majority of the Western studies highlighted the effective role of exercise in T2DM. Therefore, the main aim was to focus on the extent, type of exercise and its clinical significance in T2DM in order to educate the clinicians from developing countries, especially in Asians. Methods: Pubmed, Science Direct, Scopus, ISI Web of Knowledge and Google scholar were searched using the terms "type 2 diabetes mellitus," "type 2 DM," "exercise," and/or "physical activity," and " type 2 diabetes mellitus with exercise." Only clinical or human studies published in English language between 2000 and 2012 were included. Certain criteria were assigned to achieve appropriate results. Results: Twenty five studies met the selected criteria. The majority of the studies were randomized controlled trial study design (65%). Most of the aerobic exercise based studies showed a beneficial effect in T2DM. Resistance exercise also proved to have positive effect on T2DM patients. Minimal studies related to other types of exercises such as yoga classes, joba riding and endurance-type exercise were found. On the other hand, United States of America (USA) showed strong interest of exercise management towards T2DM. Conclusion: Aerobic exercise is more common in clinical practice compared to resistance exercise in managing T2DM. Treatment of T2DM with exercise training showed promising role in USA. A large number of researches are mandatory in the developing countries for incorporating exercise in the effective management of T2DM.	[Thent, Zar Chi; Das, Srijit] Univ Kebangsaan Malaysia, Fac Med, Dept Anat, Kuala Lumpur, Malaysia; [Henry, Leonard Joseph] Univ Kebangsaan Malaysia, Fac Hlth Sci, Physiotherapy Programme, Kuala Lumpur, Malaysia	Universiti Kebangsaan Malaysia; Universiti Kebangsaan Malaysia	Das, S (corresponding author), Univ Kebangsaan Malaysia, Fac Med, Dept Anat, Kuala Lumpur, Malaysia.	drsrijit@gmail.com	Das, Srijit/E-8457-2017; theint, zar chi/AAA-5780-2019	Das, Srijit/0000-0001-8302-7257; theint, zar chi/0000-0002-7915-0364				AgursCollins TD, 1997, DIABETES CARE, V20, P1503, DOI 10.2337/diacare.20.10.1503; Angadi SS, 2009, CLIN SPORT MED, V28, P379, DOI 10.1016/j.csm.2009.02.002; Bacchi E, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049937; Balducci S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049297; Bauer TA, 2007, DIABETES CARE, V30, P2880, DOI 10.2337/dc07-0843; Bello AI, 2011, INT J GEN MED, V4, P723, DOI 10.2147/IJGM.S16717; Boudou P, 2000, DIABETES METAB, V26, P450; Boule NG, 2001, JAMA-J AM MED ASSOC, V286, P1218, DOI 10.1001/jama.286.10.1218; Boule NG, 2003, DIABETOLOGIA, V46, P1071, DOI 10.1007/s00125-003-1160-2; Brazeau AS, 2008, DIABETES CARE, V31, P2108, DOI 10.2337/dc08-0720; Brooks Naomi, 2006, Int J Med Sci, V4, P19; Bruce CR, 2004, DIABETOLOGIA, V47, P23, DOI 10.1007/s00125-003-1265-7; Castaneda C, 2002, DIABETES CARE, V25, P2335, DOI 10.2337/diacare.25.12.2335; Church TS, 2010, JAMA-J AM MED ASSOC, V304, P2253, DOI 10.1001/jama.2010.1710; Eves ND, 2006, DIABETES CARE, V29, P1933, DOI 10.2337/dc05-1981; Garvey WT, 1998, J CLIN INVEST, V101, P2377, DOI 10.1172/JCI1557; Goldhaber-Fiebert JD, 2003, DIABETES CARE, V26, P24, DOI 10.2337/diacare.26.1.24; Gordon PL, 2006, INT J IMMUNOPATH PH, V19, P739, DOI 10.1177/039463200601900404; Hayashi T, 1997, AM J PHYSIOL-ENDOC M, V273, pE1039, DOI 10.1152/ajpendo.1997.273.6.E1039; Holloszy JO, 1996, REV PHYSIOL BIOCH P, V128, P99; Hordern MD, 2011, J SCI MED SPORT, V14, P238, DOI 10.1016/j.jsams.2010.11.003; Hosaka Y, 2010, NAGOYA J MED SCI, V72, P129; Hunter GR, 2004, SPORTS MED, V34, P329, DOI 10.2165/00007256-200434050-00005; Hurley BF, 2000, SPORTS MED, V30, P249, DOI 10.2165/00007256-200030040-00002; Innes KE, 2007, EVID-BASED COMPL ALT, V4, P469, DOI 10.1093/ecam/nel103; Ishii T, 2001, METABOLISM, V50, P1136, DOI 10.1053/meta.2001.26745; Janevic MR, 2013, CHRONIC ILLN, V9, P251, DOI 10.1177/1742395313475461; Kubota M, 2006, DIABETES RES CLIN PR, V71, P124, DOI 10.1016/j.diabres.2005.06.012; Li GW, 2008, LANCET, V371, P1783, DOI 10.1016/S0140-6736(08)60766-7; Ligtenberg PC, 1997, CLIN SCI, V93, P127, DOI 10.1042/cs0930127; Loimaala A, 2003, DIABETES, V52, P1837, DOI 10.2337/diabetes.52.7.1837; Maiorana A, 2001, J AM COLL CARDIOL, V38, P860, DOI 10.1016/S0735-1097(01)01439-5; Manders RJF, 2010, MED SCI SPORT EXER, V42, P219, DOI 10.1249/MSS.0b013e3181b3b16d; Vancea DMM, 2009, ARQ BRAS CARDIOL, V92, P22, DOI 10.1590/S0066-782X2009000100005; Mogensen CE, 2002, HDB EXERCISE DIABETE, P433; Morais PK, 2011, DIABETES METAB, V37, P112, DOI 10.1016/j.diabet.2010.08.008; Musi N, 2001, DIABETES, V50, P921, DOI 10.2337/diabetes.50.5.921; Ng CLW, 2010, J PHYSIOTHER, V56, P163, DOI 10.1016/S1836-9553(10)70021-7; Otterman NM, 2011, DIABETIC MED, V28, P212, DOI 10.1111/j.1464-5491.2010.03128.x; Peirce NS, 1999, BRIT J SPORT MED, V33, P161, DOI 10.1136/bjsm.33.3.161; Plotnikoff RC, 2000, DIABETES EDUCATOR, V26, P450, DOI 10.1177/014572170002600312; Poehlman ET, 2000, J CLIN ENDOCR METAB, V85, P2463, DOI 10.1210/jc.85.7.2463; Pourmoghaddas A, 2013, ARYA ATHEROSCLER, V9, P167; Riddell MC, 2006, PEDIATR DIABETES, V7, P60, DOI 10.1111/j.1399-543X.2006.00146.x; Riddell Michael, 2009, J Diabetes Sci Technol, V3, P914; Ross R, 2000, ANN INTERN MED, V133, P92, DOI 10.7326/0003-4819-133-2-200007180-00008; SEGAL KR, 1991, J APPL PHYSIOL, V71, P2402, DOI 10.1152/jappl.1991.71.6.2402; Sigal RJ, 2004, DIABETES CARE, V27, P2518, DOI 10.2337/diacare.27.10.2518; Skoro-Kondza L, 2009, BMC HEALTH SERV RES, V9, DOI 10.1186/1472-6963-9-33; Snowling NJ, 2006, DIABETES CARE, V29, P2518, DOI 10.2337/dc06-1317; Stewart KJ, 2002, JAMA-J AM MED ASSOC, V288, P1622, DOI 10.1001/jama.288.13.1622; Sukala WR, 2012, AUSTRALAS MED J, V5, P429, DOI 10.4066/AMJ.2012.1311; Tecilazich F, 2013, J VASC SURG, V57, P997, DOI 10.1016/j.jvs.2012.10.011; Tuomilehto J, 2001, NEW ENGL J MED, V344, P1343, DOI 10.1056/NEJM200105033441801; van Dijk JW, 2012, DIABETOLOGIA, V55, P1273, DOI 10.1007/s00125-011-2380-5; Wallberg-Henriksson H, 1998, SPORTS MED, V25, P25, DOI 10.2165/00007256-199825010-00003; YAMANOUCHI K, 1995, DIABETES CARE, V18, P775, DOI 10.2337/diacare.18.6.775; Yavari A, 2010, J SPORT MED PHYS FIT, V50, P501; Yokoyama H, 2004, DIABETES RES CLIN PR, V65, P85, DOI 10.1016/j.diabres.2003.12.005; Yokoyama H, 2004, DIABETES CARE, V27, P1756, DOI 10.2337/diacare.27.7.1756; Zachwieja JJ, 1996, METABOLISM, V45, P254, DOI 10.1016/S0026-0495(96)90063-3	61	56	63	0	24	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 13	2013	8	11							e80436	10.1371/journal.pone.0080436	http://dx.doi.org/10.1371/journal.pone.0080436			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	255QK	24236181	Green Published, Green Submitted, gold			2023-01-03	WOS:000327254700182
J	Jencks, SF; Brock, JE				Jencks, Stephen F.; Brock, Jane E.			Hospital Accountability and Population Health: Lessons From Measuring Readmission Rates	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							REHOSPITALIZATIONS; PROGRAM		CFMC, Englewood, CO USA		Jencks, SF (corresponding author), 8 Midvale Rd, Baltimore, MD 21210 USA.	steve.jencks@comcast.net			Integrating Care for Populations & Communities National Coordinating Center at CFMC; Centers for Medicare & Medicaid Services, an agency of the U.S. Department of Health and Human Services	Integrating Care for Populations & Communities National Coordinating Center at CFMC; Centers for Medicare & Medicaid Services, an agency of the U.S. Department of Health and Human Services	Dr. Brock was partially supported by the Integrating Care for Populations & Communities National Coordinating Center at CFMC with the Centers for Medicare & Medicaid Services, an agency of the U.S. Department of Health and Human Services.	Berenson RA, 2012, NEW ENGL J MED, V366, P1364, DOI 10.1056/NEJMp1201268; Brock J, 2013, JAMA-J AM MED ASSOC, V309, P381, DOI 10.1001/jama.2012.216607; Department of Health and Human Services Centers for Medicare & Medicaid Services, 2012, FED REGISTER, V77, P27870; Epstein AM, 2011, NEW ENGL J MED, V365, P2287, DOI 10.1056/NEJMsa1101942; Gorodeski EZ, 2010, NEW ENGL J MED, V363, P297, DOI 10.1056/NEJMc1001882; Jencks SF, 2009, NEW ENGL J MED, V360, P1418, DOI 10.1056/NEJMsa0803563; Krumholz HM, 2013, JAMA-J AM MED ASSOC, V309, P587, DOI 10.1001/jama.2013.333; Medicare.gov, 2013, FREQ ASK QUEST CMS P; U. S. Department of Health and Human Services, 2011, C NAT STRAT QUAL IMP	9	17	17	0	16	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 5	2013	159	9					629	630		10.7326/0003-4819-159-9-201311050-00010	http://dx.doi.org/10.7326/0003-4819-159-9-201311050-00010			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	249HX	24189596				2023-01-03	WOS:000326769400008
J	Fang, Z; Lu, BX; Liu, MY; Zhang, MX; Yi, ZH; Wen, CP; Shi, TL				Fang, Zhao; Lu, Bingxin; Liu, Mingyao; Zhang, Meixia; Yi, Zhenghui; Wen, Chengping; Shi, Tieliu			Evaluating the Pharmacological Mechanism of Chinese Medicine Si-Wu-Tang through Multi-Level Data Integration	PLOS ONE			English	Article							DREAM; GENE; CONSTITUENTS; POLYMORPHISM; ASSOCIATION; CYTOSCAPE; ABUNDANCE; NETWORKS; RECEPTOR; DENSITY	Si-Wu-Tang (SWT) is a Traditional Chinese Medicine (TCM) formula widely used for the treatments of gynecological diseases. To explore the pharmacological mechanism of SWT, we incorporated microarray data of SWT with our herbal target database TCMID to analyze the potential activity mechanism of SWT's herbal ingredients and targets. We detected 2,405 differentially expressed genes in the microarray data, 20 of 102 proteins targeted by SWT were encoded by these DEGs and can be targeted by 2 FDA-approved drugs and 39 experimental drugs. The results of pathway enrichment analysis of the 20 predicted targets were consistent with that of 2,405 differentially expressed genes, elaborating the potential pharmacological mechanisms of SWT. Further study from a perspective of protein-protein interaction (PPI) network showed that the predicted targets of SWT function cooperatively to perform their multi-target effects. We also constructed a network to combine herbs, ingredients, targets and drugs together which bridges the gap between SWT and conventional medicine, and used it to infer the potential mechanisms of herbal ingredients. Moreover, based on the hypothesis that the same or similar effects between different TCM formulae may result from targeting the same proteins, we analyzed 27 other TCM formulae which can also treat the gynecological diseases, the subsequent result provides additional insight to understand the potential mechanisms of SWT in treating amenorrhea. Our bioinformatics approach to detect the pharmacology of SWT may shed light on drug discovery for gynecological diseases and could be utilized to investigate other TCM formulae as well.	[Fang, Zhao; Lu, Bingxin; Liu, Mingyao; Shi, Tieliu] E China Normal Univ, Ctr Bioinformat & Computat Biol, Inst Biomed Sci, Shanghai Key Lab Regulatory Biol, Shanghai 200062, Peoples R China; [Fang, Zhao; Lu, Bingxin; Liu, Mingyao; Shi, Tieliu] E China Normal Univ, Sch Life Sci, Shanghai 200062, Peoples R China; [Zhang, Meixia] Sichuan Univ, West China Hosp, Dept Ophthalmol, Chengdu, Sichuan, Peoples R China; [Yi, Zhenghui] Shanghai Jiao Tong Univ, Sch Med, Shanghai Mental Hlth Ctr, Schizophrenia Program, Shanghai 200030, Peoples R China; [Wen, Chengping] Zhejiang Univ Chinese Med, TCM Clin Basis Inst, Hangzhou, Zhejiang, Peoples R China; [Shi, Tieliu] Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Plant Physiol & Ecol, Shanghai, Peoples R China	East China Normal University; East China Normal University; Sichuan University; Shanghai Jiao Tong University; Zhejiang Chinese Medical University; Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS	Shi, TL (corresponding author), E China Normal Univ, Ctr Bioinformat & Computat Biol, Inst Biomed Sci, Shanghai Key Lab Regulatory Biol, Shanghai 200062, Peoples R China.	tieliushi01@gmail.com		LU, BINGXIN/0000-0002-0606-5150; chengping, Wen/0000-0001-9254-6235; Liu, Mingyao/0000-0001-7339-5048	National 973 Key Basic Research Program [2013CB127000, 2010CB945401]; National Natural Science Foundation of China [31240038, 31071162, 31000590]; Science and Technology Commission of Shanghai Municipality [11DZ2260300]	National 973 Key Basic Research Program(National Basic Research Program of China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Science and Technology Commission of Shanghai Municipality(Science & Technology Commission of Shanghai Municipality (STCSM))	This work was supported by the National 973 Key Basic Research Program (Grant No. 2013CB127000 and 2010CB945401), the National Natural Science Foundation of China (Grant No. 31240038, 31071162, and 31000590), the Science and Technology Commission of Shanghai Municipality (11DZ2260300). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bindea G, 2009, BIOINFORMATICS, V25, P1091, DOI 10.1093/bioinformatics/btp101; Carrion AM, 1999, NATURE, V398, P80, DOI 10.1038/18044; Chan E, 2010, CURR OPIN DRUG DISC, V13, P50; Chen ZW, 2010, CHINA OCCUPATIONAL M, V37, P279; Cheng HYM, 2002, CELL, V108, P31, DOI 10.1016/S0092-8674(01)00629-8; Cheung F, 2011, NATURE, V480, pS82, DOI 10.1038/480S82a; Dai Y, 2002, BIOL PHARM BULL, V25, P1175, DOI 10.1248/bpb.25.1175; Debnath B, 2010, DRUG NEWS PERSPECT, V23, P670, DOI 10.1358/dnp.2010.23.10.1506088; Gao Y, 2003, TIANJIN J TRADIT CHI, V20, P47; Greenbaum D, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-117; Gygi SP, 1999, MOL CELL BIOL, V19, P1720, DOI 10.1128/mcb.19.3.1720; Hinke V, 2001, CALCIFIED TISSUE INT, V69, P315, DOI 10.1007/s002230020024; [华永庆 HUA Yongqing], 2008, [中国药科大学学报, Journal of China Pharmaceutical University], V39, P72; Leng F, 2012, SCI CHINA LIFE SCI, V55, P1022; Li GB, 2012, SCI CHINA LIFE SCI, V55, P1022, DOI 10.1007/s11427-012-4397-5; Li S, 2007, IET SYST BIOL, V1, P51, DOI 10.1049/iet-syb:20060032; Li Y, 2008, NEUROCHEM RES, V33, P2070, DOI 10.1007/s11064-008-9686-9; Liang QD, 2006, BIOL PHARM BULL, V29, P1378, DOI 10.1248/bpb.29.1378; [刘立 Liu Li], 2012, [中药药理与临床, Pharmacology and Clinics of Chinese Materia Medica], V28, P2; Liu L, 2012, BIOORG MED CHEM LETT, V22, P154, DOI 10.1016/j.bmcl.2011.11.041; Ma Zeng-chun, 2003, Zhongguo Zhongyao Zazhi, V28, P1050; NARANJO JR, 1991, NEURON, V6, P607, DOI 10.1016/0896-6273(91)90063-6; Narvekar N, 2006, HUM REPROD, V21, P2312, DOI 10.1093/humrep/del182; OHTA H, 1993, PHARMACOL BIOCHEM BE, V45, P719, DOI 10.1016/0091-3057(93)90530-7; Os I, 2002, J INTERN MED, V251, P223, DOI 10.1046/j.1365-2796.2002.00950.x; Prasad TSK, 2009, NUCLEIC ACIDS RES, V37, pD767, DOI 10.1093/nar/gkn892; Seal RL, 2011, NUCLEIC ACIDS RES, V39, pD514, DOI 10.1093/nar/gkq892; Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303; Singh A, 2010, ANTIOXID REDOX SIGN, V13, P1627, DOI 10.1089/ars.2010.3219; Szklarczyk D, 2011, NUCLEIC ACIDS RES, V39, pD561, DOI 10.1093/nar/gkq973; Tian P, 2011, NATURE, V480, pS84, DOI 10.1038/480S84a; Wang L, 2008, P NATL ACAD SCI USA, V105, P4826, DOI 10.1073/pnas.0712365105; Wang L, 2011, INT J PHARMACEUT, V406, P99, DOI 10.1016/j.ijpharm.2011.01.001; Wang ZJ, 2009, J PHARMACEUT BIOMED, V50, P232, DOI 10.1016/j.jpba.2009.04.001; Watanabe Hiroshi, 1998, Journal of Toxicological Sciences, V23, P234; Wen ZN, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018278; Xiao X., 2002, TRADITIONAL CHINESE, V13, P11; Xue RC, 2013, NUCLEIC ACIDS RES, V41, pD1089, DOI 10.1093/nar/gks1100; Yamada Y, 1998, J BONE MINER RES, V13, P1569, DOI 10.1359/jbmr.1998.13.10.1569; Yan Shi-Kai, 2009, Chinese Journal of Natural Medicines, V7, P249, DOI 10.3724/SP.J.1009.2009.00249; Yeh LLL, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000719; Yue G., 2010, WORLD SCI TECHNOLOGY, V12, P211; Zhang B, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/456747; Zhang CB, 2007, PHARM CLIN RES, V15, P459; Zhang HJ, 2004, J PHARMACEUT BIOMED, V34, P705, DOI 10.1016/S0731-7085(03)00650-2; Zhang T, 2000, J BEIJING U TRADIT C, V23, P36; Zhao J, 2010, BRIEF BIOINFORM, V11, P417, DOI 10.1093/bib/bbp063	48	44	49	0	34	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 4	2013	8	11							e72334	10.1371/journal.pone.0072334	http://dx.doi.org/10.1371/journal.pone.0072334			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	245ZC	24223693	Green Submitted, Green Published, gold			2023-01-03	WOS:000326503400001
J	Schmolzer, GM; Kumar, M; Pichler, G; Aziz, K; O'Reilly, M; Cheung, PY				Schmoelzer, Georg M.; Kumar, Manoj; Pichler, Gerhard; Aziz, Khalid; O'Reilly, Megan; Cheung, Po-Yin			Non-invasive versus invasive respiratory support in preterm infants at birth: systematic review and meta-analysis	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CHRONIC LUNG-DISEASE; BRONCHOPULMONARY DYSPLASIA; NASAL CPAP; OXYGEN; RESUSCITATION; INTUBATION; RATES	Objective To assess the role of nasal continuous positive airway pressure (CPAP) initiated at birth for prevention of death and bronchopulmonary dysplasia in very preterm infants. Design Systematic review. Data sources PubMed, Embase, the Cochrane Central Register of Controlled Trials, and online Pediatric Academic Society abstracts from the year of inception to June 2013. Eligibility criteria for selecting studies Randomised controlled trials evaluating the effect of nasal CPAP compared with intubation in preterm infants born at less than 32 weeks' gestation and presenting the outcomes of either death or bronchopulmonary dysplasia, or both (defined as the need for oxygen support or mechanical ventilation at 36 weeks corrected gestation), during hospital stay. Results Four randomised controlled trials (2782 participants) met the inclusion criteria, with 1296 infants in the nasal CPAP group and 1486 in the intubation group. All the trials reported bronchopulmonary dysplasia independently at 36 weeks corrected gestation, with borderline significance in favour of the nasal CPAP group (relative risk 0.91, 95% confidence interval 0.82 to 1.01, risk difference -0.03, 95% confidence interval -0.07 to 0.01). No difference in death was observed (relative risk 0.88, 0.68 to 1.14, risk difference -0.02, -0.04 to 0.01, respectively). Pooled analysis showed a significant benefit for the combined outcome of death or bronchopulmonary dysplasia, or both, at 36 weeks corrected gestation for babies treated with nasal CPAP (relative risk 0.91, 0.84 to 0.99, risk difference -0.04, -0.07 to 0.00), number needed to treat of 25). Conclusion One additional infant could survive to 36 weeks without bronchopulmonary dysplasia for every 25 babies treated with nasal CPAP in the delivery room rather than being intubated.	[Schmoelzer, Georg M.; Kumar, Manoj; Pichler, Gerhard; Aziz, Khalid; O'Reilly, Megan; Cheung, Po-Yin] Univ Alberta, Dept Pediat, Edmonton, AB, Canada; [Schmoelzer, Georg M.; Kumar, Manoj; Pichler, Gerhard; Aziz, Khalid; O'Reilly, Megan; Cheung, Po-Yin] Royal Alexandra Hosp, Neonatal Res Unit, Edmonton, AB, Canada; [Schmoelzer, Georg M.; Pichler, Gerhard] Med Univ, Div Neonatol, Dept Pediat, Graz, Austria	University of Alberta; Royal Alexandra Hospital; Medical University of Graz	Schmolzer, GM (corresponding author), Univ Alberta, Dept Pediat, Edmonton, AB, Canada.	georg.schmoelzer@me.com	Schmölzer, Georg M/E-7883-2010; Cheung, Po-Yin/C-2804-2013	Schmölzer, Georg M/0000-0001-9798-2415; Cheung, Po-Yin/0000-0002-7141-1523; Pichler, Gerhard/0000-0003-2405-7143; Kumar, Manoj/0000-0001-7879-7724				Ammari A, 2005, J PEDIATR-US, V147, P341, DOI 10.1016/j.jpeds.2005.04.062; AVERY ME, 1987, PEDIATRICS, V79, P26; Baraldi E, 2007, NEW ENGL J MED, V357, P1946, DOI 10.1056/NEJMra067279; Davis PG, 2004, LANCET, V364, P1329, DOI 10.1016/S0140-6736(04)17189-4; Dawson JA, 2012, J PEDIATR-US, V160, P158, DOI 10.1016/j.jpeds.2011.07.045; Dawson JA, 2010, PEDIATRICS, V125, pE1340, DOI 10.1542/peds.2009-1510; Doyle LW, 2006, PEDIATRICS, V118, P108, DOI 10.1542/peds.2005-2522; Doyle LW, 2009, SEMIN FETAL NEONAT M, V14, P391, DOI 10.1016/j.siny.2009.08.004; Dunn MS, 2011, PEDIATRICS, V128, pE1069, DOI 10.1542/peds.2010-3848; Finer NN, 2010, NEW ENGL J MED, V362, P1970, DOI 10.1056/NEJMoa0911783; Gagliardi L, 2011, ARCH DIS CHILD-FETAL, V96, pF30, DOI 10.1136/adc.2010.183905; HIGGINS JPT, 2011, COCHRANE HDB SYSTEMA, V0001; Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186; Jobe Alan H., 2001, American Journal of Respiratory and Critical Care Medicine, V163, P1723; Kinsella JP, 2006, LANCET, V367, P1421, DOI 10.1016/S0140-6736(06)68615-7; Lau J, 1997, ANN INTERN MED, V127, P820, DOI 10.7326/0003-4819-127-9-199711010-00008; Moher D, 2007, PLOS MED, V4, P447, DOI 10.1371/journal.pmed.0040078; Morley CJ, 2008, NEW ENGL J MED, V358, P700, DOI 10.1056/NEJMoa072788; Rabi Y, 2006, J PEDIATR-US, V148, P590, DOI 10.1016/j.jpeds.2005.12.047; Sandri F, 2010, PEDIATRICS, V125, pE1402, DOI 10.1542/peds.2009-2131; Schmolzer GM, 2008, J PEDIATR-US, V153, P741, DOI 10.1016/j.jpeds.2008.08.016; Van Marter LJ, 2000, PEDIATRICS, V105, P1194, DOI 10.1542/peds.105.6.1194; Vaucher YE, 2012, NEW ENGL J MED, V367, P2495, DOI 10.1056/NEJMoa1208506; Vento M, 2009, NEONATOLOGY, V95, P286, DOI 10.1159/000178770	24	298	316	0	29	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 17	2013	347								f5980	10.1136/bmj.f5980	http://dx.doi.org/10.1136/bmj.f5980			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	238WP	24136633	Green Published, hybrid			2023-01-03	WOS:000325982700003
J	Rahman, CV; Smith, SJ; Morgan, PS; Langmack, KA; Clarke, PA; Ritchie, AA; Macarthur, DC; Rose, FR; Shakesheff, KM; Grundy, RG; Rahman, R				Rahman, Cheryl V.; Smith, Stuart J.; Morgan, Paul S.; Langmack, Keith A.; Clarke, Phil A.; Ritchie, Alison A.; Macarthur, Donald C.; Rose, Felicity R.; Shakesheff, Kevin M.; Grundy, Richard G.; Rahman, Ruman			Adjuvant Chemotherapy for Brain Tumors Delivered via a Novel Intra-Cavity Moldable Polymer Matrix	PLOS ONE			English	Article							DRUG-DELIVERY; LOCAL-DELIVERY; RADIATION-THERAPY; NANOPARTICLES; BIOCOMPATIBILITY; RELEASE; MICROSPHERES; PACLITAXEL; CANCER; GLIOMA	Introduction: Polymer-based delivery systems offer innovative intra-cavity administration of drugs, with the potential to better target micro-deposits of cancer cells in brain parenchyma beyond the resected cavity. Here we evaluate clinical utility, toxicity and sustained drug release capability of a novel formulation of poly(lactic-co-glycolic acid) (PLGA)/poly(ethylene glycol) (PEG) microparticles. Methods: PLGA/PEG microparticle-based matrices were molded around an ex vivo brain pseudo-resection cavity and analyzed using magnetic resonance imaging and computerized tomography. In vitro toxicity of the polymer was assessed using tumor and endothelial cells and drug release from trichostatin A-, etoposide-and methotrexate-loaded matrices was determined. To verify activity of released agents, tumor cells were seeded onto drug-loaded matrices and viability assessed. Results: PLGA/PEG matrices can be molded around a pseudo-resection cavity wall with no polymer-related artifact on clinical scans. The polymer withstands fractionated radiotherapy, with no disruption of microparticle structure. No toxicity was evident when tumor or endothelial cells were grown on control matrices in vitro. Trichostatin A, etoposide and methotrexate were released from the matrices over a 3-4 week period in vitro and etoposide released over 3 days in vivo, with released agents retaining cytotoxic capabilities. PLGA/PEG microparticle-based matrices molded around a resection cavity wall are distinguishable in clinical scanning modalities. Matrices are non-toxic in vitro suggesting good biocompatibility in vivo. Active trichostatin A, etoposide and methotrexate can be incorporated and released gradually from matrices, with radiotherapy unlikely to interfere with release. Conclusion: The PLGA/PEG delivery system offers an innovative intra-cavity approach to administer chemotherapeutics for improved local control of malignant brain tumors.	[Rahman, Cheryl V.; Rose, Felicity R.; Shakesheff, Kevin M.] Univ Nottingham, Sch Pharm, Div Drug Delivery & Tissue Engn, Nottingham NG7 2RD, England; [Smith, Stuart J.; Grundy, Richard G.; Rahman, Ruman] Univ Nottingham, Childrens Brain Tumor Res Ctr, Sch Clin Sci, Nottingham NG7 2RD, England; [Smith, Stuart J.; Clarke, Phil A.; Ritchie, Alison A.] Univ Nottingham, Div Preclin Oncol, Nottingham NG7 2RD, England; [Morgan, Paul S.; Langmack, Keith A.] Univ Nottingham Hosp, Nottingham NG7 2UH, England; [Macarthur, Donald C.] Univ Nottingham Hosp, Queens Med Ctr, Dept Neurosurg, Nottingham NG7 2UH, England	University of Nottingham; University of Nottingham; University of Nottingham; University of Nottingham; University of Nottingham	Rahman, R (corresponding author), Univ Nottingham, Childrens Brain Tumor Res Ctr, Sch Clin Sci, Nottingham NG7 2RD, England.	ruman.rahman@nottingham.ac.uk	Shakesheff, Kevin/AAR-6603-2021; Rahman, Ruman/FFR-5799-2022; Shakesheff, Kevin/O-6371-2018	Rahman, Ruman/0000-0002-6541-9983; Rose, Felicity/0000-0001-6640-8840; Clarke, Philip/0000-0002-9042-4856; Shakesheff, Kevin/0000-0003-3236-2439; Smith, Stuart/0000-0002-4556-2707; Morgan, Paul/0000-0002-5870-1446	Joseph Foote Foundation; Nottingham Advanced Research Fellowship; Medical Research Council [MC_G0900866] Funding Source: researchfish; MRC [MC_G0900866] Funding Source: UKRI	Joseph Foote Foundation; Nottingham Advanced Research Fellowship; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	This work was supported by the Joseph Foote Foundation and a Nottingham Advanced Research Fellowship. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Anderson JM, 1997, ADV DRUG DELIVER REV, V28, P5, DOI 10.1016/S0169-409X(97)00048-3; Athanasiou KA, 1996, BIOMATERIALS, V17, P93, DOI 10.1016/0142-9612(96)85754-1; Bagley CA, 2007, J NEUROSURG-SPINE, V7, P194, DOI 10.3171/SPI-07/08/194; Bjugstad KB, 2008, CELL TRANSPLANT, V17, P409; Brem H, 1995, J NEURO-ONCOL, V26, P111, DOI 10.1007/BF01060217; Brem H, 2001, J CONTROL RELEASE, V74, P63, DOI 10.1016/S0168-3659(01)00311-X; Brem S, 2007, CANCER CHEMOTH PHARM, V60, P643, DOI 10.1007/s00280-006-0407-2; Dhillon A, 2011, J MATER SCI-MATER M, V22, P2599, DOI 10.1007/s10856-011-4443-z; DOMB AJ, 1995, BIOMATERIALS, V16, P1069, DOI 10.1016/0142-9612(95)98902-Q; Duffner PK, 2004, NEUROLOGIST, V10, P293, DOI 10.1097/01.nrl.0000144287.35993.96; DuValla GA, 2009, ANTI-CANCER DRUG, V20, P89, DOI 10.1097/CAD.0b013e3283222c12; Elstad NL, 2009, ADV DRUG DELIVER REV, V61, P785, DOI 10.1016/j.addr.2009.04.010; Emerich DF, 1999, CELL TRANSPLANT, V8, P47, DOI 10.1177/096368979900800114; Fleming AB, 2002, CLIN PHARMACOKINET, V41, P403, DOI 10.2165/00003088-200241060-00002; Fredenberg S, 2011, INT J PHARMACEUT, V415, P34, DOI 10.1016/j.ijpharm.2011.05.049; Gould TW, 2013, LARYNGOSCOPE; Grundy RG, 2007, LANCET ONCOL, V8, P696, DOI 10.1016/S1470-2045(07)70208-5; Hadjipanayis CG, 2010, CANCER RES, V70, P6303, DOI 10.1158/0008-5472.CAN-10-1022; Higaki M, 2005, ANN RHEUM DIS, V64, P1132, DOI 10.1136/ard.2004.030759; Jang SH, 2003, PHARM RES-DORDR, V20, P1337, DOI 10.1023/A:1025785505977; Kasperczyk J, 2009, INT J PHARMACEUT, V382, P124, DOI 10.1016/j.ijpharm.2009.08.022; Kim S, 2010, BIOMATERIALS, V31, P4157, DOI 10.1016/j.biomaterials.2010.01.139; Langer R, 1998, NATURE, V392, P5; Menei P, 2010, ANN SURG ONCOL, V17, P1740, DOI 10.1245/s10434-010-1081-5; Missirlis D, 2006, EUR J PHARM SCI, V29, P120, DOI 10.1016/j.ejps.2006.06.003; Moses MA, 2003, CANCER CELL, V4, P337, DOI 10.1016/S1535-6108(03)00276-9; Ong BYS, 2009, BIOMATERIALS, V30, P3189, DOI 10.1016/j.biomaterials.2009.02.030; Petri B, 2007, J CONTROL RELEASE, V117, P51, DOI 10.1016/j.jconrel.2006.10.015; Price SJ, 2006, AM J NEURORADIOL, V27, P1969; Rahman C.V., 2012, J TISSUE ENG REGEN M; Rahman CV, 2013, J BIOMED MATER RES B, V101B, P648, DOI 10.1002/jbm.b.32867; Rahman R, 2010, MOL CANCER THER, V9, P2568, DOI 10.1158/1535-7163.MCT-10-0272; Ranganath SH, 2010, BIOMATERIALS, V31, P5199, DOI 10.1016/j.biomaterials.2010.03.002; Ranganath SH, 2009, PHARM RES-DORDR, V26, P2101, DOI 10.1007/s11095-009-9922-2; Stummer W, 2008, NEURO-ONCOLOGY, V10, P1092; Tang BC, 2010, BIOMATERIALS, V31, P339, DOI 10.1016/j.biomaterials.2009.09.033; Trapani A, 2011, AAPS PHARMSCITECH, V12, P1302, DOI 10.1208/s12249-011-9695-x; Tyler B, 2010, J NEUROSURG, V113, P210, DOI 10.3171/2009.11.JNS08162; Urbinati G, 2010, INT J PHARMACEUT, V397, P184, DOI 10.1016/j.ijpharm.2010.06.046; Westphal M, 2003, NEURO-ONCOLOGY, V5, P79, DOI 10.1215/15228517-5-2-79; Wilne S, 2007, LANCET ONCOL, V8, P685, DOI 10.1016/S1470-2045(07)70207-3; Wolff JE, 2010, NEURO-ONCOLOGY, V12, pII89; Wright KD, 2009, CHILD NERV SYST, V25, P1275, DOI 10.1007/s00381-009-0809-7; Zentner GM, 2001, J CONTROL RELEASE, V72, P203, DOI 10.1016/S0168-3659(01)00276-0; Zhang YH, 2011, MED ONCOL, V28, P901, DOI 10.1007/s12032-010-9531-2	45	25	28	1	33	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 14	2013	8	10							e77435	10.1371/journal.pone.0077435	http://dx.doi.org/10.1371/journal.pone.0077435			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	237RD	24155955	Green Accepted, Green Published, gold			2023-01-03	WOS:000325887300089
J	Llor, C; Moragas, A; Bayona, C; Morros, R; Pera, H; Plana-Ripoll, O; Cots, JM; Miravitlles, M				Llor, Carl; Moragas, Ana; Bayona, Carolina; Morros, Rosa; Pera, Helena; Plana-Ripoll, Oleguer; Cots, Josep M.; Miravitlles, Marc			Efficacy of anti-inflammatory or antibiotic treatment in patients with non-complicated acute bronchitis and discoloured sputum: randomised placebo controlled trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							RESPIRATORY-TRACT INFECTIONS; PRIMARY-CARE; ACUTE COUGH; HUMAN METAPNEUMOVIRUS; AMBULATORY CARE; EXACERBATIONS; MANAGEMENT; THERAPY; MANIFESTATIONS; AMOXICILLIN	Objective To evaluate the efficacy of oral anti-inflammatory or antibiotic treatment compared with placebo in the resolution of cough in patients with uncomplicated acute bronchitis and discoloured sputum. Design Multicentre, parallel, single blinded placebo controlled, randomised clinical trial. Setting Nine primary care centres in Spain. Participants Adults aged 18 to 70 presenting symptoms associated with respiratory tract infection of less than one week's duration, with cough as the predominant symptom, the presence of discoloured sputum, and at least one other symptom of lower respiratory tract infection (dyspnoea, wheezing, chest discomfort, or chest pain). Interventions Patients were randomised to receive either ibuprofen 600 mg three times daily, amoxicillin-clavulanic acid 500 mg/125 mg three times daily, or placebo three times daily for 10 days. The duration of symptoms was measured with a diary card. Main outcome measure Number of days with frequent cough after the randomisation visit. Results 416 participants were randomised (136 to ibuprofen, 137 to antibiotic, and 143 to placebo) and 390 returned their symptom diaries fully completed. The median number of days with frequent cough was slightly lower among patients assigned to ibuprofen (9 days, 95% confidence interval 8 to 10 days) compared with those receiving amoxicillin-clavulanic acid (11 days, 10 to 12 days) or placebo (11 days, 8 to 14 days), albeit without statistically significant differences. Neither amoxicillin-clavulanic acid nor ibuprofen increased the probability of cough resolution (hazard ratio 1.03, 95% confidence interval 0.78 to 1.35 and 1.23, 0.93 to 1.61, respectively) compared with placebo. Adverse events were observed in 27 patients, and were more common in the antibiotic arm (12%) than ibuprofen or placebo arms (5% and 3%, respectively; P<0.01). Conclusion No significant differences were observed in the number of days with cough between patients with uncomplicated acute bronchitis and discoloured sputum treated with ibuprofen, amoxicillin-clavulanic acid, or placebo.	[Llor, Carl; Moragas, Ana] Univ Rovira & Virgili, Dept Gen Pathol, Primary Care Ctr Jaume 1, Tarragona 43005, Spain; [Morros, Rosa; Pera, Helena; Plana-Ripoll, Oleguer] Univ Inst Primary Care Res Jordi Gol, Barcelona, Spain; [Bayona, Carolina] Primary Care Ctr Valls Urba, Valls, Tarragona, Spain; [Morros, Rosa] Autonomous Univ Barcelona, Dept Pharmacol & Therapeut, E-08193 Barcelona, Spain; [Plana-Ripoll, Oleguer] Aarhus Univ, Dept Publ Hlth, Sect Epidemiol, DK-8000 Aarhus C, Denmark; [Cots, Josep M.] Univ Barcelona, Primary Care Ctr La Marina, Barcelona, Spain; [Miravitlles, Marc] Hosp Univ Vall dHebron, Serv Pneumol, CIBER Enfermedades Resp, Barcelona, Spain	Universitat Rovira i Virgili; Autonomous University of Barcelona; Aarhus University; University of Barcelona; CIBER - Centro de Investigacion Biomedica en Red; CIBERES; Hospital Universitari Vall d'Hebron	Llor, C (corresponding author), Cardiff Univ, Sch Med, Inst Primary Care & Publ Hlth, Cardiff CF10 3AX, S Glam, Wales.	carles.llor@urv.cat	Plana-Ripoll, Oleguer/E-1448-2015; Miravitlles, Marc/AAH-5284-2019	Plana-Ripoll, Oleguer/0000-0002-6470-7465; Miravitlles, Marc/0000-0002-9850-9520; Moragas Moreno, Ana/0000-0002-1307-0943; Llor, Carl/0000-0001-6644-717X; Morros, Rosa/0000-0001-6752-8748	Instituto de Salud Carlos III (Spanish Ministry of Health) [EC07/90333]	Instituto de Salud Carlos III (Spanish Ministry of Health)(Instituto de Salud Carlos IIISpanish Government)	This clinical trial was supported by a grant from the Instituto de Salud Carlos III (Spanish Ministry of Health) (EC07/90333). The funder had no role in the design, conduct, or analysis of this study.	ANTHONISEN NR, 1987, ANN INTERN MED, V106, P196, DOI 10.7326/0003-4819-106-2-196; Ashworth M, 2005, BRIT J GEN PRACT, V55, P603; Bastien N, 2003, J CLIN MICROBIOL, V41, P4642, DOI 10.1128/JCM.41.10.4642-4646.2003; Becker LA, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001726.pub4; Bent S, 1999, AM J MED, V107, P62, DOI 10.1016/S0002-9343(99)00167-9; Boivin G, 2002, J INFECT DIS, V186, P1330, DOI 10.1086/344319; Butler CC, 2011, EUR RESPIR J, V38, P119, DOI 10.1183/09031936.00133910; Butler CC, 2009, BRIT MED J, V338, DOI 10.1136/bmj.b2242; Centre for Clinical Practice at NICE (UK), 2008, RESP TRACT INF ANT P; Chalmers JD, 2011, BRIT MED J, V343, DOI 10.1136/bmj.d5840; CHOW AW, 1992, CLIN INFECT DIS, V15, pS62, DOI 10.1093/clind/15.Supplement_1.S62; Coenen S, 2006, BRIT J GEN PRACT, V56, P183; Dosh SA, 2000, J FAM PRACTICE, V49, P407; DUNLAY J, 1984, J FAM PRACTICE, V18, P719; El-Gohary M, 2013, FAM PRACT, V30, P492, DOI 10.1093/fampra/cmt034; Fischer Thomas, 2005, BMC Fam Pract, V6, P6, DOI 10.1186/1471-2296-6-6; FRANK A, 1985, RESPIRATION, V48, P122, DOI 10.1159/000194811; Freestone C, 1997, J PHARM PHARMACOL, V49, P1045, DOI 10.1111/j.2042-7158.1997.tb06039.x; Gillissen A, 2007, J PHYSIOL PHARMACOL, V58, P223; Girbino G, 1990, Riv Eur Sci Med Farmacol, V12, P359; Gonzales R, 2001, CLIN INFECT DIS, V33, P757, DOI 10.1086/322627; Gonzales R, 1999, J GEN INTERN MED, V14, P151, DOI 10.1046/j.1525-1497.1999.00306.x; Gonzales R, 1997, JAMA-J AM MED ASSOC, V278, P901, DOI 10.1001/jama.278.11.901; Goossens H, 2005, LANCET, V365, P579, DOI 10.1016/S0140-6736(05)17907-0; GRAMBSCH PM, 1994, BIOMETRIKA, V81, P515; Gwaltney JM, 2002, J INFECT DIS, V186, P147, DOI 10.1086/341455; HUMMERSPRADIER E, 1999, EUR J GEN PRACT, V5, P15; Johnstone KJ, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009305.pub2; Kicska G, 2003, CLIN NUCL MED, V28, P511, DOI 10.1097/00003072-200306000-00017; Kim SY, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006362.pub2; Linder JA, 2008, CLIN INFECT DIS, V47, P744, DOI 10.1086/591149; Little P, 2013, LANCET INFECT DIS, V13, P123, DOI 10.1016/S1473-3099(12)70300-6; Llor C, 2012, AM J RESP CRIT CARE, V186, P716, DOI 10.1164/rccm.201206-0996OC; Llor C, 2011, BMC PULM MED, V11, DOI 10.1186/1471-2466-11-38; Macfarlane J, 2001, THORAX, V56, P109, DOI 10.1136/thorax.56.2.109; Macfarlane JT, 2008, MED HIST, V52, P47, DOI 10.1017/S0025727300000156; Mainous AG, 1996, ARCH FAM MED, V5, P79, DOI 10.1001/archfami.5.2.79; Miravitlles M, 2008, ARCH BRONCONEUMOL, V44, P100, DOI 10.1016/S1579-2129(08)60013-0; Miravitlles M, 2012, EUR RESPIR J, V39, P1354, DOI 10.1183/09031936.00042111; Moragas A, 2012, ARCH BRONCONEUMOL, V48, P261, DOI 10.1016/j.arbres.2012.02.006; Nduba VN, 2008, THORAX, V63, P999, DOI 10.1136/thx.2008.097311; Ponsioen BP, 2005, EUR RESPIR J, V25, P147, DOI 10.1183/09031936.04.00053604; Pornsuriyasak P, 2005, RESPIROLOGY, V10, P520, DOI 10.1111/j.1440-1843.2005.00732.x; Raherison C, 2003, RESP MED, V97, P995, DOI 10.1016/S0954-6111(03)00030-1; REINER M, 1983, CURR MED RES OPIN, V8, P487, DOI 10.1185/03007998309109787; Sevilla-Sanchez D, 2010, ARCH BRONCONEUMOL, V46, P244, DOI 10.1016/j.arbres.2009.10.008; Smith SM, 2012, COCHRANE DB SYST REV; Smith SM, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001831.pub4; Snow V, 2001, ANN INTERN MED, V134, P518, DOI 10.7326/0003-4819-134-6-200103200-00020; Stanton N, 2010, EUR RESPIR J, V35, P761, DOI 10.1183/09031936.00168409; STOTT NCH, 1976, BRIT MED J, V2, P556, DOI 10.1136/bmj.2.6035.556; Woodhead M, 2011, CLIN MICROBIOL INFEC, V17, pE1, DOI 10.1111/j.1469-0691.2011.03672.x	52	28	31	0	9	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 4	2013	347								f5762	10.1136/bmj.f5762	http://dx.doi.org/10.1136/bmj.f5762			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	231PN	24097128	hybrid, Green Published			2023-01-03	WOS:000325429300001
J	Krais, JJ; De Crescenzo, O; Harrison, RG				Krais, John J.; De Crescenzo, Olivier; Harrison, Roger G.			Purine Nucleoside Phosphorylase Targeted by Annexin V to Breast Cancer Vasculature for Enzyme Prodrug Therapy	PLOS ONE			English	Article							FLUDARABINE PHOSPHATE; ANIONIC PHOSPHOLIPIDS; TUMOR-CELLS; IN-VIVO; GENE-THERAPY; GROWTH; PHOSPHATIDYLSERINE; MALIGNANCIES; SUPPRESSES; METABOLISM	Background and Purpose: The targeting of therapeutics is a promising approach for the development of new cancer treatments that seek to reduce the devastating side effects caused by the systemic administration of current drugs. This study evaluates a fusion protein developed as an enzyme prodrug therapy targeted to the tumor vasculature. Cytotoxicity would be localized to the site of the tumor using a protein fusion of purine nucleoside phosphorylase (PNP) and annexin V. Annexin V acts as the tumor-targeting component of the fusion protein as it has been shown to bind to phosphatidylserine expressed externally on cancer cells and the endothelial cells of the tumor vasculature, but not normal vascular endothelial cells. The enzymatic component of the fusion, PNP, converts the FDA-approved cancer therapeutic, fludarabine, into a more cytotoxic form. The purpose of this study is to determine if this system has a good potential as a targeted therapy for breast cancer. Methods: A fusion of E. coli purine nucleoside phosphorylase and human annexin V was produced in E. coli and purified. Using human breast cancer cell lines MCF-7 and MDA-MB-231 and non-confluent human endothelial cells grown in vitro, the binding strength of the fusion protein and the cytotoxicity of the enzyme prodrug system were determined. Endothelial cells that are not confluent expose phosphatidylserine and therefore mimic the tumor vasculature. Results: The purified recombinant fusion protein had good enzymatic activity and strong binding to the three cell lines. There was significant cell killing (p < 0.001) by the enzyme prodrug treatment for all three cell lines, with greater than 80% cytotoxicity obtained after 6 days of treatment. Conclusion: These results suggest that this treatment could be useful as a targeted therapy for breast cancer.	[Krais, John J.; De Crescenzo, Olivier; Harrison, Roger G.] Univ Oklahoma, Ctr Bioengn, Norman, OK 73019 USA; [Krais, John J.; De Crescenzo, Olivier; Harrison, Roger G.] Univ Oklahoma, Sch Chem Biol & Mat Engn, Norman, OK 73019 USA; [Harrison, Roger G.] Univ Oklahoma, Hlth Sci Ctr, Stephenson Canc Ctr, Oklahoma City, OK USA	University of Oklahoma System; University of Oklahoma - Norman; University of Oklahoma System; University of Oklahoma - Norman; University of Oklahoma System; University of Oklahoma Health Sciences Center	Harrison, RG (corresponding author), Univ Oklahoma, Ctr Bioengn, Norman, OK 73019 USA.	rharrison@ou.edu		Krais, John/0000-0002-3916-3435	Oklahoma Center for the Advancement of Science and Technology Health Research Program [HR11-210]; School of Chemical, Biological and Materials Engineering at the University of Oklahoma	Oklahoma Center for the Advancement of Science and Technology Health Research Program; School of Chemical, Biological and Materials Engineering at the University of Oklahoma	This study was supported by a grant from the Oklahoma Center for the Advancement of Science and Technology Health Research Program (grant number HR11-210; www.ok.gov/ocast) and by funding from the School of Chemical, Biological and Materials Engineering at the University of Oklahoma (www.cbme.ou.edu). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Afshar S, 2009, MOL CANCER THER, V8, P185, DOI 10.1158/1535-7163.MCT-08-0652; Boogaerts MA, 2004, HEMATOL J, V5, pS31, DOI 10.1038/sj.thj.6200389; CASPER ES, 1985, CANCER CHEMOTH PHARM, V15, P233; Chan N, 2011, BLOOD BRAIN BARRIER, V686; DANHAUSER L, 1986, CANCER CHEMOTH PHARM, V18, P145; Ding XY, 2008, EXPERT REV OPHTHALMO, V3, P97, DOI 10.1586/17469899.3.1.97; HERSHFIELD MS, 1991, P NATL ACAD SCI USA, V88, P7185, DOI 10.1073/pnas.88.16.7185; Hong JS, 2004, CANCER RES, V64, P6610, DOI 10.1158/0008-5472.CAN-04-0012; Kikuchi E, 2007, CANCER GENE THER, V14, P279, DOI 10.1038/sj.cgt.7701013; Koellner G, 2002, J MOL BIOL, V315, P351, DOI 10.1006/jmbi.2001.5211; Kremmidiotis G, 2010, MOL CANCER THER, V9, P1562, DOI 10.1158/1535-7163.MCT-09-0815; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee J, 2001, PROTEIN EXPRES PURIF, V22, P180, DOI 10.1006/prep.2001.1437; LEVELT CN, 1994, CYTOMETRY, V15, P84, DOI 10.1002/cyto.990150114; Mao C, 1997, STRUCTURE, V5, P1373, DOI 10.1016/S0969-2126(97)00287-6; Martiniello-Wilks R, 2004, J GENE MED, V6, P1343, DOI 10.1002/jgm.629; Mikleusevic G, 2011, BIOCHIMIE, V93, P1610, DOI 10.1016/j.biochi.2011.05.030; MITTELMAN A, 1988, CANCER CHEMOTH PHARM, V22, P63; Modrak-Wojcik A, 2006, PROTEIN SCI, V15, P1794, DOI 10.1110/ps.062183206; Mohr L, 2000, HEPATOLOGY, V31, P606, DOI 10.1002/hep.510310310; MONTGOMERY JA, 1969, J MED CHEM, V12, P498, DOI 10.1021/jm00303a605; O'Brien J, 2000, EUR J BIOCHEM, V267, P5421, DOI 10.1046/j.1432-1327.2000.01606.x; Parker WB, 1998, BIOCHEM PHARMACOL, V55, P1673, DOI 10.1016/S0006-2952(98)00034-3; Parker WB, 1997, HUM GENE THER, V8, P1637, DOI 10.1089/hum.1997.8.14-1637; Pierige F, 2010, INT J ONCOL, V37, P133, DOI 10.3892/ijo_00000661; Ran S, 2005, CLIN CANCER RES, V11, P1551, DOI 10.1158/1078-0432.CCR-04-1645; Ran S, 2002, CANCER RES, V62, P6132; Riedl S, 2011, BBA-BIOMEMBRANES, V1808, P2638, DOI 10.1016/j.bbamem.2011.07.026; Sigma, 1994, ENZ ASS NUCL PHOSPH; SUGIMURA M, 1994, BLOOD COAGUL FIBRIN, V5, P365; UTSUGI T, 1991, CANCER RES, V51, P3062; Van Den Neste E, 2005, INT J ONCOL, V27, P1113; Van Rite BD, 2011, CANCER LETT, V307, P53, DOI 10.1016/j.canlet.2011.03.016; Van Rite BD, 2011, CANCER LETT, V301, P177, DOI 10.1016/j.canlet.2010.11.013; VONHOFF DD, 1990, SEMIN ONCOL, V17, P33; Xie X, 2011, J GENE MED; Zang XP, 2006, ANTICANCER RES, V26, P1745	37	14	16	2	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 3	2013	8	10							e76403	10.1371/journal.pone.0076403	http://dx.doi.org/10.1371/journal.pone.0076403			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	232HM	24098491	gold, Green Published, Green Submitted			2023-01-03	WOS:000325483600043
J	Alves, CRR; Merege, CAA; Benatti, FB; Brucki, S; Pereira, RMR; Pinto, ALD; Lima, FR; Roschel, H; Gualano, B				Rodrigues Alves, Christiano Robles; Abujabra Merege Filho, Carlos Alberto; Benatti, Fabiana Braga; Brucki, Sonia; Pereira, Rosa Maria R.; de Sa Pinto, Ana Lucia; Lima, Fernanda Rodrigues; Roschel, Hamilton; Gualano, Bruno			Creatine Supplementation Associated or Not with Strength Training upon Emotional and Cognitive Measures in Older Women: A Randomized Double-Blind Study	PLOS ONE			English	Article							MINI-MENTAL-STATE; PHYSICAL-ACTIVITY; ORAL SUPPLEMENTATION; HUMAN BRAIN; EXERCISE; PERFORMANCE; MONOHYDRATE; DEPRESSION; STRESS; MOOD	Purpose: To assess the effects of creatine supplementation, associated or not with strength training, upon emotional and cognitive measures in older woman. Methods: This is a 24-week, parallel-group, double-blind, randomized, placebo-controlled trial. The individuals were randomly allocated into one of the following groups (n=14 each): 1) placebo, 2) creatine supplementation, 3) placebo associated with strength training or 4) creatine supplementation associated with strength training. According to their allocation, the participants were given creatine (4 x 5 g/d for 5 days followed by 5 g/d) or placebo (dextrose at the same dosage) and were strength trained or not. Cognitive function, assessed by a comprehensive battery of tests involving memory, selective attention, and inhibitory control, and emotional measures, assessed by the Geriatric Depression Scale, were evaluated at baseline, after 12 and 24 weeks of the intervention. Muscle strength and food intake were evaluated at baseline and after 24 weeks. Results: After the 24-week intervention, both training groups (ingesting creatine supplementation and placebo) had significant reductions on the Geriatric Depression Scale scores when compared with the non-trained placebo group (p = 0.001 and p = 0.01, respectively) and the non-trained creatine group (p < 0.001 for both comparison). However, no significant differences were observed between the non-trained placebo and creatine (p = 0.60) groups, or between the trained placebo and creatine groups (p = 0.83). Both trained groups, irrespective of creatine supplementation, had better muscle strength performance than the non-trained groups. Neither strength training nor creatine supplementation altered any parameter of cognitive performance. Food intake remained unchanged. Conclusion: Creatine supplementation did not promote any significant change in cognitive function and emotional parameters in apparently healthy older individuals. In addition, strength training per se improved emotional state and muscle strength, but not cognition, with no additive effects of creatine supplementation.	[Rodrigues Alves, Christiano Robles; Roschel, Hamilton; Gualano, Bruno] Univ Sao Paulo, Sch Phys Educ & Sport, Sao Paulo, Brazil; [Abujabra Merege Filho, Carlos Alberto; Benatti, Fabiana Braga; Brucki, Sonia; Pereira, Rosa Maria R.; de Sa Pinto, Ana Lucia; Lima, Fernanda Rodrigues; Roschel, Hamilton; Gualano, Bruno] Univ Sao Paulo, Sch Med, Sao Paulo, Brazil	Universidade de Sao Paulo; Universidade de Sao Paulo	Gualano, B (corresponding author), Univ Sao Paulo, Sch Phys Educ & Sport, Sao Paulo, Brazil.	gualano@usp.br	Gualano, Bruno/C-7190-2012; Brucki, Sonia/L-4201-2019; Roschel, Hamilton/D-4353-2012; Alves, Christiano RR/C-5912-2013; Brucki, Sonia MD/B-5736-2014; Gualano, Bruno/ABA-9571-2020; Pereira, Rosa M R/C-5192-2012; Benatti, Fabiana/H-7167-2016	Gualano, Bruno/0000-0001-7100-8681; Brucki, Sonia/0000-0002-8303-6732; Roschel, Hamilton/0000-0002-9513-6132; Alves, Christiano RR/0000-0002-2646-9689; Brucki, Sonia MD/0000-0002-8303-6732; Gualano, Bruno/0000-0001-7100-8681; Pereira, Rosa M R/0000-0002-3723-5028; Benatti, Fabiana/0000-0002-8320-7044	Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq); Fundacao de Amparo a Pesquisa do Estado de Sao Paulo	Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq)(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); Fundacao de Amparo a Pesquisa do Estado de Sao Paulo(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP))	The authors received support from Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq) and Fundacao de Amparo a Pesquisa do Estado de Sao Paulo. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	AGREN H, 1988, J NEURAL TRANSM, V74, P55, DOI 10.1007/BF01243575; ALMEIDA OP, 2003, ARQ NEURO-PSIQUIAT, V57, P421; Amital D, 2006, J CLIN PSYCHIAT, V67, P836, DOI 10.4088/JCP.v67n0521c; Andres RH, 2008, BRAIN RES BULL, V76, P329, DOI 10.1016/j.brainresbull.2008.02.035; Arbuthnott K, 2000, J CLIN EXP NEUROPSYC, V22, P518, DOI 10.1076/1380-3395(200008)22:4;1-0;FT518; BENTON D, 2010, BJ NUTR, V105, P1; Brucki SMD, 2003, ARQ NEURO-PSIQUIAT, V61, P777, DOI 10.1590/S0004-282X2003000500014; Burroughs S., 2007, CURRENT ANAESTHESIA, V18, P4, DOI [10.1016/j.cacc.2007.01.007, DOI 10.1016/J.CACC.2007.01.007]; Cassilhas RC, 2007, MED SCI SPORT EXER, V39, P1401, DOI 10.1249/mss.0b013e318060111f; Cassilhas RC, 2010, PERCEPT MOTOR SKILL, V110, P265, DOI 10.2466/PMS.110.1.265-276; Colcombe S, 2003, PSYCHOL SCI, V14, P125, DOI 10.1111/1467-9280.t01-1-01430; CRONHOLM B, 1956, Nord Med, V56, P1612; Czeh B, 2001, P NATL ACAD SCI USA, V98, P12796, DOI 10.1073/pnas.211427898; Dechent P, 1999, AM J PHYSIOL-REG I, V277, pR698, DOI 10.1152/ajpregu.1999.277.3.R698; Dechent P, 1999, BIOL PSYCHIAT, V46, P406, DOI 10.1016/S0006-3223(98)00346-1; Duman RS, 1999, BIOL PSYCHIAT, V46, P1181, DOI 10.1016/S0006-3223(99)00177-8; Etnier JL, 2006, BRAIN RES REV, V52, P119, DOI 10.1016/j.brainresrev.2006.01.002; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Gabbay V, 2007, AM J PSYCHIAT, V164, P1881, DOI 10.1176/appi.ajp.2007.06122032; Heyn P, 2004, ARCH PHYS MED REHAB, V85, P1694, DOI 10.1016/j.apmr.2004.03.019; Hillman CH, 2008, NAT REV NEUROSCI, V9, P58, DOI 10.1038/nrn2298; Iosifescu DV, 2008, BIOL PSYCHIAT, V63, P1127, DOI 10.1016/j.biopsych.2007.11.020; Kaldis P, 1996, DEV NEUROSCI-BASEL, V18, P542, DOI 10.1159/000111452; Kalia M, 2005, METABOLISM, V54, P24, DOI 10.1016/j.metabol.2005.01.009; KATO T, 1994, J AFFECT DISORDERS, V31, P125, DOI 10.1016/0165-0327(94)90116-3; Larson EB, 2006, ANN INTERN MED, V144, P73, DOI 10.7326/0003-4819-144-2-200601170-00004; Lautenschlager NT, 2008, JAMA-J AM MED ASSOC, V300, P1027, DOI 10.1001/jama.300.9.1027; Liu-Ambrose T, 2010, ARCH INTERN MED, V170, P170, DOI 10.1001/archinternmed.2009.494; Lyoo IK, 2003, PSYCHIAT RES-NEUROIM, V123, P87, DOI 10.1016/S0925-4927(03)00046-5; Manji HK, 2000, MOL PSYCHIATR, V5, P578, DOI 10.1038/sj.mp.4000811; Manji HK, 2001, NAT MED, V7, P541, DOI 10.1038/87865; McEwen BS, 2005, METABOLISM, V54, P20, DOI 10.1016/j.metabol.2005.01.008; McMorris T, 2007, PHYSIOL BEHAV, V90, P21, DOI 10.1016/j.physbeh.2006.08.024; McMorris T, 2007, AGING NEUROPSYCHOL C, V14, P517, DOI 10.1080/13825580600788100; Moore CM, 1997, AM J PSYCHIAT, V154, P116; Moretti A, 2003, MOL PSYCHIATR, V8, P773, DOI 10.1038/sj.mp.4001353; Nitrini R, 2004, J INT NEUROPSYCH SOC, V10, P634, DOI 10.1017/S1355617704104062; Parkin AJ, 1999, NEUROPSYCHOLOGY, V13, P539, DOI 10.1037/0894-4105.13.4.539; Perrig-Chiello P, 1998, AGE AGEING, V27, P469, DOI 10.1093/ageing/27.4.469; Rae C, 2003, P ROY SOC B-BIOL SCI, V270, P2147, DOI 10.1098/rspb.2003.2492; Rawson ES, 2011, AMINO ACIDS, V40, P1349, DOI 10.1007/s00726-011-0855-9; Roitman S, 2007, BIPOLAR DISORD, V9, P754, DOI 10.1111/j.1399-5618.2007.00532.x; Salomons GS, 2003, J INHERIT METAB DIS, V26, P309, DOI 10.1023/A:1024405821638; Sofi F, 2011, J INTERN MED, V269, P107, DOI 10.1111/j.1365-2796.2010.02281.x; SPIRDUSO WW, 1975, J GERONTOL, V30, P435, DOI 10.1093/geronj/30.4.435; Spreen O., 1998, COMPENDIUM NEUROPSYC, Vsecond; Stockler S, 1996, LANCET, V348, P789, DOI 10.1016/S0140-6736(96)04116-5; van Gool CH, 2007, AM J PUBLIC HEALTH, V97, P2121, DOI [10.2105/AJPH.2004.053199, 10.2105/AJPH.2004.053199e]; van Gool CH, 2003, AGE AGEING, V32, P81, DOI 10.1093/ageing/32.1.81; Watanabe A, 2002, NEUROSCI RES, V42, P279, DOI 10.1016/S0168-0102(02)00007-X; Wyss M, 2000, PHYSIOL REV, V80, P1107, DOI 10.1152/physrev.2000.80.3.1107	51	36	38	5	27	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 3	2013	8	10							e76301	10.1371/journal.pone.0076301	http://dx.doi.org/10.1371/journal.pone.0076301			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	232HM	24098469	Green Published, gold, Green Submitted			2023-01-03	WOS:000325483600037
J	Li, Y; Li, J; Li, Y; Wang, XX; Cao, AC				Li, Yan; Li, Jun; Li, Yuan; Wang, Xia-xia; Cao, Ao-cheng			Antimicrobial Constituents of the Leaves of Mikania micrantha H. B. K.	PLOS ONE			English	Article							OCCURRING TERPENE DERIVATIVES; SESQUITERPENE LACTONES; PHENOLIC CONSTITUENTS; SCANDENOLIDE	Background: To isolate plant-derived compounds with antimicrobial activity from the leaves of Mikania micrantha, to determine the compounds configuration, and to evaluate their antimicrobial activity against eight plant pathogenic fungi (Exserohilum turcicum, Colletotrichum lagenarium, Pseudoperonispora cubensis, Botrytis cirerea, Rhizoctonia solani, Phytophthora parasitica, Fusarium solani, and Pythium aphanidermatum,) and four plant pathogenic bacteria (gram negative bacteria: Ralstonia dolaanacearum, Xanthomonas oryzae pv. Oryzae, Xanthomonas Campestris pv. Vesicatoria, and Xanthomonas campestris pv. Citri), and four bacteria (gram positive bacteria: Staphyloccocus aureus, Bacillus subtilis, Micrococcus luteus, and Bacillus cereus). Methods and Results: Antimicrobial constituents of the leaves of M. micrantha were isolated using bioactivity-guided fractionation. The antifungal activity of the isolated compounds was evaluated by the inhibit hypha growth method and inhibit spore germination method. Characterization of antibacterial activity was carried out using the minimum inhibitory concentrations (MICs) and the minimum bactericidal concentrations (MBCs). MIC and MBC were determined by the broth microdilution method. Six compounds - deoxymikanolide, scandenolide, dihydroscandenolide, mikanolide, dihydromikanolide, and m - methoxy benzoic acid - have been isolated from leaves of Mikania micrantha H. B. K. Deoxymikanolide, scandenolide, and dihydroscandenolide were new compounds. The result of bioassay showed that all of isolated compounds were effective against tested strains and deoxymikanolide showed the strongest activity. Conclusions and Significance: The leaves of M. micrantha may be a promising source in the search for new antimicrobial drugs due to its efficacy and the broadest range. Meanwhile, adverse impact of M. micrantha will be eliminated.	[Li, Yan; Li, Jun; Li, Yuan; Cao, Ao-cheng] Chinese Acad Agr Sci, Inst Plant Protect, Beijing 100193, Peoples R China; [Li, Jun] South China Agr Univ, Coll Resources & Environm, Guangzhou, Guangdong, Peoples R China; [Wang, Xia-xia] Anhui Acad Agr Sci, Inst Anim Sci, Hefei, Peoples R China	Chinese Academy of Agricultural Sciences; Institute of Plant Protection, CAAS; South China Agricultural University; Anhui Academy of Agricultural Sciences	Cao, AC (corresponding author), Chinese Acad Agr Sci, Inst Plant Protect, Beijing 100193, Peoples R China.	caoac@vip.sina.com			Study of Invasive Plants Comprehensive Prevention [201103027]; Research of Chemistry Prevention and Control Technology [1610142012012]	Study of Invasive Plants Comprehensive Prevention; Research of Chemistry Prevention and Control Technology	Thanks are due to the Study of Invasive Plants Comprehensive Prevention (201103027) and the Research of Chemistry Prevention and Control Technology about Mikania micrantha (1610142012012) for its financial support to the present research. The funders had no role in study design, data collection and analysis, decision to publishi, or preparation of the manuscript.	Ahmed M, 2001, FITOTERAPIA, V72, P919, DOI 10.1016/S0367-326X(01)00318-5; [Anonymous], 1997, M7A4 NCCLS; Ayensu E. S., 1981, MED PLANTS W INDIES; Bakir M, 2004, ACTA CRYSTALLOGR C, V60, pO798, DOI 10.1107/S0108270104017809; BOEKER R, 1987, PLANTA MED, P105, DOI 10.1055/s-2006-962638; BOHLMANN F, 1984, PHYTOCHEMISTRY, V23, P1099, DOI 10.1016/S0031-9422(00)82617-5; BOHLMANN F, 1982, PHYTOCHEMISTRY, V21, P1349, DOI 10.1016/0031-9422(82)80140-4; BOHLMANN F, 1982, PHYTOCHEMISTRY, V21, P173, DOI 10.1016/0031-9422(82)80037-X; CUENCA MD, 1988, J NAT PROD, V51, P625, DOI 10.1021/np50057a040; Dolomanov OV, 2009, J APPL CRYSTALLOGR, V42, P339, DOI 10.1107/S0021889808042726; Facey PC, 1999, J PHARM PHARMACOL, V51, P1455, DOI 10.1211/0022357991777119; Feng Hui-ling, 2002, Journal of Tropical and Subtropical Botany, V10, P263; Francis JS, 2005, CLIN INFECT DIS, V40, P100, DOI 10.1086/427148; GUTIERREZ AB, 1985, PHYTOCHEMISTRY, V24, P2967, DOI 10.1016/0031-9422(85)80037-6; HERZ W, 1970, J ORG CHEM, V35, P1453, DOI 10.1021/jo00830a043; HERZ W, 1975, PHYTOCHEMISTRY, V14, P233, DOI 10.1016/0031-9422(75)85045-X; HERZ W, 1981, PHYTOCHEMISTRY, V20, P1740, DOI 10.1016/S0031-9422(00)98568-6; Huang HJ, 2008, BIOCHEM SYST ECOL, V36, P867, DOI 10.1016/j.bse.2008.09.004; Jiang RW, 2001, CHEM PHARM BULL, V49, P1166, DOI 10.1248/cpb.49.1166; Kruszewska D, 2004, J ANTIMICROB CHEMOTH, V54, P648, DOI 10.1093/jac/dkh387; Li Yan, 2013, African Journal of Microbiology Research, V7, P2409; Lowe S, 2001, 100 WORLDS WORST INV; MATHUR SB, 1973, PHYTOCHEMISTRY, V12, P226, DOI 10.1016/S0031-9422(00)84663-4; NCCLS, 1999, METHODS DETERMINING; NICOLLIER G, 1981, PHYTOCHEMISTRY, V20, P2587, DOI 10.1016/0031-9422(81)83102-0; Palatinus L, 2007, J APPL CRYSTALLOGR, V40, P786, DOI 10.1107/S0021889807029238; PICMAN AK, 1986, BIOCHEM SYST ECOL, V14, P255, DOI 10.1016/0305-1978(86)90101-8; Sheldrick GM, 2008, ACTA CRYSTALLOGR A, V64, P112, DOI 10.1107/S0108767307043930; Valdes DA, 1998, BIOCHEM SYST ECOL, V26, P685, DOI 10.1016/S0305-1978(98)00026-X; Wang RL, 2009, ALLELOPATHY J, V24, P35; Wei XY, 2004, BIOCHEM SYST ECOL, V32, P1091, DOI 10.1016/j.bse.2004.04.013; YSRAEL MC, 1990, PLANTA MED, V56, P268, DOI 10.1055/s-2006-960953; Zhuang ShiHong, 2010, Journal of Zhejiang University (Agriculture and Life Sciences), V36, P293	33	13	14	2	55	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 2	2013	8	10							e76725	10.1371/journal.pone.0076725	http://dx.doi.org/10.1371/journal.pone.0076725			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	231RG	24098556	gold, Green Published, Green Submitted			2023-01-03	WOS:000325434500084
J	Brownlow, ML; Benner, L; D'Agostino, D; Gordon, MN; Morgan, D				Brownlow, Milene L.; Benner, Leif; D'Agostino, Dominic; Gordon, Marcia N.; Morgan, Dave			Ketogenic Diet Improves Motor Performance but Not Cognition in Two Mouse Models of Alzheimer's Pathology	PLOS ONE			English	Article							FRONTOTEMPORAL DEMENTIA; ENERGY-METABOLISM; BRAIN METABOLISM; MEMORY DEFICITS; DISEASE; DECLINE; KETONES; PROTEIN	Dietary manipulations are increasingly viewed as possible approaches to treating neurodegenerative diseases. Previous studies suggest that Alzheimer's disease (AD) patients present an energy imbalance with brain hypometabolism and mitochondrial deficits. Ketogenic diets (KDs), widely investigated in the treatment and prevention of seizures, have been suggested to bypass metabolic deficits present in AD brain by providing ketone bodies as an alternative fuel to neurons. We investigated the effects of a ketogenic diet in two transgenic mouse lines. Five months old APP/PS1 (a model of amyloid deposition) and Tg4510 (a model of tau deposition) mice were offered either a ketogenic or a control (NIH-31) diet for 3 months. Body weight and food intake were monitored throughout the experiment, and blood was collected at 4 weeks and 4 months for ketone and glucose assessments. Both lines of transgenic mice weighed less than nontransgenic mice, yet, surprisingly, had elevated food intake. The ketogenic diet did not affect these differences in body weight or food consumption. Behavioral testing during the last two weeks of treatment found that mice offered KD performed significantly better on the rotarod compared to mice on the control diet independent of genotype. In the open field test, both transgenic mouse lines presented increased locomotor activity compared to nontransgenic, age-matched controls, and this effect was not influenced by KD. The radial arm water maze identified learning deficits in both transgenic lines with no significant differences between diets. Tissue measures of amyloid, tau, astroglial and microglial markers in transgenic lines showed no differences between animals fed the control or the ketogenic diet. These data suggest that ketogenic diets may play an important role in enhancing motor performance in mice, but have minimal impact on the phenotype of murine models of amyloid or tau deposition.	[Brownlow, Milene L.; D'Agostino, Dominic; Gordon, Marcia N.; Morgan, Dave] Univ S Florida, Coll Med, Dept Mol Pharmacol & Physiol, Tampa, FL 33620 USA; [Brownlow, Milene L.; Benner, Leif; Gordon, Marcia N.; Morgan, Dave] USF Hlth Byrd Alzheimers Inst, Tampa, FL USA	State University System of Florida; University of South Florida; State University System of Florida; University of South Florida	Morgan, D (corresponding author), Univ S Florida, Coll Med, Dept Mol Pharmacol & Physiol, Tampa, FL 33620 USA.	scientist.dave@gmail.com	D'Agostino, Dominic/GPJ-9744-2022; Brownlow, Milene/ABC-1063-2020; Morgan, David G/J-5989-2012	Brownlow, Milene/0000-0002-5804-6445	 [IIRG-10-174448]		This research was supported by: IIRG-10-174448. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alamed J, 2006, NAT PROTOC, V1, P1671, DOI 10.1038/nprot.2006.275; ANISMAN H, 1975, PSYCHOL REV, V82, P359; BECKETT TL, 2013, BRAIN RES; Blass JP, 2001, J NEUROSCI RES, V66, P851, DOI 10.1002/jnr.10087; Blass JP, 2000, ANN NY ACAD SCI, V903, P204, DOI 10.1111/j.1749-6632.2000.tb06370.x; Bolognani F, 2007, NEUROBIOL LEARN MEM, V87, P635, DOI 10.1016/j.nlm.2006.11.004; Bough K, 2008, EPILEPSIA, V49, P91, DOI 10.1111/j.1528-1167.2008.01846.x; Bough KJ, 2007, EPILEPSIA, V48, P43, DOI 10.1111/j.1528-1167.2007.00915.x; Caraballo Roberto H, 2012, Handb Clin Neurol, V108, P783, DOI 10.1016/B978-0-444-52899-5.00027-7; Costantini LC, 2008, BMC NEUROSCI, V9, DOI 10.1186/1471-2202-9-S2-S16; Dickey C, 2009, AM J PATHOL, V174, P228, DOI 10.2353/ajpath.2009.080764; Diehl J, 2004, NEUROBIOL AGING, V25, P1051, DOI 10.1016/j.neurobiolaging.2003.10.007; Diehl-Schmid J, 2007, NEUROBIOL AGING, V28, P42, DOI 10.1016/j.neurobiolaging.2005.11.002; FOSTER NL, 1983, NEUROLOGY, V33, P961, DOI 10.1212/WNL.33.8.961; Freeman JM, 2007, PEDIATRICS, V119, P535, DOI 10.1542/peds.2006-2447; Gordon MN, 2002, EXP NEUROL, V173, P183, DOI 10.1006/exnr.2001.7754; HAMMAMI MM, 1997, ANN SAUDI MED, V17, P264; Holcomb L, 1998, NAT MED, V4, P97, DOI 10.1038/nm0198-097; KASHIWAYA Y, 2012, NEUROBIOL AGING; Kim Do Y, 2012, PLOS ONE, V7, DOI DOI 10.1371/J0URNAL.P0NE.0035476.PUBMED:22567104; Knight EM, 2012, NEUROBIOL AGING, V33, P187, DOI 10.1016/j.neurobiolaging.2010.02.003; Krikorian R, 2012, NEUROBIOL AGING, V33, DOI 10.1016/j.neurobiolaging.2010.10.006; LaManna JC, 2009, ADV EXP MED BIOL, V645, P301, DOI 10.1007/978-0-387-85998-9_45; Lee DC, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-56; Liu YMC, 2008, EPILEPSIA, V49, P33, DOI 10.1111/j.1528-1167.2008.01830.x; Mohamed HE, 2010, J CLIN NEUROSCI, V17, P899, DOI 10.1016/j.jocn.2009.11.005; Morgan D, 2008, BEHAV NEUROSCI, V122, P730, DOI 10.1037/0735-7044.122.3.730; Morris M, 2013, NEUROBIOL AGING, V34, P1523, DOI 10.1016/j.neurobiolaging.2012.12.003; Mosconi L, 2008, NEUROBIOL AGING, V29, P676, DOI 10.1016/j.neurobiolaging.2006.12.008; NASH KR, 2013, NEUROBIOL AGING; Noh HS, 2003, EPILEPSY RES, V53, P119, DOI 10.1016/S0920-1211(02)00262-0; Paoli A, 2012, J INT SOC SPORT NUTR, V9, DOI 10.1186/1550-2783-9-34; Patel NV, 2005, NEUROBIOL AGING, V26, P995, DOI 10.1016/j.neurobiolaging.2004.09.014; Prins ML, 2005, J NEUROSCI RES, V82, P413, DOI 10.1002/jnr.20633; Ramsden M, 2005, J NEUROSCI, V25, P10637, DOI 10.1523/JNEUROSCI.3279-05.2005; Reger MA, 2004, NEUROBIOL AGING, V25, P311, DOI 10.1016/S0197-4580(03)00087-3; SantaCruz K, 2005, SCIENCE, V309, P476, DOI 10.1126/science.1113694; Spires TL, 2006, AM J PATHOL, V168, P1598, DOI 10.2353/ajpath.2006.050840; Srivastava S, 2012, FASEB J, V26, P2351, DOI 10.1096/fj.11-200410; Van der Auwera Ingrid, 2005, Nutr Metab (Lond), V2, P28, DOI 10.1186/1743-7075-2-28; Wang PN, 2004, J NEUROL, V251, P314, DOI 10.1007/s00415-004-0316-4; Westman Eric C, 2003, Curr Atheroscler Rep, V5, P476, DOI 10.1007/s11883-003-0038-6; Yancy WS, 2004, ANN INTERN MED, V140, P769, DOI 10.7326/0003-4819-140-10-200405180-00006; Yao J, 2011, MOL ASPECTS MED, V32, P247, DOI 10.1016/j.mam.2011.10.005; Yao J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021788; Yao J, 2010, BBA-GEN SUBJECTS, V1800, P1121, DOI 10.1016/j.bbagen.2010.06.002; YEH YY, 1976, J NUTR, V106, P58, DOI 10.1093/jn/106.1.58; Zhao W, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049191; Zhao Z, 2006, BMC NEUROSCI, V7, DOI 10.1186/1471-2202-7-29	49	88	93	3	20	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 12	2013	8	9							e75713	10.1371/journal.pone.0075713	http://dx.doi.org/10.1371/journal.pone.0075713			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	242KO	24069439	Green Published, Green Submitted, gold			2023-01-03	WOS:000326240100128
J	Audet, CM; Salato, J; Blevins, M; Amsalem, D; Vermund, SH; Gaspar, F				Audet, Carolyn M.; Salato, Jose; Blevins, Meridith; Amsalem, David; Vermund, Sten H.; Gaspar, Felisbela			Educational Intervention Increased Referrals to Allopathic Care by Traditional Healers in Three High HIV-Prevalence Rural Districts in Mozambique	PLOS ONE			English	Article							SEEKING BEHAVIOR; HEALTH-CARE; ANTIRETROVIRAL THERAPY; TUBERCULOSIS-CONTROL; PREVENTION; PROGRAM; AIDS; MALARIA; ACCESS; DETERMINANTS	Introduction: Delayed uptake of clinical services impedes favorable clinical outcomes in Mozambique. Care is delayed among patients who initiate care with traditional healers; patients with conditions like human immunodeficiency virus (HIV) or tuberculosis are rarely referred to the health system in a timely fashion. Methods: We conducted a pre-post educational intervention with traditional healers, assessing healer referral rates and HIV knowledge in three rural districts in Zambezia Province. Results: The median monthly referral rate prior to the intervention was 0.25 patients (interquartile range [IQR]: 0-0.54) compared with a post-intervention rate of 0.34 patients (IQR: 0-0.71), a 35% increase (p = 0.046). A median HIV knowledge score of 67% (IQR: 59-78) was noted 4-months pre-intervention and a median score of 81% (IQR: 74-89) was recorded 2K months post-intervention (p<0.001). One hundred and eleven healers referred 127 adults, 36 pregnant women, and 188 children to health facilities. Referred patients were most likely to be diagnosed with bronchopneumonia (20% adults; 13% children) and/or malaria (15% adults; 37% children). Of 315 non-pregnant persons referred, 3.5% were tested for HIV and 2.5% were tested for tuberculosis. Discussion: We engaged traditional healers with some success; referral rates were low, but increased post-intervention. Once seen in the clinics, patients were rarely tested for HIV or tuberculosis, though symptoms suggested screening was indicated. We found increased referral rates through an inexpensive intervention with traditional healers, a viable, cost-effective method of directing patients to health facilities. However, quality improvement within the clinics is necessary before a substantial impact can be expected.	[Audet, Carolyn M.; Blevins, Meridith; Amsalem, David; Vermund, Sten H.] Vanderbilt Univ, Sch Med, Inst Global Hlth, Nashville, TN 37212 USA; [Audet, Carolyn M.] Vanderbilt Univ, Sch Med, Dept Prevent Med, Nashville, TN 37212 USA; [Blevins, Meridith] Vanderbilt Univ, Sch Med, Dept Biostat, Nashville, TN 37212 USA; [Vermund, Sten H.] Vanderbilt Univ, Sch Med, Dept Pediat, Nashville, TN 37212 USA; [Vermund, Sten H.] Friends Global Hlth, Quelimane, Mozambique; [Gaspar, Felisbela] Minist Hlth, Maputo, Mozambique	Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University	Audet, CM (corresponding author), Vanderbilt Univ, Sch Med, Inst Global Hlth, Nashville, TN 37212 USA.	carolyn.m.audet@vanderbilt.edu	Vermund, Sten/AAD-3592-2020	Vermund, Sten/0000-0001-7289-8698; Blevins, Meridith/0000-0002-3861-9859	Amos Christie Chair Endowment at Vanderbilt University; Clinician and Translational Science Award (CTSA)/Vanderbilt Clinical & Translational Research Scholars (VCTRS) grant [2UL1TR000445]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000445] Funding Source: NIH RePORTER	Amos Christie Chair Endowment at Vanderbilt University; Clinician and Translational Science Award (CTSA)/Vanderbilt Clinical & Translational Research Scholars (VCTRS) grant; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS))	Research funds were provided by a grant from the Amos Christie Chair Endowment at Vanderbilt University. CMA is supported in part by Clinician and Translational Science Award (CTSA)/Vanderbilt Clinical & Translational Research Scholars (VCTRS) grant (2UL1TR000445). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ahorlu CK, 2006, TROP MED INT HEALTH, V11, P1022, DOI 10.1111/j.1365-3156.2006.01660.x; Anglemyer A, 2011, COCHRANE DATABASE SY; [Anonymous], 1998, Sex Health Exch, P8; [Anonymous], 2002, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD003510; Audet C, 2012, 19 INT AIDS C WASH C; Audet CM, 2012, SAHARA J-J SOC ASP H, V9, P41, DOI 10.1080/17290376.2012.665257; Audet CM, 2012, J ALTERN COMPLEM MED, V18, P1; Babb Dale A, 2007, Psychol Health Med, V12, P314, DOI 10.1080/13548500600621511; Bassett IV, 2010, CLIN INFECT DIS, V50, pS77, DOI 10.1086/651477; Bell D, 2006, NAT REV MICROBIOL, pS7, DOI [10.1038/nrmico1525, 10.1038/nrmicro1525]; BERGER RA, 1994, AIDS, V8, P1511, DOI 10.1097/00002030-199410000-00028; Bunnell R, 2006, AIDS, V20, P85, DOI 10.1097/01.aids.0000196566.40702.28; Burnett A, 1999, AIDS CARE, V11, P481, DOI 10.1080/09540129947875; Bwambale FM, 2008, BMC PUBLIC HEALTH, V8, DOI 10.1186/1471-2458-8-263; Ciampa PJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048676; Cohen MS, 2011, NEW ENGL J MED, V365, P493, DOI [10.1056/NEJMoa1105243, 10.1056/NEJMoa1600693]; Colvin M, 2003, INT J TUBERC LUNG D, V7, pS86; Cu-Uvin S, 2000, AIDS, V14, P415, DOI 10.1097/00002030-200003100-00015; Fideli OS, 2001, AIDS RES HUM RETROV, V17, P901, DOI 10.1089/088922201750290023; Fitzwater SP, 2010, CLIN INFECT DIS, V51, P371, DOI 10.1086/655127; Fleming J, 1995, J Int Assoc Physicians AIDS Care, V1, P32; Furin J, 2011, J COMMUN HEALTH, V36, P849, DOI 10.1007/s10900-011-9385-3; Getahun A, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-320; Gqaleni N, 2011, BIOMEDICAL TRADITION; Green EC, 2000, J ALTERN COMPLEM MED, V6, P1, DOI 10.1089/acm.2000.6.1; GREEN EC, 1995, SOC SCI MED, V40, P503, DOI 10.1016/0277-9536(94)E0105-2; Green Edward C, 1994, AIDS STDS AFRICA BRI; Groh K, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-650; Harper ME, 2004, INT J TUBERC LUNG D, V8, P1266; Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010; Hayes R, 2011, CURR HIV RES, V9, P429, DOI 10.2174/157016211798038515; Hensen B, 2012, TROP MED INT HEALTH, V17, P59, DOI 10.1111/j.1365-3156.2011.02893.x; Hopkins H, 2009, BRIT MED J, V339, DOI 10.1136/bmj.b2606; INSIDA, 2009, NAT SURV PREV BEH RI; Joint United Nations Programme on HIV/AIDS (UNAIDS), 2008, REP GOLB HIV AIDS EP; KAMBO IP, 1994, STUD FAMILY PLANN, V25, P32, DOI 10.2307/2137987; Kayombo EJ, 2007, J ETHNOBIOL ETHNOMED, V3, DOI 10.1186/1746-4269-3-6; King R., 2000, COLLABORATION TRADIT; Liverpool J, 2004, J NATL MED ASSOC, V96, P822; Madamombe I., 2006, AFRICAN RENEWAL JANU, V19, P10, DOI DOI 10.18356/C58EE076-EN; Matovu JKB, 2007, TROP MED INT HEALTH, V12, P1315, DOI 10.1111/j.1365-3156.2007.01923.x; Mbeh George N, 2010, Glob Health Promot, V17, P17, DOI 10.1177/1757975910363925; McMillen H, 2004, SOC SCI MED, V59, P889, DOI 10.1016/j.socscimed.2003.12.008; Nations MK, 1997, TROP DOCT, V27, P60, DOI 10.1177/00494755970270S118; Njau IW, 2012, PAN AFR MED J, V12; OSWALD IH, 1983, SOC SCI MED, V17, P255, DOI 10.1016/0277-9536(83)90327-1; Pinkoane M G, 2005, Curationis, V28, P20; PlusNews, 2010, PLUSNEWS; Poudel KC, 2005, TROP MED INT HEALTH, V10, P640, DOI 10.1111/j.1365-3156.2005.01443.x; Quinn TC, 2000, NEW ENGL J MED, V342, P921, DOI 10.1056/NEJM200003303421303; Raviglione MC, 2007, B WORLD HEALTH ORGAN, V85, P327, DOI 10.2471/BLT.06.038513; Rudolph M J, 2007, Curationis, V30, P56; Somse P, 1998, AIDS EDUC PREV, V10, P558; Ssali A, 2005, AIDS BEHAV, V9, P485, DOI 10.1007/s10461-005-9019-9; Stekelenburg J, 2005, HEALTH POLICY, V71, P67, DOI 10.1016/j.healthpol.2004.05.008; van Dyk A C, 2003, Curationis, V26, P4; Vermund SH, 2012, 19 INT AIDS C WASH D; Vernazza PL, 1997, AIDS, V11, P1249, DOI 10.1097/00002030-199710000-00008; Volmink J, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003510.pub2; WARREN DM, 1982, SOC SCI MED, V16, P1873, DOI 10.1016/0277-9536(82)90448-8; World Health Organization, 2012, MAL DIAGN TREATM; Zachariah R, 2010, T ROY SOC TROP MED H, V104, P387, DOI 10.1016/j.trstmh.2010.01.004	62	74	74	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 1	2013	8	8							e70326	10.1371/journal.pone.0070326	http://dx.doi.org/10.1371/journal.pone.0070326			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	219PB	23936407	gold, Green Submitted, Green Published			2023-01-03	WOS:000324518400054
J	Mayer, K; Beyrer, C				Mayer, Kenneth; Beyrer, Chris			WHO's new HIV guidelines: opportunities and challenges	LANCET			English	Editorial Material							AFRICA; ART		[Mayer, Kenneth] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Fenway Hlth, Boston, MA 02215 USA; [Beyrer, Chris] Johns Hopkins Bloomberg Sch Publ Hlth, Ctr Publ Hlth & Human Rights, Dept Epidemiol, Baltimore, MD USA	Fenway Health; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	Mayer, K (corresponding author), Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Fenway Hlth, Boston, MA 02215 USA.	khmayer@gmail.com						[Anonymous], 2013, HUMAN RIGHTS WATCH; [Anonymous], 2012, GLOB REP UNAIDS REP; Audelin AM, 2013, JAIDS-J ACQ IMM DEF, V62, P102, DOI 10.1097/QAI.0b013e318276becc; Birrell PJ, 2013, LANCET INFECT DIS, V13, P313, DOI 10.1016/S1473-3099(12)70341-9; Cohen MS, 2011, NEW ENGL J MED, V365, P493, DOI [10.1056/NEJMoa1105243, 10.1056/NEJMoa1600693]; De Cock KM, 2013, NEW ENGL J MED, V368, P886, DOI 10.1056/NEJMp1300458; Deeks S, 2013, 7 IAS C PATH TREATM; International Diabetes Federation, 2013, IDF DIABETES ATLAS, V6th ed.; Lundgren JD, 2013, CLIN INFECT DIS, V57, P888, DOI 10.1093/cid/cit381; Tanser F, 2013, SCIENCE, V339, P966, DOI 10.1126/science.1228160; WHO, 2010, ANT THER HIV INF AD	11	8	8	0	7	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JUL 27	2013	382	9889					287	288		10.1016/S0140-6736(13)61578-0	http://dx.doi.org/10.1016/S0140-6736(13)61578-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	193FT	23890033				2023-01-03	WOS:000322544900004
J	Jones, LM; Rayson, SJ; Flemming, AJ; Urwin, PE				Jones, Laura M.; Rayson, Samantha J.; Flemming, Anthony J.; Urwin, Peter E.			Adaptive and Specialised Transcriptional Responses to Xenobiotic Stress in Caenorhabditis elegans Are Regulated by Nuclear Hormone Receptors	PLOS ONE			English	Article							ARYL-HYDROCARBON RECEPTOR; PREGNANE-X-RECEPTOR; DRUG-METABOLIZING-ENZYMES; OXIDATIVE STRESS; GENE-EXPRESSION; C. ELEGANS; BETA-NAPHTHOFLAVONE; DROSOPHILA; NEMATODES; TUBULIN	Characterisation of the pathways by which xenobiotics are metabolised and excreted in both target and non-target organisms is crucial for the rational design of effective and specific novel bioactive molecules. Consequently, we have investigated the induced responses of the model nematode Caenorhabditis elegans to a variety of xenobiotics which represent a range of putative modes of action. The majority of genes that were specifically induced in preliminary microarray analyses encoded enzymes from Phase I and II metabolism, including cytochrome P450s, short chain dehydrogenases, UDP-glucuronosyl transferases and glutathione transferases. Changes in gene expression were confirmed by quantitative PCR and GFP induction in reporter strains driven by promoters for transcription of twelve induced enzymes was investigated. The particular complement of metabolic genes induced was found to be highly contingent on the xenobiotic applied. The known regulators of responses to applied chemicals ahr-1, hif-1, mdt-15 and nhr-8 were not required for any of these inducible responses and skn-1 regulated GFP expression from only two of the promoters. Reporter strains were used in conjunction with systematic RNAi screens to identify transcription factors which drive expression of these genes under xenobiotic exposure. These transcription factors appeared to regulate specific xenobiotic responses and have no reported phenotypes under standard conditions. Focussing on nhr-176 we demonstrate the role of this transcription factor in mediating the resistance to thiabendazole.	[Jones, Laura M.; Rayson, Samantha J.; Urwin, Peter E.] Univ Leeds, Sch Biol, Leeds, W Yorkshire, England; [Flemming, Anthony J.] Syngenta, Jealotts Hill Int Res Ctr, Bracknell, Berks, England	University of Leeds; Syngenta	Urwin, PE (corresponding author), Univ Leeds, Sch Biol, Leeds, W Yorkshire, England.	p.e.urwin@leeds.ac.uk		Urwin, Peter Edward/0000-0003-0398-2372	Biotechnology and Biological Sciences Research Council of the UK (BBSRC); Syngenta UK through an Industrial Partnership Award [BB/G007071/1]; BBSRC; Syngenta through an industrial CASE award; Biotechnology and Biological Sciences Research Council [BB/G007071/1] Funding Source: researchfish; BBSRC [BB/G007071/1] Funding Source: UKRI; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH [P40OD010440] Funding Source: NIH RePORTER	Biotechnology and Biological Sciences Research Council of the UK (BBSRC)(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Syngenta UK through an Industrial Partnership Award(Syngenta); BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Syngenta through an industrial CASE award(Syngenta); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	The work was funded by the Biotechnology and Biological Sciences Research Council of the UK (BBSRC) in partnership with Syngenta UK through an Industrial Partnership Award (Grant No. BB/G007071/1). SJR was the recipient of a PhD studentship funded by BBSRC in partnership with Syngenta through an industrial CASE award. One of the authors, Dr Anthony J. Flemming, is an employee of Syngenta UK. AJF, an employee of Syngenta UK, was involved in study design and preparation of the manuscript.	An JH, 2003, GENE DEV, V17, P1882, DOI 10.1101/gad.1107803; Antebi A, 1998, DEVELOPMENT, V125, P1191; Ashrafi K, 2003, NATURE, V421, P268, DOI 10.1038/nature01279; Bakhetia M, 2008, INT J PARASITOL, V38, P1589, DOI 10.1016/j.ijpara.2008.05.003; BOWERMAN B, 1992, CELL, V68, P1061, DOI 10.1016/0092-8674(92)90078-Q; Butler RA, 2001, GENE, V278, P223, DOI 10.1016/S0378-1119(01)00724-7; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; Ceron J, 2007, BMC DEV BIOL, V7, DOI 10.1186/1471-213X-7-30; Chakrapani BPS, 2008, J BIOSCIENCES, V33, P269, DOI 10.1007/s12038-008-0044-5; CHUKWUDEBE AC, 1994, J AGR FOOD CHEM, V42, P2964, DOI 10.1021/jf00048a060; Copple IM, 2012, ADV PHARMACOL, V63, P43, DOI 10.1016/B978-0-12-398339-8.00002-1; Custodia N, 2001, ANN NY ACAD SCI, V948, P32; DRISCOLL M, 1989, J CELL BIOL, V109, P2993, DOI 10.1083/jcb.109.6.2993; Duncan DM, 1998, GENE DEV, V12, P1290, DOI 10.1101/gad.12.9.1290; Dupuy D, 2004, GENOME RES, V14, P2169, DOI 10.1101/gr.2497604; Gu YZ, 2000, ANNU REV PHARMACOL, V40, P519, DOI 10.1146/annurev.pharmtox.40.1.519; Haerty W, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-399; Harris TW, 2010, NUCLEIC ACIDS RES, V38, pD463, DOI 10.1093/nar/gkp952; Hart AC, 2006, BEHAVIOUR; Hasegawa K, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009267; Heinemeyer T, 1998, NUCLEIC ACIDS RES, V26, P362, DOI 10.1093/nar/26.1.362; Horner MA, 2009, GENE DEV, V23, P2711, DOI 10.1101/gad.1833609; Jia YZ, 2005, P NATL ACAD SCI USA, V102, P12531, DOI 10.1073/pnas.0506000102; Johnstone IL, 1999, PRACT APPROACH SER, V213, P201; Kamath RS, 2001, GENOME BIOL, V2, DOI 10.1186/gb-2000-2-1-research0002; King-Jones K, 2006, CELL METAB, V4, P37, DOI 10.1016/j.cmet.2006.06.006; Kohle C, 2009, BIOCHEM PHARMACOL, V77, P689, DOI 10.1016/j.bcp.2008.05.020; KWA MSG, 1995, J MOL BIOL, V246, P500, DOI 10.1006/jmbi.1994.0102; Laing ST, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031367; Laing ST, 2010, BIOCHEM J, V432, P505, DOI 10.1042/BJ20101346; Lewis JA, 1995, METHOD CELL BIOL, P365; Lindblom TH, 2001, CURR BIOL, V11, P864, DOI 10.1016/S0960-9822(01)00236-6; LUBEGA GW, 1991, EXP PARASITOL, V73, P203, DOI 10.1016/0014-4894(91)90023-P; Maglich JM, 2002, MOL PHARMACOL, V62, P638, DOI 10.1124/mol.62.3.638; Maglich JM, 2001, GENOME BIOL, V2; Magner DB, 2008, TRENDS ENDOCRIN MET, V19, P153, DOI 10.1016/j.tem.2008.02.005; Masuyama H, 2005, MOL ENDOCRINOL, V19, P1170, DOI 10.1210/me.2004-0434; Matyash V, 2004, PLOS BIOL, V2, P1561, DOI 10.1371/journal.pbio.0020280; Menzel R, 2001, ARCH BIOCHEM BIOPHYS, V395, P158, DOI 10.1006/abbi.2001.2568; Menzel R, 2007, J MOL BIOL, V370, P1, DOI 10.1016/j.jmb.2007.04.058; Misra JR, 2011, GENE DEV, V25, P1796, DOI 10.1101/gad.17280911; Motola DL, 2006, CELL, V124, P1209, DOI 10.1016/j.cell.2006.01.037; Omiecinski CJ, 2011, TOXICOL SCI, V120, pS49, DOI 10.1093/toxsci/kfq338; Park SK, 2009, AGING CELL, V8, P258, DOI 10.1111/j.1474-9726.2009.00473.x; Pascussi JM, 2008, ANNU REV PHARMACOL, V48, P1, DOI 10.1146/annurev.pharmtox.47.120505.105349; Powell-Coffman JA, 1998, P NATL ACAD SCI USA, V95, P2844, DOI 10.1073/pnas.95.6.2844; Pretti C, 2001, COMP BIOCHEM PHYS C, V130, P133, DOI 10.1016/S1532-0456(01)00231-9; Przybysz AJ, 2009, MECH AGEING DEV, V130, P357, DOI 10.1016/j.mad.2009.02.004; Qin HT, 2004, DEV BIOL, V270, P64, DOI 10.1016/j.ydbio.2004.02.004; Reece-Hoyes JS, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2168-8-27; Reichert K, 2005, CHEMOSPHERE, V61, P229, DOI 10.1016/j.chemosphere.2005.01.077; Ruiz-Laguna J, 2005, GENE EXPRESSION, V12, P165, DOI 10.3727/000000005783992061; Ruiz-Laguna J, 2006, ENVIRON SCI TECHNOL, V40, P3646, DOI 10.1021/es060056e; Schleit J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028036; Singh MP, 2011, TOXICOL APPL PHARM, V253, P14, DOI 10.1016/j.taap.2011.03.006; Sluder AE, 1999, GENOME RES, V9, P103; Stiernagle T, 1999, PRACT APPROACH SER, V213, P51; Taubert S, 2006, GENE DEV, V20, P1137, DOI 10.1101/gad.1395406; Taubert S, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000021; Taubert S, 2011, MOL CELL ENDOCRINOL, V334, P49, DOI 10.1016/j.mce.2010.04.021; Tolson AH, 2010, ADV DRUG DELIVER REV, V62, P1238, DOI 10.1016/j.addr.2010.08.006; Tomita M, 2006, INT J MOL MED, V17, P37; Tullet JMA, 2008, CELL, V132, P1025, DOI 10.1016/j.cell.2008.01.030; Van Gilst M, 2002, CRIT REV EUKAR GENE, V12, P65; VANFLETEREN JR, 1972, NEMATOLOGICA, V18, P325, DOI 10.1163/187529272X00593; Vinuela A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012145; Vrailas-Mortimer A, 2011, DEV CELL, V21, P783, DOI 10.1016/j.devcel.2011.09.002; Weber KP, 2012, BMC EVOL BIOL, V12, DOI 10.1186/1471-2148-12-81; Wren JF, 2011, ECOTOXICOLOGY, V20, P397, DOI 10.1007/s10646-010-0591-z; Yang FJ, 2006, NATURE, V442, P700, DOI 10.1038/nature04942	70	33	56	1	25	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 26	2013	8	7							e69956	10.1371/journal.pone.0069956	http://dx.doi.org/10.1371/journal.pone.0069956			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	197GU	23922869	Green Published, gold, Green Submitted			2023-01-03	WOS:000322838900120
J	Leconet, W; Larbouret, C; Chardes, T; Thomas, G; Neiveyans, M; Busson, M; Jarlier, M; Radosevic-Robin, N; Pugniere, M; Bernex, F; Penault-Llorca, F; Pasquet, JM; Pelegrin, A; Robert, B				Leconet, W.; Larbouret, C.; Chardes, T.; Thomas, G.; Neiveyans, M.; Busson, M.; Jarlier, M.; Radosevic-Robin, N.; Pugniere, M.; Bernex, F.; Penault-Llorca, F.; Pasquet, J-M; Pelegrin, A.; Robert, B.			Preclinical validation of AXL receptor as a target for antibody-based pancreatic cancer immunotherapy	ONCOGENE			English	Article						RTK; monoclonal antibodies; pancreatic cancer; targeted therapy	TO-MESENCHYMAL TRANSITION; TYROSINE KINASE AXL; THERAPEUTIC TARGET; DRUG-RESISTANCE; MONOCLONAL-ANTIBODY; CELL INVASION; TUMOR-GROWTH; ACTIVATION; EGFR; OVEREXPRESSION	AXL receptor tyrosine kinase (RTK) is implicated in proliferation and invasion of many cancers, particularly in pancreatic ductal adenocarcinoma (PDAC), for which new therapeutic options are urgently required. We investigated whether inhibition of AXL activity by specific monoclonal antibodies (mAbs) is efficient in limiting proliferation and migration of pancreatic cancer cells. Expression of AXL was evaluated by immunohistochemistry in 42 PDAC. The AXL role in oncogenesis was studied using the short hairpin RNA approach in a pancreatic carcinoma cell line. We further generated antihuman AXL mAbs and evaluated their inhibitory effects and the AXL downstream signaling pathways first in vitro, in a panel of pancreatic cancer cell lines and then in vivo, using subcutaneous or orthotopic pancreatic tumor xenografts. AXL receptor was found expressed in 76% (32/ 42) of PDAC and was predominantly present in invasive cells. The AXL-knockdown Panc-1 cells decreased in vitro cell migration, survival and proliferation, and reduced in vivo tumor growth. Two selected anti-AXL mAbs (D9 and E8), which inhibited phosphorylation of AXL and of its downstream target AKT without affecting growth arrest-specific factor 6 (GAS6) binding, induced downexpression of AXL by internalization, leading to an inhibition of proliferation and migration in the four pancreatic cancer cell lines studied. In vivo, treatment by anti-AXL mAbs significantly reduced growth of both subcutaneous and orthotopic pancreatic tumor xenografts independently of their KRAS mutation status. Our in vitro and preclinical in vivo data demonstrate that anti-human AXL mAbs could represent a new approach to the pancreatic cancer immunotherapy.	[Leconet, W.; Larbouret, C.; Chardes, T.; Thomas, G.; Neiveyans, M.; Busson, M.; Pugniere, M.; Bernex, F.; Pelegrin, A.; Robert, B.] Univ Montpellier I, INSERM U896, IRCM, CRLC Val dAurelle Paul Lamarque, Montpellier 5, France; [Jarlier, M.] CRLC Val dAurelle Paul Lamarque, Unite Biostat, F-34298 Montpellier 5, Languedoc Rouss, France; [Radosevic-Robin, N.; Penault-Llorca, F.] Ctr Jean Perrin, Dept Biopathol, F-63011 Clermont Ferrand 1, France; [Radosevic-Robin, N.; Penault-Llorca, F.] Univ Auvergne, ERTICa EA4677, Clermont Ferrand, France; [Pasquet, J-M] Univ Victor Segalen, Hematol Lab, CHU Bordeaux, INSERM U876, Bordeaux, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; UNICANCER; Centre Jean Perrin; Universite Clermont Auvergne (UCA); CHU Bordeaux; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite de Bordeaux	Robert, B (corresponding author), CRLC Val dAurelle Paul Lamarque, IRCM INSERM U896, 208 Rue Apothicaires, F-34298 Montpellier 5, Languedoc Rouss, France.	bruno.robert@inserm.fr	PASQUET, JEAN-MAX/T-4906-2019; PUGNIERE, Martine/AAD-4315-2020; PASQUET, JEAN-MAX/I-9702-2014; Pugniere, Martine/T-1355-2017; ROBERT, Bruno/AAB-7581-2020; Chardès, Thierry/B-5420-2019; Pèlegrin, André/J-3167-2016; Leconet, Wilhem/AAH-5681-2020	PASQUET, JEAN-MAX/0000-0002-1345-3776; PUGNIERE, Martine/0000-0002-2049-2909; Pugniere, Martine/0000-0002-2049-2909; ROBERT, Bruno/0000-0001-5573-6945; Chardès, Thierry/0000-0002-1836-7439; Pelegrin, Andre/0000-0001-9254-2648	INSERM; Oribase Pharma	INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); Oribase Pharma	We thank Florence Frayssinoux, Sabine Bousquie and Genevieve Heintz for their technical help. We also thank the ICRM animal facility staff and the 'Reseau d'Histologie Experimentale de Montpellier' histology facility for processing our animal tissues and RIO Imaging facilities. This work was supported by INSERM and Oribase Pharma.	Beck A, 2010, NAT REV IMMUNOL, V10, P345, DOI 10.1038/nri2747; Bibeau F, 2009, J CLIN ONCOL, V27, P1122, DOI 10.1200/JCO.2008.18.0463; Bossard C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044787; Byers LA, 2013, CLIN CANCER RES, V19, P279, DOI 10.1158/1078-0432.CCR-12-1558; Cartron G, 2002, BLOOD, V99, P754, DOI 10.1182/blood.V99.3.754; Clynes RA, 2000, NAT MED, V6, P443, DOI 10.1038/74704; Gaborit N, 2011, J BIOL CHEM, V286, P11337, DOI 10.1074/jbc.M111.223503; Gioia R, 2011, BLOOD, V118, P2211, DOI 10.1182/blood-2010-10-313692; Gjerdrum C, 2010, P NATL ACAD SCI USA, V107, P1124, DOI 10.1073/pnas.0909333107; Hong CC, 2008, CANCER LETT, V268, P314, DOI 10.1016/j.canlet.2008.04.017; Jones S, 2008, SCIENCE, V321, P1801, DOI 10.1126/science.1164368; Kim EJ, 2011, CURR OPIN GASTROEN, V27, P460, DOI 10.1097/MOG.0b013e328349e31f; Koorstra JBM, 2009, CANCER BIOL THER, V8, P618, DOI 10.4161/cbt.8.7.7923; Krantz SB, 2012, J SURG RES, V173, P105, DOI 10.1016/j.jss.2011.09.020; Larbouret C, 2007, CLIN CANCER RES, V13, P3356, DOI 10.1158/1078-0432.CCR-06-2302; Lay JD, 2007, CANCER RES, V67, P3878, DOI 10.1158/0008-5472.CAN-06-3191; Li Y, 2009, ONCOGENE, V28, P3442, DOI 10.1038/onc.2009.212; Linger RMA, 2013, ONCOGENE, V32, P3420, DOI 10.1038/onc.2012.355; Linger RMA, 2008, ADV CANCER RES, V100, P35, DOI 10.1016/S0065-230X(08)00002-X; Linger RM, 2010, EXPERT OPIN THER TAR, V14, P1073, DOI 10.1517/14728222.2010.515980; LIU E, 1988, P NATL ACAD SCI USA, V85, P1952, DOI 10.1073/pnas.85.6.1952; Liu L, 2009, CANCER RES, V69, P6871, DOI 10.1158/0008-5472.CAN-08-4490; Macleod K, 2005, CANCER RES, V65, P6789, DOI 10.1158/0008-5472.CAN-04-2684; Mahadevan D, 2007, ONCOGENE, V26, P3909, DOI 10.1038/sj.onc.1210173; Mishra A, 2012, MOL CANCER RES, V10, P703, DOI 10.1158/1541-7786.MCR-11-0569; Musolino A, 2008, J CLIN ONCOL, V26, P1789, DOI 10.1200/JCO.2007.14.8957; Nelson NJ, 2007, J NATL CANCER I, V99, P1432, DOI 10.1093/jnci/djm180; Rankin EB, 2010, CANCER RES, V70, P7570, DOI 10.1158/0008-5472.CAN-10-1267; Robert B, 1996, CANCER RES, V56, P4758; Song XZ, 2011, CANCER-AM CANCER SOC, V117, P734, DOI 10.1002/cncr.25483; Tai KY, 2008, ONCOGENE, V27, P4044, DOI 10.1038/onc.2008.57; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Tredan O, 2007, J NATL CANCER I, V99, P1441, DOI 10.1093/jnci/djm135; Troiani T, 2012, CURR DRUG TARGETS, V13, P802, DOI 10.2174/138945012800564158; Vanneman M, 2012, NAT REV CANCER, V12, P237, DOI 10.1038/nrc3237; Verma A, 2011, MOL CANCER THER, V10, P1763, DOI 10.1158/1535-7163.MCT-11-0116; Vuoriluoto K, 2011, ONCOGENE, V30, P1436, DOI 10.1038/onc.2010.509; Wong HH, 2009, NAT REV GASTRO HEPAT, V6, P412, DOI 10.1038/nrgastro.2009.89; Ye X, 2010, ONCOGENE, V29, P5254, DOI 10.1038/onc.2010.268; Zhang ZF, 2012, NAT GENET, V44, P852, DOI 10.1038/ng.2330	40	69	78	0	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 20	2014	33	47					5405	5414		10.1038/onc.2013.487	http://dx.doi.org/10.1038/onc.2013.487			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AT7MG	24240689	Green Accepted, Green Submitted, Green Published			2023-01-03	WOS:000345120700002
J	Kim, F; Nichol, G; Maynard, C; Hallstrom, A; Kudenchuk, PJ; Rea, T; Copass, MK; Carlbom, D; Deem, S; Longstreth, WT; Olsufka, M; Cobb, LA				Kim, Francis; Nichol, Graham; Maynard, Charles; Hallstrom, Al; Kudenchuk, Peter J.; Rea, Thomas; Copass, Michael K.; Carlbom, David; Deem, Steven; Longstreth, W. T., Jr.; Olsufka, Michele; Cobb, Leonard A.			Effect of Prehospital Induction of Mild Hypothermia on Survival and Neurological Status Among Adults With Cardiac Arrest A Randomized Clinical Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INTERNATIONAL LIAISON COMMITTEE; EMERGENCY CARDIOVASCULAR CARE; AMERICAN-HEART-ASSOCIATION; THERAPEUTIC HYPOTHERMIA; COMATOSE SURVIVORS; RESUSCITATION; CARDIOPULMONARY; STATEMENT; LONG	IMPORTANCE Hospital cooling improves outcome after cardiac arrest, but prehospital cooling immediately after return of spontaneous circulation may result in better outcomes. OBJECTIVE To determine whether prehospital cooling improves outcomes after resuscitation from cardiac arrest in patients with ventricular fibrillation (VF) and without VF. DESIGN, SETTING, AND PARTICIPANTS A randomized clinical trial that assigned adults with prehospital cardiac arrest to standard care with or without prehospital cooling, accomplished by infusing up to 2 L of 4 degrees C normal saline as soon as possible following return of spontaneous circulation. Adults in King County, Washington, with prehospital cardiac arrest and resuscitated by paramedics were eligible and 1359 patients (583 with VF and 776 without VF) were randomized between December 15, 2007, and December 7, 2012. Patient follow-up was completed by May 1, 2013. Nearly all of the patients resuscitated from VF and admitted to the hospital received hospital cooling regardless of their randomization. MAIN OUTCOMES AND MEASURES The primary outcomes were survival to hospital discharge and neurological status at discharge. RESULTS The intervention decreased mean core temperature by 1.20 degrees C (95% CI, -1.33 degrees C to -1.07 degrees C) in patients with VF and by 1.30 degrees C (95% CI, -1.40 degrees C to -1.20 degrees C) in patients without VF by hospital arrival and reduced the time to achieve a temperature of less than 34 degrees C by about 1 hour compared with the control group. However, survival to hospital discharge was similar among the intervention and control groups among patients with VF (62.7% [95% CI, 57.0%-68.0%] vs 64.3% [95% CI, 58.6%-69.5%], respectively; P = .69) and among patients without VF (19.2% [95% CI, 15.6%-23.4%] vs 16.3% [95% CI, 12.9%-20.4%], respectively; P = .30). The intervention was also not associated with improved neurological status of full recovery or mild impairment at discharge for either patients with VF (57.5% [95% CI, 51.8%-63.1%] of cases had full recovery or mild impairment vs 61.9%[95% CI, 56.2%-67.2%] of controls; P = .69) or those without VF (14.4% [95% CI, 11.3%-18.2%] of cases vs 13.4% [95% CI, 10.4%-17.2%] of controls; P = .30). Overall, the intervention group experienced rearrest in the field more than the control group (26% [95% CI, 22%-29%] vs 21% [95% CI, 18%-24%], respectively; P = .008), as well as increased diuretic use and pulmonary edema on first chest x-ray, which resolved within 24 hours after admission. CONCLUSION AND RELEVANCE Although use of prehospital cooling reduced core temperature by hospital arrival and reduced the time to reach a temperature of 34 degrees C, it did not improve survival or neurological status among patients resuscitated from prehospital VF or those without VF.	[Kim, Francis; Nichol, Graham; Kudenchuk, Peter J.; Rea, Thomas; Carlbom, David; Olsufka, Michele; Cobb, Leonard A.] Univ Washington, Sch Med, Dept Med, Seattle, WA 98104 USA; [Maynard, Charles] Univ Washington, Sch Publ Hlth, Dept Hlth Serv, Seattle, WA 98104 USA; [Hallstrom, Al] Univ Washington, Sch Publ Hlth, Dept Biostat, Seattle, WA 98104 USA; [Copass, Michael K.; Longstreth, W. T., Jr.] Univ Washington, Sch Med, Dept Neurol, Seattle, WA 98104 USA; [Deem, Steven] Univ Washington, Sch Med, Dept Anesthesiol, Seattle, WA 98104 USA; [Longstreth, W. T., Jr.] Univ Washington, Sch Publ Hlth, Dept Epidemiol, Seattle, WA 98104 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Kim, F (corresponding author), Univ Washington, Harborview Med Ctr, 325 9th Ave, Seattle, WA 98104 USA.	fkim@u.washington.edu	Nichol, Graham/Z-4996-2019; Maynard, Charles/N-3906-2015	Maynard, Charles/0000-0002-1644-7814	National Heart, Lung, and Blood Institute [RO1 HL089554, 5U01HL07786]; Medic One Foundation (Seattle, Washington); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL089554] Funding Source: NIH RePORTER	National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Medic One Foundation (Seattle, Washington); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This study was funded by grants RO1 HL089554 and 5U01HL07786 from the National Heart, Lung, and Blood Institute and with additional support from the Medic One Foundation (Seattle, Washington).	Bernard S, 2004, CRIT CARE MED, V32, P897, DOI 10.1097/01.CCM.0000115263.08805.EF; Bernard S, 2003, RESUSCITATION, V56, P9, DOI 10.1016/S0300-9572(02)00276-9; Bernard SA, 2002, NEW ENGL J MED, V346, P557, DOI 10.1056/NEJMoa003289; Bernard SA, 2012, CRIT CARE MED, V40, P747, DOI 10.1097/CCM.0b013e3182377038; Bernard SA, 2010, CIRCULATION, V122, P737, DOI 10.1161/CIRCULATIONAHA.109.906859; Castren M, 2010, CIRCULATION, V122, P729, DOI 10.1161/CIRCULATIONAHA.109.931691; Holzer M, 2002, NEW ENGL J MED, V346, P549; JENNETT B, 1975, LANCET, V1, P480; KELSEY SF, 1991, CONTROL CLIN TRIALS, V12, P525; Kim F, 2007, CIRCULATION, V115, P3064, DOI 10.1161/CIRCULATIONAHA.106.655480; KUBOYAMA K, 1993, CRIT CARE MED, V21, P1348, DOI 10.1097/00003246-199309000-00019; Longstreth W T Jr, 1988, Acta Anaesthesiol Belg, V39, P115; Longstreth WT, 2002, NEUROLOGY, V59, P506, DOI 10.1212/WNL.59.4.506; Neumar RW, 2008, CIRCULATION, V118, P2452, DOI 10.1161/CIRCULATIONAHA.108.190652; Nolan JP, 2003, CIRCULATION, V108, P118, DOI 10.1161/01.CIR.0000079019.02601.90; Peberdy MA, 2010, CIRCULATION, V122, pS768, DOI 10.1161/CIRCULATIONAHA.110.971002; Phelps R, 2013, CRIT CARE MED, V41, P1252, DOI 10.1097/CCM.0b013e31827ca975; RAICHLE ME, 1983, ANN NEUROL, V13, P2, DOI 10.1002/ana.410130103; Rea TD, 2003, ANN EMERG MED, V41, P494, DOI 10.1067/mem.2003.149; ROINE RO, 1993, JAMA-J AM MED ASSOC, V269, P237, DOI 10.1001/jama.269.2.237; Yannopoulos D, 2009, CIRCULATION, V120, P1426, DOI 10.1161/CIRCULATIONAHA.109.848424	21	407	441	1	38	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 1	2014	311	1					45	52		10.1001/jama.2013.282173	http://dx.doi.org/10.1001/jama.2013.282173			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	282HN	24240712	Bronze			2023-01-03	WOS:000329161400017
J	Alzaid, F; Cheung, HM; Preedy, VR; Sharp, PA				Alzaid, Fawaz; Cheung, Hoi-Man; Preedy, Victor R.; Sharp, Paul A.			Regulation of Glucose Transporter Expression in Human Intestinal Caco-2 Cells following Exposure to an Anthocyanin-Rich Berry Extract	PLOS ONE			English	Article							RAT SMALL-INTESTINE; SUGAR ABSORPTION; DIFFERENTIAL EXPRESSION; DIFFUSIVE COMPONENT; DIETARY POLYPHENOLS; EPITHELIAL-CELLS; APICAL GLUT2; SGLT1; MICE; ENTEROCYTES	Polyphenols contained within plant tissues are consumed in significant amounts in the human diet and are known to influence a number of biological processes. This study investigated the effects of an anthocyanin-rich berry-extract on glucose uptake by human intestinal Caco-2 cells. Acute exposure (15 min) to berry extract (0.125%, w/v) significantly decreased both sodium-dependent (Total uptake) and sodium-independent (facilitated uptake) H-3-D-glucose uptake. In longer-term studies, SGLT1 mRNA and GLUT2 mRNA expression were reduced significantly. Polyphenols are known to interact directly with glucose transporters to regulate the rate of glucose absorption. Our in vitro data support this mechanism and also suggest that berry flavonoids may modulate post-prandial glycaemia by decreasing glucose transporter expression. Further studies are warranted to investigate the longer term effects of berry flavonoids on the management of glycaemia in human volunteers.	[Alzaid, Fawaz; Cheung, Hoi-Man; Preedy, Victor R.; Sharp, Paul A.] Kings Coll London, Diabet & Nutr Sci Div, London WC2R 2LS, England	University of London; King's College London	Preedy, VR (corresponding author), Kings Coll London, Diabet & Nutr Sci Div, London WC2R 2LS, England.	victor.preedy@kcl.ac.uk; paul.a.sharp@kcl.ac.uk		Sharp, Paul Anthony/0000-0003-3400-6702; Alzaid, Fawaz/0000-0003-3056-3640	Ministry of Higher Education of the state of Kuwait; Arab-British Chamber of Commerce	Ministry of Higher Education of the state of Kuwait; Arab-British Chamber of Commerce	The authors thank the Ministry of Higher Education of the state of Kuwait and the Arab-British Chamber of Commerce for providing a studentship and extra consumables funding, respectively to F. Alzaid. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ait-Omar A, 2011, DIABETES, V60, P2598, DOI 10.2337/db10-1740; BURANT CF, 1994, AM J PHYSIOL, V267, pG71, DOI 10.1152/ajpgi.1994.267.1.G71; CHANTRET I, 1994, J CELL SCI, V107, P213; Chaston T, 2008, GUT, V57, DOI 10.1136/gut.2007.131722; Corpe CP, 1996, PFLUG ARCH EUR J PHY, V432, P192, DOI 10.1007/s004240050124; DEBNAM ES, 1975, J PHYSIOL-LONDON, V246, P181, DOI 10.1113/jphysiol.1975.sp010885; Faria A, 2009, MOL NUTR FOOD RES, V53, P1430, DOI 10.1002/mnfr.200900007; FERRARIS RP, 1993, P NATL ACAD SCI USA, V90, P5868, DOI 10.1073/pnas.90.12.5868; Gorboulev V, 2012, DIABETES, V61, P187, DOI 10.2337/db11-1029; Gouyon F, 2003, J PHYSIOL-LONDON, V552, P823, DOI 10.1113/jphysiol.2003.049247; Helliwell PA, 2000, BIOCHEM J, V350, P163, DOI 10.1042/0264-6021:3500163; Johnston K, 2005, FEBS LETT, V579, P1653, DOI 10.1016/j.febslet.2004.12.099; Kellett GL, 2008, ANNU REV NUTR, V28, P35, DOI 10.1146/annurev.nutr.28.061807.155518; Kellett GL, 2000, BIOCHEM J, V350, P155, DOI 10.1042/0264-6021:3500155; Kellett GL, 2001, J PHYSIOL-LONDON, V531, P585, DOI 10.1111/j.1469-7793.2001.0585h.x; Khoursandi S, 2004, AM J PHYSIOL-CELL PH, V287, pC1041, DOI 10.1152/ajpcell.00197.2004; Kwon O, 2007, FASEB J, V21, P366, DOI 10.1096/fj.06-6620com; Le Gall M, 2007, J CELL PHYSIOL, V213, P834, DOI 10.1002/jcp.21245; Mace OJ, 2007, J PHYSIOL-LONDON, V582, P379, DOI 10.1113/jphysiol.2007.130906; MAHRAOUI L, 1994, BIOCHEM J, V298, P629, DOI 10.1042/bj2980629; Manzano S, 2010, MOL NUTR FOOD RES, V54, P1773, DOI 10.1002/mnfr.201000019; Margolskee RF, 2007, P NATL ACAD SCI USA, V104, P15075, DOI 10.1073/pnas.0706678104; McDougall GJ, 2005, J AGR FOOD CHEM, V53, P2760, DOI 10.1021/jf0489926; Morgan EL, 2007, J PHYSIOL-LONDON, V580, P593, DOI 10.1113/jphysiol.2006.124768; Oliveira DM, 2008, J AGR FOOD CHEM, V56, P10527, DOI 10.1021/jf8021404; Puupponen-Pimia R, 2005, BIOFACTORS, V23, P243, DOI 10.1002/biof.5520230410; Raybould HE, 2008, J PHYSIOL BIOCHEM, V64, P349, DOI 10.1007/BF03174091; Sharp PA, 1996, GUT, V39, P545, DOI 10.1136/gut.39.4.545; Tobin V, 2008, DIABETES, V57, P555, DOI 10.2337/db07-0928; Torronen R, 2010, BRIT J NUTR, V103, P1094, DOI 10.1017/S0007114509992868; Williams M, 2002, BBA-BIOMEMBRANES, V1559, P179, DOI 10.1016/S0005-2736(01)00449-7; Williamson G, 2013, MOL NUTR FOOD RES, V57, P48, DOI 10.1002/mnfr.201200511	32	87	90	3	64	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 13	2013	8	11							e78932	10.1371/journal.pone.0078932	http://dx.doi.org/10.1371/journal.pone.0078932			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	255QK	24236070	gold, Green Published, Green Submitted			2023-01-03	WOS:000327254700067
J	OuYang, PY; Su, Z; Mao, YP; Deng, WG; Xie, FY				OuYang, Pu-Yun; Su, Zhen; Mao, Yan-Ping; Deng, Wuguo; Xie, Fang-Yun			Combination of EGFR-TKIs and Chemotherapy as First-Line Therapy for Advanced NSCLC: A Meta-Analysis	PLOS ONE			English	Article							CELL LUNG-CANCER; GROWTH-FACTOR RECEPTOR; TYROSINE KINASE INHIBITORS; PHASE-III TRIAL; GEFITINIB; MUTATIONS; ERLOTINIB; PACLITAXEL; CARBOPLATIN; SENSITIVITY	The impact of combining epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) and chemotherapy as first-line therapy for patients with advanced non-small-cell lung cancer (NSCLC) remains controversial. Therefore, randomized trials that compared this combined regimen with chemotherapy or EGFR-TKIs monotherapy were included for this meta-analysis. We used published hazard ratios (HRs), if available, or derived treatment estimates from other survival data. Pooled estimates of treatment efficacy of the combined regimen in the entire unselected population and selected patients by EGFR-mutation status and smoking history were calculated. Eight trials eventually entered into this meta-analysis, including 4585 patients. Overall, the combined regimen significantly delayed disease progression (HR = 0.81, 95% CI 0.69-0.95, P = 0.01); subgroup analysis showed significantly higher progression free survival advantages in Asian patients (P<0.001), with sequential combination of TKIs and chemotherapy (P = 0.02). In selected patients by EGFR-mutation, both mutation positive (HR = 0.48, 95% CI 0.28-0.83, P = 0.009) and negative (HR = 0.84, 95% CI 0.72-0.98, P = 0.02) patients gained progression free survival benefit from the combined regimen, albeit the magnitude of benefit was marginally larger in mutation positive patients (P = 0.05). In selected patients by smoking history, never/light smokers achieved a great progression free survival benefit from the combined regimen (HR = 0.51, 95% CI 0.35-0.74, P = 0.0004). Unfortunately, the combined regimen had no significant impact on overall survival, irrespective of ethnicity, dose schedules or EGFR-mutation status. Severe anorexia (RR = 2.01, 95% CI 1.11-3.63; P = 0.02) and diarrhea (RR = 2.70, 95% CI 1.94-3.76; P<0.001) were more frequent in the combined regimen arm. This strategy of combining EGFR-TKIs and chemotherapy deserved to be considered in the future, although it is not approved for advanced NSCLC at the moment.	[OuYang, Pu-Yun; Su, Zhen; Mao, Yan-Ping; Deng, Wuguo; Xie, Fang-Yun] Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Guangzhou, Guangdong, Peoples R China; [OuYang, Pu-Yun; Su, Zhen; Mao, Yan-Ping; Xie, Fang-Yun] Sun Yat Sen Univ, Ctr Canc, Dept Radiat Oncol, Guangzhou 510275, Guangdong, Peoples R China	State Key Lab Oncology South China; Sun Yat Sen University	Deng, WG (corresponding author), Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Guangzhou, Guangdong, Peoples R China.	dengwg@sysucc.org.cn; xiefy@sysucc.org.cn						Bai H, 2012, J CLIN ONCOL, V30, P3077, DOI 10.1200/JCO.2011.39.3744; Bell DW, 2005, J CLIN ONCOL, V23, P8081, DOI 10.1200/JCO.2005.02.7078; Bria E, 2011, ANN ONCOL, V22, P2277, DOI 10.1093/annonc/mdq742; Carey KD, 2006, CANCER RES, V66, P8163, DOI 10.1158/0008-5472.CAN-06-0453; Chan SK, 2006, EUR J CANCER, V42, P17, DOI 10.1016/j.ejca.2005.07.031; Chen P, 2011, EUR J CLIN PHARMACOL, V67, P235, DOI 10.1007/s00228-010-0965-4; Ciardiello F, 2000, CLIN CANCER RES, V6, P2053; Davies AM, 2006, CLIN LUNG CANCER, V7, P385, DOI 10.3816/CLC.2006.n.021; Eberhard DA, 2005, J CLIN ONCOL, V23, P5900, DOI 10.1200/JCO.2005.02.857; Gao GH, 2012, INT J CANCER, V131, pE822, DOI 10.1002/ijc.27396; Gatzemeier U, 2007, J CLIN ONCOL, V25, P1545, DOI 10.1200/JCO.2005.05.1474; Giaccone G, 2004, J CLIN ONCOL, V22, P777, DOI 10.1200/JCO.2004.08.001; Greulich H, 2005, PLOS MED, V2, P1167, DOI 10.1371/journal.pmed.0020313; Herbst RS, 2004, J CLIN ONCOL, V22, P785, DOI 10.1200/JCO.2004.07.215; Herbst RS, 2005, J CLIN ONCOL, V23, P5892, DOI 10.1200/JCO.2005.02.840; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Hirsch FR, 2011, J CLIN ONCOL, V29, P3567, DOI 10.1200/JCO.2010.34.4929; Hotta K, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026646; Janne PA, 2012, J CLIN ONCOL, V30, P2063, DOI 10.1200/JCO.2011.40.1315; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Maemondo M, 2010, NEW ENGL J MED, V362, P2380, DOI 10.1056/NEJMoa0909530; Mitsudomi T, 2010, LANCET ONCOL, V11, P121, DOI 10.1016/S1470-2045(09)70364-X; Mok TS, 2009, NEW ENGL J MED, V361, P947, DOI 10.1056/NEJMoa0810699; Mok TSK, 2009, J CLIN ONCOL, V27, P5080, DOI 10.1200/JCO.2008.21.5541; Moyer JD, 1997, CANCER RES, V57, P4838; Mukohara T, 2005, JNCI-J NATL CANCER I, V97, P1185, DOI 10.1093/jnci/dji238; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Pao W, 2004, P NATL ACAD SCI USA, V101, P13306, DOI 10.1073/pnas.0405220101; Parmar MKB, 1998, STAT MED, V17, P2815, DOI 10.1002/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8; Petrelli F, 2012, CLIN LUNG CANCER, V13, P107, DOI 10.1016/j.cllc.2011.08.005; Shigematsu H, 2006, INT J CANCER, V118, P257, DOI 10.1002/ijc.21496; Sirotnak FM, 2000, CLIN CANCER RES, V6, P4885; Solit DB, 2005, CLIN CANCER RES, V11, P1983, DOI 10.1158/1078-0432.CCR-04-1347; Wu YL, 2013, LANCET ONCOL, V14, P777, DOI 10.1016/S1470-2045(13)70254-7; Yun CH, 2007, CANCER CELL, V11, P217, DOI 10.1016/j.ccr.2006.12.017; Zhou CC, 2011, LANCET ONCOL, V12, P735, DOI 10.1016/S1470-2045(11)70184-X	36	16	18	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 13	2013	8	11							e79000	10.1371/journal.pone.0079000	http://dx.doi.org/10.1371/journal.pone.0079000			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	255QK	24236082	Green Published, gold, Green Submitted			2023-01-03	WOS:000327254700080
J	Leung, YY; McGrath, C; Cheung, LK				Leung, Yiu Yan; McGrath, Colman; Cheung, Lim Kwong			Trigeminal Neurosensory Deficit and Patient Reported Outcome Measures: The Effect on Quality of Life	PLOS ONE			English	Article							SURGERY	Objectives: To investigate the effect of persistent neurosensory disturbance of the lingual nerve (LN) or inferior alveolar nerve (IAN) on general health and oral health-related quality of life (QoL). Methods: The study design was a case-control study. Patients with persistent neurosensory deficit of LN or IAN after lower third molar surgery (for 12 months or more) were the study group. The control group was an age and gender matched sample of patients who had dental extractions or lower third molar surgeries without trigeminal neurosensory deficit. The outcome variables were the general health and oral health-related QoL. General health-related QoL was assessed using the 36-item Short Form Health Survey (SF-36) and oral health-related QoL using the 14-item Short Form Oral Health Impact Profile (OHIP-14). Differences in SF-36 scores and OHIP-14 scores between the groups were compared. Results: Forty-eight subjects (24 cases and 24 controls) were recruited. When compared to the control group, patients with neurosensory deficits had poorer Mental-Health Component Scores (MCS) (p = 0.005), General Health (p = 0.023), Vitality (p = 0.048), Social Functioning (p = 0.003), Role-emotion (p = 0.008) and Mental Health (p = 0.022). The OHIP-14 scores were also significantly worse in this patients with neurosensory deficits compared with the control group (p = 0.002). When compared within the study group, older patient with neurosensory deficit was found to correlate with worse Physical Health Component Scores (PCS) (p = 0.02) and OHIP-14 scores (p = 0.02), while more severe visualized analog scaling rating of numbness was correlated with a worse PCS (p = 0.034). Conclusions: Patients with persistent LN or IAN deficit after lower third molar surgery have poorer health-related QoL and poorer oral health-related QoL than those without such deficits.	[Leung, Yiu Yan; McGrath, Colman; Cheung, Lim Kwong] Univ Hong Kong, Fac Dent, Hong Kong, Hong Kong, Peoples R China	University of Hong Kong	Leung, YY (corresponding author), Univ Hong Kong, Fac Dent, Hong Kong, Hong Kong, Peoples R China.	mikeyyleung@hku.hk		McGrath, Colman Patrick Joseph/0000-0001-9379-0889; Cheung, Lim Kwong/0000-0002-2248-286X; /0000-0001-7038-3279				Cella D, 2010, J CLIN EPIDEMIOL, V63, P1179, DOI 10.1016/j.jclinepi.2010.04.011; Cheung LK, 2009, INT J ORAL MAXILLOF, V108, P821; Cohen J., 2013, STAT POWER ANAL BEHA; Hupp James R, 2007, Oral Maxillofac Surg Clin North Am, V19, P129, DOI 10.1016/j.coms.2006.11.008; Lam CLK, 2005, J CLIN EPIDEMIOL, V58, P815, DOI 10.1016/j.jclinepi.2004.12.008; Leung YY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072891; Locker D, 2007, COMMUNITY DENT ORAL, V35, P401, DOI 10.1111/j.1600-0528.2007.00418.x; McGrath C, 2001, Community Dent Health, V18, P138; McGrath C, 2003, BRIT J ORAL MAX SURG, V41, P43, DOI 10.1016/S0266-4356(02)00289-9; McGrath C, 1999, Prim Dent Care, V6, P53; Pogrel MA, 2011, J ORAL MAXIL SURG, V69, P2284, DOI 10.1016/j.joms.2011.02.023; Reisine S, 2012, INT J ORAL MAX SURG, V41, P1558, DOI 10.1016/j.ijom.2012.04.019; Rustemeyer J, 2012, J CRANIO MAXILL SURG, V40, P400, DOI 10.1016/j.jcms.2011.07.009; SANDSTEDT P, 1995, J ORAL MAXIL SURG, V53, P498, DOI 10.1016/0278-2391(95)90055-1; Ware JE., 1994, SF 36 PHYS MENTAL HL; Wong W, 2012, QUAL LIFE RES, V21, P873, DOI 10.1007/s11136-011-9987-3	16	16	16	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 29	2013	8	10							e77391	10.1371/journal.pone.0077391	http://dx.doi.org/10.1371/journal.pone.0077391			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	242VF	24204820	gold, Green Published, Green Submitted			2023-01-03	WOS:000326270700028
J	Wang, KY; Chau, TT				Wang, Kuo-Ying; Chau, Tang-Tat			An Association between Air Pollution and Daily Outpatient Visits for Respiratory Disease in a Heavy Industry Area	PLOS ONE			English	Article							HOSPITAL ADMISSIONS; ALLERGIC RHINITIS; SUBTROPICAL CITY; ASTHMA; TAIPEI; CONSULTATIONS; QUALITY; MORTALITY; LONDON	In this work we used daily outpatient data from the Landseed Hospital in a heavily industrial area in northern Taiwan to study the associations between daily outpatient visits and air pollution in the context of a heavily polluted atmospheric environment in Chung-Li area during the period 2007-2011. We test the normality of each data set, control for the confounding factors, and calculate correlation coefficient between the outpatient visits and air pollution and meteorology, and use multiple linear regression analysis to seek significance of these associations. Our results show that temperature and relative humidity tend to be negatively associated with respiratory diseases. NO and NO2 are two main air pollutants that are positively associated with respiratory diseases, followed by PM10, PM2.5, O-3, CO, and SO2. Young outpatients (age 0-15 years) are most sensitive to changing air pollution and meteorology factors, followed by the eldest (age >= 66 years) and age 16-65 years of outpatients. Outpatients for COPD diseases are most sensitive to air pollution and meteorology factors, followed by allergic rhinitis, asthma, and pneumonia diseases. In the context of sex difference to air pollution and meteorological factors, male outpatients are more sensitive than female outpatients in the 16-65 age groups, while female outpatients are more sensitive than male outpatients in the young 0-15 age groups and in the eldest age groups. In total, female outpatients are more sensitive to air pollution and meteorological factors than male outpatients.	[Wang, Kuo-Ying] Natl Cent Univ, Dept Atmospher Sci, Chungli 32054, Taiwan; [Chau, Tang-Tat] Taiwan Landseed Hosp, Dept Community Med, Ping Jen, Taiwan	National Central University	Wang, KY (corresponding author), Natl Cent Univ, Dept Atmospher Sci, Chungli 32054, Taiwan.	kuoying@mail.atm.ncu.edu.tw			National Central University-Landseed Hospital [100-A-004, 101-A-006]	National Central University-Landseed Hospital	This work was supported by National Central University-Landseed Hospital-100-A-004 and National Central University-Landseed Hospital-101-A-006. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ahrens C.D., 2021, METEOROLOGY TODAY IN; Braga LHP, 2012, CAN J SURG, V55, P132, DOI 10.1503/cjs.036311; Brookhart MA, 2010, MED CARE, V48, pS114, DOI 10.1097/MLR.0b013e3181dbebe3; Brunekreef B, 2002, LANCET, V360, P1233, DOI 10.1016/S0140-6736(02)11274-8; Chang CC, 2005, ENVIRON RES, V98, P114, DOI 10.1016/j.envres.2004.07.005; Chang SC, 2008, J ENVIRON MANAGE, V86, P627, DOI 10.1016/j.jenvman.2006.12.029; Cheng MF, 2007, J TOXICOL ENV HEAL A, V70, P2021, DOI 10.1080/15287390701601020; Department of Health, 2011, 2010 STAT GEN HLTH; Department of Health, 2012, 2011 TAIW HLTH REP; DOCKERY DW, 1993, NEW ENGL J MED, V329, P1753, DOI 10.1056/NEJM199312093292401; DOCKERY DW, 1994, ANNU REV PUBL HEALTH, V15, P107, DOI 10.1146/annurev.pu.15.050194.000543; Enia G, 2007, NEPHROL DIAL TRANSPL, V22, P538, DOI 10.1093/ndt/gfl605; Executive Yuan, 2011, MONTHL B STAT REP CH; Fang SH, 1996, ATMOS ENVIRON, V30, P735; Hajat S, 2002, OCCUP ENVIRON MED, V59, P294, DOI 10.1136/oem.59.5.294; Hajat S, 2001, AM J EPIDEMIOL, V153, P704, DOI 10.1093/aje/153.7.704; Hajat S, 1999, THORAX, V54, P597, DOI 10.1136/thx.54.7.597; Hsu CY, 2006, ANN INTERN MED, V144, P21, DOI 10.7326/0003-4819-144-1-200601030-00006; Hwang JS, 2002, AM J EPIDEMIOL, V155, P1, DOI 10.1093/aje/155.1.1; Jager KJ, 2008, KIDNEY INT, V73, P256, DOI 10.1038/sj.ki.5002650; Bin J, 2006, J EXPO SCI ENV EPID, V16, P225, DOI 10.1038/sj.jea.7500451; Kleinbaum D.G., 2008, APPL REGRESSION ANAL; Krzyzanowski M, 2008, AIR QUAL ATMOS HLTH, V1, P7, DOI 10.1007/s11869-008-0008-9; Loomis D, 1999, EPIDEMIOLOGY, V10, P118, DOI 10.1097/00001648-199903000-00006; McConnell R, 1999, ENVIRON HEALTH PERSP, V107, P757, DOI 10.2307/3434662; McNamee R, 2005, OCCUP ENVIRON MED, V62, P500, DOI 10.1136/oem.2002.001115; More DS, 2000, STAT CONCEPTS CONTRO; Penna M L, 1991, Bull Pan Am Health Organ, V25, P47; Press W., 1992, NUMERICAL RECIPES AR, DOI DOI 10.2277/052143064X; SCHWARTZ J, 1993, AM REV RESPIR DIS, V147, P826, DOI 10.1164/ajrccm/147.4.826; SCHWARTZ J, 1994, ENVIRON RES, V64, P26, DOI 10.1006/enrs.1994.1004; Sheppard L, 1999, EPIDEMIOLOGY, V10, P23, DOI 10.1097/00001648-199901000-00006; Stone R, 2002, SCIENCE, V298, P2106; Sunyer J, 1997, THORAX, V52, P760, DOI 10.1136/thx.52.9.760; Taiwan Landseed Hospital, 2010, STAT ANN REP MED SER; Taiwan Landseed Hospital, 2011, STAT ANN REP MED SER; Taiwan Landseed Hospital, 2009, STAT ANN REP MED SER; Taiwan Landseed Hospital, 2008, STAT ANN REP MED SER; Tripepi G, 2008, KIDNEY INT, V73, P806, DOI 10.1038/sj.ki.5002787; Villeneuve PJ, 2006, ALLERGY, V61, P750, DOI 10.1111/j.1398-9995.2006.01070.x; Wang KY, 2005, J GEOPHYS RES-ATMOS, V110, DOI 10.1029/2004JD005326; Wang KY, 2004, WATER AIR SOIL POLL, V156, P29, DOI 10.1023/B:WATE.0000036788.41409.5b; WHITTEMORE AS, 1980, AM J PUBLIC HEALTH, V70, P687, DOI 10.2105/AJPH.70.7.687; Wong TW, 2006, THORAX, V61, P585, DOI 10.1136/thx.2005.051730; World Bank, 2007, COST POLL CHIN; Wu TY, 2010, LONDON J PRIM CARE, V3, P115, DOI 10.1080/17571472.2010.11493315; XU XP, 1995, ARCH ENVIRON HEALTH, V50, P214, DOI 10.1080/00039896.1995.9940390; XU XP, 1995, ENVIRON HEALTH PERSP, V103, P286, DOI 10.2307/3432550; Yang CY, 2007, J TOXICOL ENV HEAL A, V70, P1214, DOI 10.1080/15287390701380880; Yang CY, 2007, J TOXICOL ENV HEAL A, V70, P111, DOI 10.1080/15287390600755059	50	50	54	2	58	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 25	2013	8	10							e75220	10.1371/journal.pone.0075220	http://dx.doi.org/10.1371/journal.pone.0075220			25	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	241GW	24204573	gold, Green Published, Green Submitted			2023-01-03	WOS:000326155400007
J	Stonington, SD				Stonington, Scott D.			The Debt of Life - Thai Lessons on a Process-Oriented Ethical Logic	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material								In Thailand, families of dying patients often advocate for aggressive ICU care in order to pay their debt of life. Their reasoning is based on process, not outcome. Many Americans may similarly see the process of providing care as in some ways more important than cure. We love him so much, said Ms. M., standing over her father as he lay on life support in a Boston ICU where I was an intern. We want to do everything or at least I want to, she said tearfully, acknowledging the disagreement among her siblings about how to proceed. Later that morning, I presented her father's case on rounds: after a failed bone marrow transplant, he'd had a myocardial infarction, which had led to heart failure, then renal failure, then pneumonia and sepsis. He was receiving maximal doses of pressors and couldn't be weaned from the ventilator. ...	[Stonington, Scott D.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA; [Stonington, Scott D.] Harvard Univ, Sch Med, Dept Global Hlth & Social Med, Boston, MA USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Harvard Medical School	Stonington, SD (corresponding author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA.			Stonington, Scott/0000-0002-0472-3885				Quill TE, 2009, ANN INTERN MED, V151, P345, DOI 10.7326/0003-4819-151-5-200909010-00010; Stonington SD, 2012, SOC SCI MED, V75, P836, DOI 10.1016/j.socscimed.2012.03.045	2	12	12	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 24	2013	369	17					1583	1585		10.1056/NEJMp1308613	http://dx.doi.org/10.1056/NEJMp1308613			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	239MZ	24152259				2023-01-03	WOS:000326031100006
J	Hao, CZ; Wu, F; Lu, L; Wang, J; Guo, Y; Liu, AJ; Liao, WJ; Zheng, GQ				Hao, Chi-zi; Wu, Fan; Lu, Lin; Wang, Juan; Guo, Yi; Liu, Ai-ju; Liao, Wei-jing; Zheng, Guo-qing			Chinese Herbal Medicine for Diabetic Peripheral Neuropathy: An Updated Meta-Analysis of 10 High-Quality Randomized Controlled Studies	PLOS ONE			English	Article							GLYCEMIC CONTROL; TRIALS; GUIDELINES; STATEMENT; EXERCISE	Background: Diabetic peripheral neuropathy (DPN) is very common in people with diabetes. Chinese herbal medicine (CHM) therapy has been developed for DPN empirically over the years. The aim of this systematic review and meta-analysis was to assess the efficacy and safety of CHMs for patients suffering from DPN. Methods: We performed a meta-analysis of randomized-controlled clinical trials (RCTs) evaluating the efficacy and safety of CHM on DPN. Six databases were searched up to November 2012. The primary outcome measures were the absolute values or changing of motor or sensory nerve conduction velocity (NCV), and the secondary outcome measurements were clinical symptoms improvements and adverse events. The methodological quality was assessed by Jadad scale and the twelve criteria recommended by the Cochrane Back Review Group. Results: One hundred and sixty-three studies claimed RCTs. Ten studies with 653 individuals were further identified based on the Jadad score >= 3. These 10 studies were all of high methodological quality with a low risk of bias. Meta-analysis showed the effects of NCV favoring CHMs when compared with western conventional medicines (WCM) (P<0.05 or P<0.01). There is a significant difference in the total efficacy rate between the two groups (P<0.001). Adverse effects were reported in all of the ten included studies, and well tolerated in all patients with DPN. Conclusion: Despite of the apparently positive findings and low risk of bias, it is premature to conclude the efficacy of CHMs for the treatment of DPN because of the high clinical heterogeneity and small sample sizes of the included studies. However, CHM therapy was safe for DPN. Further standardized preparation, large sample-size and rigorously designed RCTs are required.	[Hao, Chi-zi; Wang, Juan; Liao, Wei-jing] Wuhan Univ, Dept Rehabil, Zhongnan Hosp, Wuhan 430072, Peoples R China; [Wu, Fan; Lu, Lin; Liu, Ai-ju; Zheng, Guo-qing] Wenzhou Med Coll, Ctr Neurol, Affiliated Hosp 2, Wenzhou, Peoples R China; [Guo, Yi] Wuhan Univ, Sch Publ Hlth, Dept Epidemiol, Wuhan 430072, Peoples R China; [Guo, Yi] Wuhan Univ, State Key Lab Virol, Wuhan 430072, Peoples R China	Wuhan University; Wenzhou Medical University; Wuhan University; Wuhan University	Liao, WJ (corresponding author), Wuhan Univ, Dept Rehabil, Zhongnan Hosp, Wuhan 430072, Peoples R China.	weijingliao@sina.com; gq_zheng@sohu.com	Zheng, Guo-qing/A-4412-2019	Zheng, Guo-qing/0000-0001-5286-5696				Agrawal Y, 2010, OTOL NEUROTOL, V31, P1445, DOI 10.1097/MAO.0b013e3181f2f035; *AM DIAB ASS, 1997, DIABETES CARE S, V1, pS1; Balducci S, 2006, J DIABETES COMPLICAT, V20, P216, DOI 10.1016/j.jdiacomp.2005.07.005; Boulton AJM, 2005, DIABETES CARE, V28, P956, DOI 10.2337/diacare.28.4.956; CAO Y, 2011, THESIS SHANDONG U TR; CHEN L, 2011, THESIS BEIJING U CHI; Chen W, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007796.pub2; Chen W, 2011, FORSCH KOMPLEMENTMED, V18, P134, DOI 10.1159/000328457; CHEN ZQ, 2010, SHANDONG MED J, V50, P9; DAHLJORGENSEN K, 1986, BRIT MED J, V293, P1195, DOI 10.1136/bmj.293.6556.1195; DeAngelis CD, 2004, JAMA-J AM MED ASSOC, V292, P1363, DOI 10.1001/jama.292.11.1363; Furlan AD, 2009, SPINE, V34, P1929, DOI 10.1097/BRS.0b013e3181b1c99f; Gagnier JJ, 2006, ANN INTERN MED, V144, P364, DOI 10.7326/0003-4819-144-5-200603070-00013; GAO B, 2005, MED J LIAONING, V19, P12; HENG XP, 2004, J TRADIT CHIN MED, V45, P917; HU JP, 2012, THESIS GUANGZHOU U C; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; JI JL, 2009, J EMERGENCY TRADITIO, V8, P1304; Kjaergard LL, 2001, ANN INTERN MED, V135, P982, DOI 10.7326/0003-4819-135-11-200112040-00010; Kluding PM, 2012, J DIABETES COMPLICAT, V26, P424, DOI 10.1016/j.jdiacomp.2012.05.007; LI L, 2011, THESIS NANJING U CHI; LI YZ, 2005, THESIS HEBEI MED U; LIU Q, 2005, THESIS CHENGDU U TRA; LIU SG, 2004, THESIS FUJIAN COLL T; MA ST, 2005, SICHUAN J PHYSL SCI, V27, P103; Moher David, 2012, Int J Surg, V10, P28, DOI 10.1016/j.ijsu.2011.10.001; Moser JT, 2013, DIABETES RES CLIN PR, V100, pE3, DOI 10.1016/j.diabres.2013.01.015; Perkins BA, 2001, DIABETES CARE, V24, P748, DOI 10.2337/diacare.24.4.748; Rubino Annalisa, 2007, Prim Care Diabetes, V1, P129, DOI 10.1016/j.pcd.2007.07.006; Schulz KF, 2010, ANN INTERN MED, V152, P726, DOI 10.7326/0003-4819-152-11-201006010-00232; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; Sigal RJ, 2007, ANN INTERN MED, V147, P357, DOI 10.7326/0003-4819-147-6-200709180-00005; Stracke H, 1996, EXP CLIN ENDOCR DIAB, V104, P311, DOI 10.1055/s-0029-1211460; Sun W, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039647; Sun Yu, 2005, Acta Neurol Taiwan, V14, P48; Turner RC, 1998, LANCET, V352, P837, DOI 10.1016/s0140-6736(98)07019-6; WANG MX, 2010, HENAN TRADITIONAL CH, V30, P354; Wang Y, 2012, COMPLEMENT THER MED, V20, P143, DOI 10.1016/j.ctim.2011.12.004; WHO (World Health Organization), 1999, WHONCDNCS992, DOI DOI 10.1002/(SICI)1096-9136(199807)15:7; Wooten K, 2009, PHYS MED REH CLIN N, V20, P657, DOI 10.1016/j.pmr.2009.06.011; WU J, 2010, CHONGQING MED, V39, P1377; Wu Q.L., 2012, WORLD J INTEGRATED T, V7, P860, DOI [10.13935/j.cnki.sjzx.2012.10.008, DOI 10.13935/J.CNKI.SJZX.2012.10.008]; Xu HB, 2012, J ETHNOPHARMACOL, V143, P701, DOI 10.1016/j.jep.2012.07.034; XUE HL, 2005, J CHINESE INTEGRATIV, V3, P31; YAQUB BA, 1992, CLIN NEUROL NEUROSUR, V94, P105, DOI 10.1016/0303-8467(92)90066-C; Zeng Jiang-zheng, 2005, Zhong Nan Da Xue Xue Bao Yi Xue Ban, V30, P49; ZHANG Q, 2011, THESIS BEIJING U CHI; ZHANG TJ, 2008, THESIS BEIJING U CHI; ZHANG XK, 2005, SHANXI J TRADITIONAL, V26, P728; Zheng X., 2002, GUIDING PRINCIPLES C, P233; ZHOU XH, 2010, THESIS CHENGDU U TRA	51	13	15	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 16	2013	8	10							e76113	10.1371/journal.pone.0076113	http://dx.doi.org/10.1371/journal.pone.0076113			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	239JR	24146822	Green Published, gold, Green Submitted			2023-01-03	WOS:000326019400037
J	Song, S; Cheong, LZ; Falkeborg, M; Liu, L; Dong, MD; Jensen, HM; Bertelsen, K; Thorsen, M; Tan, TW; Xu, XB; Guo, Z				Song, Shuang; Cheong, Ling-Zhi; Falkeborg, Mia; Liu, Lei; Dong, Mingdong; Jensen, Henrik Max; Bertelsen, Kresten; Thorsen, Michael; Tan, Tianwei; Xu, Xuebing; Guo, Zheng			Facile Synthesis of Phosphatidyl Saccharides for Preparation of Anionic Nanoliposomes with Enhanced Stability	PLOS ONE			English	Article							GENE DELIVERY; LIPOSOMES; CRYOPROTECTANTS; INTERNALIZATION; VITRIFICATION; COMPLEXES; SUGARS	Physical stability during storage and against processing such as dehyration/rehydration are the cornerstone in designing delivery vehicles. In this work, mono-, di- and tri-saccharides were enzymatically conjugated to phosphatidyl group through a facile approach namely phospholipase D (PLD) mediated transphosphatidylation in a biphasic reaction system. The purified products were structurally identified and the connectivities of carbohydrate to phosphatidyl moiety precisely mapped by H-1, P-31, C-13 NMR pulse sequences and LC-ESI-FTMS. The synthetic phosphatidyl saccharides were employed as the sole biomimetic component for preparation of nanoliposomes. It was found that the critical micelle concentration (CMC) of phosphatidyl saccharides increases as more bulky sugar moiety (mono- to tri-) is introduced. Phosphatidyl di- saccharide had the largest membrane curvature. In comparison to the zwitterionic phosphatidylcholine liposome, all phosphatidyl saccharides liposomes are anionic and demonstrated significantly enhanced stability during storage. According to the confocal laser scan microscopy (CLSM) and atom force microscopy (AFM) analyses, the nanoliposomes formed by the synthetic phosphatidyl saccharides also show excellent stability against dehydration/rehydration process in which most of the liposomal structures remained intact. The abundance hydroxyl groups in the saccharide moieties might provide sufficient H-bondings for stabilization. This work demonstrated the synthesized phosphatidyl saccharides are capable of functioning as enzymatically liable materials which can form stable nanoliposomes without addition of stabilizing excipients.	[Song, Shuang; Cheong, Ling-Zhi; Falkeborg, Mia; Xu, Xuebing; Guo, Zheng] Aarhus Univ, Dept Engn, Aarhus, Denmark; [Tan, Tianwei] Beijing Univ Chem Technol, Coll Life Sci & Technol, Beijing 100029, Peoples R China; [Liu, Lei; Dong, Mingdong] Aarhus Univ, Interdisciplinary Nanosci Ctr iNANO, Aarhus, Denmark; [Jensen, Henrik Max; Bertelsen, Kresten; Thorsen, Michael] DuPont Nutr & Hlth, Adv Anal, Brabrand, Denmark	Aarhus University; Beijing University of Chemical Technology; Aarhus University	Tan, TW (corresponding author), Beijing Univ Chem Technol, Coll Life Sci & Technol, Beijing 100029, Peoples R China.	twtan@mail.buct.edu.cn; guo@mb.au.dk	Thorsen, Michael/GQI-1726-2022; Dong, Mingdong/AAC-3023-2020; Xu, Xuebing/GLQ-7148-2022; Dong, Mingdong/B-3341-2010; Cheong, Ling-Zhi/F-5092-2015; dong, mingdong/AAK-9315-2020	Dong, Mingdong/0000-0002-2025-2171; Dong, Mingdong/0000-0002-2025-2171; Cheong, Ling-Zhi/0000-0001-6760-8553; 	"Innovationskonsortiet"; Danish Technological Institute; 973 program [2011CB710800, 2009CB724703, 2011CB200905]; National Nature Science Foundation of China [21076017, 21106005]; Key Projects in the National Science & Technology Pillar Program during the 12th Five-Year Plan Period [2011BAD22B04]; DuPont; Marine Bioproducts; Altlantic Biotechnology; University of Southern Denmark; Villum Fonden [00007194] Funding Source: researchfish	"Innovationskonsortiet"; Danish Technological Institute; 973 program(National Basic Research Program of China); National Nature Science Foundation of China(National Natural Science Foundation of China (NSFC)); Key Projects in the National Science & Technology Pillar Program during the 12th Five-Year Plan Period; DuPont; Marine Bioproducts; Altlantic Biotechnology; University of Southern Denmark; Villum Fonden(Villum Fonden)	This project was funded by "Innovationskonsortiet" and in collaboration with Danish Technological Institute, DuPont, Marine Bioproducts, Altlantic Biotechnology and University of Southern Denmark. This work was also supported by 973 program (2011CB710800, 2009CB724703, 2011CB200905), the National Nature Science Foundation of China (21076017, 21106005), and Key Projects in the National Science & Technology Pillar Program during the 12th Five-Year Plan Period (2011BAD22B04). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ahmed M, 2012, BIOMATERIALS, V33, P7858, DOI 10.1016/j.biomaterials.2012.07.004; ANANTHAPADMANABHAN KP, 1985, LANGMUIR, V1, P352, DOI 10.1021/la00063a015; AUSBORN M, 1994, J CONTROL RELEASE, V30, P105, DOI 10.1016/0168-3659(94)90257-7; Chen CJ, 2010, J CONTROL RELEASE, V142, P299, DOI 10.1016/j.jconrel.2009.10.024; Crowe JH, 1996, BBA-BIOMEMBRANES, V1280, P187, DOI 10.1016/0005-2736(95)00287-1; CROWE LM, 1985, ARCH BIOCHEM BIOPHYS, V242, P240, DOI 10.1016/0003-9861(85)90498-9; FISHER K, 2000, FORMATION SELF ASSEM; Gratton SEA, 2008, P NATL ACAD SCI USA, V105, P11613, DOI 10.1073/pnas.0801763105; Hsu CYM, 2012, BIOMATERIALS, V33, P7834, DOI 10.1016/j.biomaterials.2012.06.093; Huang Z, 2008, J AM CHEM SOC, V130, P15702, DOI 10.1021/ja8065557; Ingvarsson PT, 2011, EXPERT OPIN DRUG DEL, V8, P375, DOI 10.1517/17425247.2011.553219; KOSTER KL, 1994, BBA-BIOMEMBRANES, V1193, P143, DOI 10.1016/0005-2736(94)90343-3; Latxague L, 2011, CHEM COMMUN, V47, P12598, DOI 10.1039/c1cc13948g; Li L. L., 2012, ANGEW CHEM INT EDIT, V51, P1, DOI DOI 10.1002/ANIE.201106864; Liu SC, 2002, J AM CHEM SOC, V124, P6037, DOI 10.1021/ja0123507; Ma MM, 2011, CHEM COMMUN, V47, P2853, DOI 10.1039/c0cc05137c; Mady MM, 2011, AFR J PHARM PHARMACO, V5, P1898, DOI 10.5897/AJPP11.462; Maitani Y, 2008, INT J PHARM, V356, P69, DOI 10.1016/j.ijpharm.2007.12.033; Miniadis-Meimaroglou S, 2008, CHEM PHYS LIPIDS, V152, P104, DOI 10.1016/j.chemphyslip.2008.01.003; Murthy BN, 2012, RSC ADV, V2, P1329, DOI 10.1039/c2ra01192a; Perttu EK, 2012, J AM CHEM SOC, V134, P4485, DOI 10.1021/ja210989h; Qi W, 2010, J MATER CHEM, V20, P2121, DOI 10.1039/b920469p; SANTAELLA C, 1991, ANGEW CHEM INT EDIT, V30, P567, DOI 10.1002/anie.199105671; Schafer J, 2010, BIOMATERIALS, V31, P6892, DOI 10.1016/j.biomaterials.2010.05.043; SHINODA K, 1959, J PHYS CHEM-US, V63, P648, DOI 10.1021/j150575a003; Song S, 2012, FOOD CHEM, V135, P373, DOI 10.1016/j.foodchem.2012.05.020; Stark B, 2010, EUR J PHARM SCI, V41, P546, DOI 10.1016/j.ejps.2010.08.010; Torchilin VP, 2005, NAT REV DRUG DISCOV, V4, P145, DOI 10.1038/nrd1632; vanHal DA, 1996, J COLLOID INTERF SCI, V178, P263, DOI 10.1006/jcis.1996.0114	29	14	14	3	42	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 12	2013	8	9							e73891	10.1371/journal.pone.0073891	http://dx.doi.org/10.1371/journal.pone.0073891			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	242KO	24069243	Green Published, gold, Green Submitted			2023-01-03	WOS:000326240100067
J	Metaxakis, A; Partridge, L				Metaxakis, Athanasios; Partridge, Linda			Dietary Restriction Extends Lifespan in Wild-Derived Populations of Drosophila melanogaster	PLOS ONE			English	Article							CALORIC RESTRICTION; NUTRITION; HISTORY	Dietary restriction (DR) can result in lifespan-extension and improved function and health during ageing. Although the impact of DR on lifespan and health has been established in a variety of organisms, most DR experiments are carried out on laboratory strains that have often undergone adaptation to laboratory conditions. The effect of DR on animals recently derived from wild populations is rarely assessed. We measured the DR response of four populations of Drosophila melanogaster within two generations of collection from the wild. All populations responded to DR with an increase in lifespan and a decrease in female fecundity, similarly to a control, laboratory-adapted strain. These effects of DR are thus not a result of adaptation to laboratory conditions, and reflect the characteristics of natural populations.	[Metaxakis, Athanasios; Partridge, Linda] Max Planck Inst Biol Ageing, Cologne, Germany; [Metaxakis, Athanasios; Partridge, Linda] UCL, Inst Healthy Ageing, London, England; [Metaxakis, Athanasios; Partridge, Linda] UCL, Dept Genet Evolut & Environm, London, England	Max Planck Society; University of London; University College London; University of London; University College London	Partridge, L (corresponding author), Max Planck Inst Biol Ageing, Cologne, Germany.	Partridge@age.mpg.de	Partridge, Linda/E-7342-2015	Partridge, Linda/0000-0001-9615-0094	Max Planck grant	Max Planck grant	Max Planck grant. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bass TM, 2007, J GERONTOL A-BIOL, V62, P1071, DOI 10.1093/gerona/62.10.1071; Chapman T, 1996, P ROY SOC B-BIOL SCI, V263, P755, DOI 10.1098/rspb.1996.0113; CHAPMAN T, 1994, J EVOLUTION BIOL, V7, P51, DOI 10.1046/j.1420-9101.1994.7010051.x; CHIPPINDALE AK, 1993, J EVOLUTION BIOL, V6, P171, DOI 10.1046/j.1420-9101.1993.6020171.x; Clancy David J., 2001, Drosophila Information Service, V84, P168; Colman RJ, 2009, SCIENCE, V325, P201, DOI 10.1126/science.1173635; Fontana L, 2010, SCIENCE, V328, P321, DOI 10.1126/science.1172539; Grandison RC, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004067; Harper JM, 2006, AGING CELL, V5, P441, DOI 10.1111/j.1474-9726.2006.00236.x; Jiang JC, 2000, FASEB J, V14, P2135; Kaeberlein M, 2004, PLOS BIOL, V2, P1381, DOI 10.1371/journal.pbio.0020296; KLASS MR, 1977, MECH AGEING DEV, V6, P413, DOI 10.1016/0047-6374(77)90043-4; Lakowski B, 1998, P NATL ACAD SCI USA, V95, P13091, DOI 10.1073/pnas.95.22.13091; Liao CY, 2010, AGING CELL, V9, P92, DOI 10.1111/j.1474-9726.2009.00533.x; Linnen C, 2001, EVOL ECOL RES, V3, P877; Mair W, 2005, PLOS BIOL, V3, P1305, DOI 10.1371/journal.pbio.0030223; Mattison JA, 2012, NATURE, V489, P318, DOI 10.1038/nature11432; McCay CM, 1935, J NUTR, V10, P63, DOI 10.1093/jn/10.1.63; Partridge L, 2011, AGING CELL, V10, P5, DOI 10.1111/j.1474-9726.2010.00649.x; Sgro CM, 2001, AM NAT, V158, P657, DOI 10.1086/323592; Sutphin GL, 2008, EXP GERONTOL, V43, P130, DOI 10.1016/j.exger.2007.10.019; Tatar M, 2011, EXP GERONTOL, V46, P363, DOI 10.1016/j.exger.2010.12.002; Weindruch R., 1988, RETARDATION AGING DI; Wong R, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006063	24	22	22	0	25	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 10	2013	8	9							e74681	10.1371/journal.pone.0074681	http://dx.doi.org/10.1371/journal.pone.0074681			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	259PK	24040317	Green Published, gold, Green Submitted			2023-01-03	WOS:000327538600107
J	Tomeczkowski, J; Stern, S; Muller, A; von Heymann, C				Tomeczkowski, Joerg; Stern, Sean; Mueller, Alfred; von Heymann, Christian			Potential Cost Saving of Epoetin alfa in Elective Hip or Knee Surgery due to Reduction in Blood Transfusions and Their Side Effects: A Discrete-Event Simulation Model	PLOS ONE			English	Article							PREOPERATIVE ANEMIA; ORTHOPEDIC-SURGERY; INTRAOPERATIVE TRANSFUSION; CONSERVATION ALGORITHM; IRON SUPPLEMENTATION; DEMOGRAPHIC-CHANGES; ERYTHROPOIETIN; ARTHROPLASTY; MANAGEMENT; REPLACEMENT	Objectives: Transfusion of allogeneic blood is still common in orthopedic surgery. This analysis evaluates from the perspective of a German hospital the potential cost savings of Epoetin alfa (EPO) compared to predonated autologous blood transfusions or to a nobloodconservationstrategy (allogeneic blood transfusion strategy)during elective hip and knee replacement surgery. Methods: Individual patients (N=50,000) were simulated based on data from controlled trials, the German DRG institute (InEK) and various publications and entered into a stochastic model (Monte-Carlo) of three treatment arms: EPO, preoperative autologous donation and nobloodconservationstrategy. All three strategies lead to a different risk for an allogeneic blood transfusion. The model focused on the costs and events of the three different procedures. The costs were obtained from clinical trial databases, the German DRG system, patient records and medical publications: transfusion (allogeneic red blood cells: (sic)320/unit and autologous red blood cells: (sic)250/unit), pneumonia treatment ((sic)5,000), and length of stay ((sic)300/day). Probabilistic sensitivity analyses were performed to determine which factors had an influence on the model's clinical and cost outcomes. Results: At acquisition costs of (sic)200/40,000 IU EPO is cost saving compared to autologous blood donation, and costeffective compared to a nobloodconservationstrategy. The results were most sensitive to the cost of EPO, blood units and hospital days. Conclusions: EPO might become an attractive blood conservation strategy for anemic patients at reasonable costs due to the reduction in allogeneic blood transfusions, in the modeled incidence of transfusion-associated pneumonia and the prolongedlength of stay.	[Tomeczkowski, Joerg] Janssen Cilag GmbH, Dept Hlth Econ, Neuss, Germany; [Stern, Sean] United Biosource Corp, Bethesda, MD USA; [Mueller, Alfred] Analyt Serv GmbH, Munich, Germany; [von Heymann, Christian] Charite, Dept Anesthesiol & Intens Care Med, D-13353 Berlin, Germany	Johnson & Johnson; United Biosource Corporation; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Tomeczkowski, J (corresponding author), Janssen Cilag GmbH, Dept Hlth Econ, Neuss, Germany.	jtomeczk@its.jnj.com			Janssen-Cilag Germany GmbH	Janssen-Cilag Germany GmbH	The work on the model was funded by Janssen-Cilag Germany GmbH. Confounding and bias is therefore possible.	Abraham I, 2012, TRANSFUSION, V52, P1983, DOI 10.1111/j.1537-2995.2011.03532.x; Alsaleh KA, 2013, J ARTHROPLASTY; [Anonymous], 2010, OPERATIONEN PROZEDUR; [Anonymous], 2011, G DRG REP BROWS HA V; Beattie WS, 2009, ANESTHESIOLOGY, V110, P574, DOI 10.1097/ALN.0b013e31819878d3; Bernard AC, 2009, J AM COLL SURGEONS, V208, P931, DOI 10.1016/j.jamcollsurg.2008.11.019; Borkent-Raven BA, 2010, TRANSFUSION, V50, P2455, DOI 10.1111/j.1537-2995.2010.02716.x; Carson JL, 2012, ANN INTERN MED, V157, P49, DOI 10.7326/0003-4819-157-1-201206190-00429; Carson JL, 2002, TRANSFUS MED REV, V16, P187, DOI 10.1053/tmrv.2002.33461; Coyle D, 1999, TRANSFUSION MED, V9, P21; Davis L, 2006, COST EFECTIVENESS CE, V10; Delasotta LA, 2012, ADV ORTHOP, V2012, DOI 10.1155/2012/595027; Delasotta Lawrence A, 2012, Open Orthop J, V6, P179, DOI 10.2174/1874325001206010179; Feagan BG, 2000, ANN INTERN MED, V133, P845, DOI 10.7326/0003-4819-133-11-200012050-00008; Feagan BG, 2001, TRANSFUSION MED, V11, P87, DOI 10.1046/j.1365-3148.2001.00291.x; Fergusson DA, 2005, CAN J ANAESTH, V52, P347; Ferraris VA, 2011, ANN THORAC SURG, V91, P1674, DOI 10.1016/j.athoracsur.2011.01.025; Flegel WA, 2012, BLOOD TRANSFUS-ITALY, V10, P247, DOI 10.2450/2012.0105-12; Freedman J, 2008, TRANSFUSION, V48, P237, DOI 10.1111/j.1537-2995.2007.01515.x; Goodnough LT, 2011, BRIT J ANAESTH, V106, P13, DOI 10.1093/bja/aeq361; Goodnough LT, 1998, CLIN ORTHOP RELAT R, P82; Green WS, 2010, J ARTHROPLASTY, V25, P93, DOI 10.1016/j.arth.2008.10.005; Greinacher A, 2011, TRANSFUSION, V51, P702, DOI 10.1111/j.1537-2995.2010.02882.x; Greinacher A, 2010, TRANSFUS MED HEMOTH, V37, P141, DOI 10.1159/000313949; Grosflam J M, 1995, Arthritis Care Res, V8, P167, DOI 10.1002/art.1790080309; Hardwick ME, 2004, CLIN ORTHOP RELAT R, P240, DOI 10.1097/01.blo.0000130206.58617.9e; Henry DA, 2002, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD003602; Henseler O, 2011, REPORT NOTIFICATIONS; Hod EA, 2011, BLOOD, V118, P6675, DOI 10.1182/blood-2011-08-371849; Janssen-Cilag GmbH, FACH ERYPO; Karkouti K, 2012, ANESTHESIOLOGY, V117, P1175, DOI 10.1097/ALN.0b013e318271604e; Katherine Luke RN, ONTRAC ONTARIO NURSE; Kendoff D, 2011, ORTHOPADE, V40, P1018, DOI 10.1007/s00132-011-1789-3; Kotze A, 2012, BRIT J ANAESTH, V108, P943, DOI 10.1093/bja/aes135; Mahadevan D, 2010, J ORTHOP TRAUMATOL, V11, P159, DOI 10.1007/s10195-010-0105-z; Martinez V, 2007, BRIT J ANAESTH, V99, P794, DOI 10.1093/bja/aem266; Muller-Lobeck Lutz, THESIS RUPRECHT KARL; Munoz M, 2009, VOX SANG, V96, P1, DOI 10.1111/j.1423-0410.2008.01108.x; Olijhoek G, 2001, TRANSFUSION, V41, P957, DOI 10.1046/j.1537-2995.2001.41070957.x; Pandey Prashant, 2010, Asian J Transfus Sci, V4, P78, DOI 10.4103/0973-6247.67021; Pedersen AB, 2009, BMC MUSCULOSKEL DIS, V10, DOI 10.1186/1471-2474-10-167; Pierson JL, 2004, J BONE JOINT SURG AM, V86A, P1512, DOI 10.2106/00004623-200407000-00022; Rashiq S, 2004, ANESTH ANALG, V99, P1239, DOI 10.1213/01.ANE.0000132928.45858.92; Rosencher N, 2005, CAN J ANAESTH, V52, P160, DOI 10.1007/BF03027722; Rosencher N, 2003, TRANSFUSION, V43, P459, DOI 10.1046/j.1537-2995.2003.00348.x; Sauer J, 2004, Z ORTHOP GRENZGEB, V142, P673, DOI 10.1055/s-2004-820380; Seifried E, 2011, Vox Sang, V100, P10, DOI 10.1111/j.1423-0410.2010.01446.x; Shander A, 2010, TRANSFUSION, V50, P753, DOI 10.1111/j.1537-2995.2009.02518.x; Slappendel R, 2005, TIJDSCHRIFTVOORORTHO, V12, P212; Slappendel R, 2006, ACTA ORTHOP, V77, P677, DOI 10.1080/17453670610012782; Spahn DR, 2008, ANESTHESIOLOGY, V109, P951, DOI 10.1097/ALN.0b013e31818e3d75; Stowell CP, 1999, ORTHOPEDICS, V22, pS105; VinniJuneja M, CONTINUING REASSESSM; Weber EWG, 2005, EUR J ANAESTH, V22, P249, DOI 10.1017/S0265021505000426; Weber EWG, 2005, ANESTH ANALG, V100, P1416, DOI 10.1213/01.ANE.0000150610.44631.9D; Wong CJ, 2007, TRANSFUSION, V47, P832, DOI 10.1111/j.1537-2995.2007.01197.x; World Health Organization, 2006, APPR CLIN US BLOOD B	57	11	17	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 9	2013	8	9							e72949	10.1371/journal.pone.0072949	http://dx.doi.org/10.1371/journal.pone.0072949			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	244QV	24039829	Green Published, gold, Green Submitted			2023-01-03	WOS:000326405300037
J	Ko, MJ; Wu, HY; Chen, HY; Chiu, YL; Hsu, SP; Pai, MF; Ju-YehYang; Lai, CF; Lu, HM; Huang, SC; Yang, SY; Wen, SY; Chiu, HC; Hu, FC; Peng, YS; Jee, SH				Ko, Mei-Ju; Wu, Hon-Yen; Chen, Hung-Yuan; Chiu, Yen-Ling; Hsu, Shih-Ping; Pai, Mei-Fen; Ju-YehYang; Lai, Chun-Fu; Lu, Hui-Min; Huang, Shu-Chen; Yang, Shao-Yu; Wen, Su-Yin; Chiu, Hsien-Ching; Hu, Fu-Chang; Peng, Yu-Sen; Jee, Shiou-Hwa			Uremic Pruritus, Dialysis Adequacy, and Metabolic Profiles in Hemodialysis Patients: A Prospective 5-Year Cohort Study	PLOS ONE			English	Article							DOUBLE-BLIND; MEMBRANE; FLUX; DISAPPEARANCE; NALTREXONE; SURVIVAL	Background: Uremic pruritus is a common and intractable symptom in patients on chronic hemodialysis, but factors associated with the severity of pruritus remain unclear. This study aimed to explore the associations of metabolic factors and dialysis adequacy with the aggravation of pruritus. Methods: We conducted a 5-year prospective cohort study on patients with maintenance hemodialysis. A visual analogue scale (VAS) was used to assess the intensity of pruritus. Patient demographic and clinical characteristics, laboratory parameters, dialysis adequacy (assessed by Kt/V), and pruritus intensity were recorded at baseline and follow-up. Change score analysis of the difference score of VAS between baseline and follow-up was performed using multiple linear regression models. The optimal threshold of Kt/V, which is associated with the aggravation of uremic pruritus, was determined by generalized additive models and receiver operating characteristic analysis. Results: A total of 111 patients completed the study. Linear regression analysis showed that lower Kt/V and use of low-flux dialyzer were significantly associated with the aggravation of pruritus after adjusting for the baseline pruritus intensity and a variety of confounding factors. The optimal threshold value of Kt/V for pruritus was 1.5 suggested by both generalized additive models and receiver operating characteristic analysis. Conclusions: Hemodialysis with the target of Kt/V >1.5 and use of high-flux dialyzer may reduce the intensity of pruritus in patients on chronic hemodialysis. Further clinical trials are required to determine the optimal dialysis dose and regimen for uremic pruritus.	[Ko, Mei-Ju; Wen, Su-Yin] Taipei City Hosp, Ren Ai Branch, Dept Dermatol, Taipei, Taiwan; [Wu, Hon-Yen; Chen, Hung-Yuan; Chiu, Yen-Ling; Hsu, Shih-Ping; Pai, Mei-Fen; Ju-YehYang; Lai, Chun-Fu; Yang, Shao-Yu; Peng, Yu-Sen] Far Eastern Mem Hosp, Dept Internal Med, New Taipei City, Taiwan; [Lu, Hui-Min; Huang, Shu-Chen] Far Eastern Mem Hosp, Dept Nursing, New Taipei City, Taiwan; [Ko, Mei-Ju; Chiu, Hsien-Ching; Jee, Shiou-Hwa] Natl Taiwan Univ Hosp, Dept Dermatol, Taipei, Taiwan; [Ko, Mei-Ju; Wu, Hon-Yen; Chen, Hung-Yuan; Chiu, Yen-Ling; Hsu, Shih-Ping; Pai, Mei-Fen; Ju-YehYang; Lai, Chun-Fu; Yang, Shao-Yu; Chiu, Hsien-Ching; Peng, Yu-Sen; Jee, Shiou-Hwa] Natl Taiwan Univ, Coll Med, Taipei 10764, Taiwan; [Wu, Hon-Yen; Chen, Hung-Yuan; Chiu, Yen-Ling; Hsu, Shih-Ping; Pai, Mei-Fen; Ju-YehYang; Lai, Chun-Fu; Yang, Shao-Yu; Peng, Yu-Sen] Natl Taiwan Univ Hosp, Dept Internal Med, Taipei 100, Taiwan; [Ko, Mei-Ju; Hu, Fu-Chang] Natl Taiwan Univ, Grad Inst Clin Med, Taipei 10764, Taiwan; [Wu, Hon-Yen] Natl Taiwan Univ, Grad Inst Epidemiol & Prevent Med, Taipei 10764, Taiwan; [Hu, Fu-Chang] Natl Taiwan Univ, Sch Nursing, Taipei 10764, Taiwan	Taipei City Hospital; Far Eastern Memorial Hospital; Far Eastern Memorial Hospital; National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University; National Taiwan University	Peng, YS (corresponding author), Far Eastern Mem Hosp, Dept Internal Med, New Taipei City, Taiwan.	taan70@yahoo.com.tw; shiouhwa@ntu.edu.tw	peng, yu/GXW-2071-2022; Chiu, Yen-Ling/AAV-3431-2021; Yang, SY/AAN-1918-2021	Chiu, Yen-Ling/0000-0003-4504-5571; CHIU, HSIEN-CHING/0000-0002-1409-8470; YANG, SHAO-YU/0000-0001-9170-2566; JEE, SHIOU-HWA/0000-0001-6737-6297; LAI, CHUN-FU/0000-0003-2109-1522	Taipei City Hospital; Ta-Tung Kidney Foundation; Mrs. Hsiu-Chin Lee Kidney Research Foundation (Taipei, Taiwan)	Taipei City Hospital; Ta-Tung Kidney Foundation; Mrs. Hsiu-Chin Lee Kidney Research Foundation (Taipei, Taiwan)	This work was financially supported by grants from the Taipei City Hospital (to Dr. Mei-Ju Ko), the Ta-Tung Kidney Foundation, and the Mrs. Hsiu-Chin Lee Kidney Research Foundation (Taipei, Taiwan). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2006, AM J KIDNEY DIS, DOI [10.1053/j.ajkd.2006.03.051, DOI 10.1053/J.AJKD.2006.03.051.MEDLINE]; Benedetti A, 2009, INT J BIOSTAT, V5, DOI 10.2202/1557-4679.1172; Chen HY, 2010, QJM-INT J MED, V103, P837, DOI 10.1093/qjmed/hcq036; Chertow GM, 2010, NEW ENGL J MED, V363, P2287, DOI 10.1056/NEJMoa1001593; Chiu YL, 2008, NEPHROL DIAL TRANSPL, V23, P3685, DOI 10.1093/ndt/gfn303; Clarke PS, 2004, EPIDEMIOLOGY, V15, P414, DOI 10.1097/01.ede.0000120882.86399.e8; Daugirdas J T, 1995, Adv Ren Replace Ther, V2, P295; DESTRIHOU CV, 1991, KIDNEY INT, V39, P1012, DOI 10.1038/ki.1991.128; Duque MI, 2006, CLIN NEPHROL, V66, P184; Dyachenko P, 2006, INT J DERMATOL, V45, P664, DOI 10.1111/j.1365-4632.2005.02592.x; Eknoyan G, 2002, NEW ENGL J MED, V347, P2010, DOI 10.1056/NEJMoa021583; GRAF H, 1979, BRIT MED J, V2, P1478, DOI 10.1136/bmj.2.6203.1478-a; Hastie T, 1990, GAM PACKAGE; Hastie T.J., 1991, GEN ADDITIVE MODELS, DOI DOI 10.1111/APT.14066; HIROSHIGE K, 1995, AM J KIDNEY DIS, V25, P413, DOI 10.1016/0272-6386(95)90102-7; Kaysen GA, 2001, J AM SOC NEPHROL, V12, P1549, DOI 10.1681/ASN.V1271549; Ko MJ, 2011, BRIT J DERMATOL, V165, P633, DOI 10.1111/j.1365-2133.2011.10448.x; Koda Y, 1997, KIDNEY INT, V52, P1096, DOI 10.1038/ki.1997.434; MASI CM, 1992, NEPHRON, V62, P257, DOI 10.1159/000187055; MASSRY SG, 1968, NEW ENGL J MED, V279, P697, DOI 10.1056/NEJM196809262791308; Mathur VS, 2010, CLIN J AM SOC NEPHRO, V5, P1410, DOI 10.2215/CJN.00100110; Mistik S, 2006, J EUR ACAD DERMATOL, V20, P672, DOI 10.1111/j.1468-3083.2006.01570.x; Morton CA, 1996, NEPHROL DIAL TRANSPL, V11, P2031, DOI 10.1093/oxfordjournals.ndt.a027092; Narita I, 2006, KIDNEY INT, V69, P1626, DOI 10.1038/sj.ki.5000251; Narita I, 2008, J NEPHROL, V21, P161; Owen WF, 1998, JAMA-J AM MED ASSOC, V280, P1764, DOI 10.1001/jama.280.20.1764; Pauli-Magnus C, 2000, J AM SOC NEPHROL, V11, P514, DOI 10.1681/ASN.V113514; Peer G, 1996, LANCET, V348, P1552, DOI 10.1016/S0140-6736(96)04176-1; Pisoni RL, 2006, NEPHROL DIAL TRANSPL, V21, P3495, DOI 10.1093/ndt/gfl461; Port FK, 2002, J AM SOC NEPHROL, V13, DOI 10.1681/ASN.V1341061; SERES DS, 1993, J AM SOC NEPHROL, V3, P1409; WARE JH, 1985, AM STAT, V39, P95, DOI 10.2307/2682803; Wikstrom B, 2005, J AM SOC NEPHROL, V16, P3742, DOI 10.1681/ASN.2005020152; Wolfe RA, 2000, AM J KIDNEY DIS, V35, P80, DOI 10.1016/S0272-6386(00)70305-2; Yee TW, 1996, J ROY STAT SOC B MET, V58, P481; Yee TW, 2012, VGAM VECTOR GEN LINE; Yosipovitch G, 2001, ACTA DERM-VENEREOL, V81, P108; YOUDEN WJ, 1950, CANCER-AM CANCER SOC, V3, P32, DOI 10.1002/1097-0142(1950)3:1<32::AID-CNCR2820030106>3.0.CO;2-3; Zucker I, 2003, J AM ACAD DERMATOL, V49, P842, DOI 10.1016/S0190-9622(03)02478-2	39	50	53	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 6	2013	8	8							e71404	10.1371/journal.pone.0071404	http://dx.doi.org/10.1371/journal.pone.0071404			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	217ZG	23940749	Green Submitted, gold, Green Published			2023-01-03	WOS:000324401500069
J	Chan, AS; Sze, SL; Siu, NY; Lau, EM; Cheung, MC				Chan, Agnes S.; Sze, Sophia L.; Siu, Nicolson Y.; Lau, Eliza M.; Cheung, Mei-chun			A Chinese Mind-Body Exercise Improves Self-Control of Children with Autism: A Randomized Controlled Trial	PLOS ONE			English	Article							PROGRESSIVE MUSCLE-RELAXATION; ANTERIOR CINGULATE CORTEX; YOUNG-CHILDREN; SPECTRUM DISORDERS; PREFRONTAL CORTEX; INTERVENTIONS; ADOLESCENTS; AGGRESSION; ACTIVATION; THERAPIES	Self-control problems commonly manifest as temper outbursts and repetitive/rigid/impulsive behaviors, in children with autism spectrum disorders (ASD), which often contributes to learning difficulties and caregiver burden. The present study aims to compare the effect of a traditional Chinese Chan-based mind-body exercise, Nei Yang Gong, with that of the conventional Progressive Muscle Relaxation (PMR) technique in enhancing the self-control of children with ASD. Forty-six age-and IQ-matched ASD children were randomly assigned to receive group training in Nei Yang Gong (experimental group) or PMR (control group) twice per week for four weeks. The participants' self-control was measured by three neuropsychological tests and parental rating on standardized questionnaires, and the underlying neural mechanism was assessed by the participants' brain EEG activity during an inhibitory-control task before and after intervention. The results show that the experimental group demonstrated significantly greater improvement in self-control than the control group, which concurs with the parental reports of reduced autistic symptoms and increased control of temper and behaviors. In addition, the experimental group showed enhanced EEG activity in the anterior cingulate cortex, a region that mediates self-control, whereas the PMR group did not. The present findings support the potential application of Chinese Chan-based mind-body exercises as a form of neuropsychological rehabilitation for patients with self-control problems. Chinese Clinical Trial Registry; Registration No.: ChiCTR-TRC-12002561; URL: www.chictr.org.	[Chan, Agnes S.; Sze, Sophia L.; Siu, Nicolson Y.; Lau, Eliza M.] Chinese Univ Hong Kong, Dept Psychol, Neuropsychol Lab, Shatin, Hong Kong, Peoples R China; [Chan, Agnes S.; Sze, Sophia L.] Chinese Univ Hong Kong, Integrat Neuropsychol Rehabil Ctr, Shatin, Hong Kong, Peoples R China; [Chan, Agnes S.] Henan Songshan Res Inst Chanwuyi, Chanwuyi, Henan, Peoples R China; [Cheung, Mei-chun] Hong Kong Polytech Univ, Inst Text & Clothing, Kowloon, Hong Kong, Peoples R China	Chinese University of Hong Kong; Chinese University of Hong Kong; Hong Kong Polytechnic University	Chan, AS (corresponding author), Chinese Univ Hong Kong, Dept Psychol, Neuropsychol Lab, Shatin, Hong Kong, Peoples R China.	aschan@psy.cuhk.edu.hk	Cheung, Mei-chun/A-1261-2014	Cheung, Mei-chun/0000-0002-0210-0772; Siu, Yat Fan/0000-0001-9465-8310	Hong Kong Polytechnic University [A-PK67, 4-ZZD1]	Hong Kong Polytechnic University(Hong Kong Polytechnic University)	This study was partly supported by a donation from Mr. Sau Hung Li to The Chinese University of Hong Kong and partly by the research fund from The Hong Kong Polytechnic University (A-PK67 and 4-ZZD1). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adams JB, 2004, J ALTERN COMPLEM MED, V10, P1033, DOI 10.1089/acm.2004.10.1033; Agam Y, 2010, NEUROIMAGE, V52, P336, DOI 10.1016/j.neuroimage.2010.04.010; Allam H, 2008, J ALTERN COMPLEM MED, V14, P109, DOI 10.1089/acm.2007.0508; American Psychiatric Association, 2000, DIAGNOSTIC STAT MANU; Asada H, 1999, NEUROSCI LETT, V274, P29, DOI 10.1016/S0304-3940(99)00679-5; Autism Treatment Evaluation Checklist, 2000, REL SCOR DISTR; Bahrami F, 2012, RES DEV DISABIL, V33, P1183, DOI 10.1016/j.ridd.2012.01.018; Beider S, 2007, EVID-BASED COMPL ALT, V4, P23, DOI 10.1093/ecam/nel068; Benson H., 2000, J RES DEV EDUC, V33, P156; Botvinick MM, 2004, TRENDS COGN SCI, V8, P539, DOI 10.1016/j.tics.2004.10.003; Chan A. S., 2008, J PSYCHOL CHINESE SO, V9, P225; Chan A. S, 2013, CONT APPL SHAOLIN ME; Chan A. S., 2010, SHAOLIN CHANWUYI CHI; Chan A. S., 2008, MIND BODY RELAXATION, P165; Chan AS, 2012, J AFFECT DISORDERS, V142, P283, DOI 10.1016/j.jad.2012.05.018; Chan AS, 2012, SCI WORLD J, DOI 10.1100/2012/235206; Chan AS, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/262136; Chan AS, 2011, EVID-BASED COMPL ALT, V2011, DOI 10.1155/2011/180704; Chan AS, 2011, RES AUTISM SPECT DIS, V5, P254, DOI 10.1016/j.rasd.2010.04.007; Chan Agnes S, 2009, Cases J, V2, P9080, DOI 10.1186/1757-1626-2-9080; CHAN AS, 2011, EVID-BASED COMPL ALT, P1, DOI DOI 10.1093/ECAM/NEP043; Chan AS, 2013, COMPREHENSI IN PRESS; CHAN AS, 2011, EVID-BASED COMPL ALT, P1, DOI DOI 10.1155/2011/549254; Chen KW, 2012, DEPRESS ANXIETY, V29, P545, DOI 10.1002/da.21964; Cheuk DKL, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007849.pub2; Chiang LC, 2009, INT J NURS STUD, V46, P1061, DOI 10.1016/j.ijnurstu.2009.01.013; Culbertson WC, 2005, TOWER LONDON DX MANU; Cullen-Powell Lesley A, 2005, J Child Health Care, V9, P245, DOI 10.1177/1367493505056479; Diamond A, 2011, SCIENCE, V333, P959, DOI 10.1126/science.1204529; Elliott R, 1998, NEUROIMAGE, V8, P17, DOI 10.1006/nimg.1998.0344; Goin-Kochel RP, 2007, RES AUTISM SPECT DIS, V1, P195, DOI 10.1016/j.rasd.2006.08.006; Gold C, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004381.pub2; Goldbeck L, 2003, J AM ACAD CHILD PSY, V42, P1046, DOI 10.1097/01.CHI.0000070244.24125.F; Granpeesheh D, 2010, RES AUTISM SPECT DIS, V4, P268, DOI 10.1016/j.rasd.2009.09.014; Haznedar MM, 2006, AM J PSYCHIAT, V163, P1252, DOI 10.1176/appi.ajp.163.7.1252; Hyman SL, 2011, EVIDENCE-BASED PRACTICES AND TREATMENTS FOR CHILDREN WITH AUTISM, P275, DOI 10.1007/978-1-4419-6975-0_10; Ishii R, 1999, NEUROREPORT, V10, P675, DOI 10.1097/00001756-199903170-00003; Jacobson E., 1962, YOU MUST RELAX; JARUSIEWICZ B, 2002, J NEUROTHERAPY, V6, P39, DOI [DOI 10.1300/J184V06N04_05, 10.1300/J184v06n04_05]; Kenworthy L, 2008, NEUROPSYCHOL REV, V18, P320, DOI 10.1007/s11065-008-9077-7; Klem G H, 1999, Electroencephalogr Clin Neurophysiol Suppl, V52, P3; Lakes KD, 2004, J APPL DEV PSYCHOL, V25, P283, DOI 10.1016/j.appdev.2004.04.002; Langen M, 2012, CORTEX, V48, P183, DOI 10.1016/j.cortex.2011.05.018; Lohaus A, 2003, PSYCHOL HEALTH, V18, P237, DOI 10.1080/0887044021000057257; Lonsdale D, 2002, NEUROENDOCRINOL LETT, V23, P303; Lopata C, 2003, BEHAV DISORDERS, V28, P162; Lopata C, 2006, TEACH EXCEPT CHILD, V38, P20, DOI 10.1177/004005990603800403; LORD C, 1994, J AUTISM DEV DISORD, V24, P659, DOI 10.1007/BF02172145; Magiati I, 2011, J INTELL DISABIL RES, V55, P302, DOI 10.1111/j.1365-2788.2010.01359.x; Malloy-Diniz Leandro Fernandes, 2008, Dement. neuropsychol., V2, P26, DOI [10.1590/S1980-57642009DN20100006, 10.1590/s1980-57642009dn20100006]; Matson JL, 2008, RES AUTISM SPECT DIS, V2, P60, DOI 10.1016/j.rasd.2007.03.003; Mullins JL, 2001, RES DEV DISABIL, V22, P449; Mulloy A, 2010, RES AUTISM SPECT DIS, V4, P328, DOI 10.1016/j.rasd.2009.10.008; National Research Council, 2001, ED CHILDR AUT; Naylor KT, 2011, EVID-BASED COMPL ALT, V2011, P1, DOI 10.1155/2011/464759; OMIZO MM, 1982, ACAD THER, V17, P603, DOI 10.1177/105345128201700514; Ospina MB, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003755; Pascual-Marqui RD, 2002, METHOD FIND EXP CLIN, V24, P5; Pizzagalli D, 2001, AM J PSYCHIAT, V158, P405, DOI 10.1176/appi.ajp.158.3.405; Reaven JA, 2009, FOCUS AUTISM DEV DIS, V24, P27, DOI 10.1177/1088357608327666; REGARD M, 1982, PERCEPT MOTOR SKILL, V55, P839, DOI 10.2466/pms.1982.55.3.839; Robinson S, 2009, BRAIN COGNITION, V71, P362, DOI 10.1016/j.bandc.2009.06.007; Rosenblatt LE, 2011, J ALTERN COMPLEM MED, V17, P1029, DOI 10.1089/acm.2010.0834; Russell AJ, 2013, DEPRESS ANXIETY, V30, P697, DOI 10.1002/da.22053; Sarris J, 2011, SLEEP MED REV, V15, P99, DOI 10.1016/j.smrv.2010.04.001; Sattler, 1986, STANFORD BINET INTEL; Silva LMT, 2007, AM J CHINESE MED, V35, P393, DOI 10.1142/S0192415X07004916; Singh Vijay Pratap, 2009, Chron Respir Dis, V6, P209, DOI 10.1177/1479972309346754; Srinivasan P, 2009, ANN CLIN PSYCHIATRY, V21, P237; Strauss E., 2006, COMPENDIUM NEUROPSYC; Suhr J, 1999, NEUROPSYCHOL REHABIL, V9, P31, DOI 10.1080/713755590; TRULSON ME, 1986, HUM RELAT, V39, P1131, DOI 10.1177/001872678603901204; Vismara LA, 2010, ANNU REV CLIN PSYCHO, V6, P447, DOI 10.1146/annurev.clinpsy.121208.131151; Wahbeh H, 2008, NEUROLOGY, V70, P2321, DOI 10.1212/01.wnl.0000314667.16386.5e; Wechsler D, 2010, WISC 4 WECHSLER INTE; Whipple J, 2004, J MUSIC THER, V41, P90, DOI 10.1093/jmt/41.2.90; WILLIAMS J, 1995, ARCH CLIN NEUROPSYCH, V10, P211, DOI 10.1016/0887-6177(94)00041-N; Wisner BL, 2010, CHILD SCH, V32, P150, DOI 10.1093/cs/32.3.150; Xiao T, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046569; Yeh GY, 2009, J CARDIOPULM REHABIL, V29, P152, DOI 10.1097/HCR.0b013e3181a33379; ZIPKIN D, 1985, J SPEC EDUC, V19, P283, DOI 10.1177/002246698501900305	81	31	34	3	61	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 10	2013	8	7							e68184	10.1371/journal.pone.0068184	http://dx.doi.org/10.1371/journal.pone.0068184			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	182SU	23874533	Green Published, gold, Green Submitted			2023-01-03	WOS:000321765300032
J	Murata, Y; Nishio, K; Mochiyama, T; Konishi, M; Shimada, M; Ohta, H; Itoh, N				Murata, Yusuke; Nishio, Kyoji; Mochiyama, Takayuki; Konishi, Morichika; Shimada, Masaya; Ohta, Hiroya; Itoh, Nobuyuki			Fgf21 Impairs Adipocyte Insulin Sensitivity in Mice Fed a Low-Carbohydrate, High-Fat Ketogenic Diet	PLOS ONE			English	Article							HEPATIC GLUCONEOGENESIS; MEDIATED INDUCTION; PPAR-ALPHA; METABOLISM; RESISTANCE; FIBROBLAST-GROWTH-FACTOR-21; PGC-1-ALPHA; FGF-21; GAMMA	Background: A low-carbohydrate, high-fat ketogenic diet (KD) induces hepatic ketogenesis and is believed to affect energy metabolism in mice. As hepatic Fgf21 expression was markedly induced in mice fed KD, we examined the effects of KD feeding on metabolism and the roles of Fgf21 in metabolism in mice fed KD using Fgf21 knockout mice. Methodology/Principal Findings: We examined C57BL/6 mice fed KD for 6 or 14 days. Blood beta-hydroxybutyrate levels were greatly increased at 6 days, indicating that hepatic ketogenesis was induced effectively by KD feeding for 6 days. KD feeding for 6 and 14 days impaired glucose tolerance and insulin sensitivity, although it did not affect body weight, blood NEFA, and triglyceride levels. Hepatic Fgf21 expression and blood Fgf21 levels were markedly increased in mice fed KD for 6 days. Blood beta-hydroxybutyrate levels in the knockout mice fed KD for 6 days were comparable to those in wild-type mice fed KD, indicating that Fgf21 is not required for ketogenesis. However, the impaired glucose tolerance and insulin sensitivity caused by KD feeding were improved in the knockout mice. Insulin-stimulated Akt phosphorylation was significantly decreased in the white adipose tissue in wild-type mice fed KD compared with those fed normal chow, but not in the muscle and liver. Its phosphorylation in the white adipose tissue was significantly increased in the knockout mice fed KD compared with wild-type mice fed KD. In contrast, hepatic gluconeogenic gene expression in Fgf21 knockout mice fed KD was comparable to those in the wild-type mice fed KD. Conclusions/Significance: The present findings indicate that KD feeding impairs insulin sensitivity in mice due to insulin resistance in white adipose tissue. In addition, our findings indicate that Fgf21 induced to express by KD is a negative regulator of adipocyte insulin sensitivity in adaptation to a low-carbohydrate malnutritional state.	[Murata, Yusuke; Nishio, Kyoji; Mochiyama, Takayuki; Konishi, Morichika; Shimada, Masaya; Ohta, Hiroya; Itoh, Nobuyuki] Kyoto Univ, Grad Sch Pharmaceut Sci, Dept Biochem Genet, Sakyo Ku, Kyoto, Japan; [Konishi, Morichika] Kobe Pharmaceut Univ, Dept Microbial Chem, Kobe, Hyogo 658, Japan	Kyoto University; Kobe Pharmaceutical University	Konishi, M (corresponding author), Kyoto Univ, Grad Sch Pharmaceut Sci, Dept Biochem Genet, Sakyo Ku, Kyoto, Japan.	mkonishi@kobepharma-u.ac.jp; itohnobu@pharm.kyoto-u.ac.jp			Ministry of Education, Science, Culture and Sports of Japan; Takeda Science Foundation, Japan	Ministry of Education, Science, Culture and Sports of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Takeda Science Foundation, Japan(Takeda Science Foundation (TSF))	This work was supported by a Grant-in-aid for Scientific Research from the Ministry of Education, Science, Culture and Sports of Japan and the Takeda Science Foundation, Japan. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; This work was supported by a Grant-in-aid for Scientific Research from the Ministry of Education, Science, Culture and Sports of Japan and the Takeda Science Foundation, Japan.	Andrews RC, 1999, CLIN SCI, V96, P513, DOI 10.1042/cs0960513; Astrup A, 2004, LANCET, V364, P897, DOI 10.1016/S0140-6736(04)16986-9; Badman MK, 2007, CELL METAB, V5, P426, DOI 10.1016/j.cmet.2007.05.002; Badman MK, 2009, ENDOCRINOLOGY, V150, P4931, DOI 10.1210/en.2009-0532; Cho H, 2001, SCIENCE, V292, P1728, DOI 10.1126/science.292.5522.1728; Fisher FM, 2012, GENE DEV, V26, P271, DOI 10.1101/gad.177857.111; Fisher FM, 2011, ENDOCRINOLOGY, V152, P2996, DOI 10.1210/en.2011-0281; Hotta Y, 2009, ENDOCRINOLOGY, V150, P4625, DOI 10.1210/en.2009-0119; Inagaki T, 2007, CELL METAB, V5, P415, DOI 10.1016/j.cmet.2007.05.003; Itoh N, 2008, DEV DYNAM, V237, P18, DOI 10.1002/dvdy.21388; Itoh N, 2011, J BIOCHEM, V149, P121, DOI 10.1093/jb/mvq121; JAMES DE, 1985, DIABETES, V34, P1049, DOI 10.2337/diabetes.34.10.1049; Kennedy AR, 2007, AM J PHYSIOL-ENDOC M, V292, pE1724, DOI 10.1152/ajpendo.00717.2006; Kharitonenkov A, 2005, J CLIN INVEST, V115, P1627, DOI 10.1172/JCI23606; Kharitonenkov A, 2011, TRENDS ENDOCRIN MET, V22, P81, DOI 10.1016/j.tem.2010.11.003; Kim YD, 2012, J BIOL CHEM, V287, P37098, DOI 10.1074/jbc.M112.339887; Kubota N, 1999, MOL CELL, V4, P597, DOI 10.1016/S1097-2765(00)80210-5; Lee MW, 2010, CELL METAB, V11, P331, DOI 10.1016/j.cmet.2010.02.016; Melvin RG, 2009, TRENDS ENDOCRIN MET, V20, P490, DOI 10.1016/j.tem.2009.09.005; Murata Y, 2011, J NUTR METAB, V2011, DOI 10.1155/2011/981315; Nishimura T, 2000, BBA-GENE STRUCT EXPR, V1492, P203, DOI 10.1016/S0167-4781(00)00067-1; Oishi K, 2010, NEUROENDOCRINOL LETT, V31, P198; Potthoff MJ, 2009, P NATL ACAD SCI USA, V106, P10853, DOI 10.1073/pnas.0904187106; Schenk S, 2008, J CLIN INVEST, V118, P2992, DOI 10.1172/JCI34260; Wei W, 2012, P NATL ACAD SCI USA, V109, P3143, DOI 10.1073/pnas.1200797109	25	40	42	2	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 9	2013	8	7							e69330	10.1371/journal.pone.0069330	http://dx.doi.org/10.1371/journal.pone.0069330			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	182JD	23874946	gold, Green Published, Green Submitted			2023-01-03	WOS:000321736900153
J	Mourvillier, B; Tubach, F; van de Beek, D; Garot, D; Pichon, N; Georges, H; Lefevre, LM; Bollaert, PE; Boulain, T; Luis, D; Cariou, A; Girardie, P; Chelha, R; Megarbane, B; Delahaye, A; Chalumeau-Lemoine, L; Legriel, S; Beuret, P; Brivet, F; Bruel, C; Camou, F; Chatellier, D; Chillet, P; Clair, B; Constantin, JM; Duguet, A; Galliot, R; Bayle, F; Hyvernat, H; Ouchenir, K; Plantefeve, G; Quenot, JP; Richecoeur, J; Schwebel, C; Sirodot, M; Esposito-Farese, M; Le Tulzo, Y; Wolff, M				Mourvillier, Bruno; Tubach, Florence; van de Beek, Diederik; Garot, Denis; Pichon, Nicolas; Georges, Hugues; Lefevre, Laurent Martin; Bollaert, Pierre-Edouard; Boulain, Thierry; Luis, David; Cariou, Alain; Girardie, Patrick; Chelha, Riad; Megarbane, Bruno; Delahaye, Arnaud; Chalumeau-Lemoine, Ludivine; Legriel, Stephane; Beuret, Pascal; Brivet, Francois; Bruel, Cedric; Camou, Fabrice; Chatellier, Delphine; Chillet, Patrick; Clair, Bernard; Constantin, Jean-Michel; Duguet, Alexandre; Galliot, Richard; Bayle, Frederique; Hyvernat, Herve; Ouchenir, Kader; Plantefeve, Gaetan; Quenot, Jean-Pierre; Richecoeur, Jack; Schwebel, Carole; Sirodot, Michel; Esposito-Farese, Marina; Le Tulzo, Yves; Wolff, Michel			Induced Hypothermia in Severe Bacterial Meningitis A Randomized Clinical Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PNEUMOCOCCAL MENINGITIS; ADULTS; BENEFIT; INJURY; DEXAMETHASONE; GUIDELINES; INDUCTION; FEATURES; THERAPY	IMPORTANCE Despite advances in care, mortality and morbidity remain high in adults with acute bacterial meningitis, particularly when due to Streptococcus pneumoniae. Induced hypothermia is beneficial in other conditions with global cerebral hypoxia. OBJECTIVE To test the hypothesis that induced hypothermia improves outcome in patients with severe bacterial meningitis. DESIGN, SETTING, AND PATIENTS An open-label, multicenter, randomized clinical trial in 49 intensive care units in France, February 2009-November 2011. In total, 130 patients were assessed for eligibility and 98 comatose adults (Glasgow Coma Scale [GCS] score of <= 8 for <12 hours) with community-acquired bacterial meningitis were randomized. INTERVENTIONS Hypothermia group received a loading dose of 4 degrees C cold saline and were cooled to 32 degrees C to 34 degrees C for 48 hours. The rewarming phase was passive. Controls received standard care. MAIN OUTCOMES AND MEASURES Primary outcome measure was the Glasgow Outcome Scale score at 3 months (a score of 5 [favorable outcome] vs a score of 1-4 [unfavorable outcome]). All patients received appropriate antimicrobial therapy and vital support. Analyses were performed on an intention-to-treat basis. The data and safety monitoring board (DSMB) reviewed severe adverse events and mortality rate every 50 enrolled patients. RESULTS After inclusion of 98 comatose patients, the trial was stopped early at the request of the DSMB because of concerns over excess mortality in the hypothermia group (25 of 49 patients [51%]) vs the control group (15 of 49 patients [31%]; relative risk [RR], 1.99; 95% CI, 1.05-3.77; P = .04). Pneumococcal meningitis was diagnosed in 77% of patients. Mean (SD) temperatures achieved 24 hours after randomization were 33.3 degrees C (0.9 degrees C) and 37.0 degrees C (0.9 degrees C) in the hypothermia and control group, respectively. At 3 months, 86% in the hypothermia group compared with 74% of controls had an unfavorable outcome (RR, 2.17; 95% CI, 0.78-6.01; P = .13). After adjustment for age, score on GCS at inclusion, and the presence of septic shock at inclusion, mortality remained higher, although not significantly, in the hypothermia group (hazard ratio, 1.76; 95% CI, 0.89-3.45; P = .10). Subgroup analysis on patients with pneumococcal meningitis showed similar results. Post hoc analysis showed a low probability to reach statistically significant difference in favor of hypothermia at the end of the 3 planned sequential analyses (probability to conclude in favor of futility, 0.977). CONCLUSIONS AND RELEVANCE Moderate hypothermia did not improve outcome in patients with severe bacterial meningitis and may even be harmful. Careful evaluation of safety issues in future trials on hypothermia are needed and may have important implications in patients presenting with septic shock or stroke.	[Mourvillier, Bruno; Wolff, Michel] Univ Paris Diderot, Sorbonne Paris Cite, Grp Hosp Bichat Claude Bernard, AP HP, Paris, France; [Tubach, Florence; Esposito-Farese, Marina] Univ Paris Diderot, Sorbonne Paris Cite, Hop Bichat, AP HP,Dept Epidemiol & Rech Clin,INSERM,CIE 801, Paris, France; [van de Beek, Diederik] Univ Amsterdam, Acad Med Ctr, Dept Neurol, Ctr Infect & Immun Amsterdam, NL-1105 AZ Amsterdam, Netherlands; [Garot, Denis] CHU Tours, Hop Bretonneau, Serv Reanimat Med, Tours, France; [Pichon, Nicolas] Ctr Hosp Univ Dupuytren, Limoges, France; [Georges, Hugues] Ctr Hosp Univ Tourcoing, Tourcoing, France; [Lefevre, Laurent Martin] Ctr Hosp Dept Les Oudaries, Serv Reanimat Polyvalente, La Roche Sur Yon, France; [Bollaert, Pierre-Edouard] Hop Cent, Ctr Hosp Univ Nancy, Serv Reanimat Med, Nancy, France; [Boulain, Thierry] Ctr Hosp Reg Orleans, Serv Reanimat Polyvalente, Orleans, France; [Luis, David] Ctr Hosp Univ Jean Verdier, AP HP, Serv Reanimat Med Chirurg, Bondy, France; [Cariou, Alain] Serv Reanimat Med, Paris, France; [Cariou, Alain] Ctr Hosp Univ Cochin St Vincent Paul Site Cochin, AP HP, Paris, France; [Girardie, Patrick] CHRU Lille, Hop Roger Salengro, Serv Reanimat Polyvalente, F-59037 Lille, France; [Chelha, Riad] Ctr Hosp Intercommunal Andre Gregoire Montreuil, Serv Reanimat Polyvalente, Montreuil, France; [Megarbane, Bruno] Ctr Hosp Univ Lariboisiere, Assistance Publ Hop, Serv Reanimat Med & Toxicol, Paris, France; [Delahaye, Arnaud] Ctr Hosp, Serv Reanimat Polyvalente, Rodez, France; [Chalumeau-Lemoine, Ludivine] Ctr Hosp Univ Tenon, AP HP, Serv Reanimat Med Chirurg, Paris, France; [Legriel, Stephane] Ctr Hosp Versailles, Serv Reanimat, Le Chesnay, France; [Beuret, Pascal] Ctr Hosp, Serv Reanimat Med Chirurg, Roanne, France; [Brivet, Francois] Ctr Hosp Univ Antoine Beclere, AP HP, Reanimat Med Ctr, Clamart, France; [Bruel, Cedric] Grp Hosp Paris St Joseph, Serv Reanimat Polyvalente, Paris, France; [Camou, Fabrice] Ctr Hosp Univ, Hop St Andre, Bordeaux, France; [Chatellier, Delphine] Ctr Hosp Univ, Serv Reanimat Med, Poitiers, France; [Chillet, Patrick] Ctr Hosp, Serv Reanimat Polyvalente, Chalons Sur Marne, France; [Clair, Bernard] AP HP, Serv Reanimat Med Chirurg, Garches, France; [Constantin, Jean-Michel] Ctr Hosp Univ Estaing, Serv Reanimat Adultes, Clermont Ferrand, France; [Constantin, Jean-Michel] Ctr Hosp Univ Estaing, USC, Clermont Ferrand, France; [Duguet, Alexandre] Ctr Hosp Univ La Pitie Salpetriere, AP HP, Serv Pneumol & Reanimat Med, Paris, France; [Galliot, Richard] Hop Foch, Suresnes, France; [Bayle, Frederique] Hop Croix Rousse, Ctr Hosp Univ, Serv Reanimat Med & Resp, F-69317 Lyon, France; [Hyvernat, Herve] Hop Archet, Serv Reanimat Med, Nice, France; [Ouchenir, Kader] Les Hop Chartres, Chartres, France; [Plantefeve, Gaetan] Ctr Hosp, Serv Reanimat Polyvalente, Dargenteuil, France; [Quenot, Jean-Pierre] Ctr Hosp Univ, Serv Reanimat Med, Dijon, France; [Richecoeur, Jack] CH Rene Dubos, Serv Reanimat Med Chirurg, Pontoise, France; [Schwebel, Carole] Hop A Michallon, Ctr Hosp Univ, Serv Reanimat Med, La Tronche, France; [Sirodot, Michel] Ctr Hosp Reg Annecy, Serv Reanimat Polyvalente, Pringy, France; [Le Tulzo, Yves] Hop Pontchaillou, Ctr Hosp Univ, Serv Reanimat Med & Infect, Rennes, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; University of Amsterdam; Academic Medical Center Amsterdam; CHU Tours; CHU Limoges; CHU de Nancy; Centre Hospitalier Regional d'Orleans; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Jean-Verdier - APHP; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite; Universite de Lille - ISITE; CHU Lille; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Tenon - APHP; UDICE-French Research Universities; Sorbonne Universite; Centre Hospitalier de Versailles; UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Antoine-Beclere - APHP; Hopital Paris Saint-Joseph; UDICE-French Research Universities; Universite Paris Cite; CHU Bordeaux; CHU Poitiers; Universite de Poitiers; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Raymond-Poincare - APHP; CHU Clermont Ferrand; CHU Clermont Ferrand; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Hospital Foch; CHU Lyon; CHU Nice; CHU Dijon Bourgogne; Centre Hospitalier Rene Dubos, Pontoise; CHU Grenoble Alpes; Centre Hospitalier Annecy Genevois; CHU Rennes	Mourvillier, B (corresponding author), Grp Hosp Bichat Claude Bernard, AP HP, 46 Rue Henri Huchard, F-75018 Paris, France.	bruno.mourvillier@bch.aphp.fr	Boulain, Thierry/M-3309-2019; legriel, stephane/H-5735-2019; schwebel, carole/M-6189-2014; Legriel, Stephane/J-1307-2017; van de Beek, Diederik/Y-2713-2019	Boulain, Thierry/0000-0003-4664-3661; legriel, stephane/0000-0003-4782-6734; Legriel, Stephane/0000-0003-4782-6734; van de Beek, Diederik/0000-0002-4571-044X; Megarbane, Bruno/0000-0002-2522-2764; Camou, Fabrice/0000-0003-4715-224X; QUENOT, Jean-Pierre/0000-0003-2351-682X; MOURVILLIER, BRUNO/0000-0001-5227-1468	French Ministry of Health (Programme Hospitalier de Recherche Clinique) [PHRC-AOM06038]; IST Cardiology company; Covidien company; Netherlands Organization for Health Research and Development [917.11.358]; European Research Council [281156]	French Ministry of Health (Programme Hospitalier de Recherche Clinique); IST Cardiology company; Covidien company; Netherlands Organization for Health Research and Development(Netherlands Organization for Health Research and Development); European Research Council(European Research Council (ERC)European Commission)	This work was funded by a research grant from the French Ministry of Health (Programme Hospitalier de Recherche Clinique PHRC-AOM06038) and by unrestricted grants from IST Cardiology and Covidien companies. IST Cardiology provided endovascular catheters and cooling devices for 12 centers at decreased rates. Covidien provided free esophageal temperature probes for all included patients. Dr van de Beek was supported by grants 917.11.358 from the Netherlands Organization for Health Research and Development and 281156 from the European Research Council. The sponsor was the Departement a la Recherche Clinique et au Developpement, Assistance Publique-Hopitaux de Paris.	Angstwurm K, 2000, J CEREBR BLOOD F MET, V20, P834, DOI 10.1097/00004647-200005000-00010; [Anonymous], 2009, MED MALADIES INFECT, V39, P175, DOI DOI 10.1038/NGE0440; Auburtin M, 2006, CRIT CARE MED, V34, P2758, DOI 10.1097/01.CCM.0000239434.26669.65; Bassler D, 2010, JAMA-J AM MED ASSOC, V303, P1180, DOI 10.1001/jama.2010.310; Bernard SA, 2002, NEW ENGL J MED, V346, P557, DOI 10.1056/NEJMoa003289; Brouwer MC, 2010, NEUROLOGY, V75, P1533, DOI 10.1212/WNL.0b013e3181f96297; Brouwer MC, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004405.pub4; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; Cuthbertson BH, 2004, ANAESTHESIA, V59, P908, DOI 10.1111/j.1365-2044.2004.03748.x; de Gans J, 2002, NEW ENGL J MED, V347, P1549, DOI 10.1056/NEJMoa021334; Fayol P., 2004, Annales de Readaptation et de Medecine Physique, V47, P142, DOI 10.1016/j.annrmp.2004.01.004; Gluckman PD, 2005, LANCET, V365, P663, DOI 10.1016/S0140-6736(05)17946-X; Hansson L, 1992, Blood Press, V1, P113, DOI 10.3109/08037059209077502; Holzer M, 2002, NEW ENGL J MED, V346, P549; Iltis AS, 2005, J MED ETHICS, V31, P410, DOI 10.1136/jme.2004.008771; Irazuzta JE, 2000, BRAIN RES, V881, P88, DOI 10.1016/S0006-8993(00)02894-8; Irazuzta JE, 1999, BRAIN RES, V847, P143, DOI 10.1016/S0006-8993(99)02120-4; Irazuzta JE, 2002, CRIT CARE MED, V30, P2553, DOI 10.1097/00003246-200211000-00025; JENNETT B, 1975, LANCET, V1, P480; Lepur D, 2011, J INFECTION, V62, P172, DOI 10.1016/j.jinf.2010.10.001; McIntyre LA, 2003, JAMA-J AM MED ASSOC, V289, P2992, DOI 10.1001/jama.289.22.2992; McIntyre PB, 2012, LANCET, V380, P1703, DOI 10.1016/S0140-6736(12)61187-8; Montori VM, 2005, JAMA-J AM MED ASSOC, V294, P2203, DOI 10.1001/jama.294.17.2203; Mook-Kanamori BB, 2011, CLIN MICROBIOL REV, V24, P557, DOI 10.1128/CMR.00008-11; Nunnally ME, 2011, CRIT CARE MED, V39, P1113, DOI 10.1097/CCM.0b013e318206bab2; Pirozzo S, 2003, BRIT MED J, V327, P967, DOI 10.1136/bmj.327.7421.967; Polderman KH, 2005, CRIT CARE MED, V33, P2744, DOI 10.1097/01.CCM.0000190427.88735.19; Rowin ME, 2001, INFLAMMATION, V25, P137, DOI 10.1023/A:1011044312536; Shankaran S, 2005, NEW ENGL J MED, V353, P1574, DOI 10.1056/NEJMcps050929; Silverman Henry, 2007, Proc Am Thorac Soc, V4, P180, DOI 10.1513/pats.200701-010GC; Tunkel AR, 2004, CLIN INFECT DIS, V39, P1267, DOI 10.1086/425368; van de Beek D, 2007, J INFECTION, V55, P381, DOI 10.1016/j.jinf.2007.06.009; van de Beek D, 2012, LANCET, V380, P1693, DOI 10.1016/S0140-6736(12)61186-6; Weisfelt M, 2006, LANCET NEUROL, V5, P123, DOI 10.1016/S1474-4422(05)70288-X; Whitehead J, 1997, DESIGN ANAL SEQUENTI; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Xu LJ, 2002, J CEREBR BLOOD F MET, V22, P21, DOI 10.1097/00004647-200201000-00003	39	117	122	0	14	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 27	2013	310	20					2174	2183		10.1001/jama.2013.280506	http://dx.doi.org/10.1001/jama.2013.280506			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	257RS	24105303	Bronze			2023-01-03	WOS:000327404400026
J	Atzema, CL; Austin, PC; Wu, LB; Brzozowski, M; Feldman, MJ; McDonnell, M; Mazurik, L				Atzema, Clare L.; Austin, Peter C.; Wu, Libo; Brzozowski, Michael; Feldman, Michael J.; McDonnell, Michael; Mazurik, Laurie			Speak Fast, Use Jargon, and Don't Repeat Yourself: A Randomized Trial Assessing the Effectiveness of Online Videos to Supplement Emergency Department Discharge Instructions	PLOS ONE			English	Article							CARE; COMPREHENSION; INFORMATION; QUALITY	Background: Emergency department discharge instructions are variably understood by patients, and in the setting of emergency department crowding, innovations are needed to counteract shortened interaction times with the physician. We evaluated the effect of viewing an online video of diagnosis-specific discharge instructions on patient comprehension and recall of instructions. Methods: In this prospective, single-center, randomized controlled trial conducted between November 2011 and January 2012, we randomized emergency department patients who were discharged with one of 38 diagnoses to either view (after they left the emergency department) a vetted online video of diagnosis-specific discharge instructions, or to usual care. Patients were subsequently contacted by telephone and asked three standardized questions about their discharge instructions; one point was awarded for each correct answer. Using an intention-to-treat analysis, differences between groups were assessed using univariate testing, and with logistic regression that accounted for clustering on managing physician. A secondary outcome measure was patient satisfaction with the videos, on a 10-point scale. Results: Among 133 patients enrolled, mean age was 46.1 (s.d.D. 21.5) and 55% were female. Patients in the video group had 19% higher mean scores (2.5, s.d. 0.7) than patients in the control group (2.1, s.d. 0.8) (p=0.002). After adjustment for patient age, sex, first language, triage acuity score, and clustering, the odds of achieving a fully correct score (3 out of 3) were 3.5 (95% CI, 1.7 to 7.2) times higher in the video group, compared to the control group. Among those who viewed the videos, median rating of the videos was 10 (IQR 8 to 10). Conclusions: In this single-center trial, patients who viewed an online video of their discharge instructions scored higher on their understanding of key concepts around their diagnosis and subsequent care. Those who viewed the videos found them to be a helpful addition to standard care.	[Atzema, Clare L.; Brzozowski, Michael; Feldman, Michael J.; McDonnell, Michael; Mazurik, Laurie] Univ Toronto, Dept Med, Div Emergency Med, Toronto, ON, Canada; [Atzema, Clare L.; Wu, Libo; Brzozowski, Michael; Feldman, Michael J.; McDonnell, Michael; Mazurik, Laurie] Sunnybrook Hlth Sci Ctr, Toronto, ON M4N 3M5, Canada; [Atzema, Clare L.; Austin, Peter C.] Inst Clin Evaluat Sci, Toronto, ON, Canada	University of Toronto; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto	Atzema, CL (corresponding author), Univ Toronto, Dept Med, Div Emergency Med, Toronto, ON, Canada.	clare.atzema@ices.on.ca		Austin, Peter/0000-0003-3337-233X; Atzema, Clare/0000-0002-7236-5522	Academic Physician's Fund (AFP); Department of Emergency Services at Sunnybrook Health Sciences Centre; Department of Medicine, University of Toronto; Sunnybrook Research Institute; Heart and Stroke Foundation	Academic Physician's Fund (AFP); Department of Emergency Services at Sunnybrook Health Sciences Centre; Department of Medicine, University of Toronto(University of Toronto); Sunnybrook Research Institute(University of Toronto); Heart and Stroke Foundation(Heart & Stroke Foundation of Canada)	This project was supported by a grant from the Academic Physician's Fund (AFP). Dr. Atzema is supported by the Practice Plan of the Department of Emergency Services at Sunnybrook Health Sciences Centre, the Department of Medicine, University of Toronto, and the Sunnybrook Research Institute. Dr. Austin is supported by a Career Investigator award from the Heart and Stroke Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ambulatory and Hospital Care Statistics Branch, 2013, NAT HOSP AMB MED CAR; Atzema CL, 2012, INT J CLIN MED, V3, P758, DOI [10.4236/ijcm.2012.37A133, DOI 10.4236/IJCM.2012.37A133]; AUSTIN PE, 1995, ANN EMERG MED, V25, P317, DOI 10.1016/S0196-0644(95)70286-5; Beveridge R., 1998, IMPLEMENTATION GUIDE; Chan BT, 2001, ATLAS REPORT EMERGEN; Choi S, 2009, SOUTH MED J, V102, P239, DOI 10.1097/SMJ.0b013e318197f319; Clark PA, 2005, PATIENT EDUC COUNS, V59, P56, DOI 10.1016/j.pec.2004.09.010; Clarke Collin, 2005, CJEM, V7, P5; Dalkey NC, 1969, DELPHI METHOD EXPT A; Department of Health & Human Services (DHHS) Centers for Medicare & Medicaid Services (CMS), 2008, REV APP A INT GUID H; Derlet RW, 2001, ACAD EMERG MED, V8, P151, DOI 10.1111/j.1553-2712.2001.tb01280.x; Engel KG, 2009, ANN EMERG MED, V53, P454, DOI 10.1016/j.annemergmed.2008.05.016; Fatovich DM, 2005, EMERG MED J, V22, P351, DOI 10.1136/emj.2004.018002; Institute of Medicine, 2006, HOSP BAS EM CAR BREA; Jack BW, 2009, ANN INTERN MED, V150, P178, DOI 10.7326/0003-4819-150-3-200902030-00007; Johnson A., 2003, COCHRANE DB SYST REV, V4, DOI DOI 10.1002/14651858.CD003716; Kawano T, 2013, EMERG MED J; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; Lindsay P, 2002, ACAD EMERG MED, V9, P1131, DOI 10.1197/aemj.9.11.1131; Mace CA, 1962, PSYCHOL STUDY; Miro O, 1999, Eur J Emerg Med, V6, P105; Papa L, 2008, CAN J EMERG MED, V10, P347; Rhodes KV, 2004, ANN EMERG MED, V44, P262, DOI 10.1016/j.annemergmed.2004.02.035; Rowe B, 2006, FREQUENCY DETERMINEN; SPANDORFER JM, 1995, ANN EMERG MED, V25, P71, DOI 10.1016/S0196-0644(95)70358-6; The World Bank, 2012, INT US PER 100 PEOPL; VanSuch M, 2006, QUAL SAF HEALTH CARE, V15, P414, DOI 10.1136/qshc.2005.017640; Waisman Y, 2003, ISRAEL MED ASSOC J, V5, P567; Waisman Y, 2005, EUR J EMERG MED, V12, P159, DOI 10.1097/00063110-200508000-00003	29	24	24	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 11	2013	8	11							e77057	10.1371/journal.pone.0077057	http://dx.doi.org/10.1371/journal.pone.0077057			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	255EG	24244272	gold, Green Submitted, Green Published			2023-01-03	WOS:000327221600006
J	Conforti, A; Biagini, S; Del Bufalo, F; Sirleto, P; Angioni, A; Starc, N; Pira, GL; Moretta, F; Proia, A; Contoli, B; Genovese, S; Ciardi, C; Avanzini, MA; Rosti, V; Lo-Coco, F; Locatelli, F; Bernardo, ME				Conforti, Antonella; Biagini, Simone; Del Bufalo, Francesca; Sirleto, Pietro; Angioni, Adriano; Starc, Nadia; Pira, Giuseppina Li; Moretta, Francesca; Proia, Alessandra; Contoli, Benedetta; Genovese, Silvia; Ciardi, Claudia; Avanzini, Maria Antonietta; Rosti, Vittorio; Lo-Coco, Francesco; Locatelli, Franco; Bernardo, Maria Ester			Biological, Functional and Genetic Characterization of Bone Marrow-Derived Mesenchymal Stromal Cells from Pediatric Patients Affected by Acute Lymphoblastic Leukemia	PLOS ONE			English	Article							VERSUS-HOST-DISEASE; STEM-CELLS; IN-VITRO; MICROENVIRONMENT; VIVO; CLASSIFICATION; ABERRATIONS; CHILDREN; SURVIVAL; PROFILE	Alterations in hematopoietic microenvironment of acute lymphoblastic leukemia patients have been claimed to occur, but little is known about the components of marrow stroma in these patients. In this study, we characterized mesenchymal stromal cells (MSCs) isolated from bone marrow (BM) of 45 pediatric patients with acute lymphoblastic leukemia (ALL-MSCs) at diagnosis (day+0) and during chemotherapy treatment (days: +15; +33; +78), the time points being chosen according to the schedule of BM aspirates required by the AIEOP-BFM ALL 2009 treatment protocol. Morphology, proliferative capacity, immunophenotype, differentiation potential, immunomodulatory properties and ability to support long-term hematopoiesis of ALL-MSCs were analysed and compared with those from 41 healthy donors (HD-MSCs). ALL-MSCs were also genetically characterized through array-CGH, conventional karyotyping and FISH analysis. Moreover, we compared ALL-MSCs generated at day+0 with those isolated during chemotherapy. Morphology, immunophenotype, differentiation potential and in vitro life-span did not differ between ALL-MSCs and HD-MSCs. ALL-MSCs showed significantly lower proliferative capacity (p<0.001) and ability to support in vitro hematopoiesis (p=0.04) as compared with HD-MSCs, while they had similar capacity to inhibit in vitro mitogen-induced T-cell proliferation (p=N.S.). ALL-MSCs showed neither the typical translocations carried by the leukemic clone (when present), nor other genetic abnormalities acquired during ex vivo culture. Our findings indicate that ALL-MSCs display reduced ability to proliferate and to support long-term hematopoiesis in vitro. ALL-MSCs isolated at diagnosis do not differ from those obtained during treatment.	[Conforti, Antonella; Biagini, Simone; Del Bufalo, Francesca; Starc, Nadia; Pira, Giuseppina Li; Moretta, Francesca; Proia, Alessandra; Contoli, Benedetta; Locatelli, Franco; Bernardo, Maria Ester] Bambino Gesu Pediat Hosp, IRCCS, Dept Pediat Hematol Oncol, Rome, Italy; [Sirleto, Pietro; Angioni, Adriano; Genovese, Silvia] Bambino Gesu Pediat Hosp, IRCCS, Cytogenet & Mol Genet Unit, Rome, Italy; [Ciardi, Claudia; Lo-Coco, Francesco] Univ Tor Vergata, Fdn Santa Lucia, Lab Neuro Oncohematol, Rome, Italy; [Avanzini, Maria Antonietta] Fdn IRCCS Policlin San Matteo, Dept Pediat Hematol Oncol, Pavia, Italy; [Rosti, Vittorio] Fdn IRCCS Policlin San Matteo, Ctr Studio Cura Mielofibrosi, Lab Sperimentali Ric, Area Biotecnol, Pavia, Italy; [Locatelli, Franco] Univ Pavia, I-27100 Pavia, Italy	IRCCS Bambino Gesu; IRCCS Bambino Gesu; IRCCS Santa Lucia; University of Rome Tor Vergata; IRCCS Fondazione San Matteo; IRCCS Fondazione San Matteo; University of Pavia	Bernardo, ME (corresponding author), Bambino Gesu Pediat Hosp, IRCCS, Dept Pediat Hematol Oncol, Rome, Italy.	mariaester.bernardo@opbg.net	angioni, adriano/G-1160-2014; Pira, Giuseppina Li/F-7105-2012; Contoli, Benedetta/AAB-2696-2022; Moretta, Francesca/Z-3169-2019; Avanzini, Maria Antonietta/K-7839-2016; Rosti, Vittorio/K-1743-2018; Conforti, Antonella/H-2209-2012; Genovese, Silvia/AAH-9425-2019; sirleto, pietro/G-3902-2014; del bufalo, francesca/AAB-2436-2019; del bufalo, francesca/K-4314-2018	angioni, adriano/0000-0003-0862-2456; Pira, Giuseppina Li/0000-0002-6293-4314; Moretta, Francesca/0000-0002-1150-8622; Avanzini, Maria Antonietta/0000-0002-6056-9018; Rosti, Vittorio/0000-0003-4195-2289; Conforti, Antonella/0000-0001-8524-5936; Genovese, Silvia/0000-0002-5514-5018; sirleto, pietro/0000-0001-5292-3315; Contoli, Benedetta/0000-0003-0479-7822; Sirleto, Pietro/0000-0002-3569-4829; del bufalo, francesca/0000-0001-9643-3465	Istituto Superiore di Sanita (National Program on Stem Cells); MIUR (Ministero dell'Istruzione, dell'Universita e della Ricerca; Progetti di Rilevante Interesse Nazionale, PRIN); AIRC [56x1000]; Associazione Italiana per la Ricerca sul Cancro (AIRC) [IG9062]; Bando Giovani Ricercatori	Istituto Superiore di Sanita (National Program on Stem Cells); MIUR (Ministero dell'Istruzione, dell'Universita e della Ricerca(Ministry of Education, Universities and Research (MIUR)); Progetti di Rilevante Interesse Nazionale, PRIN)(Ministry of Education, Universities and Research (MIUR)Research Projects of National Relevance (PRIN)); AIRC(Fondazione AIRC per la ricerca sul cancro); Associazione Italiana per la Ricerca sul Cancro (AIRC)(Fondazione AIRC per la ricerca sul cancro); Bando Giovani Ricercatori	This work has been partly supported by grants from Istituto Superiore di Sanita (National Program on Stem Cells), MIUR (Ministero dell'Istruzione, dell'Universita e della Ricerca, Progetti di Rilevante Interesse Nazionale, PRIN) and by the special grant "56x1000'' from AIRC to FL; and grants from Associazione Italiana per la Ricerca sul Cancro (AIRC) IG9062 and Bando Giovani Ricercatori 2008 to MEB. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Anker PSI, 2003, HAEMATOLOGICA, V88, P845; Ball LM, 2007, BLOOD, V110, P2764, DOI 10.1182/blood-2007-04-087056; Barachini S, 2009, STEM CELLS DEV, V18, P293, DOI 10.1089/scd.2008.0017; Bartholomew A, 2002, EXP HEMATOL, V30, P42, DOI 10.1016/S0301-472X(01)00769-X; BENNETT JM, 1976, BRIT J HAEMATOL, V33, P451, DOI 10.1111/j.1365-2141.1976.tb03563.x; Bernardo ME, 2007, CANCER RES, V67, P9142, DOI 10.1158/0008-5472.CAN-06-4690; BERTINO JR, 1963, CANCER RES, V23, P1286; Blau O, 2007, EXP HEMATOL, V35, P221, DOI 10.1016/j.exphem.2006.10.012; Caligaris-Cappio F, 2003, BRIT J HAEMATOL, V123, P380, DOI 10.1046/j.1365-2141.2003.04679.x; Campioni D, 2012, ANN HEMATOL, V91, P1563, DOI 10.1007/s00277-012-1500-8; Ciccocioppo R, 2011, GUT, V60, P788, DOI 10.1136/gut.2010.214841; Corre J, 2007, LEUKEMIA, V21, P1079, DOI 10.1038/sj.leu.2404621; Dander E, 2012, LEUKEMIA, V26, P1681, DOI 10.1038/leu.2011.384; Di Nicola M, 2002, BLOOD, V99, P3838, DOI 10.1182/blood.V99.10.3838; Dimitriou H, 2008, CYTOTHERAPY, V10, P125, DOI 10.1080/14653240701851332; Duijvestein M, 2010, GUT, V59, P1662, DOI 10.1136/gut.2010.215152; FRIEDENSTEIN AJ, 1968, TRANSPLANTATION, V6, P230, DOI 10.1097/00007890-196803000-00009; Gabert J, 2003, LEUKEMIA, V17, P2318, DOI 10.1038/sj.leu.2403135; Greaves MF, 2003, NAT REV CANCER, V3, P639, DOI 10.1038/nrc1164; Jiang YH, 2002, NATURE, V418, P41, DOI 10.1038/nature00870; LeBlanc K, 2008, LANCET, V371, P1579, DOI 10.1016/S0140-6736(08)60690-X; Lecourt S, 2010, STEM CELLS DEV, V19, P203, DOI 10.1089/scd.2009.0062; Lopez-Villar O, 2009, LEUKEMIA, V23, P664, DOI 10.1038/leu.2008.361; McGookin R, 1985, Methods Mol Biol, V2, P113, DOI 10.1385/0-89603-064-4:113; Menendez P, 2009, J EXP MED, V206, P3131, DOI 10.1084/jem.20091050; Mudry RE, 2000, BLOOD, V96, P1926, DOI 10.1182/blood.V96.5.1926.h8001926_1926_1932; Nagasawa T, 2006, NAT REV IMMUNOL, V6, P107, DOI 10.1038/nri1780; Nauta AJ, 2007, BLOOD, V110, P3499, DOI 10.1182/blood-2007-02-069716; NEUSS N, 1964, Adv Chemother, V12, P133; Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143; Pui CH, 2006, NEW ENGL J MED, V354, P166, DOI 10.1056/NEJMra052603; Pui CH, 2008, LANCET, V371, P1030, DOI 10.1016/S0140-6736(08)60457-2; Ramakrishnan A, 2006, BLOOD, V108, P772, DOI 10.1182/blood-2006-02-001479; Shalapour S, 2010, J MOL MED, V88, P249, DOI 10.1007/s00109-009-0583-8; Soenen-Cornu V, 2005, ONCOGENE, V24, P2441, DOI 10.1038/sj.onc.1208405; Stenderup K, 2003, BONE, V33, P919, DOI 10.1016/j.bone.2003.07.005; Vardiman JW, 2009, BLOOD, V114, P937, DOI 10.1182/blood-2009-03-209262; Wiemels Joseph, 2009, V538, P7, DOI 10.1007/978-1-59745-418-6_2; Zhang JW, 2003, NATURE, V425, P836, DOI 10.1038/nature02041; Zhao ZG, 2006, LEUKEMIA RES, V30, P993, DOI 10.1016/j.leukres.2005.12.010	40	27	27	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 7	2013	8	11							e76989	10.1371/journal.pone.0076989	http://dx.doi.org/10.1371/journal.pone.0076989			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	254KD	24244271	Green Published, gold, Green Submitted			2023-01-03	WOS:000327162900005
J	Buiting, HM; Terpstra, W; Dalhuisen, F; Gunnink-Boonstra, N; Sonke, GS; den Hartogh, G				Buiting, Hilde M.; Terpstra, Wim; Dalhuisen, Floriske; Gunnink-Boonstra, Nicolette; Sonke, Gabe S.; den Hartogh, Govert			The Facilitating Role of Chemotherapy in the Palliative Phase of Cancer: Qualitative Interviews with Advanced Cancer Patients	PLOS ONE			English	Article							SHARED DECISION-MAKING; OF-LIFE CARE; BREAST-CANCER; HEALTH-CARE; END; AGGRESSIVENESS; COMMUNICATION; PERSPECTIVES; DISCUSSIONS; PROGNOSIS	Objective: To explore the extent to which patients have a directing role in decisions about chemotherapy in the palliative phase of cancer and (want to) anticipate on the last stage of life. Design: Qualitative interview study. Methods: In depth-interviews with 15 patients with advanced colorectal or breast cancer at the medical oncology department in a Dutch teaching hospital; interviews were analysed following the principles of thematic content-analysis. Results: All patients reported to know that the chemotherapy they received was with palliative intent. Most of them did not express the wish for information about (other) treatment options and put great trust in their physicians' treatment advice. The more patients were aware of the severity of their disease, the more they seemed to 'live their life' in the present and enjoy things besides having cancer. Such living in the present seemed to be facilitated by the use of chemotherapy. Patients often considered the 'chemotherapy-free period' more stressful than periods when receiving chemotherapy despite their generally improved physical condition. Chemotherapy (regardless of side-effects) seemed to shift patients' attention away from the approaching last stage of life. Interestingly, although patients often discussed advance care planning, they were reluctant to bring on end-of-life issues that bothered them at that specific moment. Expressing real interest in people 'as a person' was considered an important element of appropriate care. Conclusions: Fearing their approaching death, patients deliberately focus on living in the present. Active (chemotherapy) treatment facilitates this focus, regardless of the perceived side-effects. However, if anxiety for what lies ahead is the underlying reason for treatment, efforts should be made in assisting patients to find other ways to cope with this fear. Simultaneously, such an approach may reduce the use of burdensome and sometimes costly treatment in the last stage of life.	[Buiting, Hilde M.; Dalhuisen, Floriske; Sonke, Gabe S.] Comprehens Canc Ctr Netherlands, Dept Registry & Res, Utrecht, Netherlands; [Buiting, Hilde M.; den Hartogh, Govert] Univ Amsterdam, Dept Philosophy, Amsterdam, Netherlands; [Terpstra, Wim; Gunnink-Boonstra, Nicolette] Onze Lieve Vrouw Hosp, Dept Internal Med, Amsterdam, Netherlands; [Sonke, Gabe S.] Antoni van Leeuwenhoek Hosp, Netherlands Canc Inst, Dept Med Oncol, Amsterdam, Netherlands	University of Amsterdam; Onze Lieve Vrouwe Gasthuis Hospital; Netherlands Cancer Institute	Buiting, HM (corresponding author), Comprehens Canc Ctr Netherlands, Dept Registry & Res, Utrecht, Netherlands.	h.buiting@iknl.nl		Sonke, Gabe/0000-0001-8088-9628	ZonMw, The Netherlands Organization for Health Research and Development [70-71300-98-048]; Comprehensive Cancer Centre The Netherlands	ZonMw, The Netherlands Organization for Health Research and Development(Netherlands Organization for Health Research and DevelopmentNetherlands Government); Comprehensive Cancer Centre The Netherlands	This study was supported by a grant from ZonMw, The Netherlands Organization for Health Research and Development. Grant number: 70-71300-98-048. The study was further supported by the Comprehensive Cancer Centre The Netherlands. The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Amado RG, 2008, J CLIN ONCOL, V26, P1626, DOI 10.1200/JCO.2007.14.7116; Balboni T, 2011, CANCER-AM CANCER SOC, V117, P5383, DOI 10.1002/cncr.26221; Barclay S, 2010, BMJ-BRIT MED J, V341, DOI 10.1136/bmj.c4862; Bensing J, 2013, PATIENT EDUC COUNS, V90, P287, DOI 10.1016/j.pec.2013.01.005; Buiting HM, 2011, J PAIN SYMPTOM MANAG, V42, P32, DOI 10.1016/j.jpainsymman.2010.10.260; Buiting HM, 2011, BMJ-BRIT MED J, V342, DOI 10.1136/bmj.d1933; Buiting HM, 2011, PALLIATIVE MED, V25, P83, DOI 10.1177/0269216310382589; Cardoso F, 2002, ANN ONCOL, V13, P197, DOI 10.1093/annonc/mdf101; Charles C, 1997, SOC SCI MED, V44, P681, DOI 10.1016/S0277-9536(96)00221-3; Clayton JM, 2007, J CLIN ONCOL, V25, P715, DOI 10.1200/JCO.2006.06.7827; Clayton JM, 2013, PALLIATIVE MED, V27, P236, DOI 10.1177/0269216312449683; de Kort S, 2009, THESIS; Earle CC, 2004, J CLIN ONCOL, V22, P315, DOI 10.1200/JCO.2004.08.136; Earle CC, 2008, J CLIN ONCOL, V26, P3860, DOI 10.1200/JCO.2007.15.8253; Grant L, 2010, BMJ-BRIT MED J, V341, DOI 10.1136/bmj.c4859; Greenhalgh T, 1997, BMJ-BRIT MED J, V315, P740, DOI 10.1136/bmj.315.7110.740; Greer JA, 2012, J CLIN ONCOL, V30, P394, DOI 10.1200/JCO.2011.35.7996; Harrington SE, 2008, JAMA-J AM MED ASSOC, V299, P2667, DOI 10.1001/jama.299.22.2667; Ho TH, 2011, J CLIN ONCOL, V29, P1587, DOI 10.1200/JCO.2010.31.9897; Kiely BE, 2011, J CLIN ONCOL, V29, P456, DOI 10.1200/JCO.2010.30.2174; Mack JW, 2012, J CLIN ONCOL, V30, P2715, DOI 10.1200/JCO.2012.42.4564; Mack JW, 2012, ANN INTERN MED, V156, P204, DOI 10.7326/0003-4819-156-3-201202070-00008; Mack JW, 2010, J CLIN ONCOL, V28, P1203, DOI 10.1200/JCO.2009.25.4672; Nappa U, 2011, ANN ONCOL, V22, P2375, DOI 10.1093/annonc/mdq778; Oostendorp LJM, 2011, LANCET ONCOL, V12, P1053, DOI 10.1016/S1470-2045(11)70045-6; Pasman HRW, 2009, J PAIN SYMPTOM MANAG, V38, P145, DOI 10.1016/j.jpainsymman.2008.07.008; Pope C, 2000, BMJ-BRIT MED J, V320, P114, DOI 10.1136/bmj.320.7227.114; Ritchie J, 2007, QUALITATIVE RES PRAC, P336; Schuette W, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-14; Stiggelbout AM, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e256; SULMASY DP, 1994, J MED ETHICS, V20, P218, DOI 10.1136/jme.20.4.218; Tang ST, 2009, J CLIN ONCOL, V27, P4613, DOI 10.1200/JCO.2008.20.5096; Temel JS, 2010, NEW ENGL J MED, V363, P733, DOI 10.1056/NEJMoa1000678; The AM, 2000, BRIT MED J, V321, P1376, DOI 10.1136/bmj.321.7273.1376; Van Cutsem E, 2009, ANN ONCOL, V20, P1842, DOI 10.1093/annonc/mdp233; van Laarhoven HWM, 2011, J PAIN SYMPTOM MANAG, V41, P1048, DOI 10.1016/j.jpainsymman.2010.08.015; van Vliet L, 2013, PATIENT EDUC COUNS, V90, P315, DOI 10.1016/j.pec.2011.03.021; Walczak A, 2013, PATIENT EDUC COUNS, V90, P307, DOI 10.1016/j.pec.2011.08.009; Weeks JC, 2012, NEW ENGL J MED, V367, P1616, DOI 10.1056/NEJMoa1204410; Weinfurt KP, 2013, NEW ENGL J MED, V368, P479, DOI 10.1056/NEJMc1214249	40	36	36	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 6	2013	8	11							e77959	10.1371/journal.pone.0077959	http://dx.doi.org/10.1371/journal.pone.0077959			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	247XD	24223130	gold, Green Submitted, Green Published			2023-01-03	WOS:000326656200022
J	Hammerstingl, C; Schueler, R; Wiesen, M; Momcilovic, D; Pabst, S; Nickenig, G; Skowasch, D				Hammerstingl, Christoph; Schueler, Robert; Wiesen, Martin; Momcilovic, Diana; Pabst, Stefan; Nickenig, Georg; Skowasch, Dirk			Impact of Untreated Obstructive Sleep Apnea on Left and Right Ventricular Myocardial Function and Effects of CPAP Therapy	PLOS ONE			English	Article							POSITIVE AIRWAY PRESSURE; QUANTITATIVE ASSESSMENT; DYSFUNCTION; ECHOCARDIOGRAPHY; HEART; COMMITTEE; TRACKING; STRAIN	Background: Obstructive sleep apnea (OSA) has deteriorating effect on LV function, whereas its impact on RV function is controversial. We aimed to determine the effect of OSA and continuous positive airway pressure (CPAP) treatment on left and right ventricular (LV, RV) function using transthoracic echocardiography (TTE) and 2 dimensional speckle tracking (2D ST) analysis of RV deformation capability. Methods and Results: 82 patients with OSA and need for CPAP therapy were prospectively enrolled and underwent TTE at study inclusion and after 6 months of follow up (FU). Multivariate regression analysis revealed an independent association between baseline apical right ventricular longitudinal strain (RV-Sl), BMI and the severity of OSA (apical RV-Sl: P = 0.0002, BMI: P = 0.02). After CPAP therapy, LV functional parameters (LVEF: P<0.0001, LV performance index: P = 0.03, stroke volume: P = 0.042), and apical RV-Sl (P = 0.001) improved significantly. The effect of CPAP therapy was related to severity of OSA (LVEF: AHI 5-14, 66.4 +/- 8.8%, 68.5 +/- 10.6% [P = ns]; AHI 15-30:59.8 +/- 7.7%, 68.6 +/- 9.3% [P = 0.002]; AHI>30:54.1 +/- 12.4%, 68.2 +/- 13.6%[P<0.0001]; apical RV-Sl: AHI 5-14: -17.3 +/- 8.7%, -16.0 +/- 10.8% [P = ns], AHI 15-30: -9.8 +/- 6.0%, -15.4 +/- 10.9% [P = 0.028], AHI>30: -6.3 +/- 5.7%, -17.9 +/- 11.2% [P<0.0001]). Conclusions: OSA seems to have deteriorating effect on LV and RV function. We found a beneficial effect of CPAP on LV and RV functional parameters predominately in patients with severe OSA. 2D speckle tracking might be of value to determine early changes in global and regional right ventricular function.	[Hammerstingl, Christoph; Schueler, Robert; Wiesen, Martin; Momcilovic, Diana; Pabst, Stefan; Nickenig, Georg; Skowasch, Dirk] Univ Bonn, Dept Internal Med Cardiol Pulmonol & Angiol 2, Bonn, Germany	University of Bonn	Schueler, R (corresponding author), Univ Bonn, Dept Internal Med Cardiol Pulmonol & Angiol 2, Bonn, Germany.	robert.schueler@ukb.uni-bonn.de	Schueler, Robert/D-7407-2017; Hammerstingl, Christoph/GQQ-3316-2022					Altekin RE, 2012, CARDIOL J, V19, P130, DOI 10.5603/CJ.2012.0024; American Academy of Sleep Medicine, 2005, INT CLASS SLEEP DIS; Artis NJ, 2008, INT J CARDIOL, V123, P240, DOI 10.1016/j.ijcard.2007.02.046; Becker M, 2006, HEART, V92, P1102, DOI 10.1136/hrt.2005.077107; BERMAN EJ, 1991, CHEST, V100, P347, DOI 10.1378/chest.100.2.347; Bradley TD, 2009, LANCET, V373, P82, DOI 10.1016/S0140-6736(08)61622-0; BRADLEY TD, 1992, CLIN CHEST MED, V13, P459; Butt M, 2012, CIRC-HEART FAIL, V5, P226, DOI 10.1161/CIRCHEARTFAILURE.111.964106; Chami HA, 2008, CIRCULATION, V117, P2599, DOI 10.1161/CIRCULATIONAHA.107.717892; Chan JYS, 2009, THORAX, V64, P233, DOI 10.1136/thx.2007.094904; Colish J, 2012, CHEST, V141, P674, DOI 10.1378/chest.11-0615; D'hooge J, 2000, Eur J Echocardiogr, V1, P154, DOI 10.1053/euje.2000.0031; Danbrauskaite V, 2007, J AM SOC ECHOCARDIOG, V20, P1172, DOI 10.1016/j.echo.2007.02.005; Douglas PS, 2011, J AM SOC ECHOCARDIOG, V24, P229, DOI 10.1016/j.echo.2010.12.008; Fernandez-Friera L, 2011, HEART, V97, P1250, DOI 10.1136/hrt.2010.216101; Flemons WW, 1999, SLEEP, V22, P667, DOI 10.1093/sleep/22.5.667; German Society of Sleep Research and Sleep medicine (DGSM), 2009, SOMNOLOGIE, V13, P1; Gottdiener JS, 2004, J AM SOC ECHOCARDIOG, V17, P1086, DOI 10.1016/j.echo.2004.07.013; Guidry UC, 2001, AM J RESP CRIT CARE, V164, P933, DOI 10.1164/ajrccm.164.6.2001092; Hammerstingl C, 2012, INT J CARDIOL, V155, P465, DOI 10.1016/j.ijcard.2011.12.026; Haruki N, 2009, EUR J ECHOCARDIOGR, V10, P769, DOI 10.1093/ejechocard/jep068; Jurcut R, 2010, EUR J ECHOCARDIOGR, V11, P81, DOI 10.1093/ejechocard/jep234; Kim SH, 2008, AM J CARDIOL, V101, P1663, DOI 10.1016/j.amjcard.2008.01.056; Koshino Y, 2010, CIRC-CARDIOVASC IMAG, V3, P282, DOI 10.1161/CIRCIMAGING.109.901561; Langeland S, 2005, CIRCULATION, V112, P2157, DOI 10.1161/CIRCULATIONAHA.105.554006; Lopez-Candales A, 2009, CAN J CARDIOL, V25, pE73, DOI 10.1016/S0828-282X(09)70045-5; Lopez-Jimenez F, 2008, CHEST, V133, P793, DOI 10.1378/chest.07-0800; Masood A, 2000, Curr Opin Pulm Med, V6, P479, DOI 10.1097/00063198-200011000-00003; Park JG, 2011, MAYO CLIN PROC, V86, P549, DOI 10.4065/mcp.2010.0810; Romero-Corral A, 2007, CHEST, V132, P1863, DOI 10.1378/chest.07-0966; Rydman R, 2010, ECHOCARDIOGR-J CARD, V27, P286, DOI 10.1111/j.1540-8175.2009.01015.x; Sanner BM, 1997, EUR RESPIR J, V10, P2079, DOI 10.1183/09031936.97.10092079; Shivalkar B, 2006, J AM COLL CARDIOL, V47, P1433, DOI 10.1016/j.jacc.2005.11.054; Somers VK, 2008, CIRCULATION, V118, P1080, DOI 10.1161/CIRCULATIONAHA.107.189375; Tei C, 1996, J Am Soc Echocardiogr, V9, P838, DOI 10.1016/S0894-7317(96)90476-9; Tei C, 1995, J Cardiol, V26, P357; Teske AJ, 2009, J AM SOC ECHOCARDIOG, V22, P920, DOI 10.1016/j.echo.2009.05.014; Usui Y, 2013, SLEEP MED, V14, P155, DOI 10.1016/j.sleep.2010.09.014; Weidemann F, 2001, BASIC RES CARDIOL, V96, P595, DOI 10.1007/s003950170011	39	27	31	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 11	2013	8	10							e76352	10.1371/journal.pone.0076352	http://dx.doi.org/10.1371/journal.pone.0076352			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	236SL	24146857	Green Published, Green Submitted, gold			2023-01-03	WOS:000325819400053
J	Bon, I; Lembo, D; Rusnati, M; Clo, A; Morini, S; Miserocchi, A; Bugatti, A; Grigolon, S; Musumeci, G; Landolfo, S; Re, MC; Gibellini, D				Bon, Isabella; Lembo, David; Rusnati, Marco; Clo, Alberto; Morini, Silvia; Miserocchi, Anna; Bugatti, Antonella; Grigolon, Sonia; Musumeci, Giuseppina; Landolfo, Santo; Re, Maria Carla; Gibellini, Davide			Peptide-Derivatized SB105-A10 Dendrimer Inhibits the Infectivity of R5 and X4 HIV-1 Strains in Primary PBMCs and Cervicovaginal Histocultures	PLOS ONE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; HEPARAN-SULFATE PROTEOGLYCANS; ENVELOPE GLYCOPROTEIN GP120; PREEXPOSURE PROPHYLAXIS; ENTRY INHIBITORS; ANTIRETROVIRAL THERAPY; QUANTITATIVE DETECTION; TOPICAL MICROBICIDES; VAGINAL TRANSMISSION; ANTIVIRAL ACTIVITY	Peptide dendrimers are a class of molecules that exhibit a large array of biological effects including antiviral activity. In this report, we analyzed the antiviral activity of the peptide-derivatized SB105-A10 dendrimer, which is a tetra-branched dendrimer synthetized on a lysine core, in activated peripheral blood mononuclear cells (PBMCs) that were challenged with reference and wild-type human immunodeficiency virus type 1 (HIV-1) strains. SB105-A10 inhibited infections by HIV-1 X4 and R5 strains, interfering with the early phases of the viral replication cycle. SB105-A10 targets heparan sulfate proteoglycans (HSPGs) and, importantly, the surface plasmon resonance (SPR) assay revealed that SB105-A10 strongly binds gp41 and gp120, most likely preventing HIV-1 attachment/entry through multiple mechanisms. Interestingly, the antiviral activity of SB105-A10 was also detectable in an organ-like structure of human cervicovaginal tissue, in which SB105-A10 inhibited the HIV-1(ada) R5 strain infection without altering the tissue viability. These results demonstrated the strong antiviral activity of SB105-A10 and suggest a potential microbicide use of this dendrimer to prevent the heterosexual transmission of HIV-1.	[Bon, Isabella; Clo, Alberto; Morini, Silvia; Miserocchi, Anna; Musumeci, Giuseppina; Re, Maria Carla; Gibellini, Davide] Univ Bologna, Dept Expt Diagnost & Specialty Med DIMES, Microbiol Sect, Bologna, Italy; [Lembo, David] Univ Turin, Dept Clin & Biol Sci, Turin, Italy; [Rusnati, Marco; Bugatti, Antonella] Univ Brescia, Dept Biomed Sci & Biotechnol, Brescia, Italy; [Grigolon, Sonia] Spider Biotech Srl, Colleretto Giacosa, Turin, Italy; [Landolfo, Santo] Univ Turin, Dept Publ Hlth & Microbiol, Turin, Italy; [Re, Maria Carla] INBB, Interuniv Consortium, Rome, Italy	University of Bologna; University of Turin; University of Brescia; University of Turin	Gibellini, D (corresponding author), Univ Bologna, Dept Expt Diagnost & Specialty Med DIMES, Microbiol Sect, Bologna, Italy.	davide.gibellini@unibo.it	Gibellini, Davide/K-8725-2016; BON, ISABELLA/HIK-0216-2022; Rusnati, Marco/F-1168-2010	Gibellini, Davide/0000-0003-3688-1252; BON, ISABELLA/0000-0002-9433-5201; Rusnati, Marco/0000-0001-9968-5908; Lembo, David/0000-0002-0969-100X; Re, Maria Carla/0000-0003-1486-9033; MUSUMECI, GIUSEPPINA/0000-0003-0118-4537	Italian Ministry of Health; University of Bologna; MURST; Spider Biotech grant	Italian Ministry of Health(Ministry of Health, Italy); University of Bologna; MURST(Ministry of Education, Universities and Research (MIUR)); Spider Biotech grant	This work was supported by Italian Ministry of Health (AIDS project), University of Bologna (selected topics) and MURST 60%. The authors acknowledge a grant for the Lagrange Project - Crt Foundation. This study was partially funded by Spider Biotech grant to DG for the purchase of reagents. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abner SR, 2005, J INFECT DIS, V192, P1545, DOI 10.1086/462424; Abraham BK, 2012, CURR OPIN HIV AIDS, V7, P600, DOI 10.1097/COH.0b013e328358b9ce; Argyris EG, 2003, J VIROL, V77, P12140, DOI 10.1128/JVI.77.22.12140-12151.2003; Asaftei S, 2012, J MED CHEM, V55, P10405, DOI 10.1021/jm301337y; Baeten JM, 2012, NEW ENGL J MED, V367, P399, DOI 10.1056/NEJMoa1108524; BALZARINI J, 1991, ANTIMICROB AGENTS CH, V35, P410, DOI 10.1128/AAC.35.3.410; Barth H, 2003, J BIOL CHEM, V278, P41003, DOI 10.1074/jbc.M302267200; Basmaciogullari S, 2002, J VIROL, V76, P10791, DOI 10.1128/JVI.76.21.10791-10800.2002; Bekker LG, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a007435; Blumenthal R, 2012, J BIOL CHEM, V287, P40841, DOI 10.1074/jbc.R112.406272; Borges A. Rosa, 2005, Current Drug Targets - Infectious Disorders, V5, P247, DOI 10.2174/1568005054880127; Broder S, 2010, ANTIVIR RES, V85, P1, DOI 10.1016/j.antiviral.2009.10.002; Cai LF, 2010, CHEMMEDCHEM, V5, P1813, DOI 10.1002/cmdc.201000289; Calarese DA, 2003, SCIENCE, V300, P2065, DOI 10.1126/science.1083182; Chang DK, 2007, ANTIVIR RES, V74, P51, DOI 10.1016/j.antiviral.2006.12.006; Chen YP, 1997, NAT MED, V3, P866, DOI 10.1038/nm0897-866; Cladera J, 2001, EMBO J, V20, P19, DOI 10.1093/emboj/20.1.19; Cloninger MJ, 2002, CURR OPIN CHEM BIOL, V6, P742, DOI 10.1016/S1367-5931(02)00400-3; Coates TJ, 2008, LANCET, V372, P669, DOI 10.1016/S0140-6736(08)60886-7; Cohen Myron S, 2004, Top HIV Med, V12, P104; Cole AL, 2007, IMMUNOLOGY, V121, P140, DOI 10.1111/j.1365-2567.2006.02553.x; Cole AL, 2006, J IMMUNOL, V176, P6900, DOI 10.4049/jimmunol.176.11.6900; Cummins Jr JE, 2007, ANTIMICROB AGENTS CH, V5; Dahl V, 2010, ANTIVIR RES, V85, P286, DOI 10.1016/j.antiviral.2009.09.016; De Clercq E, 2010, CURR OPIN PHARMACOL, V10, P507, DOI 10.1016/j.coph.2010.04.011; Dezzutti CS, 2004, ANTIMICROB AGENTS CH, V48, P3834, DOI 10.1128/AAC.48.10.3834-3844.2004; Donalisio M, 2012, ANTIMICROB AGENTS CH, V56, P5278, DOI 10.1128/AAC.00771-12; Donalisio M, 2010, ANTIMICROB AGENTS CH, V54, P4290, DOI 10.1128/AAC.00471-10; Feldman SA, 2000, J VIROL, V74, P6442, DOI 10.1128/JVI.74.14.6442-6447.2000; Foss AM, 2009, SEX TRANSM INFECT, V85, P276, DOI 10.1136/sti.2008.032458; Gartner S, 1990, HIV TECHNIQUES, P53; Gibellini D, 2004, J CLIN VIROL, V29, P282, DOI 10.1016/S1386-6532(03)00169-0; Gibellini D, 2004, J VIROL METHODS, V115, P183, DOI 10.1016/j.jviromet.2003.09.030; Girard MP, 2012, CURR OPIN HIV AIDS, V7, P4, DOI 10.1097/COH.0b013e32834ddc96; Girard MP, 2011, VACCINE, V29, P6191, DOI [10.1016/j.vaccine.2011.08.031, 10.1016/j.vaccine.2011.06.085]; Giroglou T, 2001, J VIROL, V75, P1565, DOI 10.1128/JVI.75.3.1565-1570.2001; Grobler A, 2012, AIDS, V26, P2261, DOI 10.1097/QAD.0b013e328355ce08; HANSEN JES, 1989, AIDS, V3, P635, DOI 10.1097/00002030-198910000-00003; Heegaard Peter M H, 2006, Recent Pat Antiinfect Drug Discov, V1, P331; Higgins JA, 2010, AM J PUBLIC HEALTH, V100, P435, DOI 10.2105/AJPH.2009.159723; Huskens D, 2009, ANTIVIR RES, V84, P38, DOI 10.1016/j.antiviral.2009.07.013; Jiang YH, 2005, AIDS RES HUM RETROV, V21, P207, DOI 10.1089/aid.2005.21.207; Jones KS, 2005, J VIROL, V79, P12692, DOI 10.1128/JVI.79.20.12692-12702.2005; Karim QA, 2010, SCIENCE, V329, P1168, DOI 10.1126/science.1193748; Kilby JM, 2002, AIDS RES HUM RETROV, V18, P685, DOI 10.1089/088922202760072294; Kuhmann SE, 2008, ANNU REV PHARMACOL, V48, P425, DOI 10.1146/annurev.pharmtox.48.113006.094847; Kwong PD, 1998, NATURE, V393, P648, DOI 10.1038/31405; Lackman-Smith C, 2008, ANTIMICROB AGENTS CH, V52, P1768, DOI 10.1128/AAC.01328-07; Lalezari JP, 2003, AIDS, V17, P691, DOI 10.1097/00002030-200303280-00007; Lederman MM, 2008, RETROVIROLOGY, V5, DOI 10.1186/1742-4690-5-116; Lederman MM, 2006, NAT REV IMMUNOL, V6, P371, DOI 10.1038/nri1848; Liu SW, 2007, CURR PHARM DESIGN, V13, P143, DOI 10.2174/138161207779313722; Luganini A, 2010, ANTIVIR RES, V85, P532, DOI 10.1016/j.antiviral.2010.01.003; Maldarelli F, 2011, CURR OPIN HIV AIDS, V6, P49, DOI 10.1097/COH.0b013e32834134ea; Marsden MD, 2009, J ANTIMICROB CHEMOTH, V63, P7, DOI 10.1093/jac/dkn455; Masse PJ, 2008, ANNU REV MED, V59, P455, DOI 10.1146/annurev.med.59.061206.112737; McCarthy TD, 2005, MOL PHARMACEUT, V2, P312, DOI 10.1021/mp050023q; McEnery Regina, 2011, IAVI Rep, V15, P21; McGowan I, 2010, CURR OPIN INFECT DIS, V23, P26, DOI 10.1097/QCO.0b013e328334fe70; Mondor I, 1998, J VIROL, V72, P3623, DOI 10.1128/JVI.72.5.3623-3634.1998; Mori T, 2005, J BIOL CHEM, V280, P9345, DOI 10.1074/jbc.M411122200; Morris GC, 2010, CURR OPIN INFECT DIS, V23, P57, DOI 10.1097/QCO.0b013e328334de6d; Moulard M, 2000, J VIROL, V74, P1948, DOI 10.1128/JVI.74.4.1948-1960.2000; Ohshiro Y, 1996, MICROBIOL IMMUNOL, V40, P827, DOI 10.1111/j.1348-0421.1996.tb01148.x; Pang W, 2008, VIROLOGY, V377, P80, DOI 10.1016/j.virol.2008.04.013; PATEL M, 1993, AIDS RES HUM RETROV, V9, P167, DOI 10.1089/aid.1993.9.167; Pini A, 2005, ANTIMICROB AGENTS CH, V49, P2665, DOI 10.1128/AAC.49.7.2665-2672.2005; Quinn TC, 2008, AIDS, V22, pS7, DOI 10.1097/01.aids.0000327510.68503.e8; Rizzuto CD, 1998, SCIENCE, V280, P1949, DOI 10.1126/science.280.5371.1949; Roan NR, 2009, J VIROL, V83, P73, DOI 10.1128/JVI.01366-08; RODERIQUEZ G, 1995, J VIROL, V69, P2233, DOI 10.1128/JVI.69.4.2233-2239.1995; Salvador B, 2013, J VIROL, V87, P3295, DOI 10.1128/JVI.01621-12; Saphire ACS, 2001, J VIROL, V75, P9187, DOI 10.1128/JVI.75.19.9187-9200.2001; Sarrazin S., 2011, COLD SPRING HARB PER, V3, P7; SATTENTAU QJ, 1993, J VIROL, V67, P7383, DOI 10.1128/JVI.67.12.7383-7393.1993; SHIEH MT, 1992, J CELL BIOL, V116, P1273, DOI 10.1083/jcb.116.5.1273; Smith RJ, 2005, AIDS, V19, P413, DOI 10.1097/01.aids.0000161771.44276.92; Spillmann D, 2001, BIOCHIMIE, V83, P811, DOI 10.1016/S0300-9084(01)01290-1; Svicher V, 2010, NEW MICROBIOL, V33, P195; Telwatte S, 2011, ANTIVIR RES, V90, P195, DOI 10.1016/j.antiviral.2011.03.186; Thigpen MC, 2012, NEW ENGL J MED, V367, P423, DOI 10.1056/NEJMoa1110711; Tilton JC, 2010, ANTIVIR RES, V85, P91, DOI 10.1016/j.antiviral.2009.07.022; Tsai CC, 2003, AIDS RES HUM RETROV, V19, P535, DOI 10.1089/088922203322230897; Tyagi M, 2001, J BIOL CHEM, V276, P3254, DOI 10.1074/jbc.M006701200; Tyssen D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012309; Ugolini S, 1999, TRENDS MICROBIOL, V7, P144, DOI 10.1016/S0966-842X(99)01474-2; Van Damme L, 2012, NEW ENGL J MED, V367, P411, DOI 10.1056/NEJMoa1202614; van der Straten A, 2012, AIDS, V26, pF13, DOI 10.1097/QAD.0b013e3283522272; Vives RR, 2005, J BIOL CHEM, V280, P21353, DOI 10.1074/jbc.M500911200; Weissenhorn W, 1997, NATURE, V387, P426, DOI 10.1038/387426a0; WHO UNAIDS Unicef, 2011, GLOB HIV AIDS RESP E; WILD C, 1993, AIDS RES HUM RETROV, V9, P1051, DOI 10.1089/aid.1993.9.1051; Wilson LE, 2009, CLIN INFECT DIS, V48, P214, DOI 10.1086/595701; WYATT R, 1995, J VIROL, V69, P5723, DOI 10.1128/JVI.69.9.5723-5733.1995	94	27	28	0	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 7	2013	8	10							e76482	10.1371/journal.pone.0076482	http://dx.doi.org/10.1371/journal.pone.0076482			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	232NS	24116111	Green Published, Green Submitted, gold			2023-01-03	WOS:000325501300059
J	Lee, HS; Jang, MS; Kim, JH; Hong, CP; Lee, EJ; Jeun, EJ; Kim, C; Kim, EK; Ahn, KS; Yang, BG; Ahn, KS; Jang, YP; Ahn, KS; Kim, YM; Jang, MH				Lee, Han-Sung; Jang, Min Seong; Kim, Jung-Hwan; Hong, Chun-Pyo; Lee, Eun-Jung; Jeun, Eun Ji; Kim, Chan; Kim, Eun-Kyung; Ahn, Kwang-Seong; Yang, Bo-Gie; Ahn, Kwang Seok; Jang, Young Pyo; Ahn, Kyoo-Seok; Kim, You-Me; Jang, Myoung Ho			Ulmus davidiana var. japonica Nakai Upregulates Eosinophils and Suppresses Th1 and Th17 Cells in the Small Intestine	PLOS ONE			English	Article							DENDRITIC CELLS; LAMINA-PROPRIA; T-CELLS; IN-VIVO; IMMUNITY; SIGNALS; IL-17	The bark of Ulmus davidiana var. japonica Nakai (Ulmaceae) has been used in traditional Korean medicine for chronic inflammation in the gastrointestinal tract. Here we investigated the frequency and cytokine profile of the major immune cells in the small intestinal lamina propria (SI LP), spleen, and mesenteric lymph nodes (MLNs) of mice treated orally with Ulmus davidiana var. japonica Nakai bark water extract (UDE) to address the immunomodulatory role of this herb in intestinal homeostasis. B6 mice were given 5g/kg UDE once daily for 14 days. They were then sacrificed, and cells were isolated from the spleen, MLNs, and SI LP. The proportion of B versus T lymphocytes, CD4(+) versus CD8(+) T lymphocytes, Th1 and Th17 cells, and Foxp3(+) regulatory T cells in the spleen, MLNs, and SI LP were analyzed. The frequency of antigen-presenting cells (APCs), including dendritic cells, macrophages, and eosinophils in the SI LP and the expression of costimulatory molecules on APCs were also evaluated. The numbers and frequencies of Th1 and Th17 cells in the SI LP were significantly reduced in the UDE-treated mice compared with PBS controls. In addition, the proportion of IL-4-producing eosinophils in the SI LP was significantly elevated in the UDE-treated mice compared with controls. Taken together, these data indicate that UDE up-regulates the number and frequency of SI LP eosinophils, which can down-regulate the Th1 and Th17 responses via IL-4 secretion and contribute to intestinal homeostasis.	[Lee, Han-Sung; Jang, Min Seong; Kim, Jung-Hwan; Hong, Chun-Pyo; Lee, Eun-Jung; Jeun, Eun Ji; Kim, Chan; Yang, Bo-Gie; Kim, You-Me; Jang, Myoung Ho] Pohang Univ Sci & Technol, Div Integrat Biosci & Biotechnol, Pohang, South Korea; [Lee, Han-Sung; Ahn, Kwang Seok; Ahn, Kyoo-Seok] Kyung Hee Univ, Coll Korean Med, Dept Pathol, Seoul, South Korea; [Kim, Eun-Kyung; Ahn, Kwang-Seong; Jang, Young Pyo] Kyung Hee Univ, Coll Pharm, Div Pharmacognosy, Seoul, South Korea; [Jang, Myoung Ho] AIM, IBS, Pohang, South Korea	Pohang University of Science & Technology (POSTECH); Kyung Hee University; Kyung Hee University; Institute for Basic Science - Korea (IBS)	Jang, MH (corresponding author), Pohang Univ Sci & Technol, Div Integrat Biosci & Biotechnol, Pohang, South Korea.	jangmh@ibs.re.kr	Jang, Myoung Ho/D-1714-2009; Kim, You-Me/I-5553-2013; Jang, Young Pyo/AAJ-8782-2020	Jang, Myoung Ho/0000-0001-8909-4725; Kim, You-Me/0000-0001-8780-704X; Jang, Young Pyo/0000-0001-5865-9228; Yang, Bo-Gie/0000-0002-1538-8488	National Research Foundation of Korea (NRF); Ministry of Education, Science and Technology of Korea (MEST) [2013030693]; Institute for Basic Science (IBS); World Class Universities Project, NRF, MEST [R31-10105]	National Research Foundation of Korea (NRF)(National Research Foundation of Korea); Ministry of Education, Science and Technology of Korea (MEST)(Ministry of Education, Science & Technology (MEST), Republic of Korea); Institute for Basic Science (IBS); World Class Universities Project, NRF, MEST(National Research Foundation of KoreaMinistry of Education, Science & Technology (MEST), Republic of Korea)	This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Ministry of Education, Science and Technology of Korea (MEST) (No. 2013030693), the Institute for Basic Science (IBS) and the World Class Universities Project, NRF, MEST (R31-10105). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Carlens J, 2009, J IMMUNOL, V183, P5600, DOI 10.4049/jimmunol.0801581; Chirdo FG, 2005, EUR J IMMUNOL, V35, P1831, DOI 10.1002/eji.200425882; Choi SY, 2010, J MED FOOD, V13, P1019, DOI 10.1089/jmf.2009.1207; Coombes JL, 2008, NAT REV IMMUNOL, V8, P435, DOI 10.1038/nri2335; Denning TL, 2007, NAT IMMUNOL, V8, P1086, DOI 10.1038/ni1511; Guo Z, 2008, INT IMMUNOL, V20, P307, DOI 10.1093/intimm/dxm143; Jacobsen EA, 2007, J ALLERGY CLIN IMMUN, V119, P1313, DOI 10.1016/j.jaci.2007.03.043; Jang MH, 2006, J IMMUNOL, V176, P803, DOI 10.4049/jimmunol.176.2.803; Kim YC, 2007, FITOTERAPIA, V78, P196, DOI 10.1016/j.fitote.2006.11.013; Korn T, 2009, ANNU REV IMMUNOL, V27, P485, DOI 10.1146/annurev.immunol.021908.132710; Lee EH, 2013, J ETHNOPHARMACOL, V146, P608, DOI 10.1016/j.jep.2013.01.035; Lee SJ, 2007, FOOD CHEM TOXICOL, V45, P990, DOI 10.1016/j.fct.2006.12.006; Maul J, 2005, GASTROENTEROLOGY, V128, P1868, DOI 10.1053/j.gastro.2005.03.043; Mishra A, 1999, J CLIN INVEST, V103, P1719, DOI 10.1172/JCI6560; Mohrs M, 2001, IMMUNITY, V15, P303, DOI 10.1016/S1074-7613(01)00186-8; Park JW, 2011, ORIENTAL PHARM EXP M, V11, P107, DOI 10.1007/s13596-011-0011-9; Rankin SM, 2000, MOL MED TODAY, V6, P20, DOI 10.1016/S1357-4310(99)01635-4; Rothenberg ME, 2001, IMMUNOL REV, V179, P139, DOI 10.1034/j.1600-065X.2001.790114.x; SCHREIBER S, 1995, GASTROENTEROLOGY, V108, P1434, DOI 10.1016/0016-5085(95)90692-4; Song IK, 2007, ENVIRON TOXICOL PHAR, V23, P102, DOI 10.1016/j.etap.2006.07.013; Straumann A, 2004, ALLERGY, V59, P15, DOI 10.1046/j.1398-9995.2003.00382.x; Strober W, 2007, J CLIN INVEST, V117, P514, DOI 10.1172/JCI30587; Strober W, 2011, GASTROENTEROLOGY, V140, P1756, DOI 10.1053/j.gastro.2011.02.016; Stumhofer JS, 2007, SEMIN IMMUNOL, V19, P394, DOI 10.1016/j.smim.2007.11.006; Sun CM, 2007, J EXP MED, V204, P1775, DOI 10.1084/jem.20070602; Svensson-Frej M, 2011, J INNATE IMMUN, V3, P565, DOI 10.1159/000328799; Uematsu S, 2008, NAT IMMUNOL, V9, P769, DOI 10.1038/ni.1622; Wen T, 2012, J IMMUNOL, V188, P1075, DOI 10.4049/jimmunol.1102222; Yu CN, 2002, J EXP MED, V195, P1387, DOI 10.1084/jem.20020656; Zhang Z, 2006, INFLAMM BOWEL DIS, V12, P382, DOI 10.1097/01.MIB.0000218764.06959.91	30	5	6	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 7	2013	8	10							e76716	10.1371/journal.pone.0076716	http://dx.doi.org/10.1371/journal.pone.0076716			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	232NS	24116141	Green Submitted, Green Published, gold			2023-01-03	WOS:000325501300084
J	Wissenberg, M; Lippert, FK; Folke, F; Weeke, P; Hansen, CM; Christensen, EF; Jans, H; Hansen, PA; Lang-Jensen, T; Olesen, JB; Lindhardsen, J; Fosbol, EL; Nielsen, SL; Gislason, GH; Kober, L; Torp-Pedersen, C				Wissenberg, Mads; Lippert, Freddy K.; Folke, Fredrik; Weeke, Peter; Hansen, Carolina Malta; Christensen, Erika Frischknecht; Jans, Henning; Hansen, Poul Anders; Lang-Jensen, Torsten; Olesen, Jonas Bjerring; Lindhardsen, Jesper; Fosbol, Emil L.; Nielsen, Soren L.; Gislason, Gunnar H.; Kober, Lars; Torp-Pedersen, Christian			Association of National Initiatives to Improve Cardiac Arrest Management With Rates of Bystander Intervention and Patient Survival After Out-of-Hospital Cardiac Arrest	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							AMERICAN-HEART-ASSOCIATION; PUBLIC-ACCESS DEFIBRILLATION; LONG-TERM SURVIVAL; CARDIOPULMONARY-RESUSCITATION; GUIDELINES; STATEMENT; IMPLEMENTATION; PROFESSIONALS; COMMITTEE; CPR	IMPORTANCE Out-of-hospital cardiac arrest is a major health problem associated with poor outcomes. Early recognition and intervention are critical for patient survival. Bystander cardiopulmonary resuscitation (CPR) is one factor among many associated with improved survival. OBJECTIVE To examine temporal changes in bystander resuscitation attempts and survival during a 10-year period in which several national initiatives were taken to increase rates of bystander resuscitation and improve advanced care. DESIGN, SETTING, AND PARTICIPANTS Patients with out-of-hospital cardiac arrest for which resuscitation was attempted were identified between 2001 and 2010 in the nationwide Danish Cardiac Arrest Registry. Of 29 111 patients with cardiac arrest, we excluded those with presumed noncardiac cause of arrest (n = 7390) and those with cardiac arrests witnessed by emergency medical services personnel (n = 2253), leaving a study population of 19 468 patients. MAIN OUTCOMES AND MEASURES Temporal trends in bystander CPR, bystander defibrillation, 30-day survival, and 1-year survival. RESULTS The median age of patients was 72 years; 67.4% were men. Bystander CPR increased significantly during the study period, from 21.1%(95% CI, 18.8%-23.4%) in 2001 to 44.9% (95% CI, 42.6%-47.1%) in 2010 (P<.001), whereas use of defibrillation by bystanders remained low (1.1% [95% CI, 0.6%-1.9%] in 2001 to 2.2% [95% CI, 1.5%-2.9%] in 2010; P=.003). More patients achieved survival on hospital arrival (7.9% [95% CI, 6.4%-9.5%] in 2001 to 21.8% [95% CI, 19.8%-23.8%] in 2010; P<.001). Also, 30-day survival improved (3.5% [95% CI, 2.5%-4.5%] in 2001 to 10.8% [95% CI, 9.4%-12.2%] in 2010; P<.001), as did 1-year survival (2.9% [95% CI, 2.0%-3.9%] in 2001 to 10.2% [95% CI, 8.9%-11.6%] in 2010; P<.001). Despite a decrease in the incidence of out-of-hospital cardiac arrests during the study period (40.4 to 34.4 per 100 000 persons in 2001 and 2010, respectively; P=.002), the number of survivors per 100 000 persons increased significantly (P<.001). For the entire study period, bystander CPR was positively associated with 30-day survival, regardless of witnessed status (30-day survival for nonwitnessed cardiac arrest, 4.3% [95% CI, 3.4%-5.2%] with bystander CPR and 1.0% [95% CI, 0.8%-1.3%] without; odds ratio, 4.38 [95% CI, 3.17-6.06]). For witnessed arrest the corresponding values were 19.4%(95% CI, 18.1%-20.7%) vs 6.1% (95% CI, 5.4%-6.7%); odds ratio, 3.74 (95% CI, 3.26-4.28). CONCLUSIONS AND RELEVANCE In Denmark between 2001 and 2010, an increase in survival following out-of-hospital cardiac arrest was significantly associated with a concomitant increase in bystander CPR. Because of the co-occurrence of other related initiatives, a causal relationship remains uncertain.	[Wissenberg, Mads; Folke, Fredrik; Weeke, Peter; Hansen, Carolina Malta; Olesen, Jonas Bjerring; Lindhardsen, Jesper; Gislason, Gunnar H.] Univ Copenhagen, Gentofte Hosp, Dept Cardiol, DK-2900 Hellerup, Denmark; [Fosbol, Emil L.; Kober, Lars] Copenhagen Univ Hosp, Rigshosp, Ctr Heart, Copenhagen, Denmark; [Torp-Pedersen, Christian] Aalborg Univ, Inst Hlth Sci & Technol, Aalborg, Denmark	University of Copenhagen; Herlev & Gentofte Hospital; Rigshospitalet; University of Copenhagen; Aalborg University	Wissenberg, M (corresponding author), Univ Copenhagen, Gentofte Hosp, Dept Cardiol, Niels Andersens Vej 65,Post 635, DK-2900 Hellerup, Denmark.	mads.wissenberg.joergensen@regionh.dk	Christensen, Erika Frischknecht/H-8753-2017; Gislason, Gunnar/B-7561-2009; Folke, Fredrik/P-3601-2014	Christensen, Erika Frischknecht/0000-0003-3673-9694; Gislason, Gunnar/0000-0002-0548-402X; Lippert, Freddy/0000-0002-2356-8809; Fosbol, Emil/0000-0002-2048-4167; Folke, Fredrik/0000-0002-2284-7857; Wissenberg, Mads/0000-0001-7067-3372; Kober, Lars/0000-0002-6635-1466	Danish foundation TrygFonden (Denmark); Danish Heart Foundation (Denmark); Health Insurance Foundation (Denmark); TrygFonden; Novo Nordisk Foundation	Danish foundation TrygFonden (Denmark); Danish Heart Foundation (Denmark); Health Insurance Foundation (Denmark); TrygFonden; Novo Nordisk Foundation(Novo Nordisk FoundationNovocure Limited)	This study was supported by the Danish foundation TrygFonden, the Danish Heart Foundation, and the Health Insurance Foundation (all from Denmark). The Danish Cardiac Arrest Registry and the Automated External Defibrillator (AED) Network are supported by TrygFonden, which has no commercial interests in the field of cardiac arrest. Dr Gislason is supported by an independent research scholarship from the Novo Nordisk Foundation.	Abella BS, 2008, CIRCULATION, V117, P704, DOI 10.1161/CIRCULATIONAHA.107.188486; [Anonymous], DAN LEARN CARD RES; [Anonymous], 2011, AUT EXT DEF AED PLAC; [Anonymous], SUMM VIT STAT; [Anonymous], INCR NUMB DAN CIT WH; Berdowski J, 2010, RESUSCITATION, V81, P1479, DOI 10.1016/j.resuscitation.2010.08.006; Buch P, 2003, TREATMENT OUT OF HOS; Caffrey SL, 2002, NEW ENGL J MED, V347, P1242, DOI 10.1056/NEJMoa020932; CUMMINS RO, 1991, CIRCULATION, V83, P1832, DOI 10.1161/01.CIR.83.5.1832; Davies CS, 2005, HEART, V91, P1299, DOI 10.1136/hrt.2003.032631; Field JM, 2010, CIRCULATION, V122, pS640, DOI 10.1161/CIRCULATIONAHA.110.970889; Hallstrom AP, 2004, NEW ENGL J MED, V351, P637; Hollenberg J, 2008, CIRCULATION, V118, P389, DOI 10.1161/CIRCULATIONAHA.107.734137; Holler NG, 2007, RESUSCITATION, V75, P23, DOI 10.1016/j.resuscitation.2007.03.015; Iwami T, 2009, CIRCULATION, V119, P728, DOI 10.1161/CIRCULATIONAHA.108.802058; Jacobs I, 2004, CIRCULATION, V110, P3385, DOI 10.1161/01.CIR.0000147236.85306.15; Kitamura T, 2012, CIRCULATION, V126, P2834, DOI 10.1161/CIRCULATIONAHA.112.109496; Kitamura T, 2010, NEW ENGL J MED, V362, P994, DOI 10.1056/NEJMoa0906644; Kuilman M, 1999, RESUSCITATION, V41, P25, DOI 10.1016/S0300-9572(99)00016-7; Kuramoto N, 2008, RESUSCITATION, V79, P475, DOI 10.1016/j.resuscitation.2008.07.005; Lindner TW, 2011, RESUSCITATION, V82, P1508, DOI 10.1016/j.resuscitation.2011.06.016; McNally Bryan, 2011, Morbidity and Mortality Weekly Report, V60, P1; Neumar RW, 2010, CIRCULATION, V122, pS729, DOI 10.1161/CIRCULATIONAHA.110.970988; Nichol G, 2008, JAMA-J AM MED ASSOC, V300, P1423, DOI 10.1001/jama.300.12.1423; Nielsen AM, 2013, RESUSCITATION, V84, P430, DOI 10.1016/j.resuscitation.2012.11.008; Nielsen AM, 2012, RESUSCITATION, V83, P1067, DOI 10.1016/j.resuscitation.2012.04.012; Rea TD, 2010, ANN EMERG MED, V55, P249, DOI 10.1016/j.annemergmed.2009.09.018; Rea TD, 2010, CIRCULATION, V121, P1134, DOI 10.1161/CIRCULATIONAHA.109.899799; Roger VL, 2011, CIRCULATION, V123, pE18, DOI 10.1161/CIR.0b013e3182009701; Sasson C, 2010, CIRC-CARDIOVASC QUAL, V3, P63, DOI 10.1161/CIRCOUTCOMES.109.889576; Vaillancourt C, 2008, CAN J EMERG MED, V10, P51, DOI 10.1017/S1481803500010010; Valenzuela TD, 2000, NEW ENGL J MED, V343, P1206, DOI 10.1056/NEJM200010263431701	33	771	785	4	38	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 2	2013	310	13					1377	1384		10.1001/jama.2013.278483	http://dx.doi.org/10.1001/jama.2013.278483			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	227GB	24084923	Bronze			2023-01-03	WOS:000325098100023
J	Wu, ZQ; Zhang, XQ; Shen, L; Xiong, YY; Wu, X; Huo, R; Wei, ZY; Cai, L; Qi, GY; Xu, QQ; Cui, DX; Cui, DH; Zhao, GC; He, L; Qin, SY				Wu, Zhenqiang; Zhang, Xiaoqing; Shen, Lu; Xiong, Yuyu; Wu, Xi; Huo, Ran; Wei, Zhiyun; Cai, Lei; Qi, Guoyang; Xu, Qingqing; Cui, Daxiang; Cui, Donghong; Zhao, Gengchun; He, Lin; Qin, Shengying			A Systematically Combined Genotype and Functional Combination Analysis of CYP2E1, CYP2D6, CYP2C9, CYP2C19 in Different Geographic Areas of Mainland China - A Basis for Personalized Therapy	PLOS ONE			English	Article							GENETIC-POLYMORPHISM ANALYSIS; HAN POPULATIONS; DRUG-METABOLISM; CYTOCHROME-P450; PHARMACOGENETICS; MEDICINE; ENZYMES	The cytochrome P450 is the major enzyme involved in drug metabolism. Single CYP genotypes and metabolic phenotypes have been widely studied, but no combination analysis has been conducted in the context of specific populations and geographical areas. This study is the first to systematically analyze the combined genotypes and functional combinations of 400 samples of major CYP genes-CYP2E1, CYP2D6, CYP2C9, and CYP2C19 in four geographical areas of mainland China. 167 different genotype combinations were identified, of which 25 had a greater than 1% frequency in the Chinese Han population. In addition, phenotypes of the four genes for each sample were in line with the predictions of previous studies of the four geographical areas. On the basis of the genotype classification, we were able to produce a systemic functional combinations analysis for the population. 25 of the combinations detected had at least two non-wild phenotypes and four showed a frequency above 1%. A bioinformatics analysis of the relationship between particular drugs and multi-genes was conducted. This is the first systematic study to analyze genotype combinations and functional combinations across whole Chinese population and could make a significant contribution in the field of personalized medicine and therapy.	[Wu, Zhenqiang; Zhang, Xiaoqing; Shen, Lu; Xiong, Yuyu; Wu, Xi; Huo, Ran; Wei, Zhiyun; Cai, Lei; Xu, Qingqing; Cui, Daxiang; Cui, Donghong; He, Lin; Qin, Shengying] Shanghai Jiao Tong Univ, Minist Educ, Key Lab Genet Dev & Neuropsychiat Disorders, Bio X Inst, Shanghai 200030, Peoples R China; [Wu, Zhenqiang; Shen, Lu; Xiong, Yuyu; Wu, Xi; Huo, Ran; Wei, Zhiyun; Xu, Qingqing; He, Lin; Qin, Shengying] Shanghai Geno MePilot Inst Genom & Human Hlth, Shanghai, Peoples R China; [He, Lin] Fudan Univ, Inst Biomed Sci, Shanghai 200433, Peoples R China; [Zhang, Xiaoqing] Tongji Univ, Sch Med, Shanghai Pulm Hosp, Dept Pharm, Shanghai 200092, Peoples R China; [Qi, Guoyang] Wuxi Mental Hlth Ctr, Wuxi, Jiangsu, Peoples R China; [Cui, Daxiang] Shanghai Jiao Tong Univ, Res Inst Micro Nano Sci & Technol, Shanghai 200030, Peoples R China; [Cui, Donghong] Shanghai Inst Mental Hlth, Shanghai, Peoples R China; [Zhao, Gengchun] Shanghai Jiao Tong Univ, Sch Life Sci & Biotechnol, Shanghai 200030, Peoples R China	Shanghai Jiao Tong University; Fudan University; Tongji University; Shanghai Jiao Tong University; Shanghai Jiao Tong University	Qin, SY (corresponding author), Shanghai Jiao Tong Univ, Minist Educ, Key Lab Genet Dev & Neuropsychiat Disorders, Bio X Inst, Shanghai 200030, Peoples R China.	chinsir@sjtu.edu.cn	cui, donghong/AAV-2619-2020; Lu, Shen/B-2644-2008; Wei, Zhiyun/E-2008-2016; Cai, Lei/H-3972-2017	Lu, Shen/0000-0002-0659-2399; Wei, Zhiyun/0000-0002-3554-4142; Cai, Lei/0000-0002-5726-2971	863 Program [2012AA02A515]; 973 Program [2010CB529600]; National Key Technology RD Program [2012BAI01B09]; National Nature Science Foundation of China [81273596, 81121001, 30900799, 30972823]; Shanghai Jiao Tong University Med-X Fund [YG2010MS61]; Public Science and Technology Research Funds [201210056]; Shanghai Jiao Tong University Interdisciplinary Research fund; Major Program of Shanghai Committee of Science and Technology [11dz1950300]; Shanghai Leading Academic Discipline Project [B205]	863 Program(National High Technology Research and Development Program of China); 973 Program(National Basic Research Program of China); National Key Technology RD Program(National Key Technology R&D Program); National Nature Science Foundation of China(National Natural Science Foundation of China (NSFC)); Shanghai Jiao Tong University Med-X Fund; Public Science and Technology Research Funds; Shanghai Jiao Tong University Interdisciplinary Research fund; Major Program of Shanghai Committee of Science and Technology(Shanghai Science & Technology Committee); Shanghai Leading Academic Discipline Project(Shanghai Leading Academic Discipline Project)	This work was supported by the 863 Program (2012AA02A515), the 973 Program (2010CB529600), the National Key Technology R&D Program (2012BAI01B09), the National Nature Science Foundation of China (81273596, 81121001, 30900799, 30972823), the Shanghai Jiao Tong University Med-X Fund (YG2010MS61), the Public Science and Technology Research Funds(201210056), the Shanghai Jiao Tong University Interdisciplinary Research fund, the Major Program of Shanghai Committee of Science and Technology (11dz1950300) and the Shanghai Leading Academic Discipline Project (B205). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bertilsson L, 2002, BRIT J CLIN PHARMACO, V53, P111, DOI 10.1046/j.0306-5251.2001.01548.x; BERTILSSON L, 1992, CLIN PHARMACOL THER, V51, P388, DOI 10.1038/clpt.1992.38; Chen LL, 2008, PHARMACOGENOMICS, V9, P691, DOI 10.2217/14622416.9.6.691; de Leon J, 2006, EXPERT REV MOL DIAGN, V6, P277, DOI 10.1586/14737159.6.3.277; Eichelbaum M, 2006, ANNU REV MED, V57, P119, DOI 10.1146/annurev.med.56.082103.104724; EVANS WE, 1993, J CLIN INVEST, V91, P2150, DOI 10.1172/JCI116441; Gardiner SJ, 2006, PHARMACOL REV, V58, P521, DOI 10.1124/pr.58.3.6; Guengerich FP, 2008, CHEM RES TOXICOL, V21, P70, DOI 10.1021/tx700079z; GUIYUN M, 2005, J CHENGDE MED COLL, V22; Lazarou J, 1998, JAMA-J AM MED ASSOC, V279, P1200, DOI 10.1001/jama.279.15.1200; MADISEN L, 1987, AM J MED GENET, V27, P379, DOI 10.1002/ajmg.1320270216; Marshall A, 1997, NAT BIOTECHNOL, V15, P1249, DOI 10.1038/nbt1197-1249; McGraw J, 2012, EXPERT OPIN DRUG MET, V8, P371, DOI 10.1517/17425255.2012.657626; Meyer UA, 2000, LANCET, V356, P1667, DOI 10.1016/S0140-6736(00)03167-6; Qin SY, 2008, GENOMICS, V92, P152, DOI 10.1016/j.ygeno.2008.05.004; Rendic S, 1997, DRUG METAB REV, V29, P413, DOI 10.3109/03602539709037591; Tang KF, 2010, GENOMICS, V95, P224, DOI 10.1016/j.ygeno.2010.01.005; WATKINS PB, 1990, SEMIN LIVER DIS, V10, P235, DOI 10.1055/s-2008-1040480; Wolf CR, 2000, BRIT MED J, V320, P987, DOI 10.1136/bmj.320.7240.987; Xiong YY, 2011, GENOMICS, V97, P277, DOI 10.1016/j.ygeno.2010.11.004	20	7	7	0	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 2	2013	8	10							e71934	10.1371/journal.pone.0071934	http://dx.doi.org/10.1371/journal.pone.0071934			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	231RG	24098323	Green Published, gold, Green Submitted			2023-01-03	WOS:000325434500002
J	Qaseem, A; Holty, JEC; Owens, DK; Dallas, P; Starkey, M; Shekelle, P				Qaseem, Amir; Holty, Jon-Erik C.; Owens, Douglas K.; Dallas, Paul; Starkey, Melissa; Shekelle, Paul		Amer Coll Phys	Management of Obstructive Sleep Apnea in Adults: A Clinical Practice Guideline From the American College of Physicians	ANNALS OF INTERNAL MEDICINE			English	Article							POSITIVE AIRWAY PRESSURE; QUALITY-OF-LIFE; RANDOMIZED CONTROLLED-TRIAL; CONTROLLED CROSSOVER TRIAL; PLACEBO-CONTROLLED TRIAL; ORAL APPLIANCE THERAPY; TEMPERATURE-CONTROLLED-RADIOFREQUENCY; CHRONIC HEART-FAILURE; CPAP THERAPY; APNEA/HYPOPNEA SYNDROME	Description: The American College of Physicians (ACP) developed this guideline to present the evidence and provide clinical recommendations on the management of obstructive sleep apnea (OSA) in adults. Methods: This guideline is based on published literature from 1966 to September 2010 that was identified by using MEDLINE, the Cochrane Central Register of Controlled Trials, and the Cochrane Database of Systematic Reviews. A supplemental MEDLINE search identified additional articles through October 2012. Searches were limited to English-language publications. The clinical outcomes evaluated for this guideline included cardiovascular disease (such as heart failure, hypertension, stroke, and myocardial infarction), type 2 diabetes, death, sleep study measures (such as the Apnea-Hypopnea Index), measures of cardiovascular status (such as blood pressure), measures of diabetes status (such as hemoglobin A(1c) levels), and quality of life. This guideline grades the evidence and recommendations using ACP's clinical practice guidelines grading system. Recommendation 1: ACP recommends that all overweight and obese patients diagnosed with OSA should be encouraged to lose weight. (Grade: strong recommendation; low-quality evidence) Recommendation 2: ACP recommends continuous positive airway pressure treatment as initial therapy for patients diagnosed with OSA. (Grade: strong recommendation; moderate-quality evidence) Recommendation 3: ACP recommends mandibular advancement devices as an alternative therapy to continuous positive airway pressure treatment for patients diagnosed with OSA who prefer mandibular advancement devices or for those with adverse effects associated with continuous positive airway pressure treatment. (Grade: weak recommendation; low-quality evidence)	[Qaseem, Amir] Amer Coll Physicians, Philadelphia, PA 19106 USA; Stanford Univ, Stanford, CA 94305 USA; Vet Affairs Palo Alto Hlth Care Syst, Palo Alto, CA USA; Virginia Tech Univ, Caril Sch Med, Roanoke, VA USA; W Los Angeles Vet Affairs Med Ctr, Los Angeles, CA 90073 USA	American College of Physicians; Stanford University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System; West Los Angeles VA Medical Center	Qaseem, A (corresponding author), Amer Coll Physicians, 190 N Independence Mall West, Philadelphia, PA 19106 USA.	aqaseem@acponline.org		Starkey, Melissa/0000-0002-5818-0265	ACP operating budget	ACP operating budget	Financial support for the development of this guideline comes exclusively from the ACP operating budget.	Agency for Healthcare Research and Quality, 2010, METH REF GUID EFF CO; ANAND VK, 1991, OTOLARYNG HEAD NECK, V105, P382, DOI 10.1177/019459989110500306; Anderson FE, 2003, SLEEP, V26, P721, DOI 10.1093/sleep/26.6.721; Antic NA, 2009, AM J RESP CRIT CARE, V179, P501, DOI 10.1164/rccm.200810-1558OC; Back LJJ, 2009, LARYNGOSCOPE, V119, P1621, DOI 10.1002/lary.20562; Balk EM, 2011, AHRQ PUBLICATION; Ballard RD, 2007, J CLIN SLEEP MED, V3, P706; Ballester E, 1999, AM J RESP CRIT CARE, V159, P495, DOI 10.1164/ajrccm.159.2.9804061; Barbe F, 2001, ANN INTERN MED, V134, P1015, DOI 10.7326/0003-4819-134-11-200106050-00007; Barbe F, 2012, JAMA-J AM MED ASSOC, V307, P2161, DOI 10.1001/jama.2012.4366; Barbe F, 2010, AM J RESP CRIT CARE, V181, P718, DOI 10.1164/rccm.200901-0050OC; Barnes M, 2004, AM J RESP CRIT CARE, V170, P656, DOI 10.1164/rccm.200311-1571OC; Barnes M, 2002, AM J RESP CRIT CARE, V165, P773, DOI 10.1164/ajrccm.165.6.2003166; Benazzo M, 2008, ACTA OTO-LARYNGOL, V128, P680, DOI 10.1080/00016480701636884; Bloch KE, 2000, AM J RESP CRIT CARE, V162, P246, DOI 10.1164/ajrccm.162.1.9908112; Bradshaw DA, 2006, CHEST, V130, P1369, DOI 10.1378/chest.130.5.1369; Buchner NJ, 2007, AM J RESP CRIT CARE, V176, P1274, DOI 10.1164/rccm.200611-1588OC; Campos-Rodriguez F, 2005, CHEST, V128, P624, DOI 10.1378/chest.128.2.624; Campos-Rodriguez F, 2012, ANN INTERN MED, V156, P115, DOI 10.7326/0003-4819-156-2-201201170-00006; Carley DW, 2007, SLEEP, V30, P35, DOI 10.1093/sleep/30.1.35; Ceylan K, 2009, ARCH OTOLARYNGOL, V135, P915, DOI 10.1001/archoto.2009.117; Chasens ER, 2005, WESTERN J NURS RES, V27, P307, DOI 10.1177/0193945904273283; Chervin RD, 1997, SLEEP, V20, P284, DOI 10.1093/sleep/20.4.284; Clark GT, 1996, CHEST, V109, P1477, DOI 10.1378/chest.109.6.1477; Comondore VR, 2009, LUNG, V187, P17, DOI 10.1007/s00408-008-9115-5; Conradt R, 1998, J SLEEP RES, V7, P217, DOI 10.1046/j.1365-2869.1998.00116.x; Damjanovic D, 2009, EUR RESPIR J, V33, P804, DOI 10.1183/09031936.00023408; DeMolles DA, 2004, MED CARE, V42, P764, DOI 10.1097/01.mlr.0000132353.99209.fe; Doherty LS, 2005, CHEST, V127, P2076, DOI 10.1378/chest.127.6.2076; Dolan DC, 2009, SLEEP BREATH, V13, P73, DOI 10.1007/s11325-008-0199-1; Drager LF, 2007, AM J RESP CRIT CARE, V176, P706, DOI 10.1164/rccm.200703-500OC; Egea CJ, 2008, SLEEP MED, V9, P660, DOI 10.1016/j.sleep.2007.06.018; Engleman HM, 1997, THORAX, V52, P114, DOI 10.1136/thx.52.2.114; Engleman HM, 1999, AM J RESP CRIT CARE, V159, P461, DOI 10.1164/ajrccm.159.2.9803121; ENGLEMAN HM, 1994, LANCET, V343, P572, DOI 10.1016/S0140-6736(94)91522-9; Engleman HM, 1998, THORAX, V53, P341, DOI 10.1136/thx.53.5.341; Engleman HM, 1996, SLEEP, V19, P378, DOI 10.1093/sleep/19.5.378; Engleman HM, 2002, AM J RESP CRIT CARE, V166, P855, DOI 10.1164/rccm.2109023; ESCLAMADO RM, 1989, LARYNGOSCOPE, V99, P1125; Eskafi M, 2004, SWED DENT J, V28, P1; Ferguson KA, 2003, AM J RESP CRIT CARE, V167, P15, DOI 10.1164/rccm.2108050; Ferguson KA, 1996, CHEST, V109, P1269, DOI 10.1378/chest.109.5.1269; FLETCHER EC, 1991, AM REV RESPIR DIS, V143, P936, DOI 10.1164/ajrccm/143.5_Pt_1.936; Foster GD, 2009, ARCH INTERN MED, V169, P1619, DOI 10.1001/archinternmed.2009.266; Friedman M, 2004, LARYNGOSCOPE, V114, P454, DOI 10.1097/00005537-200403000-00013; Friedman M, 2007, LARYNGOSCOPE, V117, P1859, DOI 10.1097/MLG.0b013e3180f62b4d; Gagnadoux F, 2009, EUR RESPIR J, V34, P914, DOI 10.1183/09031936.00148208; Gay PC, 2003, SLEEP, V26, P864, DOI 10.1093/sleep/26.7.864; Gotsopoulos H, 2002, AM J RESP CRIT CARE, V166, P743, DOI 10.1164/rccm.200203-208OC; Gotsopoulos H, 2004, SLEEP, V27, P934, DOI 10.1093/sleep/27.5.934; Grunstein RR, 2007, SLEEP, V30, P703, DOI 10.1093/sleep/30.6.703; Guilleminault C, 2008, SLEEP, V31, P1527, DOI 10.1093/sleep/31.11.1527; HAAVISTO L, 1994, CLIN OTOLARYNGOL, V19, P243, DOI 10.1111/j.1365-2273.1994.tb01224.x; Hans MG, 1997, AM J ORTHOD DENTOFAC, V111, P562, DOI 10.1016/S0889-5406(97)70293-2; HARMON JD, 1989, SOUTHERN MED J, V82, P161, DOI 10.1097/00007611-198902000-00004; HE J, 1988, CHEST, V94, P9, DOI 10.1378/chest.94.1.9; Hoekema A, 2008, J DENT RES, V87, P882, DOI 10.1177/154405910808700917; Hoekema A, 2007, J SEX MED, V4, P1153, DOI 10.1111/j.1743-6109.2006.00341.x; Holmdahl C, 2009, SLEEP MED, V10, P869, DOI 10.1016/j.sleep.2008.08.008; Hoy CJ, 1999, AM J RESP CRIT CARE, V159, P1096, DOI 10.1164/ajrccm.159.4.9808008; Hudgel DW, 2000, SLEEP, V23, P645; Hui DSC, 2000, CHEST, V117, P1410, DOI 10.1378/chest.117.5.1410; Hui DSC, 2001, CHEST, V120, P170, DOI 10.1378/chest.120.1.170; Ip S, 2012, SYST REV, V1, DOI 10.1186/2046-4053-1-20; Izci B, 2005, RESP MED, V99, P337, DOI 10.1016/j.rmed.2004.07.007; Jennum P, 2011, THORAX, V66, P560, DOI 10.1136/thx.2010.143958; Johansson K, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b4609; Johnston CD, 2002, EUR J ORTHODONT, V24, P251, DOI 10.1093/ejo/24.3.251; Kaneko Y, 2003, NEW ENGL J MED, V348, P1233, DOI 10.1056/NEJMoa022479; Kato J, 2000, CHEST, V117, P1065, DOI 10.1378/chest.117.4.1065; KATSANTONIS GP, 1988, LARYNGOSCOPE, V98, P304; KEENAN SP, 1994, CHEST, V105, P155, DOI 10.1378/chest.105.1.155; Kezirian EJ, 2004, LARYNGOSCOPE, V114, P450, DOI 10.1097/00005537-200403000-00012; Khanna R, 2003, SLEEP MED, V4, P333, DOI 10.1016/S1389-9457(03)00063-7; Khayat RN, 2008, CHEST, V134, P1162, DOI 10.1378/chest.08-0346; Kiely JL, 2004, THORAX, V59, P50; Kompanje EJO, 2008, J SLEEP RES, V17, P464, DOI [10.1111/j.1365-2869.2008.00672.x, 10.1111/j.1365-2869.2008.00683.x, 10.1111/j.1365-2869.2008.00682.x, 10.1111/j.1365-2869.2008.00667.x, 10.1111/j.1365-2869.2008.00663.x]; Korostovtseva LS, 2011, MED SCI MONITOR, V17, pCR146, DOI 10.12659/MSM.881448; Koutsourelakis I, 2008, EUR RESPIR J, V31, P110, DOI 10.1183/09031936.00087607; Kraiczi H, 1999, SLEEP, V22, P61; Krieger J, 1996, SLEEP, V19, pS136, DOI 10.1093/sleep/19.suppl_9.S136; Lam B, 2007, THORAX, V62, P354, DOI 10.1136/thx.2006.063644; Leidag M, 2008, J PHYSIOL PHARMACOL, V59, P401; Lettieri CJ, 2009, ANN INTERN MED, V151, P696, DOI 10.7326/0003-4819-151-10-200911170-00006; Lettieri CJ, 2009, CHEST, V136, P1263, DOI 10.1378/chest.09-0811; Lewis KE, 2006, SLEEP MED, V7, P241, DOI 10.1016/j.sleep.2005.09.007; Li HY, 2009, AM J RHINOL ALLERGY, V23, pE51, DOI 10.2500/ajra.2009.23.3358; Lin SW, 2006, LARYNGOSCOPE, V116, P1012, DOI 10.1097/01.mlg.0000217242.16814.da; Lojander J, 1996, CHEST, V110, P114, DOI 10.1378/chest.110.1.114; Lojander J, 1999, J SLEEP RES, V8, P71, DOI 10.1046/j.1365-2869.1999.00141.x; Lundkvist K, 2009, ACTA OTO-LARYNGOL, V129, P1280, DOI 10.3109/00016480802654380; Mador MJ, 2005, CHEST, V128, P2151, DOI 10.1378/chest.128.4.2151; Mansfield DR, 2004, AM J RESP CRIT CARE, V169, P361, DOI 10.1164/rccm.200306-752OC; Marin JM, 2005, LANCET, V365, P1046, DOI 10.1016/S0140-6736(05)71141-7; Marrone O, 2004, SLEEP MED, V5, P247, DOI 10.1016/j.sleep.2003.09.011; Marshall NS, 2005, THORAX, V60, P427, DOI 10.1136/thx.2004.032078; Marti S, 2002, EUR RESPIR J, V20, P1511, DOI 10.1183/09031936.02.00306502; Massie CA, 1999, CHEST, V116, P403, DOI 10.1378/chest.116.2.403; Massie CA, 2003, CHEST, V123, P1112, DOI 10.1378/chest.123.4.1112; McArdle N, 1999, AM J RESP CRIT CARE, V159, P1108, DOI 10.1164/ajrccm.159.4.9807111; Mehta A, 2001, AM J RESP CRIT CARE, V163, P1457, DOI 10.1164/ajrccm.163.6.2004213; Meurice JC, 2007, SLEEP MED, V8, P37, DOI 10.1016/j.sleep.2006.05.010; Minnerup J, 2012, STROKE, V43, P1137, DOI 10.1161/STROKEAHA.111.637611; Monasterio C, 2001, AM J RESP CRIT CARE, V164, P939, DOI 10.1164/ajrccm.164.6.2008010; Montserrat JM, 2001, AM J RESP CRIT CARE, V164, P608, DOI 10.1164/ajrccm.164.4.2006034; Morrish E, 2008, RESP MED, V102, P1231, DOI 10.1016/j.rmed.2008.04.014; Mortimore IL, 1998, THORAX, V53, P290, DOI 10.1136/thx.53.4.290; Naismith SL, 2005, J CLIN SLEEP MED, V1, P374; Nakamura H, 2009, SLEEP BIOL RHYTHMS, V7, P103, DOI 10.1111/j.1479-8425.2009.00395.x; Neill AM, 2003, EUR RESPIR J, V22, P258, DOI 10.1183/09031936.03.00035603; Nilius G, 2006, CHEST, V130, P1018, DOI 10.1378/chest.130.4.1018; Noseda A, 2004, CHEST, V126, P31, DOI 10.1378/chest.126.1.31; Palmer S, 2004, SLEEP MED, V5, P61, DOI 10.1016/S1389-9457(03)00166-7; Parra O, 2011, EUR RESPIR J, V37, P1128, DOI 10.1183/09031936.00034410; Parthasarathy S, 2006, J CLIN SLEEP MED, V2, P133; PARTINEN M, 1988, CHEST, V94, P1200, DOI 10.1378/chest.94.6.1200; PARTINEN M, 1990, CHEST, V97, P27, DOI 10.1378/chest.97.1.27; Peker Y, 2006, EUR RESPIR J, V28, P596, DOI 10.1183/09031936.06.00107805; Peker Y, 2000, AM J RESP CRIT CARE, V162, P81, DOI 10.1164/ajrccm.162.1.9905035; Peker Y, 2002, AM J RESP CRIT CARE, V166, P159, DOI 10.1164/rccm.2105124; Pepin JL, 2009, CHEST, V136, P490, DOI 10.1378/chest.08-2646; Petri N, 2008, J SLEEP RES, V17, P221, DOI 10.1111/j.1365-2869.2008.00645.x; Piper AJ, 2008, THORAX, V63, P395, DOI 10.1136/thx.2007.081315; Planes C, 2003, SLEEP, V26, P156, DOI 10.1093/sleep/26.2.156; Qaseem A, 2010, ANN INTERN MED, V153, P194, DOI 10.7326/0003-4819-153-3-201008030-00010; Randerath WJ, 2002, CHEST, V122, P569, DOI 10.1378/chest.122.2.569; Randerath WJ, 2001, AM J RESP CRIT CARE, V163, P652, DOI 10.1164/ajrccm.163.3.2006168; RANDERATH WJ, 2003, MED SCI MONITOR, V9, P353; REEVESHOCHE MK, 1995, AM J RESP CRIT CARE, V151, P443, DOI 10.1164/ajrccm.151.2.7842204; Resta O, 2004, Monaldi Arch Chest Dis, V61, P153; Richards D, 2007, SLEEP, V30, P635, DOI 10.1093/sleep/30.5.635; Robinson S, 2009, OTOLARYNG HEAD NECK, V141, P257, DOI 10.1016/j.otohns.2009.03.022; ROTH T, 1990, PROG CLIN BIOL RES, V345, P347; Ryan S, 2009, J CLIN SLEEP MED, V5, P422; Salgado Sara Moreira da Silva Trindade, 2008, J. bras. pneumol., V34, P690, DOI 10.1590/S1806-37132008000900009; Senn O, 2003, AM J RESP CRIT CARE, V168, P1506, DOI 10.1164/rccm.200304-542OC; Series F, 1997, ANN INTERN MED, V127, P588, DOI 10.7326/0003-4819-127-8_Part_1-199710150-00002; Siccoli MM, 2008, SLEEP, V31, P1551, DOI 10.1093/sleep/31.11.1551; Skinner MA, 2004, CHEST, V125, P118, DOI 10.1378/chest.125.1.118; Smith CE, 2009, PATIENT EDUC COUNS, V74, P184, DOI 10.1016/j.pec.2008.08.008; Smith LA, 2007, EUR HEART J, V28, P1221, DOI 10.1093/eurheartj/ehm131; Stepnowsky CJ, 2007, J MED INTERNET RES, V9, DOI 10.2196/jmir.9.2.e14; Suurna MV, 2008, OTOLARYNG HEAD NECK, V139, P286, DOI 10.1016/j.otohns.2008.03.012; Tan YK, 2002, EUR J ORTHODONT, V24, P239, DOI 10.1093/ejo/24.3.239; Taylor Y, 2006, SLEEP BREATH, V10, P132, DOI 10.1007/s11325-006-0059-9; Teschler H, 2000, EUR RESPIR J, V15, P990, DOI 10.1034/j.1399-3003.2000.01503.x; To KW, 2008, RESPIROLOGY, V13, P79, DOI 10.1111/j.1440-1843.2007.01138.x; Tuomilehto HPI, 2009, AM J RESP CRIT CARE, V179, P320, DOI 10.1164/rccm.200805-669OC; Veale D, 2000, EUR RESPIR J, V15, P326, DOI 10.1034/j.1399-3003.2000.15b18.x; Veasey SC, 2006, SLEEP, V29, P1036, DOI 10.1093/sleep/29.8.1036; Vennelle M, 2010, SLEEP, V33, P267, DOI 10.1093/sleep/33.2.267; Vicini C, 2010, AM J OTOLARYNG, V31, P14, DOI 10.1016/j.amjoto.2008.09.002; Walker-Engstrom ML, 2000, J SLEEP RES, V9, P303; Walker-Engstrom ML, 2002, CHEST, V121, P739, DOI 10.1378/chest.121.3.739; Weaver EM, 2004, OTOLARYNG HEAD NECK, V130, P659, DOI 10.1016/j.otohns.2003.12.012; WHYTE KF, 1988, SLEEP, V11, P463, DOI 10.1093/sleep/11.5.463; Wiese HJ, 2005, SLEEP MED, V6, P171, DOI 10.1016/j.sleep.2004.08.006; Wild MR, 2004, EUR RESPIR J, V24, P461, DOI 10.1183/09031936.04.00114603; Wilhelmsson B, 1999, ACTA OTO-LARYNGOL, V119, P503; Woodson BT, 2003, OTOLARYNG HEAD NECK, V128, P848, DOI 10.1016/S0194-5998(03)00461-3; Woodson BT, 2001, OTOLARYNG HEAD NECK, V125, P303, DOI 10.1067/mhn.2001.118958; Young T, 2005, J APPL PHYSIOL, V99, P1592, DOI 10.1152/japplphysiol.00587.2005; ZORICK F J, 1990, Henry Ford Hospital Medical Journal, V38, P223	163	208	231	1	29	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 1	2013	159	7					471	U94		10.7326/00030003-4819-159-7-201310010-00704	http://dx.doi.org/10.7326/00030003-4819-159-7-201310010-00704			18	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	234FQ	24061345				2023-01-03	WOS:000325628000005
J	Shen, F; Tsuruda, PR; Smith, JAM; Obedencio, GP; Martin, WJ				Shen, Fei; Tsuruda, Pamela R.; Smith, Jacqueline A. M.; Obedencio, Glenmar P.; Martin, William J.			Relative Contributions of Norepinephrine and Serotonin Transporters to Antinociceptive Synergy between Monoamine Reuptake Inhibitors and Morphine in the Rat Formalin Model	PLOS ONE			English	Article							DESCENDING MODULATION; INDUCED NOCICEPTION; POSTOPERATIVE PAIN; 5-HT3 RECEPTORS; DULOXETINE; CLONIDINE; FACILITATION; TRAMADOL; COMBINATIONS; POTENTIATION	Multimodal analgesia is designed to optimize pain relief by coadministering drugs with distinct mechanisms of action or by combining multiple pharmacologies within a single molecule. In clinical settings, combinations of monoamine reuptake inhibitors and opioid receptor agonists have been explored and one currently available analgesic, tapentadol, functions as both a m-opioid receptor agonist and a norepinephrine transporter inhibitor. However, it is unclear whether the combination of selective norepinephrine reuptake inhibition and m-receptor agonism achieves an optimal antinociceptive synergy. In this study, we assessed the pharmacodynamic interactions between morphine and monoamine reuptake inhibitors that possess different affinities and selectivities for norepinephrine and serotonin transporters. Using the rat formalin model, in conjunction with measurements of ex vivo transporter occupancy, we show that neither the norepinephrine-selective inhibitor, esreboxetine, nor the serotonin-selective reuptake inhibitor, fluoxetine, produce antinociceptive synergy with morphine. Atomoxetine, a monoamine reuptake inhibitor that achieves higher levels of norepinephrine than serotonin transporter occupancy, exhibited robust antinociceptive synergy with morphine. Similarly, a fixed-dose combination of esreboxetine and fluoxetine which achieves comparable levels of transporter occupancy potentiated the antinociceptive response to morphine. By contrast, duloxetine, a monoamine reuptake inhibitor that achieves higher serotonin than norepinephrine transporter occupancy, failed to potentiate the antinociceptive response to morphine. However, when duloxetine was coadministered with the 5-HT3 receptor antagonist, ondansetron, potentiation of the antinociceptive response to morphine was revealed. These results support the notion that inhibition of both serotonin and norepinephrine transporters is required for monoamine reuptake inhibitor and opioid-mediated antinociceptive synergy; yet, excess serotonin, acting via 5-HT3 receptors, may reduce the potential for synergistic interactions. Thus, in the rat formalin model, the balance between norepinephrine and serotonin transporter inhibition influences the degree of antinociceptive synergy observed between monoamine reuptake inhibitors and morphine.	[Shen, Fei; Martin, William J.] Theravance Inc, Dept Pharmacol, San Francisco, CA USA; [Tsuruda, Pamela R.; Smith, Jacqueline A. M.; Obedencio, Glenmar P.] Theravance Inc, Dept Mol Biol, San Francisco, CA USA; [Tsuruda, Pamela R.; Smith, Jacqueline A. M.; Obedencio, Glenmar P.] Theravance Inc, Dept Cell Biol, San Francisco, CA USA; Theravance Inc, Dept Drug Metab, San Francisco, CA USA; Theravance Inc, Dept Pharmacokinet, San Francisco, CA USA	Theravance; Theravance; Theravance; Theravance; Theravance	Shen, F (corresponding author), Theravance Inc, Dept Pharmacol, San Francisco, CA USA.	fshen@theravance.com	Martin, William J/L-9033-2017	Martin, William J/0000-0002-2749-3365				ABBOTT FV, 1995, PAIN, V60, P91, DOI 10.1016/0304-3959(94)00095-V; Bajic D, 2010, BRAIN RES, V1306, P29, DOI 10.1016/j.brainres.2009.10.010; Bohn LM, 2000, J NEUROSCI, V20, P9040; Bourdet DL, 2012, J PHARMACOL EXP THER, V341, P137, DOI 10.1124/jpet.111.188417; BURNETT A, 1991, BRAIN RES, V546, P271, DOI 10.1016/0006-8993(91)91491-I; Chen S, 2010, CURR MED RES OPIN, V26, P2507, DOI 10.1185/03007995.2010.518438; Dogrul A, 2009, BRAIN RES, V1280, P52, DOI 10.1016/j.brainres.2009.05.001; DRASNER K, 1988, PAIN, V32, P309, DOI 10.1016/0304-3959(88)90042-5; Fields H., 1994, CENTRAL NERVOUS SYST, V3rd edi; Gao KM, 1998, J NEUROSCI, V18, P1860; GESSNER PK, 1970, J PHARMACOL EXP THER, V174, P247; Green GM, 2000, PAIN, V89, P81, DOI 10.1016/S0304-3959(00)00346-8; Hartrick CT, 2009, EXPERT OPIN PHARMACO, V10, P2687, DOI 10.1517/14656560903313734; Ho KY, 2010, BRIT J ANAESTH, V105, P371, DOI 10.1093/bja/aeq158; HYLDEN JLK, 1983, J PHARMACOL EXP THER, V226, P398; Jones CK, 2007, EUR J PAIN, V11, P208, DOI 10.1016/j.ejpain.2006.02.008; Jones CK, 2006, NEUROPHARMACOLOGY, V51, P1172, DOI 10.1016/j.neuropharm.2006.08.005; Le Bars D, 2001, PHARMACOL REV, V53, P597; LEVINE JD, 1986, PAIN, V27, P45, DOI 10.1016/0304-3959(86)90220-4; LIU MY, 1988, PAIN, V33, P123, DOI 10.1016/0304-3959(88)90211-4; Michelet D, 2012, ANESTH ANALG, V114, P393, DOI 10.1213/ANE.0b013e31823d0b45; Millan MJ, 2002, PROG NEUROBIOL, V66, P355, DOI 10.1016/S0301-0082(02)00009-6; Montes A, 2000, BRIT J ANAESTH, V85, P217, DOI 10.1093/bja/85.2.217; Munro G, 2010, NEUROPHARMACOLOGY, V59, P208, DOI 10.1016/j.neuropharm.2010.05.010; Munro G, 2009, EUR J PHARMACOL, V605, P95, DOI 10.1016/j.ejphar.2009.01.004; Neil Nancy, 2013, J Med Econ, V16, P307, DOI 10.3111/13696998.2012.756401; Obata H, 2010, J PHARMACOL EXP THER, V334, P1059, DOI 10.1124/jpet.110.168336; Omote K, 1998, BRAIN RES, V814, P194, DOI 10.1016/S0006-8993(98)01086-5; OSSIPOV MH, 1990, J PHARMACOL EXP THER, V255, P1107; Paul D, 2001, J PHARMACOL EXP THER, V298, P674; Paul D, 1997, ANALGESIA, V3, P43; Persec J, 2007, COLLEGIUM ANTROPOL, V31, P1065; Pertovaara A, 2006, PROG NEUROBIOL, V80, P53, DOI 10.1016/j.pneurobio.2006.08.001; Pettersen VLA, 2009, ANESTH ANALG, V109, P1312, DOI 10.1213/ane.0b013e3181b16ff5; Porreca F, 2002, TRENDS NEUROSCI, V25, P319, DOI 10.1016/S0166-2236(02)02157-4; Puig MM, 2000, ANESTHESIOLOGY, V93, P219, DOI 10.1097/00000542-200007000-00033; Puig S, 1996, PAIN, V64, P345, DOI 10.1016/0304-3959(95)00121-2; RAFFA RB, 1992, J PHARMACOL EXP THER, V260, P275; Ren K, 2002, PAIN, V100, P1, DOI 10.1016/S0304-3959(02)00368-8; Robinson DA, 2004, CURR NEUROVASC RES, V1, P11, DOI 10.2174/1567202043480189; Schiene K, 2011, J PHARMACOL EXP THER, V339, P537, DOI 10.1124/jpet.111.181263; Schroder W, 2011, J PHARMACOL EXP THER, V337, P312, DOI 10.1124/jpet.110.175042; Snijdelaar DG, 2005, PAIN, V119, P159, DOI 10.1016/j.pain.2005.09.027; Suzuki R, 2005, NEUROSIGNALS, V14, P175, DOI 10.1159/000087656; Suzuki R, 2004, TRENDS PHARMACOL SCI, V25, P613, DOI 10.1016/j.tips.2004.10.002; Svensson CI, 2006, FEBS LETT, V580, P6629, DOI 10.1016/j.febslet.2006.11.012; Takano A, 2006, PSYCHOPHARMACOLOGY, V185, P395, DOI 10.1007/s00213-005-0304-0; Tallarida R.J., 2000, DRUG SYNERGISM DOSE; Tallarida RJ, 1997, LIFE SCI, V61, pPL417, DOI 10.1016/S0024-3205(97)01030-8; TALLARIDA RJ, 1992, PAIN, V49, P93, DOI 10.1016/0304-3959(92)90193-F; Trivedi MH, 2008, INT CLIN PSYCHOPHARM, V23, P161, DOI 10.1097/YIC.0b013e3282f41d7e; Tsuruda PR, 2010, J PHARMACOL TOXICOL, V61, P192, DOI 10.1016/j.vascn.2009.12.003; Tzschentke TM, 2007, J PHARMACOL EXP THER, V323, P265, DOI 10.1124/jpet.107.126052; van Rijn CM, 2004, EPILEPSY RES, V59, P181, DOI 10.1016/j.eplepsyres.2004.04.003; van Rijn CM, 1999, EUR J PHARMACOL, V371, P213, DOI 10.1016/S0014-2999(99)00178-8; Wei F, 2010, J NEUROSCI, V30, P8624, DOI 10.1523/JNEUROSCI.5389-09.2010; WILCOX GL, 1987, BRAIN RES, V405, P84, DOI 10.1016/0006-8993(87)90992-9; Wu CT, 2004, ANESTH ANALG, V99, P502, DOI 10.1213/01.ANE.0000117146.46373.51; Yaksh TL, 2001, J APPL PHYSIOL, V90, P2386, DOI 10.1152/jappl.2001.90.6.2386; YEOMANS DC, 1992, PAIN, V48, P449, DOI 10.1016/0304-3959(92)90098-V; Zeitz KP, 2002, J NEUROSCI, V22, P1010, DOI 10.1523/JNEUROSCI.22-03-01010.2002	61	19	20	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 30	2013	8	9							e74891	10.1371/journal.pone.0074891	http://dx.doi.org/10.1371/journal.pone.0074891			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	231NL	24098676	Green Published, gold, Green Submitted			2023-01-03	WOS:000325423500047
J	Storm, C; Danne, O; Ueland, PM; Leithner, C; Hasper, D; Schroeder, T				Storm, Christian; Danne, Oliver; Ueland, Per Magne; Leithner, Christoph; Hasper, Dietrich; Schroeder, Tim			Serial Plasma Choline Measurements after Cardiac Arrest in Patients Undergoing Mild Therapeutic Hypothermia: A Prospective Observational Pilot Trial	PLOS ONE			English	Article							PHOSPHOLIPASE-D; RAT-BRAIN; CITICOLINE; HUMANS; MULTICENTER; SURGERY; RELEASE; BETAINE; INJURY	Objective: Choline is related to phospholipid metabolism and is a marker for global ischaemia with a small reference range in healthy volunteers. The aim of our study was to characterize the early kinetics of plasma free choline in patients after cardiac arrest. Additionally, we investigated the potential of plasma free choline to predict neurological outcome. Methods: Twenty patients admitted to our medical intensive care unit were included in this prospective, observational trial. All patients were enrolled between May 2010 and May 2011. They received post cardiac arrest treatment including mild therapeutic hypothermia which was initiated with a combination of cold fluid and a feedback surface cooling device according to current guidelines. Sixteen blood samples per patient were analysed for plasma free choline levels within the first week after resuscitation. Choline was detected by liquid chromatography-tandem mass spectrometry. Results: Most patients showed elevated choline levels on admission (median 14.8 mmol/L; interquartile range; IQR 9.9-20.1) which subsequently decreased. 48 hours after cardiac arrest choline levels in all patients reached subnormal levels at a median of 4.0 mmol/L (IQR 3-4.9; p = 0.001). Subsequently, choline levels normalized within seven days. There was no significant difference in choline levels when groups were analyzed in relation to neurological outcome. Conclusions: Our data indicate a choline deficiency in the early postresucitation phase. This could potentially result in impaired cell membrane recovery. The detailed characterization of the early choline time course may aid in planning of choline supplementation trials. In a limited number of patients, choline was not promising as a biomarker for outcome prediction.	[Storm, Christian; Hasper, Dietrich; Schroeder, Tim] Charite, Campus Virchow Klinikum, Dept Intens Care Med & Nephrol, D-13353 Berlin, Germany; [Danne, Oliver] Charite, Campus Virchow Klinikum, Dept Emergency Med, D-13353 Berlin, Germany; [Ueland, Per Magne] Univ Bergen, Inst Med, Pharmacol Sect, Bergen, Norway; [Ueland, Per Magne] Haukeland Hosp, Lab Clin Biochem, N-5021 Bergen, Norway; [Leithner, Christoph] Charite, Campus Virchow Klinikum, Dept Neurol, D-13353 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Bergen; University of Bergen; Haukeland University Hospital; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Storm, C (corresponding author), Charite, Campus Virchow Klinikum, Dept Intens Care Med & Nephrol, D-13353 Berlin, Germany.	christian.storm@charite.de	Schroeder, Tim/AAD-9114-2022; Ueland, Per M/C-7340-2013	Schroeder, Tim/0000-0002-5399-0576; Ueland, Per Magne/0000-0002-1903-0571; Leithner, Christoph/0000-0002-8277-846X	Medivance Inc. Colorado, USA	Medivance Inc. Colorado, USA	Laboratory work was sponsored by a grant of 5000(sic) by Medivance Inc. Colorado, USA. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bouwes A, 2012, J NEUROL, V259, P537, DOI 10.1007/s00415-011-6224-5; Bruhl A, 2004, LIFE SCI, V75, P1609, DOI 10.1016/j.lfs.2004.03.019; Buchman AL, 2009, GASTROENTEROLOGY, V137, pS119, DOI 10.1053/j.gastro.2009.08.010; Danne O, 2007, CLIN CHIM ACTA, V383, P103, DOI 10.1016/j.cca.2007.05.001; Danne O, 2010, EXPERT REV MOL DIAGN, V10, P159, DOI 10.1586/ERM.10.2; Davalos A, 2012, LANCET, V380, P349, DOI 10.1016/S0140-6736(12)60813-7; Holm PI, 2003, CLIN CHEM, V49, P286, DOI 10.1373/49.2.286; Ilcol YO, 2004, CLIN CHEM LAB MED, V42, P1390, DOI 10.1515/CCLM.2004.259; KLEIN J, 1993, BRAIN RES, V630, P337, DOI 10.1016/0006-8993(93)90674-C; Konstantinova SV, 2008, J NUTR, V138, P914, DOI 10.1093/jn/138.5.914; Korth U, 2003, RESUSCITATION, V58, P209, DOI 10.1016/S0300-9572(03)00119-9; LeLeiko RM, 2009, AM J CARDIOL, V104, P638, DOI 10.1016/j.amjcard.2009.04.047; Mortberg E, 2011, RESUSCITATION, V82, P26, DOI 10.1016/j.resuscitation.2010.10.011; Roivainen A, 2000, EUR J NUCL MED, V27, P25, DOI 10.1007/PL00006658; Sahin S, 2010, J CLIN NEUROSCI, V17, P227, DOI 10.1016/j.jocn.2009.05.016; Samaniego EA, 2011, NEUROCRIT CARE, V15, P113, DOI 10.1007/s12028-010-9412-8; Savendahl L, 1997, AM J CLIN NUTR, V66, P622, DOI 10.1093/ajcn/66.3.622; Saver Jeffrey L, 2008, Rev Neurol Dis, V5, P167; Secades JJ, 2006, CEREBROVASC DIS, V21, P380, DOI 10.1159/000091547; Ulus IH, 1998, NEUROCHEM RES, V23, P727, DOI 10.1023/A:1022455325657; Vanek VW, 2012, NUTR CLIN PRACT, V27, P440, DOI 10.1177/0884533612446706; Wu BTF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043448; Zafonte R, 2009, J NEUROTRAUM, V26, P2207, DOI 10.1089/neu.2009.1015; Zafonte RD, 2012, JAMA-J AM MED ASSOC, V308, P1993, DOI 10.1001/jama.2012.13256; ZEISEL SH, 1985, BIOCHIM BIOPHYS ACTA, V835, P331, DOI 10.1016/0005-2760(85)90289-9	25	5	5	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 30	2013	8	9							e76720	10.1371/journal.pone.0076720	http://dx.doi.org/10.1371/journal.pone.0076720			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	231NL	24098804	Green Published, gold, Green Submitted			2023-01-03	WOS:000325423500175
J	Lee, JY; Choi, DC; Oh, TH; Yune, TY				Lee, Jee Y.; Choi, Doo C.; Oh, Tae H.; Yune, Tae Y.			Analgesic Effect of Acupuncture Is Mediated via Inhibition of JNK Activation in Astrocytes after Spinal Cord Injury	PLOS ONE			English	Article							TERMINAL KINASE JNK; PERIPHERAL-NERVE INJURY; PRIMARY SENSORY NEURONS; NEUROPATHIC PAIN; PROTEIN-KINASE; MICROGLIAL ACTIVATION; MECHANICAL ALLODYNIA; SIGNAL-TRANSDUCTION; CCL20 PRODUCTION; UP-REGULATION	Acupuncture (AP) has been used worldwide to relieve pain. However, the mechanism of action of AP is poorly understood. Here, we found that AP relieved neuropathic pain (NP) by inhibiting Jun-N-terminal kinase (JNK) activation in astrocytes after spinal cord injury (SCI). After contusion injury which induces the below-level (L4-L5) NP, Shuigou (GV26) and Yanglingquan (GB34) acupoints were applied. At 31 d after injury, both mechanical allodynia and thermal hyperalgesia were significantly alleviated by AP applied at GV26 and GB34. Immunocytochemistry revealed that JNK activation was mainly observed in astrocytes after injury. AP inhibited JNK activation in astrocytes at L4-L5 level of spinal cord. The level of p-c-Jun known, a downstream molecule of JNK, was also decreased by AP. In addition, SCI-induced GFAP expression, a marker for astrocytes, was decreased by AP as compared to control groups. Especially, the number of hypertrophic, activated astrocytes in laminae I-II of dorsal horn at L4-5 was markedly decreased by AP treatment when compared with vehicle and simulated AP-treated groups. When animals treated with SP600125, a specific JNK inhibitor, after SCI, both mechanical allodynia and thermal hyperalgesia were significantly attenuated by the inhibitor, suggesting that JNK activation is likely involved in SCI-induced NP. Also, the expression of chemokines which is known to be mediated through JNK pathway was significantly decreased by AP and SP600125 treatment. Therefore, our results indicate that analgesic effect of AP is mediated in part by inhibiting JNK activation in astrocytes after SCI.	[Lee, Jee Y.; Choi, Doo C.; Oh, Tae H.; Yune, Tae Y.] Kyung Hee Univ, Age Related & Brain Dis Res Ctr, Seoul, South Korea; [Lee, Jee Y.; Yune, Tae Y.] Kyung Hee Univ, Neurodegenerat Control Res Ctr, Seoul, South Korea; [Yune, Tae Y.] Kyung Hee Univ, Dept Biochem & Mol Biol, Sch Med, Seoul, South Korea	Kyung Hee University; Kyung Hee University; Kyung Hee University	Yune, TY (corresponding author), Kyung Hee Univ, Age Related & Brain Dis Res Ctr, Seoul, South Korea.	tyune@khu.ac.kr			National Research Foundation of Korea; Ministry of Science, ICT & Future Planning [2010-0019349, 2008-0061888]; Korea Health technology Research & Development Project, Ministry of Health & Welfare, Republic of Korea [A101198]	National Research Foundation of Korea(National Research Foundation of Korea); Ministry of Science, ICT & Future Planning(Ministry of Science, ICT & Future Planning, Republic of Korea); Korea Health technology Research & Development Project, Ministry of Health & Welfare, Republic of Korea	This study was supported by National Research Foundation of Korea funded by the Ministry of Science, ICT & Future Planning [No. 2010-0019349 (Pioneer Research Center Program), No. 2008-0061888 (SRC)] and a grant of the Korea Health technology Research & Development Project, Ministry of Health & Welfare, Republic of Korea (A101198). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ambrosini E, 2005, J NEUROPATH EXP NEUR, V64, P706, DOI 10.1097/01.jnen.0000173893.01929.fc; Baron R, 2006, NAT CLIN PRACT NEURO, V2, P95, DOI 10.1038/ncpneuro0113; BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; Beric A, 1997, PAIN, V72, P295, DOI 10.1097/00006396-199709000-00001; Bernateck M, 2008, FORSCH KOMPLEMENTMED, V15, P187, DOI 10.1159/000141929; Bogoyevitch MA, 2006, MICROBIOL MOL BIOL R, V70, P1061, DOI 10.1128/MMBR.00025-06; CHAPLAN SR, 1994, J NEUROSCI METH, V53, P55, DOI 10.1016/0165-0270(94)90144-9; Cherkin DC, 2009, ARCH INTERN MED, V169, P858, DOI 10.1001/archinternmed.2009.65; Choi DC, 2012, EXP NEUROL, V236, P268, DOI 10.1016/j.expneurol.2012.05.014; Choi DC, 2010, NEUROBIOL DIS, V39, P272, DOI 10.1016/j.nbd.2010.04.003; Christensen MD, 1997, J NEUROTRAUM, V14, P517, DOI 10.1089/neu.1997.14.517; Coyle DE, 1998, GLIA, V23, P75; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Gao YJ, 2010, PHARMACOL THERAPEUT, V126, P56, DOI 10.1016/j.pharmthera.2010.01.002; Gao YJ, 2009, J NEUROSCI, V29, P4096, DOI 10.1523/JNEUROSCI.3623-08.2009; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; Gwak YS, 2009, NEUROSCIENCE, V161, P895, DOI 10.1016/j.neuroscience.2009.03.055; Hains BC, 2006, J NEUROSCI, V26, P4308, DOI 10.1523/JNEUROSCI.0003-06.2006; Hains BC, 2001, J NEUROTRAUM, V18, P409, DOI 10.1089/089771501750170994; HARGREAVES K, 1988, PAIN, V32, P77, DOI 10.1016/0304-3959(88)90026-7; Hopton A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056806; HYLDEN JLK, 1980, EUR J PHARMACOL, V67, P313, DOI 10.1016/0014-2999(80)90515-4; Ji RR, 2001, NEUROBIOL DIS, V8, P1, DOI 10.1006/nbdi.2000.0360; JI RR, 2004, SCI STKE, V252, P54629; Ji RR, 2009, BRAIN RES REV, V60, P135, DOI 10.1016/j.brainresrev.2008.12.011; Jin SX, 2003, J NEUROSCI, V23, P4017; Kanda N, 2009, EUR J IMMUNOL, V39, P996, DOI 10.1002/eji.200838852; Kang JM, 2007, BRAIN RES, V1131, P211, DOI 10.1016/j.brainres.2006.10.089; Katsura H, 2008, GLIA, V56, P723, DOI 10.1002/glia.20648; Lau WK, 2008, NEUROSCIENCE, V155, P463, DOI 10.1016/j.neuroscience.2008.06.016; Ledeboer A, 2005, PAIN, V115, P71, DOI 10.1016/j.pain.2005.02.009; Lee HL, 2004, NEUROREPORT, V15, P2807; Lee JY, 2012, ENDOCRINOLOGY, V153, P3815, DOI 10.1210/en.2012-1068; Li M, 2011, J CLIN ENDOCR METAB, V96, P2502, DOI 10.1210/jc.2011-0055; Li QM, 2007, J NEUROSCI, V27, P8395, DOI 10.1523/JNEUROSCI.2478-07.2007; Liu J, 2007, NEUROSCI LETT, V412, P268, DOI 10.1016/j.neulet.2006.11.022; Ma WY, 2002, PAIN, V99, P175, DOI 10.1016/S0304-3959(02)00097-0; Mei XP, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-6; MESTRE C, 1994, J PHARMACOL TOX MET, V32, P197, DOI 10.1016/1056-8719(94)90087-6; Migita K, 2009, RHEUMATOLOGY, V48, P741, DOI 10.1093/rheumatology/kep089; Milligan ED, 2003, J NEUROSCI, V23, P1026; Moalem G, 2006, BRAIN RES REV, V51, P240, DOI 10.1016/j.brainresrev.2005.11.004; Norrbrink C, 2011, ACUPUNCT MED, V29, P108, DOI 10.1136/aim.2010.003269; Obata K, 2004, J NEUROSCI, V24, P10211, DOI 10.1523/JNEUROSCI.3388-04.2004; Ohtori S, 2004, SPINE, V29, P1082, DOI 10.1097/00007632-200405150-00006; Raivich G, 1999, BRAIN RES REV, V30, P77, DOI 10.1016/S0165-0173(99)00007-7; Repici M, 2012, NEUROBIOL DIS, V46, P710, DOI 10.1016/j.nbd.2012.03.014; Siddall PJ, 1997, SPINAL CORD, V35, P69, DOI 10.1038/sj.sc.3100365; Woolf CJ, 1999, LANCET, V353, P1959, DOI 10.1016/S0140-6736(99)01307-0; Yeh ML, 2010, ALTERN THER HEALTH M, V16, P10; Yin CS, 2008, RES VET SCI, V84, P159, DOI 10.1016/j.rvsc.2007.04.004; Yoshimura K, 2011, NEUROSCI RES, V71, P266, DOI 10.1016/j.neures.2011.07.1830; Yune TY, 2007, J NEUROSCI, V27, P7751, DOI 10.1523/JNEUROSCI.1661-07.2007; Zhang H, 2007, J NEUROSCI, V27, P12067, DOI 10.1523/JNEUROSCI.0496-07.2007; Zhao P, 2007, J NEUROSCI, V27, P2357, DOI 10.1523/JNEUROSCI.0138-07.2007; Zhou Z, 2008, GENE THER, V15, P183, DOI 10.1038/sj.gt.3303054; Zhuang ZY, 2006, J NEUROSCI, V26, P3551, DOI 10.1523/JNEUROSCI.5290-05.2006	57	32	44	1	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 9	2013	8	9							e73948	10.1371/journal.pone.0073948	http://dx.doi.org/10.1371/journal.pone.0073948			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	244QV	24040124	Green Published, Green Submitted, gold			2023-01-03	WOS:000326405300144
J	Takebayashi, K; Mekata, E; Sonoda, H; Shimizu, T; Shiomi, H; Naka, S; Endo, Y; Tani, T				Takebayashi, Katsushi; Mekata, Eiji; Sonoda, Hiromichi; Shimizu, Tomoharu; Shiomi, Hisanori; Naka, Shigeyuki; Endo, Yoshihiro; Tani, Tohru			Differences in Chemosensitivity between Primary and Metastatic Tumors in Colorectal Cancer	PLOS ONE			English	Article							DROPLET EMBEDDED-CULTURE; DRUG-SENSITIVITY TEST; THYMIDYLATE SYNTHASE; EXPRESSION LEVEL; CHEMOTHERAPY; RESECTION; PREDICTION	Purpose: We retrospectively evaluated the in vitro chemosensitivity of primary site and metastatic site tumors in colorectal cancer. Methods: Various resected tumor samples (33 from lymph nodes, 42 from liver, six from lung, and 68 primary tumors) were assessed via a collagen gel droplet-embedded culture drug sensitivity test to determine chemosensitivity to a single agent or a combination of agents. Results: Sensitivity to combination chemotherapy was significantly higher than that of monotherapy in the primary site group, lymph node group, and liver group. There was significant difference between chemosensitivity of primary site and that of liver metastasis in each agent (5-FU, p<0.001; SN38, p = 0.045; 5-FU/SN38, p<0.001; OHP, p = 0.037; 5-FU/OHP, p = 0.045). Conclusions: Tumors showed greater in vitro chemosensitivity to combination therapy when compared with monotherapy. Further, tumors that had metastasized to the liver were more resistant to chemotherapy when compared with matched primary tumors.	[Takebayashi, Katsushi; Mekata, Eiji; Sonoda, Hiromichi; Shimizu, Tomoharu; Shiomi, Hisanori; Naka, Shigeyuki; Endo, Yoshihiro; Tani, Tohru] Shiga Univ Med Sci, Dept Surg, Otsu, Shiga 52021, Japan	Shiga University of Medical Science	Mekata, E (corresponding author), Shiga Univ Med Sci, Dept Surg, Otsu, Shiga 52021, Japan.	mekata@belle.shiga-med.ac.jp	Sonoda, Hiromichi/AAN-2617-2020		Shiga University of Medical Science, Japan	Shiga University of Medical Science, Japan(Shiga University of Medical Science)	This work was funded by Shiga University of Medical Science, Japan. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adam R, 2003, ANN ONCOL, V14, P13, DOI 10.1093/annonc/mdg731; Akagi Y, 2012, ANTICANCER RES, V32, P2277; Gorlick R, 1998, J CLIN ONCOL, V16, P1465, DOI 10.1200/JCO.1998.16.4.1465; Hanatani Y, 2000, ONCOL REP, V7, P1027; Higashiyama M, 2001, ONCOL REP, V8, P279; Kawamura M, 2007, CANCER CHEMOTH PHARM, V59, P507, DOI 10.1007/s00280-006-0292-8; Kobayashi H, 1997, INT J ONCOL, V11, P449; Kobayashi H, 2003, RECENT RESULTS CANC, V161, P48; Kopetz S, 2009, J CLIN ONCOL, V27, P3677, DOI 10.1200/JCO.2008.20.5278; Mekata E, 2013, MOL CLIN ON IN PRESS; Mentha G, 2006, BRIT J SURG, V93, P872, DOI 10.1002/bjs.5346; Midgley R, 2001, EXPERT OPIN INV DRUG, V10, P1011; Mori T, 2002, ONCOL REP, V9, P301; Ochiai T, 2005, ONCOL REP, V14, P201; Okumura K, 2006, ONCOL REP, V15, P875; Okumura K, 2008, CANCER CHEMOTH PHARM, V61, P587, DOI 10.1007/s00280-007-0511-y; Pessino A, 2008, ANN ONCOL, V19, P711, DOI 10.1093/annonc/mdm516; Poultsides GA, 2009, J CLIN ONCOL, V27, P3379, DOI 10.1200/JCO.2008.20.9817; Price TJ, 2012, ANN ONCOL, V23, P1531, DOI 10.1093/annonc/mdr488; SCHEELE J, 1995, WORLD J SURG, V19, P59, DOI 10.1007/BF00316981; Shimizu T, 2007, J GASTROENTEROL, V42, P918, DOI 10.1007/s00535-007-2105-1; Takamura Y, 2002, INT J CANCER, V98, P450, DOI 10.1002/ijc.10208; Takebayashi K, 2013, CANCER CHEMOTH PHARM, V72, P217, DOI 10.1007/s00280-013-2189-7; Yasuda H, 1998, J Hepatobiliary Pancreat Surg, V5, P261, DOI 10.1007/s005340050044	24	9	9	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 28	2013	8	8							e73215	10.1371/journal.pone.0073215	http://dx.doi.org/10.1371/journal.pone.0073215			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	209DG	24015297	gold, Green Published, Green Submitted			2023-01-03	WOS:000323733800094
J	Song, XX; Kim, SY; Lee, YJ				Song, Xinxin; Kim, Seog-Young; Lee, Yong J.			Evidence for Two Modes of Synergistic Induction of Apoptosis by Mapatumumab and Oxaliplatin in Combination with Hyperthermia in Human Colon Cancer Cells	PLOS ONE			English	Article							AGONISTIC MONOCLONAL-ANTIBODY; ISOLATED HEPATIC PERFUSION; TUMOR-NECROSIS-FACTOR; C-FLIP; COLORECTAL-CANCER; LIVER METASTASES; BCL-XL; DOWN-REGULATION; TRAIL; DEATH	Colorectal cancer is the third leading cause of cancer-related mortality in the world- the main cause of death from colorectal cancer is hepatic metastases, which can be treated with isolated hepatic perfusion (IHP). Searching for the most clinically relevant approaches for treating colorectal metastatic disease by isolated hepatic perfusion (IHP), we developed the application of oxaliplatin concomitantly with hyperthermia and humanized death receptor 4 (DR4) antibody mapatumumab (Mapa), and investigated the molecular mechanisms of this multimodality treatment in human colon cancer cell lines CX-1 and HCT116 as well as human colon cancer stem cells Tu-12, Tu-21 and Tu-22. We showed here, in this study, that the synergistic effect of the multimodality treatment-induced apoptosis was caspase dependent and activated death signaling via both the extrinsic apoptotic pathway and the intrinsic pathway. Death signaling was activated by c-Jun N-terminal kinase (JNK) signaling which led to Bcl-xL phosphorylation at serine 62, decreasing the anti-apoptotic activity of Bcl-xL, which contributed to the intrinsic pathway. The downregulation of cellular FLICE inhibitory protein long isoform (c-FLIPL) in the extrinsic pathway was accomplished through ubiquitination at lysine residue (K) 195 and protein synthesis inhibition. Overexpression of c-FLIPL mutant (K195R) and Bcl-xL mutant (S62A) completely abrogated the synergistic effect. The successful outcome of this study supports the application of multimodality strategy to patients with colorectal hepatic metastases who fail to respond to standard chemoradiotherapy that predominantly targets the mitochondrial apoptotic pathway.	[Song, Xinxin; Kim, Seog-Young; Lee, Yong J.] Univ Pittsburgh, Sch Med, Dept Surg, Pittsburgh, PA 15260 USA; [Lee, Yong J.] Univ Pittsburgh, Sch Med, Dept Pharmacol & Chem Biol, Pittsburgh, PA USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Lee, YJ (corresponding author), Univ Pittsburgh, Sch Med, Dept Surg, Pittsburgh, PA 15260 USA.	leeyj@upmc.edu		Song, Xinxin/0000-0003-3868-2644	NCI [CA140554];  [P30CA047904]; NATIONAL CANCER INSTITUTE [P30CA047904, R01CA140554] Funding Source: NIH RePORTER	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by the following grant: NCI grant fund (CA140554). This project used the UPCI Core Facility and was supported in part by award P30CA047904. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alcala MA, 2010, J CELL BIOCHEM, V110, P1073, DOI 10.1002/jcb.22619; Alexander HR, 2005, ANN SURG ONCOL, V12, P138, DOI 10.1245/ASO.2005.05.003; Atallah D, 2004, INT J HYPERTHER, V20, P405, DOI 10.1080/02656730310001637325; Bartke T, 2001, ONCOGENE, V20, P571, DOI 10.1038/sj.onc.1204124; Cummins Jordan M., 2004, Cancer Research, V64, P3006; Dimberg LY, 2013, ONCOGENE, V32, P1341, DOI 10.1038/onc.2012.164; El Fajoui Z, 2011, GASTROENTEROLOGY, V141, P663, DOI 10.1053/j.gastro.2011.04.055; Gao W, 2013, GASTROENTEROLOGY; Greco FA, 2008, LUNG CANCER, V61, P82, DOI 10.1016/j.lungcan.2007.12.011; HAFSTROM LR, 1994, SURG ONCOL, V3, P103, DOI 10.1016/0960-7404(94)90005-1; Hegewisch-Becker S, 2002, ANN ONCOL, V13, P1197, DOI 10.1093/annonc/mdf216; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.20107]; Korkolopoulou P, 2007, HISTOPATHOLOGY, V51, P150, DOI 10.1111/j.1365-2559.2007.02723.x; Krueger A, 2001, J BIOL CHEM, V276, P20633, DOI 10.1074/jbc.M101780200; Krueger A, 2001, MOL CELL BIOL, V21, P8247, DOI 10.1128/MCB.21.24.8247-8254.2001; Lavrik IN, 2012, CELL DEATH DIFFER, V19, P36, DOI 10.1038/cdd.2011.155; Lee MJ, 2012, CELL, V149, P780, DOI 10.1016/j.cell.2012.03.031; Lee YJ, 2001, CANCER GENE THER, V8, P397, DOI 10.1038/sj.cgt.7700310; Libutti SK, 2000, J AM COLL SURGEONS, V191, P519, DOI 10.1016/S1072-7515(00)00733-X; Lin YD, 2008, MOL CANCER THER, V7, P3556, DOI 10.1158/1535-7163.MCT-08-0648; Liu C, 2012, MOL BIOL REP, V39, P8717, DOI 10.1007/s11033-012-1731-8; Longley DB, 2006, ONCOGENE, V25, P838, DOI 10.1038/sj.onc.1209122; Mahalingam D, 2011, CURR DRUG TARGETS, V12, P2079, DOI 10.2174/138945011798829357; Mawji IA, 2007, CANCER RES, V67, P8307, DOI 10.1158/0008-5472.CAN-07-1687; Mom CH, 2009, CLIN CANCER RES, V15, P5584, DOI 10.1158/1078-0432.CCR-09-0996; Odoux C, 2008, CANCER RES, V68, P6932, DOI 10.1158/0008-5472.CAN-07-5779; Raymond E, 2002, MOL CANCER THER, V1, P227; Ruers T, 2002, EUR J CANCER, V38, P1023, DOI 10.1016/S0959-8049(02)00059-X; Safa AR, 2008, CURR CANCER DRUG TAR, V8, P37, DOI 10.2174/156800908783497087; Seo BR, 2013, BIOCHIMIE, V95, P858, DOI 10.1016/j.biochi.2012.12.002; Song X, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.104; Song XX, 2012, MOL CANCER RES, V10, P1567, DOI 10.1158/1541-7786.MCR-12-0209-T; Song XX, 2012, J CELL BIOCHEM, V113, P1547, DOI 10.1002/jcb.24023; Trarbach T, 2010, BRIT J CANCER, V102, P506, DOI 10.1038/sj.bjc.6605507; Ubersax JA, 2007, NAT REV MOL CELL BIO, V8, P530, DOI 10.1038/nrm2203; Ullenhag GJ, 2007, CLIN CANCER RES, V13, P5070, DOI 10.1158/1078-0432.CCR-06-2547; Upreti M, 2008, J BIOL CHEM, V283, P35517, DOI 10.1074/jbc.M805019200; Varghese S, 2010, ANN SURG ONCOL, V17, P1870, DOI 10.1245/s10434-010-0998-z; Vulfovich M, 2005, CURR OPIN MOL THER, V7, P502; Wilson TR, 2007, CANCER RES, V67, P5754, DOI 10.1158/0008-5472.CAN-06-3585; Yang JS, 2011, ACTA HISTOCHEM, V113, P810, DOI 10.1016/j.acthis.2011.01.002; Yoo JS, 2008, J CELL BIOCHEM, V103, P98, DOI 10.1002/jcb.21389; Younes A, 2010, BRIT J CANCER, V103, P1783, DOI 10.1038/sj.bjc.6605987; Yu JW, 2008, ONCOGENE, V27, P6216, DOI 10.1038/onc.2008.299; Zeh HJ, 2009, ANN SURG ONCOL, V16, P385, DOI 10.1245/s10434-008-0179-5; Zhang LD, 2005, CANCER GENE THER, V12, P228, DOI 10.1038/sj.cgt.7700792; Zhang YL, 2008, WORLD J GASTROENTERO, V14, P3069, DOI 10.3748/wjg.14.3069; Zhao LQ, 2011, MOL CANCER THER, V10, P2415, DOI 10.1158/1535-7163.MCT-11-0401	49	13	13	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 27	2013	8	8							e73654	10.1371/journal.pone.0073654	http://dx.doi.org/10.1371/journal.pone.0073654			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	210FR	24013390	Green Accepted, Green Published, gold, Green Submitted			2023-01-03	WOS:000323815200085
J	Grasmeijer, F; Hagedoorn, P; Frijlink, HW; de Boer, AH				Grasmeijer, Floris; Hagedoorn, Paul; Frijlink, Henderik W.; de Boer, Anne H.			Drug Content Effects on the Dispersion Performance of Adhesive Mixtures for Inhalation	PLOS ONE			English	Article							DRY POWDER INHALATION; CLASSIFIER-BASED INHALER; IN-VITRO EVALUATION; PARTICLE DETACHMENT; AIR CLASSIFIER; CARRIER CRYSTALS; LACTOSE; FORMULATIONS; COMPRESSION; RELEVANT	The drug content in adhesive mixtures for inhalation is known to influence their dispersion performance, but the direction and magnitude of this influence depends on other variables. In the past decades several mechanisms have been postulated to explain this finding and a number of possible interacting variables have been identified. Still, the role of drug content in the formulation of adhesive mixtures for inhalation, which includes its significance as an interacting variable to other parameters, is poorly understood. Therefore, the results from a series of drug detachment experiments are presented in which the effect of drug content and its dependence on flow rate, the mixing time and the type of drug is studied. Furthermore, it is investigated whether the effect depends on the range within which the drug content is changed. Quantitative and qualitative multiple order interactions are observed between these variables, which may be explained by a shifting balance between three different mechanisms. The results therefore demonstrate that accounting for (multiple order) interactions between variables has to be part of quality by design activities and the rational design of future experiments.	[Grasmeijer, Floris; Hagedoorn, Paul; Frijlink, Henderik W.; de Boer, Anne H.] Univ Groningen, Dept Pharmaceut Technol & Biopharm, Groningen, Netherlands	University of Groningen	Grasmeijer, F (corresponding author), Univ Groningen, Dept Pharmaceut Technol & Biopharm, Groningen, Netherlands.	F.Grasmeijer@rug.nl	Frijlink, Henderik Willem/AAD-7382-2020	Frijlink, Henderik Willem/0000-0001-7901-8198	Department of Pharmaceutical Technology and Biopharmacy of the University of Groningen	Department of Pharmaceutical Technology and Biopharmacy of the University of Groningen	The work was funded by the Department of Pharmaceutical Technology and Biopharmacy of the University of Groningen. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	BRYAN L, 1979, POWDER TECHNOL, V22, P147, DOI 10.1016/0032-5910(79)80020-0; de Boer AH, 2012, ADV DRUG DELIVER REV, V64, P257, DOI 10.1016/j.addr.2011.04.004; de Boer AH, 2004, PHARM RES-DORDR, V21, P2158, DOI 10.1007/s11095-004-7668-4; de Boer AH, 2004, PHARM RES-DORDR, V21, P2167, DOI 10.1007/s11095-004-5171-6; de Boer AH, 2003, INT J PHARMACEUT, V260, P187, DOI 10.1016/S0378-5173(03)00250-3; de Boer AH, 2005, INT J PHARMACEUT, V294, P173, DOI 10.1016/j.ijpharm.2005.01.035; de Koning JP, 2001, DRY POWDER INHALATIO; Dickhoff B.H.J., 2006, ADHESIVE MIXTURES PO; Dickhoff BHJ, 2003, EUR J PHARM BIOPHARM, V56, P291, DOI 10.1016/S0939-6411(03)00109-7; HERSEY JA, 1975, POWDER TECHNOL, V11, P41, DOI 10.1016/0032-5910(75)80021-0; Hooton JC, 2006, J PHARM SCI-US, V95, P1288, DOI 10.1002/jps.20618; Jones MD, 2008, PHARM RES-DORDR, V25, P337, DOI 10.1007/s11095-007-9467-1; Jones MD, 2008, EUR J PHARM BIOPHARM, V69, P496, DOI 10.1016/j.ejpb.2007.11.019; KULVANICH P, 1987, J PHARM PHARMACOL, V39, P673, DOI 10.1111/j.2042-7158.1987.tb06968.x; LAM KK, 1991, POWDER TECHNOL, V65, P167, DOI 10.1016/0032-5910(91)80179-M; Le VNP, 2012, INT J PHARMACEUT, V424, P44, DOI 10.1016/j.ijpharm.2011.12.020; Louey MD, 2002, PHARM RES-DORDR, V19, P1524, DOI 10.1023/A:1020464801786; Price R, 2010, C LACT CARR INH PROD; STANIFORTH JN, 1987, J PHARM PHARMACOL, V39, P329, DOI 10.1111/j.2042-7158.1987.tb03393.x; Staniforth JN., 1981, INT J PHARM TECH PRO, V2, P7; Steckel H, 2004, EUR J PHARM BIOPHARM, V57, P495, DOI 10.1016/j.ejpb.2003.12.003; Steckel H, 1997, INT J PHARM, V154, P31, DOI 10.1016/S0378-5173(97)00115-4; TIMSINA MP, 1994, INT J PHARM, V101, P1, DOI 10.1016/0378-5173(94)90070-1; Young PA, 2005, INT J PHARMACEUT, V296, P26, DOI 10.1016/j.ijpharm.2005.02.004	24	25	26	0	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 14	2013	8	8							e71339	10.1371/journal.pone.0071339	http://dx.doi.org/10.1371/journal.pone.0071339			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	202MQ	23967195	Green Published, Green Submitted, gold			2023-01-03	WOS:000323221500077
J	Lobo, ML; Esteves, F; de Sousa, B; Cardoso, F; Cushion, MT; Antunes, F; Matos, O				Lobo, Maria Luisa; Esteves, Francisco; de Sousa, Bruno; Cardoso, Fernando; Cushion, Melanie T.; Antunes, Francisco; Matos, Olga			Therapeutic Potential of Caspofungin Combined with Trimethoprim-Sulfamethoxazole for Pneumocystis Pneumonia: A Pilot Study in Mice	PLOS ONE			English	Article							INVASIVE FUNGAL-INFECTIONS; CELL-WALL; CARINII PNEUMONIA; EPIDEMIOLOGY; GLUCAN; POLYMORPHISMS; ECHINOCANDIN; INFLAMMATION; DIAGNOSIS; EFFICACY	Pneumocystis pneumonia (PcP) is a major cause of mortality and morbidity in immunocompromised patients. There are limited alternative therapeutic choices to trimethoprim-sulfamethoxazole (TMP-SMX) which is the standard first line therapy/prophylaxis for PcP. The efficacy of low doses of caspofungin and caspofungin in association with TMP-SMX standard-prophylactic dose was evaluated in an experimental model of Pneumocystis. Susceptibility of Pneumocystis spp. to low doses of caspofungin and caspofungin/TMP-SMX was evaluated in Balb/c immunosuppressed mice, infected intranasally with P. murina. Caspofungin was administered once daily at 0.1 mg/kg, 0.05 mg/kg, and 0.001 mg/kg and TMP-SMX was administered by oral gavage (12.25 mg/62.5 mg/day), for 21 days. Efficacy was calculated based on the reduction in organism burden determined through quantitative fluorescent-based real-time PCR (qPCR). Serum beta-1,3-D-glucan was measured as an additional marker of infection. The present data showed that caspofungin demonstrated anti-Pneumomocystis effect. However, the doses administrated were too low to achieve Pneumocystis eradication, which suggests that echinocandin treatment should not be administrated as mono-therapy. After 21 days of treatment, P. murina was not detected in the lungs of mice with either TMP-SMX or caspofungin/TMP-SMX. The results showed that, even at the lowest concentrations tested, the efficacy of caspofungin in association with TMP-SMX was higher than the efficacy of either drug used alone. The administration of caspofungin/TMP-SMX was at least 1.4 times more effective against P. murina infection than TMP-SMX used alone. The most promising result was achieved with the combination of caspofungin 0.05 mg/kg/day with TMP-SMX 12.5 mg-62.5 mg/day, which reduced the parasite burden to undetectable levels immediately at the 14th day of treatment, showing a highly marked anti-Pneumomocystis effect. These data suggest that the administration of low doses of caspofungin in combination with low doses of TMP-SMX may provide an improved treatment protocol for Pneumocystis infection clearance.	[Lobo, Maria Luisa; Esteves, Francisco; Cardoso, Fernando; Matos, Olga] Univ Nova Lisboa, Inst Higiene & Med Trop, Grp Protozoarios Oportunistas VIH & Outros Protoz, Unidade Parasitol Med,CMDT, P-1200 Lisbon, Portugal; [de Sousa, Bruno] Univ Coimbra, CMDT, Fac Psicol & Ciencias Educ, Coimbra, Portugal; [Cushion, Melanie T.] Univ Cincinnati, Coll Med, Cincinnati, OH USA; [Antunes, Francisco] Univ Lisbon, Fac Med, Hosp Santa Maria, P-1699 Lisbon, Portugal	Universidade Nova de Lisboa; Institute of Hygiene & Tropical Medicine - UNL; Universidade de Coimbra; University System of Ohio; University of Cincinnati; Universidade de Lisboa; Hospital Santa Maria	Matos, O (corresponding author), Univ Nova Lisboa, Inst Higiene & Med Trop, Grp Protozoarios Oportunistas VIH & Outros Protoz, Unidade Parasitol Med,CMDT, P-1200 Lisbon, Portugal.	omatos@ihmt.unl.pt	Lobo, Maria/I-3527-2012; de Sousa, Bruno/A-1654-2012; Matos, Olga/J-8859-2012; de Sousa, Bruno/S-2600-2019; Cardoso, Fernando/A-7753-2013	Lobo, Maria/0000-0001-5811-7568; de Sousa, Bruno/0000-0001-9918-8100; Matos, Olga/0000-0001-5793-7716; Antunes, Francisco/0000-0001-7932-1154; Cardoso, Fernando/0000-0003-1501-9479; Esteves, Francisco/0000-0002-3046-1313; Cushion, Melanie T./0000-0001-6621-2784	Merck Sharp Dohme Corp [38903]	Merck Sharp Dohme Corp(Merck & Company)	The present study was supported by the scientific project Ref. 38903 financed by Merck Sharp & Dohme Corp. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aliouat-Denis CM, 2008, INFECT GENET EVOL, V8, P708, DOI 10.1016/j.meegid.2008.05.001; Annaloro C, 2006, EUR J CLIN MICROBIOL, V25, P52, DOI 10.1007/s10096-005-0065-z; Barry S M, 2001, HIV Med, V2, P123, DOI 10.1046/j.1468-1293.2001.00062.x; Beltz K, 2006, KLIN PADIATR, V218, P177, DOI 10.1055/s-2006-933433; Calderon EJ, 2010, EXPERT REV ANTI-INFE, V8, P683, DOI [10.1586/eri.10.42, 10.1586/eri.10.11, 10.1586/ERI.10.42]; Costa MC, 2005, SCAND J INFECT DIS, V37, P766, DOI 10.1080/00365540510038505; Cushion MT, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008524; Enoch DA, 2006, J MED MICROBIOL, V55, P809, DOI 10.1099/jmm.0.46548-0; Esgalhado R, 2013, MED MYCOL, V51, P66, DOI 10.3109/13693786.2012.700123; Espinel-Ingroff A, 2009, REV IBEROAM MICOL, V26, P15, DOI 10.1016/S1130-1406(09)70004-X; Esteves F, 2012, CLIN MICROBIOL INFEC, V18, pE177, DOI 10.1111/j.1469-0691.2012.03828.x; Esteves F, 2010, CLIN MICROBIOL INFEC, V16, P878, DOI 10.1111/j.1469-0691.2009.03030.x; Finkelman MA, 2010, CRIT REV MICROBIOL, V36, P271, DOI 10.3109/1040841X.2010.484001; HOLTENANDERSEN W, 1989, APMIS, V97, P745, DOI 10.1111/j.1699-0463.1989.tb00472.x; Huang Laurence, 2011, Proc Am Thorac Soc, V8, P294, DOI 10.1513/pats.201009-062WR; Hufeldt MR, 2010, LAB ANIM-UK, V44, P283, DOI 10.1258/la.2010.010058; Letscher-Bru V, 2003, J ANTIMICROB CHEMOTH, V51, P513, DOI 10.1093/jac/dkg117; Limper AH, 2003, J EUKARYOT MICROBIOL, V50, P646, DOI 10.1111/j.1550-7408.2003.tb00667.x; Linke MJ, 2013, INFECT IMMUN, V81, P984, DOI 10.1128/IAI.01181-12; Matos O, 2010, PARASITE, V17, P219, DOI 10.1051/parasite/2010173219; MATSUMOTO Y, 1991, J PROTOZOOL, V38, pS6; Morris A, 2008, COPD, V5, P43, DOI 10.1080/15412550701817656; Persat F, 2008, J CLIN MICROBIOL, V46, P1009, DOI 10.1128/JCM.02091-07; Powles MA, 1998, ANTIMICROB AGENTS CH, V42, P1985, DOI 10.1128/AAC.42.8.1985; Redhead S, 2006, J EUKARYOT MICROBIOL, V53, P2, DOI 10.1111/j.1550-7408.2005.00072.x; Ruan SB, 2002, INFECT IMMUN, V70, P6107, DOI 10.1128/IAI.70.11.6107-6113.2002; SCHMATZ DM, 1990, P NATL ACAD SCI USA, V87, P5950, DOI 10.1073/pnas.87.15.5950; Stringer JR, 1996, CLIN MICROBIOL REV, V9, P489, DOI 10.1128/CMR.9.4.489; Thomas CF, 2007, NAT REV MICROBIOL, V5, P298, DOI 10.1038/nrmicro1621; Utili R, 2007, TRANSPLANTATION, V84, P685, DOI 10.1097/01.tp.0000280546.91617.6c; Vassallo R, 2000, J IMMUNOL, V164, P3755, DOI 10.4049/jimmunol.164.7.3755; Vazquez JA, 2006, CLIN INFECT DIS, V43, P215, DOI 10.1086/505204; WALZER PD, 1992, ANTIMICROB AGENTS CH, V36, P1935, DOI 10.1128/AAC.36.9.1935; Yoshida M, 1996, J LAB CLIN MED, V128, P103, DOI 10.1016/S0022-2143(96)90119-5	34	37	45	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 5	2013	8	8							e70619	10.1371/journal.pone.0070619	http://dx.doi.org/10.1371/journal.pone.0070619			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	218XC	23940606	Green Published, gold, Green Submitted			2023-01-03	WOS:000324465000100
J	Simonsen, KA; Hunskaar, S; Sandvik, H; Rortveit, G				Simonsen, Kristian A.; Hunskaar, Steinar; Sandvik, Hogne; Rortveit, Guri			Capacity and Adaptations of General Practice during an Influenza Pandemic	PLOS ONE			English	Article							PRIMARY-CARE; A H1N1; NORWAY; INFECTIONS; ENGLAND; ILLNESS; BURDEN	Background: GPs play a major role in influenza epidemics, and most patients with influenza-like-illness (ILI) are treated in general practice or by primary care doctors on duty in out-of-hours services (OOH). Little is known about the surge capacity in primary care services during an influenza pandemic, and how the relationship between them changes. Aim: To investigate how general practice and OOH services were used by patients during the 2009 pandemic in Norway and the impact of the pandemic on primary care services in comparison to a normal influenza season. Materials: Data from electronic remuneration claims from all OOH doctors and regular GPs for 2009. Methods: We conducted a registry-based study of all ILI consultations in the 2009 pandemic with the 2008/09 influenza season (normal season) as baseline for comparison. Results: The majority (82.2%) of ILI consultations during the 2009 pandemic took place in general practice. The corresponding number in the 2008/09 season was 89.3%. Compared with general practice, the adjusted odds ratio for ILI with all other diagnoses as reference in OOH services was 1.23 (95% CI, 1.18, 1.27) for the 2008/2009 season and 1.87 (95% CI, 1.84, 1.91) for the pandemic influenza season. In total there was a 3.3-fold increase in ILI consultations during the pandemic compared to the 2008/09 season. A 5.5-fold increase of ILI consultations were observed in OOH services in comparison to the 2008/09 season. Children and young adults with ILI were the most frequent users of OOH services during influenza periods. Conclusions: The autumn pandemic wave resulted in a significantly increased demand on primary care services. However, GPs in primary care services in Norway showed the ability to increase capacity in a situation with increased patient demand.	[Simonsen, Kristian A.; Hunskaar, Steinar; Sandvik, Hogne; Rortveit, Guri] Univ Bergen, Dept Global Publ Hlth & Primary Care, Res Grp Gen Practice, Bergen, Norway; [Simonsen, Kristian A.; Rortveit, Guri] Uni Res, Res Unit Gen Practice Uni Hlth, Bergen, Norway; [Hunskaar, Steinar; Sandvik, Hogne] Uni Res, Natl Ctr Emergency Primary Hlth Care Uni Hlth, Bergen, Norway	University of Bergen	Simonsen, KA (corresponding author), Univ Bergen, Dept Global Publ Hlth & Primary Care, Res Grp Gen Practice, Bergen, Norway.	kristian.simonsen@igs.uib.no			Norwegian Medical Association's Funds for Research in General Practice; Norwegian Directorate of Health; University of Bergen	Norwegian Medical Association's Funds for Research in General Practice; Norwegian Directorate of Health; University of Bergen	This work was supported by Norwegian Medical Association's Funds for Research in General Practice, the Norwegian Directorate of Health and the University of Bergen. KAS received a PhD grant from the University of Bergen, committing him to write three peer-reviewed articles. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aldaz P, 2011, REV ESP SALUD PUBLIC, V85, P113, DOI 10.1590/S1135-57272011000100014; Anestad G, 2011, MED HYPOTHESES, V77, P1132, DOI 10.1016/j.mehy.2011.09.021; Bocquet J, 2010, AUST FAM PHYSICIAN, V39, P313; Gran JM, 2010, EPIDEMIOL INFECT, V138, P1559, DOI 10.1017/S0950268810000671; Hansen EH, 2008, BMC HEALTH SERV RES, V8, DOI 10.1186/1472-6963-8-62; HOPESIMPSON RE, 1981, J HYG-CAMBRIDGE, V86, P35, DOI 10.1017/S0022172400068728; Kacelnik O, 2011, REPORT DEATHS INFLUE; Michiels B, 2011, BMC FAM PRACT, V12, DOI 10.1186/1471-2296-12-4; Miller E, 2010, LANCET, V375, P1100, DOI 10.1016/S0140-6736(09)62126-7; Molbak K, 2011, VACCINE, V29, pB63, DOI 10.1016/j.vaccine.2011.03.064; Nossen J, 2007, 0407 NAV; Patel MS, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002269; Peiris JSM, 2009, J CLIN VIROL, V45, P169, DOI 10.1016/j.jcv.2009.06.006; Pitman RJ, 2007, J INFECTION, V54, P530, DOI 10.1016/j.jinf.2006.09.017; Press K, 2010, 32010 NAT CTR EM PRI; Rortveit Sverre, 2011, Tidsskr Nor Laegeforen, V131, P675, DOI 10.4045/tidsskr.10.0858; Sauro Alfonso, 2006, Eur J Gen Pract, V12, P34, DOI 10.1080/13814780600757153; Simonsen KA, 2012, FAM PRACT, V29, P139, DOI 10.1093/fampra/cmr064; Temte Jonathan L, 2010, WMJ, V109, P193; The Norwegian Institute of Public Health, 2013, SURV INFL ACT NORW; [No title captured]	21	12	12	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 18	2013	8	7							e69408	10.1371/journal.pone.0069408	http://dx.doi.org/10.1371/journal.pone.0069408			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	214PM	23874960	Green Published, gold			2023-01-03	WOS:000324146200076
J	Petrilli, A; Copik, A; Posadas, M; Chang, LS; Welling, DB; Giovannini, M; Fernandez-Valle, C				Petrilli, A.; Copik, A.; Posadas, M.; Chang, L-S; Welling, D. B.; Giovannini, M.; Fernandez-Valle, C.			LIM domain kinases as potential therapeutic targets for neurofibromatosis type 2	ONCOGENE			English	Article						LIMK; cell proliferation; Neurofibromatosis; schwannomas; cytoskeleton dynamics; cell cycle	NF2 TUMOR-SUPPRESSOR; COFILIN PHOSPHORYLATION; ACTIN DYNAMICS; PROTEIN-KINASE; SCHWANN-CELLS; AURORA-A; MERLIN; GENE; RAC; PROLIFERATION	Neurofibromatosis type 2 (NF2) is caused by mutations in the NF2 gene that encodes a tumor-suppressor protein called merlin. NF2 is characterized by formation of multiple schwannomas, meningiomas and ependymomas. Merlin loss-of-function is associated with increased activity of Rac and p21-activated kinases (PAKs) and deregulation of cytoskeletal organization. LIM domain kinases (LIMK1 and 2) are substrate for Cdc42/Rac-PAK and modulate actin dynamics by phosphorylating cofilin at serine-3. This modification inactivates the actin severing and depolymerizing activity of cofilin. LIMKs also translocate into the nucleus and regulate cell cycle progression. Significantly, LIMKs are overexpressed in several tumor types, including skin, breast, lung, liver and prostate. Here we report that mouse Schwann cells (MSCs) in which merlin function is lost as a result of Nf2 exon2 deletion (Nf2(Delta Ex2)) exhibited increased levels of LIMK1, LIMK2 and active phospho-Thr508/505-LIMK1/2, as well as phospho-Ser3-cofilin, compared with wild-type normal MSCs. Similarly, levels of LIMK1 and 2 total protein and active phosphorylated forms were elevated in human vestibular schwannomas compared with normal human Schwann cells (SCs). Reintroduction of wild-type NF2 into Nf2(Delta Ex2) MSC reduced LIMK1 and LIMK2 levels. We show that pharmacological inhibition of LIMK with BMS-5 decreased the viability of Nf2(Delta Ex2) MSCs in a dose-dependent manner, but did not affect viability of control MSCs. Similarly, LIMK knockdown decreased viability of Nf2(Delta Ex2) MSCs. The decreased viability of Nf2(Delta Ex2) MSCs was not due to caspase-dependent or -independent apoptosis, but rather due to inhibition of cell cycle progression as evidenced by accumulation of cells in G(2)/M phase. Inhibition of LIMKs arrests cells in early mitosis by decreasing aurora A activation. Our results suggest that LIMKs are potential drug targets for NF2 and tumors associated with merlin deficiency.	[Petrilli, A.; Copik, A.; Posadas, M.; Fernandez-Valle, C.] Univ Cent Florida, Coll Med, Burnett Sch Biomed Sci, Orlando, FL 32827 USA; [Chang, L-S] Nationwide Childrens Hosp, Res Inst, Ctr Childhood Canc, Columbus, OH USA; [Chang, L-S] Ohio State Univ, Coll Med, Dept Pediat, Columbus, OH 43210 USA; [Welling, D. B.] Ohio State Univ, Coll Med, Dept Otolaryngol, Columbus, OH 43210 USA; [Giovannini, M.] House Res Inst, Div Clin & Translat Res, Los Angeles, CA USA	State University System of Florida; University of Central Florida; University System of Ohio; Ohio State University; Nationwide Childrens Hospital; Research Institute at Nationwide Children's Hospital; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University	Fernandez-Valle, C (corresponding author), Univ Cent Florida, Coll Med, Burnett Sch Biomed Sci, 6900 Lake Nona Blvd, Orlando, FL 32827 USA.	cfv@ucf.edu	Welling, D Bradley/H-1503-2014	Welling, D. Bradley/0000-0002-9963-469X; Chang, Long-Sheng/0000-0002-5178-2992	DHHS/NIH [5R01DC10189]; Children's Tumor Foundation; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS062825] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC010189] Funding Source: NIH RePORTER	DHHS/NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Children's Tumor Foundation; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))	We thank Dr Patrick Wood, The Miami Project to Cure Paralysis, Department of Neurological Surgery, University of Miami Miller School of Medicine, Miami, FL, USA, for vials of cultured human Schwann cells, Dr Maria Elisa Manetti for the Halo-tag NF2 plasmid, Nicklaus Sparrow and Marga Bott for their creation of the Nf2<SUP>Delta Ex2</SUP> MSCs and Rashell Hallford for animal husbandry. This work was supported in part by a DHHS/NIH award to CF-V (5R01DC10189), and AP is the recipient of a Young Investigator Award from the Children's Tumor Foundation.	Amano T, 2002, J BIOL CHEM, V277, P22093, DOI 10.1074/jbc.M201444200; Arber S, 1998, NATURE, V393, P805, DOI 10.1038/31729; Asthagiri AR, 2009, LANCET, V373, P1974, DOI 10.1016/S0140-6736(09)60259-2; Bagheri-Yarmand R, 2006, INT J CANCER, V118, P2703, DOI 10.1002/ijc.21650; Barr AR, 2007, J CELL SCI, V120, P2987, DOI 10.1242/jcs.013136; Baser ME, 2002, NEUROLOGY, V59, P290, DOI 10.1212/WNL.59.2.290; Bashour AM, 2002, MOL CELL BIOL, V22, P1150, DOI 10.1128/MCB.22.4.1150-1157.2002; Cote MC, 2010, J BIOL CHEM, V285, P8013, DOI 10.1074/jbc.M109.098665; Giovannini M, 2000, GENE DEV, V14, P1617; Goyal P, 2005, J BIOL CHEM, V280, P27569, DOI 10.1074/jbc.M504448200; Horita Y, 2008, J BIOL CHEM, V283, P6013, DOI 10.1074/jbc.M706538200; Hung G, 2002, INT J ONCOL, V20, P475; Iacovelli J, 2007, GLIA, V55, P1638, DOI 10.1002/glia.20578; Johnson EO, 2012, J CELL SCI, V125, P1204, DOI 10.1242/jcs.092304; Kaji N, 2008, J BIOL CHEM, V283, P4983, DOI 10.1074/jbc.M708644200; Kalamarides Michel, 2012, Acta Neuropathol, V123, P369, DOI 10.1007/s00401-011-0905-0; Kissil JL, 2003, MOL CELL, V12, P841, DOI 10.1016/S1097-2765(03)00382-4; Kissil JL, 2002, J BIOL CHEM, V277, P10394, DOI 10.1074/jbc.M200083200; Li W, 2012, EMBO REP, V13, P204, DOI 10.1038/embor.2012.11; Manetti F, 2012, CURR CANCER DRUG TAR, V12, P543, DOI 10.2174/156800912800673266; Manetti F, 2012, MED RES REV, V32, P968, DOI 10.1002/med.20230; McConnell BV, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-75; Nakai Y, 2006, J NEUROSCI, V26, P3390, DOI 10.1523/JNEUROSCI.4865-05.2006; Nikonova AS, 2013, CELL MOL LIFE SCI, V70, P661, DOI 10.1007/s00018-012-1073-7; Okamoto I, 2005, NEOPLASIA, V7, P303, DOI 10.1593/neo.04514; Pelton PD, 1998, ONCOGENE, V17, P2195, DOI 10.1038/sj.onc.1202141; Plotkin SR, 2009, NEW ENGL J MED, V361, P358, DOI 10.1056/NEJMoa0902579; Po'uha ST, 2010, ONCOGENE, V29, P597, DOI 10.1038/onc.2009.367; Ritchey L, 2012, CELL CYCLE, V11, P296, DOI 10.4161/cc.11.2.18734; Ross-Macdonald P, 2008, MOL CANCER THER, V7, P3490, DOI 10.1158/1535-7163.MCT-08-0826; ROULEAU GA, 1993, NATURE, V363, P515, DOI 10.1038/363515a0; Scott RW, 2007, J MOL MED, V85, P555, DOI 10.1007/s00109-007-0165-6; Shaw RJ, 2001, DEV CELL, V1, P63, DOI 10.1016/S1534-5807(01)00009-0; Sparrow N, 2012, J NEUROSCI, V32, P5284, DOI 10.1523/JNEUROSCI.6207-11.2012; Stamenkovic I, 2010, CURR PROTEIN PEPT SC, V11, P471, DOI 10.2174/138920310791824011; Sumi T, 2006, EXP CELL RES, V312, P1021, DOI 10.1016/j.yexcr.2005.12.030; Thaxton C, 2008, ONCOGENE, V27, P2705, DOI 10.1038/sj.onc.1210923; Thaxton C, 2011, MOL CELL NEUROSCI, V47, P1, DOI 10.1016/j.mcn.2010.12.006; Xiao GH, 2002, J BIOL CHEM, V277, P883, DOI 10.1074/jbc.C100553200; Yang N, 1998, NATURE, V393, P809, DOI 10.1038/31735; Yi CL, 2008, CANCER RES, V68, P7932, DOI 10.1158/0008-5472.CAN-08-0866; Yokoo T, 2003, J BIOL CHEM, V278, P52919, DOI 10.1074/jbc.M309334200	42	33	34	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 3	2014	33	27					3571	3582		10.1038/onc.2013.320	http://dx.doi.org/10.1038/onc.2013.320			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AL2FK	23934191	Green Accepted			2023-01-03	WOS:000338941100009
J	Cortese, DA				Cortese, Denis A.			A Health Care Encounter of the 21st Century	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							US HEALTH; BURDEN		[Cortese, Denis A.] Arizona State Univ, Ctr Healthcare Delivery & Policy, Tempe, AZ USA	Arizona State University; Arizona State University-Tempe	Cortese, DA (corresponding author), Arizona State Univ, 13212 E Shea Blvd, Scottsdale, AZ 85259 USA.	Denis.Cortese@asu.edu						[Anonymous], HLTH CAR COSTS PRIM; [Anonymous], 2011, P CSEE, V31, P19; Bodenheimer T, 2009, HEALTH AFFAIR, V28, P64, DOI 10.1377/hlthaff.28.1.64; Cryer L, 2012, HEALTH AFFAIR, V31, P1237, DOI 10.1377/hlthaff.2011.1132; Harrington P, COMMUNITY PARTNERSHI; Murray CJL, 2013, JAMA-J AM MED ASSOC, V310, P591, DOI 10.1001/jama.2013.13805; Wu S. Y., 2000, PROJECTION CHRONIC I	7	6	7	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 13	2013	310	18					1937	1938		10.1001/jama.2013.281856	http://dx.doi.org/10.1001/jama.2013.281856			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	250EJ	24219946				2023-01-03	WOS:000326832900015
J	Jhun, JY; Moon, SJ; Yoon, BY; Byun, JK; Kim, EK; Yang, EJ; Ju, JH; Hong, YS; Min, JK; Park, SH; Kim, HY; Cho, ML				Jhun, Joo Yeon; Moon, Su-Jin; Yoon, Bo Young; Byun, Jae Kyung; Kim, Eun Kyung; Yang, Eun Ji; Ju, Ji Hyeon; Hong, Yeon Sik; Min, Jun Ki; Park, Sung Hwan; Kim, Ho Youn; Cho, Mi-La			Grape Seed Proanthocyanidin Extract-Mediated Regulation of STAT3 Proteins Contributes to Treg Differentiation and Attenuates Inflammation in a Murine Model of Obesity-Associated Arthritis	PLOS ONE			English	Article							COLLAGEN-INDUCED ARTHRITIS; BROWN ADIPOSE-TISSUE; T-CELLS; JOINT INFLAMMATION; SELF-TOLERANCE; LEPTIN; RATS; DIET; HOMEOSTASIS; ACTIVATION	Grape seed proanthocyanidin extract (GSPE) is a natural flavonoid that exerts anti-inflammatory properties. Obesity is an inflammatory condition and inflammatory cells and their secretion of pro-inflammatory molecules contribute to the pathogenesis of obesity. Rheumatoid arthritis (RA) is a chronic autoimmune disease that is characterized by inflammation of joints lined by synovium. Previously, we demonstrated that obesity augmented arthritis severity in collagen induced arthritis (CIA), a murine model of human RA. Here, we investigated whether oral administration of GSPE showed antiobesity and anti-arthritic effects in high-fat diet-induced obese (DIO) mice and in obese CIA mice, respectively. The pathophysiologic mechanisms by which GSPE attenuates weight gain and arthritis severity in vivo were also investigated. In DIO mice, GSPE administration significantly inhibited weight gain, reduced fat infiltration in liver and improved serum lipid profiles. The antiobesity effect of GSPE was associated with increased populations of regulatory T (Treg) cells and those of decreased Th17 cells. Decrease of Th17 cells was associated with significant inhibition of their key transcriptional factors, pSTAT3(Tyr705) and pSTAT3(Ser727). On the contrary, GSPE-induced Treg induction was associated with enhanced pSTAT5 expression. To identify the anti-arthritis effects of GSPE, GSPE was given orally for 7 weeks after type II collagen immunization. GSPE treatment significantly attenuated the development of autoimmune arthritis in obese CIA model. In line with DIO mice, GSPE administration decreased Th17 cells and reciprocally increased Treg cells by regulating STAT proteins in autoimmune arthritis model. The expressions of pro-inflammatory cytokines and nitrotyrosine in synovium were significantly inhibited by GSPE treatment. Taken together, GSPE functions as a reciprocal regulator of T cell differentiation - suppression of Th17 cells and induction of Tregs in both DIO and obese CIA mice. GSPE may act as a therapeutic agent to treat immunologic diseases related with enhanced STAT3 activity such as metabolic disorders and autoimmune diseases.	[Jhun, Joo Yeon; Byun, Jae Kyung; Kim, Eun Kyung; Yang, Eun Ji; Cho, Mi-La] Catholic Univ Korea, Coll Med, Conversant Res Consortium Immunol Dis, Seoul, South Korea; [Jhun, Joo Yeon; Byun, Jae Kyung; Kim, Eun Kyung; Yang, Eun Ji; Cho, Mi-La] Catholic Univ Korea, Coll Med, Rheumatism Res Ctr, Seoul, South Korea; [Moon, Su-Jin; Ju, Ji Hyeon; Hong, Yeon Sik; Min, Jun Ki; Park, Sung Hwan; Kim, Ho Youn] Catholic Univ Korea, Coll Med, Dept Internal Med, Div Rheumatol, Seoul, South Korea; [Yoon, Bo Young] Inje Univ, Dept Internal Med, Ilsan Paik Hosp, Goyang, South Korea	Catholic University of Korea; Catholic University of Korea; Catholic University of Korea; Inje University	Cho, ML (corresponding author), Catholic Univ Korea, Coll Med, Conversant Res Consortium Immunol Dis, Seoul, South Korea.	iammila@catholic.ac.kr			Korea Health Technology R&D Project, Ministry for Health, Welfare & Family Affairs, Republic of Korea [A092258]; Bio & Medical Technology Development Program of the National Research Foundation (NRF); Korean government Ministry of Education, Science and Technology (MEST) [2012049783]	Korea Health Technology R&D Project, Ministry for Health, Welfare & Family Affairs, Republic of Korea; Bio & Medical Technology Development Program of the National Research Foundation (NRF)(National Research Foundation of Korea); Korean government Ministry of Education, Science and Technology (MEST)(Ministry of Education, Science & Technology (MEST), Republic of KoreaKorean Government)	This research was supported by a grant from the Korea Health Technology R&D Project, Ministry for Health, Welfare & Family Affairs, Republic of Korea (grant number A092258), Bio & Medical Technology Development Program of the National Research Foundation (NRF) funded by the Korean government Ministry of Education, Science and Technology (MEST) (grant number 2012049783). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Antov A, 2003, J IMMUNOL, V171, P3435, DOI 10.4049/jimmunol.171.7.3435; Bagchi D, 2000, TOXICOLOGY, V148, P187, DOI 10.1016/S0300-483X(00)00210-9; Barclay JL, 2011, ENDOCRINOLOGY, V152, P181, DOI 10.1210/en.2010-0537; Bates SH, 2003, NATURE, V421, P856, DOI 10.1038/nature01388; Blade C, 2010, MOL NUTR FOOD RES, V54, P37, DOI 10.1002/mnfr.200900476; Camps M, 2005, NAT MED, V11, P936, DOI 10.1038/nm1284; Chaudhry A, 2009, SCIENCE, V326, P986, DOI 10.1126/science.1172702; Cho ML, 2009, IMMUNOL LETT, V124, P102, DOI 10.1016/j.imlet.2009.05.001; Cui Y, 2007, HEPATOLOGY, V46, P504, DOI 10.1002/hep.21713; Durant L, 2010, IMMUNITY, V32, P605, DOI 10.1016/j.immuni.2010.05.003; Fantuzzi G, 2005, J ALLERGY CLIN IMMUN, V115, P911, DOI 10.1016/j.jaci.2005.02.023; Feuerer M, 2009, NAT MED, V15, P930, DOI 10.1038/nm.2002; Gainsford T, 1996, P NATL ACAD SCI USA, V93, P14564, DOI 10.1073/pnas.93.25.14564; Inglis JJ, 2008, NAT PROTOC, V3, P612, DOI 10.1038/nprot.2008.19; Jhun JY, 2012, EXP MOL MED, V44, P424, DOI 10.3858/emm.2012.44.7.047; La Cava A, 2004, NAT REV IMMUNOL, V4, P371, DOI 10.1038/nri1350; Lazarevic V, 2011, NAT IMMUNOL, V12, P96, DOI 10.1038/ni.1969; Li WG, 2001, ACTA PHARMACOL SIN, V22, P1117; Lichtenbelt WDV, 2009, NEW ENGL J MED, V360, P1500, DOI 10.1056/NEJMoa0808718; Lord GM, 1998, NATURE, V394, P897, DOI 10.1038/29795; Maddur MS, 2012, AM J PATHOL, V181, P8, DOI 10.1016/j.ajpath.2012.03.044; Matarese G, 2005, J IMMUNOL, V174, P3137, DOI 10.4049/jimmunol.174.6.3137; Murray PJ, 2007, J IMMUNOL, V178, P2623, DOI 10.4049/jimmunol.178.5.2623; Pajuelo D, 2012, BRIT J NUTR, V107, P170, DOI 10.1017/S0007114511002728; Park MK, 2011, IMMUNOL LETT, V135, P50, DOI 10.1016/j.imlet.2010.09.011; Rasmussen SE, 2005, MOL NUTR FOOD RES, V49, P159, DOI 10.1002/mnfr.200400082; Rosloniec EF, 2001, CURR PROTOC IMMUNOL; SAKAGUCHI S, 1995, J IMMUNOL, V155, P1151; Shevach EM, 2001, ADV EXP MED BIOL, V490, P21; Sos BC, 2011, J CLIN INVEST, V121, P1412, DOI 10.1172/JCI42894; Terra X, 2009, J NUTR BIOCHEM, V20, P210, DOI 10.1016/j.jnutbio.2008.02.005; Thiruchenduran M, 2011, CARDIOVASC PATHOL, V20, P361, DOI 10.1016/j.carpath.2010.09.002; Tilg H, 2006, NAT REV IMMUNOL, V6, P772, DOI 10.1038/nri1937; Wang DM, 2010, BIOL CELL, V102, P1, DOI 10.1042/BC20090070; Weisberg SP, 2003, J CLIN INVEST, V112, P1796, DOI 10.1172/JCI200319246; Winer S, 2009, EUR J IMMUNOL, V39, P2629, DOI 10.1002/eji.200838893; Woo YJ, 2011, EXP MOL MED, V43, P561, DOI 10.3858/emm.2011.43.10.062	37	25	30	0	24	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 5	2013	8	11							e78843	10.1371/journal.pone.0078843	http://dx.doi.org/10.1371/journal.pone.0078843			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	247EE	24223854	Green Published, gold, Green Submitted			2023-01-03	WOS:000326597400041
J	Zhang, T; Rong, NN; Chen, J; Zou, CW; Jing, HY; Zhu, XL; Zhang, WL				Zhang, Tao; Rong, Ningning; Chen, Juan; Zou, Chengwei; Jing, Haiyan; Zhu, Xiaolong; Zhang, Wenlong			SIRT1 Expression Is Associated with the Chemotherapy Response and Prognosis of Patients with Advanced NSCLC	PLOS ONE			English	Article							BREAST-CANCER; PROSTATE-CANCER; CELLS; APOPTOSIS; SENESCENCE; RADIATION; MICE; TUMORIGENESIS; DEACETYLASE; METASTASIS	Aim: The role of Sirtuin 1 (SIRT 1) in carcinogenesis is controversial. This study was to explore the association between the SIRT1 expression and the clinical characteristics, the responsiveness to chemotherapy and prognosis in Non-small cell lung cancer (NSCLC). Methods: We enrolled 295 patients with inoperable advanced stage of NSCLC, namely, stage III (A+B) and IV NSCLC. All patients had received platinum-based chemotherapy after diagnosis and the chemotherapy response were evaluated. All patients were followed up for overall survival (OS) and progression free survival (PFS). In vitro, H292 cells were tranfected with SIRT1 small interfering RNA (siRNA). The cell biological behaviors and chemosensitivity to cisplatin treatment were studied. The in vivo tumorgenesis and metastasis assays were performed in nude mice. Results: We found that the SIRT1 expressions were significantly associated with the tumor stage, tumor size and differentiation status. Patients with high SIRT 1 expressions had a significantly higher chance to be resistant to chemotherapy than those with low SIRT 1 expression. Patients with high expression of SIRT1 had significantly shorter OS and DFS than those with low expression. Cox analyses confirmed that the SIRT 1 expression was a strong predictor for a poor OS and PFS in NSCLC patients underwent Platinum-based chemotherapy. In vitro studies revealed that the reduced expression SIRT 1 by siRNA technique significantly inhibited cell proliferation, migration and invasion. More importantly, SIRT1 si-RNA significantly enhanced the chemosensitivity of H292 cells to cisplatin treatment. The in vivo tumorgenesis and metastasis assays showed that SIRT1 knockdown dramatically reduced the tumor volume and the metastatic ability in nude mice. Conclusion: Collectively, our data suggest that the SIRT1 expression may be a molecular marker associated with the NSLCLC clinical features, treatment responsiveness and prognosis of advanced NSCLC.	[Zhang, Tao; Zou, Chengwei; Zhu, Xiaolong; Zhang, Wenlong] Shandong Univ, Prov Hosp Affiliated, Dept Cardiovasc Surg, Jinan 250100, Shandong, Peoples R China; [Rong, Ningning] Shandong Prov Chest Hosp, Intens Care Unit, Jinan, Shandong, Peoples R China; [Chen, Juan] Jinan seventh peoples Hosp, Dept Cardiovasc Surg, Jinan, Shandong, Peoples R China; [Jing, Haiyan] Shandong Univ, Prov Hosp Affiliated, Dept Pathol, Jinan 250100, Shandong, Peoples R China	Shandong University; Shandong University; Shandong University	Zhang, WL (corresponding author), Shandong Univ, Prov Hosp Affiliated, Dept Cardiovasc Surg, Jinan 250100, Shandong, Peoples R China.	drwenlongzhang@sina.cn			Shandong University (QL) [1B-34]	Shandong University (QL)	This study was financially supported by a grant from Shandong University (QL-No. 1B-34). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Almeida GM, 2008, INT J CANCER, V122, P1810, DOI 10.1002/ijc.23188; Bae HJ, 2012, ONCOL LETT, V4, P873, DOI 10.3892/ol.2012.875; Brooks CL, 2009, AGING-US, V1, P278, DOI 10.18632/aging.100031; Brooks CL, 2009, NAT REV CANCER, V9, P123, DOI 10.1038/nrc2562; Chang CJ, 2009, BIOCHEM BIOPH RES CO, V380, P236, DOI 10.1016/j.bbrc.2009.01.040; Chen HC, 2012, ANN SURG ONCOL, V19, P2011, DOI 10.1245/s10434-011-2159-4; Chen WY, 2013, CURR OPIN HEMATOL, V20, P308, DOI 10.1097/MOH.0b013e328360ab64; Dai CX, 2013, ENDOCRINOLOGY, V154, P1247, DOI 10.1210/en.2012-1908; Firestein R, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002020; Fu MF, 2006, MOL CELL BIOL, V26, P8122, DOI 10.1128/MCB.00289-06; Fusco S, 2012, CELL CYCLE, V11, P4135, DOI 10.4161/cc.22074; Goldstraw Peter, 2007, J Thorac Oncol, V2, P706, DOI 10.1097/JTO.0b013e31812f3c1a; Gridelli C, 2002, TUMORI J, V88, pS143, DOI 10.1177/030089160208800142; Hildebrandt MAT, 2009, EXPERT OPIN DRUG MET, V5, P745, DOI 10.1517/17425250902973711; Huffman DM, 2007, CANCER RES, V67, P6612, DOI 10.1158/0008-5472.CAN-07-0085; Jang KY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045119; Kong SY, 2012, IMMUNOL CELL BIOL, V90, P6, DOI 10.1038/icb.2011.102; Kosmidis P, 2002, LUNG CANCER, V38, pS19; Kozako T, 2012, INT J CANCER, V131, P2044, DOI 10.1002/ijc.27481; Lee H, 2011, HUM PATHOL, V42, P204, DOI 10.1016/j.humpath.2010.05.023; Li XL, 2013, ACTA BIOCH BIOPH SIN, V45, P51, DOI 10.1093/abbs/gms108; Lovaas JD, 2013, PROSTATE, V73, P522, DOI 10.1002/pros.22592; Mantel C, 2008, CURR OPIN HEMATOL, V15, P326, DOI 10.1097/MOH.0b013e3283043819; Matsushita N, 2005, GENES CELLS, V10, P321, DOI 10.1111/j.1365-2443.2005.00836.x; Metoyer Cheynita F, 2008, Pathophysiology, V15, P103, DOI 10.1016/j.pathophys.2008.04.002; Oppenheimer H, 2012, ARTHRITIS RHEUM-US, V64, P718, DOI 10.1002/art.33407; Ota H, 2006, ONCOGENE, V25, P176, DOI 10.1038/sj.onc.1209049; REMMELE W, 1987, PATHOLOGE, V8, P138; Sauve AA, 2006, ANNU REV BIOCHEM, V75, P435, DOI 10.1146/annurev.biochem.74.082803.133500; Stuschke M, 2010, NAT REV CLIN ONCOL, V7, P613, DOI 10.1038/nrclinonc.2010.165; Subramaniam Sangeetha, 2013, J Carcinog, V12, P3, DOI 10.4103/1477-3163.107958; Sun YN, 2007, LUNG CANCER, V58, P21, DOI 10.1016/j.lungcan.2007.05.013; Sundaresan NR, 2011, J MOL CELL CARDIOL, V51, P614, DOI 10.1016/j.yjmcc.2011.01.008; Suzuki K, 2012, ONCOL REP, V27, P1726, DOI 10.3892/or.2012.1750; Tsim S, 2010, RESP MED, V104, P1767, DOI 10.1016/j.rmed.2010.08.005; Wang RH, 2008, CANCER CELL, V14, P312, DOI 10.1016/j.ccr.2008.09.001; Wu FL, 2012, CELL ONCOL, V35, P175, DOI 10.1007/s13402-012-0075-7; Wu MQ, 2012, MED ONCOL, V29, P3240, DOI 10.1007/s12032-012-0260-6; Xie YX, 2012, J RADIAT RES, V53, P44, DOI 10.1269/jrr.11062; Zhou C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063142; Zschoernig B, 2008, BIOCHEM BIOPH RES CO, V376, P251, DOI 10.1016/j.bbrc.2008.08.137	41	43	51	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 5	2013	8	11							e79162	10.1371/journal.pone.0079162	http://dx.doi.org/10.1371/journal.pone.0079162			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	247EE	24223900	gold, Green Published, Green Submitted			2023-01-03	WOS:000326597400050
J	Ruyra, A; Cano-Sarabia, M; MacKenzie, SA; Maspoch, D; Roher, N				Ruyra, Angels; Cano-Sarabia, Mary; MacKenzie, Simon A.; Maspoch, Daniel; Roher, Nerea			A Novel Liposome-Based Nanocarrier Loaded with an LPS-dsRNA Cocktail for Fish Innate Immune System Stimulation	PLOS ONE			English	Article							AEROMONAS-SALMONICIDA; ORAL IMMUNIZATION; VACCINE ADJUVANTS; DELIVERY-SYSTEMS; CATIONIC LIPIDS; EXPRESSION; RESPONSES; LIPOPOLYSACCHARIDE; RECOGNITION; MICROPARTICLES	Development of novel systems of vaccine delivery is a growing demand of the aquaculture industry. Nano- and microencapsulation systems are promising tools to achieve efficient vaccines against orphan vaccine fish diseases. In this context, the use of liposomal based-nanocarriers has been poorly explored in fish; although liposomal nanocarriers have successfully been used in other species. Here, we report a new similar to 125 nm-in-diameter unilamellar liposome-encapsulated immunostimulant cocktail containing crude lipopolysaccharide (LPS) from E. coli and polyinosinic: polycytidylic acid [ poly (I: C)], a synthetic analog of dsRNA virus, aiming to be used as a non-specific vaccine nanocarrier in different fish species. This liposomal carrier showed high encapsulation efficiencies and low toxicity not only in vitro using three different cellular models but also in vivo using zebrafish embryos and larvae. We showed that such liposomal LPS-dsRNA cocktail is able to enter into contact with zebrafish hepatocytes (ZFL cell line) and trout macrophage plasma membranes, being preferentially internalized through caveolae-dependent endocytosis, although clathrin-mediated endocytosis in ZFL cells and macropinocytocis in macrophages also contribute to liposome uptake. Importantly, we also demonstrated that this liposomal LPS-dsRNA cocktail elicits a specific pro-inflammatory and anti-viral response in both zebrafish hepatocytes and trout macrophages. The design of a unique delivery system with the ability to stimulate two potent innate immunity pathways virtually present in all fish species represents a completely new approach in fish health.	[Ruyra, Angels; MacKenzie, Simon A.; Roher, Nerea] Univ Autonoma Barcelona, Inst Biotecnol & Biomed, Parc Recerca UAB, E-08193 Barcelona, Spain; [Cano-Sarabia, Mary; Maspoch, Daniel] Inst Catala Nanociencia & Nanotecnol, ICN2, Barcelona, Spain; [Maspoch, Daniel] ICREA, Barcelona, Spain	Autonomous University of Barcelona; Barcelona Institute of Science & Technology; Catalan Institute of Nanoscience & Nanotechnology (ICN2); ICREA	Maspoch, D (corresponding author), Inst Catala Nanociencia & Nanotecnol, ICN2, Campus UAB, Barcelona, Spain.	daniel.maspoch@icn.cat; nerea.roher@uab.cat	MacKenzie, Simon/Q-2362-2019; Maspoch, Daniel/AFI-3557-2022; Cano-Sarabia, Mary/A-1648-2015; Maspoch, Daniel/AAF-3727-2022; Roher, Nerea/F-3216-2016; Maspoch, Daniel/O-9266-2015	MacKenzie, Simon/0000-0003-1845-6826; Cano-Sarabia, Mary/0000-0003-4254-8157; Roher, Nerea/0000-0002-6659-4038; Maspoch, Daniel/0000-0003-1325-9161	Fundacion Ramon Areces; Fundacio Amics de la Universitat Autonoma de Barcelona-Programa Aposta; Ministry of Industry and Competitiveness (Spain); ICREA Funding Source: Custom	Fundacion Ramon Areces; Fundacio Amics de la Universitat Autonoma de Barcelona-Programa Aposta; Ministry of Industry and Competitiveness (Spain); ICREA(ICREA)	This work was supported by the Fundacion Ramon Areces (2010) and the Fundacio Amics de la Universitat Autonoma de Barcelona-Programa Aposta (2011). NR wishes to thank the Ministry of Industry and Competitiveness (Spain) for the Ramon y Cajal grant. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ali S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021076; Balazs DA, 2011, J DRUG DELIV, V2011, DOI 10.1155/2011/326497; Bassity E, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033196; Bennett-Guerrero E, 2000, INFECT IMMUN, V68, P6202, DOI 10.1128/IAI.68.11.6202-6208.2000; Coffman RL, 2010, IMMUNITY, V33, P492, DOI 10.1016/j.immuni.2010.10.002; Donate C, 2007, FISH SHELLFISH IMMUN, V23, P877, DOI 10.1016/j.fsi.2007.03.016; Dow SW, 2008, EXPERT OPIN DRUG DEL, V5, P11, DOI 10.1517/17425247.5.1.11; Evensen O., 2009, Options Mediterraneennes. Serie A, Seminaires Mediterraneens, P177; Fent K, 2010, AQUAT TOXICOL, V100, P218, DOI 10.1016/j.aquatox.2010.02.019; Filion MC, 1997, BBA-BIOMEMBRANES, V1329, P345, DOI 10.1016/S0005-2736(97)00126-0; Fredriksen BN, 2012, VACCINE, V30, P656, DOI 10.1016/j.vaccine.2011.10.105; Galindo-Villegas J, 2012, P NATL ACAD SCI USA, V109, pE2605, DOI 10.1073/pnas.1209920109; George S, 2011, ACS NANO, V5, P1805, DOI 10.1021/nn102734s; Goetz FW, 2004, DEV COMP IMMUNOL, V28, P487, DOI 10.1016/j.dci.2003.09.008; Harper SL, 2011, ACS NANO, V5, P4688, DOI 10.1021/nn200546k; Iliev DB, 2005, FEBS LETT, V579, P6519, DOI 10.1016/j.febslet.2005.10.061; Irie T, 2005, FISH SHELLFISH IMMUN, V18, P235, DOI 10.1016/j.fsi.2004.07.006; Ivanov Andrei I., 2008, V440, P15, DOI 10.1007/978-1-59745-178-9_2; Jess TJ, 1996, CELL SIGNAL, V8, P297, DOI 10.1016/0898-6568(96)00054-X; Kasturi SP, 2011, NATURE, V470, P543, DOI 10.1038/nature09737; Khan M. A., 2011, Biology and Medicine, V3, P291; KLIBANOV AL, 1990, FEBS LETT, V268, P235, DOI 10.1016/0014-5793(90)81016-H; Lee KJ, 2007, ACS NANO, V1, P133, DOI 10.1021/nn700048y; Lieschke GJ, 2009, CURR BIOL, V19, pR678, DOI 10.1016/j.cub.2009.06.068; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lonez C, 2012, ADV DRUG DELIVER REV, V64, P1749, DOI 10.1016/j.addr.2012.05.009; MacKenzie S, 2003, DEV COMP IMMUNOL, V27, P393, DOI 10.1016/S0145-305X(02)00135-0; MacKenzie SA, 2010, MOL IMMUNOL, V47, P1450, DOI 10.1016/j.molimm.2010.02.009; Milla P, 2012, CURR DRUG METAB, V13, P105, DOI 10.2174/138920012798356934; Moghimi SM, 2011, ACS NANO, V5, P8454, DOI 10.1021/nn2038252; Nakhla Anthony N., 1996, Journal of Liposome Research, V6, P141, DOI 10.3109/08982109609037209; Nordly P, 2009, EXPERT OPIN DRUG DEL, V6, P657, DOI 10.1517/17425240903018863; Palti Y, 2011, DEV COMP IMMUNOL, V35, P1263, DOI 10.1016/j.dci.2011.03.006; Peterson RT, 2012, ANNU REV PHARMACOL, V52, P433, DOI 10.1146/annurev-pharmtox-010611-134751; PUYAL C, 1995, EUR J BIOCHEM, V228, P697, DOI 10.1111/j.1432-1033.1995.0697m.x; Rodrigues AP, 2006, PROCESS BIOCHEM, V41, P638, DOI 10.1016/j.procbio.2005.08.010; Roher N, 2011, INNATE IMMUN-LONDON, V17, P16, DOI 10.1177/1753425909348232; Sepulcre MP, 2009, J IMMUNOL, V182, P1836, DOI 10.4049/jimmunol.0801755; Sommerset I, 2005, EXPERT REV VACCINES, V4, P89, DOI 10.1586/14760584.4.1.89; Takano S, 2003, PHARMACEUT RES, V20, P962, DOI 10.1023/A:1024441702398; Takeuchi O, 2010, CELL, V140, P805, DOI 10.1016/j.cell.2010.01.022; Thim HL, 2012, VACCINE, V30, P4828, DOI 10.1016/j.vaccine.2012.05.010; Tian JY, 2008, VET IMMUNOL IMMUNOP, V126, P220, DOI 10.1016/j.vetimm.2008.07.002; Wang KY, 2011, AFR J BIOTECHNOL, V10, P2751; Wang WL, 2011, FISH SHELLFISH IMMUN, V31, P10, DOI 10.1016/j.fsi.2011.01.015; Watson DS, 2012, VACCINE, V30, P2256, DOI 10.1016/j.vaccine.2012.01.070; Whyte SK, 2007, FISH SHELLFISH IMMUN, V23, P1127, DOI 10.1016/j.fsi.2007.06.005; Wieber A, 2011, INT J PHARMACEUT, V421, P151, DOI 10.1016/j.ijpharm.2011.09.011; Zhu LY, 2013, DEV COMP IMMUNOL, V39, P39, DOI 10.1016/j.dci.2012.04.001	49	32	33	3	61	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 18	2013	8	10							e76338	10.1371/journal.pone.0076338	http://dx.doi.org/10.1371/journal.pone.0076338			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	239MM	24204616	gold, Green Published, Green Submitted			2023-01-03	WOS:000326029300023
J	Lipsitz, LA				Lipsitz, Lewis A.			The 3-Night Hospital Stay and Medicare Coverage for Skilled Nursing Care	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Lipsitz, Lewis A.] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Hebrew SeniorLife, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Hebrew SeniorLife	Lipsitz, LA (corresponding author), Hebrew SeniorLife Inst Aging Res, 1200 Ctr St, Boston, MA 02131 USA.	lipsitz@hsl.harvard.edu						AARONSON WE, 1994, J HEALTH POLIT POLIC, V19, P753; Birmingham J, 2008, PROF CASE MANAG, V13, P7; Medicare Payment Advisory Commission (MEDPAC), 2013, REPORT TO CONGRESS M; Medicare Payment Advisory Commission (MEDPAC), 2010, REPORT TO CONGRESS A; Segal M., 2011, ELIGIBLE BENEFICIARI	5	16	16	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 9	2013	310	14					1441	1442		10.1001/jama.2013.254845	http://dx.doi.org/10.1001/jama.2013.254845			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	230PK	24042212				2023-01-03	WOS:000325354100014
J	Almaca, J; Faria, D; Sousa, M; Uliyakina, I; Conrad, C; Sirianant, L; Clarke, LA; Martins, JP; Santos, M; Heriche, JK; Huber, W; Schreiber, R; Pepperkok, R; Kunzelmann, K; Amaral, MD				Almaca, Joana; Faria, Diana; Sousa, Marisa; Uliyakina, Inna; Conrad, Christian; Sirianant, Lalida; Clarke, Luka A.; Martins, Jose Paulo; Santos, Miguel; Heriche, Jean-Karim; Huber, Wolfgang; Schreiber, Rainer; Pepperkok, Rainer; Kunzelmann, Karl; Amaral, Margarida D.			High-Content siRNA Screen Reveals Global ENaC Regulators and Potential Cystic Fibrosis Therapy Targets	CELL			English	Article							EPITHELIAL SODIUM-CHANNEL; TRANSMEMBRANE CONDUCTANCE REGULATOR; NA+ CHANNEL; LUNG-DISEASE; ION CHANNELS; HUMAN GENOME; CFTR; TRANSPORT; AMILORIDE; CELLS	Dysfunction of ENaC, the epithelial sodium channel that regulates salt and water reabsorption in epithelia, causes several human diseases, including cystic fibrosis (CF). To develop a global understanding of molecular regulators of ENaC traffic/function and to identify of candidate CF drug targets, we performed a large-scale screen combining high-content live-cell microscopy and siRNAs in human airway epithelial cells. Screening over 6,000 genes identified over 1,500 candidates, evenly divided between channel inhibitors and activators. Genes in the phosphatidylinositol pathway were enriched on the primary candidate list, and these, along with other ENaC activators, were examined further with secondary siRNA validation. Subsequent detailed investigation revealed ciliary neurotrophic factor receptor (CNTFR) as an ENaC modulator and showed that inhibition of (diacylglycerol kinase, iota) DGKi, a protein involved in PiP2 metabolism, downgrades ENaC activity, leading to normalization of both Na+ and fluid absorption in CF airways to non-CF levels in primary human lung cells from CF patients.	[Almaca, Joana; Faria, Diana; Sousa, Marisa; Uliyakina, Inna; Clarke, Luka A.; Amaral, Margarida D.] Univ Lisbon, Fac Sci, BioFIG Ctr Biodivers Funct & Integrat Genom, P-1749016 Lisbon, Portugal; [Faria, Diana; Sirianant, Lalida; Schreiber, Rainer; Kunzelmann, Karl] Univ Regensburg, Dept Physiol, D-93053 Regensburg, Germany; [Conrad, Christian; Heriche, Jean-Karim; Huber, Wolfgang; Pepperkok, Rainer] EMBL, Cell Biol Biophys Unit, D-69117 Heidelberg, Germany; [Martins, Jose Paulo; Santos, Miguel] EcBio R&D Biotechnol SA, P-2700451 Amadora, Portugal	Universidade de Lisboa; University of Regensburg; European Molecular Biology Laboratory (EMBL)	Amaral, MD (corresponding author), Univ Lisbon, Fac Sci, BioFIG Ctr Biodivers Funct & Integrat Genom, C8 Bdg, P-1749016 Lisbon, Portugal.	mdamaral@fc.ul.pt	Martins, Paulo/P-5735-2014; Clarke, Luka A/E-5843-2012; Santos, Jorge Miguel/B-9967-2018; Amaral, Margarida D/E-5748-2012	Martins, Paulo/0000-0002-2360-403X; Clarke, Luka A/0000-0003-3254-9121; Santos, Jorge Miguel/0000-0002-9432-3171; Amaral, Margarida D/0000-0002-0828-8630; Uliyakina, Inna/0000-0002-7091-2123; Faria, Diana/0000-0002-9861-0282; Almaca, Joana/0000-0002-9316-712X; Pepperkok, Rainer/0000-0002-9762-3583; Heriche, Jean-Karim/0000-0001-6867-9425; SOUSA, MARISA/0000-0003-2305-4813; Kunzelmann, Karl/0000-0002-4583-7037; Huber, Wolfgang/0000-0002-0474-2218	EU [LSH-2005-1.2.5-3-037365, PEst-OE/BIA/UI4046/2011, FCT/POCTI-PTDC/SAU-GMG/122299/2010]	EU(European Commission)	This work was supported by EU-grant TargetScreen2 (LSH-2005-1.2.5-3-037365), strategic grant PEst-OE/BIA/UI4046/2011 (BioFIG), and FCT/POCTI-PTDC/SAU-GMG/122299/2010; DFG SFB699 A6; Vs. 28.12.2010. J.A., D. F., M. S., and I. U. were recipients of PhD fellowships SFRH/BD/29134/2006, SFRH/BD/43313/2008, SFRH/BD/35936/2007, and SFRH/BD/69180/2010, respectively, from FCT, Portugal. We acknowledge the scientific support of Drs. Beate Neumann and Thomas Walter as well as the expert technical assistance by Miriam Reiss, Jutta Bulkescher, Brigitte Joggerst-Thomalla, Marta Palma, Tze Heng, and Volker Hilsenstein, assistance with with microscope programming by Siegfrid Winkler, and data analysis by the electronic workshop from EMBL, Heidelberg. The authors are grateful to Professor J. Fragata and his team at the Cardio-Thoracic Surgery Department of the Hospital de Santa Marta (Lisboa) for access to explanted lungs from CF patients, to Professor Jens Leipziger (Aarhus University, Denmark) for critically revising the manuscript, and to Dr. Michael Gray (Newcastle University, UK) for comments. R. P., K. K., and M. D. A. designed the study; J. A., D. F., M. S., I. U., L. S., L. A. C., J. P. M., and M. S. performed experiments and generated data; J. A., D. F., M. S., I. U., L. S., L. A. C., J.-K. H., C. C., W. H., and R. S. analyzed data; L. A. C., C. C., R. S., R. P., K. K., and M. D. A. interpreted data; J. A., K. K., and M. D. A. wrote the article; R. P., K. K., and M. D. A. revised the article; R. P., K. K., and M. D. A. obtained funding. All authors approved the final manuscript.	Almaca J, 2011, METHODS MOL BIOL, V742, P249, DOI 10.1007/978-1-61779-120-8_15; Althaus M, 2011, PULM MED, V2011, DOI 10.1155/2011/830320; Amaral MD, 2007, TRENDS PHARMACOL SCI, V28, P334, DOI 10.1016/j.tips.2007.05.004; Bonny O, 2000, KIDNEY INT, V57, P1313, DOI 10.1046/j.1523-1755.2000.00968.x; BOUCHER RC, 1988, J PHYSIOL-LONDON, V405, P77, DOI 10.1113/jphysiol.1988.sp017322; Boucher RC, 2007, TRENDS MOL MED, V13, P231, DOI 10.1016/j.molmed.2007.05.001; Bryant DM, 2008, NAT REV MOL CELL BIO, V9, P887, DOI 10.1038/nrm2523; Butterworth MB, 2009, AM J PHYSIOL-RENAL, V296, pF10, DOI 10.1152/ajprenal.90248.2008; CANESSA CM, 1994, NATURE, V367, P463, DOI 10.1038/367463a0; Carbon S, 2009, BIOINFORMATICS, V25, P288, DOI 10.1093/bioinformatics/btn615; Chen JH, 2010, CELL, V143, P911, DOI 10.1016/j.cell.2010.11.029; Chung NJ, 2008, J BIOMOL SCREEN, V13, P149, DOI 10.1177/1087057107312035; Clarke LA, 2013, RESP RES, V14, DOI 10.1186/1465-9921-14-38; Clunes LA, 2012, FASEB J, V26, P533, DOI 10.1096/fj.11-192377; Debonneville C, 2001, EMBO J, V20, P7052, DOI 10.1093/emboj/20.24.7052; Donaldson SH, 2007, CHEST, V132, P1631, DOI 10.1378/chest.07-0288; Donaldson SH, 2006, NEW ENGL J MED, V354, P241, DOI 10.1056/NEJMoa043891; Erfle H, 2007, NAT PROTOC, V2, P392, DOI 10.1038/nprot.2006.483; Filigheddu N, 2011, CELL SIGNAL, V23, P1988, DOI 10.1016/j.cellsig.2011.07.009; Gaillard EA, 2010, PFLUG ARCH EUR J PHY, V460, P1, DOI 10.1007/s00424-010-0827-z; Galvez-Santisteban M, 2012, NAT CELL BIOL, V14, P838, DOI 10.1038/ncb2541; Gentzsch M, 2010, J BIOL CHEM, V285, P32227, DOI 10.1074/jbc.M110.155259; Hirsh AJ, 2006, J MED CHEM, V49, P4098, DOI 10.1021/jm051134w; Holden NJ, 2011, MOL MED, V17, P1242, DOI 10.2119/molmed.2011.00028; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Itani OA, 2002, AM J PHYSIOL-LUNG C, V282, pL631, DOI 10.1152/ajplung.00085.2001; Ji HL, 2006, J BIOL CHEM, V281, P8233, DOI 10.1074/jbc.M512293200; Kimura T, 2011, P NATL ACAD SCI USA, V108, P3216, DOI 10.1073/pnas.1010334108; KNOWLES MR, 1990, NEW ENGL J MED, V322, P1189, DOI 10.1056/NEJM199004263221704; Koehl GE, 2010, ONCOGENE, V29, P1553, DOI 10.1038/onc.2009.435; Kunzelmann K, 2004, FASEB J, V18, P142, DOI 10.1096/fj.04-2314fje; KUNZELMANN K, 1995, PFLUG ARCH EUR J PHY, V431, P1, DOI 10.1007/BF00374371; Kunzelmann K, 2012, INT J BIOCHEM CELL B, V44, P1232, DOI 10.1016/j.biocel.2012.04.012; Lifton RP, 2001, CELL, V104, P545, DOI 10.1016/S0092-8674(01)00241-0; Lu M, 2010, J AM SOC NEPHROL, V21, P811, DOI 10.1681/ASN.2009111168; Mall M, 2004, NAT MED, V10, P487, DOI 10.1038/nm1028; Mall M, 1998, J CLIN INVEST, V102, P15, DOI 10.1172/JCI2729; Marumo M, 2012, J PHARM PHARMACOL, V64, P855, DOI 10.1111/j.2042-7158.2012.01485.x; Moniz S, 2013, ACS CHEM BIOL, V8, P432, DOI 10.1021/cb300484r; Neumann B, 2010, NATURE, V464, P721, DOI 10.1038/nature08869; OBRODOVICH H, 1991, AM J PHYSIOL, V261, pC555, DOI 10.1152/ajpcell.1991.261.4.C555; Ogilvie V, 2011, GENOMICS, V98, P327, DOI 10.1016/j.ygeno.2011.06.008; Otulakowski G, 2007, AM J RESP CELL MOL, V37, P457, DOI 10.1165/rcmb.2007-0055OC; Ousingsawat J, 2008, PFLUG ARCH EUR J PHY, V456, P847, DOI 10.1007/s00424-008-0451-3; Pochynyuk O, 2008, CURR OPIN NEPHROL HY, V17, P533, DOI 10.1097/MNH.0b013e328308fff3; Pochynyuk O, 2007, J GEN PHYSIOL, V130, P399, DOI 10.1085/jgp.200709800; Riordan JR, 2008, ANNU REV BIOCHEM, V77, P701, DOI 10.1146/annurev.biochem.75.103004.142532; Ritzerfeld J, 2011, GENOME RES, V21, P1955, DOI 10.1101/gr.116087.110; Ross AJ, 2007, AM J RESP CELL MOL, V37, P169, DOI 10.1165/rcmb.2006-0466OC; Ruffieux-Daidie D, 2008, J AM SOC NEPHROL, V19, P2170, DOI 10.1681/ASN.2007101130; Simpson JC, 2012, NAT CELL BIOL, V14, P764, DOI 10.1038/ncb2510; SNOUWAERT JN, 1992, SCIENCE, V257, P1083, DOI 10.1126/science.257.5073.1083; Staub O, 1997, EMBO J, V16, P6325, DOI 10.1093/emboj/16.21.6325; Stockando JD, 2000, J BIOL CHEM, V275, P25760, DOI 10.1074/jbc.M003615200; Wang XD, 2006, CELL, V127, P803, DOI 10.1016/j.cell.2006.09.043; Yokogami K, 2000, CURR BIOL, V10, P47, DOI 10.1016/S0960-9822(99)00268-7; Yue G, 2002, J BIOL CHEM, V277, P11965, DOI 10.1074/jbc.M108951200	57	42	43	0	30	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 12	2013	154	6					1390	1400		10.1016/j.cell.2013.08.045	http://dx.doi.org/10.1016/j.cell.2013.08.045			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	215VQ	24034256	Bronze			2023-01-03	WOS:000324239300025
J	Meyer, JP; McAvoy, KE; Jiang, J				Meyer, Jacob P.; McAvoy, Kieran E.; Jiang, Jack			Rehydration Capacities and Rates for Various Porcine Tissues after Dehydration	PLOS ONE			English	Article							HUMAN PATELLAR TENDON; VOCAL FOLD TISSUES; WATER-CONTENT; ARTICULAR-CARTILAGE; STRESS-RELAXATION; HYDRATION; COMPRESSION; BEHAVIOR; LIGAMENT; CREEP	The biphasic effects of liquid on tissue biomechanics are well known in cartilage and vocal folds, yet not extensively in other tissue types. Past studies have shown that tissue dehydration significantly impacts biomechanical properties and that rehydration can restore these properties in certain tissue types. However, these studies failed to consider how temporal exposure to dehydrating or rehydrating agents may alter tissue rehydration capacity, as overexposure to dehydration may permanently prevent rehydration to the initial liquid volume. Select porcine tissues were dehydrated until they reached between 100% and 40% of their initial mass. Each sample was allowed to rehydrate for 5 hours in a 0.9% saline solution, and the percent change between the initial and rehydrated mass values was calculated. Spearman correlation tests indicated a greater loss in mass despite rehydration when tissues were previously exposed to greater levels of dehydration. Additionally, Pearson correlation tests indicated the total liquid mass of samples after complete rehydration decreased when previously exposed to higher levels of dehydration. Rehydration rates were found by dehydrating tissues to 40% of their initial mass followed by rehydration in a 0.9% saline solution for 60 minutes, with mass measurements occurring in 15 minute intervals. All tissues rehydrated nonlinearly, most increasing significantly in mass up to 30 minutes after initial soaking. This study suggests the ability for tissues to rehydrate is dependent on the level of initial dehydration exposure. In vitro rehydration experiments therefore require controlled dosage and temporal exposure to dehydrating and rehydrating agents to avoid incomplete rehydration, and caution should be taken when combining different tissue types in models of hydration.	[Meyer, Jacob P.; McAvoy, Kieran E.; Jiang, Jack] Univ Wisconsin, Sch Med & Publ Hlth, Dept Surg, Div Otolaryngol Head & Neck Surg, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Jiang, J (corresponding author), Univ Wisconsin, Sch Med & Publ Hlth, Dept Surg, Div Otolaryngol Head & Neck Surg, Madison, WI 53706 USA.	jjjiang@wisc.edu		Jiang, Jack J./0000-0002-3070-4952	NIH from the National Institute on Deafness and other Communicative Disorders [R01 DC05522]; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC005522] Funding Source: NIH RePORTER	NIH from the National Institute on Deafness and other Communicative Disorders; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))	This study was funded by NIH grant number R01 DC05522 from the National Institute on Deafness and other Communicative Disorders. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ARMSTRONG CG, 1982, J BONE JOINT SURG AM, V64, P88, DOI 10.2106/00004623-198264010-00013; Atkinson TS, 1999, J BIOMECH, V32, P907, DOI 10.1016/S0021-9290(99)00089-5; Chan RW, 2003, ANN BIOMED ENG, V31, P482, DOI 10.1114/1.1561287; Chan RW, 2002, OTOLARYNG HEAD NECK, V126, P528, DOI 10.1067/mhn.2002.124936; CHIMICH D, 1992, J BIOMECH, V25, P831, DOI 10.1016/0021-9290(92)90223-N; HAJI T, 1992, ACTA OTO-LARYNGOL, V112, P151, DOI 10.3109/00016489209100797; Hanson KP, 2011, J VOICE, V25, P657, DOI 10.1016/j.jvoice.2010.06.005; Haut TL, 1997, J BIOMECH, V30, P79, DOI 10.1016/S0021-9290(96)00108-X; Hendriks FM, 2004, SKIN RES TECHNOL, V10, P231, DOI 10.1111/j.1600-0846.2004.00077.x; Hoffman AH, 2005, J BIOMECH, V38, P1636, DOI 10.1016/j.jbiomech.2004.07.032; MOW VC, 1980, J BIOMECH ENG-T ASME, V102, P73, DOI 10.1115/1.3138202; Soltz MA, 1998, J BIOMECH, V31, P927, DOI 10.1016/S0021-9290(98)00105-5; Thornton GM, 2001, J ORTHOPAED RES, V19, P845, DOI 10.1016/S0736-0266(01)00005-5; Vargas O, 1999, LASER SURG MED, V24, P133	14	6	6	1	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 4	2013	8	9							e72573	10.1371/journal.pone.0072573	http://dx.doi.org/10.1371/journal.pone.0072573			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	219OE	24023753	gold, Green Published, Green Submitted			2023-01-03	WOS:000324515600031
J	Csupor, D; Boros, K; Hohmann, J				Csupor, Dezso; Boros, Klara; Hohmann, Judit			Low Potency Homeopathic Remedies and Allopathic Herbal Medicines: Is There an Overlap?	PLOS ONE			English	Article							VITEX-AGNUS-CASTUS; PREMENSTRUAL-SYNDROME; CYCLICAL MASTALGIA; EXTRACTS	Classical homeopathy is based on the therapeutic application of highly diluted homeopathic stocks. The indications of such medicines are determined by proving, i.e. by applying the remedies in healthy subjects. However, there are several complex homeopathic medicinal products on the market with approved therapeutic indications. The efficacy of these medicines has been assessed in clinical trials on patients. There is no upper limit of dosing for such homeopathic remedies, and these products often contain undiluted mother tincture. The aim of our study was to compare an allopathic herbal medicine and a homeopathic product containing undiluted mother tincture based on the same plant. Two products (an allopathic herbal medicine and a homeopathic product) containing Vitex agnus-castus extract were analyzed by HPLC-DAD for their agnuside and casticin contents. The agnuside content of the allopathic product was approximately four times higher, while the amount of casticin was in the same order of magnitude. Our experiments revealed the presence of active ingredients in allopathic quantity in a homeopathic preparation, highlighting the controversy between the principles of classical and practice of contemporary homeopathy. According to the principles of classical homeopathy these remedies cannot be considered as homeopathic remedies but rather as (allopathic) herbal ones. This phenomenon necessitates a case-by-case approach towards the possible adverse effects and drug interactions of homeopathics in the daily medical practice. Homeopathic products containing active agents in allopathic doses should be treated the same way as allopathic medicines from the point of view of quality assurance and pharmacovigilance.	[Csupor, Dezso; Boros, Klara; Hohmann, Judit] Univ Szeged, Dept Pharmacognosy, Szeged, Hungary	Szeged University	Csupor, D (corresponding author), Univ Szeged, Dept Pharmacognosy, Szeged, Hungary.	csupor.dezso@pharmacognosy.hu	Csupor, Dezső/ABE-1830-2021	Csupor, Dezső/0000-0002-4088-3333; Hohmann, Judit/0000-0002-2887-6392	New Hungary Development Plan projects [TAMOP-4.2.2.A-11/1/KONV-2012-0047, TAMOP-4.2.2.A-11/1/KONV-2012-0035]	New Hungary Development Plan projects	This work was supported by the New Hungary Development Plan projects TAMOP-4.2.2.A-11/1/KONV-2012-0047 and TAMOP-4.2.2.A-11/1/KONV-2012-0035. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2009, ALTERN MED REV, V14, P67; Falch B, 2003, THERAPIEWOCHE, V19, P287; Hajdu Z, 2007, PHYTOTHER RES, V21, P391, DOI 10.1002/ptr.2021; Halaska M, 1999, BREAST, V8, P175, DOI 10.1054/brst.1999.0039; He Z, 2009, MATURITAS, V63, P99, DOI 10.1016/j.maturitas.2009.01.006; Jutte R, 2005, COMPLEMENT THER MED, V13, P291, DOI 10.1016/j.ctim.2005.10.003; Kayne SB., 2006, HOMEOPATHIC PHARM TH; Meier B, 2000, PHYTOMEDICINE, V7, P373, DOI 10.1016/S0944-7113(00)80058-6; Schellenberg R, 2001, BRIT MED J, V322, P134, DOI 10.1136/bmj.322.7279.134; Sharma A, 2012, J ANAL METHODS CHEM, V2012, DOI 10.1155/2012/109058; Sharma A, 2010, MED CHEM RES, V19, P643, DOI 10.1007/s00044-009-9219-3; van Die MD, 2009, J ALTERN COMPLEM MED, V15, P853, DOI 10.1089/acm.2008.0447; Webster DE, 2006, J ETHNOPHARMACOL, V106, P216, DOI 10.1016/j.jep.2005.12.025; Webster DE, 2011, BIOCHEM PHARMACOL, V81, P170, DOI 10.1016/j.bcp.2010.09.013; Wuttke W, 2003, PHYTOMEDICINE, V10, P348, DOI 10.1078/094471103322004866; Wuttke W, 1997, GEBURTSH FRAUENHEILK, V57, P569, DOI 10.1055/s-2007-1023139	16	7	7	0	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 3	2013	8	9							e74181	10.1371/journal.pone.0074181	http://dx.doi.org/10.1371/journal.pone.0074181			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	217DY	24019954	Green Submitted, gold, Green Published			2023-01-03	WOS:000324338200097
J	Lai, YC; Ruan, SY; Huang, CT; Kuo, PH; Yu, CJ				Lai, Yi-Chun; Ruan, Sheng-Yuan; Huang, Chun-Ta; Kuo, Ping-Hung; Yu, Chong-Jen			Hemoglobin Levels and Weaning Outcome of Mechanical Ventilation in Difficult-To-Wean Patients: A Retrospective Cohort Study	PLOS ONE			English	Article							BLOOD-TRANSFUSION; CRITICALLY-ILL; ANEMIA	Introduction: The effect of hemoglobin levels on the weaning outcomes of mechanically ventilated patients remains under debate, particularly for the patients with difficult weaning. This study aims to evaluate the effect of hemoglobin levels on weaning outcomes in difficult-to-wean patients. Methods: This retrospective cohort study was conducted in a university-affiliated teaching hospital in Taiwan. Patients who fulfilled the criteria of difficult weaning were enrolled. Medical records were reviewed to obtain data on hemograms, biochemistry tests, transfusion records, comorbidities and weaning outcome. The association between hemoglobin levels and 30-day weaning outcomes was evaluated using a logistic regression model. Results: A total of 751 patients received mechanical ventilation during the study period, 138 of whom fulfilled the criteria of difficult weaning. Compared with the patients whose hemoglobin was <8 g/dL, those with higher hemoglobin levels were more likely to be successfully weaned (odds ratio [OR], 3.69; 95% CI, 1.22-11.15 for hemoglobin 8-10 g/dL and OR, 4.16, 95% CI, 1.30-13.29 for hemoglobin >10 g/dL). Multivariate analysis showed that the odds ratio for weaning success remained significant for hemoglobin levels of 8-10 g/dL (adjusted OR, 3.3; 95% CI, 1.07-10.15) with borderline significance for hemoglobin level > 10 g/dL (adjusted OR, 2.95, 95% CI, 0.88-9.96). Conclusions: Hemoglobin level is independently associated with weaning outcome in difficult-to-wean patients. Further studies are needed to evaluate whether a restrictive transfusion trigger for acute critical illness is also appropriate for such patients.	[Lai, Yi-Chun; Ruan, Sheng-Yuan; Huang, Chun-Ta; Kuo, Ping-Hung; Yu, Chong-Jen] Natl Taiwan Univ Hosp, Dept Internal Med, Taipei 100, Taiwan; [Lai, Yi-Chun] Natl Yang Ming Univ Hosp, Dept Med, Taipei, Taiwan; [Lai, Yi-Chun] Sch Med, Taipei, Taiwan; [Ruan, Sheng-Yuan] Natl Taiwan Univ, Grad Inst Epidemiol & Prevent Med, Taipei 10764, Taiwan; [Huang, Chun-Ta] Natl Taiwan Univ Hosp, Dept Traumatol, Taipei, Taiwan	National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University; National Taiwan University Hospital	Ruan, SY (corresponding author), Natl Taiwan Univ Hosp, Dept Internal Med, Taipei 100, Taiwan.	syruan@ntu.edu.tw		HUANG, CHUN-TA/0000-0002-5234-4986; RUAN, SHENG-YUAN/0000-0002-7949-7253; KUO, PING-HUNG/0000-0003-3756-3395; Yu, Chong-Jen/0000-0001-5664-9392	National Taiwan University Hospital Yun-Lin Branch [NTUHYL 97.N008]	National Taiwan University Hospital Yun-Lin Branch	This study was supported by a grant from the National Taiwan University Hospital Yun-Lin Branch (NTUHYL 97.N008). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Boles JM, 2007, EUR RESPIR J, V29, P1033, DOI 10.1183/09031936.00010206; Dellinger R. P., 2013, INTENS CARE MED, V41, P580, DOI [DOI 10.1007/s00134-012-2769-8, 10.1007/s00134-012-2769-8]; Estenssoro E, 2005, CHEST, V127, P598, DOI 10.1378/chest.127.2.598; Hebert PC, 2007, CHEST, V131, P1583, DOI 10.1378/chest.06-1055; Hebert PC, 1999, NEW ENGL J MED, V340, P409, DOI 10.1056/NEJM199902113400601; Hebert PC, 2001, CHEST, V119, P1850, DOI 10.1378/chest.119.6.1850; Khamiees M, 2001, CHEST, V120, P1262, DOI 10.1378/chest.120.4.1262; Leach RM, 2002, THORAX, V57, P170, DOI 10.1136/thorax.57.2.170; MacIntyre NR, 2001, CHEST, V120, p375S, DOI 10.1378/chest.120.6_suppl.375S; Marik PE, 2008, CRIT CARE MED, V36, P2667, DOI 10.1097/CCM.0b013e3181844677; Ouellette DR, 2005, CHEST, V128, p576S, DOI 10.1378/chest.128.5_suppl_2.576S; Ruan SY, 2013, ANAESTH INTENS CARE, V41, P41, DOI 10.1177/0310057X1304100108; Schonhofer B, 1998, ANAESTHESIA, V53, P181, DOI 10.1046/j.1365-2044.1998.00275.x; Schonhofer B, 1998, CRIT CARE MED, V26, P1824, DOI 10.1097/00003246-199811000-00022; Silver MR, 2005, CHEST, V128, p568S, DOI 10.1378/chest.128.5_suppl_2.568S; Tinmouth A, 2006, TRANSFUSION, V46, P2014, DOI 10.1111/j.1537-2995.2006.01026.x; Vamvakas EC, 2001, TRANSFUSION, V41, P691, DOI 10.1046/j.1537-2995.2001.41050691.x; Vamvakas EC, 2007, BLOOD REV, V21, P327, DOI 10.1016/j.blre.2007.07.003; Vincent JL, 2002, JAMA-J AM MED ASSOC, V288, P1499, DOI 10.1001/jama.288.12.1499; Weiss G, 2005, NEW ENGL J MED, V352, P1011, DOI 10.1056/NEJMra041809	20	22	22	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 28	2013	8	8							e73743	10.1371/journal.pone.0073743	http://dx.doi.org/10.1371/journal.pone.0073743			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	209DG	24015310	Green Published, Green Submitted, gold			2023-01-03	WOS:000323733800105
J	McWilliams, JM; Landon, BE; Chernew, ME				McWilliams, J. Michael; Landon, Bruce E.; Chernew, Michael E.			Changes in Health Care Spending and Quality for Medicare Beneficiaries Associated With a Commercial ACO Contract	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ALTERNATIVE QUALITY; MASSACHUSETTS; COSTS	IMPORTANCE In a multipayer system, new payment incentives implemented by one insurer for an accountable care organization (ACO) may also affect spending and quality of care for another insurer's enrollees served by the ACO. Such spillover effects reflect the extent of organizational efforts to reform care delivery and can contribute to the net impact of ACOs. OBJECTIVE We examined whether the Blue Cross Blue Shield (BCBS) of Massachusetts' Alternative Quality Contract (AQC), an early commercial ACO initiative associated with reduced spending and improved quality for BCBS enrollees, was also associated with changes in spending and quality for Medicare beneficiaries, who were not covered by the AQC. DESIGN, SETTING, AND PARTICIPANTS Quasi-experimental comparisons from 2007-2010 of elderly fee-for-service Medicare beneficiaries in Massachusetts (1 761 325 person-years) served by 11 provider organizations entering the AQC in 2009 or 2010 (intervention group) vs beneficiaries served by other providers (control group). Using a difference-in-differences approach, we estimated changes in spending and quality for the intervention group in the first and second years of exposure to the AQC relative to concurrent changes for the control group. Regression and propensity score methods were used to adjust for differences in sociodemographic and clinical characteristics. MAIN OUTCOMES AND MEASURES The primary outcome was total quarterly medical spending per beneficiary. Secondary outcomes included spending by setting and type of service, 5 process measures of quality, potentially avoidable hospitalizations, and 30-day readmissions. RESULTS Before entering the AQC, total quarterly spending per beneficiary for the intervention group was $150 (95% CI, $25-$274) higher than for the control group and increased at a similar rate. In year 2 of the intervention group's exposure to the AQC, this difference was reduced to $51 (95% CI, -$109 to $210; P = .53), constituting a significant differential change of -$99 (95% CI, -$183 to -$16; P = .02) or a 3.4% savings relative to an expected quarterly mean of $2895. Savings in year 1 were not significant (differential change, -$34; 95% CI, -$83 to $16; P = .18). Year 2 savings derived largely from lower spending on outpatient care (differential change, -$73; 95% CI, -$97 to -$50; P < .001), particularly for beneficiaries with 5 or more conditions, and included significant differential changes in spending on procedures, imaging, and tests. Annual rates of low-density lipoprotein cholesterol testing differentially improved for beneficiaries with diabetes in the intervention group by 3.1 percentage points (95% CI, 1.4-4.8 percentage points; P < .001) and for those with cardiovascular disease by 2.5 percentage points (95% CI, 1.1-4.0 percentage points; P < .001), but performance on other quality measures did not differentially change. CONCLUSIONS AND RELEVANCE The AQC was associated with lower spending for Medicare beneficiaries but not with consistently improved quality. Savings among Medicare beneficiaries and previously demonstrated savings among BCBS enrollees varied similarly across settings, services, and time, suggesting that organizational responses were associated with broad changes in patient care.	[McWilliams, J. Michael; Landon, Bruce E.; Chernew, Michael E.] Harvard Univ, Sch Med, Dept Hlth Care Policy, Boston, MA 02115 USA; [McWilliams, J. Michael] Brigham & Womens Hosp, Dept Med, Div Gen Internal Med & Primary Care, Boston, MA 02115 USA; [McWilliams, J. Michael] Harvard Univ, Sch Med, Boston, MA 02115 USA; [Landon, Bruce E.] Beth Israel Deaconess Med Ctr, Dept Med, Div Gen Internal Med & Primary Care, Boston, MA 02215 USA	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center	McWilliams, JM (corresponding author), Harvard Univ, Sch Med, Dept Hlth Care Policy, 180 Longwood Ave, Boston, MA 02115 USA.	mcwilliams@hcp.med.harvard.edu			Beeson Career Development Award Program (National Institute on Aging) [K08 AG038354]; Beeson Career Development Award Program (American Federation for Aging Research); Doris Duke Charitable Foundation (Clinical Scientist Development Award) [2010053]; National Institute on Aging [P01 AG032952]; Commonwealth Fund [20110391]; NATIONAL INSTITUTE ON AGING [K08AG038354, P01AG032952] Funding Source: NIH RePORTER	Beeson Career Development Award Program (National Institute on Aging); Beeson Career Development Award Program (American Federation for Aging Research); Doris Duke Charitable Foundation (Clinical Scientist Development Award)(American Heart AssociationDoris Duke Charitable Foundation (DDCF)); National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); Commonwealth Fund; NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This study was supported by grants from the Beeson Career Development Award Program (National Institute on Aging grant K08 AG038354 and the American Federation for Aging Research), the Doris Duke Charitable Foundation (Clinical Scientist Development Award 2010053), the National Institute on Aging (grant P01 AG032952), and the Commonwealth Fund (grant 20110391).	Agency for Healthcare Research and Quality, 2013, PREVENTION QUALITY I; Ayanian JZ, 2012, NEW ENGL J MED, V367, P790, DOI 10.1056/NEJMp1208710; BINDER DA, 1983, INT STAT REV, V51, P279, DOI 10.2307/1402588; Buntin MB, 2004, J HEALTH ECON, V23, P525, DOI 10.1016/j.jhealeco.2003.10.005; Center for Medicare and Medicaid Innovation, 2011, PIONEER ACCOUNTABLE; Centers for Medicare & Medicaid Services, CHRONIC CONDITION DA; Centers for Medicare & Medicaid Services, 2012, CMS NAMES 88 NEW MED; Centers for Medicare & Medicaid Services, 2012, FIRST ACCOUNTABLE CA; Centers for Medicare & Medicaid Services, BERENSON EGGERS TYPE; Centers for Medicare & Medicaid Services, 2013, MORE DOCTORS HOSPITA; Centers for Medicare & Medicaid Services Office of Research Development and Information, 2009, PHYSICIAN GROUP PRAC; Colla CH, 2012, JAMA-J AM MED ASSOC, V308, P1015, DOI 10.1001/2012.jama.10812; Commonwealth of Massachusetts, 2013, AN ACT IMPROVING THE; Department of Health and Human Services, 2004, HIPAA ADMINISTRATIVE; Department of Health and Human Services; Centers for Medicare & Medicaid Services, 2011, MEDICARE SHARED SAVI; Fisher ES, 2009, HEALTH AFFAIR, V28, pW219, DOI 10.1377/hlthaff.28.2.w219; Fisher ES, 2003, ANN INTERN MED, V138, P273, DOI 10.7326/0003-4819-138-4-200302180-00006; Funk MJ, 2011, AM J EPIDEMIOL, V173, P761, DOI 10.1093/aje/kwq439; Ghandi N, 2012, THE ACO SURPRISE; MCGUIRE TG, 1991, J HEALTH ECON, V10, P385, DOI 10.1016/0167-6296(91)90022-F; McWilliams JM, 2007, NEW ENGL J MED, V357, P143, DOI 10.1056/NEJMsa067712; McWilliams JM, 2013, JAMA INTERN MED, V173, P1447, DOI 10.1001/jamainternmed.2013.6886; McWilliams JM, 2013, HEALTH SERV RES, V48, P1526, DOI 10.1111/1475-6773.12032; McWilliams JM, 2004, HEALTH AFFAIR, V23, P223, DOI 10.1377/hlthaff.23.4.223; Mechanic RE, 2011, HEALTH AFFAIR, V30, P1734, DOI 10.1377/hlthaff.2011.0264; Medicare Payment Advisory Commission, 2009, REPORT TO THE CONGRE; Medicare Payment Advisory Commission, 2011, REP C MED PAYM POL; Song ZR, 2013, JAMA INTERN MED, V173, P15, DOI 10.1001/jamainternmed.2013.1125; Song ZR, 2012, HEALTH AFFAIR, V31, P1885, DOI 10.1377/hlthaff.2012.0327; Song Z, 2011, NEW ENGL J MED, V365, P909, DOI 10.1056/NEJMsa1101416; Steinbrook R, 2012, JAMA-J AM MED ASSOC, V308, P1215, DOI 10.1001/2012.jama.11322; US Census Bureau, 2010 AMERICAN COMMUN; Wennberg John E, 2002, Health Aff (Millwood), VSuppl Web Exclusives, pW96; Zuvekas SH, 2010, HEALTH AFFAIR, V29, P1661, DOI 10.1377/hlthaff.2009.0361	34	100	100	0	25	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 28	2013	310	8					829	836		10.1001/jama.2013.276302	http://dx.doi.org/10.1001/jama.2013.276302			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	206YA	23982369	Green Accepted			2023-01-03	WOS:000323561400023
J	Roy, R; Kumar, D; Chakraborty, B; Chowdhury, C; Das, P				Roy, Rajneeta; Kumar, Deepak; Chakraborty, Biswajit; Chowdhury, Chinmay; Das, Padma			Apoptotic and Autophagic Effects of Sesbania grandiflora Flowers in Human Leukemic Cells	PLOS ONE			English	Article								Background: Identification of cytotoxic compounds that induce apoptosis has been the mainstay of anti-cancer therapeutics for several decades. In recent years, focus has shifted to inducing multiple modes of cell death coupled with reduced systemic toxicity. The plant Sesbania grandiflora is widely used in Indian traditional medicine for the treatment of a broad spectrum of diseases. This encouraged us to investigate into the anti-proliferative effect of a fraction (F2) isolated from S. grandiflora flowers in cancer cells and delineate the underlying involvement of apoptotic and autophagic pathways. Principal Findings: Using MTT based cell viability assay, we evaluated the cytotoxic potential of fraction F2. It was the most effective on U937 cells (IC50:18.6 mu g/ml). Inhibition of growth involved enhancement of Annexin V positivity. This was associated with elevated reactive oxygen species generation, measured by flow cytometry and reduced oxygen consumption - both effects being abrogated by anti-oxidant NAC. This caused stimulation of pro-apoptotic proteins and concomitant inhibition of anti-apoptotic protein expressions inducing mitochondrial depolarization, as measured by flow cytometry and release of cytochrome c. Interestingly, even with these molecular features of apoptosis, F2 was able to alter Atg protein levels and induce LC3 processing. This was accompanied by formation of autophagic vacuoles as revealed by fluorescence and transmission electron microscopy - confirming the occurrence of autophagy. Eventually, F2 triggered caspase cascade - executioners of programmed cell death and AIF translocation to nuclei. This culminated in cleavage of the DNA repair enzyme, poly (ADP-ribose) polymerase that caused DNA damage as proved by staining with Hoechst 33258 leading to cell death. Conclusions: The findings suggest fraction F2 triggers pro-oxidant activity and mediates its cytotoxicity in leukemic cells via apoptosis and autophagy. Thus, it merits consideration and further investigation as a therapeutic option for the treatment of leukemia.	[Roy, Rajneeta; Kumar, Deepak; Das, Padma] CSIR Indian Inst Chem Biol, Canc Biol & Inflammatory Disorder Div, Kolkata, W Bengal, India; [Chakraborty, Biswajit; Chowdhury, Chinmay] CSIR Indian Inst Chem Biol, Div Chem, Kolkata, W Bengal, India	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Indian Institute of Chemical Biology (IICB); Council of Scientific & Industrial Research (CSIR) - India; CSIR - Indian Institute of Chemical Biology (IICB)	Das, P (corresponding author), CSIR Indian Inst Chem Biol, Canc Biol & Inflammatory Disorder Div, Kolkata, W Bengal, India.	padmadas2005@yahoo.co.in	Kumar, Deepak/J-4347-2016		Department of Science and Technology, Govt. of India [SR/S1/OC-42/2009]; Department of Biotechnology, Govt. of India [BT/PR13444/PBD/17/670/2009]; Council of Scientific and Industrial Research, Govt. of India [IAP0001]; Council of Scientific and Industrial Research, Govt. of India	Department of Science and Technology, Govt. of India(Department of Science & Technology (India)); Department of Biotechnology, Govt. of India(Department of Biotechnology (DBT) India); Council of Scientific and Industrial Research, Govt. of India(Council of Scientific & Industrial Research (CSIR) - India); Council of Scientific and Industrial Research, Govt. of India(Council of Scientific & Industrial Research (CSIR) - India)	This study was supported by grants from Department of Science and Technology (SR/S1/OC-42/2009), Govt. of India; Department of Biotechnology (BT/PR13444/PBD/17/670/2009), Govt. of India and Council of Scientific and Industrial Research (IAP0001), Govt. of India. RR and DK received Senior Research fellowships from Council of Scientific and Industrial Research, Govt. of India. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Al Omar SY, 2012, INT IMMUNOL, V24, P409, DOI 10.1093/intimm/dxr122; Ballot C, 2010, APOPTOSIS, V15, P769, DOI 10.1007/s10495-010-0471-2; Bhattacharya K, 2010, BIOCHEM PHARMACOL, V79, P361, DOI 10.1016/j.bcp.2009.09.007; Bieda R, 2011, BIOMETALS, V24, P645, DOI 10.1007/s10534-011-9414-9; Brodska B, 2011, OXID MED CELL LONGEV, V2011, DOI 10.1155/2011/253529; Bursch W, 2000, J CELL SCI, V113, P1189; Chen YJ, 2009, AUTOPHAGY, V5, P173, DOI 10.4161/auto.5.2.7360; Chiu HW, 2011, J MOL MED, V89, P927, DOI 10.1007/s00109-011-0763-1; Chiu HW, 2010, AUTOPHAGY, V6, P353, DOI 10.4161/auto.6.3.11229; Daido S, 2004, CANCER RES, V64, P4286, DOI 10.1158/0008-5472.CAN-03-3084; Das B, 2010, BIOORG MED CHEM LETT, V20, P6947, DOI 10.1016/j.bmcl.2010.09.126; Daugas E, 2000, FEBS LETT, V476, P118, DOI 10.1016/S0014-5793(00)01731-2; Deeb D, 2010, BIOCHEM PHARMACOL, V79, P350, DOI 10.1016/j.bcp.2009.09.006; Doddola S, 2008, J NAT MED-TOKYO, V62, P300, DOI 10.1007/s11418-008-0235-2; Ferantinos L, 1990, PERENNIAL SESBANIA S, P105; Fong MY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042265; Galluzzi L, 2010, MOL ASPECTS MED, V31, P1, DOI 10.1016/j.mam.2009.08.002; Gibellini Lara, 2010, Cancers (Basel), V2, P1288, DOI 10.3390/cancers2021288; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Hail N, 2001, J BIOL CHEM, V276, P45614, DOI 10.1074/jbc.M106559200; Hail N, 2010, NEOPLASIA, V12, P464, DOI 10.1593/neo.10168; Harris MH, 2000, CELL DEATH DIFFER, V7, P1182, DOI 10.1038/sj.cdd.4400781; He CC, 2009, ANNU REV GENET, V43, P67, DOI 10.1146/annurev-genet-102808-114910; Jia YL, 2009, J ASIAN NAT PROD RES, V11, P918, DOI 10.1080/10286020903264077; Joshi SG, 2000, LEGUMINOCEAE TXB MED; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; Kaczanowski S, 2011, PARASITE VECTOR, V4, DOI 10.1186/1756-3305-4-44; Kasture VS, 2002, PHYTOTHER RES, V16, P455, DOI 10.1002/ptr.971; Kondo Y, 2005, NAT REV CANCER, V5, P726, DOI 10.1038/nrc1692; Kondo Y, 2006, AUTOPHAGY, V2, P85, DOI 10.4161/auto.2.2.2463; Krishna S, 2011, BIOCHEM J, V435, P545, DOI 10.1042/BJ20101996; Laladhas KP, 2010, J CELL MOL MED, V14, P636, DOI 10.1111/j.1582-4934.2008.00648.x; Lavieu G, 2006, J BIOL CHEM, V281, P8518, DOI 10.1074/jbc.M506182200; Leist M, 2001, NAT REV MOL CELL BIO, V2, P589, DOI 10.1038/35085008; Levine B, 2010, NATURE, V466, P38, DOI 10.1038/466038a; Liang C, 2006, NAT CELL BIOL, V8, P688, DOI 10.1038/ncb1426; Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257; Maiuri MC, 2007, NAT REV MOL CELL BIO, V8, P741, DOI 10.1038/nrm2239; Mandal C, 2008, APOPTOSIS, V13, P1450, DOI 10.1007/s10495-008-0271-0; Manna A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036938; McDonnell TJ, 1996, EXPERIENTIA, V52, P1008, DOI 10.1007/BF01920110; Mizushima N, 2002, CELL STRUCT FUNCT, V27, P421, DOI 10.1247/csf.27.421; Mondal S, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-239; Nag TC, 2009, ANN ANAT, V191, P556, DOI 10.1016/j.aanat.2009.08.004; Ohsumi Y, 2004, SEMIN CELL DEV BIOL, V15, P231, DOI 10.1016/j.semcdb.2003.12.004; Okada H, 2004, NAT REV CANCER, V4, P592, DOI 10.1038/nrc1412; Paglin S, 2001, CANCER RES, V61, P439; Pari L, 2003, THERAPIE, V58, P439, DOI 10.2515/therapie:2003071; Pattingre S, 2006, CANCER RES, V66, P2885, DOI 10.1158/0008-5472.CAN-05-4412; Pelicano H, 2003, J BIOL CHEM, V278, P37832, DOI 10.1074/jbc.M301546200; PRICE P, 1990, CANCER RES, V50, P1392; Qu XP, 2003, J CLIN INVEST, V112, P1809, DOI 10.1172/JCI200320039; Ramesh T, 2008, J CARDIOVASC PHARM, V52, P338, DOI 10.1097/FJC.0b013e3181888383; Rodriguez-Enriquez S, 2004, INT J BIOCHEM CELL B, V36, P2463, DOI 10.1016/j.biocel.2004.04.009; Sinha S, 2008, ONCOGENE, V27, pS137, DOI 10.1038/onc.2009.51; Sreelatha S, 2011, J ETHNOPHARMACOL, V134, P984, DOI 10.1016/j.jep.2011.01.012; Sun QM, 2009, AUTOPHAGY, V5, P713, DOI 10.4161/auto.5.5.8524; Tamboli S, 1996, IND DRUG, V33, P504; Tamboli SA, 2000, IND DRUG, V37, P95; Thayyullathil F, 2008, FREE RADICAL BIO MED, V45, P1403, DOI 10.1016/j.freeradbiomed.2008.08.014; Trachootham D, 2009, NAT REV DRUG DISCOV, V8, P579, DOI 10.1038/nrd2803; Turrens JF, 1997, BIOSCIENCE REP, V17, P3, DOI 10.1023/A:1027374931887; Vander Heiden MG, 2011, NAT REV DRUG DISCOV, V10, P671, DOI 10.1038/nrd3504; Wang N, 2010, J CELL BIOCHEM, V111, P1426, DOI 10.1002/jcb.22869; Wei YJ, 2008, AUTOPHAGY, V4, P949, DOI 10.4161/auto.6788; Wuilleme-Toumi S, 2005, LEUKEMIA, V19, P1248, DOI 10.1038/sj.leu.2403784; Yue ZY, 2003, P NATL ACAD SCI USA, V100, P15077, DOI 10.1073/pnas.2436255100; Zou H, 2003, J BIOL CHEM, V278, P8091, DOI 10.1074/jbc.M204783200	68	20	21	1	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 13	2013	8	8							e71672	10.1371/journal.pone.0071672	http://dx.doi.org/10.1371/journal.pone.0071672			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	201BN	23967233	gold, Green Submitted, Green Published			2023-01-03	WOS:000323115800073
J	Kapczynski, A				Kapczynski, Amy			Engineered in India Patent Law 2.0	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Yale Univ, Sch Law, New Haven, CT 06520 USA	Yale University	Kapczynski, A (corresponding author), Yale Univ, Sch Law, New Haven, CT 06520 USA.							Hemphill CS, 2012, J HEALTH ECON, V31, P327, DOI 10.1016/j.jhealeco.2012.01.004; Hemphill CS, 2011, J EMPIR LEGAL STUD, V8, P613, DOI 10.1111/j.1740-1461.2011.01235.x; Kapczynski A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049470	3	22	22	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 8	2013	369	6					497	499		10.1056/NEJMp1304400	http://dx.doi.org/10.1056/NEJMp1304400			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	197HX	23862973				2023-01-03	WOS:000322842000002
J	Klopotowska, JE; Wierenga, PC; Stuijt, CCM; Arisz, L; Dijkgraaf, MGW; Kuks, PFM; Asscheman, H; de Rooij, SE; Lie-A-Huen, L; Smorenburg, SM				Klopotowska, Joanna E.; Wierenga, Peter C.; Stuijt, Clementine C. M.; Arisz, Lambertus; Dijkgraaf, Marcel G. W.; Kuks, Paul F. M.; Asscheman, Henk; de Rooij, Sophia E.; Lie-A-Huen, Loraine; Smorenburg, Susanne M.		WINGS Study Grp	Adverse Drug Events in Older Hospitalized Patients: Results and Reliability of a Comprehensive and Structured Identification Strategy	PLOS ONE			English	Article							MEDICATION ERRORS; CAUSALITY ASSESSMENT; ELDERLY-PATIENTS; GERIATRIC INPATIENTS; SAFETY RESEARCH; TRIGGER TOOL; POPULATION; PHARMACISTS; RECORD; CARE	Background: Older patients are at high risk for experiencing Adverse Drug Events (ADEs) during hospitalization. To be able to reduce ADEs in these vulnerable patients, hospitals first need to measure the occurrence of ADEs, especially those that are preventable. However, data on preventable ADEs (pADEs) occurring during hospitalization in older patients are scarce, and no 'gold standard' for the identification of ADEs exists. Methodology: The study was conducted in three hospitals in the Netherlands in 2007. ADEs were retrospectively identified by a team of experts using a comprehensive and structured patient chart review (PCR) combined with a trigger-tool as an aid. This ADE identification strategy was applied to a cohort of 250 older hospitalized patients. To estimate the intra- and inter-rater reliabilities, Cohen's kappa values were calculated. Principal Findings: In total, 118 ADEs were detected which occurred in 62 patients. This ADE yield was 1.1 to 2.7 times higher in comparison to other ADE studies in older hospitalized patients. Of the 118 ADEs, 83 (70.3%) were pADEs; 51 pADEs (43.2% of all ADEs identified) caused serious patient harm. Patient harm caused by ADEs resulted in various events. The overall intra-rater agreement of the developed strategy was substantial (kappa = 0.74); the overall inter-rater agreement was only fair (kappa = 0.24). Conclusions/Significance: The ADE identification strategy provided a detailed insight into the scope of ADEs occurring in older hospitalized patients, and showed that the majority of (serious) ADEs can be prevented. Several strategy related aspects, as well as setting/study specific aspects, may have contributed to the results gained. These aspects should be considered whenever ADE measurements need to be conducted. The results regarding pADEs can be used to design tailored interventions to effectively reduce harm caused by medication errors. Improvement of the inter-rater reliability of a PCR remains challenging.	[Klopotowska, Joanna E.; Wierenga, Peter C.; Stuijt, Clementine C. M.; Kuks, Paul F. M.] Univ Amsterdam, Acad Med Ctr, Dept Hosp Pharm, NL-1105 AZ Amsterdam, Netherlands; [Wierenga, Peter C.] Deventer Hosp, Dept Hosp Pharm, Deventer, Netherlands; [Arisz, Lambertus] Univ Amsterdam, Acad Med Ctr, Dept Internal Med, NL-1105 AZ Amsterdam, Netherlands; [Dijkgraaf, Marcel G. W.] Univ Amsterdam, Acad Med Ctr, Clin Res Unit, NL-1105 AZ Amsterdam, Netherlands; [Asscheman, Henk] HAJAP, Amsterdam, Netherlands; [de Rooij, Sophia E.; Smorenburg, Susanne M.] Univ Amsterdam, Acad Med Ctr, Dept Internal Med & Geriatr, NL-1105 AZ Amsterdam, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam; Deventer Hospital; University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam	Klopotowska, JE (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Hosp Pharm, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.	j.e.klopotowska@amc.nl	Klopotowska, Joanna/HDM-2912-2022; Dijkgraaf, Marcel GW/G-6663-2011	Klopotowska, Joanna/0000-0002-9707-5740	Netherlands Organization for Health Research and Development (ZonMW) [SG300001]	Netherlands Organization for Health Research and Development (ZonMW)(Netherlands Organization for Health Research and Development)	This work was supported by The Netherlands Organization for Health Research and Development (ZonMW grant SG300001). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Agbabiaka TB, 2008, DRUG SAFETY, V31, P21, DOI 10.2165/00002018-200831010-00003; Arimone Y, 2007, BRIT J CLIN PHARMACO, V64, P482, DOI 10.1111/j.1365-2125.2007.02937.x; Azad N, 2002, J HEALTHC MANAG, V47, P295, DOI 10.1097/00115514-200209000-00005; Baker R, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005470.pub2; Bakker FC, 2011, BMJ QUAL SAF, V20, P680, DOI 10.1136/bmjqs.2010.047183; BATES DW, 1993, J GEN INTERN MED, V8, P289, DOI 10.1007/BF02600138; Bates DW, 2002, AM J HEALTH-SYST PH, V59, P2317, DOI 10.1093/ajhp/59.23.2317; Bowman Lee, 1996, Pharmacoepidemiology and Drug Safety, V5, P9, DOI 10.1002/(SICI)1099-1557(199601)5:1<9::AID-PDS192>3.3.CO;2-U; Brown C, 2008, QUAL SAF HEALTH CARE, V17, P170, DOI 10.1136/qshc.2007.023655; Cancer Therapy Evaluation Program, 2013, COMM TERM CRIT ADV E; Committee of Experts on Management of Safety and Quality in Health Care (SP-SQS) Expert Group on Safe Medication Practices, 2005, GLOSS TERMS REL PAT, P16; de Vries EN, 2008, QUAL SAF HEALTH CARE, V17, P216, DOI 10.1136/qshc.2007.023622; Doloresco F, 2009, AM J HEALTH-SYST PH, V66, pS13, DOI 10.2146/ajhp080674; Dutch Hospital Pharmacists Association, CENTR MED REG CMR; Egbring M, 2011, EUR J CLIN PHARMACOL, V67, P909, DOI 10.1007/s00228-011-1020-9; Egger T, 2003, DRUG AGING, V20, P769, DOI 10.2165/00002512-200320100-00005; Evans RS, 2005, ANN PHARMACOTHER, V39, P1161, DOI 10.1345/aph.1E642; Expert Group On Safe Medication Practices, 2006, CREAT BETT MED SAF C; Franklin Bryony Dean, 2010, Int J Pharm Pract, V18, P305, DOI 10.1111/j.2042-7174.2010.00058.x; Gallagher PF, 2011, CLIN PHARMACOL THER, V89, P845, DOI 10.1038/clpt.2011.44; Gillespie U, 2009, ARCH INTERN MED, V169, P894, DOI 10.1001/archinternmed.2009.71; Gray SL, 1998, J GERONTOL A-BIOL, V53, pM59, DOI 10.1093/gerona/53A.1.M59; Hartholt KA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013977; Harugeri A, 2010, J POSTGRAD MED, V56, P186, DOI 10.4103/0022-3859.68642; Hofer TP, 2000, MED CARE, V38, P152, DOI 10.1097/00005650-200002000-00005; Hoonhout LHF, 2010, DRUG SAFETY, V33, P853, DOI 10.2165/11536800-000000000-00000; Institute for Helathcare Improvement, 2004, TRIGG TOOL MEAS ADV; Kanjanarat P, 2003, AM J HEALTH-SYST PH, V60, P1750, DOI 10.1093/ajhp/60.17.1750; Kaushal R, 2002, AM J HEALTH-SYST PH, V59, P2323, DOI 10.1093/ajhp/59.23.2323; Kaushal R, 2001, JAMA-J AM MED ASSOC, V285, P2114, DOI 10.1001/jama.285.16.2114; Kilbridge PM, 2006, J AM MED INFORM ASSN, V13, P372, DOI 10.1197/jamia.M2069; Klopotowska JE, 2011, BMC HEALTH SERV RES, V11, DOI 10.1186/1472-6963-11-124; Kucukarslan SN, 2003, ARCH INTERN MED, V163, P2014, DOI 10.1001/archinte.163.17.2014; Kunac DL, 2006, QUAL SAF HEALTH CARE, V15, P196, DOI 10.1136/qshc.2005.014407; Kuperman GJ, 2007, J AM MED INFORM ASSN, V14, P29, DOI 10.1197/jamia.M2170; Lazarou J, 1998, JAMA-J AM MED ASSOC, V279, P1200, DOI 10.1001/jama.279.15.1200; LEAPE LL, 1991, NEW ENGL J MED, V324, P377, DOI 10.1056/NEJM199102073240605; Lilford RJ, 2003, QUAL SAF HLTH CAR S2, V12, P118, DOI DOI 10.1136/QHC.12.SUPPL_2.II8; Luck J, 2000, AM J MED, V108, P642, DOI 10.1016/S0002-9343(00)00363-6; Macedo AF, 2006, DRUG SAFETY, V29, P697, DOI 10.2165/00002018-200629080-00006; Manias E, 2012, BR J CLIN PHARM; McLean AJ, 2004, PHARMACOL REV, V56, P163, DOI 10.1124/pr.56.2.4; Michel P, 2004, BRIT MED J, V328, P199, DOI 10.1136/bmj.328.7433.199; Morimoto T, 2004, QUAL SAF HEALTH CARE, V13, P306, DOI 10.1136/qshc.2004.010611; Murff HJ, 2003, J BIOMED INFORM, V36, P131, DOI 10.1016/j.jbi.2003.08.003; Neale G, 2003, QUAL SAF HEALTH CARE, V12, P2, DOI 10.1136/qhc.12.1.2; Nebeker JR, 2002, J AM MED INFORM ASSN, V9, pS80, DOI 10.1197/jamia.M1234; Page Robert L 2nd, 2006, Am J Geriatr Pharmacother, V4, P297; Page RL, 2010, CLIN INTERV AGING, V5, P75; Passarelli MCG, 2005, DRUG AGING, V22, P767, DOI 10.2165/00002512-200522090-00005; Phansalkar S, 2007, AM J HEALTH-SYST PH, V64, P842, DOI 10.2146/ajhp060335; Racz M, 2005, J AM GERIATR SOC, V53, pS245, DOI 10.1111/j.1532-5415.2005.53350.x; Resar RK, 2003, QUAL SAF HEALTH CARE, V12, pII39, DOI 10.1136/qhc.12.suppl_2.ii39; Rozich JD, 2003, QUAL SAF HEALTH CARE, V12, P194, DOI 10.1136/qhc.12.3.194; Spinewine A, 2008, BMJ-BRIT MED J, V336, P956, DOI 10.1136/bmj.39520.686458.94; Spinewine A, 2007, J AM GERIATR SOC, V55, P658, DOI 10.1111/j.1532-5415.2007.01132.x; Steinman MA, 2010, JAMA-J AM MED ASSOC, V304, P1592, DOI 10.1001/jama.2010.1482; Tangiisuran B, 2012, DRUG AGING, V29, P669, DOI 10.2165/11632630-000000000-00000; Thomas EJ, 2000, BRIT MED J, V320, P741, DOI 10.1136/bmj.320.7237.741; Thomsen LA, 2007, ANN PHARMACOTHER, V41, P1411, DOI 10.1345/aph.1H658; Thurmann Petra A, 2003, Expert Opin Drug Saf, V2, P447; Tinetti ME, 2012, JAMA-J AM MED ASSOC, V307, P2493, DOI 10.1001/jama.2012.5265; Trivalle C, 2010, J NUTR HEALTH AGING, V14, P57, DOI 10.1007/s12603-010-0010-4; Uppsala Monitoring Centre, 2013, US WHO UMC SYST STAN; Van der Sijs H, 2006, J AM MED INFORM ASSN, V13, P138, DOI 10.1197/jamia.M1809; van der Sijs H, 2009, PHARMACOEPIDEM DR S, V18, P941, DOI 10.1002/pds.1800; van Doormaal JE, 2008, PHARMACOEPIDEM DR S, V17, P645, DOI 10.1002/pds.1586; Wolfstadt JI, 2008, J GEN INTERN MED, V23, P451, DOI 10.1007/s11606-008-0504-5; Zegers M, 2009, QUAL SAF HEALTH CARE, V18, P297, DOI 10.1136/qshc.2007.025924; Zegers M, 2007, BMC HEALTH SERV RES, V7, DOI 10.1186/1472-6963-7-27	70	35	37	0	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 5	2013	8	8							e71045	10.1371/journal.pone.0071045	http://dx.doi.org/10.1371/journal.pone.0071045			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	218XC	23940688	Green Published, gold, Green Submitted			2023-01-03	WOS:000324465000172
J	Li, HY; Liang, YX; Chiu, K; Yuan, QJ; Lin, B; Chang, RCC; So, KF				Li, Hongying; Liang, Yuxiang; Chiu, Kin; Yuan, Qiuju; Lin, Bin; Chang, Raymond Chuen-Chung; So, Kwok-Fai			Lycium Barbarum (Wolfberry) Reduces Secondary Degeneration and Oxidative Stress, and Inhibits JNK Pathway in Retina after Partial Optic Nerve Transection	PLOS ONE			English	Article							GANGLION-CELL DEATH; AMYLOID PEPTIDE NEUROTOXICITY; FACTOR MESSENGER-RNA; NEUROTROPHIC FACTOR; OCULAR HYPERTENSION; IN-VIVO; NEURONS; INJURY; MODEL; APOPTOSIS	Our group has shown that the polysaccharides extracted from Lycium barbarum (LBP) are neuroprotective for retinal ganglion cells (RGCs) in different animal models. Protecting RGCs from secondary degeneration is a promising direction for therapy in glaucoma management. The complete optic nerve transection (CONT) model can be used to study primary degeneration of RGCs, while the partial optic nerve transection (PONT) model can be used to study secondary degeneration of RGCs because primary degeneration of RGCs and secondary degeneration can be separated in location in the same retina in this model; in other situations, these types of degeneration can be difficult to distinguish. In order to examine which kind of degeneration LBP could delay, both CONT and PONT models were used in this study. Rats were fed with LBP or vehicle daily from 7 days before surgery until sacrifice at different time-points and the surviving numbers of RGCs were evaluated. The expression of several proteins related to inflammation, oxidative stress, and the c-jun N-terminal kinase (JNK) pathways were detected with Western-blot analysis. LBP did not delay primary degeneration of RGCs after either CONT or PONT, but it did delay secondary degeneration of RGCs after PONT. We found that LBP appeared to exert these protective effects by inhibiting oxidative stress and the JNK/c-jun pathway and by transiently increasing production of insulin-like growth factor-1 (IGF-1). This study suggests that LBP can delay secondary degeneration of RGCs and this effect may be linked to inhibition of oxidative stress and the JNK/c-jun pathway in the retina.	[Li, Hongying; Liang, Yuxiang; Chiu, Kin; Yuan, Qiuju; Lin, Bin; Chang, Raymond Chuen-Chung; So, Kwok-Fai] Univ Hong Kong, Li Ka Shing Fac Med, Dept Anat, Hong Kong, Hong Kong, Peoples R China; [Li, Hongying; Liang, Yuxiang; Chiu, Kin; Yuan, Qiuju; Lin, Bin; Chang, Raymond Chuen-Chung; So, Kwok-Fai] Univ Hong Kong, Li Ka Shing Fac Med, State Key Lab Brain & Cognit Sci, Hong Kong, Hong Kong, Peoples R China; [Chang, Raymond Chuen-Chung; So, Kwok-Fai] Univ Hong Kong, Li Ka Shing Fac Med, Res Ctr Heart Brain Hormone & Hlth Aging, Hong Kong, Hong Kong, Peoples R China; [So, Kwok-Fai] Jinan Univ, GMH Inst Cent Nervous Syst Regenerat, Guangzhou, Guangdong, Peoples R China	University of Hong Kong; University of Hong Kong; University of Hong Kong; Jinan University	So, KF (corresponding author), Univ Hong Kong, Li Ka Shing Fac Med, Dept Anat, Hong Kong, Hong Kong, Peoples R China.	hrmaskf@hkucc.hku.hk	Li, Hong-Ying/AAH-2462-2019; Li, Hongying/AAU-2379-2021; Chiu, Kin/ABI-7938-2020; Chang, Raymond Chuen-Chung/C-1107-2009; Li, Hongying/Q-1909-2016; Li, Hong-Ying/C-5762-2014; Yuan, Qiuju/AAJ-3101-2020; Lin, Bin/E-9871-2010	Li, Hong-Ying/0000-0002-1109-0799; Chiu, Kin/0000-0001-6581-9007; Chang, Raymond Chuen-Chung/0000-0001-8538-7993; Li, Hongying/0000-0002-1109-0799; Li, Hong-Ying/0000-0002-1109-0799; So, Kwok-Fai/0000-0003-4039-4246; Lin, Bin/0000-0003-1309-3480	Research Grants Council of the Hong Kong Special Administrative Region, China [HKU 10208849]; Fundamental Research Funds for The Central Universities [21609101]; Azalea (1972) Foundation	Research Grants Council of the Hong Kong Special Administrative Region, China(Hong Kong Research Grants Council); Fundamental Research Funds for The Central Universities(Fundamental Research Funds for the Central Universities); Azalea (1972) Foundation	The work described in this paper was substantially supported by a grant from the Research Grants Council of the Hong Kong Special Administrative Region, China (HKU 10208849). In addition, this work was partially supported by the Fundamental Research Funds for The Central Universities Grant 21609101 and the Azalea (1972) Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aicheng W, 2002, GOU QI; Chan HC, 2007, EXP NEUROL, V203, P269, DOI 10.1016/j.expneurol.2006.05.031; Cheng D, 2011, MOLECULES, V16, P2542, DOI 10.3390/molecules16032542; Chiu K, 2008, J VIS EXP; COHENCORY S, 1994, NEURON, V12, P747, DOI 10.1016/0896-6273(94)90328-X; Cui BK, 2011, MOLECULES, V16, P9116, DOI 10.3390/molecules16119116; Degterev A, 2008, NAT REV MOL CELL BIO, V9, P378, DOI 10.1038/nrm2393; Dhanasekaran DN, 2008, ONCOGENE, V27, P6245, DOI 10.1038/onc.2008.301; Fitzgerald M, 2010, J NEUROTRAUM, V27, P2107, DOI 10.1089/neu.2010.1426; Fitzgerald M, 2010, J NEUROTRAUM, V27, P439, DOI 10.1089/neu.2009.1112; Fitzgerald M, 2009, INVEST OPHTH VIS SCI, V50, P5456, DOI 10.1167/iovs.09-3717; Fitzgerald M, 2009, EXP NEUROL, V216, P219, DOI 10.1016/j.expneurol.2008.11.026; Fu QL, 2009, NEUROSCIENCE, V162, P375, DOI 10.1016/j.neuroscience.2009.04.075; Fu QL, 2008, INVEST OPHTH VIS SCI, V49, P975, DOI 10.1167/iovs.07-1199; Gao H, 1997, INVEST OPHTH VIS SCI, V38, P1840; GODEMENT P, 1987, DEVELOPMENT, V101, P697; GRASLKRAUPP B, 1995, HEPATOLOGY, V21, P1465, DOI 10.1016/0270-9139(95)90071-3; Hajali M, 2009, DOC OPHTHALMOL, V118, P233, DOI 10.1007/s10633-008-9151-8; Ho YS, 2009, CELL MOL NEUROBIOL, V29, P1233, DOI 10.1007/s10571-009-9419-x; HOFER M, 1990, EMBO J, V9, P2459, DOI 10.1002/j.1460-2075.1990.tb07423.x; Homma K, 2007, NEUROCHEM INT, V50, P741, DOI 10.1016/j.neuint.2007.01.011; Lee JJ, 2012, MOL VIS, V18, P838; Levkovitch-Verbin H, 2001, INVEST OPHTH VIS SCI, V42, P975; Levkovitch-Verbin H, 2003, INVEST OPHTH VIS SCI, V44, P3388, DOI 10.1167/iovs.02-0646; Levkovitch-Verbin H, 2011, GRAEF ARCH CLIN EXP, V249, P849, DOI 10.1007/s00417-010-1608-2; Li SY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016380; Liu Y, 2012, FREE RADICAL BIO MED, V52, P909, DOI 10.1016/j.freeradbiomed.2011.12.013; Mi XS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045469; Mura M, 2007, ARCH OPHTHALMOL-CHIC, V125, P1107, DOI 10.1001/archopht.125.8.1107; Nakatani M, 2011, EXP EYE RES, V93, P873, DOI 10.1016/j.exer.2011.09.024; Ogata-Iwao M, 2011, INVEST OPHTH VIS SCI, V52, P6671, DOI 10.1167/iovs.11-7559; Prilloff S, 2012, INVEST OPHTH VIS SCI, V53, P1460, DOI 10.1167/iovs.11-8306; QUIGLEY HA, 1995, INVEST OPHTH VIS SCI, V36, P774; Swanson KI, 2005, INVEST OPHTH VIS SCI, V46, P3737, DOI 10.1167/iovs.05-0155; Tan MH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032330; Tzekov RT, 2003, INVEST OPHTH VIS SCI, V44, P3993, DOI 10.1167/iovs.02-1104; Vander S, 2012, CURR EYE RES, V37, P740, DOI 10.3109/02713683.2012.673679; VIDALSANZ M, 1988, EXP NEUROL, V102, P92, DOI 10.1016/0014-4886(88)90081-7; Vincent A, 2011, MOL VIS, V17, P3262; Wells J, 2012, J NEUROSCI RES, V90, P606, DOI 10.1002/jnr.22784; WETMORE C, 1990, EXP NEUROL, V109, P141, DOI 10.1016/0014-4886(90)90068-4; Yoles E, 1998, EXP NEUROL, V153, P1, DOI 10.1006/exnr.1998.6811; Yu MS, 2006, NEUROSIGNALS, V15, P145; Yu MS, 2007, INT J MOL MED, V20, P261; Yu MS, 2005, EXP GERONTOL, V40, P716, DOI 10.1016/j.exger.2005.06.010	45	52	55	0	41	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 19	2013	8	7							e68881	10.1371/journal.pone.0068881	http://dx.doi.org/10.1371/journal.pone.0068881			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	191CY	23894366	Green Submitted, Green Published, gold			2023-01-03	WOS:000322391400029
J	Butt, AQ; Mills, KHG				Butt, A. Q.; Mills, K. H. G.			Immunosuppressive networks and checkpoints controlling antitumor immunity and their blockade in the development of cancer immunotherapeutics and vaccines	ONCOGENE			English	Review						immunotherapy; vaccine; antitumor immunity; immune checkpoint; regulatory T cell; Toll-like receptor agonist	REGULATORY T-CELLS; TUMOR-ASSOCIATED MACROPHAGES; MYELOID SUPPRESSOR-CELLS; SURFACE SIGNALING MOLECULES; TYROSINE KINASE INHIBITOR; TOLL-LIKE; DENDRITIC CELLS; ALTERNATIVE ACTIVATION; MONOCLONAL-ANTIBODY; RECEPTOR AGONIST	Vaccines that promote protective adaptive immune responses have been successfully developed against a range of infectious diseases, and these are normally administered prior to exposure with the relevant virus or bacteria. Adaptive immunity also plays a critical role in the control of tumors. Immunotherapeutics and vaccines that promote effector T cell responses have the potential to eliminate tumors when used in a therapeutic setting. However, the induction of protective antitumor immunity is compromised by innate immunosuppressive mechanisms and regulatory cells that often dominate the tumor microenvironment. Recent studies have shown that blocking these suppressor cells and immune checkpoints to allow induction of antitumor immunity is a successful immunotherapeutic modality for the treatment of cancer. Furthermore, stimulation of innate and consequently adaptive immune responses with concomitant inhibition of immune suppression, especially that mediated by regulatory T (Treg) cells, is emerging as a promising approach to enhance the efficacy of therapeutic vaccines against cancer. This review describes the immunosuppressive mechanisms controlling antitumor immunity and the novel strategies being employed to design effective immunotherapeutics against tumors based on inhibition of suppressor cells or blockade of immune checkpoints to allow induction of more potent effector T cell responses. This review also discusses the potential of using a combination of adjuvants with inhibition of immune checkpoint or suppressor cells for therapeutic vaccines and the translation of pre-clinical studies to the next-generation vaccines against cancer in humans.	[Butt, A. Q.; Mills, K. H. G.] Univ Dublin Trinity Coll, Trinity Biomed Sci Inst, Sch Biochem & Immunol, Immune Regulat Res Grp, Dublin 2, Ireland	Trinity College Dublin	Mills, KHG (corresponding author), Univ Dublin Trinity Coll, Trinity Biomed Sci Inst, Sch Biochem & Immunol, Immune Regulat Res Grp, Dublin 2, Ireland.	kingston.mills@tcd.ie	Mills, Kingston H/F-5684-2013	Mills, Kingston H/0000-0003-3646-8222	Science Foundation Ireland	Science Foundation Ireland(Science Foundation IrelandEuropean Commission)	Kingston Mills's research group is supported by grants from Science Foundation Ireland.	Ahn GO, 2010, P NATL ACAD SCI USA, V107, P8363, DOI 10.1073/pnas.0911378107; Akdis CA, 2003, EUR J IMMUNOL, V33, P2717, DOI 10.1002/eji.200323329; Allavena P, 2008, CRIT REV ONCOL HEMAT, V66, P1, DOI 10.1016/j.critrevonc.2007.07.004; Amendola M, 2009, MOL THER, V17, P1039, DOI 10.1038/mt.2009.48; Banchereau J, 2005, NAT REV IMMUNOL, V5, P296, DOI 10.1038/nri1592; Baxevanis CN, 2009, CANCER IMMUNOL IMMUN, V58, P317, DOI 10.1007/s00262-008-0576-4; Bluestone JA, 2003, NAT REV IMMUNOL, V3, P253, DOI 10.1038/nri1032; Brahmer JR, 2012, NEW ENGL J MED, V366, P2455, DOI 10.1056/NEJMoa1200694; Bronte V, 1998, J IMMUNOL, V161, P5313; Bunt SK, 2009, J LEUKOCYTE BIOL, V85, P996, DOI 10.1189/jlb.0708446; Byrne WL, 2011, CANCER RES, V71, P6915, DOI 10.1158/0008-5472.CAN-11-1156; Casares N, 2010, J IMMUNOL, V185, P5150, DOI 10.4049/jimmunol.1001114; Chen W, 2012, CANCER RES, V72, P1363, DOI 10.1158/0008-5472.CAN-11-2684; Chung KY, 2010, J CLIN ONCOL, V28, P3485, DOI 10.1200/JCO.2010.28.3994; Cluff CW, 2009, ADV EXP MED BIOL, V667, P111, DOI 10.1007/978-1-4419-1603-7_10; Coe D, 2010, CANCER IMMUNOL IMMUN, V59, P1367, DOI 10.1007/s00262-010-0866-5; Conroy H, 2008, ONCOGENE, V27, P168, DOI 10.1038/sj.onc.1210910; Conroy H, 2012, CANCER IMMUNOL IMMUN, V61, P425, DOI 10.1007/s00262-011-1188-y; Corsello SM, 2013, J CLIN ENDOCR METAB, V98, P1361, DOI 10.1210/jc.2012-4075; Curiel TJ, 2004, NAT MED, V10, P942, DOI 10.1038/nm1093; Curiel TJ, 2003, NAT MED, V9, P562, DOI 10.1038/nm863; Dangaj D, 2013, CANCER RES, V73, P4820, DOI 10.1158/0008-5472.CAN-12-3457; De Santo C, 2005, P NATL ACAD SCI USA, V102, P4185, DOI 10.1073/pnas.0409783102; Delano MJ, 2007, J EXP MED, V204, P1463, DOI 10.1084/jem.20062602; Di Giacomo AM, 2010, SEMIN ONCOL, V37, P499, DOI 10.1053/j.seminoncol.2010.09.007; Doedens AL, 2010, CANCER RES, V70, P7465, DOI 10.1158/0008-5472.CAN-10-1439; Edwards JP, 2010, INT IMMUNOPHARMACOL, V10, P1220, DOI 10.1016/j.intimp.2010.07.002; Fischer C, 2007, CELL, V131, P463, DOI 10.1016/j.cell.2007.08.038; Fong L, 2008, J CLIN ONCOL, V26, P5275, DOI 10.1200/JCO.2008.17.8954; Fourcade J, 2010, J EXP MED, V207, P2175, DOI 10.1084/jem.20100637; Fujita M, 2011, CANCER RES, V71, P2664, DOI 10.1158/0008-5472.CAN-10-3055; Fujiwara Y, 2011, ONCOL REP, V26, P1533, DOI 10.3892/or.2011.1454; Fujiwara Y, 2011, CANCER SCI, V102, P206, DOI 10.1111/j.1349-7006.2010.01772.x; Gabrilovich DI, 2001, J IMMUNOL, V166, P5398, DOI 10.4049/jimmunol.166.9.5398; Gabrilovich DI, 2009, NAT REV IMMUNOL, V9, P162, DOI 10.1038/nri2506; Garbi N, 2004, J IMMUNOL, V172, P5861, DOI 10.4049/jimmunol.172.10.5861; Goding SR, 2013, J IMMUNOL, V190, P4899, DOI 10.4049/jimmunol.1300271; Goldberg MV, 2011, CURR TOP MICROBIOL, V344, P269, DOI 10.1007/82_2010_114; Golgher D, 2002, EUR J IMMUNOL, V32, P3267, DOI 10.1002/1521-4141(200211)32:11<3267::AID-IMMU3267>3.0.CO;2-1; Hiraoka K, 2008, CANCER SCI, V99, P1595, DOI 10.1111/j.1349-7006.2008.00880.x; Hoechst B, 2011, BLOOD, V117, P6532, DOI 10.1182/blood-2010-11-317321; HOON DSB, 1990, CANCER RES, V50, P5358; Huang B, 2006, CANCER RES, V66, P1123, DOI 10.1158/0008-5472.CAN-05-1299; Hussain SF, 2007, CANCER RES, V67, P9630, DOI 10.1158/0008-5472.CAN-07-1243; Jarnicki AG, 2008, J IMMUNOL, V180, P3797, DOI 10.4049/jimmunol.180.6.3797; Jarnicki AG, 2006, J IMMUNOL, V177, P896, DOI 10.4049/jimmunol.177.2.896; Jiang JT, 2010, CANCER IMMUNOL IMMUN, V59, P1707, DOI 10.1007/s00262-010-0900-7; Kantoff PW, 2010, NEW ENGL J MED, V363, P411, DOI 10.1056/NEJMoa1001294; Kanzler H, 2007, NAT MED, V13, P552, DOI 10.1038/nm1589; Karanikas V, 2008, J TRANSL MED, V6, DOI 10.1186/1479-5876-6-19; KIKKAWA F, 1993, EUR J CANCER, V29A, P1542, DOI 10.1016/0959-8049(93)90291-M; Ko HJ, 2007, CANCER RES, V67, P7477, DOI 10.1158/0008-5472.CAN-06-4639; Ko JS, 2010, CANCER RES, V70, P3526, DOI 10.1158/0008-5472.CAN-09-3278; Ko JS, 2009, CLIN CANCER RES, V15, P2148, DOI 10.1158/1078-0432.CCR-08-1332; Ko K, 2005, J EXP MED, V202, P885, DOI 10.1084/jem.20050940; Kodumudi KN, 2010, CLIN CANCER RES, V16, P4583, DOI 10.1158/1078-0432.CCR-10-0733; Koebel CM, 2007, NATURE, V450, P903, DOI 10.1038/nature06309; Krieg AM, 2006, NAT REV DRUG DISCOV, V5, P471, DOI 10.1038/nrd2059; Kryczek I, 2006, J EXP MED, V203, P871, DOI 10.1084/jem.20050930; Kubota Y, 2009, J EXP MED, V206, P1089, DOI 10.1084/jem.20081605; Kusmartsev S, 2003, CANCER RES, V63, P4441; Lanier LL, 2008, NAT IMMUNOL, V9, P495, DOI 10.1038/ni1581; Lathers DMR, 2004, CANCER IMMUNOL IMMUN, V53, P422, DOI 10.1007/s00262-003-0459-7; Liao XD, 2011, J CLIN INVEST, V121, P2736, DOI 10.1172/JCI45444; Love WE, 2009, ARCH DERMATOL, V145, P1431, DOI 10.1001/archdermatol.2009.291; Manthey CL, 2009, MOL CANCER THER, V8, P3151, DOI 10.1158/1535-7163.MCT-09-0255; Marshall NA, 2012, CANCER RES, V72, P581, DOI 10.1158/0008-5472.CAN-11-0307; Melief CJM, 2008, IMMUNITY, V29, P372, DOI 10.1016/j.immuni.2008.08.004; Mills KHG, 2004, NAT REV IMMUNOL, V4, P841, DOI 10.1038/nri1485; Mirza N, 2006, CANCER RES, V66, P9299, DOI 10.1158/0008-5472.CAN-06-1690; Miselis NR, 2008, MOL CANCER THER, V7, P788, DOI 10.1158/1535-7163.MCT-07-0579; Mizutani K, 2009, NEOPLASIA, V11, P1235, DOI 10.1593/neo.09988; Morita R, 2012, IMMUNOTHERAPY-UK, V4, P1103, DOI [10.2217/IMT.12.116, 10.2217/imt.12.116]; Mougiakakos D, 2010, ADV CANCER RES, V107, P57, DOI 10.1016/S0065-230X(10)07003-X; Mullard A, 2013, NAT REV DRUG DISCOV, V12, P489, DOI 10.1038/nrd4066; Nagai T, 2009, CANCER IMMUNOL IMMUN, V58, P1577, DOI 10.1007/s00262-009-0667-x; Nagaraj S, 2010, CLIN CANCER RES, V16, P1812, DOI 10.1158/1078-0432.CCR-09-3272; Nava-Parada P, 2007, CANCER RES, V67, P1326, DOI 10.1158/0008-5472.CAN-06-3290; Nefedova Y, 2007, CANCER RES, V67, P11021, DOI 10.1158/0008-5472.CAN-07-2593; Obermajer N, 2011, BLOOD, V118, P5498, DOI 10.1182/blood-2011-07-365825; Ostrand-Rosenberg S, 2010, CANCER IMMUNOL IMMUN, V59, P1593, DOI 10.1007/s00262-010-0855-8; Ostrand-Rosenberg S, 2009, J IMMUNOL, V182, P4499, DOI 10.4049/jimmunol.0802740; Ozao-Choy J, 2009, CANCER RES, V69, P2514, DOI 10.1158/0008-5472.CAN-08-4709; Palucka K, 2010, CURR OPIN IMMUNOL, V22, P258, DOI 10.1016/j.coi.2010.02.010; Pardoll DM, 2012, NAT REV CANCER, V12, P252, DOI 10.1038/nrc3239; Pasare C, 2003, SCIENCE, V299, P1033, DOI 10.1126/science.1078231; Paulus P, 2006, CANCER RES, V66, P4349, DOI 10.1158/0008-5472.CAN-05-3523; Pello OM, 2012, BLOOD, V119, P411, DOI 10.1182/blood-2011-02-339911; Peng GY, 2005, SCIENCE, V309, P1380, DOI 10.1126/science.1113401; Peranzoni E, 2010, CURR OPIN IMMUNOL, V22, P238, DOI 10.1016/j.coi.2010.01.021; Puig-Kroger A, 2009, CANCER RES, V69, P9395, DOI 10.1158/0008-5472.CAN-09-2050; Pyonteck SM, 2012, ONCOGENE, V31, P1459, DOI 10.1038/onc.2011.337; Qian BZ, 2011, NATURE, V475, P222, DOI 10.1038/nature10138; Ralph C, 2010, CLIN CANCER RES, V16, P1662, DOI 10.1158/1078-0432.CCR-09-2870; Rasku MA, 2008, J TRANSL MED, V6, DOI 10.1186/1479-5876-6-12; Rech AJ, 2009, ANN NY ACAD SCI, V1174, P99, DOI 10.1111/j.1749-6632.2009.04939.x; Sakuishi K, 2010, J EXP MED, V207, P2187, DOI 10.1084/jem.20100643; Schmidt C, 2007, NAT BIOTECHNOL, V25, P825, DOI 10.1038/nbt0807-825; Serafini P, 2008, CANCER RES, V68, P5439, DOI 10.1158/0008-5472.CAN-07-6621; Seya T, 2012, ONCOIMMUNOLOGY, V1, P1000, DOI 10.4161/onci.19894; Sharma S, 2013, EXPERT OPIN THER TAR, V17, P481, DOI 10.1517/14728222.2013.781585; Shime H, 2012, P NATL ACAD SCI USA, V109, P2066, DOI 10.1073/pnas.1113099109; Sica A, 2008, SEMIN CANCER BIOL, V18, P349, DOI 10.1016/j.semcancer.2008.03.004; Sica A, 2007, J CLIN INVEST, V117, P1155, DOI 10.1172/JCI31422; Sinha P, 2005, CANCER IMMUNOL IMMUN, V54, P1137, DOI 10.1007/s00262-005-0703-4; Sinha P, 2005, CANCER RES, V65, P11743, DOI 10.1158/0008-5472.CAN-05-0045; Sinha P, 2005, J IMMUNOL, V174, P636, DOI 10.4049/jimmunol.174.2.636; Sinha P, 2007, J IMMUNOL, V179, P977, DOI 10.4049/jimmunol.179.2.977; Sinha P, 2007, CANCER RES, V67, P4507, DOI 10.1158/0008-5472.CAN-06-4174; Smyth MJ, 2006, ADV IMMUNOL, V90, P1, DOI 10.1016/S0065-2776(06)90001-7; Solinas G, 2009, J LEUKOCYTE BIOL, V86, P1065, DOI 10.1189/jlb.0609385; Speiser DE, 2005, J CLIN INVEST, V115, P739, DOI 10.1172/JCI200523373; Steitz J, 2001, CANCER RES, V61, P8643; Stewart TJ, 2011, CANCER METAST REV, V30, P125, DOI 10.1007/s10555-011-9280-5; Suntharalingam G, 2006, NEW ENGL J MED, V355, P1018, DOI 10.1056/NEJMoa063842; Suzuki E, 2005, CLIN CANCER RES, V11, P6713, DOI 10.1158/1078-0432.CCR-05-0883; Suzuki T, 2007, PLOS PATHOG, V3, P1082, DOI 10.1371/journal.ppat.0030111; Tan W, 2011, NATURE, V470, P548, DOI 10.1038/nature09707; Topalian SL, 2012, NEW ENGL J MED, V366, P2443, DOI 10.1056/NEJMoa1200690; Tormo D, 2006, CANCER RES, V66, P5427, DOI 10.1158/0008-5472.CAN-06-0399; Ugel S, 2009, CURR OPIN PHARMACOL, V9, P470, DOI 10.1016/j.coph.2009.06.014; Vincent J, 2010, CANCER RES, V70, P3052, DOI 10.1158/0008-5472.CAN-09-3690; Waickman AT, 2012, CANCER IMMUNOL IMMUN, V61, P917, DOI 10.1007/s00262-011-1155-7; Walter S, 2013, ONCOIMMUNOLOGY, V2, DOI 10.4161/onci.22246; Wang RF, 2006, SEMIN IMMUNOL, V18, P136, DOI 10.1016/j.smim.2006.01.008; WATANABE Y, 1987, J BIOL RESP MODIF, V6, P169; Weisser SB, 2011, EUR J IMMUNOL, V41, P1742, DOI 10.1002/eji.201041105; Wilson HL, 2006, INT REV IMMUNOL, V25, P183, DOI 10.1080/08830180600785868; Wolchok JD, 2013, NEW ENGL J MED, V369, P122, DOI 10.1056/NEJMoa1302369; Woo EY, 2001, CANCER RES, V61, P4766; Woo SR, 2012, CANCER RES, V72, P917, DOI 10.1158/0008-5472.CAN-11-1620; Xin H, 2009, CANCER RES, V69, P2506, DOI 10.1158/0008-5472.CAN-08-4323; Yang YP, 2004, NAT IMMUNOL, V5, P508, DOI 10.1038/ni1059; Yao S, 2013, NAT REV DRUG DISCOV, V12, P130, DOI 10.1038/nrd3877; Youn JI, 2008, J IMMUNOL, V181, P5791, DOI 10.4049/jimmunol.181.8.5791; Zabuawala T, 2010, CANCER RES, V70, P1323, DOI 10.1158/0008-5472.CAN-09-1474; Zeisberger SM, 2006, BRIT J CANCER, V95, P272, DOI 10.1038/sj.bjc.6603240; Zhang W, 2010, CLIN CANCER RES, V16, P3420, DOI 10.1158/1078-0432.CCR-09-2904; Zhao ED, 2012, ONCOIMMUNOLOGY, V1, P152, DOI 10.4161/onci.1.2.18480; Zhu XM, 2011, J NEURO-ONCOL, V104, P83, DOI 10.1007/s11060-010-0473-5; Zhu YW, 2011, IMMUNITY, V34, P466, DOI 10.1016/j.immuni.2011.04.008; Zou LH, 2004, CANCER RES, V64, P8451, DOI 10.1158/0008-5472.CAN-04-1987	142	101	109	1	41	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 18	2014	33	38					4623	4631		10.1038/onc.2013.432	http://dx.doi.org/10.1038/onc.2013.432			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AP3VX	24141774	Green Submitted			2023-01-03	WOS:000342007200001
J	Gunderson, EW				Gunderson, Erik W.			Synthetic Cannabinoids: A New Frontier of Designer Drugs	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							SPICE		[Gunderson, Erik W.] Univ Virginia, Charlottesville, VA USA; [Gunderson, Erik W.] Ctr Wellness & Change, Charlottesville, VA USA; Columbia Univ, New York, NY USA	University of Virginia; Columbia University	Gunderson, EW (corresponding author), Univ Virginia Hlth Syst, Box 800623, Charlottesville, VA 22908 USA.	erikgunderson@virginia.edu						American Association of Poison Control Centers, FACTS SYNTH MAR SYNT; Drug Enforcement Administration, 2013, FED REGISTER, V78, P28735; European Monitoring Centre for Drugs and Drug Addiction, 2009, UND SPIC PHEN; Gunderson EW, 2012, AM J ADDICTION, V21, P320, DOI 10.1111/j.1521-0391.2012.00240.x; Gunderson EW, 2013, SUBST ABUS IN PRESS; Gunderson EW, 2012, S 11 EM DRUGS SYNTH; Hermanns-Clausen M, 2013, ADDICTION, V108, P534, DOI 10.1111/j.1360-0443.2012.04078.x; Johnston L.D., 2013, MONITORING FUTURE NA; Substance Abuse and Mental Health Services Administration  Center for Behavioral Health Statistics and Quality, 2012, DRUG REL EM DEP VIS; United Nations Office on Drugs and Crime, WORLD DRUG REP 2013; Vandrey R, 2012, DRUG ALCOHOL DEPEN, V120, P238, DOI 10.1016/j.drugalcdep.2011.07.011	11	15	16	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 15	2013	159	8					563	+		10.7326/0003-4819-159-8-201310150-00707	http://dx.doi.org/10.7326/0003-4819-159-8-201310150-00707			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	249BH	24018791				2023-01-03	WOS:000326751200021
J	Tse, AKW; Chow, KY; Cao, HH; Cheng, CY; Kwan, HY; Yu, H; Zhu, GY; Wu, YC; Fong, WF; Yu, ZL				Tse, Anfernee Kai-Wing; Chow, Ka-Yu; Cao, Hui-Hui; Cheng, Chi-Yan; Kwan, Hiu-Yee; Yu, Hua; Zhu, Guo-Yuan; Wu, Yiu-Cheong; Fong, Wang-Fun; Yu, Zhi-Ling			The Herbal Compound Cryptotanshinone Restores Sensitivity in Cancer Cells That Are Resistant to the Tumor Necrosis Factor-related Apoptosis-inducing Ligand	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRAIL-INDUCED APOPTOSIS; KAPPA-B; MEDIATED APOPTOSIS; KILLER/DR5 GENE; TANSHINONE IIA; UP-REGULATION; ER-STRESS; RECEPTOR; EXPRESSION; MELANOMA	Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) selectively induces apoptosis and kills cancer cells but not normal cells. However, TRAIL resistance due to low level of TRAIL receptor expression is widely found in cancer cells and hampers its development for cancer treatment. Thus, the agents that can sensitize the tumor cells to TRAIL-mediated apoptosis are urgently needed. We investigated whether tanshinones, the major bioactive compounds of Salvia miltiorrhiza (danshen), can up-regulate TRAIL receptor expression. Among the major tanshinones being tested, cryptotanshinone (CT) showed the best ability to induce TRAIL receptor 2 (DR5) expression. We further showed that CT was capable of promoting TRAIL-induced cell death and apoptosis in A375 melanoma cells. CT-induced DR5 induction was not cell type-specific, as DR5 induction was observed in other cancer cell types. DR5 knockdown abolished the enhancing effect of CT on TRAIL responses. Mechanistically, induction of the DR5 by CT was found to be p53-independent but dependent on the induction of CCAAT/enhancer-binding protein-homologous protein (CHOP). Knockdown of CHOP abolished CT-induced DR5 expression and the associated potentiation of TRAIL-mediated cell death. In addition, CT-induced ROS production preceded up-regulation of CHOP and DR5 and consequent sensitization of cells to TRAIL. Interestingly, CT also converted TRAIL-resistant lung A549 cancer cells into TRAIL-sensitive cells. Taken together, our results indicate that CT can potentiate TRAIL-induced apoptosis through up-regulation of DR5.	[Tse, Anfernee Kai-Wing; Chow, Ka-Yu; Cao, Hui-Hui; Cheng, Chi-Yan; Kwan, Hiu-Yee; Yu, Hua; Zhu, Guo-Yuan; Wu, Yiu-Cheong; Fong, Wang-Fun; Yu, Zhi-Ling] Hong Kong Baptist Univ, Sch Chinese Med, Ctr Canc & Inflammat Res, Kowloon Tong, Hong Kong, Peoples R China	Hong Kong Baptist University	Yu, ZL (corresponding author), Sch Chinese Med, Jockey Club Sch Chinese Med Bldg,7 Baptist Univ R, Kowloon Tong, Hong Kong, Peoples R China.	zlyu@hkbu.edu.hk	Yu, Hua/B-8854-2012; Zhu, Guo-Yuan/AAG-7914-2019	Yu, Hua/0000-0003-0737-9925; Zhu, Guo-Yuan/0000-0002-4355-894X; KWAN, Hiu Yee/0000-0002-6088-7323; Tse, Kai Wing/0000-0002-0046-9808; Yu, Zhiling/0000-0002-2979-9608; CHENG, Brian Chi-yan/0000-0002-2447-6893	Hong Kong Baptist University [HKBU 38-40-076, FRG1/11-12/053, FRG2/11-12/057, FRG1/13-14/002]; University Grants Committee of Hong Kong [HKBU 262512]	Hong Kong Baptist University; University Grants Committee of Hong Kong	This work was supported by Hong Kong Baptist University Grants HKBU 38-40-076, FRG1/11-12/053, FRG2/11-12/057, and FRG1/13-14/002 and the University Grants Committee of Hong Kong Grant HKBU 262512.	Abdulghani J, 2010, EXPERT OPIN THER TAR, V14, P1091, DOI 10.1517/14728222.2010.519701; Aydin C, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-584; Cheng CY, 2010, MOL MED REP, V3, P645, DOI 10.3892/mmr_00000310; Chiu TL, 2010, INT J MOL MED, V25, P231, DOI 10.3892/ijmm_00000335; Dimberg LY, 2013, ONCOGENE, V32, P1341, DOI 10.1038/onc.2012.164; Eigentler TK, 2003, LANCET ONCOL, V4, P748, DOI 10.1016/S1470-2045(03)01280-4; Griffith TS, 1998, J IMMUNOL, V161, P2833; Julia F, 2012, DERMATOL THER, V25, P452, DOI 10.1111/j.1529-8019.2012.01487.x; KASTRINAKIS WV, 1995, ONCOGENE, V11, P647; Kim JH, 2011, APOPTOSIS, V16, P696, DOI 10.1007/s10495-011-0605-1; Kim YH, 2008, FREE RADICAL BIO MED, V44, P1055, DOI 10.1016/j.freeradbiomed.2007.12.001; Lee WYW, 2009, CANCER LETT, V285, P46, DOI 10.1016/j.canlet.2009.04.040; Liu AH, 2006, J PHARM PHARM SCI, V9, P1; Mellier G, 2012, FREE RADICAL RES, V46, P996, DOI 10.3109/10715762.2012.690514; Meng RD, 2001, EXP CELL RES, V262, P154, DOI 10.1006/excr.2000.5073; Moon DO, 2011, BIOCHEM PHARMACOL, V82, P1641, DOI 10.1016/j.bcp.2011.08.019; Nguyen T, 2001, CLIN CANCER RES, V7, p966S; OConnor PM, 1997, CANCER RES, V57, P4285; Pan GH, 1997, SCIENCE, V277, P815, DOI 10.1126/science.277.5327.815; Park IJ, 2012, APOPTOSIS, V17, P248, DOI 10.1007/s10495-011-0680-3; Pennarun B, 2010, BBA-REV CANCER, V1805, P123, DOI 10.1016/j.bbcan.2009.11.004; Russo M, 2010, BIOCHEM PHARMACOL, V80, P674, DOI 10.1016/j.bcp.2010.03.011; Seol JY, 2003, CANCER GENE THER, V10, P540, DOI 10.1038/sj.cgt.7700597; Sheikh MS, 1998, CANCER RES, V58, P1593; Siegelin MD, 2012, EXPERT OPIN THER TAR, V16, P801, DOI 10.1517/14728222.2012.703655; Su CC, 2012, EXP THER MED, V3, P555, DOI 10.3892/etm.2011.441; Takimoto R, 2000, ONCOGENE, V19, P1735, DOI 10.1038/sj.onc.1203489; The State Pharmacopoeia Commission of China, 2005, CHIN PHARM, P528; Tse AKW, 2005, BIOCHEM PHARMACOL, V70, P1443, DOI 10.1016/j.bcp.2005.08.011; Tse AKW, 2010, MOL IMMUNOL, V47, P1728, DOI 10.1016/j.molimm.2010.03.004; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; YAGINUMA Y, 1992, CANCER RES, V52, P4196; Yamaguchi H, 2004, J BIOL CHEM, V279, P45495, DOI 10.1074/jbc.M406933200; Yang Y, 2011, ONCOGENE, V30, P2207, DOI 10.1038/onc.2010.600; Ye YT, 2012, MOL CELL BIOCHEM, V363, P191, DOI 10.1007/s11010-011-1171-0; Yokouchi M, 2008, J BIOL CHEM, V283, P4252, DOI 10.1074/jbc.M705951200; Zhang Y, 2012, INT J MOL SCI, V13, P13621, DOI 10.3390/ijms131013621; Zhou LM, 2005, J CLIN PHARMACOL, V45, P1345, DOI 10.1177/0091270005282630	38	37	41	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 11	2013	288	41					29923	29933		10.1074/jbc.M113.483909	http://dx.doi.org/10.1074/jbc.M113.483909			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	302OT	23986445	Green Published, hybrid			2023-01-03	WOS:000330615300065
J	Laws, TR; Nelson, M; Bonnafous, C; Sicard, H; Taylor, C; Salguero, FJ; Atkins, TP; Oyston, PCF; Rowland, CA				Laws, Thomas R.; Nelson, Michelle; Bonnafous, Cecile; Sicard, Helene; Taylor, Christopher; Salguero, Francisco Javier; Atkins, Timothy P.; Oyston, Petra C. F.; Rowland, Caroline A.			In Vivo Manipulation of gamma 9(+) T Cells in the Common Marmoset (Callithrix Jacchus) with Phosphoantigen and Effect on the Progression of Respiratory Melioidosis	PLOS ONE			English	Article							LETHAL INHALATIONAL INFECTION; BURKHOLDERIA-PSEUDOMALLEI; FRANCISELLA-TULARENSIS; INTRACELLULAR MULTIPLICATION; MYCOBACTERIUM-TUBERCULOSIS; BRUCELLA-SUIS; MODEL; ACTIVATION; RESPONSES; VITRO	Burkholderia pseudomallei is a dangerous human pathogen. Phosphoantigens specifically the target primate specific gamma 9(+)delta 2(+) T cells subset and some have been developed as potential immunotherapeutics. Previously, we demonstrated that, when stimulated with the phosphoantigen CHDMAPP, gamma 9(+)delta 2(+) T cells aid in the killing of intracellular B. pseudomallei bacteria. Moreover, we found that common marmoset (Callithrix Jacchus) gamma 9(+) T cells increase in frequency and respond to the phosphoantigen CHDMAPP and/or B. pseudomallei, in combination with IL-2, in a similar manner to human gamma 9(+) delta 2(+) T cells. Here we evaluate the efficacy of the phosphoantigen CHDMAPP, in combination with IL-2, as a therapy against B. pseudomallei infection, in vivo. We found that the previous studies predicted the in vivo responsiveness of gamma 9(+) T cells to the CHDMAPP+IL-2 treatment and significant expansion of the numbers of peripheral and splenic gamma 9(+) T cells were observed. This effect was similar to those reported in other primate species treated with phosphoantigen. Furthermore, splenocytes were retrieved 7 days post onset of treatment, restimulated with CHDMAPP or heat-killed B. pseudomallei and the cultured gamma 9(+) T cells demonstrated no reduction in IFN-gamma response when CHDMAPP+IL-2 animals were compared to IL-2 only treated animals. Using an established model of B. pseudomallei infection in the marmoset, we assessed the potential for using phosphoantigen as a novel immunotherapy. The CHDMAPP treatment regime had no effect on the progression of respiratory melioidosis and this was despite the presence of elevated numbers of gamma 9(+) T cells in the spleen, liver and lung and an increased proportion of IFN-gamma(+) cells in response to infection. We therefore report that the common marmoset has proven a good model for studying the effect in vivo of gamma 9(+) T cell stimulation; however, gamma 9(+) T cells have little or no effect on the progression of lethal, respiratory B. pseudomallei infection.	[Laws, Thomas R.; Nelson, Michelle; Taylor, Christopher; Atkins, Timothy P.; Oyston, Petra C. F.; Rowland, Caroline A.] Def Sci & Technol Lab DSTL Porton Down, Dept Biomed Sci, Salisbury, Wilts, England; [Bonnafous, Cecile; Sicard, Helene] Innate Pharma, Marseille, France; [Salguero, Francisco Javier] AHVLA, Weybridge, Surrey, England		Rowland, CA (corresponding author), Def Sci & Technol Lab DSTL Porton Down, Dept Biomed Sci, Salisbury, Wilts, England.	carowland@dstl.gov.uk	Salguero, Francisco J/A-7336-2010; Laws, Thomas/L-2935-2018	Laws, Thomas/0000-0002-0142-9162; Salguero, Francisco Javier/0000-0002-5315-3882	British Ministry of Defence	British Ministry of Defence	This work was funded by the British Ministry of Defence. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Agrati C, 2011, AIDS REV, V13, P3; Ali Z, 2007, J IMMUNOL, V179, P8287, DOI 10.4049/jimmunol.179.12.8287; Ali Z, 2009, J IMMUNOL, V183, P5407, DOI 10.4049/jimmunol.0901760; Boedec A, 2008, J MED CHEM, V51, P1747, DOI 10.1021/jm701101g; Cheng AC, 2005, CLIN MICROBIOL REV, V18, P383, DOI 10.1128/CMR.18.2.383-416.2005; Chierakul W, 2005, CLIN INFECT DIS, V41, P982, DOI 10.1086/432942; COOPER AM, 1993, J EXP MED, V178, P2243, DOI 10.1084/jem.178.6.2243; Dieli F, 2000, EUR J IMMUNOL, V30, P1512, DOI 10.1002/(SICI)1521-4141(200005)30:5<1512::AID-IMMU1512>3.0.CO;2-3; Eberl M, 2003, FEBS LETT, V544, P4, DOI 10.1016/S0014-5793(03)00483-6; Elkins KL, 2010, MICROBES INFECT, V12, P28, DOI 10.1016/j.micinf.2009.09.012; Gioia C, 2002, J IMMUNOL, V168, P1484, DOI 10.4049/jimmunol.168.3.1484; Gong GM, 2009, BLOOD, V113, P837, DOI 10.1182/blood-2008-06-162792; Huang D, 2008, INFECT IMMUN, V76, P426, DOI 10.1128/IAI.01008-07; Huang D, 2009, P NATL ACAD SCI USA, V106, P7553, DOI 10.1073/pnas.0811250106; INNATE Pharma, 2009, IPH1101 HCV PHAS 2A; JouenBeades F, 1997, INFECT IMMUN, V65, P4267, DOI 10.1128/IAI.65.10.4267-4272.1997; Lever MS, 2008, INT J EXP PATHOL, V89, P171, DOI 10.1111/j.1365-2613.2008.00581.x; Liu BP, 2002, INFECT IMMUN, V70, P504, DOI 10.1128/IAI.70.2.504-511.2002; Nelson M, 2011, INT J EXP PATHOL, V92, P428, DOI 10.1111/j.1365-2613.2011.00791.x; Nelson M, 2010, J MED MICROBIOL, V59, P1107, DOI 10.1099/jmm.0.020669-0; Nelson M, 2009, INT J EXP PATHOL, V90, P109, DOI 10.1111/j.1365-2613.2008.00631.x; Ottones F, 2000, IMMUNOLOGY, V100, P252, DOI 10.1046/j.1365-2567.2000.00024.x; Ottones F, 2000, J IMMUNOL, V165, P7133, DOI 10.4049/jimmunol.165.12.7133; PARKER CM, 1990, J EXP MED, V171, P1597, DOI 10.1084/jem.171.5.1597; Poquet Y, 1998, INFECT IMMUN, V66, P2107, DOI 10.1128/IAI.66.5.2107-2114.1998; Qin G, 2011, J VIROL, V85, P10109, DOI 10.1128/JVI.05341-11; RAJCHANUVONG A, 1995, T ROY SOC TROP MED H, V89, P546, DOI 10.1016/0035-9203(95)90104-3; Rowland CA, 2006, INFECT IMMUN, V74, P5333, DOI 10.1128/IAI.02046-05; Rowland CA, 2012, CELL IMMUNOL, V280, P132, DOI 10.1016/j.cellimm.2012.12.002; Rowland CA, 2012, MICROBES INFECT, V14, P584, DOI 10.1016/j.micinf.2012.02.001; Santanirand P, 1999, INFECT IMMUN, V67, P3593, DOI 10.1128/IAI.67.7.3593-3600.1999; Shao LY, 2009, J VIROL, V83, P11959, DOI 10.1128/JVI.00689-09; Sicard H, 2005, J IMMUNOL, V175, P5471, DOI 10.4049/jimmunol.175.8.5471; Smither S.J., 2012, INT J EXP PATH UNPUB; Tan GYG, 2008, J MED MICROBIOL, V57, P508, DOI 10.1099/jmm.0.47596-0; Wiersinga WJ, 2006, NAT REV MICROBIOL, V4, P272, DOI 10.1038/nrmicro1385; Yeager JJ, 2012, INFECT IMMUN, V80, P3332, DOI 10.1128/IAI.00675-12	37	5	5	0	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 30	2013	8	9							e74789	10.1371/journal.pone.0074789	http://dx.doi.org/10.1371/journal.pone.0074789			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	231NL	24098670	gold, Green Published, Green Submitted			2023-01-03	WOS:000325423500041
J	Meurer, WJ				Meurer, William J.			Tranexamic acid reduced mortality in trauma patients who were bleeding or at risk for bleeding	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									Univ Michigan, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Meurer, WJ (corresponding author), Univ Michigan, Ann Arbor, MI 48109 USA.		Meurer, William J/A-7547-2010	Meurer, William J/0000-0002-1158-5302				Adeoye O, 2011, STROKE, V42, P1952, DOI 10.1161/STROKEAHA.110.612358; Tissue plasminogen activator for acute ischemic stroke, 1995, NEW ENGL J MED, V333, P1581, DOI [DOI 10.1056/NEJM199512143332401, 10.1056/NEJM199512143332401]	2	2	3	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 17	2013	159	6							JC3	10.7326/0003-4819-159-6-201309170-02003	http://dx.doi.org/10.7326/0003-4819-159-6-201309170-02003			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	234EY	24042386				2023-01-03	WOS:000325625900002
J	Douillard, JY; Oliner, KS; Siena, S; Tabernero, J; Burkes, R; Barugel, M; Humblet, Y; Bodoky, G; Cunningham, D; Jassem, J; Rivera, F; Kocakova, I; Ruff, P; Blasinska-Morawiec, M; Smakal, M; Canon, JL; Rother, M; Williams, R; Rong, A; Wiezorek, J; Sidhu, R; Patterson, SD				Douillard, Jean-Yves; Oliner, Kelly S.; Siena, Salvatore; Tabernero, Josep; Burkes, Ronald; Barugel, Mario; Humblet, Yves; Bodoky, Gyorgy; Cunningham, David; Jassem, Jacek; Rivera, Fernando; Kocakova, Ilona; Ruff, Paul; Blasinska-Morawiec, Maria; Smakal, Martin; Canon, Jean Luc; Rother, Mark; Williams, Richard; Rong, Alan; Wiezorek, Jeffrey; Sidhu, Roger; Patterson, Scott D.			Panitumumab-FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CETUXIMAB PLUS IRINOTECAN; RANDOMIZED PHASE-III; KRAS CODON 12; 1ST-LINE TREATMENT; LUNG-CANCER; BRAF; CHEMOTHERAPY; SURVIVAL; FLUOROURACIL; LEUCOVORIN	BackgroundPatients with metastatic colorectal cancer that harbors KRAS mutations in exon 2 do not benefit from anti-epidermal growth factor receptor (EGFR) therapy. Other activating RAS mutations may also be negative predictive biomarkers for anti-EGFR therapy. MethodsIn this prospective-retrospective analysis, we assessed the efficacy and safety of panitumumab plus oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) as compared with FOLFOX4 alone, according to RAS (KRAS or NRAS) or BRAF mutation status. A total of 639 patients who had metastatic colorectal cancer without KRAS mutations in exon 2 had results for at least one of the following: KRAS exon 3 or 4; NRAS exon 2, 3, or 4; or BRAF exon 15. The overall rate of ascertainment of RAS status was 90%. ResultsAmong 512 patients without RAS mutations, progression-free survival was 10.1 months with panitumumab-FOLFOX4 versus 7.9 months with FOLFOX4 alone (hazard ratio for progression or death with combination therapy, 0.72; 95% confidence interval [CI], 0.58 to 0.90; P=0.004). Overall survival was 26.0 months in the panitumumab-FOLFOX4 group versus 20.2 months in the FOLFOX4-alone group (hazard ratio for death, 0.78; 95% CI, 0.62 to 0.99; P=0.04). A total of 108 patients (17%) with nonmutated KRAS exon 2 had other RAS mutations. These mutations were associated with inferior progression-free survival and overall survival with panitumumab-FOLFOX4 treatment, which was consistent with the findings in patients with KRAS mutations in exon 2. BRAF mutations were a negative prognostic factor. No new safety signals were identified. ConclusionsAdditional RAS mutations predicted a lack of response in patients who received panitumumab-FOLFOX4. In patients who had metastatic colorectal cancer without RAS mutations, improvements in overall survival were observed with panitumumab-FOLFOX4 therapy. (Funded by Amgen and others; PRIME ClinicalTrials.gov number, NCT00364013.)	[Douillard, Jean-Yves] Inst Cancerol Ouest ICO Rene Gauducheau, Nantes, France; [Oliner, Kelly S.; Williams, Richard; Rong, Alan; Wiezorek, Jeffrey; Sidhu, Roger; Patterson, Scott D.] Amgen Inc, Thousand Oaks, CA USA; [Siena, Salvatore] Osped Niguarda Ca Granda, Milan, Italy; [Tabernero, Josep] Univ Autonoma Barcelona, Vall dHebron Univ Hosp, E-08193 Barcelona, Spain; [Rivera, Fernando] Hosp Univ Marques de Valdecilla, Santander, Spain; [Burkes, Ronald] Mt Sinai Hosp, Toronto, ON M5G 1X5, Canada; [Rother, Mark] Credit Valley Hosp, Mississauga, ON, Canada; [Barugel, Mario] Hosp Gastroenterol, Buenos Aires, DF, Argentina; [Humblet, Yves] Catholic Univ Louvain, B-1200 Brussels, Belgium; [Canon, Jean Luc] Grand Hop Charleroi, Charleroi, Belgium; [Bodoky, Gyorgy] Szent Laszlo Hosp, Budapest, Hungary; [Cunningham, David] Royal Marsden Natl Hlth Serv Fdn Trust, London, England; [Jassem, Jacek] Med Univ Gdansk, Gdansk, Poland; [Blasinska-Morawiec, Maria] Copernicus Mem Hosp, Lodz, Poland; [Kocakova, Ilona] Masaryk Mem Canc Inst, Brno, Czech Republic; [Smakal, Martin] Inst Oncol & Rehabil Plesi, Nova Ves Pod Plesi, Czech Republic; [Ruff, Paul] Univ Witwatersrand, Fac Hlth Sci, Johannesburg, South Africa	UNICANCER; Institut de Cancerologie de l'Ouest (ICO); Amgen; IRCCS Ca Granda Ospedale Maggiore Policlinico; Ospedale Niguarda Ca' Granda; Autonomous University of Barcelona; Hospital Universitari Vall d'Hebron; Hospital Universitario Marques de Valdecilla (HUMV); University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; University of Toronto; Trillium Health Partners; Credit Valley Hospital; Universite Catholique Louvain; Grand Hopital De Charleroi; Szent Laszlo Hospital; Royal Marsden NHS Foundation Trust; Fahrenheit Universities; Medical University Gdansk; Masaryk Memorial Cancer Institute; University of Witwatersrand	Douillard, JY (corresponding author), ICO Rene Gauducheau, Blvd Jacques Monod, F-44805 St Herblain, France.	jean-yves.douillard@ico.unicancer.fr	Smakal, Martin/E-4294-2018; Tabernero, Josep/AAG-5026-2019; SIENA, SALVATORE/AAC-5806-2019	Smakal, Martin/0000-0002-5618-5986; Tabernero, Josep/0000-0002-2495-8139; SIENA, SALVATORE/0000-0002-2681-2846; Cunningham, David/0000-0001-5158-1069; Jassem, Jacek/0000-0002-8875-6747; Bodoky, Gyorgy/0000-0002-5659-2020	Amgen	Amgen(Amgen)	Funded by Amgen and others; PRIME ClinicalTrials.gov number, NCT00364013.	Amado RG, 2008, J CLIN ONCOL, V26, P1626, DOI 10.1200/JCO.2007.14.7116; Andre T, 2013, ANN ONCOL, V24, P412, DOI 10.1093/annonc/mds465; Bokemeyer C, 2011, ANN ONCOL, V22, P1535, DOI 10.1093/annonc/mdq632; Bokemeyer C, 2012, EUR J CANCER, V48, P1466, DOI 10.1016/j.ejca.2012.02.057; De Roock W, 2011, LANCET ONCOL, V12, P594, DOI 10.1016/S1470-2045(10)70209-6; De Roock W, 2010, JAMA-J AM MED ASSOC, V304, P1812, DOI 10.1001/jama.2010.1535; De Roock W, 2010, LANCET ONCOL, V11, P753, DOI 10.1016/S1470-2045(10)70130-3; Di Nicolantonio F, 2008, J CLIN ONCOL, V26, P5705, DOI 10.1200/JCO.2008.18.0786; Douillard JY, 2010, J CLIN ONCOL, V28, P4697, DOI 10.1200/JCO.2009.27.4860; Edkins S, 2006, CANCER BIOL THER, V5, P928, DOI 10.4161/cbt.5.8.3251; Farina-Sarasqueta A, 2010, ANN ONCOL, V21, P2396, DOI 10.1093/annonc/mdq258; Fernandez-Medarde Alberto, 2011, Genes Cancer, V2, P344, DOI 10.1177/1947601911411084; Forbes SA, 2011, NUCLEIC ACIDS RES, V39, pD945, DOI 10.1093/nar/gkq929; Janakiraman M, 2010, CANCER RES, V70, P5901, DOI 10.1158/0008-5472.CAN-10-0192; Karnoub AE, 2008, NAT REV MOL CELL BIO, V9, P517, DOI 10.1038/nrm2438; Koivunen JP, 2008, BRIT J CANCER, V99, P245, DOI 10.1038/sj.bjc.6604469; Kuang Y, 2009, CLIN CANCER RES, V15, P2630, DOI 10.1158/1078-0432.CCR-08-2592; Loupakis F, 2009, BRIT J CANCER, V101, P715, DOI 10.1038/sj.bjc.6605177; Mitani N, 2007, ANN CLIN BIOCHEM, V44, P557, DOI 10.1258/000456307782268174; OKEN MM, 1982, AM J CLIN ONCOL-CANC, V5, P649, DOI 10.1097/00000421-198212000-00014; Peeters M, 2013, CLIN CANCER RES, V19, P1902, DOI 10.1158/1078-0432.CCR-12-1913; Peeters M, 2013, J CLIN ONCOL, V31, P759, DOI 10.1200/JCO.2012.45.1492; Peeters M, 2010, J CLIN ONCOL, V28, P4706, DOI 10.1200/JCO.2009.27.6055; Phipps AI, 2012, CANCER EPIDEM BIOMAR, V21, P1792, DOI 10.1158/1055-9965.EPI-12-0674; Poeta ML, 2007, NEW ENGL J MED, V357, P2552, DOI 10.1056/NEJMoa073770; Van Cutsem E, 2011, J CLIN ONCOL, V29, P2011, DOI 10.1200/JCO.2010.33.5091; Van Cutsem E, 2009, NEW ENGL J MED, V360, P1408, DOI 10.1056/NEJMoa0805019; Vaughn CP, 2011, GENE CHROMOSOME CANC, V50, P307, DOI 10.1002/gcc.20854; Wojcik P, 2008, POL J PATHOL, V59, P93; Yuen ST, 2002, CANCER RES, V62, P6451	30	1603	1661	1	113	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 12	2013	369	11					1023	1034		10.1056/NEJMoa1305275	http://dx.doi.org/10.1056/NEJMoa1305275			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	216SK	24024839				2023-01-03	WOS:000324304200011
J	Patki, G; Allam, FH; Atrooz, F; Dao, AT; Solanki, N; Chugh, G; Asghar, M; Jafri, F; Bohat, R; Alkadhi, KA; Salim, S				Patki, Gaurav; Allam, Farida H.; Atrooz, Fatin; Dao, An T.; Solanki, Naimesh; Chugh, Gaurav; Asghar, Mohammad; Jafri, Faizan; Bohat, Ritu; Alkadhi, Karim A.; Salim, Samina			Grape Powder Intake Prevents Ovariectomy-Induced Anxiety-Like Behavior, Memory Impairment and High Blood Pressure in Female Wistar Rats	PLOS ONE			English	Article							RANDOMIZED CONTROLLED-TRIAL; OXIDATIVE STRESS; COMPLEMENTARY THERAPIES; INSULIN-RESISTANCE; ANIMAL-MODEL; RISK-FACTORS; HYPERTENSION; MENOPAUSE; WOMEN; ANTIOXIDANT	Diminished estrogen influence at menopause is reported to be associated with cognitive decline, heightened anxiety and hypertension. While estrogen therapy is often prescribed to overcome these behavioral and physiological deficits, antioxidants which have been shown beneficial are gaining nutritional intervention and popularity. Therefore, in the present study, utilizing the antioxidant properties of grapes, we have examined effect of 3 weeks of grape powder (GP; 15 g/L dissolved in tap water) treatment on anxiety-like behavior, learning-memory impairment and high blood pressure in ovariectomized (OVX) rats. Four groups of female Wistar rats were used; sham control, sham-GP treated, OVX and OVX+GP treated. We observed a significant increase in systolic and diastolic blood pressure in OVX rats as compared to sham-controls. Furthermore, ovariectomy increased anxiety-like behavior and caused learning and memory impairment in rats as compared to sham-controls. Interestingly, providing grape powder treated water to OVX rats restored both systolic and diastolic blood pressure, decreased anxiety-like behavior and improved memory function. Moreover, OVX rats exhibited an impaired long term potentiation which was restored with grape powder treatment. Furthermore, ovariectomy increased oxidative stress in the brain, serum and urine, selectively decreasing antioxidant enzyme, glyoxalase-1 protein expression in the hippocampus but not in the cortex and amygdala of OVX rats, while grape powder treatment reversed these effects. Other antioxidant enzyme levels, including manganese superoxide dismutase (SOD) and Cu/Zn SOD remained unchanged. We suggest that grape powder by regulating oxidative stress mechanisms exerts its protective effect on blood pressure, learning-memory and anxiety-like behavior. Our study is the first to examine behavioral, biochemical, physiological and electrophysiological outcome of estrogen depletion in rats and to test protective role of grape powder, all in the same study.	[Patki, Gaurav; Allam, Farida H.; Atrooz, Fatin; Dao, An T.; Solanki, Naimesh; Chugh, Gaurav; Asghar, Mohammad; Jafri, Faizan; Bohat, Ritu; Alkadhi, Karim A.; Salim, Samina] Univ Houston, Dept Pharmacol & Pharmaceut Sci, Houston, TX 77204 USA	University of Houston System; University of Houston	Salim, S (corresponding author), Univ Houston, Dept Pharmacol & Pharmaceut Sci, Houston, TX 77204 USA.	ssalim@uh.edu		Atrooz, Fatin/0000-0002-1358-7926	NIH [R15 G103327, R01 AG039836]; NATIONAL INSTITUTE OF MENTAL HEALTH [R15MH093918] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG039836] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	Funding for this research was provided in parts by NIH R15 G103327 grant awarded to Samina Salim, NIH R01 AG039836 to Mohammad Asghar. No additional external funding was received for this study. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abbas AM, 2011, CAN J PHYSIOL PHARM, V89, P497, DOI 10.1139/Y11-053; Acosta JI, 2009, ENDOCRINOLOGY, V150, P4248, DOI 10.1210/en.2008-1802; Agarwal A, 2008, AM J REPROD IMMUNOL, V59, P2, DOI 10.1111/j.1600-0897.2007.00559.x; Aleisa AM, 2011, HIPPOCAMPUS, V21, P899, DOI 10.1002/hipo.20806; Alhaider IA, 2010, EUR J NEUROSCI, V31, P1368, DOI 10.1111/j.1460-9568.2010.07175.x; Allam F., 2013, J NUTR; [Anonymous], NEUROBIOLOGICAL BASI; Asghar M, 2009, AM J PHYSIOL-RENAL, V297, pF1543, DOI 10.1152/ajprenal.00366.2009; Banday AA, 2009, AM J PHYSIOL-RENAL, V297, pF397, DOI 10.1152/ajprenal.90729.2008; Becker S, 2005, HIPPOCAMPUS, V15, P722, DOI 10.1002/hipo.20095; Berk M, 2011, NEUROSCI BIOBEHAV R, V35, P804, DOI 10.1016/j.neubiorev.2010.10.001; Bethel-Brown CS, 2010, PHARMACOL BIOCHEM BE, V96, P423, DOI 10.1016/j.pbb.2010.06.014; Bhuiyan MS, 2010, MENOPAUSE, V17, P213, DOI 10.1097/gme.0b013e3181b57489; Borrelli F, 2010, MATURITAS, V66, P333, DOI 10.1016/j.maturitas.2010.05.010; Bowe J, 2006, J ENDOCRINOL, V191, P399, DOI 10.1677/joe.1.06919; Carroll D, 2010, PSYCHOSOM MED, V72, P16, DOI 10.1097/PSY.0b013e3181c4fca1; Chen TS, 2000, MECH AGEING DEV, V120, P127, DOI 10.1016/S0047-6374(00)00214-1; Ciobica A, 2011, PSYCHIAT DANUB, V23, P340; Curtin MLI, 1990, CHRONIC ILLNESS IMPA; Davidge ST, 2001, AM J PHYSIOL-REG I, V280, pR904, DOI 10.1152/ajpregu.2001.280.3.R904; de Oliveira MR, 2008, NEUROCHEM RES, V33, P378, DOI 10.1007/s11064-007-9438-2; Dennehy C, 2010, MATURITAS, V66, P370, DOI 10.1016/j.maturitas.2010.06.003; Di Loreto S, 2008, INT J BIOCHEM CELL B, V40, P245, DOI 10.1016/j.biocel.2007.07.019; Dong HW, 2001, BRAIN RES REV, V38, P192, DOI 10.1016/S0165-0173(01)00079-0; Femenia T, 2012, BRAIN RES, V1476, P58, DOI 10.1016/j.brainres.2012.03.053; Freeman EW, 2011, JAMA-J AM MED ASSOC, V305, P267, DOI 10.1001/jama.2010.2016; Fuhrman B, 2005, J NUTR, V135, P722, DOI 10.1093/jn/135.4.722; Goss PE, 2007, BREAST CANCER RES TR, V103, P293, DOI 10.1007/s10549-006-9381-y; HALLIWELL B, 1992, J NEUROCHEM, V59, P1609, DOI 10.1111/j.1471-4159.1992.tb10990.x; Hamer M, 2010, HYPERTENSION, V56, P547, DOI 10.1161/HYPERTENSIONAHA.110.153775; Hasenohrl RU, 1999, EXP BRAIN RES, V128, P435, DOI 10.1007/s002210050866; Hovatta I, 2005, NATURE, V438, P662, DOI 10.1038/nature04250; Huang YH, 2010, BRIT J NUTR, V104, P1297, DOI 10.1017/S0007114510002291; Jacobs U, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022925; JIALAL I, 1990, ATHEROSCLEROSIS, V82, P185, DOI 10.1016/0021-9150(90)90039-L; Jialal I, 2001, J NUTR, V131, p389S, DOI 10.1093/jn/131.2.389S; John JH, 2002, LANCET, V359, P1969, DOI 10.1016/S0140-6736(02)98858-6; Jonas BS, 1997, ARCH FAM MED, V6, P43, DOI 10.1001/archfami.6.1.43; Kurzer MS, 2003, J NUTR, V133, p1983S, DOI 10.1093/jn/133.6.1983S; LEDOUX JE, 1988, J NEUROSCI, V8, P2517; Lee SD, 2008, MATURITAS, V61, P268, DOI 10.1016/j.maturitas.2008.07.004; Liehr JG, 1996, J LAB CLIN MED, V128, P344, DOI 10.1016/S0022-2143(96)80002-3; Mendoza-Nunez VM, 2011, REJUV RES, V14, P25, DOI 10.1089/rej.2010.1054; Martins DB, 2012, LIFE SCI, V90, P351, DOI 10.1016/j.lfs.2011.12.006; Masood A, 2009, J PHARMACOL EXP THER, V331, P690, DOI 10.1124/jpet.109.156729; Miquel J, 2006, ARCH GERONTOL GERIAT, V42, P289, DOI 10.1016/j.archger.2005.08.005; Moura EG, 2012, J NUTR BIOCH; Moylan S, 2012, MOL PSYCHIAT; Muthusami S, 2005, CLIN CHIM ACTA, V360, P81, DOI 10.1016/j.cccn.2005.04.014; Paxinos G., 1986, RAT BRAIN STEREOTAXI, V2nd; ROY EJ, 1990, BRAIN RES BULL, V25, P221, DOI 10.1016/0361-9230(90)90064-7; Salim S, 2010, BRAIN RES, V1359, P178, DOI 10.1016/j.brainres.2010.08.093; Salim S, 2010, BEHAV BRAIN RES, V208, P545, DOI 10.1016/j.bbr.2009.12.039; Seeman MV, 1997, AM J PSYCHIAT, V154, P1641, DOI 10.1176/ajp.154.12.1641; Shin LM, 2006, ANN NY ACAD SCI, V1071, P67, DOI 10.1196/annals.1364.007; Sonmez U, 2007, NEUROSCI LETT, V420, P133, DOI 10.1016/j.neulet.2007.04.070; Stahlberg C, 2004, INT J CANCER, V109, P721, DOI 10.1002/ijc.20016; Thompson EA, 2010, MATURITAS, V66, P350, DOI 10.1016/j.maturitas.2010.02.003; Vatassery GT, 2004, J NEUROSCI RES, V75, P845, DOI 10.1002/jnr.20027; Vislocky LM, 2010, NUTR REV, V68, P656, DOI 10.1111/j.1753-4887.2010.00335.x; Vollert C, 2011, BEHAV BRAIN RES, V224, P233, DOI 10.1016/j.bbr.2011.05.010; Walf AA, 2007, PHARMACOL BIOCHEM BE, V86, P407, DOI 10.1016/j.pbb.2006.07.003; Walf AA, 2006, NEUROPSYCHOPHARMACOL, V31, P1097, DOI 10.1038/sj.npp.1301067; Walf AA, 2009, PSYCHONEUROENDOCRINO, V34, P909, DOI [10.1016/j.psyneuen.2009.01.004, 10.1016/j.psyneuen.2009.07.005]; WENGER NK, 1993, NEW ENGL J MED, V329, P247, DOI 10.1056/NEJM199307223290406; Wong VCK, 2009, GYNECOL ENDOCRINOL, V25, P166, DOI 10.1080/09513590802549866; Yanes LL, 2011, AM J HYPERTENS, V24, P740, DOI 10.1038/ajh.2011.71	67	49	51	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 9	2013	8	9							e74522	10.1371/journal.pone.0074522	http://dx.doi.org/10.1371/journal.pone.0074522			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	244QV	24040270	gold, Green Submitted, Green Published			2023-01-03	WOS:000326405300179
J	Svensson, JP; Pesudo, LQ; McRee, SK; Adeleye, Y; Carmichael, P; Samson, LD				Svensson, J. Peter; Pesudo, Laia Quiros; McRee, Siobhan K.; Adeleye, Yeyejide; Carmichael, Paul; Samson, Leona D.			Genomic Phenotyping by Barcode Sequencing Broadly Distinguishes between Alkylating Agents, Oxidizing Agents, and Non-Genotoxic Agents, and Reveals a Role for Aromatic Amino Acids in Cellular Recovery after Quinone Exposure	PLOS ONE			English	Article							SACCHAROMYCES-CEREVISIAE; OXIDATIVE STRESS; YEAST; DNA; SYSTEM; GENES; GENERATION; TRYPTOPHAN; MUTANTS; DEFENSE	Toxicity screening of compounds provides a means to identify compounds harmful for human health and the environment. Here, we further develop the technique of genomic phenotyping to improve throughput while maintaining specificity. We exposed cells to eight different compounds that rely on different modes of action: four genotoxic alkylating (methyl methanesulfonate (MMS), N-Methyl-N-nitrosourea (MNU), N,N'-bis(2-chloroethyl)-N-nitroso-urea (BCNU), N-ethylnitrosourea (ENU)), two oxidizing (2-methylnaphthalene-1,4-dione (menadione, MEN), benzene-1,4-diol (hydroquinone, HYQ)), and two non-genotoxic (methyl carbamate (MC) and dimethyl sulfoxide (DMSO)) compounds. A library of S. cerevisiae 4,852 deletion strains, each identifiable by a unique genetic 'barcode', were grown in competition; at different time points the ratio between the strains was assessed by quantitative high throughput 'barcode' sequencing. The method was validated by comparison to previous genomic phenotyping studies and 90% of the strains identified as MMS-sensitive here were also identified as MMS-sensitive in a much lower throughput solid agar screen. The data provide profiles of proteins and pathways needed for recovery after both genotoxic and non-genotoxic compounds. In addition, a novel role for aromatic amino acids in the recovery after treatment with oxidizing agents was suggested. The role of aromatic acids was further validated; the quinone subgroup of oxidizing agents were extremely toxic in cells where tryptophan biosynthesis was compromised.	[Svensson, J. Peter; Pesudo, Laia Quiros; McRee, Siobhan K.; Samson, Leona D.] MIT, Biol Engn Dept, Cambridge, MA 02139 USA; [Svensson, J. Peter; Pesudo, Laia Quiros; Samson, Leona D.] MIT, Ctr Environm Hlth Sci, Cambridge, MA 02139 USA; [Svensson, J. Peter] Karolinska Inst, Dept Biosci & Nutr, Huddinge, Sweden; [Adeleye, Yeyejide; Carmichael, Paul] Safety & Environm Assurance Ctr, Sharnbrook, Beds, England; [Samson, Leona D.] MIT, Dept Biol, Cambridge, MA USA; [Samson, Leona D.] MIT, Koch Inst Integrat Canc Res, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Karolinska Institutet; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	Samson, LD (corresponding author), MIT, Biol Engn Dept, 77 Massachusetts Ave, Cambridge, MA 02139 USA.	lsamson@mit.edu	Svensson, J Peter/B-4276-2008	Svensson, J Peter/0000-0002-5863-6250; McRee, Siobhan/0000-0002-1539-2946; Carmichael, Paul/0000-0003-1353-9032	Unilever; NCI [R01-CA055042, R01-ES022872]; CEHS center [NIEHS P30-ES002109]; Spanish Ministry of Science and Innovation; NATIONAL CANCER INSTITUTE [R01CA055042] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES002109, R01ES022872] Funding Source: NIH RePORTER	Unilever(Unilever); NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); CEHS center; Spanish Ministry of Science and Innovation(Ministry of Science and Innovation, Spain (MICINN)Spanish Government); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	This research was supported by Unilever and this work was supported by NCI R01-CA055042 (now R01-ES022872), the CEHS center grant NIEHS P30-ES002109, and Unilever. LDS is an American Cancer Society Research Professor. LQP was supported by a Spanish Ministry of Science and Innovation Fellowship. Authors AY and PC are employees of Unilever and contributed with ideas and discussions. With the exception of Unilever, the funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abdoul-Carime H, 2004, J AM CHEM SOC, V126, P12158, DOI 10.1021/ja047517l; Alia M, 2005, J BIOCHEM MOL TOXIC, V19, P119, DOI 10.1002/jbt.20061; Bauer BE, 2003, EUR J BIOCHEM, V270, P3189, DOI 10.1046/j.1432-1033.2003.03701.x; Begley TJ, 2004, MOL CELL, V16, P117, DOI 10.1016/j.molcel.2004.09.005; Begley TJ, 2002, MOL CANCER RES, V1, P103; Bennett CB, 2001, NAT GENET, V29, P426, DOI 10.1038/ng778; BRAUS GH, 1991, MICROBIOL REV, V55, P349, DOI 10.1128/MMBR.55.3.349-370.1991; Brombacher K, 2006, YEAST, V23, P741, DOI 10.1002/yea.1392; Chang M, 2002, P NATL ACAD SCI USA, V99, P16934, DOI 10.1073/pnas.262669299; Dudley AM, 2005, MOL SYST BIOL, V1, DOI 10.1038/msb4100004; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Fowler P, 2012, MUTAT RES-GEN TOX EN, V742, P11, DOI 10.1016/j.mrgentox.2011.10.014; Fu D, 2012, NAT REV CANCER, V12, P104, DOI 10.1038/nrc3185; Fu D, 2010, MOL CELL BIOL, V30, P2449, DOI 10.1128/MCB.01604-09; Gasch AP, 2000, MOL BIOL CELL, V11, P4241, DOI 10.1091/mbc.11.12.4241; Giaever G, 2002, NATURE, V418, P387, DOI 10.1038/nature00935; Gorner H, 2007, J PHOTOCH PHOTOBIO B, V88, P83, DOI 10.1016/j.jphotobiol.2007.05.003; Gresham D, 2011, GENETICS, V187, P299, DOI 10.1534/genetics.110.120766; Gutierrez PL, 2000, FRONT BIOSCI-LANDMRK, V5, pD629, DOI 10.2741/gutier; Han TX, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-6-r60; He XJ, 2009, EUKARYOT CELL, V8, P768, DOI 10.1128/EC.00021-09; HEITMAN J, 1993, MOL CELL BIOL, V13, P5010, DOI 10.1128/MCB.13.8.5010; Hillenmeyer ME, 2008, SCIENCE, V320, P362, DOI 10.1126/science.1150021; Ho CH, 2011, CURR OPIN CHEM BIOL, V15, P66, DOI 10.1016/j.cbpa.2010.10.023; Ischiropoulos H, 2003, J CLIN INVEST, V111, P163, DOI 10.1172/JCI200317638; Marnett LJ, 2003, J CLIN INVEST, V111, P583, DOI 10.1172/JCI200318022; Palmer LK, 2002, GENETICS, V161, P563; Parsons AB, 2006, CELL, V126, P611, DOI 10.1016/j.cell.2006.06.040; Penning TM, 1999, CHEM RES TOXICOL, V12, P1, DOI 10.1021/tx980143n; Pierce SE, 2007, NAT PROTOC, V2, P2958, DOI 10.1038/nprot.2007.427; Ross-Macdonald P, 1999, NATURE, V402, P413, DOI 10.1038/46558; Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303; Smith AM, 2010, PHARMACOL THERAPEUT, V127, P156, DOI 10.1016/j.pharmthera.2010.04.012; Smith AM, 2009, GENOME RES, V19, P1836, DOI 10.1101/gr.093955.109; Song Y, 2010, FREE RADICAL BIO MED, V49, P919, DOI 10.1016/j.freeradbiomed.2010.05.009; Sosa V, 2013, AGEING RES REV, V12, P376, DOI 10.1016/j.arr.2012.10.004; Svensson JP, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037368; Svensson JP, 2011, BMC SYST BIOL, V5, DOI 10.1186/1752-0509-5-157; Umebayashi K, 2003, J CELL BIOL, V161, P1117, DOI 10.1083/jcb.200303088; Vahey MD, 2013, LAB CHIP IN PRESS; Valko M, 2007, INT J BIOCHEM CELL B, V39, P44, DOI 10.1016/j.biocel.2006.07.001; Vasil'ev YV, 2006, J AM CHEM SOC, V128, P5506, DOI 10.1021/ja058464q	42	2	2	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 9	2013	8	9							e73736	10.1371/journal.pone.0073736	http://dx.doi.org/10.1371/journal.pone.0073736			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	244QV	24040048	Green Published, gold, Green Submitted			2023-01-03	WOS:000326405300121
J	Anand, S; Bitton, A; Gaziano, T				Anand, Shuchi; Bitton, Asaf; Gaziano, Thomas			The Gap between Estimated Incidence of End-Stage Renal Disease and Use of Therapy	PLOS ONE			English	Article							CHRONIC KIDNEY-DISEASE; PERITONEAL-DIALYSIS; DEVELOPING-WORLD; LATIN-AMERICA; PREVALENCE; TRENDS; MEN; PROGRESSION; COUNTRY; MRFIT	Background: Relatively few data exist on the burden of end-stage renal disease (ESRD) and use of renal replacement therapy (RRT)-a life-saving therapy-in developing regions. No study has quantified the proportion of patients who develop ESRD but are unable to access RRT. Methods: We performed a comprehensive literature search to estimate use and annual initiation of RRT worldwide, and present these estimates according to World Bank regions. We also present estimates of survival and of etiology of diseases in patients undergoing RRT. Using data on prevalence of diabetes and hypertension, we modeled the incidence of ESRD related to these risk factors in order to quantify the gap between ESRD and use of RRT in developing regions. Results: We find that 1.9 million patients are undergoing RRT worldwide, with continued use and annual initiation at 316 and 73 per million population respectively. RRT use correlates directly (Pearson's r = 0.94) with regional income. Hemodialysis remains the dominant form of RRT but there is wide regional variation in its use. With the exception of the Latin American and Caribbean region, it appears that initiation of RRT in developing regions is restricted to fewer than a quarter of patients projected to develop ESRD. This results in at least 1.2 million premature deaths each year due to lack of access to RRT as a result of diabetes and elevated blood pressure and as many as 3.2 million premature deaths due to all causes of ESRD. Conclusion: Thus, the majority of patients projected to reach ESRD due to diabetes or hypertension in developing regions are unable to access RRT; this gap will increase with rising prevalence of these risk factors worldwide.	[Anand, Shuchi] Stanford Univ, Dept Med, Sch Med, Div Nephrol, Stanford, CA 94305 USA; [Bitton, Asaf] Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Gen Med, Boston, MA 02115 USA; [Gaziano, Thomas] Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA	Stanford University; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Gaziano, T (corresponding author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA.	tgaziano@partners.org			 [F32 DK 084697]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007357, F32DK084697] Funding Source: NIH RePORTER	; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	Dr. Anand is supported by F32 DK 084697. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abu-Aisha H, 2010, PERITON DIALYSIS INT, V30, P23, DOI 10.3747/pdi.2008.00226; Adler AI, 2003, KIDNEY INT, V63, P225, DOI 10.1046/j.1523-1755.2003.00712.x; Aea El Matri, 2008, ARAB J NEPHROLOGY TR, V1, P9; [Anonymous], 2007, TREATM END STAG ORG; Australia and New Zealand Dialysis and Transplant Registry, 2006, 29 AUSTR NZ DIAL TRA; Barsoum RS, 2006, NEW ENGL J MED, V354, P997, DOI 10.1056/NEJMp058318; Barsoum RS, 2002, ARTIF ORGANS, V26, P737, DOI 10.1046/j.1525-1594.2002.07061.x; Brancati FL, 1997, JAMA-J AM MED ASSOC, V278, P2069, DOI 10.1001/jama.278.23.2069; Cusumano A, 2006, RENAL FAILURE, V28, P631, DOI 10.1080/08860220600925693; Danaei G, 2011, LANCET, V378, P31, DOI 10.1016/S0140-6736(11)60679-X; Danaei G, 2011, LANCET, V377, P568, DOI 10.1016/S0140-6736(10)62036-3; Egyptian Society of Nephrology and Transplantation, 2004, EG SOC NEPHR TRANSPL; European Renal Association-European Dialysis and Transplant Association, 2005, EUR REN ASS EUR DIAL; Finkelstein FO, 2009, PERITON DIALYSIS INT, V29, P618; Goyal M, 2002, JAMA-J AM MED ASSOC, V288, P1589, DOI 10.1001/jama.288.13.1589; Grassmann A, 2005, NEPHROL DIAL TRANSPL, V20, P2587, DOI 10.1093/ndt/gfi159; Hallan SI, 2006, J AM SOC NEPHROL, V17, P2275, DOI 10.1681/ASN.2005121273; Jha V, 2004, RENAL FAILURE, V26, P201, DOI 10.1081/JDI-120039516; Kearney PM, 2005, LANCET, V365, P217, DOI 10.1016/S0140-6736(05)70151-3; Klag MJ, 1996, NEW ENGL J MED, V334, P13, DOI 10.1056/NEJM199601043340103; Klag MJ, 1997, JAMA-J AM MED ASSOC, V277, P1293, DOI 10.1001/jama.277.16.1293; Lysaght MJ, 2002, J AM SOC NEPHROL, V13, pS37; Mahmoud KM, 2010, PERITON DIALYSIS INT, V30, P269, DOI 10.3747/pdi.2009.00001; Moosa MR, 2006, KIDNEY INT, V70, P1107, DOI 10.1038/sj.ki.5001750; Najafi I, 2009, PERITON DIALYSIS INT, V29, pS217; National Disease Registry Office and Health Promotion Board, 2000, 3 NAT DIS REG OFF HL; National Renal Registry and Malaysian Society of Nephrology, 2006, 14 NAT REN REG MAL S; Paniagua R, 2002, J AM SOC NEPHROL, V13, DOI 10.1681/ASN.V1351307; Riella MC, 2007, PERITON DIALYSIS INT, V27, P322; Saudi Arabia Center for Organ Transplantation, 2008, ANN DAT REP; Sesso R, 2007, INT J TECHNOL ASSESS, V23, P126, DOI 10.1017/S0266462307051665; Sitprija V, 2003, KIDNEY INT, V63, P128, DOI 10.1046/j.1523-1755.63.s83.27.x; The Kidney Foundation, 2006, DIAL REG PAK 2005 20; The World Bank, 2011, WE CLASS COUNTR WORL; United States Renal Data System, 2008, ANN DAT REP 2005; White SL, 2008, B WORLD HEALTH ORGAN, V86, P229, DOI 10.2471/BLT.07.041715; Wild S, 2004, DIABETES CARE, V27, P1047, DOI 10.2337/diacare.27.5.1047	37	93	95	0	31	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 30	2013	8	8							e72860	10.1371/journal.pone.0072860	http://dx.doi.org/10.1371/journal.pone.0072860			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	211BX	24023651	Green Published, gold, Green Submitted			2023-01-03	WOS:000323880200047
J	Wang, CS; Du, LJ; Si, MJ; Yin, QH; Chen, L; Shu, M; Yuan, F; Fei, XC; Ding, XY				Wang, Cheng-Sheng; Du, Lian-Jun; Si, Ming-Jue; Yin, Qi-Hua; Chen, Liang; Shu, Min; Yuan, Fei; Fei, Xiao-Chun; Ding, Xiao-Yi			Noninvasive Assessment of Response to Neoadjuvant Chemotherapy in Osteosarcoma of Long Bones with Diffusion-Weighted Imaging: An Initial In Vivo Study	PLOS ONE			English	Article							TUMOR NECROSIS; SARCOMA; VOLUME	Objectives: The purpose of our study is to investigate whether diffusion-weighted imaging (DWI) is useful for monitoring the therapeutic response after neoadjuvant chemotherapy in osteosarcoma of long bones. Materials and methods: Conventional magnetic resonance imaging (MRI) and DWI were obtained from 35 patients with histologically proven osteosarcomas. MR examinations were performed in all patients before and after 4 courses of preoperative neoadjuvant chemotherapy. Apparent diffusion coefficients (ADC) were measured. The degree of tumor necrosis was assessed macroscopically and histologically by two experienced pathologists after operation. Student's t test was performed for testing changes in ADC value. Pearson's correlation coefficient was used to estimate the correlation between necrosis rate and post- neoadjuvant chemotherapy ADC values. P<0.05 was considered to denote a significant difference. Results: The difference of the whole osteosarcoma between pre- neoadjuvant chemotherapy ADC value (1.24 +/- 0.17x10(-3) mm(2)/s) and post- (1.93 +/- 0.39x10(-3) mm(2)/s) was significant difference (P<0.01). Regarding in patients with good response, the post- neoadjuvant chemotherapy values were significantly higher than the pre- neoadjuvant chemotherapy values (P<0.01). The post- neoadjuvant chemotherapy ADC value in patients with good response was higher than that of poor response (t = 8.995, P<0.01). The differences in post- neoadjuvant chemotherapy ADC between viable (1.03 +/- 0.17x10(-3) mm(2)/s) and necrotic (2.38 +/- 0.25x10(-3) mm(2)/s) tumor was highly significant (t = 23.905, P<0.01). A positive correlation between necrosis rates and the whole tumor ADC values (r = 0.769, P<0.01) was noted, but necrosis rates were not correlated with the ADC values of necrotic (r = -0.191, P = 0.272) and viable tumor areas (r = 0.292, P = 0.089). Conclusions: DWI can identify residual viable tumor tissues and tumor necrosis induced by neoadjuvant chemotherapy in osteosarcoma. The ADC value can directly reflect the degree of tumor necrosis, and it is useful to evaluate the preoperative neoadjuvant chemotherapy response in patients with osteosarcoma.	[Wang, Cheng-Sheng; Du, Lian-Jun; Si, Ming-Jue; Yin, Qi-Hua; Chen, Liang; Shu, Min; Ding, Xiao-Yi] Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp, Dept Radiol, Shanghai 200030, Peoples R China; [Wang, Cheng-Sheng] Fujian Med Univ, Union Hosp, Dept Radiol, Fuzhou, Peoples R China; [Yuan, Fei; Fei, Xiao-Chun] Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp, Dept Pathol, Shanghai 200030, Peoples R China	Shanghai Jiao Tong University; Fujian Medical University; Shanghai Jiao Tong University	Ding, XY (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp, Dept Radiol, Shanghai 200030, Peoples R China.	dxyrj@hotmail.com			National Natural Science Foundation of China [81072188]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	Funding was received for this work from the National Natural Science Foundation of China (Project Number: 81072188). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bajpai J, 2011, PEDIATR RADIOL, V41, P441, DOI 10.1007/s00247-010-1876-3; Bammer R, 2003, EUR J RADIOL, V45, P169, DOI 10.1016/S0720-048X(02)00303-0; Bieling P, 1996, J CLIN ONCOL, V14, P848, DOI 10.1200/JCO.1996.14.3.848; DEBAERE T, 1992, RADIOLOGY, V185, P587, DOI 10.1148/radiology.185.2.1410378; der Woude HJ v, 1998, SKELETAL RADIOL, V27, P57; Dudeck O, 2008, J MAGN RESON IMAGING, V27, P1109, DOI 10.1002/jmri.21358; ENNEKING WF, 1980, CLIN ORTHOP RELAT R, P106; GOBEL V, 1987, J CANCER RES CLIN, V113, P187, DOI 10.1007/BF00391442; Hayashida Y, 2006, EUR RADIOL, V16, P2637, DOI 10.1007/s00330-006-0342-y; Kim MS, 2008, ANN SURG ONCOL, V15, P906, DOI 10.1245/s10434-007-9779-8; Koh DM, 2007, AM J ROENTGENOL, V188, P1622, DOI 10.2214/AJR.06.1403; Lang P, 1998, RADIOLOGY, V206, P227, DOI 10.1148/radiology.206.1.9423677; Oka K, 2010, SKELETAL RADIOL, V39, P141, DOI 10.1007/s00256-009-0830-7; Pakos EE, 2009, EUR J CANCER, V45, P2367, DOI 10.1016/j.ejca.2009.03.005; PICCI P, 1985, CANCER, V56, P1515, DOI 10.1002/1097-0142(19851001)56:7<1515::AID-CNCR2820560707>3.0.CO;2-6; Uhl M, 2006, INVEST RADIOL, V41, P618, DOI 10.1097/01.rli.0000225398.17315.68; Uhl M, 2006, PEDIATR RADIOL, V36, P1306, DOI 10.1007/s00247-006-0324-x; Wittig JC, 2002, AM FAM PHYSICIAN, V65, P1123	18	11	11	1	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 26	2013	8	8							e72679	10.1371/journal.pone.0072679	http://dx.doi.org/10.1371/journal.pone.0072679			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	215RU	23991141	gold, Green Published, Green Submitted			2023-01-03	WOS:000324228800083
J	Fukuzaki, Y; Sugawara, H; Yamanoha, B; Kogure, S				Fukuzaki, Yumi; Sugawara, Haruna; Yamanoha, Banri; Kogure, Shinichi			532 nm Low-Power Laser Irradiation Recovers gamma-Secretase Inhibitor-Mediated Cell Growth Suppression and Promotes Cell Proliferation via Akt Signaling	PLOS ONE			English	Article							NOTCH; BETA	Background and Objective: The gamma-secretase inhibitor (GSI) has been shown to inhibit expression of amyloid beta (A beta), but GSI also has a side effect of reducing cell survival. Since low-power laser irradiation (LLI) has been known to promote cell survival, we examined whether 532 nm LLI can rescue the GSI side effect or not. Study Design/Materials and Methods: The human-derived glioblastoma cells (A-172) were cultured in 35 mm culture dishes or 96-well plate. The center of dish or selected wells was irradiated with 532 nm laser (Nd:YVO4, CW, 60 mW) for 20, 40 and 60 min, respectively. The irradiated cells were photographed at immediately after, 24 and 48 h later and counted. GSI was supplemented in medium 3 h before LLI. The MTT assay was also used to estimate viable cells at 48 h after irradiation. The expression of phosphorylated Akt (p-Akt) or phosphorylated PTEN (p-PTEN) was examined by immunofluorescent staining and measured by fluorescence intensity using the software (BZ-9000, KEYENCE, Japan). Results: GSI application depressed cell proliferation as well as cell survival compared to control. GSI down-regulated A beta but up-regulated p-PTEN and suppressed p-Akt. Application of 532 nm LLI in the presence of GSI significantly recovered the GSI-mediated effects, i.e., LLI could decrease elevated p-PTEN, while increased p-Akt expression with keeping A beta suppression. The LLI effects had a dose-dependency. Conclusion: We confirmed that GSI potently suppressed intracellular A beta and decreased cell survival. We conclude that a combination of GSI application and 532 nm LLI can increase cell proliferation via Akt activation while keeping PTEN and A beta suppressed.	[Fukuzaki, Yumi; Sugawara, Haruna; Kogure, Shinichi] Soka Univ, Grad Sch Engn, Dept Bioinformat, Hachioji, Tokyo, Japan; [Yamanoha, Banri] Soka Univ, Fac Engn, Dept Environm Engn Symbiosis, Hachioji, Tokyo, Japan	Soka University; Soka University	Kogure, S (corresponding author), Soka Univ, Grad Sch Engn, Dept Bioinformat, Hachioji, Tokyo, Japan.	kogure@soka.ac.jp			Faculty Research Fees from Soka University; Sasakawa Scientific Research Grant of The Japan Science Society	Faculty Research Fees from Soka University; Sasakawa Scientific Research Grant of The Japan Science Society	The authors have received Faculty Research Fees (total: 1,200,000 Yen) from Soka University in 2011 and 2012. Yumi Fukuzaki received 600,000 Yen from the Sasakawa Scientific Research Grant of The Japan Science Society in 2011. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ang FY, 2012, LASER MED SCI, V27, P935, DOI 10.1007/s10103-011-1009-8; Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Azevedo LH, 2006, LASER MED SCI, V21, P86, DOI 10.1007/s10103-006-0379-9; Bijur GN, 2003, J NEUROCHEM, V87, P1427, DOI 10.1046/j.1471-4159.2003.02113.x; Bjordal JM, 2008, BMC MUSCULOSKEL DIS, V9, DOI 10.1186/1471-2474-9-75; Brosseau L, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002049.pub2; Cavett W, 1997, Biomed Sci Instrum, V33, P155; Chan SM, 2007, BLOOD, V110, P278, DOI 10.1182/blood-2006-08-039883; CONLON RA, 1995, DEVELOPMENT, V121, P1533; da Silva JP, 2010, PHOTOMED LASER SURG, V28, P17, DOI 10.1089/pho.2008.2372; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; Dovey HF, 2001, J NEUROCHEM, V76, P173, DOI 10.1046/j.1471-4159.2001.00012.x; Gao XJ, 2009, J BIOMED SCI, V16, DOI 10.1186/1423-0127-16-4; Greenwald I, 1998, GENE DEV, V12, P1751, DOI 10.1101/gad.12.12.1751; Gresner P, 2005, J PHOTOCH PHOTOBIO B, V79, P43, DOI 10.1016/j.jphotobiol.2004.11.018; Gutierrez A, 2007, CANCER CELL, V12, P411, DOI 10.1016/j.ccr.2007.10.027; Jamtvedt G, 2008, PHYS THER, V88, P123, DOI 10.2522/ptj.20070043; KARU T, 1989, HEALTH PHYS, V56, P691, DOI 10.1097/00004032-198905000-00015; Karu T, 2003, BIOMEDICAL PHOTONICS, V48; Karu TI, 2008, PHOTOCHEM PHOTOBIOL, V84, P1091, DOI 10.1111/j.1751-1097.2008.00394.x; Kassak P, 2005, GEN PHYSIOL BIOPHYS, V24, P209; Kim D, 2002, J BIOCHEM MOL BIOL, V35, P106; Li M, 2007, PROG NEUROBIOL, V83, P131, DOI 10.1016/j.pneurobio.2007.08.002; Liang JG, 2012, FREE RADICAL BIO MED, V53, P1459, DOI 10.1016/j.freeradbiomed.2012.08.003; McBride HM, 2006, CURR BIOL, V16, pR551, DOI 10.1016/j.cub.2006.06.054; MESTER E, 1968, ACTA CHIR HUNG, V9, P349; Miyamoto S, 2008, CELL DEATH DIFFER, V15, P521, DOI 10.1038/sj.cdd.4402285; Murayama H, 2012, LASER MED SCI, V27, P87, DOI 10.1007/s10103-011-0924-z; Palomero T, 2007, NAT MED, V13, P1203, DOI 10.1038/nm1636; Pancewicz J, 2010, P NATL ACAD SCI USA, V107, P16619, DOI 10.1073/pnas.1010722107; Panza F, 2009, DRUG AGING, V26, P537, DOI 10.2165/11315770-000000000-00000; Prince M, 2009, ALZHEIMERS DIS INT W; Shefer G, 2002, J CELL SCI, V115, P1461; Shefer G, 2001, J CELL PHYSIOL, V187, P73, DOI 10.1002/1097-4652(2001)9999:9999<::AID-JCP1053>3.0.CO;2-9; Stocker H, 2002, SCIENCE, V295, P2088, DOI 10.1126/science. 1068094; Su CC, 2012, AM J PHYSIOL-HEART C, V302, pH716, DOI 10.1152/ajpheart.00455.2011; Takasugi N, 2003, NATURE, V422, P438, DOI 10.1038/nature01506; Wolfe MS, 1999, BIOCHEMISTRY-US, V38, P11223, DOI 10.1021/bi991080q; Zhang JT, 2008, J CELL PHYSIOL, V217, P518, DOI 10.1002/jcp.21529; Zhang LL, 2009, J CELL PHYSIOL, V219, P553, DOI 10.1002/jcp.21697; Zhao H, 2009, CANCER CELL INT, V9, DOI 10.1186/1475-2867-9-15	41	12	12	0	18	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 7	2013	8	8							e70737	10.1371/journal.pone.0070737	http://dx.doi.org/10.1371/journal.pone.0070737			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	200ZE	23950991	Green Published, Green Submitted, gold			2023-01-03	WOS:000323109700049
J	Dyer, O				Dyer, Owen			The growth of medical marijuana	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material												owen_dyer@hotmail.com						Anderson D. M., 2011, MED MARIJUANA LAWS T; [Anonymous], CANN READ GLOB ISS L; [Anonymous], 2013, MAR ITS LEG NOW WHAT; [Anonymous], 2012 AR YOUTH SURV; Grinspoon L, 2005, HIST CANNABIS MED DR; Harper S, 2012, ANN EPIDEMIOL, V22, P207, DOI 10.1016/j.annepidem.2011.12.002; Joy JE, 1999, MARIJUANA MED ASSESS; Korn P, 2010, PORTLAND TRIBUN 0414; Lynne-Landsman SD, 2013, AM J PUBLIC HEALTH, V103, P1500, DOI 10.2105/AJPH.2012.301117	9	4	4	0	10	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 31	2013	347								f4755	10.1136/bmj.f4755	http://dx.doi.org/10.1136/bmj.f4755			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	197BI	23903247				2023-01-03	WOS:000322822200008
J	Zhang, L; Chow, EPF; Zhuang, X; Liang, YX; Wang, YF; Tang, CY; Ling, L; Tucker, JD; Wilson, DP				Zhang, Lei; Chow, Eric P. F.; Zhuang, Xun; Liang, Yanxian; Wang, Yafei; Tang, Caiyun; Ling, Li; Tucker, Joseph D.; Wilson, David P.			Methadone Maintenance Treatment Participant Retention and Behavioural Effectiveness in China: A Systematic Review and Meta-Analysis	PLOS ONE			English	Review							INJECTION-DRUG USERS; HIV RISK REDUCTION; TREATMENT CLINICS; TREATMENT PROGRAM; PUBLICATION BIAS; FOLLOW-UP; PREVALENCE; PREDICTORS; INFECTION; PROVINCE	Background: Methadone maintenance treatment (MMT) has been scaled up by the Chinese government alongside persistent compulsory drug user detention, but the extent to which detention interferes with MMT is unknown. The study systematically reviews Chinese MMT retention rates, reasons for drop out, and behavioural changes. Method: Chinese and English databases of literature are searched for studies reporting retention rates, drug use and sexual behaviours among MMT participants in China between 2004 and 2013. The estimates are summarized through a systematic review and meta-analysis. Results: A total of 74 studies representing 43,263 individuals are included in this analysis. About a third of MMT participants drop out during the first three months of treatment (retention rate 69.0% (95% CI 57.7-78.4%)). Police arrest and detention in compulsory rehabilitation was the most common cause of drop out, accounting for 22.2% of all those not retained. Among retained participants, changing unsafe drug use behaviours was more effective than changing unsafe sexual behaviours. At 12 months following MMT initiation, 24.6% (15.7-33.5%) of MMT participants had a positive urine test, 9.3% (4.7-17.8%) injected drugs and only 1.1% (0.4-3.0%) sold sex for drugs. These correspond to 0.002 (<0.001-0.011), 0.045 (0.004-0.114) and 0.209 (0.076-0.580) times lower odds than baseline. However, MMT participants did not have substantial changes in condom use rates. Conclusion: MMT is effective in drug users in China but participant retention is poor, substantially related to compulsory detention. Reforming the compulsory drug user detention system may improve MMT retention and effectiveness.	[Zhang, Lei; Chow, Eric P. F.; Zhuang, Xun; Wilson, David P.] Univ New S Wales, Kirby Inst, Sydney, NSW, Australia; [Zhuang, Xun; Liang, Yanxian; Wang, Yafei] Nantong Univ, Sch Publ Hlth, Nantong, Jiangsu, Peoples R China; [Tang, Caiyun; Ling, Li] Sun Yat Sen Univ, Sch Publ Hlth, Fac Med Stat & Epidemiol, Guangzhou, Guangdong, Peoples R China; [Tang, Caiyun; Ling, Li] Sun Yat Sen Univ, Sun Yat Sen Ctr Migrant Hlth Policy, Guangzhou, Guangdong, Peoples R China; [Tucker, Joseph D.] UNC Project China, Guangzhou, Guangdong, Peoples R China; [Tucker, Joseph D.] London Sch Hyg & Trop Med, London WC1, England	University of New South Wales Sydney; Kirby Institute; Nantong University; Sun Yat Sen University; Sun Yat Sen University; University of London; London School of Hygiene & Tropical Medicine	Zhang, L (corresponding author), Univ New S Wales, Kirby Inst, Sydney, NSW, Australia.	lzhang@kirby.unsw.edu.au; ntzhuang@163.com	Chow, Eric Pui Fung/H-3196-2013; Zhang, Lei/D-4039-2011; Wilson, David P/G-4614-2013; Chow, Eric P.F./W-6684-2019	Chow, Eric Pui Fung/0000-0003-1766-0657; Zhang, Lei/0000-0003-2343-084X; Chow, Eric P.F./0000-0003-1766-0657; Tucker, Joseph/0000-0003-2804-1181	Round 8 of the AusAID Australian Leadership Awards (ALA) Fellowships Program; Overseas Scholarship of Jiangsu Government, China; Nantong University, Jiangsu province, China; University of New South Wales; Australian Research Council [FT0991990]; National Natural Science Foundation of China [71173245]; Sun Yat-sen University, Guangdong, China; FOGARTY INTERNATIONAL CENTER [K01TW008200] Funding Source: NIH RePORTER	Round 8 of the AusAID Australian Leadership Awards (ALA) Fellowships Program; Overseas Scholarship of Jiangsu Government, China; Nantong University, Jiangsu province, China; University of New South Wales; Australian Research Council(Australian Research Council); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Sun Yat-sen University, Guangdong, China; FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC))	This study was funded from the following sources: Round 8 of the AusAID Australian Leadership Awards (ALA) Fellowships Program; Overseas Scholarship of Jiangsu Government, China; Nantong University, Jiangsu province, China; The University of New South Wales; Australian Research Council (FT0991990). National Natural Science Foundation of China (#71173245), Sun Yat-sen University, Guangdong, China. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Amato L, 2005, J SUBST ABUSE TREAT, V28, P321, DOI 10.1016/j.jsat.2005.02.007; Bao YP, 2009, INT J STD AIDS, V20, P399, DOI 10.1258/ijsa.2008.008362; Bao YP, 2009, AM J DRUG ALCOHOL AB, V35, P28, DOI 10.1080/00952990802342899; Bao Yanping, 2009, HIV Therapy, V3, P237, DOI [10.2217/hiv.09.4, 10.2217/HIV.09.4]; BAO YG, 2008, SOFT SCI HLTH, V22, P87; Borenstein M., 2009, INTRO META ANAL; Camacho LM, 1996, DRUG ALCOHOL DEPEN, V41, P1, DOI 10.1016/0376-8716(96)01235-5; CAO XY, 2009, PRACTICAL PREVENTIVE, V16, P1294; Chatham LR, 1999, SUBST USE MISUSE, V34, P1137, DOI 10.3109/10826089909039401; Che YH, 2010, DRUG ALCOHOL REV, V29, P263, DOI 10.1111/j.1465-3362.2009.00157.x; Chen Ang, 2009, Zhonghua Liu Xing Bing Xue Za Zhi, V30, P1230; CHEN C, 2010, CHIN COMMUNITY DOCTO, V12, P142; CHEN GH, 2008, CHIN J AIDS STDS, P590; CHEN J, 2007, BULLETIN, V22, P55; CHEN W, 2010, CHIN J HLTH POLICY, V3, P6; CHENG XL, 2009, ANHUI MED J, V30, P907; *CHIN MIN HLTH UN, 2003, JOINT ASS HIV AIDS P; *CHIN MOHTPSR, 2012, 2012 CHIN AIDS RESP; Chow EPF, 2010, JAIDS-J ACQ IMM DEF, V55, pE32, DOI 10.1097/QAI.0b013e3181f3d3c1; Cohen JE, 2008, PLOS MED, V5, P1682, DOI 10.1371/journal.pmed.0050234; CUI ZL, 2012, HENAN J PREVENTIVE M, V23, P1; DelRio M, 1997, ADDICTION, V92, P1353; DENG HC, 2011, CHIN COMMUNITY DOCTO, V13, P97; Dolan KA, 2003, DRUG ALCOHOL DEPEN, V72, P59, DOI 10.1016/S0376-8716(03)00187-X; DUAN YJ, 2008, CHIN J AIDS STD, V14, P240; Faggiano FV-TF, 2003, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD002208; Fang YX, 2006, ACTA PHARMACOL SIN, V27, P140, DOI 10.1111/j.1745-7254.2006.00270.x; FENG SQ, 2010, ZHONGHUA LIU XING BI, V26, P924; FENG WD, 2007, J PUBLIC HLTH PREV M, V18, P31; Fleiss J L, 1993, Stat Methods Med Res, V2, P121, DOI 10.1177/096228029300200202; FU JH, 2010, JIANGXI MED J, V45, P932; Fu LiPing, 2007, Endemic Diseases Bulletin / Di Fang Bing Tong Bao, V22, P17; GAO Q, 2008, ACTA U MED NANJING S, V8, P230; Gossop M, 2000, DRUG ALCOHOL DEPEN, V60, P275, DOI 10.1016/S0376-8716(00)00109-5; Gowing L, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004145.pub3; Gu J, 2012, ADDICTION, V107, P1641, DOI 10.1111/j.1360-0443.2012.03859.x; Hao Chun, 2007, Zhonghua Yufang Yixue Zazhi, V41, P250; He Q, 2011, SUBST USE MISUSE, V46, P749, DOI 10.3109/10826084.2010.534124; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186; HUANG YJ, 2012, J YOUJIANG MED U NAT, V34, P461; HUANG YK, 2010, JILIN MED J, V31, P153; HUANG YM, 2012, CHIN J DIS CONTROL P, V16, P1036; Huedo-Medina TB, 2006, PSYCHOL METHODS, V11, P193, DOI 10.1037/1082-989X.11.2.193; *HUM RIGHTS WATCH, 2013, CHIN FULL AB REED LA; Jardine M, 2012, HARM REDUCT J, V9, DOI 10.1186/1477-7517-9-26; JIA W, 2008, CHINESE J DRUG ABUSE, V14, P253; Jia YJ, 2008, HARM REDUCT J, V5, DOI 10.1186/1477-7517-5-29; JIANG A, 2009, MODERN PREVENTIVE ME, V36, P2920; JIANG JH, 2011, JIANKANG BIDU, V11, P302; *JOINT UN PROGR HI, 2000, DRUG US HIV VULN POL; *JOINT UN PROGR HI, 2012, COMP DRUG DET REH CT; Kelly SM, 2011, DRUG ALCOHOL DEPEN, V117, P170, DOI 10.1016/j.drugalcdep.2011.01.008; King VL, 2000, J ADDICT DIS, V19, P65, DOI 10.1300/J069v19n04_07; KONG HQ, 2011, CHIN J AESTHET MED, V20, P357; Kwiatkowski CF, 2001, J ACQ IMMUN DEF SYND, V26, P483, DOI 10.1097/00126334-200104150-00014; [赖文胜 LAI Wensheng], 2007, [中国药物依赖性杂志, Chinese Journal of Drug Dependence], V16, P299; Lau JTF, 2008, SEX TRANSM DIS, V35, P325, DOI 10.1097/OLQ.0b013e3181614364; Li HZ, 2009, BMC PUBLIC HEALTH, V9, DOI 10.1186/1471-2458-9-137; LI Q, 2008, CHIN J AIDS STDS, V14, P270; [李杏莉 Li Xingli], 2011, [中国药物依赖性杂志, Chinese Journal of Drug Dependence], V20, P362; LI XM, 2011, PREV MED TRIBUNE, V17, P32; Lin CQ, 2011, SUBST USE MISUSE, V46, P1190, DOI 10.3109/10826084.2011.561905; Liu HJ, 2006, DRUG ALCOHOL DEPEN, V84, P114, DOI 10.1016/j.drugalcdep.2006.01.004; LIU JB, 2007, CHIN J DRUG ABUSE PR, V13, P10; LIU JK, 2009, J PREV MED INF, V25, P723; [刘文艳 Liu Wenyan], 2012, [华中科技大学学报. 医学版, Acta Medicinae Universitatis Scientiae et Technologiae Huazhong], V41, P190; [刘英杰 LIU Yingjie], 2007, [中国药物依赖性杂志, Chinese Journal of Drug Dependence], V16, P302; [龙正元 Long Zhengyuan], 2006, [中国药物依赖性杂志, Chinese Journal of Drug Dependence], V15, P38; LU ML, 2010, PRACTICAL PREVENTIVE, V17, P171; Margolin A, 2003, HEALTH PSYCHOL, V22, P223, DOI 10.1037/0278-6133.22.2.223; Mattick RP, 2009, COCHRANE DB SYST REV, V3, DOI DOI 10.1002/14651858.CD002209; MU FK, 2011, CHINA MED PHARM, V1, P117; Musa R, 2012, ASIA-PAC J PUBLIC HE, V24, P826, DOI 10.1177/1010539511404396; OU BW, 2009, MOD HOSP, V9, P142; Pang L, 2007, AIDS, V21, pS103, DOI 10.1097/01.aids.0000304704.71917.64; Pearline RV, 2010, AIDS PATIENT CARE ST, V24, P345, DOI 10.1089/apc.2009.0323; Peles E, 2006, DRUG ALCOHOL DEPEN, V82, P211, DOI 10.1016/j.drugalcdep.2005.09.004; Philbin MM, 2010, AIDS CARE, V22, P623, DOI 10.1080/09540120903311490; PU YC, 2012, CHIN J AIDS STDS, V18, P815; QIAN YH, 2008, OCCUPATION HLTH, V24, P450; Qian ZH, 2005, SEX TRANSM INFECT, V81, P442, DOI 10.1136/sti.2004.014258; [石珊 Shi Shan], 2006, [中国药物依赖性杂志, Chinese Journal of Drug Dependence], V15, P35; [石珊 SHI Shan], 2008, [中国药物依赖性杂志, Chinese Journal of Drug Dependence], V17, P56; SHUAI YL, 2010, CHIN J DRUGS DEPEND, P277; Song FJ, 2002, INT J EPIDEMIOL, V31, P88, DOI 10.1093/ije/31.1.88; Sorensen JL, 2000, DRUG ALCOHOL DEPEN, V59, P17, DOI 10.1016/S0376-8716(99)00104-0; *STAT COUNC AIDS W, 2007, JT ASS HIV AIDS PREV; Strang J, 2000, ADDICTION, V95, P1631, DOI 10.1046/j.1360-0443.2000.951116314.x; [孙庆元 Sun Qingyuan], 2011, [南京医科大学学报. 自然科学版, Acta Universitatis Medicinalis Nanjing], V31, P1471; Tan Y, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003608; TANG RH, 2012, CHIN J DIS CONTROL P, V16, P1044; [唐先娅 TANG Xianya], 2008, [中国药物依赖性杂志, Chinese Journal of Drug Dependence], V17, P380; Tang YL, 2007, ADDICTION, V102, P1057, DOI 10.1111/j.1360-0443.2007.01849.x; Tang YL, 2006, ADDICTION, V101, P657, DOI 10.1111/j.1360-0443.2006.01367.x; Thompson SG, 2002, STAT MED, V21, P1559, DOI 10.1002/sim.1187; Thornton A, 2000, J CLIN EPIDEMIOL, V53, P207, DOI 10.1016/S0895-4356(99)00161-4; Tran BX, 2012, DRUG ALCOHOL DEPEN, V125, P260, DOI 10.1016/j.drugalcdep.2012.02.021; *UN DRUG CONTR PRO, 2000, CHIN COUNTR PROF; Verthein U, 2008, ADDICTION, V103, P960, DOI 10.1111/j.1360-0443.2008.02185.x; Wang Bei, 2010, Zhonghua Liu Xing Bing Xue Za Zhi, V31, P238; WANG CQ, 2009, IMHGN, V15, P78; Wang Jun, 2007, Zhonghua Liu Xing Bing Xue Za Zhi, V28, P37; WANG P, 2009, CHIN J DRUGS ABUSE P, V15, P77; WANG YZ, 2008, PRACT J MED PHARM, V25, P1304; WANG Z, 2007, J PUBLIC HLTH PREV M, V18, P10; [卫晓丽 WEI Xiaoli], 2008, [中国药物依赖性杂志, Chinese Journal of Drug Dependence], V17, P197; Wu F, 2013, J PUBLIC HEALTH-UK, V35, P206, DOI 10.1093/pubmed/fds079; Wu ZY, 2007, AIDS, V21, pS115, DOI 10.1097/01.aids.0000304706.79541.ef; Xia XS, 2008, J MED VIROL, V80, P1142, DOI 10.1002/jmv.21204; XIANG LF, 2011, CHIN J AIDS STDS, V17, P426; XING XZ, 2012, CHIN J DRUGS ABUSE P, V18, P148; XU JS, 2009, ZHONGHUA LIU XING BI, V25, P779; [薛丽燕 XUE Liyan], 2008, [中国药物依赖性杂志, Chinese Journal of Drug Dependence], V17, P192; XUE LY, 2006, CHIN J DRUGS ABUSE P, V12, P255; [颜鸿 YAN Hong], 2009, [中国药物依赖性杂志, Chinese Journal of Drug Dependence], V18, P140; YAN JF, 2010, J CHINA TRADIT CHIN, V2, P17; Yang F, 2013, HARM REDUCT J, V10, DOI 10.1186/1477-7517-10-3; Yang LJ, 2008, AM J DRUG ALCOHOL AB, V34, P5, DOI 10.1080/00952990701653867; YANG LS, 2008, J DALI U, V7, P22; YANG M, 2012, PRACTICAL PREVENTIVE, V19, P1582; Yang Yue-cheng, 2011, Zhonghua Liu Xing Bing Xue Za Zhi, V32, P125; Yin WY, 2010, INT J EPIDEMIOL, V39, pII29, DOI 10.1093/ije/dyq210; Yoast R, 2001, J ADDICT DIS, V20, P15, DOI 10.1300/J069v20n02_03; YU J, 2011, GUIDE CHINA MED, V9, P259; [张海风 ZHANG Haifeng], 2009, [中国药物依赖性杂志, Chinese Journal of Drug Dependence], V18, P43; [张晓红 ZHANG Xiaohong], 2007, [中国药物依赖性杂志, Chinese Journal of Drug Dependence], V16, P140; ZHANG YP, 2009, CHIN J DRUGS ABUSE P, V15, P316; ZHANG ZH, 2010, PRACTICAL PREVENTIVE, V17, P1884; [赵玲珑 Zhao Linglong], 2012, [中国药物依赖性杂志, Chinese Journal of Drug Dependence], V21, P144; ZHAO XC, 2010, J APPL PREVENTIVE ME, V16, P235; ZHAO XH, 2009, J PREV MED INF, V25, P457; Zhao YuTeng, 2009, Journal of Tropical Medicine (Guangzhou), V9, P329; ZHENG WX, 2012, STRAIT J PREVENTIVE, V18, P72; Zhou Y, 1999, SUBST USE MISUSE, V34, P907, DOI 10.3109/10826089909037248; ZHU QY, 2006, CHIN J AIDS STDS, V12, P290; ZHU YH, 2012, J JIUJIANG U NAT SCI, V27, P25; Zhuang X, 2012, DRUG ALCOHOL DEPEN, V126, P286, DOI 10.1016/j.drugalcdep.2012.05.028; Zhuang X, 2012, BMC INFECT DIS, V12, DOI 10.1186/1471-2334-12-130	139	48	53	0	23	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 26	2013	8	7							e68906	10.1371/journal.pone.0068906	http://dx.doi.org/10.1371/journal.pone.0068906			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	197GU	23922668	Green Published, gold, Green Accepted			2023-01-03	WOS:000322838900012
J	Kida, H; Nomura, S; Shinoyama, M; Ideguchi, M; Owada, Y; Suzuki, M				Kida, Hiroyuki; Nomura, Sadahiro; Shinoyama, Mizuya; Ideguchi, Makoto; Owada, Yuji; Suzuki, Michiyasu			The Effect of Hypothermia Therapy on Cortical Laminar Disruption following Ischemic Injury in Neonatal Mice	PLOS ONE			English	Article							OLIGODENDROCYTE LINEAGE PROGRESSION; WHITE-MATTER INJURY; RAT CEREBRAL-CORTEX; POSTISCHEMIC HYPOTHERMIA; HYPOXIA-ISCHEMIA; BRAIN-INJURY; MODERATE HYPOTHERMIA; NEWBORN RAT; ENCEPHALOPATHY; APOPTOSIS	Hypothermia has been proposed as a treatment for reducing neuronal damage in the brain induced by hypoxic ischemia. In the developing brain, hypoxic ischemia-induced injury may give rise to cerebral palsy (CP). However, it is unknown whether hypothermia might affect the development of CP. The purpose of this study was to investigate whether hypothermia would have a protective effect on the brains of immature, 3-day old (P3) mice after a challenge of cerebral ischemia. Cerebral ischemia was induced in P3 mice with a right common carotid artery ligation followed by hypoxia (6% O-2, 37 degrees C) for 30 min. Immediately after hypoxic ischemia, mice were exposed to hypothermia (32 degrees C) or normothermia (37 degrees C) for 24 h. At 4 weeks of age, mouse motor development was tested in a behavioral test. Mice were sacrificed at P4, P7, and 5 weeks to examine brain morphology. The laminar structure of the cortex was examined with immunohistochemistry (Cux1/Ctip2); the number of neurons was counted; and the expression of myelin basic protein (MBP) was determined. The hypothermia treatment was associated with improved neurological outcomes in the behavioral test. In the normothermia group, histological analyses indicated reduced numbers of neurons, reduced cortical laminar thickness in the deep, ischemic cortical layers, and significant reduction in MBP expression in the ischemic cortex compared to the contralateral cortex. In the hypothermia group, no reductions were noted in deep cortical layer thickness and in MBP expression in the ischemic cortex compared to the contralateral cortex. At 24 h after the hypothermia treatment prevented the neuronal cell death that had predominantly occurred in the ischemic cortical deep layers with normothermia treatment. Our findings may provide a preclinical basis for testing hypothermal therapies in patients with CP induced by hypoxic ischemia in the preterm period.	[Kida, Hiroyuki] Yamaguchi Univ, Dept Syst Neurosci, Grad Sch Med, Ube, Yamaguchi 755, Japan; [Nomura, Sadahiro; Shinoyama, Mizuya; Ideguchi, Makoto; Suzuki, Michiyasu] Yamaguchi Univ, Dept Neurosurg, Grad Sch Med, Ube, Yamaguchi 755, Japan; [Owada, Yuji] Yamaguchi Univ, Dept Organ Anat, Grad Sch Med, Ube, Yamaguchi 755, Japan	Yamaguchi University; Yamaguchi University; Yamaguchi University	Kida, H (corresponding author), Yamaguchi Univ, Dept Syst Neurosci, Grad Sch Med, Ube, Yamaguchi 755, Japan.	h-kida@yamaguchi-u.ac.jp		Owada, Yuji/0000-0002-5109-0531	JSPS KAKENHI [19591680, 23791603]	JSPS KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	This work was supported by JSPS KAKENHI Grant Number 19591680 to S. Nomura and 23791603 to H. Kida. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Askalan R, 2011, DEV NEUROSCI-BASEL, V33, P320, DOI 10.1159/000329924; Azzopardi DV, 2009, NEW ENGL J MED, V361, P1349, DOI 10.1056/NEJMoa0900854; Back SA, 2001, J NEUROSCI, V21, P1302; Back SA, 2002, J NEUROPATH EXP NEUR, V61, P197, DOI 10.1093/jnen/61.2.197; Barrett Robert D., 2007, Birth Defects Research, V81, P163, DOI 10.1002/bdrc.20095; BUSTO R, 1989, NEUROSCI LETT, V101, P299, DOI 10.1016/0304-3940(89)90549-1; CALEY DW, 1970, J COMP NEUROL, V138, P31, DOI 10.1002/cne.901380104; Carlsson Y, 2012, PEDIATR RES, V71, P566, DOI 10.1038/pr.2012.15; CHOI DW, 1987, J NEUROSCI, V7, P357; Clancy B, 2001, NEUROSCIENCE, V105, P7, DOI 10.1016/S0306-4522(01)00171-3; Craig A, 2003, EXP NEUROL, V181, P231, DOI 10.1016/S0014-4886(03)00032-3; Edinger AL, 2004, CURR OPIN CELL BIOL, V16, P663, DOI 10.1016/j.ceb.2004.09.011; Eilers H, 1996, ANESTHESIOLOGY, V85, P600, DOI 10.1097/00000542-199609000-00020; Fujii M, 2011, EPILEPSIA, V52, P1; Fukuda H, 2001, BRAIN RES, V910, P187, DOI 10.1016/S0006-8993(01)02659-2; Gabriel GH, 2009, BRAIN HYPOXIA ISCHEM; Gavva NR, 2008, TRENDS PHARMACOL SCI, V29, P550, DOI 10.1016/j.tips.2008.08.003; Gluckman PD, 2005, LANCET, V365, P663, DOI 10.1016/S0140-6736(05)17946-X; He Y, 2012, BRAIN RES; Huang ZH, 2009, BRAIN RES, V1301, P100, DOI 10.1016/j.brainres.2009.09.006; IGNACIO MPD, 1995, ANAT EMBRYOL, V191, P89; Joseph K S, 2003, BMC Pregnancy Childbirth, V3, P8, DOI 10.1186/1471-2393-3-8; Kida H, 2012, CLIN NEUROPHYSIOL; Lee BS, 2010, PEDIATR RES, V68, P303, DOI 10.1203/00006450-201011001-00592; Limperopoulos C, 2007, PEDIATRICS, V120, P584, DOI 10.1542/peds.2007-1041; Lipski J, 2006, BRAIN RES, V1077, P187, DOI 10.1016/j.brainres.2006.01.016; Liu YQ, 2002, PEDIATR RES, V51, P25, DOI 10.1203/00006450-200201000-00007; McQuillen PS, 2003, J NEUROSCI, V23, P3308; Muzzi M, 2012, J CEREBR BLOOD F MET, V32, P978, DOI 10.1038/jcbfm.2012.36; Nadarajah B, 2002, NAT REV NEUROSCI, V3, P423, DOI 10.1038/nrn845; Nakajima W, 2000, J NEUROSCI, V20, P7994; Ohmura A, 2005, BRAIN DEV-JPN, V27, P517, DOI 10.1016/j.braindev.2005.01.004; RICE JE, 1981, ANN NEUROL, V9, P131, DOI 10.1002/ana.410090206; ROWAN RA, 1981, AM J ANAT, V160, P247, DOI 10.1002/aja.1001600303; Shankaran S, 2005, NEW ENGL J MED, V353, P1574, DOI 10.1056/NEJMcps050929; Shankaran S, 2012, NEW ENGL J MED, V366, P2085, DOI 10.1056/NEJMoa1112066; Sizonenko SV, 2005, PEDIATR RES, V57, P865, DOI 10.1203/01.PDR.0000157673.36848.67; Sizonenko SV, 2003, PEDIATR RES, V54, P263, DOI 10.1203/01.PDR.0000072517.01207.87; Skoff RP, 2001, INT J DEV NEUROSCI, V19, P197, DOI 10.1016/S0736-5748(00)00075-7; Stadlin A, 2003, BRAIN RES, V993, P101, DOI 10.1016/j.brainres.2003.08.058; Volpe JJ, 2003, PEDIATRICS, V112, P176, DOI 10.1542/peds.112.1.176; Volpe JJ, 2001, PEDIATR RES, V50, P553, DOI 10.1203/00006450-200111000-00003; Wagner BP, 2002, PEDIATR RES, V51, P354, DOI 10.1203/00006450-200203000-00015; Witte OW, 2000, J CEREBR BLOOD F MET, V20, P1149, DOI 10.1097/00004647-200008000-00001; Xiong M, 2009, BRAIN RES BULL, V79, P351, DOI 10.1016/j.brainresbull.2009.03.011; Yager JY, 2009, PEDIATR NEUROL, V40, P156, DOI 10.1016/j.pediatrneurol.2008.10.025; Yenari MA, 2012, NAT REV NEUROSCI	47	12	12	1	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 23	2013	8	7							e68877	10.1371/journal.pone.0068877	http://dx.doi.org/10.1371/journal.pone.0068877			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	228SX	23894362	gold, Green Published, Green Submitted			2023-01-03	WOS:000325211000051
J	Wu, CC; Chuang, YT; Hsu, YT; Huang, JT; Wu, TC; Hung, CF; Yang, YC; Chang, CL				Wu, Chao-Chih; Chuang, Yin-Ting; Hsu, Yun-Ting; Huang, Jung-Tang; Wu, T. -C; Hung, Chien-Fu; Yang, Yuh-Cheng; Chang, Chih-Long			Intra-Peritoneal Hyperthermia Combining alpha-Galactosylceramide in the Treatment of Ovarian Cancer	PLOS ONE			English	Article							INTRAPERITONEAL CHEMOTHERAPY HIPEC; TUMOR-CELLS; KRN7000; NKT; INDUCTION; PREVENTS; MICE	The purpose of this study was to investigate the anti-tumor effect and potential mechanisms of i.p. hyperthermia in combination with alpha-galactosylceramide (alpha-GalCer) for the treatment of ovarian cancer. In this study, immuno-competent tumor models were established using murine ovarian cancer cell lines and treated with i.p. hyperthermia combining alpha-GalCer. Th1/Th2 cytokine expression profiles in the serum, NK cell cytotoxicity and phagocytic activities of dendritic cells (DCs) were assayed. We also analyzed the number of CD8(+)/IFN-gamma(+) tumor specific cytotoxic T cells, as well as the tumor growth based on depletion of lymphocyte sub-population. Therapeutic effect on those ovarian tumors was monitored by a non-invasive luminescent imaging system. Intra-peritoneal hyperthermia induced significant pro-inflammatory cytokines expression, and sustained the response of NK and DCs induced by alpha-GalCer treatment. The combination treatment enhanced the cytotoxic T lymphocyte (CTL) immune response in two mouse ovarian cancer models. This novel treatment modality by combination of hyperthermia and glycolipid provides a pronounced anti-tumor immune response and better survival. In conclusion, intra-peritoneal hyperthermia enhanced the pro-inflammatory cytokine secretion and phagocytic activity of DCs stimulated by alpha-GalCer. The subsequent CTL immune response induced by alpha-GalCer was further strengthened by combining with i.p. hyperthermia. Both innate and adaptive immunities were involved and resulted in a superior therapeutic effect in treating the ovarian cancer.	[Wu, Chao-Chih; Huang, Jung-Tang] Natl Taipei Univ Technol, Grad Inst Mech & Elect Engn, Taipei 106, Taiwan; [Chang, Chih-Long] Mackay Med Coll, Dept Med, New Taipei City, Taiwan; [Chang, Chih-Long] Mackay Med Coll, Inst Biomed Sci, New Taipei City, Taiwan; [Chuang, Yin-Ting; Yang, Yuh-Cheng; Chang, Chih-Long] Mackay Mem Hosp, Dept Obstet & Gynecol, Taipei, Taiwan; [Wu, Chao-Chih; Hsu, Yun-Ting] Mackay Mem Hosp, Dept Med Res, Taipei, Taiwan; [Wu, T. -C; Hung, Chien-Fu] Johns Hopkins Univ, Dept Pathol, Baltimore, MD USA; [Wu, T. -C; Hung, Chien-Fu] Johns Hopkins Univ, Dept Oncol, Baltimore, MD USA; [Wu, T. -C; Hung, Chien-Fu] Johns Hopkins Univ, Dept Obstet & Gynecol, Baltimore, MD USA; [Wu, T. -C; Hung, Chien-Fu] Johns Hopkins Univ, Dept Mol Microbiol & Immunol, Baltimore, MD USA	National Taipei University of Technology; Mackay Medical College; Mackay Medical College; Mackay Memorial Hospital; Mackay Memorial Hospital; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	Chang, CL (corresponding author), Mackay Med Coll, Dept Med, New Taipei City, Taiwan.	clchang@mmc.edu.tw	Chang, Chih-Long/AAJ-8784-2020	Chang, Chih-Long/0000-0003-3981-9366	Taiwan National Science Council [NSC 98-2314-B-195-008-MY3]	Taiwan National Science Council(Ministry of Science and Technology, Taiwan)	This research was supported by a grant from Taiwan National Science Council (NSC 98-2314-B-195-008-MY3). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Badgwell D, 2007, DIS MARKERS, V23, P397, DOI 10.1155/2007/309382; Bast RC, 2009, NAT REV CANCER, V9, P415, DOI 10.1038/nrc2644; Di Giorgio A, 2008, CANCER-AM CANCER SOC, V113, P315, DOI 10.1002/cncr.23553; Dickson J A, 1982, Natl Cancer Inst Monogr, V61, P183; Exley M, 1997, J EXP MED, V186, P109, DOI 10.1084/jem.186.1.109; Fujii S, 2002, NAT IMMUNOL, V3, P867, DOI 10.1038/ni827; Giaccone G, 2002, CLIN CANCER RES, V8, P3702; Green DR, 2009, NAT REV IMMUNOL, V9, P353, DOI 10.1038/nri2545; Guerbet M, 2007, EJSO-EUR J SURG ONC, V33, P623, DOI 10.1016/j.ejso.2007.02.027; Hayakawa Y, 2003, P NATL ACAD SCI USA, V100, P9464, DOI 10.1073/pnas.1630663100; Helm CW, 2009, ONCOLOGIST, V14, P683, DOI 10.1634/theoncologist.2008-0275; Hildebrandt B, 2002, CRIT REV ONCOL HEMAT, V43, P33, DOI 10.1016/S1040-8428(01)00179-2; Hong S, 2001, NAT MED, V7, P1052, DOI 10.1038/nm0901-1052; Inoue H, 1997, EXP HEMATOL, V25, P935; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.20107]; Kim A, 2012, J EXP CLIN CANC RES, V31, DOI 10.1186/1756-9966-31-14; Knippertz I, 2011, INT J HYPERTHER, V27, P591, DOI 10.3109/02656736.2011.589234; Kobayashi E, 2012, CANC EPIDEMIOL BIOMA; Lu Z, 2010, FUTURE ONCOL, V6, P1625, DOI 10.2217/FON.10.100; Mukhopadhaya A, 2007, CANCER RES, V67, P7798, DOI 10.1158/0008-5472.CAN-07-0203; Nakagawa R, 1998, ONCOL RES, V10, P561; Parekh VV, 2005, J CLIN INVEST, V115, P2572, DOI 10.1172/JCI24762; RASMUSSEN L, 1982, ENVIRON HEALTH PERSP, V43, P21, DOI 10.2307/3429163; SCHEIN PS, 1975, ANN INTERN MED, V82, P84, DOI 10.7326/0003-4819-82-1-84; Sharif S, 2001, NAT MED, V7, P1057, DOI 10.1038/nm0901-1057; Shimizu K, 2007, J IMMUNOL, V178, P2853, DOI 10.4049/jimmunol.178.5.2853; Spada FM, 1998, J EXP MED, V188, P1529, DOI 10.1084/jem.188.8.1529; Spisek R, 2007, BLOOD, V109, P4839, DOI 10.1182/blood-2006-10-054221; Srivastava PK, 2006, CURR OPIN IMMUNOL, V18, P201, DOI 10.1016/j.coi.2006.01.009; Van Ruth S, 2003, ANTICANCER RES, V23, P1501; Yamasaki K, 2011, CLIN IMMUNOL, V138, P255, DOI 10.1016/j.clim.2010.11.014	31	3	3	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 23	2013	8	7							e69336	10.1371/journal.pone.0069336	http://dx.doi.org/10.1371/journal.pone.0069336			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	228SX	23935988	Green Submitted, gold, Green Published			2023-01-03	WOS:000325211000103
J	Huo, Q; Zhang, N; Wang, XL; Jiang, LY; Ma, TT; Yang, QF				Huo, Qiang; Zhang, Ning; Wang, Xiaolong; Jiang, Liyu; Ma, Tingting; Yang, Qifeng			Effects of Ambient Particulate Matter on Human Breast Cancer: Is Xenogenesis Responsible?	PLOS ONE			English	Article							POLYCYCLIC AROMATIC-HYDROCARBONS; AIR-POLLUTION; NEOADJUVANT CHEMOTHERAPY; RECEPTOR STATUS; LIFE-STYLE; RISK; EXPOSURE; METABOLISM; MORTALITY; DIET	Background: Recently, evidence from several studies has revealed that air pollution is associated with the increased morbidity and mortality of breast cancer patients. However, to date, the underlying mechanism remains largely unclear. Considering the high prevalence of air pollution and breast cancer in China, it is necessary to understand how air pollution may affect breast cancer. Methods: We analyzed 1,832 female patients who had resided in the same cities for at least 10 years prior to their diagnosis. Variables including demographic data as well as clinical and tumor characteristics, including the patient's age at menarche, family history of breast cancer, tumor histopathological type, tumor size, lymph node metastasis, distant metastasis, histological grade, estrogen receptor (ER) status, progesterone receptor (PR) status and human epidermal growth factor receptor 2 (HER-2) status at the time of diagnosis were analyzed. Results: Compared to patients residing in low-pollution areas, patients living in high-pollution areas demonstrated a younger age at menarche (p < 0.001), a greater family history of breast cancer (p = 0.034) and more invasive cancers (p = 0.028) with higher tumor grades (p = 0.028) and estrogen receptor (ER)-positive status (p = 0.022). Differences in tumor grade were only found in ER-positive cases. Conclusions: Our findings and clinical data indicate that long-term air pollution exposure may contribute to the development of breast cancer by playing the role of a xenoestrogen, and also provides new insight into the association between air pollution and the morbidity and mortality of breast cancer patients. Furthermore, it is urgently necessary to study the association between air pollution and breast cancer to improve the living quality and health of females, and applicable public health strategies may need to be established or modified as soon as possible.	[Huo, Qiang; Zhang, Ning; Wang, Xiaolong; Jiang, Liyu; Ma, Tingting; Yang, Qifeng] Shandong Univ, Qilu Hosp, Dept Breast Surg, Jinan, Shandong, Peoples R China; [Huo, Qiang] Shandong Univ, Sch Med, Jinan, Shandong, Peoples R China; [Yang, Qifeng] Shandong Univ, Sch Med, Key Lab Expt Teratol, Minist Educ, Jinan 250100, Peoples R China; [Yang, Qifeng] Shandong Univ, Sch Med, Inst Mol Med & Genet, Jinan 250100, Peoples R China	Shandong University; Shandong University; Shandong University; Shandong University	Yang, QF (corresponding author), Shandong Univ, Qilu Hosp, Dept Breast Surg, Jinan, Shandong, Peoples R China.	qifengy@gmail.com	Zhang, Ning/GOJ-8058-2022; yang, qiang/GYJ-0971-2022; Zhang, Ning/GNP-1966-2022	Zhang, Ning/0000-0002-6430-4236; Yang, Qifeng/0000-0003-0576-8513	National Natural Science Foundation of China [30772133, 81072150, 81172529, 81272903]; Shandong Science and Technology Development Plan [2012GZC22115]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Shandong Science and Technology Development Plan	This work was supported by the National Natural Science Foundation of China (No. 30772133; No. 81072150; No. 81172529; No. 81272903) and the Shandong Science and Technology Development Plan (No. 2012GZC22115). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Anderson JO, 2012, J MED TOXICOL, V8, P166, DOI 10.1007/s13181-011-0203-1; Bonner MR, 2005, CANCER EPIDEM BIOMAR, V14, P53; Brody JG, 2007, CANCER-AM CANCER SOC, V109, P2627, DOI 10.1002/cncr.22656; Chameides William L., 2010, Reviews on Environmental Health, V25, P17; Chen ST, 2013, J ENVIRON SCI HEAL A, V48, P173, DOI 10.1080/10934529.2012.717809; Chen WY, 2007, NAT CLIN PRACT ONCOL, V4, P415, DOI 10.1038/ncponc0851; Crouse DL, 2010, ENVIRON HEALTH PERSP, V118, P1578, DOI 10.1289/ehp.1002221; Hu H, 2013, BREAST CANCER RES TR, V139, P217, DOI 10.1007/s10549-013-2527-9; Ibarluzea JM, 2004, CANCER CAUSE CONTROL, V15, P591, DOI 10.1023/B:CACO.0000036167.51236.86; Li DH, 1996, CANCER RES, V56, P287; Lodovici M, 2011, J TOXICOL-US, V2011, DOI 10.1155/2011/487074; MANE SS, 1990, ENVIRON MOL MUTAGEN, V15, P78, DOI 10.1002/em.2850150204; MOORE CJ, 1986, CANCER RES, V46, P4946; Nie J, 2007, CANCER CAUSE CONTROL, V18, P947, DOI 10.1007/s10552-007-9036-2; Parl FF, 2009, CANCER INFORM, V7, P109; Pieta B, 2009, EUR J GYNAECOL ONCOL, V30, P186; Rana A, 2010, FUTURE ONCOL, V6, P1369, DOI 10.2217/fon.10.112; Redden MH, 2013, SURG CLIN N AM, V93, P493, DOI 10.1016/j.suc.2013.01.006; Sagiv SK, 2009, ENVIRON RES, V109, P287, DOI 10.1016/j.envres.2008.11.005; Samet JM, 2000, NEW ENGL J MED, V343, P1742, DOI 10.1056/NEJM200012143432401; Sprague BL, 2010, BREAST CANCER RES TR, V124, P487, DOI 10.1007/s10549-010-0869-0; Stoll BA, 1998, BREAST CANCER RES TR, V49, P187, DOI 10.1023/A:1006003110909; Yanagi Y, 2012, CAD SAUDE PUBLICA, V28, P1737, DOI 10.1590/S0102-311X2012000900012; Zhang N, 2011, CANCER INVEST, V29, P594, DOI 10.3109/07357907.2011.621913	24	21	21	0	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 16	2013	8	10							e76609	10.1371/journal.pone.0076609	http://dx.doi.org/10.1371/journal.pone.0076609			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	239JR	24146897	Green Published, Green Submitted, gold			2023-01-03	WOS:000326019400076
J	Yu, HC; Lu, MC; Li, C; Huang, HL; Huang, KY; Liu, SQ; Lai, NS; Huang, HB				Yu, Hui-Chun; Lu, Ming-Chi; Li, Chin; Huang, Hsien-Lu; Huang, Kuang-Yung; Liu, Su-Qin; Lai, Ning-Sheng; Huang, Hsien-Bin			Targeted Delivery of an Antigenic Peptide to the Endoplasmic Reticulum: Application for Development of a Peptide Therapy for Ankylosing Spondylitis	PLOS ONE			English	Article							UNFOLDED PROTEIN RESPONSE; CLASS-I MOLECULES; TRANSGENIC RATS; HLA-B27; SPONDYLOARTHRITIS; SPONDYLARTHRITIS; PATHOGENESIS; DISEASE; CELLS; INTERLEUKIN-23	The development of suitable methods to deliver peptides specifically to the endoplasmic reticulum (ER) can provide some potential therapeutic applications of such peptides. Ankylosing spondylitis (AS) is strongly associated with the expression of human leukocytic antigen-B27 (HLA-B27). HLA-B27 heavy chain (HC) has a propensity to fold slowly resulting in the accumulation of misfolded HLA-B27 HC in the ER, triggering the unfolded protein response, and forming a homodimer, (B27-HC)(2). Natural killer cells and T-helper 17 cells are then activated, contributing to the major pathogenic potentials of AS. The HLA-B27 HC is thus an important target, and delivery of an HLA-B27-binding peptide to the ER capable of promoting HLA-B27 HC folding is a potential mechanism for AS therapy. Here, we demonstrate that a His(6)-ubiquitin-tagged Tat-derived peptide (THU) can deliver an HLA-B27-binding peptide to the ER promoting HLA-B27 HC folding. The THU-HLA-B27-binding peptide fusion protein crossed the cell membrane to the cytosol through the Tat-derived peptide. The HLA-B27-binding peptide was specifically cleaved from THU by cytosolic ubiquitin C-terminal hydrolases and subsequently transported into the ER by the transporter associated with antigen processing. This approach has potential application in the development of peptide therapy for AS.	[Yu, Hui-Chun; Li, Chin; Huang, Hsien-Bin] Natl Chung Cheng Univ, Dept Life Sci, Chiayi, Taiwan; [Yu, Hui-Chun; Li, Chin; Huang, Hsien-Bin] Natl Chung Cheng Univ, Inst Mol Biol, Chiayi, Taiwan; [Yu, Hui-Chun; Lu, Ming-Chi; Huang, Kuang-Yung; Liu, Su-Qin; Lai, Ning-Sheng] Buddhist DaLin Tzu Chi Hosp, Dept Med, Sect Allergy Immunol & Rheumatol, Chiayi, Taiwan; [Lu, Ming-Chi; Huang, Kuang-Yung; Lai, Ning-Sheng] Tzu Chi Univ, Sch Med, Hualien, Taiwan; [Huang, Hsien-Lu] Fooyin Univ, Dept Nutr & Hlth Sci, Kaohsiung, Taiwan	National Chung Cheng University; National Chung Cheng University; Buddhist Tzu Chi General Hospital; Dalin Tzu Chi Hospital; Tzu Chi University; Fooyin University	Lai, NS (corresponding author), Buddhist DaLin Tzu Chi Hosp, Dept Med, Sect Allergy Immunol & Rheumatol, Chiayi, Taiwan.	Q12015@tzuchi.com.tw; biohbh@ccu.edu.tw			DaLin Tzu Chi Buddhist Hospital [DTCRD SR98-2-3]	DaLin Tzu Chi Buddhist Hospital	This work was supported by grants from the DaLin Tzu Chi Buddhist Hospital [DTCRD SR98-2-3]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Allen RL, 1999, J IMMUNOL, V162, P5045; ANDROLEWICZ MJ, 1994, P NATL ACAD SCI USA, V91, P12716, DOI 10.1073/pnas.91.26.12716; BARNSTABLE CJ, 1978, CELL, V14, P9, DOI 10.1016/0092-8674(78)90296-9; Berkhoff EGM, 2004, J VIROL, V78, P5216, DOI 10.1128/JVI.78.10.5216-5222.2004; Bowness P, 2011, J IMMUNOL, V186, P2672, DOI 10.4049/jimmunol.1002653; BREWERTON DA, 1973, LANCET, V1, P904; Brook H, 2006, ADV DRUG DELIV REV, V57, P559; CAFFREY MFP, 1973, NATURE, V242, P121, DOI 10.1038/242121a0; Cascio P, 2001, EMBO J, V20, P2357, DOI 10.1093/emboj/20.10.2357; Chan AT, 2005, ARTHRITIS RHEUM, V52, P3586, DOI 10.1002/art.21395; Colbert RA, 2010, IMMUNOL REV, V233, P181, DOI 10.1111/j.0105-2896.2009.00865.x; Dangoria NS, 2002, J BIOL CHEM, V277, P23459, DOI 10.1074/jbc.M110336200; Delay ML, 2009, ARTHRITIS RHEUM-US, V60, P2633, DOI 10.1002/art.24763; Garcia F, 1997, TISSUE ANTIGENS, V49, P23, DOI 10.1111/j.1399-0039.1997.tb02705.x; Hotamisligil GS, 2010, CELL, V140, P900, DOI 10.1016/j.cell.2010.02.034; Kanaseki T, 2006, IMMUNITY, V25, P795, DOI 10.1016/j.immuni.2006.09.012; Kisselev AF, 1999, J BIOL CHEM, V274, P3363, DOI 10.1074/jbc.274.6.3363; Kollnberger S, 2004, J IMMUNOL, V173, P1699, DOI 10.4049/jimmunol.173.3.1699; Kollnberger S, 2002, ARTHRITIS RHEUM, V46, P2972, DOI 10.1002/art.10605; Lu MC, 2008, CLIN IMMUNOL, V129, P462, DOI 10.1016/j.clim.2008.08.001; Mear JP, 1999, J IMMUNOL, V163, P6665; Melis L, 2009, ARTHRITIS RES THER, V11, DOI 10.1186/ar2722; Merino E, 2008, ARTHRITIS RHEUM-US, V58, P3693, DOI 10.1002/art.24045; Pahl HL, 1999, PHYSIOL REV, V79, P683, DOI 10.1152/physrev.1999.79.3.683; Ramos M, 2002, J BIOL CHEM, V277, P37573, DOI 10.1074/jbc.M205470200; Reveille JD, 2010, NAT GENET, V42, P123, DOI 10.1038/ng.513; Ritz U, 2001, MOL MED, V7, P149, DOI 10.1007/BF03401948; Rock KL, 2004, NAT IMMUNOL, V5, P670, DOI 10.1038/ni1089; RUBEN S, 1989, J VIROL, V63, P1; Saveanu L, 2005, NAT IMMUNOL, V6, P689, DOI 10.1038/ni1208; Serwold T, 2002, NATURE, V419, P480, DOI 10.1038/nature01074; Sieper J, 2012, NAT REV RHEUMATOL, V8, P280, DOI 10.1038/nrrheum.2012.40; Smith JA, 2006, BEST PRACT RES CL RH, V20, P571, DOI 10.1016/j.berh.2006.03.001; SUGITA M, 1994, J EXP MED, V180, P2163, DOI 10.1084/jem.180.6.2163; Tam LS, 2010, NAT REV RHEUMATOL, V6, P399, DOI 10.1038/nrrheum.2010.79; Toes REM, 2001, J EXP MED, V194, P1, DOI 10.1084/jem.194.1.1; Tran TM, 2004, J IMMUNOL, V172, P5110, DOI 10.4049/jimmunol.172.8.5110; Turner MJ, 2007, ARTHRITIS RHEUM, V56, P215, DOI 10.1002/art.22295; Turner MJ, 2005, J IMMUNOL, V175, P2438, DOI 10.4049/jimmunol.175.4.2438; VANDERLINDEN S, 1984, ARTHRITIS RHEUM, V27, P361; Yan JB, 2006, J EXP MED, V203, P647, DOI 10.1084/jem.20052271; ZEMMOUR J, 1992, J IMMUNOL, V148, P1941; Zeng L, 2011, ARTHRITIS RHEUM-US, V63, P3807, DOI 10.1002/art.30593	43	6	6	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 14	2013	8	10							e77451	10.1371/journal.pone.0077451	http://dx.doi.org/10.1371/journal.pone.0077451			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	237RD	24155957	gold, Green Published, Green Submitted			2023-01-03	WOS:000325887300091
J	Huneke, NTM; Brown, CA; Burford, E; Watson, A; Trujillo-Barreto, NJ; El-Deredy, W; Jones, AKP				Huneke, Nathan T. M.; Brown, Christopher A.; Burford, Edward; Watson, Alison; Trujillo-Barreto, Nelson J.; El-Deredy, Wael; Jones, Anthony K. P.			Experimental Placebo Analgesia Changes Resting-State Alpha Oscillations	PLOS ONE			English	Article							WIDESPREAD MUSCULOSKELETAL PAIN; INTERNALLY DIRECTED ATTENTION; ANTERIOR CINGULATE CORTEX; LOW-BACK-PAIN; EEG-ALPHA; PREFRONTAL CORTEX; TONIC PAIN; ANTICIPATION; SYNCHRONIZATION; FIBROMYALGIA	The lack of clear understanding of the pathophysiology of chronic pain could explain why we currently have only a few effective treatments. Understanding how pain relief is realised during placebo analgesia could help develop improved treatments for chronic pain. Here, we tested whether experimental placebo analgesia was associated with altered resting-state cortical activity in the alpha frequency band of the electroencephalogram (EEG). Alpha oscillations have been shown to be influenced by top-down processes, which are thought to underpin the placebo response. Seventy-three healthy volunteers, split into placebo or control groups, took part in a well-established experimental placebo procedure involving treatment with a sham analgesic cream. We recorded ongoing (resting) EEG activity before, during, and after the sham treatment. We show that resting alpha activity is modified by placebo analgesia. Post-treatment, alpha activity increased significantly in the placebo group only (p < 0.001). Source analysis suggested that this alpha activity might have been generated in medial components of the pain network, including dorsal anterior cingulate cortex, medial prefrontal cortex, and left insula. These changes are consistent with a cognitive state of pain expectancy, a key driver of the placebo analgesic response. The manipulation of alpha activity may therefore present an exciting avenue for the development of treatments that directly alter endogenous processes to better control pain.	[Huneke, Nathan T. M.; Burford, Edward] Univ Manchester, Sch Med, Manchester, Lancs, England; [Brown, Christopher A.; Watson, Alison; Jones, Anthony K. P.] Univ Manchester, Inst Brain Behav & Mental Hlth, Human Pain Res Grp, Manchester, Lancs, England; [Trujillo-Barreto, Nelson J.] Cuban Neurosci Ctr, Havana, Cuba; [El-Deredy, Wael] Univ Manchester, Sch Psychol Sci, Manchester, Lancs, England	University of Manchester; University of Manchester; University of Manchester	Brown, CA (corresponding author), Univ Manchester, Inst Brain Behav & Mental Hlth, Human Pain Res Grp, Manchester, Lancs, England.	christopher.brown@manchester.ac.uk	Trujillo-Barreto, Nelson J/G-3764-2013; Huneke, Nathan/ABD-9006-2020; El-deredy, Wael/H-6521-2015	Trujillo-Barreto, Nelson J/0000-0001-6581-7503; Huneke, Nathan/0000-0001-5981-6707; El-deredy, Wael/0000-0002-9822-1092; Jones, Anthony/0000-0001-6944-9365	Dr Hadwen Trust for Humane Research; Arthritis Research UK	Dr Hadwen Trust for Humane Research; Arthritis Research UK(Versus Arthritis)	Funding came from the Dr Hadwen Trust for Humane Research (http://www.drhadwentrust.org/) and Arthritis Research UK (http://www.arthritisresearchuk.org/). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Babiloni C, 2003, EUR J NEUROSCI, V18, P1692, DOI 10.1046/j.1460-9568.2003.02851.x; Babiloni C, 2006, J PAIN, V7, P709, DOI 10.1016/j.jpain.2006.03.005; Basar E, 1997, INT J PSYCHOPHYSIOL, V26, P5, DOI 10.1016/S0167-8760(97)00753-8; Bedson J, 2008, BMC MUSCULOSKEL DIS, V9, DOI 10.1186/1471-2474-9-116; Benedetti F, 2011, NEUROPSYCHOPHARMACOL, V36, P339, DOI 10.1038/npp.2010.81; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Brown CA, 2008, PAIN, V139, P324, DOI 10.1016/j.pain.2008.04.028; Carlino E, 2011, CURR OPIN ANESTHESIO, V24, P540, DOI 10.1097/ACO.0b013e328349d0c2; CHEN ACN, 1983, INT J NEUROSCI, V18, P269, DOI 10.3109/00207458308987371; Chen Andrew C. N., 1994, Brain Topography, V7, P129, DOI 10.1007/BF01186771; Clauw DJ, 2010, NAT REV RHEUMATOL, V6, P439, DOI 10.1038/nrrheum.2010.120; *COLL ROY GEN PRAC, 1995, MORB STAT GEN PRACT, P1991; Cooper NR, 2006, NEUROREPORT, V17, P205, DOI 10.1097/01.wnr.0000198433.29389.54; Cooper NR, 2003, INT J PSYCHOPHYSIOL, V47, P65, DOI 10.1016/S0167-8760(02)00107-1; Damoiseaux JS, 2006, P NATL ACAD SCI USA, V103, P13848, DOI 10.1073/pnas.0601417103; De Luca M, 2006, NEUROIMAGE, V29, P1359, DOI 10.1016/j.neuroimage.2005.08.035; Eippert F, 2009, NEURON, V63, P533, DOI 10.1016/j.neuron.2009.07.014; EVANS AC, 1993, NUCLEAR SCIENCE SYMPOSIUM & MEDICAL IMAGING CONFERENCE, VOLS 1-3, P1813, DOI 10.1109/NSSMIC.1993.373602; Fell J, 2002, INT J NEUROSCI, V112, P1047, DOI 10.1080/00207450290026049; Fields H, 2004, NAT REV NEUROSCI, V5, P565, DOI 10.1038/nrn1431; Franciotti R, 2009, NEUROIMAGE, V46, P1082, DOI 10.1016/j.neuroimage.2009.03.034; FRYMOYER JW, 1984, J BONE JOINT SURG AM, V66A, P1048, DOI 10.2106/00004623-198466070-00011; Goldenberg DL, 2007, BEST PRACT RES CL RH, V21, P499, DOI 10.1016/j.berh.2007.02.012; Grant JA, 2010, EMOTION, V10, P43, DOI 10.1037/a0018334; HARDT JV, 1978, SCIENCE, V201, P79, DOI 10.1126/science.663641; Hsieh JC, 1999, NEUROSCI LETT, V262, P61, DOI 10.1016/S0304-3940(99)00060-9; Jensen KB, 2012, PAIN, V153, P1495, DOI 10.1016/j.pain.2012.04.010; JENSEN MC, 1994, NEW ENGL J MED, V331, P69, DOI 10.1056/NEJM199407143310201; Jensen O, 2002, CEREB CORTEX, V12, P877, DOI 10.1093/cercor/12.8.877; Jones AKP, 2003, BRIT MED BULL, V65, P83, DOI 10.1093/bmb/65.1.83; JONES AKP, 1991, P ROY SOC B-BIOL SCI, V244, P39, DOI 10.1098/rspb.1991.0048; Kamaleri Y, 2008, PAIN, V138, P41, DOI 10.1016/j.pain.2007.11.002; Klimesch W, 1999, COGNITIVE BRAIN RES, V7, P493, DOI 10.1016/S0926-6410(98)00056-1; Klimesch W, 1999, BRAIN RES REV, V29, P169, DOI 10.1016/S0165-0173(98)00056-3; Klimesch W, 2007, BRAIN RES REV, V53, P63, DOI 10.1016/j.brainresrev.2006.06.003; Knudsen L, 2011, SCAND J PAIN, V2, P108, DOI 10.1016/j.sjpain.2011.05.005; Knyazev GG, 2011, BRAIN RES, V1402, P67, DOI 10.1016/j.brainres.2011.05.052; Kong J, 2008, J NEUROSCI, V28, P13354, DOI 10.1523/JNEUROSCI.2944-08.2008; Lieberman MD, 2004, NEUROIMAGE, V22, P447, DOI 10.1016/j.neuroimage.2004.01.037; Lorenz J, 2003, BRAIN, V126, P1079, DOI 10.1093/brain/awg102; Mease PJ, 2011, J RHEUMATOL, V38, P1546, DOI 10.3899/jrheum.100759; Meissner K, 2011, J NEUROSCI, V31, P16117, DOI 10.1523/JNEUROSCI.4099-11.2011; Morton DL, 2010, NEUROPSYCHOLOGIA, V48, P1958, DOI 10.1016/j.neuropsychologia.2010.03.016; Natvig B, 2001, J REHABIL MED, V33, P21; Nemoto H, 2007, EXP BRAIN RES, V179, P655, DOI 10.1007/s00221-006-0821-z; Nir RR, 2012, CLIN NEUROPHYSIOL, V123, P605, DOI 10.1016/j.clinph.2011.08.006; Petrovic P, 2002, SCIENCE, V295, P1737, DOI 10.1126/science.1067176; Petrovic P, 2005, NEURON, V46, P957, DOI 10.1016/j.neuron.2005.05.023; Phillips C, 2008, HEALTH POLICY, V88, P166, DOI 10.1016/j.healthpol.2008.03.008; Picavet HSJ, 2003, PAIN, V102, P167, DOI 10.1016/S0304-3959(02)00372-X; Ploghaus A, 1999, SCIENCE, V284, P1979, DOI 10.1126/science.284.5422.1979; Porro CA, 2002, J NEUROSCI, V22, P3206, DOI 10.1523/JNEUROSCI.22-08-03206.2002; Sauseng P, 2005, HUM BRAIN MAPP, V26, P148, DOI 10.1002/hbm.20150; Sawamoto N, 2000, J NEUROSCI, V20, P7438; Schmidt-Wilcke T, 2011, NAT REV RHEUMATOL, V7, P518, DOI 10.1038/nrrheum.2011.98; Schreckenberger M, 2005, NEUROLOGY, V64, P1175, DOI 10.1212/01.WNL.0000156353.17305.52; Seifert F, 2009, J NEUROSCI, V29, P6167, DOI 10.1523/JNEUROSCI.4654-08.2009; TALBOT JD, 1991, SCIENCE, V251, P1355, DOI 10.1126/science.2003220; Treede RD, 1999, PAIN, V79, P105, DOI 10.1016/S0304-3959(98)00184-5; Trujillo-Barreto NJ, 2004, NEUROIMAGE, V21, P1300, DOI 10.1016/j.neuroimage.2003.11.008; Varela F, 2001, NAT REV NEUROSCI, V2, P229, DOI 10.1038/35067550; Wager TD, 2004, SCIENCE, V303, P1162, DOI 10.1126/science.1093065; Watson A, 2007, NEUROREPORT, V18, P771, DOI 10.1097/WNR.0b013e3280c1e2a8; Watson A, 2009, PAIN, V145, P24, DOI 10.1016/j.pain.2009.04.003	64	22	22	1	18	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 11	2013	8	10							e78278	10.1371/journal.pone.0078278	http://dx.doi.org/10.1371/journal.pone.0078278			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	236SL	24147129	Green Submitted, Green Published, gold			2023-01-03	WOS:000325819400151
J	Shaw, DM				Shaw, David M.			Homeopaths Without Borders practice exploitation not humanitarianism	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material									Univ Basel, Inst Biomed Eth, CH-4056 Basel, Switzerland	University of Basel	Shaw, DM (corresponding author), Univ Basel, Inst Biomed Eth, CH-4056 Basel, Switzerland.	david.shaw@unibas.ch						[Anonymous], 2005, LANCET, V366, P690; Homeopaths Without Borders (Germany), 2013, INT S; Shaw DM, 2010, J MED ETHICS, V36, P130, DOI 10.1136/jme.2009.034959	3	1	1	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 17	2013	347								f5448	10.1136/bmj.f5448	http://dx.doi.org/10.1136/bmj.f5448			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	223SB	24046156				2023-01-03	WOS:000324828300003
J	Young, C; Wong, KY; Cheung, LK				Young, Cecilia; Wong, Kin Yau; Cheung, Lim K.			Effectiveness of Educational Poster on Knowledge of Emergency Management of Dental Trauma-Part 1. Cluster Randomised Controlled Trial for Primary and Secondary School Teachers	PLOS ONE			English	Article							TOOTH AVULSION; ORAL-HEALTH; 1ST AID; INJURIES; SCHOOLCHILDREN; TEETH; PROFESSIONALS; INTERVENTION; LEAFLET; ISRAEL	Objective: To investigate the effectiveness of educational posters in improving the knowledge level of primary and secondary school teachers regarding emergency management of dental trauma. Methods: A cluster randomised controlled trial was conducted. 32 schools with a total of 515 teachers were randomised into intervention (poster) and control groups at the school level. Teachers' baseline levels of knowledge about dental trauma were obtained by using a questionnaire. Posters containing information on dental trauma management were displayed in the school medical room, the common room used by staff, and on a notice board for 2 weeks in each school of the intervention group; in the control group, no posters were displayed. Teachers in both groups completed the questionnaire after 2 weeks. Results: The teachers in the intervention schools (where posters were displayed for 2 weeks) showed statistically significant improvement in scores in cases where they had not previously learned about dental emergencies from sources other than first aid training, with an average score increase of 2.6656 (score range of questionnaire, -13 to 9; p-value < 0.0001). Conclusion: Educational posters on the management of dental trauma can significantly improve the level of knowledge of primary and secondary school teachers in Hong Kong.	[Wong, Kin Yau] Univ N Carolina, Dept Biostat, Chapel Hill, NC USA; [Cheung, Lim K.] Univ Hong Kong, Fac Dent, Hong Kong, Hong Kong, Peoples R China	University of North Carolina; University of North Carolina Chapel Hill; University of Hong Kong		ceciliatyp@yahoo.com.hk	; Young, Cecilia/K-1699-2018	Cheung, Lim Kwong/0000-0002-2248-286X; , Kin Yau/0000-0001-9066-1619; Young, Cecilia/0000-0003-1698-7738				Al-Asfour A, 2008, DENT TRAUMATOL, V24, P515, DOI 10.1111/j.1600-9657.2008.00651.x; Al-Asfour A, 2008, DENT TRAUMATOL, V24, P43, DOI 10.1111/j.1600-9657.2006.00476.x; Al-Obaida M, 2010, DENT TRAUMATOL, V26, P338, DOI 10.1111/j.1600-9657.2010.00894.x; Andreasen JO, 2002, DENT TRAUMATOL, V18, P116, DOI 10.1034/j.1600-9657.2002.00079.x; Arikan V, 2012, DENT TRAUMATOL, V28, P101, DOI 10.1111/j.1600-9657.2011.01042.x; Bendo CB, 2010, J PUBLIC HEALTH DENT, V70, P313, DOI 10.1111/j.1752-7325.2010.00190.x; DONNER A, 1986, INT STAT REV, V54, P67, DOI 10.2307/1403259; Draper N.R., 1998, APPL REGRESSION ANAL, P79; Fakhruddin KS, 2008, DENT TRAUMATOL, V24, P305, DOI 10.1111/j.1600-9657.2007.00548.x; Froud R, 2012, COMMUNITY DENT ORAL, V40, P3, DOI 10.1111/j.1600-0528.2011.00660.x; Fux-Noy A, 2011, DENT TRAUMATOL, V27, P252, DOI 10.1111/j.1600-9657.2010.00970.x; Holan G, 2006, DENT TRAUMATOL, V22, P323, DOI 10.1111/j.1600-9657.2005.00387.x; Kahabuka F K, 2001, SADJ, V56, P284; Levin L, 2007, DENT TRAUMATOL, V23, P356, DOI 10.1111/j.1600-9657.2006.00473.x; Levin L, 2010, DENT TRAUMATOL, V26, P86, DOI 10.1111/j.1600-9657.2009.00847.x; Lieger O, 2009, DENT TRAUMATOL, V25, P406, DOI 10.1111/j.1600-9657.2009.00798.x; McIntyre JD, 2008, DENT TRAUMATOL, V24, P146, DOI 10.1111/j.1600-9657.2008.00573.x; Mesgarzadeh AH, 2009, ORAL HLTH PREV DENT, V7, P297; Mohandas U, 2009, J Indian Soc Pedod Prev Dent, V27, P242, DOI 10.4103/0970-4388.57660; Mori GG, 2007, J APPL ORAL SCI, V15, P534, DOI 10.1590/S1678-77572007000600015; Naidoo S, 2009, DENT TRAUMATOL, V25, P224, DOI 10.1111/j.1600-9657.2008.00749.x; Pujita Chada, 2013, J Conserv Dent, V16, P21, DOI 10.4103/0972-0707.105293; Skapetis T, 2012, BMC MED EDUC, V12, DOI 10.1186/1472-6920-12-103; Skapetis T, 2012, AUSTRALAS EMERG NURS, V15, P14, DOI 10.1016/j.aenj.2011.12.003; Skeie MS, 2010, DENT TRAUMATOL, V26, P243, DOI 10.1111/j.1600-9657.2010.00897.x; Underwood M, 1998, BRIT J GEN PRACT, V48, P1089; Frujeri MDV, 2009, DENT TRAUMATOL, V25, P262, DOI 10.1111/j.1600-9657.2008.00760.x; Young C, 2012, HONG KONG MED J, V18, P362	28	13	13	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 11	2013	8	9							e74833	10.1371/journal.pone.0074833	http://dx.doi.org/10.1371/journal.pone.0074833			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	248VW	24147154	Green Published, gold, Green Submitted			2023-01-03	WOS:000326734500121
J	Ide, S; Nishizawa, D; Fukuda, K; Kasai, S; Hasegawa, J; Hayashida, M; Minami, M; Ikeda, K				Ide, Soichiro; Nishizawa, Daisuke; Fukuda, Ken-ichi; Kasai, Shinya; Hasegawa, Junko; Hayashida, Masakazu; Minami, Masabumi; Ikeda, Kazutaka			Association between Genetic Polymorphisms in Ca(v)2.3 (R-type) Ca2+ Channels and Fentanyl Sensitivity in Patients Undergoing Painful Cosmetic Surgery	PLOS ONE			English	Article							E CALCIUM-CHANNEL; MORPHINE ANALGESIA; ANTAGONISTS; DEPENDENCE; TOLERANCE; RESPONSES; SUBUNIT; POWER	Individual differences in the sensitivity to fentanyl, a widely used opioid analgesic, lead to different proper doses of fentanyl, which can hamper effective pain treatment. Voltage-activated Ca2+ channels (VACCs) play a crucial role in the nervous system by controlling membrane excitability and calcium signaling. Ca(v)2.3 (R-type) VACCs have been especially thought to play critical roles in pain pathways and the analgesic effects of opioids. However, unknown is whether single-nucleotide polymorphisms (SNPs) of the human CACNA1E (calcium channel, voltage-dependent, R type, alpha 1E subunit) gene that encodes Ca(v)2.3 VACCs influence the analgesic effects of opioids. Thus, the present study examined associations between fentanyl sensitivity and SNPs in the human CACNA1E gene in 355 Japanese patients who underwent painful orofacial cosmetic surgery, including bone dissection. We first conducted linkage disequilibrium (LD) analyses of 223 SNPs in a region that contains the CACNA1E gene using genomic samples from 100 patients, and a total of 13 LD blocks with 42 Tag SNPs were observed within and around the CACNA1E gene region. In the preliminary study using the same 100 genomic samples, only the rs3845446 A/G SNP was significantly associated with perioperative fentanyl use among these 42 Tag SNPs. In a confirmatory study using the other 255 genomic samples, this SNP was also significantly associated with perioperative fentanyl use. Thus, we further analyzed associations between genotypes of this SNP and all of the clinical data using a total of 355 samples. The rs3845446 A/G SNP was associated with intraoperative fentanyl use, 24 h postoperative fentanyl requirements, and perioperative fentanyl use. Subjects who carried the minor G allele required significantly less fentanyl for pain control compared with subjects who did not carry this allele. Although further validation is needed, the present findings show the possibility of the involvement of CACNA1E gene polymorphisms in fentanyl sensitivity.	[Ide, Soichiro; Nishizawa, Daisuke; Kasai, Shinya; Hasegawa, Junko; Ikeda, Kazutaka] Tokyo Metropolitan Inst Med Sci, Addict Subst Project, Tokyo 113, Japan; [Ide, Soichiro; Minami, Masabumi] Hokkaido Univ, Grad Sch Pharmaceut Sci, Dept Pharmacol, Sapporo, Hokkaido, Japan; [Fukuda, Ken-ichi] Suidoubashi Hosp, Tokyo Dent Coll, Orofacial Pain Ctr, Dept Oral Hlth & Clin Sci,Div Dent Anesthesiol, Tokyo, Japan; [Hayashida, Masakazu] Juntendo Univ, Sch Med, Dept Anesthesiol & Pain Med, Tokyo 113, Japan	Tokyo Metropolitan Institute of Medical Science; Hokkaido University; Tokyo Dental College; Juntendo University	Ikeda, K (corresponding author), Tokyo Metropolitan Inst Med Sci, Addict Subst Project, Tokyo 113, Japan.	ikeda-kz@igakuken.or.jp	Minami, Masabumi/A-3883-2012	Minami, Masabumi/0000-0002-0144-0679; Ide, Soichiro/0000-0002-9112-2841	Ministry of Education, Culture, Sports, Science and Technology [20390162, 22790518, 23390377, 25116532]; Japanese Ministry of Health, Labour and Welfare [H21-3jigan-ippan-011, H22-Iyaku-015]; Smoking Research Foundation; Astellas Foundation for Research on Metabolic Disorders	Ministry of Education, Culture, Sports, Science and Technology(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Japanese Ministry of Health, Labour and Welfare(Ministry of Health, Labour and Welfare, Japan); Smoking Research Foundation; Astellas Foundation for Research on Metabolic Disorders	This research was supported by Grants-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology (20390162, 22790518, 23390377, 25116532), Japanese Ministry of Health, Labour and Welfare (H21-3jigan-ippan-011, H22-Iyaku-015), Smoking Research Foundation, and Astellas Foundation for Research on Metabolic Disorders. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Angst MS, 2012, PAIN, V153, P1397, DOI 10.1016/j.pain.2012.02.022; Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457; Bisgaard T, 2001, PAIN, V90, P261, DOI 10.1016/S0304-3959(00)00406-1; Carlson CS, 2003, NAT GENET, V33, P518, DOI 10.1038/ng1128; Carlson CS, 2004, AM J HUM GENET, V74, P106, DOI 10.1086/381000; Catterall WA, 2000, ANNU REV CELL DEV BI, V16, P521, DOI 10.1146/annurev.cellbio.16.1.521; CONTRERAS E, 1988, EUR J PHARMACOL, V148, P463, DOI 10.1016/0014-2999(88)90129-X; Coulbault L, 2006, CLIN PHARMACOL THER, V79, P316, DOI 10.1016/j.clpt.2006.01.007; de Bakker PIW, 2005, NAT GENET, V37, P1217, DOI 10.1038/ng1669; Dogrul A, 2002, LIFE SCI, V71, P725, DOI 10.1016/S0024-3205(02)01736-8; Ertel EA, 2000, NEURON, V25, P533, DOI 10.1016/S0896-6273(00)81057-0; Faul F, 2007, BEHAV RES METHODS, V39, P175, DOI 10.3758/BF03193146; Fukuda K, 2009, PAIN, V147, P194, DOI 10.1016/j.pain.2009.09.004; Gabriel SB, 2002, SCIENCE, V296, P2225, DOI 10.1126/science.1069424; Holmkvist J, 2007, DIABETOLOGIA, V50, P2467, DOI 10.1007/s00125-007-0846-2; Ikeda K, 2005, TRENDS PHARMACOL SCI, V26, P311, DOI 10.1016/j.tips.2005.04.001; Kasai S, 2011, PHARMACOGENOMICS, V12, P1305, DOI [10.2217/PGS.11.68, 10.2217/pgs.11.68]; Loh HH, 1998, MOL BRAIN RES, V54, P321, DOI 10.1016/S0169-328X(97)00353-7; Marubio LM, 1996, RECEPTOR CHANNEL, V4, P243; Michaluk J, 1998, EUR J PHARMACOL, V352, P189, DOI 10.1016/S0014-2999(98)00373-2; Muller YL, 2007, DIABETES, V56, P3089, DOI 10.2337/db07-0587; Murakami M, 2004, BRAIN RES, V1024, P122, DOI 10.1016/j.brainres.2004.07.066; Newcomb R, 1998, BIOCHEMISTRY-US, V37, P15353, DOI 10.1021/bi981255g; Park JF, 2010, CHANNELS, V4, P510, DOI 10.4161/chan.4.6.12869; Pereverzev A, 2002, MOL CELL NEUROSCI, V21, P352, DOI 10.1006/mcne.2002.1179; Saegusa H, 2000, P NATL ACAD SCI USA, V97, P6132, DOI 10.1073/pnas.100124197; Sora I, 1997, P NATL ACAD SCI USA, V94, P1544, DOI 10.1073/pnas.94.4.1544; Sora I, 2001, NEUROPSYCHOPHARMACOL, V25, P41, DOI 10.1016/S0893-133X(00)00252-9; Westenbroek RE, 1998, J NEUROSCI, V18, P6319; YOKOYAMA CT, 1995, J NEUROSCI, V15, P6419; Yokoyama K, 2004, EUR J NEUROSCI, V20, P3516, DOI 10.1111/j.1460-9568.2004.03810.x; ZHANG JF, 1993, NEUROPHARMACOLOGY, V32, P1075, DOI 10.1016/0028-3908(93)90003-L	33	19	20	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 5	2013	8	8							e70694	10.1371/journal.pone.0070694	http://dx.doi.org/10.1371/journal.pone.0070694			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	218XC	23940630	gold, Green Published			2023-01-03	WOS:000324465000124
J	Kaur, T; Hussain, K; Koul, S; Vishwakarma, R; Vyas, D				Kaur, Tarandeep; Hussain, Khadim; Koul, Sushma; Vishwakarma, Ram; Vyas, Dhiraj			Evaluation of Nutritional and Antioxidant Status of Lepidium latifolium Linn.: A Novel Phytofood from Ladakh	PLOS ONE			English	Article							OXIDATIVE STRESS; ALLYL ISOTHIOCYANATE; EXTRACT; SULFUR; L.; BIOAVAILABILITY; AVAILABILITY; PHENOLICS; CANCER; PLANTS	Lepidium latifolium Linn. (perennial pepperweed) is one of the preferred phytofoods among cold arid region of Ladakh, India and its leaves contribute significantly to people's diet. This study was conducted to determine its nutritive value and antioxidant activity. Plant samples from three different locations were selected in the present study. Results showed that this plant is an excellent source of glucosinolates, notably sinigrin that is present in very high amount (similar to 70-90%). Its value ranged from 149 to 199 mu g per g fresh weight. Fatty acid composition analysis showed that its leaves were abundant in unsaturated fatty acids, specifically linolenic acid (18:3) whose percentage is about 50%. Higher glucose and crude protein along with higher nitrogen to sulfur ratio, supplements the nutritive value of this plant. Based on total phenol, flavanoids, free radical scavenging activity and DNA protective activity showed that this ecotype of perennial pepperweed contains high antioxidant properties. The percentage inhibition for O-2(-) scavenging activity ranged from 41.3% to 83.9%. Higher content of phenols (26.89 to 50.51 mg gallic acid equivalents per g dry weight) and flavanoids (38.66 to 76.00 mg quercetin equivalents per g dry weight) in leaves could be responsible for the free radical scavenging activity of this plant. Depending upon the location of the plants, variations were observed in different activities. Based on the systematic evaluation in this study, preparations of Lepidium latifolium from Ladakh can be promoted as substitute to dietary requirements.	[Kaur, Tarandeep; Hussain, Khadim; Vyas, Dhiraj] Indian Inst Integrat Med CSIR, Acad Sci & Innovat Res, Jammu, India; [Kaur, Tarandeep; Hussain, Khadim; Koul, Sushma; Vyas, Dhiraj] Indian Inst Integrat Med CSIR, Biodivers & Appl Bot Div, Jammu, India; [Vishwakarma, Ram] Indian Inst Integrat Med CSIR, Div Med Chem, Jammu, India	Academy of Scientific & Innovative Research (AcSIR); Council of Scientific & Industrial Research (CSIR) - India; CSIR - Indian Institute of Integrative Medicine (IIIM); Council of Scientific & Industrial Research (CSIR) - India; CSIR - Indian Institute of Integrative Medicine (IIIM); Council of Scientific & Industrial Research (CSIR) - India; CSIR - Indian Institute of Integrative Medicine (IIIM)	Vyas, D (corresponding author), Indian Inst Integrat Med CSIR, Acad Sci & Innovat Res, Canal Rd, Jammu, India.	dhirajvyas@rediffmail.com			Council of Scientific and Industrial Research (CSIR), Government of India under CSIR-networking project [BSC-0109]	Council of Scientific and Industrial Research (CSIR), Government of India under CSIR-networking project	Financial support to the present study was provided by Council of Scientific and Industrial Research (CSIR), Government of India, under CSIR-networking project (BSC-0109) on 'Plant Diversity: Studying adaptation biology and understanding/exploiting medicinally important plants for useful bioactives (SIMPLE)'. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abrol E, 2012, ACTA PHYSIOL PLANT, V34, P541, DOI 10.1007/s11738-011-0851-4; ALLAWAY WH, 1966, SOIL SCI, V101, P240, DOI 10.1097/00010694-196604000-00003; Aslam M, 2012, MOL BIOL REP, V39, P9629, DOI 10.1007/s11033-012-1828-0; Brosnan JT, 2006, J NUTR, V136, p1636S, DOI 10.1093/jn/136.6.1636S; Chung YC, 2002, J AGR FOOD CHEM, V50, P2454, DOI 10.1021/jf011369q; COLEY PD, 1985, SCIENCE, V230, P895, DOI 10.1126/science.230.4728.895; Dinkova-Kostova AT, 2012, TRENDS MOL MED, V18, P337, DOI 10.1016/j.molmed.2012.04.003; Duh PD, 1999, FOOD SCI TECHNOL-LEB, V32, P269; Elena Cartea Maria, 2008, Phytochemistry Reviews, V7, P213, DOI 10.1007/s11101-007-9072-2; FATEMI SH, 1980, LIPIDS, V15, P379, DOI 10.1007/BF02533555; Ferguson LR, 2010, MUTAT RES-FUND MOL M, V690, P3, DOI 10.1016/j.mrfmmm.2010.03.007; GARCES R, 1993, ANAL BIOCHEM, V211, P139, DOI 10.1006/abio.1993.1244; Geetha S, 2003, J ETHNOPHARMACOL, V87, P247, DOI 10.1016/S0378-8741(03)00154-5; Guleria S, 2011, J FOOD SCI, V76, pC959, DOI 10.1111/j.1750-3841.2011.02284.x; Gupta S, 2012, BASICS, P1; Halliwell B, 2007, BIOCHEM J, V401, P1, DOI 10.1042/BJ20061131; Halliwell B, 2006, J NEUROCHEM, V97, P1634, DOI 10.1111/j.1471-4159.2006.03907.x; Halliwell B, 2012, NUTR REV, V70, P257, DOI 10.1111/j.1753-4887.2012.00476.x; Halliwell B, 2011, TRENDS PHARMACOL SCI, V32, P125, DOI 10.1016/j.tips.2010.12.002; HERMS DA, 1992, Q REV BIOL, V67, P283, DOI 10.1086/417659; Hulten E, 1986, ATLAS N EUROPEAN V 1; Kaur C, 2001, INT J FOOD SCI TECH, V36, P703, DOI 10.1046/j.1365-2621.2001.00513.x; Kaur T, 2013, ACTA PHYSIOL PLANT, V35, P2501, DOI 10.1007/s11738-013-1286-x; Li HB, 2008, LWT-FOOD SCI TECHNOL, V41, P385, DOI 10.1016/j.lwt.2007.03.011; MEIR S, 1995, J AGR FOOD CHEM, V43, P1813, DOI 10.1021/jf00055a012; Mithen RF, 2000, J SCI FOOD AGR, V80, P967, DOI [10.1002/(SICI)1097-0010(20000515)80:7<967::AID-JSFA597>3.0.CO;2-V, 10.1002/(SICI)1097-0010(20000515)80:7&lt;967::AID-JSFA597&gt;3.0.CO;2-V]; NAVARRO E, 1994, J ETHNOPHARMACOL, V41, P65, DOI 10.1016/0378-8741(94)90059-0; Pal MM, 2010, INDIAN J TRADIT KNOW, V9, P303; Petersen BL, 2002, PLANTA, V214, P562, DOI 10.1007/s004250100659; Prior RL, 2005, J AGR FOOD CHEM, V53, P4290, DOI 10.1021/jf0502698; Rana JC, 2012, GENET RESOUR CROP EV, V59, P135, DOI 10.1007/s10722-011-9765-7; RiceEvans CA, 1997, TRENDS PLANT SCI, V2, P152, DOI 10.1016/S1360-1385(97)01018-2; Schreiner M, 2005, EUR J NUTR, V44, P85, DOI 10.1007/s00394-004-0498-7; Schultze-Motel W., 1986, LEPIDIUM LATIFOLIUM; Sexton PJ, 1998, CROP SCI, V38, P983, DOI 10.2135/cropsci1998.0011183X003800040017x; Sheikh G.G., 2011, INDIAN J ANIM NUTR, V28, P427; Shimoi K, 1996, MUTAT RES-FUND MOL M, V350, P153, DOI 10.1016/0027-5107(95)00116-6; Soobrattee MA, 2005, MUTAT RES-FUND MOL M, V579, P200, DOI 10.1016/j.mrfmmm.2005.03.023; Sultana T, 2002, J SCI FOOD AGR, V82, P1477, DOI 10.1002/jsfa.1218; Tabassum Nahida, 2011, Pharmacogn Rev, V5, P30, DOI 10.4103/0973-7847.79097; Trabelsi H, 2012, FOOD CHEM, V131, P434, DOI 10.1016/j.foodchem.2011.08.083; Traka M, 2009, PHYTOCHEM REV, V8, P269, DOI 10.1007/s11101-008-9103-7; Uematsu Y, 2002, J FOOD HYG SOC JPN, V43, P10, DOI 10.3358/shokueishi.43.10; Velasco P, 2011, PHYTOCHEM ANALYSIS, V22, P144, DOI 10.1002/pca.1259; Vyas D, 2005, BIOCHEM BIOPH RES CO, V329, P831, DOI 10.1016/j.bbrc.2005.02.051; Wassef W. N., 1985, FOOD CHEM, P140; Xavier J. R., 2011, Journal of Medicinal and Aromatic Plant Sciences, V33, P21; Zhang YS, 2010, MOL NUTR FOOD RES, V54, P127, DOI 10.1002/mnfr.200900323	48	27	29	0	19	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 2	2013	8	8							e69112	10.1371/journal.pone.0069112	http://dx.doi.org/10.1371/journal.pone.0069112			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	219XU	23936316	Green Published, Green Submitted, gold			2023-01-03	WOS:000324545800010
J	Hilborn, ED; Soares, RM; Servaites, JC; Delgado, AG; Magalhaes, VF; Carmichael, WW; Azevedo, SMFO				Hilborn, Elizabeth D.; Soares, Raquel M.; Servaites, Jerome C.; Delgado, Alvima G.; Magalhaes, Valeria F.; Carmichael, Wayne W.; Azevedo, Sandra M. F. O.			Sublethal Microcystin Exposure and Biochemical Outcomes among Hemodialysis Patients	PLOS ONE			English	Article							BLUE-GREEN-ALGA; LIVER-DAMAGE; CYANOBACTERIA; SERUM; CYANOTOXINS; AERUGINOSA; BRAZIL; WATER; LR; INTOXICATION	Cyanobacteria are commonly-occurring contaminants of surface waters worldwide. Microcystins, potent hepatotoxins, are among the best characterized cyanotoxins. During November, 2001, a group of 44 hemodialysis patients were exposed to microcystins via contaminated dialysate. Serum microcystin concentrations were quantified with enzyme-linked immunosorbent assay which measures free serum microcystin LR equivalents (ME). We describe serum ME concentrations and biochemical outcomes among a subset of patients during 8 weeks following exposure. Thirteen patients were included; 6 were males, patients' median age was 45 years (range 16-80), one was seropositive for hepatitis B surface antigen. The median serum ME concentration was 0.33 ng/mL (range:,0.16-0.96). One hundred thirty nine blood samples were collected following exposure. Patients' biochemical outcomes varied, but overall indicated a mixed liver injury. Linear regression evaluated each patient's weekly mean biochemical outcome with their maximum serum ME concentration; a measure of the extrinsic pathway of clotting function, prothrombin time, was negatively and significantly associated with serum ME concentrations. This group of exposed patients' biochemical outcomes display evidence of a mixed liver injury temporally associated with microcystin exposure. Interpretation of biochemical outcomes are complicated by the study population's underlying chronic disease status. It is clear that dialysis patients are a distinct 'at risk' group for cyanotoxin exposures due to direct intravenous exposure to dialysate prepared from surface drinking water supplies. Careful monitoring and treatment of water supplies used to prepare dialysate is required to prevent future cyanotoxin exposure events.	[Hilborn, Elizabeth D.] US EPA, Off Res & Dev, Natl Hlth & Environm Effects Res Lab, Res Triangle Pk, NC 27711 USA; [Soares, Raquel M.; Delgado, Alvima G.; Magalhaes, Valeria F.; Azevedo, Sandra M. F. O.] Univ Fed Rio de Janeiro, Lab Ecophysiol & Toxicol Cyanobacteria, Carlos Chagas Filho Biophys Inst, Rio De Janeiro, Brazil; [Servaites, Jerome C.; Carmichael, Wayne W.] Wright State Univ, Dept Biol Sci, Dayton, OH 45435 USA	United States Environmental Protection Agency; Universidade Federal do Rio de Janeiro; University System of Ohio; Wright State University Dayton	Hilborn, ED (corresponding author), US EPA, Off Res & Dev, Natl Hlth & Environm Effects Res Lab, Res Triangle Pk, NC 27711 USA.	hilborn.e@epa.gov	de oliveira e azevedo, sandra maria feliciano/G-8362-2015; Soares, Raquel/C-9863-2014; Magalhães, Valéria/Y-4335-2019	de oliveira e azevedo, sandra maria feliciano/0000-0002-3046-0652; Hilborn, Elizabeth/0000-0002-3035-3101; Soares, Raquel/0000-0003-3880-6248	Brazilian Council for Scientific and Technological Development (CNPq); Carlos Chagas Filho Rio de Janeiro State Research Supporting Foundation (FAPERJ); Foundation for the Coordination of Higher Education and Graduate Training (CAPES); United States Environmental Protection Agency (USEPA) [2D-5849-NAEX]; USEPA [EP-D-07-109]	Brazilian Council for Scientific and Technological Development (CNPq)(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); Carlos Chagas Filho Rio de Janeiro State Research Supporting Foundation (FAPERJ)(Fundacao Carlos Chagas Filho de Amparo a Pesquisa do Estado do Rio De Janeiro (FAPERJ)); Foundation for the Coordination of Higher Education and Graduate Training (CAPES); United States Environmental Protection Agency (USEPA)(United States Environmental Protection Agency); USEPA(United States Environmental Protection Agency)	Funded by The Brazilian Council for Scientific and Technological Development (CNPq); The Carlos Chagas Filho Rio de Janeiro State Research Supporting Foundation (FAPERJ); and The Foundation for the Coordination of Higher Education and Graduate Training (CAPES); United States Environmental Protection Agency (USEPA) Contract grant number: 2D-5849-NAEX; USEPA Contract number: EP-D-07-109. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Beasley VR, 2000, J TOXICOL ENV HEAL A, V61, P281, DOI 10.1080/00984100050136599; BENICHOU C, 1990, J HEPATOL, V11, P272; Bommer J, 2001, NEPHROL DIAL TRANSPL, V16, P1992, DOI 10.1093/ndt/16.10.1992; Burns J, 2008, ADV EXP MED BIOL, V619, P127, DOI 10.1007/978-0-387-75865-7_5; Carmichael WW, 2001, ENVIRON HEALTH PERSP, V109, P663, DOI 10.2307/3454781; Chen J, 2009, TOXICOL SCI, V108, P81, DOI 10.1093/toxsci/kfp009; CHU FS, 1990, J ASSOC OFF ANA CHEM, V73, P451; Corran P, 1999, WHO TECH REP SER, V889, P1; Ding WX, 1998, ENVIRON RES, V78, P12, DOI 10.1006/enrs.1998.3843; Fabrizi F, 2003, INT J ARTIF ORGANS, V26, P1048, DOI 10.1177/039139880302601202; FALCONER IR, 1983, MED J AUSTRALIA, V1, P511, DOI 10.5694/j.1326-5377.1983.tb136192.x; FALCONER IR, 1986, AUST J BIOL SCI, V39, P17; Favaloro EJ, 2011, PATHOLOGY, V43, P682, DOI 10.1097/PAT.0b013e32834bf5f4; Fiorillo C, 1998, CLIN CHEM LAB MED, V36, P149, DOI 10.1515/CCLM.1998.028; Foxall TL, 1981, EFFECTS HEPATIC TOXI; Galli F, 2001, KIDNEY INT, V59, pS148, DOI 10.1046/j.1523-1755.2001.07846.x; Giannuzzi L, 2011, MAR DRUGS, V9, P2164, DOI 10.3390/md9112164; GUH JY, 1995, NEPHRON, V69, P459, DOI 10.1159/000188520; Hilborn ED, 2007, ENVIRON TOXICOL, V22, P459, DOI 10.1002/tox.20281; Himmelfarb J, 2010, NEW ENGL J MED, V363, P1833, DOI 10.1056/NEJMra0902710; HOOSER SB, 1989, VET PATHOL, V26, P246, DOI 10.1177/030098588902600309; Jochimsen EM, 1998, NEW ENGL J MED, V338, P873, DOI 10.1056/NEJM199803263381304; Knight JA, 2005, J INFUS MURS, V28, P108, DOI 10.1097/00129804-200503000-00004; Kullak-Ublick GA, 2000, J HEPATOL, V32, P3, DOI 10.1016/S0168-8278(00)80411-0; Li Y, 2011, ENVIRON HEALTH PERSP, V119, P1483, DOI 10.1289/ehp.1002412; Molino D, 2004, SEMIN NEPHROL, V24, P495, DOI 10.1016/j.semnephrol.2004.06.004; ONO K, 1995, CLIN NEPHROL, V43, P405; Pouria S, 1998, LANCET, V352, P21, DOI 10.1016/S0140-6736(97)12285-1; ROBINSON NA, 1991, J PHARMACOL EXP THER, V256, P176; Runnegar MT, 1982, S AFR MED J; Sacher RA, 2000, WIDMANNS CLIN INTERP; Soares RM, 2006, ENVIRON TOXICOL, V21, P95, DOI 10.1002/tox.20160; Wada H, 2008, SEMIN THROMB HEMOST, V34, P772, DOI 10.1055/s-0029-1145259; WHO Expert Committee on Biological Standardization, 1999, WHO TECH REP SER, V889, pi; WOLF PL, 1972, CLIN CHEM, V18, P567; Yen HK, 2011, TOXICON, V58, P209, DOI 10.1016/j.toxicon.2011.06.003; Zamyadi A, 2012, WATER RES, V46, P1511, DOI 10.1016/j.watres.2011.11.012	37	24	25	1	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 24	2013	8	7							e69518	10.1371/journal.pone.0069518	http://dx.doi.org/10.1371/journal.pone.0069518			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	188BY	23894497	Green Published, Green Submitted, gold			2023-01-03	WOS:000322167900079
J	Ferner, R				Ferner, Robin			Hallucination	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material									Birmingham City Hosp, West Midlands Ctr Adverse Drug React, Birmingham B18 7QH, W Midlands, England		Ferner, R (corresponding author), Birmingham City Hosp, West Midlands Ctr Adverse Drug React, Birmingham B18 7QH, W Midlands, England.	R.E.Ferner@bham.ac.uk		Ferner, Robin/0000-0003-3769-1346				Abouesh A, 2002, J CLIN PSYCHOPHARM, V22, P71, DOI 10.1097/00004714-200202000-00012; ALLEN JR, 1985, NEW ENGL J MED, V313, P642; ARASKIEWICZ A, 1994, MED HYPOTHESES, V42, P261, DOI 10.1016/0306-9877(94)90128-7; BATCHELOR RCL, 1951, LANCET, V261, P195; Bouso JC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042421; Grob CS, 1996, J NERV MENT DIS, V184, P86, DOI 10.1097/00005053-199602000-00004; Keeley PW, 2000, BRIT MED J, V321, P1608, DOI 10.1136/bmj.321.7276.1608; Landais A, 2014, REV MED INTERNE, V35, P199, DOI 10.1016/j.revmed.2013.02.027; McKenna D.J., 1998, HEFFTER REV PSYCHEDE, V1, P65; Sacks OW, 2012, HALLUCINATIONS: RESEARCH AND PRACTICE, P133, DOI 10.1007/978-1-4614-0959-5_11	10	0	0	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 17	2013	347								f4570	10.1136/bmj.f4570	http://dx.doi.org/10.1136/bmj.f4570			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	189DG	23873925				2023-01-03	WOS:000322246700012
J	Nielsen, N; Wettersley, J; Cronberg, T; Erlinge, D; Gasche, Y; Hassager, C; Horn, J; Hovdenes, J; Kjaergaard, J; Kuiper, M; Pellis, T; Stammet, P; Wanscher, M; Wise, MP; Aneman, A; Al-Subaie, N; Boesgaard, S; Bro-Jeppesen, J; Brunetti, I; Bugge, JF; Hingston, CD; Juffermans, NP; Koopmans, M; Kober, L; Langorgen, J; Lilja, G; Moller, JE; Rundgren, M; Rylander, C; Smid, O; Werer, C; Winkel, P; Friberg, H				Nielsen, Niklas; Wettersley, Jorn; Cronberg, Tobias; Erlinge, David; Gasche, Yvan; Hassager, Christian; Horn, Janneke; Hovdenes, Jan; Kjaergaard, Jesper; Kuiper, Michael; Pellis, Tommaso; Stammet, Pascal; Wanscher, Michael; Wise, Matt P.; Aneman, Anders; Al-Subaie, Nawaf; Boesgaard, Soren; Bro-Jeppesen, John; Brunetti, Iole; Bugge, Jan Frederik; Hingston, Christopher D.; Juffermans, Nicole P.; Koopmans, Matty; Kober, Lars; Langorgen, Jorund; Lilja, Gisela; Moller, Jacob Eifer; Rundgren, Malin; Rylander, Christian; Smid, Ondrej; Werer, Christophe; Winkel, Per; Friberg, Hans		TTM Trial Investigators	Targeted Temperature Management at 33 degrees C versus 36 degrees C after Cardiac Arrest	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							AMERICAN-HEART-ASSOCIATION; THERAPEUTIC HYPOTHERMIA; CARDIOPULMONARY-RESUSCITATION; CARE; SURVIVAL; INCREASE; OUTCOMES	BackgroundUnconscious survivors of out-of-hospital cardiac arrest have a high risk of death or poor neurologic function. Therapeutic hypothermia is recommended by international guidelines, but the supporting evidence is limited, and the target temperature associated with the best outcome is unknown. Our objective was to compare two target temperatures, both intended to prevent fever. MethodsIn an international trial, we randomly assigned 950 unconscious adults after out-of-hospital cardiac arrest of presumed cardiac cause to targeted temperature management at either 33 degrees C or 36 degrees C. The primary outcome was all-cause mortality through the end of the trial. Secondary outcomes included a composite of poor neurologic function or death at 180 days, as evaluated with the Cerebral Performance Category (CPC) scale and the modified Rankin scale. ResultsIn total, 939 patients were included in the primary analysis. At the end of the trial, 50% of the patients in the 33 degrees C group (235 of 473 patients) had died, as compared with 48% of the patients in the 36 degrees C group (225 of 466 patients) (hazard ratio with a temperature of 33 degrees C, 1.06; 95% confidence interval [CI], 0.89 to 1.28; P=0.51). At the 180-day follow-up, 54% of the patients in the 33 degrees C group had died or had poor neurologic function according to the CPC, as compared with 52% of patients in the 36 degrees C group (risk ratio, 1.02; 95% CI, 0.88 to 1.16; P=0.78). In the analysis using the modified Rankin scale, the comparable rate was 52% in both groups (risk ratio, 1.01; 95% CI, 0.89 to 1.14; P=0.87). The results of analyses adjusted for known prognostic factors were similar. ConclusionsIn unconscious survivors of out-of-hospital cardiac arrest of presumed cardiac cause, hypothermia at a targeted temperature of 33 degrees C did not confer a benefit as compared with a targeted temperature of 36 degrees C. (Funded by the Swedish Heart-Lung Foundation and others; TTM ClinicalTrials.gov number, NCT01020916.)	[Nielsen, Niklas] Helsingborg Hosp, Dept Anesthesiol & Intens Care, S-25187 Helsingborg, Sweden; [Nielsen, Niklas; Cronberg, Tobias; Erlinge, David; Lilja, Gisela; Rundgren, Malin; Friberg, Hans] Lund Univ, Dept Clin Sci, Lund, Sweden; [Erlinge, David] Lund Univ, Dept Cardiol, Lund, Sweden; [Cronberg, Tobias] Skane Univ Hosp, Dept Neurol, Lund, Sweden; [Rundgren, Malin; Friberg, Hans] Skane Univ Hosp, Dept Anesthesiol & Intens Care, Lund, Sweden; [Lilja, Gisela] Skane Univ Hosp, Dept Rehabil Med, Lund, Sweden; [Rylander, Christian] Sahlgrens Univ Hosp, Dept Anesthesiol & Intens Care, Gothenburg, Sweden; [Wettersley, Jorn; Winkel, Per] Rigshosp, Copenhagen Univ Hosp, Copenhagen Trial Unit, Ctr Clin Intervent Res,Heart Ctr, DK-2100 Copenhagen, Denmark; [Hassager, Christian; Kjaergaard, Jesper; Boesgaard, Soren; Bro-Jeppesen, John; Kober, Lars; Moller, Jacob Eifer] Rigshosp, Copenhagen Univ Hosp, Dept Cardiol, Ctr Heart, DK-2100 Copenhagen, Denmark; [Wanscher, Michael] Rigshosp, Copenhagen Univ Hosp, Dept Cardiothorac Anesthesiol, Ctr Heart, DK-2100 Copenhagen, Denmark; [Gasche, Yvan] Univ Hosp Geneva, Dept Anesthesiol Pharmacol & Intens Care, Geneva, Switzerland; [Horn, Janneke; Kuiper, Michael; Juffermans, Nicole P.] Univ Amsterdam, Acad Med Ctr, Dept Intens Care, NL-1105 AZ Amsterdam, Netherlands; [Hovdenes, Jan; Bugge, Jan Frederik] Univ Oslo, Rikshosp, Oslo Univ Hosp, Dept Anesthesiol, N-0027 Oslo, Norway; [Kuiper, Michael; Koopmans, Matty] Med Ctr Leeuwarden, Dept Intens Care, Leeuwarden, Netherlands; [Pellis, Tommaso] Santa Maria Angeli, Intens Care Unit, Pordenone, Italy; [Brunetti, Iole] Univ Genoa, Ist Sci Tumori, Dept Intens Care, Ist Ricovero & Cura Carattere Sci San Martino, Genoa, Italy; [Stammet, Pascal; Werer, Christophe] Ctr Hosp Luxembourg, Dept Anesthesiol & Intens Care, Luxembourg, Luxembourg; [Wise, Matt P.; Hingston, Christopher D.] Univ Wales Hosp, Cardiff CF4 4XW, S Glam, Wales; [Aneman, Anders] Liverpool Hosp, Dept Intens Care, Sydney, NSW, Australia; [Al-Subaie, Nawaf] St George Hosp, Dept Intens Care, London, England; [Langorgen, Jorund] Haukeland Hosp, Dept Heart Dis, N-5021 Bergen, Norway; [Smid, Ondrej] Gen Univ Hosp Prague, Dept Internal Med Cardiol & Angiol 2, Prague, Czech Republic	Helsingborgs Hospital; Lund University; Lund University; Lund University; Skane University Hospital; Lund University; Skane University Hospital; Lund University; Skane University Hospital; Sahlgrenska University Hospital; Rigshospitalet; University of Copenhagen; Rigshospitalet; University of Copenhagen; Rigshospitalet; University of Copenhagen; University of Geneva; University of Amsterdam; Academic Medical Center Amsterdam; University of Oslo; National Hospital Norway; Medical Center Leeuwarden; Azienda Ospedaliera Santa Maria degli Angeli Pordenone; University of Genoa; Luxembourg Hospital Center; Cardiff University; Liverpool Hospital; St Georges University London; University of Bergen; Haukeland University Hospital; General University Hospital Prague	Nielsen, N (corresponding author), Helsingborg Hosp, Dept Anesthesia & Intens Care, Intens Care Unit, S Vallgatan 5, S-25187 Helsingborg, Sweden.	niklas.nielsen@med.lu.se	Šmíd, Ondřej/M-7545-2017; Kander, Thomas/H-8206-2019; Stammet, Pascal/CAA-1681-2022; Malik, Jan/C-4826-2008; Laake, Jon Henrik/L-3224-2019; Mellinghoff, Johannes/V-4844-2019; Stammet, Pascal/ABA-7580-2020; Kuiper, Michael/AAG-9878-2019; Malik, Jan/K-8681-2019; Rylander, Christian/AAV-3713-2020; Horn, Janneke/ACB-3607-2022; Wetterslev, Jørn/ABF-1251-2020; Ostermann, Marlies/B-8777-2015	Šmíd, Ondřej/0000-0001-9260-6509; Kander, Thomas/0000-0002-5404-2981; Malik, Jan/0000-0002-2386-3293; Laake, Jon Henrik/0000-0001-6157-5359; Mellinghoff, Johannes/0000-0002-5455-8953; Malik, Jan/0000-0002-2386-3293; Rylander, Christian/0000-0002-4534-7150; Wetterslev, Jørn/0000-0001-7778-1771; Bro-Jeppesen, John/0000-0001-7187-5734; Lilja, Gisela/0000-0003-1860-1456; Aneman, Anders/0000-0003-2096-5304; Hassager, Christian/0000-0002-1199-0981; Thompson, Kelly/0000-0003-2304-8931; Micallef, Sharon/0000-0002-8496-2324; Kober, Lars/0000-0002-6635-1466; Rulisek, Jan/0000-0002-9063-313X; Kuiper, Michael/0000-0001-6201-7332; Ostermann, Marlies/0000-0001-9500-9080; Fredholm, Merete/0000-0002-3563-7648; Kjaergaard, Jesper/0000-0001-5244-0399; Wise, Matt/0000-0002-2763-4316; Rajbhandari, Dorrilyn/0000-0001-8883-0428; Furgani, Andrea/0000-0003-1898-6034	Swedish Heart-Lung Foundation	Swedish Heart-Lung Foundation(Swedish Heart-Lung Foundation)	Funded by the Swedish Heart-Lung Foundation and others; TTM ClinicalTrials.gov number, NCT01020916.	ABRAMSON NS, 1986, NEW ENGL J MED, V314, P397; Adielsson A, 2011, HEART, V97, P1391, DOI 10.1136/hrt.2011.222711; [Anonymous], 1999, STAT MED, V18, P1905; Arrich J, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004128.pub3; Bernard SA, 2002, NEW ENGL J MED, V346, P557, DOI 10.1056/NEJMoa003289; Bro-Jeppessen J, 2013, RESUSCITATION; COLBOURNE F, 1994, BRAIN RES, V654, P265, DOI 10.1016/0006-8993(94)90488-X; Dumas F, 2012, RESUSCITATION, V83, P1001, DOI 10.1016/j.resuscitation.2012.01.029; Dumas F, 2011, CIRCULATION, V123, P877, DOI 10.1161/CIRCULATIONAHA.110.987347; Fergusson D, 2002, BMJ-BRIT MED J, V325, P652, DOI 10.1136/bmj.325.7365.652; Fisher GC, 2008, ANAESTHESIA, V63, P885, DOI 10.1111/j.1365-2044.2008.05614_1.x; Gibson Alistair, 2013, F1000Prime Rep, V5, P26, DOI 10.12703/P5-26; Gotzsche PC, 1996, CONTROL CLIN TRIALS, V17, P285, DOI 10.1016/0197-2456(95)00263-4; Grasner JT, 2011, CRIT CARE, V15, DOI 10.1186/cc10035; Holzer M, 2002, NEW ENGL J MED, V346, P549; Holzer M, 2010, NEW ENGL J MED, V363, P1256, DOI 10.1056/NEJMct1002402; Jacobs I, 2004, CIRCULATION, V110, P3385, DOI 10.1161/01.CIR.0000147236.85306.15; JENNETT B, 1975, LANCET, V1, P480; Kahan BC, 2012, STAT MED, V31, P328, DOI 10.1002/sim.4431; Leary M, 2013, RESUSCITATION, V84, P1056, DOI 10.1016/j.resuscitation.2012.11.003; Lindner TW, 2013, CRIT CARE, V17, DOI 10.1186/cc12826; Logue ES, 2007, ACAD EMERG MED, V14, P293, DOI 10.1197/j.aem.2006.10.097; Mooney MR, 2011, CIRCULATION, V124, P206, DOI 10.1161/CIRCULATIONAHA.110.986257; Moran John L, 2006, Crit Care Resusc, V8, P151; Moulaert VRMP, 2009, RESUSCITATION, V80, P297, DOI 10.1016/j.resuscitation.2008.10.034; Nichol G, 2013, RESUSCITATION, V84, P620, DOI 10.1016/j.resuscitation.2012.12.009; Nielsen N, 2009, ACTA ANAESTH SCAND, V53, P926, DOI 10.1111/j.1399-6576.2009.02021.x; Nielsen N, 2010, INT J CARDIOL; Nielsen N, 2013, TRIALS, V14, DOI 10.1186/1745-6215-14-300; Nielsen N, 2012, AM HEART J, V163, P541, DOI 10.1016/j.ahj.2012.01.013; Nielsen N, 2011, CRIT CARE MED, V39, P57, DOI 10.1097/CCM.0b013e3181fa4301; Peberdy MA, 2011, CIRCULATION, V124, pE403, DOI 10.1161/CIR.0b013e318235d047; Peberdy MA, 2010, CIRCULATION, V122, pS768, DOI 10.1161/CIRCULATIONAHA.110.971002; RANKIN J, 1957, Scott Med J, V2, P200; STERZ F, 1991, CRIT CARE MED, V19, P379, DOI 10.1097/00003246-199103000-00017; Tomte O, 2011, RESUSCITATION, V82, P1186, DOI 10.1016/j.resuscitation.2011.05.003; VANSWIETEN JC, 1988, STROKE, V19, P604, DOI 10.1161/01.STR.19.5.604; World Medical Association, 2008, 59 WMA GEN ASS OCT; Zeiner A, 2001, ARCH INTERN MED, V161, P2007, DOI 10.1001/archinte.161.16.2007; Zhang J, 1998, JAMA-J AM MED ASSOC, V280, P1690, DOI 10.1001/jama.280.19.1690	40	1821	1888	1	127	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 5	2013	369	23					2197	2206		10.1056/NEJMoa1310519	http://dx.doi.org/10.1056/NEJMoa1310519			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	263II	24237006	Green Published			2023-01-03	WOS:000327801100006
J	Wayakanon, K; Thornhill, MH; Douglas, CWI; Lewis, AL; Warren, NJ; Pinnock, A; Armes, SP; Battaglia, G; Murdoch, C				Wayakanon, Kornchanok; Thornhill, Martin H.; Douglas, C. W. Ian; Lewis, Andrew L.; Warren, Nicholas J.; Pinnock, Abigail; Armes, Steven P.; Battaglia, Giuseppe; Murdoch, Craig			Polymersome-mediated intracellular delivery of antibiotics to treat Porphyromonas gingivalis-infected oral epithelial cells	FASEB JOURNAL			English	Article						periodontal disease; antimicrobial chemotherapy; nanotechnology	ZWITTERIONIC DIBLOCK COPOLYMER; IN-VITRO; PERIODONTAL-DISEASES; INVASION; VESICLES; PH; BACTERIA; BINDING; DRUG; ENCAPSULATION	The gram-negative anaerobe Porphyromonas gingivalis colonizes the gingival crevice and is etiologically associated with periodontal disease that can lead to alveolar bone damage and resorption, promoting tooth loss. Although susceptible to antibiotics, P. gingivalis can evade antibiotic killing by residing within gingival keratinocytes. This provides a reservoir of organisms that may recolonize the gingival crevice once antibiotic therapy is complete. Polymersomes are nanosized amphiphilic block copolymer vesicles that can encapsulate drugs. Cells internalize polymersomes by endocytosis into early endosomes, where they are disassembled by the low pH, causing intracellular release of their drug load. In this study, polymersomes were used as vehicles to deliver antibiotics in an attempt to kill intracellular P. gingivalis within monolayers of keratinocytes and organotypic oral mucosal models. Polymersome-encapsulated metronidazole or doxycycline, free metronidazole, or doxycycline, or polymersomes alone as controls, were used, and the number of surviving intracellular P. gingivalis was quantified after host cell lysis. Polymersome-encapsulated metronidazole or doxycycline significantly (P<0.05) reduced the number of intracellular P. gingivalis in both monolayer and organotypic cultures compared to free antibiotic or polymersome alone controls. Polymersomes are effective delivery vehicles for antibiotics that do not normally gain entry to host cells. This approach could be used to treat recurrent periodontitis or other diseases caused by intracellular-dwelling organisms.Wayakanon, K., Thornhill, M. H., Douglas, C. W. I., Lewis, A. L., Warren, N. J., Pinnock, A., Armes, S. P., Battaglia, G., Murdoch, C. Polymersome-mediated intracellular delivery of antibiotics to treat Porphyromonas gingivalis-infected oral epithelial cells.	[Wayakanon, Kornchanok; Thornhill, Martin H.; Pinnock, Abigail; Battaglia, Giuseppe; Murdoch, Craig] Univ Sheffield, Sch Clin Dent, Acad Unit Oral & Maxillofacial Med & Surg, Sheffield S10 2TA, S Yorkshire, England; [Douglas, C. W. Ian] Univ Sheffield, Sch Clin Dent, Acad Unit Oral & Maxillofacial Pathol, Sheffield S10 2TA, S Yorkshire, England; [Warren, Nicholas J.; Armes, Steven P.] Univ Sheffield, Dept Chem, Sheffield S10 2TA, S Yorkshire, England; [Battaglia, Giuseppe] UCL, Dept Chem, London, England; [Lewis, Andrew L.] Biocompatibles UK Ltd, Farnham, Surrey, England	University of Sheffield; University of Sheffield; University of Sheffield; University of London; University College London; Biocompatibles International PLC	Murdoch, C (corresponding author), Univ Sheffield, Sch Clin Dent, Unit Oral & Maxillofacial Med & Surg, Sheffield S10 2TA, S Yorkshire, England.	g.battaglia@ucl.ac.uk; c.murdoch@sheffield.ac.uk	Warren, Nicholas/AAE-9388-2021; Battaglia, Giuseppe/I-2142-2013; Warren, Nicholas J/I-1588-2013	Warren, Nicholas/0000-0002-8298-1417; Battaglia, Giuseppe/0000-0003-3349-6770; Warren, Nicholas J/0000-0002-8298-1417; Thornhill, Martin/0000-0003-0681-4083; Armes, Steven/0000-0002-8289-6351; Murdoch, Craig/0000-0001-9724-122X; Lewis, Andrew/0000-0001-5779-5631	Oral and Dental Research Trust, UK; Biocompatibles UK Ltd.; Government of Thailand	Oral and Dental Research Trust, UK; Biocompatibles UK Ltd.; Government of Thailand	This work was supported by funding from the Oral and Dental Research Trust, UK (K. W., C. M.) and Biocompatibles UK Ltd. (G. B., A. L. L.). K. W. was the recipient of a Ph.D. scholarship from the Government of Thailand.	Ahmed F, 2006, J CONTROL RELEASE, V116, P150, DOI 10.1016/j.jconrel.2006.07.012; Ahmed F, 2006, MOL PHARMACEUT, V3, P340, DOI 10.1021/mp050103u; Andrian E, 2004, INFECT IMMUN, V72, P4689, DOI 10.1128/IAI.72.8.4689-4698.2004; Belton CM, 1999, CELL MICROBIOL, V1, P215, DOI 10.1046/j.1462-5822.1999.00022.x; Blanazs A, 2011, J AM CHEM SOC, V133, P16581, DOI 10.1021/ja206301a; Bostanci N, 2012, FEMS MICROBIOL LETT, V333, P1, DOI 10.1111/j.1574-6968.2012.02579.x; Canton I, 2013, FASEB J, V27, P98, DOI 10.1096/fj.12-212183; Canton I, 2012, CHEM SOC REV, V41, P2718, DOI 10.1039/c2cs15309b; Chen T, 2004, MICROB PATHOGENESIS, V36, P205, DOI 10.1016/j.micpath.2003.12.001; Christian DA, 2009, EUR J PHARM BIOPHARM, V71, P463, DOI 10.1016/j.ejpb.2008.09.025; Colley HE, 2011, BRIT J CANCER, V105, P1582, DOI 10.1038/bjc.2011.403; Dickinson BC, 2011, MOL ORAL MICROBIOL, V26, P210, DOI 10.1111/j.2041-1014.2011.00609.x; Discher BM, 1999, SCIENCE, V284, P1143, DOI 10.1126/science.284.5417.1143; Dorn BR, 2000, FEMS MICROBIOL LETT, V187, P139, DOI 10.1016/S0378-1097(00)00191-9; Du JZ, 2005, J AM CHEM SOC, V127, P17982, DOI 10.1021/ja056514l; GEISOW MJ, 1984, EXP CELL RES, V150, P36, DOI 10.1016/0014-4827(84)90699-2; Giacomelli C, 2006, BIOMACROMOLECULES, V7, P817, DOI 10.1021/bm0508921; Hajishengallis G, 2012, NAT REV MICROBIOL, V10, P717, DOI 10.1038/nrmicro2873; Hearnden V, 2009, PHARM RES-DORDR, V26, P1718, DOI 10.1007/s11095-009-9882-6; Hirsch R, 2012, J PERIODONTAL RES, V47, P137, DOI 10.1111/j.1600-0765.2011.01418.x; Holt SC, 2005, PERIODONTOL 2000, V38, P72, DOI 10.1111/j.1600-0757.2005.00113.x; ISOGAI E, 1992, ARCH ORAL BIOL, V37, P667, DOI 10.1016/0003-9969(92)90130-Z; JENSEN RL, 1974, J PERIODONTOL, V45, P786, DOI 10.1902/jop.1974.45.11.786; Kim Younghoon, 2006, Conf Proc IEEE Eng Med Biol Soc, V2006, P4350; Kim YH, 2009, J CONTROL RELEASE, V134, P132, DOI 10.1016/j.jconrel.2008.10.020; LAMONT RJ, 1995, INFECT IMMUN, V63, P3878, DOI 10.1128/IAI.63.10.3878-3885.1995; LAMONT RJ, 1992, ORAL MICROBIOL IMMUN, V7, P364, DOI 10.1111/j.1399-302X.1992.tb00637.x; Lomas H, 2008, FARADAY DISCUSS, V139, P143, DOI 10.1039/b717431d; Lomas H, 2010, MACROMOL BIOSCI, V10, P513, DOI 10.1002/mabi.201000083; LoPresti C, 2011, ACS NANO, V5, P1775, DOI 10.1021/nn102455z; Madianos PN, 1996, INFECT IMMUN, V64, P660, DOI 10.1128/IAI.64.2.660-664.1996; Massignani M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010459; Massignani M, 2009, SMALL, V5, P2424, DOI 10.1002/smll.200900578; Mombelli A, 2004, INT DENT J, V54, P3, DOI 10.1111/j.1875-595X.2004.tb00246.x; Mombelli A, 2012, FRONT ORAL BIOL, V15, P133, DOI 10.1159/000329676; Murdoch C, 2010, NANOMEDICINE-UK, V5, P1025, DOI [10.2217/nnm.10.97, 10.2217/NNM.10.97]; Nakagawa I, 2005, MICROBES INFECT, V7, P157, DOI 10.1016/j.micinf.2004.10.007; Nakhjiri SF, 2001, FEMS MICROBIOL LETT, V200, P145, DOI 10.1111/j.1574-6968.2001.tb10706.x; Njoroge T, 1997, INFECT IMMUN, V65, P1980, DOI 10.1128/IAI.65.5.1980-1984.1997; Poulet PP, 1999, J CLIN PERIODONTOL, V26, P261, DOI 10.1034/j.1600-051X.1999.260411.x; Shen L, 2008, LANGMUIR, V24, P10019, DOI 10.1021/la801190z; Suwannakul S, 2010, MICROBIOL-SGM, V156, P3052, DOI 10.1099/mic.0.038075-0; Tsuda K, 2008, CELL STRUCT FUNCT, V33, P123, DOI 10.1247/csf.08012; Umeda JE, 2006, ORAL MICROBIOL IMMUN, V21, P415, DOI 10.1111/j.1399-302X.2006.00312.x; VanWinkelhoff AJ, 1996, PERIODONTOL 2000, V10, P45; Wang LG, 2012, ANGEW CHEM INT EDIT, V51, P11122, DOI 10.1002/anie.201204169; Weinmann Stephen B, 2011, J Int Acad Periodontol, V13, P31; Yadev NR, 2011, MICROB PATHOGENESIS, V50, P278, DOI 10.1016/j.micpath.2010.11.009; Yilmaz O, 2003, MICROBIOL-SGM, V149, P2417, DOI 10.1099/mic.0.26483-0; Yilmaz O, 2002, CELL MICROBIOL, V4, P305, DOI 10.1046/j.1462-5822.2002.00192.x; Yuan LH, 2007, FEMS IMMUNOL MED MIC, V51, P388, DOI 10.1111/j.1574-695X.2007.00326.x	51	50	51	4	43	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2013	27	11					4455	4465		10.1096/fj.12-225219	http://dx.doi.org/10.1096/fj.12-225219			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	292YB	23921377				2023-01-03	WOS:000329937500013
J	Baker, JHE; Kyle, AH; Bartels, KL; Methot, SP; Flanagan, EJ; Balbirnie, A; Cran, JD; Minchinton, AI				Baker, Jennifer H. E.; Kyle, Alastair H.; Bartels, Kirsten L.; Methot, Stephen P.; Flanagan, Erin J.; Balbirnie, Andrew; Cran, Jordan D.; Minchinton, Andrew I.			Targeting the Tumour Vasculature: Exploitation of Low Oxygenation and Sensitivity to NOS Inhibition by Treatment with a Hypoxic Cytotoxin	PLOS ONE			English	Article							NITRIC-OXIDE SYNTHASE; PHASE-III TRIAL; OXYHEMOGLOBIN SATURATIONS; DISRUPTING AGENTS; BLOOD-VESSELS; MURINE TUMORS; L-ARGININE; IN-VIVO; TIRAPAZAMINE; CANCER	Many cancer research efforts focus on exploiting genetic-level features that may be targeted for therapy. Tissue-level features of the tumour microenvironment also represent useful therapeutic targets. Here we investigate the presence of low oxygen tension and sensitivity to NOS inhibition of tumour vasculature as potential tumour-specific features that may be targeted by hypoxic cytotoxins, a class of therapeutics currently under investigation. We have previously demonstrated that tirapazamine (TPZ) mediates central vascular dysfunction in tumours. TPZ is a hypoxic cytotoxin that is also a competitive inhibitor of NOS. Here we further investigated the vascular-targeting activity of TPZ by combining it with NOS inhibitor L-NNA, or with low oxygen content gas breathing. Tumours were analyzed via multiplex immunohistochemical staining that revealed irreversible loss of perfusion and enhanced tumour cell death when TPZ was combined with either low oxygen or a NOS inhibitor. Tumour growth rate was reduced by TPZ + NOS inhibition, and tumours previously resistant to TPZ-mediated vascular dysfunction were sensitized by low oxygen breathing. Additional mapping analysis suggests that tumours with reduced vascular-associated stroma may have greater sensitivity to these effects. These results indicate that poorly oxygenated tumour vessels, also being abnormally organized and with inadequate smooth muscle, may be successfully targeted for significant anti-cancer effects by inhibition of NOS and hypoxia-activated prodrug toxicity. This strategy illustrates a novel use of hypoxia-activated cytotoxic prodrugs as vascular targeting agents, and also represents a novel mechanism for targeting tumour vessels.	[Baker, Jennifer H. E.; Kyle, Alastair H.; Bartels, Kirsten L.; Methot, Stephen P.; Flanagan, Erin J.; Balbirnie, Andrew; Cran, Jordan D.; Minchinton, Andrew I.] BC Canc Res Ctr, Integrat Oncol Radiat Biol Unit, Vancouver, BC, Canada	British Columbia Cancer Agency	Minchinton, AI (corresponding author), BC Canc Res Ctr, Integrat Oncol Radiat Biol Unit, Vancouver, BC, Canada.	aim@bccrc.ca		Methot, Stephen/0000-0003-2854-2226	Michael Smith Foundation for Health Research; Canadian Institutes for Health Research	Michael Smith Foundation for Health Research(Michael Smith Foundation for Health Research); Canadian Institutes for Health Research(Canadian Institutes of Health Research (CIHR))	JB and AK are supported by Michael Smith Foundation for Health Research Senior Graduate Studentships (http://www.msfhr.org/funding). Funding for this research was provided by the Canadian Institutes for Health Research (http://www.cihr-irsc.gc.ca). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ADES EW, 1992, J INVEST DERMATOL, V99, P683, DOI 10.1111/1523-1747.ep12613748; Anderson RF, 2005, ORG BIOMOL CHEM, V3, P2167, DOI 10.1039/b502586a; Bains LJ, 2009, INT J RADIAT ONCOL, V74, P957, DOI 10.1016/j.ijrobp.2008.11.068; Baker JHE, 2008, CLIN CANCER RES, V14, P2171, DOI 10.1158/1078-0432.CCR-07-4465; Baluk P, 2005, CURR OPIN GENET DEV, V15, P102, DOI 10.1016/j.gde.2004.12.005; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; BOUCHER Y, 1990, CANCER RES, V50, P4478; BROWN JM, 1990, CANCER RES, V50, P7745; Butler SA, 1997, BRIT J CANCER, V76, P438, DOI 10.1038/bjc.1997.407; Cao YT, 2005, CANCER RES, V65, P5498, DOI 10.1158/0008-5472.CAN-04-4553; Dewhirst MW, 1999, BRIT J CANCER, V79, P1717, DOI 10.1038/sj.bjc.6690273; Dewhirst MW, 2003, ADV EXP MED BIOL, V510, P51; DORIE MJ, 1993, CANCER RES, V53, P4633; Elwell JH, 1997, BIOCHEM PHARMACOL, V54, P249, DOI 10.1016/S0006-2952(97)00171-8; Evans JW, 1998, CANCER RES, V58, P2098; FENTON BM, 1988, J NATL CANCER I, V80, P1612, DOI 10.1093/jnci/80.20.1612; Fukumura D, 1997, AM J PATHOL, V150, P713; Fukumura D, 2006, NAT REV CANCER, V6, P521, DOI 10.1038/nrc1910; GABOURY JP, 1994, AM J PHYSIOL, V266, pH637, DOI 10.1152/ajpheart.1994.266.2.H637; Garner AP, 1999, CANCER RES, V59, P1929; Graham MA, 1997, CANCER CHEMOTH PHARM, V40, P1, DOI 10.1007/s002800050617; Horsman MR, 1996, BRIT J CANCER, V74, pS168; Huxham LA, 2006, RADIOTHER ONCOL, V78, P138, DOI 10.1016/j.radonc.2006.01.002; Huxham LA, 2008, MICROVASC RES, V75, P247, DOI 10.1016/j.mvr.2007.09.006; Kyle AH, 2007, CLIN CANCER RES, V13, P2804, DOI 10.1158/1078-0432.CCR-06-1941; Leong KG, 2002, MOL CELL BIOL, V22, P2830, DOI 10.1128/MCB.22.8.2830-2841.2002; Marcu L, 2006, CURR CLIN PHARMACOL, V1, P71, DOI 10.2174/157488406775268192; Maseide K, 2001, CANCER LETT, V162, P245, DOI 10.1016/S0304-3835(00)00670-4; MINCHINTON AI, 1992, BRIT J CANCER, V66, P1053, DOI 10.1038/bjc.1992.409; Ng QS, 2007, LANCET ONCOL, V8, P111, DOI 10.1016/S1470-2045(07)70001-3; Patterson LH, 2000, BRIT J CANCER, V83, P1589, DOI 10.1054/bjoc.2000.1564; Peters KB, 2002, CANCER RES, V62, P5248; Le QT, 2012, CLIN CANCER RES, V18, P1798, DOI 10.1158/1078-0432.CCR-11-2094; Rischin D, 2010, J CLIN ONCOL, V28, P2989, DOI 10.1200/JCO.2009.27.4449; Seshadri M, 2007, NEOPLASIA, V9, P128, DOI 10.1593/neo.06748; Siemann DW, 2011, CANCER TREAT REV, V37, P63, DOI 10.1016/j.ctrv.2010.05.001; Siim BG, 2004, CANCER RES, V64, P736, DOI 10.1158/0008-5472.CAN-03-2488; Siim BG, 1997, CANCER RES, V57, P2922; STAMLER JS, 1994, CELL, V78, P931, DOI 10.1016/0092-8674(94)90269-0; Steeg PS, 2011, NAT REV CANCER, V11, P352, DOI 10.1038/nrc3053; THOMLINSON RH, 1955, BRIT J CANCER, V9, P539, DOI 10.1038/bjc.1955.55; Thorpe PE, 2004, CLIN CANCER RES, V10, P415, DOI 10.1158/1078-0432.CCR-0642-03; Tozer GM, 2008, BRIT J RADIOL, V81, pS12, DOI 10.1259/bjr/36205483; Tozer GM, 2008, CANCER RES, V68, P2301, DOI 10.1158/0008-5472.CAN-07-2011; Tozer GM, 1997, CANCER RES, V57, P948; Tozer GM, 2005, NAT REV CANCER, V5, P423, DOI 10.1038/nrc1628; Vaupel P, 2007, CANCER METAST REV, V26, P225, DOI 10.1007/s10555-007-9055-1; WOOD PJ, 1994, CANCER RES, V54, P6458; Wouters BG, 2001, CANCER RES, V61, P145; ZEMAN EM, 1986, INT J RADIAT ONCOL, V12, P1239, DOI 10.1016/0360-3016(86)90267-1	50	8	9	0	19	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 28	2013	8	10							e76832	10.1371/journal.pone.0076832	http://dx.doi.org/10.1371/journal.pone.0076832			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	242KW	24204680	Green Published, gold, Green Submitted			2023-01-03	WOS:000326241200015
J	Piedrafita, D; Preston, S; Kemp, J; de Veer, M; Sherrard, J; Kraska, T; Elhay, M; Meeusen, E				Piedrafita, David; Preston, Sarah; Kemp, Joanna; de Veer, Michael; Sherrard, Jayne; Kraska, Troy; Elhay, Martin; Meeusen, Els			The Effect of Different Adjuvants on Immune Parameters and Protection following Vaccination of Sheep with a Larval-Specific Antigen of the Gastrointestinal Nematode, Haemonchus contortus	PLOS ONE			English	Article							MECHANISMS; IMMUNIZATION; CHALLENGE; INFECTION; PARASITES; ALUMINUM; KINETICS; VACCINES; ANTIBODY; CELLS	It has recently been recognised that vaccine adjuvants play a critical role in directing the nature of a vaccine induced effector response. In the present study, several adjuvants were evaluated for their ability to protect sheep after field vaccination with the larval-specific Haemonchus contortus antigen, HcsL3. Using a suboptimal antigen dose, aluminium adjuvant was shown to reduce the cumulative faecal egg counts (cFEC) and worm burden by 23% and 25% respectively, in agreement with a previous study. The addition of Quil A to the aluminium-adjuvanted vaccine brought cFEC back to control levels. Vaccination with the adjuvant DEAE-dextran almost doubled the protection compared to the aluminium-adjuvanted vaccine resulting in 40% and 41% reduction in cFEC and worm counts compared to controls. Examination of skin responses following i.d. injection of exsheathed L3, revealed that cFEC was negatively correlated with wheal size and tissue eosinophils for the DEAE-dextran and aluminium-adjuvanted groups respectively. These studies have for the first time shown the potential of DEAE-dextran adjuvant for helminth vaccines, and discovered significant cellular correlates of vaccine-induced protection.	[Piedrafita, David; Preston, Sarah; Kemp, Joanna; de Veer, Michael; Sherrard, Jayne; Kraska, Troy; Meeusen, Els] Monash Univ, Sch Biomed Sci, Clayton, Vic, Australia; [Piedrafita, David; Preston, Sarah; Meeusen, Els] Monash Univ, ARC Ctr Excellence Struct & Funct Microbial Genom, Clayton, Vic, Australia; [Elhay, Martin] Pfizer Anim Hlth, Vet Med Res & Dev, Parkville, Vic, Australia	Monash University; Monash University; Pfizer	Piedrafita, D (corresponding author), Monash Univ, Sch Biomed Sci, Clayton, Vic, Australia.	david.piedrafita@monash.edu		Preston, Sarah/0000-0002-4227-1664; piedrafita, david/0000-0001-8692-990X; Meeusen, Els/0000-0003-1239-6287	Australian Research Council [LP0668945]; ARC-Centre of Excellence in Structural and Functional Microbial Genomics	Australian Research Council(Australian Research Council); ARC-Centre of Excellence in Structural and Functional Microbial Genomics(Australian Research Council)	Australian Research Council Linkage grant LP0668945 and the ARC-Centre of Excellence in Structural and Functional Microbial Genomics. The funders have no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alving CR, 2002, VACCINE, V20, pS56, DOI 10.1016/S0264-410X(02)00174-3; Anthony RM, 2007, NAT REV IMMUNOL, V7, P975, DOI 10.1038/nri2199; Balic A, 2006, PARASITE IMMUNOL, V28, P107, DOI 10.1111/j.1365-3024.2006.00816.x; BEH KJ, 1987, VET IMMUNOL IMMUNOP, V14, P187, DOI 10.1016/0165-2427(87)90053-5; Bethony JM, 2006, PARASITOLOGY, V133, pS63, DOI 10.1017/S0031182006001818; Bischof RJ, 2003, CLIN EXP ALLERGY, V33, P367, DOI 10.1046/j.1365-2222.2003.01534.x; de Veer M, 2010, VACCINE, V28, P6597, DOI 10.1016/j.vaccine.2010.07.056; de Veer M, 2011, DISCOV MED, V12, P195; Duthie MS, 2011, IMMUNOL REV, V239, P178, DOI 10.1111/j.1600-065X.2010.00978.x; Flach TL, 2011, NAT MED, V17, P479, DOI 10.1038/nm.2306; Hein WR, 2010, PARASITE IMMUNOL, V32, P541, DOI 10.1111/j.1365-3024.2010.01213.x; Jacobs HJ, 1999, VACCINE, V17, P362, DOI 10.1016/S0264-410X(98)00206-0; Jankovic D, 2004, J IMMUNOL, V173, P2419, DOI 10.4049/jimmunol.173.4.2419; Korsholm KS, 2010, IMMUNOLOGY, V129, P75, DOI 10.1111/j.1365-2567.2009.03164.x; Marrack P, 2009, NAT REV IMMUNOL, V9, P287, DOI 10.1038/nri2510; Meeusen ENT, 2005, VET IMMUNOL IMMUNOP, V108, P121, DOI 10.1016/j.vetimm.2005.07.002; Meeusen ENT, 2000, PARASITOL TODAY, V16, P95, DOI 10.1016/S0169-4758(99)01607-5; Piedrafita DP, 2012, VACCINE, V30, P7199, DOI 10.1016/j.vaccine.2012.10.019; Pulendran B, 2011, NAT IMMUNOL, V12, P509, DOI 10.1038/ni.2039; Rainbird MA, 1998, PARASITE IMMUNOL, V20, P93, DOI 10.1046/j.1365-3024.1998.00132.x; Sun HX, 2009, VACCINE, V27, P1787, DOI 10.1016/j.vaccine.2009.01.091; Thakur A, 2012, VACCINE, V30, P4907, DOI 10.1016/j.vaccine.2012.05.049; TURNBULL IF, 1992, INT J PARASITOL, V22, P537, DOI 10.1016/0020-7519(92)90157-G; Vizcarra JA, 2012, J ANIM SCI, V90, P1479, DOI 10.2527/jas.2011-4554; Zinkernagel RM, 2006, IMMUNOL REV, V211, P310, DOI 10.1111/j.0105-2896.2006.00402.x	25	19	20	0	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 21	2013	8	10							e78357	10.1371/journal.pone.0078357	http://dx.doi.org/10.1371/journal.pone.0078357			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	239NN	24205209	Green Published, gold			2023-01-03	WOS:000326032600099
J	Liu, JY; Chen, YC; Lin, CH; Kao, SH				Liu, Jer-Yuh; Chen, Yi-Ching; Lin, Chun-Hsiang; Kao, Shao-Hsuan			Perilla frutescens Leaf Extract Inhibits Mite Major Allergen Der p 2-induced Gene Expression of Pro-Allergic and Pro-Inflammatory Cytokines in Human Bronchial Epithelial Cell BEAS-2B	PLOS ONE			English	Article							NF-KAPPA-B; OBSTRUCTIVE PULMONARY-DISEASE; P38 MAPK; ACTIVATION; ASTHMA; IL-6; INTERLEUKIN-8; RELEASE; HYPERRESPONSIVENESS; PATHOGENESIS	Perilla frutescens has been used in traditional medicine for respiratory diseases due to its anti-bacterial and anti-inflammatory activity. This study aimed to investigate effects of Perilla frutescens leaf extract (PFE) on expression of pro-allergic and pro-inflammatory cytokines in airway epithelial cells exposed to mite major allergen Der p 2 (DP2) and the underlying mechanisms. Our results showed that PFE up to 100 mg/mL had no cytotoxic effect on human bronchial epithelial cell BEAS-2B. Further investigations revealed that PFE dose-dependently diminished mRNA expression of pro-allergic cytokine IL-4, IL-5, IL-13 and GM-CSF, as well as pro-inflammatory cytokine IL-6, IL-8 and MCP-1 in BEAS-2B cells treated with DP2. In parallel to mRNA, the DP-2-elevated levels of the tested cytokines were decreased. Further investigation showed that DP2-indued phosphorylation of p38 MAPK (P38) and JNK, but not Erk1/2, was also suppressed by PFE. In addition, PFE elevated cytosolic I kappa B alpha level and decreased nuclear NF-kappa B level in DP2-stimulated BEAS-2B cells. Taken together, these findings revealed that PFE significantly diminished both mRNA expression and protein levels of pro-allergic and pro-inflammatory cytokines in response to DP2 through inhibition of P38/JNK and NK-kappa B activation. These findings suggest that PFE should be beneficial to alleviate both allergic and inflammatory responses on airway epithelium in response to aeroallergens.	[Liu, Jer-Yuh] China Med Univ, Grad Inst Canc Biol, Taichung, Taiwan; [Liu, Jer-Yuh] China Med Univ Hosp, Ctr Mol Med, Taichung, Taiwan; [Chen, Yi-Ching; Lin, Chun-Hsiang; Kao, Shao-Hsuan] Chung Shan Med Univ, Inst Biochem & Biotechnol, Taichung, Taiwan; [Kao, Shao-Hsuan] Chung Shan Med Univ Hosp, Clin Lab, Taichung, Taiwan	China Medical University Taiwan; China Medical University Taiwan; China Medical University Hospital - Taiwan; Chung Shan Medical University; Chung Shan Medical University; Chung Shan Medical University Hospital	Kao, SH (corresponding author), Chung Shan Med Univ, Inst Biochem & Biotechnol, Taichung, Taiwan.	kaosh@csmu.edu.tw	Kao, Shao-Hsuan/I-3875-2019		National Science Council [NSC99-2320-B040-003-MY3, NSC99-2632-B040-001-MY3]	National Science Council(Ministry of Science and Technology, Taiwan)	This work was supported by grants from the National Science Council (NSC99-2320-B040-003-MY3, NSC99-2632-B040-001-MY3). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Asokananthan N, 2002, J IMMUNOL, V168, P3577, DOI 10.4049/jimmunol.168.7.3577; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97; Barnes PJ, 2000, NEW ENGL J MED, V343, P269, DOI 10.1056/NEJM200007273430407; BARNES PJ, 1989, J ALLERGY CLIN IMMUN, V83, P1013, DOI 10.1016/0091-6749(89)90441-7; Benson M, 1999, PEDIATR ALLERGY IMMU, V10, P178; Bhat RK, 2003, CLIN EXP ALLERGY, V33, P35, DOI 10.1046/j.1365-2222.2002.01481.x; Blau H, 2007, AM J PHYSIOL-LUNG C, V292, pL343, DOI 10.1152/ajplung.00030.2006; Chow AWM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012091; Douillet CD, 2006, AM J PHYSIOL-LUNG C, V291, pL734, DOI 10.1152/ajplung.00389.2005; Garcia-Lafuente A, 2009, INFLAMM RES, V58, P537, DOI 10.1007/s00011-009-0037-3; Graness A, 2002, J BIOL CHEM, V277, P18440, DOI 10.1074/jbc.M200468200; Heo JC, 2011, INT J MOL MED, V28, P733, DOI 10.3892/ijmm.2011.763; Hill AT, 1999, AM J RESP CRIT CARE, V160, P893, DOI 10.1164/ajrccm.160.3.9901091; Holgate Stephen T, 2008, Allergol Int, V57, P1, DOI 10.2332/allergolint.R-07-154; Ingram JL, 2012, J ALLERGY CLIN IMMUN, V130, P829, DOI 10.1016/j.jaci.2012.06.034; Jeffery Peter K, 2004, Proc Am Thorac Soc, V1, P176, DOI 10.1513/pats.200402-009MS; Lee HC, 2007, P NATL ACAD SCI USA, V104, P914, DOI 10.1073/pnas.0607305104; Liu K, 2008, J BIOL CHEM, V283, P9977, DOI 10.1074/jbc.M710257200; Liu YH, 2005, INT ARCH ALLERGY IMM, V138, P161, DOI 10.1159/000088438; Makarov SS, 2000, MOL MED TODAY, V6, P441, DOI 10.1016/S1357-4310(00)01814-1; Makino T, 1999, NEPHRON, V83, P40, DOI 10.1159/000045471; Martin Thomas R, 2005, Proc Am Thorac Soc, V2, P403, DOI 10.1513/pats.200508-090JS; Moghaddam SJ, 2008, AM J RESP CELL MOL, V38, P629, DOI 10.1165/rcmb.2007-0366OC; Moore BB, 2001, J IMMUNOL, V167, P4368, DOI 10.4049/jimmunol.167.8.4368; Natarajan R, 2002, FREE RADICAL BIO MED, V32, P1033, DOI 10.1016/S0891-5849(02)00813-4; Oh HA, 2011, EXP BIOL MED, V236, P99, DOI 10.1258/ebm.2010.010252; Osterlund C, 2009, CLIN EXP ALLERGY, V39, P1199, DOI 10.1111/j.1365-2222.2009.03284.x; Park SY, 2009, J BIOL CHEM, V284, P20099, DOI 10.1074/jbc.M109.010017; Platts-Mills TAE, 1997, J ALLERGY CLIN IMMUN, V100, pS2, DOI 10.1016/S0091-6749(97)70292-6; Profita M, 2008, EUR J PHARMACOL, V582, P145, DOI 10.1016/j.ejphar.2007.12.029; Rahman I, 2004, BIOCHEM PHARMACOL, V68, P1255, DOI 10.1016/j.bcp.2004.05.042; Roschmann KIL, 2011, CLIN EXP ALLERGY, V41, P830, DOI 10.1111/j.1365-2222.2011.03713.x; Saetta M, 1998, AM J RESP CRIT CARE, V157, P822, DOI 10.1164/ajrccm.157.3.9709027; Schneider D, 2013, AM J PHYSIOL-LUNG C, V304, pL162, DOI 10.1152/ajplung.00182.2012; Scott M, 2012, THORAX, V67, P1046, DOI 10.1136/thoraxjnl-2012-202150; Shin TY, 2000, IMMUNOPHARM IMMUNOT, V22, P489, DOI 10.3109/08923970009026007; SOLOPERTO M, 1991, AM J PHYSIOL, V260, pL530, DOI 10.1152/ajplung.1991.260.6.L530; Strieter RM, 2002, J CLIN INVEST, V109, P699, DOI 10.1172/JCI200215277; Thomas WR, 1998, ALLERGY, V53, P821, DOI 10.1111/j.1398-9995.1998.tb03987.x; Ueda H, 2001, BIOSCI BIOTECH BIOCH, V65, P1673, DOI 10.1271/bbb.65.1673; Ueda H, 1997, BIOSCI BIOTECH BIOCH, V61, P1292, DOI 10.1271/bbb.61.1292; Wang CB, 2005, ALLERGY, V60, P1378, DOI 10.1111/j.1398-9995.2005.00884.x; Wang WC, 2011, J CELL BIOCHEM, V112, P1544, DOI 10.1002/jcb.23067; Zhu Z, 2002, J IMMUNOL, V168, P2953, DOI 10.4049/jimmunol.168.6.2953	45	13	14	1	18	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 18	2013	8	10							e77458	10.1371/journal.pone.0077458	http://dx.doi.org/10.1371/journal.pone.0077458			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	239MM	24204835	Green Published, gold, Green Submitted			2023-01-03	WOS:000326029300098
J	Liu, X; Zhu, W; Guan, SH; Feng, RH; Zhang, H; Liu, QH; Sun, P; Lin, DH; Zhang, NX; Shen, J				Liu, Xia; Zhu, Wei; Guan, Shuhong; Feng, Ruihong; Zhang, Hui; Liu, Qiuhong; Sun, Peng; Lin, Donghai; Zhang, Naixia; Shen, Jun			Metabolomic Analysis of Anti-Hypoxia and Anti-anxiety Effects of Fu Fang Jin Jing Oral Liquid	PLOS ONE			English	Article							PLUS-MAZE; DEPRESSION; STRESS; MICE; RATS; SPECTROSCOPY; ADAPTATION; EXPRESSION; RECEPTORS; RESPONSES	Background: Herba Rhodiolae is a traditional Chinese medicine used by the Tibetan people for treating hypoxia related diseases such as anxiety. Based on the previous work, we developed and patented an anti-anxiety herbal formula Fu Fang Jin Jing Oral Liquid (FJJOL) with Herba Rhodiolae as a chief ingredient. In this study, the anti-hypoxia and anti-anxiety effects of FJJOL in a high altitude forced-swimming mouse model with anxiety symptoms will be elucidated by NMR-based metabolomics. Methods: In our experiments, the mice were divided randomly into four groups as flatland group, high altitude saline-treated group, high altitude FJJOL-treated group, and high altitude diazepam-treated group. To cause anxiety effects and hypoxic defects, a combination use of oxygen level decreasing (hypobaric cabin) and oxygen consumption increasing (exhaustive swimming) were applied to mice. After a three-day experimental handling, aqueous metabolites of mouse brain tissues were extracted and then subjected to NMR analysis. The therapeutic effects of FJJOL on the hypobaric hypoxia mice with anxiety symptoms were verified. Results: Upon hypoxic exposure, both energy metabolism defects and disorders of functional metabolites in brain tissues of mice were observed. PCA, PLS-DA and OPLS-DA scatter plots revealed a clear group clustering for metabolic profiles in the hypoxia versus normoxia samples. After a three-day treatment with FJJOL, significant rescue effects on energy metabolism were detected, and levels of ATP, fumarate, malate and lactate in brain tissues of hypoxic mice recovered. Meanwhile, FJJOL also up-regulated the neurotransmitter GABA, and the improvement of anxiety symptoms was highly related to this effect. Conclusions: FJJOL ameliorated hypobaric hypoxia effects by regulating energy metabolism, choline metabolism, and improving the symptoms of anxiety. The anti-anxiety therapeutic effects of FJJOL were comparable to the conventional anti-anxiety drug diazepam on the hypobaric hypoxia mice. FJJOL might serve as an alternative therapy for the hypoxia and anxiety disorders.	[Zhu, Wei; Zhang, Hui; Liu, Qiuhong; Shen, Jun] Naval Med Res Inst, Shanghai, Peoples R China; [Liu, Xia; Sun, Peng; Zhang, Naixia] Chinese Acad Sci, Shanghai Inst Mat Med, Dept Analyt Chem, Shanghai 200031, Peoples R China; [Guan, Shuhong; Feng, Ruihong] Chinese Acad Sci, Shanghai Inst Mat Med, Natl Engn Lab TCM Standardizat Technol, Shanghai 200031, Peoples R China; [Lin, Donghai] Xiamen Univ, Coll Chem & Chem Engn, Key Lab Chem Biol Fujian Prov, Xiamen, Peoples R China	Chinese Academy of Sciences; Shanghai Institute of Materia Medica, CAS; Chinese Academy of Sciences; Shanghai Institute of Materia Medica, CAS; Xiamen University	Lin, DH (corresponding author), Xiamen Univ, Coll Chem & Chem Engn, Key Lab Chem Biol Fujian Prov, Xiamen, Peoples R China.	dhlin@xmu.edu.cn; nxzhang@mail.shcnc.ac.cn; zhu_wei2002@163.com			National Natural Science Foundation of China [30900662]; Shanghai Foundation for Development of Science and Technology [08411965600]; "100 Talents Program" of Chinese Academy of Sciences	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Shanghai Foundation for Development of Science and Technology; "100 Talents Program" of Chinese Academy of Sciences(Chinese Academy of Sciences)	This work was financially supported by the National Natural Science Foundation of China (Grant No. 30900662), the Shanghai Foundation for Development of Science and Technology (Grant No. 08411965600), and the "100 Talents Program" of Chinese Academy of Sciences. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Anglin RE, 2012, TRANSL PSYCHIAT, V2, DOI 10.1038/tp.2012.107; Beckonert O, 2007, NAT PROTOC, V2, P2692, DOI 10.1038/nprot.2007.376; Beyoglu D, 2012, BIOCHEM PHARMACOL, V85, P12; Chen PJ, 2011, J MED FOOD, V14, P610, DOI 10.1089/jmf.2010.1209; Chen QG, 2009, PHYTOMEDICINE, V16, P830, DOI 10.1016/j.phymed.2009.03.011; CONNETT RJ, 1990, J APPL PHYSIOL, V68, P833, DOI 10.1152/jappl.1990.68.3.833; CzyzykKrzeska MF, 1997, RESP PHYSIOL, V110, P99, DOI 10.1016/S0034-5687(97)00076-5; D'Alessandro A, 2012, DRUG DISCOV TODAY, V17, P3, DOI 10.1016/j.drudis.2011.09.017; Fiehn O, 2000, NAT BIOTECHNOL, V18, P1157, DOI 10.1038/81137; Frey BN, 2007, BIPOLAR DISORD, V9, P119, DOI 10.1111/j.1399-5618.2007.00454.x; Hirani K, 2005, PSYCHOPHARMACOLOGY, V180, P267, DOI 10.1007/s00213-005-2169-7; Holmes A, 2000, PHYSIOL BEHAV, V71, P509, DOI 10.1016/S0031-9384(00)00373-5; Hwang GS, 2010, AM J PHYSIOL-RENAL, V298, pF461, DOI 10.1152/ajprenal.00389.2009; Kang M, 2005, AM J CHINESE MED, V33, P205, DOI 10.1142/S0192415X05002874; Kash SF, 1999, P NATL ACAD SCI USA, V96, P1698, DOI 10.1073/pnas.96.4.1698; Klimova T, 2008, CELL DEATH DIFFER, V15, P660, DOI 10.1038/sj.cdd.4402307; Lau AA, 2008, BEHAV BRAIN RES, V191, P130, DOI 10.1016/j.bbr.2008.03.024; Li T, 2008, CHEM PHARM BULL, V56, P807, DOI 10.1248/cpb.56.807; LISTER RG, 1987, PSYCHOPHARMACOLOGY, V92, P180; Liu J, 2011, INT J MOL SCI, V12, P6469, DOI 10.3390/ijms12106469; Liu J, 2010, BIOMED ENVIRON SCI, V23, P312, DOI 10.1016/S0895-3988(10)60069-4; Lu XM, 2011, TALANTA, V83, P700, DOI 10.1016/j.talanta.2010.09.026; McClintock DS, 2002, MOL CELL BIOL, V22, P94, DOI 10.1128/MCB.22.1.94-104.2002; Mole DR, 2008, PEDIATR NEPHROL, V23, P681, DOI 10.1007/s00467-007-0632-x; MONTELEONE P, 1990, J AFFECT DISORDERS, V20, P1, DOI 10.1016/0165-0327(90)90043-8; Nakanishi K, 1999, LAB INVEST, V79, P679; Nicholson G, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002270; Nicholson G, 2011, MOL SYST BIOL, V7, DOI 10.1038/msb.2011.57; Nikolaus S, 2010, REV NEUROSCIENCE, V21, P119; Przegalinski E, 1997, NEUROPHARMACOLOGY, V36, P31, DOI 10.1016/S0028-3908(96)00157-8; RAGO L, 1988, N-S ARCH PHARMACOL, V337, P675; Raud S, 2009, NEUROSCI LETT, V460, P138, DOI 10.1016/j.neulet.2009.05.054; Rojas P, 2011, NEUROCHEM INT, V59, P628, DOI 10.1016/j.neuint.2011.05.007; Semenza GL, 2000, GENE DEV, V14, P1983; Semenza GL, 1998, CURR OPIN GENET DEV, V8, P588, DOI 10.1016/S0959-437X(98)80016-6; Sheridan H, 2012, J ETHNOPHARMACOL, V140, P482, DOI 10.1016/j.jep.2012.01.050; Solomon D, 2011, AUST NZ J PSYCHIAT, V45, P123, DOI 10.3109/00048674.2010.526094; Tan GG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034157; Tan GG, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027683; van Patot MCT, 2010, AM J PHYSIOL-REG I, V298, pR166, DOI 10.1152/ajpregu.00383.2009; Vasilyev KY, 2007, B EXP BIOL MED+, V144, P695, DOI 10.1007/s10517-007-0408-0; Weljie AM, 2007, J PROTEOME RES, V6, P3456, DOI 10.1021/pr070123j; Weljie AM, 2011, J BIOMOL NMR, V49, P185, DOI 10.1007/s10858-011-9486-4; YANG YC, 1991, ZANG YAO ZHI, P34; Zhang AH, 2013, ANALYST, V138, P353, DOI 10.1039/c2an36382h; Zhang LB, 2011, MAR ENVIRON RES, V72, P33, DOI 10.1016/j.marenvres.2011.04.002; Zhong F, 2012, NEPHROL DIAL TRANSPL, V27, P556, DOI 10.1093/ndt/gfr368	47	24	26	4	67	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 18	2013	8	10							e78281	10.1371/journal.pone.0078281	http://dx.doi.org/10.1371/journal.pone.0078281			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	239MM	24205180	Green Published, gold, Green Submitted			2023-01-03	WOS:000326029300150
J	Krishnan, C; Ranganathan, R; Dhaher, YY; Rymer, WZ				Krishnan, Chandramouli; Ranganathan, Rajiv; Dhaher, Yasin Y.; Rymer, William Z.			A Pilot Study on the Feasibility of Robot-Aided Leg Motor Training to Facilitate Active Participation	PLOS ONE			English	Article							STROKE PATIENTS; GAIT; LOCOMOTION; MOVEMENT; THERAPY; REHABILITATION; PERFORMANCE; STRATEGIES; COCONTRACTION; RECOVERY	Robot-aided gait therapy offers a promising approach towards improving gait function in individuals with neurological disorders such as stroke or spinal cord injury. However, incorporation of appropriate control strategies is essential for actively engaging the patient in the therapeutic process. Although several control algorithms (such as assist-as-needed and error augmentation) have been proposed to improve active patient participation, we hypothesize that the therapeutic benefits of these control algorithms can be greatly enhanced if combined with a motor learning task to facilitate neural reorganization and motor recovery. Here, we describe an active robotic training approach (patient-cooperative robotic gait training combined with a motor learning task) using the Lokomat and pilot-tested whether this approach can enhance active patient participation during training. Six neurologically intact adults and three chronic stroke survivors participated in this pilot feasibility study. Participants walked in a Lokomat while simultaneously performing a foot target-tracking task that necessitated greater hip and knee flexion during the swing phase of the gait. We computed the changes in tracking error as a measure of motor performance and changes in muscle activation as a measure of active subject participation. Repeated practice of the motor-learning task resulted in significant reductions in target-tracking error in all subjects. Muscle activation was also significantly higher during active robotic training compared to simply walking in the robot. The data from stroke participants also showed a trend similar to neurologically intact participants. These findings provide a proof-of-concept demonstration that combining robotic gait training with a motor learning task enhances active participation.	[Krishnan, Chandramouli] Univ Michigan, Sch Med, Dept Phys Med & Rehabil, Ann Arbor, MI 48109 USA; [Krishnan, Chandramouli; Ranganathan, Rajiv; Dhaher, Yasin Y.; Rymer, William Z.] Northwestern Univ, Feinberg Sch Med, Dept Phys Med & Rehabil, Chicago, IL 60611 USA; [Krishnan, Chandramouli; Ranganathan, Rajiv; Dhaher, Yasin Y.; Rymer, William Z.] Rehabil Inst Chicago, Sensory Motor Performance Program, Chicago, IL USA	University of Michigan System; University of Michigan; Northwestern University; Feinberg School of Medicine; Shirley Ryan AbilityLab	Krishnan, C (corresponding author), Univ Michigan, Sch Med, Dept Phys Med & Rehabil, Ann Arbor, MI 48109 USA.	mouli@umich.edu	Ranganathan, Rajiv/E-3909-2010; Ranganathan, Rajiv/L-4380-2019; Ranganathan, Rajiv/ABI-2927-2020	Ranganathan, Rajiv/0000-0002-6924-253X; Ranganathan, Rajiv/0000-0002-6924-253X; 	Machines Assisting Recovery From Stroke - Rehabilitation Engineering Research Center Grant [H133E070013]; National Institute on Disability and Rehabilitation Research	Machines Assisting Recovery From Stroke - Rehabilitation Engineering Research Center Grant; National Institute on Disability and Rehabilitation Research	This study was supported by Machines Assisting Recovery From Stroke - Rehabilitation Engineering Research Center Grant (grant no. H133E070013) funded by the National Institute on Disability and Rehabilitation Research. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Altman DG, 1996, BRIT MED J, V313, P1200, DOI 10.1136/bmj.313.7066.1200; Banala SK, 2009, IEEE T NEUR SYS REH, V17, P2, DOI 10.1109/TNSRE.2008.2008280; Bezzola L, 2011, J NEUROSCI, V31, P12444, DOI 10.1523/JNEUROSCI.1996-11.2011; BOGEY RA, 1992, ARCH PHYS MED REHAB, V73, P835; Boyer DM, 2007, J HUM EVOL, V53, P119, DOI 10.1016/j.jhevol.2006.10.007; Casadio M, 2009, FUNCT NEUROL, V24, P195; Colombo G, 2000, J REHABIL RES DEV, V37, P693; Darainy M, 2008, EXP BRAIN RES, V190, P153, DOI 10.1007/s00221-008-1457-y; Dickstein R, 2008, NEUROREHAB NEURAL RE, V22, P649, DOI [10.1177/15459683080220060201, 10.1177/1545968308315997]; Dipietro L, 2012, IEEE T NEUR SYS REH, V20, P48, DOI 10.1109/TNSRE.2011.2175008; Duschau-Wicke A, 2010, J NEUROENG REHABIL, V7, DOI 10.1186/1743-0003-7-43; Duschau-Wicke A, 2010, IEEE T NEUR SYS REH, V18, P38, DOI 10.1109/TNSRE.2009.2033061; Fagenbaum R, 2003, AM J SPORT MED, V31, P233, DOI 10.1177/03635465030310021301; Fattapposta F, 2008, ARCH ITAL BIOL, V146, P147; Finley JM, 2013, J PHYSIOL-LONDON, V591, P1081, DOI 10.1113/jphysiol.2012.245506; Gaser C, 2003, J NEUROSCI, V23, P9240; Gribble PL, 2003, J NEUROPHYSIOL, V89, P2396, DOI 10.1152/jn.01020.2002; Hanggi J, 2010, HUM BRAIN MAPP, V31, P1196, DOI 10.1002/hbm.20928; Hidler J, 2009, NEUROREHAB NEURAL RE, V23, P5, DOI 10.1177/1545968308326632; Hornby TG, 2008, STROKE, V39, P1786, DOI 10.1161/STROKEAHA.107.504779; Hornby TG, 2012, PHYS THER, V92, P1278, DOI 10.2522/ptj.20110310; Husemann B, 2007, STROKE, V38, P349, DOI 10.1161/01.STR.0000254607.48765.cb; Ivanenko YP, 2002, J NEUROPHYSIOL, V87, P3070, DOI 10.1152/jn.2002.87.6.3070; Jancke L, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004785; Kao PC, 2013, GAIT POSTURE, V37, P113, DOI 10.1016/j.gaitpost.2012.06.025; Kim SH, 2010, EXP BRAIN RES, V202, P809, DOI 10.1007/s00221-010-2187-5; Kitago Tomoko, 2013, Handb Clin Neurol, V110, P93, DOI 10.1016/B978-0-444-52901-5.00008-3; Krakauer JW, 2006, CURR OPIN NEUROL, V19, P84, DOI 10.1097/01.wco.0000200544.29915.cc; Krebs Herman Igo, 2012, Am J Phys Med Rehabil, V91, pS290, DOI 10.1097/PHM.0b013e31826bcd80; Krishnamoorthy Vijaya, 2008, J Neurol Phys Ther, V32, P192, DOI 10.1097/NPT.0b013e31818e8fc2; Krishnan C, 2012, ARCH PHYS MED REHABI; Krishnan C, 2012, J NEUROENG REHABIL, V9, DOI 10.1186/1743-0003-9-57; Krishnan C, 2010, MUSCLE NERVE, V41, P868, DOI 10.1002/mus.21613; Krishnan C, 2010, EUR J APPL PHYSIOL, V109, P527, DOI 10.1007/s00421-010-1391-0; Krishnan Chandramouli, 2009, Iowa Orthop J, V29, P149; Langhorne P, 2011, LANCET, V377, P1693, DOI 10.1016/S0140-6736(11)60325-5; Lewek MD, 2009, PHYS THER, V89, P829, DOI 10.2522/ptj.20080180; Marchal-Crespo L, 2009, J NEUROENG REHABIL, V6, DOI 10.1186/1743-0003-6-20; Masia L, 2009, J NEUROENG REHABIL, V6, DOI 10.1186/1743-0003-6-44; Mayr A, 2007, NEUROREHAB NEURAL RE, V21, P307, DOI 10.1177/1545968307300697; Norouzi-Gheidari N, 2012, J REHABIL RES DEV, V49, P479, DOI 10.1682/JRRD.2010.10.0210; Ogawa T, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046349; Page SJ, 2009, NEUROREHAB NEURAL RE, V23, P382, DOI 10.1177/1545968308326427; PATLA AE, 1991, J EXP PSYCHOL HUMAN, V17, P603, DOI 10.1037/0096-1523.17.3.603; Perez MA, 2004, EXP BRAIN RES, V159, P197, DOI 10.1007/s00221-004-1947-5; Plautz EJ, 2000, NEUROBIOL LEARN MEM, V74, P27, DOI 10.1006/nlme.1999.3934; Ranganathan R, 2012, J NEUROPHYSIOL, V108, P1537, DOI 10.1152/jn.01112.2011; Reisman DS, 2009, NEUROREHAB NEURAL RE, V23, P735, DOI 10.1177/1545968309332880; Reisman DS, 2005, J NEUROPHYSIOL, V94, P2403, DOI 10.1152/jn.00089.2005; Roy A, 2011, J REHABIL RES DEV, V48, P417, DOI 10.1682/JRRD.2010.04.0078; Sanguineti V, 2009, STUD HEALTH TECHNOL, V145, P126, DOI 10.3233/978-1-60750-018-6-126; Schwartz I, 2009, PM&R, V1, P516, DOI 10.1016/j.pmrj.2009.03.009; Siengsukon C, 2009, NEUROREHAB NEURAL RE, V23, P327, DOI 10.1177/1545968308326631; Simpkins CA, 2012, NEUROSCIENCE CLIN EV; Vallery H, 2009, INT C REHAB ROBOT, P623, DOI 10.1109/ICORR.2009.5209595; Westlake KP, 2009, J NEUROENG REHABIL, V6, DOI 10.1186/1743-0003-6-18; Williamson EM, 2009, EXP AGING RES, V35, P457, DOI 10.1080/03610730903175790	57	41	43	0	27	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 11	2013	8	10							e77370	10.1371/journal.pone.0077370	http://dx.doi.org/10.1371/journal.pone.0077370			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	236SL	24146986	Green Published, gold, Green Submitted			2023-01-03	WOS:000325819400113
J	Wang, J; Xiong, XJ; Liu, W				Wang, Jie; Xiong, Xingjiang; Liu, Wei			Yoga for Essential Hypertension: A Systematic Review	PLOS ONE			English	Review							BLOOD-PRESSURE; RISK-FACTORS; MEDICINE; HEALTH; COMPLEMENTARY; PREVENTION; DISEASE	Background: Yoga is thought to be effective for health conditions. The article aims to assess the current clinical evidence of yoga for Essential hypertension (EH). Strategy: MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials (CENTRAL) in the Cochrane Library were searched until June, 2013. We included randomized clinical trials testing yoga against conventional therapy, yoga versus no treatment, yoga combined with conventional therapy versus conventional therapy or conventional therapy combined with breath awareness. Study selection, data extraction, quality assessment, and data analyses were conducted according to the Cochrane standards. Results: A total of 6 studies (involving 386 patients) were included. The methodological quality of the included trials was evaluated as generally low. A total of 6 RCTs met all the inclusion criteria. 4 of them compared yoga plus conventional therapy with conventional therapy. 1 RCT described yoga combined with conventional therapy versus conventional therapy combined with breath awareness. 2 RCT tested the effect of yoga versus conventional therapy alone. 1 RCT described yoga compared to no treatment. Only one trial reported adverse events without details, the safety of yoga is still uncertain. Conclusions: There is some encouraging evidence of yoga for lowering SBP and DBP. However, due to low methodological quality of these identified trials, a definite conclusion about the efficacy and safety of yoga on EH cannot be drawn from this review. Therefore, further thorough investigation, large-scale, proper study designed, randomized trials of yoga for hypertension will be required to justify the effects reported here.	[Wang, Jie; Xiong, Xingjiang; Liu, Wei] China Acad Chinese Med Sci, Guanganmen Hosp, Dept Cardiol, Beijing, Peoples R China	China Academy of Chinese Medical Sciences; Guang'anmen Hospital, CACMS	Liu, W (corresponding author), China Acad Chinese Med Sci, Guanganmen Hosp, Dept Cardiol, Beijing, Peoples R China.	lvzyxxg@163.com	Xiong, Xingjiang/Q-8626-2019		National Basic Research Program of China (973 Program) [2003CB517103]; National Natural Science Foundation Project of China [90209011]	National Basic Research Program of China (973 Program)(National Basic Research Program of China); National Natural Science Foundation Project of China(National Natural Science Foundation of China (NSFC))	The current work was partially supported by the National Basic Research Program of China (973 Program, No. 2003CB517103) and the National Natural Science Foundation Project of China (No. 90209011). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bijlani RL, 2005, J ALTERN COMPLEM MED, V11, P267, DOI 10.1089/acm.2005.11.267; Birdee GS, 2008, J GEN INTERN MED, V23, P1653, DOI 10.1007/s11606-008-0735-5; Calhoun DA, 2002, CURR HYPERTENS REP, V4, P221, DOI 10.1007/s11906-002-0011-8; Chaudhary A K, 1988, J Assoc Physicians India, V36, P721; Ching SM, 2013, BMC COMPLEM ALTERN M, V13, DOI 10.1186/1472-6882-13-148; Chobanian AV, 2003, HYPERTENSION, V42, P1206, DOI 10.1161/01.HYP.0000107251.49515.c2; Cleophas TJ, 2002, CIRCULATION, V105, P1669, DOI 10.1161/01.CIR.0000012745.50229.AC; Cohen DL, 2011, EVID-BASED COMPL ALT, V2011, P1, DOI 10.1093/ecam/nep130; Deepa T, 2012, J CLIN DIAGN RES, V6, P21; Dhameja K, 2012, J ALTERN COMPLEM MED, V18, P1, DOI [10.1089/acm.2011.0961., DOI 10.1089/ACM.2011.0961.PUBMED:22268965]; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Ernst E, 2005, WIEN MED WOCHENSCHR, V155, P386, DOI 10.1007/s10354-005-0205-1; Ferreira AS, 2011, CHIN J INTEGR MED, V17, P818, DOI 10.1007/s11655-011-0892-y; Hackam DG, 2010, CAN J CARDIOL, V26, P249, DOI 10.1016/S0828-282X(10)70379-2; Hawk C, 2012, PREV MED, V54, P18, DOI 10.1016/j.ypmed.2011.07.002; Jayasinghe SR, 2004, EUR J CARDIOV PREV R, V11, P369, DOI 10.1097/00149831-200410000-00002; Lee MS, 2004, J ALTERN COMPLEM MED, V10, P675; Lloyd-Jones D, 2009, CIRCULATION, V119, pE21, DOI 10.1161/CIRCULATIONAHA.108.191261; Macdonald Geraldine, 2012, Cochrane Database Syst Rev, pCD001930, DOI 10.1002/14651858.CD001930.pub3; McCaffrey Ruth, 2005, Holist Nurs Pract, V19, P173; Mizuno J, 2013, J BODYW MOV THER, V17, P35, DOI 10.1016/j.jbmt.2012.10.007; Mogra AL, 1986, J AVIAT MED, V30, P68; Moher D, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c869; Murugesan R., 2000, Indian Journal of Physiology and Pharmacology, V44, P207; Okonta NR, 2012, HOLIST NURS PRACT, V26, P137, DOI 10.1097/HNP.0b013e31824ef647; Pierdomenico SD, 2009, AM J HYPERTENS, V22, P842, DOI 10.1038/ajh.2009.103; Raub JA, 2002, J ALTERN COMPLEM MED, V8, P797, DOI 10.1089/10755530260511810; Ravinder Mamtani, 2005, CARDIOL REV, V13, P156; Slama M, 2002, CURR OPIN CARDIOL, V17, P531, DOI 10.1097/00001573-200209000-00014; Su DJ, 2011, J HEALTH CARE POOR U, V22, P296, DOI 10.1353/hpu.2011.0002; Telles S, 2013, MED SCI MONITOR, V19, P61, DOI 10.12659/MSM.883743; Wang J, 2012, EVID-BASED COMPL ALT, V2012; Wang J., 2012, INTERNAL MED, V2, P1, DOI [10.4172/2165-8048.1000113, DOI 10.4172/2165-8048.1000113]; Wang J, 2012, EVID-BASED COMPL ALT, V2012; Wolff RF, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018798; Woo KS, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/132912; Xiong XJ, 2013, HYPERTENS RES, V36, P570, DOI 10.1038/hr.2013.18; Xu H, 2008, J ALTERN COMPLEM MED, V14, P3, DOI 10.1089/acm.2006.6329; Xu H, 2012, CHIN J INTEGR MED, V18, P403, DOI 10.1007/s11655-012-1126-7; Xu H, 2011, CHIN J INTEGR MED, V17, P83, DOI 10.1007/s11655-011-0641-2; Yang K, 2007, EVID-BASED COMPL ALT, V4, P487, DOI 10.1093/ecam/nem154	41	13	16	1	33	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 4	2013	8	10							e76357	10.1371/journal.pone.0076357	http://dx.doi.org/10.1371/journal.pone.0076357			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	232JF	24124549	Green Published, gold, Green Submitted			2023-01-03	WOS:000325489100106
J	Comer, C; Redmond, AC; Bird, HA; Hensor, EMA; Conaghan, PG				Comer, Christine; Redmond, Anthony C.; Bird, Howard A.; Hensor, Elizabeth M. A.; Conaghan, Philip G.			A Home Exercise Programme Is No More Beneficial than Advice and Education for People with Neurogenic Claudication: Results from a Randomised Controlled Trial	PLOS ONE			English	Article							LUMBAR SPINAL STENOSIS; OSWESTRY DISABILITY INDEX; MANAGEMENT; SURGERY; WELL	Objective: To compare the effectiveness of a physiotherapy programme with a control treatment of advice and education in patients with neurogenic claudication symptoms. Design: Pragmatic randomised controlled clinical trial. Setting: Primary care-based musculoskeletal service. Patients: Adults aged 50 or over with neurogenic claudication symptoms causing limitation of walking. Interventions: Condition-specific home exercises combined with advice and education, or advice and education alone. Main outcome measures: The primary outcome was the difference in improvement of symptom severity scores on the Swiss Spinal Stenosis Scale at eight weeks. Secondary outcomes included measures of physical function, pain and general well-being at eight weeks and 12 months. Results: There was no significant difference between groups in the Swiss Spinal Stenosis symptom severity scale at eight weeks (t = 0.47, p = 0.643): mean change (SD) control group -0.18 (0.47), treatment group -0.10 (0.66), difference (95% CI) 0.08 (-0.19, 0.35); baseline-adjusted difference 0.06 (-0.19, 0.31)]. An unplanned subgroup analysis suggested that for patients with the top 25% of baseline symptom severity scores, the physiotherapy exercise programme resulted in an improvement in the primary outcome, and modest but consistently better secondary outcomes at both time-points compared to the control group. The effectiveness in different subgroups requires further direct evaluation. Conclusions: In the treatment of patients with neurogenic claudication symptoms, a physiotherapist-prescribed home exercise programme is no more effective than advice and education. Ethical approval: The study was approved by Leeds Central Ethics Committee and informed consent was given by all participating patients. Copyright: The Corresponding Author has the right to grant on behalf of all authors and does grant on behalf of all authors, a worldwide licence to the Publishers and its licensees in perpetuity, in all forms, formats and media (whether known now or created in the future), to i) publish, reproduce, distribute, display and store the Contribution, ii) translate the Contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or, abstracts of the Contribution, iii) create any other derivative work(s) based on the Contribution, iv) to exploit all subsidiary rights in the Contribution, v) the inclusion of electronic links from the Contribution to third party material where-ever it may be located; and, vi) licence any third party to do any or all of the above. Trial registration: ISRCTN 78288224 - doi10.1186/ISRCTN35836727; UKCRN 4814.	[Comer, Christine] Leeds Community Healthcare, Leeds Musculoskeletal & Rehabil Serv, Leeds, W Yorkshire, England; [Comer, Christine; Redmond, Anthony C.; Bird, Howard A.; Hensor, Elizabeth M. A.; Conaghan, Philip G.] Univ Leeds, Fac Hlth, Leeds Inst Rheumat & Musculoskeletal Dis, Leeds, W Yorkshire, England; [Redmond, Anthony C.; Hensor, Elizabeth M. A.; Conaghan, Philip G.] Leeds Teaching Hosp Natl Hlth Serv Trust, NIHR Leeds Musculoskeletal Biomed Res Unit, Leeds, W Yorkshire, England	University of Leeds; Leeds Biomedical Research Centre	Conaghan, PG (corresponding author), Univ Leeds, Fac Hlth, Leeds Inst Rheumat & Musculoskeletal Dis, Leeds, W Yorkshire, England.	p.conaghan@leeds.ac.uk	Redmond, Anthony C/E-2452-2018	Hensor, Elizabeth/0000-0002-5245-4755; Conaghan, Philip/0000-0002-3478-5665	Arthritis Research UK [18183]; National Institute for Health Research [PDA/03/07/047] Funding Source: researchfish	Arthritis Research UK(Versus Arthritis); National Institute for Health Research(National Institute for Health Research (NIHR))	The study was funded by project grant 18183 from Arthritis Research UK. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	AMUNDSEN T, 1995, SPINE, V20, P1178, DOI 10.1097/00007632-199505150-00013; Berger VW, 1999, CONTROL CLIN TRIALS, V20, P319, DOI 10.1016/S0197-2456(99)00014-8; Bodack MP, 2001, CLIN ORTHOP RELAT R, P144; Campbell H, 2006, SPINE, V31, P815, DOI 10.1097/01.brs.0000207257.64215.03; Comer CM, 2009, BMC MUSCULOSKEL DIS, V10, DOI 10.1186/1471-2474-10-121; Deyle GD, 2005, PHYS THER, V85, P1301, DOI 10.1093/ptj/85.12.1301; Duarte M, 2002, J AM CHIROPRACTIC AS, V39, P18; Fairbank JCT, 2000, SPINE, V25, P2940, DOI 10.1097/00007632-200011150-00017; Gaston JE, 2005, QUAL LIFE RES, V14, P71, DOI 10.1007/s11136-004-0793-z; Houedakor J., 2003, Annales de Readaptation et de Medecine Physique, V46, P227, DOI 10.1016/S0168-6054(03)00083-7; Nagler W, 1998, POSTGRAD MED, V103, P69, DOI 10.3810/pgm.1998.04.452; Paterson C, 2005, BMJ-BRIT MED J, V330, P1202, DOI 10.1136/bmj.330.7501.1202; Porter RW, 1996, SPINE, V21, P2046, DOI 10.1097/00007632-199609010-00024; Pratt RK, 2002, SPINE, V27, P84, DOI 10.1097/00007632-200201010-00020; Rittenberg Joshua D, 2003, Phys Med Rehabil Clin N Am, V14, P111, DOI 10.1016/S1047-9651(02)00082-7; Scannell JP, 2003, PHYS THER, V83, P907, DOI 10.1093/ptj/83.10.907; Simotas AC, 2001, CLIN ORTHOP RELAT R, P153; Stucki G, 1996, SPINE, V21, P796, DOI 10.1097/00007632-199604010-00004; Taylor S, 2001, Physiother Res Int, V6, P170, DOI 10.1002/pri.225; Tennant A, 2007, ARTHRIT RHEUM-ARTHR, V57, P1358, DOI 10.1002/art.23108; Tuli SK, 2006, SPINE, V31, P1276, DOI 10.1097/01.brs.0000217615.20018.6c; White IR, 2011, STAT MED, V30, P377, DOI 10.1002/sim.4067; White IR, 2005, STAT MED, V24, P993, DOI 10.1002/sim.1981; Whitman JM, 2006, SPINE, V31, P2541, DOI 10.1097/01.brs.0000241136.98159.8c; Zeifang F, 2003, ORTHOPADE, V32, P906, DOI 10.1007/s00132-003-0567-2; Zigmond AS, 1983, PSYCHIAT SCAND, V76, P361, DOI [DOI 10.1111/J.1600-0447.1983.TB09716.X, DOI 10.1111/J.1600-0447.1983.TB09716.X.PUBMED:6880820]; Zucherman JF, 2005, SPINE, V30, P1351, DOI 10.1097/01.brs.0000166618.42749.d1	27	15	15	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 30	2013	8	9							e72878	10.1371/journal.pone.0072878	http://dx.doi.org/10.1371/journal.pone.0072878			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	231NL	24098633	gold, Green Published			2023-01-03	WOS:000325423500005
J	Stegeman, BH; de Bastos, M; Rosendaal, FR; Vlieg, AV; Helmerhorst, FM; Stijnen, T; Dekkers, OM				Stegeman, Bernardine H.; de Bastos, Marcos; Rosendaal, Frits R.; Vlieg, A. van Hylckama; Helmerhorst, Frans M.; Stijnen, Theo; Dekkers, Olaf M.			Different combined oral contraceptives and the risk of venous thrombosis: systematic review and network meta-analysis	BMJ-BRITISH MEDICAL JOURNAL			English	Article							DEEP-VEIN THROMBOSIS; V-LEIDEN MUTATION; THROMBOEMBOLIC DISEASE; DIFFERENT PROGESTOGENS; PULMONARY-EMBOLISM; DROSPIRENONE; WOMEN; USERS; LEVONORGESTREL; PROGESTAGENS	Objective To provide a comprehensive overview of the risk of venous thrombosis in women using different combined oral contraceptives. Design Systematic review and network meta-analysis. Data sources PubMed, Embase, Web of Science, Cochrane, Cumulative Index to Nursing and Allied Health Literature, Academic Search Premier, and ScienceDirect up to 22 April 2013. Review methods Observational studies that assessed the effect of combined oral contraceptives on venous thrombosis in healthy women. The primary outcome of interest was a fatal or non-fatal first event of venous thrombosis with the main focus on deep venous thrombosis or pulmonary embolism. Publications with at least 10 events in total were eligible. The network meta-analysis was performed using an extension of frequentist random effects models for mixed multiple treatment comparisons. Unadjusted relative risks with 95% confidence intervals were reported. The requirement for crude numbers did not allow adjustment for potential confounding variables. Results 3110 publications were retrieved through a search strategy; 25 publications reporting on 26 studies were included. Incidence of venous thrombosis in non-users from two included cohorts was 1.9 and 3.7 per 10 000 woman years, in line with previously reported incidences of 1-6 per 10 000 woman years. Use of combined oral contraceptives increased the risk of venous thrombosis compared with non-use (relative risk 3.5, 95% confidence interval 2.9 to 4.3). The relative risk of venous thrombosis for combined oral contraceptives with 30-35 mu g ethinylestradiol and gestodene, desogestrel, cyproterone acetate, or drospirenone were similar and about 50-80% higher than for combined oral contraceptives with levonorgestrel. A dose related effect of ethinylestradiol was observed for gestodene, desogestrel, and levonorgestrel, with higher doses being associated with higher thrombosis risk. Conclusion All combined oral contraceptives investigated in this analysis were associated with an increased risk of venous thrombosis. The effect size depended both on the progestogen used and the dose of ethinylestradiol.	[Stegeman, Bernardine H.] UCL, Dept Epidemiol & Publ Hlth, London, England; [de Bastos, Marcos; Helmerhorst, Frans M.] Leiden Univ, Med Ctr, Dept Clin Epidemiol, NL-2333 ZA Leiden, Netherlands; [Stegeman, Bernardine H.; Rosendaal, Frits R.] Leiden Univ, Dept Thrombosis & Haemostasis, Einthoven Lab Expt Vasc Med, Dept Clin Epidemiol,Med Ctr, NL-2333 ZA Leiden, Netherlands; [Vlieg, A. van Hylckama] Leiden Univ, Med Ctr, Dept Clin Epidemiol, Einthoven Lab Expt Vasc Med, NL-2333 ZA Leiden, Netherlands; [Helmerhorst, Frans M.] Leiden Univ, Med Ctr, Dept Gynaecol & Reprod Med, NL-2333 ZA Leiden, Netherlands; [Stijnen, Theo] Leiden Univ, Med Ctr, Dept Med Stat, NL-2333 ZA Leiden, Netherlands; [Dekkers, Olaf M.] Leiden Univ, Med Ctr, Dept Endocrinol & Metab, Dept Clin Epidemiol, NL-2333 ZA Leiden, Netherlands	University of London; University College London; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Dekkers, OM (corresponding author), Leiden Univ, Med Ctr, Dept Endocrinol & Metab, Dept Clin Epidemiol, NL-2333 ZA Leiden, Netherlands.	o.m.dekkers@lumc.nl	van Hylckama Vlieg, Astrid/A-3323-2017; Rosendaal, Frits/Q-3842-2017	Rosendaal, Frits/0000-0003-2558-7496; Dekkers, Olaf/0000-0002-1333-7580	Netherlands Organization for Scientific Research [40-00812-98-07-045]; Capes-Nuffic, Brazil	Netherlands Organization for Scientific Research(Netherlands Organization for Scientific Research (NWO)); Capes-Nuffic, Brazil	This study received no specific funding. BHS was supported by grant 40-00812-98-07-045 from the Netherlands Organization for Scientific Research. MdB was supported by grant from Capes-Nuffic, Brazil. The funding agencies had no role in the study design, implementation, or preparation of results.	ANAND JK, 1961, LANCET, V2, P1146; Andersen BS, 1998, THROMB HAEMOSTASIS, V79, P28, DOI 10.1055/s-0037-1614213; [Anonymous], 1967, J R Coll Gen Pract, V13, P267; Bird ST, 2013, J THROMB HAEMOST, V11, P1059, DOI 10.1111/jth.12224; Bloemenkamp KWM, 1999, ARCH INTERN MED, V159, P65, DOI 10.1001/archinte.159.1.65; BLOEMENKAMP KWM, 1995, LANCET, V346, P1593, DOI 10.1016/S0140-6736(95)91929-5; FARLEY TMM, 1995, LANCET, V346, P1582; Farmer R, 1996, LANCET, V347, P259; Farmer RDT, 2000, BRIT J CLIN PHARMACO, V49, P580, DOI 10.1046/j.1365-2125.2000.00198.x; Farmer RDT, 1998, CONTRACEPTION, V57, P67, DOI 10.1016/S0010-7824(98)00002-X; GALLO MF, 2008, COCHRANE DB SYST REV, V8; Goodacre S, 2006, HEALTH TECHNOL ASSES, V10, P1; Grimes DA, 2005, LANCET, V365, P1429, DOI 10.1016/S0140-6736(05)66379-9; Gronich N, 2011, CAN MED ASSOC J, V183, pE1319, DOI 10.1503/cmaj.110463; Hedenmalm K, 2004, ACTA OBSTET GYN SCAN, V83, P576, DOI 10.1111/j.0001-6349.2004.0533.x; Heinemann LAJ, 2002, CONTRACEPTION, V65, P207, DOI 10.1016/S0010-7824(01)00309-2; Heinemann LAJ, 2010, CONTRACEPTION, V81, P401, DOI 10.1016/j.contraception.2009.12.014; Henzl MR, 2000, PROGESTINS AND ANTIPROGESTINS IN CLINICAL PRACTICE, P101; Herings RMC, 1999, LANCET, V354, P127, DOI 10.1016/S0140-6736(99)01257-X; INMAN WHW, 1968, BRIT MED J, V2, P193, DOI 10.1136/bmj.2.5599.193; INMAN WHW, 1970, BMJ-BRIT MED J, V2, P203, DOI 10.1136/bmj.2.5703.203; Jick SS, 2006, CONTRACEPTION, V73, P566, DOI 10.1016/j.contraception.2006.02.002; Jick SS, 2011, BMJ-BRIT MED J, V342, DOI 10.1136/bmj.d2151; Kemmeren JM, 2001, BRIT MED J, V323, P131, DOI 10.1136/bmj.323.7305.131; Kemmeren JM, 2004, BLOOD, V103, P927, DOI 10.1182/blood-2003-04-1285; Kemmeren JM, 2002, THROMB HAEMOSTASIS, V87, P199; Lewis MA, 1996, CONTRACEPTION, V54, P5, DOI 10.1016/0010-7824(96)00112-6; Lidegaard O, 2002, CONTRACEPTION, V65, P187, DOI 10.1016/S0010-7824(01)00307-9; Lidegaard O, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d6423; Lidegaard O, 2009, BRIT MED J, V339, DOI 10.1136/bmj.b2890; Manzoli L, 2012, DRUG SAFETY, V35, P191, DOI 10.2165/11598050-000000000-00000; Martinelli I, 1999, ARTERIOSCL THROM VAS, V19, P700, DOI 10.1161/01.ATV.19.3.700; MEADE TW, 1980, BRIT MED J, V280, P1157, DOI 10.1136/bmj.280.6224.1157; Naess IA, 2007, J THROMB HAEMOST, V5, P692, DOI 10.1111/j.1538-7836.2007.02450.x; NISCHAN P, 1993, AM J EPIDEMIOL, V138, P697, DOI 10.1093/oxfordjournals.aje.a116907; Norell SE, 1998, INT J EPIDEMIOL, V27, P1033, DOI 10.1093/ije/27.6.1033; Parkin L, 2000, LANCET, V355, P2133, DOI 10.1016/S0140-6736(00)02382-5; Parkin L, 2011, BMJ-BRIT MED J, V342, DOI 10.1136/bmj.d2139; POULTER NR, 1995, LANCET, V346, P1575; Qaseem A, 2007, ANN FAM MED, V5, P57, DOI 10.1370/afm.667; Raps M, 2012, J THROMB HAEMOST, V10, P992, DOI 10.1111/j.1538-7836.2012.04720.x; Samuelsson E, 2004, ACTA OBSTET GYN SCAN, V83, P674, DOI 10.1111/j.0001-6349.2004.00574.x; SARTWELL PE, 1969, AM J EPIDEMIOL, V90, P365, DOI 10.1093/oxfordjournals.aje.a121082; STOLLEY PD, 1975, AM J EPIDEMIOL, V102, P197, DOI 10.1093/oxfordjournals.aje.a112148; THOROGOOD M, 1993, BRIT MED BULL, V49, P124, DOI 10.1093/oxfordjournals.bmb.a072592; Todd JC, 1999, HUM REPROD, V14, P1500, DOI 10.1093/humrep/14.6.1500; van Vliet HAAM, 2005, HUM REPROD, V20, P563, DOI 10.1093/humrep/deh612; Vandenbroucke JP, 1997, AM J OBSTET GYNECOL, V177, P887, DOI 10.1016/S0002-9378(97)70289-8; Vandenbroucke JP, 2001, NEW ENGL J MED, V344, P1527, DOI 10.1056/NEJM200105173442007; VESSEY M, 1986, BRIT MED J, V292, P526, DOI 10.1136/bmj.292.6519.526; VESSEY MP, 1969, BRIT MED J, V2, P651, DOI 10.1136/bmj.2.5658.651; Vlieg AV, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2921; Vlieg AVH, 2010, ARTERIOSCL THROM VAS, V30, P2297, DOI 10.1161/ATVBAHA.110.211482; WELLS PS, 1995, LANCET, V345, P1326, DOI 10.1016/S0140-6736(95)92535-X; Wharton C, 1988, POPULATION REP, V16, P1; White IR, 2012, RES SYNTH METHODS, V3, P111, DOI 10.1002/jrsm.1045	56	202	215	0	42	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 12	2013	347								f5298	10.1136/bmj.f5298	http://dx.doi.org/10.1136/bmj.f5298			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	219SU	24030561	hybrid, Green Published			2023-01-03	WOS:000324530500002
J	Muenchmeier, N; Boecker, S; Bankel, L; Hinz, L; Rieth, N; Lapa, C; Mendler, AN; Noessner, E; Mocikat, R; Nelson, PJ				Muenchmeier, Niklas; Boecker, Sophia; Bankel, Lorenz; Hinz, Laura; Rieth, Nicole; Lapa, Constantin; Mendler, Anna N.; Noessner, Elfriede; Mocikat, Ralph; Nelson, Peter J.			A Novel CXCL10-Based GPI-Anchored Fusion Protein as Adjuvant in NK-Based Tumor Therapy	PLOS ONE			English	Article							CELL-ADHESION; IN-VIVO; TRANSENDOTHELIAL MIGRATION; ADOPTIVE IMMUNOTHERAPY; ENDOTHELIAL-CELLS; MONOCYTE ARREST; T-CELLS; EXPRESSION; CANCER; ANGIOGENESIS	Background: Cellular therapy is a promising therapeutic strategy for malignant diseases. The efficacy of this therapy can be limited by poor infiltration of the tumor by immune effector cells. In particular, NK cell infiltration is often reduced relative to T cells. A novel class of fusion proteins was designed to enhance the recruitment of specific leukocyte subsets based on their expression of a given chemokine receptor. The proteins are composed of an N-terminal chemokine head, the mucin domain taken from the membrane-anchored chemokine CX3CL1, and a C-terminal glycosylphosphatidylinositol (GPI) membrane anchor replacing the normal transmembrane domain allowing integration of the proteins into cell membranes when injected into a solid tumor. The mucin domain in conjunction with the chemokine head acts to specifically recruit leukocytes expressing the corresponding chemokine receptor. Methodology/Principal Findings: A fusion protein comprising a CXCL10 chemokine head (CXCL10-mucin-GPI) was used for proof of concept for this approach and expressed constitutively in Chinese Hamster Ovary cells. FPLC was used to purify proteins. The recombinant proteins efficiently integrated into cell membranes in a process dependent upon the GPI anchor and were able to activate the CXCR3 receptor on lymphocytes. Endothelial cells incubated with CXCL10-mucin-GPI efficiently recruited NK cells in vitro under conditions of physiologic flow, which was shown to be dependent on the presence of the mucin domain. Experiments conducted in vivo using established tumors in mice suggested a positive effect of CXCL10-mucin-GPI on the recruitment of NK cells. Conclusions: The results suggest enhanced recruitment of NK cells by CXCL10-mucin-GPI. This class of fusion proteins represents a novel adjuvant in cellular immunotherapy. The underlying concept of a chemokine head fused to the mucin domain and a GPI anchor signal sequence may be expanded into a broader family of reagents that will allow targeted recruitment of cells in various settings.	[Muenchmeier, Niklas; Boecker, Sophia; Hinz, Laura; Rieth, Nicole; Lapa, Constantin; Nelson, Peter J.] Klinikum Univ Munchen, AG Klin Biochem, Med Klin & Poliklin 4, Munich, Germany; [Bankel, Lorenz; Mendler, Anna N.; Noessner, Elfriede; Mocikat, Ralph; Nelson, Peter J.] Helmholtz Zentrum Munchen, Deutsch Forschungszentrum Gesundheit & Umwelt, Inst Mol Immunol, Munich, Germany	University of Munich; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health	Nelson, PJ (corresponding author), Helmholtz Zentrum Munchen, Deutsch Forschungszentrum Gesundheit & Umwelt, Inst Mol Immunol, Munich, Germany.	peter.nelson@med.uni-muenchen.de	Lapa, Constantin/GLV-0441-2022	Lapa, Constantin/0000-0001-7536-2207	Deutsche Forschungsgemeinschaft (DFG) [SFB-TR36]; Deutsche Krebshilfe	Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG)); Deutsche Krebshilfe(Deutsche Krebshilfe)	The work was funded by the Deutsche Forschungsgemeinschaft (DFG) SFB-TR36. ANM is supported by a grant from the Deutsche Krebshilfe. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Brenner CD, 2010, EUR J IMMUNOL, V40, P494, DOI 10.1002/eji.200939937; Buckanovich RJ, 2008, NAT MED, V14, P28, DOI 10.1038/nm1699; Clark-Lewis I, 2003, J BIOL CHEM, V278, P289, DOI 10.1074/jbc.M209470200; Colvin RA, 2004, J BIOL CHEM, V279, P30219, DOI 10.1074/jbc.M403595200; Colvin RA, 2006, MOL CELL BIOL, V26, P5838, DOI 10.1128/MCB.00556-06; Dirkx AEM, 2003, CANCER RES, V63, P2322; Fong AM, 2000, J BIOL CHEM, V275, P3781, DOI 10.1074/jbc.275.6.3781; Fregni G, 2012, ONCOIMMUNOLOGY, V1, P38, DOI 10.4161/onci.1.1.18312; Fruci D, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-30; GAMBLE JR, 1988, SCIENCE, V242, P97; Griffioen AW, 1996, CANCER RES, V56, P1111; Griffioen AW, 1999, INT J CANCER, V80, P315, DOI 10.1002/(SICI)1097-0215(19990118)80:2<315::AID-IJC23>3.0.CO;2-L; Griffioen AW, 1996, BLOOD, V88, P667, DOI 10.1182/blood.V88.2.667.bloodjournal882667; Grone HJ, 1999, FASEB J, V13, P1371, DOI 10.1096/fasebj.13.11.1371; Haraldsen G, 1996, J IMMUNOL, V156, P2558; Haskell CA, 1999, J BIOL CHEM, V274, P10053, DOI 10.1074/jbc.274.15.10053; Huang H, 2002, CELL IMMUNOL, V217, P12, DOI 10.1016/S0008-8749(02)00508-7; Imai T, 1997, CELL, V91, P521, DOI 10.1016/S0092-8674(00)80438-9; June CH, 2007, J CLIN INVEST, V117, P1466, DOI 10.1172/JCI32446; June CH, 2007, J CLIN INVEST, V117, P1204, DOI 10.1172/JCI31446; Kovalchuk AL, 2000, J EXP MED, V192, P1183, DOI 10.1084/jem.192.8.1183; Kukreti S, 1997, BLOOD, V89, P4104, DOI 10.1182/blood.V89.11.4104; Kuschert GSV, 1999, BIOCHEMISTRY-US, V38, P12959, DOI 10.1021/bi990711d; LAWRENCE MB, 1987, BLOOD, V70, P1284; Manes TD, 2006, TRANSPLANTATION, V82, pS9, DOI 10.1097/01.tp.0000231356.57576.82; Medof ME, 1996, FASEB J, V10, P574, DOI 10.1096/fasebj.10.5.8621057; Milani V, 2005, INT IMMUNOL, V17, P257, DOI 10.1093/intimm/dxh203; Mukai S, 1999, CANCER RES, V59, P5245; Peled A, 1999, J CLIN INVEST, V104, P1199, DOI 10.1172/JCI7615; Pietra G, 2012, CANCER RES, V72, P1407, DOI 10.1158/0008-5472.CAN-11-2544; POCKAJ BA, 1994, CANCER, V73, P1731, DOI 10.1002/1097-0142(19940315)73:6<1731::AID-CNCR2820730630>3.0.CO;2-H; Proudfoot AEI, 2003, P NATL ACAD SCI USA, V100, P1885, DOI 10.1073/pnas.0334864100; Proudfoot AEI, 2010, EXPERT OPIN INV DRUG, V19, P345, DOI 10.1517/13543780903535867; Ranjbaran H, 2006, CIRCULATION, V114, P1293, DOI 10.1161/CIRCULATIONAHA.106.631457; Sauty A, 2001, J IMMUNOL, V167, P7084, DOI 10.4049/jimmunol.167.12.7084; Sconocchia G, 2012, CANCER RES, V72, P5428, DOI 10.1158/0008-5472.CAN-12-1181; Senovilla L, 2012, ONCOIMMUNOLOGY, V1, P1323, DOI 10.4161/onci.22009; Shrimali RK, 2010, CANCER RES, V70, P6171, DOI 10.1158/0008-5472.CAN-10-0153; Smyth MJ, 2002, NAT REV CANCER, V2, P850, DOI 10.1038/nrc928; Smyth MJ, 2001, J EXP MED, V193, P661, DOI 10.1084/jem.193.6.661; Stachel G, 2013, STEM CELLS IN PRESS; Tromp SC, 2000, INT IMMUNOL, V12, P671, DOI 10.1093/intimm/12.5.671; von Hundelshausen P, 2001, CIRCULATION, V103, P1772, DOI 10.1161/01.CIR.103.13.1772; WU NZ, 1992, CANCER RES, V52, P4265	44	16	16	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 30	2013	8	8							e72749	10.1371/journal.pone.0072749	http://dx.doi.org/10.1371/journal.pone.0072749			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	211BX	24023642	Green Published, Green Submitted, gold			2023-01-03	WOS:000323880200038
J	Leleu, H; Minvielle, E				Leleu, Henri; Minvielle, Etienne			Relationship between Longitudinal Continuity of Primary Care and Likelihood of Death: Analysis of National Insurance Data	PLOS ONE			English	Article							HEALTH-CARE; PHYSICIAN; QUESTIONNAIRE; ASSOCIATION; OUTCOMES	Background: Continuity of care (COC) is a widely accepted core principle of primary care and has been associated with patient satisfaction, healthcare utilization and mortality in many, albeit small, studies. Objective: To assess the relationship between longitudinal continuity with a primary care physician (PCP) and likelihood of death in the French general population. Design: Observational study based on reimbursement claims from the French national health insurance (NHI) database for salaried workers (2007-2010). Setting: Primary care. Patients: We extracted data on the number and pattern of visits made to a PCP and excluded all patients who did not visit a PCP at least twice within 6 months. We recorded age, gender, comorbidities, social status, and deaths. Main outcome measures: The primary endpoint was death by all causes. We measured longitudinal continuity of care (COC) with a PCP twice a year between 2007 and 2010, using the COC index developed by Bice and Boxerman. We introduced the COC index as time-dependent variables in a survival analysis after adjustment for age, gender and stratifying on comorbidities and social status. Results: A total of 325 742 patients were included in the analysis. The average COC index ranged from 0.74 (SD: 0.35) to 0.76 (0.35) (where 1.0 is perfect continuity). Likelihood of death was lower in patients with higher continuity (hazard ratio for an increase in 0.1 of continuity, adjusted for age, sex, and stratified on comorbidities and social status: 0.96 [0.95-0.96]). Conclusion: Higher longitudinal continuity was associated with a reduced likelihood of death.	[Leleu, Henri] Publ Hlth Expertise, Hlth Econ & Outcome Res, Loos, France; [Leleu, Henri; Minvielle, Etienne] Ecole Hautes Etud Sante Publ Gustave Roussy, Res Unit, Management Healthcare Org, Villejuif, France	UNICANCER; Gustave Roussy	Leleu, H (corresponding author), Publ Hlth Expertise, Hlth Econ & Outcome Res, Loos, France.	henri.leleu@ph-expertise.com		Leleu, Henri/0000-0003-4930-6767				Alazri Mohammed, 2007, Sultan Qaboos Univ Med J, V7, P197; Aller MB, 2012, J CLIN EPIDEMIOL, V65, P578, DOI 10.1016/j.jclinepi.2011.11.009; [Anonymous], 2002, HEALTH CARE; BECKER MH, 1974, AM J PUBLIC HEALTH, V64, P1062, DOI 10.2105/AJPH.64.11.1062; BICE TW, 1977, MED CARE, V15, P347, DOI 10.1097/00005650-197704000-00010; Cabana MD, 2004, J FAM PRACTICE, V53, P974; EJLERTSSON G, 1984, MED CARE, V22, P231, DOI 10.1097/00005650-198403000-00006; ERIKSSON EA, 1983, MED CARE, V21, P858, DOI 10.1097/00005650-198309000-00003; ERIKSSON EA, 1990, MED CARE, V28, P180, DOI 10.1097/00005650-199002000-00009; Fisher LD, 1999, ANNU REV PUBL HEALTH, V20, P145, DOI 10.1146/annurev.publhealth.20.1.145; Guthrie B, 2008, BMJ-BRIT MED J, V337, DOI 10.1136/bmj.a867; Haggerty JL, 2003, BRIT MED J, V327, P1219, DOI 10.1136/bmj.327.7425.1219; HILL AB, 1965, P ROY SOC MED, V58, P295, DOI 10.1177/003591576505800503; Jee SH, 2006, MED CARE RES REV, V63, P158, DOI 10.1177/1077558705285294; Ridd MJ, 2011, ANN FAM MED, V9, P538, DOI 10.1370/afm.1322; ROGERS J, 1980, AM J PUBLIC HEALTH, V70, P122, DOI 10.2105/AJPH.70.2.122; Salisbury C, 2009, BRIT J GEN PRACT, V59, P276, DOI 10.3399/bjgp09X420257; Saultz John W, 2003, Ann Fam Med, V1, P134, DOI 10.1370/afm.23; Saultz JW, 2004, ANN FAM MED, V2, P445, DOI 10.1370/afm.91; SMEDBY O, 1986, MED CARE, V24, P511; Starfield B., 1992, PRIMARY CARE CONCEPT; Sundararajan V, 2004, J CLIN EPIDEMIOL, V57, P1288, DOI 10.1016/j.jclinepi.2004.03.012; Therneau T.M., 2000, STAT BIOL HEALTH, DOI 10.1007/978-1-4757-3294-8; Tuppin P, 2010, REV EPIDEMIOL SANTE, V58, P286, DOI 10.1016/j.respe.2010.04.005; Uijen AA, 2012, J CLIN EPIDEMIOL, V65, P577, DOI 10.1016/j.jclinepi.2011.10.015; Uijen AA, 2011, J CLIN EPIDEMIOL, V64, P1391, DOI 10.1016/j.jclinepi.2011.03.006; van Walraven C, 2010, J EVAL CLIN PRACT, V16, P947, DOI 10.1111/j.1365-2753.2009.01235.x; WASSON JH, 1984, JAMA-J AM MED ASSOC, V252, P2413; Weiss LJ, 1996, AM J PUBLIC HEALTH, V86, P1742, DOI 10.2105/AJPH.86.12.1742; Wolinsky FD, 2010, J GERONTOL A-BIOL, V65, P421, DOI 10.1093/gerona/glp188	30	34	35	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 22	2013	8	8							e71669	10.1371/journal.pone.0071669	http://dx.doi.org/10.1371/journal.pone.0071669			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	218ZA	23990970	Green Submitted, Green Published, gold			2023-01-03	WOS:000324470700019
J	Ono, M; Inkson, CA; Sonn, R; Kilts, TM; de Castro, LF; Maeda, A; Fisher, LW; Robey, PG; Berendsen, AD; Li, L; McCartney-Francis, N; Brown, AC; Crawford, NPS; Molinolo, A; Jain, A; Fedarko, NS; Young, MF				Ono, Mitsuaki; Inkson, Colette A.; Sonn, Robert; Kilts, Tina M.; de Castro, Luis F.; Maeda, Azusa; Fisher, Larry W.; Robey, Pamela G.; Berendsen, Agnes D.; Li, Li; McCartney-Francis, Nancy; Brown, Aaron C.; Crawford, Nigel P. S.; Molinolo, Alfredo; Jain, Alka; Fedarko, Neal S.; Young, Marian F.			WISP1/CCN4: A Potential Target for Inhibiting Prostate Cancer Growth and Spread to Bone	PLOS ONE			English	Article							DIFFERENTIAL EXPRESSION; FACTOR CTGF/CCN2; TUMOR-GROWTH; WISP-1; METASTASIS; CYR61; BREAST; MECHANISMS; REGULATOR; GENES	Prostate cancer (PC) is a leading cause of death in men however the factors that regulate its progression and eventual metastasis to bone remain unclear. Here we show that WISP1/CCN4 expression in prostate cancer tissues was up-regulated in early stages of the disease and, further, that it correlated with increased circulating levels of WISP1 in the sera of patients at early stages of the disease. WISP1 was also elevated in the mouse prostate cancer model TRAMP in the hypoplastic diseased tissue that develops prior to advanced carcinoma formation. When the ability of anti-WISP1 antibodies to reduce the spread of PC3-Luc cells to distant sites was tested it showed that twice weekly injections of anti-WISP1 antibodies reduced the number and overall size of distant tumors developed after intracardiac (IC) injection of PC3-Luc cells in mice. The ability of antibodies against WISP1 to inhibit growth of PC3-Luc cancer cells in mice was also evaluated and showed that twice weekly injections of anti-WISP1 antibodies reduced local tumor growth when examined in xenografts. To better understand the mechanism of action, the migration of PC3-Luc cells through membranes with or without a Matrigel (TM) barrier showed the cells were attracted to WISP1, and that this attraction was inhibited by treatment with anti-WISP1 antibodies. We also show the expression of WISP1 at the bone-tumor interface and in the stroma of early grade cancers suggested WISP1 expression is well placed to play roles in both fostering growth of the cancer and its spread to bone. In summary, the up-regulation of WISP1 in the early stages of cancer development coupled with its ability to inhibit spread and growth of prostate cancer cells makes it both a potential target and an accessible diagnostic marker for prostate cancer.	[Ono, Mitsuaki; Inkson, Colette A.; Sonn, Robert; Kilts, Tina M.; de Castro, Luis F.; Maeda, Azusa; Fisher, Larry W.; Robey, Pamela G.; Berendsen, Agnes D.; Li, Li; McCartney-Francis, Nancy; Brown, Aaron C.; Young, Marian F.] NIDCR, Craniofacial & Skeletal Dis Branch, NIH, Bethesda, MD USA; [Molinolo, Alfredo] NIDCR, Oral & Pharyngeal Canc Branch, NIH, Bethesda, MD USA; [Crawford, Nigel P. S.] NHGRI, Metastasis Genet Sect, Canc Genet Branch, NIH, Bethesda, MD 20892 USA; [Jain, Alka; Fedarko, Neal S.] Johns Hopkins Sch Med, Div Geriatr Med & Gerontol, Baltimore, MD USA; [Ono, Mitsuaki] Okayama Univ, Dept Oral Rehabil & Regenerat Med, Grad Sch Med Dent & Pharmaceut Sci, Okayama 7008530, Japan; [Inkson, Colette A.] Univ Manchester, Fac Life Sci, Manchester Immunol Grp, Manchester, Lancs, England	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); Johns Hopkins University; Johns Hopkins Medicine; Okayama University; University of Manchester	Young, MF (corresponding author), NIDCR, Craniofacial & Skeletal Dis Branch, NIH, Bethesda, MD USA.	myoung@dir.nicdr.nih.gov	Robey, Pamela Gehron/H-1429-2011; de Castro, Luis Fernandez/AAV-1858-2021	Robey, Pamela Gehron/0000-0002-5316-5576; de Castro, Luis Fernandez/0000-0003-3194-9780; Fedarko, Neal/0000-0001-6055-6279; Inkson, Colette/0000-0003-1215-312X; Young, Marian F/0000-0003-0929-8854	Division of Intramural Research, NIDCR of the Intramural Research Program, NIH, DHHS; Department of Defense [W81XWH-11-1-0239]; Howard Hughes Scholarship; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000379, ZIADE000380] Funding Source: NIH RePORTER	Division of Intramural Research, NIDCR of the Intramural Research Program, NIH, DHHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); Department of Defense(United States Department of Defense); Howard Hughes Scholarship; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))	This research was supported by the Division of Intramural Research, NIDCR of the Intramural Research Program, NIH, DHHS (MO, CAI, TMK, LFCD, AM (Maeda), LWF, PGR, ADB, LL NM-F, ACB, NPSC, AM (Molinolo) and MFY), by a grant from the Department of Defense W81XWH-11-1-0239 (AJ and NSF) and by a Howard Hughes Scholarship (RS). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Barqawi A, 2012, ADV UROL, V2012, DOI 10.1155/2012/862639; Barry MJ, 2001, NEW ENGL J MED, V344, P1373, DOI 10.1056/NEJM200105033441806; Bauer M, 2010, ONCOGENE, V29, P1732, DOI 10.1038/onc.2009.463; Bennewith KL, 2009, CANCER RES, V69, P775, DOI 10.1158/0008-5472.CAN-08-0987; Buijs JT, 2007, AM J PATHOL, V171, P1047, DOI 10.2353/ajpath.2007.070168; Center MM, 2012, EUR UROL, V61, P1079, DOI 10.1016/j.eururo.2012.02.054; Chen CC, 2009, INT J BIOCHEM CELL B, V41, P771, DOI 10.1016/j.biocel.2008.07.025; Chirgwin JM, 2000, CRIT REV EUKAR GENE, V10, P159; Chung LWK, 2005, J UROLOGY, V173, P10, DOI 10.1097/01.ju.0000141582.15218.10; Dornhofer N, 2006, CANCER RES, V66, P5816, DOI 10.1158/0008-5472.CAN-06-0081; Feeley BT, 2006, BONE, V38, P154, DOI 10.1016/j.bone.2005.07.015; French DM, 2004, AM J PATHOL, V165, P855, DOI 10.1016/S0002-9440(10)63348-2; GREENBERG NM, 1995, P NATL ACAD SCI USA, V92, P3439, DOI 10.1073/pnas.92.8.3439; Gururajan M, 2012, TRANSL ANDROL UROL, V1, P19, DOI 10.3978/j.issn.2223-4683.2012.01.03; Hashimoto Y, 1998, J EXP MED, V187, P289, DOI 10.1084/jem.187.3.289; Hou CH, 2011, BIOCHEM PHARMACOL, V81, P1286, DOI 10.1016/j.bcp.2011.03.016; Inkson CA, 2008, J CELL BIOCHEM, V104, P1865, DOI 10.1002/jcb.21754; Inkson CA, 2009, CELLS TISSUES ORGANS, V189, P153, DOI 10.1159/000151377; Jemal A, 2010, CA-CANCER J CLIN, V60, P277, DOI [10.3322/caac.20073, 10.3322/caac.20105]; Joyce JA, 2009, NAT REV CANCER, V9, P239, DOI 10.1038/nrc2618; Kapinas K, 2012, MATRIX BIOL, V31, P299, DOI 10.1016/j.matbio.2012.03.002; Khor TO, 2006, INT J COLORECTAL DIS, V21, P291, DOI 10.1007/s00384-005-0002-8; Kleer CG, 2007, CELLS TISSUES ORGANS, V185, P95, DOI 10.1159/000101308; Kobayashi A, 2011, J EXP MED, V208, P2641, DOI 10.1084/jem.20110840; Konigshoff M, 2009, J CLIN INVEST, V119, P772, DOI 10.1172/JCI33950; Langley RR, 2011, INT J CANCER, V128, P2527, DOI 10.1002/ijc.26031; Lv HZ, 2009, J CELL BIOCHEM, V106, P738, DOI 10.1002/jcb.22075; Maillard M, 2001, J CLIN PATHOL-MOL PA, V54, P275, DOI 10.1136/mp.54.4.275; Margalit O, 2003, BRIT J CANCER, V89, P314, DOI 10.1038/sj.bjc.6600977; Nagai Y, 2011, ANTICANCER RES, V31, P991; Ono M, 2011, J BONE MINER RES, V26, P193, DOI 10.1002/jbmr.205; Parisi MS, 2006, BONE, V38, P671, DOI 10.1016/j.bone.2005.10.005; Pasmant E, 2010, J NEUROPATH EXP NEUR, V69, P60, DOI 10.1097/NEN.0b013e3181c79bff; Pennica D, 1998, P NATL ACAD SCI USA, V95, P14717, DOI 10.1073/pnas.95.25.14717; Roodman GD, 2012, CANC METASTASIS REV; Sabile AA, 2011, J BONE MINER RES; Schneider A, 2005, ENDOCRINOLOGY, V146, P1727, DOI 10.1210/en.2004-1211; Shimo T, 2006, J BONE MINER RES, V21, P1045, DOI 10.1359/JBMR.060416; Sun YX, 2005, J BONE MINER RES, V20, P318, DOI 10.1359/JBMR.041109; Suva LJ, 2011, NAT REV ENDOCRINOL, V7, P208, DOI 10.1038/nrendo.2010.227; Tan TW, 2009, CARCINOGENESIS, V30, P258, DOI 10.1093/carcin/bgn284; Tanaka S, 2001, ONCOGENE, V20, P5525, DOI 10.1038/sj.onc.1204723; Tang QL, 2011, J OBSTET GYNAECOL RE, V37, P606, DOI 10.1111/j.1447-0756.2011.01631.x; Terada N, 2012, PROSTATE, V72, P966, DOI 10.1002/pros.21501; Terada N, 2012, ASIAN J ANDROL, V14, P405, DOI 10.1038/aja.2011.149; Weilbaecher KN, 2011, NAT REV CANCER, V11, P411, DOI 10.1038/nrc3055; Xie D, 2001, CANCER RES, V61, P8917; Xu LF, 2000, GENE DEV, V14, P585	48	54	54	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 14	2013	8	8							e71709	10.1371/journal.pone.0071709	http://dx.doi.org/10.1371/journal.pone.0071709			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	202MQ	23977121	Green Submitted, Green Published, gold			2023-01-03	WOS:000323221500098
J	Feder, G; Wathen, CN; MacMillan, HL				Feder, Gene; Wathen, C. Nadine; MacMillan, Harriet L.			An Evidence-Based Response to Intimate Partner Violence WHO Guidelines	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							RANDOMIZED-CONTROLLED-TRIAL		[Feder, Gene] Univ Bristol, Sch Social & Community Med, Ctr Acad Primary Care, Bristol BS8 2PS, Avon, England; [Wathen, C. Nadine] Western Univ, Fac Informat & Media Studies, London, ON, Canada; [MacMillan, Harriet L.] McMaster Univ, Dept Psychiat & Behav Neurosci, Hamilton, ON, Canada; [MacMillan, Harriet L.] McMaster Univ, Dept Pediat, Hamilton, ON, Canada	University of Bristol; Western University (University of Western Ontario); McMaster University; McMaster University	Feder, G (corresponding author), Univ Bristol, Sch Social & Community Med, 39 Whatley Rd,Canynge Hall, Bristol BS8 2PS, Avon, England.	gene.feder@bristol.ac.uk	MacMillan, Harriet/B-4530-2016	MacMillan, Harriet/0000-0002-1223-706X; Feder, Gene/0000-0002-7890-3926				Cohen JA, 2011, ARCH PEDIAT ADOL MED, V165, P16, DOI 10.1001/archpediatrics.2010.247; Feder G, 2011, LANCET, V378, P1788, DOI 10.1016/S0140-6736(11)61179-3; Feder GS, 2006, ARCH INTERN MED, V166, P22, DOI 10.1001/archinte.166.1.22; Klevens J, 2012, JAMA-J AM MED ASSOC, V308, P681, DOI 10.1001/jama.2012.6434; MacMillan HL, 2009, JAMA-J AM MED ASSOC, V302, P493, DOI 10.1001/jama.2009.1089; Moyer VA, 2013, ANN INTERN MED, V158, P478, DOI 10.7326/0003-4819-158-6-201303190-00588; Taft A, 2013, COCHRANE DB SYST REV, V4, DOI DOI 10.1002/14651858.CD007007.PUB2; World Health Organization, RESPONDING TO INTIMA	8	32	33	0	10	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 7	2013	310	5					479	480		10.1001/jama.2013.167453	http://dx.doi.org/10.1001/jama.2013.167453			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	196OZ	23925614				2023-01-03	WOS:000322786400016
J	Selvaraj, S				Selvaraj, Sakthivel			PERSONAL VIEW Africa could learn from India's burgeoning pharma sector	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material									Publ Hlth Fdn India, New Delhi, India	Public Health Foundation of India	Selvaraj, S (corresponding author), Publ Hlth Fdn India, New Delhi, India.	shakti@phfi.org	Selvaraj, Sakthivel/ABD-5873-2021; Selvaraj, Sakthivel/ABE-6897-2020	Selvaraj, Sakthivel/0000-0001-5940-1958				Centre for Monitoring Indian Economy, 2012, IND TRAD BAS DIR GEN; Emerging Market Information Services, 2012, PHARM SECT IND; Gopakumar KM, 2012, UNPACKING ISSUE COUN; Government of India, 2012, ANN REPORT; Government of India. Central Drugs Standards Control Organisation Directorate General Health Services Ministry of Health and Family Welfare, 2009, REP COUNTR SURV SPUR; Kaplan WA, 2005, LOCAL PRODUCTION PHA; Nakakeeto ON, 2013, GLOBALIZATION HEALTH, V9, DOI 10.1186/1744-8603-9-6; Pecoul B, 1999, JAMA-J AM MED ASSOC, V281, P361, DOI 10.1001/jama.281.4.361; Selvaraj Sakthivel, 2013, HINDU           0407	9	3	3	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 2	2013	347								f4235	10.1136/bmj.f4235	http://dx.doi.org/10.1136/bmj.f4235			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	197BM	23913693				2023-01-03	WOS:000322822800001
J	Chowdhury, S; Pradhan, RN; Sarkar, RR				Chowdhury, Saikat; Pradhan, Rachana N.; Sarkar, Ram Rup			Structural and Logical Analysis of a Comprehensive Hedgehog Signaling Pathway to Identify Alternative Drug Targets for Glioma, Colon and Pancreatic Cancer	PLOS ONE			English	Article							K-RAS MUTATION; SONIC-HEDGEHOG; EXPRESSION; INHIBITION; GROWTH; GENES; CELLS; PROLIFERATION; AMPLIFICATION; GLI1	Hedgehog is an evolutionarily conserved developmental pathway, widely implicated in controlling various cellular responses such as cellular proliferation and stem cell renewal in human and other organisms, through external stimuli. Aberrant activation of this pathway in human adult stem cell line may cause different types of cancers. Hence, targeting this pathway in cancer therapy has become indispensable, but the non availability of detailed molecular interactions, complex regulations by extra- and intra-cellular proteins and cross talks with other pathways pose a serious challenge to get a coherent understanding of this signaling pathway for making therapeutic strategy. This motivated us to perform a computational study of the pathway and to identify probable drug targets. In this work, from available databases and literature, we reconstructed a complete hedgehog pathway which reports the largest number of molecules and interactions to date. Using recently developed computational techniques, we further performed structural and logical analysis of this pathway. In structural analysis, the connectivity and centrality parameters were calculated to identify the important proteins from the network. To capture the regulations of the molecules, we developed a master Boolean model of all the interactions between the proteins and created different cancer scenarios, such as Glioma, Colon and Pancreatic. We performed perturbation analysis on these cancer conditions to identify the important and minimal combinations of proteins that can be used as drug targets. From our study we observed the under expressions of various oncoproteins in Hedgehog pathway while perturbing at a time the combinations of the proteins GLI1, GLI2 and SMO in Glioma; SMO, HFU, ULK3 and RAS in Colon cancer; SMO, HFU, ULK3, RAS and ERK12 in Pancreatic cancer. This reconstructed Hedgehog signaling pathway and the computational analysis for identifying new combinatory drug targets will be useful for future in-vitro and in-vivo analysis to control different cancers.	[Chowdhury, Saikat; Pradhan, Rachana N.; Sarkar, Ram Rup] CSIR Natl Chem Lab, Pune, Maharashtra, India	Council of Scientific & Industrial Research (CSIR) - India; CSIR - National Chemical Laboratory (NCL)	Sarkar, RR (corresponding author), CSIR Natl Chem Lab, Pune, Maharashtra, India.	rr.sarkar@ncl.res.in	CHOWDHURY, SAIKAT/X-9949-2019; Pradhan, Rachana/M-1374-2019	CHOWDHURY, SAIKAT/0000-0002-0783-3959; Pradhan, Rachana/0000-0001-7352-8111; SARKAR, RAM RUP/0000-0001-7115-163X	Department of Biotechnology, Govt. of India [BT/PR13689/BID/07/363/2010]; CSIR-NCL [MLP026226]	Department of Biotechnology, Govt. of India(Department of Biotechnology (DBT) India); CSIR-NCL	The work is funded by the Department of Biotechnology, Govt. of India, Grant No. BT/PR13689/BID/07/363/2010 and partly by CSIR-NCL, MLP026226. The funding agency has no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Albert R, 2003, J THEOR BIOL, V223, P1, DOI 10.1016/S0022-5193(03)00035-3; Altaba AR, 2002, NAT REV CANCER, V2, P361, DOI 10.1038/nrc796; Altaba ARI, 2002, NAT REV NEUROSCI, V3, P24; Atwood SX, 2012, J CELL BIOL, V199, P193, DOI 10.1083/jcb.201207140; Bar EE, 2007, STEM CELLS, V25, P2524, DOI 10.1634/stemcells.2007-0166; Bastian M., 2009, INT AAAI C WEBL SOC; Batagelj V, 2004, MATH VIS, P77; Beachy PA, 2012, European Patent Application, Patent No. [EP2404602, 2404602]; Berman DM, 2002, SCIENCE, V297, P1559, DOI 10.1126/science.1073733; Bian YH, 2007, WORLD J GASTROENTERO, V13, P1659, DOI 10.3748/wjg.v13.i11.1659; BOS JL, 1989, CANCER RES, V49, P4682; Buschges R, 1999, BRAIN PATHOL, V9, P435; Chakravarti A, 2001, CLIN CANCER RES, V7, P2387; Chuang PT, 2003, GENE DEV, V17, P342, DOI 10.1101/gad.1026303; Clement V, 2007, CURR BIOL, V17, P165, DOI 10.1016/j.cub.2006.11.033; Costenbader E, 2003, SOC NETWORKS, V25, P283, DOI 10.1016/S0378-8733(03)00012-1; Csardi G., 2006, INTERJ COMPLEX SYST, V1695, P1; Dai P, 2002, GENE DEV, V16, P2843, DOI 10.1101/gad.1017302; Di Marcotullio L, 2006, NAT CELL BIOL, V8, P1415, DOI 10.1038/ncb1510; Dillon R, 2003, P NATL ACAD SCI USA, V100, P10152, DOI 10.1073/pnas.1830500100; Ding H, 2001, CANCER RES, V61, P3826; Dockendorff C, 2012, ACS MED CHEM LETT, V3, P808, DOI 10.1021/ml300172p; Douard R, 2006, SURGERY, V139, P665, DOI 10.1016/j.surg.2005.10.012; Downward J, 2003, NAT REV CANCER, V3, P11, DOI 10.1038/nrc969; Elias MC, 2005, NEOPLASIA, V7, P824, DOI 10.1593/neo.04352; Evangelista M, 2006, CLIN CANCER RES, V12, P5924, DOI 10.1158/1078-0432.CCR-06-1736; Fan L, 2004, ENDOCRINOLOGY, V145, P3961, DOI 10.1210/en.2004-0079; Feldmann G, 2007, CANCER RES, V67, P2187, DOI 10.1158/0008-5472.CAN-06-3281; Funahashi Akira, 2003, Biosilico, V1, P159, DOI 10.1016/S1478-5382(03)02370-9; Galimberti F, 2012, INT J ONCOL, V41, P1751, DOI 10.3892/ijo.2012.1599; Godlewski J, 2008, CANCER RES, V68, P9125, DOI 10.1158/0008-5472.CAN-08-2629; Gysin S, 2005, CANCER RES, V65, P4870, DOI 10.1158/0008-5472.CAN-04-2848; Han SP, 2011, CELL MOL NEUROBIOL, V31, P489, DOI 10.1007/s10571-010-9643-4; Hornberg JJ, 2006, BIOSYSTEMS, V83, P81, DOI 10.1016/j.biosystems.2005.05.014; Hornik K, 2012, R FAQ; Hsieh A, 2011, J CELL PHYSIOL, V226, P1118, DOI 10.1002/jcp.22433; Jensen JB, 2002, DIGRAPHS THEORY ALGO, P2; Ji ZY, 2007, J BIOL CHEM, V282, P14048, DOI 10.1074/jbc.M611089200; Jiang J, 2008, DEV CELL, V15, P801, DOI 10.1016/j.devcel.2008.11.010; Joensuu H, 2005, J PATHOL, V207, P224, DOI 10.1002/path.1823; Kaesler S, 2000, BIOL CHEM, V381, P545, DOI 10.1515/BC.2000.070; Kasper M, 2006, EUR J CANCER, V42, P437, DOI 10.1016/j.ejca.2005.08.039; Kasper M, 2006, MOL CELL BIOL, V26, P6283, DOI 10.1128/MCB.02317-05; Katoh M, 2007, STEM CELL REV, V3, P30, DOI 10.1007/s12015-007-0006-6; Katoh Y, 2005, CANCER BIOL THER, V4, P1050, DOI 10.4161/cbt.4.10.2184; Katoh Y, 2006, INT J MOL MED, V18, P1019; Kawahira H, 2003, DEVELOPMENT, V130, P4871, DOI 10.1242/dev.00653; Kayed H, 2004, INT J CANCER, V110, P668, DOI 10.1002/ijc.20194; Kelleher FC, 2012, PHARMACOL THERAPEUT, V136, P153, DOI 10.1016/j.pharmthera.2012.08.004; Kitano H, 2005, NAT BIOTECHNOL, V23, P961, DOI 10.1038/nbt1111; Klamt S, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-56; Klamt S, 2007, BMC SYST BIOL, V1, DOI 10.1186/1752-0509-1-2; Klamt S, 2011, BIOSYSTEMS, V105, P162, DOI 10.1016/j.biosystems.2011.02.002; Kloog Y, 2000, MOL MED TODAY, V6, P398, DOI 10.1016/S1357-4310(00)01789-5; Li YW, 2012, EXPERT OPIN THER TAR, V16, P49, DOI 10.1517/14728222.2011.617367; Lindstrom E, 2006, HUM MUTAT, V27, P215, DOI 10.1002/humu.20296; Liu MG, 2006, CANCER RES, V66, P3593, DOI 10.1158/0008-5472.CAN-05-2912; Lo HW, 2009, CANCER RES, V69, P6790, DOI 10.1158/0008-5472.CAN-09-0886; Lum L, 2003, MOL CELL, V12, P1261, DOI 10.1016/S1097-2765(03)00426-X; Maloverjan A, 2010, EXP CELL RES, V316, P627, DOI 10.1016/j.yexcr.2009.10.018; Mao JH, 2002, J BIOL CHEM, V277, P35156, DOI 10.1074/jbc.M206743200; Mazumdar T, 2011, ONCOTARGET, V2, P638; McMillan R, 2012, CLIN CANCER RES, V18, P4883, DOI 10.1158/1078-0432.CCR-11-2509; Morris MK, 2010, BIOCHEMISTRY-US, V49, P3216, DOI 10.1021/bi902202q; Murone M, 2000, NAT CELL BIOL, V2, P310, DOI 10.1038/35010610; Newman MEJ, 2004, PHYS REV E, V70, DOI [10.1103/PhysRevE.70.056131, 10.1103/PhysRevE.69.026113]; Ozgur A, 2008, BIOINFORMATICS, V24, pI277, DOI 10.1093/bioinformatics/btn182; Ogden SK, 2004, BIOCHEM PHARMACOL, V67, P805, DOI 10.1016/j.bcp.2004.01.002; Olive KP, 2012, United States Patent Application Publication, Patent No. [US 2012/0020876 A1, 20120020876]; Osterlund T, 2006, TRENDS CELL BIOL, V16, P176, DOI 10.1016/j.tcb.2006.02.004; Parkinson H, 2011, NUCLEIC ACIDS RES, V39, pD1002, DOI 10.1093/nar/gkq1040; Pei HD, 2009, CANCER CELL, V16, P259, DOI 10.1016/j.ccr.2009.07.016; Qualtrough D, 2004, INT J CANCER, V110, P831, DOI 10.1002/ijc.20227; Regl G, 2004, CANCER RES, V64, P7724, DOI 10.1158/0008-5472.CAN-04-1085; Reichrath S, 2010, J STEROID BIOCHEM, V121, P420, DOI 10.1016/j.jsbmb.2010.02.028; Rohatgi R, 2007, NAT CELL BIOL, V9, P1005, DOI 10.1038/ncb435; Roth W, 2000, ONCOGENE, V19, P4210, DOI 10.1038/sj.onc.1203783; Rubin LL, 2006, NAT REV DRUG DISCOV, V5, P1026, DOI 10.1038/nrd2086; Rudin CM, 2009, NEW ENGL J MED, V361, P1173, DOI 10.1056/NEJMoa0902903; Saha K, 2006, DEVELOPMENT, V133, P889, DOI 10.1242/dev.02254; SAITOH Y, 1995, LAB INVEST, V72, P55; Samaga R, 2009, PLOS COMPUT BIOL, V5, DOI 10.1371/journal.pcbi.1000438; Sheriff M. Rahuman, 2008, Proceedings of the Indian National Science Academy, V74, P187; Shimoyama A, 2007, MOL BIOL CELL, V18, P2411, DOI 10.1091/mbc.E06-08-0743; Subramanian K, 2009, CHECKLIST ODONATA IN, P1; Sun LX, 2006, CANCER CELL, V9, P287, DOI 10.1016/j.ccr.2006.03.003; Tai CJ, 2012, POL J PATHOL, V63, P93; TANAKA M, 1994, J SURG ONCOL, V57, P57, DOI 10.1002/jso.2930570115; Tenzen T, 2006, DEV CELL, V10, P647, DOI 10.1016/j.devcel.2006.04.004; Thayer SP, 2003, NATURE, V425, P851, DOI 10.1038/nature02009; TRENT J, 1986, P NATL ACAD SCI USA, V83, P470, DOI 10.1073/pnas.83.2.470; Varjosalo M, 2007, J CELL SCI, V120, P3, DOI 10.1242/jcs.03309; Varnat F, 2009, EMBO MOL MED, V1, P338, DOI 10.1002/emmm.200900039; Villavicencio EH, 2002, GENESIS, V32, P247, DOI 10.1002/gene.10078; Wagner A, 2001, P ROY SOC B-BIOL SCI, V268, P1803, DOI 10.1098/rspb.2001.1711; Wuchty Stefan, 2006, P165; Xie JW, 2011, HEDGEHOG SIGNALING ACTIVATION IN HUMAN CANCER AND ITS CLINICAL IMPLICATIONS, P85, DOI 10.1007/978-1-4419-8435-7_7; Xu XL, 2012, ENDOCR-RELAT CANCER, V19, P167, DOI 10.1530/ERC-11-0305; Zhang X, 2005, J CLIN NEUROSCI, V12, P166, DOI 10.1016/j.jocn.2004.03.036	99	14	14	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 23	2013	8	7							e69132	10.1371/journal.pone.0069132	http://dx.doi.org/10.1371/journal.pone.0069132			24	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	228SX	23935937	Green Published, Green Submitted, gold			2023-01-03	WOS:000325211000079
J	Vlastos, D; Mademtzoglou, D; Drosopoulou, E; Efthimiou, I; Chartomatsidou, T; Pandelidou, C; Astyrakaki, M; Chalatsi, E; Mavragani-Tsipidou, P				Vlastos, Dimitris; Mademtzoglou, Despoina; Drosopoulou, Elena; Efthimiou, Ioanna; Chartomatsidou, Tatiana; Pandelidou, Christina; Astyrakaki, Melina; Chalatsi, Eleftheria; Mavragani-Tsipidou, Penelope			Evaluation of the Genotoxic and Antigenotoxic Effects of Chios Mastic Water by the In Vitro Micronucleus Test on Human Lymphocytes and the In Vivo Wing Somatic Test on Drosophila	PLOS ONE			English	Article							PISTACIA-LENTISCUS; ESSENTIAL OIL; MITOMYCIN-C; ANTIMICROBIAL ACTIVITY; ANTIOXIDANT ACTIVITIES; ANTIINFLAMMATORY ACTIVITY; CHEMICAL-COMPOSITION; RECOMBINATION TEST; SAMPLE-SIZE; SPOT-TEST	Chios mastic gum, a plant-derived product obtained by the Mediterranean bush Pistacia lentiscus (L.) var. chia (Duham), has generated considerable interest because of its antimicrobial, anticancer, antioxidant and other beneficial properties. Its aqueous extract, called Chios mastic water (CMW), contains the authentic mastic scent and all the water soluble components of mastic. In the present study, the potential genotoxic activity of CMW, as well as its antigenotoxic properties against the mutagenic agent mitomycin-C (MMC), was evaluated by employing the in vitro Cytokinesis Block MicroNucleus (CBMN) assay and the in vivo Somatic Mutation And Recombination Test (SMART). In the former assay, lymphocytes were treated with 1, 2 and 5% (v/v) of CMW with or without MMC at concentrations 0.05 and 0.50 mu g/ml. No significant micronucleus induction was observed by CMW, while co-treatment with MMC led to a decrease of the MMC-induced micronuclei, which ranged between 22.8 and 44.7%. For SMART, larvae were treated with 50 and 100% (v/v) CMW with or without MMC at concentrations 1.00, 2.50 and 5.00 mg/ml. It was shown that CMW alone did not modify the spontaneous frequencies of spots indicating lack of genotoxic activity. The simultaneous administration of MMC with 100% CMW led to considerable alterations of the frequencies of MMC-induced wing spots with the total mutant clones showing reduction between 53.5 and 74.4%. Our data clearly show a protective role of CMW against the MMC-induced genotoxicity and further research on the beneficial properties of this product is suggested.	[Mademtzoglou, Despoina; Drosopoulou, Elena; Chartomatsidou, Tatiana; Pandelidou, Christina; Astyrakaki, Melina; Chalatsi, Eleftheria; Mavragani-Tsipidou, Penelope] Aristotle Univ Thessaloniki, Dept Genet Dev & Mol Biol, GR-54006 Thessaloniki, Greece; [Vlastos, Dimitris; Efthimiou, Ioanna] Univ Patras, Dept Environm & Nat Resources Management, Agrinion, Greece	Aristotle University of Thessaloniki; University of Patras	Mavragani-Tsipidou, P (corresponding author), Aristotle Univ Thessaloniki, Dept Genet Dev & Mol Biol, GR-54006 Thessaloniki, Greece.	mavragan@bio.auth.gr	DROSOPOULOU, ELENA/N-2176-2015; Drosopoulou, Elena/AAX-6493-2020; Vlastos, Dimitris/GSD-9592-2022	Drosopoulou, Elena/0000-0001-9805-0572; Vlastos, Dimitris/0000-0002-3157-7529; MADEMTZOGLOU, Despoina/0000-0002-4494-7234	Aristotle University of Thessaloniki; University of Western Greece	Aristotle University of Thessaloniki; University of Western Greece	This work was supported by intramural funds of the Aristotle University of Thessaloniki to PM-T and of the University of Western Greece to DV. Chios mastic water used in the present study was supplied by the Chios Mastiha Growers' Association. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abdelwahed A, 2009, FOOD SCI TECHNOL INT, V15, P215, DOI 10.1177/1082013208339705; Abdelwahed A, 2007, CHEM-BIOL INTERACT, V165, P1, DOI 10.1016/j.cbi.2006.10.003; ABRAHAM SK, 1994, MUTAGENESIS, V9, P383, DOI 10.1093/mutage/9.4.383; Abraham SK, 1999, FOOD CHEM TOXICOL, V37, P733, DOI 10.1016/S0278-6915(99)00053-8; Al-Zubairi AS, 2010, TOXICOL IN VITRO, V24, P707, DOI 10.1016/j.tiv.2010.01.011; ALHABBAL MJ, 1984, CLIN EXP PHARMACOL P, V11, P541, DOI 10.1111/j.1440-1681.1984.tb00864.x; ALSAID MS, 1986, J ETHNOPHARMACOL, V15, P271, DOI 10.1016/0378-8741(86)90165-0; de Rezende AAA, 2013, FOOD CHEM TOXICOL, V55, P645, DOI 10.1016/j.fct.2013.01.050; Apidianakis Y, 2011, DIS MODEL MECH, V4, P21, DOI 10.1242/dmm.003970; Assimopoulou AN, 2005, FOOD CHEM, V92, P721, DOI 10.1016/j.foodchem.2004.08.033; Bakkali F, 2008, FOOD CHEM TOXICOL, V46, P446, DOI 10.1016/j.fct.2007.09.106; Balan KV, 2007, PHYTOMEDICINE, V14, P263, DOI 10.1016/j.phymed.2006.03.009; Banfi S, 1996, NAT GENET, V13, P167, DOI 10.1038/ng0696-167; BESTMANN HJ, 1988, J APPL ENTOMOL, V106, P144, DOI 10.1111/j.1439-0418.1988.tb00577.x; Bonassi S, 2011, MUTAGENESIS, V26, P93, DOI 10.1093/mutage/geq075; Chan NLS, 2006, TOXICOL APPL PHARM, V213, P98, DOI 10.1016/j.taap.2005.10.002; Clare G, 2006, MUTAT RES, V607, P37, DOI DOI 10.1016/J.MRGENTOX.2006.04.001; Dabos KJ, 2010, J ETHNOPHARMACOL, V127, P205, DOI 10.1016/j.jep.2009.11.021; De Flora S, 2007, MUTAT RES-FUND MOL M, V621, P5, DOI 10.1016/j.mrfmmm.2006.12.008; de Rezende AAA, 2011, FOOD CHEM TOXICOL, V49, P1235, DOI 10.1016/j.fct.2011.03.001; Dedoussis GVZ, 2004, ATHEROSCLEROSIS, V174, P293, DOI 10.1016/j.atherosclerosis.2004.02.011; DEFLORA S, 1988, MUTAT RES, V202, P285, DOI 10.1016/0027-5107(88)90193-5; Demsia G, 2007, MUTAT RES-GEN TOX EN, V634, P32, DOI 10.1016/j.mrgentox.2007.05.018; Doi K, 2009, TOXICOL APPL PHARM, V234, P135, DOI 10.1016/j.taap.2008.10.001; DOUKAS C, 2003, CHEM CHRON, V12, P36; Erickson RP, 2010, MUTAT RES-REV MUTAT, V705, P96, DOI 10.1016/j.mrrev.2010.04.002; Fenech M, 1997, MUTAT RES-GEN TOX EN, V392, P11, DOI 10.1016/S0165-1218(97)00041-4; Fenech M, 2003, MUTAT RES-GEN TOX EN, V534, P65, DOI 10.1016/S1383-5718(02)00249-8; Frank SA, 2010, P NATL ACAD SCI USA, V107, P1725, DOI 10.1073/pnas.0909343106; Franzios G, 1997, J AGR FOOD CHEM, V45, P2690, DOI 10.1021/jf960685f; FREI H, 1995, MUTAT RES-ENVIR MUTA, V334, P247, DOI 10.1016/0165-1161(95)90018-7; FREI H, 1988, MUTAT RES, V203, P297, DOI 10.1016/0165-1161(88)90019-2; Garozzo A, 2009, LETT APPL MICROBIOL, V49, P806, DOI 10.1111/j.1472-765X.2009.02740.x; Giaginis C, 2011, NUTR CANCER, V63, P1174, DOI 10.1080/01635581.2011.607546; GRAF U, 1984, ENVIRON MUTAGEN, V6, P153, DOI 10.1002/em.2860060206; He ML, 2007, ACTA PHARMACOL SIN, V28, P446, DOI 10.1111/j.1745-7254.2007.00536.x; He ML, 2006, CANCER-AM CANCER SOC, V106, P2547, DOI 10.1002/cncr.21935; HODNICK WF, 1993, CANCER RES, V53, P4907; Huang XY, 2010, ACTA PHARMACOL SIN, V31, P741, DOI 10.1038/aps.2010.54; Iauk L, 1996, J CHEMOTHERAPY, V8, P207, DOI 10.1179/joc.1996.8.3.207; Jones S, 2008, P NATL ACAD SCI USA, V105, P4283, DOI 10.1073/pnas.0712345105; Kaliora AC, 2007, WORLD J GASTROENTERO, V13, P6031, DOI 10.3748/wjg.13.6031; Kang JS, 2007, FOOD CHEM TOXICOL, V45, P494, DOI 10.1016/j.fct.2006.09.013; KASTENBAUM MA, 1970, MUTAT RES, V9, P527, DOI 10.1016/0027-5107(70)90038-2; Kato FH, 2012, MUTAT RES-GEN TOX EN, V749, P87, DOI 10.1016/j.mrgentox.2012.09.001; Kaya B, 2002, MUTAT RES-GEN TOX EN, V520, P93, DOI 10.1016/S1383-5718(02)00173-0; Kim HJ, 2009, ARCH PHARM RES, V32, P997, DOI 10.1007/s12272-009-1704-1; Kim SI, 2011, J ASIA-PAC ENTOMOL, V14, P509, DOI 10.1016/j.aspen.2011.07.001; Kirsch-Volders M, 2011, MUTAGENESIS, V26, P177, DOI 10.1093/mutage/geq068; Kounatidis I, 2012, OPEN BIOL, V2, DOI 10.1098/rsob.120075; Koutsoudaki C, 2005, J AGR FOOD CHEM, V53, P7681, DOI 10.1021/jf050639s; Lehmann M, 2000, ENVIRON MOL MUTAGEN, V36, P195, DOI 10.1002/1098-2280(2000)36:3<195::AID-EM2>3.0.CO;2-B; Lindsley D.L., 1992, GENOME DROSOPHILA ME; Loizzo MR, 2008, CELL PROLIFERAT, V41, P1002, DOI 10.1111/j.1365-2184.2008.00561.x; Lorge E, 2006, MUTAT RES-GEN TOX EN, V607, P13, DOI 10.1016/j.mrgentox.2006.04.006; Loutrari H, 2006, NUTR CANCER, V55, P86, DOI 10.1207/s15327914nc5501_11; Mademtzoglou D, 2011, FLAVOUR FRAG J, V26, P447, DOI 10.1002/ffj.2081; Magiatis P, 1999, PLANTA MED, V65, P749, DOI 10.1055/s-2006-960856; Magkouta S, 2009, NUTR CANCER, V61, P640, DOI 10.1080/01635580902825647; Mahmoudi M, 2010, EUR REV MED PHARMACO, V14, P765; MAREC F, 1994, MUTAT RES-FUND MOL M, V311, P305, DOI 10.1016/0027-5107(94)90189-9; Margaris N.S., 1981, MEDITERRANEAN TYPE S, P239; MARGOLIN BH, 1983, ENVIRON MUTAGEN, V5, P705, DOI 10.1002/em.2860050509; Mazumdar M, 2011, MUTAT RES-GEN TOX EN, V721, P147, DOI 10.1016/j.mrgentox.2011.01.007; Mills J. S., 1977, STUD CONSERV, V22, P12, DOI [10.2307/1505670, DOI 10.2307/1505670]; Mitic-Culafic D, 2009, FOOD CHEM TOXICOL, V47, P260, DOI 10.1016/j.fct.2008.11.015; Nibret E, 2010, PHYTOMEDICINE, V17, P911, DOI 10.1016/j.phymed.2010.02.009; Niikawa M, 2007, BIOMED PHARMACOTHER, V61, P113, DOI 10.1016/j.biopha.2006.07.094; PAPAPAULOU P, 2001, FRESEN ENVIRON BULL, V10, P421; Paraschos S, 2012, CURR MED CHEM, V19, P2292; Paraschos S, 2011, FOOD CHEM, V129, P907, DOI 10.1016/j.foodchem.2011.05.043; Reiter LT, 2001, GENOME RES, V11, P1114, DOI 10.1101/gr.169101; Resende FA, 2011, MUTAT RES, V700, P62; SELBY PB, 1981, MUTAT RES, V83, P403, DOI 10.1016/0027-5107(81)90022-1; SENGSTAG C, 1994, CRIT REV TOXICOL, V24, P323, DOI 10.3109/10408449409017922; Serpico M, 2000, RESINS AMBER BITUMEN; Slamenova D, 2009, MUTAT RES-GEN TOX EN, V677, P46, DOI 10.1016/j.mrgentox.2009.05.016; Speit G, 2012, MUTAGENESIS, V27, P743, DOI 10.1093/mutage/ges041; SURRALLES J, 1992, MUTAGENESIS, V7, P407, DOI 10.1093/mutage/7.6.407; SURRALLES J, 1995, MUTAT RES-GENET TOX, V341, P169, DOI 10.1016/0165-1218(95)90007-1; Takahashi K, 2003, J PERIODONTOL, V74, P501, DOI 10.1902/jop.2003.74.4.501; Tassou CC, 1995, INT BIODETER BIODEGR, V36, P411, DOI 10.1016/0964-8305(95)00103-4; Tomasz M, 1997, PHARMACOL THERAPEUT, V76, P73, DOI 10.1016/S0163-7258(97)00088-0; Triantafyllou A, 2011, NUTR J, V10, DOI 10.1186/1475-2891-10-64; Triantafyllou A, 2007, J ETHNOPHARMACOL, V111, P43, DOI 10.1016/j.jep.2006.10.031; Turkez H, 2012, CYTOTECHNOLOGY, V64, P679, DOI 10.1007/s10616-012-9447-0; Vallianou I, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020516; Vlastos D, 1998, ARCH DERMATOL RES, V290, P312, DOI 10.1007/s004030050310; Zhou L, 2009, IN VIVO, V23, P583	89	13	13	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 23	2013	8	7							e69494	10.1371/journal.pone.0069494	http://dx.doi.org/10.1371/journal.pone.0069494			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	228SX	23936030	Green Published, Green Submitted, gold			2023-01-03	WOS:000325211000128
J	Shantha, GPS; Kumar, AA; Kahan, S; Irukulla, PK; Cheskin, LJ				Shantha, Ghanshyam Palamaner Subash; Kumar, Anita Ashok; Kahan, Scott; Irukulla, Pavan Kumar; Cheskin, Lawrence Jay			Triglyceride/HDL Ratio as a Screening Tool for Predicting Success at Reducing Anti-Diabetic Medications Following Weight Loss	PLOS ONE			English	Article							DENSITY LIPOPROTEIN CHOLESTEROL; OBESITY; PREVALENCE	Background and Objectives: Intentional weight loss, by reducing insulin resistance, results in both better glycemic control and decreased need for anti-diabetic medications. However, not everyone who is successful with weight loss is able to reduce anti-diabetic medication use. In this retrospective cohort study, we assessed the predictive accuracy of baseline triglyceride (TGL)/HDL ratio, a marker of insulin resistance, to screen patients for success in reducing anti-diabetic medication use with weight loss. Methods: Case records of 121 overweight and obese attendees at two outpatient weight management centers were analyzed. The weight loss intervention consisted of a calorie-restricted diet (similar to 1000Kcal/day deficit), a behavior modification plan, and a plan for increasing physical activity. Results: Mean period of follow-up was 12.5 +/- 3.5 months. By study exit, mean weight loss and mean HbA1c% reduction were 15.4 +/- 5.5 kgs and 0.5 +/- 0.2% respectively. 81 (67%) in the study cohort achieved at least 1 dose reduction of any anti-diabetic medication. Tests for predictive accuracy of baseline TGL/HDL ratio <= 3 to determine success with dose reductions of anti-diabetic medications showed a sensitivity, specificity, positive predictive value, negative predictive value, area under the curve, likelihood ratio (LR) + and LR-of 81, 83, 90, 70, 78, 4.8 and 0.2, respectively. Reproducibility of TGL/HDL ratio was acceptable. Conclusion: TGL/HDL ratio shows promise as an effective screening tool to determine success with dose reductions of anti-diabetic medications. The results of our study may inform the conduct of a systematic review using data from prior weight loss trials.	[Shantha, Ghanshyam Palamaner Subash; Kumar, Anita Ashok] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA; [Shantha, Ghanshyam Palamaner Subash; Irukulla, Pavan Kumar] Wright Ctr Grad Med Educ, Dept Internal Med, Scranton, PA USA; [Kahan, Scott] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Hlth Policy, Baltimore, MD USA; [Cheskin, Lawrence Jay] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Hlth Behav & Soc, Baltimore, MD USA; [Kahan, Scott] George Washington Univ, Sch Publ Hlth & Hlth Serv, Dept Hlth Policy, Washington, DC USA; [Kahan, Scott; Cheskin, Lawrence Jay] Johns Hopkins Univ, Johns Hopkins Weight Management Ctr, Baltimore, MD USA	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; George Washington University; Johns Hopkins University	Cheskin, LJ (corresponding author), Johns Hopkins Bloomberg Sch Publ Hlth, Dept Hlth Behav & Soc, Baltimore, MD USA.	lcheskin@jhsph.edu	Cheskin, Lawrence/AAM-1094-2021	Cheskin, Lawrence/0000-0003-0262-1030; Kahan, Scott/0000-0002-3080-0661				Appel LJ, 2011, NEW ENGL J MED, V365, P1959, DOI 10.1056/NEJMoa1108660; CHAVEZ AG, 2011, CIR CIR, V79, P126; Colditz GA, 1999, MED SCI SPORT EXER, V31, pS663, DOI 10.1097/00005768-199911001-00026; Espeland M, 2007, DIABETES CARE, V30, P1374; Flegal KM, 2012, JAMA-J AM MED ASSOC, V307, P491, DOI 10.1001/jama.2012.39; GREENBERG RS, 2005, MED EPIDEMIOLOGY, P112; GREENBERG RS, 2005, MED EPIDEMIOLOGY, P227; Grundy SM, 2011, AM J CARDIOL, V108, P40, DOI 10.1016/j.amjcard.2011.03.003; Hatmi Zinat Nadia, 2011, Acta Med Iran, V49, P730; Jeffrey SF, 2005, HARRISONS PRINCIPLES, V1, P422; Kumar AA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032395; Mokdad AH, 2003, JAMA-J AM MED ASSOC, V289, P76, DOI 10.1001/jama.289.1.76; Nicholls SJ, 2011, J AM COLL CARDIOL, V57, P153, DOI 10.1016/j.jacc.2010.06.055; RONDANELLI M, 2012, ENDOCRINE, P88542; Shantha GPS, 2012, DIABETES EDUCATOR, V38, P417, DOI 10.1177/0145721712443293; Soska V, 2012, CLIN BIOCHEM, V45, P96, DOI 10.1016/j.clinbiochem.2011.11.001; StataCorp, 2019, STATA STAT SOFTWARE; TOVAR JR, 2012, AM SURGEON, V78, P969; WEISS ICS, 2012, CLIN CHIM ACTA, P88542; Whelton PK, 1997, ARCH INTERN MED, V157, P657, DOI 10.1001/archinte.157.6.657	20	5	5	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 15	2013	8	7							e69285	10.1371/journal.pone.0069285	http://dx.doi.org/10.1371/journal.pone.0069285			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	200ZN	23869240	gold, Green Submitted, Green Published			2023-01-03	WOS:000323110600040
J	Lee, SS; Tsai, CH; Yu, CC; Chang, YC				Lee, Shiuan-Shinn; Tsai, Chung-Hung; Yu, Cheng-Chia; Chang, Yu-Chao			Elevated Snail Expression Mediates Tumor Progression in Areca Quid Chewing-Associated Oral Squamous Cell Carcinoma via Reactive Oxygen Species	PLOS ONE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; E-CADHERIN; OXIDATIVE STRESS; UP-REGULATION; CANCER; PHENOTYPE; ARECOLINE; REPRESSOR; SURVIVAL; KINASE	Background: Snail is an important transcription factor implicated in several tumor progression and can be induced by reactive oxygen species (ROS). Areca quid chewing is a major risk factor of oral squamous cell carcinoma (OSCC). Therefore, we hypothesize that the major areca nut alkaloid arecoline may induce Snail via ROS and involve in the pathogenesis of areca quid chewing-associated OSCC. Methodology/Principal Finding: Thirty-six OSCC and ten normal oral epithelium specimens were examined by immunohistochemistry and analyzed by the clinico-pathological profiles. Cytotoxicity, 2',7'-dichlorofluorescein diacetate assay, and western blot were used to investigate the effects of arecoline in human oral keratinocytes (HOKs) and oral epithelial cell line OECM-1 cells. In addition, antioxidants N-acetyl-L-cysteine (NAC), curcumin, and epigallocatechin-3 gallate (EGCG) were added to find the possible regulatory mechanisms. Initially, Snail expression was significantly higher in OSCC specimens (p < 0.05). Elevated Snail expression was associated with lymph node metastasis (p = 0.031) and poor differentiation (p = 0.017). Arecoline enhanced the generation of intracellular ROS at the concentration higher than 40 mu g/ml (p < 0.05). Arecoline was also found to induced Snail expression in a dose- and time-dependent manner (p < 0.05). Treatment with NAC, curcumin, and EGCG markedly inhibited arecoline induced Snail expression (p < 0.05). Conclusion/Significance:: Our results suggest that Snail overexpression in areca quid chewing-associated OSCC is associated with tumors differentiation and lymph node metastasis. Arecoline-upregulated Snail expression may be mediated by ROS generation. In addition, arecoline induced Snail expression was downregulated by NAC, curcumin, and EGCG.	[Lee, Shiuan-Shinn] Chung Shan Med Univ, Sch Publ Hlth, Taichung, Taiwan; [Tsai, Chung-Hung] Chung Shan Med Univ Hosp, Dept Pathol, Taichung, Taiwan; [Yu, Cheng-Chia] Chung Shan Med Univ, Sch Dent, Taichung, Taiwan; [Chang, Yu-Chao] Chung Shan Med Univ Hosp, Dept Dent, Taichung, Taiwan	Chung Shan Medical University; Chung Shan Medical University; Chung Shan Medical University Hospital; Chung Shan Medical University; Chung Shan Medical University; Chung Shan Medical University Hospital	Chang, YC (corresponding author), Chung Shan Med Univ Hosp, Dept Dent, Taichung, Taiwan.	cyc@csmu.edu.tw	Liaw, Yung Po/AAV-6746-2021		Taiwan National Science Council [NSC100-2632-B-040-001-MY3]	Taiwan National Science Council(Ministry of Science and Technology, Taiwan)	This work was supported by research grants from a Taiwan National Science Council Research Grant (NSC100-2632-B-040-001-MY3). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ambrosone CB, 2000, ANTIOXID REDOX SIGN, V2, P903, DOI 10.1089/ars.2000.2.4-903; ARUOMA OI, 1989, FREE RADICAL BIO MED, V6, P593, DOI 10.1016/0891-5849(89)90066-X; Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Blechschmidt K, 2008, BRIT J CANCER, V98, P489, DOI 10.1038/sj.bjc.6604115; Chang Y C, 2001, Clin Oral Investig, V5, P51, DOI 10.1007/s007840000085; Chang YC, 1998, J ORAL PATHOL MED, V27, P68; Chen CL, 2002, J TOXICOL ENV HEAL A, V65, P327, DOI 10.1080/15287390252800909; Department of Health Executive Yuan Taiwan ROC, 2012, CANC REG ANN REP TAI; Fan F, 2012, CANCER MED-US, V1, P5, DOI 10.1002/cam4.4; Franz M, 2009, HISTOCHEM CELL BIOL, V131, P651, DOI 10.1007/s00418-009-0559-3; Gotzmann J, 2004, MUTAT RES-REV MUTAT, V566, P9, DOI 10.1016/S1383-5742(03)00033-4; Halliwell B, 2004, BRIT J PHARMACOL, V142, P231, DOI 10.1038/sj.bjp.0705776; He HY, 2012, CANCER SCI, V103, P1296, DOI 10.1111/j.1349-7006.2012.02295.x; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Klaunig JE, 1998, ENVIRON HEALTH PERSP, V106, P289, DOI 10.2307/3433929; KO YC, 1995, J ORAL PATHOL MED, V24, P450, DOI 10.1111/j.1600-0714.1995.tb01132.x; Korde SD, 2011, ONCOLOGY-BASEL, V80, P382, DOI 10.1159/000329811; Lee SS, 2012, ORAL DIS, V18, P713, DOI 10.1111/j.1601-0825.2012.01933.x; Lee SS, 2008, ORAL ONCOL, V44, P884, DOI 10.1016/j.oraloncology.2007.11.004; Lee SS, 2008, ORAL ONCOL, V44, P180, DOI 10.1016/j.oraloncology.2007.01.019; Lee SS, 2012, J ORAL PATHO MED, DOI [10.1111/jop. 12037, DOI 10.1111/J0P.12037]; Lee SS, 2012, J PERIODONTOL, DOI [10.1902/jop.2012.120554, DOI 10.1902/J0P.2012.120554]; Lin JK, 1999, BIOCHEM PHARMACOL, V58, P911, DOI 10.1016/S0006-2952(99)00112-4; Lundgren K, 2009, BRIT J CANCER, V101, P1769, DOI 10.1038/sj.bjc.6605369; Mendelsohn AH, 2012, AM J OTOLARYNG, V33, P6, DOI 10.1016/j.amjoto.2010.11.018; NAIR UJ, 1992, ENVIRON HEALTH PERSP, V98, P203, DOI 10.2307/3431271; Radisky DC, 2005, NATURE, V436, P123, DOI 10.1038/nature03688; Siegel R, 2012, CA-CANCER J CLIN, V62, P10, DOI 10.3322/caac.20138; Sreejayan, 1997, J PHARM PHARMACOL, V49, P105, DOI 10.1111/j.2042-7158.1997.tb06761.x; Warnakulasuriya S, 2009, ORAL ONCOL, V45, P309, DOI 10.1016/j.oraloncology.2008.06.002; Wu CL, 2012, AUST DENT J, V57, P207, DOI 10.1111/j.1834-7819.2012.01686.x; Wu WS, 2006, CANCER METAST REV, V25, P695, DOI 10.1007/s10555-006-9037-8; Yen CY, 2011, ORAL ONCOL, V47, P345, DOI 10.1016/j.oraloncology.2011.02.014; Zhao D, 2012, CLIN EXP METASTAS, V29, P957, DOI 10.1007/s10585-012-9485-1; Zhou BHP, 2004, NAT CELL BIOL, V6, P931, DOI 10.1038/ncb1173	35	21	21	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 10	2013	8	7							e67985	10.1371/journal.pone.0067985	http://dx.doi.org/10.1371/journal.pone.0067985			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	182SU	23874481	Green Published, Green Submitted, gold			2023-01-03	WOS:000321765300021
J	Lee, S; Ashizawa, AT; Kim, KS; Falk, DJ; Notterpek, L				Lee, Sooyeon; Ashizawa, Ana Tari; Kim, Kwang Sik; Falk, Darin J.; Notterpek, Lucia			Liposomes to Target Peripheral Neurons and Schwann Cells	PLOS ONE			English	Article							CAVEOLAE-MEDIATED ENDOCYTOSIS; CLATHRIN; TRANSPORT; PROTEIN; MICE	While a wealth of literature for tissue-specific liposomes is emerging, optimal formulations to target the cells of the peripheral nervous system (PNS) are lacking. In this study, we asked whether a novel formulation of phospholipid-based liposomes could be optimized for preferential uptake by microvascular endothelia, peripheral neurons and Schwann cells. Here, we report a unique formulation consisting of a phospholipid, a polymer surfactant and cholesterol that result in enhanced uptake by targeted cells. Using fluorescently labeled liposomes, we followed particle internalization and trafficking through a distinct route from dextran and escape from degradative compartments, such as lysosomes. In cultures of non-myelinating Schwann cells, liposomes associate with the lipid raft marker Cholera toxin, and their internalization is inhibited by disruption of lipid rafts or actin polymerization. In contrast, pharmacological inhibition of clathrin-mediated endocytosis does not significantly impact liposome entry. To evaluate the efficacy of liposome targeting in tissues, we utilized myelinating explant cultures of dorsal root ganglia and isolated diaphragm preparations, both of which contain peripheral neurons and myelinating Schwann cells. In these models, we detected preferential liposome uptake into neurons and glial cells in comparison to surrounding muscle tissue. Furthermore, in vivo liposome administration by intramuscular or intravenous injection confirmed that the particles were delivered to myelinated peripheral nerves. Within the CNS, we detected the liposomes in choroid epithelium, but not in myelinated white matter regions or in brain parenchyma. The described nanoparticles represent a novel neurophilic delivery vehicle for targeting small therapeutic compounds, biological molecules, or imaging reagents into peripheral neurons and Schwann cells, and provide a major advancement toward developing effective therapies for peripheral neuropathies.	[Lee, Sooyeon; Ashizawa, Ana Tari; Notterpek, Lucia] Univ Florida, Coll Med, Dept Neurosci, Gainesville, FL 32610 USA; [Notterpek, Lucia] Univ Florida, Coll Med, Dept Neurol, Gainesville, FL 32611 USA; [Kim, Kwang Sik] Johns Hopkins Childrens Ctr, Eudowood Div Pediat Infect Dis, Baltimore, MD USA; [Falk, Darin J.] Univ Florida, Coll Med, Dept Pediat, Gainesville, FL USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida; Johns Hopkins University; Johns Hopkins Medicine; State University System of Florida; University of Florida	Ashizawa, AT (corresponding author), Univ Florida, Coll Med, Dept Neurosci, Gainesville, FL 32610 USA.	anamtari@ufl.edu; notterpek@ufl.edu			University of Florida Research Opportunity Seed Fund; NIH [NS041012]; Trigeminal Neuralgia Association; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS041012] Funding Source: NIH RePORTER	University of Florida Research Opportunity Seed Fund(University of Florida); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Trigeminal Neuralgia Association; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	This work was supported by University of Florida Research Opportunity Seed Fund, NIH grant NS041012 and the Trigeminal Neuralgia Association. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Chekhonin VP, 2008, B EXP BIOL MED+, V146, P451, DOI 10.1007/s10517-009-0301-0; Chen G, 2012, GLIA, V60, P295, DOI 10.1002/glia.21263; Cheng ZL, 2012, SCIENCE, V338, P903, DOI 10.1126/science.1226338; Clayton EL, 2009, J NEUROSCI METH, V185, P76, DOI 10.1016/j.jneumeth.2009.09.016; DeCamilli P, 1996, NEURON, V16, P481, DOI 10.1016/S0896-6273(00)80068-9; Donaldson JG, 2009, CELL SIGNAL, V21, P1, DOI 10.1016/j.cellsig.2008.06.020; Feldmann A, 2011, J NEUROSCI, V31, P5659, DOI 10.1523/JNEUROSCI.6638-10.2011; Foerg C, 2005, BIOCHEMISTRY-US, V44, P72, DOI 10.1021/bi048330+; Frank PG, 2009, CELL TISSUE RES, V335, P41, DOI 10.1007/s00441-008-0659-8; Gelperina S, 2010, EUR J PHARM BIOPHARM, V74, P157, DOI 10.1016/j.ejpb.2009.09.003; Gutierrez-Puente Y, 2003, LEUKEMIA LYMPHOMA, V44, P1979, DOI 10.1080/1042819031000099733; Harris JR, 2010, CHOLRESTEROL MYELIN, P489; Hirling H, 2009, NEUROSCIENCE, V158, P36, DOI 10.1016/j.neuroscience.2008.02.057; Lin S, 2008, J NEUROSCI, V28, P3333, DOI 10.1523/JNEUROSCI.5590-07.2008; MERRITT EA, 1994, MOL MICROBIOL, V13, P745, DOI 10.1111/j.1365-2958.1994.tb00467.x; Mikol DD, 1999, GLIA, V27, P39; Notterpek L, 1999, NEUROBIOL DIS, V6, P450, DOI 10.1006/nbdi.1999.0274; Pelkmans L, 2002, TRAFFIC, V3, P311, DOI 10.1034/j.1600-0854.2002.30501.x; Rangaraju S, 2010, J NEUROSCI, V30, P11388, DOI 10.1523/JNEUROSCI.1356-10.2010; Rejman J, 2004, BIOCHEM J, V377, P159, DOI 10.1042/BJ20031253; Rejman J, 2006, J LIPOSOME RES, V16, P237, DOI 10.1080/08982100600848819; Sahay G, 2010, BIOMATERIALS, V31, P1757, DOI 10.1016/j.biomaterials.2009.11.020; Saheki Y, 2012, COLD SPRING HARBOR P, V4; Stins MF, 2001, MICROB PATHOGENESIS, V30, P19, DOI 10.1006/mpat.2000.0406; Tahara K, 2011, EUR J PHARM BIOPHARM, V77, P84, DOI 10.1016/j.ejpb.2010.11.002; Tari AM, 1999, ONCOGENE, V18, P1325, DOI 10.1038/sj.onc.1202422; Tari AM, 2007, INT J ONCOL, V31, P1243; Winterstein C, 2008, J CELL SCI, V121, P834, DOI 10.1242/jcs.022731; Yap CC, 2012, NEURON, V74, P440, DOI 10.1016/j.neuron.2012.04.015	29	18	19	0	31	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 11	2013	8	11							e78724	10.1371/journal.pone.0078724	http://dx.doi.org/10.1371/journal.pone.0078724			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	255EG	24244347	Green Submitted, gold, Green Published			2023-01-03	WOS:000327221600054
J	Khalki, L; M'hamed, SB; Sokar, Z; Bennis, M; Vinay, L; Bras, H; Viemari, JC				Khalki, Loubna; M'hamed, Saadia Ba; Sokar, Zahra; Bennis, Mohamed; Vinay, Laurent; Bras, Helene; Viemari, Jean-Charles			Prenatal Exposure to Fenugreek Impairs Sensorimotor Development and the Operation of Spinal Cord Networks in Mice	PLOS ONE			English	Article							KCL COTRANSPORTER KCC2; GRAECUM SEED POWDER; GAIT ANALYSIS; LUMBAR MOTONEURONS; RAT; LOCOMOTION; SEROTONIN; TRANSECTION; POTENTIALS; TISSUES	Fenugreek is a medicinal plant whose seeds are widely used in traditional medicine, mainly for its laxative, galactagogue and antidiabetic effects. However, consumption of fenugreek seeds during pregnancy has been associated with a range of congenital malformations, including hydrocephalus, anencephaly and spina bifida in humans. The present study was conducted to evaluate the effects of prenatal treatment of fenugreek seeds on the development of sensorimotor functions from birth to young adults. Pregnant mice were treated by gavage with 1g/kg/day of lyophilized fenugreek seeds aqueous extract (FSAE) or distilled water during the gestational period. Behavioral tests revealed in prenatally treated mice a significant delay in righting, cliff avoidance, negative geotaxis responses and the swimming development. In addition, extracellular recording of motor output in spinal cord isolated from neonatal mice showed that the frequency of spontaneous activity and fictive locomotion was reduced in FSAE-exposed mice. On the other hand, the cross-correlation coefficient in control mice was significantly more negative than in treated animals indicating that alternating patterns are deteriorated in FSAE-treated animals. At advanced age, prenatally treated mice displayed altered locomotor coordination in the rotarod test and also changes in static and dynamic parameters assessed by the CatWalk automated gait analysis system. We conclude that FSAE impairs sensorimotor and coordination functions not only in neonates but also in adult mice. Moreover, spinal neuronal networks are less excitable in prenatally FSAE-exposed mice suggesting that modifications within the central nervous system are responsible, at least in part, for the motor impairments.	[Khalki, Loubna; M'hamed, Saadia Ba; Sokar, Zahra; Bennis, Mohamed] Cadi Ayyad Univ, Ctr Natl Rech Sci & Tech URAC 37, Lab Pharmacol Neurobiol & Comportement, Marrakech, Morocco; [Khalki, Loubna; Vinay, Laurent; Bras, Helene; Viemari, Jean-Charles] Aix Marseille Univ, CNRS, Team P3M, Inst Neurosci Timone, Marseille, France	Cadi Ayyad University of Marrakech; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille	Viemari, JC (corresponding author), Aix Marseille Univ, CNRS, Team P3M, Inst Neurosci Timone, Marseille, France.	jean-charles.viemari@univ-amu.fr	Bras, Helene/L-8915-2018	Viemari, Jean-Charles/0000-0001-6614-1461; sokar, zahra/0000-0002-8646-4660	Groupement De Recherche International en Neuroscience GDRI-Neuro (CNRS/CNRST/INSERM); NEUROMED project	Groupement De Recherche International en Neuroscience GDRI-Neuro (CNRS/CNRST/INSERM); NEUROMED project	The authors acknowledge support from the Groupement De Recherche International en Neuroscience GDRI-Neuro (CNRS/CNRST/INSERM) and the NEUROMED project. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2005, GUIDANCE IND ESTIMAT; Aruga J, 1998, J NEUROSCI, V18, P284; ATSUTA Y, 1990, J NEUROPHYSIOL, V64, P727, DOI 10.1152/jn.1990.64.3.727; Bellakhdar J, 1997, EDITIONS FENNEC; BENARI Y, 1989, J PHYSIOL-LONDON, V416, P303, DOI 10.1113/jphysiol.1989.sp017762; Bin-Hafeez B, 2003, INT IMMUNOPHARMACOL, V3, P257, DOI 10.1016/S1567-5769(02)00292-8; Borodinsky LN, 2004, NATURE, V429, P523, DOI 10.1038/nature02518; Boulenguez P, 2010, NAT MED, V16, P302, DOI 10.1038/nm.2107; Brocard F, 1999, DEV BRAIN RES, V117, P81, DOI 10.1016/S0165-3806(99)00101-7; CAZALETS JR, 1990, BEHAV BRAIN RES, V40, P215, DOI 10.1016/0166-4328(90)90078-S; CAZALETS JR, 1992, J PHYSIOL-LONDON, V455, P187, DOI 10.1113/jphysiol.1992.sp019296; Cheng HR, 1997, EXP NEUROL, V148, P544, DOI 10.1006/exnr.1997.6708; Clarac F, 1998, BRAIN RES REV, V28, P35, DOI 10.1016/S0165-0173(98)00024-1; Deumens R, 2007, J NEUROSCI METH, V164, P120, DOI 10.1016/j.jneumeth.2007.04.009; Fellippa-Marques S, 2000, EUR J NEUROSCI, V12, P155, DOI 10.1046/j.1460-9568.2000.00895.x; FOX WM, 1965, ANIM BEHAV, V13, P234, DOI 10.1016/0003-3472(65)90041-2; Geisler Hildegard C., 1993, Acta Neurobiologiae Experimentalis (Warsaw), V53, P517; Hamers FPT, 2006, J NEUROTRAUM, V23, P537, DOI 10.1089/neu.2006.23.537; Hamers FPT, 2001, J NEUROTRAUM, V18, P187, DOI 10.1089/08977150150502613; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; Hanson MG, 2006, J NEUROSCI, V26, P12769, DOI 10.1523/JNEUROSCI.4170-06.2006; Huberman AD, 2006, NEURON, V52, P247, DOI 10.1016/j.neuron.2006.07.028; Jean-Xavier C, 2006, J NEUROPHYSIOL, V96, P2274, DOI 10.1152/jn.00328.2006; Jones TA, 2000, J NEUROPHYSIOL, V83, P1452, DOI 10.1152/jn.2000.83.3.1452; Jordan LM, 2008, BRAIN RES REV, V57, P183, DOI 10.1016/j.brainresrev.2007.07.019; KALLMAN, 1994, ASSESSMENT MOTORIC E, P103; KAMAL R, 1993, PHYTOTHER RES, V7, P134, DOI 10.1002/ptr.2650070208; Kassem A, 2006, CONTRACEPTION, V73, P301, DOI 10.1016/j.contraception.2005.08.020; Khalki L, 2012, J ETHNOPHARMACOL, V139, P672, DOI 10.1016/j.jep.2011.12.011; Khalki L, 2010, J ETHNOPHARMACOL, V131, P321, DOI 10.1016/j.jep.2010.06.033; Koopmans GC, 2007, PHYSIOL BEHAV, V92, P993, DOI 10.1016/j.physbeh.2007.07.018; Kumar P, 2012, EUR REV MED PHARMACO, V16, P18; Liu J, 2005, J NEUROPHYSIOL, V94, P1392, DOI 10.1152/jn.00136.2005; Myers CP, 2005, NEURON, V46, P37, DOI 10.1016/j.neuron.2005.02.022; Neumann M, 2009, J NEUROSCI METH, V176, P34, DOI 10.1016/j.jneumeth.2008.08.026; O'Donovan MJ, 1999, CURR OPIN NEUROBIOL, V9, P94, DOI 10.1016/S0959-4388(99)80012-9; Pearlstein E, 2005, EUR J NEUROSCI, V21, P1338, DOI 10.1111/j.1460-9568.2005.03971.x; Pflieger JF, 2002, J NEUROSCI, V22, P5108, DOI 10.1523/JNEUROSCI.22-12-05108.2002; Raju J, 2001, MOL CELL BIOCHEM, V224, P45, DOI 10.1023/A:1011974630828; REICHLING DB, 1994, J PHYSIOL-LONDON, V476, P411, DOI 10.1113/jphysiol.1994.sp020142; Sabiri N., 2013, J PEDIAT PUERICULT, V26, P198, DOI DOI 10.1016/J.JPP.2013.05.001; Sadlaoud K, 2010, J NEUROSCI, V30, P3358, DOI 10.1523/JNEUROSCI.6310-09.2010; Santillan ME, 2010, NUTRITION, V26, P423, DOI 10.1016/j.nut.2009.06.005; Secher T, 2006, NEUROSCIENCE, V141, P1289, DOI 10.1016/j.neuroscience.2006.04.059; Skalli S., 2006, B INFORM PHARMACOVIG, V3; Spitzer NC, 2006, NATURE, V444, P707, DOI 10.1038/nature05300; Spitzer NC, 2012, NAT REV NEUROSCI, V13, P94, DOI 10.1038/nrn3154; Stil A, 2011, EUR J NEUROSCI, V33, P1212, DOI 10.1111/j.1460-9568.2010.07592.x; Thakran S, 2004, MOL CELL BIOCHEM, V266, P151, DOI 10.1023/B:MCBI.0000049153.14295.0d; Vinay L, 2000, BRAIN RES BULL, V53, P635, DOI 10.1016/S0361-9230(00)00397-X; WESTERGA J, 1993, EARLY HUM DEV, V34, P89, DOI 10.1016/0378-3782(93)90044-U; Whelan P, 2000, J NEUROPHYSIOL, V84, P2821, DOI 10.1152/jn.2000.84.6.2821; Yakovenko S, 2005, J NEUROPHYSIOL, V94, P1057, DOI 10.1152/jn.00991.2004; Ziskind-Conhaim L, 1998, PERSPECT DEV NEUROBI, V5, P279	54	11	12	1	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 5	2013	8	11							e80013	10.1371/journal.pone.0080013	http://dx.doi.org/10.1371/journal.pone.0080013			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	247EE	24224030	Green Published, Green Submitted, gold			2023-01-03	WOS:000326597400103
J	Pielen, A; Feltgen, N; Isserstedt, C; Callizo, J; Junker, B; Schmucker, C				Pielen, Amelie; Feltgen, Nicolas; Isserstedt, Christin; Callizo, Josep; Junker, Bernd; Schmucker, Christine			Efficacy and Safety of Intravitreal Therapy in Macular Edema Due to Branch and Central Retinal Vein Occlusion: a Systematic Review	PLOS ONE			English	Review							VEGF-TRAP; TRIAMCINOLONE ACETONIDE; SUSTAINED BENEFITS; 12-MONTH OUTCOMES; STANDARD-CARE; BEVACIZUMAB; SECONDARY; RANIBIZUMAB; PEGAPTANIB; INJECTION	Background: Intravitreal agents have replaced observation in macular edema in central (CRVO) and grid laser photocoagulation in branch retinal vein occlusion (BRVO). We conducted a systematic review to evaluate efficacy and safety outcomes of intravitreal therapies for macular edema in CRVO and BRVO. Methods: And Findings: MEDLINE, Embase, and the Cochrane Library were systematically searched for RCTs with no limitations of language and year of publication. 11 RCTs investigating anti-VEGF agents (ranibizumab, bevacizumab, aflibercept) and steroids (triamcinolone, dexamethasone implant) with a minimum follow-up of 1 year were evaluated. Efficacy: CRVO: Greatest gain in visual acuity after 12 months was observed both under aflibercept 2 mg: +16.2 letters (8.5 injections), and under bevacizumab 1.25 mg: +16.1 letters (8 injections). Ranibizumab 0.5 mg improved vision by +13.9 letters (8.8 injections). Triamcinolone 1 mg and 4 mg stabilized visual acuity at a lower injection frequency (-1.2 letters, 2 injections). BRVO: Ranibizumab 0.5 mg resulted in a visual acuity gain of +18.3 letters (8.4 injections). The effect of dexamethasone implant was transient after 1.9 implants in both indications. Safety: Serious ocular adverse events were rare, e. g., endophthalmitis occurred in 0.0-0.9%. Major differences were found in an indirect comparison between steroids and anti-VEGF agents for cataract progression (19.8-35.0% vs. 0.9-7.0%) and in required treatment of increased intraocular pressure (7.0-41.0% vs. none). No major differences were identified in systemic adverse events. Conclusions: Anti-VEGF agents result in a promising gain of visual acuity, but require a high injection frequency. Dexamethasone implant might be an alternative, but comparison is impaired as the effect is temporary and it has not yet been tested in PRN regimen. The ocular risk profile seems to be favorable for anti-VEGF agents in comparison to steroids. Because comparative data from head-to-head trials are missing currently, clinicians and patients should carefully weigh the benefit-harm ratio.	[Pielen, Amelie; Junker, Bernd] Univ Freiburg, Univ Eye Hosp, D-79106 Freiburg, Germany; [Pielen, Amelie; Junker, Bernd] Hannover Med Sch, Univ Eye Hosp, Hannover, Germany; [Feltgen, Nicolas; Isserstedt, Christin; Callizo, Josep] Univ Gottingen, Univ Eye Hosp, D-37073 Gottingen, Germany; [Schmucker, Christine] Univ Med Ctr, German Cochrane Ctr, Inst Med Biometry & Med Informat, Dept Med Biometry & Stat, Freiburg, Germany	University of Freiburg; Hannover Medical School; University of Gottingen; University of Freiburg	Pielen, A (corresponding author), Univ Freiburg, Univ Eye Hosp, Hugstetter Str 55, D-79106 Freiburg, Germany.	amelie.pielen@uniklinik-freiburg.de		Pielen, Amelie/0000-0001-9401-2501; Schmucker, Christine/0000-0002-1188-3158	Bayer HealthCare; Novartis Pharma; GlaxoSmithKline; Pfizer; Alcon; Accovion; Genentech; Novartis	Bayer HealthCare(Bayer AGBayer Healthcare Pharmaceuticals); Novartis Pharma; GlaxoSmithKline(GlaxoSmithKline); Pfizer(Pfizer); Alcon(Novartis); Accovion; Genentech(Roche HoldingGenentech); Novartis(Novartis)	The authors have the following interests. Amelie Pielen is consultant for Allergan, Bayer HealthCare and Novartis Pharma, investigator in multicenter clinical trials sponsored by Bayer HealthCare, Novartis Pharma, GlaxoSmithKline, Pfizer, Alcon, Accovion and Genentech, received research grants from Novartis Pharma and travel grants from Bayer HealthCare. Nicolas Feltgen is consultant for Bayer, Novartis and Allergan, investigator in clinical trials sponsored by Bayer, Novartis and Allergan and received research and travel grants from Novartis. Josep Callizo is consultant for Bayer, Allergan and Novartis, investigator in clinical trials sponsored by Bayer, Allergan and Novartis and received travel grant from Novartis. Bernd Junker is investigator in multicenter clinical trials sponsored by Bayer HealthCare, Novartis Pharma, GlaxoSmithKline, Pfizer, Alcon, Accovion and Genentech and functioned as lecturer for Heidelberg Engeneering, Allergan and Novartis. This does not alter their adherence to all the PLOS ONE policies on sharing data and materials.	[Anonymous], 1984, AM J OPHTHALMOL, V98, P271; Boyer D, 2012, OPHTHALMOLOGY, V119, P1024, DOI 10.1016/j.ophtha.2012.01.042; Braithwaite T, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007325.pub2; Brown DM, 2013, AM J OPHTHALMOL, V155, P429, DOI 10.1016/j.ajo.2012.09.026; Brown DM, 2011, OPHTHALMOLOGY, V118, P1594, DOI 10.1016/j.ophtha.2011.02.022; Campochiaro PA, 2011, OPHTHALMOLOGY, V118, P2041, DOI 10.1016/j.ophtha.2011.02.038; Centre for Reviews and Dissemination, SYST REV ADV EFF SYS, P177; Chakravarthy U, 2006, OPHTHALMOLOGY, V113, P1508, DOI 10.1016/j.ophtha.2006.02.064; Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015; Chan CK, 2011, OPHTHALMOLOGY, V118, P1364, DOI 10.1016/j.ophtha.2010.11.020; Clarkson JC, 1997, ARCH OPHTHALMOL-CHIC, V115, P486; Cugati S, 2006, ARCH OPHTHALMOL-CHIC, V124, P726, DOI 10.1001/archopht.124.5.726; Donati S, 2012, EUR J OPHTHALMOL, V22, P607, DOI 10.5301/ejo.5000085; Epstein DL, 2012, OPHTHALMOLOGY, V119, P2587, DOI 10.1016/j.ophtha.2012.06.037; Epstein DLJ, 2012, OPHTHALMOLOGY, V119, P1184, DOI 10.1016/j.ophtha.2012.01.022; Haller JA, 2011, OPHTHALMOLOGY, V118, P2453, DOI 10.1016/j.ophtha.2011.05.014; Haller JA, 2010, OPHTHALMOLOGY, V117, P1134, DOI 10.1016/j.ophtha.2010.03.032; Heier JS, 2012, OPHTHALMOLOGY, V119, P802, DOI 10.1016/j.ophtha.2011.12.005; Holash J, 2002, P NATL ACAD SCI USA, V99, P11393, DOI 10.1073/pnas.172398299; Holz FG, 2013, BRIT J OPHTHALMOL, V97, P278, DOI 10.1136/bjophthalmol-2012-301504; Ip MS, 2009, OPHTHALMOLOGY, V116, P1770, DOI 10.1016/j.ophtha.2009.03.022; Ip MS, 2009, ARCH OPHTHALMOL-CHIC, V127, P1101, DOI 10.1001/archophthalmol.2009.234; Jain N, 2012, OPHTHALMOLOGY, V119, P132, DOI 10.1016/j.ophtha.2011.06.019; Jaissle GB, 2011, GRAEF ARCH CLIN EXP, V249, P183, DOI 10.1007/s00417-010-1470-2; Jonas JB, 2002, GRAEF ARCH CLIN EXP, V240, P782, DOI 10.1007/s00417-002-0529-0; Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069; Kondo M, 2009, RETINA-J RET VIT DIS, V29, P1242, DOI 10.1097/IAE.0b013e3181aa8e20; Kube T, 2006, GRAEF ARCH CLIN EXP, V244, P1385, DOI 10.1007/s00417-006-0326-2; Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053; Mitry D, 2013, COCHRANE DB SYST REV, V1, DOI [10.1002/14651858.CD009510.pub2, DOI 10.1002/14651858.CD009510.PUB2.PUBMED:23440840]; Moher D, 2009, PLOS MED, V6, DOI [10.1371/journal.pmed.1000097, 10.1136/bmj.b4037]; Ng EWM, 2006, NAT REV DRUG DISCOV, V5, P123, DOI 10.1038/nrd1955; Papadopoulos N, 2012, ANGIOGENESIS, V15, P171, DOI 10.1007/s10456-011-9249-6; Parodi MB, 2008, BRIT J OPHTHALMOL, V92, P1046, DOI 10.1136/bjo.2007.128025; Russo V, 2009, RETINA-J RET VIT DIS, V29, P511, DOI 10.1097/IAE.0b013e318195ca65; Schmucker C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042701; Schmucker C, 2010, CURR OPIN OPHTHALMOL, V21, P218, DOI 10.1097/ICU.0b013e3283386783; Scott IU, 2009, ARCH OPHTHALMOL-CHIC, V127, P1115, DOI 10.1001/archophthalmol.2009.233; Smiddy WE, 2011, OPHTHALMOLOGY, V118, P1827, DOI 10.1016/j.ophtha.2010.12.034; Stahl A, 2010, EUR J OPHTHALMOL, V20, P180, DOI 10.1177/112067211002000125; Wroblewski JJ, 2010, AM J OPHTHALMOL, V149, P147, DOI 10.1016/j.ajo.2009.08.005; Wroblewski JJ, 2009, ARCH OPHTHALMOL-CHIC, V127, P374, DOI 10.1001/archophthalmol.2009.14	42	78	82	0	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 25	2013	8	10							e78538	10.1371/journal.pone.0078538	http://dx.doi.org/10.1371/journal.pone.0078538			21	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	241GW	24205253	Green Published, gold, Green Submitted			2023-01-03	WOS:000326155400083
J	Steinke, SIB; Peitsch, WK; Ludwig, A; Goebeler, M				Steinke, Sabine I. B.; Peitsch, Wiebke K.; Ludwig, Alexander; Goebeler, Matthias			Cost-of-Illness in Psoriasis: Comparing Inpatient and Outpatient Therapy	PLOS ONE			English	Article							PLAQUE-TYPE PSORIASIS; HEALTH-CARE COSTS; PATIENT PREFERENCES; DISEASE SEVERITY; UNITED-STATES; MODERATE; LIFE; MULTICENTER; BIOLOGICS; GERMANY	Treatment modalities of chronic plaque psoriasis have dramatically changed over the past ten years with a still continuing shift from inpatient to outpatient treatment. This development is mainly caused by outpatient availability of highly efficient and relatively well-tolerated systemic treatments, in particular BioLogicals. In addition, inpatient treatment is time-and cost-intense, conflicting with the actual burst of health expenses and with patient preferences. Nevertheless, inpatient treatment with dithranol and UV light still is a major mainstay of psoriasis treatment in Germany. The current study aims at comparing the total costs of inpatient treatment and outpatient follow-up to mere outpatient therapy with different modalities (topical treatment, phototherapy, classic systemic therapy or BioLogicals) over a period of 12 months. To this end, a retrospective cost-of-illness study was conducted on 120 patients treated at the University Medical Centre Mannheim between 2005 and 2006. Inpatient therapy caused significantly higher direct medical, indirect and total annual costs than outpatient treatment (13,042 (sic) versus 2,984 (sic)). Its strong influence on cost levels was confirmed by regression analysis, with total costs rising by 104.3% in case of inpatient treatment. Patients receiving BioLogicals produced the overall highest costs, whereas outpatient treatment with classic systemic antipsoriatic medications was less cost-intense than other alternatives.	[Steinke, Sabine I. B.] Univ Munster, Dept Dermatol, Univ Hosp Munster, D-48149 Munster, Germany; [Steinke, Sabine I. B.; Peitsch, Wiebke K.; Goebeler, Matthias] Heidelberg Univ, Dept Dermatol, Univ Med Ctr Mannheim, Heidelberg, Germany; [Ludwig, Alexander] Univ Cologne, Ctr Macroecon Res, D-50931 Cologne, Germany; [Ludwig, Alexander] Max Planck Inst Munich, Munich Res Inst Econ Aging, Munich, Germany; [Goebeler, Matthias] Univ Wurzburg, Dept Dermatol Venereol & Allergol, Univ Hosp Wurzburg, Wurzburg, Germany	University of Munster; Ruprecht Karls University Heidelberg; University of Cologne; Max Planck Society; University of Wurzburg	Steinke, SIB (corresponding author), Univ Munster, Dept Dermatol, Univ Hosp Munster, Von Esmarch Str 56, D-48149 Munster, Germany.	sabine.steinke@ukmuenster.de	Goebeler, Matthias/P-3612-2019; Goebeler, Matthias/F-7118-2013		Deutsche Forschungsgemeinschaft; University of Muenster	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); University of Muenster	The authors acknowledge support by Deutsche Forschungsgemeinschaft and Open Access Publication Fund of University of Muenster. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Anis AH, 2011, J DERMATOL TREAT, V22, P65, DOI 10.3109/09546630903551258; Augustin M, 2008, DERMATOLOGY, V216, P366, DOI 10.1159/000119415; Balkrishnan R, 2006, J UROLOGY, V175, P1067, DOI 10.1016/S0022-5347(05)00352-6; Berger Karin, 2005, J Dtsch Dermatol Ges, V3, P511, DOI 10.1111/j.1610-0387.2005.05729.x; Beyer V, 2010, ARCH DERMATOL, V146, P46, DOI 10.1001/archdermatol.2009.319; Braun-Falco O, 2005, DERMATOL VENEROL, P476; de Miguel R, 2009, INT J DERMATOL, V48, P653, DOI 10.1111/j.1365-4632.2009.04012.x; Deutsche Agentur fur Health Technology Assessment des Deutschen Instituts fur Medizinische Dokumentation und Information, 2006, SCHRIFT HLTH TECHN A, V15-46, P91; Feldman SR, 2003, EXPERT OPIN PHARMACO, V4, P1525, DOI 10.1517/eoph.4.9.1525.21059; Finzi AF, 2001, J EUR ACAD DERMATOL, V15, P320, DOI 10.1046/j.1468-3083.2001.00256.x; Fluhr JW, 2007, DERMATOLOGY, V214, P6, DOI 10.1159/000096905; Fonia A, 2010, BRIT J DERMATOL, V163, P807, DOI 10.1111/j.1365-2133.2010.09944.x; Fowler JF, 2008, J AM ACAD DERMATOL, V59, P772, DOI 10.1016/j.jaad.2008.06.043; Galadari I, 2001, J EUR ACAD DERMATOL, V15, P290, DOI 10.1046/j.1468-3083.2001.00257.x; Ghatnekar O, 2012, EUR J DERMATOL, V22, P238, DOI 10.1684/ejd.2011.1635; Hahn M, 2005, HAUTARZT, V56, P576, DOI 10.1007/s00105-005-0946-1; Hartman M, 2002, BRIT J DERMATOL, V147, P538, DOI 10.1046/j.1365-2133.2002.04920.x; Javitz HS, 2002, J AM ACAD DERMATOL, V46, P850, DOI 10.1067/mjd.2002.119669; Kimball AB, 2011, J EUR ACAD DERMATOL, V25, P157, DOI 10.1111/j.1468-3083.2010.03730.x; Koo J, 1999, J AM ACAD DERMATOL, V41, P51, DOI 10.1016/S0190-9622(99)70406-8; Morrow Thomas, 2006, Manag Care, V15, P61; Nast A, 2011, J DTSCH DERMATOL GES, V9, pS1, DOI [10.1111/j.1610-0379.2011.07680.x, 10.1111/j.1610-0379.2011.07681.x]; Nelson A, 2005, PLOUGHSHARES, V31, P5; Opmeer BC, 2004, ARCH DERMATOL, V140, P685, DOI 10.1001/archderm.140.6.685; Pearce DJ, 2006, J DERMATOL TREAT, V17, P29, DOI 10.1080/09546630500504754; Poulin Y, 2009, J CUTAN MED SURG, V13, pS49, DOI 10.2310/7750.2009.00021; Schaarschmidt ML, 2013, J EUR ACAD DERMATOL, V27, P187, DOI 10.1111/j.1468-3083.2011.04440.x; Schaarschmidt ML, 2011, ARCH DERMATOL, V147, P1285, DOI 10.1001/archdermatol.2011.309; Schmitt J, 2007, DERMATOLOGY, V214, P68, DOI 10.1159/000096916; Schmitt JM, 2006, DERMATOLOGY, V213, P102, DOI 10.1159/000093848; Schoffski Oliver, 2007, J Dtsch Dermatol Ges, V5, P209, DOI 10.1111/j.1610-0387.2007.06240.x; Schwartz F, 2003, PUBLIC HLTH BUCH EFF, P461; Sizto S, 2009, BRIT J DERMATOL, V160, P1264, DOI 10.1111/j.1365-2133.2008.08962.x; Sohn S, 2006, DERMATOLOGY, V212, P137, DOI 10.1159/000090654; Stern RS, 2003, J AM ACAD DERMATOL, V49, P445, DOI 10.1067/S0190-9622(03)00858-2; Young Jai Il, 1998, Journal of Dermatology (Tokyo), V25, P112	36	19	21	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 23	2013	8	10							e78152	10.1371/journal.pone.0078152	http://dx.doi.org/10.1371/journal.pone.0078152			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	239PE	24194911	Green Published, Green Submitted, gold			2023-01-03	WOS:000326037000090
J	Schreuder, AB; Vanikova, J; Vitek, L; Havinga, R; Ahlfors, CE; Hulzebos, CV; Verkade, HJ				Schreuder, Andrea B.; Vanikova, Jana; Vitek, Libor; Havinga, Rick; Ahlfors, Charles E.; Hulzebos, Christian V.; Verkade, Henkjan J.			Optimizing Exchange Transfusion for Severe Unconjugated Hyperbilirubinemia: Studies in the Gunn Rat	PLOS ONE			English	Article							GLUCURONYL TRANSFERASE; BILIRUBIN; KERNICTERUS; ALBUMIN; MANAGEMENT; MORBIDITY; MORTALITY; FREQUENCY; THERAPY; MODEL	Background: Severe unconjugated hyperbilirubinemia carries the risk of neurotoxicity. Phototherapy (PT) and exchange transfusion (ET) are cornerstones in the treatment of unconjugated hyperbilirubinemia. Studies to improve ET efficacy have been hampered by the low application of ET in humans and by the lack of an in vivo model. The absence of an appropriate animal model has also prevented to determine the efficacy of adjunct or alternative treatment options such as albumin (Alb) administration. Aim: To establish an in vivo model for ET and to determine the most effective treatment (combination) of ET, PT and Alb administration. Methods: Gunn rats received either PT, PT+Alb, ET, ET+PT, ET+PT+Alb or sham operation (each n = 7). ET was performed via the right jugular vein in similar to 20 min. PT (18 mu W/cm(2)/nm) was started after ET or at T-0. Albumin i.p. injections (2.5 g/kg) were given after ET or before starting PT. Plasma unconjugated bilirubin (UCB), plasma free bilirubin (Bf), and brain bilirubin concentrations were determined. Results: We performed ET in 21 Gunn rats with 100% survival. At T-1, ET was profoundly more effective in decreasing both UCB -44%, p<0.01) and Bf -81%, p<0.05) than either PT or PT+Alb. After 48 h, the combination of ET+PT+Alb showed the strongest hypobilirubinemic effect (-54% compared to ET). Conclusions: We optimized ET for severe unconjugated hyperbilirubinemia in the Gunn rat model. Our data indicate that ET is the most effective treatment option, in the acute as well as the follow-up situation.	[Schreuder, Andrea B.; Havinga, Rick; Verkade, Henkjan J.] Univ Groningen, Univ Med Ctr Groningen, Beatrix Childrens Hosp, Ctr Liver Digest & Metab Dis,Dept Pediat, Groningen, Netherlands; [Vanikova, Jana; Vitek, Libor] Charles Univ Prague, Fac Med 1, Inst Med Biochem & Lab Diagnost, Prague 2, Czech Republic; [Vitek, Libor] Charles Univ Prague, Fac Med 1, Dept Internal Med 4, Prague 2, Czech Republic; [Ahlfors, Charles E.] Stanford Univ, Sch Med, Stanford, CA USA; [Hulzebos, Christian V.] Univ Groningen, Univ Med Ctr Groningen, Beatrix Childrens Hosp, Dept Pediat, NL-9713 AV Groningen, Netherlands	University of Groningen; Charles University Prague; Charles University Prague; Stanford University; University of Groningen	Verkade, HJ (corresponding author), Univ Groningen, Univ Med Ctr Groningen, Beatrix Childrens Hosp, Ctr Liver Digest & Metab Dis,Dept Pediat, Groningen, Netherlands.	h.j.verkade@umcg.nl	Vitek, Libor/A-2645-2008; Hulzebos, Christian Victor/AAY-6803-2021; Jasprova, Jana/H-7839-2017	Vitek, Libor/0000-0002-5318-0151; Hulzebos, Christian Victor/0000-0002-8159-7501; Jasprova, Jana/0000-0002-0579-0895; Verkade, Henkjan J/0000-0002-7034-2861				AHDABBARMADA M, 1984, J NEUROPATH EXP NEUR, V43, P45, DOI 10.1097/00005072-198401000-00004; Ahlfors CE, 2006, CLIN CHIM ACTA, V365, P78, DOI 10.1016/j.cca.2005.07.030; Ahlfors CE, 2009, J PERINATOL; Calligaris SD, 2007, PEDIATR RES, V62, P576, DOI 10.1203/PDR.0b013e3181568c94; CHAN G, 1976, J PEDIATR-US, V88, P609, DOI 10.1016/S0022-3476(76)80020-0; Cuperus FJC, 2013, J HEPATOL, V58, P134, DOI 10.1016/j.jhep.2012.08.011; Dennery PA, 2001, NEW ENGL J MED, V344, P581, DOI 10.1056/NEJM200102223440807; DIAMOND I, 1966, J CLIN INVEST, V45, P678, DOI 10.1172/JCI105383; Eguchi S, 1998, ARTIF ORGANS, V22, P847, DOI 10.1046/j.1525-1594.1998.06166.x; Gazzin S, 2012, PEDIATR RES, V71, P653, DOI 10.1038/pr.2012.23; Gourley GR, 1993, PEDIAT GASTROINTESTI, P88; HENRY CA, 1991, NUCL MED BIOL, V18, P565, DOI 10.1016/0883-2897(91)90120-A; HODGES GR, 1984, ANTIMICROB AGENTS CH, V26, P903, DOI 10.1128/AAC.26.6.903; Jackson JC, 1997, PEDIATRICS, V99, DOI 10.1542/peds.99.5.e7; JOHNSON L, 1959, AMA J DIS CHILD, V97, P591, DOI 10.1001/archpedi.1959.02070010593009; JOHNSON L, 1961, AM J DIS CHILD, V101, P322, DOI 10.1001/archpedi.1961.04020040050007; KEENAN WJ, 1985, PEDIATRICS, V75, P417; KURANTSINMILLS J, 1987, MICROVASC RES, V34, P152, DOI 10.1016/0026-2862(87)90050-1; LAUER BA, 1982, PEDIATRICS, V70, P43; LIVADITIS A, 1974, ACTA PAEDIATR SCAND, V63, P277, DOI 10.1111/j.1651-2227.1974.tb04796.x; Maisels M J, 2001, J Perinatol, V21 Suppl 1, pS93, DOI 10.1038/sj.jp.7210642; ODELL GB, 1962, PEDIATRICS, V30, P613; OSTROW JD, 1971, J CLIN INVEST, V50, P707, DOI 10.1172/JCI106541; Patra K, 2004, J PEDIATR-US, V144, P626, DOI 10.1016/j.jpeds.2004.01.054; Raat NJ, 2005, CRIT CARE MED, V33, P39, DOI 10.1097/01.CCM.0000150655.75519.02; Steiner LA, 2007, PEDIATRICS, V120, P27, DOI 10.1542/peds.2006-2910; STREBEL L, 1971, PEDIATR RES, V5, P548, DOI 10.1203/00006450-197110000-00007; TAKEDA K, 1989, TOHOKU J EXP MED, V157, P31, DOI 10.1620/tjem.157.31; Wennberg RP, 2006, PEDIATRICS, V117, P474, DOI 10.1542/peds.2005-0395; Zelenka J, 2008, J CHROMATOGR B, V867, P37, DOI 10.1016/j.jchromb.2008.03.005; Zucker SD, 1999, J BIOL CHEM, V274, P10852, DOI 10.1074/jbc.274.16.10852	31	6	6	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 15	2013	8	10							e77179	10.1371/journal.pone.0077179	http://dx.doi.org/10.1371/journal.pone.0077179			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	237TP	24143211	Green Published, Green Submitted, gold			2023-01-03	WOS:000325894100046
J	Santarcangelo, EL; Paoletti, G; Chiavacci, I; Palombo, C; Carli, G; Varanini, M				Santarcangelo, Enrica L.; Paoletti, Giulia; Chiavacci, Iacopo; Palombo, Carlo; Carli, Giancarlo; Varanini, Maurizio			Cognitive Modulation of Psychophysical, Respiratory and Autonomic Responses to Cold Pressor Test	PLOS ONE			English	Article							HEART-RATE; HYPNOTIC ANALGESIA; PAIN PERCEPTION; BLOOD-PRESSURE; HYPNOSIS; SUGGESTIONS; HYPNOTIZABILITY; SUGGESTIBILITY; SUSCEPTIBILITY; RELAXATION	In healthy subjects with high hypnotisability (highs) under hypnosis, subjectively effective suggestions for analgesia abolish the increases in blood pressure associated with cold pressor test (cpt) by reducing the peripheral vascular resistance. The aim of the present study was to investigate the effects of the suggestions of analgesia on the responses to cpt in healthy highs (n = 22) and in low hypnotisable participants (lows, n = 22) out of hypnosis. Cpt was administered without (CPT) and with suggestions for analgesia (CPT+AN). Psychophysical (pain intensity, pain threshold, cpt duration (time of immersion) and pain tolerance, defined as the difference between cpt duration and pain threshold), respiratory (amplitude and frequency) and autonomic variables (tonic skin conductance, mean RR interval (RR = 1/heart rate), blood pressure, skin blood flow) were studied. The suggestions for analgesia increased cpt duration and RR in both groups, but decreased pain intensity and enhanced pain threshold only in highs; in both groups they did not modulate systolic blood pressure, tonic skin conductance and skin blood flow; thus, increased parasympathetic activity appears responsible for the heart rate reduction induced by suggestions in both groups. In conclusion, our findings show that suggestions modulate pain experience differentially in highs and lows, and are partially effective also in lows. We hypothesize that the mechanisms responsible for the efficacy of suggestions in healthy lows may be involved also in their efficacy in chronic pain patients with low hypnotisability.	[Santarcangelo, Enrica L.; Paoletti, Giulia; Chiavacci, Iacopo] Univ Pisa, Dept Translat Res & New Technol Med & Surg, Pisa, Italy; [Palombo, Carlo] Univ Pisa, Dept Surg, Pisa, Italy; [Carli, Giancarlo] Univ Siena, Dept Physiol, I-53100 Siena, Italy; [Varanini, Maurizio] CNR, Inst Clin Physiol, Pisa, Italy	University of Pisa; University of Pisa; University of Siena; Consiglio Nazionale delle Ricerche (CNR); Istituto di Fisiologia Clinica (IFC-CNR)	Santarcangelo, EL (corresponding author), Univ Pisa, Dept Translat Res & New Technol Med & Surg, Pisa, Italy.	enricals@dfb.unipi.it	Varanini, Maurizio/B-7945-2015; SANTARCANGELO, ENRICA Laura/AAM-7275-2021	Varanini, Maurizio/0000-0001-8489-3560; santarcangelo, enrica laura/0000-0003-2519-1491	Pisa University; Fondazione ARPA (Pisa)	Pisa University; Fondazione ARPA (Pisa)	The study was funded by Pisa University and Fondazione ARPA (Pisa). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	BAKER SL, 1991, J PERS SOC PSYCHOL, V61, P504, DOI 10.1037/0022-3514.61.3.504; BALTHAZARD CG, 1989, INT J CLIN EXP HYP, V37, P70, DOI 10.1080/00207148908410534; Carli G, 2008, ARCH ITAL BIOL, V146, P75; Carvalho C, 2008, INT J CLIN EXP HYP, V56, P295, DOI 10.1080/00207140802041850; Casiglia E, 2007, AM J CLIN HYPN, V49, P255, DOI 10.1080/00029157.2007.10524503; CHEN ACN, 1989, PAIN, V37, P143, DOI 10.1016/0304-3959(89)90126-7; de la Fuente-Fernandez R, 2009, PARKINSONISM RELAT D, V15, pS72, DOI 10.1016/S1353-8020(09)70785-0; De Pascalis V, 1999, PAIN, V83, P499, DOI 10.1016/S0304-3959(99)00157-8; De Pascalis V, 2008, PAIN, V134, P197, DOI 10.1016/j.pain.2007.09.005; DEBENEDITTIS G, 1989, INT J CLIN EXP HYP, V37, P55, DOI 10.1080/00207148908410533; DePascalis V, 1996, INT J PSYCHOPHYSIOL, V21, P163, DOI 10.1016/0167-8760(95)00050-X; DEPASCALIS V, 2000, INT J CLIN EXP HYP, V48, P15; Egner T, 2005, NEUROIMAGE, V27, P969, DOI 10.1016/j.neuroimage.2005.05.002; Fillingim Roger B, 2005, Curr Rheumatol Rep, V7, P342, DOI 10.1007/s11926-005-0018-7; GOLDSTEIN B, 1994, PEDIATR RES, V36, P358, DOI 10.1203/00006450-199409000-00016; HILGARD ER, 1975, ACTA NEUROBIOL EXP, V35, P741; Hodges GJ, 2009, APPL PHYSIOL NUTR ME, V34, P829, DOI 10.1139/H09-076; Hofbauer RK, 2001, J NEUROPHYSIOL, V86, P402, DOI 10.1152/jn.2001.86.1.402; Homma I, 2008, EXP PHYSIOL, V93, P1011, DOI 10.1113/expphysiol.2008.042424; Jambrik Z, 2005, PAIN, V116, P181, DOI 10.1016/j.pain.2005.03.041; Jensen M, 2006, J BEHAV MED, V29, P95, DOI 10.1007/s10865-005-9031-6; Mekjavic IB, 2008, EUR J APPL PHYSIOL, V104, P193, DOI 10.1007/s00421-008-0727-5; MILLER MF, 1991, J ABNORM PSYCHOL, V100, P223, DOI 10.1037/0021-843X.100.2.223; Milling LS, 2008, CURR PAIN HEADACHE R, V12, P98, DOI 10.1007/s11916-008-0019-0; Milling LS, 2010, J CONSULT CLIN PSYCH, V78, P126, DOI 10.1037/a0017388; Milling LS, 2005, ANN BEHAV MED, V29, P116, DOI 10.1207/s15324796abm2902_6; Montgomery GH, 2000, INT J CLIN EXP HYP, V48, P138, DOI 10.1080/00207140008410045; Mourot L, 2009, PHYSIOL RES, V58, P83, DOI 10.33549/physiolres.931360; Oosterman JM, 2010, EUR J PAIN, V14, P1046, DOI 10.1016/j.ejpain.2010.04.004; Paoletti G, 2010, BRAIN RES BULL, V82, P65, DOI 10.1016/j.brainresbull.2010.03.003; Payne RA, 2006, J APPL PHYSIOL, V100, P136, DOI 10.1152/japplphysiol.00657.2005; PECKERMAN A, 1991, PSYCHOPHYSIOLOGY, V28, P485, DOI 10.1111/j.1469-8986.1991.tb01985.x; Pollatos O, 2012, PAIN, V153, P1680, DOI 10.1016/j.pain.2012.04.030; Rainville P, 1999, PAIN, V82, P159, DOI 10.1016/S0304-3959(99)00048-2; Ray WJ, 2000, INT J CLIN EXP HYP, V48, P22, DOI 10.1080/00207140008410358; Reckelhoff JF, 2001, HYPERTENSION, V37, P1199, DOI 10.1161/01.HYP.37.5.1199; Santarcangelo EL, 2008, INT J CLIN EXP HYP, V56, P255, DOI 10.1080/00207140802039649; Scattina E, 2012, EXP BRAIN RES, V216, P341, DOI 10.1007/s00221-011-2935-1; Sebastiani L, 2007, INT J PSYCHOPHYSIOL, V63, P125, DOI 10.1016/j.ijpsycho.2006.10.001; Sethi AK, 2012, FRONT PSYCHOL, V3, DOI 10.3389/fpsyg.2011.00395; Shea SA, 1996, EXP PHYSIOL, V81, P1; SPANOS NP, 1989, J ABNORM PSYCHOL, V98, P285, DOI 10.1037/0021-843X.98.3.285; TENENBAUM SJ, 1990, AM J CLIN HYPN, V33, P40, DOI 10.1080/00029157.1990.10402899; Tousignant-Laflamme Y, 2010, J PAIN, V11, P983, DOI 10.1016/j.jpain.2010.01.266; Wager TD, 2011, J NEUROSCI, V31, P439, DOI 10.1523/JNEUROSCI.3420-10.2011; Weise F, 1993, Clin Auton Res, V3, P303, DOI 10.1007/BF01827331	47	21	21	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 9	2013	8	10							e75023	10.1371/journal.pone.0075023	http://dx.doi.org/10.1371/journal.pone.0075023			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	236PJ	24130680	gold, Green Submitted, Green Published			2023-01-03	WOS:000325810900015
J	Uthman, OA; van der Windt, DA; Jordan, JL; Dziedzic, KS; Healey, EL; Peat, GM; Foster, NE				Uthman, Olalekan A.; van der Windt, Danielle A.; Jordan, Joanne L.; Dziedzic, Krysia S.; Healey, Emma L.; Peat, George M.; Foster, Nadine E.			Exercise for lower limb osteoarthritis: systematic review incorporating trial sequential analysis and network meta-analysis	BMJ-BRITISH MEDICAL JOURNAL			English	Review							RANDOMIZED CONTROLLED-TRIAL; LAND-BASED EXERCISE; EVIDENCE-BASED RECOMMENDATIONS; QUALITY-OF-LIFE; KNEE OSTEOARTHRITIS; OLDER-ADULTS; TAI-CHI; AQUATIC EXERCISE; PHYSICAL-ACTIVITY; META-REGRESSION	Objective To determine whether there is sufficient evidence to conclude that exercise interventions are more effective than no exercise control and to compare the effectiveness of different exercise interventions in relieving pain and improving function in patients with lower limb osteoarthritis. Data sources Nine electronic databases searched from inception to March 2012. Study selection Randomised controlled trials comparing exercise interventions with each other or with no exercise control for adults with knee or hip osteoarthritis. Data extraction Two reviewers evaluated eligibility and methodological quality. Main outcomes extracted were pain intensity and limitation of function. Trial sequential analysis was used to investigate reliability and conclusiveness of available evidence for exercise interventions. Bayesian network meta-analysis was used to combine both direct (within trial) and indirect (between trial) evidence on treatment effectiveness. Results 60 trials (44 knee, two hip, 14 mixed) covering 12 exercise interventions and with 8218 patients met inclusion criteria. Sequential analysis showed that as of 2002 sufficient evidence had been accrued to show significant benefit of exercise interventions over no exercise control. For pain relief, strengthening, flexibility plus strengthening, flexibility plus strengthening plus aerobic, aquatic strengthening, and aquatic strengthening plus flexibility, exercises were significantly more effective than no exercise control. A combined intervention of strengthening, flexibility, and aerobic exercise was also significantly more effective than no exercise control for improving limitation in function (standardised mean difference -0.63, 95% credible interval -1.16 to -0.10). Conclusions As of 2002 sufficient evidence had accumulated to show significant benefit of exercise over no exercise in patients with osteoarthritis, and further trials are unlikely to overturn this result. An approach combining exercises to increase strength, flexibility, and aerobic capacity is likely to be most effective in the management of lower limb osteoarthritis. The evidence is largely from trials in patients with knee osteoarthritis.	[Uthman, Olalekan A.; van der Windt, Danielle A.; Jordan, Joanne L.; Dziedzic, Krysia S.; Healey, Emma L.; Peat, George M.; Foster, Nadine E.] Keele Univ, Arthritis Res UK Primary Care Ctr, Keele ST5 5BG, Staffs, England; [Uthman, Olalekan A.] Univ Warwick, Warwick Med Sch, Div Hlth Sci, Warwick Ctr Appl Hlth Res & Delivery WCAHRD, Coventry CV4 7AL, W Midlands, England	Keele University; University of Warwick	van der Windt, DA (corresponding author), Keele Univ, Arthritis Res UK Primary Care Ctr, Keele ST5 5BG, Staffs, England.	d.van.der.windt@keele.ac.uk	Uthman, Olalekan/N-5584-2019; Peat, George/AAE-5869-2020; Jordan, Joanne/E-8186-2014	Uthman, Olalekan/0000-0002-8567-3081; Peat, George/0000-0002-9008-0184; Jordan, Joanne/0000-0002-7191-2977; Foster, Nadine/0000-0003-4429-9756	National Institute for Health Research (NIHR) [RP-PG-0407-10386]; National Institute for Health Research [NIHR-RP-011-015, RP-PG-0407-10386, NF-SI-0509-10183] Funding Source: researchfish	National Institute for Health Research (NIHR)(National Institute for Health Research (NIHR)); National Institute for Health Research(National Institute for Health Research (NIHR))	This study was funded by the National Institute for Health Research (NIHR) under its programme grants for applied research programme (grant reference No RP-PG-0407-10386). The NIHR had no role in the conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review of the manuscript. The conclusions and views expressed in this article are those of the authors and not necessarily those of the NHS, NIHR, or Department of Health.	Aglamis B, 2008, J BACK MUSCULOSKELET, V21, P121; ALTMAN RD, 1995, J RHEUMATOL, V22, P42; Aoki O, 2009, J PHYS THER SCI, V21, P113, DOI 10.1589/jpts.21.113; Artus M, 2010, RHEUMATOLOGY, V49, P2346, DOI 10.1093/rheumatology/keq245; Baker KR, 2001, J RHEUMATOL, V28, P1655; Bartels EM, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005523.pub2; Bautch JC, 1997, ARTHRIT CARE RES, V10, P48, DOI 10.1002/art.1790100108; Bellamy N, 1997, J RHEUMATOL, V24, P799; BELLAMY N, 1995, J RHEUMATOL, V22, P49; Bennell KL, 2010, OSTEOARTHR CARTILAGE, V18, P621, DOI 10.1016/j.joca.2010.01.010; Bennell KL, 2011, J SCI MED SPORT, V14, P4, DOI 10.1016/j.jsams.2010.08.002; Bennell KL, 2005, ANN RHEUM DIS, V64, P906, DOI 10.1136/ard.2004.026526; Borjesson M, 1996, Physiother Res Int, V1, P89; Brismee JM, 2007, CLIN REHABIL, V21, P99, DOI 10.1177/0269215506070505; Brok J, 2008, J CLIN EPIDEMIOL, V61, P763, DOI 10.1016/j.jclinepi.2007.10.007; Brooks SP, 1998, J COMPUT GRAPH STAT, V7, P434, DOI 10.2307/1390675; Caldwell DM, 2005, BMJ-BRIT MED J, V331, P897, DOI 10.1136/bmj.331.7521.897; Centre for Reviews and Dissemination, 2012, 40 CRD U YORK; Chaipinyo K, 2009, AUST J PHYSIOTHER, V55, P25, DOI 10.1016/S0004-9514(09)70057-1; Cochrane T, 2005, HEALTH TECHNOL ASSES, V9, pIII; Cohen J., 2013, STAT POWER ANAL BEHA; Cooper NJ, 2012, EPIDEMIOL REV, V34, P32, DOI 10.1093/epirev/mxr015; Dias Rosangela Correa, 2003, Physiother Res Int, V8, P121; Dias S, 2011, 3 NICE DSU NICE DEC; DiBonaventura MD, 2012, HEALTH QUAL LIFE OUT, V10, DOI 10.1186/1477-7525-10-30; Escalante Y, 2011, J SCI MED SPORT, V14, P190, DOI 10.1016/j.jsams.2010.10.004; Escalante Y, 2010, J BACK MUSCULOSKELET, V23, P175, DOI 10.3233/BMR-2010-0267; Ettinger WH, 1997, JAMA-J AM MED ASSOC, V277, P25, DOI 10.1001/jama.277.1.25; Farr JN, 2010, PHYS THER, V90, P356, DOI 10.2522/ptj.20090041; Foley A, 2003, ANN RHEUM DIS, V62, P1162, DOI 10.1136/ard.2002.005272; Fransen M, 2010, OSTEOARTHR CARTILAGE, V18, P613, DOI 10.1016/j.joca.2010.01.003; Fransen M, 2001, J RHEUMATOL, V28, P156; Fransen M, 2009, COCHRANE DB SYST REV, V3, DOI DOI 10.1002/14651858; Fransen M, 2008, COCHRANE DB SYST REV, V4, DOI DOI 10.1002/14651858.CD004376.PUB2; Fransen M, 2007, ARTHRIT RHEUM-ARTHR, V57, P407, DOI 10.1002/art.22621; Fransen M, 2009, J RHEUMATOL, V36, P1109, DOI 10.3899/jrheum.090058; Gill SD, 2009, ARCH PHYS MED REHAB, V90, P388, DOI 10.1016/j.apmr.2008.09.561; Gupta S, 2005, RHEUMATOLOGY, V44, P1531, DOI 10.1093/rheumatology/kei049; Gur H, 2002, ARCH PHYS MED REHAB, V83, P308, DOI 10.1053/apmr.2002.30620; Halbert J, 2001, ARTHRIT RHEUM-ARTHR, V45, P228, DOI 10.1002/1529-0131(200106)45:3<228::AID-ART253>3.0.CO;2-2; Hale LA, 2012, ARCH PHYS MED REHAB, V93, P27, DOI 10.1016/j.apmr.2011.08.004; Hartman CA, 2000, J AM GERIATR SOC, V48, P1553, DOI 10.1111/j.1532-5415.2000.tb03863.x; Hay EM, 2006, BRIT MED J, V333, P995, DOI 10.1136/BMJ.38977.590752.0B; Higgins Julian P T, 2011, BMJ, V343, pd5928, DOI 10.1136/bmj.d5928; Higgins JPT, 2011, STAT MED, V30, P903, DOI 10.1002/sim.4088; Hinman RS, 2007, PHYS THER, V87, P32, DOI 10.2522/ptj.20060006; Hopman-Rock M, 2000, J RHEUMATOL, V27, P1947; Hozo S.P., 2005, BMC MED RES METHODOL, V5, P13, DOI [10.1186/1471-2288-5-13, DOI 10.1186/1471-2288-5-13]; Huang MH, 2005, ARCH PHYS MED REHAB, V86, P1545, DOI 10.1016/j.apmr.2005.02.007; Huang MH, 2003, SEMIN ARTHRITIS RHEU, V32, P398, DOI 10.1053/sarh.2003.50021; Hughes SL, 2006, GERONTOLOGIST, V46, P801, DOI 10.1093/geront/46.6.801; Hurley MV, 2007, ARTHRIT RHEUM-ARTHR, V57, P1211, DOI 10.1002/art.22995; Iwamoto J, 2011, WORLD J ORTHOP, V2, P37, DOI 10.5312/wjo.v2.i5.37; Juni P, 2006, BEST PRACT RES CL RH, V20, P721, DOI 10.1016/j.berh.2006.05.002; Keefe FJ, 2004, PAIN, V110, P539, DOI 10.1016/j.pain.2004.03.022; KOVAR PA, 1992, ANN INTERN MED, V116, P529, DOI 10.7326/0003-4819-116-7-529; Krahn U, 2013, BMC MED RES METHODOL, V13, DOI 10.1186/1471-2288-13-35; Lambert PC, 2002, J CLIN EPIDEMIOL, V55, P86, DOI 10.1016/S0895-4356(01)00414-0; Le TK, 2012, PAIN PRACT, V12, P633, DOI 10.1111/j.1533-2500.2012.00535.x; Lee HJ, 2009, CLIN REHABIL, V23, P504, DOI 10.1177/0269215508101746; Lim JY, 2010, PM&R, V2, P723, DOI 10.1016/j.pmrj.2010.04.004; Lin DH, 2009, J ORTHOP SPORT PHYS, V39, P450, DOI 10.2519/jospt.2009.2923; Lu G, 2004, STAT MED, V23, P3105, DOI 10.1002/sim.1875; Lund H, 2008, J REHABIL MED, V40, P137, DOI 10.2340/16501977-0134; Macdonald Geraldine, 2012, Cochrane Database Syst Rev, pCD001930, DOI 10.1002/14651858.CD001930.pub3; McCarthy CJ, 2002, ARTHRITIS RHEUM-US, V46, pS143; Messier SP, 2004, ARTHRITIS RHEUM-US, V50, P1501, DOI 10.1002/art.20256; Mikesky AE, 2006, ARTHRIT RHEUM-ARTHR, V55, P690, DOI 10.1002/art.22245; MINOR MA, 1989, ARTHRITIS RHEUM, V32, P1396, DOI 10.1002/anr.1780321108; Murphy LB, 2010, OSTEOARTHR CARTILAGE, V18, P1372, DOI 10.1016/j.joca.2010.08.005; Murphy L, 2008, ARTHRIT RHEUM-ARTHR, V59, P1207, DOI 10.1002/art.24021; National Collaborating Centre for Chronic Conditions, 2008, OST NAT CLIN GUID CA; Nuesch E, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b3244; O'Reilly SC, 1999, ANN RHEUM DIS, V58, P15, DOI 10.1136/ard.58.1.15; Patrick DL, 2001, MED CARE, V39, P413, DOI 10.1097/00005650-200105000-00002; Peloquin L, 1999, JCR-J CLIN RHEUMATOL, V5, P126, DOI 10.1097/00124743-199906000-00004; Pogue JM, 1997, CONTROL CLIN TRIALS, V18, P580, DOI 10.1016/S0197-2456(97)00051-2; Quilty B, 2003, J RHEUMATOL, V30, P1311; Rannou F, 2010, BEST PRACT RES CL RH, V24, P93, DOI 10.1016/j.berh.2009.08.013; Ravaud P, 2004, ANN RHEUM DIS, V63, P703, DOI 10.1136/ard.2003.009803; Roddy E, 2005, RHEUMATOLOGY, V44, P67, DOI 10.1093/rheumatology/keh399; Rogind H, 1998, ARCH PHYS MED REHAB, V79, P1421, DOI 10.1016/S0003-9993(98)90238-6; Rubin D. B., 1992, STAT SCI, V7, P457, DOI DOI 10.1111/j.1469-8137.2011.03796.x; Salanti G, 2008, STAT METHODS MED RES, V17, P279, DOI 10.1177/0962280207080643; Salanti G, 2011, J CLIN EPIDEMIOL, V64, P163, DOI 10.1016/j.jclinepi.2010.03.016; Salanti G, 2009, J CLIN EPIDEMIOL, V62, P857, DOI 10.1016/j.jclinepi.2008.10.001; Salli A, 2010, ISOKINET EXERC SCI, V18, P201, DOI 10.3233/IES-2010-0385; Schilke JM, 1996, NURS RES, V45, P68, DOI 10.1097/00006199-199603000-00002; Schmid CH, 2004, J CLIN EPIDEMIOL, V57, P683, DOI 10.1016/j.jclinepi.2003.12.001; Silva LE, 2008, PHYS THER, V88, P12, DOI 10.2522/ptj.20060040; Song Fujian, 2011, BMJ, V343, pd4909, DOI 10.1136/bmj.d4909; Spiegelhalter D., 2003, WINBUGS USER MANUAL; Stener-Victorin E, 2004, CLIN J PAIN, V20, P179, DOI 10.1097/00002508-200405000-00008; Tak E, 2005, J RHEUMATOL, V32, P1106; Talbot LA, 2003, J AM GERIATR SOC, V51, P387, DOI 10.1046/j.1532-5415.2003.51113.x; Thomas KS, 2002, BMJ-BRIT MED J, V325, P752, DOI 10.1136/bmj.325.7367.752; Thompson SG, 2002, STAT MED, V21, P1559, DOI 10.1002/sim.1187; Thorlund K., 2011, USER MANUAL TRIAL SE; Thorstensson CA, 2005, BMC MUSCULOSKEL DIS, V6, DOI 10.1186/1471-2474-6-27; Topp R, 2002, ARCH PHYS MED REHAB, V83, P1187, DOI 10.1053/apmr.2002.33988; United States Bone and Joint Initiative, 2011, BURD MUSC US; van Baar ME, 2001, ANN RHEUM DIS, V60, P1123, DOI 10.1136/ard.60.12.1123; van der Tweel I, 2010, CLIN TRIALS, V7, P136, DOI 10.1177/1740774509360994; Wang CC, 2009, ARTHRIT RHEUM-ARTHR, V61, P1545, DOI 10.1002/art.24832; Wang TJ, 2007, J ADV NURS, V57, P141, DOI 10.1111/j.1365-2648.2006.04102.x; Wang TJ, 2011, J CLIN NURS, V20, P2609, DOI 10.1111/j.1365-2702.2010.03675.x; Weng MC, 2009, KAOHSIUNG J MED SCI, V25, P306, DOI 10.1016/S1607-551X(09)70521-2; Wetterslev J, 2009, BMC MED RES METHODOL, V9, DOI 10.1186/1471-2288-9-86; Williamson L, 2007, RHEUMATOLOGY, V46, P1445, DOI 10.1093/rheumatology/kem119; Yennan P, 2010, ASIAN BIOMED, V4, P739, DOI 10.2478/abm-2010-0096; Zhang W, 2008, OSTEOARTHR CARTILAGE, V16, P137, DOI 10.1016/j.joca.2007.12.013; Zhang W, 2005, ANN RHEUM DIS, V64, P669, DOI 10.1136/ard.2004.028886; Zhang W, 2010, OSTEOARTHR CARTILAGE, V18, P476, DOI 10.1016/j.joca.2010.01.013	113	201	210	1	68	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 20	2013	347								f5555	10.1136/bmj.f5555	http://dx.doi.org/10.1136/bmj.f5555			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	223TB	24055922	Green Published, Green Accepted, hybrid			2023-01-03	WOS:000324831800001
J	Meplan, C; Dragsted, LO; Ravn-Haren, G; Tjonneland, A; Vogel, U; Hesketh, J				Meplan, Catherine; Dragsted, Lars Ove; Ravn-Haren, Gitte; Tjonneland, Anne; Vogel, Ulla; Hesketh, John			Association between Polymorphisms in Glutathione Peroxidase and Selenoprotein P Genes, Glutathione Peroxidase Activity, HRT Use and Breast Cancer Risk	PLOS ONE			English	Article							SINGLE NUCLEOTIDE POLYMORPHISMS; GPX1 PRO198LEU POLYMORPHISM; NO ASSOCIATION; ALCOHOL INTAKE; HEREDITARY BREAST; OXIDATIVE STRESS; DNA-DAMAGE; SELENIUM; ESTROGEN; CONSUMPTION	Breast cancer (BC) is one of the most common cancers in women. Evidence suggests that genetic variation in antioxidant enzymes could influence BC risk, but to date the relationship between selenoproteins and BC risk remains unclear. In this report, a study population including 975 Danish cases and 975 controls matched for age and hormone replacement therapy (HRT) use was genotyped for five functional single nucleotide polymorphisms (SNPs) in SEPP1, GPX1, GPX4 and the antioxidant enzyme SOD2 genes. The influence of genetic polymorphisms on breast cancer risk was assessed using conditional logistic regression. Additionally pre-diagnosis erythrocyte GPx (eGPx) activity was measured in a sub-group of the population. A 60% reduction in risk of developing overall BC and ductal BC was observed in women who were homozygous Thr carriers for SEPP1 rs3877899. Additionally, Leu carriers for GPX1 Pro198Leu polymorphism (rs1050450) were at similar to 2 fold increased risk of developing a non-ductal BC. Pre-diagnosis eGPx activity was found to depend on genotype for rs713041 (GPX4), rs3877899 (SEPP1), and rs1050450 (GPX1) and on HRT use. Moreover, depending on genotype and HRT use, eGPx activity was significantly lower in women who developed BC later in life compared with controls. Furthermore, GPx1 protein levels increased in human breast adenocarcinoma MCF7 cells exposed to beta-estradiol and sodium selenite. In conclusion, our data provide evidence that SNPs in SEPP1 and GPX1 modulate risk of BC and that eGPx activity is modified by SNPs in SEPP1, GPX4 and GPX1 and by estrogens. Our data thus suggest a role of selenoproteins in BC development.	[Meplan, Catherine; Hesketh, John] Newcastle Univ, Inst Cell & Mol Biosci, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; [Meplan, Catherine; Hesketh, John] Newcastle Univ, Human Nutr Res Ctr, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; [Dragsted, Lars Ove; Ravn-Haren, Gitte] Univ Copenhagen, Dept Human Nutr, Frederiksberg, Denmark; [Ravn-Haren, Gitte] Tech Univ Denmark, Natl Food Inst, Soborg, Denmark; [Tjonneland, Anne] Danish Canc Soc, Res Ctr, Copenhagen, Denmark; [Vogel, Ulla] Natl Res Ctr Working Environm, Copenhagen, Denmark	Newcastle University - UK; Newcastle University - UK; University of Copenhagen; Technical University of Denmark; Danish Cancer Society; National Research Centre for the Working Environment	Vogel, U (corresponding author), Natl Res Ctr Working Environm, Copenhagen, Denmark.	ubv@nrcwe.dk; j.e.hesketh@ncl.ac.uk	Dragsted, Lars Ove/AAT-1713-2020; Vogel, Ulla/ABC-2212-2020; Ravn-Haren, Gitte/I-8551-2018; Vogel, Ulla B/I-5048-2012; Dragsted, Lars O./N-3384-2014	Dragsted, Lars Ove/0000-0003-0609-6317; Vogel, Ulla/0000-0001-6807-1524; Ravn-Haren, Gitte/0000-0002-4587-089X; Vogel, Ulla B/0000-0001-6807-1524; Dragsted, Lars O./0000-0003-0609-6317; Tjonneland, Anne/0000-0003-4385-2097	Newcastle Healthcare Charity; Biotechnology and Biological Sciences Research Council; Nutrition Biomics Innovation (NuBI) from The Danish Ministry of Food, Agriculture and Fisheries [3304-FVFP-060696]	Newcastle Healthcare Charity; Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Nutrition Biomics Innovation (NuBI) from The Danish Ministry of Food, Agriculture and Fisheries	CM was supported by Newcastle Healthcare Charity and Biotechnology and Biological Sciences Research Council. The work was supported by the grant Nutrition Biomics Innovation (NuBI) from The Danish Ministry of Food, Agriculture and Fisheries (J.nr. 3304-FVFP-060696). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ahn J, 2005, CANCER EPIDEM BIOMAR, V14, P2459, DOI 10.1158/1055-9965.EPI-05-0459; Ambrosone CB, 2000, ANTIOXID REDOX SIGN, V2, P903, DOI 10.1089/ars.2000.2.4-903; Bellinger FP, 2009, BIOCHEM J, V422, P11, DOI 10.1042/BJ20090219; Bermano G, 2010, CANCER BIOMARK, V7, P39, DOI 10.3233/CBM-2010-0146; Brigelius-Flohe R, 2009, BBA-GEN SUBJECTS, V1790, P1555, DOI 10.1016/j.bbagen.2009.03.006; Burk RF, 2009, BBA-GEN SUBJECTS, V1790, P1441, DOI 10.1016/j.bbagen.2009.03.026; Campeau PM, 2008, HUM GENET, V124, P31, DOI 10.1007/s00439-008-0529-1; Charalabopoulos K, 2006, BRIT J CANCER, V95, P674, DOI 10.1038/sj.bjc.6603292; Cooper ML, 2008, CANCER RES, V68, P10171, DOI 10.1158/0008-5472.CAN-08-1827; Cox DG, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-217; Cox DG, 2004, CANCER EPIDEM BIOMAR, V13, P1821; Crawford A, 2012, GENE, V501, P89, DOI 10.1016/j.gene.2012.04.011; Easton DF, 2008, HUM MOL GENET, V17, pR109, DOI 10.1093/hmg/ddn287; Elston C W, 2002, Histopathology, V41, P154; Forsberg L, 2000, BLOOD CELL MOL DIS, V26, P423, DOI 10.1006/bcmd.2000.0325; Ha EJ, 2003, J AM COLL NUTR, V22, P43, DOI 10.1080/07315724.2003.10719274; Hansen RD, 2009, MUTAT RES-FUND MOL M, V664, P13, DOI 10.1016/j.mrfmmm.2009.01.009; Hesketh J, 2011, P NUTR SOC, V70, P365, DOI 10.1017/S0029665111000115; Hu J, 2010, BREAST CANCER RES TR, V124, P425, DOI 10.1007/s10549-010-0841-z; Hu YJ, 2005, J NUTR, V135, p3021S, DOI 10.1093/jn/135.12.3021S; Hu YJ, 2003, CANCER RES, V63, P3347; Jablonska E, 2009, EUR J NUTR, V48, P383, DOI 10.1007/s00394-009-0023-0; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.20107]; Knight JA, 2004, CANCER EPIDEM BIOMAR, V13, P146, DOI 10.1158/1055-9965.EPI-03-0164; Larsen SB, 2010, CANCER LETT, V295, P191, DOI 10.1016/j.canlet.2010.02.023; Loft S, 1996, J MOL MED, V74, P297, DOI 10.1007/s001090050031; Lopez-Saez JB, 2003, ONCOLOGY-BASEL, V64, P227, DOI 10.1159/000069312; Meindl A, 2011, DTSCH ARZTEBL INT, V108, P323, DOI 10.3238/arztebl.2011.0323; Meplan C, 2008, AM J CLIN NUTR, V87, P1019, DOI 10.1093/ajcn/87.4.1019; Meplan C, 2007, FASEB J, V21, P3063, DOI 10.1096/fj.07-8166com; Meplan C, 2009, ANTIOXID REDOX SIGN, V11, P2631, DOI [10.1089/ars.2009.2533, 10.1089/ARS.2009.2533]; Meplan C, 2010, CARCINOGENESIS, V31, P1074, DOI 10.1093/carcin/bgq076; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; Mobley JA, 2004, CARCINOGENESIS, V25, P3, DOI 10.1093/carcin/bgg175; Peng SH, 2011, BREAST CANCER RES TR, V127, P309, DOI 10.1007/s10549-011-1459-5; Petersen RK, 2012, CANCER LETT, V315, P59, DOI 10.1016/j.canlet.2011.10.009; Ratnasinghe D, 2000, CANCER RES, V60, P6381; Ravn-Haren G, 2006, CARCINOGENESIS, V27, P820, DOI 10.1093/carcin/bgi267; Rayman MP, 2002, P NUTR SOC, V61, P203, DOI 10.1079/PNS2002153; Riscuta Gabriela, 2012, Methods Mol Biol, V863, P343, DOI 10.1007/978-1-61779-612-8_22; ROY D, 1989, CANCER RES, V49, P1475; Saito Y, 2004, BIOCHEM J, V381, P841, DOI 10.1042/BJ20040328; Serra-Majem L, 2009, BRIT J NUTR, V102, pS38, DOI 10.1017/S0007114509993138; Steinbrecher A, 2010, CANCER EPIDEM BIOMAR, V19, P2958, DOI 10.1158/1055-9965.EPI-10-0364; Terry MB, 2006, CARCINOGENESIS, V27, P840, DOI 10.1093/carcin/bgi285; Tjonneland A, 2004, J NUTR, V134, P173, DOI 10.1093/jn/134.1.173; Tsai SM, 2012, ANN CLIN BIOCHEM, V49, P152, DOI 10.1258/acb.2011.011098; Udler M, 2007, J CLIN ONCOL, V25, P3015, DOI 10.1200/JCO.2006.10.0099; Vera-Ramirez L, 2013, CRIT REV FOOD SCI, V53, P49, DOI 10.1080/10408398.2010.521600; Villette S, 2002, BLOOD CELL MOL DIS, V29, P174, DOI 10.1006/bcmd.2002.0556; Vogel U, 2003, CANCER EPIDEM BIOMAR, V12, P170; Vogel U, 2007, CARCINOGENESIS, V28, P427, DOI 10.1093/carcin/bgl170; Wang J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027642; Yager J D, 2000, J Natl Cancer Inst Monogr, P67; Yager JD, 1996, ANNU REV PHARMACOL, V36, P203, DOI 10.1146/annurev.pa.36.040196.001223; Zhou XD, 2012, J NUTR BIOCHEM, V23, P532, DOI 10.1016/j.jnutbio.2011.02.008	56	56	63	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 10	2013	8	9							e73316	10.1371/journal.pone.0073316	http://dx.doi.org/10.1371/journal.pone.0073316			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	259PK	24039907	Green Published, gold, Green Submitted			2023-01-03	WOS:000327538600024
J	Klein, E; Mann, A; Huber, S; Bloechle, J; Willmes, K; Karim, AA; Nuerk, HC; Moeller, K				Klein, Elise; Mann, Anne; Huber, Stefan; Bloechle, Johannes; Willmes, Klaus; Karim, Ahmed A.; Nuerk, Hans-Christoph; Moeller, Korbinian			Bilateral Bi-Cephalic Tdcs with Two Active Electrodes of the Same Polarity Modulates Bilateral Cognitive Processes Differentially	PLOS ONE			English	Article							DIRECT-CURRENT STIMULATION; NONINVASIVE BRAIN-STIMULATION; INTRAPARIETAL SULCUS; NUMBER; CORTEX; LANGUAGE; MEMORY; FMRI; REPRESENTATIONS; APPROXIMATE	Transcranial direct current stimulation (tDCS) is an innovative method to explore the causal structure-function relationship of brain areas. We investigated the specificity of bilateral bi-cephalic tDCS with two active electrodes of the same polarity (e.g., cathodal on both hemispheres) applied to intraparietal cortices bilaterally using a combined between-and within-task approach. Regarding between-task specificity, we observed that bilateral bi-cephalic tDCS affected a numerical (mental addition) but not a control task (colour word Stroop), indicating a specific influence of tDCS on numerical but not on domain general cognitive processes associated with the bilateral IPS. In particular, the numerical effect of distractor distance was more pronounced under cathodal than under anodal stimulation. Moreover, with respect to within-task specificity we only found the numerical distractor distance effect in mental addition to be modulated by direct current stimulation, whereas the effect of target identity was not affected. This implies a differential influence of bilateral bi-cephalic tDCS on the recruitment of different processing components within the same task (number magnitude processing vs. recognition of familiarity). In sum, this first successful application of bilateral bi-cephalic tDCS with two active electrodes of the same polarity in numerical cognition research corroborates the specific proposition of the Triple Code Model that number magnitude information is represented bilaterally in the intraparietal cortices.	[Klein, Elise; Huber, Stefan; Nuerk, Hans-Christoph; Moeller, Korbinian] Knowledge Media Res Ctr, Neurocognit Lab, Tubingen, Germany; [Klein, Elise; Willmes, Klaus] Rhein Westfal TH Aachen, Univ Hosp, Dept Neurol, Sect Neuropsychol, Aachen, Germany; [Klein, Elise; Willmes, Klaus] Rhein Westfal TH Aachen, Fac Med, Brain Imaging Facil, Interdisciplinary Ctr Clin Res, Aachen, Germany; [Klein, Elise; Mann, Anne; Huber, Stefan; Bloechle, Johannes; Nuerk, Hans-Christoph; Moeller, Korbinian] Univ Tubingen, Dept Psychol, Tubingen, Germany; [Karim, Ahmed A.] Univ Tubingen, Dept Psychiat & Psychotherapy, Tubingen, Germany	Eberhard Karls University of Tubingen; Leibniz Institut fur Wissensmedien; RWTH Aachen University; RWTH Aachen University Hospital; RWTH Aachen University; Eberhard Karls University of Tubingen; Eberhard Karls University of Tubingen	Klein, E (corresponding author), Knowledge Media Res Ctr, Neurocognit Lab, Tubingen, Germany.	e.klein@iwm-kmrc.de	Karim, Ahmed A/D-2503-2009; Willmes, Klaus F/A-1268-2014; Huber, Stefan/D-7724-2015; Moeller, Korbinian/AAC-6387-2020	Willmes, Klaus F/0000-0002-9012-0553; Huber, Stefan/0000-0002-5842-5859; Karim, Ahmed A./0000-0003-1763-1565	"Projektforderung fur NachwuchswissenschaftlerInnen" of the Eberhard Karls University Tuebingen [Az: 7532.22]; Ministry of Science, Research and Arts of Baden-Wurttemberg [Az: 35-7532.20/739]; Volkswagen; BIAL Foundation	"Projektforderung fur NachwuchswissenschaftlerInnen" of the Eberhard Karls University Tuebingen; Ministry of Science, Research and Arts of Baden-Wurttemberg; Volkswagen(Volkswagen); BIAL Foundation(Bial Foundation)	This work was supported by grants from the "Projektforderung fur NachwuchswissenschaftlerInnen 2011" of the Eberhard Karls University Tuebingen (Az: 7532.22) to Elise Klein as well as from the Ministry of Science, Research and Arts of Baden-Wurttemberg (Az: 35-7532.20/739) within the "Exzellenzinitiative Research Seed Capital Program (RiSC)" to Elise Klein. Ahmed A. Karim was supported by the Volkswagen and the BIAL Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adleman NE, 2002, NEUROIMAGE, V16, P61, DOI 10.1006/nimg.2001.1046; Andres M, 2011, NEUROIMAGE, V54, P3048, DOI 10.1016/j.neuroimage.2010.11.009; Antal A, 2004, J COGNITIVE NEUROSCI, V16, P521, DOI 10.1162/089892904323057263; Arsalidou M, 2011, NEUROIMAGE, V54, P2382, DOI 10.1016/j.neuroimage.2010.10.009; Brunoni AR, 2012, BRAIN STIMUL, V5, P175, DOI 10.1016/j.brs.2011.03.002; Cappelletti M, 2007, EXP BRAIN RES, V179, P631, DOI 10.1007/s00221-006-0820-0; Cheng GLF, 2013, BRAIN STIMUL, V6, P160, DOI 10.1016/j.brs.2012.04.005; CIPOLOTTI L, 1991, BRAIN, V114, P2619, DOI 10.1093/brain/114.6.2619; Cohen L, 2000, COGN NEUROPSYCHOL, V17, P563, DOI 10.1080/02643290050110656; Corbetta M, 2002, NAT REV NEUROSCI, V3, P201, DOI 10.1038/nrn755; Dehaene S, 1997, CORTEX, V33, P219, DOI 10.1016/S0010-9452(08)70002-9; DEHAENE S, 1991, NEUROPSYCHOLOGIA, V29, P1045, DOI 10.1016/0028-3932(91)90076-K; Dehaene S, 2003, COGN NEUROPSYCHOL, V20, P487, DOI 10.1080/02643290244000239; Dehaene S, 1995, MATH COGNITION, V1, P83; Dehaene S, 2011, NEURON, V70, P200, DOI 10.1016/j.neuron.2011.03.018; Dehaene S, 2009, ANN NY ACAD SCI, V1156, P232, DOI 10.1111/j.1749-6632.2009.04469.x; Delazer M, 1997, CORTEX, V33, P697, DOI 10.1016/S0010-9452(08)70727-5; Delazer M, 2006, NEUROPSYCHOLOGIA, V44, P1909, DOI 10.1016/j.neuropsychologia.2006.02.007; Dmochowski JP, 2011, J NEURAL ENG, V8, DOI 10.1088/1741-2560/8/4/046011; Dockery CA, 2009, J NEUROSCI, V29, P7271, DOI 10.1523/JNEUROSCI.0065-09.2009; Driver J, 2010, EXP BRAIN RES, V206, P153, DOI 10.1007/s00221-010-2205-7; Ferrucci R, 2008, NEUROLOGY, V71, P493, DOI 10.1212/01.wnl.0000317060.43722.a3; Floel A, 2008, J COGNITIVE NEUROSCI, V20, P1415, DOI 10.1162/jocn.2008.20098; Fregni F, 2005, EXP BRAIN RES, V166, P23, DOI 10.1007/s00221-005-2334-6; Fusco A, 2013, STROKE RES TREAT, V2013, DOI 10.1155/2013/837595; Gandiga PC, 2006, CLIN NEUROPHYSIOL, V117, P845, DOI 10.1016/j.clinph.2005.12.003; Jacobson L, 2012, EXP BRAIN RES, V216, P1, DOI 10.1007/s00221-011-2891-9; Kadosh RC, 2007, NEURON, V53, P307, DOI 10.1016/j.neuron.2006.12.025; Kadosh RC, 2012, CURR BIOL, V22, pR108, DOI 10.1016/j.cub.2012.01.013; Kadosh RC, 2010, CURR BIOL, V20, P2016, DOI 10.1016/j.cub.2010.10.007; Karim AA, 2010, CEREB CORTEX, V20, P205, DOI 10.1093/cercor/bhp090; Kim H, 2011, NEUROIMAGE, V54, P2446, DOI 10.1016/j.neuroimage.2010.09.045; Klein E, 2011, BEHAV BRAIN FUNCT, V7, DOI 10.1186/1744-9081-7-15; Klein E, 2010, BEHAV BRAIN FUNCT, V6, DOI 10.1186/1744-9081-6-70; Klein E, 2010, BEHAV BRAIN FUNCT, V6, DOI 10.1186/1744-9081-6-42; Klein E, 2009, BRAIN COGNITION, V69, P369, DOI 10.1016/j.bandc.2008.08.031; Knops A, 2006, NEUROIMAGE, V29, P1, DOI 10.1016/j.neuroimage.2005.07.009; Kuo HI, 2013, BRAIN STIMUL, V6, P644, DOI 10.1016/j.brs.2012.09.010; Ladeira A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025399; Lapenta OM, 2012, NEUROSCI LETT, V527, P105, DOI 10.1016/j.neulet.2012.08.076; Lemer C, 2003, NEUROPSYCHOLOGIA, V41, P1942, DOI 10.1016/S0028-3932(03)00123-4; MACLEOD CM, 1991, PSYCHOL BULL, V109, P163, DOI 10.1037/0033-2909.109.2.163; Mameli F, 2010, BEHAV BRAIN RES, V211, P164, DOI 10.1016/j.bbr.2010.03.024; Mattai A, 2011, BRAIN STIMUL, V4, P275, DOI 10.1016/j.brs.2011.01.001; Molko N, 2003, NEURON, V40, P847, DOI 10.1016/S0896-6273(03)00670-6; Mordillo-Mateos L, 2012, BRAIN STIMUL, V5, P214, DOI 10.1016/j.brs.2011.05.001; MOYER RS, 1967, NATURE, V215, P1519, DOI 10.1038/2151519a0; Nieder A, 2009, ANNU REV NEUROSCI, V32, P185, DOI 10.1146/annurev.neuro.051508.135550; Nitsche MA, 2000, J PHYSIOL-LONDON, V527, P633, DOI 10.1111/j.1469-7793.2000.t01-1-00633.x; Nitsche MA, 2011, RESTOR NEUROL NEUROS, V29, P463, DOI 10.3233/RNN-2011-0618; Nitsche MA, 2008, BRAIN STIMUL, V1, P206, DOI 10.1016/j.brs.2008.06.004; Paulus W, 2003, P 2 INT TRANSCR MAGN; Peterson BS, 1999, BIOL PSYCHIAT, V45, P1237, DOI 10.1016/S0006-3223(99)00056-6; Price CJ, 2010, ANN NY ACAD SCI, V1191, P62, DOI 10.1111/j.1749-6632.2010.05444.x; Sandrini M, 2004, NEUROPSYCHOLOGIA, V42, P1902, DOI 10.1016/j.neuropsychologia.2004.05.005; Schlaug G, 2008, EXPERT REV MED DEVIC, V5, P759, DOI 10.1586/17434440.5.6.759; Shah NJ, 2001, BRAIN, V124, P804, DOI 10.1093/brain/124.4.804; Sparing R, 2008, NEUROPSYCHOLOGIA, V46, P261, DOI 10.1016/j.neuropsychologia.2007.07.009; Sturm W, 2001, NEUROIMAGE, V14, pS76, DOI 10.1006/nimg.2001.0839; Swick D, 2002, NEUROPSYCHOLOGIA, V40, P1240, DOI 10.1016/S0028-3932(01)00226-3; Vann SD, 2009, NAT REV NEUROSCI, V10, P792, DOI 10.1038/nrn2733; Verguts T, 2004, J COGNITIVE NEUROSCI, V16, P1493, DOI 10.1162/0898929042568497; Willmes Klaus, 2008, Handb Clin Neurol, V88, P339, DOI 10.1016/S0072-9752(07)88017-1; Wood G, 2008, BRAIN RES, V1187, P154, DOI 10.1016/j.brainres.2007.09.094	64	7	7	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 8	2013	8	8							e71607	10.1371/journal.pone.0071607	http://dx.doi.org/10.1371/journal.pone.0071607			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	201ER	23951202	Green Published, Green Submitted, gold			2023-01-03	WOS:000323124000067
J	Morden, NE; Schwartz, LM; Fisher, ES; Woloshin, S				Morden, Nancy E.; Schwartz, Lisa M.; Fisher, Elliott S.; Woloshin, Steven			Accountable Prescribing	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material								<p id="p002">To avoid rewarding poor prescribing, we should move beyond numerically driven quality measures to measures that match treatment goals to the best evidence and encourage use of the safest, most effective, and lowest-cost drugs or nondrug treatments. <p id="p003">Physicians spend a lot of time treating numbers blood pressure, cholesterol levels, glycated hemoglobin levels. Professional guidelines, pharmaceutical marketing, and public health campaigns teach physicians and patients that better numbers mean success. Unfortunately, better numbers don't reliably translate into what really matters: patients who feel better and live longer. Often the health benefit gained by reaching a goal depends on how it is reached. When physicians strive for numerical goals without prioritizing the possible treatment strategies, patients may get less effective, less safe, or even unnecessary medications. <p id="p004">Many quality measures reinforce a focus on numerical goals. For example, performance-measure ...	[Morden, Nancy E.; Schwartz, Lisa M.; Fisher, Elliott S.; Woloshin, Steven] Dartmouth Inst Hlth Policy & Clin Practice, Lebanon, NH USA; [Morden, Nancy E.] Dartmouth Hitchcock Med Ctr, Lebanon, NH 03766 USA; [Morden, Nancy E.; Schwartz, Lisa M.; Fisher, Elliott S.; Woloshin, Steven] Geisel Sch Med, Dept Community & Family Med, Hanover, NH USA; [Schwartz, Lisa M.; Woloshin, Steven] Affairs Outcomes Grp, White River Jct, VT USA	Dartmouth College; Dartmouth College; Dartmouth College	Morden, NE (corresponding author), Dartmouth Inst Hlth Policy & Clin Practice, Lebanon, NH USA.				NIA NIH HHS [K23 AG035030, P01 AG019783] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [K23AG035030, P01AG019783] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		[Anonymous], 2007, ACT PIOGL HYDR TABL; Beckett NS, 2008, NEW ENGL J MED, V358, P1887, DOI 10.1056/NEJMoa0801369; Fisher ES, 2011, NEW ENGL J MED, V365, P2445, DOI 10.1056/NEJMp1112442	3	4	4	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 25	2013	369	4					299	302		10.1056/NEJMp1301805	http://dx.doi.org/10.1056/NEJMp1301805			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	188VJ	23883375	Green Accepted, Bronze			2023-01-03	WOS:000322223900003
J	Borghi, F; Vyas, V; Podesta, A; Milani, P				Borghi, Francesca; Vyas, Varun; Podesta, Alessandro; Milani, Paolo			Nanoscale Roughness and Morphology Affect the IsoElectric Point of Titania Surfaces	PLOS ONE			English	Article							AMPHIFUNCTIONALLY ELECTRIFIED INTERFACES; AQUEOUS-ELECTROLYTE SOLUTION; DOUBLE-LAYER CAPACITANCE; ATOMIC-FORCE MICROSCOPY; CLUSTER BEAM DEPOSITION; NANOSTRUCTURED TIO2; ELECTROSTATIC INTERACTIONS; ELECTROPHORETIC MOBILITY; INTERACTION ENERGY; DLVO INTERACTION	We report on the systematic investigation of the role of surface nanoscale roughness and morphology on the charging behaviour of nanostructured titania (TiO2) surfaces in aqueous solutions. IsoElectric Points (IEPs) of surfaces have been characterized by direct measurement of the electrostatic double layer interactions between titania surfaces and the micrometer-sized spherical silica probe of an atomic force microscope in NaCl aqueous electrolyte. The use of a colloidal probe provides well-defined interaction geometry and allows effectively probing the overall effect of nanoscale morphology. By using supersonic cluster beam deposition to fabricate nanostructured titania films, we achieved a quantitative control over the surface morphological parameters. We performed a systematical exploration of the electrical double layer properties in different interaction regimes characterized by different ratios of characteristic nanometric lengths of the system: the surface rms roughness Rq, the correlation length xi and the Debye length lambda(D). We observed a remarkable reduction by several pH units of IEP on rough nanostructured surfaces, with respect to flat crystalline rutile TiO2. In order to explain the observed behavior of IEP, we consider the roughness-induced self-overlap of the electrical double layers as a potential source of deviation from the trend expected for flat surfaces.	[Borghi, Francesca; Vyas, Varun; Podesta, Alessandro; Milani, Paolo] Univ Milan, Interdisciplinary Ctr Nanostruct Mat & Interfaces, Milan, Italy; [Borghi, Francesca; Vyas, Varun; Podesta, Alessandro; Milani, Paolo] Univ Milan, Dept Phys, Milan, Italy; [Vyas, Varun] SEMM, Milan, Italy	University of Milan; University of Milan	Podesta, A (corresponding author), Univ Milan, Interdisciplinary Ctr Nanostruct Mat & Interfaces, Milan, Italy.	alessandro.podesta@mi.infn.it	borghi, francesca/GSN-3089-2022; Borghi, Francesca/AAY-6302-2021; Milani, Paolo/AAN-5069-2021; Podestà, Alessandro/E-6568-2010; Vyas, Varun/AAA-7983-2021	Podestà, Alessandro/0000-0002-4169-6679; Vyas, Varun/0000-0001-7008-7349; BORGHI, FRANCESCA/0000-0001-6980-4910				Barborini E, 1999, J PHYS D APPL PHYS, V32, pL105, DOI 10.1088/0022-3727/32/21/102; Barborini E, 2003, EUR PHYS J D, V24, P277, DOI 10.1140/epjd/e2003-00189-2; Barten D, 2003, LANGMUIR, V19, P1133, DOI 10.1021/la0117092; Bergstrom L, 1997, ADV COLLOID INTERFAC, V70, P125, DOI 10.1016/S0001-8686(97)00003-1; Bhattacharjee S, 1998, LANGMUIR, V14, P3365, DOI 10.1021/la971360b; Bogdanova NF, 2010, COLLOID J+, V72, P749, DOI 10.1134/S1061933X10060049; Bonnell DA, 2008, REP PROG PHYS, V71, DOI 10.1088/0034-4885/71/4/044501; Brookes IM, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.266103; Brown GE, 1999, CHEM REV, V99, P77, DOI 10.1021/cr980011z; Bullard JW, 2006, LANGMUIR, V22, P10264, DOI 10.1021/la061900h; Butt H.-J., 1992, Nanotechnology, V3, P60, DOI 10.1088/0957-4484/3/2/003; Butt HJ, 2005, SURF SCI REP, V59, P1, DOI 10.1016/j.surfrep.2005.08.003; BUTT HJ, 1995, BIOELECTROCH BIOENER, V38, P191, DOI 10.1016/0302-4598(95)01800-T; BUTT HJ, 1991, BIOPHYS J, V60, P1438, DOI 10.1016/S0006-3495(91)82180-4; BUTT HJ, 1995, NANOTECHNOLOGY, V6, P1, DOI 10.1088/0957-4484/6/1/001; Cappella B, 1999, SURF SCI REP, V34, P1, DOI 10.1016/S0167-5729(99)00003-5; Carbone R, 2006, BIOMATERIALS, V27, P3221, DOI 10.1016/j.biomaterials.2006.01.056; Carbone R, 2007, BIOMATERIALS, V28, P2244, DOI 10.1016/j.biomaterials.2006.12.026; Caruso T, 2008, J CHEM PHYS, V128, DOI 10.1063/1.2832321; Caruso T, 2007, SURF SCI, V601, P2688, DOI 10.1016/j.susc.2006.12.025; Castellano J.A., 1992, HDB DISPLAY TECHNOLO; Chiappini Ciro, 2006, THESIS U STUDI MILAN; Considine RF, 2001, LANGMUIR, V17, P7777, DOI 10.1021/la0017227; Cremer PS, 1999, J PHYS CHEM B, V103, P2554, DOI 10.1021/jp983996x; Daikhin LI, 1996, PHYS REV E, V53, P6192, DOI 10.1103/PhysRevE.53.6192; Daikhin LI, 1997, ELECTROCHIM ACTA, V42, P2853, DOI 10.1016/S0013-4686(97)00106-0; Daikhin LI, 1998, J CHEM PHYS, V108, P1715, DOI 10.1063/1.475543; Debye P, 1923, PHYS Z, V24, P185; Delgado AV, 2005, PURE APPL CHEM, V77, P1753, DOI 10.1351/pac200577101753; DRUMMOND CJ, 1994, COLLOID SURFACE A, V87, P217, DOI 10.1016/0927-7757(94)80070-7; DUCKER WA, 1992, LANGMUIR, V8, P1831, DOI 10.1021/la00043a024; Duval J, 2002, J ELECTROANAL CHEM, V532, P337, DOI 10.1016/S0022-0728(02)00718-0; Duval J, 2001, LANGMUIR, V17, P7573, DOI 10.1021/la010833i; Duval JFL, 2011, PHYS CHEM CHEM PHYS, V13, P1037, DOI 10.1039/c004243a; Duval JFL, 2004, LANGMUIR, V20, P5052, DOI 10.1021/la030404f; ELIMELECH M, 1994, DESALINATION, V95, P269, DOI 10.1016/0011-9164(94)00064-6; Franks GV, 2002, J COLLOID INTERF SCI, V249, P44, DOI 10.1006/jcis.2002.8250; Giorgetti L, 2008, LANGMUIR, V24, P11637, DOI 10.1021/la801910p; GRAHAME DC, 1947, CHEM REV, V41, P441, DOI 10.1021/cr60130a002; Hartley PG, 1997, LANGMUIR, V13, P2207, DOI 10.1021/la960997c; Hiemstra T, 1996, J COLLOID INTERF SCI, V179, P488, DOI 10.1006/jcis.1996.0242; Hiemstra T, 1996, J COLLOID INTERF SCI, V184, P680, DOI 10.1006/jcis.1996.0666; Hoek EMV, 2006, J COLLOID INTERF SCI, V298, P50, DOI 10.1016/j.jcis.2005.12.031; Hoek EMV, 2003, LANGMUIR, V19, P4836, DOI 10.1021/la027083c; Hsu JP, 2004, J COLLOID INTERF SCI, V272, P352, DOI 10.1016/j.jcis.2003.10.007; Huang XF, 2010, LANGMUIR, V26, P2528, DOI 10.1021/la9028113; Indrieri M, 2011, REV SCI INSTRUM, V82, DOI 10.1063/1.3553499; JOHNSON SB, 1995, LANGMUIR, V11, P2367, DOI 10.1021/la00007a009; JOHNSON SB, 1995, COLLOID SURFACE A, V103, P195, DOI 10.1016/0927-7757(95)03257-E; Kallay N, 2004, LANGMUIR, V20, P2986, DOI 10.1021/la036185f; Kallay N, 2010, CROAT CHEM ACTA, V83, P357; Khin MM, 2012, ENERG ENVIRON SCI, V5, P8075, DOI 10.1039/c2ee21818f; Kholmanov IN, 2003, NANOTECHNOLOGY, V14, P1168, DOI 10.1088/0957-4484/14/11/002; Kosmulski M, 2004, ADV COLLOID INTERFAC, V112, P93, DOI 10.1016/j.cis.2004.09.005; Kosmulski M, 2003, J COLLOID INTERF SCI, V263, P152, DOI 10.1016/S0021-9797(03)00328-X; Kosmulski M, 2011, J COLLOID INTERF SCI, V353, P1, DOI 10.1016/j.jcis.2010.08.023; Langlet J, 2008, BIOPHYS J, V94, P3293, DOI 10.1529/biophysj.107.115477; LARSON I, 1993, J AM CHEM SOC, V115, P11885, DOI 10.1021/ja00078a029; Leckband D, 2001, Q REV BIOPHYS, V34, P105, DOI 10.1017/S0033583501003687; Leonard KC, 2012, LANGMUIR, V28, P6476, DOI 10.1021/la204173w; LIDE DR, 1997, HDB CHEM PHYS; LIN XY, 1993, J PHYS CHEM-US, V97, P7272, DOI 10.1021/j100130a025; Lokar WJ, 2004, LANGMUIR, V20, P378, DOI 10.1021/la035288v; Lyklema J, 2005, ADV COLLOID INTERFAC, V114, P27, DOI 10.1016/j.cis.2004.05.002; Lyklema J., 1995, FUNDAMENTALS INTERFA, V2; Martines E, 2008, COLLOID SURFACE A, V318, P45, DOI 10.1016/j.colsurfa.2007.11.035; Mazza T, 2005, APPL PHYS LETT, V87, DOI 10.1063/1.2035874; MORIMOTO T, 1969, J PHYS CHEM-US, V73, P243, DOI 10.1021/j100721a039; Oldham KB, 2008, J ELECTROANAL CHEM, V613, P131, DOI 10.1016/j.jelechem.2007.10.017; Oleson TA, 2008, LANGMUIR, V24, P4865, DOI 10.1021/la703599g; Oleson TA, 2012, J COLLOID INTERF SCI, V370, P192, DOI 10.1016/j.jcis.2011.12.031; PARKS GA, 1965, CHEM REV, V65, P177, DOI 10.1021/cr60234a002; PARSEGIAN VA, 1972, BIOPHYS J, V12, P1192, DOI 10.1016/S0006-3495(72)86155-1; Piseri P, 2001, REV SCI INSTRUM, V72, P2261, DOI 10.1063/1.1361082; Podesta A, 2009, J PHYS CHEM C, V113, P18264, DOI 10.1021/jp905930r; Preocanin T, 2006, CROAT CHEM ACTA, V79, P95; Raiteri R, 1996, BIOSENS BIOELECTRON, V11, P1009, DOI 10.1016/0956-5663(96)87660-3; Rudzinski W, 1998, COLLOID SURFACE A, V137, P57, DOI 10.1016/S0927-7757(97)00369-5; Schaub R, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.266104; Scopelliti PE, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011862; SENDEN TJ, 1995, COLLOID SURFACE A, V94, P29, DOI 10.1016/0927-7757(94)02954-Q; Sokolov I, 2006, J COLLOID INTERF SCI, V300, P475, DOI 10.1016/j.jcis.2006.04.023; Suresh L, 1996, J COLLOID INTERF SCI, V183, P199, DOI 10.1006/jcis.1996.0535; Suttiponparnit K, 2011, NANOSCALE RES LETT, V6, DOI 10.1007/s11671-010-9772-1; Tafreshi HV, 2006, J NANOSCI NANOTECHNO, V6, P1140, DOI 10.1166/jnn.2006.139; Tsao HK, 1999, J COLLOID INTERF SCI, V216, P370, DOI 10.1006/jcis.1999.6328; Vogler EA, 1998, ADV COLLOID INTERFAC, V74, P69, DOI 10.1016/S0001-8686(97)00040-7; Wegner K, 2006, J PHYS D APPL PHYS, V39, pR439, DOI 10.1088/0022-3727/39/22/R02; WHITE LR, 1983, J COLLOID INTERF SCI, V95, P286, DOI 10.1016/0021-9797(83)90103-0; Wilson CJ, 2005, TISSUE ENG, V11, P1, DOI 10.1089/ten.2005.11.1; Yang KL, 2002, J CHEM PHYS, V117, P8499, DOI 10.1063/1.1511726	91	39	39	3	45	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 16	2013	8	7							e68655	10.1371/journal.pone.0068655	http://dx.doi.org/10.1371/journal.pone.0068655			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	186SF	23874708	Green Published, Green Submitted, gold			2023-01-03	WOS:000322064300060
J	Hankey, GJ				Hankey, Graeme J.			Training caregivers of disabled patients after stroke	LANCET			English	Editorial Material							BURDEN; DETERMINANTS; SURVIVORS; CARE; LIFE		[Hankey, Graeme J.] Univ Western Australia, Sir Charles Gairdner Hosp, Dept Neurol, Perth, WA 6009, Australia; [Hankey, Graeme J.] Univ Western Australia, Sch Med & Pharmacol, Perth, WA 6009, Australia	University of Western Australia; University of Western Australia	Hankey, GJ (corresponding author), Univ Western Australia, Sir Charles Gairdner Hosp, Dept Neurol, Perth, WA 6009, Australia.	graeme.hankey@uwa.edu.au	Hankey, Graeme J/H-4968-2014	Hankey, Graeme J/0000-0002-6044-7328				Davalos A, 2012, LANCET, V380, P349, DOI 10.1016/S0140-6736(12)60813-7; Dewey HM, 2002, STROKE, V33, P1028, DOI 10.1161/01.STR.0000013067.24300.B0; Forster A, 2013, LANCET; Forster A, 2015, INT J STROKE, V10, P259, DOI 10.1111/ijs.12038; Carod-Artal FJ, 2009, CEREBROVASC DIS, V28, P472, DOI 10.1159/000236525; Kalra L, 2004, BMJ-BRIT MED J, V328, P1099, DOI 10.1136/bmj.328.7448.1099; Legg LA, 2011, COCHRANE DB SYST REV, V10; Luengo-Fernandez R, 2013, STROKE, V44, P2854, DOI 10.1161/STROKEAHA.113.001584; McCullagh E, 2005, STROKE, V36, P2181, DOI 10.1161/01.STR.0000181755.23914.53; Murray CJL, 2012, LANCET, V380, P2197, DOI 10.1016/S0140-6736(12)61689-4; Rigby H, 2009, INT J STROKE, V4, P285, DOI 10.1111/j.1747-4949.2009.00289.x; Rigby H, 2009, INT J STROKE, V4, P152, DOI 10.1111/j.1747-4949.2009.00287.x; Zhang J., 2012, COCHRANE DB SYST REV, V5	13	5	5	0	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 21	2013	382	9910					2043	2044		10.1016/S0140-6736(13)61688-8	http://dx.doi.org/10.1016/S0140-6736(13)61688-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	275OX	24054814				2023-01-03	WOS:000328687800009
J	Kadaga, R; da Silva, JB; Featherstone, L				Kadaga, Rebecca; da Silva, Jarbas Barbosa, Jr.; Featherstone, Lynne			Caring for preterm babies is a test of how we respond to our most vulnerable citizens	LANCET			English	Editorial Material									[Kadaga, Rebecca] Parliament Republ Uganda, Kampala, Uganda; [da Silva, Jarbas Barbosa, Jr.] Minist Hlth, Brasilia, DF, Brazil; [Featherstone, Lynne] Dept Int Dev, London, England		Kadaga, R (corresponding author), Parliament Republ Uganda, POB 7178, Kampala, Uganda.	ikasirye@parliament.go.ug						Blencowe H, 2012, LANCET, V379, P2162, DOI 10.1016/S0140-6736(12)60820-4; Darmstadt G, 2013, GRAND CHALLENGES BRA; Fundacao Oswaldo Cruz, 2013, RED BRAS BANC LEIT H; Jones G, 2003, LANCET, V362, P65, DOI 10.1016/S0140-6736(03)13811-1; Leadsom A, 2013, 1001 CRITICAL DAYS I; Ministerio da Saude, 2011, MET CANG MAN TECN; Paranjothy S, 2009, ARCH DIS CHILD, V94, P239, DOI 10.1136/adc.2007.115915; Portal de Saude Ministerio da Saude, 2013, RED CEG; Roberts D, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004454.pub2; Silveira MF, 2013, REV SAUDE P IN PRESS; The Partnership for Maternal Newborn & Child Health, 2013, EV NEWB ACT PLAN END; UN Commission on Life-Saving Commodities for Women and Children, 2012, COM REP; UNICEF, 2015, COMMITTING CHILD SUR	14	1	2	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 16	2013	382	9905					1613	1614		10.1016/S0140-6736(13)62305-3	http://dx.doi.org/10.1016/S0140-6736(13)62305-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	254CN	24238547				2023-01-03	WOS:000327140700006
J	Gorse, P; Nordon, C; Rouillon, F; Pham-Scottez, A; Revah-Levy, A				Gorse, Pauline; Nordon, Clementine; Rouillon, Frederic; Pham-Scottez, Alexandra; Revah-Levy, Anne			Subjective Motives for Requesting In-Patient Treatment in Female with Anorexia Nervosa: A Qualitative Study	PLOS ONE			English	Article							EATING-DISORDERS; TREATMENT ACCEPTANCE; PREDICTORS; MORTALITY; READINESS; COMMUNITY; ADMISSION; TRIAL	Background: Anorexia nervosa is a severe psychiatric disorder mainly affecting women. Its treatment is long and accepted with much difficulty, in particular in-patient treatment. Aims: To describe the subjective motives of women with anorexia nervosa for requesting in-patient admission, from a qualitative analysis of application letters. Methods: Participants were adult women (18 years and older) with anorexia nervosa who were admitted as inpatients in a referral hospital unit in France from January 2008 to December 2010. The application letters, prerequisites to admission, were studied by the interpretative phenomenological method of content analysis. Results: 63 letters have been analysed, allowing the identification of six themes related to requests for in-patient care: loss of control of behaviour, and of thoughts, mental exhaustion, isolation, inner struggle and fear of recovery. Conclusions: Requests for in-patient admission were motivated by very personal, subjective experiences, unrelated to medical reasons for admission. These results may help improve pre-admission motivational work with individuals, by basing it on their subjective experience.	[Gorse, Pauline; Rouillon, Frederic; Pham-Scottez, Alexandra] St Anne Univ Hosp, CMME, Dept Adult Psychiat, Paris, France; [Nordon, Clementine; Revah-Levy, Anne] Univ Paris 11, INSERM, Res Unit 669, Paris, France; [Nordon, Clementine; Revah-Levy, Anne] Paris Descartes Univ, Paris, France; [Revah-Levy, Anne] Argenteuil Hosp Ctr, Argenteuil, France	GHU PARIS Psychiatrie Neurosciences; UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Universite Paris Saclay; UDICE-French Research Universities; Universite Paris Cite	Revah-Levy, A (corresponding author), Univ Paris 11, INSERM, Res Unit 669, Paris, France.	anne.revah-levy@ch-argenteuil.fr		revah-levy, anne/0000-0003-1805-6275	INSERM	INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission)	This study was funded by INSERM. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	American Psychiatric Association, 2006, PRACT GUID TREATM PA; American Psychiatric Association, 2000, DIAGN STAT MAN MENT; Ametller L, 2005, J CHILD PSYCHOL PSYC, V46, P394, DOI 10.1111/j.1469-7610.2004.00360.x; Arcelus J, 2011, ARCH GEN PSYCHIAT, V68, P724, DOI 10.1001/archgenpsychiatry.2011.74; Dupont Marie-Estelle, 2008, Rev Prat, V58, P141; Espeset EMS, 2012, CLIN PSYCHOL PSYCHOT, V19, P518, DOI 10.1002/cpp.760; Espindola CR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056275; Espindola CR, 2009, ANN CLIN PSYCHIATRY, V21, P38; Feld R, 2001, INT J EAT DISORDER, V29, P393, DOI 10.1002/eat.1035; Fox JRE, 2009, CLIN PSYCHOL PSYCHOT, V16, P240, DOI 10.1002/cpp.626; Geller J, 2002, INT J EAT DISORDER, V31, P251, DOI 10.1002/eat.10045; Geller J, 2002, INT J EAT DISORDER, V32, P344, DOI 10.1002/eat.10083; Guarda AS, 2008, PHYSIOL BEHAV, V94, P113, DOI 10.1016/j.physbeh.2007.11.020; Guarda AS, 2007, AM J PSYCHIAT, V164, P108, DOI 10.1176/appi.ajp.164.1.108; Halmi KA, 2005, ARCH GEN PSYCHIAT, V62, P776, DOI 10.1001/archpsyc.62.7.776; Huas C, 2011, ACTA PSYCHIAT SCAND, V123, P62, DOI 10.1111/j.1600-0447.2010.01627.x; Jenkins J, 2012, EUR EAT DISORD REV, V20, pe23, DOI 10.1002/erv.1085; Keski-Rahkonen A, 2007, AM J PSYCHIAT, V164, P1259, DOI 10.1176/appi.ajp.2007.06081388; Miller WR, 2003, J CONSULT CLIN PSYCH, V71, P754, DOI 10.1037/0022-006X.71.4.754; Miotto P, 2002, ACTA PSYCHIAT SCAND, V105, P372, DOI 10.1034/j.1600-0447.2002.1o186.x; Morse Janice., 1995, QUALITATIVE RES METH; Mosher Catherine E, 2008, Eat Behav, V9, P497, DOI 10.1016/j.eatbeh.2008.04.002; Murnen SK, 1997, INT J EAT DISORDER, V22, P231, DOI 10.1002/(SICI)1098-108X(199711)22:3&lt;231::AID-EAT2&gt;3.0.CO;2-O; National Institute of Clinical Excellence, 2004, EAT DIS COR INT TREA, V9; Nordbo RHS, 2006, INT J EAT DISORDER, V39, P556, DOI 10.1002/eat.20276; Papadopoulos FC, 2009, BRIT J PSYCHIAT, V194, P10, DOI 10.1192/bjp.bp.108.054742; Paulson-Karlsson G, 2012, J MULTIDISCIP HEALTH, V5, P169, DOI 10.2147/JMDH.S33658; Qsr International Pty Ltd, 2012, NVIVO QUAL DAT AN SO; Reid M, 2008, J HEALTH PSYCHOL, V13, P956, DOI 10.1177/1359105308095070; Serpell L, 1999, INT J EAT DISORDER, V25, P177, DOI 10.1002/(SICI)1098-108X(199903)25:2<177::AID-EAT7>3.3.CO;2-4; Smith J, 2008, PRACTICAL GUIDE RES, V2nd ed.; Steinhausen HC, 2002, AM J PSYCHIAT, V159, P1284, DOI 10.1176/appi.ajp.159.8.1284; Strober M, 1997, INT J EAT DISORDER, V22, P339, DOI 10.1002/(SICI)1098-108X(199712)22:4&lt;339::AID-EAT1&gt;3.0.CO;2-N; Strother L, 2010, CONSCIOUS COGN, V19, P12, DOI 10.1016/j.concog.2009.12.007; Swanson SA, 2011, ARCH GEN PSYCHIAT, V68, P714, DOI 10.1001/archgenpsychiatry.2011.22; Tan J, 2003, INT J LAW PSYCHIAT, V26, P697, DOI 10.1016/j.ijlp.2003.09.010; Tasca GA, 2012, EUR EAT DISORD REV, V20, P155, DOI 10.1002/erv.1133; Treasure JL, 1997, CLIN GUIDE MANAGEMEN; Vitousek K, 1998, CLIN PSYCHOL REV, V18, P391, DOI 10.1016/S0272-7358(98)00012-9; Wallier J, 2009, INT J EAT DISORDER, V42, P636, DOI 10.1002/eat.20609; Yager J, 2012, PRACTICE GUIDELINE T, P2012	41	12	12	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 25	2013	8	10							e77757	10.1371/journal.pone.0077757	http://dx.doi.org/10.1371/journal.pone.0077757			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	241GW	24204951	Green Published, Green Submitted, gold			2023-01-03	WOS:000326155400055
J	Liu, XQ; Olsen, J; Agerbo, E; Yuan, W; Cnattingius, S; Gissler, M; Li, J				Liu, Xiaoqin; Olsen, Jorn; Agerbo, Esben; Yuan, Wei; Cnattingius, Sven; Gissler, Mika; Li, Jiong			Psychological Stress and Hospitalization for Childhood Asthma-a Nationwide Cohort Study in Two Nordic Countries	PLOS ONE			English	Article							MATERNAL DEPRESSIVE SYMPTOMS; TOBACCO-SMOKE; CHILDREN; POPULATION; EXPOSURE; VIOLENCE; ADULT; ONSET; LIFE; PRESCRIPTION	Objective: Exposures to psychological stress in early life may contribute to the development or exacerbation of asthma. We undertook a cohort study based on data from several population-based registers in Denmark and Sweden to examine whether bereavement in childhood led to increased asthma hospitalization. Methods: All singleton children born in Denmark during 1977-2008 and in Sweden during 1973-2006 were included in the study (N=5,202,576). The children were followed from birth to the date of first asthma hospitalization, emigration, death, their 18th birthday, or the end of study (31 December 2007 in Sweden and 31 December 2008 in Denmark), whichever came first. All the children were assigned to the non-bereaved group until they lost a close relative (mother, father or a sibling), from when they were included in the bereaved group. We evaluated the hazard ratio (HR) of first hospitalization for asthma in bereaved children using Cox proportional hazards regression models, compared to those who were in the non-bereaved group. We also did a sub-analysis on the association between bereavement and first asthma medication. Results: A total of 147,829 children were hospitalized for asthma. The overall adjusted HR of asthma hospitalization in bereaved children was 1.10 (95% confidence interval (CI): 1.04-1.16), compared to non-bereaved children. The risk of asthma hospitalization was increased in those who lost a close relative at age of 14-17 years (HR=1.54, 95% CI: 1.23-1.92), but not in younger age groups. The association between bereavement and asthma hospitalization did not change over time since bereavement. In the sub-analysis in singleton live births during 1996-2008 recorded in the DMBR, bereavement was associated with a lower use of asthma medication (HR=0.87, 95% CI: 0.80-0.95). Conclusions: Our data suggests that psychological stress following bereavement in late adolescence is associated with an increased risk of asthma hospitalization or lowers the threshold for asthma hospitalization.	[Liu, Xiaoqin; Olsen, Jorn; Li, Jiong] Aarhus Univ, Dept Publ Hlth, Epidemiol Sect, Aarhus, Denmark; [Liu, Xiaoqin; Yuan, Wei] WHO Collaborating Ctr Res Human Reprod, Shanghai Inst Planned Parenthood Res, Dept Epidemiol & Social Sci Reprod Hlth, Natl Populat & Family Planning Key Lab Contracept, Shanghai, Peoples R China; [Olsen, Jorn] Univ Calif Los Angeles, Dept Epidemiol, Fielding Sch Publ Hlth, Los Angeles, CA USA; [Agerbo, Esben] Aarhus Univ, Natl Ctr Register Based Res, Aarhus, Denmark; [Agerbo, Esben] Aarhus Univ, CIRRAU Ctr Integrated Register Based Res, Aarhus, Denmark; [Cnattingius, Sven] Karolinska Univ Hosp, Karolinska Inst, Clin Epidemiol Unit, Dept Med Solna, Stockholm, Sweden; [Gissler, Mika] THL Natl Inst Hlth & Welf, Dept Informat, Helsinki, Finland; [Gissler, Mika] NHV Nord Sch Publ Hlth, Gothenburg, Sweden	Aarhus University; University of California System; University of California Los Angeles; Aarhus University; Aarhus University; Karolinska Institutet; Karolinska University Hospital; Finland National Institute for Health & Welfare	Liu, XQ (corresponding author), Aarhus Univ, Dept Publ Hlth, Epidemiol Sect, Aarhus, Denmark.	lxq@soci.au.dk	Agerbo, Esben/A-2645-2012; Liu, Xiaoqin/AAB-7509-2019; li, jiong/L-6534-2014	Agerbo, Esben/0000-0002-2849-524X; Liu, Xiaoqin/0000-0003-4519-1536; li, jiong/0000-0002-1716-8067; li, jiong/0000-0003-1125-026X; Gissler, Mika/0000-0001-8254-7525	European Research Council (ERC) 'Prog Euro' [260242]; Danish Medical Research Council [09-072986]; MRC [MR/K006525/1] Funding Source: UKRI; Medical Research Council [MR/K006525/1] Funding Source: researchfish	European Research Council (ERC) 'Prog Euro'(European Research Council (ERC)); Danish Medical Research Council(Danish Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	The study was supported by the European Research Council (ERC, starting grant no. 260242, 'Prog Euro') and the Danish Medical Research Council (project no. 09-072986). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Andersen TF, 1999, DAN MED BULL, V46, P263; Bahreinian S, 2013, AM J RESP CRIT CARE, V187, P144, DOI 10.1164/rccm.201201-0025OC; Balk D., 2001, HDB BEREAVEMENT RES, P199, DOI DOI 10.1037/10436-008; Bartlett SJ, 2004, PEDIATRICS, V113, P229, DOI 10.1542/peds.113.2.229; Biank NM, 2011, OMEGA-J DEATH DYING, V63, P271, DOI 10.2190/OM.63.3.e; Black D, 1998, BMJ-BRIT MED J, V316, P931, DOI 10.1136/bmj.316.7135.931; Bloomberg GR, 2005, IMMUNOL ALLERGY CLIN, V25, P83, DOI 10.1016/j.iac.2004.09.001; Bouffard R, 2003, CAN J PSYCHIAT, V48, P546, DOI 10.1177/070674370304800806; Brooks AM, 2001, ARCH PEDIAT ADOL MED, V155, P401, DOI 10.1001/archpedi.155.3.401; Burke W, 2003, AM J PREV MED, V24, P160, DOI 10.1016/S0749-3797(02)00589-5; Christ GH, 2002, JAMA-J AM MED ASSOC, V288, P1269, DOI 10.1001/jama.288.10.1269; de Nijs SB, 2013, EUR RESPIR REV, V22, P44, DOI 10.1183/09059180.00007112; Eder W, 2006, NEW ENGL J MED, V355, P2226, DOI 10.1056/NEJMra054308; Essex MJ, 2002, BIOL PSYCHIAT, V52, P776, DOI 10.1016/S0006-3223(02)01553-6; Fang F, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027202; Frank L, 2000, SCIENCE, V287, P2398, DOI 10.1126/science.287.5462.2398; Hansen S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036328; Hesselmar Bill, 2012, J Allergy (Cairo), V2012, P163089, DOI 10.1155/2012/163089; Juel K, 1999, DAN MED BULL, V46, P354; Kanter RK, 2006, J PEDIATR-US, V148, P637, DOI 10.1016/j.jpeds.2005.11.035; Kaugars AS, 2004, J PEDIATR PSYCHOL, V29, P475, DOI 10.1093/jpepsy/jsh051; Khashan AS, 2012, PSYCHOSOM MED, V74, P635, DOI 10.1097/PSY.0b013e31825ac5e7; Kildemoes HW, 2011, SCAND J PUBLIC HEALT, V39, P38, DOI 10.1177/1403494810394717; Kocevar VS, 2004, CHEST, V125, P1680, DOI 10.1378/chest.125.5.1680; Kozyrskyj AL, 2008, AM J RESP CRIT CARE, V177, P142, DOI 10.1164/rccm.200703-381OC; Lange NE, 2011, J ALLERGY CLIN IMMUN, V127, P734, DOI 10.1016/j.jaci.2010.11.010; Lazarus R.S., 1984, STRESS APPRAISAL COP; Li J, 2011, INT J EPIDEMIOL, V40, P1161, DOI 10.1093/ije/dyq127; Lietzen R, 2011, EUR RESPIR J, V37, P1360, DOI 10.1183/09031936.00164609; Ludvigsson JF, 2009, EUR J EPIDEMIOL, V24, P659, DOI 10.1007/s10654-009-9350-y; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; McLearn KT, 2006, ARCH PEDIAT ADOL MED, V160, P279, DOI 10.1001/archpedi.160.3.279; Miranda C, 2004, J ALLERGY CLIN IMMUN, V113, P101, DOI 10.1016/j.jaci.2003.10.041; Moonie SA, 2006, J SCHOOL HEALTH, V76, P18, DOI 10.1111/j.1746-1561.2006.00062.x; National Board of Health and Welfare, 2003, SWED MED BIRTH REG A; National Board of Health and Welfare, 2013, CAUS DEATH 2010; National Board of Health and Welfare, 2009, KVAL INN PAT UTSKR F; Pedersen CB, 2006, DAN MED BULL, V53, P441; Quinn K, 2010, J URBAN HEALTH, V87, P688, DOI 10.1007/s11524-010-9465-1; Raherison C, 2007, RESP MED, V101, P107, DOI 10.1016/j.rmed.2006.04.010; Reed CE, 2006, J ALLERGY CLIN IMMUN, V118, P543, DOI 10.1016/j.jaci.2006.06.020; Rosenkranz MA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040921; Rothman KJ., 2008, MODERN EPIDEMIOLOGY; Sandberg S, 2000, LANCET, V356, P982, DOI 10.1016/S0140-6736(00)02715-X; Shalowitz MU, 2001, AMBUL PEDIATR, V1, P185, DOI 10.1367/1539-4409(2001)001<0185:TROLSA>2.0.CO;2; Statistics Sweden, 2010, BACKGR FACTS POP WEL, V3; Statistics Sweden, 2006, BACKGR FACTS EV SWED; Sternthal MJ, 2010, EUR RESPIR J, V36, P1400, DOI 10.1183/09031936.00003010; Sternthal MJ, 2011, J ALLERGY CLIN IMMUN, V128, P337, DOI 10.1016/j.jaci.2011.05.008; Subramanian SV, 2007, INT J EPIDEMIOL, V36, P569, DOI 10.1093/ije/dym007; Suglia SF, 2010, J EPIDEMIOL COMMUN H, V64, P636, DOI 10.1136/jech.2008.082842; Suglia SF, 2009, ARCH PEDIAT ADOL MED, V163, P244, DOI 10.1001/archpediatrics.2008.555; Timmermans B, 2010, DANISH INTEGRATED DA; Tsai CH, 2010, RESP RES, V11, DOI 10.1186/1465-9921-11-11; von Hertzen LC, 2002, J ALLERGY CLIN IMMUN, V109, P923, DOI 10.1067/mai.2002.124776; Willfuhr KP, 2009, AM J HUM BIOL, V21, P488, DOI 10.1002/ajhb.20909; Wisnivesky JP, 2010, J ASTHMA, V47, P100, DOI 10.3109/02770900903426989; Wright RJ, 2005, CURR OPIN ALLERGY CL, V5, P23, DOI 10.1097/00130832-200502000-00006; Wright RJ, 2004, J ALLERGY CLIN IMMUN, V113, P1051, DOI 10.1016/j.jaci.2004.03.032; Wright RJ, 2002, AM J RESP CRIT CARE, V165, P358, DOI 10.1164/ajrccm.165.3.2102016; Wright Rosalind J, 2008, Allergy Asthma Clin Immunol, V4, P29, DOI 10.1186/1710-1492-4-1-29; Zuidgeest MG, 2008, BMC HEALTH SERV RES, V8, DOI 10.1186/1472-6963-8-16	62	8	8	0	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 25	2013	8	10							e78816	10.1371/journal.pone.0078816	http://dx.doi.org/10.1371/journal.pone.0078816			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	241GW	24205324	Green Published, gold, Green Submitted			2023-01-03	WOS:000326155400108
J	Helin, K; Dhanak, D				Helin, Kristian; Dhanak, Dashyant			Chromatin proteins and modifications as drug targets	NATURE			English	Review							HISTONE METHYLTRANSFERASE EZH2; SMALL-MOLECULE INHIBITOR; THERAPEUTIC STRATEGY; SOMATIC MUTATIONS; CHEMICAL PROBE; SELECTIVE-INHIBITION; DEMETHYLASE GENE; HDAC INHIBITORS; CANCER-CELLS; LYSINE 27	A plethora of groundbreaking studies have demonstrated the importance of chromatin-associated proteins and post-translational modifications of histones, proteins and DNA (so-called epigenetic modifications) for transcriptional control and normal development. Disruption of epigenetic control is a frequent event in disease, and the first epigenetic-based therapies for cancer treatment have been approved. A generation of new classes of potent and specific inhibitors for several chromatin-associated proteins have shown promise in preclinical trials. Although the biology of epigenetic regulation is complex, new inhibitors such as these will hopefully be of clinical use in the coming years.	[Helin, Kristian] Univ Copenhagen, Biotech Res & Innovat Ctr, DK-2200 Copenhagen, Denmark; [Helin, Kristian] Univ Copenhagen, Ctr Epigenet, DK-2200 Copenhagen, Denmark; [Helin, Kristian] Univ Copenhagen, Danish Stem Cell Ctr, DK-2200 Copenhagen, Denmark; [Dhanak, Dashyant] Janssen Res & Dev, Spring House, PA 19477 USA	University of Copenhagen; University of Copenhagen; University of Copenhagen; Johnson & Johnson; Janssen Pharmaceuticals	Helin, K (corresponding author), Univ Copenhagen, Biotech Res & Innovat Ctr, Ole Maaloes Vej 5, DK-2200 Copenhagen, Denmark.	kristian.helin@bric.ku.dk; ddhanak8@ITS.JNJ.com	Helin, Kristian/K-2526-2019; Helin, Kristian/HDM-8306-2022	Helin, Kristian/0000-0003-1975-6097	Danish National Research Foundation; Danish Cancer Society; Novo Nordisk Foundation; Lundbeck Foundation; European Union; European Research Council; Excellence Programme of the University of Copenhagen	Danish National Research Foundation(Danmarks Grundforskningsfond); Danish Cancer Society(Danish Cancer Society); Novo Nordisk Foundation(Novo Nordisk FoundationNovocure Limited); Lundbeck Foundation(Lundbeckfonden); European Union(European Commission); European Research Council(European Research Council (ERC)European Commission); Excellence Programme of the University of Copenhagen	Work in the Helin laboratory is supported by the Danish National Research Foundation, the Danish Cancer Society, the Novo Nordisk Foundation, the Lundbeck Foundation, the European Union, The European Research Council and the Excellence Programme of the University of Copenhagen.	Allan M, 2009, BIOORG MED CHEM LETT, V19, P1218, DOI 10.1016/j.bmcl.2008.12.075; Amatangelo MD, 2013, CELL CYCLE, V12, P2113, DOI 10.4161/cc.25163; Anglin JL, 2012, J MED CHEM, V55, P8066, DOI 10.1021/jm300917h; [Anonymous], 2009, [No title captured], Patent No. [2009084693, WO2009084693]; Baylin SB, 2011, NAT REV CANCER, V11, P726, DOI 10.1038/nrc3130; Beguelin W, 2013, CANCER CELL, V23, P677, DOI 10.1016/j.ccr.2013.04.011; Berger SL, 2007, NATURE, V447, P407, DOI 10.1038/nature05915; Bernt KM, 2011, CANCER CELL, V20, P66, DOI 10.1016/j.ccr.2011.06.010; Bracken AP, 2003, EMBO J, V22, P5323, DOI 10.1093/emboj/cdg542; Copeland R. A., 2012, PCT Int. Appl. Pat., Patent No. [WO 2012034132, 2012034132]; Daigle S. R., 2013, BLOOD; Daigle SR, 2011, CANCER CELL, V20, P53, DOI 10.1016/j.ccr.2011.06.009; Dalgliesh GL, 2010, NATURE, V463, P360, DOI 10.1038/nature08672; Dawson MA, 2011, NATURE, V478, P529, DOI 10.1038/nature10509; Delmore JE, 2011, CELL, V146, P903, DOI 10.1016/j.cell.2011.08.017; Ehrbrecht A, 2006, J PATHOL, V208, P554, DOI 10.1002/path.1925; Ernst T, 2010, NAT GENET, V42, P722, DOI 10.1038/ng.621; Filippakopoulos P, 2012, CELL, V149, P214, DOI 10.1016/j.cell.2012.02.013; Filippakopoulos P, 2010, NATURE, V468, P1067, DOI 10.1038/nature09504; French CA, 2010, J CLIN PATHOL, V63, P492, DOI 10.1136/jcp.2007.052902; Guibourt N., 2010, [No title captured], Patent No. [WO2010084160, 2010084160, WO 2010084160 A1]; Gyuris A, 2009, BBA-GENE REGUL MECH, V1789, P413, DOI 10.1016/j.bbagrm.2009.03.005; Harris WJ, 2012, CANCER CELL, V21, P473, DOI 10.1016/j.ccr.2012.03.014; Hayami S, 2011, INT J CANCER, V128, P574, DOI 10.1002/ijc.25349; Hayami S, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-59; He J, 2011, BLOOD, V117, P3869, DOI 10.1182/blood-2010-10-312736; Herold JM, 2011, J MED CHEM, V54, P2504, DOI 10.1021/jm200045v; Huang J, 2007, NATURE, V449, P105, DOI 10.1038/nature06092; Issa JPJ, 2009, CLIN CANCER RES, V15, P3938, DOI 10.1158/1078-0432.CCR-08-2783; James LI, 2013, NAT CHEM BIOL, V9, P184, DOI [10.1038/NCHEMBIO.1157, 10.1038/nchembio.1157]; Jensen LR, 2005, AM J HUM GENET, V76, P227, DOI 10.1086/427563; Kahl P, 2006, CANCER RES, V66, P11341, DOI 10.1158/0008-5472.CAN-06-1570; Kauffman EC, 2011, MOL CARCINOGEN, V50, P931, DOI 10.1002/mc.20758; Khan O, 2012, IMMUNOL CELL BIOL, V90, P85, DOI 10.1038/icb.2011.100; Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100; Knutson SK, 2013, P NATL ACAD SCI USA, V110, P7922, DOI 10.1073/pnas.1303800110; Knutson SK, 2012, NAT CHEM BIOL, V8, P890, DOI [10.1038/NCHEMBIO.1084, 10.1038/nchembio.1084]; Konze KD, 2013, ACS CHEM BIOL, V8, P1324, DOI [10.1021/cb400133J, 10.1021/cb400133j]; Kooistra SM, 2012, NAT REV MOL CELL BIO, V13, P297, DOI 10.1038/nrm3327; Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005; Kruidenier L, 2012, NATURE, V488, P404, DOI 10.1038/nature11262; Kubicek S, 2007, MOL CELL, V25, P473, DOI 10.1016/j.molcel.2007.01.017; Kuo AJ, 2011, MOL CELL, V44, P609, DOI 10.1016/j.molcel.2011.08.042; Laumonnier F, 2005, J MED GENET, V42, P780, DOI 10.1136/jmg.2004.029439; Lee MG, 2006, CHEM BIOL, V13, P563, DOI 10.1016/j.chembiol.2006.05.004; Lewis PW, 2013, SCIENCE, V340, P857, DOI 10.1126/science.1232245; Liang Y, 2009, NAT MED, V15, P1312, DOI 10.1038/nm.2051; Liu F, 2013, J MED CHEM, V56, P2110, DOI 10.1021/jm3018332; Liu F, 2010, J MED CHEM, V53, P5844, DOI 10.1021/jm100478y; Liu G, 2009, ONCOGENE, V28, P4491, DOI 10.1038/onc.2009.297; Lu PJ, 1999, J BIOL CHEM, V274, P15633, DOI 10.1074/jbc.274.22.15633; Lynch JT, 2012, EXPERT OPIN THER TAR, V16, P1239, DOI 10.1517/14728222.2012.722206; Maes T, 2013, J CLIN ONCOL, V31; McCabe MT, 2012, NATURE, V492, P108, DOI 10.1038/nature11606; McCabe MT, 2012, P NATL ACAD SCI USA, V109, P2989, DOI 10.1073/pnas.1116418109; Metzger E, 2005, NATURE, V437, P436, DOI 10.1038/nature04020; Meyer C, 2009, LEUKEMIA, V23, P1490, DOI 10.1038/leu.2009.33; Miranda TB, 2009, MOL CANCER THER, V8, P1579, DOI 10.1158/1535-7163.MCT-09-0013; Morey L, 2010, TRENDS BIOCHEM SCI, V35, P323, DOI 10.1016/j.tibs.2010.02.009; Morin RD, 2010, NAT GENET, V42, P181, DOI 10.1038/ng.518; Mosammaparast N, 2010, ANNU REV BIOCHEM, V79, P155, DOI 10.1146/annurev.biochem.78.070907.103946; Nicodeme E, 2010, NATURE, V468, P1119, DOI 10.1038/nature09589; Nikoloski G, 2010, NAT GENET, V42, P665, DOI 10.1038/ng.620; Ntziachristos P, 2012, NAT MED, V18, P298, DOI 10.1038/nm.2651; Okada Y, 2005, CELL, V121, P167, DOI 10.1016/j.cell.2005.02.020; Pasqualucci L, 2011, NAT GENET, V43, P830, DOI 10.1038/ng.892; Picaud S, 2013, CANCER RES, V73, P3336, DOI 10.1158/0008-5472.CAN-12-3292; Puissant A, 2013, CANCER DISCOV, V3, P308, DOI 10.1158/2159-8290.CD-12-0418; Qi W, 2012, P NATL ACAD SCI USA, V109, P21360, DOI 10.1073/pnas.1210371110; Ram O, 2011, CELL, V147, P1628, DOI 10.1016/j.cell.2011.09.057; Robinson G, 2012, NATURE, V488, P43, DOI 10.1038/nature11213; Ryan RJH, 2012, SCIENCE, V336, P1513, DOI 10.1126/science.1223730; Ryan RJH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028585; Sack JS, 2011, BIOCHEM J, V436, P331, DOI 10.1042/BJ20102161; Schenk T, 2012, NAT MED, V18, P605, DOI 10.1038/nm.2661; Schulte JH, 2009, CANCER RES, V69, P2065, DOI 10.1158/0008-5472.CAN-08-1735; Seal J, 2012, BIOORG MED CHEM LETT, V22, P2968, DOI 10.1016/j.bmcl.2012.02.041; Shih AH, 2012, NAT REV CANCER, V12, P599, DOI 10.1038/nrc3343; Simon C, 2012, GENE DEV, V26, P651, DOI 10.1101/gad.186411.111; Sneeringer CJ, 2010, P NATL ACAD SCI USA, V107, P20980, DOI 10.1073/pnas.1012525107; Stronach EA, 2011, CANCER RES, V71, P4412, DOI 10.1158/0008-5472.CAN-10-4111; Structural Genomics Consortium, 2013, CHEM PROB; Takawa M, 2011, CANCER SCI, V102, P1298, DOI 10.1111/j.1349-7006.2011.01958.x; Tan J, 2007, GENE DEV, V21, P1050, DOI 10.1101/gad.1524107; Valente S, 2012, BIOCHIMIE, V94, P2308, DOI 10.1016/j.biochi.2012.06.003; van Haaften G, 2009, NAT GENET, V41, P521, DOI 10.1038/ng.349; Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075; Vedadi M, 2011, NAT CHEM BIOL, V7, P566, DOI [10.1038/NCHEMBIO.599, 10.1038/nchembio.599]; Wagener N, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-524; Wagner JM, 2010, CLIN EPIGENETICS, V1, DOI 10.1007/s13148-010-0012-4; Wan HH, 2009, BIOORG MED CHEM LETT, V19, P5063, DOI 10.1016/j.bmcl.2009.07.040; Whyte WA, 2012, NATURE, V482, P221, DOI 10.1038/nature10805; Wissmann M, 2007, NAT CELL BIOL, V9, P347, DOI 10.1038/ncb1546; Wu SC, 2009, MOL ENDOCRINOL, V23, P1323, DOI 10.1210/me.2009-0131; Yang XJ, 2010, TRENDS PHARMACOL SCI, V31, P536, DOI 10.1016/j.tips.2010.08.001; Yang ZQ, 2000, CANCER RES, V60, P4735; You JS, 2012, CANCER CELL, V22, P9, DOI 10.1016/j.ccr.2012.06.008; Yu WY, 2013, BIOORGAN MED CHEM, V21, P1787, DOI 10.1016/j.bmc.2013.01.049; Yu WY, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms2304; Yuan Y, 2012, ACS CHEM BIOL, V7, P1152, DOI 10.1021/cb300139y; Zhang JH, 2012, NATURE, V481, P157, DOI 10.1038/nature10725; Zhang K, 2005, J CELL BIOCHEM, V96, P1137, DOI 10.1002/jcb.20615; Zuccato C, 2003, NAT GENET, V35, P76, DOI 10.1038/ng1219	103	331	344	2	179	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 24	2013	502	7472					480	488		10.1038/nature12751	http://dx.doi.org/10.1038/nature12751			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	238YN	24153301	Green Submitted			2023-01-03	WOS:000325988400042
J	da Gama, PAMD; Slama, H; Caspar, EA; Gevers, W; Cleeremans, A				da Gama, Pedro A. Magalhaes De Saldanha; Slama, Hichem; Caspar, Emilie A.; Gevers, Wim; Cleeremans, Axel			Placebo-Suggestion Modulates Conflict Resolution in the Stroop Task	PLOS ONE			English	Article							HYPNOTIC SUGGESTION; IMAGINATIVE SUGGESTIBILITY; HYPNOSIS; VARIABILITY; EXPECTANCY; MEMORY; INTERFERENCE; EXPECTATIONS; EXPERIENCE; ANALGESIA	Here, we ask whether placebo-suggestion (without any form of hypnotic induction) can modulate the resolution of cognitive conflict. Nave participants performed a Stroop Task while wearing an EEG cap described as a "brain wave" machine. In Experiment 1, participants were made to believe that the EEG cap would either enhance or decrease their color perception and performance on the Stroop task. In Experiment 2, participants were explicitly asked to imagine that their color perception and performance would be enhanced or decreased (non-hypnotic imaginative suggestion). We observed effects of placebo-suggestion on Stroop interference on accuracy: interference was decreased with positive suggestion and increased with negative suggestion compared to baseline. Intra-individual variability was also increased under negative suggestion compared to baseline. Compliance with the instruction to imagine a modulation of performance, on the other hand, did not influence accuracy and only had a negative impact on response latencies and on intra-individual variability, especially in the congruent condition of the Stroop Task. Taken together, these results demonstrate that expectations induced by a placebo-suggestion can modulate our ability to resolve cognitive conflict, either facilitating or impairing response accuracy depending on the suggestion's contents. Our results also demonstrate a dissociation between placebo-suggestion and non-hypnotic imaginative suggestion.	[da Gama, Pedro A. Magalhaes De Saldanha; Caspar, Emilie A.; Cleeremans, Axel] Univ Libre Bruxelles, Consciousness Cognit & Computat Grp CO3, Brussels, Belgium; [Slama, Hichem; Gevers, Wim] Univ Libre Bruxelles, UNESCOG Res Unit Cognit Neurosci, Brussels, Belgium; [Slama, Hichem] Univ Libre Bruxelles, Neuropsychol & Funct Neuroimaging Res Unit UR2NF, Brussels, Belgium; [Slama, Hichem] Univ Libre Bruxelles, Erasme Hosp, Dept Clin & Cognit Neuropsychol, Brussels, Belgium; [da Gama, Pedro A. Magalhaes De Saldanha; Slama, Hichem; Caspar, Emilie A.; Gevers, Wim; Cleeremans, Axel] Univ Libre Bruxelles, CRCN, Brussels, Belgium; [da Gama, Pedro A. Magalhaes De Saldanha; Slama, Hichem; Caspar, Emilie A.; Gevers, Wim; Cleeremans, Axel] Univ Libre Bruxelles, UNI, Brussels, Belgium	Universite Libre de Bruxelles; Universite Libre de Bruxelles; Universite Libre de Bruxelles; Universite Libre de Bruxelles; Universite Libre de Bruxelles; Universite Libre de Bruxelles	da Gama, PAMD (corresponding author), Univ Libre Bruxelles, Consciousness Cognit & Computat Grp CO3, Brussels, Belgium.	pmagalha@ulb.ac.be	da Gama, Pedro Magalhaes De Saldanha/AAP-8856-2021; Slama, Hichem/HGA-3213-2022; Caspar, Emilie/AAC-6322-2022	da Gama, Pedro Magalhaes De Saldanha/0000-0002-8546-4482; Slama, Hichem/0000-0003-3856-4488; Caspar, Emilie/0000-0003-1415-2032	Fundacao para a Ciencia e a Tecnologia (FCT) (Science and Technology Foundation) [SFRH / BD / 44723 / 2008]	Fundacao para a Ciencia e a Tecnologia (FCT) (Science and Technology Foundation)	This work was funded by the Fundacao para a Ciencia e a Tecnologia (FCT) (Science and Technology Foundation), Grant #SFRH / BD / 44723 / 2008. http://www.fct.pt/. A. C. is a Research Director for the National Fund for Scientific Research (FRS - FNRS Belgium). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ALEXANDER CN, 1977, PERS SOC PSYCHOL B, V3, P455; Amanzio M, 1999, J NEUROSCI, V19, P484, DOI 10.1523/JNEUROSCI.19-01-00484.1999; Assefi SL, 2003, PSYCHOL SCI, V14, P77, DOI 10.1111/1467-9280.01422; Augustinova M, 2012, PSYCHON B REV, V19, P521, DOI 10.3758/s13423-012-0217-y; Baker S.L., 1993, CONT HYPNOSIS, V10, P117; Benedetti F, 2007, NEUROSCIENCE, V147, P260, DOI 10.1016/j.neuroscience.2007.02.020; Benedetti F, 1997, PROG NEUROBIOL, V52, P109, DOI 10.1016/S0301-0082(97)00006-3; Benedetti F, 2002, EVAL HEALTH PROF, V25, P369, DOI 10.1177/0163278702238051; Benedetti F, 2011, NEUROPSYCHOPHARMACOL, V36, P339, DOI 10.1038/npp.2010.81; Benham G, 1998, J PERS SOC PSYCHOL, V75, P1604, DOI 10.1037/0022-3514.75.6.1604; Bingel U, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3001244; Braffman W, 1999, J PERS SOC PSYCHOL, V77, P578, DOI 10.1037/0022-3514.77.3.578; Braffman W., 2001, CONT HYPNOSIS, V18, P107, DOI DOI 10.1002/CH.224; Colagiuri B, 2011, PSYCHON B REV, V18, P399, DOI 10.3758/s13423-010-0041-1; Colloca L, 2006, PAIN, V124, P126, DOI 10.1016/j.pain.2006.04.005; Colloca L, 2011, CURR OPIN PSYCHIATR, V24, P149, DOI 10.1097/YCO.0b013e328343803b; Colloca L, 2009, PAIN, V144, P28, DOI 10.1016/j.pain.2009.01.033; Di Blasi Z, 2001, LANCET, V357, P757, DOI 10.1016/S0140-6736(00)04169-6; Di Blasi Z, 2003, EVAL HEALTH PROF, V26, P166, DOI 10.1177/0163278703026002003; Dienes Z., 2008, UNDERSTANDING PSYCHO; DIENES Z, 2006, HYPNOSIS CONSCIOUS S, P293; Dienes Z, 2013, CORTEX, V49, P386, DOI 10.1016/j.cortex.2012.07.009; Dienes Z, 2011, PERSPECT PSYCHOL SCI, V6, P274, DOI 10.1177/1745691611406920; Dietrich A, 2003, CONSCIOUS COGN, V12, P231, DOI 10.1016/S1053-8100(02)00046-6; Eitam B, 2008, PSYCHOL SCI, V19, P261, DOI 10.1111/j.1467-9280.2008.02078.x; Elsenbruch S, 2012, Neurogastroenterol Motil, V24, P914, DOI 10.1111/j.1365-2982.2012.01950.x; Enck P, 2008, NEURON, V59, P195, DOI 10.1016/j.neuron.2008.06.030; ERIKSEN BA, 1974, PERCEPT PSYCHOPHYS, V16, P143, DOI 10.3758/BF03203267; Fields HL, 1997, PLACEBO EFFECT INTER, P93; Finniss DG, 2010, LANCET, V375, P686, DOI 10.1016/S0140-6736(09)61706-2; Flehmig H. C., 2007, PSYCHOL SCI, V49, P132; Hultsch DF, 2002, J GERONTOL B-PSYCHOL, V57, pP101, DOI 10.1093/geronb/57.2.P101; Iani C, 2006, PSYCHOL SCI, V17, P721, DOI 10.1111/j.1467-9280.2006.01772.x; Iani C, 2009, CONSCIOUS COGN, V18, P856, DOI 10.1016/j.concog.2009.07.002; Job V, 2010, PSYCHOL SCI, V21, P1686, DOI 10.1177/0956797610384745; Jones R.A., 1977, SELF FULFILLING PROP; Kirsch I, 1997, INT J CLIN EXP HYP, V45, P212, DOI 10.1080/00207149708416124; Kirsch I, 1997, APPL PREV PSYCHOL, V6, P69, DOI 10.1016/S0962-1849(05)80012-5; Kirsch I, 1999, AM PSYCHOL, V54, P504, DOI 10.1037/0003-066X.54.7.504; Kirsch I, 1999, INT J CLIN EXP HYP, V47, P40, DOI 10.1080/00207149908410021; Kirsch I, 2001, CURR DIR PSYCHOL SCI, V10, P57, DOI 10.1111/1467-8721.00115; KIRSCH I, 1985, AM PSYCHOL, V40, P1189, DOI 10.1037/0003-066X.40.11.1189; Kirsch I., 1999, ANALES PSICOLOGIA, V15, P99; Kirsch I., 2011, CONT HYPNOSIS, V28, P107; Lifshitz M, 2013, CORTEX, V49, P463, DOI 10.1016/j.cortex.2012.08.007; MacDonald SWS, 2008, J COGNITIVE NEUROSCI, V20, P779, DOI 10.1162/jocn.2008.20502; MacDonald SWS, 2006, TRENDS NEUROSCI, V29, P474, DOI 10.1016/j.tins.2006.06.011; MACLEOD CM, 1992, J EXP PSYCHOL GEN, V121, P12, DOI 10.1037/0096-3445.121.1.12; MACLEOD CM, 1991, PSYCHOL BULL, V109, P163, DOI 10.1037/0033-2909.109.2.163; McClung M, 2007, J SPORT EXERCISE PSY, V29, P382, DOI 10.1123/jsep.29.3.382; Michael RB, 2012, CURR DIR PSYCHOL SCI, V21, P151, DOI 10.1177/0963721412446369; Miller FG, 2008, J ROY SOC MED, V101, P222, DOI 10.1258/jrsm.2008.070466; Milling LS, 2005, ANN BEHAV MED, V29, P116, DOI 10.1207/s15324796abm2902_6; MORSE CK, 1993, PSYCHOL AGING, V8, P156, DOI 10.1037/0882-7974.8.2.156; ORNE MT, 1962, AM PSYCHOL, V17, P776, DOI 10.1037/h0043424; ORNE MT, 1969, RRR ROSNOW ARTIFACT, P143; Parker S, 2011, MEMORY, V19, P606, DOI 10.1080/09658211.2011.592500; PARRIS BA, HYPNOTIC SU IN PRESS; Petrovic P, 2005, NEURON, V46, P957, DOI 10.1016/j.neuron.2005.05.023; Price DD, 2008, ANNU REV PSYCHOL, V59, P565, DOI 10.1146/annurev.psych.59.113006.095941; Raz A, 2006, PSYCHOL SCI, V17, P91, DOI 10.1111/j.1467-9280.2006.01669.x; Raz A, 2005, P NATL ACAD SCI USA, V102, P9978, DOI 10.1073/pnas.0503064102; Raz A, 2003, CONSCIOUS COGN, V12, P332, DOI 10.1016/S1053-8100(03)00024-2; Raz A, 2002, ARCH GEN PSYCHIAT, V59, P1155, DOI 10.1001/archpsyc.59.12.1155; Raz A, 2002, ARCH GEN PSYCHIAT, V59, P85, DOI 10.1001/archpsyc.59.1.85; Raz A, 2007, AM J CLIN HYPN, V50, P29, DOI 10.1080/00029157.2007.10401595; Raz A, 2007, CONSCIOUS COGN, V16, P331, DOI 10.1016/j.concog.2006.04.004; Rosenthal R., 1968, PYGMALION CLASSROOM; ROSNER B, 1983, TECHNOMETRICS, V25, P165, DOI 10.2307/1268549; Sonuga-Barke EJS, 2007, NEUROSCI BIOBEHAV R, V31, P977, DOI 10.1016/j.neubiorev.2007.02.005; Staats P, 1998, J PAIN SYMPTOM MANAG, V15, P235, DOI 10.1016/S0885-3924(97)00363-1; Sterzer P, 2008, CURR BIOL, V18, pR697, DOI 10.1016/j.cub.2008.06.021; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; Van Oorsouw K, 2007, AM J PSYCHOL, V120, P287, DOI 10.2307/20445399; Wager TD, 2004, SCIENCE, V303, P1162, DOI 10.1126/science.1093065; WEGNER DM, 1987, J PERS SOC PSYCHOL, V53, P5, DOI 10.1037/0022-3514.53.1.5; WEST R, 1999, J GERONTOL B-PSYCHOL, V54, P34; WICKLESS C, 1989, J PERS SOC PSYCHOL, V57, P762, DOI 10.1037/0022-3514.57.5.762	78	10	10	0	21	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 9	2013	8	10							e75701	10.1371/journal.pone.0075701	http://dx.doi.org/10.1371/journal.pone.0075701			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	236PJ	24130735	Green Published, Green Submitted, gold			2023-01-03	WOS:000325810900053
J	Roussin, A; Bouyssi, A; Pouche, L; Pourcel, L; Lapeyre-Mestre, M				Roussin, Anne; Bouyssi, Annabelle; Pouche, Lucie; Pourcel, Laure; Lapeyre-Mestre, Maryse			Misuse and Dependence on Non-Prescription Codeine Analgesics or Sedative H1 Antihistamines by Adults: A Cross-Sectional Investigation in France	PLOS ONE			English	Article							THE-COUNTER MEDICINES; COMMUNITY PHARMACIES; ABUSE; ABUSE/MISUSE; MEDICATION; INSOMNIA; DRUGS; MODEL	Background: Given the growing worldwide market of non-prescription drugs, monitoring their misuse in the context of self-medication represents a particular challenge in Public Health. The aim of this study was to investigate the prevalence of misuse, abuse, and dependence on non-prescription psychoactive drugs. Method: During one month, in randomly solicited community pharmacies, an anonymous questionnaire was offered to adults requesting paracetamol (control group), codeine combined with paracetamol in analgesics, or sedative H1 antihistamines. Responses about misuse (drug use not in agreement with the Patient Information Leaflet) abuse (excessive drug use having detrimental consequences), and dependence (established according to questions adapted from the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition criteria) on psychoactive drugs were compared to those of the paracetamol control group. Results: 295 patients (mean age 48.5 years, 68.5% of women) having used one of the studied drugs during the previous month were included. Misuse and dependence to codeine analgesics concerned 6.8% and 17.8% of the patients exposed to these drugs, respectively, (n = 118), which was significantly higher than for paracetamol. 19.5% had used codeine analgesics daily for more than six months. Headache was the most frequent reason for persistent daily use. A high prevalence of persistent daily users of sedative H1 antihistamines was also observed. Whereas these drugs are recommended only for short treatment courses of occasional insomnia, 72.2% of the participants having taken doxylamine (n = 36) were daily users, predominantly for more than six months. Conclusions: Results on misuse and dependence on non-prescription codeine analgesics suggest that chronic pain, in particular chronic cephalalgia, requires better medical care. In addition, as for hypnotics on prescription, persistent use of doxylamine for self-medication is not justified until an acceptable benefit-risk ratio for chronic sleep disturbance is shown by clinical data.	[Roussin, Anne; Bouyssi, Annabelle; Pouche, Lucie; Pourcel, Laure; Lapeyre-Mestre, Maryse] Univ Toulouse 3, Equipe Pharmacoepidemiol, INSERM, UMR1027, F-31062 Toulouse, France; [Roussin, Anne; Lapeyre-Mestre, Maryse] Hop Toulouse, Serv Pharmacol Clin, Addictovigilance Ctr, Ctr Evaluat & Informat Pharmacodependance, Toulouse, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; CHU de Toulouse	Roussin, A (corresponding author), Univ Toulouse 3, Equipe Pharmacoepidemiol, INSERM, UMR1027, F-31062 Toulouse, France.	anne.roussin@univ-tlse3.fr	Roussin, Anne/E-3557-2018; Lapeyre-Mestre, Maryse/C-8710-2012	Lapeyre-Mestre, Maryse/0000-0002-5494-5873	Mission Interministerielle de la Lutte contre les Drogues et Toxicomanies (MILDT);  [0802707]	Mission Interministerielle de la Lutte contre les Drogues et Toxicomanies (MILDT); 	This work was supported by the Mission Interministerielle de la Lutte contre les Drogues et Toxicomanies (MILDT) (http://www.drogues.gouv.fr/) in relationship with the French Health Products Safety Agency (Afssaps) which has been renamed the Agence Nationale de Securite des Medicaments et Produits de Sante (ANSM) (http://www.ansm.sante.fr/Activites/Appels-a-projets-de-recherche). The reference grant number was: 0802707. The Scientific Commission of Afssaps has had a role in the study design by recommending to randomly select community pharmacies instead to use national sentinel network of pharmacies. Afssaps gave its agreement to publish results. However the funders did not have any role in data collection and analysis as well as preparation of the manuscript.	AFIPA, CHIFFR MARCH AUT FRA; Afssaps, 2011, ANAL VENTES MEDICAME; [Anonymous], 2008, PRESCRIRE INT, V97, P206; Bendtsen L, 2012, J HEADACHE PAIN, V13, pS1, DOI 10.1007/s10194-011-0402-9; CRAIG DF, 1990, CAN MED ASSOC J, V142, P970; Djezzar S, 2009, INT J LEGAL MED, V123, P213, DOI 10.1007/s00414-008-0291-x; Ferrari A, 2006, CEPHALALGIA, V26, P187, DOI 10.1111/j.1468-2982.2005.01020.x; Fleming GF, 2004, PHARM WORLD SCI, V26, P282, DOI 10.1023/B:PHAR.0000042891.66983.60; Frei MY, 2010, MED J AUSTRALIA, V193, P294, DOI 10.5694/j.1326-5377.2010.tb03911.x; Gauvin DV, 1995, EUR J PHARMACOL, V294, P281, DOI 10.1016/0014-2999(95)00550-1; Gonzales R, 2011, J SUBST ABUSE TREAT, V40, P224, DOI 10.1016/j.jsat.2010.11.003; Gracious B, 2010, J CHILD ADOL PSYCHOP, V20, P521, DOI 10.1089/cap.2010.0031; Howard ME, 2004, AM J RESP CRIT CARE, V170, P1014, DOI 10.1164/rccm.200312-1782oc; Hughes GF, 1999, PHARM WORLD SCI, V21, P251, DOI 10.1023/A:1008788726842; Kripke DF, 2012, BMJ OPEN, V2, DOI 10.1136/bmjopen-2012-000850; Lusher J, 2006, CLIN J PAIN, V22, P316, DOI 10.1097/01.ajp.0000176360.94644.41; MATHESON C, 2002, PHARM J, V269, P66; McDonough MA, 2011, MED J AUSTRALIA, V194, P486, DOI 10.5694/j.1326-5377.2011.tb03069.x; Meoli AL, 2005, J CLIN SLEEP MED, V1, P173; MHRA (No author listed), 2009, DRUG SAFETY UPDATE, V3, P6; Morin AK, 2007, PHARMACOTHERAPY, V27, P89, DOI 10.1592/phco.27.1.89; Orriols L, 2010, PLOS MED, V7, DOI [10.1371/journal.pmed.1000366, DOI 10.1371/J0URNAL.PMED.1000366]; Orriols L, 2009, DRUG SAFETY, V32, P859, DOI 10.2165/11316590-000000000-00000; Pates R, 2002, PHARM J, V268, P179; Richardson GS, 2002, J CLIN PSYCHOPHARM, V22, P511, DOI 10.1097/00004714-200210000-00012; Schadeck B, 1996, SEM HOP PARIS, V72, P428; Sinclair HK, 1999, PHARMACOEPIDEM DR S, V8, P479, DOI 10.1002/(SICI)1099-1557(199912)8:7<479::AID-PDS462>3.3.CO;2-2; Skurtveit S, 2011, PAIN, V152, P1555, DOI 10.1016/j.pain.2011.02.045; Thomas A, 2009, J PSYCHOPHARMACOL, V23, P101, DOI 10.1177/0269881107083809; Vallejo R, 2011, PAIN PHYSICIAN, V14, pE343; Wazaify M, 2006, PATIENT EDUC COUNS, V64, P136, DOI 10.1016/j.pec.2005.12.008; Weiler JM, 2000, ANN INTERN MED, V133, P657, DOI 10.7326/0003-4819-133-8-200010170-00024	32	57	59	0	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 3	2013	8	10							e76499	10.1371/journal.pone.0076499	http://dx.doi.org/10.1371/journal.pone.0076499			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	232HM	24098516	Green Submitted, gold, Green Published			2023-01-03	WOS:000325483600059
J	Person, B; Schilling, K; Owuor, M; Ogange, L; Quick, R				Person, Bobbie; Schilling, Katharine; Owuor, Mercy; Ogange, Lorraine; Quick, Rob			A Qualitative Evaluation of Hand Drying Practices among Kenyans	PLOS ONE			English	Article							SYSTEMATIC ANALYSIS; HYGIENE; DISEASE; RISK	Background: Recommended disease prevention behaviors of hand washing, hygienic hand drying, and covering one's mouth and nose in a hygienic manner when coughing and sneezing appear to be simple behaviors but continue to be a challenge to successfully promote and sustain worldwide. We conducted a qualitative inquiry to better understand current hand drying behaviors associated with activities of daily living, and mouth and nose covering practices, among Kenyans. Methods and Findings: We conducted 7 focus group discussions; 30 in-depth interviews; 10 structured household observations; and 75 structured observations in public venues in the urban area of Kisumu; rural communities surrounding Kisumu; and a peri-urban area outside Nairobi, Kenya. Using a grounded theory approach, we transcribed and coded the narrative data followed by thematic analysis of the emergent themes. Hand drying, specifically on a clean towel, was not a common practice among our participants. Most women dried their hands on their waist cloth, called a leso, or their clothes whether they were cooking, eating or cleaning the nose of a young child. If men dried their hands, they used their trousers or a handkerchief. Children rarely dried their hands; they usually just wiped them on their clothes, shook them, or left them wet as they continued with their activities. Many people sneezed into their hands and wiped them on their clothes. Men and women used a handkerchief fairly often when they had a runny nose, cold, or the flu. Most people coughed into the air or their hand. Conclusions: Drying hands on dirty clothes, rags and lesos can compromise the benefits of handwashing. Coughing and sneezing in to an open hand can contribute to spread of disease as well. Understanding these practices can inform health promotion activities and campaigns for the prevention and control of diarrheal disease and influenza.	[Person, Bobbie] Ctr Dis Control & Prevent, Off Director, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30329 USA; [Schilling, Katharine; Quick, Rob] Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis, Div Foodborne Waterborne & Environm Dis, Atlanta, GA USA; [Owuor, Mercy; Ogange, Lorraine] Kenya Govt Med Res Ctr, Kisumu, Kenya	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Kenya Medical Research Institute	Person, B (corresponding author), Ctr Dis Control & Prevent, Off Director, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30329 USA.	bperson@cdc.gov			Vestergaard Frandsen SA	Vestergaard Frandsen SA	This qualitative inquiry was funded by Vestergaard Frandsen SA(http://www.vestergaard-frandsen.com/) as part of a larger hand hygiene investigation but they had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aiello AE, 2008, AM J PUBLIC HEALTH, V98, P1372, DOI 10.2105/AJPH.2007.124610; Burt R. S., 2005, BROKERAGE CLOSURE IN; *CDCP, 2009, COUGH SNEEZ; *CDCP, 2011, HANDW CLEAN HANDS SA; DeWalt KathleenM., 2011, PARTICIPANT OBSERVAT; Glaster B. G., 1967, THEORETICAL SENSITIV; *GLOB PUBL PRIV PA, 2011, PARTN; Gulis G, 2004, ENVIRON RES, V96, P219, DOI 10.1016/j.envres.2004.01.016; Gustafson DR, 2000, MAYO CLIN PROC, V75, P705; Jumaa PA, 2005, INT J INFECT DIS, V9, P3, DOI 10.1016/j.ijid.2004.05.005; Liu L, 2012, LANCET, V379, P2151, DOI 10.1016/S0140-6736(12)60560-1; Lopez AD, 2006, LANCET, V367, P1747, DOI 10.1016/S0140-6736(06)68770-9; MERCY KJ, 2008, THESIS METROPOLIA U; Miles M., 1994, EARLY STEPS ANAL QUA, P50; Patrick DR, 1997, EPIDEMIOL INFECT, V119, P319, DOI 10.1017/S0950268897008261; Patton MQ, 2002, QUALITATIVE ANAL INT, V3rd, P431; Ray Sandip Kumar, 2010, Indian J Public Health, V54, P126, DOI 10.4103/0019-557X.75734; Suchdev PS, 2010, FOOD NUTR BULL, V31, pS168, DOI 10.1177/15648265100312S209; Todd ECD, 2010, J FOOD PROTECT, V73, P1937, DOI 10.4315/0362-028X-73.10.1937; *WHO, 2010, KEN HLTH PROF	20	10	10	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 19	2013	8	9							e74370	10.1371/journal.pone.0074370	http://dx.doi.org/10.1371/journal.pone.0074370			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	223BC	24069302	Green Published, gold			2023-01-03	WOS:000324777300033
J	Alon, D; Stein, GY; Korenfeld, R; Fuchs, S				Alon, Danny; Stein, Gideon Y.; Korenfeld, Roman; Fuchs, Shmuel			Predictors and Outcomes of Infection-Related Hospital Admissions of Heart Failure Patients	PLOS ONE			English	Article							DYSFUNCTION; POPULATION	Background: Infections are one of the most common causes for hospitalization of patients with heart failure (HF). Yet, little is known regarding the prevalence and predictors of different types of acute infections as well as their impact on outcome among this growing population. Methods and Results: We identified all patients aged 50 or older with a major diagnosis of HF and at least one echocardiography examination who had been hospitalized over a 10-year period (January 2000 and December 2009). Infection-associated admissions were identified according to discharge diagnoses. Among 9,335 HF patients, 3530 (38%) were hospitalized at least once due to infections. The most frequent diagnoses were respiratory infection (52.6%) and sepsis/bacteremia (23.6%) followed by urinary (15.7%) and skin and soft tissue infections (7.8%). Hospitalizations due to infections compared to other indications were associated with increased 30-day mortality (13% vs. 8%, p<0.0001). These higher mortality rates were predominately related to respiratory infections (OR 1.28 [95% CI 1.09, 1.5]) and sepsis\bacteremia (OR 3.13 [95% CI 2.6, 3.7]). Important predictors for these serious infections included female gender, chronic obstructive pulmonary disease, past myocardial infarction and echocardiography-defined significant right (RV) but not left ventricular dysfunction. Conclusions: Major infection-related hospitalizations are frequent among patients with HF and are associated with increased mortality rates. Elderly female patients with multiple comorbidities and those with severe RV dysfunction are at higher risk for these infections.	[Fuchs, Shmuel] Rabin Med Ctr, Petah Tiqwa, Israel; Tel Aviv Univ, Sackler Sch Med, IL-69978 Tel Aviv, Israel	Rabin Medical Center; Tel Aviv University; Sackler Faculty of Medicine	Fuchs, S (corresponding author), Rabin Med Ctr, Beilinson Campus, Petah Tiqwa, Israel.	shmuelf@clalit.org.il						ARMENGOL S, 1992, INT J CARDIOL, V37, P418, DOI 10.1016/0167-5273(92)90276-9; Castro P, 2004, REV MED CHILE, V132, P655; Colombo PC, 2012, HEART FAIL REV, V17, P177, DOI 10.1007/s10741-011-9261-3; Corrales-Medina VF, CIRCULATION, V125, P773; Dai SL, 2012, CAN J CARDIOL, V28, P74, DOI 10.1016/j.cjca.2011.05.002; Daneshvar D, 2010, AM HEART J, V160, P394, DOI 10.1016/j.ahj.2010.06.040; Egorova E N, 2011, Patol Fiziol Eksp Ter, P42; Fonarow GC, 2008, ARCH INTERN MED, V168, P847, DOI 10.1001/archinte.168.8.847; Fonarow GC, 2008, AM HEART J, V155, P200, DOI 10.1016/j.ahj.2006.10.043; Lang RM, 2006, EUR J ECHOCARDIOGR, V7, P79, DOI 10.1016/j.euje.2005.12.014; Maeder M, 2006, CHEST, V129, P1349, DOI 10.1378/chest.129.5.1349; Mamas MA, 2008, INT J CARDIOL, V130, P304, DOI 10.1016/j.ijcard.2008.04.044; Mullerova H, 2012, RESP MED, V106, P1124, DOI 10.1016/j.rmed.2012.04.008; Paz A, 2002, CARDIOLOGY, V97, P83, DOI 10.1159/000057677; Sarmento Pedro Moraes, 2006, Rev Port Cardiol, V25, P13; Shafazand Masoud, 2012, BMC Res Notes, V5, P132, DOI 10.1186/1756-0500-5-132; Stein GY, 2012, J CARD FAIL, V18, P645, DOI 10.1016/j.cardfail.2012.05.007; Wang GQ, 2002, MICROBIOL-SGM, V148, P3955, DOI 10.1099/00221287-148-12-3955	18	52	57	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 23	2013	8	8							e72476	10.1371/journal.pone.0072476	http://dx.doi.org/10.1371/journal.pone.0072476			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	217ZW	24009684	Green Submitted, gold, Green Published			2023-01-03	WOS:000324403200025
J	Murad, MH; Haydour, Q; Benkhadra, K				Murad, M. Hassan; Haydour, Qusay; Benkhadra, Khalid			Review: In patients with chronic diabetic foot ulcers, hyperbaric oxygen reduces major amputations	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									[Murad, M. Hassan; Haydour, Qusay; Benkhadra, Khalid] Mayo Clin, Rochester, MN 55905 USA	Mayo Clinic	Murad, MH (corresponding author), Mayo Clin, Rochester, MN 55905 USA.		Murad, M. Hassan/AAW-4367-2020					GESSELL LB, 2008, HYPERBARIC OXYGEN TH; Margolis DJ, 2013, DIABETES CARE, V36, P1961, DOI 10.2337/dc12-2160	2	3	3	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 20	2013	159	4							JC9	10.7326/0003-4819-159-4-201308200-02009	http://dx.doi.org/10.7326/0003-4819-159-4-201308200-02009			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	205DM	24026285				2023-01-03	WOS:000323421700008
J	Kirpalani, H; Millar, D; Lemyre, B; Yoder, BA; Chiu, A; Roberts, RS				Kirpalani, Haresh; Millar, David; Lemyre, Brigitte; Yoder, Bradley A.; Chiu, Aaron; Roberts, Robin S.		NIPPV Study Grp	A Trial Comparing Noninvasive Ventilation Strategies in Preterm Infants	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							POSITIVE AIRWAY PRESSURE; RESPIRATORY-DISTRESS-SYNDROME; BIRTH-WEIGHT INFANTS; BRONCHOPULMONARY DYSPLASIA; NASAL; EXTUBATION; NCPAP	BackgroundTo reduce the risk of bronchopulmonary dysplasia in extremely-low-birth-weight infants, clinicians attempt to minimize the use of endotracheal intubation by the early introduction of less invasive forms of positive airway pressure. MethodsWe randomly assigned 1009 infants with a birth weight of less than 1000 g and a gestational age of less than 30 weeks to one of two forms of noninvasive respiratory support nasal intermittent positive-pressure ventilation (IPPV) or nasal continuous positive airway pressure (CPAP) at the time of the first use of noninvasive respiratory support during the first 28 days of life. The primary outcome was death before 36 weeks of postmenstrual age or survival with bronchopulmonary dysplasia. ResultsOf the 497 infants assigned to nasal IPPV for whom adequate data were available, 191 died or survived with bronchopulmonary dysplasia (38.4%), as compared with 180 of 490 infants assigned to nasal CPAP (36.7%) (adjusted odds ratio, 1.09; 95% confidence interval, 0.83 to 1.43; P=0.56). The frequencies of air leaks and necrotizing enterocolitis, the duration of respiratory support, and the time to full feedings did not differ significantly between treatment groups. ConclusionsAmong extremely-low-birth-weight infants, the rate of survival to 36 weeks of postmenstrual age without bronchopulmonary dysplasia did not differ significantly after noninvasive respiratory support with nasal IPPV as compared with nasal CPAP. (Funded by the Canadian Institutes of Health Research; NIPPV ClinicalTrials.gov number, NCT00433212; Controlled-Trials.com number, ISRCTN15233270.) In a randomized trial involving extremely-low-birth-weight infants eligible for noninvasive ventilation, the survival rate without bronchopulmonary dysplasia after nasal intermittent positive-pressure ventilation was similar to the rate after nasal continuous positive airway pressure. In extremely-low-birth-weight infants, bronchopulmonary dysplasia remains a leading cause of early death,(1) a strong predictor of later neurologic impairment,(2) and a major reason for resource use(3) and rehospitalization during the first year of life.(4) Improvements in survival rates among such infants have led to rates of bronchopulmonary dysplasia of up to 60% at the lowest gestational ages.(1),(5),(6) Tracheal intubation and mechanical ventilation are associated with ventilator-induced lung injury and airway inflammation, leading to bronchopulmonary dysplasia.(7),(8) Prolonged duration of intubation and mechanical ventilation in extremely-low-birth-weight infants is associated with an increased risk of death or survival with neurologic ...	[Kirpalani, Haresh] Childrens Hosp Philadelphia, Div Neonatol, Philadelphia, PA 19104 USA; [Kirpalani, Haresh; Roberts, Robin S.] McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON, Canada; [Lemyre, Brigitte] Univ Ottawa, Dept Pediat, Ottawa, ON K1N 6N5, Canada; [Chiu, Aaron] Univ Manitoba, Dept Pediat, Winnipeg, MB R3T 2N2, Canada; [Millar, David] Royal Matern Hosp, Dept Neonatol, Belfast, Antrim, North Ireland; [Yoder, Bradley A.] Univ Utah, Sch Med, Dept Neonatol, Salt Lake City, UT USA; [Yoder, Bradley A.] Univ Utah, Sch Med, Dept Pediat, Salt Lake City, UT USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; McMaster University; University of Ottawa; University of Manitoba; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	Kirpalani, H (corresponding author), Childrens Hosp Philadelphia, Div Neonatol, 34th St & Civ Ctr Blvd, Philadelphia, PA 19104 USA.	kirpalanih@email.chop.edu	Lemyre, Brigitte/I-2571-2019; Abubakar, Kabir M/AAC-9972-2020; Ranu, Sukhvinder/AAI-2753-2020; Chandrasekharan, Praveen/X-1729-2019; Dempsey, Eugene Michael/H-8051-2015	Lemyre, Brigitte/0000-0003-2743-0417; Ranu, Sukhvinder/0000-0001-9077-076X; Halliday, Henry/0000-0001-7978-4992; Jonsson, Baldvin/0000-0002-9812-732X; Miletin, Jan/0000-0003-0489-6054; Hubbard, Marie/0000-0003-0388-4983; Dempsey, Eugene Michael/0000-0002-6266-3462; McNamara, Patrick/0000-0001-7648-8872; Chandrasekharan, Praveen/0000-0001-8727-3017	Canadian Institutes of Health Research [MCT-80246]	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR))	Supported by the Canadian Institutes of Health Research (MCT-80246).	BELL MJ, 1978, ANN SURG, V187, P1, DOI 10.1097/00000658-197801000-00001; Chang HY, 2011, PEDIATR RES, V69, P84, DOI 10.1203/PDR.0b013e3181ff6770; Cui Yun-Pu, 2009, Zhonghua Er Ke Za Zhi, V47, P532; Davis PG, 2010, J PEDIATR-US, V156, P382, DOI 10.1016/j.jpeds.2009.09.069; Davis PG, 2001, COCHRANE DATABASE SY, V3; Dumpa V, 2012, J PERINATOL, V32, P438, DOI 10.1038/jp.2011.117; Dunn MS, 2011, PEDIATRICS, V128, pE1069, DOI 10.1542/peds.2010-3848; Finer NN, 2010, NEW ENGL J MED, V362, P2235; Finer NN, 2010, NEW ENGL J MED, V362, P1970, DOI 10.1056/NEJMoa0911783; GARLAND JS, 1985, PEDIATRICS, V76, P406; Gortner L, 2011, NEONATOLOGY, V99, P112, DOI 10.1159/000313024; Greenough A, 2008, COCHRANE DATABASE SY, V1; GREGORY GA, 1971, NEW ENGL J MED, V284, P1333, DOI 10.1056/NEJM197106172842401; Jackson JK, 2003, PEDIATRICS, V111; Jobe Alan H., 2001, American Journal of Respiratory and Critical Care Medicine, V163, P1723; Kiciman NM, 1998, PEDIATR PULM, V25, P175, DOI 10.1002/(SICI)1099-0496(199803)25:3<175::AID-PPUL7>3.0.CO;2-L; Kieran EA, 2011, ARCH DIS CHILD-FETAL, V96, pF156, DOI 10.1136/adc.2010.203190; Kirpalani H, 2006, J PEDIATR-US, V149, P301, DOI 10.1016/j.jpeds.2006.05.011; Laughon MM, 2011, AM J RESP CRIT CARE, V183, P1715, DOI 10.1164/rccm.201101-0055OC; Lemyre B, 2002, COCHRANE DATABASE SY, V1; LESOUEF PN, 1983, J APPL PHYSIOL, V55, P359, DOI 10.1152/jappl.1983.55.2.359; LLEWELLYN MA, 1970, ARCH DIS CHILD, V45, P453, DOI 10.1136/adc.45.242.453; LOFTUS BC, 1994, LARYNGOSCOPE, V104, P1019; Meneses J, 2012, ARCH PEDIAT ADOL MED, V166, P372, DOI 10.1001/archpediatrics.2011.1142; Moretti C, 1999, EARLY HUM DEV, V56, P167, DOI 10.1016/S0378-3782(99)00046-8; Moretti C, 2008, PEDIATR INT, V50, P85, DOI 10.1111/j.1442-200X.2007.02525.x; Morley CJ, 2008, NEW ENGL J MED, V358, P700, DOI 10.1056/NEJMoa072788; O'Brien K, 2012, BMC PEDIATR, V12, DOI 10.1186/1471-2431-12-43; Owen L S, 2008, Arch Dis Child Fetal Neonatal Ed, V93, pF148; Owen LS, 2011, ARCH DIS CHILD-FETAL, V96, pF422, DOI 10.1136/adc.2010.205195; Schmidt B, 2003, JAMA-J AM MED ASSOC, V289, P1124, DOI 10.1001/jama.289.9.1124; Shinwell ES, 2007, ARCH DIS CHILD-FETAL, V92, pF30, DOI 10.1136/adc.2006.094474; Smith VC, 2004, J PEDIATR-US, V144, P799, DOI 10.1016/j.jpeds.2004.03.026; Stefanescu BM, 2003, PEDIATRICS, V112, P1031, DOI 10.1542/peds.112.5.1031; Stoll BJ, 2010, PEDIATRICS, V126, P443, DOI 10.1542/peds.2009-2959; Stroustrup A, 2010, PEDIATRICS, V126, pE291, DOI 10.1542/peds.2009-3456; van Kaam A, 2011, NEONATOLOGY, V99, P338, DOI 10.1159/000326843; Walsh MC, 2005, J PEDIATR-US, V146, P798, DOI 10.1016/j.jpeds.2005.01.047; Walsh Michele C, 2003, J Perinatol, V23, P451, DOI 10.1038/sj.jp.7210963; Wright CJ, 2011, PEDIATRICS, V128, P111, DOI 10.1542/peds.2010-3875	40	144	161	0	12	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 15	2013	369	7					611	620		10.1056/NEJMoa1214533	http://dx.doi.org/10.1056/NEJMoa1214533			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	243YO	23944299				2023-01-03	WOS:000326354500007
J	Cheng, SH; Lau, KM; Li, CK; Chan, NPH; Ip, RKL; Cheng, CK; Lee, V; Shing, MMK; Leung, AWK; Ha, SY; Cheuk, DKL; Lee, ACW; Li, CH; Luk, CW; Ling, SC; Hrusak, O; Mejstrikova, E; Leung, Y; Ng, MHL				Cheng, Suk Hang; Lau, Kin Mang; Li, Chi Kong; Chan, Natalie P. H.; Ip, Rosalina K. L.; Cheng, Chi Keung; Lee, Vincent; Shing, Matthew M. K.; Leung, Alex W. K.; Ha, Shau Yin; Cheuk, Daniel K. L.; Lee, Anselm C. W.; Li, Chak Ho; Luk, Chung Wing; Ling, Siu Cheung; Hrusak, Ondrej; Mejstrikova, Ester; Leung, Yonna; Ng, Margaret H. L.			Minimal Residual Disease-Based Risk Stratification in Chinese Childhood Acute Lymphoblastic Leukemia by Flow Cytometry and Plasma DNA Quantitative Polymerase Chain Reaction	PLOS ONE			English	Article							CANCER-PATIENTS; CLINICAL-SIGNIFICANCE; GENE REARRANGEMENTS; PROGNOSTIC-FACTORS; CHILDREN; QUANTIFICATION; CLASSIFICATION; MULTICENTER; INTEGRITY; CELLS	Minimal residual disease, or MRD, is an important prognostic indicator in childhood acute lymphoblastic leukemia. In ALL-IC-BFM 2002 study, we employed a standardized method of flow cytometry MRD monitoring for multiple centers internationally using uniformed gating, and determined the relevant MRD-based risk stratification strategies in our local patient cohort. We also evaluated a novel method of PCR MRD quantitation using peripheral blood plasma. For the bone marrow flow MRD study, patients could be stratified into 3 risk groups according to MRD level using a single time-point at day-15 (Model I) (I-A: <0.1%, I-B: 0.1-10%, I-C: >10%), or using two time-points at day-15 and day-33 (Model II) (II-A: day-15<10% and day-33<0.01%, II-B: day-15 >= 10% or day-33 >= 0.01% but not both, II-C: day-15 >= 10% and day-33 >= 0.01%), which showed significantly superior prediction of relapse (p = .00047 and <0.0001 respectively). Importantly, patients with good outcome (frequency: 56.0%, event-free survival: 90.1%) could be more accurately predicted by Model II. In peripheral blood plasma PCR MRD investigation, patients with day-15-MRD >= 10(-4) were at a significantly higher risk of relapse (p = 0.0117). By multivariate analysis, MRD results from both methods could independently predict patients' prognosis, with 20-35-fold increase in risk of relapse for flow MRD I-C and II- C respectively, and 5.8-fold for patients having plasma MRD of >= 10(-4). We confirmed that MRD detection by flow cytometry is useful for prognostic evaluation in our Chinese cohort of childhood ALL after treatment. Moreover, peripheral blood plasma DNA MRD can be an alternative where bone marrow specimen is unavailable and as a less invasive method, which allows close monitoring.	[Cheng, Suk Hang; Lau, Kin Mang; Chan, Natalie P. H.; Ip, Rosalina K. L.; Cheng, Chi Keung; Leung, Yonna; Ng, Margaret H. L.] Chinese Univ Hong Kong, Prince Wales Hosp, Dept Anat & Cellular Pathol, Hong Kong, Hong Kong, Peoples R China; [Li, Chi Kong; Shing, Matthew M. K.; Leung, Alex W. K.] Chinese Univ Hong Kong, Prince Wales Hosp, Dept Pediat, Hong Kong, Hong Kong, Peoples R China; [Ha, Shau Yin; Cheuk, Daniel K. L.] Queen Mary Hosp, Dept Pediat, Hong Kong, Hong Kong, Peoples R China; [Lee, Anselm C. W.; Li, Chak Ho] Tuen Mun Hosp, Dept Pediat, Hong Kong, Hong Kong, Peoples R China; [Luk, Chung Wing] Queen Elizabeth Hosp, Dept Pediat, Hong Kong, Hong Kong, Peoples R China; [Ling, Siu Cheung] Princess Margaret Hosp, Dept Pediat, Hong Kong, Hong Kong, Peoples R China; [Hrusak, Ondrej; Mejstrikova, Ester] Charles Univ Prague, Fac Med 2, Dept Pediat Hematol & Oncol, Prague, Czech Republic; [Ng, Margaret H. L.] Chinese Univ Hong Kong, State Key Lab Oncol South China, Hong Kong, Hong Kong, Peoples R China	Chinese University of Hong Kong; Prince of Wales Hospital; Chinese University of Hong Kong; Prince of Wales Hospital; University of Hong Kong; Tuen Mun Hospital; Charles University Prague; Chinese University of Hong Kong; State Key Lab Oncology South China	Ng, MHL (corresponding author), Chinese Univ Hong Kong, Prince Wales Hosp, Dept Anat & Cellular Pathol, Hong Kong, Hong Kong, Peoples R China.	margaretng@cuhk.edu.hk	Li, Chi-kong/J-8456-2013; Cheng, Suk Hang/A-6177-2009; Leung, Kwan Alex/ABD-7456-2020; Lee, Anselm/AAP-6028-2020	Li, Chi-kong/0000-0002-2810-5758; Cheng, Suk Hang/0000-0002-2880-2289; Lee, Anselm/0000-0002-0148-8875; Lau, Kin-Mang/0000-0001-5888-1937; Cheuk, Daniel/0000-0001-9553-3528; HA, Shau Yin/0000-0002-9191-8743; Leung, Wing kwan/0000-0001-9781-5908	Research Grant Council Earmarked Grant [4408/06M]; Children's Cancer Foundation of Hong Kong SAR	Research Grant Council Earmarked Grant; Children's Cancer Foundation of Hong Kong SAR	The study was supported by Research Grant Council Earmarked Grant 4408/06M, and Children's Cancer Foundation of Hong Kong SAR. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Basso G, 2009, J CLIN ONCOL, V27, P5168, DOI 10.1200/JCO.2008.20.8934; Borowitz MJ, 2008, BLOOD, V111, P5477, DOI 10.1182/blood-2008-01-132837; Cave H, 1998, NEW ENGL J MED, V339, P591, DOI 10.1056/NEJM199808273390904; Coustan-Smith E, 2002, BLOOD, V100, P52, DOI 10.1182/blood-2002-01-0006; Coustan-Smith E, 1998, LANCET, V351, P550, DOI 10.1016/S0140-6736(97)10295-1; Coustan-Smith E, 2006, BLOOD, V108, P97, DOI 10.1182/blood-2006-01-0066; Diehl F, 2005, P NATL ACAD SCI USA, V102, P16368, DOI 10.1073/pnas.0507904102; Dworzak MN, 2008, CYTOM PART B-CLIN CY, V74B, P331, DOI 10.1002/cyto.b.20430; Esteller M, 1999, CANCER RES, V59, P67; Flohr T, 2008, LEUKEMIA, V22, P771, DOI 10.1038/leu.2008.5; Fronkova E, 2008, LEUKEMIA, V22, P989, DOI 10.1038/leu.2008.22; Gao YJ, 2010, CLIN CHEM LAB MED, V48, P1651, DOI 10.1515/CCLM.2010.311; Jahr S, 2001, CANCER RES, V61, P1659; Kalina T, 2005, BMC CANCER, V5, DOI 10.1186/1471-2407-5-38; LGSM Shaffer, 2009, ISCN 2009 INT SYSTEM, DOI DOI 10.1007/S00439-009-0726-6; Lo YMD, 1998, AM J HUM GENET, V62, P768, DOI 10.1086/301800; Mejstrikova E, 2010, PEDIATR BLOOD CANCER, V54, P62, DOI 10.1002/pbc.22261; Ng MHL, 2001, HUM PATHOL, V32, P1016, DOI 10.1053/hupa.2001.27122; Patkar N, 2012, CYTOM PART B-CLIN CY, V82B, P252, DOI 10.1002/cyto.b.21017; Pui CH, 2008, LANCET, V371, P1030, DOI 10.1016/S0140-6736(08)60457-2; Schultz KR, 2007, BLOOD, V109, P926, DOI 10.1182/blood-2006-01-024729; Schwarz AK, 2009, ANN HEMATOL, V88, P897, DOI 10.1007/s00277-009-0698-6; Schwarzenbach H, 2011, NAT REV CANCER, V11, P426, DOI 10.1038/nrc3066; Smith M, 1996, J CLIN ONCOL, V14, P18, DOI 10.1200/JCO.1996.14.1.18; Thorn I, 2011, BRIT J HAEMATOL, V152, P743, DOI 10.1111/j.1365-2141.2010.08456.x; van der Velden VHJ, 2007, LEUKEMIA, V21, P604, DOI 10.1038/sj.leu.2404586; van Dongen JJM, 1998, LANCET, V352, P1731, DOI 10.1016/S0140-6736(98)04058-6; Vrooman LM, 2009, CURR OPIN PEDIATR, V21, P1, DOI 10.1097/MOP.0b013e32831f1f24; Wang BG, 2003, CANCER RES, V63, P3966	29	20	25	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 25	2013	8	7							e69467	10.1371/journal.pone.0069467	http://dx.doi.org/10.1371/journal.pone.0069467			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	191SQ	23936021	Green Published, Green Submitted, gold			2023-01-03	WOS:000322433300040
J	Kravitz, RL; Franks, P; Feldman, MD; Tancredi, DJ; Slee, CA; Epstein, RM; Duberstein, PR; Bell, RA; Jackson-Triche, M; Paterniti, DA; Cipri, C; Iosif, AM; Olson, S; Kelly-Reif, S; Hudnut, A; Dvorak, S; Turner, C; Jerant, A				Kravitz, Richard L.; Franks, Peter; Feldman, Mitchell D.; Tancredi, Daniel J.; Slee, Christina A.; Epstein, Ronald M.; Duberstein, Paul R.; Bell, Robert A.; Jackson-Triche, Maga; Paterniti, Debora A.; Cipri, Camille; Iosif, Ana-Maria; Olson, Sarah; Kelly-Reif, Steven; Hudnut, Andrew; Dvorak, Simon; Turner, Charles; Jerant, Anthony			Patient Engagement Programs for Recognition and Initial Treatment of Depression in Primary Care A Randomized Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							TO-CONSUMER TELEVISION; PREFERENCES; DIAGNOSIS; PHYSICIAN; SEVERITY; MESSAGE; QUALITY; STIGMA; PHQ-9; COST	IMPORTANCE Encouraging primary care patients to address depression symptoms and care with clinicians could improve outcomes but may also result in unnecessary treatment. OBJECTIVE To determine whether a depression engagement video (DEV) or a tailored interactive multimedia computer program (IMCP) improves initial depression care compared with a control without increasing unnecessary antidepressant prescribing. DESIGN, SETTING, AND PARTICIPANTS Randomized clinical trial comparing DEV, IMCP, and control among 925 adult patients treated by 135 primary care clinicians (603 patients with depression and 322 patients without depression, defined by Patient Health Questionnaire-9 [PHQ-9] score) conducted from June 2010 through March 2012 at 7 primary care clinical sites in California. INTERVENTIONS DEV targeted to sex and income, an IMCP tailored to individual patient characteristics, and a sleep hygiene video (control). MAIN OUTCOMES AND MEASURES Among depressed patients, superiority assessment of the composite measure of patient-reported antidepressant drug recommendation, mental health referral, or both (primary outcome); depression at 12-week follow-up, measured by the PHQ-8 (secondary outcome). Among nondepressed patients, noninferiority assessment of clinician-and patient-reported antidepressant drug recommendation (primary outcomes) with a noninferiority margin of 3.5%. Analyses were cluster adjusted. RESULTS Of the 925 eligible patients, 867 were included in the primary analysis (depressed, 559; nondepressed, 308). Among depressed patients, rates of achieving the primary outcome were 17.5% for DEV, 26% for IMCP, and 16.3% for control (DEV vs control, 1.1 [95% CI, -6.7 to 8.9], P = .79; IMCP vs control, 9.9 [95% CI, 1.6 to 18.2], P = .02). There were no effects on PHQ-8 measured depression score at the 12-week follow-up: DEV vs control, -0.2 (95% CI, -1.2 to 0.8); IMCP vs control, 0.9 (95% CI, -0.1 to 1.9). Among nondepressed patients, clinician-reported antidepressant prescribing in the DEV and IMCP groups was noninferior to control (mean percentage point difference [PPD]: DEV vs control, -2.2 [90% CI, -8.0 to 3.49], P = .0499 for noninferiority; IMCP vs control, -3.3 [90% CI, -9.1 to 2.4], P = .02 for noninferiority); patient-reported antidepressant recommendation did not achieve noninferiority (mean PPD: DEV vs control, 0.9 [90% CI, -4.9 to 6.7], P = .23 for noninferiority; IMCP vs control, 0.3 [90% CI, -5.1 to 5.7], P = .16 for noninferiority). CONCLUSIONS AND RELEVANCE A tailored IMCP increased clinician recommendations for antidepressant drugs, a mental health referral, or both among depressed patients but had no effect on mental health at the 12-week follow-up. The possibility that the IMCP and DEV increased patient-reported clinician recommendations for an antidepressant drug among nondepressed patients could not be excluded.	[Kravitz, Richard L.] Univ Calif Davis, Div Gen Med, Sacramento, CA 95817 USA; [Kravitz, Richard L.; Franks, Peter; Tancredi, Daniel J.; Bell, Robert A.; Paterniti, Debora A.; Cipri, Camille; Jerant, Anthony] Univ Calif Davis, Ctr Healthcare Policy & Res, Sacramento, CA 95817 USA; [Franks, Peter; Jerant, Anthony] Univ Calif Davis, Dept Family & Community Med, Sacramento, CA 95817 USA; [Feldman, Mitchell D.; Olson, Sarah] Univ Calif San Francisco, Div Gen Internal Med, San Francisco, CA 94143 USA; [Tancredi, Daniel J.] Univ Calif Davis, Dept Pediat, Sacramento, CA 95817 USA; [Slee, Christina A.] Univ Calif Davis, Med Ctr, Sacramento, CA 95817 USA; [Epstein, Ronald M.; Duberstein, Paul R.] Univ Rochester, Dept Family Med, Rochester, NY USA; [Epstein, Ronald M.; Duberstein, Paul R.] Univ Rochester, Dept Psychiat, Rochester, NY USA; [Epstein, Ronald M.] Univ Rochester, Dept Oncol, Rochester, NY USA; [Bell, Robert A.] Univ Calif Davis, Dept Commun & Publ Hlth Sci, Davis, CA 95616 USA; [Jackson-Triche, Maga] Univ Calif Davis, VA Northern Calif Hlth Care Syst, Sacramento, CA 95817 USA; [Paterniti, Debora A.] Univ Calif Davis, Dept Internal Med & Sociol, Sacramento, CA 95817 USA; [Iosif, Ana-Maria] Univ Calif Davis, Dept Publ Hlth Sci, Davis, CA 95616 USA; [Kelly-Reif, Steven] Permanente Med Grp Inc, Sacramento, CA USA; [Hudnut, Andrew] Sutter Med Fdn, Sacramento, CA USA; [Dvorak, Simon; Turner, Charles] Univ Calif Davis, Acad Technol Serv, Davis, CA 95616 USA	University of California System; University of California Davis; University of California System; University of California Davis; University of California System; University of California Davis; University of California System; University of California San Francisco; University of California System; University of California Davis; University of California System; University of California Davis; University of Rochester; University of Rochester; University of Rochester; University of California System; University of California Davis; University of California System; University of California Davis; University of California System; University of California Davis; University of California System; University of California Davis; Permanente Medical Groups; University of California System; University of California Davis	Kravitz, RL (corresponding author), Univ Calif Davis, Div Gen Med, 4150 V St,Ste 2400 PSSB, Sacramento, CA 95817 USA.	rlkravitz@ucdavis.edu	Tancredi, Daniel J/O-3381-2013; Kravitz, Richard/AAF-7425-2021; Duberstein, Paul Raphael/AAO-5302-2020	Tancredi, Daniel J/0000-0002-3884-7907; Duberstein, Paul Raphael/0000-0001-6882-0898; Iosif, Ana-Maria/0000-0001-7283-2015; Kravitz, Richard/0000-0001-5575-529X	National Institute of Mental Health [1R01MH079387, K24MH072756, K24 K24MH072712]; NATIONAL CANCER INSTITUTE [P30CA093373] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [K24MH072756, R01MH079387, K24MH072712] Funding Source: NIH RePORTER	National Institute of Mental Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))	This work was supported by grants 1R01MH079387 (Kravitz), K24MH072756 (Kravitz), and K24 K24MH072712 (Duberstein) from the National Institute of Mental Health.	Avery RJ, 2012, J HEALTH ECON, V31, P705, DOI 10.1016/j.jhealeco.2012.05.002; Bell RA, 2011, ANN FAM MED, V9, P439, DOI 10.1370/afm.1277; Bell RA, 2010, PATIENT EDUC COUNS, V78, P198, DOI 10.1016/j.pec.2009.07.007; Berardi D, 2005, PSYCHOTHER PSYCHOSOM, V74, P225, DOI 10.1159/000085146; Block AE, 2007, PHARMACOECONOMICS, V25, P511, DOI 10.2165/00019053-200725060-00006; Cabana MD, 1999, JAMA-J AM MED ASSOC, V282, P1458, DOI 10.1001/jama.282.15.1458; Cooper AE, 2003, J NERV MENT DIS, V191, P339, DOI 10.1097/00005053-200305000-00010; CooperPatrick L, 1997, J GEN INTERN MED, V12, P431, DOI 10.1046/j.1525-1497.1997.00075.x; DECI EL, 1987, J PERS SOC PSYCHOL, V53, P1024, DOI 10.1037/0022-3514.53.6.1024; DeSouza CM, 2009, J BIOPHARM STAT, V19, P1055, DOI 10.1080/10543400903242795; Donohue JM, 2007, NEW ENGL J MED, V357, P673, DOI 10.1056/NEJMsa070502; Duffy SA, 2006, CANCER EPIDEM BIOMAR, V15, P2203, DOI 10.1158/1055-9965.EPI-05-0880; Dwight-Johnson M, 2001, MED CARE, V39, P934, DOI 10.1097/00005650-200109000-00004; Dwight-Johnson M, 2000, J GEN INTERN MED, V15, P527, DOI 10.1046/j.1525-1497.2000.08035.x; Epstein A., 2011, COMMON SLEEPING PROB; Epstein RM, 2010, J GEN INTERN MED, V25, P954, DOI 10.1007/s11606-010-1367-0; Fleishman JA, 2010, QUAL LIFE RES, V19, P231, DOI 10.1007/s11136-009-9582-z; Hauck WW, 1998, CONTROL CLIN TRIALS, V19, P249, DOI 10.1016/S0197-2456(97)00147-5; Jerant A, 2011, PATIENT EDUC COUNS, V85, P323, DOI 10.1016/j.pec.2010.11.012; Kanter JW, 2008, J NERV MENT DIS, V196, P663, DOI 10.1097/NMD.0b013e318183f8af; Karasz A, 2003, J GEN INTERN MED, V18, P475, DOI 10.1046/j.1525-1497.2003.20636.x; Katon W, 2010, GEN HOSP PSYCHIAT, V32, P456, DOI 10.1016/j.genhosppsych.2010.04.001; Kravitz RL, 2008, J GEN INTERN MED, V23, P1722, DOI 10.1007/s11606-008-0763-1; Kravitz RL, 2013, PATIENT EDUC COUNS, V90, P411, DOI 10.1016/j.pec.2011.07.003; Kravitz RL, 2011, PATIENT EDUC COUNS, V82, P207, DOI 10.1016/j.pec.2010.05.007; Kravitz RL, 2005, JAMA-J AM MED ASSOC, V293, P1995, DOI 10.1001/jama.293.16.1995; Kreuter M., 2000, TAILORING HLTH MESSA; Kroenke K, 2002, PSYCHIAT ANN, V32, P509, DOI 10.3928/0048-5713-20020901-06; Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x; Kroenke K, 2009, J AFFECT DISORDERS, V114, P163, DOI 10.1016/j.jad.2008.06.026; Lotfi L, 2010, NORD J PSYCHIAT, V64, P421, DOI 10.3109/08039481003786378; MacArthur Foundation, IN DEPR PRIM CAR; Maly RC, 1998, J AM GERIATR SOC, V46, P889, DOI 10.1111/j.1532-5415.1998.tb02725.x; Mintzes B, 2003, CAN MED ASSOC J, V169, P405; Niederdeppe J, 2013, J GEN INTERN MED, V28, P886, DOI 10.1007/s11606-013-2379-3; Nutting PA, 2000, ARCH FAM MED, V9, P1059, DOI 10.1001/archfami.9.10.1059; Petty R.E., 1986, COMMUN PERSUATION, P1; Ryan GL, 2001, HEALTH EDUC RES, V16, P555, DOI 10.1093/her/16.5.555; Schmid KL, 2008, MARK HEALTH SERV, V28, P32; Simon GE, 2004, AM J PSYCHIAT, V161, P1626, DOI 10.1176/appi.ajp.161.9.1626; Stata Corp, 2011, STAT STAT SOFTW COMP; Stewart WF, 2003, JAMA-J AM MED ASSOC, V289, P3135, DOI 10.1001/jama.289.23.3135; Tancredi DJ, 2013, BMC HEALTH SERV RES, V13, DOI 10.1186/1472-6963-13-141; Unutzer J, 2002, JAMA-J AM MED ASSOC, V288, P2836, DOI 10.1001/jama.288.22.2836; Ware JE, 1996, MED CARE, V34, P220, DOI 10.1097/00005650-199603000-00003; Wells KB, 1997, J CLIN PSYCHIAT, V58, P24; Wells TS, 2013, J AFFECT DISORDERS, V148, P77, DOI 10.1016/j.jad.2012.11.052	47	29	29	0	13	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 6	2013	310	17					1818	1828		10.1001/jama.2013.280038	http://dx.doi.org/10.1001/jama.2013.280038			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	246PH	24193079	Green Accepted, Bronze			2023-01-03	WOS:000326550900015
J	Cordina-Duverger, E; Truong, T; Anger, A; Sanchez, M; Arveux, P; Kerbrat, P; Guenel, P				Cordina-Duverger, Emilie; Truong, Therese; Anger, Antoinette; Sanchez, Marie; Arveux, Patrick; Kerbrat, Pierre; Guenel, Pascal			Risk of Breast Cancer by Type of Menopausal Hormone Therapy: a Case-Control Study among Post-Menopausal Women in France	PLOS ONE			English	Article							REPLACEMENT THERAPY; ENDOMETRIAL CARCINOMA; DIFFERENT REGIMENS; ESTROGEN; PROGESTINS; PROGESTERONE; MORTALITY	Background: There is extensive epidemiological evidence that menopausal hormone therapy (MHT) increases breast cancer risk, particularly combinations of estrogen and progestagen (EP). We investigated the effects of the specific formulations and types of therapies used by French women. Progestagen constituents, regimen (continuous or sequential treatment by the progestagen), and time interval between onset of menopause and start of MHT were examined. Methods: We conducted a population-based case-control study in France in 1555 menopausal women (739 cases and 816 controls). Detailed information on MHT use was obtained during in-person interviews. Odds ratios and 95% confidence interval adjusted for breast cancer risk factors were calculated. Results: We found that breast cancer risk differed by type of progestagen among current users of EP therapies. No increased risk was apparent among EP therapy users treated with natural micronized progesterone. Among users of EP therapy containing a synthetic progestin, the odds ratio was 1.57 (0.99-2.49) for progesterone-derived and 3.35 (1.07-10.4) for testosterone-derived progestagen. Women with continuous regimen were at greater risk than women treated sequentially, but regimen and type of progestagen could not be investigated independently, as almost all EP combinations containing a testosterone-derivative were administered continuously and vice-versa. Tibolone was also associated with an increased risk of breast cancer. Early users of MHT after onset of menopause were at greater risk than users who delayed treatment. Conclusion: This study confirms differential effects on breast cancer risk of progestagens and regimens specifically used in France. Formulation of EP therapies containing natural progesterone, frequently prescribed in France, was not associated with increased risk of breast cancer but may poorly protect against endometrial cancer.	[Cordina-Duverger, Emilie; Truong, Therese; Anger, Antoinette; Sanchez, Marie; Guenel, Pascal] Ctr Rech Epidemiol & Sante Populat, CESP, INSERM, U1018, Villejuif, France; [Cordina-Duverger, Emilie; Truong, Therese; Anger, Antoinette; Sanchez, Marie; Guenel, Pascal] Univ Paris 11, UMRS 1018, Villejuif, France; [Arveux, Patrick] Breast Canc Registry Cote dOr, Ctr Georges Francois Leclerc, Dijon, France; [Kerbrat, Pierre] Ctr Eugene Marquis, Rennes, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; UDICE-French Research Universities; Universite Paris Saclay; UNICANCER; Centre Georges-Francois Leclerc; UNICANCER; Centre Eugene Marquis	Guenel, P (corresponding author), Ctr Rech Epidemiol & Sante Populat, CESP, INSERM, U1018, Villejuif, France.	pascal.guenel@inserm.fr	Guenel, Pascal/AAS-7688-2021; truong, therese/A-2837-2013; Guenel, Pascal/H-3728-2018	Guenel, Pascal/0000-0002-8359-518X; truong, therese/0000-0002-2943-6786; Guenel, Pascal/0000-0002-8359-518X	French National Institute of Cancer (INCa); Fondation de France; French Agency for Environmental and Occupational Health Safety (ANSES - ex-AFSSET); French National Research Agency (ANR); League against Cancer (Grand Ouest)	French National Institute of Cancer (INCa)(Institut National du Cancer (INCA) France); Fondation de France(Fondation de France); French Agency for Environmental and Occupational Health Safety (ANSES - ex-AFSSET); French National Research Agency (ANR)(French National Research Agency (ANR)); League against Cancer (Grand Ouest)	The CECILE study was supported by grants from the French National Institute of Cancer (INCa), Fondation de France, the French Agency for Environmental and Occupational Health Safety (ANSES - ex-AFSSET), the French National Research Agency (ANR), the League against Cancer (Grand Ouest). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Allen NE, 2010, AM J EPIDEMIOL, V172, P1394, DOI 10.1093/aje/kwq300; Anderson GL, 2012, LANCET ONCOL, V13, P476, DOI 10.1016/S1470-2045(12)70075-X; Bakken K, 2011, INT J CANCER, V128, P144, DOI 10.1002/ijc.25314; Banks E, 2003, LANCET, V362, P419, DOI 10.1016/S0140-6736(03)14065-2; Belot A, 2008, REV EPIDEMIOL SANTE, V56, P159, DOI 10.1016/j.respe.2008.03.117; Beral V, 1997, LANCET, V350, P1047, DOI 10.1016/S0140-6736(97)08233-0; Beral V, 2011, JNCI-J NATL CANCER I, V103, P296, DOI 10.1093/jnci/djq527; Campagnoli C, 2005, J STEROID BIOCHEM, V96, P95, DOI 10.1016/j.jsbmb.2005.02.014; Campagnoli C, 2005, J STEROID BIOCHEM, V97, P441, DOI 10.1016/j.jsbmb.2005.08.015; Daubisse-Marliac L, 2011, ANN ONCOL, V22, P329, DOI 10.1093/annonc/mdq396; Dinger Juergen C, 2006, BMC Womens Health, V6, P13, DOI 10.1186/1472-6874-6-13; Fiesch-Janys D, 2008, INT J CANCER, V123, P933, DOI 10.1002/ijc.23655; Fournier A, 2005, INT J CANCER, V114, P448, DOI 10.1002/ijc.20710; Fournier A, 2008, J CLIN ONCOL, V26, P1260, DOI 10.1200/JCO.2007.13.4338; Fournier A, 2008, BREAST CANCER RES TR, V107, P103, DOI 10.1007/s10549-007-9523-x; Fournier A, 2011, MENOPAUSE, V18, P219, DOI 10.1097/gme.0b013e3181ecf3ec; Fournier A, 2009, J CLIN ONCOL, V27, P5138, DOI 10.1200/JCO.2008.21.6432; Hersh AL, 2004, JAMA-J AM MED ASSOC, V291, P47, DOI 10.1001/jama.291.1.47; IARC (International Agency for Research on Cancer), 2012, IARC MON, V100F; Kuhl H, 2005, MATURITAS, V51, P83, DOI 10.1016/j.maturitas.2005.02.018; Lee SA, 2005, BRIT J CANCER, V92, P2049, DOI 10.1038/sj.bjc.6602617; Li CI, 2003, JAMA-J AM MED ASSOC, V289, P3254, DOI 10.1001/jama.289.24.3254; Lyytinen HK, 2010, INT J CANCER, V126, P483, DOI 10.1002/ijc.24738; Milanese TR, 2006, J NATL CANCER I, V98, P1600, DOI 10.1093/jnci/djj439; Opatrny L, 2008, BJOG-INT J OBSTET GY, V115, P169, DOI 10.1111/j.1471-0528.2007.01520.x; Prentice RL, 2008, AM J EPIDEMIOL, V167, P1207, DOI 10.1093/aje/kwn044; Reeves GK, 2006, LANCET ONCOL, V7, P910, DOI 10.1016/S1470-2045(06)70911-1; Ross RK, 2000, JNCI-J NATL CANCER I, V92, P328, DOI 10.1093/jnci/92.4.328; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; Schindler AE, 2008, MATURITAS, V61, P171, DOI 10.1016/j.maturitas.2008.11.013; SMITH DC, 1975, NEW ENGL J MED, V293, P1164, DOI 10.1056/NEJM197512042932302; Stahlberg C, 2004, INT J CANCER, V109, P721, DOI 10.1002/ijc.20016; THOM MH, 1979, LANCET, V2, P455; von Euler-Chelpin M, 2010, CANCER CAUSE CONTROL; WHITEHEAD MI, 1981, NEW ENGL J MED, V305, P1599, DOI 10.1056/NEJM198112313052701; ZIEL HK, 1975, NEW ENGL J MED, V293, P1167, DOI 10.1056/NEJM197512042932303	36	87	91	1	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 1	2013	8	11							e78016	10.1371/journal.pone.0078016	http://dx.doi.org/10.1371/journal.pone.0078016			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	245XZ	24223752	Green Submitted, Green Published, gold			2023-01-03	WOS:000326499300017
J	Kim, A; Im, M; Yim, NH; Jung, YP; Ma, JY				Kim, Aeyung; Im, Minju; Yim, Nam-Hui; Jung, Young Pil; Ma, Jin Yeul			Aqueous Extract of Bambusae Caulis in Taeniam Inhibits PMA-Induced Tumor Cell Invasion and Pulmonary Metastasis: Suppression of NF-kappa B Activation through ROS Signaling	PLOS ONE			English	Article							TRITERPENOID-RICH EXTRACT; BAMBOO SHAVINGS; DOWN-REGULATION; IN-TAENIAM; CANCER; EXPRESSION; MMP-9; ANGIOGENESIS; MATRIX-METALLOPROTEINASE-9	Bamboo shavings (Bambusae Caulis in Taeniam, BCT) are widely used as a traditional Chinese medicine to control hypertension and cardiovascular disease, and to alleviate fever, vomiting, and diarrhea. It has been demonstrated that BCT reduces ovalbumin-induced airway inflammation by regulating pro-inflammatory cytokines, and decreases tumor growth in tumor-bearing mice. However, the effects of BCT on the metastatic potential of malignant cancer cells and the detailed mechanism of its anti-metastatic activity have not been examined previously. In this study, we investigated whether an aqueous extract of BCT (AE-BCT) reduces the metastatic potential of HT1080 cells, and elucidated the underlying anti-metastatic mechanism. In addition, we examined whether AE-BCT administration inhibits pulmonary metastasis of intravenously injected B16F10 cells in C57BL/6J mice. AE-BCT (50-250 mu g/ml) dose-dependently suppressed colony-forming activity under anchorage-dependent and -independent growth conditions. Pretreatment with AE-BCT efficiently inhibited cell migration, invasion, and adhesion. AE-BCT also dramatically suppressed PMA-induced MMP-9 activity and expression by blocking NF-kappa B activation and ERK phosphorylation. Production of intracellular ROS, a key regulator of NF-kappa B-induced MMP-9 activity, was almost completely blocked by pretreatment with AE-BCT. Furthermore, daily oral administration of AE-BCT at doses of 50 and 100 mg/kg efficiently inhibited lung metastasis of B16F10 cells injected into the tail veins of C57BL/6J mice with no systemic toxicity. These results demonstrate that AE-BCT significantly reduced the metastatic activity of highly malignant cancer cells by suppressing MMP-9 activity via inhibition of ROS-mediated NF-kappa B activation. These results indicate that AE-BCT may be a safe natural product for treatment of metastatic cancer.	[Kim, Aeyung; Im, Minju; Yim, Nam-Hui; Jung, Young Pil; Ma, Jin Yeul] Korea Inst Oriental Med KIOM, Korean Med KM Based Herbal Drug Dev Grp, Taejon, South Korea	Korea Institute of Oriental Medicine (KIOM)	Ma, JY (corresponding author), Korea Inst Oriental Med KIOM, Korean Med KM Based Herbal Drug Dev Grp, Taejon, South Korea.	jyma@kiom.re.kr			Ministry of Education, Science and Technology (MEST), Republic of Korea [K12050]	Ministry of Education, Science and Technology (MEST), Republic of Korea(Ministry of Education, Science & Technology (MEST), Republic of Korea)	This work has been supported by the a Grant K12050 awarded to Korea Institute of Oriental Medicine (KIOM) from Ministry of Education, Science and Technology (MEST), Republic of Korea. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Binker MG, 2011, BIOCHEM BIOPH RES CO, V405, P140, DOI 10.1016/j.bbrc.2011.01.023; Bussemakers MJG, 1996, WORLD J UROL, V14, P151; Chambers AF, 2002, NAT REV CANCER, V2, P563, DOI 10.1038/nrc865; Choi JH, 2010, FOOD CHEM TOXICOL, V48, P564, DOI 10.1016/j.fct.2009.11.033; Eom HW, 2012, INT J MOL MED, V30, P1512, DOI 10.3892/ijmm.2012.1128; Gondi CS, 2004, NEURON GLIA BIOL, V1, P165, DOI 10.1017/S1740925X04000237; Ham I, 2009, IMMUNOPHARM IMMUNOT, V31, P439, DOI 10.1080/08923970902769638; Hsieh HL, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-88; Jiang Zhong-Qing, 2003, Ai Zheng, V22, P178; Jiao JJ, 2007, PHYTOTHER RES, V21, P1135, DOI 10.1002/ptr.2223; Jin GH, 2012, ENVIRON TOXICOL PHAR, V34, P315, DOI 10.1016/j.etap.2012.05.001; Jinga DC, 2006, J CELL MOL MED, V10, P499, DOI 10.1111/j.1582-4934.2006.tb00415.x; Jung SH, 2007, BIOL PHARM BULL, V30, P1569, DOI 10.1248/bpb.30.1569; Kim A, 2009, CARCINOGENESIS, V30, P927, DOI 10.1093/carcin/bgp072; Kim BH, 2013, MOL CELLS, V35, P410, DOI 10.1007/s10059-013-0031-z; Kim SC, 2010, FOOD CHEM TOXICOL, V48, P1478, DOI 10.1016/j.fct.2010.03.014; Kim TS, 1999, J KOREAN MED SCI, V14, P263, DOI 10.3346/jkms.1999.14.3.263; Lee KJ, 2008, CANCER LETT, V268, P233, DOI 10.1016/j.canlet.2008.03.058; Lee KJ, 2006, FOOD CHEM TOXICOL, V44, P1890, DOI 10.1016/j.fct.2006.06.009; Lee SO, 2006, BIOCHEM BIOPH RES CO, V351, P118, DOI 10.1016/j.bbrc.2006.10.006; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; London CA, 2003, CANCER GENE THER, V10, P823, DOI 10.1038/sj.cgt.7700642; Lu BY, 2010, AFR J BIOTECHNOL, V9, P6430; McCawley LJ, 2000, MOL MED TODAY, V6, P149, DOI 10.1016/S1357-4310(00)01686-5; Morais C, 2010, APOPTOSIS, V15, P412, DOI 10.1007/s10495-009-0414-y; Patel LR, 2011, FUTURE ONCOL, V7, P1285, DOI [10.2217/fon.11.112, 10.2217/FON.11.112]; Ra J, 2010, J ETHNOPHARMACOL, V128, P241, DOI 10.1016/j.jep.2010.01.023; Seki T, 2010, EVID-BASED COMPL ALT, V7, P447, DOI 10.1093/ecam/nen026; Tobar N, 2010, MOL CELL BIOCHEM, V340, P195, DOI 10.1007/s11010-010-0418-5; Tsunoda S, 1998, ANTICANCER RES, V18, P153; Yang SF, 2010, FOOD CHEM TOXICOL, V48, P1052, DOI 10.1016/j.fct.2010.01.019; Yi L, 2012, BIOCHIMIE, V94, P2035, DOI 10.1016/j.biochi.2012.05.027	32	21	23	5	22	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 28	2013	8	10							e78061	10.1371/journal.pone.0078061	http://dx.doi.org/10.1371/journal.pone.0078061			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	242KW	24205091	Green Published, gold, Green Submitted			2023-01-03	WOS:000326241200052
J	Bhandari, S				Bhandari, Sunil			PERSONAL VIEW South Asian hospitals that lack DNAR orders deny patients holistic care	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material									[Bhandari, Sunil] Hull & East Yorkshire Hosp NHS Trust, Kingston Upon Hull HU3 2JZ, Yorks, England; [Bhandari, Sunil] Hull Royal Infirm, Dept Renal Med, Hull York Med Sch, Kingston Upon Hull HU3 2JZ, Yorks, England	University of Hull; University of York - UK	Bhandari, S (corresponding author), Hull & East Yorkshire Hosp NHS Trust, Kingston Upon Hull HU3 2JZ, Yorks, England.	sunil.bhandari@hey.nhs.uk		bhandari, sunil/0000-0002-0996-9622					0	0	0	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 25	2013	347								f6300	10.1136/bmj.f6300	http://dx.doi.org/10.1136/bmj.f6300			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	243CM	24163086				2023-01-03	WOS:000326294200006
J	Padte, NN; Boente-Carrera, M; Andrews, CD; McManus, J; Grasperge, BF; Gettie, A; Coelho-dos-Reis, JG; Li, XM; Wu, D; Bruder, JT; Sedegah, M; Patterson, N; Richie, TL; Wong, CH; Ho, DD; Vasan, S; Tsuji, M				Padte, Neal N.; Boente-Carrera, Mar; Andrews, Chasity D.; McManus, Jenny; Grasperge, Brooke F.; Gettie, Agegnehu; Coelho-dos-Reis, Jordana G.; Li, Xiangming; Wu, Douglass; Bruder, Joseph T.; Sedegah, Martha; Patterson, Noelle; Richie, Thomas L.; Wong, Chi-Huey; Ho, David D.; Vasan, Sandhya; Tsuji, Moriya			A Glycolipid Adjuvant, 7DW8-5, Enhances CD8+T Cell Responses Induced by an Adenovirus-Vectored Malaria Vaccine in Non-Human Primates	PLOS ONE			English	Article							KILLER T-CELLS; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; PHASE I/II TRIAL; ALPHA-GALACTOSYLCERAMIDE; DENDRITIC CELLS; NKT CELLS; IN-VIVO; CIRCUMSPOROZOITE PROTEIN; PROTECTIVE IMMUNITY; PERIPHERAL-BLOOD	A key strategy to a successful vaccine against malaria is to identify and develop new adjuvants that can enhance T-cell responses and improve protective immunity. Upon co-administration with a rodent malaria vaccine in mice, 7DW8-5, a recently identified novel analog of alpha-galactosylceramide (alpha-GalCer), enhances the level of malaria-specific protective immune responses more strongly than the parent compound. In this study, we sought to determine whether 7DW8-5 could provide a similar potent adjuvant effect on a candidate human malaria vaccine in the more relevant non-human primate (NHP) model, prior to committing to clinical development. The candidate human malaria vaccine, AdPfCA (NMRC-M3V-Ad-PfCA), consists of two non-replicating recombinant adenoviral (Ad) vectors, one expressing the circumsporozoite protein (CSP) and another expressing the apical membrane antigen-1 (AMA1) of Plasmodium falciparum. In several phase 1 clinical trials, AdPfCA was well tolerated and demonstrated immunogenicity for both humoral and cell-mediated responses. In the study described herein, 25 rhesus macaques received prime and boost intramuscular (IM) immunizations of AdPfCA alone or with an ascending dose of 7DW8-5. Our results indicate that 7DW8-5 is safe and well-tolerated and provides a significant enhancement (up to 9-fold) in malaria-specific CD8+ T-cell responses after both priming and boosting phases, supporting further clinical development.	[Padte, Neal N.; Boente-Carrera, Mar; Andrews, Chasity D.; McManus, Jenny; Coelho-dos-Reis, Jordana G.; Li, Xiangming; Ho, David D.; Vasan, Sandhya; Tsuji, Moriya] Rockefeller Univ, Aaron Diamond AIDS Res Ctr, New York, NY 10021 USA; [Grasperge, Brooke F.; Gettie, Agegnehu] Tulane Univ, Med Ctr, Tulane Natl Primate Res Ctr, Covington, LA USA; [Wu, Douglass; Wong, Chi-Huey] Scripps Res Inst, Dept Chem, La Jolla, CA 92037 USA; [Bruder, Joseph T.] GenVec Inc, Res, Gaithersburg, MD USA; [Sedegah, Martha; Patterson, Noelle; Richie, Thomas L.] Naval Med Res Ctr, US Mil Malaria Vaccine Program, Silver Spring, MD USA; [Patterson, Noelle] Henry M Jackson Fdn Adv Mil Med, Bethesda, MD USA	Rockefeller University; Tulane University; Scripps Research Institute; Naval Medical Research Center (NMRC); Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc	Vasan, S (corresponding author), Henry M Jackson Fdn, Armed Forces Res Inst Med Sci, US Mil HIV Res Program, Bangkok, Thailand.	sandhya.vasan@afrims.org; mtsuji@adarc.org	Coelho-dos-Reis, Jordana/HGU-6453-2022	Richie, Thomas/0000-0002-2946-5456; Tsuji, Moriya/0000-0001-8587-277X	NIH [AI070258]; Bill and Melinda Gates Foundation Collaboration for AIDS Vaccine Discovery [38648]; Irene Diamond Foundation; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI070258, R56AI070258] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH [P51OD011104] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Bill and Melinda Gates Foundation Collaboration for AIDS Vaccine Discovery; Irene Diamond Foundation; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This work was partially supported by a grant from NIH AI070258 (M. T.), the Bill and Melinda Gates Foundation Collaboration for AIDS Vaccine Discovery (Grant Number 38648 to D. D. H), and the Irene Diamond Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bassett JD, 2011, EXPERT REV VACCINES, V10, P1307, DOI [10.1586/ERV.11.88, 10.1586/erv.11.88]; Bendelac A, 1997, ANNU REV IMMUNOL, V15, P535, DOI 10.1146/annurev.immunol.15.1.535; Bontkes HJ, 2010, CLIN IMMUNOL, V136, P364, DOI 10.1016/j.clim.2010.04.019; Brossay L, 1998, J EXP MED, V188, P1521, DOI 10.1084/jem.188.8.1521; Chackerian A, 2002, INFECT IMMUN, V70, P6302, DOI 10.1128/IAI.70.11.6302-6309.2002; Courtney AN, 2011, EUR J IMMUNOL, V41, P3312, DOI 10.1002/eji.201041359; Crompton PD, 2010, J CLIN INVEST, V120, P4168, DOI 10.1172/JCI44423; Crowe NY, 2002, J EXP MED, V196, P119, DOI 10.1084/jem.20020092; Epstein JE, 2011, SCIENCE, V334, P475, DOI 10.1126/science.1211548; Fernandez CS, 2009, J VIROL, V83, P1617, DOI 10.1128/JVI.02138-08; Fujii S, 2003, J EXP MED, V198, P267, DOI 10.1084/jem.20030324; Fujii SI, 2004, J EXP MED, V199, P1607, DOI 10.1084/jem.20040317; Gansuvd B, 2008, J MED PRIMATOL, V37, P1, DOI 10.1111/j.1600-0684.2007.00222.x; Gardiner DF, 2006, VACCINE, V24, P287, DOI 10.1016/j.vaccine.2005.07.075; Giaccone G, 2002, CLIN CANCER RES, V8, P3702; Gonzalez-Aseguinolaza G, 2000, P NATL ACAD SCI USA, V97, P8461, DOI 10.1073/pnas.97.15.8461; Gonzalez-Aseguinolaza G, 2002, J EXP MED, V195, P617, DOI 10.1084/jem.20011889; Good MF, 2010, IMMUNITY, V33, P555, DOI 10.1016/j.immuni.2010.10.005; Hermans IF, 2003, J IMMUNOL, V171, P5140, DOI 10.4049/jimmunol.171.10.5140; Hong S, 2001, NAT MED, V7, P1052, DOI 10.1038/nm0901-1052; Ishii KJ, 2007, J CLIN IMMUNOL, V27, P363, DOI 10.1007/s10875-007-9087-x; Ishikawa A, 2005, CLIN CANCER RES, V11, P1910, DOI 10.1158/1078-0432.CCR-04-1453; Jahng AW, 2001, J EXP MED, V194, P1789, DOI 10.1084/jem.194.12.1789; Kakimi K, 2000, J EXP MED, V192, P921, DOI 10.1084/jem.192.7.921; Kawai T, 2010, NAT IMMUNOL, V11, P373, DOI 10.1038/ni.1863; Kawakami K, 2001, INFECT IMMUN, V69, P6643, DOI 10.1128/IAI.69.11.6643-6650.2001; Kawakami K, 2001, INFECT IMMUN, V69, P213, DOI 10.1128/IAI.69.1.213-220.2001; Kawano T, 1998, P NATL ACAD SCI USA, V95, P5690, DOI 10.1073/pnas.95.10.5690; Kronenberg M, 2005, ANNU REV IMMUNOL, V23, P877, DOI 10.1146/annurev.immunol.23.021704.115742; Li XM, 2010, P NATL ACAD SCI USA, V107, P13010, DOI 10.1073/pnas.1006662107; Mitchell D, 2011, HUM VACCINES, V7, P85, DOI 10.4161/hv.7.0.14567; Motsinger A, 2003, J VIROL, V77, P8153, DOI 10.1128/JVI.77.14.8153-8158.2003; Nieda M, 2004, BLOOD, V103, P383, DOI 10.1182/blood-2003-04-1155; Padte NN, 2011, CLIN IMMUNOL, V140, P142, DOI 10.1016/j.clim.2010.11.009; Parekh VV, 2005, J CLIN INVEST, V115, P2572, DOI 10.1172/JCI24762; Robinson SP, 1999, EUR J IMMUNOL, V29, P2769, DOI 10.1002/(SICI)1521-4141(199909)29:09<2769::AID-IMMU2769>3.0.CO;2-2; Rodrigues EG, 1997, J IMMUNOL, V158, P1268; RODRIGUES MM, 1991, INT IMMUNOL, V3, P579, DOI 10.1093/intimm/3.6.579; ROMERO P, 1989, NATURE, V341, P323, DOI 10.1038/341323a0; Rout N, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009787; Schneiders FL, 2011, CLIN IMMUNOL, V140, P130, DOI 10.1016/j.clim.2010.11.010; SCHOFIELD L, 1987, NATURE, V330, P664, DOI 10.1038/330664a0; Schwartz L, 2012, MALARIA J, V11, DOI 10.1186/1475-2875-11-11; Sedegah M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024586; Sharif S, 2001, NAT MED, V7, P1057, DOI 10.1038/nm0901-1057; Silk JD, 2004, J CLIN INVEST, V114, P1800, DOI 10.1172/JCI200422046; Singh AK, 2001, J EXP MED, V194, P1801, DOI 10.1084/jem.194.12.1801; Spada FM, 2000, EUR J IMMUNOL, V30, P3468, DOI 10.1002/1521-4141(2000012)30:12<3468::AID-IMMU3468>3.0.CO;2-C; Tamminga C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025868; Veldt BJ, 2007, J HEPATOL, V47, P356, DOI 10.1016/j.jhep.2007.04.018; Venkataswamy MM, 2009, J IMMUNOL, V183, P1644, DOI 10.4049/jimmunol.0900858; Vezys V, 2009, NATURE, V457, P196, DOI 10.1038/nature07486; Warshakoon HJ, 2009, HUM VACCINES, V5, P381, DOI 10.4161/hv.5.6.8175; Weiss WR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031247; WEISS WR, 1988, P NATL ACAD SCI USA, V85, P573, DOI 10.1073/pnas.85.2.573; Wilson MT, 2003, P NATL ACAD SCI USA, V100, P10913, DOI 10.1073/pnas.1833166100; Woltman AM, 2009, ANTIVIR THER, V14, P809, DOI 10.3851/IMP1295	57	34	35	0	23	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 25	2013	8	10							e78407	10.1371/journal.pone.0078407	http://dx.doi.org/10.1371/journal.pone.0078407			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	241GW	24205224	Green Published, gold, Green Submitted			2023-01-03	WOS:000326155400081
J	Bianchi, M; Clavenna, A; Sequi, M; Bortolotti, A; Fortino, I; Merlino, L; Bonati, M				Bianchi, Marina; Clavenna, Antonio; Sequi, Marco; Bortolotti, Angela; Fortino, Ida; Merlino, Luca; Bonati, Maurizio			Childhood Asthma Management Pre- and Post-Incident Asthma Hospitalization	PLOS ONE			English	Article							CHILDREN; EXACERBATIONS; POPULATION; SPIROMETRY; PREDICTORS; SYMPTOMS; OUTCOMES	Many hospitalizations for asthma could potentially be avoided with appropriate management. The aim of this study was to analyze data on disease management of a paediatric population with a hospitalization for asthma. The study population comprised 6-17 year old subjects belonging to three local health units of the Lombardy Region, northern Italy. Regional administrative databases were used to collect data on: the number of children with an incident hospitalization for asthma during the 2004-2006 period, anti-asthma therapy, specialist visit referrals, and claims for spirometry, released in the 12 months before and after hospitalization. Each patient's asthma management profile was compared with GINA guideline recommendations. Among the 183 hospitalized subjects, 101 (55%) received therapy before hospitalization and 82 (45%) did not. 10% did not receive any therapy either before or after hospital admission and in 13% the therapy was discontinued afterward. Based on GINA guidelines, asthma management adhered to recommendations only for 55% of subjects. Results may suggest that for half of hospitalized subjects, inaccurate diagnosis, under-treatment/scarce compliance with asthma guidelines by physicians, and/or scarce compliance to therapy by patients/their parents occurred. In all these cases, hospitalization would be a proxy indicator of preventable poor control of disease, rather than a proxy indicator of severity.	[Bianchi, Marina; Clavenna, Antonio; Sequi, Marco; Bortolotti, Angela; Fortino, Ida; Merlino, Luca; Bonati, Maurizio] IRCCS, Ist Ric Farmacol Mario Negri, Dept Publ Hlth, Lab Mother & Child Hlth, Milan, Italy; [Bortolotti, Angela; Fortino, Ida; Merlino, Luca] Reg Hlth Minist, Milan, Italy	Istituto di Ricerche Farmacologiche Mario Negri IRCCS	Bianchi, M (corresponding author), IRCCS, Ist Ric Farmacol Mario Negri, Dept Publ Hlth, Lab Mother & Child Hlth, Milan, Italy.	marina.bianchi@marionegri.it	Bonati, Maurizio/K-8980-2016; Clavenna, Antonio/J-6830-2018	Bonati, Maurizio/0000-0003-3997-3726; Clavenna, Antonio/0000-0001-5536-4192; MERLINO, Luca Giuseppe/0000-0001-9232-9994	Regione Lombardia (Progetto Epidemiologia dei farmaci - EPIFARM)	Regione Lombardia (Progetto Epidemiologia dei farmaci - EPIFARM)(Regione Lombardia)	This study has been funded in part by Regione Lombardia (Progetto Epidemiologia dei farmaci - EPIFARM). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. No additional external funding received for this study.	[Anonymous], 2012, GLOB STRAT ASTHM MAN; Bianchi M, 2012, RESP MED, V106, P1383, DOI 10.1016/j.rmed.2012.06.005; Bianchi M, 2011, BMC PULM MED, V11, DOI 10.1186/1471-2466-11-48; Bianchi M, 2011, EUR J CLIN PHARMACOL, V67, P967, DOI 10.1007/s00228-011-1033-4; Bianchi M, 2009, PEDIAT ALLERG IMM-UK, V20, P585, DOI 10.1111/j.1399-3038.2008.00797.x; Cabana M, 2006, PEDIATRICS, V118, pE151, DOI 10.1542/peds.2005-2352; Cates CJ, 2013, COCHRANE DB SYST REV, V6; Chipps BE, 2012, J ALLERGY CLIN IMMUN, V130, P332, DOI 10.1016/j.jaci.2012.04.014; Chroinin M Ni, 2009, COCHRANE DB SYST REV, V4; Covar RA, 2008, J ALLERGY CLIN IMMUN, V122, P741, DOI 10.1016/j.jaci.2008.08.021; Delmas M-C, 2011, Rev Mal Respir, V28, pe115, DOI 10.1016/j.rmr.2011.09.023; Ducharme FM, 2010, COCHRANE DB SYST REV, V5; Friedman B, 2004, MED CARE RES REV, V61, P225, DOI 10.1177/1077558704263799; Friedman HS, 2009, CLIN THER, V31, P1056, DOI 10.1016/j.clinthera.2009.05.008; Galant SP, 2006, PEDIATRICS, V117, P1038, DOI 10.1542/peds.2005-1076; Gershon AS, 2012, CHEST, V141, P1190, DOI 10.1378/chest.11-0831; Lu S, 2012, ACAD PEDIATR, V12, P436, DOI 10.1016/j.acap.2012.06.006; Tierney WM, 2004, J GEN INTERN MED, V19, P237, DOI 10.1111/j.1525-1497.2004.30311.x; Wu AC, 2011, CHEST, V140, P100, DOI 10.1378/chest.10-2794	19	3	4	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 18	2013	8	10							e76439	10.1371/journal.pone.0076439	http://dx.doi.org/10.1371/journal.pone.0076439			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	239MM	24204628	gold, Green Published, Green Submitted			2023-01-03	WOS:000326029300029
J	Svensson, CR; Messing, ME; Lundqvist, M; Schollin, A; Deppert, K; Pagels, JH; Rissler, J; Cedervall, T				Svensson, Christian R.; Messing, Maria E.; Lundqvist, Martin; Schollin, Alexander; Deppert, Knut; Pagels, Joakim H.; Rissler, Jenny; Cedervall, Tommy			Direct Deposition of Gas Phase Generated Aerosol Gold Nanoparticles into Biological Fluids - Corona Formation and Particle Size Shifts	PLOS ONE			English	Article							DIESEL EXHAUST PARTICLES; HUMAN RESPIRATORY-TRACT; AIR-LIQUID INTERFACE; CARBON NANOTUBES; EPITHELIAL-CELLS; PROTEIN CORONA; EXPOSURE; TOXICITY; MOBILITY; ANALYZER	An ongoing discussion whether traditional toxicological methods are sufficient to evaluate the risks associated with nanoparticle inhalation has led to the emergence of Air-Liquid interface toxicology. As a step in this process, this study explores the evolution of particle characteristics as they move from the airborne state into physiological solution. Airborne gold nanoparticles (AuNP) are generated using an evaporation-condensation technique. Spherical and agglomerate AuNPs are deposited into physiological solutions of increasing biological complexity. The AuNP size is characterized in air as mobility diameter and in liquid as hydrodynamic diameter. AuNP: Protein aggregation in physiological solutions is determined using dynamic light scattering, particle tracking analysis, and UV absorption spectroscopy. AuNPs deposited into homocysteine buffer form large gold-aggregates. Spherical AuNPs deposited in solutions of albumin were trapped at the Air-Liquid interface but was readily suspended in the solutions with a size close to that of the airborne particles, indicating that AuNP: Protein complex formation is promoted. Deposition into serum and lung fluid resulted in larger complexes, reflecting the formation of a more complex protein corona. UV absorption spectroscopy indicated no further aggregation of the AuNPs after deposition in solution. The corona of the deposited AuNPs shows differences compared to AuNPs generated in suspension. Deposition of AuNPs from the aerosol phase into biological fluids offers a method to study the protein corona formed, upon inhalation and deposition in the lungs in a more realistic way compared to particle liquid suspensions. This is important since the protein corona together with key particle properties (e. g. size, shape and surface reactivity) to a large extent may determine the nanoparticle effects and possible translocation to other organs.	[Svensson, Christian R.; Pagels, Joakim H.; Rissler, Jenny] Lund Univ, Dept Design Sci, Div Ergon & Aerosol Technol, Lund, Sweden; [Messing, Maria E.; Deppert, Knut] Lund Univ, Dept Phys, Div Solid State Phys, S-22362 Lund, Sweden; [Messing, Maria E.] Lund Univ, Dept Phys, Div Synchrotron Radiat Res, S-22362 Lund, Sweden; [Lundqvist, Martin; Schollin, Alexander; Cedervall, Tommy] Lund Univ, Dept Biochem & Struct Biol, Lund, Sweden	Lund University; Lund University; Lund University; Lund University	Svensson, CR (corresponding author), Lund Univ, Dept Design Sci, Div Ergon & Aerosol Technol, Lund, Sweden.	Christian.Svensson@design.lth.se	Lundqvist, Martin/K-3908-2012; Cedervall, Tommy/AAT-9766-2021; Pagels, Joakim/G-9118-2014; Rissler, Jenny/B-9176-2014; Messing, Maria E/D-5546-2009; Deppert, Knut/A-6719-2008	Lundqvist, Martin/0000-0003-1175-9103; Cedervall, Tommy/0000-0003-2255-8446; Pagels, Joakim/0000-0002-7423-3240; Rissler, Jenny/0000-0001-8650-4741; Messing, Maria E/0000-0003-1834-236X; Deppert, Knut/0000-0002-0471-951X	Forte - Swedish Research Council for Health, Working Life and Welfare [2009-1291]; FORMAS [216-2009-1294]; VINNOVA [2009-01117]; Nanometer Structure Consortium at Lund University	Forte - Swedish Research Council for Health, Working Life and Welfare; FORMAS(Swedish Research Council Formas); VINNOVA(Vinnova); Nanometer Structure Consortium at Lund University	The authors acknowledge Forte - Swedish Research Council for Health, Working Life and Welfare, Grant nr. 2009-1291; FORMAS, Grant nr. 216-2009-1294; VINNOVA, Grant nr. 2009-01117; and the Nanometer Structure Consortium at Lund University for their generous funding. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ahamed M, 2011, TOXICOL IN VITRO, V25, P930, DOI 10.1016/j.tiv.2011.02.015; Albanese A, 2011, ACS NANO, V5, P5478, DOI 10.1021/nn2007496; Baughman RH, 2002, SCIENCE, V297, P787, DOI 10.1126/science.1060928; Bitterle E, 2006, CHEMOSPHERE, V65, P1784, DOI 10.1016/j.chemosphere.2006.04.035; Blank F, 2006, J AEROSOL MED, V19, P392, DOI 10.1089/jam.2006.19.392; BONDI A, 1964, J PHYS CHEM-US, V68, P441, DOI 10.1021/j100785a001; Casals E, 2010, ACS NANO, V4, P3623, DOI 10.1021/nn901372t; Cedervall T, 2007, ANGEW CHEM INT EDIT, V46, P5754, DOI 10.1002/anie.200700465; Cedervall T, 2007, P NATL ACAD SCI USA, V104, P2050, DOI 10.1073/pnas.0608582104; Chen X, 2007, CHEM REV, V107, P2891, DOI 10.1021/cr0500535; Cukalevski R, 2011, LANGMUIR, V27, P14360, DOI 10.1021/la203290a; Dell'Orco D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010949; Deppert K., 1996, J AEROSOL SCI, V27, P151, DOI DOI 10.1016/0021-8502(96)00148-6; Dobrovolskaia MA, 2009, NANOMED-NANOTECHNOL, V5, P106, DOI 10.1016/j.nano.2008.08.001; Donaldson K, 2006, TOXICOL SCI, V92, P5, DOI 10.1093/toxsci/kfj130; Ehara K, 1996, J AEROSOL SCI, V27, P217, DOI 10.1016/0021-8502(95)00562-5; Gaschen A, 2010, ENVIRON SCI TECHNOL, V44, P1424, DOI 10.1021/es902261m; Hellstrand E, 2009, FEBS J, V276, P3372, DOI 10.1111/j.1742-4658.2009.07062.x; Hinds W.C, 1999, AEROSOL TECHNOLOGY P; Huber DL, 2005, SMALL, V1, P482, DOI 10.1002/smll.200500006; Jacobsen NR, 2009, PART FIBRE TOXICOL, V6, DOI 10.1186/1743-8977-6-2; Ji ZX, 2010, ENVIRON SCI TECHNOL, V44, P7309, DOI 10.1021/es100417s; Knutson E. O., 1975, Journal of Aerosol Science, V6, P443, DOI 10.1016/0021-8502(75)90060-9; Lacerda SHD, 2010, ACS NANO, V4, P365, DOI 10.1021/nn9011187; Link S, 1999, J PHYS CHEM B, V103, P4212, DOI 10.1021/jp984796o; Londahl J, 2008, INHAL TOXICOL, V20, P923, DOI 10.1080/08958370802087124 ; Lu JR, 1999, LANGMUIR, V15, P6975, DOI 10.1021/la990131h; Lundqvist M, 2008, P NATL ACAD SCI USA, V105, P14265, DOI 10.1073/pnas.0805135105; Lynch I, 2009, NAT NANOTECHNOL, V4, P546, DOI 10.1038/nnano.2009.248; Maiorano G, 2010, ACS NANO, V4, P7481, DOI 10.1021/nn101557e; McMurry PH, 2002, AEROSOL SCI TECH, V36, P227, DOI 10.1080/027868202753504083; Messing ME, 2013, NANOTOXICOLOGY, V7, P1052, DOI 10.3109/17435390.2012.697589; Messing ME, 2009, GOLD BULL, V42, P20, DOI 10.1007/BF03214902; Miyabara Y, 1998, EUR RESPIR J, V11, P291, DOI 10.1183/09031936.98.11020291; Montes-Burgos I, 2010, J NANOPART RES, V12, P47, DOI 10.1007/s11051-009-9774-z; Pal S, 2007, APPL ENVIRON MICROB, V73, P1712, DOI 10.1128/AEM.02218-06; Pan Y, 2007, SMALL, V3, P1941, DOI 10.1002/smll.200700378; Park K, 2008, AEROSOL SCI TECH, V42, P801, DOI 10.1080/02786820802339561; Paur HR, 2011, J AEROSOL SCI, V42, P668, DOI 10.1016/j.jaerosci.2011.06.005; Reischl GP, 1997, AEROSOL SCI TECH, V27, P651, DOI 10.1080/02786829708965503; Rissler J, 2012, J AEROSOL SCI, V48, P18, DOI 10.1016/j.jaerosci.2012.01.005; Royal Commission on Environmental Pollution, 2008, NOV MAT ENV CAS NAN; SCHEIBEL HG, 1983, J AEROSOL SCI, V14, P113, DOI 10.1016/0021-8502(83)90035-6; Schroedter A, 2002, ANGEW CHEM INT EDIT, V41, P3218, DOI 10.1002/1521-3773(20020902)41:17<3218::AID-ANIE3218>3.0.CO;2-P; Shin WG, 2010, J AEROSOL SCI, V41, P665, DOI 10.1016/j.jaerosci.2010.04.009; Shin WG, 2009, J AEROSOL SCI, V40, P573, DOI 10.1016/j.jaerosci.2009.02.006; Tantra R, 2010, COLLOID SURFACE B, V75, P275, DOI 10.1016/j.colsurfb.2009.08.049; Tippe A, 2002, J AEROSOL SCI, V33, P207, DOI 10.1016/S0021-8502(01)00158-6; Trouiller B, 2009, CANCER RES, V69, P8784, DOI 10.1158/0008-5472.CAN-09-2496; Tsai DH, 2011, LANGMUIR, V27, P2464, DOI 10.1021/la104124d; Tsurudome Y, 1999, CARCINOGENESIS, V20, P1573, DOI 10.1093/carcin/20.8.1573; Weir E, 2008, ANALYST, V133, P835, DOI 10.1039/b715532h; WIEDENSOHLER A, 1988, J AEROSOL SCI, V19, P387, DOI 10.1016/0021-8502(88)90278-9; Xie YM, 2012, TOXICOL SCI, V125, P450, DOI 10.1093/toxsci/kfr251	54	6	6	2	36	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 27	2013	8	9							e74702	10.1371/journal.pone.0074702	http://dx.doi.org/10.1371/journal.pone.0074702			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	228WY	24086363	Green Published, gold, Green Submitted			2023-01-03	WOS:000325223900029
J	Brennan, LD; Roland, T; Morton, DG; Fellman, SM; Chung, SY; Soltani, M; Kevek, JW; McEuen, PM; Kemphues, KJ; Wang, MD				Brennan, Lucy D.; Roland, Thibault; Morton, Diane G.; Fellman, Shanna M.; Chung, SueYeon; Soltani, Mohammad; Kevek, Joshua W.; McEuen, Paul M.; Kemphues, Kenneth J.; Wang, Michelle D.			Small Molecule Injection into Single-Cell C. elegans Embryos via Carbon-Reinforced Nanopipettes	PLOS ONE			English	Article							ANTERIOR-POSTERIOR AXIS; PAR PROTEINS; POLARITY; MYOSIN; POLARIZATION; ESTABLISHMENT; REORGANIZATION; MICROINJECTION; MICROFILAMENTS; COMMUNICATION	The introduction of chemical inhibitors into living cells at specific times in development is a useful method for investigating the roles of specific proteins or cytoskeletal components in developmental processes. Some embryos, such as those of Caenorhabditis elegans, however, possess a tough eggshell that makes introducing drugs and other molecules into embryonic cells challenging. We have developed a procedure using carbon-reinforced nanopipettes (CRNPs) to deliver molecules into C. elegans embryos with high temporal control. The use of CRNPs allows for cellular manipulation to occur just subsequent to meiosis II with minimal damage to the embryo. We have used our technique to replicate classical experiments using latrunculin A to inhibit microfilaments and assess its effects on early polarity establishment. Our injections of latrunculin A confirm the necessity of microfilaments in establishing anterior-posterior polarity at this early stage, even when microtubules remain intact. Further, we find that latrunculin A treatment does not prevent association of PAR-2 or PAR-6 with the cell cortex. Our experiments demonstrate the application of carbon-reinforced nanopipettes to the study of one temporally-confined developmental event. The use of CRNPs to introduce molecules into the embryo should be applicable to investigations at later developmental stages as well as other cells with tough outer coverings.	[Brennan, Lucy D.; Roland, Thibault; Fellman, Shanna M.; Chung, SueYeon; Soltani, Mohammad; Kevek, Joshua W.; McEuen, Paul M.; Wang, Michelle D.] Cornell Univ, Dept Phys, Lab Atom & Solid State Phys, Ithaca, NY 14853 USA; [Roland, Thibault; Fellman, Shanna M.; Chung, SueYeon; Soltani, Mohammad; Wang, Michelle D.] Cornell Univ, Howard Hughes Med Inst, Ithaca, NY USA; [Morton, Diane G.; Kemphues, Kenneth J.] Cornell Univ, Dept Mol Biol & Genet, Ithaca, NY 14853 USA	Cornell University; Cornell University; Howard Hughes Medical Institute; Cornell University	Kemphues, KJ (corresponding author), Cornell Univ, Dept Mol Biol & Genet, Ithaca, NY 14853 USA.	kjk1@cornell.edu; mdw17@cornell.edu	Chung, SueYeon/ABI-7940-2020	Brennan, Lucy/0000-0002-4019-6904; Chung, SueYeon/0000-0001-5726-4865	NSF MRSEC program [DMR-1120296]; NIH [GM059849, GM79112, T32GM008267]; NSF [MCB-0820293]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008267, R01GM079112, R01GM059849] Funding Source: NIH RePORTER	NSF MRSEC program(National Science Foundation (NSF)NSF - Directorate for Mathematical & Physical Sciences (MPS)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NSF(National Science Foundation (NSF)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work made use of the Cornell Center for Materials Research Shared Facilities which are supported through the NSF MRSEC program (DMR-1120296). We wish to acknowledge support from NIH grants (GM059849 to M.D.W; GM79112 to KJK), an NIH Molecular Biophysics Training grant (T32GM008267, traineeship for LB), and an NSF grant (MCB-0820293 to M.D.W). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aono S, 2004, DEVELOPMENT, V131, P2865, DOI 10.1242/dev.01146; BOSSINGER O, 1992, DEV BIOL, V151, P401, DOI 10.1016/0012-1606(92)90180-O; Bossinger O, 1996, DEV GENES EVOL, V206, P25, DOI 10.1007/s004270050027; Boyd L, 1996, DEVELOPMENT, V122, P3075; BRENNER S, 1974, GENETICS, V77, P71; Carvalho A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024656; Cheeks RJ, 2004, CURR BIOL, V14, P851, DOI 10.1016/j.cub.2004.05.022; Chitwood BG, 1974, INTRO NEMATOADE; COUE M, 1987, FEBS LETT, V213, P316, DOI 10.1016/0014-5793(87)81513-2; Cowan CR, 2007, DEVELOPMENT, V134, P1035, DOI 10.1242/dev.000513; Cuenca AA, 2003, DEVELOPMENT, V130, P1255, DOI 10.1242/dev.00284; Edgar LG, 1995, METHOD CELL BIOL, V48, P303; ETEMADMOGHADAM B, 1995, CELL, V83, P743, DOI 10.1016/0092-8674(95)90187-6; Goehring NW, 2011, SCIENCE, V334, P1137, DOI 10.1126/science.1208619; Goehring NW, 2011, J CELL BIOL, V193, P583, DOI 10.1083/jcb.201011094; Gonczy P, 2000, NATURE, V408, P331, DOI 10.1038/35042526; Gonczy P., 2005, ASYMMETRIC CELL DIVI; Guo S, 1996, NATURE, V382, P455, DOI 10.1038/382455a0; Hao YS, 2006, DEV CELL, V10, P199, DOI 10.1016/j.devcel.2005.12.015; HILL DP, 1990, DEVELOPMENT, V108, P159; HIRD SN, 1993, J CELL BIOL, V121, P1343, DOI 10.1083/jcb.121.6.1343; Hung TJ, 1999, DEVELOPMENT, V126, P127; HYMAN AA, 1987, J CELL BIOL, V105, P2123, DOI 10.1083/jcb.105.5.2123; Johnston WL, 2012, GENESIS, V50, P333, DOI 10.1002/dvg.20823; Johnston WL, 2006, BIOMED CENTRAL BIOL, V4; KIRBY C, 1990, DEV BIOL, V142, P203, DOI 10.1016/0012-1606(90)90164-E; Laffafian I, 1998, BIOPHYS J, V75, P2558, DOI 10.1016/S0006-3495(98)77700-8; Lee JY, 2003, DEVELOPMENT, V130, P307, DOI 10.1242/dev.00211; Motegi F, 2011, NAT CELL BIOL, V13, P1361, DOI 10.1038/ncb2354; Munro E, 2004, DEV CELL, V7, P413, DOI 10.1016/j.devcel.2004.08.001; Munro E, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a003400; Nance J, 2003, DEVELOPMENT, V130, P5339, DOI 10.1242/dev.00735; Nance J, 2011, DEVELOPMENT, V138, P799, DOI 10.1242/dev.053538; Noatynska A, 2012, ESSAYS BIOCHEM, V53, P1, DOI [10.1042/BSE0530001, 10.1042/bse0530001]; O'Connell KF, 2000, DEV BIOL, V222, P55, DOI 10.1006/dbio.2000.9714; Olson SK, 2012, J CELL BIOL, V198, P731, DOI 10.1083/jcb.201206008; Rappleye CA, 1999, GENE DEV, V13, P2838, DOI 10.1101/gad.13.21.2838; Schonegg S, 2006, DEVELOPMENT, V133, P3507, DOI 10.1242/dev.02527; Schrlau MG, 2008, NANOTECHNOLOGY, V19, DOI 10.1088/0957-4484/19/01/015101; Schrlau MG, 2009, ACS NANO, V3, P563, DOI 10.1021/nn800851d; Schrlau MG, 2008, NANOTECHNOLOGY, V19, DOI 10.1088/0957-4484/19/32/325102; Severson AF, 2003, J CELL BIOL, V161, P21, DOI 10.1083/jcb.200210171; Severson AF, 2002, CURR BIOL, V12, P2066, DOI 10.1016/S0960-9822(02)01355-6; Shelton CA, 1999, J CELL BIOL, V146, P439, DOI 10.1083/jcb.146.2.439; Stone TW, 1985, MICROIONTOPHORESIS P; STROME S, 1983, CELL, V35, P15, DOI 10.1016/0092-8674(83)90203-9; Tabuse Y, 1998, DEVELOPMENT, V125, P3607; Tagawa A, 2001, DEV BIOL, V233, P412, DOI 10.1006/dbio.2001.0234; Timmons L, 1998, NATURE, V395, P854, DOI 10.1038/27579; Timmons L, 2001, GENE, V263, P103, DOI 10.1016/S0378-1119(00)00579-5; Tsai MC, 2007, J CELL BIOL, V179, P397, DOI 10.1083/jcb.200708101; Velarde N, 2007, BMC DEV BIOL, V7, DOI 10.1186/1471-213X-7-142; Wallenfang MR, 2000, NATURE, V408, P89, DOI 10.1038/35040562; Wang XY, 2013, CHEM SOC REV, V42, P202, DOI 10.1039/c2cs35259a; Watts JL, 1996, DEVELOPMENT, V122, P3133; Wood E., 1994, BIOCHEM EDUC, V22, P83, DOI [10.1016/0307-4412(94)90083-3, DOI 10.1016/0307-4412(94)90083-3]; Zhang Y, 2007, MICROINJECTION TECHN; Zhang Y, 2008, BIOESSAYS, V30, P606, DOI 10.1002/bies.20759; Zonies S, 2010, DEVELOPMENT, V137, P1669, DOI 10.1242/dev.045823	59	9	11	1	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 26	2013	8	9							e75712	10.1371/journal.pone.0075712	http://dx.doi.org/10.1371/journal.pone.0075712			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	228VP	24086620	Green Published, Green Submitted, gold			2023-01-03	WOS:000325220000036
J	Sollenberger, JF; Holloway, RG				Sollenberger, Julia F.; Holloway, Robert G., Jr.			The Evolving Role and Value of Libraries and Librarians in Health Care	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							SERVICES		[Sollenberger, Julia F.] Univ Rochester, Edward G Miner Lib, Rochester, NY 14642 USA; [Holloway, Robert G., Jr.] Univ Rochester, Sch Med & Dent, Dept Neurol, Rochester, NY 14642 USA	University of Rochester; University of Rochester	Sollenberger, JF (corresponding author), Univ Rochester, Edward G Miner Lib, 601 Elmwood Ave, Rochester, NY 14642 USA.	julia_sollenberger@urmc.rochester.edu		Sollenberger, Julia/0000-0002-6993-953X				Aitken EM, 2011, ACAD MED, V86, P1508, DOI 10.1097/ACM.0b013e31823595cd; Association of Academic Health Sciences Libraries, 2010, ANN STAT MED SCH LIB; Association of Academic Health Sciences Libraries (AAHSL), 2013, ANN STAT MED SCH LIB; Banks DE, 2007, J MED LIBR ASSOC, V95, P381, DOI 10.3163/1536-5050.95.4.381; Brettle A, 2011, HEALTH INFO LIBR J, V28, P3, DOI 10.1111/j.1471-1842.2010.00925.x; Marshall JG, 2013, J MED LIBR ASSOC, V101, P38, DOI 10.3163/1536-5050.101.1.007; McGowan J, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003785; Oliver KB, 2011, J MED LIBR ASSOC, V99, P237, DOI 10.3163/1536-5050.99.3.011; Sievert M, 2011, J HOSP LIBRARIANSHIP, V11, P140, DOI [10.1080/15323269.2011.558882, DOI 10.1080/15323269.2011.558882]	9	25	29	0	21	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 25	2013	310	12					1231	1232		10.1001/jama.2013.277050	http://dx.doi.org/10.1001/jama.2013.277050			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	222SO	24065006				2023-01-03	WOS:000324751800016
J	Martiny, VY; Carbonell, P; Lagorce, D; Villoutreix, BO; Moroy, G; Miteva, MA				Martiny, Virginie Y.; Carbonell, Pablo; Lagorce, David; Villoutreix, Bruno O.; Moroy, Gautier; Miteva, Maria A.			In Silico Mechanistic Profiling to Probe Small Molecule Binding to Sulfotransferases	PLOS ONE			English	Article							CRYSTAL-STRUCTURE; METABOLIZING-ENZYMES; STRUCTURAL GENOMICS; DRUG-METABOLISM; SITE; INHIBITION; DYNAMICS; DOCKING; PREDICTION; SULFATION	Drug metabolizing enzymes play a key role in the metabolism, elimination and detoxification of xenobiotics, drugs and endogenous molecules. While their principal role is to detoxify organisms by modifying compounds, such as pollutants or drugs, for a rapid excretion, in some cases they render their substrates more toxic thereby inducing severe side effects and adverse drug reactions, or their inhibition can lead to drug-drug interactions. We focus on sulfotransferases (SULTs), a family of phase II metabolizing enzymes, acting on a large number of drugs and hormones and showing important structural flexibility. Here we report a novel in silico structure-based approach to probe ligand binding to SULTs. We explored the flexibility of SULTs by molecular dynamics (MD) simulations in order to identify the most suitable multiple receptor conformations for ligand binding prediction. Then, we employed structure-based docking-scoring approach to predict ligand binding and finally we combined the predicted interaction energies by using a QSAR methodology. The results showed that our protocol successfully prioritizes potent binders for the studied here SULT1 isoforms, and give new insights on specific molecular mechanisms for diverse ligands' binding related to their binding sites plasticity. Our best QSAR models, introducing predicted protein-ligand interaction energy by using docking, showed accuracy of 67.28%, 78.00% and 75.46%, for the isoforms SULT1A1, SULT1A3 and SULT1E1, respectively. To the best of our knowledge our protocol is the first in silico structure-based approach consisting of a protein-ligand interaction analysis at atomic level that considers both ligand and enzyme flexibility, along with a QSAR approach, to identify small molecules that can interact with II phase dug metabolizing enzymes.	[Martiny, Virginie Y.; Lagorce, David; Villoutreix, Bruno O.; Moroy, Gautier; Miteva, Maria A.] Univ Paris Diderot, Sorbonne Paris Cite, INSERM, Mol Therapeut In Silico,UMR S 973, Paris, France; [Martiny, Virginie Y.; Lagorce, David; Villoutreix, Bruno O.; Moroy, Gautier; Miteva, Maria A.] INSERM, U973, Paris, France; [Carbonell, Pablo] Univ Evry, iSSB, Evry, France; [Carbonell, Pablo] CNRS, iSSB, Evry, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Miteva, MA (corresponding author), Univ Paris Diderot, Sorbonne Paris Cite, INSERM, Mol Therapeut In Silico,UMR S 973, Paris, France.	maria.miteva@univ-paris-diderot.fr	Moroy, Gautier/AAT-1608-2020; Miteva, Maria M/N-2419-2018; Carbonell, Pablo/A-3572-2011; Villoutreix, Bruno/I-4565-2015	Moroy, Gautier/0000-0002-8973-0477; Miteva, Maria M/0000-0001-6895-1214; Carbonell, Pablo/0000-0002-0993-5625; Villoutreix, Bruno/0000-0002-6456-7730	doctoral school 'MTCE' at the University Paris Descartes; doctoral school 'MTCE' at the University Paris Diderot	doctoral school 'MTCE' at the University Paris Descartes; doctoral school 'MTCE' at the University Paris Diderot	V.Y.M. was supported by the doctoral school 'MTCE' at the Universities Paris Descartes and Paris Diderot. P. C. was supported by Genopole (ATIGE grant) and Agence Nationale de la Recherche. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Allali-Hassani A, 2007, PLOS BIOL, V5, P1063, DOI 10.1371/journal.pbio.0050097; Berger I, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026794; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Bidwell LM, 1999, J MOL BIOL, V293, P521, DOI 10.1006/jmbi.1999.3153; Bojarova P, 2008, CURR OPIN CHEM BIOL, V12, P573, DOI 10.1016/j.cbpa.2008.06.018; Bolton EE, 2010, ANN REP COMP CHEM, V4, P217, DOI 10.1016/S1574-1400(08)00012-1; Breiman L., 2001, Machine Learning, V45, P5, DOI 10.1023/A:1010933404324; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; Campagna-Slater V, 2009, J CHEM INF MODEL, V49, P2082, DOI 10.1021/ci900219u; Carbonell P, 2013, J CHEM INF MODEL; Cavasotto CN, 2011, METHODS MOL BIOL, V685, P155, DOI 10.1007/978-1-60761-931-4_8; Chapman E, 2004, ANGEW CHEM INT EDIT, V43, P3526, DOI 10.1002/anie.200300631; Cook I, 2013, BIOCHEMISTRY-US, V52, P415, DOI 10.1021/bi301492j; Dong D, 2012, EXPERT OPIN DRUG MET, V8, P635, DOI 10.1517/17425255.2012.677027; Eagle K, 2012, J APPL TOXICOL, V32, P751, DOI 10.1002/jat.2764; Ekuase EJ, 2011, CHEM RES TOXICOL, V24, P1720, DOI 10.1021/tx200260h; Gamage N, 2006, TOXICOL SCI, V90, P5, DOI 10.1093/toxsci/kfj061; Gamage NU, 2005, J BIOL CHEM, V280, P41482, DOI 10.1074/jbc.M508289200; Gamage NU, 2003, J BIOL CHEM, V278, P7655, DOI 10.1074/jbc.M207246200; Gleeson MP, 2008, J MED CHEM, V51, P817, DOI 10.1021/jm701122q; Gleeson MP, 2012, CURR PHARM DESIGN, V18, P1266; Grigorov MG, 2011, METHODS MOL BIOL, V719, P153, DOI 10.1007/978-1-61779-027-0_7; Haberthur U, 2008, J COMPUT CHEM, V29, P701, DOI 10.1002/jcc.20832; Hamon J, 2009, FUTURE MED CHEM, V1, P645, DOI 10.4155/FMC.09.51; Isvoran A, 2011, BMC STRUCT BIOL, V11, DOI 10.1186/1472-6807-11-24; Ivetac A, 2011, CURR PHARM DESIGN, V17, P1663, DOI 10.2174/138161211796355056; Jones G, 1997, J MOL BIOL, V267, P727, DOI 10.1006/jmbi.1996.0897; Kakuta Y, 1998, J BIOL CHEM, V273, P27325, DOI 10.1074/jbc.273.42.27325; Karatzoglou A, 2004, J STAT SOFTW, V11, P1, DOI [10.18637/jss.v011.i09, DOI 10.18637/JSS.V011.I09, 10.18637/jss.v0]; Kuhn M, 2008, J STAT SOFTW, V28, P1, DOI 10.18637/jss.v028.i05; Lagorce D, 2011, ADMET MED CHEMISTS, P29; Lagorce D, 2011, BIOINFORMATICS, V27, P2018, DOI 10.1093/bioinformatics/btr333; Liang J, 1998, PROTEIN SCI, V7, P1884, DOI 10.1002/pro.5560070905; Lu JH, 2005, BIOCHEM BIOPH RES CO, V335, P417, DOI 10.1016/j.bbrc.2005.07.091; Mackerell AD, 2004, J COMPUT CHEM, V25, P1400, DOI 10.1002/jcc.20065; MacKerell AD, 1998, J PHYS CHEM B, V102, P3586, DOI 10.1021/jp973084f; Martiny VY, 2013, PREDICTIVE ADMETINTE; Meng SN, 2012, MOL PHARMACEUT, V9, P862, DOI 10.1021/mp200400s; Merlot C, 2010, DRUG DISCOV TODAY, V15, P16, DOI 10.1016/j.drudis.2009.09.010; Michielan L, 2010, J CHEM INF MODEL, V50, P961, DOI 10.1021/ci100072z; Miteva MA, 2005, NUCLEIC ACIDS RES, V33, pW372, DOI 10.1093/nar/gki365; Moroy G, 2012, DRUG DISCOV TODAY, V17, P44, DOI 10.1016/j.drudis.2011.10.023; Morris GM, 2009, J COMPUT CHEM, V30, P2785, DOI 10.1002/jcc.21256; Moustakas DT, 2006, J COMPUT AID MOL DES, V20, P601, DOI 10.1007/s10822-006-9060-4; Nair Rajesh, 2009, Journal of Structural and Functional Genomics, V10, P181, DOI 10.1007/s10969-008-9055-6; Najmanovich RJ, 2007, BIOINFORMATICS, V23, pE104, DOI 10.1093/bioinformatics/btl292; Nigsch F, 2011, EXPERT OPIN DRUG MET, V7, P1497, DOI 10.1517/17425255.2011.632632; R Core Team, 2021, R LANG ENV STAT COMP; Rohn KJ, 2012, DRUG METAB DISPOS, V40, P1588, DOI 10.1124/dmd.112.045583; Rueda M, 2009, J CHEM INF MODEL, V49, P716, DOI 10.1021/ci8003732; RYCKAERT JP, 1977, J COMPUT PHYS, V23, P327, DOI 10.1016/0021-9991(77)90098-5; Scheer M, 2011, NUCLEIC ACIDS RES, V39, pD670, DOI 10.1093/nar/gkq1089; Sharma V, 2005, METHOD ENZYMOL, V400, P249, DOI 10.1016/S0076-6879(05)00014-5; Shawahna R, 2011, MOL PHARMACEUT, V8, P1332, DOI 10.1021/mp200129p; Shevtsov S, 2003, ENVIRON HEALTH PERSP, V111, P884, DOI 10.1289/ehp.6056; Shimada T, 2006, DRUG METAB PHARMACOK, V21, P257, DOI 10.2133/dmpk.21.257; Sipila J, 2003, J CHEM INF COMP SCI, V43, P1563, DOI 10.1021/ci034089e; Sperandio O, 2011, IN SILICO LEAD DISCOVERY, P20; Sperandio O, 2010, EUR BIOPHYS J BIOPHY, V39, P1365, DOI 10.1007/s00249-010-0592-0; Stjernschantz E, 2010, MOL CELL ENDOCRINOL, V317, P127, DOI 10.1016/j.mce.2009.12.001; Stoll F, 2011, DRUG DISCOV TODAY, V16, P530, DOI 10.1016/j.drudis.2011.04.008; Sun H, 2010, CHEM BIOL DRUG DES, V75, P3, DOI 10.1111/j.1747-0285.2009.00899.x; Surh YJ, 1998, CHEM-BIOL INTERACT, V109, P221, DOI 10.1016/S0009-2797(97)00134-8; Taboureau O, 2012, CHEM BIOL, V19, P29, DOI 10.1016/j.chembiol.2011.12.007; Taskinen J, 2003, DRUG METAB DISPOS, V31, P1187, DOI 10.1124/dmd.31.9.1187; Teague SJ, 2003, NAT REV DRUG DISCOV, V2, P527, DOI 10.1038/nrd1129; Testa B, 2012, DRUG DISCOV TODAY, V17, P549, DOI 10.1016/j.drudis.2012.01.017; Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334; Varnek A, 2012, J CHEM INF MODEL, V52, P1413, DOI 10.1021/ci200409x; Vaz RJ, 2010, EXPERT OPIN DRUG MET, V6, P851, DOI 10.1517/17425255.2010.499123; Vedani A, 2009, ATLA-ALTERN LAB ANIM, V37, P477, DOI 10.1177/026119290903700506; Veith H, 2009, NAT BIOTECHNOL, V27, P1050, DOI 10.1038/nbt.1581; Volkamer A, 2012, J CHEM INF MODEL, V52, P360, DOI 10.1021/ci200454v; Wang JL, 2007, EXPERT OPIN DRUG MET, V3, P641, DOI 10.1517/17425225.3.5.641; WARWICKER J, 1982, J MOL BIOL, V157, P671, DOI 10.1016/0022-2836(82)90505-8; Wolber G, 2005, J CHEM INF MODEL, V45, P160, DOI 10.1021/ci049885e; Xie L, 2011, CURR OPIN STRUC BIOL, V21, P189, DOI 10.1016/j.sbi.2011.01.004; Zoete V, 2011, J COMPUT CHEM, V32, P2359, DOI 10.1002/jcc.21816	78	18	21	0	19	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 6	2013	8	9							e73587	10.1371/journal.pone.0073587	http://dx.doi.org/10.1371/journal.pone.0073587			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	224BO	24039991	Green Published, gold			2023-01-03	WOS:000324856500048
J	Gomez-Cabrero, A; Wrasidlo, W; Reisfeld, RA				Gomez-Cabrero, Azucena; Wrasidlo, Wolfgang; Reisfeld, Ralph A.			IMD-0354 Targets Breast Cancer Stem Cells: A Novel Approach for an Adjuvant to Chemotherapy to Prevent Multidrug Resistance in a Murine Model	PLOS ONE			English	Article							KINASE-BETA-INHIBITOR; KAPPA-B; DRUG-RESISTANCE; LEGUMAIN EXPRESSION; SIDE POPULATION; TUMOR-GROWTH; METASTASIS; SUPPRESSES; BIOLOGY; HYPOXIA	Although early detection of breast cancer improved in recent years, prognosis of patients with late stage breast cancer remains poor, mostly due to development of multidrug resistance (MDR) followed by tumor recurrence. Cancer stem cells (CSCs), with higher drug efflux capability and other stem cell-like properties, are concentrated in a side population (SP) of cells, which were proposed to be responsible for MDR and tumor repopulation that cause patients to succumb to breast cancer. Therefore, targeting of CSCs as an adjuvant to chemotherapy should be able to provide a more effective treatment of this disease. Here, we used IMD-0354, an inhibitor of NF-kappa B, identified for targeting CSCs, in a combination therapy with doxorubicin encapsulated in targeted nanoparticles. IMD-0354 did target CSCs, evidenced by a decrease in the SP, demonstrated by the inhibition of the following: dye/drug efflux, reduction in ABC transporters as well as in colony formation in soft agar and low attachment plates. Decrease of stem-like gene expression of Oct4, Nanog and Sox2, and apoptosis resistance related to the Survivin gene also was observed after treatment with this compound. In addition, IMD-0354 targeted non-CSCs as indicated by reducing viability and increasing apoptosis. Targeted drug delivery, achieved with a legumain inhibitor, proved to enhance drug delivery under hypoxia, a hallmark of the tumor microenvironment, but not under normoxia. Together, this allowed a safe, non-toxic delivery of both anticancer agents to the tumor microenvironment of mice bearing syngeneic metastatic breast cancer. Targeting both bulk tumor cells with a chemotherapeutic agent and CSCs with IMD-0354 should be able to reduce MDR. This could eventually result in decreasing tumor recurrences and/or improve the outcome of metastatic disease.	[Gomez-Cabrero, Azucena; Reisfeld, Ralph A.] Scripps Res Inst, Dept Immunol & Microbial Sci, La Jolla, CA 92037 USA; [Wrasidlo, Wolfgang] Univ Calif San Diego, Moores Canc Ctr, San Diego, CA 92103 USA	Scripps Research Institute; University of California System; University of California San Diego	Gomez-Cabrero, A (corresponding author), Scripps Res Inst, Dept Immunol & Microbial Sci, La Jolla, CA 92037 USA.	agomezcabrero@hotmail.com			NIH [1R01CA134364]; DOD/CDMRP [W81XWH-10-1-0764]; NATIONAL CANCER INSTITUTE [R01CA134364] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); DOD/CDMRP(United States Department of Defense); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was funded by NIH 1R01CA134364 (www.nih.gov) and DOD/CDMRP W81XWH-10-1-0764 (http://cdmrp.army.mil) grants. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ailles LE, 2007, CURR OPIN BIOTECH, V18, P460, DOI 10.1016/j.copbio.2007.10.007; Airoldi M, 2011, TUMORI, V97, P690, DOI 10.1700/1018.11082; Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; ASLAKSON CJ, 1992, CANCER RES, V52, P1399; Baccelli I, 2012, J CELL BIOL, V198, P281, DOI 10.1083/jcb.201202014; Bajjuri KM, 2011, CHEMMEDCHEM, V6, P54, DOI 10.1002/cmdc.201000478; Berenson JR, 2001, SEMIN ONCOL, V28, P626, DOI 10.1053/sonc.2001.29542; Dean M, 2009, J MAMMARY GLAND BIOL, V14, P3, DOI 10.1007/s10911-009-9109-9; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Dontu G, 2003, GENE DEV, V17, P1253, DOI 10.1101/gad.1061803; Ekici OD, 2004, J MED CHEM, V47, P1889, DOI 10.1021/jm049938j; Fillmore CM, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1982; Gawenda J, 2007, BREAST CANCER RES TR, V102, P1, DOI 10.1007/s10549-006-9311-z; Giaccia AJ, 2004, GENE DEV, V18, P2183, DOI 10.1101/gad.1243304; Gomez-Cabrero A, 2005, MOL VIS, V11, P1071; Goodell MA, 2005, CURR PROTOC CYTOM, V9; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; HIGUCHI M, 1980, CLIN EXP IMMUNOL, V39, P90; Hiraga T, 2011, ONCOL REP, V25, P289, DOI 10.3892/or_00001073; Hood JD, 2002, SCIENCE, V296, P2404, DOI 10.1126/science.1070200; Hwang-Verslues WW, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008377; Kawanabe N, 2006, BIOCHEM BIOPH RES CO, V344, P1278, DOI 10.1016/j.bbrc.2006.03.237; Kim Ran-Ju, 2011, Lab Anim Res, V27, P147, DOI 10.5625/lar.2011.27.2.147; Kim SY, 2013, CELL SIGNAL, V25, P961, DOI 10.1016/j.cellsig.2013.01.007; Kruger JA, 2006, BLOOD, V108, P3906, DOI 10.1182/blood-2006-05-024687; Liao D, 2011, NANOMED-NANOTECHNOL, V7, P665, DOI 10.1016/j.nano.2011.03.001; Ling J, 2012, CANCER LETT, V322, P119, DOI 10.1016/j.canlet.2012.02.033; Lorger M, 2010, AM J PATHOL, V176, P2958, DOI 10.2353/ajpath.2010.090838; Luo YP, 2006, J CLIN INVEST, V116, P2132, DOI 10.1172/JCI27648; Mak KK, 2013, MOL NUTR FOOD RES, V57, P1123, DOI 10.1002/mnfr.201200549; Mantovani A, 2010, CURR MOL MED, V10, P369, DOI 10.2174/156652410791316968; MILLER FR, 1983, INVAS METAST, V3, P22; Nagler C, 2011, ADV EXP MED BIOL, V714, P173, DOI 10.1007/978-94-007-0782-5_9; Ochiai Takanori, 2008, J Med Dent Sci, V55, P49; Octavia Y, 2012, J MOL CELL CARDIOL, V52, P1213, DOI 10.1016/j.yjmcc.2012.03.006; Ogawa K, 2013, ANTICANCER RES, V33, P747; Ohno Y, 2013, WORLD J UROL, V31, P359, DOI 10.1007/s00345-012-0977-z; Onai Y, 2004, CARDIOVASC RES, V63, P51, DOI 10.1016/j.cardiores.2004.03.002; PRICE JE, 1990, CANCER RES, V50, P717; PRICE JE, 1990, CANCER-AM CANCER SOC, V66, P1313, DOI 10.1002/1097-0142(19900915)66:14+<1313::AID-CNCR2820661403>3.0.CO;2-4; Prud'homme GJ, 2012, CURR PHARM DESIGN, V18, P2838; Prud'homme GJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013831; Pulaski BA, 1998, CANCER RES, V58, P1486; Sambrook J., 2001, MOL CLONING LAB MANU, V3; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Siegel R, 2012, CA-CANCER J CLIN, V62, P10, DOI 10.3322/caac.20138; Sugita A, 2009, INT ARCH ALLERGY IMM, V148, P186, DOI 10.1159/000161579; Sullivan R, 2007, CANCER METAST REV, V26, P319, DOI 10.1007/s10555-007-9062-2; Sutherland RM, 1998, ACTA ONCOL, V37, P567, DOI 10.1080/028418698430278; Tanaka A, 2006, CANCER RES, V66, P419, DOI 10.1158/0008-5472.CAN-05-0741; Tanaka A, 2005, BLOOD, V105, P2324, DOI 10.1182/blood-2004-08-3247; Tirino V, 2013, FASEB J, V27, P13, DOI 10.1096/fj.12-218222; Uota S, 2012, CANCER SCI, V103, P100, DOI 10.1111/j.1349-7006.2011.02110.x; Vinogradov S, 2012, NANOMEDICINE-UK, V7, P597, DOI [10.2217/NNM.12.22, 10.2217/nnm.12.22]; Volkova M, 2011, CURR CARDIOL REV, V7, P214, DOI 10.2174/157340311799960645; Wang LN, 2012, J CELL BIOCHEM, V113, P2679, DOI 10.1002/jcb.24143	57	42	48	0	27	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 27	2013	8	8							e73607	10.1371/journal.pone.0073607	http://dx.doi.org/10.1371/journal.pone.0073607			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	210FR	24014113	Green Submitted, gold, Green Published			2023-01-03	WOS:000323815200084
J	Nguyen, NP; Ceizyk, M; Vock, J; Vos, P; Chi, A; Vincent, VH; Pugh, J; Khan, R; Truong, C; Albala, G; Locke, A; Karlsson, U; Gelumbauskas, S; Smith-Raymond, L				Nguyen, Nam P.; Ceizyk, Misty; Vock, Jacqueline; Vos, Paul; Chi, Alexander; Vincent Vinh-Hung; Pugh, Judy; Khan, Rihan; Christina Truong; Albala, Gabby; Locke, Angela; Karlsson, Ulf; Gelumbauskas, Steve; Smith-Raymond, Lexie			Feasibility of Image-Guided Radiotherapy for Elderly Patients with Locally Advanced Rectal Cancer	PLOS ONE			English	Article							INTENSITY-MODULATED RADIOTHERAPY; PREOPERATIVE HELICAL TOMOTHERAPY; PHASE-III TRIAL; RADIATION-THERAPY; POSTOPERATIVE CHEMORADIOTHERAPY; CAPECITABINE; RADIOCHEMOTHERAPY; OXALIPLATIN; TOXICITY; BOOST	Purpose: The study aims to assess the tolerance of elderly patients (70 years or older) with locally advanced rectal cancers to image-guided radiotherapy (IGRT). A retrospective review of 13 elderly patients with locally advanced rectal cancer who underwent preoperative chemoradiation using IGRT was performed. Grade 3-4 acute toxicities, survival, and long-term complications were compared to 17 younger patients (<70 years) with the same disease stage. Results: Grade 3-4 hematologic toxicities occurred in 7.6% and 0% (p = 0.4) and gastrointestinal toxicities, and, in 15.2% and 5% (p = 0.5), of elderly and younger patients, respectively. Surgery was aborted in three patients, two in the elderly group and one in the younger group. One patient in the elderly group died after surgery from cardiac arrhythmia. After a median follow-up of 34 months, five patients had died, two in the elderly and three in the younger group. The 3-year survival was 90.9% and 87.5% (p = 0.7) for the elderly and younger group respectively. Two patients in the younger group developed ischemic colitis and fecal incontinence. There was no statistically significant difference in acute and late toxicities as well as survival between the two groups. Conclusions and Clinical Relevance: Elderly patients with locally advanced rectal cancers may tolerate preoperative chemoradiation with IGRT as well as younger patients. Further prospective studies should be performed to investigate the potential of IGRT for possible cure in elderly patients with locally advanced rectal cancer.	[Nguyen, Nam P.; Ceizyk, Misty; Christina Truong; Albala, Gabby; Locke, Angela; Gelumbauskas, Steve; Smith-Raymond, Lexie] Univ Arizona, Dept Radiat Oncol, Tucson, AZ 85721 USA; [Vock, Jacqueline] Lindenhofspital, Dept Radiat Oncol, Bern, Switzerland; [Vos, Paul] E Carolina Univ, Dept Biostat, Greenville, NC USA; [Chi, Alexander] W Virginia Univ, Dept Radiat Oncol, Morgantown, WV 26506 USA; [Vincent Vinh-Hung] Univ Hosp Geneva, Dept Radiat Oncol, Geneva, Switzerland; [Pugh, Judy] Univ Arizona, Dept Pathol, Tucson, AZ 85721 USA; [Khan, Rihan] Univ Arizona, Dept Radiol, Tucson, AZ 85721 USA; [Karlsson, Ulf] Marshfield Clin Fdn Med Res & Educ, Dept Radiat Oncol, Marshfield, WI USA	University of Arizona; University of North Carolina; East Carolina University; West Virginia University; University of Geneva; University of Arizona; University of Arizona; Marshfield Clinic	Nguyen, NP (corresponding author), Univ Arizona, Dept Radiat Oncol, Tucson, AZ 85721 USA.	NamPhong.Nguyen@yahoo.com	Vinh-Hung, Vincent/A-5762-2008	Vinh-Hung, Vincent/0000-0002-6403-6120				Aparicio T, 2009, CRIT REV ONCOL HEMAT, V71, P249, DOI 10.1016/j.critrevonc.2008.11.006; Arbea L, 2012, INT J RADIAT ONCOL, V83, P587, DOI 10.1016/j.ijrobp.2011.06.2008; Arbea L, 2010, RADIAT ONCOL, V5, DOI 10.1186/1748-717X-5-17; Ballonoff A, 2008, AM J CLIN ONCOL-CANC, V31, P264, DOI 10.1097/COC.0b013e318161dbd3; Beavis AW, 2004, BRIT J RADIOL, V77, P285, DOI 10.1259/bjr/22666727; Chang GJ, 2007, ANN SURG, V246, P215, DOI 10.1097/SLA.0b013e318070838f; Chen RC, 2012, INT J RADIAT ONCOL, V83, pE513, DOI 10.1016/j.ijrobp.2012.01.013; Chi A, 2012, TECHNOL CANCER RES T, V11, P353, DOI 10.7785/tcrt.2012.500283; Dale David C, 2003, J Support Oncol, V1, P11; Engels B, 2012, INT J RADIAT ONCOL, V83, P142, DOI 10.1016/j.ijrobp.2011.05.068; Engels B, 2009, INT J RADIAT ONCOL, V74, P1476, DOI 10.1016/j.ijrobp.2008.10.017; Hofheinz RD, 2012, LANCET ONCOL, V13, DOI 10.1016/S1470-2045(12)70116-X; Ippolito E, 2008, ACTA ONCOL, V47, P1317, DOI 10.1080/02841860802256459; Jabbour SK, 2012, INT J SURG ONCOL, V2012, DOI 10.1155/2012/891067; Kalofonos HP, 2008, EUR J CANCER, V44, P1693, DOI 10.1016/j.ejca.2008.05.025; Kiran RP, 2007, DIS COLON RECTUM, V50, P604, DOI 10.1007/s10350-006-0802-0; Li JL, 2012, RADIOTHER ONCOL, V102, P4, DOI 10.1016/j.radonc.2011.07.030; Margalit DN, 2011, INT J RADIAT ONCOL, V81, pE735, DOI 10.1016/j.ijrobp.2010.12.056; Nguyen NP, 2011, ANN SURG ONCOL, V18, P380, DOI 10.1245/s10434-010-1329-0; Samuelian JM, 2012, INT J RADIAT ONCOL, V82, P1981, DOI 10.1016/j.ijrobp.2011.01.051; Sauer R, 2004, NEW ENGL J MED, V351, P1731, DOI 10.1056/NEJMoa040694; Sauer R, 2012, J CLIN ONCOL, V30, P1926, DOI 10.1200/JCO.2011.40.1836; Winkler J, 2012, STRAHLENTHER ONKOL, V188, P377, DOI 10.1007/s00066-012-0073-8	23	3	4	1	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 13	2013	8	8							e71250	10.1371/journal.pone.0071250	http://dx.doi.org/10.1371/journal.pone.0071250			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	201BN	23967173	Green Published, Green Submitted, gold			2023-01-03	WOS:000323115800045
J	Rusine, J; Asiimwe-Kateera, B; van de Wijgert, J; Boer, KR; Mukantwali, E; Karita, E; Gasengayire, A; Jurriaans, S; de Jong, M; Ondoa, P				Rusine, John; Asiimwe-Kateera, Brenda; van de Wijgert, Janneke; Boer, Kimberly Rachel; Mukantwali, Enatha; Karita, Etienne; Gasengayire, Agnes; Jurriaans, Suzanne; de Jong, Menno; Ondoa, Pascale			Low Primary and Secondary HIV Drug-Resistance after 12 Months of Antiretroviral Therapy in Human Immune-Deficiency Virus Type 1 (HIV-1)-Infected Individuals from Kigali, Rwanda	PLOS ONE			English	Article							LOGISTIC-REGRESSION ANALYSIS; SUB-SAHARAN AFRICA; REVERSE-TRANSCRIPTASE; SOUTH-AFRICA; MUTATIONS; SURVEILLANCE; ZIDOVUDINE; FAILURE; PATTERNS; STRATEGY	Treatment outcomes of HIV patients receiving antiretroviral therapy (ART) in Rwanda are scarcely documented. HIV viral load (VL) and HIV drug-resistance (HIVDR) outcomes at month 12 were determined in a prospective cohort study of antiretroviral-naive HIV patients initiating first-line therapy in Kigali. Treatment response was monitored clinically and by regular CD4 counts and targeted HIV viral load (VL) to confirm drug failure. VL measurements and HIVDR genotyping were performed retrospectively on baseline and month 12 samples. One hundred and fifty-eight participants who completed their month 12 follow-up visit had VL data available at month 12. Most of them (88%) were virologically suppressed (VL <= 1000 copies/mL) but 18 had virological failure (11%), which is in the range of WHO-suggested targets for HIVDR prevention. If only CD4 criteria had been used to classify treatment response, 26% of the participants would have been misclassified as treatment failure. Pre-therapy HIVDR was documented in 4 of 109 participants (3.6%) with an HIVDR genotyping results at baseline. Eight of 12 participants (66.7%) with virological failure and HIVDR genotyping results at month 12 were found to harbor mutation(s), mostly NNRTI resistance mutations, whereas 4 patients had no HIVDR mutations. Almost half (44%) of the participants initiated ART at CD4 count <= 200cell/mu l and severe CD4 depletion at baseline (<50 cells/mu l) was associated with virological treatment failure (p = 0.008). Although the findings may not be generalizable to all HIV patients in Rwanda, our data suggest that first-line ART regimen changes are currently not warranted. However, the accumulation of acquired HIVDR mutations in some participants underscores the need to reinforce HIVDR prevention strategies, such as increasing the availability and appropriate use of VL testing to monitor ART response, ensuring high quality adherence counseling, and promoting earlier identification of HIV patients and enrollment into HIV care and treatment programs.	[Rusine, John; Asiimwe-Kateera, Brenda; van de Wijgert, Janneke; Boer, Kimberly Rachel; Ondoa, Pascale] Univ Amsterdam, Acad Med Ctr, Dept Global Hlth, Amsterdam Inst Global Hlth & Dev, NL-1105 AZ Amsterdam, Netherlands; [Rusine, John; Mukantwali, Enatha; Gasengayire, Agnes] Natl Reference Lab, Kigali, Rwanda; [Karita, Etienne] Project San Francisco, Kigali, Rwanda; [Jurriaans, Suzanne; de Jong, Menno] Univ Amsterdam, Acad Med Ctr, Dept Med Microbiol, NL-1105 AZ Amsterdam, Netherlands; [van de Wijgert, Janneke] Univ Liverpool, Inst Infect & Global Hlth, Liverpool L69 3BX, Merseyside, England; [Boer, Kimberly Rachel] Royal Trop Inst, NL-1105 AZ Amsterdam, Netherlands; [Rusine, John; Asiimwe-Kateera, Brenda; Boer, Kimberly Rachel] Infect Dis Network Treatment & Res Africa INTERAC, Kigali, Rwanda	University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; University of Liverpool	Ondoa, P (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Global Hlth, Amsterdam Inst Global Hlth & Dev, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.	p.ondoa@aighd.org	Asiimwe-Kateera, Brenda/H-3378-2019	Asiimwe Kateera, Brenda/0000-0001-6134-1042; van de Wijgert, Janneke H.H.M./0000-0003-2728-4560	Netherlands-African Partnership for Capacity Development and Clinical Interventions against Poverty-Related Diseases of the Netherlands Organisation for Scientific Research (NACCAP-NWO/WOTRO); European and Developing Countries Clinical Trials Partnership (EDCTP) [CT_ct_05_33070_001]	Netherlands-African Partnership for Capacity Development and Clinical Interventions against Poverty-Related Diseases of the Netherlands Organisation for Scientific Research (NACCAP-NWO/WOTRO); European and Developing Countries Clinical Trials Partnership (EDCTP)	This work was part of the INTERACT Programme funded by the Netherlands-African Partnership for Capacity Development and Clinical Interventions against Poverty-Related Diseases of the Netherlands Organisation for Scientific Research - The Netherlands Foundation for the Advancement of Tropical Research (NACCAP-NWO/WOTRO, www.nwo.nl). Funding was also received from the European and Developing Countries Clinical Trials Partnership (EDCTP, www.edctp.org) as part of a project entitled: 'Preparing for Phase III vaginal microbicide trials in Rwanda and Kenya: Preparedness studies, capacity building, and strengthening of medical referral systems' (CT_ct_05_33070_001). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ait-Khaled M, 2002, AIDS, V16, P1686, DOI 10.1097/00002030-200208160-00017; Barth RE, 2010, LANCET INFECT DIS, V10, P155, DOI 10.1016/S1473-3099(09)70328-7; Bennett DE, 2008, ANTIVIR THER, V13, P1; Bennett DE, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004724; Blower S, 2005, AIDS, V19, P1, DOI 10.1097/00002030-200501030-00001; Brinkhof MWG, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000066; Center for Research and Treatment on AIDS Malaria Tuberculosis and Other Epidemics Rwanda, 2010, HIV AIDS RWAND 2010; de Oliveira T, 2005, BIOINFORMATICS, V21, P3797, DOI 10.1093/bioinformatics/bti607; Delaugerre C, 2009, ANTIMICROB AGENTS CH, V53, P2934, DOI 10.1128/AAC.01643-08; El-Khatib Z, 2009, SAMJ S AFR MED J, V99, P412; Gilks CF, 2006, LANCET, V368, P505, DOI 10.1016/S0140-6736(06)69158-7; Gupta A, 2011, PLOS ONE, V6, DOI [10.1371/journal.pone.0022730, 10.1371/journal.pone.0028691]; Gupta RK, 2012, LANCET, V380, P1250, DOI 10.1016/S0140-6736(12)61038-1; Gupta RK, 2009, LANCET INFECT DIS, V9, P409, DOI 10.1016/S1473-3099(09)70136-7; Hamers RL, 2012, CLIN INFECT DIS, V54, P1660, DOI 10.1093/cid/cis254; Hamers RL, 2011, LANCET INFECT DIS, V11, P750, DOI 10.1016/S1473-3099(11)70149-9; Hunt GM, 2012, CLIN INFECT DIS, V54, pS334, DOI 10.1093/cid/cir1017; Johnson Victoria A, 2010, Top HIV Med, V18, P156; Kayigamba FR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036792; Levison JH, 2013, CLIN INFECT DIS, V56, P587, DOI 10.1093/cid/cis887; Liegeois F, 2012, J INT AIDS SOC, V15, DOI 10.7448/IAS.15.2.17985; Lyagoba F, 2010, JAIDS-J ACQ IMM DEF, V55, P277, DOI 10.1097/QAI.0b013e3181ea0df8; Mugglin C, 2012, TROP MED INT HEALTH, DOI [10.1111/j.1365-3156.2012.03089.x, DOI 10.1111/J.1365-3156.2012.03089.X.[]; Nash D, 2011, AIDS, V25, P1523, DOI 10.1097/QAD.0b013e32834811b2; Nijhuis M, 1997, J INFECT DIS, V176, P398, DOI 10.1086/514056; Pillay V, 2008, ANTIVIR THER, V13, P101; Price MA, 2011, AIDS RES HUM RETROV, V27, P5, DOI 10.1089/aid.2010.0030; Rawizza HE, 2011, CLIN INFECT DIS, V53, P1283, DOI 10.1093/cid/cir729; Rusine J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042557; Rwanda Ministry of Health, 2009, GUID PROV COMPR CAR; Shafer RW, 2007, AIDS, V21, P215, DOI 10.1097/QAD.0b013e328011e691; Sigaloff KCE, 2011, JAIDS-J ACQ IMM DEF, V58, P23, DOI 10.1097/QAI.0b013e318227fc34; Stadeli KM, 2013, ANTIVIR THER, V18, P115, DOI 10.3851/IMP2437; Steyerberg EW, 2001, MED DECIS MAKING, V21, P45, DOI 10.1177/0272989X0102100106; Steyerberg EW, 2000, STAT MED, V19, P1059, DOI 10.1002/(SICI)1097-0258(20000430)19:8<1059::AID-SIM412>3.3.CO;2-S; Turner D, 2004, MICROBIOLOGICA, V27, P31; Vyankandondera J, 2013, AIDS CARE, V25, P1504, DOI 10.1080/09540121.2013.779626; Wainberg MA, 1998, JAMA-J AM MED ASSOC, V279, P1977, DOI 10.1001/jama.279.24.1977; WHO, 2010, ANT THER HIV INF AD; WHO, 2012, WHO HIV DRUG RES REP; Wittkop L, 2011, LANCET INFECT DIS, V377, P1580; World Health Organization, 2011, GLOB AIDS RESP EP UP	42	22	22	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 12	2013	8	8							e64345	10.1371/journal.pone.0064345	http://dx.doi.org/10.1371/journal.pone.0064345			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	200UV	23950859	Green Published, gold, Green Submitted			2023-01-03	WOS:000323097300001
J	Meier, ER; Byrnes, C; Lee, YT; Wright, EC; Schechter, AN; Luban, NLC; Miller, JL				Meier, Emily Riehm; Byrnes, Colleen; Lee, Y. Terry; Wright, Elizabeth C.; Schechter, Alan N.; Luban, Naomi L. C.; Miller, Jeffery L.			Increased Reticulocytosis during Infancy Is Associated with Increased Hospitalizations in Sickle Cell Anemia Patients during the First Three Years of Life	PLOS ONE			English	Article							FETAL-HEMOGLOBIN; ADVERSE OUTCOMES; DISEASE; CHILDREN; COHORT; PREDICTION; SEVERITY; TRIAL	Objective: Among older children with sickle cell anemia, leukocyte counts, hemoglobin, and reticulocytosis have previously been suggested as disease severity markers. Here we explored whether these blood parameters may be useful to predict early childhood disease severity when tested in early infancy, defined as postnatal ages 60-180 days. Study Design: Data from fifty-nine subjects who were followed at Children's National Medical Center's Sickle Cell Program for at least three years was retrospectively analyzed. Comparisons were made between white blood cell counts, hemoglobin and reticulocyte levels measured at ages 60-180 days and the clinical course of sickle cell anemia during infancy and childhood. Results: A majority of subjects had demonstrable anemia with increased reticulocytosis. Only increased absolute reticulocyte levels during early infancy were associated with a significant increase in hospitalization during the first three years of life. Higher absolute reticulocyte counts were also associated with a markedly shorter time to first hospitalizations and a four-fold higher cumulative frequency of clinical manifestations over the first three years of life. No significant increase in white blood cell counts was identified among the infant subjects. Conclusions: These data suggest that during early infancy, increased reticulocytosis among asymptomatic SCA subjects is associated with increased severity of disease in childhood.	[Meier, Emily Riehm; Byrnes, Colleen; Lee, Y. Terry; Schechter, Alan N.; Miller, Jeffery L.] NIDDK, Mol Med Branch, NIH, Bethesda, MD USA; [Meier, Emily Riehm; Luban, Naomi L. C.] Childrens Natl Med Ctr, Ctr Canc & Blood Disorders, Washington, DC 20010 USA; [Wright, Elizabeth C.] NIDDK, Off Director, NIH, Bethesda, MD USA; [Meier, Emily Riehm; Luban, Naomi L. C.] George Washington Univ, Med Ctr, Dept Pediat, Washington, DC 20037 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Children's National Health System; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); George Washington University	Miller, JL (corresponding author), NIDDK, Mol Med Branch, NIH, Bethesda, MD USA.	jm7f@nih.gov		Schechter, Alan N/0000-0002-5235-9408	Intramural Research Program of the National Institute of Diabetes and Digestive and Kidney Diseases; Marshall B. Coyne Foundation; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [ZIADK025094, ZIADK025016, ZIADK025098] Funding Source: NIH RePORTER	Intramural Research Program of the National Institute of Diabetes and Digestive and Kidney Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Marshall B. Coyne Foundation; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	The Intramural Research Program of the National Institute of Diabetes and Digestive and Kidney Diseases supported this work. Emily R. Meier is also supported by funds from the Marshall B. Coyne Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adams RJ, 1998, NEW ENGL J MED, V339, P5, DOI 10.1056/NEJM199807023390102; Battersby AJ, 2010, PEDIATR BLOOD CANCER, V55, P401, DOI 10.1002/pbc.22461; BRAY GL, 1994, AM J PEDIAT HEMATOL, V16, P50; Browne PV, 1996, J LAB CLIN MED, V127, P340, DOI 10.1016/S0022-2143(96)90181-X; Brugnara C., 2003, HEMATOLOGY INFANCY C, P1835; EMOND AM, 1985, J PEDIATR-US, V107, P201, DOI 10.1016/S0022-3476(85)80125-6; GASTON M, 1982, AM J PEDIAT HEMATOL, V4, P197; GASTON MH, 1986, NEW ENGL J MED, V314, P1593, DOI 10.1056/NEJM198606193142501; GILL FM, 1995, BLOOD, V86, P776, DOI 10.1182/blood.V86.2.776.bloodjournal862776; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; Josephson CD, 2007, TRANSFUS MED REV, V21, P118, DOI 10.1016/j.tmrv.2006.11.003; McGann PT, 2012, BLOOD, V120; Meier ER, 2011, PEDIATR BLOOD CANCER, V56, P103, DOI 10.1002/pbc.22643; Miller ST, 2000, NEW ENGL J MED, V342, P83, DOI 10.1056/NEJM200001133420203; NOGUCHI CT, 1988, NEW ENGL J MED, V318, P96, DOI 10.1056/NEJM198801143180207; OBRIEN RT, 1971, J PEDIATR-US, V79, P132, DOI 10.1016/S0022-3476(71)80076-8; Oneal PA, 2006, BLOOD, V108, P2081, DOI 10.1182/blood-2006-04-015859; PEARSON HA, 1969, NEW ENGL J MED, V281, P923, DOI 10.1056/NEJM196910232811703; Platt OS, 2008, NEW ENGL J MED, V358, P1362, DOI 10.1056/NEJMct0708272; Quinn CT, 2008, BLOOD, V111, P544, DOI 10.1182/blood-2007-07-100719; Quinn CT, 2010, BLOOD, V115, P3447, DOI 10.1182/blood-2009-07-233700; Sebastiani P, 2010, AM J HEMATOL, V85, P29, DOI 10.1002/ajh.21572; SERJEANT GR, 1981, BRIT J HAEMATOL, V48, P533, DOI 10.1111/j.1365-2141.1981.tb02750.x; Serjeant GR, 2001, SICKLE CELL DIS; Silva CM, 2011, PEDIATR BLOOD CANCER, V56, P116, DOI 10.1002/pbc.22680; Walters MC, 1996, NEW ENGL J MED, V335, P369, DOI 10.1056/NEJM199608083350601; Wang WC, 2011, LANCET, V377, P1663, DOI 10.1016/S0140-6736(11)60355-3; Weatherall DJ, 2001, B WORLD HEALTH ORGAN, V79, P704	28	15	15	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 7	2013	8	8							e70794	10.1371/journal.pone.0070794	http://dx.doi.org/10.1371/journal.pone.0070794			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	200ZE	23951011	Green Published, gold, Green Submitted			2023-01-03	WOS:000323109700054
J	Sun, P; Zhou, KW; Wang, S; Li, P; Chen, SJ; Lin, GP; Zhao, Y; Wang, TH				Sun, Peng; Zhou, Kewen; Wang, Sheng; Li, Ping; Chen, Sijuan; Lin, Guiping; Zhao, Yan; Wang, Tinghuai			Involvement of MAPK/NF-kappa B Signaling in the Activation of the Cholinergic Anti-Inflammatory Pathway in Experimental Colitis by Chronic Vagus Nerve Stimulation	PLOS ONE			English	Article							NICOTINIC ACETYLCHOLINE-RECEPTOR; HEART-RATE-VARIABILITY; INFLAMMATORY-BOWEL-DISEASE; PHOSPHORYLATION; RATS; SUPPRESSION; BIOFEEDBACK; THERAPIES; EFFICACY; PROTEIN	Background: Autonomic nervous system dysfunction is implicated in the etiopathogenesis of inflammatory bowel diseases (IBD). Therapies that increase cardiovagal activity, such as Mind-Body interventions, are currently confirmed to be effective in clinical trials in IBD. However, a poor understanding of pathophysiological mechanisms limits the popularization of therapies in clinical practice. The aim of the present study was to explore the mechanisms of these therapies against 2,4,6-trinitrobenzenesulfonic acid (TNBS)-induced colitis in rats using a chronic vagus nerve stimulation model in vivo, as well as the lipopolysaccharide (LPS)-induced inflammatory response in human epithelial colorectal adenocarcinoma cells (Caco-2) by acetylcholine in vitro. Methods and Results: Colitis was induced in rats with rectal instillation of TNBS, and the effect of chronic VNS (0.25 mA, 20 Hz, 500 ms) on colonic inflammation was evaluated. Inflammatory responses were assessed by disease activity index (DAI), histological scores, myeloperoxidase (MPO) activity, inducible nitric oxide synthase (iNOS), TNF-alpha and IL-6 production. The expression of Mitogen-activated protein kinases (MAPK) family members, I kappa B-alpha, and nuclear NF-kappa B p65 were studied by immunoblotting. Heart rate variability (HRV) analysis was also applied to assess the sympathetic-vagal balance. DAI, histological scores, MPO activity, iNOS, TNF-alpha and IL-6 levels were significantly decreased by chronic VNS. Moreover, both VNS and acetylcholine reduced the phosphorylation of MAPKs and prevented the nuclear translocation of NF-kappa B p65. Methyllycaconitine (MLA) only reversed the inhibitory effect on p-ERK and intranuclear NF-kappa B p65 expression by ACh in vitro, no significant change was observed in the expression of p-p38 MAPK or p-JNK by MLA. Conclusion: Vagal activity modification contributes to the beneficial effects of the cholinergic anti-inflammatory pathway in IBD-related inflamed colonic mucosa based on the activation of MAPKs and nuclear translocation of NF-kappa B. Our work may provide key pathophysiological mechanistic evidence for novel therapeutic strategies that increase the cardiovagal activity in IBD patients.	[Sun, Peng; Zhou, Kewen; Wang, Sheng; Li, Ping; Chen, Sijuan; Lin, Guiping; Zhao, Yan; Wang, Tinghuai] Sun Yat Sen Univ, Dept Physiol, Zhongshan Sch Med, Guangzhou 510275, Guangdong, Peoples R China	Sun Yat Sen University	Wang, TH (corresponding author), Sun Yat Sen Univ, Dept Physiol, Zhongshan Sch Med, Guangzhou 510275, Guangdong, Peoples R China.	wangth@mail.sysu.edu.cn			Science and technology projects in Guangdong Province [2008B030301098]; Science and technology projects in Guangzhou [2007J1-C0171]	Science and technology projects in Guangdong Province; Science and technology projects in Guangzhou	This work was supported by the funded projects of Science and technology projects in Guangdong Province (No.2008B030301098) and the Science and technology projects in Guangzhou (No.2007J1-C0171). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Rosillo MA, 2012, PHARMACOL RES, V66, P235, DOI 10.1016/j.phrs.2012.05.006; Atreya I, 2008, J INTERN MED, V263, P591, DOI 10.1111/j.1365-2796.2008.01953.x; Babior BM, 2000, AM J MED, V109, P33, DOI 10.1016/S0002-9343(00)00481-2; Bengtsson M, 2007, BMC GASTROENTEROL, V7, DOI 10.1186/1471-230X-7-16; Bevilacqua MA, 2002, ARCH BIOCHEM BIOPHYS, V407, P39, DOI 10.1016/S0003-9861(02)00436-8; Billman GE, 2011, FRONT PHYSIOL, V2, DOI 10.3389/fphys.2011.00086; Bonaz BL, 2013, GASTROENTEROLOGY, V144, P36, DOI 10.1053/j.gastro.2012.10.003; Borovikova LV, 2000, NATURE, V405, P458, DOI 10.1038/35013070; Bozkurt A, 2003, REGUL PEPTIDES, V116, P109, DOI 10.1016/S0167-0115(03)00194-0; BRENNA O, 2013, PLOS ONE IN PRESS, P20239; Broom OJ, 2009, CLIN EXP IMMUNOL, V158, P272, DOI 10.1111/j.1365-2249.2009.04033.x; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; COOPER HS, 1993, LAB INVEST, V69, P238; Coskun M, 2011, CLIN CHIM ACTA, V412, P513, DOI 10.1016/j.cca.2010.12.020; Cucina A, 2012, J SURG RES, V178, P233, DOI 10.1016/j.jss.2011.12.029; de Jonge WJ, 2007, BRIT J PHARMACOL, V151, P915, DOI 10.1038/sj.bjp.0707264; Ghia JE, 2006, GASTROENTEROLOGY, V131, P1122, DOI 10.1053/j.gastro.2006.08.016; Ghia JE, 2007, AM J PHYSIOL-GASTR L, V293, pG711, DOI 10.1152/ajpgi.00240.2007; Gubbins EJ, 2010, BRAIN RES, V1328, P1, DOI 10.1016/j.brainres.2010.02.083; Hahm KB, 2001, GUT, V49, P190, DOI 10.1136/gut.49.2.190; Handforth A, 2001, MOVEMENT DISORD, V16, P84, DOI 10.1002/1531-8257(200101)16:1<84::AID-MDS1010>3.0.CO;2-S; Huang JA, 2010, J NEURAL TRANSM, V117, P729, DOI 10.1007/s00702-010-0407-6; Huston JM, 2006, J EXP MED, V203, P1623, DOI 10.1084/jem.20052362; Langmead L, 2006, ALIMENT PHARM THER, V23, P341, DOI 10.1111/j.1365-2036.2006.02761.x; Ley K, 2007, NAT REV IMMUNOL, V7, P678, DOI 10.1038/nri2156; Li DL, 2011, J CELL PHYSIOL, V226, P1052, DOI 10.1002/jcp.22424; Lo Giudice P, 2002, DIABETES RES CLIN PR, V56, P173, DOI 10.1016/S0168-8227(01)00375-8; Manta S, 2013, INT J NEUROPSYCHOPH, V16, P459, DOI 10.1017/S1461145712000387; Maunder RG, 2012, INFLAMM BOWEL DIS, V18, P737, DOI 10.1002/ibd.21794; Meregnani J, 2011, AUTON NEUROSCI-BASIC, V160, P82, DOI 10.1016/j.autneu.2010.10.007; MORRIS GP, 1989, GASTROENTEROLOGY, V96, P795, DOI 10.1016/0016-5085(89)90904-9; Nathan C, 2002, NATURE, V420, P846, DOI 10.1038/nature01320; NATHAN CF, 1989, BLOOD, V73, P301; Nishitani Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062441; Nolan RP, 2012, J INTERN MED, V272, P161, DOI 10.1111/j.1365-2796.2012.02523.x; O'Shea JJ, 2008, IMMUNITY, V28, P477, DOI 10.1016/j.immuni.2008.03.002; Orr-Urtreger A, 2005, NEUROREPORT, V16, P1123, DOI 10.1097/00001756-200507130-00018; PATIL VK, 2007, J BASIC CLIN PHYSL P, V18, P307; Pellissier S, 2010, PSYCHONEUROENDOCRINO, V35, P653, DOI 10.1016/j.psyneuen.2009.10.004; Petersen AMW, 2005, J APPL PHYSIOL, V98, P1154, DOI 10.1152/japplphysiol.00164.2004; Podolsky DK, 2002, NEW ENGL J MED, V347, P417, DOI 10.1056/NEJMra0804647; Reyt S, 2010, NEUROIMAGE, V52, P1456, DOI 10.1016/j.neuroimage.2010.05.021; Roncucci L, 2008, CANCER EPIDEM BIOMAR, V17, P2291, DOI 10.1158/1055-9965.EPI-08-0224; Rosas-Ballina M, 2009, J INTERN MED, V265, P663, DOI 10.1111/j.1365-2796.2009.02098.x; Rosas-Ballina M, 2008, P NATL ACAD SCI USA, V105, P11008, DOI 10.1073/pnas.0803237105; Rosas-Ballina M, 2011, SCIENCE, V334, P98, DOI 10.1126/science.1209985; Rutgeerts P, 2009, GASTROENTEROLOGY, V136, P1182, DOI 10.1053/j.gastro.2009.02.001; RYOYAMA K, 1993, CANCER IMMUNOL IMMUN, V37, P385, DOI 10.1007/BF01526795; Sackeim HA, 2001, NEUROPSYCHOPHARMACOL, V25, P713, DOI 10.1016/S0893-133X(01)00271-8; Sands BE, 2007, J GASTROENTEROL, V42, P16, DOI 10.1007/s00535-006-1995-7; Schroecksnadel S, 2013, THROMB RES, V131, pE264, DOI 10.1016/j.thromres.2013.02.012; Snoek SA, 2010, BRIT J PHARMACOL, V160, P322, DOI 10.1111/j.1476-5381.2010.00699.x; Tak PP, 2001, J CLIN INVEST, V107, P7, DOI 10.1172/JCI11830; Taylor CT, 2007, AUTON NEUROSCI-BASIC, V133, P104, DOI 10.1016/j.autneu.2006.11.005; Tracey KJ, 2007, J CLIN INVEST, V117, P289, DOI 10.1172/JCI30555; Tracey KJ, 2009, NAT REV IMMUNOL, V9, P418, DOI 10.1038/nri2566; Tracey KJ, 2002, NATURE, V420, P853, DOI 10.1038/nature01321; Tsune I, 2003, GASTROENTEROLOGY, V125, P775, DOI 10.1016/S0016-5085(03)01067-9; Vallabhapurapu S, 2009, ANNU REV IMMUNOL, V27, P693, DOI 10.1146/annurev.immunol.021908.132641; Van der Zanden EP, 2009, NEUROGASTROENT MOTIL, V21, P6, DOI 10.1111/j.1365-2982.2008.01252.x; Wang SZ, 2010, J ALTERN COMPLEM MED, V16, P1039, DOI 10.1089/acm.2009.0577; Xu XY, 2007, J HUM HYPERTENS, V21, P973, DOI 10.1038/sj.jhh.1002237; Yoshikawa H, 2006, CLIN EXP IMMUNOL, V146, P116, DOI 10.1111/j.1365-2249.2006.03169.x	63	136	138	1	22	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 2	2013	8	8							e69424	10.1371/journal.pone.0069424	http://dx.doi.org/10.1371/journal.pone.0069424			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	219XU	23936328	gold, Green Published, Green Submitted			2023-01-03	WOS:000324545800018
J	Valcour, VG; Ananworanich, J; Agsalda, M; Sailasuta, N; Chalermchai, T; Schuetz, A; Shikuma, C; Liang, CY; Jirajariyavej, S; Sithinamsuwan, P; Tipsuk, S; Clifford, DB; Paul, R; Fletcher, JLK; Marovich, MA; Slike, BM; DeGruttola, V; Shiramizu, B				Valcour, Victor G.; Ananworanich, Jintanat; Agsalda, Melissa; Sailasuta, Napapon; Chalermchai, Thep; Schuetz, Alexandra; Shikuma, Cecilia; Liang, Chin-Yuan; Jirajariyavej, Supunee; Sithinamsuwan, Pasiri; Tipsuk, Somporn; Clifford, David B.; Paul, Robert; Fletcher, James L. K.; Marovich, Mary A.; Slike, Bonnie M.; DeGruttola, Victor; Shiramizu, Bruce		SEARCH 011 Protocol Team	HIV DNA Reservoir Increases Risk for Cognitive Disorders in cART-Naive Patients	PLOS ONE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; CIRCULATING MONOCYTES; DISEASE PROGRESSION; DEMENTIA; IMPAIRMENT; INFECTION; HAART; CELLS; AIDS	Objectives: Cognitive impairment remains frequent in HIV, despite combination antiretroviral therapy (cART). Leading theories implicate peripheral monocyte HIV DNA reservoirs as a mechanism for spread of the virus to the brain. These reservoirs remain present despite cART. The objective of this study was to determine if the level of HIV DNA in CD14(+) enriched monocytes predicted cognitive impairment and brain injury. Methods: We enrolled 61 cART-naive HIV-infected Thais in a prospective study and measured HIV DNA in CD14+ enriched monocyte samples in a blinded fashion. We determined HAND diagnoses by consensus panel and all participants underwent magnetic resonance spectroscopy (MRS) to measure markers of brain injury. Immune activation was measured via cytokines in cerebrospinal fluid (CSF). Results: The mean (SD) age was 35 (6.9) years, CD4 T-lymphocyte count was 236 (139) and log(10) plasma HIV RNA was 4.8 (0.73). Twenty-eight of 61 met HAND criteria. The log(10) CD14(+) HIV DNA was associated with HAND in unadjusted and adjusted models (p=0.001). There was a 14.5 increased odds ratio for HAND per 1 log-value of HIV DNA (10-fold increase in copy number). Plasma CD14(+) HIV DNA was associated with plasma and CSF neopterin (p = 0.023) and with MRS markers of neuronal injury (lower N-acetyl aspartate) and glial dysfunction (higher myoinositol) in multiple brain regions. Interpretation: Reservoir burden of HIV DNA in monocyte-enriched (CD14(+)) peripheral blood cells increases risk for HAND in treatment-naive HIV+ subjects and is directly associated with CSF immune activation and both brain injury and glial dysfunction by MRS.	[Valcour, Victor G.] Univ Calif San Francisco, Dept Neurol, Memory & Aging Ctr, San Francisco, CA 94143 USA; [Valcour, Victor G.] Univ Calif San Francisco, Dept Med, Div Geriatr Med, San Francisco, CA USA; [Ananworanich, Jintanat; Chalermchai, Thep; Tipsuk, Somporn; Fletcher, James L. K.] Thai Red Cross AIDS Res Ctr, SEARCH, Bangkok, Thailand; [Ananworanich, Jintanat] Thai Red Cross AIDS Res Ctr, HIV NAT, Bangkok, Thailand; [Ananworanich, Jintanat] Chulalongkorn Univ, Fac Med, Bangkok 10330, Thailand; [Ananworanich, Jintanat; Agsalda, Melissa; Shikuma, Cecilia; Liang, Chin-Yuan; Shiramizu, Bruce] Univ Hawaii, Hawaii Ctr AIDS, Honolulu, HI 96822 USA; [Sailasuta, Napapon] Huntington Med Res Inst, Pasadena, CA USA; [Schuetz, Alexandra] Armed Forces Res Inst Med Sci, Dept Retrovirol, Bangkok 10400, Thailand; [Jirajariyavej, Supunee] Taksin Hosp, Bangkok, Thailand; [Sithinamsuwan, Pasiri] Phramongkutklao Hosp, Dept Med, Div Neurol, Bangkok, Thailand; [Clifford, David B.] Washington Univ, Dept Neurol, St Louis, MO USA; [Paul, Robert] Univ Missouri, Dept Psychol, St Louis, MO 63121 USA; [Marovich, Mary A.] NIAID, Div Aids, NIH, Bethesda, MD 20892 USA; [Marovich, Mary A.; Slike, Bonnie M.] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA; [Slike, Bonnie M.] Queen Savang Vadhana Mem Hosp, Si Racha, Thailand; [DeGruttola, Victor] Thai Red Cross AIDS Res Ctr, Bangkok, Thailand	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Thai Red Cross Society; Thai Red Cross Society; Chulalongkorn University; University of Hawaii System; Huntington Medical Research Institutes; United States Department of Defense; United States Army; Walter Reed Army Institute of Research (WRAIR); Armed Forces Research Institute of Medical Science (AFRIMS); Phramongkutklao Hospital; Washington University (WUSTL); University of Missouri System; University of Missouri Saint Louis; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Harvard University; Harvard T.H. Chan School of Public Health; Thai Red Cross Society	Valcour, VG (corresponding author), Univ Calif San Francisco, Dept Neurol, Memory & Aging Ctr, San Francisco, CA 94143 USA.	vvalcour@memory.ucsf.edu	Ananworanich, Jintanat/AAC-6348-2021	Ananworanich, Jintanat/0000-0003-1369-3224; Chalermchai, Thep/0000-0001-7839-7835	NINDS/NIH [R01-NS053359, R01-NS061696, R01-NS053345]; NIMH/NIH [R21-MH072388]; NIMHD/NIH [MD007584]; National Center for Advancing Translational Sciences, National Institutes of Health (NIH), through UCSF-CTSI [UL1 TR000004]; Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc [W81XWH-11-2-0174]; U.S. Department of Defense [W81XWH-11-2-0174]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000004] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [U54RR026136] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [F31AI081450] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R21MH072388] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS061696, R01NS053359, R01NS053345] Funding Source: NIH RePORTER; National Institute on Minority Health and Health Disparities [U54MD007584] Funding Source: NIH RePORTER	NINDS/NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIMH/NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMHD/NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Center for Advancing Translational Sciences, National Institutes of Health (NIH), through UCSF-CTSI; Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc; U.S. Department of Defense(United States Department of Defense); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); National Institute on Minority Health and Health Disparities(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Minority Health & Health Disparities (NIMHD))	This work was supported by R01-NS053359 (NINDS/NIH - SRK), R01-NS061696 (NINDS/NIH - VV), R21-MH072388 (NIMH/NIH - VV), R01-NS053345 (NINDS/NIH - BS), and MD007584 (NIMHD/NIH - BS, CS). Added statistical assistance was supported by the National Center for Advancing Translational Sciences, National Institutes of Health (NIH), through UCSF-CTSI Grant Number UL1 TR000004. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIH. This work was supported in part by a cooperative agreement (W81XWH-11-2-0174) between the Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc, and the U.S. Department of Defense. The views expressed are those of the authors and should not be construed to represent the positions of the US Army or the Department of Defense. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alexaki A, 2008, CURR HIV RES, V6, P388, DOI 10.2174/157016208785861195; Anthony IC, 2005, J NEUROPATH EXP NEUR, V64, P529, DOI 10.1093/jnen/64.6.529; Antinori A, 2007, NEUROLOGY, V69, P1789, DOI 10.1212/01.WNL.0000287431.88658.8b; Avettand-Fenoel V, 2008, J CLIN VIROL, V42, P399, DOI 10.1016/j.jcv.2008.03.013; Bell JE, 1998, BRAIN, V121, P2043, DOI 10.1093/brain/121.11.2043; Cantres-Rosario Y, 2013, AIDS, V27, P347, DOI 10.1097/QAD.0b013e32835b3e47; Chun TW, 1997, P NATL ACAD SCI USA, V94, P13193, DOI 10.1073/pnas.94.24.13193; Coleman CM, 2009, RETROVIROLOGY, V6, DOI 10.1186/1742-4690-6-51; GLASS JD, 1995, ANN NEUROL, V38, P755, DOI 10.1002/ana.410380510; Gonzalez-Scarano F, 2005, NAT REV IMMUNOL, V5, P69, DOI 10.1038/nri1527; Heaps JM, 2012, J CLIN EXPT IN PRESS; Lambotte O, 2000, J ACQ IMMUN DEF SYND, V23, P114; Le Douce V, 2010, RETROVIROLOGY, V7, DOI 10.1186/1742-4690-7-32; MAJ M, 1994, ARCH GEN PSYCHIAT, V51, P51; PROVENCHER SW, 1993, MAGNET RESON MED, V30, P672, DOI 10.1002/mrm.1910300604; Rouzioux C, 2005, J INFECT DIS, V192, P46, DOI 10.1086/430610; Ryan LA, 2001, J INFECT DIS, V184, P699, DOI 10.1086/323036; Schirmer T, 2000, NMR BIOMED, V13, P28, DOI 10.1002/(SICI)1099-1492(200002)13:1<28::AID-NBM606>3.0.CO;2-L; Shikuma CM, 2012, ANTIVIR THER, V17, P1233, DOI 10.3851/IMP2411; Shiramizu B, 2005, AIDS, V19, P45, DOI 10.1097/00002030-200501030-00005; Shiramizu B, 2012, J NEUROVIROL, V18, P69, DOI 10.1007/s13365-011-0068-8; Shiramizu B, 2007, J NEUROPSYCH CLIN N, V19, P157, DOI 10.1176/appi.neuropsych.19.2.157; Sungkanuparph S, 2010, ASIAN BIOMED, V4, P515, DOI 10.2478/abm-2010-0066; Valcour VG, 2007, NEUROLOGY, V68, P525, DOI 10.1212/01.wnl.0000253196.78193.c7; Valcour VG, 2009, NEUROLOGY, V72, P992, DOI 10.1212/01.wnl.0000344404.12759.83; Valcour VG, 2010, J LEUKOCYTE BIOL, V87, P621, DOI 10.1189/jlb.0809571; Wirachsilp Piyanot, 2007, Southeast Asian Journal of Tropical Medicine and Public Health, V38, P814; Wright SM, 1997, NMR BIOMED, V10, P394, DOI 10.1002/(SICI)1099-1492(199712)10:8<394::AID-NBM494>3.0.CO;2-0; Yuan L, 2013, J NEUROVIROL	29	62	62	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 31	2013	8	7							e70164	10.1371/journal.pone.0070164	http://dx.doi.org/10.1371/journal.pone.0070164			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	194LB	23936155	Green Published, gold			2023-01-03	WOS:000322633700058
J	Kuhla, A; Lange, S; Holzmann, C; Maass, F; Petersen, J; Vollmar, B; Wree, A				Kuhla, Angela; Lange, Sophie; Holzmann, Carsten; Maass, Fabian; Petersen, Jana; Vollmar, Brigitte; Wree, Andreas			Lifelong Caloric Restriction Increases Working Memory in Mice	PLOS ONE			English	Article							CHRONIC FOOD RESTRICTION; ANXIETY-LIKE BEHAVIORS; OPEN-FIELD BEHAVIOR; AGE-RELATED DECLINE; KETOGENIC DIET; PLUS-MAZE; EXPRESSION; BRAIN; RATS; PERFORMANCE	Caloric restriction (CR) is argued to positively affect general health, longevity and the normally occurring age-related reduction of cognition. This issue is well examined, but most studies investigated the effect of short-term periods of CR. Herein, 4 weeks old female mice were fed caloric restricted for 4, 20 and especially for 74 weeks. CR mice received 60% of food eaten by their ad libitum (AL) fed littermates, and all age-matched groups were behaviorally analyzed. The motor coordination, which was tested by rotarod/accelerod, decreased age-related, but was not influenced by the different periods of CR. In contrast, the age-related impairment of spontaneous locomotor activity and anxiety, both being evaluated by open field and by elevated plus maze test, was found aggravated by a lifelong CR. Measurement of cognitive performance with morris water maze showed that the working memory decreased age-related in AL mice, while a lifelong CR caused a better cognitive performance and resulted in a significantly better spatial memory upon 74 weeks CR feeding. However, a late-onset CR feeding in 66 weeks old mice did not ameliorate the working memory. Therefore, a lifelong CR seems to be necessary to improve working memory.	[Kuhla, Angela; Vollmar, Brigitte] Univ Rostock, Inst Expt Surg, D-18055 Rostock, Germany; [Lange, Sophie; Maass, Fabian; Petersen, Jana; Wree, Andreas] Univ Rostock, Inst Anat, D-18055 Rostock, Germany; [Holzmann, Carsten] Univ Rostock, Inst Med Genet, D-18055 Rostock, Germany	University of Rostock; University of Rostock; University of Rostock	Kuhla, A (corresponding author), Univ Rostock, Inst Expt Surg, D-18055 Rostock, Germany.	angela.kuhla@uni-rostock.de	Holzmann, Carsten/B-9254-2008	Holzmann, Carsten/0000-0001-7977-9093; Maass, Fabian/0000-0002-4077-2852	University of Rostock	University of Rostock	This work was supported by an intramural grant of the FORUN program of the University of Rostock to AW. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adams MM, 2008, EXP NEUROL, V211, P141, DOI 10.1016/j.expneurol.2008.01.016; BARNES CA, 1979, J COMP PHYSIOL PSYCH, V93, P74, DOI 10.1037/h0077579; Bellush LL, 1996, PHYSIOL BEHAV, V60, P541, DOI 10.1016/S0031-9384(96)80029-1; Bergado Jorge A., 2002, Neural Plasticity, V9, P217, DOI 10.1155/NP.2002.217; BOGO V, 1981, NEUROTOXICOLOGY, V2, P765; Carter CS, 2009, J GERONTOL A-BIOL, V64, P850, DOI 10.1093/gerona/glp060; Churchill JD, 2002, NEUROBIOL AGING, V23, P941, DOI 10.1016/S0197-4580(02)00028-3; DAWSON GR, 1995, TRENDS PHARMACOL SCI, V16, P33, DOI 10.1016/S0165-6147(00)88973-7; DEFRIES JC, 1966, SCIENCE, V154, P1577, DOI 10.1126/science.154.3756.1577; DENENBERG VH, 1969, ANN NY ACAD SCI, V159, P852, DOI 10.1111/j.1749-6632.1969.tb12983.x; Deng L, 2009, INT J NEUROSCI, V119, P291, DOI 10.1080/00207450802328250; Dhahbi JM, 2004, P NATL ACAD SCI USA, V101, P5524, DOI 10.1073/pnas.0305300101; Eikelis N, 2000, Stress, V3, P319, DOI 10.3109/10253890009001137; Erickson KI, 2011, P NATL ACAD SCI USA, V108, P3017, DOI 10.1073/pnas.1015950108; Fahlstrom A, 2011, NEUROBIOL AGING, V32, P1868, DOI 10.1016/j.neurobiolaging.2009.11.003; Forster MJ, 1996, P NATL ACAD SCI USA, V93, P4765, DOI 10.1073/pnas.93.10.4765; Forster MJ, 2003, FASEB J, V17, P690, DOI 10.1096/fj.02-0533fje; GAGE FH, 1984, J NEUROSCI, V4, P2856; GALLAGHER M, 1989, NEUROBIOL AGING, V10, P691, DOI 10.1016/0197-4580(89)90006-7; Geng YQ, 2007, P ANN INT IEEE EMBS, P2393, DOI 10.1109/IEMBS.2007.4352809; Geng YQ, 2011, J CELL BIOCHEM, V112, P3755, DOI 10.1002/jcb.23315; Gillette-Guyonnet S, 2008, CURR OPIN CLIN NUTR, V11, P686, DOI 10.1097/MCO.0b013e328313968f; Hashimoto T, 2005, NEUROREPORT, V16, P1129, DOI 10.1097/00001756-200507130-00019; Hof PR, 2004, TRENDS NEUROSCI, V27, P607, DOI 10.1016/j.tins.2004.07.013; Holzmann C, 2012, BEHAV BRAIN RES, V234, P107, DOI 10.1016/j.bbr.2012.06.008; INGRAM DK, 1988, NEUROBIOL AGING, V9, P475, DOI 10.1016/S0197-4580(88)80101-5; Jahng JW, 2007, BRAIN RES, V1150, P100, DOI 10.1016/j.brainres.2007.02.080; JONES BJ, 1968, J PHARM PHARMACOL, V20, P302, DOI 10.1111/j.2042-7158.1968.tb09743.x; Karl T, 2003, EXP TOXICOL PATHOL, V55, P69, DOI 10.1078/0940-2993-00301; Krikorian R, 2012, NEUROBIOL AGING, V33, DOI 10.1016/j.neurobiolaging.2010.10.006; Kwon YS, 2008, EPILEPSY RES, V78, P186, DOI 10.1016/j.eplepsyres.2007.11.010; Levay EA, 2007, PHYSIOL BEHAV, V92, P889, DOI 10.1016/j.physbeh.2007.06.018; LISTER RG, 1987, PSYCHOPHARMACOLOGY, V92, P180; Maalouf M, 2009, BRAIN RES REV, V59, P293, DOI 10.1016/j.brainresrev.2008.09.002; Masoro EJ, 2006, BIOGERONTOLOGY, V7, P153, DOI 10.1007/s10522-006-9015-0; Matochik JA, 2004, NEUROBIOL AGING, V25, P193, DOI 10.1016/S0197-4580(03)00092-7; MEANS LW, 1993, PHYSIOL BEHAV, V54, P503, DOI 10.1016/0031-9384(93)90243-9; Minor RK, 2008, BEHAV BRAIN RES, V189, P202, DOI 10.1016/j.bbr.2007.12.030; Mouton PR, 2009, NEUROSCI LETT, V464, P184, DOI 10.1016/j.neulet.2009.08.038; Noh HS, 2008, EPILEPSIA, V49, P120, DOI 10.1111/j.1528-1167.2008.01855.x; Prut L, 2003, EUR J PHARMACOL, V463, P3, DOI 10.1016/S0014-2999(03)01272-X; Pugh TD, 1999, CANCER RES, V59, P1642; Rodgers RJ, 1997, NEUROSCI BIOBEHAV R, V21, P801, DOI 10.1016/S0149-7634(96)00058-9; Smith LK, 2005, PHYSIOL BEHAV, V85, P581, DOI 10.1016/j.physbeh.2005.06.013; Terry RD, 2001, NEUROBIOL AGING, V22, P347, DOI 10.1016/S0197-4580(00)00250-5; Tomiyama AJ, 2010, PSYCHOSOM MED, V72, P357, DOI 10.1097/PSY.0b013e3181d9523c; WADDEN TA, 1986, J CONSULT CLIN PSYCH, V54, P482, DOI 10.1037/0022-006X.54.4.482; WOOLEY SC, 1991, J AM DIET ASSOC, V91, P1248; Yamamoto Y, 2009, PHYSIOL GENOMICS, V39, P227, DOI 10.1152/physiolgenomics.00082.2009	49	69	70	0	31	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 10	2013	8	7							e68778	10.1371/journal.pone.0068778	http://dx.doi.org/10.1371/journal.pone.0068778			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	182SU	23874758	gold, Green Submitted, Green Published			2023-01-03	WOS:000321765300066
J	Bullen, C; Howe, C; Laugesen, M; McRobbie, H; Parag, V; Williman, J; Walker, N				Bullen, Christopher; Howe, Colin; Laugesen, Murray; McRobbie, Hayden; Parag, Varsha; Williman, Jonathan; Walker, Natalie			Electronic cigarettes for smoking cessation: a randomised controlled trial	LANCET			English	Article							NICOTINE DELIVERY; PREFERENCES; PROTOCOL	Background Electronic cigarettes (e-cigarettes) can deliver nicotine and mitigate tobacco withdrawal and are used by many smokers to assist quit attempts. We investigated whether e-cigarettes are more effective than nicotine patches at helping smokers to quit. Methods We did this pragmatic randomised-controlled superiority trial in Auckland, New Zealand, between Sept 6, 2011, and July 5, 2013. Adult (>= 18 years) smokers wanting to quit were randomised (with computerised block randomisation, block size nine, stratified by ethnicity [Maori; Pacific; or non-Maori, non-Pacific], sex [men or women], and level of nicotine dependence [>5 or <= 5 Fagerstrom test for nicotine dependence]) in a 4:4:1 ratio to 16 mg nicotine e-cigarettes, nicotine patches (21 mg patch, one daily), or placebo e-cigarettes (no nicotine), from 1 week before until 12 weeks after quit day, with low intensity behavioural support via voluntary telephone counselling. The primary outcome was biochemically verified continuous abstinence at 6 months (exhaled breath carbon monoxide measurement <10 ppm). Primary analysis was by intention to treat. This trial is registered with the Australian New Zealand Clinical Trials Registry, number ACTRN12610000866000. Findings 657 people were randomised (289 to nicotine e-cigarettes, 295 to patches, and 73 to placebo e-cigarettes) and were included in the intention-to-treat analysis. At 6 months, verified abstinence was 7.3% (21 of 289) with nicotine e-cigarettes, 5.8% (17 of 295) with patches, and 4.1% (three of 73) with placebo e-cigarettes (risk difference for nicotine e-cigarette vs patches 1.51 [95% CI -2.49 to 5.51]; for nicotine e-cigarettes vs placebo e-cigarettes 3.16 [95% CI -2.29 to 8.61]). Achievement of abstinence was substantially lower than we anticipated for the power calculation, thus we had insufficient statistical power to conclude superiority of nicotine e-cigarettes to patches or to placebo e-cigarettes. We identified no significant differences in adverse events, with 137 events in the nicotine e-cigarettes group, 119 events in the patches group, and 36 events in the placebo e-cigarettes group. We noted no evidence of an association between adverse events and study product. Interpretation E-cigarettes, with or without nicotine, were modestly effective at helping smokers to quit, with similar achievement of abstinence as with nicotine patches, and few adverse events. Uncertainty exists about the place of e-cigarettes in tobacco control, and more research is urgently needed to clearly establish their overall benefits and harms at both individual and population levels.	[Bullen, Christopher; Howe, Colin; Parag, Varsha; Walker, Natalie] Univ Auckland, Sch Populat Hlth, Natl Inst Hlth Innovat, Auckland 1142, New Zealand; [Laugesen, Murray] Hlth New Zealand, Christchurch, New Zealand; [McRobbie, Hayden] Queen Mary Univ London, UK Ctr Tobacco Control Studies, Wolfson Inst Prevent Med, London, England; [Williman, Jonathan] Univ Otago, Dept Publ Hlth & Gen Practice, Christchurch, New Zealand	University of Auckland; University of London; Queen Mary University London; University of Otago	Bullen, C (corresponding author), Univ Auckland, Sch Populat Hlth, Natl Inst Hlth Innovat, Private Bag 92019, Auckland 1142, New Zealand.	c.bullen@nihi.auckland.ac.nz	McRobbie, Hayden/B-4552-2018; Bullen, Chris/E-4594-2017; Williman, Jonathan/E-8206-2016	McRobbie, Hayden/0000-0002-7777-1845; Bullen, Chris/0000-0001-6807-2930; Williman, Jonathan/0000-0001-5080-4435	Health Research Council of New Zealand; Economic and Social Research Council [ES/G007489/1] Funding Source: researchfish; Medical Research Council [MR/K023195/1, MR/K023195/1B] Funding Source: researchfish	Health Research Council of New Zealand(Health Research Council of New Zealand); Economic and Social Research Council(UK Research & Innovation (UKRI)Economic & Social Research Council (ESRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	Health Research Council of New Zealand.	Bullen C, 2010, TOB CONTROL, V19, P98, DOI 10.1136/tc.2009.031567; Bullen C, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-210; Burstyn I., TECHNICAL REPORT; Caponnetto P, 2011, EUR RESPIR J, V38, P1005, DOI 10.1183/09031936.00109610; Caponnetto P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066317; Cobb NK, 2013, LANCET RESP MED, V1, P431, DOI 10.1016/S2213-2600(13)70160-7; Cormack D., 2010, CLASSIFICATION OUTPU; Dawkins L, 2013, ADDICTION, V108, P1115, DOI 10.1111/add.12150; DiFranza JR, 2009, PSYCHOL ADDICT BEHAV, V23, P656, DOI 10.1037/a0017439; Etter JF, 2010, BMC PUBLIC HEALTH, V10, DOI 10.1186/1471-2458-10-231; Fagerstrom K O, 1997, Tob Control, V6, P311; Fiore M. C., 2008, TREATING TOBACCO USE; Glover ED, 2005, AM J HEALTH BEHAV, V29, P443, DOI 10.5993/AJHB.29.5.7; Goniewicz M, 2013, TOB CONTROL, V6, P6; Goniewicz ML, 2013, NICOTINE TOB RES, V15, P158, DOI 10.1093/ntr/nts103; Hajek P, 2013, LANCET RESP MED, V1, P429, DOI 10.1016/S2213-2600(13)70124-3; HEATHERTON TF, 1991, BRIT J ADDICT, V86, P1119; Mariner DC, 2011, REGUL TOXICOL PHARM, V61, pS39, DOI 10.1016/j.yrtph.2010.05.006; Ministry of Health, 2007, NZ SMOK CESS GUID; Polosa R, 2014, INTERN EMERG MED, V9, P537, DOI 10.1007/s11739-013-0977-z; Price E, 2003, NZ EFFECTIVE ACCESS; Purkayastha D., 2013, BAT RAMPS UP E CIGAR; Schulz KF, 2010, BMJ-BRIT MED J, V340, DOI [10.1136/bmj.c332, 10.1186/1741-7015-8-18]; Shiffman S, 2002, ADDICTION, V97, P97, DOI 10.1046/j.1360-0443.2002.0050b.x; Stead LF, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000146.pub3; Ursprung WWSA, 2011, J ADOLESCENT HEALTH, V48, P338, DOI 10.1016/j.jadohealth.2010.07.011; US Food and Drug Administration, SUMM RES LAB AN EL C; Vansickel AR, 2013, NICOTINE TOB RES, V15, P267, DOI 10.1093/ntr/ntr316; Walker N, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-880; West R, 2005, ADDICTION, V100, P299, DOI 10.1111/j.1360-0443.2004.00995.x; West R., 2012, SMOKING TOOLKIT STUD	31	821	837	14	497	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 16	2013	382	9905					1629	1637		10.1016/S0140-6736(13)61842-5	http://dx.doi.org/10.1016/S0140-6736(13)61842-5			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	254CN	24029165				2023-01-03	WOS:000327140700021
J	Streijger, F; Plunet, WT; Lee, JHT; Liu, J; Lam, CK; Park, S; Hilton, BJ; Fransen, BL; Matheson, KAJ; Assinck, P; Kwon, BK; Tetzlaff, W				Streijger, Femke; Plunet, Ward T.; Lee, Jae H. T.; Liu, Jie; Lam, Clarrie K.; Park, Soeyun; Hilton, Brett J.; Fransen, Bas L.; Matheson, Keely A. J.; Assinck, Peggy; Kwon, Brian K.; Tetzlaff, Wolfram			Ketogenic Diet Improves Forelimb Motor Function after Spinal Cord Injury in Rodents	PLOS ONE			English	Article							MONOCARBOXYLATE TRANSPORTER MCT1; ACTIVATED PROTEIN-KINASE; BETA-HYDROXYBUTYRATE; RAT-BRAIN; NEURONAL DAMAGE; STAIRCASE TEST; SYNAPTIC PLASTICITY; MOUSE-BRAIN; LEPTIN; ADULT	High fat, low carbohydrate ketogenic diets (KD) are validated non-pharmacological treatments for some forms of drug-resistant epilepsy. Ketones reduce neuronal excitation and promote neuroprotection. Here, we investigated the efficacy of KD as a treatment for acute cervical spinal cord injury (SCI) in rats. Starting 4 hours following C5 hemi-contusion injury animals were fed either a standard carbohydrate based diet or a KD formulation with lipid to carbohydrate plus protein ratio of 3: 1. The forelimb functional recovery was evaluated for 14 weeks, followed by quantitative histopathology. Post-injury 3: 1 KD treatment resulted in increased usage and range of motion of the affected forepaw. Furthermore, KD improved pellet retrieval with recovery of wrist and digit movements. Importantly, after returning to a standard diet after 12 weeks of KD treatment, the improved forelimb function remained stable. Histologically, the spinal cords of KD treated animals displayed smaller lesion areas and more grey matter sparing. In addition, KD treatment increased the number of glucose transporter-1 positive blood vessels in the lesion penumbra and monocarboxylate transporter-1 (MCT1) expression. Pharmacological inhibition of MCTs with 4-CIN (alpha-cyano-4-hydroxycinnamate) prevented the KD-induced neuroprotection after SCI, In conclusion, post-injury KD effectively promotes functional recovery and is neuroprotective after cervical SCI. These beneficial effects require the function of monocarboxylate transporters responsible for ketone uptake and link the observed neuroprotection directly to the function of ketones, which are known to exert neuroprotection by multiple mechanisms. Our data suggest that current clinical nutritional guidelines, which include relatively high carbohydrate contents, should be revisited.	[Streijger, Femke; Plunet, Ward T.; Lee, Jae H. T.; Liu, Jie; Lam, Clarrie K.; Park, Soeyun; Hilton, Brett J.; Fransen, Bas L.; Matheson, Keely A. J.; Assinck, Peggy; Kwon, Brian K.; Tetzlaff, Wolfram] Blusson Spinal Cord Ctr, Int Collaborat Repair Discoveries ICORD, Vancouver, BC, Canada; [Kwon, Brian K.; Tetzlaff, Wolfram] Univ British Columbia, Dept Zool, Vancouver, BC, Canada; [Kwon, Brian K.] Univ British Columbia, Dept Orthopaed, Combined Neurosurg & Orthopaed Spine Program, Vancouver, BC V5Z 1M9, Canada	University of British Columbia; University of British Columbia	Tetzlaff, W (corresponding author), Blusson Spinal Cord Ctr, Int Collaborat Repair Discoveries ICORD, Vancouver, BC, Canada.	tetzlaff@icord.org	Assinck, Peggy/ABA-9634-2020; Fransen, Bas/AAC-1020-2020; Hilton, Brett/N-9290-2019; Assinck, Peggy/ABD-5333-2020; Tetzlaff, Wolfram/AAY-4430-2020	Assinck, Peggy/0000-0001-6085-8162; Hilton, Brett/0000-0003-2813-2294; Assinck, Peggy/0000-0001-6085-8162; Fransen, Bas/0000-0001-8865-8656	Craig Neilsen Foundation; Christopher and Dana Reeve Foundation; Canadian Institutes for Health Research; Rick Hansen Foundation	Craig Neilsen Foundation; Christopher and Dana Reeve Foundation; Canadian Institutes for Health Research(Canadian Institutes of Health Research (CIHR)); Rick Hansen Foundation	This research was supported by The Craig Neilsen Foundation (to WT; www.chnfoundation.org), The Christopher and Dana Reeve Foundation (to FS; www.christopherreeve.org), and the Canadian Institutes for Health Research (to WT; www.cihr-irsc.gc.ca). WT holds the Edie Ehlers Chair in Spinal Cord Research funded by the Rick Hansen Foundation (www.rickhansen.com). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Anderson KD, 2004, J NEUROTRAUM, V21, P1371, DOI 10.1089/neu.2004.21.1371; Ben-Shachar D, 2004, INT REV NEUROBIOL, V59, P273; Blazquez C, 1999, J NEUROCHEM, V73, P1674, DOI 10.1046/j.1471-4159.1999.731674.x; Bough KJ, 2006, ANN NEUROL, V60, P223, DOI 10.1002/ana.20899; Chen DF, 1997, NATURE, V385, P434, DOI 10.1038/385434a0; Chiry O, 2006, BRAIN RES, V1070, P65, DOI 10.1016/j.brainres.2005.11.064; *CNS, 2002, NEUROSURGERY, V50, DOI DOI 10.1097/00006123-200203001-00015.PUBMED:12431291; Cruse JM, 2000, EXP MOL PATHOL, V68, P38, DOI 10.1006/exmp.1999.2292; Dasgupta B, 2007, P NATL ACAD SCI USA, V104, P7217, DOI 10.1073/pnas.0610068104; Davis LM, 2008, J NEUROSCI RES, V86, P1812, DOI 10.1002/jnr.21628; Duelli R, 1999, BRAIN RES, V831, P254, DOI 10.1016/S0006-8993(99)01463-8; Duelli R, 2001, NEWS PHYSIOL SCI, V16, P71; DUIJVESTIJN AM, 1992, LAB INVEST, V66, P459; ELWOOD JC, 1960, J BIOL CHEM, V235, P573; Enerson BE, 2003, J PHARM SCI-US, V92, P1531, DOI 10.1002/jps.10389; Genovese T, 2005, J PINEAL RES, V38, P198, DOI 10.1111/j.1600-079X.2004.00194.x; Genovese T, 2007, NEUROSCI LETT, V423, P41, DOI 10.1016/j.neulet.2007.05.058; Genovese T, 2006, SHOCK, V25, P608, DOI 10.1097/01.shk.0000209560.54328.69; Gensel JC, 2006, J NEUROTRAUM, V23, P36, DOI 10.1089/neu.2006.23.36; Girgis J, 2007, BRAIN, V130, P2993, DOI 10.1093/brain/awm245; Guzman M, 2004, PROSTAG LEUKOTR ESS, V70, P287, DOI 10.1016/j.plefa.2003.05.001; Halestrap AP, 1999, BIOCHEM J, V343, P281, DOI 10.1042/0264-6021:3430281; Halestrap AP, 2004, PFLUG ARCH EUR J PHY, V447, P619, DOI 10.1007/s00424-003-1067-2; Harvey J, 2006, PROG LIPID RES, V45, P369, DOI 10.1016/j.plipres.2006.03.001; HAWKINS RA, 1971, BIOCHEM J, V122, P13, DOI 10.1042/bj1220013; Hillard VH, 2004, J NEUROTRAUM, V21, P1405, DOI 10.1089/neu.2004.21.1405; Imamura K, 2006, J NEUROSCI RES, V84, P1376, DOI 10.1002/jnr.21021; Irving AJ, 2006, NEUROSCIENCE, V138, P1137, DOI 10.1016/j.neuroscience.2005.11.042; ITOH T, 1970, BIOCHEM J, V116, P641, DOI 10.1042/bj1160641; Jaerve A, 2012, INT J BIOCHEM CELL B, V44, P452, DOI 10.1016/j.biocel.2011.11.023; Jeong MA, 2011, J NEUROTRAUM, V28, P479, DOI 10.1089/neu.2010.1609; Jiao JW, 2005, EMBO J, V24, P1068, DOI 10.1038/sj.emboj.7600589; Kashiwaya Y, 2000, P NATL ACAD SCI USA, V97, P5440, DOI 10.1073/pnas.97.10.5440; Kim DY, 2008, CURR OPIN CLIN NUTR, V11, P113, DOI 10.1097/MCO.0b013e3282f44c06; Kim HM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004987; Kleman AM, 2008, J NEUROSCI METH, V167, P292, DOI 10.1016/j.jneumeth.2007.08.028; Kloth V, 2006, BRAIN RES BULL, V70, P68, DOI 10.1016/j.brainresbull.2006.04.006; Kweon GR, 2004, J BIOL CHEM, V279, P51783, DOI 10.1074/jbc.M407336200; KWON BK, 2011, J NEUROTRAUMA; Leaver SG, 2006, EUR J NEUROSCI, V24, P3323, DOI 10.1111/j.1460-9568.2006.05230.x; Lee JHT, 2012, JOVE-J VIS EXP, DOI 10.3791/3313; Lee JHT, 2010, EXP NEUROL, V225, P219, DOI 10.1016/j.expneurol.2010.06.018; Leino RL, 2001, NEUROCHEM INT, V38, P519, DOI 10.1016/S0197-0186(00)00102-9; Li Z, 2004, CELL, V119, P873, DOI 10.1016/j.cell.2004.11.003; Liu D, 1999, NEUROSCIENCE, V93, P1383, DOI 10.1016/S0306-4522(99)00278-X; Liu Y, 1999, J NEUROSCI, V19, P4370; Lutas A, 2013, TRENDS NEUROSCI, V36, P32, DOI 10.1016/j.tins.2012.11.005; Maalouf M, 2007, NEUROSCIENCE, V145, P256, DOI 10.1016/j.neuroscience.2006.11.065; Madri JA, 2009, J PHYSIOL PHARMACOL, V60, P95; Makuc J, 2004, FEMS YEAST RES, V4, P795, DOI 10.1016/j.femsyr.2004.06.003; Massieu L, 2003, NEUROSCIENCE, V120, P365, DOI 10.1016/S0306-4522(03)00266-5; Mattson MP, 2003, BIOCHEM BIOPH RES CO, V304, P539, DOI 10.1016/S0006-291X(03)00627-2; Mejia-Toiber J, 2006, NEUROCHEM RES, V31, P1399, DOI 10.1007/s11064-006-9189-5; Melo TM, 2006, NEUROCHEM INT, V48, P498, DOI 10.1016/j.neuint.2005.12.037; Metz GAS, 2000, BEHAV BRAIN RES, V116, P111, DOI 10.1016/S0166-4328(00)00245-X; MONTOYA CP, 1991, J NEUROSCI METH, V36, P219, DOI 10.1016/0165-0270(91)90048-5; Morris AAM, 2005, J INHERIT METAB DIS, V28, P109, DOI 10.1007/s10545-005-5518-0; Nikkhah G, 1998, BEHAV BRAIN RES, V92, P85, DOI 10.1016/S0166-4328(97)00128-9; Noh HS, 2006, J NEUROSCI RES, V84, P1829, DOI 10.1002/jnr.21057; Noh HS, 2004, MOL BRAIN RES, V129, P80, DOI 10.1016/j.molbrainres.2004.06.020; O'Malley D, 2007, MOL CELL NEUROSCI, V35, P559, DOI 10.1016/j.mcn.2007.05.001; Oomura Y, 2006, PEPTIDES, V27, P2738, DOI 10.1016/j.peptides.2006.07.001; Pan JW, 2002, J CEREBR BLOOD F MET, V22, P890, DOI 10.1097/00004647-200207000-00014; Pellerin L, 1998, P NATL ACAD SCI USA, V95, P3990, DOI 10.1073/pnas.95.7.3990; Pierre K, 2000, NEUROSCIENCE, V100, P617, DOI 10.1016/S0306-4522(00)00294-3; Plunet WT, 2008, EXP NEUROL, V213, P28, DOI 10.1016/j.expneurol.2008.04.011; Plunet WT, 2010, ANN NY ACAD SCI, V1198, pE1, DOI 10.1111/j.1749-6632.2010.05564.x; Prins ML, 2005, J NEUROSCI RES, V82, P413, DOI 10.1002/jnr.20633; Puchowicz MA, 2007, AM J PHYSIOL-ENDOC M, V292, pE1607, DOI 10.1152/ajpendo.00512.2006; Puchowicz MA, 2008, J CEREBR BLOOD F MET, V28, P1907, DOI 10.1038/jcbfm.2008.79; RILEY KO, 2001, NEUROLOGICAL INJURY; RODRIGUEZ DJ, 1999, NUTR SUPPORT; ROSEN GD, 1990, J NEUROSCI METH, V35, P115, DOI 10.1016/0165-0270(90)90101-K; Sacrey LAR, 2009, BEHAV BRAIN RES, V204, P153, DOI 10.1016/j.bbr.2009.05.035; Schallert T, 2000, NEUROPHARMACOLOGY, V39, P777, DOI 10.1016/S0028-3908(00)00005-8; Schultke E, 2003, J NEUROTRAUM, V20, P583, DOI 10.1089/089771503767168500; Schurr A, 2001, BRAIN RES, V895, P268, DOI 10.1016/S0006-8993(01)02082-0; Shanley LJ, 2001, J NEUROSCI, V21, part. no., DOI 10.1523/JNEUROSCI.21-24-j0001.2001; Shimazu T, 2013, SCIENCE, V339, P211, DOI 10.1126/science.1227166; Streijger F, 2013, J NEUROTRAUM, V30, P869, DOI 10.1089/neu.2012.2405; Sullivan PG, 2004, ANN NEUROL, V55, P576, DOI 10.1002/ana.20062; Suzuki M, 2002, JPN J PHARMACOL, V89, P36, DOI 10.1254/jjp.89.36; Tai KK, 2008, J NEURAL TRANSM, V115, P1011, DOI 10.1007/s00702-008-0050-7; Tai KK, 2007, NEUROSCI LETT, V425, P34, DOI 10.1016/j.neulet.2007.08.007; Taub E, 1976, Exerc Sport Sci Rev, V4, P335; TAUB E, 1993, ARCH PHYS MED REHAB, V74, P347; Thio LL, 2006, PEDIATR RES, V60, P413, DOI 10.1203/01.pdr.0000238244.54610.27; Tieu K, 2003, J CLIN INVEST, V112, P892, DOI 10.1172/JCI200318797; Tysseling VM, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-16; Valerio A, 2006, J BIOL CHEM, V281, P12950, DOI 10.1074/jbc.M508691200; Van der Auwera Ingrid, 2005, Nutr Metab (Lond), V2, P28, DOI 10.1186/1743-7075-2-28; VanItallie TB, 2005, NEUROLOGY, V64, P728, DOI 10.1212/01.WNL.0000152046.11390.45; Vavrek R, 2006, BRAIN, V129, P1534, DOI 10.1093/brain/awl087; Veech RL, 2004, PROSTAG LEUKOTR ESS, V70, P309, DOI 10.1016/j.plefa.2003.09.007; Whetstone WD, 2003, J NEUROSCI RES, V74, P227, DOI 10.1002/jnr.10759; WHISHAW IQ, 1994, BEHAV BRAIN RES, V61, P65, DOI 10.1016/0166-4328(94)90009-4; Xiaowei H, 2006, SPINAL CORD, V44, P35, DOI 10.1038/sj.sc.3101813; Yudkoff M, 2007, ANNU REV NUTR, V27, P415, DOI 10.1146/annurev.nutr.27.061406.093722	98	67	74	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 4	2013	8	11							e78765	10.1371/journal.pone.0078765	http://dx.doi.org/10.1371/journal.pone.0078765			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	245ZC	24223849	gold, Green Published, Green Submitted			2023-01-03	WOS:000326503400088
J	Lieu, CH; Tran, H; Jiang, ZQ; Mao, ML; Overman, MJ; Lin, E; Eng, C; Morris, J; Ellis, L; Heymach, JV; Kopetz, S				Lieu, Christopher H.; Hai Tran; Jiang, Zhi-Qin; Mao, Muling; Overman, Michael J.; Lin, E.; Eng, Cathy; Morris, Jeffrey; Ellis, Lee; Heymach, John V.; Kopetz, Scott			The Association of Alternate VEGF Ligands with Resistance to Anti-VEGF Therapy in Metastatic Colorectal Cancer	PLOS ONE			English	Article							ENDOTHELIAL GROWTH-FACTOR; INDUCED ANGIOGENESIS; TUMOR-GROWTH; BEVACIZUMAB; PATHWAY; SWITCH	Background: Circulating angiogenic factors are altered in patients with mCRC receiving bevacizumab. Evaluation of alterations in levels of VEGF ligands may provide insights into possible resistance mechanisms. Methods: PlGF, VEGF-A, VEGF-C, and VEGF-D were measured from two cohorts of patients. Sequential plasma samples were obtained from a discovery cohort of 42 patients treated with chemotherapy and bevacizumab. A validation cohort included plasma samples from a cross-sectional of 403 patients prior to chemotherapy, or after progression on a regimen with or without bevacizumab. Results: In the discovery cohort, VEGF-C was increased prior to progression and at progression (+49% and +95%, respectively, p<0.01), consistent with previously reported elevations in PlGF. Levels of VEGF-D were increased (+23%) at progression (p=0.05). In the validation cohort, samples obtained from patients after progression on a regimen with bevacizumab had higher levels of PlGF and VEGF-D (+43% and +6%, p=0.02, p=0.01, respectively) compared to untreated patients, but failed to validate the increase in VEGF-C seen in the first cohort. Patients who progressed on chemotherapy with bevacizumab had significantly elevated levels of PlGF (+88%) but not VEGF-C and VEGF-D compared to patients treated with chemotherapy alone. Elevations of PlGF and VEGF-D appeared transient and returned to baseline with a half-life of 6 weeks. Conclusions: Increases in PlGF and VEGF-D were observed after progression on chemotherapy with bevacizumab. These changes appear to be reversible after discontinuing therapy. These ligands are associated with resistance to bevacizumab-containing chemotherapy in mCRC, but causation remains to be established.	[Lieu, Christopher H.] Univ Colorado, Div Med Oncol, Denver, CO 80202 USA; [Jiang, Zhi-Qin; Mao, Muling; Overman, Michael J.; Lin, E.; Eng, Cathy; Kopetz, Scott] Univ Texas MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, Houston, TX 77030 USA; [Hai Tran; Heymach, John V.] Univ Texas MD Anderson Canc Ctr, Dept Thoracic Head & Neck Med Oncol, Houston, TX 77030 USA; [Morris, Jeffrey] Univ Texas MD Anderson Canc Ctr, Dept Biostat, Houston, TX 77030 USA; [Ellis, Lee] Univ Texas MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA	University of Colorado System; University of Colorado Denver; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Lieu, CH (corresponding author), Univ Colorado, Div Med Oncol, Denver, CO 80202 USA.	christopher.lieu@ucdenver.edu	Jiang, Zhi-Qin/O-8999-2014; Heymach, John/AAG-2361-2019; Kopetz, Scott/AAC-1387-2019	Jiang, Zhi-Qin/0000-0002-0931-5418; Heymach, John/0000-0001-9068-8942; Kopetz, Scott/0000-0001-9647-3416; Eng, Cathy/0000-0003-2335-0612; Tran, Hai/0000-0003-4065-9355	Conquer Cancer Foundation Young Investigators Award; Circadian Technologies Limited; NATIONAL CANCER INSTITUTE [P01CA130821, P30CA016672] Funding Source: NIH RePORTER	Conquer Cancer Foundation Young Investigators Award; Circadian Technologies Limited; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Conquer Cancer Foundation Young Investigators Award (http://www.conquercancerfoundation.org/) to C. L., and a research grant from Circadian Technologies Limited (http://circadian.com.au/) to S. K. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adler D, 2005, VIOPLOT VIOLIN PLOT; Autiero M, 2003, NAT MED, V9, P936, DOI 10.1038/nm884; Bagley RG, 2011, CLIN CANCER RES, V17, P976, DOI 10.1158/1078-0432.CCR-10-2687; Batchelor TT, 2007, CANCER CELL, V11, P83, DOI 10.1016/j.ccr.2006.11.021; Bergers G, 2008, NAT REV CANCER, V8, P592, DOI 10.1038/nrc2442; Bjorndahl M, 2004, CIRC RES, V94, P1443, DOI 10.1161/01.RES.0000129194.61747.bf; Broll R, 2001, EUR J SURG ONCOL, V27, P37, DOI 10.1053/ejso.2000.1052; Cao RH, 2004, CIRC RES, V94, P664, DOI 10.1161/01.RES.0000118600.91698.BB; Carmeliet P, 2001, NAT MED, V7, P575, DOI 10.1038/87904; Casanovas O, 2005, CANCER CELL, V8, P299, DOI 10.1016/j.ccr.2005.09.005; Ellis LM, 2008, CLIN CANCER RES, V14, P6371, DOI 10.1158/1078-0432.CCR-07-5287; Eriksson A, 2002, CANCER CELL, V1, P99, DOI 10.1016/S1535-6108(02)00028-4; Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669; FOLKMAN J, 1990, JNCI-J NATL CANCER I, V82, P4, DOI 10.1093/jnci/82.1.4; GROTHEY A, 2012, J CLIN ONCOL, P30; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hanrahan EO, 2010, J CLIN ONCOL, V28, P193, DOI 10.1200/JCO.2009.22.4279; Hanrahan V, 2003, J PATHOL, V200, P183, DOI 10.1002/path.1339; Hansen BB, 2006, J COMPUT GRAPH STAT, V15, P609, DOI 10.1198/106186006X137047; Hicklin DJ, 2005, J CLIN ONCOL, V23, P1011, DOI 10.1200/JCO.2005.06.081; Hindryckx P, 2010, LAB INVEST, V90, P566, DOI 10.1038/labinvest.2010.37; Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691; Kerbel RS, 2005, CANCER CELL, V8, P269, DOI 10.1016/j.ccr.2005.09.016; KOPETZ S, 2009, J CLIN ONCOL, V2024, P8252; Lambrechts D, 2012, LANCET ONCOL, V13, P724, DOI 10.1016/S1470-2045(12)70231-0; Matsumoto K, 2003, ANTICANCER RES, V23, P4953; Parr C, 2005, EUR J CANCER, V41, P2819, DOI 10.1016/j.ejca.2005.07.022; Pepper MS, 1998, J CELL PHYSIOL, V177, P439, DOI 10.1002/(SICI)1097-4652(199812)177:3<439::AID-JCP7>3.0.CO;2-2; Ribatti D, 2008, ANGIOGENESIS, V11, P215, DOI 10.1007/s10456-008-9114-4; Saaristo A, 2002, FASEB J, V16, P1041, DOI 10.1096/fj.01-1042com; Saltz LB, 2008, J CLIN ONCOL, V26, P2013, DOI 10.1200/JCO.2007.14.9930; Valtola R, 1999, AM J PATHOL, V154, P1381, DOI 10.1016/S0002-9440(10)65392-8; Weickhardt AJ, 2011, J CLIN ONCOL, V29; Willett CG, 2009, J CLIN ONCOL, V27, P3020, DOI 10.1200/JCO.2008.21.1771; YAO J, 2011, P NATL ACAD SCI	36	86	89	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 15	2013	8	10							e77117	10.1371/journal.pone.0077117	http://dx.doi.org/10.1371/journal.pone.0077117			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	237TP	24143206	gold, Green Published, Green Submitted			2023-01-03	WOS:000325894100041
J	Chang, YN; Guo, HL; Li, J; Song, Y; Zhang, MY; Jin, JJ; Xing, GM; Zhao, YL				Chang, Ya-Nan; Guo, Haili; Li, Juan; Song, Yan; Zhang, Mingyi; Jin, Junjiang; Xing, Gengmei; Zhao, Yuliang			Adjusting the Balance between Effective Loading and Vector Migration of Macrophage Vehicles to Deliver Nanoparticles	PLOS ONE			English	Article							COLONY-STIMULATING FACTOR; IRON-OXIDE NANOPARTICLES; CELL-MIGRATION; DRUG-DELIVERY; TUMOR; ADHESION; NANOTECHNOLOGY; RECOGNITION; METASTASIS; PARTICLES	The nature of macrophage allows the possibility that this cell type could be used as drug delivery system to track therapeutic drug nanoparticles (NPs) in cancer. However, there is no existing research on the regulation between effective loading of NPs and targeted delivery of macrophages. Here, we investigated the important parameters of intracellular NP quantity and the vector migration rate. Macrophage loading capacity was obtained by comparing the uptake quantity of varisized NPs, and the delivery ability of loaded cells was determined by measuring vector migration rates. We observed a positive correlation between the size of NPs and directed macrophage migration. Our findings suggest that the molecular mechanism of migration vector rate regulation involved increased expression levels of colony-stimulating factor-1 (CSF-1) receptor and integrin induced by 100-nm and 500-nm particles. The ability of macrophages uptake to varisized NPs showed the opposite trend, with the increased vector rate of cell migration influenced by NPs. We are able to demonstrate the important balance between effective macrophage loading and targeted delivery. By adjusting the balance parameters, it will be possible to utilize NPs in macrophage-mediated disease diagnosis and therapy.	[Chang, Ya-Nan; Guo, Haili; Li, Juan; Song, Yan; Zhang, Mingyi; Jin, Junjiang; Xing, Gengmei; Zhao, Yuliang] Chinese Acad Sci, Inst High Energy Phys, Key Lab Biomed Effects Nanomat & Nanosafety, Beijing, Peoples R China; [Zhao, Yuliang] Chinese Acad Sci, Natl Ctr Nanosci & Technol China, Key Lab Biomed Effects Nanomat & Nanosafety, Beijing, Peoples R China	Chinese Academy of Sciences; Institute of High Energy Physics, CAS; Chinese Academy of Sciences; National Center for Nanoscience & Technology - China	Xing, GM (corresponding author), Chinese Acad Sci, Inst High Energy Phys, Key Lab Biomed Effects Nanomat & Nanosafety, Beijing, Peoples R China.	xinggm@ihep.ac.cn; zhaoyuliang@ihep.ac.cn		Chang, Yanan/0000-0003-4745-6876; Li, Juan/0000-0003-4110-3295	National Basic Research Program of China (973 Program) [2013CB932703, 2012CB932601]	National Basic Research Program of China (973 Program)(National Basic Research Program of China)	The authors are grateful for the support of the National Basic Research Program of China (973 Program) (2013CB932703 and 2012CB932601). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Banno A, 2008, BIOCHEM SOC T, V36, P229, DOI 10.1042/BST0360229; Beduneau A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004343; Chellat F, 2005, BIOMATERIALS, V26, P7260, DOI 10.1016/j.biomaterials.2005.05.044; Condeelis J, 2006, CELL, V124, P263, DOI 10.1016/j.cell.2006.01.007; Cui ZG, 2004, PHARM RES-DORDR, V21, P1018, DOI 10.1023/B:PHAM.0000029292.66792.4f; Ferrari M, 2005, NAT REV CANCER, V5, P161, DOI 10.1038/nrc1566; Friedl P, 2000, CELL MOL LIFE SCI, V57, P41, DOI 10.1007/s000180050498; Gendelman HE, 2009, J NEUROIMMUNE PHARM, V4, P47, DOI 10.1007/s11481-008-9135-1; Horwitz R, 2003, CURR BIOL, V13, pR756, DOI 10.1016/j.cub.2003.09.014; Hume DA, 2012, BLOOD, V119, P1810, DOI 10.1182/blood-2011-09-379214; Ikehara Y, 2006, CANCER RES, V66, P8740, DOI 10.1158/0008-5472.CAN-06-0470; Jiang W, 2008, NAT NANOTECHNOL, V3, P145, DOI 10.1038/nnano.2008.30; Kindwall-Keller TL, 2008, CYTOKINE, V43, P114, DOI 10.1016/j.cyto.2008.04.015; Kingsley JD, 2006, J NEUROIMMUNE PHARM, V1, P340, DOI 10.1007/s11481-006-9032-4; Kluth DC, 2004, KIDNEY INT, V66, P542, DOI 10.1111/j.1523-1755.2004.00773.x; KOLBBACHOFEN V, 1991, CARBOHYD RES, V213, P201, DOI 10.1016/S0008-6215(00)90609-8; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Lee JY, 2008, N-S ARCH PHARMACOL, V377, P111, DOI 10.1007/s00210-008-0266-y; McCarthy JR, 2006, SMALL, V2, P983, DOI 10.1002/smll.200600139; Meng FY, 1998, EMBO J, V17, P4391, DOI 10.1093/emboj/17.15.4391; Nahrendorf M, 2008, CIRCULATION, V117, P379, DOI 10.1161/CIRCULATIONAHA.107.741181; Nel AE, 2009, NAT MATER, V8, P543, DOI [10.1038/NMAT2442, 10.1038/nmat2442]; Parsons JT, 2010, NAT REV MOL CELL BIO, V11, P633, DOI 10.1038/nrm2957; Pollard JW, 2004, NAT REV CANCER, V4, P71, DOI 10.1038/nrc1256; Pollard TD, 2003, CELL, V112, P453, DOI 10.1016/S0092-8674(03)00120-X; Raynal I, 2004, INVEST RADIOL, V39, P56, DOI 10.1097/01.rli.0000101027.57021.28; Ridley AJ, 2003, SCIENCE, V302, P1704, DOI 10.1126/science.1092053; Sahai E, 2007, NAT REV CANCER, V7, P737, DOI 10.1038/nrc2229; Schwartz MA, 2006, CELL, V125, P1223, DOI 10.1016/j.cell.2006.06.015; Settles M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025197; Solinas G, 2009, J LEUKOCYTE BIOL, V86, P1065, DOI 10.1189/jlb.0609385; Valois CRA, 2010, BIOMATERIALS, V31, P366, DOI 10.1016/j.biomaterials.2009.09.053; Wang L, 2008, CANCER RES, V68, P5639, DOI 10.1158/0008-5472.CAN-07-5804; Xia T, 2008, ACS NANO, V2, P85, DOI 10.1021/nn700256c; Zahr AS, 2005, LANGMUIR, V21, P403, DOI 10.1021/la0478595; Zaman MH, 2006, P NATL ACAD SCI USA, V103, P10889, DOI 10.1073/pnas.0604460103; Zeisberger SM, 2006, BRIT J CANCER, V95, P272, DOI 10.1038/sj.bjc.6603240; Zhang MY, 2011, ARCH TOXICOL, V85, P1575, DOI 10.1007/s00204-011-0725-y; Zhao YL, 2011, NANOMEDICINE-UK, V6, P25, DOI [10.2217/nnm.10.129, 10.2217/NNM.10.129]	39	10	10	0	19	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 8	2013	8	10							e76024	10.1371/journal.pone.0076024	http://dx.doi.org/10.1371/journal.pone.0076024			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	233FK	24116086	Green Published, gold, Green Submitted			2023-01-03	WOS:000325552200046
J	Wagner, J; Gabler, NB; Ratcliffe, SJ; Brown, SES; Strom, BL; Halpern, SD				Wagner, Jason; Gabler, Nicole B.; Ratcliffe, Sarah J.; Brown, Sydney E. S.; Strom, Brian L.; Halpern, Scott D.			Outcomes Among Patients Discharged From Busy Intensive Care Units	ANNALS OF INTERNAL MEDICINE			English	Article							CRITICALLY-ILL PATIENTS; READMISSION RATE; BED NUMBERS; STATES; MORTALITY; ASSOCIATION; MEDICINE; SERVICES; QUALITY; CRISIS	Background: Strains on the capacities of intensive care units (ICUs) may influence the quality of ICU-to-floor transitions. Objective: To determine how 3 metrics of ICU capacity strain (ICU census, new admissions, and average acuity) measured on days of patient discharges influence ICU length of stay (LOS) and post-ICU discharge outcomes. Design: Retrospective cohort study from 2001 to 2008. Setting: 155 ICUs in the United States. Patients: 200 730 adults discharged from ICUs to hospital floors. Measurements: Associations between ICU capacity strain metrics and discharged patient ICU LOS, 72-hour ICU readmissions, subsequent in-hospital death, post-ICU discharge LOS, and hospital discharge destination. Results: Increases in the 3 strain variables on the days of ICU discharge were associated with shorter preceding ICU LOS (all P < 0.001) and increased odds of ICU readmissions (all P < 0.050). Going from the 5th to 95th percentiles of strain was associated with a 6.3-hour reduction in ICU LOS (95% CI, 5.3 to 7.3 hours) and a 1.0% increase in the odds of ICU readmission (CI, 0.6% to 1.5%). No strain variable was associated with increased odds of subsequent death, reduced odds of being discharged home from the hospital, or longer total hospital LOS. Limitation: Long-term outcomes could not be measured. Conclusion: When ICUs are strained, triage decisions seem to be affected such that patients are discharged from the ICU more quickly and, perhaps consequentially, have slightly greater odds of being readmitted to the ICU. However, short-term patient outcomes are unaffected. These results suggest that bed availability pressures may encourage physicians to discharge patients from the ICU more efficiently and that ICU readmissions are unlikely to be causally related to patient outcomes. Primary Funding Source: Agency for Healthcare Research and Quality; National Heart, Lung, and Blood Institute; and Society of Critical Care Medicine.	Univ Penn, Leonard Davis Inst, Ctr Hlth Incent & Behav Econ, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA; Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine	Wagner, J (corresponding author), Univ Penn, Perelman Sch Med, Div Pulm Allergy & Crit Care Med, 839 W Gates Bldg,3600 Spruce St, Philadelphia, PA 19104 USA.	jason.wagner@uphs.upenn.edu	Ratcliffe, Sarah J/GYR-1110-2022	Ratcliffe, Sarah J/0000-0002-6644-8284; Brown, Sydney/0000-0003-0374-0824	Agency for Healthcare Research and Quality; National Heart, Lung, and Blood Institute; Society of Critical Care Medicine; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [K08HS018406] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F30HL107020, T32HL098054] Funding Source: NIH RePORTER	Agency for Healthcare Research and Quality(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Society of Critical Care Medicine; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	Agency for Healthcare Research and Quality; National Heart, Lung, and Blood Institute; and Society of Critical Care Medicine.	Angus DC, 2006, CRIT CARE MED, V34, P1016, DOI 10.1097/01.CCM.0000206105.05626.15; Angus DC, 2000, JAMA-J AM MED ASSOC, V284, P2762, DOI 10.1001/jama.284.21.2762; Angus DC, 1998, CRIT CARE MED, V26, P1779, DOI 10.1097/00003246-199811000-00008; Baker DR, 2009, CRIT CARE MED, V37, P2882, DOI 10.1097/CCM.0b013e3181b01caf; Brody H, 2012, NEW ENGL J MED, V366, P1949, DOI 10.1056/NEJMp1203365; Brown SES, 2012, AM J RESP CRIT CARE, V185, P955, DOI 10.1164/rccm.201109-1720OC; Chalfin DB, 2007, CRIT CARE MED, V35, P1477, DOI 10.1097/01.CCM.0000266585.74905.5A; Chrusch CA, 2009, CRIT CARE MED, V37, P2753, DOI 10.1097/CCM.0b013e3181a57b0c; CLEVELAND WS, 1979, J AM STAT ASSOC, V74, P829, DOI 10.2307/2286407; Cooper GS, 1999, MED CARE, V37, P399, DOI 10.1097/00005650-199904000-00009; Cooper RA, 2004, ANN INTERN MED, V141, P705, DOI 10.7326/0003-4819-141-9-200411020-00012; Gershengorn HB, 2012, CRIT CARE MED, V40, P2009, DOI 10.1097/CCM.0b013e31824e9eae; Glance LG, 2006, CRIT CARE MED, V34, P1925, DOI 10.1097/01.CCM.0000226415.93237.84; Halpern NA, 2004, CRIT CARE MED, V32, P1254, DOI 10.1097/01.CCM.0000128577.31689.4C; Halpern NA, 2010, CRIT CARE MED, V38, P65, DOI 10.1097/CCM.0b013e3181b090d0; Halpern SD, 2011, CURR OPIN CRIT CARE, V17, P648, DOI 10.1097/MCC.0b013e32834c7a53; Higgins TL, 2007, CRIT CARE MED, V35, P827, DOI 10.1097/01.CCM.0000257337.63529.9F; Howell MD, 2011, CURR OPIN CRIT CARE, V17, P626, DOI 10.1097/MCC.0b013e32834b3e6e; Kahn JM, 2006, CURR OPIN CRIT CARE, V12, P399, DOI 10.1097/01.ccx.0000244117.08753.38; Kelley MA, 2004, CHEST, V125, P1514, DOI 10.1378/chest.125.4.1514; Kelley MA, 2008, CRIT CARE MED, V36, P1385, DOI 10.1097/CCM.0b013e31816a0bd3; Kramer AA, 2013, CRIT CARE MED, V41, P24, DOI 10.1097/CCM.0b013e3182657b8a; Kramer AA, 2012, CRIT CARE MED, V40, P3, DOI 10.1097/CCM.0b013e31822d751e; Levy MM, 2008, ANN INTERN MED, V148, P801, DOI 10.7326/0003-4819-148-11-200806030-00002; Localio AR, 2001, ANN INTERN MED, V135, P112, DOI 10.7326/0003-4819-135-2-200107170-00012; Luce JM, 2002, AM J RESP CRIT CARE, V165, P750, DOI 10.1164/ajrccm.165.6.2109045; Pronovost PJ, 2002, JAMA-J AM MED ASSOC, V288, P2151, DOI 10.1001/jama.288.17.2151; Rhodes A, 2012, INTENS CARE MED, V38, P1647, DOI 10.1007/s00134-012-2627-8; Roberts RR, 1999, JAMA-J AM MED ASSOC, V281, P644, DOI 10.1001/jama.281.7.644; Seymour CW, 2012, ARCH INTERN MED, V172, P1226, DOI 10.1001/archinternmed.2012.3773; Seymour CW, 2012, HEALTH SERV RES, V47, P2060, DOI 10.1111/j.1475-6773.2012.01402.x; SINGER DE, 1983, NEW ENGL J MED, V309, P1155, DOI 10.1056/NEJM198311103091905; STRAUSS MJ, 1986, JAMA-J AM MED ASSOC, V255, P1143, DOI 10.1001/jama.255.9.1143; Truog RD, 2006, CRIT CARE MED, V34, P958, DOI 10.1097/01.CCM.0000206116.10417.D9; Vranas KR, 2012, AM J RESP CRIT CARE, V185, pA1608; Walther SM, 2001, INTENS CARE MED, V27, P700, DOI 10.1007/s001340100899; Ward NS, 2008, CRIT CARE MED, V36, P471, DOI 10.1097/CCM.0B013E3181629511; Wunsch H, 2012, CHEST, V141, P1393, DOI 10.1378/chest.11-2819; Wunsch H, 2009, AM J RESP CRIT CARE, V180, P875, DOI 10.1164/rccm.200902-0201OC; Young MJ, 2012, CRIT CARE MED, V40, P261, DOI 10.1097/CCM.0b013e31822d750d; Zimmerman JE, 2010, J CRIT CARE, V25, P205, DOI 10.1016/j.jcrc.2009.06.010	41	94	96	0	10	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 1	2013	159	7					447	U151		10.7326/0003-4819-159-7-201310010-00004	http://dx.doi.org/10.7326/0003-4819-159-7-201310010-00004			15	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	234FQ	24081285	Green Accepted			2023-01-03	WOS:000325628000002
J	Myburgh, JA; Mythen, MG				Myburgh, John A.; Mythen, Michael G.			Resuscitation Fluids	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							HYDROXYETHYL STARCH; 0.9-PERCENT SALINE; RENAL-FUNCTION; SEVERE SEPSIS; MORTALITY; MANAGEMENT; SURGERY; INJURY; PRESSURE; EXCHANGE		[Myburgh, John A.] Univ New S Wales, Div Crit Care & Trauma, George Inst Global Hlth, Sydney, NSW, Australia; [Myburgh, John A.] St George Hosp, Dept Intens Care Med, Sydney, NSW 2217, Australia; [Mythen, Michael G.] Univ Coll London Hosp, Biomed Res Ctr, Natl Inst Hlth Res, London, England	George Institute for Global Health; University of New South Wales Sydney; University of Sydney; St George Hospital; University College London Hospitals NHS Foundation Trust; University of London; University College London	Myburgh, JA (corresponding author), St George Hosp, Dept Intens Care Med, Gray St, Sydney, NSW 2217, Australia.	jmyburgh@georgeinstitute.org.au		Myburgh, John/0000-0003-4088-7016	Fresenius Kabi; Aqix; Baxter; B. Braun; Beacon Pharmaceuticals; Cosmed; Cranlea; Deltex; Edwards; Imacor; LiDCO; Masimo; Medgraphics; Orion Pharma; Pulsion; Vitalograph	Fresenius Kabi; Aqix; Baxter; B. Braun; Beacon Pharmaceuticals; Cosmed; Cranlea; Deltex; Edwards; Imacor; LiDCO; Masimo; Medgraphics; Orion Pharma; Pulsion; Vitalograph	Dr. Myburgh reports receiving travel support and lecture fees, as well as grant support to his institution, from Fresenius Kabi; and Dr. Mythen, receiving consulting fees paid to himself and his institution by Aqix, grant support to his institution from Fresenius Kabi, lecture fees and travel support from Baxter, B. Braun, and Fresenius Kabi, and fees for the development and presentation of educational materials from B. Braun. Dr. Mythen also reports organizing nonprofit educational conferences for the Evidence-Based Perioperative Medicine (EBPOM) project, which has received financial support from Baxter, B. Braun, Beacon Pharmaceuticals, Cosmed, Cranlea, Deltex, Edwards, Fresenius Kabi, Imacor, LiDCO, Masimo, Medgraphics, Orion Pharma, Pulsion, and Vitalograph. No other potential conflict of interest relevant to this article was reported.	American College of Surgeons Committee on Trauma, 2012, ADV TRAUM LIF SUPP A, V9th; [Anonymous], COCHRANE DATABASE SY; [Anonymous], 2011, BRIT CONSENSUS GUIDE; Arlati S, 2007, RESUSCITATION, V72, P371, DOI 10.1016/j.resuscitation.2006.07.010; Awad S, 2008, CLIN NUTR, V27, P179, DOI 10.1016/j.clnu.2008.01.008; Bayer O, 2011, CRIT CARE MED, V39, P1335, DOI 10.1097/CCM.0b013e318212096a; Boyd JH, 2011, CRIT CARE MED, V39, P259, DOI 10.1097/CCM.0b013e3181feeb15; Brandstrup B, 2012, BRIT J ANAESTH, V109, P191, DOI 10.1093/bja/aes163; Brunkhorst FM, 2008, NEW ENGL J MED, V358, P125, DOI 10.1056/NEJMoa070716; Bunn F, 2012, COCHRANE DB SYST REV, V7; Chua HR, 2012, J CRIT CARE, V27, P138, DOI 10.1016/j.jcrc.2012.01.007; Cooper DJ, 2004, JAMA-J AM MED ASSOC, V291, P1350, DOI 10.1001/jama.291.11.1350; Cooper DJ, 2013, J NEUROTRAUMA; Corcoran T, 2012, ANESTH ANALG, V114, P640, DOI 10.1213/ANE.0b013e318240d6eb; Cordemans C, 2012, ANN INTENSIVE CARE, V2, DOI 10.1186/2110-5820-2-S1-S1; Dellinger RP, 2008, CRIT CARE MED, V36, P1394; Finfer S, 2004, NEW ENGL J MED, V350, P2247; Finfer S, 2006, BRIT MED J, V333, P1044, DOI 10.1136/bmj.38985.398704.7C; Finfer S, 2011, INTENS CARE MED, V37, P86, DOI 10.1007/s00134-010-2039-6; Finfer S, 2010, CRIT CARE, V14, DOI 10.1186/cc9293; Funk DJ, 2013, CRIT CARE MED, V41, P255, DOI 10.1097/CCM.0b013e3182772ab6; Guidet B, 2012, CRIT CARE, V16, DOI 10.1186/cc11358; Guidet B, 2010, CRIT CARE, V14, DOI 10.1186/cc9230; Hadimioglu N, 2008, ANESTH ANALG, V107, P264, DOI 10.1213/ane.0b013e3181732d64; Handy JM, 2008, BRIT J ANAESTH, V101, P141, DOI 10.1093/bja/aen148; Hartog CS, 2011, INTENS CARE MED, V37, P1725, DOI 10.1007/s00134-011-2385-z; James MFM, 2011, BRIT J ANAESTH, V107, P693, DOI 10.1093/bja/aer229; Kellum JA, 2004, CRIT CARE, V8, P331, DOI 10.1186/cc2900; Krogh A, 1932, J CLIN INVEST, V11, P63, DOI 10.1172/JCI100408; LEE JA, 1981, ANAESTHESIA, V36, P1115, DOI 10.1111/j.1365-2044.1981.tb08698.x; Lee WL, 2010, NEW ENGL J MED, V363, P689, DOI 10.1056/NEJMcibr1007320; Levick JR, 2010, CARDIOVASC RES, V87, P198, DOI 10.1093/cvr/cvq062; Lewins R, 1832, LONDON MED GAZ, P257; Maitland K, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-68; Maitland K, 2011, NEW ENGL J MED, V364, P2483, DOI 10.1056/NEJMoa1101549; McSwain NE, 2011, J TRAUMA, V70, pS2, DOI 10.1097/TA.0b013e31821b201d; Morgan TJ, 2004, INTENS CARE MED, V30, P1432, DOI 10.1007/s00134-004-2176-x; Murphy CV, 2009, CHEST, V136, P102, DOI 10.1378/chest.08-2706; Myburgh J, 2007, NEW ENGL J MED, V357, P874; Myburgh JA, 2012, NEW ENGL J MED, V367, P1901, DOI 10.1056/NEJMoa1209759; Perner A, 2012, NEW ENGL J MED, V367, P124, DOI 10.1056/NEJMoa1204242; Persichini R, 2012, CRIT CARE MED, V40, P3146, DOI 10.1097/CCM.0b013e318260c6c3; Roberts I, 1998, BMJ-BRIT MED J, V317, P235; Schortgen F, 2001, LANCET, V357, P911, DOI 10.1016/S0140-6736(00)04211-2; Shaw AD, 2012, ANN SURG, V255, P821, DOI 10.1097/SLA.0b013e31825074f5; Starling E H, 1896, J Physiol, V19, P312; Weinbaum S, 2007, ANNU REV BIOMED ENG, V9, P121, DOI 10.1146/annurev.bioeng.9.060906.151959; Wiedemann HP, 2006, NEW ENGL J MED, V354, P2564; Woodcock TE, 2012, BRIT J ANAESTH, V108, P384, DOI 10.1093/bja/aer515; Yunos NM, 2012, JAMA-J AM MED ASSOC, V308, P1566, DOI 10.1001/jama.2012.13356	50	354	387	1	35	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 26	2013	369	13					1243	1251		10.1056/NEJMra1208627	http://dx.doi.org/10.1056/NEJMra1208627			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	224LT	24066745				2023-01-03	WOS:000324888200011
J	Choi, S; Choi, HJ; Cheong, Y; Lim, YJ; Park, HK				Choi, Samjin; Choi, Hyuk Jai; Cheong, Youjin; Lim, Young-Jin; Park, Hun-Kuk			Internal-Specific Morphological Analysis of Sciatic Nerve Fibers in a Radiofrequency-Induced Animal Neuropathic Pain Model	PLOS ONE			English	Article							DORSAL-ROOT GANGLION; PULSED RADIOFREQUENCY; EXTRACELLULAR-MATRIX; PERIPHERAL-NERVE; TRANSMISSION ELECTRON; COLLAGEN; EXPRESSION; CELLS; DISTINCT; LESIONS	This study investigated the reversible effects of pulsed radiofrequency (PRF) treatment at 42 degrees C on the ultrastructural and biological changes in nerve and collagen fibers in the progression of neuropathic pain after rat sciatic nerve injury. Assessments of morphological changes in the extracellular matrices by atomic force microscopy and hematoxylin-eosin, Masson's trichrome and picrosirius-red staining as well as the expressions of two fibril-forming collagens, types-I and -III, and two inflammatory cytokines, TNF-alpha and IL-6, were evaluated on day 30 after RF exposure. There were four groups for different RF thermal treatments: no treatment, no current, PRF, and continuous RF (CRF). An RF procedure similar to that used in human clinical trials was used in this study. The CRF treatment at 82 degrees C led to neural and collagen damage by the permanent blockage of sensory nociceptors. The PRF treatment led to excellent performance and high expandability compared to CRF, with effects including slight damage and swelling of myelinated axons, a slightly decreased amount of collagen fibers, swelling of collagen fibril diameters, decreased immunoreactivity of collagen types-I and -III, presence of newly synthesized collagen, and recovery of inflammatory protein immunoreactivity. These evidence-based findings suggest that PRF-based pain relief is responsible for the temporary blockage of nerve signals as well as the preferential destruction of pain-related principal sensory fibers like the Ad and C fibers. This suggestion can be supported by the interaction between the PRF-induced electromagnetic field and cell membranes; therefore, PRF treatment provides pain relief while allowing retention of some tactile sensation.	[Choi, Samjin; Cheong, Youjin; Park, Hun-Kuk] Kyung Hee Univ, Dept Biomed Engn, Seoul, South Korea; [Choi, Samjin; Cheong, Youjin; Park, Hun-Kuk] Kyung Hee Univ, Healthcare Ind Res Inst, Seoul, South Korea; [Choi, Hyuk Jai] Hallym Univ, Dept Neurosurg, Chunchon, South Korea; [Lim, Young-Jin] Kyung Hee Univ, Dept Neurosurg, Seoul, South Korea; [Park, Hun-Kuk] Kyung Hee Univ, Dept Med Engn, Seoul, South Korea	Kyung Hee University; Kyung Hee University; Hallym University; Kyung Hee University; Kyung Hee University	Park, HK (corresponding author), Kyung Hee Univ, Dept Biomed Engn, Seoul, South Korea.	sigmoidus@khu.ac.kr	Choi, Hyukjai/GSE-1138-2022	Choi, Samjin/0000-0003-3498-0652	Bio R&D Program through the National Research Foundation of Korea; Ministry of Education, Science, and Technology [2009-0092562]	Bio R&D Program through the National Research Foundation of Korea(National Research Foundation of Korea); Ministry of Education, Science, and Technology(Ministry of Education, Science & Technology (MEST), Republic of Korea)	This study was supported by the Bio R&D Program through the National Research Foundation of Korea, funded by the Ministry of Education, Science, and Technology (Grant 2009-0092562). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Benazzoug Y, 1998, EXP GERONTOL, V33, P445, DOI 10.1016/S0531-5565(98)00015-1; BORNSTEIN P, 1980, ANNU REV BIOCHEM, V49, P957, DOI 10.1146/annurev.bi.49.070180.004521; Bradley JL, 2000, ACTA NEUROPATHOL, V99, P539, DOI 10.1007/s004010051158; Chernousov MA, 2006, J NEUROSCI, V26, P508, DOI 10.1523/JNEUROSCI.2544-05.2006; Choi S, 2012, LASER MED SCI, V27, P923, DOI 10.1007/s10103-011-1016-9; Cohen Steven P, 2003, Urology, V61, P645, DOI 10.1016/S0090-4295(02)02423-8; Cosman ER, 2005, PAIN MED, V6, P405, DOI 10.1111/j.1526-4637.2005.00076.x; de Louw AJA, 2001, EUR J PAIN-LONDON, V5, P169; Dubovy P, 2010, NEURON GLIA BIOL, V6, P73, DOI 10.1017/S1740925X10000074; Erdine S, 2005, EUR J PAIN, V9, P251, DOI 10.1016/j.ejpain.2004.07.002; Erdine S, 2009, PAIN PRACT, V9, P407, DOI 10.1111/j.1533-2500.2009.00317.x; Esposito E, 2013, MINI-REV MED CHEM, V13, P237; Fehrenbacher JC, 2005, PAIN, V113, P113, DOI 10.1016/j.pain.2004.09.031; Gess B, 2011, J NEUROSCI, V31, P17180, DOI 10.1523/JNEUROSCI.3457-11.2011; Geurts JWM, 2003, LANCET, V361, P21, DOI 10.1016/S0140-6736(03)12115-0; Grimal S, 2010, GLIA, V58, P1977, DOI 10.1002/glia.21066; Kiguchi N, 2010, PAIN, V149, P305, DOI 10.1016/j.pain.2010.02.025; Kiguchi N, 2009, ANESTH ANALG, V109, P1305, DOI 10.1213/ane.0b013e3181b1dca2; Kwak HW, 2013, MICROSC RES TECHNIQ, V76, P219, DOI 10.1002/jemt.22119; Layton BE, 2004, J BIOMECH ENG-T ASME, V126, P803, DOI 10.1115/1.1824118; Li W, 2011, PLOS ONE, V6, DOI [10.1371/journal.pone.0016945, 10.1371/journal.pone.0021082]; Maeda T, 2009, P NATL ACAD SCI USA, V106, P13076, DOI 10.1073/pnas.0903524106; Micera S, 2009, INT REV NEUROBIOL, V86, P23, DOI 10.1016/S0074-7742(09)86002-9; Moalem G, 2006, BRAIN RES REV, V51, P240, DOI 10.1016/j.brainresrev.2005.11.004; MYERS DB, 1977, ACTA NEUROPATHOL, V37, P7, DOI 10.1007/BF00684533; NASH TP, 1986, PAIN, V24, P67, DOI 10.1016/0304-3959(86)90027-8; Okamoto K, 2001, EXP NEUROL, V169, P386, DOI 10.1006/exnr.2001.7677; Plumb DA, 2007, J BIOL CHEM, V282, P12791, DOI 10.1074/jbc.C700021200; Podhajsky RJ, 2005, SPINE, V30, P1008, DOI 10.1097/01.brs.0000161005.31398.58; Protasoni M, 2009, EUR SPINE J, V18, P473, DOI 10.1007/s00586-008-0870-z; Scholz J, 2007, NAT NEUROSCI, V10, P1361, DOI 10.1038/nn1992; Shah RV, 2004, ARCH PHYS MED REHAB, V85, P1013, DOI 10.1016/j.apmr.2003.07.017; Shibasaki M, 2010, PAIN, V149, P514, DOI 10.1016/j.pain.2010.03.023; Slappendel R, 1997, PAIN, V73, P159, DOI 10.1016/S0304-3959(97)00094-8; Sluijter M, 2002, Pain Pract, V2, P195, DOI 10.1046/j.1533-2500.2002.02023.x; Sluijter ME, 1998, PAIN CLINIC, V11, P109; Thorsteinsdottir S, 2011, DEV BIOL, V354, P191, DOI 10.1016/j.ydbio.2011.03.015; Tofaris GK, 2002, J NEUROSCI, V22, P6696; Tun K, 2009, SURG NEUROL, V72, P496, DOI 10.1016/j.surneu.2008.11.016; Tun K, 2006, NEUROL RES, V28, P841, DOI 10.1179/016164106X110409; USHIKI T, 1990, CELL TISSUE RES, V260, P175, DOI 10.1007/BF00297503; van Wijk RMAW, 2001, J NEUROSURG, V94, P227, DOI 10.3171/spi.2001.94.2.0227; Van Zundert J, 2002, Pain Pract, V2, P269, DOI 10.1046/j.1533-2500.2002.02036.x; Van Zundert J, 2003, PAIN, V104, P449, DOI 10.1016/S0304-3959(03)00066-6; Vatansever D, 2008, CLIN J PAIN, V24, P717, DOI 10.1097/AJP.0b013e318173c27a; Wang H, 2003, DIABETES-METAB RES, V19, P288, DOI 10.1002/dmrr.372; White FA, 2007, P NATL ACAD SCI USA, V104, P20151, DOI 10.1073/pnas.0709250104; Williams PE, 2000, HISTOPATHOLOGY, V36, P551, DOI 10.1046/j.1365-2559.2000.00897.x; Zimmermann M, 2001, EUR J PHARMACOL, V429, P23, DOI 10.1016/S0014-2999(01)01303-6	49	14	16	1	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 16	2013	8	9							e73913	10.1371/journal.pone.0073913	http://dx.doi.org/10.1371/journal.pone.0073913			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	219GJ	24066083	Green Submitted, gold, Green Published			2023-01-03	WOS:000324494000065
J	Furumi, F; Koyasu, M				Furumi, Fumikazu; Koyasu, Masuo			Role-Play Experience Facilitates Reading the Mind of Individuals with Different Perception	PLOS ONE			English	Article							PERSPECTIVE; KNOWLEDGE; REPRESENTATION; BELIEFS; AUTISM	The present study examined effects of role-play experience on reading the mind of people with different perception. It is normally difficult but very important in daily life to understand people with different characteristics, including those with restricted color vision. We explored the mechanisms of reading the mind of people with different perception. Forty university students were introduced to a communication task in which the use of mindreading was essential. During each trial, participants viewed a shelf, presented on a laptop computer, which contained several familiar objects, and they were instructed to touch an object on the shelf following an instruction issued by a partner who stood at the opposite side of the shelf. There were two partners: one was a monkey with normal color vision and the other was a dog with restricted color vision. The monkey could see all the objects in the same colors as the participants, whereas the dog saw some objects in different colors (e. g., he saw as yellow objects that the participants saw as red). Participants were required to respond according to the partner's instruction. In the restricted color vision condition, the dog saw the colors of objects differently; thus, participants had to work out his intentions (i.e., mind read), according to his different perspective. In the normal color vision condition, all objects were in the same colors as those seen by the monkey. Before the test phase, the role-play group had a role-play experience in which participants assumed the role of people with restricted color vision. No-role-play participants made significantly more errors in the restricted color vision condition than in the normal color vision condition, whereas among role-play participants, there was no difference between conditions. These results suggest that role-play experience facilitates reading the mind of people with perceptual experiences different from our own.	[Furumi, Fumikazu; Koyasu, Masuo] Kyoto Univ, Grad Sch Educ, Kyoto, Japan; [Furumi, Fumikazu] Japan Soc Promot Sci, Tokyo, Japan	Kyoto University; Japan Society for the Promotion of Science	Furumi, F (corresponding author), Kyoto Univ, Grad Sch Educ, Kyoto, Japan.	fumikazu.furumi@gmail.com	FURUMI, FUMIKAZU/Q-2535-2019	FURUMI, FUMIKAZU/0000-0002-4716-3056				Apperly I., 2011, MINDREADERS; BARONCOHEN S, 1985, COGNITION, V21, P37, DOI 10.1016/0010-0277(85)90022-8; Birch J, 2012, J OPT SOC AM A, V29, P313, DOI 10.1364/JOSAA.29.000313; Dumontheil I, 2010, NEUROIMAGE, V52, P1574, DOI 10.1016/j.neuroimage.2010.05.056; Dumontheil I, 2010, DEVELOPMENTAL SCI, V13, P331, DOI 10.1111/j.1467-7687.2009.00888.x; FLAVELL JH, 1981, DEV PSYCHOL, V17, P99, DOI 10.1037/0012-1649.17.1.99; Furumi Fumikazu, 2012, Shinrigaku Kenkyu, V83, P18; Happe F, 1999, TRENDS COGN SCI, V3, P216, DOI 10.1016/S1364-6613(99)01318-2; Keysar B, 2000, PSYCHOL SCI, V11, P32, DOI 10.1111/1467-9280.00211; Komeda H, 2013, MOL AUTISM, V4, DOI 10.1186/2040-2392-4-20; Komeda H, 2009, COGNITION EMOTION, V23, P135, DOI 10.1080/02699930801949116; Lin SH, 2010, J EXP SOC PSYCHOL, V46, P551, DOI 10.1016/j.jesp.2009.12.019; Oyserman D, 2008, PSYCHOL BULL, V134, P311, DOI 10.1037/0033-2909.134.2.311; PERNER J, 1989, CHILD DEV, V60, P689, DOI 10.1111/j.1467-8624.1989.tb02749.x; PERNER J, 1985, J EXP CHILD PSYCHOL, V39, P437, DOI 10.1016/0022-0965(85)90051-7; Samson D, 2010, J EXP PSYCHOL HUMAN, V36, P1255, DOI 10.1037/a0018729; Senju A, 2012, NEUROSCIENTIST, V18, P108, DOI 10.1177/1073858410397208; SHEPARD RN, 1992, PSYCHOL SCI, V3, P97, DOI 10.1111/j.1467-9280.1992.tb00006.x; Surtees ADR, 2012, BRIT J DEV PSYCHOL, V30, P75, DOI 10.1111/j.2044-835X.2011.02063.x; WIMMER H, 1983, COGNITION, V13, P103, DOI 10.1016/0010-0277(83)90004-5	20	2	2	1	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 4	2013	8	9							e74899	10.1371/journal.pone.0074899	http://dx.doi.org/10.1371/journal.pone.0074899			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	219OE	24023966	Green Submitted, gold, Green Published			2023-01-03	WOS:000324515600160
J	Chesterton, LS; Lewis, AM; Sim, J; Mallen, CD; Mason, EE; Hay, EM; van der Windt, DA				Chesterton, Linda S.; Lewis, A. Martyn; Sim, Julius; Mallen, Christian D.; Mason, Elizabeth E.; Hay, Elaine M.; van der Windt, Danielle A.			Transcutaneous electrical nerve stimulation as adjunct to primary care management for tennis elbow: pragmatic randomised controlled trial (TATE trial)	BMJ-BRITISH MEDICAL JOURNAL			English	Article							HEALTHY-HUMAN PARTICIPANTS; CORTICOSTEROID INJECTIONS; LATERAL EPICONDYLALGIA; PARAMETER MANIPULATION; EXPERIMENTAL PAIN; TENS; PHYSIOTHERAPY; INTERVENTIONS; PREVALENCE; INTENSITY	Objective To investigate the effectiveness of supplementing information and advice on analgesia and exercise from a general practitioner with transcutaneous electrical nerve stimulation (TENS) as a non-drug form of analgesia to reduce pain intensity in patients with tennis elbow. Design Pragmatic randomised controlled trial in primary care. Setting and 38 general practices in the West Midlands, UK. Participants 241 adults consulting with a first or new (no consultation in previous six months) clinical diagnosis of tennis elbow. Interventions Participants were randomly allocated to either primary care management alone, consisting of a consultation with a general practitioner followed by information and advice on exercises, or primary care management plus TENS to be used once a day for 45 minutes over six weeks (or until symptom resolution) for pain relief. Outcome measures The primary outcome was self reported intensity of elbow pain (0-10 rating scale) at six weeks. Primary and secondary outcomes were measured at baseline and at six weeks, six months, and 12 months by postal questionnaire. Analysis was by intention to treat. Results 121 participants were randomised to primary care management plus TENS and 120 to primary care management only (first episode, n=197 (82%); duration <1-3 months, n=138 (57%)). Adherence to exercise and TENS recommendations reported at six weeks was low; only 42 participants in the primary care management plus TENS group met a priori defined adherence criteria. Both intervention groups showed large improvements in pain and secondary outcomes, especially during the first six weeks of follow-up. However, no clinically or statistically significant differences were seen between groups at any follow-up timepoint. At the primary endpoint (six weeks), the between group difference in improvement of pain was -0.33 (95% confidence interval -0.96 to 0.31; P=0.31) in favour of the primary care management only group, with adjustment for age, sex, and baseline pain score. Conclusions This trial does not provide evidence for additional benefit of TENS as an adjunct to primary care management of tennis elbow. Poor adherence to interventions is evidence of the challenges of implementing self management treatment strategies in primary care. Trial registration Current Controlled Trials ISRCTN87141084.	[Chesterton, Linda S.; Lewis, A. Martyn; Sim, Julius; Mallen, Christian D.; Mason, Elizabeth E.; Hay, Elaine M.; van der Windt, Danielle A.] Keele Univ, Arthrit Res UK Primary Care Ctr, Keele ST5 5BG, Staffs, England; [Sim, Julius] Keele Univ, Sch Hlth & Rehabil, Keele ST5 5BG, Staffs, England	Keele University; Keele University	Chesterton, LS (corresponding author), Keele Univ, Arthrit Res UK Primary Care Ctr, Keele ST5 5BG, Staffs, England.	l.s.chesterton@keele.ac.uk		Mallen, Christian/0000-0002-2677-1028; Chesterton, Linda/0000-0002-1639-4441	National Institute for Health Research (NIHR) [PB-PG-0407-13189]; Arthritis Research UK [20202]; National Institute for Health Research [PB-PG-0407-13189, NF-SI-0611-10078] Funding Source: researchfish; Versus Arthritis [19634] Funding Source: researchfish	National Institute for Health Research (NIHR)(National Institute for Health Research (NIHR)); Arthritis Research UK(Versus Arthritis); National Institute for Health Research(National Institute for Health Research (NIHR)); Versus Arthritis(Versus Arthritis)	This paper presents independent research funded by the National Institute for Health Research (NIHR) under the Research for Patient Benefit Programme (grant reference No PB-PG-0407-13189). CDM is supported by an Arthritis Research UK clinician scientist award. EMH is an NIHR senior investigator. The Institute for Primary Care and Health Sciences at Keele has been awarded the Arthritis Research UK Primary Care Centre of Excellence (grant No 20202). The NIHR had no role in the conduct of the study; collection, management, analysis, and interpretation of the data; or preparation and review of the manuscript. The conclusions and views expressed in this article are those of the authors and not necessarily those of the NHS, NIHR, or Department of Health.	ALLANDER E, 1974, SCAND J RHEUMATOL, V3, P145, DOI 10.3109/03009747409097141; [Anonymous], EX MAN TENN ELB; Barlas P, 2005, WALL MELZACKS TXB PA, P583; Bisset L, 2005, BRIT J SPORT MED, V39, P411, DOI 10.1136/bjsm.2004.016170; Bisset L, 2006, BMJ-BRIT MED J, V333, P939, DOI 10.1136/bmj.38961.584653.AE; Brazier JE, 2004, MED CARE, V42, P851, DOI 10.1097/01.mlr.0000135827.18610.0d; Chartered Society of Physiotherapy, 2006, GUID US EL AG; Chen CC, 2011, CLIN J PAIN, V27, P434, DOI 10.1097/AJP.0b013e318208c926; Chesterton LS, 2011, OPEN ACCESS J SPORTS, V2, P53, DOI 10.2147/OAJSM.S10310; Chesterton LS, 2009, BMC MUSCULOSKEL DIS, V10, DOI 10.1186/1471-2474-10-156; Chesterton LS, 2003, PAIN, V106, P73, DOI 10.1016/S0304-3959(03)00292-6; Chesterton LS, 2002, PAIN, V99, P253, DOI 10.1016/S0304-3959(02)00118-5; Claydon LS, 2013, CLIN J PAIN, V29, P533, DOI 10.1097/AJP.0b013e318262330f; Claydon LS, 2011, CLIN J PAIN, V27, P635, DOI 10.1097/AJP.0b013e31821962b4; Coombes BK, 2009, BRIT J SPORT MED, V43, P252, DOI 10.1136/bjsm.2008.052738; Coombes BK, 2013, JAMA-J AM MED ASSOC, V309, P461, DOI 10.1001/jama.2013.129; Coombes BK, 2010, LANCET, V376, P1751, DOI 10.1016/S0140-6736(10)61160-9; Cyriax JH, 1936, J BONE JOINT SURG, V18, P921; DeSantana Josimari M, 2008, Curr Rheumatol Rep, V10, P492; Farrar JT, 2001, PAIN, V94, P149, DOI 10.1016/S0304-3959(01)00349-9; Gabel Gerard T., 1999, Current Opinion in Rheumatology, V11, P138, DOI 10.1097/00002281-199903000-00010; Gladwell PW, 2013, THESIS U W ENGLAND; Halle J S, 1986, J Orthop Sports Phys Ther, V8, P62; HAMILTON PG, 1986, J ROY COLL GEN PRACT, V36, P464; Hay EM, 1999, BRIT MED J, V319, P964, DOI 10.1136/bmj.319.7215.964; Hudak PL, 1996, ARCH PHYS MED REHAB, V77, P586, DOI 10.1016/S0003-9993(96)90300-7; Hughes N, 2013, CLIN J PAIN, V29, P146, DOI 10.1097/AJP.0b013e3182579919; Johnson MI, 2011, EXPERT REV NEUROTHER, V11, P735, DOI [10.1586/ern.11.48, 10.1586/ERN.11.48]; Johnson M, 2007, PAIN, V130, P157, DOI 10.1016/j.pain.2007.02.007; Kennedy A, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f2882; Khadilkar A, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003008.pub3; Lewis M, 2005, CLIN J PAIN, V21, P330, DOI 10.1097/01.ajp.0000125268.40304.b3; Lewis M, 2002, SCAND J WORK ENV HEA, V28, P109, DOI 10.5271/sjweh.654; Moran F, 2011, J PAIN, V12, P929, DOI 10.1016/j.jpain.2011.02.352; Moss-Morris R, 2002, PSYCHOL HLTH, V17; Murtagh J E, 1988, Aust Fam Physician, V17, P90; Murtagh JE, 1988, AUST FAM PHYSICIAN, V17, P5; Murtagh JE, 1988, AUST FAM PHYSICIAN, V17, P91; Nnoaham KE, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003222.pub2; Overend T J, 1999, J Hand Ther, V12, P31; Pantaleao MA, 2011, J PAIN, V12, P581, DOI 10.1016/j.jpain.2010.11.001; RANNEY D, 1995, ERGONOMICS, V38, P1408, DOI 10.1080/00140139508925198; Rutjes AWS, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002823.pub2; Shiri R, 2006, AM J EPIDEMIOL, V164, P1065, DOI 10.1093/aje/kwj325; Sluka KA, 2003, J PAIN, V4, P109, DOI 10.1054/jpai.2003.434; Sluka KA, 2013, PHYS THER; Smidt N, 2002, LANCET, V359, P657, DOI 10.1016/S0140-6736(02)07811-X; Smidt N, 2006, BMJ-BRIT MED J, V333, P927, DOI 10.1136/bmj.39017.396389.BE; Sun X, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f3949; Vitolins MZ, 2000, CONTROL CLIN TRIALS, V21, p188S, DOI 10.1016/S0197-2456(00)00077-5; Walsh DM, 1997, 10S CLIN APPL RELATE; Watson T, 2000, MANUAL THER, V5, P132, DOI 10.1054/math.2000.0363; Weng CS, 2005, BIOMED ENG-APP BAS C, V17, P236, DOI 10.4015/S1016237205000354; White IR, 2011, STAT MED, V30, P377, DOI 10.1002/sim.4067; WILLIAMS A, 1990, HEALTH POLICY, V16, P199; WOLFE F, 1990, ARTHRITIS RHEUM-US, V33, P160, DOI 10.1002/art.1780330203	56	23	23	0	44	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 2	2013	347								f5160	10.1136/bmj.f5160	http://dx.doi.org/10.1136/bmj.f5160			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	215ND	23999980	Green Published, hybrid			2023-01-03	WOS:000324216000001
J	Okemoto, K; Wagner, B; Meisen, H; Haseley, A; Kaur, B; Chiocca, EA				Okemoto, Kazuo; Wagner, Benjamin; Meisen, Hans; Haseley, Amy; Kaur, Balveen; Chiocca, Ennio Antonio			STAT3 Activation Promotes Oncolytic HSV1 Replication in Glioma Cells	PLOS ONE			English	Article							GLIOBLASTOMA-MULTIFORME; GENE-EXPRESSION; SMALL-MOLECULE; BRAIN-TUMORS; VIRUS; INHIBITION	Recent studies report that STAT3 signaling is a master regulator of mesenchymal transformation of gliomas and that STAT3 modulated genes are highly expressed in the mesenchymal transcriptome of gliomas. A currently studied experimental treatment for gliomas consists of intratumoral injection of oncolytic viruses (OV), such as oncolytic herpes simplex virus type 1 (oHSV). We have described one particular oHSV (rQNestin34.5) that exhibits potent anti-glioma activity in animal models. Here, we hypothesized that alterations in STAT3 signaling in glioma cells may affect the replicative ability of rQNestin34.5. In fact, human U251 glioma cells engineered to either over-express STAT3 or with genetic down-regulation of STAT3 supported oHSV replication to a significantly higher or lesser degree, respectively, when compared to controls. Administration of pharmacologic agents that increase STAT3 phosphorylation/activation (Valproic Acid) or increase STAT3 levels (Interleukin 6) also significantly enhanced oHSV replication. Instead, administration of inhibitors of STAT3 phosphorylation/activation (LLL12) significantly reduced oHSV replication. STAT3 led to a reduction in interferon signaling in oHSV infected cells and inhibition of interferon signaling abolished the effect of STAT3 on oHSV replication. These data thus indicate that STAT3 signaling in malignant gliomas enhances oHSV replication, likely by inhibiting the interferon response in infected glioma cells, thus suggesting avenues for possible potentiation of oncolytic virotherapy.	[Okemoto, Kazuo; Wagner, Benjamin; Meisen, Hans; Haseley, Amy; Kaur, Balveen; Chiocca, Ennio Antonio] Ohio State Univ, James Canc Hosp, Ctr Comprehens Canc,Dept Neurol Surg, Dardinger Ctr Neurooncol & Neurosci,Solove Res In, Columbus, OH 43210 USA; [Okemoto, Kazuo; Wagner, Benjamin; Meisen, Hans; Haseley, Amy; Kaur, Balveen; Chiocca, Ennio Antonio] Ohio State Univ, Wexner Med Ctr, Columbus, OH 43210 USA; [Chiocca, Ennio Antonio] Brigham & Womens Faulkner Hosp, Inst Neurosci Brigham, Dept Neurosurg, Harvey Cushing Neurooncol Labs, Boston, MA USA; [Chiocca, Ennio Antonio] Dana Farber Canc Inst, Ctr Neurooncol, Boston, MA 02115 USA	James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; Harvard University; Dana-Farber Cancer Institute	Chiocca, EA (corresponding author), Ohio State Univ, James Canc Hosp, Ctr Comprehens Canc,Dept Neurol Surg, Dardinger Ctr Neurooncol & Neurosci,Solove Res In, Columbus, OH 43210 USA.	Eachiocca@partners.org	kaur, Balveen/E-3355-2011		NIH [1P01CA163205-01A1]; NATIONAL CANCER INSTITUTE [P01CA163205, R01CA150153] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS064607] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	This work was supported by NIH grant 1P01CA163205-01A1 to EAC. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Agarwalla PK, 2012, METHODS MOL BIOL, V797, P1, DOI 10.1007/978-1-61779-340-0_1; Ahmed AU, 2012, METHODS MOL BIOL, V797, P97, DOI 10.1007/978-1-61779-340-0_8; Alvarez-Breckenridge CA, 2012, J VIROL, V86, P4566, DOI 10.1128/JVI.05545-11; Ball S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018820; Carro MS, 2010, NATURE, V463, P318, DOI 10.1038/nature08712; Cooper LAD, 2012, AM J PATHOL, V180, P2108, DOI 10.1016/j.ajpath.2012.01.040; Dempsey MF, 2006, NUCL MED COMMUN, V27, P611, DOI 10.1097/00006231-200608000-00003; Freeman AI, 2006, MOL THER, V13, P221, DOI 10.1016/j.ymthe.2005.08.016; Hernandez-Alcoceba R, 2011, CLIN TRANSL ONCOL, V13, P229, DOI 10.1007/s12094-011-0647-4; Hussain SF, 2007, CANCER RES, V67, P9630, DOI 10.1158/0008-5472.CAN-07-1243; Kambara H, 2005, CANCER RES, V65, P2832, DOI 10.1158/0008-5472.CAN-04-3227; Kohsaka S, 2012, MOL CANCER THER, V11, P1289, DOI 10.1158/1535-7163.MCT-11-0801; Lin L, 2010, NEOPLASIA, V12, P39, DOI 10.1593/neo.91196; Liu Y, 2010, ANTI-CANCER AGENT ME, V10, P512, DOI 10.2174/187152010793498636; Otsuki A, 2008, MOL THER, V16, P1546, DOI 10.1038/mt.2008.155; Pesonen S, 2011, MOL PHARMACEUT, V8, P12, DOI 10.1021/mp100219n; Wang WB, 2011, J IMMUNOL, V187, P2578, DOI 10.4049/jimmunol.1004128; Wei J, 2011, PLOS ONE, V6, DOI [10.1371/journal.pone.0016195, 10.1371/journal.pone.0017868]; Wollmann G, 2012, CANCER J, V18, P69, DOI 10.1097/PPO.0b013e31824671c9	19	19	20	1	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 2	2013	8	8							e71932	10.1371/journal.pone.0071932	http://dx.doi.org/10.1371/journal.pone.0071932			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	219XU	23936533	Green Submitted, Green Published, gold			2023-01-03	WOS:000324545800072
J	Shingai, M; Nishimura, Y; Klein, F; Mouquet, H; Donau, OK; Plishka, R; Buckler-White, A; Seaman, M; Piatak, M; Lifson, JD; Dimitrov, DS; Nussenzweig, MC; Martin, MA				Shingai, Masashi; Nishimura, Yoshiaki; Klein, Florian; Mouquet, Hugo; Donau, Olivia K.; Plishka, Ronald; Buckler-White, Alicia; Seaman, Michael; Piatak, Michael, Jr.; Lifson, Jeffrey D.; Dimitrov, Dimiter S.; Nussenzweig, Michel C.; Martin, Malcolm A.			Antibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia	NATURE			English	Article							SIMIAN/HUMAN IMMUNODEFICIENCY VIRUS; NEUTRALIZING ANTIBODIES; PASSIVE TRANSFER; RHESUS MACAQUES; POTENT NEUTRALIZATION; HIV-1; BROAD; PROTECTION; CHALLENGE; THERAPY	Neutralizing antibodies can confer immunity to primate lentiviruses by blocking infection in macaque models of AIDS(1-4). However, earlier studies of anti-human immunodeficiency virus type 1 (HIV-1) neutralizing antibodies administered to infected individuals or humanized mice reported poor control of virus replication and the rapid emergence of resistant variants(5-7). A new generation of anti-HIV-1 monoclonal antibodies, possessing extraordinary potency and breadth of neutralizing activity, has recently been isolated from infected individuals(8). These neutralizing antibodies target different regions of the HIV-1 envelope glycoprotein including the CD4-binding site, glycans located in the V1/V2, V3 and V4 regions, and the membrane proximal external region of gp41 (refs 9-14). Here we have examined two of the new antibodies, directed to the CD4-binding site and the V3 region (3BNC117 and 10-1074, respectively), for their ability to block infection and suppress viraemia in macaques infected with the R5 tropic simian-human immunodeficiency virus (SHIV)-AD8, which emulates many of the pathogenic and immunogenic properties of HIV-1 during infections of rhesus macaques(15,16). Either antibody alone can potently block virus acquisition. When administered individually to recently infected macaques, the 10-1074 antibody caused a rapid decline in virus load to undetectable levels for 4-7 days, followed by virus rebound during which neutralization-resistant variants became detectable. When administered together, a single treatment rapidly suppressed plasma viraemia for 3-5 weeks in some long-term chronically SHIV-infected animals with low CD41 T-cell levels. A second cycle of anti-HIV-1 monoclonal antibody therapy, administered to two previously treated animals, successfully controlled virus rebound. These results indicate that immunotherapy or a combination of immunotherapy plus conventional antiretroviral drugs might be useful as a treatment for chronically HIV-1-infected individuals experiencing immune dysfunction.	[Shingai, Masashi; Nishimura, Yoshiaki; Donau, Olivia K.; Plishka, Ronald; Buckler-White, Alicia; Martin, Malcolm A.] NIAID, Lab Mol Microbiol, NIH, Bethesda, MD 20892 USA; [Klein, Florian; Nussenzweig, Michel C.] Rockefeller Univ, Lab Mol Immunol, New York, NY 10065 USA; [Mouquet, Hugo] Inst Pasteur, Dept Immunol, Lab Humoral Response Pathogens, F-75015 Paris, France; [Seaman, Michael] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Ctr Virol & Vaccine Res, Boston, MA 02115 USA; [Piatak, Michael, Jr.; Lifson, Jeffrey D.] SAIC Frederick Inc, AIDS & Canc Virus Program, Frederick Natl Lab Canc Res, Frederick, MD 21702 USA; [Dimitrov, Dimiter S.; Nussenzweig, Michel C.] NCI, Ctr Canc Res, NIH, Bethesda, MD 20892 USA; [Nussenzweig, Michel C.] Rockefeller Univ, Howard Hughes Med Inst, New York, NY 10065 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Rockefeller University; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Howard Hughes Medical Institute; Rockefeller University	Nussenzweig, MC (corresponding author), Rockefeller Univ, Lab Mol Immunol, New York, NY 10065 USA.	nussen@mail.rockefeller.edu; malm@nih.gov	Mouquet, Hugo/M-2750-2014; Nussenzweig, Michel/AAE-7292-2019	Mouquet, Hugo/0000-0002-4230-610X; 	Intramural Research Program of the National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH); National Cancer Institute, NIH [HHSN261200800001E]; NATIONAL CANCER INSTITUTE [ZIABC011155] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI100148, ZIAAI000998] Funding Source: NIH RePORTER	Intramural Research Program of the National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH); National Cancer Institute, NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	We thank K. Tomioka and R. Kruthers for determining plasma viral RNA loads and B. Skopets, W. Magnanelli and R. Petros for diligently assisting in the maintenance of animals and assisting with procedures. We also thank D. R. Burton, The Scripps Institute, for providing anti-dengue virus neutralizing monoclonal antibody (DEN-3). This work was supported by the Intramural Research Program of the National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH) and, in part, with federal funds from the National Cancer Institute, NIH, under contract HHSN261200800001E.	Burton DR, 2012, CELL HOST MICROBE, V12, P396, DOI 10.1016/j.chom.2012.09.008; Diskin R, 2013, J EXP MED, V210, P1235, DOI 10.1084/jem.20130221; Endo Y, 2000, J VIROL, V74, P6935, DOI 10.1128/JVI.74.15.6935-6945.2000; Gautam R, 2012, J VIROL, V86, P8516, DOI 10.1128/JVI.00644-12; Hansen SG, 2011, NATURE, V473, P523, DOI 10.1038/nature10003; Horwitz J. A., 2013, P NATL ACAD SCI US; Huang JH, 2012, NATURE, V491, P406, DOI 10.1038/nature11544; Igarashi T, 1999, NAT MED, V5, P211, DOI 10.1038/5576; Keele BF, 2009, J EXP MED, V206, P1117, DOI 10.1084/jem.20082831; Klein F, 2012, NATURE, V492, P118, DOI 10.1038/nature11604; Kong L, 2013, NAT STRUCT MOL BIOL, V20, P796, DOI 10.1038/nsmb.2594; Mascola JR, 1999, J VIROL, V73, P4009, DOI 10.1128/JVI.73.5.4009-4018.1999; Mehandru S, 2007, J VIROL, V81, P11016, DOI 10.1128/JVI.01340-07; Moldt B, 2012, P NATL ACAD SCI USA, V109, P18921, DOI 10.1073/pnas.1214785109; Montefiori David C, 2005, Curr Protoc Immunol, VChapter 12, DOI 10.1002/0471142735.im1211s64; Mouquet H, 2012, P NATL ACAD SCI USA, V109, pE3268, DOI 10.1073/pnas.1217207109; Nishimura Y, 2002, J VIROL, V76, P2123, DOI 10.1128/jvi.76.5.2123-2130.2002; Nishimura Y, 2010, J VIROL, V84, P4769, DOI 10.1128/JVI.02279-09; Parren PWHI, 2001, J VIROL, V75, P8340, DOI 10.1128/JVI.75.17.8340-8347.2001; Poignard P, 1999, IMMUNITY, V10, P431, DOI 10.1016/S1074-7613(00)80043-6; Polis MA, 2001, LANCET, V358, P1760, DOI 10.1016/S0140-6736(01)06802-7; Sadjadpour R, 2013, J VIROL, V87, P8798, DOI 10.1128/JVI.00878-13; Scheid JF, 2011, SCIENCE, V333, P1633, DOI 10.1126/science.1207227; Shingai M, 2012, P NATL ACAD SCI USA, V109, P19769, DOI 10.1073/pnas.1217443109; Trkola A, 2005, NAT MED, V11, P615, DOI 10.1038/nm1244; Walker LM, 2011, P NATL ACAD SCI USA, V108, P20125, DOI 10.1073/pnas.1117531108; Walker LM, 2011, NATURE, V477, P466, DOI 10.1038/nature10373; Walker LM, 2009, SCIENCE, V326, P285, DOI 10.1126/science.1178746; Wu XL, 2010, SCIENCE, V329, P856, DOI 10.1126/science.1187659; Zhou TQ, 2010, SCIENCE, V329, P811, DOI 10.1126/science.1192819	30	348	379	0	49	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 14	2013	503	7475					277	+		10.1038/nature12746	http://dx.doi.org/10.1038/nature12746			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	250YX	24172896	Green Accepted			2023-01-03	WOS:000326894200054
J	Demirors, AF; Pillai, PP; Kowalczyk, B; Grzybowski, BA				Demiroers, Ahmet F.; Pillai, Pramod P.; Kowalczyk, Bartlomiej; Grzybowski, Bartosz A.			Colloidal assembly directed by virtual magnetic moulds	NATURE			English	Article							CRYSTALS; ARRAYS; MOLECULES; SYMMETRY; FORCES; GROWTH; FIELD	Interest in assemblies of colloidal particles(1-4) has long been motivated by their applications in photonics(5,6), electronics(7,8), sensors(8) and microlenses(9). Existing assembly schemes(10-15) can position colloids of one type relatively flexibly into a range of desired structures, but it remains challenging to produce multicomponent lattices, clusters with precisely controlled symmetries and three-dimensional assemblies(16). A few schemes can efficiently produce complex colloidal structures(2,17,18), but they require system-specific procedures. Here we show that magnetic field microgradients established in a paramagnetic fluid(19,20) can serve as 'virtual moulds' to act as templates for the assembly of large numbers (similar to 10(8)) of both non-magnetic and magnetic colloidal particles with micrometre precision and typical yields of 80 to 90 per cent. We illustrate the versatility of this approach by producing single-component and multicomponent colloidal arrays, complex three-dimensional structures and a variety of colloidal molecules from polymeric particles, silica particles and live bacteria and by showing that all of these structures can be made permanent. In addition, although our magnetic moulds currently resemble optical traps in that they are limited to the manipulation of micrometre-sized objects, they are massively parallel and can manipulate non-magnetic and magnetic objects simultaneously in two and three dimensions.	[Demiroers, Ahmet F.; Pillai, Pramod P.; Kowalczyk, Bartlomiej; Grzybowski, Bartosz A.] Northwestern Univ, Dept Chem, Evanston, IL 60208 USA; [Demiroers, Ahmet F.; Pillai, Pramod P.; Kowalczyk, Bartlomiej; Grzybowski, Bartosz A.] Northwestern Univ, Dept Chem & Biol Engn, Evanston, IL 60208 USA	Northwestern University; Northwestern University	Grzybowski, BA (corresponding author), Northwestern Univ, Dept Chem, 2145 Sheridan Rd, Evanston, IL 60208 USA.	grzybor@northwestern.edu	Pillai, Pramod/G-8334-2015; Demirörs, Ahmet/R-9614-2019; Grzybowski, Bartosz A/H-5741-2017	Grzybowski, Bartosz/0000-0001-6613-4261; Demirors, Ahmet/0000-0002-2748-1516	US Department of Energy, Office of Science, Office of Basic Energy Sciences [DE-SC0000989]; Non-equilibrium Energy Research Center, Energy Frontier Research Center	US Department of Energy, Office of Science, Office of Basic Energy Sciences(United States Department of Energy (DOE)); Non-equilibrium Energy Research Center, Energy Frontier Research Center	We thank P. E. Fuller for his Matlab scripts. This work was supported by the Non-equilibrium Energy Research Center, which is an Energy Frontier Research Center funded by the US Department of Energy, Office of Science, Office of Basic Energy Sciences under award number DE-SC0000989.	Ahn BY, 2009, SCIENCE, V323, P1590, DOI 10.1126/science.1168375; Aizenberg J, 2000, PHYS REV LETT, V84, P2997, DOI 10.1103/PhysRevLett.84.2997; Bakker CJG, 2006, MAGN RESON MED, V56, P1107, DOI 10.1002/mrm.21069; Bishop KJM, 2009, SMALL, V5, P1600, DOI 10.1002/smll.200900358; Chen Q, 2011, NATURE, V469, P381, DOI 10.1038/nature09713; Coey JMD, 2009, P NATL ACAD SCI USA, V106, P8811, DOI 10.1073/pnas.0900561106; Dong AG, 2011, NANO LETT, V11, P1804, DOI 10.1021/nl200468p; Erb RM, 2009, NATURE, V457, P999, DOI 10.1038/nature07766; Hochbaum AI, 2005, NANO LETT, V5, P457, DOI 10.1021/nl047990x; Hoogenboom JP, 2004, NANO LETT, V4, P205, DOI 10.1021/nl034867h; Jiang P, 2006, APPL PHYS LETT, V89, DOI 10.1063/1.2218832; Lu Y, 2001, ADV MATER, V13, P34, DOI 10.1002/1521-4095(200101)13:1<34::AID-ADMA34>3.3.CO;2-T; Manoharan VN, 2003, SCIENCE, V301, P483, DOI 10.1126/science.1086189; Mirica KA, 2009, J AM CHEM SOC, V131, P10049, DOI 10.1021/ja900920s; Miszta K, 2011, NAT MATER, V10, P872, DOI [10.1038/nmat3121, 10.1038/NMAT3121]; Perro A, 2009, ANGEW CHEM INT EDIT, V48, P361, DOI 10.1002/anie.200802562; Rosensweig RE., 1997, FERROHYDRODYNAMICS; Shevkoplyas SS, 2007, LAB CHIP, V7, P1294, DOI 10.1039/b705045c; Shipway AN, 2000, CHEMPHYSCHEM, V1, P18, DOI 10.1002/1439-7641(20000804)1:1<18::AID-CPHC18>3.0.CO;2-L; Sun Z, 2011, J APPL PHYS, V109, DOI 10.1063/1.3579426; van Blaaderen A, 2003, SCIENCE, V301, P470; vanBlaaderen A, 1997, NATURE, V385, P321, DOI 10.1038/385321a0; Wang YF, 2012, NATURE, V491, P51, DOI 10.1038/nature11564; Xia YN, 2001, ADV MATER, V13, P409, DOI 10.1002/1521-4095(200103)13:6<409::AID-ADMA409>3.0.CO;2-C; Yang JC, 2010, NANO LETT, V10, P3173, DOI 10.1021/nl102078j; Yellen BB, 2005, P NATL ACAD SCI USA, V102, P8860, DOI 10.1073/pnas.0500409102; Yethiraj A, 2004, ADV MATER, V16, P596, DOI 10.1002/adma.200306192	27	146	146	2	298	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 7	2013	503	7474					99	103		10.1038/nature12591	http://dx.doi.org/10.1038/nature12591			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	247AS	24141949				2023-01-03	WOS:000326585600039
J	Sultan, AA; West, J; Tata, LJ; Fleming, KM; Nelson-Piercy, C; Grainge, MJ				Sultan, Alyshah Abdul; West, Joe; Tata, Laila J.; Fleming, Kate M.; Nelson-Piercy, Catherine; Grainge, Matthew J.			Risk of first venous thromboembolism in pregnant women in hospital: population based cohort study from England	BMJ-BRITISH MEDICAL JOURNAL			English	Article							EPISODE STATISTICS; PUERPERIUM; THROMBOSIS	Objective To examine the potential for preventing venous thromboembolism during and after antepartum hospital admissions in pregnant women. Design Cohort study using linked primary (Clinical Practice Research Datalink) and secondary (Hospital Episode Statistics) care records. Setting Primary and secondary care centres, England. Participants 206 785 women aged 15-44 who had one or more pregnancies from 1997 up to 2010. Main outcome measure Risk of first venous thromboembolism in pregnant women admitted to hospital for one or more days for reasons other than delivery or venous thromboembolism. Risk was assessed by calculating the absolute rate of venous thromboembolism and comparing these rates with those observed during follow-up time not associated with hospital admission using a Poisson regression model to estimate incidence rate ratios. Results Admission to hospital in pregnancy was associated with an increased risk of venous thromboembolism (absolute rate 1752/100 000 person years; incidence rate ratio 17.5, 95% confidence interval 7.69 to 40.0) compared with time outside hospital. The rate of venous thromboembolism was also high during the 28 days after discharge (absolute rate 676; 6.27, 3.74 to 10.5). The rate during and after admission combined was highest in the third trimester (961; 5.57, 3.32 to 9.34) and in those aged >= 35 years (1756; 21.7, 9.62 to 49.0). While the absolute rate in the combined period was highest for those with three or more days in hospital (1511; 12.2, 6.65 to 22.7), there was also a fourfold increase (558; 4.05, 2.23 to 7.38) in the risk of venous thromboembolism for those admitted to hospital for less than three days. Conclusion The overall risk of first venous thromboembolism in pregnant women increased during admissions to hospital not related to delivery, and remained significantly higher in the 28 days after discharge. During these periods need for thromboprophylaxis should receive careful consideration.	[Sultan, Alyshah Abdul; West, Joe; Tata, Laila J.; Fleming, Kate M.; Grainge, Matthew J.] Univ Nottingham, City Hosp, Div Epidemiol & Publ Hlth, Nottingham NG5 1PB, England; [Nelson-Piercy, Catherine] St Thomas Hosp, Guys & St Thomas Fdn Trust, Womens Hlth Acad Ctr, London SE1 7EH, England	Nottingham University Hospital NHS Trust; Nottingham City Hospital; University of Nottingham; Guy's & St Thomas' NHS Foundation Trust	Sultan, AA (corresponding author), Univ Nottingham, City Hosp, Div Epidemiol & Publ Hlth, Clin Sci Bldg Phase 2, Nottingham NG5 1PB, England.	alyshah.sultan@hotmail.com	West, Joe/M-3867-2019; West, Joe/I-6637-2012; Fleming, Kate M/A-6475-2010; Tata, Laila/J-5227-2012	West, Joe/0000-0002-1135-9356; West, Joe/0000-0002-1135-9356; Fleming, Kate M/0000-0002-6572-5016; Tata, Laila/0000-0002-6404-8658; Grainge, Matthew/0000-0001-7181-4042	Aga Khan Foundation; University of Nottingham	Aga Khan Foundation; University of Nottingham	AAS is funded by a scholarship awarded by the Aga Khan Foundation. JW is funded by a University of Nottingham senior clinical research fellowship, which also contributes to AAS's funding.	Burns H, 2011, BJOG-INT J OBSTET GY, V118, P5, DOI 10.1111/j.1471-0528.2010.02847.x; Campbell SE, 2001, J PUBLIC HEALTH MED, V23, P205, DOI 10.1093/pubmed/23.3.205; Crooks C, 2013, THESIS U NOTTINGHAM; Dattani N, 2012, HLTH STAT Q, P53; Department of Health, 2013, VEN THROMB PREV PAT; Drife J, 2003, BRIT MED BULL, V67, P177, DOI 10.1093/bmb/ldg010; Eaton SC, 2008, PHARMACOEPIDEM DR S, V17, pS214; Geerts WH, 2008, CHEST, V133, p381S, DOI 10.1378/chest.08-0656; Greer IA, 2005, BLOOD, V106, P401, DOI 10.1182/blood-2005-02-0626; Heit JA, 2001, MAYO CLIN PROC, V76, P1102, DOI 10.4065/76.11.1102; Jacobsen AF, 2008, J THROMB HAEMOST, V6, P905, DOI 10.1111/j.1538-7836.2008.02961.x; Knight M, 2008, BJOG-INT J OBSTET GY, V115, P453, DOI 10.1111/j.1471-0528.2007.01622.x; Larsen TB, 2007, THROMB RES, V120, P505, DOI 10.1016/j.thromres.2006.12.003; Lawrenson R, 2000, BRIT J CLIN PHARMACO, V49, P591, DOI 10.1046/j.1365-2125.2000.00199.x; National Institute for Health and Clinical Excellence, 2008, DIAB PREGN MAN DIAB; National Institute for Health and Clinical Excellence, 2010, VEN THROMB RED RISK; Royal College of Obstetricians and Gynaecologist, 2010, AC MAN THROMB EMB PR, V37b; Royal College of Obstetricians and Gynaecologists, 2009, RED RISK THROMB EMB; Simpson EL, 2001, BRIT J OBSTET GYNAEC, V108, P56, DOI 10.1111/j.1471-0528.2001.00004.x; Sultan AA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070310; Thompson A, 2004, BRIT J PSYCHIAT, V185, P334, DOI 10.1192/bjp.185.4.334; Walker RL, 2009, CAN J CARDIOL, V25, pE284, DOI 10.1016/S0828-282X(09)70125-4; Wik HS, 2012, J THROMB HAEMOST, V10, P840, DOI 10.1111/j.1538-7836.2012.04690.x; Zhang J, 1997, EPIDEMIOL REV, V19, P218, DOI 10.1093/oxfordjournals.epirev.a017954	24	54	55	0	9	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 7	2013	347								f6099	10.1136/bmj.f6099	http://dx.doi.org/10.1136/bmj.f6099			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	250XQ	24201164	Green Published, Green Accepted, hybrid			2023-01-03	WOS:000326890500001
J	Lai, KR; Cui, JT; Ni, S; Zhang, YD; He, JL; Yao, K				Lai, Kairan; Cui, Jiantao; Ni, Shuang; Zhang, Yidong; He, Jiliang; Yao, Ke			The Effects of Postmenopausal Hormone Use on Cataract: A Meta-Analysis	PLOS ONE			English	Article							FEMALE REPRODUCTIVE FACTORS; REPLACEMENT THERAPY; LENS OPACITIES; RISK-FACTORS; ESTROGEN-RECEPTOR; EYE DISEASE; AGE; POPULATION; WOMEN; PROGRESSION	Background: Cataract is the leading cause of blindness worldwide. Many observational studies assessed the relationship between postmenopausal hormone replacement therapy (HRT) and risk of cataract development, but the reported results were controversial. The aim of present meta-analysis was to evaluate the association of postmenopausal hormone replacement therapy with risk of cataract development. Methods: The eligible observational studies, including cross-sectional, case-control and cohort studies, were identified by searching PubMed and Embase during March of 2013. Either a fixed-or a random-effects model was used to calculate the pooled odds ratio (OR) with its 95% confidence interval (95% CI). Subgroup analysis on cataract types was performed. Results: A total of four cohort and five case-control or cross-sectional studies were finally included into this meta-analysis. Overall, a significant decreased risk of developing any type of cataract was found in ever HRT group as compared with non-HRT group among cohort studies (OR 0.83; 95% CI: 0.71,0.97) and case-control or cross-sectional studies (OR 0.74; 95% CI: 0.59,0.93). Subgroup analysis on cataract types determined that the significantly decreased risk of nuclear cataract in current HRT group (OR 0.72; 95% CI: 0.61,0.85) and also a critically reduced risk of nuclear cataract in ever HRT group (OR 0.80; 95% CI: 0.64,1.01) were found among case-control or cross-sectional studies, as compared with non-HRT group. No association of HRT with risk of cortical and posterior subcapsular cataract was observed. Conclusions: The results of present meta-analysis indicate that postmenopausal hormone use may play a protective role in cataract development.	[Lai, Kairan; Cui, Jiantao; Ni, Shuang; Zhang, Yidong; Yao, Ke] Zhejiang Univ, Sch Med, Ctr Eye, Affiliated Hosp 2, Hangzhou 310003, Zhejiang, Peoples R China; [He, Jiliang] Zhejiang Univ, Sch Med, Inst Environm Med, Hangzhou 310003, Zhejiang, Peoples R China; [Yao, Ke] Zhejiang Prov Key Lab Ophthalmol, Hangzhou, Zhejiang, Peoples R China	Zhejiang University; Zhejiang University	Yao, K (corresponding author), Zhejiang Univ, Sch Med, Ctr Eye, Affiliated Hosp 2, Hangzhou 310003, Zhejiang, Peoples R China.	xlren@zju.edu.cn	Yao, Ke/AAM-6866-2021	Yao, Ke/0000-0002-6764-7365	National Natural Science Foundation of China [81130018, 81371001]; National "Twelfth Five-Year" Plan for Science & Technology Support of China [2012BAI08B01]; Zhejiang Key Innovation Team Project of China [2009R50039]; Zhejiang Key Laboratory Fund of China [2011E10006]; Chinese Ministry of Health	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National "Twelfth Five-Year" Plan for Science & Technology Support of China; Zhejiang Key Innovation Team Project of China; Zhejiang Key Laboratory Fund of China; Chinese Ministry of Health	The present study was supported by the Key Program of National Natural Science Foundation of China (Grant No. 81130018), Program of National Natural Science Foundation of China (No. 81371001), National "Twelfth Five-Year" Plan for Science & Technology Support of China (No. 2012BAI08B01), Zhejiang Key Innovation Team Project of China (2009R50039), Zhejiang Key Laboratory Fund of China (2011E10006) and Project of National Clinical Key Discipline of Chinese Ministry of Health. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ABRAHAM S, 1995, MATURITAS, V21, P91, DOI 10.1016/0378-5122(94)00881-7; Aina FO, 2006, EYE, V20, P417, DOI 10.1038/sj.eye.6701877; BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446; Beral V, 2005, LANCET, V365, P1543, DOI 10.1016/S0140-6736(05)66455-0; Bigsby RM, 1999, P NATL ACAD SCI USA, V96, P9328, DOI 10.1073/pnas.96.16.9328; Chang JR, 2011, OPHTHALMOLOGY, V118, P2113, DOI 10.1016/j.ophtha.2011.03.032; Cumming RG, 1997, AM J EPIDEMIOL, V145, P242; Davis VL, 2002, P NATL ACAD SCI USA, V99, P9427, DOI 10.1073/pnas.132247999; Defay R, 2003, ANN EPIDEMIOL, V13, P638, DOI 10.1016/S1047-2797(03)00058-9; delCastillo JMB, 1997, OPHTHALMOLOGY, V104, P970; Delcourt C, 2000, AM J EPIDEMIOL, V151, P497; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Durant JS, 2006, EYE, V20, P1254, DOI 10.1038/sj.eye.6702087; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Freeman EE, 2004, EPIDEMIOLOGY, V15, P451, DOI 10.1097/01.ede.0000129517.92192.29; Freeman EE, 2001, ARCH OPHTHALMOL-CHIC, V119, P1687; Gray S, 2003, LANCET, V362, P1332, DOI 10.1016/S0140-6736(03)14598-9; Hales AM, 1997, J EXP MED, V185, P273, DOI 10.1084/jem.185.2.273; HALES AM, 1994, CURR EYE RES, V13, P885, DOI 10.3109/02713689409015091; Hamling J, 2008, STAT MED, V27, P954, DOI 10.1002/sim.3013; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; HILLER R, 1986, AM J EPIDEMIOL, V124, P916, DOI 10.1093/oxfordjournals.aje.a114481; Kanthan GL, 2010, ACTA OPHTHALMOL, V88, P773, DOI 10.1111/j.1755-3768.2009.01565.x; Klein B E, 1993, Trans Am Ophthalmol Soc, V91, P517; Klein BEK, 2000, AM J OPHTHALMOL, V130, P322, DOI 10.1016/S0002-9394(00)00474-8; KLEIN BEK, 1994, ARCH OPHTHALMOL-CHIC, V112, P85, DOI 10.1001/archopht.1994.01090130095025; KLEIN BEK, 1992, OPHTHALMOLOGY, V99, P546; Leske MC, 2000, OPHTHALMOLOGY, V107, P1267, DOI 10.1016/S0161-6420(00)00155-X; Lindblad BE, 2010, OPHTHALMOLOGY, V117, P424, DOI 10.1016/j.ophtha.2009.07.046; McCarty CA, 1999, AM J OPHTHALMOL, V128, P446, DOI 10.1016/S0002-9394(99)00218-4; Mitchell P, 1997, OPHTHALMOLOGY, V104, P581, DOI 10.1016/S0161-6420(97)30266-8; Moher D, 2009, PLOS MED, V6, DOI [10.1371/journal.pmed.1000097, 10.1136/bmj.b4037]; MOORADIAN AD, 1993, J STEROID BIOCHEM, V45, P509, DOI 10.1016/0960-0760(93)90166-T; Nirmalan PK, 2004, INVEST OPHTH VIS SCI, V45, P4273, DOI 10.1167/iovs.04-0285; Noran NH, 2007, ASIA-PAC J PUBLIC HE, V19, P23, DOI 10.1177/10105395070190020501; Ogueta SB, 1999, INVEST OPHTH VIS SCI, V40, P1906; Pascolini D, 2012, BRIT J OPHTHALMOL, V96, P614, DOI 10.1136/bjophthalmol-2011-300539; Pelit A, 2007, TURK KLIN TIP BILIM, V27, P811; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; Uncu G, 2006, GYNECOL ENDOCRINOL, V22, P501, DOI 10.1080/09513590600917919; Wang XF, 2003, INVEST OPHTH VIS SCI, V44, P2067, DOI 10.1167/iovs.02-0841; Weintraub JM, 2002, OPHTHALMIC EPIDEMIOL, V9, P179, DOI 10.1076/opep.9.3.179.1513; Wells GA., 2012, NEWCASTLE OTTAWA SCA; WOOLF B, 1955, ANN HUM GENET, V19, P251, DOI 10.1111/j.1469-1809.1955.tb01348.x; Worzala K, 2001, ARCH INTERN MED, V161, P1448, DOI 10.1001/archinte.161.11.1448; Younan C, 2002, AM J EPIDEMIOL, V155, P997, DOI 10.1093/aje/155.11.997; ZHANG JJ, 1994, J CLIN INVEST, V94, P1690, DOI 10.1172/JCI117514	47	18	18	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 24	2013	8	10							e78647	10.1371/journal.pone.0078647	http://dx.doi.org/10.1371/journal.pone.0078647			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	241FR	24205286	Green Published, Green Submitted, gold			2023-01-03	WOS:000326152300076
J	Bag, P; Ojha, D; Mukherjee, H; Halder, UC; Mondal, S; Chandra, NS; Nandi, S; Sharon, A; Sarkar, MC; Chakrabarti, S; Chattopadhyay, D				Bag, Paromita; Ojha, Durbadal; Mukherjee, Hemanta; Halder, Umesh Chandra; Mondal, Supriya; Chandra, Nidhi S.; Nandi, Suman; Sharon, Ashoke; Sarkar, Mamta Chawla; Chakrabarti, Sekhar; Chattopadhyay, Debprasad			An Indole Alkaloid from a Tribal Folklore Inhibits Immediate Early Event in HSV-2 Infected Cells with Therapeutic Efficacy in Vaginally Infected Mice	PLOS ONE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; ACYCLOVIR-RESISTANT; GENITAL HERPES; IN-VITRO; SIMPLEX; HARMALINE; GENE; ACTIVATION; MECHANISMS; HARMINE	Herpes genitalis, caused by HSV-2, is an incurable genital ulcerative disease transmitted by sexual intercourse. The virus establishes life-long latency in sacral root ganglia and reported to have synergistic relationship with HIV-1 transmission. Till date no effective vaccine is available, while the existing therapy frequently yielded drug resistance, toxicity and treatment failure. Thus, there is a pressing need for non-nucleotide antiviral agent from traditional source. Based on ethnomedicinal use we have isolated a compound 7-methoxy-1-methyl-4,9-dihydro-3H-pyrido[3,4-b]indole (HM) from the traditional herb Ophiorrhiza nicobarica Balkr, and evaluated its efficacy on isolates of HSV-2 in vitro and in vivo. The cytotoxicity (CC50), effective concentrations (EC50) and the mode of action of HM was determined by MTT, plaque reduction, time-of-addition, immunofluorescence (IFA), Western blot, qRT-PCR, EMSA, supershift and co-immunoprecipitation assays; while the in vivo toxicity and efficacy was evaluated in BALB/c mice. The results revealed that HM possesses significant anti-HSV-2 activity with EC50 of 1.1-2.8 mu g/ml, and selectivity index of >20. The time kinetics and IFA demonstrated that HM dose dependently inhibited 50-99% of HSV-2 infection at 1.5-5.0 mu g/ml at 2-4 h post-infection. Further, HM was unable to inhibit viral attachment or penetration and had no synergistic interaction with acyclovir. Moreover, Western blot and qRT-PCR assays demonstrated that HM suppressed viral IE gene expression, while the EMSA and co-immunoprecipitation studies showed that HM interfered with the recruitment of LSD-1 by HCF-1. The in vivo studies revealed that HM at its virucidal concentration was nontoxic and reduced virus yield in the brain of HSV-2 infected mice in a concentration dependent manner, compared to vaginal tissues. Thus, our results suggest that HM can serve as a prototype to develop non-nucleotide antiviral lead targeting the viral IE transcription for the management of HSV-2 infections.	[Bag, Paromita; Ojha, Durbadal; Mukherjee, Hemanta; Mondal, Supriya; Chandra, Nidhi S.; Chakrabarti, Sekhar; Chattopadhyay, Debprasad] ID & BG Hosp, ICMR Virus Unit, Kolkata, India; [Halder, Umesh Chandra; Nandi, Suman; Sarkar, Mamta Chawla; Chakrabarti, Sekhar] Natl Inst Cholera & Enter Dis, Kolkata, India; [Sharon, Ashoke] Birla Inst Technol, Dept Appl Chem, Ranchi, Bihar, India	Indian Council of Medical Research (ICMR); ICMR - National Institute of Cholera & Enteric Diseases (NICED); ICMR - Virus Unit, Kolkata; Indian Council of Medical Research (ICMR); ICMR - National Institute of Cholera & Enteric Diseases (NICED); Birla Institute of Technology Mesra	Chattopadhyay, D (corresponding author), ID & BG Hosp, ICMR Virus Unit, Kolkata, India.	debprasadc@yahoo.co.in	Sharon, Ashoke/C-3916-2009; Sharon, Ashoke/GYU-7600-2022	Sharon, Ashoke/0000-0001-5738-1607; Sharon, Ashoke/0000-0001-5738-1607; CHATTOPADHYAY, Dr DEBPRASAD/0000-0002-7999-329X	Department of Biotechnology [BT/PR13759/PBD/ 17/686/2010]; Indian Council of Medical Research, New Delhi [45/2 /2010/PHA -BMS]	Department of Biotechnology; Indian Council of Medical Research, New Delhi(Indian Council of Medical Research (ICMR))	The authors acknowledge financial support from the Department of Biotechnology (BT/PR13759/PBD/ 17/686/2010) and the Indian Council of Medical Research (45/2 /2010/PHA -BMS), New Delhi. The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Akhtar J, 2009, FEBS J, V276, P7228, DOI 10.1111/j.1742-4658.2009.07402.x; Bag P, 2012, VIROL J, V9, DOI 10.1186/1743-422X-9-98; Berrougui H, 2006, PHARMACOL RES, V54, P150, DOI 10.1016/j.phrs.2006.04.001; CHATIS PA, 1991, VIROLOGY, V180, P793, DOI 10.1016/0042-6822(91)90093-Q; Chattopadhyay D, 2006, CHEMOTHERAPY, V52, P151, DOI 10.1159/000092859; Chattopadhyay Debprasad, 2007, Oriental Pharmacy and Experimental Medicine, V7, P395; Chiang LC, 2003, J ANTIMICROB CHEMOTH, V52, P194, DOI 10.1093/jac/dkg291; COCKTON JR, 1952, J PHARM PHARMACOL, V4, P959, DOI 10.1111/j.2042-7158.1952.tb13229.x; Corey L, 2004, JAIDS-J ACQ IMM DEF, V35, P435, DOI 10.1097/00126334-200404150-00001; DAGAR HS, 1991, ECON BOT, V45, P114, DOI 10.1007/BF02860056; FELSER JM, 1988, J VIROL, V62, P2076, DOI 10.1128/JVI.62.6.2076-2082.1988; Frazia SL, 2006, ANTIVIR THER, V11, P995; Ghosh S, 2012, J ETHNOPHARMACOL, V142, P714, DOI 10.1016/j.jep.2012.05.048; GIUS D, 1989, J VIROL, V63, P555, DOI 10.1128/JVI.63.2.555-563.1989; GNANN JW, 1983, PHARMACOTHERAPY, V3, P275; Habif T, 2004, WARTS HERPES SIMPLEX, P381; Jahaniani F, 2005, PHYTOCHEMISTRY, V66, P1581, DOI 10.1016/j.phytochem.2005.04.035; Kanekiyo K, 2007, BIOL PHARM BULL, V30, P1573, DOI 10.1248/bpb.30.1573; Khandelwal M, 2006, OBSTET GYNECOL, V107, P740, DOI 10.1097/01.AOG.0000202543.49213.6c; King NJC, 1998, J IMMUNOL, V160, P1173; Kleymann Gerald, 2003, Herpes, V10, P46; Kurokawa M, 2001, J PHARMACOL EXP THER, V297, P372; Liang Y, 2009, NAT MED, V15, P1312, DOI 10.1038/nm.2051; Lin LT, 2011, J VIROL, V85, P4386, DOI 10.1128/JVI.01492-10; Mayaud P, 2001, BRIT MED BULL, V58, P129, DOI 10.1093/bmb/58.1.129; Morfin F, 2003, J CLIN VIROL, V26, P29, DOI 10.1016/S1386-6532(02)00263-9; Nagot N, 2007, NEW ENGL J MED, V356, P790, DOI 10.1056/NEJMoa062607; OSTROVE JM, 1987, J VIROL, V61, P3726, DOI 10.1128/JVI.61.12.3726-3732.1987; Piret J, 2002, ANTIMICROB AGENTS CH, V46, P2933, DOI 10.1128/AAC.46.9.2933-2942.2002; Posavad CM, 1997, P NATL ACAD SCI USA, V94, P10289, DOI 10.1073/pnas.94.19.10289; REED L. J., 1938, AMER JOUR HYG, V27, P493; Reyes M, 2003, ARCH INTERN MED, V163, P76, DOI 10.1001/archinte.163.1.76; Sandri-Goldin RM., 2006, ALPH HERP MOL CELL; Shia SY, 2007, J CHROMATOGR B, V859, P119, DOI 10.1016/j.jchromb.2007.09.016; Stanberry LR, 2004, HERPES S3, V11, p161A; Stanford JA, 1998, NEUROSCI LETT, V241, P41, DOI 10.1016/S0304-3940(97)00974-9; Swetter SM, 1998, J INFECT DIS, V177, P543, DOI 10.1086/514229; VILLAMIL SM, 1995, ANTIVIR CHEM CHEMOTH, V6, P239, DOI 10.1177/095632029500600406; Wang QY, 2005, P NATL ACAD SCI USA, V102, P16055, DOI 10.1073/pnas.0505850102; Wang X, 2008, J SEP SCI, V31, P3543, DOI 10.1002/jssc.200800322; Zheng XY, 2009, ARCH PHARM RES, V32, P1245, DOI 10.1007/s12272-009-1910-x; Zhou CH, 2002, J VIROL, V76, P5893, DOI 10.1128/JVI.76.12.5893-5904.2002	42	19	21	0	18	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 22	2013	8	10							e77937	10.1371/journal.pone.0077937	http://dx.doi.org/10.1371/journal.pone.0077937			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	239OF	24167591	Green Published, gold, Green Submitted			2023-01-03	WOS:000326034500050
J	Cramer, H; Krucoff, C; Dobos, G				Cramer, Holger; Krucoff, Carol; Dobos, Gustav			Adverse Events Associated with Yoga: A Systematic Review of Published Case Reports and Case Series	PLOS ONE			English	Review							NEUROPATHY; GLAUCOMA; TEACHER; NECK	While yoga is gaining increased popularity in North America and Europe, its safety has been questioned in the lay press. The aim of this systematic review was to assess published case reports and case series on adverse events associated with yoga. Medline/Pubmed, Scopus, CAMBase, IndMed and the Cases Database were screened through February 2013; and 35 case reports and 2 case series reporting a total of 76 cases were included. Ten cases had medical preconditions, mainly glaucoma and osteopenia. Pranayama, hatha yoga, and Bikram yoga were the most common yoga practices; headstand, shoulder stand, lotus position, and forceful breathing were the most common yoga postures and breathing techniques cited. Twenty-seven adverse events (35.5%) affected the musculoskeletal system; 14 (18.4%) the nervous system; and 9 (11.8%) the eyes. Fifteen cases (19.7%) reached full recovery; 9 cases (11.3%) partial recovery; 1 case (1.3%) no recovery; and 1 case (1.3%) died. As any other physical or mental practice, yoga should be practiced carefully under the guidance of a qualified instructor. Beginners should avoid extreme practices such as headstand, lotus position and forceful breathing. Individuals with medical preconditions should work with their physician and yoga teacher to appropriately adapt postures; patients with glaucoma should avoid inversions and patients with compromised bone should avoid forceful yoga practices.	[Cramer, Holger; Dobos, Gustav] Univ Duisburg Essen, Fac Med, Kliniken Essen Mitte, Dept Internal & Integrat Med, Essen, Germany; [Krucoff, Carol] Duke Univ, Duke Integrat Med, Durham, NC USA	Kliniken Essen-Mitte; University of Duisburg Essen; Duke University	Cramer, H (corresponding author), Univ Duisburg Essen, Fac Med, Kliniken Essen Mitte, Dept Internal & Integrat Med, Essen, Germany.	h.cramer@kliniken-essen-mitte.de	Cramer, Holger/AAH-1794-2019	Cramer, Holger/0000-0002-3640-8046				Barnes Patricia M, 2004, Adv Data, P1; Barnes Patricia M, 2008, Natl Health Stat Report, P1; Barsky AJ, 1997, JAMA-J AM MED ASSOC, V278, P673, DOI 10.1001/jama.278.8.673; Baskaran M, 2006, OPHTHALMOLOGY, V113, P1327, DOI 10.1016/j.ophtha.2006.02.063; Bertschinger DR, 2007, BRIT J OPHTHALMOL, V91, P1413, DOI 10.1136/bjo.2007.114546; Bianchi G., 2004, J ORTHOP TRAUMATOL, V5, P188, DOI [10.1007/s10195-004-0069-y, DOI 10.1007/S10195-004-0069-Y]; Bikram Yoga College of India, 2012, BIKR YOG; Birdee GS, 2008, J GEN INTERN MED, V23, P1653, DOI 10.1007/s11606-008-0735-5; Biswas R, 2003, INT J CLIN PRACT, V57, P340; Biswas R, 2002, INT J CLIN PRACT, V56, P723; Brauer Jeremy A, 2011, Dermatol Online J, V17, P14; Broad WJ, 2012, NY TIMES; Bussing A, 2011, EVID-BASED COMPL ALT, V2011, DOI 10.1155/2011/329023; Caso V, 2005, FRONT NEUROL NEUROSC, V20, P44, DOI 10.1159/000088134; Chakraborty J, 2011, BMJ CASE REPORTS; Choi Y, 2009, AM J EMERG MED, V27, P956, DOI 10.1016/j.ajem.2008.07.035; CHUSID J, 1971, J AMER MED ASSOC, V217, P827, DOI 10.1001/jama.1971.03190060065025; COHEN JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P1360, DOI 10.1001/archopht.1995.01100110020011; CORRIGAN GE, 1969, J AMER MED ASSOC, V210, P1923, DOI 10.1001/jama.1969.03160360069025; Cramer H, 2013, BMC COMPLEM ALTERN M, V13, DOI 10.1186/1472-6882-13-172; Cramer H, 2013, J ALTERN COMPLEM MED, V19, P536, DOI 10.1089/acm.2011.0885; Cramer H, 2013, CLIN J PAIN, V29, P450, DOI 10.1097/AJP.0b013e31825e1492; Cramer H, 2013, BMC PSYCHIATRY, V13, DOI 10.1186/1471-244X-13-32; Cramer H, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-412; Cramer H, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/863905; Cushman A, 1994, YOGA J, V118, P47; Dacci P, 2012, NEUROL SCI; Dangerfield A, 2009, BBC NEWS MAGAZI 0123; de Barros DSM, 2008, OPHTHAL SURG LAS IM, V39, P339; De Michaelis E, 2005, HIST MODERN YOGA PAT; FAHMY JA, 1973, ACTA OPHTHALMOL, V51, P80; Farooq MU, 2008, J BRACHIAL PLEX PERI, V3, DOI 10.1186/1749-7221-3-2; Feuerstein G., 1998, YOGA TRADITION ITS H; Fishman L., 2009, INT J YOGA THER, V19, P47, DOI [DOI 10.17761/IJYT.19.1.922087896T1H2180, 10.17761/ijyt.19.1.922087896t1h2180]; Fong K Y, 1993, Clin Exp Neurol, V30, P104; Gallardo MJ, 2006, ADV THER, V23, P921, DOI 10.1007/BF02850214; GEORGE HR, 1970, BRIT J PSYCHIAT, V117, P521, DOI 10.1192/bjp.117.540.521; Grant D, 2012, NEW YORK OBSERV 1212; HANUS SH, 1977, ARCH NEUROL-CHICAGO, V34, P574, DOI 10.1001/archneur.1977.00500210076015; Hari Yogi, 2006, HATHA YOGA PRADIPIKA; Hillsman D, 2005, CHEST, V127, P1863, DOI 10.1378/chest.127.5.1863; Hwa Charlotte, 2011, J Am Acad Dermatol, V65, pe149, DOI 10.1016/j.jaad.2011.07.027; Iyengar B. K. S., 1966, LIGHT YOGA; Johnson DB, 2004, CHEST, V125, P1951, DOI 10.1378/chest.125.5.1951; Kashyap AS, 2007, EMERG MED J, V24, P231, DOI 10.1136/emj.2006.036459; KENNEDY RB, 1976, AM J PSYCHIAT, V133, P1326; KHALIL PN, 2008, MMW FORTSCH MEDIZIN, V150, P39; Kim NN, 2010, J FAM PRACTICE, V59, P399; Kohanzadeh S, 2012, AM SURGEON, V78, pE361; Krucoff C, 2003, YOGA J, V120-124, P203; Kugler J, 1972, Med Klin, V67, P1195; Lamb T, 2006, YOGA STAT DEMOGRAPHI; Le Corroller T, 2012, AM J ROENTGENOL, V199, P413, DOI 10.2214/AJR.11.7440; LOVELLSMITH HD, 1985, NEW ZEAL MED J, V98, P443; Lu JS, 2007, AM J PSYCHIAT, V164, P1761, DOI 10.1176/appi.ajp.2007.07060960; Macy D, 2008, YOGA J; MARGO CE, 1992, AM J OPHTHALMOL, V113, P726, DOI 10.1016/S0002-9394(14)74810-X; MATTIO TG, 1992, NEUROLOGY, V42, P1636, DOI 10.1212/WNL.42.8.1636; McCall T, 2013, YOGA J; Meshramkar R, 2007, INT DENT J, V57, P184; Mikkonen J, 2008, INT J YOGA THER, V18, P59, DOI DOI 10.17761/IJYT.18.1.L0748P25K2558V77; NAGLER W, 1973, ARCH PHYS MED REHAB, V54, P237; Patel S C, 2008, J Orthop Surg (Hong Kong), V16, P378; Penman Stephen, 2012, Int J Yoga, V5, P92, DOI 10.4103/0973-6131.98217; Reynolds CJ, 2012, BMJ CASE REP, V2012; RICE R, 1985, AM J OPHTHALMOL, V100, P738, DOI 10.1016/0002-9394(85)90634-8; Schievink WI, 2007, HEADACHE, V47, P284, DOI 10.1111/j.1526-4610.2006.00696.x; Shah NJ, 2009, INDIAN J OPHTHALMOL, V57, P69, DOI 10.4103/0301-4738.44496; Sharma H, 2007, BRIT J SPORT MED, V41, P688, DOI 10.1136/bjsm.2007.036087; Sharma VP, 2007, INT J YOGA THERAP, V17, P75; Sinaki M, 2013, PAIN PRACT, V13, P68, DOI 10.1111/j.1533-2500.2012.00545.x; TAMARIN FM, 1988, THORAX, V43, P731, DOI 10.1136/thx.43.9.731; Vishnu-devananda S, 1988, COMPLETE ILLUSTRATED; VOGEL CM, 1991, NEUROLOGY, V41, P605, DOI 10.1212/WNL.41.4.605; Walker M, 2005, NEUROLOGIST, V11, P176, DOI 10.1097/01.nrl.0000159986.75426.d5; Yeh TS, 2011, J MED ULTRASOUND, V19, P91, DOI 10.1016/j.jmu.2011.08.004; Yochum TR, 1997, J MANIP PHYSIOL THER, V20, P56; Yorston G.A., 2001, MENTAL HLTH RELIG CU, V4, P209, DOI DOI 10.1080/713685624; Yoshikawa Y, 2013, YOGA J	79	75	75	0	43	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 16	2013	8	10							e75515	10.1371/journal.pone.0075515	http://dx.doi.org/10.1371/journal.pone.0075515			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	239JR	24146758	gold, Green Published, Green Submitted			2023-01-03	WOS:000326019400009
J	Behar, M; Barken, D; Werner, SL; Hoffmann, A				Behar, Marcelo; Barken, Derren; Werner, Shannon L.; Hoffmann, Alexander			The Dynamics of Signaling as a Pharmacological Target	CELL			English	Article							NF-KAPPA-B; GENE-EXPRESSION; TEMPORAL CONTROL; CELL FATE; KINASE; SPECIFICITY; INHIBITION; ACTIVATION; INFLAMMATION; MECHANISMS	Highly networked signaling hubs are often associated with disease, but targeting them pharmacologically has largely been unsuccessful in the clinic because of their functional pleiotropy. Motivated by the hypothesis that a dynamic signaling code confers functional specificity, we investigated whether dynamic features may be targeted pharmacologically to achieve therapeutic specificity. With a virtual screen, we identified combinations of signaling hub topologies and dynamic signal profiles that are amenable to selective inhibition. Mathematical analysis revealed principles that may guide stimulus-specific inhibition of signaling hubs, even in the absence of detailed mathematical models. Using the NFkB signaling module as a test bed, we identified perturbations that selectively affect the response to cytokines or pathogen components. Together, our results demonstrate that the dynamics of signaling may serve as a pharmacological target, and we reveal principles that delineate the opportunities and constraints of developing stimulus-specific therapeutic agents aimed at pleiotropic signaling hubs.	[Behar, Marcelo; Barken, Derren; Werner, Shannon L.; Hoffmann, Alexander] Univ Calif San Diego, Dept Chem & Biochem, Signaling Syst Lab, La Jolla, CA 92093 USA; [Behar, Marcelo; Hoffmann, Alexander] Univ Calif San Diego, San Diego Ctr Syst Biol, La Jolla, CA 92093 USA; [Behar, Marcelo; Hoffmann, Alexander] Univ Calif Los Angeles, Computat Biosci Inst, Los Angeles, CA 90025 USA; [Behar, Marcelo; Hoffmann, Alexander] Univ Calif Los Angeles, Dept Microbiol Immunol & Mol Genet, Los Angeles, CA 90025 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Hoffmann, A (corresponding author), Univ Calif San Diego, Dept Chem & Biochem, Signaling Syst Lab, La Jolla, CA 92093 USA.	ahoffmann@ucla.edu			NIH [P50 GM085764, R01 GM 089976, R01 GM072024, R01 CA141722, R01 GM071573]; Cancer Research Institute; NATIONAL CANCER INSTITUTE [R01CA141722] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM071862, R01GM089976, R01GM072024, R01GM071573, P50GM085764] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Cancer Research Institute; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We acknowledge helpful discussions with members of the San Diego Center of Systems Biology, critical reading by P. Loriaux (UCSD), and helpful suggestions by an anonymous reviewer. The work presented here was supported by grants from the NIH P50 GM085764, R01 GM 089976, R01 GM072024, R01 CA141722, R01 GM071573, and a postdoctoral research fellowship from the Cancer Research Institute.	Bardwell L, 2006, BIOCHEM SOC T, V34, P837, DOI 10.1042/BST0340837; Becker V, 2012, ADV EXP MED BIOL, V736, P313, DOI 10.1007/978-1-4419-7210-1_18; Behar M, 2007, P NATL ACAD SCI USA, V104, P16146, DOI 10.1073/pnas.0703894104; Behar M, 2013, BIOPHYS J, V105, P231, DOI 10.1016/j.bpj.2013.05.013; Behar M, 2010, CURR OPIN GENET DEV, V20, P684, DOI 10.1016/j.gde.2010.09.007; Berger SI, 2011, WIRES SYST BIOL MED, V3, P129, DOI 10.1002/wsbm.114; Bitterman PB, 2012, CELL CYCLE, V11, P1097, DOI 10.4161/cc.11.6.19610; Brennan P, 1996, BIOCHEM J, V320, P975, DOI 10.1042/bj3200975; Chalmers CJ, 2007, CELL SIGNAL, V19, P695, DOI 10.1016/j.cellsig.2006.09.001; Chavali S, 2010, BMC SYST BIOL, V4, DOI 10.1186/1752-0509-4-78; Cohen P, 2002, NAT REV DRUG DISCOV, V1, P309, DOI 10.1038/nrd773; DiDonato JA, 2012, IMMUNOL REV, V246, P379, DOI 10.1111/j.1600-065X.2012.01099.x; Force T, 2007, NAT REV CANCER, V7, P332, DOI 10.1038/nrc2106; Frelin C, 2005, BLOOD, V105, P804, DOI 10.1182/blood-2004-04-1463; Gandhi TKB, 2006, NAT GENET, V38, P285, DOI 10.1038/ng1747; Gao C, 2010, CELL SIGNAL, V22, P717, DOI 10.1016/j.cellsig.2009.11.021; Ghoreschi K, 2009, NAT IMMUNOL, V10, P356, DOI 10.1038/ni.1701; Haney S, 2010, BMC SYST BIOL, V4, DOI 10.1186/1752-0509-4-119; Hao N, 2008, J BIOL CHEM, V283, P33798, DOI 10.1074/jbc.C800179200; Hoffmann A, 2006, IMMUNOL REV, V210, P171, DOI 10.1111/j.0105-2896.2006.00375.x; Hoffmann A, 2002, SCIENCE, V298, P1241, DOI 10.1126/science.1071914; Karin M, 2008, CELL RES, V18, P334, DOI 10.1038/cr.2008.30; Kearns JD, 2006, J CELL BIOL, V173, P659, DOI 10.1083/jcb.200510155; KLUSSMANN E, 2008, PROTEIN PROTEIN INTE; Komarova NL, 2005, MOL SYST BIOL, V1, DOI 10.1038/msb4100031; Kubota H, 2012, MOL CELL, V46, P820, DOI 10.1016/j.molcel.2012.04.018; Lin WW, 2007, J CLIN INVEST, V117, P1175, DOI 10.1172/JCI31537; Ma'ayan A, 2007, MT SINAI J MED, V74, P27, DOI 10.1002/msj.20002; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Oda K, 2006, MOL SYST BIOL, V2, DOI 10.1038/msb4100057; Park SH, 2003, SCIENCE, V299, P1061, DOI 10.1126/science.1076979; Purvis JE, 2013, CELL, V152, P945, DOI 10.1016/j.cell.2013.02.005; Purvis JE, 2012, SCIENCE, V336, P1440, DOI 10.1126/science.1218351; Roering Michael, 2012, Critical Reviews in Oncogenesis, V17, P97; Schneider A, 2012, BIOESSAYS, V34, P542, DOI 10.1002/bies.201100172; Schrofelbauer B, 2012, MOL CELL, V47, P111, DOI 10.1016/j.molcel.2012.04.020; Seki E, 2012, GASTROENTEROLOGY, V143, P307, DOI 10.1053/j.gastro.2012.06.004; Sung MH, 2004, MOL PHARMACOL, V66, P70, DOI 10.1124/mol.66.1.70; Sung MH, 2008, MOL PHARMACOL, V74, P1215, DOI 10.1124/mol.108.049114; Weinberg RA, 2007, BIOL CANC; Werner SL, 2005, SCIENCE, V309, P1857, DOI 10.1126/science.1113319; Zalatan JG, 2012, SCIENCE, V337, P1218, DOI 10.1126/science.1220683; Zhang X, 2008, TRENDS BIOTECHNOL, V26, P295, DOI 10.1016/j.tibtech.2008.02.008	43	94	96	0	35	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 10	2013	155	2					448	461		10.1016/j.cell.2013.09.018	http://dx.doi.org/10.1016/j.cell.2013.09.018			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	235LH	24120141	Green Accepted, Bronze			2023-01-03	WOS:000325719800020
J	Ding, GX; Feng, CC; Jiang, HW; Ding, Q; Zhang, LM; Na, R; Xu, H; Liu, J				Ding, Guanxiong; Feng, Chenchen; Jiang, Haowen; Ding, Qiang; Zhang, Limin; Na, Rong; Xu, Hua; Liu, Jun			Combination of Rapamycin, CI-1040, and 17-AAG Inhibits Metastatic Capacity of Prostate Cancer via Slug Inhibition	PLOS ONE			English	Article							TRANSCRIPTION FACTOR SNAIL; E-CADHERIN EXPRESSION; MESENCHYMAL TRANSITION; GENE-EXPRESSION; CELLS; CARCINOMA; PATHWAYS; TRANSFORMATION; STATISTICS; RESISTANCE	Though prostate cancer (PCa) has slow progression, the hormone refractory (HRCP) and metastatic entities are substantially lethal and lack effective treatments. Transcription factor Slug is critical in regulating metastases of various tumors including PCa. Here we studied targeted therapy against Slug using combination of 3 drugs targeting 3 pathways respectively converging via Slug and further regulating PCa metastasis. Using in vitro assays we confirmed that Slug up-regulation incurred inhibition of E-cadherin that was anti-metastatic, and inhibited Bim-regulated cell apoptosis in PCa. Upstream PTEN/Akt, mTOR, Erk, and AR/Hsp90 pathways were responsible for Slug up-regulation and each of these could be targeted by rapamycin, CI-1040, and 17-AAG respectively. In 4 PCa cell lines with different traits in terms of PTEN loss and androgen sensitivity we tested the efficacy of mono-and combined therapy with the drugs. We found that metastatic capacity of the cells was maximally inhibited only when all 3 drugs were combined, due to the crosstalk between the pathways. 17-AAG decreases Slug expression via blockade of HSP90-dependent AR stability. Combination of rapamycin and CI-1040 diminishes invasiveness more potently in PCa cells that are androgen insensitive and with PTEN loss. Slug inhibited Bim-mediated apoptosis that could be rescued by mTOR/Erk/HSP90 inhibitors. Using mouse models for circulating PCa DNA quantification, we found that combination of mTOR/Erk/HSP90 inhibitors reduced circulating PCa cells in vivo significantly more potently than combination of 2 or monotherapy. Conclusively, combination of mTOR/Erk/Hsp90 inhibits metastatic capacity of prostate cancer via Slug inhibition.	[Ding, Guanxiong; Feng, Chenchen; Jiang, Haowen; Ding, Qiang; Zhang, Limin; Na, Rong; Xu, Hua; Liu, Jun] Fudan Univ, Huashan Hosp, Dept Urol, Shanghai 200433, Peoples R China	Fudan University	Liu, J (corresponding author), Fudan Univ, Huashan Hosp, Dept Urol, Shanghai 200433, Peoples R China.	drliujun@126.com	Xu, Hua/AAH-2453-2019; Na, Rong/AAN-8655-2021	Na, Rong/0000-0001-7470-5108; Feng, Chenchen/0000-0002-1854-356X	Fudan University [144]; National Natural Science Foundation of China [NSFC-81202002]	Fudan University; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This study was supported in part by Youth Elites Scientific Funding of Fudan University (No. 144) and Youth Scientific Funding of National Natural Science Foundation of China (NSFC-81202002). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Chen CD, 2004, NAT MED, V10, P33, DOI 10.1038/nm972; Chen Y, 2009, LANCET ONCOL, V10, P981, DOI 10.1016/S1470-2045(09)70229-3; Cooper CR, 2003, CANCER-AM CANCER SOC, V97, P739, DOI 10.1002/cncr.11181; Csermely P, 1998, PHARMACOL THERAPEUT, V79, P129, DOI 10.1016/S0163-7258(98)00013-8; Graham TR, 2008, CANCER RES, V68, P2479, DOI 10.1158/0008-5472.CAN-07-2559; Hajra KM, 2002, GENE CHROMOSOME CANC, V34, P255, DOI 10.1002/gcc.10083; He SQ, 2013, INT J ONCOL, V42, P35, DOI 10.3892/ijo.2012.1698; Holzbeierlein J, 2004, AM J PATHOL, V164, P217, DOI 10.1016/S0002-9440(10)63112-4; Hugo H, 2007, J CELL PHYSIOL, V213, P374, DOI 10.1002/jcp.21223; Ivanova L, 2008, AM J PHYSIOL-RENAL, V294, pF1238, DOI 10.1152/ajprenal.00326.2007; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; Jemal A, 2004, CA-CANCER J CLIN, V54, P8, DOI 10.3322/canjclin.54.1.8; Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43; Kolch W, 2000, BIOCHEM J, V351, P289, DOI 10.1042/0264-6021:3510289; Liu J, 2010, PROSTATE, V70, P1768, DOI 10.1002/pros.21213; Malumbres M, 1998, FRONT BIOSCI-LANDMRK, V3, P887; Martin KA, 2002, ADV CANCER RES, V86, P1, DOI 10.1016/S0065-230X(02)86001-8; McCluggage WG, 2011, PATHOLOGY, V43, P420, DOI 10.1097/PAT.0b013e328348a6e7; Moody SE, 2005, CANCER CELL, V8, P197, DOI 10.1016/j.ccr.2005.07.009; Nawshad A, 2005, CELLS TISSUES ORGANS, V179, P11, DOI 10.1159/000084505; Nollet F, 1999, Mol Cell Biol Res Commun, V2, P77, DOI 10.1006/mcbr.1999.0155; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; Peinado HC, 2004, INT J DEV BIOL, V48, P365, DOI 10.1387/ijdb.041794hp; Saegusa M, 2009, AM J PATHOL, V174, P2107, DOI 10.2353/ajpath.2009.081018; Waltering KK, 2012, MOL CELL ENDOCRINOL, V360, P38, DOI 10.1016/j.mce.2011.12.019; Wu J, 2011, ONCOGENE, V30, P4410, DOI 10.1038/onc.2011.149	28	23	23	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 10	2013	8	10							e77400	10.1371/journal.pone.0077400	http://dx.doi.org/10.1371/journal.pone.0077400			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	236QM	24130883	gold, Green Submitted, Green Published			2023-01-03	WOS:000325814200086
J	Kroezen, M; van Dijk, L; Groenewegen, PP; Francke, AL				Kroezen, Marieke; van Dijk, Liset; Groenewegen, Peter P.; Francke, Anneke L.			Knowledge Claims, Jurisdictional Control and Professional Status: The Case of Nurse Prescribing	PLOS ONE			English	Article							ANGLO-SAXON COUNTRIES; HEALTH-CARE WORKFORCE; LEGITIMACY CLAIMS; WORKPLACE; PERSPECTIVES; MEDICINES; ORDER; POWER	Over the past decades, professional boundaries in health care have come under pressure, and the expansion of prescriptive authority to include nurses touches on issues of professional domains and interprofessional competition. Knowledge claims play an important role in achieving jurisdictional control. Knowledge can take on multiple forms, ranging from indeterminate to technical (I/T ratio) and from everyday to exclusive knowledge. To investigate the interrelatedness of jurisdiction, knowledge claims and professional status, we examine which knowledge claims were made by the medical and nursing professions in the Netherlands to secure or obtain, respectively, jurisdictional control over prescribing, and which form this knowledge took. The study is based on thirteen semi-structured stakeholder interviews and an extensive document analysis. We found that the nursing profession in its knowledge claims strongly emphasized the technicality and everyday knowledge character of the prescribing task, by asserting that nurses were already prescribing medicines, albeit on an illegal basis. Their second claim focused on the indeterminate knowledge skills of nurses and stated that nurse prescribing would do justice to nurses' skills and expertise. This is a strong claim in a quest for (higher) professional status. Results showed that the medical profession initially proclaimed that prescribing should be reserved for doctors as it is a task requiring medical knowledge, i.e. indeterminate knowledge. Gradually, however, the medical profession adjusted its claims and tried to reduce nurse prescribing to a task almost exclusively based on technicality knowledge, among others by stating that nurses could prescribe in routine cases, which would generate little professional status. By investigating the form that professional knowledge claims took, this study was able to show the interconnectedness of jurisdictional control, knowledge claims and professional status. Knowledge claims are not mere rhetoric, but actively influence the everyday realities of professional status, interprofessional competition and jurisdictional division between professions.	[Kroezen, Marieke; van Dijk, Liset; Groenewegen, Peter P.; Francke, Anneke L.] Netherlands Inst Hlth Serv Res NIVEL, Utrecht, Netherlands; [Groenewegen, Peter P.] Univ Utrecht, Dept Sociol, Utrecht, Netherlands; [Groenewegen, Peter P.] Univ Utrecht, Dept Human Geog, Utrecht, Netherlands; [Francke, Anneke L.] Vrije Univ Amsterdam, Med Ctr, EMGO Inst Hlth & Care Res EMGO, Dept Publ & Occupat Hlth, Amsterdam, Netherlands	Netherlands Institute for Health Services Research; Utrecht University; Utrecht University; Vrije Universiteit Amsterdam	Kroezen, M (corresponding author), Netherlands Inst Hlth Serv Res NIVEL, Utrecht, Netherlands.	M.Kroezen@nivel.nl		Groenewegen, Peter/0000-0003-2127-8442	Dutch Ministry of Education, Culture and Science	Dutch Ministry of Education, Culture and Science	This study was funded by a grant to NIVEL from the Dutch Ministry of Education, Culture and Science. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aarts J, 2009, HEALTH AFFAIR, V28, P404, DOI 10.1377/hlthaff.28.2.404; Abbott A., 2014, SYSTEM PROFESSIONS E; ADAMSON BJ, 1995, J ADV NURS, V21, P172, DOI 10.1046/j.1365-2648.1995.21010172.x; Allen D, 1997, SOCIOL HEALTH ILL, V19, P498; [Anonymous], 2009, REACT KNMG EV WET BI; Apesoa-Varano EC, 2011, QUAL HEALTH RES, V21, P1469, DOI 10.1177/1049732311412788; Associatie van Eerste, 2007, EADV MAGAZINE, V22, P27; Associatie van Eerste, 2006, EADV MAGAZINE, V2, P94; Ball J., 2009, IMPLEMENTING NURSE P; Bechky BA, 2003, AM J SOCIOL, V109, P720, DOI 10.1086/379527; Buchan J, 2002, B WORLD HEALTH ORGAN, V80, P575; BUCKLEY P, 2006, PHARM J, V277, P394; Cooper R, 2008, J AMBUL CARE MANAG, V31, P244, DOI 10.1097/01.JAC.0000324670.91153.b4; Drennan J., 2009, NATL INDEPENDENT EVA; Fisher R, 2010, INT J NURS PRACT, V16, P579, DOI 10.1111/j.1440-172X.2010.01884.x; Freidson E., 1988, PROFESSION MED STUDY; Gerrish Kate, 2003, Nurs Inq, V10, P103, DOI 10.1046/j.1440-1800.2003.00168.x; Glucksmann MA, 2009, SOCIOLOGY, V43, P878, DOI 10.1177/0038038509340727; Goundrey-Smith S., 2008, PRINCIPLES ELECT PRE, P119; Green J., 2004, QUALITATIVE METHODS; Hendriks AC, 2011, MEDISCH CONTACT, V66, P555; Hirschkorn KA, 2006, SOCIOL HEALTH ILL, V28, P533, DOI 10.1111/j.1467-9566.2006.00506.x; Huisartsen Vereniging Landelijke, 2010, LHV BEZW TEG VOORSCH, P8; Implementatie Commissie Opleidingscontinuum en Taakherschikking, 2003, ZORG MORG FLEX SAM C; Jamous H., 1970, PROFESSIONS PROFESSI; Kaljouw M, 2010, NRC HANDELSBLAD; Kennedy J, 2002, WELOVERWOGEN DOOD; Koninklijke, 2011, NED MAATSCH BEV GEN; Koninklijke, 2006, MEDISCH CONTACT, V18, P728; Koninklijke, 2006, MEDISCH CONTACT, V18, P761; Kroezen M, 2012, INT J NURS STUD, V49, P1002, DOI 10.1016/j.ijnurstu.2012.02.002; Kroezen M, 2011, BMC HEALTH SERV RES, V11, DOI 10.1186/1472-6963-11-127; Lewis R, 2001, NURSE LED PRIMARY CA; MAXQDA, 2007, VERBI SOFTW; McCann T V, 2002, J Psychiatr Ment Health Nurs, V9, P175, DOI 10.1046/j.1365-2850.2002.00454.x; Mclaughlin J, 1998, SOCIOL REV, V46, P781, DOI 10.1111/1467-954X.00140; Nancarrow SA, 2005, SOCIOL HEALTH ILL, V27, P897, DOI 10.1111/j.1467-9566.2005.00463.x; NILSSON M, 1994, LANCET, V344, P1077; Pickard S, 2009, SOCIOLOGY, V43, P250, DOI 10.1177/0038038508101164; Plonczynski D, 2003, NURSE PRESCRIBING, V1, P170; PORTER S, 1992, J ADV NURS, V17, P720, DOI 10.1111/j.1365-2648.1992.tb01970.x; Raadvoor de Volksgezondheid en Zorg, 2002, TAAKH GEZ; Reed MI, 1996, ORGAN STUD, V17, P573, DOI 10.1177/017084069601700402; Sanders T, 2008, SOCIOL HEALTH ILL, V30, P289, DOI 10.1111/j.1467-9566.2007.01052.x; Snelgrove S, 2000, J ADV NURS, V31, P661, DOI 10.1046/j.1365-2648.2000.01321.x; Tong A, 2007, INT J QUAL HEALTH C, V19, P349, DOI 10.1093/intqhc/mzm042; Traynor M, 2010, SOC SCI MED, V71, P1506, DOI 10.1016/j.socscimed.2010.07.029; Van der Peet R, 2010, TIJDSCHRIFT VERPLEEG, V120, P45; Van der Peet R., 2010, TIJDSCHRIFT VERPLEEG, V120, P50; Van Meersbergen W., 2011, WORLD MED J, V57, P126; van Volksgezondheid Ministerie WeS, 2012, MEVABOA3109304 VOLKS; Verpleegkundigen Verzorgenden. Nederland, 2013, VOORSCHR VERPL JAN 2	52	26	26	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 4	2013	8	10							e77279	10.1371/journal.pone.0077279	http://dx.doi.org/10.1371/journal.pone.0077279			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	232JF	24124613	Green Published, gold, Green Submitted			2023-01-03	WOS:000325489100170
J	Reyskens, KMSE; Fisher, TL; Schisler, JC; O'Connor, WG; Rogers, AB; Willis, MS; Planesse, C; Rondeau, P; Bourdon, E; Essop, MF				Reyskens, Kathleen M. S. E.; Fisher, Tarryn-Lee; Schisler, Jonathan C.; O'Connor, Wendi G.; Rogers, Arlin B.; Willis, Monte S.; Planesse, Cynthia; Rondeau, Philippe; Bourdon, Emmanuel; Essop, M. Faadiel			The Maladaptive Effects of HIV Protease Inhibitors (Lopinavir/Ritonavir) on the Rat Heart	PLOS ONE			English	Article							ELEMENT-BINDING PROTEINS; INSULIN SENSITIVITY; PERIPHERAL LIPODYSTROPHY; T-LYMPHOCYTES; ATHEROSCLEROSIS; HYPERLIPIDEMIA; DEGRADATION; PGC-1-ALPHA; PREVALENCE; MECHANISMS	Although antiretroviral treatment decreases HIV-AIDS morbidity/mortality, long-term effects include onset of insulin resistance and cardiovascular diseases. Increased oxidative stress and dysregulation of the ubiquitin-proteasome system (UPS) are implicated in protease-inhibitor (PI)-mediated cardio-metabolic pathophysiology. We hypothesized that PI treatment (Lopinavir/Ritonavir) elevates myocardial oxidative stress and concomitantly inhibits the UPS, thereby attenuating cardiac function. Lopinavir/Ritonavir was dissolved in 1% ethanol (vehicle) and injected into mini-osmotic pumps that were surgically implanted into Wistar rats for 8 weeks vs. vehicle and sham controls. Subsequently, we evaluated metabolic parameters and heart function (ex vivo Langendorff perfusions) at baseline and following ischemia-reperfusion. PI-treated rats exhibited weight gain, increased serum LDL-cholesterol, higher tissue triglycerides (heart, liver), but no evidence of insulin resistance. It also upregulated hepatic gene expression of acetyl-CoA carboxylase beta and 3-hydroxy-3-methylglutaryl-CoA-reductase, key regulators of fatty acid oxidation and cholesterol synthesis, respectively. PI-treated hearts displayed impaired UPS, increased SOD activity and unaltered superoxide levels, and elevated peroxisome proliferator-activated receptor-gamma coactivator 1-alpha (PGC-1 alpha) peptide levels. Perfusion data revealed contractile dysfunction at baseline and following ischemia-reperfusion, while post-ischemic hearts exhibited decreased ATPase specific activity vs. matched controls. Early changes initiated by PI treatment resemble the metabolic syndrome and reflect a pre-atherogenic profile. Moreover, the effects of PIs on cardiac contractile function may in part be triggered by impaired UPS activity together with strain on the mitochondrial energetic system. Our study alerts to cardio-metabolic side effects of PI treatment and raises the question of the most appropriate co-therapies for patients on chronic antiretroviral treatment.	[Reyskens, Kathleen M. S. E.; Fisher, Tarryn-Lee; Essop, M. Faadiel] Univ Stellenbosch, Dept Physiol Sci, Cardiometab Res Grp, ZA-7600 Stellenbosch, South Africa; [Schisler, Jonathan C.; O'Connor, Wendi G.; Rogers, Arlin B.; Willis, Monte S.] Univ N Carolina, Dept Pathol & Lab Med, McAllister Heart Inst, Chapel Hill, NC USA; [Planesse, Cynthia; Rondeau, Philippe; Bourdon, Emmanuel] Univ Reunion, Grp Etud Inflammat Chron & Obes, Plateforme CYROI, St Denis, Reunion, France	Stellenbosch University; University of North Carolina; University of North Carolina Chapel Hill; University of La Reunion	Essop, MF (corresponding author), Univ Stellenbosch, Dept Physiol Sci, Cardiometab Res Grp, ZA-7600 Stellenbosch, South Africa.	mfessop@sun.ac.za	Bourdon, Emmanuel/P-8455-2019; rondeau, philippe/Q-1967-2019; Willis, Monte S/J-9994-2015; rondeau, philippe/F-6755-2015; Schisler, Jonathan C./C-1301-2008	rondeau, philippe/0000-0002-4652-1376; Willis, Monte S/0000-0002-0769-5816; Schisler, Jonathan C./0000-0001-7382-2783; Essop, Faadiel/0000-0002-8434-4294; Bourdon, Emmanuel/0000-0003-3731-150X	South African National Research Foundation; Stellenbosch University; Conseil Regional de La Reunion; l'Europethe Jefferson; Pilot Fellowship in Academic Medicine; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL104129] Funding Source: NIH RePORTER	South African National Research Foundation(National Research Foundation - South Africa); Stellenbosch University; Conseil Regional de La Reunion; l'Europethe Jefferson; Pilot Fellowship in Academic Medicine; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This work was supported by the South African National Research Foundation and Stellenbosch University (MFE), the Conseil Regional de La Reunion and l'Europethe Jefferson (EB), and a Pilot Fellowship in Academic Medicine (MSW). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aebi H, 1984, Methods Enzymol, V105, P121; Andersen CL, 2004, CANCER RES, V64, P5245, DOI 10.1158/0008-5472.CAN-04-0496; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Armstrong W, 2005, CLEV CLIN J MED, V72, P73, DOI 10.3949/ccjm.72.1.73; Becker AC, 2010, J INTERV CARDIOL, V23, P70, DOI 10.1111/j.1540-8183.2009.00520.x; Bernal E, 2012, MED CLIN-BARCELONA, V139, P561, DOI 10.1016/j.medcli.2012.03.037; Boudina S, 2005, CIRCULATION, V112, P2686, DOI 10.1161/CIRCULATIONAHA.105.554360; Cacho J, 2008, AM J PHYSIOL-ENDOC M, V295, pE1269, DOI 10.1152/ajpendo.90207.2008; Carr A, 1999, LANCET, V353, P2093, DOI 10.1016/S0140-6736(98)08468-2; Carr A, 1998, AIDS, V12, pF51, DOI 10.1097/00002030-199807000-00003; Carr A, 1998, LANCET, V351, P1881, DOI 10.1016/S0140-6736(98)03391-1; Carr A, 2008, AIDS, V22, P2313, DOI 10.1097/QAD.0b013e328315a7a5; Darley-Usmar VM, 2012, J MOL CELL CARDIOL, V52, P538, DOI 10.1016/j.yjmcc.2011.08.009; Eberle D, 2004, BIOCHIMIE, V86, P839, DOI 10.1016/j.biochi.2004.09.018; Farhoud MH, 2012, PROTEOMICS, V12, P1349, DOI 10.1002/pmic.201100326; Ferrer E, 2011, AIDS RES HUM RETROV, V27, P1061, DOI [10.1089/aid.2010.0254, 10.1089/AID.2010.0254]; Friis-Moller N, 2007, NEW ENGL J MED, V356, P1723, DOI 10.1056/NEJMoa062744; Gan SK, 2002, DIABETES, V51, P3163, DOI 10.2337/diabetes.51.11.3163; GREENSPAN HC, 1994, IMMUNOL TODAY, V15, P209, DOI 10.1016/0167-5699(94)90245-3; Grinspoon SK, 2008, JAIDS-J ACQ IMM DEF, V48, P369, DOI 10.1161/CIRCULATIONAHA.107.189622; Hecker PA, 2012, AM J PHYSIOL-ENDOC M, V303, pE959, DOI 10.1152/ajpendo.00202.2012; Hirano Y, 2001, J BIOL CHEM, V276, P36431, DOI 10.1074/jbc.M105200200; Hui DY, 2003, PROG LIPID RES, V42, P81, DOI 10.1016/S0163-7827(02)00046-2; Jeon HB, 2007, BIOCHEM BIOPH RES CO, V357, P731, DOI 10.1016/j.bbrc.2007.04.015; Jerico C, 2006, STROKE, V37, P812, DOI 10.1161/01.STR.0000204037.26797.7f; Jiang B, 2007, TOXICOL APPL PHARM, V224, P60, DOI 10.1016/j.taap.2007.06.010; Lagathu C, 2005, BIOCHIMIE, V87, P65, DOI 10.1016/j.biochi.2004.12.007; Lekakis J, 2008, CLIN SCI, V115, P189, DOI 10.1042/CS20070353; Levine RL, 2000, METH MOL B, V99, P15; Liang JS, 2001, NAT MED, V7, P1327, DOI 10.1038/nm1201-1327; Lo J, 2010, AIDS, V24, P243, DOI 10.1097/QAD.0b013e328333ea9e; MACHO A, 1995, BLOOD, V86, P2481; Mapanga RF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047322; Matarrese P, 2003, J IMMUNOL, V170, P6006, DOI 10.4049/jimmunol.170.12.6006; Melekhin VV, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006961; Mondy KE, 2011, CLIN INFECT DIS, V52, P378, DOI 10.1093/cid/ciq066; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; Panther LA, 2002, AM J PHYSIOL-HEART C, V283, pH1, DOI 10.1152/ajpheart.00212.2002; Puigserver P, 2005, INT J OBESITY, V29, pS5, DOI 10.1038/sj.ijo.0802905; Punga T, 2006, J BIOL CHEM, V281, P25278, DOI 10.1074/jbc.M604983200; Riddle TM, 2001, J BIOL CHEM, V276, P37514, DOI 10.1074/jbc.M104557200; Rudich A, 2005, ACTA PHYSIOL SCAND, V183, P75, DOI 10.1111/j.1365-201X.2004.01383.x; Schmidtke G, 1999, J BIOL CHEM, V274, P35734, DOI 10.1074/jbc.274.50.35734; Sivitz W, 2010, ANTIOXID REDOX SIGN, V12, P1; Spiegelman BM, 2007, NOVART FDN SYMP, V287, P60; Taylor EB, 2011, BIOCHEM SOC T, V39, P1509, DOI 10.1042/BST0391509; Trausch-Azar J, 2010, J BIOL CHEM, V285, P40192, DOI 10.1074/jbc.M110.131615; Vallett SM, 1996, J BIOL CHEM, V271, P12247, DOI 10.1074/jbc.271.21.12247; Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034; Vernochet C, 2005, J BIOL CHEM, V280, P2238, DOI 10.1074/jbc.M408687200; Walmsley S, 2002, NEW ENGL J MED, V346, P2039, DOI 10.1056/NEJMoa012354; WHO UNAIDS Unicef, 2011, GLOB HIV AIDS RESP E; Willis MS, 2007, CIRC RES, V100, P456, DOI 10.1161/01.RES.0000259559.48597.32; Willis MS, 2009, CIRC RES, V105, P80, DOI 10.1161/CIRCRESAHA.109.194928	54	31	33	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 30	2013	8	9							e73347	10.1371/journal.pone.0073347	http://dx.doi.org/10.1371/journal.pone.0073347			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	231NL	24098634	Green Published, Green Submitted, gold			2023-01-03	WOS:000325423500006
J	Ross, JS; Kesselheim, AS				Ross, Joseph S.; Kesselheim, Aaron S.			Prescription-Drug Coupons - No Such Thing as a Free Lunch	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material								Many websites for brand-name drugs available in the United States contain links to drug coupons. But since many are for medications for which lower-cost alternatives are available, this marketing practice threatens to increase societal costs in the long run. Visit nearly any official website for a brand-name drug available in the United States and, mixed in with links to prescribing and safety information, you'll find links to drug coupons, including copayment-assistance programs and monthly savings cards. Most offers are variations on Why pay more? With the [drug] savings card, you can get [drug] for only $18 per prescription if eligible or Get a free 30-capsule trial of [drug] with your doctor's prescription and ask your doctor if [drug] is right for you. Why do manufacturers offer drug coupons? Are they good for patients in the long run? Are they ...	[Ross, Joseph S.] Yale Univ, Sch Med, Gen Internal Med Sect, New Haven, CT 06520 USA; [Ross, Joseph S.] Yale Univ, Sch Med, Robert Wood Johnson Clin Scholars Program, New Haven, CT USA; [Ross, Joseph S.] Yale New Haven Med Ctr, Ctr Outcomes Res & Evaluat, New Haven, CT 06504 USA; [Kesselheim, Aaron S.] Brigham & Womens Hosp, Dept Med, Div Pharmacoepidemiol & Pharmacoecon, Boston, MA 02115 USA; [Kesselheim, Aaron S.] Harvard Univ, Sch Med, Boston, MA USA	Yale University; Yale University; Yale University; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Ross, JS (corresponding author), Yale Univ, Sch Med, Gen Internal Med Sect, New Haven, CT 06520 USA.			Ross, Joseph/0000-0002-9218-3320				Grande D, 2012, JAMA-J AM MED ASSOC, V307, P2375, DOI 10.1001/jama.2012.5603; IMS Institute for Healthcare Informatics, 2012, US MED US REV 2011; Kravitz RL, 2005, JAMA-J AM MED ASSOC, V294, P2436; Kravitz RL, 2005, JAMA-J AM MED ASSOC, V293, P1995, DOI 10.1001/jama.293.16.1995; Pharmaceutical Care Management Association, 2011, COP COUP COULD RAIS; Shrank WH, 2010, HEALTH AFFAIR, V29, P1383, DOI 10.1377/hlthaff.2009.0424	6	51	51	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 26	2013	369	13					1188	1189		10.1056/NEJMp1301993	http://dx.doi.org/10.1056/NEJMp1301993			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	224LT	23984672				2023-01-03	WOS:000324888200003
J	Widya, RL; Hammer, S; Boon, MR; van der Meer, RW; Smit, JWA; de Roos, A; Rensen, PCN; Lamb, HJ				Widya, Ralph L.; Hammer, Sebastiaan; Boon, Mariette R.; van der Meer, Rutger W.; Smit, Johannes W. A.; de Roos, Albert; Rensen, Patrick C. N.; Lamb, Hildo J.			Effects of Short-Term Nutritional Interventions on Right Ventricular Function in Healthy Men	PLOS ONE			English	Article							MYOCARDIAL TRIGLYCERIDE CONTENT; DOPPLER WAVE-FORM; CALORIC RESTRICTION; TRIACYLGLYCEROL ACCUMULATION; DIASTOLIC DYSFUNCTION; HEART-DISEASE; PLASMA CETP; HIGH-FAT; METABOLISM; REPRODUCIBILITY	Background: A physiological model of increased plasma nonesterified fatty acid (NEFA) levels result in myocardial triglyceride (TG) accumulation, which is related to cardiac dysfunction. A pathophysiological model of increased plasma NEFA levels result in hepatic steatosis, which has been linked to abnormal myocardial energy metabolism. Hepatic steatosis is accompanied by hepatic inflammation, reflected by plasma cholesteryl ester transfer protein (CETP) levels. The current study aimed to investigate effects of these models via different nutritional interventions on right ventricular (RV) function. Methods: Fifteen men (age 25.0 +/- 6.6 years) were included and underwent magnetic resonance imaging and spectroscopy in this prospective crossover intervention study. RV function, myocardial and hepatic TG content, and CETP levels were assessed on three occasions: after normal diet, very low-calorie diet (VLCD, physiological model) and high-fat high-energy (HFHE, pathophysiological model) diet (all 3-days diets, randomly ordered, washout phase at least 14 days). Results: VLCD induced a decrease in mean E deceleration by 27%. Myocardial TG content increased by 55%, whereas hepatic TG content decreased by 32%. Plasma CETP levels decreased by 14% (all P<0.05). HFHE diet induced a decrease in E/A by 19% (P<0.05). Myocardial TG content did not change, whereas hepatic TG content increased by 112% (P<0.01). Plasma CETP levels increased by 14% (P<0.05). Conclusions: These findings show that RV diastolic function is impaired after short-term VLCD and HFHE diet in healthy men, respectively a physiological and a pathophysiological model of increased plasma NEFA levels. After short-term VLCD, myocardial lipotoxicity may be of importance in decreased RV diastolic function. RV diastolic dysfunction is accompanied by increased hepatic TG content and plasma CETP levels after short-term HFHE diet, suggesting that systemic inflammation reflecting local macrophage infiltration in the heart may be involved in RV dysfunction.	[Widya, Ralph L.; Hammer, Sebastiaan; van der Meer, Rutger W.; de Roos, Albert; Lamb, Hildo J.] Leiden Univ, Med Ctr, Dept Radiol, Leiden, Netherlands; [Widya, Ralph L.; Boon, Mariette R.; Smit, Johannes W. A.; Rensen, Patrick C. N.] Leiden Univ, Med Ctr, Dept Endocrinol & Metab, Leiden, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Widya, RL (corresponding author), Leiden Univ, Med Ctr, Dept Radiol, Leiden, Netherlands.	R.L.Widya@lumc.nl	Boon, Mariëtte/O-3660-2016; Lamb, Hildo/ABE-1171-2021; Smit, J.W.A./H-8091-2014; Rensen, Patrick C.N./D-7176-2018	Lamb, Hildo/0000-0002-6969-2418; Smit, J.W.A./0000-0003-1052-9314; Rensen, Patrick C.N./0000-0002-8455-4988; Widya, Ralph/0000-0003-4747-939X; Hammer, Sebastiaan/0000-0002-1576-1190	Center for Translational Molecular Medicine project PREDICCt [01C-104]; Netherlands Heart Foundation; Dutch Diabetes Research Foundation; Dutch Kidney Foundation; Board of Directors of the Leiden University Medical Center, the Netherlands (Excellent MD/PhD program for Medical Students)	Center for Translational Molecular Medicine project PREDICCt; Netherlands Heart Foundation(Netherlands Heart Foundation); Dutch Diabetes Research Foundation; Dutch Kidney Foundation; Board of Directors of the Leiden University Medical Center, the Netherlands (Excellent MD/PhD program for Medical Students)	This research was performed within the framework of the Center for Translational Molecular Medicine (CTMM; www.ctmm.nl), project PREDICCt (grant 01C-104), and supported by the Netherlands Heart Foundation, the Dutch Diabetes Research Foundation and Dutch Kidney Foundation. M.R.B. is supported by the Board of Directors of the Leiden University Medical Center, the Netherlands (Excellent MD/PhD program for Medical Students). P.C.N.R. is an Established Investigator of the Netherlands Heart Foundation (2009T038). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aziz EF, 2010, J CARD FAIL, V16, P827, DOI 10.1016/j.cardfail.2010.05.004; Balschi JA, 1997, J MOL CELL CARDIOL, V29, P471, DOI 10.1006/jmcc.1996.9997; Cappuzzello C, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-28; Christoffersen C, 2003, ENDOCRINOLOGY, V144, P3483, DOI 10.1210/en.2003-0242; FERRANNINI E, 1993, AM J PHYSIOL, V264, pE308, DOI 10.1152/ajpendo.1993.264.2.E308; Ghio S, 2001, J AM COLL CARDIOL, V37, P183, DOI 10.1016/S0735-1097(00)01102-5; Grothues F, 2004, AM HEART J, V147, P218, DOI 10.1016/j.ahj.2003.10.005; Hammer S, 2008, J CLIN ENDOCR METAB, V93, P497, DOI 10.1210/jc.2007-2015; Han XL, 2004, BIOCHEMISTRY-US, V43, P15584, DOI 10.1021/bi048307o; HESLER CB, 1987, J BIOL CHEM, V262, P2275; HIRSCH J, 1964, J CLIN INVEST, V43, P1776, DOI 10.1172/JCI105052; HUANG JMC, 1992, P NATL ACAD SCI USA, V89, P6452, DOI 10.1073/pnas.89.14.6452; Korvald C, 2000, AM J PHYSIOL-HEART C, V278, pH1345, DOI 10.1152/ajpheart.2000.278.4.H1345; Lamb HJ, 2008, CURR OPIN CLIN NUTR, V11, P573, DOI 10.1097/MCO.0b013e32830a98e3; Li ZS, 2012, BIOCHEM PHARMACOL, V84, P821, DOI 10.1016/j.bcp.2012.06.020; Meluzin J, 2003, Eur J Echocardiogr, V4, P262, DOI 10.1016/S1525-2167(02)00171-3; Mertens LL, 2010, NAT REV CARDIOL, V7, P551, DOI 10.1038/nrcardio.2010.118; MIYATAKE K, 1984, AM J CARDIOL, V53, P586, DOI 10.1016/0002-9149(84)90035-3; MOSTELLER RD, 1987, NEW ENGL J MED, V317, P1098, DOI 10.1056/nejm198710223171717; Naressi A, 2001, MAGN RESON MATER PHY, V12, P141, DOI 10.1007/BF02668096; Oguzkurt L, 2005, EUR J RADIOL, V54, P253, DOI 10.1016/j.ejrad.2004.05.011; Ouwens DM, 2005, DIABETOLOGIA, V48, P1229, DOI 10.1007/s00125-005-1755-x; PATTYNAMA PMT, 1995, MAGN RESON IMAGING, V13, P53, DOI 10.1016/0730-725X(94)00076-F; Perseghin G, 2008, HEPATOLOGY, V47, P51, DOI 10.1002/hep.21983; REBERGEN SA, 1993, AM HEART J, V126, P1439, DOI 10.1016/0002-8703(93)90544-J; Rijzewijk LJ, 2010, J AM COLL CARDIOL, V56, P225, DOI 10.1016/j.jacc.2010.02.049; Schaffer JE, 2003, CURR OPIN LIPIDOL, V14, P281, DOI 10.1097/00041433-200306000-00008; Schilling JD, 2012, AM J PHYSIOL-HEART C, V303, pH1366, DOI 10.1152/ajpheart.00111.2012; Simms MG, 1999, AM J PHYSIOL-HEART C, V277, pH253, DOI 10.1152/ajpheart.1999.277.1.H253; Solhjoo E, 2011, HEPAT MON, V11, P740, DOI [10.5812/kowsar.1735143X.729, 10.5812/kowsar.1735143X.404]; Unger RH, 2002, ANNU REV MED, V53, P319, DOI 10.1146/annurev.med.53.082901.104057; Unger RH, 2002, BBA-MOL CELL BIOL L, V1585, P202, DOI 10.1016/S1388-1981(02)00342-6; van den Brom CE, 2010, CARDIOVASC DIABETOL, V9, DOI 10.1186/1475-2840-9-25; van der Meer RW, 2008, J CLIN ENDOCR METAB, V93, P2702, DOI 10.1210/jc.2007-2524; van der Meer RW, 2007, DIABETES, V56, P2849, DOI 10.2337/db07-0768; van der Meer RW, 2007, RADIOLOGY, V245, P251, DOI 10.1148/radiol.2451061904; Wang YA, 2011, DIABETES CARE, V34, P2576, DOI 10.2337/dc11-0685; Warnes CA, 2009, J AM COLL CARDIOL, V54, P1903, DOI 10.1016/j.jacc.2009.06.048; Widya RL, 2013, DIABETES CARE, V36, P457, DOI 10.2337/dc12-0474; Winhofer Y, 2012, DIABETES, V61, P1210, DOI 10.2337/db11-1275; Zhou YT, 2000, P NATL ACAD SCI USA, V97, P1784, DOI 10.1073/pnas.97.4.1784; Zile MR, 2002, CIRCULATION, V105, P1503, DOI 10.1161/hc1202.105290	42	3	3	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 23	2013	8	9							e76406	10.1371/journal.pone.0076406	http://dx.doi.org/10.1371/journal.pone.0076406			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	246EK	24086738	gold, Green Submitted, Green Published			2023-01-03	WOS:000326520200136
J	Hawkes, N				Hawkes, Nigel			Hospitals without walls	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material												nigel.hawkes1@btinternet.com						Future Hospital Programme, 2013, FUT HOSP COMM	1	9	9	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 12	2013	347								f5479	10.1136/bmj.f5479	http://dx.doi.org/10.1136/bmj.f5479			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	219SU	24030563				2023-01-03	WOS:000324530500008
J	Bote, ME; Garcia, JJ; Hinchado, MD; Ortega, E				Elena Bote, Maria; Jose Garcia, Juan; Dolores Hinchado, Maria; Ortega, Eduardo			Fibromyalgia: Anti-Inflammatory and Stress Responses after Acute Moderate Exercise	PLOS ONE			English	Article							INFLAMMATORY RESPONSE; INDUCED STIMULATION; CYTOKINE; NEUROENDOCRINE; INNATE; HSP72; CLASSIFICATION; INTERLEUKIN-18; CHEMOTAXIS; MEDIATORS	Fibromyalgia (FM) is characterized in part by an elevated inflammatory status, and "modified exercise'' is currently proposed as being a good therapeutic help for these patients. However, the mechanisms involved in the exercise-induced benefits are still poorly understood. The objective was to evaluate the effect of a single bout of moderate cycling (45 min at 55% VO2 max) on the inflammatory (serum IL-8; chemotaxis and O-2(-) production by neutrophils; and IL-1 beta, TNF-alpha, IL-6, IL-10, and IL-18 release by monocytes) and stress (cortisol; NA; and eHsp72) responses in women diagnosed with FM compared with an aged-matched control group of healthy women (HW). IL-8, NA, and eHsp72 were determined by ELISA. Cytokines released by monocytes were determined by Bio-Plex (R) system (LUMINEX). Cortisol was determined by electrochemoluminiscence, chemotaxis was evaluated in Boyden chambers and O-2(-) production by NBT reduction. In the FM patients, the exercise induced a decrease in the systemic concentration of IL-8, cortisol, NA, and eHsp72; as well as in the neutrophil's chemotaxis and O-2(-) production and in the inflammatory cytokine release by monocytes. This was contrary to the completely expected exercise-induced increase in all those biomarkers in HW. In conclusion, single sessions of moderate cycling can improve the inflammatory status in FM patients, reaching values close to the situation of aged-matched HW at their basal status. The neuroendocrine mechanism seems to be an exercise-induced decrease in the stress response of these patients.	[Elena Bote, Maria; Jose Garcia, Juan; Dolores Hinchado, Maria; Ortega, Eduardo] Univ Extremadura, Dept Physiol, Badajoz, Spain	Universidad de Extremadura	Ortega, E (corresponding author), Univ Extremadura, Dept Physiol, Badajoz, Spain.	orincon@unex.es	Garcia, Juan J/C-7383-2013; Ortega, Eduardo/H-9891-2016; Ortega, Eduardo/GXN-2560-2022	Garcia, Juan J/0000-0002-8222-4213; Ortega, Eduardo/0000-0002-7007-7615; Bote, Maria Elena/0000-0002-3112-9259; SANCHEZ-MORO, MARIA DOLORES/0000-0002-9709-4714	MICINN-FEDER of Spain [DEP2009-10041]; Junta de Extremadura-FEDER [PRI09A003, GR10020]	MICINN-FEDER of Spain(Ministry of Science and Innovation, Spain (MICINN)Spanish Government); Junta de Extremadura-FEDER	This work was supported by grants from MICINN-FEDER (DEP2009-10041) of Spain, Junta de Extremadura-FEDER (PRI09A003, GR10020). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ASTRAND PO, 1954, J APPL PHYSIOL, V7, P218, DOI 10.1152/jappl.1954.7.2.218; Bazzichi L, 2007, CLIN EXP RHEUMATOL, V25, P225; Bote ME, 2012, NEUROIMMUNOMODULAT, V19, P343, DOI 10.1159/000341664; BOYDEN S, 1962, J EXP MED, V115, P453, DOI 10.1084/jem.115.3.453; Dinarello CA, 1998, J LEUKOCYTE BIOL, V63, P658, DOI 10.1002/jlb.63.6.658; Fleshner M, 2003, EXERC IMMUNOL REV, V9, P6; Giraldo E, 2008, MOL CELL BIOCHEM, V313, P147, DOI 10.1007/s11010-008-9752-2; Giraldo E, 2010, BRAIN BEHAV IMMUN, V24, P672, DOI 10.1016/j.bbi.2010.02.003; Giraldo E, 2009, NEUROIMMUNOMODULAT, V16, P237, DOI 10.1159/000212384; IIZASA H, 2001, CYTOKINE REFERENCE, P1061; Kohno K, 1998, CLIN IMMUNOL IMMUNOP, V86, P11, DOI 10.1006/clin.1997.4475; Mannerkorpi K, 2007, BEST PRACT RES CL RH, V21, P513, DOI 10.1016/j.berh.2007.04.001; Meksawan K, 2004, J AM COLL NUTR, V23, P331, DOI 10.1080/07315724.2004.10719376; Muller W, 2007, RHEUMATOL INT, V27, P1005, DOI 10.1007/s00296-007-0403-9; NORTHOFF H, 1994, INT J SPORTS MED, V15, pS167, DOI 10.1055/s-2007-1021132; Ortega E, 2006, EUR J APPL PHYSIOL, V98, P250, DOI 10.1007/s00421-006-0269-7; ORTEGA E, 1993, EUR J APPL PHYSIOL O, V66, P60, DOI 10.1007/BF00863401; Ortega E, 2003, EXERC IMMUNOL REV, V9, P70; Ortega E, 2012, SCAND J MED SCI SPOR, V22, P104, DOI 10.1111/j.1600-0838.2010.01132.x; Ortega E, 2009, EXERC IMMUNOL REV, V15, P42; Ortega E, 1997, J PHYSIOL-LONDON, V498, P729, DOI 10.1113/jphysiol.1997.sp021897; Ortega E, 2007, NEUROIMMUNOMODULAT, V14, P206, DOI 10.1159/000110648; Ortega E, 2010, HEAT SHOCK PROTEINS, V5, P327, DOI 10.1007/978-90-481-3381-9_19; Ortega E, 2009, STRESS, V12, P240, DOI 10.1080/10253890802309853; Ortega Rincon E, 1994, INT J SPORTS MED, V15, P173; Peake J, 2005, EXERC IMMUNOL REV, V11, P64; Pedersen BK, 2006, SCAND J MED SCI SPOR, V16, P3, DOI 10.1111/j.1600-0838.2006.00520.x; Petersen AMW, 2005, J APPL PHYSIOL, V98, P1154, DOI 10.1152/japplphysiol.00164.2004; Ploeger HE, 2009, EXERC IMMUNOL REV, V15, P6; Suzuki K, 2002, EXERC IMMUNOL REV, V8, P6; van West D, 2001, BIODRUGS, V15, P521, DOI 10.2165/00063030-200115080-00004; Wallace DJ, 2001, RHEUMATOLOGY, V40, P743, DOI 10.1093/rheumatology/40.7.743; WOLFE F, 1990, ARTHRITIS RHEUM-US, V33, P160, DOI 10.1002/art.1780330203; Woods JA, 2006, NEUROL CLIN, V24, P585, DOI 10.1016/j.ncl.2006.03.008	34	57	59	0	17	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 4	2013	8	9							e74524	10.1371/journal.pone.0074524	http://dx.doi.org/10.1371/journal.pone.0074524			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	219OE	24023948	gold, Green Submitted, Green Published			2023-01-03	WOS:000324515600144
J	Ravani, P; Maas, R; Malberti, F; Pecchini, P; Mieth, M; Quinn, R; Tripepi, G; Mallamaci, F; Zoccali, C				Ravani, Pietro; Maas, Renke; Malberti, Fabio; Pecchini, Paola; Mieth, Maren; Quinn, Robert; Tripepi, Giovanni; Mallamaci, Francesca; Zoccali, Carmine			Homoarginine and Mortality in Pre-Dialysis Chronic Kidney Disease (CKD) Patients	PLOS ONE			English	Article							MASS-SPECTROMETRIC DETERMINATION; ASYMMETRIC DIMETHYLARGININE; RENAL-DISEASE; RISK-FACTOR; PLASMA; ARGININE; MODELS; TARGET; ADMA	Background and Aims: Homoarginine, a precursor of nitric oxide, is an inverse predictor of death in dialysis patients and in subjects with cardiovascular disease and normal kidney function but its relationship with clinical outcomes in chronic kidney disease (CKD) patients not yet on dialysis is unknown. Design, setting, participants and measurements: We enrolled 168 consecutive predialysis CKD patients (Age: 70 +/- 11 yrs; 26% Diabetics; eGFR 34 +/- 18 ml/min/1.73 m(2)) referred to a tertiary care centre and measured laboratory data on kidney function and cardiovascular risk factors. We modeled progression to dialysis or death as a function of homoarginine, using Cox's regression, accounting for clinical characteristics, baseline levels of kidney function, and markers of inflammation. Results: On crude and adjusted analyses homoarginine was directly associated with the eGFR and patients with more compromised renal function exhibited lower homoarginine levels. Furthermore homoarginine was also independently related to L-arginine, serum albumin and body mass index, and inversely related to proteinuria, C-reactive protein and age. During the study (follow up median time 4 years, inter-quartile range 1.7 to 7.0 years) 56 patients started dialysis and 103 died and homoarginine was a strong inverse predictor of the incidence rate of both outcomes (P = 0.002 and P = 0.017). Conclusions: Homoarginine declines with advancing renal disease and is inversely related to progression to dialysis and mortality. The nature of the link between homoarginine and clinical outcomes is amenable to testing in clinical trials.	[Ravani, Pietro; Quinn, Robert] Univ Calgary, Dept Med, Calgary, AB, Canada; [Ravani, Pietro; Quinn, Robert] Univ Calgary, Fac Med, Calgary, AB, Canada; [Maas, Renke; Mieth, Maren] Univ Erlangen Nurnberg, Inst Clin & Expt Pharmacol & Toxicol, Nurnberg, Germany; [Malberti, Fabio; Pecchini, Paola] Azienda Ist Ospitalieri Cremona, Div Nefrol, Cremona, Italy; [Tripepi, Giovanni; Mallamaci, Francesca; Zoccali, Carmine] Osped Riuniti Reggio Calabria, Div Nefrol, Reggio Di Calabria, Italy; [Tripepi, Giovanni; Mallamaci, Francesca; Zoccali, Carmine] CNR IBIM, Reggio Di Calabria, Italy	University of Calgary; University of Calgary; University of Erlangen Nuremberg; Consiglio Nazionale delle Ricerche (CNR); Istituto di Biomedicina e di Immunologia Molecolare "Alberto Monroy" (IBIM-CNR)	Zoccali, C (corresponding author), Osped Riuniti Reggio Calabria, Div Nefrol, Reggio Di Calabria, Italy.	carmine.zoccali@tin.it	Quinn, Robert R/E-7017-2011; Ravani, Pietro/J-3050-2015	Ravani, Pietro/0000-0001-6973-8570; Zoccali, Carmine/0000-0002-6616-1996; Maas, Renke/0000-0002-5498-9761	National Research Council	National Research Council(Consiglio Nazionale delle Ricerche (CNR))	No current external funding sources for this study. The institutional funder (National Research Council) had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Atzler D, 2011, J CHROMATOGR B, V879, P2294, DOI 10.1016/j.jchromb.2011.06.016; Baylis C, 2008, AM J PHYSIOL-RENAL, V294, pF1, DOI 10.1152/ajprenal.00424.2007; Curtis BM, 2005, NEPHROL DIAL TRANSPL, V20, P147, DOI 10.1093/ndt/gfh585; Drechsler C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063560; Fliser D, 2010, J NEPHROL, V23, P369; Kielstein JT, 2008, CURR OPIN NEPHROL HY, V17, P609, DOI 10.1097/MNH.0b013e328314b6ca; LEVILLAIN O, 1995, KIDNEY INT, V47, P464, DOI 10.1038/ki.1995.59; Marz W, 2010, CIRCULATION, V122, P967, DOI 10.1161/CIRCULATIONAHA.109.908988; Meinitzer A, 2007, CLIN CHIM ACTA, V384, P141, DOI 10.1016/j.cca.2007.07.006; Pilz S, 2011, HEART, V97, P1222, DOI 10.1136/hrt.2010.220731; Ravani P, 2008, NEPHROL DIAL TRANSPL, V23, P1484, DOI 10.1093/ndt/gfn138; Schwedhelm E, 2007, J CHROMATOGR B, V851, P211, DOI 10.1016/j.jchromb.2006.11.052; Schwedhelm E, 2011, NAT REV NEPHROL, V7, P275, DOI 10.1038/nrneph.2011.31; THERNEAU TM, 1990, BIOMETRIKA, V77, P147, DOI 10.2307/2336057; Valtonen P, 2008, CIRC J, V72, P1879, DOI 10.1253/circj.CJ-08-0240; WEI LJ, 1989, J AM STAT ASSOC, V84, P1065, DOI 10.2307/2290084; Zoccali C, 2006, J HYPERTENS, V24, P611, DOI 10.1097/01.hjh.0000217839.26971.8d	17	31	33	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 4	2013	8	9							e72694	10.1371/journal.pone.0072694	http://dx.doi.org/10.1371/journal.pone.0072694			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	219OE	24023762	Green Published, gold, Green Submitted			2023-01-03	WOS:000324515600035
J	Turner, C; Carrara, V; Thein, NAM; Win, NCMM; Turner, P; Bancone, G; White, NJ; McGready, R; Nosten, F				Turner, Claudia; Carrara, Verena; Thein, Naw Aye Mya; Win, Naw Chit Mo Mo; Turner, Paul; Bancone, Germana; White, Nicholas J.; McGready, Rose; Nosten, Francois			Neonatal Intensive Care in a Karen Refugee Camp: A 4 Year Descriptive Study	PLOS ONE			English	Article							CHILD-MORTALITY; SYSTEMATIC ANALYSIS; NATIONAL CAUSES; SURVIVAL; BIRTH; INTERVENTIONS; BURMESE; COUNTRY; BABIES; COST	Background: A third of all deaths in children aged <5 years occur in the neonatal period. Neonatal intensive care is often considered too complex and expensive to be implemented in resource poor settings. Consequently the reductions that have been made in infant mortality in the poorest countries have not been made in the neonatal period. This manuscript describes the activities surrounding the introduction of special care baby unit (SCBU) in a refugee setting and the resulting population impact. Methods: A SCBU was developed in Maela refugee camp on the Thailand-Myanmar border. This unit comprised of a dedicated area, basic equipment, drugs and staff training. Training was built around neonatal guidelines, comprising six clinical steps: recognition, resuscitation, examination, supportive medical care, specialised medical care, and counselling of parents with sick newborns. Results: From January 2008 until December 2011, 952 infants were admitted to SCBU. The main admission diagnoses were early onset neonatal sepsis, jaundice and prematurity. Early prematurity (<34 weeks) carried the highest risk of mortality (OR 9.5, 95% CI 5.4-16.5, p<0.001). There was a significant decrease in mortality from 19.3% (2008) to 4.8% (2011) among the infants admitted for prematurity (p=0.03). The neonatal mortality in Maela camp as a whole declined by 51% from 21.8 to 10.7 deaths per 1000 live births over the corresponding period (p=0.04). Staff expressed more confidence in their ability to take care of neonates and there was a more positive attitude towards premature infants. Conclusion: Neonatal mortality can be reduced in a resource poor setting by introduction of a simple low cost unit specialising in care of sick neonates and run by local health workers following adequate training. Training in recognition and provision of simple interventions at a high standard can increase staff confidence and reduce fatalistic attitudes towards premature neonates.	[Turner, Claudia; Carrara, Verena; Thein, Naw Aye Mya; Win, Naw Chit Mo Mo; Turner, Paul; Bancone, Germana; McGready, Rose; Nosten, Francois] Shoklo Malaria Res Unit, Mae Sot, Thailand; [Turner, Claudia; Turner, Paul; White, Nicholas J.; McGready, Rose; Nosten, Francois] Mahidol Oxford Trop Med Res Unit, Bangkok, Thailand; [Turner, Claudia; Turner, Paul; White, Nicholas J.; McGready, Rose; Nosten, Francois] Univ Oxford, Ctr Trop Med, Oxford, England	Mahidol University; Mahidol Oxford Tropical Medicine Research Unit (MORU); University of Oxford	Turner, C (corresponding author), Shoklo Malaria Res Unit, Mae Sot, Thailand.	claudia@tropmedres.ac	White, Nick/AAC-6527-2019; Carrara, Verena/R-6492-2019; Nosten, Francois/AAC-5509-2019; McGready, Rose/A-3290-2014	White, Nick/0000-0002-1897-1978; Carrara, Verena/0000-0002-2758-0872; Nosten, Francois/0000-0002-7951-0745; McGready, Rose/0000-0003-1621-3257; Turner, Paul/0000-0002-1013-7815; Bancone, Germana/0000-0003-4550-0431	Wellcome Trust of Great Britain [077166/Z/05]	Wellcome Trust of Great Britain(Wellcome Trust)	CT, RM and FN are supported by the Wellcome Trust of Great Britain (Grant No. 077166/Z/05). Shoklo Malaria Research Unit is part of the Mahidol-Oxford University Tropical Medicine Research Program at the Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand, and supported by the Wellcome Trust of Great Britain. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Amouzou A, 2012, LANCET, V380, P1169, DOI 10.1016/S0140-6736(12)61376-2; Ballot DE, 2012, BMC PEDIATR, V12, DOI 10.1186/1471-2431-12-11; BEUTLER E, 1968, BLOOD, V32, P816, DOI 10.1182/blood.V32.5.816.816; Black RE, 2003, LANCET, V361, P2226, DOI 10.1016/S0140-6736(03)13779-8; Black RE, 2010, LANCET, V375, P1969, DOI 10.1016/S0140-6736(10)60549-1; Cheah PY, 2010, INT HEALTH, V2, P123, DOI 10.1016/j.inhe.2010.02.001; Darmstadt GL, 2005, LANCET, V365, P977, DOI 10.1016/S0140-6736(05)71088-6; Iams JD, 2008, LANCET, V371, P164, DOI 10.1016/S0140-6736(08)60108-7; Jalloh S, 2005, PEDIATR INT, V47, P258, DOI 10.1111/j.1442-200x.2005.02052.x; Lawn JE, 2005, LANCET, V365, P891, DOI 10.1016/S0140-6736(05)71048-5; Liu L, 2012, LANCET, V379, P2151, DOI 10.1016/S0140-6736(12)60560-1; Luxemburger C, 2003, T ROY SOC TROP MED H, V97, P251, DOI 10.1016/S0035-9203(03)90134-9; Martines J, 2005, LANCET, V365, P1189, DOI 10.1016/S0140-6736(05)71882-1; McGready R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040244; Nuchprayoon I, 2008, J HUM GENET, V53, P48, DOI 10.1007/s10038-007-0217-3; Rijken MJ, 2012, ULTRASOUND OBST GYN, V40, P151, DOI 10.1002/uog.11091; Rijken MJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031411; St John EB, 2000, AM J OBSTET GYNECOL, V182, P170, DOI 10.1016/S0002-9378(00)70509-6; UNICEF, 2012, THAIL STAT; UNICEF, 2012, REP UN MYANM STAT	21	22	22	1	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 22	2013	8	8							e72721	10.1371/journal.pone.0072721	http://dx.doi.org/10.1371/journal.pone.0072721			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	218ZA	23991145	Green Published, Green Submitted, gold			2023-01-03	WOS:000324470700049
J	Beers, E; Egberts, TCG; Leufkens, HGM; Jansen, PAF				Beers, Erna; Egberts, Toine C. G.; Leufkens, Hubert G. M.; Jansen, Paul A. F.			The Views of Healthcare Professionals, Drug Developers and Regulators on Information about Older People Needed for Rational Drug Prescription	PLOS ONE			English	Article							CLINICAL-TRIALS; EXCLUSION; BENEFITS; CRITERIA; ADULTS; WOMEN; LIFE	Background: The ICH E7 guideline intends to improve the knowledge about medicines in geriatric patients. As a legislative document, it might not reflect the needs of healthcare professionals. This study investigated what information healthcare professionals, regulatory agencies and pharmaceutical industries consider necessary for rational drug prescribing to older individuals. Methods and Findings: A 29-item-questionnaire was composed, considering the representation in trials, pharmacokinetics, efficacy, safety, and convenience of use in older individuals, with space for additions. Forty-three European professionals with an interest in medication for older individuals were included. In order to investigate their relevance, five items were included in a second questionnaire, with 11 control items. Median scores, differences between clinical and non-clinical respondents and response consistency were analysed. Consistency was present in 10 control items. Therefore, all items of the first questionnaire and the five additional items were analysed. Thirty-seven (86%) respondents returned the first questionnaire; 31/37 (84%) the second. Information about age-related differences in adverse events, locomotor effects, drug-disease interactions, dosing instructions, and information about the proportion of included 65+ patients was considered necessary by most respondents. Clinicians considered information significantly more important than the non-clinical respondents about the inclusion of 75+, time-until-benefit in older people, anticholinergic effects, drug-disease interactions, and convenience of use. Main study limitations are the focus on information for daily practice, while the ICH E7 guideline is a legislative document focused on market approval of a new medicine. Also, a questionnaire with a Likert scale has its limitations; this was addressed by providing space for comments. Conclusions: This study reveals that items considered necessary are currently not included in the ICH E7 guideline. Also, clinicians' and non-clinicians' opinions differed significantly in 15% of the items. Therefore, all stakeholders should collaborate to improve the availability of information for the rational prescribing to older individuals.	[Beers, Erna; Jansen, Paul A. F.] Univ Med Ctr Utrecht, Dept Geriatr Med, Utrecht, Netherlands; [Beers, Erna; Jansen, Paul A. F.] Univ Med Ctr Utrecht, Expertise Ctr Pharmacotherapy Old Persons EPHOR, Utrecht, Netherlands; [Egberts, Toine C. G.; Leufkens, Hubert G. M.] Univ Utrecht, Dept Pharmacoepidemiol, UIPS, Utrecht, Netherlands; [Egberts, Toine C. G.; Leufkens, Hubert G. M.] Univ Utrecht, Dept Clin Pharmacol, UIPS, Utrecht, Netherlands; [Egberts, Toine C. G.] Univ Med Ctr Utrecht, Dept Clin Pharm, Utrecht, Netherlands; [Leufkens, Hubert G. M.; Jansen, Paul A. F.] Dutch Med Evaluat Board, The Hague, Netherlands	Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University; Utrecht University; Utrecht University Medical Center	Beers, E (corresponding author), Univ Med Ctr Utrecht, Dept Geriatr Med, Utrecht, Netherlands.	e.beers@umcutrecht.nl	Egberts, Toine/A-6625-2012; Egberts, Toine/K-4579-2019	Egberts, Toine/0000-0003-1758-7779; Egberts, Toine/0000-0003-1758-7779	Netherlands Organisation for Health Research and Development (ZonMW)	Netherlands Organisation for Health Research and Development (ZonMW)(Netherlands Organization for Health Research and Development)	EB had support from the Dutch Society of Clinical Pharmacology & Biopharmacy (NVKF&B) for her training in clinical pharmacology and therapeutics; this manuscript was written in the context of her training. EB and PAFJ are working at the Expertise Centre Pharmacotherapy in Old Persons (EPHOR), which is financially supported by The Netherlands Organisation for Health Research and Development (ZonMW); no financial relationships with any organisations that might have an interest in the submitted work in the previous 3 years; no other relationships or activities that could appear to have influenced the submitted work.	Bartlett C, 2003, HEART, V89, P327, DOI 10.1136/heart.89.3.327; Beers E, 2013, DRUG AGING, V30, P255, DOI 10.1007/s40266-013-0059-y; Cherubini A, 2010, J AM GERIATR SOC, V58, P1791, DOI 10.1111/j.1532-5415.2010.03032.x; Committee for medicinal products for human use (CHMP), 2010, ICH TOP E7 STUD SUPP; Crome P, 2011, DRUG AGING, V28, P667, DOI 10.2165/11591990-000000000-00000; Dodd KS, 2011, J AM GERIATR SOC, V59, P506, DOI 10.1111/j.1532-5415.2010.03305.x; European Commission, 2012, GUID SUMM PROD CHAR; Fick D, 2012, J AM GERIATR SOC, V60, P616, DOI 10.1111/j.1532-5415.2012.03923.x; Fitch K, 2001, ARCH INTERN MED; Fitzsimmons PR, 2012, PARKINSONISM RELAT D, V18, P585, DOI 10.1016/j.parkreldis.2012.03.003; Gallagher P, 2008, INT J CLIN PHARM TH, V46, P72; Holmes HM, 2006, ARCH INTERN MED, V166, P605, DOI 10.1001/archinte.166.6.605; Huisman-Baron M, 2011, DRUG AGING, V28, P391, DOI 10.2165/11587200-000000000-00000; ICH expert working group, 1993, GERIATRICS E; McMurdo MET, 2011, AGE AGEING, V40, P659, DOI 10.1093/ageing/afr115; McMurdo MET, 2005, BMJ-BRIT MED J, V331, P1036, DOI 10.1136/bmj.331.7524.1036; Molzon JA, 2011, CLIN PHARMACOL THER, V89, P503, DOI 10.1038/clpt.2011.10; PREDICT Consortium, 2010, PREDICT CHART RIGHTS; Rahmner PB, 2012, BRIT J CLIN PHARMACO, V73, P115, DOI 10.1111/j.1365-2125.2011.04058.x; Rockwood K, 2011, CAN MED ASSOC J, V183, pE487, DOI 10.1503/cmaj.101271; Rudolph JL, 2008, ARCH INTERN MED, V168, P508, DOI 10.1001/archinternmed.2007.106; Ward J, 2010, APPL ERGON, V41, P682, DOI 10.1016/j.apergo.2009.12.005; Wild S, 2004, DIABETES CARE, V27, P1047, DOI 10.2337/diacare.27.5.1047; Witham MD, 2007, DRUG AGING, V24, P187, DOI 10.2165/00002512-200724030-00002	24	7	7	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 16	2013	8	8							e72060	10.1371/journal.pone.0072060	http://dx.doi.org/10.1371/journal.pone.0072060			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	207BA	23977208	Green Published, gold, Green Submitted			2023-01-03	WOS:000323570200055
J	Shin, J; Mashour, GA; Ku, S; Kim, S; Lee, U				Shin, Jeongkyu; Mashour, George A.; Ku, Seungwoo; Kim, Seunghwan; Lee, Uncheol			Subgraph "Backbone" Analysis of Dynamic Brain Networks during Consciousness and Anesthesia	PLOS ONE			English	Article							PROPOFOL-INDUCED LOSS; CONNECTIVITY CHANGES; UNCONSCIOUSNESS; INTEGRATION; INFORMATION; SYNCHRONY	General anesthesia significantly alters brain network connectivity. Graph-theoretical analysis has been used extensively to study static brain networks but may be limited in the study of rapidly changing brain connectivity during induction of or recovery from general anesthesia. Here we introduce a novel method to study the temporal evolution of network modules in the brain. We recorded multichannel electroencephalograms (EEG) from 18 surgical patients who underwent general anesthesia with either propofol (n = 9) or sevoflurane (n = 9). Time series data were used to reconstruct networks; each electroencephalographic channel was defined as a node and correlated activity between the channels was defined as a link. We analyzed the frequency of subgraphs in the network with a defined number of links; subgraphs with a high probability of occurrence were deemed network "backbones." We analyzed the behavior of network backbones across consciousness, anesthetic induction, anesthetic maintenance, and two points of recovery. Constitutive, variable and state-specific backbones were identified across anesthetic state transitions. Brain networks derived from neurophysiologic data can be deconstructed into network backbones that change rapidly across states of consciousness. This technique enabled a granular description of network evolution over time. The concept of network backbones may facilitate graph-theoretical analysis of dynamically changing networks.	[Shin, Jeongkyu] Pohang Univ Sci & Technol, Dept Phys, Pohang Si, Gyeongsangbuk D, South Korea; [Shin, Jeongkyu; Lee, Uncheol] Univ Michigan, Dept Anesthesiol, Sch Med, Ann Arbor, MI 48109 USA; [Mashour, George A.] Univ Michigan, Dept Anesthesiol, Sch Med, Grad Program Neurosci, Ann Arbor, MI 48109 USA; [Ku, Seungwoo] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Anesthesiol, Ulsan 680749, South Korea; [Kim, Seunghwan] Pohang Univ Sci & Technol, Dept Phys, Inst Edge Theoret Sci, Pohang Si, Gyeongsangbuk D, South Korea	Pohang University of Science & Technology (POSTECH); University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Ulsan; Asan Medical Center; Pohang University of Science & Technology (POSTECH)	Kim, S (corresponding author), Pohang Univ Sci & Technol, Dept Phys, Inst Edge Theoret Sci, Pohang Si, Gyeongsangbuk D, South Korea.	swan@postech.ac.kr; uclee@med.umich.edu		KIM, Seunghwan/0000-0002-0563-3902	Original Technology Research Program for Brain Science through the National Research Foundation of Korea (NRF); Ministry of Education, Science and Technology [2010-0018847]; National Institutes of Health, Bethesda, MD, USA [1RO1GM098578]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM098578] Funding Source: NIH RePORTER	Original Technology Research Program for Brain Science through the National Research Foundation of Korea (NRF)(National Research Foundation of Korea); Ministry of Education, Science and Technology(Ministry of Education, Science & Technology (MEST), Republic of Korea); National Institutes of Health, Bethesda, MD, USA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	JS was supported by the Original Technology Research Program for Brain Science through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology (No. 2010-0018847). GAM and UCL are supported by the National Institutes of Health, Bethesda, MD, USA, grant 1RO1GM098578. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alkire MT, 2008, SCIENCE, V322, P876, DOI 10.1126/science.1149213; Boly M, 2012, J NEUROSCI, V32, P7082, DOI 10.1523/JNEUROSCI.3769-11.2012; Boveroux P, 2010, ANESTHESIOLOGY, V113, P1038, DOI 10.1097/ALN.0b013e3181f697f5; Breshears JD, 2010, P NATL ACAD SCI USA, V107, P21170, DOI 10.1073/pnas.1011949107; Bressler SL, 2001, TRENDS COGN SCI, V5, P26, DOI 10.1016/S1364-6613(00)01564-3; Buzsaki G., 2006, RHYTHMS BRAIN, P448; Cantero JL, 2004, NEUROIMAGE, V22, P1271, DOI 10.1016/j.neuroimage.2004.03.014; Fingelkurts AA, 2004, INT J NEUROSCI, V114, P843, DOI 10.1080/00207450490450046; Fingelkurts AA, 2012, COGN PROCESS, V13, P111, DOI 10.1007/s10339-011-0416-x; Hudetz A., 2006, SEMIN ANESTH PERIO M, V25, P196, DOI [DOI 10.1053/j.sane.2006.09.003, 10.1053/j.sane.2006.09.003]; Imas OA, 2006, NEUROSCI LETT, V402, P216, DOI 10.1016/j.neulet.2006.04.003; John ER, 2005, ANESTHESIOLOGY, V102, P447, DOI 10.1097/00000542-200502000-00030; Jordan D, 2008, ANESTHESIOLOGY, V109, P1014, DOI 10.1097/ALN.0b013e31818d6c55; Kiviniemi VJ, 2005, MAGN RESON IMAGING, V23, P531, DOI 10.1016/j.mri.2005.02.009; Koenig T, 1999, EUR ARCH PSY CLIN N, V249, P205, DOI 10.1007/s004060050088; Ku SW, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025155; Lachaux JP, 1999, HUM BRAIN MAPP, V8, P194, DOI 10.1002/(SICI)1097-0193(1999)8:4<194::AID-HBM4>3.0.CO;2-C; Lee U, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046313; Lee U, 2011, ANESTHESIOLOGY, V114, P872, DOI 10.1097/ALN.0b013e31821102c9; Lee U, 2009, CONSCIOUS COGN, V18, P1069, DOI 10.1016/j.concog.2009.04.004; Lewis LD, 2012, P NATL ACAD SCI USA, V109, pE3377, DOI 10.1073/pnas.1210907109; Li D, 2010, J NEURAL ENG, V7, DOI 10.1088/1741-2560/7/4/046010; Mashour GA, 2006, ANESTH ANALG, V103, P975, DOI 10.1213/01.ane.0000232442.69757.4a; Milo R, 2002, SCIENCE, V298, P824, DOI 10.1126/science.298.5594.824; MUNGLANI R, 1993, BRIT J ANAESTH, V71, P633, DOI 10.1093/bja/71.5.633; Peltier SJ, 2005, NEUROREPORT, V16, P285, DOI 10.1097/00001756-200502280-00017; Scholvinck ML, 2010, NEUROIMAGE, V107, P10238; Schrouff J, 2011, NEUROIMAGE, V57, P198, DOI 10.1016/j.neuroimage.2011.04.020; Sporns O, 2004, PLOS BIOL, V2, P1910, DOI 10.1371/journal.pbio.0020369; Stamatakis EA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014224; THEILER J, 1992, PHYSICA D, V58, P77, DOI 10.1016/0167-2789(92)90102-S; Tononi G, 2005, PROG BRAIN RES, V150, P109, DOI 10.1016/S0079-6123(05)50009-8; Tononi Giulio, 2004, BMC Neurosci, V5, P42, DOI 10.1186/1471-2202-5-42; Tononi G, 2008, BIOL BULL-US, V215, P216, DOI 10.2307/25470707; Vincent JL, 2007, NATURE, V447, P83, DOI 10.1038/nature05758	35	5	5	1	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 15	2013	8	8							e70899	10.1371/journal.pone.0070899	http://dx.doi.org/10.1371/journal.pone.0070899			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	204OU	23967131	Green Published, Green Submitted, gold			2023-01-03	WOS:000323378000021
J	Higginson, DS; Sahgal, A; Lawrence, MV; Moyer, S; Stefanescu, M; Willson, AK; Qaqish, B; Zanation, A; Marks, LB; Garg, S; Chera, BS				Higginson, Daniel S.; Sahgal, Alok; Lawrence, Michael V.; Moyer, Sarah; Stefanescu, Mihaela; Willson, Adam K.; Qaqish, Bahjat; Zanation, Adam; Marks, Lawrence B.; Garg, Seema; Chera, Bhishamjit S.			External Beam Radiotherapy for Head and Neck Cancers Is Associated with Increased Variability in Retinal Vascular Oxygenation	PLOS ONE			English	Article							RADIATION RETINOPATHY; SATURATION; IRRADIATION; OXIMETRY; OCCLUSION; VESSELS	Background: Radiation retinopathy is a possible post-treatment complication of radiation therapy. The pathophysiologic mechanism is hypothesized to be microvascular in origin, but evidence is limited. In an effort to study retinal oxygenation in these patients, we herein evaluate the repeatability and variability of retinal oximetry measurements in subjects who had previously received radiation and make comparisons to a cohort of unirradiated subjects. Methods: Using retinal oximetry, a non-invasive imaging modality, we performed in vivo measurements of arteriole (SaO(2)) and venule SO2 (SvO(2)) in subjects (n = 9, 18 retinas) who had received incidental radiation to their retinas (>= 45 Gy to one retina) and in healthy subjects (n = 20, 40 retinas). A total of 1367 SO2 observations on 593 vessels in 29 persons were analyzed to assess three sources of variance in vessel SO2: 1) variance in repeated measurements of the same vessel ("repeatability"), 2) variance in different vessels within the same subject ("within-subject variability"), and 3) variance between subjects ("between-subject variability"). Results: Retinal oximetry measurements were highly repeatable in both irradiated patients and unirradiated subjects. The within-subject variability of SvO(2) and SaO(2) measurements constituted the highest component of variance in both groups and was significantly higher in venules vs. arterioles (relative effect size 1.8, p<0.001) and in irradiated subjects vs. unirradiated subjects (relative effect size 1.6, p<0.001). Conclusions: Retinal oximetry is a highly repeatable technology and can be reliably used to study vascular oxygenation in irradiated subjects. Different vessels within the same subject exhibit a high degree of variability, suggesting that pooled analyses of multiple vessels are most likely to be informative of regional retinal oxygenation. Finally, irradiated subjects exhibited significantly higher within-subject variability in SO2 measurements, suggesting that radiation may cause regional alterations in retinal oxygen delivery and/or metabolism.	[Higginson, Daniel S.] Mem Sloan Kettering Canc Ctr, Dept Radiat Oncol, New York, NY 10021 USA; [Sahgal, Alok; Moyer, Sarah; Garg, Seema] Univ N Carolina, Sch Med, Dept Ophthalmol, Chapel Hill, NC USA; [Lawrence, Michael V.; Stefanescu, Mihaela; Willson, Adam K.; Marks, Lawrence B.; Chera, Bhishamjit S.] Univ N Carolina, Sch Med, Dept Radiat Oncol, Chapel Hill, NC 27599 USA; [Qaqish, Bahjat] Univ N Carolina, Dept Biostat, Gillings Sch Global Publ Hlth, Chapel Hill, NC USA; [Zanation, Adam] Univ N Carolina, Dept Otolaryngol, Chapel Hill, NC USA	Memorial Sloan Kettering Cancer Center; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Chera, BS (corresponding author), Univ N Carolina, Sch Med, Dept Radiat Oncol, Chapel Hill, NC 27599 USA.	bchera@med.unc.edu	Higginson, Daniel/AAW-4021-2020; Higginson, Daniel/X-8619-2018	Higginson, Daniel/0000-0002-6686-7454; Higginson, Daniel/0000-0002-6686-7454	National Center for Research Resources [UL1RR025747]; RSNA Research Resident Grant; Research to Prevent Blindness; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR025747] Funding Source: NIH RePORTER	National Center for Research Resources(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); RSNA Research Resident Grant; Research to Prevent Blindness(Research to Prevent Blindness (RPB)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))	This work was supported by the National Center for Research Resources (UL1RR025747 to BSC); RSNA Research Resident Grant (to DSH); and an unrestricted (ophthalmology) departmental grant from Research to Prevent Blindness. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Center for Research Resources or the National Institutes of Health. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	AMOAKU WMK, 1990, EYE, V4, P657, DOI 10.1038/eye.1990.93; ARCHER D B, 1991, Eye (London), V5, P239; Beach JM, 1999, J APPL PHYSIOL, V86, P748, DOI 10.1152/jappl.1999.86.2.748; CHAN RC, 1976, RADIOLOGY, V120, P673, DOI 10.1148/120.3.673; Emami B, 1991, J NUCL MED, V15, P109, DOI DOI 10.1016/0360-3016(91)90171-Y; FERRIS FL, 1982, AM J OPHTHALMOL, V94, P91, DOI 10.1016/0002-9394(82)90197-0; GASS JDM, 1968, ARCH OPHTHALMOL-CHIC, V80, P606, DOI 10.1001/archopht.1968.00980050608006; Hammer M, 2009, GRAEF ARCH CLIN EXP, V247, P1025, DOI 10.1007/s00417-009-1078-6; Hammer M, 2008, J BIOMED OPT, V13, DOI 10.1117/1.2976032; Hardarson SH, 2006, INVEST OPHTH VIS SCI, V47, P5011, DOI 10.1167/iovs.06-0039; Hardarson SH, 2012, BRIT J OPHTHALMOL, V96, P560, DOI 10.1136/bjophthalmol-2011-300640; Hardarson SH, 2010, AM J OPHTHALMOL, V150, P871, DOI 10.1016/j.ajo.2010.06.020; HAYREH SS, 1970, BRIT J OPHTHALMOL, V54, P705, DOI 10.1136/bjo.54.11.705; IRVINE AR, 1987, AM J OPHTHALMOL, V103, P790, DOI 10.1016/S0002-9394(14)74395-8; JIANG GL, 1994, RADIOTHER ONCOL, V30, P17, DOI 10.1016/0167-8140(94)90005-1; Monroe AT, 2005, INT J RADIAT ONCOL, V61, P856, DOI 10.1016/j.ijrobp.2004.07.664; Palsson O, 2012, INVEST OPHTH VIS SCI, V53, P1729, DOI 10.1167/iovs.11-8621; PARSONS JT, 1994, INT J RADIAT ONCOL, V30, P765, DOI 10.1016/0360-3016(94)90347-6; Schweitzer D, 1999, IEEE T BIO-MED ENG, V46, P1454, DOI 10.1109/10.804573; Traustason S, 2009, BRIT J OPHTHALMOL, V93, P1064, DOI 10.1136/bjo.2008.148460; Traustason S, 2011, INVEST OPHTH VIS SCI, V52, P5064, DOI 10.1167/iovs.11-7275; World Health Organization, 1980, INT CLASS IMP DIS HA	22	2	2	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 6	2013	8	8							e69657	10.1371/journal.pone.0069657	http://dx.doi.org/10.1371/journal.pone.0069657			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	217ZG	23936342	gold, Green Published, Green Submitted			2023-01-03	WOS:000324401500015
J	Boudousq, V; Bobyk, L; Busson, M; Garambois, V; Jarlier, M; Charalambatou, P; Pelegrin, A; Paillas, S; Chouin, N; Quenet, F; Maquaire, P; Torgue, J; Navarro-Teulon, I; Pouget, JP				Boudousq, Vincent; Bobyk, Laure; Busson, Muriel; Garambois, Veronique; Jarlier, Marta; Charalambatou, Paraskevi; Pelegrin, Andre; Paillas, Salome; Chouin, Nicolas; Quenet, Francois; Maquaire, Patrick; Torgue, Julien; Navarro-Teulon, Isabelle; Pouget, Jean-Pierre			Comparison between Internalizing Anti-HER2 mAbs and Non-Internalizing Anti-CEA mAbs in Alpha-Radioimmunotherapy of Small Volume Peritoneal Carcinomatosis Using Pb-212	PLOS ONE			English	Article							HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY; EPITHELIAL OVARIAN-CANCER; MONOCLONAL-ANTIBODY; THERAPEUTIC-EFFICACY; NUDE-MICE; CYTOREDUCTIVE SURGERY; PROSTATE-CANCER; BREAST-CANCER; PARTICLE RADIOIMMUNOTHERAPY; CARCINOEMBRYONIC ANTIGEN	Background and Purpose: We assessed the contribution of antibody internalization in the efficacy and toxicity of intraperitoneal alpha-radioimmunotherapy (RIT) of small volume carcinomatosis using Pb-212-labeled monoclonal antibodies (mAbs) that target HER2 (internalizing) or CEA (non-internalizing) receptors. Materials and Methods: Athymic nude mice bearing 2-3 mm intraperitoneal tumor xenografts were intraperitoneally injected with similar activities (370, 740 and 1480 kBq; 37 MBq/mg) of Pb-212-labeled 35A7 (anti-CEA), trastuzumab (anti-HER2) or PX (non-specific) mAbs, or with equivalent amounts of unlabeled mAbs, or with NaCl. Tumor volume was monitored by bioluminescence and survival was reported. Hematologic toxicity and body weight were assessed. Biodistribution of Pb-212-labeled mAbs and absorbed dose-effect relationships using MIRD formalism were established. Results: Transient hematological toxicity, as revealed by white blood cells and platelets numbering, was reported in mice treated with the highest activities of Pb-212-labeled mAbs. The median survival (MS) was significantly higher in mice injected with 1.48 MBq of Pb-212-35A7 (non-internalizing mAbs) (MS = 94 days) than in animals treated with the same activity of Pb-212-PX mAbs or with NaCl (MS = 18 days). MS was even not reached after 130 days when follow-up was discontinued in mice treated with 1.48 MBq of Pb-212-trastuzumab. The later efficacy was unexpected since final absorbed dose resulting from injection of 1.48 MBq, was higher for Pb-212-35A7 (35.5 Gy) than for Pb-212-trastuzumab (27.6 Gy). These results also highlight the lack of absorbed dose-effect relationship when mean absorbed dose was calculated using MIRD formalism and the requirement to perform small-scale dosimetry. Conclusions: These data indicate that it might be an advantage of using internalizing anti-HER2 compared with non-internalizing anti-CEA Pb-212-labeled mAbs in the therapy of small volume xenograft tumors. They support clinical investigations of Pb-212-mAbs RIT as an adjuvant treatment after cytoreductive surgery in patients with peritoneal carcinomatosis.	[Boudousq, Vincent; Bobyk, Laure; Busson, Muriel; Garambois, Veronique; Charalambatou, Paraskevi; Pelegrin, Andre; Paillas, Salome; Navarro-Teulon, Isabelle; Pouget, Jean-Pierre] Univ Montpellier, Inst Natl Sante & Rech Med U896, Inst Rech Cancerol Montpellier, F-34059 Montpellier, France; [Boudousq, Vincent] Ctr Hosp Univ Nimes, Nucl Med Serv, Nimes, France; [Boudousq, Vincent; Bobyk, Laure; Busson, Muriel; Garambois, Veronique; Jarlier, Marta; Charalambatou, Paraskevi; Pelegrin, Andre; Paillas, Salome; Quenet, Francois; Navarro-Teulon, Isabelle; Pouget, Jean-Pierre] Inst Reg Canc Montpellier, Montpellier, France; [Chouin, Nicolas] Oniris, Nantes, France; [Maquaire, Patrick] AREVA NC, Beaumont Hague, France; [Torgue, Julien] AREVA Med LLC, Bethesda, MD USA	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Universite de Montpellier; CHU de Nimes; UNICANCER; Universite de Montpellier; Institut Regional du Cancer Montpellier / Val d'Aurelle (ICM); Ecole Nationale Veterinaire, Agroalimentaire et de l'Alimentation Nantes-Atlantique; Areva; Areva	Pouget, JP (corresponding author), Univ Montpellier, Inst Natl Sante & Rech Med U896, Inst Rech Cancerol Montpellier, F-34059 Montpellier, France.	jean-pierre.pouget@inserm.fr	Pèlegrin, André/J-3167-2016; Chouin, Nicolas/M-7914-2016	Chouin, Nicolas/0000-0003-1489-4351; Pelegrin, Andre/0000-0001-9254-2648; POUGET, Jean-Pierre/0000-0001-8551-2029; Torgue, Julien/0000-0002-5898-1521	Institut National du Cancer [R09080FF/RPT09005FFA]; Action No1.1 of Plan Cancer [ASC 13038FSA]; AREVA Med LLC	Institut National du Cancer(Institut National du Cancer (INCA) France); Action No1.1 of Plan Cancer; AREVA Med LLC	This work was supported by the Institut National du Cancer, grant R09080FF/RPT09005FFA, by Action No1.1 of Plan Cancer 2009-2013 (ASC 13038FSA) and by AREVA Med LLC. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Julien Torgue and Patrick Maquaire have affiliation to the commercial funders of this research (AREVA Med LLC). This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials.	Aarts F, 2007, ANN SURG ONCOL, V14, P3274, DOI 10.1245/s10434-007-9509-2; Allen BJ, 2011, IMMUNOTHERAPY-UK, V3, P1041, DOI [10.2217/IMT.11.97, 10.2217/imt.11.97]; Almqvist Y, 2007, CANCER BIOTHER RADIO, V22, P480, DOI 10.1089/cbr.2007.349A; Andersson H, 2009, J NUCL MED, V50, P1153, DOI 10.2967/jnumed.109.062604; Baselga J, 1998, CANCER RES, V58, P2825; Bell JC, 2012, ANN SURG ONCOL; Boswell CA, 2007, NUCL MED BIOL, V34, P757, DOI 10.1016/j.nucmedbio.2007.04.001; Boudousq V, 2010, J NUCL MED, V51, P1748, DOI 10.2967/jnumed.110.080226; Ceelen WP, 2010, NAT REV CLIN ONCOL, V7, P108, DOI 10.1038/nrclinonc.2009.217; Chappell LL, 2000, NUCL MED BIOL, V27, P93, DOI 10.1016/S0969-8051(99)00086-4; Chouin N, 2009, RADIAT RES, V171, P657, DOI 10.1667/RR1371.1; Dadachova E, 1999, NUCL MED BIOL, V26, P977, DOI 10.1016/S0969-8051(99)00054-2; Dahle J, 2011, CURR RADIOPHARM, V4, P321, DOI 10.2174/1874471011104040321; Eckerman K. F., 2008, MIRD RADIONUCLIDE DA; Elgqvist J, 2005, J NUCL MED, V46, P1907; Elgqvist J, 2006, NUCL MED BIOL, V33, P1065, DOI 10.1016/j.nucmedbio.2006.07.009; Elias D, 2012, ANN SURG ONCOL, V19, P5, DOI 10.1245/s10434-011-1897-7; Glehen O, 2004, LANCET ONCOL, V5, P219, DOI 10.1016/S1470-2045(04)01425-1; Glockzin G, 2009, WORLD J SURG ONCOL, V7, DOI 10.1186/1477-7819-7-5; Gustafsson AME, 2012, NUCL MED BIOL, V39, P15, DOI 10.1016/j.nucmedbio.2011.07.003; HAMMARSTROM S, 1989, CANCER RES, V49, P4852; Horak E, 1997, J NUCL MED, V38, P1944; Hudis CA, 2007, NEW ENGL J MED, V357, P39, DOI 10.1056/NEJMra043186; Jurcic JG, 2002, BLOOD, V100, P1233, DOI 10.1182/blood.V100.4.1233.h81602001233_1233_1239; KOHLER G, 1976, EUR J IMMUNOL, V6, P292, DOI 10.1002/eji.1830060411; Koppe MJ, 2005, BRIT J SURG, V92, P264, DOI 10.1002/bjs.4936; Li Y, 2009, CLIN CANCER RES, V15, P865, DOI 10.1158/1078-0432.CCR-08-1203; Lingappa M, 2010, CANCER RES, V70, P6815, DOI 10.1158/0008-5472.CAN-09-4548; McDevitt MR, 2000, CANCER RES, V60, P6095; Milenic DE, 2005, CANCER BIOTHER RADIO, V20, P557, DOI 10.1089/cbr.2005.20.557; Milenic DE, 2008, CLIN CANCER RES, V14, P5108, DOI 10.1158/1078-0432.CCR-08-0256; Milenic DE, 2007, CLIN CANCER RES, V13, P1926, DOI 10.1158/1078-0432.CCR-06-2300; Nikula TK, 1999, J NUCL MED, V40, P166; Oei AL, 2007, INT J CANCER, V120, P2710, DOI 10.1002/ijc.22663; Palm S, 2007, INT J RADIAT ONCOL, V69, P572, DOI 10.1016/j.ijrobp.2007.06.023; Pfost B, 2009, J NUCL MED, V50, DOI 10.2967/jnumed.109.065961; Pomel C, 2010, EJSO-EUR J SURG ONC, V36, P589, DOI 10.1016/j.ejso.2010.04.005; Pouget JP, 2008, RADIAT RES, V170, P192, DOI 10.1667/RR1359.1; Pouget JP, 2011, NAT REV CLIN ONCOL, V8, P720, DOI 10.1038/nrclinonc.2011.160; Robert B, 1996, CANCER RES, V56, P4758; Rosenblat TL, 2010, CLIN CANCER RES, V16, P5303, DOI 10.1158/1078-0432.CCR-10-0382; Ruble G, 1996, INT J RADIAT ONCOL, V34, P609, DOI 10.1016/0360-3016(95)02119-1; RUEGG CL, 1990, CANCER RES, V50, P4221; Santoro L, 2009, J NUCL MED, V50, P2033, DOI 10.2967/jnumed.109.066993; Sgouros G, 2010, J NUCL MED, V51, P311, DOI 10.2967/jnumed.108.058651; Sharkey RM, 2011, IMMUNOTHERAPY-UK, V3, P349, DOI 10.2217/IMT.10.114; Song EY, 2008, CANCER BIOL THER, V7, P76, DOI 10.4161/cbt.7.1.5132; Song H, 2008, CANCER RES, V68, P3873, DOI 10.1158/0008-5472.CAN-07-6308; Sugarbaker PH, 2011, AM J SURG, V201, P157, DOI 10.1016/j.amjsurg.2010.04.010; Sugarbaker PH, 2009, EXPERT OPIN PHARMACO, V10, P1965, DOI 10.1517/14656560903044974; Tan ZQ, 2012, INT J ONCOL, V40, P1881, DOI 10.3892/ijo.2012.1357; Verheijen RH, 2006, J CLIN ONCOL, V24, P571, DOI 10.1200/JCO.2005.02.5973; Wild D, 2011, CANCER RES, V71, P1009, DOI 10.1158/0008-5472.CAN-10-1186; Yong K, 2011, DALTON T, V40, P6068, DOI 10.1039/c0dt01387k; Zalutsky MR, 2008, J NUCL MED, V49, P30, DOI 10.2967/jnumed.107.046938; Zhang Z, 2006, BLOOD, V108, P1007, DOI 10.1182/blood-2005-11-4757	56	43	46	0	20	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 29	2013	8	7							e69613	10.1371/journal.pone.0069613	http://dx.doi.org/10.1371/journal.pone.0069613			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	204MP	23922757	Green Published, gold			2023-01-03	WOS:000323369700055
J	Hew, CS; Khoo, BY; Gam, LH				Hew, Chaw-Sen; Khoo, Boon-Yin; Gam, Lay-Harn			The Anti-Cancer Property of Proteins Extracted from Gynura procumbens (Lour.) Merr.	PLOS ONE			English	Article							SUPEROXIDE-DISMUTASE; CELL-PROLIFERATION; PLANT; IL-6; INTERLEUKIN-6; DOMAIN	Gynura procumbens (Lour.) Merr. belongs to the Asteraceae Family. The plant is a well-known traditional herb in South East Asia and it is widely used to treat inflammation, kidney discomfort, high cholesterol level, diabetic, cancer and high blood pressure. Our earlier study showed the presence of valuable plant defense proteins, such as peroxidase, thaumatin-like proteins and miraculin in the leaf of G. procumbens. However, the effects of these defense proteins on cancers have never been determined previously. In the present study, we investigated the bioactivity of gel filtration fractionated proteins of G. procumbens leaf extract. The active protein fraction, SN-F11/12, was found to inhibit the growth of a breast cancer cell line, MDA-MB-231, at an EC50 value of 3.8 mu g/mL. The mRNA expressions of proliferation markers, Ki67 and PCNA, were reduced significantly in the MDA-MB-23 cells treated with SN-F11/12. The expression of invasion marker, CCL2, was also found reduced in the treated MDA-MB-231 cells. All these findings highlight the anti-cancer property of SN-F11/12, therefore, the proteins in this fraction can be a potential chemotherapeutic agent for breast cancer treatment.	[Hew, Chaw-Sen; Gam, Lay-Harn] Univ Sains Malaysia, Sch Pharmaceut Sci, George Town, Malaysia; [Khoo, Boon-Yin] Univ Sains Malaysia, Inst Res Mol Med INFORMM, George Town, Malaysia	Universiti Sains Malaysia; Universiti Sains Malaysia	Gam, LH (corresponding author), Univ Sains Malaysia, Sch Pharmaceut Sci, George Town, Malaysia.	layharn@usm.my	Khoo, Boon Yin/AAF-2783-2019; Khoo, Boon Yin/A-9256-2011	Khoo, Boon Yin/0000-0003-1915-6606	Universiti Sains Malaysia [1001/PFARMASI/815034]; Institute for Graduate Studies of Universiti Sains Malaysia	Universiti Sains Malaysia(Universiti Sains Malaysia); Institute for Graduate Studies of Universiti Sains Malaysia	This work was supported by RU grant from Universiti Sains Malaysia (Project number: 1001/PFARMASI/815034). The authors also thank The Institute for Graduate Studies of Universiti Sains Malaysia for providing scholarship to Hew Chaw-Sen. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ara T, 2010, EUR J CANCER, V46, P1223, DOI 10.1016/j.ejca.2010.02.026; Arakaki AK, 1997, FASEB J, V11, P133, DOI 10.1096/fasebj.11.2.9039955; Bernoux M, 2011, CELL HOST MICROBE, V9, P200, DOI 10.1016/j.chom.2011.02.009; Blanchard F, 2009, CYTOKINE GROWTH F R, V20, P19, DOI 10.1016/j.cytogfr.2008.11.004; Bokesch HR, 2001, J NAT PROD, V64, P249, DOI 10.1021/np000372l; Coll NS, 2011, CELL DEATH DIFFER, V18, P1247, DOI 10.1038/cdd.2011.37; David F, 2007, VET SURG, V36, P221, DOI 10.1111/j.1532-950X.2007.00253.x; Fridovich I, 1998, PROTEIN SCI, V7, P2688, DOI 10.1002/pro.5560071225; Gam LH, 2002, J BIOSAINS, V13, P27; Gasparri F, 2004, J BIOMOL SCREEN, V9, P232, DOI 10.1177/1087057103262836; Gong HJ, 2003, PLANT GROWTH REGUL, V40, P139, DOI 10.1023/A:1024243414584; Gorjanovic S, 2007, J I BREWING, V113, P206, DOI 10.1002/j.2050-0416.2007.tb00277.x; Hadji I, 2007, APPL BIOCHEM BIOTECH, V143, P129, DOI 10.1007/s12010-007-0042-3; Harvey AL, 2008, DRUG DISCOV TODAY, V13, P894, DOI 10.1016/j.drudis.2008.07.004; Hew CS, 2010, BIOTECHNOL BIOTEC EQ, V24, P2132, DOI 10.2478/v10133-010-0075-6; Hew CS, 2011, APPL BIOCHEM BIOTECH, V165, P1577, DOI 10.1007/s12010-011-9377-x; Hodge DR, 2005, EUR J CANCER, V41, P2502, DOI 10.1016/j.ejca.2005.08.016; Iskander MN, 2002, PLANT FOOD HUM NUTR, V57, P233, DOI 10.1023/A:1021851230890; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.20107]; Jenie RI, 2007, INDONESIAN J PHARM, V18, P81; Kiba A, 2003, PLANT CELL PHYSIOL, V44, P296, DOI 10.1093/pcp/pcg035; Kim Jeewon, 2008, Nutr Res Pract, V2, P80, DOI 10.4162/nrp.2008.2.2.80; Kim JY, 2009, INT J MOL SCI, V10, P2860, DOI 10.3390/ijms10062860; Knupfer H, 2007, BREAST CANCER RES TR, V102, P129, DOI 10.1007/s10549-006-9328-3; Lee Hee Jae, 2007, Korean Journal of Physiology & Pharmacology, V11, P145; Liu XD, 2007, AM J RESP CELL MOL, V37, P121, DOI 10.1165/rcmb.2005-0253OC; Losa M, 1998, CLIN SCI, V95, P129, DOI 10.1042/CS19970206; Lu X, 2009, J BIOL CHEM, V284, P29087, DOI 10.1074/jbc.M109.035899; Mandyam CD, 2007, NEUROSCIENCE, V146, P108, DOI 10.1016/j.neuroscience.2006.12.064; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; Mediavilla MG, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013501; Mishra P, 2011, J LEUKOCYTE BIOL, V89, P31, DOI 10.1189/jlb.0310182; Nawrot R, 2010, BMC COMPLEM ALTERN M, V10, DOI 10.1186/1472-6882-10-78; Perry LM, 1980, MED PLANTS E SE ASIA; Puangpronpitag D., 2010, Asian Journal of Plant Sciences, V9, P146; Qian BZ, 2011, NATURE, V475, P222, DOI 10.1038/nature10138; Sfaxi IH, 2012, MOL BIOTECHNOL, V52, P49, DOI 10.1007/s12033-011-9473-8; Shirano Y, 2002, PLANT CELL, V14, P3149, DOI 10.1105/tpc.005348; Sica A, 2009, ENCY CANC, P3064; Tepkeeva II, 2008, B EXP BIOL MED+, V145, P464, DOI 10.1007/s10517-008-0119-1; Tomaz T, 2010, PLANT PHYSIOL, V154, P1143, DOI 10.1104/pp.110.161612; Tsugane K, 1999, PLANT CELL, V11, P1195, DOI 10.1105/tpc.11.7.1195; Ward WW, 2009, CURR ANAL CHEM, V5, P85, DOI 10.2174/157341109787846171; Wiart Christophe, 2006, P1; Yerushalmi Rinat, 2010, Lancet Oncol, V11, P174, DOI 10.1016/S1470-2045(09)70262-1; Zhang X. F., 2000, SMJ, V41, P9; Zhang Y, 2002, CANCER RES, V62, P1205; Zinzalla G, 2010, BIOORG MED CHEM LETT, V20, P7029, DOI 10.1016/j.bmcl.2010.09.117	48	32	33	1	25	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 11	2013	8	7							e68524	10.1371/journal.pone.0068524	http://dx.doi.org/10.1371/journal.pone.0068524			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	188UA	23874655	Green Published, Green Submitted, gold			2023-01-03	WOS:000322218800035
J	Carbone, JW; Margolis, LM; McClung, JP; Cao, JJ; Murphy, NE; Sauter, ER; Combs, GF; Young, AJ; Pasiakos, SM				Carbone, John W.; Margolis, Lee M.; McClung, James P.; Cao, Jay J.; Murphy, Nancy E.; Sauter, Edward R.; Combs, Gerald F., Jr.; Young, Andrew J.; Pasiakos, Stefan M.			Effects of energy deficit, dietary protein, and feeding on intracellular regulators of skeletal muscle proteolysis	FASEB JOURNAL			English	Article						ubiquitin proteasome; caspase-3; negative energy balance; high-protein diets	GASTRIC-CANCER PATIENTS; FAT-FREE MASS; ENDURANCE EXERCISE; CATABOLIC CONDITIONS; GENE-EXPRESSION; WEIGHT-LOSS; PROTEASOME; RESPONSES; PATHWAY; SUPPLEMENTATION	This study was undertaken to characterize the ubiquitin proteasome system (UPS) response to varied dietary protein intake, energy deficit (ED), and consumption of a mixed meal. A randomized, controlled trial of 39 adults consuming protein at 0.8 (recommended dietary allowance [RDA]), 1.6 (2x-RDA), or 2.4 (3x-RDA) g.kg(-1).d(-1) for 31 d. A 10-d weight maintenance (WM) period was followed by 21 d of 40% ED. Ubiquitin (Ub)-mediated proteolysis and associated gene expression were assessed in the postabsorptive (fasted) and postprandial (fed; 480 kcal, 20 g protein) states after WM and ED by using muscle biopsies, fluorescence-based assays, immunoblot analysis, and real-time qRT-PCR. In the assessment of UPS responses to varied protein intakes, ED, and feeding, the RDA, WM, and fasted measures served as appropriate controls. ED resulted in the up-regulation of UPS-associated gene expression, as mRNA expression of the atrogenes muscle RING finger-1 (MuRF1) and atrogin-1 were 1.2- and 1.3-fold higher (P<0.05) for ED than for WM. However, mixed-meal consumption attenuated UPS-mediated proteolysis, independent of energy status or dietary protein, as the activities of the 26S proteasome subunits beta 1, beta 2, and beta 5 were lower (P<0.05) for fed than for fasted. Muscle protein ubiquitylation was also 45% lower (P<0.05) for fed than for fasted, regardless of dietary protein and energy manipulations. Independent of habitual protein intake and despite increased MuRF1 and atrogin-1 mRNA expression during ED, consuming a protein-containing mixed meal attenuates Ub-mediated proteolysis.	[Carbone, John W.] Eastern Michigan Univ, Sch Hlth Sci, Ypsilanti, MI 48197 USA; [Margolis, Lee M.; McClung, James P.; Murphy, Nancy E.; Young, Andrew J.; Pasiakos, Stefan M.] US Army Res Inst Environm Med, Mil Nutr Div, Natick, MA 01760 USA; [Cao, Jay J.; Sauter, Edward R.; Combs, Gerald F., Jr.] ARS, Grand Forks Human Nutr Res Ctr, USDA, Grand Forks, ND USA; [Sauter, Edward R.] Univ N Dakota, Sch Med & Hlth Sci, Grand Forks, ND 58201 USA	Eastern Michigan University; United States Department of Defense; United States Army; United States Department of Agriculture (USDA); University of North Dakota Grand Forks	Pasiakos, SM (corresponding author), US Army Res Inst Environm Med, Mil Nutr Div, 15 Kansas St,Bldg 42, Natick, MA 01760 USA.	stefan.pasiakos@us.army.mil	Pasiakos, Stefan M/E-6295-2014; McClung, James P/A-1989-2009	Pasiakos, Stefan M/0000-0002-5378-5820; , Lee/0000-0002-0652-1304; Margolis, Lee/0000-0003-1697-825X	U.S. Army Medical Research and Material Command (USAMRMC); USDA, Agricultural Research Service (ARS); Eastern Michigan University College of Health and Human Services; Dairy Research Institute; USDA; USAMRMC; USDA, ARS [58-1950-7-707]	U.S. Army Medical Research and Material Command (USAMRMC)(United States Department of DefenseUnited States ArmyU.S. Army Medical Research & Materiel Command (USAMRMC)); USDA, Agricultural Research Service (ARS)(United States Department of Agriculture (USDA)USDA Agricultural Research Service); Eastern Michigan University College of Health and Human Services; Dairy Research Institute; USDA(United States Department of Agriculture (USDA)); USAMRMC(United States Department of DefenseUnited States ArmyU.S. Army Medical Research & Materiel Command (USAMRMC)); USDA, ARS(United States Department of Agriculture (USDA)USDA Agricultural Research Service)	The authors thank the volunteers who participated in this research experiment and LuAnn Johnson [U.S. Department of Agriculture (USDA) Grand Forks Human Nutrition Research Center, Grand Forks, SD, USA] for significant contributions to the data analysis. The study was supported by the U.S. Army Medical Research and Material Command (USAMRMC); the USDA, Agricultural Research Service (ARS); and the Eastern Michigan University College of Health and Human Services. S. M. P. reported that his institution received a grant from the Dairy Research Institute for work outside this publication. E. R. S. reported that his institution received a grant and travel support from the USDA for work associated with this publication. E. R. S. is a consultant for Halo Health, has received royalties for book editorship, and has been granted a patent. J.P.M. reported that his institution received a grant from the USAMRMC for work outside this publication. The other authors report no conflicts of interest. The opinions or assertions contained herein are the private views of the authors and are not to be construed as official or as reflecting the views of the U. S. Army or the U. S. Department of Defense. Any citations of commercial organizations and trade names in this report do not constitute an official Department of the Army endorsement of approval of the products or services of these organizations. This material is based on work supported by the USDA, ARS, under agreement 58-1950-7-707. Any opinions, findings, conclusion, or recommendations expressed in this publication are those of the authors and do not necessarily reflect the view of the USDA. This trial is registered at ClinicalTrials.gov (http://www.clinicaltrials.gov) as number NCT01292395.	Ainsworth BE, 2000, MED SCI SPORT EXER, V32, pS498, DOI 10.1097/00005768-200009001-00009; [Anonymous], 2005, DIET REF INT EN CARB; Bolster DR, 2005, AM J PHYSIOL-ENDOC M, V289, pE678, DOI 10.1152/ajpendo.00060.2005; Bossola M, 2003, ANN SURG, V237, P384, DOI 10.1097/00000658-200303000-00013; Bossola M, 2001, AM J PHYSIOL-REG I, V280, pR1518, DOI 10.1152/ajpregu.2001.280.5.R1518; Burnham K.P., 2002, MODEL SELECTION MULT; Carbone JW, 2012, ADV NUTR, V3, P119, DOI 10.3945/an.111.001792; Chaston TB, 2007, INT J OBESITY, V31, P743, DOI 10.1038/sj.ijo.0803483; Cuthbertson D, 2004, FASEB J, V18, P422, DOI 10.1096/fj.04-2640fje; Du J, 2004, J CLIN INVEST, V113, P115, DOI 10.1172/JCI200418330; Finn PF, 2006, NUTRITION, V22, P830, DOI 10.1016/j.nut.2006.04.008; Groll M, 2003, INT J BIOCHEM CELL B, V35, P606, DOI 10.1016/S1357-2725(02)00390-4; Jagoe RT, 2002, FASEB J, V16, P1697, DOI 10.1096/fj.02-0312com; Kandarian SC, 2006, MUSCLE NERVE, V33, P155, DOI 10.1002/mus.20442; KASCH FW, 1976, J APPL PHYSIOL, V40, P982, DOI 10.1152/jappl.1976.40.6.982; Kumari R, 2011, BIOCHEM BIOPH RES CO, V412, P644, DOI 10.1016/j.bbrc.2011.08.017; Lunn WR, 2012, MED SCI SPORT EXER, V44, P682, DOI 10.1249/MSS.0b013e3182364162; Pasiakos SM, 2013, FASEB J, V27, P3837, DOI 10.1096/fj.13-230227; Pasiakos SM, 2011, AM J CLIN NUTR, V94, P809, DOI 10.3945/ajcn.111.017061; Pasiakos SM, 2010, INT J SPORT NUTR EXE, V20, P282, DOI 10.1123/ijsnem.20.4.282; Pasiakos SM, 2010, J NUTR, V140, P745, DOI 10.3945/jn.109.118372; Raina N, 2004, AM J PHYSIOL-ENDOC M, V286, pE481, DOI 10.1152/ajpendo.00355.2003; Raina N, 2003, CYTOKINE, V22, P180, DOI 10.1016/S1043-4666(03)00105-4; ROZA AM, 1984, AM J CLIN NUTR, V40, P168, DOI 10.1093/ajcn/40.1.168; Salem M, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-328; Schakman O, 2012, AM J PHYSIOL-ENDOC M, V303, pE729, DOI 10.1152/ajpendo.00060.2012; Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73; Scott NW, 2002, CONTROL CLIN TRIALS, V23, P662, DOI 10.1016/S0197-2456(02)00242-8; Tiao G, 1997, J CLIN INVEST, V99, P163, DOI 10.1172/JCI119143; Vary T C, 1998, Curr Opin Clin Nutr Metab Care, V1, P217, DOI 10.1097/00075197-199803000-00013; Weinheimer EM, 2010, NUTR REV, V68, P375, DOI 10.1111/j.1753-4887.2010.00298.x; Williams A, 1999, SURGERY, V126, P744, DOI 10.1067/msy.2099.99888; Wohlgemuth SE, 2011, REJUV RES, V14, P315, DOI 10.1089/rej.2010.1132; Wolf DH, 2004, BBA-MOL CELL RES, V1695, P19, DOI 10.1016/j.bbamcr.2004.10.007; Workeneh BT, 2006, J AM SOC NEPHROL, V17, P3233, DOI 10.1681/ASN.2006020131; Wycherley TP, 2012, AM J CLIN NUTR, V96, P1281, DOI 10.3945/ajcn.112.044321	36	32	32	0	21	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2013	27	12					5104	5111		10.1096/fj.13-239228	http://dx.doi.org/10.1096/fj.13-239228			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	293UK	23965841				2023-01-03	WOS:000329999000042
J	Zhu, JQ; Kang, LY; Ye, QF; Fan, GW; Liang, YB; Yan, C; Orgah, J				Zhu, Jinqiang; Kang, Liyuan; Ye, Qiaofeng; Fan, Guanwei; Liang, Yubin; Yan, Chen; Orgah, John			Effects of Shenfu Injection and Its Main Components on the Contraction of Isolated Rat Thoracic Aortic Rings	PLOS ONE			English	Article							GINSENOSIDES; RELAXATION; INJURY; FU	Background and Purpose: Shenfu injection (SFI), derived from the ancient traditional Chinese medicine (Red Radix Ginseng and Radix Aconitum Carmichaeli), has been widely used in the clinical for the treatment of cardiovascular diseases for more than 20 years. The present study aims to investigate the effects of SFI and its main components on the contraction of isolated rat thoracic aorta rings and the potential mechanisms of this action. Methodology/Principal Findings: The isolated rat thoracic aorta rings were initially treated with different concentrations of SFI, Hongshen injection (HSI, mainly containing ginsenoside) or Fupian injection (FPI, mainly containing aconite total alkaloids) separately. The control group was added an equal volume Krebs-Henseleit (K-H) solution. All three injections exhibited no obviously effects on the basal tension of the rings in the resting state. However, in the isolated thoracic aorta rings with intact endothelium, when the rings were first induced by 60 mM potassium chloride (KCl) or 1 mu M norepinephrine (NE) to the maximal contraction and then treated with above injections, SFI and HSI significantly inhibited the vasoconstriction induced by KCl or NE. In addition, FPI has a tendency to inhibit KCl-induced vasoconstriction and facilitate NE-induced vasoconstriction, but no significant difference. None of them showed obvious effect on the endothelium denuded vessels. Moreover, this procedure was repeated after pre-incubation of nitric oxide synthase (NOS) inhibitor N-G-nitro-L-arginine methyl ester (L-NAME), which suppressed the vasorelaxation effect of SFI and HSI. Conclusions and Implications: These results demonstrate that both SFI and HSI caused an apparent thoracic aorta relaxation by endothelium-dependent manner, which was associated with eNOS system, while FPI had no detectable vasodilator effect. This suggested that the ginsenoside from red Radix Ginseng may be the main active ingredient of SFI's vasodilator effect.	[Zhu, Jinqiang; Kang, Liyuan; Ye, Qiaofeng; Fan, Guanwei; Liang, Yubin; Yan, Chen] Tianjin Univ Tradit Chinese Med, Tianjin Key Lab Chinese Med Pharmacol, Inst Tradit Chinese Med, Tianjin, Peoples R China; [Orgah, John] Tianjin Int Joint Acad Biotechnol & Med, Res & Dev Ctr TCM, Tianjin, Peoples R China	Tianjin University of Traditional Chinese Medicine; Tianjin International Joint Academy of Biomedicine	Kang, LY (corresponding author), Tianjin Univ Tradit Chinese Med, Tianjin Key Lab Chinese Med Pharmacol, Inst Tradit Chinese Med, Tianjin, Peoples R China.	klyzm@163.com	guanwei, fan/M-8193-2019; Orgah, John Owoicho/Q-7645-2019; FAN, GUANWEI/GWV-6480-2022		National Key Basic Research and Development Program (973 Program) [2012CB518404]	National Key Basic Research and Development Program (973 Program)(National Basic Research Program of China)	This work was supported by the National Key Basic Research and Development Program (973 Program)-Component Compatibility regulation of the effective prescription for the treatment of cardiovascular disease (No.: 2012CB518404). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Angulo J, 2003, BRIT J PHARMACOL, V138, P63, DOI 10.1038/sj.bjp.0705027; [Anonymous], [No title captured]; [Anonymous], 2005, CHIN J NAT MED; [Anonymous], [No title captured]; Deng Q. Y., 2012, J NEW CHINESE MED, V44, P15; Ding YD, 2009, SHANDONG MED J, V49, P64; Gu W, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/464650; [侯雅竹 Hou Yazhu], 2011, [中国循证医学杂志, Chinese Journal of Evidence-Based Medicine], V11, P292; Hu HH, 2005, CHINESE J INTEGRATIV, V3, P67; Huang W, 2007, J LIAONING U TRADITI, V9, P5; Ji XF, 2013, CHINESE MED J-PEKING, V126, P697, DOI 10.3760/cma.j.issn.0366-6999.20121320; Ji XF, 2011, SHOCK, V35, P530, DOI 10.1097/SHK.0b013e31820e2058; KANG SY, 1995, LIFE SCI, V56, P1577, DOI 10.1016/0024-3205(95)00124-O; KIM ND, 1994, GEN PHARMACOL-VASC S, V25, P1071, DOI 10.1016/0306-3623(94)90121-X; Li QB, 1999, J GUANGDONG MED COLL, V17, P138; Li QB, 1999, J GUANGDONG MED COLL, V17, P138; Liu J. W., 2010, J LIAONING U TRADITI, V12, P242; Liu XH, 2010, CHINA PHARM, V19, P12; Liu YH, 2010, LIAONING J TRADITI S, VS1, P42; Liu Z, 2001, J NEW CHINESE MED, V33, P6; Nie Y.J., 2012, CHIN MED PHARM CHIN, V2, P64; Tu QY, 2009, LIAONING J TRADITION, V36, P1908; Wang YS, 1983, CHINESE MED PHARM AP, P16; Wang ZC, 2008, INT J TRADITIONAL CH, V30, P445; Xu SY, 1994, PHARM EXPT METHODOLO, P886; [闫福曼 Yan Fuman], 2009, [中药药理与临床, Pharmacology and Clinics of Chinese Materia Medica], V25, P8; Yang RJ, 2012, STUDY CHEM CONSTITUE; Zhang JZ, 2009, PRACTICAL J CARDIAC, V17, P470; [张晓膺 Zhang Xiaoying], 2005, [江苏医药, Jiangsu medical Journal], V31, P113; Zhao JR, 2009, PRACTICAL J CARDIAC, V17, P776; Zheng CD, 2008, CHIN J INTEGR MED, V14, P10, DOI 10.1007/s11655-008-0010-y; Zheng HK, 1997, TRADITIONAL CHINESE, P109; Zheng SY, 2004, AM J CHINESE MED, V32, P209, DOI 10.1142/S0192415X04001874; Zheng SY, 2004, J NANJING U NATURAL, V40, P193; Zhou LQ, 2007, J J LIAONING U TCM, V9, P209; [邹磊 ZOU Lei], 2009, [重庆医科大学学报, Acta Universitatis Scientiae Medicinae Chongqing], V34, P903	36	31	34	0	21	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 30	2013	8	10							e78026	10.1371/journal.pone.0078026	http://dx.doi.org/10.1371/journal.pone.0078026			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	243RL	24205074	Green Submitted, gold, Green Published			2023-01-03	WOS:000326334500090
J	Wong, FC; Woo, CC; Hsu, A; Tan, BKH				Wong, Fang Cheng; Woo, Chern Chiuh; Hsu, Annie; Tan, Benny Kwong Huat			The Anti-Cancer Activities of Vernonia amygdalina Extract in Human Breast Cancer Cell Lines Are Mediated through Caspase-Dependent and p53-Independent Pathways	PLOS ONE			English	Article							SESQUITERPENE LACTONES; INDEPENDENT APOPTOSIS; DNA-DAMAGE; P53; SUPPRESSION; TARGET; DEL	Breast cancer is currently the leading cause of cancer-related deaths among women globally. Notably, medicinal plant extracts may be a potential source for treatments of breast cancer. Vernonia amygdalina (VA) is a woody shrub reported to have not only diverse therapeutic effects but also anti-cancer properties. However, current research about the mechanisms of the anti-cancer potential of VA has been limited. This study aimed to investigate the mechanisms of action of VA that underlie its anti-cancer effects in human breast cancer cell lines (MCF-7 and MDA-MB-231 cells). Results from MTT assay revealed that VA inhibits the proliferation of MCF-7 and MDA-MB-231, in a time-and dose-dependent manner. The underlying mechanism of this growth inhibition involved the stimulation of cell-type specific G1/S phase cell cycle arrest in only MCF-7 cells, and not in MDA-MB-231 cells. While the growth arrest was associated with increased levels of p53 and p21, and a concomitant decrease in the levels of cyclin D1 and cyclin E, it was shown that VA causes cell cycle arrest through a p53-independent pathway as tested by the wild type p53 inhibitor, pifithrin-alpha. Furthermore, this study revealed that VA induces apoptosis in the two cell lines, as indicated by the increase in Annexin V-positive cells and sub-G1 population, and that this VA-induced apoptosis occurred through both extrinsic and intrinsic apoptotic pathways. The apoptosis in MCF-7 cells was also likely to be caspase-dependent and not p53 transcriptional-dependent. Given that approximately 70% of diagnosed breast cancers express ER-alpha, a crucial finding was that VA inhibits the expression of ER-alpha and its downstream player, Akt, highlighting the potential clinical significance of VA. Moreover, VA exhibits synergism when combined with doxorubicin, suggesting that it can complement current chemotherapy. Overall, this study demonstrates the potential applications of VA as an anti-cancer drug for breast cancer treatment.	[Wong, Fang Cheng; Woo, Chern Chiuh; Hsu, Annie; Tan, Benny Kwong Huat] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Pharmacol, Singapore 117595, Singapore	National University of Singapore	Tan, BKH (corresponding author), Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Pharmacol, Singapore 117595, Singapore.	benny_tan@nuhs.edu.sg			Department of Pharmacology, National University of Singapore [C-184-000-610-031]	Department of Pharmacology, National University of Singapore	This study was supported by a grant (C-184-000-610-031) from the Department of Pharmacology, National University of Singapore (http://medicine.nus.edu.sg/medphc/). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alawa CBI, 2003, VET PARASITOL, V113, P73, DOI 10.1016/S0304-4017(03)00040-2; Berger CE, 2012, J BIOL CHEM, V287, P30117, DOI 10.1074/jbc.M112.367326; Borner C, 1999, CELL DEATH DIFFER, V6, P497, DOI 10.1038/sj.cdd.4400525; Chen TF, 2009, INT J BIOCHEM CELL B, V41, P666, DOI 10.1016/j.biocel.2008.07.014; Christophorou MA, 2006, NATURE, V443, P214, DOI 10.1038/nature05077; Farombi EO, 2011, INT J ENV RES PUB HE, V8, P2533, DOI 10.3390/ijerph8062533; Ford CHJ, 2011, ANTICANCER RES, V31, P521; Fukutomi Takashi, 2002, Breast Cancer, V9, P95, DOI 10.1007/BF02967572; Han K, 2007, GYMNANTHEMUM AMYGDAL; Hao TQ, 2008, CHIN MED J, V121, P602; Ijeh II, 2011, J MED PLANTS RES, V5, P1051; Izevbigie EB, 2003, EXP BIOL MED, V228, P293, DOI 10.1177/153537020322800308; JISAKA M, 1993, BIOSCI BIOTECH BIOCH, V57, P833, DOI 10.1271/bbb.57.833; KUPCHAN SM, 1969, J ORG CHEM, V34, P3908, DOI 10.1021/jo01264a035; Ligresti G, 2008, MOL MED REP, V1, P451; Lumachi F, 2013, CURR MED CHEM, V20, P596, DOI 10.2174/092986713804999303; Moll UM, 2005, CURR OPIN CELL BIOL, V17, P631, DOI 10.1016/j.ceb.2005.09.007; Opata Michael M, 2006, Int J Environ Res Public Health, V3, P174, DOI 10.3390/ijerph2006030019; Rang H.P., 2007, RANG DALES PHARM, V6th; Rasoanaivo P, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-S1-S4; Slee EA, 2004, ONCOGENE, V23, P2809, DOI 10.1038/sj.onc.1207516; Steelman LS, 2008, EXPERT OPIN THER TAR, V12, P1139, DOI [10.1517/14728222.12.9.1139, 10.1517/14728222.12.9.1139 ]; Suzuki K, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/978312; Wang DD, 2012, J BIOL CHEM, V287, P12612, DOI 10.1074/jbc.M111.334151; Wang Z, 2010, TRANSL ONCOL, V3, P1, DOI 10.1593/tlo.09250; Watson MI, 2005, MOL CANCER THER, V4, P1369; Xiang JL, 1996, P NATL ACAD SCI USA, V93, P14559, DOI 10.1073/pnas.93.25.14559; Yap TA, 2008, CURR OPIN PHARMACOL, V8, P393, DOI 10.1016/j.coph.2008.08.004; Yeap SK, 2010, J MED PLANTS RES, V4, P2787; Yedjou Clement, 2008, Int J Environ Res Public Health, V5, P337	30	54	55	0	29	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 24	2013	8	10							e78021	10.1371/journal.pone.0078021	http://dx.doi.org/10.1371/journal.pone.0078021			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	241FR	24205071	Green Published, Green Submitted, gold			2023-01-03	WOS:000326152300040
J	Nacoulma, AP; Megalizzi, V; Pottier, LR; De Lorenzi, M; Thoret, S; Dubois, J; Vandeputte, OM; Duez, P; Vereecke, D; El Jaziri, M				Nacoulma, Aminata P.; Megalizzi, Veronique; Pottier, Laurent R.; De Lorenzi, Manuela; Thoret, Sylviane; Dubois, Joelle; Vandeputte, Olivier M.; Duez, Pierre; Vereecke, Danny; El Jaziri, Mondher			Potent Antiproliferative Cembrenoids Accumulate in Tobacco upon Infection with Rhodococcus fascians and Trigger Unusual Microtubule Dynamics in Human Glioblastoma Cells	PLOS ONE			English	Article							NICOTIANA-TABACUM; IN-VITRO; TUBULIN; POLYMERIZATION; INHIBITION; COLCHICINE; TRICHOMES; EXTRACTS; CANCER; DEATH	Aims: Though plant metabolic changes are known to occur during interactions with bacteria, these were rarely challenged for pharmacologically active compounds suitable for further drug development. Here, the occurrence of specific chemicals with antiproliferative activity against human cancer cell lines was evidenced in hyperplasia (leafy galls) induced when plants interact with particular phytopathogens, such as the Actinomycete Rhodococcus fascians. Methods: We examined leafy galls fraction F3.1.1 on cell proliferation, cell division and cytoskeletal disorganization of human cancer cell lines using time-lapse videomicroscopy imaging, combined with flow cytometry and immunofluorescence analysis. We determined the F3.1.1-fraction composition by gas chromatography coupled to mass spectrometry. Results: The leafy galls induced on tobacco by R. fascians yielded fraction F3.1.1 which inhibited proliferation of glioblastoma U373 cells with an IC50 of 4.5 mu g/mL, F.3.1.1 was shown to increase cell division duration, cause nuclear morphological deformations and cell enlargement, and, at higher concentrations, karyokinesis defects leading to polyploidization and apoptosis. F3.1.1 consisted of a mixture of isomers belonging to the cembrenoids. The cellular defects induced by F3.1.1 were caused by a peculiar cytoskeletal disorganization, with the occurrence of fragmented tubulin and strongly organized microtubule aggregates within the same cell. Colchicine, paclitaxel, and cembrene also affected U373 cell proliferation and karyokinesis, but the induced microtubule rearrangement was very different from that provoked by F3.1.1. Altogether our data indicate that the cembrenoid isomers in F3.1.1 have a unique mode of action and are able to simultaneously modulate microtubule polymerization and stability.	[Nacoulma, Aminata P.; Megalizzi, Veronique; De Lorenzi, Manuela] Univ Libre Brussels, Fac Pharm, Toxicol Lab, Brussels, Belgium; [Pottier, Laurent R.; Duez, Pierre] Univ Libre Brussels, Fac Pharm, Lab Pharmacognosie Bromatol & Nutr Humaine, Brussels, Belgium; [Thoret, Sylviane; Dubois, Joelle] Ctr Natl Rech Sci, Inst Chim Subst Nat, Unite PR 2301, Gif Sur Yvette, France; [Vandeputte, Olivier M.; El Jaziri, Mondher] Univ Libre Brussels, Fac Sci, Lab Biotechnol Vegetale, Gosselies, Belgium; [Vereecke, Danny] Univ Ghent, Univ Coll Ghent, Dept Plant Prod, B-9000 Ghent, Belgium	Universite Libre de Bruxelles; Universite Libre de Bruxelles; Centre National de la Recherche Scientifique (CNRS); Ghent University; HOGENT University College of Applied Sciences & Arts	Megalizzi, V (corresponding author), Univ Libre Brussels, Fac Pharm, Toxicol Lab, Brussels, Belgium.	vmegaliz@ulb.ac.be		El Jaziri, Mondher/0000-0001-5787-6319; Duez, Pierre/0000-0002-0484-1478	Belgian National Fund for Scientific Research (FNRS) [FRFC 2.4.593.09]	Belgian National Fund for Scientific Research (FNRS)(Fonds de la Recherche Scientifique - FNRS)	O.M.V. is a post-doctoral researcher of the F.R.S.-F.N.R.S. (Fonds de la Recherche Scientifique, Belgium). The authors gratefully thank the Belgian National Fund for Scientific Research (FNRS) (FRFC 2.4.593.09). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Baraka HN, 2011, PLANTA MED, V77, P467, DOI 10.1055/s-0030-1250478; Bekier ME, 2009, MOL CANCER THER, V8, P1646, DOI 10.1158/1535-7163.MCT-08-1084; Bhattacharyya B, 2010, METHOD CELL BIOL, V95, P301, DOI 10.1016/S0091-679X(10)95017-6; Bombuwala K, 2006, BEILSTEIN J ORG CHEM, V2, DOI 10.1186/1860-5397-2-13; Bury M, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.85; Capo-Chichi CD, 2009, MOL CELL BIOL, V29, P4766, DOI 10.1128/MCB.00087-09; Clarke SJ, 1999, CLIN PHARMACOKINET, V36, P99, DOI 10.2165/00003088-199936020-00002; Cui H, 2011, BMC PLANT BIOL, V11, DOI 10.1186/1471-2229-11-76; Debeir O, 2008, EXP CELL RES, V314, P2985, DOI 10.1016/j.yexcr.2008.06.010; Forizs L, 2009, CURR MICROBIOL, V58, P483, DOI 10.1007/s00284-008-9352-0; GUO ZH, 1995, PLANT SCI, V110, P1, DOI 10.1016/0168-9452(95)04174-S; Hamm S, 2005, PHYTOCHEMISTRY, V66, P1499, DOI 10.1016/j.phytochem.2005.04.025; Kavallaris M, 2010, NAT REV CANCER, V10, P194, DOI 10.1038/nrc2803; KEATES RAB, 1981, CAN J BIOCHEM CELL B, V59, P361, DOI 10.1139/o81-050; Kwiatkowski N, 2012, ACS CHEM BIOL, V7, P185, DOI 10.1021/cb200305u; Lin KL, 2011, CHEM-BIOL INTERACT, V194, P148, DOI 10.1016/j.cbi.2011.10.002; Megalizzi V, 2011, THESIS U LIBRE BRUXE; Moussaieff A, 2008, J CEREBR BLOOD F MET, V28, P1341, DOI 10.1038/jcbfm.2008.28; Nacoulma AP, 2013, INT J MOL SCI, V14, P12533, DOI 10.3390/ijms140612533; Nacoulma AP, 2012, J PHYTOPATHOL, V160, P617, DOI 10.1111/j.1439-0434.2012.01953.x; Rajaonson S, 2011, ENVIRON MICROBIOL, V13, P1236, DOI 10.1111/j.1462-2920.2011.02424.x; Stes E, 2011, ANNU REV PHYTOPATHOL, V49, P69, DOI 10.1146/annurev-phyto-072910-095217; Villanueva HE, 2010, REC NAT PROD, V4, P115; WAHLBERG I, 1987, NAT PROD REP, V4, P237, DOI 10.1039/np9870400237; ZAVALA F, 1980, J MED CHEM, V23, P546, DOI 10.1021/jm00179a014	25	7	8	1	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 22	2013	8	10							e77529	10.1371/journal.pone.0077529	http://dx.doi.org/10.1371/journal.pone.0077529			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	239OF	24167576	Green Published, Green Submitted, gold			2023-01-03	WOS:000326034500035
J	Ding, XB; Guo, L; Zhang, Y; Fan, SJ; Gu, M; Lu, Y; Jiang, D; Li, YM; Huang, C; Zhou, ZQ				Ding, Xiaobo; Guo, Lu; Zhang, Yu; Fan, Shengjie; Gu, Ming; Lu, Yan; Jiang, Dong; Li, Yiming; Huang, Cheng; Zhou, Zhiqin			Extracts of Pomelo Peels Prevent High-Fat Diet-Induced Metabolic Disorders in C57BL/6 Mice through Activating the PPAR alpha and GLUT4 Pathway	PLOS ONE			English	Article							MESSENGER-RNA LEVELS; CITRUS FLAVONOIDS; INSULIN-RESISTANCE; SERUM-CHOLESTEROL; ENERGY-METABOLISM; OXIDATIVE STRESS; NARINGIN; OBESITY; ANTIOBESITY; ANTIOXIDANT	Objective: Metabolic syndrome is a serious health problem in both developed and developing countries. The present study investigated the anti-metabolic disorder effects of different pomelo varieties on obese C57BL/6 mice induced by high-fat (HF) diet. Design: The peels of four pomelo varieties were extracted with ethanol and the total phenols and flavonoids content of these extracts were measured. For the animal experiment, the female C57BL/6 mice were fed with a Chow diet or a HF diet alone or supplemented with 1% (w/w) different pomelo peel extracts for 8 weeks. Body weight and food intake were measured every other day. At the end of the treatment, the fasting blood glucose, glucose tolerance and insulin (INS) tolerance test, serum lipid profile and insulin levels, and liver lipid contents were analyzed. The gene expression analysis was performed with a quantitative real-time PCR assay. Result: The present study showed that the Citrus grandis liangpinyou (LP) and beibeiyou (BB) extracts were more potent in anti-metabolic disorder effects than the duanshiyou (DS) and wubuyou (WB) extracts. Both LP and BB extracts blocked the body weight gain, lowered fasting blood glucose, serum TC, liver lipid levels, and improved glucose tolerance and insulin resistance, and lowered serum insulin levels in HF diet-fed mice. Compared with the HF group, LP and BB peel extracts increased the mRNA expression of PPAR alpha and its target genes, such as FAS, PGC-1 alpha and PGC-1 beta, and GLUT4 in the liver and white adipocyte tissue (WAT). Conclusion: We found that that pomelo peel extracts could prevent high-fat diet-induced metabolic disorders in C57BL/6 mice through the activation of the PPAR alpha and GLUT4 signaling. Our results indicate that pomelo peels could be used as a dietary therapy and the potential source of drug for metabolic disorders.	[Ding, Xiaobo; Guo, Lu; Zhang, Yu; Fan, Shengjie; Gu, Ming; Lu, Yan; Li, Yiming; Huang, Cheng] Shanghai Univ Tradit Chinese Med, Sch Pharm, Shanghai, Peoples R China; [Ding, Xiaobo; Lu, Yan; Zhou, Zhiqin] Southwest Univ, Coll Hort & Landscape Architecture, Chongqing, Peoples R China; [Ding, Xiaobo; Lu, Yan; Zhou, Zhiqin] Minist Educ, Key Lab Hort Sci Southern Mountainous Reg, Chongqing, Peoples R China; [Jiang, Dong] Chinese Acad Agr Sci, Citrus Res Inst, Chongqing, Peoples R China	Shanghai University of Traditional Chinese Medicine; Southwest University - China; Chinese Academy of Agricultural Sciences	Li, YM (corresponding author), Shanghai Univ Tradit Chinese Med, Sch Pharm, Shanghai, Peoples R China.	ymlius@163.com; chuang.shutcm@gmail.com; zzqswu@yahoo.com	Guo, Lu/AAZ-7783-2020	Guo, Lu/0000-0003-2121-6401	National Natural Science Foundation of China [31171930]; Fundamental Research Funds for the Central Universities [XDJK2013A014]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Fundamental Research Funds for the Central Universities(Fundamental Research Funds for the Central Universities)	This research was supported by the the National Natural Science Foundation of China (31171930) and the Fundamental Research Funds for the Central Universities (XDJK2013A014). All surgery was performed under ethyl urethane anesthesia, and all efforts were made to minimize suffering. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2011, OVERVIEW CITRUS AURA, DOI DOI 10.5897/AJPS; Bok SH, 1999, J NUTR, V129, P1182, DOI 10.1093/jn/129.6.1182; Cleeman JI, 2001, JAMA-J AM MED ASSOC, V285, P2486, DOI 10.1001/jama.285.19.2486; Committee CP, 2005, CHINESE PHARMACOPOEI, P1; Demonty I, 2010, J NUTR, V140, P1615, DOI 10.3945/jn.110.124735; Ding XB, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/678592; FOLCH J, 1957, J BIOL CHEM, V226, P497; Galleano M, 2012, ANN NY ACAD SCI, V1259, P87, DOI 10.1111/j.1749-6632.2012.06511.x; Goto T, 2013, MOL NUTR FOOD RES, V57, P20, DOI 10.1002/mnfr.201200522; Goto T, 2011, AM J PHYSIOL-ENDOC M, V301, pE1022, DOI 10.1152/ajpendo.00061.2011; Hong HJ, 2010, DANGYUJA CITRUS GRAN, P361; Hsu MH, 2001, J BIOL CHEM, V276, P27950, DOI 10.1074/jbc.M100258200; Hung JY, 2010, LUNG CANCER, V68, P366, DOI 10.1016/j.lungcan.2009.08.013; Huong DTT, 2006, NUTRITION, V22, P546, DOI 10.1016/j.nut.2005.11.006; Jang HD, 2010, FOOD CHEM, V118, P554, DOI 10.1016/j.foodchem.2009.05.020; Jung UJ, 2003, CLIN NUTR, V22, P561, DOI 10.1016/S0261-5614(03)00059-1; Jung UJ, 2006, INT J BIOCHEM CELL B, V38, P1134, DOI 10.1016/j.biocel.2005.12.002; Kang SI, 2012, BIOL PHARM BULL, V35, P223, DOI 10.1248/bpb.35.223; Kersten S, 2000, NATURE, V405, P421, DOI 10.1038/35013000; Lee YS, 2013, J NUTR BIOCHEM, V24, P156, DOI 10.1016/j.jnutbio.2012.03.014; Lee YS, 2011, PHYTOMEDICINE, V18, P648, DOI 10.1016/j.phymed.2010.11.005; Lefebvre P, 2006, J CLIN INVEST, V116, P571, DOI 10.1172/JCI27989; Lien DN, 2010, VNU J SCI NAT SCI TE, V26, P224; Mahmoud AM, 2012, J DIABETES COMPLICAT, V26, P483, DOI 10.1016/j.jdiacomp.2012.06.001; Mulvihill EE, 2012, PPAR RES, V2012, DOI 10.1155/2012/857142; Ono E, 2011, BIOCHEM BIOPH RES CO, V410, P677, DOI 10.1016/j.bbrc.2011.06.055; Park HJ, 2013, J NUTR BIOCHEM, V24, P419, DOI 10.1016/j.jnutbio.2011.12.009; Pu P, 2012, ARCH BIOCHEM BIOPHYS, V518, P61, DOI 10.1016/j.abb.2011.11.026; Raasmaja A, 2013, FOOD CHEM, V138, P1392, DOI 10.1016/j.foodchem.2012.09.140; Ramful D, 2010, J AGR FOOD CHEM, V58, P11119, DOI 10.1021/jf102762s; Roza JM, 2007, ALTERN THER HEALTH M, V13, P44; Sharma AK, 2011, BRIT J NUTR, V106, P1713, DOI 10.1017/S000711451100225X; Shin HS, 2011, FOOD SCI BIOTECHNOL, V20, P1235, DOI 10.1007/s10068-011-0170-y; Singhal J, 2012, CANCER PREV RES, V5, P473, DOI 10.1158/1940-6207.CAPR-11-0318; Steiner G, 2001, LANCET, V357, P905; Tanaka T, 2012, J BIOMED BIOTECHNOL, DOI 10.1155/2012/516981; Tsuchida A, 2005, DIABETES, V54, P3358, DOI 10.2337/diabetes.54.12.3358; Wang YC, 2008, FOOD CHEM, V106, P277, DOI 10.1016/j.foodchem.2007.05.086; Wu SJ, 2011, AFR J BIOTECHNOL, V10, P7668; Yamada T, 2011, J EPIDEMIOL, V21, P169, DOI 10.2188/jea.JE20100084; Zarina Z., 2013, International Food Research Journal, V20, P313; Zhang Y, 2012, PPAR RES, V2012, DOI 10.1155/2012/374936; Zimmet P, 2005, J ATHEROSCLER THROMB, V12, P295, DOI 10.5551/jat.12.295	43	47	50	2	36	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 16	2013	8	10							e77915	10.1371/journal.pone.0077915	http://dx.doi.org/10.1371/journal.pone.0077915			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	239JR	24147098	Green Published, gold, Green Submitted			2023-01-03	WOS:000326019400142
J	Voak, AA; Gobalakrishnapillai, V; Seifert, K; Balczo, E; Hu, LQ; Hall, BS; Wilkinson, SR				Voak, Andrew A.; Gobalakrishnapillai, Vithurshaa; Seifert, Karin; Balczo, Edina; Hu, Longqin; Hall, Belinda S.; Wilkinson, Shane R.			An Essential Type I Nitroreductase from Leishmania major Can Be Used to Activate Leishmanicidal Prodrugs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article						Drug Discovery; Drug Screening; Oxidation-Reduction; Parasite; Trypanosoma brucei; Trypanosome	ESCHERICHIA-COLI; DRUG CANDIDATE; RESPIRATORY-CHAIN; PURIFICATION; NIFURTIMOX; RAT; CARCINOGENESIS; FEXINIDAZOLE; NITAZOXANIDE; BENZNIDAZOLE	Nitroaromatic prodrugs are used to treat a range of microbial infections with selectivity achieved by specific activation reactions. For trypanosomatid parasites, this is mediated by type I nitroreductases. Here, we demonstrate that the causative agent of leishmaniasis, Leishmania major, expresses an FMN-containing nitroreductase (LmNTR) that metabolizes a wide range of substrates, and based on electron donor and acceptor preferences, it may function as an NADH:quinone oxidoreductase. Using gene deletion approaches, we demonstrate that this activity is essential to L. major promastigotes, the parasite forms found in the insect vector. Intriguingly, LmNTR(+/-) heterozygote promastigote parasites could readily differentiate into infectious metacyclic cells but these were unable to establish infections in cultured mammalian cells and caused delayed pathology in mice. Furthermore, we exploit the LmNTR activity evaluating a library of nitrobenzylphosphoramide mustards using biochemical and phenotypic screens. We identify a subset of compounds that display significant growth inhibitory properties against the intracellular parasite form found in the mammalian hosts. The leishmanicidal activity was shown to be LmNTR-specific as the LmNTR(+/-) heterozygote promastigotes displayed resistance to the most potent mustards. We conclude that LmNTR can be targeted for drug development by exploiting its prodrug activating property or by designing specific inhibitors to block its endogenous function.	[Voak, Andrew A.; Gobalakrishnapillai, Vithurshaa; Balczo, Edina; Hall, Belinda S.; Wilkinson, Shane R.] Queen Mary Univ London, Sch Biol & Chem Sci, Queen Mary Preclin Drug Discovery Grp, London E1 4NS, England; [Seifert, Karin] Univ London London Sch Hyg & Trop Med, Immunol & Infect Dept, London WC1E 7HT, England; [Hu, Longqin] Rutgers State Univ, Dept Med Chem, Ernest Mario Sch Pharm, Piscataway, NJ 08854 USA	University of London; Queen Mary University London; University of London; London School of Hygiene & Tropical Medicine; Rutgers State University New Brunswick	Wilkinson, SR (corresponding author), Queen Mary Univ London, Sch Biol & Chem Sci, Queen Mary Preclin Drug Discovery Grp, Mile End Rd, London E1 4NS, England.	s.r.wilkinson@qmul.ac.uk	Hu, Longqin/AAR-7076-2021; Hall, Belinda/AGU-6214-2022	Hu, Longqin/0000-0002-1799-5652; Voak, Andrew/0000-0002-1010-4781; Hall, Belinda/0000-0002-3753-1978	Queen Mary University of London Graduate Training Studentship	Queen Mary University of London Graduate Training Studentship	Recipient of a Queen Mary University of London Graduate Training Studentship. Present address: Immunology and Infection Dept., London School of Hygiene and Tropical Medicine, London WC1E 7HT, United Kingdom.	Adagu IS, 2002, J ANTIMICROB CHEMOTH, V49, P103, DOI 10.1093/jac/49.1.103; Arya SC, 2009, BJU INT, V103, P994, DOI [10.1111/j.1464-410X.2009.08510_1.x, 10.1111/j.1464-410X.2009.08510_2.x]; Balasegaram M, 2008, PLOS NEGLECT TROP D, V2, DOI 10.1371/journal.pntd.0000234; BRYANT C, 1991, J BIOL CHEM, V266, P4119; Charest H, 1996, J BIOL CHEM, V271, P17081, DOI 10.1074/jbc.271.29.17081; Chen S, 1997, J BIOL CHEM, V272, P1437, DOI 10.1074/jbc.272.3.1437; Chen Y, 2009, MED RES REV, V29, P29, DOI 10.1002/med.20137; Croft SL, 2011, CLIN MICROBIOL INFEC, V17, P1478, DOI 10.1111/j.1469-0691.2011.03630.x; Croft SL, 2006, CLIN MICROBIOL REV, V19, P111, DOI 10.1128/CMR.19.1.111-126.2006; Cruz I, 2002, LANCET, V359, P1124, DOI 10.1016/S0140-6736(02)08160-6; DASILVA R, 1987, INFECT IMMUN, V55, P2802, DOI 10.1128/IAI.55.11.2802-2806.1987; de Oliveira IM, 2007, BIOCHEM BIOPH RES CO, V355, P919, DOI 10.1016/j.bbrc.2007.02.049; Denny WA, 2003, J BIOMED BIOTECHNOL, P48; FAEDER EJ, 1973, ANAL BIOCHEM, V53, P332, DOI 10.1016/0003-2697(73)90442-9; Gonzalez C, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000585; GRUNBERG E, 1973, ANNU REV MICROBIOL, V27, P317, DOI 10.1146/annurev.mi.27.100173.001533; Hall BS, 2012, ANTIMICROB AGENTS CH, V56, P5821, DOI 10.1128/AAC.01227-12; Hall BS, 2012, ANTIMICROB AGENTS CH, V56, P115, DOI 10.1128/AAC.05135-11; Hall BS, 2011, J BIOL CHEM, V286, P13088, DOI 10.1074/jbc.M111.230847; Hall BS, 2010, ANTIMICROB AGENTS CH, V54, P1193, DOI 10.1128/AAC.01213-09; HART DT, 1981, MOL BIOCHEM PARASIT, V4, P39, DOI 10.1016/0166-6851(81)90027-X; Hiraku Y, 2004, CANCER LETT, V215, P141, DOI 10.1016/j.canlet.2004.05.016; Hu LQ, 2011, BIOORG MED CHEM LETT, V21, P3986, DOI 10.1016/j.bmcl.2011.05.009; Hu LQ, 2003, J MED CHEM, V46, P4818, DOI 10.1021/jm034133h; Jiang YY, 2008, BIOORG MED CHEM LETT, V18, P4059, DOI 10.1016/j.bmcl.2008.05.099; Jiang YY, 2006, J MED CHEM, V49, P4333, DOI 10.1021/jm051246n; Kaiser M, 2011, ANTIMICROB AGENTS CH, V55, P5602, DOI 10.1128/AAC.00246-11; Korba BE, 2008, ANTIVIR RES, V77, P56, DOI 10.1016/j.antiviral.2007.08.005; Matsumoto M, 2006, PLOS MED, V3, P2131, DOI 10.1371/journal.pmed.0030466; MCCALLA DR, 1983, ENVIRON MUTAGEN, V5, P745, DOI 10.1002/em.2860050512; MORENO SNJ, 1984, J BIOL CHEM, V259, P6298; Opperdoes FR, 2008, TRENDS PARASITOL, V24, P310, DOI 10.1016/j.pt.2008.03.013; Pal D, 2009, ANTIMICROB AGENTS CH, V53, P458, DOI 10.1128/AAC.00909-08; Pavli A, 2010, INT J INFECT DIS, V14, pE1032, DOI 10.1016/j.ijid.2010.06.019; PETERSON FJ, 1979, J BIOL CHEM, V254, P4009; Race PR, 2007, J MOL BIOL, V368, P481, DOI 10.1016/j.jmb.2007.02.012; ROVERA G, 1979, SCIENCE, V204, P868, DOI 10.1126/science.286421; Santhamma KR, 1995, MOL BIOCHEM PARASIT, V75, P43, DOI 10.1016/0166-6851(95)02510-3; Sholler GLS, 2006, J PEDIAT HEMATOL ONC, V28, P693, DOI 10.1097/01.mph.0000212994.56812.f2; Stover CK, 2000, NATURE, V405, P962, DOI 10.1038/35016103; Stuart K, 2008, J CLIN INVEST, V118, P1301, DOI 10.1172/JCI33945; Takahashi M, 2000, CANCER LETT, V156, P177, DOI 10.1016/S0304-3835(00)00459-6; Trunz BB, 2011, EUR J MED CHEM, V46, P1524, DOI 10.1016/j.ejmech.2011.01.071; Tweats D, 2012, MUTAGENESIS, V27, P523, DOI 10.1093/mutage/ges015; VanHellemond JJ, 1997, MOL BIOCHEM PARASIT, V85, P135, DOI 10.1016/S0166-6851(97)02828-4; Watanabe M, 1998, J BIOL CHEM, V273, P23922, DOI 10.1074/jbc.273.37.23922; Wilkinson SR, 2008, P NATL ACAD SCI USA, V105, P5022, DOI 10.1073/pnas.0711014105; Wyllie S, 2013, ANTIMICROB AGENTS CH, V57, P901, DOI 10.1128/AAC.01788-12; Wyllie S, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003326; Zenno S, 1996, J BIOCHEM-TOKYO, V120, P736	50	22	23	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 4	2013	288	40					28466	28476		10.1074/jbc.M113.494781	http://dx.doi.org/10.1074/jbc.M113.494781			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	298BL	23946481	Green Published, Green Submitted, hybrid			2023-01-03	WOS:000330298800005
J	Mateos, MV; Hernandez, MT; Giraldo, P; de la Rubia, J; de Arriba, F; Corral, LL; Rosinol, L; Paiva, B; Palomera, L; Bargay, J; Oriol, A; Prosper, F; Lopez, J; Olavarria, E; Quintana, N; Garcia, JL; Blade, J; Lahuerta, JJ; San Miguel, JF				Mateos, Maria-Victoria; Hernandez, Miguel-Teodoro; Giraldo, Pilar; de la Rubia, Javier; de Arriba, Felipe; Lopez Corral, Lucia; Rosinol, Laura; Paiva, Bruno; Palomera, Luis; Bargay, Joan; Oriol, Albert; Prosper, Felipe; Lopez, Javier; Olavarria, Eduardo; Quintana, Nuria; Garcia, Jose-Luis; Blade, Joan; Lahuerta, Juan-Jose; San Miguel, Jesus-F.			Lenalidomide plus Dexamethasone for High-Risk Smoldering Multiple Myeloma	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							STAGE-I; PROGNOSTIC-SIGNIFICANCE; ZOLEDRONIC ACID; BONE-MARROW; THALIDOMIDE; PROGRESSION; DISEASE; THERAPY; MULTICENTER; DIAGNOSIS	Background For patients with smoldering multiple myeloma, the standard of care is observation until symptoms develop. However, this approach does not identify high-risk patients who may benefit from early intervention. Methods In this randomized, open-label, phase 3 trial, we randomly assigned 119 patients with high-risk smoldering myeloma to treatment or observation. Patients in the treatment group received an induction regimen (lenalidomide at a dose of 25 mg per day on days 1 to 21, plus dexamethasone at a dose of 20 mg per day on days 1 to 4 and days 12 to 15, at 4-week intervals for nine cycles), followed by a maintenance regimen (lenalidomide at a dose of 10 mg per day on days 1 to 21 of each 28-day cycle for 2 years). The primary end point was time to progression to symptomatic disease. Secondary end points were response rate, overall survival, and safety. Results After a median follow-up of 40 months, the median time to progression was significantly longer in the treatment group than in the observation group (median not reached vs. 21 months; hazard ratio for progression, 0.18; 95% confidence interval [CI], 0.09 to 0.32; P<0.001). The 3-year survival rate was also higher in the treatment group (94% vs. 80%; hazard ratio for death, 0.31; 95% CI, 0.10 to 0.91; P=0.03). A partial response or better was achieved in 79% of patients in the treatment group after the induction phase and in 90% during the maintenance phase. Toxic effects were mainly grade 2 or lower. Conclusions Early treatment for patients with high-risk smoldering myeloma delays progression to active disease and increases overall survival.	[Mateos, Maria-Victoria; Lopez Corral, Lucia; Paiva, Bruno; San Miguel, Jesus-F.] Univ Salamanca, Hosp Univ Salamanca, Inst Biol Mol & Celular Canc, Consejo Super Invest Cient,Inst Invest Biomed Sal, E-37008 Salamanca, Spain; [Hernandez, Miguel-Teodoro] Hosp Univ Canarias, Santa Cruz De Tenerife, Spain; [Giraldo, Pilar] Hosp Univ Miguel Servet, Zaragoza, Spain; [Palomera, Luis] Hosp Clin Univ Lozano Blesa, Zaragoza, Spain; [de la Rubia, Javier] Univ Catolica Valencia San Vicente Martir, Hosp Univ La Fe, Valencia, Spain; [de Arriba, Felipe] Hosp Gen Univ Morales Meseguer, Murcia, Spain; [Rosinol, Laura; Blade, Joan] Hosp Clin Barcelona, Barcelona, Spain; [Rosinol, Laura; Blade, Joan] Inst Invest Biomed August Pi i Sunyer, Barcelona, Spain; [Bargay, Joan] Hosp Sont Llatzer, Palma De Mallorca, Spain; [Oriol, Albert] Hosp Badalona Germans Trias & Pujol, Badalona, Spain; [Prosper, Felipe] Univ Navarra Clin, Pamplona, Spain; [Olavarria, Eduardo] Hosp Navarra, Pamplona, Spain; [Lopez, Javier] Hosp Ramon & Cajal, E-28034 Madrid, Spain; [Quintana, Nuria; Garcia, Jose-Luis] Celgene, Madrid, Spain; [Lahuerta, Juan-Jose] Hosp 12 Octubre, E-28041 Madrid, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-USAL - Instituto de Biologia Molecular y Celular del Cancer de Salamanca (IBMCC); University of Salamanca; Universidad de la Laguna; Miguel Servet University Hospital; Lozano Blesa University Clinical Hospital; Hospital Universitari i Politecnic La Fe; Universidad Catolica de Valencia San Vicente Martir; Meseguer General University Hospital Morales; University of Barcelona; Hospital Clinic de Barcelona; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; Hospital Universitari Son Llatzer; Hospital Germans Trias i Pujol; University of Navarra; Servicio Navarro de Salud - Osasunbidea; Hospital Universitario Ramon y Cajal; Hospital Universitario 12 de Octubre	San Miguel, JF (corresponding author), Univ Hosp Salamanca, Dept Hematol, Paseo San Vicente 58-182, Salamanca 37007, Spain.	sanmiguel@usal.es	Oriol, Albert/K-9923-2017; Llàtzer, Son/ABG-1829-2020; San-Miguel, Jesús F./V-8977-2018; López-Corral, Lucía/A-4230-2019; Prosper, Felipe/H-6859-2017; Paiva, Bruno/AAB-8881-2021; garcia, Juan/B-4617-2017	Oriol, Albert/0000-0001-6804-2221; Llàtzer, Son/0000-0002-6739-3916; San-Miguel, Jesús F./0000-0002-9183-4857; López-Corral, Lucía/0000-0003-1908-5596; Prosper, Felipe/0000-0001-6115-8790; Paiva, Bruno/0000-0003-1977-3815; de la Rubia, Javier/0000-0002-8354-768X; garcia, Juan/0000-0002-2146-5726				[Anonymous], 2003, J CLIN ONCOL, V21, P16; Barlogie B, 2008, BLOOD, V112, P3122, DOI 10.1182/blood-2008-06-164228; Bianchi G, 2013, LEUKEMIA, V27, P680, DOI 10.1038/leu.2012.237; D'Arena G, 2011, LEUKEMIA LYMPHOMA, V52, P771, DOI 10.3109/10428194.2011.553000; Dimopoulos M, 2009, NEW ENGL J MED, V361, P544; Dimopoulos MA, 2000, ACTA ONCOL, V39, P823; Dispenzieri A, 2008, BLOOD, V111, P785, DOI 10.1182/blood-2007-08-108357; Grignani G, 1996, BRIT J CANCER, V73, P1101, DOI 10.1038/bjc.1996.212; Hillengass J, 2010, J CLIN ONCOL, V28, P1606, DOI 10.1200/JCO.2009.25.5356; HJORTH M, 1993, EUR J HAEMATOL, V50, P95; Kyle RA, 2003, BRIT J HAEMATOL, V121, P749; Kyle RA, 2007, NEW ENGL J MED, V356, P2582, DOI 10.1056/NEJMoa070389; Larsen JT, LEUKEMIA; Lust JA, 2009, MAYO CLIN PROC, V84, P114, DOI 10.4065/84.2.114; Mariette X, 1999, BRIT J HAEMATOL, V104, P723, DOI 10.1046/j.1365-2141.1999.01244.x; Martin A, 2002, BRIT J HAEMATOL, V118, P239, DOI 10.1046/j.1365-2141.2002.03549.x; Moulopoulos LA, 2005, ANN ONCOL, V16, P1824, DOI 10.1093/annonc/mdi362; Musto P, 2008, CANCER-AM CANCER SOC, V113, P1588, DOI 10.1002/cncr.23783; National Cancer Institute National Institutes of Health, COMM TERM CRIT ADV E; Palumbo A, 2012, NEW ENGL J MED, V366, P1759, DOI 10.1056/NEJMoa1112704; Perez-Persona E, 2007, BLOOD, V110, P2586, DOI 10.1182/blood-2007-05-088443; Rajkumar SV, 2010, LANCET ONCOL, V11, P14; Rajkumar SV, 2011, NEW ENGL J MED, V365, P474, DOI 10.1056/NEJMc1106428; Rajkumar SV, 2011, BLOOD, V117, P4691, DOI 10.1182/blood-2010-10-299487; Rajkumar SV, 2003, LEUKEMIA, V17, P775, DOI 10.1038/sj.leu.2402866; Riccardi A, 2000, BRIT J CANCER, V82, P1254; Rosinol L, 2003, BRIT J HAEMATOL, V123, P631, DOI 10.1046/j.1365-2141.2003.04654.x; Weber DM, 2007, NEW ENGL J MED, V357, P2133, DOI 10.1056/NEJMoa070596; Witzig TE, 2013, LEUKEMIA, V27, P220, DOI 10.1038/leu.2012.236	29	342	356	0	37	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 1	2013	369	5					438	447		10.1056/NEJMoa1300439	http://dx.doi.org/10.1056/NEJMoa1300439			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	193GQ	23902483				2023-01-03	WOS:000322547400010
J	Tracy, SK; Hartz, DL; Tracy, MB; Allen, J; Forti, A; Hall, B; White, J; Lainchbury, A; Stapleton, H; Beckmann, M; Bisits, A; Homer, C; Foureur, M; Welsh, A; Kildea, S				Tracy, Sally K.; Hartz, Donna L.; Tracy, Mark B.; Allen, Jyai; Forti, Amanda; Hall, Bev; White, Jan; Lainchbury, Anne; Stapleton, Helen; Beckmann, Michael; Bisits, Andrew; Homer, Caroline; Foureur, Maralyn; Welsh, Alec; Kildea, Sue			Caseload midwifery care versus standard maternity care for women of any risk: M@NGO, a randomised controlled trial	LANCET			English	Article							TO-ONE MIDWIFERY; CESAREAN-SECTION; TRENDS; BIRTH	Background Women at low risk of pregnancy complications benefit from continuity of midwifery care, but no trial evidence exists for women with identified risk factors. We aimed to assess the clinical and cost outcomes of caseload midwifery care for women irrespective of risk factors. Methods In this unblinded, randomised, controlled, parallel-group trial, pregnant women at two metropolitan teaching hospitals in Australia were randomly assigned to either caseload midwifery care or standard maternity care by a telephone-based computer randomisation service. Women aged 18 years and older were eligible if they were less than 24 weeks pregnant at the first booking visit. Those who booked with another care provider, had a multiple pregnancy, or planned to have an elective caesarean section were excluded. Women allocated to caseload care received antenatal, intrapartum, and postnatal care from a named caseload midwife (or back-up caseload midwife). Controls received standard care with rostered midwives in discrete wards or clinics. The participant and the clinician were not masked to assignment. The main primary outcome was the proportion of women who had a caesarean section. The other primary maternal outcomes were the proportions who had an instrumental or unassisted vaginal birth, and the proportion who had epidural analgesia during labour. Primary neonatal outcomes were Apgar scores, preterm birth, and admission to neonatal intensive care. We analysed all outcomes by intention to treat. The trial is registered with the Australian New Zealand Clinical Trials Registry, number ACTRN12609000349246. Findings Publicly insured women were screened at the participating hospitals between Dec 8, 2008, and May 31, 2011. 1748 pregnant women were randomly assigned, 871 to caseload and 877 to standard care. The proportion of caesarean sections did not differ between the groups (183 [21%] in the caseload group vs 204 [23%] in the standard care group; odds ratio [OR] 0.88, 95% CI 0.70-1.10; p=0.26). The proportion of women who had elective caesarean sections (before onset of labour) differed significantly between caseload and standard care (69 [8%] vs 94 [11%]; OR 0.72, 95% CI 0.52-0.99; p=0.05). Proportions of instrumental birth were similar (172 [20%] vs 171 [19%]; p=0.90), as were the proportions of unassisted vaginal births (487 [56%] vs 454 [52%]; p=0.08) and epidural use (314 [36%] vs 304 [35%]; p=0.54). Neonatal outcomes did not differ between the groups. Total cost of care per woman was AUS$566.74 (95% 106.17-1027.30; p=0.02) less for caseload midwifery than for standard maternity care. Interpretation Our results show that for women of any risk, caseload midwifery is safe and cost-effective.	[Tracy, Sally K.; Hartz, Donna L.; Hall, Bev] Univ Sydney, Royal Hosp Women, Midwifery & Womens Hlth Res Unit, Randwick, NSW 2031, Australia; [Tracy, Mark B.] Univ Sydney, Westmead Hosp, Neonatal Intens Care Unit, Westmead, NSW 2145, Australia; [Allen, Jyai; Forti, Amanda; Stapleton, Helen; Kildea, Sue] Australian Catholic Univ, Mater Res & Mater Mothers Hosp, Midwifery Res Unit, Brisbane, Qld, Australia; [Beckmann, Michael] Mater Res & Mater Mothers Hosp, Womens Hlth Serv, Brisbane, Qld, Australia; [Beckmann, Michael] Mater Res & Mater Mothers Hosp, Newborn Serv, Brisbane, Qld, Australia; [White, Jan; Lainchbury, Anne] Royal Hosp Women, Sydney, NSW, Australia; [Bisits, Andrew; Welsh, Alec] Univ New S Wales, Royal Hosp Women, Dept Obstet & Maternal Fetal Med, Kensington, NSW 2033, Australia; [Homer, Caroline; Foureur, Maralyn] Univ Technol Sydney, Fac Hlth, Ctr Midwifery Child & Family Hlth, Sydney, NSW 2007, Australia	University of Sydney; University of Sydney; Australian Catholic University; Mater Research; Mater Research; Mater Research; University of New South Wales Sydney; University of Technology Sydney	Tracy, SK (corresponding author), Univ Sydney, Royal Hosp Women, Midwifery & Womens Hlth Res Unit, Randwick, NSW 2031, Australia.	sally.tracy@sydney.edu.au	Foureur, Maralyn/ABC-2997-2021; Homer, Caroline S. E./J-2101-2014; Foureur, Maralyn/I-9672-2014; Beckmann, Mike/ABB-4964-2020; Kildea, Sue/I-1548-2014; Beckmann, Michael/L-4760-2013	Homer, Caroline S. E./0000-0002-7454-3011; Foureur, Maralyn/0000-0002-0454-0165; Kildea, Sue/0000-0001-8591-4968; Beckmann, Michael/0000-0001-7319-6938; Tracy, Mark/0000-0001-5648-468X; Hartz, Donna/0000-0002-4964-2106; Tracy, Sally Katherine/0000-0002-3753-5362; Welsh, Alec/0000-0002-7389-0513; Allen, Jyai/0000-0003-3196-0883	National Health and Medical Research Council (Australia)	National Health and Medical Research Council (Australia)(National Health and Medical Research Council (NHMRC) of Australia)	Funding National Health and Medical Research Council (Australia).	Australian College of Midwives, 2008, NATIONAL MIDWIFERY G; Beasley S, 2012, AUST NZ J OBSTET GYN, V52, P576, DOI 10.1111/ajo.12003; Braithwaite J, 2009, QUAL SAF HEALTH CARE, V18, P37, DOI 10.1136/qshc.2007.023317; Brew BK, 2012, PEDIAT ALLERG IMM-UK, V23, P75, DOI 10.1111/j.1399-3038.2011.01229.x; Cardwell CR, 2008, DIABETOLOGIA, V51, P726, DOI 10.1007/s00125-008-0941-z; Chantry CJ, 2006, PEDIATRICS, V117, P425, DOI 10.1542/peds.2004-2283; Dahlen HG, 2012, BMJ OPEN, V2, DOI 10.1136/bmjopen-2012-001723; Declercq E, 2011, BIRTH-ISS PERINAT C, V38, P99, DOI 10.1111/j.1523-536X.2010.00459.x; Guilliland K, 1995, THE MIDWIFERY MARTNE; Hartz DL, 2012, AUST HEALTH REV, V36, P169, DOI 10.1071/AH11012; Hatem M, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004667.pub2; Hyde MJ, 2012, BIOL REV, V87, P229, DOI 10.1111/j.1469-185X.2011.00195.x; IECEU, 2017, 34 IECEU; Knight M, 2009, BMC PREGNANCY CHILDB, V9, DOI 10.1186/1471-2393-9-55; Kramer MS, 2001, JAMA-J AM MED ASSOC, V285, P413, DOI 10.1001/jama.285.4.413; Li Z, 2011, AUSTRALIAS MOTHERS A; Macfarlane Fraser, 2011, J Health Organ Manag, V25, P55; McLachlan HL, 2012, BJOG-INT J OBSTET GY, V119, P1483, DOI 10.1111/j.1471-0528.2012.03446.x; Moher David, 2010, BMJ, V340, pc869, DOI [10.1016/j.jclinepi.2010.03.004, 10.1136/bmj.c869]; N Shaffordshire Changing Childbirth, 2000, MIDWIFERY, V16, P295; New South Wales Health, 2010, MATERNITY TOWARDS NO; NHS Insititute for Innovation and Improvement, 2011, PROMOTING NORMAL BIR; O'Leary CM, 2007, BJOG-INT J OBSTET GY, V114, P855, DOI 10.1111/j.1471-0528.2007.01307.x; Page L, 1999, J PUBLIC HEALTH MED, V21, P243, DOI 10.1093/pubmed/21.3.243; Page L, 2003, J MIDWIFERY WOM HEAL, V48, P119, DOI 10.1016/S1526-9523(02)00425-7; Pairman S., 1999, NZ COLL MIDWIVES J, V21, P6; Schlinzig T, 2009, ACTA PAEDIATR, V98, P1096, DOI 10.1111/j.1651-2227.2009.01371.x; Tracy SK, 2011, BMC PREGNANCY CHILDB, V11, DOI 10.1186/1471-2393-11-82; Turnbull D, 1996, LANCET, V348, P213; UK MRC, 2008, DEVELOPING AND EVALU; US Department of Health and Human Services, 2010, HEALTHY PEOPLE 2010; Weng SF, 2012, ARCH DIS CHILD, V97, P1019, DOI 10.1136/archdischild-2012-302263	32	184	184	0	31	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 23	2013	382	9906					1723	1732		10.1016/S0140-6736(13)61406-3	http://dx.doi.org/10.1016/S0140-6736(13)61406-3			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	259PX	24050808				2023-01-03	WOS:000327539900029
J	Kidoaki, S; Sakashita, H				Kidoaki, Satoru; Sakashita, Hiroyuki			Rectified Cell Migration on Saw-Like Micro-Elastically Patterned Hydrogels with Asymmetric Gradient Ratchet Teeth	PLOS ONE			English	Article							FORCE MICROSCOPY; STEM-CELLS; MOTILITY; HAPTOTAXIS; SUBSTRATE; MOVEMENT; MORPHOGENESIS; RIGIDITY; GELATIN	To control cell motility is one of the essential technologies for biomedical engineering. To establish a methodology of the surface design of elastic substrate to control the long-range cell movements, here we report a sophisticated cell culture hydrogel with a micro-elastically patterned surface that allows long-range durotaxis. This hydrogel has a sawlike pattern with asymmetric gradient ratchet teeth, and rectifies random cell movements. Durotaxis only occurs at boundaries in which the gradient strength of elasticity is above a threshold level. Consequently, in gels with unit teeth patterns, durotaxis should only occur at the sides of the teeth in which the gradient strength of elasticity is above this threshold level. Therefore, such gels are expected to support the long-range biased movement of cells via a mechanism similar to the Feynman-Smoluchowski ratchet, i.e., rectified cell migration. The present study verifies this working hypothesis by using photolithographic microelasticity patterning of photocurable gelatin gels. Gels in which each teeth unit was 100-120 mu m wide with a ratio of ascending: descending elasticity gradient of 1: 2 and a peak elasticity of ca. 100 kPa supported the efficient rectified migration of 3T3 fibroblast cells. In addition, long-range cell migration was most efficient when soft lanes were introduced perpendicular to the saw-like patterns. This study demonstrates that asymmetric elasticity gradient patterning of cell culture gels is a versatile means of manipulating cell motility.	[Kidoaki, Satoru] Kyushu Univ, Inst Mat Chem & Engn, Res Field Biomed & Biophys Chem, Fukuoka 812, Japan; [Sakashita, Hiroyuki] Kyushu Univ, Grad Sch Engn, Fukuoka 812, Japan	Kyushu University; Kyushu University	Kidoaki, S (corresponding author), Kyushu Univ, Inst Mat Chem & Engn, Res Field Biomed & Biophys Chem, Fukuoka 812, Japan.	kidoaki@ms.ifoc.kyushu-u.ac.jp	Kidoaki, Satoru/AAR-2704-2020	Kidoaki, Satoru/0000-0001-9138-0018	Management Expenses Grants for National Universities Corporations "Nano-Macro Materials, Devices and System Research Alliance" from the Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan; PRESTO program "Nanosystems and Emergent Functions" from the Japan Science Technology (JST) Agency; Cabinet Office, Government of Japan	Management Expenses Grants for National Universities Corporations "Nano-Macro Materials, Devices and System Research Alliance" from the Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan; PRESTO program "Nanosystems and Emergent Functions" from the Japan Science Technology (JST) Agency; Cabinet Office, Government of Japan	This work was supported by the Management Expenses Grants for National Universities Corporations "Nano-Macro Materials, Devices and System Research Alliance" from the Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan, the PRESTO program "Nanosystems and Emergent Functions" from the Japan Science Technology (JST) Agency, and the Funding Program for World-Leading Innovative R&D on Science and Technology "Innovative NanoBiodevice based on Single Molecule Analysis" from the Cabinet Office, Government of Japan. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aman A, 2010, DEV BIOL, V341, P20, DOI 10.1016/j.ydbio.2009.11.014; Beningo KA, 2002, TRENDS CELL BIOL, V12, P79, DOI 10.1016/S0962-8924(01)02205-X; Bernstein Lori R., 1994, Current Opinion in Oncology, V6, P106, DOI 10.1097/00001622-199401000-00015; Braiman-Wiksman L, 2007, TOXICOL PATHOL, V35, P767, DOI 10.1080/01926230701584189; BRANDLEY BK, 1989, DEV BIOL, V135, P74, DOI 10.1016/0012-1606(89)90159-0; CARTER SB, 1965, NATURE, V208, P1183, DOI 10.1038/2081183a0; CARTER SB, 1967, NATURE, V213, P256, DOI 10.1038/213256a0; Discher DE, 2005, SCIENCE, V310, P1139, DOI 10.1126/science.1116995; Engler AJ, 2006, CELL, V126, P677, DOI 10.1016/j.cell.2006.06.044; ERICKSON CA, 1984, J CELL BIOL, V98, P296, DOI 10.1083/jcb.98.1.296; Feynman RP., 1963, FEYNMAN LECT PHYS, V1, P46; Gray DS, 2003, J BIOMED MATER RES A, V66A, P605, DOI 10.1002/jbm.a.10585; Guo WH, 2006, BIOPHYS J, V90, P2213, DOI 10.1529/biophysj.105.070144; Hertz H., 1881, J FU R REINE ANGEW M, V171, P156, DOI [10.1515/crll.1882.92.156, DOI 10.1515/CRLL.1882.92.156]; Hess DA, 2011, METHODS MOL BIOL, V750, P25, DOI 10.1007/978-1-61779-145-1_2; Ingber DE, 2003, J CELL SCI, V116, P1397, DOI 10.1242/jcs.00360; Ingber DE, 2003, J CELL SCI, V116, P1157, DOI 10.1242/jcs.00359; Jiang XY, 2005, P NATL ACAD SCI USA, V102, P975, DOI 10.1073/pnas.0408954102; Kawano T, 2011, BIOMATERIALS, V32, P2725, DOI 10.1016/j.biomaterials.2011.01.009; Keller R, 2005, CURR OPIN CELL BIOL, V17, P533, DOI 10.1016/j.ceb.2005.08.006; Kidoaki A, 2008, J BIOTECHNOL, V133, P225, DOI 10.1016/j.jbiotec.2007.08.015; Kim DH, 2009, ADV FUNCT MATER, V19, P1579, DOI 10.1002/adfm.200801174; Ko YG, 2013, BIOMATERIALS, V34, P353, DOI 10.1016/j.biomaterials.2012.09.071; Kumar G, 2007, ADV MATER, V19, P1084, DOI 10.1002/adma.200601629; LANGER R, 1993, SCIENCE, V260, P920, DOI 10.1126/science.8493529; Lo CM, 2000, BIOPHYS J, V79, P144, DOI 10.1016/S0006-3495(00)76279-5; Lowe B, 1997, J EXP BIOL, V200, P1593; Mahmud G, 2009, NAT PHYS, V5, P606, DOI 10.1038/NPHYS1306; Martin P, 1997, SCIENCE, V276, P75, DOI 10.1126/science.276.5309.75; MCCARTHY JB, 1983, J CELL BIOL, V97, P772, DOI 10.1083/jcb.97.3.772; McLennan R, 2012, DEVELOPMENT, V139, P2935, DOI 10.1242/dev.081471; Munevar S, 2001, BIOPHYS J, V80, P1744, DOI 10.1016/S0006-3495(01)76145-0; Okino H, 2002, J BIOMED MATER RES, V59, P233, DOI 10.1002/jbm.1237; PARENTE L, 1979, AGENTS ACTIONS, V9, P190, DOI 10.1007/BF02024733; RADMACHER M, 1995, BIOPHYS J, V69, P264, DOI 10.1016/S0006-3495(95)79897-6; Rhoads DS, 2007, EXP CELL RES, V313, P3859, DOI 10.1016/j.yexcr.2007.06.005; Sanchez-Madrid F, 1999, EMBO J, V18, P501, DOI 10.1093/emboj/18.3.501; Saranak J, 1997, NATURE, V387, P465, DOI 10.1038/387465a0; TRINKAUS JP, 1985, J NEUROSCI RES, V13, P1, DOI 10.1002/jnr.490130102; Winer JP, 2009, TISSUE ENG PT A, V15, P147, DOI 10.1089/ten.tea.2007.0388; Wu HW, 1998, SCANNING, V20, P389; Yang J, 2008, DEV CELL, V14, P818, DOI 10.1016/j.devcel.2008.05.009	42	17	18	0	22	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 17	2013	8	10							e78067	10.1371/journal.pone.0078067	http://dx.doi.org/10.1371/journal.pone.0078067			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	239KL	24147112	Green Published, Green Submitted, gold			2023-01-03	WOS:000326022200095
J	Priebe, S; Yeeles, K; Bremner, S; Lauber, C; Eldridge, S; Ashby, D; David, AS; O'Connell, N; Forrest, A; Burns, T				Priebe, Stefan; Yeeles, Ksenija; Bremner, Stephen; Lauber, Christoph; Eldridge, Sandra; Ashby, Deborah; David, Anthony S.; O'Connell, Nicola; Forrest, Alexandra; Burns, Tom			Effectiveness of financial incentives to improve adherence to maintenance treatment with antipsychotics: cluster randomised controlled trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							SEVERE MENTAL-ILLNESS; REDUCE SUBSTANCE USE; MONETARY REINFORCEMENT; CONTINGENCY MANAGEMENT; MEDICATION ADHERENCE; HEALTH-CARE; SCHIZOPHRENIA; PEOPLE; INDIVIDUALS; ABSTINENCE	Objective To test whether offering financial incentives to patients with psychotic disorders is effective in improving adherence to maintenance treatment with antipsychotics. Design Cluster randomised controlled trial. Setting Community mental health teams in secondary psychiatric care in the United Kingdom. Participants Patients with a diagnosis of schizophrenia, schizoaffective disorder, or bipolar disorder, who were prescribed long acting antipsychotic (depot) injections but had received 75% or less of the prescribed injections. We randomly allocated 73 teams with a total of 141 patients. Primary outcome data were available for 35 intervention teams with 75 patients (96% of randomised) and for 31 control teams with 56 patients (89% of randomised). Interventions Participants in the intervention group were offered 15 pound ((sic)17; $22) for each depot injection over a 12 month period. Participants in the control condition received treatment as usual. Main outcome measure The primary outcome was the percentage of prescribed depot injections given during the 12 month intervention period. Results 73 teams with 141 consenting patients were randomised, and outcomes were assessed for 131 patients (93%).double down arrow Average baseline adherence was 69% in the intervention group and 67% in the control group. During the 12 month trial period adherence was 85% in the intervention group and 71% in the control group. The adjusted effect estimate was 11.5% (95% confidence interval 3.9% to 19.0%, P=0.003). A secondary outcome was an adherence of >= 95%, which was achieved in 28% of the intervention group and 5% of the control group (adjusted odds ratio 8.21, 95% confidence interval 2.00 to 33.67, P=0.003). Although differences in clinician rated clinical improvement between the groups failed to reach statistical significance, patients in the intervention group had more favourable subjective quality of life ratings (beta=0.71, 95% confidence interval 0.26 to 1.15, P=0.002). The number of admissions to hospital and adverse events were low in both groups and did not show substantial differences. Conclusion Offering modest financial incentives to patients with psychotic disorders is an effective method for improving adherence to maintenance treatment with antipsychotics.	[Priebe, Stefan; O'Connell, Nicola] Queen Mary Univ London, Unit Social & Community Psychiat, Newham Ctr Mental Hlth, London E13 8SP, England; [Yeeles, Ksenija; Burns, Tom] Univ Oxford, Warneford Hosp, Dept Psychiat, Oxford, England; [Bremner, Stephen; Eldridge, Sandra] Barts & London Queen Marys Sch Med & Dent, Blizard Inst, Ctr Primary Care & Publ Hlth, London, England; [Lauber, Christoph] Jura Bernois, Psychiat Serv, Bienne Seeland, Bellelay, Switzerland; [Ashby, Deborah] Univ London Imperial Coll Sci Technol & Med, Sch Publ Hlth, London, England; [David, Anthony S.] Kings Coll London, Inst Psychiat, Dept Psychosis Studies, London, England	University of London; Queen Mary University London; University of Oxford; University of London; Queen Mary University London; Imperial College London; University of London; King's College London	Priebe, S (corresponding author), Queen Mary Univ London, Unit Social & Community Psychiat, Newham Ctr Mental Hlth, London E13 8SP, England.	s.priebe@qmul.ac.uk	Bremner, Stephen/R-4038-2016; David, Anthony/O-1750-2019; David, Anthony S/C-1315-2011	Bremner, Stephen/0000-0003-0790-7070; David, Anthony/0000-0003-0967-774X; David, Anthony S/0000-0003-0967-774X; O'Connell, Nicola/0000-0002-5143-1797; Yeeles, Ksenija/0000-0002-7757-0154; Eldridge, Sandra/0000-0001-5638-2317; Priebe, Stefan/0000-0001-9864-3394	National Institute for Health Research Health Technology Assessment (NIHR HTA) programme [07/60/43]; National Institute for Health Research [07/60/43] Funding Source: researchfish	National Institute for Health Research Health Technology Assessment (NIHR HTA) programme(National Institute for Health Research (NIHR)); National Institute for Health Research(National Institute for Health Research (NIHR))	This trial was funded by the National Institute for Health Research Health Technology Assessment (NIHR HTA) programme (project No 07/60/43) and will be published in full in Health Technology Assessment. The views and opinions expressed therein are those of the authors and do not necessarily reflect those of the HTA programme, NIHR, NHS, or the Department of Health. The trial is registered with ISRCTN (SRCTN77769281) and is adopted into the UKCRN and MHRN portfolios. The funder had no role in study design, data collection, data analysis, interpretation, writing of the report, or decision to submit for publication. All study researchers were independent from a funder. All authors had full access to all of the data (including statistical reports and tables) in the study and can take responsibility for the integrity of the data and the accuracy of the data analysis.	[Anonymous], 2009, STAT STAT 10 1 PROGR; Burns T, 2007, BRIT MED J, V335, P232, DOI 10.1136/bmj.39286.399514.BE; Burton A, 2010, EPIDEMIOL PSICHIAT S, V19, P233; CAREY KB, 1990, J BEHAV THER EXP PSY, V21, P205, DOI 10.1016/0005-7916(90)90008-9; Claassen D, 2007, PSYCHIATR BULL, V31, P4, DOI 10.1192/pb.31.1.4; Claassen D, 2007, J MED ETHICS, V33, P189, DOI 10.1136/jme.2006.016188; Conley RR, 2001, BIOL PSYCHIAT, V50, P898, DOI 10.1016/S0006-3223(01)01271-9; Cookson R., 2008, BMJ-BRIT MED J, V337, pa589, DOI DOI 10.1136/BMJ.A589; Drebing CE, 2005, J APPL BEHAV ANAL, V38, P359, DOI 10.1901/jaba.2005.100-03; Giuffrida A, 1997, BRIT MED J, V315, P703, DOI 10.1136/bmj.315.7110.703; Glover GR, 1999, BRIT J PSYCHIAT, V175, P544, DOI 10.1192/bjp.175.6.544; Gray R, 2006, BRIT J PSYCHIAT, V189, P508, DOI 10.1192/bjp.bp.105.019489; Guy W., 1976, ECDEU ASSESSMENT MAN, P218, DOI DOI 10.1037/E591322011-001; Helmus TC, 2003, PSYCHOL ADDICT BEHAV, V17, P249, DOI 10.1037/0893-164X.17.3.249; Knapp M, 2004, BRIT J PSYCHIAT, V184, P509, DOI 10.1192/bjp.184.6.509; Marteau TM, 2009, BMJ-BRIT MED J, V338, DOI 10.1136/bmj.b1415; McDonald HP, 2002, JAMA-J AM MED ASSOC, V288, P2868, DOI 10.1001/jama.288.22.2868; National Collaborating Centre for Mental Health, 2009, SCHIZ COR INT TREATM, P41; Nose M, 2003, BRIT J PSYCHIAT, V183, P197, DOI 10.1192/bjp.183.3.197; Novick D, 2010, PSYCHIAT RES, V176, P109, DOI 10.1016/j.psychres.2009.05.004; OLSON RP, 1972, J CONSULT CLIN PSYCH, V38, P376, DOI 10.1037/h0032910; Popay Jennie, 2008, BMJ, V337, pa594, DOI 10.1136/bmj.a594; Post EP, 2006, PSYCHIAT SERV, V57, P414, DOI 10.1176/appi.ps.57.3.414; Priebe S, 2007, BRIT J PSYCHIAT, V191, P420, DOI 10.1192/bjp.bp.107.036939; Priebe S, 2012, BMC PSYCHIATRY, V12, DOI 10.1186/1471-244X-12-113; Priebe S, 2010, J MED ETHICS, V36, P463, DOI 10.1136/jme.2009.035071; Promberger M, 2011, J MED ETHICS, V37, P682, DOI 10.1136/jme.2010.039347; Ries RK, 2004, PSYCHIAT SERV, V55, P445, DOI 10.1176/appi.ps.55.4.445; Roll JM, 1998, EXP CLIN PSYCHOPHARM, V6, P157, DOI 10.1037/1064-1297.6.2.157; Roll JM, 2004, PSYCHIAT RES, V125, P61, DOI 10.1016/j.psychres.2003.10.003; Ryan P, 1998, STATA TECHNICAL B, V41, P43; Shaner A, 1997, PSYCHIAT SERV, V48, P807; Shaw Joanne, 2007, BMJ, V335, P233, DOI 10.1136/bmj.39286.422639.BE; Sigmon SC, 2000, EXP CLIN PSYCHOPHARM, V8, P509, DOI 10.1037//1064-1297.8.4.509; Staring ABP, 2010, PSYCHOPHARMACOL BULL, V43, P5; Tidey JW, 2012, PREV MED, V55, pS54, DOI 10.1016/j.ypmed.2011.11.010; Tidey JW, 2002, EXP CLIN PSYCHOPHARM, V10, P241, DOI 10.1037//1064-1297.10.3.241; Tracy K, 2007, AM J DRUG ALCOHOL AB, V33, P253, DOI 10.1080/00952990601174931; Vieta E, 2005, J CLIN PSYCHIAT, V66, P24; W.H. Organization, 1993, WHO APPL ICD 10 DEAT, V2; Wise J., 2010, BMJ, V340, pc2747, DOI [10.1136/bmj.c2747, DOI 10.1136/BMJ.C2747]	41	76	76	0	11	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 7	2013	347								f5847	10.1136/bmj.f5847	http://dx.doi.org/10.1136/bmj.f5847			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	235OG	24100934	Green Published, Green Accepted, hybrid			2023-01-03	WOS:000325728300001
J	Betses, M; Brennan, T				Betses, Mitch; Brennan, Troyen			Abusive Prescribing of Controlled Substances - A Pharmacy View	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							OPIOID PRESCRIPTION; GUIDELINES	Pharmacies have a role to play in the oversight of prescriptions for controlled substances, especially opioids. The pharmacy chain CVS recently used its aggregated information on all prescriptions filled at its stores to attempt to limit inappropriate prescribing. Public health advocates are increasingly focused on illness and deaths caused by inappropriate use of controlled substances in particular, opioid analgesics. Opioid prescriptions have increased dramatically, by more than 300% between 1999 and 2010.(1) This increase has led to substantial iatrogenic disease. Most strikingly, the number of deaths due to overdose in the United States increased from 4000 in 1999 to 16,600 in 2010.(2) Indeed, overdose is now the second-leading cause of accidental death in this country, where more than 2.4 million people were considered opioid abusers in 2010.(3) The causes of increases in prescriptions and the prevalence of ...	[Betses, Mitch; Brennan, Troyen] CVS Caremark, Woonsocket, RI USA		Betses, M (corresponding author), CVS Caremark, Woonsocket, RI USA.							Dowell D, 2013, JAMA-J AM MED ASSOC, V309, P2219, DOI 10.1001/jama.2013.5794; Drug Enforcement Administration, 2013, DEA SERV AN WALGR PH; Kunins HV, 2013, ANN INTERN MED, V158, P841, DOI 10.7326/0003-4819-158-11-201306040-00631; Lembke A, 2012, NEW ENGL J MED, V367, P1580, DOI 10.1056/NEJMp1208498; Rosenau AM, 2013, ANN INTERN MED, V158, P843, DOI 10.7326/0003-4819-158-11-201306040-00632	5	39	40	0	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 12	2013	369	11					989	991		10.1056/NEJMp1308222	http://dx.doi.org/10.1056/NEJMp1308222			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	216SK	23964897	Bronze			2023-01-03	WOS:000324304200004
J	Pires-Neto, RC; Kawaguchi, YMF; Hirota, AS; Fu, C; Tanaka, C; Caruso, P; Park, M; Carvalho, CRR				Pires-Neto, Ruy Camargo; Fogaca Kawaguchi, Yurika Maria; Hirota, Adriana Sayuri; Fu, Carolina; Tanaka, Clarice; Caruso, Pedro; Park, Marcelo; Ribeiro Carvalho, Carlos Roberto			Very Early Passive Cycling Exercise in Mechanically Ventilated Critically Ill Patients: Physiological and Safety Aspects - A Case Series	PLOS ONE			English	Article							INTENSIVE-CARE-UNIT; CARDIAC-OUTPUT; MOBILITY; THERAPY	Introduction: Early mobilization can be performed in critically ill patients and improves outcomes. A daily cycling exercise started from day 5 after ICU admission is feasible and can enhance functional capacity after hospital discharge. In the present study we verified the physiological changes and safety of an earlier cycling intervention (<< 72 hrs of mechanical ventilation) in critical ill patients. Methods: Nineteen hemodynamically stable and deeply sedated patients within the first 72 hrs of mechanical ventilation were enrolled in a single 20 minute passive leg cycling exercise using an electric cycle ergometer. A minute-by-minute evaluation of hemodynamic, respiratory and metabolic variables was undertaken before, during and after the exercise. Analyzed variables included the following: cardiac output, systemic vascular resistance, central venous blood oxygen saturation, respiratory rate and tidal volume, oxygen consumption, carbon dioxide production and blood lactate levels. Results: We enrolled 19 patients (42% male, age 55 +/- 17 years, SOFA = 6 +/- 3, SAPS3 score = 58 +/- 13, PaO2/FIO2 = 223 +/- 75). The median time of mechanical ventilation was 1 day (02), and 68% (n=13) of our patients required norepinephrine (maximum concentration = 0.47 mu g. kg(-1). min(-1)). There were no clinically relevant changes in any of the analyzed variables during the exercise, and two minor adverse events unrelated to hemodynamic instability were observed. Conclusions: In our study, this very early passive cycling exercise in sedated, critically ill, mechanically ventilated patients was considered safe and was not associated with significant alterations in hemodynamic, respiratory or metabolic variables even in those requiring vasoactive agents.	[Pires-Neto, Ruy Camargo; Fogaca Kawaguchi, Yurika Maria; Hirota, Adriana Sayuri; Fu, Carolina; Tanaka, Clarice] Univ Sao Paulo Sao Paulo ICHC FMUSP, Fac Med, Inst Cent Hosp Clin, Phys Therapy Serv, Sao Paulo, Brazil; [Pires-Neto, Ruy Camargo] Univ Sao Paulo, Fac Med, Dept Pathol, Sao Paulo, Brazil; [Fu, Carolina; Tanaka, Clarice] Univ Sao Paulo, Fac Med, Dept Phys Therapy Speech Pathologist Therapist &, Sao Paulo, Brazil; [Caruso, Pedro; Ribeiro Carvalho, Carlos Roberto] Univ Sao Paulo, Fac Med, Hosp Clin, Div Pulm & Crit Care,Heart Inst InCor, Sao Paulo, Brazil; [Park, Marcelo] Univ Sao Paulo ICHC FMUSP, Fac Med, Med Emergency ICU Hosp Clin, Sao Paulo, Brazil	Universidade de Sao Paulo; Universidade de Sao Paulo; Universidade de Sao Paulo	Pires-Neto, RC (corresponding author), Univ Sao Paulo Sao Paulo ICHC FMUSP, Fac Med, Inst Cent Hosp Clin, Phys Therapy Serv, Sao Paulo, Brazil.	ruy@usp.br	Pires-Neto, Ruy/G-5520-2013; Caruso, Pedro/B-6054-2016; Fu, Carolina/D-6572-2012; Caruso, Pedro/AAY-8176-2021; Park, Marcelo/H-7851-2016; Carvalho, Carlos Roberto R/N-9827-2018; Tanaka, Clarice/J-5075-2016	Caruso, Pedro/0000-0002-1051-8458; Carvalho, Carlos Roberto R/0000-0002-1618-8509; Tanaka, Clarice/0000-0003-3900-5944	Respiratory and Medical Emergency ICU Research Fund - Hospital das Cl nicas (ICHC/FMUSP)	Respiratory and Medical Emergency ICU Research Fund - Hospital das Cl nicas (ICHC/FMUSP)	This study was supported by the Respiratory and Medical Emergency ICU Research Fund - Hospital das Cl nicas (ICHC/FMUSP). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	AARC Clinical Practice guideline, 2004, RESP CARE, V49, P1073; Bailey P, 2007, CRIT CARE MED, V35, P139, DOI 10.1097/01.CCM.0000251130.69568.87; Ballaz L, 2007, ARCH PHYS MED REHAB, V88, P471, DOI 10.1016/j.apmr.2007.01.011; Bourdin G, 2010, RESP CARE, V55, P400; Burtin C, 2009, CRIT CARE MED, V37, P2499, DOI 10.1097/CCM.0b013e3181a38937; De Backer D, 2011, INTENS CARE MED, V37, P233, DOI 10.1007/s00134-010-2098-8; Gosselink R, 2008, INTENS CARE MED, V34, P1188, DOI 10.1007/s00134-008-1026-7; Hodgin KE, 2009, CRIT CARE MED, V37, P561, DOI 10.1097/CCM.0b013e3181957449; Horiuchi K, 1997, CRIT CARE MED, V25, P1347, DOI 10.1097/00003246-199708000-00022; Kho ME, 2012, J CRIT CARE, V27, DOI 10.1016/j.jcrc.2011.08.017; Kobayashi M, 2008, EXPERT REV MED DEVIC, V5, P311, DOI 10.1586/17434440.5.3.311; Luetz A, 2012, CURR OPIN ANESTHESIO, V25, P164, DOI 10.1097/ACO.0b013e32834f8ce7; McLellan S, 2002, INTENS CARE MED, V28, P870, DOI 10.1007/s00134-002-1323-5; Monnet X, 2012, BRIT J ANAESTH, V108, P615, DOI 10.1093/bja/aer491; Morris PE, 2008, CRIT CARE MED, V36, P2238, DOI 10.1097/CCM.0b013e318180b90e; Morris PE, 2007, CRIT CARE CLIN, V23, P1, DOI 10.1016/j.ccc.2006.11.003; Morris PE, 2011, AM J MED SCI, V341, P373, DOI 10.1097/MAJ.0b013e31820ab4f6; Norrenberg M, 2000, INTENS CARE MED, V26, P988, DOI 10.1007/s001340051292; Norrenberg M, 1999, CLIN INTENSIVE CARE, V10, P1, DOI DOI 10.3109/tcic.10.1.1.6; Riker RR, 2001, INTENS CARE MED, V27, P853, DOI 10.1007/s001340100912; Salluh JIF, 2009, J CRIT CARE, V24, P556, DOI 10.1016/j.jcrc.2009.04.004; Schweickert WD, 2009, LANCET, V373, P1874, DOI 10.1016/S0140-6736(09)60658-9; Stockley RC, 2010, PHYSIOTHERAPY, V96, P228, DOI 10.1016/j.physio.2009.11.014; Thomsen GE, 2008, CRIT CARE MED, V36, P1119, DOI 10.1097/CCM.0b013e318168f986; van Lieshout JJ, 2001, BRIT J ANAESTH, V86, P467, DOI 10.1093/bja/86.4.467	25	49	49	0	22	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 9	2013	8	9							e74182	10.1371/journal.pone.0074182	http://dx.doi.org/10.1371/journal.pone.0074182			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	244QV	24040200	Green Published, gold, Green Submitted			2023-01-03	WOS:000326405300165
J	Briggs, JP; Killen, J				Briggs, Josephine P.; Killen, Jack			Perspectives on Complementary and Alternative Medicine Research	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Briggs, Josephine P.; Killen, Jack] NIH, Natl Ctr Complementary & Alternat Med, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Center for Complementary & Alternative Medicine	Briggs, JP (corresponding author), Natl Ctr Complementary & Alternat Med, 31 Ctr Dr,Bldg 31,Ste 2B11, Bethesda, MD 20814 USA.	briggsj@mail.nih.gov						[Anonymous], 2012, NBJS SUPPLEMENT BUSI; [Anonymous], SPOTLIGHTED RESEARCH; [Anonymous], 2010, PAIN MANAGEMENT TASK; Barnes Patricia M., 2008, NATL HLTH STAT REPOR, V12, P1, DOI DOI 10.1037/E623942009-001; Chou R, 2007, ANN INTERN MED, V147, P478, DOI 10.7326/0003-4819-147-7-200710020-00006; Offit PA, 2012, JAMA-J AM MED ASSOC, V307, P1803, DOI 10.1001/jama.2012.518; Schultz AM, 2009, INTEGRATIVE MEDICINE	7	21	22	0	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 21	2013	310	7					691	692		10.1001/jama.2013.6540	http://dx.doi.org/10.1001/jama.2013.6540			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	202XP	23990064				2023-01-03	WOS:000323254500015
J	Dugravier, R; Tubach, F; Saias, T; Guedeney, N; Pasquet, B; Purper-Ouakil, D; Tereno, S; Welniarz, B; Matos, J; Guedeney, A; Greacen, T				Dugravier, Romain; Tubach, Florence; Saias, Thomas; Guedeney, Nicole; Pasquet, Blandine; Purper-Ouakil, Diane; Tereno, Susana; Welniarz, Bertrand; Matos, Joana; Guedeney, Antoine; Greacen, Tim		CAPEDP Study Grp	Impact of a Manualized Multifocal Perinatal Home-Visiting Program Using Psychologists on Postnatal Depression: The CAPEDP Randomized Controlled Trial	PLOS ONE			English	Article							MATERNAL DEPRESSION; POSTPARTUM DEPRESSION; CHILD-ABUSE; SCALE EPDS; HIGH-RISK; WOMEN; PARENTS; PREVENTION; PREVALENCE; VISITATION	Context: Postnatal maternal depression (PND) is a significant risk factor for infant mental health. Although often targeted alongside other factors in perinatal home-visiting programs with vulnerable families, little impact on PND has been observed. Objective: This study evaluates the impact on PND symptomatology of a multifocal perinatal home-visiting intervention using psychologists in a sample of women presenting risk factors associated with infant mental health difficulties. Methods: 440 primiparous women were recruited at their seventh month of pregnancy. All were future first-time mothers, under 26, with at least one of three additional psychosocial risk factors: low educational level, low income, or planning to raise the child without the father. The intervention consisted of intensive multifocal home visits through to the child's second birthday. The control group received care as usual. PND symptomatology was assessed at baseline and three months after birth using the Edinburgh Postnatal Depression Scale (EPDS). Results: At three months postpartum, mean (SD) EPDS scores were 9.4 (5.4) for the control group and 8.6 (5.4) for the intervention group (p = 0.18). The difference between the mean EPDS scores was 0.85 (95% CI: 0.35; 1.34). The intervention group had significantly lower EPDS scores than controls in certain subgroups: women with few depressive symptoms at inclusion (EPDS <8): difference = 1.66 (95%CI: 0.17; 3.15), p = 0.05, adjusted for baseline EPDS score), women who were planning to raise the child with the child's father: difference = 1.45 (95%CI: 0.27; 2.62), p = 0.04 (adjusted); women with a higher educational level: difference = 1.59 (95%CI: 0.50; 2.68) p = 0.05 (adjusted). Conclusion: CAPEDP failed to demonstrate an overall impact on PND. However, post-hoc analysis reveals the intervention was effective in terms of primary prevention and in subgroups of women without certain risk factors. Effective overall reduction of PND symptomatology for young, first-time mothers presenting additional psychosocial risk factors may require more tailored interventions.	[Dugravier, Romain] Ctr Hosp St Anne, Unite Perinatal, Paris, France; [Dugravier, Romain; Guedeney, Antoine] INSERM, PSIGIAM U669, Paris, France; [Tubach, Florence; Pasquet, Blandine] Hop Bichat Claude Bernard, AP HP, Dept Epidemiol & Rech Clin, F-75877 Paris, France; [Tubach, Florence] Univ Paris Diderot, Sorbonne Paris Cite, Paris, France; [Tubach, Florence; Pasquet, Blandine] INSERM, CIE801, Paris, France; [Saias, Thomas; Greacen, Tim] Etab Publ Sante Maison Blanche, Lab Rech, Paris, France; [Saias, Thomas] Inst Natl Prevent & Educ Sante, St Denis, France; [Saias, Thomas] Univ Quebec, Dept Psychol, Montreal, PQ H3C 3P8, Canada; [Guedeney, Nicole] Inst Mutualiste Montsouris, Paris, France; [Purper-Ouakil, Diane] Hop St Eloi, CHRU Montpellier, Montpellier, France; [Purper-Ouakil, Diane] INSERM, U894, Ctr Psychiat & Neurosci, Team 1, Paris, France; [Tereno, Susana] Univ Paris 05, Inst Psychol, Sorbonne Paris Cite, Paris, France; [Tereno, Susana] LPPS, EA4057, Paris, France; [Welniarz, Bertrand] Etab Publ Sante Ville Evrard, Neuilly Sur Marne, France; [Matos, Joana] CHU Pitie Salpetriere, AP HP, Paris, France; [Guedeney, Antoine] Hop Bichat Claude Bernard, AP HP, Serv Pedopsychiat, F-75877 Paris 18, France	GHU PARIS Psychiatrie Neurosciences; UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); University of Quebec; University of Quebec Montreal; Institute Mutualiste Montsouris; UDICE-French Research Universities; Universite Paris Cite; Universite de Montpellier; CHU de Montpellier; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP	Dugravier, R (corresponding author), Ctr Hosp St Anne, Unite Perinatal, Paris, France.	romain.dugravier@gmail.com	Purper-Ouakil, Diane/AAC-5024-2019	Purper-Ouakil, Diane/0000-0003-0454-1579; Guedeney, Antoine/0000-0002-2346-4495; Tereno, Susana/0000-0001-5258-7913; Azria, Elie/0000-0002-6159-6253	National Ministry of Health Hospital Clinical Research Programme [PHRC AOM 05056]; National Institute for Promotion and Health Education; Clinical Research and Development Department of the APHP	National Ministry of Health Hospital Clinical Research Programme; National Institute for Promotion and Health Education; Clinical Research and Development Department of the APHP	The project was financed with a grant from the National Ministry of Health Hospital Clinical Research Programme (PHRC AOM 05056) and the National Institute for Promotion and Health Education. The sponsor was the Clinical Research and Development Department of the APHP. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adouard F, 2005, ARCH WOMEN MENT HLTH, V8, P89, DOI 10.1007/s00737-005-0077-9; Ammerman RT, 2010, AGGRESS VIOLENT BEH, V15, P191, DOI 10.1016/j.avb.2009.12.002; [Anonymous], MAK DIFF LIV CHILDR; [Anonymous], 1969, ATTACHMENT LOSS ATTA; BANDURA A, 1977, PSYCHOL REV, V84, P191, DOI 10.1037/0033-295X.84.2.191; Boath E, 2005, J PSYCHOSOM OBST GYN, V26, P185, DOI 10.1080/01674820400028431; Brett K., 2008, Morbidity and Mortality Weekly Report, V57, P361; Bronfenbrenner U, 1979, ECOLOGY HUMAN DEV EX; Chabrol H, 2002, PSYCHOL MED, V32, P1039, DOI 10.1017/S0033291702006062; Chabrol Henri, 2007, Expert Rev Neurother, V7, P557; Chazan-Cohen R, 2007, INFANT MENT HEALTH J, V28, P151, DOI 10.1002/imhj.20127; Daro D, 2003, CHILD ABUSE NEGLECT, V27, P1101, DOI 10.1016/j.chiabu.2003.09.007; Daro DA, 1999, FUTURE CHILD, V9, P152, DOI 10.2307/1602726; Dennis CL, 2005, BRIT MED J; Duggan A, 2004, CHILD ABUSE NEGLECT, V28, P623, DOI 10.1016/j.chiabu.2003.08.008; Duggan A, 2007, CHILD ABUSE NEGLECT, V31, P801, DOI 10.1016/j.chiabu.2006.06.011; DuMont K, 2008, CHILD ABUSE NEGLECT, V32, P295, DOI 10.1016/j.chiabu.2007.07.007; Gavin NI, 2005, OBSTET GYNECOL, V106, P1071, DOI 10.1097/01.AOG.0000183597.31630.db; Goodman SH, 2008, HDB CLIN PSYCHOL; Guedeney N, 1998, EUR PSYCHIAT, V13, P83, DOI 10.1016/S0924-9338(98)80023-0; Guedeney N., 1995, DEVENIR, V7, P69; Hansson L, 1992, Blood Press, V1, P113, DOI 10.3109/08037059209077502; HOBFOLL SE, 1995, J CONSULT CLIN PSYCH, V63, P445, DOI 10.1037/0022-006X.63.3.445; Martins C, 2000, J CHILD PSYCHOL PSYC, V41, P737, DOI 10.1111/1469-7610.00661; Mitchell-Herzfeld S, 2005, 1 YEAR PROGR IMP; Murray L, 2006, DEV PSYCHOPATHOL, V18, P489, DOI 10.1017/S0954579406060263; O'Hara MW, 2009, J CLIN PSYCHOL, V65, P1258, DOI 10.1002/jclp.20644; Olds D, 1997, J COMMUNITY PSYCHOL, V25, P9; Olds David L, 2002, Prev Sci, V3, P153, DOI 10.1023/A:1019990432161; Pawlby S, 2008, J AFFECT DISORDERS, V107, P241, DOI 10.1016/j.jad.2007.08.002; Rahman A, 2012, BRIT J PSYCHIAT, V201, P451, DOI 10.1192/bjp.bp.112.109207; Saias T, 2012, PLOS ONE; Schreiber LM, 2007, IMPRINT, V49; Tubach F, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-648; Verkerk GJM, 2003, J AFFECT DISORDERS, V77, P159, DOI 10.1016/S0165-0327(02)00146-5; Zigler E, 2008, J PRIM PREV, V29, P103, DOI 10.1007/s10935-008-0132-1; Zlotnick C, 2001, AM J PSYCHIAT, V158, P638, DOI 10.1176/appi.ajp.158.4.638	37	13	13	1	39	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 19	2013	8	8							e72216	10.1371/journal.pone.0072216	http://dx.doi.org/10.1371/journal.pone.0072216			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	205ER	23977257	Green Published, Green Submitted, gold			2023-01-03	WOS:000323425700150
J	Liotta, G; Mancinelli, S; Nielsen-Saines, K; Gennaro, E; Scarcella, P; Magid, NA; Germano, P; Jere, H; Guidotti, G; Buonomo, E; Ciccacci, F; Palombi, L; Marazzi, MC				Liotta, Giuseppe; Mancinelli, Sandro; Nielsen-Saines, Karin; Gennaro, E.; Scarcella, Paola; Magid, Nurja Abdul; Germano, Paola; Jere, Haswell; Guidotti, Gianni; Buonomo, Ersilia; Ciccacci, Fausto; Palombi, Leonardo; Marazzi, Maria Cristina			Reduction of Maternal Mortality with Highly Active Antiretroviral Therapy in a Large Cohort of HIV-Infected Pregnant Women in Malawi and Mozambique	PLOS ONE			English	Article							1ST YEAR; HIV/AIDS; AFRICA; INCOME	Background: HIV infection is a major contributor to maternal mortality in resource-limited settings. The Drug Resource Enhancement Against AIDS and Malnutrition Programme has been promoting HAART use during pregnancy and postpartum for Prevention-of-mother-to-child-HIV transmission (PMTCT) irrespective of maternal CD4 cell counts since 2002. Methods: Records for all HIV+ pregnancies followed in Mozambique and Malawi from 6/2002 to 6/2010 were reviewed. The cohort was comprised by pregnancies where women were referred for PMTCT and started HAART during prenatal care (n = 8172, group 1) and pregnancies where women were referred on established HAART (n = 1978, group 2). Results: 10,150 pregnancies were followed. Median (IQR) baseline values were age 26 years (IQR:23-30), CD4 count 392 cells/mm(3) (IQR:258-563), Viral Load log(10) 3.9 (IQR:3.2-4.4), BMI 23.4 (IQR:21.5-25.7), Hemoglobin 10.0 (IQR:9.0-11.0). 101 maternal deaths (0.99%) occurred during pregnancy to 6 weeks postpartum: 87 (1.1%) in group 1 and 14 (0.7%) in group 2. Mortality was 1.3% in women with <than 350 CD4 cells/mm(3) and 0.7% in women with greater than 350 CD4s cells/mm(3) [OR = 1.9 (CL 1.3-2.9) p = 0.001]. Mortality was higher in patients with shorter antenatal HAART: 22/991 (2.2%) if less than 30 days and 79/9159 (0.9%) if 31 days or greater [OR = 2.6 (CL 1.6-4.2) p<0.001]. By multivariate analysis, shorter antenatal HAART (p, 0.001), baseline values for CD4 cell count (p = 0.012), hemoglobin (p = 0.02), and BMI (p<0.001) were associated with mortality. Four years later, survival was 92% for women with shorter antenatal HAART and 98% for women on established therapy prior to pregnancy, p = 0.001. Conclusions: Antiretrovirals for PMTCT purposes have significant impact on maternal mortality as do CD4 counts and nutritional status. In resource-limited settings, PMTCT programs should provide universal HAART to all HIV+ pregnant women given its impact in prevention of maternal death.	[Liotta, Giuseppe; Mancinelli, Sandro; Scarcella, Paola; Buonomo, Ersilia; Palombi, Leonardo] Univ Roma Tor Vergata, Dept Biomed & Prevent, Rome, Italy; [Nielsen-Saines, Karin] David Geffen UCLA Sch Med, Dept Pediat, Los Angeles, CA USA; [Gennaro, E.] Univ G DAnnunzio, Dept Publ Hlth, Chieti, Italy; [Magid, Nurja Abdul] Community St Egidio, DREAM Program Dept, Maputo, Mozambique; [Germano, Paola; Ciccacci, Fausto] Community St Egidio, DREAM Program Dept, Rome, Italy; [Jere, Haswell] Community St Egidio, DREAM Program Dept, Blantyre, Malawi; [Guidotti, Gianni] Natl Inst Infect Dis, Dept Infect Dis, Rome, Italy; [Marazzi, Maria Cristina] Lumsa Univ, Dept Community Hlth, Rome, Italy; [Ciccacci, Fausto] Univ Roma La Sapienza, Dept Infect Dis, Rome, Italy	University of Rome Tor Vergata; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; G d'Annunzio University of Chieti-Pescara; Universita LUMSA; Sapienza University Rome	Nielsen-Saines, K (corresponding author), David Geffen UCLA Sch Med, Dept Pediat, Los Angeles, CA USA.	knielsen@mednet.ucla.edu	Palombi, Leonardo/I-4043-2019; Ciccacci, Fausto/AAF-8625-2020	Palombi, Leonardo/0000-0003-1806-5278; Ciccacci, Fausto/0000-0003-0262-707X; SCARCELLA, Paola/0000-0002-3319-7925; BUONOMO, ERSILIA/0000-0002-3924-9917; Guidotti, Giovanni/0000-0002-8462-2901; MARAZZI, Maria Cristina/0000-0003-2031-5213; liotta, giuseppe/0000-0002-1990-1816	World Bank Treatment Acceleration Program; German Agency for Technical Cooperation; Agence Francaise de De'veloppement; Catalan Agency for Development Cooperation; Belgium Development Cooperation; United States President Emergency Plan for AIDS Relief; Intesa Sanpaolo, Italy; CARIPLO Foundation, Italy	World Bank Treatment Acceleration Program; German Agency for Technical Cooperation; Agence Francaise de De'veloppement; Catalan Agency for Development Cooperation; Belgium Development Cooperation(CGIAR); United States President Emergency Plan for AIDS Relief; Intesa Sanpaolo, Italy; CARIPLO Foundation, Italy(Fondazione Cariplo)	The DREAM (Drug Resource Enhancement Against AIDS and Malnutrition) Program, of the Sant'Egidio Community, a faith-based NGO in Rome, Italy is sponsored by multiple organizations including the World Bank Treatment Acceleration Program, several Italian private banks, several governmental cooperations including the German Agency for Technical Cooperation, the Agence Francaise de De'veloppement, the Catalan Agency for Development Cooperation, the Belgium Development Cooperation, and the United States President Emergency Plan for AIDS Relief among others. DREAM Program-Project Malawi was funded in Malawi by Intesa Sanpaolo, Italy and the CARIPLO Foundation, Italy. The present analysis was not funded by a specific award. Funders do not have any role in study design, data collection and analysis, decision to publish or preparation of the manuscript.	Abdool Karim Q, 2010, LANCET, V375, P1948, DOI 10.1016/S0140-6736(10)60747-7; Black V, 2009, OBSTET GYNECOL, V114, P292, DOI 10.1097/AOG.0b013e3181af33e6; Braitstein P, 2006, LANCET, V367, P817, DOI 10.1016/S0140-6736(06)68337-2; Brinkhof MWG, 2008, B WORLD HEALTH ORGAN, V86, P559, DOI 10.2471/BLT.07.044248; European HIV Obst Grp, 2004, AIDS, V18, P933, DOI [10.1097/00002030-200404090-00011, 10.1097/01.aids.0000125910.42055.c1]; Ezechi O, 2012, J PREGNANCY, V2012, DOI 10.1155/2012/140826; Grange J, 2010, INT J GYNECOL OBSTET, V108, P181, DOI 10.1016/j.ijgo.2009.12.005; Gray RH, 2005, LANCET, V366, P1182, DOI 10.1016/S0140-6736(05)67481-8; Louis J, 2007, OBSTET GYNECOL, V110, P385, DOI 10.1097/01.AOG.0000275263.81272.fc; Marazzi MC, 2011, AIDS, V25, P1611, DOI 10.1097/QAD.0b013e3283493ed0; Marazzi MC, 2008, AIDS RES HUM RETROV, V24, P555, DOI 10.1089/aid.2007.0217; Melo VH, 2011, MEM I OSWALDO CRUZ, V106, P97, DOI 10.1590/S0074-02762011000100016; Mishra R.K, 2011, MILLENNIUM DEV GOALS; National Committee for the Confidential Enquiries into Maternal Deaths, 2008, 4 NAT COMM CONF ENQ; Nucita A, 2009, BMC MED INFORM DECIS, V9, DOI 10.1186/1472-6947-9-42; Vitoria M, 2009, AM J CLIN PATHOL, V131, P844, DOI 10.1309/AJCP5XHDB1PNAEYT; WHO UNAIDS Unicef, 2011, GLOB HIV AIDS RESP E; World Health Organization (WHO), 2012, TRENDS MAT MORT 1990	18	21	21	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 19	2013	8	8							e71653	10.1371/journal.pone.0071653	http://dx.doi.org/10.1371/journal.pone.0071653			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	205ER	23990966	Green Submitted, Green Published, gold			2023-01-03	WOS:000323425700079
J	Dobs, AS				Dobs, Adrian S.			A little better than placebo is still better than nothing	NATURE MEDICINE			English	Editorial Material								Doctors often dismiss drugs as ineffective if they fail to outperform dummy pills in randomized trials. That's a mistake. When active medicines have few side effects and produce a strong placebo effect, such drugs, even if they prove just slightly better than placebo, should be embraced for the relief they can bring to patients who have few safe alternatives.	[Dobs, Adrian S.] Johns Hopkins Univ, Sch Med, Johns Hopkins Clin Res Network, Baltimore, MD 21218 USA; [Dobs, Adrian S.] Johns Hopkins Univ, Sch Med, Johns Hopkins Ctr Reduct Canc Disparities, Baltimore, MD USA	Johns Hopkins University; Johns Hopkins University	Dobs, AS (corresponding author), Johns Hopkins Univ, Sch Med, Johns Hopkins Clin Res Network, Baltimore, MD 21218 USA.	adobs@jhu.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK079637] Funding Source: NIH RePORTER; NIDDK NIH HHS [P30 DK079637] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BEECHER HK, 1955, JAMA-J AM MED ASSOC, V159, P1602, DOI 10.1001/jama.1955.02960340022006; Pae CU, 2010, EXPERT OPIN PHARMACO, V11, P185, DOI 10.1517/14656560903451708; Stearns V, 2003, JAMA-J AM MED ASSOC, V289, P2827, DOI 10.1001/jama.289.21.2827	3	1	1	0	5	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	AUG	2013	19	8					962	962		10.1038/nm0813-962	http://dx.doi.org/10.1038/nm0813-962			1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	196ML	23921736	Bronze			2023-01-03	WOS:000322779600014
J	Moon, HG; Zheng, YJ; An, CH; Kim, YK; Jin, Y				Moon, Hyung-Geun; Zheng, Yijie; An, Chang Hyeok; Kim, Yoon-Keun; Jin, Yang			CCN1 Secretion Induced by Cigarette Smoking Extracts Augments IL-8 Release from Bronchial Epithelial Cells	PLOS ONE			English	Article							OBSTRUCTIVE PULMONARY-DISEASE; AIRWAY INFLAMMATION; INTERLEUKIN-8; LUNG; AUTOPHAGY; CYR61; EMPHYSEMA; SMOKERS; PATHOGENESIS; PROTEIN-1	Inflammation involves in many cigarette smoke (CS) related diseases including the chronic obstructive pulmonary disease (COPD). Lung epithelial cell released IL-8 plays a crucial role in CS induced lung inflammation. CS and cigarette smoke extracts (CSE) both induce IL-8 secretion and subsequently, IL-8 recruits inflammatory cells into the lung parenchyma. However, the molecular and cellular mechanisms by which CSE triggers IL-8 release remain not completely understood. In this study, we identified a novel extracellular matrix (ECM) molecule, CCN1, which mediated CSE induced IL-8 secretion by lung epithelial cells. We first found that CS and CSE up-regulated CCN1 expression and secretion in lung epithelial cells in vivo and in vitro. CSE up-regulated CCN1 via induction of reactive oxygen spices (ROS) and endoplasmic reticulum (ER) stress. p38 MAPK and JNK activation were also found to mediate the signal pathways in CSE induced CCN1. CCN1 was secreted into ECM via Golgi and membrane channel receptor aquaporin4. After CSE exposure, elevated ECM CCN1 functioned via an autocrine or paracrine manner. Importantly, CCN1 activated Wnt pathway receptor LRP6, subsequently stimulated Wnt pathway component Dvl2 and triggered beta-catenin translocation from cell membrane to cytosol and nucleus. Treatment of Wnt pathway inhibitor suppressed CCN1 induced IL-8 secretion from lung epithelial cells. Taken together, CSE increased CCN1 expression and secretion in lung epithelial cells via induction of ROS and ER stress. Increased ECM CCN1 resulted in augmented IL-8 release through the activation of Wnt pathway.	[Moon, Hyung-Geun; Zheng, Yijie; An, Chang Hyeok; Jin, Yang] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med,Div Pulm & Crit Care, Boston, MA 02115 USA; [Moon, Hyung-Geun; Kim, Yoon-Keun] Pohang Univ Sci & Technol POSTECH, Dept Life Sci, Pohang, South Korea; [Moon, Hyung-Geun; Kim, Yoon-Keun] Pohang Univ Sci & Technol POSTECH, Div Mol & Life Sci, Pohang, South Korea	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Pohang University of Science & Technology (POSTECH); Pohang University of Science & Technology (POSTECH)	Jin, Y (corresponding author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med,Div Pulm & Crit Care, Boston, MA 02115 USA.	yjin@rics.bwh.harvard.edu		An, Chang Hyeok/0000-0001-9145-1322	National Institutes of Health [R01 HL102076]; FAMRI CIA; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL102076] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); FAMRI CIA; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This work is supported by National Institutes of Health R01 HL102076 (Y.J.) and FAMRI CIA (Y.J.). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aaron SD, 2001, AM J RESP CRIT CARE, V163, P349, DOI 10.1164/ajrccm.163.2.2003122; An CH, 2012, AM J PHYSIOL-LUNG C, V303, pL748, DOI 10.1152/ajplung.00102.2012; Baggiolini M, 2000, IMMUNOL TODAY, V21, P418, DOI 10.1016/S0167-5699(00)01672-8; Barnes PJ, 2001, PHARMACOL REV, V56, P515; Brigstock DR, 2003, J ENDOCRINOL, V178, P169, DOI 10.1677/joe.0.1780169; Chen ZH, 2010, P NATL ACAD SCI USA, V107, P18880, DOI 10.1073/pnas.1005574107; Chen ZH, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003316; Chung Kian F., 2005, Current Drug Targets - Inflammation and Allergy, V4, P619, DOI 10.2174/156801005774912806; Crooks SW, 2000, EUR RESPIR J, V15, P274, DOI 10.1034/j.1399-3003.2000.15b09.x; de Boer WI, 2000, J PATHOL, V190, P619, DOI 10.1002/(SICI)1096-9896(200004)190:5<619::AID-PATH555>3.0.CO;2-6; FLETCHER C, 1977, BMJ-BRIT MED J, V1, P1645, DOI 10.1136/bmj.1.6077.1645; HUNNINGHAKE GW, 1983, AM REV RESPIR DIS, V128, P833; Jin Y, 2005, AM J RESP CELL MOL, V33, P297, DOI 10.1165/rcmb.2005-0144OC; Jin Y, 2009, FASEB J, V23, P341, DOI 10.1096/fj.08-108423; Jorgensen E, 2008, BMC CANCER, V11, p[1471, 1478, 1229]; Jun JI, 2011, NAT REV DRUG DISCOV, V10, P945, DOI 10.1038/nrd3599; Keatings VM, 1996, AM J RESP CRIT CARE, V153, P530, DOI 10.1164/ajrccm.153.2.8564092; Kelsen SG, 2012, PULM PHARMACOL THER, V25, P447, DOI 10.1016/j.pupt.2012.07.005; Kim HP, 2009, METHOD ENZYMOL, V453, P197, DOI 10.1016/S0076-6879(08)04010-X; Koval M, 2002, AM J PHYSIOL-LUNG C, V283, pL875, DOI 10.1152/ajplung.00078.2002; Leu SJ, 2002, J BIOL CHEM, V277, P46248, DOI 10.1074/jbc.M209288200; MCCREA KA, 1994, AM J RESP CRIT CARE, V150, P696, DOI 10.1164/ajrccm.150.3.8087340; Menendez JA, 2003, ENDOCR-RELAT CANCER, V10, P141, DOI 10.1677/erc.0.0100141; Mio T, 1997, AM J RESP CRIT CARE, V155, P1770, DOI 10.1164/ajrccm.155.5.9154890; Ning W, 2004, P NATL ACAD SCI USA, V101, P14895, DOI 10.1073/pnas.0401168101; Nocker RET, 1996, INT ARCH ALLERGY IMM, V109, P183, DOI 10.1159/000237218; Roth M, 2008, INT J TUBERC LUNG D, V12, P375; Schutze N, 2001, J CLIN PATHOL-MOL PA, V54, P170, DOI 10.1136/mp.54.3.170; SHERRILL DL, 1991, AM REV RESPIR DIS, V144, P17, DOI 10.1164/ajrccm/144.1.17; Tanino M, 2002, THORAX, V57, P405, DOI 10.1136/thorax.57.5.405; THOMPSON AB, 1989, AM REV RESPIR DIS, V140, P1527, DOI 10.1164/ajrccm/140.6.1527; van der Toorn M, 2007, AM J PHYSIOL-LUNG C, V292, pL1211, DOI 10.1152/ajplung.00291.2006; Wang BN, 2003, INFECT IMMUN, V71, P5523, DOI 10.1128/IAI.71.10.5523-5530.2003; Xu CY, 2005, J CLIN INVEST, V115, P2656, DOI 10.1172/JCI26373; Yoshida H, 2007, FEBS J, V274, P630, DOI 10.1111/j.1742-4658.2007.05639.x	35	21	25	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 9	2013	8	7							e68199	10.1371/journal.pone.0068199	http://dx.doi.org/10.1371/journal.pone.0068199			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	182JD	23874538	Green Submitted, Green Published, gold			2023-01-03	WOS:000321736900066
J	Huang, R; Zhao, M; Yang, XF; Huang, JM; Yang, Y; Chen, BF; Tan, JB; Huang, JK; Li, Z; Lv, YJ; Ji, GY				Huang, Rui; Zhao, Min; Yang, Xingfen; Huang, Junming; Yang, Ying; Chen, Bifeng; Tan, Jianbin; Huang, Jiankang; Li, Zhi; Lv, Yingjian; Ji, Guiyuan			Effects of Prunella vulgaris on the Mice Immune Function	PLOS ONE			English	Article							EXTRACT; ACID	The present study was designed to evaluate the effects of Prunella Vulgaris (P. vulgaris) on the immune function in mice. The mice were randomly divided into one control group and three treatment groups of 10 mice each. The control group received pure water and the treatment groups received P. vulgaris extract at concentrations of 0.15, 0.30 and 0.90 g/kg BW orally for 30 days, respectively. Changes in cell immune function, non-specific immunity and humoral immunity function were evaluated. Active lymphocytes and T lymphocyte subsets were determined by fluorescence-activated cell sorting (FACS). Certain Serum concentrations of cytokines were measured by enzyme-linked immunosorbent assay (ELISA). The results showed that, for cell immune function, compared with the control group, foot pad thickness in high dose group increased significantly (p<0.01), whereas no significant difference in the proliferative ability of splenic lymphocytes was observed among all groups (p>0.05). For non-specific immunity, NK cell activity increased significantly in a dose-dependent manner in P. vulgaris treated mice (p<0.01), mononuclear-macrophage function in medium and high dose P. vulgaris treated mice were significantly higher than that of the control group (p<0.05). For humoral immunity, no significant differences were observed in terms of the half value of hemolysis (HC50), number of hemolytic plaques and serum IgG level (p>0.05). The percentage of active T and Th lymphocytes of mice peripheral blood in high dose group were significantly higher than that of the control group (p<0.01). There was no significant difference in serum levels of IL-1 beta, IL-4, IL-10 and IFN-gamma among all of the four groups (p>0.05). The data indicated that 0.90 g/kg BW P. vulgaris extract (equivalent to 7.5 g/kg BW crude drug) had some effect on cellular immune function and non-specific immune function in mice.	[Huang, Rui; Zhao, Min; Yang, Xingfen; Huang, Junming; Yang, Ying; Chen, Bifeng; Tan, Jianbin; Huang, Jiankang; Li, Zhi; Lv, Yingjian; Ji, Guiyuan] Guangdong Prov Ctr Dis Control & Prevent, Guangzhou, Guangdong, Peoples R China; [Huang, Rui; Ji, Guiyuan] Guangdong Prov Inst Publ Hlth, Guangzhou, Guangdong, Peoples R China; [Huang, Rui] Sun Yat Sen Univ, Sch Publ Hlth, Guangzhou 510275, Guangdong, Peoples R China	Chinese Center for Disease Control & Prevention; Guangdong Provincial Center for Disease Control & Prevention; Sun Yat Sen University	Yang, XF (corresponding author), Guangdong Prov Ctr Dis Control & Prevent, Guangzhou, Guangdong, Peoples R China.	xingfenyang@hotmail.com			National High Technology Research and Development Program 863 [2010AA023001]; Guangdong Natural Science Foundation [S2013010013289]; Guangdong science and technology plan project [201300000161]; Guangdong provincial bureau of Chinese medicine project [20132108]	National High Technology Research and Development Program 863(National High Technology Research and Development Program of China); Guangdong Natural Science Foundation(National Natural Science Foundation of Guangdong Province); Guangdong science and technology plan project; Guangdong provincial bureau of Chinese medicine project	The authors thank the National High Technology Research and Development Program 863 (2010AA023001), Guangdong Natural Science Foundation project (S2013010013289), Guangdong science and technology plan project (201300000161), and the Guangdong provincial bureau of Chinese medicine project (20132108) for their financial contributions. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Chen C.Y., 2009, CHIN GER J CLIN ONCO, V8, P426, DOI [10.1007/s10330-009-0067-x, DOI 10.1007/S10330-009-0067-X]; Fan YL, 2001, PHARM CLIN CHINESE M, V17, P10; Fuentes-Arderiu X, 2009, CYTOM PART B-CLIN CY, V76B, P291, DOI 10.1002/cyto.b.20479; Han EH, 2009, FOOD CHEM TOXICOL, V47, P62, DOI 10.1016/j.fct.2008.10.010; Harput US, 2006, PHYTOTHER RES, V20, P157, DOI 10.1002/ptr.1805; He R., 2009, WORLD SCI TECH, V11, P834; Huang N, 2009, J AGR FOOD CHEM, V57, P10579, DOI 10.1021/jf9023728; Ikeda Y, 2007, J IMMUNOL, V178, P4854, DOI 10.4049/jimmunol.178.8.4854; Jiang LH, 2007, LISHIZHEN MED MAT ME, V18, P2622; Liu GM, 2009, J CHIN MED MAT, V3, P1920; Ministry of Health of the people's Republic of China, 2003, INT SIST U ESP ESP E, P22; Pharmacopoeia Commission of People's Republic of China, 2010, PHARM PEOPL REP CH 1; Psotova J, 2005, FITOTERAPIA, V76, P556, DOI 10.1016/j.fitote.2005.04.019; Ryu SY, 2000, PLANTA MED, V66, P358, DOI 10.1055/s-2000-8531; Wang GX, 2009, CH J PUBLIC HLTH, V25, P1468; Warnatz K, 2008, CYTOM PART B-CLIN CY, V74B, P261, DOI 10.1002/cyto.b.20432; Yang Kun, 2007, Zhongguo Zhong Xi Yi Jie He Za Zhi, V27, P37; Zdarilova A, 2009, TOXICOL IN VITRO, V23, P386, DOI 10.1016/j.tiv.2008.12.021; Zheng Y., 2004, CHINESE J INTEGRATED, V12, P10; 陆军, 2012, [临床检验杂志, Chinese Journal of Clinical Laboratory Science], V30, P49; 王文佳, 2010, [时珍国医国药, Lishizhen Medicine and Materia Medica Research], V21, P107	21	15	16	0	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 30	2013	8	10							e77355	10.1371/journal.pone.0077355	http://dx.doi.org/10.1371/journal.pone.0077355			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	243RL	24204816	Green Published, Green Submitted, gold			2023-01-03	WOS:000326334500025
J	El-Khoury, F; Cassou, B; Charles, MA; Dargent-Molina, P				El-Khoury, Fabienne; Cassou, Bernard; Charles, Marie-Aline; Dargent-Molina, Patricia			The effect of fall prevention exercise programmes on fall induced injuries in community dwelling older adults: systematic review and meta-analysis of randomised controlled trials	BMJ-BRITISH MEDICAL JOURNAL			English	Article							HEALTH-CARE COSTS; ELDERLY PERSONS; REDUCES FALLS; HIP FRACTURE; RISK-FACTORS; TAI-CHI; BALANCE; INTERVENTIONS; OSTEOPOROSIS; PEOPLE	Objective To determine whether, and to what extent, fall prevention exercise interventions for older community dwelling people are effective in preventing different types of fall related injuries. Data sources Electronic databases (PubMed, the Cochrane Library, Embase, and CINAHL) and reference lists of included studies and relevant reviews from inception to July 2013. Study selection Randomised controlled trials of fall prevention exercise interventions, targeting older (>60 years) community dwelling people and providing quantitative data on injurious falls, serious falls, or fall related fractures. Data synthesis Based on a systematic review of the case definitions used in the selected studies, we grouped the definitions of injurious falls into more homogeneous categories to allow comparisons of results across studies and the pooling of data. For each study we extracted or calculated the rate ratio of injurious falls. Depending on the available data, a given study could contribute data relevant to one or more categories of injurious falls. A pooled rate ratio was estimated for each category of injurious falls based on random effects models. Results 17 trials involving 4305 participants were eligible for meta-analysis. Four categories of falls were identified: all injurious falls, falls resulting in medical care, severe injurious falls, and falls resulting in fractures. Exercise had a significant effect in all categories, with pooled estimates of the rate ratios of 0.63 (95% confidence interval 0.51 to 0.77, 10 trials) for all injurious falls, 0.70 (0.54 to 0.92, 8 trials) for falls resulting in medical care, 0.57 (0.36 to 0.90, 7 trials) for severe injurious falls, and 0.39 (0.22 to 0.66, 6 trials) for falls resulting in fractures, but significant heterogeneity was observed between studies of all injurious falls (I-2=50%, P=0.04). Conclusions Exercise programmes designed to prevent falls in older adults also seem to prevent injuries caused by falls, including the most severe ones. Such programmes also reduce the rate of falls leading to medical care.	[El-Khoury, Fabienne; Charles, Marie-Aline; Dargent-Molina, Patricia] Univ Paris 11, UMRS 1018, F-94807 Villejuif, France; [El-Khoury, Fabienne; Charles, Marie-Aline; Dargent-Molina, Patricia] INSERM, Ctr Res Epidemiol & Populat Hlth CESP, U1018, F-94807 Villejuif, France; [Cassou, Bernard] Univ Versailles, EA 25 06, Lab Sante Environm Vieillissement, F-78035 Versailles, France; [Cassou, Bernard] Hop St Perrine, AP HP, Ctr Gerontol, F-75016 Paris, France	UDICE-French Research Universities; Universite Paris Saclay; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Sainte-Perine - APHP	El-Khoury, F (corresponding author), Hop Paul Brousse, INSERM, CESP, Equipe10, Batiment 15-16,16 Ave Paul Vaillant Couturier, F-94807 Villejuif, France.	fabienne.khoury@gmail.com	Khoury, Fabienne/AAB-2123-2020; Dargent-Molina, Patricia/N-3887-2017; Charles, Marie Aline/F-8567-2017; Charles, Marie Aline/S-1866-2019	Khoury, Fabienne/0000-0002-6915-6850; Dargent-Molina, Patricia/0000-0001-8596-6899; Charles, Marie Aline/0000-0003-4025-4390; Charles, Marie Aline/0000-0003-4025-4390				Babitsch Birgit, 2012, Psychosoc Med, V9, pDoc11, DOI 10.3205/psm000089; Barnett A, 2003, AGE AGEING, V32, P407, DOI 10.1093/ageing/32.4.407; Bischoff-Ferrari HA, 2010, ARCH INTERN MED, V170, P813, DOI 10.1001/archinternmed.2010.67; Campbell AJ, 1997, BMJ-BRIT MED J, V315, P1065, DOI 10.1136/bmj.315.7115.1065; Cheung AM, 2008, JAMA-J AM MED ASSOC, V299, P1468, DOI 10.1001/jama.299.12.1468; Cornillon E., 2002, Annales de Readaptation et de Medecine Physique, V45, P493, DOI 10.1016/S0168-6054(02)00302-1; CUMMINGS P, 1995, ANNU REV PUBL HEALTH, V16, P381; DargentMolina P, 1996, LANCET, V348, P145, DOI 10.1016/S0140-6736(96)01440-7; Davis JC, 2010, OSTEOPOROSIS INT, V21, P1295, DOI 10.1007/s00198-009-1162-0; de Kam D, 2009, OSTEOPOROSIS INT, V20, P2111, DOI 10.1007/s00198-009-0938-6; Fitzharris MP, 2010, AGE AGEING, V39, P728, DOI 10.1093/ageing/afq109; Freiberger E, 2012, J AM GERIATR SOC, V60, P437, DOI 10.1111/j.1532-5415.2011.03859.x; Gill TM, 2013, AM J EPIDEMIOL, V178, P418, DOI 10.1093/aje/kws554; Gillespie Lesley D, 2012, Cochrane Database Syst Rev, pCD007146, DOI 10.1002/14651858.CD007146.pub3; Haines TP, 2009, CLIN REHABIL, V23, P973, DOI 10.1177/0269215509338998; Hannan MT, 2010, AM J EPIDEMIOL, V171, P1031, DOI 10.1093/aje/kwq024; Hartholt KA, 2011, J TRAUMA, V71, P748, DOI 10.1097/TA.0b013e3181f6f5e5; Higgins J. P., 2011, COCHRANE HDB SYST RE, V4, DOI [10.1002/9780470712184, DOI 10.1002/9780470712184]; Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186; Higgins JPT, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d5928; Howe TE, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004963.pub2; Iwamoto J, 2009, OSTEOPOROSIS INT, V20, P1233, DOI 10.1007/s00198-008-0794-9; Jarvinen TLN, 2008, BRIT MED J, V336, P124, DOI 10.1136/bmj.39428.470752.AD; Kannus P, 2005, AM J PUBLIC HEALTH, V95, P422, DOI 10.2105/AJPH.2004.047779; Kemmler W, 2010, ARCH INTERN MED, V170, P179, DOI 10.1001/archinternmed.2009.499; Korpelainen R, 2005, OSTEOPOROSIS INT, V17, P109; Lamb SE, 2011, TRIALS, V12, DOI 10.1186/1745-6215-12-125; Laybourne AH, 2008, AGE AGEING, V37, P10, DOI 10.1093/ageing/afm190; Li FZ, 2005, J GERONTOL A-BIOL, V60, P187, DOI 10.1093/gerona/60.2.187; Liberati A, 2009, PLOS MED, V6, DOI [10.1371/journal.pmed.1000100, 10.1136/bmj.b2700, 10.7326/0003-4819-151-4-200908180-00136]; Liu-Ambrose T, 2010, ARCH INTERN MED, V170, P170, DOI 10.1001/archinternmed.2009.494; LORD SR, 1995, J AM GERIATR SOC, V43, P1198, DOI 10.1111/j.1532-5415.1995.tb07394.x; Luukinen H, 2006, SCAND J PRIM HEALTH, V24, P199, DOI 10.1080/02813430600958476; MacRae PG, 1994, J AGING PHYS ACTIV, V2, P127, DOI DOI 10.1123/JAPA.2.2.127; Martin FC, 2009, AGE AGEING, V38, P640, DOI 10.1093/ageing/afp185; McMurdo MET, 1997, BRIT MED J, V314, P569, DOI 10.1136/bmj.314.7080.569; Means KM, 2005, AM J PHYS MED REHAB, V84, P238, DOI 10.1097/01.PHM.0000151944.22116.5A; Morrison A, 2013, CLINICOECONOMIC OUTC, V5, P9, DOI 10.2147/CEOR.S38721; NEVITT MC, 1993, J AM GERIATR SOC, V41, P1226, DOI 10.1111/j.1532-5415.1993.tb07307.x; PROVINCE MA, 1995, JAMA-J AM MED ASSOC, V273, P1341, DOI 10.1001/jama.273.17.1341; Quant S, 2001, NEUROREPORT, V12, P2821, DOI 10.1097/00001756-200109170-00014; Robertson MC, 2002, J AM GERIATR SOC, V50, P905, DOI 10.1046/j.1532-5415.2002.50218.x; Robertson MC, 2001, BRIT MED J, V322, P697, DOI 10.1136/bmj.322.7288.697; Rubenstein LZ, 2006, AGE AGEING, V35, P37, DOI 10.1093/ageing/afl084; Schwenk M, 2012, BMC MED RES METHODOL, V12, DOI 10.1186/1471-2288-12-50; Sherrington C, 2008, J AM GERIATR SOC, V56, P2234, DOI 10.1111/j.1532-5415.2008.02014.x; Sherrington Catherine, 2011, N S W Public Health Bull, V22, P78, DOI 10.1071/NB10056; Shumway-Cook A, 2009, PHYS THER, V89, P324, DOI 10.2522/ptj.20070107; Sjosten N, 2008, AGING MENT HEALTH, V12, P30, DOI 10.1080/13607860701366079; Skelton D, 2005, AGE AGEING, V34, P636, DOI 10.1093/ageing/afi174; Skelton DA, 2003, SCAND J MED SCI SPOR, V13, P77, DOI 10.1034/j.1600-0838.2003.00300.x; Smulders E, 2010, ARCH PHYS MED REHAB, V91, P1705, DOI 10.1016/j.apmr.2010.08.004; Stevens JA, 2008, J SAFETY RES, V39, P345, DOI 10.1016/j.jsr.2008.05.002; Stone KL, 2003, J BONE MINER RES, V18, P1947, DOI 10.1359/jbmr.2003.18.11.1947; Thomas S, 2010, AGE AGEING, V39, P681, DOI 10.1093/ageing/afq102; Tinetti ME, 2003, NEW ENGL J MED, V348, P42, DOI 10.1056/NEJMcp020719; Wolf SL, 1996, J AM GERIATR SOC, V44, P489, DOI 10.1111/j.1532-5415.1996.tb01432.x	57	294	300	4	72	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 29	2013	347								f6234	10.1136/bmj.f6234	http://dx.doi.org/10.1136/bmj.f6234			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	247EV	24169944	Green Published, Green Submitted			2023-01-03	WOS:000326599500005
J	Santa-Ana-Tellez, Y; Mantel-Teeuwisse, AK; Dreser, A; Leufkens, HGM; Wirtz, VJ				Santa-Ana-Tellez, Yared; Mantel-Teeuwisse, Aukje K.; Dreser, Anahi; Leufkens, Hubert G. M.; Wirtz, Veronika J.			Impact of Over-the-Counter Restrictions on Antibiotic Consumption in Brazil and Mexico	PLOS ONE			English	Article							RESISTANCE	Background: In Latin American countries over-the-counter (OTC) dispensing of antibiotics is common. In 2010, both Mexico and Brazil implemented policies to enforce existing laws of restricting consumption of antibiotics only to patients presenting a prescription. The objective of the present study is therefore to evaluate the impact of OTC restrictions (2010) on antibiotics consumption in Brazil and Mexico. Methods and Findings: Retail quarterly sales data in kilograms of oral and injectable antibiotics between January 2007 and June 2012 for Brazil and Mexico were obtained from IMS Health. The unit of analysis for antibiotics consumption was the defined daily dose per 1,000 inhabitants per day (DDD/TID) according to the WHO ATC classification system. Interrupted time series analysis was conducted using antihypertensives as reference group to account for changes occurring independently of the OTC restrictions directed at antibiotics. To reduce the effect of (a) seasonality and (b) autocorrelation, dummy variables and Prais-Winsten regression were used respectively. Between 2007 and 2012 total antibiotic usage increased in Brazil (from 5.7 to 8.5 DDD/TID, +49.3%) and decreased in Mexico (10.5 to 7.5 DDD/TID, -29.2%). Interrupted time series analysis showed a change in level of consumption of -1.35 DDD/TID (p<0.01) for Brazil and -1.17 DDD/TID (p<0.00) for Mexico. In Brazil the penicillins, sulfonamides and macrolides consumption had a decrease in level after the intervention of 0.64 DDD/TID (p = 0.02), 0.41 (p = 0.02) and 0.47 (p = 0.01) respectively. While in Mexico it was found that only penicillins and sulfonamides had significant changes in level of 20.86 DDD/TID (p<0.00) and -0.17 DDD/TID (p = 0.07). Conclusions: Despite different overall usage patterns of antibiotics in Brazil and Mexico, the effect of the OTC restrictions on antibiotics usage was similar. In Brazil the trend of increased usage of antibiotics was tempered after the OTC restrictions; in Mexico the trend of decreased usage was boosted.	[Santa-Ana-Tellez, Yared; Mantel-Teeuwisse, Aukje K.; Leufkens, Hubert G. M.] UIPS, WHO Collaborating Ctr Pharmaceut Policy & Regulat, Utrecht, Netherlands; [Dreser, Anahi; Wirtz, Veronika J.] Natl Inst Publ Hlth, Ctr Hlth Syst Res, Cuernavaca, Morelos, Mexico; [Wirtz, Veronika J.] Boston Univ, Ctr Global Hlth & Dev, Boston, MA 02215 USA	Utrecht University; Instituto Nacional de Salud Publica; Boston University	Wirtz, VJ (corresponding author), Natl Inst Publ Hlth, Ctr Hlth Syst Res, Cuernavaca, Morelos, Mexico.	vwirtz@bu.edu	Dreser, Anahí/AAS-5886-2021; Dreser, Anahi/A-8317-2013; Wirtz, Veornika/AAG-9712-2019; Mantel-Teeuwisse, Aukje/I-8902-2016	Dreser, Anahí/0000-0001-9019-2330; Dreser, Anahi/0000-0001-9019-2330; Wirtz, Veronika J./0000-0002-0863-8768; Santa-Ana-Tellez, Yared/0000-0003-3086-446X	CONACYT (National Council of Science and Technology Mexico)	CONACYT (National Council of Science and Technology Mexico)(Consejo Nacional de Ciencia y Tecnologia (CONACyT))	Yared Santa-Ana-Tellez received funding from CONACYT (National Council of Science and Technology Mexico). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ANVISA, 2012, SIST GER PROD CONTR; ANVISA, 2013, DEF NOV DAT CONTR EL; Bavestrello L, 2002, REV MED CHILE, V130, P1265; CHIPMAN JS, 1979, ECONOMETRICA, V47, P115, DOI 10.2307/1912350; Diario Oficial de la Federacino, 2010, AC QUE SE SET LIN QU; Diekema DJ, 2000, EMERG INFECT DIS, V6, P552, DOI 10.3201/eid0605.000519; Dreser A, 2008, SALUD PUBLICA MEXICO, V50, pS480, DOI 10.1590/S0036-36342008001000009; Dreser A, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-1051; Ferech M, 2006, J ANTIMICROB CHEMOTH, V58, P401, DOI 10.1093/jac/dkl188; Goossens H, 2005, LANCET, V365, P579, DOI 10.1016/S0140-6736(05)17907-0; Health IMS, 2008, PHARM MARK; IMS Health, 2006, PHARM SHAK UP; Luis BF, 2011, REV CHIL INFECTOL, V28, P107, DOI /S0716-10182011000200001; Pan American Health Organization, 2004, LEG ANT AM LAT; Pan American Health Organization, 1999, PREV CONTR ANT RES; Pan American Health Organization (n.d.), PAN AM HLTH ORG DAT; StataCorp, 2011, BEVOLKING; Wagner AK, 2002, J CLIN PHARM THER, V27, P299, DOI 10.1046/j.1365-2710.2002.00430.x; Wirtz VJ, 2013, TROP MED INT HEALTH, V18, P665, DOI 10.1111/tmi.12096; Wirtz VJ, 2010, REV PANAM SALUD PUBL, V27, P219, DOI 10.1590/S1020-49892010000300009; World Health Organization Collaborating Centre for Drug Statistics Methodology Norwegian Institute of Public Health, 2012, ATC DDD IND	21	77	78	1	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 16	2013	8	10							e75550	10.1371/journal.pone.0075550	http://dx.doi.org/10.1371/journal.pone.0075550			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	239JR	24146761	gold, Green Submitted, Green Published			2023-01-03	WOS:000326019400010
J	Smith, DA				Smith, Donald A.			A lifestyle intervention did not reduce cardiovascular outcomes in overweight or obese patients with type 2 diabetes	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									Mt Sinai Sch Med, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai	Smith, DA (corresponding author), Mt Sinai Sch Med, New York, NY 10029 USA.							Grundy SM, 2002, CIRCULATION, V106, P3143, DOI 10.1161/circ.106.25.3143; Rejeski WJ, 2012, NEW ENGL J MED, V366, P1209, DOI 10.1056/NEJMoa1110294; Williamson DF, 2000, DIABETES CARE, V23, P1499, DOI 10.2337/diacare.23.10.1499	3	1	1	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 15	2013	159	8							JC4	10.7326/0003-4819-159-8-201310150-02004	http://dx.doi.org/10.7326/0003-4819-159-8-201310150-02004			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	249BH	24126665				2023-01-03	WOS:000326751200003
J	Benhajali, H; Ezzaouia, M; Lunel, C; Charfi, F; Hausberger, M				Benhajali, Haifa; Ezzaouia, Mohammed; Lunel, Christophe; Charfi, Faouzia; Hausberger, Martine			Temporal Feeding Pattern May Influence Reproduction Efficiency, the Example of Breeding Mares	PLOS ONE			English	Article							STRESS-LIKE CONCENTRATIONS; LUTEINIZING-HORMONE; ESTROUS BEHAVIOR; TIME BUDGET; SECRETION; CORTISOL; LEPTIN; LH; TRANSPORTATION; INHIBITION	Discomfort in farm animals may be induced by inappropriate types or timing of food supplies. Thus, time restriction of meals and lack of roughage have been shown to be one source of emergence of oral stereotypies and abnormal behaviour in horses which have evolved to eat high-fibre diets in small amounts over long periods of time. This feeding pattern is often altered in domestic environment where horses are often fed low fibre meals that can be rapidly consumed. This study aimed at determining the effect of the temporal pattern of feeding on reproductive efficiency of breeding mares, One hundred Arab breeding mares were divided into two groups that differed only in the temporal pattern of roughage availability: only at night for the standard feeding pattern group (SFP mares), night and day for the "continuous feeding" group (CF mares). The total amount of roughage provided was the same as the CF mares received half of the hay during the day while in paddock (haynets). Mares were tested for oestrus detection by teasing with one stallion and were then examined clinically by rectal palpations and ultrasound before being mated naturally or inseminated by fresh or frozen semen. Multivariate logistic regression was used to analyse data. The treatment affected significantly the reproductive efficiency of the mares with fewer oestrus abnormalities (p = 0.0002) and more fertility (p = 0.024) in CF mares (conception rate = 81% versus 55% in SFP mares). Ensuring semi-continous feeding by providing roughage may be a way of fulfilling the basic physiological needs of the horses' digestive system, reducing stress and associated inhibitors of reproduction. To our knowledge, this study provides the first evidence of an impact of temporal feeding patterns on reproductive success in a Mammal. Temporal patterns of feeding may be a major and underestimated factor in breeding.	[Benhajali, Haifa; Lunel, Christophe; Hausberger, Martine] Univ Rennes 1, CNRS, UMR Ethol Anim & Humaine 6552, Rennes, France; [Benhajali, Haifa; Ezzaouia, Mohammed] Haras Natl Sidi Thabet, Sidi Thabet, Tunisia; [Charfi, Faouzia] Univ Tunis ElManar, Unite Biol Anim & Systemat Evolut, Tunis, Tunisia	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Rennes; Universite de Tunis-El-Manar	Hausberger, M (corresponding author), Univ Rennes 1, CNRS, UMR Ethol Anim & Humaine 6552, Rennes, France.	martine.hausberger@univ-rennes1.fr			Universite Rennes 1	Universite Rennes 1	Universite Rennes 1 (http://www.univ-rennes1.fr/). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adam CL, 2003, REPRODUCTION, P283; Amstalden M, 2003, BIOL REPROD, V69, P1539, DOI 10.1095/biolreprod.103.018119; BALDWIN DM, 1974, ENDOCRINOLOGY, V94, P1397, DOI 10.1210/endo-94-5-1397; Barb CR, 1999, J ANIM SCI, V77, P1249; BARB CR, 1982, J REPROD FERTIL, V64, P85, DOI 10.1530/jrf.0.0640085; BARNETT JL, 1991, ANIM REPROD SCI, V25, P265, DOI 10.1016/0378-4320(91)90021-Q; BAUCUS KL, 1990, J ANIM SCI, V68, P345; BAUCUS KL, 1990, J ANIM SCI, V68, P419; Benhajali H, 2009, ANIMAL, V3, P1308, DOI 10.1017/S1751731109004820; Benhajali H, 2007, HORSE BEHAV WELFARE; Benhajali H, 2008, APPL ANIM BEHAV SCI, V112, P196, DOI 10.1016/j.applanim.2007.08.007; Berger A, 1999, APPL ANIM BEHAV SCI, V64, P1, DOI 10.1016/S0168-1591(99)00026-X; Berghold P, 2007, ANIM REPROD SCI, V102, P276, DOI 10.1016/j.anireprosci.2006.11.009; Bhardwaj SK, 2004, REPROD NUTR DEV, V44, P29, DOI 10.1051/rnd:2004014; BOISSY A, 1995, Q REV BIOL, V70, P165, DOI 10.1086/418981; BOYD LE, 1988, APPL ANIM BEHAV SCI, V21, P5, DOI 10.1016/0168-1591(88)90098-6; Broom D. M., 1993, Equine Veterinary Education, V5, P151, DOI 10.1111/j.2042-3292.1993.tb01026.x; Buff PR, 2007, DOMEST ANIM ENDOCRIN, V33, P430, DOI 10.1016/j.domaniend.2006.08.007; Chebel RC, 2007, ANIM REPROD SCI, V101, P208, DOI 10.1016/j.anireprosci.2006.09.010; CHEN MD, 1992, NEUROENDOCRINOLOGY, V56, P666, DOI 10.1159/000126291; Chrousos George P., 1998, Annals of Internal Medicine, V129, P229; Daley CA, 1999, BIOL REPROD, V60, P158, DOI 10.1095/biolreprod60.1.158; Dobson H, 1999, J REPROD FERTIL, V116, P1, DOI 10.1530/jrf.0.1160001; Dobson H, 2000, ANIM REPROD SCI, V60, P743, DOI 10.1016/S0378-4320(00)00080-4; DUBEY AK, 1985, BIOL REPROD, V33, P423, DOI 10.1095/biolreprod33.2.423; EHNERT K, 1991, J ANIM SCI, V69, P2988, DOI 10.2527/1991.6972988x; Ferreira-Dias G, 2005, DOMEST ANIM ENDOCRIN, V29, P203, DOI 10.1016/j.domaniend.2005.02.006; Fitzgerald BP, 2000, BIOL REPROD, V63, P335, DOI 10.1095/biolreprod63.1.335; Gastal M. O., 2004, Animal Reproduction, V1, P115; Guillaume D, 2007, EQUIDEE, V59, P52; Harris P, 2005, VET J, V170, P10, DOI 10.1016/j.tvjl.2004.08.007; Harris PA, 1999, PROC BEVA SPEC DAYS, P45; Hausberger M, 2004, J COMP PSYCHOL, V118, P434, DOI 10.1037/0735-7036.118.4.434; HENNEKE DR, 1984, THERIOGENOLOGY, V21, P897, DOI 10.1016/0093-691X(84)90383-2; HENNEKE DR, 1983, EQUINE VET J, V15, P371, DOI 10.1111/j.2042-3306.1983.tb01826.x; Komesaroff PA, 1998, AM J PHYSIOL-ENDOC M, V275, pE671, DOI 10.1152/ajpendo.1998.275.4.E671; LEE AH, 1986, AM J VET RES, V47, P2000; Macfarlane MS, 2000, ANIM REPROD SCI, V63, P167, DOI 10.1016/S0378-4320(00)00179-2; Madhuranath B N, 2006, Indian J Exp Biol, V44, P28; Mann GE, 2001, VET J, V161, P301, DOI 10.1053/tvjl.2000.0522; MCGREEVY PD, 1995, EQUINE VET J, V27, P86, DOI 10.1111/j.2042-3306.1995.tb03041.x; Merl S, 2000, J EQUINE VET SCI, V20, P586, DOI 10.1016/S0737-0806(00)70267-X; Murray MJ, 1996, EQUINE VET J, V28, P368, DOI 10.1111/j.2042-3306.1996.tb03107.x; Nambo Yasuo, 1996, Journal of Equine Science, V7, P1, DOI 10.1294/jes.7.1; Nicol CJ, 2002, VET REC, V151, P658, DOI 10.1136/vr.151.22.658; Phogat JB, 1999, J REPROD FERTIL, V116, P9, DOI 10.1530/jrf.0.1160009; Piccione G, 2013, BIOL RHYTHM RES, V44, P143, DOI 10.1080/09291016.2012.656245; RABIN DS, 1990, BIOL REPROD, V42, P74, DOI 10.1095/biolreprod42.1.74; SAKAKURA M, 1975, J CLIN ENDOCR METAB, V40, P774, DOI 10.1210/jcem-40-5-774; SMITH ER, 1971, NEUROENDOCRINOLOGY, V8, P94, DOI 10.1159/000121997; Soede NM, 1997, ANIM REPROD SCI, V46, P133, DOI 10.1016/S0378-4320(96)01609-0; STOEBEL DP, 1982, J DAIRY SCI, V65, P1016, DOI 10.3168/jds.S0022-0302(82)82303-5; Tischner M, 2006, ANIM REPROD SCI, V94, P234, DOI 10.1016/j.anireprosci.2006.04.043; TSUMA VT, 1995, J VET MED A, V42, P153, DOI 10.1111/j.1439-0442.1995.tb00367.x; Waring G., 2003, HORSE BEHAV; WILLARD JG, 1977, J ANIM SCI, V45, P87, DOI 10.2527/jas1977.45187x; Wronska-Fortuna D, 1997, P 6 INT S MOL PHYS A, P417; ZIECIK AJ, 1995, ANIM REPROD SCI, V37, P337, DOI 10.1016/0378-4320(94)01336-K	58	14	14	1	45	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 30	2013	8	9							e73858	10.1371/journal.pone.0073858	http://dx.doi.org/10.1371/journal.pone.0073858			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	231NL	24098636	Green Submitted, Green Published, gold			2023-01-03	WOS:000325423500007
J	Sakharwade, SC; Sharma, PK; Mukhopadhaya, A				Sakharwade, Sanica C.; Sharma, Praveen K.; Mukhopadhaya, Arunika			Vibrio cholerae Porin OmpU Induces Pro-Inflammatory Responses, but Down-Regulates LPS-Mediated Effects in RAW 264.7, THP-1 and Human PBMCs	PLOS ONE			English	Article							OUTER-MEMBRANE-PROTEIN; TNF-ALPHA; CYTOKINE PRODUCTION; EPITHELIAL-CELLS; NITRIC-OXIDE; EXPRESSION; RELEASE; VACCINE; RESISTANCE; TOLERANCE	Vibrio cholerae porin OmpU plays a crucial role in the survival of the organism in the human gut. Various observations suggest critical involvement of OmpU in V. cholerae pathogenesis. However, OmpU is poorly characterized in terms of its ability to evoke cellular responses, particularly in the context of host immune system. Therefore, towards characterizing V. cholerae OmpU for its host immunomodulatory functions, we have studied the ability of OmpU to elicit pro-inflammatory responses in a range of immune cells which include, mouse RAW 264.7 macrophages, human THP-1 monocytes and human PBMCs. We have observed that purified OmpU induces pro-inflammatory responses in terms of production of NO, TNF and IL-6. Interestingly, pre-treatment of the cells with OmpU suppresses the production of NO, TNF, IL-6 as well as IL-12 upon subsequent activation with LPS. Our results therefore suggest that V. cholerae OmpU may have a differential regulatory role in terms of host immunomodulatory function: it can induce pro-inflammatory responses in target host immune cells, whereas it can also exert suppressive effect on LPS-induced pro-inflammatory responses. In addition, our study indicates that purified OmpU may have the ability to skew the Th1 response towards the Th2 response, presumably via suppression of IL-12 production.	[Sakharwade, Sanica C.; Sharma, Praveen K.; Mukhopadhaya, Arunika] Indian Inst Sci Educ & Res IISER Mohali, Dept Biol Sci, Mohali, Punjab, India	Indian Institute of Science Education & Research (IISER) - Mohali	Mukhopadhaya, A (corresponding author), Indian Inst Sci Educ & Res IISER Mohali, Dept Biol Sci, Mohali, Punjab, India.	arunika@iisermohali.ac.in		Mukhopadhaya, Arunika/0000-0003-2121-7885	Department of Biotechnology (DBT), India (DBT) [BT/PR1205/MED/29/318/2011]; IISER Mohali	Department of Biotechnology (DBT), India (DBT); IISER Mohali	This work was supported by a grant from the Department of Biotechnology (DBT), India (DBT Grant No. BT/PR1205/MED/29/318/2011) and funding from IISER Mohali. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	BERNARDINI ML, 1993, INFECT IMMUN, V61, P3625, DOI 10.1128/IAI.61.9.3625-3635.1993; Biancone L, 1997, EXP NEPHROL, V5, P330; Biswas T, 2000, FEMS IMMUNOL MED MIC, V29, P129; Burkart V, 2002, J IMMUNOL, V168, P1730, DOI 10.4049/jimmunol.168.4.1730; Cai SH, 2013, J FISH DIS, V36, P695, DOI 10.1111/jfd.12036; Chakrabarti Sr, 1996, J BACTERIOL, V178, P524, DOI 10.1128/jb.178.2.524-530.1996; Chan ED, 1999, J IMMUNOL, V162, P415; Chen PL, 2002, J IMMUNOL, V169, P6408, DOI 10.4049/jimmunol.169.11.6408; DIRITA VJ, 1991, P NATL ACAD SCI USA, V88, P5403, DOI 10.1073/pnas.88.12.5403; Domingos MO, 2009, TOXICON, V53, P570, DOI 10.1016/j.toxicon.2008.12.017; Duperthuy M, 2011, P NATL ACAD SCI USA, V108, P2993, DOI 10.1073/pnas.1015326108; Duperthuy M, 2010, ENVIRON MICROBIOL, V12, P951, DOI 10.1111/j.1462-2920.2009.02138.x; Duret G, 2006, J BIOL CHEM, V281, P19899, DOI 10.1074/jbc.M602426200; Fan HK, 2004, J ENDOTOXIN RES, V10, P71, DOI 10.1179/096805104225003997; GALDIERO F, 1993, INFECT IMMUN, V61, P155, DOI 10.1128/IAI.61.1.155-161.1993; Galdiero M, 2003, FEMS MICROBIOL LETT, V226, P57, DOI 10.1016/S0378-1097(03)00562-7; Galdiero M, 2001, MICROBIOL-SGM, V147, P2697, DOI 10.1099/00221287-147-10-2697; Galdiero M, 2004, INFECT IMMUN, V72, P1204, DOI 10.1128/IAI.72.2.1204-1209.2004; Goel AK, 2010, WORLD J MICROB BIOT, V26, P281, DOI 10.1007/s11274-009-0171-7; Goo SY, 2006, INFECT IMMUN, V74, P5586, DOI 10.1128/IAI.00171-06; Gupta S, 1999, MOL CELL BIOCHEM, V194, P235, DOI 10.1023/A:1006971621653; HEINRICH PC, 1990, BIOCHEM J, V265, P621, DOI 10.1042/bj2650621; HIRANO T, 1985, P NATL ACAD SCI USA, V82, P5490, DOI 10.1073/pnas.82.16.5490; Holm MM, 2004, INFECT IMMUN, V72, P1906, DOI 10.1128/IAI.72.4.1906-1913.2004; HOUSSIAU FA, 1989, J IMMUNOL, V143, P2520; Khan J, 2012, PROTEIN EXPRES PURIF, V85, P204, DOI 10.1016/j.pep.2012.08.005; Kumar H, 2011, INT REV IMMUNOL, V30, P16, DOI 10.3109/08830185.2010.529976; Latz E, 2004, J IMMUNOL, V172, P2431, DOI 10.4049/jimmunol.172.4.2431; Massari P, 2002, J IMMUNOL, V168, P1533, DOI 10.4049/jimmunol.168.4.1533; Mathur J, 2004, INFECT IMMUN, V72, P3577, DOI 10.1128/IAI.72.6.3577-3583.2004; Merrell DS, 2001, J BACTERIOL, V183, P2746, DOI 10.1128/JB.183.9.2746-2754.2001; Muller A, 1999, EMBO J, V18, P339, DOI 10.1093/emboj/18.2.339; Nakasone N, 1998, INFECT IMMUN, V66, P4726, DOI 10.1128/IAI.66.10.4726-4728.1998; Negm RS, 1999, CAN J MICROBIOL, V45, P658, DOI 10.1139/cjm-45-8-658; Nikaido H, 2003, MICROBIOL MOL BIOL R, V67, P593, DOI 10.1128/MMBR.67.4.593-656.2003; Provenzano D, 2000, P NATL ACAD SCI USA, V97, P10220, DOI 10.1073/pnas.170219997; Provenzano D, 2001, J BACTERIOL, V183, P3652, DOI 10.1128/JB.183.12.3652-3662.2001; Roach DR, 2002, J IMMUNOL, V168, P4620, DOI 10.4049/jimmunol.168.9.4620; Rolhion N, 2007, MOL MICROBIOL, V63, P1684, DOI 10.1111/j.1365-2958.2007.05638.x; Sarkar M, 2012, FEBS J, V279, P1464, DOI 10.1111/j.1742-4658.2012.08539.x; Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73; SETRAKIAN JC, 1994, ARCH SURG-CHICAGO, V129, P187; Sorci G, 2009, PHILOS T R SOC B, V364, P71, DOI 10.1098/rstb.2008.0151; Spandidos A, 2010, NUCLEIC ACIDS RES, V38, pD792, DOI 10.1093/nar/gkp1005; SPERANDIO V, 1995, INFECT IMMUN, V63, P4433, DOI 10.1128/IAI.63.11.4433-4438.1995; TABARAIE B, 1994, MICROBIOL IMMUNOL, V38, P553, DOI 10.1111/j.1348-0421.1994.tb01822.x; Thanassi DG, 1997, J BACTERIOL, V179, P2512, DOI 10.1128/jb.179.8.2512-2518.1997; Tsatsanis C, 2005, BIOCHEM BIOPH RES CO, V335, P1254, DOI 10.1016/j.bbrc.2005.07.197; Viana CFG, 2002, TOXICON, V40, P1487, DOI 10.1016/S0041-0101(02)00170-8; Wang Q, 2011, LETT APPL MICROBIOL, V53, P22, DOI 10.1111/j.1472-765X.2011.03062.x; Whitaker WB, 2012, INFECT IMMUN, V80, P1834, DOI 10.1128/IAI.06284-11; Wibbenmeyer JA, 2002, INFECT IMMUN, V70, P121, DOI 10.1128/IAI.70.1.121-126.2002; Xiong XP, 2010, MAR BIOTECHNOL, V12, P686, DOI 10.1007/s10126-009-9256-4	53	20	21	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 27	2013	8	9							e76583	10.1371/journal.pone.0076583	http://dx.doi.org/10.1371/journal.pone.0076583			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	228WY	24086753	Green Published, gold, Green Submitted			2023-01-03	WOS:000325223900106
J	Black, ME				Black, Mary E.			How to get out of hospital	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material												drmaryblack@gmail.com							0	0	0	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 25	2013	347								f5788	10.1136/bmj.f5788	http://dx.doi.org/10.1136/bmj.f5788			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	227CW	24068724				2023-01-03	WOS:000325087200021
J	Chisti, MJ; Salam, MA; Ashraf, H; Faruque, ASG; Bardhan, PK; Hossain, MI; Shahid, ASMSB; Shahunja, KM; Das, SK; Imran, G; Ahmed, T				Chisti, Mohammod Jobayer; Salam, Mohammed Abdus; Ashraf, Hasan; Faruque, Abu S. G.; Bardhan, Pradip Kumar; Hossain, Md Iqbal; Shahid, Abu S. M. S. B.; Shahunja, K. M.; Das, Sumon Kumar; Imran, Gazi; Ahmed, Tahmeed			Clinical Risk Factors of Death From Pneumonia in Children with Severe Acute Malnutrition in an Urban Critical Care Ward of Bangladesh	PLOS ONE			English	Article							DIARRHEA TREATMENT CENTER; MALNOURISHED CHILDREN; PREDICTORS; MORTALITY; INFANTS; MECHANISMS; HYPOXEMIA; DIAGNOSIS; ETIOLOGY; FEATURES	Background: Risks of death are high when children with pneumonia also have severe acute malnutrition (SAM) as a comorbidity. However, there is limited published information on risk factors of death from pneumonia in SAM children. We evaluated clinically identifiable factors associated with death in under-five children who were hospitalized for the management of pneumonia and SAM. Methods: For this unmatched case-control design, SAM children of either sex, aged 0-59 months, admitted to the Dhaka Hospital of the International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b) during April 2011 to July 2012 with radiological pneumonia were studied. The SAM children with pneumonia who had fatal outcome constituted the cases (n = 35), and randomly selected SAM children with pneumonia who survived constituted controls (n = 105). Results: The median (inter-quartile range) age (months) was comparable among the cases and the controls [8.0 (4.9, 11.0) vs. 9.7 (5.0, 18.0); p = 0.210)]. In logistic regression analysis, after adjusting for potential confounders, such as vomiting, abnormal mental status, and systolic hypotension (<70 mm of Hg) in absence of dehydration, fatal cases of severely malnourished under-five children with pneumonia were more often hypoxemic (OR = 23.15, 95% CI = 4.38-122.42), had clinical dehydration (some/severe) (OR = 9.48, 95% CI = 2.42-37.19), abdominal distension at admission (OR = 4.41, 95% CI = 1.12-16.52), and received blood transfusion (OR = 5.50, 95% CI = 1.21-24.99) for the management of crystalloid resistant systolic hypotension. Conclusion and Significance: We identified hypoxemia, clinical dehydration, and abdominal distension as the independent predictors of death in SAM children with pneumonia. SAM children with pneumonia who required blood transfusion for the management of crystalloid resistant systolic hypotension were also at risk for death. Thus, early identification and prompt management of these simple clinically recognizable predictors of death and discourage the use of blood transfusion for the management of crystalloid resistant systolic hypotension may help reduce deaths in such population.	[Chisti, Mohammod Jobayer; Ashraf, Hasan; Faruque, Abu S. G.; Bardhan, Pradip Kumar; Hossain, Md Iqbal; Shahid, Abu S. M. S. B.; Shahunja, K. M.; Das, Sumon Kumar; Ahmed, Tahmeed] Icddr B, CNFS, Dhaka, Bangladesh; [Chisti, Mohammod Jobayer; Ashraf, Hasan; Bardhan, Pradip Kumar; Hossain, Md Iqbal] Icddr B, Dhaka Hosp, Dhaka, Bangladesh; [Salam, Mohammed Abdus] Icddr B, Res Adm, Dhaka, Bangladesh; [Imran, Gazi] Dhaka Shishu Children Hosp, Dhaka, Bangladesh	International Centre for Diarrhoeal Disease Research (ICDDR); International Centre for Diarrhoeal Disease Research (ICDDR); International Centre for Diarrhoeal Disease Research (ICDDR)	Chisti, MJ (corresponding author), Icddr B, CNFS, Dhaka, Bangladesh.	chisti@icddrb.org	Chisti, Mohammod J/A-7216-2018; Das, Sumon Kumar/AAD-1551-2019; Das, Sumon Kumar/T-6384-2019; Shahunja, K M/AAR-6229-2020	Shahunja, K M/0000-0002-9345-206X	Dhaka Hospital of International Centre for Diarrhoeal Disease Research, Bangladesh (ICDDR, B) [Gr-00233]	Dhaka Hospital of International Centre for Diarrhoeal Disease Research, Bangladesh (ICDDR, B)	This research study was funded by the Dhaka Hospital of International Centre for Diarrhoeal Disease Research, Bangladesh (ICDDR, B; grant no Gr-00233) and its donors, which provide unrestricted support to ICDDR, B for its operations and research. Current donors providing unrestricted support include: Australian Agency for International Development, Government of the People's Republic of Bangladesh, Canadian International Development Agency, Swedish International Development Cooperation Agency, and the Department for International Development, United Kingdom. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ADEGBOLA RA, 1994, PEDIATR INFECT DIS J, V13, P975, DOI 10.1097/00006454-199411000-00008; Adegbola RA, 2000, ANN TROP MED PARASIT, V94, P197, DOI 10.1080/00034980050006366; Ahmed T, 1999, LANCET, V353, P1919, DOI 10.1016/S0140-6736(98)07499-6; Alam Nure H, 2003, Paediatr Drugs, V5, P151, DOI 10.2165/00128072-200305030-00002; [Anonymous], PEDIAT ADV LIFE SUPP; Bachou Hanifa, 2006, BMC Pediatr, V6, P7, DOI 10.1186/1471-2431-6-7; Black RE, 2010, LANCET, V375, P1969, DOI 10.1016/S0140-6736(10)60549-1; BROOKS SEH, 1994, W INDIAN MED J, V43, P52; Carcillo Joseph A, 2005, Pediatr Crit Care Med, V6, pS157, DOI 10.1097/01.PCC.0000161574.36857.CA; Cherian T, 2005, B WORLD HEALTH ORGAN, V83, P353; Chisti MJ, 2011, ANN TROP PAEDIATR, V31, P311, DOI 10.1179/1465328111Y.0000000033; Chisti MJ, 2010, ANN TROP PAEDIATR, V30, P311, DOI 10.1179/146532810X12858955921230; Chisti MJ, 2009, ANN TROP PAEDIATR, V29, P45, DOI 10.1179/146532809X402024; Chisti MJ, 2012, TROP MED INT HEALTH, V17, P106, DOI 10.1111/j.1365-3156.2011.02890.x; Chisti MJ, 2011, ACTA PAEDIATR, V100, pE275, DOI 10.1111/j.1651-2227.2011.02368.x; Chisti MJ, 2010, PEDIATR CRIT CARE ME, V11, P92, DOI 10.1097/PCC.0b013e3181b063e1; Chisti MJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0051376; Chisti MJ, 2010, PEDIATR INFECT DIS J, V29, P174, DOI 10.1097/INF.0b013e3181b9a4d5; Chisti MJ, 2009, TROP MED INT HEALTH, V14, P1173, DOI 10.1111/j.1365-3156.2009.02364.x; Chisti MJ, 2009, ACTA PAEDIATR, V98, P873, DOI 10.1111/j.1651-2227.2008.01196.x; Eisenhut Michael, 2006, J Inflamm (Lond), V3, P5, DOI 10.1186/1476-9255-3-5; Eisenhut M, 2007, MED HYPOTHESES, V68, P361, DOI 10.1016/j.mehy.2006.07.012; Falade AG, 1997, ANN TROP PAEDIATR, V17, P315, DOI 10.1080/02724936.1997.11747904; Gauvin F, 2012, PAED CHILD HEALT-CAN, V17, P235, DOI 10.1093/pch/17.5.235; Holder AL, 2013, CRIT CARE, V17, DOI 10.1186/cc12533; Liu L, 2012, LANCET; Lozano JM, 2001, INT J TUBERC LUNG D, V5, P496; Maitland K, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-68; Muriova K, 2010, Vnitr Lek, V56, P220; Nair H, 2013, LANCET; PARKS DA, 1985, ARCH INTERN MED, V145, P1278, DOI 10.1001/archinte.145.7.1278; Rudiger A, 2007, CRIT CARE MED, V35, P1599, DOI 10.1097/01.CCM.0000266683.64081.02; Rudiger A, 2013, CURR VASC PHARMACOL, V11, P187; Smyth A, 1998, ANN TROP PAEDIATR, V18, P31, DOI 10.1080/02724936.1998.11747923; West JB., 2008, WESTS RESP PHYSL ESS, V9th; WHO, 2006, POCK BOOK HOSP CAR C, P173; World Health Organization, 1999, MAN SEV MALN MAN PHY	37	27	28	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 9	2013	8	9							e73728	10.1371/journal.pone.0073728	http://dx.doi.org/10.1371/journal.pone.0073728			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	244QV	24040043	Green Published, Green Submitted, gold			2023-01-03	WOS:000326405300118
J	Reddy, S; Taylor, M; Zhao, MJ; Cherubin, P; Geden, S; Ray, S; Francis, D; Teter, K				Reddy, Srikar; Taylor, Michael; Zhao, Mojun; Cherubin, Patrick; Geden, Sandra; Ray, Supriyo; Francis, David; Teter, Ken			Grape Extracts Inhibit Multiple Events in the Cell Biology of Cholera Intoxication	PLOS ONE			English	Article							TOXIN A1 SUBUNIT; INTESTINAL EPITHELIAL-CELLS; NATURAL POLYPHENOLS; PLANT POLYPHENOLS; CULTURED-CELLS; INTERNALIZATION; DEGRADATION; TRANSPORT; REDUCTION; BINDING	Vibrio cholerae produces cholera toxin (CT), an AB(5) protein toxin that is primarily responsible for the profuse watery diarrhea of cholera. CT is secreted into the extracellular milieu, but the toxin attacks its Gs alpha target within the cytosol of a host cell. Thus, CT must cross a cellular membrane barrier in order to function. This event only occurs after the toxin travels by retrograde vesicular transport from the cell surface to the endoplasmic reticulum (ER). The catalytic A1 polypeptide then dissociates from the rest of the toxin and assumes an unfolded conformation that facilitates its transfer to the cytosol by a process involving the quality control system of ER-associated degradation. Productive intoxication is blocked by alterations to the vesicular transport of CT and/or the ER-to-cytosol translocation of CTA1. Various plant compounds have been reported to inhibit the cytopathic activity of CT, so in this work we evaluated the potential anti-CT properties of grape extract. Two grape extracts currently sold as nutritional supplements inhibited CT and Escherichia coli heat-labile toxin activity against cultured cells and intestinal loops. CT intoxication was blocked even when the extracts were added an hour after the initial toxin exposure. A specific subset of host-toxin interactions involving both the catalytic CTA1 subunit and the cell-binding CTB pentamer were affected. The extracts blocked toxin binding to the cell surface, prevented unfolding of the isolated CTA1 subunit, inhibited CTA1 translocation to the cytosol, and disrupted the catalytic activity of CTA1. Grape extract could thus potentially serve as a novel therapeutic to prevent or possibly treat cholera.	[Reddy, Srikar; Taylor, Michael; Cherubin, Patrick; Geden, Sandra; Ray, Supriyo; Teter, Ken] Univ Cent Florida, Coll Med, Burnett Sch Biomed Sci, Orlando, FL 32816 USA; [Reddy, Srikar] Lake Highland Preparatory Sch, Orlando, FL USA; [Zhao, Mojun; Francis, David] S Dakota State Univ, Dept Vet & Biomed Sci, Ctr Infect Dis Res & Vaccinol, Brookings, SD 57007 USA	State University System of Florida; University of Central Florida; South Dakota State University	Teter, K (corresponding author), Univ Cent Florida, Coll Med, Burnett Sch Biomed Sci, Orlando, FL 32816 USA.	kteter@mail.ucf.edu	Ray, Supriyo/L-1020-2019	Cherubin, Patrick/0000-0002-3567-836X; Teter, Ken/0000-0003-4176-9361				APTER FM, 1993, INFECT IMMUN, V61, P5271, DOI 10.1128/IAI.61.12.5271-5278.1993; Arts ICW, 2005, AM J CLIN NUTR, V81, p317S, DOI 10.1093/ajcn/81.1.317S; Banerjee T, 2010, BIOCHEMISTRY-US, V49, P8839, DOI 10.1021/bi101201c; Brijesh S, 2009, BMC COMPLEM ALTERN M, V9, DOI 10.1186/1472-6882-9-47; Charlton AJ, 2002, J AGR FOOD CHEM, V50, P1593, DOI 10.1021/jf010897z; Choi O, 2007, MICROB PATHOGENESIS, V42, P215, DOI 10.1016/j.micpath.2007.01.007; de Haan L, 2004, MOL MEMBR BIOL, V21, P77, DOI 10.1080/09687680410001663267; Dell'Aica I, 2004, EMBO REP, V5, P418, DOI 10.1038/sj.embor.7400118; FISHMAN PH, 1982, J CELL BIOL, V93, P860, DOI 10.1083/jcb.93.3.860; Friedman M, 2007, MOL NUTR FOOD RES, V51, P116, DOI 10.1002/mnfr.200600173; Fujinaga Y, 2003, MOL BIOL CELL, V14, P4783, DOI 10.1091/mbc.E03-06-0354; Haslam E, 1996, J NAT PROD, V59, P205, DOI 10.1021/np960040+; Hazes B, 1997, BIOCHEMISTRY-US, V36, P11051, DOI 10.1021/bi971383p; Kammerer D, 2004, J AGR FOOD CHEM, V52, P4360, DOI 10.1021/jf049613b; Lauer S, 2002, BIOCHEMISTRY-US, V41, P1742, DOI 10.1021/bi0112816; LENCER WI, 1993, J CLIN INVEST, V92, P2941, DOI 10.1172/JCI116917; Majoul I, 1997, FEBS LETT, V401, P104, DOI 10.1016/S0014-5793(96)01447-0; Massey S, 2011, INFECT IMMUN, V79, P4739, DOI 10.1128/IAI.05503-11; Massey S, 2009, J MOL BIOL, V393, P1083, DOI 10.1016/j.jmb.2009.09.013; MEKALANOS JJ, 1979, J BIOL CHEM, V254, P5855; Monagas M, 2006, ANAL CHIM ACTA, V563, P401, DOI 10.1016/j.aca.2005.10.065; Morinaga N, 2005, J BIOL CHEM, V280, P23303, DOI 10.1074/JBC.M502093200; Morinaga N, 2001, J BIOL CHEM, V276, P22838, DOI 10.1074/jbc.M101184200; Morinaga N, 2010, TOXICON, V56, P29, DOI 10.1016/j.toxicon.2010.03.009; Nakatsukasa K, 2008, TRAFFIC, V9, P861, DOI 10.1111/j.1600-0854.2008.00729.x; Oi H, 2002, P NATL ACAD SCI USA, V99, P3042, DOI 10.1073/pnas.052709499; Orlandi PA, 1998, J CELL BIOL, V141, P905, DOI 10.1083/jcb.141.4.905; ORLANDI PA, 1993, J BIOL CHEM, V268, P12010; Orlandi PA, 1997, J BIOL CHEM, V272, P4591; Pande AH, 2007, J MOL BIOL, V374, P1114, DOI 10.1016/j.jmb.2007.10.025; Podlipnik C, 2009, ACTA CHIM SLOV, V56, P156; Quinones B, 2009, APPL ENVIRON MICROB, V75, P1410, DOI 10.1128/AEM.02230-08; Ray S, 2012, J BIOL CHEM, V287, P30395, DOI 10.1074/jbc.M112.385575; Richards AA, 2002, MOL BIOL CELL, V13, P1750, DOI 10.1091/mbc.01-12-0592; Rodighiero C, 2002, EMBO REP, V3, P1222, DOI 10.1093/embo-reports/kvf239; Sack DA, 2004, LANCET, V363, P223, DOI 10.1016/S0140-6736(03)15328-7; Saito T, 2002, MICROBIOL IMMUNOL, V46, P249, DOI 10.1111/j.1348-0421.2002.tb02693.x; Sandvig K, 2010, FEBS LETT, V584, P2626, DOI 10.1016/j.febslet.2010.04.008; Shi John, 2003, Journal of Medicinal Food, V6, P291, DOI 10.1089/109662003772519831; Shogomori H, 2001, J NEUROCHEM, V78, P991, DOI 10.1046/j.1471-4159.2001.00489.x; Sivaprakasapillai B, 2009, METABOLISM, V58, P1743, DOI 10.1016/j.metabol.2009.05.030; SOMAN G, 1986, BIOCHEMISTRY-US, V25, P4113, DOI 10.1021/bi00362a019; SPANGLER BD, 1992, MICROBIOL REV, V56, P622, DOI 10.1128/MMBR.56.4.622-647.1992; Sugita-Konishi Y, 1999, BBA-GEN SUBJECTS, V1472, P42, DOI 10.1016/S0304-4165(99)00102-6; SWAISGOOD HE, 1993, J DAIRY SCI, V76, P3054, DOI 10.3168/jds.S0022-0302(93)77645-6; Taylor M, 2012, JOVE-J VIS EXP, DOI 10.3791/3686; Taylor M, 2011, J BIOL CHEM, V286, P22090, DOI 10.1074/jbc.M111.237966; Taylor ME, 2011, APPL MATH SCI, V116, P1, DOI 10.1007/978-1-4419-7052-7_1; Teter K, 2003, TRAFFIC, V4, P232, DOI 10.1034/j.1600-0854.2003.00070.x; Teter K, 2002, INFECT IMMUN, V70, P6172, DOI 10.1128/IAI.70.11.6172-6179.2002; Tsai B, 2001, CELL, V104, P937, DOI 10.1016/S0092-8674(01)00289-6; Vinson Joe A., 2001, J Med Food, V4, P17, DOI 10.1089/10966200152053677; Wernick NLB, 2010, TOXINS, V2, P310, DOI 10.3390/toxins2030310; Winkeler A, 2003, FEBS LETT, V554, P439, DOI 10.1016/S0014-5793(03)01217-1; Wolf AA, 2002, J BIOL CHEM, V277, P16249, DOI 10.1074/jbc.M109834200; Xia EQ, 2010, INT J MOL SCI, V11, P622, DOI 10.3390/ijms11020622; Yahiro K, 2005, HELICOBACTER, V10, P231, DOI 10.1111/j.1523-5378.2005.00315.x; Yoshino N, 2009, VACCINE, V27, P4808, DOI 10.1016/j.vaccine.2009.05.081	58	17	17	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 5	2013	8	9							e73390	10.1371/journal.pone.0073390	http://dx.doi.org/10.1371/journal.pone.0073390			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	219CG	24039929	Green Published, Green Submitted, gold			2023-01-03	WOS:000324481600069
J	Lim, SW; Doh, KC; Jin, L; Piao, SG; Heo, SB; Zheng, YF; Bae, SK; Chung, BH; Yang, CW				Lim, Sun Woo; Doh, Kyoung Chan; Jin, Long; Piao, Shang Guo; Heo, Seong Beom; Zheng, Yu Fen; Bae, Soo Kyung; Chung, Byung Ha; Yang, Chul Woo			Oral Administration of Ginseng Ameliorates Cyclosporine-Induced Pancreatic Injury in an Experimental Mouse Model	PLOS ONE			English	Article							KOREAN RED GINSENG; POSTTRANSPLANT DIABETES-MELLITUS; BETA-CELLS; OXIDATIVE STRESS; INDUCED NEPHROTOXICITY; ISLET DYSFUNCTION; GLUCOSE TOXICITY; ANTIAGING GENE; IN-VIVO; RATS	Background: This study was performed to investigate whether ginseng has a protective effect in an experimental mouse model of cyclosporine-induced pancreatic injury. Methods: Mice were treated with cyclosporine (30 mg/kg/day, subcutaneously) and Korean red ginseng extract (0.2 or 0.4 g/kg/day, oral gavage) for 4 weeks while on a 0.01% salt diet. The effect of ginseng on cyclosporine-induced pancreatic islet dysfunction was investigated by an intraperitoneal glucose tolerance test and measurements of serum insulin level, beta cell area, macrophage infiltration, and apoptosis. Using an in vitro model, we further examined the effect of ginseng on a cyclosporine-treated insulin-secreting cell line. Oxidative stress was measured by the concentration of 8-hydroxy-2'-deoxyguanosine in serum, tissue sections, and culture media. Results: Four weeks of cyclosporine treatment increased blood glucose levels and decreased insulin levels, but cotreatment with ginseng ameliorated the cyclosporine-induced glucose intolerance and hyperglycemia. Pancreatic beta cell area was also greater with ginseng cotreatment compared with cyclosporine monotherapy. The production of proinflammatory molecules, such as induced nitric oxide synthase and cytokines, and the level of apoptotic cell death also decreased in pancreatic beta cell with ginseng treatment. Consistent with the in vivo results, the in vitro study showed that the addition of ginseng protected against cyclosporine-induced cytotoxicity, inflammation, and apoptotic cell death. These in vivo and in vitro changes were accompanied by decreases in the levels of 8-hydroxy-2'-deoxyguanosine in pancreatic beta cell in tissue section, serum, and culture media during cotreatment of ginseng with cyclosporine. Conclusions: The results of our in vivo and in vitro studies demonstrate that ginseng has a protective effect against cyclosporine-induced pancreatic beta cell injury via reducing oxidative stress.	[Lim, Sun Woo; Doh, Kyoung Chan; Jin, Long; Piao, Shang Guo; Heo, Seong Beom; Chung, Byung Ha; Yang, Chul Woo] Catholic Univ Korea, Convergent Res Consortium Immunol Dis, Seoul, South Korea; [Lim, Sun Woo; Doh, Kyoung Chan; Jin, Long; Piao, Shang Guo; Heo, Seong Beom; Chung, Byung Ha; Yang, Chul Woo] Catholic Univ Korea, Transplant Res Ctr, Seoul, South Korea; [Chung, Byung Ha; Yang, Chul Woo] Catholic Univ Korea, Seoul St Marys Hosp, Dept Internal Med, Div Nephrol, Seoul, South Korea; [Bae, Soo Kyung] Catholic Univ Korea, Coll Pharm, Seoul, South Korea; [Zheng, Yu Fen] Seoul Natl Univ, Coll Pharm, Seoul, South Korea; [Piao, Shang Guo] YanBian Univ Hosp, Dept Internal Med, Nephrol & Dialysis Unit, Yanji, Jilin, Peoples R China	Catholic University of Korea; Catholic University of Korea; Catholic University of Korea; Seoul St. Mary's Hospital; Catholic University of Korea; Seoul National University (SNU); Yanbian University	Yang, CW (corresponding author), Catholic Univ Korea, Convergent Res Consortium Immunol Dis, Seoul, South Korea.	yangch@catholic.ac.kr			Korean Society of Ginseng; Korea Ginseng Corporation, Basic Science Research Program through the National Research Foundation of Korea (NRF); Ministry of Education, Science and Technology [2012R1A1A3001890]; Korean Health Technology R&D Project, Ministry for Health & Welfare, Republic of Korea [A092258]	Korean Society of Ginseng; Korea Ginseng Corporation, Basic Science Research Program through the National Research Foundation of Korea (NRF)(National Research Foundation of Korea); Ministry of Education, Science and Technology(Ministry of Education, Science & Technology (MEST), Republic of Korea); Korean Health Technology R&D Project, Ministry for Health & Welfare, Republic of Korea	This work was supported by the 2011 grant from the Korean Society of Ginseng funded by Korea Ginseng Corporation, Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology (2012R1A1A3001890), and the Korean Health Technology R&D Project, Ministry for Health & Welfare, Republic of Korea (A092258). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ajabnoor MA, 2007, LIFE SCI, V80, P345, DOI 10.1016/j.lfs.2006.09.034; BANISACCHI T, 1990, TRANSPLANTATION, V49, P982, DOI 10.1097/00007890-199005000-00028; BASADONNA G, 1988, AM J SURG, V156, P191, DOI 10.1016/S0002-9610(88)80064-3; BIERER BE, 1993, CURR OPIN IMMUNOL, V5, P763, DOI 10.1016/0952-7915(93)90135-F; Bollheimer LC, 2005, BIOCHEM BIOPH RES CO, V330, P327, DOI 10.1016/j.bbrc.2005.01.168; Bugliani M, 2009, ISLETS, V1, P106, DOI 10.4161/isl.1.2.9142; Capasso G, 2008, NEPHROL DIAL TRANSPL, V23, P1186, DOI 10.1093/ndt/gfm784; Chen M, 2002, ENDOCRINOLOGY, V143, P2341, DOI 10.1210/en.143.6.2341; Chung BH, 2005, AM J TRANSPLANT, V5, P1856, DOI 10.1111/j.1600-6143.2005.00979.x; Duclos A, 2006, DRUG AGING, V23, P781, DOI 10.2165/00002512-200623100-00002; Erbagci AB, 2001, CLIN BIOCHEM, V34, P645, DOI 10.1016/S0009-9120(01)00275-2; First MR, 2002, TRANSPLANTATION, V73, P379, DOI 10.1097/00007890-200202150-00011; Han DH, 2010, TRANSPLANTATION, V90, P135, DOI 10.1097/TP.0b013e3181e117b4; Hong Chang-Eui, 2011, Immune Netw, V11, P42, DOI 10.4110/in.2011.11.1.42; ISHIZUKA J, 1993, TRANSPLANTATION, V56, P1486, DOI 10.1097/00007890-199312000-00039; Joo KR, 2009, PANCREAS, V38, P661, DOI 10.1097/MPA.0b013e3181a9eb85; Kaneto H, 1996, BIOCHEM J, V320, P855, DOI 10.1042/bj3200855; Kim JW, 2009, BIOCHEM BIOPH RES CO, V390, P763, DOI 10.1016/j.bbrc.2009.10.046; Kim SH, 2011, NEPHROL DIAL TRANSPL, V26, P1502, DOI 10.1093/ndt/gfq640; Kim WH, 2005, DIABETES, V54, P2602, DOI 10.2337/diabetes.54.9.2602; Lee AYW, 1999, FASEB J, V13, P23, DOI 10.1096/fasebj.13.1.23; Li SY, 2012, APOPTOSIS, V17, P113, DOI 10.1007/s10495-011-0671-4; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Piao SG, 2012, TRANSPLANTATION, V93, P383, DOI 10.1097/TP.0b013e3182421604; Robertson RP, 2003, DIABETES, V52, P581, DOI 10.2337/diabetes.52.3.581; Ryu JK, 2005, UROLOGY, V65, P611, DOI 10.1016/j.urology.2004.10.038; Satyanarayana PSV, 2002, RENAL FAILURE, V24, P259, DOI 10.1081/JDI-120005360; Shihab FS, 1999, KIDNEY INT, V56, P2147, DOI 10.1046/j.1523-1755.1999.00794.x; Song HK, 2009, AM J TRANSPLANT, V9, P2024, DOI 10.1111/j.1600-6143.2009.02751.x; Sung JD, 2000, AM J CHINESE MED, V28, P205, DOI 10.1142/S0192415X00000258; Tanaka Y, 1999, P NATL ACAD SCI USA, V96, P10857, DOI 10.1073/pnas.96.19.10857; Tariq M, 1999, NEPHROL DIAL TRANSPL, V14, P923, DOI 10.1093/ndt/14.4.923; van Engeland M, 1998, CYTOMETRY, V31, P1, DOI 10.1002/(SICI)1097-0320(19980101)31:1<1::AID-CYTO1>3.0.CO;2-R; Vuksan V, 2008, NUTR METAB CARDIOVAS, V18, P46, DOI 10.1016/j.numecd.2006.04.003; Yang ZD, 2005, AM J TRANSPLANT, V5, P475, DOI 10.1111/j.1600-6143.2005.00707.x; Yang ZG, 2006, CHEM BIODIVERS, V3, P187, DOI 10.1002/cbdv.200690022; Yoon HE, 2012, NEPHRON EXP NEPHROL, V120, pE123, DOI 10.1159/000342117; Yoon Hye Eun, 2009, Korean Journal of Internal Medicine, V24, P81, DOI 10.3904/kjim.2009.24.2.81; Zhang DX, 1996, FREE RADICAL BIO MED, V20, P145, DOI 10.1016/0891-5849(95)02020-9	39	15	16	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 29	2013	8	8							e72685	10.1371/journal.pone.0072685	http://dx.doi.org/10.1371/journal.pone.0072685			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	209DO	24009697	Green Submitted, gold, Green Published			2023-01-03	WOS:000323734600033
J	Guida, B; Cataldi, M; Riccio, E; Grumetto, L; Pota, A; Borrelli, S; Memoli, A; Barbato, F; Argentino, G; Salerno, G; Memoli, B				Guida, Bruna; Cataldi, Mauro; Riccio, Eleonora; Grumetto, Lucia; Pota, Andrea; Borrelli, Silvio; Memoli, Andrea; Barbato, Francesco; Argentino, Gennaro; Salerno, Giuliana; Memoli, Bruno			Plasma p-Cresol Lowering Effect of Sevelamer in Peritoneal Dialysis Patients: Evidence from a Cross-Sectional Observational Study	PLOS ONE			English	Article							CHRONIC KIDNEY-DISEASE; UREMIC TOXINS; PHOSPHATE BINDERS; CARDIOVASCULAR-DISEASE; SYSTEMIC INFLAMMATION; RETENTION SOLUTE; MORTALITY RISK; URIC-ACID; HEMODIALYSIS; SERUM	p-Cresol is a by-product of the metabolism of aromatic aminoacid operated by resident intestinal bacteria. In patients with chronic kidney disease, the accumulation of p-cresol and of its metabolite p-cresyl-sulphate causes endothelial dysfunction and ultimately increases the cardiovascular risk of these patients. Therapeutic strategies to reduce plasma p-cresol levels are highly demanded but not available yet. Because it has been reported that the phosphate binder sevelamer sequesters p-cresol in vitro we hypothesized that it could do so also in peritoneal dialysis patients. To explore this hypothesis we measured total cresol plasma concentrations in 57 patients with end-stage renal disease on peritoneal dialysis, 29 receiving sevelamer for the treatment of hyperphosphatemia and 28 patients not assuming this drug. Among the patients not assuming sevelamer, 16 were treated with lanthanum whereas the remaining 12 received no drug because they were not hyperphosphatemic. Patients receiving sevelamer had plasma p-cresol and serum high sensitivity C-reactive protein concentrations significantly lower than those receiving lanthanum or no drug. Conversely, no difference was observed among the different groups either in residual glomerular filtration rate, total weekly dialysis dose, total clearance, urine volume, protein catabolic rate, serum albumin or serum phosphate levels. Multiple linear regression analysis showed that none of these variables predicted plasma p-cresol concentrations that, instead, negatively correlated with the use of sevelamer. These results suggest that sevelamer could be an effective strategy to lower p-cresol circulating levels in peritoneal dialysis patients in which it could also favorably affect cardiovascular risk because of its anti-inflammatory effect.	[Guida, Bruna] Univ Naples Federico II, Dept Clin Med & Surg, Div Physiol, Naples, Italy; [Cataldi, Mauro] Univ Naples Federico II, Dept Neurosci Reprod & Odontostomatol Sci, Div Pharmacol, Naples, Italy; [Riccio, Eleonora; Pota, Andrea; Memoli, Andrea; Argentino, Gennaro; Memoli, Bruno] Univ Naples Federico II, Dept Nephrol, Naples, Italy; [Grumetto, Lucia; Barbato, Francesco] Univ Naples Federico II, Dept Pharmaceut & Toxicol Chem, Naples, Italy; [Salerno, Giuliana] Univ Naples Federico II, Dept Biochem & Med Biotechnol, Naples, Italy; [Borrelli, Silvio] Univ Naples 2, Div Nephrol, Naples, Italy	University of Naples Federico II; University of Naples Federico II; University of Naples Federico II; University of Naples Federico II; University of Naples Federico II; Universita della Campania Vanvitelli	Guida, B (corresponding author), Univ Naples Federico II, Dept Clin Med & Surg, Div Physiol, Naples, Italy.	bguida@unina.it	Cataldi, Mauro/AAB-3642-2019; Borrelli, Silvio/AAH-8549-2019; Barbato, Francesco/I-5863-2015	Cataldi, Mauro/0000-0001-7787-3406; Borrelli, Silvio/0000-0002-4414-4597; Grumetto, Lucia/0000-0002-3529-1819; Barbato, Francesco/0000-0001-6709-3545				Amer Diabet Assoc, 2010, DIABETES CARE, V33, pS62, DOI 10.2337/dc10-s062; Amer Diabet Assoc, 2009, DIABETES CARE, V32, pS13, DOI 10.2337/dc09-S013; Bammens B, 2003, KIDNEY INT, V64, P2238, DOI 10.1046/j.1523-1755.2003.00310.x; Bammens B, 2006, KIDNEY INT, V69, P1081, DOI 10.1038/sj.ki.5000115; Brandenburg VM, 2010, NEPHROL DIAL TRANSPL, V25, P2672, DOI 10.1093/ndt/gfq053; Burke SK, 2003, ADV RENAL REPLACE TH, V10, P133, DOI 10.1053/jarr.2003.50016; Caglar K, 2008, CLIN J AM SOC NEPHRO, V3, P61, DOI 10.2215/CJN.02810707; Cerini C, 2004, THROMB HAEMOSTASIS, V92, P140, DOI 10.1160/th03-07-0491; Cohen J., 2013, STAT POWER ANAL BEHA; CUMMINGS JH, 1983, LANCET, V1, P1206; Davenport A, 2011, HEMODIAL INT, V15, pS49, DOI 10.1111/j.1542-4758.2011.00602.x; De Smet R, 1998, CLIN CHIM ACTA, V278, P1, DOI 10.1016/S0009-8981(98)00124-7; De Smet R, 2004, J AM SOC NEPHROL, V15, p505A; Evenepoel P, 1999, AM J PHYSIOL-GASTR L, V277, pG935, DOI 10.1152/ajpgi.1999.277.5.G935; Evenepoel P, 2009, KIDNEY INT, V76, pS12, DOI 10.1038/ki.2009.402; Evenepoel P, 2009, NEPHROL DIAL TRANSPL, V24, P278, DOI 10.1093/ndt/gfn488; Ferramosca E, 2005, AM HEART J, V149, P820, DOI 10.1016/j.ahj.2004.07.023; Garg JP, 2005, ARTHRITIS RHEUM-US, V52, P290, DOI 10.1002/art.20781; Goldsmith DR, 2008, DRUGS, V68, P85, DOI 10.2165/00003495-200868010-00006; Goto S, 2011, THER APHER DIAL, V15, P132, DOI 10.1111/j.1744-9987.2010.00891.x; Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group, 2009, Kidney Int Suppl, pS1, DOI 10.1038/ki.2009.188; Krieter DH, 2010, NEPHROL DIAL TRANSPL, V25, P212, DOI 10.1093/ndt/gfp437; Leypoldt JK, 1999, AM J KIDNEY DIS, V33, P349, DOI 10.1016/S0272-6386(99)70311-2; Liabeuf S, 2010, NEPHROL DIAL TRANSPL, V25, P1183, DOI 10.1093/ndt/gfp592; Lin CJ, 2011, INT J GERONTOL, V5, P80, DOI 10.1016/j.ijge.2011.04.010; Lin CJ, 2010, NEPHROL DIAL TRANSPL, V25, P3693, DOI 10.1093/ndt/gfq251; McIntyre CW, 2011, CLIN J AM SOC NEPHRO, V6, P133, DOI 10.2215/CJN.04610510; Meijers BKI, 2008, KIDNEY INT, V73, P1174, DOI 10.1038/ki.2008.31; Meijers BKI, 2010, CLIN J AM SOC NEPHRO, V5, P1182, DOI 10.2215/CJN.07971109; Meijers BKI, 2009, AM J KIDNEY DIS, V54, P891, DOI 10.1053/j.ajkd.2009.04.022; Navarro-Gonzalez JF, 2011, CLIN J AM SOC NEPHRO, V6, P2272, DOI 10.2215/CJN.01650211; NIWA T, 1993, NEPHRON, V65, P82, DOI 10.1159/000187446; Ohno I, 2009, INTERNAL MED, V48, P415, DOI 10.2169/internalmedicine.48.1817; Perianayagam MC, 2008, AM J NEPHROL, V28, P802, DOI 10.1159/000135691; Phan O, 2005, CIRCULATION, V112, P2875, DOI 10.1161/CIRCULATIONAHA105.541854; Ritz E, 2011, BLOOD PURIFICAT, V31, P70, DOI 10.1159/000321848; Shantouf R, 2008, AM J NEPHROL, V28, P275, DOI 10.1159/000111061; Stinghen AEM, 2010, BLOOD PURIFICAT, V29, P352, DOI 10.1159/000302723; Sun PP, 2009, J RENAL NUTR, V19, P432, DOI 10.1053/j.jrn.2009.01.022; Takei T, 2008, NEPHRON CLIN PRACT, V108, pC278, DOI 10.1159/000127361; Tonelli M, 2006, J AM SOC NEPHROL, V17, P2034, DOI 10.1681/ASN.2005101085; Vanholder R, 2003, NEPHROL DIAL TRANSPL, V18, P463, DOI 10.1093/ndt/18.3.463; Vanholder R, 2003, KIDNEY INT, V63, P1934, DOI 10.1046/j.1523-1755.2003.00924.x; Vanholder R, 2011, NEPHROL DIAL TRANSPL, V26, P1464, DOI 10.1093/ndt/gfr056; Vlassara H, 2012, CLIN J AM SOC NEPHRO, V7, P934, DOI 10.2215/CJN.12891211; Yamada K, 2005, RENAL FAILURE, V27, P361, DOI 10.1081/JDI-200065259; Ying Y, 2011, CIRC J, V75, P2252, DOI 10.1253/circj.CJ-11-0046; Zimmermann J, 1999, KIDNEY INT, V55, P648, DOI 10.1046/j.1523-1755.1999.00273.x	49	23	23	0	30	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 28	2013	8	8							e73558	10.1371/journal.pone.0073558	http://dx.doi.org/10.1371/journal.pone.0073558			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	209DG	24015307	Green Published, gold, Green Submitted			2023-01-03	WOS:000323733800102
J	Mazzaccara, C; Conti, V; Liguori, R; Simeon, V; Toriello, M; Severini, A; Perricone, C; Meccariello, A; Meccariello, P; Vitale, DF; Filippelli, A; Sacchetti, L				Mazzaccara, Cristina; Conti, Valeria; Liguori, Rosario; Simeon, Vittorio; Toriello, Mario; Severini, Angelo; Perricone, Corrado; Meccariello, Alfonso; Meccariello, Pasquale; Vitale, Dino Franco; Filippelli, Amelia; Sacchetti, Lucia			Warfarin Anticoagulant Therapy: A Southern Italy Pharmacogenetics-Based Dosing Model	PLOS ONE			English	Article							INTERINDIVIDUAL VARIABILITY; VKORC1; CYP4F2; CYP2C9; METAANALYSIS; POLYMORPHISM; MAINTENANCE; POPULATION; VARIANTS; GENE	Background and Aim: Warfarin is the most frequently prescribed anticoagulant worldwide. However, warfarin therapy is associated with a high risk of bleeding and thromboembolic events because of a large interindividual dose-response variability. We investigated the effect of genetic and non genetic factors on warfarin dosage in a South Italian population in the attempt to setup an algorithm easily applicable in the clinical practice. Materials and Methods: A total of 266 patients from Southern Italy affected by cardiovascular diseases were enrolled and their clinical and anamnestic data recorded. All patients were genotyped for CYP2C9*2,*3, CYP4F2*3, VKORC1-1639 G>A by the TaqMan assay and for variants VKORC1 1173 C>T and VKORC1 3730 G>A by denaturing high performance liquid chromatography and direct sequencing. The effect of genetic and not genetic factors on warfarin dose variability was tested by multiple linear regression analysis, and an algorithm based on our data was established and then validated by the Jackknife procedure. Results: Warfarin dose variability was influenced, in decreasing order, by VKORC1-1639 G>A (29.7%), CYP2C9*3 (11.8%), age (8.5%), CYP2C9*2 (3.5%), gender (2.0%) and lastly CYP4F2*3 (1.7%); VKORC1 1173 C>T and VKORC1 3730 G>A exerted a slight effect (<1% each). Taken together, these factors accounted for 58.4% of the warfarin dose variability in our population. Data obtained with our algorithm significantly correlated with those predicted by the two online algorithms: Warfarin dosing and Pharmgkb (p<0.001; R-2 = 0.805 and p<0.001; R-2 = 0.773, respectively). Conclusions: Our algorithm, which is based on six polymorphisms, age and gender, is user-friendly and its application in clinical practice could improve the personalized management of patients undergoing warfarin therapy.	[Mazzaccara, Cristina; Liguori, Rosario; Sacchetti, Lucia] CEINGE Biotecnol Avanzate Sc Ar L, Naples, Italy; [Mazzaccara, Cristina; Liguori, Rosario; Toriello, Mario; Severini, Angelo; Sacchetti, Lucia] Univ Naples Federico II, Dipartimento Med Mol & Biotecnol Med, Naples, Italy; [Conti, Valeria; Filippelli, Amelia] Univ Salerno, Dipartimento Med & Chirurg, I-84100 Salerno, Italy; [Simeon, Vittorio] Ist Ricovero & Cura Carattere Sci, Ctr Riferimento Oncol Basilicata, Lab Ric Preclin & Traslaz Oncol, Rionero In Vulture, Pz, Italy; [Perricone, Corrado] AORN Santobono Pausillipon, Naples, Italy; [Meccariello, Alfonso; Meccariello, Pasquale] Univ Naples Federico II, Dipartimento Med Interna, Naples, Italy; [Vitale, Dino Franco] IRCCS Ist Campoli Telese, Fdn Salvatore Maugeri, Benevento, Italy	CEINGE Biotecnologie Avanzate; University of Naples Federico II; University of Salerno; IRCCS CROB; University of Naples Federico II; Istituti Clinici Scientifici Maugeri IRCCS	Sacchetti, L (corresponding author), CEINGE Biotecnol Avanzate Sc Ar L, Naples, Italy.	sacchett@unina.it	Simeon, Vittorio/K-6373-2016; Mazzaccara, Cristina/AAC-5361-2022; toriello, mario/AAA-4255-2022; Filippelli, Amelia/AAC-5321-2022	Simeon, Vittorio/0000-0003-2387-4125; Mazzaccara, Cristina/0000-0001-7774-2799; Filippelli, Amelia/0000-0002-8235-9118; conti, valeria/0000-0001-6964-2739	CEINGE Regione Campania [DGRC 1901/2009]; POR Campania FSE	CEINGE Regione Campania; POR Campania FSE(Regione Campania)	The present work was supported by grants from CEINGE Regione Campania (DGRC 1901/2009); POR Campania FSE 2007-2013, project CREME. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ansell J, 2012, HEMATOL-AM SOC HEMAT, P221; Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457; Borgiani P, 2009, PHARMACOGENOMICS, V10, P261, DOI 10.2217/14622416.10.2.261; Borgiani P, 2007, PHARMACOGENOMICS, V8, P1545, DOI 10.2217/14622416.8.11.1545; Burmester JK, 2011, CLIN MED RES, V9, P119, DOI 10.3121/cmr.2011.951; Caldwell MD, 2008, BLOOD, V111, P4106, DOI 10.1182/blood-2007-11-122010; Cini M, 2012, EUR J CLIN PHARMACOL, V68, P1167, DOI 10.1007/s00228-012-1226-5; Cooper GM, 2008, BLOOD, V112, P1022, DOI 10.1182/blood-2008-01-134247; D'Andrea G, 2005, BLOOD, V105, P645, DOI 10.1182/blood-2004-06-2111; Danese E, 2012, CLIN PHARMACOL THER, V92, P746, DOI 10.1038/clpt.2012.184; Fareed J, 2012, ANNU REV PHARMACOL, V52, P79, DOI 10.1146/annurev-pharmtox-010611-134633; Finkelman BS, 2011, J AM COLL CARDIOL, V57, P612, DOI 10.1016/j.jacc.2010.08.643; Gage BF, 2008, J THROMB THROMBOLYS, V25, P45, DOI 10.1007/s11239-007-0104-y; Gong IY, 2011, BLOOD, V118, P3163, DOI 10.1182/blood-2011-03-345173; Gould WW, 1995, STATA TECHNICAL B, V24, p[sg34, 25]; Gulseth MP, 2009, AM J HEALTH-SYST PH, V66, P123, DOI 10.2146/ajhp080127; Hill CE, 2008, CLIN LAB MED, V28, P513, DOI 10.1016/j.cll.2008.09.002; Homme MB, 2008, CLIN LAB MED, V28, P539, DOI 10.1016/j.cll.2008.10.002; Johnson JA, 2011, CLIN PHARMACOL THER, V90, P625, DOI 10.1038/clpt.2011.185; Kamali F, 2010, ANNU REV MED, V61, P63, DOI 10.1146/annurev.med.070808.170037; Kim MJ, 2009, J CLIN PHARMACOL, V49, P138, DOI 10.1177/0091270008328098; Klein TE, 2009, NEW ENGL J MED, V360, P753, DOI 10.1056/NEJMoa0809329; Kringen MK, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/739751; Kurnik D, 2009, PHARMACOGENOMICS, V10, P1955, DOI 10.2217/PGS.09.149; Kutyavin IV, 2000, NUCLEIC ACIDS RES, V28, P655, DOI 10.1093/nar/28.2.655; Lane S, 2012, BRIT J CLIN PHARMACO, V73, P66, DOI 10.1111/j.1365-2125.2011.04051.x; Leitner JM, 2008, PHARMACOGENOMICS, V9, P423, DOI 10.2217/14622416.9.4.423; Lenzini P, 2010, CLIN PHARMACOL THER, V87, P572, DOI 10.1038/clpt.2010.13; Li T, 2004, NATURE, V427, P541, DOI 10.1038/nature02254; Liang RJ, 2012, THROMB RES, V130, P38, DOI 10.1016/j.thromres.2011.11.043; Limdi NA, 2008, PHARMACOGENOMICS, V9, P511, DOI 10.2217/14622416.9.5.511; Limdi NA, 2010, BLOOD, V115, P3827, DOI 10.1182/blood-2009-12-255992; Livak KJ, 1999, GENET ANAL-BIOMOL E, V14, P143, DOI 10.1016/S1050-3862(98)00019-9; Mahajan P, 2011, INT J CLIN PHARM-NET, V33, P10, DOI 10.1007/s11096-011-9486-1; McDonald MG, 2009, MOL PHARMACOL, V75, P1337, DOI 10.1124/mol.109.054833; Miller CS, 2012, AM J CARDIOL, V110, P453, DOI 10.1016/j.amjcard.2012.03.049; Pavani A, 2012, PHARMACOGENOMICS J, V12, P306, DOI 10.1038/tpj.2011.4; Pirmohamed M, 2004, BMJ-BRIT MED J, V329, P15, DOI 10.1136/bmj.329.7456.15; Ross KA, 2010, J HUM GENET, V55, P582, DOI 10.1038/jhg.2010.73; Sanderson S, 2005, GENET MED, V7, P97, DOI 10.1097/01.GIM.0000153664.65759.CF; Scott SA, 2010, PHARMACOGENOMICS, V11, P781, DOI [10.2217/pgs.10.49, 10.2217/PGS.10.49]; Suarez-Kurtz G, 2011, BRIT J CLIN PHARMACO, V72, P451, DOI 10.1111/j.1365-2125.2011.04018.x; Takeuchi F, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000433; Teh LK, 2012, J CLIN PHARM THER, V37, P232, DOI 10.1111/j.1365-2710.2011.01262.x; Wu Alan Hb, 2011, Clin Proteomics, V8, P12, DOI 10.1186/1559-0275-8-12; Yang LM, 2010, THROMB RES, V125, pE159, DOI 10.1016/j.thromres.2009.10.017; You JHS, 2011, EXPERT OPIN PHARMACO, V12, P435, DOI 10.1517/14656566.2011.521153; Zambon CF, 2011, PHARMACOGENOMICS, V12, P15, DOI [10.2217/pgs.10.162, 10.2217/PGS.10.162]	48	27	30	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 26	2013	8	8							e71505	10.1371/journal.pone.0071505	http://dx.doi.org/10.1371/journal.pone.0071505			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	215RU	23990957	Green Submitted, Green Published, gold			2023-01-03	WOS:000324228800009
J	Francis, JH; Gobin, YP; Dunkel, IJ; Marr, BP; Brodie, SE; Jonna, G; Abramson, DH				Francis, Jasmine H.; Gobin, Y. Pierre; Dunkel, Ira J.; Marr, Brian P.; Brodie, Scott E.; Jonna, Gowtham; Abramson, David H.			Carboplatin +/- Topotecan Ophthalmic Artery Chemosurgery for Intraocular Retinoblastoma	PLOS ONE			English	Article							SUBCONJUNCTIVAL CARBOPLATIN; INTRAARTERIAL CHEMOTHERAPY; BILATERAL RETINOBLASTOMA; RETINAL FUNCTION; PHASE-I/II; OTOTOXICITY; MANAGEMENT; INJECTION; SURVIVORS; THERAPY	Purpose: Carboplatin administered systemically or periocularly can result in dramatic and prompt regression of retinoblastoma. However, both routes are rarely curative alone and have undesirable side effects. We aimed to assess the efficacy and toxicity of carboplatin +/- topotecan delivered by ophthalmic artery chemosurgery whereby chemotherapy is infused into the eye via the ophthalmic artery. Methods: This retrospective, IRB-approved study investigated retinoblastoma patients whom received carboplatin +/- topotecan ophthalmic artery chemosurgery. Patient survival, ocular survival, hematologic toxicity, ocular toxicity, second cancer development and electroretinogram response were all evaluated. Results: 57 carboplatin +/- topotecan infusions (of 111 total) were performed in 31 eyes of 24 patients. The remaining infusions were melphalan-containing. All patients were alive and no patient developed a second malignancy at a median follow up of 25 months. The Kaplan-Meier estimate of ocular survival at two years was 89.9% (95% confidence interval [CI], 82.1-97.9%) for all eyes. Grade 3 or 4 neutropenia developed in two patients and one patient developed metastatic disease. By univariate analysis, neither increasing maximum carboplatin/ topotecan dose nor cumulative carboplatin/ topotecan dose was associated with statistically significant reduction in the electroretinogram responses. Conclusion: Carboplatin +/- topotecan infusions are effective for ophthalmic artery chemosurgery in retinoblastoma: they demonstrate low hematologic and ocular toxicity and no statistically significant influence on electroretinogram responses, and used in conjunction with melphalan-containing OAC, demonstrate excellent patient survival and satisfactory ocular survival.	[Francis, Jasmine H.; Marr, Brian P.; Brodie, Scott E.; Jonna, Gowtham; Abramson, David H.] Mem Sloan Kettering Canc Ctr, Ophthalm Oncol Serv, New York, NY 10021 USA; [Gobin, Y. Pierre] New York Presbyterian Hosp, Weill Cornell Med Coll, Dept Neurosurg Neurol, Serv Intervent Neuroradiol, New York, NY USA; [Gobin, Y. Pierre] New York Presbyterian Hosp, Weill Cornell Med Coll, Dept Radiol, New York, NY USA; [Dunkel, Ira J.] Mem Sloan Kettering Canc Ctr, Dept Pediat, New York, NY 10021 USA; [Dunkel, Ira J.] Weill Cornell Med Coll, Dept Pediat, New York, NY USA; [Marr, Brian P.; Abramson, David H.] Weill Cornell Med Coll, Dept Ophthalmol, New York, NY USA; [Brodie, Scott E.] Mt Sinai Sch Med, Dept Ophthalmol, New York, NY USA	Memorial Sloan Kettering Cancer Center; Cornell University; NewYork-Presbyterian Hospital; Cornell University; NewYork-Presbyterian Hospital; Memorial Sloan Kettering Cancer Center; Cornell University; Cornell University; Icahn School of Medicine at Mount Sinai	Francis, JH (corresponding author), Mem Sloan Kettering Canc Ctr, Ophthalm Oncol Serv, 1275 York Ave, New York, NY 10021 USA.	francij1@mskcc.org		Brodie, Scott/0000-0002-3303-4552; Francis, Jasmine/0000-0002-7637-3108; Dunkel, Ira/0000-0001-8091-6067	Fund for Ophthalmic Knowledge; New York Community Trust	Fund for Ophthalmic Knowledge; New York Community Trust	This work was supported by The Fund for Ophthalmic Knowledge and The New York Community Trust. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abramson DH, 2008, OPHTHALMOLOGY, V115, P1398, DOI 10.1016/j.ophtha.2007.12.014; Abramson DH, 2011, ARCH OPHTHALMOL-CHIC, V129, P1492, DOI 10.1001/archophthalmol.2011.354; Abramson DH, 2010, ARCH OPHTHALMOL-CHIC, V128, P370, DOI 10.1001/archophthalmol.2010.7; Abramson DH, 1999, OPHTHALMOLOGY, V106, P1947, DOI 10.1016/S0161-6420(99)90406-2; Abramson DH, 1998, OPHTHALMOLOGY, V105, P573, DOI 10.1016/S0161-6420(98)94006-4; Abramson DH, 2005, BRIT J OPHTHALMOL, V89, P1616, DOI 10.1136/bjo.2005.072033; ABRAMSON DH, 1976, T AM ACAD OPHTHALMOL, V81, pP454; Benz MS, 2000, ARCH OPHTHALMOL-CHIC, V118, P577; Brodie SE, 2009, DOC OPHTHALMOL, V119, P13, DOI 10.1007/s10633-008-9164-3; Calvaruso G, 2001, INT J ONCOL, V18, P1233; Chantada Guillermo L, 2004, Ophthalmic Genet, V25, P37, DOI 10.1076/opge.25.1.37.28996; DOZ F, 1995, J CLIN ONCOL, V13, P902, DOI 10.1200/JCO.1995.13.4.902; Dunkel IJ, 2007, PEDIATR BLOOD CANCER, V49, P643, DOI 10.1002/pbc.21163; ENG C, 1993, JNCI-J NATL CANCER I, V85, P1121, DOI 10.1093/jnci/85.14.1121; Francis JH, 2012, ARCH OPHTHALMOL-CHIC, V130, P1605, DOI 10.1001/archophthalmol.2012.2284; FRANCIS JH, 2012, BR J OPHTHALMOL; Gallie BL, 1996, ARCH OPHTHALMOL-CHIC, V114, P1321, DOI 10.1001/archopht.1996.01100140521001; Gobin YP, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044322; Gobin YP, 2011, ARCH OPHTHALMOL-CHIC, V129, P732, DOI 10.1001/archophthalmol.2011.5; Gombos DS, 2006, BRIT J OPHTHALMOL, V90, P1168, DOI 10.1136/bjo.2006.091223; Gombos DS, 2007, OPHTHALMOLOGY, V114, P1378, DOI 10.1016/j.ophtha.2007.03.074; Graeber CP, 2011, OPEN OPHTHALMOL J, V5, P1, DOI 10.2174/1874364101105010001; Harbour JW, 1996, INVEST OPHTH VIS SCI, V37, P1892; INOMATA M, 1987, JPN J CANCER RES, V78, P858; Jeruss JS, 2009, NEW ENGL J MED, V360, P902, DOI 10.1056/NEJMra0801454; Kim Jeong Hun, 2003, Korean J Ophthalmol, V17, P35; KLUFAS MA, 2012, AJNR AM J NEURORADIO; KUPFER C, 1953, AM J OPHTHALMOL, V36, P1721, DOI 10.1016/0002-9394(53)90009-9; Laurie NA, 2005, CLIN CANCER RES, V11, P7569, DOI 10.1158/1078-0432.CCR-05-0849; Marees T, 2008, J NATL CANCER I, V100, P1771, DOI 10.1093/jnci/djn394; MARR BP, 2012, BR J OPHTHALMOL; Marr B, 2010, MIDDLE EAST AFR J OP, V17, P207, DOI 10.4103/0974-9233.65492; Mendelsohn ME, 1998, ARCH OPHTHALMOL-CHIC, V116, P1209, DOI 10.1001/archopht.116.9.1209; Mulvihill A, 2003, ARCH OPHTHALMOL-CHIC, V121, P1120, DOI 10.1001/archopht.121.8.1120; Murphree AL, 1996, ARCH OPHTHALMOL-CHIC, V114, P1348, DOI 10.1001/archopht.1996.01100140548005; PALIOURA S, 2012, PEDIAT BLOOD CANC; Pardue MT, 2004, RETINA-J RET VIT DIS, V24, P776, DOI 10.1097/00006982-200410000-00015; Liberman PHP, 2011, CLIN TRANSL ONCOL, V13, P348, DOI 10.1007/s12094-011-0665-2; PRATT CB, 1994, J CLIN ONCOL, V12, P539, DOI 10.1200/JCO.1994.12.3.539; Qaddoumi I, 2012, J CLIN ONCOL, V30, P1034, DOI 10.1200/JCO.2011.36.9744; REESE AB, 1954, AMA ARCH OPHTHALMOL, V153, P505; Schaiquevich P, 2012, INVEST OPHTH VIS SCI, V53, P4205, DOI 10.1167/iovs.12-9501; Schefler AC, 2008, CURR OPIN OPHTHALMOL, V19, P526, DOI 10.1097/ICU.0b013e328312975b; Schmack I, 2006, AM J OPHTHALMOL, V142, P310, DOI 10.1016/j.ajo.2006.02.044; Shearer P, 2009, PEDIATR BLOOD CANCER, V53, P517, DOI 10.1002/pbc.22095; Shields CL, 1996, ARCH OPHTHALMOL-CHIC, V114, P1330, DOI 10.1001/archopht.1996.01100140530002; STEWART DJ, 1992, NEUROSURGERY, V30, P512; Suzuki Shigenobu, 2004, Int J Clin Oncol, V9, P1, DOI 10.1007/s10147-003-0366-0; Suzuki S, 2011, OPHTHALMOLOGY, V118, P2081, DOI 10.1016/j.ophtha.2011.03.013; Van Quill KR, 2005, OPHTHALMOLOGY, V112, P1151, DOI 10.1016/j.ophtha.2004.11.060; Wilson MW, 2001, OPHTHALMOLOGY, V108, P2106, DOI 10.1016/S0161-6420(01)00805-3; Yamane Takashi, 2004, Int J Clin Oncol, V9, P69, DOI 10.1007/s10147-004-0392-6; ZLIOBA A, 1988, ANN OPHTHALMOL, V20, P71	53	29	29	1	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 21	2013	8	8							e72441	10.1371/journal.pone.0072441	http://dx.doi.org/10.1371/journal.pone.0072441			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	218YW	23991112	Green Submitted, Green Published, gold			2023-01-03	WOS:000324470100103
J	Hou, SW; Lee, YK; Hsu, CY; Lee, CC; Su, YC				Hou, Sheng-Wen; Lee, Yi-Kung; Hsu, Chen-Yang; Lee, Ching-Chih; Su, Yung-Cheng			Increased Risk of Acute Pancreatitis in Patients with Chronic Hemodialysis: A 4-Year Follow-Up Study	PLOS ONE			English	Article							CHRONIC DIALYSIS PATIENTS; CHRONIC-RENAL-FAILURE; PERITONEAL-DIALYSIS; SEVERITY; DISEASE; TAIWAN	Background: The risk of acute pancreatitis in patients on long-term peritoneal dialysis is higher as compared to the general population. However, the relationship between long-term hemodialysis and acute pancreatitis has never been established. Objectives: We investigated the incidence of acute pancreatitis among patients on long-term hemodialysis in Taiwan to evaluate if there is a higher risk of acute pancreatitis in comparison to the general population. Methods: We utilized a National Health Insurance (NHI) claims data sample containing one million beneficiaries. We followed all adult beneficiaries from January 1, 2007 until December 31, 2010 to see if they had been hospitalized for acute pancreatitis during this period. We further identified patients on chronic hemodialysis and compared their risk of acute pancreatitis with the general population. Results: This study included 2603 patients with long-term hemodialysis and 773,140 patients without hemodialysis. After controlling for age, gender, Charlson Comorbidity Index Score, geographic region, socioeconomic status and urbanization level, the adjusted hazard ratio was 3.44 (95% Confidence interval, 2.5-4.7). Conclusions: The risk of acute pancreatitis in patients on long-term hemodialysis is significantly higher in comparison to the general population.	[Hou, Sheng-Wen] Shin Kong Wu Ho Su Mem Hosp, Emergency Dept, Taipei, Taiwan; [Lee, Yi-Kung; Su, Yung-Cheng] Buddhist Tzu Chi Dalin Gen Hosp, Emergency Dept, Chiayi, Taiwan; [Lee, Yi-Kung; Lee, Ching-Chih; Su, Yung-Cheng] Tzu Zhi Univ, Sch Med, Hualien, Taiwan; [Hsu, Chen-Yang; Lee, Ching-Chih] Natl Taiwan Univ, Dept Publ Heath, Taipei 10764, Taiwan; [Lee, Ching-Chih] Natl Yang Ming Univ, Community Med Res Ctr, Taipei 112, Taiwan; [Lee, Ching-Chih] Natl Yang Ming Univ, Inst Publ Hlth, Taipei 112, Taiwan; [Lee, Ching-Chih] Buddhist Dalin Tzu Chi Gen Hosp, Dept Otolaryngol, Chiayi, Taiwan; [Lee, Ching-Chih] Buddhist Dalin Tzu Chi Gen Hosp, Ctr Canc, Chiayi, Taiwan	Shin Kong Wu Ho Su Memorial Hospital; Buddhist Tzu Chi General Hospital; National Taiwan University; National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University; Buddhist Tzu Chi General Hospital; Dalin Tzu Chi Hospital; Buddhist Tzu Chi General Hospital; Dalin Tzu Chi Hospital	Su, YC (corresponding author), Buddhist Tzu Chi Dalin Gen Hosp, Emergency Dept, Chiayi, Taiwan.	drsu119@gmail.com						ARAKI T, 1992, INT J PANCREATOL, V12, P263; Bruno MJ, 2000, GUT, V46, P385, DOI 10.1136/gut.46.3.385; Chang CM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044325; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Chiang TL, 1997, HEALTH POLICY, V39, P225, DOI 10.1016/S0168-8510(96)00877-9; DEYO RA, 1992, J CLIN EPIDEMIOL, V45, P613, DOI 10.1016/0895-4356(92)90133-8; Greenberger NJ, 2012, HARRISONS PRINCIPLES; Lankisch PG, 2008, NEPHROL DIAL TRANSPL, V23, P1401, DOI 10.1093/ndt/gfm769; Lee YK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062422; Lee YK, 2013, EMERG MED J; Manga F, 2012, EUR J GASTROEN HEPAT, V24, P95, DOI 10.1097/MEG.0b013e32834d4bcc; OWYANG C, 1982, GUT, V23, P357, DOI 10.1136/gut.23.5.357; Quraishi ER, 2005, AM J GASTROENTEROL, V100, P2288, DOI 10.1111/j.1572-0241.2005.41646.x; SACHS EF, 1983, AM J GASTROENTEROL, V78, P170; Schneeweiss S, 2006, PHARMACOEPIDEM DR S, V15, P291, DOI 10.1002/pds.1200; Shen HN, 2012, PANCREAS, V41, P696, DOI 10.1097/MPA.0b013e31823db941; Shen HN, 2012, DIABETES CARE, V35, P1061, DOI 10.2337/dc11-1925; SIRINEK KR, 1984, AM J SURG, V148, P732, DOI 10.1016/0002-9610(84)90426-4; VAZIRI ND, 1987, NEPHRON, V46, P347, DOI 10.1159/000184387	19	26	28	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 20	2013	8	8							e71801	10.1371/journal.pone.0071801	http://dx.doi.org/10.1371/journal.pone.0071801			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	219RU	23977145	gold, Green Published, Green Submitted			2023-01-03	WOS:000324527300038
J	Bonsante, F; Iacobelli, S; Latorre, G; Rigo, J; De Felice, C; Robillard, PY; Gouyon, JB				Bonsante, Francesco; Iacobelli, Silvia; Latorre, Giuseppe; Rigo, Jacques; De Felice, Claudio; Robillard, Pierre Yves; Gouyon, Jean Bernard			Initial Amino Acid Intake Influences Phosphorus and Calcium Homeostasis in Preterm Infants - It Is Time to Change the Composition of the Early Parenteral Nutrition	PLOS ONE			English	Article							BIRTH-WEIGHT INFANTS; REFEEDING SYNDROME; ELECTROLYTE; PROTEIN; HYPOPHOSPHATEMIA; NITROGEN; BALANCE; FLUID	Background: Early aggressive parenteral nutrition (PN), consisting of caloric and nitrogen intake soon after birth, is currently proposed for the premature baby. Some electrolyte disturbances, such as hypophosphatemia and hypercalcemia, considered unusual in early life, were recently described while using this PN approach. We hypothesize that, due to its impact on cell metabolism, the initial amino acid (AA) amount may specifically influence the metabolism of phosphorus, and consequently of calcium. We aim to evaluate the influence of AA intake on calcium-phosphorus metabolism, and to create a calculation tool to estimate phosphorus needs. Methods: Prospective observational study. Phosphate and calcium plasma concentrations and calcium balance were evaluated daily during the first week of life in very preterm infants, and their relationship with nutrition was studied. For this purpose, infants were divided into three groups: high, medium and low AA intake (HAA, MAA, LAA). A calculation formula to assess phosphorus needs was elaborated, with a theoretical model based on AA and calcium intake, and the cumulative deficit of phosphate intake was estimated. Results: 154 infants were included. Hypophosphatemia (12.5%) and hypercalcemia (9.8%) were more frequent in the HAA than in the MAA (4.6% and 4.8%) and in the LAA group (0% and 1.9%); both p<0.001. Discussion: Calcium-phosphorus homeostasis was influenced by the early AA intake. We propose to consider phosphorus and calcium imbalances as being part of a syndrome, related to incomplete provision of nutrients after the abrupt discontinuation of the placental nutrition at birth (PI-ReFeeding syndrome). We provide a simple tool to calculate the optimal phosphate intake. The early introduction of AA in the PN soon after birth might be completed by an early intake of phosphorus, since AA and phosphorus are (along with potassium) the main determinants of cellular growth.	[Latorre, Giuseppe] Miulli Hosp, NICU, Acquaviva Delle Fonti, Italy; [Latorre, Giuseppe] Miulli Hosp, Acquaviva Delle Fonti, Italy; [Rigo, Jacques] Univ Liege, Neonatal Unit, Dept Paediat, Liege, Belgium; [De Felice, Claudio] Univ Hosp, Policlin Scotte, NICU, Siena, Italy; [De Felice, Claudio] Univ Hosp, Policlin Scotte, Siena, Italy	University of Liege; University of Siena; University Hospital of Siena; University of Siena; University Hospital of Siena		fbonsante@yahoo.com	De Felice, Claudio/AAB-6859-2022; Robillard, Pierre-Yves/AAD-9774-2021; La Torre, Giuseppe/AAI-6866-2020	De Felice, Claudio/0000-0002-9881-3119; La Torre, Giuseppe/0000-0002-1233-2040	University Hospital of Dijon	University Hospital of Dijon	The study was entirely supported by the institution, University Hospital of Dijon. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bonsante F, 2011, EUR J CLIN NUTR, V65, P1088, DOI 10.1038/ejcn.2011.79; BRITSCHGI F, 1991, SCHWEIZ MED WSCHR, V121, P1163; Elser JJ, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001028; Elser JJ, 2007, PLOS BIOL, V5, P1403, DOI 10.1371/journal.pbio.0050181; Elstgeest LE, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009033; Ghaddar S, 2012, J RENAL NUTR, V22, P67, DOI 10.1053/j.jrn.2011.05.001; Gillooly JF, 2005, P NATL ACAD SCI USA, V102, P11923, DOI 10.1073/pnas.0504756102; Iacobelli S, 2010, Minerva Pediatr, V62, P203; Iacobelli S, 2010, NEONATOLOGY, V98, P84, DOI 10.1159/000276979; Ichikawa G, 2012, J PEDIATR ENDOCR MET, V25, P317, DOI 10.1515/jpem-2011-0485; Jamin A, 2010, NEONATOLOGY, V97, P321, DOI 10.1159/000260135; Koletzko Berthold, 2005, J Pediatr Gastroenterol Nutr, V41 Suppl 2, pS1, DOI 10.1097/01.mpg.0000181841.07090.f4; Mariotti F, 2008, CRIT REV FOOD SCI, V48, P177, DOI 10.1080/10408390701279749; Mizumoto H, 2012, PEDIATR INT, V54, P715, DOI 10.1111/j.1442-200X.2012.03590.x; Moltu SJ, 2013, CLIN NUTR, V32, P207, DOI 10.1016/j.clnu.2012.09.004; Pieltain C, 2013, WORLD REV NUTR DIET, V106, P181, DOI 10.1159/000342680; Ponomareva NI, 2009, RUSS J GEN CHEM+, V79, P186, DOI 10.1134/S1070363209020030; Rigo J, 2011, NEONATAL PERINATAL M, P1523; Rigo J, 2012, NEONATOLOGY PRACTICA, V47, P311; Rigo J., 2012, CALCIUM PHOSPHORUS H, P333; Skipper A, 2012, NUTR CLIN PRACT, V27, P34, DOI 10.1177/0884533611427916; Thureen PJ, 2003, PEDIATR RES, V53, P24, DOI 10.1203/00006450-200301000-00008; VANGOUDOEVER JB, 1995, J PEDIATR-US, V127, P458, DOI 10.1016/S0022-3476(95)70083-8	23	72	72	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 15	2013	8	8							e72880	10.1371/journal.pone.0072880	http://dx.doi.org/10.1371/journal.pone.0072880			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	204OU	23977367	Green Published, Green Submitted, gold			2023-01-03	WOS:000323378000115
J	Litton, E; Xiao, J; Ho, KM				Litton, Edward; Xiao, Jing; Ho, Kwok M.			Safety and efficacy of intravenous iron therapy in reducing requirement for allogeneic blood transfusion: systematic review and meta-analysis of randomised clinical trials	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CHRONIC KIDNEY-DISEASE; RECOMBINANT-HUMAN-ERYTHROPOIETIN; PERITONEAL-DIALYSIS PATIENTS; CHEMOTHERAPY-RELATED ANEMIA; INFLAMMATORY-BOWEL-DISEASE; CHRONIC HEART-FAILURE; EVERY 3 WEEKS; ORAL IRON; DEFICIENCY ANEMIA; FERRIC CARBOXYMALTOSE	Objectives To evaluate the efficacy and safety of intravenous iron, focusing primarily on its effects on haemoglobin, requirement for transfusion, and risk of infection. Design Systematic review and meta-analysis of randomised controlled trials investigating the safety and efficacy of intravenous iron therapy. Data sources Randomised controlled trials from Medline, Embase, and the Cochrane Central Register of Controlled Trials from 1966 to June 2013, with no language restrictions. Eligibility criteria for selecting studies Eligible trials were randomised controlled trials of intravenous iron compared with either no iron or oral iron. Crossover and observational studies were excluded. Main outcome measures Change in haemoglobin concentration and risk of allogeneic red blood cell transfusion (efficacy) and risk of infection (safety). Results Of the 75 trials meeting the inclusion criteria, 72 studies including 10 605 patients provided quantitative outcome data for meta-analysis. Intravenous iron was associated with an increase in haemoglobin concentration (standardised mean difference 6.5 g/L, 95% confidence interval 5.1 g/L to 7.9 g/L) and a reduced risk of requirement for red blood cell transfusion (risk ratio 0.74, 95% confidence interval 0.62 to 0.88), especially when intravenous iron was used with erythroid stimulating agents (ESAs) or in patients with a lower baseline plasma ferritin concentration. There were no significant interactions between the efficacy of intravenous iron and type or dose administered. Intravenous iron was, however, associated with a significant increase in risk of infection (relative risk 1.33, 95% confidence interval 1.10 to 1.64) compared with oral or no iron supplementation. The results remained similar when only high quality trials were analysed. Conclusions Intravenous iron therapy is effective in increasing haemoglobin concentration and reducing the risk of allogeneic red blood cell transfusion and could have broad applicability to a range of acute care settings. This potential benefit is counterbalanced by a potential increased risk of infection.	[Litton, Edward; Xiao, Jing; Ho, Kwok M.] Royal Perth Hosp, Dept Intens Care Med, Perth, WA 6000, Australia; [Litton, Edward] Univ Western Australia, Sch Med & Pharmacol, Perth, WA 6009, Australia; [Ho, Kwok M.] Univ Western Australia, Sch Populat Hlth, Perth, WA 6009, Australia	Royal Perth Hospital; University of Western Australia; University of Western Australia; University of Western Australia	Litton, E (corresponding author), Royal Perth Hosp, Dept Intens Care Med, Perth, WA 6000, Australia.	ed.litton@health.wa.gov.au	Ho, Kwok M./E-3546-2010; litton, edward/C-5384-2017	Ho, Kwok M./0000-0002-6705-6004; litton, edward/0000-0002-5125-6829				Adhikary L, 2011, J NEPAL MED ASSOC, V51, P133; Agarwal R, 2006, AM J NEPHROL, V26, P445, DOI 10.1159/000096174; Aggarwal H K, 2003, J Assoc Physicians India, V51, P170; Al RA, 2005, OBSTET GYNECOL, V106, P1335, DOI 10.1097/01.AOG.0000185260.82466.b4; Allen RP, 2011, SLEEP MED, V12, P906, DOI 10.1016/j.sleep.2011.06.009; AlMomen AK, 1996, EUR J OBSTET GYN R B, V69, P121, DOI 10.1016/0301-2115(95)02538-3; ANG O, 1990, INT J EXP PATHOL, V71, P507; Anker SD, 2009, NEW ENGL J MED, V361, P2436, DOI 10.1056/NEJMoa0908355; Serrano-Trenas JA, 2011, TRANSFUSION, V51, P97, DOI 10.1111/j.1537-2995.2010.02769.x; Auerbach M, 2004, J CLIN ONCOL, V22, P1301, DOI 10.1200/JCO.2004.08.119; Auerbach M, 2010, AM J HEMATOL, V85, P655, DOI 10.1002/ajh.21779; Bastit L, 2008, J CLIN ONCOL, V26, P1611, DOI 10.1200/JCO.2006.10.4620; Bayoumeu F, 2002, AM J OBSTET GYNECOL, V186, P518, DOI 10.1067/mob.2002.121894; Beck-da-Silva L, 2013, INT J CARDIOL, V168, P3439, DOI 10.1016/j.ijcard.2013.04.181; Bencaiova G, 2009, EUR J OBSTET GYN R B, V144, P135, DOI 10.1016/j.ejogrb.2009.03.006; Bhandal N, 2006, BJOG-INT J OBSTET GY, V113, P1248, DOI 10.1111/j.1471-0528.2006.01062.x; Birgegard G, 2010, VOX SANG, V99, P354, DOI 10.1111/j.1423-0410.2010.01368.x; Breymann C, 2008, INT J GYNECOL OBSTET, V101, P67, DOI 10.1016/j.ijgo.2007.10.009; Charytan C, 2005, NEPHRON CLIN PRACT, V100, pC55, DOI 10.1159/000085049; Corwin HL, 2007, NEW ENGL J MED, V357, P965, DOI 10.1056/NEJMoa071533; Coyne DW, 2007, J AM SOC NEPHROL, V18, P975, DOI 10.1681/ASN.2006091034; Dangsuwan P, 2010, GYNECOL ONCOL, V116, P522, DOI 10.1016/j.ygyno.2009.12.004; Deeba S, 2012, J OBSTET GYN INDIA, V62, P317, DOI 10.1007/s13224-012-0222-0; Edwards TJ, 2009, BRIT J SURG, V96, P1122, DOI 10.1002/bjs.6688; Evstatiev R, 2013, CLIN GASTROENTEROL H, V11, P269, DOI 10.1016/j.cgh.2012.10.013; Fishbane S, 1999, AM J KIDNEY DIS, V34, pS47, DOI 10.1053/ajkd.1999.v34.aajkd0344b0047; Fleming RE, 2012, NEW ENGL J MED, V366, P348, DOI 10.1056/NEJMra1004967; Friedrich JO, 2007, BMC MED RES METHODOL, V7, DOI 10.1186/1471-2288-7-5; FRIEL JK, 1995, JPEN-PARENTER ENTER, V19, P114, DOI 10.1177/0148607195019002114; Froessler B, 2013, J MATERN-FETAL NEO M, V26, P654, DOI 10.3109/14767058.2012.746299; Gafter-Gvili A, 2013, ACTA ONCOL, V52, P18, DOI 10.3109/0284186X.2012.702921; Garrido-Martin P, 2012, INTERACT CARDIOV TH, V15, P1013, DOI 10.1093/icvts/ivs344; Goodnough LT, 2012, TRANSFUSION, V52, P1584, DOI 10.1111/j.1537-2995.2011.03495.x; Goodnough LT, 2010, BLOOD, V116, P4754, DOI 10.1182/blood-2010-05-286260; Grote L, 2009, MOVEMENT DISORD, V24, P1445, DOI 10.1002/mds.22562; Hedenus M, 2007, LEUKEMIA, V21, P627, DOI 10.1038/sj.leu.2404562; Heming N, 2012, CRIT CARE MED, V40, P2141, DOI 10.1097/CCM.0b013e31824e6713; Henry DH, 2007, ONCOLOGIST, V12, P231, DOI 10.1634/theoncologist.12-2-231; Higgins Julian P T, 2011, BMJ, V343, pd5928, DOI 10.1136/bmj.d5928; Hofmann A, 2012, CURR OPIN ANESTHESIO, V25, P66, DOI 10.1097/ACO.0b013e32834eb726; Hulin S, 2005, ANN FR ANESTH, V24, P1262, DOI 10.1016/j.annfar.2005.05.023; Isbister JP, 2011, TRANSFUS MED REV, V25, P89, DOI 10.1016/j.tmrv.2010.11.001; Karkouti K, 2006, CAN J ANAESTH, V53, P11, DOI 10.1007/BF03021522; Kasper SM, 1998, TRANSFUSION, V38, P764, DOI 10.1046/j.1537-2995.1998.38898375516.x; KDOQI, 2006, Am J Kidney Dis, V47, pS16; Khalafallah A, 2010, J INTERN MED, V268, P286, DOI 10.1111/j.1365-2796.2010.02251.x; Kim YT, 2007, GYNECOL ONCOL, V105, P199, DOI 10.1016/j.ygyno.2006.11.014; Kim YH, 2009, ACTA HAEMATOL-BASEL, V121, P37, DOI 10.1159/000210062; Kochhar PK, 2013, J OBSTET GYNAECOL RE, V39, P504, DOI 10.1111/j.1447-0756.2012.01982.x; Krayenbuehl PA, 2011, BLOOD, V118, P3222, DOI 10.1182/blood-2011-04-346304; Kulnigg S, 2008, AM J GASTROENTEROL, V103, P1182, DOI 10.1111/j.1572-0241.2007.01744.x; Li H, 2008, PERITON DIALYSIS INT, V28, P149; Li H, 2008, BLOOD PURIFICAT, V26, P151, DOI 10.1159/000113529; Li Han, 2009, Zhonghua Yi Xue Za Zhi, V89, P457; Lindgren S, 2009, SCAND J GASTROENTERO, V44, P838, DOI 10.1080/00365520902839667; Locatelli F, 2011, CONTRIB NEPHROL, V171, P255, DOI 10.1159/000327328; Lyseng-Williamson KA, 2009, DRUGS, V69, P739, DOI 10.2165/00003495-200969060-00007; Maccio A, 2010, ONCOLOGIST, V15, P894, DOI 10.1634/theoncologist.2010-0020; Macdougall IC, 1996, KIDNEY INT, V50, P1694, DOI 10.1038/ki.1996.487; Madi-Jebara SN, 2004, J CARDIOTHOR VASC AN, V18, P59, DOI 10.1053/j.jvca.2003.10.012; Marik PE, 2008, CRIT CARE MED, V36, P2667, DOI 10.1097/CCM.0b013e3181844677; Maynor L, 2007, ANN PHARMACOTHER, V41, P1476, DOI 10.1345/aph.1K187; McLean E, 2008, WORLDWIDE PREVALENCE; McMahon LP, 2010, NEPHROL DIAL TRANSPL, V25, P920, DOI 10.1093/ndt/gfp584; Meyer MP, 1996, J PEDIATR-US, V129, P258, DOI 10.1016/S0022-3476(96)70251-2; Moher D, 2009, ANN INTERN MED, V151, P264, DOI 10.7326/0003-4819-151-4-200908180-00135; Moore R Andrew, 2011, BMC Blood Disord, V11, P4, DOI 10.1186/1471-2326-11-4; Na HS, 2011, TRANSFUSION, V51, P118, DOI 10.1111/j.1537-2995.2010.02783.x; Neeru Syal, 2012, Indian J Community Med, V37, P214, DOI 10.4103/0970-0218.103467; Notebaert E, 2007, TRANSFUSION, V47, P1905, DOI 10.1111/j.1537-2995.2007.01415.x; Okonko DO, 2008, J AM COLL CARDIOL, V51, P103, DOI 10.1016/j.jacc.2007.09.036; Olijhoek G, 2001, TRANSFUSION, V41, P957, DOI 10.1046/j.1537-2995.2001.41070957.x; Onken JE, 2014, TRANSFUSION, V54, P306, DOI 10.1111/trf.12289; Pedrazzoli P, 2008, J CLIN ONCOL, V26, P1619, DOI 10.1200/JCO.2007.12.2051; Pollak A, 2001, PEDIATRICS, V107, P78, DOI 10.1542/peds.107.1.78; Provenzano R, 2009, CLIN J AM SOC NEPHRO, V4, P386, DOI 10.2215/CJN.02840608; Qunibi WY, 2011, NEPHROL DIAL TRANSPL, V26, P1599, DOI 10.1093/ndt/gfq613; Schaller G, 2005, KIDNEY INT, V68, P2814, DOI 10.1111/j.1523-1755.2005.00754.x; SCHINDLER E, 1994, INFUSIONSTHERAPIE, V21, P236; Schroder O, 2005, AM J GASTROENTEROL, V100, P2503, DOI 10.1111/j.1572-0241.2005.00250.x; Seid MH, 2008, AM J OBSTET GYNECOL, V199, DOI 10.1016/j.ajog.2008.07.046; Shander A, 2010, TRANSFUSION, V50, P719, DOI 10.1111/j.1537-2995.2009.02492.x; Singh H, 2006, CLIN J AM SOC NEPHRO, V1, P475, DOI 10.2215/CJN.01541005; Singh K, 1998, EUR J HAEMATOL, V60, P119; Sloand JA, 2004, AM J KIDNEY DIS, V43, P663, DOI 10.1053/j.ajkd.2003.11.021; Spinowitz BS, 2008, J AM SOC NEPHROL, V19, P1599, DOI 10.1681/ASN.2007101156; Steensma DP, 2011, J CLIN ONCOL, V29, P97, DOI 10.1200/JCO.2010.30.3644; Stewart GB, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046042; Stoves J, 2001, NEPHROL DIAL TRANSPL, V16, P967, DOI 10.1093/ndt/16.5.967; Sunayana Verma, 2011, Journal of SAFOG (South Asian Federation of Obstetrics and Gynaecology), V3, P67; Toblli JE, 2007, J AM COLL CARDIOL, V50, P1657, DOI 10.1016/j.jacc.2007.07.029; Torres Susan, 2006, Surg Infect (Larchmt), V7, P361, DOI 10.1089/sur.2006.7.361; van Iperen CE, 2000, CRIT CARE MED, V28, P2773, DOI 10.1097/00003246-200008000-00015; Van Wyck DB, 2007, OBSTET GYNECOL, V110, P267, DOI 10.1097/01.AOG.0000275286.03283.18; Van Wyck DB, 2009, TRANSFUSION, V49, P2719, DOI 10.1111/j.1537-2995.2009.02327.x; Van Wyck DB, 2005, KIDNEY INT, V68, P2846, DOI 10.1111/j.1523-1755.2005.00758.x; Warady BA, 2004, PEDIATR NEPHROL, V19, P655, DOI 10.1007/s00467-004-1457-5; Weisbach V, 1999, TRANSFUSION, V39, P465, DOI 10.1046/j.1537-2995.1999.39050465.x; Westad S, 2008, ACTA OBSTET GYN SCAN, V87, P916, DOI 10.1080/00016340802317802	99	220	227	0	24	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 15	2013	347								f4822	10.1136/bmj.f4822	http://dx.doi.org/10.1136/bmj.f4822			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	203ZD	23950195	Green Published, hybrid			2023-01-03	WOS:000323332700001
J	Burton, JO; Hamali, HA; Singh, R; Abbasian, N; Parsons, R; Patel, AK; Goodall, AH; Brunskill, NJ				Burton, James O.; Hamali, Hassan A.; Singh, Ruchir; Abbasian, Nima; Parsons, Ruth; Patel, Amit K.; Goodall, Alison H.; Brunskill, Nigel J.			Elevated Levels of Procoagulant Plasma Microvesicles in Dialysis Patients	PLOS ONE			English	Article							CIRCULATING ENDOTHELIAL MICROPARTICLES; PLATELET-DERIVED MICROPARTICLES; STAGE RENAL-FAILURE; MEMBRANE MICROPARTICLES; CARDIOVASCULAR-DISEASE; THROMBIN GENERATION; TISSUE FACTOR; HIGH-RISK; HEMODIALYSIS; MONOCYTE	Cardiovascular (CV) death remains the largest cause of mortality in dialysis patients, unexplained by traditional risk factors. Endothelial microvesicles (EMVs) are elevated in patients with traditional CV risk factors and acute coronary syndromes while platelet MVs (PMVs) are associated with atherosclerotic disease states. This study compared relative concentrations of circulating MVs from endothelial cells and platelets in two groups of dialysis patients and matched controls and investigated their relative thromboembolic risk. MVs were isolated from the blood of 20 haemodialysis (HD), 17 peritoneal dialysis (PD) patients and 20 matched controls. Relative concentrations of EMVs (CD144(+ve)) and PMVs (CD42b(+ve)) were measured by Western blotting and total MV concentrations were measured using nanoparticle-tracking analysis. The ability to support thrombin generation was measured by reconstituting the MVs in normal plasma, using the Continuous Automated Thrombogram assay triggered with 1 mu M tissue factor. The total concentration of MVs as well as the measured sub-types was higher in both patient groups compared to controls (p<0.05). MVs from HD and PD patients were able to generate more thrombin than the controls, with higher peak thrombin, and endogenous thrombin potential levels (p<0.02). However there were no differences in either the relative quantity or activity of MVs between the two patient groups (p>0.3). Dialysis patients have higher levels of circulating procoagulant MVs than healthy controls. This may represent a novel and potentially modifiable mediator or predictor of occlusive cardiovascular events in these patients.	[Burton, James O.; Singh, Ruchir; Abbasian, Nima; Parsons, Ruth; Patel, Amit K.; Brunskill, Nigel J.] Univ Leicester, Dept Infect Immun & Inflammat, Leicester, Leics, England; [Burton, James O.; Brunskill, Nigel J.] Leicester Gen Hosp, Dept Renal Med, Leicester LE5 4PW, Leics, England; [Hamali, Hassan A.; Goodall, Alison H.] Univ Leicester, Dept Cardiovasc Sci, Leicester, Leics, England; [Hamali, Hassan A.] King Khalid Univ, Dept Clin Lab Sci, Abha, Saudi Arabia; [Patel, Amit K.] Maimonides Hosp, Dept Paediat Emergency Med, New York, NY USA; [Goodall, Alison H.] Glenfield Hosp, Leicester Natl Inst Hlth Res, Biomed Res Unit Cardiovasc Dis, Leicester, Leics, England	University of Leicester; University Hospitals of Leicester NHS Trust; Leicester General Hospital; University of Leicester; King Khalid University; Maimonides Medical Center; University Hospitals of Leicester NHS Trust; University of Leicester; Glenfield Hospital	Burton, JO (corresponding author), Univ Leicester, Dept Infect Immun & Inflammat, Leicester, Leics, England.	jb343@leicester.ac.uk	Burton, James O/AAQ-7361-2021; Patel, Amit/AAU-6430-2020	Burton, James O/0000-0003-1176-7592; Patel, Amit/0000-0001-5737-4319; Hamali, Hassan A./0000-0003-3791-460X; Goodall, Alison/0000-0002-7883-9645; Abbasian, Nima/0000-0002-6906-2563; Nigel, Brunskill/0000-0002-7109-7108	Kidney Research UK [RP28/2010] Funding Source: researchfish; National Institute for Health Research [CL-2007-11-003] Funding Source: researchfish	Kidney Research UK(Kidney Research UK (KRUK)); National Institute for Health Research(National Institute for Health Research (NIHR))		Aggarwal A, 2002, AM J KIDNEY DIS, V40, P315, DOI 10.1053/ajkd.2002.34510; Aleman MM, 2011, J THROMB HAEMOST, V9, P2251, DOI 10.1111/j.1538-7836.2011.04488.x; Amabile N, 2012, NEPHROL DIAL TRANSPL, V27, P1873, DOI 10.1093/ndt/gfr573; Ambuhl PM, 1997, NEPHROL DIAL TRANSPL, V12, P2355, DOI 10.1093/ndt/12.11.2355; Ando M, 2002, KIDNEY INT, V62, P1757, DOI 10.1046/j.1523-1755.2002.00627.x; Ashma N, 2003, NEPHROL DIAL TRANSPL, V18, P2088, DOI 10.1093/ndt/gfg348; Bernal-Mizrachi L, 2004, INT J CARDIOL, V97, P439, DOI 10.1016/j.ijcard.2003.10.029; Biro E, 2004, J THROMB HAEMOST, V2, P1843, DOI 10.1111/j.1538-7836.2004.00937.x; Bombeli T, 1997, BLOOD, V89, P2429, DOI 10.1182/blood.V89.7.2429; Boulanger CM, 2007, HYPERTENSION, V49, P902, DOI 10.1161/01.HYP.0000259667.22309.df; Caby MP, 2005, INT IMMUNOL, V17, P879, DOI 10.1093/intimm/dxh267; Casserly LF, 2000, AM J KIDNEY DIS, V36, P405, DOI 10.1053/ajkd.2000.8983; CASTILLO R, 1986, BLOOD, V68, P337; Daniel L, 2006, KIDNEY INT, V69, P1416, DOI 10.1038/sj.ki.5000306; Daniel L, 2008, NEPHROL DIAL TRANSPL, V23, P2129, DOI 10.1093/ndt/gfn029; Diamant M, 2004, EUR J CLIN INVEST, V34, P392, DOI 10.1111/j.1365-2362.2004.01355.x; Dragovic RA, 2011, NANOMED-NANOTECHNOL, V7, P780, DOI 10.1016/j.nano.2011.04.003; Dursun I, 2009, NEPHROL DIAL TRANSPL, V24, P2511, DOI 10.1093/ndt/gfp066; Faure V, 2006, J THROMB HAEMOST, V4, P566, DOI 10.1111/j.1538-7836.2005.01780.x; Foley RN, 1998, AM J KIDNEY DIS, V32, pS112, DOI 10.1053/ajkd.1998.v32.pm9820470; GAWAZ M, 1994, CLIN INVESTIGATOR, V72, P424; GEORGE JN, 1982, BLOOD, V60, P834; Hemker HC, 2003, PATHOPHYSIOL HAEMO T, V33, P4, DOI 10.1159/000071636; Jy W, 2005, J THROMB HAEMOST, V3, P1301, DOI 10.1111/j.1538-7836.2005.01384.x; Kalantar-Zadeh K, 2003, KIDNEY INT, V63, P793, DOI 10.1046/j.1523-1755.2003.00803.x; Kaw D, 2006, SEMIN DIALYSIS, V19, P317, DOI 10.1111/j.1525-139X.2006.00179.x; LEE YJ, 1993, THROMB RES, V72, P295, DOI 10.1016/0049-3848(93)90138-E; Mallat Z, 2000, CIRCULATION, V101, P841, DOI 10.1161/01.CIR.101.8.841; McIntyre CW, 2011, CLIN J AM SOC NEPHRO, V6, P133, DOI 10.2215/CJN.04610510; McIntyre NJ, 2010, CLIN J AM SOC NEPHRO, V5, P51, DOI 10.2215/CJN.05350709; Metcalfe P, 1997, BRIT J HAEMATOL, V98, P86, DOI 10.1046/j.1365-2141.1997.1572983.x; Nampoory MRN, 2003, AM J KIDNEY DIS, V42, P797, DOI 10.1016/S0272-6386(03)00860-6; Nomura S, 2004, CLIN APPL THROMB-HEM, V10, P133, DOI 10.1177/107602960401000203; Owens AP, 2010, THROMB HAEMOSTASIS, V104, P432, DOI 10.1160/TH09-11-0771; Piccin A, 2007, BLOOD REV, V21, P157, DOI 10.1016/j.blre.2006.09.001; Robert S, 2012, ARTERIOSCL THROM VAS, V32, P1054, DOI 10.1161/ATVBAHA.111.244616; Rosenson RS, 1998, JAMA-J AM MED ASSOC, V279, P1643, DOI 10.1001/jama.279.20.1643; Sinauridze EI, 2007, THROMB HAEMOSTASIS, V97, P425, DOI 10.1160/TH06-06-0313; SLOAND EM, 1991, BRIT J HAEMATOL, V77, P375, DOI 10.1111/j.1365-2141.1991.tb08587.x; Sreedhara R, 1996, AM J KIDNEY DIS, V27, P355, DOI 10.1016/S0272-6386(96)90358-3; Steppich B, 2005, THROMB HAEMOSTASIS, V93, P35, DOI 10.1160/TH04-06-0393; Trappenburg MC, 2012, NEPHROL DIAL TRANSPL, V27, P1446, DOI 10.1093/ndt/gfr474; Tveit DP, 2002, AM J KIDNEY DIS, V39, P1011, DOI 10.1053/ajkd.2002.32774; VAZIRI ND, 1994, AM J KIDNEY DIS, V23, P828, DOI 10.1016/S0272-6386(12)80136-3; Wautier JL, 2004, CIRC RES, V95, P233, DOI 10.1161/01.RES.0000137876.28454.64; Xiao KY, 2003, J BIOL CHEM, V278, P19199, DOI 10.1074/jbc.M211746200; Zeiger F, 2000, BLOOD COAGUL FIBRIN, V11, P723, DOI 10.1097/00001721-200012000-00005	47	32	32	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 2	2013	8	8							e72663	10.1371/journal.pone.0072663	http://dx.doi.org/10.1371/journal.pone.0072663			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	219XU	23936542	Green Published, Green Submitted, gold			2023-01-03	WOS:000324545800076
J	Li, XL; Li, BY; Cheng, M; Yu, F; Yin, WB; Cai, Q; Zhang, Z; Zhang, JH; Wang, JF; Zhou, RH; Gao, HQ				Li, Xiao-li; Li, Bao-ying; Cheng, Mei; Yu, Fei; Yin, Wen-bin; Cai, Qian; Zhang, Zhen; Zhang, Jian-hua; Wang, Jun-fu; Zhou, Rui-hai; Gao, Hai-qing			PIMT Prevents the Apoptosis of Endothelial Cells in Response to Glycated Low Density Lipoproteins and Protective Effects of Grape Seed Procyanidin B2	PLOS ONE			English	Article							NF-KAPPA-B; PROANTHOCYANIDIN EXTRACTS; ISOASPARTYL METHYLTRANSFERASE; MITOCHONDRIAL DYSFUNCTION; OXIDATIVE STRESS; EXPRESSION; LDL; PROLIFERATION; INVOLVEMENT; ACTIVATION	Background: The development of diabetic angiopathy is associated with profound vascular endothelial cells (VEC) dysfunction and apoptosis. Glycated low density lipoproteins (gly-LDL) continuously produced in the setting of diabetic patients play an important role in causing VEC dysfunction and apoptosis. However, the underlying molecular mechanism remains largely elusive. Protein L-isoaspartyl methyltransferase (PIMT) is a widely expressed protein repair enzyme by multiple cell types of arterial wall including VEC. Our previous proteomic studies showed that the expression of PIMT was significantly decreased in the aorta of diabetic rats as compared with control rats and treatment with grape seed procyanidin extracts significantly increased the PIMT expression in diabetic rats. We hypothesized that PIMT plays a critical role in gly-LDL induced VEC apoptosis; grape seed procyanidin B2 (GSPB2) protect against gly-LDL induced VEC apoptosis through PIMT regulation. Methods and Results: HUVEC transfected negative control and PIMT siRNA were treated with or without GSPB2 (10 mu mol/L) for 48 h. Moreover, HUVEC of PIMT overexpression were stimulated by gly-LDL (50 mu g/ml) in the presence or absence of GSPB2 (10 mu mol/L) for 48 h. Our results showed that gly-LDL downregulated PIMT expression and PIMT overexpression or GSPB2 significantly attenuated gly-LDL induced VEC apoptosis. PIMT siRNA increased VEC apoptosis with up-regulation of p53, cytochrome c release, caspase-9 and caspase-3 activation. Mechanistically, overexpression of PIMT or GSPB2 increased the phosphorylation of ERK1/2 and GSK3 beta in the gly-LDL induced VEC. Conclusion: In summary, our study identified PIMT as a key player responsible for gly-LDL induced VEC apoptosis and GSPB2 protect against gly-LDL induced VEC apoptosis by PIMT up-regulation. Targeting PIMT including use of GSPB2 could be turned into clinical application in the fighting against diabetic vascular complications.	[Li, Xiao-li; Li, Bao-ying; Cheng, Mei; Yu, Fei; Yin, Wen-bin; Cai, Qian; Zhang, Zhen; Gao, Hai-qing] Shandong Univ, Qi Lu Hosp, Dept Geriatr Endocrinol, Key Lab Cardiovasc Prote Shandong Prov, Jinan 250100, Peoples R China; [Li, Xiao-li] Shandong Univ, Qi Lu Hosp, Dept Drug Purchase & Supply, Jinan 250100, Peoples R China; [Zhang, Jian-hua; Wang, Jun-fu] Med Sci Acad Shandong, Inst Basic Sci, Jinan, Peoples R China; [Zhou, Rui-hai] Univ N Carolina, Div Cardiol, Chapel Hill, NC USA	Shandong University; Shandong University; Shandong First Medical University & Shandong Academy of Medical Sciences; University of North Carolina; University of North Carolina Chapel Hill	Gao, HQ (corresponding author), Shandong Univ, Qi Lu Hosp, Dept Geriatr Endocrinol, Key Lab Cardiovasc Prote Shandong Prov, Jinan 250100, Peoples R China.	gaohaiqing52@hotmail.com			National Natural Science Foundation of China [81000340, 81100595]; China Postdoctoral Science Foundation [2011M500748]; Natural Science Foundation of Shandong Province [ZR2010HQ067]; Traditional Chinese Medicine Science and Technology Development Projects of Shandong Province [2009-154]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); China Postdoctoral Science Foundation(China Postdoctoral Science Foundation); Natural Science Foundation of Shandong Province(Natural Science Foundation of Shandong Province); Traditional Chinese Medicine Science and Technology Development Projects of Shandong Province	This work was supported by National Natural Science Foundation of China (81000340, 81100595), China Postdoctoral Science Foundation (2011M500748), Natural Science Foundation of Shandong Province (ZR2010HQ067) and Traditional Chinese Medicine Science and Technology Development Projects of Shandong Province (2009-154). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Acehan D, 2002, MOL CELL, V9, P423, DOI 10.1016/S1097-2765(02)00442-2; Artwohl M, 2003, DIABETES, V52, P1240, DOI 10.2337/diabetes.52.5.1240; Cai Q, 2011, BIOSCI BIOTECH BIOCH, V75, P1692, DOI 10.1271/bbb.110194; Cedo L, 2013, FOOD CHEM, V138, P524, DOI 10.1016/j.foodchem.2012.10.088; Chen TS, 2010, J BIOL CHEM, V285, P37281, DOI 10.1074/jbc.M110.157008; Cimmino A, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003258; Desrosiers Richard R, 2011, Curr Aging Sci, V4, P8; Devi SA, 2011, EXP GERONTOL, V46, P958, DOI 10.1016/j.exger.2011.08.006; Eriksson L, 2012, CARDIOVASC DIABETOL, V11, DOI 10.1186/1475-2840-11-27; Fanelus I, 2008, BIOCHEM BIOPH RES CO, V371, P203, DOI 10.1016/j.bbrc.2008.04.009; Huebscher KJ, 1999, GENE, V240, P333, DOI 10.1016/S0378-1119(99)00443-6; Jin KL, 2002, J NEUROCHEM, V80, P119, DOI 10.1046/j.0022-3042.2001.00678.x; Kang R, 2011, AUTOPHAGY, V7, P91, DOI 10.1038/cdd.2009.149; Kinaci MK, 2012, EXP THER MED, V3, P249, DOI 10.3892/etm.2011.382; Kindrachuk J, 2003, J BIOL CHEM, V278, P50880, DOI 10.1074/jbc.M308423200; Lanthier J, 2006, BIOCHEM CELL BIOL, V84, P684, DOI 10.1139/O06-055; Lee HJ, 2004, J NEUROCHEM, V88, P647, DOI 10.1111/j.1471-4159.2004.02191.x; Lee JB, 2012, YONSEI MED J, V53, P53, DOI 10.3349/ymj.2012.53.1.53; Li BY, 2008, J CELL BIOCHEM, V104, P668, DOI 10.1002/jcb.21658; Li BY, 2011, APOPTOSIS, V16, P732, DOI 10.1007/s10495-011-0602-4; Li BY, 2011, CELL BIOL INT, V35, P663, DOI 10.1042/CBI20100656; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Li XL, 2010, INT J MOL MED, V25, P237, DOI 10.3892/ijmm_00000336; Li XL, 2009, BIOSCI BIOTECH BIOCH, V73, P1348, DOI 10.1271/bbb.90008; Liu MJ, 2004, TOXICOL APPL PHARM, V194, P141, DOI 10.1016/j.taap.2003.08.017; Mackenzie GG, 2008, BIOCHEM PHARMACOL, V75, P1461, DOI 10.1016/j.bcp.2007.12.013; Quintela AM, 2012, FREE RADICAL BIO MED, V53, P730, DOI 10.1016/j.freeradbiomed.2012.05.045; Mishra R, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-144; Morrison GJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043288; Okouchi M, 2009, CURR NEUROVASC RES, V6, P267, DOI 10.2174/156720209789630348; Onat D, 2011, CURR DIABETES REP, V11, P193, DOI 10.1007/s11892-011-0182-2; Petit-Paitel A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005491; Piao S, 2011, J CLIN BIOCHEM NUTR, V49, P50, DOI 10.3164/jcbn.10-120; Prasad R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043064; Sakahira H, 1998, NATURE, V391, P96, DOI 10.1038/34214; Sangle GV, 2010, ENDOCRINOLOGY, V151, P4455, DOI 10.1210/en.2010-0323; Sangle GV, 2010, FREE RADICAL BIO MED, V48, P781, DOI 10.1016/j.freeradbiomed.2009.12.017; Shamsara J, 2011, GENE, V487, P107, DOI 10.1016/j.gene.2011.07.020; Soulez M, 2010, STEM CELLS, V28, P810, DOI 10.1002/stem.403; Toma L, 2009, BIOCHEM BIOPH RES CO, V390, P877, DOI 10.1016/j.bbrc.2009.10.066; Turk Z, 2011, LIFE SCI, V89, P485, DOI 10.1016/j.lfs.2011.07.021; van den Oever IAM, 2010, MEDIAT INFLAMM, V2010, DOI 10.1155/2010/792393; Wagner AM, 2007, DIABETOLOGIA, V50, P676, DOI 10.1007/s00125-006-0556-1; Wagner Ana M, 2008, Rev Diabet Stud, V5, P225, DOI 10.1900/RDS.2008.5.225; Wortzel Inbal, 2011, Genes Cancer, V2, P195, DOI 10.1177/1947601911407328; Yang ZH, 2008, APOPTOSIS, V13, P1331, DOI 10.1007/s10495-008-0257-y; Yu F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052541; Zhang JY, 1998, ARTERIOSCL THROM VAS, V18, P1140, DOI 10.1161/01.ATV.18.7.1140; Zhang X, 2011, ACTA BIOCH BIOPH SIN, V43, P787, DOI 10.1093/abbs/gmr072	49	13	15	1	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 26	2013	8	7							e69979	10.1371/journal.pone.0069979	http://dx.doi.org/10.1371/journal.pone.0069979			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	197GU	23922881	Green Published, gold, Green Submitted			2023-01-03	WOS:000322838900129
J	Baugh, CW; Schuur, JD				Baugh, Christopher W.; Schuur, Jeremiah D.			Observation Care - High-Value Care or a Cost-Shifting Loophole?	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material								<p id="p002">Protocolized observation care in dedicated hospital units can result in higher-value care for some conditions, but by treating observation billing for inpatient care the same as for observation-unit care, current policy promotes cost shifting without rewarding higher value. <p id="p003">A 2012 New York Times article told the story of Miriam Nyman, an 83-year-old Rhode Island woman who was hospitalized after a fall in 2009.(1) Mrs. Nyman broke her neck and spent 4 nights in the hospital, so she was shocked to learn that the entire hospitalization was classified as an outpatient visit and billed as an observation stay. That meant that her subsequent stay in a skilled nursing facility was not covered by Medicare, and she was left with more than $35,000 in out-of-pocket expenses. Similar cases reported elsewhere in the United States highlight a critical and overlooked Medicare ...	[Baugh, Christopher W.; Schuur, Jeremiah D.] Brigham & Womens Hosp, Dept Emergency Med, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital	Baugh, CW (corresponding author), Brigham & Womens Hosp, Dept Emergency Med, 75 Francis St, Boston, MA 02115 USA.		Baugh, Christopher William/AAJ-3688-2021	Baugh, Christopher William/0000-0002-2360-1891				American Hospital's Association, 2013, EXPL IMP RAC PROGR H; Baugh CW, 2012, HEALTH AFFAIR, V31, P2314, DOI 10.1377/hlthaff.2011.0926; Feng ZL, 2012, HEALTH AFFAIR, V31, P1251, DOI 10.1377/hlthaff.2012.0129; Medicare Payment Advisory Commission, 2012, EXPL IMP RAC PROGR H; Span P., 2012, NEW YORK TIMES  0622	5	52	52	0	10	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 25	2013	369	4					302	305		10.1056/NEJMp1304493	http://dx.doi.org/10.1056/NEJMp1304493			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	188VJ	23883376				2023-01-03	WOS:000322223900004
J	Chinthapalli, K				Chinthapalli, Krishna			PALLIATIVE CARE The birth and death of the Liverpool care pathway	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material												kchinthapalli@bmj.com	Chinthapalli, Krishna/P-8428-2019	Chinthapalli, Krishna/0000-0003-4136-4882				Doughty, 2012, DAILY MAIL; Economist Intelligence Unit, 2010, QUAL DEATH RANK END; Hawkes N, 2013, BMJ-BRIT MED J, V347, DOI 10.1136/bmj.f4568; Koestler-Grack RA, 2009, M CURIE SCI; Neuberger J., 2013, MORE CARE LESS PATHW	5	7	7	0	9	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 24	2013	347								f4669	10.1136/bmj.f4669	http://dx.doi.org/10.1136/bmj.f4669			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	193BM	23884973				2023-01-03	WOS:000322531800012
J	Kim, HS; Park, SH; Gunzl, A; Cross, GAM				Kim, Hee-Sook; Park, Sung Hee; Guenzl, Arthur; Cross, George A. M.			MCM-BP Is Required for Repression of Life-Cycle Specific Genes Transcribed by RNA Polymerase I in the Mammalian Infectious Form of Trypanosoma brucei	PLOS ONE			English	Article							VSG EXPRESSION SITE; ORIGIN RECOGNITION COMPLEX; BLOOD-STREAM FORMS; POLO-LIKE KINASE; DNA-REPLICATION; ANTIGENIC VARIATION; TOPOISOMERASE-II; DISTINCT ROLES; PROTEIN; TELOMERES	Trypanosoma brucei variant surface glycoprotein (VSG) expression is a classic example of allelic exclusion. While the genome of T. brucei contains >2,000 VSG genes and VSG pseudogenes, only one allele is expressed at the surface of each infectious trypanosome and the others are repressed. Along with recombinatorial VSG switching, allelic exclusion provides a major host evasion mechanism for trypanosomes, a phenomenon known as antigenic variation. To extend our understanding of how trypanosomes escape host immunity by differential expression of VSGs, we attempted to identify genes that contribute to VSG silencing, by performing a loss-of-silencing screen in T. brucei using a transposon-mediated random insertional mutagenesis. One identified gene, which we initially named LOS1, encodes a T. brucei MCM-Binding Protein (TbMCM-BP). Here we show that TbMCM-BP is essential for viability of infectious bloodstream-form (BF) trypanosome and is required for proper cell-cycle progression. Tandem affinity purification of TbMCM-BP followed by mass spectrometry identified four subunits (MCM4-MCM7) of the T. brucei MCM complex, a replicative helicase, and MCM8, a subunit that is uniquely co-purified with TbMCM-BP. TbMCM-BP is required not only for repression of subtelomeric VSGs but also for silencing of life-cycle specific, insect-stage genes, procyclin and procyclin-associated genes (PAGs), that are normally repressed in BF trypanosomes and are transcribed by RNA polymerase I. Our study uncovers a functional link between chromosome maintenance and RNA pol I-mediated gene silencing in T. brucei.	[Kim, Hee-Sook; Cross, George A. M.] Rockefeller Univ, Mol Parasitol Lab, New York, NY 10021 USA; [Park, Sung Hee; Guenzl, Arthur] Univ Connecticut, Ctr Hlth, Dept Genet & Dev Biol, Storrs, CT 06269 USA; [Guenzl, Arthur] Univ Connecticut, Ctr Hlth, Dept Mol Microbial & Struct Biol, Storrs, CT 06269 USA	Rockefeller University; University of Connecticut; University of Connecticut	Kim, HS (corresponding author), Rockefeller Univ, Mol Parasitol Lab, New York, NY 10021 USA.	khee-sook@rockefeller.edu	; Cross, George/B-7444-2011	Gunzl, Arthur/0000-0002-7487-2261; Cross, George/0000-0003-1374-6955	Rockefeller University Women in Science Fellowship; U.S. National Institutes of Health (NIH) [R01 AI021729, R01 AI059377]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021729, R01AI059377] Funding Source: NIH RePORTER	Rockefeller University Women in Science Fellowship; U.S. National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	The work was supported by the Rockefeller University Women in Science Fellowship to HK and by grants R01 AI021729 (GAMC) and R01 AI059377 (AG) from the U.S. National Institutes of Health (NIH). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Allergy and Infectious Diseases (NIAID) or the NIH. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ALARCON CM, 1994, MOL CELL BIOL, V14, P5579, DOI 10.1128/MCB.14.8.5579; Alsford S, 2007, MOL MICROBIOL, V63, P724, DOI 10.1111/j.1365-2958.2006.05553.x; Alsford S, 2012, NUCLEIC ACIDS RES, V40, P10150, DOI 10.1093/nar/gks813; Becker M, 2004, GENOME RES, V14, P2319, DOI 10.1101/gr.2955304; Benmerzouga I, 2013, MOL MICROBIOL, V87, P196, DOI 10.1111/mmi.12093; Biebinger S, 1996, NUCLEIC ACIDS RES, V24, P1202, DOI 10.1093/nar/24.7.1202; Boothroyd CE, 2009, NATURE, V459, P278, DOI 10.1038/nature07982; BRUN R, 1979, ACTA TROP, V36, P289; CROSS GAM, 1973, PARASITOLOGY, V67, P315, DOI 10.1017/S0031182000046540; DaFonseca CJ, 2001, P NATL ACAD SCI USA, V98, P3034, DOI 10.1073/pnas.061487598; Dang HQ, 2011, J BIOL CHEM, V286, P32424, DOI 10.1074/jbc.M111.240143; Godoy PDD, 2009, EUKARYOT CELL, V8, P1592, DOI 10.1128/EC.00161-09; Denninger V, 2010, MOL MICROBIOL, V78, P459, DOI 10.1111/j.1365-2958.2010.07350.x; Ding L, 2011, J BIOL CHEM, V286, P32918, DOI 10.1074/jbc.M111.282541; Dziak R, 2003, J BIOL CHEM, V278, P27372, DOI 10.1074/jbc.M301110200; Fachinetti D, 2010, MOL CELL, V39, P595, DOI 10.1016/j.molcel.2010.07.024; Figueiredo LM, 2008, PLOS BIOL, V6, P1539, DOI 10.1371/journal.pbio.0060161; Forsburg SL, 2004, MICROBIOL MOL BIOL R, V68, P109, DOI 10.1128/MMBR.68.1.109-131.2004; Fox CA, 1997, SCIENCE, V276, P1547, DOI 10.1126/science.276.5318.1547; Germe T, 2009, EMBO J, V28, P2803, DOI 10.1038/emboj.2009.223; GLOVER TW, 1984, HUM GENET, V67, P136, DOI 10.1007/BF00272988; GueirosFilho FJ, 1996, MOL CELL BIOL, V16, P5655; Gunzl A, 2003, EUKARYOT CELL, V2, P542, DOI 10.1128/EC.2.3.542-551.2003; Hammarton TC, 2007, MOL MICROBIOL, V65, P1229, DOI 10.1111/j.1365-2958.2007.05866.x; Hammarton TC, 2003, J BIOL CHEM, V278, P22877, DOI 10.1074/jbc.M300813200; Hertz-Fowler C, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003527; HIRUMI H, 1989, J PARASITOL, V75, P985, DOI 10.2307/3282883; Holland L, 2002, EUR J BIOCHEM, V269, P5192, DOI 10.1046/j.1432-1033.2002.03224.x; Horn D, 2005, CHROMOSOME RES, V13, P525, DOI 10.1007/s10577-005-0991-8; Horn D, 1997, EMBO J, V16, P7422, DOI 10.1093/emboj/16.24.7422; HORN D, 1995, CELL, V83, P555, DOI 10.1016/0092-8674(95)90095-0; Horn D, 2010, CURR OPIN MICROBIOL, V13, P700, DOI 10.1016/j.mib.2010.08.009; Hughes K, 2007, EMBO J, V26, P2400, DOI 10.1038/sj.emboj.7601678; Ishimi Y, 1996, J BIOL CHEM, V271, P24115, DOI 10.1074/jbc.271.39.24115; Jagannathan M, 2012, J CELL SCI, V125, P133, DOI 10.1242/jcs.089938; Johnson A, 2005, ANNU REV BIOCHEM, V74, P283, DOI 10.1146/annurev.biochem.73.011303.073859; Kawahara T, 2008, MOL MICROBIOL, V69, P1054, DOI 10.1111/j.1365-2958.2008.06346.x; Kim HS, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000992; Kim HY, 2011, PLOS ONE, V6, DOI [10.1371/journal.pone.0024749, 10.1371/journal.pone.0019867]; Landeira D, 2009, J CELL BIOL, V186, P243, DOI 10.1083/jcb.200902119; Leal S, 2004, J BIOL CHEM, V279, P28979, DOI 10.1074/jbc.M403479200; Li B, 2005, MOL CELL BIOL, V25, P5011, DOI 10.1128/MCB.25.12.5011-5021.2005; Li JJ, 2011, FEBS LETT, V585, P3850, DOI 10.1016/j.febslet.2011.10.033; Li ZY, 2006, EUKARYOT CELL, V5, P1026, DOI 10.1128/EC.00129-06; Lowell JE, 2004, J CELL SCI, V117, P5937, DOI 10.1242/jcs.01515; Luo KT, 2009, NAT CELL BIOL, V11, P204, DOI 10.1038/ncb1828; Majka J, 2004, PROG NUCLEIC ACID RE, V78, P227, DOI 10.1016/S0079-6603(04)78006-X; Mancio-Silva L, 2008, J CELL SCI, V121, P2046, DOI 10.1242/jcs.026427; Mayer ML, 2001, MOL CELL, V7, P959, DOI 10.1016/S1097-2765(01)00254-4; NAGOSHI YL, 1995, MOL BIOCHEM PARASIT, V72, P33, DOI 10.1016/0166-6851(95)00062-6; Narayanan MS, 2011, NUCLEIC ACIDS RES, V39, P2018, DOI 10.1093/nar/gkq950; Nishiyama A, 2011, GENE DEV, V25, P165, DOI 10.1101/gad.614411; Nitiss JL, 2009, NAT REV CANCER, V9, P327, DOI 10.1038/nrc2608; Oberholzer M, 2006, MOL BIOCHEM PARASIT, V145, P117, DOI 10.1016/j.molbiopara.2005.09.002; Parrilla-Castellar ER, 2004, DNA REPAIR, V3, P1009, DOI 10.1016/j.dnarep.2004.03.032; Peacock L, 2011, P NATL ACAD SCI USA, V108, P3671, DOI 10.1073/pnas.1019423108; Ploubidou A, 1999, J CELL SCI, V112, P4641; Pospiech H, 2010, SUBCELL BIOCHEM, V50, P79, DOI 10.1007/978-90-481-3471-7_5; Povelones ML, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1003010; Prasanth SG, 2010, P NATL ACAD SCI USA, V107, P15093, DOI 10.1073/pnas.1009945107; ROBINSON DR, 1995, J CELL BIOL, V128, P1163, DOI 10.1083/jcb.128.6.1163; Sakwe AM, 2007, MOL CELL BIOL, V27, P3044, DOI 10.1128/MCB.02384-06; Scahill MD, 2008, MOL BIOCHEM PARASIT, V157, P73, DOI 10.1016/j.molbiopara.2007.10.003; Schimanski B, 2005, EUKARYOT CELL, V4, P1942, DOI 10.1128/EC.4.11.1942-1950.2005; Shareef MM, 2001, MOL BIOL CELL, V12, P1671, DOI 10.1091/mbc.12.6.1671; Sheader K, 2004, J BIOL CHEM, V279, P13363, DOI 10.1074/jbc.M312307200; Snyder M, 2005, P NATL ACAD SCI USA, V102, P14539, DOI 10.1073/pnas.0507479102; Stanne TM, 2011, EUKARYOT CELL, V10, P964, DOI 10.1128/EC.05048-11; Takahashi N, 2008, EMBO J, V27, P1840, DOI 10.1038/emboj.2008.107; Takahashi N, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000817; Tiengwe C, 2012, CELL REP, V2, P185, DOI 10.1016/j.celrep.2012.06.007; Tiengwe C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032674; Nguyen T, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035931; Tu XM, 2005, EUKARYOT CELL, V4, P755, DOI 10.1128/EC.4.4.755-764.2005; Umeyama T, 2008, EUKARYOT CELL, V7, P1582, DOI 10.1128/EC.00150-08; Vanhamme L, 2000, MOL MICROBIOL, V36, P328, DOI 10.1046/j.1365-2958.2000.01844.x; Wang QP, 2010, MOL MICROBIOL, V77, P1237, DOI 10.1111/j.1365-2958.2010.07284.x; Wickstead B, 2004, GENOME RES, V14, P1014, DOI 10.1101/gr.2227704; Wirtz E, 1999, MOL BIOCHEM PARASIT, V99, P89, DOI 10.1016/S0166-6851(99)00002-X; Yang XF, 2009, CELL, V137, P99, DOI 10.1016/j.cell.2009.01.037	80	100	102	1	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 25	2013	8	2							e57001	10.1371/journal.pone.0057001	http://dx.doi.org/10.1371/journal.pone.0057001			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	115ZB	23451133	Green Submitted, Green Published, gold			2023-01-03	WOS:000316849500052
J	Singh, RR; Lankadeva, YR; Denton, KM; Moritz, KM				Singh, Reetu R.; Lankadeva, Yugeesh R.; Denton, Kate M.; Moritz, Karen M.			Improvement in Renal Hemodynamics following Combined Angiotensin II Infusion and AT1R Blockade in Aged Female Sheep following Fetal Unilateral Nephrectomy	PLOS ONE			English	Article							LOW-PROTEIN DIET; REDUCED NEPHRON NUMBER; LIVING KIDNEY DONORS; BLOOD-PRESSURE; ADULT SHEEP; PRENATAL EXPOSURE; GLUCOCORTICOID TREATMENT; ANTENATAL BETAMETHASONE; CARDIOVASCULAR-DISEASE; ARTERIAL-PRESSURE	Renin-angiotensin system (RAS) is a powerful modulator of renal hemodynamic and fluid homeostasis. Up-regulation in components of intra-renal RAS occurs with ageing. Recently we reported that 2 year old uninephrectomised (uni-x) female sheep have low renin hypertension and reduced renal function. By 5 years of age, these uni-x sheep had augmented decrease in renal blood flow (RBF) compared to sham. We hypothesised that this decrease in RBF in 5 year old uni-x sheep was due to an up-regulation in components of the intra-renal RAS. In this study, renal responses to angiotensin II (AngII) infusion and AngII type 1 receptor (AT1R) blockade were examined in the same 5 year old sheep. We also administered AngII in the presence of losartan to increase AngII bioavailability to the AT2R in order to understand AT2R contribution to renal function in this model. Uni-x animals had significantly lower renal cortical content of renin, AngII (similar to 40%) and Ang 1-7 (similar to 60%) and reduced cortical expression of AT1R gene than sham animals. In response to both AngII infusion and AT1R blockade via losartan, renal hemodynamic responses and tubular sodium excretion were significantly attenuated in uni-x animals compared to sham. However, AngII infusion in the presence of losartan caused similar to 33% increase in RBF in uni-x sheep compared to similar to 14% in sham (P<0.05). This was associated with a significant decrease in renal vascular resistance in the uni-x animals (22% vs 15%, P<0.05) without any changes in systemic blood pressure. The present study shows that majority of the intra-renal RAS components are suppressed in this model of low renin hypertension. However, increasing the availability of AngII to AT2R by AT1R blockade improved renal blood flow in uni-x sheep. This suggests that manipulation of the AT2R maybe a potential therapeutic target for treatment of renal dysfunction associated with a congenital nephron deficit.	[Singh, Reetu R.; Moritz, Karen M.] Univ Queensland, Sch Biomed Sci, St Lucia, Qld, Australia; [Singh, Reetu R.; Lankadeva, Yugeesh R.; Denton, Kate M.] Monash Univ, Dept Physiol, Clayton, Vic 3168, Australia; [Singh, Reetu R.] Monash Univ, Dept Anat & Dev Biol, Clayton, Vic, Australia	University of Queensland; Monash University; Monash University	Singh, RR (corresponding author), Univ Queensland, Sch Biomed Sci, St Lucia, Qld, Australia.	Reetu.Singh@monash.edu	Moritz, Karen/G-2508-2015; Lankadeva, Yugeesh/R-9253-2019; Denton, Kate/AAG-2423-2019	Moritz, Karen/0000-0002-8085-0034; Lankadeva, Yugeesh/0000-0002-3589-9111; RAMAKRISHNA, RACHUMALLU/0000-0002-8112-2450; singh, RAJBIR/0000-0002-2307-2360; Denton, Kate/0000-0002-5929-4387	Monash University Bridging Post-Doctoral Fellowship; Faculty Scholarship, Monash University; NH&MRC Senior Research Fellowships; National Heart Foundation; Monash University Strategic Grant Scheme	Monash University Bridging Post-Doctoral Fellowship; Faculty Scholarship, Monash University; NH&MRC Senior Research Fellowships; National Heart Foundation(National Heart Foundation of Australia); Monash University Strategic Grant Scheme(Monash University)	R.R.S was supported by a Monash University Bridging Post-Doctoral Fellowship. Y.R.L was supported by a Faculty Scholarship, Monash University. K. M. M and K. M. D were supported by NH&MRC Senior Research Fellowships. The project was funded by the National Heart Foundation and Monash University Strategic Grant Scheme. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Agarwal R, 2002, AM J PHYSIOL-RENAL, V283, pF236, DOI 10.1152/ajprenal.00336.2001; Barker DJP, 2005, J AM SOC NEPHROL, V16, P2537, DOI 10.1681/ASN.2005020160; Brenner BM, 1997, KIDNEY INT, pS124; Bucher BS, 2012, THER UMSCH, V69, P295, DOI 10.1024/0040-5930/a000288; Dodic M, 2006, J PHYSIOL-LONDON, V571, P651, DOI 10.1113/jphysiol.2005.102186; Dodic M, 2002, HYPERTENSION, V40, P729, DOI 10.1161/01.HYP.0000036455.62159.7E; Dodic M, 1998, CLIN SCI, V94, P149, DOI 10.1042/cs0940149; Dodic M, 1999, CLIN EXP PHARMACOL P, V26, P550, DOI 10.1046/j.1440-1681.1999.03076.x; Douglas-Denton R, 2002, J AM SOC NEPHROL, V13, P406, DOI 10.1681/ASN.V132406; Fehrman-Ekholm I, 2001, TRANSPLANTATION, V72, P444, DOI 10.1097/00007890-200108150-00015; Ferrario CM, 1998, AM J HYPERTENS, V11, P137, DOI 10.1016/S0895-7061(97)00400-7; Gossmann J, 2005, AM J TRANSPLANT, V5, P2417, DOI 10.1111/j.1600-6143.2005.01037.x; Herrera M, 2013, HYPERTENSION, V61; Hilliard LM, 2012, HYPERTENSION, V59, P409, DOI 10.1161/HYPERTENSIONAHA.111.184986; Hilliard LM, 2011, HYPERTENSION, V58, pE94; Hilliard LM, 2011, HYPERTENSION, V57, P275, DOI 10.1161/HYPERTENSIONAHA.110.166827; Hoppe CC, 2007, AM J PHYSIOL-REG I, V292, pR462, DOI 10.1152/ajpregu.00079.2006; Ibrahim HN, 1998, J AM SOC NEPHROL, V9, P72; Joly E, 2006, AM J PHYSIOL-REG I, V291, pR977, DOI 10.1152/ajpregu.00401.2005; Kobori H, 2007, PHARMACOL REV, V59, P251, DOI 10.1124/pr.59.3.3; Langley-Evans SC, 1999, LIFE SCI, V64, P965, DOI 10.1016/S0024-3205(99)00022-3; Lankadeva YR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047528; Luyckx VA, 2005, KIDNEY INT, V68, pS68, DOI 10.1111/j.1523-1755.2005.09712.x; McInnes GT, 1999, J CARDIOVASC PHARM, V33, pS29, DOI 10.1097/00005344-199900001-00006; McMullen S, 2005, AM J PHYSIOL-REG I, V288, pR85, DOI 10.1152/ajpregu.00435.2004; Miller JA, 2006, J AM SOC NEPHROL, V17, P2554, DOI 10.1681/ASN.2005101095; Moritz KM, 2010, PLACENTA, V31, pS40, DOI 10.1016/j.placenta.2010.01.006; Moritz KM, 2011, AM J PHYSIOL-REG I, V301, pR500, DOI 10.1152/ajpregu.00818.2010; Moritz KM, 2002, ENDOCRINOLOGY, V143, P4455, DOI 10.1210/en.2002-220534; Moritz KM, 2002, HYPERTENSION, V39, P1071, DOI 10.1161/01.HYP.0000019131.77075.54; Moritz KM, 1999, PEDIATR NEPHROL, V13, P171, DOI 10.1007/s004670050587; Navar LG, 2004, KIDNEY INT, V65, P1522, DOI 10.1111/j.1523-1755.2004.00539.x; Sahajpal V, 2005, J PHYSIOL-LONDON, V563, P193, DOI 10.1113/jphysiol.2004.078642; Salazar F, 2008, HYPERTENSION, V51, P1184, DOI 10.1161/HYPERTENSIONAHA.107.100750; Sampson AK, 2008, HYPERTENSION, V52, P666, DOI 10.1161/HYPERTENSIONAHA.108.114058; Schreuder MF, 2008, J PAEDIATR CHILD H, V44, P363, DOI 10.1111/j.1440-1754.2008.01315.x; Schulman IH, 2010, AM J NEPHROL, V32, P249, DOI 10.1159/000318607; Shaltout HA, 2010, AM J PHYSIOL-HEART C, V299, pH541, DOI 10.1152/ajpheart.00100.2010; Singh RR, 2007, AM J PHYSIOL-RENAL, V293, pF548, DOI 10.1152/ajprenal.00156.2007; Singh RR, 2007, J PHYSIOL-LONDON, V579, P503, DOI 10.1113/jphysiol.2006.125773; Singh RR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042400; Singh RR, 2012, AM J PHYSIOL-REG I, V302, pR868, DOI 10.1152/ajpregu.00579.2011; Singh RR, 2011, AM J PHYSIOL-RENAL, V301, pF1168, DOI 10.1152/ajprenal.00463.2011; Singh RR, 2011, AM J PHYSIOL-RENAL, V301, pF319, DOI 10.1152/ajprenal.00139.2011; Singh RR, 2009, J HYPERTENS, V27, P386, DOI 10.1097/HJH.0b013e32831bc778; Steckelings UM, 2012, CURR OPIN NEPHROL HY, V21, P142, DOI 10.1097/MNH.0b013e328350261b; Vize PD, 1997, DEV BIOL, V188, P189, DOI 10.1006/dbio.1997.8629; Westland R, PEDIATRICS, V131, pe478; Wintour EM, 2003, J PHYSIOL-LONDON, V549, P929, DOI 10.1113/jphysiol.2003.042408; Woods LL, 2004, KIDNEY INT, V65, P1339, DOI 10.1111/j.1523-1755.2004.00511.x; Woods LL, 2001, PEDIATR RES, V49, P460, DOI 10.1203/00006450-200104000-00005; Yanes LL, 2006, AM J PHYSIOL-REG I, V291, pR383, DOI 10.1152/ajpregu.00510.2005; Zhang J, 2010, REPROD SCI, V17, P186, DOI 10.1177/1933719109351098	53	16	17	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 1	2013	8	7							e68036	10.1371/journal.pone.0068036	http://dx.doi.org/10.1371/journal.pone.0068036			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	175ZH	23840884	Green Published, Green Submitted, gold			2023-01-03	WOS:000321271900023
J	Xie, F; Yan, L; Li, JJ; Zheng, T; Shi, CY; Ying, J; Shen, RX; Yang, JM				Xie, Feng; Yan, Long; Li, Jiongjiong; Zheng, Tao; Shi, Changying; Ying, Jun; Shen, Rongxi; Yang, Jiamei			Effects of Nucleoside Analogue on Patients with Chronic Hepatitis B-Associated Liver Failure: Meta-Analysis	PLOS ONE			English	Article							ADEFOVIR DIPIVOXIL; ACUTE EXACERBATION; LAMIVUDINE; ENTECAVIR; THERAPY; TRANSPLANTATION; DECOMPENSATION; EFFICACY	Purpose: The effectiveness of nucleoside analogue on patients with chronic hepatitis B-associated liver failure is still controversial. To address this issue, we did a review of the literatures and analyzed the data with emphasis on the survival and reduction in serum HBV DNA level. Methods: We searched 11 randomized controlled trials that included 654 patients with chronic hepatitis B-associated liver failure. 340 patients adopted nucleoside analogue, such as lamivudine (LAM), entecavir (ETV), telbivudine (LdT), or tenofovir disoproxil fumarate (TDF), and the remaining 314 patients adopted no nucleoside analogue or placebo. A meta-analysis was carried out to examine the survival, HBV e antigen serologic conversion, and reduction in serum HBV DNA level. The pooled odds ratio (OR) was used to reflect the treatment effects. Results: The overall analysis revealed nucleoside analogue significantly improved 1-month(OR = 2.10; 95% CI, [1.29, 3.41]; p = 0.003), 3-month (OR = 2.15; 95% CI, [1.26, 3.65]; p = 0.005), 12-month survival (OR = 4.62; 95% CI, [1.96, 10.89]; p = 0.0005). Comparison of 3-month HBV DNA showed significant reduction for adoptive nucleoside analogue patients (OR = 54.47; 95% CI, [16.37, 201.74]; p < 0.00001). Comparison of 3-month HBV e antigen serologic conversion showed a highly significant improvement of HBV e antigen lost for patients received adoptive antiviral therapy (OR = 6.57; 95% CI, [1.64, 26.31]; p = 0.008). Conclusions: The benefits of nucleoside analogue on patients with chronic hepatitis B-associated liver failure is significant for improving patient survival, HBV e antigen serologic conversion, and rapid reduction of HBV DNA levels.	[Xie, Feng; Yan, Long; Li, Jiongjiong; Zheng, Tao; Shi, Changying; Ying, Jun; Shen, Rongxi; Yang, Jiamei] Second Mil Med Univ, Eastern Hepatobiliary Surg Hosp, Dept Special Treatment & Liver Transplantat, Shanghai, Peoples R China	Naval Medical University	Yang, JM (corresponding author), Second Mil Med Univ, Eastern Hepatobiliary Surg Hosp, Dept Special Treatment & Liver Transplantat, Shanghai, Peoples R China.	jiameiyang@gmail.com		Everbach, E. Carr/0000-0002-7125-939X	China Postdoctoral Science Fund [20100470107]; China Postdoctoral Science Special Fund [201104750]; CSCO Fund [Y-B2011-006]; Fund of the Ministry of Science and Technology of China [2008ZX10002-018]	China Postdoctoral Science Fund(China Postdoctoral Science Foundation); China Postdoctoral Science Special Fund; CSCO Fund; Fund of the Ministry of Science and Technology of China	This work was supported in part by grants from the China Postdoctoral Science Fund (20100470107), China Postdoctoral Science Special Fund (201104750), CSCO Fund (Y-B2011-006) and the Fund of the Ministry of Science and Technology of China (2008ZX10002-018). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Board of liver diseases infectious diseases and parasitic diseases of Chinese Medical Association, 2000, CHIN J HEPATOL, V6, P324; Chan HLY, 2012, J VIRAL HEPATITIS, V19, P732, DOI 10.1111/j.1365-2893.2012.01600.x; Chen J, 2009, HEPATOB PANCREAT DIS, V8, P261; Chien RN, 2003, J HEPATOL, V38, P322, DOI 10.1016/S0168-8278(02)00419-1; Cui YL, 2010, DIGEST DIS SCI, V55, P2373, DOI 10.1007/s10620-010-1257-7; EVERHART JE, 1992, GASTROENTEROLOGY, V103, P1692, DOI 10.1016/0016-5085(92)91198-D; Fontana RJ, 2004, AM J GASTROENTEROL, V99, P64, DOI 10.1111/j.1572-0241.2004.04032.x; Fontana RJ, 2002, GASTROENTEROLOGY, V123, P719, DOI 10.1053/gast.2002.35352; Garg H, 2011, HEPATOLOGY, V53, P774, DOI 10.1002/hep.24109; [过建春 Guo Jianchun], 2003, [中国现代应用药学, Chinese Journal of Modern Applied Pharmacy], V20, P313; Guo Y, 2008, CHIN J PREV CONTR CH, V16, P289; Hadziyannis SJ, 2005, NEW ENGL J MED, V352, P2673, DOI 10.1056/NEJMoa042957; Han Z, 2009, CHIN J CLIN HEPATOL, V25, P188; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; Jefferson T, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000975.pub2; Liaw YF, 2004, NEW ENGL J MED, V351, P1521, DOI 10.1056/NEJMoa033364; Liaw YF, 2011, HEPATOLOGY, V54, P91, DOI 10.1002/hep.24361; Liaw YF, 2011, HEPATOLOGY, V53, P62, DOI 10.1002/hep.23952; Liver Failure and Artificial Liver Group Chinese Society of Infectious Diseases Chinese Medical Association, 2006, Zhonghua Gan Zang Bing Za Zhi, V14, P643; Lok ASF, 2009, HEPATOLOGY, V50, P661, DOI 10.1002/hep.23190; Marrero J, 2003, AM J RESP CRIT CARE, V168, P1421, DOI 10.1164/rccm.200303-361UP; Papatheodoridis G, 2012, J HEPATOL, V57, P167, DOI 10.1016/j.jhep.2012.02.010; Qin R, 2012, MOD HOSP, V12, P55; Qiu S, 2009, CHIN J CLIN HEPATOL, V25, P190; Sarin SK, 2009, HEPATOL INT, V3, P269, DOI 10.1007/s12072-008-9106-x; Schiff ER, 2003, HEPATOLOGY, V38, P1419, DOI 10.1016/j.hep.2003.09.040; Shim JH, 2010, J HEPATOL, V52, P176, DOI 10.1016/j.jhep.2009.11.007; Sun LJ, 2010, J GASTROEN HEPATOL, V25, P583, DOI 10.1111/j.1440-1746.2009.06089.x; Sun Qing-feng, 2006, Zhonghua Gan Zang Bing Za Zhi, V14, P410; Tsubota A, 2005, J GASTROEN HEPATOL, V20, P426, DOI 10.1111/j.1440-1746.2004.03534.x; Uemoto S, 2000, TRANSPLANTATION, V70, P152; VICKERS C, 1988, J HEPATOL, V7, P143, DOI 10.1016/S0168-8278(88)80475-6; World Health Organisation, 2012, HEP B FACT SHEET 204; Xun J, 2004, J CLIN HEPATOL, V7, P214; Yang H, 2008, JPMT, V15, P1100; Zhao R, 2009, CHIN J PUBLIC HLTH, V25, P758; Zhong X, 2009, CHIN J CLIN HEPATOL, V25, P331	38	39	47	0	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 28	2013	8	1							e54773	10.1371/journal.pone.0054773	http://dx.doi.org/10.1371/journal.pone.0054773			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	093SF	23922797	Green Published, gold, Green Submitted			2023-01-03	WOS:000315211500026
J	Chen, WF; Chang, KP; Chen, CH; Shyu, VBH; Kao, HK				Chen, Wei F.; Chang, Kai-Ping; Chen, Chih-Hao; Shyu, Victor Bong-Hang; Kao, Huang-Kai			Outcomes of Anterolateral Thigh Flap Reconstruction for Salvage Laryngopharyngectomy for Hypopharyngeal Cancer after Concurrent Chemoradiotherapy	PLOS ONE			English	Article							FUNCTIONAL OUTCOMES; PHARYNGOESOPHAGEAL RECONSTRUCTION; CARCINOMA; HEAD; RESECTION	Objective: To evaluate the functional and oncological outcomes of anterolateral thigh flap reconstruction for salvage laryngopharyngectomy after concurrent chemoradiotherapy for patients with hypopharyngeal carcinoma. Materials/Methods: A retrospective review was conducted on patients who underwent pharyngoesophageal reconstruction using anterolateral thigh flap after salvage laryngopharyngectomy for recurrent hypopharyngeal carcinoma between June 2003 and May 2010 at Chang Gung Memorial Hospital. The perioperative morbidity, mortality, functional outcomes, and oncological outcomes were evaluated. Results: 33 patients were entered into the study. The mean follow-up time was 19.5 +/- 12.3 months. Recurrent pathological TNM stages included 3 (9.1%), 2 (6.1%), and 28 (84.8%) patients with stage II, III, and IV disease, respectively. Mean ICU stay was 10.3 days and the mean hospital stay was 39.9 days. Peri-operative mortality occurred in one patient (3%). 16 patients (48.5%) developed recipient site complications. Among them, 14 patients (42.4%) developed fistulas and 9 patients (27.3%) developed strictures. Except for 4 patients (12.1%), all achieved varying degree of oral intake with 29 patients (60.6%) being completely independent from tube feeding. The mean interval to start oral intake was 15.1 days. The 5-year overall survival and disease-free survival rates were 51.8% and 53.7%, respectively. The pN status is an independent predictor of overall survival and disease-free survival (P = 0.027 and 0.038, respectively). Conclusion: Pharyngoesophageal reconstruction after salvage laryngopharyngectomy remains challenging even in the experienced hands. Reconstructive microsurgeons who are prepared to take on these cases should be equally well prepared to manage the potential postoperative complications.	[Chen, Wei F.] Univ Iowa Hosp & Clin, Dept Surg, Div Plast & Reconstruct Surg, Iowa City, IA 52242 USA; [Chang, Kai-Ping] Chang Gung Mem Hosp, Dept Otolaryngol Head & Neck Surg, Tao Yuan, Taiwan; [Chang, Kai-Ping; Chen, Chih-Hao; Shyu, Victor Bong-Hang; Kao, Huang-Kai] Chang Gung Univ, Coll Med, Tao Yuan, Taiwan; [Chen, Chih-Hao; Shyu, Victor Bong-Hang; Kao, Huang-Kai] Chang Gung Mem Hosp, Dept Plast & Reconstruct Surg, Tao Yuan, Taiwan	University of Iowa; Chang Gung Memorial Hospital; Chang Gung University; Chang Gung Memorial Hospital	Kao, HK (corresponding author), Chang Gung Mem Hosp, Dept Plast & Reconstruct Surg, Tao Yuan, Taiwan.	kai3488@gmail.com		Yang, Guoyan (Emily)/0000-0002-8012-2379; Liu, Bo/0000-0003-3101-650X; Chen, Wei/0000-0002-4163-6641; Liu, Jianping/0000-0002-0320-061X	NCCIH NIH HHS [R24 AT001293] Funding Source: Medline	NCCIH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine)		Ali Rozina S, 2009, Plast Reconstr Surg, V124, pe395, DOI 10.1097/PRS.0b013e3181bcf05c; Chan YW, 2011, J PLAST RECONSTR AES, V64, P1022, DOI 10.1016/j.bjps.2011.03.021; Chang MFT, 2010, RADIAT ONCOL, V5, DOI 10.1186/1748-717X-5-91; Chen KT, 2007, PLAST RECONSTR SURG, V120, P187, DOI 10.1097/01.prs.0000264077.07779.50; Chu PY, 2005, HEAD NECK-J SCI SPEC, V27, P901, DOI 10.1002/hed.20262; Guibert M, 2011, EUR ANN OTORHINOLARY, V128, P218, DOI 10.1016/j.anorl.2011.02.010; Kadota H, 2010, LARYNGOSCOPE, V120, P1103, DOI 10.1002/lary.20887; Kao HK, 2009, ORAL ONCOL, V45, P1058, DOI 10.1016/j.oraloncology.2009.07.010; Lewin JS, 2005, LARYNGOSCOPE, V115, P1266, DOI 10.1097/01.MLG.0000165456.01648.B8; Lutz BS, 2005, CLIN PLAST SURG, V32, P421, DOI 10.1016/j.cps.2005.02.006; Murray DJ, 2007, HEAD NECK-J SCI SPEC, V29, P147, DOI 10.1002/hed.20489; Paximadis P, 2012, INT J RADIAT ONCOL, V82, P1515, DOI 10.1016/j.ijrobp.2011.04.064; Relic A, 2009, EUR ARCH OTO-RHINO-L, V266, P1799, DOI 10.1007/s00405-009-0946-3; Sagar B, 2010, J PLAST RECONSTR AES, V63, P970, DOI 10.1016/j.bjps.2009.04.019; Shellenberger TD, 2011, ARCH OTOLARYNGOL, V137, P1086, DOI 10.1001/archoto.2011.177; Takes RP, 2012, HEAD NECK-J SCI SPEC, V34, P270, DOI 10.1002/hed.21613; Tsou YA, 2010, HEAD NECK-J SCI SPEC, V32, P1494, DOI 10.1002/hed.21352; Wang HM, 2002, CANCER, V94, P2989, DOI 10.1002/cncr.10570; Wong CH, 2010, HEAD NECK-J SCI SPEC, V32, P1236, DOI 10.1002/hed.21284; Yu PR, 2006, PLAST RECONSTR SURG, V117, P968, DOI 10.1097/01.prs.0000200622.13312.d3	20	205	209	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 8	2013	8	1							e53985	10.1371/journal.pone.0053985	http://dx.doi.org/10.1371/journal.pone.0053985			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	069IY	24069229	gold, Green Submitted, Green Published			2023-01-03	WOS:000313429800078
J	Chen, WK; Miao, CH				Chen, Wan-Kun; Miao, Chang-Hong			The Effect of Anesthetic Technique on Survival in Human Cancers: A Meta-Analysis of Retrospective and Prospective Studies	PLOS ONE			English	Article							EPIDURAL-ANESTHESIA; COLORECTAL-CANCER; NEURAXIAL ANESTHESIA; SPINAL-ANESTHESIA; SURGERY; RECURRENCE; ANALGESIA; REDUCTION; ASSOCIATION; MORTALITY	Animal models have shown that regional anesthesia (combined with or without general anesthesia) would attenuate the surgical stress response by preserving immune function and result in better long-term outcome. In order to test the hypothesis that cancer patients who had surgery with epidural anesthesia (EA) would have better outcome (either overall survival [OS] or recurrence-free survival [RFS]) than those who were general anesthesia (GA), we performed this meta-analysis. By searching relevant literature, a total of 14 studies containing 18 sub-studies (seven in OS analysis and eleven in RFS analysis) were identified and meta-analyzed. Adjusted hazard ratios (HRs) with 95% confidence intervals (CIs) were used to assess the strength of association. For OS, the random-effects model was used to analyze the data and demonstrated an OS benefit in favor of EA compared with GA alone (HR = 0.84, 95% CI 0.74-0.96, P = 0.013). The influence analysis showed the robustness of the results. Specifically, a significantly positive association between EA and improved OS was observed in colorectal cancer (HR = 0.65, 95% CI 0.43-0.99, P = 0.045). For RFS, the random-effects model was used to analyze the data and no significant relationship between RFS benefit and EA (HR = 0.88, 95% CI 0.64-1.22, P = 0.457) was detected. In conclusion, our meta-analysis suggests that epidural anesthesia and/or analgesia might be associated with improved overall survival in patients with operable cancer undergoing surgery (especially in colorectal cancer), but it does not support an association between epidural anesthesia and cancer control. Prospective studies are needed to determine whether the association between epidural use and survival is causative.	[Chen, Wan-Kun] Fudan Univ, Dept Anesthesiol, Shanghai Canc Ctr, Shanghai 200433, Peoples R China; Fudan Univ, Inst Canc, Shanghai Med Coll, Shanghai 200433, Peoples R China	Fudan University; Fudan University	Chen, WK (corresponding author), Fudan Univ, Dept Anesthesiol, Shanghai Canc Ctr, Shanghai 200433, Peoples R China.	wkchen1981@hotmail.com; miaochh@yahoo.com.cn		Yang, Guoyan (Emily)/0000-0002-8012-2379; Liu, Bo/0000-0003-3101-650X; Chen, Wei/0000-0002-4163-6641; Liu, Jianping/0000-0002-0320-061X	Shanghai Committee of Science and Technology [114119a4400]; NCCIH NIH HHS [R24 AT001293] Funding Source: Medline	Shanghai Committee of Science and Technology(Shanghai Science & Technology Committee); NCCIH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine)	This research is supported by grants from Guide Project of Shanghai Committee of Science and Technology (2011-2013, 114119a4400). The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bar-Yosef S, 2001, ANESTHESIOLOGY, V94, P1066, DOI 10.1097/00000542-200106000-00022; BEILIN B, 1989, Brain Behavior and Immunity, V3, P129, DOI 10.1016/0889-1591(89)90013-5; Biagi JJ, 2011, JAMA-J AM MED ASSOC, V305, P2335, DOI 10.1001/jama.2011.749; Biki B, 2008, ANESTHESIOLOGY, V109, P180, DOI 10.1097/ALN.0b013e31817f5b73; Christopherson R, 2008, ANESTH ANALG, V107, P325, DOI 10.1213/ane.0b013e3181770f55; Cummings KC, 2012, ANESTHESIOLOGY, V116, P797, DOI 10.1097/ALN.0b013e31824674f6; de Oliveira GS, 2011, REGION ANESTH PAIN M, V36, P271, DOI 10.1097/AAP.0b013e318217aada; ERSKINE R, 1992, CAN J ANAESTH, V39, P905, DOI 10.1007/BF03008337; Exadaktylos AK, 2006, ANESTHESIOLOGY, V105, P660, DOI 10.1097/00000542-200610000-00008; Gottschalk A, 2010, ANESTHESIOLOGY, V113, P27, DOI 10.1097/ALN.0b013e3181de6d0d; Gupta A, 2011, BRIT J ANAESTH, V107, P164, DOI 10.1093/bja/aer100; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Ismail H, 2010, BRIT J ANAESTH, V105, P145, DOI 10.1093/bja/aeq156; Koodie L, 2010, AM J PATHOL, V177, P984, DOI 10.2353/ajpath.2010.090621; Lai RC, 2012, ANESTH ANALG, V114, P290, DOI 10.1213/ANE.0b013e318239c2e3; Landoni G, 2012, J CARDIOTHOR VASC AN, V26, P764, DOI 10.1053/j.jvca.2012.04.018; Larsson SC, 2010, JAMA-J AM MED ASSOC, V303, P1077, DOI 10.1001/jama.2010.263; LEWIS J W, 1983, Natural Immunity and Cell Growth Regulation, V3, P43; Liberati A, 2009, PLOS MED, V6, DOI [10.1371/journal.pmed.1000100, 10.1136/bmj.b2700, 10.7326/0003-4819-151-4-200908180-00136]; Lin L, 2011, BRIT J ANAESTH, V106, P814, DOI 10.1093/bja/aer055; Luo CF, 2010, EUR J ANAESTH, V27, P212, DOI 10.1097/00003643-201006121-00682; Macdonald Geraldine, 2012, Cochrane Database Syst Rev, pCD001930, DOI 10.1002/14651858.CD001930.pub3; MARKOVIC SN, 1993, ANESTHESIOLOGY, V78, P700, DOI 10.1097/00000542-199304000-00013; Myles PS, 2011, BMJ-BRIT MED J, V342, DOI 10.1136/bmj.d1491; Rodgers A, 2000, BMJ-BRIT MED J, V321, P1493, DOI 10.1136/bmj.321.7275.1493; Snyder GL, 2010, BRIT J ANAESTH, V105, P106, DOI 10.1093/bja/aeq164; Tsui BCH, 2010, CAN J ANAESTH, V57, P107, DOI 10.1007/s12630-009-9214-7; Urwin SC, 2000, BRIT J ANAESTH, V84, P450, DOI 10.1093/oxfordjournals.bja.a013468; Wijeysundera DN, 2008, LANCET, V372, P562, DOI 10.1016/S0140-6736(08)61121-6; Wuethrich PY, 2010, ANESTHESIOLOGY, V113, P570, DOI 10.1097/ALN.0b013e3181e4f6ec; Zhou D, 2012, WORLD J GASTROENTERO, V18, P3089, DOI 10.3748/wjg.v18.i24.3089	31	205	209	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 20	2013	8	2							e56540	10.1371/journal.pone.0056540	http://dx.doi.org/10.1371/journal.pone.0056540			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	093IE	24069229	Green Published, Green Submitted, gold			2023-01-03	WOS:000315184200100
J	Li, M; Zhang, YM; Zhang, ZY; Ji, XH; Zhang, R; Liu, DL; Gao, LP; Zhang, J; Wang, BA; Wu, YS; Wu, SJ; Chen, XL; Feng, SQ; Chen, XS				Li, Min; Zhang, Yanmin; Zhang, Zongying; Ji, Xiaohao; Zhang, Rui; Liu, Daliang; Gao, Liping; Zhang, Jing; Wang, Biao; Wu, Yusen; Wu, Shujing; Chen, Xiaoliu; Feng, Shouqian; Chen, Xuesen			Hypersensitive Ethylene Signaling and ZMdPG1 Expression Lead to Fruit Softening and Dehiscence	PLOS ONE			English	Article							DNA-BINDING PROTEINS; GOLDEN-DELICIOUS APPLES; GCC-BOX; TOMATO FRUIT; ARABIDOPSIS-THALIANA; RESPONSIVE ELEMENT; PLANT DEVELOPMENT; GENE-EXPRESSION; MESSENGER-RNA; CIS-ELEMENTS	Taishanzaoxia' fruit rapid softening and dehiscence during ripening stage and this process is very sensitive to endogenous ethylene. In this study, we cloned five ethylene signal transcription factors (ZMdEIL1, ZMdEIL2, ZMdEIL3, ZMdERF1 and ZMdERF2) and one functional gene, ZMdPG1, encoding polygalacturonase that could loose the cell connection which associated with fruit firmness decrease and fruit dehiscence to illustrate the reasons for this specific fruit phenotypic and physiological changes. Expression analysis showed that ZMdERF1 and ZMdEIL2 transcription were more abundant in 'Taishanzaoxia' softening fruit and dehiscent fruit and their expression was inhibited by an ethylene inhibitor 1-methylcyclopropene. Therefore, ZMdERF1 and ZMdEIL2 expression were responses to endogenous ethylene and associated with fruit softening and dehiscence. ZMdPG1 expression was induced when fruit softening and dehiscence but this induction can be blocked by 1-MCP, indicating that ZMdPG1 was essential for fruit softening and dehiscence and its expression was mediated by the endogenously occurred ethylene. ZMdPG1 overexpression in Arabidopsis led to silique early dehiscence while suppressing ZMdPG1 expression by antisense ZMdPG1 prevented silique naturally opening. The result also suggested that ZMdPG1 related with the connection between cells that contributed to fruit softening and dehiscence. ZMdERF1 was more closely related with ethylene signaling but it was not directly regulated the ZMdPG1, which might be regulated by the synergic pattern of ethylene transcription factors because of both the ZMdERF1 and ZMdERF2 could interact with ZMdEIL2.	[Li, Min; Zhang, Zongying; Ji, Xiaohao; Zhang, Rui; Liu, Daliang; Gao, Liping; Zhang, Jing; Wu, Yusen; Wu, Shujing; Chen, Xiaoliu; Feng, Shouqian; Chen, Xuesen] Shandong Agr Univ, State Key Lab Crop Biol, Tai An, Shandong, Peoples R China; [Zhang, Yanmin] Shandong Agr Univ, Coll Life Sci, Tai An, Shandong, Peoples R China; [Wang, Biao] Chinese Acad Agr Sci, Inst Plant Protect, State Key Lab Biol Plant Dis & Insect Pests, Beijing 100193, Peoples R China	Shandong Agricultural University; Shandong Agricultural University; Chinese Academy of Agricultural Sciences; Institute of Plant Protection, CAAS	Chen, XS (corresponding author), Shandong Agr Univ, State Key Lab Crop Biol, Tai An, Shandong, Peoples R China.	chenxs@sdau.edu.cn	zhang, qiu/GXG-5600-2022; Li, Rachel Wei/T-2261-2019; Wang, Shaolin/M-2282-2013	Li, Rachel Wei/0000-0001-7053-7928; Li, Min/0000-0002-6059-7756; Wang, Shaolin/0000-0003-0866-4584	National Key Basic Research Program of China [2011CB100606]; National Natural Science Foundation of China [31171932, 31272132]	National Key Basic Research Program of China(National Basic Research Program of China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported by grants from the National Key Basic Research Program of China (2011CB100606 and the National Natural Science Foundation of China (31171932 and 31272132). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Allen MD, 1998, EMBO J, V17, P5484, DOI 10.1093/emboj/17.18.5484; Atkinson R.G., 2008, New Zealand Patent, Patent No. [NZ570886, 570886]; ATKINSON RG, 1994, PLANT PHYSIOL, V105, P1437, DOI 10.1104/pp.105.4.1437; Atkinson RG, 2002, PLANT PHYSIOL, V129, P122, DOI 10.1104/pp.010986; Bapat VA, 2010, BIOTECHNOL ADV, V28, P94, DOI 10.1016/j.biotechadv.2009.10.002; Brummell DA, 2001, PLANT MOL BIOL, V47, P311, DOI 10.1023/A:1010656104304; Buttner M, 1997, P NATL ACAD SCI USA, V94, P5961, DOI 10.1073/pnas.94.11.5961; Camps C, 2005, J TEXTURE STUD, V36, P387, DOI 10.1111/j.1745-4603.2005.00023.x; Cara B, 2008, PLANT SCI, V175, P106, DOI 10.1016/j.plantsci.2008.03.021; Chakravarthy S, 2003, PLANT CELL, V15, P3033, DOI 10.1105/tpc.017574; Chao QM, 1997, CELL, V89, P1133, DOI 10.1016/S0092-8674(00)80300-1; Chen SB, 2009, PLANT PHYSIOL, V150, P1111, DOI 10.1104/pp.109.137125; Clough SJ, 1998, PLANT J, V16, P735, DOI 10.1046/j.1365-313x.1998.00343.x; DELLAPENNA D, 1986, P NATL ACAD SCI USA, V83, P6420, DOI 10.1073/pnas.83.17.6420; DELLAPENNA D, 1989, PLANT PHYSIOL, V90, P1372, DOI 10.1104/pp.90.4.1372; Hiwasa K, 2004, J EXP BOT, V55, P2281, DOI 10.1093/jxb/erh250; Huang SZ, 2010, PLANT SCI, V178, P251, DOI 10.1016/j.plantsci.2010.01.005; Jiang CZ, 2008, J EXP BOT, V59, P973, DOI 10.1093/jxb/ern023; Kendrick MD, 2008, CURR OPIN PLANT BIOL, V11, P479, DOI 10.1016/j.pbi.2008.06.011; Li YC, 2007, PLANT CELL REP, V26, P1999, DOI 10.1007/s00299-007-0394-8; Liu ChaoChao, 2011, Acta Horticulturae Sinica, V38, P133; Liu MeiYan, 2012, Acta Horticulturae Sinica, V39, P845; Liu YG, 2007, BIOTECHNIQUES, V43, P649, DOI 10.2144/000112601; Mir NA, 2001, J AM SOC HORTIC SCI, V126, P618, DOI 10.21273/JASHS.126.5.618; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; Nakano T, 2006, PLANT PHYSIOL, V140, P411, DOI 10.1104/pp.105.073783; Ogawa M, 2009, PLANT CELL, V21, P216, DOI 10.1105/tpc.108.063768; OHMETAKAGI M, 1995, PLANT CELL, V7, P173, DOI 10.1105/tpc.7.2.173; Okamuro JK, 1997, P NATL ACAD SCI USA, V94, P7076, DOI 10.1073/pnas.94.13.7076; Patterson SE, 2004, PLANT PHYSIOL, V134, P194, DOI 10.1104/pp.103.028027; Peace CP, 2005, MOL BREEDING, V16, P21, DOI 10.1007/s11032-005-0828-3; Pirrello J, 2006, PLANT CELL PHYSIOL, V47, P1195, DOI 10.1093/pcp/pcj084; Rieu I, 2003, J EXP BOT, V54, P2239, DOI 10.1093/jxb/erg240; Roeder Adrienne H K, 2006, Arabidopsis Book, V4, pe0075, DOI 10.1199/tab.0075; Saftner RA, 2003, J AM SOC HORTIC SCI, V128, P120, DOI 10.21273/JASHS.128.1.0120; Sawada K, 2000, J NEUROCHEM, V74, P1731, DOI 10.1046/j.1471-4159.2000.0741731.x; Schupp JR, 2004, HORTSCIENCE, V39, P1030, DOI 10.21273/HORTSCI.39.5.1030; Sieburth LE, 1997, PLANT CELL, V9, P355, DOI 10.1105/tpc.9.3.355; Solano R, 1998, GENE DEV, V12, P3703, DOI 10.1101/gad.12.23.3703; Song SJ, 2011, J MECH SCI TECHNOL, V25, P3; SPEIRS J, 1990, J PLANT PHYSIOL, V135, P576, DOI 10.1016/S0176-1617(11)80639-5; Tacken E, 2010, PLANT PHYSIOL, V153, P294, DOI 10.1104/pp.109.151092; Tieman DM, 2001, PLANT J, V26, P47, DOI 10.1046/j.1365-313x.2001.01006.x; TIEMAN DM, 1994, PLANT PHYSIOL, V106, P429, DOI 10.1104/pp.106.2.429; Toivonen PMA, 2005, J HORTIC SCI BIOTECH, V80, P439, DOI 10.1080/14620316.2005.11511957; Tournier B, 2003, FEBS LETT, V550, P149, DOI 10.1016/S0014-5793(03)00757-9; Wakasa Y, 2006, POSTHARVEST BIOL TEC, V39, P193, DOI 10.1016/j.postharvbio.2005.10.005; Wang AD, 2009, POSTHARVEST BIOL TEC, V52, P38, DOI 10.1016/j.postharvbio.2008.09.001; Wang A, 2007, J EXP BOT, V58, P3743, DOI 10.1093/jxb/erm224; Wang ZY, 2000, PLANT MOL BIOL, V42, P317, DOI 10.1023/A:1006309529922; Wei JM, 2010, POSTHARVEST BIOL TEC, V56, P147, DOI 10.1016/j.postharvbio.2009.12.003; Weinthal D, 2009, TRENDS PLANT SCI, V14, P59, DOI 10.1016/j.tplants.2008.11.002; Yin XR, 2008, J EXP BOT, V59, P2097, DOI 10.1093/jxb/ern067; Yin XR, 2010, PLANT PHYSIOL, V153, P1280, DOI 10.1104/pp.110.157081; Yin XueRen, 2009, Acta Horticulturae Sinica, V36, P133; Yokotani N, 2003, J EXP BOT, V54, P2775, DOI 10.1093/jxb/erg308; Yuan RC, 2007, HORTSCIENCE, V42, P101, DOI 10.21273/HORTSCI.42.1.101	57	69	79	0	38	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 20	2013	8	3							e58745	10.1371/journal.pone.0058745	http://dx.doi.org/10.1371/journal.pone.0058745			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	125SW	24205245	Green Published, gold, Green Submitted			2023-01-03	WOS:000317562600038
J	Li, M; Zhang, QP; Liu, LN; Lu, WP; Wei, H; Li, RW; Lu, S				Li, Mei; Zhang, Qiuping; Liu, Lina; Lu, Weipeng; Wei, Hong; Li, Rachel W.; Lu, Shen			Expression of the Mismatch Repair Gene hMLH1 Is Enhanced in Non-Small Cell Lung Cancer with EGFR Mutations	PLOS ONE			English	Article							GROWTH-FACTOR RECEPTOR; TYROSINE KINASE INHIBITORS; CLINICAL-SIGNIFICANCE; ACQUIRED-RESISTANCE; SOMATIC MUTATIONS; SIGNALING PATHWAY; KRAS MUTATIONS; CARCINOMAS; PROTEINS; HMSH2	Mismatch repair (MMR) plays a pivotal role in keeping the genome stable. MMR dysfunction can lead to carcinogenesis by gene mutation accumulation. HMSH2 and hMLH1 are two key components of MMR. High or low expression of them often mark the status of MMR function. Mutations (EGFR, KRAS, etc) are common in non-small cell lung cancer (NSCLC). However, it is not clear what role MMR plays in NSCLC gene mutations. The expression of MMR proteins hMSH2 and hMLH1, and the proliferation markers PCNA and Ki67 were measured by immunohistochemistry in 181 NSCLCs. EGFR and KRAS mutations were identified by high resolution melting analysis. Stronger hMLH1 expression correlated to a higher frequency of EGFR mutations in exon 19 and 21 (p<0.0005). Overexpression of hMLH1 and the adenocarcinoma subtype were both independent factors that related to EGFR mutations in NSCLCs (p=0.013 and p<0.0005). The expression of hMLH1, hMSH2 and PCNA increased, while Ki67 expression significantly decreased (p=0.030) in NSCLCs with EGFR mutations. Overexpression of hMLH1 could be a new molecular marker to predict the response to EGFR-TKIs in NSCLCs. Furthermore, EGFR mutations might be an early event of NSCLC that occur before MMR dysfunction.	[Li, Mei; Lu, Weipeng; Wei, Hong; Lu, Shen] Dalian Med Univ, Hosp 2, Cent Lab, Dalian, Peoples R China; [Zhang, Qiuping] Dalian Med Univ, Hosp 1, Dept Pathol, Dalian, Peoples R China; [Liu, Lina] Dalian Med Univ, Hosp 1, Dept Internal Med, Dalian, Peoples R China; [Li, Rachel W.] Australian Med Univ, Sch Med, Canberra, ACT, Australia	Dalian Medical University; Dalian Medical University; Dalian Medical University	Lu, S (corresponding author), Dalian Med Univ, Hosp 2, Cent Lab, Dalian, Peoples R China.	lvshen1956@126.com	zhang, qiu/GXG-5600-2022; Li, Rachel Wei/T-2261-2019; Wang, Shaolin/M-2282-2013	Li, Rachel Wei/0000-0001-7053-7928; Li, Min/0000-0002-6059-7756; Wang, Shaolin/0000-0003-0866-4584	National Nature Science Funds in China [81071805]; Dalian Merricon Gene Diagnosis Technology Co., Ltd.	National Nature Science Funds in China; Dalian Merricon Gene Diagnosis Technology Co., Ltd.	This work was supported by the National Nature Science Funds in China (Fund No. 81071805; URL: http://isisn.nsfc.gov.cn/egrantweb/), and Dalian Merricon Gene Diagnosis Technology Co., Ltd. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	An Y, 2008, LUNG CANCER, V59, P164, DOI 10.1016/j.lungcan.2007.08.003; Balak MN, 2006, CLIN CANCER RES, V12, P6494, DOI 10.1158/1078-0432.CCR-06-1570; Betz BL, 2011, AM J CLIN PATHOL, V136, P564, DOI 10.1309/AJCP84TUTQOSUONG; Bischoff J, 2012, CLIN EXP METASTAS, V29, P889, DOI 10.1007/s10585-012-9478-0; Chung H, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003463; Donehower LA, 2013, J PATHOL, V229, P99, DOI 10.1002/path.4087; Kawaguchi M, 2009, INT J ONCOL, V34, P1541, DOI 10.3892/ijo_00000283; Kouso H, 2008, J SURG ONCOL, V98, P377, DOI 10.1002/jso.21108; Lee SY, 2010, J THORAC ONCOL, V5, P1734, DOI 10.1097/JTO.0b013e3181f0beca; Li M, 2011, NEOPLASMA, V58, P74, DOI 10.4149/neo_2011_01_74; Li M, 2008, ONCOL REP, V19, P401; Li M, 2009, ONCOL REP, V22, P1013, DOI 10.3892/or_00000529; Lo FY, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-235; Luchtenborg M, 2005, BMC CANCER, V5, DOI 10.1186/1471-2407-5-160; Lujan SA, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1003016; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Massarelli E, 2007, CLIN CANCER RES, V13, P2890, DOI 10.1158/1078-0432.CCR-06-3043; Nielsen FC, 2004, ONCOGENE, V23, P1457, DOI 10.1038/sj.onc.1207265; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Pao W, 2005, PLOS MED, V2, P225, DOI 10.1371/journal.pmed.0020073; Poulogiannis G, 2010, HISTOPATHOLOGY, V56, P167, DOI 10.1111/j.1365-2559.2009.03392.x; Pu X, 2011, LUNG CANCER, V71, P82, DOI 10.1016/j.lungcan.2010.04.008; Romeo F, 2011, INT J BIOCHEM CELL B, V43, P1754, DOI 10.1016/j.biocel.2011.08.011; Rosell R, 2009, NEW ENGL J MED, V361, P958, DOI 10.1056/NEJMoa0904554; Saletta F, 2007, CANCER RES, V67, P7088, DOI 10.1158/0008-5472.CAN-06-4420; Sasaki H, 2006, LUNG CANCER, V54, P103, DOI 10.1016/j.lungcan.2006.06.003; Scartozzi M, 2006, LUNG CANCER, V53, P103, DOI 10.1016/j.lungcan.2006.03.008; Schmid K, 2009, CLIN CANCER RES, V15, P4554, DOI 10.1158/1078-0432.CCR-09-0089; Shah SN, 2010, CANCER RES, V70, P431, DOI 10.1158/0008-5472.CAN-09-3049; Shigematsu H, 2006, INT J CANCER, V118, P257, DOI 10.1002/ijc.21496; Shigematsu H, 2005, JNCI-J NATL CANCER I, V97, P339, DOI 10.1093/jnci/dji055; Shih CM, 2010, INT J MOL MED, V25, P165, DOI 10.3892/ijmm_00000327; Sholl LM, 2010, AM J CLIN PATHOL, V133, P922, DOI 10.1309/AJCPST1CTHZS3PSZ; Stoehr C, 2012, PATHOBIOLOGY, V79, P162, DOI 10.1159/000335642; Stubbert LJ, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-207; Tada T, 2006, JNCI-J NATL CANCER I, V98, P396, DOI 10.1093/jnci/djj093; Takahashi Y, 2005, MOL CARCINOGEN, V42, P150, DOI 10.1002/mc.20073; Tol J, 2010, EUR J CANCER, V46, P1997, DOI 10.1016/j.ejca.2010.03.036; Vageli D, 2009, LUNG CANCER, V64, P282, DOI 10.1016/j.lungcan.2008.09.018; Vageli DP, 2012, INT J BIOL MARKER, V27, pE400, DOI 10.5301/JBM.2012.9420; van Puijenbroek M, 2008, FAM CANCER, V7, P319, DOI 10.1007/s10689-008-9194-8; Vogelsang M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036962; Wang Y, 2000, GENE DEV, V14, P927; Wang YC, 2003, J CLIN INVEST, V111, P887, DOI 10.1172/JCI200315475; Wu CC, 2008, CANCER, V113, P3199, DOI 10.1002/cncr.23925; Xinarianos G, 2000, CANCER RES, V60, P4216; Yamaguchi F, 2012, LUNG CANCER, V78, P201, DOI 10.1016/j.lungcan.2012.08.014	47	69	79	0	38	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 24	2013	8	10							e78500	10.1371/journal.pone.0078500	http://dx.doi.org/10.1371/journal.pone.0078500			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	241FR	24205245	gold, Green Published, Green Submitted			2023-01-03	WOS:000326152300065
J	Lin, YL; Tsai, YJ; Liu, YF; Cheng, YC; Hung, CM; Lee, YJ; Pan, HC; Li, C				Lin, Yu-ling; Tsai, Yun-Jung; Liu, Yu-Fang; Cheng, Yi-Chuan; Hung, Chuan-Mao; Lee, Yi-Jen; Pan, Huichin; Li, Chuan			The Critical Role of Protein Arginine Methyltransferase prmt8 in Zebrafish Embryonic and Neural Development Is Non-Redundant with Its Paralogue prmt1	PLOS ONE			English	Article							METHYLATION; PROTEIN-ARGININE-METHYLTRANSFERASE-8; IDENTIFICATION; BINDING; FAMILY; DOMAIN; GENES; BRAIN; REST	Protein arginine methyltransferase (PRMT) 1 is the most conserved and widely distributed PRMT in eukaryotes. PRMT8 is a vertebrate-restricted paralogue of PRMT1 with an extra N-terminal sequence and brain-specific expression. We use zebrafish (Danio rerio) as a vertebrate model to study PRMT8 function and putative redundancy with PRMT1. The transcripts of zebrafish prmt8 were specifically expressed in adult zebrafish brain and ubiquitously expressed from zygotic to early segmentation stage before the neuronal development. Whole-mount in situ hybridization revealed ubiquitous prmt8 expression pattern during early embryonic stages, similar to that of prmt1. Knockdown of prmt8 with antisense morpholino oligonucleotide phenocopied prmt1-knockdown, with convergence/extension defects at gastrulation. Other abnormalities observed later include short body axis, curled tails, small and malformed brain and eyes. Catalytically inactive prmt8 failed to complement the morphants, indicating the importance of methyltransferase activity. Full-length prmt8 but not prmt1 cRNA can rescue the phenotypic changes. Nevertheless, cRNA encoding Prmt1 fused with the N-terminus of Prmt8 can rescue the prmt8 morphants. In contrast, N-terminus-deleted but not full-length prmt8 cRNA can rescue the prmt1 morphants as efficiently as prmt1 cRNA. Abnormal brain morphologies illustrated with brain markers and loss of fluorescent neurons in a transgenic fish upon prmt8 knockdown confirm the critical roles of prmt8 in neural development. In summery, our study is the first report showing the expression and function of prmt8 in early zebrafish embryogenesis. Our results indicate that prmt8 may play important roles non-overlapping with prmt1 in embryonic and neural development depending on its specific N-terminus.	[Lin, Yu-ling; Tsai, Yun-Jung; Liu, Yu-Fang; Hung, Chuan-Mao; Lee, Yi-Jen; Pan, Huichin; Li, Chuan] Chung Shan Med Univ, Dept Biomed Sci, Taichung, Taiwan; [Liu, Yu-Fang; Pan, Huichin; Li, Chuan] Chung Shan Med Univ Hosp, Dept Med Res, Taichung, Taiwan; [Cheng, Yi-Chuan] Chang Gung Univ, Dept Biochem & Mol Biol, Tao Yuan, Taiwan	Chung Shan Medical University; Chung Shan Medical University; Chung Shan Medical University Hospital; Chang Gung University	Li, C (corresponding author), Chung Shan Med Univ, Dept Biomed Sci, Taichung, Taiwan.	cli@csmu.edu.tw	Liu, Ying/Q-6444-2017; Liu, Yuxuan/F-4226-2018; Yuan, Lixing/I-2727-2012; van den Berg, Anke/H-1718-2011; Liu, Ying/GLN-6419-2022; Wu, Ping-Hsun/S-8746-2017; Chang, Chin-Kuo/E-4991-2010	Liu, Ying/0000-0001-5753-4247; Yuan, Lixing/0000-0003-0233-6184; van den Berg, Anke/0000-0002-8894-2638; Liu, Ying/0000-0001-5753-4247; Chen, Fanjun/0000-0001-8105-1683; Wu, Ping-Hsun/0000-0003-1021-8161; Liu, Yang/0000-0002-2362-9501; Lin, Ming-Yen/0000-0002-8194-4833; Chang, Chin-Kuo/0000-0002-8338-7196	National Science Council [95-2320-B-040-042, 96-2320-B-040-022-MY2, 98-2320-B-040-011-MY3]; Chung Shan Medical University [CSMU 94-OM-A-023, 97-OM-A-136, 98OM-A-060]	National Science Council(Ministry of Science and Technology, Taiwan); Chung Shan Medical University	The project was supported by 95-2320-B-040-042, 96-2320-B-040-022-MY2 and 98-2320-B-040-011-MY3 from National Science Council and CSMU 94-OM-A-023, 97-OM-A-136 and 98OM-A-060 from Chung Shan Medical University. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abramovich C, 1997, EMBO J, V16, P260, DOI 10.1093/emboj/16.2.260; Aubert J, 2003, P NATL ACAD SCI USA, V100, P11836, DOI 10.1073/pnas.1734197100; Balint BL, 2005, MOL CELL BIOL, V25, P5648, DOI 10.1128/MCB.25.13.5648-5663.2005; Ballas N, 2005, CELL, V121, P645, DOI 10.1016/j.cell.2005.03.013; Batut J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025427; Bedford MT, 2009, MOL CELL, V33, P1, DOI 10.1016/j.molcel.2008.12.013; Bruce AW, 2009, GENOME RES, V19, P994, DOI 10.1101/gr.089086.108; Bruce AW, 2004, P NATL ACAD SCI USA, V101, P10458, DOI 10.1073/pnas.0401827101; Gates KP, 2010, DEV BIOL, V340, P293, DOI 10.1016/j.ydbio.2010.01.029; Hung CJ, 2007, J BIOCHEM MOL BIOL, V40, P617; Hung CM, 2004, GENE, V340, P179, DOI 10.1016/j.gene.2004.07.039; KIMMEL CB, 1995, DEV DYNAM, V203, P253, DOI 10.1002/aja.1002030302; Kousaka A, 2009, NEUROSCIENCE, V163, P1146, DOI 10.1016/j.neuroscience.2009.06.061; Lee J, 2005, J BIOL CHEM, V280, P32890, DOI 10.1074/jbc.M506944200; Lin CH, 2002, J PROTEIN CHEM, V21, P447, DOI 10.1023/A:1021394903025; Lin WJ, 1996, J BIOL CHEM, V271, P15034, DOI 10.1074/jbc.271.25.15034; Link V, 2006, BMC DEV BIOL, V6, DOI 10.1186/1471-213X-6-1; Lu JG, 2012, BMC GENOMICS, V13, DOI 10.1186/1471-2164-13-246; Nicholson TB, 2009, PHARMACOL RES, V60, P466, DOI 10.1016/j.phrs.2009.07.006; Pahlich S, 2008, PROTEINS, V72, P1125, DOI 10.1002/prot.22004; Pahlich S, 2006, BBA-PROTEINS PROTEOM, V1764, P1890, DOI 10.1016/j.bbapap.2006.08.008; Robu ME, 2007, PLOS GENET, V3, P787, DOI 10.1371/journal.pgen.0030078; Sayegh J, 2007, J BIOL CHEM, V282, P36444, DOI 10.1074/jbc.M704650200; Taneda T, 2007, BRAIN RES, V1155, P1, DOI 10.1016/j.brainres.2007.03.086; Tsai YJ, 2011, FEBS J, V278, P905, DOI 10.1111/j.1742-4658.2011.08006.x; Wang YC, 2012, FEBS J, V279, P932, DOI 10.1111/j.1742-4658.2012.08490.x; Westerfield M., 2007, ZEBRAFISH BOOK GUIDE; Zhang X, 2003, STRUCTURE, V11, P509, DOI 10.1016/S0969-2126(03)00071-6; Zurita-Lopez CI, 2012, J BIOL CHEM, V287, P7859, DOI 10.1074/jbc.M111.336271	29	267	278	12	44	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 12	2013	8	3							e55221	10.1371/journal.pone.0055221	http://dx.doi.org/10.1371/journal.pone.0055221			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	107WV	23554853	Green Submitted, Green Published, gold			2023-01-03	WOS:000316252500001
J	Liu, Y; Zhang, AQ; Cao, L; Xia, HT; Ma, JJ				Liu, Yong; Zhang, An-Qiang; Cao, Lin; Xia, Hong-Tao; Ma, Jun-Jie			Taurolidine Lock Solutions for the Prevention of Catheter-Related Bloodstream Infections: A Systematic Review and Meta-Analysis of Randomized Controlled Trials	PLOS ONE			English	Review							HOME PARENTERAL-NUTRITION; CENTRAL VENOUS CATHETERS; TARGETED USE; HEMODIALYSIS; BACTEREMIA; CITRATE; HEPARIN; SEPSIS; CANCER; TAUROLOCK(R)	Background: Catheter-related bloodstream infections (CRBSIs) are a significant cause of morbidity and mortality in critically ill patients, contributing to prolonged hospital stays and increased costs. Whether taurolidine lock solutions (TLS) are beneficial for the prevention of CRBSIs remains controversial. In this meta-analysis, we aim to assess the efficacy of TLS for preventing CRBSIs. Methods: We conducted a systematic search of PubMed, EMBASE, and the Cochrane Central Register of Controlled Trials. Eligible studies included randomized controlled trials that reported on the effects of TLS for preventing CRBSIs. The primary outcome in these studies was catheter-related bloodstream infections, with microbial distribution of CRBSI and catheter-associated thrombosis as secondary outcomes. Data were combined using random-effects models owing to significant clinical heterogeneity. Results: Six randomized controlled trials (RCTs) conducted from 2004 through 2013 involving 431 patients and 86,078 catheter-days were included in the review. TLS were significantly associated with a lower incidence of CRBSIs when compared to heparin lock solutions (Risk Ratio [RR], 0.34; 95% Confidence Interval [CI], 0.21-0.55). Use of TLS significantly decreased the incidence of CRBSIs from gram-negative (G-) bacteria (P = 0.004; RR, 0.27; CI, 0.11-0.65), and was associated with a non-significant decrease in gram-positive (G+) bacterial infections (P = 0.07; RR, 0.41; CI, 0.15-1.09). No significant association was observed with TLS and catheter-associated thrombosis (RR, 1.99; CI, 0.75-5.28). Conclusions: The use of TLS reduced the incidence of CRBSIs without obvious adverse effects or bacterial resistance. However, the susceptibility of G+ and G- bacteria to taurolidine and the risk for catheter-associated thrombosis of TLS are indeterminate due to limited data. The results should be treated with caution due to the limited sample sizes and methodological deficiencies of included studies. Therefore, additional well-designed and adequately powered RCTs are needed to confirm these findings.	[Liu, Yong; Cao, Lin; Xia, Hong-Tao; Ma, Jun-Jie] Suining Cent Hosp, Intens Care Unit, Suining, Sichuan, Peoples R China; [Zhang, An-Qiang] Third Mil Med Univ, Daping Hosp, Inst Surg Res, State Key Lab Trauma Burns & Combined Injury, Chongqing, Peoples R China	Army Medical University	Liu, Y (corresponding author), Suining Cent Hosp, Intens Care Unit, Suining, Sichuan, Peoples R China.	616756156@qq.com	Liu, Ying/Q-6444-2017; Liu, Yuxuan/F-4226-2018; Yuan, Lixing/I-2727-2012; van den Berg, Anke/H-1718-2011; Liu, Ying/GLN-6419-2022; Wu, Ping-Hsun/S-8746-2017; Chang, Chin-Kuo/E-4991-2010	Liu, Ying/0000-0001-5753-4247; Yuan, Lixing/0000-0003-0233-6184; van den Berg, Anke/0000-0002-8894-2638; Liu, Ying/0000-0001-5753-4247; Chen, Fanjun/0000-0001-8105-1683; Wu, Ping-Hsun/0000-0003-1021-8161; Liu, Yang/0000-0002-2362-9501; Lin, Ming-Yen/0000-0002-8194-4833; Chang, Chin-Kuo/0000-0002-8338-7196				Akyuz C, 2010, PEDIATR BLOOD CANCER, V55, P949; Al-Amin A, 2012, BRIT J SURG, V99, P158; Allon M, 2003, CLIN INFECT DIS, V36, P1539, DOI 10.1086/375234; Betjes MGH, 2004, NEPHROL DIAL TRANSPL, V19, P1546, DOI 10.1093/ndt/gfh014; Bisseling TM, 2010, CLIN NUTR, V29, P464, DOI 10.1016/j.clnu.2009.12.005; Bradshaw JH, 2008, J PEDIATR GASTR NUTR, V47, P179, DOI 10.1097/MPG.0b013e318162c428; Branger B, 2008, ARTIF ORGANS, V32, P918, DOI 10.1111/j.1525-1594.2008.00684.x; Braumann C, 2005, J SURG RES, V129, P129, DOI 10.1016/j.jss.2005.03.012; Chu HP, 2012, J PEDIATR GASTR NUTR, V55, P403, DOI 10.1097/MPG.0b013e31825bb0ae; Dumichen MJ, 2012, J HOSP INFECT, V80, P304, DOI 10.1016/j.jhin.2012.01.003; Filiopoulos V, 2011, AM J NEPHROL, V33, P260, DOI 10.1159/000324685; Geron R, 2006, HAREFUAH, V145, P943; Geron Ronit, 2006, Harefuah, V145, P881; GORMAN SP, 1987, J APPL BACTERIOL, V62, P315, DOI 10.1111/j.1365-2672.1987.tb04926.x; Haag GM, 2011, J VASC ACCESS, V12, P244, DOI 10.5301/JVA.2011.6265; Handrup MM, 2012, APMIS, V120, P794, DOI 10.1111/j.1600-0463.2012.02910.x; Handrup MM, 2013, PEDIAT BLOOD CANC; Higgins J. P., 2011, COCHRANE HDB SYST RE, V4, DOI [10.1002/9780470712184, DOI 10.1002/9780470712184]; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Hill SM, 2011, J PEDIAT GASTROEN S1, V52, pE64; Jonkers C., 2012, CLIN NUTR S, V7, P203; Jurewitsch B, 2005, CLIN NUTR, V24, P462, DOI 10.1016/j.clnu.2005.02.001; Jurewitsch B, 1998, JPEN-PARENTER ENTER, V22, P242, DOI 10.1177/0148607198022004242; Labriola L, 2008, NEPHROL DIAL TRANSPL, V23, P1666, DOI 10.1093/ndt/gfm847; Mermel LA, 2009, CLIN INFECT DIS, V49, P1, DOI 10.1086/599376; Meyer B, 2010, J HOSP INFECT, V76, P200, DOI 10.1016/j.jhin.2010.05.020; Moher David, 2009, BMJ, V339, pb2535, DOI [10.1016/j.ijsu.2010.02.007, 10.1136/bmj.b2535]; Novikov A, 2012, ANTIMICROB RESIST IN, V1, DOI 10.1186/2047-2994-1-40; O'Grady NP, 2011, CLIN INFECT DIS, V52, P1087, DOI 10.1093/cid/cir138; O'Grady NP, 2002, CLIN INFECT DIS, V35, P1281, DOI 10.1086/344188; O'Horo JC, 2011, AM J NEPHROL, V34, P415, DOI 10.1159/000331262; Oliveira C, 2012, PEDIATRICS, V129, P318, DOI 10.1542/peds.2011-1602; Olthof ED, 2012, CLIN NUTR; Olthof ED, 2012, CLIN NUTR S7, V7, P149; Rafferty GP, 2010, GUT, V59, pA35, DOI 10.1136/gut.2009.208991f; Rommes JH, 2001, CURR ANAESTH CRIT CA, V12, P25; Schiavone PA, 2010, PRACT GASTROENTEROL, V34, P22; Schiffer CA, 2013, J CLIN ONCOL; Shah CB, 2002, ANTIMICROB AGENTS CH, V46, P1674, DOI 10.1128/AAC.46.6.1674-1679.2002; Simon A, 2008, BMC INFECT DIS, V8, DOI 10.1186/1471-2334-8-102; Solomon LR, 2012, SEMIN DIALYSIS, V25, P233, DOI 10.1111/j.1525-139X.2011.00951.x; Solomon LR, 2010, AM J KIDNEY DIS, V55, P1060, DOI 10.1053/j.ajkd.2009.11.025; Sweet S, 2009, AM J KIDNEY DIS, V53, pA74; Tacconelli E, 2009, J HOSP INFECT, V72, P97, DOI 10.1016/j.jhin.2008.12.012; Taylor C, 2008, J REN CARE, V34, P116, DOI 10.1111/j.1755-6686.2008.00027.x; Thompson SG, 2002, STAT MED, V21, P1559, DOI 10.1002/sim.1187; Torres-Viera C, 2000, ANTIMICROB AGENTS CH, V44, P1720, DOI 10.1128/AAC.44.6.1720-1724.2000; Toure A, 2012, CLIN NUTR, V31, P567, DOI 10.1016/j.clnu.2012.01.001; van de Wetering MD, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003295.pub2; Vernon MA, 2006, SCOT MED J, V51, P54; Weber M, 2009, ZBL CHIR, V134, P350, DOI 10.1055/s-0028-1098929; Yahav D, 2008, CLIN INFECT DIS, V47, P83, DOI 10.1086/588667; Zwiech R, 2013, AM J THER	53	267	278	12	44	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 21	2013	8	11							e79417	10.1371/journal.pone.0079417	http://dx.doi.org/10.1371/journal.pone.0079417			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	259PW	23554853	Green Published, Green Submitted, gold			2023-01-03	WOS:000327539800007
J	Liu, Y; Lai, NW; Gao, K; Chen, FJ; Yuan, LX; Mi, GH				Liu, Ying; Lai, Ningwei; Gao, Kun; Chen, Fanjun; Yuan, Lixing; Mi, Guohua			Ammonium Inhibits Primary Root Growth by Reducing the Length of Meristem and Elongation Zone and Decreasing Elemental Expansion Rate in the Root Apex in Arabidopsis thaliana	PLOS ONE			English	Article							AUXIN TRANSPORT; GRAVITROPISM; STRESS; EFFLUX; NH4+; ORGANIZATION; SENSITIVITY; MUTATIONS; TOXICITY; NITROGEN	The inhibitory effect of ammonium on primary root growth has been well documented; however the underlying physiological and molecular mechanisms are still controversial. To avoid ammonium toxicity to shoot growth, we used a vertical two-layer split plate system, in which the upper layer contained nitrate and the lower layer contained ammonium. In this way, nitrogen status was maintained and only the apical part of the root system was exposed to ammonium. Using a kinematic approach, we show here that 1 mM ammonium reduces primary root growth, decreasing both elemental expansion and cell production. Ammonium inhibits the length of elongation zone and the maximum elemental expansion rate. Ammonium also decreases the apparent length of the meristem as well as the number of dividing cells without affecting cell division rate. Moreover, ammonium reduces the number of root cap cells but appears to affect neither the status of root stem cell niche nor the distal auxin maximum at the quiescent center. Ammonium also inhibits root gravitropism and concomitantly down-regulates the expression of two pivotal auxin transporters, AUX1 and PIN2. Insofar as ammonium inhibits root growth rate in AUX1 and PIN2 loss-of-function mutants almost as strongly as in wild type, we conclude that ammonium inhibits root growth and gravitropism by largely distinct pathways.	[Liu, Ying; Lai, Ningwei; Gao, Kun; Chen, Fanjun; Yuan, Lixing; Mi, Guohua] China Agr Univ, Coll Resources & Environm Sci, Key Lab Plant Soil Interact, MOE,Ctr Resources Environm & Food Secur, Beijing 100094, Peoples R China	China Agricultural University	Mi, GH (corresponding author), China Agr Univ, Coll Resources & Environm Sci, Key Lab Plant Soil Interact, MOE,Ctr Resources Environm & Food Secur, Beijing 100094, Peoples R China.	miguohua@cau.edu.cn	Liu, Ying/Q-6444-2017; Liu, Yuxuan/F-4226-2018; Yuan, Lixing/I-2727-2012; van den Berg, Anke/H-1718-2011; Liu, Ying/GLN-6419-2022; Wu, Ping-Hsun/S-8746-2017; Chang, Chin-Kuo/E-4991-2010	Liu, Ying/0000-0001-5753-4247; Yuan, Lixing/0000-0003-0233-6184; van den Berg, Anke/0000-0002-8894-2638; Liu, Ying/0000-0001-5753-4247; Chen, Fanjun/0000-0001-8105-1683; Wu, Ping-Hsun/0000-0003-1021-8161; Liu, Yang/0000-0002-2362-9501; Lin, Ming-Yen/0000-0002-8194-4833; Chang, Chin-Kuo/0000-0002-8338-7196	NSFC [30771289, 31121062]	NSFC(National Natural Science Foundation of China (NSFC))	This work was supported by NSFC (No.30771289), the innovative group grant of NSFC (No.31121062) [http://isisn.nsfc.gov.cn]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 1994, SOIL SOLUTION CHEM A; Baskin TI, 2013, WIRES DEV BIOL, V2, P65, DOI 10.1002/wdev.94; Beemster GTS, 1998, PLANT PHYSIOL, V116, P1515, DOI 10.1104/pp.116.4.1515; Blilou I, 2005, NATURE, V433, P39, DOI 10.1038/nature03184; Britto DT, 2001, P NATL ACAD SCI USA, V98, P4255, DOI 10.1073/pnas.061034698; Britto DT, 2002, J PLANT PHYSIOL, V159, P567, DOI 10.1078/0176-1617-0774; CAO YW, 1993, PLANT PHYSIOL, V102, P983, DOI 10.1104/pp.102.3.983; Colon-Carmona A, 1999, PLANT J, V20, P503, DOI 10.1046/j.1365-313x.1999.00620.x; Dello Ioio R, 2007, CURR BIOL, V17, P678, DOI 10.1016/j.cub.2007.02.047; Friml J, 2003, CURR OPIN PLANT BIOL, V6, P7, DOI 10.1016/S1369526602000031; Friml J, 2002, NATURE, V415, P806, DOI 10.1038/415806a; Friml J, 2002, CELL, V108, P661, DOI 10.1016/S0092-8674(02)00656-6; Gazzarrini S, 1999, PLANT CELL, V11, P937, DOI 10.1105/tpc.11.5.937; Geisler M, 2002, PLANT PHYSIOL, V130, P1747, DOI 10.1104/pp.011197; Giehl RFH, 2012, PLANT CELL, V24, P33, DOI 10.1105/tpc.111.092973; Jiang K, 2005, ANNU REV CELL DEV BI, V21, P485, DOI 10.1146/annurev.cellbio.21.122303.114753; Kudoyarova GR, 1997, PLANT GROWTH REGUL, V23, P207, DOI 10.1023/A:1005990725068; Lewis DR, 2007, PLANT CELL, V19, P1838, DOI 10.1105/tpc.107.051599; Li Q, 2010, PLANT CELL ENVIRON, V33, P1529, DOI 10.1111/j.1365-3040.2010.02162.x; Ma Z, 2003, PLANT PHYSIOL, V131, P1381, DOI 10.1104/pp.012161; Malamy JE, 1997, DEVELOPMENT, V124, P33; Marchant A, 1999, EMBO J, V18, P2066, DOI 10.1093/emboj/18.8.2066; Michniewicz M, 2007, CELL, V130, P1044, DOI 10.1016/j.cell.2007.07.033; MORRIS AK, 1992, B MATH BIOL, V54, P1069, DOI 10.1007/BF02460667; Mosier AR, 2004, AGR NITROGEN CYCLE A; Overvoorde P, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a001537; Perez-Torres CA, 2008, PLANT CELL, V20, P3258, DOI 10.1105/tpc.108.058719; Petrasek J, 2009, DEVELOPMENT, V136, P2675, DOI 10.1242/dev.030353; PICKETT FB, 1990, PLANT PHYSIOL, V94, P1462, DOI 10.1104/pp.94.3.1462; Qin C, 2008, P NATL ACAD SCI USA, V105, P18308, DOI 10.1073/pnas.0806168105; Remans T, 2006, P NATL ACAD SCI USA, V103, P19206, DOI 10.1073/pnas.0605275103; Robert HS, 2009, NAT CHEM BIOL, V5, P325, DOI 10.1038/nchembio.170; Rogato A, 2010, PLANT PHYSIOL, V154, P784, DOI 10.1104/pp.110.160309; ROMAN G, 1995, GENETICS, V139, P1393; SHARP RE, 1988, PLANT PHYSIOL, V87, P50, DOI 10.1104/pp.87.1.50; SILK WK, 1992, INT J PLANT SCI, V153, pS49, DOI 10.1086/297063; Swarup R, 2005, NAT CELL BIOL, V7, P1057, DOI 10.1038/ncb1316; Walch-Liu P, 2000, J EXP BOT, V51, P227, DOI 10.1093/jexbot/51.343.227; West G, 2004, PLANT PHYSIOL, V135, P1050, DOI 10.1104/pp.104.040022; Xu J, 2005, PLANT CELL, V17, P525, DOI 10.1105/tpc.104.028449; Yamaguchi M, 2010, PLANT CELL ENVIRON, V33, P223, DOI 10.1111/j.1365-3040.2009.02073.x; Yuan LX, 2007, PLANT CELL, V19, P2636, DOI 10.1105/tpc.107.052134; Zhang HM, 1998, SCIENCE, V279, P407, DOI 10.1126/science.279.5349.407; Zou N, 2012, J EXP BOT, V63, P3777, DOI 10.1093/jxb/ers068	44	267	278	12	44	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 8	2013	8	4							e61031	10.1371/journal.pone.0061031	http://dx.doi.org/10.1371/journal.pone.0061031			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	130FG	23554853	Green Submitted, gold, Green Published			2023-01-03	WOS:000317898000091
J	Liu, YX; van den Berg, A; Veenstra, R; Rutgers, B; Nolte, I; van Imhoff, G; Visser, L; Diepstra, A				Liu, Yuxuan; van den Berg, Anke; Veenstra, Rianne; Rutgers, Bea; Nolte, Ilja; van Imhoff, Gustaaf; Visser, Lydia; Diepstra, Arjan			PML Nuclear Bodies and SATB1 Are Associated with HLA Class I Expression in EBV plus Hodgkin Lymphoma	PLOS ONE			English	Article							EPSTEIN-BARR-VIRUS; REED-STERNBERG CELLS; ARCHITECTURE; RESPONSES; CHROMATIN	Tumor cells of classical Hodgkin lymphoma (cHL) are characterized by a general loss of B cell phenotype, whereas antigen presenting properties are commonly retained. HLA class I is expressed in most EBV+ cHL cases, with an even enhanced expression in a proportion of the cases. Promyelocytic leukemia protein (PML) and special AT-rich region binding protein 1 (SATB1) are two global chromatin organizing proteins that have been shown to regulate HLA class I expression in Jurkat cells. We analyzed HLA class I, number of PML nuclear bodies (NBs) and SATB1 expression in tumor cells of 54 EBV+ cHL cases and used 27 EBV- cHL cases as controls. There was a significant difference in presence of HLA class I staining between EBV+ and EBV2 cases (p < 0.0001). We observed normal HLA class I expression in 35% of the EBV+ and in 19% of the EBV- cases. A stronger than normal HLA class I expression was observed in approximately 40% of EBV+ cHL and not in EBV- cHL cases. 36 EBV+ cHL cases contained less than 10 PML-NBs per tumor cell, whereas 16 cases contained more than 10 PMLNBs. The number of PML-NBs was positively correlated to the level of HLA class I expression (p < 0.01). The percentage of SATB1 positive cells varied between 0% to 100% in tumor cells and was inversely correlated with the level of HLA class I expression, but only between normal and strong expression (p < 0.05). Multivariable analysis indicated that the number of PML-NBs and the percentage of SATB1+ tumor cells are independent factors affecting HLA class I expression in EBV+ cHL. In conclusion, both PML and SATB1 are correlated to HLA class I expression levels in EBV+ cHL.	[Liu, Yuxuan; van den Berg, Anke; Veenstra, Rianne; Rutgers, Bea; Visser, Lydia; Diepstra, Arjan] Univ Groningen, Univ Med Ctr Groningen, Dept Pathol & Med Biol, Groningen, Netherlands; [Nolte, Ilja] Univ Groningen, Univ Med Ctr Groningen, Dept Epidemiol, Groningen, Netherlands; [van Imhoff, Gustaaf] Univ Groningen, Univ Med Ctr Groningen, Dept Hematol, Groningen, Netherlands	University of Groningen; University of Groningen; University of Groningen	Diepstra, A (corresponding author), Univ Groningen, Univ Med Ctr Groningen, Dept Pathol & Med Biol, Groningen, Netherlands.	a.diepstra@umcg.nl	Liu, Ying/Q-6444-2017; Liu, Yuxuan/F-4226-2018; Yuan, Lixing/I-2727-2012; van den Berg, Anke/H-1718-2011; Liu, Ying/GLN-6419-2022; Wu, Ping-Hsun/S-8746-2017; Chang, Chin-Kuo/E-4991-2010	Liu, Ying/0000-0001-5753-4247; Yuan, Lixing/0000-0003-0233-6184; van den Berg, Anke/0000-0002-8894-2638; Liu, Ying/0000-0001-5753-4247; Chen, Fanjun/0000-0001-8105-1683; Wu, Ping-Hsun/0000-0003-1021-8161; Liu, Yang/0000-0002-2362-9501; Lin, Ming-Yen/0000-0002-8194-4833; Chang, Chin-Kuo/0000-0002-8338-7196	Abel Tasman Talent Program (ATTP), University Medical Center Groningen; Dutch Cancer Society (KWF) [RUG 2009-4313]	Abel Tasman Talent Program (ATTP), University Medical Center Groningen; Dutch Cancer Society (KWF)(KWF Kankerbestrijding)	This work was supported by grants from Abel Tasman Talent Program (ATTP), University Medical Center Groningen and the Dutch Cancer Society (KWF: RUG 2009-4313). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alvarez JD, 2000, GENE DEV, V14, P521; Cai ST, 2006, NAT GENET, V38, P1278, DOI 10.1038/ng1913; Cai ST, 2003, NAT GENET, V34, P42, DOI 10.1038/ng1146; Chang SK, 2002, MOL CELLS, V14, P130; Condemine W, 2006, CANCER RES, V66, P6192, DOI 10.1158/0008-5472.CAN-05-3792; DELABIE J, 1995, LEUKEMIA LYMPHOMA, V18, P35, DOI 10.3109/10428199509064920; Dellaire G, 2004, BIOESSAYS, V26, P963, DOI 10.1002/bies.20089; Diepstra A, 2008, TISSUE ANTIGENS, V71, P219, DOI 10.1111/j.1399-0039.2008.01005.x; Diepstra A, 2005, LANCET, V365, P2216, DOI 10.1016/S0140-6736(05)66780-3; Diepstra A, 2009, J CLIN ONCOL, V27, P3815, DOI 10.1200/JCO.2008.20.5138; Hislop AD, 2007, J EXP MED, V204, P1863, DOI 10.1084/jem.20070256; Huang X, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010865; Jarrett RF, 2002, ANN ONCOL, V13, P23, DOI 10.1093/annonc/13.S1.23; Kumar P, 2007, NAT CELL BIOL, V9, P45, DOI 10.1038/ncb1516; Kuppers R, 2006, TRENDS IMMUNOL, V27, P203, DOI 10.1016/j.it.2006.03.001; Lallemand-Breitenbach V, COLD SPRING HARB PER, V2; Lee SP, 1997, J IMMUNOL, V158, P3325; Niens M, 2007, BLOOD, V110, P3310, DOI 10.1182/blood-2007-05-086934; Oudejans JJ, 1996, BLOOD, V87, P3844, DOI 10.1182/blood.V87.9.3844.bloodjournal8793844; Rickinson AB, 1997, ANNU REV IMMUNOL, V15, P405, DOI 10.1146/annurev.immunol.15.1.405; ROWE M, 1995, EUR J IMMUNOL, V25, P1374, DOI 10.1002/eji.1830250536; Shiels C, 2001, J CELL SCI, V114, P3705; Sides MD, 2011, VIROLOGY, V416, P86, DOI 10.1016/j.virol.2011.04.005; Steidl C, 2012, BLOOD, V120, P3530, DOI 10.1182/blood-2012-06-439570; Stein H, 2008, WHO CLASSIFICATION T, V2, P321; Wang J, 2004, J CELL BIOL, V164, P515, DOI 10.1083/jcb.200305142; Woodberry T, 2005, J INFECT DIS, V192, P1513, DOI 10.1086/491741; Zuo J, 2008, J VIROL, V82, P2385, DOI 10.1128/JVI.01946-07; Zuo JM, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000255	29	267	278	12	44	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 29	2013	8	8							e72930	10.1371/journal.pone.0072930	http://dx.doi.org/10.1371/journal.pone.0072930			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	209DO	23554853	gold, Green Published, Green Submitted			2023-01-03	WOS:000323734600043
